FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Xiao, XY
   Zou, SJ
   Chen, JW
AF Xiao, Xiaoyue
   Zou, Shujuan
   Chen, Jianwei
TI Cyclic tensile force modifies calvarial osteoblast function via the
   interplay between ERK1/2 and STAT3
SO BMC MOLECULAR AND CELL BIOLOGY
LA English
DT Article
DE Osteoblasts; Cyclic tensile stress; Osteogenesis; ERK1; 2; STAT3
ID MECHANICAL STRAIN; DIFFERENTIATION; KINASE; CSF
AB BackgroundMechanical therapies, such as distraction osteogenesis, are widely used in dental clinics. During this process, the mechanisms by which tensile force triggers bone formation remain of interest. Herein, we investigated the influence of cyclic tensile stress on osteoblasts and identified the involvement of ERK1/2 and STAT3.Materials and methodsRat clavarial osteoblasts were subjected to tensile loading (10% elongation, 0.5 Hz) for different time periods. RNA and protein levels of osteogenic markers were determined using qPCR and western blot after inhibition of ERK1/2 and STAT3. ALP activity and ARS staining revealed osteoblast mineralization capacity. The interaction between ERK1/2 and STAT3 was investigated by immunofluorescence, western blot, and Co IP.ResultsThe results showed that tensile loading significantly promoted osteogenesis related genes, proteins and mineralized nodules. In loading induced osteoblasts, inhibition of ERK1/2 or STAT3 decreased osteogenesis related biomarkers significantly. Moreover, ERK1/2 inhibition suppressed STAT3 phosphorylation, and STAT3 inhibition disrupted the nuclear translocation of pERK1/2 induced by tensile loading. In the non loading environment, inhibition of ERK1/2 hindered osteoblast differentiation and mineralization, while STAT3 phosphorylation was elevated after ERK1/2 inhibition. STAT3 inhibition also increased ERK1/2 phosphorylation, but did not significantly affect osteogenesis related factors.ConclusionTaken together, these data suggested that ERK1/2 and STAT3 interacted in osteoblasts. ERK1/2 STAT3 were sequentially activated by tensile force loading, and both affected osteogenesis during the process.
C1 [Xiao, Xiaoyue; Zou, Shujuan; Chen, Jianwei] Sichuan Univ, State Key Lab Oral Dis, Dept Orthodont, West China Hosp Stomatol, Chengdu, Peoples R China.
   [Xiao, Xiaoyue; Zou, Shujuan; Chen, Jianwei] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont, Chengdu, Peoples R China.
   [Xiao, Xiaoyue] Chongqing Med Univ, Chongqing Key Lab Oral Dis & Biomed Sci, Stomatol Hosp, Chongqing, Peoples R China.
   [Xiao, Xiaoyue] Chongqing Med Univ, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Stomatol Hosp, Chongqing, Peoples R China.
C3 Sichuan University; Sichuan University; Chongqing Medical University;
   Chongqing Medical University
RP Chen, JW (通讯作者)，Sichuan Univ, State Key Lab Oral Dis, Dept Orthodont, West China Hosp Stomatol, Chengdu, Peoples R China.; Chen, JW (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Dept Orthodont, Chengdu, Peoples R China.
EM chenjianwei2017@vip.163.com
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bhatt KA, 2007, J SURG RES, V143, P329, DOI 10.1016/j.jss.2007.01.023
   Cheng Y, SYNTHESIS STUTTGART
   Gong XY, 2023, J BONE MINER RES, V38, P214, DOI 10.1002/jbmr.4744
   Hou XL, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 022 00924 1
   Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238
   Kamezaki K, 2005, STEM CELLS, V23, P252, DOI 10.1634/stemcells.2004 0173a
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Kim DW, 2006, ANN NY ACAD SCI, V1068, P568, DOI 10.1196/annals.1346.054
   Knoll BI, 2005, PLAST RECONSTR SURG, V116, P224, DOI 10.1097/01.PRS.0000169704.74248.91
   Lawson LY, 2022, FASEB J, V36, DOI 10.1096/fj.202200591R
   Li Y, 2010, J BONE MINER RES, V25, P154, DOI 10.1359/jbmr.090705
   Li YY, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860 017 0133 0
   McGregor NE, 2022, J BONE MINER RES, V37, P547, DOI 10.1002/jbmr.4484
   Motokawa M, 2005, J DENT RES, V84, P422, DOI 10.1177/154405910508400505
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Ren KW, 2011, BRAZ J MED BIOL RES, V44, P1231, DOI 10.1590/S0100 879X2011007500150
   Tang L, 2006, BIOCHEM BIOPH RES CO, V344, P122, DOI 10.1016/j.bbrc.2006.03.123
   Wornham DP, 2014, OSTEOPOROSIS INT, V25, P2477, DOI 10.1007/s00198 014 2791 5
   Xu P, 2023, ARCH BIOCHEM BIOPHYS, V734, DOI 10.1016/j.abb.2022.109486
   Xu Y, 2019, J PERIODONTOL, V90, P1002, DOI 10.1002/JPER.18 0639
   Yamauchi Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050 1738(01)00066 4
   Yi L, 2020, BIOPHYS CHEM, V267, DOI 10.1016/j.bpc.2020.106483
   Yoneda M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194960
   Zhang HL, 2021, J NEUROCHEM, V159, P1016, DOI 10.1111/jnc.15531
   Zheng ZY, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04941 3
   Zhou HK, 2011, BONE, V49, P404, DOI 10.1016/j.bone.2011.04.020
NR 29
TC 1
Z9 2
U1 2
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2661 8850
J9 BMC MOL CELL BIOL
JI BMC Mol. Cell Biol.
PD MAR 8
PY 2023
VL 24
IS 1
AR 9
DI 10.1186/s12860 023 00471 8
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 9R4FN
UT WOS:000945611000001
PM 36890454
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, RX
   Wang, Y
   Niu, YT
   He, DQ
   Jin, SS
   Li, ZX
   Zhu, LS
   Chen, LY
   Wu, XL
   Ding, CY
   Wu, TH
   Shi, XM
   Zhang, H
   Li, C
   Wang, X
   Xie, ZW
   Li, WR
   Liu, Y
AF Wang, Ruoxi
   Wang, Yu
   Niu, Yuting
   He, Danqing
   Jin, Shanshan
   Li, Zixin
   Zhu, Lisha
   Chen, Liyuan
   Wu, Xiaolan
   Ding, Chengye
   Wu, Tianhao
   Shi, Xinmeng
   Zhang, He
   Li, Chang
   Wang, Xin
   Xie, Zhengwei
   Li, Weiran
   Liu, Yan
TI Deep Learning Predicted Dihydroartemisinin Rescues Osteoporosis by
   Maintaining Mesenchymal Stem Cell Stemness through Activating Histone 3
   Lys 9 Acetylation
SO ACS CENTRAL SCIENCE
LA English
DT Article
ID MESOPOROUS SILICA; OSTEOGENIC DIFFERENTIATION; BONE; DRUG; ARTEMISININ;
   OSTEOBLAST; EFFICACY; MALARIA
AB Maintaining the stemness of bone marrow mesenchymal stem cells (BMMSCs) is crucial for bone homeostasis and regeneration. However, in vitro expansion and bone diseases impair BMMSC stemness, limiting its functionality in bone tissue engineering. Using a deep learning based efficacy prediction system and bone tissue sequencing, we identify a natural small molecule compound, dihydroartemisinin (DHA), that maintains BMMSC stemness and enhances bone regeneration. During long term in vitro expansion, DHA preserves BMMSC stemness characteristics, including its self renewal ability and unbiased differentiation. In an osteoporosis mouse model, oral administration of DHA restores the femur trabecular structure, bone density, and BMMSC stemness in situ. Mechanistically, DHA maintains BMMSC stemness by promoting histone 3 lysine 9 acetylation via GCN5 activation both in vivo and in vitro. Furthermore, the bone targeted delivery of DHA by mesoporous silica nanoparticles improves its therapeutic efficacy in osteoporosis. Collectively, DHA could be a promising therapeutic agent for treating osteoporosis by maintaining BMMSC stemness.
C1 [Wang, Ruoxi; Wang, Yu; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Lab Biomimet Nanomat, Beijing 100081, Peoples R China.
   [Wang, Ruoxi; Wang, Yu; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, Natl Ctr Stomatol, Beijing 100081, Peoples R China.
   [Wang, Ruoxi; Wang, Yu; Niu, Yuting; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Beijing 100081, Peoples R China.
   [Wang, Ruoxi; Wang, Yu; Niu, Yuting; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China.
   [Wang, Ruoxi; Wang, Yu; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, Beijing Key Lab Digital Stomatol, Beijing 100081, Peoples R China.
   [Wang, Ruoxi; Wang, Yu; Niu, Yuting; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, Res Ctr Engn & Technol Computerized Dent, Minist Hlth, Beijing 100081, Peoples R China.
   [Wang, Ruoxi; Wang, Yu; Niu, Yuting; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, NMPA Key Lab Dent Mat, Beijing 100081, Peoples R China.
   [Wang, Ruoxi; Wang, Yu; He, Danqing; Jin, Shanshan; Li, Zixin; Zhu, Lisha; Chen, Liyuan; Wu, Xiaolan; Ding, Chengye; Wu, Tianhao; Shi, Xinmeng; Zhang, He; Li, Chang; Li, Weiran; Liu, Yan] Peking Univ, Sch & Hosp Stomatol, Translat Res Ctr Orocraniofacial Stem Cells & Syst, Beijing 100081, Peoples R China.
   [Niu, Yuting] Peking Univ, Sch & Hosp Stomatol, Natl Ctr Stomatol, Cent Lab, Beijing 100081, Peoples R China.
   [Niu, Yuting] Peking Univ, Sch & Hosp Stomatol, Translat Res Ctr Orocraniofacial Stem Cells & Syst, Cent Lab, Beijing 100081, Peoples R China.
   [Wang, Xin; Xie, Zhengwei] Peking Univ, Hlth Sci Ctr, Peking Univ Int Canc Inst, Beijing 100083, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University; Peking University; Peking University; Peking University;
   Peking University; Peking University; Peking University; Peking
   University
RP Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Lab Biomimet Nanomat, Beijing 100081, Peoples R China.; Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Natl Ctr Stomatol, Beijing 100081, Peoples R China.; Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Natl Clin Res Ctr Oral Dis, Beijing 100081, Peoples R China.; Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China.; Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Beijing Key Lab Digital Stomatol, Beijing 100081, Peoples R China.; Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Res Ctr Engn & Technol Computerized Dent, Minist Hlth, Beijing 100081, Peoples R China.; Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, NMPA Key Lab Dent Mat, Beijing 100081, Peoples R China.; Li, WR; Liu, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Translat Res Ctr Orocraniofacial Stem Cells & Syst, Beijing 100081, Peoples R China.; Xie, ZW (通讯作者)，Peking Univ, Hlth Sci Ctr, Peking Univ Int Canc Inst, Beijing 100083, Peoples R China.
EM xiezhengwei@hsc.pku.edu.cn; weiranli@163.com; orthoyan@bjmu.edu.cn
RI Xie, Zhengwei/AGW 2107 2022; Wu, Tianhao/AAX 8318 2021; Li,
   Weiran/R 6769 2019; liu, yan/HGV 1365 2022; Niu, Yuting/J 6688 2017
OI Niu, Yuting/0000 0003 3342 5438
FU National Natural Science Foundations of China [82230030, 81871492,
   82201020, 81901054]; Beijing International Science and Technology
   Cooperation [Z221100002722003]; Beijing Natural Science Foundation
   [JL23002]; Peking University Clinical Medicine Plus X   Young Scholars
   [PKU2023LCXQ004]; Ten Thousand Talents Program [QNBJ2019 2]; Key R & D
   Plan of Ningxia Hui Autonomous Region [2020BCG01001]; Innovative
   Research Team of High Level Local Universities in Shanghai
   [SHSMU ZLCX20212402]; Beijing Nova Program [Z211100002121043]; China
   National Postdoctoral Program for Innovative Talents [BX2021022,
   2019M660010]; China Postdoctoral Science Foundation [2019M660010,
   2021M700281]; Peking University Medicine Sailing Program for Young
   Scholars' Scientific & Technological Innovation [BMU2023YFJHMX009]
FX This work was supported by the National Natural Science Foundations of
   China Nos. 82230030 (Y.L.), 81871492 (Y.L.), 82201020 (Y.W.), and
   81901054 (Y.N), Beijing International Science and Technology Cooperation
   Project No. Z221100002722003 (Y.L.), the Beijing Natural Science
   Foundation No. JL23002 (Y.L.), Peking University Clinical Medicine Plus
   X   Young Scholars Project No. PKU2023LCXQ004 ( Y.L.), the Ten Thousand
   Talents Program No. QNBJ2019 2 (Y.L.), Key R & D Plan of Ningxia Hui
   Autonomous Region 2020BCG01001 (Y.L.), the Innovative Research Team of
   High Level Local Universities in Shanghai No. SHSMU ZLCX20212402 (Y.L.),
   Beijing Nova Program No. Z211100002121043 (Y.W.), the China National
   Postdoctoral Program for Innovative Talents No. BX2021022 (Y.W.), the
   China Postdoctoral Science Foundation No. 2021M700281 (Y.W.), No.
   2019M660010 (Y.N.), and the Peking University Medicine Sailing Program
   for Young Scholars' Scientific & Technological Innovation No.
   BMU2023YFJHMX009 (Y.N).
CR Ayers C, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 0684
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Brown C, 2017, NATURE, V550, pS15, DOI 10.1038/550S15a
   Cakouros D, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115440
   Cakouros D, 2019, AGING DIS, V10, P174, DOI 10.14336/AD.2017.1213
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Cheng YH, 2019, WORLD J STEM CELLS, V11, P1084, DOI 10.4252/wjsc.v11.i12.1084
   Collins M, 2015, P ROY SOC B BIOL SCI, V282, DOI 10.1098/rspb.2014.3003
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   De D, 2017, CHEM SOC REV, V46, P6241, DOI 10.1039/c7cs00330g
   Deng P, 2021, CELL STEM CELL, V28, P1057, DOI 10.1016/j.stem.2021.01.010
   Efferth T, 2021, MED RES REV, V41, P3023, DOI 10.1002/med.21842
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gutman J, 2017, LANCET INFECT DIS, V17, P184, DOI 10.1016/S1473 3099(16)30378 4
   Huang L, 2018, BIOMATERIALS, V182, P58, DOI 10.1016/j.biomaterials.2018.07.046
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Jeal W, 1997, DRUGS, V53, P415, DOI 10.2165/00003495 199753030 00006
   Jin SS, 2019, ACS NANO, V13, P6581, DOI 10.1021/acsnano.9b00489
   Jing H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0231 0
   Jing H, 2017, FASEB J, V31, P4422, DOI 10.1096/fj.201700118R
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   Kim J, 2009, ARCH PHARM RES, V32, P117, DOI 10.1007/s12272 009 1125 1
   Kuenzi BM, 2020, CANCER CELL, V38, P672, DOI 10.1016/j.ccell.2020.09.014
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li QL, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 04454 5
   Lu P, 2016, CELL RES, V26, P1169, DOI 10.1038/cr.2016.108
   Luu YK, 2009, J BONE MINER RES, V24, P50, DOI [10.1359/jbmr.080817, 10.1359/JBMR.080817]
   Mizokami A, 2017, BIOCHEM PHARMACOL, V132, P1, DOI 10.1016/j.bcp.2017.02.001
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Niu Y., 2022, Aptamer immobilizedbone targeting nanoparticles in situ reduce sclerostin for osteoporosistreatment, V45, P101529, DOI [10.1016/j.nantod.2022.101529, DOI 10.1016/J.NANTOD.2022.101529]
   Pan PP, 2021, ADV SCI, V8, DOI 10.1002/advs.202004586
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raut N, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104350
   Ren HH, 2017, J MATER CHEM B, V5, P1585, DOI 10.1039/c6tb02552h
   Rippo MR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.115
   Shen DK, 2014, NANO LETT, V14, P923, DOI 10.1021/nl404316v
   Shvedunova M, 2022, NAT REV MOL CELL BIO, V23, P329, DOI 10.1038/s41580 021 00441 y
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Wang RX, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8836258
   Wang Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21545 1
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Xiong Y, 2022, MILITARY MED RES, V9, DOI 10.1186/s40779 022 00426 8
   Xu G, 2017, J PHARM PHARMACOL, V69, P684, DOI 10.1111/jphp.12704
   Yu B, 2016, TRENDS MOL MED, V22, P641, DOI 10.1016/j.molmed.2016.06.002
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007
   Zhang P, 2016, STEM CELLS, V34, P2332, DOI 10.1002/stem.2424
   Zhang P, 2016, J BONE MINER RES, V31, P391, DOI 10.1002/jbmr.2704
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
   Zhu J, 2021, NAT BIOTECHNOL, V39, P1444, DOI 10.1038/s41587 021 00946 z
   Zhu LS, 2023, NPJ REGEN MED, V8, DOI 10.1038/s41536 023 00289 0
NR 58
TC 12
Z9 14
U1 1
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2374 7943
EI 2374 7951
J9 ACS CENTRAL SCI
JI ACS Central Sci.
PD OCT 18
PY 2023
VL 9
IS 10
BP 1927
EP 1943
DI 10.1021/acscentsci.3c00794
PG 17
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA W2QC1
UT WOS:001090117200001
PM 37901168
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cruz Neves, S
   Ribeiro, N
   Graça, I
   Jerónimo, C
   Sousa, SR
   Monteiro, FJ
AF Cruz Neves, Susana
   Ribeiro, Nilza
   Graca, Ines
   Jeronimo, Carmen
   Sousa, Susana R.
   Monteiro, Fernando J.
TI Behavior of prostate cancer cells in a nanohydroxyapatite/collagen bone
   scaffold
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE nanohydroxyapatite; collagen scaffold; tumor 3D model; SPARC; prostate
   cancer; bone metastasis; MC3T3 E1
ID METASTASIS; GROWTH; SPARC; HYDROXYAPATITE; ADSORPTION; ADHESION;
   CULTURE; FIBRONECTIN; MATRICES; COLLAGEN
AB Prostate cancer (PCa) is the second leading cause of death among men in Europe and U.S. The metastatic dissemination pattern of PCa is unique, developing bone metastasis as the only site of progression, consequently with a prognosis very poor. The cancer cells interactions within the surrounding bone environment are critical for tumor growth and progression. Secreted protein, acidic and rich in cysteine (SPARC) is described to be involved in PCa cells migration and invasion into bone. Three dimensional (3D) in vitro systems that are able to closely resemble the in vivo microenvironment are recently taking importance in cancer research. Original nanohydroxyapatite/collagen scaffolds were designed to resemble bone microenvironment in order to be applied as substitutes in bone defects and as potential biomaterials to mimic skeletal tumors. In fact, these 3D structures were cytocompatible and able to support osteoblast (MC3T3 E1) colonization and to promote bone ingrowth. Additionally, SPARC adsorption onto the scaffolds affected PC3 and LNCaP PCa cell lines behavior. PC3 cells were found to adapt and colonize the scaffolds, differing from LNCaP where cells underwent morphogenic changes and grew as clusters. Furthermore, for the tested SPARC concentration, SPARC plays a role in retaining LNCaP cells at the latter time points while with PC3 cells no significant differences were observed. This characterization study is required to establish a bone model to provide new insights into the poorly understood PCa mechanisms of metastasis to bone and the generation of improved therapies. (c) 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 2035 2046, 2017.
C1 [Cruz Neves, Susana; Ribeiro, Nilza; Sousa, Susana R.; Monteiro, Fernando J.] Univ Porto, Inst Invest & Inovacao Saude i3S, Oporto, Portugal.
   [Cruz Neves, Susana; Ribeiro, Nilza; Sousa, Susana R.; Monteiro, Fernando J.] Univ Porto, Div Biomat, INEB Inst Engn Biomed, Rua Alfredo Allen, P 4200135 Oporto, Portugal.
   [Cruz Neves, Susana; Ribeiro, Nilza; Monteiro, Fernando J.] Univ Porto, Dept Engn Met & Mat, Fac Engn, Rua Roberto Frias, P 4200465 Oporto, Portugal.
   [Graca, Ines; Jeronimo, Carmen] Portuguese Oncol Inst, Res Ctr, Canc Biol & Epigenet Grp, Oporto, Portugal.
   [Graca, Ines] ESTSP, Inst Politecn Porto, Oporto, Portugal.
   [Jeronimo, Carmen] Univ Porto, Inst Biomed Sci Abel Salazar ICBAS, Dept Pathol & Mol Immunol, Oporto, Portugal.
   [Sousa, Susana R.] Inst Politecn Porto, ISEP, Rua Dr Antonio Bernardino de Almeida 431, P 4200072 Oporto, Portugal.
C3 Universidade do Porto; i3S   Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade do
   Porto; Portuguese Institute of Oncology; Instituto Politecnico do Porto;
   Universidade do Porto; Instituto Politecnico do Porto
RP Sousa, SR (通讯作者)，Univ Porto, Inst Invest & Inovacao Saude i3S, Oporto, Portugal.; Sousa, SR (通讯作者)，Inst Politecn Porto, ISEP, Rua Dr Antonio Bernardino de Almeida 431, P 4200072 Oporto, Portugal.
EM ssousa@ineb.up.pt
RI R. Sousa, Susana/D 5356 2013; Sousa, Susana/AAE 8637 2020; Jerónimo,
   Carmen/H 3284 2013; Jeronimo, Carmen/H 3284 2013; Monteiro,
   Fernando/ABB 7538 2020
OI R. Sousa, Susana/0000 0001 8018 4310; Monteiro,
   Fernando/0000 0002 1361 4605; Jeronimo, Carmen/0000 0003 4186 5345;
   Ribeiro, Nilza/0000 0002 9975 5432
FU NanoForBone Project, ON2 QREN (Portugal) [NORTE 070202 FEDER 005372];
   Projeto Estrategico; COMPETE/FEDER (Portugal) [PEst C/SAU/LA0002/2013]
FX Contract grant sponsor: NanoForBone Project, ON2 QREN (Portugal);
   contract grant number: NORTE 070202 FEDER 005372 Contract grant sponsor:
   Projeto Estrategico; COMPETE/FEDER (Portugal); contract grant number:
   PEst C/SAU/LA0002/2013
CR Amaral Isabel F, 2013, Biomatter, V3, DOI 10.4161/biom.24791
   Arnold SA, 2009, J CELL COMMUN SIGNAL, V3, P255, DOI 10.1007/s12079 009 0072 4
   Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945 053X(00)00105 0
   Chang MC, 2002, BIOMATERIALS, V23, P4811, DOI 10.1016/S0142 9612(02)00232 6
   Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897
   Cunningham E., 2011, J TISSUE SCI ENG, Vs1., DOI [DOI 10.4172/2157 7552.S1 001, 10.4172/2157 7552.S1 001]
   De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200
   Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091
   GILLES MA, 1990, ANAL BIOCHEM, V184, P244, DOI 10.1016/0003 2697(90)90675 Y
   González García C, 2010, COLLOID SURFACE B, V77, P181, DOI 10.1016/j.colsurfb.2010.01.021
   Guda T, 2013, J BIOMATER APPL
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Ho ST, 2006, BIOMATERIALS, V27, P1362, DOI 10.1016/j.biomaterials.2005.08.035
   Ishaug SL, 1997, J BIOMED MATER RES, V36, P17
   Jacob K, 1999, CANCER RES, V59, P4453
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kiefer Jeffrey, 2004, Cancer Treat Res, V118, P101
   Kim BS, 1998, TRENDS BIOTECHNOL, V16, P224, DOI 10.1016/S0167 7799(98)01191 3
   KLEINMAN HK, 1981, J CELL BIOL, V88, P473, DOI 10.1083/jcb.88.3.473
   Koeneman KS, 1999, PROSTATE, V39, P246
   Li J, 2012, PROSTATE CANCER, V2012, DOI 10.1155/2012/691380
   Marzec E, 2008, BIOPHYS CHEM, V132, P89, DOI 10.1016/j.bpc.2007.10.012
   Murphy CM, 2010, BIOMATERIALS, V31, P461, DOI 10.1016/j.biomaterials.2009.09.063
   Reichert JC, 2010, BIOMATERIALS, V31, P7928, DOI 10.1016/j.biomaterials.2010.06.055
   Ribeiro CC, 2006, BIOMATERIALS, V27, P1749, DOI 10.1016/j.biomaterials.2005.09.043
   Ribeiro N, 2010, J COLLOID INTERF SCI, V351, P398, DOI 10.1016/j.jcis.2010.08.013
   Ribeiro N, 2016, J BIOMED NANOTECHNOL, V12, P1667, DOI 10.1166/jbn.2016.2276
   Ribeiro N, 2014, J CELL BIOCHEM, V115, P17, DOI 10.1002/jcb.24649
   Rivera LB, 2011, CELL MOL LIFE SCI, V68, P3165, DOI 10.1007/s00018 011 0781 8
   Sang LC, 2011, LANGMUIR, V27, P13828, DOI 10.1021/la202907f
   Shariat SF, 2004, CANCER, V100, P751, DOI 10.1002/cncr.20039
   Sieh S, 2014, BONE, V63, P121, DOI 10.1016/j.bone.2014.02.001
   Sieh S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040217
   Sieh S, 2010, ORGANOGENESIS, V6, P181, DOI 10.4161/org.6.3.12041
   Sopyan I, 2007, SCI TECHNOL ADV MAT, V8, P116, DOI 10.1016/j.stam.2006.11.017
   Sturge J, 2011, NAT REV CLIN ONCOL, V8, P357, DOI 10.1038/nrclinonc.2011.67
   Talukdar S, 2011, BIOMATERIALS, V32, P2149, DOI 10.1016/j.biomaterials.2010.11.052
   Teixeira S, 2009, MAT SCI ENG C BIO S, V29, P1510, DOI 10.1016/j.msec.2008.09.052
   VANWACHEM PB, 1994, J BIOMED MATER RES, V28, P353, DOI 10.1002/jbm.820280310
   Wang RX, 2005, SEMIN CANCER BIOL, V15, P353, DOI 10.1016/j.semcancer.2005.05.005
   Wissink MJB, 2001, BIOMATERIALS, V22, P151, DOI 10.1016/S0142 9612(00)00164 2
   Wong SY, 2008, CLIN EXP METASTAS, V25, P109, DOI 10.1007/s10585 007 9126 2
   Xu X, 2012, BIOMATERIALS, V33, P9049, DOI 10.1016/j.biomaterials.2012.08.061
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
NR 44
TC 7
Z9 8
U1 1
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUL
PY 2017
VL 105
IS 7
BP 2035
EP 2046
DI 10.1002/jbm.a.36070
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA EW1UF
UT WOS:000402279500018
PM 28371333
DA 2025 08 17
ER

PT J
AU Zhang, WC
   Ye, GX
   Bi, ZR
   Chen, WS
   Qian, J
   Zhang, MM
   Ding, D
   Wang, MJ
   Chen, J
AF Zhang, Weichen
   Ye, Guoxin
   Bi, Zhaori
   Chen, Weisheng
   Qian, Jing
   Zhang, Minmin
   Ding, Ding
   Wang, Mengjing
   Chen, Jing
TI Higher one year achievement rate of serum phosphate associated with
   lower cardiovascular mortality in hemodialysis patients
SO BMC NEPHROLOGY
LA English
DT Article
DE Achievement rate of serum phosphate; Cardiovascular mortality; Relative
   weights; Mineral and bone metabolism disorders
ID CHRONIC KIDNEY DISEASE; PARATHYROID HORMONE; DIALYSIS PATIENTS;
   PHOSPHORUS; CALCIUM; CKD; HYPERPHOSPHATEMIA; RISK; PREVALENCE;
   METABOLISM
AB Background Estimation of phosphate load in hemodialysis patients is always controversial in clinical practice. The aim of this study was to verify individual achievement rate of serum phosphate as the evaluation of phosphate load through investigating its impact on cardiovascular mortality in hemodialysis patients. Methods This was a single center, retrospective cohort study. A total of 251 maintenance hemodialysis patients were enrolled. The individual achievement rate of serum phosphate was defined as the times of tests within the target range divided by total times of tests over a period of time. Cox regression model was used to examine the relationship between individual achievement rate of serum phosphate and cardiovascular mortality. Results The mean age of the study population was 61 +/  13 years old. A total of 44 (17.5%) patients died from cardiovascular disease (CVD) during a median follow up of 65 months. Multivariable Cox analysis showed that one year serum phosphate achievement rate of 0% (HR = 4.117, P = 0.016) and 25% (HR = 3.343, P = 0.023) increased the risk of cardiovascular mortality while the achievement rate of 50% (HR = 2.129, P = 0.162) and 75% (HR = 1.080, P = 0.902) did not, compared to the rate of 100%. Urea reduction ratio (URR) was positively, while serum intact parathyroid hormone (iPTH), alkaline phosphatase (ALP), normalized protein catabolic rate (nPCR), and total phosphate binding capacity of drug were negatively associated with achievement in target of serum phosphate. Conclusions Keeping one year achievement rate of serum phosphate higher than 50% provides significant clinical benefits in reducing cardiovascular mortality.
C1 [Zhang, Weichen; Ye, Guoxin; Chen, Weisheng; Qian, Jing; Zhang, Minmin; Wang, Mengjing; Chen, Jing] Fudan Univ, Huashan Hosp, Div Nephrol, 12 Middle Wurumuqi Rd, Shanghai 200040, Peoples R China.
   [Bi, Zhaori; Ding, Ding; Chen, Jing] Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, 12 Middle Wurumuqi Rd, Shanghai, Peoples R China.
   [Ding, Ding] Fudan Univ, Huashan Hosp, Inst Neurol, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Wang, MJ; Chen, J (通讯作者)，Fudan Univ, Huashan Hosp, Div Nephrol, 12 Middle Wurumuqi Rd, Shanghai 200040, Peoples R China.; Chen, J (通讯作者)，Fudan Univ, Huashan Hosp, Natl Clin Res Ctr Aging & Med, 12 Middle Wurumuqi Rd, Shanghai, Peoples R China.
EM fiyona27@126.com; chenjing1998@fudan.edu.cn
RI Zhang, Minghui/M 1873 2015; Ding, Ding/MGV 4161 2025; Chen,
   Jing/AAM 2184 2021; bi, zhaori/ACW 5634 2022
FU National Key Research and Development Program [2020YFC2005003]; Shanghai
   medical leading talents project [2019LJ03]; Shanghai municipal science
   and technology commission [17411950701]; Three year action plan to
   promote clinical skills and clinical innovation capability in municipal
   hospitals [SHDC2020CR4014]; Shanghai Engineering Research Center of AI
   Assisted Clinical Service for Aging Associated Diseases [19DZ2251700]
FX This work was financially supported by National Key Research and
   Development Program No. 2020YFC2005003 (Jing Chen), Shanghai medical
   leading talents project No. 2019LJ03 (Jing Chen), Shanghai municipal
   science and technology commission researching fund No. 17411950701 (Jing
   Chen), Three year action plan to promote clinical skills and clinical
   innovation capability in municipal hospitals No. SHDC2020CR4014
   (Mengjing Wang), Shanghai Engineering Research Center of AI Assisted
   Clinical Service for Aging Associated Diseases No. 19DZ2251700 (Jing
   Chen).
CR Abrita Rodrigo Reis, 2018, Braz. J. Nephrol., V40, P26, DOI 10.1590/2175 8239 JBN 3527
   Achinger SG, 2006, J AM SOC NEPHROL, V17, pS255, DOI 10.1681/ASN.2006080923
   Agar BU, 2011, CLIN J AM SOC NEPHRO, V6, P2854, DOI 10.2215/CJN.03860411
   Da JJ, 2015, AM J KIDNEY DIS, V66, P258, DOI 10.1053/j.ajkd.2015.01.009
   Dai ZL, 2016, BONE, V83, P171, DOI 10.1016/j.bone.2015.11.005
   Daugirdas JT, 2011, SEMIN DIALYSIS, V24, P41, DOI 10.1111/j.1525 139X.2011.00849.x
   DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205
   Díaz Tocados JM, 2019, KIDNEY INT, V95, P1064, DOI 10.1016/j.kint.2018.12.015
   Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939
   Felsenfeld AJ, 2015, SEMIN DIALYSIS, V28, P564, DOI 10.1111/sdi.12411
   Fernández Martín JL, 2019, NEPHROL DIAL TRANSPL, V34, P673, DOI 10.1093/ndt/gfy093
   Ge YF, 2019, INT UROL NEPHROL, V51, P1443, DOI 10.1007/s11255 019 02217 y
   Isakova T, 2017, AM J KIDNEY DIS, V70, P737, DOI 10.1053/j.ajkd.2017.07.019
   Jorgensen HS, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882 017 0692 5
   Keihani S, 2018, J TRAUMA ACUTE CARE, V84, P418, DOI 10.1097/TA.0000000000001796
   Komaba H, 2017, KIDNEY INT, V92, P599, DOI 10.1016/j.kint.2017.02.014
   Lertdumrongluk P, 2013, J RENAL NUTR, V23, P411, DOI 10.1053/j.jrn.2013.01.018
   Li JZ, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000010937, 10.1097/md.0000000000010937]
   Nishizawa Y, 2005, J RENAL NUTR, V15, P178, DOI 10.1053/j.jrn.2004.09.027
   Okparavero A, 2016, NEPHROL DIAL TRANSPL, V31, P439, DOI 10.1093/ndt/gfv370
   OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404
   Ozechowski TJ, 2007, PSYCHOL METHODS, V12, P317, DOI 10.1037/1082 989X.12.3.317
   Palmer SC, 2011, JAMA J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308
   Rayner HC, 2017, CLIN J AM SOC NEPHRO, V12, P2000, DOI 10.2215/CJN.03280317
   Rivara MB, 2015, J AM SOC NEPHROL, V26, P1671, DOI 10.1681/ASN.2014050472
   Salam S, 2018, J AM SOC NEPHROL, V29, P1557, DOI 10.1681/ASN.2017050584
   Sardiwal S, 2013, AM J KIDNEY DIS, V62, P810, DOI 10.1053/j.ajkd.2013.02.366
   Sigrist M, 2013, NEPHROL DIAL TRANSPL, V28, P161, DOI 10.1093/ndt/gfs405
   Streja E, 2014, BONE, V61, P201, DOI 10.1016/j.bone.2014.01.016
   Streja E, 2013, KIDNEY INT SUPPL, V3, P462, DOI 10.1038/kisup.2013.96
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Termorshuizen F, 2004, J AM SOC NEPHROL, V15, P1061, DOI 10.1097/01.ASN.0000117976.29592.93
   Uhlig K, 2010, AM J KIDNEY DIS, V55, P773, DOI 10.1053/j.ajkd.2010.02.340
   Vervloet MG, 2018, KIDNEY INT, V93, P1060, DOI 10.1016/j.kint.2017.11.036
   Vervloet MG, 2011, CLIN J AM SOC NEPHRO, V6, P383, DOI 10.2215/CJN.04730510
   WARD MM, 1993, J RHEUMATOL, V20, P1494
   WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27
   Zhu MX, 2018, CLIN NEPHROL, V90, P79, DOI 10.5414/CN109265
NR 38
TC 5
Z9 7
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD DEC 1
PY 2021
VL 22
IS 1
AR 398
DI 10.1186/s12882 021 02547 z
PG 10
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA XG4WE
UT WOS:000724754000003
PM 34852774
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Liang, ZC
   Han, YX
   Chen, T
   Wang, JW
   Lin, KL
   Yuan, LY
   Li, XF
   Xu, H
   Wang, TT
   Liu, Y
   Xiao, LB
   Liang, QQ
AF Liang, Zhichao
   Han, Yunxi
   Chen, Tao
   Wang, Jinwu
   Lin, Kaili
   Yuan, Luying
   Li, Xuefei
   Xu, Hao
   Wang, Tengteng
   Liu, Yang
   Xiao, Lianbo
   Liang, Qianqian
TI Application of 3D bioprinting technology apply to assessing
   Dangguiniantongtang (DGNT) decoctions in arthritis
SO CHINESE MEDICINE
LA English
DT Article
DE 3D bioprinting; Chondrocytes; Osteoblasts; Arthritis; Decoction
ID INDUCED INFLAMMATORY INJURY; PROMOTES OSTEOGENIC DIFFERENTIATION;
   CHONDROGENIC ATDC5 CELLS; OSTEOBLAST DIFFERENTIATION; STEM CELLS;
   LIPOPOLYSACCHARIDE; MC3T3 E1; LPS; APOPTOSIS; PATHWAY
AB The aim of this study was to develop a three dimensional (3D) cell model in order to evaluate the effectiveness of a traditional Chinese medicine decoction in the treatment of arthritis. Chondrocytes (ATDC5) and osteoblasts (MC3T3 E1) were 3D printed separately using methacryloyl gelatin (GelMA) hydrogel bioinks to mimic the natural 3D cell environment. Both cell types showed good biocompatibility in GelMA. Lipopolysaccharide (LPS) was added to the cell models to create inflammation models, which resulted in increased expression of inflammatory factors IL 1 beta, TNF alpha, iNOS, and IL 6, and decreased expression of cell functional genes such as Collagen II (COLII), transcription factor SOX 9 (Sox9), Aggrecan, alkaline phosphatase (ALP), RUNX family transcription factor 2 (Runx2), Collagen I (COLI), Osteopontin (OPN), and bone morphogenetic protein 2 (BMP 2). The created inflammation model was then used to evaluate the effectiveness of Dangguiniantongtang (DGNT) decoctions. The results showed that DGNT reduced the expression of inflammatory factors and increased the expression of functional genes in the cell model. In summary, this study established a 3D cell model to assess the effectiveness of traditional Chinese medicine (TCM) decoctions, characterized the gene expression profile of the inflammatory state model, and provided a practical reference for future research on TCM efficacy evaluation for arthritis treatment.
C1 [Liang, Zhichao; Han, Yunxi; Chen, Tao; Yuan, Luying; Li, Xuefei; Xu, Hao; Wang, Tengteng; Liu, Yang; Liang, Qianqian] Shanghai Univ Tradit Chinese Med, Longhua Hosp, 725 Wan Ping South Rd, Shanghai 200032, Peoples R China.
   [Liang, Zhichao; Xiao, Lianbo] Shanghai Univ Tradit Chinese Med, Guanghua Hosp, 540 Xinhua Rd, Shanghai 200052, Peoples R China.
   [Liang, Zhichao; Han, Yunxi; Chen, Tao; Yuan, Luying; Li, Xuefei; Xu, Hao; Wang, Tengteng; Liu, Yang; Liang, Qianqian] Shanghai Univ Tradit Chinese Med, Spine Inst, 725 Wan Ping South Rd, Shanghai 200032, Peoples R China.
   [Liang, Zhichao; Han, Yunxi; Chen, Tao; Yuan, Luying; Li, Xuefei; Xu, Hao; Wang, Tengteng; Liu, Yang; Liang, Qianqian] Shanghai Univ Tradit Chinese Med, Key Lab Theory & Therapy Muscles & Bones, Minist Educ, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
   [Xiao, Lianbo] Shanghai Acad Tradit Chinese Med, Inst Arthrit Res Integrat Med, 540 Xinhua Rd, Shanghai 200052, Peoples R China.
   [Wang, Jinwu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implant, Sch Med,Dept Orthopaed Surg, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Chen, Tao; Wang, Jinwu] Shanghai Univ Tradit Chinese Med, Engn Res Ctr Tradit Chinese Med Intelligent Rehabi, Sch Rehabil Sci, Minist Educ,Inst Rehabil Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
   [Lin, Kaili] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Dept Oral & Cranio Maxillofacial Surg,Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Shanghai University of Traditional Chinese Medicine;
   Shanghai Jiao Tong University; Shanghai University of Traditional
   Chinese Medicine; Shanghai Jiao Tong University
RP Liu, Y; Liang, QQ (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, 725 Wan Ping South Rd, Shanghai 200032, Peoples R China.; Xiao, LB (通讯作者)，Shanghai Univ Tradit Chinese Med, Guanghua Hosp, 540 Xinhua Rd, Shanghai 200052, Peoples R China.; Liu, Y; Liang, QQ (通讯作者)，Shanghai Univ Tradit Chinese Med, Spine Inst, 725 Wan Ping South Rd, Shanghai 200032, Peoples R China.; Liu, Y; Liang, QQ (通讯作者)，Shanghai Univ Tradit Chinese Med, Key Lab Theory & Therapy Muscles & Bones, Minist Educ, 1200 Cailun Rd, Shanghai 201203, Peoples R China.; Xiao, LB (通讯作者)，Shanghai Acad Tradit Chinese Med, Inst Arthrit Res Integrat Med, 540 Xinhua Rd, Shanghai 200052, Peoples R China.
EM lyshtcm@126.com; 13701888178@163.com; liangqianqiantcm@126.com
RI ; Wang, Jinwu/AAG 4431 2021; xu, hao/NMK 5605 2025; Xiao,
   Lianbo/HKF 8530 2023
OI Chen, Tao/0000 0001 6325 5260; 
FU National Natural Science Foundation
FX Not applicable.
CR Alhaque S, 2018, PHILOS T R SOC B, V373, DOI 10.1098/rstb.2017.0216
   Biju TS, 2023, DRUG DELIV TRANSL RE, V13, P2239, DOI 10.1007/s13346 023 01327 6
   Bindu S, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114147
   Bourebaba L, 2020, J CELL MOL MED, V24, P7282, DOI 10.1111/jcmm.15294
   Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003
   Chen M, 2023, CYTOKINE GROWTH F R, V70, P54, DOI 10.1016/j.cytogfr.2023.03.002
   Chen SH., 2021, Chinese General Practice, V24, P3116
   Chen W, 2022, BIOENGINEERED, V13, P4051, DOI 10.1080/21655979.2022.2032970
   Chen X, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12680
   Ciuzas D, 2022, BIOCHEM ENG J, V185, DOI 10.1016/j.bej.2022.108531
   Costello RE, 2021, RHEUMATOLOGY, V60, P132, DOI 10.1093/rheumatology/keaa209
   Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016
   Esmaeili A, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 22592 4
   Fan L, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109180
   Fang Y, 2017, SLAS DISCOV, V22, P456, DOI 10.1177/1087057117696795
   Gatenholm B, 2021, CARTILAGE, V13, p1755S, DOI 10.1177/1947603520903788
   Gomes JM, 2024, ACTA BIOMATER, V173, P298, DOI 10.1016/j.actbio.2023.11.014
   Guo C, 2015, INT J MOL MED, V35, P1427, DOI 10.3892/ijmm.2015.2130
   Guo C, 2014, INFLAMMATION, V37, P621, DOI 10.1007/s10753 013 9778 9
   He S, 2021, AGING US, V13, P5150, DOI 10.18632/aging.202434
   Herreros Pomares A, 2021, MAT SCI ENG C MATER, V122, DOI 10.1016/j.msec.2021.111914
   Hou ZY, 2019, LAB INVEST, V99, P271, DOI 10.1038/s41374 018 0149 x
   Hu GH, 2023, MATER TODAY BIO, V21, DOI 10.1016/j.mtbio.2023.100695
   Huang JH, 2021, BIOMATER SCI UK, V9, P2620, DOI 10.1039/d0bm02103b
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Jensen C, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00033
   Jiang R, 2019, INT IMMUNOPHARMACOL, V69, P373, DOI 10.1016/j.intimp.2019.02.014
   Jin F, 2021, INT J IMMUNOGENET, V48, P435, DOI 10.1111/iji.12534
   Jung SS, 2023, BIOMED MATER, V18, DOI 10.1088/1748 605X/aca0d5
   Li HW, 2012, CARTILAGE, V3, P128, DOI 10.1177/1947603511429698
   Li WY, 2023, CURR PHARM BIOTECHNO, V24, P450, DOI 10.2174/1389201023666220520102001
   Lin J, A three dimensional co culture model for rheumatoid arthritis pannus tissue, P2296
   Liu GY, 2019, INT IMMUNOPHARMACOL, V66, P354, DOI 10.1016/j.intimp.2018.11.038
   Liu HZ, 2016, J TOXICOL SCI, V41, P185, DOI 10.2131/jts.41.185
   Liu YZ, 2021, BIOMATERIALS, V279, DOI 10.1016/j.biomaterials.2021.121216
   Luan L, 2018, BIOMED PHARMACOTHER, V103, P628, DOI 10.1016/j.biopha.2018.04.051
   Mei XL, 2019, MOL MED REP, V20, P3867, DOI 10.3892/mmr.2019.10639
   Owida HA, 2021, CARTILAGE, V13, p847S, DOI 10.1177/1947603519870839
   Peck Y, 2018, J TISSUE ENG REGEN M, V12, pE237, DOI 10.1002/term.2399
   Philippon EML, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1188835
   Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394
   Rosser J, 2019, MATER TODAY BIO, V4, DOI 10.1016/j.mtbio.2019.100023
   Samavedi S, 2017, TISSUE ENG PT A, V23, P101, DOI [10.1089/ten.tea.2016.0007, 10.1089/ten.TEA.2016.0007]
   Shams S, The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions, P1663
   Singh YP, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200209
   Sui C, 2019, MOL MED REP, V20, P2633, DOI 10.3892/mmr.2019.10493
   Sung TC, 2021, J MATER SCI TECHNOL, V63, P9, DOI 10.1016/j.jmst.2020.05.003
   Tevlek A, 2021, J BIOMATER APPL, V36, P818, DOI 10.1177/08853282211027889
   Wang XC, 2014, MOL MED REP, V10, P3320, DOI 10.3892/mmr.2014.2633
   Wang Y, 2019, PHYTOTHER RES, V33, P1827, DOI 10.1002/ptr.6372
   Wolff A, 2022, CELLS BASEL, V11, DOI 10.3390/cells11081313
   Yang GH, 2021, THERANOSTICS, V11, P48, DOI 10.7150/thno.50794
   Yao L., 2018, J Sichuan Tradit Chin Med, V36, P37
   Yin W, 2020, SMALL, V16, DOI 10.1002/smll.201905977
   Ying HL, 2019, INT IMMUNOPHARMACOL, V69, P313, DOI 10.1016/j.intimp.2019.01.056
   Zeng WF, 2013, PROTEIN CELL, V4, P539, DOI 10.1007/s13238 013 3003 3
NR 56
TC 2
Z9 2
U1 7
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD JUL 8
PY 2024
VL 19
IS 1
AR 96
DI 10.1186/s13020 024 00948 4
PG 12
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA XW8D1
UT WOS:001264796700001
PM 38978120
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Petrusca, DN
   Toscani, D
   Wang, FM
   Park, C
   Crean, CD
   Anderson, JL
   Marino, S
   Mohammad, KS
   Zhou, D
   Silbermann, R
   Sun, QH
   Kurihara, N
   Galson, DL
   Giuliani, N
   Roodman, GD
AF Petrusca, Daniela N.
   Toscani, Denise
   Wang, Feng Ming
   Park, Cheolkyu
   Crean, Colin D.
   Anderson, Judith L.
   Marino, Silvia
   Mohammad, Khalid S.
   Zhou, Dan
   Silbermann, Rebecca
   Sun, Quanhong
   Kurihara, Noriyoshi
   Galson, Deborah L.
   Giuliani, Nicola
   Roodman, G. David
TI Growth factor independence 1 expression in myeloma cells enhances their
   growth, survival, and osteoclastogenesis
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Gfi1; Multiple myeloma; p53; Bone disease; Apoptosis and osteolysis
ID ZINC FINGER PROTEIN; MULTIPLE MYELOMA; GFI 1; ACTIVATION; PROLIFERATION;
   LEUKEMIA; MYC; DIFFERENTIATION; REPRESSION; APOPTOSIS
AB Background: In spite of major advances in treatment, multiple myeloma (MM) is currently an incurable malignancy due to the emergence of drug resistant clones. We previously showed that MM cells upregulate the transcriptional repressor, growth factor independence 1 (Gfi1), in bone marrow stromal cells (BMSCs) that induces prolonged inhibition of osteoblast differentiation. However, the role of Gfi1 in MM cells is unknown.
   Methods: Human primary CD138+ and BMSC were purified from normal donors and MM patients' bone marrow aspirates. Gfi1 knockdown and overexpressing cells were generated by lentiviral mediated shRNA. Proliferation/apoptosis studies were done by flow cytometry, and protein levels were determined by Western blot and/or immunohistochemistry. An experimental MM mouse model was generated to investigate the effects of MM cells overexpressing Gfi1 on tumor burden and osteolysis in vivo.
   Results: We found that Gfi1 expression is increased in patient's MM cells and MM cell lines and was further increased by co culture with BMSC, IL 6, and sphingosine 1 phosphate. Modulation of Gfi1 in MM cells had major effects on their survival and growth. Knockdown of Gfi1 induced apoptosis in p53 wt, p53 mutant, and p53 deficient MM cells, while Gfi1 overexpression enhanced MM cell growth and protected MM cells from bortezomib induced cell death. Gfi1 enhanced cell survival of p53 wt MM cells by binding to p53, thereby blocking binding to the promoters of the pro apoptotic BAX and NOXA genes. Further, Gfi1 p53 binding could be blocked by HDAC inhibitors. Importantly, inoculation of MM cells overexpressing Gfi1 in mice induced increased bone destruction, increased osteoclast number and size, and enhanced tumor growth.
   Conclusions: These results support that Gfi1 plays a key role in MM tumor growth, survival, and bone destruction and contributes to bortezomib resistance, suggesting that Gfi1 may be a novel therapeutic target for MM.
C1 [Petrusca, Daniela N.; Toscani, Denise; Wang, Feng Ming; Park, Cheolkyu; Crean, Colin D.; Anderson, Judith L.; Marino, Silvia; Zhou, Dan; Silbermann, Rebecca; Kurihara, Noriyoshi; Roodman, G. David] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, 980 Walnut St,Walther Hall,Room C346, Indianapolis, IN 46202 USA.
   [Toscani, Denise; Giuliani, Nicola] Univ Parma, Dept Med & Surg, Myeloma Unit, Parma, Italy.
   [Wang, Feng Ming] Texas A&M Univ, Coll Dent, Endodont, Dallas, TX USA.
   [Mohammad, Khalid S.] Indiana Univ Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
   [Sun, Quanhong; Galson, Deborah L.] Univ Pittsburgh, McGowan Inst Regenerat Med, UPMC Hillman Canc Ctr, Dept Med,Div Hematol Oncol, Pittsburgh, PA USA.
   [Roodman, G. David] Rodebush VA Med Ctr, Indianapolis, IN USA.
C3 Indiana University System; Indiana University Bloomington; University of
   Parma; Texas A&M University System; Indiana University System; Indiana
   University Bloomington; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh
RP Petrusca, DN (通讯作者)，Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, 980 Walnut St,Walther Hall,Room C346, Indianapolis, IN 46202 USA.
EM dpetrusc@iu.edu
RI ; Giuliani, Nicola/AAT 7968 2020; toscani, denise/N 8100 2019; Galson,
   Deborah/E 9370 2010; Mohammad, Khalid/AFE 4205 2022
OI Petrusca, Daniela/0000 0002 6782 2995; , Khalid/0009 0006 9708 2111;
   Toscani, Denise/0000 0003 3492 4415; 
FU VA Merit Review [2I01CX000623 05]; NIH NCI [R01 CA209882 01A1];
   Commonwealth of PA SAP [4100057687]; ACS IRG [IRG 16 192 31]
FX This research was supported by the VA Merit Review 2I01CX000623 05
   (GDR), NIH NCI R01 CA209882 01A1 (GDR), Commonwealth of PA SAP#
   4100057687 (DLG), and ACS IRG # IRG 16 192 31 (DNP).
CR Anderson KC, 2005, ONCOLOGY NY, V19, P983
   Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood 2014 11 568881
   Boyd KD, 2011, GENE CHROMOSOME CANC, V50, P765, DOI 10.1002/gcc.20899
   Campbell CJV, 2010, BLOOD, V116, P1433, DOI 10.1182/blood 2009 12 258095
   Chng WJ, 2007, LEUKEMIA, V21, P582, DOI 10.1038/sj.leu.2404524
   Chng WJ, 2011, LEUKEMIA, V25, P1026, DOI 10.1038/leu.2011.53
   Choong ML, 2009, CELL CYCLE, V8, P2810, DOI 10.4161/cc.8.17.9503
   Cumova J, 2010, INT J HEMATOL, V92, P314, DOI 10.1007/s12185 010 0651 4
   D'Souza S, 2011, BLOOD, V118, P6871, DOI 10.1182/blood 2011 04 346775
   Darimont C, 2002, CELL GROWTH DIFFER, V13, P59
   Du P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073542
   Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338 10351.2005
   Duan ZJ, 2003, P NATL ACAD SCI USA, V100, P5932, DOI 10.1073/pnas.1031694100
   Fonseca R, 2003, BLOOD, V101, P4569, DOI 10.1182/blood 2002 10 3017
   Fu J, 2016, J CLIN INVEST, V126, P1759, DOI 10.1172/JCI80276
   GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759
   Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569
   Karsunky H, 2002, ONCOGENE, V21, P1571, DOI 10.1038/sj/onc/1205216
   Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008 5472.CAN 04 0633
   Kazanjian A, 2006, CRIT REV ONCOL HEMAT, V59, P85, DOI 10.1016/j.critrevonc.2006.02.002
   Khandanpour C, 2013, CANCER CELL, V23, P200, DOI 10.1016/j.ccr.2013.01.011
   Kumar SK, 2012, LEUKEMIA, V26, P149, DOI 10.1038/leu.2011.196
   Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood 2007 10 116129
   KURIHARA N, 1991, J BONE MINER RES, V6, P257
   KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo 126 5 2733
   Landgren O, 2017, J INTERN MED, V281, P365, DOI 10.1111/joim.12590
   Liu Y, 2009, CELL STEM CELL, V4, P37, DOI 10.1016/j.stem.2008.11.006
   Marino Silvia, 2014, Bonekey Rep, V3, P570, DOI 10.1038/bonekey.2014.65
   Marteijn JAF, 2007, BLOOD, V109, P100, DOI 10.1182/blood 2006 02 003590
   Minami R, 2000, EXP HEMATOL, V28, P244, DOI 10.1016/S0301 472X(99)00156 3
   Möröy T, 2015, BLOOD, V126, P2561, DOI 10.1182/blood 2015 06 655043
   Möröy T, 2011, SEMIN IMMUNOL, V23, P368, DOI 10.1016/j.smim.2011.08.006
   Nadav Dagan L, 2010, MOL CANCER RES, V8, P482, DOI 10.1158/1541 7786.MCR 09 0182
   Nakazawa Y, 2007, ONCOGENE, V26, P3541, DOI 10.1038/sj.onc.1210140
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114
   Rödel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845
   Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039
   Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9 16.1997
   Schlafer D, 2017, EXPERT OPIN DRUG SAF, V16, P167, DOI 10.1080/14740338.2017.1259310
   Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528
   Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349
   Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008 5472.CAN 08 2419
   Soliera AR, 2012, LEUKEMIA, V26, P1555, DOI 10.1038/leu.2012.19
   Teoh PJ, 2014, LEUKEMIA, V28, P2066, DOI 10.1038/leu.2014.102
   Tsuda H, 2005, CELL, V122, P633, DOI 10.1016/j.cell.2005.06.012
   van der Meer LT, 2010, LEUKEMIA, V24, P1834, DOI 10.1038/leu.2010.195
   Vo BT, 2017, CELL REP, V18, P2907, DOI 10.1016/j.celrep.2017.02.073
   Wright DG, 2016, ONCOTARGET, V7, P1687, DOI 10.18632/oncotarget.6424
   Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074 7613(02)00317 5
   Zhuang DZ, 2006, J BIOL CHEM, V281, P10745, DOI 10.1074/jbc.M510924200
   Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883
   Zornig M, 1996, ONCOGENE, V12, P1789
NR 54
TC 16
Z9 17
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756 8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD OCT 4
PY 2018
VL 11
AR 123
DI 10.1186/s13045 018 0666 5
PG 14
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA GV8MX
UT WOS:000446398200001
PM 30286780
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, JS
   Yi, JK
   An, SY
   Heo, JS
AF Lee, Jeong Seok
   Yi, Jin Kyu
   An, Seong Yeong
   Heo, Jung Sun
TI Increased Osteogenic Differentiation of Periodontal Ligament Stem Cells
   on Polydopamine Film Occurs via Activation of Integrin and PI3K
   Signaling Pathways
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Polydopamine; Periodontal ligament stem cells; Osteogenic
   differentiation; Integrin; PI3K
ID INSPIRED SURFACE MODIFICATION; FOCAL ADHESION KINASE; BONE FORMATION;
   IN VITRO; OSTEOBLAST; EXPRESSION; 3 KINASE; MARROW; FUNCTIONALIZATION;
   REGENERATION
AB Background/Aims: Mussel inspired polydopamine (PDA) is known to be an effective bioadhesive and bioactive material for controlling stem cell fate, which is important in stem cellbased regenerative medicine; however, the effect of PDA on osteogenic differentiation of periodontal ligament stem cells (PDLSCs) is not fully understood. In this study, we investigated the osteoinductive effect of PDA on PDLSCs and examined how this phenomenon is encouraged. Methods: Osteogenic induction of PDLSCs was established by culturing cells on PDA film or on an uncoated polystyrene surface as a control. Osteogenic differentiation of PDLSCs was assessed by measurement of intracellular calcium levels and alkaline phosphatase (ALP) activity as well as by evaluation of protein expression of osteocalcin (OCN), osterix (OSX), and runt related transcription factor 2 (RUNX2). Results: The PDLSCs cultured on PDA film showed higher osteogenic activity than those on the control surface. Moreover, PDLSCs on PDA film expressed increased levels of the integrin adhesion receptors integrin alpha 5 and beta 1 compared to control cells. Expression of one isoform of the intracellular signaling protein phosphatidylinositol 3 kinase (PI3K), p110 gamma, was increased in PDLSCs on PDA film in a PDA dose dependent manner. This signaling protein was found to interact with integrin beta 1, demonstrating integrin linked PI3K activation in response to PDA. Finally, the blockage of PI3K reduced the PDA induced osteogenic activity of PDLSCs. Conclusion: our findings suggest that the bioadhesive PDA stimulates osteogenic differentiation of PDLSCs via activation of the integrin alpha 5/beta 1 and PI3K signaling pathways. Copyright (C) 2014 S. Karger AG, Basel
C1 [Lee, Jeong Seok; An, Seong Yeong; Heo, Jung Sun] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Biomed Engn, Seoul 130701, South Korea.
   [Lee, Jeong Seok; An, Seong Yeong; Heo, Jung Sun] Kyung Hee Univ, Sch Dent, Inst Oral Biol, Seoul 130701, South Korea.
   [Yi, Jin Kyu] Kyung Hee Univ, Sch Dent, Dept Conservat Dent, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Heo, JS (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Maxillofacial Biomed Engn, 26 Kyunghee Daero, Seoul 130701, South Korea.
EM heojs@khu.ac.kr
FU Kyung Hee University [KHU 20131081]
FX This work was supported by a grant from Kyung Hee University in 2013
   (KHU 20131081).
CR Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Bhang SH, 2013, BIOCHEM BIOPH RES CO, V430, P1294, DOI 10.1016/j.bbrc.2012.11.123
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   Gay IC, 2007, ORTHOD CRANIOFAC RES, V10, P149, DOI 10.1111/j.1601 6343.2007.00399.x
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Goessler UR, 2009, J CELL MOL MED, V13, P1175, DOI 10.1111/j.1582 4934.2008.00451.x
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hamidouche Z, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 44
   Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106
   Hohenester S, 2010, J HEPATOL, V53, P918, DOI 10.1016/j.jhep.2010.05.015
   Ku SH, 2010, BIOMATERIALS, V31, P2535, DOI 10.1016/j.biomaterials.2009.12.020
   Lai M, 2011, BIOMACROMOLECULES, V12, P1097, DOI 10.1021/bm1014365
   Lee H, 2006, P NATL ACAD SCI USA, V103, P12999, DOI 10.1073/pnas.0605552103
   Lindroos B, 2008, BIOCHEM BIOPH RES CO, V368, P329, DOI 10.1016/j.bbrc.2008.01.081
   Liu XM, 2007, BIOMATERIALS, V28, P4535, DOI 10.1016/j.biomaterials.2007.06.016
   Liu YT, 2013, COLLOID SURFACE B, V106, P37, DOI 10.1016/j.colsurfb.2013.01.023
   Lynge ME, 2011, ACS APPL MATER INTER, V3, P2142, DOI 10.1021/am200358p
   Moshaverinia A, 2014, TISSUE ENG PT A, V20, P611, DOI 10.1089/ten.TEA.2013.0229
   Nakashima M, 2009, CYTOKINE GROWTH F R, V20, P435, DOI 10.1016/j.cytogfr.2009.10.012
   Park SY, 2015, J BIOMED MATER RES A, V103, P38, DOI 10.1002/jbm.a.35145
   Rached MT, 2010, CELL METAB, V11, P147, DOI 10.1016/j.cmet.2010.01.001
   Rim NG, 2012, COLLOID SURFACE B, V91, P189, DOI 10.1016/j.colsurfb.2011.10.057
   Rokutanda S, 2009, DEV BIOL, V328, P78, DOI 10.1016/j.ydbio.2009.01.009
   Salasznyk RM, 2007, EXP CELL RES, V313, P22, DOI 10.1016/j.yexcr.2006.09.013
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shill YR, 2010, J BONE MINER RES, V26, P730
   Singhatanadgit W, 2009, TISSUE ENG PT A, V15, P2625, DOI [10.1089/ten.tea.2008.0442, 10.1089/ten.TEA.2008.0442]
   Sipilä K, 2014, FASEB J, V28, P3758, DOI 10.1096/fj.13 247767
   STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107
   Vogel V, 2006, NAT REV MOL CELL BIO, V7, P265, DOI 10.1038/nrm1890
   Wang JL, 2013, MACROMOL BIOSCI, V13, P483, DOI 10.1002/mabi.201200390
   Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988
   Xu JP, 2009, STEM CELLS DEV, V18, P487, DOI 10.1089/scd.2008.0113
   Yu BH, 2014, J BIOMATER APPL, V29, P243, DOI 10.1177/0885328214521846
   Zainal Ariffins SH, 2012, SCI WORLD J, V2012
   Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318
NR 42
TC 49
Z9 54
U1 0
U2 22
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2014
VL 34
IS 5
BP 1824
EP 1834
DI 10.1159/000366381
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA AW4TY
UT WOS:000346274400035
PM 25502639
OA gold
DA 2025 08 17
ER

PT J
AU Sitasuwan, P
   Lee, LA
   Bo, P
   Davis, EN
   Lin, Y
   Wang, Q
AF Sitasuwan, Pongkwan
   Lee, L. Andrew
   Bo, Peng
   Davis, Erin N.
   Lin, Yuan
   Wang, Qian
TI A plant virus substrate induces early upregulation of BMP2 for rapid
   bone formation
SO INTEGRATIVE BIOLOGY
LA English
DT Article
ID MESENCHYMAL STEM CELLS; TOBACCO MOSAIC VIRUS; TITANIUM
   SURFACE ROUGHNESS; OSTEOBLAST LIKE CELLS; MARROW STROMAL CELLS;
   MORPHOGENETIC PROTEIN 2; EXTRACELLULAR MATRIX; IN VITRO;
   SIGNAL TRANSDUCTION; DIFFERENTIATION
AB Many nanoscale materials have been developed to investigate the effects on stem cell differentiations via topographical and chemical cues for applications in tissue engineering and regenerative medicine. The use of plant viruses as cell supporting substrates has been of particular interest due to the rapid induction of bone marrow derived mesenchymal stem cells (BMSCs) towards osteogenic cells. In this study, the role of Tobacco mosaic virus (TMV) and its early effects on osteoinduction with particular emphasis on the regulation of bone morphogenetic protein 2 (BMP2) was examined. We observed that the cells on the virus substrate immediately aggregated and formed bone like nodules within 24 hours. An immediate increase in BMP2 gene and protein expression for cells on the TMV substrate was observed within 8 hours of osteoinduction. Moreover, BMP2 expression was highly localized to cells within the cell aggregates. This enhanced differentiation only occurred when TMV was coated on a solid support but not upon adding the virus to the media solution. Taken together, the results from this study highlight the potential of virus based nanomaterials to promote endogenous BMP2 production which may prove to be a unique approach to studying the regulatory mechanisms involved in early osteoblastic differentiation.
C1 [Sitasuwan, Pongkwan; Lee, L. Andrew; Davis, Erin N.; Wang, Qian] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.
   [Bo, Peng; Lin, Yuan] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
C3 University of South Carolina System; University of South Carolina
   Columbia; Chinese Academy of Sciences; Changchun Institute of Applied
   Chemistry, CAS
RP Sitasuwan, P (通讯作者)，Univ S Carolina, Dept Chem & Biochem, 631 Sumter St, Columbia, SC 29208 USA.
EM linyuan@ciac.jl.cn; wang@mail.chem.sc.edu
RI ; Wang, Qian/J 2144 2012; lin, yuan/G 9390 2013
OI Lee, Lim/0000 0001 7622 8392; Wang, Qian/0000 0002 2149 384X; 
FU US NSF [CHE 0748690]; Alfred P. Sloan Scholarship; Camille Dreyfus
   Teacher Scholar Award; W. M. Keck Foundation; State Key Laboratory of
   Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry,
   Chinese Academy of Sciences; National Natural Science Foundation of
   China [21128002, 21104080]; Direct For Mathematical & Physical Scien;
   Division Of Chemistry [0748690] Funding Source: National Science
   Foundation
FX This work was supported by the US NSF (CHE 0748690), the Alfred P. Sloan
   Scholarship, the Camille Dreyfus Teacher Scholar Award, and the W. M.
   Keck Foundation. The authors would like to acknowledge the financial
   support from State Key Laboratory of Polymer Physics and Chemistry,
   Changchun Institute of Applied Chemistry, Chinese Academy of Sciences,
   and National Natural Science Foundation of China (Programs 21128002 and
   21104080). Finally, we thank Ms Cheryl Cook for media recipes and Ms
   Quyen Nguyen for immunohistochemical staining.
CR Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Ayres CE, 2010, WIRES NANOMED NANOBI, V2, P20, DOI 10.1002/wnan.55
   Bi LX, 1999, CALCIFIED TISSUE INT, V64, P63, DOI 10.1007/s002239900580
   Biggs MJP, 2008, J R SOC INTERFACE, V5, P1231, DOI 10.1098/rsif.2008.0035
   Biggs MJP, 2009, J BIOMED MATER RES A, V91A, P195, DOI 10.1002/jbm.a.32196
   Bruckman MA, 2008, CHEMBIOCHEM, V9, P519, DOI 10.1002/cbic.200700559
   Cambien B, 2001, BLOOD, V97, P359, DOI 10.1182/blood.V97.2.359
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Drost AC, 2009, ANN NY ACAD SCI, V1176, P135, DOI 10.1111/j.1749 6632.2009.04610.x
   Dvir T, 2011, NAT NANOTECHNOL, V6, P13, DOI [10.1038/nnano.2010.246, 10.1038/NNANO.2010.246]
   Filion TM, 2011, BIOORG MED CHEM LETT, V21, P5067, DOI 10.1016/j.bmcl.2011.04.032
   García AJ, 2005, J DENT RES, V84, P407, DOI 10.1177/154405910508400502
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Gong Z, 2009, TISSUE ENG PT A, V15, P319, DOI 10.1089/ten.tea.2008.0161
   Higashino K, 2011, TISSUE ENG PT A, V17, P523, DOI 10.1089/ten.tea.2010.0168
   Hou CH, 2009, J CELL BIOCHEM, V106, P7, DOI 10.1002/jcb.21934
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009
   Ishibashi O, 2010, J CELL PHYSIOL, V222, P465, DOI 10.1002/jcp.21968
   Javed A, 2010, ORAL MAXIL SURG CLIN, V22, P283, DOI 10.1016/j.coms.2010.05.001
   Jiang LB, 2006, VACCINE, V24, P109, DOI 10.1016/j.vaccine.2005.09.060
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kärner E, 2009, BBA GEN SUBJECTS, V1790, P110, DOI 10.1016/j.bbagen.2008.10.004
   Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047
   Kaur G, 2008, BIOMATERIALS, V29, P4074, DOI 10.1016/j.biomaterials.2008.06.029
   Kaur G, 2010, BIOMATERIALS, V31, P5813, DOI 10.1016/j.biomaterials.2010.04.017
   Kaur G, 2010, BIOMATERIALS, V31, P1732, DOI 10.1016/j.biomaterials.2009.11.041
   Kawaski T, 2010, BIOMATERIALS, V31, P1191, DOI 10.1016/j.biomaterials.2009.10.048
   Kim YS, 2010, J ENDODONT, V36, P1824, DOI 10.1016/j.joen.2010.08.020
   Lee JH, 2010, BIOMATERIALS, V31, P3512, DOI 10.1016/j.biomaterials.2010.01.075
   Lee LA, 2011, ORG BIOMOL CHEM, V9, P6189, DOI 10.1039/c1ob05700f
   Lenhert S, 2005, BIOMATERIALS, V26, P563, DOI 10.1016/j.biomaterials.2004.02.068
   Lin YA, 2011, LANGMUIR, V27, P1398, DOI 10.1021/la103917x
   Lin Y, 2010, ANGEW CHEM INT EDIT, V49, P868, DOI 10.1002/anie.200904993
   Lipski AM, 2007, ADV MATER, V19, P553, DOI 10.1002/adma.200502617
   Lohmann CH, 1999, J BIOMED MATER RES, V47, P139, DOI 10.1002/(SICI)1097 4636(199911)47:2<139::AID JBM4>3.0.CO;2 2
   Lovmand J, 2009, BIOMATERIALS, V30, P2015, DOI 10.1016/j.biomaterials.2008.12.081
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Mammoto A, 2009, CURR OPIN CELL BIOL, V21, P864, DOI 10.1016/j.ceb.2009.08.001
   MARTIN JY, 1995, J BIOMED MATER RES, V29, P389, DOI 10.1002/jbm.820290314
   McCormick AA, 2006, VACCINE, V24, P6414, DOI 10.1016/j.vaccine.2006.06.003
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   McNamara LE, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/120623
   Mendonça DBS, 2011, BONE, V49, P463, DOI 10.1016/j.bone.2011.04.019
   Mierke CT, 2009, CELL BIOCHEM BIOPHYS, V53, P115, DOI 10.1007/s12013 009 9047 6
   Minguell JJ, 2001, EXP BIOL MED, V226, P507, DOI 10.1177/153537020122600603
   Nakamura I, 2006, VITAM HORM, V74, P357, DOI 10.1016/S0083 6729(06)74015 8
   Niu ZW, 2007, LANGMUIR, V23, P6719, DOI 10.1021/la070096b
   Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22 3 377
   Park J, 2007, NANO LETT, V7, P1686, DOI 10.1021/nl070678d
   Park J, 2009, SMALL, V5, P666, DOI 10.1002/smll.200801476
   Pennazio S, 2000, RIV BIOL BIOL FORUM, V93, P253
   Peterson L., 2002, Focal adhesions and focal complexes
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Porada CD, 2010, ADV DRUG DELIVER REV, V62, P1156, DOI 10.1016/j.addr.2010.08.010
   Rifas L, 2006, J CELL BIOCHEM, V98, P706, DOI 10.1002/jcb.20933
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Schlick KH, 2005, MOL PHARMACEUT, V2, P295, DOI 10.1021/mp050014h
   Schwartz Z, 1996, J BIOMED MATER RES, V30, P145
   Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72
   Si YL, 2011, AGEING RES REV, V10, P93, DOI 10.1016/j.arr.2010.08.005
   Siebers MC, 2005, BIOMATERIALS, V26, P137, DOI 10.1016/j.biomaterials.2004.02.021
   Teixeira AI, 2003, J CELL SCI, V116, P1881, DOI 10.1242/jcs.00383
   Vunjak Novakovic G., 2006, Culture of Specialized Cells
   Wang L, 2010, ANN BIOMED ENG, V38, P77, DOI 10.1007/s10439 009 9841 8
   Wang XN, 2008, J BIOMED MATER RES A, V87A, P8, DOI 10.1002/jbm.a.31617
   Wu LY, 2011, LANGMUIR, V27, P9490, DOI 10.1021/la201580v
   Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186
   Xu JW, 2009, J ORTHOP RES, V27, P1306, DOI 10.1002/jor.20890
   Young M, 2008, ANNU REV PHYTOPATHOL, V46, P361, DOI 10.1146/annurev.phyto.032508.131939
NR 73
TC 46
Z9 53
U1 0
U2 30
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1757 9694
J9 INTEGR BIOL UK
JI Integr. Biol.
PY 2012
VL 4
IS 6
BP 651
EP 660
DI 10.1039/c2ib20041d
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 948EV
UT WOS:000304487300008
PM 22532088
DA 2025 08 17
ER

PT J
AU Kook, SH
   Jang, YS
   Lee, JC
AF Kook, Sung Ho
   Jang, Yong Suk
   Lee, Jeong Chae
TI Involvement of JNK AP 1 and ERK NF κB signaling in tension stimulated
   expression of Type I collagen and MMP 1 in human periodontal ligament
   fibroblasts
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE tensile force; mechanosignal transduction pathway
ID ORTHODONTIC TOOTH MOVEMENT; OSTEOBLAST LIKE CELLS; SMOOTH MUSCLE CELLS;
   TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR; MECHANICAL STRAIN;
   MESSENGER RNA; MAP KINASES; MATRIX METALLOPROTEINASES; GINGIVAL
   FIBROBLASTS
AB Kook SH, Jang YS, Lee JC. Involvement of JNK AP 1 and ERK NF kappa B signaling in tension stimulated expression of Type I collagen and MMP 1 in human periodontal ligament fibroblasts. J Appl Physiol 111: 1575 1583, 2011. First published July 14, 2011; doi:10.1152/japplphysiol.00348.2011. Type I collagen (COL I) and matrix metalloproteinase 1 (MMP 1) are the predominant matrix proteins in the extracellular matrix of the human periodontal ligament (PDL). The expression of these proteins in PDL fibroblasts (PLF) is sensitive to physiological and mechanical stress and is critical for PDL remodeling accompanied by alveolar bone remodeling. This study examined how dose tensile force regulates the expression of COL I and MMP 1 and explored the possible roles of mitogen activated protein kinases (MAPKs) and transcription factors, such as activator protein 1 (AP 1) and nuclear factor kappa B (NF kappa B). Tensile force stimulated the mRNA expression of COL I and MMP 1 in the cells and also activated MAPKs including extracellular signal regulated kinase (ERK), c Jun NH2 terminal kinase (JNK), and p38 MAPK. A pharmacological inhibitor of ERK or JNK prevented the expression of matrix genes and the nuclear translocation of c Jun proteins in the force applied PLF. The knockdown of c Jun by transfecting the cells with its antisense oligonucleotides reduced the force induced increase in matrix gene expression. In particular, the ERK inhibitor but not JNK or p38 MAPK inhibitor attenuated the force mediated stimulation of NF kappa B DNA binding and MMP 1 expression. Overall, these results highlight the mechanotransduction pathways involved in matrix gene expression in PLF, where the tension stimulated expression of COL I and MMP 1 is controlled by the ERK/JNK AP 1 and ERK NF kappa B signaling pathways.
C1 [Lee, Jeong Chae] Chonbuk Natl Univ, Inst Oral Biosci, Jeonju 561756, South Korea.
   [Lee, Jeong Chae] Chonbuk Natl Univ, Sch Dent, Program BK21, Jeonju 561756, South Korea.
   [Jang, Yong Suk; Lee, Jeong Chae] Chonbuk Natl Univ, Res Ctr Bioact Mat, Jeonju 561756, South Korea.
   [Kook, Sung Ho] Univ Pittsburgh, Dept Med, Div Hematol & Oncol, Inst Canc, Pittsburgh, PA USA.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh
RP Lee, JC (通讯作者)，Chonbuk Natl Univ, Inst Oral Biosci, Jeonju 561756, South Korea.
EM leejc88@jbnu.ac.kr
FU National Research Foundation, Republic of Korea [2009 0084511]
FX This work was supported by the grant of Mid Career Research Program from
   National Research Foundation, Republic of Korea (Grant No.
   2009 0084511).
CR Agarwal S, 2003, FASEB J, V17, P899, DOI 10.1096/fj.02 0901fje
   Bartold PM, 2006, PERIODONTOL 2000, V40, P29, DOI 10.1111/j.1600 0757.2005.00140.x
   Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600 0757.1997.tb00094.x
   BERKOVITZ BKB, 1990, EUR J ORTHODONT, V12, P51, DOI 10.1093/ejo/12.1.51
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Bolcato Bellemin AL, 2000, J DENT RES, V79, P1712, DOI 10.1177/00220345000790091201
   BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Bumann A, 1997, EUR J ORTHODONT, V19, P29, DOI 10.1093/ejo/19.1.29
   Chambard JC, 2007, BBA MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010
   Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p
   Colombo A, 2008, P I MECH ENG H, V222, P1235, DOI 10.1243/09544119JEIM428
   Cortez DM, 2007, AM J PHYSIOL HEART C, V293, pH3356, DOI 10.1152/ajpheart.00928.2007
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   Domon S, 2001, EUR J ORTHODONT, V23, P339, DOI 10.1093/ejo/23.4.339
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Garlet TP, 2007, EUR J ORAL SCI, V115, P355, DOI 10.1111/j.1600 0722.2007.00469.x
   He YL, 2004, CONNECT TISSUE RES, V45, P28, DOI 10.1080/03008200490278124
   Hipskind R.A., 1998, FRONT BIOSCI, V3, P804, DOI [10.2741/A323, DOI 10.2741/A323]
   Hong SY, 2010, MOL CELL BIOCHEM, V335, P263, DOI 10.1007/s11010 009 0276 1
   Howard PS, 1998, J PERIODONTAL RES, V33, P500
   Hsieh HL, 2006, J CELL PHYSIOL, V206, P246, DOI 10.1002/jcp.20457
   Huh S, 2007, BIOTECHNOL APPL BIOC, V47, P27, DOI 10.1042/BA20060122
   Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01 0354fje
   Jeon YM, 2009, MOL CELL BIOCHEM, V320, P45, DOI 10.1007/s11010 008 9897 z
   Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955 0674(97)80068 3
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052
   Kletsas D, 1998, FEBS LETT, V430, P358, DOI 10.1016/S0014 5793(98)00695 4
   KOOK SH, 2011, J CELL PHYSL    0512
   Kook SH, 2009, J CELL BIOCHEM, V106, P1060, DOI 10.1002/jcb.22085
   Lee JC, 2003, EXP CELL RES, V291, P386, DOI 10.1016/S0014 4827(03)00410 5
   Lekic P, 1996, ANAT REC, V245, P327
   LI C, 2000, ARTERIOSCLER THROMB, V20, P1
   Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273
   Liedert A, 2006, BIOCHEM BIOPH RES CO, V349, P1, DOI 10.1016/j.bbrc.2006.07.214
   Liu J, 2007, CELL BIOL INT, V31, P1220, DOI 10.1016/j.cellbi.2007.04.005
   Long P, 2002, BONE, V30, P547, DOI 10.1016/S8756 3282(02)00673 7
   Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229
   NAKAGAWA M, 1994, ARCH ORAL BIOL, V39, P289, DOI 10.1016/0003 9969(94)90119 8
   Ning QM, 2007, RESPIROLOGY, V12, P792, DOI 10.1111/j.1440 1843.2007.01166.x
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898 6568(99)00071 6
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Redlich M, 2004, J PERIODONTAL RES, V39, P27, DOI 10.1111/j.1600 0765.2004.00700.x
   Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502 e131
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026
   SODEK J, 1979, J BIOL CHEM, V254, P496
   Takano M, 2009, ORTHOD CRANIOFAC RES, V12, P282, DOI 10.1111/j.1601 6343.2009.01463.x
   Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599
   Urakami S, 1997, BIOCHEM BIOPH RES CO, V241, P24, DOI 10.1006/bbrc.1997.7731
   Von Böhl M, 2004, ANGLE ORTHOD, V74, P16
   Von den Hoff JW, 2003, J PERIODONTAL RES, V38, P449, DOI 10.1034/j.1600 0765.2003.00404.x
   Wang JHC, 2003, J BIOMECH, V36, P97, DOI 10.1016/S0021 9290(02)00233 6
   Wei FL, 2008, ARCH ORAL BIOL, V53, P35, DOI 10.1016/j.archoralbio.2007.07.008
   Wescott DC, 2007, J DENT RES, V86, P1212, DOI 10.1177/154405910708601214
   Whitmarsh AJ, 1996, J MOL MED JMM, V74, P589, DOI 10.1007/s001090050063
   Wu CC, 2006, J CELL BIOCHEM, V98, P632, DOI 10.1002/jcb.20697
   YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972
   Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471 4914(02)00009 6
   Zampetaki A, 2005, AM J PHYSIOL HEART C, V288, pH2946, DOI 10.1152/ajpheart.00919.2004
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   ZHANG XL, 1993, J HISTOCHEM CYTOCHEM, V41, P245, DOI 10.1177/41.2.7678270
   Zhao YH, 2008, EUR J ORAL SCI, V116, P199, DOI 10.1111/j.1600 0722.2008.00533.x
   Zhou J, 2006, J PERIODONTAL RES, V41, P47, DOI 10.1111/j.1600.0765.2005.00835.x
NR 65
TC 72
Z9 81
U1 0
U2 16
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
EI 1522 1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD DEC
PY 2011
VL 111
IS 6
BP 1575
EP 1583
DI 10.1152/japplphysiol.00348.2011
PG 9
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 865YF
UT WOS:000298346100010
PM 21757573
DA 2025 08 17
ER

PT J
AU Cheng, MY
   Zhao, Y
   Cui, YZ
   Zhong, CF
   Zha, YG
   Li, SF
   Cao, GX
   Li, MA
   Zhang, L
   Ning, K
   Han, JX
AF Cheng, Mingyue
   Zhao, Yan
   Cui, Yazhou
   Zhong, Chaofang
   Zha, Yuguo
   Li, Shufeng
   Cao, Guangxiang
   Li, Mian
   Zhang, Lei
   Ning, Kang
   Han, Jinxiang
TI Stage specific roles of microbial dysbiosis and metabolic disorders in
   rheumatoid arthritis
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
DE rheumatoid arthritis; osteoarthritis; rheumatoid factor; synovial fluid
ID L ARGININE; BONE LOSS; AUTOIMMUNITY; SULFATE; ACID
AB Objective Rheumatoid arthritis (RA) is a progressive disease including four stages, where gut microbiome is associated with pathogenesis. We aimed to investigate stage specific roles of microbial dysbiosis and metabolic disorders in RA. Methods We investigated stage based profiles of faecal metagenome and plasma metabolome of 76 individuals with RA grouped into four stages (stages I IV) according to 2010 RA classification criteria, 19 individuals with osteroarthritis and 27 healthy individuals. To verify bacterial invasion of joint synovial fluid, 16S rRNA gene sequencing, bacterial isolation and scanning electron microscopy were conducted on another validation cohort of 271 patients from four RA stages. Results First, depletion of Bacteroides uniformis and Bacteroides plebeius weakened glycosaminoglycan metabolism (p<0.001), continuously hurting articular cartilage across four stages. Second, elevation of Escherichia coli enhanced arginine succinyltransferase pathway in the stage II and stage III (p<0.001), which was correlated with the increase of the rheumatoid factor (p=1.35x10( 3)) and could induce bone loss. Third, abnormally high levels of methoxyacetic acid (p=1.28x10( 8)) and cysteine S sulfate (p=4.66x10( 12)) inhibited osteoblasts in the stage II and enhanced osteoclasts in the stage III, respectively, promoting bone erosion. Fourth, continuous increase of gut permeability may induce gut microbial invasion of the joint synovial fluid in the stage IV. Conclusions Clinical microbial intervention should consider the RA stage, where microbial dysbiosis and metabolic disorders present distinct patterns and played stage specific roles. Our work provides a new insight in understanding gut joint axis from a perspective of stages, which opens up new avenues for RA prognosis and therapy.
C1 [Cheng, Mingyue; Zhao, Yan; Cui, Yazhou; Li, Shufeng; Cao, Guangxiang; Li, Mian; Ning, Kang; Han, Jinxiang] Shandong First Med Univ & Shandong Acad Med Sci, Affiliated Hosp 1, Biomed Sci Coll, Inst Med Genom,Shandong First Med Univ, Jinan, Shandong, Peoples R China.
   [Cheng, Mingyue; Zhao, Yan; Cui, Yazhou; Li, Shufeng; Cao, Guangxiang; Li, Mian; Ning, Kang; Han, Jinxiang] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Acad Med Sci, Shandong Med Biotechnol Ctr, NHC Key Lab Biotechnol Drugs,Key Lab Rare & Uncom, Jinan, Shandong, Peoples R China.
   [Cheng, Mingyue; Zhong, Chaofang; Zha, Yuguo; Ning, Kang] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Ctr AI Biol,Minist Educ,Hubei Key Lab Bioinformat, Dept Bioinformat & Syst Biol,Key Lab Mol Biophys, Wuhan, Hubei, Peoples R China.
   [Zhang, Lei] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Microbiome X,Natl Inst Hlth Data Sci China, Jinan, Shandong, Peoples R China.
   [Zhang, Lei] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Inst Med Dataol,Dept Biostat, Jinan, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; University of Jinan; Shandong First Medical University &
   Shandong Academy of Medical Sciences; Huazhong University of Science &
   Technology; Shandong University; Shandong University
RP Han, JX (通讯作者)，Shandong First Med Univ & Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.; Ning, K (通讯作者)，Huazhong Univ Sci & Technol, Wuhan, Hubei, Peoples R China.; Zhang, L (通讯作者)，Shandong Univ, Jinan, Shandong, Peoples R China.
EM zhanglei7@sdu.edu.cn; ningkang@hust.edu.cn; jxhan@sdfmu.edu.cn
RI Zhang, Zhonghua/HDO 2400 2022; Ning, Kang/ABD 3446 2020; Cheng,
   Mingyue/JGM 3703 2023; cao, Guangxiang/GWC 4414 2022
OI Ning, Kang/0000 0003 3325 5387; Cheng, Mingyue/0000 0003 1243 5039; 
FU National Natural Science Foundation of China [31871334, 82003766,
   32071465, 31671374]; Academic Promotion Programme of Shandong First
   Medical University [2019LJ001]; Key Research and Development project of
   Shandong Province [2021ZDSYS27]
FX This work was partially funded by the National Natural Science
   Foundation of China (grant numbers 31871334, 82003766, 32071465, and
   31671374), the Academic Promotion Programme of Shandong First Medical
   University (grant number 2019LJ001) and the Key Research and Development
   project of Shandong Province (grant number 2021ZDSYS27).
CR Abdelkarem Hala M., 2018, Journal of Dietary Supplements, V15, P300, DOI 10.1080/19390211.2017.1343889
   ABRAMS E, 1964, ANN RHEUM DIS, V23, P295, DOI 10.1136/ard.23.4.295
   Almutairi K, 2021, RHEUMATOL INT, V41, P863, DOI 10.1007/s00296 020 04731 0
   Balakrishnan B, 2019, MIL MED, V184, P529, DOI 10.1093/milmed/usy309
   Barhum L., 2021, WHAT DOES RHEUMATOID
   BROWN NA, 1984, TOXICOL LETT, V22, P93, DOI 10.1016/0378 4274(84)90051 1
   Carr AC, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111211
   Chen J, 2016, GENOME MED, V8, DOI 10.1186/s13073 016 0299 7
   de La Cuesta Zuluag J, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00261 19
   Fiore CE, 2000, EUR J PHARMACOL, V408, P323, DOI 10.1016/S0014 2999(00)00800 1
   Henrotin Y, 2010, THER ADV MUSCULOSKEL, V2, P335, DOI 10.1177/1759720X10383076
   Jura Póltorak A, 2014, CLIN CHIM ACTA, V433, P20, DOI 10.1016/j.cca.2014.02.027
   KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
   Li PS, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10478
   Lugli GA, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111720
   Maeda Y, 2017, J CLIN MED, V6, DOI 10.3390/jcm6060060
   Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507
   Marriott D, 2007, J CLIN MICROBIOL, V45, P672, DOI 10.1128/JCM.01633 06
   Miller R R, 1982, Fundam Appl Toxicol, V2, P158, DOI 10.1016/S0272 0590(82)80039 0
   Pianta A, 2017, ARTHRITIS RHEUMATOL, V69, P964, DOI 10.1002/art.40003
   Scher JU, 2013, ELIFE, V2, DOI 10.7554/eLife.01202
   Schwartz DJ, 2020, GENOME MED, V12, DOI 10.1186/s13073 020 00782 x
   Severmann AC, 2020, OSTEOARTHR CARTILAGE, V28, P977, DOI 10.1016/j.joca.2020.04.002
   Shamdani S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02352 3
   Silvestre Rangil J, 2016, CLIN ORAL INVEST, V20, P2575, DOI 10.1007/s00784 016 1745 z
   Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Sparks NR., 2018, EMBRYOTOXIC EFFECTS, P73
   STEINBROCKER O, 1949, JAMA J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001
   Tito RY, 2017, ARTHRITIS RHEUMATOL, V69, P114, DOI 10.1002/art.39802
   Vieira SM, 2018, SCIENCE, V359, P1156, DOI 10.1126/science.aar7201
   Zaiss MM, 2021, NAT REV RHEUMATOL, V17, P224, DOI 10.1038/s41584 021 00585 3
   Zhao Y, 2022, GUT, V71, P1041, DOI 10.1136/gutjnl 2021 325209
NR 33
TC 75
Z9 77
U1 6
U2 58
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD DEC
PY 2022
VL 81
IS 12
BP 1669
EP 1677
DI 10.1136/ard 2022 222871
EA AUG 2022
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 6M4EU
UT WOS:000842980000001
PM 35985811
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Yan, JL
   Zhou, J
   Ma, HP
   Ma, XN
   Gao, YH
   Shi, WG
   Fang, QQ
   Ren, Q
   Xian, CJ
   Chen, KM
AF Yan, Juan Li
   Zhou, Jian
   Ma, Hui Ping
   Ma, Xiao Ni
   Gao, Yu Hai
   Shi, Wen Gui
   Fang, Qing Qing
   Ren, Qian
   Xian, Cory J.
   Chen, Ke Ming
TI Pulsed electromagnetic fields promote osteoblast mineralization and
   maturation needing the existence of primary cilia
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Pulsed electromagnetic fields; Primary cilia; RNA interference;
   Osteoblasts; Differentiation; Mineralization
ID OSTEOGENIC DIFFERENTIATION; PROLIFERATION; STIMULATION; CELLS;
   TRANSDUCTION; CALCIUM; PATHWAY
AB Although pulsed electromagnetic fields (PEMFs) have been approved as a therapy for osteoporosis, action mechanisms and optimal parameters are elusive. To determine the optimal intensity, exposure effects of 50 Hz PEMPs of 0.6 3.6 mT (0.6 interval at 90 min/day) were investigated on proliferation and osteogenic differentiation of cultured calvarial osteoblasts. All intensity groups stimulated proliferation significantly with the highest effect at 0.6 mT. The 0.6 mT group also obtained the optimal osteogenic effect as demonstrated by the highest ALP activity, ALP(+) CPU f colony formation, nodule mineralization, and expression of COL 1 and BMP 2. To verify our hypothesis that the primary cilia are the cellular sensors for PEMFs, osteoblasts were also transfected with IFT88 siRNA or scrambled control, and osteogenesis promoting effects of 0.6 mT PEMFs were found abrogated when primary cilia were inhibited by IFT88 siRNA. Thus primary cilia of osteoblasts play an indispensable role in mediating PEMF osteogenic effect in vitro. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Yan, Juan Li; Zhou, Jian; Ma, Xiao Ni; Gao, Yu Hai; Shi, Wen Gui; Fang, Qing Qing; Ren, Qian; Chen, Ke Ming] Lanzhou Command CPLA, Lanzhou Gen Hosp, Inst Orthopaed, Lanzhou 730050, Peoples R China.
   [Ma, Hui Ping] Lanzhou Command CPLA, Lanzhou Gen Hosp, Dept Pharm, Lanzhou 730050, Peoples R China.
   [Xian, Cory J.] Univ S Australia, Sch Pharm & Med Sci, Sansom Inst Hlth Res, Adelaide, SA 5001, Australia.
C3 University of South Australia
RP Chen, KM (通讯作者)，Lanzhou Command CPLA, Lanzhou Gen Hosp, Inst Orthopaed, Lanzhou 730050, Peoples R China.
EM chenkm@lut.cn
RI fang, qingqing/GZK 4330 2022; Gao, Yuhai/AHB 5767 2022; Xian,
   Cory/D 2646 2009
OI Xian, Cory/0000 0002 8467 2845
FU National Natural Sciences Foundation of China [81270963, 81471090]
FX This work was supported by the National Natural Sciences Foundation of
   China (No. 81270963 and No. 81471090).
CR Aaron RK, 1996, J ORTHOP RES, V14, P582, DOI 10.1002/jor.1100140412
   Bodle JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062554
   Boyle P, 2001, J Epidemiol Biostat, V6, P185, DOI 10.1080/135952201753172944
   Ceccarelli G, 2013, BIORESEARCH OPEN ACC, V2, P283, DOI 10.1089/biores.2013.0016
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   Cheng GZ, 2011, NITRIC OXIDE BIOL CH, V25, P316, DOI 10.1016/j.niox.2011.05.009
   Clement CA, 2009, METHOD CELL BIOL, V94, P181, DOI 10.1016/S0091 679X(08)94009 7
   Delaine Smith RM, 2014, FASEB J, V28, P430, DOI 10.1096/fj.13 231894
   Diniz P, 2002, NITRIC OXIDE BIOL CH, V7, P18, DOI 10.1016/S1089 8603(02)00004 6
   FEDERMAN M, 1974, CALC TISS RES, V17, P81, DOI 10.1007/BF02547216
   FITZSIMMONS RJ, 1994, CLIN PLAST SURG, V21, P401
   FITZSIMMONS RJ, 1992, J CELL PHYSIOL, V150, P84, DOI 10.1002/jcp.1041500112
   Fitzsimmons RJ, 2008, J ORTHOP RES, V26, P854, DOI 10.1002/jor.20590
   Funk RHW, 2009, PROG HISTOCHEM CYTO, V43, P177, DOI 10.1016/j.proghi.2008.07.001
   Garland D E, 1999, J Spinal Cord Med, V22, P239
   Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774
   HOJEVIK P, 1995, BIOELECTROMAGNETICS, V16, P33, DOI 10.1002/bem.2250160109
   Huang HD, 2004, AM J PHYSIOL CELL PH, V287, pC1, DOI 10.1152/ajpcell.00559.2003
   Huber C, 2012, AM J MED GENET C, V160C, P165, DOI 10.1002/ajmg.c.31336
   Jing D., 2013, PLOS ONE, V11
   Jing D, 2010, BONE, V46, P487, DOI 10.1016/j.bone.2009.09.021
   Johnson JLF, 2010, TRENDS CELL BIOL, V20, P435, DOI 10.1016/j.tcb.2010.05.005
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kindzelskii AL, 2005, EUR BIOPHYS J BIOPHY, V35, P1, DOI 10.1007/s00249 005 0001 2
   Li K, 2011, PROG ELECTROMAGN RES, V112, P139, DOI 10.2528/PIER10110203
   Li KC, 2014, ARCH ORAL BIOL, V59, P921, DOI 10.1016/j.archoralbio.2014.05.015
   Lin HY, 2011, BIOELECTROMAGNETICS, V32, P552, DOI 10.1002/bem.20668
   Liu CX, 2013, BIOELECTROMAGNETICS, V34, P453, DOI 10.1002/bem.21791
   Ma HP, 2011, J CELL BIOCHEM, V112, P916, DOI 10.1002/jcb.23007
   Mahjoub MR, 2013, ORGANOGENESIS, V9, P61, DOI 10.4161/org.25144
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Markov M.S., 2005, Environmentalist, V25, P67, DOI [10.1007/s10669 005 4268 8, DOI 10.1007/S10669 005 4268 8]
   Markov MS, 2007, ELECTROMAGN BIOL MED, V26, P1, DOI 10.1080/15368370600925342
   Martin L. P., 2013, J CELL MOL MED, V17, P958, DOI DOI 10.1111/jcmm.12088
   Morgado Valle C, 1998, CELL TISSUE RES, V291, P217, DOI 10.1007/s004410050992
   Nauli SM, 2013, METHOD ENZYMOL, V525, P1, DOI 10.1016/B978 0 12 397944 5.00001 8
   Piacentini R, 2008, J CELL PHYSIOL, V215, P129, DOI 10.1002/jcp.21293
   Pilla A, 2011, BBA GEN SUBJECTS, V1810, P1236, DOI 10.1016/j.bbagen.2011.10.001
   Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534
   Song MY, 2014, CELL BIOCHEM BIOPHYS, V69, P47, DOI 10.1007/s12013 013 9764 8
   Sul AR, 2006, YONSEI MED J, V47, P852, DOI 10.3349/ymj.2006.47.6.852
   Sun LY, 2009, BIOELECTROMAGNETICS, V30, P251, DOI 10.1002/bem.20472
   Tabrah FL, 1998, BIOELECTROMAGNETICS, V19, P75, DOI 10.1002/(SICI)1521 186X(1998)19:2<75::AID BEM3>3.0.CO;2 0
   Veland IR, 2009, NEPHRON PHYSIOL, V111, P39, DOI 10.1159/000208212
   Xu J, 2009, OSTEOARTHR CARTILAGE, V17, P397, DOI 10.1016/j.joca.2008.07.001
   Zhang XJ, 2007, ELECTROMAGN BIOL MED, V26, P167, DOI 10.1080/15368370701580756
   Zhang X, 2010, BIOCHEM BIOPH RES CO, V396, P662, DOI 10.1016/j.bbrc.2010.04.154
   Zhou J, 2014, BIOELECTROMAGNETICS, V35, P30, DOI 10.1002/bem.21794
   Zhou J, 2011, BONE, V49, P753, DOI 10.1016/j.bone.2011.06.026
   Zhou J, 2012, ARCH MED RES, V43, P274, DOI 10.1016/j.arcmed.2012.06.002
NR 50
TC 53
Z9 74
U1 0
U2 36
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303 7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD MAR 15
PY 2015
VL 404
IS C
BP 132
EP 140
DI 10.1016/j.mce.2015.01.031
PG 9
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA CE2KY
UT WOS:000351645700015
PM 25661534
DA 2025 08 17
ER

PT J
AU Yu, H
   Liu, Y
   Yang, XW
   He, JJ
   Zhang, F
   Zhong, Q
   Guo, XJ
AF Yu, Hao
   Liu, Yan
   Yang, Xiangwen
   He, Jiajing
   Zhang, Fan
   Zhong, Qun
   Guo, Xiaojing
TI Strontium ranelate promotes chondrogenesis through inhibition of the
   Wnt/β catenin pathway
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Strontium ranelate; BMSCs; Chondrogenesis; Cartilage regeneration;
   Wnt/beta catenin pathway
ID MESENCHYMAL STEM CELLS; CARTILAGE REPAIR; BONE; OSTEOARTHRITIS; WNT;
   DIFFERENTIATION; OSTEOBLAST; DISEASE
AB Background: Cartilage regeneration is a key step in functional reconstruction for temporomandibular joint osteoarthritis (TMJ OA) but is a difficult issue to address. Strontium ranelate (SrR) is an antiosteoporosis drug that has been proven to affect OA in recent years, but its effect on chondrogenesis and the underlying mechanism are still unclear.
   Methods: Bone mesenchymal stem cells (BMSCs) from Sprague Dawley (SD) rats were induced in chondrogenic differentiation medium with or without SrR, XAV 939, and LiCl. CCK 8 assays were used to examine cell proliferation, and alcian blue staining, toluidine blue staining, immunofluorescence, and PCR analysis were performed. Western blot (WB) analyses were used to assess chondrogenic differentiation of the cells. For an in vivo study, 30 male SD rats with cartilage defects on both femoral condyles were used. The defect sites were not filled, filled with silica nanosphere plus gelatine methacryloyl (GelMA), or filled with SrR loaded silica nanosphere plus GelMA. After 3 months of healing, paraffin sections were made, and toluidine blue staining, safranin O/fast green staining, and immunofluorescent or immunohistochemical staining were performed for histological evaluation. The data were analyzed by SPSS 26.0 software.
   Results: Low concentrations of SrR did not inhibit cell proliferation, and the cells treated with SrR (0.25 mmol/L) showed stronger chondrogenesis than the control. XAV 939, an inhibitor of beta catenin, significantly promoted chondrogenesis, and SrR did not suppress this effect, while LiCl, an agonist of beta catenin, strongly suppressed chondrogenesis, and SrR reversed this inhibitory effect. In vivo study showed a significantly better cartilage regeneration and a lower activation level of beta catenin by SrR loaded GelMA than the other treatments.
   Conclusion: SrR could promote BMSCs chondrogenic differentiation by inhibiting the Wnt/beta catenin signaling pathway and accelerate cartilage regeneration in rat femoral condyle defects.
C1 [Yu, Hao; Liu, Yan; Yang, Xiangwen; He, Jiajing; Zhong, Qun; Guo, Xiaojing] Fudan Univ, Shanghai Stomatol Hosp, Dept Prosthodont, Shanghai 200001, Peoples R China.
   [Yu, Hao; Liu, Yan; Yang, Xiangwen; He, Jiajing; Zhang, Fan; Zhong, Qun; Guo, Xiaojing] Fudan Univ, Shanghai Key Lab Craniomaxillofacial Dev & Dis, Shanghai 200001, Peoples R China.
   [Zhang, Fan] Fudan Univ, Shanghai Stomatol Hosp, Dept Orthodont, Shanghai 200001, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Guo, XJ (通讯作者)，Fudan Univ, Shanghai Stomatol Hosp, Dept Prosthodont, Shanghai 200001, Peoples R China.; Guo, XJ (通讯作者)，Fudan Univ, Shanghai Key Lab Craniomaxillofacial Dev & Dis, Shanghai 200001, Peoples R China.
EM guo_xiaojing@fudan.edu.cn
FU Shanghai Commission of Science and Technology [19YF1442400]
FX The authors thank the core facilities of Shanghai Key Laboratory of
   Craniomaxillofacial Development and Diseases, Fudan University, and
   Shanghai Research Centre of Model Organisms (SRCMO) for assistances and
   executing all of the experiments. The authors also acknowledge the
   financial supports from the Shanghai Commission of Science and
   Technology (19YF1442400).
CR Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   Alexandersen P, 2007, BONE, V40, P218, DOI 10.1016/j.bone.2006.07.028
   Bergholt NL, 2019, CARTILAGE, V10, P370, DOI 10.1177/1947603518764262
   Bernhardt O, 2007, ANN ANAT, V189, P342, DOI 10.1016/j.aanat.2007.02.008
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Chen L, 2019, WIRES COMPUT STAT, V11
   Clément Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Fang M, 2014, ARTERIOSCL THROM VAS, V34, P2601, DOI 10.1161/ATVBAHA.114.304579
   Fromigué O, 2010, J BIOL CHEM, V285, P25251, DOI 10.1074/jbc.M110.110502
   Guo XJ, 2016, INT J BIOL SCI, V12, P1511, DOI 10.7150/ijbs.16499
   Han WY, 2017, EXPERT OPIN INV DRUG, V26, P375, DOI 10.1080/13543784.2017.1283403
   Henrotin Y, 2001, J BONE MINER RES, V16, P299, DOI 10.1359/jbmr.2001.16.2.299
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Im GI, 2010, TISSUE ENG PT A, V16, P2405, DOI [10.1089/ten.tea.2009.0359, 10.1089/ten.TEA.2009.0359]
   Irani S, 2020, POLYM ADVAN TECHNOL, V31, P1395, DOI 10.1002/pat.4869
   Lories RJ, 2013, NAT REV RHEUMATOL, V9, P328, DOI 10.1038/nrrheum.2013.25
   Luo SM, 2013, BIOMED PHARMACOTHER, V67, P819, DOI 10.1016/j.biopha.2013.03.008
   Mainil Varlet P, 2010, AM J SPORT MED, V38, P880, DOI 10.1177/0363546509359068
   Marie PJ, 2011, OSTEOPOROSIS INT, V22, P1659, DOI 10.1007/s00198 010 1369 0
   Monteagudo S, 2017, NAT REV RHEUMATOL, V13, P670, DOI 10.1038/nrrheum.2017.171
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Pelletier JP, 2015, ANN RHEUM DIS, V74, P422, DOI 10.1136/annrheumdis 2013 203989
   Pelletier JP, 2013, ANN RHEUM DIS, V72, P250, DOI 10.1136/annrheumdis 2012 201710
   Qiao YS, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901239
   Reginster JY, 2013, ANN RHEUM DIS, V72, P179, DOI 10.1136/annrheumdis 2012 202231
   REINHOLT FP, 1985, COLLAGEN REL RES, V5, P41
   Rodrigues TA, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20187440, 10.1590/1414 431x20187440]
   Roseti L, 2019, CELLS BASEL, V8, DOI 10.3390/cells8111305
   Shoukri B, 2019, J DENT RES, V98, P1103, DOI 10.1177/0022034519865187
   Solchaga LA, 2011, METHODS MOL BIOL, V698, P253, DOI 10.1007/978 1 60761 999 4_20
   Tat SK, 2011, BONE, V49, P559, DOI 10.1016/j.bone.2011.06.005
   Tenti S, 2014, MOD RHEUMATOL, V24, P881, DOI 10.3109/14397595.2014.888156
   Wang XD, 2015, J DENT RES, V94, P666, DOI 10.1177/0022034515574770
   Wang ZF, 2019, MATER HORIZONS, V6, P733, DOI [10.1039/C8MH01208C, 10.1039/c8mh01208c]
   Yu DG, 2013, ACTA PHARMACOL SIN, V34, P393, DOI 10.1038/aps.2012.167
   Yue K, 2015, BIOMATERIALS, V73, P254, DOI 10.1016/j.biomaterials.2015.08.045
   Zhang SP, 2015, STEM CELL REV REP, V11, P728, DOI 10.1007/s12015 015 9604 x
   Zhang Y, 2019, NANOSCALE, V11, P6315, DOI 10.1039/c8nr09818b
NR 43
TC 43
Z9 49
U1 3
U2 52
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAY 20
PY 2021
VL 12
IS 1
AR 296
DI 10.1186/s13287 021 02372 z
PG 14
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA SM7JA
UT WOS:000657775700004
PM 34016181
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Tsai, MT
   Lin, DJ
   Huang, S
   Lin, HT
   Chang, W
AF Tsai, Ming Tzu
   Lin, Dan Jae
   Huang, Sherry
   Lin, Hsiu Ting
   Chang, Walter H.
TI Osteogenic differentiation is synergistically influenced by
   osteoinductive treatment and direct cell cell contact between murine
   osteoblasts and mesenchymal stem cells
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
ID PROGENITOR CELLS; ENDOTHELIAL CELLS; BONE FORMATION; IN VITRO;
   COCULTURE; MECHANISM; DEFECTS; SYSTEM; GROWTH; WNT
AB The present study was designed to address whether osteoblasts play a synergistic role in promoting mesenchymal stem cell (MSC) osteogenesis in a direct cell cell contact co culture model.
   Murine C3H10T1/2 and MC3T3 E1 cell lines were mixed and plated onto 12 well culture plates and co cultured at various ratios of initial cell densities. To compare the possible improvement on osteogenic differentiation, co culture cells were served with or without osteogenic supplements in culture medium.
   Weak osteogenesis was induced in MSCs co cultured in an untreated medium with different ratios of osteoblasts. An osteoblast dependent increase in osteogenic gene expression of Runx2, type I collagen, and osteocalcin was observed over time. Moreover, both alkaline phosphatase (ALP) activity and calcium deposition were distinctly enhanced at levels that were proportional to the quantity of osteoblasts in the culture. The increases in mRNA expression and ALP activity were greater in co cultures treated with osteogenic supplements than in untreated cultures. However, the production of ALP activity followed by a distinct matrix mineralization was lower in osteogenic treated cultures containing greater numbers of osteoblasts. This suggests that a higher density of osteoblasts may lead to weak osteogenesis of MSCs by direct cell cell contact co culture in an untreated environment. Furthermore, additional osteogenic supplements may act synergistically with osteoblasts to accelerate matrix mineralization by reducing the process of osteogenic differentiation in osteogenic treated co cultures.
   The present work may improve the understanding of MSC osteogenesis and may provide benefits for regenerative medicine.
C1 [Huang, Sherry; Lin, Hsiu Ting; Chang, Walter H.] Chung Yuan Christian Univ, Dept Biomed Engn, Chungli 32023, Taoyuan, Taiwan.
   [Lin, Dan Jae] China Med Univ & Hosp, Dept Dent Hyg, Taichung 40402, Taiwan.
   [Tsai, Ming Tzu] Hungkuang Univ, Dept Biomed Engn, Taichung 43302, Taiwan.
C3 Chung Yuan Christian University; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; Hungkuang University
RP Chang, W (通讯作者)，Chung Yuan Christian Univ, Dept Biomed Engn, 200 Chung Pei Rd, Chungli 32023, Taoyuan, Taiwan.
EM whchang@cycu.edu.tw
RI ; Tsai, Annie/GSM 9284 2022; Chang, Wen Hao/C 4906 2013; Lin,
   Dan Jae/D 6901 2013
OI /0000 0003 3636 5506; Chang, Wen Hao/0000 0003 4880 6006; Lin,
   Dan Jae/0000 0001 8967 7090
FU National Science Council, Taiwan, R.O.C. [NSC 98 2627 B 033 001]
FX This work was supported by grants from the National Science Council,
   Taiwan, R.O.C. (NSC 98 2627 B 033 001). The authors also thank Prof. Yeu
   Su (National Yang Ming University, Taipei, Taiwan) for generously
   providing the C3H10T1/2 cell line as a gift.
CR Ahn SE, 2006, BIOCHEM BIOPH RES CO, V340, P403, DOI 10.1016/j.bbrc.2005.12.020
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Ball SG, 2004, INT J BIOCHEM CELL B, V36, P714, DOI 10.1016/j.biocel.2003.10.015
   Borovecki F, 2007, INT ORTHOP, V31, P799, DOI 10.1007/s00264 007 0408 8
   Chen KY, 2009, J MED BIOL ENG, V29, P284
   Csaki C, 2009, HISTOCHEM CELL BIOL, V131, P251, DOI 10.1007/s00418 008 0524 6
   Gerstenfeld LC, 2002, J BONE MINER RES, V17, P221, DOI 10.1359/jbmr.2002.17.2.221
   Hao W, 2010, INT ORTHOP, V34, P1341, DOI 10.1007/s00264 009 0946 3
   Heino TJ, 2004, EXP CELL RES, V294, P458, DOI 10.1016/j.yexcr.2003.11.016
   Ilmer M, 2009, TISSUE ENG PT A, V15, P2397, DOI 10.1089/ten.tea.2008.0427
   Jung Y, 2005, CYTOKINE, V32, P155, DOI 10.1016/j.cyto.2005.09.001
   Jung YG, 2008, STEM CELLS, V26, P2042, DOI 10.1634/stemcells.2008 0149
   Kim H, 2003, YONSEI MED J, V44, P187, DOI 10.3349/ymj.2003.44.2.187
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Ozturk AM, 2005, INT ORTHOP, V29, P73, DOI 10.1007/s00264 004 0623 5
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Stahl A, 2004, BIOCHEM BIOPH RES CO, V322, P684, DOI 10.1016/j.bbrc.2004.07.175
   Wang Y, 2007, J TISSUE ENG REGEN M, V1, P39, DOI 10.1002/term.6
   Watanabe T, 2010, J ORTHOP RES, V28, P623, DOI 10.1002/jor.21036
   Whu SW, 2009, J MED BIOL ENG, V29, P52
   Yu HY, 2008, J ORTHOP RES, V26, P1147, DOI 10.1002/jor.20609
   Zhang SM, 2009, CLIN EXP METASTAS, V26, P993, DOI 10.1007/s10585 009 9289 0
   Zhou H, 2008, J BIOL CHEM, V283, P1936, DOI 10.1074/jbc.M702687200
NR 24
TC 28
Z9 33
U1 0
U2 31
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341 2695
EI 1432 5195
J9 INT ORTHOP
JI Int. Orthop.
PD JAN
PY 2012
VL 36
IS 1
BP 199
EP 205
DI 10.1007/s00264 011 1259 x
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 873CC
UT WOS:000298857500030
PM 21567150
OA Green Published
DA 2025 08 17
ER

PT J
AU Rothe, R
   Schulze, S
   Neuber, C
   Hauser, S
   Rammelt, S
   Pietzsch, J
AF Rothe, Rebecca
   Schulze, Sabine
   Neuber, Christin
   Hauser, Sandra
   Rammelt, Stefan
   Pietzsch, Jens
TI Adjuvant drug assisted bone healing: Part II   Modulation of
   angiogenesis
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE Critical size bone defects; neovascularization; nitric oxide donors;
   signaling; small molecules; sphingosine 1 phosphate receptor
ID NITRIC OXIDE DONOR; ENDOTHELIAL GROWTH FACTOR; HYPOXIA INDUCIBLE
   FACTOR 1 ALPHA; MACROPHAGE RECRUITMENT AGENT; BIOACTIVE GLASS SCAFFOLDS;
   MESENCHYMAL STEM CELLS; LYSOPHOSPHATIDIC ACID; SPHINGOSINE 1 PHOSPHATE;
   OSTEOCLAST DIFFERENTIATION; LOCAL DELIVERY
AB The treatment of critical size bone defects following complicated fractures, infections or tumor resections is a major challenge. The same applies to fractures in patients with impaired bone healing due to systemic inflammatory and metabolic diseases. Despite considerable progress in development and establishment of new surgical techniques, design of bone graft substitutes and imaging techniques, these scenarios still represent unresolved clinical problems. However, the development of new active substances offers novel potential solutions for these issues. This work discusses therapeutic approaches that influence angiogenesis or hypoxic situations in healing bone and surrounding tissue. In particular, literature on sphingosine 1 phosphate receptor modulators and nitric oxide (NO center dot) donors, including bi functional (hybrid) compounds like NO center dot releasing cyclooxygenase 2 inhibitors, was critically reviewed with regard to their local and systemic mode of action.
C1 [Rothe, Rebecca; Neuber, Christin; Hauser, Sandra; Pietzsch, Jens] Helmholtz Zentrum Dresden Rossendorf, Dept Radiopharmaceut & Chem Biol, Inst Radiopharmaceut Canc Res, Bautzner Landstr 400, D 01328 Dresden, Germany.
   [Schulze, Sabine; Rammelt, Stefan] Univ Hosp Carl Gustav Carus, Univ Ctr Orthopaed & Traumatol OUC, Dresden, Germany.
   [Schulze, Sabine; Rammelt, Stefan] Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Schulze, Sabine; Rammelt, Stefan] Tech Univ Dresden, Fac Med, Dresden, Germany.
   [Rammelt, Stefan] CRTD, Tatzberg 4, Dresden, Germany.
   [Pietzsch, Jens] Tech Univ Dresden, Sch Sci, Fac Chem & Food Chem, Dresden, Germany.
C3 Helmholtz Association; Helmholtz Zentrum Dresden Rossendorf (HZDR);
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Technische Universitat Dresden; Technische Universitat Dresden;
   Technische Universitat Dresden
RP Pietzsch, J (通讯作者)，Helmholtz Zentrum Dresden Rossendorf, Dept Radiopharmaceut & Chem Biol, Inst Radiopharmaceut Canc Res, Bautzner Landstr 400, D 01328 Dresden, Germany.; Rammelt, S (通讯作者)，Univ Hosp Carl Gustav Carus, Univ Ctr Orthopaed & Traumatol, Fetscherstr 74, D 01307 Dresden, Germany.
EM stefan.rammelt@uniklinikum dresden.de; j.pietzsch@hzdr.de
RI Sabine, Sabine/AIF 3731 2022; Rammelt, Stefan/AAE 5863 2019; Pietzsch,
   Jens/O 5070 2017
OI Neuber, Christin/0000 0002 0646 5808; Rammelt,
   Stefan/0000 0003 1141 6493; Rothe, Rebecca/0000 0002 0615 1112;
   Pietzsch, Jens/0000 0002 1610 1493; Hauser, Sandra/0000 0001 8206 6000
FU Deutsche Forschungsgemeinschaft (DFG) within the Collaborative Research
   Center Transregio 67 "Functional Biomaterials for Controlling Healing
   Processes in Bone und Skin   From Material Science to Clinical
   Application" [CRC/TRR 67/3]; Helmholtz Association through the Helmholtz
   Cross Programme Initiative "Technology and Medicine   Adaptive Systems"
FX We wish to apologize to those researchers whose works have not been
   mentioned due to restrictions in space. The authors are thankful to the
   Deutsche Forschungsgemeinschaft (DFG) for supporting this work within
   the Collaborative Research Center Transregio 67 "Functional Biomaterials
   for Controlling Healing Processes in Bone und Skin   From Material
   Science to Clinical Application" (CRC/TRR 67/3). The authors also thank
   the Helmholtz Association for funding a part of this work through the
   Helmholtz Cross Programme Initiative "Technology and Medicine   Adaptive
   Systems".
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Alp HH, 2017, EXP BIOL MED, V242, P1051, DOI 10.1177/1535370217703352
   Amadeu TP, 2008, J SURG RES, V149, P84, DOI 10.1016/j.jss.2007.10.015
   Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200
   Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067
   Araldi E, 2010, BONE, V47, P190, DOI 10.1016/j.bone.2010.04.606
   Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   Arnett TR, 2010, ARCH BIOCHEM BIOPHYS, V503, P103, DOI 10.1016/j.abb.2010.07.021
   Aronin CEP, 2010, BIOMATERIALS, V31, P6417, DOI 10.1016/j.biomaterials.2010.04.061
   Aronin CEP, 2010, TISSUE ENG PT A, V16, P1801, DOI [10.1089/ten.tea.2009.0539, 10.1089/ten.TEA.2009.0539]
   Arthur A, 2013, J BONE MINER RES, V28, P926, DOI 10.1002/jbmr.1821
   Atalay Y, 2015, DRUG DES DEV THER, V9, P5195, DOI 10.2147/DDDT.S89669
   Awojoodu AO, 2013, P NATL ACAD SCI USA, V110, P13785, DOI 10.1073/pnas.1221309110
   Aydin K, 2011, EKLEM HAST CERRAHISI, V22, P160
   Baecker N, 2005, J BONE MINER RES, V20, P471, DOI 10.1359/JBMR.041121
   Baeumer Wolfgang, 2007, Inflammation & Allergy Drug Targets, V6, P17, DOI 10.2174/187152807780077318
   Baldik Y, 2005, BONE, V37, P32, DOI 10.1016/j.bone.2004.10.002
   Baldik Y, 2002, CLIN ORTHOP RELAT R, P343, DOI 10.1097/01.blo.0000022182.66847.8b
   Bandhuvula P, 2005, J BIOL CHEM, V280, P33697, DOI 10.1074/jbc.C500294200
   Beamer Brandon, 2010, HSS J, V6, P85, DOI 10.1007/s11420 009 9129 4
   Bechmann N, 2015, BIOORG MED CHEM LETT, V25, P3295, DOI 10.1016/j.bmcl.2015.05.059
   Beyer S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102913
   Bigaud M, 2014, BBA MOL CELL BIOL L, V1841, P745, DOI 10.1016/j.bbalip.2013.11.001
   Binder BYK, 2015, TISSUE ENG PART B RE, V21, P531, DOI [10.1089/ten.teb.2015.0107, 10.1089/ten.TEB.2015.0107]
   Blackburn J, 2012, BONE, V50, P756, DOI 10.1016/j.bone.2011.12.002
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Buca BR, 2018, MED SURG J, V122, P347
   Burke B, 2003, AM J PATHOL, V163, P1233, DOI 10.1016/S0002 9440(10)63483 9
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Chan MC, 2016, MOL ASPECTS MED, V47 48, P54, DOI 10.1016/j.mam.2016.01.001
   Chaparro O., 2016, Advanced Techniques in Bone Regeneration, P253, DOI [10.5772/61425, DOI 10.5772/61425]
   Chegaev K, 2007, J MED CHEM, V50, P1449, DOI 10.1021/jm0607247
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Cho EA, 2013, J CELL BIOCHEM, V114, P864, DOI 10.1002/jcb.24423
   Chu HH, 2012, THER DELIV, V3, P693, DOI 10.4155/TDE.12.50
   Coulet F, 2003, J BIOL CHEM, V278, P46230, DOI 10.1074/jbc.M305420200
   D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200
   Das A, 2015, BIOMATERIALS, V64, P98, DOI 10.1016/j.biomaterials.2015.06.019
   Das A, 2014, J BIOMED MATER RES A, V102, P1210, DOI 10.1002/jbm.a.34779
   Das A, 2013, BIOMATERIALS, V34, P9853, DOI 10.1016/j.biomaterials.2013.08.015
   David M, 2014, J BIOL CHEM, V289, P6551, DOI 10.1074/jbc.M113.533232
   David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741
   del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200
   Dincel YM, 2018, J ORTHOP SURG HONG K, V26, DOI 10.1177/2309499018777885
   Ding H, 2014, STEM CELLS DEV, V23, P990, DOI 10.1089/scd.2013.0486
   Dittmer KE, 2017, J VET DIAGN INVEST, V29, P385, DOI 10.1177/1040638716679861
   Diwan AD, 2000, J BONE MINER RES, V15, P342, DOI 10.1359/jbmr.2000.15.2.342
   Donneys A, 2012, PLAST RECONSTR SURG, V129, P850, DOI 10.1097/PRS.0b013e31824422f2
   Drager J, 2017, TISSUE ENG PT A, V23, P1372, DOI [10.1089/ten.tea.2016.0526, 10.1089/ten.TEA.2016.0526]
   Drager J, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.4
   During A, 2015, PROG LIPID RES, V59, P126, DOI 10.1016/j.plipres.2015.06.002
   Dyke HJ, 2002, EXPERT OPIN INV DRUG, V11, P1
   Fan LH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/239356
   Fong GH, 2009, J MOL MED JMM, V87, P549, DOI 10.1007/s00109 009 0458 z
   Fraisl P, 2009, NAT REV DRUG DISCOV, V8, P139, DOI 10.1038/nrd2761
   Frost MC, 2005, BIOMATERIALS, V26, P1685, DOI 10.1016/j.biomaterials.2004.06.006
   Gardell SE, 2006, TRENDS MOL MED, V12, P65, DOI 10.1016/j.molmed.2005.12.001
   Gennero I, 2011, BONE, V49, P395, DOI 10.1016/j.bone.2011.04.018
   Geusens P, 2009, EXPERT OPIN BIOL TH, V9, P649, DOI [10.1517/14712590902926071 , 10.1517/14712590902926071]
   Ghanbari H., 2016, Adv Tech Bone Regen, P3, DOI DOI 10.5772/63912
   Gong Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.510
   Grüneboom A, 2019, NAT METAB, V1, P236, DOI 10.1038/s42255 018 0016 5
   Gur S, 2012, CURR PHARM DESIGN, V18, P5590, DOI 10.2174/138161212803307554
   Haider HK, 2010, AM J PHYSIOL HEART C, V299, pH1395, DOI 10.1152/ajpheart.00437.2010
   Hankenson KD, 2014, INJURY, V45, pS8, DOI 10.1016/j.injury.2014.04.003
   Hankenson KD, 2011, INJURY, V42, P556, DOI 10.1016/j.injury.2011.03.035
   Hao YF, 2005, CLIN ORTHOP RELAT R, P226, DOI 10.1097/01.blo.0000153990.74837.73
   Hauser S, 2017, TRENDS BIOTECHNOL, V35, P265, DOI 10.1016/j.tibtech.2016.09.007
   Heilmann A, 2013, J ORTHOP RES, V31, P1845, DOI 10.1002/jor.22426
   Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003
   Histing T, 2011, J ORTHOP RES, V29, P867, DOI 10.1002/jor.21324
   Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hoogstraate Janet, 2003, Inflammopharmacology, V11, P423
   Horiuchi H, 2002, BONE, V30, P589, DOI 10.1016/S8756 3282(02)00681 6
   Horiuchi H, 2001, BONE, V28, P290, DOI 10.1016/S8756 3282(00)00450 6
   Hu K, 2016, BONE, V91, P30, DOI 10.1016/j.bone.2016.06.013
   Huang C, 2012, CELL TISSUE RES, V347, P553, DOI 10.1007/s00441 011 1217 3
   Huang J, 2015, MOL MED REP, V12, P5951, DOI 10.3892/mmr.2015.4122
   Hughes JE, 2008, CIRC RES, V102, P950, DOI 10.1161/CIRCRESAHA.107.170779
   Huyut Z, 2018, MED SCI MONIT BASIC, V24, P47, DOI 10.12659/MSMBR.908504
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Jamal SA, 2004, J BONE MINER RES, V19, P1512, DOI 10.1359/JBMR.040716
   Ji F, 2015, BIOCHEM BIOPH RES CO, V458, P568, DOI 10.1016/j.bbrc.2015.02.007
   Jiang B, 2011, REGENERATIVE MED TIS, DOI [10.5772/23223, DOI 10.5772/23223]
   Jung C, 2016, CLIN HEMORHEOL MICRO, V63, P169, DOI 10.3233/CH 1663301
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kalyanaraman H, 2017, J BONE MINER RES, V32, P46, DOI 10.1002/jbmr.2909
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Karagiosis SA, 2007, BIOCHEM BIOPH RES CO, V357, P194, DOI 10.1016/j.bbrc.2007.03.121
   Karagiosis SA, 2009, J CELL PHYSIOL, V219, P716, DOI 10.1002/jcp.21720
   Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449
   Kdolsky RK, 2005, WIEN KLIN WOCHENSCHR, V117, P693, DOI 10.1007/s00508 005 0431 y
   Kihara Y, 2014, BRIT J PHARMACOL, V171, P3575, DOI 10.1111/bph.12678
   Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407
   Kim YH, 2016, J BIOMED MATER RES A, V104, P942, DOI 10.1002/jbm.a.35635
   Kim YH, 2014, BIOMATERIALS, V35, P214, DOI 10.1016/j.biomaterials.2013.09.103
   Kim Shapiro DB, 2018, CLIN HEMORHEOL MICRO, V68, P223, DOI 10.3233/CH 189009
   Kimmel HM, 2016, WOUNDS, V28, P264
   Kinoshita T, 2000, BONE, V27, P811, DOI 10.1016/S8756 3282(00)00395 1
   Knowles HJ, 2009, HISTOL HISTOPATHOL, V24, P337, DOI 10.14670/HH 24.337
   Knowles HJ, 2015, HYPOXIA, V3, P73, DOI 10.2147/HP.S95960
   Komatsu DE, 2010, J CELL BIOCHEM, V109, P302, DOI 10.1002/jcb.22418
   Komatsu DE, 2004, BONE, V34, P680, DOI 10.1016/j.bone.2003.12.024
   Kong YX, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/565369
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kono M, 2015, EXP CELL RES, V333, P178, DOI 10.1016/j.yexcr.2014.11.023
   Kosaki N, 2007, BIOCHEM BIOPH RES CO, V354, P846, DOI 10.1016/j.bbrc.2006.12.234
   Kramer M, 2014, PLOS ONE, V9
   Krausz A, 2015, FUTUR SCI OA, V1, DOI [10.4155/fso.15.56, 10.4155/FSO.15.56]
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008 5472.CAN 05 2001
   Lapierre DM, 2010, J BIOL CHEM, V285, P25792, DOI 10.1074/jbc.M110.109322
   Largo RA, 2011, REGENERATIVE MEDICINE AND TISSUE ENGINEERING   CELLS AND BIOMATERIALS, P433
   Laube M, 2016, ANTIOXIDANTS BASEL, V5, DOI 10.3390/antiox5020014
   Le Stunff H, 2004, J CELL BIOCHEM, V92, P882, DOI 10.1002/h=jcb.20097
   Lechler P, 2011, CLIN HEMORHEOL MICRO, V49, P279, DOI 10.3233/CH 2011 1478
   Lee H, 2000, AM J PHYSIOL CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612
   Lin CI, 2008, CELL SIGNAL, V20, P1804, DOI 10.1016/j.cellsig.2008.06.008
   Lin IC, 2008, PLAST RECONSTR SURG, V121, P1554, DOI 10.1097/PRS.0b013e31816c3bd7
   Liu YB, 2010, J CELL BIOCHEM, V109, P794, DOI 10.1002/jcb.22471
   Lu CY, 2013, BONE, V52, P220, DOI 10.1016/j.bone.2012.09.037
   Mac Gabhann F, 2010, WIRES SYST BIOL MED, V2, P694, DOI 10.1002/wsbm.92
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Maes C, 2012, NAT REV RHEUMATOL, V8, P358, DOI 10.1038/nrrheum.2012.36
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   Mansell JP, 2011, PROSTAG OTH LIPID M, V95, P45, DOI [10.1016/j.prostaglandins.2011.05.002, 10.1016/j.prostaglandins.2011.05.003]
   Mao H, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00034
   Mechtcheriakova D, 2007, FEBS LETT, V581, P3063, DOI 10.1016/j.febslet.2007.05.069
   Meesters DM, 2016, BONE, V83, P111, DOI 10.1016/j.bone.2015.11.006
   Mendelson K, 2014, DEVELOPMENT, V141, P5, DOI 10.1242/dev.094805
   Meshcheryakova A, 2017, EXPERT OPIN THER TAR, V21, P725, DOI 10.1080/14728222.2017.1332180
   Miller MR, 2007, BRIT J PHARMACOL, V151, P305, DOI 10.1038/sj.bjp.0707224
   Milstien S, 2006, CANCER CELL, V9, P148, DOI 10.1016/j.ccr.2006.02.025
   Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081
   Morris AJ, 2009, TRENDS CARDIOVAS MED, V19, P135, DOI 10.1016/j.tcm.2009.07.005
   Mosch B, 2010, J ONCOL, V2010, DOI 10.1155/2010/135285
   Nabhan AF, 2008, INT J GYNECOL OBSTET, V103, P213, DOI 10.1016/j.ijgo.2008.07.011
   Nagel S, 2010, ANTIOXID REDOX SIGN, V12, P481, DOI 10.1089/ars.2009.2711
   Nakajima C, 2014, DEVELOPMENT, V141, P4513, DOI 10.1242/dev.109124
   Nangaku M, 2007, ARTERIOSCL THROM VAS, V27, P2548, DOI 10.1161/ATVBAHA.107.148551
   Nichols SP, 2012, ADV DRUG DELIVER REV, V64, P1177, DOI 10.1016/j.addr.2012.03.002
   Ogle ME, 2014, ACTA BIOMATER, V10, P4704, DOI 10.1016/j.actbio.2014.08.007
   Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200
   Oo ML, 2007, J BIOL CHEM, V282, P9082, DOI 10.1074/jbc.M610318200
   Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006 291X(02)02671 2
   Parker JD, 2004, J CLIN INVEST, V113, P352, DOI 10.1172/JCI200421003
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014 5793(03)01168 2
   Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603 677
   Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875
   Rajfer RA, 2017, BONE JOINT RES, V6, P90, DOI 10.1302/2046 3758.62.BJR 2016 0164.R2
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Rankin Erinn B, 2011, Curr Osteoporos Rep, V9, P46, DOI 10.1007/s11914 011 0047 2
   Rejnmark L, 2006, J BONE MINER RES, V21, P1811, DOI 10.1359/JBMR.060804
   Riddle RC, 2009, J MOL MED, V87, P583, DOI 10.1007/s00109 009 0477 9
   Roelofsen T, 2008, J CELL BIOCHEM, V105, P1128, DOI 10.1002/jcb.21915
   Rosen H, 2008, IMMUNOL REV, V223, P221, DOI 10.1111/j.1600 065X.2008.00645.x
   Rothe R, 2019, CLIN HEMORHEOL MICRO, V73, P439, DOI 10.3233/CH 199104
   Rothea R, 2019, CLIN HEMORHEOL MICRO, V73, P381, DOI 10.3233/CH 199102
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   Salles JP, 2013, BBA MOL CELL BIOL L, V1831, P93, DOI 10.1016/j.bbalip.2012.07.018
   Salous AK, 2013, J LIPID RES, V54, P2775, DOI 10.1194/jlr.M039685
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Sartawi Z, 2017, PHARMACOL RES, V125, P232, DOI 10.1016/j.phrs.2017.08.013
   Sato C, 2012, BIOCHEM BIOPH RES CO, V423, P200, DOI 10.1016/j.bbrc.2012.05.130
   Saura M, 2010, THESCIENTIFICWORLDJO, V10, P624, DOI 10.1100/tsw.2010.58
   Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]
   Schmidt Bleek K, 2014, J TISSUE ENG REGEN M, V8, P120, DOI 10.1002/term.1505
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Sefcik LS, 2008, BIOMATERIALS, V29, P2869, DOI 10.1016/j.biomaterials.2008.03.017
   Sefcik LS, 2011, TISSUE ENG PT A, V17, P617, DOI 10.1089/ten.TEA.2010.0404
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Selma JM, 2018, CELL MOL BIOENG, V11, P241, DOI 10.1007/s12195 018 0532 0
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886
   Sheng XY, 2015, DEVELOPMENT, V142, P1390, DOI 10.1242/dev.121723
   Silva BR, 2017, MED CHEM, V13, P319, DOI 10.2174/1573406412666161228115627
   Sims SM, 2013, BBA MOL CELL BIOL L, V1831, P109, DOI 10.1016/j.bbalip.2012.08.001
   Smyth SS, 2008, BBA MOL CELL BIOL L, V1781, P563, DOI 10.1016/j.bbalip.2008.05.008
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200
   Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974
   Spitler R, 2013, CELL SIGNAL, V25, P2374, DOI 10.1016/j.cellsig.2013.07.029
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Stewart R, 2011, J ORTHOP TRAUMA, V25, P472, DOI 10.1097/BOT.0b013e31822588d8
   Takabe K, 2014, J LIPID RES, V55, P1839, DOI 10.1194/jlr.R046656
   Takami M, 2005, FEBS LETT, V579, P832, DOI 10.1016/j.febslet.2004.12.066
   Tazzyman S, 2014, HYPOXIA, V2, P185, DOI 10.2147/HP.S49717
   Teixeira CC, 2008, DEV BIOL, V319, P171, DOI 10.1016/j.ydbio.2008.04.031
   Tengood JE, 2010, BIOMATERIALS, V31, P7805, DOI 10.1016/j.biomaterials.2010.07.010
   Togral G, 2015, EKLEM HAST CERRAHISI, V26, P137, DOI 10.5606/ehc.2015.29
   Tokuhara Y, 2010, J BONE MINER METAB, V28, P17, DOI 10.1007/s00774 009 0103 5
   Tomsig JL, 2009, BIOCHEM J, V419, P611, DOI 10.1042/BJ20081888
   Towler Dwight A, 2008, Curr Osteoporos Rep, V6, P67, DOI 10.1007/s11914 008 0012 x
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Vashghani Farahani Mohammad Mahdi, 2017, Lab Anim Res, V33, P15, DOI 10.5625/lar.2017.33.1.15
   Velázquez C, 2005, BIOORGAN MED CHEM, V13, P2749, DOI 10.1016/j.bmc.2005.02.034
   Vendégh Z, 2010, CLIN HEMORHEOL MICRO, V45, P9, DOI 10.3233/CH 2010 1282
   Wacker BK, 2006, BIOMACROMOLECULES, V7, P1335, DOI 10.1021/bm050948r
   Wallace JL, 2009, TRENDS PHARMACOL SCI, V30, P112, DOI 10.1016/j.tips.2009.01.001
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wan C, 2010, ANN NY ACAD SCI, V1192, P322, DOI 10.1111/j.1749 6632.2009.05238.x
   Wang HY, 2009, J MOL MED, V87, P435, DOI 10.1007/s00109 009 0445 4
   Wang LQ, 2018, AM J PHYSIOL ENDOC M, V315, pE446, DOI 10.1152/ajpendo.00130.2018
   Wang T, 2016, DRUG DELIV TRANSL RE, V6, P96, DOI 10.1007/s13346 015 0244 0
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wimalawansa S, 2000, J BONE MINER RES, V15, P1119, DOI 10.1359/jbmr.2000.15.6.1119
   Wimalawansa SJ, 2000, CALCIFIED TISSUE INT, V66, P56, DOI 10.1007/s002230050011
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
   Wimalawansa SJ, 2007, ANN NY ACAD SCI, V1117, P283, DOI 10.1196/annals.1402.066
   Wimalawansa SJ, 2010, ANN NY ACAD SCI, V1192, P391, DOI 10.1111/j.1749 6632.2009.05230.x
   Wimalawansa SJ, 2008, EXPERT OPIN PHARMACO, V9, P3025, DOI 10.1517/14656560802197162 
   Woclawek Potocka I, 2009, EXP BIOL MED, V234, P986, DOI 10.3181/0901 RM 36
   Wu CT, 2013, ACTA BIOMATER, V9, P9159, DOI 10.1016/j.actbio.2013.06.026
   Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042
   Xing YG, 2015, SCI REP UK, V5, DOI 10.1038/srep10020
   Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P636, DOI 10.1167/iovs.06 0203
   Yaman F, 2011, EUR REV MED PHARMACO, V15, P1301
   Yoo SY, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/127170
   Yu ZL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7537630
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhu W, 2002, J BONE MINER RES, V17, P1470, DOI 10.1359/jbmr.2002.17.8.1470
   Zhu W, 2001, J BONE MINER RES, V16, P535, DOI 10.1359/jbmr.2001.16.3.535
   Zou DH, 2011, STEM CELLS, V29, P1380, DOI 10.1002/stem.693
NR 232
TC 8
Z9 9
U1 0
U2 6
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386 0291
EI 1875 8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2019
VL 73
IS 3
BP 409
EP 438
DI 10.3233/CH 199103
PG 30
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA KA3DN
UT WOS:000505678600003
PM 31177206
DA 2025 08 17
ER

PT J
AU Font, RG
   Garcia, ML
   Martinez, JM
AF Gomez Font, Rafael
   Martinez Garcia, Maria Luisa
   Olmos Martinez, Jose Manuel
TI Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update
SO MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
LA English
DT Article
DE osteonecrosis; necrosis due to phosphorus; bisphosphonates;
   diphosphonates; myeloma; breast cancer; metastatic cancer; osteoporosis
ID OSTEONECROSIS; OSTEOPOROSIS; PAMIDRONATE; ALENDRONATE; PREVENTION
AB Bisphosphonates ( BP), were initially used in industry and later as a drug due to their great affinity to osseous tissue, because of their powerful antiresorptive effect as a treatment in various osteopathies, such as osteoporosis, Paget disease or hypercalcemia associated with some malignant tumors, as myeloma or breast cancer.
   They are administered orally or intravenously, and although well tolerated, the most frequent side effects are gastrointestinal, in addition to osteonecrosis when they are administered via endovenous.
   The aim of this work has been to evaluate the existing publications in accredited scientific literature on biphosphonates and their action mechanism and the relationship with the appearance of osteonecrosis of the jaws.
   Although the mechanism by which osteonecrosis of the jaws develops is not known exactly, there seems to be influence by osteoclast inhibiton, antiangiogenic action, an inhibitory effect on the cellular cycle by the keratinocytes, as well as, reinforcement of the chemiotoxic action in oncological patients treated with other drugs.
   Clinically, it ranges from a non specificity of symptoms to lesions such as osteomyelitis with necrosis and osseous sequesters that may be accompanied by fetor ex oris, with the appearance of many Actinomyces contaminated lesions.
   As for published antecedents on osteonecrosis due to bisphosphonate treatment found until 2006: 46.5% had a previous diagnosis of multiple myeloma; 38.8% were patients with metastatic breast cancer; 6.2% patients of metastatic prostate cancer; 4.1% suffered from osteoporosis; 3.5% from other metastatic diseases and 0.8% had Paget disease.
   The drugs that seem to have the highest incidence of osteochemionecrosis are: zoledronate, pamidronate, alendronate, risendronate and ibandronate, from the greatest to the least. Additionally, the risk of osteonecrosis being produced is accumulative and may reach 21% in the third year of intravenous bisphosphonate use.
C1 [Gomez Font, Rafael; Martinez Garcia, Maria Luisa] European Univ Madrid, Master Oral Surg Program, Madrid, Spain.
   [Olmos Martinez, Jose Manuel] Univ Cantabria, E 39005 Santander, Spain.
C3 European University of Madrid; Universidad de Cantabria
RP Font, RG (通讯作者)，C Melendez Valdes 10, Madrid 28015, Spain.
EM rafael.gomez@uem.es
OI Olmos, Jose M./0000 0002 7765 0891
CR Bagan Jose, 2007, Med Oral Patol Oral Cir Bucal, V12, pE336
   Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Cheng A, 2005, AUST DENT J, V50, pS4, DOI 10.1111/j.1834 7819.2005.tb00384.x
   Estefania Fresco R, 2006, MED ORAL PATOL ORAL, V11, pE456
   Farrugia MC, 2006, LARYNGOSCOPE, V116, P115, DOI 10.1097/01.mlg.0000187398.51857.3c
   FERNANDEZ NP, 2006, MED ORAL PATOL ORAL, V11, pE396
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Gonzalez Moles MA, 2000, J ORAL PATHOL MED, V29, P514, DOI 10.1034/j.1600 0714.2000.291006.x
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Markiewicz MR, 2005, J AM DENT ASSOC, V136, P1669, DOI 10.14219/jada.archive.2005.0109
   MARTINEZ JMO, 2005, FORMADORES HUESO, P13
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2007, J ORAL MAXIL SURG, V65, P2397, DOI 10.1016/j.joms.2007.08.003
   Melo MD, 2005, J AM DENT ASSOC, V136, P1675, DOI 10.14219/jada.archive.2005.0110
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Narai S, 2003, INT J ORAL MAX IMPL, V18, P218
   Pastor Zuazaga Daniel, 2006, Med Oral Patol Oral Cir Bucal, V11, pE76
   RINCON IH, 2007, MED ORAL PATOL ORAL, V12, pE267
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Scully C, 2006, BRIT DENT J, V200, P153, DOI 10.1038/sj.bdj.4813249
   Shane E, 2006, J BONE MINER RES, V21, P1503, DOI 10.1359/JBMR.060712
   Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 26
TC 42
Z9 44
U1 0
U2 2
PU MEDICINA ORAL S L
PI VALENCIA
PA CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN
SN 1698 6946
J9 MED ORAL PATOL ORAL
JI Med. Oral Patol. Oral Cir. Bucal
PD MAY
PY 2008
VL 13
IS 5
BP E318
EP E324
AR 1001111473
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 354VH
UT WOS:000259666600010
PM 18449117
DA 2025 08 17
ER

PT J
AU Cao, XR
   Li, H
   Tao, HR
   Wu, N
   Yu, LF
   Zhang, DW
   Lu, XZ
   Zhu, JY
   Lu, ZF
   Zhu, QS
AF Cao, Xiaorui
   Li, Huan
   Tao, Huiren
   Wu, Ning
   Yu, Lifeng
   Zhang, Dawei
   Lu, Xiaozhao
   Zhu, Jinyu
   Lu, Zifan
   Zhu, Qingsheng
TI Metformin Inhibits Vascular Calcification in Female Rat Aortic Smooth
   Muscle Cells via the AMPK eNOS NO Pathway
SO ENDOCRINOLOGY
LA English
DT Article
ID ACTIVATED PROTEIN KINASE; CHRONIC KIDNEY DISEASE; ANTIDIABETIC DRUG
   METFORMIN; NITRIC OXIDE SYNTHASE; OVARIECTOMIZED RATS; BONE MASS;
   EXPRESSION; PROGRESSION; CALCIUM; ATHEROSCLEROSIS
AB Metformin exhibits diverse protective effects against diabetic complications, such as bone loss. Here, we investigated the effect of metformin on vascular calcification, another type 2 diabetes complication. In female rat aortic smooth muscle cells (RASMCs), we observed that metformin significantly alleviated beta glycerophosphate induced Ca deposition and alkaline phosphatase activity, corresponding with reduced expression of some specific genes in osteoblast like cells, including Runx2 and bone morphogenetic protein 2, and positive effects on beta actin expression, a specific marker of smooth muscle cells. Mechanistic analysis showed that phosphorylation levels of both AMP activated protein kinase (AMPK) and endothelial nitric oxide synthase (eNOS) were increased with NO overproduction. After inhibition of either AMPK or eNOS with the pharmacologic inhibitors, compound C or N omega Nitro L argininemethyl ester, NO production was lowered and metformin meditated vascular protection against beta glycerophosphate induced Ca deposition was removed. Our results support that metformin prevents vascular calcification via AMPK eNOS NO pathway.
C1 [Cao, Xiaorui; Tao, Huiren; Wu, Ning; Yu, Lifeng; Zhang, Dawei; Zhu, Jinyu; Zhu, Qingsheng] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.
   [Li, Huan] Fourth Mil Med Univ, Xijing Hosp, Dept Cardiol, Xian 710032, Peoples R China.
   [Lu, Xiaozhao; Lu, Zifan] Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Biochem & Mol Biol, Xian 710032, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University
RP Lu, ZF (通讯作者)，Fourth Mil Med Univ, State Key Lab Canc Biol, Dept Biochem & Mol Biol, Xian 710032, Peoples R China.
EM luzfliuq@fmmu.edu.cn; zhuqsh@fmmu.edu.cn
RI Zhang, Bin/M 3689 2014; Zhang, Dawei/C 5981 2008
OI ZHU, JINYU/0000 0002 7811 752X
FU National Science Foundation of China [NSF:81070698, NSF:81170256,
   NSF:31270843]
FX This work was supported by National Science Foundation of China Grants
   (NSF:81070698, NSF:81170256, and NSF:31270843).
CR Aoyagi K, 2001, CALCIFIED TISSUE INT, V69, P20, DOI 10.1007/s002230020003
   Cannata Andia JB, 2011, NEPHROL DIAL TRANSPL, V26, P3429, DOI 10.1093/ndt/gfr591
   Chen NX, 2002, KIDNEY INT, V62, P1724, DOI 10.1046/j.1523 1755.2002.00625.x
   Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014 5793(98)01705 0
   Christian RC, 2002, J CLIN ENDOCR METAB, V87, P1062, DOI 10.1210/jc.87.3.1062
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Davies MR, 2005, J AM SOC NEPHROL, V16, P917, DOI 10.1681/ASN.2004100835
   Demer LL, 2002, INT J EPIDEMIOL, V31, P737, DOI 10.1093/ije/31.4.737
   Di Bartolo BA, 2011, CARDIOVASC RES, V91, P537, DOI 10.1093/cvr/cvr084
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Ghatak SB, 2011, EUR J PHARMACOL, V659, P213, DOI 10.1016/j.ejphar.2011.03.029
   Jie KSG, 1996, CALCIFIED TISSUE INT, V59, P352, DOI 10.1007/s002239900139
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kanno Y, 2008, CARDIOVASC RES, V77, P221, DOI 10.1093/cvr/cvm049
   Kiel DP, 2001, CALCIFIED TISSUE INT, V68, P271, DOI 10.1007/BF02390833
   KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249
   KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513
   Li XW, 2006, CIRC RES, V98, P905, DOI 10.1161/01.RES.0000216409.20863.e7
   Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]
   Lomashvili KA, 2009, KIDNEY INT, V75, P617, DOI 10.1038/ki.2008.646
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Mathew S, 2007, J AM SOC NEPHROL, V18, P122, DOI 10.1681/ASN.2006050490
   Moe SM, 2004, CIRC RES, V95, P560, DOI 10.1161/01.RES.0000141775.67189.98
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Naves M, 2008, OSTEOPOROSIS INT, V19, P1161, DOI 10.1007/s00198 007 0539 1
   Park JH, 2008, ACTA PHYSIOL, V193, P47, DOI 10.1111/j.1748 1716.2007.01799.x
   Ray Jenna Lynn, 2001, Methods in Cell Science, V23, P185
   REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476 5381.1990.tb14151.x
   Reynolds JL, 2004, J AM SOC NEPHROL, V15, P2857, DOI 10.1097/01.ASN.0000141960.01035.28
   Richards J, 2013, AM J PATHOL, V182, P1922, DOI 10.1016/j.ajpath.2013.01.037
   Schulz E, 2004, J CLIN ENDOCR METAB, V89, P4246, DOI 10.1210/jc.2003 030964
   SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003
   Sofer E, 2011, METABOLISM, V60, P1278, DOI 10.1016/j.metabol.2011.01.011
   Son BK, 2008, ENDOCRINOLOGY, V149, P1646, DOI 10.1210/en.2007 1021
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755
   Zhang YJ, 2006, ARTERIOSCL THROM VAS, V26, P1281, DOI 10.1161/01.ATV.0000221230.08596.98
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
   Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200
NR 42
TC 72
Z9 74
U1 1
U2 30
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0013 7227
J9 ENDOCRINOLOGY
JI Endocrinology
PD OCT
PY 2013
VL 154
IS 10
BP 3680
EP 3689
DI 10.1210/en.2013 1002
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 222VH
UT WOS:000324759600021
PM 24025223
OA Bronze
DA 2025 08 17
ER

PT J
AU Garcia, T
   Jackson, A
   Bachelier, R
   Clément Lacroix, P
   Baron, R
   Clézardin, P
   Pujuguet, P
AF Garcia, Teresa
   Jackson, Amanda
   Bachelier, Richard
   Clement Lacroix, Philippe
   Baron, Roland
   Clezardin, Philippe
   Pujuguet, Philippe
TI A convenient clinically relevant model of human breast cancer bone
   metastasis
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE animal model; bioluminescence; bone metastases; genome profiling; human
   breast cancer; osteomimicry
ID GENE EXPRESSION; PROSTATE CANCER; CELL INVASION; MOUSE; PROGRESSION;
   MICROENVIRONMENT; TRANSCRIPTION; OSTEOBLASTS; MIGRATION; RUNX2
AB Breast cancer patients with advanced disease exhibit bone metastases, leading to the formation of osteolytic lesions for which the only currently available treatments are palliative. Here, we describe how we refined a mouse model of human breast cancer metastasis into bone, characterized its transcriptome and demonstrated its clinical relevance. Cells were selected from bone metastases caused by MDA MB 231 cells after several in vivo passages, and engineered to express luciferase. Whole body bioluminescence live imaging indicated that the selected isogenic B02 clone was unique in its ability to form rapidly growing osteolytic bone metastases. B02 cells were detected as early as 10 days after tail vein injection, as opposed to 1 month after cardiac injection in other haematogenous models. Whole transcriptomic analysis identified 114 upregulated and 247 downregulated genes in B02 cells compared to the parental cells, several of which represent novel targets. In addition, there was a 50% overlap between the B02 signature and a recently described signature obtained from human breast cancer bone metastases. Consistent with the plasticity of an aggressive metastatic variant, 10% of the regulated genes are involved in proliferation, migration, invasion and angiogenesis. Strikingly, B02 cells also express osteoblast specific genes, thus mimicking a process referred to as osteomimicry in the clinic. The B02 cells "human bone metastatic signature", the expression of bone specific genes, as well as the live imaging of this convenient model highlight its clinical relevance and usefulness during drug development.
C1 [Garcia, Teresa; Clement Lacroix, Philippe; Pujuguet, Philippe] Galapagos SASU, F 93230 Romainville, France.
   [Jackson, Amanda] Univ London Imperial Coll Sci Technol & Med, London, England.
   [Bachelier, Richard; Clezardin, Philippe] INSERM, Laennec Sch Med, Unit Res U664, F 69372 Lyon, France.
   [Baron, Roland] Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA.
C3 Galapagos NV; Imperial College London; Institut National de la Sante et
   de la Recherche Medicale (Inserm); Yale University
RP Pujuguet, P (通讯作者)，Galapagos SASU, 102 Route Noisy, F 93230 Romainville, France.
EM teresa.garcia@glpg.com; a.jackson@imperial.ac.uk;
   bachelier@lyon.inserm.fr; philippe.clement lacroix@glpg.com;
   roland.baron@yale.edu; clezardin@lyon.inserm.fr;
   philippe.pujuguet@glpg.com
RI Clezardin, Philippe/M 8071 2014
OI Clezardin, Philippe/0000 0003 0149 4463
CR BELLAHEENE A, 2006, BREAST CANC RES TREA, V101, P135
   Bendre MS, 2005, CANCER RES, V65, P11001, DOI 10.1158/0008 5472.CAN 05 2630
   Berg RW, 1999, GENOMICS, V56, P169, DOI 10.1006/geno.1998.5707
   Boucharaba A, 2004, J CLIN INVEST, V114, P1714, DOI 10.1172/JCI200422123
   Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177
   Eccles SA, 2005, CURR OPIN GENET DEV, V15, P77, DOI 10.1016/j.gde.2004.12.001
   GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kamb A, 2005, NAT REV DRUG DISCOV, V4, P161, DOI 10.1038/nrd1635
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kim SJ, 2005, CANCER RES, V65, P3707, DOI 10.1158/0008 5472.CAN 04 3601
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008 5472.CAN 04 1408
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Littlepage LE, 2005, CANCER CELL, V7, P499, DOI 10.1016/j.ccr.2005.05.019
   MATSUSHIMA T, 1996, TRENDS CHEM PHYS, V4, P1
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01 0911fje
   Peyruchaud O, 2003, J BIOL CHEM, V278, P45826, DOI 10.1074/jbc.M309024200
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Roman Roman S, 2003, BONE, V32, P474, DOI 10.1016/S8756 3282(03)00052 8
   Rosol TJ, 2003, CANCER AM CANCER SOC, V97, P748, DOI 10.1002/cncr.11150
   Schroeder Tania M., 2005, Birth Defects Research, V75, P213, DOI 10.1002/bdrc.20043
   Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434
   Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Theilhaber J, 2001, J COMPUT BIOL, V8, P585, DOI 10.1089/106652701753307502
   Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722
   van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002 9440(10)61773 7
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002 9440(10)64934 6
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
   Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435
NR 37
TC 25
Z9 33
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD MAR
PY 2008
VL 25
IS 1
BP 33
EP 42
DI 10.1007/s10585 007 9099 1
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 257NR
UT WOS:000252806300003
PM 17902030
DA 2025 08 17
ER

PT J
AU Aurich Barrera, B
   Wilton, L
   Harris, S
   Shakir, SAW
AF Aurich Barrera, B
   Wilton, L
   Harris, S
   Shakir, SAW
TI Ophthalmological events in patients receiving risedronate   Summary of
   information gained through follow up in a prescription event monitoring
   study in England
SO DRUG SAFETY
LA English
DT Article
ID BISPHOSPHONATES; PAMIDRONATE; UVEITIS; ALENDRONATE; OSTEOCLAST;
   SCLERITIS; DISODIUM; PATHWAY; DISEASE
AB Background: In the UK, the nitrogen bisphosphonate risedronate is licensed for the prevention and treatment of osteoporosis and corticosteroid induced osteoporosis in postmenopausal women. It is also licensed for the treatment of Paget's disease. During a prescription event monitoring (PEM) study on risedronate we noted a number of ophthalmological events. Recently, case reports of ophthalmological adverse drug reactions in patients taking bisphosphonates were published in the medical literature. The aim of this study was to further evaluate the association of ophthalmological events reported in relation to risedronate treatment during a PEM study on the drug.
   Methods: An observational cohort study (PEM study) was conducted in England between September 2000 and June 2002. General practitioners (GPs) were asked for follow up information on selected events. Events followed up were classified as either 'probably', 'possibly' or 'unlikely' to be related to risedronate, using a modified WHO classification. If insufficient information was obtained on the follow up questionnaire, the cases were categorised as 'unassessable'.
   Results: Of the total PEM study cohort of 13 643 patients, 11 156 (82%) were females and 2398 (18%) were males. We received 359 reports of ophthalmological events in 313 patients during the entire study period. Of these we followed up 178 events in 178 patients. Nineteen events in 19 patients were assessed as possibly or probably related to risedronate. The age range for these patients was 50 92 years and the time to onset ranged from 7 days to 5 months. Dry eye (six reports), sore eye (five reports) and conjunctivitis (three reports) were the most frequently reported ophthalmological events assessed as probably or possibly related to risedronate therapy. GPs also reported several other inflammatory conditions of the eye, amongst them two events each of iritis and episcleritis as well as one of keratitis. However, the information received on follow up of these events was insufficient to make causality assessments.
   Conclusion: Patients receiving risedronate can present with a variety of signs and symptoms affecting the eye with different degrees of severity. Patients may present after the first month of treatment. Doctors should have an increased awareness of possible ophthalmological adverse drug reactions in patients receiving this drug, which may affect the eyesight in a population at increased risk of fracture if they fall.
C1 Drug Safety Res Unit, Southampton SO31 1AA, Hants, England.
   Univ Portsmouth, Portsmouth, Hants, England.
   Univ Southampton, Southampton, Hants, England.
C3 University of Portsmouth; University of Southampton
RP Drug Safety Res Unit, Bursledon Hall,Blundell Lane, Southampton SO31 1AA, Hants, England.
EM lynda.wilton@dsru.org
CR BARRERA BA, 2005, OSTEOPOROS INT
   Biswas PN, 2003, OSTEOPOROSIS INT, V14, P507, DOI 10.1007/s00198 003 1399 y
   Brown JP, 2000, BONE, V26, P263, DOI 10.1016/S8756 3282(99)00271 9
   *CIOMS WHO, 1993, INT GUID BIOM RES IN
   DE S, 1995, BRIT J RHEUMATOL, V34, P479
   Durnian JM, 2005, EYE, V19, P221, DOI 10.1038/sj.eye.6701461
   Fietta P, 2003, ANN RHEUM DIS, V62, P378, DOI 10.1136/ard.62.4.378
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   Fraunfelder FW, 2003, NEW ENGL J MED, V348, P1187, DOI 10.1056/NEJM200303203481225
   Fraunfelder FW, 2003, AM J OPHTHALMOL, V135, P219, DOI 10.1016/S0002 9394(02)01840 8
   GHOSE K, 1994, AUST NZ J MED, V24, P320, DOI 10.1111/j.1445 5994.1994.tb02186.x
   Haverbeke G, 2003, Bull Soc Belge Ophtalmol, P71
   Heeley E, 2001, LANCET, V358, P1872, DOI 10.1016/S0140 6736(01)06898 2
   Leung S, 2005, SOUTH MED J, V98, P733, DOI 10.1097/01.SMJ.0000152753.80490.9F
   MACAROL V, 1994, AM J OPHTHALMOL, V118, P220, DOI 10.1016/S0002 9394(14)72902 2
   Malik AR, 2002, BRIT J OPHTHALMOL, V86, P1443, DOI 10.1136/bjo.86.12.1443
   Mbekeani JN, 1999, ARCH OPHTHALMOL CHIC, V117, P837
   McAvoy BR, 1996, BRIT MED J, V313, P732
   *MULT RES ETH COMM, 2000, EX ENQ SURV PUBL INT, P21
   Nelson JD, 2000, ADV THER, V17, P84, DOI 10.1007/BF02854841
   ODONNELL NP, 1995, BRIT J CLIN PRACT, V49, P272
   *PROCT GAMBL PHARM, 2002, ACT 30MG SUMM PROD C
   *PROCT GAMBL PHARM, 2003, ACT ONC WEEK 35MG SU
   *PROCT GAMBL PHARM, 2002, ACT 5MG SUMM PROD CH
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Reszka Alfred A, 2003, Curr Rheumatol Rep, V5, P65, DOI 10.1007/s11926 003 0085 6
   Rey J, 2000, JOINT BONE SPINE, V67, P337
   Rogers HL, 2002, BONE, V30, p43S
   *ROYAL COLL PHYS L, 1996, GUID PRACT ETH COMM
   Salmen Siham, 2002, Invest. clín, V43, P49
   SANCHEZ VMA, 2004, ARCH SOC ESP OFTALMO, V2, P2
   Sanders JM, 2004, J MED CHEM, V47, P375, DOI 10.1021/jm0303709
   Santini D, 2004, BIODRUGS, V18, P269, DOI 10.2165/00063030 200418040 00004
   Shakir SAW, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P203
   SHAKIR SAW, 2004, STEPHENS DETECTION N, P329
   SIRIS ES, 1993, LANCET, V341, P436, DOI 10.1016/0140 6736(93)93029 Z
   SPRINGUEL P, 2003, CANADIAN ADVERSE DRU, P1
   Stewart GO, 1996, AUST NZ J MED, V26, P414, DOI 10.1111/j.1445 5994.1996.tb01932.x
   TOPLISS D, 2004, AUST ADV DRUG REACTI, V23, P7
   Viñas G, 2002, MED CLIN BARCELONA, V118, P598, DOI 10.1016/S0025 7753(02)72464 0
   ZHANG D, 1995, J CELL SCI, V108, P2285
NR 44
TC 12
Z9 13
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114 5916
EI 1179 1942
J9 DRUG SAFETY
JI Drug Saf.
PY 2006
VL 29
IS 2
BP 151
EP 160
DI 10.2165/00002018 200629020 00005
PG 10
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA 022ET
UT WOS:000236038400005
PM 16454542
DA 2025 08 17
ER

PT J
AU Figurek, A
   Spasovski, G
AF Figurek, Andreja
   Spasovski, Goce
TI Is serum sclerostin a marker of atherosclerosis in patients with chronic
   kidney disease mineral and bone disorder?
SO INTERNATIONAL UROLOGY AND NEPHROLOGY
LA English
DT Article
DE Sclerostin; Chronic kidney disease; Mineral and bone disorder;
   Intima media thickness; Biomarker
ID PREVALENT HEMODIALYSIS PATIENTS; INTIMA MEDIA THICKNESS; VASCULAR
   CALCIFICATION; RENAL OSTEODYSTROPHY; CKD; PROGRESSION; MORTALITY;
   THERAPY; PATHWAY; FGF 23
AB Purpose The complexity of chronic kidney disease mineral and bone disorder (CKD MBD) led to many preclinical and clinical trials. The role of sclerostin in renal pathophysiology remained unresolved, and question whether sclerostin is related to cardiovascular (CV) outcome in patients with CKD is still open. Our aim was to evaluate the possible association between serum sclerostin levels and carotid intima media thickness (CIMT) in CV pathophysiology through various CKD stages.
   Methods Eighty eight patients in various CKD stages were involved in this analysis. CKD EPI (Chronic kidney disease Epidemiology Collaboration Equation) was used to estimate glomerular filtration rate (eGFR). CKD MBD parameters were determined in patients' serum after an overnight fasting. Early atherosclerosis was assessed by ultrasound measurement of CIMT. In order to assess the association between serum sclerostin with other CKD MBD parameters and CIMT, correlation and regression analyses were performed.
   Results Mean age was 62.84 +/  11.37years and 56% were female. Mean values of serum sclerostin were 1.67 +/  0.44ng/ml. Negative correlation was noticed with serum calcium and phosphate product (CaxP), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), serum creatinine, and HbA1c level. There was no association with FGF23, CIMT, and carotid atherosclerotic plaque occurence. Serum levels of sclerostin were significantly higher in female patients compared to males (p<0.001).
   Conclusion Advanced CKD showed a trend of declining sclerostin levels and significantly higher CIMT levels. Serum sclerostin was not associated with CIMT. More studies are needed in order to reveal the exact role of sclerostin in the complexity of CKD MBD pathophysiological mechanism.
C1 [Figurek, Andreja] Univ Clin Ctr Republ Srpska, Dept Nephrol, Banja Luka, Bosnia & Herceg.
   [Figurek, Andreja] Univ Banja Luka, Fac Med, Banja Luka, Republic Of Srp, Bosnia & Herceg.
   [Spasovski, Goce] Univ Skopje, Univ Dept Nephrol, Med Fac, Skopje, Macedonia.
C3 University of Banja Luka (UNIBL); Saints Cyril & Methodius University of
   Skopje
RP Figurek, A (通讯作者)，Univ Clin Ctr Republ Srpska, Dept Nephrol, Banja Luka, Bosnia & Herceg.; Figurek, A (通讯作者)，Univ Banja Luka, Fac Med, Banja Luka, Republic Of Srp, Bosnia & Herceg.
EM andrejafigurek@yahoo.com
RI Figurek, Andreja/AAK 7236 2020
CR Behets GJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176411
   Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 219
   Brkljacic B, 2010, VASCULAR ULTRASOUND
   Bruzzese A, 2016, RENAL FAILURE, V38, P759, DOI 10.3109/0886022X.2016.1160207
   Cejka D, 2014, J CLIN ENDOCR METAB, V99, P248, DOI 10.1210/jc.2013 2786
   Claes KJ, 2013, J CLIN ENDOCR METAB, V98, P3221, DOI 10.1210/jc.2013 1521
   Costa AG, 2015, CURR OPIN NEPHROL HY, V24, P324, DOI 10.1097/MNH.0000000000000133
   Delanaye P, 2014, NEPHRON CLIN PRACT, V128, P127, DOI 10.1159/000366449
   Figurek A, 2017, THESIS
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   Gaudio A, 2014, DIABETES VASC DIS RE, V11, P48, DOI 10.1177/1479164113510923
   Graciolli FG, 2017, KIDNEY INT, V91, P1436, DOI 10.1016/j.kint.2016.12.029
   Kanbay M, 2016, INT UROL NEPHROL, V48, P2029, DOI 10.1007/s11255 016 1387 8
   Kanbay M, 2014, J CLIN ENDOCR METAB, V99, pE1854, DOI 10.1210/jc.2014 2042
   Kirkpantur A, 2016, NEFROLOGIA, V36, P24, DOI 10.1016/j.nefro.2015.07.006
   Kirkpantur A, 2015, CLIN KIDNEY J, V8, P737, DOI 10.1093/ckj/sfv077
   Lv W, 2016, INT UROL NEPHROL, V48, P2043, DOI 10.1007/s11255 016 1379 8
   Morales Santana S, 2013, DIABETES CARE, V36, P1667, DOI 10.2337/dc12 1691
   Morena M, 2015, NEPHROL DIAL TRANSPL, V30, P1345, DOI 10.1093/ndt/gfv081
   Pelletier S, 2013, CLIN J AM SOC NEPHRO, V8, P819, DOI 10.2215/CJN.07670712
   Qureshi AR, 2015, KIDNEY INT, V88, P1356, DOI 10.1038/ki.2015.194
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630
   Schiavi SC, 2016, KIDNEY INT, V90, P17, DOI 10.1016/j.kint.2016.03.028
   Sinha MD, 2012, NEPHROL DIAL TRANSPL, V27, P4361, DOI 10.1093/ndt/gfs109
   Tartaglione L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178637
   Torino C, 2017, NUTR METAB CARDIOVAS, V27, P260, DOI 10.1016/j.numecd.2016.11.005
   Touboul PJ, 2007, CEREBROVASC DIS, V23, P75, DOI 10.1159/000097034
   Wang XR, 2017, NEPHROLOGY, V22, P286, DOI 10.1111/nep.12813
   Yamashita H, 2005, J CLIN ENDOCR METAB, V90, P4211, DOI 10.1210/jc.2004 2498
   Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002 021105
   Zeng C, 2018, DIABETES VASC DIS RE, V15, P99, DOI 10.1177/1479164117742316
NR 32
TC 13
Z9 14
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 1623
EI 1573 2584
J9 INT UROL NEPHROL
JI Int. Urol. Nephrol.
PD OCT
PY 2018
VL 50
IS 10
BP 1863
EP 1870
DI 10.1007/s11255 018 1935 5
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA GV8UA
UT WOS:000446422300015
PM 30030677
DA 2025 08 17
ER

PT J
AU Klavdianou, K
   Liossis, SN
   Papachristou, DJ
   Theocharis, G
   Sirinian, C
   Kottorou, A
   Filippopoulou, A
   Andonopoulos, AP
   Daoussis, D
AF Klavdianou, Kalliopi
   Liossis, Stamatis Nick
   Papachristou, Dionysios J.
   Theocharis, Georgios
   Sirinian, Chaido
   Kottorou, Anastasia
   Filippopoulou, Alexandra
   Andonopoulos, Andrew P.
   Daoussis, Dimitrios
TI Decreased Serotonin Levels and Serotonin Mediated Osteoblastic
   Inhibitory Signaling in Patients With Ankylosing Spondylitis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANKYLOSING SPONDYLITIS; SEROTONIN; NEW BONE FORMATION;
   OSTEOBLASTOGENESIS; SPONDYLOARTHROPATHIES; ANTI TNF TREATMENT; TNF
   BLOCKER
ID BONE MINERAL DENSITY; NECROSIS FACTOR ALPHA; RHEUMATOID ARTHRITIS;
   RADIOGRAPHIC PROGRESSION; BOWEL DISEASE; SPONDYLOARTHROPATHY; INCREASE;
   THERAPY; RISK; MASS
AB Evidence suggests that serotonin is an inhibitor of bone formation. We aimed to assess: 1) serum serotonin levels in patients with ankylosing spondylitis (AS), a prototype bone forming disease, compared with patients with rheumatoid arthritis (RA) and healthy subjects; 2) the effect(s) of TNF blockers on serum serotonin levels in patients with AS and RA; and 3) the effect(s) of serum of AS patients on serotonin signaling. Serum serotonin levels were measured in 47 patients with AS, 28 patients with RA, and 40 healthy subjects by radioimmunoassay; t test was used to assess differences between groups. The effect of serum on serotonin signaling was assessed using the human osteoblastic cell line Saos2, evaluating levels of phospho CREB by Western immunoblots. Serotonin serum levels were significantly lower in patients with AS compared with healthy subjects (mean +/  SEM ng/mL 122.9 +/  11.6 versus 177.4 +/  24.58, p=0.038) and patients with RA (mean +/  SEM ng/mL 244.8 +/  37.5, p=0.0004). Patients with AS receiving TNF blockers had significantly lower serotonin levels compared with patients with AS not on such treatment (mean +/  SEM ng/mL 95.8 +/  14.9 versus 149.2 +/  16.0, p=0.019). Serotonin serum levels were inversely correlated with pCREB induction in osteoblast like Saos 2 cells. Serotonin levels are low in patients with AS and decrease even further during anti TNF treatment. Differences in serotonin levels are shown to have a functional impact on osteoblast like Saos 2 cells. Therefore, serotonin may be involved in new bone formation in AS. (c) 2015 American Society for Bone and Mineral Research.
C1 [Klavdianou, Kalliopi; Liossis, Stamatis Nick; Filippopoulou, Alexandra; Andonopoulos, Andrew P.; Daoussis, Dimitrios] Univ Patras, Sch Med, Patras Univ Hosp, Div Rheumatol, GR 26110 Patras, Greece.
   [Papachristou, Dionysios J.] Univ Patras, Sch Med, Lab Bone & Soft Tissue Studies, Dept Anat Histol Embryol, GR 26110 Patras, Greece.
   [Theocharis, Georgios] Univ Patras, Sch Med, Patras Univ Hosp, Dept Gastroenterol, GR 26110 Patras, Greece.
   [Sirinian, Chaido; Kottorou, Anastasia] Univ Patras, Sch Med, Patras Univ Hosp, Clin & Mol Oncol Lab, GR 26110 Patras, Greece.
C3 University of Patras; University of Patras; University of Patras;
   University of Patras
RP Klavdianou, K (通讯作者)，Patras Univ Hosp, Div Rheumatol, Dept Internal Med, Patras 26504, Greece.
EM jimdaoussis@hotmail.com
RI ; Filippopoulou, Alexandra/IAN 3595 2023; Liossis,
   Stamatis Nick/K 5383 2019
OI Liossis, Stamatis Nick/0000 0003 2511 8083; 
FU Hellenic Rheumatology Society; Professional Organization for
   Rheumatologists
FX This study was funded by the Hellenic Rheumatology Society and
   Professional Organization for Rheumatologists.
CR Allali F, 2003, ANN RHEUM DIS, V62, P347, DOI 10.1136/ard.62.4.347
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Bab Itai, 2010, Curr Osteoporos Rep, V8, P185, DOI 10.1007/s11914 010 0026 z
   Baraliakos X, 2014, ANN RHEUM DIS, V73, P710, DOI 10.1136/annrheumdis 2012 202698
   Barnabe C, 2009, SEMIN ARTHRITIS RHEU, V39, P116, DOI 10.1016/j.semarthrit.2008.04.004
   Berger M, 2009, ANNU REV MED, V60, P355, DOI 10.1146/annurev.med.60.042307.110802
   Bliziotes M, 2010, J CLIN ENDOCR METAB, V95, P4124, DOI 10.1210/jc.2010 0861
   Colombo E, 2009, WORLD J GASTROENTERO, V15, P2456, DOI 10.3748/wjg.15.2456
   Côté F, 2004, TRENDS MOL MED, V10, P232, DOI 10.1016/j.molmed.2004.03.007
   Daoussis D, 2010, ARTHRITIS RHEUM US, V62, P150, DOI 10.1002/art.27231
   Diem SJ, 2007, ARCH INTERN MED, V167, P1240, DOI 10.1001/archinte.167.12.1240
   Durnez A, 2013, J RHEUMATOL, V40, P1712, DOI 10.3899/jrheum.121417
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   Haney EM, 2007, ARCH INTERN MED, V167, P1246, DOI 10.1001/archinte.167.12.1246
   Haroon N, 2013, ARTHRITIS RHEUM US, V65, P2645, DOI 10.1002/art.38070
   Jacques P, 2014, ANN RHEUM DIS, V73, P437, DOI 10.1136/annrheumdis 2013 203643
   Jaschko G, 2007, ANN RHEUM DIS, V66, P1267, DOI 10.1136/ard.2006.058842
   Kang KY, 2013, RHEUMATOLOGY, V52, P718, DOI 10.1093/rheumatology/kes364
   Kang KY, 2011, JOINT BONE SPINE, V78, P188, DOI 10.1016/j.jbspin.2010.05.010
   Karsenty G, 2011, ANNU REV MED, V62, P323, DOI 10.1146/annurev med 090710 133426
   Karsenty G, 2010, J CLIN ENDOCR METAB, V95, P4795, DOI 10.1210/jc.2010 1030
   Klingberg E, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3833
   Kopp S, 2002, MEDIAT INFLAMM, V11, P211, DOI 10.1080/09629350290000069
   Long FX, 2008, CELL, V135, P795, DOI 10.1016/j.cell.2008.11.007
   Lories RJ, 2013, NAT REV RHEUMATOL, V9, P328, DOI 10.1038/nrrheum.2013.25
   Lories RJU, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2135
   Lories RJU, 2012, RHEUM DIS CLIN N AM, V38, P555, DOI 10.1016/j.rdc.2012.08.003
   Maksymowych WP, 2012, ARTHRITIS RHEUM US, V64, P1713, DOI 10.1002/art.34442
   Mawe GM, 2006, ALIMENT PHARM THER, V23, P1067, DOI 10.1111/j.1365 2036.2006.02858.x
   Mödder UI, 2010, J BONE MINER RES, V25, P415, DOI 10.1359/jbmr.090721
   Oury F, 2011, TRENDS ENDOCRIN MET, V22, P382, DOI 10.1016/j.tem.2011.04.006
   Peluso R, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/631408
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304 3940(02)01423 4
   Richards JB, 2007, ARCH INTERN MED, V167, P188, DOI 10.1001/archinte.167.2.188
   Rudwaleit M, 2006, BEST PRACT RES CL RH, V20, P451, DOI 10.1016/j.berh.2006.03.010
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P1324, DOI 10.1002/art.23471
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Verdel BM, 2010, BONE, V47, P604, DOI 10.1016/j.bone.2010.06.006
   Visvanathan S, 2009, ANN RHEUM DIS, V68, P175, DOI 10.1136/ard.2007.084426
   Wanders AJB, 2004, ARTHRITIS RHEUM US, V50, P2622, DOI 10.1002/art.20446
   Warden SJ, 2010, BONE, V46, P4, DOI 10.1016/j.bone.2009.06.029
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
NR 46
TC 20
Z9 22
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2016
VL 31
IS 3
BP 630
EP 639
DI 10.1002/jbmr.2724
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DI6GI
UT WOS:000373596800015
PM 26420546
OA Bronze
DA 2025 08 17
ER

PT J
AU Hernández, JL
   Garcés, CA
   Sumillera, M
   Fernández Aldasoro, EV
   García Ibarbia, C
   Ortiz Gómez, JA
   Arozamena, J
   Alonso, MA
   Riancho, JA
AF Hernandez, Jose L.
   Garces, Carlos A.
   Sumillera, Manuel
   Fernandez Aldasoro, Eugenio V.
   Garcia Ibarbia, Carmen
   Ortiz Gomez, Jesus A.
   Arozamena, Jana
   Alonso, Maria A.
   Riancho, Jose A.
TI Aromatase expression in osteoarthritic and osteoporotic bone
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID ARTICULAR CHONDROCYTES; ESTROGEN; CARTILAGE; THERAPY; REPLACEMENT;
   ESTRADIOL; TISSUE
AB Objective. Estrogen deprivation is a central mechanism in the development of osteoporosis with aging. Results from recent studies also suggest the involvement of estrogens in the pathophysiology of osteoarthritis (OA). Aromatization of androgenic precursors in peripheral tissue is the main source of estrogens in postmenopausal women and in men. However, the importance of aromatase expression in bone is a subject of controversy. This study was undertaken to determine aromatase expression in bone samples from patients with hip fracture and patients with OA.
   Methods. We studied 104 patients with hip fracture (n = 60) or primary hip OA (n = 44). Aromatase expression was determined in trabecular bone samples from the femoral neck and in osteoblast cultures grown by the primary explant technique (n = 6.2), using real time reverse transcriptase polymerase chain reaction.
   Results. Aromatase RNA was detected in bone samples at levels similar to those found in adipose tissue. Transcript levels were significantly lower in bone tissue samples obtained from patients with OA than in those obtained from patients with fracture (P = 0.00001). Likewise, primary cultures of osteoblast cells from OA patients revealed lower aromatase expression than those of cells from fracture patients (P = 0.012). Results were independent of age or sex differences.
   Conclusion. Our findings indicate that. the aromatase gene is expressed in bone tissue in high amounts, similar to those found in adipose tissue, but transcript levels are lower in tissue samples and osteoblast cultures from patients with OA than in those from patients with hip fracture. Since estrogens may help to prevent local cartilage degradation, it can be speculated that such a reduced expression of aromatase could facilitate the development of OA.
C1 [Riancho, Jose A.] Univ Cantabria, Dept Internal Med, Hosp UM Valdecilla, IFIMAV, Santander 39008, Spain.
C3 Hospital Universitario Marques de Valdecilla (HUMV); Universidad de
   Cantabria
RP Riancho, JA (通讯作者)，Univ Cantabria, Dept Internal Med, Hosp UM Valdecilla, IFIMAV, Avenida Valdecilla S N, Santander 39008, Spain.
EM rianchoj@unican.es
RI HERNANDEZ, JOSE LUIS/ABB 4604 2020; Hernandez, Jose/H 9562 2019
OI HERNANDEZ, JOSE LUIS/0000 0002 6585 8847; 
CR Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6
   Cirillo DJ, 2006, ARTHRITIS RHEUM US, V54, P3194, DOI 10.1002/art.22138
   Claassen H, 2005, CELL TISSUE RES, V319, P439, DOI 10.1007/s00441 004 1029 9
   Englert C, 2006, ARTHRITIS RHEUM US, V54, P3890, DOI 10.1002/art.22250
   Enjuanes A, 2003, EUR J ENDOCRINOL, V148, P519, DOI 10.1530/eje.0.1480519
   Ham KD, 2002, ARTHRITIS RHEUM US, V46, P1956, DOI 10.1002/art.10406
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1443, DOI 10.1210/jc.87.4.1443
   Lea CK, 1997, BONE, V21, P433, DOI 10.1016/S8756 3282(97)00168 3
   McCloskey E, 2006, EUR J CANCER, V42, P1044, DOI 10.1016/j.ejca.2005.10.028
   Ravn P, 2004, BONE, V35, P1216, DOI 10.1016/j.bone.2004.07.017
   Richette P, 2003, JOINT BONE SPINE, V70, P257, DOI 10.1016/S1297 319X(03)00067 8
   Richette P, 2007, ANN RHEUM DIS, V66, P345, DOI 10.1136/ard.2006.059550
   Sasano H, 1997, J BONE MINER RES, V12, P1416, DOI 10.1359/jbmr.1997.12.9.1416
   Simpson ER, 2005, ENDOCR REV, V26, P322, DOI 10.1210/er.2004 0020
   Sowers MR, 2006, ARTHRITIS RHEUM US, V54, P2481, DOI 10.1002/art.22005
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
NR 16
TC 32
Z9 34
U1 0
U2 2
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0004 3591
J9 ARTHRITIS RHEUM
JI Arthritis Rheum.
PD JUN
PY 2008
VL 58
IS 6
BP 1696
EP 1700
DI 10.1002/art.23500
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 313EW
UT WOS:000256724900016
PM 18512790
DA 2025 08 17
ER

PT J
AU Sun, YY
   Wu, XW
   Chen, L
   Luo, L
AF Sun, Yanyan
   Wu, Xiwen
   Chen, Lei
   Luo, Li
TI Synthesis and cytotoxicity of N,N′ dibisphosphonate ethylenediamine
   derivatives and platinum(II) complexes with high binding property to
   hydroxyapatite
SO INORGANICA CHIMICA ACTA
LA English
DT Article
DE Bisphosphonates; Platinum(II) complexes; Cytotoxicity; Hydroxyapatite
   affinity; Apoptosis
ID BIOLOGICAL EVALUATION; ANTICANCER AGENTS; BONE RESORPTION;
   BISPHOSPHONATES; DRUGS; OSTEOSARCOMA; DNA; INHIBITORS; AFFINITY; LIGANDS
AB A series of N,N ' dibisphosphonate ethylenediamine derivatives (L1 L6) and their corresponding dichloroplatinum(II) complexes (1 6) have been prepared and characterized by elemental analysis, H 1 NMR, C 13 NMR, P 31 NMR, and HRMS spectra. The in vitro antitumor of compounds L1 L6 and 1 6 was tested by WST 8 assay with Cell Counting Kit 8, indicating that platinum based complexes 1 6 showed higher cytotoxic efficacy than platinum free compounds L1 L6 against SKOV3 and MG 63, especially complex 2 (R = CH3, n = 2) with comparable cytotoxicity to cisplatin after 72 h incubation. And complexes 1 6 were highly selective in cytotoxicity against MG 63 tumor cells than hFOB 1.19 normal cells. The in vitro hydroxyapatite binding test revealed that complexes 1 and 2 showed higher affinity (K ' = 4.2 and 3.5, respectively) for bone hydroxyapatite than cisplatin (K ' < 0.1) and zoledronate (K ' = 2.8). On basis of flow cytometry results, complex 2 induced cell death by apoptosis effect similar to cisplatin, different from zoledronate. Representative complex 2 has been proved to be a promising bone targeting antitumor agent for subsequent in vivo study. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Sun, Yanyan; Wu, Xiwen; Chen, Lei; Luo, Li] Suzhou Univ Sci & Technol, Sch Chem Biol & Mat Engn, Suzhou 215009, Peoples R China.
C3 Suzhou University of Science & Technology
RP Sun, YY (通讯作者)，Suzhou Univ Sci & Technol, Sch Chem Biol & Mat Engn, Suzhou 215009, Peoples R China.
EM sunyy0628@163.com
FU National Natural Science Foundation of China [21401137]; College
   Students' Innovation and Entrepreneurship Project of Jiangsu Province
   [201510332057X]; College and Institute's High level Elite Project of
   Suzhou
FX We are grateful to the National Natural Science Foundation of China
   (21401137) for financial support to this study. Chen and Wu would like
   to thank the College Students' Innovation and Entrepreneurship Project
   of Jiangsu Province (201510332057X). Sun also appreciate very much the
   financial support from the College and Institute's High level Elite
   Project of Suzhou.
CR Bersworth FC, 1948, [No title captured], Patent No. [US2558923, 2558923]
   Bersworth FC, 1945, [No title captured], Patent No. [US2387735, 2387735]
   Bohacek RS, 2001, J MED CHEM, V44, P660, DOI 10.1021/jm0002681
   Bortolini O, 2012, EUR J MED CHEM, V52, P221, DOI 10.1016/j.ejmech.2012.03.020
   Bose RN, 2008, P NATL ACAD SCI USA, V105, P18314, DOI 10.1073/pnas.0803094105
   Chougrani K, [No title captured], Patent No. [WO2012140235A1, 2012140235]
   Diwela V.N., 2007, SYNTHETIC COMMUN, V37, P4359
   FICK R, 1936, Patent No. 638071
   Galanski M, 2003, J MED CHEM, V46, P4946, DOI 10.1021/jm0308040
   Ganta A, 1989, VESTN SLOV KEM DRUS, V36, P391
   Gao CZ, 2016, MINI REV MED CHEM, V16, P872, DOI 10.2174/1389557516666151120115947
   Gorelov I.P., 1986, [No title captured], Patent No. [SU 1244141, 1244141]
   Guo ZJ, 1999, ANGEW CHEM INT EDIT, V38, P1513
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Hoechst F., 1967, FR, Patent No. [1554236, 1967, 1554236]
   Huang KB, 2013, EUR J MED CHEM, V64, P554, DOI 10.1016/j.ejmech.2013.04.024
   Jakupec MA, 2008, DALTON T, P183, DOI 10.1039/b712656p
   Keglevich G, 2011, TETRAHEDRON LETT, V52, P2744, DOI 10.1016/j.tetlet.2011.03.093
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Kotsikorou E, 2003, J MED CHEM, V46, P2932, DOI 10.1021/jm030054u
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mao JF, 2009, CHEM COMMUN, P908, DOI 10.1039/b817968a
   Margiotta N, 2007, DALTON T, P3131, DOI 10.1039/b705239a
   Margiotta N, 2011, J INORG BIOCHEM, V105, P548, DOI 10.1016/j.jinorgbio.2010.12.011
   Margiotta N, 2009, DALTON T, P10904, DOI 10.1039/b919721d
   Margiotta N, 2008, J INORG BIOCHEM, V102, P2078, DOI 10.1016/j.jinorgbio.2008.07.008
   Papapoulos SE, 2006, BONE, V38, P613, DOI 10.1016/j.bone.2006.01.141
   Pasello M, 2008, CANCER RES, V68, P6661, DOI 10.1158/0008 5472.CAN 07 5840
   Piccinonna S, 2012, DALTON T, V41, P9689, DOI 10.1039/c2dt30712j
   Qiu L, 2016, MOLECULES, V21, DOI 10.3390/molecules21030255
   Qiu L, 2015, J BIOL INORG CHEM, V20, P1263, DOI 10.1007/s00775 015 1305 z
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Sanders JM, 2005, J MED CHEM, V48, P2957, DOI 10.1021/jm040209d
   Sasanelli R, 2007, J MED CHEM, V50, P3434, DOI 10.1021/jm061435l
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Sun Y., 2016, BIOORG MED IN PRESS
   Sun YY, 2014, CHEM BIODIVERS, V11, P115, DOI 10.1002/cbdv.201300092
   van Zutphen S, 2005, COORDIN CHEM REV, V249, P2845, DOI 10.1016/j.ccr.2005.03.005
   Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Wild A, 2012, CHEM COMMUN, V48, P6357, DOI 10.1039/c2cc31275a
   Wilson JJ, 2012, J MED CHEM, V55, P5326, DOI 10.1021/jm3002857
   Xing RM, 2009, DALTON T, P1710, DOI 10.1039/b900256c
   Xue ZQ, 2010, CHEM COMMUN, V46, P1212, DOI 10.1039/b922222g
   Yang H, 2016, TUMOR BIOL, V37, P10981, DOI 10.1007/s13277 016 4977 2
   Yang Z, 2007, CHEM COMMUN, P3453, DOI 10.1039/b705326f
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhao YM, 2006, DALTON T, P2617, DOI 10.1039/b601739h
NR 49
TC 5
Z9 5
U1 1
U2 33
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0020 1693
EI 1873 3255
J9 INORG CHIM ACTA
JI Inorg. Chim. Acta
PD MAR 1
PY 2017
VL 457
BP 46
EP 52
DI 10.1016/j.ica.2016.12.006
PG 7
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA EI8SJ
UT WOS:000392777700007
DA 2025 08 17
ER

PT J
AU Shiirevnyamba, A
   Takahashi, T
   Shan, H
   Ogawa, H
   Yano, S
   Kanayama, H
   Izumi, K
   Uehara, H
AF Shiirevnyamba, A.
   Takahashi, T.
   Shan, H.
   Ogawa, H.
   Yano, S.
   Kanayama, H.
   Izumi, K.
   Uehara, H.
TI Enhancement of osteoclastogenic activity in osteolytic prostate cancer
   cells by physical contact with osteoblasts
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE physical contact; cell to cell interaction; prostate cancer; bone
   metastasis; osteoclastogenesis
ID BONE METASTASIS; BREAST CANCER; N CADHERIN; IN VITRO; DIFFERENTIATION;
   CARCINOMA; INTERLEUKIN 6; PROGRESSION; EXPRESSION; MARROW
AB BACKGROUND: The interaction between prostate cancer cells and osteoblasts is critical for the development of bone metastasis. Metastatic cancer cells may physically contact osteoblasts in the bone microenvironment; however, the biological significance of this interaction is not fully understood.
   METHODS: Human prostate cancer cells (the osteolytic cell line PC 3 and the osteoblastic cell line MDA PCa 2b) and human osteoblasts (hFOB1.19) were cocultured under two different conditions (bilayer and contact conditions). Differential gene expression profiles of prostate cancer cells were then investigated using microarray analysis. Differentially expressed genes were analysed using RT PCR and western blotting, and the effect of anti cadherin neutralising antibodies on their expression was assayed. The osteoclastogenic activity of cells grown under these different conditions was also investigated using an in vitro assay.
   RESULTS: When PC 3 or MDA PCa 2b cells were cocultured with hFOB1.19 cells under contact conditions, the expression of eight genes was upregulated and that of one gene was downregulated in PC 3 cells compared with gene expression in bilayer culture. No differentially expressed genes were detected in MDA PCa 2b cells. Four of the eight upregulated genes (interleukin 1 beta (IL 1 beta), cyclooxygenase 2 (COX 2), IL 6 and the third component of complement (C3)) have already been reported to participate in osteoclastogenesis. Indeed, a cell lysate of PC 3 cells grown under contact coculture conditions significantly enhanced osteoclastogenesis in vitro (P<0.005). neutralisation of cadherin 11 with a specific antibody inhibited upregulation of COX 2 and C3 mRNA in PC 3 cells. In contrast, neutralisation of N cadherin induced upregulation of COX 2 mRNA.
   CONCLUSION: Physical contact between osteolytic prostate cancer cells and osteoblasts may upregulate osteoclastogenesis related gene expression in prostate cancer cells and enhance osteoclastogenesis. Additionally, cadherin 11 and N cadherin are involved in this process. These data provide evidence supporting new therapies of prostate cancer bone metastasis that target direct cancer cell osteoblast cell cell contact. British Journal of Cancer (2011) 1 04, 505 513. doi:10.1038/sj.bjc.6606070 www.bjcancer.com Published online 4 January 2011 (C) 2011 Cancer Research UK
C1 [Shiirevnyamba, A.; Takahashi, T.; Shan, H.; Ogawa, H.; Izumi, K.; Uehara, H.] Univ Tokushima, Grad Sch, Dept Mol & Environm Pathol, Tokushima 7708503, Japan.
   [Shiirevnyamba, A.; Kanayama, H.] Univ Tokushima, Grad Sch, Dept Urol, Inst Hlth Biosci, Tokushima 7708503, Japan.
   [Yano, S.] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 9200934, Japan.
C3 Tokushima University; Tokushima University; Kanazawa University
RP Uehara, H (通讯作者)，Univ Tokushima, Grad Sch, Dept Mol & Environm Pathol, 3 18 15 Kuramoto Cho, Tokushima 7708503, Japan.
EM uehara@basic.med.tokushima u.ac.jp
RI izumi, keisuke/L 3416 2013; YANO, SEIJI/D 8465 2015
OI Avirmed, Shiirevnyamba/0000 0002 1010 8221; 
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [21390442]; Cancer Research Institute, Kanazawa University;
   Grants in Aid for Scientific Research [21390442, 21390256, 23592380]
   Funding Source: KAKEN
FX We thank Megumi Kume and Hitomi Umemoto for technical assistance. This
   work was supported by a Grant in Aid for Scientific Research (No.
   21390442 to H.K.) provided by the Ministry of Education, Culture,
   Sports, Science and Technology, Japan, and was partly supported by an
   Extramural Collaborative Research Grant from the Cancer Research
   Institute, Kanazawa University.
CR AKATSU T, 1989, J BONE MINER RES, V4, P29
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   CHARHON SA, 1983, CANCER AM CANCER SOC, V51, P918, DOI 10.1002/1097 0142(19830301)51:5<918::AID CNCR2820510526>3.0.CO;2 J
   Cheng SL, 1998, J BONE MINER RES, V13, P633, DOI 10.1359/jbmr.1998.13.4.633
   Cheville JC, 2002, CANCER AM CANCER SOC, V95, P1028, DOI 10.1002/cncr.10788
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Chung TDK, 1999, PROSTATE, V38, P199
   Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Fujita T, 2002, J ORAL PATHOL MED, V31, P345, DOI 10.1034/j.1600 0714.2002.00188.x
   García Moreno C, 2002, PROSTATE, V50, P241, DOI 10.1002/pros.10050
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078 0432.CCR 07 1263
   HARRIS SA, 1995, J BONE MINER RES, V10, P178
   Hullinger TG, 2000, J CELL BIOCHEM, V78, P607, DOI 10.1002/1097 4644(20000915)78:4<607::AID JCB10>3.0.CO;2 F
   Jacob K, 1999, CANCER RES, V59, P4453
   Jemal A, 2008, CA CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Kido J, 1997, J CELL BIOCHEM, V67, P248
   Kii I, 2004, J BONE MINER RES, V19, P1840, DOI 10.1359/JBMR.040812
   LANG SH, 1995, PROSTATE, V27, P287, DOI 10.1002/pros.2990270508
   Liu XH, 2005, ENDOCRINOLOGY, V146, P1991, DOI 10.1210/en.2004 1167
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   MANGHAM DC, 1993, J CLIN PATHOL, V46, P517, DOI 10.1136/jcp.46.6.517
   Marie PJ, 2002, J CELL PHYSIOL, V190, P297, DOI 10.1002/jcp.10073
   Martinez J, 1996, J CELL BIOCHEM, V61, P18, DOI 10.1002/(SICI)1097 4644(19960401)61:1<18::AID JCB3>3.0.CO;2 5
   Mbalaviele G, 2006, J BONE MINER RES, V21, P1821, DOI 10.1359/JBMR.060811
   Menter DG, 2010, CLIN CANCER RES, V16, P1384, DOI 10.1158/1078 0432.CCR 09 0788
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Morrissey C, 2010, PROSTATE, V70, P412, DOI 10.1002/pros.21075
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ohshiba T, 2003, BIOCHEM BIOPH RES CO, V300, P957, DOI 10.1016/S0006 291X(02)02937 6
   Pishvaian MJ, 1999, CANCER RES, V59, P947
   Richardsen E, 2010, CANCER EPIDEMIOL, V34, P316, DOI 10.1016/j.canep.2010.03.019
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046 8177(03)00190 4
   Said N, 2009, ONCOGENE, V28, P3487, DOI 10.1038/onc.2009.205
   SATO T, 1993, ENDOCRINOLOGY, V133, P397, DOI 10.1210/en.133.1.397
   SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022 5347(17)35267 9
   Sim HG, 2005, EUR J CANCER, V41, P834, DOI 10.1016/j.ejca.2004.12.033
   Singh B, 2007, ONCOGENE, V26, P3789, DOI 10.1038/sj.onc.1210154
   Takahashi T, 2008, MOL CANCER THER, V7, P2807, DOI 10.1158/1535 7163.MCT 08 0153
   Tomita K, 2000, CANCER RES, V60, P3650
   Trebec Reynolds DP, 2010, J CELL BIOCHEM, V109, P975, DOI 10.1002/jcb.22476
   Tsai CY, 2009, J CELL BIOCHEM, V108, P489, DOI 10.1002/jcb.22278
   Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458
   Wang J, 2006, INT J MOL MED, V17, P849
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
NR 47
TC 24
Z9 29
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD FEB 1
PY 2011
VL 104
IS 3
BP 505
EP 513
DI 10.1038/sj.bjc.6606070
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 722IY
UT WOS:000287427100019
PM 21206493
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Xu, TT
   Sheng, LY
   He, L
   Weng, J
   Duan, K
AF Xu, Taotao
   Sheng, Luyao
   He, Lei
   Weng, Jie
   Duan, Ke
TI Enhanced osteogenesis of hydroxyapatite scaffolds by coating with
   BMP 2 loaded short polylactide nanofiber: a new drug loading method for
   porous scaffolds
SO REGENERATIVE BIOMATERIALS
LA English
DT Article
DE short fibers; surface modification; drug release; hydroxyapatite;
   polylactide
ID COMPOSITE SCAFFOLD; BONE; REGENERATION; DIFFERENTIATION; OSTEOINDUCTION;
   BIOCERAMICS; DELIVERY; COLLAGEN; PROMOTE; PLLA
AB Porous hydroxyapatite (HA) is widely used in porous forms to assist bone defect healing. However, further improvements in biological functions are desired for meeting complex clinical situations such as impaired bone regeneration in poor bone stock. The extracellular matrix (ECM) of human tissues is characterized by nanofibrous structures and a variety of signal molecules. Emulating these characteristics are expected to create a favorable microenvironment for cells and simultaneously allow release of osteogenic molecules. In this study, short polylactide fibers containing BMP 2 were prepared by electrospinning and coated on porous HA scaffolds. The coating did not affect porosity or pore interconnectivity of the scaffold but improved its compressive strength markedly. This fiber coating produced burst BMP 2 release in 1day followed by a linear release for 24days. The coating had a significantly lower rat calvarial osteoblasts (RCOBs) adhesion (vs. uncoated scaffold) but allowed normal proliferation subsequently. Bone marrow stem cells (MSCs) on the coated scaffolds expressed a significantly increased alkaline phosphatase activity relative to the uncoated ones. After implantation in canine dorsal muscles, the coated scaffolds formed significantly more new bone at Weeks 4 and 12, and more blood vessels at Week 12. This method offers a new option for drug delivery systems.
C1 [Xu, Taotao; Sheng, Luyao; He, Lei; Weng, Jie] Southwest Jiaotong Univ, Sch Mat Sci & Engn, Key Lab Adv Technol Mat MOE, Chengdu 610031, Peoples R China.
   [Duan, Ke] Southwest Med Univ, Affiliated Hosp, Dept Bone & Joint Surg, Sichuan Prov Lab Orthopaed Engn, Luzhou 646000, Peoples R China.
C3 Southwest Jiaotong University; Southwest Medical University
RP Weng, J (通讯作者)，Southwest Jiaotong Univ, Sch Mat Sci & Engn, Key Lab Adv Technol Mat MOE, Chengdu 610031, Peoples R China.; Duan, K (通讯作者)，Southwest Med Univ, Affiliated Hosp, Dept Bone & Joint Surg, Sichuan Prov Lab Orthopaed Engn, Luzhou 646000, Peoples R China.
EM jweng@swjtu.edu.cn; keduan9@126.com
RI Weng, Jie/AAW 5626 2021
OI Weng, Jie/0000 0002 7034 3215
FU National Key Research and Development Program of China [2016YFB0700803];
   National Natural Science Foundation of China [51572228, 81071456];
   Department of Science and Technology of Sichuan Province
   [2018SZYZF0012]; Startup Program of Affiliated Hospital of Southwest
   Medical University [19038]
FX This study was funded by the National Key Research and Development
   Program of China (2016YFB0700803), National Natural Science Foundation
   of China (51572228, 81071456), Department of Science and Technology of
   Sichuan Province (2018SZYZF0012) and Startup Program of Affiliated
   Hospital of Southwest Medical University (19038).
CR Bieniasz M, 2009, LUNG CANCER, V66, P319, DOI 10.1016/j.lungcan.2009.02.020
   Bittner SM, 2019, ACTA BIOMATER, V90, P37, DOI 10.1016/j.actbio.2019.03.041
   Bohner M, 2019, MATER TODAY, V22, P132, DOI 10.1016/j.mattod.2018.10.036
   Chen WC, 2018, BIOCHEM PHARMACOL, V150, P254, DOI 10.1016/j.bcp.2018.02.021
   Cheng LJ, 2010, ACTA BIOMATER, V6, P1569, DOI 10.1016/j.actbio.2009.10.050
   Comaposada J, 2015, LWT FOOD SCI TECHNOL, V64, P212, DOI 10.1016/j.lwt.2015.05.043
   Deng N, 2019, ARCH ORAL BIOL, V102, P16, DOI 10.1016/j.archoralbio.2019.03.023
   Duan R, 2018, BLOOD, V4, P5
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Gong Y, 2019, MATER LETT, V250, P206, DOI 10.1016/j.matlet.2019.05.015
   Han L, 2019, COLLOID SURFACE B, V179, P470, DOI 10.1016/j.colsurfb.2019.04.024
   Hinderer S, 2016, ADV DRUG DELIVER REV, V97, P260, DOI 10.1016/j.addr.2015.11.019
   Huang KC, 2017, ACTA BIOMATER, V59, P12, DOI 10.1016/j.actbio.2017.06.041
   Iviglia G, 2016, MAT SCI ENG C MATER, V68, P701, DOI 10.1016/j.msec.2016.06.050
   Kang YQ, 2011, EUR POLYM J, V47, P1569, DOI 10.1016/j.eurpolymj.2011.05.004
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kim HW, 2005, J MATER SCI MATER M, V16, P189, DOI 10.1007/s10856 005 6679 y
   Lai YX, 2018, BIOMATERIALS, V153, P1, DOI 10.1016/j.biomaterials.2017.10.025
   LeGeros RZ, 2008, CHEM REV, V108, P4742, DOI 10.1021/cr800427g
   Li JY, 2016, MATER LETT, V169, P148, DOI 10.1016/j.matlet.2016.01.076
   Murr LE, 2019, J MATER SCI TECHNOL, V35, P231, DOI 10.1016/j.jmst.2018.09.003
   Othman Z, 2019, BIOMATERIALS, V210, P12, DOI 10.1016/j.biomaterials.2019.04.021
   Ravindran S, 2014, EXP CELL RES, V325, P148, DOI 10.1016/j.yexcr.2014.01.018
   Shi F, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa6c8d
   Smith LA, 2010, BIOMATERIALS, V31, P5526, DOI 10.1016/j.biomaterials.2010.03.065
   Son JS, 2011, J CONTROL RELEASE, V153, P133, DOI 10.1016/j.jconrel.2011.03.010
   Su W, 2018, J MATER CHEM B, V6, P4338, DOI 10.1039/c8tb00405f
   Sun XY, 2018, REGEN BIOMATER, V5, P93, DOI 10.1093/rb/rbx018
   Tian T, 2008, MAT SCI ENG C BIO S, V28, P51, DOI 10.1016/j.msec.2006.12.017
   Wang H, 2013, ACTA BIOMATER, V9, P8413, DOI 10.1016/j.actbio.2013.05.026
   Wei DX, 2018, SMALL, V14, DOI 10.1002/smll.201800063
   Woo KM, 2003, J BIOMED MATER RES A, V67A, P531, DOI 10.1002/jbm.a.10098
   Yang Y, 2016, ACTA BIOMATER, V46, P112, DOI 10.1016/j.actbio.2016.09.035
   Zhang BJ, 2018, J BIOMED MATER RES A, V106, P95, DOI 10.1002/jbm.a.36210
   Zhao CC, 2015, J MATER CHEM B, V3, P968, DOI 10.1039/c4tb01838a
   Zhao J, 2009, COLLOID SURFACE B, V74, P159, DOI 10.1016/j.colsurfb.2009.07.012
   Zhou CX, 2018, BIOMATERIALS, V176, P50, DOI 10.1016/j.biomaterials.2018.05.039
   Zhou C, 2018, BIOMATER SCI UK, V6, P1946, DOI 10.1039/c8bm00473k
NR 38
TC 19
Z9 19
U1 1
U2 49
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2056 3418
EI 2056 3426
J9 REGEN BIOMATER
JI Regen. Biomater.
PD FEB
PY 2020
VL 7
IS 1
BP 91
EP 98
DI 10.1093/rb/rbz040
PG 8
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA NO5KV
UT WOS:000569529300011
PM 32440360
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, J
   Wang, XW
   Zhou, C
   Liu, LK
   Wu, YN
   Wang, DM
   Jiang, HB
AF Li, Jun
   Wang, Xianwei
   Zhou, Chen
   Liu, Laikui
   Wu, Yunong
   Wang, Dongmiao
   Jiang, Hongbing
TI Perioperative glucocorticosteroid treatment delays early healing of a
   mandible wound by inhibiting osteogenic differentiation
SO INJURY INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Bone wound healing; Mandible; Dexamethasone; Cyclooxygenase 2;
   Osteogenic differentiation
ID BONE FORMATION; DEXAMETHASONE; CYCLOOXYGENASE 2; MECHANISMS; FRACTURES;
   SEQUELAE; REMOVAL; SURGERY
AB Aim: The purpose of this study is to investigate the effects of dexamethasone on repair of a critical size defect of the mandible in male Sprague Dawley rats.
   Materials and methods: Fifty rats were divided into 2 groups: saline control and dexamethasone treated groups. A 1 mm x 3 mm full thickness bone defect was created at the inferior border of the mandible. Saline or dexamethasone was administered once a day for 5 days after postoperative palinesthesia. On days 1, 3, 6, 10 and 17, after cessation of drug administration, 5 samples from each group were analysed. The bone defect healing process was examined and analysed by stereology, radiology, histology and histochemical staining for total collagen, tartrate resistant acid phosphatase staining for osteoclasts and immunohistochemical staining for the COX 2, RUNX2 and osteocalcin antigens.
   Results: The dexamethasone treated rats exhibited significantly lower radiopacity properties compared to the control rats. Histological staining revealed that the osteogenic differentiation and maturation of a callus in the defect region was significantly delayed from day 1 to day 10 in the dexamethasone group after cessation of drug administration compared to the control group. Consistent with the histological data, the level of total collagen protein was significantly lower in the dexamethasone group than in the control group. However, there was no significant difference between the 2 groups at day 17. Immunohistochemical analysis of COX 2, RUNX2 and osteocalcin expression showed that, at day 1, COX 2 and RUNX2 expression in the dexamethasone group was significantly lower than in the control group. There was no significant difference in osteocalcin expression between the two groups at each time point. There was no significant difference in the number of osteoclasts between the two groups.
   Conclusion: In a model of bone healing of a mandible defect, dexamethasone treated rats exhibited impaired osteogenic differentiation and maturation due to the inhibition of COX 2, osteogenic gene, RUNX2 and collagen protein expression, which resulted in delayed bone repair. Although perioperative short term therapy did not exhibit long term effects on wound healing of the maxillofacial bone, the application of glucocorticoids should be cautiously considered in the clinic. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Li, Jun; Wang, Xianwei; Zhou, Chen; Wu, Yunong; Wang, Dongmiao; Jiang, Hongbing] Nanjing Med Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, Nanjing 210029, Jiangsu, Peoples R China.
   [Li, Jun; Wang, Xianwei; Zhou, Chen; Liu, Laikui; Jiang, Hongbing] Nanjing Med Univ, Sch Stomatol, Inst Stomatol, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Jiang, HB (通讯作者)，Nanjing Med Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, Nanjing 210029, Jiangsu, Peoples R China.
EM jhbcd@sina.com
RI Wang, Xianwei/E 2146 2011
FU National Natural Science Foundation of China [81070810]; Foundation of
   Jiangsu Educational Committee [09KJB320003]
FX This study was partly supported by a National Natural Science Foundation
   of China grant (81070810) and a Foundation of Jiangsu Educational
   Committee grant (09KJB320003).
CR Advani S, 1997, BONE, V20, P41, DOI 10.1016/S8756 3282(96)00314 6
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   Aslan M, 2005, DENT TRAUMATOL, V21, P222, DOI 10.1111/j.1600 9657.2005.00300.x
   BLUNT JW, 1950, P SOC EXP BIOL MED, V73, P678
   Buyukkurt MC, 2006, J ORAL MAXIL SURG, V64, P1761, DOI 10.1016/j.joms.2005.11.107
   Chikazu D, 2011, INT J ORAL MAX SURG, V40, P322, DOI 10.1016/j.ijom.2010.10.011
   Dan AEB, 2010, J ORAL MAXIL SURG, V68, P2207, DOI 10.1016/j.joms.2010.04.019
   Dimmen S, 2009, CLIN ORTHOP RELAT R, V467, P1992, DOI 10.1007/s11999 009 0783 0
   Esen E, 1999, J ORAL MAXIL SURG, V57, P1201, DOI 10.1016/S0278 2391(99)90486 X
   Flood TR, 1999, BRIT J ORAL MAX SURG, V37, P312, DOI 10.1054/bjom.1999.0024
   Graziani F, 2006, INT J ORAL MAX SURG, V35, P241, DOI 10.1016/j.ijom.2005.07.010
   Grossi GB, 2007, J ORAL MAXIL SURG, V65, P2218, DOI 10.1016/j.joms.2006.11.036
   Helms JA, 2003, NATURE, V423, P326, DOI 10.1038/nature01656
   Herschman HR, 1996, BBA LIPID LIPID MET, V1299, P125, DOI 10.1016/0005 2760(95)00194 8
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771 780.2001
   Leucht P, 2008, DEVELOPMENT, V135, P2845, DOI 10.1242/dev.023788
   LUKERT B, 1991, J BONE MINER RES, V6, P453
   OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888
   Pountos I, 2008, INJURY, V39, P384, DOI 10.1016/j.injury.2007.10.035
   Probst A, 1997, J INVEST SURG, V10, P77, DOI 10.3109/08941939709032137
   Rehman Q, 2003, MED PEDIATR ONCOL, V41, P212, DOI 10.1002/mpo.10339
   Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325
   SATO S, 1986, JPN J PHARMACOL, V42, P71, DOI 10.1254/jjp.42.71
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Seidenberg AB, 2004, PHARMACOL RES, V50, P151, DOI 10.1016/j.phrs.2003.12.017
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Thorén H, 2009, J ORAL MAXIL SURG, V67, P1884, DOI 10.1016/j.joms.2009.04.089
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951
   WEBER CR, 1994, J ORAL MAXIL SURG, V52, P35, DOI 10.1016/0278 2391(94)90010 8
   Yoon DS, 2010, STEM CELLS DEV, V19, P1523, DOI 10.1089/scd.2009.0393
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 36
TC 15
Z9 17
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020 1383
EI 1879 0267
J9 INJURY
JI Injury Int. J. Care Inj.
PD AUG
PY 2012
VL 43
IS 8
BP 1284
EP 1289
DI 10.1016/j.injury.2012.04.014
PG 6
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 970FG
UT WOS:000306112900009
PM 22658419
DA 2025 08 17
ER

PT J
AU Warady, BA
   Ng, E
   Bloss, L
   Mo, M
   Schaefer, F
   Bacchetta, J
AF Warady, Bradley A.
   Ng, Eric
   Bloss, Laura
   Mo, May
   Schaefer, Franz
   Bacchetta, Justine
TI Cinacalcet studies in pediatric subjects with secondary
   hyperparathyroidism receiving dialysis
SO PEDIATRIC NEPHROLOGY
LA English
DT Article
DE Cinacalcet; CKD MBD; Dialysis; Pediatric; sHPT
ID CHRONIC KIDNEY DISEASE; RENAL BONE DISEASE; FIBROBLAST GROWTH FACTOR 23;
   VITAMIN D ANALOGS; CARDIOVASCULAR DISEASE; PARATHYROID HORMONE;
   CHILDREN; HEMODIALYSIS; THERAPY; FAILURE
AB Background Secondary hyperparathyroidism (sHPT), a complication of chronic kidney disease (CKD) characterized by persistently elevated parathyroid hormone (PTH), alterations in calcium phosphorus homeostasis, and vitamin D metabolism, affects 50% of children receiving dialysis. A significant proportion of these children develop CKD mineral and bone disorder (CKD MBD), associated with an increased risk of fractures and vascular calcification. The standard of care for sHPT in children includes vitamin D sterols, calcium supplementation, and phosphate binders. Several agents are approved for sHPT treatment in adults undergoing dialysis, including vitamin D analogs and calcimimetics, with limited information on their safety and efficacy in children. The calcimimetic cinacalcet is approved for use in adults with sHPT on dialysis, but is not approved for pediatric use outside Europe. Methods This review provides dosing, safety, and efficacy information from Amgen sponsored cinacalcet pediatric trials and data from non Amgen sponsored clinical studies. Results The Amgen cinacalcet pediatric clinical development program consisted of two Phase 3 randomized studies, one Phase 3 single arm extension study, one open label Phase 2 study, and two open label Phase 1 studies. Effects of cinacalcet on PTH varied across studies. Overall, 7.4 to 57.1% of subjects who received cinacalcet in an Amgen clinical trial attained PTH levels within recommended target ranges and 22.2 to 70.6% observed a >= 30% reduction in PTH. In addition, significant reductions in PTH were demonstrated in all non Amgen supported studies. Conclusions To help inform the pediatric nephrology community, this manuscript contains the most comprehensive review of cinacalcet usage in pediatric CKD patients to date.
C1 [Warady, Bradley A.] Childrens Mercy Kansas City, Div Pediat Nephrol, Kansas City, MO 64108 USA.
   [Ng, Eric; Bloss, Laura; Mo, May] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Schaefer, Franz] Heidelberg Univ Hosp, Heidelberg, Germany.
   [Bacchetta, Justine] Femme Mere Enfant Hosp, Dept Pediat Nephrol Rheumatol & Dermatol, Bron, France.
C3 Children's Mercy Hospital; Amgen; Ruprecht Karls University Heidelberg;
   CHU Lyon
RP Warady, BA (通讯作者)，Childrens Mercy Kansas City, Div Pediat Nephrol, Kansas City, MO 64108 USA.
EM bwarady@cmh.edu
RI Bacchetta, Justine/B 3842 2016
FU Amgen Inc., Thousand Oaks, CA, USA
FX This study was funded by Amgen Inc., Thousand Oaks, CA, USA.
CR Akizawa T, 2016, SCI REP UK, V6, DOI 10.1038/srep19612
   Alharthi AA, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000401
   [Anonymous], 2018, SENSIPAR CINACALCET
   [Anonymous], 2011, SENSIPAR CINACALCET
   [Anonymous], 2017, Sci. Rep., V7, P1
   Bacchetta J, 2020, NEPHROL DIAL TRANSPL, V35, P47, DOI 10.1093/ndt/gfz159
   Baxter Jones ADG, 2011, J BONE MINER RES, V26, P1729, DOI 10.1002/jbmr.412
   Behets GJ, 2015, KIDNEY INT, V87, P846, DOI 10.1038/ki.2014.349
   Chen P, 2019, BRIT J CLIN PHARMACO, V85, P1312, DOI 10.1111/bcp.13900
   Chertow GM, 2012, NEW ENGL J MED, V367, P2482, DOI 10.1056/NEJMoa1205624
   Coen G, 1996, NEPHROL DIAL TRANSPL, V11, P813, DOI 10.1093/oxfordjournals.ndt.a027404
   Cozzolino M, 2014, NEPHROL DIAL TRANSPL, V29, P899, DOI 10.1093/ndt/gfu011
   CUNDY T, 1985, BMJ BRIT MED J, V290, P271, DOI 10.1136/bmj.290.6464.271
   Dasgupta I, 2013, NEPHRON CLIN PRACT, V124, P1, DOI 10.1159/000354711
   de Ferranti SD, 2019, CIRCULATION, V139, pE603, DOI 10.1161/CIR.0000000000000618
   de Francisco ALM, 1998, KIDNEY INT, V54, P2140, DOI 10.1046/j.1523 1755.1998.00221.x
   Denburg MR, 2016, J AM SOC NEPHROL, V27, P543, DOI 10.1681/ASN.2015020152
   Díaz Tocados JM, 2019, KIDNEY INT, V95, P1064, DOI 10.1016/j.kint.2018.12.015
   Friedl C, 2017, EUR J INTERN MED, V42, P89, DOI 10.1016/j.ejim.2017.05.002
   Goodman WG, 2008, KIDNEY INT, V74, P276, DOI 10.1038/sj.ki.5002287
   Harambat J, 2012, PEDIATR NEPHROL, V27, P363, DOI 10.1007/s00467 011 1939 1
   Isakova T, 2017, AM J KIDNEY DIS, V70, P737, DOI 10.1053/j.ajkd.2017.07.019
   Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018
   Khouzam NM, 2015, PEDIATR NEPHROL, V30, P1379, DOI 10.1007/s00467 014 2919 z
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Klaus G, 2006, PEDIATR NEPHROL, V21, P151, DOI 10.1007/s00467 005 2082 7
   Kuizon BD, 1999, J BONE MINER RES, V14, P1680, DOI 10.1359/jbmr.1999.14.10.1680
   Moe SM, 2015, CIRCULATION, V132, P27, DOI 10.1161/CIRCULATIONAHA.114.013876
   Morales AJA, 2019, PEDIATR NEPHROL, V34, P129, DOI 10.1007/s00467 018 4055 7
   Muscheites J, 2008, PEDIATR NEPHROL, V23, P1823, DOI 10.1007/s00467 008 0810 5
   National Institutes of Health, 2015, 2015 USRDS ANN DAT R, V2
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Padhi D, 2012, PEDIATR NEPHROL, V27, P1953, DOI 10.1007/s00467 012 2186 9
   Platt C, 2010, PEDIATR NEPHROL, V25, P143, DOI 10.1007/s00467 009 1294 7
   Rees L, 2017, LANCET CHILD ADOLESC, V1, P68, DOI 10.1016/S2352 4642(17)30018 4
   SALUSKY IB, 1987, KIDNEY INT, V32, P89, DOI 10.1038/ki.1987.176
   Sanchez Cheryl P, 2003, Paediatr Drugs, V5, P763, DOI 10.2165/00148581 200305110 00005
   Shroff R, 2013, J AM SOC NEPHROL, V24, P179, DOI 10.1681/ASN.2011121191
   Silverstein DM, 2008, PEDIATR NEPHROL, V23, P1817, DOI 10.1007/s00467 007 0742 5
   Slatopolsky E, 2001, AM J KIDNEY DIS, V37, pS54, DOI 10.1053/ajkd.2001.20740
   Sohn WY, 2019, PEDIATR NEPHROL, V34, P145, DOI 10.1007/s00467 018 4054 8
   Spasovski GB, 2003, NEPHROL DIAL TRANSPL, V18, P1159, DOI 10.1093/ndt/gfg116
   Sprague SM, 2015, CLIN J AM SOC NEPHRO, V10, P1021, DOI 10.2215/CJN.03270314
   Strippoli GFM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006254
   Walter S, 2013, J PHARMACOL EXP THER, V346, P229, DOI 10.1124/jpet.113.204834
   Warady BA, 2019, PEDIATR NEPHROL, V34, P475, DOI 10.1007/s00467 018 4116 y
   Wesseling Perry K, 2012, CLIN J AM SOC NEPHRO, V7, P146, DOI 10.2215/CJN.05940611
   Wetmore JB, 2009, NAT CLIN PRACT NEPHR, V5, P24, DOI 10.1038/ncpneph0977
   Wetzsteon RJ, 2011, J BONE MINER RES, V26, P2235, DOI 10.1002/jbmr.427
NR 49
TC 11
Z9 12
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0931 041X
EI 1432 198X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD SEP
PY 2020
VL 35
IS 9
BP 1679
EP 1697
DI 10.1007/s00467 020 04516 4
EA MAY 2020
PG 19
WC Pediatrics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Urology & Nephrology
GA MQ4WD
UT WOS:000530171600002
PM 32367309
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Choi, CKK
   Li, JM
   Wei, KC
   Xu, YJ
   Ho, LWC
   Zhu, ML
   To, KKW
   Choi, CHJ
   Bian, LM
AF Choi, Chun Kit K.
   Li, Jinming
   Wei, Kongchang
   Xu, Yang J.
   Ho, Lok Wai C.
   Zhu, Meiling
   To, Kenneth K. W.
   Choi, Chung Hang J.
   Bian, Liming
TI A Gold@Polydopamine Core Shell Nanoprobe for Long Term Intracellular
   Detection of MicroRNAs in Differentiating Stem Cells
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID MESSENGER RNA DETECTION; QUENCHED FLUORESCENT OLIGONUCLEOTIDES;
   NUCLEIC ACID; LIVING CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC
   DIFFERENTIATION; PHOTOTHERMAL THERAPY; NANOPARTICLES; BONE; DELIVERY
AB The capability of monitoring the differentiation process in living stem cells is crucial to the understanding of stem cell biology and the practical application of stem cell based therapies, yet conventional methods for the analysis of biomarkers related to differentiation require a large number of cells as well as cell lysis. Such requirements lead to the unavoidable loss of cell sources and preclude real time monitoring of cellular events. In this work, we report the detection of microRNAs (miRNAs) in living human mesenchymal stem cells (hMSCs) by using polydopamine coated gold nanoparticles (Au@PDA NPs). The PDA shell facilitates the immobilization of fluorescently labeled hairpin DNA strands (hpDNAs) that can recognize specific miRNA targets. The gold core and PDA shell quench the fluorescence of the immobilized hpDNAs, and subsequent binding of the hpDNAs to the target miRNAs leads to their dissociation from Au@PDA NPs and the recovery of fluorescence signals. Remarkably, these Au@PDA hpDNA nanoprobes can naturally enter stem cells, which are known for their poor transfection efficiency, without the aid of transfection agents. Upon cellular uptake of these nanoprobes, we observe intense and time dependent fluorescence responses from two important osteogenic marker miRNAs, namely, miR 29b and rniR 31, only in hMSCs undergoing osteogenic differentiation and living primary osteoblasts but not in undifferentiated hMSCs and 3T3 fibroblasts. Strikingly, our nanoprobes can afford long term tracking of miRNAs (5 days) in the differentiating hMSCs without the need of continuously replenishing cell culture medium with fresh nanoprobes. Our results demonstrate the capability of our Au@PDA hpDNA nanoprobes for monitoring the differentiation status of hMSCs (i.e., differentiating versus undifferentiated) via the detection of specific miRNAs in living stem cells. Our nanoprobes show great promise in the investigation of the long term dynamics of stem cell differentiation, identification and isolation of specific cell types, and high throughput drug screening.
C1 [Choi, Chun Kit K.; Li, Jinming; Wei, Kongchang; Xu, Yang J.; Zhu, Meiling; Bian, Liming] Chinese Univ Hong Kong, Dept Mech & Automat Engn Biomed Engn, Shatin, Hong Kong, Peoples R China.
   [Ho, Lok Wai C.; Choi, Chung Hang J.] Chinese Univ Hong Kong, Dept Elect Engn Biomed Engn, Shatin, Hong Kong, Peoples R China.
   [To, Kenneth K. W.] Chinese Univ Hong Kong, Sch Pharm, Shatin, Hong Kong, Peoples R China.
   [Li, Jinming; Wei, Kongchang; Choi, Chung Hang J.; Bian, Liming] Chinese Univ Hong Kong, Shun Hing Inst Adv Engn, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Chinese University of Hong Kong
RP Choi, CHJ (通讯作者)，Chinese Univ Hong Kong, Dept Elect Engn Biomed Engn, Shatin, Hong Kong, Peoples R China.
EM jchchoi@ee.cuhk.edu.hk; lbian@mae.cuhk.edu.hk
RI To, Kenneth/M 4500 2013; Bian, Liming/A 7183 2011; Wei,
   Kongchang/K 2096 2013; , Chun Kit K. Choi/AAE 1038 2020
OI To, Kenneth/0000 0003 2755 0283; Choi, Chun Kit K./0000 0003 1994 1719;
   Choi, Chung Hang Jonathan/0000 0003 2935 7217; Bian,
   Liming/0000 0003 4739 0918; Wei, Kongchang/0000 0002 6555 2768; 
FU Research Grants Council of Hong Kong [439913]; Shun Hing Institute of
   Advanced Engineering, The Chinese University of Hong Kong (CUHK)
   [BME 8115043]; Chow Yuk Ho Technology Centre for Innovative Medicine,
   CUHK; Innovation Technology Fund (ITF, Tier 3), Hong Kong [ITS/218/13]
FX The work described in this paper was supported by an Early Career Scheme
   grant from the Research Grants Council of Hong Kong (Project No.
   439913). This research was supported by project BME 8115043 of the Shun
   Hing Institute of Advanced Engineering, The Chinese University of Hong
   Kong (CUHK). This research was supported by Chow Yuk Ho Technology
   Centre for Innovative Medicine, CUHK. This research was supported by an
   Innovation Technology Fund (ITF, Tier 3, ITS/218/13), Hong Kong. The
   authors would like to thank Dr. Wayne Lee and Professor Gang Li from the
   Department of Orthopaedics and Traumatology (CUHK) for their generous
   contribution of mouse primary osteoblasts and related supplies. The
   authors would also like to thank Mr. Kin Pan Chung and Professor Liwen
   Jiang from the Department of Biology (CUHK) for their help in conducting
   the confocal microscopy experiments. Dark field microscopy and TEM
   imaging were performed at the Department of Physics (CUHK). FT IR
   spectroscopy, ICP OES, and DLS measurements were performed at the
   Department of Chemistry (CUHK). Confocal microscopy was performed in the
   Centre for Cell and Developmental Biology (CUHK). Ultramicrotomy and
   bio TEM imaging were performed in the School of Biomedical Sciences
   (CUHK).
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Bastús NG, 2011, LANGMUIR, V27, P11098, DOI 10.1021/la201938u
   Black KCL, 2013, NANOMEDICINE UK, V8, P17, DOI [10.2217/NNM.12.82, 10.2217/nnm.12.82]
   Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097 4644(199702)64:2<278::AID JCB11>3.0.CO;2 F
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Choi CHJ, 2013, P NATL ACAD SCI USA, V110, P7625, DOI 10.1073/pnas.1305804110
   Cutler JI, 2012, J AM CHEM SOC, V134, P1376, DOI 10.1021/ja209351u
   Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627
   Dong HF, 2011, BIOMATERIALS, V32, P3875, DOI 10.1016/j.biomaterials.2011.02.001
   Dubertret B, 2001, NAT BIOTECHNOL, V19, P365, DOI 10.1038/86762
   Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541
   Fukuda H, 2006, STEM CELLS, V24, P763, DOI 10.1634/stemcells.2005 0137
   Giljohann DA, 2007, NANO LETT, V7, P3818, DOI 10.1021/nl072471q
   Granchi D, 2010, TISSUE ENG PART C ME, V16, P511, DOI [10.1089/ten.tec.2009.0405, 10.1089/ten.TEC.2009.0405]
   GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139
   Halo TL, 2014, P NATL ACAD SCI USA, V111, P17104, DOI 10.1073/pnas.1418637111
   Ham HO, 2011, ANGEW CHEM INT EDIT, V50, P732, DOI 10.1002/anie.201005001
   Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651
   Huang L, 1997, NAT BIOTECHNOL, V15, P620, DOI 10.1038/nbt0797 620
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Ivey KN, 2008, CELL STEM CELL, V2, P219, DOI 10.1016/j.stem.2008.01.016
   Jiang JH, 2011, LANGMUIR, V27, P14180, DOI 10.1021/la202877k
   Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30
   Jiao J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010551
   Kaneto CM, 2014, BMC MED GENET, V15, DOI 10.1186/1471 2350 15 45
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kim TH, 2013, BIOMATERIALS, V34, P8660, DOI 10.1016/j.biomaterials.2013.07.101
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lin LS, 2014, ACS NANO, V8, P3876, DOI 10.1021/nn500722y
   Liu Q, 2014, SENSOR ACTUAT B CHEM, V191, P567, DOI 10.1016/j.snb.2013.10.050
   Liu XS, 2013, ACS NANO, V7, P9384, DOI 10.1021/nn404117j
   Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prigodich AE, 2012, ANAL CHEM, V84, P2062, DOI 10.1021/ac202648w
   Prigodich AE, 2011, J AM CHEM SOC, V133, P2120, DOI 10.1021/ja110833r
   Pruszak J, 2007, STEM CELLS, V25, P2257, DOI 10.1634/stemcells.2006 0744
   Qiang WB, 2014, CHEM SCI, V5, P3018, DOI 10.1039/c4sc00085d
   Ryoo SR, 2013, ACS NANO, V7, P5882, DOI 10.1021/nn401183s
   Seferos DS, 2007, J AM CHEM SOC, V129, P15477, DOI 10.1021/ja0776529
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347
   Suh JS, 2013, BIOMATERIALS, V34, P4347, DOI 10.1016/j.biomaterials.2013.02.039
   Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019
   Tyagi S, 2009, NAT METHODS, V6, P331, DOI [10.1038/NMETH.1321, 10.1038/nmeth.1321]
   Wu XCA, 2014, J AM CHEM SOC, V136, P7726, DOI 10.1021/ja503010a
   Xie Y, 2015, CHEM COMMUN, V51, P2156, DOI 10.1039/c4cc08912j
   Yang RH, 2008, J AM CHEM SOC, V130, P8351, DOI 10.1021/ja800604z
NR 51
TC 199
Z9 214
U1 4
U2 580
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002 7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD JUN 17
PY 2015
VL 137
IS 23
BP 7337
EP 7346
DI 10.1021/jacs.5b01457
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA CL2DL
UT WOS:000356753700019
PM 25996312
DA 2025 08 17
ER

PT J
AU Herberg, S
   Kondrikova, G
   Periyasamy Thandavan, S
   Howie, RN
   Elsalanty, ME
   Weiss, L
   Campbell, P
   Hill, WD
   Cray, JJ
AF Herberg, Samuel
   Kondrikova, Galina
   Periyasamy Thandavan, Sudharsan
   Howie, R. Nicole
   Elsalanty, Mohammed E.
   Weiss, Lee
   Campbell, Phil
   Hill, William D.
   Cray, James J.
TI Inkjet based biopatterning of SDF 1β augments BMP 2 induced repair of
   critical size calvarial bone defects in mice
SO BONE
LA English
DT Article
DE Bone; Healing; Biopatterning; BMP 2; SDF 1 beta; TGF beta 1
ID MESENCHYMAL STEM CELLS; GROWTH FACTOR BETA 1; OPEN TIBIAL FRACTURES;
   MORPHOGENETIC PROTEIN 2; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; EXPERIMENTAL MODEL; COLLAGEN SPONGES; GENE EXPRESSION;
   HIV 1 ENTRY
AB Background: A major problem in craniofacial surgery is non healing bone defects. Autologous reconstruction remains the standard of care for these cases. Bone morphogenetic protein 2 (BMP 2) therapy has proven its clinical utility, although non targeted adverse events occur due to the high milligram level doses used. Ongoing efforts explore the use of different growth factors, cytokines, or chemokines, as well as co therapy to augment healing.
   Methods: Here we utilize inkjet based biopatterning to load acellular DermaMatrix delivery matrices with nanogram level doses of BMP 2, stromal cell derived factor 1 beta (SDF 1 beta), transforming growth factor beta 1 (TGF beta 1), or co therapies thereof. We tested the hypothesis that bioprinted SDF 1 beta co delivery enhances BMP 2 and TGF beta 1 driven osteogenesis both in vitro and in vivo using a mouse calvarial critical size defect (CSD) model.
   Results: Our data showed that BMP 2 bioprinted in low doses induced significant new bone formation by four weeks post operation. TGF beta 1 was less effective compared to BMP 2, and SDF 1 beta therapy did not enhance osteogenesis above control levels. However, co delivery of BMP 2 + SDF 1 beta was shown to augment BMP 2 induced bone formation compared to BMP 2 alone. In contrast, co delivery of TGF beta 1 + SDF 1 beta decreased bone healing compared to TGF 1 beta alone. This was further confirmed in vitro by osteogenic differentiation studies using MC3T3 E1 pre osteoblasts.
   Conclusions: Our data indicates that sustained release delivery of a low dose growth factor therapy using biopatterning technology can aid in healing CSD injuries. SDF 1 beta augments the ability for BMP 2 to drive healing, a result confirmed in vivo and in vitro; however, because SDF 1 beta is detrimental to TGF 1 beta driven osteogenesis, its effect on osteogenesis is not universal. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Herberg, Samuel; Kondrikova, Galina; Periyasamy Thandavan, Sudharsan; Hill, William D.; Cray, James J.] Georgia Regents Univ, Dept Cellular Biol & Anat, Augusta, GA USA.
   [Howie, R. Nicole; Elsalanty, Mohammed E.; Cray, James J.] Georgia Regents Univ, Dept Oral Biol, Augusta, GA USA.
   [Hill, William D.; Cray, James J.] Georgia Regents Univ, Dept Orthopaed Surg, Augusta, GA USA.
   [Cray, James J.] Georgia Regents Univ, Div Plast Surg, Dept Orthodont & Surg, Augusta, GA USA.
   [Elsalanty, Mohammed E.; Hill, William D.; Cray, James J.] Georgia Regents Univ, Inst Regenerat & Reparat Med, Augusta, GA USA.
   [Weiss, Lee] Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.
   [Campbell, Phil] Carnegie Mellon Univ, Inst Complex Engn Syst, Pittsburgh, PA 15213 USA.
   [Weiss, Lee; Campbell, Phil] McGowan Inst Regenerat Med, Pittsburgh, PA USA.
   [Hill, William D.] Charlie Norwood VA Med Ctr, Augusta, GA USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University; University
   System of Georgia; Augusta University; Carnegie Mellon University;
   Carnegie Mellon University; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Charlie Norwood VA Medical Center
RP Cray, JJ (通讯作者)，Med Univ S Carolina, Dept Oral Hlth Sci, BSB 2308,173 Ashley Ave, Charleston, SC 29425 USA.
EM crayj@musc.edu
RI ; Hill, William/F 9632 2012; Herberg, Samuel/I 3811 2019
OI Herberg, Samuel/0000 0001 7196 2010; 
FU Musculoskeletal Transplant Foundation; Institute for Regenerative and
   Reparative Medicine at Georgia Regents University; U.S. Department of
   Veterans Affairs [VA104462]; National Institute on Aging [NIH NIA
   PO1 AG036675]
FX This study was supported by a grant from the Musculoskeletal Transplant
   Foundation (JC), the Institute for Regenerative and Reparative Medicine
   at Georgia Regents University (JC), the U.S. Department of Veterans
   Affairs VA104462 (WDH), and the National Institute on Aging NIH NIA
   PO1 AG036675 (WDH). The authors would like to thank Mr. Kameron
   Khaksarfard for his help with this study. The contents of this
   publication do not represent the views of the Department of Veterans
   Affairs, or the United States Government.
CR Bess S, 2012, NEUROSURGERY, V71, pE556, DOI 10.1227/01.neu.0000417730.19602.c4
   Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Boerckel JD, 2011, BIOMATERIALS, V32, P5241, DOI 10.1016/j.biomaterials.2011.03.063
   BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brugger SM, 2004, DEVELOPMENT, V131, P5153, DOI 10.1242/dev.01390
   Burt C W, 1998, Vital Health Stat 13, P1
   Campbell PG, 2005, BIOMATERIALS, V26, P6762, DOI 10.1016/j.biomaterials.2005.04.032
   Campbell PG, 2007, EXPERT OPIN BIOL TH, V7, P1123, DOI 10.1517/14712598.7.8.1123
   Capron C, 2010, BLOOD, V116, P1244, DOI 10.1182/blood 2009 05 221093
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27
   Chim H, 2012, CELL TISSUE RES, V350, P89, DOI 10.1007/s00441 012 1449 x
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Cooper GM, 2010, PLAST RECONSTR SURG, V125, P1685, DOI 10.1097/PRS.0b013e3181cb63a3
   Cooper GM, 2010, TISSUE ENG PT A, V16, P1749, DOI [10.1089/ten.tea.2009.0650, 10.1089/ten.TEA.2009.0650]
   Cowan CM, 2005, TISSUE ENG, V11, P645, DOI 10.1089/ten.2005.11.645
   Crawford Charles H 3rd, 2009, Am J Orthop (Belle Mead NJ), V38, P567
   Cray JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069067
   David L, 2005, J CRANIOFAC SURG, V16, P129, DOI 10.1097/00001665 200501000 00026
   Davis DA, 2005, BLOOD, V105, P4561, DOI 10.1182/blood 2004 12 4618
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   DeCesare GE, 2011, PLAST RECONSTR SURG, V127, P588, DOI 10.1097/PRS.0b013e3181fed5c5
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Friess W, 1999, INT J PHARM, V187, P91, DOI 10.1016/S0378 5173(99)00174 X
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Hasegawa T, 2012, INT J MOL MED, V30, P35, DOI 10.3892/ijmm.2012.957
   He DM, 2010, J NEUROSURG, V112, P319, DOI 10.3171/2009.1.JNS08976
   Heesen M, 1996, J IMMUNOL, V157, P5455
   Herberg S, 2014, TISSUE ENG PT A, V20, P1444, DOI [10.1089/ten.tea.2013.0442, 10.1089/ten.TEA.2013.0442]
   Herberg S, 2013, TISSUE ENG PT A, V19, P1, DOI [10.1089/ten.tea.2012.0085, 10.1089/ten.TEA.2012.0085]
   Higashino K, 2011, TISSUE ENG PT A, V17, P523, DOI 10.1089/ten.tea.2010.0168
   Hodges SD, 2012, ORTHOPEDICS, V35, pE895, DOI 10.3928/01477447 20120525 30
   Hollinger J O, 1990, J Craniofac Surg, V1, P60, DOI 10.1097/00001665 199001000 00011
   Hosogane N, 2010, INT J BIOCHEM CELL B, V42, P1132, DOI 10.1016/j.biocel.2010.03.020
   Johnson EE, 2000, CLIN ORTHOP RELAT R, P61, DOI 10.1097/00003086 200002000 00008
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kinsella CR, 2011, PLAST RECONSTR SURG, V127, P1865, DOI 10.1097/PRS.0b013e31820cf2c9
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097 4644(19990401)73:1<114::AID JCB13>3.3.CO;2 D
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Marquez Curtis L, 2008, STEM CELLS, V26, P1211, DOI 10.1634/stemcells.2007 0725
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Miller ED, 2006, BIOMATERIALS, V27, P2213, DOI 10.1016/j.biomaterials.2005.10.021
   Miller ED, 2009, COMB CHEM HIGH T SCR, V12, P604, DOI 10.2174/138620709788681907
   Miraoui H, 2010, GENE, V468, P1, DOI 10.1016/j.gene.2010.07.013
   Mitchener TA, 2010, AM J PREV MED, V38, pS86, DOI 10.1016/j.amepre.2009.10.016
   Morey JS, 2006, BIOL PROCED ONLINE, V8, P175, DOI 10.1251/bpo126
   Otsuru S, 2008, STEM CELLS, V26, P223, DOI 10.1634/stemcells.2007 0515
   Ratanavaraporn J, 2011, BIOMATERIALS, V32, P2797, DOI 10.1016/j.biomaterials.2010.12.052
   Ripoll CB, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471 2121 10 3
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Schmitz JP., 1986, CLIN ORTHOP RELAT R, V205, P299
   Sen MK, 2007, INJURY, V38, pS75, DOI 10.1016/j.injury.2007.02.012
   Sierra MD, 2004, BLOOD, V103, P2452
   Smith DM, 2008, J CRANIOFAC SURG, V19, P1315, DOI 10.1097/SCS.0b013e3181843369
   Smith DM, 2008, J CRANIOFAC SURG, V19, P1244, DOI 10.1097/SCS.0b013e3181843312
   Smith DM, 2012, ANN PLAS SURG, V69, P485, DOI 10.1097/SAP.0b013e31824cfe64
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Swiontkowski MF, 2006, J BONE JOINT SURG AM, V88A, P1258, DOI 10.2106/JBJS.E.00499
   Tzakas P, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471 2474 6 29
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Wise JK, 2012, TISSUE ENG PT A, V18, P861, DOI [10.1089/ten.tea.2011.0187, 10.1089/ten.TEA.2011.0187]
   Yang HS, 2012, EXP MOL MED, V44, P350, DOI 10.3858/emm.2012.44.5.039
   Zhu W, 2007, J BIOL CHEM, V282, P18676, DOI 10.1074/jbc.M610232200
   Zhu W, 2011, J BIOL CHEM, V286, P26794, DOI 10.1074/jbc.M111.250985
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074 7613(00)80165 X
NR 71
TC 42
Z9 52
U1 0
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2014
VL 67
BP 95
EP 103
DI 10.1016/j.bone.2014.07.007
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AO3KJ
UT WOS:000341227800012
PM 25016095
OA Green Accepted
DA 2025 08 17
ER

PT J
AU De Boer, J
   Licht, R
   Bongers, M
   Van Der Klundert, T
   Arends, R
   Van Blitterswijk, C
AF De Boer, Jan
   Licht, Ruud
   Bongers, Marloes
   Van Der Klundert, Tessa
   Arends, Roel
   Van Blitterswijk, Clemens
TI Inhibition of histone acetylation as a tool in bone tissue engineering
SO TISSUE ENGINEERING
LA English
DT Article
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; TRICHOSTATIN A; IN VITRO;
   OSTEOGENIC DIFFERENTIATION; DEACETYLASE INHIBITORS; VALPROATE THERAPY;
   GENE EXPRESSION; ACID; VIVO
AB Our approach to bone tissue engineering is the in vitro expansion and osteogenic differentiation of bone marrow derived human mesenchymal stem cells (hMSCs) and their subsequent implantation on porous ceramic materials. Current osteogenic differentiation protocols use dexamethasone to initiate the osteogenic process, thus ignoring the multiple signaling pathways that control osteogenesis in vivo. Supporting osteogenesis at multiple stages might further enhance the bone forming capacity of hMSCs. As reported previously, inhibition of so called histone deacetylases (HDACs) stimulates osteoblast maturation, and in this report, we investigated whether trichostatin A (TSA), a widely used HDAC inhibitor, can be implemented in bone tissue engineering. We confirmed that TSA treatment of hMSCs results in increased expression of alkaline phosphatase (ALP) with concomitant increase in mineralization. Flow cytometry demonstrated that TSA increases the percentage of ALP positive hMSCs as well as their average ALP expression level, but the robustness of the response differs between donors. Unfortunately, TSA has a profound negative effect on cell proliferation, so we investigated whether hMSCs respond to TSA after reaching confluence. Confluent hMSCs on tissue culture plastic displayed enhanced ALP expression. Therefore, we seeded TSA treated hMSCs onto ceramic particles and analyzed ectopic bone formation upon implantation in immune deficient mice. Unfortunately, TSA treated hMSCs did not display better bone formation in vivo than control cells. Finally, we observed that TSA treatment strongly enhanced bone formation of ex vivo cultured mouse calvaria, which warrants further exploration of TSA in bone tissue engineering.
C1 Univ Twente, Inst Biomed Technol, NL 7500 AE Enschede, Netherlands.
   NV Organon, Dept Pharmacol, NL 5340 BH Oss, Netherlands.
C3 University of Twente; Merck & Company; Merck & Company Netherlands
RP De Boer, J (通讯作者)，Univ Twente, Inst Biomed Technol, POB 217, NL 7500 AE Enschede, Netherlands.
EM j.deboer@tnw.utwente.nl
OI van Blitterswijk, Clemens/0000 0003 2371 4615; de Boer,
   Jan/0000 0001 9188 9324
CR Bianco P, 2001, NATURE, V414, P118, DOI 10.1038/35102181
   BOTH SK, IN PRESS TISSUE ENG
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471 4914(01)02016 0
   CASTROMALASPINA H, 1980, BLOOD, V56, P289
   Caterson EJ, 2001, J BIOMED MATER RES, V57, P394, DOI 10.1002/1097 4636(20011205)57:3<394::AID JBM1182>3.0.CO;2 9
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753
   de Bruijn J D, 1999, Adv Dent Res, V13, P74
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825
   Fenic I, 2004, J ANDROL, V25, P811
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   GarciaVillalba P, 1997, DNA CELL BIOL, V16, P421, DOI 10.1089/dna.1997.16.421
   GOSHIMA J, 1991, CLIN ORTHOP RELAT R, P298
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   HEATH JK, 1989, CONNECT TISSUE RES, V20, P15, DOI 10.3109/03008208909023870
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Mellor J, 2005, MOL CELL, V19, P147, DOI 10.1016/j.molcel.2005.06.023
   Mendes SC, 2002, J MATER SCI MATER M, V13, P575, DOI 10.1023/A:1015178827323
   Mendes SC, 2002, TISSUE ENG, V8, P911, DOI 10.1089/107632702320934010
   Mendes SC, 1998, J MATER SCI MATER M, V9, P855, DOI 10.1023/A:1008904413859
   MITOMA C, 1960, J BIOL CHEM, V235, P426
   Nervi C, 2001, CANCER RES, V61, P1247
   Ogston N, 2002, STEROIDS, V67, P895, DOI 10.1016/S0039 128X(02)00054 5
   Pavlakis SG, 1998, PEDIATR NEUROL, V19, P143, DOI 10.1016/S0887 8994(98)00024 1
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Pittenger MF, 2001, COLD SPRING HARBOR M, P349
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood 2002 08 2622
   Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   SIDDAPPA R, UNPUB CELL AUTONOMOU
   Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200
   Stock SR, 2004, J STRUCT BIOL, V147, P185, DOI 10.1016/j.jsb.2004.03.003
   Takeda M, 2004, MOL BIOL CELL, V15, P963, DOI 10.1091/mbc.E03 07 0478
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873 2884.2005
   YOON K, 1988, BIOCHEMISTRY US, V27, P8521, DOI 10.1021/bi00423a003
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   ZERNIK J, 1990, DIFFERENTIATION, V44, P207, DOI 10.1111/j.1432 0436.1990.tb00619.x
   Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106 5118.2004
NR 48
TC 65
Z9 68
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1076 3279
J9 TISSUE ENG
JI Tissue Eng.
PD OCT
PY 2006
VL 12
IS 10
BP 2927
EP 2937
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 105PU
UT WOS:000242045600021
PM 17518660
DA 2025 08 17
ER

PT J
AU Ritchlin, CT
AF Ritchlin, Christopher T.
TI From skin to bone: Translational perspectives on psoriatic disease
SO JOURNAL OF RHEUMATOLOGY
LA English
DT Article
DE psoriatic arthritis; psoriasis; synovium; enthesis; dactylitis; bone
   remodeling
ID OSTEOCLAST DIFFERENTIATION; RADIOGRAPHIC PROGRESSION; EARLY SYNOVITIS;
   JOINT DISEASE; ARTHRITIS; PATHOGENESIS; DACTYLITIS; MODULATION;
   PATTERNS; THERAPY
AB In recent years, translational research has provided fresh insights into the mechanisms that underlie both skin and joint inflammation in psoriatic arthritis (PsA). Application of immunological and molecular techniques to the study of involved tissues, combined with magnetic resonance imaging and relevant preclinical models, has unveiled pivotal inflammatory cascades and cytokine networks that lead to sustained inflammation and altered tissue architecture. In this brief overview of a presentation from the 2007 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) the key pathophysiologic events associated with inflammation in psoriatic plaques, synovial membranes, and soft tissues (entheses, tendons), and with abnormal bone remodeling are discussed.
C1 Univ Rochester, Med Ctr, Clin Immunol Res Ctr, Rochester, NY 14642 USA.
C3 University of Rochester
RP Ritchlin, CT (通讯作者)，Univ Rochester, Med Ctr, Clin Immunol Res Ctr, 601 Elmwood Ave,Box 695, Rochester, NY 14642 USA.
EM christopher_ritchlin@urmc.rochester.edu
OI ritchlin, christopher/0000 0002 2602 1219
CR Aldridge SE, 2005, BIOCHEM BIOPH RES CO, V335, P793, DOI 10.1016/j.bbrc.2005.07.145
   Anandarajah AP, 2008, ANN RHEUM DIS, V67, P296, DOI 10.1136/ard.2007.076091
   Benjamin M, 2007, ARTHRITIS RHEUM, V56, P3601, DOI 10.1002/art.23078
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cañete JD, 2007, ANN RHEUM DIS, V66, P720, DOI 10.1136/ard.2006.062042
   Clark RA, 2006, J CLIN INVEST, V116, P2084, DOI 10.1172/JCI29441
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Fearon U, 2003, J RHEUMATOL, V30, P260
   Fitch Erin, 2007, Curr Rheumatol Rep, V9, P461, DOI 10.1007/s11926 007 0075 1
   GOTTLIEB A, 2008, ARTHRITIS R IN PRESS, V54
   Healy PJ, 2008, RHEUMATOLOGY, V47, P92, DOI 10.1093/rheumatology/kem315
   Kane D, 2003, RHEUMATOLOGY, V42, P1460, DOI 10.1093/rheumatology/keg384
   Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382
   Kruithof E, 2005, ARTHRITIS RES THER, V7, pR569, DOI 10.1186/ar1698
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Lories RJU, 2004, ANN RHEUM DIS, V63, P595, DOI 10.1136/ard.2003.013599
   Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663
   McGonagle D, 2008, ANN RHEUM DIS, V67, P1, DOI 10.1136/ard.2007.080952
   McHugh NJ, 2003, RHEUMATOLOGY, V42, P778, DOI 10.1093/rheumatology/keg217
   MOLL J M H, 1973, Seminars in Arthritis and Rheumatism, V3, P55, DOI 10.1016/0049 0172(73)90035 8
   Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500
   Olivieri I, 2002, ARTHRITIS RHEUM US, V46, P2964, DOI 10.1002/art.10633
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Reece RJ, 1999, ARTHRITIS RHEUM, V42, P1481, DOI 10.1002/1529 0131(199907)42:7<1481::AID ANR23>3.0.CO;2 E
   Ritchlin C, 1998, J RHEUMATOL, V25, P1544
   Ritchlin C, 2007, NAT CLIN PRACT RHEUM, V3, P698, DOI 10.1038/ncprheum0670
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Scarpa R, 2006, J RHEUMATOL, V33, P210
   Van der Heijde D, 2007, ANN RHEUM DIS, V66, P85
   van der Heijde DM, 2006, ANN RHEUM DIS, V65, P81
   van Kuijk AWR, 2006, ANN RHEUM DIS, V65, P1551, DOI 10.1136/ard.2005.050963
   Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963
NR 32
TC 24
Z9 26
U1 0
U2 0
PU J RHEUMATOL PUBL CO
PI TORONTO
PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA
SN 0315 162X
EI 1499 2752
J9 J RHEUMATOL
JI J. Rheumatol.
PD JUL
PY 2008
VL 35
IS 7
BP 1434
EP 1437
PG 4
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 324YD
UT WOS:000257554400039
PM 18609740
DA 2025 08 17
ER

PT J
AU Cozzolino, M
   Ketteler, M
   Martin, KJ
   Sharma, A
   Goldsmith, D
   Khan, S
AF Cozzolino, Mario
   Ketteler, Markus
   Martin, Kevin J.
   Sharma, Amit
   Goldsmith, David
   Khan, Samina
TI Paricalcitol  or cinacalcet centred therapy affects markers of bone
   mineral disease in patients with secondary hyperparathyroidism receiving
   haemodialysis: results of the IMPACT SHPT study
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE bone turnover marker; chronic kidney disease; cinacalcet; paricalcitol;
   secondary hyperparathyroidism
ID CHRONIC KIDNEY DISEASE; STAGE RENAL DISEASE; DOSE VITAMIN D; MORTALITY
   RISK; CALCIFICATION; FIBROBLAST GROWTH FACTOR 23; SURVIVAL; EFFICACY;
   HORMONE; FGF 23
AB Background. In this Phase 4 international study, efficacy and safety of paricalcitol centred therapy were compared with that of cinacalcet centred therapy for the treatment of chronic kidney disease (CKD) associated secondary hyperparathyroidism (SHPT) in patients undergoing haemodialysis (ClinicalTrials. gov identifier NCT00977080).
   Methods. Patients >= 18 years of age with Stage 5 CKD and SHPT [intact parathyroid hormone (iPTH) level of 300 800 pg/mL, calcium level of 8.4 10.0 mg/dL and phosphate concentration of <= 6.5 mg/dL] who were undergoing haemodialysis were included. Patients were randomized by mode of paricalcitol administration [i.e. intravenous (IV) or oral strata] to receive paricalcitol or cinacalcet centred therapy for <= 28 weeks. Changes in metabolic markers [total alkaline phosphatase (AP), bone specific AP and fibroblast growth factor 23 (FGF 23)] and the proportion of patients in each treatment group who achieved an iPTH level of 150 300 pg/mL during Weeks 8, 16 and 21 28 as a composite value were evaluated.
   Results. Compared with cinacalcet centred therapy, levels of both bone turnover markers were significantly reduced from baseline with IV and oral paricalcitol centred treatment (P < 0.05 for both dosing strata) at Weeks 8, 16 and 28. Levels of FGF 23 were increased with paricalcitol versus cinacalcet centred treatment. A greater proportion of patients receiving paricalcitol centred therapy achieved target iPTH levels (i.e. 150 300 pg/mL) throughout the study in the IV and oral dosing strata compared with patients receiving cinacalcet centred treatment.
   Conclusions. In patients with CKD and SHPT undergoing haemodialysis, paricalcitol centred therapy reduced circulating bone turnover markers and iPTH levels and increased FGF 23 levels compared with cinacalcet centred treatment.
C1 [Cozzolino, Mario] Univ Milan, Dept Hlth Sci, Renal Div, San Paolo Hosp, Milan, Italy.
   [Ketteler, Markus] Rhein Westfal TH Aachen, Univ Hosp, Dept Nephrol & Clin Immunol, D 52062 Aachen, Germany.
   [Martin, Kevin J.] St Louis Univ, Dept Internal Med, Div Nephrol, St Louis, MO 63103 USA.
   [Sharma, Amit] Nephrian, Eagle, ID USA.
   [Goldsmith, David] Guys Hosp, Adult Renal & Transplantat Unit, London SE1 9RT, England.
   [Khan, Samina] AbbVie Inc, N Chicago, IL USA.
C3 University of Milan; San Paolo Polo Universitaria Hospital; RWTH Aachen
   University; RWTH Aachen University Hospital; Saint Louis University;
   Guy's & St Thomas' NHS Foundation Trust; AbbVie
RP Cozzolino, M (通讯作者)，Univ Milan, Dept Hlth Sci, Renal Div, San Paolo Hosp, Milan, Italy.
EM mario.cozzolino@unimi.it
RI Martin, Kevin/AAA 3212 2021; Goldsmith, David/H 6965 2018; Cozzolino,
   Mario/AAB 9965 2022
OI Goldsmith, David/0000 0002 4349 9193; Cozzolino,
   Mario/0000 0002 8494 6252
FU AbbVie Inc
FX AbbVie Inc provided funding for the IMPACT SHPT study and was involved
   in the study design, research analysis, interpretation of data and
   reviewing and approval of the publication. The principal investigators
   of the IMPACT SHPT study and authors on the publication prepared the
   manuscript and designed the figures without compensation. Medical
   writing and editorial support, funded by AbbVie Inc, were provided under
   the direction of the authors by Jillian Gee, Sophie Bolick and Jennifer
   Rossi, MedThink SciCom.
CR Barreto DV, 2005, KIDNEY INT, V67, P1576, DOI 10.1111/j.1523 1755.2005.00239.x
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Drüeke TB, 2009, CLIN J AM SOC NEPHRO, V4, P234, DOI 10.2215/CJN.04520908
   Fox CS, 2012, LANCET, V380, P1662, DOI 10.1016/S0140 6736(12)61350 6
   Grams ME, 2013, NAT REV NEPHROL, V9, P18, DOI 10.1038/nrneph.2012.248
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Sánchez JGH, 2011, NEFROLOGIA, V31, P697, DOI 10.3265/Nefrologia.pre2011.Aug.11030
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kazama JJ, 2005, KIDNEY INT, V67, P1120, DOI 10.1111/j.1523 1755.2005.00178.x
   Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018
   Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P1942, DOI 10.1093/ndt/gfr531
   Khan AM, 2012, CLIN J AM SOC NEPHRO, V7, P2017, DOI 10.2215/CJN.02160212
   Koizumi M, 2012, NEPHROL DIAL TRANSPL, V27, P784, DOI 10.1093/ndt/gfr384
   Lee GH, 2007, J RENAL NUTR, V17, P38, DOI 10.1053/j.jrn.2006.07.006
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003 4819 150 9 200905050 00006
   Lewis R, 2012, ANN CLIN BIOCHEM, V49, P432, DOI 10.1258/acb.2012.012004
   Liu SG, 2006, J AM SOC NEPHROL, V17, P1305, DOI 10.1681/ASN.2005111185
   Martin KJ, 2007, J AM SOC NEPHROL, V18, P875, DOI 10.1681/ASN.2006070771
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Mejía N, 2011, NEFROLOGIA, V31, P514, DOI 10.3265/Nefrologia.pre2011.Jun.10926
   National Kidney Foundation, 2003, KDOQI CLIN PRACT GUI
   Nitta K, 2010, INT J NEPHROL, V2010, DOI 10.4061/2010/167984
   Ott SM, 2008, CLIN J AM SOC NEPHRO, V3, pS151, DOI 10.2215/CJN.04301206
   Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735 1097(01)01781 8
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Tonbul HZ, 2012, RENAL FAILURE, V34, P297, DOI 10.3109/0886022X.2011.647298
   United States Renal Data System (USRDS), 2012 ATL CKD ESRD, V1
NR 28
TC 31
Z9 32
U1 1
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD APR
PY 2014
VL 29
IS 4
BP 899
EP 905
DI 10.1093/ndt/gfu011
PG 7
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA AH4JR
UT WOS:000336093700029
PM 24500308
DA 2025 08 17
ER

PT J
AU Boddy, SL
   Chen, W
   Romero Guevara, R
   Kottam, L
   Bellantuono, I
   Rivolta, MN
AF Boddy, Sarah L.
   Chen, Wei
   Romero Guevara, Ricardo
   Kottam, Lucksy
   Bellantuono, Illaria
   Rivolta, Marcelo N.
TI Inner ear progenitor cells can be generated in vitro from human
   bone marrow mesenchymal stem cells
SO REGENERATIVE MEDICINE
LA English
DT Article
DE deafness; hair cell; human mesenchymal stem cell; sensory neuron; WNT
ID STROMAL CELLS; DIFFERENTIATION; TRANSPLANTATION; PROLIFERATION; COCHLEA;
   IDENTIFICATION; PLURIPOTENCY; EXPRESSION; THERAPIES; DISEASE
AB Aim: Mouse mesenchymal stem cells (MSCs) can generate sensory neurons and produce inner ear hair cell like cells. An equivalent source from humans is highly desirable, given their potential application in patient specific regenerative therapies for deafness. In this study, we explored the ability of human MSCs (hMSCs) to differentiate into otic lineages. Materials & methods: hMSCs were exposed to culture media conditioned by human fetal auditory stem cells. Results: Conditioned media induced the expression of otic progenitor markers PAX8, PAX2, GATA3 and SOX2. After 4 weeks, cells coexpressed ATOH1, MYO7A and POU4F3 (indicators of hair cell lineage) or neuronal markers NEUROG1, POU4F1 and NEFH. Inhibition of WNT signaling prevented differentiation into otic progenitors, while WNT activation partially phenocopied results seen with the conditioned media. Conclusion: This study demonstrates that hMSCs can be driven to express key genes found in the otic lineages and thereby promotes their status as candidates for regenerative therapies for deafness.
C1 [Boddy, Sarah L.; Chen, Wei; Romero Guevara, Ricardo; Rivolta, Marcelo N.] Univ Sheffield, Ctr Stem Cell Biol, Sheffield S10 2TN, S Yorkshire, England.
   [Boddy, Sarah L.; Chen, Wei; Romero Guevara, Ricardo; Rivolta, Marcelo N.] Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England.
   [Kottam, Lucksy; Bellantuono, Illaria] Univ Sheffield, Acad Unit Bone Biol, Mellanby Ctr Bone Res, Sch Med, Sheffield S10 STA, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield
RP Rivolta, MN (通讯作者)，Univ Sheffield, Ctr Stem Cell Biol, Alfred Denny Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.
EM m.n.rivolta@sheffield.ac.uk
RI ; Bellantuono, Ilaria/ABF 2700 2021
OI Romero Guevara, Ricardo/0000 0002 4102 8128; Bellantuono,
   Ilaria/0000 0001 9994 6987; 
FU Deafness Research UK; RNID [515:SHE:MR] Funding Source: researchfish
FX This work was supported by a Deafness Research UK award to MN Rivolta.
   The authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Bae KS, 2011, YONSEI MED J, V52, P401, DOI 10.3349/ymj.2011.52.3.401
   Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22 5 675
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Chen W, 2009, UK NATL STEM CELL NE
   Chen W, 2012, NATURE, V490, P278, DOI 10.1038/nature11415
   Chen W, 2009, STEM CELLS, V27, P1196, DOI 10.1002/stem.62
   Cho YB, 2011, J KOREAN MED SCI, V26, P492, DOI 10.3346/jkms.2011.26.4.492
   Deafness Research UK, GOALS STRAT
   Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935
   Dinarvand P, 2010, BIOL PHARM BULL, V33, P1212, DOI 10.1248/bpb.33.1212
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Alonso MBD, 2012, REGEN MED, V7, P769, DOI [10.2217/RME.12.65, 10.2217/rme.12.65]
   Fu LJ, 2008, STEM CELLS DEV, V17, P1109, DOI 10.1089/scd.2008.0068
   Ginis I, 2004, DEV BIOL, V269, P360, DOI 10.1016/j.ydbio.2003.12.034
   Grabel L, 2012, J CELL BIOCHEM, V113, P381, DOI 10.1002/jcb.23364
   Greber B, 2010, CELL STEM CELL, V6, P215, DOI 10.1016/j.stem.2010.01.003
   Hildebrand MS, 2005, JARO J ASSOC RES OTO, V6, P341, DOI 10.1007/s10162 005 0012 9
   Jeon SJ, 2007, MOL CELL NEUROSCI, V34, P59, DOI 10.1016/j.mcn.2006.10.003
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kamiya K, 2007, AM J PATHOL, V171, P214, DOI 10.2353/ajpath.2007.060948
   Karow M, 2009, J CELL MOL MED, V13, P2506, DOI 10.1111/j.1582 4934.2008.00619.x
   Kondo T, 2005, P NATL ACAD SCI USA, V102, P4789, DOI 10.1073/pnas.0408239102
   Kondo T, 2011, STEM CELLS, V29, P836, DOI 10.1002/stem.624
   Ladher RK, 2000, SCIENCE, V290, P1965, DOI 10.1126/science.290.5498.1965
   Lang HN, 2008, JARO J ASSOC RES OTO, V9, P225, DOI 10.1007/s10162 008 0119 x
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Montzka K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471 2202 10 16
   Na J, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt33
   Ohyama T, 2006, DEVELOPMENT, V133, P865, DOI 10.1242/dev.02271
   Oshima K, 2010, CELL, V141, P704, DOI 10.1016/j.cell.2010.03.035
   Pandit SR, 2011, STEM CELLS, V29, P670, DOI 10.1002/stem.609
   Paul S, 2008, NEOPLASMA, V55, P165
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Qin H, 2011, ACTA OTO LARYNGOL, V131, P1136, DOI 10.3109/00016489.2011.603135
   Riccomagno MM, 2005, GENE DEV, V19, P1612, DOI 10.1101/gad.1303905
   Shi FX, 2010, J BIOL CHEM, V285, P392, DOI 10.1074/jbc.M109.059055
   Sohni A, 2011, BEST PRACT RES CL HA, V24, P3, DOI 10.1016/j.beha.2011.01.006
   Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 52
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   WHO, 2006, FAC FAC HEAR IMP
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
NR 42
TC 27
Z9 33
U1 0
U2 21
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746 0751
EI 1746 076X
J9 REGEN MED
JI Regen. Med.
PD NOV
PY 2012
VL 7
IS 6
BP 757
EP 767
DI 10.2217/RME.12.58
PG 11
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA 031QC
UT WOS:000310656000012
PM 23164077
DA 2025 08 17
ER

PT J
AU Ballini, A
   Mastrangelo, F
   Gastaldi, G
   Tettamanti, L
   Bukvic, N
   Cantore, S
   Cocco, T
   Saini, R
   Desiate, A
   Gherlone, E
   Scacco, S
AF Ballini, A.
   Mastrangelo, F.
   Gastaldi, G.
   Tettamanti, L.
   Bukvic, N.
   Cantore, S.
   Cocco, T.
   Saini, R.
   Desiate, A.
   Gherlone, E.
   Scacco, S.
TI OSTEOGENIC DIFFERENTIATION AND GENE EXPRESSION OF DENTAL PULP STEM CELLS
   UNDER LOW LEVEL LASER IRRADIATION: A GOOD PROMISE FOR TISSUE ENGINEERING
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE dental pulp stem cells; low level laser therapy; RUNX2; osterix;
   osteoblasts
ID LOW ENERGY LASER; AUTOLOGOUS BONE; HEALING PROCESS; THERAPY; MECHANISM;
   EFFICACY; CULTURES; DEFECTS; WOUNDS; RATS
AB The effects of low level laser therapy (LLLT) has been the focus of recent studies as being assumed responsible for promoting photostimulatory and photobiomodulatory effects in vivo and in vitro, increasing cell metabolism, improving cell regeneration and invoking an anti inflammatory response. A positive effect of LLLT on the bone proliferation of some cell types has been observed, but little is known about its effect on dental pulp stem cells (DPSCs). Here, we accurately describe the technical procedure to isolate mesenchymal DPSCs, and assay their osteogenic capacity when irradiated with an LLLT source. These preliminary results show that LLLT irradiation influences the in vitro proliferation of DPSCs and increases the expression of essential proteins for bone formation, although it is necessary to carry out further experiments on other cell types and to uniform the methodological designs.
C1 [Ballini, A.; Cantore, S.; Cocco, T.; Scacco, S.] Univ Bari Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy.
   [Mastrangelo, F.; Gastaldi, G.; Gherlone, E.] Vita & Salute San Raffaele Univ, IRCCS San Raffaele Sci Inst, Unit Dent, I 20132 Milan, Italy.
   [Tettamanti, L.] Rural Dent Coll Loni Maharashtra, Dept Periodontol & Oral Implantol, Ahmednagar, Maharashtra, India.
   [Bukvic, N.] Univ Hosp Bari Policlin, Med Genet Unit Bari, Bari, Italy.
   [Saini, R.] Insubria Univ Varese, Dept Oral Sci, Varese, Italy.
   [Desiate, A.] Univ Hosp Bari Policlin, Dept Interdisciplinary Med, Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Vita Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; University of Insubria
RP Mastrangelo, F (通讯作者)，Vita & Salute San Raffaele Univ, IRCCS San Raffaele Sci Inst, Unit Dent, Via Olgettina 60, I 20132 Milan, Italy.
EM filibertomastrangelo@hotmail.com
RI ; Cocco, Tiziana/AAG 9064 2020; Bukvic, Nenad/ABH 7268 2020; Gherlone,
   Enrico/M 7376 2016; Scacco, Salvatore/AAC 7406 2022; Ballini,
   Andrea/R 5821 2016; MASTRANGELO, Filiberto/U 7540 2017
OI Ballini, Andrea/0000 0001 8758 1415; Cocco, Tiziana
   Maria/0000 0001 7171 3460; Scacco, Salvatore/0000 0003 2717 2489;
   Bukvic, MD, PhD, Nenad/0000 0002 9235 8987; Cantore,
   Stefania/0000 0001 9521 2521; Gherlone, Enrico/0000 0002 5193 8467;
   MASTRANGELO, Filiberto/0000 0002 3746 5675
CR Abramovitch Gottlib L, 2005, LASER MED SCI, V20, P138, DOI 10.1007/s10103 005 0355 9
   Ballini A, 2007, INT J IMMUNOPATH PH, V20, P9, DOI 10.1177/039463200702000102
   Ballini A, 2007, Int J Med Sci, V4, P174
   Ballini A, 2009, INT J MED SCI, V6, P65
   BARUSHKA O, 1995, BONE, V16, P47, DOI 10.1016/S8756 3282(94)00006 9
   Brunetti G, 2013, CELL BIOCHEM BIOPHYS, V67, P1127, DOI 10.1007/s12013 013 9616 6
   Chen A., 2009, P SPIE, V7165, P71650
   Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439 011 0454 7
   Giorgini E, 2011, VIB SPECTROSC, V57, P30, DOI 10.1016/j.vibspec.2011.04.004
   Grassi FR, 2011, J BIOL REG HOMEOS AG, V25, P603
   Haxsen V, 2008, LASER MED SCI, V23, P381, DOI 10.1007/s10103 007 0511 5
   Herascu N, 2005, PHOTOMED LASER SURG, V23, P70, DOI 10.1089/pho.2005.23.70
   KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032 198905000 00015
   Kemmotsu O., 1991, Laser Therapy, V3, P1
   Loreti EH, 2015, PHOTOMED LASER SURG, V33, P104, DOI 10.1089/pho.2014.3772
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Miloro M, 2002, ORAL SURG ORAL MED O, V93, P27, DOI 10.1067/moe.2002.119518
   Mori G, 2010, J BIOL REG HOMEOS AG, V24, P167
   Mori G, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/108451
   Mori G, 2012, INT J MED SCI, V9, P480, DOI 10.7150/ijms.4583
   Mori G, 2011, ANN NY ACAD SCI, V1237, P47, DOI 10.1111/j.1749 6632.2011.06234.x
   Nissan J, 2006, J ORAL REHABIL, V33, P619, DOI 10.1111/j.1365 2842.2006.01601.x
   Pinheiro ALB, 2005, PHOTOMED LASER SURG, V23, P485, DOI 10.1089/pho.2005.23.485
   Posten W, 2005, DERMATOL SURG, V31, P334, DOI 10.1097/00042728 200503000 00016
   PUCHTLER H, 1978, HISTOCHEMISTRY, V56, P177, DOI 10.1007/BF00495978
   Quaranta N, 2015, EUR ARCH OTORHINOLAR
   SAPERIA D, 1986, BIOCHEM BIOPH RES CO, V138, P1123, DOI 10.1016/S0006 291X(86)80399 0
   Sattayut S., 1999, Laser Therapy, V11, P88
   Scattarella A, 2010, INT J MED SCI, V7, P267
   TAKEDA Y, 1988, INT J ORAL MAX SURG, V17, P388, DOI 10.1016/S0901 5027(88)80070 5
NR 30
TC 50
Z9 51
U1 0
U2 11
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393 974X
EI 1724 6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD OCT DEC
PY 2015
VL 29
IS 4
BP 813
EP 822
PG 10
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA DB0UD
UT WOS:000368222100008
PM 26753641
DA 2025 08 17
ER

PT J
AU Del Mare, S
   Husanie, H
   Iancu, O
   Abu Odeh, M
   Evangelou, K
   Lovat, F
   Volinia, S
   Gordon, J
   Amir, G
   Stein, J
   Stein, GS
   Croce, CM
   Gorgoulis, V
   Lian, JB
   Aqeilan, RI
AF Del Mare, Sara
   Husanie, Hussam
   Iancu, Ortal
   Abu Odeh, Mohammad
   Evangelou, Konstantinos
   Lovat, Francesca
   Volinia, Stefano
   Gordon, Jonathan
   Amir, Gail
   Stein, Janet
   Stein, Gary S.
   Croce, Carlo M.
   Gorgoulis, Vassilis
   Lian, Jane B.
   Aqeilan, Rami I.
TI WWOX and p53 Dysregulation Synergize to Drive the Development of
   Osteosarcoma
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR SUPPRESSOR GENE; CANCER CELLS; RUNX2; DIFFERENTIATION;
   INACTIVATION; PATHOGENESIS; PROGRESSION; ACTIVATION; EXPRESSION;
   OCCUPANCY
AB Osteosarcoma is a highly metastatic form of bone cancer in adolescents and young adults that is resistant to existing treatments. Development of an effective therapy has been hindered by very limited understanding of the mechanisms of osteosarcomagenesis. Here, we used genetically engineered mice to investigate the effects of deleting the tumor suppressor Wwox selectively in either osteoblast progenitors or mature osteoblasts. Mice with conditional deletion of Wwox in preosteoblasts (Wwox(Delta osx1)) displayed a severe inhibition of osteogenesis accompanied by p53 upregulation, effects that were not observed in mice lacking Wwox in mature osteoblasts. Deletion of p53 in Wwox(Delta osx1) mice rescued the osteogenic defect. In addition, the Wwox; p53(Delta osx1) double knockout mice developed poorly differentiated osteosarcomas that resemble human osteosarcoma in histology, location, metastatic behavior, and gene expression. Strikingly, the development of osteosarcomas in these mice was greatly accelerated compared with mice lacking p53 only. In contrast, combined WWOX and p53 inactivation in mature osteoblasts did not accelerate osteosarcomagenesis compared with p53 inactivation alone. These findings provide evidence that a WWOX p53 network regulates normal bone formation and that disruption of this network in osteoprogenitors results in accelerated osteosarcoma. The Wwox; p53(Delta osx1) double knockout establishes a new osteosarcoma model with significant advancement over existing models. (C) 2016 AACR.
C1 [Del Mare, Sara; Husanie, Hussam; Iancu, Ortal; Abu Odeh, Mohammad; Aqeilan, Rami I.] Hebrew Univ Jerusalem, Fac Med, IMRIC, Lautenberg Ctr Immunol & Canc Res, IL 91905 Jerusalem, Israel.
   [Evangelou, Konstantinos; Gorgoulis, Vassilis] Univ Athens, Dept Histol & Embryol, Sch Med, Athens, Greece.
   [Lovat, Francesca; Croce, Carlo M.; Aqeilan, Rami I.] Ohio State Univ, Wexner Med Ctr, Dept Canc Biol & Genet CBG, Columbus, OH 43210 USA.
   [Volinia, Stefano; Lian, Jane B.] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Gordon, Jonathan; Stein, Janet; Stein, Gary S.; Aqeilan, Rami I.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   [Amir, Gail] Hadassah Univ Hosp, Dept Pathol, Jerusalem, Israel.
   [Gorgoulis, Vassilis] Acad Athens, Biomed Res Fdn, Athens, Greece.
   [Gorgoulis, Vassilis] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Inst Canc Sci, Manchester, Lancs, England.
   [Gorgoulis, Vassilis] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester Ctr Cellular Metab, Manchester, Lancs, England.
C3 Hebrew University of Jerusalem; National & Kapodistrian University of
   Athens; University System of Ohio; Ohio State University; University of
   Ferrara; University of Vermont; Hebrew University of Jerusalem; Hadassah
   University Hospital; Academy of Athens; University of Manchester;
   University of Manchester
RP Aqeilan, RI (通讯作者)，Hebrew Univ Jerusalem, Hadassah Med Sch, POB 12272, IL 91120 Jerusalem, Israel.
EM ramiaq@ekmd.huji.ac.il
RI Aqeilan, Rami/AAT 7785 2020; Volinia, Stefano/A 3029 2010; Gorgoulis,
   Vassilis/AAD 3630 2019; Evangelou, Konstantinos/AAG 5092 2020
OI Volinia, Stefano/0000 0003 0910 3893; Gorgoulis,
   Vassilis/0000 0001 9001 4112; 
FU NCI NIH HHS [P30 CA016058, P01 CA082834, R35 CA197706] Funding Source:
   Medline; NIDCR NIH HHS [R37 DE012528] Funding Source: Medline
CR Abdeen SK, 2013, J CELL PHYSIOL, V228, P1377, DOI 10.1002/jcp.24308
   Abu Odeh M, 2016, ONCOTARGET, V7, P4344, DOI 10.18632/oncotarget.6571
   Abu Odeh M, 2014, P NATL ACAD SCI USA, V111, pE4716, DOI 10.1073/pnas.1409252111
   Aqeilan RI, 2008, J BIOL CHEM, V283, P21629, DOI 10.1074/jbc.M800855200
   Aqeilan RI, 2007, CANCER RES, V67, P5606, DOI 10.1158/0008 5472.CAN 07 1081
   Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   Chang NS, 2003, BIOCHEM PHARMACOL, V66, P1347, DOI 10.1016/S0006 2952(03)00484 2
   Chang NS, 2002, INT J MOL MED, V9, P19
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   DEGRAFF WG, 1992, FREE RADICAL BIO MED, V13, P479, DOI 10.1016/0891 5849(92)90142 4
   Del Mare S, 2011, AM J CANCER RES, V1, P585
   Gardenswartz A, 2014, EXP BIOL MED, V239, P253, DOI 10.1177/1535370213519213
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008 5472.CAN 11 2663
   Jones Kevin B., 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/694136
   Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747
   Kurek KC, 2010, CANCER RES, V70, P5577, DOI 10.1158/0008 5472.CAN 09 4602
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Liontos M, 2009, AM J PATHOL, V175, P376, DOI 10.2353/ajpath.2009.081160
   Mirabello L, 2015, JNCI J NATL CANCER I, V107, DOI 10.1093/jnci/djv101
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Pratap J, 2011, BONE, V48, P30, DOI 10.1016/j.bone.2010.05.035
   Quist T, 2015, ONCOGENE, V34, P4278, DOI 10.1038/onc.2014.354
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Salah Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.6
   Uluckan Ozge, 2015, Methods Mol Biol, V1267, P297, DOI 10.1007/978 1 4939 2297 0_14
   van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Yang JL, 2010, CANCER LETT, V291, P31, DOI 10.1016/j.canlet.2009.09.018
   Yang SC, 2015, J CELL SCI, V128, P728, DOI 10.1242/jcs.160051
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
NR 38
TC 39
Z9 41
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD OCT
PY 2016
VL 76
IS 20
BP 6107
EP 6117
DI 10.1158/0008 5472.CAN 16 0621
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DZ1UW
UT WOS:000385627600021
PM 27550453
OA Green Accepted, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Dandekar, DS
   Lopez, M
   Carey, RI
   Lokeshwar, BL
AF Dandekar, DS
   Lopez, M
   Carey, RI
   Lokeshwar, BL
TI Cyclooxygenase 2 inhibitor celecoxib augments chemotherapeutic
   drug induced apoptosis by enhancing activation of caspase 3 and 9 in
   prostate cancer cells
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE prostate cancer; chemotherapy; combination therapy; cyclooxygenase 2
   celecoxib; Taxotere; COL 3
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IN VITRO; MULTIDRUG RESISTANCE;
   TUMOR PROGRESSION; OVER EXPRESSION; GROWTH; CARCINOMA; AGENTS; TARGET;
   ANGIOGENESIS
AB Many tumors constitutively express high levels of the inducible form of proinflammatory enzyme, cyclooxvgenase 2 (COX 2). Increased COX 2 expression is associated with tumor cell resistance to many cytotoxic chemotherapy drugs. Furthermore, increased resistance to cytotoxic antitumor drugs is also known to be dependent on associated stromal cells in many tumors. We investigated whether prostate tumor associated stromal cells, marrow derived osteoblasts, affect cytotoxicity of 2 antitumor drugs, COL 3 and docetaxel (TXTR), and whether it is dependent on COX 2 activity. We further examined whether inhibiting the activity of COX 2 negate the stroma induced decrease in drug sensitivity in tumor cells. COX 2 specific inhibitor celecoxib (CXB) was used to inhibit COX 2 activity and associated alteration in cell death signaling was investigated. Coculturing PC 3ML cells with osteoblasts decreased the cytotoxicity of the tested antitumor drugs and was associated with increased COX 2 activity in PC3ML cells. A significant decrease in drug induced PGE(2) increase and an increase in cytotoxicity were observed when cells were treated with COL 3 or TXTR combined with CXB. Cytotoxicity of single or combination treatment increased apoptosis, which was associated with caspase 3 and  9 activation, PARP cleavage, increased BAD protein, but decreased protein levels of XIAP and BCL (xL ) Oral administration of CXB (40 mg/kg) to mice with PC3ML tumors for 42 days increased tumor latency, decreased tumor growth and enhanced tumor control with COL 3 or TXTR. Overall, a synergistic enhancement of antitumor activity in combination treatment was observed in vitro and an additive effect in vivo. These observations suggest a potential clinical use of combined dosing of COX 2 inhibitors and cytotoxic drugs at lower, nontoxic dose than currently used to treat advanced prostate cancer. (c) 2005 Wiley Liss, Inc.
C1 Univ Miami, Sch Med, Dept Urol, Res Labs, Miami, FL 33101 USA.
   Univ Miami, Sch Med, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA.
C3 University of Miami; University of Miami
RP Univ Miami, Sch Med, Dept Urol, Res Labs, POB 016960 M 800, Miami, FL 33101 USA.
EM blokeshw@med.miami.edu
RI ; Lokeshwar, Bal/O 3196 2019
OI Dandekar, PhD., DABT, Deven/0009 0004 8931 9014; 
FU NCI NIH HHS [2R01 CA061038 10A1] Funding Source: Medline
CR [Anonymous], CA CANC J CLIN
   BAICH CM, 1984, SURGERY, V95, P71
   BARNETT J, 1994, BBA PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167 4838(94)90148 1
   Bottone FG, 2004, CARCINOGENESIS, V25, P349, DOI 10.1093/carcin/bgh016
   Chou TC, 2001, P NATL ACAD SCI USA, V98, P8113, DOI 10.1073/pnas.131153098
   Chou TC, 1987, NEW AVENUES DEV CANC, P37
   Dandekar DS, 2003, CANCER CHEMOTH PHARM, V52, P59, DOI 10.1007/s00280 003 0612 1
   De Marzo AM, 2003, UROLOGY, V62, P55, DOI 10.1016/j.urology.2003.09.053
   Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225
   Devi GR, 2004, DRUG NEWS PERSPECT, V17, P127, DOI 10.1358/dnp.2004.17.2.829046
   DONELLI MG, 1975, INT J CANCER, V32, P78
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Duffy CP, 1998, EUR J CANCER, V34, P1250, DOI 10.1016/S0959 8049(98)00045 8
   Ferrandina G, 2002, CANCER AM CANCER SOC, V95, P801, DOI 10.1002/cncr.10736
   Ferrandina G, 2002, J CLIN ONCOL, V20, P973, DOI 10.1200/JCO.20.4.973
   Ferrandina G, 2002, ANN ONCOL, V13, P1205, DOI 10.1093/annonc/mdf207
   Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3
   Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67
   FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698
   Gambaro G, 2003, J INTERN MED, V253, P643, DOI 10.1046/j.1365 2796.2003.01146.x
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01 0299fje
   Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097 0045(20000101)42:1<73::AID PROS9>3.0.CO;2 G
   Hayward SW, 1997, BRIT J UROL, V79, P18, DOI 10.1111/j.1464 410X.1997.tb16917.x
   Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943
   Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397
   Hussain T, 2003, CANCER LETT, V191, P125, DOI 10.1016/S0304 3835(02)00524 4
   Johnson AJ, 2001, ADV ENZYME REGUL, V41, P221, DOI 10.1016/S0065 2571(00)00015 7
   Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317
   Kirschenbaum A, 2001, UROLOGY, V58, P127, DOI 10.1016/S0090 4295(01)01255 9
   Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008 5472.CAN 03 2396
   Lai GH, 2003, MOL CANCER THER, V2, P265
   Lanza Jacoby S, 2003, CANCER EPIDEM BIOMAR, V12, P1486
   Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022 5347(05)67321 1
   Lokeshwar B L, 1998, Adv Dent Res, V12, P97
   Lokeshwar Bal L, 2001, ScientificWorldJournal, V1, P59, DOI 10.1100/tsw.2001.168
   Lokeshwar BL, 2002, INT J CANCER, V98, P297, DOI 10.1002/ijc.10168
   LOKESHWAR BL, 2003, P 94 ANN M
   Madaan S, 2000, BJU INT, V86, P736, DOI 10.1046/j.1464 410x.2000.00867.x
   MEAD JF, 1986, PROSTAGLANDINS THROM, P149
   Narayanan BA, 2003, CLIN CANCER RES, V9, P3503
   Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240 003 0300 y
   North GLT, 2001, ANN PHARMACOTHER, V35, P1638
   Patel VA, 2002, J BIOL CHEM, V277, P38915, DOI 10.1074/jbc.M206855200
   Perazella MA, 2001, AM J MED, V111, P64, DOI 10.1016/S0002 9343(01)00757 4
   Pinski J, 2001, CANCER RES, V61, P6372
   Plum SM, 2003, CLIN CANCER RES, V9, P4619
   Rainsford KD, 2001, J PHYSIOL PARIS, V95, P11, DOI 10.1016/S0928 4257(01)00004 3
   Sausville EA, 2001, CANCER METAST REV, V20, P117, DOI 10.1023/A:1013127605407
   Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313
   Sokoloff MH, 1996, CANCER AM CANCER SOC, V77, P1862
   Song XQ, 2002, J NATL CANCER I, V94, P585
   Soriano AF, 1999, CANCER RES, V59, P6178
   Srinivasu MK, 2000, J PHARMACEUT BIOMED, V22, P949, DOI 10.1016/S0731 7085(00)00303 4
   Subbarayan V, 2001, CANCER RES, V61, P2720
   Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259
   Sun YJ, 2002, CANCER RES, V62, P6323
   Tang XM, 2002, CANCER RES, V62, P4903
   TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497
   Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092 8674(00)81433 6
   Uotila P, 2001, UROL RES, V29, P25, DOI 10.1007/s002400000148
   van Brussel JP, 1999, EUR J CANCER, V35, P664, DOI 10.1016/S0959 8049(98)00435 3
   van Brussel JR, 2003, ONKOLOGIE, V26, P175, DOI 10.1159/000071510
   WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432 0436.1991.tb00250.x
   Zha S, 2001, CANCER RES, V61, P8617
   Zhu BQ, 1999, ANN NY ACAD SCI, V878, P642, DOI 10.1111/j.1749 6632.1999.tb07750.x
NR 66
TC 92
Z9 103
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 20
PY 2005
VL 115
IS 3
BP 484
EP 492
DI 10.1002/ijc.20878
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 925BD
UT WOS:000229025600021
PM 15688368
DA 2025 08 17
ER

PT J
AU McCleese, JK
   Bear, MD
   Fossey, SL
   Mihalek, RM
   Foley, KP
   Ying, WW
   Barsoum, J
   London, CA
AF McCleese, Jennifer K.
   Bear, Misty D.
   Fossey, Stacey L.
   Mihalek, Robert M.
   Foley, Kevin P.
   Ying, Weiwen
   Barsoum, James
   London, Cheryl A.
TI The novel HSP90 inhibitor STA 1474 exhibits biologic activity against
   osteosarcoma cell lines
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE osteosarcoma; HSP90; Met; STAT3; AKT
ID MOLECULAR CHAPERONE; ATP BINDING; SIGNAL TRANSDUCTION; MURAMYL
   TRIPEPTIDE; JAK STAT; HEAT SHOCK PROTEIN 90; RECEPTOR; GROWTH;
   EXPRESSION; TUMORS
AB Osteosarcoma (OSA), the most common malignant bone tumor in dogs and children, exhibits a similar clinical presentation and molecular biology in both species. Unfortunately, 30 40% of children and 90% of dogs still die of disease despite aggressive therapy. The purpose of this study was to test the biologic activity of a novel heat shock protein 90 (HSP90) inhibitor, STA 1474, against OSA. Canine and human OSA cell lines and normal canine osteoblasts were treated with STA 1474 and evaluated for effects on proliferation (CyQuant), apoptosis (Annexin V, PARP cleavage, caspase 3/7 activation) and known HSP90 client proteins. HSP90 was immunoprecipitated from normal and malignant osteoblasts and Western blotting for co chaperones was performed. Mice bearing canine OSA xenografts were treated with STA 1474, and tumors samples were evaluated for caspase 3 activation and loss of p Akt/Akt. Treatment with STA 1474 promoted loss of cell viability, inhibition of cell proliferation and induction of apoptosis in OSA cell lines. STA 1474 and its active metabolite STA 9090 also demonstrated increased potency compared to 17 AAG. STA 1474 exhibited selectivity for OSA cells versus normal canine osteoblasts, and HSP90 co precipitated with co chaperones p23 and Hop in canine OSA cells but not in normal canine osteoblasts. Furthermore, STA 1474 downregulated the expression of p Met/Met, p Akt/Akt and p STAT3. Finally, STA 1474 induced tumor regression, caspase 3 activation and downregulation of p Met/Met and p Akt/Akt in OSA xenografts. Together, these data suggest that HSP90 represents a relevant target for therapeutic intervention in OSA. (C) 2009 UICC
C1 [McCleese, Jennifer K.; Bear, Misty D.; Fossey, Stacey L.; London, Cheryl A.] Ohio State Univ, Dept Vet Biosci, Coll Vet Med, Columbus, OH 43210 USA.
   [Mihalek, Robert M.; Foley, Kevin P.; Ying, Weiwen; Barsoum, James] Synta Pharmaceut Corp, Lexington, MA USA.
C3 University System of Ohio; Ohio State University; Synta Pharmaceuticals
RP London, CA (通讯作者)，Ohio State Univ, Dept Vet Biosci, Coll Vet Med, 454 VMAB,1925 Coffey Rd, Columbus, OH 43210 USA.
EM london.20@osu.edu
RI Foley, Kevin/ABC 1041 2020; London, Cheryl/E 6561 2012
OI Foley, Kevin/0000 0001 5148 7689; 
FU Morris Animal Foundation; Synta Pharmaceuticals Corp
FX Grant sponsors: Morris Animal Foundation and Synta Pharmaceuticals Corp.
CR Al Shaer L, 2008, BRIT J HAEMATOL, V141, P483, DOI 10.1111/j.1365 2141.2008.07053.x
   Bagatell R, 2005, INT J CANCER, V113, P179, DOI 10.1002/ijc.20611
   Bagatell R, 2007, CLIN CANCER RES, V13, P1783, DOI 10.1158/1078 0432.CCR 06 1892
   Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200
   Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1
   Birch JM, 2003, EUR J CANCER, V39, P2622, DOI 10.1016/j.ejca.2003.08.006
   Chen CL, 2007, BMC CANCER, V7, DOI 10.1186/1471 2407 7 111
   Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432 007 0330 x
   CORBETT T, 1997, ANTICANCER DRUG DEV, P75
   FERRACINI R, 1995, ONCOGENE, V10, P739
   Ferracini R, 2000, J CELL PHYSIOL, V184, P191, DOI 10.1002/1097 4652(200008)184:2<191::AID JCP6>3.0.CO;2 B
   Flint AE, 2004, VET PATHOL, V41, P291, DOI 10.1354/vp.41 3 291
   Fukaya Y, 2005, ONCOL REP, V14, P847
   Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525
   Hostein I, 2001, CANCER RES, V61, P4003
   Kamal A, 2004, TRENDS MOL MED, V10, P283, DOI 10.1016/j.molmed.2004.04.006
   Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913
   Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982
   Khanna C, 2002, CLIN CANCER RES, V8, P2406
   KIM SY, 2007, CLIN EXP METASTASIS
   Kurzman ID, 1995, CLIN CANCER RES, V1, P1595
   Lang SA, 2007, CLIN CANCER RES, V13, P6459, DOI 10.1158/1078 0432.CCR 07 1104
   Lesko E, 2007, ANTI CANCER DRUG, V18, P1173, DOI 10.1097/CAD.0b013e3282ef532d
   Levy JB, 1996, ENDOCRINOLOGY, V137, P1159, DOI 10.1210/en.137.4.1159
   Liao AT, 2007, VET COMP ONCOL, V5, P177, DOI 10.1111/j.1476 5829.2007.00137.x
   Lin TY, 2008, EXP HEMATOL, V36, P1266, DOI 10.1016/j.exphem.2008.05.001
   MacEwen EG, 2004, J CELL BIOCHEM, V92, P77, DOI 10.1002/jcb.20046
   MACEWEN EG, 1994, J DRUG TARGET, V2, P391, DOI 10.3109/10611869408996814
   MacEwen EG, 2003, CLIN EXP METASTAS, V20, P421
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Moore AS, 2007, J VET INTERN MED, V21, P783, DOI 10.1892/0891 6640(2007)21[783:DABFTT]2.0.CO;2
   Mueller F, 2007, ANTICANCER RES, V27, P155
   Neckers Len, 2005, Expert Opin Emerg Drugs, V10, P137, DOI 10.1517/14728214.10.1.137
   Nishimura R, 1998, J BONE MINER RES, V13, P777, DOI 10.1359/jbmr.1998.13.5.777
   Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901
   Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829
   Patané S, 2006, CANCER RES, V66, P4750, DOI 10.1158/0008 5472.CAN 05 4422
   PAOLONI M, 2006, 4 INT CAN CANC C, V4, P19
   Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640
   Powers MV, 2006, ENDOCR RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324
   Sato N, 2003, BIOCHEM BIOPH RES CO, V300, P847, DOI 10.1016/S0006 291X(02)02941 8
   Stühmer T, 2008, LEUKEMIA, V22, P1604, DOI 10.1038/leu.2008.111
   Vastag B, 2006, NAT BIOTECHNOL, V24, P1307, DOI 10.1038/nbt1106 1307
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Williams CR, 2007, J UROLOGY, V178, P1528, DOI 10.1016/j.juro.2007.05.120
   WITHROW SJ, 1991, CLIN ORTHOP RELAT R, P159
   Withrow SJ., 2001, SMALL ANIMAL CLIN ON
   Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012
   Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078 0432.CCR 06 2966
   Yano M, 1996, JPN J CANCER RES, V87, P908, DOI 10.1111/j.1349 7006.1996.tb02119.x
NR 50
TC 68
Z9 77
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0020 7136
EI 1097 0215
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 15
PY 2009
VL 125
IS 12
BP 2792
EP 2801
DI 10.1002/ijc.24660
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 523CJ
UT WOS:000272049000006
PM 19544563
DA 2025 08 17
ER

PT J
AU Osakada, F
   Takahashi, M
AF Osakada, Fumitaka
   Takahashi, Masayo
TI Neural Induction and Patterning in Mammalian Pluripotent Stem Cells
SO CNS & NEUROLOGICAL DISORDERS DRUG TARGETS
LA English
DT Article
DE Cell fate; embryonic stem (ES) cell; default model; induced pluripotent
   stem (iPS) cell; neurogenesis; photoreceptor; regeneration; retina
ID IN VITRO DIFFERENTIATION; HOMEOBOX GENE; PHOTORECEPTOR DEVELOPMENT;
   RETINOIC ACID; DIRECTED DIFFERENTIATION; TRANSPLANTATION THERAPY;
   DOPAMINERGIC NEURONS; EFFICIENT GENERATION; INT 1 PROTOONCOGENE; HUMAN
   FIBROBLASTS
AB Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of blastocyst stage embryos, while induced pluripotent stem (iPS) cells are generated from somatic cells through transient overexpression of defined transcription factors. When transplanted into a preimplantation embryo, ES cells and iPS cells can differentiate into any cell type, including germ cells. Moreover, they can grow in culture indefinitely while maintaining pluripotency. In vitro differentiation of ES cells and iPS cells recapitulates many aspects of in vivo embryogenesis. The acquisition of neural fates (neural induction) in ES cells can be controlled by bone morphogenetic protein (BMP), fibroblast growth factor (FGF), and Wnt signaling, while the production of specific neural cell types (neural patterning) can be controlled by exogenous patterning signals such as Wnt, BMP, Shh, FGF, and retinoic acid. In response to these signals, ES cells can differentiate into a wide range of neural cell types that correlate with their positions along the anterior posterior and dorsal ventral axes. ES cell and iPS cell culture systems will provide materials for cell replacement therapy, and can be used as in vitro models for disease and drug testing as well as development. Here we review spatiotemporal control of neural differentiation of mammalian pluripotent stem cells, with a special emphasis on the relationship between in vivo embryogenesis and in vitro ES cell differentiation. Retinal differentiation from ES cells and iPS cells is also outlined.
C1 [Osakada, Fumitaka] Salk Inst Biol Studies, Syst Neurobiol Lab, La Jolla, CA 92037 USA.
   [Takahashi, Masayo] RIKEN, Lab Retinal Regenerat, Ctr Dev Biol, Wako, Saitama, Japan.
C3 Salk Institute; RIKEN
RP Osakada, F (通讯作者)，Salk Inst Biol Studies, Syst Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM fosakada@salk.edu
OI Osakada, Fumitaka/0000 0002 9078 1458
FU Japan Society for the Promotion of Science; Mochida Memorial Foundation
   for Medical and Pharmaceutical Research; Kanae Foundation for the
   Promotion of Medical Science; Uchara Memorial Foundation; Naito
   Foundation
FX We thank Yoshiki Sasai (RIKEN) for the SDIA and SFEB methods, Hirofumi
   Suemori and Norio Nakatsuji (Kyoto University) for the human ES cell
   lines; Jun Takahashi (Kyoto University) for the monkey ES cell lines;
   Hitoshi Niwa (RIKEN) for the mouse ES cell lines; and Sinya Yamanaka
   (Kyoto University) for the mouse and human iPS cell lines; Akinori
   Akaike (Kyoto University) for his continued support and challenging
   discussions; members of the Takahashi laboratory, the Sasai laboratory
   and the Akaike laboratory for stimulating discussions. F.O. is thankful
   to Noriko Osakada for constant encouragement. This work was supported by
   Grants in Aid for Scientific Research from the Japan Society for the
   Promotion of Science, the Mochida Memorial Foundation for Medical and
   Pharmaceutical Research, the Kanae Foundation for the Promotion of
   Medical Science, the Uchara Memorial Foundation, and the Naito
   Foundation (F.O.). We apologize to those authors whose articles,
   although relevant to this subject, have not been cited in this review
   due to space limitations.
CR ALTSHULER D, 1992, DEVELOPMENT, V114, P947
   Andreazzoli M, 1999, DEVELOPMENT, V126, P2451
   Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763
   BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085
   Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870
   Bäumer N, 2003, DEVELOPMENT, V130, P2903, DOI 10.1242/dev.00450
   Boland MJ, 2009, NATURE, V461, P91, DOI 10.1038/nature08310
   Bora N, 1998, DEV DYNAM, V213, P283, DOI 10.1002/(SICI)1097 0177(199811)213:3<283::AID AJA5>3.0.CO;2 H
   Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007
   Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cavodeassi F, 2005, NEURON, V47, P43, DOI 10.1016/j.neuron.2005.05.026
   Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896 6273(00)80394 3
   CHEN YP, 1994, DEV BIOL, V161, P70, DOI 10.1006/dbio.1994.1008
   Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0
   Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008
   CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910
   Choo AB, 2008, STEM CELLS, V26, P1454, DOI 10.1634/stemcells.2007 0576
   Chow RL, 1999, DEVELOPMENT, V126, P4213
   Chuang JC, 1999, MECH DEVELOP, V84, P195, DOI 10.1016/S0925 4773(99)00077 5
   Delaune E, 2005, DEVELOPMENT, V132, P299, DOI 10.1242/dev.01582
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Domingos PM, 2001, DEV BIOL, V239, P148, DOI 10.1006/dbio.2001.0431
   Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677
   Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002
   ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092 8674(95)90536 7
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fukuda H, 2006, STEM CELLS, V24, P763, DOI 10.1634/stemcells.2005 0137
   Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092 8674(00)80439 0
   Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088
   Galceran J, 2000, DEVELOPMENT, V127, P469
   Gaspard N, 2008, NATURE, V455, P351, DOI 10.1038/nature07287
   Gunhaga L, 2003, NAT NEUROSCI, V6, P701, DOI 10.1038/nn1068
   GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622
   Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140 6736(06)69740 7
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03 1034
   Hatakeyama J, 2004, DEVELOPMENT, V131, P5539, DOI 10.1242/dev.01436
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042 6989(03)00457 7
   Hyatt GA, 1996, P NATL ACAD SCI USA, V93, P13298, DOI 10.1073/pnas.93.23.13298
   Hyatt GA, 1997, INVEST OPHTH VIS SCI, V38, P1471
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Jadhav AR, 2006, DEVELOPMENT, V133, P913, DOI 10.1242/dev.02245
   Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541
   Jin ZB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017084
   Kang L, 2009, CELL STEM CELL, V5, P135, DOI 10.1016/j.stem.2009.07.001
   Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896 6273(00)00083 0
   KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955 0674(95)80071 9
   Kelly C, 2000, DEVELOPMENT, V127, P3899
   Kiecker C, 2001, DEVELOPMENT, V128, P4189
   Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04 0511
   Knecht AK, 2002, NAT REV GENET, V3, P453, DOI 10.1038/nrg819
   Kuroda H, 2005, GENE DEV, V19, P1022, DOI 10.1101/gad.1306605
   Lagutin O, 2001, DEV DYNAM, V221, P342, DOI 10.1002/dvdy.1148
   Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lee HY, 2005, DEV BIOL, V284, P464, DOI 10.1016/j.ydbio.2005.06.010
   Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536
   Lee SMK, 2000, DEVELOPMENT, V127, P457
   Li HS, 1997, DEVELOPMENT, V124, P603
   Li JY, 2008, TRENDS NEUROSCI, V31, P146, DOI 10.1016/j.tins.2007.12.001
   Li P, 2008, CELL, V135, P1299, DOI 10.1016/j.cell.2008.12.006
   Linker C, 2004, DEVELOPMENT, V131, P5671, DOI 10.1242/dev.01445
   Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Marchetto MCN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007076
   Martin MJ, 2005, NAT MED, V11, P228, DOI 10.1038/nm1181
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901 877
   Massé K, 2007, NATURE, V449, P1058, DOI 10.1038/nature06189
   Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968 08.2008
   MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092 8674(90)90385 R
   Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056
   Miura K, 2009, NAT BIOTECHNOL, V27, P743, DOI 10.1038/nbt.1554
   Mizuseki K, 2003, P NATL ACAD SCI USA, V100, P5828, DOI 10.1073/pnas.1037282100
   Morrow EM, 1999, DEVELOPMENT, V126, P23
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534 5807(01)00041 7
   NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102
   Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155
   Nishikawa S, 2008, NAT REV MOL CELL BIO, V9, P725, DOI 10.1038/nrm2466
   Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787
   Nordström U, 2002, NAT NEUROSCI, V5, P525, DOI 10.1038/nn854
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Oliver G, 1995, DEVELOPMENT, V121, P4045
   Onuma Y, 2002, P NATL ACAD SCI USA, V99, P2020, DOI 10.1073/pnas.022626999
   Ooto S, 2004, P NATL ACAD SCI USA, V101, P13654, DOI 10.1073/pnas.0402129101
   Osakada F, 2011, INFLAMM REGEN, V31, P33
   OSAKADA F, 2006, EXP MED, V24, P256
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193 06.2007
   Osakada F, 2010, BIOTECHNOL GENET ENG, V26, P297
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Osakada F, 2009, J PHARMACOL SCI, V109, P168, DOI 10.1254/jphs.08R19FM
   Pera MF, 2004, J CELL SCI, V117, P1269, DOI 10.1242/jcs.00970
   Pick M, 2009, STEM CELLS, V27, P2686, DOI 10.1002/stem.205
   Pouton CW, 2007, NAT REV DRUG DISCOV, V6, P605, DOI 10.1038/nrd2194
   Rallu M, 2002, DEVELOPMENT, V129, P4963
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12 11 04565.1992
   REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558
   Rodríguez Pizà I, 2010, STEM CELLS, V28, P36, DOI 10.1002/stem.248
   SAHA MS, 1992, NEURON, V8, P1003, DOI 10.1016/0896 6273(92)90123 U
   SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321
   Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017
   Su HL, 2006, DEV BIOL, V290, P287, DOI 10.1016/j.ydbio.2005.11.010
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960 9822(01)00459 6
   Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721
   THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896 6273(01)00263 X
   Ueno M, 2006, P NATL ACAD SCI USA, V103, P9554, DOI 10.1073/pnas.0600104103
   Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615
   Wässle H, 2004, NAT REV NEUROSCI, V5, P747, DOI 10.1038/nrn1497
   Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402
   Wataya T, 2008, P NATL ACAD SCI USA, V105, P11796, DOI 10.1073/pnas.0803078105
   Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944
   Wessely O, 2001, DEV BIOL, V234, P161, DOI 10.1006/dbio.2001.0258
   Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092 8674(02)00835 8
   Wilson SI, 2001, NATURE, V411, P325, DOI 10.1038/35077115
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Yamanaka S, 2009, NATURE, V460, P49, DOI 10.1038/nature08180
   Yaron O, 2006, DEVELOPMENT, V133, P1367, DOI 10.1242/dev.02311
   Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968
   Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780
   Young TL, 2004, NEURON, V41, P867, DOI 10.1016/S0896 6273(04)00141 2
   Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033
   Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
NR 139
TC 15
Z9 21
U1 0
U2 24
PU BENTHAM SCIENCE PUBL
PI BUSUM
PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS
SN 1871 5273
EI 1996 3181
J9 CNS NEUROL DISORD DR
JI CNS Neurol. Disord. Drug Targets
PD JUN
PY 2011
VL 10
IS 4
BP 419
EP 432
DI 10.2174/187152711795563958
PG 14
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 777PG
UT WOS:000291634700003
PM 21495966
DA 2025 08 17
ER

PT J
AU Li, WJ
   Kezele, I
   Collins, DL
   Zijdenbos, A
   Keyak, J
   Kornak, J
   Koyama, A
   Saeed, I
   LeBlanc, A
   Harris, T
   Lu, Y
   Lang, T
AF Li, Wenjun
   Kezele, Irina
   Collins, D. Louis
   Zijdenbos, Alex
   Keyak, Joyce
   Kornak, John
   Koyama, Alain
   Saeed, Isra
   LeBlanc, Adnian
   Harris, Tamara
   Lu, Ying
   Lang, Thomas
TI Voxel based modeling and quantification of the proximal femur using
   inter subject registration of quantitative CT images
SO BONE
LA English
DT Article
DE image processing; image registration; modeling; quantitative computed
   tomography; proximal femur; bone mineral density; bone loss;
   spaceflight; osteoporosis
ID FINITE ELEMENT MODELS; COMPUTED TOMOGRAPHY; PARATHYROID HORMONE;
   OSTEOPOROSIS; SEGMENTATION; HIP; ALENDRONATE; VALIDATION; STRENGTH;
   FRACTURE
AB We have developed a general framework which employs quantitative computed tomography (QCT) imaging and inter subject image registration to model the three dimensional structure of the hip, with the goal of quantifying changes in the spatial distribution of bone as it is affected by aging, drug treatment or mechanical unloading. We have adapted rigid and non rigid inter subject registration techniques to transform groups of hip QCT scans into a common reference space and to construct composite proximal femoral models. We have applied this technique to a longitudinal study of 16 astronauts who on average, incurred high losses of hip bone density during spaceflights of 4 6 months on the International Space Station (ISS). We compared the pre flight and post flight composite hip models, and observed the gradients of the bone loss distribution. We performed paired t tests, on a voxel by voxel basis, corrected for multiple comparisons using false discovery rate (FDR), and observed regions inside the proximal femur that showed the most significant bone loss. To validate our registration algorithm, we selected the 16 pre flight scans and manually marked 4 landmarks for each scan. After registration, the average distance between the mapped landmarks and the corresponding landmarks in the target scan was 2.56 mm. The average error due to manual landmark identification was 1.70 mm. (c) 2007 Elsevier Inc. All rights reserved.
C1 Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
   Montreal Neurol Inst Montreal, McConnell Brain Imaging Ctr, Montreal, PQ H3A 2B4, Canada.
   Univ Calif Irvine, Dept Orthopaed Surg, Irvine, CA 92697 USA.
   Univ Space Res Assoc, Houston, TX 77058 USA.
   Baylor Coll Med, Houston, TX 77058 USA.
   Natl Inst Hlth, NIA, Lab Epidemiol Demog & Biomet, Bethesda, MD 20892 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California Irvine;
   Universities Space Research Association (USRA); Baylor College of
   Medicine; National Institutes of Health (NIH)   USA; NIH National
   Institute on Aging (NIA)
RP Li, WJ (通讯作者)，Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
EM wenjun.li@radiology.ucsf.edu
RI Collins, D. Louis/ABD 7708 2021; Lang, Thomas/B 2685 2012
OI Lang, Thomas/0000 0002 3720 8038; Lu, Ying/0000 0002 7698 8962; Collins,
   D. Louis/0000 0002 8432 7021
FU NIAMS NIH HHS [R42 AR45713, R42 AR045713] Funding Source: Medline
CR Adam F, 2001, SKELETAL RADIOL, V30, P77, DOI 10.1007/s002560000308
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cody DD, 1999, J BIOMECH, V32, P1013, DOI 10.1016/S0021 9290(99)00099 8
   Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304
   Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597
   Collins TC, 2003, J GEN INTERN MED, V18, P192
   Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037
   Gray H., 1918, ANATOMY HUMAN BODY
   Kang Y, 2003, IEEE T MED IMAGING, V22, P586, DOI 10.1109/TMI.2003.812265
   Keyak JH, 2000, J BIOMECH, V33, P209, DOI 10.1016/S0021 9290(99)00152 9
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   Lang TF, 1997, BONE, V21, P101, DOI 10.1016/S8756 3282(97)00072 0
   Li WJ, 2006, BONE, V38, P273, DOI 10.1016/j.bone.2005.08.014
   LOTZ JC, 1990, J BONE JOINT SURG AM, V72A, P689, DOI 10.2106/00004623 199072050 00008
   Studholme C, 1999, PATTERN RECOGN, V32, P71, DOI 10.1016/S0031 3203(98)00091 0
   Tanner C, 2002, LECT NOTES COMPUT SC, V2488, P307
NR 18
TC 30
Z9 34
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD NOV
PY 2007
VL 41
IS 5
BP 888
EP 895
DI 10.1016/j.bone.2007.07.006
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 225PD
UT WOS:000250528900018
PM 17707712
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Liu, GB
   Cheng, YX
   Li, HM
   Liu, Y
   Sun, LX
   Wu, Q
   Guo, SF
   Li, TT
   Dong, CL
   Sun, G
AF Liu, Gui Bo
   Cheng, Yong Xia
   Li, Hua Min
   Liu, Yong
   Sun, Li Xin
   Wu, Qi
   Guo, Shang Fu
   Li, Ting Ting
   Dong, Chuan Ling
   Sun, Ge
TI Ghrelin promotes cardiomyocyte differentiation of adipose tissue derived
   mesenchymal stem cells by DDX17 mediated regulation of the
   SFRP4/Wnt/β catenin axis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE ghrelin; dead box helicase 17; secreted frizzled related protein 4;
   adipose tissue derived mesenchymal stem cell; Wnt/beta catenin signaling
   pathway; cardiomyocyte differentiation
ID WNT/BETA CATENIN; MYOCARDIAL INFARCTION; BONE MARROW; RNA HELICASES;
   APOPTOSIS; TUMORIGENESIS; MONONUCLEAR; ACTIVATION; SFRP4
AB Adipose tissue derived mesenchymal stem cells (ADMSCs) differentiate into cardiomyocytes and may be an ideal cell source for myocardial regenerative medicine. Ghrelin is a gastric secreted peptide hormone involved in the multilineage differentiation of MSCs. To the best of our knowledge, however, the role and potential downstream regulatory mechanism of ghrelin in cardiomyocyte differentiation of ADMSCs is still unknown. The mRNA and protein levels were measured by reverse transcription quantitative PCR and western blotting. Immunofluorescence staining was used to show the expression and cellular localization of cardiomyocyte markers and beta catenin. RNA sequencing was used to explore the differentially expressed genes (DEGs) that regulated by ghrelin. The present study found that ghrelin promoted cardiomyocyte differentiation of ADMSCs in a concentration dependent manner, as shown by increased levels of cardiomyocyte markers GATA binding protein 4, alpha myosin heavy chain (alpha MHC), ISL LIM homeobox 1, NK2 homeobox 5 and troponin T2, cardiac type. Ghrelin increased beta catenin accumulation in nucleus and decreased the protein expression of secreted frizzled related protein 4 (SFRP4), an inhibitor of Wnt signaling. RNA sequencing was used to determine the DEGs regulated by ghrelin. Functional enrichment showed that DEGs were more enriched in cardiomyocyte differentiation associated terms and Wnt pathways. Dead box helicase 17 (DDX17), an upregulated DEG, showed enhanced mRNA and protein expression levels following ghrelin addition. Overexpression of DDX17 promoted protein expression of cardiac specific markers and beta catenin and enhanced the fluorescence intensity of a MHC and beta catenin. DDX17 upregulation inhibited protein expression of SFRP4. Rescue assay confirmed that the addition of SFRP4 partially reversed ghrelin enhanced protein levels of cardiac specific markers and the fluorescence intensity of alpha MHC. In conclusion, ghrelin promoted cardiomyocyte differentiation of ADMSCs by DDX17 mediated regulation of the SFRP4/Wnt/beta catenin axis.
C1 [Liu, Gui Bo; Dong, Chuan Ling] Mudanjiang Med Univ, Sch Basic Med Sci, Dept Anat, Mudanjiang 157011, Heilongjiang, Peoples R China.
   [Cheng, Yong Xia; Wu, Qi] Mudanjiang Med Univ, Dept Pathol, Clin Med Sch 1, Mudanjiang 157011, Heilongjiang, Peoples R China.
   [Li, Hua Min] Mudanjiang Med Univ, Dept Pathol, Hongqi Hosp, Mudanjiang 157000, Heilongjiang, Peoples R China.
   [Liu, Yong] Mudanjiang Med Univ, Dept Res Platform, Mudanjiang 157011, Heilongjiang, Peoples R China.
   [Sun, Li Xin] Mudanjiang Med Univ, Off Educ Adm, Mudanjiang 157011, Heilongjiang, Peoples R China.
   [Guo, Shang Fu] Mudanjiang Med Univ, Dept Asset Management, Mudanjiang 157011, Heilongjiang, Peoples R China.
   [Li, Ting Ting] Mudanjiang Med Univ, Sch Basic Med Sci, Dept Pathol, Mudanjiang 157011, Heilongjiang, Peoples R China.
   [Sun, Ge] Mudanjiang Med Univ, Dept Orthoped, Affiliated Hosp 2, Mudanjiang 157010, Heilongjiang, Peoples R China.
   [Sun, Ge] Mudanjiang Med Univ, Affiliated Hosp 2, Dept Orthoped, 15 Dongxiaoyun St, Mudanjiang 157010, Heilongjiang, Peoples R China.
C3 Mudanjiang Medical University; Mudanjiang Medical University; Mudanjiang
   Medical University; Mudanjiang Medical University; Mudanjiang Medical
   University; Mudanjiang Medical University; Mudanjiang Medical
   University; Mudanjiang Medical University; Mudanjiang Medical University
RP Sun, G (通讯作者)，Mudanjiang Med Univ, Affiliated Hosp 2, Dept Orthoped, 15 Dongxiaoyun St, Mudanjiang 157010, Heilongjiang, Peoples R China.
EM sunge0913@163.com
RI Sun, Lixin/AAT 1932 2020
FU Joint Guidance Project of Natural Science Foundation of Heilongjiang
   Province [LH2020H074]; Scientific Research Project of Basic Scientific
   Research Business Expenses of Provincial Colleges and Universities in
   Heilongjiang Province [2020 KYYWF 0780]
FX The present study was supported by the Joint Guidance Project of Natural
   Science Foundation of Heilongjiang Province (grant no. LH2020H074) and
   the Scientific Research Project of Basic Scientific Research Business
   Expenses of Provincial Colleges and Universities in Heilongjiang
   Province (grant number 2020 KYYWF 0780).
CR Beitnes JO, 2012, CELL TRANSPLANT, V21, P1697, DOI 10.3727/096368911X627462
   Cai LY, 2009, STEM CELLS, V27, P230, DOI 10.1634/stemcells.2008 0273
   Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003
   Casteilla Louis, 2011, World J Stem Cells, V3, P25, DOI 10.4252/wjsc.v3.i4.25
   Cho JW, 2019, REGEN THER, V11, P192, DOI 10.1016/j.reth.2019.07.005
   Choi YH, 2011, HUM GENE THER, V22, P3, DOI 10.1089/hum.2010.211
   Davy PMC, 2015, STEM CELLS CLONING, V8, P135, DOI 10.2147/SCCAA.S86925
   Eid RA, 2019, ARCH PHYSIOL BIOCHEM, V125, P93, DOI 10.1080/13813455.2018.1437751
   Eid RA, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395 018 0671 4
   Fang X, 2019, J MOL CELL CARDIOL, V134, P1, DOI 10.1016/j.yjmcc.2019.06.014
   Fraser JK, 2006, TRENDS BIOTECHNOL, V24, P150, DOI 10.1016/j.tibtech.2006.01.010
   Fu Q, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658 019 0195 4
   Gao MJ, 2013, INT J CARDIOL, V167, P2724, DOI 10.1016/j.ijcard.2012.06.106
   Gay D, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3704
   Ge SH, 2022, MOL CELL ENDOCRINOL, V548, DOI 10.1016/j.mce.2022.111612
   Germann S, 2012, ONCOGENE, V31, P4536, DOI 10.1038/onc.2011.618
   Gong B, 2020, J CELL PHYSIOL, V235, P8558, DOI 10.1002/jcp.29699
   Gou HY, 2019, CANCER RES, V79, P3332, DOI 10.1158/0008 5472.CAN 18 2986
   Gupta S, 2021, STEM CELL REV REP, V17, P1666, DOI 10.1007/s12015 021 10168 0
   Han D, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/858349
   Han F, 2018, EBIOMEDICINE, V31, P253, DOI 10.1016/j.ebiom.2018.04.026
   Irion CI, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/4327965
   Jiang M, 2020, STEM CELLS DEV, V29, P1229, DOI 10.1089/scd.2020.0025
   Joo HJ, 2017, KOREAN CIRC J, V47, P151, DOI 10.4070/kcj.2016.0207
   Khatib MN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126697
   Klaus A, 2012, P NATL ACAD SCI USA, V109, P10921, DOI 10.1073/pnas.1121236109
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Kuraitis D, 2011, CARDIOVASC DRUG THER, V25, P349, DOI 10.1007/s10557 011 6311 y
   Kuwahara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094408
   Li B, 2015, ENDOCRINOLOGY, V156, P203, DOI 10.1210/en.2014 1539
   Li K, 2017, CANCER LETT, V400, P194, DOI 10.1016/j.canlet.2017.02.029
   Li KJ, 2022, SCI CHINA LIFE SCI, V65, P927, DOI 10.1007/s11427 021 1983 y
   Lian XJ, 2013, NAT PROTOC, V8, P162, DOI 10.1038/nprot.2012.150
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Lin B, 2016, MOL MED REP, V14, P3376, DOI 10.3892/mmr.2016.5600
   Liu GB, 2020, KAOHSIUNG J MED SCI, V36, P405, DOI 10.1002/kjm2.12188
   Liu XY, 2016, BIOCHEM BIOPH RES CO, V477, P902, DOI 10.1016/j.bbrc.2016.06.156
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacGrogan D, 2018, NAT REV CARDIOL, V15, P685, DOI 10.1038/s41569 018 0100 2
   Miyahara Y, 2006, NAT MED, V12, P459, DOI 10.1038/nm1391
   Müller Ehmsen J, 2006, J MOL CELL CARDIOL, V41, P876, DOI 10.1016/j.yjmcc.2006.07.023
   Neshati V, 2018, J CELL BIOCHEM, V119, P6146, DOI 10.1002/jcb.26818
   Penicka M, 2005, CIRCULATION, V112, pE63, DOI 10.1161/CIRCULATIONAHA.104.496133
   Qazi REM, 2020, MOL CELL BIOCHEM, V475, P27, DOI 10.1007/s11010 020 03855 y
   Qu RZ, 2019, INFLAMMATION, V42, P1652, DOI 10.1007/s10753 019 01026 w
   Russo C, 2021, HISTOCHEM CELL BIOL, V156, P35, DOI 10.1007/s00418 021 01980 3
   Sato A, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01386 2
   Serysheva E, 2013, EMBO REP, V14, P718, DOI 10.1038/embor.2013.88
   Shafei AE, 2017, J GENE MED, V19, DOI 10.1002/jgm.2995
   Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008 5472.CAN 06 4652
   Sun LQ, 2021, EUR J PHARMACOL, V903, DOI 10.1016/j.ejphar.2021.174142
   Tian YY, 2016, CELL SIGNAL, V28, P1806, DOI 10.1016/j.cellsig.2016.08.010
   Tokudome T, 2019, P JPN ACAD B PHYS, V95, P459, DOI 10.2183/pjab.95.032
   Tokudome T, 2019, PEPTIDES, V111, P42, DOI 10.1016/j.peptides.2018.05.006
   Tong Q, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935 022 02692 x
   Ueno S, 2007, P NATL ACAD SCI USA, V104, P9685, DOI 10.1073/pnas.0702859104
   Visweswaran M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118005
   Wang Ming Ke, 2012, World J Stem Cells, V4, P28
   Yamada A, 2013, BIOMATERIALS, V34, P3270, DOI 10.1016/j.biomaterials.2013.01.066
   Yang J, 2011, ACTA PHARMACOL SIN, V32, P1239, DOI 10.1038/aps.2011.79
   Yang YX, 2018, FASEB J, V32, P3096, DOI 10.1096/fj.201700830RR
   Yuan MJ, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20203387
   Zeng WH, 2019, J PHARMACOL SCI, V140, P14, DOI 10.1016/j.jphs.2019.04.003
   Zhang YL, 2020, ADIPOCYTE, V9, P374, DOI 10.1080/21623945.2020.1792614
   Zhao B, 2022, HUM CELL, V35, P1487, DOI 10.1007/s13577 022 00737 x
   Zhao XH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935 020 1136 z
   Zhou ZL, 2013, CYTOTHERAPY, V15, P434, DOI 10.1016/j.jcyt.2012.11.015
NR 67
TC 0
Z9 0
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2023
VL 28
IS 3
AR 164
DI 10.3892/mmr.2023.13050
PG 14
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA O6HN3
UT WOS:001044797100001
PM 37449526
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Hu, B
   El Haj, AJ
   Dobson, J
AF Hu, Bin
   El Haj, Alicia J.
   Dobson, Jon
TI Receptor Targeted, Magneto Mechanical Stimulation of Osteogenic
   Differentiation of Human Bone Marrow Derived Mesenchymal Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE magnetic force bioreactor; tissue engineering; mechanotransduction;
   human mesenchymal stem cells; osteogenic differentiation
ID GROWTH FACTOR; IN VITRO; MAGNETIC FORCE; SPECTROSCOPIC CHARACTERIZATION;
   OSTEOBLAST DIFFERENTIATION; IMATINIB MESYLATE; STROMAL CELLS;
   NANOPARTICLES; MICROSCOPY; CARTILAGE
AB Mechanical cues are employed to promote stem cell differentiation and functional tissue formation in tissue engineering and regenerative medicine. We have developed a Magnetic Force Bioreactor (MFB) that delivers highly targeted local forces to cells at a pico newton level, utilizing magnetic micro  and nano particles to target cell surface receptors. In this study, we investigated the effects of magnetically targeting and actuating specific two mechanical sensitive cell membrane receptorsplatelet derived growth factor receptor (PDGFR) and integrin (3). It was found that a higher mineral to matrix ratio was obtained after three weeks of magneto mechanical stimulation coupled with osteogenic medium culture by initially targeting PDGFR compared with targeting integrin (3) and non treated controls. Moreover, different initiation sites caused a differentiated response profile when using a 2 day lagged magneto mechanical stimulation over culture periods of 7 and 12 days). However, both resulted in statistically higher osteogenic marker genes expression compared with immediate magneto mechanical stimulation. These results provide insights into important parameters for designing appropriate protocols for ex vivo induced bone formation via magneto mechanical actuation.
C1 [Hu, Bin; El Haj, Alicia J.] Keele Univ, Inst Sci & Technol Med, Guy Hilton Res Ctr, Stoke On Trent ST4 7QB, Staffs, England.
   [Dobson, Jon] Univ Florida, Dept Mat Sci & Engn, J Crayton Puritt Family Dept Biomed Engn, ICERM, Gainesville, FL 32611 USA.
C3 Keele University; State University System of Florida; University of
   Florida
RP Dobson, J (通讯作者)，Univ Florida, Dept Mat Sci & Engn, J Crayton Puritt Family Dept Biomed Engn, ICERM, Gainesville, FL 32611 USA.
EM b.hu@keele.ac.uk; a.j.el.haj@keele.ac.uk; jdobson@ufl.edu
RI Dobson, Jon/C 8323 2009; Haj, Alicia/B 3315 2012
OI Dobson, Jon/0000 0002 8108 5362; El Haj, Alicia/0000 0003 3544 5678;
   /0000 0002 5642 8300
FU EU FP7 [EXPERTISSUES NMP3 CT 2004 500328]; EPSRC [EP/H028277/1] Funding
   Source: UKRI; Engineering and Physical Sciences Research Council
   [EP/H028277/1] Funding Source: researchfish
FX The Authors would like to thank EU FP7 Grant EXPERTISSUES
   NMP3 CT 2004 500328. The Authors also thank Thomas Chippendale for
   assisting in proof reading.
CR Alsberg E, 2006, TISSUE ENG, V12, P3247, DOI 10.1089/ten.2006.12.3247
   Baas E, 2010, J BIOMECH, V43, P733, DOI 10.1016/j.jbiomech.2009.10.016
   Bodine PVN, 1996, J BONE MINER RES, V11, P806
   Boskey AL, 2005, VIB SPECTROSC, V38, P107, DOI 10.1016/j.vibspec.2005.02.015
   Cartmell SH, 2005, BIOREACTORS FOR TISSUE ENGINEERING: PRINCIPLES, DESIGN AND OPERATION, P193, DOI 10.1007/1 4020 3741 4_8
   Cartmell Sarah H, 2002, IEEE Trans Nanobioscience, V1, P92, DOI 10.1109/TNB.2002.806945
   Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014
   Dobrowolski R, 2012, NAT REV MOL CELL BIO, V13, P53, DOI 10.1038/nrm3244
   Dobson J, 2008, NAT NANOTECHNOL, V3, P139, DOI 10.1038/nnano.2008.39
   Dobson J, 2006, IEEE T NANOBIOSCI, V5, P173, DOI 10.1109/TNB.2006.880823
   Dobson J, 2010, NAT MATER, V9, P95, DOI 10.1038/nmat2604
   Fayol D, 2013, ADV MATER, V25, P2611, DOI 10.1002/adma.201300342
   Fierro F, 2007, CELL PROLIFERAT, V40, P355, DOI 10.1111/j.1365 2184.2007.00438.x
   Fitter S, 2008, BLOOD, V111, P2538, DOI 10.1182/blood 2007 07 104281
   Graham S, 2009, EXPERT OPIN INV DRUG, V18, P1633, DOI 10.1517/13543780903241607
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   HU B, 2013, NANOMEDICINE
   Hughes S, 2008, J R SOC INTERFACE, V5, P855, DOI 10.1098/rsif.2007.1274
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   Kanczler JM, 2010, TISSUE ENG PT A, V16, P3241, DOI [10.1089/ten.tea.2009.0638, 10.1089/ten.TEA.2009.0638]
   Kang KS, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.11
   Karp JM, 2006, STEM CELLS, V24, P835, DOI 10.1634/stemcells.2005 0383
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464
   Marolt D, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt10
   Mendelsohn R, 1999, J BIOMED OPT, V4, P14, DOI 10.1117/1.429916
   Mitlak BH, 1996, J BONE MINER RES, V11, P238
   Mofrad MRK, 2005, ACTA BIOMATER, V1, P281, DOI 10.1016/j.actbio.2005.02.008
   NASH TJ, 1994, BONE, V15, P203, DOI 10.1016/8756 3282(94)90709 9
   Nii M, 2013, ACTA BIOMATER, V9, P5475, DOI 10.1016/j.actbio.2012.11.002
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   Pankhurst QA, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022 3727/42/22/224001
   Paschalis EP, 2001, J BONE MINER RES, V16, P1821, DOI 10.1359/jbmr.2001.16.10.1821
   Pedersen JA, 2005, ANN BIOMED ENG, V33, P1469, DOI 10.1007/s10439 005 8159 4
   Ranly DM, 2005, J BONE JOINT SURG AM, V87A, P2052, DOI 10.2106/JBJS.D.02752
   Shimizu K, 2007, J BIOMED MATER RES B, V82B, P471, DOI 10.1002/jbm.b.30752
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Thomas GP, 1996, CALCIFIED TISSUE INT, V58, P101, DOI 10.1007/s002239900018
   Vikjaer D, 1997, EUR J ORAL SCI, V105, P59, DOI 10.1111/j.1600 0722.1997.tb00181.x
   WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161
   Yamaguchi Sekino S, 2011, MAGN RESON MED SCI, V10, P1, DOI 10.2463/mrms.10.1
   Yamamoto Y, 2011, TISSUE ENG PT A, V17, P107, DOI [10.1089/ten.tea.2010.0312, 10.1089/ten.TEA.2010.0312]
NR 44
TC 73
Z9 80
U1 0
U2 41
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2013
VL 14
IS 9
BP 19276
EP 19293
DI 10.3390/ijms140919276
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 274RN
UT WOS:000328623900108
PM 24065106
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Ye, WL
   Zhao, YP
   Na, R
   Li, F
   Mei, QB
   Zhao, MG
   Zhou, SY
AF Ye, Wei Liang
   Zhao, Yi Pu
   Na, Ren
   Li, Fei
   Mei, Qi Bing
   Zhao, Ming Gao
   Zhou, Si Yuan
TI Actively Targeted Delivery of Doxorubicin to Bone Metastases by a
   pH Sensitive Conjugation
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE bone targeted drug delivery; doxorubicin; controlled release;
   alendronate; conjugaton; p glycoprotein; cytotoxicity; imaging methods;
   cancer
ID BREAST CANCER PATIENTS; ZOLEDRONIC ACID; TUMOR GROWTH; ALENDRONATE;
   BISPHOSPHONATES; NANOPARTICLES; ACIDIFICATION; MECHANISMS; RESORPTION;
   RESISTANCE
AB Alendronate monoethyl adipate (hydrazone) doxorubicin conjugate (ALN MA hyd DOX) was synthesized to specifically deliver doxorubicin (DOX) to bone tumor tissue. The binding kinetics of ALN MA hyd DOX with hydroxyapatite (HA) and natural bone were detected by using spectrophotometer. Cytotoxicity of ALN MA hyd DOX on tumor cells was determined by MTT [3 (4,5 dimethylthiaol 2 yl) 2,5 diphenyl tetrazolium bromide] method. The cellular uptake of ALN MA hyd DOX was observed by using fluorescence microscopy. The in vivo antitumor activity of ALN MA hyd DOX was investigated by using tumor bearing nude mice model. The results indicated that ALN MA hyd DOX was able to quickly bind with HA and natural bone. ALN MA hyd DOX immobilized on the natural bone released more DOX in pH 5.0 medium than that in pH 6.0 or 7.4 medium. The cytotoxicity of ALN MA hyd DOX toward A549 cells and MDA MB 231/ADR cells was greater than DOX. ALN MA hyd DOX was rapidly uptaken by A549 cells and MDA MB 231/ADR cells. Compared with the same dose of free DOX, ALN MA hyd DOX significantly decreased tumor volume of tumor bearing nude mice. DOX mainly distributed in bone tumor tissue after ALN MA hyd DOX was intravenously administered to tumor bearing nude mice, whereas DOX distributed through the whole body after DOX was intravenously administered to tumor bearing nude mice. These findings implied that the ALN MA hyd DOX was a promising bone targeted conjugate for treating bone neoplasms. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:2293 2303, 2015
C1 [Ye, Wei Liang; Zhao, Yi Pu; Li, Fei; Zhou, Si Yuan] Fourth Mil Med Univ, Sch Pharm, Dept Pharmaceut, Xian 710032, Peoples R China.
   [Na, Ren] West Changle Sanat Xian Army Retired Cadres Fourt, Xian 710032, Peoples R China.
   [Mei, Qi Bing; Zhao, Ming Gao] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Peoples R China.
C3 Air Force Medical University; Air Force Medical University
RP Zhou, SY (通讯作者)，Fourth Mil Med Univ, Sch Pharm, Dept Pharmaceut, Xian 710032, Peoples R China.
EM zhousy@fmmu.edu.cn
RI ; na, ren/KRP 9782 2024
OI Li, Fei/0000 0002 7679 1641; Zhao, Ming gao/0000 0002 7539 3887
FU Shaanxi Science and Technology Innovation Project [2012KTCL03 18]
FX This research was supported by the Shaanxi Science and Technology
   Innovation Project (2012KTCL03 18).
CR Arnett T, 2003, P NUTR SOC, V62, P511, DOI 10.1079/PNS2003268
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Bagi CM, 2005, ADV DRUG DELIVER REV, V57, P995, DOI 10.1016/j.addr.2004.12.014
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Chytil P, 2006, J CONTROL RELEASE, V115, P26, DOI 10.1016/j.jconrel.2006.06.028
   Clyburn RD, 2010, CANCER CHEMOTH PHARM, V65, P969, DOI 10.1007/s00280 009 1106 6
   Colleoni M, 2000, J CLIN ONCOL, V18, P3925, DOI 10.1200/JCO.2000.18.23.3925
   Diel I J, 2000, Clin Breast Cancer, V1, P43, DOI 10.3816/CBC.2000.n.003
   Doschak MR, 2009, MOL PHARMACEUT, V6, P634, DOI 10.1021/mp8002368
   El Mabhouh AA, 2006, NUCL MED BIOL, V33, P715, DOI 10.1016/j.nucmedbio.2006.06.004
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Ferretti G, 2007, CLIN CANCER RES, V13, P6850, DOI 10.1158/1078 0432.CCR 07 4036
   Gittens SA, 2005, ADV DRUG DELIVER REV, V57, P1011, DOI 10.1016/j.addr.2004.12.015
   Gonzalez Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Hashimoto K, 2005, CANCER RES, V65, P540
   Janjan N, 2009, J PALLIAT MED, V12, P417, DOI 10.1089/jpm.2009.9633
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Liang CH, 2014, MOL PHARMACEUT, V11, P1378, DOI 10.1021/mp4004139
   Ling V, 1997, CANCER CHEMOTH PHARM, V40, pS3, DOI 10.1007/s002800051053
   Long JT, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/s12951 014 0037 5
   Molinuevo MS, 2007, EUR J PHARMACOL, V562, P28, DOI 10.1016/j.ejphar.2007.01.054
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Negi LM, 2014, COLLOID SURFACE B, V123, P600, DOI 10.1016/j.colsurfb.2014.09.062
   Oh KT, 2009, INT J PHARMACEUT, V376, P134, DOI 10.1016/j.ijpharm.2009.04.021
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Sevcik MA, 2004, PAIN, V111, P169, DOI 10.1016/j.pain.2004.06.015
   Seymour LW, 2002, J CLIN ONCOL, V20, P1668, DOI 10.1200/JCO.2002.20.6.1668
   Su D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054505
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Tuomela JM, 2008, BMC CANCER, V8, DOI 10.1186/1471 2407 8 81
   Ulbrich K, 2004, ADV DRUG DELIVER REV, V56, P1023, DOI 10.1016/j.addr.2003.10.040
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   Walker Mark S, 2013, J Med Econ, V16, P179, DOI 10.3111/13696998.2012.737883
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Ye WL, 2013, J PHARM SCI US, V102, P530, DOI 10.1002/jps.23381
   Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070
NR 41
TC 17
Z9 20
U1 0
U2 75
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0022 3549
EI 1520 6017
J9 J PHARM SCI US
JI J. Pharm. Sci.
PD JUL
PY 2015
VL 104
IS 7
BP 2293
EP 2303
DI 10.1002/jps.24476
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA CL1LT
UT WOS:000356705500020
PM 25980534
DA 2025 08 17
ER

PT J
AU Zhang, XQ
   Mao, JL
   Shao, L
   Liu, S
   Zhou, JW
   Mei, MR
   Zhang, ZJ
AF Zhang, Xiaoqin
   Mao, Jiale
   Shao, Lu
   Liu, Shuang
   Zhou, Jiwang
   Mei, Mingrong
   Zhang, Zunjing
TI Screening of active components of melastoma dodecandrum lour. against
   diabetic osteoporosis using cell membrane chromatography mass
   spectrometry
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE melastoma dodecandrum lour.; isovitexin; RAGE pathway; diabetic
   osteoporosis; cell membrane chromatography
ID GLYCATION END PRODUCTS; TNF ALPHA
AB Background Melastoma dodecandrum Lour. (MD), a traditional botanical drug known for its hypoglycemic, antioxidant, and anti inflammatory properties, is commonly used to treat diabetes, osteoarthritis, and osteoporosis. However, its specific active components against diabetic osteoporosis remain unclear.Purpose This study aimed to identify the key active components in MD using cell membrane chromatography coupled with mass spectrometry and validate their effects in vitro.Methods An AGEs induced osteoblast injury model was established. MTT assays measured cell viability, and ALP activity was assessed using a biochemical kit. Western blotting was employed to detect the expression levels of osteoblast related proteins OCN and RUNX2 and the AGE receptor protein RAGE. ELISA was used to determine the levels of SOD, MDA, CAT, and GPx. PCR quantified TNF alpha expression to evaluate the protective effects and potential mechanisms of MD. The AGEs induced osteoblast cell membrane chromatography mass spectrometry method facilitated the rapid identification of potentially active compounds based on their affinity for the osteoblast cell membrane. Cell experiments further validated the activity of the characteristic component isovitexin.Results MD significantly improved cell viability in AGEs damaged osteoblasts, enhanced ALP, SOD, CAT, and GPx activities, reduced MDA levels, increased OCN and RUNX2 protein expression, and decreased TNF alpha mRNA and RAGE protein expression. Cell membrane chromatography identified 20 chemical constituents, including 13 flavonoids, 4 organic acids, 1 phenylpropanoids, 1 terpenoids, and 1 alkaloid. Cell experiments have confirmed that isovitexin has significant protective activity against osteoblasts and can inhibit the expression of specific receptor RAGE on the osteoblast membrane, consistent with the effect of MD.Conclusion MD and its active component, isovitexin, provide protective effects against AGEs induced osteoblast injury, offering a basis for subsequent drug development.
C1 [Zhang, Xiaoqin; Mao, Jiale; Liu, Shuang; Zhou, Jiwang; Zhang, Zunjing] Zhejiang Chinese Med Univ, Lishui Hosp Tradit Chinese Med, Lishui TCM Hosp, Pharm Dept, Lishui, Peoples R China.
   [Zhang, Xiaoqin; Mao, Jiale; Liu, Shuang] Zhejiang Prov Key Lab She Med Inheritance Innovat, Lishui, Peoples R China.
   [Zhang, Xiaoqin; Mao, Jiale; Liu, Shuang] Lishui She Med Inheritance Innovat Dev & Applicat, Lishui, Peoples R China.
   [Mao, Jiale] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou, Peoples R China.
   [Shao, Lu] Qingdao Univ, Qingdao Hiser Hosp, Qingdao Tradit Chinese Med Hosp, Qingdao, Peoples R China.
   [Mei, Mingrong] Zhejiang Prov Ethn Hosp, Jingning, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Qingdao University
RP Zhang, ZJ (通讯作者)，Zhejiang Chinese Med Univ, Lishui Hosp Tradit Chinese Med, Lishui TCM Hosp, Pharm Dept, Lishui, Peoples R China.
EM 382149034@qq.com
FU Lishui Science and Technology Project [2021GYX18, 2022SJZC075,
   2024GYX34]; Lishui Public Welfare Project [2022GYX69]; Science and
   Technology Project of Zhejiang Provincial Administration of Traditional
   Chinese Medicine [GZY ZJ KJ 23097, GZY ZJ KJ 24099, 2023ZF203]; Lishui
   Key Research and Development Project [2022ZDYF24]; Lishui Medical Key
   Discipline She Medical Pharmacy [2022 2024Z]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This research
   was supported by the Lishui Science and Technology Project (2021GYX18,
   2022SJZC075, and 2024GYX34), Lishui Public Welfare Project (2022GYX69),
   Science and Technology Project of Zhejiang Provincial Administration of
   Traditional Chinese Medicine (GZY ZJ KJ 23097, GZY ZJ KJ 24099, and
   2023ZF203), Lishui Key Research and Development Project (2022ZDYF24) and
   Lishui Medical Key Discipline She Medical Pharmacy (2022 2024Z cycle).
CR Abdulai Ibrahim Luru, 2021, ScientificWorldJournal, V2021, P6641128, DOI 10.1155/2021/6641128
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Behera J, 2022, DIABETES, V71, P2777, DOI 10.2337/db21 0573
   Cavati G, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12040928
   Chen C, 2014, PHARMACOLOGY, V94, P265, DOI 10.1159/000369074
   Chen N, 2022, PHYTOMEDICINE, V98, DOI 10.1016/j.phymed.2022.153982
   Cheng YZ, 2018, LIFE SCI, V205, P184, DOI 10.1016/j.lfs.2018.04.042
   Deo P, 2020, MUTAGENESIS, V35, P291, DOI 10.1093/mutage/geaa012
   Franke S, 2011, CLIN EXP RHEUMATOL, V29, P650
   Ge WW, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12656
   Han SL, 2018, PHYTOCHEM ANALYSIS, V29, P341, DOI 10.1002/pca.2756
   He JB, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01344
   He M, 2016, FITOTERAPIA, V115, P74, DOI 10.1016/j.fitote.2016.09.011
   Huang G, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10239
   Jiang JJ, 2022, EXP CLIN ENDOCR DIAB, V130, P671, DOI 10.1055/a 1861 2388
   Kuang W, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.37
   Lee EJ, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071052
   Li XM, 2021, J CELL MOL MED, V25, P11278, DOI 10.1111/jcmm.17054
   Li Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12834
   Li Z, 2021, EUR J MED RES, V26, DOI 10.1186/s40001 021 00559 x
   Lin JA, 2018, J AGR FOOD CHEM, V66, P2065, DOI 10.1021/acs.jafc.7b05943
   Liu BY, 2019, CELL TISSUE BANK, V20, P173, DOI 10.1007/s10561 019 09751 0
   Liu CY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01239
   Ma RF, 2017, CELL PHYSIOL BIOCHEM, V41, P55, DOI 10.1159/000455936
   Ma WN, 2021, J CHROMATOGR A, V1639, DOI 10.1016/j.chroma.2021.461916
   Mohsin S, 2019, EXPERT OPIN BIOL TH, V19, P937, DOI 10.1080/14712598.2019.1618266
   Moldogazieva NT, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3085756
   Ott C, 2014, REDOX BIOL, V2, P411, DOI 10.1016/j.redox.2013.12.016
   Pal S, 2022, CALCIFIED TISSUE INT, V111, P196, DOI 10.1007/s00223 022 00979 9
   Suh KS, 2014, FREE RADICAL RES, V48, P206, DOI 10.3109/10715762.2013.859387
   Takeuchi M, 1999, MOL MED, V5, P393, DOI 10.1007/BF03402128
   Tanaka K, 2013, BIOCHEM BIOPH RES CO, V438, P463, DOI 10.1016/j.bbrc.2013.07.126
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang JF, 2017, MOLECULES, V22, DOI 10.3390/molecules22030476
   Wang NN, 2020, PHYTOMEDICINE, V75, DOI 10.1016/j.phymed.2020.153247
   Wang N, 2017, J SEP SCI, V40, P4311, DOI 10.1002/jssc.201700688
   Wang T, 2017, CURR DRUG TARGETS, V18, P1051, DOI 10.2174/1389450118666170321105425
   Wang TT, 2017, CURR DRUG TARGETS, V18, P1664, DOI 10.2174/1389450118666170104153512
   Weinberg E, 2014, J MOL ENDOCRINOL, V52, P67, DOI 10.1530/JME 13 0229
   Weng JY, 2019, PHARM BIOL, V57, P807, DOI 10.1080/13880209.2019.1693605
   Xu X. S., 2023, masters thesis
   Xu Y, 2023, FOOD CHEM, V399, DOI 10.1016/j.foodchem.2022.133999
NR 42
TC 1
Z9 1
U1 6
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 25
PY 2024
VL 15
AR 1450154
DI 10.3389/fphar.2024.1450154
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA L3M3Q
UT WOS:001349792000001
PM 39525628
OA gold
DA 2025 08 17
ER

PT J
AU Bae, S
   Lee, HJ
   Lee, JS
   Webb, K
AF Bae, Sooneon
   Lee, Ho Joon
   Lee, Jeoung Soo
   Webb, Ken
TI Cell Mediated Dexamethasone Release from Semi IPNs Stimulates Osteogenic
   Differentiation of Encapsulated Mesenchymal Stem Cells
SO BIOMACROMOLECULES
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 2; HYALURONIC ACID; IN VITRO; SMALL
   MOLECULES; REGENERATION; HYDROGELS; DELIVERY; CONJUGATE; FUSION; VIVO
AB Scaffold based delivery of bioactive molecules capable of directing stem cell differentiation is critical to the development of point of care cell therapy for orthopedic repair. Dexamethasone conjugated hyaluronic acid (HA DXM) was synthesized and combined with hydrolytically degradable, photo cross linkable PEG bis(2 acryloyloxy propanoate) (PEG bis AP) to form semi IPNs. Dexamethasone (DX) release was limited in physiological buffer and substantially increased in the presence of encapsulated human mesenchymal stem cells (hMSCs) or exogenous hyaluronidase, confirming that release occurred primarily by a cell mediated enzymatic mechanism. hMSCs encapsulated in PEG bis AP/HA DXM semi IPNs increased osteoblast specific gene expression, alkaline phosphatase activity, and matrix mineralization, attaining levels that were not significantly different from positive controls consisting of hMSCs in PEG bis AP/native HA cultured with DX supplementation in the culture medium. These studies demonstrate that PEG bis AP/HA DXM semi IPNs can provide cell mediated release of bioactive free DX that induces hMSC osteogenic differentiation. This approach offers an efficient system for local delivery of osteogenic molecules empowering point of care applications.
C1 [Bae, Sooneon; Lee, Ho Joon; Webb, Ken] Clemson Univ, Dept Bioengn, Microenvironm Engn Lab, Clemson, SC 29634 USA.
   [Lee, Jeoung Soo] Clemson Univ, Dept Bioengn, Drug Design Dev & Delivery Lab, Clemson, SC 29634 USA.
C3 Clemson University; Clemson University
RP Lee, JS (通讯作者)，Clemson Univ, Dept Bioengn, Drug Design Dev & Delivery Lab, 301 Rhodes Res Ctr, Clemson, SC 29634 USA.
EM ljspia@clemson.edu; kwebb@clemson.edu
FU National Institute of Health through the SCBioCRAFT COBRE Center of
   Regeneration and Formation of Tissues [8P20GM103444 04]
FX This study was supported by the National Institute of Health (Grant
   8P20GM103444 04) through the SCBioCRAFT COBRE Center of Regeneration and
   Formation of Tissues.
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Benoit DSW, 2006, BIOMATERIALS, V27, P6102, DOI 10.1016/j.biomaterials.2006.06.031
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Campoccia D, 1998, BIOMATERIALS, V19, P2101, DOI 10.1016/S0142 9612(98)00042 8
   Cho E, 2009, J BIOMED MATER RES A, V90A, P1073, DOI 10.1002/jbm.a.32172
   Choi YS, 2005, BIOMATERIALS, V26, P5855, DOI 10.1016/j.biomaterials.2005.02.022
   Coelho MB, 2012, ANNU REV BIOMED ENG, V14, P325, DOI 10.1146/annurev bioeng 071811 150041
   Comer GC, 2012, SPINE J, V12, P881, DOI 10.1016/j.spinee.2012.09.040
   Dawes GJS, 2012, J BIOMATER APPL, V27, P477, DOI 10.1177/0885328211412634
   Dawes GJS, 2010, J MATER SCI MATER M, V21, P215, DOI 10.1007/s10856 009 3846 6
   Decaris ML, 2011, ANN BIOMED ENG, V39, P1174, DOI 10.1007/s10439 010 0217 x
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Everts M, 2002, J IMMUNOL, V168, P883, DOI 10.4049/jimmunol.168.2.883
   Gothard D, 2014, EUR CELLS MATER, V28, P166, DOI 10.22203/eCM.v028a13
   Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097 4636(199802)39:2<266::AID JBM14>3.0.CO;2 B
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Ito T, 2007, BIOMATERIALS, V28, P1778, DOI 10.1016/j.biomaterials.2006.12.012
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Koehler KC, 2013, BIOMATERIALS, V34, P4150, DOI 10.1016/j.biomaterials.2013.02.020
   Kutty JK, 2007, BIOMATERIALS, V28, P4928, DOI 10.1016/j.biomaterials.2007.08.007
   Kutty JK, 2009, J BIOMAT SCI POLYM E, V20, P737, DOI 10.1163/156856209X426763
   Kyburz KA, 2015, ANN BIOMED ENG, V43, P489, DOI 10.1007/s10439 015 1297 4
   Lee HJ, 2015, ACTA BIOMATER, V14, P43, DOI 10.1016/j.actbio.2014.12.007
   Lee H, 2008, BIOCONJUGATE CHEM, V19, P1319, DOI 10.1021/bc8000485
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo KWH, 2012, REGEN MED, V7, P535, DOI [10.2217/rme.12.33, 10.2217/RME.12.33]
   Luo Y, 1999, BIOCONJUGATE CHEM, V10, P755, DOI 10.1021/bc9900338
   Ma JL, 2014, STEM CELL TRANSL MED, V3, P98, DOI 10.5966/sctm.2013 0126
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Nuttelman CR, 2006, J BIOMED MATER RES A, V76A, P183, DOI 10.1002/jbm.a.30537
   Oh EJ, 2009, BIOMATERIALS, V30, P6026, DOI 10.1016/j.biomaterials.2009.07.024
   Park BW, 2012, DIFFERENTIATION, V83, P249, DOI 10.1016/j.diff.2012.02.008
   Phelps EA, 2010, P NATL ACAD SCI USA, V107, P3323, DOI 10.1073/pnas.0905447107
   POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P339, DOI 10.1021/bc00028a010
   RAMP WK, 1984, AM J PHYSIOL, V246, pC30, DOI 10.1152/ajpcell.1984.246.1.C30
   Rosato A, 2006, UROL ONCOL SEMIN ORI, V24, P207, DOI 10.1016/j.urolonc.2005.08.020
   Sahoo S, 2008, BIOMACROMOLECULES, V9, P1088, DOI 10.1021/bm800051m
   Segar CE, 2013, CURR PHARM DESIGN, V19, P3403, DOI 10.2174/1381612811319190007
   Sensebé L, 2011, HUM GENE THER, V22, P19, DOI 10.1089/hum.2010.197
   Shi XT, 2010, J MATER CHEM, V20, P9140, DOI 10.1039/c0jm00976h
   Shi XT, 2010, EUR J PHARM SCI, V39, P59, DOI 10.1016/j.ejps.2009.10.012
   Shimer AL, 2009, INJURY, V40, P32
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P229, DOI 10.1016/S0169 409X(01)00116 8
   Sipp D, 2012, SCIENCE, V338, P1296, DOI 10.1126/science.1229918
   Song IH, 2009, J ORTHOP RES, V27, P916, DOI 10.1002/jor.20838
   Vaidya R, 2007, EUR SPINE J, V16, P1257, DOI 10.1007/s00586 007 0351 9
   Vaidya R, 2008, J SPINAL DISORD TECH, V21, P557, DOI 10.1097/BSD.0b013e31815ea897
   Vyavahare N, 1997, CIRCULATION, V95, P479
   Wang Y, 2009, PHARM RES DORDR, V26, P785, DOI 10.1007/s11095 008 9762 5
   White AP, 2007, INT ORTHOP, V31, P735, DOI 10.1007/s00264 007 0422 x
   Wilson AN, 2014, INT J PHARMACEUT, V461, P214, DOI 10.1016/j.ijpharm.2013.11.061
   Wong DA, 2008, SPINE J, V8, P1011, DOI 10.1016/j.spinee.2007.06.014
   Xin DC, 2010, PHARM RES DORDR, V27, P380, DOI 10.1007/s11095 009 9997 9
   Yang C, 2012, J CONTROL RELEASE, V162, P612, DOI 10.1016/j.jconrel.2012.08.002
   Yoon E, 2007, TISSUE ENG, V13, P619, DOI 10.1089/ten.2006.0102
   Zisch AH, 2003, FASEB J, V17, P2260, DOI 10.1096/fj.02 1041fje
NR 58
TC 10
Z9 11
U1 1
U2 31
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD SEP
PY 2015
VL 16
IS 9
BP 2757
EP 2765
DI 10.1021/acs.biomac.5b00694
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA CR4WV
UT WOS:000361341700022
PM 26259127
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Jean, G
   Mayor, B
   Hurot, JM
   Deleaval, P
   Lorriaux, C
   Zaoui, E
   Chazot, C
AF Jean, Guillaume
   Mayor, Brice
   Hurot, Jean Marc
   Deleaval, Patrik
   Lorriaux, Christie
   Zaoui, Eric
   Chazot, Charles
TI Biological impact of targeted dialysate calcium changes in haemodialysis
   patients: the key role of parathyroid hormone
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE alkaline phosphatases; dialysate calcium; haemodialysis; parathyroid
   hormone; phosphorus
ID KDIGO GUIDELINE; IONIZED CALCIUM; BONE DISEASE; METABOLISM; CARBONATE;
   OUTCOMES; MANAGEMENT; STIFFNESS; BALANCE; BLOOD
AB Background. Establishing an optimal dialysate calcium (DCa) concentration in haemodialysis patients is crucial. DCa individualization has been advocated but most dialysis centres use a fixed DCa, preferably 1.25 mmol/L in the USA and 1.5 mmol/L in European countries. The aim of the study was to assess the short term biological impact of individual DCa prescription aiming at maintaining normal serum calcium and serum parathyroid hormone (PTH) between 150 and 300 pg/mL.
   Methods. Between January 2008 and December 2010, all prevalent patients were checked for the need for DCa change according to our usual strategy Baseline (TO) and after 3 months (T3), values were compared for serum calcium, phosphate, total alkaline phosphatases (t ALP) and PTH.
   Results. Seventy eight patients were followed up for analysis with only one DCa change. Vitamin D derivatives, oral calcium and cinacalcet doses remained stable. Increasing DCa from 1.25 to 1.5 mmol/L and from 1.5 to 1.75 mmol/L led to a significant increase of calcaemia (+2.2 and +1.7%) and a decrease of phosphataemia ( 7 and  9%), t ALP ( 10 and  12%) and PTH ( 50 and  62%). Decreasing DCa from 1.75 to 1.5 mmoll/L and from 1.5 to 1.25 mmol/L led to a decrease of calcaemia ( 2.5 and  1.7%) and an increase of phosphataemia (+11 and +12%), t ALP (+12 and +10%) and PTH (+138 and +175%).
   Conclusions. DCa individualization has a significant impact on mineral metabolism parameters, especially on serum PTH levels, and could be considered as an additional therapy in a more global strategy together with phosphate binder, vitamin D and calcimimetics prescription.
C1 [Jean, Guillaume; Mayor, Brice; Hurot, Jean Marc; Deleaval, Patrik; Lorriaux, Christie; Chazot, Charles] NephroCare Tassin Charcot, Sainte Foy Les Lyon, France.
   [Zaoui, Eric] Lab Grand Vallon, Sainte Foy Les Lyon, France.
RP Jean, G (通讯作者)，NephroCare Tassin Charcot, Sainte Foy Les Lyon, France.
EM guillaume jean crat@wanadoo.fr
OI Jean, guillaume/0000 0003 4757 9956
CR Argiles A, 1998, NEPHROL DIAL TRANSPL, V13, P62, DOI 10.1093/ndt/13.suppl_3.62
   Basile C, 2010, NEPHROL DIAL TRANSPL, V25, P1356, DOI 10.1093/ndt/gfp700
   Drüeke TB, 2009, NEPHROL DIAL TRANSPL, V24, P2990, DOI 10.1093/ndt/gfp365
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Fabrizi F, 1996, NEPHRON, V72, P530, DOI 10.1159/000188934
   Gauci C, 2008, J AM SOC NEPHROL, V19, P1592, DOI 10.1681/ASN.2007040449
   Gotch FA, 2010, KIDNEY INT, V78, P343, DOI 10.1038/ki.2010.157
   HOU SH, 1991, AM J KIDNEY DIS, V18, P217, DOI 10.1016/S0272 6386(12)80882 1
   Jean G, 2002, CLIN NEPHROL, V57, P91
   Jean G, 2012, NEPHRON CLI IN PRESS
   Jean G, 2011, HEMODIAL INT, V15, P485, DOI 10.1111/j.1542 4758.2011.00575.x
   Jean G, 2009, HEMODIAL INT, V13, P526, DOI 10.1111/j.1542 4758.2009.00394.x
   Jean G, 2009, NEPHROL DIAL TRANSPL, V24, P2792, DOI 10.1093/ndt/gfp191
   Jean G, 2009, NEPHROL DIAL TRANSPL, V24, P948, DOI 10.1093/ndt/gfn571
   JESPERSEN B, 1991, NEPHROL DIAL TRANSPL, V6, P98, DOI 10.1093/ndt/6.2.98
   JOHNSON WJ, 1976, NEPHRON, V17, P241, DOI 10.1159/000180729
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kyriazis J, 2002, KIDNEY INT, V61, P276, DOI 10.1046/j.1523 1755.2002.00100.x
   LeBeouf A, 2009, NEPHROL DIAL TRANSPL, V24, P3788, DOI 10.1093/ndt/gfp351
   Lindley EJ, 2009, J REN CARE, V35, P101, DOI 10.1111/j.1755 6686.2009.00053.x
   Lindsay RM, 2003, AM J KIDNEY DIS, V42, pS24, DOI 10.1016/S0272 6386(03)00534 1
   Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P723, DOI 10.1093/ndt/17.5.723
   London GM, 2008, J AM SOC NEPHROL, V19, P1827, DOI 10.1681/ASN.2007050622
   MALBERTI F, 1989, NEPHROL DIAL TRANSPL, V4, P758, DOI 10.1093/ndt/4.8.758
   Moe SM, 2011, KIDNEY INT, V79, P478, DOI 10.1038/ki.2010.480
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Molina Vila P, 2008, HEMODIAL INT, V12, P73, DOI 10.1111/j.1542 4758.2008.00244.x
   Näppi SE, 2000, KIDNEY INT, V57, P2117, DOI 10.1046/j.1523 1755.2000.00062.x
   Palmer BF, 2001, SEMIN DIALYSIS, V14, P41, DOI 10.1046/j.1525 139x.2001.00013.x
   REGAN RJ, 1976, KIDNEY INT, V10, P246, DOI 10.1038/ki.1976.104
   Spasovski G, 2007, BONE, V41, P698, DOI 10.1016/j.bone.2007.06.014
   TSUKAMOTO Y, 1991, NEPHRON, V57, P23, DOI 10.1159/000186210
   vanKuijk WHM, 1997, CLIN NEPHROL, V47, P190
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 34
TC 27
Z9 28
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JAN
PY 2013
VL 28
IS 1
BP 176
EP 182
DI 10.1093/ndt/gfs119
PG 7
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA 098HN
UT WOS:000315540100031
PM 22764192
OA hybrid
DA 2025 08 17
ER

PT J
AU Kircher, J
   Martinek, V
   Mittelmeier, W
AF Kircher, Joern
   Martinek, Vladimir
   Mittelmeier, Wolfram
TI Heterotopic ossification after minimally invasive rotator cuff repair
SO ARTHROSCOPY THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
LA English
DT Article
DE heterotopic bone formation; rotator cuff repair; deltoid fascia;
   arthroscopy
AB Heterotopic ossification is a common phenomenon after spinal cord injury, head injury, neurologic disorders, bums and other trauma, and joint arthroplasty. Periarticular ossifications after shoulder surgery have been known to occur since the 19th century, at an incidence of up to 27%. After arthroscopic and minimally invasive shoulder surgical procedures were introduced and came into broad use, reports about heterotopic ossification became very rare. We describe here a case of heterotopic bone formation in the subdeltoid fascia after arthroscopic subacromial decompression, acromioclavicular joint resection, and mini open rotator cuff reconstruction were performed with 2 absorbable suture anchors 3 months postoperatively. Computed tomography (CT) confirmed a massive heterotopic ossification of the deltoid muscle. During revision surgery, a 4 X 6.5 cm bone shell that consisted primarily of immature trabecular bone and lamellar bone in smaller proportions was removed. The case presented here is unique in the scientific literature. Although risk factors have been identified, the underlying pathomorphogenetic mechanism of such heterotopic bone formation remains unclear. Prophylactic administration of nonsteroidal anti inflammatory drugs (NSAIDs) or radiation for arthroscopic or minimally invasive shoulder surgery is not justified, given the low incidence of heterotopic ossification and the known adverse effects. Apparently, information on basic science and on evidence based therapy is lacking.
C1 [Kircher, Joern; Martinek, Vladimir; Mittelmeier, Wolfram] Univ Rostock, Orthopad Klin & Poliklin, D 18057 Rostock, Germany.
C3 University of Rostock
RP Kircher, J (通讯作者)，Univ Rostock, Orthopad Klin & Poliklin, Doberaner Str 142, D 18057 Rostock, Germany.
EM joern.kircher@med.uni rostock de
RI ; Kircher, Jörn/H 3434 2019
OI Kircher, Jorn/0000 0002 9285 5836; 
CR Berg E E, 1995, J Shoulder Elbow Surg, V4, P188, DOI 10.1016/S1058 2746(05)80050 3
   BERG EE, 1994, ARTHROSCOPY, V10, P158, DOI 10.1016/S0749 8063(05)80086 6
   Boynton MD, 1999, J SHOULDER ELB SURG, V8, P495, DOI 10.1016/S1058 2746(99)90083 6
   Degreef I, 2006, CLIN RHEUMATOL, V25, P251, DOI 10.1007/s10067 004 0983 7
   Erggelet C, 1999, ARCH ORTHOP TRAUM SU, V119, P168, DOI 10.1007/s004020050383
NR 5
TC 17
Z9 18
U1 0
U2 1
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0749 8063
J9 ARTHROSCOPY
JI Arthroscopy
PD DEC
PY 2007
VL 23
IS 12
AR 1359.e1
DI 10.1016/j.arthro.2006.10.020
PG 3
WC Orthopedics; Sport Sciences; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Sport Sciences; Surgery
GA 248XE
UT WOS:000252189700021
PM 18063185
DA 2025 08 17
ER

PT J
AU Peng, H
   Yang, M
   Guo, Q
   Su, T
   Xiao, Y
   Xia, ZY
AF Peng, Hui
   Yang, Mi
   Guo, Qi
   Su, Tian
   Xiao, Ye
   Xia, Zhu Ying
TI Dendrobium officinale polysaccharides regulate age related lineage
   commitment between osteogenic and adipogenic differentiation
SO CELL PROLIFERATION
LA English
DT Article
DE BMSCs; Dendrobium officinale polysaccharides; osteoporosis; oxidative
   stress
ID OXIDATIVE STRESS; BONE MARROW; PROTECTIVE ROLES; NRF2; OSTEOPOROSIS;
   MECHANISMS; OSTEOBLAST; MICE
AB Objectives Excessive oxidative stress and diminished antioxidant defences could contribute to age related tissue damage and various diseases including age related osteoporosis. Dendrobium officinale polysaccharides (DOPs), a major ingredient from a traditional Chinese medicine, have a great potential of antioxidative activity. In this study, we explore the role of DOP in age related osteoporosis that remains elusive. Materials and methods Oxidative stimulation and DOP were used to treat bone marrow mesenchymal stem cells (BMSCs), whose lineage commitment was measured by adipogenic  and osteoblastic induced differentiation analysis. The oxidative stress and antioxidant capacity of BMSCs under the treatment of DOP were analysed by the level of MDA, SOD. Related mechanism studies were confirmed by qRT PCR, Western blotting and siRNA transfection. DOP was orally administrated in aged mice whose phenotype was confirmed by micro CT, immunofluorescence, immunochemistry and calcein double labelling analysis. Results Dendrobium officinale polysaccharide treatment markedly increased osteogenic differentiation of BMSCs, while inhibiting adipogenic differentiation. In vitro, DOP could rescue H2O2 induced switch of BMSCs differentiation fate. However, this effect was abolished in BMSCs when interfered with Nrf2 siRNA. Furthermore, administration of DOP to aged mice significantly increased the bone mass and reduced the marrow adipose tissue (MAT) accompanied with decreased oxidative stress of BMSCs. Conclusions Our study reveals that DOP can attenuate bone loss and MAT accumulation through NRF2 antioxidant signalling, which may represent as potential therapeutic agent for age related osteoporosis.
C1 [Peng, Hui; Yang, Mi; Guo, Qi; Su, Tian; Xiao, Ye; Xia, Zhu Ying] Cent S Univ, Xiangya Hosp, Endocrinol Res Ctr, Dept Endocrinol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
C3 Central South University
RP Xia, ZY (通讯作者)，Cent S Univ, Xiangya Hosp, Endocrinol Res Ctr, Dept Endocrinol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM zhuyingxia27@163.com
RI ; Mi, Yang/HIR 5089 2022; 彭, 慧/HHZ 6594 2022; Guo, Qi/U 5576 2019
OI Peng, Hui/0000 0002 7673 3919; Xiao, Ye/0000 0002 5876 4367
FU Major International (Regional) Joint Research Project of National
   Natural Science Foundation of China (NSFC) [81520108008]; National
   Natural Science Foundation of China (NSFC) [81700785]; Training Program
   of the Major Research Plan of National Natural Science Foundation of
   China (NSFC) [91749105]
FX Major International (Regional) Joint Research Project of National
   Natural Science Foundation of China (NSFC), Grant/Award Number:
   81520108008; National Natural Science Foundation of China (NSFC),
   Grant/Award Number: 81700785; Training Program of the Major Research
   Plan of National Natural Science Foundation of China (NSFC), Grant/Award
   Number: 91749105
CR Abarrategi A, 2018, J EXP MED, V215, P729, DOI 10.1084/jem.20172139
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Altindag O, 2008, RHEUMATOL INT, V28, P317, DOI 10.1007/s00296 007 0452 0
   Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Chen C, 2015, J EXP MED, V212, P73, DOI 10.1084/jem.20140643
   Cornelis FMF, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar8426
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569 018 0064 2
   Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337
   Guitart AV, 2017, J EXP MED, V214, P719, DOI 10.1084/jem.20161087
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hendrickx G, 2015, NAT REV RHEUMATOL, V11, P462, DOI 10.1038/nrrheum.2015.48
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Huang TY, 2017, J EXP MED, V214, P3669, DOI 10.1084/jem.20171413
   Ibanez L, 2014, OXID MED CELL LONGEV, V2014, P1
   Kim WK, 2010, J CELL BIOCHEM, V111, P1199, DOI 10.1002/jcb.22846
   Krane SM, 2005, J EXP MED, V201, P841, DOI 10.1084/jem.20050354
   Kubben N, 2016, CELL, V165, P1361, DOI 10.1016/j.cell.2016.05.017
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Liang J, 2018, CARBOHYD POLYM, V185, P159, DOI 10.1016/j.carbpol.2018.01.013
   Liang J, 2018, INT J BIOL MACROMOL, V107, P2201, DOI 10.1016/j.ijbiomac.2017.10.085
   Lin X, 2011, INT IMMUNOPHARMACOL, V11, P2025, DOI 10.1016/j.intimp.2011.08.014
   Luo QL, 2016, INT J BIOL MACROMOL, V89, P219, DOI 10.1016/j.ijbiomac.2016.04.067
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Murakami S, 2015, FREE RADICAL BIO MED, V88, P168, DOI 10.1016/j.freeradbiomed.2015.06.030
   Ng TB, 2012, APPL MICROBIOL BIOT, V93, P1795, DOI 10.1007/s00253 011 3829 7
   Park CK, 2014, BONE, V63, P36, DOI 10.1016/j.bone.2014.01.025
   Pellegrini GG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171161
   Seo H A, 2013, OXID MED CELL LONGEV, V2013, P1
   Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474 9726.2006.00213.x
   Su T, 2019, ACS NANO, V13, P2450, DOI 10.1021/acsnano.8b09375
   SUN Y, 2015, J BIOMED SCI, V22, P1, DOI DOI 10.1186/S12929 015 0212 5
   Sun YX, 2015, BONE, V74, P1, DOI 10.1016/j.bone.2014.12.066
   Tang HX, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/7436259
   Wang Q, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00966
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wu YY, 2018, BIOMED PHARMACOTHER, V101, P953, DOI 10.1016/j.biopha.2018.03.030
   Yang LC, 2014, CARBOHYD POLYM, V111, P856, DOI 10.1016/j.carbpol.2014.05.007
   Yoon DS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.3
   Yu B, 2018, CELL STEM CELL, V23, P193, DOI 10.1016/j.stem.2018.06.009
   Zhang ZH, 2016, BIOMED PHARMACOTHER, V84, P1350, DOI 10.1016/j.biopha.2016.10.074
   Zhao YJ, 2017, FOOD SCI TECH BRAZIL, V37, P303, DOI [10.1590/1678 457X.22716, 10.1590/1678 457x.22716]
NR 45
TC 47
Z9 57
U1 4
U2 66
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD JUL
PY 2019
VL 52
IS 4
AR e12624
DI 10.1111/cpr.12624
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IM3RS
UT WOS:000477913100008
PM 31038249
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shum, LC
   White, NS
   Mills, BN
   Bentley, KLD
   Eliseev, RA
AF Shum, Laura C.
   White, Noelle S.
   Mills, Bradley N.
   Bentley, Karen L. de Mesy
   Eliseev, Roman A.
TI Energy Metabolism in Mesenchymal Stem Cells During Osteogenic
   Differentiation
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID HYPOXIA INDUCIBLE FACTORS; MITOCHONDRIAL DYSFUNCTION; OSTEOBLAST
   DIFFERENTIATION; BONE FORMATION; MEDICINE; OXYGEN
AB There is emerging interest in stem cell energy metabolism and its effect on differentiation. Bioenergetic changes in differentiating bone marrow mesenchymal stem cells (MSCs) are poorly understood and were the focus of our study. Using bioenergetic profiling and transcriptomics, we have established that MSCs activate the mitochondrial process of oxidative phosphorylation (OxPhos) during osteogenic differentiation, but they maintain levels of glycolysis similar to undifferentiated cells. Consistent with their glycolytic phenotype, undifferentiated MSCs have high levels of hypoxia inducible factor 1 (HIF 1). Osteogenically induced MSCs downregulate HIF 1 and this downregulation is required for activation of OxPhos. In summary, our work provides important insights on MSC bioenergetics and proposes a HIF based mechanism of regulation of mitochondrial OxPhos in MSCs.
C1 [Shum, Laura C.; White, Noelle S.; Bentley, Karen L. de Mesy; Eliseev, Roman A.] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Mills, Bradley N.] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA.
   [Bentley, Karen L. de Mesy; Eliseev, Roman A.] Univ Rochester, Sch Med & Dent, Dept Pathol, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester; University of
   Rochester
RP Eliseev, RA (通讯作者)，Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, 575 Elmwood Ave Room 1 8541, Rochester, NY 14642 USA.
EM roman_eliseev@urmc.rochester.edu
OI Shum, Laura/0000 0002 0167 4133
FU NIH/NIAMS [K01 AR064610, R03 AR061515, P30 AR061307]
FX We would like to thank Drs. Regis O'Keefe, Matthew Hilton, Paul Brookes,
   Sergiy Nadtochiy, and George Porter for fruitful discussions, Dr. Marc
   Halterman for sharing his resources, and Jerry Madukwe for his
   assistance. Financial support was from the NIH/NIAMS K01 AR064610,
   NIH/NIAMS R03 AR061515, and NIH/NIAMS P30 AR061307 grants.
CR Baker N, 2015, BONE, V70, P37, DOI 10.1016/j.bone.2014.10.014
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Gao L, 2011, AM J PATHOL, V178, P969, DOI 10.1016/j.ajpath.2010.11.051
   Giang AH, 2013, J BIOL CHEM, V288, P33303, DOI 10.1074/jbc.M113.507129
   Goda N, 2012, INT J HEMATOL, V95, P457, DOI 10.1007/s12185 012 1069 y
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013 1974
   Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Nam SY, 2011, BRIT J CANCER, V104, P166, DOI 10.1038/sj.bjc.6606020
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Pattappa G, 2011, J CELL PHYSIOL, V226, P2562, DOI 10.1002/jcp.22605
   Picard M, 2013, AM J PHYSIOL REG I, V304, pR393, DOI 10.1152/ajpregu.00584.2012
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111
   Riddle RC, 2011, J BIOL CHEM, V286, P44449, DOI 10.1074/jbc.M111.276683
   Saito Mitsuru, 2013, Front Endocrinol (Lausanne), V4, P72, DOI 10.3389/fendo.2013.00072
   Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Shapovalov Y, 2011, J BIOL CHEM, V286, P22331, DOI 10.1074/jbc.M111.250092
   Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914
NR 23
TC 200
Z9 229
U1 2
U2 54
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD JAN 15
PY 2016
VL 25
IS 2
BP 114
EP 122
DI 10.1089/scd.2015.0193
PG 9
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA DB0KV
UT WOS:000368197900002
PM 26487485
OA Green Published
DA 2025 08 17
ER

PT J
AU Song, J
   Li, J
   Yang, FJ
   Ning, G
   Zhen, LM
   Wu, LN
   Zheng, YY
   Zhang, Q
   Lin, DJ
   Xie, C
   Peng, L
AF Song, Jie
   Li, Jing
   Yang, Fangji
   Ning, Gang
   Zhen, Limin
   Wu, Lina
   Zheng, Yongyuan
   Zhang, Qi
   Lin, Dongjun
   Xie, Chan
   Peng, Liang
TI Nicotinamide mononucleotide promotes osteogenesis and reduces
   adipogenesis by regulating mesenchymal stromal cells via the SIRT1
   pathway in aged bone marrow
SO CELL DEATH & DISEASE
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; EXPRESSION; RUNX2; DIFFERENTIATION;
   ADIPOCYTES; ACTIVATION; MECHANISMS; PROTECTS; FRACTION; MURINE
AB Mesenchymal stromal cells (MSCs) can differentiate to various cell types including osteoblasts, chondrocytes, and adipocytes. This cellular flexibility contributes to widespread clinical use of MSCs in tissue repair. However, challenges remain in efficient cellular expansion of MSCs for stem cell therapy. Current MSC culture methods have resulted in reduced self renewal of MSCs and compromised therapeutic outcomes. This study identifies that nicotinamide mononucleotide (NMN), a key natural NAD(+) intermediate, effectively encourages MSC expansion in vitro and in vivo. The in vitro expanded MSCs had heightened osteogenesis, but reduced adipogenesis. Furthermore, NMN supplementation stimulated osteogenesis of endogenous MSCs, and protected bone from aging and irradiation induced damage in mice. Mechanistically, we found that NMN treatment upregulated SIRT1. Genetically   overexpressing SIRT1 in MSCs by using Prx1 cre; ColAl(flox stoptIox SIRT1) mice promoted osteogenesis and reduced adipogenesis in aged mice. Overall, our data demonstrate that NMN promoted MSC self renewal with strengthened osteogenesis and reduced adipogenesis via upregulating SIRT1 in aged mice.
C1 [Song, Jie; Yang, Fangji; Ning, Gang; Zhen, Limin; Wu, Lina; Zheng, Yongyuan; Xie, Chan; Peng, Liang] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   [Li, Jing] Jinan Univ, Guangdong Hongkong Macau Inst CNS Regenerat, Minist Educ CNS Regenerat Collaborat Joint Lab, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Qi] Sun Yat Sen Univ, Cell Gene Therapy Translat Med Res Ctr, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   [Lin, Dongjun] Sun Yat Sen Univ, Dept Haematol, Affiliated Hosp 7, Shenzhen, Peoples R China.
C3 Sun Yat Sen University; Jinan University; Sun Yat Sen University; Sun
   Yat Sen University
RP Xie, C; Peng, L (通讯作者)，Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.; Lin, DJ (通讯作者)，Sun Yat Sen Univ, Dept Haematol, Affiliated Hosp 7, Shenzhen, Peoples R China.
EM lindongjun0168@163.com; xchan@mail.sysu.edu.cn; pliang@mail.sysu.edu.cn
RI ; Ning, Gang/AAV 3228 2020
OI Song, Jie/0000 0003 0959 6181; 
FU National Natural Science Foundation of China [81873572, 81570539,
   81870127, 81472259]; National Science and Technology Major Project of
   China [2018ZX10302204, 2018ZX10302205002, 2017YFA0105500]; Science and
   Technology Project of Guangzhou [201604016070]; Fundamental Research
   Funds for the Central Universities [16ykpy40]
FX This work was funded by the National Natural Science Foundation of China
   (No. 81873572, 81570539, 81870127, 81472259), the National Science and
   Technology Major Project of China (No. 2018ZX10302204,
   2018ZX10302205002, 2017YFA0105500), the Science and Technology Project
   of Guangzhou (No. 201604016070), the Fundamental Research Funds for the
   Central Universities (No. 16ykpy40).
CR Aguilar S, 2007, STEM CELLS, V25, P1586, DOI 10.1634/stemcells.2006 0762
   Arpin CC, 2016, MOL CANCER THER, V15, P794, DOI 10.1158/1535 7163.MCT 15 0003
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cantó C, 2015, CELL METAB, V22, P31, DOI 10.1016/j.cmet.2015.05.023
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Espeland MA, 2017, J GERONTOL A BIOL, V72, P355, DOI 10.1093/gerona/glw220
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756 3282(96)00258 X
   Guan Y, 2017, J AM SOC NEPHROL, V28, P2337, DOI 10.1681/ASN.2016040385
   Hansen S, 2015, AGEING RES REV, V20, P11, DOI 10.1016/j.arr.2014.12.002
   Healey MK, 2016, PSYCHOL REV, V123, P23, DOI 10.1037/rev0000015
   Hur J, 2016, CELL STEM CELL, V18, P508, DOI 10.1016/j.stem.2016.01.013
   Joe IS, 2015, NEUROSCI LETT, V584, P97, DOI 10.1016/j.neulet.2014.10.024
   Kassem M, 2011, AGING CELL, V10, P191, DOI 10.1111/j.1474 9726.2011.00669.x
   Kim J, 2009, ARCH PHARM RES, V32, P117, DOI 10.1007/s12272 009 1125 1
   Lee JS, 2011, BIOMATERIALS, V32, P760, DOI 10.1016/j.biomaterials.2010.09.042
   Leko V, 2012, BLOOD, V119, P1856, DOI 10.1182/blood 2011 09 377077
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002
   Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367
   Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506
   Mills KF, 2016, CELL METAB, V24, P795, DOI 10.1016/j.cmet.2016.09.013
   Nishikawa K, 2010, J CLIN INVEST, V120, P3455, DOI 10.1172/JCI42528
   Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593
   Petsko GA, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 12 113
   Ramadori G, 2011, CELL METAB, V14, P301, DOI 10.1016/j.cmet.2011.06.014
   ROZMAN C, 1989, EXP HEMATOL, V17, P34
   Signer RAJ, 2013, CELL STEM CELL, V12, P152, DOI 10.1016/j.stem.2013.01.001
   Suire C, 2012, BLOOD, V119, pE86, DOI 10.1182/blood 2011 08 372334
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Wagner W, 2010, AGING US, V2, P224, DOI 10.18632/aging.100136
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wang XN, 2016, BRAIN RES, V1643, P1, DOI 10.1016/j.brainres.2016.04.060
   Wright LE, 2015, J BONE MINER RES, V30, P1268, DOI 10.1002/jbmr.2458
   Yue R, 2016, ELIFE, V5, DOI 10.7554/eLife.18782
   Zhang LM, 2010, J PINEAL RES, V49, P364, DOI 10.1111/j.1600 079X.2010.00803.x
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zhu XH, 2015, P NATL ACAD SCI USA, V112, P2876, DOI 10.1073/pnas.1417921112
NR 39
TC 87
Z9 98
U1 2
U2 48
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR 18
PY 2019
VL 10
AR 336
DI 10.1038/s41419 019 1569 2
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA HZ2EW
UT WOS:000468663000003
PM 31000692
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hu, J
   Huang, X
   Zheng, LW
   Zhang, YX
   Zeng, H
   Nie, L
   Pang, XX
   Zhang, HM
AF Hu, Jing
   Huang, Xia
   Zheng, Liwen
   Zhang, Yuxin
   Zeng, Huan
   Nie, Li
   Pang, Xiaoxiao
   Zhang, Hongmei
TI MiR 199a 5P promotes osteogenic differentiation of human stem cells from
   apical papilla via targeting IFIT2 in apical periodontitis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE apical periodontitis; microRNA; miR 199a 5p; human stem cells from
   apical papilla (hSCAPs); osteogenic differentiation; bone regeneration
ID MICRORNAS; REGENERATION; OSTEOBLASTS; STAGE; BETA
AB IntroductionPeriapical alveolar bone loss is the common consequence of apical periodontitis (AP) caused by persistent local inflammation around the apical area. Human stem cells from apical papilla (hSCAPs) play a crucial role in the restoration of bone lesions during AP. Studies have recently identified the critical role of microRNAs (miRNAs) involved in AP pathogenesis, but little is known about their function and potential molecular mechanism, especially in the osteogenesis of hSCAPs during AP. Here, we investigated the role of clinical sample based specific miRNAs in the osteogenesis of hSCAPs. MethodsDifferential expression of miRNAs were detected in the periapical tissues of normal and patients with AP via transcriptomic analysis, and the expression of miR 199a 5p was confirmed by qRT PCR. Treatment of hSCAPs with miR 199a 5p mimics while loaded onto beta tricalcium phosphate (beta TCP) ceramic particle scaffold to explore its effect on osteogenesis in vivo. RNA binding protein immunoprecipitation (RIP) and Luciferase reporter assay were conducted to identify the target gene of miR 199a 5p. ResultsThe expression of miR 199a 5p was decreased in the periapical tissues of AP patients, and miR 199a 5p mimics markedly enhanced cell proliferation and osteogenic differentiation of hSCAPs, while miR 199a 5p antagomir dramatically attenuated hSCAPs osteogenesis. Moreover, we identified and confirmed Interferon Induced Protein with Tetratricopeptide Repeats 2 (IFIT2) as a specific target of miR 199a 5p, and silencing endogenous IFIT2 expression alleviated the inhibitory effect of miR 199a 5p antagomir on the osteogenic differentiation of hSCAPs. Furthermore, miR 199a 5p mimics transfected hSCAPs loaded onto beta tricalcium phosphate (beta TCP) scaffolds induced robust subcutaneous ectopic bone formation in vivo. DiscussionThese results strengthen our understanding of predictors and facilitators of the key AP miRNAs (miR 199a 5p) in bone lesion repair under periapical inflammatory conditions. And the regulatory networks will be instrumental in exploring the underlying mechanisms of AP and lay the foundation for future regenerative medicine based on dental mesenchymal stem cells.
C1 [Hu, Jing; Huang, Xia; Zheng, Liwen; Zhang, Yuxin; Zeng, Huan; Nie, Li; Pang, Xiaoxiao; Zhang, Hongmei] Chongqing Med Univ, Chongqing Key Lab Oral Dis & Biomed Sci, Affiliated Hosp Stomatol, Chongqing, Peoples R China.
   [Hu, Jing; Zheng, Liwen; Zhang, Yuxin; Zeng, Huan; Zhang, Hongmei] Chongqing Med Univ, Affiliated Stomatol Hosp, Dept Pediat Dent, Chongqing, Peoples R China.
   [Pang, Xiaoxiao] Chongqing Med Univ, Coll Stomatol, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University
RP Pang, XX; Zhang, HM (通讯作者)，Chongqing Med Univ, Chongqing Key Lab Oral Dis & Biomed Sci, Affiliated Hosp Stomatol, Chongqing, Peoples R China.; Zhang, HM (通讯作者)，Chongqing Med Univ, Affiliated Stomatol Hosp, Dept Pediat Dent, Chongqing, Peoples R China.; Pang, XX (通讯作者)，Chongqing Med Univ, Coll Stomatol, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing, Peoples R China.
EM pangxxhi@hospital.cqmu.edu.cn; hmzhang@hospital.cqmu.edu.cn
FU National Natural Science Foundation of China [81870758, 32000572];
   Natural Science Foundation of Chongqing [cstc2021jcyjmsxmX0560];
   Postdoctoral Project of Chongqing Natural Science Foundation
   [cstc2020jcyj bshX0107]; China Postdoctoral Science Foundation
   [2020M683267]
FX Funding The reported work was supported in part by research grants from
   the National Natural Science Foundation of China (81870758 to HZ and
   32000572 to XP), Natural Science Foundation of Chongqing
   (cstc2021jcyjmsxmX0560 to HZ), Postdoctoral Project of Chongqing Natural
   Science Foundation (cstc2020jcyj bshX0107 to XP), and China Postdoctoral
   Science Foundation (2020M683267 to XP).
CR Cintra LTA, 2021, ODONTOLOGY, V109, P741, DOI 10.1007/s10266 021 00636 x
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bohner M, 2020, ACTA BIOMATER, V113, P23, DOI 10.1016/j.actbio.2020.06.022
   Boyan BD, 2022, CELLS BASEL, V11, DOI 10.3390/cells11101619
   Canadian Collaboration on Clinical Practice Guidelines in Dentistry (CCCD), 2004, Evid Based Dent, V5, P7
   Chan LT, 2013, J ENDODONT, V39, P1498, DOI 10.1016/j.joen.2013.08.032
   Chen X, 2015, BIOMATERIALS, V53, P239, DOI 10.1016/j.biomaterials.2015.02.071
   Cotti E, 2022, INT ENDOD J, V55, P1085, DOI 10.1111/iej.13828
   Cui Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1428 1
   Cui YJ, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368 020 0085 7
   De Berdt P, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04210 8
   Deng ZH, 2020, ELIFE, V9, DOI 10.7554/eLife.59659
   Ebadi M, 2023, BIOL PROCED ONLINE, V25, DOI 10.1186/s12575 023 00190 6
   Fan Y, 2023, ELIFE, V12, DOI [10.7554/eLife.82537, 10.7554/eLife.82537.sa0, 10.7554/eLife.82537.sa1, 10.7554/eLife.82537.sa2]
   Gomes BPFD, 2018, BRAZ ORAL RES, V32, P82, DOI 10.1590/1807 3107bor 2018.vol32.0069
   Guan XY, 2021, INT IMMUNOPHARMACOL, V98, DOI 10.1016/j.intimp.2021.107843
   Gungor AS, 2023, OPER DENT, V48, P317, DOI 10.2341/22 023 L
   Guo K, 2019, J CELL BIOCHEM, V120, P7024, DOI 10.1002/jcb.27968
   Guo L, 2019, J CELL PHYSIOL, V234, P581, DOI 10.1002/jcp.26788
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Huang GTJ, 2008, J ENDODONT, V34, P645, DOI 10.1016/j.joen.2008.03.001
   Isola G, 2023, J PERIODONTAL RES, V58, P165, DOI 10.1111/jre.13078
   Jalali P, 2019, J ENDODONT, V45, P1114, DOI 10.1016/j.joen.2019.05.018
   Jiang X, 2023, J MED VIROL, V95, DOI 10.1002/jmv.28574
   Jin CY, 2016, STEM CELLS, V34, P2707, DOI 10.1002/stem.2439
   Lai KC, 2016, CANCER LETT, V370, P207, DOI 10.1016/j.canlet.2015.10.016
   Lee DK, 2021, BIOMATER RES, V25, DOI 10.1186/s40824 021 00214 w
   Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025
   Liu C, 2016, INT ENDOD J, V49, P950, DOI 10.1111/iej.12551
   Liu JY, 2021, ACTA PHARM SIN B, V11, P2783, DOI 10.1016/j.apsb.2021.01.001
   Loureiro C, 2023, CLIN ORAL INVEST, V27, P591, DOI 10.1007/s00784 022 04754 w
   Luo XT, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.908859
   Lv PY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01815 3
   Lyu P, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12121737
   Maqbool M, 2023, ODONTOLOGY, V111, P531, DOI 10.1007/s10266 022 00762 0
   Nada OA, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00103
   Nam SH, 2022, BIOMATER RES, V26, DOI 10.1186/s40824 022 00336 9
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Owen GR, 2018, J BIOMED MATER RES B, V106, P2493, DOI 10.1002/jbm.b.34049
   Rosset EM, 2020, J PERIODONTAL RES, V55, P107, DOI 10.1111/jre.12694
   Sen GC, 2012, CELL RES, V22, P1407, DOI 10.1038/cr.2012.130
   Shao LN, 2019, J CELL BIOCHEM, V120, P645, DOI 10.1002/jcb.27422
   Shaw AE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2004086
   Shen H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0107 3
   Shen Z, 2023, J ENDODONT, V49, P286, DOI 10.1016/j.joen.2022.12.013
   Shen Z, 2021, J APPL ORAL SCI, V29, DOI 10.1590/1678 7757 2020 1058
   Shen Z, 2021, J ENDODONT, V47, P263, DOI 10.1016/j.joen.2020.11.016
   Songsaad A, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02069 9
   Sonoyama W, 2008, J ENDODONT, V34, P166, DOI 10.1016/j.joen.2007.11.021
   Tibúrcio Machado CS, 2021, INT ENDOD J, V54, P712, DOI 10.1111/iej.13467
   Venskutonis T, 2016, G ITAL ENDO, V30, P14, DOI 10.1016/j.gien.2016.04.002
   Wang RK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2377 4
   Wang T, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1579 0
   Wang Z, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10060741
   Woeckel VJ, 2012, J CELL PHYSIOL, V227, P3258, DOI 10.1002/jcp.24020
   Woeckel VJ, 2012, J CELL PHYSIOL, V227, P2668, DOI 10.1002/jcp.23009
   Xia W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26302 y
   Yue JL, 2016, J ENDODONT, V42, P1773, DOI 10.1016/j.joen.2016.08.013
   Zhang L, 2017, J BONE MINER RES, V32, P2466, DOI 10.1002/jbmr.3230
   Zhang SJ, 2018, INT J BIOL MACROMOL, V107, P2094, DOI 10.1016/j.ijbiomac.2017.10.080
   Zheng HJ, 2019, BONE, V123, P92, DOI 10.1016/j.bone.2019.03.020
NR 62
TC 7
Z9 7
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD MAR 30
PY 2023
VL 14
AR 1149339
DI 10.3389/fimmu.2023.1149339
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA D3JN3
UT WOS:000967721400001
PM 37063854
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, C
   Zheng, HX
   Qi, SS
AF Chen, Chen
   Zheng, Hongxing
   Qi, Shanshan
TI Genistein and Silicon Synergistically Protects Against
   Ovariectomy Induced Bone Loss Through Upregulating OPG/RANKL Ratio
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Genistein; Silicon; Ovariectomy; Osteoporosis; OPG; RANKL
ID HORMONE REPLACEMENT THERAPY; MINERAL DENSITY; ALKALINE PHOSPHATASE;
   OSTEOCLAST FORMATION; ESTROGEN DEFICIENCY; SIGNALING PATHWAYS;
   OSTEOPOROSIS; RANKL; WOMEN; OPG
AB We have reported that genistein (Gen) and silicon (Si) have synergistic effects on ovariectomy induced bone loss in rat; however, the potential mechanisms behind this effect were not fully clarified yet. This study was performed to evaluate the bone protective mechanisms of concomitant intake of genistein and silicon in ovariectomized rat by OPG/RANKL axis. Three month old Sprague Dawley female rats were subjected to ovariectomy (OVX) or sham surgery; after surgery, the OVX rats were randomly divided into five groups: OVX Gen, OVX Si, OVX Gen Si, OVX E, and OVX. Genistein, silicon, and 17 estradiol supplementation were started after ovariectomy and continued for 10weeks. The results showed that genistein and silicon treatment increased the bone mineral density (BMD) of ovariectomized rats. In addition, the BMD of the tibia and femur were highest in the OVX Gen Si group compared with OVX Gen and OVX Si group (p<0.05). After 10weeks treatment with genistein and silicon, the bone structure of ovariectomized rats was recovered, there was no difference of bone histomorphometric parameters between OVX Gen Si, OVX E, and SHAM group (p>0.05), and there was no difference in the concentration of serum ALP, Ca, P, OPG, and RANKL between OVX Gen Si, SHAM, and OVX E groups (p>0.05). RT PCR showed that genistein and silicon treatment could effectively increase the OPG mRNA expression and decreased the RANKL mRNA expression compared to that of the OVX group (p<0.05), the OPG/RANKL mRNA ratios were significantly decreased in the OVX group (p<0.05), and it was nearly to normal in the OVX Gen Si group. Immunohistochemical staining results showed that genistein and silicon supplementation could effectively increase the protein expression of OPG and decrease the protein expression of RANKL in bone tissues; there were no significant differences in OPG and RANKL positive expression areas between OVX Gen Si, SHAM, and OVX E group (p>0.05). The results above indicate that genistein and silicon supplementation can effectively reduce RANKL, increase OPG levels, and OPG/RANKL ratios in the serum and bone tissue of ovariectomized rats; this is the main mechanism by which genistein and silicon play a bone protective role in ovariectomized rats.
C1 [Chen, Chen; Zheng, Hongxing] Shaanxi Univ Technol, Qinling Bashan Mt Bioresources Comprehens Dev CIC, Coll Biol Sci & Engn, Chinese German Joint Lab Nat Prod Res, Chaoyang Rd, Hanzhong 723000, Shaanxi, Peoples R China.
   [Qi, Shanshan] Shaanxi Univ Technol, Vitamin D Res Inst, Chaoyang Rd, Hanzhong 723000, Shaanxi, Peoples R China.
C3 Shaanxi University of Technology; Shaanxi University of Technology
RP Zheng, HX (通讯作者)，Shaanxi Univ Technol, Qinling Bashan Mt Bioresources Comprehens Dev CIC, Coll Biol Sci & Engn, Chinese German Joint Lab Nat Prod Res, Chaoyang Rd, Hanzhong 723000, Shaanxi, Peoples R China.; Qi, SS (通讯作者)，Shaanxi Univ Technol, Vitamin D Res Inst, Chaoyang Rd, Hanzhong 723000, Shaanxi, Peoples R China.
EM zhenghongxing100@126.com; qishanshan101@126.com
RI Zheng, Hongxing/D 7472 2011; Qi, Shanshan/IVU 8388 2023
FU High end Foreign Experts Recruitment Programme of State Administration
   of Foreign Experts Affairs [GDT20176100048]; Key Project of Agricultural
   Science and Technology of Shaanxi Province [2017NY 082]; Shaanxi Science
   and Technology Coordinating Innovation Engineering Program
   [2015KTTSSF01 03, 2015HBGC 18]; Shaanxi Province Key Research and
   Development Plan [2017SF 074]; Shaanxi Provincial Education Department
   [17JK0135]; Shaanxi University of Technology [SLGBH16 03];
   Qinling Bashan Mountains Bioresources Comprehensive Development,
   Collaborative Innovation Center Research Funds [QBXT 17 9]
FX This work was supported by the High end Foreign Experts Recruitment
   Programme of State Administration of Foreign Experts Affairs
   (GDT20176100048), the Key Project of Agricultural Science and Technology
   of Shaanxi Province (2017NY 082), Shaanxi Science and Technology
   Coordinating Innovation Engineering Program (2015KTTSSF01 03,
   2015HBGC 18), Shaanxi Province Key Research and Development Plan
   (2017SF 074), Research Project of Shaanxi Provincial Education
   Department (17JK0135), Postodoctoral Project of Shaanxi University of
   Technology (SLGBH16 03), and Qinling Bashan Mountains Bioresources
   Comprehensive Development, Collaborative Innovation Center Research
   Funds (QBXT 17 9).
CR Al Anazi Abdullah Foraih, 2011, J Nat Sci Biol Med, V2, P154, DOI 10.4103/0976 9668.92322
   Bae YJ, 2008, BIOL TRACE ELEM RES, V124, P157, DOI 10.1007/s12011 008 8138 3
   Bijelic Radojka, 2017, Med Arch, V71, P25, DOI 10.5455/medarh.2017.71.25 28
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Crockett JC, 2011, OSTEOPOROSIS INT, V22, P1, DOI 10.1007/s00198 010 1272 8
   Day TF, 2008, J BONE JOINT SURG AM, V90A, P19, DOI 10.2106/JBJS.G.01174
   Enjuanes A, 2010, ENDOCRINE, V37, P322, DOI 10.1007/s12020 009 9306 8
   Gade TP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022608
   Greendale GA, 2002, AM J EPIDEMIOL, V155, P746, DOI 10.1093/aje/155.8.746
   Hao YH, 2018, TOXICOL APPL PHARM, V343, P62, DOI 10.1016/j.taap.2018.02.015
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   HOTT M, 1993, CALCIFIED TISSUE INT, V53, P174, DOI 10.1007/BF01321834
   Jia B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105604
   Jugdaohsingh R, 2007, J NUTR HEALTH AGING, V11, P99
   Jugdaohsingh R, 2004, J BONE MINER RES, V19, P297, DOI 10.1359/JBMR.0301225
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Khosla S, 2011, J BONE MINER RES, V26, P441, DOI 10.1002/jbmr.262
   Kim MH, 2009, BIOL TRACE ELEM RES, V128, P239, DOI 10.1007/s12011 008 8273 x
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Levis S, 2011, ARCH INTERN MED, V171, P1363, DOI 10.1001/archinternmed.2011.330
   Listed N, 2007, ANN INTERN MED, V146, P134
   Liu JM, 2005, CALCIFIED TISSUE INT, V76, P1, DOI 10.1007/s00223 004 0007 2
   Marsden J, 2002, J STEROID BIOCHEM, V83, P123, DOI 10.1016/S0960 0760(02)00258 3
   Messina M, 2014, AM J CLIN NUTR, V100, p423S, DOI 10.3945/ajcn.113.071464
   Miraj S, 2016, PHARM LETT, V8, P421
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   Persson I, 1997, J CLIN EPIDEMIOL, V50, P611, DOI 10.1016/S0895 4356(97)00004 8
   Qi SS, 2018, BIOL TRACE ELEM RES, V183, P288, DOI 10.1007/s12011 017 1134 8
   Qi SS, 2017, BIOL TRACE ELEM RES, V177, P281, DOI 10.1007/s12011 016 0882 1
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Seeman Ego, 2004, Curr Osteoporos Rep, V2, P90, DOI 10.1007/s11914 004 0016 0
   Sun FF, 2014, INT J GYNECOL OBSTET, V41, P146
   Thompson WR, 2012, GENE, V503, P179, DOI 10.1016/j.gene.2012.04.076
   Wang JS, 2018, BIOL TRACE ELEM RES, V183, P270, DOI 10.1007/s12011 017 1123 y
   Watts NB, 2001, OSTEOPOROSIS INT, V12, P279, DOI 10.1007/s001980170117
   Zhang XL, 2005, ARCH INTERN MED, V165, P1890, DOI 10.1001/archinte.165.16.1890
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 39
TC 23
Z9 25
U1 0
U2 13
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD APR
PY 2019
VL 188
IS 2
BP 441
EP 450
DI 10.1007/s12011 018 1433 8
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA HP9DE
UT WOS:000461991600022
PM 30014283
DA 2025 08 17
ER

PT J
AU Zhang, X
   Jia, WT
   Gua, YF
   Wei, XA
   Liu, X
   Wang, DP
   Zhang, CQ
   Huang, WH
   Rahaman, MN
   Day, DE
   Zhou, N
AF Zhang, Xin
   Jia, WeiTao
   Gua, YiFei
   Wei Xiao
   Liu, Xin
   Wang, DePing
   Zhang, ChangQing
   Huang, WenHai
   Rahaman, Mohamed N.
   Day, Delbert E.
   Zhou, Nai
TI Teicoplanin loaded borate bioactive glass implants for treating chronic
   bone infection in a rabbit tibia osteomyelitis model
SO BIOMATERIALS
LA English
DT Article
DE Osteomyelitis; Bone infection; Bone regeneration; Borate bioactive
   glass; Drug release
ID DRUG DELIVERY; STAPHYLOCOCCUS AUREUS; BOROSILICATE GLASSES; HUMAN
   OSTEOBLASTS; IONIC PRODUCTS; HYDROXYAPATITE; SYSTEMS; BORON; MECHANISMS;
   EXPRESSION
AB The treatment of chronic osteomyelitis (bone infection) remains a clinical challenge. In this work, pellets composed of a chitosan bonded mixture of borate bioactive glass particles (<50 mu m) and teicoplanin powder (antibiotic), were evaluated in vitro and in vivo for treating chronic osteomyelitis induced by methicillin resistant Staphylococcus aureus (MRSA) in a rabbit model. When immersed in phosphate buffered saline, the pellets showed sustained release of teicoplanin over 20 30 days, while the bioactive glass converted to hydroxyapatite (HA) within 7 days, eventually forming a porous HA structure. Implantation of the teicoplanin loaded pellets in a rabbit tibia osteomyelitis model resulted in the detection of teicoplanin in the blood for about 9 days. The implants converted to a bone like HA graft, and supported the ingrowth of new bone into the tibia defects within 12 weeks of implantation. Microbiological, histological and scanning electron microscopy techniques showed that the implants provided a cure for the bone infection. The results indicate that the teicoplanin loaded borate bioactive glass implant, combining sustained drug release with the ability to support new bone ingrowth, could provide a method for treating chronic osteomyelitis. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Zhang, Xin; Gua, YiFei; Wei Xiao; Liu, Xin; Wang, DePing; Huang, WenHai] Tongji Univ, Inst Bioengn & Informat Technol Mat, Shanghai 200092, Peoples R China.
   [Jia, WeiTao; Zhang, ChangQing] Shanghai Jiao Tong Univ, Dept Orthoped Surg, Shanghai Peoples Hosp 6, Shanghai 200233, Peoples R China.
   [Liu, Xin; Rahaman, Mohamed N.; Day, Delbert E.] Missouri Univ Sci & Technol, Dept Mat Sci & Engn, Rolla, MO 65409 USA.
   [Liu, Xin; Rahaman, Mohamed N.; Day, Delbert E.] Missouri Univ Sci & Technol, Ctr Bone & Tissue Repair & Regenerat, Rolla, MO 65409 USA.
   [Wang, DePing; Zhou, Nai] Tongji Univ, Key Lab Adv Civil Engn Mat, Shanghai 200092, Peoples R China.
C3 Tongji University; Shanghai Jiao Tong University; University of Missouri
   System; Missouri University of Science & Technology; University of
   Missouri System; Missouri University of Science & Technology; Tongji
   University
RP Huang, WH (通讯作者)，Tongji Univ, Inst Bioengn & Informat Technol Mat, Shanghai 200092, Peoples R China.
EM whhuang@tongji.edu.cn
RI ; Wang, Deping/A 3123 2012; changqing, zhang/JJE 9538 2023
OI Liu, Xin/0000 0001 7035 8540; zhang, changqing/0000 0002 7408 4126; 
FU Shanghai Committee of Science and Technology [084411900500];
   nano technology promotion project [0952nm03400]
FX This work was supported by the Shanghai Committee of Science and
   Technology through the major project (Grant No. 084411900500), and the
   nano technology promotion project (Grant No. 0952nm03400).
CR ADCOCK PM, 1997, SEMIN PEDIAT INFECT, V8, P234
   Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010
   [Anonymous], 2000, M7A5 NAT COMM CLIN L
   Bohner M, 2009, BIOMATERIALS, V30, P6403, DOI 10.1016/j.biomaterials.2009.08.007
   Cao WP, 1996, CERAM INT, V22, P493, DOI 10.1016/0272 8842(95)00126 3
   Couto DS, 2009, ACTA BIOMATER, V5, P115, DOI 10.1016/j.actbio.2008.08.006
   Day DE, 2003, GLASS TECHNOL, V44, P75
   Domingues ZR, 2004, BIOMATERIALS, V25, P327, DOI 10.1016/S0142 9612(03)00524 6
   Eisler R., 1990, Boron hazards to fish, wildlife, and invertebrates: a synoptic review
   FU Q, J BIOMED A IN PRESS
   Ginebra MP, 2006, J CONTROL RELEASE, V113, P102, DOI 10.1016/j.jconrel.2006.04.007
   Habraken WJEM, 2007, ADV DRUG DELIVER REV, V59, P234, DOI 10.1016/j.addr.2007.03.011
   Han X, 2007, J MATER SCI MATER M, V18, P1837, DOI 10.1007/s10856 007 3053 2
   Huang WH, 2006, PHYS CHEM GLASSES B, V47, P647
   Huang WH, 2006, J MATER SCI MATER M, V17, P583, DOI 10.1007/s10856 006 9220 z
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Kanellakopoulou K, 2009, INT J ANTIMICROB AG, V33, P354, DOI 10.1016/j.ijantimicag.2008.09.008
   Laakso J, 2001, CLIN CHEM, V47, P1796
   Leach JK, 2006, BIOMATERIALS, V27, P3249, DOI 10.1016/j.biomaterials.2006.01.033
   Leu A, 2008, PHARM RES DORDR, V25, P1222, DOI 10.1007/s11095 007 9508 9
   Liang W, 2008, J NON CRYST SOLIDS, V354, P1690, DOI 10.1016/j.jnoncrysol.2007.10.003
   Liu X, 2010, J MATER SCI MATER M, V21, P575, DOI 10.1007/s10856 009 3897 8
   MCCOY H, 1994, ENVIRON HEALTH PERSP, V102, P49, DOI 10.2307/3431962
   MURAKAMI K, 1991, J CLIN MICROBIOL, V29, P2240, DOI 10.1128/JCM.29.10.2240 2244.1991
   Nandi SK, 2009, MAT SCI ENG C MATER, V29, P2478, DOI 10.1016/j.msec.2009.07.014
   Nielsen FH, 1997, PLANT SOIL, V193, P199, DOI 10.1023/A:1004276311956
   Ning J, 2007, MATER LETT, V61, P5223, DOI 10.1016/j.matlet.2007.04.089
   NORDEN CW, 1980, BRIT J EXP PATHOL, V61, P451
   Pan HB, 2010, J R SOC INTERFACE, V7, P1025, DOI 10.1098/rsif.2009.0504
   Queiroz CM, 2006, MATER SCI FORUM, V514 516, P1073, DOI 10.4028/www.scientific.net/MSF.514 516.1073
   Sia IG, 2006, BEST PRACT RES CL RH, V20, P1065, DOI 10.1016/j.berh.2006.08.014
   Whittlesey KJ, 2004, EXP NEUROL, V190, P1, DOI 10.1016/j.expneurol.2004.06.020
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   Zhao D, 2009, ACTA BIOMATER, V5, P1265, DOI 10.1016/j.actbio.2008.11.021
   Zhou J, 2010, BIOMATERIALS, V31, P1171, DOI 10.1016/j.biomaterials.2009.10.043
NR 36
TC 131
Z9 151
U1 4
U2 85
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2010
VL 31
IS 22
BP 5865
EP 5874
DI 10.1016/j.biomaterials.2010.04.005
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 614XK
UT WOS:000279092900017
PM 20434766
DA 2025 08 17
ER

PT J
AU Pahlevanzadeh, F
   Bakhsheshi Rad, HR
   Kasiri Asgarani, M
   Emadi, R
   Omidi, M
   Ismail, AF
   Afrand, M
   Berto, F
AF Pahlevanzadeh, F.
   Bakhsheshi Rad, H. R.
   Kasiri Asgarani, M.
   Emadi, R.
   Omidi, M.
   Ismail, A. F.
   Afrand, M.
   Berto, F.
TI Mechanical property, antibacterial activity and cytocompatibility of a
   PMMA based bone cement loaded with clindamycin for orthopaedic surgeries
SO MATERIALS TECHNOLOGY
LA English
DT Article
DE PMMA based bone cement; clindamycin; mechanical properties;
   antibacterial activity; biocompatibility
ID MAGNETIC NANOPARTICLE CARRIER; DELIVERY SYSTEM SYNTHESIS; TARGETED
   DRUG DELIVERY; GRAPHENE OXIDE; FUNCTIONAL RESPONSE; OSTEOBLASTS;
   BEHAVIOR; MICROSTRUCTURE; MINERALIZATION; INTERPLAY
AB Local delivery of antibiotics utilising bone cement is a well known approach for controlling postoperative infections related to implant. 1, 5 and 10 wt.% of clindamycin (Cli) was embedded into polymethylmethacrylate (PMMA) based bone cement for inhibiting postsurgical infection. Clindamycin antibiotic drug was homogeneously embedded into the matrix of PMMA based cement. The results revealed that the fabricated PMMA based cement loaded with Cli presented a high compressive strength (similar to 120 MPa). The PMMA based cement loaded with low Cli presented better cytocompatibility compared with its counterpart loaded with high Cli owing to the better cell attachment on the surface of the cement with a lower release of Cli. The embedding of Cli into the cement improved its antibacterial performance, as implied by the considerably improved inhibition zone with amplifying Cli concentration. Taken together, PMMA based cement loaded with 1 5 wt% Cli might be a promising antimicrobial bone cement to be employed in orthopaedic surgeries.
C1 [Pahlevanzadeh, F.] Islamic Azad Univ, Najafabad Branch, Dept Tissue Engn, Najafabad, Iran.
   [Bakhsheshi Rad, H. R.; Kasiri Asgarani, M.; Omidi, M.] Islamic Azad Univ, Najafabad Branch, Dept Mat Engn, Adv Mat Res Ctr, Najafabad, Iran.
   [Emadi, R.] Isfahan Univ Technol, Dept Mat Engn, Esfahan, Iran.
   [Ismail, A. F.] Univ Teknol Malaysia, Adv Membrane Technol Res Ctr AMTEC, Skudai, Kagawa, Malaysia.
   [Afrand, M.] Ton Duc Thang Univ, Fac Appl Sci, Ho Chi Minh City, Vietnam.
   [Berto, F.] Norwegian Univ Sci & Technol, Dept Mech & Ind Engn, Trondheim, Norway.
C3 Islamic Azad University; Islamic Azad University; Isfahan University of
   Technology; Universiti Teknologi Malaysia; Ton Duc Thang University;
   Norwegian University of Science & Technology (NTNU)
RP Bakhsheshi Rad, HR (通讯作者)，Islamic Azad Univ, Najafabad Branch, Dept Mat Engn, Adv Mat Res Ctr, Najafabad, Iran.
EM rezabakhsheshi@gmail.com
RI Afrand, Masoud/E 6060 2019; Berto, Filippo/J 7204 2019; mahdi omidi  
   Islamic Azad University, Najafabad/AAN 2849 2021; Bakhsheshi Rad, Hamid
   Reza/A 9636 2012
OI Kasiri Asgarani, Masoud/0000 0002 9105 7162; Bakhsheshi Rad, Hamid
   Reza/0000 0002 0719 6312; omidi, mahdi/0000 0001 5584 9616; 
CR [Anonymous], 2015, ENG SOLID MECH, DOI DOI 10.5267/J.ESM.2014.12.001
   Berto F, 2012, ENG FRACT MECH, V90, P143, DOI 10.1016/j.engfracmech.2012.05.001
   Chandrasekaran S, 2016, J MATER CHEM A, V4, P13271, DOI 10.1039/c6ta05043c
   Chaudhary P, 2012, J BIOMED MATER RES A, V100A, P3157, DOI 10.1002/jbm.a.34232
   Chen L, 2019, COLLOID SURFACE B, V183, DOI 10.1016/j.colsurfb.2019.110448
   Chen L, 2015, RSC ADV, V5, P37314, DOI 10.1039/c5ra04646g
   Depan D, 2014, BIOMATER SCI UK, V2, P264, DOI 10.1039/c3bm60192g
   Depan D, 2013, ACTA BIOMATER, V9, P6084, DOI 10.1016/j.actbio.2012.12.019
   Depan D, 2012, MAT SCI ENG C MATER, V32, P1704, DOI 10.1016/j.msec.2012.04.045
   Depan D, 2011, MAT SCI ENG C MATER, V31, P1305, DOI 10.1016/j.msec.2011.04.010
   Geipel U, 2009, INT J MED SCI, V6, P234
   Gonçalves G, 2012, NANOSCALE, V4, P2937, DOI 10.1039/c2nr30303e
   Huang H, 2011, ADV DRUG DELIVER REV, V63, P1332, DOI 10.1016/j.addr.2011.04.001
   Liu X, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.191028
   Mao ZP, 2020, POLYM TEST, V85, DOI 10.1016/j.polymertesting.2020.106425
   Misra RDK, 2008, MATER SCI TECH LOND, V24, P1011, DOI 10.1179/174328408X341690
   Misra RDK, 2013, J BIOMED MATER RES A, V101, P1059, DOI 10.1002/jbm.a.34409
   Misra RDK, 2010, MATER TECHNOL, V25, P118, DOI 10.1179/175355510X12723642365241
   Misra RDK, 2012, ADV ENG MATER, V14, pB247, DOI 10.1002/adem.201180071
   Mohamed AI, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010007
   Neut D, 2006, J ORTHOP RES, V24, P291, DOI 10.1002/jor.20058
   Nune KC, 2017, COLLOID SURFACE B, V150, P78, DOI 10.1016/j.colsurfb.2016.09.050
   Pahlevanzadeh F, 2019, MATER LETT, V240, P9, DOI 10.1016/j.matlet.2018.12.049
   Pahlevanzadeh F, 2018, J MECH BEHAV BIOMED, V82, P257, DOI 10.1016/j.jmbbm.2018.03.016
   Pahlevanzadeh F, 2019, INT J APPL CERAM TEC, V16, P2006, DOI 10.1111/ijac.13298
   Patil SS, 2018, J POLYM SCI POL CHEM, V56, P2080, DOI 10.1002/pola.29168
   Peel S, 2017, P I MECH ENG H, V231, P509, DOI 10.1177/0954411916681346
   Sa Y, 2015, J BIOMED MATER RES B, V103, P548, DOI 10.1002/jbm.b.33233
   Sangnim T, 2018, ASIAN J PHARM SCI, V13, P450, DOI 10.1016/j.ajps.2018.01.002
   Smieja M, 1998, Can J Infect Dis, V9, P22
   Spízek J, 2004, APPL MICROBIOL BIOT, V64, P455, DOI 10.1007/s00253 003 1545 7
   Wang K, 2016, J BIOMAT SCI POLYM E, V27, P441, DOI 10.1080/09205063.2016.1143673
   Wate PS, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957 4484/23/41/415101
   Yuan Q, 2008, ACTA BIOMATER, V4, P1024, DOI 10.1016/j.actbio.2008.02.002
   Yuan Q, 2010, ACTA BIOMATER, V6, P1140, DOI 10.1016/j.actbio.2009.08.027
   Zhang J, 2008, ACTA BIOMATER, V4, P40, DOI 10.1016/j.actbio.2007.06.006
   Zhao ZY, 2018, MATER LETT, V232, P202, DOI 10.1016/j.matlet.2018.08.036
   Zhao ZY, 2019, J ALLOY COMPD, V792, P203, DOI 10.1016/j.jallcom.2019.04.007
   Zhou XP, 2019, THEOR APPL FRACT MEC, V101, P207, DOI 10.1016/j.tafmec.2019.03.002
NR 39
TC 10
Z9 10
U1 0
U2 23
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1066 7857
EI 1753 5557
J9 MATER TECHNOL
JI Mater. Technol.
PY 2021
VL 36
IS 9
BP 564
EP 573
DI 10.1080/10667857.2020.1780812
EA JUN 2020
PG 10
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA ZA7KG
UT WOS:000548130300001
DA 2025 08 17
ER

PT S
AU Coughlin, TR
   Kennedy, OD
AF Coughlin, Thomas R.
   Kennedy, Oran D.
BE Sun, HB
TI The role of subchondral bone damage in post traumatic osteoarthritis
SO MUSCULOSKELETAL REPAIR AND REGENERATION
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 4th Annual Musculoskeletal Repair and Regeneration Symposium
CY OCT, 2015
CL New York City, NY
DE subchondral; bone; PTOA; crosstalk
ID ANTERIOR CRUCIATE LIGAMENT; ARTICULAR CALCIFIED CARTILAGE; KNEE
   OSTEOARTHRITIS; TRABECULAR BONE; RABBIT MODEL; DEGRADATION; INHIBITION;
   DEGENERATION; CHONDROCYTES; TRANSECTION
AB Osteoarthritis (OA), the most common musculoskeletal disease in the United States, is characterized by cartilage breakdown, pain, and restricted movement. Post traumatic OA (PTOA) occurs subsequent to traumatic joint injury, such as anterior cruciate ligament (ACL) rupture, and makes up 12% of the overall disease burden, with healthcare costs of approximately $3 billion/year. The current paradigm for PTOA is based on the observation that joint injury affects multiple tissues, all of which may contribute to subsequent joint failure. Subchondral bone plays a significant role in PTOA, as shown by magnetic resonance imaging evidence that subchondral bone marrow lesions (BMLs) are present in 80% of ACL rupture cases immediately after joint injury. The presence of BMLs indicates an acute consequence of injury, specifically in subchondral bone, which could be targeted with preventative therapy. BMLs may be a direct representation of physical damage to bone tissue. Interestingly, microdamage is known to induce osteoclast mediated remodeling in bone. Furthermore, the contiguous link between subchondral bone and articular cartilage may allow transport of small molecules, resulting from these remodeling processes, to cross the osteochondral junction and contribute to PTOA development. Targeting subchondral bone by inhibiting subchondral remodeling, particularly in the early phase postinjury, may be a potential approach for preventing PTOA.
C1 [Coughlin, Thomas R.; Kennedy, Oran D.] NYU, Sch Med, Dept Orthoped Surg, 301 E 17th St,Suite 1500, New York, NY 10003 USA.
   [Kennedy, Oran D.] NYU, Tandon Sch Engn, Dept Mech & Aerosp Engn, New York, NY USA.
C3 New York University; New York University; New York University Tandon
   School of Engineering
RP Kennedy, OD (通讯作者)，NYU, Sch Med, Dept Orthoped Surg, 301 E 17th St,Suite 1500, New York, NY 10003 USA.
EM Oran.Kennedy@nyumc.org
OI Kennedy, Oran D./0000 0003 3343 2873
CR Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256 200333010 00006
   Anderson DD, 2011, J ORTHOP RES, V29, P802, DOI 10.1002/jor.21359
   Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123 199802000 00091
   Bellido M, 2011, OSTEOARTHR CARTILAGE, V19, P1228, DOI 10.1016/j.joca.2011.07.003
   Bellido M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3103
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Botter SM, 2006, BIORHEOLOGY, V43, P379
   BROWN TD, 1984, J BIOMECH, V17, P437, DOI 10.1016/0021 9290(84)90035 6
   Brown TD, 2006, J ORTHOP TRAUMA, V20, P739, DOI 10.1097/01.bot.0000246468.80635.ef
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Burr David B., 1998, Current Opinion in Rheumatology, V10, P256, DOI 10.1097/00002281 199805000 00017
   Burr DB, 2004, J RHEUMATOL, V31, P77
   Burr DB, 1997, MICROSC RES TECHNIQ, V37, P343, DOI 10.1002/(SICI)1097 0029(19970515)37:4<343::AID JEMT9>3.0.CO;2 L
   Caramés B, 2012, ARTHRITIS RHEUM US, V64, P1182, DOI 10.1002/art.33444
   Carlson CS, 1996, J BONE MINER RES, V11, P1209
   Chan BY, 2011, OSTEOARTHR CARTILAGE, V19, P874, DOI 10.1016/j.joca.2011.04.014
   Chang JC, 2017, J ORTHOP RES, V35, P474, DOI 10.1002/jor.23263
   Christiansen BA, 2015, OSTEOARTHR CARTILAGE, V23, P1627, DOI 10.1016/j.joca.2015.05.009
   Christiansen BA, 2012, OSTEOARTHR CARTILAGE, V20, P773, DOI 10.1016/j.joca.2012.04.014
   CLARK JM, 1990, J BONE JOINT SURG BR, V72, P866, DOI 10.1302/0301 620X.72B5.2211774
   Davis AR, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055939, 10.1371/journal.pone.0064808]
   Desmouliere A, 1997, INT J BIOCHEM CELL B, V29, P19, DOI 10.1016/S1357 2725(96)00117 3
   Dreier R, 2001, J CELL SCI, V114, P3813
   DUNCAN H, 1987, J BONE JOINT SURG AM, V69A, P1212, DOI 10.2106/00004623 198769080 00015
   Eckstein F, 1998, J ANAT, V192, P81, DOI 10.1046/j.1469 7580.1998.19210081.x
   Felson DT, 2016, OSTEOARTHR CARTILAGE, V24, P458, DOI 10.1016/j.joca.2015.09.013
   Ferguson VL, 2003, J ANAT, V203, P191, DOI 10.1046/j.1469 7580.2003.00193.x
   Findlay DM, 2014, CURR OSTEOPOROS REP, V12, P127, DOI 10.1007/s11914 014 0192 5
   Fisher M, 2004, CEREBROVASC DIS, V17, P1, DOI 10.1159/000074790
   Florea C, 2015, OSTEOARTHR CARTILAGE, V23, P414, DOI 10.1016/j.joca.2014.11.023
   Funck Brentano T, 2011, CYTOKINE GROWTH F R, V22, P91, DOI 10.1016/j.cytogfr.2011.04.003
   Furman BD, 2007, J ORTHOP RES, V25, P578, DOI 10.1002/jor.20331
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   GREEN WT, 1970, ARCH PATHOL, V90, P151
   Haslauer CM, 2013, OSTEOARTHR CARTILAGE, V21, P1950, DOI 10.1016/j.joca.2013.09.003
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529 0131(199805)41:5<891::AID ART17>3.0.CO;2 X
   Intema F, 2010, J BONE MINER RES, V25, P1650, DOI 10.1002/jbmr.39
   Isaac DI, 2010, J BIOMECH ENG T ASME, V132, DOI 10.1115/1.4001111
   Kadri A, 2008, ARTHRITIS RHEUM US, V58, P2379, DOI 10.1002/art.23638
   Kadri A, 2010, ANN RHEUM DIS, V69, P1533, DOI 10.1136/ard.2009.124586
   Kennedy OD, 2008, BONE, V43, P889, DOI 10.1016/j.bone.2008.07.235
   Kennedy OD, 2014, BONE, V64, P132, DOI 10.1016/j.bone.2014.03.049
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kiapour AM, 2014, BONE JOINT RES, V3, P20, DOI 10.1302/2046 3758.32.2000241
   Ko FC, 2013, ARTHRITIS RHEUM US, V65, P1569, DOI 10.1002/art.37906
   Lampropoulou Adamidou K, 2014, J ORTHOP RES, V32, P1646, DOI 10.1002/jor.22712
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Little CB, 2012, OSTEOARTHR CARTILAGE, V20, P261, DOI 10.1016/j.joca.2012.01.017
   Liu WH, 2003, J ORTHOP RES, V21, P730, DOI 10.1016/S0736 0266(03)00002 0
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lohmander LS, 2007, AM J SPORT MED, V35, P1756, DOI 10.1177/0363546507307396
   Lyons TJ, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 52
   Maerz T, 2016, OSTEOARTHR CARTILAGE, V24, P698, DOI 10.1016/j.joca.2015.11.005
   Marijnissen ACA, 2002, OSTEOARTHR CARTILAGE, V10, P145, DOI 10.1053/joca.2001.0491
   Martel Pelletier J, 2010, EKLEM HAST CERRAHISI, V21, P2
   MILZ S, 1994, J ANAT, V185, P103
   Mohan G, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3543
   MORI S, 1993, ARCH PATHOL LAB MED, V117, P196
   Nebbaki SS, 2013, J RHEUMATOL, V40, P877, DOI 10.3899/jrheum.120738
   Pan J, 2009, J ORTHOP RES, V27, P1347, DOI 10.1002/jor.20883
   Pelletier JP, 2004, BONE, V34, P527, DOI 10.1016/j.bone.2003.11.021
   Pond M J, 1973, Ann Rheum Dis, V32, P387, DOI 10.1136/ard.32.4.387
   Poulet B, 2015, OSTEOARTHR CARTILAGE, V23, P940, DOI 10.1016/j.joca.2015.01.012
   Racine Jennifer, 2014, R I Med J (2013), V97, P25
   RADIN E L, 1984, Journal of Orthopaedic Research, V2, P221, DOI 10.1002/jor.1100020303
   RADIN EL, 1970, ARTHRITIS RHEUM, V13, P139, DOI 10.1002/art.1780130206
   RADIN EL, 1970, ARTHRITIS RHEUM, V13, P400, DOI 10.1002/art.1780130406
   RADIN EL, 1978, CLIN ORTHOP RELAT R, P288
   Ramme AJ, 2016, OSTEOARTHR CARTILAGE, V24, P1776, DOI 10.1016/j.joca.2016.05.017
   Rangger C, 1998, ACTA ORTHOP SCAND, V69, P291, DOI 10.3109/17453679809000933
   Roemer FW, 2015, ARTHRITIS RHEUMATOL, V67, P2085, DOI 10.1002/art.39176
   Roos H, 1998, ARTHRITIS RHEUM, V41, P687, DOI 10.1002/1529 0131(199804)41:4<687::AID ART16>3.0.CO;2 2
   Saag KG, 2008, ANN RHEUM DIS, V67, P1358, DOI 10.1136/ard.2008.089912
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P988, DOI 10.1016/j.joca.2005.07.012
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P979, DOI 10.1016/j.joca.2005.03.008
   Schaffler MB, 2014, CALCIFIED TISSUE INT, V94, P5, DOI 10.1007/s00223 013 9790 y
   Shirai T, 2011, J ORTHOP RES, V29, P1572, DOI 10.1002/jor.21394
   Smith GN, 2002, OSTEOARTHR CARTILAGE, V10, P321, DOI 10.1053/joca.2002.0520
   Sniekers YH, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 20
   SOKOLOFF L, 1993, ARCH PATHOL LAB MED, V117, P191
   Tat S. Kwan, 2010, CLIN RHEUMATOL, V24, P51
   Tat SK, 2009, RHEUMATOLOGY, V48, P1482, DOI 10.1093/rheumatology/kep300
   Torres AM, 2016, P NATL ACAD SCI USA, V113, P2892, DOI 10.1073/pnas.1520539113
   Verborgt O, 2002, J BONE MINER RES, V17, P907, DOI 10.1359/jbmr.2002.17.5.907
   Wang BL, 2015, SCI REP UK, V5, DOI 10.1038/srep13667
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   YU LP, 1992, ARTHRITIS RHEUM, V35, P1150, DOI 10.1002/art.1780351007
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
   Zhang Y, 2012, INT J MED SCI, V9, P353, DOI 10.7150/ijms.4276
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 92
TC 33
Z9 43
U1 0
U2 18
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077 8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2016
VL 1383
BP 58
EP 66
DI 10.1111/nyas.13261
PG 9
WC Rheumatology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA BG6YZ
UT WOS:000391042900005
PM 27671712
DA 2025 08 17
ER

PT J
AU Wu, DC
   Wan, MX
AF Wu, Daocheng
   Wan, Mingxi
TI Methylene diphosphonate conjugated adriamycin liposomes: preparation,
   characteristics, and targeted therapy for osteosarcomas in vitro
   and in vivo
SO BIOMEDICAL MICRODEVICES
LA English
DT Article
DE Methylenediphosphonate; Adriamycin liposomes; Osteosarcomas; Targeted
   therapy
ID BONE; DOXORUBICIN; DRUG; APOPTOSIS; BISPHOSPHONATES; CHEMOTHERAPY;
   RESISTANCE; CISPLATIN; PROTEINS; ONCOLOGY
AB Methylenediphosphonate (MDP) conjugated adriamycin liposomes (MDP LADMs) were prepared using mild dynamic dialysis equilibrium method, and their targeted therapeutic effects against osteosarcomas and metastatic SOSP M lung nodules were evaluated . The drug loading and encapsulation efficiency of the MDP LADMs were measured via high performance liquid chromatography, and their size and morphology of the MDP LADMs were determined using transmission electron microscopy and a particle size analyzer, respectively. Cells apoptosis were evaluated by flow cytometry and caspase 3 activity. The targeted therapeutic effects of MDP LADMs against UMR106 and SOSP M osteosarcoma cells were evaluated using the 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) method. Tumor growth and animal survival rates were evaluated after UMR106 osteosarcomas were established in Sprague Dawley rats and SOSP M pulmonary metastatic osteosarcoma model were established in nude mice, respectively. The results show that the average diameter of the MDP LADMs was 152 +/  14 nm, and their ADM encapsulation efficiency was 91.7% with respect to a 250 mu g/ml of loading efficiency. The conjugation efficiency between technetium MDP and LADMs was 87.6%. Infrared spectra results of the samples dissolved in deuterated water confirmed that the methylenediphosphonate (MDP) was conjugated with LADMs through hydrogen bonding. The toxicity assay revealed a median lethal dose of 26.78 mg/kg for MDP LADMs, which was significantly higher than doses observed for free ADM of 9.64 mg/kg ( < 0.05) and LADMs of 15.02 mg/kg( < 0.05). Tumor growth and animal survival in the MDP LADMs group were significantly higher than those in the ADM only, MDP only ( < 0.01) and LADMs groups ( < 0.05). These findings indicate that MDP LADMs have higher therapeutic efficacy against osteosarcomas, demonstrate lower toxicity and their clearly targets osteosarcomas more clearly than the stand alone systems, making them as a promising novel targeted therapy for the treatment of osteosarcoma.
C1 [Wu, Daocheng; Wan, Mingxi] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Educ Minist, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
C3 Xi'an Jiaotong University
RP Wu, DC (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Educ Minist, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
EM wudaocheng@mail.xjtu.edu.cn
RI ; Wu, Daocheng/AFM 3605 2022
OI Wu, Daocheng/0000 0002 6183 539X; 
FU National Basic Research Program 973 of China [2010CB732603]; National
   Nature Science Foundation of China [30772658, 30970712]
FX This study was supported in part by the grants of National Basic
   Research Program 973 of China (Nos. 2010CB732603) and the National
   Nature Science Foundation of China (Nos.30772658, and 30970712).
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Anderson AB, 2002, J CHROMATOGR B, V769, P97, DOI 10.1016/S1570 0232(01)00633 X
   [Anonymous], PROG POLYM SCI
   Bao A, 2003, J NUCL MED, V44, P1992
   Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005 2736(91)90167 7
   DAVIS M A, 1976, Seminars in Nuclear Medicine, V6, P19, DOI 10.1016/S0001 2998(76)80033 5
   El Mabhouh A, 2005, APPL RADIAT ISOTOPES, V62, P541, DOI 10.1016/j.apradiso.2004.10.004
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   El Mabhouh AA, 2006, NUCL MED BIOL, V33, P715, DOI 10.1016/j.nucmedbio.2006.06.004
   Franzius C, 2000, CLIN NUCL MED, V25, P874, DOI 10.1097/00003072 200011000 00004
   Gabizon AA, 2001, CANCER INVEST, V19, P424, DOI 10.1081/CNV 100103136
   GALLO JM, 1989, J PHARM SCI, V78, P190, DOI 10.1002/jps.2600780303
   Gazitt Y, 2009, INT J ONCOL, V34, P551, DOI 10.3892/ijo_00000181
   Gulyaev AE, 1999, PHARM RES DORDR, V16, P1564, DOI 10.1023/A:1018983904537
   Karita M, 2008, ANTICANCER RES, V28, P1449
   Lee RJ, 1996, J BIOL CHEM, V271, P8481, DOI 10.1074/jbc.271.14.8481
   Li XS, 2007, CANCER BIOTHER RADIO, V22, P772, DOI 10.1089/cbr.2007.352
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Longmuir K. J., 2006, PHARM RES, V23, P760
   Lukyanov AN, 2004, J CONTROL RELEASE, V100, P135, DOI 10.1016/j.jconrel.2004.08.007
   McCracken M, 2001, CLIN ORAL IMPLAN RES, V12, P372, DOI 10.1034/j.1600 0501.2001.012004372.x
   Messerschmitt PJ, 2009, J AM ACAD ORTHOP SUR, V17, P515, DOI 10.5435/00124635 200908000 00005
   Michiro S, 2009, BMC CANCER, V9, P399
   Mitra A, 2006, CURR PHARM DESIGN, V12, P4729, DOI 10.2174/138161206779026317
   Pamina K., 2002, TECH VASR INT RADIO, V5, P127
   REES CR, 1986, SKELETAL RADIOL, V15, P365, DOI 10.1007/BF00348863
   Samuel Z. A., 1996, J PHARM SCI, V85, P133
   Saul JM, 2003, J CONTROL RELEASE, V92, P49, DOI 10.1016/S0168 3659(03)00295 5
   Schally AV, 2008, HORM METAB RES, V40, P315, DOI 10.1055/s 2008 1073142
   Schwartz CL, 2007, J CLIN ONCOL, V25, P2057, DOI 10.1200/JCO.2006.07.7776
   Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030
   SEYMOUR RW, 1970, MACROMOLECULES, V3, P579, DOI 10.1021/ma60017a021
   Solomon R, 2008, CLIN LYMPHOMA MYELOM, V8, P21, DOI 10.3816/CLM.2008.n.001
   Soma CE, 2000, BIOMATERIALS, V21, P1
   Spector M., 1981, CLIN ORTHOP, V242
   Stefov V, 2003, J MOL STRUCT, V649, P231, DOI 10.1016/S0022 2860(02)00633 6
   SUZUKI S, 1995, BBA GEN SUBJECTS, V1245, P9, DOI 10.1016/0304 4165(95)00066 K
   Uludag H, 2002, BIOTECHNOL PROGR, V18, P604, DOI 10.1021/bp0200447
   Van Den Bossche B, 2004, J CLIN ONCOL, V22, P3593, DOI 10.1200/JCO.2004.10.216
   Wu DC, 2010, BIOMED PHARMACOTHER, V64, P615, DOI 10.1016/j.biopha.2010.03.001
   Wu H, 2006, J BIOMED MATER RES B, V78B, P56, DOI 10.1002/jbm.b.30458
NR 44
TC 19
Z9 19
U1 0
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1387 2176
EI 1572 8781
J9 BIOMED MICRODEVICES
JI Biomed. Microdevices
PD JUN
PY 2012
VL 14
IS 3
BP 497
EP 510
DI 10.1007/s10544 011 9626 3
PG 14
WC Engineering, Biomedical; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics
GA 940DY
UT WOS:000303871400007
PM 22278099
DA 2025 08 17
ER

PT J
AU Li, J
   Cao, JJ
   Chen, QP
   Liu, D
   Li, R
AF Li, Juan
   Cao, Junjie
   Chen, Qingping
   Liu, Dan
   Li, Rui
TI Investigating the therapeutic potential of sinomenine in rheumatoid
   arthritis: anti inflammatory, antioxidant, and immunomodulatory
   mechanisms
SO NAUNYN SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Article
DE Sinomenine; Rheumatoid arthritis; Oxidative stress; Inflammation;
   RANK/RANKL/OPG
ID ADJUVANT INDUCED ARTHRITIS
AB An autoimmune disease, rheumatoid arthritis (RA) is characterized by the onset of inflammation and subsequent damage to the joints. Although several therapies are available for RA, none are effective, and many have undesirable side effects. The roots of Sinomenium acutum produce an alkaloid called Sinomenine (SIN), which has been used for centuries in Chinese medicine to treat arthritis due to its anti inflammatory properties. This study aimed to explore the potential therapeutic benefits of SIN through oral administration following RA induction using Freund's complete adjuvant (FCA) injections. The study monitored changes in the arthritic index, hind paw volume, inflammation and oxidative stress markers. Results demonstrated that SIN effectively inhibited the activity of NF kappa B and IKK beta in knee joint tissues, which led to a decrease in tissue levels of TNF alpha, IL 6, IL 1 beta, and iNOS in RA induced rats. The production of anti inflammatory cytokines such as IL 10, Arg 1, and Fizz1 also increased. In rat knee joints, SIN elevated the expression of TIMP 1 and TIMP 3 and decreased the expression of MMP 2 and MMP 9. Additionally, SIN modulated the RANK/RANKL/OPG pathway in RA induced rat knee joint tissues, reducing RANKL expression and increasing OPG. SIN also effectively decreased MDA, NO, and elevated antioxidant enzymes (SOD, CAT, GPx, and GSH) in RA induced rats via Nrf2/Keap 1 signaling pathway activation. In conclusion, this study suggests that SIN possesses potential therapeutic benefits for treating RA by modulating the RANK/RANKL/OPG pathway, which may impact osteoclast activity, oxidative stress, and inflammation in knee joint tissues.
C1 [Li, Juan; Chen, Qingping; Li, Rui] Xian No 5 Hosp, Dept Geriatr, Xian, Peoples R China.
   [Cao, Junjie] Xian Med Coll, Dept Pathol, Xian 710000, Shanxi, Peoples R China.
   [Liu, Dan] Xian Med Univ, Affiliated Hosp 1, Dept Cardiol, Xian 710061, Peoples R China.
C3 Xi'an Medical University; Xi'an Medical University
RP Li, R (通讯作者)，Xian No 5 Hosp, Dept Geriatr, Xian, Peoples R China.
EM liruigz1108@sina.com
RI Cao, Junjie/HKW 6852 2023
FU Shaanxi Provincial Key Research and Development Program [2021SF 259];
   Xi'an Science and Technology Bureau Innovation Ability Strong Foundation
   Program [21YXYJ0003]
FX Shaanxi Provincial Key Research and Development Program (No.
   2021SF 259); Xi'an Science and Technology Bureau Innovation Ability
   Strong Foundation Program Project (No. 21YXYJ0003).
CR Alabarse PVG, 2018, J CACHEXIA SARCOPENI, V9, P603, DOI 10.1002/jcsm.12280
   Azizi G, 2014, INT J RHEUM DIS, V17, P369, DOI 10.1111/1756 185X.12280
   Bi FF, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10079
   Bing Z., 2003, CHIN J INF TRADIT CH, V10, P25
   Bullock J, 2018, MED PRIN PRACT, V27, P501, DOI 10.1159/000493390
   Chadha S, 2020, CURR RES TRANSL MED, V68, P171, DOI 10.1016/j.retram.2020.05.002
   Chang YH, 2008, CLIN BIOCHEM, V41, P955, DOI 10.1016/j.clinbiochem.2008.04.012
   Chen Z, 2017, EXP THER MED, V13, P2405, DOI 10.3892/etm.2017.4237
   Cheng BCY, 2016, SCI REP UK, V6, DOI 10.1038/srep20042
   Dogan S, 2022, CLIN RHEUMATOL, V41, P2341, DOI 10.1007/s10067 022 06180 5
   Elbaz EM, 2020, INFLAMMOPHARMACOLOGY, V28, P1407, DOI 10.1007/s10787 020 00743 1
   Fan H, 2022, FOOD CHEM TOXICOL, V159, DOI 10.1016/j.fct.2021.112759
   Farrow M, 2021, RHEUMATOLOGY, V60, P1216, DOI 10.1093/rheumatology/keaa364
   Gao WJ, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105513
   Geusens P, 2012, THER ADV MUSCULOSKEL, V4, P225, DOI 10.1177/1759720X12438080
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Hong HX, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1015035
   Jaleel GAA, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111347
   Jiang H, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 30922 3
   López Armada MJ, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11061151
   KATSIKIS PD, 1994, J EXP MED, V179, P1517, DOI 10.1084/jem.179.5.1517
   Khalil ASM, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119605
   Kondo N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010922
   Lai WD, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.1041006
   Lan Z, 2016, IUBMB LIFE, V68, P429, DOI 10.1002/iub.1499
   Li RZ, 2023, PHYTOMEDICINE, V114, DOI 10.1016/j.phymed.2023.154751
   Li XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074274
   Liao KS, 2021, BIOMED PHARMACOTHER, V135, DOI 10.1016/j.biopha.2020.111195
   Liu WF, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00228
   Liu XY, 2017, INT IMMUNOPHARMACOL, V44, P105, DOI 10.1016/j.intimp.2017.01.010
   Nasuti C, 2019, ANTIOXIDANTS BASEL, V8, DOI 10.3390/antiox8090342
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Papadaki M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00097
   Pathade V, 2023, LIFE SCI, V312, DOI 10.1016/j.lfs.2022.121257
   Pope JE, 2021, SEMIN ARTHRITIS RHEU, V51, P219, DOI 10.1016/j.semarthrit.2020.11.005
   Prasad P, 2023, MOL CELL BIOCHEM, V478, P69, DOI 10.1007/s11010 022 04492 3
   Qian X, 2018, MOL MED REP, V18, P49, DOI 10.3892/mmr.2018.8959
   Shaker Olfat Gamil, 2020, Asian Pac J Cancer Prev, V21, P355, DOI 10.31557/APJCP.2020.21.2.355
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Sun YQ, 2023, J ETHNOPHARMACOL, V301, DOI 10.1016/j.jep.2022.115839
   Tian Z, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13585
   Vasdev N, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15041150
   Wahab NAA, 2022, PHYTOMEDICINE, V107, DOI 10.1016/j.phymed.2022.154464
   WANG J, 1992, PHYTOTHER RES, V6, P117, DOI 10.1002/ptr.2650060302
   Wang QX, 2011, INT IMMUNOPHARMACOL, V11, P373, DOI 10.1016/j.intimp.2010.11.018
   Wei ST, 2015, MED SCI MONITOR, V21, P4030, DOI 10.12659/MSM.895116
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   Yamamoto K, 2021, CALCIFIED TISSUE INT, V109, P277, DOI 10.1007/s00223 020 00739 7
   Yao RB, 2017, PHARMAZIE, V72, P355, DOI 10.1691/ph.2017.6946
   Yap HY, 2018, CELLS BASEL, V7, DOI 10.3390/cells7100161
   Zampeli E, 2015, J AUTOIMMUN, V65, P1, DOI 10.1016/j.jaut.2015.10.003
   Zeng LT, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3302886
   Zhang LL, 2019, NEUROCHEM RES, V44, P763, DOI 10.1007/s11064 018 02706 z
   Zhang MW, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.749113
   Zhao XX, 2012, PHARM BIOL, V50, P1053, DOI 10.3109/13880209.2012.656847
   Zhou XQ, 2021, TRADIT MED RES, V6, DOI 10.12032/TMR20200814194
NR 56
TC 8
Z9 8
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0028 1298
EI 1432 1912
J9 N S ARCH PHARMACOL
JI Naunyn Schmiedebergs Arch. Pharmacol.
PD JUN
PY 2024
VL 397
IS 6
BP 3945
EP 3958
DI 10.1007/s00210 023 02810 0
EA NOV 2023
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA RS4A9
UT WOS:001123667100004
PM 37991542
DA 2025 08 17
ER

PT J
AU Abrahamsen, B
   Eiken, P
   Brixen, K
AF Abrahamsen, B.
   Eiken, P.
   Brixen, K.
TI Atrial fibrillation in fracture patients treated with oral
   bisphosphonates
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Article
DE alendronate; atrial fibrillation; etidronate; myocardial infarction;
   stroke
ID BONE MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; HIP FRACTURE;
   VERTEBRAL FRACTURES; ZOLEDRONIC ACID; WOMEN; RISK; ALENDRONATE;
   MORTALITY; VALIDITY
AB To determine if patients receiving oral bisphosphonates are at excess risk of atrial fibrillation (AF), stroke and myocardial infarction.
   Register based restricted cohort study.
   National Hospital Discharge Register and National Prescriptions Database (1995 2005).
   Fracture patients beginning bisphosphonates (n = 15 795) were matched with unexposed fracture patients of the same age, sex and fracture type (n = 31 590).
   Incidence rates of AF were 16.5/1000 person years in untreated fracture patients and 20.6/1000 person years in bisphosphonate users. An age  and sex adjusted hazard ratio (HR) of 1.29 (1.17 1.41) was found for probable AF by Cox proportional hazards analysis. The effect size was reduced to HR of 1.18 (1.08 1.29) by adjustment for co medications and comorbidity. Selective prescribing was suggested by the observation that (i) risks were increased even in patients who stopped therapy after the first packet and (ii) risks were not increased by high adherence. Bisphosphonate exposed patients were at increased risk of hospital treated AF [adjusted HR: 1.13 (1.01 1.26)], but the risk amongst bisphosphonate users was inversely proportional to adherence. There was no increased risk of ischaemic stroke and an increased risk of myocardial infarction was not significant after adjustment for comorbidity.
   The increased occurrence of AF in fracture patients who are users of oral bisphosphonates should be attributed to targeting of bisphosphonates to patients who are already at increased risk of cardiovascular events.
C1 [Abrahamsen, B.] Copenhagen Univ Hosp, Dept Internal Med & Endocrinol, DK 2900 Gentofte, Denmark.
   [Eiken, P.] Cent Hosp Hillerod, Dept Cardiol & Endocrinol, Hillerod, Denmark.
   [Brixen, K.] Odense Univ Hosp, Dept Endocrinol, DK 5000 Odense, Denmark.
C3 University of Copenhagen; Copenhagen University Hospital; University of
   Southern Denmark; Odense University Hospital
RP Abrahamsen, B (通讯作者)，Copenhagen Univ Hosp, Dept Internal Med, DK 2900 Gentofte, Denmark.
EM b.abrahamsen@physician.dk
RI ; Abrahamsen, Bo/B 8920 2008
OI Abrahamsen, Bo/0000 0002 2730 6080; Eiken, Pia/0000 0001 7278 5968
FU Kaptajnlojnant Harald Jensen og Hustrus Fond
FX The financial support of Kaptajnlojnant Harald Jensen og Hustrus Fond is
   gratefully acknowledged.
CR Abrahamsen B, 2003, J BONE MINER RES, V18, P723, DOI 10.1359/jbmr.2003.18.4.723
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021 9681(87)90171 8
   Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   de Vries F, 2007, CALCIFIED TISSUE INT, V80, P69, DOI 10.1007/s00223 006 0213 1
   *EUR AG EV MED PRO, 2008, CPMPEWP90899 EMEA EU
   Friberg J, 2006, J INTERN MED, V259, P173, DOI 10.1111/j.1365 2796.2005.01595.x
   Friberg J, 2003, EPIDEMIOLOGY, V14, P666, DOI 10.1097/01.ede.0000091649.26364.c0
   From AM, 2007, MAYO CLIN PROC, V82, P679
   Heckbert SR, 2008, ARCH INTERN MED, V168, P826, DOI 10.1001/archinte.168.8.826
   Hoidrup S, 2000, INT J EPIDEMIOL, V29, P253, DOI 10.1093/ije/29.2.253
   HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002 9343(90)90182 D
   Karam R, 2007, NEW ENGL J MED, V357, P712
   Krarup LH, 2007, NEUROEPIDEMIOLOGY, V28, P150, DOI 10.1159/000102143
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lyles KW, 2007, NEW ENGL J MED, V357, P1799, DOI 10.1056/NEJMoa074941
   Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895 4356(02)00591 7
   Penrod JD, 2007, J AM GERIATR SOC, V55, P407, DOI 10.1111/j.1532 5415.2007.01078.x
   Price PA, 2006, KIDNEY INT, V70, P1577, DOI 10.1038/sj.ki.5001841
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Sennerby U, 2007, OSTEOPOROSIS INT, V18, P1355, DOI 10.1007/s00198 007 0386 0
   Shimshi M, 2005, BIOCHEM BIOPH RES CO, V328, P790, DOI 10.1016/j.bbrc.2004.12.091
   Sorensen HT, 2008, BMJ BRIT MED J, V336, P813, DOI 10.1136/bmj.39507.551644.BE
   STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Ylitalo R, 1998, PHARMACOL TOXICOL, V83, P125, DOI 10.1111/j.1600 0773.1998.tb01455.x
NR 29
TC 84
Z9 87
U1 0
U2 2
PU WILEY BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0954 6820
J9 J INTERN MED
JI J. Intern. Med.
PD MAY
PY 2009
VL 265
IS 5
BP 581
EP 592
DI 10.1111/j.1365 2796.2008.02065.x
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 429ZQ
UT WOS:000264959000007
PM 19141097
OA Bronze
DA 2025 08 17
ER

PT J
AU Amini, AA
   Nair, LS
AF Amini, Ashley A.
   Nair, Lakshmi S.
TI Enzymatically cross linked injectable gelatin gel as osteoblast delivery
   vehicle
SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS
LA English
DT Article
DE Gelatin; hydrogels; injectable biomaterial; cell delivery; tissue
   engineering; intercellular signaling; osteogenic function; encapsulated
   cells; enzymatic cross linking; injectable gelatin
ID TYRAMINE HYDROGEL SYSTEM; BIOMEDICAL APPLICATIONS; REGENERATIVE
   MEDICINE; ELECTROSPUN MEMBRANES; PHOTOCURABLE GELATIN; DIFFERENTIATION;
   LINKING; COLLAGEN; RELEASE; SCAFFOLDS
AB Injectable and degradable hydrogels are potential candidates as cell delivery vehicles for the regeneration of osseous defects. We evaluated the potential of injectable enzymatically cross linked gelatin gel as an osteoblast delivery vehicle using murine preosteoblast MC3T3 E1 cells. Injectable hydrogels were prepared by enzymatic cross linking of the phenol derivatives of gelatin (tyramine modified) in the presence of hydrogen peroxide (H2O2) and horseradish peroxidase. The effect of gelatin concentration on gel morphology and in supporting the adhesion and spreading of encapsulated MC3T3 E1 cells, activation of intercellular signaling in MC3T3 E1 cells by extracellular signal regulated kinase phosphorylation, beta catenin and Runx2 was evaluated. Both tyramine modified and unmodified gelatins as well as gelatin gels did not activate intercellular signaling pathways in MC3T3 E1 cells. The encapsulated cells in gelatin gel showed extracellular signal regulated kinase phosphorylation and active beta catenin expression in the presence of inductive molecules such as insulin and LiCl. The gelatin gels formed from 10 to 25 mg/mL tyramine modified gelatin supported the adhesion, spreading, and three dimensional growth of MC3T3 E1 cells. However, the lack of activation of intercellular signaling in the gelatin gel indicates the need to add exogenous bioactive molecules to modulate the osteogenic functions of the encapsulated cells.
C1 [Nair, Lakshmi S.] Univ Connecticut, Ctr Hlth, Inst Regenerat Engn, Dept Orthopaed Surg, Farmington, CT 06030 USA.
   [Amini, Ashley A.] Univ Connecticut, Ctr Hlth, Sch Dent Med, Farmington, CT 06030 USA.
   [Nair, Lakshmi S.] Univ Connecticut, Biomed Engn Program, Inst Mat Sci, Dept Chem Mat & Biomol Engn, Farmington, CT 06030 USA.
C3 University of Connecticut; University of Connecticut; University of
   Connecticut
RP Nair, LS (通讯作者)，Univ Connecticut, Ctr Hlth, Inst Regenerat Engn, Dept Orthopaed Surg, Farmington, CT 06030 USA.
EM nair@uchc.edu
FU Department of Defense [W81XWH 10 1 0947]; UConn Center for Science and
   Technology Commercialization (CSTC)
FX This work was supported by the Department of Defense (W81XWH 10 1 0947)
   and UConn Center for Science and Technology Commercialization (CSTC).
CR Alvarez Perez MA, 2010, BIOMACROMOLECULES, V11, P2238, DOI 10.1021/bm100221h
   Annabi N, 2010, TISSUE ENG PART B RE, V16, P371, DOI [10.1089/ten.teb.2009.0639, 10.1089/ten.TEB.2009.0639]
   ATKINSON SJ, 1992, BIOCHEM J, V288, P605, DOI 10.1042/bj2880605
   Attia J, 2011, J BIOACT COMPAT POL, V26, P71, DOI 10.1177/0883911510391445
   Balakrishnan B, 2005, BIOMATERIALS, V26, P3941, DOI 10.1016/j.biomaterials.2004.10.005
   Benoit DSW, 2007, BIOMATERIALS, V28, P66, DOI 10.1016/j.biomaterials.2006.08.033
   Betz MW, 2010, BIOMACROMOLECULES, V11, P1160, DOI 10.1021/bm100061z
   Buhus G, 2009, J BIOACT COMPAT POL, V24, P525, DOI 10.1177/0883911509349687
   Choi JY, 1996, J CELL BIOCHEM, V61, P609, DOI 10.1002/(SICI)1097 4644(19960616)61:4<609::AID JCB15>3.0.CO;2 A
   COBBETT WG, 1962, BIOCHEM J, V84, P468, DOI 10.1042/bj0840468
   Darr A, 2009, J MATER SCI MATER M, V20, P33, DOI 10.1007/s10856 008 3540 0
   Davis NE, 2010, BIOMATERIALS, V31, P7288, DOI 10.1016/j.biomaterials.2010.06.003
   Dreesmann L, 2007, BIOMATERIALS, V28, P5536, DOI 10.1016/j.biomaterials.2007.08.040
   Fukaya C, 2009, J BIOMED MATER RES B, V91B, P329, DOI 10.1002/jbm.b.31406
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Guarino V, 2011, J BIOACT COMPAT POL, V26, P144, DOI 10.1177/0883911511399410
   Hennink WE, 2012, ADV DRUG DELIVER REV, V64, P223, DOI 10.1016/j.addr.2012.09.009
   Hoshikawa A, 2006, TISSUE ENG, V12, P2333, DOI 10.1089/ten.2006.12.2333
   Hu M, 2009, BIOMATERIALS, V30, P3523, DOI 10.1016/j.biomaterials.2009.03.004
   Hwang CM, 2010, BIOFABRICATION, V2, DOI 10.1088/1758 5082/2/3/035003
   Jiang T, 2008, CURR TOP MED CHEM, V8, P354
   Kawazoe N, 2009, J BIOACT COMPAT POL, V24, P25, DOI 10.1177/0883911508099439
   Kim K, 2010, TISSUE ENG PART B RE, V16, P523, DOI [10.1089/ten.teb.2010.0171, 10.1089/ten.TEB.2010.0171]
   Kopecek J, 2009, ACTA BIOMATER, V5, P805, DOI 10.1016/j.actbio.2008.10.001
   Kuijpers AJ, 2000, J BIOMAT SCI POLYM E, V11, P225, DOI 10.1163/156856200743670
   Kuwahara K, 2010, TISSUE ENG PART C ME, V16, P609, DOI [10.1089/ten.tec.2009.0406, 10.1089/ten.TEC.2009.0406]
   Kwon YJ, 2002, BIOTECHNIQUES, V33, P212, DOI 10.2144/02331dd05
   Lee F, 2008, SOFT MATTER, V4, P880, DOI 10.1039/b719557e
   Lee F, 2009, J CONTROL RELEASE, V134, P186, DOI 10.1016/j.jconrel.2008.11.028
   Lee YH, 2010, APPL SURF SCI, V256, P5882, DOI 10.1016/j.apsusc.2010.03.069
   Liu X, 2009, BIOMATERIALS, V30, P2252, DOI 10.1016/j.biomaterials.2008.12.068
   Minh KN, 2010, MACROMOL BIOSCI, V10, P563, DOI 10.1002/mabi.200900402
   Musso H., 1963, Angew. Chem., V2, P723, DOI [10.1002/anie.196307231, DOI 10.1002/ANIE.196307231]
   Nair LS, 2007, BIOMACROMOLECULES, V8, P3779, DOI 10.1021/bm7006967
   Nicodemus GD, 2008, TISSUE ENG PT B REV, V14, P149, DOI 10.1089/ten.teb.2007.0332
   Okino H, 2002, J BIOMED MATER RES, V59, P233, DOI 10.1002/jbm.1237
   Olsen D, 2003, ADV DRUG DELIVER REV, V55, P1547, DOI 10.1016/j.addr.2003.08.008
   Park KM, 2011, J MATER CHEM, V21, P13180, DOI 10.1039/c1jm12527c
   Peng S, 2011, CELL BIOL INT, V35, P587, DOI 10.1042/CBI20100452
   Rydholm AE, 2005, BIOMATERIALS, V26, P4495, DOI 10.1016/j.biomaterials.2004.11.046
   Sakai S, 2009, J MATER CHEM, V19, P230, DOI 10.1039/b812086b
   Sakai S, 2009, BIOMATERIALS, V30, P3371, DOI 10.1016/j.biomaterials.2009.03.030
   Shimokawa K, 2002, MOL HUM REPROD, V8, P32, DOI 10.1093/molehr/8.1.32
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Spotnitz WD, 2008, TRANSFUSION, V48, P1502, DOI 10.1111/j.1537 2995.2008.01703.x
   STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sutter M, 2007, J CONTROL RELEASE, V119, P301, DOI 10.1016/j.jconrel.2007.03.003
   Terao K, 2003, J BIOMAT SCI POLYM E, V14, P1197, DOI 10.1163/156856203322553437
   Wang CM, 2010, ADV DRUG DELIVER REV, V62, P699, DOI 10.1016/j.addr.2010.02.001
   Yamamoto M, 1999, J BIOACT COMPAT POL, V14, P474, DOI 10.1177/088391159901400603
   Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k
   Yung CW, 2010, J BIOMED MATER RES A, V95A, P25, DOI 10.1002/jbm.a.32740
   Zhao XH, 2011, P NATL ACAD SCI USA, V108, P67, DOI 10.1073/pnas.1007862108
NR 54
TC 29
Z9 33
U1 2
U2 65
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0883 9115
EI 1530 8030
J9 J BIOACT COMPAT POL
JI J. Bioact. Compat. Polym.
PD JUL
PY 2012
VL 27
IS 4
BP 342
EP 355
DI 10.1177/0883911512444713
PG 14
WC Biotechnology & Applied Microbiology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Materials Science; Polymer Science
GA 970NH
UT WOS:000306137300004
DA 2025 08 17
ER

PT J
AU Dey, G
   Sinai Turyansky, R
   Yakobovich, E
   Merquiol, E
   Loboda, J
   Sridharan, N
   Houri Haddad, Y
   Polak, D
   Yona, S
   Turk, D
   Wald, O
   Blum, G
AF Dey, Gourab
   Sinai Turyansky, Reut
   Yakobovich, Evalyn
   Merquiol, Emmanuelle
   Loboda, Jure
   Sridharan, Nikhila
   Houri Haddad, Yael
   Polak, David
   Yona, Simon
   Turk, Dusan
   Wald, Ori
   Blum, Galia
TI Development and Application of Reversible and Irreversible Covalent
   Probes for Human and Mouse Cathepsin K Activity Detection, Revealing
   Nuclear Activity
SO ADVANCED SCIENCE
LA English
DT Article
DE activity based probes; cathepsin K; covalent probes; imaging protease
   activity; proteases
ID GINGIVAL CREVICULAR FLUID; BONE RESORPTION; IN VITRO; EXPRESSION;
   FLUORESCENCE; PROTEASE; DERIVATIVES; INHIBITORS; DESIGN; VIVO
AB Cathepsin K (CTSK) is an osteoclast secreted cysteine protease that efficiently cleaves extracellular matrices and promotes bone homeostasis and remodeling, making it an excellent therapeutic target. Detection of CTSK activity in complex biological samples using tailored tools such as activity based probes (ABPs) will aid tremendously in drug development. Here, potent and selective CTSK probes are designed and created, comparing irreversible and reversible covalent ABPs with improved recognition components and electrophiles. The newly developed CTSK ABPs precisely detect active CTSK in mouse and human cells and tissues, from diseased and healthy states such as inflamed tooth implants, osteoclasts, and lung samples, indicating changes in CTSK's activity in the pathological samples. These probes are used to study how acidic pH stimulates mature CTSK activation, specifically, its transition from pro form to mature form. Furthermore, this study reveals for the first time, why intact cells and cell lysate exhibit diverse CTSK activity while having equal levels of mature CTSK enzyme. Interestingly, these tools enabled the discovery of active CTSK in human osteoclast nuclei and in the nucleoli. Altogether, these novel probes are excellent research tools and can be applied in vivo to examine CTSK activity and inhibition in diverse diseases without immunogenicity hazards.
   Highly selective reversible  and irreversible covalent cathepsin K (CTSK) activity based probes are developed and applied to detect CTSK activity in human and mice samples, detecting changes in activity in pathological samples. These non toxic probes also enabled studying CTSK activation by pH changes, unique inhibition in cell lysates, and remarkable nuclei localization in human osteoclasts. image
C1 [Dey, Gourab; Sinai Turyansky, Reut; Yakobovich, Evalyn; Merquiol, Emmanuelle; Blum, Galia] Hebrew Univ Jerusalem, Inst Drug Res, Fac Med, Sch Pharm, IL 9112001 Jerusalem, Israel.
   [Loboda, Jure; Turk, Dusan] J Stefan Inst, Dept Biochem Mol & Struct Biol, Ljubljana SI 1000, Slovenia.
   [Sridharan, Nikhila; Yona, Simon] Hebrew Univ Jerusalem, Inst Biomed & Oral Res, Fac Dent Med, IL 9112001 Jerusalem, Israel.
   [Houri Haddad, Yael; Polak, David] Hebrew Univ Jerusalem, Fac Dent Med, Dept Prosthodont, IL 9112001 Jerusalem, Israel.
   [Wald, Ori] Hebrew Univ Jerusalem, Hadassah Hebrew Univ Med Ctr, Fac Med, Dept Cardiothorac Surg, IL 9112001 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Slovenian Academy of Sciences & Arts
   (SASA); Jozef Stefan Institute; Hebrew University of Jerusalem; Hebrew
   University of Jerusalem; Hebrew University of Jerusalem; Hadassah
   University Hospital
RP Blum, G (通讯作者)，Hebrew Univ Jerusalem, Inst Drug Res, Fac Med, Sch Pharm, IL 9112001 Jerusalem, Israel.
EM galiabl@ekmd.huji.ac.il
RI Yona, Simon/ABE 6572 2020
OI Dey, Gourab/0000 0002 9570 5032
FU Israel Science Foundation [1638/19]
FX This work was funded by grants from the Israel Science Foundation
   1638/19 to G.B. G.D. is thankful to TEVA Pharmaceuticals for providing
   the Bio Innovetors award.
CR Abdallah D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00632
   Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   Baraghithy S, 2019, J BONE MINER RES, V34, P93, DOI 10.1002/jbmr.3591
   Bashore C, 2020, ACS CHEM BIOL, V15, P1392, DOI 10.1021/acschembio.0c00031
   Behring L, 2023, J MED CHEM, V66, P3818, DOI 10.1021/acs.jmedchem.2c01360
   Beklen A, 2015, ORAL DIS, V21, P163, DOI 10.1111/odi.12230
   Bender KO, 2015, J AM CHEM SOC, V137, P4771, DOI 10.1021/jacs.5b00315
   Blum G, 2005, NAT CHEM BIOL, V1, P203, DOI 10.1038/nchembio728
   Brogi S, 2022, MOLECULES, V27, DOI 10.3390/molecules27082561
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Bühling F, 2004, AM J PATHOL, V164, P2203, DOI 10.1016/S0002 9440(10)63777 7
   Bühling F, 1999, AM J RESP CELL MOL, V20, P612
   Chihara T, 2010, CELL DEATH DIFFER, V17, P1917, DOI 10.1038/cdd.2010.60
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   de Avila ED, 2020, J PERIODONTAL RES, V55, P165, DOI 10.1111/jre.12707
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Fleming FF, 2010, J MED CHEM, V53, P7902, DOI 10.1021/jm100762r
   Fragkioudakis Ioannis, 2021, Eur J Dent, V15, P379, DOI 10.1055/s 0040 1721903
   Gan ZQ, 2023, BIOACT MATER, V25, P347, DOI 10.1016/j.bioactmat.2023.01.011
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Goto T, 2003, J ELECTRON MICROSC, V52, P551, DOI 10.1093/jmicro/52.6.551
   Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002 9440(10)63068 4
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hughes G, 2007, ANGEW CHEM INT EDIT, V46, P1839, DOI 10.1002/anie.200603745
   Husmann K, 2008, MOL CARCINOGEN, V47, P66, DOI 10.1002/mc.20362
   Ishida M., 2012, J EUR ACAD DERMATOL, V27
   Jaffer FA, 2007, CIRCULATION, V115, P2292, DOI 10.1161/CIRCULATIONAHA.106.660340
   Janiszewski T, 2023, CELL CHEM BIOL, V30, P159, DOI 10.1016/j.chembiol.2023.01.001
   Jerome C, 2011, OSTEOPOROSIS INT, V22, P3001, DOI 10.1007/s00198 011 1529 x
   KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042
   Katunuma Nobuhiko, 2010, J Signal Transduct, V2010, P375345, DOI 10.1155/2010/375345
   Kleer CG, 2008, CLIN CANCER RES, V14, P5357, DOI 10.1158/1078 0432.CCR 08 0732
   Kondo A., 2017, JOVE J VIS EXP, V129
   Kozloff KM, 2009, BONE, V44, P190, DOI 10.1016/j.bone.2008.10.036
   Kumar S, 2007, BONE, V40, P122, DOI 10.1016/j.bone.2006.07.015
   Law S, 2017, BIOCHEM J, V474, P851, DOI 10.1042/BCJ20160985
   Lecaille F, 2003, BIOCHEM J, V375, P307, DOI 10.1042/BJ20030468
   Lecaille F, 2002, BIOCHEMISTRY US, V41, P8447, DOI 10.1021/bi025638x
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   Lemke C, 2021, J MED CHEM, V64, P13793, DOI 10.1021/acs.jmedchem.1c01178
   Liu CL, 2018, NAT REV CARDIOL, V15, P351, DOI 10.1038/s41569 018 0002 3
   McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955
   Mogi M, 2007, ARCH ORAL BIOL, V52, P894, DOI 10.1016/j.archoralbio.2007.01.006
   Mons E, 2019, J AM CHEM SOC, V141, P3507, DOI 10.1021/jacs.8b11027
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Myochin T, 2012, J AM CHEM SOC, V134, P13730, DOI 10.1021/ja303931b
   Panyain N, 2021, RSC MED CHEM, V12, P1935, DOI 10.1039/d1md00218j
   Richard ET, 2021, BIOCONJUGATE CHEM, V32, P916, DOI 10.1021/acs.bioconjchem.1c00036
   Rodnick ME, 2014, NUCL MED BIOL, V41, P384, DOI 10.1016/j.nucmedbio.2014.02.004
   Schmit JM, 2012, J VET INTERN MED, V26, P126, DOI 10.1111/j.1939 1676.2011.00834.x
   Senkane K, 2019, ANGEW CHEM INT EDIT, V58, P11385, DOI 10.1002/anie.201905829
   SMITH DJ, 1985, J PERIODONTAL RES, V20, P357, DOI 10.1111/j.1600 0765.1985.tb00447.x
   Stoch SA, 2008, CLIN PHARMACOL THER, V83, P172, DOI 10.1038/sj.clpt.6100450
   Stone JA, 2019, BRIT J CLIN PHARMACO, V85, P1072, DOI 10.1111/bcp.13869
   Tafech A, 2024, BIOLOGY BASEL, V13, DOI 10.3390/biology13040225
   Tan Gong Jun, 2013, World J Biol Chem, V4, P91, DOI 10.4331/wjbc.v4.i4.91
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
   Toutchkine A, 2002, BIOCONJUGATE CHEM, V13, P387, DOI 10.1021/BC015558q
   Turk V, 2012, BBA PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Verbovsek U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111819
   Wilson S, 2010, J PEDIATR REHAB MED, V3, P139, DOI 10.3233/PRM 2010 0116
   Yadati T, 2020, CELLS BASEL, V9, DOI 10.3390/cells9071679
   Yan X, 2011, J EUR ACAD DERMATOL, V25, P362, DOI 10.1111/j.1468 3083.2010.03743.x
   Yang H, 2020, MOLECULES, V25, DOI 10.3390/molecules25184136
   Yitzhak Y, 2022, MOLECULES, V27, DOI 10.3390/molecules27030842
   Zhang TH, 2019, CELL CHEM BIOL, V26, P1486, DOI 10.1016/j.chembiol.2019.09.012
   Zhu GC, 2022, INT J BIOL SCI, V18, P5522, DOI 10.7150/ijbs.72211
NR 68
TC 3
Z9 3
U1 8
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD OCT
PY 2024
VL 11
IS 38
DI 10.1002/advs.202401518
EA JUL 2024
PG 16
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA J4B6U
UT WOS:001262718900001
PM 38970171
OA gold
DA 2025 08 17
ER

PT J
AU Ikhena, DE
   Liu, SM
   Kujawa, S
   Esencan, E
   Coon, VJS
   Robins, J
   Bulun, SE
   Yin, P
AF Ikhena, Deborah E.
   Liu, Shimeng
   Kujawa, Stacy
   Esencan, Ecem
   Coon, John S., V
   Robins, Jared
   Bulun, Serdar E.
   Yin, Ping
TI RANKL/RANK Pathway and Its Inhibitor RANK Fc in Uterine Leiomyoma Growth
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; CELLS; WOMEN; BONE
AB Context: Uterine leiomyomas are the most common type of gynecologic tumor in women.
   Objective: To determine the role of the cytokine receptor activator of nuclear factor kappa B ligand (RANKL); its receptor, receptor activator of nuclear factor kappa B (RANK); and the RANKL/RANK pathway inhibitor RANK Fe in leiomyoma growth.
   Design: Messenger RNA (mRNA) or protein levels of RANKL, RANK, and proliferation markers cyclin D1 and Ki67 were assessed in various leiomyoma tissues and cell populations. Human xenograft experiments were performed to determine the effects of RANK Fe on leiomyoma growth in vivo.
   Setting: Research laboratory.
   Patients: Twenty four regularly cycling premenopausal women (age 28 to 49 years) who were not receiving hormone therapy.
   Interventions: None.
   Main Outcome Measure: Tumor growth in a murine xenograft model following targeting of the RANKL/RANK pathway with RANK Fc.
   Results: RANKL mRNA levels in leiomyoma were significantly higher than those in myometrial tissues. The highest RANK levels were found in the leiomyoma stem cell population, which is deficient in progesterone receptor (PR). Conversely, the highest RAN KL levels were found in the PR rich leiomyoma intermediate cell (LIC) population. R5020, a PR agonist, specifically increased RANKL expression in LICs. RANK Fc blocked RANKL induced expression of the proliferative gene cyclin D1. Treatment with RANK Fe also significantly decreased tumor growth in vivo and diminished the expression of proliferation marker Ki67 in tumors (P < 0.01; n = 4).
   Conclusions: Treatment with the RANKL/RANK pathway inhibitor RANK Fc significantly decreased human leiomyoma cell proliferation and tumor growth. This suggests that the RANKL/RANK pathway could serve as a potential target for the prevention and treatment of uterine leiomyoma.
C1 [Ikhena, Deborah E.; Liu, Shimeng; Kujawa, Stacy; Esencan, Ecem; Coon, John S., V; Robins, Jared; Bulun, Serdar E.; Yin, Ping] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Div Reprod Sci Med, 303 East Super St,Suite 4 121, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine
RP Yin, P (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Div Reprod Sci Med, 303 East Super St,Suite 4 121, Chicago, IL 60611 USA.
EM p yin@northwestern.edu
RI ; Esencan, Ecem/MZQ 9302 2025; Yin, Ping/A 3699 2014
OI esencan, ecem/0000 0002 4942 6067; 
FU National Institutes of Health [P01 HD057877]
FX This study was supported by National Institutes of Health Grant P01
   HD057877 (to S.E.B.).
CR American College of Obstetricians and Gynecologists, 2008, Obstet Gynecol, V112, P387, DOI 10.1097/AOG.0b013e318183fbab
   AMGEN, PROL DON
   Baird DD, 2003, AM J OBSTET GYNECOL, V188, P100, DOI 10.1067/mob.2003.99
   Bulun SE, 2013, NEW ENGL J MED, V369, P1344, DOI 10.1056/NEJMra1209993
   Cardozo ER, 2012, AM J OBSTET GYNECOL, V206, DOI [10.1016/j.ajog.2011.12.002, 10.1016/j.ajog.2012.08.020]
   HANN HWL, 1992, CANCER, V70, P2051, DOI 10.1002/1097 0142(19921015)70:8<2051::AID CNCR2820700806>3.0.CO;2 1
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ishikawa H, 2010, ENDOCRINOLOGY, V151, P2433, DOI 10.1210/en.2009 1225
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Marsh EE, 2013, FERTIL STERIL, V99, P1951, DOI 10.1016/j.fertnstert.2013.02.017
   Moravek MB, 2015, HUM REPROD UPDATE, V21, P1, DOI 10.1093/humupd/dmu048
   Ogasawara T, 2004, J BONE MINER RES, V19, P1128, DOI 10.1359/jbmr.2004.19.7.1128
   Ono M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036935
   Riggs BL, 2000, J CLIN INVEST, V106, P1203, DOI 10.1172/JCI11468
   Sigl V, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160230
   Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654
   Whang PG, 2005, J ORTHOP RES, V23, P1475, DOI 10.1016/j.orthres.2005.05.004
   Yin P, 2015, J CLIN ENDOCR METAB, V100, pE601, DOI 10.1210/jc.2014 2134
NR 20
TC 23
Z9 25
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY
PY 2018
VL 103
IS 5
BP 1842
EP 1849
DI 10.1210/jc.2017 01585
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GF9PE
UT WOS:000432309500012
PM 29741640
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Sano, T
   Sun, X
   Feng, Y
   Liu, SZ
   Hase, M
   Fan, Y
   Zha, RR
   Wu, D
   Aryal, UK
   Li, BY
   Sudo, A
   Yokota, H
AF Sano, Tomohiko
   Sun, Xun
   Feng, Yan
   Liu, Shengzhi
   Hase, Misato
   Fan, Yao
   Zha, Rongrong
   Wu, Di
   Aryal, Uma K.
   Li, Bai Yan
   Sudo, Akihiro
   Yokota, Hiroki
TI Inhibition of the Growth of Breast Cancer Associated Brain Tumors by the
   Osteocyte Derived Conditioned Medium
SO CANCERS
LA English
DT Article
DE breast cancer; osteocytes; conditioned medium; Lrp5; &#946;  catenin;
   IL1ra; histone H4
ID EPITHELIAL MESENCHYMAL TRANSITION; WNT SIGNALING PATHWAY; TGF BETA;
   METASTASIS; PATTERNS; SUPPRESSOR; SURVIVAL; THERAPY; BIOLOGY; PROTEIN
AB Simple Summary
   Breast cancer is a common malignancy in women in the US. While brain metastases frequently occur from advanced breast cancer, current treatments are of limited effectiveness. In this study, we found that osteocytes and their conditioned medium (CM) presented the tumor suppressing capability, and the overexpression of Lrp5, IL1ra, and beta catenin enhanced their anti tumor actions. In a mouse model, the administration of osteocytes and their CM inhibited the progression of mammary tumors and tumors in the bone and brain. The minimally invasive administration allowed tumor suppressing factors in CM to diffuse into the brain. Besides p53 and Trail, mass spectrometry based whole genome proteomics revealed that extracellular histone H4 was enriched in CM and acted as a tumor suppressor. We also observed that Lrp5 overexpressing mesenchymal stem cells presented the tumor suppressing capability.
   The brain is a common site of metastasis from advanced breast cancer but few effective treatments are available. We examined a therapeutic option with a conditioned medium (CM), focusing on the role of Lrp5 and beta catenin in Wnt signaling, and IL1ra in osteocytes. Osteocytes presented the innate anti tumor effect and the overexpression of the above genes strengthened their action. In a mouse model, the injection of their CM inhibited mammary tumors and tumor driven osteolysis. Importantly, Lrp5  and/or IL1ra overexpressing osteocytes or the local administration of beta catenin overexpressing CM markedly inhibited brain tumors. In the transport analysis, tumor suppressing factors in CM were shown to diffuse through the skull. Mechanistically, the CM with overexpression of the above genes downregulated oncogenic genes such as MMP9, Runx2, TGF beta, and Snail in breast cancer cells. Also, the CM with beta catenin overexpression downregulated CXCL1 and CXCL5 and upregulated tumor suppressors such as LIMA1, DSP, p53, and TRAIL in breast cancer cells. Notably, whole genome proteomics revealed that histone H4 was enriched in CM and acted as an atypical tumor suppressor. Lrp5 overexpressing MSCs were also shown to act as anti tumor agents. Collectively, this study demonstrated the therapeutic role of engineered CM in brain tumors and the tumor suppressing action of extracellular histone H4. The result sheds light on the potential CM based therapy for breast cancer associated brain metastases in a minimally invasive manner.
C1 [Sano, Tomohiko; Sun, Xun; Feng, Yan; Liu, Shengzhi; Hase, Misato; Fan, Yao; Zha, Rongrong; Wu, Di; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Sano, Tomohiko; Sudo, Akihiro] Mie Univ, Grad Sch Med, Dept Orthoped Surg, Edobashi Tsu 2174, Japan.
   [Sun, Xun; Feng, Yan; Fan, Yao; Zha, Rongrong; Wu, Di; Li, Bai Yan; Yokota, Hiroki] Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin 150081, Peoples R China.
   [Hase, Misato] Mie Univ, Grad Sch Engn, Edobashi Tsu 2174, Japan.
   [Aryal, Uma K.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA.
   [Yokota, Hiroki] Indiana Univ Sch Med, Simon Canc Res Ctr, Indianapolis, IN 46202 USA.
   [Yokota, Hiroki] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; Harbin Medical University; Purdue University System;
   Purdue University; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington
RP Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin 150081, Peoples R China.; Yokota, H (通讯作者)，Indiana Univ Sch Med, Simon Canc Res Ctr, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
EM tomohiko0122@clin.medic.mie u.ac.jp; sunxun@iu.edu; fengya@iu.edu;
   liu441@iupui.edu; misahase@iu.edu; fanyao0124@163.com; zhar@iu.edu;
   hmuwudi@163.com; uaryal@purdue.edu; liby@ems.hrbmu.edu.cn;
   a sudou@clin.medic.mie u.ac.jp; hyokota@iupui.edu
RI Aryal, Uma/HLV 8481 2023
OI Li, Bai yan/0000 0002 1853 0216; Aryal, Uma/0000 0003 4543 1536; Sano,
   Tomohiko/0000 0002 5437 1806; Yokota, Hiroki/0000 0002 7881 8959; Sudo,
   Akihiro/0000 0003 0474 4368
FU NIH [R01AR052144, R03CA238555]
FX This research was funded by NIH R01AR052144 and R03CA238555 to H.Y.
CR Barbeito L, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1006 y
   Berman AT, 2013, CLIN BREAST CANCER, V13, P88, DOI 10.1016/j.clbc.2012.11.001
   Bonar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035979
   Chen A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23833 1
   Custódio Santos T, 2017, BBA REV CANCER, V1868, P132, DOI 10.1016/j.bbcan.2017.03.004
   Dabovic B, 2002, J ENDOCRINOL, V175, P129, DOI 10.1677/joe.0.1750129
   Duchartre Y, 2016, CRIT REV ONCOL HEMAT, V99, P141, DOI 10.1016/j.critrevonc.2015.12.005
   Egi M., 2021, IN PRESS
   Ewens A, 2005, ANTICANCER RES, V25, P3905
   Fan Y, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0083 6
   Ferrari N, 2013, J CELL PHYSIOL, V228, P1137, DOI 10.1002/jcp.24285
   Gao HQ, 2017, MOL MED REP, V16, P317, DOI 10.3892/mmr.2017.6608
   Gil OG, 2016, CR PALEVOL, V15, P527, DOI 10.1016/j.crpv.2015.04.0061631
   Goldring SR, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000049
   Guo FZ, 2019, ONCOL LETT, V18, P5699, DOI 10.3892/ol.2019.10957
   Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767
   Hardy SD, 2017, ONCOTARGET, V8, P103302, DOI 10.18632/oncotarget.21871
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Joiner DM, 2013, TRENDS ENDOCRIN MET, V24, P31, DOI 10.1016/j.tem.2012.10.003
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078 0432.CCR 06 2316
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kumar K, 2020, CURR GENET, V66, P945, DOI 10.1007/s00294 020 01088 6
   Langley RR, 2013, CLIN CHEM, V59, P180, DOI [10.1373/clinchem.2012.193342, 10.1097/PPO.0000000000000126]
   Liu SZ, 2018, CANCER RES, V78, P3865, DOI 10.1158/0008 5472.CAN 18 0056
   Liu Y, 2013, MED ONCOL, V30, DOI 10.1007/s12032 012 0366 x
   Liu ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077131
   Mena HA, 2016, J THROMB HAEMOST, V14, P397, DOI 10.1111/jth.13223
   Miller KD, 2003, ANN ONCOL, V14, P1072, DOI 10.1093/annonc/mdg300
   Nie ZL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6908
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Paster EV, 2009, COMPARATIVE MED, V59, P234
   Phillips GDL, 2017, BREAST CANCER RES TR, V164, P581, DOI 10.1007/s10549 017 4279 4
   Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315
   Pisetsky DS, 2013, EUR J IMMUNOL, V43, P3163, DOI 10.1002/eji.201344175
   Refaat A, 2014, ONCOL LETT, V7, P1327, DOI 10.3892/ol.2014.1922
   Reyes RC, 2012, ASN NEURO, V4, P33, DOI 10.1042/AN20110059
   Rostami R, 2016, J NEURO ONCOL, V127, P407, DOI 10.1007/s11060 016 2075 3
   Sharif Y, 2018, CLIN ANAT, V31, P812, DOI 10.1002/ca.23083
   Sorlie T, 2016, CLIN CHEM, V62, P1150, DOI 10.1373/clinchem.2015.253229
   Tawara Ken, 2019, Oncotarget, V10, P2068, DOI 10.18632/oncotarget.26699
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055 9965.EPI 15 0578
   Uzunalli Gozde, 2019, Oncotarget, V10, P6334, DOI 10.18632/oncotarget.27274
   Valencia K, 2012, CLIN CANCER RES, V18, P969, DOI 10.1158/1078 0432.CCR 11 1686
   Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050
   Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102
   Witzel I, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058 015 0665 1
   Yang LL, 2012, CARCINOGENESIS, V33, P1863, DOI 10.1093/carcin/bgs226
   Yau T, 2006, ACTA ONCOL, V45, P196, DOI 10.1080/02841860500486630
   Yin P, 2018, CANCER SCI, V109, P3368, DOI 10.1111/cas.13771
   Zimmerlin L, 2013, BIOCHIMIE, V95, P2235, DOI 10.1016/j.biochi.2013.05.010
NR 52
TC 20
Z9 20
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD MAR
PY 2021
VL 13
IS 5
AR 1061
DI 10.3390/cancers13051061
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QV5CP
UT WOS:000627989800001
PM 33802279
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Peng, Y
   Kenney, HM
   Bentley, KLD
   Xing, LP
   Ritchlin, CT
   Schwarz, EM
AF Peng, Yue
   Kenney, H. Mark
   Bentley, Karen L. de Mesy
   Xing, Lianping
   Ritchlin, Christopher T.
   Schwarz, Edward M.
TI Distinct mast cell subpopulations within and around lymphatic vessels
   regulate lymph flow and progression of inflammatory erosive arthritis in
   TNF transgenic mice
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE T32GM007356; F30AG076326; R01AG059775; R01AR069000; R01AR056702; mast
   cell; lymphatic vessel; inflammatory erosive arthritis
ID TUMOR NECROSIS FACTOR; RHEUMATOID ARTHRITIS; MODEL; DEGRANULATION;
   CONTRACTILE; MODULATION; HISTAMINE; LIGAND; LOCUS; MOUSE
AB ObjectiveInflammatory erosive arthritis is exacerbated by dysfunction of joint draining popliteal lymphatic vessels (PLVs). Synovial mast cells are known to be pro inflammatory in rheumatoid arthritis (RA). In other settings they have anti inflammatory and tissue reparative effects. Herein, we elucidate the role of mast cells on PLV function and inflammatory erosive arthritis in tumor necrosis factor transgenic (TNF tg) mice that exhibit defects in PLVs commensurate with disease progression.MethodsWhole mount immunofluorescent microscopy, toluidine blue stained histology, scanning electron microscopy, and in silico bioinformatics were performed to phenotype and quantify PLV mast cells. Ankle bone volumes were assessed by mu CT, while corresponding histology quantified synovitis and osteoclasts. Near infrared indocyanine green imaging measured lymphatic clearance as an outcome of PLV draining function. Effects of genetic MC depletion were assessed via comparison of 4.5 month old WT, TNF tg, MC deficient KitW sh/W sh (cKit / ), and TNF tg x cKit /  mice. Pharmacological inhibition of mast cells was assessed by treating TNF tg mice with placebo or cromolyn sodium (3.15mg/kg/day) for 3 weeks.ResultsPLVs are surrounded by MCT+/MCPT1+/MCPT4+ mast cells whose numbers are increased 2.8 fold in TNF tg mice. The percentage of peri vascular degranulating mast cells was inversely correlated with ICG clearance. A population of MCT+/MCPT1 /MCPT4  mast cells were embedded within the PLV structure. In silico single cell RNA seq (scRNAseq) analyses identified a population of PLV associated mast cells (marker genes: Mcpt4, Cma1, Cpa3, Tpsb2, Kit, Fcer1a & Gata2) with enhanced TGF beta related signaling that are phenotypically distinct from known MC subsets in the Mouse Cell Atlas. cKit /  mice have greater lymphatic defects than TNF tg mice with exacerbation of lymphatic dysfunction and inflammatory erosive arthritis in TNF tg x cKit /  vs. TNF Tg mice. Cromolyn sodium therapy stabilized PLV mast cells, increased TNF induced bone loss, synovitis, and osteoclasts, and decreased ICG clearance.ConclusionsMast cells are required for normal lymphatic function. Genetic ablation and pharmacological inhibition of mast cells exacerbates TNF induced inflammatory erosive arthritis with decreased lymphatic clearance. Together, these findings support an inflammatory role of activated/degranulated peri PLV mast cells during arthritic progression, and a homeostatic role of intra PLV mast cells, in which loss of the latter dominantly exacerbates arthritis secondary to defects in joint draining lymphatics, warranting investigation into specific cellular mechanisms.
C1 [Peng, Yue; Kenney, H. Mark; Bentley, Karen L. de Mesy; Xing, Lianping; Ritchlin, Christopher T.; Schwarz, Edward M.] Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14642 USA.
   [Peng, Yue; Kenney, H. Mark; Bentley, Karen L. de Mesy; Xing, Lianping; Schwarz, Edward M.] Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Rochester, NY 14642 USA.
   [Ritchlin, Christopher T.] Univ Rochester, Dept Med, Div Allergy, Immunol,Rheumatol,Med Ctr, Rochester, NY USA.
C3 University of Rochester; University of Rochester; University of
   Rochester
RP Schwarz, EM (通讯作者)，Univ Rochester, Ctr Musculoskeletal Res, Med Ctr, Rochester, NY 14642 USA.; Schwarz, EM (通讯作者)，Univ Rochester, Dept Pathol & Lab Med, Med Ctr, Rochester, NY 14642 USA.
EM Edward_Schwarz@URMC.Rochester.edu
OI Peng, Yue/0000 0001 5524 4772
FU National Institute of Arthritis and Musculoskeletal and Skin
   Diseases10.13039/100000069; Molecular Imaging Core at the University of
   Rochester Medical Center
FX We would like to thank the faculty and staff at the Genomics Research
   Center and Histology, Biochemistry, the Electron Microscopy Resource in
   the Center for Advanced Resource Technologies, and Molecular Imaging
   Core at the University of Rochester Medical Center.
CR Bacci S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031820
   Bell RD, 2020, ARTHRITIS RHEUMATOL, V72, P1447, DOI 10.1002/art.41311
   Bell RD, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2039 z
   Bouta EM, 2018, NAT REV RHEUMATOL, V14, P94, DOI 10.1038/nrrheum.2017.205
   Bouta EM, 2017, ARTHRITIS RHEUMATOL, V69, P1187, DOI 10.1002/art.40047
   Bouta EM, 2015, SEMIN CELL DEV BIOL, V38, P90, DOI 10.1016/j.semcdb.2015.01.001
   BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671
   BROMLEY M, 1984, ANN RHEUM DIS, V43, P76, DOI 10.1136/ard.43.1.76
   Chang MH, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109902
   Fei LJ, 2022, NAT GENET, V54, P1051, DOI 10.1038/s41588 022 01118 8
   Fox JLR, 2002, BRIT J PHARMACOL, V136, P1210, DOI 10.1038/sj.bjp.0704820
   GODFREY HP, 1984, ARTHRITIS RHEUM US, V27, P852, DOI 10.1002/art.1780270803
   Gravallese EM, 2023, NEW ENGL J MED, V388, P529, DOI 10.1056/NEJMra2103726
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002 9440(10)62055 X
   GRYFE A, 1971, ANN RHEUM DIS, V30, P24, DOI 10.1136/ard.30.1.24
   Guma M, 2010, P NATL ACAD SCI USA, V107, P22122, DOI 10.1073/pnas.1016401107
   Gutowski L, 2023, LIFE BASEL, V13, DOI 10.3390/life13081690
   Han XP, 2018, CELL, V173, P1307, DOI 10.1016/j.cell.2018.05.012
   Hori Y, 2015, J BIOL CHEM, V290, P1966, DOI 10.1074/jbc.M114.586602
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Kenney HM, 2023, ARTHRITIS RES THER, V25, DOI 10.1186/s13075 022 02985 6
   Kenney HM, 2023, CURR RHEUMATOL REV, V19, P246, DOI 10.2174/1573397119666230127144711
   Kenney HM, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 16884 y
   Kenney HM, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02730 z
   Kenney HM, 2022, BONE REP, V16, DOI 10.1016/j.bonr.2022.101167
   Kenney HM, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 75190 7
   Krystel Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620
   Kunder CA, 2011, BLOOD, V118, P5383, DOI 10.1182/blood 2011 07 358432
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   Li J, 2013, ARTHRITIS RHEUM US, V65, P130, DOI 10.1002/art.37709
   Li J, 2010, J IMMUNOL, V184, P6142, DOI 10.4049/jimmunol.0903489
   Löfvall H, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1564 5
   MALONE DG, 1987, ARTHRITIS RHEUM US, V30, P130, DOI 10.1002/art.1780300202
   Nagata K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094972
   Nigrovic PA, 2005, ARTHRITIS RES THER, V7, P1, DOI 10.1186/ar1446
   NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460 2075.1990.tb08305.x
   Pal S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01234
   Pitman N, 2011, ANN RHEUM DIS, V70, P1170, DOI 10.1136/ard.2010.134528
   Plaku KJ, 2006, MICROCIRCULATION, V13, P219, DOI 10.1080/10739680600556902
   Rivellese F, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01051
   Rivellese F, 2018, ANN RHEUM DIS, V77, P1773, DOI 10.1136/annrheumdis 2018 213418
   Sasaki H, 2021, BIOCHEM BIOPH RES CO, V551, P127, DOI 10.1016/j.bbrc.2021.03.025
   Scallan JP, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.745096
   Scallan JP, 2014, MICROCIRCULATION, V21, P575, DOI 10.1111/micc.12162
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   Schubert N, 2015, ARTHRITIS RHEUMATOL, V67, P903, DOI 10.1002/art.38996
   Solimando AG, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232214004
   Sridharan Gokul, 2012, J Oral Maxillofac Pathol, V16, P251, DOI 10.4103/0973 029X.99081
   van der Velden D, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1036 8
   Wang RY, 2023, NUCLEIC ACIDS RES, V51, P501, DOI 10.1093/nar/gkac633
   Wilgus TA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249673
   Zhang LZ, 2017, J BONE MINER RES, V32, P1870, DOI 10.1002/jbmr.3178
   ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092 8674(90)90302 U
NR 54
TC 3
Z9 3
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 14
PY 2023
VL 14
AR 1275871
DI 10.3389/fimmu.2023.1275871
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA DZ7H7
UT WOS:001135979800001
PM 38155962
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rodríguez Sanz, M
   García Giralt, N
   Prieto Alhambra, D
   Servitja, S
   Balcells, S
   Pecorelli, R
   Díez Pérez, A
   Grinberg, D
   Tusquets, I
   Nogués, X
AF Rodriguez Sanz, M.
   Garcia Giralt, N.
   Prieto Alhambra, D.
   Servitja, S.
   Balcells, S.
   Pecorelli, R.
   Diez Perez, A.
   Grinberg, D.
   Tusquets, I.
   Nogues, X.
TI CYP11A1 expression in bone is associated with aromatase
   inhibitor related bone loss
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
DE CYP11A1; aromatase inhibitors; bone loss; breast cancer; genetic
   association
ID EARLY BREAST CANCER; VITAMIN D DEFICIENCY; POSTMENOPAUSAL WOMEN; MINERAL
   DENSITY; GENETIC DETERMINANTS; CYTOCHROME P450SCC; PROSPECTIVE COHORT;
   RECEPTOR GENE; CYP19A1 GENE; RISK
AB Aromatase inhibitors (AIs) used as adjuvant therapy in postmenopausal women with hormone receptor positive breast cancer cause diverse musculoskeletal side effects that include bone loss and its associated fracture. About half of the 391 patients treated with AIs in the Barcelona Aromatase induced bone loss in early breast cancer cohort suffered a significant bone loss at lumbar spine (LS) and/or femoral neck (FN) after 2 years on AI treatment. In contrast, up to one third (19.6% LS, 38.6% FN) showed no decline or even increased bone density. The present study aimed to determine the genetic basis for this variability. SNPs in candidate genes involved in vitamin D and estrogen hormone response pathways (CYP11A1, CYP17A1, HSD3B2, HSD17B3, CYP19A1, CYP2C19, CYP2C9, ESR1, DHCR7, GC, CYP2R1, CYP27B1, VDR and CYP24A1) were genotyped for association analysis with AI related bone loss (AIBL). After multiple testing correction, 3 tag SNPs (rs4077581, s11632698 and rs900798) located in the CYP11A1 gene were significantly associated (P<0.005) with FN AIBL at 2 years of treatment. Next, CYP11A1 expression in human fresh bone tissue and primary osteoblasts was demonstrated by RT PCR. Both common isoforms of human cholesterol side chain cleavage enzyme (encoded by CYP11A1 gene) were detected in osteoblasts by western blot. In conclusion, the genetic association of CYP11A1 gene with AIBL and its expression in bone tissue reveals a potential local function of this enzyme in bone metabolism regulation, offering a new vision of the steroidogenic ability of this tissue and new understanding of AI induced bone loss.
C1 [Rodriguez Sanz, M.; Garcia Giralt, N.; Prieto Alhambra, D.; Pecorelli, R.; Diez Perez, A.; Nogues, X.] IMIM Hosp Mar Res Inst, Red Temat Invest Cooperat Envejecimiento & Fragil, ISCIII, Barcelona 08003, Spain.
   [Pecorelli, R.; Diez Perez, A.; Nogues, X.] Univ Autonoma Barcelona, Hosp del Mar, Dept Internal Med, E 08193 Barcelona, Spain.
   [Prieto Alhambra, D.] Univ Autonoma Barcelona, IDIAP Jordi Gol Primary Care Res Inst, E 08193 Barcelona, Spain.
   [Prieto Alhambra, D.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford NIHR Musculoskeletal Biomed Res Unit, Oxford, England.
   [Prieto Alhambra, D.] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Servitja, S.; Tusquets, I.] Univ Autonoma Barcelona, Hosp del Mar, IMIM Hosp Mar Res Inst, Med Oncol Dept, E 08193 Barcelona, Spain.
   [Balcells, S.; Grinberg, D.] Univ Barcelona, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Dept Genet, IBUB,ISCIII, Barcelona, Spain.
C3 Instituto de Salud Carlos III; Hospital del Mar Research Institute;
   Autonomous University of Barcelona; Hospital del Mar Research Institute;
   Hospital del Mar; Autonomous University of Barcelona; University of
   Oxford; University of Southampton; Hospital del Mar Research Institute;
   Hospital del Mar; Autonomous University of Barcelona; Instituto de Salud
   Carlos III; CIBER   Centro de Investigacion Biomedica en Red; CIBERER;
   University of Barcelona
RP García Giralt, N (通讯作者)，IMIM Hosp Mar Res Inst, Red Temat Invest Cooperat Envejecimiento & Fragil, ISCIII, Carrer Doctor Aiguader 88, Barcelona 08003, Spain.
EM ngarcia@imim.es
RI ; Servitja, Sonia/AAC 4081 2021; Balcells, Susana/C 5222 2017; SANZ,
   MARIA/AAB 5627 2019; Garcia Giralt, Natalia/AAA 7588 2021; Grinberg,
   Daniel/F 3641 2010
OI Garcia Giralt, Natalia/0000 0001 6507 0147; Balcells,
   Susana/0000 0003 1211 1907; Diez Perez, Adolfo/0000 0001 8162 0209;
   Grinberg, Daniel/0000 0001 9859 2590; Prieto Alhambra,
   Daniel/0000 0002 3950 6346; Nogues, Xavier/0000 0001 8201 9933; Nogues,
   Xavier/0000 0002 5537 1859
FU Red Tematica de Investigacion Cooperativa en Envejecimiento y Fragilidad
   (RETICEF) [RD12/0043/0022]; Carlos III Health Institute, Science and
   Innovation Ministry [FIS PI10/01464, PI13/00444]; Generalitat de
   Catalunya [DIUE 2014 SGR 775]; FEDER funds
FX This work was supported by the Red Tematica de Investigacion Cooperativa
   en Envejecimiento y Fragilidad (RETICEF, RD12/0043/0022), and the Grant
   FIS PI10/01464 and PI13/00444 (Carlos III Health Institute, Science and
   Innovation Ministry); Grants from the Generalitat de Catalunya (DIUE
   2014 SGR 775) and FEDER funds have supported this study.
CR Aranda PS, 2012, ELECTROPHORESIS, V33, P366, DOI 10.1002/elps.201100335
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Blake G, 2013, PRIMER METABOLIC BON, P251
   Bouvard B, 2014, ANN ONCOL, V25, P843, DOI 10.1093/annonc/mdu008
   Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   Cranney Ann, 2007, Evid Rep Technol Assess (Full Rep), P1
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Eastell R, 2006, J BONE MINER RES, V21, P1215, DOI 10.1359/JBMR.060508
   Enjuanes A, 2006, BONE, V38, P738, DOI 10.1016/j.bone.2005.10.010
   Eriksen EF, 2002, BIOGERONTOLOGY, V3, P73, DOI 10.1023/A:1015263514765
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Gao Gui hua, 2010, Zhonghua Fu Chan Ke Za Zhi, V45, P191
   Garcia Giralt N, 2013, BREAST CANCER RES TR, V140, P385, DOI 10.1007/s10549 013 2638 3
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549 007 9774 6
   Janssen JMMF, 1999, J CELL BIOCHEM, V75, P528
   Kobayashi S, 1996, J BONE MINER RES, V11, P306
   Langdahl BL, 2000, EUR J CLIN INVEST, V30, P608
   Laroche F, 2014, J PAIN, V15, P293, DOI 10.1016/j.jpain.2013.11.004
   Muir M, 2004, J CLIN ENDOCR METAB, V89, P4685, DOI 10.1210/jc.2004 0049
   Napoli N, 2013, BONE, V55, P309, DOI 10.1016/j.bone.2013.04.021
   Nguyen MN, 2009, DRUG METAB DISPOS, V37, P761, DOI 10.1124/dmd.108.025619
   Nogues X, 2010, MATURITAS, V66, P291, DOI 10.1016/j.maturitas.2010.03.012
   Payne AH, 2004, ENDOCR REV, V25, P947, DOI 10.1210/er.2003 0030
   Prieto Alhambra D, 2012, BREAST CANCER RES TR, V133, P1159, DOI 10.1007/s10549 012 2013 9
   Prieto Alhambra D, 2011, BREAST CANCER RES TR, V125, P869, DOI 10.1007/s10549 010 1075 9
   Reed MJ, 2005, ENDOCR REV, V26, P171, DOI 10.1210/er.2004 0003
   Reid DM, 2008, CANCER TREAT REV, V34, pS3, DOI 10.1016/j.ctrv.2008.03.007
   Saito H, 1998, J INT MED RES, V26, P1
   Servitja S, 2012, BREAST, V21, P95, DOI 10.1016/j.breast.2011.09.001
   Slominski A, 2006, FEBS J, V273, P2891, DOI 10.1111/j.1742 4658.2006.05302.x
   Sun MY, 2012, INT J MOL SCI, V13, P4896, DOI 10.3390/ijms13044896
   Teplyuk NM, 2009, MOL ENDOCRINOL, V23, P849, DOI 10.1210/me.2008 0270
   Terry K, 2010, GYNECOL ONCOL, V117, P255, DOI 10.1016/j.ygyno.2010.02.002
   Tuckey RC, 2008, FEBS J, V275, P2585, DOI 10.1111/j.1742 4658.2008.06406.x
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140 6736(10)60588 0
   Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121
   Zarrabeitia MT, 2004, EUR J ENDOCRINOL, V150, P699, DOI 10.1530/eje.0.1500699
   Zheng W, 2004, CANCER EPIDEM BIOMAR, V13, P709
NR 38
TC 23
Z9 25
U1 0
U2 8
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0952 5041
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD AUG
PY 2015
VL 55
IS 1
BP 69
EP 79
DI 10.1530/JME 15 0079
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CT0PL
UT WOS:000362498500007
PM 26108486
OA Bronze
DA 2025 08 17
ER

PT J
AU Chen, SY
   Luo, Z
   Wu, LZ
   Xie, CL
   Xiao, XF
AF Chen, Shunyu
   Luo, Zhi
   Wu, Linzhao
   Xie, Chunling
   Xiao, Xiufeng
TI Amino Modified Polylactic Acid Nanofibre Microspheres as Drug Sustained
   Release Carriers for Alendronate
SO POLYMER PLASTICS TECHNOLOGY AND ENGINEERING
LA English
DT Article
DE Absorption; alendronate; amino polylactic acid; nanofibrous
   microspheres; sustained release
ID DELIVERY SYSTEMS; IN VITRO; BISPHOSPHONATES; THERAPY; BONE;
   MICROPARTICLES; NANOPARTICLES; PARTICLES; MECHANISM; MATRICES
AB Amino modified polylactic acid (EPLA) nanofibre microspheres with a high porosity, large specific surface area, strong adsorption capacity, and rich in active amino groups were developed for drug delivery applications. Alendronate, a well known antiresorptive agent, was chosen as a model drug to evaluate the loading capacity and release properties of the prepared EPLA microspheres. SEM micrographs clearly showed that the drug was loaded into the microspheres within the pores between the nanofibers and as well as being adsorbed on their surface. XRD and FTIR spectra analyses also confirmed drug loading. UV/Vis absorption spectrophotometry was used to study the impact of various parameters, including adsorption time and initial concentration and pH value of the alendronate solution, on the microsphere drug loading capacity. Under optimum conditions, EPLA microspheres exhibited a high alendronate adsorption capacity of up to 503 mg/g. In vitro release studies showed that alendronate loaded EPLA nanofibre microspheres exhibited a perfect release performance, with alendronate being released in a sustained manner for approximately 15 days without any obvious initial burst. Therefore, EPLA nanofibre microspheres hold great potential as efficient, controlled release drug delivery carriers of alendronate.
   [GRAPHICS]
   .
C1 [Chen, Shunyu; Luo, Zhi; Wu, Linzhao; Xie, Chunling; Xiao, Xiufeng] Fujian Normal Univ, Coll Chem & Chem Engn, Fujian Prov Key Lab Adv Mat Oriented Chem Engn, Fuzhou 350007, Fujian, Peoples R China.
C3 Fujian Normal University
RP Xiao, XF (通讯作者)，Fujian Normal Univ, Coll Chem & Chem Engn, Fujian Prov Key Lab Adv Mat Oriented Chem Engn, Fuzhou 350007, Fujian, Peoples R China.
EM xfxiao@fjnu.edu.cn
CR Bae J, 2015, INT J PHARMACEUT, V480, P37, DOI 10.1016/j.ijpharm.2015.01.020
   Black DM, 2012, NEW ENGL J MED, V366, P2051, DOI 10.1056/NEJMp1202623
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Bouza R, 2016, POLYM BULL, V73, P3485, DOI 10.1007/s00289 016 1687 2
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   Deca A G, 2015, Curr Health Sci J, V41, P246, DOI 10.12865/CHSJ.41.03.09
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Dredan J, 1996, INT J PHARM, V145, P61, DOI 10.1016/S0378 5173(96)04725 4
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Fan QZ, 2016, COLLOID SURFACE A, V500, P177, DOI 10.1016/j.colsurfa.2016.04.028
   Floyd JA, 2016, J BIOMED MATER RES A, V104, P544, DOI 10.1002/jbm.a.35547
   Gaba B, 2015, DRUG DELIV, V22, P691, DOI 10.3109/10717544.2014.898110
   HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210
   Hosny KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154926
   Jadranka K., 2002, J PHARM BIOMED ANAL, V28, P1215
   LANGER RS, 1981, BIOMATERIALS, V2, P201, DOI 10.1016/0142 9612(81)90059 4
   Lassalle V, 2007, MACROMOL BIOSCI, V7, P767, DOI 10.1002/mabi.200700022
   Liu YF, 2016, TROP J PHARM RES, V15, P1353, DOI 10.4314/tjpr.v15i7.1
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Pinon Segundo Elizabeth, 2012, Recent Pat Drug Deliv Formul, V6, P224
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168 3659(87)90034 4
   SAMUELOV Y, 1979, J PHARM SCI US, V68, P325, DOI 10.1002/jps.2600680318
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Silverman SL, 2007, SEMIN ARTHRITIS RHEU, V37, P1, DOI 10.1016/j.semarthrit.2006.12.003
   Srinivasan S, 2012, CARBOHYD POLYM, V87, P274, DOI 10.1016/j.carbpol.2011.07.058
   Wang YJ, 2016, INT J PHARMACEUT, V503, P150, DOI 10.1016/j.ijpharm.2016.03.002
   Whitaker M, 2012, NEW ENGL J MED, V366, P2048, DOI 10.1056/NEJMp1202619
   Wright JEI, 2006, BIOMATERIALS, V27, P769, DOI 10.1016/j.biomaterials.2005.06.012
   Yang H, 2016, J MICROENCAPSUL, V33, P421, DOI 10.1080/02652048.2016.1202347
   Zafar N, 2016, MAT SCI ENG C MATER, V61, P85, DOI 10.1016/j.msec.2015.12.017
   Zhou Y, 2010, AM J PHYSIOL GASTR L, V298, pG722, DOI 10.1152/ajpgi.00387.2009
NR 33
TC 10
Z9 10
U1 2
U2 80
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0360 2559
EI 1525 6111
J9 POLYM PLAST TECHNOL
JI Polym. Plast. Technol. Eng.
PD DEC 12
PY 2018
VL 57
IS 18
BP 1873
EP 1881
DI 10.1080/03602559.2018.1447122
PG 9
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA HA8ED
UT WOS:000450520600003
DA 2025 08 17
ER

PT J
AU Xie, DB
   Xu, YT
   Zhang, YM
   Cai, WP
   Lan, X
   Yan, H
AF Xie, Dingbang
   Xu, Yunteng
   Zhang, Yimin
   Cai, Wanping
   Lan, Xin
   Yan, Hui
TI Pyruvate dehydrogenase kinase 1 dependent metabolic reprogramming: A
   promising target for postmenopausal osteoporosis treatment
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Postmenopausal osteoporosis; Osteoclastogenesis; Icariin; Metabolic
   reprogramming; Pyruvate dehydrogenase subunit alpha pSer 232; Pyruvate
   dehydrogenase kinase 1
ID PHOSPHORYLATION; ICARIIN
AB Postmenopausal osteoporosis (PMOP) is a classic endocrine disorder characterized by an imbalance between bone formation and bone resorption. Abnormal glucose metabolic reprogramming has been widely explored in endocrine disorders, but its role in PMOP has not been elucidated. Icariin (ICA), as a bioactive component of the traditional Chinese medicine Epimedium grandiflorum, has been testified to be effective for PMOP treatment, but its effects on glucose metabolism are poorly studied. In this study, pyruvate dehydrogenase was proved to be a key regulator of the metabolic switch in PMOP and the efficacy of ICA. The augmentation of pyruvate dehydrogenase subunit alpha (PDHA) pSer232, which was excited in osteoclasts; the decreased expression of citrate synthase; elevated expression of lactate dehydrogenase; and changes in the pyruvate, lactate, and citrate pools all indicated the preference for aerobic glycolysis in PMOP. Further study showed that the expression and activity of pyruvate dehydrogenase kinase 1 (PDK1) which regulated the phosphorylation status of PDHA Ser232 were both increased in ovariectomized rats. Furthermore, the genetic knockdown of PDK1 and pharmaceutical inhibition of PDK1 markedly suppressed osteoclastogenesis. Meanwhile, ICA might reverse metabolic reprogramming by inhibiting PDK1. In conclusion, this study revealed that PDK1 dependent metabolic reprogramming is a potential therapeutic target for PMOP treatment. ICA alleviates PMOP by inhibiting PDK1 in osteoclasts, indicating its potential for clinical use.
C1 [Xie, Dingbang; Xu, Yunteng; Zhang, Yimin; Cai, Wanping; Lan, Xin; Yan, Hui] Fujian Univ Tradit Chinese Med, Key Lab Integrat Med Chron Dis, Synthesized Lab Integrat Med, Coll Integrat Med,Lab Pathophysiol,Fujian Prov Uni, Fuzhou, Peoples R China.
   [Xu, Yunteng] Fujian Univ Tradit Chinese Med, Acad Integrat Med, Fuzhou, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of
   Traditional Chinese Medicine
RP Yan, H (通讯作者)，Fujian Univ Tradit Chinese Med, Key Lab Integrat Med Chron Dis, Synthesized Lab Integrat Med, Coll Integrat Med,Lab Pathophysiol,Fujian Prov Uni, Fuzhou, Peoples R China.
EM 2020042@fjtcm.edu.cn
RI Zhang, Yimin/GPX 5711 2022
CR Anwar S, 2021, BBA REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188568
   Bei JX, 2022, J PROTEOMICS, V252, DOI 10.1016/j.jprot.2021.104451
   Biswas SK, 2015, IMMUNITY, V43, P435, DOI 10.1016/j.immuni.2015.09.001
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Chen MX, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090563
   Cipriani C., 2020, FRONT ENDOCRINOL, P11
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Gambacciani M, 2004, Minerva Med, V95, P507
   Goodpaster BH, 2017, CELL METAB, V25, P1027, DOI 10.1016/j.cmet.2017.04.015
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018 013 1539 2
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015
   Huang M, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2982480
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jia ZR, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.720387
   Jing XZ, 2019, J CELL PHYSIOL, V234, P10123, DOI 10.1002/jcp.27678
   Karner CM, 2018, BONE, V115, P2, DOI 10.1016/j.bone.2017.08.008
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kim S, 2021, NUCLEIC ACIDS RES, V49, pD1388, DOI 10.1093/nar/gkaa971
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200
   Lee JM, 2021, J BONE MINER RES, V36, P553, DOI 10.1002/jbmr.4202
   Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1
   Li HT, 2018, MED SCI MONITOR, V24, P5071, DOI 10.12659/MSM.908699
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Liu GF, 2018, J CELL BIOCHEM, V119, P4469, DOI 10.1002/jcb.26550
   Ming LG, 2013, J CELL PHYSIOL, V228, P513, DOI 10.1002/jcp.24158
   Nayak S, 2018, J BONE MINER RES, V33, P1585, DOI 10.1002/jbmr.3437
   Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Poznyak A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051835
   Qi SS, 2019, MOLECULES, V24, DOI 10.3390/molecules24101871
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rardin MJ, 2009, ANAL BIOCHEM, V389, P157, DOI 10.1016/j.ab.2009.03.040
   Stacpoole PW, 2017, JNCI J NATL CANCER I, V109, DOI 10.1093/jnci/djx071
   Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Tian L, 2020, CIRC RES, V126, P1723, DOI 10.1161/CIRCRESAHA.120.316443
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang XX, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204402
   Wang Z, 2018, OSTEOPOROSIS INT, V29, P535, DOI 10.1007/s00198 017 4255 1
   Weng YT, 2022, CELL RES, V32, P814, DOI 10.1038/s41422 022 00687 x
   Xu HY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12743
   Xu JH, 2016, MENOPAUSE, V23, P1152, DOI 10.1097/GME.0000000000000673
   Zhou LP, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153413
   Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698
NR 47
TC 1
Z9 1
U1 2
U2 20
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2023
VL 160
AR 114411
DI 10.1016/j.biopha.2023.114411
EA FEB 2023
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 9S7YJ
UT WOS:000946553300001
OA gold
DA 2025 08 17
ER

PT J
AU Hemnes, AR
   Zhao, M
   West, J
   Newman, JH
   Rich, S
   Archer, SL
   Robbins, IM
   Blackwell, TS
   Cogan, J
   Loyd, JE
   Zhao, ZM
   Gaskill, C
   Jetter, C
   Kropski, JA
   Majka, SM
   Austin, ED
AF Hemnes, Anna R.
   Zhao, Min
   West, James
   Newman, John H.
   Rich, Stuart
   Archer, Stephen L.
   Robbins, Ivan M.
   Blackwell, Timothy S.
   Cogan, Joy
   Loyd, James E.
   Zhao, Zhongming
   Gaskill, Christa
   Jetter, Christopher
   Kropski, Jonathan A.
   Majka, Susan M.
   Austin, Eric D.
TI Critical Genomic Networks and Vasoreactive Variants in Idiopathic
   Pulmonary Arterial Hypertension
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Article
DE whole exome sequencing; pulmonary arterial hypertension; vasodilator
   responsive
ID RARE VARIANTS; ODDS RATIOS; MUTATIONS; GENE; IDENTIFICATION; BMPR2;
   SIGNATURE; DISCOVERY; SCANS
AB Rationale: Idiopathic pulmonary arterial hypertension (IPAH) is usually without an identified genetic cause, despite clinical and molecular similarity to bone morphogenetic protein receptor type 2 mutation associated heritable pulmonary arterial hypertension (PAH). There is phenotypic heterogeneity in IPAH, with a minority of patients showing long term improvement with calcium channel blocker therapy.
   Objectives: We sought to identify gene variants (GVs) underlying IPAH and determine whether GVs differ in vasodilator responsive IPAH (VR PAH) versus vasodilator nonresponsive IPAH (VN PAH).
   Methods: We performed whole exome sequencing (WES) on 36 patients with IPAH: 17 with VR PAH and 19 with VN PAH. Wnt pathway differences were explored in human lung fibroblasts.
   Measurements and Main Results: We identified 1,369 genes with 1,580 variants unique to IPAH. We used a gene ontology approach to analyze variants and identified overrepresentation of several pathways, including cytoskeletal function and ion binding. By mapping WES data to prior genome wide association study data, Wnt pathway genes were highlighted. Using the connectivity map to define genetic differences between VR PAH and VN PAH, we found enrichment in vascular smooth muscle cell contraction pathways and greater genetic variation in VR PAH versus VN PAH. Using human lung fibroblasts, we found increased stimulated Wnt activity in IPAH versus controls.
   Conclusions: A pathway based analysis of WES data in IPAH demonstrated multiple rare GVs that converge on key biological pathways, such as cytoskeletal function and Wnt signaling pathway. Vascular smooth muscle contraction related genes were enriched in VR PAH, suggesting a potentially different genetic predisposition for VR PAH. This pathway based approach may be applied to next generation sequencing data in other diseases to uncover the contribution of unexpected or multiple GVs to a phenotype.
C1 [Hemnes, Anna R.; West, James; Newman, John H.; Robbins, Ivan M.; Blackwell, Timothy S.; Loyd, James E.; Kropski, Jonathan A.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, T1218 Med Ctr North,1161 21st Ave South, Nashville, TN 37232 USA.
   [Zhao, Min; Zhao, Zhongming; Gaskill, Christa; Jetter, Christopher; Majka, Susan M.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA.
   [Cogan, Joy] Vanderbilt Univ, Sch Med, Dept Pediat Med Genet, Nashville, TN 37212 USA.
   [Austin, Eric D.] Vanderbilt Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, Nashville, TN 37212 USA.
   [Rich, Stuart] Univ Chicago, Div Cardiol, Chicago, IL 60637 USA.
   [Archer, Stephen L.] Queens Univ, Dept Med, Kingston, ON, Canada.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; University of Chicago; Queens University   Canada
RP Hemnes, AR (通讯作者)，Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, T1218 Med Ctr North,1161 21st Ave South, Nashville, TN 37232 USA.
EM anna.r.hemnes@vanderbilt.edu
RI ; Hemnes, Anna/HDN 4762 2022; Zhao, Min/J 6588 2019; Austin,
   Eric/A 6070 2013; Kropski, Jonathan/LXU 9640 2024; Robbins,
   Ivan/MBH 7238 2025; West, James/E 2960 2010
OI Zhao, Min/0000 0001 5498 3434; West, James/0000 0002 6004 0202; Cogan,
   Joy/0000 0001 8106 1216; Loyd, James/0000 0002 5042 7390
FU National Center for Advancing Translational Sciences [UL1TR000445];
   American Thoracic Society/Pulmonary Hypertension Association; NHLBI [1
   PO1 HL 108800, 5 PO1 HL 092870 05]; Canada Research Chair in
   Mitochondrial Dynamics; William J. Henderson Foundation; National
   Institutes of Health [RO1 HL071115, 1RC1HL099462 01]
FX Supported by Clinical and Translational Science Award UL1TR000445 from
   the National Center for Advancing Translational Sciences; American
   Thoracic Society/Pulmonary Hypertension Association Research grant
   (E.D.A.); NHLBI grant 1 PO1 HL 108800 (E.D.A., J.E.L., A.R.H., J.H.N.,
   I.M.R., and J.W.); NHLBI grant 5 PO1 HL 092870 05 (J.E.L., M.Z., Z.Z.,
   and J.C.); and Canada Research Chair in Mitochondrial Dynamics, William
   J. Henderson Foundation, and National Institutes of Health grants
   RO1 HL071115 and 1RC1HL099462 01 (S.L.A.).
CR Aldred MA, 2006, HUM MUTAT, V27, DOI 10.1002/humu.9398
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Archer SL, 1998, J CLIN INVEST, V101, P2319, DOI 10.1172/JCI333
   Archer SL, 2010, CIRCULATION, V121, P2661, DOI 10.1161/CIRCULATIONAHA.109.916098
   Austin ED, 2012, CIRC CARDIOVASC GENE, V5, P336, DOI 10.1161/CIRCGENETICS.111.961888
   Austin Eric D, 2011, Pulm Circ, V1, P389, DOI 10.4103/2045 8932.87308
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Best DH, 2014, CHEST, V145, P231, DOI 10.1378/chest.13 2366
   Blinov ML, 2014, BIOINFORMATICS, V30, P292, DOI 10.1093/bioinformatics/btt660
   Bowden J, 2009, GENET EPIDEMIOL, V33, P406, DOI 10.1002/gepi.20394
   Chow K, 2013, PULM CIRC, V3, P31, DOI 10.4103/2045 8932.109912
   Cirulli ET, 2010, NAT REV GENET, V11, P415, DOI 10.1038/nrg2779
   Cogan JD, 2015, AM J RESP CRIT CARE, V191, P646, DOI 10.1164/rccm.201408 1510OC
   Das M, 2002, AM J PHYSIOL LUNG C, V282, pL976, DOI 10.1152/ajplung.00382.2001
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Drake KM, 2013, AM J RESP CELL MOL, V49, P403, DOI 10.1165/rcmb.2013 0100OC
   Elliott CG, 2006, CIRCULATION, V113, P2509, DOI 10.1161/CIRCULATIONAHA.105.601930
   Eyries M, 2014, NAT GENET, V46, P65, DOI 10.1038/ng.2844
   Faye LL, 2011, STAT MED, V30, P1898, DOI 10.1002/sim.4228
   Galiè N, 2013, J AM COLL CARDIOL, V62, pD60, DOI 10.1016/j.jacc.2013.10.031
   Germain M, 2013, NAT GENET, V45, P518, DOI 10.1038/ng.2581
   Ghosh A, 2008, AM J HUM GENET, V82, P1064, DOI 10.1016/j.ajhg.2008.03.002
   Guo Q, 2014, HYPERTENS RES, V37, P116, DOI 10.1038/hr.2013.129
   Hemnes AR, 2015, CIRCULATION, V131, P401, DOI 10.1161/CIRCULATIONAHA.114.013317
   Hoeper MM, 2013, J AM COLL CARDIOL, V62, pD42, DOI 10.1016/j.jacc.2013.10.032
   Johnson JA, 2012, AM J PHYSIOL LUNG C, V302, pL474, DOI 10.1152/ajplung.00202.2011
   Kiezun A, 2012, NAT GENET, V44, P623, DOI 10.1038/ng.2303
   Klei L, 2012, MOL AUTISM, V3, DOI 10.1186/2040 2392 3 9
   Lam HYK, 2012, NAT BIOTECHNOL, V30, P78, DOI 10.1038/nbt.2065
   Langleben D, 2015, ANN INTERN MED, V162, P154, DOI 10.7326/M14 1402
   Ma L, 2013, NEW ENGL J MED, V369, P351, DOI 10.1056/NEJMoa1211097
   Newman JH, 2001, NEW ENGL J MED, V345, P319, DOI 10.1056/NEJM200108023450502
   Newman JH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7863
   Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646
   Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499
   Norton N, 2011, AM J HUM GENET, V88, P273, DOI 10.1016/j.ajhg.2011.01.016
   Perez VADJ, 2014, AM J RESP CRIT CARE, V189, P1260, DOI [10.1164/rccm.201310 17490C, 10.1164/rccm.201310 1749OC]
   Perez VADJ, 2009, J CELL BIOL, V184, P83, DOI 10.1083/jcb.200806049
   Picardi E, 2012, NAT METHODS, V9, P523, DOI 10.1038/nmeth.2029
   Plecita Hlavata L, 2015, AM J RESP CELL MOL B, DOI [10.1165/romb.2015 0142OC, DOI 10.1165/ROMB.2015 0142OC]
   RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135
   Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945
   Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI [10.1016/j.jacc.2009.04.012, 10.1016/j.jacc.2013.10.029]
   Sitbon O, 2005, CIRCULATION, V111, P3105, DOI 10.1161/CIRCULATIONAHA.104.488486
   Sun L, 2011, HUM GENET, V129, P545, DOI 10.1007/s00439 011 0948 2
   West JD, 2014, AM J PHYSIOL CELL PH, V307, pC415, DOI 10.1152/ajpcell.00057.2014
   Wojciak Stothard B, 2006, AM J PHYSIOL LUNG C, V290, pL1173, DOI 10.1152/ajplung.00309.2005
   Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483
   Yamamura A, 2013, CIRC RES, V112, P640, DOI 10.1161/CIRCRESAHA.113.300897
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
NR 50
TC 70
Z9 71
U1 1
U2 23
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073 449X
EI 1535 4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD AUG 15
PY 2016
VL 194
IS 4
BP 464
EP 475
DI 10.1164/rccm.201508 1678OC
PG 12
WC Critical Care Medicine; Respiratory System
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Respiratory System
GA DT4JQ
UT WOS:000381446400011
PM 26926454
OA Green Published
DA 2025 08 17
ER

PT J
AU Mishra, SK
   Teotia, AK
   Kumar, A
   Kannan, S
AF Mishra, Sandeep K.
   Teotia, Arun K.
   Kumar, Ashok
   Kannan, Sanjeevi
TI Mechanically tuned nanocomposite coating on titanium metal with
   integrated properties of biofilm inhibition, cell proliferation, and
   sustained drug delivery
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Microwave synthesis; Silver nanoparticles; Nanohybrid; Chitosan;
   Nanoindentation; Naproxen
ID SILVER NANOPARTICLES; GREEN SYNTHESIS; SURFACE WETTABILITY; COMPOSITE
   COATINGS; CHITOSAN; IMPLANT; OSTEOGENESIS; ACTIVATION; MECHANISMS;
   RESISTANCE
AB The clinical success of coated implants in executing biological functions inclusive of sustainable drug release and long term antibacterial activity without antibiotics is critical. To this aim, a nanohybrid of silver nanoparticles (AgNPs) cored in polyvinyl alcohol nanocapsules (Ag PVA NCs) embedded in chitosan (CS) matrix loaded with anti inflammatory drug naproxen was prepared. The synthesized nanohybrids that were subjected to coatings on (3 aminopropyl) triethoxysilane (APTES) treated titanium (Ti) metal exhibited dual role of excellent inhibition on biofilm formation and sustained drug release. These dual characteristics are achieved mainly based on intrinsic antibacterial property of AgNPs and differential entrapment of drug in PVA polymeric shell of AgNPs and CS matrix. The coatings also demonstrated enhanced mechanical properties with increasing inorganic filler and stress shielding on Ti metal. The biocompatibility tests involving adhesion, proliferation and differentiation of osteoblast cells demonstrated the efficacy of Ag PVA NCs embedded in CS matrix as a suitable coating material for orthopedic applications. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Mishra, Sandeep K.; Kannan, Sanjeevi] Pondicherry Univ, Ctr Nanosci & Technol, Pondicherry, India.
   [Teotia, Arun K.; Kumar, Ashok] Indian Inst Technol, Ctr Environm Sci & Engn, Dept Biol Sci & Bioengn, Kanpur, Uttar Pradesh, India.
C3 Pondicherry University; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT)   Kanpur
RP Kannan, S (通讯作者)，Pondicherry Univ, Ctr Nanosci & Technol, Pondicherry, India.
EM para_kanna@yahoo.com
RI Teotia, Arun/AAT 3688 2020; Kumar, Ashok/G 8515 2015; S,
   Kannan/Q 4342 2017; Sanjeevi, Kannan/Q 4342 2017; Mishra, Sandeep
   Kumar/I 7133 2017
OI Kumar, Ashok/0000 0002 4910 9440; Teotia, Arun/0000 0003 0031 6155;
   Sanjeevi, Kannan/0000 0003 2285 4907; Mishra, Sandeep
   Kumar/0000 0002 1016 0206
FU Department of Science and Technology, DST, India [SB/FT/CS 101/2012(SR)]
FX The financial assistance received from the Department of Science and
   Technology, DST [Reference: SB/FT/CS 101/2012(SR)], India is
   acknowledged. The facilities availed from the (1) Central
   Instrumentation Facility (CIF) of Pondicherry University, India, (2)
   Department of Biological Sciences & Bioengineering (BSBE), Indian
   Institute of Technology (IIT), Kanpur, India, (3) Advanced Centre for
   Materials Science (ACMS), IIT Kanpur and (4) Advanced Imaging Centre,
   IIT Kanpur, India are gratefully acknowledged.
CR Arciola CR, 2012, BIOMATERIALS, V33, P5967, DOI 10.1016/j.biomaterials.2012.05.031
   Chandra J., 2001, Natl. Reviiew Microbiol, V9, P109, DOI DOI 10.1128/JB.183.18.5385
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Davies D, 2003, NAT REV DRUG DISCOV, V2, P114, DOI 10.1038/nrd1008
   Di Martino A, 2005, BIOMATERIALS, V26, P5983, DOI 10.1016/j.biomaterials.2005.03.016
   Elyada A, 2014, BIOMACROMOLECULES, V15, P3511, DOI 10.1021/bm5006245
   Eustis S, 2006, CHEM SOC REV, V35, P209, DOI 10.1039/b514191e
   Feng YF, 2013, BIOMATERIALS, V34, P2234, DOI 10.1016/j.biomaterials.2012.12.023
   Gittens RA, 2011, BIOMATERIALS, V32, P3395, DOI 10.1016/j.biomaterials.2011.01.029
   Hajipour MJ, 2012, TRENDS BIOTECHNOL, V30, P499, DOI 10.1016/j.tibtech.2012.06.004
   Hoffman LR, 2005, NATURE, V436, P1171, DOI 10.1038/nature03912
   Horbett T. A., 1982, PROTEIN ADSORPTION B
   Horbett TA, 1996, PROTEINS STRUCTURE P
   Hu B, 2008, J PHYS CHEM C, V112, P11169, DOI 10.1021/jp801267j
   Huang YH, 2014, ACS APPL MATER INTER, V6, P20324, DOI 10.1021/am5057213
   Kahrilas GA, 2014, ACS SUSTAIN CHEM ENG, V2, P367, DOI 10.1021/sc4003664
   Kayal S, 2010, MAT SCI ENG C MATER, V30, P484, DOI 10.1016/j.msec.2010.01.006
   Khor E, 2003, BIOMATERIALS, V24, P2339, DOI 10.1016/S0142 9612(03)00026 7
   Kim JS, 2007, NANOMED NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Li X, 2015, BIOMATERIALS, V36, P44, DOI 10.1016/j.biomaterials.2014.09.012
   Liz Marzán LM, 2006, LANGMUIR, V22, P32, DOI 10.1021/la0513353
   Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469 0691.2011.03570.x
   Matsumura S, 1999, MACROMOLECULES, V32, P7753, DOI 10.1021/ma990727b
   Michiardi A, 2007, BIOMATERIALS, V28, P586, DOI 10.1016/j.biomaterials.2006.09.040
   Mishra SK, 2015, CARBOHYD POLYM, V121, P37, DOI 10.1016/j.carbpol.2014.12.027
   Mishra SK, 2014, J MECH BEHAV BIOMED, V40, P314, DOI 10.1016/j.jmbbm.2014.08.014
   Noimark S, 2015, ADV FUNCT MATER, V25, P1367, DOI 10.1002/adfm.201402980
   Oliver WC, 2004, J MATER RES, V19, P3, DOI 10.1557/jmr.2004.19.1.3
   Park JH, 2012, BIOMATERIALS, V33, P7386, DOI 10.1016/j.biomaterials.2012.06.066
   Park JH, 2012, BIOMATERIALS, V33, P5267, DOI 10.1016/j.biomaterials.2012.03.074
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   SCHWARTZ Z, 1994, J CELL BIOCHEM, V56, P340, DOI 10.1002/jcb.240560310
   Sharma S, 2016, NANOMED NANOTECHNOL, V12, P1193, DOI 10.1016/j.nano.2015.12.385
   Sharma VK, 2009, ADV COLLOID INTERFAC, V145, P83, DOI 10.1016/j.cis.2008.09.002
   Shi YY, 2016, J MATER SCI MATER M, V27, DOI 10.1007/s10856 015 5634 9
   Song JK, 2016, NANOMED NANOTECHNOL, V12, P1357, DOI 10.1016/j.nano.2016.02.005
   Sun HJ, 2014, ACS NANO, V8, P6202, DOI 10.1021/nn501640q
   Teotia RS, 2015, ACS BIOMATER SCI ENG, V1, P372, DOI 10.1021/ab500061j
   Thet NT, 2015, ACS APPL MATER INTER, V7, P8932
   Trajkovski B, 2012, ADV DRUG DELIVER REV, V64, P1142, DOI 10.1016/j.addr.2012.05.016
   Xu LC, 2007, BIOMATERIALS, V28, P3273, DOI 10.1016/j.biomaterials.2007.03.032
   Yoshinari M, 2001, BIOMATERIALS, V2043 2048, P22
   Zajac A, 2015, SPECTROCHIM ACTA A, V134, P114, DOI 10.1016/j.saa.2014.06.071
   Zhang Y, 2013, J CELL BIOCHEM, V114, P2595, DOI 10.1002/jcb.24607
   Zhong ZY, 2015, MAT SCI ENG C MATER, V49, P251, DOI 10.1016/j.msec.2015.01.020
   Zhu HB, 2012, BIOMATERIALS, V33, P3058, DOI 10.1016/j.biomaterials.2012.01.003
NR 46
TC 21
Z9 21
U1 1
U2 53
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JAN
PY 2017
VL 13
IS 1
BP 23
EP 35
DI 10.1016/j.nano.2016.08.010
PG 13
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA EO0HF
UT WOS:000396378200003
PM 27558354
DA 2025 08 17
ER

PT J
AU Pérez Campo, FM
   Riancho, JA
AF Perez Campo, Flor M.
   Riancho, Jose A.
TI Epigenetic Mechanisms Regulating Mesenchymal Stem Cell Differentiation
SO CURRENT GENOMICS
LA English
DT Article
DE Epigenetics; Bone; Osteoporosis; Mesenchymal stem cells; Histone
   acetylation; Histone methylation; DNA methylation
ID HISTONE DEACETYLASE INHIBITORS; PROMOTER DNA METHYLATION; UMBILICAL CORD
   BLOOD; MARROW STROMAL CELLS; HUMAN ADIPOSE TISSUE; OSTEOGENIC
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; GENE EXPRESSION;
   BONE MARROW; OSTEOCALCIN GENE
AB Human Mesenchymal Stem Cells (hMSCs) have emerged in the last few years as one of the most promising therapeutic cell sources and, in particular, as an important tool for regenerative medicine of skeletal tissues. Although they present a more restricted potency than Embryonic Stem (ES) cells, the use of hMCS in regenerative medicine avoids many of the drawbacks characteristic of ES cells or induced pluripotent stem cells. The challenge in using these cells lies into developing precise protocols for directing cellular differentiation to generate a specific cell lineage. In order to achieve this goal, it is of the upmost importance to be able to control de process of fate decision and lineage commitment. This process requires the coordinate regulation of different molecular layers at transcriptional, posttranscriptional and translational levels. At the transcriptional level, switching on and off different sets of genes is achieved not only through transcriptional regulators, but also through their interplay with epigenetic modifiers. It is now well known that epigenetic changes take place in an orderly way through development and are critical in the determination of lineage specific differentiation. More importantly, alteration of these epigenetic changes would, in many cases, lead to disease generation and even tumour formation. Therefore, it is crucial to elucidate how epigenetic factors, through their interplay with transcriptional regulators, control lineage commitment in hMSCs.
C1 [Perez Campo, Flor M.; Riancho, Jose A.] Univ Cantabria, Hosp Univ Marques Valdecilla IDIVAL, Dept Internal Med, Santander 39008, Cantabria, Spain.
C3 Universidad de Cantabria; Hospital Universitario Marques de Valdecilla
   (HUMV)
RP Pérez Campo, FM (通讯作者)，Univ Cantabria, Hosp Univ Marques Valdecilla IDIVAL, Dept Internal Med, Santander 39008, Cantabria, Spain.
EM f.perezcampo@unican.es
OI Perez Campo, Flor Maria/0000 0002 9872 7990
FU Instituto de Salud Carlos III European Union FEDER funds [PI 12/615]
FX Suppoted by a grant from Instituto de Salud Carlos III European Union
   FEDER funds (PI 12/615).
CR Addison WN, 2014, MOL CELL BIOL, V34, P3076, DOI 10.1128/MCB.00185 14
   Agger K, 2008, CURR OPIN GENET DEV, V18, P159, DOI 10.1016/j.gde.2007.12.003
   Alison M, 1998, J HEPATOL, V29, P676, DOI 10.1016/S0168 8278(98)80165 7
   Anjos Afonso F, 2004, J CELL SCI, V117, P5655, DOI 10.1242/jcs.01488
   Aranda P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007809
   Arnsdorf EJ, 2010, J BIOMECH, V43, P2881, DOI 10.1016/j.jbiomech.2010.07.033
   Asp P, 2011, P NATL ACAD SCI USA, V108, pE149, DOI 10.1073/pnas.1102223108
   BARTEL RL, 1984, MOL PHARMACOL, V25, P418
   Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003
   Ben Porath I, 2001, MOL CELL, V8, P933, DOI 10.1016/S1097 2765(01)00399 9
   Berdasco M, 2012, AM J PATHOL, V181, P2079, DOI 10.1016/j.ajpath.2012.08.016
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030
   Bibikova M, 2006, GENOME RES, V16, P1075, DOI 10.1101/gr.5319906
   Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124 2135.2002
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092 8674(00)81532 9
   Boquest AC, 2007, STEM CELLS, V25, P852, DOI 10.1634/stemcells.2006 0428
   Borgel J, 2010, NAT GENET, V42, P1093, DOI 10.1038/ng.708
   Brewer S, 2004, DEV BIOL, V267, P135, DOI 10.1016/j.ydbio.2003.10.039
   Calvanese V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003294
   Chan MF, 2001, MOL CELL BIOL, V21, P7587, DOI 10.1128/MCB.21.22.7587 7600.2001
   Chen CC, 2013, J BIOL CHEM, V288, P9084, DOI 10.1074/jbc.M112.445585
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   Cho YD, 2014, J BIOL CHEM, V289, P20120, DOI 10.1074/jbc.M114.558064
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Cohen Kfir E, 2011, ENDOCRINOLOGY, V152, P4514, DOI 10.1210/en.2011 1128
   Collas P, 2010, EPIGENETICS US, V5, DOI 10.4161/epi.5.6.12517
   Conrad S, 2008, NATURE, V456, P344, DOI 10.1038/nature07404
   Davis CD, 2007, NUTR REV, V65, P88, DOI 10.1301/nr.2007.feb.88 94
   De Boer J, 2006, TISSUE ENG, V12, P2927
   Delgado Calle J, 2012, J BONE MINER RES, V27, P926, DOI 10.1002/jbmr.1491
   Delgado Calle J, 2012, EPIGENETICS US, V7, P83, DOI 10.4161/epi.7.1.18753
   Delgado Calle J, 2011, BONE, V49, P830, DOI 10.1016/j.bone.2011.06.006
   Di Bernardo G, 2009, STEM CELLS DEV, V18, P573, DOI 10.1089/scd.2008.0172
   El Serafi AT, 2011, DIFFERENTIATION, V81, P35, DOI 10.1016/j.diff.2010.09.183
   Erickson GR, 2002, BIOCHEM BIOPH RES CO, V290, P763, DOI 10.1006/bbrc.2001.6270
   Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913
   Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206
   Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007
   Fouse SD, 2008, CELL STEM CELL, V2, P160, DOI 10.1016/j.stem.2007.12.011
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630 06
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849
   Gupta RK, 2010, NATURE, V464, P619, DOI 10.1038/nature08816
   Gurkan UA, 2008, ANN BIOMED ENG, V36, P1978, DOI 10.1007/s10439 008 9577 x
   Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200
   Haasper C, 2008, EXP TOXICOL PATHOL, V59, P355, DOI [10.1016/j.etp.2007.11.008, 10.1016/j.etp.2007.11.013]
   Håkelien AM, 2014, STEM CELLS, V32, P2780, DOI 10.1002/stem.1759
   Halvorsen YDC, 2001, METABOLISM, V50, P407, DOI 10.1053/meta.2001.21690
   Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02 06 0356
   Hatzfeld A, 2007, LEUKEMIA, V21, P714, DOI 10.1038/sj.leu.2404589
   Haudenschild AK, 2009, ANN BIOMED ENG, V37, P492, DOI 10.1007/s10439 008 9629 2
   Hermes M, 2004, EXP CELL RES, V294, P325, DOI 10.1016/j.yexcr.2003.12.001
   Hsiao SH, 2010, BIOCHEM BIOPH RES CO, V400, P305, DOI 10.1016/j.bbrc.2010.08.048
   Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang HY, 2009, P NATL ACAD SCI USA, V106, P12670, DOI 10.1073/pnas.0906266106
   Huang J, 2008, CURR OPIN GENET DEV, V18, P152, DOI 10.1016/j.gde.2008.01.012
   Huang K, 2014, HUM MOL GENET, V23, P6448, DOI 10.1093/hmg/ddu365
   Huynh KD, 2000, GENE DEV, V14, P1810
   IWAMI K, 1993, INT J BIOCHEM, V25, P1631, DOI 10.1016/0020 711X(93)90522 G
   Jackson Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jagodzinski M, 2008, J BIOMECH, V41, P1885, DOI 10.1016/j.jbiomech.2008.04.001
   Javed A, 1999, MOL CELL BIOL, V19, P7491
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Jilka RL, 2003, MED PEDIATR ONCOL, V41, P182, DOI 10.1002/mpo.10334
   Jin WZ, 2006, DEV CELL, V10, P461, DOI 10.1016/j.devcel.2006.02.016
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797
   Kang MI, 2007, J CELL BIOCHEM, V102, P224, DOI 10.1002/jcb.21291
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064
   Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Kim SH, 2007, EPILEPSY BEHAV, V10, P291, DOI 10.1016/j.yebeh.2006.11.007
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Koç ON, 2001, BONE MARROW TRANSPL, V27, P235, DOI 10.1038/sj.bmt.1702791
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lagarkova MA, 2006, CELL CYCLE, V5, P416, DOI 10.4161/cc.5.4.2440
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Lee JY, 2006, MOL CELLS, V22, P182
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood 2003 05 1670
   Lee S, 2009, CELL PROLIFERAT, V42, P711, DOI 10.1111/j.1365 2184.2009.00633.x
   Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002
   Li Y, 2011, BIOPHYS J, V100, P1902, DOI 10.1016/j.bpj.2011.03.008
   MARGOLIS J, 1995, DEVELOPMENT, V121, P3797
   McCauley LK, 2010, J CLIN INVEST, V120, P3440, DOI 10.1172/JCI44786
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Melton LJ, 1998, J BONE MINER RES, V13, P1915, DOI 10.1359/jbmr.1998.13.12.1915
   Misof BM, 2012, J BONE MINER RES, V27, P2551, DOI 10.1002/jbmr.1699
   Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007
   Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013
   Nayak A, 2014, MOL CELL, V55, P47, DOI 10.1016/j.molcel.2014.05.011
   Nissen Meyer LSH, 2007, EPILEPSIA, V48, P1850, DOI 10.1111/j.1528 1167.2007.01176.x
   Paredes R, 2002, BIOCHEM J, V363, P667, DOI 10.1042/0264 6021:3630667
   Pelaez D, 2012, BIOCHEM BIOPH RES CO, V417, P1286, DOI 10.1016/j.bbrc.2011.12.131
   Pelletier N, 2002, ONCOGENE, V21, P2729, DOI 10.1038/sj.onc.1205367
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246
   Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100
   Qiu J, 2006, NATURE, V441, P143, DOI 10.1038/441143a
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092 8674(02)00644 X
   Sánchez C, 2007, MOL CELL PROTEOMICS, V6, P820, DOI 10.1074/mcp.M600275 MCP200
   Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445
   Schmitz KM, 2009, MOL CELL, V33, P344, DOI 10.1016/j.molcel.2009.01.015
   Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0
   Schroeder TM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 362
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schwarz D, 2014, DEVELOPMENT, V141, P867, DOI 10.1242/dev.094342
   Senn SM, 2010, EPILEPSIA, V51, P984, DOI 10.1111/j.1528 1167.2009.02516.x
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339 3351.2003
   Sorensen AL, 2010, STEM CELLS DEV, V19, P1257, DOI 10.1089/scd.2009.0309
   Sorensen AL, 2010, MOL BIOL CELL, V21, P2066, DOI 10.1091/mbc.E10 01 0018
   Takanashi M, 2009, AM J PATHOL, V174, P309, DOI 10.2353/ajpath.2009.080148
   Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005 0620
   Tsai CC, 2012, MOL CELL, V47, P169, DOI 10.1016/j.molcel.2012.06.020
   Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221
   Tsukahara H, 2002, PEDIATR INT, V44, P247, DOI 10.1046/j.1442 200X.2002.01561.x
   Vaes BLT, 2010, BONE, V46, P514, DOI 10.1016/j.bone.2009.09.033
   Vaissière T, 2008, MUTAT RES REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Van Hoof D, 2009, CELL STEM CELL, V5, P214, DOI 10.1016/j.stem.2009.05.021
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113
   Vincent A, 2009, DIFFERENTIATION, V78, P99, DOI 10.1016/j.diff.2009.07.002
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wang CY, 2013, J BONE MINER METAB, V31, P381, DOI 10.1007/s00774 013 0428 y
   Wang LF, 2013, EMBO J, V32, P45, DOI 10.1038/emboj.2012.306
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139
   Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442
   Xu J, 2013, INT J ORAL SCI, V5, P200, DOI 10.1038/ijos.2013.77
   Yan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090846
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Zhang RP, 2011, J BIOL CHEM, V286, P41083, DOI 10.1074/jbc.M111.258715
   Zhou G.S., 2009, Cytotechnology
   Zhu XW, 2014, EUR REV MED PHARMACO, V18, P3004
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 151
TC 39
Z9 44
U1 1
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 2029
EI 1875 5488
J9 CURR GENOMICS
JI Curr. Genomics
PY 2015
VL 16
IS 6
BP 368
EP 383
DI 10.2174/1389202916666150817202559
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CS2EJ
UT WOS:000361880300002
PM 27019612
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Jin, W
   Chen, BB
   Li, JY
   Zhu, H
   Huang, M
   Gu, SM
   Wang, QQ
   Chen, JY
   Yu, SJ
   Wu, J
   Shao, ZM
AF Jin, Wei
   Chen, Bo bin
   Li, Ji yu
   Zhu, Hua
   Huang, Mark
   Gu, Sheng mei
   Wang, Qiao qiao
   Chen, Jia ying
   Yu, Sanjian
   Wu, Jiong
   Shao, Zhi ming
TI TIEG1 Inhibits Breast Cancer Invasion and Metastasis by Inhibition of
   Epidermal Growth Factor Receptor (EGFR) Transcription and the EGFR
   Signaling Pathway
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID INDUCIBLE EARLY GENE; HUMAN OSTEOBLASTS; HUMAN P53; PROMOTER; CELLS;
   EXPRESSION; IDENTIFICATION; APOPTOSIS; THERAPY; POLYMORPHISM
AB TIEG1 can induce apoptosis of cancer cells, but its role in inhibiting invasion and metastasis has not been reported and is unclear. In this study, we find that decreased TIEG1 expression is associated with increased human epidermal growth factor receptor (EGFR) expression in breast cancer tissues and cell lines. TIEG1 plays an important role in suppressing transcription of EGFR by directly binding to the EGFR promoter. While overexpression of TIEG1 attenuates EGFR expression, knockdown of TIEG1 stimulates EGFR expression. Furthermore, TIEG1 and HDAC1 form a complex, which binds to Sp1 sites on the EGFR promoter and inhibits its transcription by suppressing histone acetylation. TIEG1 significantly inhibits breast cancer cell invasion, suppresses mammary tumorigenesis in xenografts in mice, and decreases lung metastasis by inhibition of EGFR gene transcription and the EGFR signaling pathway. Therefore, TIEG1 is an antimetastasis gene product; regulation of EGFR expression by TIEG1 may be part of an integral signaling pathway that determines and explains breast cancer invasion and metastasis.
C1 [Jin, Wei; Li, Ji yu; Gu, Sheng mei; Wang, Qiao qiao; Chen, Jia ying; Yu, Sanjian; Wu, Jiong; Shao, Zhi ming] Fudan Univ, Dept Breast Surg, Breast Canc Inst, Shanghai Canc Ctr,Dept Oncol,Shanghai Med Coll, Shanghai 200433, Peoples R China.
   [Chen, Bo bin] Fudan Univ, Dept Hematol, Huashan Hosp, Shanghai 200433, Peoples R China.
   [Zhu, Hua; Huang, Mark] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Canc Inst New Jersey, New Brunswick, NJ USA.
C3 Fudan University; Fudan University; Rutgers University System; Rutgers
   University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers Cancer Institute of New Jersey
RP Wu, J (通讯作者)，Fudan Univ, Dept Breast Surg, Breast Canc Inst, Shanghai Canc Ctr,Dept Oncol,Shanghai Med Coll, Shanghai 200433, Peoples R China.
EM wujiong1122@vip.sina.com; zhimingshao@yahoo.com
RI Li, Jiyu/GLT 7360 2022; chen, jiaying/LIA 9732 2024; wang,
   qiaoqiao/AAP 1027 2020; Wu, Jiong/LFT 4903 2024; Zhu, Hua/G 4409 2010
OI Zhu, Hua/0000 0001 7136 7326; 
FU National Natural Science Foundation of China [81072166]; National Basic
   Research Program of China [2010CB834305]; Shanghai Municipal Education
   Commission [09ZZ04]; Natural Science Foundation of Science and
   Technology Commission of Shanghai Municipality [09ZR1406900]; Shanghai
   Pujiang Program
FX The work was supported by grants from National Natural Science
   Foundation of China (81072166), National Basic Research Program of China
   (2010CB834305), Innovation Program of Shanghai Municipal Education
   Commission (grant 09ZZ04), the Natural Science Foundation of Science and
   Technology Commission of Shanghai Municipality (grant 09ZR1406900), and
   Shanghai Pujiang Program (2008).
CR Alvarez Rodiguez R, 2007, J BIOL CHEM, V282, P37170, DOI 10.1074/jbc.M705414200
   Baselga J, 2002, ANN ONCOL, V13, P8, DOI 10.1093/annonc/mdf092
   Brandt B, 2006, CLIN CANCER RES, V12, P7252, DOI 10.1158/1078 0432.CCR 06 0626
   Capdevila J, 2009, CANCER TREAT REV, V35, P354, DOI 10.1016/j.ctrv.2009.02.001
   Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014 5793(99)01051 0
   Chang XZ, 2008, BREAST CANCER RES TR, V111, P65, DOI 10.1007/s10549 007 9761 y
   Clem BF, 2006, MOL ENDOCRINOL, V20, P100, DOI 10.1210/me.2004 0495
   Dahl KDC, 2008, CANCER RES, V68, P4606, DOI 10.1158/0008 5472.CAN 07 5046
   DEB SP, 1994, ONCOGENE, V9, P1341
   Feng LY, 2009, CLIN CANCER RES, V15, P2962, DOI 10.1158/1078 0432.CCR 08 2495
   Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002
   Grossmann C, 2007, AM J PHYSIOL ENDOC M, V292, pE1790, DOI 10.1152/ajpendo.00708.2006
   Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519
   Hirota T, 2010, GENES CELLS, V15, P111, DOI 10.1111/j.1365 2443.2009.01371.x
   Huang Y, 2004, CANCER RES, V64, P2712, DOI 10.1158/0008 5472.CAN 03 3184
   HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536
   Jin W, 2007, FEBS LETT, V581, P3826, DOI 10.1016/j.febslet.2007.07.008
   Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065 230X(08)60765 4
   Liu WQ, 2005, CANCER RES, V65, P46
   Liu WQ, 2003, CLIN CANCER RES, V9, P1009
   Liu ZB, 2010, ONCOGENE, V29, P2996, DOI 10.1038/onc.2010.70
   LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009
   Peng SC, 2010, NUCLEIC ACIDS RES, V38, P7446, DOI 10.1093/nar/gkq634
   Pitteri SJ, 2010, CANCER RES, V70, P8598, DOI 10.1158/0008 5472.CAN 10 1676
   Pore N, 2006, CANCER RES, V66, P3197, DOI 10.1158/0008 5472.CAN 05 3090
   PUSZTAI L, 1993, J PATHOL, V169, P191, DOI 10.1002/path.1711690204
   Reinholz MM, 2004, BREAST CANCER RES TR, V86, P75, DOI 10.1023/B:BREA.0000032926.74216.7d
   Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620
   Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907
   Subramaniam M, 2010, BIOCHEM BIOPH RES CO, V392, P72, DOI 10.1016/j.bbrc.2009.12.171
   Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418
   Tau KR, 1998, ENDOCRINOLOGY, V139, P1346, DOI 10.1210/en.139.3.1346
   Toulany M, 2007, MOL CANCER RES, V5, P863, DOI 10.1158/1541 7786.MCR 06 0297
   van Diest PJ, 2006, CLIN CANCER RES, V12, P670, DOI 10.1158/1078 0432.CCR 05 2098
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278
   Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041 5049.2001
   ZHELEZNOVA NN, 2010, BIOCHIM BIOPHYS ACTA, V1812, P1301
   ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225
NR 40
TC 52
Z9 64
U1 0
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0270 7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JAN
PY 2012
VL 32
IS 1
BP 50
EP 63
DI 10.1128/MCB.06152 11
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 866FN
UT WOS:000298366000005
PM 22025675
OA Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Sandomierski, M
   Jakubowski, M
   Gajewski, P
   Szczesniak, K
   Voelkel, A
AF Sandomierski, Mariusz
   Jakubowski, Marcel
   Gajewski, Piotr
   Szczesniak, Katarzyna
   Voelkel, Adam
TI Hydrogels with Phosphate Groups as Potential Carriers of Bisphosphonates
SO JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS
LA English
DT Article
DE Hydrogel; Bisphosphonate; Risedronate; Drug delivery; Carrier
ID BURST RELEASE; OSTEOPOROSIS; DELIVERY; MANAGEMENT; MECHANISMS; MODEL
AB Hydrogels are potential materials in many biomedical applications. A particularly promising application is their use in bone tissue engineering as implants or layers on the surface of titanium alloys. Disadvantage in the use of hydrogels in drug release system is often "burst release" effect what obstructs controlled release of pharmaceutically active agent. This functionality can be obtained by using an appropriate hydrogel, which has in its structure ions to which the drug is complexed. In this work, hydrogel materials containing mers with phosphate groups were prepared and used in the controlled drug release. The prepared material was functionalized with Ca2+, Mg2+, and Sr2+ ions. These ions were chosen because they support the osseointegration process. The possibility of sorption of the drug for osteoporosis (risedronate) was tested on the prepared hydrogels. Sorption was effective only on the hydrogel with calcium ions. The drug was evenly distributed throughout the hydrogel. The new hydrogel has proven to be able to retain the drug and slowly release it in small doses. We assume that the prepared material has the potential to be used as a coating for bone implants or as an implantable hydrogel for people suffering from osteoporosis.
C1 [Sandomierski, Mariusz; Jakubowski, Marcel; Gajewski, Piotr; Szczesniak, Katarzyna; Voelkel, Adam] Poznan Univ Tech, Inst Chem Technol & Engn, Ul Berdychowo 4, PL 60965 Poznan, Poland.
   [Szczesniak, Katarzyna] Adam Mickiewicz Univ, NanoBioMed Ctr, Ul Wszechnicy Piastowskiej 3, PL 61614 Poznan, Poland.
C3 Poznan University of Technology; Adam Mickiewicz University
RP Sandomierski, M (通讯作者)，Poznan Univ Tech, Inst Chem Technol & Engn, Ul Berdychowo 4, PL 60965 Poznan, Poland.
EM mariusz.sandomierski@put.poznan.pl
RI Voelkel, Adam/P 2904 2019; Szcześniak, Katarzyna/T 3542 2019; Gajewski,
   Piotr/H 5703 2015
OI Sandomierski, Mariusz/0000 0001 8227 8062; 
FU This research was funded by the Ministry of Education and Science
   (Poland). Mariusz Sandomierski was supported by the Foundation for
   Polish Sciences (FNP). Authors would like to acknowledge the National
   Centre for Research and Development, Poland, grant nu; Ministry of
   Education and Science (Poland); Foundation for Polish Sciences (FNP)
   [DWM/WPC2/285/2020]; National Centre for Research and Development,
   Poland
FX This research was funded by the Ministry of Education and Science
   (Poland). Mariusz Sandomierski was supported by the Foundation for
   Polish Sciences (FNP). Authors would like to acknowledge the National
   Centre for Research and Development, Poland, grant number
   DWM/WPC2/285/2020, for help in SEM imaging.
CR Abtahi J, 2013, J DENT RES, V92, P279, DOI 10.1177/0022034512472335
   [Anonymous], 2018, POLYM ADVAN TECHNOL, DOI [10.1002/pat.4233, DOI 10.1002/PAT.4233]
   Bisphosphonates, BISPH MECH ACT ROL C
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   da Silva EP, 2016, RSC ADV, V6, P19060, DOI 10.1039/c5ra27865a
   Ferrari R, 2018, NANOSCALE, V10, P22701, DOI 10.1039/c8nr05933k
   Fleisch H., 2002, PRINCIPLES BONE BIOL, V2nd, P1361
   Fu J, 2018, NEW J CHEM, V42, P17162, DOI 10.1039/c8nj03482f
   Gajewski P, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13203495
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Greenwood N.N., 1997, Chem. Elem, V2nd, P107, DOI [DOI 10.1016/B978 0 7506 3365 9.50011 0, 10.1016/B978 0 7506 3365 9.50011 0]
   Guimaraes MB, 2017, INT J ORAL MAX SURG, V46, P1429, DOI 10.1016/j.ijom.2017.04.014
   Huang X, 2001, J CONTROL RELEASE, V73, P121, DOI 10.1016/S0168 3659(01)00248 6
   Jakubowski M, 2023, SPECTROCHIM ACTA A, V297, DOI 10.1016/j.saa.2023.122748
   Jiang YL, 2020, NPG ASIA MATER, V12, DOI 10.1038/s41427 020 0199 6
   Kemal E, 2011, J MATER CHEM, V21, P2237, DOI 10.1039/c0jm02984j
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Krajewska B, 2004, ENZYME MICROB TECH, V35, P126, DOI 10.1016/j.enzmictec.2003.12.013
   Liu YW, 2020, NEW J CHEM, V44, P4092, DOI 10.1039/d0nj00214c
   Mahanta AK, 2019, MOL PHARMACEUT, V16, P327, DOI 10.1021/acs.molpharmaceut.8b00995
   Narayanaswamy R, 2019, MOLECULES, V24, DOI 10.3390/molecules24030603
   Parameswaran Thankam A, 2018, ACS OMEGA, V3, P15158, DOI 10.1021/acsomega.8b01765
   Pazianas M, 2011, BONE, V49, P103, DOI 10.1016/j.bone.2011.01.003
   Poole KES, 2006, BMJ BRIT MED J, V333, P1251, DOI 10.1136/bmj.39050.597350.47
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sahana H, 2013, J BIOMED NANOTECHNOL, V9, P193, DOI 10.1166/jbn.2013.1482
   Sánchez Fernández MJ, 2019, ADV MATER INTERFACES, V6, DOI 10.1002/admi.201802021
   Soares AP, 2016, ENVIRON TOXICOL PHAR, V42, P212, DOI 10.1016/j.etap.2016.01.015
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Talebian S, 2018, ADV MATER, V30, DOI 10.1002/adma.201706665
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Vassaki M, 2021, APPL SCI BASEL, V11, DOI 10.3390/app112311383
   Vigata M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121188
   Wang WQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020487
   Zhang KY, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201701642
NR 37
TC 1
Z9 1
U1 1
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1574 1443
EI 1574 1451
J9 J INORG ORGANOMET P
JI J. Inorg. Organomet. Polym. Mater.
PD MAR
PY 2024
VL 34
IS 3
BP 1293
EP 1300
DI 10.1007/s10904 023 02871 x
EA OCT 2023
PG 8
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA MR4V3
UT WOS:001093516800001
OA hybrid
DA 2025 08 17
ER

PT J
AU Mentink, A
   Hulsman, M
   Groen, N
   Licht, R
   Dechering, KJ
   van der Stok, J
   Alves, HA
   Dhert, WJ
   van Someren, EP
   Reinders, MJT
   van Blitterswijk, CA
   de Boer, J
AF Mentink, Anouk
   Hulsman, Marc
   Groen, Nathalie
   Licht, Ruud
   Dechering, Koen J.
   van der Stok, Johan
   Alves, Hugo A.
   Dhert, Wouter J.
   van Someren, Eugene P.
   Reinders, Marcel J. T.
   van Blitterswijk, Clemens A.
   de Boer, Jan
TI Predicting the therapeutic efficacy of MSC in bone tissue engineering
   using the molecular marker CADM1
SO BIOMATERIALS
LA English
DT Article
DE Bone tissue engineering; Mesenchymal stromal cells; Diagnostic marker;
   Gene expression profiling; CADM1
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; IN VIVO; ADHESION
   MOLECULE; DONOR VARIATION; DIFFERENTIATION; RECEPTOR; CANCER;
   CHONDROCYTES; EXPRESSION
AB Mesenchymal stromal cells (hMSCs) are advancing into the clinic but the therapeutic efficacy of hMSCs faces the problem of donor variability. In bone tissue engineering, no reliable markers have been identified which are able to predict the bone forming capacity of hMSCs prior to implantation. To this end, we isolated hMSCs from 62 donors and characterized systematically their in vitro lineage differentiation capacity, gene expression signature and in vivo capacity for ectopic bone formation. Our data confirms the large variability of in vitro differentiation capacity which did not correlate with in vivo ectopic bone formation. Using DNA microarray analysis of early passage hMSCs we identified a diagnostic bone forming classifier. In fact, a single gene, CADM1, strongly correlated with the bone forming capacity of hMSCs and could be used as a reliable in vitro diagnostic marker. Furthermore, data mining of genes expressed correlating with in vivo bone formation represented involvement in neurogenic processes and Wnt signaling. We will apply our data set to predict therapeutic efficacy of hMSCs and to gain novel insight in the process of bone regeneration. Our bio informatics driven approach may be used in other fields of cell therapy to establish diagnostic markers for clinical efficacy. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Mentink, Anouk; Groen, Nathalie; Licht, Ruud; Alves, Hugo A.; van Blitterswijk, Clemens A.; de Boer, Jan] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Tissue Regenerat, NL 7522 NB Enschede, Netherlands.
   [Hulsman, Marc; van Someren, Eugene P.; Reinders, Marcel J. T.] Delft Univ Technol, Delft Bioinformat Lab, Fac Elect Engn Math & Comp Sci, Delft, Netherlands.
   [Dechering, Koen J.] Schering Plough Res Inst, Dept Pharmacol, Oss, Netherlands.
   [van der Stok, Johan] Univ Med Ctr Rotterdam, Erasmus MC, Orthoped Res Lab, Dept Orthopaed, Rotterdam, Netherlands.
   [Dhert, Wouter J.] Univ Med Ctr Utrecht, Div Surg Specialties, Dept Orthopaed, Utrecht, Netherlands.
C3 University of Twente; Delft University of Technology; Merck & Company;
   Merck & Company Netherlands; Erasmus University Rotterdam; Erasmus MC;
   Utrecht University; Utrecht University Medical Center
RP de Boer, J (通讯作者)，Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Tissue Regenerat, Drienerlolaan 5, NL 7522 NB Enschede, Netherlands.
EM j.deboer@tnw.utwente.nl
OI Dhert, Wouter/0000 0001 9150 6143; van Blitterswijk,
   Clemens/0000 0003 2371 4615; de Boer, Jan/0000 0001 9188 9324
FU Smart Mix Program of the Netherlands Ministry of Economic Affairs;
   Netherlands Ministry of Education, Culture and Science; SenterNovem;
   VIDI
FX We thank the Central Laboratory Animal Institute in Utrecht for taking
   good care of our animals and the Department of Medical Oncology,
   University Medical Center Groningen for providing us with hSCLC cells.
   Funding: The authors gratefully acknowledge the support of the Smart Mix
   Program of the Netherlands Ministry of Economic Affairs and the
   Netherlands Ministry of Education, Culture and Science (AM, JdB),
   SenterNovem (JdB, MR, RL, AM, CvB), DPTE (HA, RL) and VIDI (JdB).
CR Alves H, 2010, J CELL MOL MED, V14, P2729, DOI 10.1111/j.1582 4934.2009.00931.x
   Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086 199608000 00037
   Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301 472X(00)00160 0
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356
   Both SK, 2007, TISSUE ENG, V13, P3, DOI 10.1089/ten.2005.0513
   Burns JS, 2010, TISSUE ENG PT A, V16, P2331, DOI [10.1089/ten.tea.2009.0735, 10.1089/ten.TEA.2009.0735]
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460
   Chatterjea A, 2012, J TISSUE ENG REGEN M, V6, P103, DOI 10.1002/term.403
   Cheng ZQ, 2007, ENDOCRINOLOGY, V148, P4984, DOI 10.1210/en.2007 0653
   Cobb J, 2006, P NATL ACAD SCI USA, V103, P4511, DOI 10.1073/pnas.0510544103
   De Bari C, 2008, ARTHRITIS RHEUM, V58, P240, DOI 10.1002/art.23143
   de Boer J, 2004, BONE, V34, P818, DOI 10.1016/j.bone.2004.01.016
   De Boer J, 2006, TISSUE ENG, V12, P2927
   de Bruijn J D, 1999, Adv Dent Res, V13, P74
   Dell'Accio F, 2001, ARTHRITIS RHEUM US, V44, P1608, DOI 10.1002/1529 0131(200107)44:7<1608::AID ART284>3.0.CO;2 T
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Djouad F, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2153
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Drabek K, 2011, J BONE MINER RES, V26, P2045, DOI 10.1002/jbmr.435
   Fernandes H, 2010, TISSUE ENG PT A, V16, P1693, DOI 10.1089/ten.TEA.2009.0341
   French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002 9440(10)63348 2
   Fujita E, 2006, MOL CELL BIOL, V26, P718, DOI 10.1128/MCB.26.2.718 726.2006
   Galuska SP, 2010, P NATL ACAD SCI USA, V107, P10250, DOI 10.1073/pnas.0912103107
   Hasstedt SJ, 2009, BLOOD, V114, P3084, DOI 10.1182/blood 2009 05 219485
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Ito Akihiko, 2008, Journal of Smooth Muscle Research, V44, P83, DOI 10.1540/jsmr.44.83
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934
   Larsen KH, 2010, J BONE MINER RES, V25, P796, DOI 10.1359/jbmr.091018
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   López Bendito G, 2002, EUR J NEUROSCI, V15, P1766, DOI 10.1046/j.1460 9568.2002.02032.x
   Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415
   Meijer GJ, 2007, INT J ORAL MAX SURG, V36, P646, DOI 10.1016/j.ijom.2007.02.002
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Mendes SC, 2004, J MATER SCI MATER M, V15, P1123, DOI 10.1023/B:JMSM.0000046394.53153.21
   Oliveira Conceicao S, 2011, Endocrinol Nutr, V58, P433, DOI 10.1016/j.endonu.2011.06.005
   Oyajobi BO, 1999, J BONE MINER RES, V14, P351, DOI 10.1359/jbmr.1999.14.3.351
   Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097 4644(19991201)75:3<424::AID JCB8>3.0.CO;2 8
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quirici N, 2002, EXP HEMATOL, V30, P783, DOI 10.1016/S0301 472X(02)00812 3
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Schmidmaier G, 2001, BONE, V28, P341, DOI 10.1016/S8756 3282(00)00456 7
   Sekiya I, 2001, BIOCHEM BIOPH RES CO, V284, P411, DOI 10.1006/bbrc.2001.4898
   Siddappa Ramakrishnaiah, 2007, Curr Stem Cell Res Ther, V2, P209, DOI 10.2174/157488807781696267
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Singh S, 2009, J CELL BIOCHEM, V108, P839, DOI 10.1002/jcb.22312
   Sontrop HMJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 389
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tamma R, 2009, P NATL ACAD SCI USA, V106, P7149, DOI 10.1073/pnas.0901890106
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Van der Heijden F, 2006, PRTOOLS VERSION 4 0
   van Vliet MH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001047
   Vickerman L, 2011, DEV BIOL, V350, P323, DOI 10.1016/j.ydbio.2010.11.031
   Waarsing JH, 2004, BONE, V34, P163, DOI 10.1016/j.bone.2003.08.012
   Wasaha S, 1996, AM J NURS, V96, P24, DOI 10.2307/3464848
   Woronowicz A, 2008, HIPPOCAMPUS, V18, P1051, DOI 10.1002/hipo.20462
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
NR 64
TC 44
Z9 47
U1 0
U2 35
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2013
VL 34
IS 19
BP 4592
EP 4601
DI 10.1016/j.biomaterials.2013.03.001
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 135CE
UT WOS:000318262800005
PM 23541110
DA 2025 08 17
ER

PT J
AU Schett, G
   Rudwaleit, M
AF Schett, Georg
   Rudwaleit, Martin
TI Can we stop progression of ankylosing spondylitis?
SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
LA English
DT Article
DE ankylosis; syndesmophyte; bone formation; structural progression
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SHORT TERM IMPROVEMENT;
   BONE FORMATION; RADIOGRAPHIC PROGRESSION; SPINAL INFLAMMATION; OUTCOME
   PARAMETER; SCLEROSTIN; INFLIXIMAB; EXPRESSION; ADALIMUMAB
AB Ankylosing spondylitis is characterised by inflammation of the spine and the entheses followed by bone formation. Excessive bone formation in ankylosing spondylitis leads to the formation of bone spurs, such as syndesmophytes and enthesiophytes, which contribute to ankylosis of joints and poor physical function. This process is based on increased differentiation of osteoblasts from their mesenchymal precursors, which allows to rapidly build up new bone. Prostaglandins, bone morphogenic proteins and Wnt proteins play an essential role in this process. By contrast, tumour necrosis factor (TNF) does not appear to be the direct trigger for osteophyte formation in ankylosing spondylitis. The article reviews the current knowledge regarding the mechanisms and clinical role of ankylosis and explains strategies on how to prevent it in patients with ankylosing spondylitis. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.
C1 [Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
   [Rudwaleit, Martin] Charite, Dept Internal Med 1, Berlin, Germany.
C3 University of Erlangen Nuremberg; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Schett, G (通讯作者)，Univ Erlangen Nurnberg, Dept Internal Med 3, Krankenhausstr 12, D 91054 Erlangen, Germany.
EM georg.schett@uk erlangen.de
RI Rudwaleit, Martin/AAK 7838 2020
FU Deutsche Forschungsgemeinschaft DFG [SFB643, SPP1468, FOR661];
   Bundesministerium fur Forschung und Bildung BMBF; European Union;
   Interdisziplinares Zentrum fur Klinische Forschung Erlangen;
   Spondyloarthritis Immunology Reserach Alliance (SpIRAL)
FX GS' work is supported by the Deutsche Forschungsgemeinschaft DFG
   (SFB643, SPP1468, FOR661), the Bundesministerium fur Forschung und
   Bildung BMBF (project ANKYLOSS), the European Union projects
   Masterswitch, Kinacept and Adipoa, the Interdisziplinares Zentrum fur
   Klinische Forschung Erlangen and the Spondyloarthritis Immunology
   Reserach Alliance (SpIRAL).
CR Anderson JJ, 2001, ARTHRITIS RHEUM US, V44, P1876, DOI 10.1002/1529 0131(200108)44:8<1876::AID ART326>3.0.CO;2 F
   Appel H, 2008, NAT CLIN PRACT RHEUM, V4, P578, DOI 10.1038/ncprheum0930
   Appel H, 2006, ARTHRITIS RHEUM US, V54, P2845, DOI 10.1002/art.22060
   Appel H, 2009, ARTHRITIS RHEUM US, V60, P3257, DOI 10.1002/art.24888
   Baraliakos X, 2005, ANN RHEUM DIS, V64, P730, DOI 10.1136/ard.2004.029298
   Baraliakos X, 2009, ARTHRIT RHEUM ARTHR, V61, P764, DOI 10.1002/art.24425
   Baraliakos X, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2496
   Baron R, 2007, ENDOCRINOLOGY, V148, P2635, DOI 10.1210/en.2007 0270
   BENJAMIN M, 2008, ANN RHEUMATIC D 0714
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   BOERSMA JW, 1976, SCAND J RHEUMATOL, V5, P60
   Brandt J, 2004, ANN RHEUM DIS, V63, P1438, DOI 10.1136/ard.2003.016717
   Braun J, 2008, RHEUMATOLOGY, V47, P1738, DOI 10.1093/rheumatology/ken357
   Braun J, 2006, ARTHRITIS RHEUM, V54, P1646, DOI 10.1002/art.21790
   CRUICKSHANK B, 1956, J PATHOL BACTERIOL, V71, P73, DOI 10.1002/path.1700710111
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   GARRETT S, 1994, J RHEUMATOL, V21, P2286
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Lambert RGW, 2007, ARTHRITIS RHEUM, V56, P4005, DOI 10.1002/art.23044
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lories RJU, 2007, ARTHRITIS RHEUM, V56, P489, DOI 10.1002/art.22372
   Lories RJU, 2006, ARTHRITIS RHEUM, V54, P1736, DOI 10.1002/art.21897
   Lukas C, 2009, ANN RHEUM DIS, V68, P18, DOI 10.1136/ard.2008.094870
   Maksymowych WP, 2009, ARTHRITIS RHEUM US, V60, P93, DOI 10.1002/art.24132
   RALSTON SH, 1990, BMJ BRIT MED J, V300, P563, DOI 10.1136/bmj.300.6724.563
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Rudwaleit M, 2004, ANN RHEUM DIS, V63, P535, DOI 10.1136/ard.2003.011247
   Rudwaleit M, 2009, RHEUMATOLOGY, V48, P551, DOI 10.1093/rheumatology/kep022
   Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200
   Schett G, 2007, ANN RHEUM DIS, V66, P709, DOI 10.1136/ard.2007.071159
   Schett G, 2009, ARTHRITIS RHEUM US, V60, P2644, DOI 10.1002/art.24767
   Semënov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200
   Sieper J, 2005, RHEUMATOLOGY, V44, P1525, DOI 10.1093/rheumatology/kei046
   Sieper J, 2002, ANN RHEUM DIS, V61, P8
   Sieper J, 2008, ARTHRITIS RHEUM US, V58, P649, DOI 10.1002/art.23260
   UDERHARDT S, 2009, ANN RHEUMATIC D 0326
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P1324, DOI 10.1002/art.23471
   van der Heijde D, 2008, ANN RHEUM DIS, V67, P182, DOI 10.1136/ard.2007.076166
   van der Heijde D, 2009, ANN RHEUM DIS, V68, P1811, DOI 10.1136/ard.2008.100826
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2794
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   Wanders AJB, 2004, ARTHRITIS RHEUM US, V50, P2622, DOI 10.1002/art.20446
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zochling J, 2006, ANN RHEUM DIS, V65, P442, DOI 10.1136/ard.2005.041137
NR 47
TC 63
Z9 67
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521 6942
EI 1521 1770
J9 BEST PRACT RES CL RH
JI Best Pract. Res. Clin. Rheumatol.
PD JUN
PY 2010
VL 24
IS 3
BP 363
EP 371
DI 10.1016/j.berh.2010.01.005
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 618QM
UT WOS:000279370800007
PM 20534370
DA 2025 08 17
ER

PT J
AU Chang, JF
   Hsieh, CY
   Liou, JC
   Liu, SH
   Hung, CF
   Lu, KC
   Lin, CC
   Wu, CC
   Ka, SM
   Wen, LL
   Wu, MS
   Zheng, CM
   Ko, WC
AF Chang, Jia Feng
   Hsieh, Chih Yu
   Liou, Jian Chiun
   Liu, Shih Hao
   Hung, Chi Feng
   Lu, Kuo Cheng
   Lin, Chih Cheng
   Wu, Chang Chin
   Ka, Shuk Man
   Wen, Li Li
   Wu, Mai Szu
   Zheng, Cai Mei
   Ko, Wen Chin
TI Scavenging Intracellular ROS Attenuates p Cresyl
   Sulfate Triggered Osteogenesis through MAPK Signaling Pathway and NF κB
   Activation in Human Arterial Smooth Muscle Cells
SO TOXINS
LA English
DT Article
DE alkaline phosphatase; c Jun N terminal kinase; extracellular
   signal regulated kinase; mitogen activated protein kinase; nuclear
   factor kappa B; osteogenesis; p Cresyl Sulfate; reactive oxygen species;
   Runt related transcription factor 2; uremic vascular calcification
ID OSTEOBLAST SPECIFIC PROTEINS; INDOXYL SULFATE; CALCIFICATION;
   EXPRESSION; JNK
AB Osteogenesis in human arterial smooth muscle cell (HASMC) is a key feature of uremic vascular calcification (UVC). Concerning pro oxidant properties of p cresyl sulfate (PCS), the therapeutic effect of reactive oxygen species (ROS) scavenger on PCS triggered inflammatory signaling transduction in osteogenesis was investigated in this translational research. Based on severity level of chronic kidney disease (CKD), arterial specimens with immunohistochemistry stain were quantitatively analyzed for UVC, oxidative injury and osteogenesis along with PCS concentrations. To mimic human UVC, HASMC model was used to explore whether PCS induced ROS could trigger mitogen activated protein kinase (MAPK) pathways with nuclear factor kappa B (NF kappa B) translocation that drive context specific gene/protein expression, including Runt related transcription factor 2 (Runx2) and alkaline phosphatase (ALP). In parallel with PCS accumulation, CKD arteries corresponded with UVC severity, oxidative DNA damage (8 hydroxy 2 ' deoxyguanosine), Runx2 and ALP. PCS directly phosphorylated extracellular signal regulated kinase (ERK)/c Jun N terminal kinase (JNK)/P38 (pERK/pJNK/pP38) and modulated NF kappa B translocation to promote expressions of Runx2 and ALP in HASMC. Notably, intracellular ROS scavenger attenuated pERK signaling cascade and downstream osteogenic differentiation. Collectively, our data demonstrate PCS induces osteogenesis through triggering intracellular ROS, pERK/pJNK/pP38 MAPK pathways and NF kappa B translocation to drive Runx2 and ALP expressions, culminating in UVC. Beyond mineral dysregulation, osteocytic conversion in HASMC could be the stimulation of PCS. Thus PCS may act as a pro osteogenic and pro calcific toxin. From the perspective of translational medicine, PCS and intracellular ROS could serve as potential therapeutic targets for UVC in CKD patients.
C1 [Chang, Jia Feng] En Chu Kong Hosp, Dept Internal Med, Div Nephrol, New Taipei 237, Taiwan.
   [Chang, Jia Feng; Hsieh, Chih Yu] Natl Def Med Ctr, Triserv Gen Hosp, Dept Pathol, Taipei 114, Taiwan.
   [Chang, Jia Feng; Ka, Shuk Man] Natl Def Med Ctr, Acad Med, Grad Inst Aerosp & Undersea Med, Taipei 114, Taiwan.
   [Chang, Jia Feng] Yuanpei Univ Med Technol, Dept Nursing, Hsinchu 300, Taiwan.
   [Chang, Jia Feng; Hsieh, Chih Yu] Renal Care Joint Fdn, New Taipei 200, Taiwan.
   [Chang, Jia Feng; Hsieh, Chih Yu; Wu, Mai Szu; Zheng, Cai Mei] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Div Nephrol, New Taipei 235, Taiwan.
   [Hsieh, Chih Yu; Liou, Jian Chiun] Taipei Med Univ, Sch Biomed Engn, Taipei 110, Taiwan.
   [Liu, Shih Hao] En Chu Kong Hosp, Div Pathol, New Taipei 237, Taiwan.
   [Hung, Chi Feng; Ko, Wen Chin] Fu Jen Catholic Univ, Sch Med, New Taipei 242, Taiwan.
   [Lu, Kuo Cheng] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Med, Div Nephrol, New Taipei 231, Taiwan.
   [Lin, Chih Cheng] Yuanpei Univ, Dept Biotechnol & Pharmaceut, Hsinchu 300, Taiwan.
   [Wu, Chang Chin] Yuanpei Univ Med Technol, Dept Biomed Engn, Hsinchu 300, Taiwan.
   [Wu, Chang Chin] En Chu Kong Hosp, Dept Orthopaed Surg, New Taipei 237, Taiwan.
   [Wen, Li Li] En Chu Kong Hosp, Dept Clin Lab, New Taipei 237, Taiwan.
   [Wu, Mai Szu; Zheng, Cai Mei] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med,Div Nephrol, Taipei 110, Taiwan.
   [Ko, Wen Chin] Cathay Gen Hosp, Dept Cardiovasc Ctr, Div Cardiac Electrophysiol, Taipei 106, Taiwan.
C3 National Defense Medical University; Tri Service General Hospital;
   National Defense Medical University; Taipei Medical University; Shuang
   Ho Hospital; Taipei Medical University; Fu Jen Catholic University;
   Buddhist Tzu Chi General Hospital; Taipei Tzu Chi Hospital; Taipei
   Medical University; Cathay General Hospital
RP Ko, WC (通讯作者)，Fu Jen Catholic Univ, Sch Med, New Taipei 242, Taiwan.; Ko, WC (通讯作者)，Cathay Gen Hosp, Dept Cardiovasc Ctr, Div Cardiac Electrophysiol, Taipei 106, Taiwan.
EM cjf6699@gmail.com; fish37435@hotmail.com; jcliou@tmu.edu.tw;
   01393@km.eck.org.tw; 054317@mail.fju.edu.tw; Kuochenglu@gmail.com;
   lcc@mail.ypu.edu.tw; Dtorth65@yahoo.com.tw; mariaka@ndmctsgh.edu.tw;
   eckwen@yahoo.com; maiszuwu@gmail.com; 11044@s.tmu.edu.tw; wck@cgh.org.tw
RI Chang, Jia Feng/AAW 1326 2020; Hsieh, Chih Yu/GWQ 8343 2022; Hung,
   Chi Feng/AAL 4977 2021; Ko, Wen chin/ABI 3879 2020; Wu,
   Shawn/J 8611 2014; Lin, Chih Cheng/LCA 2492 2024
OI Hsieh, Chih Yu/0000 0001 9770 6779; Lin, Chih Cheng/0000 0003 1842 666X;
   Chang, Jia Feng/0000 0002 9903 7473; 
FU Ministry of Science and Technology [MOST 109 2628 B 385  001,
   109 2221 E 038  013]; Renal Care Joint Foundation; Cathay General
   Hospital [CGH MR A10811]; Academia and Industry Collaboration Project of
   Taipei Medical University & En Chu Kong Hospital & Pharmofoods Medical
   Editing Co., Ltd. [A 108 031]
FX This work was financially supported by Ministry of Science and
   Technology (MOST 109 2628 B 385  001 and 109 2221 E 038  013), and the
   Renal Care Joint Foundation. This research was also funded by a grant
   (CGH MR A10811) from the Cathay General Hospital, and the Academia and
   Industry Collaboration Project of Taipei Medical University & En Chu
   Kong Hospital & Pharmofoods Medical Editing Co., Ltd. (A 108 031).
CR Adijiang A, 2008, NEPHROL DIAL TRANSPL, V23, P1892, DOI 10.1093/ndt/gfm861
   Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609
   Berti DA, 2017, METHODS MOL BIOL, V1487, P175, DOI 10.1007/978 1 4939 6424 6_13
   Chang JF, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00102
   Chang JF, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00078
   Chang JF, 2018, J CLIN MED, V7, DOI 10.3390/jcm7090266
   Chang JF, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000106
   Cozzolino M, 2019, TOXINS, V11, DOI 10.3390/toxins11040213
   Suassuna PGD, 2018, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00206
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470
   Hénaut L, 2018, TOXINS, V10, DOI 10.3390/toxins10060218
   Hénaut L, 2015, ANN BIOL CLIN PARIS, V73, P271, DOI 10.1684/abc.2015.1044
   Hsieh CY, 2019, J CELL PHYSIOL, V234, P4081, DOI 10.1002/jcp.27204
   Hua KF, 2015, J CELL PHYSIOL, V230, P863, DOI 10.1002/jcp.24815
   Ko WC, 2018, J CLIN MED, V7, DOI 10.3390/jcm7100300
   Liabeuf S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131707
   Muteliefu G, 2009, NEPHROL DIAL TRANSPL, V24, P2051, DOI 10.1093/ndt/gfn757
   Opdebeeck B, 2019, J AM SOC NEPHROL, V30, P751, DOI 10.1681/ASN.2018060609
   Proudfoot D, 2000, CIRC RES, V87, P1055, DOI 10.1161/01.RES.87.11.1055
   Shimizu H, 2012, LIFE SCI, V90, P525, DOI 10.1016/j.lfs.2012.01.013
   Shroff RC, 2007, J AM SOC NEPHROL, V18, P2996, DOI 10.1681/ASN.2006121397
   Shroff RC, 2010, J AM SOC NEPHROL, V21, P103, DOI 10.1681/ASN.2009060640
   Tanaka H, 2013, BONE, V56, P347, DOI 10.1016/j.bone.2013.07.002
   Vanholder R, 2014, J AM SOC NEPHROL, V25, P1897, DOI 10.1681/ASN.2013101062
   Wakamatsu T, 2018, TOXINS, V10, DOI 10.3390/toxins10030124
   Wu YR, 2016, RENAL FAILURE, V38, P1702, DOI 10.3109/0886022X.2016.1155397
   Yeh JC, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110439
NR 28
TC 19
Z9 20
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6651
J9 TOXINS
JI Toxins
PD AUG
PY 2020
VL 12
IS 8
AR 472
DI 10.3390/toxins12080472
PG 15
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Toxicology
GA NG6EA
UT WOS:000564073800001
PM 32722241
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, YY
   Thottappillil, N
   Gomez Salazar, M
   Tower, RJ
   Qin, QZ
   Alvia, ICD
   Xu, MX
   Cherief, M
   Cheng, R
   Archer, M
   Arondekar, S
   Reddy, S
   Broderick, K
   Péault, B
   James, AW
AF Wang, Yiyun
   Thottappillil, Neelima
   Gomez Salazar, Mario
   Tower, Robert J.
   Qin, Qizhi
   Alvia, Ishbel Camila Del Rosario
   Xu, Mingxin
   Cherief, Masnsen
   Cheng, Ray
   Archer, Mary
   Arondekar, Shreya
   Reddy, Sashank
   Broderick, Kristen
   Peault, Bruno
   James, Aaron W.
TI Integrated transcriptomics of human blood vessels defines a spatially
   controlled niche for early mesenchymal progenitor cells
SO DEVELOPMENTAL CELL
LA English
DT Article
ID HEMATOPOIETIC STEM; GENE EXPRESSION; DIFFERENTIATION; DACT2; WNT;
   PROLIFERATION; HOMEOSTASIS; ADVENTITIA; ACTIVATION; ADHESION
AB Human blood vessel walls show concentric layers, with the outermost tunica adventitia harboring mesenchymal progenitor cells. These progenitor cells maintain vessel homeostasis and provide a robust cell source for cell based therapies. However, human adventitial stem cell niche has not been studied in detail. Here, using spatial and single cell transcriptomics, we characterized the phenotype, potential, and microanatomic distribution of human perivascular progenitors. Initially, spatial transcriptomics identified heterogeneity between perivascular layers of arteries and veins and delineated the tunica adventitia into inner and outer layers. From this spatial atlas, we inferred a hierarchy of mesenchymal progenitors dictated by a more primitive cell with a high surface expression of CD201 ( PROCR ). When isolated from humans and mice, CD201Low expression typified a mesodermal committed subset with higher osteogenesis and less proliferation than CD201High cells, with a downstream effect on canonical Wnt signaling through DACT2. CD201Low cells also displayed high translational potential for bone tissue generation.
C1 [Wang, Yiyun; Thottappillil, Neelima; Gomez Salazar, Mario; Qin, Qizhi; Alvia, Ishbel Camila Del Rosario; Xu, Mingxin; Cherief, Masnsen; Cheng, Ray; Archer, Mary; Arondekar, Shreya; James, Aaron W.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA.
   [Tower, Robert J.] Univ Texas Southwestern Med Ctr, Dept Surg, Dallas, TX 75390 USA.
   [Reddy, Sashank; Broderick, Kristen] Johns Hopkins Univ, Dept Plast & Reconstruct Surg, Baltimore, MD 21205 USA.
   [Broderick, Kristen; Peault, Bruno] Univ Calif Los Angeles, Dept Orthoped Surg, Los Angeles, CA USA.
   [Broderick, Kristen; Peault, Bruno] Univ Calif Los Angeles, Orthoped Hosp Res Ctr, Los Angeles, CA USA.
C3 Johns Hopkins University; University of Texas System; University of
   Texas Southwestern Medical Center; Johns Hopkins University; University
   of California System; University of California Los Angeles; University
   of California System; University of California Los Angeles
RP James, AW (通讯作者)，Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21205 USA.
EM awjames@jhmi.edu
RI ; Xu, Mingxin/AAK 7932 2021; Wang, Yiyun/HGB 6202 2022
OI Thottappillil, Neelima/0000 0003 3973 7117; 
FU American Journal of Pathology; NIH/NIAMS [P01 AG066603, R01 AR079171,
   R21 AR078919]; Maryland Stem Cell Research Foundation
   [2021 MSCRFD 5641]; NIH/NIDCR [R01 DE031488, R01 DE031028]; American
   Cancer Society [DBG 23 1155131 01 IBCD]; Department of Defense USAMRAA
   [HT9425 24 1 0051]
FX We thank the JHU microscopy facility, the JHMI deep sequencing and
   micro array facility, and the animal care facility. We thank Hao Zhang
   of JHU Bloom berg Flow Cytometry, Alan Long within the JHU Agilent Core
   lab facility, and Connie Talbot of the JHU deep sequencing facility for
   their technical assis tance. Funding: NIH/NIAMS P01 AG066603, R01
   AR079171, and R21 AR078919 (A.W.J. and B.P.) . Maryland Stem Cell
   Research Foundation 2021 MSCRFD 5641 (A.W.J.) . NIH/NIDCR R01 DE031488
   and R01 DE031028 (A.W.J.) . American Cancer Society
   DBG 23 1155131 01 IBCD (A.W.J.) . Department of Defense USAMRAA
   HT9425 24 1 0051 (A.W.J.) . The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Institute of Health, the Department of Defense, or the U.S.
   Army.
CR Asp M, 2019, CELL, V179, P1647, DOI 10.1016/j.cell.2019.11.025
   Berglund E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04724 5
   Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534 5807(02)00140 5
   Corselli M, 2012, STEM CELLS DEV, V21, P1299, DOI 10.1089/scd.2011.0200
   Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Ding LJ, 2020, STEM CELLS, V38, P261, DOI 10.1002/stem.3112
   Dong H, 2022, NAT METAB, V4, P90, DOI 10.1038/s42255 021 00509 1
   Esmon CT, 2000, THROMB HAEMOSTASIS, V83, P639
   Gomez Salazar M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00148
   Gulati GS, 2020, SCIENCE, V367, P405, DOI 10.1126/science.aax0249
   Guo L, 2018, ONCOL LETT, V15, P3287, DOI 10.3892/ol.2017.7633
   Haston S, 2017, DEVELOPMENT, V144, P2141, DOI 10.1242/dev.150490
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hwang WL, 2022, NAT GENET, V54, P1178, DOI 10.1038/s41588 022 01134 8
   Ji AL, 2020, CELL, V182, P1661, DOI 10.1016/j.cell.2020.08.043
   Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446
   Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   Kramann R, 2016, CELL STEM CELL, V19, P628, DOI 10.1016/j.stem.2016.08.001
   Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004
   Kuppe C, 2022, NATURE, V608, P766, DOI 10.1038/s41586 022 05060 x
   Lee C, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111598
   Lee WC, 2010, AM J PHYSIOL RENAL, V299, pF740, DOI 10.1152/ajprenal.00148.2010
   Li JY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03647 3
   Li X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054868
   Liu Yuan, 2020, Cell Regen, V9, P14, DOI 10.1186/s13619 020 00053 5
   Lu LL, 2018, PHARMACOL RES, V129, P318, DOI 10.1016/j.phrs.2017.11.032
   Ma XY, 2020, EXP BIOL MED, V245, P562, DOI 10.1177/1535370220910690
   Majesky MW, 2012, CELLS TISSUES ORGANS, V195, P73, DOI 10.1159/000331413
   Majesky MW, 2011, ARTERIOSCL THROM VAS, V31, P1530, DOI 10.1161/ATVBAHA.110.221549
   Man S, 2019, ANGIOGENESIS, V22, P3, DOI 10.1007/s10456 018 9639 0
   Merrick D, 2019, SCIENCE, V364, P353, DOI 10.1126/science.aav2501
   Navarro JF, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101556
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Qin QZ, 2022, CANCER RES, V82, P2734, DOI 10.1158/0008 5472.CAN 22 0732
   Qin QZ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00216 x
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]
   Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699
   Ritsma L, 2014, NATURE, V507, P362, DOI 10.1038/nature12972
   Rompolas P, 2013, NATURE, V502, P513, DOI 10.1038/nature12602
   Sacchetti B, 2016, STEM CELL REP, V6, P897, DOI 10.1016/j.stemcr.2016.05.011
   Sanchez Duffhues G, 2016, J PATHOL, V238, P378, DOI 10.1002/path.4653
   Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957
   Schubert FR, 2014, BMC EVOL BIOL, V14, DOI 10.1186/1471 2148 14 157
   Sensiate LA, 2014, DEV DYNAM, V243, P428, DOI 10.1002/dvdy.23948
   Smith EA, 2019, TRENDS CANCER, V5, P411, DOI 10.1016/j.trecan.2019.05.009
   Spradling AC, 2008, COLD SH Q B, V73, P49, DOI 10.1101/sqb.2008.73.023
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Su EY, 2022, STEM CELL REP, V17, P427, DOI 10.1016/j.stemcr.2021.12.018
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Thiriot A, 2017, BMC BIOL, V15, DOI 10.1186/s12915 017 0381 7
   Thottappillil N, 2023, STEM CELLS, V41, P862, DOI 10.1093/stmcls/sxad047
   Tower RJ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103087118
   Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA
   van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687
   Vazquez SE, 2015, EXP HEMATOL, V43, P578, DOI 10.1016/j.exphem.2015.04.001
   Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900
   Vieujean S, 2022, J CROHNS COLITIS, V16, P506, DOI 10.1093/ecco jcc/jjab154
   Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851
   Wang S, 2015, ONCOGENE, V34, P2575, DOI 10.1038/onc.2014.201
   Wang YY, 2020, STEM CELLS, V38, P276, DOI 10.1002/stem.3108
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Xie YC, 2009, NATURE, V457, P97, DOI 10.1038/nature07639
   Xu JJ, 2020, ELIFE, V9, DOI 10.7554/eLife.58990
   Xu LM, 2014, J GASTROEN HEPATOL, V29, P1620, DOI 10.1111/jgh.12653
   Yan KS, 2012, P NATL ACAD SCI USA, V109, P466, DOI 10.1073/pnas.1118857109
   Yap C, 2021, ARTERIOSCL THROM VAS, V41, P2693, DOI 10.1161/ATVBAHA.121.316600
   Yu QC, 2016, CELL RES, V26, P1079, DOI 10.1038/cr.2016.85
   Zeng Y, 2022, INT J BIOL SCI, V18, P4532, DOI 10.7150/ijbs.70784
   Zhang Y, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148 018 0459 2
NR 71
TC 2
Z9 2
U1 2
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1534 5807
EI 1878 1551
J9 DEV CELL
JI Dev. Cell
PD OCT 21
PY 2024
VL 59
IS 20
DI 10.1016/j.devcel.2024.06.015
EA OCT 2024
PG 24
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA K2C5R
UT WOS:001342010700001
PM 39025061
DA 2025 08 17
ER

PT J
AU Nilsson, S
   Huelsenbeck, J
   Fritz, G
AF Nilsson, S.
   Huelsenbeck, J.
   Fritz, G.
TI Mevalonate pathway inhibitors affect anticancer drug induced cell death
   and DNA damage response of human sarcoma cells
SO CANCER LETTERS
LA English
DT Article
DE Mevalonate pathway; Small GTPases; Anticancer drugs; DNA damage response
   (DDR); Sarcoma cells
ID LOVASTATIN INDUCED APOPTOSIS; STATIN INDUCED INHIBITION; ACTIVATED
   PROTEIN KINASE; HUMAN ENDOTHELIAL CELLS; BREAST CANCER CELLS; ZOLEDRONIC
   ACID; GLIOMA CELLS; RHO GTPASES; METFORMIN; THERAPY
AB Lovastatin (Lov), bisphosphonates (BP) and metformin (Met) are widely used drugs, having in common that they interfere with the mevalonate pathway (MP). The MP generates isoprene moieties required for the function of regulatory GTPases controlling cell proliferation and survival. Here, we addressed the question whether MP inhibitors interfere with the anti tumor efficacy of anticancer drugs. We comparatively analyzed the effect of equitoxic doses of Lov, BP and Met on cell viability, cell cycle progression, apoptosis and DNA damage response (DDR) of human osteo  and fibrosarcoma cells exposed to doxorubicin or cisplatin. We found that Lov, BP and Met modulated the anticancer drug sensitivity of sarcoma cells in an agent , dose and time dependent fashion. Mostly, the MP inhibitors increased the cytotoxicity of the anticancer drugs in an additive manner. MP modulators differed from each other regarding their impact on anticancer drug induced DNA damage response as measured by the phosphorylation status of SAPK/JNK, Chk 1 and H2AX as well as p53 protein level. In this regard, lovastatin and metformin turned out as the most effective inhibitory drugs. The data show that MP inhibitors can affect the anti tumor efficacy of anticancer drugs and impact the DDR of human sarcoma cells. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Fritz, G.] Univ Dusseldorf, Inst Toxicol, D 40225 Dusseldorf, Germany.
   [Nilsson, S.; Huelsenbeck, J.; Fritz, G.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Toxicol, D 55131 Mainz, Germany.
C3 Heinrich Heine University Dusseldorf; Johannes Gutenberg University of
   Mainz
RP Fritz, G (通讯作者)，Univ Dusseldorf, Inst Toxicol, Univ Str 1, D 40225 Dusseldorf, Germany.
EM fritz@uni duesseldorf.de
FU Deutsche Forschungsgemeinschaft [Fr 1241/5 3]; Inneruniversitare
   Forschungsforderung of the Johannes Gutenberg University Mainz
FX This work was supported by the Deutsche Forschungsgemeinschaft (Fr
   1241/5 3) and the Inneruniversitare Forschungsforderung of the Johannes
   Gutenberg University Mainz. We would like to thank B. Kaina for very
   helpful discussion.
CR ADAMSON P, 1992, J BIOL CHEM, V267, P20033
   Agarwal B, 1999, CLIN CANCER RES, V5, P2223
   Anfossi G, 2010, CURR VASC PHARMACOL, V8, P327, DOI 10.2174/157016110791112359
   Bardeleben RV, 2002, INT J MOL MED, V10, P473
   Baumann M, 2007, RADIOTHER ONCOL, V83, P238, DOI 10.1016/j.radonc.2007.04.006
   Cafforio P, 2005, CARCINOGENESIS, V26, P883, DOI 10.1093/carcin/bgi036
   Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015
   Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521
   CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960 9822(00)00070 1
   Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306
   Damrot J, 2006, BRIT J PHARMACOL, V149, P988, DOI 10.1038/sj.bjp.0706953
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318
   Dimitroulakos J, 2001, CLIN CANCER RES, V7, P158
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008 5472.CAN 07 2310
   Evans JMM, 2005, BMJ BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Faneyte IF, 2004, ANTICANCER RES, V24, P2931
   Feleszko W, 2000, CLIN CANCER RES, V6, P2044
   Frampton JE, 2008, DRUGS, V68, P2683, DOI 10.2165/0003495 200868180 00011
   FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES
   Fritz G, 2009, CURR CANCER DRUG TAR, V9, P626, DOI 10.2174/156800909789057033
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fromigué O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200
   Fromigué O, 2008, J PHARMACOL EXP THER, V325, P595, DOI 10.1124/jpet.108.136127
   Gnad R, 2000, MOL PHARMACOL, V58, P1389, DOI 10.1124/mol.58.6.1389
   Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010
   Guerra L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002254
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015
   Hausding M, 2000, BRIT J PHARMACOL, V131, P553, DOI 10.1038/sj.bjp.0703607
   Haydont V, 2007, CLIN CANCER RES, V13, P5331, DOI 10.1158/1078 0432.CCR 07 0625
   Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065 230X(02)84003 9
   Kaneta S, 2003, ATHEROSCLEROSIS, V170, P237, DOI 10.1016/S0021 9150(03)00301 0
   Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200
   Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748
   Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08 2175
   Lyseng Williamson KA, 2008, DRUGS, V68, P2661, DOI 10.2165/0003495 200868180 00010
   Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852
   MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092 8674(05)80019 4
   Miyagawa K, 2008, CANCER SCI, V99, P187, DOI 10.1111/j.1349 7006.2007.00644.x
   Motoshima H, 2006, J PHYSIOL LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324
   Neville Webbe HL, 2005, INT J CANCER, V113, P364, DOI 10.1002/ijc.20602
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092 8674(95)90370 4
   Nübel T, 2006, CLIN CANCER RES, V12, P933, DOI 10.1158/1078 0432.CCR 05 1903
   Okamoto I, 2010, FEBS J, V277, P309, DOI 10.1111/j.1742 4658.2009.07449.x
   Ostrau C, 2009, RADIOTHER ONCOL, V92, P492, DOI 10.1016/j.radonc.2009.06.020
   Pääjärvi G, 2004, FASEB J, V18, P476, DOI 10.1096/fj.04 2745fje
   Pavlovsky C, 2009, AM J HEMATOL, V84, P287, DOI 10.1002/ajh.21380
   QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0
   Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706 5715.2003
   Sandrock K, 2010, TRAFFIC, V11, P198, DOI 10.1111/j.1600 0854.2009.01015.x
   Skorta I, 2009, CANCER RES, V69, P9337, DOI 10.1158/0008 5472.CAN 09 0548
   SOMA MR, 1992, CANCER RES, V52, P4348
   Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008 5472.CAN 03 3207
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   von Bardeleben R, 2003, BIOCHEM BIOPH RES CO, V307, P401, DOI 10.1016/S0006 291X(03)01205 1
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008 5472.CAN 06 1500
   Zhang L, 2007, AM J PHYSIOL HEART C, V293, pH457, DOI 10.1152/ajpheart.00002.2007
NR 65
TC 22
Z9 27
U1 0
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304 3835
EI 1872 7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 1
PY 2011
VL 304
IS 1
BP 60
EP 69
DI 10.1016/j.canlet.2010.12.022
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 748ID
UT WOS:000289383400007
PM 21356574
DA 2025 08 17
ER

PT J
AU Song, CL
   Wang, JY
   Song, QS
   Li, X
   Chen, ZQ
   Ma, QJ
   Liu, ZJ
   Jia, HT
   Dang, GT
AF Song, Chunli
   Wang, Jingying
   Song, Quansheng
   Li, Xu
   Chen, Zhongqiang
   Ma, Qingjun
   Liu, Zhongjun
   Jia, Hongti
   Dang, Gengting
TI Simvastatin induces estrogen receptor alpha (ER α) in murine bone marrow
   stromal cells
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE simvastatin; bone marrow stromal cells (BMSCs); osteoblast; cell
   differentiation; estrogen receptor alpha (ER alpha); osteoporosis
ID HYPERCHOLESTEROLEMIC POSTMENOPAUSAL WOMEN; HORMONE REPLACEMENT THERAPY;
   COA REDUCTASE INHIBITORS; MINERAL DENSITY; OSTEOBLASTIC DIFFERENTIATION;
   GENE EXPRESSION; KOREAN WOMEN; STATINS; OSTEOPOROSIS; FRACTURE
AB Simvastatin has been shown to stimulate osteogenesis both in vitro and in vivo. However, the mechanism by which simvastatin exerts its effects is still unclear. We previously reported that simvastatin promotes bone morphogenetic protein 2 (BMP 2) expression, induces osteoblastic differentiation, and inhibits adipocytic differentiation in mouse bone marrow stromal cells (BMSCs), and that this occurs, at least in part, via a BMP 2 dependent pathway. The aim of this study was to investigate further the mechanisms by which simvastatin stimulates osteogenesis in mouse BMSCs. To determine whether simvastatin mediated osteogenesis was dependent on BMP 2, mouse BMSCs were treated with nonimmune normal mouse IgG or BMP 2 neutralizing antibodies combined with different concentrations of simvastatin. Surprisingly, the stimulatory effect of simvastatin on alkaline phosphatase (ALP) activity was not completely blocked by neutralizing BMP 2 monoclonal antibody treatment. Interestingly, we found that estrogen receptor alpha (ER alpha) protein levels increased after mouse BMSCs were treated with simvastatin for 72 h in a concentration dependent manner. Moreover, the stimulatory effect of simvastatin on ALP activity in BMSCs was blocked by the estrogen receptor agonist ICI 182,780, and cotreatment with 17 beta estradiol and simvastatin increased ALP activities by two to threefold in the BMSCs compared with treatment with simvastatin alone. These results suggest that simvastatin induced in vitro osteogenesis in mouse BMSCs is mediated, at least in part, by induction of ER alpha and not by BMP 2 alone. These results provide new insight into the mechanisms of simvastatin induced bone formation in BMSCs.
C1 [Song, Chunli; Wang, Jingying; Song, Quansheng; Li, Xu; Chen, Zhongqiang; Ma, Qingjun; Liu, Zhongjun; Jia, Hongti; Dang, Gengting] Peking Univ, Peking Univ Hosp 3, Dept Orthoped, Beijing 100083, Peoples R China.
   [Jia, Hongti] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.
C3 Peking University; Peking University
RP Song, CL (通讯作者)，Peking Univ, Peking Univ Hosp 3, Dept Orthoped, Beijing 100083, Peoples R China.
EM schl@bjmu.edu.cn
RI Wang, Jingying/IUQ 5751 2023
CR Banu J, 2004, BONE, V34, P432, DOI 10.1016/j.bone.2003.10.008
   Bodine PVN, 1998, ENDOCRINOLOGY, V139, P2048, DOI 10.1210/en.139.4.2048
   Braidman I, 2000, BONE, V26, P423, DOI 10.1016/S8756 3282(00)00246 5
   Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140 6736(00)02400 4
   De Leo V, 2003, GYNECOL ENDOCRINOL, V17, P329, DOI 10.1080/713603298
   ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021
   ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003 4819 102 3 319
   Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471
   Kano K, 2005, CLIN NEPHROL, V63, P74
   Komulainen M, 2000, OSTEOPOROSIS INT, V11, P211, DOI 10.1007/s001980050283
   Lambertini E, 2002, J ENDOCRINOL, V172, P683, DOI 10.1677/joe.0.1720683
   Leskelä HV, 2006, BONE, V39, P1026, DOI 10.1016/j.bone.2006.05.003
   Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Montagnani A, 2003, BONE, V32, P427, DOI 10.1016/S8756 3282(03)00034 6
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mundy GR, 2001, BONE, V29, P495, DOI 10.1016/S8756 3282(01)00606 8
   Nam HS, 2005, J BONE MINER METAB, V23, P84, DOI 10.1007/s00774 004 0545 8
   Okazaki R, 2002, ENDOCRINOLOGY, V143, P2349, DOI 10.1210/en.143.6.2349
   Oreffo ROC, 1999, J CELL BIOCHEM, V75, P382, DOI 10.1002/(SICI)1097 4644(19991201)75:3<382::AID JCB4>3.0.CO;2 N
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Rejnmark L, 2004, J BONE MINER RES, V19, P737, DOI 10.1359/JBMR.040209
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Schlienger RG, 2003, DRUG AGING, V20, P321, DOI 10.2165/00002512 200320050 00002
   Skoglund B, 2002, J BONE MINER RES, V17, P2004, DOI 10.1359/jbmr.2002.17.11.2004
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Wang PS, 2000, JAMA J AM MED ASSOC, V283, P3211, DOI 10.1001/jama.283.24.3211
   Wang Q, 2006, BIOCHEM BIOPH RES CO, V347, P117, DOI 10.1016/j.bbrc.2006.06.070
   Yazawa H, 2005, J PERIODONTOL, V76, P295, DOI 10.1902/jop.2005.76.2.295
   Yim CH, 2005, J BONE MINER METAB, V23, P395, DOI 10.1007/s00774 005 0619 2
NR 31
TC 22
Z9 32
U1 0
U2 17
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2008
VL 26
IS 3
BP 213
EP 217
DI 10.1007/s00774 007 0820 6
PG 5
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 299HH
UT WOS:000255746200002
PM 18470660
DA 2025 08 17
ER

PT J
AU Kvam, JM
   Nybo, ML
   Torz, L
   Sustarsic, RK
   Jensen, KHR
   Nielsen, JE
   Frederiksen, H
   Gadgaard, S
   Spiess, K
   Poulsen, SS
   Thomsen, JS
   Cowin, P
   Jensen, MB
   Kurita, T
   Rosenkilde, MM
AF Kvam, Jone Marita
   Nybo, Maja Lind
   Torz, Lola
   Sustarsic, Riia Karolina
   Jensen, Kristian Hoj Reveles
   Nielsen, John Erik
   Frederiksen, Hanne
   Gadgaard, Sarina
   Spiess, Katja
   Poulsen, Steen Seier
   Thomsen, Jesper Skovhus
   Cowin, Pamela
   Blomberg Jensen, Martin
   Kurita, Takeshi
   Rosenkilde, Mette Marie
TI High incidence of imperforate vagina in ADGRA3 deficient mice
SO BMC BIOLOGY
LA English
DT Article
DE Adhesion GPCR; ADGRA3; Female fertility; Imperforate vagina
ID EPITHELIAL PROGESTERONE RECEPTOR; BCL 2 FAMILY; CELL POLARITY; GPR125;
   ABNORMALITIES; PREVALENCE; GENERATION; ANOMALIES; ESTRADIOL; APOPTOSIS
AB Background Ten percent of the female population suffers from congenital abnormalities of the vagina, uterus, or oviducts, with severe consequences for reproductive and psychological health. Yet, the underlying causes of most of these malformations remain largely unknown. ADGRA3 (GPR125) is involved in WNT signaling and planar cell polarity, mechanisms vital to female reproductive tract development. Although ADGRA3 is a well established spermatogonial stem cell marker, its role within the female urogenital system remains unclear.Results In this study, we found Adgra3 to be expressed throughout the murine female urogenital system, with higher expression pre puberty than after sexual maturation. We generated a global Adgra3  /  mouse line and observed imperforate vagina in 44% of Adgra3  /  females, resulting in distension of the reproductive tract and infertility. Ovarian morphology, plasma estradiol, ovarian Cyp19a1, and vaginal estrogen receptor alpha (Esr1) expression were unaffected. However, compared to controls, a significantly lower bone mineral density was found in Adgra3  /  mice. Whereas vaginal opening in mice is an estrogen dependent process, 17 beta estradiol treatment failed to induce vaginal canalization in Adgra3  /  mice. Furthermore, a marked reduction in vaginal and ovarian progesterone receptor expression was observed concomitant with an upregulation of apoptotic regulators Bcl2, Bid, and Bmf in adult Adgra3  /  females with a closed vagina.Conclusions Our collective results shed new insights into the complex mechanisms by which the adhesion receptor ADGRA3 regulates distal vaginal tissue remodeling during vaginal canalization via altered sex hormone responsiveness and balance in apoptotic regulators. This highlights the potential of ADGRA3 as a target in diagnostic screening and/or therapy for obstructive vaginal malformations in humans.
C1 [Kvam, Jone Marita; Nybo, Maja Lind; Torz, Lola; Sustarsic, Riia Karolina; Jensen, Kristian Hoj Reveles; Gadgaard, Sarina; Spiess, Katja; Poulsen, Steen Seier; Rosenkilde, Mette Marie] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark.
   [Nielsen, John Erik; Frederiksen, Hanne] Copenhagen Univ Hosp, Dept Growth & Reprod, Rigshosp, Copenhagen, Denmark.
   [Nielsen, John Erik; Frederiksen, Hanne] Copenhagen Univ Hosp, Int Ctr Res & Res Training Endocrine Disrupt Male, Rigshosp, Copenhagen, Denmark.
   [Gadgaard, Sarina] Bainan Biotech, Copenhagen, Denmark.
   [Thomsen, Jesper Skovhus] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
   [Cowin, Pamela] NYU, Dept Cell Biol, Sch Med, New York, NY USA.
   [Cowin, Pamela] NYU, Sch Med, Dept & Dermatol, New York, NY USA.
   [Blomberg Jensen, Martin] Univ Copenhagen, Dept Growth & Reprod, Grp Skeletal Mineral & Gonadal Endocrinol, Rigshosp, Copenhagen, Denmark.
   [Blomberg Jensen, Martin] Copenhagen Univ Hosp Herlev & Gentofte, Dept Endocrinol & Internal Med, Div Translat Endocrinol, Copenhagen, Denmark.
   [Kurita, Takeshi] Ohio State Univ, Dept Canc Biol & Genet, Columbus, OH USA.
C3 University of Copenhagen; University of Copenhagen; Copenhagen
   University Hospital; Rigshospitalet; Rigshospitalet; University of
   Copenhagen; Copenhagen University Hospital; Aarhus University; New York
   University; New York University; University of Copenhagen; Copenhagen
   University Hospital; Rigshospitalet; University System of Ohio; Ohio
   State University
RP Rosenkilde, MM (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark.
EM rosenkilde@sund.ku.dk
RI Jensen, Martin Blomberg/U 3338 2017; Spiess, Katja/LZH 6010 2025;
   blomberg jensen, martin/U 3338 2017; Frederiksen, Hanne/N 8632 2013;
   Thomsen, Jesper/HKN 2794 2023; Kurita, Takeshi/A 2236 2013
OI Jensen, Martin Blomberg/0000 0003 3800 4253; Rosenkilde, Mette
   Marie/0000 0001 9600 3254; Poulsen, Steen Seier/0000 0003 4419 4911;
   Frederiksen, Hanne/0000 0002 3180 9879; Torz, Lola/0000 0001 6013 3081;
   Thomsen, Jesper Skovhus/0000 0001 9386 6679; Sustarsic, Riia
   Karoliina/0000 0001 8138 7363; Spiess, Katja/0000 0002 2388 4617;
   Kurita, Takeshi/0000 0003 4281 5884; Nybo, Maja Lind/0000 0001 7284 987X
FU HORIZON EUROPE European Research Council; Core Facility for Integrated
   Microscopy, Faculty of Health and Medical Sciences, University of
   Copenhagen
FX Thanks to Richard Behringer for critical discussion and Ana Ricci
   Nielsen, Heidi Marie Paulsen, Bente Staergaard, and Sussi M &
   oslash;rkeberg Kristoffersen for excellent technical assistance. We
   acknowledge the Core Facility for Integrated Microscopy, Faculty of
   Health and Medical Sciences, University of Copenhagen.
CR Acien M., 2015, Female genital tract congenital malformations: classification, diagnosis and management, P3, DOI [10.1007/978 1 4471 5146 3_1, DOI 10.1007/978 1 4471 5146 3_1]
   [Anonymous], 2008, Fertility and Sterility, V90, pS219, DOI [DOI 10.1016/J.FERTNSTERT.2008.08.038, 10.1016/j.fertnstert.2008.08.038]
   Arbuckle JL., 2016, Curr Treat Options Pediatr, V2, P131, DOI [10.1007/s40746 016 0064 6, DOI 10.1007/S40746 016 0064 6]
   Ataca D, 2016, BIOL OPEN, V5, P1585, DOI 10.1242/bio.019711
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cano Gauci DF, 1999, J CELL BIOL, V146, P255
   Chan YY, 2011, HUM REPROD UPDATE, V17, P761, DOI 10.1093/humupd/dmr028
   Cora MC, 2015, TOXICOL PATHOL, V43, P776, DOI 10.1177/0192623315570339
   Cunha GR, 2019, DIFFERENTIATION, V110, P49, DOI 10.1016/j.diff.2019.07.004
   Dai X, 1998, GENE DEV, V12, P3452, DOI 10.1101/gad.12.21.3452
   Dietrich JE, 2014, J PEDIATR ADOL GYNEC, V27, P396, DOI 10.1016/j.jpag.2014.09.001
   Dreisler E, 2014, FERTIL STERIL, V102, P525, DOI 10.1016/j.fertnstert.2014.04.043
   Duffy SL, 2008, GENESIS, V46, P553, DOI 10.1002/dvg.20434
   Frederiksen H, 2020, J CLIN ENDOCR METAB, V105, P754, DOI 10.1210/clinem/dgz196
   Fu JF, 2013, INT J CANCER, V133, P1792, DOI 10.1002/ijc.28195
   Hamilton KJ, 2014, REPROD BIOL, V14, P3, DOI 10.1016/j.repbio.2013.12.002
   Hammes A, 2005, CELL, V122, P751, DOI 10.1016/j.cell.2005.06.032
   Holt LJ, 2012, FASEB J, V26, P3658, DOI 10.1096/fj.11 199349
   Hoover RH, 2012, OBSTET GYNECOL SURV, V67, P94, DOI 10.1097/OGX.0b013e318247c7e1
   Hübner A, 2010, MOL CELL BIOL, V30, P98, DOI 10.1128/MCB.01155 09
   Iizuka Kogo A, 2007, DEVELOPMENT, V134, P1799, DOI 10.1242/dev.02830
   Ince TA, 2002, AM J PATHOL, V161, P1111, DOI 10.1016/S0002 9440(10)64387 8
   Ito T, 2015, MOL MED REP, V11, P829, DOI 10.3892/mmr.2014.2773
   James RG, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000230
   Jensen MB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22734 8
   Kale J, 2018, CELL DEATH DIFFER, V25, P65, DOI 10.1038/cdd.2017.186
   Knapp B, 2019, ANN NY ACAD SCI, V1456, P144, DOI 10.1111/nyas.14220
   Kurita T, 2000, BIOL REPROD, V62, P821, DOI 10.1095/biolreprod62.4.831
   Kurita T, 2020, ENDOMETRIAL GENE EXPRESSION: AN EMERGING PARADIGM FOR REPRODUCTIVE DISORDERS, P1, DOI 10.1007/978 3 030 28584 5_1
   Laufer MR, 2012, Pediatric surgery, P1591, DOI [DOI 10.1016/B978 0 323 07255 7.00124 0, 10.1016/B978 0 323 07255 7.00124 0]
   Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495 007 0746 4
   Lee DM, 1998, FERTIL STERIL, V70, P135, DOI 10.1016/S0015 0282(98)00126 5
   Li X, 2013, DEVELOPMENT, V140, P3028, DOI 10.1242/dev.094839
   Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097 2765(00)00136 2
   LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266
   Manno FAM, 2008, PHYSIOL BEHAV, V93, P364, DOI 10.1016/j.physbeh.2007.09.011
   MASANGKAY JS, 1983, EXP ANIM TOKYO, V32, P139, DOI 10.1538/expanim1978.32.3_139
   Mehta FF, 2016, ONCOTARGET, V7, P17455, DOI 10.18632/oncotarget.8159
   Mittag J, 2007, ENDOCRINOLOGY, V148, P719, DOI 10.1210/en.2006 1054
   Mullen RD, 2014, SEX DEV, V8, P281, DOI 10.1159/000364935
   Murata T, 2014, SCI REP UK, V4, DOI 10.1038/srep06959
   Nikaido Y, 2005, IN VIVO, V19, P487
   Nybo ML, 2023, FASEB J, V37, DOI 10.1096/fj.202200762RR
   O'Malley BW, 2020, J MOL ENDOCRINOL, V65, pC1, DOI 10.1530/JME 20 0042
   Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217
   Rodriguez I, 1997, DEV BIOL, V184, P115, DOI 10.1006/dbio.1997.8522
   RUBINSTEIN L, 1963, P SOC EXP BIOL MED, V113, P1043
   Sakurai T, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.102475
   Scholz N, 2019, ANN NY ACAD SCI, V1456, P80, DOI 10.1111/nyas.14192
   Seandel M, 2008, CELL CYCLE, V7, P135, DOI 10.4161/cc.7.2.5248
   Seandel M, 2007, NATURE, V449, P346, DOI 10.1038/nature06129
   Shiraishi K, 2020, J UROLOGY, V203, P809, DOI 10.1097/JU.0000000000000682
   Simpson KJ, 2004, INT J DEV BIOL, V48, P675, DOI 10.1387/ijdb.041849ks
   Soeborg T, 2017, CLIN CHIM ACTA, V468, P180, DOI 10.1016/j.cca.2017.03.002
   Spiess K, 2019, ANN NY ACAD SCI, V1456, P186, DOI 10.1111/nyas.14263
   Spina E, 2020, bioRxiv, V2020
   Spina E, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 28937 x
   St Jean G, 2019, BIOL REPROD, V100, P49, DOI 10.1093/biolre/ioy160
   STEELE RE, 1974, ENDOCRINOLOGY, V95, P513, DOI 10.1210/endo 95 2 513
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Tang CY, 2022, INT J BIOL SCI, V18, P2392, DOI 10.7150/ijbs.70620
   Vandenberg AL, 2009, DEVELOPMENT, V136, P1559, DOI 10.1242/dev.034066
   Vanhollebeke B, 2015, ELIFE, V4, DOI 10.7554/eLife.06489
   Warr N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019572
   Wu H, 2008, MOL REPROD DEV, V75, P1775, DOI 10.1002/mrd.20917
   Wu YB, 2018, MED SCI MONITOR, V24, P6608, DOI 10.12659/MSM.910105
   Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495
   Zhao F, 2016, SCI REP UK, V6, DOI 10.1038/srep23037
NR 68
TC 1
Z9 1
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1741 7007
J9 BMC BIOL
JI BMC Biol.
PD APR 8
PY 2024
VL 22
IS 1
AR 77
DI 10.1186/s12915 024 01873 6
PG 14
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA ND9J4
UT WOS:001198630100001
PM 38589878
OA gold
DA 2025 08 17
ER

PT J
AU Wan, H
   Qian, TY
   Hu, XJ
   Huang, CY
   Yao, WF
AF Wan, Hui
   Qian, Tie Yong
   Hu, Xiao Jing
   Huang, Ci You
   Yao, Wei Feng
TI Correlation of Serum CCL3/MIP 1α Levels with Disease Severity in
   Postmenopausal Osteoporotic Females
SO BALKAN MEDICAL JOURNAL
LA English
DT Article
DE CCL3; Chemokine; osteoporosis; post menopausal; severity
ID RESISTANT ACID PHOSPHATASE; QUALITY OF LIFE; BONE TURNOVER; CHEMOKINES;
   FRACTURE; HEALTH; PAIN; OSTEOCLASTS; RECEPTORS; CYTOKINES
AB Background: The pro inflammatory protein chemokine cytokine ligand 3 is well established as a vital regulator of bone resorption and osteoclast stimulation.
   Aims: To investigate if serum cytokine ligand 3 levels correlated with disease severity in postmenopausal osteoporotic women.
   Study Design: Cross sectional study.
   Methods: Eighty two postmenopausal osteoporotic women, 76 postmenopausal non osteoporotic women, and 80 healthy women of childbearing age were recruited. The total hip, femoral neck, and L1 L4 spine bone mineral density were assessed by dual energy X ray absorptiometry. Serum cytokine ligand 3 concentrations were examined using a commercial enzyme linked immunosorbent assay kit. Serum inflammatory cytokine interleukin 6, tumor necrosis factor alpha, and the bone metabolic markers. carboxy terminal crosslinked and tartrate resistant acid phosphatase 5b were also examined. Scores on both the visual analogue scale and the Oswestry Disability Index were utilized to assess clinical severity.
   Results: Patients in the postmenopausal osteoporotic group had significantly increased serum cytokine ligand 3 levels compared with those in both the postmenopausal non osteoporotic group (40.9)+/  15.1 pg/mL vs 24.2 +/  8.7 pg/mL, p<0.00l) and control group (40.9 +/  15.1 pg/mL vs 23.9 +/  9.1 pg/mL, p<0.001). Serum cytokine ligand 3 levels negatively correlated with bone mineral density at the total hip (r= 0.345, p=0.002), femoral neck (r= 0.329, p=0.003), and L1 L4 lumbar spine (r= 0.354, p=0.001 )and positively correlated with visual analogue scale scores (r=0.413, p<0.001) and the Oswestry Disability Index (r=0.360, p<0.001). Moreover, serum cytokine ligand 3 levels were correlated with increased tumor necrosis factor alpha (r=0.305, p=0.005), interleukin 6 (r=0.288. p=0.008), terminal crosslinked and tartrate resistant acid phosphatase 5b(r=0.371, p<0.001), and carboxy terminal crosslinked (r=0.317, p=0.004) levels. All correlations were still significant after adjusting for both body mass index and age.
   Conclusion: Chemokine cytokine ligand 3 may be a useful biomarker that can be used to predict disease severity of postmenopausal osteoporosis. Therapies targeting cytokine ligand 3 and its related signaling pathways to inhibit and delay the osteoclastogenesis process deserve further investigation.
C1 [Wan, Hui; Qian, Tie Yong; Hu, Xiao Jing; Huang, Ci You; Yao, Wei Feng] Nanjing Med Univ, Dept Endocrinol, Affiliated Wuxi Hosp 2, Wuxi, Peoples R China.
C3 Nanjing Medical University
RP Qian, TY (通讯作者)，Nanjing Med Univ, Dept Endocrinol, Affiliated Wuxi Hosp 2, Wuxi, Peoples R China.
EM qiantieyong0122@163.com
RI Yao, Weifeng/I 7394 2013
FU Wuxi Hospital Management for Medical Development Program [YGM 1130]
FX This research was funded by Wuxi Hospital Management for Medical
   Development Program (YGM 1130).
CR Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198 009 0920 3
   [Anonymous], 1994, World Health Organ Tech Rep Ser, V843, P1
   Baba T, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29899
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Brincat S D, 2014, Minerva Ginecol, V66, P391
   Chan CKY, 2016, BRIT MED BULL, V119, P129, DOI 10.1093/bmb/ldw033
   Charles JF, 2014, CURR OSTEOPOROS REP, V12, P1, DOI 10.1007/s11914 014 0195 2
   Cockerill W, 2004, OSTEOPOROSIS INT, V15, P113, DOI 10.1007/s00198 003 1547 4
   Compston J, 2016, CLIN MED LOND S6, V16, P121
   Eastell R, 2008, P NUTR SOC, V67, P157, DOI 10.1017/S002966510800699X
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632 200011150 00017
   Fan YL, 2016, SEMIN MUSCULOSKEL R, V20, P235, DOI 10.1055/s 0036 1592371
   Fechtenbaum J, 2005, OSTEOPOROSIS INT, V16, P2175, DOI 10.1007/s00198 005 2023 0
   Fu R, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935 014 0132 6
   Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543
   Hayman AR, 2001, J HISTOCHEM CYTOCHEM, V49, P675, DOI 10.1177/002215540104900601
   HAYMAN AR, 1991, BIOCHEM J, V277, P631, DOI 10.1042/bj2770631
   Iwamoto J, 2004, CLIN RHEUMATOL, V23, P383, DOI 10.1007/s10067 004 0881 z
   Jämsen E, 2017, J BIOMED MATER RES A, V105, P454, DOI 10.1002/jbm.a.35913
   Johansson H, 2014, CALCIFIED TISSUE INT, V94, P560, DOI 10.1007/s00223 014 9842 y
   Kawana K, 2002, CLIN CHIM ACTA, V316, P109, DOI 10.1016/S0009 8981(01)00742 2
   Kawao N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123982
   Kim MS, 2006, J CELL BIOCHEM, V97, P512, DOI 10.1002/jcb.20649
   Kukita T, 1997, ENDOCRINOLOGY, V138, P4384, DOI 10.1210/en.138.10.4384
   Kukita T, 1997, LAB INVEST, V76, P399
   Legler DF, 2016, CHIMIA, V70, P856, DOI 10.2533/chimia.2016.856
   Llorián Salvador M, 2016, BASIC CLIN PHARMACOL, V119, P32, DOI 10.1111/bcpt.12543
   Obrant KJ, 2005, BONE, V36, P786, DOI 10.1016/j.bone.2005.02.009
   Ohtori S, 2010, J CLIN NEUROSCI, V17, P209, DOI 10.1016/j.jocn.2009.06.013
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Pisani P, 2016, WORLD J ORTHOP, V7, P171, DOI 10.5312/wjo.v7.i3.171
   Schweser KM, 2017, CURR REV MUSCULOSKE, V10, P265, DOI 10.1007/s12178 017 9410 y
   Shetty Sahana, 2016, Indian J Endocrinol Metab, V20, P846
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Teodorczyk Injeyan JA, 2011, J MANIP PHYSIOL THER, V34, P498, DOI 10.1016/j.jmpt.2011.08.010
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Wu YL, 2009, J PHARMACEUT BIOMED, V49, P1203, DOI 10.1016/j.jpba.2009.03.002
   Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065 2776(01)78002 9
   Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007
NR 39
TC 13
Z9 14
U1 0
U2 3
PU GALENOS PUBL HOUSE
PI ISTANBUL
PA  MOLLA GURANI MAHALLESI KACAMAK SOKAK NO 21 1, ISTANBUL, TURKEY
SN 2146 3123
EI 2146 3131
J9 BALK MED J
JI Balk. Med. J.
PD JUL
PY 2018
VL 35
IS 4
BP 320
EP 325
DI 10.4274/balkanmedj.2017.1165
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA GN9DP
UT WOS:000439486200005
PM 29666038
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Lee, YT
   Ng, HY
   Kuo, CC
   Chen, TC
   Wu, CS
   Chiu, TTY
   Lee, WC
   Lee, CT
AF Lee, Yueh Ting
   Ng, Hwee Yeong
   Kuo, Chien Chun
   Chen, Te Chuan
   Wu, Chien Shing
   Chiu, Terry Ting Yu
   Lee, Wen Chin
   Lee, Chien Te
TI Comparison between Calcitriol and Calcitriol Plus Low Dose Cinacalcet
   for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in
   Chronic Dialysis Patients
SO NUTRIENTS
LA English
DT Article
DE cinacalcet; uremic hyperparathyroidism; dialysis; parathyroid hormone
ID PARATHYROID HORMONE LEVELS; CHRONIC KIDNEY DISEASE; VITAMIN D; MINERAL
   METABOLISM; CALCIUM LEVELS; HEMODIALYSIS; PARICALCITOL; SURVIVAL;
   PHOSPHORUS; THERAPY
AB Aim: Uremic hyperparathyroidism (UHPT) has been shown to contribute to the development and progression of chronic kidney disease mineral bone disorder. UHPT is frequently observed in chronic dialysis patients, and patients with UHPT are associated with increased risk of all cause and cardiovascular mortality. Cinacalcet is a novel agent that increases sensitivity to the calcium sensing receptor and is approved for control of UHPT. Nevertheless, cinacalcet is costly and information regarding efficacy of low dose cinacalcet on UHPT is limited. Methods: We conducted a retrospective study to evaluate treatment with either low dose calcitriol combined with low dose cinacalcet (25 mg) (D Cinacalcet) or calcitriol alone (VitD) in dialysis patients with moderate to severe UHPT. A total of 81 dialysis patients were enrolled (40 subjects in D Cinacalcet group and 41 subjects in VitD group). Demographic data including age, gender, duration on dialysis and biochemical data were reviewed and recorded. Results: At the end of the study, the intact parathyroid hormone (iPTH) levels of the D Cinacalcet group declined significantly (from 1166.0 +/  469.3 pg/mL to 679.8 +/  421.6 pg/mL, p < 0.0001), while there was no significant change in the VitD group. Significant decrease of serum calcium (Ca: 9.9 +/  0.6 mg/dL vs. 9.6 +/  0.8 mg/dL, p = 0.002), phosphorus (P: 5.9 +/  1.3 mg/dL vs. 4.9 +/  0.9 mg/dL, p < 0.0001) and calcium phosphate product (Ca x P: 58.7 +/  15.0 mg(2)/dL(2) vs. 46.9 +/  8.9 mg(2)/dL(2), p < 0.0001) were observed in the D Cinacalcet group. In addition, the subjects in the D Cinacalcet group had a greater proportion to achieve Kidney Disease Outcomes Quality Initiative (KDOQI) recommended biochemical targets than the subjects in the VitD group (Ca: 48% vs. 24%; P: 78% vs. 32%; Ca x P: 85% vs. 37%; iPTH: 15% vs. 0%). Conclusions: We conclude that combination therapy of low dose cinacalcet and calcitriol is more effective than calcitriol alone as a treatment for moderate and severe UHPT in chronic dialysis patients. Furthermore, this therapy is associated with improvement in hyperphosphatemia and hypercalcemia.
C1 [Lee, Yueh Ting; Ng, Hwee Yeong; Kuo, Chien Chun; Chen, Te Chuan; Wu, Chien Shing; Chiu, Terry Ting Yu; Lee, Wen Chin; Lee, Chien Te] Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Div Nephrol,Dept Internal Med, Kaohsiung 833, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University
RP Lee, CT (通讯作者)，Chang Gung Univ, Coll Med, Kaohsiung Chang Gung Mem Hosp, Div Nephrol,Dept Internal Med, Kaohsiung 833, Taiwan.
EM yuai@adm.cgmh.org.tw; kujiben@gmail.com; gary@adm.cgmh.org.tw;
   puppy@adm.cgmh.org.tw; vjf3@adm.cgmh.org.tw; tytc107@gmail.com;
   leewc@adm.cgmh.org.tw; chientel@gmail.com
RI LEE, Wen Chin/AAQ 8466 2021
OI LEE, Wen Chin/0000 0001 6172 1483
CR Antonsen JE, 1998, KIDNEY INT, V53, P223, DOI 10.1046/j.1523 1755.1998.00735.x
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 2008, NEPHROL DIAL TRANSPL, V23, P2311, DOI 10.1093/ndt/gfn026
   Block GA, 2010, KIDNEY INT, V78, P578, DOI 10.1038/ki.2010.167
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Fishbane S, 2008, CLIN J AM SOC NEPHRO, V3, P1718, DOI 10.2215/CJN.01040308
   Frazao JM, 2011, CLIN NEPHROL, V76, P233, DOI 10.5414/CN106965
   Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534
   Goodman WG, 2000, KIDNEY INT, V58, P436, DOI 10.1046/j.1523 1755.2000.00183.x
   Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Krajisnik T, 2007, J ENDOCRINOL, V195, P125, DOI 10.1677/JOE 07 0267
   Lee CT, 2009, J RENAL NUTR, V19, P220, DOI 10.1053/j.jrn.2008.11.004
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Li D, 2013, ENDOCRINE, V43, P68, DOI 10.1007/s12020 012 9711 2
   Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Palmer SC, 2007, ANN INTERN MED, V147, P840, DOI 10.7326/0003 4819 147 12 200712180 00004
   Palmer SC, 2011, JAMA J AM MED ASSOC, V305, P1119, DOI 10.1001/jama.2011.308
   Panda DK, 2004, J BIOL CHEM, V279, P16754, DOI 10.1074/jbc.M310271200
   PITTS TO, 1988, J CLIN ENDOCR METAB, V67, P876, DOI 10.1210/jcem 67 5 876
   Ross EA, 2008, AM J NEPHROL, V28, P97, DOI 10.1159/000109398
   Rothe Hansjorg M, 2005, Pharmacogenet Genomics, V15, P29
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
NR 29
TC 5
Z9 12
U1 0
U2 31
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 2072 6643
J9 NUTRIENTS
JI Nutrients
PD APR
PY 2013
VL 5
IS 4
BP 1336
EP 1348
DI 10.3390/nu5041336
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 131TP
UT WOS:000318019300019
PM 23603995
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Tousi, NS
   Velten, MF
   Bishop, TJ
   Leong, KK
   Barkhordar, NS
   Marshall, GW
   Loomer, PM
   Aswath, PB
   Varanasi, VG
AF Tousi, Neda Saffarian
   Velten, Megen F.
   Bishop, Timothy J.
   Leong, Kelly K.
   Barkhordar, Nicole S.
   Marshall, Grayson W.
   Loomer, Peter M.
   Aswath, Pranesh B.
   Varanasi, Venu G.
TI Combinatorial effect of Si<SUP>4+</SUP>, Ca<SUP>2+</SUP>, and
   Mg<SUP>2+</SUP> released from bioactive glasses on osteoblast
   osteocalcin expression and biomineralization
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Bioactive glasses; Tissue engineering; Bone regeneration; Dental implant
ID IN VITRO; BONE; COATINGS; MINERALIZATION; DISSOLUTION; TI6AL4V; TIME
AB Osteocalcin (OCN) expression is an essential osteogenic marker of successful bone regeneration therapies. This study hypothesizes that Si4+ and Ca2+ combinatorial released by bioactive glass enhance osteoblast biomineralization through up regulation of OCN expression; and Mg2+ release delays such enhancement. Osteoblasts (MC3T3 E1) were treated with ionic products of bioactive glass dissolution (6P53 b experimental bioactive glass and 45S5 commercial Bioglass (TM)). Results showed that gene expressions, including OCN and its up stream transcription factors (Runx2, ATF4, MSX1, SP7/OSX), growth factors and signaling proteins (BMP2, BMP6, SMAD3), were enhanced in both 45S5 and 6P53 b glass conditioned mediums (GCMs). This up regulation led to enhanced mineral formation by 45S5 glass conditioned mediums ([GCM], Si4+ + Ca2+) after 20 days, and by 45S5 GCM and 6P53 b GCM (Si4+ + Ca2+ + Mg2+) after 30 days. In examining the extracellular matrix generated by cells when exposed to each GCM, it was found that 45S5 GCM had slightly elevated levels of mineral content within ECM as compared to 6P53 b GCM after 30 days while control treatments exhibited no mineral content. The formation of well defined mineralized nodules (distinct PO43  [960 cm( 1)] and CO32  [1072 cm( 1)] peaks from Raman Spectra) was observed for each GCM as the soluble glass content increased. In examining the individual and combined ion effects between Si4+, Ca2+, and Mg2+, it was found Mg2+ down regulates OCN expression. Thus, ions released from both 45S5 and 6P53 b bioactive glasses up regulate OCN expression and biomineralization while 6P53 b GCM Mg2+ release down regulated OCN expression and delayed osteoblast biomineralization. These results indicate that Si4+, Ca2+, and Mg2+ combinatorially regulate osteoblast OCN expression and biomineralization. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Tousi, Neda Saffarian; Varanasi, Venu G.] Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dept Biomed Sci, Dallas, TX 75246 USA.
   [Velten, Megen F.; Aswath, Pranesh B.] Univ Texas Arlington, Dept Mat Sci & Engn, Arlington, TX 75019 USA.
   [Bishop, Timothy J.; Leong, Kelly K.; Loomer, Peter M.] Univ Calif San Francisco, Sch Dent, Div Periodontol, San Francisco, CA 94143 USA.
   [Barkhordar, Nicole S.; Marshall, Grayson W.] Univ Calif San Francisco, Sch Dent, Dept Prevent & Restorat Dent Sci, San Francisco, CA 94143 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; University of Texas System; University of
   Texas Arlington; University of California System; University of
   California San Francisco; University of California System; University of
   California San Francisco
RP Varanasi, VG (通讯作者)，Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dept Biomed Sci, Sci Bldg,Room 130 H,3302 Gaston Ave, Dallas, TX 75246 USA.
EM varanasi@bcd.tamhsc.edu
RI Aswath, Pranesh/O 8215 2019
OI Aswath, Pranesh/0000 0003 2885 1918; Marshall, Grayson
   W/0000 0001 8921 3253
FU American Academy for Implant Dentistry (dental student fellowship);
   National Institutes for Health; National Institute for Dental and
   Craniofacial Research [1 K25 DE018230 01, A107380]
FX The authors would like to thank Ariel Tsao, Elise Lee, Lisa M. Dominia,
   Mariam Muhanna, and Rinkesh Patel for their contribution to this work.
   The authors would also like to thank the American Academy for Implant
   Dentistry (dental student fellowship) and the National Institutes for
   Health and the National Institute for Dental and Craniofacial Research
   (grant 1 K25 DE018230 01 (Varanasi, PI) and A107380 (Varanasi, PI)) for
   their support.
CR [Anonymous], 2011, CALCIF TISSUE INT, V88, P246
   Cai Y.Z., 2010, J BIOMED MAT RES A, V95, P49
   CARPENTER TO, 1992, AM J PHYSIOL, V263, pE107, DOI 10.1152/ajpendo.1992.263.1.E107
   Ciapetti G, 2003, BIOMATERIALS, V24, P3815, DOI 10.1016/S0142 9612(03)00263 1
   Eastell R, 2010, BONE, V46, P929, DOI 10.1016/j.bone.2009.12.021
   Fedorova MZ, 2009, B EXP BIOL MED+, V148, P822, DOI 10.1007/s10517 010 0826 2
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009 1703
   Gomez Vega JM, 2001, J BIOMED MATER RES, V56, P382, DOI 10.1002/1097 4636(20010905)56:3<382::AID JBM1107>3.0.CO;2 P
   Hench LL, 1998, J AM CERAM SOC, V81, P1705
   Hisa I, 2011, J BIOL CHEM, V286, P9787, DOI 10.1074/jbc.M110.179127
   Hu YY, 2003, J BIOMED MATER RES A, V67A, P591, DOI 10.1002/jbm.a.10070
   Inanc B, 2006, TISSUE ENG, V12, P257, DOI 10.1089/ten.2006.12.257
   Kontonasaki E, 2002, CRYST RES TECHNOL, V37, P1165, DOI 10.1002/1521 4079(200211)37:11<1165::AID CRAT1165>3.0.CO;2 R
   Leidi M, 2011, MAGNESIUM RES, V24, P1, DOI 10.1684/mrh.2011.0271
   Oku T, 2001, J MATER SCI MATER M, V12, P413, DOI 10.1023/A:1011296903316
   Petricca SE, 2006, ACTA BIOMATER, V2, P277, DOI 10.1016/j.actbio.2005.12.004
   Qiu H, 2007, BIOTECHNIQUES, V42, P355, DOI 10.2144/000112331
   Saiz E, 2002, BIOMATERIALS, V23, P3749, DOI 10.1016/S0142 9612(02)00109 6
   Sepulveda P, 2000, KEY ENG MAT, V192 1, P629, DOI 10.4028/www.scientific.net/KEM.192 195.629
   Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190
   Stewart S, 2002, J RAMAN SPECTROSC, V33, P536, DOI 10.1002/jrs.892
   Tomsia A.P., 2011, GLASS CERAMIC COATIN
   Varanasi VG, 2009, ACTA BIOMATER, V5, P3536, DOI 10.1016/j.actbio.2009.05.035
   Varanasi V.G., 2006, MAT RES SOC S P
   Varanasi VG, 2012, J ORAL IMPLANTOL, V38, P325, DOI 10.1563/AAID JOI D 11 00108
   Varanasi VG, 2011, J BIOMED MATER RES A, V98A, P177, DOI 10.1002/jbm.a.33102
   WILSON J, 1992, J APPL BIOMATER, V3, P123, DOI 10.1002/jab.770030208
   Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103
NR 28
TC 90
Z9 95
U1 2
U2 57
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 4931
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD JUL 1
PY 2013
VL 33
IS 5
BP 2757
EP 2765
DI 10.1016/j.msec.2013.02.044
PG 9
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA 153VH
UT WOS:000319630100037
PM 23623093
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Eastell, R
   Hannon, RA
AF Eastell, Richard
   Hannon, Rosemary A.
TI Biomarkers of bone health and osteoporosis risk
SO PROCEEDINGS OF THE NUTRITION SOCIETY
LA English
DT Article; Proceedings Paper
CT Symposium on Diet and Cancer/Diet and Bone Health/Diet and CVD
CY JUL 16 19, 2008
CL Univ Ulster, Coleraine, IRELAND
HO Univ Ulster
DE bone turnover markers; bone mineral density; bone health; osteoporosis
ID HORMONE REPLACEMENT THERAPY; PYRIDINIUM CROSS LINKS; VERTEBRAL FRACTURE
   RISK; RANDOMIZED CLINICAL TRIAL; ALENDRONATE 70 MG; BIOCHEMICAL MARKERS;
   POSTMENOPAUSAL WOMEN; ELDERLY WOMEN; I COLLAGEN; URINARY EXCRETION
AB The assay features of biochemical markers of bone turnover have markedly improved in the past few years. The most sensitive and specific markers of bone formation include serum bone alkaline phosphatase, total osteocalcin (including the intact molecule and the large N mid fragment) and the procollagen type I N terminal propeptide assay. Among the various markers of bone resorption, measurements of the urinary excretion of N  and C terminal cross linked telopeptides) and of serum C terminal cross linked telopeptides are the most sensitive and specific. Markers of bone turnover can be used to predict the rate of bone loss in postmenopausal women and can also be used to assess the risk of fractures. In osteoporosis treatment studies (with alendronate, risedronate, raloxifene) markers of bone turnover appear even more strongly associated with fracture risk reduction than bone mineral density (BMD). These observations support the use of markers of bone turnover as surrogates for fracture risk reduction, perhaps even more so than BMD. Bone markers can also be used to monitor the efficacy of antiresorptive therapy such as hormone replacement therapy, raloxifene and bisphosphonates in individual patients. Furthermore, they have also proved to be helpful in monitoring the response to nutritional interventions and have the advantage over BMD in that they provide information about mechanism of effect and changes are often observed much more rapidly.
C1 [Eastell, Richard; Hannon, Rosemary A.] Univ Sheffield, No Gen Hosp, Acad Unit Bone Metab, Metab Bone Ctr, Sheffield S5 7AU, S Yorkshire, England.
C3 University of Sheffield; Northern General Hospital
RP Eastell, R (通讯作者)，Univ Sheffield, No Gen Hosp, Acad Unit Bone Metab, Metab Bone Ctr, Sheffield S5 7AU, S Yorkshire, England.
EM r.eastell@sheffield.ac.uk
RI Eastell, Richard/G 5851 2011
CR Bauer DC, 1999, J BONE MINER RES, V14, P1404, DOI 10.1359/jbmr.1999.14.8.1404
   BAUER DC, 2006, J CLIN ENDOCRIN 0131
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Cosman F, 1996, CALCIFIED TISSUE INT, V58, P236
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140 6736(93)92555 8
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Delmas PD, 2002, J CLIN ENDOCR METAB, V87, P3609, DOI 10.1210/jc.87.8.3609
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   DresnerPollak R, 1996, CALCIFIED TISSUE INT, V59, P328, DOI 10.1007/s002239900135
   EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem 67 4 741
   EASTELL R, 1993, OSTEOPOROSIS INT, V3, P255, DOI 10.1007/BF01623829
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Ebeling PR, 1996, J CLIN ENDOCR METAB, V81, P3366, DOI 10.1210/jc.81.9.3366
   Garnero P, 1998, OSTEOPOROSIS INT, V8, P563, DOI 10.1007/s001980050100
   Garnero P, 2002, J BONE MINER RES, V17, P826, DOI 10.1359/jbmr.2002.17.5.826
   GARNERO P, 1995, J BONE MINER RES, V10, P641
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Garnero P, 1996, J BONE MINER RES, V11, P1531
   Garnero P, 1999, J BONE MINER RES, V14, P1614, DOI 10.1359/jbmr.1999.14.9.1614
   Gerdhem P, 2004, J BONE MINER RES, V19, P386, DOI 10.1359/JBMR.0301244
   Gorai I, 1997, CALCIFIED TISSUE INT, V60, P317, DOI 10.1007/s002239900235
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P2762, DOI 10.1210/jc.2004 1091
   Greenspan SL, 2002, J BONE MINER RES, V17, P1988
   Greenspan SL, 2000, J CLIN ENDOCR METAB, V85, P3537, DOI 10.1210/jc.85.10.3537
   Griesmacher A, 1997, SCAND J CLIN LAB I S, V227, P64
   Hannon RA, 2004, BONE, V34, P187, DOI 10.1016/j.bone.2003.04.002
   Hannon Rosemary A, 2003, J Br Menopause Soc, V9, P10, DOI 10.1258/136218003100322080
   Hansdóttir H, 2004, J AM GERIATR SOC, V52, P779, DOI 10.1111/j.1532 5415.2004.52218.x
   HANSON DA, 1992, J BONE MINER RES, V7, P1251
   Harris ST, 2001, J CLIN ENDOCR METAB, V86, P1890, DOI 10.1210/jc.86.5.1890
   HASSAGER C, 1994, OSTEOPOROSIS INT, V4, P349, DOI 10.1007/BF01622196
   HASSAGER C, 1992, CLIN ENDOCRINOL, V37, P45, DOI 10.1111/j.1365 2265.1992.tb02282.x
   Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413
   Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198 007 0343 y
   KELLY PJ, 1989, J CLIN ENDOCR METAB, V69, P1160, DOI 10.1210/jcem 69 6 1160
   Kerschan Schindl K, 2005, EXP GERONTOL, V40, P532, DOI 10.1016/j.exger.2005.04.001
   KUSHIDA K, 1995, J CLIN ENDOCR METAB, V80, P2447, DOI 10.1210/jc.80.8.2447
   Marshall LA, 1996, OBSTET GYNECOL, V87, P350, DOI 10.1016/0029 7844(95)00424 6
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Meier C, 2006, CLIN LAB, V52, P1
   Melkko J, 1996, CLIN CHEM, V42, P947
   Melton LJ, 1997, J BONE MINER RES, V12, P1083, DOI 10.1359/jbmr.1997.12.7.1083
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   MOLE PA, 1992, EUR J CLIN INVEST, V22, P767, DOI 10.1111/j.1365 2362.1992.tb01444.x
   Perrien DS, 2006, J CLIN ENDOCR METAB, V91, P1848, DOI 10.1210/jc.2005 2423
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   Ravn P, 1996, BONE, V19, P291, DOI 10.1016/8756 3282(96)00201 3
   Ravn P, 2003, BONE, V33, P150, DOI 10.1016/S8756 3282(03)00168 6
   Reginster JY, 2004, BONE, V34, P344, DOI 10.1016/j.bone.2003.10.004
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Rogers A, 2000, J BONE MINER RES, V15, P1398, DOI 10.1359/jbmr.2000.15.7.1398
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Sarkar S, 2004, J BONE MINER RES, V19, P394, DOI 10.1359/JBMR.0301243
   Schneider DL, 1997, ARCH INTERN MED, V157, P1241, DOI 10.1001/archinte.157.11.1241
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   UEBELHART D, 1990, BONE MINER, V8, P87, DOI 10.1016/0169 6009(91)90143 N
   UEBELHART D, 1991, J CLIN ENDOCR METAB, V72, P367, DOI 10.1210/jcem 72 2 367
   VALIMAKI MJ, 1994, EUR J ENDOCRINOL, V131, P258, DOI 10.1530/eje.0.1310258
NR 59
TC 154
Z9 175
U1 2
U2 12
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0029 6651
J9 P NUTR SOC
JI Proc. Nutr. Soc.
PD MAY
PY 2008
VL 67
IS 2
BP 157
EP 162
DI 10.1017/S002966510800699X
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Nutrition & Dietetics
GA 301EF
UT WOS:000255878500004
PM 18412989
OA Bronze
DA 2025 08 17
ER

PT J
AU Rejnmark, L
   Vestergaard, P
   Heickendorff, L
   Mosekilde, L
AF Rejnmark, Lars
   Vestergaard, Peter
   Heickendorff, Lene
   Mosekilde, Leif
TI Simvastatin Does Not Affect Vitamin D Status, but Low Vitamin D Levels
   Are Associated with Dyslipidemia: Results from a Randomised, Controlled
   Trial
SO INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID BONE MINERAL DENSITY; MYOCARDIAL INFARCTION; POSTMENOPAUSAL WOMEN;
   PARATHYROID HORMONE; SERUM LEVELS; STATINS; RISK; 25 HYDROXYVITAMIN D;
   ATORVASTATIN; PRAVASTATIN
AB Objectives. Statin drugs act as inhibitors of the 3 hydroxy 3methylglutaryl coenzyme A (HMG CoA) reductase enzyme early in the mevalonate pathway, thereby reducing the endogenous cholesterol synthesis. In recent studies, it has been suggested from epidemiological data that statins also may improve vitamin D status, as measured by increased plasma 25 hydroxyvitamin D (25OHD) levels. We now report the results from a randomised controlled trial on effects of simvastatin on plasma 25OHD levels. Design and Methods. We randomised 82 healthy postmenopausal women to one year of treatment with either simvastatin 40 mg/d or placebo and performed measurement at baseline and after 26 and 52 weeks of treatment. The study was completed by 77 subjects. Results. Compared with placebo, plasma levels of cholesterol and low density lipoproteins decreased in response to treatment with simvastatin, but our study showed no effect of simvastatin on vitamin D status. However, plasma levels of triglycerides were inversely associated with tertiles of plasma 25OHD levels and changes in plasma triglycerides levels correlated inversely with seasonal changes in vitamin D status. Conclusion. Our data do not support a pharmacological effect of statins on vitamin D status, but do suggest that vitamin D may influence plasma lipid profile and thus be of importance to cardiovascular health.
C1 [Rejnmark, Lars; Vestergaard, Peter; Mosekilde, Leif] Aarhus Univ Hosp, Aarhus Sygehus, Dept Endocrinol & Metab C, DK 8000 Aarhus, Denmark.
   [Heickendorff, Lene] Aarhus Univ Hosp, Aarhus Sygehus, Dept Clin Biochem, DK 8000 Aarhus, Denmark.
C3 Aarhus University; Aarhus University
RP Rejnmark, L (通讯作者)，Aarhus Univ Hosp, Aarhus Sygehus, Dept Endocrinol & Metab C, DK 8000 Aarhus, Denmark.
EM rejnmark@post6.tele.dk
OI Rejnmark, Lars/0000 0002 2152 4247
CR Aloia JF, 2007, AM J CARDIOL, V100, P1329, DOI 10.1016/j.amjcard.2007.05.024
   Bauer DC, 2004, ARCH INTERN MED, V164, P146, DOI 10.1001/archinte.164.2.146
   Bone HG, 2007, J CLIN ENDOCR METAB, V92, P4671, DOI 10.1210/jc.2006 1909
   CARLSON LA, 1970, ATHEROSCLEROSIS, V12, P313, DOI 10.1016/0021 9150(70)90111 5
   DOBS AS, 1991, METABOLISM, V40, P524, DOI 10.1016/0026 0495(91)90235 O
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Farwell WR, 2008, JNCI J NATL CANCER I, V100, P134, DOI 10.1093/jnci/djm286
   Gannagé Yared MH, 2003, J ENDOCRINOL INVEST, V26, P748, DOI 10.1007/BF03347358
   Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174
   Hatzigeorgiou C, 2005, OSTEOPOROSIS INT, V16, P990, DOI 10.1007/s00198 004 1793 0
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   ISMAIL F, 1990, CLIN THER, V12, P427
   Krause R, 1998, LANCET, V352, P709, DOI 10.1016/S0140 6736(05)60827 6
   Le Ngoc Anh, 2007, Curr Atheroscler Rep, V9, P110, DOI 10.1007/s11883 007 0006 7
   Li YC, 2004, J STEROID BIOCHEM, V89 90, P387, DOI 10.1016/j.jsbmb.2004.03.004
   Lupattelli G, 2004, METABOLISM, V53, P744, DOI 10.1016/j.metabol.2004.01.010
   Mak RHK, 1998, KIDNEY INT, V53, P1353, DOI 10.1046/j.1523 1755.1998.00865.x
   Martins D, 2007, ARCH INTERN MED, V167, P1159, DOI 10.1001/archinte.167.11.1159
   Maunsell Z, 2005, CLIN CHEM, V51, P1683, DOI 10.1373/clinchem.2005.052936
   Melamed ML, 2008, ARCH INTERN MED, V168, P1629, DOI 10.1001/archinte.168.15.1629
   MERKE J, 1989, J CLIN INVEST, V83, P1903, DOI 10.1172/JCI114097
   MONTAGNANI M, 1994, CLIN THER, V16, P824
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   OConnell TD, 1997, AM J PHYSIOL HEART C, V272, pH1751
   Pérez Castrillón JL, 2008, EUR REV MED PHARMACO, V12, P83
   Perez Castrillón JL, 2007, AM J CARDIOL, V99, P903, DOI 10.1016/j.amjcard.2006.11.036
   Querfeld U, 1999, J AM SOC NEPHROL, V10, P2158
   Rejnmark L, 2006, CALCIFIED TISSUE INT, V79, P27, DOI 10.1007/s00223 006 0024 4
   Rejnmark L, 2004, OSTEOPOROSIS INT, V15, P452, DOI 10.1007/s00198 003 1568 z
   Rejnmark L, 2002, EUR J CLIN INVEST, V32, P581, DOI 10.1046/j.1365 2362.2002.01024.x
   REJNMARK L, 2001, J BONE MINER RES, V19, P737
   SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   TUPPURAINEN M, 1995, MATURITAS, V22, P55, DOI 10.1016/0378 5122(95)00909 5
   van Staa TP, 2001, JAMA J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850
   Wilczek H, 1994, Cas Lek Cesk, V133, P727
   Wilczek H, 1989, Cas Lek Cesk, V128, P1254
   Wu Wong JR, 2007, J VASC RES, V44, P11, DOI 10.1159/000097812
NR 38
TC 58
Z9 63
U1 0
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 8337
EI 1687 8345
J9 INT J ENDOCRINOL
JI Int. J. Endocrinol.
PY 2010
VL 2010
AR 957174
DI 10.1155/2010/957174
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 689PG
UT WOS:000284939700001
PM 20016680
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Liu, HX
   Shen, Y
   Zhao, BK
   Poon, EH
   Qi, SC
   Ker, DFE
   Billiar, TR
   Cooper, GM
   Xu, YZ
   Wang, D
AF Liu, Haixia
   Shen, Yun
   Zhao, Bingkun
   Poon, Enoch H.
   Qi, Shengcai
   Ker, Dai Fei Elmer
   Billiar, Timothy R.
   Cooper, Gregory M.
   Xu, Yuanzhi
   Wang, Dan
TI Short Term Administration of HIV Protease Inhibitor Saquinavir Improves
   Skull Bone Healing with Enhanced Osteoclastogenesis
SO PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID HMGB1; TLR4/MYD88/NF KAPPA B; DIFFERENTIATION; CELLS
AB Background: Using immunomodulatory methods to address the challenging issue of craniofacial bone repair may be a potentially effective approach. The protease inhibitor saquinavir has been shown to inhibit the inflammatory response by targeting the toll like receptor 4/myeloid differentiation primary response complex. Independently, inhibition of toll like receptor 4 or myeloid differentiation primary response led to enhanced skull bone repair. Therefore, the authors aimed to investigate the effects of saquinavir on skull bone healing.
   Methods: The effects of saquinavir on skull bone healing were assessed by means of gene expression, histology, immunohistochemistry, and tomography in a mouse calvarial defect model. Subsequently, the role of saquinavir in cell viability, migration, and osteogenic and osteoclastogenic differentiation was also evaluated in vitro.
   Results: One week saquinavir administration improved skull bone healing based on micro computed tomographic and histomorphometric analyses. Compared to the vehicle control, 1 week saquinavir treatment (1) enhanced osteoclast infiltration (tartrate resistant acid phosphatase staining) at day 7, but not at days 14 and 28; (2) induced more CD206(+) M2 macrophage infiltration, but not F4/80(+) M0 macrophages at days 7, 14, and 28; and (3) elevated osteoclastogenic gene RANKL(quantitative polymerase chain reaction) expression and other osteogenic and cytokine expression. Furthermore, in vitro data showed that saquinavir administration did not influence MC3T3 E1 cell migration or mineralization, whereas higher concentrations of saquinavir inhibited cell viability. Saquinavir treatment also enhanced the osteoclastic differentiation of bone marrow derived precursors, and partially reversed high mobility group box 1 driven osteoclastogenesis inhibition and elevated proinflammatory cytokine expression.
   Conclusion: The improved skull bone repair following short term saquinavir treatment may involve enhanced osteoclastogenesis and modulated inflammatory response following skull injury.
   Clinical Relevance Statement: The authors' work demonstrates improved skull bone healing by short term application of saquinavir, a drug traditionally used in the treatment of acquired immunodeficiency syndrome. As such, saquinavir may be repurposed for skeletal repair.
C1 Tongji Univ, Dept Stomatol, Shanghai Peoples Hosp 10, Sch Med, Shanghai, Peoples R China.
   Chinese Univ Hong Kong, Inst Tissue Engn & Regenerat Med, Hong Kong, Peoples R China.
   Chinese Univ Hong Kong, Key Lab Regenerat Med, Minist Educ, Sch Biomed Sci,Fac Med, Hong Kong, Peoples R China.
   Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
   Univ Pittsburgh, Dept Plast Surg, Pittsburgh, PA USA.
   Univ Pittsburgh, Dept Oral Biol, Pittsburgh, PA USA.
   Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA.
C3 Tongji University; Chinese University of Hong Kong; Chinese University
   of Hong Kong; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Wang, D (通讯作者)，Chinese Univ Hong Kong, Inst Tissue Engn & Regenerat Med, Area 39, Shatin, 422A,Lo Kwee Seong Integrated Biomed Sci Bldg, Hong Kong, Peoples R China.; Xu, YZ (通讯作者)，Tongji Univ, Peoples Hosp 10, Dept Stomatol, 299 Yanchang Rd, Shanghai, Peoples R China.
EM 18917683819@163.com; wangmd@cuhk.edu.hk
RI Ker, Dai Fei Elmer/R 5959 2018; Zhang, Guangyuan/AAD 5494 2020; Billiar,
   Timothy R./JTU 2118 2023; shenghai, qi/S 4522 2019; Wang,
   Dan/R 5941 2018; Cooper, Gregory/ABI 4744 2022
OI Ker, Dai Fei Elmer/0000 0003 3434 8390; Wang, Dan/0000 0002 5934 9085; 
FU National Natural Science Foundation of China [8102141]
FX This work was supported by the National Natural Science Foundation of
   China No. 8102141 (principal investigator, Dan Wang). Funding sources
   were not involved in the study design, data collection, data analysis,
   manuscript preparation, or submission.
CR Aukrust P, 1999, J CLIN ENDOCR METAB, V84, P145, DOI 10.1210/jc.84.1.145
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Bykowski MR, 2019, CLIN PLAST SURG, V46, P173, DOI 10.1016/j.cps.2018.11.003
   Chao MT, 2009, CRANIOMAX TRAUM REC, V2, P103, DOI 10.1055/s 0029 1215873
   Chen QJ, 2016, ACTA PHARM SIN B, V6, P183, DOI 10.1016/j.apsb.2016.02.004
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Fishero BA, 2015, CRANIOMAX TRAUM REC, V8, P23, DOI 10.1055/s 0034 1393724
   Gao LL, 2018, J BIOMED MATER RES A, V106, P1878, DOI 10.1002/jbm.a.36391
   Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916
   Huang RL, 2014, STEM CELLS DEV, V23, P277, DOI 10.1089/scd.2013.0345
   Ilango P, 2016, J CLIN DIAGN RES, V10, pZC86, DOI [10.7860/JCDR/2016/18.53.8027, 10.7860/JCDR/2016/18353.8027]
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008 00034.Klune
   Lalla E, 2000, J CLIN INVEST, V105, P1117, DOI 10.1172/JCI8942
   Lalloo R, 2020, INJURY PREV, V26, P27, DOI 10.1136/injuryprev 2019 043297
   MacIsaac ZM, 2016, ANN PLAS SURG, V76, P205, DOI 10.1097/SAP.0000000000000515
   Molteni M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6978936
   Phillips A M, 2005, Injury, V36 Suppl 3, pS5, DOI 10.1016/j.injury.2005.07.027
   Pribis JP, 2015, MOL MED, V21, P749, DOI 10.2119/molmed.2015.00197
   Rho J, 2004, MOL CELLS, V17, P1
   Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983
   Shi MC, 2016, ACTA BIOMATER, V30, P334, DOI 10.1016/j.actbio.2015.11.033
   Spiller KL, 2015, BIOMATERIALS, V37, P194, DOI 10.1016/j.biomaterials.2014.10.017
   Streit M, 2014, NAT METHODS, V11, P117, DOI 10.1038/nmeth.2807
   Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Vijayan V, 2014, BRIT J PHARMACOL, V171, P107, DOI 10.1111/bph.12434
   Wang D, 2020, TISSUE ENG PART B RE, V26, P46, DOI [10.1089/ten.teb.2018.0353, 10.1089/ten.TEB.2018.0353]
   Wang D, 2017, PLAST RECONSTR SURG, V140, p296E, DOI 10.1097/PRS.0000000000003541
   Wang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046945
   Zuk PA, 2008, PEDIATR RES, V63, P478, DOI 10.1203/PDR.0b013e31816bdf36
NR 31
TC 1
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0032 1052
EI 1529 4242
J9 PLAST RECONSTR SURG
JI Plast. Reconstr. Surg.
PD DEC
PY 2022
VL 150
IS 6
BP 1264E
EP 1274E
DI 10.1097/PRS.0000000000009734
PG 11
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 6R5TA
UT WOS:000892364200018
PM 36112847
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Frank, M
   Grabos, A
   Reisinger, AG
   Burr, DB
   Pahr, DH
   Allen, MR
   Thurner, PJ
AF Frank, Martin
   Grabos, Andreas
   Reisinger, Andreas G.
   Burr, David B.
   Pahr, Dieter H.
   Allen, Matthew R.
   Thurner, Philipp J.
TI Effects of anti resorptive treatment on the material properties of
   individual canine trabeculae in cyclic tensile tests
SO BONE
LA English
DT Article
DE Individual trabeculae; Anti resorptive treatment; Material properties;
   Cyclic test; Microdamage
ID SUPPRESSED BONE TURNOVER; TERM BISPHOSPHONATE THERAPY; VERTEBRAL
   FRACTURE RISK; AGE RELATED CHANGES; MECHANICAL PROPERTIES; CORTICAL
   BONE; MICRODAMAGE ACCUMULATION; CANCELLOUS BONE; BIOMECHANICAL
   PROPERTIES; ALENDRONATE TREATMENT
AB Osteoporosis is defined as a decrease of bone mass and strength, as well as an increase in fracture risk. It is conventionally treated with antiresorptive drugs, such as bisphosphonates (BPs) and selective estrogen receptor modulators (SERMs). Although both drug types successfully decrease the risk of bone fractures, their effect on bone mass and strength is different. For instance, BP treatment causes an increase of bone mass, stiffness and strength of whole bones, whereas SERM treatment causes only small (4%) increases of bone mass, but increased bone toughness. Such improved mechanical behavior of whole bones can be potentially related to the bone mass, bone structure or material changes. While bone mass and architecture have already been investigated previously, little is known about the mechanical behavior at the tissue/material level, especially of trabecular bone. As such, the goal of the work presented here was to fill this gap by performing cyclic tensile tests in a wet, close to physiologic environment of individual trabeculae retrieved from the vertebrae of beagle dogs treated with alendronate (a BP), raloxifene (a SERM) or without treatments. Identification of material properties was performed with a previously developed rheological model and of mechanical properties via fitting of envelope curves. Additionally, tissue mineral density (TMD) and microdamage formation were analyzed. Alendronate treatment resulted in a higher trabecular tissue stiffness and strength, associated with higher levels of TMD. In contrast, raloxifene treatment caused a higher trabecular toughness, pre dominantly in the post yield region. Microdamage formation during testing was not affected by either anti resorptive treatment regimens. These findings highlight that the improved mechanical behavior of whole bones after anti resorptive treatment is at least partly caused by improved material properties, with different mechanisms for alendronate and raloxifene. This study further shows the power of performing a mechanical characterization of trabecular bone at the level of individual trabeculae for better understanding of clinically relevant mechanical behavior of bone.
C1 [Frank, Martin; Grabos, Andreas; Pahr, Dieter H.; Thurner, Philipp J.] TU Wien, Inst Lightweight Design & Struct Biomech, Gumpendorfer Str 7, A 1060 Vienna, Austria.
   [Grabos, Andreas; Burr, David B.; Allen, Matthew R.] Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, 340 West 10th St Fairbanks Hall,Suite 6200, Indianapolis, IN 46202 USA.
   [Reisinger, Andreas G.; Pahr, Dieter H.] Karl Landsteiner Univ Hlth Sci, Dept Anat & Biomech, Div Biomech, Dr Karl Dorrek Str 30, A 3500 Krems An Der Donau, Austria.
C3 Technische Universitat Wien; Indiana University System; Indiana
   University Bloomington
RP Thurner, PJ (通讯作者)，TU Wien, Inst Lightweight Design & Struct Biomech, Gumpendorfer Str 7, A 1060 Vienna, Austria.
EM frankm@ilsb.tuwien.ac.at; Andreas.Reisinger@kl.ac.at; dburr@iupui.edu;
   dieter.pahr@kl.ac.at; matallen@iu.edu; philipp.thurner@tuwien.ac.at
RI Allen, Matthew/A 8799 2015; Thurner, Philipp/A 3887 2012
OI Bittner Frank, Martin/0000 0002 8740 3923; 
FU Austrian Marshall Plan Foundation; NIH [5R01AR047838]; Lilly Research
   Labs; TU Wien Bibliothek
FX Funding sources This work was supported by the Austrian Marshall Plan
   Foundation. The animal studies were supported by NIH grant 5R01AR047838,
   and a grant from Lilly Research Labs. Merck and Co. kindly provided the
   alendronate under a material transfer agreement. The authors further
   acknowledge TU Wien Bibliothek for financial support through its Open
   Access Funding Programme.
CR Acevedo C, 2015, BONE, V81, P352, DOI 10.1016/j.bone.2015.08.002
   Allen MR, 2008, OSTEOPOROSIS INT, V19, P329, DOI 10.1007/s00198 007 0533 7
   Allen MR, 2008, CALCIFIED TISSUE INT, V82, P354, DOI 10.1007/s00223 008 9131 8
   Allen MR, 2007, ENDOCRINOLOGY, V148, P3908, DOI 10.1210/en.2007 0275
   Allen MR, 2006, BONE, V39, P1130, DOI 10.1016/j.bone.2006.05.007
   Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   Allen MR, 2011, BONE, V49, P56, DOI 10.1016/j.bone.2010.10.159
   Allen MR., 2007, IBMS BoneKEy, V4, P49, DOI [10.1138/20060248, DOI 10.1138/20060248]
   Bajaj D, 2014, BONE, V64, P57, DOI 10.1016/j.bone.2014.03.045
   Bala Y, 2012, J BONE MINER RES, V27, P825, DOI 10.1002/jbmr.1501
   Bala Y, 2011, EUR J ENDOCRINOL, V165, P647, DOI 10.1530/EJE 11 0333
   Banse X, 2002, J BONE MINER RES, V17, P1621, DOI 10.1359/jbmr.2002.17.9.1621
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   Boyce TM, 1998, J ORTHOP RES, V16, P322, DOI 10.1002/jor.1100160308
   Brock Garry R, 2015, Bone Rep, V2, P8
   Burket JC, 2013, BONE, V52, P326, DOI 10.1016/j.bone.2012.10.018
   Burr DB, 2009, J ORTHOP RES, V27, P1288, DOI 10.1002/jor.20895
   Burr DB, 2002, BONE, V31, P8, DOI 10.1016/S8756 3282(02)00815 3
   Carretta R, 2013, J MECH BEHAV BIOMED, V20, P6, DOI 10.1016/j.jmbbm.2012.12.003
   Cherraf Schweyer C., 2007, Computer Methods in Biomechanics and Biomedical Engineering, V10, P195, DOI 10.1080/10255840701284002
   Currey J, 2004, J THEOR BIOL, V231, P569, DOI 10.1016/j.jtbi.2004.07.013
   Currey JD, 2004, J BIOMECH, V37, P549, DOI 10.1016/j.jbiomech.2003.08.008
   Day JS, 2004, J ORTHOP RES, V22, P465, DOI 10.1016/j.orthres.2003.05.001
   Diab T, 2005, BONE, V37, P96, DOI 10.1016/j.bone.2005.03.014
   Ding M, 2003, CALCIFIED TISSUE INT, V72, P737, DOI 10.1007/s00223 002 2066 6
   Doube M, 2011, P ROY SOC B BIOL SCI, V278, P3067, DOI 10.1098/rspb.2011.0069
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Epstein S, 2005, MAYO CLIN PROC, V80, P379, DOI 10.4065/80.3.379
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Frank M, 2021, J BIOMECH, V115, DOI 10.1016/j.jbiomech.2020.110131
   Frank M, 2018, J MECH BEHAV BIOMED, V87, P296, DOI 10.1016/j.jmbbm.2018.07.039
   Frank M, 2017, 2017 13TH IASTED INTERNATIONAL CONFERENCE ON BIOMEDICAL ENGINEERING (BIOMED), P141, DOI 10.2316/P.2017.852 023
   Fyhrie DP, 2015, CALCIFIED TISSUE INT, V97, P213, DOI 10.1007/s00223 015 9997 1
   Gallant MA, 2014, BONE, V61, P191, DOI 10.1016/j.bone.2014.01.009
   Garnero Patrick, 2012, Bonekey Rep, V1, P182, DOI 10.1038/bonekey.2012.182
   Güerri Fernández RC, 2013, J BONE MINER RES, V28, P162, DOI 10.1002/jbmr.1731
   Jin A, 2017, BONE JOINT RES, V6, P602, DOI 10.1302/2046 3758.610.BJR 2016 0321.R1
   Komatsubara S, 2004, J BONE MINER RES, V19, P999, DOI 10.1359/JBMR.040126
   Komatsubara S, 2003, J BONE MINER RES, V18, P512, DOI 10.1359/jbmr.2003.18.3.512
   Kostenuik P., 2013, EVOLUTION CONT ROLES, VFourth, DOI [10.1016/B978 0 12 415853 5.00037 6, DOI 10.1016/B978 0 12 415853 5.00037 6]
   Krause M, 2014, EUR CELLS MATER, V28, P152, DOI 10.22203/eCM.v028a12
   LAKES RS, 1974, J BIOMECH, V7, P259, DOI 10.1016/0021 9290(74)90017 7
   LAKES RS, 1979, J BIOMECH, V12, P657, DOI 10.1016/0021 9290(79)90016 2
   Lee TC, 2003, J ANAT, V203, P161, DOI 10.1046/j.1469 7580.2003.00211.x
   Lloyd AA, 2017, P NATL ACAD SCI USA, V114, P8722, DOI 10.1073/pnas.1704460114
   Ma S, 2017, SCI REP UK, V7, DOI 10.1038/srep43399
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Miller Paul D, 2005, Curr Osteoporos Rep, V3, P103, DOI 10.1007/s11914 005 0018 6
   Mulder L, 2005, ANAT REC PART A, V285A, P659, DOI 10.1002/ar.a.20208
   Mulder L, 2008, J BIOMED MATER RES A, V84A, P508, DOI 10.1002/jbm.a.31474
   Nobakhti S, 2018, CURR OSTEOPOROS REP, V16, P404, DOI 10.1007/s11914 018 0449 5
   Pienkowski D, 2019, OSTEOPOROSIS INT, V30, P277, DOI 10.1007/s00198 018 4760 x
   Poundarik AA, 2015, J MECH BEHAV BIOMED, V52, P120, DOI 10.1016/j.jmbbm.2015.08.012
   Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889 8529(02)00055 5
   Recker R, 2005, CURR MED RES OPIN, V21, P185, DOI 10.1185/030079904X20259
   Reisinger AG, 2020, BIOMECH MODEL MECHAN, V19, P2149, DOI 10.1007/s10237 020 01329 0
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Saito M, 2008, OSTEOPOROSIS INT, V19, P1343, DOI 10.1007/s00198 008 0585 3
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Siegmund T, 2010, J THEOR BIOL, V265, P202, DOI 10.1016/j.jtbi.2010.04.009
   Tang SY, 2011, J BIOMECH, V44, P330, DOI 10.1016/j.jbiomech.2010.10.016
   Tang SY, 2009, OSTEOPOROSIS INT, V20, P887, DOI 10.1007/s00198 008 0754 4
   Thurner PJ, 2007, ENG FRACT MECH, V74, P1928, DOI 10.1016/j.engfracmech.2006.05.024
   Torres AM, 2016, P NATL ACAD SCI USA, V113, P2892, DOI 10.1073/pnas.1520539113
   Turunen MJ, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 69850 x
   Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756 3282(01)00697 4
   Wang XD, 2001, J ORTHOP RES, V19, P1021, DOI 10.1016/S0736 0266(01)00047 X
   Warriner A.H., 2016, AMY J CLIN EPIDEMIOL, V64, P46, DOI [10.1016/j.physbeh.2017.03.040, DOI 10.1016/J.PHYSBEH.2017.03.040]
   Willems NMBK, 2014, J BONE MINER METAB, V32, P29, DOI 10.1007/s00774 013 0464 7
   Wu D, 2018, ACTA BIOMATER, V78, P1, DOI 10.1016/j.actbio.2018.08.001
   Zimmermann EA, 2016, SCI REP UK, V6, DOI 10.1038/srep21072
   Zimmermann EA, 2011, P NATL ACAD SCI USA, V108, P14416, DOI 10.1073/pnas.1107966108
NR 74
TC 3
Z9 3
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2021
VL 150
AR 115995
DI 10.1016/j.bone.2021.115995
EA MAY 2021
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA TF0MS
UT WOS:000670402300005
PM 33940224
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Hoff, M
   Kvien, TK
   Kälvesten, J
   Elden, A
   Kavanaugh, A
   Haugeberg, G
AF Hoff, Mari
   Kvien, Tore K.
   Kalvesten, Johan
   Elden, Aake
   Kavanaugh, Arthur
   Haugeberg, Glenn
TI Adalimumab reduces hand bone loss in rheumatoid arthritis independent of
   clinical response: Subanalysis of the PREMIER study
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID X RAY RADIOGRAMMETRY; PLUS METHOTREXATE; METACARPAL INDEX; MINERAL
   DENSITY; THERAPY; TRIAL
AB Background: Anti TNF therapy has been shown to reduce radiographic joint damage in rheumatoid arthritis (RA) independent of clinical response. This has previously not been examined for periarticular bone loss, the other characteristic feature of bone involvement in RA.
   The objective of this study was to examine if treatment with the TNF alpha inhibitor adalimumab also could reduce periarticular bone loss in RA patients independent of disease activity.
   Methods: RA patients were recruited from the PREMIER study and included 214 patients treated with methotrexate (MTX) plus adalimumab and 188 patients treated with MTX monotherapy. Periarticular bone loss was assessed by digital X ray radiogrammetry metacarpal cortical index (DXR MCI). Change in DXR MCI was evaluated in patients with different levels of clinical response, as assessed by changes in DAS28 score at 52 weeks and in mean C reactive protein (CRP) levels during follow up.
   Results: In the MTX group, there was a greater median DXR MCI loss among patients with moderate and high disease activity compared to those in remission or with low disease activity ( 3.3% vs.  2.2%, p = 0.01). In contrast, periarticular bone loss was independent of disease activity ( 1.9% vs.  2.4%, p = 0.99) in the combination group. In the MTX group patients with a mean CRP of >= 10 mg/l lost significantly more DXR MCI than patients with low CRP ( 3.1% vs.  1.9%, p < 0.01) whereas in the combination group no significant differences between the two CRP groups was seen ( 2.4% vs.  2.0%, p = 0.48).
   Conclusion: Adalimumab in combination with MTX reduces periarticular bone loss independently of clinical response. These results support the hypothesis that TNF alpha stimulates the osteoclast not only by the inflammatory pathway but do also have a direct effect on the osteoclast.
C1 [Hoff, Mari] St Olavs Hosp, Dept Rheumatol, N 7006 Trondheim, Norway.
   [Hoff, Mari; Haugeberg, Glenn] Norwegian Univ Sci & Technol, Fac Med, N 7491 Trondheim, Norway.
   [Kvien, Tore K.] Univ Oslo, Diakonhjemmet Hosp, Dept Rheumatol, N 0319 Oslo, Norway.
   [Kvien, Tore K.] Univ Oslo, Fac Med, N 0319 Oslo, Norway.
   [Kalvesten, Johan] Sectra, SE 58330 Linkoping, Sweden.
   [Elden, Aake] Abbott Labs, N 1330 Oslo, Norway.
   [Kavanaugh, Arthur] Univ Calif San Diego, Ctr Innovat Therapy, San Diego, CA 92037 USA.
   [Haugeberg, Glenn] Sorlandet Hosp, Dept Rheumatol, N 4604 Kristiansand S, Norway.
C3 Norwegian University of Science & Technology (NTNU); Norwegian
   University of Science & Technology (NTNU); University of Oslo;
   Diakonhjemmet Hospital; University of Oslo; Sectra AB; University of
   California System; University of California San Diego
RP Hoff, M (通讯作者)，St Olavs Hosp, Dept Rheumatol, N 7006 Trondheim, Norway.
EM mari.hoff@ntnu.no
RI ; Hoff, Mari/AAZ 7302 2021
OI Hoff, Mari/0000 0002 9992 8663; Kalvesten, Johan/0000 0002 3486 796X
FU Abbott Laboratories
FX We acknowledge Abbott Laboratories for financial support regarding
   collection of the radiographs and dxr analysis. No other funding was
   received.
CR Breedveld FC, 2006, ARTHRITIS RHEUM US, V54, P26, DOI 10.1002/art.21519
   Clair EWS, 2004, ARTHRITIS RHEUM US, V50, P3432, DOI 10.1002/art.20568
   Emery P, 1997, J RHEUMATOL, V24, P1436
   Emery P, 2009, J RHEUMATOL, V36, P1429, DOI 10.3899/jrheum.081018
   Güler Yüksel M, 2009, ANN RHEUM DIS, V68, P330, DOI 10.1136/ard.2007.086348
   Hoff M., 2008, ANN RHEUM DIS S, V67, P563
   Hoff M, 2009, ANN RHEUM DIS, V68, P1171, DOI 10.1136/ard.2008.091264
   Hoff M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2280
   Hyldstrup L, 2001, J CLIN DENSITOM, V4, P299, DOI 10.1385/JCD:4:4:299
   Hyldstrup L, 2001, CALCIFIED TISSUE INT, V68, P135, DOI 10.1007/s002230001204
   Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Nielsen SP, 2001, J CLIN DENSITOM, V4, P199, DOI 10.1385/JCD:4:3:199
   PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107
   Rosholm A, 2001, OSTEOPOROSIS INT, V12, P961, DOI 10.1007/s001980170026
   Schett G, 2009, J BONE MINER RES, V24, P1142, DOI 10.1359/jbmr.090533
   Smolen JS, 2009, ANN RHEUM DIS, V68, P823, DOI 10.1136/ard.2008.090019
   van Gestel AM, 1999, J RHEUMATOL, V26, P705
NR 19
TC 42
Z9 48
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD FEB 27
PY 2011
VL 12
AR 54
DI 10.1186/1471 2474 12 54
PG 6
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 732TY
UT WOS:000288213800001
PM 21352592
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, GL
   Zhao, F
   Yang, D
   Wang, J
   Qiu, LH
   Pang, XN
AF Wang, Guiling
   Zhao, Feng
   Yang, Di
   Wang, Jing
   Qiu, Lihong
   Pang, Xining
TI Human amniotic epithelial cells regulate osteoblast differentiation
   through the secretion of TGFβ1 and microRNA 34a 5p
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE human amniotic epithelial cells; human amniotic mesenchymal stem cells;
   osteoblast; transforming growth factor beta(1); microRNA 34a 5p
ID MESENCHYMAL STEM CELLS; TRANSFORMING GROWTH FACTOR BETA 1; STROMAL
   CELLS; MECHANISMS; EXOSOMES; CANCER; REPAIR; BETA
AB Since the beginning of the use of stem cells in tissue regenerative medicine, there has been a search for optimal sources of stem cells. Human amniotic epithelial cells (hAECs) are derived from human amnions, which are typically discarded as medical waste, but were recently found to include cells with trilineage differentiation potential in vitro. Previous study has focused on the osteogenic differentiation ability of hAECs as seed cells in bone regeneration; however, their paracrine effects on osteoblasts (OBs) are yet to be elucidated. In the present study, conditioned medium (CM) derived from hAECs was used to determine their paracrine effects on the human fetal OB cell line (hFOB1.19), and the potential bioactive factors involved in this process were investigated. The results suggested that hAEC CM markedly promoted the proliferation, migration and osteogenic differentiation of hFOB1.19 cells. Expression of transforming growth factor (1) (TGF(1)) and microRNA 34a 5p (miR 34a 5p) were detected in hAECs. Furthermore, it was demonstrated that TGF(1) and miR 34a 5p stimulated the differentiation of hFOB1.19 cells, and that TGF(1) promoted cell migration. Moreover, the effects of hAEC CM were downregulated following the depletion of either TGF(1) or miR 34a 5p. These results demonstrated that hAECs promote OB differentiation through the secretion of TGF(1) and miR 34a 5p, and that hAECs may be an optimal cell source in bone regenerative medicine.
C1 [Wang, Guiling; Yang, Di; Qiu, Lihong] China Med Univ, Sch Stomatol, Dept Endodont, 117 Nanjing North St, Shenyang 110002, Liaoning, Peoples R China.
   [Wang, Guiling; Zhao, Feng; Pang, Xining] China Med Univ, Minist Publ Hlth China, Key Lab Cell Biol, Dept Stem Cells & Regenerat Med, 77 Puhe St, Shenyang 110013, Liaoning, Peoples R China.
   [Wang, Jing] China Med Univ, Affiliated Hosp 1, Dept Anal & Intestinal Surg, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Qiu, LH (通讯作者)，China Med Univ, Sch Stomatol, Dept Endodont, 117 Nanjing North St, Shenyang 110002, Liaoning, Peoples R China.; Pang, XN (通讯作者)，China Med Univ, Minist Publ Hlth China, Key Lab Cell Biol, Dept Stem Cells & Regenerat Med, 77 Puhe St, Shenyang 110013, Liaoning, Peoples R China.
EM drqlh@yahoo.com; pangxining@126.com
RI Liu, Fenjin/AAW 2537 2021
FU Program for National Basic Research Program of China [2012CB518103];
   National Natural Science Foundation of China [81450017]; Science and
   Technology Planning Project of Liaoning Province [2014305012]; Science
   and Technology Planning Project of Shenyang [F14 201 4 00]; Shenyang Key
   Laboratory Project [F15 157 1 00]
FX The present study was supported by the Program for National Basic
   Research Program of China (grant no. 2012CB518103), the National Natural
   Science Foundation of China (grant no. 81450017), the Science and
   Technology Planning Project of Liaoning Province (grant no. 2014305012),
   the Science and Technology Planning Project of Shenyang (grant no.
   F14 201 4 00), and the Shenyang Key Laboratory Project (grant no.
   F15 157 1 00).
CR An JH, 2013, TISSUE ENG PT A, V19, P685, DOI [10.1089/ten.tea.2012.0047, 10.1089/ten.TEA.2012.0047]
   Ando Y, 2014, BONE, V61, P82, DOI 10.1016/j.bone.2013.12.029
   Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74
   Bilic G, 2008, CELL TRANSPLANT, V17, P955, DOI 10.3727/096368908786576507
   Burke J, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5802529
   Davis LA, 2011, METHODS MOL BIOL, V690, P255, DOI 10.1007/978 1 60761 962 8_17
   Desrochers LM, 2016, DEV CELL, V37, P301, DOI 10.1016/j.devcel.2016.04.019
   Dittmer J, 2014, INT J ONCOL, V44, P1789, DOI 10.3892/ijo.2014.2385
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Eichner A, 2002, EXP CELL RES, V275, P132, DOI 10.1006/excr.2002.5488
   Fan C, 2016, STEM CELL REP, V7, P236, DOI 10.1016/j.stemcr.2016.06.010
   Furuta T, 2016, STEM CELL TRANSL MED, V5, P1620, DOI 10.5966/sctm.2015 0285
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004 0001
   Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928
   Kassem M, 2000, EUR J CLIN INVEST, V30, P429
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Lawson C, 2016, J ENDOCRINOL, V228, pR57, DOI 10.1530/JOE 15 0201
   Magatti M, 2015, CELL TRANSPLANT, V24, P1733, DOI 10.3727/096368914X684033
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Miki T, 2005, STEM CELLS, V23, P1549, DOI 10.1634/stemcells.2004 0357
   Osugi M, 2012, TISSUE ENG PT A, V18, P1479, DOI [10.1089/ten.tea.2011.0325, 10.1089/ten.TEA.2011.0325]
   Si JW, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/565732
   Si JW, 2014, STEM CELL TRANSL MED, V3, P1504, DOI 10.5966/sctm.2014 0118
   van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983
   Vosdoganes P, 2013, CELL TRANSPLANT, V22, P1337, DOI 10.3727/096368912X657657
   Vosdoganes P, 2013, CYTOTHERAPY, V15, P1021, DOI 10.1016/j.jcyt.2013.03.004
   Wang YL, 2016, MOL CELLS, V39, P186, DOI 10.14348/molcells.2016.2159
   Wolbank S, 2007, TISSUE ENG, V13, P1173, DOI 10.1089/ten.2006.0313
   Yan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033778
   Yao XF, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4148923
   Zhou Q, 2015, HUM CELL, V28, P22, DOI 10.1007/s13577 014 0099 6
NR 32
TC 18
Z9 19
U1 0
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD FEB
PY 2018
VL 41
IS 2
BP 791
EP 799
DI 10.3892/ijmm.2017.3261
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FT5VV
UT WOS:000423222200021
PM 29207015
OA hybrid, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Shi, X
   Cheng, Q
   Zhao, YZ
   Zou, SP
   Sun, MH
AF Shi, X.
   Cheng, Q.
   Zhao, Y.  z.
   Zou, S.  p.
   Sun, M.  h.
TI A real world pharmacovigilance study of abaloparatide based on the FDA
   Adverse Event Reporting System (FAERS)
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Abaloparatide; Adverse events; Data mining; FAERS; Osteoporosis;
   Pharmacovigilance
ID BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN; OSTEOPOROSIS; FRACTURES;
   SAFETY
AB Abaloparatide (ABL) is a US Food and Drug Administration approved parathyroid hormone related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. However, real world data regarding its long term safety and tolerability in large sample population are incomplete. We evaluated abaloparatide associated safety signals by data mining of the FDA pharmacovigilance database.IntroductionWe investigated 33,480(0.14%) ABL related adverse events (AEs) through data mining of Food and Drug Administration Adverse Event Reporting System (FAERS) retrospectively.MethodsReporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi item gamma Poisson shrinker (MGPS) were employed to quantify the signals of ABL related AEs from 2017Quarter2 to 2022.Serious and non serious cases were compared by Mann Whitney U test or Chi squared (& chi;(2)) test.ResultsWe collected 8,470,497 reports from the FAERS database, including 11,487 reports defined ABL as the primary suspected (PS) drug. Additionally, 36.16% of the reports were submitted by healthcare professionals (n=4154), compared to 62.26% reported by consumers (n=7140). A total 99 signals simultaneously conforming to four algorithms were detected, among which, 35 signals were identified as unexpected signals. Such as growing pains (n=13), waist circumference increased (n=21), sensory disturbance (n=103), tinnitus (n=65), visual acuity reduced (n=54), blood alkaline phosphatase increased (n=61), and hair growth abnormal (n=13). Patient age (p < 0.001) might be associated with an increased risk of AEs severity. The most common timeframe for AE occurrence was 0 7 days.ConclusionOur study provided a deeper and broader understanding of abaloparatide's safety profiles, which would help healthcare professionals to mitigate the risk of AEs in clinical practice, a low number of unexpected AEs supporting ongoing additional pharmacovigilance.
C1 [Shi, X.; Cheng, Q.; Zhao, Y.  z.; Zou, S.  p.; Sun, M.  h.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430000, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Sun, MH (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430000, Hubei, Peoples R China.
EM Smh007tj@163.com
OI Sun, M/0000 0002 1556 543X; Shi, Xuan/0000 0002 6226 8833
CR [Anonymous], FDA FAERS PUBL DASHB
   [Anonymous], 2019, TYML
   Ayers C, 2023, ANN INTERN MED, V176, DOI 10.7326/M22 0684
   Bahar H, 2016, CALCIFIED TISSUE INT, V99, P489, DOI 10.1007/s00223 016 0171 1
   Coloma PM, 2013, DRUG SAFETY, V36, P183, DOI 10.1007/s40264 013 0018 x
   Cosman F, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa450
   Esbrit P, 2016, CALCIFIED TISSUE INT, V98, P359, DOI 10.1007/s00223 015 0050 1
   Guo ML, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 23726 4
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hauben M, 2021, PHARMACOEPIDEM DR S, V30, P1140, DOI 10.1002/pds.5265
   Hu YY, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106601
   Jolette J, 2017, REGUL TOXICOL PHARM, V86, P356, DOI 10.1016/j.yrtph.2017.04.001
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lindquist M, 2000, DRUG SAFETY, V23, P533, DOI 10.2165/00002018 200023060 00004
   Merlotti D, 2019, EXPERT OPIN PHARMACO, V20, P805, DOI 10.1080/14656566.2019.1583208
   Miller PD, 2020, CURR MED RES OPIN, V36, P1861, DOI 10.1080/03007995.2020.1824897
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Moreira CA, 2017, BONE, V97, P314, DOI 10.1016/j.bone.2016.11.004
   Parallel ADR., 2019, TSINGHUA SCI TECHNOL, V24, P195, DOI [10.26599/TST.2018.9010074, DOI 10.26599/TST.2018.9010074]
   Peng L, 2020, EXPERT OPIN DRUG SAF, V19, P1505, DOI 10.1080/14740338.2020.1799975
   Reginster JY, 2019, OSTEOPOROSIS INT, V30, P1465, DOI 10.1007/s00198 019 04947 2
   Sakaeda T, 2013, INT J MED SCI, V10, P796, DOI 10.7150/ijms.6048
   Song Y, 2020, ONCOL RES TREAT, V43, P96, DOI 10.1159/000505376
   Ventola C Lee, 2018, P T, V43, P340
   Vilar S, 2018, BRIEF BIOINFORM, V19, P863, DOI 10.1093/bib/bbx010
   Zhang Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.817662
NR 26
TC 5
Z9 5
U1 2
U2 8
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2023
VL 34
IS 12
BP 2047
EP 2058
DI 10.1007/s00198 023 06877 6
EA AUG 2023
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA Y1TJ3
UT WOS:001050501800001
PM 37594595
DA 2025 08 17
ER

PT J
AU Amirpour, N
   Razavi, S
   Esfandiari, E
   Hashemibeni, B
   Kazemi, M
   Salehi, H
AF Amirpour, Noushin
   Razavi, Shahnaz
   Esfandiari, Ebrahim
   Hashemibeni, Batoul
   Kazemi, Mohammad
   Salehi, Hossein
TI Hanging drop culture enhances differentiation of human adipose derived
   stem cells into anterior neuroectodermal cells using small molecules
SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE
LA English
DT Article
DE hADSCs; Neuroectoderm; Small molecules; Hanging drop
ID IN VITRO DIFFERENTIATION; NEURAL DIFFERENTIATION; BONE MARROW;
   CHONDROGENIC DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; RETINAL CELLS;
   STROMAL CELLS; TISSUE; GENERATION; PROLIFERATION
AB Inspired by in vivo developmental process, several studies were conducted to design a protocol for differentiating of mesenchymal stem cells into neural cells in vitro. Human adipose derived stem cells (hADSCs) as mesenchymal stem cells are a promising source for this purpose. At current study, we applied a defined neural induction medium by using small molecules for direct differentiation of hADSCs into anterior neuroectodermal cells. Anterior neuroectodermal differentiation of hADSCs was performed by hanging drop and monolayer protocols. At these methods, three small molecules were used to suppress the BMP, Nodal, and Wnt signaling pathways in order to obtain anterior neuroectodermal (eye field) cells from hADSCs. After two and three weeks of induction, the differentiated cells with neural morphology expressed anterior neuroectodermal markers such as OTX2, SIX3, beta TUB III and PAX6. The protein expression of such markers was confirmed by real time, RT PCR and immunocytochemistry methods According to our data, it seems that the hanging drop method is a proper approach for neuroectodermal induction of hADSCs. Considering wide availability and immunosuppressive properties of hADSCs, these cells may open a way for autologous cell therapy of neurodegenerative disorders. (C) 2017 ISDN. Published by Elsevier Ltd. All rights reserved.
C1 [Amirpour, Noushin; Razavi, Shahnaz; Esfandiari, Ebrahim; Hashemibeni, Batoul; Salehi, Hossein] Isfahan Univ Med Sci, Sch Med, Dept Anat Sci & Mol Biol, Esfahan, Iran.
   [Kazemi, Mohammad] Isfahan Univ Med Sci, Sch Med, Dept Genet & Mol Biol, Esfahan, Iran.
C3 Isfahan University of Medical Sciences; Isfahan University of Medical
   Sciences
RP Salehi, H (通讯作者)，Isfahan Univ Med Sci, Sch Med, Dept Anat Sci & Mol Biol, Esfahan, Iran.
EM ho_salehi@med.mui.ac.ir
RI kazemi, mohammad/E 6492 2012; Hashemibeni, batool/V 6848 2017; Salehi,
   Hossein/A 4290 2016; Razavi, Shahnaz/I 7599 2019; amirpour,
   noushin/V 7055 2017; Esfandiari, Ebrahim/E 7334 2012; salehi,
   hossein/AAD 9948 2020
OI Salehi, Hossein/0000 0002 0231 4498; Esfandiari,
   Ebrahim/0000 0001 6436 5672; , Shahnaz/0000 0003 1726 9324; Kazemi,
   Mohammad/0000 0002 6794 6891
FU Research Council of Isfahan University of Medical Sciences, Iran
   [191076]; Iran national Science Foundation [92018501]
FX This study was funded by grants from Research Council of Isfahan
   University of Medical Sciences, Iran, (Grant no. 191076) and Iran
   national Science Foundation (Grant no. 92018501).
CR Amirpour N, 2012, STEM CELLS DEV, V21, P42, DOI 10.1089/scd.2011.0073
   Arribas MI, 2014, REGEN MED, V9, P279, DOI [10.2217/RME.14.11, 10.2217/rme.14.11]
   Ashjian PH, 2003, PLAST RECONSTR SURG, V111, P1922, DOI 10.1097/01.PRS.0000055043.62589.05
   Baer PC, 2013, J TISSUE ENG REGEN M, V7, P271, DOI 10.1002/term.518
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Daiger SP, 2007, ARCH OPHTHALMOL CHIC, V125, P151, DOI 10.1001/archopht.125.2.151
   de Girolamo L, 2007, J TISSUE ENG REGEN M, V1, P154, DOI 10.1002/term.12
   Erba P, 2010, CURR STEM CELL RES T, V5, P153, DOI 10.2174/157488810791268645
   Erickson GR, 2002, BIOCHEM BIOPH RES CO, V290, P763, DOI 10.1006/bbrc.2001.6270
   Fan JB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0072474, 10.1371/journal.pone.0076701]
   Fekany Lee K, 2000, DEVELOPMENT, V127, P2333
   Francis KR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.22
   Lambert APF, 2009, DIFFERENTIATION, V77, P221, DOI 10.1016/j.diff.2008.10.016
   Goudenege S, 2009, MOL THER, V17, P1064, DOI 10.1038/mt.2009.67
   Grauss RW, 2008, STEM CELLS, V26, P1083, DOI 10.1634/stemcells.2007 0523
   Guilak F, 2006, J CELL PHYSIOL, V206, P229, DOI 10.1002/jcp.20463
   Havlas V, 2011, ACTA CHIR ORTHOP TR, V78, P138
   Horie N, 2004, FEBS LETT, V571, P237, DOI 10.1016/j.febslet.2004.06.085
   Howard MJ, 2005, DEV BIOL, V277, P271, DOI 10.1016/j.ydbio.2004.09.034
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Jeon ES, 2006, J CELL SCI, V119, P4994, DOI 10.1242/jcs.03281
   Cardozo AJ, 2011, J MOL NEUROSCI, V44, P186, DOI 10.1007/s12031 011 9503 9
   Kelm JM, 2004, TISSUE ENG, V10, P201, DOI 10.1089/107632704322791853
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kim HJ, 2012, J TISSUE ENG, V3, DOI 10.1177/2041731412466405
   Kim JE, 2011, P NATL ACAD SCI USA, V108, P3005, DOI 10.1073/pnas.1007753108
   Kimura C, 2000, DEV BIOL, V225, P304, DOI 10.1006/dbio.2000.9835
   Kokai LE, 2005, PLAST RECONSTR SURG, V116, P1453, DOI 10.1097/01.prs.0000182570.62814.e3
   Kompisch KM, 2010, HISTOCHEM CELL BIOL, V134, P453, DOI 10.1007/s00418 010 0740 8
   Krampera M, 2007, BONE, V40, P382, DOI 10.1016/j.bone.2006.09.006
   Kurokawa D, 2014, DEV BIOL, V387, P203, DOI 10.1016/j.ydbio.2014.01.011
   Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Li WL, 2012, STEM CELLS, V30, P61, DOI 10.1002/stem.768
   Lupo G, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120167
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Mochizuki H, 2011, J BIOSCI BIOENG, V111, P92, DOI 10.1016/j.jbiosc.2010.09.001
   Moviglia GA, 2012, OPHTHALMIC RES, V48, P1, DOI 10.1159/000339839
   Muñoz Sanjuán I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786
   NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P33, DOI 10.1002/jez.1401200103
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rodriguez AM, 2004, BIOCHEM BIOPH RES CO, V315, P255, DOI 10.1016/j.bbrc.2004.01.053
   Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006 291X(02)00469 2
   Salehi H, 2016, STEM CELL REV REP, V12, P26, DOI 10.1007/s12015 015 9631 7
   Shen MM, 2007, DEVELOPMENT, V134, P1023, DOI 10.1242/dev.000166
   Shi YC, 2012, NAT PROTOC, V7, P1836, DOI 10.1038/nprot.2012.116
   Smith JR, 2008, DEV BIOL, V313, P107, DOI 10.1016/j.ydbio.2007.10.003
   Stern CD, 2006, INT J DEV BIOL, V50, P3, DOI 10.1387/ijdb.052095cs
   Sung MS, 2013, BIOCHEM BIOPH RES CO, V437, P156, DOI 10.1016/j.bbrc.2013.06.058
   Surmacz B, 2012, STEM CELLS, V30, P1875, DOI 10.1002/stem.1166
   Teraoka ME, 2009, DEV BIOL, V330, P389, DOI 10.1016/j.ydbio.2009.04.008
   Touboul T, 2010, HEPATOLOGY, V51, P1754, DOI 10.1002/hep.23506
   Viczian Andrea S, 2013, J Ophthalmic Vis Res, V8, P147
   Wilson L, 2005, DEV BIOL, V282, P1, DOI 10.1016/j.ydbio.2005.02.027
   Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365
   Xu FT, 2014, CAN J PHYSIOL PHARM, V92, P467, DOI 10.1139/cjpp 2013 0377
   Yu JM, 2011, METHODS MOL BIOL, V702, P219, DOI 10.1007/978 1 61737 960 4_16
   Zavan B, 2010, DISCOV MED, V10, P37
   Zhao X, 2002, BIOCHEM BIOPH RES CO, V297, P177, DOI 10.1016/S0006 291X(02)02126 5
   Zuber ME, 2003, DEVELOPMENT, V130, P5155, DOI 10.1242/dev.00723
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 64
TC 13
Z9 15
U1 0
U2 12
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0736 5748
EI 1873 474X
J9 INT J DEV NEUROSCI
JI Int. J. Dev. Neurosci.
PD JUN
PY 2017
VL 59
BP 21
EP 30
DI 10.1016/j.ijdevneu.2017.03.002
PG 10
WC Developmental Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology; Neurosciences & Neurology
GA EW2XW
UT WOS:000402360300004
PM 28285945
DA 2025 08 17
ER

PT J
AU Zhao, YX
   Ding, S
AF Zhao, Yuanxiang
   Ding, Sheng
TI A high throughput siRNA library screen identifies osteogenic suppressors
   in human mesenchyrnal stem cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE adipogenic differentiation; osteogenic differentiation; high throughput
   RNAi screen
ID MARROW STROMAL CELLS; PROGRESSIVE OSSEOUS HETEROPLASIA; ACTIVATED
   PROTEIN KINASE; SHORT INTERFERING RNAS; STIMULATORY G PROTEIN; AMP
   RESPONSE ELEMENT; MAMMALIAN CELLS; BONE MARROW; GENE EXPRESSION; GNAS1
   GENE
AB Tissue specific (or adult) stem/progenitor cells are regarded as the source for normal tissue homeostasis and tissue repair. They also provide tremendous promise for regenerative medicine because of their capacity to proliferate and differentiate into a variety of mature cell types. Human mesenchymal stem cells (hMSCs) can differentiate into osteocytes, adipocytes, chondrocytes, muscle cells, and neurons. However, the molecular mechanisms underlying these differentiation processes are poorly understood. We screened a synthetic siRNA library targeting 5,000 human genes to identify the endogenous repressors of osteogenic specification, which when silenced could initiate differentiation of hMSCs into osteoblasts. This screen yielded 53 candidate suppressors, and 12 of those were further confirmed for their dynamic roles in suppressing osteogenic specification in hMSCs. Furthermore, cAMP was identified to play opposing roles in osteogenesis vs. adipogenesis. This study provides a basis for further elucidation of the genetic network controlling osteogenesis and, potentially, the molecular rationale for treating bone diseases.
C1 Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
C3 Scripps Research Institute; Scripps Research Institute
RP Ding, S (通讯作者)，Cellular Dynam Int Inc, 525 Sci Dr, Madison, WI 53711 USA.
EM sding@scripps.edu
OI Zhao, Yuanxiang/0000 0003 1611 4590
CR Acampora D, 1999, DEVELOPMENT, V126, P3795
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371
   Bianco P, 2000, J BONE MINER RES, V15, P120, DOI 10.1359/jbmr.2000.15.1.120
   Bilezikian J.P., 2002, PRINCIPLES BONE BIOL
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798
   Chan I, 2004, CLIN EXP DERMATOL, V29, P77, DOI 10.1111/j.1365 2230.2004.01439.x
   Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126
   Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969
   COTTAM HB, 1993, J MED CHEM, V36, P3424, DOI 10.1021/jm00074a024
   Davenport TG, 2003, DEVELOPMENT, V130, P2263, DOI 10.1242/dev.00431
   DESOUZA NJ, 1983, MED RES REV, V3, P201, DOI 10.1002/med.2610030205
   Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935
   DUEY P, 1997, CELL, V89, P747
   Eddy MC, 2000, J BONE MINER RES, V15, P2074, DOI 10.1359/jbmr.2000.15.11.2074
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092 8674(91)90503 Q
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399
   Ikeda R, 2005, J BIOL CHEM, V280, P8523, DOI 10.1074/jbc.M409442200
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502 500
   Lietman SA, 2005, CLIN ORTHOP RELAT R, P231, DOI 10.1097/01.blo.0000153279.90512.38
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Miura M, 2004, J CLIN INVEST, V114, P1704, DOI 10.1172/JCI200420427
   Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502 497
   MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0
   Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002
   Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370
   Park YG, 1999, J BIOL CHEM, V274, P1573, DOI 10.1074/jbc.274.3.1573
   Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502 505
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 2002, NAT BIOTECHNOL, V20, P791, DOI 10.1038/nbt0802 791
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842
   Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092 8674(00)80249 4
   Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476 9255 2 8
   Shore EM, 2002, NEW ENGL J MED, V346, P99, DOI 10.1056/NEJMoa011262
   Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599
   Tsutsumimoto T, 2002, BONE, V31, P396, DOI 10.1016/S8756 3282(02)00839 6
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403
   WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Yamane T, 2005, P NATL ACAD SCI USA, V102, P3312, DOI 10.1073/pnas.0500167102
   Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499
   Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100
NR 59
TC 56
Z9 68
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 5
PY 2007
VL 104
IS 23
BP 9673
EP 9678
DI 10.1073/pnas.0703407104
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 176VX
UT WOS:000247114100025
PM 17535907
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Madani, P
   Hesaraki, S
   Saeedifar, M
   Nasab, NA
AF Madani, Parisa
   Hesaraki, Saeed
   Saeedifar, Maryam
   Nasab, Navid Ahmadi
TI The controlled release, bioactivity and osteogenic gene expression of
   Quercetin loaded gelatin/tragacanth/ nano hydroxyapatite bone tissue
   engineering scaffold
SO JOURNAL OF BIOMATERIALS SCIENCE POLYMER EDITION
LA English
DT Article
DE Quercetin; osteogenic activity; human bone mesenchymal stem cells;
   real time PCR; alkaline phosphatase activity; MTT assay; drug delivery
ID MESENCHYMAL STEM CELLS; FIBROBLAST GROWTH FACTOR; OSTEOBLAST
   DIFFERENTIATION; DRUG RELEASE; GELATIN; PATHWAY; PROLIFERATION;
   REGENERATION; OSTEOPOROSIS; MC3T3 E1
AB In this study, a Gelatin/Tragacanth/Nano hydroxyapatite scaffold was fabricated via freeze drying method. A highly porous scaffold with an average pore diameter of 142 mu m and porosity of 86% was found by the micro computed tomography. The mean compressive strength of the scaffold was about 1.5 MPa, a value in the range of the spongy bone. The scaffold lost 10 wt.% of its initial weight after 28 days soaking in PBS that shows a fair degradation rate for a bone tissue engineering scaffold. Apatite formation ability of the scaffold was confirmed via scanning electron microscopy, X ray diffraction and Fourier transforming infrared spectroscopy, after 28 days soaking in simulated body fluid. The scaffold was able to deliver 93% of the loaded drug, Quercetin, during 120 h in phosphate buffered solution, in a sustainable manner. The MTT assay using human bone mesenchymal stem cells showed 84% cell viability of the Quercetin loaded scaffold. The expression of the osteogenic genes including Col I, Runx 2, BGLAP (gene of osteocalcin), bFGF, SP7 (gene of osterix) and SPP1 (gene of osteopontin) were all upregulated when Quercetin was loaded on the scaffold, which indicates the synergetic effect of the drug and the scaffold.
C1 [Madani, Parisa; Hesaraki, Saeed; Saeedifar, Maryam] Mat & Energy Res Ctr, Dept Nanotechnol & Adv Mat, Biomat Grp, POB 31787 316, Karaj, Iran.
   [Nasab, Navid Ahmadi] Univ Hormozgan, Fac Marine Sci & Technol, Dept Marine Biol, Bandar Abbas, Iran.
C3 Materials & Energy Research Center (MERC); University of Hormozgan
RP Hesaraki, S (通讯作者)，Mat & Energy Res Ctr, Dept Nanotechnol & Adv Mat, Biomat Grp, POB 31787 316, Karaj, Iran.
EM s hesaraki@merc.ac.ir
RI ; Ahmadi Nasab, Navid/N 5500 2017
OI Hesaraki, Saeed/0000 0001 9147 5850; Saeidifar,
   Maryam/0000 0002 1116 2932
CR Allo BA, 2012, J FUNCT BIOMATER, V3, DOI 10.3390/jfb3020432
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Barrett Connor E, 2003, MENOPAUSE, V10, P412, DOI 10.1097/01.GME.0000086467.82759.DA
   Bose S, 2012, TRENDS BIOTECHNOL, V30, P546, DOI 10.1016/j.tibtech.2012.07.005
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Chandrasekaran A., 2013, International Journal of Physical Sciences, V8, P1639, DOI DOI 10.5897/IJPS2013.3990
   Chen QZ, 2012, PROG BIOMATER, V1, DOI 10.1186/2194 0517 1 2
   Croisier F, 2013, EUR POLYM J, V49, P780, DOI 10.1016/j.eurpolymj.2012.12.009
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Fallah M, 2016, J IND TEXT, V46, P562, DOI 10.1177/1528083715594978
   FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612
   FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715
   Gao YG, 2004, GENE, V341, P101, DOI 10.1016/j.gene.2004.05.026
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Guo X, 2006, BIOMED MATER, V1, P93, DOI 10.1088/1748 6041/1/3/001
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Haeri SMJ, 2016, BIOLOGICALS, V44, P123, DOI 10.1016/j.biologicals.2016.03.004
   Hajinasrollah K, 2019, J ENG FIBER FABR, V14, DOI 10.1177/1558925019881142
   Havaldar R, 2012, IOSR J Dent Med Sci, V1, P12
   Hesaraki S, 2014, J BIOMED MATER RES B, V102, P108, DOI 10.1002/jbm.b.32987
   Hoque M.E., 2015, POLYM RES J, V9, P15
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jacinto Tinajero Juan Carlos, 2014, J Exp Orthop, V1, P11, DOI 10.1186/s40634 014 0011 z
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Katti KS, 2008, BIOMED MATER, V3, DOI 10.1088/1748 6041/3/3/034122
   Kim YJ, 2006, BIOCHEM PHARMACOL, V72, P1268, DOI 10.1016/j.bcp.2006.08.021
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kora AJ, 2012, J NANOMATER, V2012, DOI 10.1155/2012/869765
   Kosmidis K, 2003, J CHEM PHYS, V119, P6373, DOI 10.1063/1.1603731
   Kothapalli CR, 2005, ACTA BIOMATER, V1, P653, DOI 10.1016/j.actbio.2005.06.005
   Kulanthaivel S, 2017, J MATER CHEM B, V5, P4177, DOI 10.1039/c7tb00390k
   Kuznetsov SA, 2000, TRANSPLANTATION, V70, P1780, DOI 10.1097/00007890 200012270 00018
   Lecoeur L, 1997, BIOMATERIALS, V18, P989, DOI 10.1016/S0142 9612(97)00025 2
   Lee JH, 2014, ACTA BIOMATER, V10, P2750, DOI 10.1016/j.actbio.2014.01.021
   Lett JA, 2019, MAT SCI ENG C MATER, V96, P487, DOI 10.1016/j.msec.2018.11.082
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   Liedert A, 2010, BIOCHEM BIOPH RES CO, V394, P755, DOI 10.1016/j.bbrc.2010.03.065
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marcarini JC, 2011, EXP TOXICOL PATHOL, V63, P459, DOI 10.1016/j.etp.2010.03.005
   Mostafa NZ, 2012, CONNECT TISSUE RES, V53, P117, DOI 10.3109/03008207.2011.611601
   Nakase T, 1998, ACTA HISTOCHEM, V100, P287, DOI 10.1016/S0065 1281(98)80015 9
   ncbi, J BIOMAT SCI POLYM E
   Notoya M, 2004, EUR J PHARMACOL, V485, P89, DOI 10.1016/j.ejphar.2003.11.058
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Pneumaticos SG, 2010, J CELL MOL MED, V14, P2561, DOI 10.1111/j.1582 4934.2010.01062.x
   Pradini D, 2018, MALAYS J FUNDAM APPL, V14, P325, DOI 10.11113/mjfas.v14n3.942
   Rawdkuen S, 2013, INT J FOOD SCI TECH, V48, P1093, DOI 10.1111/ijfs.12067
   Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168 3659(87)90035 6
   Santiago Mora R, 2011, OSTEOPOROSIS INT, V22, P675, DOI 10.1007/s00198 010 1270 x
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Schilling T, 2014, J STEROID BIOCHEM, V139, P252, DOI 10.1016/j.jsbmb.2012.12.006
   Schmidt A, 2006, STEM CELLS, V24, P1750, DOI 10.1634/stemcells.2005 0191
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P139, DOI 10.1016/S0169 409X(01)00112 0
   Song WO, 2007, J MED FOOD, V10, P571, DOI 10.1089/jmf.2006.0620
   Su K, 2015, BIOTECHNOL LETT, V37, P2139, DOI 10.1007/s10529 015 1907 0
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Teiten MH, 2012, CURR PHARM BIOTECHNO, V13, P245, DOI 10.2174/138920112798868593
   Thomas PS, 2012, POLYM ENG SCI, V52, P689, DOI 10.1002/pen.22135
   Van Vooren L, 2001, DRUG DEV IND PHARM, V27, P885, DOI 10.1081/DDC 100107254
   Wang JC, 2003, J BONE JOINT SURG AM, V85A, P905, DOI 10.2106/00004623 200305000 00020
   Wiseman H, 2000, EXPERT OPIN INV DRUG, V9, P1829, DOI 10.1517/13543784.9.8.1829
   Xu J, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957 4484/24/2/025701
   Yaylaoglu MB, 1999, BIOMATERIALS, V20, P1513, DOI 10.1016/S0142 9612(99)00062 9
   Zhao Y, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/637415
   Zheng YH, 2011, J TISSUE ENG REGEN M, V5, P540, DOI 10.1002/term.346
   Zhou YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129605
NR 72
TC 16
Z9 16
U1 2
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0920 5063
EI 1568 5624
J9 J BIOMAT SCI POLYM E
JI J. Biomater. Sci. Polym. Ed.
PD JAN 22
PY 2023
VL 34
IS 2
BP 217
EP 242
DI 10.1080/09205063.2022.2113293
EA AUG 2022
PG 26
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science; Polymer Science
GA 7L0LN
UT WOS:000844215700001
PM 35960146
DA 2025 08 17
ER

PT J
AU Zhang, D
   Li, XJ
   Li, JM
   Liu, WX
   Yu, Y
   Wang, SQ
   Ye, XJ
AF Zhang, Dong
   Li, Xuejia
   Li, Jianmin
   Liu, Wanxin
   Yu, Ying
   Wang, Shuqiang
   Ye, Xiaojian
TI Casticin promotes osteogenic differentiation of bone marrow stromal
   cells and improves osteoporosis in rats by regulating nuclear
   factor κB/mitogen activated protein kinase
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE casticin; NF kappa B; MAPK; osteogenic differentiation; osteoporosis
ID OSTEOCLASTOGENESIS
AB Background: Osteoporosis has influenced millions of people, especially postmenopausal women, which has become a big burden to the whole world. Although the diverse roles of casticin (CAS) on different diseases were identified, whether it was implicated with osteoporosis was unknown.
   Methods: A rat model of osteoporosis was established through dexamethasone (DEX) treatment and a cell model reflecting the osteogenic and osteoclast induction was constructed in bone marrow stromal cells (BMSCs). The calcification at the late stage of induction was measured via Alizarin Red S staining. Western blot was applied to evaluate the levels of proteins.
   Results: Hematoxylin and eosin staining revealed that the number of bone trabecular in DEX induced osteoporosis rats was decreased, while increased doses of CAS treatment elevated the number of bone trabecular. CAS treatment alleviated DEX induced osteoporosis in rats. Moreover, we found that CAS inhibited the nuclear factor kappa B/mitogen activated protein kinase (NF kappa B/MAPK) pathway. In addition, CAS promoted osteogenic differentiation of BMSCs and reduced osteoclastogenesis of bone marrow monocytes. Finally, CAS was observed to retard the receptor activator of NF kappa B ligand induced NF kappa B/MAPK pathway.
   Conclusion: CAS promoted osteogenic differentiation of BMSCs and improved osteoporosis in rats by regulating the NF kappa B/MAPK pathway. This might shed a light into using CAS as a drug treating osteoporosis in the future.
C1 [Zhang, Dong; Li, Xuejia; Li, Jianmin; Liu, Wanxin; Yu, Ying; Ye, Xiaojian] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Orthoped, 110 Ganhe Rd, Shanghai 200437, Peoples R China.
   [Wang, Shuqiang] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Spine Surg, 110 Ganhe Rd, Shanghai 200437, Peoples R China.
   [Ye, Xiaojian] Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Orthoped, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai Jiao Tong University
RP Ye, XJ (通讯作者)，Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Orthoped, 110 Ganhe Rd, Shanghai 200437, Peoples R China.; Wang, SQ (通讯作者)，Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Spine Surg, 110 Ganhe Rd, Shanghai 200437, Peoples R China.
EM misspinal@163.com; yexj616@126.com
RI liu, wanxin/KDM 4967 2024; Li, Jianmin/AFP 4454 2022; Wang,
   Shuqiang/ADI 9291 2022
CR AlQahtani RM, 2021, SIGNA VITAE, V17, P169, DOI 10.22514/sv.2020.16.0085
   AlSharari SD, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5436745
   Anam AK, 2021, MED CLIN N AM, V105, P1117, DOI 10.1016/j.mcna.2021.05.016
   Chaichit S, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14060536
   Chan EWC, 2018, J INTEGR MED JIM, V16, P147, DOI 10.1016/j.joim.2018.03.001
   Chang YW, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02468 5
   Chen HW, 2020, J CELL MOL MED, V24, P9067, DOI 10.1111/jcmm.15543
   Chu M, 2021, THERANOSTICS, V11, P6717, DOI 10.7150/thno.56607
   Clausen NG, 2021, SIGNA VITAE, V17, P1, DOI 10.22514/sv.2021.088
   Dong MM, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.829741
   Ehsan N., 2021, BRAZ J BIOL, V83, DOI 10.1590/1519 6984.243438
   Hsiao CY, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00613
   Jing WB, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02690 1
   Ko HM, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13071028
   Lam HYP, 2022, J MICROBIOL IMMUNOL, V55, P314, DOI 10.1016/j.jmii.2021.03.017
   Li LC, 2022, MOLECULES, V27, DOI 10.3390/molecules27010078
   Ling XP, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/7795527
   Omar G, 2020, BRAZ J BIOL, V80, P763, DOI 10.1590/1519 6984.219186
   Ou ZP, 2021, ECOTOX ENVIRON SAFE, V225, DOI 10.1016/j.ecoenv.2021.112746
   Ramchandani S, 2020, MOLECULES, V25, DOI 10.3390/molecules25061287
   Regginato A., 2021, Braz. J. Biol., V81, P621, DOI 10.1590/1519 6984.227388
   Shi YF, 2021, PHYTOTHER RES, V35, P5694, DOI 10.1002/ptr.7229
   Sun C, 2022, J SURG RES, V274, P145, DOI 10.1016/j.jss.2021.12.007
   Xu DD, 2021, BBA MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2021.166230
   Xu GP, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820980117
   Xu H, 2022, Zhonghua Zhong Liu Za Zhi, V44, P334, DOI 10.3760/cma.j.cn112152 20200507 00420
   Xu HH, 2018, BIOMED PHARMACOTHER, V102, P539, DOI 10.1016/j.biopha.2018.03.125
   Xu Y, 2020, NANO LETT, V20, P2558, DOI 10.1021/acs.nanolett.9b05340
   Zerlotin R, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020690
   Zhang CY, 2021, EUR J GYNAECOL ONCOL, V42, P353, DOI 10.31083/j.ejgo.2021.02.5419
   Zhang YQ, 2021, EXP BIOL MED, V246, P1650, DOI 10.1177/15353702211002136
   Zheng CX, 2020, TRENDS MOL MED, V26, P89, DOI 10.1016/j.molmed.2019.04.008
   Zhou DA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 239
NR 33
TC 2
Z9 3
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1756 1841
EI 1756 185X
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PD JAN
PY 2023
VL 26
IS 1
BP 80
EP 87
DI 10.1111/1756 185X.14451
EA OCT 2022
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 7M1KJ
UT WOS:000863795200001
PM 36195975
DA 2025 08 17
ER

PT J
AU Wang, LT
   Hu, P
   Jiang, H
   Zhao, JH
   Tang, J
   Jiang, DJ
   Wang, JX
   Shi, JL
   Jia, WT
AF Wang, Lingtian
   Hu, Ping
   Jiang, Han
   Zhao, Jinhui
   Tang, Jin
   Jiang, Dajun
   Wang, Jiaxing
   Shi, Jianlin
   Jia, Weitao
TI Mild hyperthermia mediated osteogenesis and angiogenesis play a critical
   role in magnetothermal composite induced bone regeneration
SO NANO TODAY
LA English
DT Article
DE Bone defect; Magnetic hyperthermia; Heat shock protein; PI3K/Akt
   pathway; Osteogenesis
ID IRON OXIDE NANOPARTICLES; ALTERNATING MAGNETIC FIELD; MESENCHYMAL
   STEM CELLS; HEAT SHOCK PROTEINS; SCAFFOLDS; TISSUE; DIFFERENTIATION;
   ENHANCEMENT; PROMOTE; CANCER
AB Mild hyperthermia is greatly beneficial to the healing of bone defects; however, how to generat hyperthermia directly at the bone defect site remains an unsolved problem due to the poor thermal conversion capability of currently commercially available materials and the thickness of soft tissues. Herein, we applied mild magnetic hyperthermia therapy (MHT) to restore critical sized bone defect using an Arg Gly Asp (RGD) coated, core shell structured magnetic iron oxide nanoparticle (MION; CoFe2O4@MnFe2O4) material to fabricate an optimized osteoinductive nanoparticles hydrogel composite by embedding the nanoparticles in the agarose with a prominent magnetothermal effect. An alternating magnetic field with strong tissue penetration could evoke a mild MHT (41 42 degrees C) in the composites, which significantly promoted the osteogenic differentiation and biomineralization of pre osteoblasts via a heat shock protein (HSP) 90 activated PI3K/Akt pathway. Simultaneously, the cobalt element in the CoFe2O4@MnFe2O4 upregulated the expression of the angiogenesis related gene HIF 1 alpha, which was further promoted under mild heat stimulation. The dual effects notably facilitated the formation of new blood vessels at the lesion. This work demonstrates the great potential of MION induced mild magnetothermal therapy for the efficient regeneration of critical sized bone defects. (C) 2022 Elsevier Ltd. All rights reserved.
C1 [Wang, Lingtian; Zhao, Jinhui; Jiang, Dajun; Wang, Jiaxing; Jia, Weitao] Shanghai Jiao Tong Univ, Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai 200233, Peoples R China.
   [Hu, Ping; Jiang, Han; Shi, Jianlin] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.
   [Jiang, Han] Univ Chinese Acad Sci, Ctr Mat Sci & Optoelect Engn, Beijing 100049, Peoples R China.
   [Tang, Jin] Shanghai Jiao Tong Univ, Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Clin Lab, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Ceramics, CAS; Chinese Academy of Sciences; University of
   Chinese Academy of Sciences, CAS; Shanghai Jiao Tong University
RP Wang, JX; Jia, WT (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai 200233, Peoples R China.; Shi, JL (通讯作者)，Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.
EM jxwang@shsmu.edu.cn; jlshi@mail.sic.ac.cn; jiaweitao@shsmu.edu.cn
RI ; , jianlin Shi/HTM 8889 2023
OI Jia, Weitao/0000 0002 6067 9794; jia, weitao/0000 0001 9363 5598
FU National Natural Science Foundation of China [52072394, 21835007,
   81802181]; Shanghai Science and Technology Committee Rising Star Program
   [19QA1410100]; Shanghai International Cooperation Project [20490714200];
   Key Research Program of Frontier Sciences, Chinese Academy of Sciences
   [ZDBS LY SLH029]; National Key Research and Development Program of China
   [2018YFC1106300]; Shanghai Municipal Education Commission Gaofeng
   Clinical Medicine Grant Support [20172026]
FX This work was sponsored by the National Natural Science Foundation of
   China (Grant No. 52072394, 21835007 and 81802181), Shanghai Science and
   Technology Committee Rising Star Program (No. 19QA1410100), Shanghai
   International Cooperation Project (20490714200), Key Research Program of
   Frontier Sciences, Chinese Academy of Sciences (grant no.
   ZDBS LY SLH029), the National Key Research and Development Program of
   China (No. 2018YFC1106300) and Shanghai Municipal Education
   Commission Gaofeng Clinical Medicine Grant Support (Grant No. 20172026).
CR Abbasi N, 2020, J SCI ADV MATER DEV, V5, P1, DOI 10.1016/j.jsamd.2020.01.007
   Albarqi HA, 2019, ACS NANO, V13, P6383, DOI 10.1021/acsnano.8b06542
   Bose S, 2013, TRENDS BIOTECHNOL, V31, P594, DOI 10.1016/j.tibtech.2013.06.005
   Branco Price C, 2012, CANCER CELL, V21, P52, DOI 10.1016/j.ccr.2011.11.017
   Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006
   Chen EM, 2015, FEBS LETT, V589, P4088, DOI 10.1016/j.febslet.2015.11.021
   Cheng L, 2020, SMALL, V16, DOI 10.1002/smll.202005433
   Cui HQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 2723 6
   Du XY, 2018, J MATER CHEM B, V6, P4397, DOI 10.1039/c8tb00677f
   Duan JM, 2019, REGEN BIOMATER, V6, P221, DOI 10.1093/rb/rbz024
   Fan W, 2010, BIOMATERIALS, V31, P3580, DOI 10.1016/j.biomaterials.2010.01.083
   Fuhrmann Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00314 z
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Hu JX, 2016, INT J BIOL MACROMOL, V82, P134, DOI 10.1016/j.ijbiomac.2015.09.077
   Jayapaul J, 2011, BIOMATERIALS, V32, P5863, DOI 10.1016/j.biomaterials.2011.04.056
   Jiang SJ, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10206
   Jin CY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01965 4
   Jo J, 2010, J CONTROL RELEASE, V142, P465, DOI 10.1016/j.jconrel.2009.11.014
   Kim HJ, 2020, BIOMATER SCI UK, V8, P4334, DOI 10.1039/d0bm00588f
   Lee H, 2018, NANO RES, V11, P5997, DOI 10.1007/s12274 018 2114 9
   Lee JH, 2011, NAT NANOTECHNOL, V6, P418, DOI [10.1038/nnano.2011.95, 10.1038/NNANO.2011.95]
   Li J, 2019, NANOSCALE, V11, P6905, DOI 10.1039/c8nr09802f
   Li XY, 2019, INT J NANOMED, V14, P573, DOI 10.2147/IJN.S184920
   Lin H, 2017, J AM CHEM SOC, V139, P16235, DOI 10.1021/jacs.7b07818
   Meng J, 2010, NANOSCALE, V2, P2565, DOI 10.1039/c0nr00178c
   Miao YL, 2019, BIOMATER SCI UK, V7, P4046, DOI 10.1039/c9bm01072f
   Norgaard R, 2006, ANN NY ACAD SCI, V1067, P443, DOI 10.1196/annals.1354.063
   O'Neal DP, 2004, CANCER LETT, V209, P171, DOI 10.1016/j.canlet.2004.02.004
   Pan J, 2020, ACS NANO, V14, P1033, DOI 10.1021/acsnano.9b08550
   Paris JL, 2019, ACTA BIOMATER, V86, P441, DOI 10.1016/j.actbio.2019.01.013
   Quarto R, 2001, NEW ENGL J MED, V344, P385, DOI 10.1056/NEJM200102013440516
   Quinlan E, 2015, BIOMATERIALS, V52, P358, DOI 10.1016/j.biomaterials.2015.02.006
   Sayed S, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110027
   Shi HS, 2019, APPL MATER TODAY, V15, P100, DOI 10.1016/j.apmt.2019.01.002
   Shiota M, 2010, ARTERIOSCL THROM VAS, V30, P491, DOI 10.1161/ATVBAHA.109.193631
   Shui CX, 2001, J BONE MINER RES, V16, P731, DOI 10.1359/jbmr.2001.16.4.731
   Stelling MP, 2019, FEBS J, V286, P2950, DOI 10.1111/febs.14986
   Thomas KA., 2016, Encyclopedia of Cell Biology, P102, DOI [10.1016/B978 0 12 394447 4.40019 2, DOI 10.1016/B978 0 12 394447 4.40019 2]
   Tong LP, 2019, BIOMATERIALS, V193, P1, DOI 10.1016/j.biomaterials.2018.12.008
   Wang JX, 2021, ADV SCI, V8, DOI 10.1002/advs.202004010
   Wang QW, 2017, NANO RES, V10, P626, DOI 10.1007/s12274 016 1322 4
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Wang YQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10761 5
   Wang Z, 2019, ADV SCI, V6, DOI 10.1002/advs.201901690
   Wu TT, 2020, MAT SCI ENG C MATER, V109, DOI 10.1016/j.msec.2019.110481
   Yan H, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201705710
   Ye CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1904 7
   Yu Y, 2018, ISCIENCE, V3, P134, DOI 10.1016/j.isci.2018.04.012
   Zhang BGX, 2014, INT J MOL SCI, V15, P11878, DOI 10.3390/ijms150711878
   Zhao FJ, 2018, BIOMATERIALS, V178, P36, DOI 10.1016/j.biomaterials.2018.06.004
   Zhou J, 2004, J BIOL CHEM, V279, P13506, DOI 10.1074/jbc.M310164200
NR 51
TC 75
Z9 75
U1 23
U2 207
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1748 0132
EI 1878 044X
J9 NANO TODAY
JI Nano Today
PD APR
PY 2022
VL 43
AR 101401
DI 10.1016/j.nantod.2022.101401
EA JAN 2022
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 2P6FJ
UT WOS:000819834100001
DA 2025 08 17
ER

PT J
AU Jeon, WJ
   Kim, KM
   Kim, EJ
   Jang, WG
AF Jeon, Wan Jin
   Kim, Kyeong Min
   Kim, Eun Jung
   Jang, Won Gu
TI Costunolide increases osteoblast differentiation via ATF4 dependent HO 1
   expression in C3H10T1/2 cells
SO LIFE SCIENCES
LA English
DT Article
DE Costunolide; ATF4; HO 1; SnPP; Osteogenesis
ID SESQUITERPENE LACTONE; HEME OXYGENASE 1; BONE; ACTIVATION; ALPHA;
   SUPPRESSION; PATHWAY; CBFA1
AB Aims: Costunolide is a sesquiterpene lactones used in many herbal medicines, with well established anti inflammatory and anti oxidant functions modulating endoplasmic reticulum (ER) stress pathways, and which promotes the expression of anti oxidant genes. The aim of this study is to investigate whether costunolide is involved in osteoblast differentiation and, determine the mechanisms of differentiation in mesenchymal stem cells.
   Main methods: The cytotoxicity of costunolide was identified using the 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) assay. The mRNA and protein expression levels of osteogenic genes were determined by RT PCR and Western blot analysis. Alkaline phosphate (ALP) staining and Alizarin red S (ARS) staining were performed to evaluate ALP activity and matrix mineralization. Transcriptional activity was detected using a luciferase reporter assay.
   Key findings: In this study, we determined that costunolide increased the expression of distal less homeobox 5 (Dlx5), runt related transcription factor 2 (Runx2), ALP, and osteocalcin (OC) in C3H10T 1/2 cells. Furthermore, costunolide increased ALP activity and matrix mineralization. Interestingly, costunolide increased ER stress by Bip, activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP). However, it did not exert effects on expression of activating transcription factor 6 (ATF6). ATF4 activation has a protective role in oxidative stress, and its transcription induces anti oxidant genes in cells. Heme oxygenase 1 (HO 1) is a major anti oxidant enzyme, and is regulated by ATF4. We showed that costunolide treatment increased HO 1 expression. Furthermore, the HO 1 inhibitor, Sn(IV) Protoporphyrin IX dichloride (SnPP) was blocked costunolide induced Runx2 expression.
   Significance: Our results revealed that costunolide induced osteoblast differentiation is regulated by ATF4 dependent HO 1 expression. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Jeon, Wan Jin; Kim, Kyeong Min; Jang, Won Gu] Daegu Univ, Dept Biotechnol, Coll Engn, Gyeongbuk 38453, South Korea.
   [Jeon, Wan Jin; Kim, Kyeong Min; Jang, Won Gu] Daegu Univ, Res Inst Antiaging, Gyeongbuk 38453, South Korea.
   [Kim, Eun Jung] Kyungpook Natl Univ, Brain Sci & Engn Inst, Sch Med, Daegu, South Korea.
   Daegu Univ, Inst Ind & Technol, Gyeongbuk 38453, South Korea.
C3 Daegu University; Daegu University; Kyungpook National University (KNU);
   Daegu University; Korea Institute of Industrial Technology (KITECH)
RP Jang, WG (通讯作者)，Daegu Univ, Dept Biotechnol, Coll Engn, Gyeongbuk 38453, South Korea.; Kim, EJ (通讯作者)，Kyungpook Natl Univ, Brain Sci & Engn Inst, Sch Med, Daegu, South Korea.
EM eunjungkim@knu.ac.kr; jangwg@daegu.ac.kr
RI KIM, EUNJUNG/KFC 0377 2024
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education, Science and Technology
   [NRF 2016R1D1A1B03930733]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (NRF 2016R1D1A1B03930733).
CR Chen C.T., 2008, STEM CELLS, V960
   Cheon YH, 2014, PHYTOTHER RES, V28, P586, DOI 10.1002/ptr.5034
   Choi Y. K., 2013, EVID BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/93625723997800
   Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200
   Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eliza J, 2010, CHEM BIOL INTERACT, V188, P467, DOI 10.1016/j.cbi.2010.08.002
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097 2765(03)00105 9
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Hughes Fulford Millie, 2004, Sci STKE, V2004, pRE12
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Jiang YB, 2011, CHINESE MED J PEKING, V124, P401, DOI 10.3760/cma.j.issn.0366 6999.2011.03.015
   Kang JS, 2004, BIOCHEM BIOPH RES CO, V313, P171, DOI 10.1016/j.bbrc.2003.11.109
   Ke K, 2015, MOL CELL ENDOCRINOL, V409, P11, DOI 10.1016/j.mce.2015.03.022
   Kim KS, 2016, MOLECULES, V21, DOI 10.3390/molecules21091206
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097 4644(19990401)73:1<114::AID JCB13>3.3.CO;2 D
   Lee YS, 2011, INT IMMUNOPHARMACOL, V11, P712, DOI 10.1016/j.intimp.2011.01.018
   Liang WN, 2012, INT J MOL MED, V30, P889, DOI 10.3892/ijmm.2012.1079
   Liu HY, 2011, BIOMATERIALS, V32, P6773, DOI 10.1016/j.biomaterials.2011.05.080
   Kreuger MRO, 2012, ANTI CANCER DRUG, V23, P883, DOI 10.1097/CAD.0b013e328356cad9
   Pae HO, 2007, INFLAMM RES, V56, P520, DOI 10.1007/s00011 007 7015 4
   Park HJ, 1996, J NAT PROD, V59, P1128, DOI 10.1021/np960452i
   Park SY, 2016, ENDOCRINOL METAB, V31, P336, DOI 10.3803/EnM.2016.31.2.336
   Robinson A, 2008, BIOORG MED CHEM LETT, V18, P4015, DOI 10.1016/j.bmcl.2008.06.008
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Sakai E, 2012, J CELL BIOCHEM, V113, P486, DOI 10.1002/jcb.23372
   Shu T, 2010, TISSUE CELL, V42, P217, DOI 10.1016/j.tice.2010.04.004
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   TANIGUCHI M, 1995, BIOSCI BIOTECH BIOCH, V59, P2064, DOI 10.1271/bbb.59.2064
   Trigona WL, 2007, ANTIOXID REDOX SIGN, V9, P751, DOI 10.1089/ars.2007.1602
   Tsubokawa T, 2010, AM J PHYSIOL HEART C, V298, pH1320, DOI 10.1152/ajpheart.01330.2008
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Vanella L, 2011, PROSTAG OTH LIPID M, V96, P54, DOI 10.1016/j.prostaglandins.2011.07.005
   Wang Z, 2016, CELL BIOL INT, V40, P289, DOI 10.1002/cbin.10564
   Xiao HH, 2014, J STEROID BIOCHEM, V143, P141, DOI 10.1016/j.jsbmb.2014.02.019
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yu YQ, 2014, MOL MED REP, V10, P1371, DOI 10.3892/mmr.2014.2353
   Zhang C, 2016, BIOMED PHARMACOTHER, V80, P253, DOI 10.1016/j.biopha.2016.03.031
   Zhang LF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0099946, 10.1371/journal.pone.0084950]
NR 43
TC 27
Z9 29
U1 0
U2 16
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD JUN 1
PY 2017
VL 178
BP 94
EP 99
DI 10.1016/j.lfs.2017.04.012
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EW4BS
UT WOS:000402447600012
PM 28435036
DA 2025 08 17
ER

PT J
AU Kim, K
   Fisher, JP
AF Kim, Kyobum
   Fisher, John P.
TI Nanoparticle technology in bone tissue engineering
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE nanoparticle; composite scaffold; growth factor; gene delivery; bone
   tissue engineering
ID MESENCHYMAL STEM CELLS; INCREASED OSTEOBLAST FUNCTIONS; CHITOSAN DNA
   NANOPARTICLES; GENE DELIVERY; GROWTH FACTOR; COMPOSITE SCAFFOLDS;
   DRUG DELIVERY; TRANSFECTION; FUTURE; POLYMERS
AB Nanotechnology has been increasingly utilized to enhance bone tissue engineering strategies. In particular, nanotechnology has been employed to overcome some of the current limitations associated with bone regeneration methods including insufficient mechanical strength of scaffold materials, ineffective cell growth and osteogenic differentiation at the defect site, as well as unstable and insufficient production of growth factors to stimulate bone cell growth. Among the tremendous technologies of nanoparticles in biological systems, we focus here on the three major nanoparticle research areas that have been developed to overcome these limitations and disadvantages: ( a) the generation of nanoparticle  composite scaffolds to provide increased mechanical strength for bone graft, ( b) the fabrication of nanofibrous scaffolds to support cell growth and differentiation through morphologically  favored architectures, and ( c) the development of novel delivery and targeting systems of genetic material, especially those encoding osteogenic growth factors. These nanoparticle  based bone tissue engineering technologies possess a great potential to ensure the efficacy of clinical bone regeneration.
C1 Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA.
   Univ Maryland, Dept Chem & Biomol Engn, College Pk, MD 20742 USA.
C3 University System of Maryland; University of Maryland College Park;
   University System of Maryland; University of Maryland College Park
RP Fisher, JP (通讯作者)，Univ Maryland, Fischell Dept Bioengn, 3238 Jeong H Kim Engn Bldg, College Pk, MD 20742 USA.
EM jpfisher@umd.edu
RI Fisher, John/F 8078 2012; Kim, Kyobum/AAC 8652 2019
OI Kim, Kyobum/0000 0003 3678 2078
CR Babensee JE, 2000, PHARM RES DORDR, V17, P497, DOI 10.1023/A:1007502828372
   Bhattacharya S, 2005, MINER PROCESS EXTR M, V26, P31, DOI 10.1080/08827500490477586
   Bhattarai SR, 2004, BIOMATERIALS, V25, P2595, DOI 10.1016/j.biomaterials.2003.09.043
   CHANDRASEKAR D, 2006, IN PRESS BIOMATERIAL
   Chen JL, 2006, J BIOMED MATER RES A, V79A, P307, DOI 10.1002/jbm.a.30799
   Chen VJ, 2006, BIOMATERIALS, V27, P3973, DOI 10.1016/j.biomaterials.2006.02.043
   Choi JS, 2006, INT J PHARMACEUT, V320, P171, DOI 10.1016/j.ijpharm.2006.05.002
   Choi SW, 2005, METH MOL B, V303, P121
   Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
   Corsi K, 2003, BIOMATERIALS, V24, P1255, DOI 10.1016/S0142 9612(02)00507 0
   Dang JM, 2006, ADV DRUG DELIVER REV, V58, P487, DOI 10.1016/j.addr.2006.03.001
   DUNCAN R, 2006, NAT REV CANCER, V6, P1
   Emerich DF, 2005, CURR NANOSCI, V1, P177, DOI 10.2174/157341305774642911
   Erbacher P, 1998, PHARMACEUT RES, V15, P1332, DOI 10.1023/A:1011981000671
   Goto K, 2005, BIOMATERIALS, V26, P6496, DOI 10.1016/j.biomaterials.2005.04.044
   Horch RA, 2004, BIOMACROMOLECULES, V5, P1990, DOI 10.1021/bm049768s
   Hosseinkhani H, 2006, J NANOSCI NANOTECHNO, V6, P2320, DOI 10.1166/jnn.2006.507
   Jang JS, 2006, J CONTROL RELEASE, V113, P173, DOI 10.1016/j.jconrel.2006.03.021
   Kanayama N, 2006, CHEMMEDCHEM, V1, P439, DOI 10.1002/cmdc.200600008
   KARMALI PP, 2006, IN PRESS MED RES REV
   Kay S, 2002, TISSUE ENG, V8, P753, DOI 10.1089/10763270260424114
   Kim SS, 2007, J BIOMED MATER RES A, V80A, P206, DOI 10.1002/jbm.a.30836
   Kim SS, 2006, BIOMATERIALS, V27, P1399, DOI 10.1016/j.biomaterials.2005.08.016
   Kirker Head CA, 2000, ADV DRUG DELIVER REV, V43, P65, DOI 10.1016/S0169 409X(00)00078 8
   Kofron MD, 2006, ADV DRUG DELIVER REV, V58, P555, DOI 10.1016/j.addr.2006.03.008
   Kushibiki T, 2005, J BIOMAT SCI POLYM E, V16, P1447, DOI 10.1163/156856205774472326
   Li RH, 2001, TRENDS BIOTECHNOL, V19, P255, DOI 10.1016/S0167 7799(01)01665 1
   Li WJ, 2005, BIOMATERIALS, V26, P5158, DOI 10.1016/j.biomaterials.2005.01.002
   Li WJ, 2002, J BIOMED MATER RES, V60, P613, DOI 10.1002/jbm.10167
   Li WJ, 2005, BIOMATERIALS, V26, P599, DOI 10.1016/j.biomaterials.2004.03.005
   Li YP, 2001, J CONTROL RELEASE, V71, P203, DOI 10.1016/S0168 3659(01)00218 8
   Liu HN, 2005, NANOTECHNOLOGY, V16, pS601, DOI 10.1088/0957 4484/16/7/038
   Liu H, 2006, J BIOMED MATER RES A, V78A, P798, DOI 10.1002/jbm.a.30734
   Liu ZX, 1998, J OPERAT THEOR, V40, P3
   Lu LC, 2001, J BONE JOINT SURG AM, V83A, pS82
   Mansouri S, 2004, EUR J PHARM BIOPHARM, V57, P1, DOI 10.1016/S0939 6411(03)00155 3
   Mansouri S, 2006, BIOMATERIALS, V27, P2060, DOI 10.1016/j.biomaterials.2005.09.020
   Matsuo T, 2003, J BIOMED MATER RES A, V66A, P747, DOI 10.1002/jbm.a.10002
   McAllister K, 2002, J AM CHEM SOC, V124, P15198, DOI 10.1021/ja027759q
   Meinel L, 2001, J CONTROL RELEASE, V70, P193, DOI 10.1016/S0168 3659(00)00352 7
   Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04 2747rev
   MURAKAMI Y, 2006, IN PRESS J BIOMED A
   Nishiyama N, 2006, ADV POLYM SCI, V193, P67, DOI 10.1007/12_025
   Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006
   Ohashi S, 2001, J Orthop Sci, V6, P75, DOI 10.1007/s007760170028
   Oldham JB, 2000, J BIOMECH ENG T ASME, V122, P289, DOI 10.1115/1.429662
   Ono I, 2004, BIOMATERIALS, V25, P4709, DOI 10.1016/j.biomaterials.2003.11.038
   Orban JM, 2002, TISSUE ENG, V8, P529, DOI 10.1089/107632702760240454
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169 409X(02)00228 4
   Park J, 2003, GENE THER, V10, P1089, DOI 10.1038/sj.gt.3301960
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378 5173(02)00315 0
   Putnam D, 2006, NAT MATER, V5, P439, DOI 10.1038/nmat1645
   Rose FRAJ, 2004, J PHARM PHARMACOL, V56, P415, DOI 10.1211/0022357023312
   Rose FRAJ, 2002, BIOCHEM BIOPH RES CO, V292, P1, DOI 10.1006/bbrc.2002.6519
   Salgado AJ, 2004, MACROMOL BIOSCI, V4, P743, DOI 10.1002/mabi.200400026
   Sato M, 2004, EXPERT REV MED DEVIC, V1, P105, DOI 10.1586/17434440.1.1.105
   Shen H, 2004, NAT MATER, V3, P569, DOI 10.1038/nmat1179
   Shi XF, 2006, BIOMACROMOLECULES, V7, P2237, DOI 10.1021/bm060391v
   Shin M, 2004, TISSUE ENG, V10, P33, DOI 10.1089/107632704322791673
   Smith LA, 2004, COLLOID SURFACE B, V39, P125, DOI [10.1016/j.colsurfb.2003.12.004, 10.1016/j.colsurfb.2003.l2.004]
   Southwood LL, 2004, VET SURG, V33, P565, DOI 10.1111/j.1532 950X.2004.04080.x
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Tabata Y, 2005, METH MOL B, V300, P81
   Tuzlakoglu K, 2005, J MATER SCI MATER M, V16, P1099, DOI 10.1007/s10856 005 4713 8
   Webster TJ, 1999, BIOMATERIALS, V20, P1221, DOI 10.1016/S0142 9612(99)00020 4
   Webster TJ, 2005, J BIOMED MATER RES A, V74A, P677, DOI 10.1002/jbm.a.30358
   Wei GB, 2004, BIOMATERIALS, V25, P4749, DOI 10.1016/j.biomaterials.2003.12.005
   Woo KM, 2003, J BIOMED MATER RES A, V67A, P531, DOI 10.1002/jbm.a.10098
   Woo KM, 2007, BIOMATERIALS, V28, P335, DOI 10.1016/j.biomaterials.2006.06.013
   XIN X, 2006, IN PRESS BIOMATERIAL
   Xu HHK, 1999, J DENT RES, V78, P1304, DOI 10.1177/00220345990780070401
   Xu HHK, 2004, BIOMATERIALS, V25, P4615, DOI 10.1016/j.biomaterials.2003.12.058
   Yamamoto M, 2006, ADV DRUG DELIVER REV, V58, P535, DOI 10.1016/j.addr.2006.03.003
   Yi F, 2006, J CLIN PHARM THER, V31, P43, DOI 10.1111/j.1365 2710.2006.00702.x
   Yoo JJ, 2004, J BIOMED MATER RES A, V68A, P401, DOI 10.1002/jbm.a.20038
   Yoshimoto H, 2003, BIOMATERIALS, V24, P2077, DOI 10.1016/S0142 9612(02)00635 X
NR 76
TC 85
Z9 97
U1 2
U2 43
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061 186X
EI 1029 2330
J9 J DRUG TARGET
JI J. Drug Target.
PY 2007
VL 15
IS 4
BP 241
EP 252
DI 10.1080/10611860701289818
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 175FR
UT WOS:000246999100001
PM 17487693
DA 2025 08 17
ER

PT J
AU Kolli, V
   Stechschulte, LA
   Dowling, AR
   Rahman, S
   Czernik, PJ
   Lecka Czernik, B
AF Kolli, Vipula
   Stechschulte, Lance A.
   Dowling, Abigail R.
   Rahman, Sima
   Czernik, Piotr J.
   Lecka Czernik, Beata
TI Partial Agonist, Telmisartan, Maintains PPARγ Serine 112
   Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone
   Mass
SO PLOS ONE
LA English
DT Article
ID RENIN ANGIOTENSIN SYSTEM; MESENCHYMAL STEM CELLS; BROWN ADIPOSE TISSUE;
   MOLECULAR CHARACTERIZATION; INSULIN RESISTANCE; DIABETIC PATIENTS;
   RECEPTOR; FAT; OSTEOPOROSIS; INCREASES
AB Peroxisome proliferator activated receptor gamma (PPAR gamma) controls both glucose metabolism and an allocation of marrow mesenchymal stem cells (MSCs) toward osteoblast and adipocyte lineages. Its activity is determined by interaction with a ligand which directs posttranscriptional modifications of PPAR gamma protein including dephosphorylation of Ser112 and Ser273, which results in acquiring of pro adipocytic and insulin sensitizing activities, respectively. PPAR gamma full agonist TZD rosiglitazone (ROSI) decreases phosphorylation of both Ser112 and Ser273 and its prolonged use causes bone loss in part due to diversion of MSCs differentiation from osteoblastic toward adipocytic lineage. Telmisartan (TEL), an anti hypertensive drug from the class of angiotensin receptor blockers, also acts as a partial PPAR gamma agonist with insulin sensitizing and a weak pro adipocytic activity. TEL decreased (S273)pPPAR gamma and did not affect (S112)pPPAR gamma levels in a model of marrow MSC differentiation, U 33/gamma 2 cells. In contrast to ROSI, TEL did not affect osteoblast phenotype and actively blocked ROSI induced anti osteoblastic activity and dephosphorylation of (S112)pPPAR gamma. The effect of TEL on bone was tested side by side with ROSI. In contrast to ROSI, TEL administration did not affect bone mass and bone biomechanical properties measured by micro indentation method and did not induce fat accumulation in bone, and it partially protected from ROSI induced bone loss. In addition, TEL induced "browning'' of epididymal white adipose tissue marked by increased expression of UCP1, FoxC2, Wnt10b and IGFBP2 and increased overall energy expenditure. These studies point to the complexity of mechanisms by which PPAR gamma acquires anti osteoblastic and pro adipocytic activities and suggest an importance of Ser112 phosphorylation status as being a part of the mechanism regulating this process. These studies showed that TEL acts as a full PPAR gamma agonist for insulin sensitizing activity and as a partial agonist/partial antagonist for pro adipocytic and antiosteoblastic activities. They also suggest a relationship between PPAR gamma fat "browning'' activity and a lack of antiosteoblastic activity.
C1 [Kolli, Vipula; Stechschulte, Lance A.; Rahman, Sima; Czernik, Piotr J.; Lecka Czernik, Beata] Univ Toledo, Dept Orthopaed Surg, Coll Med, Toledo, OH 43606 USA.
   [Dowling, Abigail R.; Lecka Czernik, Beata] Univ Toledo, Dept Physiol & Pharmacol, Coll Med, Toledo, OH 43606 USA.
   [Kolli, Vipula; Stechschulte, Lance A.; Dowling, Abigail R.; Rahman, Sima; Lecka Czernik, Beata] Univ Toledo, Ctr Diabet & Endocrine Res, Coll Med, Toledo, OH 43606 USA.
C3 University System of Ohio; University of Toledo; University System of
   Ohio; University of Toledo; University System of Ohio; University of
   Toledo
RP Lecka Czernik, B (通讯作者)，Univ Toledo, Dept Orthopaed Surg, Coll Med, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM beata.leckaczernik@utoledo.edu
OI Stechschulte, Lance/0000 0001 9783 6194
FU NIH [AG028935]; American Diabetes Association [N 120614]; National
   Institute of Diabetes and Digestive and Kidney Diseases [P30DK020572]
   Funding Source: NIH RePORTER
FX This work was supported by NIH AG028935 and American Diabetes
   Association N 120614. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159
   Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Amano Y, 2012, HYPERTENS RES, V35, P715, DOI 10.1038/hr.2012.17
   Araki K, 2006, HYPERTENSION, V48, P51, DOI 10.1161/01.HYP.0000225402.69580.1d
   Asaba Y, 2009, J BONE MINER RES, V24, P241, DOI [10.1359/jbmr.081006, 10.1359/JBMR.081006]
   Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57
   BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092 8674(05)80067 4
   Cawthorn WP, 2012, BONE, V50, P477, DOI 10.1016/j.bone.2011.08.010
   Choi JH, 2011, NATURE, V477, P477, DOI 10.1038/nature10383
   Furuhashi M, 2003, HYPERTENSION, V42, P76, DOI 10.1161/01.HYP.0000078490.59735.6E
   Grainger DJ, 1999, OSTEOPOROSIS INT, V9, P398, DOI 10.1007/s001980050163
   Gu SS, 2012, BIOSCI BIOTECH BIOCH, V76, P1367, DOI 10.1271/bbb.120123
   Hedbacker K, 2010, CELL METAB, V11, P11, DOI 10.1016/j.cmet.2009.11.007
   Henriksen EJ, 2001, HYPERTENSION, V38, P884, DOI 10.1161/hy1101.092970
   Hinds TD, 2011, J BIOL CHEM, V286, P42911, DOI 10.1074/jbc.M111.311662
   Holdsworth DW, 2002, TRENDS BIOTECHNOL, V20, pS34, DOI 10.1016/S0167 7799(02)02004 8
   Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100
   Huang S, 2010, BONE, V46, P1138, DOI 10.1016/j.bone.2009.12.020
   Izu Y, 2009, J BIOL CHEM, V284, P4857, DOI 10.1074/jbc.M807610200
   Katavetin Pisut, 2006, Journal of the Medical Association of Thailand, V89, P170
   Kawai M, 2011, J BIOL CHEM, V286, P14670, DOI 10.1074/jbc.M110.193334
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Lecka Czernik Beata, 2010, Curr Osteoporos Rep, V8, P178, DOI 10.1007/s11914 010 0027 y
   Lewis G, 2008, J BIOMED MATER RES B, V87B, P286, DOI 10.1002/jbm.b.31092
   Li YQ, 2009, CAN J PHYSIOL PHARM, V87, P51, DOI 10.1139/Y08 097
   Liu LC, 2013, BONE, V52, P247, DOI 10.1016/j.bone.2012.09.038
   Liu LC, 2012, CALCIFIED TISSUE INT, V91, P139, DOI 10.1007/s00223 012 9623 4
   Lynn H, 2006, BONE, V38, P584, DOI 10.1016/j.bone.2005.09.011
   Ma L, 2010, BONE, V47, P5, DOI 10.1016/j.bone.2010.03.016
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Mori H, 2012, ADV THER, V29, P635, DOI 10.1007/s12325 012 0032 x
   Nedergaard J, 2010, CELL METAB, V11, P268, DOI 10.1016/j.cmet.2010.03.007
   Ohno H, 2012, CELL METAB, V15, P395, DOI 10.1016/j.cmet.2012.01.019
   Olmsted Davis E, 2007, AM J PATHOL, V170, P620, DOI 10.2353/ajpath.2007.060692
   Qiang L, 2012, CELL, V150, P620, DOI 10.1016/j.cell.2012.06.027
   Rahman S, 2013, ENDOCRINOLOGY, V154, P2687, DOI 10.1210/en.2012 2162
   Rahman S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051746
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Salisbury E, 2012, HUM PATHOL, V43, P2213, DOI 10.1016/j.humpath.2012.03.013
   Schupp M, 2005, DIABETES, V54, P3442, DOI 10.2337/diabetes.54.12.3442
   Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Shiota A, 2012, EUR J PHARMACOL, V692, P84, DOI 10.1016/j.ejphar.2012.07.026
   Shockley KR, 2009, J CELL BIOCHEM, V106, P232, DOI 10.1002/jcb.21994
   Storka A, 2008, EUR J CLIN INVEST, V38, P820, DOI 10.1111/j.1365 2362.2008.02025.x
   Tagami T, 2009, ENDOCRINOLOGY, V150, P862, DOI 10.1210/en.2008 0502
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Usui I, 2007, DIABETES RES CLIN PR, V77, P210, DOI 10.1016/j.diabres.2006.11.014
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wolff GL, 1999, PHYSIOL GENOMICS, V1, P151, DOI 10.1152/physiolgenomics.1999.1.3.151
   Wu J, 2012, CELL, V150, P366, DOI 10.1016/j.cell.2012.05.016
   Younis F, 2010, METABOLISM, V59, P1200, DOI 10.1016/j.metabol.2009.11.013
NR 56
TC 39
Z9 45
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2014
VL 9
IS 5
AR e96323
DI 10.1371/journal.pone.0096323
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AK1XT
UT WOS:000338213300030
PM 24810249
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Lee, E
   Jang, M
   Lim, TG
   Kim, T
   Ha, H
   Lee, JH
   Hong, HD
   Cho, CW
AF Lee, Eunjung
   Jang, Mi
   Lim, Tae Gyu
   Kim, Taesoo
   Ha, Hyunil
   Lee, Jeong Hoon
   Hong, Hee Do
   Cho, Chang Won
TI Selective activation of the estrogen receptor β by the polysaccharide
   from Cynanchum wilfordii alleviates menopausal syndrome in
   ovariectomized mice
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Cynanchum wilfordii; Polysaccharide; Menopausal symptoms
ID BREAST CANCER; POSTMENOPAUSAL WOMEN; HORMONE THERAPY; BONE; ALPHA;
   OSTEOCLASTS; EXPRESSION; SYMPTOMS; EXTRACT; BRAIN
AB The menopausal syndrome caused by rapid changes in hormone levels greatly influences the quality of life of women. Though hormone replacement therapy (HRT) is widely used to treat the menopausal syndrome, it exhibits many side effects, including the risk of thrombosis, cardiovascular diseases, and increased incidence of breast cancer; thus, diversifying the interest for phytotherapy based materials as alternatives to HRT. Here, we isolated a crude polysaccharide fraction (CWPF) from Cynanchum wilfordii root that alleviated the ovariectomy induced uterine atrophy and bone loss without changes in plasma estradiol concentration in mice. Increased plasma levels of follicle stimulating hormone (FSH), alkaline phosphatase (ALP), osteocalcin (OC) in ovariectomized mice were also reduced to normal levels by CWPF administration. We found that the inhibitory effects of CWPF onmenopausal symptoms were mediated by the estrogen receptor beta (ER beta) specific activation, not ER alpha. Moreover, CWPF treatment suppressed the phosphorylation of Akt, suggesting that CWPF alleviates post menopausal symptoms by regulating ER beta related Akt signaling pathway. These results demonstrate that the polysaccharides corresponding to CWPF among the water soluble extracts of CW could be used as a beneficial herbal alternative for the development of therapeutic agents to prevent menopausal syndrome in women. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Lee, Eunjung; Lim, Tae Gyu; Hong, Hee Do; Cho, Chang Won] Korea Food Res Inst, Res Grp Tradit Food, Wonju 55365, South Korea.
   [Jang, Mi] Korea Food Res Inst, Food Stand Res Ctr, Wonju 55365, South Korea.
   [Lim, Tae Gyu] Sejong Univ, Dept Food Sci & Biotechnol, Seoul 05006, South Korea.
   [Kim, Taesoo; Ha, Hyunil] Korea Inst Oriental Med, Herbal Med Res Div, Daejeon 34054, South Korea.
   [Lee, Jeong Hoon] Natl Inst Hort & Herbal Sci, Dept Herbal Crop Res, RDA, Eumseong 27709, South Korea.
C3 Korea Food Research Institute (KFRI); Korea Food Research Institute
   (KFRI); Sejong University; Korea Institute of Oriental Medicine (KIOM);
   National Institute of Horticultural & Herbal Science (NIHHS), Republic
   of Korea; Rural Development Administration (RDA), Republic of Korea
RP Cho, CW (通讯作者)，Korea Food Res Inst, Wonju 55365, South Korea.
EM cwcho@kfri.re.kr
RI Lim, Tae Gyu/AAO 8475 2020; Cho, Chang Won/GPF 4456 2022
FU Korea Food Research Institute (KFRI)   Ministry of Science and ICT
   [E0201100]
FX This project was supported by Main Research Program (E0201100) of the
   Korea Food Research Institute (KFRI) funded by the Ministry of Science
   and ICT.
CR Allred CD, 2001, CANCER RES, V61, P5045
   한송희, 2015, [Korean Journal of Food Science and Technology, 한국식품과학회지], V47, P667, DOI 10.9721/KJFST.2015.47.5.667
   [Anonymous], 2014, PLOS ONE
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Chang A, 2012, PHYTOTHER RES, V26, P510, DOI 10.1002/ptr.3597
   Chhibber A, 2017, PSYCHONEUROENDOCRINO, V82, P107, DOI 10.1016/j.psyneuen.2017.05.016
   Cotrim CZ, 2013, ONCOGENE, V32, P2390, DOI 10.1038/onc.2012.261
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Glidewell Kenney C, 2008, ENDOCRINOLOGY, V149, P4168, DOI 10.1210/en.2007 1807
   Gompel A, 2012, CLIMACTERIC, V15, P241, DOI 10.3109/13697137.2012.666456
   Grodstein F, 2006, J WOMENS HEALTH, V15, P35, DOI 10.1089/jwh.2006.15.35
   Ha H, 2014, MOLECULES, V19, P3940, DOI 10.3390/molecules19043940
   Han JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181175
   Hartz AMS, 2010, J PHARMACOL EXP THER, V334, P467, DOI 10.1124/jpet.110.168930
   Huang B, 2014, P NATL ACAD SCI USA, V111, P1933, DOI 10.1073/pnas.1323719111
   Jang M, 2018, J FUNCT FOODS, V40, P329, DOI 10.1016/j.jff.2017.11.023
   Jang M, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100600
   Jeon H, 2016, ONCOTARGET, V7, P67223, DOI 10.18632/oncotarget.11615
   Kargozar Rahele, 2017, Electron Physician, V9, P5826, DOI 10.19082/5826
   Kim MinKyeoung Kim MinKyeoung, 2013, Journal of Medicinal Plants Research, V7, P2584
   Kim SJ, 2017, TOXICOL RES GER, V33, P71, DOI 10.5487/TR.2017.33.1.071
   Kitajima Y, 2015, SCI REP UK, V5, DOI 10.1038/srep12861
   Lee E, 2013, TOXICOL APPL PHARM, V272, P12, DOI 10.1016/j.taap.2013.04.030
   Lee Gyuok, 2016, Prev Nutr Food Sci, V21, P373, DOI 10.3746/pnf.2016.21.4.373
   Lee H, 2018, MOL MED REP, V17, P3758, DOI 10.3892/mmr.2017.8309
   Lindberg K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2865
   Mano H, 2001, CYTOTECHNOLOGY, V35, P17, DOI 10.1023/A:1008188120766
   Martin Millan M, 2010, MOL ENDOCRINOL, V24, P323, DOI 10.1210/me.2009 0354
   Muka T, 2016, MATURITAS, V86, P28, DOI 10.1016/j.maturitas.2016.01.009
   Nilsson S, 2011, CLIN PHARMACOL THER, V89, P44, DOI 10.1038/clpt.2010.226
   Ou L, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102 865020190050000002
   Rice S, 2006, ENDOCR RELAT CANCER, V13, P995, DOI 10.1677/erc.1.01159
   RYAN PJ, 1992, BRIT J OBSTET GYNAEC, V99, P325, DOI 10.1111/j.1471 0528.1992.tb13732.x
   Santoro N, 2015, ENDOCRIN METAB CLIN, V44, P497, DOI 10.1016/j.ecl.2015.05.001
   Solomon CG, 2003, NEW ENGL J MED, V348, P579, DOI 10.1056/NEJMp030006
   Song YA, 2009, J KOREAN ACAD NURS, V39, P868, DOI 10.4040/jkan.2009.39.6.868
   Ström A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Tagliaferri MA, 2016, J ALTERN COMPLEM MED, V22, P722, DOI 10.1089/acm.2015.0021
   Verkooijen HM, 2009, MATURITAS, V64, P80, DOI 10.1016/j.maturitas.2009.07.015
   Wang Y, 2019, EVID BASED COMPL ALT, V2019, DOI 10.1155/2019/2089586
   Warner M, 2017, TRENDS PHARMACOL SCI, V38, P92, DOI 10.1016/j.tips.2016.10.006
   Zhao CY, 2010, J BIOL CHEM, V285, P39575, DOI 10.1074/jbc.R110.180109
   Zhou S, 2018, EXP THER MED, V15, P3623, DOI 10.3892/etm.2018.5839
   Zhou XD, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6869350
   Zhu L, 2013, DIABETES, V62, P424, DOI 10.2337/db11 1718
   Zhu Y, 2002, SCIENCE, V295, P505, DOI 10.1126/science.1065250
NR 47
TC 6
Z9 7
U1 4
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC 15
PY 2020
VL 165
BP 1029
EP 1037
DI 10.1016/j.ijbiomac.2020.09.165
PN A
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA PI0CG
UT WOS:000600768200093
PM 32991896
DA 2025 08 17
ER

PT J
AU Zhang, BB
   Deng, L
   Wu, HS
   Lu, XZ
   Peng, LH
   Wu, RR
   Guo, WB
   Chen, JD
   Li, LH
   Zhao, JP
AF Zhang, Beibei
   Deng, Lu
   Wu, Haishan
   Lu, Xiaozi
   Peng, Lihong
   Wu, Renrong
   Guo, Wenbin
   Chen, Jindong
   Li, Lehua
   Zhao, Jingping
TI Relationship between long term use of a typical antipsychotic medication
   by Chinese schizophrenia patients and the bone turnover markers serum
   osteocalcin and β CrossLaps
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Antipsychotics; Bone turnover; Osteoporosis; Lipid;
   Glucose
ID BIOCHEMICAL MARKERS; MINERAL DENSITY; GLUCOSE; RESORPTION; METABOLISM;
   PROLACTIN; HORMONES; INSULIN; LIFE; MASS
AB Background: Increasing evidence shows that schizophrenia patients with long term exposure to antipsychotic medications have decreased bone mass, which suggests that they are at a high risk of osteoporosis. However, the mechanism underlying this remains unclear. In this study, we selected two bone turnover markers to explore whether atypical antipsychotics can affect bone metabolism and identified possible influencing factors.
   Methods: A total of 116 schizophrenia patients (18 40 years old) participated in the study. The subjects included 31 drug naive first episode patients and 85 patients who had undergone atypical antipsychotic monotherapy for at least 6 months. A total of 71 subjects were assigned as normal controls. Demographic and physical examination data were analyzed for all subjects. The positive and negative syndrome scale (PANSS) was used to assess psychopathology in schizophrenia patients. Levels of the bone turnover markers osteocalcin and beta CrossLaps were measured. Serum prolactin (PRL), lipid, sex hormone, glucose, insulin, and parathyroid hormone levels were also measured.
   Results: The serum beta CrossLaps levels of patients who had been treated with atypical antipsychotics were higher compared with those of drug naive first episode patients and normal subjects. Atypical antipsychotics, schizophrenia, age, gender, and body mass index, as well as serum levels of PRL, triglyceride, high density lipoprotein cholesterol, glucose, and testosterone, were significantly associated with serum osteocalcin and beta CrossLaps levels. Serum insulin was only positively associated with serum osteocalcin, whereas estradiol was only negatively associated with serum beta CrossLaps.
   Conclusion: Patients who had been treated with atypical antipsychotics had accelerated bone resorption. Our findings uncover a link between atypical antipsychotics and bone metabolism, possibly through abnormalities in glucose and lipid metabolism and insulin resistance. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Zhang, Beibei; Deng, Lu; Wu, Haishan; Wu, Renrong; Guo, Wenbin; Chen, Jindong; Li, Lehua; Zhao, Jingping] Cent S Univ, Dept Psychiat, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Lu, Xiaozi] Qingdao Mental Hlth Ctr, Qingdao 266034, Shandong, Peoples R China.
   [Peng, Lihong] Cent S Univ, Xiangya Hosp 2, Metab Endocrinol Inst, Changsha 410011, Hunan, Peoples R China.
   [Zhang, Beibei; Deng, Lu; Wu, Haishan; Wu, Renrong; Guo, Wenbin; Chen, Jindong; Li, Lehua; Zhao, Jingping] Cent S Univ, Chinese Natl Clin Res Ctr Mental Disorders Xiangy, Hunan Key Lab Psychiat & Mental Hlth,Xiangya Hosp, Chinese Natl Technol Inst Mental Disorders,Mental, Changsha 410011, Hunan, Peoples R China.
C3 Central South University; Central South University; Central South
   University
RP Chen, JD (通讯作者)，Cent S Univ, Dept Psychiat, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.; Chen, JD (通讯作者)，Cent S Univ, Chinese Natl Clin Res Ctr Mental Disorders Xiangy, Hunan Key Lab Psychiat & Mental Hlth,Xiangya Hosp, Chinese Natl Technol Inst Mental Disorders,Mental, Changsha 410011, Hunan, Peoples R China.
EM chenjd269@163.com
FU National Natural Science Foundation of China [81501163]
FX This study was subsidized by National Natural Science Foundation of
   China (approve number: 81501163).
CR Abraham G, 2003, AM J PSYCHIAT, V160, P1618, DOI 10.1176/appi.ajp.160.9.1618
   Bishop JR, 2012, THER ADV PSYCHOPHARM, V2, P95, DOI 10.1177/2045125312442080
   Bruce J.K., 2013, CLIN SCHIZOPHR RELAT, V7, P115
   Chailurkit LO, 2008, CLIN ENDOCRINOL, V68, P858, DOI 10.1111/j.1365 2265.2007.03159.x
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198 005 1863 y
   Doknic M, 2011, NEUROENDOCRINOLOGY, V94, P246, DOI 10.1159/000329391
   Fujimaki T., 1994, ACTA OBSTET GYNAECOL, V46, P423
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Guo XF, 2013, INT J PSYCHIAT CLIN, V17, P16, DOI 10.3109/13651501.2012.745574
   Halbreich U, 2003, PSYCHONEUROENDOCRINO, V28, P53, DOI 10.1016/S0306 4530(02)00112 9
   Henriksen DB, 2003, J BONE MINER RES, V18, P2180, DOI 10.1359/jbmr.2003.18.12.2180
   Jeong TD, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/398397
   Kishimoto T, 2008, J CLIN PSYCHIAT, V69, P385, DOI 10.4088/JCP.v69n0307
   Kunchur R, 2009, J ORAL MAXIL SURG, V67, P1167, DOI 10.1016/j.joms.2009.02.004
   Majima T, 2008, ENDOCR J, V55, P143, DOI 10.1507/endocrj.K07E 004
   Meyer JM, 2004, SCHIZOPHR RES, V70, P1, DOI 10.1016/j.schres.2004.01.014
   O'Keane Veronica, 2008, J Psychopharmacol, V22, P70, DOI 10.1177/0269881107088439
   Okamoto K, 2010, LIFE SCI, V87, P686, DOI 10.1016/j.lfs.2010.10.006
   Pramojanee SN, 2014, ENDOCR RES, V39, P144, DOI 10.3109/07435800.2013.879168
   Starup Linde J, 2014, OSTEOPOROSIS INT, V25, P1697, DOI 10.1007/s00198 014 2676 7
   Thomas P., 2011, BONE, V49, P824
   Thrailkill KM, 2005, AM J PHYSIOL ENDOC M, V289, pE735, DOI 10.1152/ajpendo.00159.2005
   Wu XL, 2013, SCHIZOPHR RES, V150, P157, DOI 10.1016/j.schres.2013.07.051
   Young SL, 2015, J PSYCHOPHARMACOL, V29, P353, DOI 10.1177/0269881114562090
   Zhou M, 2009, EUR J ENDOCRINOL, V161, P723, DOI 10.1530/EJE 09 0585
NR 25
TC 22
Z9 23
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920 9964
EI 1573 2509
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD OCT
PY 2016
VL 176
IS 2 3
BP 259
EP 263
DI 10.1016/j.schres.2016.06.034
PG 5
WC Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA DX1LZ
UT WOS:000384130200028
PM 27377977
DA 2025 08 17
ER

PT J
AU Ying, J
   Wang, P
   Ding, QW
   Shen, J
   O'Keefe, RJ
   Chen, D
   Tong, PJ
   Jin, HT
AF Ying, Jun
   Wang, Pinger
   Ding, Quanwei
   Shen, Jie
   O'Keefe, Regis J.
   Chen, Di
   Tong, Peijian
   Jin, Hongting
TI Peripheral Blood Stem Cell Therapy Does Not Improve Outcomes of Femoral
   Head Osteonecrosis With Cap Shaped Separated Cartilage Defect
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE osteonecrosis of femoral head; cap shaped separated cartilage; stem
   cells; osteoclasts; treatment
ID AVASCULAR NECROSIS; ISCHEMIC NECROSIS; EXPRESSION; MECHANISM; RECEPTOR;
   RANKL; VEGF; HIP
AB A combination treatment with porous tantalum rod implantation and intra arterial infusion of peripheral blood stem cells (PBSCs) provides a promise for treating early and intermediate stages of osteonecrosis of the femoral head (ONFH). However, its clinical indications and application restrictions remain unclear. This study aims to determine the clinical, histological, and radiological outcomes of a combination treatment using mechanical support and a targeted intra arterial infusion of PBSCs for painful ONFH with a cap shaped separation (CSS) cartilage defect. Compared with the standard pain management (control group), this combination treatment did not improve the Harris Hip Score (HHS) at 36 months. Micro CT and histologic analyses showed severe focal destruction in all CSS ONFH femoral heads in both the combination and control groups. Femoral heads showed a higher percentage of bone lesions in the combination treatment group than in the control group. There was no significant difference in osteoclast number in the subchondral bone areas between the two groups. A high level of expression of inflammatory cytokines, including tumor necrosis factor alpha and interleukin 1 beta, was detected in blood vessels around the subchondral bone in both groups. The RANKL/OPG (receptor activator of the nuclear factor kB ligand/osteoprotegerin) ratio was also similar between the control and combination treatment groups. Our results indicate that this combination treatment is not an effective method for the treatment of patients with painful CSS ONFH. Moreover, this combination treatment did not inhibit inflammatory osteoclastogenesis in patients with more advanced disease. (c) 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res
C1 [Ying, Jun; Ding, Quanwei] Zhejiang Chinese Med Univ, Coll Clin Med 1, Hangzhou 310053, Zhejiang, Peoples R China.
   [Ying, Jun; Wang, Pinger; Ding, Quanwei; Jin, Hongting] Zhejiang Chinese Med Univ, Dept Orthopaed & Traumatol, Affiliated Hosp 1, Hangzhou 310053, Zhejiang, Peoples R China.
   [Tong, Peijian] Zhejiang Chinese Med Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Hangzhou 310006, Zhejiang, Peoples R China.
   [Ying, Jun; Shen, Jie; O'Keefe, Regis J.] Washington Univ, Dept Orthopaed Surg, St Louis, MO 63110 USA.
   [Chen, Di] Rush Univ, Dept Biochem, Med Ctr, Chicago, IL 60612 USA.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University; Washington University
   (WUSTL); Rush University
RP Jin, HT (通讯作者)，Zhejiang Chinese Med Univ, Dept Orthopaed & Traumatol, Affiliated Hosp 1, Hangzhou 310053, Zhejiang, Peoples R China.; Tong, PJ (通讯作者)，Zhejiang Chinese Med Univ, Dept Orthopaed Surg, Affiliated Hosp 1, Hangzhou 310006, Zhejiang, Peoples R China.
EM tongpeijian@163.com; hongtingjin@163.com
RI ; Chen, Di/AAJ 3665 2021
OI Ying, Jun/0000 0002 5289 489X; 
CR Al Aly Z, 2007, ARTERIOSCL THROM VAS, V27, P2589, DOI 10.1161/ATVBAHA.107.153668
   [Anonymous], 2015, INT J AGRON, DOI DOI 10.1155/2015/547386
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Cao HJ, 2015, BONE, V74, P58, DOI 10.1016/j.bone.2014.12.060
   Chen JY, 2017, ORTHOP SURG, V9, P3, DOI 10.1111/os.12302
   Du JL, 2016, ONCOTARGET, V7, P68434, DOI 10.18632/oncotarget.12034
   Feng Y, 2010, BONE, V46, P32, DOI 10.1016/j.bone.2009.09.001
   Han YG, 2017, INFLAMMATION, V40, P946, DOI 10.1007/s10753 017 0539 z
   HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623 196951040 00012
   HOPSON CN, 1988, J BONE JOINT SURG AM, V70A, P1048, DOI 10.2106/00004623 198870070 00013
   Jiang YN, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0334 7
   Jin HT, 2012, INT ORTHOP, V36, P2589, DOI 10.1007/s00264 012 1674 7
   Kim HKW, 2004, J BONE JOINT SURG AM, V86A, P129, DOI 10.2106/00004623 200401000 00019
   Kitaura H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/181849
   Ko JY, 2010, BONE, V46, P584, DOI 10.1016/j.bone.2009.10.030
   Kong XY, 2017, INT J BIOL SCI, V13, P480, DOI 10.7150/ijbs.18430
   Li WZ, 2009, J ORTHOP RES, V27, P694, DOI 10.1002/jor.20802
   Liu XL, 2017, INT J BIOL SCI, V13, P232, DOI 10.7150/ijbs.16951
   Liu YS, 2016, INT ORTHOP, V40, P1397, DOI 10.1007/s00264 015 2897 1
   Mao Q, 2015, J BONE MINER RES, V30, P647, DOI 10.1002/jbmr.2390
   Mont MA, 2015, J BONE JOINT SURG AM, V97A, P1604, DOI 10.2106/JBJS.O.00071
   Okazaki S, 2009, RHEUMATOLOGY, V48, P227, DOI 10.1093/rheumatology/ken462
   Panteli M, 2015, INJURY, V46, P445, DOI 10.1016/j.injury.2014.12.031
   Papakostidis C, 2016, ACTA ORTHOP, V87, P72, DOI 10.3109/17453674.2015.1077418
   Schmitt Sody M, 2008, INT ORTHOP, V32, P283, DOI 10.1007/s00264 007 0320 2
   SMITH SW, 1995, J BONE JOINT SURG AM, V77A, P674, DOI 10.2106/00004623 199505000 00003
   Song Y, 2017, BONE, V101, P104, DOI 10.1016/j.bone.2017.05.002
   Vincent C, 2009, J BONE MINER RES, V24, P1434, DOI [10.1359/JBMR.090305, 10.1359/jbmr.090305]
   Watson RM, 2004, RADIOL CLIN N AM, V42, P207, DOI 10.1016/S0033 8389(03)00166 0
   Xiong MY, 2016, AM J TRANSL RES, V8, P3133
   Yan ZQ, 2009, J ORTHOP RES, V27, P442, DOI 10.1002/jor.20759
   Zhang QK, 2018, J INT MED RES, V46, P2141, DOI 10.1177/0300060517700299
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhang YL, 2016, INT J BIOL SCI, V12, P776, DOI 10.7150/ijbs.15248
NR 34
TC 10
Z9 11
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD FEB
PY 2020
VL 38
IS 2
BP 269
EP 276
DI 10.1002/jor.24471
PG 8
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA KD1TK
UT WOS:000507655600004
PM 31520480
OA Bronze
DA 2025 08 17
ER

PT J
AU Neuerburg, C
   Wedemeyer, C
   Goedel, J
   Schlepper, R
   Hilken, G
   Schwindenhammer, B
   Schilling, AF
   Jäger, M
   Kauther, MD
AF Neuerburg, Carl
   Wedemeyer, Christian
   Goedel, Jan
   Schlepper, Ruediger
   Hilken, Gero
   Schwindenhammer, Benjamin
   Schilling, Arndt Friedrich
   Jaeger, Marcus
   Kauther, Max Daniel
TI The role of calcitonin receptor signalling in polyethylene
   particle induced osteolysis
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Calcitonin receptor; UHMWPE; Aseptic loosening; RANKL; OPG
ID GENE RELATED PEPTIDE; INDUCED BONE RESORPTION; KAPPA B LIGAND; IN VIVO;
   DEFICIENT MICE; SUBSTANCE P; CGRP; AMYLIN; OSTEOPROTEGERIN;
   HYPERCALCEMIA
AB The detection of peptides from the calcitonin (CT) family in the periarticular tissue of loosened implants has raised hopes of opening new regenerative therapies in the process of aseptic loosening, which remains the major cause of early implant failure in endoprosthetic surgery. We have previously shown the roles of a calcitonin gene related peptide (alpha CGRP) and the CALCA gene which encodes alpha CGRP/CT in this process. To uncover the role of direct calcitonin receptor (CTR) mediated signalling, we studied particle induced osteolysis (PIO) in a murine calvaria model with a global deletion of the CTR (CTR KO) using IICT analysis and histomorphometiy. As expected, CTR KO mice revealed reduced bone volume compared to wild type (WT) controls (p < 0.05). In CTR KO mice we found significantly higher RAMC(receptor activator of NF kappa B ligand) expression in the particle group than in the control group. The increase in osteoclast numbers by the particles was twice as high as the increase of osteoclasts in the WT mice (400 vs. 200%). Changes in the eroded surface and actual osteolysis due to ultrahigh molecular weight polyethylene particles were similar in WTs and CTR KOs. Taken together, our findings strengthen the relevance of the OPG/RANK/RANKL system in the PIO process. CTR seems to have an effect on osteoclast differentiation in this context. As there were no obvious changes of the amount of PIO in CTR deficiency, regenerative strategies in aseptic loosening of endoprosthetic implants based on peptides arising from the CT family should rather focus on the impact of a CGRP. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Neuerburg, Carl] Munich Univ Hosp LMU, Dept Trauma Surg, D 80336 Munich, Germany.
   [Wedemeyer, Christian; Goedel, Jan; Schlepper, Ruediger; Jaeger, Marcus] Univ Duisburg Essen, Univ Hosp, Dept Orthoped, Essen, Germany.
   [Jaeger, Marcus; Kauther, Max Daniel] Univ Duisburg Essen, Univ Hosp, Dept Trauma Surg, Essen, Germany.
   [Hilken, Gero] Univ Duisburg Essen, Univ Hosp, Cent Anim Lab, Essen, Germany.
   [Schwindenhammer, Benjamin] Univ Duisburg Essen, Univ Hosp, Inst Pathol & Neuropathol, Essen, Germany.
   [Schilling, Arndt Friedrich] Tech Univ Munich, Klinikum Rechts Isar, Clin Plast & Hand Surg, D 80290 Munich, Germany.
C3 University of Munich; University of Duisburg Essen; University of
   Duisburg Essen; University of Duisburg Essen; University of Duisburg
   Essen; Technical University of Munich
RP Neuerburg, C (通讯作者)，Munich Univ Hosp LMU, Dept Trauma Surg, Campus Innenstadt,Nussbaumstr 20, D 80336 Munich, Germany.
EM carl.neuerburg@med.uni muenchen.de
RI Kauther, Max/A 1505 2016; Neuerburg, Carl/AAE 7269 2020
OI Kauther, Max/0000 0003 3795 6068; Jager, Marcus/0000 0001 9516 1058; 
FU Deutsche Forschungsgemeinschaft [WE 3634/1 2]
FX The authors wish to thank Prof. D. Galson (Division of
   Hematology/Oncology, University of Pittsburgh, US) for providing the
   CTR KO mice. Many thanks to Ulrike von Hehn (medistat GmbH, Kiel,
   Germany) for supporting the statistical analysis. The authors also wish
   to thank Martina Broecker Preuss (Department of Endocrinology, Division
   of Clinical Chemistry and Laboratory Medicine, University of
   Duisburg Essen) for technical assistance throughout the experiment, and
   Kaye Schreyer for editorial assistance with the manuscript. The study
   was supported by Deutsche Forschungsgemeinschaft grant WE 3634/1 2
   (Christian Wedemeyer).
CR Anusaksathien O, 2001, J BIOL CHEM, V276, P22663, DOI 10.1074/jbc.M007104200
   Armour SL, 1999, J PHARMACOL TOXICOL, V42, P217, DOI 10.1016/S1056 8719(00)00074 5
   Barwell J, 2012, BRIT J PHARMACOL, V166, P51, DOI 10.1111/j.1476 5381.2011.01525.x
   BODY JJ, 1993, HORM RES, V39, P166, DOI 10.1159/000182719
   Cornish J, 2001, BONE, V29, P162, DOI 10.1016/S8756 3282(01)00494 X
   Dacquin R, 2004, J CELL BIOL, V164, P509, DOI 10.1083/jcb.200312135
   Davey RA, 2008, J BONE MINER RES, V23, P1182, DOI [10.1359/jbmr.080310, 10.1359/JBMR.080310]
   Davey RA, 2013, J BONE MINER RES, V28, P973, DOI 10.1002/jbmr.1869
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Garellick G., 2011, Annual Report
   Granchi D, 2006, J BONE JOINT SURG AM, V88A, P1501, DOI 10.2106/JBJS.E.01038
   Granholm S, 2011, J CELL BIOCHEM, V112, P3300, DOI 10.1002/jcb.23256
   Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218
   Huebner AK, 2006, J BONE MINER RES, V21, P1924, DOI 10.1359/JBMR.060820
   Jablonski H, 2014, NEUROIMMUNOMODULATIO
   Kauther MD, 2013, BIOMATERIALS, V34, P2911, DOI 10.1016/j.biomaterials.2013.01.034
   Kauther MD, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 186
   Kauther MD, 2010, INT J BIOL SCI, V6, P525
   Kukita T, 1996, HISTOL HISTOPATHOL, V11, P821
   Lerner U. H., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P87
   Naot D, 2008, BONE, V43, P813, DOI 10.1016/j.bone.2008.07.003
   Neuerburg C, 2012, TRENDS BIOMATER ARTI, V26, P161
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pondel M, 2000, INT J EXP PATHOL, V81, P405, DOI 10.1046/j.1365 2613.2000.00176.x
   Qian YB, 2008, ACTA ORTHOP, V79, P342, DOI 10.1080/17453670710015238
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Saxler G, 2007, EUR J PAIN, V11, P67, DOI 10.1016/j.ejpain.2005.12.011
   Schinke T, 2004, J BONE MINER RES, V19, P2049, DOI 10.1359/JBMR.040915
   Turner AG, 2011, BONE, V48, P354, DOI 10.1016/j.bone.2010.09.013
   von Knoch M, 2004, Z ORTHOP GRENZGEB, V142, P366, DOI 10.1055/s 2004 822589
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V80, P268, DOI 10.1007/s00223 007 9005 5
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
   Wedemeyer C, 2007, J BONE MINER RES, V22, P1011, DOI 10.1359/JBMR.070408
   Xu J, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 83
NR 35
TC 11
Z9 11
U1 0
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAR 1
PY 2015
VL 14
BP 125
EP 132
DI 10.1016/j.actbio.2014.11.051
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA CB6JR
UT WOS:000349733800013
PM 25486133
DA 2025 08 17
ER

PT J
AU Gavazzo, P
   Viti, F
   Donnelly, H
   Oliva, MAG
   Salmeron Sanchez, M
   Dalby, MJ
   Vassalli, M
AF Gavazzo, Paola
   Viti, Federica
   Donnelly, Hannah
   Oliva, Mariana Azevedo Gonzalez
   Salmeron Sanchez, Manuel
   Dalby, Matthew J.
   Vassalli, Massimo
TI Biophysical phenotyping of mesenchymal stem cells along the osteogenic
   differentiation pathway
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE Mesenchymal stem cells; Osteogenic differentiation; Biophysical tools;
   Cell morphology; Cellular biomechanics; Calcium homoeostasis
ID EXTRACELLULAR MATRIX; OSTEOBLAST DIFFERENTIATION; DIGITAL HOLOGRAPHY;
   BONE TISSUE; ADHESION; LINEAGE; CYTOSKELETON; MECHANOTRANSDUCTION;
   TRANSCRIPTION; STIMULATION
AB Mesenchymal stem cells represent an important resource, for bone regenerative medicine and therapeutic applications. This review focuses on new advancements and biophysical tools which exploit different physical and chemical markers of mesenchymal stem cell populations, to finely characterize phenotype changes along their osteogenic differentiation process. Special attention is paid to recently developed label free methods, which allow monitoring cell populations with minimal invasiveness. Among them, quantitative phase imaging, suitable for single cell morphometric analysis, and nanoindentation, functional to cellular biomechanics investigation. Moreover, the pool of ion channels expressed in cells during differentiation is discussed, with particular interest for calcium homoeostasis.Altogether, a biophysical perspective of osteogenesis is proposed, offering a valuable tool for the assessment of the cell stage, but also suggesting potential physiological links between apparently independent phenomena.
C1 [Gavazzo, Paola; Viti, Federica] CNR, Inst Biophys, Genoa, Italy.
   [Donnelly, Hannah; Dalby, Matthew J.] Univ Glasgow, Ctr Cellular Microenvironm, Inst Mol Cell & Syst Biol, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland.
   [Oliva, Mariana Azevedo Gonzalez; Salmeron Sanchez, Manuel; Vassalli, Massimo] Univ Glasgow, Ctr Cellular Microenvironm, Div Biomed Engn, Sch Engn, Glasgow, Lanark, Scotland.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica
   (IBF CNR); University of Glasgow; University of Glasgow
RP Viti, F (通讯作者)，CNR, Inst Biophys, Genoa, Italy.
EM federica.viti@ibf.cnr.it
RI ; Dalby, Matthew/G 2426 2012; Viti, Federica/IAR 5194 2023; Vassalli,
   Massimo/F 6762 2011; Salmeron Sanchez, Manuel/E 4680 2010
OI Viti, Federica/0000 0002 9651 8896; Azevedo Gonzalez Oliva,
   Mariana/0000 0002 3195 067X; Donnelly, Hannah/0000 0002 5154 9971;
   Gavazzo, Paola/0000 0002 2016 4702
FU Biotechnology and Biological Sciences Research Council [BB/P00220X/1]
   Funding Source: researchfish; BBSRC [BB/P00220X/1] Funding Source: UKRI
CR Alford AI, 2015, INT J BIOCHEM CELL B, V65, P20, DOI 10.1016/j.biocel.2015.05.008
   Anderson HJ, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00038
   [Anonymous], 2015, World report on ageing and health
   Aquino Martínez R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178158
   Banik BL, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00041
   Barradas AMC, 2012, BIOMATERIALS, V33, P3205, DOI 10.1016/j.biomaterials.2012.01.020
   Bartolozzi A, 2020, J MECH BEHAV BIOMED, V103, DOI 10.1016/j.jmbbm.2019.103581
   Barty A, 1998, OPT LETT, V23, P817, DOI 10.1364/OL.23.000817
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Biggs MJP, 2009, BIOMATERIALS, V30, P5094, DOI 10.1016/j.biomaterials.2009.05.049
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Briggs T, 2009, J BIOMED MATER RES A, V91A, P975, DOI 10.1002/jbm.a.32310
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Ceccarelli G, 2013, BIORESEARCH OPEN ACC, V2, P283, DOI 10.1089/biores.2013.0016
   Childs PG, 2016, ACTA BIOMATER, V34, P159, DOI 10.1016/j.actbio.2015.11.045
   COREY DP, 1979, BIOPHYS J, V26, P499, DOI 10.1016/S0006 3495(79)85267 4
   Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270
   Cox CD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10366
   Curry AS, 2016, MATRIX BIOL, V52 54, P397, DOI 10.1016/j.matbio.2016.02.011
   Cutiongco MFA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15114 1
   Dalby MJ, 2007, J CELL BIOCHEM, V102, P1234, DOI 10.1002/jcb.21354
   Dalby MJ, 2007, NAT MATER, V6, P997, DOI 10.1038/nmat2013
   Dalby MJ, 2007, J CELL BIOCHEM, V100, P326, DOI 10.1002/jcb.21058
   Dalby MJ, 2018, NAT REV MATER, V3, DOI 10.1038/natrevmats.2017.91
   Dimitriou R, 2011, INJURY, V42, pS3, DOI 10.1016/j.injury.2011.06.015
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Domura R, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8020018
   Donnelly H, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2018.0388
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Fassina L, 2008, J BIOMED MATER RES A, V87A, P750, DOI 10.1002/jbm.a.31827
   Ferraro P, 2011, SPRINGER SER SURF SC, V46, P1, DOI 10.1007/978 3 642 15813 1
   Fitzsimmons REB, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8031718
   Ford J, 2013, INT J LAB HEMATOL, V35, P351, DOI 10.1111/ijlh.12082
   FRIEDENSTEIN AJ, 1976, INT REV CYTOL, V47, P327, DOI 10.1016/S0074 7696(08)60092 3
   Gasser JA., 2017, BONE TOXICOLOGY MOL, P27, DOI DOI 10.1007/978 3 319 56192 9
   Ge C, 2016, J CELL PHYSL, V231, P69
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Ghali O, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0056 6
   Giannoudis PV, 2011, INJURY, V42, pS1, DOI 10.1016/j.injury.2011.06.001
   He L, 2019, EXP CELL RES, V374, P259, DOI 10.1016/j.yexcr.2018.11.016
   Hei HY, 2016, MOL CELLS, V39, P530, DOI 10.14348/molcells.2016.0033
   Heubach JF, 2004, J PHYSIOL LONDON, V554, P659, DOI 10.1113/jphysiol.2003.055806
   Huang CYC, 2004, STEM CELLS, V22, P313, DOI 10.1634/stemcells.22 3 313
   Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446
   Ingber DE, 2003, J CELL SCI, V116, P1397, DOI 10.1242/jcs.00360
   Ingber DE, 2003, J CELL SCI, V116, P1157, DOI 10.1242/jcs.00359
   Ito T, 2010, TRANSPLANTATION, V89, P1438, DOI 10.1097/TP.0b013e3181db09c4
   Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597
   Kawaguchi N, 2003, J CELL SCI, V116, P3893, DOI 10.1242/jcs.00699
   Kawano S, 2003, CELL CALCIUM, V34, P145, DOI 10.1016/S0143 4160(03)00069 1
   Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143416002001240
   Kobayashi T, 2010, CURR OPIN CELL BIOL, V22, P669, DOI 10.1016/j.ceb.2010.08.023
   Kou SS, 2010, OPT LETT, V35, P447, DOI 10.1364/OL.35.000447
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kuo SW, 2012, BIOMATERIALS, V33, P5013, DOI 10.1016/j.biomaterials.2012.03.080
   Lane SW, 2014, NAT BIOTECHNOL, V32, P795, DOI 10.1038/nbt.2978
   Langelier E, 2000, J HISTOCHEM CYTOCHEM, V48, P1307, DOI 10.1177/002215540004801002
   Lavenus S, 2011, EUR CELLS MATER, V22, P84, DOI 10.22203/eCM.v022a07
   Lee K, 2013, SENSORS BASEL, V13, P4170, DOI 10.3390/s130404170
   Li GR, 2005, STEM CELLS, V23, P371, DOI 10.1634/stemcells.2004 0213
   Li J, 2014, NATURE, V515, P279, DOI 10.1038/nature13701
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Liu YSA, 2014, CELL TRANSPLANT, V23, P1, DOI 10.3727/096368912X659925
   Loewke NO, 2018, IEEE T MED IMAGING, V37, P929, DOI 10.1109/TMI.2017.2775604
   Long EG, 2019, BIOACT MATER, V4, P249, DOI 10.1016/j.bioactmat.2019.08.001
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Loye AM, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 27098 6
   Maloney JM, 2010, BIOPHYS J, V99, P2479, DOI 10.1016/j.bpj.2010.08.052
   Mao AS, 2016, BIOMATERIALS, V98, P184, DOI 10.1016/j.biomaterials.2016.05.004
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Martino F, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00824
   Matsuoka F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055082
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McNamara LE, 2010, J TISSUE ENG, V1, DOI 10.4061/2010/120623
   McNamara LE, 2012, BIOMATERIALS, V33, P2835, DOI 10.1016/j.biomaterials.2011.11.047
   McQuin C, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005970
   Mehler VJ, 2019, STEM CELLS, V37, P298, DOI 10.1002/stem.2948
   Merola F, 2013, LAB CHIP, V13, P4512, DOI 10.1039/c3lc50515d
   Mobasseri R, 2017, BIOCHEM BIOPH RES CO, V483, P312, DOI 10.1016/j.bbrc.2016.12.146
   Mohammed D, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00162
   Mousawi F, 2020, STEM CELLS, V38, P410, DOI 10.1002/stem.3114
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Necas D, 2012, CENT EUR J PHYS, V10, P181, DOI 10.2478/s11534 011 0096 2
   Paino F, 2017, CLIN SCI, V131, P699, DOI 10.1042/CS20170047
   Paluch EK, 2015, BMC BIOL, V13, DOI 10.1186/s12915 015 0150 4
   Panaroni C, 2014, CURR OSTEOPOROS REP, V12, P22, DOI 10.1007/s11914 014 0190 7
   Park Y, 2020, FRONT PHYS LAUSANNE, V7, DOI 10.3389/fphy.2019.00226
   Parpaite T, 2017, CURR BIOL, V27, pR250, DOI 10.1016/j.cub.2017.01.048
   Pathak MM, 2014, P NATL ACAD SCI USA, V111, P16148, DOI 10.1073/pnas.1409802111
   Paturzo M, 2018, OPT LASER ENG, V104, P32, DOI 10.1016/j.optlaseng.2017.11.013
   Pchelintseva E, 2018, J CELL PHYSIOL, V233, P3755, DOI 10.1002/jcp.26120
   Petecchia L, 2017, EXP CELL RES, V358, P111, DOI 10.1016/j.yexcr.2017.06.008
   Petecchia L, 2015, SCI REP UK, V5, DOI 10.1038/srep13856
   Pileggi A, 2013, CURR OPIN ORGAN TRAN, V18, P672, DOI 10.1097/MOT.0000000000000029
   Pinho S, 2019, NAT REV MOL CELL BIO, V20, P303, DOI 10.1038/s41580 019 0103 9
   Popescu G, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.11.111201
   Ranade SS, 2015, NEURON, V87, P1162, DOI 10.1016/j.neuron.2015.08.032
   Rangamani P, 2013, CELL, V154, P1356, DOI 10.1016/j.cell.2013.08.026
   Rezakhaniha R, 2012, BIOMECH MODEL MECHAN, V11, P461, DOI 10.1007/s10237 011 0325 z
   Ridone P, 2020, J GEN PHYSIOL, V152, DOI 10.1085/jgp.201912515
   Ridone Pietro, 2019, Biophys Rev, V11, P795, DOI 10.1007/s12551 019 00584 5
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859 017 1934 z
   Sbrana F, 2017, J APPL PHYCOL, V29, P1363, DOI 10.1007/s10811 017 1069 7
   Schakenraad K, 2019, ARXIV190509805PHYSIC
   Schiller HB, 2013, EMBO REP, V14, P509, DOI 10.1038/embor.2013.49
   Schwartz Z, 2008, J ORTHOP RES, V26, P1250, DOI 10.1002/jor.20591
   Shih YRV, 2014, P NATL ACAD SCI USA, V111, P990, DOI 10.1073/pnas.1321717111
   Shyy JY, 2002, CIRC RES, V91, P769, DOI 10.1161/01.RES.0000038487.19924.18
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Sonowal H, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 71
   Su H, 2013, MED IMAGE ANAL, V17, P746, DOI 10.1016/j.media.2013.04.004
   Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583
   Sugimoto A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18089 0
   Sun S, 2007, FASEB J, V21, P1472, DOI 10.1096/fj.06 7153com
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Szpalski C, 2012, TISSUE ENG PART B RE, V18, P246, DOI [10.1089/ten.teb.2011.0427, 10.1089/ten.TEB.2011.0427]
   Tan YZ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12623
   Tanikake Y, 2017, CELL TRANSPLANT, V26, P1067, DOI 10.3727/096368916X694166
   Tao R, 2011, J CELL MOL MED, V15, P2684, DOI 10.1111/j.1582 4934.2011.01263.x
   Theveneau E, 2012, CURR OPIN CELL BIOL, V24, P677, DOI 10.1016/j.ceb.2012.08.002
   Titushkin I, 2007, BIOPHYS J, V93, P3693, DOI 10.1529/biophysj.107.107797
   Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107
   Tsimbouri P, 2014, J CELL BIOCHEM, V115, P380, DOI 10.1002/jcb.24673
   Tsimbouri PM, 2017, NAT BIOMED ENG, V1, P758, DOI 10.1038/s41551 017 0127 4
   Tsimbouri PM, 2013, BIOMATERIALS, V34, P2177, DOI 10.1016/j.biomaterials.2012.12.019
   Varga Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027957
   Vining KH, 2017, NAT REV MOL CELL BIO, V18, P728, DOI 10.1038/nrm.2017.108
   Viti F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148173
   WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839
   Wang CG, 2018, EUR J VASC ENDOVASC, V55, P257, DOI 10.1016/j.ejvs.2017.10.012
   Wang N, 2009, NAT REV MOL CELL BIO, V10, P75, DOI 10.1038/nrm2594
   Wu PH, 2015, SCI REP UK, V5, DOI 10.1038/srep18437
   Yang JL, 2014, ACS NANO, V8, P9941, DOI 10.1021/nn504767g
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
   Yu VWC, 2005, J CELL BIOL, V169, P591, DOI 10.1083/jcb.200412139
   Zahanich I, 2005, J BONE MINER RES, V20, P1637, DOI 10.1359/JBMR.050521
   Zhang S, 2018, MOL MED REP, V18, P2097, DOI 10.3892/mmr.2018.9172
   Zhang YY, 2014, J CELL PHYSIOL, V229, P202, DOI 10.1002/jcp.24435
   Zuo C., 2013, FRING 2013 7 INT WOR, P137
NR 145
TC 11
Z9 12
U1 1
U2 40
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742 2091
EI 1573 6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD DEC
PY 2021
VL 37
IS 6
BP 915
EP 933
DI 10.1007/s10565 020 09569 7
EA JAN 2021
PG 19
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Toxicology
GA XA6SL
UT WOS:000606244600001
PM 33420657
DA 2025 08 17
ER

PT J
AU Takakubo, Y
   Miyaji, T
   Ohta, D
   Ito, J
   Oki, H
   Momma, R
   Naganuma, Y
   Honma, R
   Akabane, T
   Uno, T
   Sasaki, A
   Suran, Y
   Dairaku, K
   Goto, S
   Goto, Y
   Kanauchi, Y
   Kobayashi, S
   Nakajima, T
   Matsuda, M
   Masuda, K
   Mura, N
   Takenouchi, K
   Tsuchida, H
   Onuma, Y
   Shibuya, J
   Nagase, T
   Yamaguchi, O
   Urayama, Y
   Furukawa, T
   Okuda, S
   Huang, HQ
   Noro, A
   Ogura, K
   Nakamura, T
   Sasaki, K
   Ishi, M
   Takagi, M
AF Takakubo, Yuya
   Miyaji, Takahiro
   Ohta, Daichi
   Ito, Juji
   Oki, Hiroharu
   Momma, Ryosuke
   Naganuma, Yasushi
   Honma, Ryusuke
   Akabane, Takeru
   Uno, Tomohiro
   Sasaki, Akiko
   Suran, Yang
   Dairaku, Katsuyuki
   Goto, Shinichi
   Goto, Yasuo
   Kanauchi, Yumiko
   Kobayashi, Shinji
   Nakajima, Taku
   Matsuda, Michiharu
   Masuda, Keiji
   Mura, Nariyuki
   Takenouchi, Kenji
   Tsuchida, Hiroyuki
   Onuma, Yasushi
   Shibuya, Junichirou
   Nagase, Takaaki
   Yamaguchi, Osamu
   Urayama, Yasuhiro
   Furukawa, Takashi
   Okuda, Shouta
   Huang, Hanqing
   Noro, Atsushi
   Ogura, Ken
   Nakamura, Takeshi
   Sasaki, Kan
   Ishi, Masaji
   Takagi, Michiaki
TI Differences in subtrochanteric and diaphyseal atypical femoral fractures
   in a super aging prefectural area: YamaCAFe Study
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Atypical femoral fracture; Subtrochanteric; Diaphyseal; Super aging;
   Prefectural area
ID RISK FACTORS; BONE; ASSOCIATION; JAPANESE; SHAFT
AB Introduction Atypical femoral fractures (AFFs) have been correlated with long term use of bisphosphonates (BPs), glucocorticoids (GCs), and femoral geometry. We investigated the incidence and characteristics of subtrochanteric (ST) and diaphyseal (DP) AFFs in all institutes in a super aging prefectural area. Materials and methods We performed a blinded analysis of radiographic data in 87 patients with 98 AFFs in all institutes in Yamagata prefectural area from 2009 to 2014. Among the 98 AFFs, 57 AFFs comprising 11 ST fractures in 9 patients and 46 DP fractures in 41 patients with adequate medical records and X rays were surveyed for time to bone healing and geometry. Results Of the 87 patients, 67 received BPs/denosumab (77%) and 10 received GCs (11%). Surgery was performed in 94 AFFs. Among 4 AFFs with conservative therapy, 3 required additional surgery. In univariate regression analyses for ST group versus DP group, male to female ratio was 2/7 versus 1/40, mean age at fracture was 58.2 (37 75) versus 78 (60 89) years, rheumatic diseases affected 55.5% (5/9) versus 4.9% (2/41), femoral lateral bowing angle was 1.7 (0 6) versus 11.8 (0.8 24)degrees, GC usage was 67% (6/9) versus 4.9% (2/41), and bone healing time was 12.1 (6 20) versus 8.1 (3 38) months (p < 0.05). In multivariate analyses, higher male to female ratio, younger age, greater proportion affected by rheumatic diseases, and higher GC usage remained significant (p < 0.05). Conclusions The incidence of AFFs in our prefectural area was 1.43 cases/100,000 persons/year. This study suggests that the onset of ST AFFs have greater correlation with the worse bone quality, vice versa, the onset of DP AFFs correlated with the bone geometry. The developmental mechanisms of AFFs may differ significantly between ST and DP fractures.
C1 [Takakubo, Yuya] Yamagata Univ, Fac Orthopaed Surg & Rehabil, Yamagata, Japan.
   [Miyaji, Takahiro; Ohta, Daichi; Ito, Juji; Momma, Ryosuke; Honma, Ryusuke; Akabane, Takeru; Uno, Tomohiro; Suran, Yang; Nagase, Takaaki; Huang, Hanqing; Takagi, Michiaki] Yamagata Univ, Fac Orthopaed Surg, Yamagata, Japan.
   [Oki, Hiroharu; Sasaki, Akiko; Sasaki, Kan; Ishi, Masaji] Yamagata Saisei Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Naganuma, Yasushi] Yamagata Prefectural Cent Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Dairaku, Katsuyuki] Okitama Publ Gen Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Goto, Shinichi] Tsuruoka Municipal Shonai Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Goto, Yasuo] Sagae City Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Kanauchi, Yumiko] Yamagata Prefectural Kahoku Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Kobayashi, Shinji] Shiseido Gen Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Nakajima, Taku] Sanyudo Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Matsuda, Michiharu] Tohoku Cent Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Masuda, Keiji; Noro, Atsushi] Yamagata City Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Mura, Nariyuki; Furukawa, Takashi] Yoshioka Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Takenouchi, Kenji] Kitamurayama Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Tsuchida, Hiroyuki] Miyukikai Hosp, Miyuki Social Med Corp, Fac Orthopaed Surg, Yamagata, Japan.
   [Onuma, Yasushi] Yamagata Tokusyukai Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Shibuya, Junichirou] Yamagata Prefectural Shinjo Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Yamaguchi, Osamu] Sinoda Gen Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Urayama, Yasuhiro] Mamurogawa Town Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Okuda, Shouta] Nihonkai Gen Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Ogura, Ken] Yonezawa City Hosp, Fac Orthopaed Surg, Yamagata, Japan.
   [Ogura, Ken] Ogura Orthopaed Clin, Yamagata, Japan.
   [Ogura, Ken] Yonezawa City Hosp, Fac Orthopaed Surg, Sendai, Miyagi, Japan.
   [Ogura, Ken] Ogura Orthopaed Clin, Sendai, Miyagi, Japan.
   [Nakamura, Takeshi] Funayama Hosp, Fac Orthopaed Surg, Yamagata, Japan.
C3 Yamagata University; Yamagata University; Yamagata Prefectural Central
   Hospital
RP Takakubo, Y (通讯作者)，Yamagata Univ, Fac Orthopaed Surg & Rehabil, Yamagata, Japan.
EM takakubo y@med.id.yamagata u.ac.jp
RI ; Goto, Shinya/AAU 6045 2020; Naganuma, Yasushi/IAR 4992 2023; Uno,
   Tomohiro/GXF 9892 2022; AKABANE, TAKERU/MTA 3761 2025
OI Takakubo, Yuya/0000 0003 3535 8419; Ito, Juji/0000 0002 3410 2940; Uno,
   Tomohiro/0000 0002 3389 5272; Goto, Shinichi/0000 0002 0450 0331; 
CR Banffy MB, 2011, CLIN ORTHOP RELAT R, V469, P2028, DOI 10.1007/s11999 011 1828 8
   Bawa HS, 2015, J BONE JOINT SURG AM, V97A, P1555, DOI 10.2106/JBJS.N.01275
   BLACK DM, 2007, NEW ENGL J MED, V356, P1809, DOI DOI 10.1056/NEJMOA067312
   Cho YJ, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0457 1
   Cooper C, 2011, OSTEOPOROSIS INT, V22, P1277, DOI 10.1007/s00198 011 1601 6
   DE DAS S, 2010, J BONE JOINT SURG BR, V92, P679
   Dell RM, 2012, J BONE MINER RES, V27, P2544, DOI 10.1002/jbmr.1719
   Ettinger B, 2013, BONE, V55, P495, DOI 10.1016/j.bone.2013.02.004
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Hagen JE, 2014, J BONE JOINT SURG AM, V96A, P1905, DOI 10.2106/JBJS.N.00075
   Hyodo K, 2017, J BONE MINER METAB, V35, P209, DOI 10.1007/s00774 016 0747 x
   Kishimoto H, 2015, ARCH OSTEOPOROS, V10, DOI 10.1007/s11657 015 0231 6
   Kondo N, 2017, TOHOKU J EXP MED, V243, P247, DOI 10.1620/tjem.243.247
   Lee KJ, 2017, INJURY, V48, P941, DOI 10.1016/j.injury.2017.02.036
   Lo JC, 2016, BONE, V85, P142, DOI 10.1016/j.bone.2016.01.002
   Markman LH, 2013, ENDOCR PRACT, V19, P456, DOI 10.4158/EP12179.OR
   Meier RPH, 2012, ARCH INTERN MED, V172, P930, DOI 10.1001/archinternmed.2012.1796
   Miyakoshi N, 2015, J BONE MINER METAB, V33, P553, DOI 10.1007/s00774 014 0617 3
   NAKAMURA T, 1994, J BONE MINER RES, V9, P1071
   National Institute of Population and Social Security Research, 2014, JAP MORT DAT
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Oh Y, 2014, INJURY, V45, P1764, DOI 10.1016/j.injury.2014.08.037
   Park Young Chang, 2019, J Bone Metab, V26, P123, DOI 10.11005/jbm.2019.26.2.123
   Saita Y, 2015, J BONE MINER METAB, V33, P311, DOI 10.1007/s00774 014 0591 9
   Sato H, 2016, OSTEOPOROSIS INT, V27, P1217, DOI 10.1007/s00198 015 3382 9
   Schilcher J, 2015, INJURY, V46, P2468, DOI 10.1016/j.injury.2015.09.031
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Takakubo Y, 2017, TOHOKU J EXP MED, V242, P327, DOI 10.1620/tjem.242.327
   Tamaki J, 2019, OSTEOPOROSIS INT, V30, P975, DOI 10.1007/s00198 019 04844 8
   van de Laarschot DM, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz295
   Weil YA, 2011, J TRAUMA, V71, P186, DOI 10.1097/TA.0b013e31821957e3
   Yamagata prefecture government Health and longevity Promotion Section, 2014, RAT ELD PEOPL YAM PR
NR 35
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2021
VL 39
IS 4
BP 700
EP 711
DI 10.1007/s00774 021 01215 4
EA APR 2021
PG 12
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA TG4FX
UT WOS:000636943200005
PM 33821304
DA 2025 08 17
ER

PT J
AU Wang, P
   Ma, T
   Guo, D
   Hu, K
   Shu, Y
   Xu, HHK
   Schneider, A
AF Wang, Ping
   Ma, Tao
   Guo, Dong
   Hu, Kevin
   Shu, Yan
   Xu, Hockin H. K.
   Schneider, Abraham
TI Metformin induces osteoblastic differentiation of human induced
   pluripotent stem cell derived mesenchymal stem cells
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE bone regeneration; metformin; osteoblasts; osteogenic markers;
   periodontal regeneration; tissue engineering
ID IN VIVO; BONE; KINASE; TRANSPORTER; ACTIVATION; EXPRESSION; DERIVATION;
   LKB1
AB Metformin, a first line antidiabetic drug used by millions of patients, has been shown to have potential osteogenic properties. The present study was performed to test the hypothesis that clinically relevant doses of metformin promote the osteogenic differentiation and mineralization of induced pluripotent stem cell derived mesenchymal stem cells (iPSC MSCs). iPSC MSCs were treated with metformin (10 m) to assess cell viability, osteogenic differentiation, mineralization and activation of the LKB1/AMP activated protein kinase (AMPK) signalling pathway, a surrogate marker of metformin action. To determine its potential application in MSC based bone and periodontal tissue engineering, iPSC MSCs were also treated with metformin when seeded on to calcium phosphate cement (CPC) scaffolds. Immunoblotting and cellular uptake assays showed that iPSC MSCs express functional organic cation transporter 1 (OCT 1), a transmembrane protein that mediates the intracellular uptake of metformin. Although metformin treatment did not impair iPSC MSC viability, it significantly stimulated alkaline phosphatase activity, enhanced mineralized nodule formation and increased expression of osteogenic markers, including Runt related transcription factor 2 (RUNX2) and osterix. Inhibition of LKB1 activity, a common upstream AMPK kinase, markedly reversed metformin induced AMPK activation, RUNX2 expression and nuclear localization. Moreover, metformin substantially increased mineralized nodule formation of iPSC MSC seeded on CPC scaffolds. Collectively, functional OCT expressing iPSC MSCs responded to metformin by inducing an osteogenic effect in part mediated by the LKB1/AMPK pathway. Considering the widespread use of metformin in diabetics, this work may lead to novel tissue engineering platforms where autogenous OCT expressing iPSC MSCs might be used to enhance bone and periodontal regeneration in diabetic patients prescribed with daily doses of metformin.
C1 [Wang, Ping; Ma, Tao; Hu, Kevin; Schneider, Abraham] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, 650 West Baltimore St,Room 7265, Baltimore, MD 21201 USA.
   [Guo, Dong; Shu, Yan] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Xu, Hockin H. K.] Univ Maryland, Sch Dent, Dept Endodont Periodont & Prosthodont, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Schneider, A (通讯作者)，Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, 650 West Baltimore St,Room 7265, Baltimore, MD 21201 USA.
EM schneider66@umaryland.edu
RI Schneider, Abraham/AAR 5941 2021
FU National Institute of Dental and Craniofacial Research [ROI DE023578]
FX National Institute of Dental and Craniofacial Research, Grant/Award
   Number: ROI DE023578
CR Chapple ILC, 2013, J PERIODONTOL, V84, pS106, DOI [10.1902/jop.2013.1340011, 10.1111/jcpe.12077]
   Chen LG, 2014, P NATL ACAD SCI USA, V111, P9983, DOI 10.1073/pnas.1314939111
   Chou BK, 2011, CELL RES, V21, P518, DOI 10.1038/cr.2011.12
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   McCarthy AD, 2016, WORLD J DIABETES, V7, P122, DOI 10.4239/wjd.v7.i6.122
   Fadini GP, 2014, STEM CELL TRANSL MED, V3, P949, DOI 10.5966/sctm.2014 0052
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Hynes K, 2013, J DENT RES, V92, P833, DOI 10.1177/0022034513498258
   Hynes K, 2012, PERIODONTOL 2000, V59, P203, DOI 10.1111/j.1600 0757.2012.00443.x
   Jaacks LM, 2016, BEST PRACT RES CL EN, V30, P331, DOI 10.1016/j.beem.2016.05.003
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Jung YJ, 2012, STEM CELLS, V30, P42, DOI 10.1002/stem.727
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015
   Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312
   Nies AT, 2011, HANDB EXP PHARMACOL, V201, P105, DOI 10.1007/978 3 642 14541 4_3
   Pagni G, 2012, ADV DRUG DELIVER REV, V64, P1310, DOI 10.1016/j.addr.2012.03.005
   Patel H, 2013, J ORAL PATHOL MED, V42, P250, DOI 10.1111/j.1600 0714.2012.01196.x
   Pilipchuk SP, 2015, DENT MATER, V31, P317, DOI 10.1016/j.dental.2015.01.006
   Pradeep A. R., 2015, J INVESTIGATIVE CLIN, V7, P239
   Rosa V, 2012, DENT MATER, V28, P341, DOI 10.1016/j.dental.2011.11.025
   Schneider A, 2008, NEOPLASIA, V10, P1295, DOI 10.1593/neo.08586
   Schurman L, 2008, EXP CLIN ENDOCR DIAB, V116, P333, DOI 10.1055/s 2007 992786
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tang MH, 2014, TISSUE ENG PT A, V20, P1295, DOI [10.1089/ten.tea.2013.0211, 10.1089/ten.TEA.2013.0211]
   Villa Diaz LG, 2012, STEM CELLS, V30, P1174, DOI 10.1002/stem.1084
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Wang P, 2014, J DENT RES, V93, P618, DOI 10.1177/0022034514534689
   Wang P, 2016, DENT MATER, V32, P252, DOI 10.1016/j.dental.2015.11.019
   Wang P, 2015, ACTA BIOMATER, V18, P236, DOI 10.1016/j.actbio.2015.02.011
   Wu QQ, 2017, TISSUE ENG PART B RE, V23, P1, DOI [10.1089/ten.TEB.2015.0559, 10.1089/ten.teb.2015.0559]
   Yang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100285
   Zhao QG, 2015, P NATL ACAD SCI USA, V112, P530, DOI 10.1073/pnas.1423008112
   Zhen DH, 2010, J DIABETES COMPLICAT, V24, P334, DOI 10.1016/j.jdiacomp.2009.05.002
NR 37
TC 93
Z9 100
U1 1
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD FEB
PY 2018
VL 12
IS 2
BP 437
EP 446
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA FW3CY
UT WOS:000425184900071
PM 28494141
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nussler, AK
   Wildemann, B
   Freude, T
   Litzka, C
   Soldo, P
   Friess, H
   Hammad, S
   Hengstler, JG
   Braun, KF
   Trak Smayra, V
   Godoy, P
   Ehnert, S
AF Nussler, Andreas K.
   Wildemann, Britt
   Freude, Thomas
   Litzka, Christian
   Soldo, Petra
   Friess, Helmut
   Hammad, Seddik
   Hengstler, Jan G.
   Braun, Karl F.
   Trak Smayra, Viviane
   Godoy, Patricio
   Ehnert, Sabrina
TI Chronic CCl4 intoxication causes liver and bone damage
   similar to the human pathology of hepatic osteodystrophy: a mouse model
   to analyse the liver bone axis
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Mouse model; Hepatic osteodystrophy; Bone mineral density; CCl4; 25 OH
   vitamin D; TGF beta
ID PRIMARY BILIARY CIRRHOSIS; MINERAL METABOLISM; GENE EXPRESSION; DISEASE;
   TRANSPLANTATION; OSTEOPOROSIS; DISORDERS; FIBROGENESIS; OSTEOBLASTS;
   DENSITY
AB Patients with chronic liver diseases frequently exhibit decreased bone mineral densities (BMD), which is defined as hepatic osteodystrophy (HOD). HOD is a multifactorial disease whose regulatory mechanisms are barely understood. Thus, an early diagnosis and therapy is hardly possible. Therefore, the aim of our study consisted in characterizing a mouse model reflecting the human pathomechanism. Serum samples were collected from patients with chronic liver diseases and 12 week old C57Bl6/N mice after 6 week treatment with carbon tetrachloride (CCl4). Repetitive injections of CCl4 induced liver damage in mice, resembling liver fibrosis in patients, as assessed by serum analysis and histological staining. Although CCl4 did not affect primary osteoblast cultures, mu CT analysis revealed significantly decreased BMD, bone volume, trabecular number and thickness in CCl4 treated mice. In both HOD patients and CCl4 treated mice, an altered vitamin D metabolism with decreased CYP27A1, CYP2R1, vitamin D binding protein GC and increased 7 dehydrocholesterol reductase hepatic gene expression, results in decreased 25 OH vitamin D serum levels. Moreover, both groups exhibit excessively high active transforming growth factor beta (TGF beta) serum levels, inhibiting osteoblast function in vitro. Summarizing, our mouse model presents possible mediators of HOD, e.g. altered vitamin D metabolism and increased active TGF beta. Liver damage and significant changes in bone structure and mineralization are already visible by mu CT analysis after 6 weeks of CCl4 treatment. This fast response and easy transferability makes it an ideal model to investigate specific gene functions in HOD.
C1 [Nussler, Andreas K.; Freude, Thomas; Ehnert, Sabrina] Univ Tubingen, Siegfried Weller Inst Trauma Res, D 72076 Tubingen, Germany.
   [Wildemann, Britt] Univ Med Berlin, Julius Wolff Inst, Berlin Brandenburg Ctr Regenerat Therapies BCRT, Charite, D 13353 Berlin, Germany.
   [Litzka, Christian; Soldo, Petra; Braun, Karl F.] Tech Univ Munich, Dept Traumatol, Klinikum Rechts Isar, D 81675 Munich, Germany.
   [Friess, Helmut] Tech Univ Munich, Dept Surg, Klinikum Rechts Isar, MRI, D 81675 Munich, Germany.
   [Hammad, Seddik; Hengstler, Jan G.; Godoy, Patricio] TU Dortmund, Leibniz Inst Arbeitsforsch Ifado, D 44139 Dortmund, Germany.
   [Hammad, Seddik] South Valley Univ, Dept Forens Med & Vet Toxicol, Fac Vet Med, Qena 83523, Egypt.
   [Trak Smayra, Viviane] St Joseph Univ, Fac Med, Beirut, Lebanon.
C3 Eberhard Karls University of Tubingen; Free University of Berlin;
   Humboldt University of Berlin; Charite Universitatsmedizin Berlin;
   Technical University of Munich; Technical University of Munich; Dortmund
   University of Technology; Leibniz Association; Leibniz Institut for
   Arbeitsforschung an der TU Dortmund (IFADO); Egyptian Knowledge Bank
   (EKB); South Valley University Egypt
RP Nussler, AK (通讯作者)，Univ Tubingen, Siegfried Weller Inst Trauma Res, Schnarrenbergstr 95, D 72076 Tubingen, Germany.
EM andreas.nuessler@gmail.com
RI ; Godoy, Patricio/L 5001 2014; Hengstler, Jan/O 1415 2013; Hammad,
   Seddik/J 7342 2019; Wildemann, Britt/G 7732 2012; Nussler,
   Andreas/H 3557 2019; Ehnert, Sabrina/AAE 8163 2019; Friess,
   Helmut/ABO 1348 2022
OI Ehnert, Sabrina/0000 0003 4347 1702; Braun, Karl/0000 0003 2420 7201;
   Wildemann, Britt/0000 0002 8365 1188; Hengstler, Jan
   Georg/0000 0002 1427 5246; Hammad, Seddik/0000 0003 0571 4208
FU BG trauma clinic; Federal Ministry of Education and Research
   [BMBF 0315741 Virtual Liver]
FX The work was partially supported by funding of the BG trauma clinic and
   by the Federal Ministry of Education and Research (BMBF 0315741 Virtual
   Liver).
CR Angulo P, 2011, GASTROENTEROLOGY, V140, P180, DOI 10.1053/j.gastro.2010.10.014
   Arteh J, 2010, DIGEST DIS SCI, V55, P2624, DOI 10.1007/s10620 009 1069 9
   Bu FX, 2010, HUM GENET, V128, P549, DOI 10.1007/s00439 010 0881 9
   Choudhary NS, 2011, DIGEST DIS SCI, V56, P3323, DOI 10.1007/s10620 011 1722 y
   Christensen MHE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056019
   Collier J, 2007, HEPATOLOGY, V46, P1271, DOI 10.1002/hep.21852
   COMPSTON JE, 1986, GUT, V27, P1073, DOI 10.1136/gut.27.9.1073
   Cunningham J, 2005, TRANSPLANTATION, V79, P629, DOI 10.1097/01.TP.0000149698.79739.EF
   DIAMOND T, 1990, GUT, V31, P82, DOI 10.1136/gut.31.1.82
   Dooley S, 2008, GASTROENTEROLOGY, V135, P642, DOI 10.1053/j.gastro.2008.04.038
   Ehnert S, 2011, CELL TRANSPLANT, V20, P1465, DOI 10.3727/096368910X550224
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Gaudio A, 2005, J ENDOCRINOL INVEST, V28, P677, DOI 10.1007/BF03347549
   George J, 2009, WORLD J GASTROENTERO, V15, P3516, DOI 10.3748/wjg.15.3516
   Goel Varun, 2010, Trop Gastroenterol, V31, P82
   Guañabens N, 2011, CLIN RES HEPATOL GAS, V35, P438, DOI 10.1016/j.clinre.2011.03.007
   Guañabens N, 2010, GASTROENTEROLOGY, V138, P2348, DOI 10.1053/j.gastro.2010.02.016
   Guañabens N, 2009, J BONE MINER METAB, V27, P347, DOI 10.1007/s00774 009 0042 1
   Hamburg SM, 2000, OSTEOPOROSIS INT, V11, P600, DOI 10.1007/s001980070081
   Hamzavi J, 2008, J CELL MOL MED, V12, P2130, DOI 10.1111/j.1582 4934.2008.00262.x
   Hildebrand TOR, 1997, Comput Methods Biomech Biomed Engin, V1, P15, DOI 10.1080/01495739708936692
   Hochrath K, 2013, BONE, V55, P501, DOI 10.1016/j.bone.2013.03.012
   Högler W, 2012, J PEDIATR GASTR NUTR, V54, P313, DOI 10.1097/MPG.0b013e31823e9412
   Knobeloch D, 2012, METHODS MOL BIOL, V806, P99, DOI 10.1007/978 1 61779 367 7_8
   Konstantynowicz J, 2011, J BONE MINER METAB, V29, P315, DOI 10.1007/s00774 010 0219 7
   Lavi Moshayoff V, 2010, AM J PHYSIOL RENAL, V299, pF882, DOI 10.1152/ajprenal.00360.2010
   Lind M, 1998, ACTA ORTHOP SCAND, V69, P2
   Liu TH, 2012, BIOMARK INSIGHTS, V7, P105, DOI 10.4137/BMI.S10009
   Loria I, 2010, TRANSPL P, V42, P1191, DOI 10.1016/j.transproceed.2010.03.096
   Luxon Bruce A, 2011, Curr Gastroenterol Rep, V13, P40, DOI 10.1007/s11894 010 0166 4
   Maalouf Naim M, 2006, Curr Treat Options Gastroenterol, V9, P456, DOI 10.1007/s11938 006 0002 y
   Mansueto P, 2013, INTERN EMERG MED, V8, P377, DOI 10.1007/s11739 012 0753 5
   Mitchell R, 2011, WORLD J HEPATOL, V3, P157, DOI 10.4254/wjh.v3.i6.157
   Monegal A, 2007, LIVER INT, V27, P492, DOI 10.1111/j.1478 3231.2007.01448.x
   Mounach A, 2008, J BONE MINER METAB, V26, P379, DOI 10.1007/s00774 007 0833 1
   Nakano A, 1996, J GASTROEN HEPATOL, V11, P1143, DOI 10.1111/j.1440 1746.1996.tb01843.x
   PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P49, DOI 10.1002/jbmr.5650050109
   Putz Bankuti C, 2012, LIVER INT, V32, P845, DOI 10.1111/j.1478 3231.2011.02735.x
   Ritter CS, 2011, J MOL ENDOCRINOL, V46, P63, DOI 10.1677/JME 10 0128
   ROBEY PG, 1987, J CELL BIOL, V105, P457, DOI 10.1083/jcb.105.1.457
   Rode A, 2010, GASTROEN CLIN BIOL, V34, P618, DOI 10.1016/j.gcb.2010.07.009
   Rudic JS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009144.pub2
   Sarahrudi K, 2011, INJURY, V42, P833, DOI 10.1016/j.injury.2011.03.055
   Tejwani V, 2013, NUTRIENTS, V5, P1913, DOI 10.3390/nu5061913
   van der Merwe SW, 2003, GUT, V52, P580, DOI 10.1136/gut.52.4.580
   Wariaghli G, 2010, EUR J GASTROEN HEPAT, V22, P1397, DOI 10.1097/MEG.0b013e3283405939
   Weng HL, 2009, HEPATOLOGY, V50, P230, DOI 10.1002/hep.22934
   Wibaux C, 2011, JOINT BONE SPINE, V78, P387, DOI 10.1016/j.jbspin.2011.03.001
   Yurci A, 2011, EUR J GASTROEN HEPAT, V23, P1206, DOI 10.1097/MEG.0b013e32834cd6f6
NR 49
TC 39
Z9 42
U1 4
U2 30
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0340 5761
EI 1432 0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD APR
PY 2014
VL 88
IS 4
BP 997
EP 1006
DI 10.1007/s00204 013 1191 5
PG 10
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA AD3BZ
UT WOS:000333113600011
PM 24381012
DA 2025 08 17
ER

PT J
AU Abruzzese, E
   Iuliano, F
   Trawinska, MM
   Di Maio, M
AF Abruzzese, Elisabetta
   Iuliano, Francesco
   Trawinska, Malgorzata Monika
   Di Maio, Massimo
TI <SUP>153</SUP>SM:: its use in multiple myeloma and report of a clinical
   experience
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE bone metastasis; multiple myeloma; radiopharmaceutical; Sm 153
ID DIAMINE TETRAMETHYLENE PHOSPHONATE; THALIDOMIDE PLUS DEXAMETHASONE;
   ZOLEDRONIC ACID; TARGETED RADIOTHERAPY; SM 153 LEXIDRONAM; ARSENIC
   TRIOXIDE; BONE METASTASES; THERAPY; BISPHOSPHONATE; CHEMOTHERAPY
AB Background: In the past years the bone seeking radiopharmaceutical samarium lexidronam (Sm 153 EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis. Objective: Its use has been explored in different solid tumours. In this report we explore its interesting characteristics and describe our experience in multiple myeloma (MM). Methods: Sm 153 EDTMP has an affinity for bone and concentrates in areas of bone turnover. It decays as a therapeutic P emission and at the same time as gamma photon that can be used for tracking its concentration with bone scan imaging. Ten patients with symptomatic MM were treated to achieve pain control. Results: Encouraging results were obtained in MM patients. The use of this radioisotope could be largely improved.
C1 [Abruzzese, Elisabetta; Trawinska, Malgorzata Monika] Univ Roma Tor Vergata, S Eugenio Hosp, I 00144 Rome, Italy.
   [Iuliano, Francesco; Di Maio, Massimo] N Giannettasio Hosp, Hematol Oncol Unit, Rossano Calabro, CS, Italy.
C3 Sant'Eugenio Hospital; University of Rome Tor Vergata
RP Abruzzese, E (通讯作者)，Univ Roma Tor Vergata, S Eugenio Hosp, Ple Umanesimo 10, I 00144 Rome, Italy.
EM elisabetta.abruzzese@uniroma2.it
RI abruzzese, elisabetta/D 4408 2019; DI MAIO, Massimo/K 9990 2016;
   Abruzzese, Elisabetta/D 4408 2019; Di Maio, Massimo/K 9990 2016
OI abruzzese, elisabetta/0000 0001 5228 6491; DI MAIO,
   Massimo/0000 0001 8906 3785; 
CR Adams J, 1999, CANCER RES, V59, P2615
   ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484
   Anderson P, 2007, EXPERT REV ANTICANC, V7, P1517, DOI 10.1586/14737140.7.11.1517
   Anderson Pete, 2008, Cancer Control, V15, P38
   Anderson PM, 2005, CLIN CANCER RES, V11, P6895, DOI 10.1158/1078 0432.CCR 05 0628
   [Anonymous], 1998, J Clin Oncol, V16, P3832
   Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   BAYOUTH JE, 1994, J NUCL MED, V35, P63
   Berenson JR, 2007, CLIN CANCER RES, V13, P1762, DOI 10.1158/1078 0432.CCR 06 1812
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Body JJ, 1998, EUR J CANCER, V34, P263, DOI 10.1016/S0959 8049(97)10136 8
   Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340
   Davies FE, 2007, HAEMATOLOGICA, V92, P1149, DOI 10.3324/haematol.11228
   Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210
   Dimopoulos MA, 2003, J CLIN ONCOL, V21, P4444, DOI 10.1200/JCO.2003.07.200
   Dispenzieri A, 2005, LEUKEMIA, V19, P118, DOI 10.1038/sj.leu.2403575
   EARY JF, 1993, J NUCL MED, V34, P1031
   Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Goel A, 2006, BLOOD, V107, P4063, DOI 10.1182/blood 2005 09 3870
   Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868
   Hayashi T, 2002, MOL CANCER THER, V1, P851
   HEGGIE JCP, 1991, J NUCL MED, V32, P840
   Hussein MA, 2004, BRIT J HAEMATOL, V125, P470, DOI 10.1111/j.1365 2141.2004.04941.x
   Iuliano F, 2003, BLOOD, V102, p446A
   Jagannath S, 2004, BRIT J HAEMATOL, V127, P165, DOI 10.1111/j.1365 2141.2004.05188.x
   Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood 2007 10 078022
   MANINI C, 2004, EUR J NUCL MED MO S1, V31, P171
   Marcus CS, 2002, CLIN NUCL MED, V27, P427, DOI 10.1097/00003072 200206000 00008
   Mariani S, 2005, LEUKEMIA, V19, P664, DOI 10.1038/sj.leu.2403693
   Mitsiades CS, 2007, BEST PRACT RES CL HA, V20, P797, DOI 10.1016/j.beha.2007.09.008
   Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood 2005 03 1158
   Niscola P, 2004, HEMATOL J, V5, P293, DOI 10.1038/sj.thj.6200530
   Palumbo A, 2001, HAEMATOLOGICA, V86, P399
   RADL J, 1985, CANCER AM CANCER SOC, V55, P1030, DOI 10.1002/1097 0142(19850301)55:5<1030::AID CNCR2820550518>3.0.CO;2 Y
   Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221
   Resche I, 1997, EUR J CANCER, V33, P1583, DOI 10.1016/S0959 8049(97)00155 X
   Ricci S, 2007, EUR J NUCL MED MOL I, V34, P1023, DOI 10.1007/s00259 006 0343 8
   RICHARDSON H, 2007, J NATL COMPR CANC NE, V5, P149
   Richardson P, 2005, BLOOD, V106, p715A
   Saad F, 2007, SEMIN ONCOL, V34, pS17, DOI 10.1053/j.seminoncol.2007.10.006
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   Sartor O, 2004, UROLOGY, V63, P940, DOI 10.1016/j.urology.2004.01.034
   SARTOR O, 2003, REV UROL, V6, pS4
   Sartor O, 2007, CANCER AM CANCER SOC, V109, P637, DOI 10.1002/cncr.22431
   Savage AD, 1996, BLOOD, V88, P409
   Serafini AN, 1998, J CLIN ONCOL, V16, P1574, DOI 10.1200/JCO.1998.16.4.1574
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Srikanth M, 2008, EXPERT OPIN INV DRUG, V17, P1, DOI 10.1517/13543784.17.1.1
   Tian JH, 1999, EUR J NUCL MED, V26, P2, DOI 10.1007/s002590050351
   Tripathi M, 2006, Indian J Cancer, V43, P86
   World Health Organization, 1986, Cancer pain relief
   Yaccoby S, 2002, BRIT J HAEMATOL, V116, P278, DOI 10.1046/j.1365 2141.2002.03257.x
   Yeh HS, 2006, EUR J CANCER, V42, P1554, DOI 10.1016/j.ejca.2005.11.035
   Yuasa T, 2007, CURR MED CHEM, V14, P2126
   ZHANG XG, 1989, BLOOD, V74, P11
NR 57
TC 10
Z9 10
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354 3784
EI 1744 7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD SEP
PY 2008
VL 17
IS 9
BP 1379
EP 1387
DI 10.1517/13543780802332960
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 343VD
UT WOS:000258882500009
PM 18694370
DA 2025 08 17
ER

PT J
AU Liu, X
   Wang, W
   Zhu, F
   Xu, HB
   Ge, GR
   Liang, XL
   Yang, HL
   Xu, YZ
   Xu, W
   Wei, MG
   Zhou, Q
   Geng, DC
AF Liu, Xin
   Wang, Wei
   Zhu, Feng
   Xu, Haibo
   Ge, Gaoran
   Liang, Xiaolong
   Yang, Huilin
   Xu, Yaozeng
   Xu, Wei
   Wei, Minggang
   Zhou, Qi
   Geng, Dechun
TI Osteoblastic ferroptosis inhibition by small molecule promoting GPX4
   activation for peri prosthetic osteolysis therapy
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Peri prosthesis osteolysis; Titanium nanoparticles; Osteoblastogenesis;
   Ferroptosis; GPX4; Urolithin A
ID TOTAL JOINT ARTHROPLASTY; MESENCHYMAL STEM CELLS; LIPID PEROXIDATION;
   UROLITHIN; MITOPHAGY; DEATH
AB Peri prosthesis osteolysis (PPO) represents the most severe complication of total joint arthroplasty (TJA) surgery and imposes the primary cause of prosthesis failure and subsequent revision surgery. Antiresorptive therapies are usually prescribed to treat PPO, especially for elderly people. Nevertheless, the efficacy of anti osteoporotic medications remains constrained. Recent therapeutic strategies to promote periprosthetic osseointegration by restoring osteoblast function are considered more effective approaches. However, the precise mechanism underlying the inhibition of osteogenesis triggered by wear particles remains enigmatic. Herein, we demonstrate that wear particles inhibit osteoblast function by inducing ferroptosis to sabotage extracellular mineralization and arouse periprosthetic osteolysis. The suppression of ferroptosis could significantly rescue osteogenesis thus alleviating PPO. Furthermore, Glutathione Peroxidase 4 (GPX4) has been identified as a key target in regulating osteoblastic ferroptosis. By utilizing virtual screening techniques, we have successfully conducted a comprehensive screening of a natural compound known as Urolithin A (UA), which exhibits remarkable inhibition of osteoblastic ferroptosis while simultaneously promoting the process of osteogenesis through its precise targeting mechanism on GPX4. Meanwhile, UA improves the osteolytic conditions significantly in vivo even when the adjunction of titanium (Ti) nanoparticles. This strategy has great potential in treating peri prosthesis osteolysis and potentially broadens the scope of clinical therapy.
C1 [Liu, Xin; Wang, Wei; Zhu, Feng; Xu, Haibo; Ge, Gaoran; Liang, Xiaolong; Yang, Huilin; Xu, Yaozeng; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Suzhou Med Coll, Dept Orthopaed Surg,Orthopaed Inst, Suzhou 215006, Jiangsu, Peoples R China.
   [Xu, Wei] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215006, Jiangsu, Peoples R China.
   [Wei, Minggang] Soochow Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhou, Qi] Naval Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai 200070, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; Naval Medical University
RP Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Suzhou Med Coll, Dept Orthopaed Surg,Orthopaed Inst, Suzhou 215006, Jiangsu, Peoples R China.; Xu, W (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215006, Jiangsu, Peoples R China.; Wei, MG (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Tradit Chinese Med, Suzhou 215006, Jiangsu, Peoples R China.; Zhou, Q (通讯作者)，Naval Med Univ, Changzheng Hosp, Dept Orthoped, Shanghai 200070, Peoples R China.
EM 13962157016@139.com; weiminggang@suda.edu.cn; zq590@sina.com;
   szgengdc@suda.edu.cn
RI Geng, Dechun/LMO 1733 2024; Wang, Wei/AAH 3829 2021; Liang,
   Xiaolong/M 1941 2018; Zhu, Feng/HPE 8548 2023
OI Zhou, Qi/0000 0003 2260 0181; 
FU National Natural Science Foundation of China; Natural Science Foundation
   of Jiangsu Province [BK2021650]; Priority Academic Program Development
   of Jiangsu Higher Education Institutions (PAPD); Jiangsu Medical
   Research Project [ZD2022014]; Orthopaedic Medical Innovation Center of
   Jiangsu [CXZX202209]; Key Laboratory of Orthopaedics of Suzhou
   [SZS2022017]; Program of Suzhou Health Commission [GSWS2022002];
   National and Local Engineering Laboratory of New Functional Polymer
   Materials [SDGC2205]; Foundation of National Center for Translational
   Medicine (Shanghai) SHU Branch [SUITM 202403]; National Key R&D Program
   of China; MOST [2023YFC2509900]; Jiangsu Province Leading Talents
   Cultivation Project for Traditional Chinese Medicine [SLJ0330]; 
   [82072425];  [82072498];  [82272157];  [82472525]
FX This work was supported by the National Natural Science Foundation of
   China (82072425, 82072498, 82272157, 82472525), Natural Science
   Foundation of Jiangsu Province (BK2021650), Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu
   Medical Research Project (ZD2022014), Orthopaedic Medical Innovation
   Center of Jiangsu (CXZX202209), Key Laboratory of Orthopaedics of Suzhou
   (SZS2022017), Program of Suzhou Health Commission (GSWS2022002),
   National and Local Engineering Laboratory of New Functional Polymer
   Materials (SDGC2205), Foundation of National Center for Translational
   Medicine (Shanghai) SHU Branch (SUITM 202403), National Key R&D Program
   of China, MOST (2023YFC2509900), Jiangsu Province Leading Talents
   Cultivation Project for Traditional Chinese Medicine (SLJ0330). The
   graphical abstract and flow chart in this study were created with
   BioRender.com.
CR Andreux PA, 2019, NAT METAB, V1, P595, DOI 10.1038/s42255 019 0073 4
   Balogh E, 2016, BBA MOL BASIS DIS, V1862, P1640, DOI 10.1016/j.bbadis.2016.06.003
   Bialonska D, 2009, J AGR FOOD CHEM, V57, P10181, DOI 10.1021/jf9025794
   Cásedas G, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9020177
   Cen WJ, 2018, J CELL PHYSIOL, V233, P6779, DOI 10.1002/jcp.26405
   Chen JY, 2022, CELL DEATH DIFFER, V29, P467, DOI 10.1038/s41418 022 00941 0
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen WS, 2021, BIOMATER SCI UK, V9, P4922, DOI 10.1039/d1bm00691f
   Chen X, 2021, CELL DEATH DIFFER, V28, P1135, DOI 10.1038/s41418 020 00728 1
   Cherian JJ, 2015, CLIN ORTHOP RELAT R, V473, P2700, DOI 10.1007/s11999 015 4220 2
   COVENTRY MB, 1979, MAYO CLIN PROC, V54, P493
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]
   Fang XX, 2023, NAT REV CARDIOL, V20, P7, DOI 10.1038/s41569 022 00735 4
   FITZGERALD RH, 1979, MAYO CLIN PROC, V54, P590
   Fu X, 2019, FOOD FUNCT, V10, P6135, DOI 10.1039/c9fo01332f
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   He Q, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.113915
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580 020 00324 8
   Jing Z, 2023, REDOX BIOL, V67, DOI 10.1016/j.redox.2023.102922
   Kadoya Y, 1996, J ORTHOP RES, V14, P473, DOI 10.1002/jor.1100140318
   Karuppagounder SS, 2018, ANN NEUROL, V84, P854, DOI 10.1002/ana.25356
   Lee H, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556 020 0461 8
   Lee HJ, 2021, CELL DEATH DIFFER, V28, P184, DOI 10.1038/s41418 020 0593 1
   Li Y, 2019, CELL DEATH DIFFER, V26, P2284, DOI 10.1038/s41418 019 0299 4
   Li YX, 2021, J CELL PHYSIOL, V236, P1950, DOI 10.1002/jcp.29978
   Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111
   Lou LJ, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1067402
   Luo C, 2022, FREE RADICAL BIO MED, V188, P337, DOI 10.1016/j.freeradbiomed.2022.06.236
   Miao Y, 2022, EBIOMEDICINE, V76, DOI 10.1016/j.ebiom.2022.103847
   Miotto G, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101328
   O'Neill SC, 2013, BONE JOINT J, V95B, P1022, DOI 10.1302/0301 620X.95B8.31229
   Pula W, 2024, EUR J PHARM BIOPHARM, V200, DOI 10.1016/j.ejpb.2024.114334
   Qiu JX, 2020, BIOMATER SCI UK, V8, P3147, DOI 10.1039/d0bm00147c
   Quicke JG, 2022, OSTEOARTHR CARTILAGE, V30, P196, DOI 10.1016/j.joca.2021.10.003
   Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/NCHEM.2479, 10.1038/nchem.2479]
   Ryu D, 2016, NAT MED, V22, P879, DOI 10.1038/nm.4132
   Scarpellini C, 2023, TRENDS PHARMACOL SCI, V44, P902, DOI 10.1016/j.tips.2023.08.012
   Seibt TM, 2019, FREE RADICAL BIO MED, V133, P144, DOI 10.1016/j.freeradbiomed.2018.09.014
   Shen ZS, 2024, INNOVATION AMSTERDAM, V5, DOI 10.1016/j.xinn.2023.100547
   Singh JA, 2019, J RHEUMATOL, V46, P1134, DOI 10.3899/jrheum.170990
   Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a
   Stockwell BR, 2020, TRENDS CELL BIOL, V30, P478, DOI 10.1016/j.tcb.2020.02.009
   Tao HQ, 2021, PHARMACOL RES, V174, DOI 10.1016/j.phrs.2021.105967
   Ursini F, 2020, FREE RADICAL BIO MED, V152, P175, DOI 10.1016/j.freeradbiomed.2020.02.027
   von Knoch M, 2004, J ORTHOP RES, V22, P237, DOI 10.1016/j.orthres.2003.08.013
   Wan JR, 2019, STROKE VASC NEUROL, V4, P93, DOI 10.1136/svn 2018 000205
   Wang Q, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01351 7
   Wu YL, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01320 0
   Xia DM, 2019, J CELL PHYSIOL, V234, P15668, DOI 10.1002/jcp.28217
   Xu PC, 2022, FREE RADICAL BIO MED, V193, P720, DOI 10.1016/j.freeradbiomed.2022.11.013
   Xu YM, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13142
   Yang YQ, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00198 w
   Yin CL, 2023, INNOVATION AMSTERDAM, V4, DOI 10.1016/j.xinn.2023.100492
   Zeng X, 2018, NUCLEIC ACIDS RES, V46, pD1217, DOI 10.1093/nar/gkx1026
   Zhang L, 2020, PHARMACOL THERAPEUT, V216, DOI 10.1016/j.pharmthera.2020.107686
   Zhang ST, 2023, INNOVATION AMSTERDAM, V4, DOI 10.1016/j.xinn.2023.100503
   Zhao H, 2023, NUCLEIC ACIDS RES, V51, pD621, DOI 10.1093/nar/gkac1069
NR 59
TC 0
Z9 0
U1 4
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD DEC 18
PY 2024
VL 22
IS 1
AR 758
DI 10.1186/s12951 024 03049 4
PG 21
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA P8B6I
UT WOS:001380099100007
PM 39696565
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Kopher, RA
   Penchev, VR
   Islam, MS
   Hill, KL
   Khosla, S
   Kaufman, DS
AF Kopher, Ross A.
   Penchev, Vesselin R.
   Islam, Mohammad S.
   Hill, Katherine L.
   Khosla, Sundeep
   Kaufman, Dan S.
TI Human embryonic stem cell derived CD34<SUP>+</SUP> cells function as MSC
   progenitor cells
SO BONE
LA English
DT Article
DE Human embryonic stem cells; Mesenchymal stem cells; Hematopoietic stem
   cells; Progenitor cells; Differentiation
ID UMBILICAL CORD BLOOD; HUMAN BONE MARROW; OSTEOBLAST LINEAGE CELLS; OP9
   STROMAL CELLS; HEMATOPOIETIC STEM; ADIPOSE TISSUE; INFARCTED MYOCARDIUM;
   PERIPHERAL BLOOD; MOUSE EMBRYOS; ANTIGEN CD34
AB Mesenchymal stem/stromal cells (MSCs) have been isolated from various tissues and utilized for an expanding number of therapies. The developmental pathways involved in producing MSCs and the phenotypic precursor/progenitor cells that give rise to human MSCs remain poorly defined. Human embryonic stem cells (hESCs) have the capability to generate functional hemato endothelial cells and other mesoderm lineage cells. hESC derived CD73(+) cells have been isolated and found to have similar phenotypic and functional characteristics as adult MSCs. Here we demonstrate hESC derived CD34(+)CD73( ) cells can serve as MSC progenitor cells with the ability to differentiate into adipocytes, osteoblasts and chondrocytes. Additionally, gene array analysis of hESC derived MSCs show substantially different gene expression compared to bone marrow (BM) derived MSCs, especially with increased expression of pluripotent and multipotent stem cell and endothelial cell associated genes. The isolation of functional MSCs from hESC derived CD34(+)CD73( ) cells provides improved understanding of MSC development and utilization of pluripotent stem cells to produce MSCs suited for novel regenerative therapies. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Kopher, Ross A.; Penchev, Vesselin R.; Hill, Katherine L.; Kaufman, Dan S.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Kopher, Ross A.; Penchev, Vesselin R.; Hill, Katherine L.; Kaufman, Dan S.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
   [Kopher, Ross A.; Islam, Mohammad S.] Univ Minnesota, Dept Diagnost & Biol Sci, Minneapolis, MN 55455 USA.
   [Khosla, Sundeep] Mayo Clin, Coll Med, Endocrine Res Unit, Rochester, MN USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   Mayo Clinic
RP Kaufman, DS (通讯作者)，Univ Minnesota, Dept Med, 420 Delaware St SE,MMC 480, Minneapolis, MN 55455 USA.
EM kaufm0200@umn.edu
RI Islam, MohammadSaiful/LNR 1208 2024; Khosla, Sundeep/AAE 6170 2020
OI Kaufman, Dan/0000 0002 2003 2494; Khosla, Sundeep/0000 0002 2936 4372
FU NIH/NHLBI [R01 HL77923]; University of Minnesota Mayo Clinic; Minnesota
   Craniofacial Research Training Program; National Institute of Dental and
   Craniofacial Research [T32DE007288, F32DE020976]
FX We would like to thank Dr. Genya Gekker for her assistance in the
   operation and data analysis for flow cytometry and sorting. We would
   like to thank the Masonic Cancer Center Pathology Shared Resource at the
   University of Minnesota for explant processing and histology. We would
   also like to thank Jeremy Allred and Dr. Anita Undale for their
   technical assistance. This project was supported by NIH/NHLBI
   R01 HL77923 (D.S.K.), a University of Minnesota Mayo Clinic
   Collaborative Grant (D.S.K. and S.K.), and the Minnesota Craniofacial
   Research Training Program (R.A.K.). The project described was supported
   by Grant Numbers T32DE007288 and F32DE020976 from the National Institute
   of Dental and Craniofacial Research. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institute of Dental and Craniofacial
   Research or the National Institutes of Health.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Anker PSI, 2003, HAEMATOLOGICA, V88, P845
   Arpornmaeklong P, 2009, STEM CELLS DEV, V18, P955, DOI 10.1089/scd.2008.0310
   Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Bieback K, 2004, STEM CELLS, V22, P625, DOI 10.1634/stemcells.22 4 625
   Brown SE, 2009, CELLS TISSUES ORGANS, V189, P256, DOI 10.1159/000151746
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood 2003 03 0832
   Chang YJ, 2006, STEM CELLS, V24, P679, DOI 10.1634/stemcells.2004 0308
   Chen JL, 1997, STEM CELLS, V15, P368, DOI 10.1002/stem.150368
   Eghbali Fatourechi GZ, 2007, BONE, V40, P1370, DOI 10.1016/j.bone.2006.12.064
   Eghbali Fatourechi GZ, 2005, NEW ENGL J MED, V352, P1959, DOI 10.1056/NEJMoa044264
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Gangenahalli GU, 2006, STEM CELLS DEV, V15, P305, DOI 10.1089/scd.2006.15.305
   Gössl M, 2008, J AM COLL CARDIOL, V52, P1314, DOI 10.1016/j.jacc.2008.07.019
   Greenberg AW, 2000, BLOOD, V95, P478, DOI 10.1182/blood.V95.2.478
   Guilak F, 2004, BIORHEOLOGY, V41, P389
   Healy L, 1995, P NATL ACAD SCI USA, V92, P12240, DOI 10.1073/pnas.92.26.12240
   Hicok KC, 1998, J BONE MINER RES, V13, P205, DOI 10.1359/jbmr.1998.13.2.205
   Hill KL, 2008, CURR PROTOC STEM CEL
   Kaiser S, 2007, CYTOTHERAPY, V9, P439, DOI 10.1080/14653240701358445
   Kaufman DS, 2004, BLOOD, V103, P1325, DOI 10.1182/blood 2003 03 0799
   Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598
   Kennedy M, 2007, BLOOD, V109, P2679, DOI 10.1182/blood 2006 09 047704
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557
   Lazarus HM, 2005, BIOL BLOOD MARROW TR, V11, P389, DOI 10.1016/j.bbmt.2005.02.001
   Lian QZ, 2007, STEM CELLS, V25, P425, DOI 10.1634/stemcells.2006 0420
   Lu SJ, 2007, NAT METHODS, V4, P501, DOI 10.1038/nmeth1041
   Maitra B, 2004, BONE MARROW TRANSPL, V33, P597, DOI 10.1038/sj.bmt.1704400
   MARTIN GR, 1981, P NATL ACAD SCI BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634
   Matsumoto T, 2006, AM J PATHOL, V169, P1440, DOI 10.2353/ajpath.2006.060064
   Olivier EN, 2006, STEM CELLS, V24, P1914, DOI 10.1634/stemcells.2005 0648
   Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rebelatto CK, 2008, EXP BIOL MED, V233, P901, DOI 10.3181/0712 RM 356
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003 4975(02)03517 8
   Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402
   SIMMONS PJ, 1991, BLOOD, V78, P2848
   THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tian Xinghui, 2008, V430, P119, DOI 10.1007/978 1 59745 182 6_8
   Tondreau T, 2005, STEM CELLS, V23, P1105, DOI 10.1634/stemcells.2004 0330
   Trivedi P, 2008, EXP HEMATOL, V36, P350, DOI 10.1016/j.exphem.2007.10.007
   Trivedi P, 2007, EXP HEMATOL, V35, P146, DOI 10.1016/j.exphem.2006.09.003
   Uematsu K, 2005, BIOMATERIALS, V26, P4273, DOI 10.1016/j.biomaterials.2004.10.037
   Vodyanik MA, 2005, BLOOD, V105, P617, DOI 10.1182/blood 2004 04 1649
   Wagner W, 2007, STEM CELL REV, V3, P239, DOI 10.1007/s12015 007 9001 1
   Wang LS, 2004, IMMUNITY, V21, P31, DOI 10.1016/j.immuni.2004.06.006
   Woll PS, 2008, BLOOD, V111, P122, DOI 10.1182/blood 2007 04 084186
   Yamada Y, 2007, BIOCHEM BIOPH RES CO, V353, P182, DOI 10.1016/j.bbrc.2006.12.017
   Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128
   Zambidis ET, 2005, BLOOD, V106, P860, DOI 10.1182/blood 2004 11 4522
   Zhang SH, 2005, CELL TRANSPLANT, V14, P787, DOI 10.3727/000000005783982558
   Zhang SH, 2006, J CELL BIOCHEM, V99, P1132, DOI 10.1002/jcb.20949
NR 57
TC 47
Z9 56
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2010
VL 47
IS 4
BP 718
EP 728
DI 10.1016/j.bone.2010.06.020
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 651NZ
UT WOS:000281935700002
PM 20601304
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Dormer, NH
   Singh, M
   Wang, LM
   Berkland, CJ
   Detamore, MS
AF Dormer, Nathan H.
   Singh, Milind
   Wang, Limin
   Berkland, Cory J.
   Detamore, Michael S.
TI Osteochondral Interface Tissue Engineering Using Macroscopic Gradients
   of Bioactive Signals
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE Osteochondral; Interface; Gradient; Microsphere; Umbilical cord stem
   cells; PLGA; BMP 2; TGF beta(1)
ID MESENCHYMAL STEM CELLS; OSTEOBLAST LIKE CELLS; UMBILICAL CORD; IN VITRO;
   OSTEOGENIC DIFFERENTIATION; STROMAL CELLS; ALKALINE PHOSPHATASE; BONE
   SIALOPROTEIN; DRUG RELEASE; GROWTH
AB Continuous gradients exist at osteochondral interfaces, which may be engineered by applying spatially patterned gradients of biological cues. In the present study, a protein loaded microsphere based scaffold fabrication strategy was applied to achieve spatially and temporally controlled delivery of bioactive signals in three dimensional (3D) tissue engineering scaffolds. Bone morphogenetic protein 2 and transforming growth factor beta(1) loaded poly(d,l lactic co glycolic acid) microspheres were utilized with a gradient scaffold fabrication technology to produce microsphere based scaffolds containing opposing gradients of these signals. Constructs were then seeded with human bone marrow stromal cells (hBMSCs) or human umbilical cord mesenchymal stromal cells (hUCMSCs), and osteochondral tissue regeneration was assessed in gradient scaffolds and compared to multiple control groups. Following a 6 week cell culture, the gradient scaffolds produced regionalized extracellular matrix, and outperformed the blank control scaffolds in cell number, glycosaminoglycan production, collagen content, alkaline phosphatase activity, and in some instances, gene expression of major osteogenic and chondrogenic markers. These results suggest that engineered signal gradients may be beneficial for osteochondral tissue engineering.
C1 [Berkland, Cory J.; Detamore, Michael S.] Univ Kansas, Dept Chem & Petr Engn, Lawrence, KS 66045 USA.
   [Berkland, Cory J.] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA.
   [Wang, Limin] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Singh, Milind] Rice Univ, Dept Bioengn, Houston, TX 77005 USA.
   [Dormer, Nathan H.] Univ Kansas, Bioengn Program, Lawrence, KS 66045 USA.
C3 University of Kansas; University of Kansas; University of Michigan
   System; University of Michigan; Rice University; University of Kansas
RP Detamore, MS (通讯作者)，Univ Kansas, Dept Chem & Petr Engn, 1530 W 15th St,4132 Learned Hall, Lawrence, KS 66045 USA.
EM detamore@ku.edu
RI ; Singh, Milind/B 3496 2011; Berkland, Cory/MAH 8821 2025; Wang,
   Limin/K 3398 2012
OI Berkland, Cory/0000 0002 7164 7886; 
FU Arthritis Foundation; National Institutes of Health (NIH/NIDCR) [1 R21
   DE017673 01]; NIGMS/NIH Pharmaceutical Aspects of Biotechnology
   [T32 GM008359]
FX The authors would like to express their gratitude to the Arthritis
   Foundation, the National Institutes of Health (NIH/NIDCR 1 R21
   DE017673 01) for their support, to NIGMS/NIH Pharmaceutical Aspects of
   Biotechnology Training grant (T32 GM008359) for supporting N. H. Dormer,
   and to Dr. Xinkun Wang of the K. U. Genomics Facility for his guidance
   in RT PCR.
CR An YH., 2003, Handbook of histology methods for bone and cartilage
   Aronin CEP, 2009, J BIOMED MATER RES A, V89A, P632, DOI 10.1002/jbm.a.32015
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Batycky RP, 1997, J PHARM SCI, V86, P1464, DOI 10.1021/js9604117
   Berkland C, 2003, PHARMACEUT RES, V20, P1055, DOI 10.1023/A:1024466407849
   Berkland C, 2001, J CONTROL RELEASE, V73, P59, DOI 10.1016/S0168 3659(01)00289 9
   BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854
   Botchwey EA, 2003, BIORHEOLOGY, V40, P299
   Botchwey EA, 2001, J BIOMED MATER RES, V55, P242
   BOYAN BD, 1989, J BIOL CHEM, V264, P11879
   BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453
   Cao X, 2003, NEUROSCIENCE, V122, P381, DOI 10.1016/j.neuroscience.2003.08.018
   Choi ST, 2008, RHEUMATOLOGY, V47, P1775, DOI 10.1093/rheumatology/ken385
   Ciavarella S, 2009, STEM CELLS DEV, V18, P1211, DOI 10.1089/scd.2008.0340
   Dickhut A, 2010, TISSUE ENG PT A, V16, P453, DOI [10.1089/ten.tea.2009.0168, 10.1089/ten.TEA.2009.0168]
   Dodla MC, 2006, J BIOMED MATER RES A, V78A, P213, DOI 10.1002/jbm.a.30747
   EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009 8981(80)90192 8
   Eufinger H, 2007, BIOMATERIALS, V28, P475, DOI 10.1016/j.biomaterials.2006.08.055
   Gerstenfeld LC, 2002, J BONE MINER RES, V17, P221, DOI 10.1359/jbmr.2002.17.2.221
   Gordeladze JO, 2009, ACTA PHARMACOL SIN, V30, P1369, DOI 10.1038/aps.2009.143
   Guo X, 2009, BIOMATERIALS, V30, P2741, DOI 10.1016/j.biomaterials.2009.01.048
   Heng BC, 2004, STEM CELLS, V22, P1152, DOI 10.1634/stemcells.2004 0062
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Holland TA, 2007, OSTEOARTHR CARTILAGE, V15, P187, DOI 10.1016/j.joca.2006.07.006
   Holland TA, 2005, J BIOMED MATER RES A, V75A, P156, DOI 10.1002/jbm.a.30379
   Hou TY, 2009, TISSUE ENG PT A, V15, P2325, DOI 10.1089/ten.tea.2008.0402
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kapur TA, 2004, J BIOMED MATER RES A, V68A, P235, DOI 10.1002/jbm.a.10168
   Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006 0286
   Knapp DM, 1999, EXP CELL RES, V247, P543, DOI 10.1006/excr.1998.4364
   Knippenberg M, 2006, BIOCHEM BIOPH RES CO, V342, P902, DOI 10.1016/j.bbrc.2006.02.052
   Kramer J, 2000, MECH DEVELOP, V92, P193, DOI 10.1016/S0925 4773(99)00339 1
   Liang S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/516469
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu LL, 2006, HAEMATOLOGICA, V91, P1017
   Lu XF, 2008, EUR POLYM J, V44, P2476, DOI 10.1016/j.eurpolymj.2008.06.002
   MATTHIAS W, 2007, J BIOMED MATER RES B, V82, P494
   Meirelles L, 2008, CLIN IMPLANT DENT R, V10, P245, DOI 10.1111/j.1708 8208.2008.00089.x
   MOSS DW, 1982, CLIN CHEM, V28, P2007
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   Phillips JE, 2008, P NATL ACAD SCI USA, V105, P12170, DOI [10.1073/pnas.0801988105, 10.1073/pnas.0B019BB105]
   REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004 0166
   Scaglione S, 2009, TISSUE ENG PT A, V15, P155, DOI 10.1089/ten.tea.2007.0410
   SHEN H, 2009, ACTA BIOMATER
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Singh M, 2008, TISSUE ENG PART B RE, V14, P341, DOI 10.1089/ten.teb.2008.0304
   Singh M, 2008, TISSUE ENG PART C ME, V14, P299, DOI 10.1089/ten.tec.2008.0167
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Stokes DG, 2001, BIOCHEM J, V360, P461, DOI 10.1042/0264 6021:3600461
   Torres FG, 2007, COMPOS SCI TECHNOL, V67, P1139, DOI 10.1016/j.compscitech.2006.05.018
   Tracy MA, 1999, BIOMATERIALS, V20, P1057, DOI 10.1016/S0142 9612(99)00002 2
   Tuan RS, 2003, ARTHRITIS RES THER, V5, P32, DOI 10.1186/ar614
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Wang L, 2010, TISSUE ENG A
   Wang LM, 2009, J TISSUE ENG REGEN M, V3, P398, DOI 10.1002/term.176
   Wang LM, 2009, TISSUE ENG PT A, V15, P1009, DOI 10.1089/ten.tea.2008.0012
   Wang XQ, 2009, J CONTROL RELEASE, V134, P81, DOI 10.1016/j.jconrel.2008.10.021
   Wang YJ, 2009, MAT SCI ENG C MATER, V29, P2502, DOI 10.1016/j.msec.2009.07.018
   Wu KH, 2007, ANN THORAC SURG, V83, P1491, DOI 10.1016/j.athoracsur.2006.10.066
   Wu LB, 2004, BIOMATERIALS, V25, P5821, DOI 10.1016/j.biomaterials.2004.01.038
   Yang XB, 2001, BONE, V29, P523, DOI 10.1016/S8756 3282(01)00617 2
   Zhang HN, 2009, J BIOMAT SCI POLYM E, V20, P1975, DOI 10.1163/156856208X396074
   Zhao L, 2010, BIOMATERIALS, V31, P840, DOI 10.1016/j.biomaterials.2009.09.106
NR 65
TC 103
Z9 130
U1 0
U2 67
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090 6964
EI 1573 9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD JUN
PY 2010
VL 38
IS 6
SI SI
BP 2167
EP 2182
DI 10.1007/s10439 010 0028 0
PG 16
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 596UJ
UT WOS:000277710700019
PM 20379780
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Kazimierczak, P
   Koziol, M
   Przekora, A
AF Kazimierczak, Paulina
   Koziol, Malgorzata
   Przekora, Agata
TI The Chitosan/Agarose/NanoHA Bone Scaffold Induced M2 Macrophage
   Polarization and Its Effect on Osteogenic Differentiation In Vitro
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE biomaterial; bone regeneration; mesenchymal stem cells; osteoblasts;
   osteogenic differentiation; co culture; cytokines
ID ANGIOGENESIS; BIOCOMPATIBILITY; PLASTICITY
AB Chronic immune response to bone implant may lead to delayed healing and its failure. Thus, newly developed biomaterials should be characterized by high biocompatibility. Moreover, it is well known that macrophages play a crucial role in the controlling of biomaterial induced inflammatory response. Immune cells synthesize also a great amount of signaling molecules that regulate cell differentiation and tissue remodeling. Non activated macrophages (M0) may be activated (polarized) into two main types of macrophage phenotype: proinflammatory type 1 macrophages (M1) and anti inflammatory type 2 macrophages (M2). The aim of the present study was to assess the influence of the newly developed chitosan/agarose/nanohydroxyapatite bone scaffold (Polish Patent) on the macrophage polarization and osteogenic differentiation. Obtained results showed that macrophages cultured on the surface of the biomaterial released an elevated level of anti inflammatory cytokines (interleukin 4,  10,  13, transforming growth factor beta), which is typical of the M2 phenotype. Moreover, an evaluation of cell morphology confirmed M2 polarization of the macrophages on the surface of the bone scaffold. Importantly, in this study, it was demonstrated that the co culture of macrophages seeded biomaterial with bone marrow derived stem cells (BMDSCs) or human osteoblasts (hFOB 1.19) enhanced their osteogenic ability, confirming the immunomodulatory effect of the macrophages on the osteogenic differentiation process. Thus, it was proved that the developed biomaterial carries a low risk of inflammatory response and induces macrophage polarization into the M2 phenotype with osteopromotive properties, which makes it a promising bone scaffold for regenerative medicine applications.
C1 [Kazimierczak, Paulina; Przekora, Agata] Med Univ Lublin, Chair & Dept Biochem & Biotechnol, Chodzki 1, PL 20093 Lublin, Poland.
   [Koziol, Malgorzata] Med Univ Lublin, Chair & Dept Med Microbiol, Chodzki 1, PL 20093 Lublin, Poland.
C3 Medical University of Lublin; Medical University of Lublin
RP Kazimierczak, P (通讯作者)，Med Univ Lublin, Chair & Dept Biochem & Biotechnol, Chodzki 1, PL 20093 Lublin, Poland.
EM paulina.kazimierczak@umlub.pl; malgorzata.koziol@umlub.pl;
   agata.przekora@umlub.pl
RI ; Przekora, Agata/H 8422 2019; Koziol, Malgorzata/AAQ 8613 2021
OI Koziol, Malgorzata/0000 0001 9079 8594; Kazimierczak,
   Paulina/0000 0002 5893 7168; Przekora Kusmierz,
   Agata/0000 0002 6076 1309; 
FU National Science Centre (NCN) in Poland [UMO 2018/31/B/ST8/00945];
   Operational Program Development of Eastern Poland 2007 2013, Priority
   Axis I, Modern Economy, Operations 1.3. Innovations Promotion
   [POPW.01.03.00 06 010/09 00]
FX This research was funded by National Science Centre (NCN) in Poland
   within OPUS 16 grant no. UMO 2018/31/B/ST8/00945. The paper was
   developed using the equipment purchased within agreement no.
   POPW.01.03.00 06 010/09 00 Operational Program Development of Eastern
   Poland 2007 2013, Priority Axis I, Modern Economy, Operations 1.3.
   Innovations Promotion.
CR Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Bastidas Coral AP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1318256
   Brodbeck WG, 2002, CYTOKINE, V18, P311, DOI 10.1006/cyto.2002.1048
   Brown BN, 2012, BIOMATERIALS, V33, P3792, DOI 10.1016/j.biomaterials.2012.02.034
   Chang HI, 2011, REGENERATIVE MEDICINE AND TISSUE ENGINEERING   CELLS AND BIOMATERIALS, P569
   Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668
   Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001
   Dolcimascolo A., 2019, IntechOpen, DOI [DOI 10.5772/INTECHOPEN.83839, 10.5772/intechopen.83839]
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   Ellis S, 2018, CURR DERMATOL REP, V7, P350, DOI 10.1007/s13671 018 0234 9
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Kazimierczak P, 2020, J MATER SCI TECHNOL, V43, P52, DOI 10.1016/j.jmst.2020.01.006
   Kazimierczak P, 2019, INT J NANOMED, V14, P6615, DOI 10.2147/IJN.S217245
   Kazimierczak P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153835
   Li B, 2018, BIOMATER SCI UK, V6, P3202, DOI 10.1039/c8bm00901e
   Loi F, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0276 5
   Lyons FG, 2010, BIOMATERIALS, V31, P9232, DOI 10.1016/j.biomaterials.2010.08.056
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   Przekora A, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/1/015009
   Przekora A, 2019, MAT SCI ENG C MATER, V97, P1036, DOI 10.1016/j.msec.2019.01.061
   Przekora A, 2016, MAT SCI ENG C MATER, V61, P355, DOI 10.1016/j.msec.2015.12.066
   Rostam HM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03780 z
   Schett G, 2011, EUR J CLIN INVEST, V41, P1361, DOI 10.1111/j.1365 2362.2011.02545.x
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Tang LP, 2000, BIOMATERIALS ENGINEERING AND DEVICES: HUMAN APPLICATIONS, VOL 1, P3
   Tang ZR, 2018, REGEN BIOMATER, V5, P43, DOI 10.1093/rb/rbx024
   Tarique AA, 2015, AM J RESP CELL MOL, V53, P676, DOI 10.1165/rcmb.2015 0012OC
   Wang J, 2017, J MATER CHEM B, V5, P3364, DOI 10.1039/c6tb03364d
   Wang M, 2016, BIOMATER SCI UK, V4, P1574, DOI 10.1039/c6bm00290k
   Xie YJ, 2020, REGEN BIOMATER, V7, P233, DOI 10.1093/rb/rbaa006
   Yamada A, 2007, IMMUNOLOGY, V120, P573, DOI 10.1111/j.1365 2567.2006.02538.x
   Zhang Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/284836
   Zhao FJ, 2018, BIOMATERIALS, V178, P36, DOI 10.1016/j.biomaterials.2018.06.004
NR 34
TC 33
Z9 34
U1 1
U2 25
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 3
AR 1109
DI 10.3390/ijms22031109
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QD1KC
UT WOS:000615285400001
PM 33498630
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Molinuevo, MS
   Schurman, L
   McCarthy, AD
   Cortizo, AM
   Tolosa, MJ
   Gangoiti, MV
   Arnol, V
   Sedlinsky, C
AF Silvina Molinuevo, M.
   Schurman, Leon
   McCarthy, Antonio D.
   Cortizo, Ana M.
   Tolosa, Maria J.
   Virginia Gangoiti, M.
   Arnol, Veronica
   Sedlinsky, Claudia
TI Effect of Metformin on Bone Marrow Progenitor Cell Differentiation: In
   Vivo and In Vitro Studies
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE BONE MARROW PROGENITOR CELLS; METFORMIN; ROSIGLITAZONE;
   OSTEOBLASTOGENESIS; ADIPOGENESIS; DIABETES MELLITUS
ID GLYCATION END PRODUCTS; MESENCHYMAL STEM CELLS; GROWTH FACTOR;
   ROSIGLITAZONE; OSTEOBLASTS; CULTURE
AB Diabetes mellitus is associated with bone loss. Patients with type 2 diabetes are frequently treated with oral antidiabetic drugs such as sulfonylureas, biguanides, and thiazolidinediones. Rosiglitazone treatment has been shown to increase adipogenesis in bone marrow and to induce bone loss. In this study we evaluated the effect of in vivo and in vitro treatment with metformin on bone marrow progenitor cells (BMPCs), as well as the involvement of AMPK pathway in its effects. The in vitro effect of coincubation with metformin and rosiglitazone on the adipogenic differentiation of BMPCs also was studied. In addition, we evaluated the effect of in vivo metformin treatment on bone regeneration in a model of parietal lesions in nondiabetic and streptozotocin induced diabetic rats. We found that metformin administration both in vivo and in vitro caused an increase in alkaline phosphatase activity, type I collagen synthesis, osteocalcin expression, and extracellular calcium deposition of BMPCs. Moreover, metformin significantly activated AMPK in undifferentiated BMPCs. In vivo, metformin administration enhanced the expression of osteoblast specific transcription factor Runx2/Cbfa1 and activation of AMPK in a time dependent manner. Metformin treatment also stimulated bone lesion regeneration in control and diabetic rats. In vitro, metformin partially inhibited the adipogenic actions of rosiglitazone on BMPCs. In conclusion, our results indicate that metformin causes an osteogenic effect both in vivo and in vitro, possibly mediated by Runx2/Cbfa1 and AMPK activation, suggesting a possible action of metformin in a shift toward the osteoblastic differentiation of BMPCs. (C) 2010 American Society for Bone and Mineral Research.
C1 [Sedlinsky, Claudia] Natl Univ La Plata, Fac Ciencias Exactas, GIOMM, Sch Exact Sci,Dept Biol Sci, RA 1900 La Plata, Argentina.
C3 National University of La Plata
RP Sedlinsky, C (通讯作者)，Natl Univ La Plata, Fac Ciencias Exactas, GIOMM, Sch Exact Sci,Dept Biol Sci, 47 & 115, RA 1900 La Plata, Argentina.
EM gabari@fibertel.com.ar
RI ; McCarthy, Antonio/AAN 2596 2020
OI Sedlinsky, Claudia/0009 0006 1825 9397; McCarthy, Antonio
   Desmond/0000 0002 9175 6596
FU Universidad Nacional de La Plata; Agencia Nacional de Promocion
   Cientifica y Tecnologica (ANPCyT) [BID 1728/OC AR, 22398]; Comision de
   Investigaciones Cientificas de la Provincia de Buenos Aires (CICPBA);
   Quimica Montpellier
FX We would like to thank Quimica (Montpellier, Argentina) for providing
   the rosiglitazone and metformin used in this study. This study was
   supported in part by grants from the Universidad Nacional de La Plata,
   Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT)
   (BID 1728/OC AR, PAE No. 22398), Comision de Investigaciones Cientificas
   de la Provincia de Buenos Aires (CICPBA), and Quimica Montpellier. MSM
   is a member of Carrera del Investigador CONICET. AMC is a member of
   Carrera del Investigador CICPBA, and MVG is a fellow of CICPBA.
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   El Batran SA, 2006, PHARMACOL RES, V53, P69, DOI 10.1016/j.phrs.2005.08.008
   Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756 3282(96)00258 X
   Gin H, 2002, DIABETES METAB, V28, P350
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359 6101(00)00030 7
   Kahn SE, 2008, DIABETES CARE, V31, P845, DOI 10.2337/dc07 2270
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lazarenko OP, 2006, BONE, V38, P74, DOI 10.1016/j.bone.2005.07.008
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   Meier C, 2008, ARCH INTERN MED, V168, P820, DOI 10.1001/archinte.168.8.820
   Mercer N, 2004, MOL CELL BIOCHEM, V266, P17, DOI 10.1023/B:MCBI.0000049128.71095.ac
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Santana RB, 2003, DIABETES, V52, P1502, DOI 10.2337/diabetes.52.6.1502
   Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Ueno A, 2001, MATRIX BIOL, V20, P347, DOI 10.1016/S0945 053X(01)00141 X
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Vlassara H, 2002, J INTERN MED, V251, P87, DOI 10.1046/j.1365 2796.2002.00932.x
   Yamagishi S, 2005, MED HYPOTHESES, V65, P1013, DOI 10.1016/j.mehy.2005.07.017
NR 35
TC 186
Z9 215
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2010
VL 25
IS 2
BP 211
EP 221
DI 10.1359/jbmr.090732
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 564LJ
UT WOS:000275215500005
PM 19594306
OA Bronze, Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Xiong, ML
   Feng, Y
   Huang, SJ
   Lv, SY
   Deng, YH
   Li, M
   Wang, PF
   Luo, MJ
   Wen, HT
   Zhang, WM
AF Xiong, Moliang
   Feng, Yun
   Huang, Shujie
   Lv, Siyuan
   Deng, Yuhao
   Li, Min
   Wang, Pengfei
   Luo, Minjie
   Wen, Huangtao
   Zhang, Wangming
TI Teriparatide induces angiogenesis in ischemic cerebral infarction zones
   of rats through AC/PKA signaling and reduces ischemia reperfusion injury
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Teriparatide; Ischemic cerebral infarction; Blood brain barrier;
   Angiogenesis; Oxidative stress; Neuroinflammation
ID POSTMENOPAUSAL OSTEOPOROSIS; ARTERY OCCLUSION; PROTECTIVE ROLE; BRAIN;
   ANGIOPOIETIN 1; EXPRESSION; DAMAGE; ISCHEMIA/REPERFUSION; INDUCTION;
   DENOSUMAB
AB Teriparatide is a commonly used drug indicated for the treatment of osteoporosis in postmenopausal women. Teriparatide can also upregulate Ang 1 expression through the AC/PKA signaling pathway to promote angiogenesis. At present, promoting angiogenesis is a promising but unrealized strategy for the treatment of ischemic cerebral infarction. However, there are few studies on the application of teriparatide in the treatment of cerebral infarction. We used teriparatide to treat ischemic cerebral infarction in rats and obtained three major findings. First, teriparatide can promote angiogenesis, reduce cerebral infarct size, and increase cerebral perfusion by upregulating Ang 1 expression. Second, teriparatide can promote the expression of HO1, SOD2 and inhibit the production of pro inflammatory cytokines IL 1 beta, IL 6 by upregulating Nrf2 expression. Third, we further found that teriparatide can mitigate blood brain barrier disruption and brain edema by downregulating the expressions of MMP9, Ang 2 and AQP4. Our results indicate that teriparatide is neuroprotective through multiple mechanisms of action that include promoting angiogenesis, inhibiting oxidative stress and neuroinflammation, protecting blood brain barrier, and reducing brain edema.
C1 [Xiong, Moliang; Huang, Shujie; Lv, Siyuan; Deng, Yuhao; Li, Min; Wang, Pengfei; Luo, Minjie; Wen, Huangtao; Zhang, Wangming] Southern Med Univ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Dept Neurosurg,Zhujiang Hosp,Neurosurg Inst Guang, Engn Technol Res Ctr,Educ Minist China,Natl Key C, Guangzhou 510282, Peoples R China.
   [Feng, Yun] Hosp 74th Grp Army Chinese Peoples Liberat Army, Dept Pediat, Guangzhou 510282, Peoples R China.
   [Zhang, Wangming] Zhujiang Hosp, Guangzhou, Guangdong, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP Zhang, WM (通讯作者)，Southern Med Univ, Guangdong Prov Key Lab Brain Funct Repair & Regen, Dept Neurosurg,Zhujiang Hosp,Neurosurg Inst Guang, Engn Technol Res Ctr,Educ Minist China,Natl Key C, Guangzhou 510282, Peoples R China.
EM wzhang@vip.126.com
RI Huang, Shujie/HLP 3114 2023; wang, pengfei/ABD 7479 2021; Xiong,
   Moliang/OBN 6905 2025; Zhang, Wangming/IUP 4390 2023
OI Zhang, Wangming/0000 0003 4506 6321
CR Amani H, 2019, INT J NANOMED, V14, P8013, DOI 10.2147/IJN.S210035
   Amano H, 2001, JPN J PHARMACOL, V87, P181, DOI 10.1254/jjp.87.181
   Ardelt AA, 2005, STROKE, V36, P337, DOI 10.1161/01.STR.0000153795.38388.72
   Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647 199710000 00006
   Ben Zvi A, 2014, NATURE, V509, P507, DOI 10.1038/nature13324
   Betsholtz C, 2014, NATURE, V509, P432, DOI 10.1038/nature13339
   Bollong MJ, 2018, NATURE, V562, P600, DOI 10.1038/s41586 018 0622 0
   Bonita R, 2004, LANCET NEUROL, V3, P391, DOI 10.1016/S1474 4422(04)00800 2
   Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Dhillon RS, 2013, J BONE MINER RES, V28, P586, DOI 10.1002/jbmr.1765
   Egashira Y, 2015, STROKE, V46, P2909, DOI 10.1161/STROKEAHA.115.010351
   Elstrott BK, 2020, BLOOD, V136, DOI 10.1182/blood 2020 139011
   GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627
   Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481
   Gu H, 2016, INT NEUROUROL J, V20, P288, DOI 10.5213/inj.1632692.346
   Gurnik S, 2016, ACTA NEUROPATHOL, V131, P753, DOI 10.1007/s00401 016 1551 3
   Jin F, 2021, J INFLAMM RES, V14, P2667, DOI 10.2147/JIR.S315281
   Jin J, 2021, EUR NEUROL, V83, P581, DOI 10.1159/000511238
   Kamada H, 2007, STROKE, V38, P1044, DOI 10.1161/01.STR.0000258041.75739.cb
   Kitchen P, 2020, CELL, V181, P784, DOI 10.1016/j.cell.2020.03.037
   Kiyohara T, 2021, STROKE, V52, P2621, DOI 10.1161/STROKEAHA.120.031392
   Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624
   Kumar H, 2014, NAT PROD REP, V31, P109, DOI 10.1039/c3np70065h
   Leder BZ, 2015, LANCET, V386, P1147, DOI 10.1016/S0140 6736(15)61120 5
   Lee KY, 2012, STROKE, V43, P1632, DOI 10.1161/STROKEAHA.111.639427
   Liu L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00153
   Liu L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00074
   Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256
   Mi XN, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.624387
   Nag S, 2005, LAB INVEST, V85, P1189, DOI 10.1038/labinvest.3700325
   Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365 2990.2010.01138.x
   Narayanan SV, 2015, STROKE, V46, P1626, DOI 10.1161/STROKEAHA.115.008921
   Park JH, 2006, EXP CLIN ENDOCR DIAB, V114, P438, DOI 10.1055/s 2006 924400
   Roemer SF, 2007, BRAIN, V130, P1194, DOI 10.1093/brain/awl371
   Romero A, 2019, AGING CELL, V18, DOI 10.1111/acel.12913
   Shah ZA, 2010, J CEREBR BLOOD F MET, V30, P1951, DOI 10.1038/jcbfm.2010.53
   Shin HY, 2010, J NEUROSCI RES, V88, P1052, DOI 10.1002/jnr.22274
   Si ZH, 2019, J CELL MOL MED, V23, P2468, DOI 10.1111/jcmm.14120
   Singh D, 2019, NEUROCHEM INT, V126, P96, DOI 10.1016/j.neuint.2019.03.010
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092 8674(00)81813 9
   Tang ZH, 2013, NEUROPHARMACOLOGY, V67, P8, DOI 10.1016/j.neuropharm.2012.10.017
   Tao JH, 2018, BIOMED PHARMACOTHER, V106, P1003, DOI 10.1016/j.biopha.2018.07.026
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Varshney V, 2021, MOL BIOL REP, V48, P4319, DOI 10.1007/s11033 021 06447 1
   Walsh J, 2021, BRAIN, V144, P1361, DOI 10.1093/brain/awab003
   Wang BX, 2019, EUR REV MED PHARMACO, V23, P732, DOI 10.26355/eurrev_201901_16887
   Wang L, 2019, EXP NEUROL, V321, DOI 10.1016/j.expneurol.2019.113042
   Weyemi U, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03948 9
   Wu J, 2015, EUR J PHARMACOL, V748, P30, DOI 10.1016/j.ejphar.2014.12.007
   Zhang F, 2012, STROKE, V43, P1390, DOI 10.1161/STROKEAHA.111.647420
   Zhang LZ, 2017, J BONE MINER RES, V32, P1870, DOI 10.1002/jbmr.3178
   Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306 4522(02)00175 6
   Zhou MG, 2019, LANCET, V394, P1145, DOI 10.1016/S0140 6736(19)30427 1
   Zhu YQ, 2005, STROKE, V36, P1533, DOI 10.1161/01.STR.0000170712.46106.2e
NR 57
TC 12
Z9 12
U1 0
U2 28
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD APR
PY 2022
VL 148
AR 112728
DI 10.1016/j.biopha.2022.112728
EA FEB 2022
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 0D6ET
UT WOS:000776087100003
PM 35220030
OA gold
DA 2025 08 17
ER

PT J
AU Rymuza, J
   Popow, M
   Zurecka, Z
   Przedlacki, J
   Bednarczuk, T
   Miskiewicz, P
AF Rymuza, Joanna
   Popow, Michal
   Zurecka, Zuzanna
   Przedlacki, Jerzy
   Bednarczuk, Tomasz
   Miskiewicz, Piotr
TI Therapy of moderate to severe Graves' orbitopathy with intravenous
   methylprednisolone pulses is not associated with loss of bone mineral
   density
SO ENDOCRINE
LA English
DT Article
DE Bone mineral density; Gucocorticoid induced Osteoporosis;
   Methylprednisolone; Graves' ophthalmopathy; Graves' orbitopathy;
   Trabecular bone score
ID PARATHYROID HORMONE; GLUCOCORTICOID THERAPY; INDUCED OSTEOPOROSIS;
   BIOCHEMICAL MARKERS; VITAMIN D; MECHANISMS; TURNOVER; RISK;
   CORTICOSTEROIDS; HYPERTHYROIDISM
AB PurposeTo evaluate the influence of intravenous methylprednisolone (IVMP) pulse administration on bone mineral density (BMD) of the lumbar spine and the femoral neck in patients with moderate to severe Graves' orbitopathy (GO).MethodsThirty five patients with GO in euthyreosis were treated with 12 IVMP pulses (6x0.5g, 6x0.25g on a weekly schedule). Supplementation with 1.0g of calcium and 800IU of vitamin D was initiated in all patients before beginning therapy. BMD of the lumbar spine (L1 L4) and the femoral neck were assessed at baseline and after the last IVMP pulse using dual energy X ray absorptiometry. To determine differences in BMD between values at baseline and after treatment, we used the least significant change (LSC) methodology. LSC values were calculated to be 3 and 5% for the lumbar spine and the femoral neck, respectively. Change in BMD equal to or exceeding the LSC was assessed as either increase or decrease of BMD. We then compared pre treatment and post treatment mean BMD values at the lumbar spine and the femoral neck.ResultsWe did not observe a decrease of BMD at any site equal to or exceeding the LSC. We found an increase of BMD in at least one measurement site equal to or exceeding the LSC value in 43% of patients, mostly in the lumbar spine (31%). Mean femoral neck BMD did not change while mean lumbar BMD increased.ConclusionsIVMP given in weekly intravenous pulses does not lead to loss of BMD of the lumbar spine and the femoral neck.
C1 [Rymuza, Joanna; Popow, Michal; Zurecka, Zuzanna; Bednarczuk, Tomasz; Miskiewicz, Piotr] Med Univ Warsaw, Dept Internal Med & Endocrinol, Banacha 1a, PL 02097 Warsaw, Poland.
   [Przedlacki, Jerzy] Med Univ Warsaw, Dept Nephrol Dialysis & Internal Med, Banacha 1a, PL 02097 Warsaw, Poland.
C3 Medical University of Warsaw; Medical University of Warsaw
RP Miskiewicz, P (通讯作者)，Med Univ Warsaw, Dept Internal Med & Endocrinol, Banacha 1a, PL 02097 Warsaw, Poland.
EM piotr.miskiewicz@wum.edu.pl
RI ; Bednarczuk, Tomasz/AFQ 8418 2022; Rymuza, Joanna/NHQ 7140 2025
OI , Piotr/0000 0002 9024 9015; Bednarczuk, Tomasz/0000 0002 5752 8709;
   Popow, Michal/0009 0004 0584 7259
CR AMIN S, 1925, ARTHRITIS RHEUM, V42, P1740, DOI DOI 10.1002/1529 0131(199908)42:8
   Ardissone P, 2002, J ENDOCRINOL INVEST, V25, P129, DOI 10.1007/BF03343976
   Aslan D, 2012, SCAND J CLIN LAB INV, V72, P14, DOI 10.3109/00365513.2011.624631
   Bartalena L, 2016, EUR THYROID J, V5, P9, DOI 10.1159/000443828
   BIJLSMA JWJ, 1986, ANN RHEUM DIS, V45, P757, DOI 10.1136/ard.45.9.757
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441
   DIAMOND T, 1994, ANN INTERN MED, V120, P8, DOI 10.7326/0003 4819 120 1 199401010 00002
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   Frediani B, 2004, J RHEUMATOL, V31, P1083
   GARNERO P, 1994, J CLIN ENDOCR METAB, V78, P955, DOI 10.1210/jc.78.4.955
   Gasinska T, 2012, POL ARCH MED WEWN, V122, P341, DOI 10.20452/pamw.1301
   Haugeberg G, 2004, ANN RHEUM DIS, V63, P940, DOI 10.1136/ard.2003.011734
   HOMIK J, 2000, COCHRANE DB SYST REV, V2
   Huybers S, 2007, AM J PHYSIOL GASTR L, V292, pG92, DOI 10.1152/ajpgi.00317.2006
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Karga H, 2004, CLIN ENDOCRINOL, V61, P466, DOI 10.1111/j.1365 2265.2004.02110.x
   Marcocci C, 2012, EUR J ENDOCRINOL, V166, P247, DOI 10.1530/EJE 11 0779
   Miskiewicz P, 2018, J ENDOCRINOL INVEST, V36, P1
   Miskiewicz P, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/1978590
   Miskiewicz P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102918
   Miskiewicz P, 2014, ENDOKRYNOL POL, V65, P402, DOI 10.5603/EP.2014.0056
   Moleti M, 2016, ENDOCRINE, V54, P259, DOI 10.1007/s12020 016 0928 3
   Munns CF, 2016, HORM RES PAEDIAT, V85, P83, DOI [10.1159/000443136, 10.1210/jc.2015 2175]
   Natsui K, 2006, OSTEOPOROSIS INT, V17, P105, DOI 10.1007/s00198 005 1923 3
   O'Brien CA, 2004, ENDOCRINOLOGY, V145, P1835, DOI 10.1210/en.2003 0990
   Pludowski P, 2013, ENDOKRYNOL POL, V64, P319, DOI 10.5603/EP.2013.0012
   Poole KES, 2005, CURR OPIN PHARMACOL, V5, P612, DOI 10.1016/j.coph.2005.07.004
   Schwid SR, 1996, ARCH NEUROL CHICAGO, V53, P753, DOI 10.1001/archneur.1996.00550080071014
   Siddiqi A, 1997, J CLIN ENDOCR METAB, V82, P753, DOI 10.1210/jc.82.3.753
   Stiebel Kalish H, 2009, J CLIN ENDOCR METAB, V94, P2708, DOI 10.1210/jc.2009 0376
   Svare A, 2009, EUR J ENDOCRINOL, V161, P779, DOI 10.1530/EJE 09 0139
   Tomaschitz A, 2014, METABOLISM, V63, P20, DOI 10.1016/j.metabol.2013.08.016
   Tuchendler D, 2014, THYROID RES, V7, DOI 10.1186/s13044 014 0012 0
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Vestergaard P, 2003, THYROID, V13, P585, DOI 10.1089/105072503322238854
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yamashita H, 2001, ENDOCR J, V48, P63, DOI 10.1507/endocrj.48.63
NR 41
TC 8
Z9 8
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD MAY
PY 2019
VL 64
IS 2
BP 308
EP 315
DI 10.1007/s12020 018 1823 x
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HZ4SM
UT WOS:000468840200013
PM 30506426
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Wiren, KM
   Zhang, XW
   Olson, DA
   Turner, RT
   Iwaniec, UT
AF Wiren, Kristine M.
   Zhang, Xiao Wei
   Olson, Dawn A.
   Turner, Russell T.
   Iwaniec, Urszula T.
TI Androgen prevents hypogonadal bone loss via inhibition of resorption
   mediated by mature osteoblasts/osteocytes
SO BONE
LA English
DT Article
DE Osteoblast; Osteocyte; Testosterone; Androgen receptor; Resorption;
   Anabolic
ID BIOCHEMICAL MARKERS; BODY COMPOSITION; TRABECULAR BONE; SEX STEROIDS;
   MALE RATS; MEN; TESTOSTERONE; TURNOVER; MASS; FAT
AB Androgen receptor (AR) is expressed throughout the osteoblast lineage. Two different AR transgenic families (AR2.3 tg and AR3.6 tg mice) demonstrating overlapping and distinct expression profiles were employed to assess the effects of enhanced androgen sensitivity to ameliorate hypogonadal loss. Two different paradigms of steroid replacement following orchidectomy (ORX) were used as either preventative or therapeutic therapy. ORX was performed in male wild type (WO, AR2.3 tg and AR3.6 tg mice at 5 months with immediate DHT replacement (prevention, higher turnover) or at 3 months with DHT treatment delayed for 2 months (therapeutic, lower turnover), both with treatment for the last 6 weeks. Dual energy X ray absorptiometry (DXA), micro computed tomography (mu CT), and histomorphometry were performed. In the prevention model, ORX significantly reduced BMD and BMC in all genotypes compared to sham and DHT was effective at prevention of osteopenia. In the therapeutic model, all genotypes became osteopenic compared to sham, but after a prolonged hypogonadal period, delayed DHT treatment provided little benefit. mu CT analysis of mid shaft total bone in all genotypes generally showed reductions after ORX. Delayed DHT was ineffective at restoring bone volume in any genotype whereas immediate treatment prevented loss only in AR transgenic mice. Cortical thickness also decreased with ORX but immediate DHT treatment was effective to increase thickness only in WT mice, likely due to expansion of marrow volume in both AR tg lines. In metabolically highly active cancellous bone, ORX resulted in lower bone volume/tissue volume (BV/TV) in all genotypes, consistent among 3 sites measured. Again with delayed treatment, there was little effect of DHT to restore BV/TV, but when administered at the time of ORX, DHT completely prevented the decrease in cancellous bone in all genotypes. Improvement in cancellous bone architecture was seen with immediate DHT replacement that was enhanced in AR transgenic lines compared to WT. In contrast, there were only modest changes in all genotypes using the delayed treatment paradigm. With ORX in both paradigms, trabecular number was decreased while spacing increased. Thus, androgen therapy is effective for the prevention of endosteal and cancellous osteopenia primarily through its anti resorptive properties, but shows little anabolic action as a therapeutic strategy to restore bone. Given the similarity in response to androgen treatment in both AR transgenic lines, overlapping expression profiles suggest that the target cells mediating androgen action in vivo are mature osteoblast/osteocytes. Combined, these results demonstrate that in the adult mouse, androgen treatment can reduce bone resorption but has little overall anabolic activity. Published by Elsevier Inc.
C1 [Wiren, Kristine M.; Zhang, Xiao Wei] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA.
   [Wiren, Kristine M.; Zhang, Xiao Wei] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
   [Wiren, Kristine M.; Zhang, Xiao Wei] Dept Vet Affairs Med Ctr, Portland, OR 97239 USA.
   [Olson, Dawn A.; Turner, Russell T.; Iwaniec, Urszula T.] Oregon State Univ, Skeletal Biol Lab, Corvallis, OR USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Portland Health Care System; Oregon State University
RP Wiren, KM (通讯作者)，Oregon Hlth & Sci Univ, Dept Med, 3710 SW Vet Hosp Rd, Portland, OR 97239 USA.
EM wirenk@ohsu.edu
OI Wiren, Kristine/0000 0002 6159 4450
FU National Institute of Diabetes and Digestive and Kidney Diseases [R01
   DK067541]; United States Army Medical Research Acquisition Activity
   [W81XWH 05 1 0086]; Veterans Affairs Merit Review Program
FX We thank Dr. Robert Klein (OHSU) for the use of the Piximus II work
   station for DXA analysis. We also thank Anthony A. Semirale for
   assistance with surgeries and DXA analysis. This publication was made
   possible by grants from the National Institute of Diabetes and Digestive
   and Kidney Diseases R01 DK067541 (KMW) and the United States Army
   Medical Research Acquisition Activity award no. W81XWH 05 1 0086 (KMW).
   KMW is a Research Career Scientist in the Department of Veterans Affairs
   and received support from the Veterans Affairs Merit Review Program. All
   work was performed in facilities provided by the Department of Veterans
   Affairs.
CR Benito M, 2005, J BONE MINER RES, V20, P1785, DOI 10.1359/JBMR.050606
   Falahati Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942
   Frenkel B, 2010, J CELL PHYSIOL, V224, P305, DOI 10.1002/jcp.22159
   GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003 4819 110 7 526
   GUNNESS M, 1995, J BONE MINER RES, V10, P1735
   Hannon K, 1991, J BONE MINER RES 201, V6, P325
   Henriksen K, 2009, BONE, V44, P1026, DOI 10.1016/j.bone.2009.03.671
   Iwaniec Urszula T., 2008, V447, P325, DOI 10.1007/978 1 59745 242 7_21
   Kenny AM, 2002, J REPROD MED, V47, P63
   Kenny AM, 2010, J AM GERIATR SOC, V58, P1134, DOI 10.1111/j.1532 5415.2010.02865.x
   Leder BZ, 2003, J CLIN ENDOCR METAB, V88, P204, DOI 10.1210/jc.2002 021036
   Liegibel UM, 2002, J EXP MED, V196, P1387, DOI 10.1084/jem.20021017
   LUISETTO G, 1993, BONE MINER, V22, P9, DOI 10.1016/S0169 6009(08)80077 3
   Ma J, 2004, MOL PHARMACOL, V65, P730, DOI 10.1124/mol.65.3.730
   Notini AJ, 2007, J BONE MINER RES, V22, P347, DOI 10.1359/JBMR.061117
   Orwoll ES, 1996, TRENDS ENDOCRIN MET, V7, P77, DOI 10.1016/1043 2760(96)00024 0
   Raisz LG, 1996, J CLIN ENDOCR METAB, V81, P37, DOI 10.1210/jc.81.1.37
   Richman C, 2001, J BONE MINER RES, V16, P386, DOI 10.1359/jbmr.2001.16.2.386
   Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006 1864
   Sacks Sydney S, 2005, Clin Biochem Rev, V26, P43
   Sanyal A, 2008, J BONE MINER RES, V23, P705, DOI 10.1359/JBMR.071212
   Semirale AA, 2011, J CELL BIOCHEM, V112, P1773, DOI 10.1002/jcb.23098
   Simon JA, 2006, OBSTET GYNECOL SURV, V61, P115, DOI 10.1097/01.ogx.0000189152.95070.f8
   Syed F, 2005, BIOCHEM BIOPH RES CO, V328, P688, DOI 10.1016/j.bbrc.2004.11.097
   Tivesten A, 2004, J BONE MINER RES, V19, P1833, DOI 10.1359/JBMR.040819
   TURNER RT, 1989, J BONE MINER RES, V4, P557
   VANDERSCHUEREN D, 1994, BONE MINER, V26, P123, DOI 10.1016/S0169 6009(08)80057 8
   VANDERSCHUEREN D, 1992, ENDOCRINOLOGY, V130, P2906, DOI 10.1210/en.130.5.2906
   VERHAS M, 1986, CALCIFIED TISSUE INT, V39, P74, DOI 10.1007/BF02553294
   Vignozzi L, 2010, J Endocrinol Invest, V33, P27
   Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003 032006
   Wiren KM, 2005, CURR OPIN PHARMACOL, V5, P626, DOI 10.1016/j.coph.2005.06.003
   Wiren KM, 2004, ENDOCRINOLOGY, V145, P3507, DOI 10.1210/en.2003 1016
   Wiren KM, 2008, BONE, V43, P440, DOI 10.1016/j.bone.2008.04.026
   Wiren KM, 2011, J CELL BIOCHEM, V112, P3638, DOI 10.1002/jcb.23288
   Wiren KM, 2011, BONE, V49, P662, DOI 10.1016/j.bone.2011.06.010
   Wiren KM, 2010, BONE, V46, P710, DOI 10.1016/j.bone.2009.10.039
NR 37
TC 35
Z9 38
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2012
VL 51
IS 5
BP 835
EP 846
DI 10.1016/j.bone.2012.08.111
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 015FX
UT WOS:000309432900001
PM 22910580
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kondo, H
   Kondo, M
   Hayashi, K
   Kusafuka, S
   Hamamura, K
   Tanaka, K
   Kodama, D
   Hirai, T
   Sato, T
   Ariji, Y
   Miyazawa, K
   Ariji, E
   Goto, S
   Togari, A
AF Kondo, Hisataka
   Kondo, Mayo
   Hayashi, Kaori
   Kusafuka, Sae
   Hamamura, Kazunori
   Tanaka, Kenjiro
   Kodama, Daisuke
   Hirai, Takao
   Sato, Takuma
   Ariji, Yoshiko
   Miyazawa, Ken
   Ariji, Eiichiro
   Goto, Shigemi
   Togari, Akifumi
TI Orthodontic tooth movement activated sensory neurons contribute to
   enhancing osteoclast activity and tooth movement through sympathetic
   nervous signalling
SO EUROPEAN JOURNAL OF ORTHODONTICS
LA English
DT Article
ID GENE RELATED PEPTIDE; BONE FORMATION; PERIODONTAL LIGAMENT; SUBSTANCE P;
   CAPSAICIN; FIBERS; CGRP; RESORPTION; SYSTEM
AB Objectives Orthodontic tooth movement (OTM) increases sympathetic and sensory neurological markers in periodontal tissue. However, the relationship between the sympathetic and sensory nervous systems during OTM remains unclear. Therefore, the present study investigated the relationship between the sympathetic and sensory nervous systems activated by OTM using pharmacological methods. Materials and Methods We compared the effects of sympathectomy and sensory nerve injury during OTM in C57BL6/J mice. Capsaicin (CAP) was used to induce sensory nerve injury. Sympathectomy was performed using 6 hydroxydopamine. To investigate the effects of a beta agonist on sensory nerve injury, isoproterenol (ISO) was administered to CAP treated mice. Furthermore, to examine the role of the central nervous system in OTM, the ventromedial hypothalamic nucleus (VMH) was ablated using gold thioglucose. Results Sensory nerve injury and sympathectomy both suppressed OTM and decreased the percent of the alveolar socket covered with osteoclasts (Oc.S/AS) in periodontal tissue. Sensory nerve injury inhibited increases in OTM induced calcitonin gene related peptide (CGRP) immunoreactivity (IR), a marker of sensory neurons, and tyrosine hydroxylase (TH) IR, a marker of sympathetic neurons, in periodontal tissue. Although sympathectomy did not decrease the number of CGRP IR neurons in periodontal tissue, OTM induced increases in the number of TH IR neurons were suppressed. The ISO treatment restored sensory nerve injury inhibited tooth movement and Oc.S/AS. Furthermore, the ablation of VMH, the centre of the sympathetic nervous system, suppressed OTM induced increases in tooth movement and Oc.S/AS. Conclusions The present results suggest that OTM activated sensory neurons contribute to enhancements in osteoclast activity and tooth movement through sympathetic nervous signalling.
C1 [Kondo, Hisataka; Kondo, Mayo; Hayashi, Kaori; Kusafuka, Sae; Hamamura, Kazunori; Tanaka, Kenjiro; Kodama, Daisuke; Hirai, Takao; Togari, Akifumi] Aichi Gakuin Univ, Sch Dent, Dept Pharmacol, Nagoya, Aichi, Japan.
   [Kondo, Mayo; Hayashi, Kaori; Kusafuka, Sae; Sato, Takuma; Miyazawa, Ken; Goto, Shigemi] Aichi Gakuin Univ, Sch Dent, Dept Orthodont, Nagoya, Aichi, Japan.
   [Ariji, Yoshiko; Ariji, Eiichiro] Aichi Gakuin Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, Nagoya, Aichi, Japan.
C3 Aichi Gakuin University; Aichi Gakuin University; Aichi Gakuin
   University
RP Kondo, H (通讯作者)，Aichi Gakuin Univ, Chikusa Ku, 1 100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.
EM kondoh@dpc.agu.ac.jp
RI Ariji, Eiichiro/AAD 9857 2021; Kodama, Daisuke/M 6912 2013
OI Sato, Takuma/0000 0002 5555 7709; Kondo, Hisataka/0000 0002 7373 9282
FU Japan Society for the Promotion of Science [15K11061, 19K10416];
   Grants in Aid for Scientific Research [15K11061, 19K10416, 20K10194]
   Funding Source: KAKEN
FX Research in the author's laboratory is partially supported by
   Grantsin Aid for Scientific Research (15K11061 and 19K10416 to Hisataka
   Kondo) from the Japan Society for the Promotion of Science.
CR Adam C, 2000, EXP PHYSIOL, V85, P61, DOI 10.1111/j.1469 445X.2000.01930.x
   Akhoundi MSA, 2010, AUST ORTHOD J, V26, P113
   ALAM ASMT, 1993, EXP PHYSIOL, V78, P183, DOI 10.1113/expphysiol.1993.sp003679
   Arias OR, 2006, AM J ORTHOD DENTOFAC, V130, P364, DOI 10.1016/j.ajodo.2004.12.027
   Ariji Y, 2018, INT J ORAL SCI, V10, DOI 10.1038/s41368 017 0001 y
   Blair HA, 2018, DRUGS, V78, P1489, DOI 10.1007/s40265 018 0982 7
   BUCK SH, 1986, PHARMACOL REV, V38, P179
   Cao H, 2014, J DENT RES, V93, P1163, DOI 10.1177/0022034514551769
   CHAMBERS TJ, 1993, BONE MINER, V20, P167, DOI 10.1016/S0169 6009(08)80025 6
   Cherruau M, 2003, J CELL PHYSIOL, V194, P341, DOI 10.1002/jcp.10209
   Ding YX, 2010, BONE, V46, P1591, DOI 10.1016/j.bone.2010.02.022
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   George A, 2008, CLIN RADIOL, V63, P499, DOI 10.1016/j.crad.2007.12.006
   Hino K, 2006, J CELL BIOCHEM, V99, P845, DOI 10.1002/jcb.20935
   Huebner AK, 2006, J BONE MINER RES, V21, P1924, DOI 10.1359/JBMR.060820
   IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478
   Ishizuka K, 2005, NEUROSCI LETT, V379, P47, DOI 10.1016/j.neulet.2004.12.046
   Karthi M, 2012, J PHARM BIOALLIED SC, V4, pS304, DOI 10.4103/0975 7406.100280
   Kato J, 1996, ACTA ANAT, V157, P53
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Kondo M, 2013, BONE, V52, P39, DOI 10.1016/j.bone.2012.09.007
   Long H, 2015, NEUROPEPTIDES, V52, P31, DOI 10.1016/j.npep.2015.06.006
   MACINTYRE I, 1989, LANCET, V2, P1026
   Messlinger Karl, 2011, Keio Journal of Medicine, V60, P82
   MULLENDER MG, 1995, J ORTHOPAED RES, V13, P503, DOI 10.1002/jor.1100130405
   NAGY JI, 1983, J NEUROSCI, V3, P399
   NOREVALL LI, 1995, EUR J ORTHODONT, V17, P311, DOI 10.1093/ejo/17.4.311
   Offley SC, 2005, J BONE MINER RES, V20, P257, DOI 10.1359/JBMR.041108
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   POWLEY TL, 1986, BRAIN RES, V367, P192, DOI 10.1016/0006 8993(86)91592 1
   RUBIN CT, 1995, J BONE MINER RES, V10, P488
   SAITO I, 1991, ARCH ORAL BIOL, V36, P689, DOI 10.1016/0003 9969(91)90023 N
   Schinke T, 2004, J BONE MINER RES, V19, P2049, DOI 10.1359/JBMR.040915
   Supowit SC, 2005, AM J PHYSIOL HEART C, V289, pH1169, DOI 10.1152/ajpheart.00973.2004
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   VandevskaRadunovic V, 1997, EUR J ORTHODONT, V19, P517, DOI 10.1093/ejo/19.5.517
   VIRUS RM, 1983, EUR J PHARMACOL, V92, P1, DOI 10.1016/0014 2999(83)90101 2
   WALDO CM, 1954, J DENT RES, V33, P481, DOI 10.1177/00220345540330040701
   YAMASAKI K, 1980, J DENT RES, V59, P1635, DOI 10.1177/00220345800590101301
   Yamashiro T, 2000, BONE, V26, P663, DOI 10.1016/S8756 3282(00)00282 9
NR 40
TC 14
Z9 16
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0141 5387
EI 1460 2210
J9 EUR J ORTHODONT
JI Eur. J. Orthodont.
PD AUG 16
PY 2022
VL 44
IS 4
BP 404
EP 411
DI 10.1093/ejo/cjab072
EA OCT 2021
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 3U3IG
UT WOS:000790081600001
PM 34642757
DA 2025 08 17
ER

PT J
AU Mansoorianfar, M
   Shokrgozar, MA
   Mehrjoo, M
   Tamjid, E
   Simchi, A
AF Mansoorianfar, Mojtaba
   Shokrgozar, Mohammad Ali
   Mehrjoo, Morteza
   Tamjid, Elnaz
   Simchi, Arash
TI Nanodiamonds for surface engineering of orthopedic implants: Enhanced
   biocompatibility in human osteosarcoma cell culture
SO DIAMOND AND RELATED MATERIALS
LA English
DT Article
DE Nanodiamond; Electrophoresis; Polysaccharide; Nanocomposite; Cell
   viability
ID ELECTROPHORETIC DEPOSITION; BIOACTIVE GLASS; CARBON NANOTUBES; COMPOSITE
   COATINGS; DRUG DELIVERY; PARTICLES; PHOSPHATE; NANOCOMPOSITES;
   NANOPARTICLES; SCAFFOLDS
AB Recently, nanodiamonds have attracted interest in biomedical applications such as drug delivery, targeted cancer therapies, fabrication of tissue scaffolds, and biosensors. We incorporated diamond nanoparticles in alginate bioactive glass films by electrophoretic process to prepare functional coatings for biomedical implants. Turbidity examination by time resolved laser transmittance measurement revealed that a stable multi component aqueous suspension of alginate, bioactive glass and diamond particles could be obtained at concentrations of 0.6, 1.3, and 0.65 g/I, respectively. Uniform films with similar to 5 mu m thickness were deposited on 316 stainless steel foils by employing constant field strength of 15 V/cm for 45s. Scanning electron microscopy and simultaneous thermal analysis showed that the composite films were homogeneous and contained similar to 39 wt% inorganic particles. In vitro bioactivity assessment in simulated body fluid for 4 weeks and 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MU) assay using human osteoblast like cell line (MG 63) and mouse fibroblast cell line (L929) exhibited enhanced biocompatibility and bioactivity of the composite films. Results show advantages of alginate nanodiamonds in cell culture, tissue engineering, and pharmaceutical applications. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Mansoorianfar, Mojtaba; Simchi, Arash] Sharif Univ Technol, Dept Mat Sci & Engn, Tehran, Iran.
   [Shokrgozar, Mohammad Ali; Mehrjoo, Morteza] Inst Pasteur, Natl Cell Bank, Tehran 1316943551, Iran.
   [Tamjid, Elnaz; Simchi, Arash] Sharif Univ Technol, Inst Nanosci & Nanotechnol, Tehran, Iran.
   [Tamjid, Elnaz] Sharif Univ Technol, Inst Biotechnol & Environm Res, Tehran, Iran.
C3 Sharif University of Technology; Pasteur Network; Pasteur Institute of
   Iran; Sharif University of Technology; Sharif University of Technology
RP Simchi, A (通讯作者)，Sharif Univ Technol, Dept Mat Sci & Engn, Tehran, Iran.
EM simchi@sharif.edu
RI shokrgozar, mohammad/L 4149 2017; shokrgozar, mohammad ali/L 4149 2017;
   Simchi, Abdolreza/X 7831 2018; Mansoorianfar, Mojtaba/AAA 8521 2020
OI shokrgozar, mohammad ali/0000 0001 5123 4155; Mehrjoo,
   Morteza/0000 0002 8072 728X; Simchi, Abdolreza/0000 0002 9111 2977; 
CR Affoune AM, 2001, LANGMUIR, V17, P547, DOI 10.1021/la001317f
   ANDERSSON OH, 1991, J BIOMED MATER RES, V25, P1019, DOI 10.1002/jbm.820250808
   Armentano I, 2010, POLYM DEGRAD STABIL, V95, P2126, DOI 10.1016/j.polymdegradstab.2010.06.007
   Besra L, 2007, PROG MATER SCI, V52, P1, DOI 10.1016/j.pmatsci.2006.07.001
   Boccaccini AR, 2007, ADV FUNCT MATER, V17, P2815, DOI 10.1002/adfm.200600887
   Boccaccini AR, 2010, COMPOS SCI TECHNOL, V70, P1764, DOI 10.1016/j.compscitech.2010.06.002
   Chen QZZ, 2006, BIOMATERIALS, V27, P2414, DOI 10.1016/j.biomaterials.2005.11.025
   Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078 0432.CCR 07 1441
   Chung PH, 2006, DIAM RELAT MATER, V15, P622, DOI 10.1016/j.diamond.2005.11.019
   Doostmohammadi A, 2011, CERAM INT, V37, P2311, DOI 10.1016/j.ceramint.2011.03.026
   Fraczek A, 2008, ACTA BIOMATER, V4, P1593, DOI 10.1016/j.actbio.2008.05.018
   Giuseppe S.A. Longo Sorbello., 2006, Cytotoxicity and Cell Growth Assays, cell and tissue culture: assorted techniques, P315, DOI [10.1016/B978 012164730 8/50039 3, DOI 10.1016/B978 012164730 8/50039 3]
   Graham S, 1996, J CRYST GROWTH, V165, P106, DOI 10.1016/0022 0248(95)00994 9
   Grausova L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020943
   Hench LL, 2006, J MATER SCI MATER M, V17, P967, DOI 10.1007/s10856 006 0432 z
   Huang HJ, 2008, ACS NANO, V2, P203, DOI 10.1021/nn7000867
   Huang TS, 2004, DIAM RELAT MATER, V13, P1098, DOI 10.1016/j.diamond.2003.11.047
   Jain N, 2010, ASIAN J PHARM CLIN R, V3, P159
   Jirka I, 2013, MAT SCI ENG C MATER, V33, P1636, DOI 10.1016/j.msec.2012.12.073
   Kim HW, 2005, BIOMATERIALS, V26, P4395, DOI 10.1016/j.biomaterials.2004.11.008
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Lam R, 2008, ACS NANO, V2, P2095, DOI 10.1021/nn800465x
   Liu KK, 2009, BIOMATERIALS, V30, P4249, DOI 10.1016/j.biomaterials.2009.04.056
   Ma J, 2003, BIOMATERIALS, V24, P3505, DOI 10.1016/S0142 9612(03)00203 5
   Meng DC, 2009, J MATER SCI MATER M, V20, P2139, DOI 10.1007/s10856 009 3770 9
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Pishbin F, 2011, SURF COAT TECH, V205, P5260, DOI 10.1016/j.surfcoat.2011.05.026
   POWERS RW, 1975, J ELECTROCHEM SOC, V122, P490, DOI 10.1149/1.2134246
   Puzyr AP, 2007, DIAM RELAT MATER, V16, P2124, DOI 10.1016/j.diamond.2007.07.025
   Qureshi A, 2010, DIAM RELAT MATER, V19, P457, DOI 10.1016/j.diamond.2010.01.012
   Rahaman MN, 2011, ACTA BIOMATER, V7, P2355, DOI 10.1016/j.actbio.2011.03.016
   Raynaud S, 2002, BIOMATERIALS, V23, P1073, DOI 10.1016/S0142 9612(01)00219 8
   Russell A.J., 2000, BIOMEDICAL ENG HDB, P672
   Schausten MC, 2010, CERAM INT, V36, P307, DOI 10.1016/j.ceramint.2009.09.008
   Schrand AM, 2007, DIAM RELAT MATER, V16, P2118, DOI 10.1016/j.diamond.2007.07.020
   Schrand AM, 2009, CRIT REV SOLID STATE, V34, P18, DOI 10.1080/10408430902831987
   Shen L, 2009, J MATER SCI MATER M, V20, P2259, DOI 10.1007/s10856 009 3785 2
   Shenderova O, 2007, DIAM RELAT MATER, V16, P1213, DOI 10.1016/j.diamond.2006.11.086
   Shenderova OA, 2002, CRIT REV SOLID STATE, V27, P227, DOI 10.1080/10408430208500497
   Shimkunas RA, 2009, BIOMATERIALS, V30, P5720, DOI 10.1016/j.biomaterials.2009.07.004
   Simchi A, 2009, MATER LETT, V63, P2253, DOI 10.1016/j.matlet.2009.07.046
   Stappers L, 2008, J COLLOID INTERF SCI, V328, P436, DOI 10.1016/j.jcis.2008.09.022
   Tamjid E., 2013, J BIOMED MATER RES A, DOI DOI 10.1002/JBM.A34584
   Tasman AJ, 2000, LARYNGO RHINO OTOL, V79, P30
   Thein Han WW, 2009, ACTA BIOMATER, V5, P1182, DOI 10.1016/j.actbio.2008.11.025
   Thomas V, 2012, ACTA BIOMATER, V8, P1939, DOI 10.1016/j.actbio.2012.01.033
   Vernon L., 2012, Bone regeneration
   Wang HD, 2010, DIAM RELAT MATER, V19, P441, DOI 10.1016/j.diamond.2010.01.032
   Williams OA, 2010, ACS NANO, V4, P4824, DOI 10.1021/nn100748k
   Xing Y, 2009, NANOMEDICINE UK, V4, P207, DOI 10.2217/17435889.4.2.207
   Zhang QW, 2011, BIOMATERIALS, V32, P87, DOI 10.1016/j.biomaterials.2010.08.090
   Zhang XY, 2010, TOXICOL LETT, V198, P237, DOI 10.1016/j.toxlet.2010.07.001
   Zhitomirsky D, 2009, J MATER PROCESS TECH, V209, P1853, DOI 10.1016/j.jmatprotec.2008.04.034
   Zhitomirsky I, 1997, J MATER SCI MATER M, V8, P213, DOI 10.1023/A:1018587623231
   Zhitomirsky I., 2000, J EUR CERAM SOC, V20, P646
   Zhu Y, 2012, THERANOSTICS, V2, P302, DOI 10.7150/thno.3627
NR 56
TC 30
Z9 31
U1 2
U2 47
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925 9635
EI 1879 0062
J9 DIAM RELAT MATER
JI Diam. Relat. Mat.
PD NOV
PY 2013
VL 40
BP 107
EP 114
DI 10.1016/j.diamond.2013.10.012
PG 8
WC Materials Science, Multidisciplinary; Materials Science, Coatings &
   Films; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Physics
GA 282DN
UT WOS:000329150600017
DA 2025 08 17
ER

PT J
AU Glendenning, P
   Inderjeeth, CA
AF Glendenning, Paul
   Inderjeeth, Charles A.
TI Screening for vitamin D deficiency: defining vitamin D deficiency,
   target thresholds of treatment and estimating the benefits of treatment
SO PATHOLOGY
LA English
DT Article
DE Cost benefit analyses; target of therapy; vitamin D
ID SERUM 25 HYDROXYVITAMIN D; RANDOMIZED CONTROLLED TRIALS; BONE MINERAL
   DENSITY; HIP FRACTURES; D INSUFFICIENCY; CARDIOVASCULAR DISEASE;
   PARATHYROID HORMONE; CLINICAL PRACTICE; DECISION LIMITS; CALCIUM INTAKE
AB Vitamin D sufficiency has been associated with improved health outcomes but cost benefit analyses of published data adopt a number of assumptions. Firstly, definitions of vitamin D deficiency vary Secondly, available methods used for the analysis of 25 hydroxyvitamin D (25OHD) have significant limitations which could affect the adoption of specific target thresholds for treatment. Thirdly, although a variety of diseases are associated with vitamin D deficiency, randomised clinical trial data demonstrating the benefit of vitamin D supplementation only exist for the prevention of falls or fractures. This review will summarise the current evidence regarding an appropriate target threshold of 25OHD and review proposed therapeutic target thresholds of treatment. The limitations of current methods will be reviewed and objective data relating to the costs of diagnosis, the costs of treatment, and the level of evidence that screening could lessen disease burden in the community, will be provided. Finally, information needed by governments and health organisations to help justify population screening and what strategies could be adopted to make screening more cost effective will be explored.
C1 [Glendenning, Paul] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, Perth, WA 6000, Australia.
   [Glendenning, Paul; Inderjeeth, Charles A.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
   [Glendenning, Paul] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia.
   [Inderjeeth, Charles A.] N Metropolitan Hlth Serv, Area Rehab & Aged Care, Perth, WA, Australia.
C3 East Metropolitan Health Service; Royal Perth Hospital; University of
   Western Australia; University of Western Australia; University of
   Western Australia
RP Glendenning, P (通讯作者)，Royal Perth Hosp, Dept Core Clin Pathol & Biochem, North Block,Wellington St, Perth, WA 6000, Australia.
EM paul.glendenning@health.wa.gov.au
CR Aloia JF, 2007, EPIDEMIOL INFECT, V135, P1095, DOI 10.1017/S0950268807008308
   [Anonymous], 2002, EC BURD ILLN CAN 199
   Bischoff Ferrari HA, 2009, BMJ BRIT MED J, V339, DOI 10.1136/bmj.b3692
   Bischoff Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029
   Bischoff Ferrari HA, 2004, JAMA J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999
   Bischoff Ferrari HA, 2009, ARCH INTERN MED, V169, P551, DOI 10.1001/archinternmed.2008.600
   Boudville N, 2010, CLIN ENDOCRINOL, V73, P299, DOI 10.1111/j.1365 2265.2010.03821.x
   Carter GD, 2004, CLIN CHEM, V50, P2195, DOI 10.1373/clinchem.2004.040683
   Carter GD, 2011, CURR DRUG TARGETS, V12, P19
   Carter GD, 2009, ANN CLIN BIOCHEM, V46, P79, DOI 10.1258/acb.2008.008135
   Cauley JA, 2008, ANN INTERN MED, V149, P242, DOI 10.7326/0003 4819 149 4 200808190 00005
   Cavalier E, 2011, CLIN CHEM LAB MED, V49, P555, DOI 10.1515/CCLM.2011.072
   CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   Connell AB, 2011, PATHOLOGY, V43, P368, DOI 10.1097/PAT.0b013e328346431c
   Dawson Hughes B, 2010, OSTEOPOROSIS INT, V21, P1151, DOI 10.1007/s00198 010 1285 3
   Duque G, 2010, MED J AUSTRALIA, V193, P173, DOI 10.5694/j.1326 5377.2010.tb03839.x
   Ebeling PR, 2011, MED J AUSTRALIA, V194, P332, DOI 10.5694/j.1326 5377.2011.tb02999.x
   Ensrud KE, 2009, J CLIN ENDOCR METAB, V94, P2773, DOI 10.1210/jc.2008 2786
   Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174
   Glendenning P, 2006, ANN CLIN BIOCHEM, V43, P23, DOI 10.1258/000456306775141650
   Glendenning P, 2003, INTERN MED J, V33, P598, DOI 10.1111/j.1445 5994.2003.00484.x
   Glendenning P, 2003, AM J CLIN NUTR, V77, P522, DOI 10.1093/ajcn/77.2.522
   Glendenning P, 2003, ANN CLIN BIOCHEM, V40, P546, DOI 10.1258/000456303322326470
   Glendenning P, 2009, BONE, V45, P870, DOI 10.1016/j.bone.2009.07.015
   Grant WB, 2009, DERM ENDOCRINOL, V1, P37, DOI 10.4161/derm.1.1.7250
   Grant WB, 2010, MOL NUTR FOOD RES, V54, P1172, DOI 10.1002/mnfr.200900420
   Grant WB, 2009, PROG BIOPHYS MOL BIO, V99, P104, DOI 10.1016/j.pbiomolbio.2009.02.003
   Grethen E, 2011, J CLIN ENDOCR METAB, V96, P1320, DOI 10.1210/jc.2010 2202
   Hansen KE, 2008, J BONE MINER RES, V23, P1052, DOI 10.1359/JBMR.080230
   Heaney RP, 2003, J AM COLL NUTR, V22, P142, DOI 10.1080/07315724.2003.10719287
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI [10.1210/jc.2011 0385, 10.1210/jc.2011 1193]
   Institute of Medicine, 2011, DIETARY REFERENCE IN
   Jeng L, 2009, J TRANSL MED, V7, DOI 10.1186/1479 5876 7 28
   Jesudason D, 2002, BONE, V31, P626, DOI 10.1016/S8756 3282(02)00866 9
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P669, DOI 10.1007/s001980070064
   Knekt P, 2008, EPIDEMIOLOGY, V19, P666, DOI 10.1097/EDE.0b013e318176b8ad
   Kuchuk NO, 2009, J CLIN ENDOCR METAB, V94, P1244, DOI 10.1210/jc.2008 1832
   Lappe JM, 2007, AM J CLIN NUTR, V85, P1586, DOI 10.1093/ajcn/85.6.1586
   Lips P, 2001, J CLIN ENDOCR METAB, V86, P1212, DOI 10.1210/jc.86.3.1212
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lips P, 1999, OSTEOPOROSIS INT, V9, P394, DOI 10.1007/s001980050162
   Lips P, 2007, J BONE MINER RES, V22, P1668, DOI 10.1359/JBMR.070716
   Lips P, 2010, CLIN ENDOCRINOL, V73, P277, DOI 10.1111/j.1365 2265.2009.03701.x
   Malabanan A, 1998, LANCET, V351, P805, DOI 10.1016/S0140 6736(05)78933 9
   Manson JE, 2011, NEW ENGL J MED, V364, P1385, DOI 10.1056/NEJMp1102022
   Noble JM, 2002, MED J AUSTRALIA, V177, P280, DOI 10.5694/j.1326 5377.2002.tb04775.x
   Nuti R, 2001, J INTERN MED, V250, P361, DOI 10.1046/j.1365 2796.2001.00895.x
   Peiris AN, 2008, MIL MED, V173, P1214, DOI 10.7205/MILMED.173.12.1214
   Phinney KW, 2008, AM J CLIN NUTR, V88, p511S, DOI 10.1093/ajcn/88.2.511S
   Pilz S, 2008, STROKE, V39, P2611, DOI 10.1161/STROKEAHA.107.513655
   Pittas AG, 2006, DIABETES CARE, V29, P650, DOI 10.2337/diacare.29.03.06.dc05 1961
   Seymour HM, 2005, MED J AUSTRALIA, V183, P213, DOI 10.5694/j.1326 5377.2005.tb07001.x
   Shah I, 2011, NUTR J, V10, DOI 10.1186/1475 2891 10 46
   Singh RJ, 2006, J CLIN ENDOCR METAB, V91, P3055, DOI 10.1210/jc.2006 0710
   Slomski A, 2011, JAMA J AM MED ASSOC, V305, P453, DOI 10.1001/jama.2011.50
   Souberbielle JC, 2010, AUTOIMMUN REV, V9, P709, DOI 10.1016/j.autrev.2010.06.009
   Steingrimsdottir L, 2005, JAMA J AM MED ASSOC, V294, P2336, DOI 10.1001/jama.294.18.2336
   Stepman HCM, 2011, CLIN CHEM LAB MED, V49, P253, DOI 10.1515/CCLM.2011.050
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140 6736(07)61342 7
   Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201
   Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127
   Wharton B, 2003, LANCET, V362, P1389, DOI 10.1016/S0140 6736(03)14636 3
   Willis MS, 2002, INT J TECHNOL ASSESS, V18, P791, DOI 10.1017/S0266462302000600
NR 64
TC 11
Z9 12
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0031 3025
EI 1465 3931
J9 PATHOLOGY
JI Pathology
PD FEB
PY 2012
VL 44
IS 2
BP 160
EP 165
DI 10.1097/PAT.0b013e32834e8df6
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA 937CC
UT WOS:000303635600015
PM 22186673
DA 2025 08 17
ER

PT J
AU Mori, S
   Kou, I
   Sato, H
   Emi, M
   Ito, H
   Hosoi, T
   Ikegawa, S
AF Mori, Seijiro
   Kou, Ikuyo
   Sato, Hidenori
   Emi, Mitsuru
   Ito, Hideki
   Hosoi, Takayuki
   Ikegawa, Shiro
TI Nucleotide variations in genes encoding carbonic anhydrase 8 and 10
   associated with femoral bone mineral density in Japanese female with
   osteoporosis
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Association study; Bone mineral density; CA8; CA10; Single nucleotide
   polymorphism
ID POLYMORPHISM; THERAPY; WOMEN
AB Osteoporosis is a multi factorial common disease, which is caused by combination of genetic as well as environmental factors. Among several factors, osteoclast acidification pathways during bone resorption might play an important role. Carbonic anhydrases, consisting of a gene family, are essential for pH regulation by the osteoclast. Clinically, use of carbonic anhydrase inhibitors has been known to be associated with a bone sparing effect as judged by spine bone mineral density (BMD). Here, we investigated single nucleotide polymorphisms (SNPs) in carbonic anhydrase genes that are expressed in bone tissues, i.e., CA8 and CA10, for possible association with femoral and lumbar BMD among 337 Japanese women with osteoporosis participated in BioBank Japan project. Significant correlation was observed between CA8 SNP, rs6984526, and femoral BMD (P = 0.00029); homozygous carriers of the major (C) allele (n = 166) had the highest BMD (0.754 +/  A 0.006 g/cm(2), mean +/  A SD), while heterozygous carriers (n = 135) were intermediate (0.741 +/  A 0.07 g/cm(2)) and homozygous T allele carriers (n = 31) had the lowest BMD (0.691 +/  A 0.012 g/cm(2)). CA8 SNP as well displayed significant association with lumbar BMD in recessive model (P = 0.00017). In addition, CA10 SNP, rs2106329, also displayed strong association with femoral BMD (P = 0.00002). The results suggest that the variations of CA8 and CA10 loci may be important determinants of osteoporosis in Japanese women.
C1 [Mori, Seijiro] Tokyo Metropolitan Geriatr Hosp, Dept Internal Med, Itabashi Ku, Tokyo 1730015, Japan.
   [Kou, Ikuyo; Sato, Hidenori; Ito, Hideki; Hosoi, Takayuki] RIKEN, SNP Res Ctr, Tokyo, Japan.
   [Sato, Hidenori; Emi, Mitsuru] HuBit Genomix Res Inst, Tokyo, Japan.
   [Sato, Hidenori; Emi, Mitsuru] DNA Chip Res Inst, Yokohama, Kanagawa, Japan.
   [Hosoi, Takayuki] Natl Ctr Geriatr & Gerontol, Aichi, Japan.
C3 RIKEN; DNA Chip Research Inc.; National Center for Geriatrics &
   Gerontology
RP Mori, S (通讯作者)，Tokyo Metropolitan Geriatr Hosp, Dept Internal Med, Itabashi Ku, 35 2 Sakae Cho, Tokyo 1730015, Japan.
EM mori_seijiro@tmgh.metro.tokyo.jp
RI Ikegawa, Shiro/N 6895 2015
OI Kou, Ikuyo/0009 0005 2442 9965
FU Ministry of Education, Culture, Sports, Science and Technology ( MEXT).
FX We appreciate all the volunteers and participating institutions of
   BioBank Japan, University of Tokyo, Institute of Medical Science, Japan,
   for precious clinical data and samples. We also thank Prof. Yusuke
   Nakamura and Dr. Michiaki Kubo in RIKEN SNP Research Center, Tokyo,
   Japan, for their generous support in accomplishment of this work. The
   BioBank Japan Project on the implementation of personalized medicine was
   supported by the Ministry of Education, Culture, Sports, Science and
   Technology ( MEXT).
CR Albagha OME, 2003, ENDOCRIN METAB CLIN, V32, P65, DOI 10.1016/S0889 8529(02)00059 2
   Breton S, 2001, JOP, V2, P159
   KENNY AD, 1985, PHARMACOLOGY, V31, P97, DOI 10.1159/000138104
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Liu YZ, 2003, J ENDOCRINOL, V177, P147, DOI 10.1677/joe.0.1770147
   Mein CA, 2000, GENOME RES, V10, P330, DOI 10.1101/gr.10.3.330
   Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001
   Ota N, 2001, J HUM GENET, V46, P267, DOI 10.1007/s100380170077
   Peacock M, 2002, ENDOCR REV, V23, P303, DOI 10.1210/er.23.3.303
   PIERCE WM, 1991, J BONE MINER RES, V6, P347
   Rousselle AV, 2002, BONE, V30, P533, DOI 10.1016/S8756 3282(02)00672 5
   Taniuchi K, 2002, NEUROSCIENCE, V112, P93, DOI 10.1016/S0306 4522(02)00066 0
   Tsukamoto K, 2000, J BONE MINER METAB, V18, P27, DOI 10.1007/s007740050006
NR 13
TC 12
Z9 13
U1 0
U2 2
PU SPRINGER TOKYO
PI TOKYO
PA 1 11 11 KUDAN KITA, CHIYODA KU, TOKYO, 102 0073, JAPAN
SN 0914 8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2009
VL 27
IS 2
BP 213
EP 216
DI 10.1007/s00774 008 0031 9
PG 4
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 411JS
UT WOS:000263646400013
PM 19172221
DA 2025 08 17
ER

PT J
AU Muñoz Garcia, J
   Vargas Franco, JW
   Brounais Le Royer, B
   Cochonneau, D
   Amiaud, J
   Heymann, MF
   Heymann, D
   Lézot, F
AF Munoz Garcia, Javier
   William Vargas Franco, Jorge
   Brounais Le Royer, Benedicte
   Cochonneau, Denis
   Amiaud, Jerome
   Heymann, Marie Francoise
   Heymann, Dominique
   Lezot, Frederic
TI Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone
   Protective Action of RANKL Inhibition and Reduces Metastatic
   Dissemination in Osteosarcoma
SO CANCERS
LA English
DT Article
DE osteosarcoma; RANKL; endothelin; bone protection; metastases
ID NF KAPPA B; ZOLEDRONIC ACID; DOWN REGULATION; MESSENGER RNA; OPEN LABEL;
   EXPRESSION; CHEMOTHERAPY; EURAMOS 1; CELLS
AB Simple Summary The efficacy of current osteosarcoma therapy is diminished by two adverse events, namely resistance to chemotherapy and metastatic dissemination. In recent decades, research has been devoted to reducing these adverse events. Inhibiting bone resorption has shown promising effects on metastatic dissemination and tumor growth, with, however, the formation of significant tumoral mineralized tissue. Endothelin signaling is implicated in activating the cell that forms the mineralized tissues, consequently the impact of inhibiting it alone and in combination with the inhibition of bone resorption was evaluated using osteosarcoma models. The results obtained showed that inhibiting endothelin signaling significantly reduced the formation of mineralized tumor tissue concomitantly to metastatic dissemination without affecting sensitivity to chemotherapy. This inhibition appears to be a promising new therapeutic tool in the fight against osteosarcoma. Current treatments for osteosarcoma, combining conventional polychemotherapy and surgery, make it possible to attain a five year survival rate of 70% in affected individuals. The presence of chemoresistance and metastases significantly shorten the patient's lifespan, making identification of new therapeutic tools essential. Inhibiting bone resorption has been shown to be an efficient adjuvant strategy impacting the metastatic dissemination of osteosarcoma, tumor growth, and associated bone destruction. Unfortunately, over apposition of mineralized matrix by normal and tumoral osteoblasts was associated with this inhibition. Endothelin signaling is implicated in the functional differentiation of osteoblasts, raising the question of the potential value of inhibiting it alone, or in combination with bone resorption repression. Using mouse models of osteosarcoma, the impact of macitentan, an endothelin receptor inhibitor, was evaluated regarding tumor growth, metastatic dissemination, matrix over apposition secondary to RANKL blockade, and safety when combined with chemotherapy. The results showed that macitentan has no impact on tumor growth or sensitivity to ifosfamide, but significantly reduces tumoral osteoid tissue formation and the metastatic capacity of the osteosarcoma. To conclude, macitentan appears to be a promising therapeutic adjuvant for osteosarcoma alone or associated with bone resorption inhibitors.
C1 [Munoz Garcia, Javier; Cochonneau, Denis; Heymann, Marie Francoise; Heymann, Dominique] Inst Cancerol Ouest, F 44805 Saint Herblain, France.
   [William Vargas Franco, Jorge] Univ Antioquia, Fac Odontol, Dept Basic Studies, Medellin 53108, Colombia.
   [Brounais Le Royer, Benedicte; Amiaud, Jerome] Nantes Univ, F 44000 Nantes, France.
   [Heymann, Dominique] Nantes Univ, US2B, CNRS, UMR 6286, F 44322 Nantes, France.
   [Heymann, Dominique] Univ Sheffield, Med Sch, Dept Oncol & Metab, Sheffield S10 2TN, S Yorkshire, England.
   [Lezot, Frederic] Sorbonne Univ, Hop Trousseau, AP HP, INSERM,UMR933, F 75012 Paris, France.
C3 Universidad de Antioquia; Nantes Universite; Nantes Universite; Centre
   National de la Recherche Scientifique (CNRS); CNRS   National Institute
   for Biology (INSB); University of Sheffield; Assistance Publique
   Hopitaux Paris (APHP); Sorbonne Universite; Hopital Universitaire
   Armand Trousseau   APHP; Institut National de la Sante et de la
   Recherche Medicale (Inserm)
RP Lézot, F (通讯作者)，Sorbonne Univ, Hop Trousseau, AP HP, INSERM,UMR933, F 75012 Paris, France.
EM javier.munoz@ico.unicancer.fr; jorge.vargas@udea.edu.co;
   benedicte.brounais@univ nantes.fr; denis.cochonneau@ico.unicancer.fr;
   jerome.amiaud@univ nantes.fr; marie francoise.heymann@ico.unicancer.fr;
   dominique.heymann@univ nantes.fr; frederic.lezot@inserm.fr
RI MUNOZ, Javier/IQW 9374 2023; Lezot, Frederic/K 8075 2015; ROYER,
   Bénédicte/AAY 8894 2020; Heymann, Dominique/AAC 6014 2019
OI Heymann, Dominique/0000 0001 7777 0669; Heymann,
   Marie Francoise/0000 0002 5585 8261; /0000 0002 4556 9853; Munoz Garcia,
   Javier/0000 0002 2978 1192; Lezot, Frederic/0000 0001 6274 6981; 
FU La Ligue contre le Cancer, Comite 44 et 49
FX This research was funded by "La Ligue contre le Cancer, Comite 44 et 49"
   to Frederic Lezot.
CR ASADA S, 1995, J CARDIOVASC PHARM, V26, pS272
   Battaglia S, 2011, J BONE MINER RES, V26, P2439, DOI 10.1002/jbmr.453
   Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006 0346
   Clines GA, 2011, J BONE MINER RES, V26, P2523, DOI 10.1002/jbmr.450
   Davenport AP, 2016, PHARMACOL REV, V68, P357, DOI 10.1124/pr.115.011833
   Felx M, 2006, CLIN SCI, V110, P645, DOI 10.1042/CS20050286
   Gama A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040898
   Gama Andrea, 2019, Orthod Fr, V90, P55, DOI 10.1051/orthodfr/2019008
   Grunewald TGP, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911131
   Heymann MF, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115523
   Hu LW, 2017, EXP CELL RES, V357, P25, DOI 10.1016/j.yexcr.2017.04.018
   Isawa M, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 56151 1
   Jacques C, 2018, J BONE ONCOL, V12, P7, DOI 10.1016/j.jbo.2018.02.004
   Johnson MG, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13088
   Joliat MJ, 2002, IN VIVO, V16, P223
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797
   Kristianto J, 2017, ENDOCRIN METAB CLIN, V46, P51, DOI 10.1016/j.ecl.2016.09.014
   Lee MS, 2019, FASEB J, V33, P996, DOI 10.1096/fj.201800614R
   LEE SK, 1995, J BONE MINER RES, V10, P1343
   Lézot F, 2015, BONE, V73, P51, DOI 10.1016/j.bone.2014.12.011
   Lézot F, 2014, BONE, V68, P146, DOI 10.1016/j.bone.2014.08.018
   Li Xinyue, 2010, J Oral Sci, V52, P221
   Li Y, 2012, MOL MED REP, V5, P1391, DOI 10.3892/mmr.2012.842
   Liu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093576
   Liu B, 2013, ONCOL LETT, V5, P505, DOI 10.3892/ol.2012.1056
   Marina NM, 2016, LANCET ONCOL, V17, P1396, DOI 10.1016/S1470 2045(16)30214 5
   Marion A, 2012, INT J CANCER, V130, P2514, DOI 10.1002/ijc.26246
   Mödder UI, 2011, J CELL BIOCHEM, V112, P1392, DOI 10.1002/jcb.23048
   NAMBI P, 1995, MOL PHARMACOL, V47, P266
   Navet B, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110426
   Navet B, 2018, CANCERS, V10, DOI 10.3390/cancers10110398
   Neumann ZL, 2015, J VET INTERN MED, V29, P1584, DOI 10.1111/jvim.13635
   Piperno Neumann S, 2016, LANCET ONCOL, V17, P1070, DOI 10.1016/S1470 2045(16)30096 1
   SAKURAI T, 1992, BIOCHEM BIOPH RES CO, V186, P342, DOI 10.1016/S0006 291X(05)80813 7
   Selej M, 2015, ANN NY ACAD SCI, V1358, P68, DOI 10.1111/nyas.12856
   SEMLER DE, 1995, J PHARMACOL EXP THER, V272, P1052
   SHIOIDE M, 1993, J CELL BIOCHEM, V53, P176, DOI 10.1002/jcb.240530211
   Sin A, 2015, OSTEOARTHR CARTILAGE, V23, P516, DOI 10.1016/j.joca.2014.11.002
   Smeland S, 2019, EUR J CANCER, V109, P36, DOI 10.1016/j.ejca.2018.11.027
   Someya A, 2006, EUR J PHARMACOL, V543, P14, DOI 10.1016/j.ejphar.2006.06.035
   Stark Z, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750 1172 4 5
   Suzuki A, 1997, BONE, V21, P143, DOI 10.1016/S8756 3282(97)00096 3
   Vargas Franco JW, 2019, BIOCHEM PHARMACOL, V168, P133, DOI 10.1016/j.bcp.2019.06.027
   Zang XF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073349
   Zhao YT, 2011, CLIN ORTHOP RELAT R, V469, P3190, DOI 10.1007/s11999 011 1939 2
   Zhou Y, 2014, PEDIATR BLOOD CANCER, V61, P612, DOI 10.1002/pbc.24790
NR 47
TC 4
Z9 4
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD APR
PY 2022
VL 14
IS 7
AR 1765
DI 10.3390/cancers14071765
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 0L5CJ
UT WOS:000781491000001
PM 35406536
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, XH
   Sui, X
   Yang, Q
   Li, YQ
   Li, N
   Shi, XZ
   Han, D
   Li, YP
   Huang, XW
   Yu, P
   Qu, XB
AF Li, Xiaohua
   Sui, Xin
   Yang, Qing
   Li, Yinqing
   Li, Na
   Shi, Xiaozheng
   Han, Dong
   Li, Yiping
   Huang, Xiaowei
   Yu, Peng
   Qu, Xiaobo
TI Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by
   regulating TGF/BMP2 signaling
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE ORPH; Menopausal osteoporosis; TGF; BMP2; BMD; ALP
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; BONE MORPHOGENETIC PROTEIN 2;
   OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; POSTMENOPAUSAL
   WOMEN; GENE; POLYMORPHISMS; MUTATIONS; TERM
AB PurposeIt is known that menopausal osteoporosis (MOP) is the most typical form of osteoporosis, which is characterized by low bone mass and microstructure damage of the bone tissue, leading to increased bone fragility and risk of fracture. This study aimed to evaluate the protective effects of Oviductus Ranae protein hydrolyzate (ORPH) on the MOP in vivo.MethodsOsteoporosis model was induced by ovariectomy, treated with ORPH 150 or 75mgkg( 1). Body weight and bone mineral density (BMD) of rats were measured at the beginning and the end of the experiment, and femoral maximum load was determined immediately after killing. The expression levels of alkaline phosphatase (ALP), Smad4, tartrate acid phosphatase (TRAP), BMP2, Runx2, CPB, ColI and osteocalcin were examined by RT PCR or western blotting. HE staining was used to observe the pathological changes in the femurs. Immunohistochemistry was used to detect the expression of ALP and BMP2. All data were analyzed by SPSS 13.0.ResultsThe results revealed that ORPH had no effect on the weight of normal and osteoporotic rats. ORPH could significantly improve the femur BMD and increase the maximum load of the osteoporotic rats. ORPH could significantly upregulate the expression level of bone formation makers, ALP, osteocalcin, ColI, and Runx2, and downregulate the expression level of bone resorption marker, TRAP. In the ORPH group, the expression levels of BMP2, Smad4, and CPB of key proteins in the TGF/BMP2 signaling pathway were significantly upregulated. In addition, immunohistochemistry showed that ALP and BMP2 expression in femurs of the ORPH group was stranger. H&E staining showed that ORPH (150mgkg( 1)) significantly increased the thickness of trabeculae and decreased fracture risk.ConclusionCollectively, ORPH plays a role in the prevention and treatment of osteoporosis, which may be a potential anti osteoporosis drug.
C1 [Li, Xiaohua; Yang, Qing; Li, Yinqing; Li, Na; Shi, Xiaozheng; Han, Dong; Li, Yiping; Huang, Xiaowei; Yu, Peng; Qu, Xiaobo] Changchun Univ Chinese Med, Boshuo Rd 1035, Changchun 130117, Jilin, Peoples R China.
   [Sui, Xin] Changchun Univ Chinese Med, Affiliated Hosp, Changchun 130021, Jilin, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of
   Chinese Medicine
RP Qu, XB (通讯作者)，Changchun Univ Chinese Med, Boshuo Rd 1035, Changchun 130117, Jilin, Peoples R China.
EM xiaohua130319@163.com; 631731843@qq.com; 782830740@qq.com;
   liyinqing2168@qq.com; 646265404@qq.com; jilinsxz@sina.com;
   857269316@qq.com; 2863990015@qq.com; 1132753082@qq.com;
   342905933@qq.com; quxiaobo0504@hotmail.com
RI Han, Dong/GXG 5929 2022; Li, YiPing/ICL 4465 2023
OI li, xiaohua/0000 0002 3794 4211; Han, Dong/0000 0002 1150 9748; 
FU Jilin Province Traditional Chinese Medicine Science and Technology
   Project [2017002, 2018024]; Jilin Provincial Department of Education
   Science Research Project [JJKH20181266KJ]; Jilin province science and
   technology backbone training project for health and hygiene [2018Q043]
FX This study was funded by the Jilin Province Traditional Chinese Medicine
   Science and Technology Project (2017002, 2018024); the Jilin Provincial
   Department of Education Science Research Project (JJKH20181266KJ); the
   Jilin province science and technology backbone training project for
   health and hygiene (2018Q043).
CR [Anonymous], 2010, PHARM PEOPLES REPU 1, P239
   Cairoli E, 2015, J ENDOCRINOL INVEST, V38, P303, DOI 10.1007/s40618 014 0236 9
   CHARLES P, 1985, J CLIN INVEST, V76, P2254, DOI 10.1172/JCI112234
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   DELMAS PD, 1985, BONE, V6, P339, DOI 10.1016/8756 3282(85)90326 6
   Du X, 1998, NAT PROD RES DEV, V04, P94
   Feldbrin Z, 2016, MENOPAUSE, V23, P55, DOI 10.1097/GME.0000000000000480
   Feng M, 2014, J STEROID BIOCHEM, V144, P455, DOI 10.1016/j.jsbmb.2014.09.005
   Gundberg CM, 2000, CLIN LAB MED, V20, P489
   Ji GR, 2009, J INT MED RES, V37, P1725, DOI 10.1177/147323000903700608
   Jin H, 2011, OSTEOPOROSIS INT, V22, P911, DOI 10.1007/s00198 010 1364 5
   Jönsson S, 2012, J BONE MINER METAB, V30, P119, DOI 10.1007/s00774 011 0323 3
   Kanzler B, 2000, DEVELOPMENT, V127, P1095
   Lee AJ, 2000, ANN CLIN BIOCHEM, V37, P432, DOI 10.1258/0004563001899573
   Liang Lei, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P982
   Medici M, 2006, J BONE MINER RES, V21, P845, DOI 10.1359/JBMR.060306
   Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316
   Mousavi A, 2014, COMPUT INTEL NEUROSC, V14, P428
   Ohara N, 2004, BIOMATERIALS, V25, P1749, DOI 10.1016/j.biomaterials.2003.08.022
   Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Reid IR, 2015, NAT REV ENDOCRINOL, V11, P418, DOI 10.1038/nrendo.2015.71
   Rojano Mejía D, 2013, AGE, V35, P471, DOI 10.1007/s11357 011 9363 9
   Romas E, 2005, BEST PRACT RES CL RH, V19, P1065, DOI 10.1016/j.berh.2005.06.008
   Samir SM, 2014, J PHYSIOL PHARMACOL, V65, P687
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318
   Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343
   Wang DH, 2013, CHIN J INTEGR MED, V19, P532, DOI 10.1007/s11655 012 1220 x
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Yoshida T, 2003, BLOOD CELL MOL DIS, V30, P184, DOI 10.1016/S1079 9796(03)00020 2
   Zhang HB, 1996, DEVELOPMENT, V122, P2977
   Zhang XN, 2016, CHEM BIOL INTERACT, V256, P188, DOI 10.1016/j.cbi.2016.07.003
NR 34
TC 11
Z9 13
U1 1
U2 36
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0932 0067
EI 1432 0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD MAR
PY 2019
VL 299
IS 3
BP 873
EP 882
DI 10.1007/s00404 018 5033 9
PG 10
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA HM8VJ
UT WOS:000459760600033
PM 30649603
DA 2025 08 17
ER

PT J
AU Chen, J
   Zhang, LM
   Liu, CY
   Liang, YL
AF Chen, Jie
   Zhang, Limiao
   Liu, Chenyan
   Liang, Yuelei
TI MiR 497 5p promotes osteogenic/odontogenic differentiation of stem cells
   from the apical papilla by regulation of the TGF β Smad pathway through
   Smurf2
SO TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
LA English
DT Article
DE MiR 497 5p; Smurf2 regulation; TGF beta Smad route; Stem cells; Apical
   papilla (SCAP); Osteogenic/ odontogenic differentiation
ID METASTASIS; CARCINOMA; SURVIVAL
AB Purpose: To study the influence of miR 497 5p on osteogenic/odontogenic differentiation (OOD) of SCAP, and the signal route involved.
   Methods: Four groups were set up: miR 497 5p overexpression group (OEG), overexpression control OEC), miR 497 5p inhibition group, and inhibition control group. Alkaline phosphatase (ALP) activity was assayed, and calcified nodules measured. Protein expression levels of dentine salivary phosphoprotein (DSPP), collagen type I, ALP, osteoblast related factors (Runx2, OSX and OPN) were also assayed. The mRNA expression levels of osteogenesis/dentin related genes were determined.
   Results: ALP activity was significantly higher in miR 497 5p overexpression cells than in control, but was reduced, relative to inhibition control group (p < 0.05). The miR 497 5p OEG had significantly more calcified nodules than OEC (p < 0.05). There were markedly up regulated protein expressions in cells of miR 497 5p OEG than in OCG. Furthermore, protein expressions of Smad2, Smad3 and Smad4 in cells of miR 497 5p OEG were significantly up regulated, relative to those in OEC, but wer lower in miR 4975p inhibitory cells than in inhibitory cells.
   Conclusion: MiR 497 5p enhances the OOD of SCAP via a mechanism involving TGF beta Smad pathway and Smurf2. Thus, Mir 497 5p may be used as a target for OOD related drugs.
C1 [Chen, Jie; Zhang, Limiao; Liu, Chenyan; Liang, Yuelei] Zhejiang Zhoushan Putuo Peoples Hosp, Dept Stomatol, Zhoushan 316100, Peoples R China.
RP Zhang, LM (通讯作者)，Zhejiang Zhoushan Putuo Peoples Hosp, Dept Stomatol, Zhoushan 316100, Peoples R China.
EM eutt57@163.com
CR Cantore S, 2017, J BIOL REG HOMEOS AG, V31, P901
   Chrepa V, 2017, J ENDODONT, V43, P561, DOI 10.1016/j.joen.2016.09.024
   Ha M, 2020, DENT MATER, V36, P88, DOI 10.1016/j.dental.2019.10.013
   Hajizadeh Niusha, 2018, Iran Endod J, V13, P94, DOI 10.22037/iej.v13i1.17860
   Kang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6104738
   Karamali F, 2018, DIFFERENTIATION, V101, P8, DOI 10.1016/j.diff.2018.02.003
   Khosla R, 2019, LIVER INT, V39, P1692, DOI 10.1111/liv.14188
   [林诗晗 Lin Shihan], 2018, [实用口腔医学杂志, Journal of Practical Stomatology], V34, P239
   Liu JQ, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.582366
   Orimoto A, 2017, ARCH ORAL BIOL, V79, P7, DOI 10.1016/j.archoralbio.2017.02.019
   Pilarska M, 2016, PROTOPLASMA, V253, P345, DOI 10.1007/s00709 015 0814 5
   Scott MB, 2018, J ENDODONT, V44, P263, DOI 10.1016/j.joen.2017.09.001
   Wu YY, 2020, ADV CLIN EXP MED, V29, P777, DOI 10.17219/acem/121933
   Yang GC, 2016, CANCER LETT, V378, P80, DOI 10.1016/j.canlet.2016.05.007
   You Y H, 2016, J ORAL SCI RES, P733
   Zhang L, 2016, EXP CELL RES, V341, P157, DOI 10.1016/j.yexcr.2016.01.006
NR 16
TC 1
Z9 1
U1 0
U2 7
PU PHARMACOTHERAPY GROUP
PI BENIN CITY
PA UNIV BENIN, FACULTY PHARMACY, BENIN CITY, 00000, NIGERIA
SN 1596 5996
J9 TROP J PHARM RES
JI Trop. J. Pharm. Res.
PD JUN
PY 2021
VL 20
IS 6
BP 1113
EP 1118
DI 10.4314/tjpr.v20i6.2
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA TC2NE
UT WOS:000668477500002
OA gold
DA 2025 08 17
ER

PT J
AU Carvalho, RLD
   Leonardo, PSLM
   Mendes, GD
   Lima, FPS
   Lima, MO
   Marcos, RL
   Lopes Martins, RAB
AF de Paiva Carvalho, Rodrigo Leal
   Leonardo, P. S. L. M.
   Mendes, Gustavo Duarte
   Silva Lima, Fernanda Pupio
   Lima, Mario Oliveira
   Marcos, Rodrigo Labat
   Brandao Lopes Martins, Rodrigo Alvaro
TI Pharmacokinetic and Pharmacodynamics of Sodium Diclofenac (Topical and
   IM) Associated with Laser Photobiomodulation on Skeletal Muscle Strain
   in Rats
SO INTERNATIONAL JOURNAL OF PHOTOENERGY
LA English
DT Article
ID SKIN MICROCIRCULATION; THERAPY; IRRADIATION; SORENESS; EXERCISE;
   DELIVERY; FATIGUE; STIMULATION; ENHANCEMENT; DAMAGE
AB Purpose. The practice of physical activities is considered a primary factor for the maintenance of good health status. However, exhaustive or unusual physical activities can lead to muscle injuries. Several treatments are used to recover muscle injuries; however, systemic NSAIDs often result in serious adverse events. In this study, we aimed to investigate the association of laser therapy (LLLT) and topical diclofenac, evaluating the kinetics of the drug and its pharmacodynamic effect in stretching induced muscle injury in rats. Methods. Male Wistar rats weighing 200g were randomized and divided into groups of 6 animals. Plasma concentrations of diclofenac were quantified by mass spectrometry at different times (15min to 24 hours) in all animals. The laser energy used was 3 Joules (830nm; 100mW, 30s). Treated groups received diclofenac at the dose of 1mg/kg IM or topically applied with or without laser therapy. The electric stimulation was used to study the functional status of the muscles. Results. After topical administration of diclofenac, the peak plasma concentration (t max) occurred for 30 minutes in the irradiated group and 4 hours in the nonirradiated group. The AUC (0 24hs) was 442 (ng/h/mL( 1)) in the nonirradiated group and 712 (ng/h/mL( 1)) in the irradiated group. Conclusion. LLLT was effective to provide a significant improvement in functional patterns. Taken together, our results demonstrate the synergistic effect between LLLT and topical diclofenac in muscle injury induced by stretching in rats.
C1 [de Paiva Carvalho, Rodrigo Leal] Univ Estadual Paulista UNESP, Dept Phys Educ, Bauru, SP, Brazil.
   [Leonardo, P. S. L. M.; Brandao Lopes Martins, Rodrigo Alvaro] Univ Vale Paraiba UNIVAP, Lab Biophoton & Expt Therapeut, IP&D, Sao Jose Dos Campos, SP, Brazil.
   [Mendes, Gustavo Duarte] Univ Metropolitana Santos UNIMES, Programa Posgrad Saude & Meio Ambiente, Santos, SP, Brazil.
   [Mendes, Gustavo Duarte] Fac Med Sao Leopoldo Mandic, Campinas, SP, Brazil.
   [Silva Lima, Fernanda Pupio; Lima, Mario Oliveira] Univ Vale Paraiba UNIVAP, Lab Sensory Motor Rehabil, IP&D, Sao Jose Dos Campos, SP, Brazil.
   [Marcos, Rodrigo Labat] Univ Nove Julho, Postgrad Program Biophoton Appl Hlth Sci, Sao Paulo, Brazil.
C3 Universidade Estadual Paulista; Universidade do Vale do Paraiba;
   Faculdade Sao Leopoldo Mandic; Universidade do Vale do Paraiba;
   Universidade Nove de Julho
RP Lopes Martins, RAB (通讯作者)，Univ Vale Paraiba UNIVAP, Lab Biophoton & Expt Therapeut, IP&D, Sao Jose Dos Campos, SP, Brazil.
EM rodcarvalho2002@yahoo.com.br; patricia.martins@univap.br;
   mendesgd@yahoo.com.br; fpupiolima@gmail.com; mol@univap.br;
   labatrm@gmail.com; ralopesmartins@gmail.com
RI Lopes Martins, Rodrigo/E 2013 2013; Martins, Rodrigo/C 4337 2013; Lima,
   Fernanda/ABG 9245 2020; mendes, gustavo/K 3796 2012; Lima,
   Mário/ABG 9272 2020; Carvalho, Rodrigo/R 2107 2019; Marcos,
   Rodrigo/F 3524 2015
OI Lopes Martins, Rodrigo/0000 0002 4533 1335; Lima,
   Mario/0000 0001 9990 5296; Martins, Rodrigo/0000 0002 1997 7669; Leal de
   Paiva Carvalho, Rodrigo/0000 0002 0147 0122; Lima,
   Fernanda/0000 0001 9834 7800; MENDES, GUSTAVO/0000 0001 8700 5709;
   Leonardo Lopes Martins, Patricia Sardinha/0000 0002 7662 7702; 
FU FAPESP/CEPOF [2013/07276 1, 2015/06502 3]; CAPES, Brazil
FX This study was funded by FAPESP/CEPOF 2013/07276 1 and 2015/06502 3;
   Patricia Sardinha Leonardo Lopes Martins was supported by PhD
   Scholarship, CAPES, Brazil.
CR Amaral AC, 2001, LASER MED SCI, V16, P44, DOI 10.1007/PL00011336
   APPELL HJ, 1992, SPORTS MED, V13, P108, DOI 10.2165/00007256 199213020 00006
   Banning M, 2008, EXPERT OPIN PHARMACO, V9, P2921, DOI [10.1517/14656566.9.16.2921, 10.1517/14656566.9.16.2921 ]
   CHEN DB, 1995, HUM REPROD, V10, P2773, DOI 10.1093/oxfordjournals.humrep.a135790
   CLARKSON PM, 1986, INT J SPORTS MED, V7, P152, DOI 10.1055/s 2008 1025753
   du Souich P, 2017, PHARMACOL THERAPEUT, V175, P1, DOI 10.1016/j.pharmthera.2017.02.029
   FRIDEN J, 1986, J APPL PHYSIOL, V61, P2175, DOI 10.1152/jappl.1986.61.6.2175
   Gómez C, 2011, J PHARM SCI US, V100, P223, DOI 10.1002/jps.22270
   Ihsan FRM, 2005, PHOTOMED LASER SURG, V23, P289, DOI 10.1089/pho.2005.23.289
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jacobs TL, 2000, J PHYSIOL LONDON, V524, P929, DOI 10.1111/j.1469 7793.2000.00929.x
   Järvinen TAH, 2002, J MUSCLE RES CELL M, V23, P245, DOI 10.1023/A:1020904518336
   KAMI T, 1985, ANN PLAS SURG, V14, P278, DOI 10.1097/00000637 198503000 00013
   Karu TI, 1998, DOKL AKAD NAUK+, V360, P267
   Kazemikhoo N, 2016, LASER MED SCI, V31, P1537, DOI 10.1007/s10103 016 2012 x
   Kipshidze N, 2000, PHOTOCHEM PHOTOBIOL, V72, P579, DOI 10.1562/0031 8655(2000)072<0579:POVIAE>2.0.CO;2
   Lee S, 2002, LASER SURG MED, V31, P207, DOI 10.1002/lsm.10099
   Liu CH, 2010, LASER SURG MED, V42, P132, DOI 10.1002/lsm.20900
   Lopes Martins RAB, 2006, J APPL PHYSIOL, V101, P283, DOI 10.1152/japplphysiol.01318.2005
   Lopes Martins RAB, 2016, PHOTOMED LASER SURG, V34, P273, DOI 10.1089/pho.2016.4130
   MacIntyre DL, 1996, J APPL PHYSIOL, V80, P1006, DOI 10.1152/jappl.1996.80.3.1006
   Maegawa Y, 2000, LASER SURG MED, V27, P427, DOI 10.1002/1096 9101(2000)27:5<427::AID LSM1004>3.0.CO;2 A
   MagalhAes P, 2000, THESIS
   McAuliffe DJ, 1997, LASER SURG MED, V20, P216
   McCormack PL, 2008, DRUGS, V68, P123, DOI 10.2165/00003495 200868010 00008
   MIRO AM, 1989, CHEST, V96, P1430, DOI 10.1378/chest.96.6.1430
   Miyatake S, 2009, BRIT J CLIN PHARMACO, V67, P125, DOI 10.1111/j.1365 2125.2008.03333.x
   Moitra J, 2007, TRANSL RES, V150, P253, DOI 10.1016/j.trsl.2007.03.013
   NEWHAM DJ, 1983, J NEUROL SCI, V61, P109, DOI 10.1016/0022 510X(83)90058 8
   Nosaka K, 1997, J SPORT SCI, V15, P477, DOI 10.1080/026404197367119
   Oishi JC, 2017, LIFE SCI, V178, P56, DOI 10.1016/j.lfs.2017.04.011
   Leal ECP, 2009, PHOTOMED LASER SURG, V27, P617, DOI 10.1089/pho.2008.2350
   Plass CA, 2012, LASER SURG MED, V44, P705, DOI 10.1002/lsm.22075
   Ramos L, 2012, PHOTOCHEM PHOTOBIOL, V88, P154, DOI 10.1111/j.1751 1097.2011.01030.x
   Raphael AP, 2015, CURR PHARM DESIGN, V21, P2830, DOI 10.2174/1381612821666150428144852
   Roberts JM, 1999, BRIT J SPORT MED, V33, P259, DOI 10.1136/bjsm.33.4.259
   Rodrigues L. A., 2007, Revista de Ciencias Farmaceuticas Basica e Aplicada, V28, P45
   Samoilova KA, 2008, PHOTOMED LASER SURG, V26, P443, DOI 10.1089/pho.2007.2205
   Santos RS, 2002, ISOKINET EXERC SCI, V10, P153, DOI 10.3233/IES 2002 0096
   Schindl A, 2002, MICROVASC RES, V64, P240, DOI 10.1006/mvre.2002.2429
   Soares J., 1989, Rev Port Med Desp, V7, P187
   Stanos SP, 2007, J PAIN SYMPTOM MANAG, V33, P342, DOI 10.1016/j.jpainsymman.2006.11.005
   Thompson JL, 1999, ANAT REC, V254, P39, DOI 10.1002/(SICI)1097 0185(19990101)254:1<39::AID AR6>3.0.CO;2 K
   Twist C, 2005, EUR J APPL PHYSIOL, V94, P652, DOI 10.1007/s00421 005 1357 9
   Wright Carpenter T, 2004, INT J SPORTS MED, V25, P588, DOI 10.1055/s 2004 821304
NR 45
TC 4
Z9 4
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1110 662X
EI 1687 529X
J9 INT J PHOTOENERGY
JI Int. J. Photoenergy
PY 2019
VL 2019
AR 2782709
DI 10.1155/2019/2782709
PG 12
WC Chemistry, Physical; Energy & Fuels; Optics; Physics, Atomic, Molecular
   & Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Energy & Fuels; Optics; Physics
GA HP4NZ
UT WOS:000461654100001
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Liu, CX
   Yu, JZ
   Yang, Y
   Tang, XY
   Zhao, DM
   Zhao, WC
   Wu, H
AF Liu, Chaoxu
   Yu, Jizhe
   Yang, Yong
   Tang, Xiangyu
   Zhao, Dongming
   Zhao, Wenchun
   Wu, Hua
TI Effect of 1mT sinusoidal electromagnetic fields on proliferation and
   osteogenic differentiation of rat bone marrow mesenchymal stromal cells
SO BIOELECTROMAGNETICS
LA English
DT Article
DE electromagnetic field; stem cell; cytotoxicity; osteoblast;
   mineralization
ID DENERVATION DISUSE OSTEOPOROSIS; COUPLED ELECTRICAL STIMULATION;
   STEM CELLS; TISSUE CULTURE; IN VITRO; EXPRESSION; REPAIR;
   MINERALIZATION; CYTOTOXICITY; OSTEOBLASTS
AB Electromagnetic field (EMF) stimulation is clinically beneficial for fracture nonunion and a wide range of bone disorders. However, no consensus has been reached on the optimal parameters of the EMF. The exact mechanism by which EMFs enhance osteogenesis has also not been defined. In the present study, a sinusoidal 1mT EMF at frequencies of 10, 30, 50, and 70Hz were administered to rat bone marrow mesenchymal stromal cells (rBMSCs) in the cyclic mode of 2h exposures followed by 4h of culture without exposure. The cell viability, proliferation, expression of some osteogenic genes, and mineralization of the extracellular matrix were investigated. It was found that the cell viability was decreased by EMF exposures of 50 and 70Hz. The proliferation of rBMSCs was elevated significantly in the 10Hz EMF treated group during the culture periods. The expression of alkaline phosphatase (ALP) and osteocalcin (OC), two early phase osteogenic differentiation markers, was up regulated by the 1mT, 10Hz EMF after 1 week. However, the expression of genes that marked the later phase osteogenic differentiation and maturation of osteoblasts was elevated by the stimulation of 50Hz EMFs after 2 weeks. In addition, it was observed that the mineralization of the extracellular matrix was enhanced by 50Hz EMF exposure. These results indicated that the 1mT EMF at different frequencies had disparate effects on the viability, proliferation and osteogenic differentiation of rBMSCs, and may be beneficial for developing novel therapeutic approaches in bone regenerative medicine. Bioelectromagnetics. 34:453 464. (c) 2013 Wiley Periodicals, Inc.
C1 [Liu, Chaoxu; Yu, Jizhe; Yang, Yong; Zhao, Dongming; Wu, Hua] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Tang, Xiangyu] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Radiol, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Zhao, Wenchun] Navy Univ Engn, Wuhan, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology
RP Wu, H (通讯作者)，Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthopaed, Tongji Med Coll, Jiefang Rd 1095, Wuhan 430030, Peoples R China.
EM wuhua360@yahoo.com.cn
FU National Natural Sciences Foundation of China [50477043, 51077065]
FX Grant sponsor: National Natural Sciences Foundation of China; Grant
   numbers: 50477043, 51077065.
CR BASSEN H, 1992, BIOELECTROMAGNETICS, V13, P183, DOI 10.1002/bem.2250130303
   BASSETT CA, 1964, NATURE, V204, P652, DOI 10.1038/204652a0
   BASSETT CAL, 1974, SCIENCE, V184, P575
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   BRIGHTON CT, 1985, BONE, V6, P87, DOI 10.1016/8756 3282(85)90312 6
   BRIGHTON CT, 1985, J BONE JOINT SURG AM, V67A, P1022, DOI 10.2106/00004623 198567070 00005
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   FARNDALE RW, 1985, CALCIFIED TISSUE INT, V37, P178, DOI 10.1007/BF02554838
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Gong ZD, 2004, ALCOHOL CLIN EXP RES, V28, P468, DOI 10.1097/01.ALC.0000118315.58404.C1
   Goto T, 2010, J ORTHOP SCI, V15, P661, DOI 10.1007/s00776 010 1510 0
   Grace KLR, 1998, ORTHOPEDICS, V21, P297
   HODGSON SF, 1985, ANN INTERN MED, V103, P855, DOI 10.7326/0003 4819 103 6 855
   Hughes Fulford M, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749 799X 6 8
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Lacy Hulbert A, 1998, FASEB J, V12, P395, DOI 10.1096/fasebj.12.6.395
   Liboff AR, 2010, ELECTROMAGN BIOL MED, V29, P105, DOI 10.3109/15368378.2010.493129
   Mayer Wagner S, 2011, BIOELECTROMAGNETICS, V32, P283, DOI 10.1002/bem.20633
   MCLEOD KJ, 1992, J BONE JOINT SURG AM, V74A, P920, DOI 10.2106/00004623 199274060 00014
   MCLEOD KJ, 1993, J BONE MINER RES, V8, P977, DOI 10.1002/jbmr.5650080811
   Nikolova T, 2005, FASEB J, V19, P1686, DOI 10.1096/fj.04 3549fje
   NORTON LA, 1982, CLIN ORTHOP RELAT R, P280
   NORTON LA, 1988, J ORTHOP RES, V6, P685, DOI 10.1002/jor.1100060510
   Salgado AJ, 2004, TISSUE ENG, V10, P465, DOI 10.1089/107632704323061825
   Steinau M, 2006, J MOL DIAGN, V8, P113, DOI 10.2353/jmoldx.2006.050088
   Sun LY, 2010, BIOELECTROMAGNETICS, V31, P209, DOI 10.1002/bem.20550
   Tokalov SV, 2004, ENVIRON RES, V94, P145, DOI 10.1016/S0013 9351(03)00088 4
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   WEI LX, 1990, BIOELECTROMAGNETICS, V11, P269, DOI 10.1002/bem.2250110403
   Wolf FI, 2005, BBA MOL CELL RES, V1743, P120, DOI 10.1016/j.bbamcr.2004.09.005
   Wu Hua, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P185
   Yang Y, 2010, BIOELECTROMAGNETICS, V31, P277, DOI 10.1002/bem.20560
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
   Zhao DM, 2008, J HUAZHONG U SCI MED, V28, P152, DOI 10.1007/s11596 008 0209 3
   Zhou J, 2011, BONE, V49, P753, DOI 10.1016/j.bone.2011.06.026
NR 38
TC 36
Z9 41
U1 1
U2 43
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0197 8462
J9 BIOELECTROMAGNETICS
JI Bioelectromagnetics
PD SEP
PY 2013
VL 34
IS 6
BP 453
EP 464
DI 10.1002/bem.21791
PG 12
WC Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics
GA 179YR
UT WOS:000321559600005
PM 23589052
DA 2025 08 17
ER

PT J
AU Bhatt, S
   Diaz, R
   Trainor, PA
AF Bhatt, Shachi
   Diaz, Raul
   Trainor, Paul A.
TI Signals and Switches in Mammalian Neural Crest Cell Differentiation
SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY
LA English
DT Article
ID DOPAMINE BETA HYDROXYLASE; ADRENAL CHROMAFFIN CELLS; NERVE
   GROWTH FACTOR; TRANSCRIPTION FACTOR SOX10; WNT/BETA CATENIN; PHARYNGEAL
   ARCH; SONIC HEDGEHOG; SKELETOGENIC DIFFERENTIATION; CHONDROCYTE
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION
AB Neural crest cells (NCCs) comprise a multipotent, migratory cell population that generates a diverse array of cell and tissue types during vertebrate development. These include cartilage and bone, tendons, and connective tissue, as well as neurons, glia, melanocytes, and endocrine and adipose cells; this remarkable lineage potential persists into adult life. Taken together with a limited capacity for self renewal, neural crest cells bear the hallmarks of stem and progenitor cells and are considered to be synonymous with vertebrate evolution. The neural crest has provided a system for exploring the mechanisms that govern developmental processes such as morphogenetic induction, cell migration, and fate determination. Today, much of the focus on neural crest cells revolves around their stem cell like characteristics and potential for use in regenerative medicine. A thorough understanding of the signals and switches that govern mammalian neural crest patterning is central to potential therapeutic application of these cells and better appreciation of the role that neural crest cells play in vertebrate evolution, development, and disease.
C1 [Bhatt, Shachi; Diaz, Raul; Trainor, Paul A.] Stowers Inst Med Res, Kansas City, MO 64110 USA.
C3 Stowers Institute for Medical Research
RP Trainor, PA (通讯作者)，Stowers Inst Med Res, Kansas City, MO 64110 USA.
EM pat@stowers.org
OI Trainor, Paul/0000 0003 2774 3624
FU NIDCR NIH HHS [R01 DE016082] Funding Source: Medline
CR Abzhanov A, 2004, DEV BIOL, V273, P134, DOI 10.1016/j.ydbio.2004.05.028
   Abzhanov A, 2003, DEVELOPMENT, V130, P4567, DOI 10.1242/dev.00673
   Abzhanov A, 2007, DEVELOPMENT, V134, P3133, DOI 10.1242/dev.002709
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Akiyama H, 2005, P NATL ACAD SCI USA, V102, P14665, DOI 10.1073/pnas.0504750102
   Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101
   ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021
   Andres R, 2008, NEUROSCI LETT, V431, P241, DOI 10.1016/j.neulet.2007.11.045
   Aoto K, 2009, DEV BIOL, V327, P106, DOI 10.1016/j.ydbio.2008.11.022
   Bei M, 1998, DEVELOPMENT, V125, P4325
   Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697 174
   Benouaiche L, 2008, DEVELOPMENT, V135, P2221, DOI 10.1242/dev.020123
   Blentic A, 2008, DEV DYNAM, V237, P592, DOI 10.1002/dvdy.21439
   Bolós V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719
   Brault V, 2001, DEVELOPMENT, V128, P1253
   Brito JM, 2008, DEVELOPMENT, V135, P2311, DOI 10.1242/dev.019125
   Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825
   Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601
   Bronner Fraser M, 2004, SCIENCE, V303, P966, DOI 10.1126/science.1094732
   Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959 437X(02)00322 2
   Büchmann Moller S, 2009, DEV BIOL, V330, P329, DOI 10.1016/j.ydbio.2009.04.001
   Calloni GW, 2009, P NATL ACAD SCI USA, V106, P8947, DOI 10.1073/pnas.0903780106
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925 4773(96)00503 5
   Cebra Thomas JA, 2007, EVOL DEV, V9, P267, DOI 10.1111/j.1525 142X.2007.00159.x
   Chai Y, 2000, DEVELOPMENT, V127, P1671
   Chen CL, 2006, NEURON, V49, P365, DOI 10.1016/j.neuron.2005.10.036
   Chung IH, 2010, GENESIS, V48, P645, DOI 10.1002/dvg.20671
   COHEN AM, 1972, J EXP ZOOL, V179, P167, DOI 10.1002/jez.1401790204
   Cohn MJ, 2002, NATURE, V416, P386, DOI 10.1038/416386a
   Couly G, 2002, DEVELOPMENT, V129, P1061
   Crane JF, 2006, ANNU REV CELL DEV BI, V22, P267, DOI 10.1146/annurev.cellbio.22.010305.103814
   David NB, 2002, DEVELOPMENT, V129, P4457
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955 0674(00)00276 3
   DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045
   Depew MJ, 1999, DEVELOPMENT, V126, P3831
   Depew MJ, 2005, J ANAT, V207, P501, DOI 10.1111/j.1469 7580.2005.00487.x
   Dong XZ, 2001, CELL, V106, P619, DOI 10.1016/S0092 8674(01)00483 4
   Dottori M, 2001, DEVELOPMENT, V128, P4127
   DOUPE AJ, 1985, J NEUROSCI, V5, P2119
   Dupin E, 2010, CELL CYCLE, V9, P238, DOI 10.4161/cc.9.2.10491
   Dutton KA, 2001, DEVELOPMENT, V128, P4113
   EPPERLEIN HH, 1974, DIFFERENTIATION, V2, P151, DOI 10.1111/j.1432 0436.1974.tb00349.x
   Finotto S, 1999, DEVELOPMENT, V126, P2935
   Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896 6273(00)80989 7
   Fontaine Pérus J, 2005, INT J DEV BIOL, V49, P349, DOI 10.1387/ijdb.041943jf
   Francis NJ, 1999, ANNU REV NEUROSCI, V22, P541, DOI 10.1146/annurev.neuro.22.1.541
   Fraser GJ, 2010, BIOESSAYS, V32, P808, DOI 10.1002/bies.200900151
   Garcia Miñaur S, 2003, EUR J HUM GENET, V11, P892, DOI 10.1038/sj.ejhg.5201062
   Gershon MD, 1998, AM J PHYSIOL GASTR L, V275, pG869, DOI 10.1152/ajpgi.1998.275.5.G869
   Gilbert SF, 2007, INTEGR COMP BIOL, V47, P401, DOI 10.1093/icb/icm020
   Gitton Y, 2011, DEVELOPMENT, V138, P897, DOI 10.1242/dev.057505
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   González Martínez T, 2004, BRAIN RES, V1002, P120, DOI 10.1016/j.brainres.2004.01.003
   Gordon CT, 2010, EVOL DEV, V12, P459, DOI 10.1111/j.1525 142X.2010.00432.x
   Grammatopoulos GA, 2000, DEVELOPMENT, V127, P5355
   Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704
   Hall B.K., 1999, NEURAL CREST DEV EVO
   HALL BK, 1980, J EMBRYOL EXP MORPH, V58, P251
   Han J, 2007, MECH DEVELOP, V124, P729, DOI 10.1016/j.mod.2007.06.006
   Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hasegawa H, 2008, J COMP NEUROL, V511, P543, DOI 10.1002/cne.21862
   Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097 0177(199905)215:1<69::AID DVDY8>3.0.CO;2 N
   HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Hirsch MR, 1998, DEVELOPMENT, V125, P599
   Howard MJ, 2000, DEVELOPMENT, V127, P4073
   HOWARD MJ, 1986, DEV BIOL, V117, P45, DOI 10.1016/0012 1606(86)90346 5
   Hu D, 2003, DEVELOPMENT, V130, P1749, DOI 10.1242/dev.00397
   Hu D, 2012, DEV DYNAM, V241, P732, DOI 10.1002/dvdy.23764
   Hu D, 2009, DEVELOPMENT, V136, P107, DOI 10.1242/dev.026583
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Ido A, 2006, DEV DYNAM, V235, P361, DOI 10.1002/dvdy.20635
   Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925
   Inoue KI, 2008, NEURAL DEV, V3, DOI 10.1186/1749 8104 3 20
   Ishii M, 2003, DEVELOPMENT, V130, P6131, DOI 10.1242/dev.00793
   Ishii M, 2005, DEVELOPMENT, V132, P4937, DOI 10.1242/dev.02072
   JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092 8674(93)90379 5
   Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304
   Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012 1606(98)80005 5
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   John N, 2011, STEM CELLS, V29, P689, DOI 10.1002/stem.607
   Jumlongras D, 2001, AM J HUM GENET, V69, P67, DOI 10.1086/321271
   Kanzler B, 1998, DEVELOPMENT, V125, P2587
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kim HS, 1998, J NEUROSCI, V18, P8247
   Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896 6273(03)00163 6
   Kléber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095
   Kolpakova E, 2005, DEV CELL, V8, P626, DOI 10.1016/j.devcel.2005.04.008
   Kramer I, 2006, NEURON, V49, P379, DOI 10.1016/j.neuron.2006.01.008
   Kulesa P, 2004, DEV DYNAM, V229, P14, DOI 10.1002/dvdy.10485
   Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125
   LEDOUARI.NM, 1974, DEV BIOL, V41, P162, DOI 10.1016/0012 1606(74)90291 7
   LEDOUARIN NM, 1999, NEURAL CREST
   Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Lei L, 2005, GENE DEV, V19, P1354, DOI 10.1101/gad.1227705
   Lenton K, 2011, GENESIS, V49, P784, DOI 10.1002/dvg.20768
   Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370
   Li SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014033
   Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080
   Lo LC, 1998, DEVELOPMENT, V125, P609
   Lo LC, 1997, CURR BIOL, V7, P440, DOI 10.1016/S0960 9822(06)00191 6
   Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896 6273(00)80729 1
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luo WQ, 2007, NEURON, V54, P739, DOI 10.1016/j.neuron.2007.04.027
   Ma L, 2003, DEVELOPMENT, V130, P3525, DOI 10.1242/dev.00582
   Ma QF, 1997, J NEUROSCI, V17, P3644
   Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092 8674(00)81321 5
   Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   MACKENZIE A, 1991, DEVELOPMENT, V113, P601
   Marcucio RS, 2011, GENESIS, V49, P177, DOI 10.1002/dvg.20710
   Marcucio RS, 2005, DEV BIOL, V284, P48, DOI 10.1016/j.ydbio.2005.04.030
   Marmigère F, 2007, NAT REV NEUROSCI, V8, P114, DOI 10.1038/nrn2057
   Maro GS, 2004, NAT NEUROSCI, V7, P930, DOI 10.1038/nn1299
   McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0
   McGonnell IM, 2002, CURR BIOL, V12, P767, DOI 10.1016/S0960 9822(02)00818 7
   McKeown SJ, 2003, DEV BIOL, V255, P62, DOI 10.1016/S0012 1606(02)00076 3
   Merrill AE, 2012, AM J HUM GENET, V90, P550, DOI 10.1016/j.ajhg.2012.02.005
   Minoux M, 2009, DEVELOPMENT, V136, P637, DOI 10.1242/dev.028621
   Mitsiadis TA, 2003, P NATL ACAD SCI USA, V100, P6541, DOI 10.1073/pnas.1137104100
   Molliver DC, 1997, J COMP NEUROL, V381, P428, DOI 10.1002/(SICI)1096 9861(19970519)381:4<428::AID CNE3>3.0.CO;2 4
   Mori Akiyama Y, 2003, P NATL ACAD SCI USA, V100, P9360, DOI 10.1073/pnas.1631288100
   Morikawa Y, 2009, DEVELOPMENT, V136, P3575, DOI 10.1242/dev.038133
   Murray SA, 2006, P NATL ACAD SCI USA, V103, P10300, DOI 10.1073/pnas.0602234103
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487
   Nie XG, 2008, DEV BIOL, V316, P417, DOI 10.1016/j.ydbio.2008.02.006
   NORR SC, 1973, DEV BIOL, V34, P16, DOI 10.1016/0012 1606(73)90336 9
   PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995 40
   Paratore C, 2002, INT J DEV BIOL, V46, P193
   Paratore C, 2001, DEVELOPMENT, V128, P3949
   Partanen J, 1998, GENE DEV, V12, P2332, DOI 10.1101/gad.12.15.2332
   Pasqualetti M, 2000, DEVELOPMENT, V127, P5367
   Pattyn A, 2000, MOL CELL NEUROSCI, V15, P235, DOI 10.1006/mcne.1999.0826
   Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700
   Perez Pinera P, 2008, NEUROSCI LETT, V433, P43, DOI 10.1016/j.neulet.2007.12.035
   Piotrowski T, 2000, DEV BIOL, V225, P339, DOI 10.1006/dbio.2000.9842
   Potrebic S, 2003, J NEUROSCI, V23, P10988
   Reissmann E, 1996, DEVELOPMENT, V122, P2079
   Remboutsika E, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00016
   RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092 8674(93)90620 6
   Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402
   Rychlik JL, 2003, J BIOL CHEM, V278, P49652, DOI 10.1074/jbc.M308577200
   Samad OA, 2010, MOL PAIN, V6, DOI 10.1186/1744 8069 6 45
   Sarkar S, 2001, DEVELOPMENT, V128, P2143
   SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494 348
   Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231
   SCHILLING TF, 1994, DEVELOPMENT, V120, P483
   Schneider C, 1999, NEURON, V24, P861, DOI 10.1016/S0896 6273(00)81033 8
   Schneider RA, 2003, SCIENCE, V299, P565, DOI 10.1126/science.1077827
   Scott A, 2011, J NEUROSCI, V31, P6741, DOI 10.1523/JNEUROSCI.5883 10.2011
   Sefton M, 1998, DEVELOPMENT, V125, P3111
   SELLECK MAJ, 1995, DEVELOPMENT, V121, P525
   Semba I, 2000, DEV DYNAM, V217, P401, DOI 10.1002/(SICI)1097 0177(200004)217:4<401::AID DVDY7>3.0.CO;2 D
   Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092 8674(00)81112 5
   Shimizu S, 2007, BRAIN RES, V1154, P95, DOI 10.1016/j.brainres.2006.10.021
   Snider WD, 1996, NEURON, V16, P229, DOI 10.1016/S0896 6273(00)80039 2
   Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896 6273(00)81003 X
   Stanke M, 1999, DEVELOPMENT, V126, P4087
   Takio Y, 2004, NATURE, V429, DOI 10.1038/nature02616
   TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012 1606(83)90349 4
   Tokita M, 2009, DEV BIOL, V331, P311, DOI 10.1016/j.ydbio.2009.05.548
   Trainor P, 2000, NAT CELL BIOL, V2, P96, DOI 10.1038/35000051
   Trainor PA, 2005, SEMIN CELL DEV BIOL, V16, P683, DOI 10.1016/j.semcdb.2005.06.007
   Trainor PA, 2003, INT J DEV BIOL, V47, P541
   Trainor PA, 2001, CURR OPIN CELL BIOL, V13, P698, DOI 10.1016/S0955 0674(00)00273 8
   Trainor Paul A, 2003, ScientificWorldJournal, V3, P240
   Tran TH, 2010, DEVELOPMENT, V137, P3973, DOI 10.1242/dev.056473
   Trokovic R, 2003, EMBO J, V22, P1811, DOI 10.1093/emboj/cdg169
   Tsarovina K, 2004, DEVELOPMENT, V131, P4775, DOI 10.1242/dev.01370
   UNSICKER K, 1978, CELL TISSUE RES, V189, P109
   UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498
   UNSICKER K, 1973, Z ZELLFORSCH MIK ANA, V145, P389, DOI 10.1007/BF00307164
   Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092
   VARLEY JE, 1995, DEV DYNAM, V203, P434, DOI 10.1002/aja.1002030406
   Varley JE, 1996, EXP NEUROL, V140, P84, DOI 10.1006/exnr.1996.0118
   Veistinen L, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00121
   Veistinen L, 2009, J EXP ZOOL PART B, V312B, P351, DOI 10.1002/jez.b.21276
   Vickaryous MK, 2009, J ANAT, V214, P441, DOI 10.1111/j.1469 7580.2008.01043.x
   Vitelli F, 2006, DEV BIOL, V295, P559, DOI 10.1016/j.ydbio.2006.03.044
   VOGEL KS, 1990, DEV BIOL, V139, P1, DOI 10.1016/0012 1606(90)90273 L
   Wada H, 1997, DEV BIOL, V187, P240, DOI 10.1006/dbio.1997.8626
   WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092 8674(94)90041 8
   Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811
   Walshe J, 2000, MECH DEVELOP, V90, P103, DOI 10.1016/S0925 4773(99)00225 7
   Walshe J, 2003, DEV BIOL, V264, P522, DOI 10.1016/j.ydbio.2003.08.010
   Wilke TA, 1997, DEV DYNAM, V210, P41, DOI 10.1002/(SICI)1097 0177(199709)210:1<41::AID AJA5>3.0.CO;2 1
   Wilkie AOM, 2000, NAT GENET, V24, P387, DOI 10.1038/74224
   Wurdak H, 2005, GENE DEV, V19, P530, DOI 10.1101/gad.317405
   Xu HM, 2003, DEV BIOL, V262, P183, DOI 10.1016/S0012 1606(03)00361 0
   Yamagishi C, 2006, PEDIATR RES, V59, P349, DOI 10.1203/01.pdr.0000199911.17287.3e
   Yang CY, 1998, J NEUROCHEM, V71, P1813
   Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007
   Zellmer E, 1995, J NEUROSCI, V15, P8109
   Zhou G, 2006, P NATL ACAD SCI USA, V103, P19004, DOI 10.1073/pnas.0605170103
   Zilian O, 2001, CURR BIOL, V11, P494, DOI 10.1016/S0960 9822(01)00149 X
   Zirlinger M, 2002, P NATL ACAD SCI USA, V99, P8084, DOI 10.1073/pnas.122231199
   Zylka MJ, 2003, P NATL ACAD SCI USA, V100, P10043, DOI 10.1073/pnas.1732949100
NR 205
TC 132
Z9 169
U1 0
U2 27
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1943 0264
J9 CSH PERSPECT BIOL
JI Cold Spring Harbor Perspect. Biol.
PD FEB
PY 2013
VL 5
IS 2
AR a008326
DI 10.1101/cshperspect.a008326
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 104HY
UT WOS:000315984100018
PM 23378583
OA Green Published
DA 2025 08 17
ER

PT J
AU Kaur, K
   Paiva, SS
   Caffrey, D
   Cavanagh, BL
   Murphy, CM
AF Kaur, Kulwinder
   Paiva, Silvia Sa'
   Caffrey, David
   Cavanagh, Brenton L.
   Murphy, Ciara M.
TI Injectable chitosan/collagen hydrogels nano engineered with
   functionalized single wall carbon nanotubes for minimally invasive
   applications in bone
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Mechanically robust hydrogels; Natural biomaterials; Injectable
   hydrogels; Bone regeneration
ID HYDROXYL APATITE NANOPARTICLES; BIOMEDICAL APPLICATIONS; HYDROXYAPATITE
   COMPOSITE; NANOCOMPOSITE HYDROGELS; POLYELECTROLYTE COMPLEX;
   BETA GLYCEROPHOSPHATE; ENZYMATIC HYDROLYSIS; NETWORK STRUCTURE;
   DRUG DELIVERY; GEL BEADS
AB Mechanical robustness is an essential consideration in the development of hydrogel platforms for bone regeneration, and despite significant advances in the field of injectable hydrogels, many fail in this regard. Inspired by the mechanical properties of carboxylated single wall carbon nanotubes (COOH SWCNTs) and the biological advantages of natural polymers, COOH SWCNTs were integrated into chitosan and collagen to formulate mechanically robust, injectable and thermoresponsive hydrogels with interconnected molecular structure for loadbearing applications. This study presents a complete characterisation of the structural and biological properties, and mechanism of gelation of these novel formulated hydrogels. Results demonstrate that beta glycerophosphate (beta GP) and temperature play important roles in attaining gelation at physiological conditions, and the integration with COOH SWCNTs significantly changed the structural morphology of the hydrogels to a more porous and aligned network. This led to a crystalline structure and significantly increased the mechanical strength of the hydrogels from kPa to MPa, which is closer to the mechanical strength of the bone. Moreover, increased osteoblast proliferation and rapid adsorption of hydroxyapatite on the surface of the hydrogels indicates increased bioactivity with addition of COOH SWCNTs. Therefore, these nano engineered hydrogels are expected to have wide utility in the area of bone tissue engineering and regenerative medicine.
C1 [Kaur, Kulwinder; Paiva, Silvia Sa'; Murphy, Ciara M.] Royal Coll Surg RCSI, Tissue Engn Res Grp, Dept Anat & Regenerat Med, Dublin D02 YN77, Ireland.
   [Caffrey, David] Trinity Coll Dublin, Sch Phys, Dublin D02 PN40, Ireland.
   [Caffrey, David] Trinity Coll Dublin, Ctr Res Adapt Nanostruct & Nanodevices CRANN, Dublin D02 PN40, Ireland.
   [Cavanagh, Brenton L.] Royal Coll Surgeons Ireland, Cellular & Mol Imaging Core, Dublin D02 YN77, Ireland.
   [Murphy, Ciara M.] Trinity Coll Dublin TCD, Trinity Ctr Biomed Engn, Dublin D02 YN7, Ireland.
   [Murphy, Ciara M.] RCSI, Adv Mat & Bioengn Res Ctr AMBER, Dublin, Ireland.
   [Murphy, Ciara M.] TCD, Dublin, Ireland.
C3 Royal College of Surgeons   Ireland; Trinity College Dublin; Trinity
   College Dublin; Royal College of Surgeons   Ireland; Trinity College
   Dublin; Royal College of Surgeons   Ireland; Trinity College Dublin
RP Murphy, CM (通讯作者)，Royal Coll Surg RCSI, Tissue Engn Res Grp, Dept Anat & Regenerat Med, Dublin D02 YN77, Ireland.
EM ciaramurphy@rcsi.ie
RI Kaur, Kulwinder/AAY 8138 2021; murphy, ciara/JKI 3456 2023; Cavanagh,
   Brenton/D 2382 2009; Caffrey, David/M 3918 2018
OI Cavanagh, Brenton/0000 0002 1582 5756; Murphy,
   Ciara/0000 0002 9653 5477; Kaur, Kulwinder/0000 0001 5352 0542; 
FU Irish Research Council, Government of Ireland [GOIPD/2019/793]
FX The author acknowledges Irish Research Council, Government of Ireland
   Post Doctoral Fellowship (GOIPD/2019/793) for funding. Collagen
   materials were provided by Integra Life Sciences, Inc. through a
   Material Transfer Agreement.
CR Amaral IF, 2009, BIOMATERIALS, V30, P5465, DOI 10.1016/j.biomaterials.2009.06.056
   AMIJI MM, 1995, CARBOHYD POLYM, V26, P211, DOI 10.1016/0144 8617(94)00095 B
   Anand V, 2016, CERAM INT, V42, P3638, DOI 10.1016/j.ceramint.2015.11.029
   Anand V, 2014, J NON CRYST SOLIDS, V406, P88, DOI 10.1016/j.jnoncrysol.2014.09.050
   Annabi N, 2014, ADV MATER, V26, P85, DOI 10.1002/adma.201303233
   Balani K, 2007, BIOMATERIALS, V28, P618, DOI 10.1016/j.biomaterials.2006.09.013
   Barrientos Durán A, 2014, INT J NANOMED, V9, P4277, DOI 10.2147/IJN.S62538
   Bayrak GK, 2017, CARBOHYD POLYM, V157, P803, DOI 10.1016/j.carbpol.2016.10.016
   Campbell SB, 2013, BIOMACROMOLECULES, V14, P644, DOI 10.1021/bm301703x
   Chen J, 2017, CHEM COMMUN, V53, P6949, DOI 10.1039/c7cc02782f
   Chen LA, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957 4484/22/10/105708
   Chen YJ, 2014, ACTA BIOMATER, V10, P4561, DOI 10.1016/j.actbio.2014.07.005
   Chenite A, 2001, CARBOHYD POLYM, V46, P39, DOI 10.1016/S0144 8617(00)00281 2
   Chenite A, 2000, BIOMATERIALS, V21, P2155, DOI 10.1016/S0142 9612(00)00116 2
   Chik MW, 2019, DRUG DELIV TRANSL RE, V9, P578, DOI 10.1007/s13346 018 0505 9
   Chimene D, 2016, ANN BIOMED ENG, V44, P2090, DOI 10.1007/s10439 016 1638 y
   Cho JY, 2005, BIOMACROMOLECULES, V6, P3267, DOI 10.1021/bm050313s
   Choi SJ, 2009, J INORG BIOCHEM, V103, P463, DOI 10.1016/j.jinorgbio.2008.12.017
   Cholas R, 2016, MAT SCI ENG C MATER, V63, P499, DOI 10.1016/j.msec.2016.03.022
   Couto DS, 2009, ACTA BIOMATER, V5, P115, DOI 10.1016/j.actbio.2008.08.006
   Crompton KE, 2005, BIOPHYS CHEM, V117, P47, DOI 10.1016/j.bpc.2005.03.009
   Dang QF, 2011, CARBOHYD POLYM, V83, P171, DOI 10.1016/j.carbpol.2010.07.038
   Dang QF, 2017, CARBOHYD POLYM, V167, P145, DOI 10.1016/j.carbpol.2017.03.053
   De France KJ, 2020, ACS APPL POLYM MATER, V2, P1016, DOI 10.1021/acsapm.9b00981
   Deng AP, 2017, MAT SCI ENG C MATER, V78, P1147, DOI 10.1016/j.msec.2017.04.109
   Desbrieres J, 1996, INT J BIOL MACROMOL, V19, P21, DOI 10.1016/0141 8130(96)01095 1
   Diba M, 2018, MAT SCI ENG C MATER, V92, P143, DOI 10.1016/j.msec.2018.06.038
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Dorozhkin SV, 2013, MAT SCI ENG C MATER, V33, P3085, DOI 10.1016/j.msec.2013.04.002
   Douglas TEL, 2018, J TISSUE ENG REGEN M, V12, P1313, DOI 10.1002/term.2654
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142 9612(03)00340 5
   Duque JG, 2008, J AM CHEM SOC, V130, P2626, DOI 10.1021/ja0777234
   Eivazzadeh Keihan R, 2019, J ADV RES, V18, P185, DOI 10.1016/j.jare.2019.03.011
   El Masri F, 2012, COMPUT METHOD BIOMEC, V15, P23, DOI 10.1080/10255842.2011.565751
   Ezoddini Ardakani Fatemeh, 2012, Dent Res J (Isfahan), V9, P694
   Fariba G., 2010, THEORETICAL DESCRIPT
   Fernandes LL, 2011, POLIMEROS, V21, P1, DOI 10.1590/S0104 14282011005000008
   Fuchs S, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901396
   Ganji F, 2007, J SOL GEL SCI TECHN, V42, P47, DOI 10.1007/s10971 006 9007 1
   Gao G, 2019, ACS BIOMATER SCI ENG, V5, P1150, DOI 10.1021/acsbiomaterials.8b00691
   García Astrain C, 2016, CARBOHYD POLYM, V149, P94, DOI 10.1016/j.carbpol.2016.04.091
   Gholizadeh S, 2017, INT J BIOL MACROMOL, V97, P365, DOI 10.1016/j.ijbiomac.2016.12.086
   Gigli M, 2012, GREEN CHEM, V14, P2885, DOI 10.1039/c2gc35876j
   Giri TK, 2012, ACTA PHARM SIN B, V2, P439, DOI 10.1016/j.apsb.2012.07.004
   Haraguchi K, 2002, ADV MATER, V14, P1120, DOI 10.1002/1521 4095(20020816)14:16<1120::AID ADMA1120>3.0.CO;2 9
   Holkar K, 2021, ACS BIOMATER SCI ENG, V7, P2687, DOI 10.1021/acsbiomaterials.1c00386
   Hsu HH, 2016, J BIOSCI BIOENG, V122, P219, DOI 10.1016/j.jbiosc.2016.01.001
   Jansen J, 2005, ORTHOP CLIN N AM, V36, P89, DOI 10.1016/j.ocl.2004.06.014
   Jeon SJ, 2016, BIOMATERIALS, V110, P71, DOI 10.1016/j.biomaterials.2016.09.016
   Kamba AS, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/215097
   Karajanagi SS, 2006, LANGMUIR, V22, P1392, DOI 10.1021/la0528201
   Kasaai MR, 2000, FOOD RES INT, V33, P63, DOI 10.1016/S0963 9969(00)00024 7
   Kaur K, 2017, CERAM INT, V43, P10097, DOI 10.1016/j.ceramint.2017.05.029
   Kaur K, 2017, MAT SCI ENG C MATER, V71, P780, DOI 10.1016/j.msec.2016.10.055
   Kaur K, 2016, CERAM INT, V42, P12651, DOI 10.1016/j.ceramint.2016.05.001
   KHARE AR, 1995, BIOMATERIALS, V16, P559, DOI 10.1016/0142 9612(95)91130 Q
   Kim SJ, 2004, J APPL POLYM SCI, V93, P1097, DOI 10.1002/app.20560
   Klumpp C, 2006, BBA BIOMEMBRANES, V1758, P404, DOI 10.1016/j.bbamem.2005.10.008
   Kobayashi K, 1999, MACROMOLECULES, V32, P7070, DOI 10.1021/ma990242n
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Kretlow JD, 2007, ADV DRUG DELIVER REV, V59, P263, DOI 10.1016/j.addr.2007.03.013
   Lassègues JC, 2009, J PHYS CHEM A, V113, P6419, DOI 10.1021/jp903160r
   Lavertu M, 2008, BIOMACROMOLECULES, V9, P640, DOI 10.1021/bm700745d
   Lee CH, 2001, INT J PHARMACEUT, V221, P1, DOI 10.1016/S0378 5173(01)00691 3
   Li HY, 2013, ACTA BIOMATER, V9, P5379, DOI 10.1016/j.actbio.2012.10.019
   Li L, 2001, LANGMUIR, V17, P8062, DOI 10.1021/la010917r
   Li X, 2014, J MATER CHEM B, V2, P1234, DOI 10.1039/c3tb21628d
   Li X, 2014, SOFT MATER, V12, P1, DOI 10.1080/1539445X.2011.584269
   Liu C, 2014, BIOMACROMOLECULES, V15, P436, DOI 10.1021/bm401780v
   Luz GM, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/5/054104
   Maiti D, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01401
   Mao HL, 2015, COLLOID SURFACE B, V126, P63, DOI 10.1016/j.colsurfb.2014.12.013
   Mehrali M, 2017, ADV MATER, V29, DOI 10.1002/adma.201603612
   Merino S, 2015, ACS NANO, V9, P4686, DOI 10.1021/acsnano.5b01433
   Meskinfam M, 2018, MAT SCI ENG C MATER, V82, P130, DOI 10.1016/j.msec.2017.08.064
   Mi FL, 1999, J APPL POLYM SCI, V74, P1868, DOI 10.1002/(SICI)1097 4628(19991114)74:7<1868::AID APP32>3.3.CO;2 E
   Mi FL, 1999, J POLYM SCI POL PHYS, V37, P1551, DOI 10.1002/(SICI)1099 0488(19990715)37:14<1551::AID POLB1>3.3.CO;2 8
   Midha S, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aad2a9
   MJOBERG B, 1991, ACTA ORTHOP SCAND, V62, P500, DOI 10.3109/17453679108996658
   Mohamed M, 2017, ARAB J CHEM, V10, pS1726, DOI 10.1016/j.arabjc.2013.06.022
   Moreira CDF, 2016, MAT SCI ENG C MATER, V58, P1207, DOI 10.1016/j.msec.2015.09.075
   Natarajan M, 2021, TISSUE CELL, V71, DOI 10.1016/j.tice.2021.101571
   Oh HH, 2012, J BIOACT COMPAT POL, V27, P97, DOI 10.1177/0883911511435590
   Oh H, 2013, LANGMUIR, V29, P11154, DOI 10.1021/la4022933
   Panda NN, 2013, J BIOMAT SCI POLYM E, V24, P2031, DOI 10.1080/09205063.2013.822247
   Payne C, 2017, DRUG DELIV TRANSL RE, V7, P132, DOI 10.1007/s13346 016 0347 2
   PEPPAS NA, 1983, J POLYM SCI POL PHYS, V21, P983, DOI 10.1002/pol.1983.180210614
   Peppas NA, 2006, ADV MATER, V18, P1345, DOI 10.1002/adma.200501612
   Philippova OE, 2001, BIOMACROMOLECULES, V2, P483, DOI 10.1021/bm005649a
   Porter TL, 2007, SENSORS BASEL, V7, P1980, DOI 10.3390/s7091980
   Queiroz MF, 2015, MAR DRUGS, V13, P141, DOI 10.3390/md13010141
   Raphey VR, 2019, MAT SCI ENG C MATER, V100, P616, DOI 10.1016/j.msec.2019.03.043
   Ravarian R, 2010, CERAM INT, V36, P291, DOI 10.1016/j.ceramint.2009.09.016
   Ravarian R, 2015, RSC ADV, V5, P60681, DOI 10.1039/c5ra08824k
   Ravi M, 2015, J CELL PHYSIOL, V230, P16, DOI 10.1002/jcp.24683
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168 3659(87)90035 6
   Ruel Gariépy E, 2000, INT J PHARM, V203, P89, DOI 10.1016/S0378 5173(00)00428 2
   Santos MH, 2013, MAT SCI ENG C MATER, V33, P790, DOI 10.1016/j.msec.2012.11.003
   Shokri S, 2015, APPL SURF SCI, V357, P1758, DOI 10.1016/j.apsusc.2015.10.048
   SIFFERT RS, 1951, J EXP MED, V93, P415, DOI 10.1084/jem.93.5.415
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Soh E, 2015, CERAM INT, V41, P1031, DOI 10.1016/j.ceramint.2014.09.026
   Tao H, 2000, MACROMOLECULES, V33, P1747, DOI 10.1021/ma991983r
   Tienen TG, 2003, BIOMATERIALS, V24, P2541, DOI 10.1016/S0142 9612(03)00053 X
   Türk S, 2018, MAT SCI ENG C MATER, V92, P757, DOI 10.1016/j.msec.2018.07.020
   Vaezifar S, 2015, INT J POLYM MATER PO, V64, P64, DOI 10.1080/00914037.2014.886244
   Venkatesan J, 2011, CARBOHYD POLYM, V83, P569, DOI 10.1016/j.carbpol.2010.08.019
   Wang JQ, 2008, J APPL POLYM SCI, V109, P3018, DOI 10.1002/app.28403
   Wang LM, 2010, BIOMATERIALS, V31, P3976, DOI 10.1016/j.biomaterials.2010.01.131
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Xavier JR, 2015, ACS NANO, V9, P3109, DOI 10.1021/nn507488s
   Yang HS, 2016, J BIOMECH, V49, P1134, DOI 10.1016/j.jbiomech.2016.02.045
   Yao MZ, 2016, INT J NANOMED, V11, P6181, DOI 10.2147/IJN.S106929
   Yasmeen S., 2016, International Research Journal of Pure and Applied Chemistry, V10, P1
   Yazdimamaghani M, 2014, MATER LETT, V132, P106, DOI 10.1016/j.matlet.2014.06.036
   Yin CC, 2017, J BIOMED MATER RES A, V105, P757, DOI 10.1002/jbm.a.35941
   Yoon IK, 2014, CARBON, V77, P379, DOI 10.1016/j.carbon.2014.05.041
   Yoshimoto H, 2003, BIOMATERIALS, V24, P2077, DOI 10.1016/S0142 9612(02)00635 X
   Zhang TT, 2010, J PHYS CHEM A, V114, P12251, DOI 10.1021/jp104458u
   Zhao B, 2005, CHEM MATER, V17, P3235, DOI 10.1021/cm0500399
   Zhou HY, 2015, CARBOHYD POLYM, V117, P524, DOI 10.1016/j.carbpol.2014.09.094
   Zhou T, 2016, COLLOID SURFACE B, V143, P415, DOI 10.1016/j.colsurfb.2016.03.052
   Zhou YS, 2013, MATER LETT, V99, P8, DOI 10.1016/j.matlet.2013.02.068
NR 124
TC 47
Z9 48
U1 4
U2 39
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD SEP
PY 2021
VL 128
AR 112340
DI 10.1016/j.msec.2021.112340
EA AUG 2021
PG 18
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA UK1VB
UT WOS:000691762500004
PM 34474890
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Vidoni, C
   Ferraresi, A
   Secomandi, E
   Vallino, L
   Gardin, C
   Zavan, B
   Mortellaro, C
   Isidoro, C
AF Vidoni, Chiara
   Ferraresi, Alessandra
   Secomandi, Eleonora
   Vallino, Letizia
   Gardin, Chiara
   Zavan, Barbara
   Mortellaro, Carmen
   Isidoro, Ciro
TI Autophagy drives osteogenic differentiation of human gingival
   mesenchymal stem cells
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE AMPK; BECLIN 1; Phytotherapy; Osteoblast; Resveratrol
ID BONE REPAIR; PROMOTES OSTEOGENESIS; GENE EXPRESSION; RESVERATROL; AMPK;
   PHOSPHORYLATION; PROLIFERATION; MODULATION; MECHANISM
AB Background/aim Autophagy is a macromolecular degradation process playing a pivotal role in the maintenance of stem like features and in the morpho functional remodeling of the tissues undergoing differentiation. In this work we investigated the involvement of autophagy in the osteogenic differentiation of mesenchymal stem cells originated from human gingiva (HGMSC). METHODS: To promote the osteogenic differentiation of HGMSCs we employed resveratrol, a nutraceutical known to modulate autophagy and cell differentiation, together with osteoblastic inductive factors. Osteoblastic differentiation and autophagy were monitored through western blotting and immunofluorescence staining of specific markers. Results We show that HGMSCs can differentiate into osteoblasts when cultured in the presence of appropriate factors and that resveratrol accelerates this process by up regulating autophagy. The prolonged incubation with dexamethasone, beta glycerophosphate and ascorbic acid induced the osteogenic differentiation of HGMSCc with increased expression of autophagy markers. Resveratrol (1 mu M) alone elicited a less marked osteogenic differentiation yet it greatly induced autophagy and, when added to the osteogenic differentiation factors, it provoked a synergistic effect. Resveratrol and osteogenic inductive factors synergistically induced the AMPK BECLIN 1 pro autophagic pathway in differentiating HGMSCs, that was thereafter downregulated in osteoblastic differentiated cells. Pharmacologic inhibition of BECLIN 1 dependent autophagy precluded the osteogenic differentiation of HGMSCs. Conclusions Autophagy modulation is instrumental for osteoblastic differentiation of HGMSCs. The present findings can be translated into the regenerative cell therapy of maxillary / mandibular bone defects.
C1 [Vidoni, Chiara; Ferraresi, Alessandra; Secomandi, Eleonora; Vallino, Letizia; Isidoro, Ciro] Univ Piemonte Orientale, Dept Hlth Sci, Lab Mol Pathol, Via P Solaroli 17, I 28100 Novara, Italy.
   [Gardin, Chiara; Zavan, Barbara] Maria Cecilia Hosp, GVM Care & Res, Via Corriera 1, I 48033 Cotignola, Ravenna, Italy.
   [Zavan, Barbara] Univ Ferrara, Med Sci Dept, Via Fossato Mortara 70, Ferrara, Italy.
   [Mortellaro, Carmen] Univ Piemonte Orientale, Dept Med Sci, Oral Surg Unit, Novara, Italy.
C3 University of Eastern Piedmont Amedeo Avogadro; Maria Cecilia Hospital;
   University of Ferrara; University of Eastern Piedmont Amedeo Avogadro
RP Isidoro, C (通讯作者)，Univ Piemonte Orientale, Dept Hlth Sci, Lab Mol Pathol, Via P Solaroli 17, I 28100 Novara, Italy.
EM ciro.isidoro@med.uniupo.it
RI Isidoro, Ciro/J 6063 2016; Ferraresi, Alessandra/H 1518 2017
OI Isidoro, Ciro/0000 0002 5494 3034; Vallino, Letizia/0000 0002 1802 9675
FU Universita del Piemonte Orientale
FX This research had the financial support of the Universita del Piemonte
   Orientale.
CR Boya P, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146506
   Casarin RC, 2014, INT J ORAL MAX SURG, V43, P900, DOI 10.1016/j.ijom.2014.01.009
   Chen Y, 2016, MOL MED REP, V14, P3565, DOI 10.3892/mmr.2016.5726
   Chevallier N, 2010, BIOMATERIALS, V31, P270, DOI 10.1016/j.biomaterials.2009.09.043
   Dai Z, 2007, PHYTOMEDICINE, V14, P806, DOI 10.1016/j.phymed.2007.04.003
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580 018 0003 4
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Du LQ, 2016, J DENT SCI, V11, P304, DOI 10.1016/j.jds.2016.03.010
   DUCY P, 1995, MOL CELL BIOL, V15, P1858
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   El Sayed KMF, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7154327
   Ferraresi A, 2017, MOL CARCINOGEN, V56, P2681, DOI 10.1002/mc.22711
   Follo C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0354 2
   Fortini P, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.50
   Fortini P, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00237
   Gardin C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124064
   Ge SH, 2012, REGEN MED, V7, P819, DOI [10.2217/RME.12.61, 10.2217/rme.12.61]
   Girija DM, 2017, J CELL PHYSIOL, V232, P1591, DOI 10.1002/jcp.25835
   Gong JQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0054 z
   Grässel S, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926 014 0452 5
   Griffin M, 2011, J BONE JOINT SURG BR, V93B, P427, DOI 10.1302/0301 620X.93B4.25249
   Ha DH, 2016, MOL MED REP, V14, P69, DOI 10.3892/mmr.2016.5217
   He X, 2010, BIOCHEM BIOPH RES CO, V401, P356, DOI 10.1016/j.bbrc.2010.09.053
   Jaber FA, 2019, J CELL PHYSIOL, V234, P12105, DOI 10.1002/jcp.27071
   Kamath MS, 2014, INT J NANOMED, V9, P183, DOI 10.2147/IJN.S49460
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Lee KE, 2013, GENET MOL RES, V12, P4567, DOI 10.4238/2013.October.15.5
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Long MW, 2001, BLOOD CELL MOL DIS, V27, P677, DOI 10.1006/bcmd.2001.0431
   Matsuda Y, 2018, ORAL DIS, V24, P412, DOI 10.1111/odi.12785
   Mobasheri A, 2013, ANN NY ACAD SCI, V1290, P59, DOI 10.1111/nyas.12145
   Murgia D, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030094
   Ornstrup MJ, 2016, CALCIFIED TISSUE INT, V99, P155, DOI 10.1007/s00223 016 0130 x
   Pagni G, 2012, ADV DRUG DELIVER REV, V64, P1310, DOI 10.1016/j.addr.2012.03.005
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Rafe T, 2019, CURR PHARM DESIGN, V25, P1345, DOI 10.2174/1381612825666190410153307
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shakoori P, 2017, ORAL MAXIL SURG CLIN, V29, P19, DOI 10.1016/j.coms.2016.08.009
   Sotthibundhu A, 2018, CELL TISSUE RES, V374, P205, DOI 10.1007/s00441 018 2829 7
   Suvorova II, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420 019 0137 y
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
   Wang F, 2011, STEM CELLS DEV, V20, P2093, DOI 10.1089/scd.2010.0523
   Wang S, 2015, CELL MOL LIFE SCI, V72, P1699, DOI 10.1007/s00018 014 1829 3
   Xi G, 2016, ENDOCRINOLOGY, V157, P268, DOI 10.1210/en.2015 1690
   Xu DH, 2014, INT J BIOCHEM CELL B, V51, P1, DOI 10.1016/j.biocel.2014.03.005
   Zhao NB, 2015, CRIT REV EUKAR GENE, V25, P135, DOI 10.1615/CritRevEukaryotGeneExpr.2015012539
NR 49
TC 78
Z9 86
U1 1
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1478 811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD AUG 19
PY 2019
VL 17
IS 1
AR 98
DI 10.1186/s12964 019 0414 7
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IT5MJ
UT WOS:000482907200001
PM 31426798
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Vaiselbuh, SR
   Edelman, M
   Lipton, JM
   Liu, JM
AF Vaiselbuh, Sarah R.
   Edelman, Morris
   Lipton, Jeffrey M.
   Liu, Johnson M.
TI Ectopic Human Mesenchymal Stem Cell Coated Scaffolds in NOD/SCID Mice:
   An In Vivo Model of the Leukemia Niche
SO TISSUE ENGINEERING PART C METHODS
LA English
DT Article
ID MICROENVIRONMENT; MIGRATION; THERAPY
AB Human mesenchymal stem cells form the supportive structure in which the functional cells of a differentiated tissue reside. We describe the creation of ectopic niches within polyurethane scaffolds coated with human mesenchymal stem cells. When implanted subcutaneously in NOD/SCID mice, these niches supported engraftment of primary human acute myeloid leukemia cells. The scaffolds showed vascularization and presence of osteoclasts and adipocytes, suggestive of an organizing human bone marrow microenvironment in the murine host. The chemokine stromal derived factor 1 (SDF 1 or CXCL12) and its receptor CXCR4 are critical for homing and migration of acute myeloid leukemia. We found that a CXCR4 antagonist could disrupt homing to the ectopic niches, possibly by modulation of the mesenchymal stroma. We believe that these scaffold niches provide a new and powerful tool to study the leukemia stem cell microenvironment and may be useful for identification of novel drug targets.
C1 [Vaiselbuh, Sarah R.] Feinstein Inst Med Res, Div Pediat Hemato Oncol, Manhasset, NY 11030 USA.
   [Vaiselbuh, Sarah R.; Lipton, Jeffrey M.; Liu, Johnson M.] Cohen Childrens Med Ctr, Dept Pediat Hemato Oncol, New Hyde Pk, NY USA.
   [Edelman, Morris] Cohen Childrens Med Ctr, Dept Pediat Pathol, New Hyde Pk, NY USA.
C3 Northwell Health; Northwell Health; North Shore University Hospital;
   Steven & Alexandra Cohen Children's Medical Center of New York;
   Northwell Health; North Shore University Hospital; Steven & Alexandra
   Cohen Children's Medical Center of New York
RP Vaiselbuh, SR (通讯作者)，Feinstein Inst Med Res, Div Pediat Hemato Oncol, 350 Community Dr,Rm 119, Manhasset, NY 11030 USA.
EM smeeus@nshs.edu
FU Saint Baldrick's Research Grant; Saint Baldrick's Career Development
   Award; Pediatric Cancer Foundation
FX We would like to thank C. Mason, M. Keogh, and the orthopedic team at
   North Shore LIJ Health System, New York, for collecting anonymous human
   bone marrow samples via the Tissue Donation Program at The Feinstein
   Institute. The polyurethane scaffolds were kindly provided by Biomerix
   (Material Transfer Agreement). S. Teichberg assisted with electron
   microscopy. B. Steinberg (The Feinstein Institute) and K. Sakamoto
   (University of California at Los Angeles [UCLA]) improved the manuscript
   with valuable suggestions. S. R. Vaiselbuh is funded by a
   Saint Baldrick's Research Grant and a Saint Baldrick's Career
   Development Award. This research is also supported by a grant from the
   Pediatric Cancer Foundation.
CR Cheng LZ, 2000, J CELL PHYSIOL, V184, P58, DOI 10.1002/(SICI)1097 4652(200007)184:1<58::AID JCP6>3.0.CO;2 B
   Colmone A, 2008, SCIENCE, V322, P1861, DOI 10.1126/science.1164390
   Crazzolara R, 2001, BRIT J HAEMATOL, V115, P545, DOI 10.1046/j.1365 2141.2001.03164.x
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Gillette JM, 2009, NAT CELL BIOL, V11, P303, DOI 10.1038/ncb1838
   Guo X, 2009, BIOMATERIALS, V30, P2741, DOI 10.1016/j.biomaterials.2009.01.048
   Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499
   Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823
   Kopp HG, 2005, PHYSIOLOGY, V20, P349, DOI 10.1152/physiol.00025.2005
   Lane SW, 2009, BLOOD, V114, P1150, DOI 10.1182/blood 2009 01 202606
   Liu Y, 2009, EXP CELL RES, V315, P2544, DOI 10.1016/j.yexcr.2009.05.013
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Muguruma Y, 2006, BLOOD, V107, P1878, DOI 10.1182/blood 2005 06 2211
   Muschler GF, 2010, TISSUE ENG PART B RE, V16, P123, DOI [10.1089/ten.teb.2009.0658, 10.1089/ten.TEB.2009.0658]
   Nervi B, 2009, BLOOD, V113, P6206, DOI 10.1182/blood 2008 06 162123
   Pelled G, 2002, CURR PHARM DESIGN, V8, P1917, DOI 10.2174/1381612023393666
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rosenbaum Andrew J, 2008, Organogenesis, V4, P23
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Spitkovsky D, 2008, MINIM INVASIV THER, V17, P79, DOI 10.1080/13645700801969758
   Stappenbeck TS, 2009, SCIENCE, V324, P1666, DOI 10.1126/science.1172687
   Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008 5472.CAN 03 3693
   Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood 2008 05 158311
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 25
TC 36
Z9 39
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3384
EI 1937 3392
J9 TISSUE ENG PART C ME
JI Tissue Eng. Part C Methods
PD DEC
PY 2010
VL 16
IS 6
BP 1523
EP 1531
DI 10.1089/ten.tec.2010.0179
PG 9
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA 685KG
UT WOS:000284627000030
PM 20586611
DA 2025 08 17
ER

PT J
AU Odineal, DD
   Marois, MT
   Ward, D
   Schmid, CH
   Cabrera, R
   Sim, I
   Wang, YD
   Wilsey, B
   Duan, NH
   Henry, SG
   Kravitz, RL
AF Odineal, David D.
   Marois, Maria T.
   Ward, Deborah
   Schmid, Christopher H.
   Cabrera, Rima
   Sim, Ida
   Wang, Youdan
   Wilsey, Barth
   Duan, Naihua
   Henry, Stephen G.
   Kravitz, Richard L.
TI Effect of Mobile Device Assisted N of 1 Trial Participation on Analgesic
   Prescribing for Chronic Pain: Randomized Controlled Trial
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE N of 1 trials; chronic pain; non steroidal anti inflammatory agent;
   opioid; analgesic
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TERM OPIOID THERAPY; OF HEALTH
   PATHWAYS; NONOPIOID ANALGESICS; KNEE OSTEOARTHRITIS; CDC GUIDELINE;
   UNITED STATES; RISK; IBUPROFEN; EFFICACY
AB Objectives Opioids and non steroidal anti inflammatory drugs (NSAIDs) are frequently prescribed for chronic musculoskeletal pain, despite limited evidence of effectiveness and well documented adverse effects. We assessed the effects of participating in a structured, personalized self experiment ("N of 1 trial") on analgesic prescribing in patients with chronic musculoskeletal pain. Methods We randomized 215 patients with chronic pain to participate in an N of 1 trial facilitated by a mobile health app or to receive usual care. Medical records of participating patients were reviewed at enrollment and 6 months later to assess analgesic prescribing. We established thresholds of >= 50, >= 20, and > 0 morphine milligram equivalents (MMEs) per day to capture patients taking relatively high doses only, patients taking low moderate as well as relatively high doses, and patients taking any dose of opioids, respectively. Results There was no significant difference between the N of 1 and control groups in the percentage of patients prescribed any opioids (relative odds ratio (ROR) = 1.05; 95% confidence interval [CI] = 0.61 to 1.80, p = 0.87). There was a clinically substantial but statistically not significant reduction of the percentage of patients receiving >= 20 MME (ROR = 0.58; 95% CI = 0.33 to 1.04, p = 0.07) and also in the percentage receiving >= 50 MME (ROR = 0.50; 95% CI = 0.19 to 1.34, p = 0.17). There was a significant reduction in the proportion of patients in the N of 1 group prescribed NSAIDs compared with control (relative odds ratio = 0.53; 95% CI = 0.29 to 0.96, p = 0.04), with no concomitant increase in average pain intensity. There was no significant change in use of adjunctive medications (acetaminophen, gabapentenoids, or topicals). Discussion These exploratory results suggest that participation in N of 1 trials may reduce long term use of NSAIDs; there is also a weak signal for an effect on use of opioids. Additional research is needed to confirm these results and elucidate possible mechanisms.
C1 [Odineal, David D.] Madigan Army Med Ctr, Dept Med, Joint Base Lewis McChord, Tacoma, WA 98431 USA.
   [Odineal, David D.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA.
   [Marois, Maria T.; Cabrera, Rima] Univ Calif Davis, Ctr Hlth Care Policy & Res, Sacramento, CA 95817 USA.
   [Ward, Deborah] Univ Calif Davis, Betty Irene Moore Sch Nursing, Sacramento, CA 95817 USA.
   [Schmid, Christopher H.; Wang, Youdan] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI 02912 USA.
   [Schmid, Christopher H.] Brown Univ, Sch Publ Hlth, Ctr Evidence Synth Hlth, Providence, RI 02912 USA.
   [Sim, Ida] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA.
   [Sim, Ida] Open mHlth, New York, NY USA.
   [Wilsey, Barth] Vet Affairs Northern Calif Hlth Care Syst, Sacramento Med Ctr, Mather, CA USA.
   [Wilsey, Barth] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
   [Duan, Naihua] Columbia Coll Phys & Surg, Dept Psychiat, New York, NY USA.
   [Henry, Stephen G.; Kravitz, Richard L.] Univ Calif Davis, Dept Internal Med, Div Gen Med, Sacramento, CA 95817 USA.
C3 Madigan Army Medical Center; University of California System; University
   of California Davis; University of California System; University of
   California Davis; University of California System; University of
   California Davis; Brown University; Brown University; University of
   California System; University of California San Francisco; University of
   California System; University of California San Diego; Columbia
   University; University of California System; University of California
   Davis
RP Kravitz, RL (通讯作者)，Univ Calif Davis, Dept Internal Med, Div Gen Med, Sacramento, CA 95817 USA.
EM rlkravitz@ucdavis.edu
RI ; Schmid, Christopher/J 2398 2014; Kravitz, Richard/AAF 7425 2021
OI Duan, Naihua/0000 0001 9411 2924; Odineal, David/0000 0001 6141 8636;
   Schmid, Christopher/0000 0002 0855 5313; 
CR [Anonymous], 2019, HLTH UCD ED CTR HEAL
   Arfè A, 2016, BMJ BRIT MED J, V354, DOI 10.1136/bmj.i4857
   Babatunde OO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178621
   Bally M, 2017, BMJ BRIT MED J, V357, DOI 10.1136/bmj.j1909
   Bannuru RR, 2015, ANN INTERN MED, V162, P46, DOI 10.7326/M14 1231
   Barr C, 2015, TRIALS, V16, DOI 10.1186/s13063 015 0590 8
   Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833
   Chang AK, 2017, JAMA J AM MED ASSOC, V318, P1661, DOI 10.1001/jama.2017.16190
   Chou R, 2017, ANN INTERN MED, V166, P480, DOI 10.7326/M16 2458
   Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14 2559
   Davis JS, 2017, OPEN HEART, V4, DOI 10.1136/openhrt 2016 000550
   DAVIS MS, 1968, AM J PUBLIC HEALTH N, V58, P274, DOI 10.2105/AJPH.58.2.274
   Derry S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008609.pub2
   Derry S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007400.pub3
   DiJulio B, 2016, WASHINGTON POST KAIS
   Dima AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174426
   Dowell Deborah, 2016, MMWR Recomm Rep, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr6501e1]
   Gooch K, 2007, AM J MED, V120, DOI 10.1016/j.amjmed.2006.02.015
   Greene J, 2015, HEALTH AFFAIR, V34, P431, DOI 10.1377/hlthaff.2014.0452
   GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003 4819 102 4 520
   Gudin JA, 2018, POSTGRAD MED, V130, P42, DOI 10.1080/00325481.2018.1414551
   Guy GP Jr, 2017, MMWR MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4
   Huerta C, 2005, AM J KIDNEY DIS, V45, P531, DOI 10.1053/j.ajkd.2004.12.005
   Kaufman DW, 2018, PHARMACOEPIDEM DR S, V27, P322, DOI 10.1002/pds.4391
   Kravitz RL, 2018, JAMA INTERN MED, V178, P1368, DOI 10.1001/jamainternmed.2018.3981
   Kravitz RL, 2014, J GEN INTERN MED, V29, P551, DOI 10.1007/s11606 014 2789 x
   Krebs EE, 2018, JAMA J AM MED ASSOC, V319, P872, DOI 10.1001/jama.2018.0899
   Krebs EE, 2009, J GEN INTERN MED, V24, P733, DOI 10.1007/s11606 009 0981 1
   Labianca R, 2012, CLIN DRUG INVEST, V32, P53, DOI 10.2165/11630080 000000000 00000
   Lee M, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081670
   Moore RA, 2015, EUR J PAIN, V19, P1213, DOI 10.1002/ejp.649
   Nelson DA, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7896
   Rasmussen Barr Eva, 2016, Cochrane Database Syst Rev, V10, pCD012382
   Reuben DB, 2015, ANN INTERN MED, V162, P295, DOI 10.7326/M14 2775
   Rios R, 2011, HEALTH PSYCHOL, V30, P58, DOI 10.1037/a0022025
   Schneider V, 2006, AM J EPIDEMIOL, V164, P881, DOI 10.1093/aje/kwj331
   Shanthanna H, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002369
   Smith DM, 2008, DISABIL REHABIL, V30, P418, DOI 10.1080/09638280701625237
   Sondergaard KB, 2017, EUR HEART J CARD PHA, V3, P100, DOI 10.1093/ehjcvp/pvw041
   SPICER CC, 1982, BRIT J CLIN PHARMACO, V14, P765, DOI 10.1111/j.1365 2125.1982.tb02034.x
   Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027
   Timmermans EJ, 2015, J RHEUMATOL, V42, P1885, DOI 10.3899/jrheum.141594
   Timmermans EJ, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 66
   Trelle S, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.c7086
   Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b
   Wehling M, 2014, EUR J CLIN PHARMACOL, V70, P1159, DOI 10.1007/s00228 014 1734 6
   Welsch P, 2015, SCHMERZ, V29, P85, DOI 10.1007/s00482 014 1436 0
   Whitney RL, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/10291
   Wiese AD, 2018, ANN INTERN MED, V168, P396, DOI 10.7326/M17 1907
   Zucker DR, 2006, J RHEUMATOL, V33, P2069
NR 50
TC 14
Z9 15
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0884 8734
EI 1525 1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JAN
PY 2020
VL 35
IS 1
BP 102
EP 111
DI 10.1007/s11606 019 05303 0
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA KJ2CJ
UT WOS:000511865500018
PM 31463686
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Luan, FJ
   Ma, KL
   Mao, J
   Yang, F
   Zhang, MH
   Luan, HX
AF Luan, Fujun
   Ma, Kunlong
   Mao, Jia
   Yang, Fan
   Zhang, Minghua
   Luan, Hexu
TI Differentiation of human amniotic epithelial cells into osteoblasts is
   induced by mechanical stretch via the Wnt/ catenin signalling pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE human amniotic epithelial cells; stem cell; mechanical stretch;
   osteogenic differentiation; cell therapy
ID GENE EXPRESSION; BETA CATENIN; STEM CELLS; BONE FORMATION;
   PROLIFERATION; STRAIN; REGENERATION; OSTEOGENESIS
AB Human amniotic epithelial cells (hAECs) have recently been recognized as a potential source of stem cells. The present study was designed to investigate the effects of mechanical stretch on the osteogenic differentiation of hAECs. As it has been previously reported that the physical environment is an important factor in maintaining the phenotype and functionality of differentiated cells, mechanical stretch was use to mimic the mechanical environment in the present study, with the following parameters: 5% elongation of the hAECs at a frequency of 0.5 Hz, with evaluation at 2, 6, 12 and 24 h time points. The osteogenic differentiation process of the hAECs followed by mechanical stimulation was evaluated by reverse transcription quantitative polymerase chain reaction (RT qPCR), western blotting and immunocytochemistry. Additionally, in a parallel study, a runt related transcription factor 2 (Runx2)/core binding factor 1 (Cbfa1) specific short hairpin RNA (shRNA) plasmid vector and a scrambled shRNA control plasmid was constructed for transfection into the hAECs prior to mechanical stimulation. The cultured hAECs exhibited a cobblestone shaped epithelial like phenotype and were positive for stage specific embryonic antigen 4, cytokeratin 19, cluster of differentiation 44 and octamer binding protein 4, as detected by flow cytometry, western blotting or confocal microscopy. The qPCR and western blotting data demonstrated that the mRNA and protein expression levels of Runx2/Cbfa1, alkaline phosphatase and osteocalcin were upregulated compared with the control group following stretching and they peaked at 12 h. These results indicated that the osteogenic differentiation of the hAECs was induced by mechanical stimuli. Additionally, the mRNA and protein expression levels of  catenin and cyclin D were increased significantly following stretching; however, they were decreased following Runx2/Cbfa1 shRNA transfection as observed by RT qPCR and western blotting. These results suggested that the Wnt/ catenin pathway may have an important role in mechanical stretch induced osteogenic differentiation of the hAECs. Furthermore, the combination of stretch and osteogenic induction medium had synergistic effects on the osteogenic differentiation. The results of the present study demonstrated that mechanical stimuli have an important role in osteogenic differentiation of hAECs via the Wnt/ catenin signalling pathway, which may be a potential therapeutic strategy in bone regenerative medicine.
C1 [Luan, Fujun; Ma, Kunlong; Yang, Fan; Zhang, Minghua; Luan, Hexu] Chongqing Med Univ, Yongchuan Hosp, Dept Orthoped, 439 Xuanhua Rd, Chongqing 402160, Peoples R China.
   [Mao, Jia] Chongqing Med Univ, Yongchuan Hosp, Dept Dermatol, Chongqing 402160, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University
RP Luan, HX (通讯作者)，Chongqing Med Univ, Yongchuan Hosp, Dept Orthoped, 439 Xuanhua Rd, Chongqing 402160, Peoples R China.
EM xiaoyuer20131213@126.com
FU Yongchuan Science and Technology Commission [2015nc5006]
FX The present study was supported by the Yongchuan Science and Technology
   Commission (grant no. YCSTC, 2015nc5006).
CR Dao DY, 2012, J BONE MINER RES, V27, P1680, DOI 10.1002/jbmr.1639
   DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070
   Gao J, 2016, MOL MED REP, V14, P218, DOI 10.3892/mmr.2016.5239
   Hata M, 2013, TISSUE ENG PT A, V19, P625, DOI 10.1089/ten.tea.2012.0099
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Hodge A, 2014, CYTOTHERAPY, V16, P1132, DOI 10.1016/j.jcyt.2014.01.005
   Ilancheran S, 2009, PLACENTA, V30, P2, DOI 10.1016/j.placenta.2008.09.009
   Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806
   Kakishita K, 2000, EXP NEUROL, V165, P27, DOI 10.1006/exnr.2000.7449
   Kestler HA, 2008, PHILOS T R SOC B, V363, P1333, DOI 10.1098/rstb.2007.2251
   Kim IS, 2010, J DENT RES, V89, P1129, DOI 10.1177/0022034510375283
   Koike M, 2005, J BONE MINER METAB, V23, P219, DOI 10.1007/s00774 004 0587 y
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Liu C., 2014, BIOMED RES INT UK, V2014, DOI [10.1155/2014/627380, DOI 10.1155/2014/627380]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maul TM, 2011, BIOMECH MODEL MECHAN, V10, P939, DOI 10.1007/s10237 010 0285 8
   Miki T, 2007, J REPROD IMMUNOL, V75, P91, DOI 10.1016/j.jri.2007.03.017
   Miki Toshio, 2010, Curr Protoc Stem Cell Biol, VChapter 1, DOI [10.1002/9780470151808.sc01e03s3, 10.1002/9780470151808.sc01e03s12]
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Niknejad H, 2010, EUR CELLS MATER, V19, P22, DOI 10.22203/eCM.v019a03
   Parolini O, 2008, STEM CELLS, V26, P300, DOI 10.1634/stemcells.2007 0594
   Qi MC, 2009, INT J ORAL SCI, V1, P143, DOI 10.4248/IJOS.09021
   Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249
   Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200
   Toda A, 2007, J PHARMACOL SCI, V105, P215, DOI 10.1254/jphs.CR0070034
   Wang Q, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 271
   WLODARSK.K, 1971, B ACAD POL SCI BIOL, V19, P821
   Wu YQ, 2013, MOL CELL BIOCHEM, V382, P273, DOI 10.1007/s11010 013 1744 1
   Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200
   Yang YQ, 2006, FRONT BIOSCI LANDMRK, V11, P776, DOI 10.2741/1835
NR 30
TC 9
Z9 11
U1 0
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2018
VL 18
IS 6
BP 5717
EP 5725
DI 10.3892/mmr.2018.9571
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HA7DE
UT WOS:000450440600108
PM 30365100
OA Bronze
DA 2025 08 17
ER

PT J
AU Still, K
   Grabowski, P
   Mackie, I
   Perry, M
   Bishop, N
AF Still, Karen
   Grabowski, Peter
   Mackie, Ian
   Perry, Mark
   Bishop, Nick
TI The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists
   Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and
   Induce Periosteal Bone Formation In Vivo
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Peroxisome proliferator activator receptor; Bone formation;
   Osteoporosis; Periosteum
ID PPAR DELTA; TRANSCRIPTIONAL REPRESSION; PROSTAGLANDIN E 2; NUCLEAR
   RECEPTOR; MALE RATS; MARROW; CELLS; INFLAMMATION; EICOSANOIDS; ALPHA
AB We showed previously that some actions of prostaglandin E(2) (PGE(2)) on bone are caused by its degradation product, PGA(2), which mediates its effects via a class of nuclear receptors known as the peroxisome proliferator activator receptors (PPARs), suggesting that the PPARs may be involved in the regulation of bone formation. The aims of this study were to determine the effects of PPAR alpha/delta agonists on bone in vitro and in vivo. PPAR agonists were examined in vitro using the fibroblastic colony forming unit (CFU f) assay. The PPAR alpha/delta agonists linoleic acid (LA) and bezafibrate (Bez) were then administered to intact male rats by daily s.c. injection for 12 weeks with either vehicle (10% dimethyl sulfoxide), LA (0.3 mg/kg), or Bez (1 mg/kg). CFU f assays were performed on stromal cells ex vivo. Bone mineral density (BMD) and serum markers of formation and resorption were measured. Bone histomorphometry was performed at cancellous and cortical bone sites. PPAR alpha/delta agonists increased significantly the number of osteoblastic colonies as demonstrated by increased alkaline phosphatase activity, collagen production, and calcification. This increase was typically equal to or greater than that achieved with the known bone anabolic agent PGE(2). In intact male rats, LA and Bez increased metaphyseal BMD by 7% and 11%, respectively. Increased BMD was associated with an increase in total bone area, although no changes were observed in bone formation rate within the trabecular compartment. Serum osteocalcin and osteoprogenitor numbers were increased, whereas there was no change in either tartrate resistant acid phosphatase 5b or osteoclast number. Both LA and Bez increased cortical bone area by approximately 38%, periosteal perimeter by 15%, and periosteal bone formation by 221% and 140%, respectively. There was no effect on medullary cavity area or endocortical perimeter. These data suggest that PPAR alpha/delta may have roles in bone anabolism, specifically in the regulation of periosteal bone formation. They are potential therapeutic targets for osteoporosis therapy.
C1 [Still, Karen; Grabowski, Peter; Mackie, Ian; Bishop, Nick] Univ Sheffield, Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield S10 2TH, S Yorkshire, England.
   [Perry, Mark] Univ Bristol, Dept Anat, Bristol, Avon, England.
C3 University of Sheffield; Sheffield Children's NHS Foundation Trust;
   Sheffield Children's Hospital; University of Bristol
RP Still, K (通讯作者)，Univ Sheffield, Sheffield Childrens Hosp, Acad Unit Child Hlth, Sheffield S10 2TH, S Yorkshire, England.
EM k.still@sheffield.ac.uk
RI ; Grabowski, Peter/G 2345 2010; perry, mark/B 7854 2009
OI Mackie, Ian/0000 0003 1224 3870; Grabowski, Peter/0000 0001 5924 1587;
   Still, Karen/0000 0001 9156 7640
FU Research into Ageing and Strakan Pharmaceuticals
FX This work was supported by grants from Research into Ageing and Strakan
   Pharmaceuticals.
CR Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920
   *BRIT MED J ROYAL, 2005, BRIT NAT FORM, V50
   Chan BY, 2007, BONE, V40, P149, DOI 10.1016/j.bone.2006.07.029
   Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0
   Dobson KR, 1999, CALCIFIED TISSUE INT, V65, P411, DOI 10.1007/s002239900723
   Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312
   Fredenrich A, 2005, DIABETES METAB, V31, P23, DOI 10.1016/S1262 3636(07)70162 3
   Jackson SM, 2000, FEBS LETT, V471, P119, DOI 10.1016/S0014 5793(00)01372 7
   Kafienah W, 2007, STEM CELLS, V25, P2460, DOI 10.1634/stemcells.2007 0059
   Kawaguchi H, 2005, J BONE MINER METAB, V23, P275, DOI 10.1007/s00774 005 0599 2
   KE HZ, 1992, CALCIFIED TISSUE INT, V50, P245, DOI 10.1007/BF00296289
   Lee CH, 2003, SCIENCE, V302, P453, DOI 10.1126/science.1087344
   MA YF, 1994, BONE, V15, P137, DOI 10.1016/8756 3282(94)90700 5
   Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958 1669(99)00030 0
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rzonca SO, 2004, ENDOCRINOLOGY, V145, P401, DOI 10.1210/en.2003 0746
   Sampath H, 2005, ANNU REV NUTR, V25, P317, DOI 10.1146/annurev.nutr.25.051804.101917
   Scutt A, 2003, METH MOLEC MED, V80, P29
   Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099
   Still K, 2001, PROSTAG OTH LIPID M, V65, P21, DOI 10.1016/S0090 6980(01)00117 4
   Still K, 2003, CALCIFIED TISSUE INT, V73, P173, DOI 10.1007/s00223 002 2076 4
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g
   Yao W, 1999, BONE, V25, P697, DOI 10.1016/S8756 3282(99)00220 3
   YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975
NR 25
TC 51
Z9 58
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD OCT
PY 2008
VL 83
IS 4
BP 285
EP 292
DI 10.1007/s00223 008 9175 9
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 363IO
UT WOS:000260261200006
PM 18836674
DA 2025 08 17
ER

PT J
AU Huertas, RM
   De Luna Bertos, E
   Ramos Torrecillas, J
   Leyva, FM
   Ruiz, C
   García Martínez, O
AF Medina Huertas, Rosa
   De Luna Bertos, Elvira
   Ramos Torrecillas, Javier
   Medina Leyva, Francisco
   Ruiz, Concepcion
   Garcia Martinez, Olga
TI Effect and Clinical Implications of the Low Energy Diode Laser on Bone
   Cell Proliferation
SO BIOLOGICAL RESEARCH FOR NURSING
LA English
DT Article
DE diode laser; cell proliferation; osteoblasts; bone; cell growth
ID NODULE FORMATION; IRRADIATION; THERAPY; DIFFERENTIATION; EXPRESSION
AB Laser is a simple, noninvasive technique that has proven useful for treating damaged tissue. However, its effects on bone regeneration and the mechanisms involved are poorly understood. The objective of this study was to evaluate the effects on MG 63 cell proliferation of application of a pulsed diode laser (Ezlase) of 940 nm at low energy levels. After 24 hr of culture, osteoblasts underwent pulsed laser radiation at 0.5, 1, 1.5, and 2 W and fluences of 1 5 J. A control group was not irradiated. After the treatment, cells were incubated for 24 hr, and cell proliferation was analyzed using a spectrophotometric measure of cell respiration (MTT assay). Results were expressed as percentage proliferation versus controls. At 24 hr culture, cell proliferation was increased in laser treated cells at intensities of 0.5, 1, and 1.5 W/cm(2 )versus controls; the energy density was positively correlated with cell growth, which reached a peak at 3 J and decreased at higher fluences. The use of pulsed low level laser with low energy density range thus appears to exert a biostimulatory effect on bone tissue. Although the data on cell proliferation are robust, in depth investigation is required into the effect of these irradiation doses on other cell parameters. The present findings demonstrate that laser therapy could be highly useful in tissue regeneration in different clinical settings, including nursing, physical therapy, dentistry, and traumatology.
C1 [Medina Huertas, Rosa; De Luna Bertos, Elvira; Ramos Torrecillas, Javier; Medina Leyva, Francisco; Ruiz, Concepcion; Garcia Martinez, Olga] Univ Granada, Fac Hlth Sci, Biomed Grp BIO277, Dept Nursing, E 18071 Granada, Spain.
   [Medina Huertas, Rosa] Univ Granada, Dept Stomatol, E 18071 Granada, Spain.
   [Ruiz, Concepcion] Univ Granada, Inst Neurosci, Armilla, Granada, Spain.
C3 University of Granada; University of Granada; University of Granada
RP García Martínez, O (通讯作者)，Univ Granada, Fac Hlth Sci, Biomed Grp BIO277, Dept Nursing, Avda Madrid S N, E 18071 Granada, Spain.
EM ogm@ugr.es
RI Ruiz, Concepcion/L 2808 2014; De Luna Bertos, Elvira/F 8544 2016;
   Concepcion, Ruiz/L 2808 2014; García Martínez, Olga/L 2782 2014;
   Garcia Martinez, Olga/L 2782 2014; Ramos Torrecillas, Javier/F 3746 2012
OI De Luna Bertos, Elvira/0000 0002 4381 5942; Concepcion,
   Ruiz/0000 0003 4332 6812; Garcia Martinez, Olga/0000 0003 1912 4639;
   Ramos Torrecillas, Javier/0000 0002 6631 7866
FU research group BIO277 (Junta de Andalucia); Department of Nursing of the
   Health Sciences, School of the University of Granada
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This study
   was supported by research group BIO277 (Junta de Andalucia) and by the
   Department of Nursing of the Health Sciences, School of the University
   of Granada.
CR Biko Y., 2010, LASER MED SCI, V25, P559
   Bostrom M., 2000, Curr Opin Orthop, V11, P403, DOI DOI 10.1097/00001433 200010000 00013
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Cobb CM, 2006, J PERIODONTOL, V77, P545, DOI 10.1902/jop.2006.050417
   Coombe A R, 2001, Clin Orthod Res, V4, P3, DOI 10.1034/j.1600 0544.2001.040102.x
   Diaz Rodriguez C. L., 2010, ACTA PHARMACOL SIN, V31, P1495
   Diaz Rodriguez L., 2012, ADV SCI LETT, V5, P1
   Díaz Rodríguez L, 2012, BIOL RES NURS, V14, P98, DOI 10.1177/1099800411398933
   Eduardo CD, 2010, LASER MED SCI, V25, P781, DOI 10.1007/s10103 010 0812 y
   Hamajima S, 2003, LASER MED SCI, V18, P78, DOI 10.1007/s10103 003 0255 9
   Howard G., 1998, ULTRAMEDICINE BIOL, V23, P1107
   Jakse N, 2007, CLIN ORAL IMPLAN RES, V18, P517, DOI 10.1111/j.1600 0501.2007.01369.x
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Lin TH, 2007, BONE, V41, P562, DOI 10.1016/j.bone.2007.06.017
   Martini L, 2003, CLIN ORTHOP RELAT R, P269, DOI 10.1097/01.blo.0000073344.50837.cd
   MORIMOTO Y, 1994, LASER SURG MED, V15, P191, DOI 10.1002/lsm.1900150207
   Ninomiya T, 2007, BONE, V40, P140, DOI 10.1016/j.bone.2006.07.026
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pearson G J, 2003, Dent Update, V30, P70
   Pejcic A, 2010, PHOTOMED LASER SURG, V28, P69, DOI 10.1089/pho.2008.2301
   Pinheiro ALB, 2006, PHOTOMED LASER SURG, V24, P169, DOI 10.1089/pho.2006.24.169
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Saracino S, 2009, LASER SURG MED, V41, P298, DOI 10.1002/lsm.20762
   Saygun I, 2008, LASER MED SCI, V23, P211, DOI 10.1007/s10103 007 0477 3
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479
NR 27
TC 36
Z9 40
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1099 8004
EI 1552 4175
J9 BIOL RES NURS
JI Biol. Res. Nurs.
PD APR
PY 2014
VL 16
IS 2
BP 191
EP 196
DI 10.1177/1099800413482695
PG 6
WC Nursing
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nursing
GA AB3QF
UT WOS:000331704600009
PM 23559459
DA 2025 08 17
ER

PT J
AU Ding, TX
   Li, Y
   Liu, FW
   Chen, J
   Chen, YC
   Kong, L
   Han, Y
   Zhang, L
AF Ding, Tiexin
   Li, Yan
   Liu, Fuwei
   Chen, Jun
   Chen, Yicheng
   Kong, Liang
   Han, Yong
   Zhang, Lan
TI Electron Spin Polarization Engineering in Ferromagnetic
   Bioheterojunction for Sonotherapy of Osteomyelitis
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE anti infection; bone regeneration; mechanosensitive ion channels;
   sonotherapy; spin polarization
ID STATIC MAGNETIC FIELD; PHOTODYNAMIC THERAPY; NANOPARTICLES;
   BIOMATERIALS; SPINTRONICS; CHALLENGES; STABILITY; MEMBRANES; EFFICIENT;
   BEHAVIOR
AB Electron spinning polarization has garnered increased attention for its potential to enhance device properties. However, its application in life health, specifically in anti infection and tissue repair, remains under explored. In this study, a ferromagnetic heterojunction CF (Fe3O4/TiO2) is constructed with spin polarized electrons, demonstrating efficient antibiosis performance with ultrasound (US) assistance. The antibacterial mechanism is elucidated as follows: spin polarized metallic states of Fe3O4 induce an asymmetric distribution in the electron spin state of TiO2, increasing the density of states of spin polarized electrons near the Fermi level of CF. Under US treatment, the built in electric field and spin polarized electrons in CF synergistically suppress the recombination of sono activated carriers, promoting reactive oxygen species (ROS) production. Simultaneously, the bacterial membrane is influenced by the micromagnetic field induced by spin polarized electrons, causing a severe disturbance in the bacterial respiratory chain. The combined damage from ROS and disturbed respiratory chain results in bacterial death. Fortunately, the micromagnetic field built by CF activates specific mechanosensitive ion channels, including TREK1, Piezo1, and related pathways, enhancing osteoblast differentiation. Sonotherapy using CF exhibits an excellent therapeutic effect in treating osteomyelitis. This study provides novel insights into manipulating spin electrons for applications in life health.
   Magnetite Fe3O4 influences the electron spin states of TiO2, endowing the TiO2/Fe3O4 bioheterojunction with a heightened spin polarization state and magnetic moment. The spin polarized electrons in the bioheterojunction enhance sono induced ROS production and disturb the bacterial respiratory chain, leading to bacterial death; they also form a micromagnetic field, activating mechanosensitive channels of osteoblasts, promoting osteogenesis differentiation and bone regeneration after antibiotic therapy. image
C1 [Ding, Tiexin; Li, Yan; Han, Yong; Zhang, Lan] Xi An Jiao Tong Univ, State key Lab Mech Behav Mat, Xian 710049, Peoples R China.
   [Liu, Fuwei; Chen, Yicheng; Kong, Liang] Fourth Mil Med Univ, Sch Stomatol, Natl Clin Res Ctr Oral Dis,Dept Oral & Maxillofaci, Shaanxi Clin Res Ctr Oral Dis,State Key Lab Oral &, Xian 710032, Peoples R China.
   [Chen, Jun] Xian Peoples Hosp, Xian 4 Hosp, Dept Osteol, Xian 710100, Peoples R China.
   [Han, Yong] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Orthopaed, Xian 710061, Peoples R China.
   [Zhang, Lan] Shanghai Univ, Natl Ctr Translat Med Shanghai, SHU Branch, Shanghai 200444, Peoples R China.
C3 Xi'an Jiaotong University; Air Force Medical University; Xi'an Jiaotong
   University; Shanghai University
RP Han, Y; Zhang, L (通讯作者)，Xi An Jiao Tong Univ, State key Lab Mech Behav Mat, Xian 710049, Peoples R China.; Han, Y (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Orthopaed, Xian 710061, Peoples R China.; Zhang, L (通讯作者)，Shanghai Univ, Natl Ctr Translat Med Shanghai, SHU Branch, Shanghai 200444, Peoples R China.
EM yonghan@mail.xjtu.edu.cn; lan.zhang@mail.xjtu.edu.cn
RI Chang, Ti Cheng/N 3252 2018
OI Ding, Tiexin/0009 0001 2469 7637; Zhang, Lan/0000 0002 2162 3333
FU National Natural Science Foundation of China [51771142, 51971171];
   Research Fund for the National Natural Science Foundation of China
   [2021JC 070, 2023 JC ZD 20]; Natural Science Foundation of Shaanxi
   Province [SUITM 202311]; Foundation of National Center for Translational
   Medicine (Shanghai) SHU Branch
FX The authors appreciate the Research Fund for the National Natural
   Science Foundation of China (Grant No. 51771142, 51971171), Natural
   Science Foundation of Shaanxi Province (No. 2021JC 070, 2023 JC ZD 20),
   and the Foundation of National Center for Translational Medicine
   (Shanghai) SHU Branch (No. SUITM 202311) for financially supporting this
   work. The authors also acknowledge Prof. Yanhuai Li from Xi'an Jiaotong
   University for the TEM observation.
CR Ansaloni L, 2015, J MEMBRANE SCI, V490, P18, DOI 10.1016/j.memsci.2015.03.097
   Armiento AR, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909874
   Awschalom DD, 2007, NAT PHYS, V3, P153, DOI 10.1038/nphys551
   Bi H, 2021, J MATER CHEM A, V9, P3940, DOI 10.1039/d0ta12612h
   Bian J, 2021, ANGEW CHEM INT EDIT, V60, P20906, DOI 10.1002/anie.202106929
   Binhi VN, 2001, BIOELECTROMAGNETICS, V22, P79, DOI 10.1002/1521 186X(200102)22:2<79::AID BEM1009>3.0.CO;2 7
   Biz C, 2021, ACS CATAL, V11, P14249, DOI 10.1021/acscatal.1c03135
   Bjorck ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05615 5
   Bliem R, 2016, P NATL ACAD SCI USA, V113, P8921, DOI 10.1073/pnas.1605649113
   BLOCHL PE, 1994, PHYS REV B, V49, P16223, DOI 10.1103/PhysRevB.49.16223
   Cai Y, 2024, ADV MATER, V36, DOI 10.1002/adma.202306676
   Cao FF, 2019, ANGEW CHEM INT EDIT, V58, P16236, DOI 10.1002/anie.201908289
   Carmeli I, 2014, ANGEW CHEM INT EDIT, V53, P8953, DOI 10.1002/anie.201404382
   Chen J, 2019, ADV MATER, V31, DOI 10.1002/adma.201902902
   Chen JZ, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201702714
   Chen S, 2023, ADV MATER, V35, DOI 10.1002/adma.202203836
   Cheng SN, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202212489
   Deng H, 2005, ANGEW CHEM INT EDIT, V44, P2782, DOI 10.1002/anie.200462551
   Dieny B, 2020, NAT ELECTRON, V3, P446, DOI 10.1038/s41928 020 0461 5
   Ding T., 2023, Small, V19
   Ding TX, 2024, NANO TODAY, V54, DOI 10.1016/j.nantod.2023.102069
   Dobson J, 2008, NAT NANOTECHNOL, V3, P139, DOI 10.1038/nnano.2008.39
   Dudarev SL, 1998, PHYS REV B, V57, P1505, DOI 10.1103/PhysRevB.57.1505
   Elzerman JM, 2004, NATURE, V430, P431, DOI 10.1039/nature02693
   Ermis M, 2018, BIOACT MATER, V3, P355, DOI 10.1016/j.bioactmat.2018.05.005
   Fang JJ, 2023, SMALL, V19, DOI 10.1002/smll.202207467
   Feng ZZ, 2018, SMALL, V14, DOI 10.1002/smll.201704347
   Fu H, 2023, ADV SCI, V10, DOI 10.1002/advs.202206865
   Fu JN, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202304162
   Gao WQ, 2023, NANO ENERGY, V110, DOI 10.1016/j.nanoen.2023.108381
   Gartzke J, 2002, AM J PHYSIOL CELL PH, V283, pC1333, DOI 10.1152/ajpcell.00167.2002
   Gmitrov J, 2020, BIOELECTROMAGNETICS, V41, P447, DOI 10.1002/bem.22272
   Guan H., 2023, ADV MATER
   Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092 8674(00)81279 9
   Guo Q, 2019, ADV MATER, V31, DOI 10.1002/adma.201901997
   Hebbar RS, 2016, J MATER CHEM A, V4, P764, DOI 10.1039/c5ta09281g
   Inoue S, 2023, BONE, V177, DOI 10.1016/j.bone.2023.116916
   Ji B, 2022, THERANOSTICS, V12, P434, DOI 10.7150/thno.67300
   Jiang PL, 2021, BIOACT MATER, V6, P1118, DOI 10.1016/j.bioactmat.2020.10.006
   Jin LG, 2023, ACS NANO, V17, P18200, DOI 10.1021/acsnano.3c05130
   Ju S, 2012, J AM CHEM SOC, V134, P13780, DOI 10.1021/ja305167h
   KRESSE G, 1994, J PHYS CONDENS MAT, V6, P8245, DOI 10.1088/0953 8984/6/40/015
   Ku MY, 2023, ACS NANO, V17, P14840, DOI 10.1021/acsnano.3c03134
   Kuang HJ, 2023, NAT METAB, V5, P111, DOI 10.1038/s42255 022 00723 5
   Li HD, 2022, CELLS BASEL, V11, DOI 10.3390/cells11050827
   Li HN, 2023, THERANOSTICS, V13, P5386, DOI 10.7150/thno.87854
   Li HN, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1670
   Li JF, 2023, ADV MATER, V35, DOI 10.1002/adma.202210296
   Li L, 2023, ADV MATER, V35, DOI 10.1002/adma.202302966
   Li M, 2019, ADV SCI, V6, DOI 10.1002/advs.201900599
   Li Y., 2021, Nat. Commun, V12, P2608, DOI DOI 10.1038/S41467 021 22865 Y
   Li YY, 2022, ENERG ENVIRON SCI, V15, P265, DOI 10.1039/d1ee02222a
   Li ZJ, 2021, ACS NANO, V15, P7105, DOI 10.1021/acsnano.1c00251
   Lin CC, 2022, J AM CHEM SOC, V144, P15718, DOI 10.1021/jacs.2c06060
   Lopez Heredia MA, 2008, BIOMATERIALS, V29, P2608, DOI 10.1016/j.biomaterials.2008.02.021
   Martín Rodríguez AJ, 2023, TRENDS MICROBIOL, V31, P120, DOI 10.1016/j.tim.2022.08.007
   Michaeli K, 2019, P NATL ACAD SCI USA, V116, P5931, DOI 10.1073/pnas.1816956116
   Milner AA, 2017, PHYS REV LETT, V118, DOI 10.1103/PhysRevLett.118.243201
   Minot ED, 2004, NATURE, V428, P536, DOI 10.1038/nature02425
   Murphy WL, 2014, NAT MATER, V13, P547, DOI [10.1038/NMAT3937, 10.1038/nmat3937]
   Orapiriyakul W, 2020, ACS NANO, V14, P10027, DOI 10.1021/acsnano.0c03130
   Ouyang QL, 2023, SMALL, V19, DOI 10.1002/smll.202205292
   Pan L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14333 w
   Perdew JP, 1997, PHYS REV LETT, V78, P1396, DOI 10.1103/PhysRevLett.77.3865
   Qin L, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00168 8
   Ramsteiner A, 2002, PHYSICA E, V13, P529, DOI 10.1016/S1386 9477(02)00187 X
   Sadowska JM, 2021, MATER TODAY, V46, P136, DOI 10.1016/j.mattod.2020.12.018
   Singh A, 2018, ACS APPL BIO MATER, V1, P3, DOI 10.1021/acsabm.8b00033
   Sohail M, 2024, NANOSCALE ADV, V6, P1286, DOI 10.1039/d3na00442b
   Song SQ, 2022, PROG BIOPHYS MOL BIO, V172, P39, DOI 10.1016/j.pbiomolbio.2022.04.006
   Sorenson TA, 2002, J AM CHEM SOC, V124, P7604, DOI 10.1021/ja0201101
   Stausholm Moller J, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3492449
   Sun D, 2020, ACS NANO, V14, P2063, DOI 10.1021/acsnano.9b08667
   Sun ZM, 2022, J AM CHEM SOC, V144, P8204, DOI 10.1021/jacs.2c01153
   Unnithan AR, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202201311
   Wang CF, 2023, ADV FUNCT MATER, DOI 10.1002/adfm.202306493
   Wang D, 2023, NANO TODAY, V49, DOI 10.1016/j.nantod.2023.101803
   Wang L. J., 2020, NAT COMMUN, P11
   Wang WT, 2024, ADV MATER, V36, DOI 10.1002/adma.202307785
   Wang ZH, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 43074 9
   Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389
   Wosik J, 2018, BIOPHYS J, V114, P2001, DOI 10.1016/j.bpj.2018.03.002
   Xiang YM, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf0854
   Xu QL, 2020, CHEM US, V6, P1543, DOI 10.1016/j.chempr.2020.06.010
   Yang HY, 2021, NANO MICRO LETT, V13, DOI 10.1007/s40820 020 00561 8
   Yoneda M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194960
   Yu Y, 2023, ACS NANO, V17, P21018, DOI 10.1021/acsnano.3c03858
   Yuan M, 2023, ADV MATER, V35, DOI 10.1002/adma.202209589
   Zaki E, 2018, PHYS CHEM CHEM PHYS, V20, P15764, DOI 10.1039/c8cp02333f
   Zeng YX, 2023, SMALL METHODS, V7, DOI 10.1002/smtd.202201248
   Zhang C, 2023, ADV MATER, V35, DOI 10.1002/adma.202303059
   Zhang CL, 2022, ACS NANO, DOI 10.1021/acsnano.2c06030
   Zhang CY., 2022, Angew. Chem., V61
   Zhang M, 2016, ACTA PHARMACOL SIN, V37, P1190, DOI 10.1038/aps.2016.65
   Zhang XY, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202300866
   Zhang Y, 2009, CHEM REV, V109, P4828, DOI 10.1021/cr800557s
   Zhou TF, 2020, ELIFE, V9, DOI 10.7554/eLife.52779
   Zhu LY, 2020, J FUNCT FOODS, V64, DOI 10.1016/j.jff.2019.103697
NR 98
TC 8
Z9 8
U1 38
U2 130
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD AUG
PY 2024
VL 34
IS 34
DI 10.1002/adfm.202401795
EA APR 2024
PG 20
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA D6Y1G
UT WOS:001194238300001
DA 2025 08 17
ER

PT J
AU Juffroy, O
   Noël, D
   Delanoye, A
   Viltart, O
   Wolowczuk, I
   Verwaerde, C
AF Juffroy, Olivier
   Noel, Daniele
   Delanoye, Anne
   Viltart, Odile
   Wolowczuk, Isabelle
   Verwaerde, Claudie
TI Subcutaneous graft of D1 mouse mesenchymal stem cells leads to the
   formation of a bone like structure
SO DIFFERENTIATION
LA English
DT Article
DE Mesenchymal stem cells; Differentiation; Graft; Bone; Adipocyte
ID MARROW STROMAL CELLS; IN VITRO; HUMAN PLACENTA; DIFFERENTIATION;
   ADIPOGENESIS; EXPRESSION; OSTEOIMMUNOLOGY; REGENERATION; PROGENITORS;
   MECHANISMS
AB Mesenchymal stem cells (MSC) are capable of both self renewal and multi lineage differentiation into mesoderm type cells such as osteoblasts, chondrocytes, adipocytes and myocytes. Together the multipotent nature of MSCs and the facility to expand them in vitro make these cells ideal resources for regenerative medicine, particularly for bone reconstruction, and therefore research efforts focused on defining efficient protocols for directing their differentiation into the requisite lineage. Despite much progress in identifying mechanisms and factors that direct and control in vitro osteogenic differentiation of MSCs, a rapid and simple model to evaluate in vivo tissue formation is still lacking. Here, we describe the unique capacity of the murine bone marrow derived D1 MSC cell line, which differentiates in vitro into at least three cell lineages, to form in vivo a structure resembling bone. This bone like structure was obtained after subcutaneous grafting of D1 cells into immunocompetent mice without the need of neither an osteogenic factor nor scaffold material. These data allow us to propose this cell model as a tool for exploring in vivo the mechanisms and/or factors that govern and potentially regulate osteogenesis. (C) 2009 International Society of Differentiation. Published by Elsevier Ltd. All rights reserved.
C1 [Delanoye, Anne; Viltart, Odile; Wolowczuk, Isabelle; Verwaerde, Claudie] Inst Pasteur, Lab NeuroImmunoEndocrinol, IFR 142, F 59019 Lille, France.
   [Juffroy, Olivier; Delanoye, Anne; Wolowczuk, Isabelle; Verwaerde, Claudie] Inst Pasteur, CNRS, UMR 8527, F 59019 Lille, France.
   [Noel, Daniele] Hop St Eloi, INSERM, U844, F 34295 Montpellier, France.
C3 Pasteur Network; Universite de Lille; Institut Pasteur Lille; Centre
   National de la Recherche Scientifique (CNRS); Pasteur Network;
   Universite de Lille; Institut Pasteur Lille; Universite de Montpellier;
   CHU de Montpellier; Institut National de la Sante et de la Recherche
   Medicale (Inserm)
RP Verwaerde, C (通讯作者)，Inst Pasteur, Lab NeuroImmunoEndocrinol, IFR 142, 1 Rue Pr Calmette,BP447, F 59019 Lille, France.
EM claudie.verwaerde@ibl.fr
RI Noel, Daniele/E 5719 2016
OI Noel, Daniele/0000 0002 3498 3776; wolowczuk,
   isabelle/0000 0001 6692 6904
CR Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067
   ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294
   Awad HA, 2007, TISSUE ENG, V13, P1973, DOI 10.1089/ten.2006.0107
   Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249
   Bieback Karen, 2007, Curr Stem Cell Res Ther, V2, P310, DOI 10.2174/157488807782793763
   Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623 199707000 00012
   Cui QJ, 2000, CONNECT TISSUE RES, V41, P45
   Dahir GA, 2000, CLIN ORTHOP RELAT R, pS134
   DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092 8674(87)90585 X
   DIDUCH DR, 1993, J BONE JOINT SURG AM, V75A, P92, DOI 10.2106/00004623 199301000 00012
   Ferrari G, 1998, SCIENCE, V281, P923
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   FRIEDENSTEIN AJ, 1974, TRANSPLANTATION, V17, P331, DOI 10.1097/00007890 197404000 00001
   Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22 5 649
   Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959
   Granero Molto F, 2008, EXPERT OPIN BIOL TH, V8, P255, DOI 10.1517/14712598.8.3.255 
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   Jorgensen C, 2008, BEST PRACT RES CL RH, V22, P269, DOI 10.1016/j.berh.2008.01.005
   Khan Y, 2008, J BONE JOINT SURG AM, V90A, P36, DOI 10.2106/JBJS.G.01260
   Kimelman N, 2007, TISSUE ENG, V13, P1135, DOI 10.1089/ten.2007.0096
   Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Muraglia A, 2000, J CELL SCI, V113, P1161
   Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168 9525(03)00176 8
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   PINNEY DF, 1989, ENVIRON HEALTH PERSP, V80, P221, DOI 10.2307/3430747
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Porada Christopher D, 2006, Curr Stem Cell Res Ther, V1, P365
   Post S, 2008, BONE, V43, P32, DOI 10.1016/j.bone.2008.03.011
   REZNIKOFF CA, 1973, CANCER RES, V33, P3231
   Rosen ED, 2000, GENE DEV, V14, P1293
   Singh R, 2003, ENDOCRINOLOGY, V144, P5081, DOI 10.1210/en.2003 0741
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092 8674(79)90317 9
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097 4547(20000815)61:4<364::AID JNR2>3.0.CO;2 C
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 39
TC 21
Z9 24
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0301 4681
J9 DIFFERENTIATION
JI Differentiation
PD NOV
PY 2009
VL 78
IS 4
BP 223
EP 231
DI 10.1016/j.diff.2009.07.005
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 555RU
UT WOS:000274532600004
PM 19682787
DA 2025 08 17
ER

PT J
AU Zheng, L
AF Zheng, Li
TI Luteolin Stimulates Proliferation and Inhibits Late Differentiation of
   Primary Rat Calvarial Osteoblast Induced by High dose Dexamethasone via
   Sema3A/NRP1/Pleixin A1
SO CURRENT PHARMACEUTICAL BIOTECHNOLOGY
LA English
DT Article
DE Osteoblast; dexamethasone; luteolin; semaphorin 3A; neuropilin 1; plexin
   A1; proliferation; differentiation
AB Background: Although Semaphorin 3A (Sema3A)/ Neuropilin 1(NRP1)/Plexin A1 is one of the important targets in bone metabolism, few studies are performed on this target in the glucocorticoids induced osteoporosis. Luteolin is a chemical component of Honeysuckle and it has various bioactivities. The effect of Luteolin on the glucocorticoids induced osteoporosis (primary osteoblasts model) remain unknown. Objective: The aim of this study was to investigate the action of Sema3A/ NRP1/Plexin A1 in Luteolin induced osteoprotection against high dose Dexamethasone. Methods: The effect of Luteolin on the proliferation, late differentiation, and apoptosis of primary osteoblasts model of glucocorticoids induced osteoporosis in vitro as well as the expression of Sema3A/NRP1/Plexin A1 are investigated by using 3 (4,5 dimethyl 2 thiazolyl) 2,5 diphenyl 2 Htetrazolium bromide, Cell Counting Kit 8, reverse transcription quantitative real time polymerase chain reaction, western bolting and so on. Results: Suckling SD rats' calvarial osteoblasts were isolated and identified. The glucocorticoidsinduced primary osteoporosis cell model was established by 100 mu M Dexamethasone in 48 h (P<0.01). Luteolin promotes osteoblasts either in physiological condition (without Dexamethasone) or pathological condition (with Dexamethasone) at 1 mu M concentration for 48h (P<0.01). Luteolin partly reverses down regulated expression of proliferation markers such as proliferating cell nuclear and CyclinD1. (P<0.01) Similarly, Luteolin partly reverses up regulated expression of apoptosis markers such as Bax/B cell lymphoma 2. (P<0.01) The expression of mRNA and protein of Sema3A/ NRP1/Plexin A1 decreased in model one which significantly increased in Luteolin protecting one. (P<0.05) Interestingly, the late differentiation marker such as osteocalcin and collagenase I sharply decreased in Luteolin protecting group compared with model one. (P<0.01) Conclusion: The thesis concludes that Luteolin promoted the proliferation of osteoblast and inhibited its apoptosis and late differentiation in this glucocorticoids induced primary osteoporosis cell model. This function may be related to the expression of up regulated Sema3A/NRP1/Plexin A1. Therefore, Luteolin may be a potential medicine for the glucocorticoids induced osteoporosis.
C1 [Zheng, Li] Hebei Med Univ, Xingtai Med Coll, Coll Integrated Chinese & Western Med, Dept Pharm, 168 Gangtie Rd,361 East Zhongshan Rd, Shijiazhuang 054000, Hebei, Peoples R China.
C3 Xingtai Medical College; Hebei Medical University
RP Zheng, L (通讯作者)，Hebei Med Univ, Xingtai Med Coll, Coll Integrated Chinese & Western Med, Dept Pharm, 168 Gangtie Rd,361 East Zhongshan Rd, Shijiazhuang 054000, Hebei, Peoples R China.
EM lizheng_come_34@163.com
FU Xingtai Municipal Science and Technology Bureau [2018ZC133]
FX This research received a grant from Xingtai Municipal Science and
   Technology Bureau Selffunded Projects (2018ZC133) .
CR Adami G, 2019, CURR OPIN RHEUMATOL, V31, P388, DOI 10.1097/BOR.0000000000000608
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   Crasto GJ, 2013, J CELL BIOCHEM, V114, P929, DOI 10.1002/jcb.24434
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Jing Z, 2019, J CELL PHYSIOL, V234, P4472, DOI 10.1002/jcp.27252
   Kwon SM, 2016, J NUTR BIOCHEM, V30, P24, DOI 10.1016/j.jnutbio.2015.11.013
   Li CR, 2014, AM J CHINESE MED, V42, P1, DOI 10.1142/S0192415X14500013
   Liu YQ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00375
   Lotz EM, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115260
   Melguizo Rodríguez L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081722
   Melguizo Rodríguez L, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12904
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Qiao Q, 2018, J MOL HISTOL, V49, P369, DOI 10.1007/s10735 018 9776 1
   Shi YC, 2007, BONE, V41, P87, DOI 10.1016/j.bone.2007.04.174
   SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301 620X.69B4.3611151
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Yang K, 2018, BONE, V114, P40, DOI 10.1016/j.bone.2018.06.003
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   Yin H, 2018, BIOMED PHARMACOTHER, V97, P995, DOI 10.1016/j.biopha.2017.11.029
   Zhou MR, 2017, EXP THER MED, V14, P2445, DOI 10.3892/etm.2017.4802
NR 20
TC 11
Z9 12
U1 2
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 2010
EI 1873 4316
J9 CURR PHARM BIOTECHNO
JI Curr. Pharm. Biotechnol.
PY 2021
VL 22
IS 11
BP 1538
EP 1545
DI 10.2174/1389201021666201216150442
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA TM8ZX
UT WOS:000675837000012
PM 33327910
DA 2025 08 17
ER

PT J
AU Quinlan, E
   Partap, S
   Azevedo, MM
   Jell, G
   Stevens, MM
   O'Brien, FJ
AF Quinlan, Elaine
   Partap, Sonia
   Azevedo, Maria M.
   Jell, Gavin
   Stevens, Molly M.
   O'Brien, Fergal J.
TI Hypoxia mimicking bioactive glass/collagen glycosaminoglycan composite
   scaffolds to enhance angiogenesis and bone repair
SO BIOMATERIALS
LA English
DT Article
DE Collagen; Scaffold; Bioactive glass; Cobalt; Angiogenesis; Regenerative
   medicine
ID ENDOTHELIAL GROWTH FACTOR; COLLAGEN GAG SCAFFOLDS; INDUCIBLE
   FACTOR 1 ALPHA; IN VITRO; GLASS SCAFFOLDS; PORE SIZE; CELLS;
   REGENERATION; EXPRESSION; IMPROVES
AB One of the biggest challenges in regenerative medicine is promoting sufficient vascularisation of tissue engineered constructs. One approach to overcome this challenge is to target the cellular hypoxia inducible factor (HIF 1 alpha) pathway, which responds to low oxygen concentration (hypoxia) and results in the activation of numerous pro angiogenic genes including vascular endothelial growth factor (VEGF). Cobalt ions are known to mimic hypoxia by artificially stabilising the HIF 1 alpha transcription factor. Here, resorbable bioactive glass particles (38 gm and 100 gm) with cobalt ions incorporated into the glass network were used to create bioactive glass/collagen glycosaminoglycan scaffolds optimised for bone tissue engineering. Inclusion of the bioactive glass improved the compressive modulus of the resulting composite scaffolds while maintaining high degrees of porosity (>97%). Moreover, in vitro analysis demonstrated that the incorporation of cobalt bioactive glass with a mean particle size of 100 gm significantly enhanced the production and expression of VEGF in endothelial cells, and cobalt bioactive glass/collagen glycosaminoglycan scaffold conditioned media also promoted enhanced tubule formation. Furthermore, our results prove the ability of these scaffolds to support osteoblast cell proliferation and osteogenesis in all bioactive glass/collagen glycosaminoglycan scaffolds irrespective of the particle size. In summary, we have developed a hypoxia mimicking tissue engineered scaffold with pro angiogenic and pro osteogenic capabilities that may encourage bone tissue regeneration and overcome the problem of inadequate vascularisation of grafts commonly seen in the field of tissue engineering. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Quinlan, Elaine; Partap, Sonia; O'Brien, Fergal J.] Royal Coll Surgeons Ireland, Dept Anat, Tissue Engn Res Grp, Dublin 2, Ireland.
   [Quinlan, Elaine; Partap, Sonia; O'Brien, Fergal J.] Univ Dublin Trinity Coll, Trinity Ctr Bioengn, Dept Mech Engn, Dublin 2, Ireland.
   [Quinlan, Elaine; O'Brien, Fergal J.] RCSI, Adv Mat & BioEngn Res Ctr AMBER, Dublin 2, Ireland.
   [Quinlan, Elaine; O'Brien, Fergal J.] TCD, Dublin 2, Ireland.
   [Azevedo, Maria M.; Jell, Gavin; Stevens, Molly M.] Univ London Imperial Coll Sci Technol & Med, Dept Mat, London SW7 2AZ, England.
   [Azevedo, Maria M.; Stevens, Molly M.] Univ London Imperial Coll Sci Technol & Med, Inst Biomed Engn, London SW7 2AZ, England.
   [Jell, Gavin] UCL, Div Surg & Intervent Sci, London NW3 2QG, England.
C3 Royal College of Surgeons   Ireland; Trinity College Dublin; Royal
   College of Surgeons   Ireland; Trinity College Dublin; Imperial College
   London; Imperial College London; University of London; University
   College London
RP O'Brien, FJ (通讯作者)，Royal Coll Surgeons Ireland, Dept Anat, 123 St Stephens Green, Dublin 2, Ireland.
EM fjobrien@rcsi.ie
RI ; O'Brien, Fergal/F 9485 2011; Azevedo, Maria/M 5228 2013; Jell,
   Gavin/C 4893 2009; Stevens, Martin/J 6495 2013
OI Stevens, Molly/0000 0002 7335 266X; O'Brien, Fergal/0000 0003 2030 8005;
   Jell, Gavin/0000 0001 8115 1609; Azevedo, Maria/0000 0003 2703 3163;
   Partap, Sonia/0000 0002 5773 166X
FU European Research Council [239685]; European Research Council (ERC)
   [239685] Funding Source: European Research Council (ERC)
FX The authors would like to thank the European Research Council (239685  
   CollRegen ERC 2009 STG) for providing financial support to this project
   and Integra Life Sciences Inc. for supplying collagen through a
   Materials Transfer Agreement.
CR Ahmed I, 2010, J BIOMATER APPL, V24, P555, DOI 10.1177/0885328209102761
   Alcaide M, 2010, ACTA BIOMATER, V6, P892, DOI 10.1016/j.actbio.2009.09.008
   Alhag M, 2012, ORAL MAXILLOFAC SURG, V16, P47, DOI 10.1007/s10006 011 0299 0
   Alhag M, 2011, ORAL MAXILLOFAC SURG, V15, P31, DOI 10.1007/s10006 010 0241 x
   Azevedo MM, 2010, J MATER CHEM, V20, P8854, DOI 10.1039/c0jm01111h
   Azevedo MM, 2015, TISSUE ENG PT A, V21, P382, DOI [10.1089/ten.tea.2014.0083, 10.1089/ten.TEA.2014.0083]
   Azevedo MM, 2014, TISSUE ENG A
   Bergeron E, 2007, J MATER SCI MATER M, V18, P255, DOI 10.1007/s10856 006 0687 4
   Buttyan R, 2003, J UROLOGY, V169, P2402, DOI 10.1097/01.ju.0000058406.16931.93
   Cunniffe GM, 2010, J MATER SCI MATER M, V21, P2293, DOI 10.1007/s10856 009 3964 1
   Epstein Nancy E, 2011, Surg Neurol Int, V2, P10, DOI 10.4103/2152 7806.76147
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Gleeson JP, 2010, EUR CELLS MATER, V20, P218
   Gorustovich AA, 2010, TISSUE ENG PART B RE, V16, P199, DOI [10.1089/ten.teb.2009.0416, 10.1089/ten.TEB.2009.0416]
   Hamm A, 2002, TISSUE ENG, V8, P235, DOI 10.1089/107632702753725003
   Hattar S, 2005, BIOMATERIALS, V26, P839, DOI 10.1016/j.biomaterials.2004.03.026
   Haugh MG, 2009, J BIOMED MATER RES A, V89A, P363, DOI 10.1002/jbm.a.31955
   Hench LL, 2009, J EUR CERAM SOC, V29, P1257, DOI 10.1016/j.jeurceramsoc.2008.08.002
   Hench LL, 2002, SCIENCE, V295, P1014, DOI 10.1126/science.1067404
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Hu XY, 2008, J THORAC CARDIOV SUR, V135, P799, DOI 10.1016/j.jtcvs.2007.07.071
   Jones JR, 2007, ELEMENTS, V3, P393, DOI 10.2113/GSELEMENTS.3.6.393
   Jones JR, 2007, BIOMATERIALS, V28, P1653, DOI 10.1016/j.biomaterials.2006.11.022
   Kim HH, 2002, CYTOKINE, V17, P14, DOI 10.1006/cyto.2001.0985
   LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529
   Leach JK, 2006, BIOMATERIALS, V27, P3249, DOI 10.1016/j.biomaterials.2006.01.033
   Leu A, 2008, PHARM RES DORDR, V25, P1222, DOI 10.1007/s11095 007 9508 9
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lyons FG, 2010, BIOMATERIALS, V31, P9232, DOI 10.1016/j.biomaterials.2010.08.056
   Maeno S, 2005, BIOMATERIALS, V26, P4847, DOI 10.1016/j.biomaterials.2005.01.006
   Malda J, 2007, TISSUE ENG, V13, P2153, DOI 10.1089/ten.2006.0417
   Matsiko A, 2012, J MECH BEHAV BIOMED, V11, P41, DOI 10.1016/j.jmbbm.2011.11.012
   Murphy CM, 2010, CELL ADHES MIGR, V4, P377, DOI 10.4161/cam.4.3.11747
   Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189
   Novosel EC, 2011, ADV DRUG DELIVER REV, V63, P300, DOI 10.1016/j.addr.2011.03.004
   O'Brien FJ, 2011, MATER TODAY, V14, P88, DOI 10.1016/S1369 7021(11)70058 X
   O'Brien FJ, 2005, BIOMATERIALS, V26, P433, DOI 10.1016/j.biomaterials.2004.02.052
   O'Brien FJ, 2004, BIOMATERIALS, V25, P1077, DOI 10.1016/S0142 9612(03)00630 6
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Peters K, 2001, J MATER SCI MATER M, V12, P955, DOI 10.1023/A:1012852814570
   Rahaman MN, 2011, ACTA BIOMATER, V7, P2355, DOI 10.1016/j.actbio.2011.03.016
   Schoubben A, 2010, CHEM ENG J, V160, P363, DOI 10.1016/j.cej.2010.02.062
   Semenza GL, 2007, SCIENCE, V318, P62, DOI 10.1126/science.1147949
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058
   Steinbrech DS, 2000, AM J PHYSIOL CELL PH, V278, pC853, DOI 10.1152/ajpcell.2000.278.4.C853
   Street J, 2000, CLIN ORTHOP RELAT R, P224, DOI 10.1097/00003086 200009000 00033
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Tierney CM, 2009, J MECH BEHAV BIOMED, V2, P202, DOI 10.1016/j.jmbbm.2008.08.007
   Tierney CM, 2009, J BIOMED MATER RES A, V91A, P92, DOI 10.1002/jbm.a.32207
   Trentin D, 2006, P NATL ACAD SCI USA, V103, P2506, DOI 10.1073/pnas.0505964102
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131 198909000 00002
NR 57
TC 201
Z9 215
U1 0
U2 280
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2015
VL 52
BP 358
EP 366
DI 10.1016/j.biomaterials.2015.02.006
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA CG2FT
UT WOS:000353091000034
PM 25818442
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Cathonnas, R
   Rothermundt, C
   Bode, B
   Fuchs, B
   von Moos, R
   Schwitter, M
AF Cathonnas, Richard
   Rothermundt, Christian
   Bode, Beata
   Fuchs, Bruno
   von Moos, Roger
   Schwitter, Michael
TI RANK Ligand Blockade with Denosumab in Combination with Sorafenib in
   Chemorefractory Osteosarcoma: A Possible Step Forward?
SO ONCOLOGY
LA English
DT Article
DE Denosumab; Sorafenib; RANK; RANK ligand; Osteosarcoma
ID THERAPY; TUMOR; PROLIFERATION; INHIBITION; EFFICACY; PATHWAY; GROWTH;
   MODEL
AB Background:There is no established systemic treatment option for unresectable osteosarcoma progressing after standard chemotherapy. A recently published clinical trial has demonstrated some activity of sorafenib in this situation. Preclinical research suggests a role for the inhibition of the receptor activator of nuclear factor kappa B ligand (RANKL), but no clinical data have been reported so far.
   Case Report: A 37 year old man was diagnosed with unresectable osteoblastic, osteoblastoma like osteosarcoma in the C7/Th1 vertebra. The tumour progressed locally despite two lines of chemotherapy and stereotactic radiotherapy. On treatment with sorafenib and denosumab, a complete metabolic remission was achieved and is ongoing for over 18 months. lmnnunohistochemistry revealed an overexpression of RANK and RANKL in the patient's primary tumour.
   Discussion:This is the first report of activity achieved by the combination of the tyrosine kinase inhibitor sorafenib and the RANKL inhibitor denosumab in a patient with osteosarconna. It confirms preclinical data on RANK/RANKL inhibition in osteosarcoma and could serve as a hypothesis generating approach for clinical trials in this patient population.
   (C) 2014 S. Karger AG, Basel
C1 [Cathonnas, Richard; von Moos, Roger; Schwitter, Michael] Kantonsspital Graubunden, Div Oncol Haematol, CH 7000 Chur, Switzerland.
   [Rothermundt, Christian] Kantonsspital, Div Oncol Haematol, St Gallen, Switzerland.
   [Bode, Beata] Univ Zurich Hosp, Inst Surg Pathol, CH 8091 Zurich, Switzerland.
   [Fuchs, Bruno] Balgrist Univ Hosp Zurich, Sarcoma Ctr, Zurich, Switzerland.
   [Fuchs, Bruno] Balgrist Univ Hosp Zurich, Dept Orthopaed, Lab Orthopaed Res, Zurich, Switzerland.
C3 Kantonsspital Graubunden; Kantonsspital St. Gallen; Kantonsspital Aarau
   AG (KSA); University of Zurich; University Zurich Hospital; University
   of Zurich; University of Zurich
RP Cathonnas, R (通讯作者)，Kantonsspital Graubunden, Div Oncol Haematol, CH 7000 Chur, Switzerland.
EM richard.cathomas@ksgr.ch
RI von Moos, Roger/AAG 4570 2020; Cathomas, Richard/LEN 0672 2024
OI Rothermundt, Christian/0000 0002 2104 7794; 
CR Akiyama T, 2010, CLIN EXP METASTAS, V27, P207, DOI 10.1007/s10585 010 9319 y
   Akiyama T, 2010, J PHARM PHARMACOL, V62, P470, DOI 10.1211/jpp.62.04.0009
   Anninga JK, 2011, EUR J CANCER, V47, P2431, DOI 10.1016/j.ejca.2011.05.030
   Bago Horvath Z, 2014, PATHOLOGY, V46, P411, DOI 10.1097/PAT.0000000000000116
   Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029
   Bielack SS, 2009, J CLIN ONCOL, V27, P557, DOI 10.1200/JCO.2008.16.2305
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Collins M, 2013, J CLIN ONCOL, V31, P2303, DOI 10.1200/JCO.2012.43.8598
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Grignani G, 2012, ANN ONCOL, V23, P508, DOI 10.1093/annonc/mdr151
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lamoureux F, 2008, MOL CANCER THER, V7, P3389, DOI 10.1158/1535 7163.MCT 08 0497
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Lee JA, 2011, PEDIATR BLOOD CANCER, V56, P738, DOI 10.1002/pbc.22720
   Mei J, 2014, CELL BIOCHEM BIOPHYS, V69, P151, DOI 10.1007/s12013 013 9781 7
   Peddi P, 2013, CANCER TREAT REV, V39, P97, DOI 10.1016/j.ctrv.2012.07.002
   Pignochino Y, 2009, MOL CANCER, V8, DOI 10.1186/1476 4598 8 118
   Schoenfeld AJ, 2010, SPINE J, V10, P708, DOI 10.1016/j.spinee.2010.05.017
NR 18
TC 26
Z9 30
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0030 2414
EI 1423 0232
J9 ONCOLOGY BASEL
JI Oncology
PY 2015
VL 88
IS 4
BP 257
EP 260
DI 10.1159/000369975
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA CE5OJ
UT WOS:000351884700009
PM 25531914
OA Green Published
DA 2025 08 17
ER

PT J
AU Fellenberg, J
   Losch, S
   Tripel, E
   Lehner, B
   Melnik, S
AF Fellenberg, Joerg
   Losch, Sarina
   Tripel, Elena
   Lehner, Burkhard
   Melnik, Svitlana
TI The Warburg Trap: A Novel Therapeutic Approach for Targeting
   Osteosarcoma
SO CELLS
LA English
DT Article
DE osteosarcoma; Warburg Trap; chemotherapy; apoptosis; cancer stem cells
ID HIGH GRADE OSTEOSARCOMA; CHEMOTHERAPY; EURAMOS 1; METFORMIN; CANCER;
   BIOAVAILABILITY; EPIDEMIOLOGY; PROGRESSION; MAP
AB Although urgently needed, no significant improvements in osteosarcoma (OS) therapy have been achieved within the last decades. Here, we present a new therapeutic approach based on drug combinations consisting of mitochondrial complex I (MCI) inhibitors and ionophores that induce cancer cell specific cell death based on a modulation of cellular energy metabolism and intracellular pH (pHi) named the Warburg Trap (WT). The effects of several drug combinations on intracellular pH, cell viability, colony forming capacity and expression of WNT target genes were analysed using OS cell lines and primary human osteoblasts (HOB). Tumour take rates and tumour volumes were analysed in vivo using a chicken chorioallantoic membrane assay (CAM). Several WT drug combinations induced the intracellular acidification and apoptotic cell death in OS cells, whereas HOBs tolerated the treatment. A significant inhibition of the colony forming ability of OS cells and downregulation of WNT target genes suggest that cancer stem cells (CSCs) are also targeted by the WT approach. In vivo, we observed a significant reduction in the tumour take rates in response to WT drug treatment. Our data suggest that the Warburg Trap is a promising approach for the development of a novel and effective OS therapy to replace or supplement the current OS chemotherapy.
C1 [Fellenberg, Joerg; Losch, Sarina; Tripel, Elena; Lehner, Burkhard; Melnik, Svitlana] Univ Hosp Heidelberg, Dept Orthopaed, D 69118 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Fellenberg, J (通讯作者)，Univ Hosp Heidelberg, Dept Orthopaed, D 69118 Heidelberg, Germany.
EM joerg.fellenberg@med.uni heidelberg.de;
   sarina.losch@med.uni heidelberg.de; elena.tripel@med.uni heidelberg.de;
   burkhard.lehner@med.uni heidelberg.de; svitlana.melnik@gmail.com
OI Melnik, Svitlana/0000 0001 7227 3321; Fellenberg,
   Joerg/0000 0002 6187 6474
CR Avnet S, 2016, ONCOTARGET, V7, P63408, DOI 10.18632/oncotarget.11503
   Bielack SS, 2015, J CLIN ONCOL, V33, P2279, DOI 10.1200/JCO.2014.60.0734
   Bolaji OO, 1996, EUR J DRUG METAB PH, V21, P217, DOI 10.1007/BF03189716
   Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87
   Chou AJ, 2009, CANCER AM CANCER SOC, V115, P5339, DOI 10.1002/cncr.24566
   Fang Fang, 2018, Oncotarget, V9, P36780, DOI 10.18632/oncotarget.26377
   Fatehullah A, 2021, NAT CELL BIOL, V23, P1299, DOI 10.1038/s41556 021 00793 9
   Fellenberg J, 2023, CANCERS, V15, DOI 10.3390/cancers15061868
   Friebele Jill C, 2015, Am J Orthop (Belle Mead NJ), V44, P547
   Gelderblom H, 2011, EUR J CANCER, V47, P895, DOI 10.1016/j.ejca.2010.11.036
   Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280
   Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102
   Henri J, 2009, J VET PHARMACOL THER, V32, P451, DOI 10.1111/j.1365 2885.2009.01063.x
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008 5472.CAN 09 2994
   HUDSON M, 1990, J CLIN ONCOL, V8, P1988, DOI 10.1200/JCO.1990.8.12.1988
   Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008 5472.CAN 10 3471
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kunz P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215312
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Lv ZQ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00191
   Marina NM, 2016, LANCET ONCOL, V17, P1396, DOI 10.1016/S1470 2045(16)30214 5
   Melnik S, 2018, CELL DISCOV, V4, DOI 10.1038/s41421 018 0033 2
   Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Morikawa N, 1996, J NEUROCHEM, V66, P1174
   Neri D, 2011, NAT REV DRUG DISCOV, V10, P767, DOI 10.1038/nrd3554
   Ottaviani G, 2009, CANCER TREAT RES, V152, P421, DOI 10.1007/978 1 4419 0284 9_23
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Palorini Roberta, 2013, Int J Cell Biol, V2013, P243876, DOI 10.1155/2013/243876
   Pecina Slaus N, 2010, CANCER CELL INT, V10, DOI 10.1186/1475 2867 10 22
   Podhorecka M, 2017, POSTEP HIG MED DOSW, V71, P170
   Rajendran V, 2018, CURR TOP MED CHEM, V18, P1976, DOI 10.2174/1568026619666181129141151
   Saraei P, 2019, CANCER MANAG RES, V11, P3295, DOI 10.2147/CMAR.S200059
   Schwartz L, 2017, ANTI CANCER AGENT ME, V17, P164, DOI 10.2174/1871520616666161031143301
   Ta H, 2009, CANCER METAST REV, V28, P247, DOI 10.1007/s10555 009 9186 7
   Whelan JS, 2015, ANN ONCOL, V26, P407, DOI 10.1093/annonc/mdu526
   Wu L, 2015, SCI REP UK, V5, DOI 10.1038/srep10147
NR 37
TC 1
Z9 1
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JAN
PY 2024
VL 13
IS 1
AR 61
DI 10.3390/cells13010061
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA EM0A8
UT WOS:001139214200001
PM 38201265
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fan, P
   Pu, D
   Lv, XH
   Hu, N
   Feng, XY
   Hao, ZM
   Sun, YN
   He, L
AF Fan, Ping
   Pu, Dan
   Lv, Xiaohong
   Hu, Nan
   Feng, Xiuyuan
   Hao, Zhiming
   Sun, Yining
   He, Lan
TI Cav 1.3 damages the osteogenic differentiation in osteoporotic rats by
   negatively regulating Spred 2 mediated autophagy induced cell senescence
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE BMSCs; Cav 1; 3; osteogenic differentiation; Spred 2
ID BONE; OSTEOARTHRITIS; EPIDEMIOLOGY; THERAPY; DOMAIN; P85
AB Cav 1.3 can affect the classical osteoclast differentiation pathway through calcium signalling pathway. Here, we performed cell transfection, real time fluorescence quantitative PCR (qPCR), flow cytometry, SA beta Gal staining, Alizarin Red S staining, ALP activity test, immunofluorescence, Western blot and cell viability assay to analyse cell viability, cell cycle, osteogenesis differentiation and autophagy activities in vitro. Meanwhile, GST pull down and CHIP experiments were conducted to explore the influence of Cav 1.3 and Sprouty related EVH1 domain 2 (Spred 2) on bone marrow derived mesenchymal stem cells (BMSCs). The results showed that OS lead to the decreased of bone mineral density and differentiation ability of BMSCs in rats. Cav 1.3 was up regulated in OS rats. Overexpression of Cav 1.3 inhibited the activity of BMSCs, the expression of alkaline phosphatase (ALP), runt related transcription factor 2 (RUNX2) and osteocalcin (OCN), as well as promoted the cell cycle arrest and senescence. Furthermore, the negative correlation between Cav 1.3 and Spred 2 was found through GST pull down and CHIP. Overexpression of Spred 2 increased the expressions of microtubule associated protein 1 light chain 3 (LC3) and Beclin 1 of BMSCs, which ultimately promoted the cell activity of BMSCs and ALP, RUNX2, OCN expression. In conclusion, Cav 1.3 negatively regulates Spred 2 mediated autophagy and cell senescence, and damages the activity and osteogenic differentiation of BMSCs in OS rats.
C1 [Fan, Ping; Pu, Dan; Lv, Xiaohong; Hu, Nan; Feng, Xiuyuan; Hao, Zhiming; Sun, Yining; He, Lan] Xi An Jiao Tong Univ, Sch Med, Dept Rheumatism & Immunol, Affiliated Hosp 1, 277 West Yanta St, Xian 710061, Peoples R China.
C3 Xi'an Jiaotong University
RP He, L (通讯作者)，Xi An Jiao Tong Univ, Sch Med, Dept Rheumatism & Immunol, Affiliated Hosp 1, 277 West Yanta St, Xian 710061, Peoples R China.
EM xajdhl87@mail.xjtu.edu.cn
RI hu, nan/KHE 4563 2024
FU National Natural Science Foundation of China [81900800]; Science and
   Technology Project of Shaanxi [2019JM 560]
FX National Natural Science Foundation of China (No. 81900800); the Science
   and Technology Project of Shaanxi (2019JM 560).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Cianfanelli V, 2015, AUTOPHAGY, V11, P1705, DOI 10.1080/15548627.2015.1053681
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Grol MW, 2018, CURR OPIN PHARMACOL, V40, P59, DOI 10.1016/j.coph.2018.03.005
   Holliday LS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010158
   Jevotovsky DS, 2018, OSTEOARTHR CARTILAGE, V26, P711, DOI 10.1016/j.joca.2018.02.906
   Jiang K, 2016, ONCOTARGET, V7, P25652, DOI 10.18632/oncotarget.8357
   Jo S, 2018, BIOCHEM BIOPH RES CO, V495, P1257, DOI 10.1016/j.bbrc.2017.11.155
   Jonasson G, 2016, CLIN COSMET INV DENT, V8, P95, DOI 10.2147/CCIDE.S92774
   Li D, 2010, J BIOL CHEM, V285, P35374, DOI 10.1074/jbc.M110.148445
   Lotz EM, 2018, ACTA BIOMATER, V68, P296, DOI 10.1016/j.actbio.2017.12.039
   Meng SS, 2012, INT J BIOCHEM CELL B, V44, P748, DOI 10.1016/j.biocel.2012.01.014
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Pinggera A, 2016, J PHYSIOL LONDON, V594, P5839, DOI 10.1113/JP270672
   Qin ZH, 2019, ADV EXP MED BIOL, V1206, P1, DOI 10.1007/978 981 15 0602 4
   Revuelta M, 2017, AGING CELL, V16, P912, DOI 10.1111/acel.12655
   Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200
   Sims NA, 2016, J BONE MINER RES, V31, P1917, DOI 10.1002/jbmr.2994
   Thomas AC, 2017, J ATHL TRAINING, V52, P491, DOI 10.4085/1062 6050 51.5.08
   Vina ER, 2018, CURR OPIN RHEUMATOL, V30, P160, DOI 10.1097/BOR.0000000000000479
   Wang Q, 2015, PAIN PHYSICIAN, V18, pE1005
NR 23
TC 6
Z9 8
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD DEC
PY 2020
VL 24
IS 23
BP 13863
EP 13875
DI 10.1111/jcmm.15978
EA OCT 2020
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA PB5NP
UT WOS:000585036700001
PM 33124763
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Cao, LL
   Zhou, SM
   Qiu, XS
   Qiu, S
AF Cao, Lili
   Zhou, Siming
   Qiu, Xueshan
   Qiu, Shui
TI 被撤回的出版物: Trehalose improves palmitic acid induced apoptosis of
   osteoblasts by regulating SIRT3 medicated autophagy via the
   AMPK/mTOR/ULK1 pathway
SO FASEB JOURNAL
LA English
DT Article; Retracted Publication
DE autophagy; lipotoxicity; palmitic acid; SIRT3; Trehalose
ID MESENCHYMAL STEM CELLS; POSTMENOPAUSAL WOMEN; DIFFERENTIATION;
   MECHANISM; THERAPY
AB Accumulation of lipid substances decreased the activity of osteoblasts. Trehalose is a typical stress metabolite to form a protective membrane on cell surface which has been demonstrated to regulate lipid metabolism. This activity of Trehalose indicates the potential effect of osteoporosis treatment. Our study aimed to determine the therapeutic effect of Trehalose in high fat induced osteoporosis. We used palmitic acid (PA) to mimic the state of high fat and observed the apoptosis ratio of osteoblasts increased. After adding Trehalose, the apoptosis ratio decreased obviously. Autophagy is a regulatory means involved in the process of apoptosis. We detected the autophagy protein and found that the expression of Beclin 1, Atg5, and LC3 II increased, and p62 decreased after Trehalose treatment. When adding an autophagy inhibitor (3 MA), the expression of Beclin 1, Atg5, and LC3 II decreased, and p62 increased. These results indicated autophagy was an important factor involved in the preventive effect of Trehalose in PA induced apoptosis. SIRT3 is a mitochondrial gene that can inhibit apoptosis, which has been reported to promote autophagy. We used SIRT3 siRNA to silence the expression of SIRT3 and found the effect of Trehalose was counteracted. The apoptosis ratio increased and the expression of Beclin 1, Atg5, and LC3 II decreased, p62 increased. Additionally, we also fed the mice with a high fat diet (HFD) and intragastrical Trehalose. The results showed that Trehalose could inhibit the bone mass loss with HFD. Our study revealed the effect and mechanism of Trehalose in the treatment of osteoporosis.
C1 [Cao, Lili] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Peoples R China.
   [Zhou, Siming; Qiu, Shui] China Med Univ, Hosp 1, Dept Orthoped, 155 Nanjing North St, Shenyang, Peoples R China.
   [Qiu, Xueshan] China Med Univ, Hosp 1, Dept Pathol, Shenyang, Peoples R China.
   [Qiu, Xueshan] Coll Basic Med Sci, Shenyang, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Qiu, S (通讯作者)，China Med Univ, Hosp 1, Dept Orthoped, 155 Nanjing North St, Shenyang, Peoples R China.
EM qiushuii@hotmail.com
FU China Medical University (CMU)
FX China Medical University (CMU)
CR Arai C, 2020, NUTR METAB, V17, DOI 10.1186/s12986 020 00443 1
   Benini C, 2021, MINERVA OBSTET GYNEC, V73, P704, DOI 10.23736/S2724 606X.20.04682 1
   Casado Díaz A, 2017, EXP GERONTOL, V90, P71, DOI 10.1016/j.exger.2017.01.024
   Cefalu WT, 2001, J WOMEN HEALTH GEN B, V10, P241, DOI 10.1089/152460901300139998
   Dalla Valle A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00726
   Elbers LPB, 2021, DRUGS, V81, P1645, DOI 10.1007/s40265 021 01587 x
   Fathollahi A, 2018, LUPUS, V27, P1053, DOI 10.1177/0961203318768889
   GUDMANDHOYER E, 1994, AM J CLIN NUTR, V59, p735S, DOI 10.1093/ajcn/59.3.735S
   Hase K, 2021, METABOLITES, V11, DOI 10.3390/metabo11060348
   Hsu YC, 2016, SEMIN CELL DEV BIOL, V52, P119, DOI 10.1016/j.semcdb.2016.02.011
   Huang SY, 2022, BIOPRESERV BIOBANK, V20, P384, DOI 10.1089/bio.2021.0071
   Ji ZJ, 2022, J GENET GENOMICS, V49, P287, DOI 10.1016/j.jgg.2021.11.005
   Kang DW, 2021, BBA MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2021.166084
   Lee HJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0749 9
   Lei SS, 2021, INT J BIOL MACROMOL, V193, P1996, DOI 10.1016/j.ijbiomac.2021.11.030
   Leonhardt Y, 2021, QUANT IMAG MED SURG, V11, P3715, DOI 10.21037/qims 20 1373
   Li ZZ, 2022, BIOCHEM PHARMACOL, V197, DOI 10.1016/j.bcp.2021.114904
   Li ZY, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.680328
   Lu WJ, 2021, FOOD FUNCT, V12, P2995, DOI [10.1039/D0FO02906H, 10.1039/d0fo02906h]
   Ma BC, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/5563660
   Mehta D, 2023, J ORTHOP SCI, V28, P460, DOI 10.1016/j.jos.2021.11.005
   Migliorini F, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02678 x
   Moseley KF, 2018, ENDOCR RES, V43, P155, DOI 10.1080/07435800.2018.1441868
   Pan B, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.774709
   Pilato CA, 2018, JOVE J VIS EXP, DOI 10.3791/57263
   Pomeisl K, 2020, MOLECULES, V25, DOI 10.3390/molecules25030497
   Saad RK, 2022, OSTEOPOROSIS INT, V33, P511, DOI 10.1007/s00198 021 06206 9
   Wang Z, 2021, INT J BIOL SCI, V17, P4192, DOI 10.7150/ijbs.61950
   Wu NX, 2020, MOL CELL BIOCHEM, V470, P175, DOI 10.1007/s11010 020 03760 4
   Xu XQ, 2020, FASEB J, V34, P8402, DOI 10.1096/fj.201902528RRR
   Yang KD, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10751
   Yang SH, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.649698
   Yu LB, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02636 8
   Zhao JW, 2011, AM J MED SCI, V341, P460, DOI 10.1097/MAJ.0b013e31820865d5
   Zhao WY, 2021, LIFE SCI, V286, DOI 10.1016/j.lfs.2021.120005
   Zhao X, 2019, EXP CLIN ENDOCR DIAB, V127, P50, DOI 10.1055/a 0762 0341
   Zhou XJ, 2021, INT J BIOL SCI, V17, P3456, DOI 10.7150/ijbs.60401
NR 37
TC 12
Z9 14
U1 0
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD SEP
PY 2022
VL 36
IS 9
AR e22491
DI 10.1096/fj.202200608RR
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 3R2QH
UT WOS:000838762600001
PM 35947089
DA 2025 08 17
ER

PT J
AU Kim, HH
   Jeong, SH
   Park, MY
   Bhosale, PB
   Abusaliya, A
   Kim, HW
   Seong, JK
   Ahn, M
   Park, KI
   Heo, JD
   Kim, YS
   Kim, GS
AF Kim, Hun Hwan
   Jeong, Se Hyo
   Park, Min Yeong
   Bhosale, Pritam Bhagwan
   Abusaliya, Abuyaseer
   Kim, Hyun Wook
   Seong, Je Kyung
   Ahn, Meejung
   Park, Kwang Il
   Heo, Jeong Doo
   Kim, Young Sil
   Kim, Gon Sup
TI Potential Joint Protective and Anti Inflammatory Effects of Integrin
   αvβ3 in IL 1β Treated Chondrocytes Cells
SO BIOMEDICINES
LA English
DT Article
DE chondrocyte; anti inflammation; chondrogenesis; integrin
   alpha(v)beta(3); IL 1 beta
ID SELECTIVE COX 2 INHIBITION; KAPPA B; IL 1 BETA INDUCED INFLAMMATION;
   OSTEOBLAST DIFFERENTIATION; KNEE OSTEOARTHRITIS; CHONDROITIN SULFATE;
   BONE; APOPTOSIS; ACTIVATION; CHON 001
AB In osteoarthritis (OA), the articular cartilage covering the articular surface of the bone wears out, exposing the subchondral bone, and the synovial membrane surrounding the joint becomes inflamed, causing pain and deformity. OA causes pain, stiffness, and swelling, and discomfort in the knee when climbing stairs is a typical symptom. Although drug development studies are conducted to treat these inflammatory joint diseases, it is difficult to find conclusive research results which could reduce inflammation and slow cartilage tear. The development of drugs to relieve inflammatory pain often utilizes inflammatory triggers. Interleukins, one of the proteins in the limelight as pro inflammatory factors, are immune system stimulating factors that promote the body's fight against harmful factors such as bacteria. In this study, inflammation was induced in Chondrocytes cells (Chon 001 cells) with IL 1 beta and then treated with integrin alpha(v)beta(3) to show anti inflammatory and chondrogenesis effects. Integrin alpha(v)beta(3) was not toxic to Chon 001 cells in any concentration groups treated with or without IL 1 beta. COX 2 and iNOS, which are major markers of inflammation, were significantly reduced by integrin alpha(v)beta(3) treatment. Expressions of p ERK, p JNK, and p p38 corresponding to the MAPKs signaling pathway and p I kappa B alpha and p p65 corresponding to the NF kappa B signaling pathway were also decreased in a dose dependent manner upon integrin alpha(v)beta(3) treatment, indicating that inflammation was inhibited, whereas treatment with integrin alpha(v)beta(3) significantly increased the expression of ALP, RUNX2, BMP2, BMP4, Aggrecan, SOX9, and COL2A1, suggesting that osteogenesis and chondrogenesis were induced. These results suggest that integrin alpha(v)beta(3) in duces an anti inflammatory effect, osteogenesis, and chondrogenesis on IL 1 beta induced Chon 001 cells.
C1 [Kim, Hun Hwan; Jeong, Se Hyo; Park, Min Yeong; Bhosale, Pritam Bhagwan; Abusaliya, Abuyaseer; Park, Kwang Il; Kim, Gon Sup] Gyeongsang Natl Univ, Res Inst Life Sci, Jinju 52828, South Korea.
   [Kim, Hun Hwan; Jeong, Se Hyo; Park, Min Yeong; Bhosale, Pritam Bhagwan; Abusaliya, Abuyaseer; Park, Kwang Il; Kim, Gon Sup] Gyeongsang Natl Univ, Coll Vet Med, Jinju 52828, South Korea.
   [Kim, Hyun Wook] Div Anim Biosci & Intergrated Biotechnol, Jinju 52725, South Korea.
   [Seong, Je Kyung] Seoul Natl Univ, Lab Dev Biol & Genom, Res Inst Vet Sci, BK21 PLUS Program Creat Vet Sci Res,Coll Vet Med, Seoul 08826, South Korea.
   [Ahn, Meejung] Sangji Univ, Coll Life Sci, Dept Anim Biotechnol, Wonju 26339, South Korea.
   [Heo, Jeong Doo] Korea Inst Toxicol Gyeongnam Branch KIT, Bioenvironm Sci & Toxicol Div, Biol Resources Res Grp, Jinju 52834, South Korea.
   [Kim, Young Sil] T Stem Co Ltd, Chang Won 51573, South Korea.
C3 Gyeongsang National University; Gyeongsang National University; Seoul
   National University (SNU); Sangji University
RP Kim, GS (通讯作者)，Gyeongsang Natl Univ, Res Inst Life Sci, Jinju 52828, South Korea.; Kim, GS (通讯作者)，Gyeongsang Natl Univ, Coll Vet Med, Jinju 52828, South Korea.
EM shark159753@naver.com; tpgy123@gmail.com; lilie17@daum.net;
   shelake.pritam@gmail.com; yaseerbiotech21@gmail.com; hwkim@gnu.ac.kr;
   snumouse@snu.ac.kr; meeahn20@sangji.ac.kr; kipark@gnu.ac.kr;
   jdher@kitox.re.kr; askand@naver.com; gonskim@gnu.ac.kr
RI ; Kim, Ji/AAN 5655 2021; Kim, Hun Hwan/ISB 3284 2023
OI Kim, Hyun Wook/0000 0002 4397 9664; Kim, Hun Hwan/0000 0002 4983 2321;
   Abusaliya, Abuyaseer/0000 0001 6088 1485
FU National Research Foundation of Korea   Ministry of Science and ICT
   [2022R1A6A3A01086899, RS 2023 0024337661382]; T Stem Co., Ltd.
FX This study was supported by the National Research Foundation of Korea
   funded by the Ministry of Science and ICT (grant no. 2022R1A6A3A01086899
   and RS 2023 0024337661382) and T Stem Co., Ltd.
CR Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Campbell ID, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004994
   Cheleschi S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010133
   Chen PC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133300
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Chen XX, 2019, ARTIF CELL NANOMED B, V47, P3614, DOI 10.1080/21691401.2019.1657877
   Cheng C, 2019, BIOMED PHARMACOTHER, V109, P2464, DOI 10.1016/j.biopha.2018.11.017
   Cheng WD, 2013, INT ORTHOP, V37, P2065, DOI 10.1007/s00264 013 1990 6
   Cho H, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/595273
   de Boer TN, 2009, OSTEOARTHR CARTILAGE, V17, P482, DOI 10.1016/j.joca.2008.09.002
   Deng H, 2022, CARTILAGE, V13, DOI 10.1177/19476035221087706
   Desai SJ, 2018, NUTR CANCER, V70, P350, DOI 10.1080/01635581.2018.1446091
   Fields GB, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090984
   Fioravanti A, 2012, J PHARMACOL SCI, V120, P6, DOI 10.1254/jphs.12016FP
   Fusco M, 2017, PAIN PRACT, V17, P522, DOI 10.1111/papr.12551
   Gao Shi Chao, 2014, Zhongguo Gu Shang, V27, P441
   Giridharan S, 2018, J INFLAMM RES, V11, P407, DOI 10.2147/JIR.S140188
   Goldring SR, 2004, CLIN ORTHOP RELAT R, pS27, DOI 10.1097/01.blo.0000144854.66565.8f
   Gupta S, 2005, RHEUMATOLOGY, V44, P1531, DOI 10.1093/rheumatology/kei049
   Han YX, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106528
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Haseeb A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019152118
   Huang YJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184487
   Kawahara K, 2015, BBA MOL CELL BIOL L, V1851, P414, DOI 10.1016/j.bbalip.2014.07.008
   Kim HL, 2020, MOLECULES, V25, DOI 10.3390/molecules25092033
   Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276
   Kwon JY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32206 7
   Lauder SN, 2007, RHEUMATOLOGY, V46, P752, DOI 10.1093/rheumatology/kel419
   Lefebvre V, 2017, CONNECT TISSUE RES, V58, P2, DOI 10.1080/03008207.2016.1183667
   Li ST, 2018, ACTA PHARMACOL SIN, V39, P1294, DOI 10.1038/aps.2017.143
   Li W, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/9978651
   Lian CJ, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0046 y
   Lim HD, 2012, J PINEAL RES, V53, P225, DOI 10.1111/j.1600 079X.2012.00991.x
   Liu DD, 2022, J DENT RES, V101, P1227, DOI 10.1177/00220345221093518
   Lubis AMT, 2017, ACTA MED INDONES, V49, P105
   Ma ZQ, 2016, INFLAMMATION, V39, P543, DOI 10.1007/s10753 015 0278 y
   Mansfield K, 2001, BONE, V28, P1, DOI 10.1016/S8756 3282(00)00409 9
   Marchev AS, 2017, ANN NY ACAD SCI, V1401, P114, DOI 10.1111/nyas.13407
   Mastbergen SC, 2002, RHEUMATOLOGY, V41, P801, DOI 10.1093/rheumatology/41.7.801
   Miao DS, 2002, J HISTOCHEM CYTOCHEM, V50, P333, DOI 10.1177/002215540205000305
   Nasry WHS, 2018, CANCERS, V10, DOI 10.3390/cancers10100348
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Peng Y, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02597 y
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Roughley Peter J, 2014, J Exp Orthop, V1, P8, DOI 10.1186/s40634 014 0008 7
   Rutgers M, 2013, TISSUE ENG PT A, V19, P59, DOI [10.1089/ten.tea.2011.0416, 10.1089/ten.TEA.2011.0416]
   Sellam J, 2020, JOINT BONE SPINE, V87, P548, DOI 10.1016/j.jbspin.2020.09.004
   Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787 007 0013 x
   Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871
   Shi JM, 2021, BIOENGINEERED, V12, P1445, DOI 10.1080/21655979.2021.1905247
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Tuerlings M, 2022, ADV MATER TECHNOL US, V7, DOI 10.1002/admt.202101310
   Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Xie CF, 2019, BIOORGAN MED CHEM, V27, P516, DOI 10.1016/j.bmc.2018.12.033
   Yamashita A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010998
   Yao ZZ, 2017, BIOMED PHARMACOTHER, V96, P1209, DOI 10.1016/j.biopha.2017.11.097
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
   Zhai GJ, 2021, ADV CLIN CHEM, V101, P95, DOI 10.1016/bs.acc.2020.06.001
   Zhou SJ, 2022, J ORTHOP RES, V40, P1492, DOI 10.1002/jor.25347
NR 60
TC 2
Z9 2
U1 0
U2 5
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2023
VL 11
IS 10
AR 2745
DI 10.3390/biomedicines11102745
PG 15
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA X4NO9
UT WOS:001098237700001
PM 37893118
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bradaschia Correa, V
   Josephson, AM
   Mehta, D
   Mizrahi, M
   Neibart, SS
   Liu, C
   Kennedy, OD
   Castillo, AB
   Egol, KA
   Leucht, P
AF Bradaschia Correa, Vivian
   Josephson, Anne M.
   Mehta, Devan
   Mizrahi, Matthew
   Neibart, Shane S.
   Liu, Chao
   Kennedy, Oran D.
   Castillo, Alesha B.
   Egol, Kenneth A.
   Leucht, Philipp
TI The Selective Serotonin Reuptake Inhibitor Fluoxetine Directly Inhibits
   Osteoblast Differentiation and Mineralization During Fracture Healing in
   Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE OSTEOPOROSIS; DEPRESSION; OSTEOBLAST; OSTEOPROGENITOR CELL; BONE
ID BONE MASS; 5 HYDROXYTRYPTAMINE; ANTIDEPRESSANTS; REGENERATION;
   MEDICATIONS; EXPRESSION; DEPRESSION; ORIGIN; COHORT; US
AB Chronic use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression has been linked to osteoporosis. In this study, we investigated the effect of chronic SSRI use on fracture healing in two murine models of bone regeneration. First, we performed a comprehensive analysis of endochondral bone healing in a femur fracture model. C57/BL6 mice treated with fluoxetine, the most commonly prescribed SSRI, developed a normal cartilaginous soft callus at 14 days after fracture and demonstrated a significantly smaller and biomechanically weaker bony hard callus at 28 days. In order to further dissect the mechanism that resulted in a smaller bony regenerate, we used an intramembranous model of bone healing and revealed that fluoxetine treatment resulted in a significantly smaller bony callus at 7 and 14 days postinjury. In order to test whether the smaller bony regenerate following fluoxetine treatment was caused by an inhibition of osteogenic differentiation and/or mineralization, we employed in vitro experiments, which established that fluoxetine treatment decreases osteogenic differentiation and mineralization and that this effect is serotonin independent. Finally, in a translational approach, we tested whether cessation of the medication would result in restoration of the regenerative potential. However, histologic and CT analysis revealed non union formation in these animals with fibrous tissue interposition within the callus. In conclusion, fluoxetine exerts a direct, inhibitory effect on osteoblast differentiation and mineralization, shown in two disparate murine models of bone repair. Discontinuation of the drug did not result in restoration of the healing potential, but rather led to complete arrest of the repair process. Besides the well established effect of SSRIs on bone homeostasis, our study provides strong evidence that fluoxetine use negatively impacts fracture healing. (c) 2017 American Society for Bone and Mineral Research.
C1 [Bradaschia Correa, Vivian; Josephson, Anne M.; Mehta, Devan; Mizrahi, Matthew; Neibart, Shane S.; Liu, Chao; Kennedy, Oran D.; Castillo, Alesha B.; Egol, Kenneth A.; Leucht, Philipp] NYU, Dept Orthopaed Surg, Hosp Joint Dis, Langone Med Ctr, New York, NY USA.
   [Liu, Chao; Kennedy, Oran D.; Castillo, Alesha B.] NYU, Dept Mech & Aerosp Engn, Tandon Sch Engn, New York, NY USA.
   [Leucht, Philipp] NYU, Sch Med, Dept Cell Biol, 550 First Ave,MSB 617, New York, NY 10016 USA.
C3 NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York
   University; New York University; New York University Tandon School of
   Engineering; New York University
RP Leucht, P (通讯作者)，NYU, Sch Med, Dept Cell Biol, 550 First Ave,MSB 617, New York, NY 10016 USA.; Leucht, P (通讯作者)，NYU, Sch Med, Dept Orthopaed Surg, 550 First Ave,MSB 617, New York, NY 10016 USA.
EM philipp.leucht@nyumc.org
RI Leucht, Philipp/H 7238 2019; Castillo, Alesha/AAC 9961 2019; Liu,
   Chao/E 2667 2019; Castillo, Alesha/A 8728 2014
OI Kennedy, Oran D./0000 0003 3343 2873; Liu, Chao/0000 0001 6637 1689;
   Liu, Chuan ju/0000 0002 7181 8032; Neibart, Shane/0000 0003 1294 6082;
   Castillo, Alesha/0000 0002 1371 7567; Leucht,
   Philipp/0000 0002 8409 8513
FU NIH [1 S10 OD010751 01A1]
FX We thank Ripa Chowdhury (New York University College of Dentistry) for
   assistance with the mu CT imaging (supported by NIH 1 S10
   OD010751 01A1), Jessica Lavery for the assistance with the statistical
   analysis, and Matin Lendhey for the biomechanical testing.
CR Banovic M, 2010, PLATELETS, V21, P429, DOI 10.3109/09537104.2010.487582
   Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756 3282(01)00593 2
   Bolo NR, 2004, MAGN RESON MATER PHY, V16, P268, DOI 10.1007/s10334 004 0033 0
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Collet C, 2008, FASEB J, V22, P418, DOI 10.1096/fj.07 9209com
   Cray JJ, 2014, BIRTH DEFECTS RES A, V100, P912, DOI 10.1002/bdra.23323
   Dulawa SC, 2004, NEUROPSYCHOPHARMACOL, V29, P1321, DOI 10.1038/sj.npp.1300433
   Fernandes BS, 2016, DRUG AGING, V33, P21, DOI 10.1007/s40266 015 0323 4
   Feuer AJ, 2015, BONE, V78, P28, DOI 10.1016/j.bone.2015.04.042
   Hill CR, 2014, BONE, V62, P10, DOI 10.1016/j.bone.2014.01.019
   Hodge JM, 2013, BIOL PSYCHIAT, V74, P32, DOI 10.1016/j.biopsych.2012.11.003
   Kelly NH, 2014, BONE, V68, P1, DOI 10.1016/j.bone.2014.07.022
   Lanteigne A, 2015, CNS DRUGS, V29, P245, DOI 10.1007/s40263 015 0231 5
   Leucht P, 2008, DEVELOPMENT, V135, P2845, DOI 10.1242/dev.023788
   Leucht P, 2007, BONE, V40, P919, DOI 10.1016/j.bone.2006.10.027
   Michalowska M, 2015, J PHYSIOL PHARMACOL, V66, P779
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Mortazavi SH, 2009, ORAL SURG ORAL MED O, V108, P22, DOI 10.1016/j.tripleo.2009.01.006
   O'Neill KR, 2012, BONE, V50, P1357, DOI 10.1016/j.bone.2012.03.008
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Rauma PH, 2016, BONE, V89, P25, DOI 10.1016/j.bone.2016.05.003
   Richter T, 2014, NEUROENDOCRINOL LETT, V35, P7
   Rizzoli R, 2012, BONE, V51, P606, DOI 10.1016/j.bone.2012.05.018
   Salai M, 2013, BONE JOINT J, V95B, P1575, DOI 10.1302/0301 620X.95B11.31158
   Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004 1259
   Warden SJ, 2008, MENOPAUSE, V15, P1176, DOI 10.1097/gme.0b013e318173566b
   Warden SJ, 2010, BONE, V46, P4, DOI 10.1016/j.bone.2009.06.029
   Wysowski DK, 2006, PHARMACOECONOMICS, V24, P233, DOI 10.2165/00019053 200624030 00003
NR 28
TC 52
Z9 61
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR
PY 2017
VL 32
IS 4
BP 821
EP 833
DI 10.1002/jbmr.3045
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ES6SE
UT WOS:000399678900019
PM 27869327
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Kalgutkar, AS
   Griffith, DA
   Ryder, T
   Sun, H
   Miao, ZA
   Bauman, JN
   Didiuk, MT
   Frederick, KS
   Zhao, SX
   Prakash, C
   Soglia, JR
   Bagley, SW
   Bechle, BM
   Kelley, RM
   Dirico, K
   Zawistoski, M
   Li, JK
   Oliver, R
   Guzman Perez, A
   Liu, KKC
   Walker, DP
   Benbow, JW
   Morris, J
AF Kalgutkar, Amit S.
   Griffith, David A.
   Ryder, Tim
   Sun, Hao
   Miao, Zhuang
   Bauman, Jonathan N.
   Didiuk, Mary T.
   Frederick, Kosea S.
   Zhao, Sabrina X.
   Prakash, Chandra
   Soglia, John R.
   Bagley, Scott W.
   Bechle, Bruce M.
   Kelley, Ryan M.
   Dirico, Kenneth
   Zawistoski, Michael
   Li, Jianke
   Oliver, Robert
   Guzman Perez, Angel
   Liu, Kevin K. C.
   Walker, Daniel P.
   Benbow, John W.
   Morris, Joel
TI Discovery Tactics To Mitigate Toxicity Risks Due to Reactive Metabolite
   Formation with
   2 (2 Hydroxyaryl) 5 (trifluoromethyl)pyrido[4,3 d]pyrimidin 4(3H) one Derivatives, Potent Calcium Sensing Receptor Antagonists and
   Clinical Candidate(s) for the Treatment of Osteoporosis
SO CHEMICAL RESEARCH IN TOXICOLOGY
LA English
DT Article
ID DEPENDENT COVALENT BINDING; IN VITRO METABOLISM; PARATHYROID HORMONE
   SECRETION; MASS SPECTROMETRY; NONHEPATOTOXIC DRUGS; INTRINSIC CLEARANCE;
   LIVER MICROSOMES; RALOXIFENE; BIOACTIVATION; REMOXIPRIDE
AB The synthesis and structure activity relationship studies on 5 trifluoromethylpyrido[4,3 dipyrimidin 4(3H) ones as antagonists of the human calcium receptor (CaSR) have been recently disclosed [Didiuk et al. (2009) Bioorg. Med. Chem. Lett. 19, 4555 4559). On the basis of its pharmacology and disposition attributes, (R) 2 (2 hydroxypheny1) 3 (1 phenylpropan 2 y1) 5 (tritluoromethyl)pyrido[4,3d]pyrimidin 4(3H) one (1) was considered for rapid advancement to first in human (FIH) trials to mitigate uncertainty surrounding the pharmacokinetic/pharmacodynamic (PK/PD) predictions for a short acting bone anabolic agent. During the course of metabolic profiling, however, glutathione (GSH) conjugates of 1 were detected in human liver microsomes in an NADPH dependent fashion. Characterization of the GSH conjugate structures allowed insight(s) into the bioactivation pathway, which involved CYP3A4mediated phenol ring oxidation to the catechol, followed by further oxidation to the elcctrophilic orthoquinone species. While the reactive metabolite (RM) liability raised concerns around the likelihood of a potential toxicological outcome, a more immediate program goal was establishing confidence in human PK predictions in the study. Furthermore, the availability of a clinical biomarker (serum parathyroid hormone) meant that PID could be assessed side by side with PK, an ideal scenario for a relatively unprecedented pharmacologic target. Consequently, progressing 1 into the clinic was given a high priority, provided the compound demonstrated an adequate safety profile to support FIFI studies. Despite forming identical RMs in rat liver microsomes, no clinical or histopathological signs prototypical of target organ toxicity were observed with 1 in in vivo safety assessments in rats. Compound I was also devoid of metabolism based mutagenicity in in vitro (e.g., Salmonella Ames) and in vivo assessments (micronuclei induction in bone marrow) in rats. Likewise, metabolism based studies (e.g., evaluation of (letoxicating routes of clearance and exhaustive PK/PD studies in animals to prospectively predict the likelihood of a low human efficacious close) were also conducted, which mitigated the risks of idiosyncratic toxicity to a large degree. In parallel, medicinal chemistry efforts were initiated to identify additional compounds with a complementary range of human PK predictions, which would maximize the likelihood of achieving the desired PD effect in the clinic. The back up strategy also incorporated an overarching goal of reducing/ eliminating reactive metabolite formation observed with in. Herein, the collective findings from our discovery efforts in the CaSR program, which include the incorporation of appropriate derisking steps when dealing with RM issues are summarized.
C1 [Kalgutkar, Amit S.; Ryder, Tim; Sun, Hao; Miao, Zhuang; Bauman, Jonathan N.; Frederick, Kosea S.; Zhao, Sabrina X.; Prakash, Chandra; Soglia, John R.] Pfizer Global Res & Dev, Pharmacokinet Dynam & Metab Dept, Groton, CT 06340 USA.
   [Griffith, David A.; Didiuk, Mary T.; Bagley, Scott W.; Bechle, Bruce M.; Kelley, Ryan M.; Dirico, Kenneth; Zawistoski, Michael; Li, Jianke; Oliver, Robert; Guzman Perez, Angel; Liu, Kevin K. C.; Walker, Daniel P.; Benbow, John W.; Morris, Joel] Pfizer Global Res & Dev, Dept Med Chem, Groton, CT 06340 USA.
C3 Pfizer; Pfizer USA; Pfizer; Pfizer USA
RP Kalgutkar, AS (通讯作者)，Pfizer Global Res & Dev, Pharmacokinet Dynam & Metab Dept, Groton, CT 06340 USA.
EM amit.kalgutkar@pfizer.com
RI Kelley, Ryan/JEP 5103 2023
OI Sun, Hao/0000 0002 8480 9645; Bagley, Scott/0000 0002 7365 7332;
   Griffith, David/0000 0002 7592 2478
CR ABRAHAM AK, 2010, J PHARM EXP IN PRESS
   Arey BJ, 2005, ENDOCRINOLOGY, V146, P2015, DOI 10.1210/en.2004 1318
   BAILLIE TA, 1993, BIOL MASS SPECTROM, V22, P319, DOI 10.1002/bms.1200220602
   Balan G, 2009, BIOORG MED CHEM LETT, V19, P3328, DOI 10.1016/j.bmcl.2009.04.044
   Bauman JN, 2009, CHEM RES TOXICOL, V22, P332, DOI 10.1021/tx800407w
   Berry SD, 2010, OSTEOPOROSIS INT, V21, P53, DOI 10.1007/s00198 009 1127 3
   Blick SKA, 2008, DRUGS, V68, P2709, DOI 10.2165/0003495 200868180 00012
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Chen Q, 2002, CHEM RES TOXICOL, V15, P907, DOI 10.1021/tx0200109
   Dalvie D, 2008, CHEM RES TOXICOL, V21, P2260, DOI 10.1021/tx800323w
   Deal C, 2009, NAT CLIN PRACT RHEUM, V5, P20, DOI 10.1038/ncprheum0977
   Didiuk MT, 2009, BIOORG MED CHEM LETT, V19, P4555, DOI 10.1016/j.bmcl.2009.07.004
   Dobo KL, 2009, CHEM RES TOXICOL, V22, P348, DOI 10.1021/tx8004339
   Erve JCL, 2004, CHEM RES TOXICOL, V17, P564, DOI 10.1021/tx034238n
   Evans DC, 2004, CHEM RES TOXICOL, V17, P3, DOI 10.1021/tx034170b
   GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919
   GIACHETTI C, 1989, BIOMED ENVIRON MASS, V18, P592, DOI 10.1002/bms.1200180814
   Gowen M, 2000, J CLIN INVEST, V105, P1595, DOI 10.1172/JCI9038
   Hartz RA, 2009, J MED CHEM, V52, P7653, DOI 10.1021/jm900716v
   Hosea NA, 2009, J CLIN PHARMACOL, V49, P513, DOI 10.1177/0091270009333209
   *INT TABL XRAY CRY, 1974, INT TABL XRAY CRYST, V4, P55
   Ju C., 2002, Current Drug Metabolism, V3, P367, DOI 10.2174/1389200023337333
   Kalgutkar AS, 2007, CURR DRUG METAB, V8, P407
   KIRSCH NH, 1994, J CHROMATOGR A, V684, P277, DOI 10.1016/0021 9673(94)00619 9
   LAPIERRE YD, 1992, J PSYCHIATR NEUROSCI, V17, P134
   Liebler DC, 2005, NAT REV DRUG DISCOV, V4, P410, DOI 10.1038/nrd1720
   Marnett LJ, 1999, IARC SCI PUBL, P17
   Marquis RW, 2009, J MED CHEM, V52, P6599, DOI 10.1021/jm900563e
   Miller MA, 1998, BONE, V23, P257, DOI 10.1016/S8756 3282(98)00098 2
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Obach RS, 2008, CHEM RES TOXICOL, V21, P1814, DOI 10.1021/tx800161s
   Obach RS, 2008, CHEM RES TOXICOL, V21, P1890, DOI 10.1021/tx800185b
   Obach RS, 1999, DRUG METAB DISPOS, V27, P1350
   Olson H, 2000, REGUL TOXICOL PHARM, V32, P56, DOI 10.1006/rtph.2000.1399
   Samuel K, 2003, J MASS SPECTROM, V38, P211, DOI 10.1002/jms.434
   Shcherbakova I, 2005, BIOORG MED CHEM LETT, V15, P1557, DOI 10.1016/j.bmcl.2005.01.078
   Soglia JR, 2004, J PHARMACEUT BIOMED, V36, P105, DOI 10.1016/j.jpba.2004.04.019
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038
   Yang W, 2005, BIOORG MED CHEM LETT, V15, P1225, DOI 10.1016/j.bmcl.2004.11.071
   Yu LN, 2004, CHEM RES TOXICOL, V17, P879, DOI 10.1021/tx0342722
   Zhao SX, 2007, CHEM RES TOXICOL, V20, P1649, DOI 10.1021/tx700132x
NR 41
TC 16
Z9 16
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0893 228X
EI 1520 5010
J9 CHEM RES TOXICOL
JI Chem. Res. Toxicol.
PD JUN
PY 2010
VL 23
IS 6
BP 1115
EP 1126
DI 10.1021/tx100137n
PG 12
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry; Toxicology
GA 611ZH
UT WOS:000278863700014
PM 20507089
DA 2025 08 17
ER

PT J
AU Zafar, S
   Coates, DE
   Cullinan, MP
   Drummond, BK
   Milne, T
   Seymour, GJ
AF Zafar, S.
   Coates, D. E.
   Cullinan, M. P.
   Drummond, B. K.
   Milne, T.
   Seymour, G. J.
TI Zoledronic acid and geranylgeraniol regulate cellular behaviour and
   angiogenic gene expression in human gingival fibroblasts
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE Bisphosphonate related osteonecrosis of the jaw; geranylgeraniol; human
   gingival fibroblasts; mevalonate pathway; zoledronic acid
ID EPIDERMAL GROWTH FACTOR; BISPHOSPHONATES INHIBIT; IN VITRO; EPIREGULIN;
   VEGF; SURVIVAL; CELLS; OSTEONECROSIS; THERAPY; BIOLOGY
AB The mevalonate pathway (MVP) and the anti angiogenic effect of bisphosphonates have been shown to play a role in the pathogenesis of bisphosphonate related osteonecrosis of the jaw (BRONJ). This study determined the effect of the bisphosphonate, zoledronic acid and the replenishment of the MVP by geranylgeraniol on human gingival fibroblasts. Cell viability, apoptosis, morphological analysis using transmission electron microscopy, and gene expression for vascular endothelial growth factor A, bone morphogenic protein 2, ras homologue gene family member B, epiregulin and interferon alpha were conducted. Results showed cellular viability was decreased in the presence of zoledronic acid and the co addition of zoledronic acid with geranylgeraniol restored cell viability to control levels. Caspase 3/7 was detected in zoledronic acid treated cells indicating apoptosis. Transmission electron microscopy revealed dilation of the rough endoplasmic reticulum with zoledronic acid and the appearance of multiple lipid like vesicles following the addition of geranylgeraniol. Zoledronic acid significantly (P<0.05, FR>+/  2) up regulated vascular endothelial growth factor A, bone morphogenic protein 2, ras homologue gene family member B and epiregulin at one or more time points but not interferon alpha. Addition of geranylgeraniol resulted in a reduction in the expression of all five genes compared with zoledronic acid treated human gingival fibroblasts. The study concluded geranylgeraniol partially reversed the effects of zoledronic acid in human gingival fibroblasts both at the cellular and genetic levels, suggesting the regulation of these genes is mediated via the mevalonate pathway.
C1 [Zafar, S.; Coates, D. E.; Cullinan, M. P.; Drummond, B. K.; Milne, T.; Seymour, G. J.] Univ Otago, Sir John Walsh Res Inst, Fac Dent, Dunedin 9054, New Zealand.
C3 University of Otago
RP Coates, DE (通讯作者)，Univ Otago, Sir John Walsh Res Inst, Fac Dent, POB 647, Dunedin 9054, New Zealand.
EM dawn.coates@otago.ac.nz
RI Milne, Trudy/G 2630 2011; Coates, Dawn/B 5134 2012; Zafar,
   Sobia/AAT 4630 2021; Seymour, Gregory/L 4482 2019
OI Zafar, Sobia/0000 0001 5551 8147; Cullinan, Mary/0000 0002 0423 1581;
   Seymour, Gregory/0000 0001 7595 5651; Coates, Dawn/0000 0003 4242 6846; 
FU New Zealand Dental Association Research Foundation; Maurice and Phyllis
   Paykel Trust, New Zealand
FX This research was funded by the New Zealand Dental Association Research
   Foundation and the Maurice and Phyllis Paykel Trust, New Zealand. The
   foundation is a non profit organisation. The funders played no role in
   the experiment design, execution, analysis or preparation of the paper.
CR Agis H, 2010, J DENT RES, V89, P40, DOI 10.1177/0022034509354298
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Aukhil I, 2000, PERIODONTOL 2000, V22, P44, DOI 10.1034/j.1600 0757.2000.2220104.x
   Bickel PE, 2009, BBA MOL CELL BIOL L, V1791, P419, DOI 10.1016/j.bbalip.2009.04.002
   Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582 4934.2005.tb00379.x
   Carmeliet P, 2005, ONCOLOGY BASEL, V69, P4, DOI 10.1159/000088478
   Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Coscia M, 2010, J CELL MOL MED, V14, P2803, DOI 10.1111/j.1582 4934.2009.00926.x
   Cozin M, 2011, J ORAL MAXIL SURG, V69, P2564, DOI 10.1016/j.joms.2011.03.005
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Ferretti G, 2005, ONCOLOGY BASEL, V69, P35, DOI 10.1159/000087286
   Fournier P, 2002, CANCER RES, V62, P6538
   Fujimoto T, 2008, HISTOCHEM CELL BIOL, V130, P263, DOI 10.1007/s00418 008 0449 0
   Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092 8674(00)81731 6
   Green JR, 2002, CURR OPIN ONCOL, V14, P609, DOI 10.1097/00001622 200211000 00004
   Hartman IZ, 2010, J BIOL CHEM, V285, P19288, DOI 10.1074/jbc.M110.134213
   Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200
   Howe GA, 2012, VASC CELL, V4, DOI 10.1186/2045 824X 4 1
   Ivanovski S, 2001, ARCH ORAL BIOL, V46, P679, DOI 10.1016/S0003 9969(01)00036 X
   Kellouche S, 2007, EXP CELL RES, V313, P486, DOI 10.1016/j.yexcr.2006.10.023
   Khambata Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Kyrgidis A., 2009, Bioscience Hypotheses, V2, P153
   Lee D, 2004, MOL CELL BIOL, V24, P8907, DOI 10.1128/MCB.24.20.8907 8916.2004
   Liu MX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045694
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002 220682
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Nishimoto Hazuku A, 2008, J CARDIOVASC PHARM, V51, P267, DOI 10.1097/FJC.0b013e3181624b44
   Ohlrich EJ, 2010, THESIS U OTAGO
   Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2
   Ploegh HL, 2007, NATURE, V448, P435, DOI 10.1038/nature06004
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008 5472.CAN 04 0677
   Scheper MA, 2009, BRIT J HAEMATOL, V144, P667, DOI 10.1111/j.1365 2141.2008.07504.x
   Shigeishi H, 2008, ONCOL REP, V19, P1557
   Smith MR, 2005, CANCER TREAT REV, V31, pS19, DOI 10.1016/j.ctrv.2005.09.004
   SOMERMAN MJ, 1988, J DENT RES, V67, P66, DOI 10.1177/00220345880670011301
   Stamatakis K, 2002, J BIOL CHEM, V277, P49389, DOI 10.1074/jbc.M204049200
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Takashima A, 2003, CURRENT PROTOCOLS CE, P218
   Tas F, 2008, MED ONCOL, V25, P346, DOI 10.1007/s12032 008 9043 5
   Thogersen VB, 2001, CANCER RES, V61, P6227
   TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495
   Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069
   Vincenzi B, 2005, J INTERF CYTOK RES, V25, P144, DOI 10.1089/jir.2005.25.144
   Wang J, 2011, BIOCHEM PHARMACOL, V81, P1036, DOI 10.1016/j.bcp.2011.01.025
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zhang XY, 2009, J IMMUNOL, V183, P1291, DOI 10.4049/jimmunol.0803075
   Ziebart T, 2011, ORAL ONCOL, V47, P195, DOI 10.1016/j.oraloncology.2010.12.003
NR 56
TC 37
Z9 38
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0904 2512
EI 1600 0714
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD OCT
PY 2014
VL 43
IS 9
BP 711
EP 721
DI 10.1111/jop.12181
PG 11
WC Dentistry, Oral Surgery & Medicine; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Pathology
GA AQ4HF
UT WOS:000342753600010
PM 24762323
DA 2025 08 17
ER

PT J
AU Liu, H
   Tian, FM
   Hu, YP
   Ping, SH
   Zhang, L
AF Liu, Hao
   Tian, Faming
   Hu, Yunpeng
   Ping, Shaohua
   Zhang, Liu
TI Liraglutide in Combination with Insulin Has a Superior Therapeutic
   Effect to Either Alone on Fracture Healing in Diabetic Rats
SO DIABETES METABOLIC SYNDROME AND OBESITY
LA English
DT Article
DE type 2 diabetes mellitus; fracture; liraglutide; bone mineral density
ID BONE MINERAL DENSITY; PEPTIDE 1 RECEPTOR AGONISTS; OVARIECTOMIZED RATS;
   TYPE 2; DIFFERENTIATION; APOPTOSIS; CARTILAGE; STRENGTH; DELIVERY; CELLS
AB Purpose: Fractures in patients with type 2 diabetes mellitus are at a high risk of delayed union or non union. Previous studies have shown a protective effect of liraglutide on bone. In the present study, we aimed to investigate the effects of a combination of liraglutide and insulin on fracture healing in a rat model of diabetes and the mechanisms involved. Materials and Methods: Closed femoral mid shaft fractures were established in male Sprague Dawley rats with or without diabetes mellitus, and the diabetic rats were administered insulin and/or liraglutide. Six weeks after femoral fracture, the femoral callus was evaluated by immunohistochemistry, histology, and micro computed tomography. Additionally, the effects of liraglutide on highglucose stimulated MC3T3 E1 cells were analyzed by Western blotting. Results: Micro computed tomography and safranin O/fast green staining showed that fracture healing was delayed in the diabetic rats, and this was accompanied by much lower expression of osteogenic markers and greater osteoclast activity. However, treatment with insulin and/or liraglutide prevented these changes. Liraglutide in combination with insulin treatment resulted in lower blood glucose concentrations and significantly higher osteocalcin (OCN) and collagen I (Col I) expression six weeks following fracture. Western blot analysis showed that liraglutide prevented the low expression of the bone morphogenetic protein 2, osterix/SP7, OCN, Col I, and beta catenin in high glucose stimulated MC3T3 E1 cells. Conclusion: These results demonstrate that insulin and/or liraglutide promotes bone fracture healing in the DF model. The combination was more effective than either single treatment, which may be because of the two drugs' additive effects on the osteogenic ability of osteoblast precursors.
C1 [Liu, Hao; Zhang, Liu] Hebei Med Univ, Dept Orthoped Surg, Shijiazhuang, Hebei, Peoples R China.
   [Liu, Hao; Ping, Shaohua] North China Univ Sci & Technol, Affiliated Hosp, Dept Orthoped Syrgery, Tangshan, Hebei, Peoples R China.
   [Tian, Faming; Hu, Yunpeng] North China Univ Sci & Technol, Sch Publ Hlth, Tangshan, Hebei, Peoples R China.
   [Zhang, Liu] Emergency Management Gen Hosp, Dept Orthoped Surg, Beijing, Peoples R China.
   [Zhang, Liu] Emergency Management Gen Hosp, Dept Orthoped Surg, Xibahenanli 29, Beijing 100028, Peoples R China.
C3 Hebei Medical University; North China University of Science &
   Technology; North China University of Science & Technology
RP Zhang, L (通讯作者)，Emergency Management Gen Hosp, Dept Orthoped Surg, Xibahenanli 29, Beijing 100028, Peoples R China.
EM zhliu130@sohu.com
RI tian, tfm9911316/GZB 1057 2022
CR Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Cao GL, 2018, MED SCI MONITOR, V24, P6525, DOI 10.12659/MSM.911573
   Cao XH, 2014, J CLIN INVEST, V124, P4351, DOI 10.1172/JCI74726
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Creecy A, 2016, CALCIFIED TISSUE INT, V99, P289, DOI 10.1007/s00223 016 0149 z
   de Waard EAC, 2017, BONE, V101, P156, DOI 10.1016/j.bone.2017.05.004
   Depalle B, 2021, ACTA BIOMATER, V120, P194, DOI 10.1016/j.actbio.2020.04.040
   Duan PP, 2016, INT J BIOCHEM CELL B, V77, P23, DOI 10.1016/j.biocel.2016.05.015
   Eom YS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168569
   Figeac F, 2022, STEM CELLS, V40, P149, DOI 10.1093/stmcls/sxab011
   Gandhi A, 2005, BONE, V37, P482, DOI 10.1016/j.bone.2005.04.039
   Gilbert MP, 2016, ENDOCR PRACT, V22, P406, DOI 10.4158/EP15758.OR
   Gonzalez Y, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471 2172 13 19
   Gortler H, 2018, INJURY, V49, P177, DOI 10.1016/j.injury.2017.11.006
   Harris K, 2018, ANN PHARMACOTHER, V52, P69, DOI 10.1177/1060028017726348
   Hou CJ, 2012, INT J ORAL MAX SURG, V41, P400, DOI 10.1016/j.ijom.2011.10.004
   Hou HW, 2020, EUR REV MED PHARMACO, V24, P12408, DOI 10.26355/eurrev_202012_24037
   Hou KJ, 2015, PAK J PHARM SCI, V28, P2227
   Huang CF, 2023, DIABET METAB SYND OB, V16, P31, DOI 10.2147/DMSO.S389964
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Julien A, 2020, STEM CELL REP, V15, P955, DOI 10.1016/j.stemcr.2020.08.005
   Kayal RA, 2010, J BONE MINER RES, V25, P1604, DOI 10.1002/jbmr.59
   Kayal R, 2009, BONE, V44, P357, DOI 10.1016/j.bone.2008.10.042
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Koromani F, 2021, CURR OSTEOPOROS REP, V19, P50, DOI 10.1007/s11914 020 00646 8
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Li SF, 2019, TOXICOL APPL PHARM, V369, P17, DOI 10.1016/j.taap.2019.02.015
   Liu GY, 2017, OSTEOPOROSIS INT, V28, P3043, DOI 10.1007/s00198 017 4148 3
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lu N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132744
   Ma X, 2013, J BONE MINER RES, V28, P1641, DOI 10.1002/jbmr.1898
   Miao DS, 2002, BMC MUSCULOSKELET DI, V3, DOI 10.1186/1471 2474 3 16
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Nuche Berenguer B, 2009, CALCIFIED TISSUE INT, V84, P453, DOI 10.1007/s00223 009 9220 3
   Paglia DN, 2013, J ORTHOP RES, V31, P783, DOI 10.1002/jor.22288
   Picke AK, 2016, BONE, V82, P108, DOI 10.1016/j.bone.2015.06.001
   Sassenrath K, 2022, J PHARM PRACT, V35, P979, DOI 10.1177/08971900211010678
   Schmidmaier G, 2002, BONE, V30, P816, DOI 10.1016/S8756 3282(02)00740 8
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Shi PP, 2021, BONE, V153, DOI 10.1016/j.bone.2021.116101
   Srinivasan K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/j.phrs.2005.05.004
   Su B, 2015, ENDOCRINE, V48, P107, DOI 10.1007/s12020 014 0361 4
   Sun HX, 2015, J DIABETES, V7, P584, DOI 10.1111/1753 0407.12282
   Wen BH, 2018, EXP THER MED, V15, P5077, DOI 10.3892/etm.2018.6043
   Wong SA, 2021, J ORTHOP RES, V39, P1622, DOI 10.1002/jor.24904
   Wysham Carol H, 2018, Clin Diabetes, V36, P149, DOI 10.2337/cd17 0064
   Yang L, 2019, J ENDOCRINOL INVEST, V42, P1125, DOI 10.1007/s40618 019 01034 5
NR 49
TC 3
Z9 3
U1 0
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 7007
J9 DIABET METAB SYND OB
JI Diabetes Metab. Syndr. Obes.
PY 2023
VL 16
BP 1235
EP 1245
DI 10.2147/DMSO.S404392
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA F6DZ7
UT WOS:000983243000001
PM 37151908
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, B
   Su, YW
   Shen, EP
   Song, M
   Liu, DP
   Qi, H
AF Huang, Ba
   Su, Yongwei
   Shen, Enpu
   Song, Meng
   Liu, Danping
   Qi, Hui
TI Extracellular vesicles from GPNMB modified bone marrow mesenchymal stem
   cells attenuate bone loss in an ovariectomized rat model
SO LIFE SCIENCES
LA English
DT Article
DE Glycoprotein non melanoma clone B; Extracellular vesicles; Mesenchymal
   stem cells; Osteogenesis; Osteoporosis
ID FORMATION IN VIVO; OSTEOBLAST DIFFERENTIATION; FEMORAL HEAD;
   OSTEOACTIVIN; OSTEOPOROSIS; REGENERATION; PREVENTION
AB Aims: The efficacy of anti osteoporotic treatments is still limited. Our study aimed to investigate the effect of extracellular vesicles (EVs) derived from bone marrow derived MSCs (BMSCs) overexpressing glycoprotein non melanoma clone B (GPNMB) on osteoporosis (OP).
   Main methods: Lentiviral vector for GPNMB overexpression or its negative control was generated and transfected into BMSCs. EVs enriched with GPNMB (GPNMB EVs) were extracted from GPNMB modified BMSC conditioned medium and then identified. Cellular uptake and proliferation were analyzed using the Dil labeled assay and CCK 8 assay, respectively. Cytochemical staining, western blot, and RT qPCR analysis were performed to assess the effect of GPNMB EVs on osteogenic differentiation of BMSCs in vitro. Dickkopf 1 (DKK1) as the inhibitor was applied to explore the Wnt/beta catenin signaling pathway involved in the GPNMB EV induced osteogenic differentiation. In vivo experiments were conducted using an ovariectomized (OVX) rat model of postmenopausal osteoporosis, and then assessed the effect of GPNMB EVs by micro CT, and histological and immunohistochemical assays.
   Key findings: GPNMB EVs were taken up by BMSCs, and they noticeably promoted the proliferation of BMSCs. Additionally, GPNMB EVs activated the Wnt/beta catenin signaling to stimulate osteogenesis in BMSCs. In vivo examination showed that GPNMB EVs remarkably improved trabecular bone regeneration and alleviated the osteoporotic phenotype in the OVX induced rat model of OP.
   Significance: EVs derived from GPNMB modified BMSCs significantly stimulated the proliferation and osteogenic differentiation of BMSCs via the activation of Wnt/beta catenin signaling and attenuated the bone loss in the OVX induced rat model of OP. Our findings suggest the promising potential of GPNMB EVs as cell free therapy for the treatment of OP.
C1 [Huang, Ba; Shen, Enpu; Song, Meng; Liu, Danping] Jinzhou Med Univ, Dept Orthopaed, Affiliated Hosp 1, Jinzhou 121000, Peoples R China.
   [Su, Yongwei] Yixian Peoples Hosp, Dept Orthopaed, Yixian 121100, Peoples R China.
   [Qi, Hui] Beijing Jishuitan Hosp, Beijing Res Inst Traumatol & Orthopaed, Beijing 100035, Peoples R China.
C3 Jinzhou Medical University
RP Liu, DP (通讯作者)，Jinzhou Med Univ, Dept Orthopaed, Affiliated Hosp 1, Jinzhou 121000, Peoples R China.; Qi, H (通讯作者)，Beijing Jishuitan Hosp, Beijing Res Inst Traumatol & Orthopaed, Beijing 100035, Peoples R China.
EM liudanping2009@sohu.com; kellyqhqh2002@163.com
RI su, Yongwei/LXA 0681 2024
FU National Natural Science Foundation of China [81572140]; Natural Science
   Foundation of Beijing Municipality [7172036]; Beijing Municipal Health
   Commission [BMC2018 4, BMC2019 9]
FX This research was supported by the National Natural Science Foundation
   of China (grant number: 81572140), the Natural Science Foundation of
   Beijing Municipality (grant number: 7172036), and Beijing Municipal
   Health Commission (grant number: BMC2018 4; BMC2019 9).
CR Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Abdelmagid SM, 2007, J CELL PHYSIOL, V210, P26, DOI 10.1002/jcp.20841
   Abdelmagid SM, 2014, AM J PATHOL, V184, P697, DOI 10.1016/j.ajpath.2013.11.031
   Akbari A, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117447
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Armstrong JPK, 2017, ACS NANO, V11, P69, DOI 10.1021/acsnano.6b07607
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Chen CY, 2020, ACTA BIOMATER, V111, P208, DOI 10.1016/j.actbio.2020.05.020
   Chen CY, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0056 9
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Frara N, 2016, J CELL PHYSIOL, V231, P72, DOI 10.1002/jcp.25020
   Furuta T, 2016, STEM CELL TRANSL MED, V5, P1620, DOI 10.5966/sctm.2015 0285
   Hu H, 2018, BIOMED PHARMACOTHER, V105, P66, DOI 10.1016/j.biopha.2018.05.051
   Hu Y, 2020, THERANOSTICS, V10, P2293, DOI 10.7150/thno.39238
   Huang CC, 2020, ACTA BIOMATER, V109, P182, DOI 10.1016/j.actbio.2020.04.017
   Huang YY, 2016, EXPERT OPIN THER TAR, V20, P1357, DOI 10.1080/14728222.2016.1212018
   Ingato D, 2016, J CONTROL RELEASE, V241, P174, DOI 10.1016/j.jconrel.2016.09.016
   Jabbari N, 2020, J CELL PHYSIOL, V235, P6345, DOI 10.1002/jcp.29668
   Jabbari N, 2020, LASER MED SCI, V35, P531, DOI 10.1007/s10103 019 02880 8
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev physiol 021014 071641
   Li HL, 2017, CELL BIOL INT, V41, P1379, DOI 10.1002/cbin.10869
   Li Y, 2018, CURR STEM CELL RES T, V13, P362, DOI 10.2174/1574888X13666180403163456
   Lötvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Ma J, 2017, STEM CELL TRANSL MED, V6, P51, DOI 10.5966/sctm.2016 0038
   Maqsood M, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.118002
   Moussa FM, 2014, J CELL BIOCHEM, V115, P1243, DOI 10.1002/jcb.24760
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Phan J, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1522236
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Rani S, 2016, ADV MATER, V28, P5542, DOI 10.1002/adma.201504009
   Rani S, 2015, MOL THER, V23, P812, DOI 10.1038/mt.2015.44
   Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010
   Sondag GR, 2014, J CELL PHYSIOL, V229, P955, DOI 10.1002/jcp.24512
   Song H, 2019, NANO LETT, V19, P3040, DOI 10.1021/acs.nanolett.9b00287
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Sun L, 2016, CYTOTHERAPY, V18, P413, DOI 10.1016/j.jcyt.2015.11.018
   Takeuchi R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225472
   Woo CH, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1735249
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   Yang BC, 2020, BIOCHEM BIOPH RES CO, V524, P883, DOI 10.1016/j.bbrc.2020.02.001
   Zhang ZW, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002856
   Zhao P, 2018, EUR REV MED PHARMACO, V22, P3962, DOI 10.26355/eurrev_201806_15280
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
   Zuo R, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1121 9
NR 50
TC 33
Z9 36
U1 2
U2 34
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024 3205
EI 1879 0631
J9 LIFE SCI
JI Life Sci.
PD MAY 1
PY 2021
VL 272
AR 119208
DI 10.1016/j.lfs.2021.119208
EA FEB 2021
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA QW8PU
UT WOS:000628911100014
PM 33582177
DA 2025 08 17
ER

PT J
AU Ominsky, MS
   Niu, QT
   Li, CY
   Li, XD
   Ke, HZ
AF Ominsky, Michael S.
   Niu, Qing Tian
   Li, Chaoyang
   Li, Xiaodong
   Ke, Hua Zhu
TI Tissue Level Mechanisms Responsible for the Increase in Bone Formation
   and Bone Volume by Sclerostin Antibody
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE SCLEROSTIN ANTIBODY; BONE FORMATION; BONE MODELING; BONE REMODELING;
   OSTEOPOROSIS
ID PROSTAGLANDIN E 2; WOMEN; RATS; TERIPARATIDE; SURFACES; THERAPY; MASS
AB Bone formation can be remodeling based (RBF) or modeling based (MBF), the former coupled to bone resorption and the latter occurring directly on quiescent surfaces. Unlike osteoanabolic therapies such as parathyroid hormone (PTH) 1 34 that increase bone remodeling and thus both formation and resorption, sclerostin antibody (Scl Ab) increases bone formation while decreasing bone resorption. With this unique profile, we tested our hypothesis that Scl Ab primarily elicited MBF by examining bones from Scl Ab treated ovariectomized (OVX) rats and male cynomolgus monkeys (cynos). Histomorphometry was performed to quantify and characterize bone surfaces in OVX rats administered vehicle or Scl Ab (25mg/kg) subcutaneously (sc) twice/week for 5 weeks and in adolescent cynos administered vehicle or Scl Ab (30mg/kg) sc every 2 weeks for 10 weeks. Fluorochrome labeled surfaces in L 2 vertebra and femur endocortex (cynos only) were considered to be MBF or RBF based on characteristics of their associated cement lines. In OVX rats, Scl Ab increased MBF by eightfold (from 7% to 63% of bone surface, compared to vehicle). In cynos, Scl Ab markedly increased MBF on trabecular (from 0.6% to 34%) and endocortical surfaces (from 7% to 77%) relative to vehicle. Scl Ab did not significantly affect RBF in rats or cynos despite decreased resorption surface in both species. In cynos, Scl Ab resulted in a greater proportion of RBF and MBF containing sequential labels from week 2, indicating an increase in the lifespan of the formative site. This extended formation period was associated with robust increases in the percent of new bone volume formed. These results demonstrate that Scl Ab increased bone volume by increasing MBF and prolonged the formation period at both modeling and remodeling sites while reducing bone resorption. Through these unique effects on bone formation and resorption, Scl Ab may prove to be an effective therapeutic to rapidly increase bone mass in diseases such as osteoporosis. (c) 2014 American Society for Bone and Mineral Research.
C1 [Ominsky, Michael S.; Niu, Qing Tian; Li, Chaoyang; Li, Xiaodong; Ke, Hua Zhu] Amgen Inc, Dept Metab Disorders, Thousand Oaks, CA 91320 USA.
C3 Amgen
RP Ominsky, MS (通讯作者)，Amgen Inc, Metab Disorders, MS 29 M B,One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM mominsky@amgen.com
OI Li, Xiaodong/0000 0002 2089 5046
FU Amgen Inc.; UCB Pharma
FX Amgen Inc. and UCB Pharma sponsored this study. We thank Lisa A
   Humphries, PhD, for providing formatting and editing support on behalf
   of Amgen Inc.
CR Cui L, 2001, J BONE MINER METAB, V19, P29, DOI 10.1007/s007740170057
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Erben RG, 1996, ANAT REC, V246, P39, DOI 10.1002/(SICI)1097 0185(199609)246:1<39::AID AR5>3.0.CO;2 A
   FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Ke HZ, 2012, ENDOCR REV, V33, P747, DOI 10.1210/er.2011 1060
   Kim SW, 2012, J BONE MINER RES, V27, P2075, DOI 10.1002/jbmr.1665
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Ominsky MS, 2011, J BONE MINER RES, V26, P1012, DOI 10.1002/jbmr.307
   Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Toumi H, 2013, J BONE MINER RES, V28
   Tsai JN, 2013, LANCET, V382, P50, DOI 10.1016/S0140 6736(13)60856 9
   Tu XL, 2012, BONE, V50, P209, DOI 10.1016/j.bone.2011.10.025
   Yao W, 1999, BONE, V25, P697, DOI 10.1016/S8756 3282(99)00220 3
NR 21
TC 115
Z9 127
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2014
VL 29
IS 6
BP 1424
EP 1430
DI 10.1002/jbmr.2152
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AH3DJ
UT WOS:000336001500015
PM 24967455
OA Bronze
DA 2025 08 17
ER

PT J
AU Deng, X
   Yu, ZQ
   Funayama, H
   Yamaguchi, K
   Sasano, T
   Sugawara, S
   Endo, Y
AF Deng, Xue
   Yu, Zhiqian
   Funayama, Hiromi
   Yamaguchi, Kouji
   Sasano, Takashi
   Sugawara, Shunji
   Endo, Yasuo
TI Histidine decarboxylase stimulating and inflammatory effects of
   alendronate in mice:: Involvement of mevalonate pathway, TNFα,
   macrophages, and T cells
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE bisphosphonates; alendronate; side effects; statins; histidine
   decarboxylase; mevalonate; TNF
ID ACUTE PHASE RESPONSE; NECROSIS FACTOR ALPHA; BONE RESORPTION; HISTAMINE
   SYNTHESIS; IFN GAMMA; IN VITRO; BISPHOSPHONATE; AMINOBISPHOSPHONATES;
   INDUCTION; MOUSE
AB Nitrogen containing bisphosphonates (NBPs) are powerful anti bone resorptive drugs, but they frequently induce various inflammatory side effects. Recent clinical applications have disclosed an unexpected new side effect, jaw bone necrosis and exposure. In vitro studies suggest that the inflammatory effects of NBPs are due to V gamma 2V delta 2 T cells, stimulated directly and/or indirectly [the latter via isopentenylpyrophosphate (IPP) in the mevalonate pathway]. Rats and mice, however, lack V gamma 2V delta 2 T cells, yet NBPs still induce necrotic and inflammatory reactions. In mice, NBPs induce IL 1 dependent inflammatory reactions, such as inductions of histidine decarboxylase (HDC, the histamine forming enzyme) in the liver, lung, spleen, and bone marrow, an increase in granulocytic cells in the peritoneal cavity, pleural exudation, and splenomegaly. Here, we examined the involvement of IPP, TNF, macrophages, and T cells in the inflammatory actions of alendronate (a typical NBP) in mice. Various statins (mevalonate synthesis inhibitors) suppressed the alendronate induced HDC inductions, while mevalonate itself augmented such inductions. IPP injection also induced HDC. Like IL 1 deficient mice, TNF deficient mice were resistant to alendronate stimulated HDC induction. Alendronate stimulated HDC inductions were significantly weaker in macrophage depleted mice and in nude mice than in control mice. Similar, though generally less clear cut, results were obtained when other alendronate induced inflammatory reactions were examined. These results suggest that (i) inhibition of the mevalonate pathway causes and/or modifies at least some inflammatory actions of alendronate in mice, (ii) in addition to IL 1, TNF is also involved in the inflammatory actions of alendronate, and (iii) alendronate may act on a variety of cells, including macrophages and T cells. (c) 2006 Elsevier B.V. All rights reserved.
C1 Tohoku Univ, Grad Sch Dent, Dept Mol Regulat, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Tohoku Univ, Grad Sch Dent, Dept Oral Diag, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Tohoku Univ, Grad Sch Dent, Dept Oral Microbiol, Aoba Ku, Sendai, Miyagi 9808575, Japan.
   Tohoku Univ, Grad Sch Dent, Dept Oral & Maxillofacial Surg, Aoba Ku, Sendai, Miyagi 9808575, Japan.
C3 Tohoku University; Tohoku University; Tohoku University; Tohoku
   University
RP Endo, Y (通讯作者)，Tohoku Univ, Grad Sch Dent, Dept Mol Regulat, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM endo@pharmac.dent.tohoku.ac.jp
RI yu, zhiqian/M 5041 2016
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   AMIN D, 1992, J LIPID RES, V33, P1657
   Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   Burk MR, 1997, J EXP MED, V185, P91, DOI 10.1084/jem.185.1.91
   Deng X, 2006, TOXICOL APPL PHARM, V213, P64, DOI 10.1016/j.taap.2005.09.005
   Dy M, 2004, CYTOKINE GROWTH F R, V15, P393, DOI 10.1016/j.cytogfr.2004.06.003
   ENDO Y, 1983, BIOCHEM PHARMACOL, V32, P3835
   ENDO Y, 1995, BRIT J PHARMACOL, V114, P187, DOI 10.1111/j.1476 5381.1995.tb14924.x
   Endo Y, 1999, BRIT J PHARMACOL, V126, P903, DOI 10.1038/sj.bjp.0702367
   ENDO Y, 1993, CALCIFIED TISSUE INT, V52, P248, DOI 10.1007/BF00298728
   Fleisch HA, 1997, ANN MED, V29, P55, DOI 10.3109/07853899708998743
   Funayama H, 2000, ARCH ORAL BIOL, V45, P787, DOI 10.1016/S0003 9969(00)00039 X
   Girardi M, 2006, J INVEST DERMATOL, V126, P25, DOI 10.1038/sj.jid.5700003
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365 2249.2005.02665.x
   Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463
   Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272
   Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Kunzmann V, 2000, BLOOD, V96, P384
   LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022 1759(94)90005 1
   LIN JH, 1991, DRUG METAB DISPOS, V19, P926
   MACAROL V, 1994, AM J OPHTHALMOL, V118, P220, DOI 10.1016/S0002 9394(14)72902 2
   Mariani S, 2005, LEUKEMIA, V19, P664, DOI 10.1038/sj.leu.2403693
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Miyagawa F, 2001, J IMMUNOL, V166, P5508, DOI 10.4049/jimmunol.166.9.5508
   MONKKONEN J, 1990, PHARMACOL TOXICOL, V66, P294
   MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074 7613(95)90178 7
   Munns CF, 2004, BONE, V35, P231, DOI 10.1016/j.bone.2004.03.008
   Nakamura M, 1996, BRIT J PHARMACOL, V119, P205, DOI 10.1111/j.1476 5381.1996.tb15972.x
   Nakamura M, 1999, BRIT J HAEMATOL, V107, P779, DOI 10.1046/j.1365 2141.1999.01774.x
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   SCHENK R, 1986, CALCIFIED TISSUE INT, V38, P342, DOI 10.1007/BF02555748
   Shiraishi M, 2000, IMMUNOLOGY, V99, P600, DOI 10.1046/j.1365 2567.2000.00986.x
   SIRIS ES, 1993, LANCET, V341, P436, DOI 10.1016/0140 6736(93)93029 Z
   Sugawara S, 1998, BRIT J PHARMACOL, V125, P735, DOI 10.1038/sj.bjp.0702151
   Tagawa Y, 1997, J IMMUNOL, V159, P1418
   Takagi K, 2005, J IMMUNOL, V174, P1801, DOI 10.4049/jimmunol.174.4.1801
   Tanaka S, 2002, J EXP MED, V196, P229, DOI 10.1084/jem.20012037
   TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0
   TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yamaguchi K, 2000, BRIT J PHARMACOL, V130, P1646, DOI 10.1038/sj.bjp.0703460
   Yamaguchi K, 2006, BBA MOL BASIS DIS, V1762, P269, DOI 10.1016/j.bbadis.2005.11.010
   Yu ZQ, 2005, BASIC CLIN PHARMACOL, V97, P222, DOI 10.1111/j.1742 7843.2005.pto_138.x
NR 54
TC 31
Z9 32
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD FEB
PY 2007
VL 7
IS 2
BP 152
EP 161
DI 10.1016/j.intimp.2006.09.009
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 126YG
UT WOS:000243550900005
PM 17178381
DA 2025 08 17
ER

PT J
AU Hassan, N
   Gregson, CL
   Tang, HT
   van der Kamp, M
   Leo, P
   McInerney Leo, AM
   Zheng, J
   Brandi, ML
   Tang, JCY
   Fraser, W
   Stone, MD
   Grundberg, E
   Brown, MA
   Duncan, EL
   Tobias, JH
AF Hassan, Neelam
   Gregson, Celia L. L.
   Tang, Haotian
   van der Kamp, Marc
   Leo, Paul
   McInerney Leo, Aideen M.
   Zheng, Jie
   Brandi, Maria Luisa
   Tang, Jonathan C. Y.
   Fraser, William
   Stone, Michael D.
   Grundberg, Elin
   Brown, Matthew A.
   Duncan, Emma L.
   Tobias, Jonathan H.
CA Anglo Australasian Genet
TI Rare and Common Variants in GALNT3 May Affect Bone Mass
   Independently of Phosphate Metabolism
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HIGH BONE MASS; EXOME SEQUENCING; MONOGENIC; GALNT3; PHOSPHATE
ID FAMILIAL TUMORAL CALCINOSIS; HYPEROSTOSIS HYPERPHOSPHATEMIA SYNDROME;
   GENOME WIDE ASSOCIATION; GENETIC ARCHITECTURE; MISSENSE MUTATION;
   MINERAL DENSITY; SOST GENE; IDENTIFICATION; LOCI; METAANALYSIS
AB Anabolic treatment options for osteoporosis remain limited. One approach to discovering novel anabolic drug targets is to identify genetic causes of extreme high bone mass (HBM). We investigated a pedigree with unexplained HBM within the UK HBM study, a national cohort of probands with HBM and their relatives. Whole exome sequencing (WES) in a family with HBM identified a rare heterozygous missense variant (NM_004482.4:c.1657C > T, p.Arg553Trp) in GALNT3, segregating appropriately. Interrogation of data from the UK HBM study and the Anglo Australasian Osteoporosis Genetics Consortium (AOGC) revealed an unrelated individual with HBM with another rare heterozygous variant (NM_004482.4:c.831 T > A, p.Asp277Glu) within the same gene. In silico protein modeling predicted that p.Arg553Trp would disrupt salt bridge interactions, causing instability of GALNT3, and that p.Asp277Glu would disrupt manganese binding and consequently GALNT3 catalytic function. Bi allelic loss of function GALNT3 mutations alter FGF23 metabolism, resulting in hyperphosphatemia and causing familial tumoral calcinosis (FTC). However, bone mineral density (BMD) in FTC cases, when reported, has been either normal or low. Common variants in the GALNT3 locus show genome wide significant associations with lumbar, femoral neck, and total body BMD. However, no significant associations with BMD are observed at loci coding for FGF23, its receptor FGFR1, or coreceptor klotho. Mendelian randomization analysis, using expression quantitative trait loci (eQTL) data from primary human osteoblasts and genome wide association studies data from UK Biobank, suggested increased expression of GALNT3 reduces total body, lumbar spine, and femoral neck BMD but has no effect on phosphate concentrations. In conclusion, rare heterozygous loss of function variants in GALNT3 may cause HBM without altering phosphate concentration. These findings suggest that GALNT3 may affect BMD through pathways other than FGF23 regulation, the identification of which may yield novel anabolic drug targets for osteoporosis.(c) 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Hassan, Neelam; Gregson, Celia L. L.; Tobias, Jonathan H.] Univ Bristol, Bristol Med Sch, Musculoskeletal Res Unit, Translat Hlth Sci, Bristol, England.
   [Gregson, Celia L. L.; Tang, Haotian; Zheng, Jie; Tobias, Jonathan H.] Univ Bristol, Bristol Med Sch, MRC Integrated Epidemiol Unit, Populat Hlth Sci, Bristol, England.
   [van der Kamp, Marc] Univ Bristol, Sch Biochem, Bristol, England.
   [Leo, Paul] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Fac Hlth, Translat Genom Grp, Brisbane, Qld, Australia.
   [McInerney Leo, Aideen M.] Univ Queensland, Frazer Inst, Fac Med, Woolloongabba, Qld, Australia.
   [Zheng, Jie] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Endocrine & Metab Dis, Dept Endocrine & Metab Dis,Sch Med, Shanghai, Peoples R China.
   [Zheng, Jie] Shanghai Jiao Tong Univ, Shanghai Natl Clin Res Ctr Metab Dis, Key Lab Endocrine & Metab Dis, Natl Hlth Commiss PR China,Sch Med, Shanghai, Peoples R China.
   [Zheng, Jie] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Key Lab Endocrine Tumor, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China.
   [Brandi, Maria Luisa] FIRMO Fdn, Florence, Italy.
   [Tang, Jonathan C. Y.; Fraser, William] Univ East Anglia, Norwich Med Sch, Norwich, England.
   [Tang, Jonathan C. Y.] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Dept Lab Med, Clin Biochem, Norwich, England.
   [Fraser, William] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Dept Diabet Endocrinol & Clin Biochem, Norwich, England.
   [Stone, Michael D.] Univ Hosp Llandough, Cardiff & Vale Univ Hlth Board, Cardiff, Wales.
   [Grundberg, Elin] Childrens Mercy Kansas City, Genom Med Ctr, Kansas City, MO USA.
   [Brown, Matthew A.] Genom England, London, England.
   [Duncan, Emma L.] Kings Coll London, Fac Life Sci & Med, Sch Life Course & Populat Sci, Dept Twin Res & Genet Epidemiol, London, England.
C3 University of Bristol; University of Bristol; University of Bristol;
   Queensland University of Technology (QUT); University of Queensland;
   Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Shanghai Jiao Tong University; University of East
   Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust;
   Norfolk & Norwich University Hospitals NHS Foundation Trust; Children's
   Mercy Hospital; University of London; King's College London
RP Tobias, JH (通讯作者)，Univ Bristol, Bristol Med Sch, Musculoskeletal Res Unit, Translat Hlth Sci,Southmead Hosp, Learning & Res Bldg Level 1, Bristol BS10 5NB, Avon, England.
EM jon.tobias@bristol.ac.uk
RI ; Tobias, Jon/E 2832 2014; Leo, Paul/B 3470 2011; van der Kamp,
   Marc/F 6000 2013; Duncan, Emma/L 1224 2013; Brown, Matthew/E 5749 2010;
   van der Kamp, Marc/AAJ 8176 2020; Tang, Jonathan/G 3090 2011; Gregson,
   Celia/AAE 1216 2021; McInerney Leo, Aideen/D 8302 2016
OI Hassan, Neelam/0000 0001 7052 5708; Tobias, Jon/0000 0002 7475 3932; van
   der Kamp, Marc/0000 0002 8060 3359; Tang, Haotian/0000 0002 5717 8390;
   McInerney Leo, Aideen/0000 0002 0059 5732; Duncan,
   Emma/0000 0002 8143 4403; Gregson, Celia/0000 0001 6414 0529; Tang,
   Jonathan/0000 0001 6305 6333; 
FU Medical Research Council [MR/V00199X/1]; Elizabeth Blackwell Institute
   for Health Research, University of Bristol; Wellcome Trust Institutional
   Strategic Support Fund [8064/Hassan/WT ISSF 3]; Wellcome Trust
   [080280/Z/06/Z]; EU 7th Framework Programme [247642]; Versus Arthritis
   [20000]; National Health and Medical Research Council (Australia)
   Principal Research Fellowship   National Health and Medical Research
   Council (Australia) Career Development Award [569807]; National Health
   and Medical Research Council Early Career Fellowship [APP1158111];
   National Health and Medical Research Council (Australia) [511132];
   Australian Cancer Research Foundation; British Geriatric Society travel
   grant; Rebecca Cooper Foundation (Australia); National Health and
   Medical Research Council (Australia) Principal Research Fellowship; MRC
   [MR/V00199X/1] Funding Source: UKRI; Wellcome Trust [080280/Z/06/Z]
   Funding Source: Wellcome Trust
FX AOGC investigators include Eugene McCloskey,1 Geoffrey C. Nicholson,2
   Richard Eastell,1 Richard L. Prince,3 John A. Eisman,4,5 Graeme Jones,6
   Philip Sambrook7 (deceased), Ian R. Reid,8 Elaine M. Dennison,9 and John
   Wark.2 NH was supported by the Medical Research Council (MR/V00199X/1),
   Elizabeth Blackwell Institute for Health Research, University of
   Bristol, and the Wellcome Trust Institutional Strategic Support Fund
   (8064/Hassan/WT ISSF 3). CLG was funded by the Wellcome Trust
   (080280/Z/06/Z), the EU 7th Framework Programme Ref. 247642 (GEoCoDE), a
   British Geriatric Society travel grant, and Versus Arthritis (formerly
   Arthritis Research UK) (Grant Ref. 20000). MAB was funded by a National
   Health and Medical Research Council (Australia) Principal Research
   Fellowship. ELD was funded by a National Health and Medical Research
   Council (Australia) Career Development Award (569807). AML was funded by
   a National Health and Medical Research Council Early Career Fellowship
   (APP1158111). The AOGC was funded by the National Health and Medical
   Research Council (Australia) (Grant Ref. 511132). Funding was also
   received from the Australian Cancer Research Foundation and Rebecca
   Cooper Foundation (Australia).1University of Sheffield, UK, 2University
   of Melbourne, Geelong, Australia, 3University of Western Australia,
   Perth, Australia, 4St Vincent's Clinical School, University of New South
   Wales, 5Menzies Research Institute, University of Tasmania, Hobart,
   Australia, 6Kolling Institute, Royal North Shore Hospital, University of
   Sydney, Australia, 7University of Auckland, New Zealand, 8Medical
   Research Council Resource Centre, Southampton, UK.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410 248
   Balemans W, 2002, J MED GENET, V39, P91, DOI 10.1136/jmg.39.2.91
   Balemans W, 2007, J BONE MINER RES, V22, P708, DOI 10.1359/JBMR.070211
   Barbieri AM, 2007, J HUM GENET, V52, P464, DOI 10.1007/s10038 007 0126 5
   Bonàs Guarch S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02380 9
   Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Burgess S, 2017, STAT METHODS MED RES, V26, P2333, DOI 10.1177/0962280215597579
   Campagnoli MF, 2006, J CLIN PATHOL, V59, P440, DOI 10.1136/jcp.2005.026369
   Carmichael KD, 2009, J BONE JOINT SURG AM, V91A, P664, DOI 10.2106/JBJS.G.01512
   Chen J, 2019, DIABETOLOGIA, V62, P1204, DOI 10.1007/s00125 019 4880 7
   Chen P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079767
   Consortium STD., 2014, NATURE, V506, P97, DOI [DOI 10.1038/nature12828, 10.1038/nature12828]
   Dauchez A, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10185
   Dayal D, 2021, INTRACTABLE RARE DIS, V10, P55, DOI 10.5582/irdr.2020.03084
   de las Rivas M, 2020, NAT CHEM BIOL, V16, P351, DOI 10.1038/s41589 019 0444 x
   Dumitrescu CE, 2009, OSTEOPOROSIS INT, V20, P1273, DOI 10.1007/s00198 008 0775 z
   Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372
   Ekinci RMK, 2019, J CLIN RES PEDIATR E, V11, P94, DOI 10.4274/jcrpe.galenos.2018.2018.0134
   El Demellawy D, 2015, SCAND J RHEUMATOL, V44, P170, DOI 10.3109/03009742.2014.958100
   Esapa CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043205
   Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249
   Finer G, 2014, AM J MED GENET A, V164, P1545, DOI 10.1002/ajmg.a.36476
   Flannick J, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.179
   Frishberg Y, 2005, J MOL MED, V83, P33, DOI 10.1007/s00109 004 0610 8
   Frishberg Y, 2007, J BONE MINER RES, V22, P235, DOI 10.1359/JBMR.061105
   Frost M, 2011, J BONE MINER RES, V26, P1721, DOI 10.1002/jbmr.376
   Fuchsberger C, 2016, NATURE, V536, P41, DOI 10.1038/nature18642
   Garringer HJ, 2007, AM J MED GENET A, V143A, P2390, DOI 10.1002/ajmg.a.31947
   Gaulton KJ, 2015, NAT GENET, V47, P1415, DOI 10.1038/ng.3437
   Gok F, 2009, ACTA ORTHOP, V80, P131, DOI 10.1080/17453670902807482
   Gregson CL, 2012, OSTEOPOROSIS INT, V23, P643, DOI 10.1007/s00198 011 1603 4
   Gregson CL, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.595653
   Gregson CL, 2020, J BONE MINER RES, V35, P92, DOI 10.1002/jbmr.3875
   Gregson CL, 2018, BONE, V114, P62, DOI 10.1016/j.bone.2018.06.001
   Gregson CL, 2016, J BONE MINER RES, V31, P640, DOI 10.1002/jbmr.2706
   Gregson CL, 2013, J CLIN ENDOCR METAB, V98, P818, DOI 10.1210/jc.2012 3342
   Grundberg E, 2009, GENOME RES, V19, P1942, DOI 10.1101/gr.095224.109
   Guerra MG, 2020, SCAND J RHEUMATOL, V49, P80, DOI 10.1080/03009742.2019.1602883
   Guindo Martínez M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21952 4
   Hamersma H, 2003, CLIN GENET, V63, P192, DOI 10.1034/j.1399 0004.2003.00036.x
   Hardcastle SA, 2014, OSTEOARTHR CARTILAGE, V22, P1120, DOI 10.1016/j.joca.2014.06.007
   Hartley A, 2020, OSTEOARTHR CARTILAGE, V28, P1180, DOI 10.1016/j.joca.2020.03.020
   Hartley A, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 020 02371 0
   Hébert HL, 2018, INT J EPIDEMIOL, V47, P380, DOI 10.1093/ije/dyx140
   Ichikawa S, 2005, J CLIN ENDOCR METAB, V90, P2420, DOI 10.1210/jc.2004 2302
   Ichikawa S, 2007, J CLIN ENDOCR METAB, V92, P1943, DOI 10.1210/jc.2006 1825
   Ichikawa S, 2006, J CLIN ENDOCR METAB, V91, P4472, DOI 10.1210/jc.2006 1247
   Ichikawa S, 2010, AM J MED GENET A, V152A, P896, DOI 10.1002/ajmg.a.33337
   Ito N, 2021, CALCIFIED TISSUE INT, V108, P104, DOI 10.1007/s00223 020 00659 6
   Joseph L, 2010, SKELETAL RADIOL, V39, P63, DOI 10.1007/s00256 009 0808 5
   Kanai M, 2018, NAT GENET, V50, P390, DOI 10.1038/s41588 018 0047 6
   Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782
   Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586 020 2308 7
   Kato K, 2021, MOLECULES, V26, DOI 10.3390/molecules26185504
   Kemp JP, 2017, NAT GENET, V49, P1468, DOI 10.1038/ng.3949
   Kiel DP, 2020, J BONE MINER RES, V35, P1626, DOI 10.1002/jbmr.4147
   King EA, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008489
   Koller G, 2020, OSTEOPOROSIS INT, V31, P2093, DOI 10.1007/s00198 020 05507 9
   Laakso M, 2017, J LIPID RES, V58, P481, DOI 10.1194/jlr.O072629
   Laleye A, 2008, GENET COUNSEL, V19, P183
   Leupin O, 2011, J BIOL CHEM, V286, P19489, DOI 10.1074/jbc.M110.190330
   López Ferrando V, 2017, NUCLEIC ACIDS RES, V45, pW222, DOI 10.1093/nar/gkx313
   Mahajan A, 2018, NAT GENET, V50, P559, DOI 10.1038/s41588 018 0084 1
   Mahajan A, 2014, NAT GENET, V46, P234, DOI 10.1038/ng.2897
   Mahjoubi F, 2020, J ENDOCRINOL INVEST, V43, P1125, DOI 10.1007/s40618 020 01203 x
   Masi L, 2015, CALCIFIED TISSUE INT, V96, P438, DOI 10.1007/s00223 015 9974 8
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   McInerney Leo AM, 2013, AM J HUM GENET, V93, P515, DOI 10.1016/j.ajhg.2013.06.022
   Medina Gomez C, 2018, AM J HUM GENET, V102, P88, DOI 10.1016/j.ajhg.2017.12.005
   Mercader JM, 2017, DIABETES, V66, P2903, DOI 10.2337/db17 0187
   Morris AP, 2012, NAT GENET, V44, P981, DOI 10.1038/ng.2383
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314
   Ng MCY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004517
   Olauson H, 2008, EUR J ENDOCRINOL, V158, P929, DOI 10.1530/EJE 08 0011
   Rafaelsen S, 2014, BMC GENET, V15, DOI 10.1186/s12863 014 0098 3
   Ramnitz MS, 2016, J BONE MINER RES, V31, P1845, DOI 10.1002/jbmr.2870
   Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890
   Scott RA, 2017, DIABETES, V66, P2888, DOI 10.2337/db16 1253
   Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539
   Specktor P, 2006, J HUM GENET, V51, P487, DOI 10.1007/s10038 006 0377 6
   Spracklen CN, 2020, NATURE, V582, P240, DOI 10.1038/s41586 020 2263 3
   Staehling Hampton K, 2002, AM J MED GENET, V110, P144, DOI 10.1002/ajmg.10401
   Sun LH, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.38
   Topaz O, 2004, NAT GENET, V36, P579, DOI 10.1038/ng1358
   Watanabe K, 2019, NAT GENET, V51, P1339, DOI 10.1038/s41588 019 0481 0
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wessel J., 2020, MEDRXIV
   Whyte MP, 2004, NEW ENGL J MED, V350, P2096
   Yancovitch A, 2011, J BONE MINER METAB, V29, P621, DOI 10.1007/s00774 011 0260 1
   Zankl A, 2012, AM J HUM GENET, V90, P494, DOI 10.1016/j.ajhg.2012.01.003
   Zhao W, 2017, NAT GENET, V49, P1450, DOI 10.1038/ng.3943
   Zheng HF, 2015, NATURE, V526, P112, DOI 10.1038/nature14878
   Zhu ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02317 2
NR 97
TC 0
Z9 1
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2023
VL 38
IS 5
BP 678
EP 691
DI 10.1002/jbmr.4795
EA MAR 2023
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AS3C9
UT WOS:000948636100001
PM 36824040
OA hybrid, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Tsuda, T
   Imanishi, M
   Oogoshi, M
   Goda, M
   Kihira, Y
   Horinouchi, Y
   Zamami, Y
   Ishizawa, K
   Ikeda, Y
   Hashimoto, I
   Tamaki, T
   Izawa Ishizawa, Y
AF Tsuda, Tatsuya
   Imanishi, Masaki
   Oogoshi, Mizuho
   Goda, Mitsuhiro
   Kihira, Yoshitaka
   Horinouchi, Yuya
   Zamami, Yoshito
   Ishizawa, Keisuke
   Ikeda, Yasumasa
   Hashimoto, Ichiro
   Tamaki, Toshiaki
   Izawa Ishizawa, Yuki
TI Rho associated protein kinase and cyclophilin a are involved in
   inorganic phosphate induced calcification signaling in vascular smooth
   muscle cells
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Arterial calcification; Cyclophilin A; Rho associated protein kinase;
   Vascular smooth muscle cell; Atherosclerosis
ID ROCK; SECRETION; PATHWAY; STRESS
AB Arterial calcification, a risk factor of cardiovascular events, develops with differentiation of vascular smooth muscle cells (VSMCs) into osteoblast like cells. Cyclophilin A (CypA) is a peptidyl prolyl isomerase involved in cardiovascular diseases such as atherosclerosis and aortic aneurysms, and rho associated protein kinase (ROCK) is involved in the pathogenesis of vascular calcification. CypA is secreted in a ROCK activity dependent manner and works as a mitogen via autocrine or paracrine mechanisms in VSMCs. We examined the involvement of the ROCK CypA axis in VSMC calcification induced by inorganic phosphate (Pi), a potent cell mineralization initiator. We found that Pi stimulated ROCK activity, CypA secretion, extracellular signal regulated protein kinase (ERK) 1/2 phosphorylation, and runt related transcription factor 2 expression, resulting in calcium accumulation in rat aortic smooth muscle cells (RASMCs). The ROCK inhibitor Y 27632 significantly suppressed Pi induced CypA secretion, ERK1/2 phosphorylation, and calcium accumulation. Recombinant CypA was found to be associated with increased calcium accumulation in RASMCs. Based on these results, we suggest that autocrine CypA is mediated by ROCK activity and is involved in Pi induced ERK1/2 phosphorylation following calcification signaling in RASMCs. (C) 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
C1 [Tsuda, Tatsuya; Hashimoto, Ichiro] Tokushima Univ, Inst Biomed Sci, Dept Plast & Reconstruct Surg, Grad Sch, Tokushima, Japan.
   [Imanishi, Masaki; Goda, Mitsuhiro; Zamami, Yoshito; Ishizawa, Keisuke] Tokushima Univ Hosp, Dept Pharm, Tokushima, Japan.
   [Oogoshi, Mizuho; Horinouchi, Yuya; Ikeda, Yasumasa; Tamaki, Toshiaki; Izawa Ishizawa, Yuki] Tokushima Univ, Inst Biomed Sci, Dept Pharmacol, Grad Sch, Tokushima, Japan.
   [Oogoshi, Mizuho] Tokushima Univ, Student Lab, Sch Med, Tokushima, Japan.
   [Kihira, Yoshitaka] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Fukuyama, Hiroshima, Japan.
   [Zamami, Yoshito; Ishizawa, Keisuke] Tokushima Univ, Inst Biomed Sci, Dept Clin Pharmacol & Therapeut, Grad Sch, Tokushima, Japan.
   [Tamaki, Toshiaki] Anan Med Ctr, Tokushima, Japan.
   [Izawa Ishizawa, Yuki] Tokushima Univ, AWA Support Ctr, 3 18 15 Kuramoto, Tokushima 7708503, Japan.
C3 Tokushima University; Tokushima University; Tokushima University;
   Tokushima University; Fukuyama University; Tokushima University;
   Tokushima University
RP Izawa Ishizawa, Y (通讯作者)，Tokushima Univ, AWA Support Ctr, 3 18 15 Kuramoto, Tokushima 7708503, Japan.
EM ishizawa.yuki@tokushima u.ac.jp
RI Nguyen, Trang/CAA 2720 2022; Goda, MITSUHIRO/HJZ 0657 2023; Hashimoto,
   Ichiro/AFK 5986 2022
OI Ikeda, Yasumasa/0000 0003 4318 7349; Imanishi,
   Masaki/0000 0003 1305 5943; Goda, Mitsuhiro/0000 0001 5345 1479
FU JSPS KAKENHI [JP26860172, JP16K08549]; Naito Foundation
FX This work was supported by grants from JSPS KAKENHI Grant Number
   JP26860172, JP16K08549 (Y.I. I.), and the Naito Foundation (Y.I. I.).
CR Chang CS, 2018, CURR NEUROVASC RES, V15, P111, DOI 10.2174/1567202615666180516120959
   Chen NX, 2010, AM J PHYSIOL RENAL, V299, pF674, DOI 10.1152/ajprenal.00730.2009
   Chiu PF, 2018, FREE RADICAL RES, V52, P1456, DOI 10.1080/10715762.2018.1523545
   Dayanand P, 2018, CURR CARDIOL REV, V14, P192, DOI 10.2174/1573403X14666180619103258
   Gu XX, 2011, AM J PHYSIOL HEART C, V300, pH448, DOI 10.1152/ajpheart.01178.2009
   Guo M, 2016, SCI REP UK, V6, DOI 10.1038/srep22378
   Imanishi M, 2018, PHARMACOLOGY, V102, P287, DOI 10.1159/000492577
   Izawa Ishizawa Y, 2019, J HYPERTENS, V37, P73, DOI 10.1097/HJH.0000000000001898
   Kihira Y, 2015, BIOL PHARM BULL, V38, P514, DOI 10.1248/bpb.b14 00612
   Kim DH, 2018, ANN TRANSPL, V23, P112, DOI 10.12659/AOT.908168
   Koike S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091567
   Kondo M, 2019, AM J HYPERTENS, V32, P249, DOI 10.1093/ajh/hpy157
   Motobayashi Y, 2009, HYPERTENS RES, V32, P188, DOI 10.1038/hr.2008.19
   Nakano Kurimoto R, 2009, AM J PHYSIOL HEART C, V297, pH1673, DOI 10.1152/ajpheart.00455.2009
   National Research Council, 2010, Guide for the Care and Use of Laboratory Animals, DOI DOI 10.17226/12910
   Nigro P, 2011, J EXP MED, V208, P53, DOI 10.1084/jem.20101174
   Ramachandran S, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475 2840 13 38
   Satoh K, 2009, NAT MED, V15, P649, DOI 10.1038/nm.1958
   Shin HR, 2016, J BIOL CHEM, V291, P5555, DOI 10.1074/jbc.M115.698563
   Su ZZ, 2016, J VASC RES, V53, P206, DOI 10.1159/000449387
   Suzuki J, 2006, CIRC RES, V98, P811, DOI 10.1161/01.RES.0000216405.85080.a6
   Terao Y, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933 015 0271 7
   Vos A, 2018, ATHEROSCLEROSIS, V276, P44, DOI 10.1016/j.atherosclerosis.2018.07.008
   Williams MC, 2019, J AM COLL CARDIOL, V73, P291, DOI 10.1016/j.jacc.2018.10.066
   Xue C, 2017, ARTERIOSCL THROM VAS, V37, P1138, DOI 10.1161/ATVBAHA.117.309212
   Yang WW, 2016, FEBS OPEN BIO, V6, P1310, DOI 10.1002/2211 5463.12151
   Yurchenko V, 2002, J BIOL CHEM, V277, P22959, DOI 10.1074/jbc.M201593200
NR 27
TC 8
Z9 8
U1 4
U2 9
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAR
PY 2020
VL 142
IS 3
BP 109
EP 115
DI 10.1016/j.jphs.2019.12.005
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA KL9ZD
UT WOS:000513775600004
PM 31882204
OA gold
DA 2025 08 17
ER

PT J
AU Wang, AT
   Guo, DM
   Cheng, HY
   Jiang, H
   Liu, XJ
   Yun, ZZ
AF Wang, Aitao
   Guo, Dongmei
   Cheng, Hongyu
   Jiang, Hui
   Liu, Xiaojuan
   Yun, Zhizhong
TI Transcriptome Sequencing Explores the Mechanism of Baicalin on Bone
   Cancer Pain
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Article
DE breast cancer; bone cancer pain; baicalin; transcriptome sequencing
ID CELLS; METASTASIS; APOPTOSIS
AB Introduction: Bone cancer pain is characterized by persistent pain, usually requiring drugs to relieve pain. Baicalin, a flavonoid compound extracted from Scutellaria baicalensis, which has antioxidant and analgesic effects. But, the effect of baicalin on bone cancer pain is unclear. Thus, this study aimed to explore the mechanism of baicalin on SD rats with bone cancer pain. Materials and Methods: The MADB 106 breast cancer cells induced bone pain model was constructed and carried out baicalin treatment. The therapeutic effect of baicalin on bone cancer pain model was observed by hematoxylin eosin staining and immunofluorescence staining. We also performed transcriptome sequencing analysis of baicalin in the treatment of bone metastases. Also, RT qPCR and ELISA were used to detect the expression levels of inflammation factors. Results: After baicalin treatment, osteoclast activation was inhibited and the number of bone trabeculae was increased. Baicalin inhibited the protein expression level of inflammatory factors (IL 1 beta, IL 6, TNF alpha and PGE2) in the bone metastases group. Based on the transcriptome sequencing of the bone metastases group and the baicalin treatment group, baicalin inhibited the expression of ALPP, DUSP1, CYR61, ALPPL2, SPP1 and TLR4. RTqPCR was also used to validate the expression levels of these cytokine genes. Conclusion: Baicalin had a certain inhibitory effect on the SD rat model of bone metastasis cancer. These insights can guide future research on the molecular mechanism of bone cancer pain and provide a theoretical basis for baicalin in the treatment of bone pain caused by breast cancer in the future.
C1 [Wang, Aitao; Guo, Dongmei; Liu, Xiaojuan] Inner Mongolia Peoples Hosp, Dept Anesthesiol, Hohhot 010017, Inner Mongolia, Peoples R China.
   [Cheng, Hongyu] Inner Mongolia Med Univ, Dept Anesthesiol, Hohhot 010110, Inner Mongolia, Peoples R China.
   [Jiang, Hui] Baotou Med Coll, Dept Anesthesiol, Baotou 014040, Inner Mongolia, Peoples R China.
   [Yun, Zhizhong] Inner Mongolia Peoples Hosp, Dept Urinary Surg, 20 Zhaowuda Rd, Hohhot 010017, Inner Mongolia, Peoples R China.
C3 Inner Mongolia Medical University; Baotou Medical College
RP Yun, ZZ (通讯作者)，Inner Mongolia Peoples Hosp, Dept Urinary Surg, 20 Zhaowuda Rd, Hohhot 010017, Inner Mongolia, Peoples R China.
EM yzzyb168@126.com
RI dongmei, guo/AAC 3418 2019
FU  [2019GG124]
FX This work was supported by the mechanism of Baicalin inhibiting TLR 4
   mediated central immune response to alleviate bone cancer pain
   (2019GG124) .
CR Chen WC, 2012, MOLECULES, V17, P3844, DOI 10.3390/molecules17043844
   Cheng P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00547
   Cherng CH, 2014, J FORMOS MED ASSOC, V113, P513, DOI 10.1016/j.jfma.2013.04.007
   Chiou CS, 2016, ANESTHESIOLOGY, V125, P779, DOI 10.1097/ALN.0000000000001237
   Chou TC, 2003, ANESTH ANALG, V97, P1724, DOI 10.1213/01.ANE.0000087066.71572.3F
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Liberal FDCG, 2016, APPL RADIAT ISOTOPES, V110, P87, DOI 10.1016/j.apradiso.2016.01.003
   Hu XF, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974 017 0988 1
   Hua BJ, 2015, EXPERT OPIN THER TAR, V19, P227, DOI 10.1517/14728222.2014.980815
   Huynh DL, 2020, MOL BIOL REP, V47, P9779, DOI 10.1007/s11033 020 05972 9
   Jung MA, 2012, BIOMOL THER, V20, P36, DOI 10.4062/biomolther.2012.20.1.036
   Koo HJ, 2014, J ETHNOPHARMACOL, V151, P951, DOI 10.1016/j.jep.2013.12.008
   Li P, 2020, NAT PROD COMMUN, V15, DOI 10.1177/1934578X19899562
   Li P, 2018, NEUROREPORT, V29, P1492, DOI [10.1097/WNR.0000000000001138, 10.1097/wnr.0000000000001138]
   Linher Melville K, 2019, MOL PAIN, V15, DOI 10.1177/1744806918823477
   Liu YF, 2012, NEUROCHEM RES, V37, P1670, DOI 10.1007/s11064 012 0771 8
   Min W, 2015, PHOTOCHEM PHOTOBIOL, V91, P1435, DOI 10.1111/php.12505
   Pacharinsak C, 2008, COMPARATIVE MED, V58, P220
   Sun YY, 2017, PHYTOTHER RES, V31, P899, DOI 10.1002/ptr.5811
   Turabi A, 2012, J SURG ONCOL, V105, P494, DOI 10.1002/jso.21707
   Wang BM, 2020, BREAST CANCER RES TR, V184, P711, DOI 10.1007/s10549 020 05904 y
   Wang YM, 2017, ANTI CANCER DRUG, V28, P581, DOI [10.1097/CAD.0000000000000495, 10.1097/cad.0000000000000495]
   Yu ZQ, 2020, MOL CELL BIOCHEM, V469, P169, DOI 10.1007/s11010 020 03739 1
   Yuan QL, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0117146, 10.1371/journal.pone.0119403]
   Zhai MZ, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.665085
   Zhang J, 2015, INT J CLIN EXP MED, V8, P634
   Zhou QM, 2009, ACTA PHARMACOL SIN, V30, P1648, DOI 10.1038/aps.2009.166
   Zhu XC, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S87568
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304 3959(83)90201 4
NR 29
TC 9
Z9 12
U1 3
U2 44
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178 7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2021
VL 14
BP 5999
EP 6010
DI 10.2147/JIR.S336028
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA XA0QN
UT WOS:000720363000003
PM 34815689
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jeong, YJ
   Park, SA
   Park, YH
   Kim, LK
   Lee, HR
   Kim, HJ
   Heo, TH
AF Jeong, Young Jin
   Park, Sun Ae
   Park, Yeon Hwa
   Kim, Lee Kyung
   Lee, Hae Ri
   Kim, Hee Jung
   Heo, Tae Hwe
TI Anti inflammatory effect of the combined treatment of LMT 28 and
   kaempferol in a collagen induced arthritis mouse model
SO PLOS ONE
LA English
DT Article
ID FIBROBLAST LIKE SYNOVIOCYTES; RHEUMATOID ARTHRITIS; T CELLS; CYTOKINES;
   OSTEOCLASTOGENESIS; ACTIVATION; EXPRESSION; MIGRATION; INVASION;
   RECEPTOR
AB Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and swelling. Several studies have demonstrated that RA fibroblast like synovial cells (RA FLS) play an important role in RA pathogenesis. Activated RA FLS contribute to synovial inflammation by secreting inflammatory cytokines including interleukin (IL) 1 beta, IL 6 and tumor necrosis factor alpha. LMT 28 is derivative of oxazolidone and exerts anti inflammatory effects on RA via IL 6 signaling pathway regulation. LMT 28 also regulates T cell differentiation in RA condition. However, the effect of LMT 28 on the migration and invasion of RA FLS remains unknown. Kaempferol has been reported to have pharmacological effects on various diseases, such as inflammatory diseases, autoimmune diseases, and cancer. Additionally, kaempferol has been reported to inhibit RA FLS migration and invasion, but it is not known about the therapeutic mechanism including molecular mechanism such as receptor. The present study aimed to investigate the synergistic effects of the combined treatment of LMT 28 and kaempferol on RA FLS activation and RA pathogenesis in mouse model. LMT 28 and kaempferol co administration inhibited RA disease severity and histological collapse in the joint tissues of CIA mice, as well as downregulated the levels of pro inflammatory cytokines in mouse serum. Additionally, the combined treatment inhibited excessive differentiation of T helper 17 cells and osteoclasts. Furthermore, compared with single treatments, combined treatment showed enhanced inhibitory effects on the hyperactivation of IL 6 induced signaling pathway in RA FLS. Combined treatment also inhibited RA FLS cell proliferation, migration, and invasion and suppressed the expression of matrix metalloproteinase in RA FLS. Furthermore, we confirmed that the combined treatment inhibited chondrocyte proliferation, migration, and invasion. In conclusion, our results suggest that the combined treatment of LMT 28 and kaempferol exerts a synergistic effect on the RA development via the regulation of IL 6 induced hyperactivation of RA FLS. Furthermore, this study suggests that combination therapies can be an effective therapeutic option for arthritis.
C1 [Jeong, Young Jin; Park, Sun Ae; Kim, Lee Kyung; Lee, Hae Ri; Kim, Hee Jung; Heo, Tae Hwe] Catholic Univ Korea, Lab Pharmacoimmunol, Coll Pharm, FOUR Team Adv Program Smart Pharm Leaders BK21,Int, Bucheon, Gyeonggi, South Korea.
   [Park, Yeon Hwa] Biowave, Seoul, South Korea.
C3 Catholic University of Korea
RP Kim, HJ; Heo, TH (通讯作者)，Catholic Univ Korea, Lab Pharmacoimmunol, Coll Pharm, FOUR Team Adv Program Smart Pharm Leaders BK21,Int, Bucheon, Gyeonggi, South Korea.
EM thhur92@catholic.ac.kr; hjk0114@catholic.ac.kr
RI ; Lee, Hae Ri/AAH 1010 2020; Kim, Hee Jung/O 4581 2019
OI Heo, Tae Hwe/0009 0002 8054 4448; Kim, Hee Jung/0000 0002 6122 6906
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education, Science, and Technology
   [2018R1A6A1A03025108, 2022R1A2C2009911]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science, and Technology [grant number. 2018R1A6A1A03025108
   and 2022R1A2C2009911]. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alam W, 2020, MOLECULES, V25, DOI 10.3390/molecules25184073
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burska A, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/545493
   Bustamante MF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1303 3
   Cope AP, 2007, CLIN EXP RHEUMATOL, V25, pS4
   Cope AP, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2412
   Dayer JM, 2010, RHEUMATOLOGY, V49, P15, DOI 10.1093/rheumatology/kep329
   Ding Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01331 9
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Goldring MB, 2000, ARTHRITIS RHEUM US, V43, P1916, DOI 10.1002/1529 0131(200009)43:9<1916::AID ANR2>3.0.CO;2 I
   Grassi W, 1998, EUR J RADIOL, V27, pS18, DOI 10.1016/S0720 048X(98)00038 2
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313
   Hashizume M, 2011, ARTHRITIS, DOI 10.1155/2011/765624
   Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Lao MX, 2016, J IMMUNOL, V196, P596, DOI 10.4049/jimmunol.1403254
   Leipe J, 2010, ARTHRITIS RHEUM US, V62, P2876, DOI 10.1002/art.27622
   Lin W, 2022, ACS OMEGA, V7, P29868, DOI 10.1021/acsomega.2c02766
   Liu S, 2021, CLIN IMMUNOL, V230, DOI 10.1016/j.clim.2021.108793
   Lopez Acevedo Micael, 2014, Gynecol Oncol Res Pract, V1, P2, DOI 10.1186/2053 6844 1 2
   Maini RN, 2000, ANNU REV MED, V51, P207, DOI 10.1146/annurev.med.51.1.207
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Mor A, 2005, CLIN IMMUNOL, V115, P118, DOI 10.1016/j.clim.2004.12.009
   Pan DM, 2018, INT IMMUNOPHARMACOL, V55, P174, DOI 10.1016/j.intimp.2017.12.011
   Park YH, 2020, CLIN EXP PHARMACOL P, V47, P628, DOI 10.1111/1440 1681.13215
   Qu FN, 2019, NAT REV RHEUMATOL, V15, P167, DOI 10.1038/s41584 018 0151 0
   Robak T, 1998, MEDIAT INFLAMM, V7, P347, DOI 10.1080/09629359890875
   Takeuchi T, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102884
   Takeuchi T, 2016, ANN RHEUM DIS, V75, P983, DOI 10.1136/annrheumdis 2015 208052
   Tchetverikov I, 2004, ANN RHEUM DIS, V63, P881, DOI 10.1136/ard.2003.013243
   Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975
   Walker JG, 2005, J RHEUMATOL, V32, P1650
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Yap HY, 2018, CELLS BASEL, V7, DOI 10.3390/cells7100161
   Yoon HY, 2013, INT J MOL MED, V32, P971, DOI 10.3892/ijmm.2013.1468
   Yue PYK, 2010, J BIOMOL SCREEN, V15, P427, DOI 10.1177/1087057110361772
NR 46
TC 5
Z9 6
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2024
VL 19
IS 7
AR e0302119
DI 10.1371/journal.pone.0302119
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA D0R6E
UT WOS:001293346700005
PM 39083495
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jo, S
   Lee, SH
   Park, J
   Nam, B
   Kim, H
   Youn, J
   Lee, S
   Kim, TJ
   Sung, IH
   Choi, SH
   Park, YS
   Inman, RD
   Kim, TH
AF Jo, Sungsin
   Lee, Seung Hoon
   Park, Jinsung
   Nam, Bora
   Kim, Hyunsung
   Youn, Jeehee
   Lee, Seunghun
   Kim, Tae Jong
   Sung, Il Hoon
   Choi, Sung Hoon
   Park, Ye Soo
   Inman, Robert D.
   Kim, Tae Hwan
TI Platelet Derived Growth Factor B Is a Key Element in the Pathological
   Bone Formation of Ankylosing Spondylitis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE ANKYLOSING SPONDYLITIS; PDGFB/PDGFRB SIGNALING; ENTHESIS; BONE
   MINERALIZATION; ENTHESOPHYTE FORMATION
ID PDGF; PROGRESSION; ACTIVATION; ARTHRITIS; DISEASE
AB Enthesophyte formation plays a crucial role in the development of spinal ankylosis in ankylosing spondylitis (AS). We aimed to investigate the role of platelet derived growth factor B (PDGFB) in enthesophyte formation of AS using in vitro and in vivo models and to determine the association between PDGFB and spinal progression in AS. Serum PDGFB levels were measured in AS patients and healthy controls (HC). Human entheseal tissues attached to facet joints or spinous processes were harvested at the time of surgery and investigated for bone forming activity. The impact of a pharmacological agonist and antagonist of platelet derived growth factor B receptor (PDGFRB) were investigated respectively in curdlan treated SKG mice. PDGFB levels were elevated in AS sera and correlated with radiographic progression of AS in the spine. Mature osteoclasts secreting PDGFB proteins were increased in the AS group compared with HC and were observed in bony ankylosis tissues of AS. Expression of PDGFRB was significantly elevated in the spinous enthesis and facet joints of AS compared with controls. Moreover, recombinant PDGFB treatment accelerated bone mineralization of enthesis cells, which was pronounced in AS, whereas PDGFRB inhibition efficiently reduced the PDGFB induced bone mineralization. Also, PDGFRB inhibition attenuated the severity of arthritis and enthesophyte formation at the joints of curdlan treated SKG mice. This study suggests that regulating PDGFB/PDGFRB signaling could be a novel therapeutic strategy to block key pathophysiological processes of AS. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Jo, Sungsin; Lee, Seung Hoon; Park, Jinsung; Nam, Bora; Kim, Tae Hwan] Hanyang Univ, Inst Rheumatol Res HYIRR, Seoul, South Korea.
   [Nam, Bora; Kim, Tae Hwan] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South Korea.
   [Kim, Hyunsung] Hanyang Univ Hosp, Dept Pathol, Seoul, South Korea.
   [Youn, Jeehee] Hanyang Univ, Coll Med, Dept Anat & Cell Biol, Seoul, South Korea.
   [Lee, Seunghun] Hanyang Univ Hosp Rheumat Dis, Dept Radiol, Seoul, South Korea.
   [Kim, Tae Jong] Chonnam Natl Univ, Med Sch & Hosp, Dept Rheumatol, Gwangju, South Korea.
   [Sung, Il Hoon; Choi, Sung Hoon] Hanyang Univ Hosp, Dept Orthopaed Surg, Seoul, South Korea.
   [Park, Ye Soo] Hanyang Univ, Guri Hosp, Coll Med, Dept Orthoped Surg, Guri, South Korea.
   [Inman, Robert D.] Univ Toronto, Univ Hlth Network, Shroeder Arthrit Inst, Toronto, ON, Canada.
   [Kim, Tae Hwan] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, 222 1 Wangsimni Ro, Seoul 04763, South Korea.
C3 Hanyang University; Hanyang University; Hanyang University Hospital;
   Hanyang University; Hanyang University Hospital; Hanyang University;
   Hanyang University; Hanyang University Hospital; Chonnam National
   University; Hanyang University; Hanyang University Hospital; Hanyang
   University; University of Toronto; University Health Network Toronto;
   Hanyang University; Hanyang University Hospital
RP Kim, TH (通讯作者)，Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, 222 1 Wangsimni Ro, Seoul 04763, South Korea.
EM thkim@hanyang.ac.kr
RI ; Kim, Jin Sug/AAY 6890 2021; Kim, Tae Hwan/M 3962 2017; Jo,
   Sungsin/AAL 3659 2021; lee, sang/Q 4650 2019
OI Jo, Sungsin/0000 0003 3034 5029; 
FU Basic Science Research Program through the National Research Foundation
   of Korea;  [2019R1A2C2004214];  [2020R1A2C1102386]; 
   [2021R1A6A1A03038899]
FX Acknowledgments We thank our laboratory members for their support
   throughout the course of this work. This work was supported by the Basic
   Science Research Program through the National Research Foundation of
   Korea (2019R1A2C2004214, 2020R1A2C1102386, and 2021R1A6A1A03038899).
CR Benjamin M, 2009, ANN RHEUM DIS, V68, P1003, DOI 10.1136/ard.2008.091074
   Benjamin M, 2001, J ANAT, V199, P503, DOI 10.1046/j.1469 7580.2001.19950503.x
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brun J, 2020, J BONE MINER RES, V35, P2458, DOI 10.1002/jbmr.4150
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140 6736(06)69446 4
   Feng XZ, 2020, CELL MOL BIOL, V66, P127, DOI 10.14715/cmb/2020.66.6.23
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Gao B, 2019, J CLIN INVEST, V129, P2578, DOI 10.1172/JCI98857
   Inman RD, 2021, J RHEUMAT DIS, V28, P55, DOI 10.4078/jrd.2021.28.2.55
   Jo S, 2022, OSTEOARTHR CARTILAGE, V30, P280, DOI 10.1016/j.joca.2021.11.013
   Jo S, 2021, RHEUMATOLOGY, V60, P3923, DOI 10.1093/rheumatology/keaa846
   Jo S, 2021, J RHEUMAT DIS, V28, P216, DOI 10.4078/jrd.2021.28.4.216
   Jo S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02217 9
   Jo S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1582 3
   Koo BS, 2020, ANN RHEUM DIS, V79, P1327, DOI 10.1136/annrheumdis 2019 216741
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Kwon SR, 2022, J RHEUMAT DIS, V29, P1, DOI 10.4078/jrd.2022.29.1.1
   Li X, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012109
   Li X, 2018, ARTHRITIS RHEUMATOL, V70, P1056, DOI 10.1002/art.40468
   Li ZH, 2021, ANN RHEUM DIS, V80, P891, DOI 10.1136/annrheumdis 2021 220002
   Liu CH, 2019, J CLIN INVEST, V129, P5357, DOI 10.1172/JCI125212
   Lories RJU, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2642
   Lories RJU, 2005, J CLIN INVEST, V115, P1571, DOI 10.1172/JCI23738
   Ma MJ, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102791
   McGonagle D, 2002, ANN RHEUM DIS, V61, P534, DOI 10.1136/ard.61.6.534
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Nakamura A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abg1210
   Pohlers D, 2006, ARTHRITIS RHEUM US, V54, P788, DOI 10.1002/art.21670
   Ranganathan V, 2017, NAT REV RHEUMATOL, V13, P359, DOI 10.1038/nrrheum.2017.56
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Shao FL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26750 6
   SHEEHAN NJ, 1983, ANN RHEUM DIS, V42, P563, DOI 10.1136/ard.42.5.563
   Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140 6736(16)31591 4
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Trojanowska M, 2008, RHEUMATOLOGY, V47, pV2, DOI 10.1093/rheumatology/ken265
   van der Heijde D, 2019, RHEUMATOLOGY, V58, P388, DOI 10.1093/rheumatology/key128
   Van Mechelen M, 2018, CALCIFIED TISSUE INT, V102, P547, DOI 10.1007/s00223 017 0356 2
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xie ZY, 2016, ARTHRITIS RHEUMATOL, V68, P430, DOI 10.1002/art.39433
   Yu T, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00140 6
   Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984
   Zheng G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1586 1
NR 43
TC 14
Z9 15
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2023
VL 38
IS 2
BP 300
EP 312
DI 10.1002/jbmr.4751
EA DEC 2022
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA D4OB1
UT WOS:000895305300001
PM 36422470
DA 2025 08 17
ER

PT J
AU Cao, XX
   Wang, ZR
   Jiao, Y
   Diao, WY
   Geng, QS
   Zhao, L
   Wang, ZH
   Wang, X
   Zhang, MX
   Xu, JH
   Wang, BL
   Deng, TT
   Xiao, C
AF Cao, Xiaoxue
   Wang, Zhaoran
   Jiao, Yi
   Diao, Wenya
   Geng, Qishun
   Zhao, Lu
   Wang, Zihan
   Wang, Xing
   Zhang, Mengxiao
   Xu, Jiahe
   Wang, Bailiang
   Deng, Tingting
   Xiao, Cheng
TI Dihydroartemisinin alleviates erosive bone destruction by modifying
   local Treg cells in inflamed joints: A novel role in the treatment of
   rheumatoid arthritis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Dihydroartemisinin; Rheumatoid arthritis; Treg cell; Treg cell BMM
   coculture system; Erosive bone destruction; DIA PASEF technology
ID SIGNALING PATHWAY; REGULATORY CELLS; DIFFERENTIATION; SUPPRESSES
AB Treg cell based therapy has exhibited promising efficacy in combatting rheumatoid arthritis (RA). Dihydroartemisinin (DHA) exerts broad immunomodulatory effects across various diseases, with its recent spotlight on T cell regulation in autoimmune conditions. The modulation of DHA on Treg cells and its therapeutic role in RA has yet to be fully elucidated. This study seeks to unveil the influence of DHA on Treg cells in RA and furnish innovative substantiation for the potential of DHA to ameliorate RA. To this end, we initially scrutinized the impact of DHA modulated Treg cells on osteoclast (OC) formation in vitro using Treg cell bone marrow derived monocyte (BMM) coculture systems. Subsequently, employing the collagen induced arthritis (CIA) rat model, we validated the efficacy of DHA and probed its influence on Treg cells in the spleen and popliteal lymph nodes (PLN). Finally, leveraging deep proteomic analysis with data independent acquisition (DIA) and parallel accumulation serial fragmentation (PASEF) technology, we found the alterations in the Treg cell proteome in PLN by proteomic analysis. Our findings indicate that DHA augmented suppressive Treg cells, thereby impeding OC formation in vitro. Consistently, DHA mitigated erosive joint destruction and osteoclastogenesis by replenishing splenic and joint draining lymph node Treg cells in CIA rats. Notably, DHA induced alterations in the Treg cell proteome in PLN, manifesting distinct upregulation of alloantigen Col2a1 (Type II collagen alfa 1 chain) and CD8a (T cell surface glycoprotein CD8 alpha chain) in Treg cells, signifying DHA's targeted modulation of Treg cells, rendering them more adept at sustaining immune tolerance and impeding bone erosion. These results unveil a novel facet of DHA in the treatment of RA.
C1 [Cao, Xiaoxue; Wang, Zhaoran; Geng, Qishun; Zhang, Mengxiao; Deng, Tingting; Xiao, Cheng] China Japan Friendship Hosp, Inst Clin Med, Beijing, Peoples R China.
   [Cao, Xiaoxue; Wang, Zhaoran; Geng, Qishun; Xiao, Cheng] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China.
   [Jiao, Yi; Diao, Wenya; Wang, Zihan; Wang, Xing] Beijing Univ Chinese Med, China Japan Friendship Clin Med Coll, Beijing, Peoples R China.
   [Zhao, Lu] Capital Med Univ, China Japan Friendship Hosp, Beijing, Peoples R China.
   [Xu, Jiahe] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China.
   [Wang, Bailiang] China Japan Friendship Hosp, Dept Orthopaed Surg, Beijing, Peoples R China.
   [Xiao, Cheng] China Japan Friendship Hosp, Dept Emergency, Beijing, Peoples R China.
   [Wang, Bailiang; Deng, Tingting; Xiao, Cheng] Inst Clin Med Sci, Beijing 100029, Peoples R China.
C3 China Japan Friendship Hospital; Chinese Academy of Medical Sciences  
   Peking Union Medical College; Peking Union Medical College; Beijing
   University of Chinese Medicine; China Japan Friendship Hospital; Capital
   Medical University; Peking University; China Japan Friendship Hospital;
   China Japan Friendship Hospital
RP Wang, BL; Deng, TT; Xiao, C (通讯作者)，Inst Clin Med Sci, Beijing 100029, Peoples R China.
EM snowcxx93@student.pumc.edu.cn; b2023023018@pumc.edu.cn;
   20220941348@bucm.edu.cn; 20230941361@bucm.edu.cn;
   zrgengqs@student.pumc.edu.cn; zhaolu@mail.ccmu.edu.cn;
   20220941353@bucm.edu.cn; 20210941326@bucm.edu.cn; a11232023@163.com;
   2311210688@pku.edu.cn; wangbailiang@zryhyy.com.cn;
   dengtingting@zryhyy.com.cn; xiaocheng@zryhyy.com.cn
RI Wang, Zihan/HGE 3658 2022; Xiao, Cheng/AAM 7764 2020; mengxiao,
   zhang/GYU 3986 2022; Wang, Bailiang/T 3483 2018
FU National High Level Hospital Clinical Research Funding of China  Japan
   Friendship Hospital [2023 NHLHCRF DJZD 02]; National High Level Hospital
   Clinical Research Funding & Elite Medical Professionals Project of China
    Japan Friendship Hospital [ZRJY2021 TD01]
FX This study was financially supported by the National High Level Hospital
   Clinical Research Funding of China  Japan Friendship Hospital
   (2023 NHLHCRF DJZD 02) , National High Level Hospital Clinical Research
   Funding & Elite Medical Professionals Project of China  Japan Friendship
   Hospital (No. ZRJY2021 TD01) .
CR Ahmad S, 2017, CANCER RES, V77, P1892, DOI 10.1158/0008 5472.CAN 16 1839
   Bouta EM, 2015, SEMIN CELL DEV BIOL, V38, P90, DOI 10.1016/j.semcdb.2015.01.001
   Chen JR, 2021, CELL MOL IMMUNOL, V18, P2516, DOI 10.1038/s41423 021 00764 y
   Chen YC, 2020, THERANOSTICS, V10, P10466, DOI 10.7150/thno.45211
   Dai XS, 2021, INT J BIOL SCI, V17, P603, DOI 10.7150/ijbs.50364
   Diao L, 2019, INT J NANOMED, V14, P8627, DOI 10.2147/IJN.S220754
   Essig K, 2017, IMMUNITY, V47, P1067, DOI 10.1016/j.immuni.2017.11.008
   Fan ML, 2018, INT IMMUNOPHARMACOL, V65, P233, DOI 10.1016/j.intimp.2018.10.015
   Gao X, 2024, MED RES REV, V44, P867, DOI 10.1002/med.22001
   Gosselt HR, 2020, RHEUMATOL THER, V7, P837, DOI 10.1007/s40744 020 00230 7
   He J, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abm1511
   Hu CQ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.883835
   Ibfelt EH, 2021, RHEUMATOLOGY, V60, P346, DOI 10.1093/rheumatology/keaa327
   Ishigaki K, 2022, NAT GENET, V54, P1640, DOI 10.1038/s41588 022 01213 w
   Körholz J, 2023, RHEUMATOLOGY, V62, P1699, DOI 10.1093/rheumatology/keac575
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Kondo Y, 2018, ARTHRITIS RHEUMATOL, V70, P653, DOI 10.1002/art.40398
   Kuchler Bopp S, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368 019 0072 z
   Levescot A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141008
   Lewis SM, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau6085
   Li D, 2019, FREE RADICAL BIO MED, V143, P260, DOI 10.1016/j.freeradbiomed.2019.08.013
   Li QL, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 04454 5
   Li QL, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01028 5
   Li XY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00131
   Li ZH, 2023, PHYTOMEDICINE, V108, DOI 10.1016/j.phymed.2022.154475
   Luo CY, 2011, CELL MOL IMMUNOL, V8, P50, DOI 10.1038/cmi.2010.54
   Mangal JL, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121079
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Meier F, 2020, NAT METHODS, V17, P1229, DOI 10.1038/s41592 020 00998 0
   Park MJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01526
   Raverdeau M, 2019, EMBO REP, V20, DOI 10.15252/embr.201847121
   Roodenrijs NMT, 2021, RHEUMATOLOGY, V60, P3778, DOI 10.1093/rheumatology/keaa860
   Santinon F, 2020, ARTHRITIS RHEUMATOL, V72, P576, DOI 10.1002/art.41134
   Scheinecker C, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102376
   Smolen JS, 2023, ANN RHEUM DIS, V82, P3, DOI 10.1136/ard 2022 223356
   Sohn HS, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abo5284
   Svensson MND, 2019, J CLIN INVEST, V129, P1193, DOI 10.1172/JCI123267
   SYMMONS DPM, 1995, BRIT MED BULL, V51, P243, DOI 10.1093/oxfordjournals.bmb.a072958
   Takeuchi Y, 2020, IMMUNOL REV, V294, P164, DOI 10.1111/imr.12841
   Thangavelu G, 2022, CELL MOL IMMUNOL, V19, P820, DOI 10.1038/s41423 022 00869 y
   Verma ND, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02397
   Wang J, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.947341
   Wang L, 2023, MATER TODAY BIO, V19, DOI 10.1016/j.mtbio.2023.100557
   Watanabe R., 2023, J. Clin. Med., V12
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Xia Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.746786
   Xiao XY, 2020, J AUTOIMMUN, V108, DOI 10.1016/j.jaut.2020.102404
   Yan SF, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04563 0
   Yan SC, 2019, MOLECULES, V24, DOI 10.3390/molecules24132475
   Yang SJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb0606
   Yu JF, 2023, INT IMMUNOPHARMACOL, V117, DOI 10.1016/j.intimp.2023.109918
   Zhang B, 2019, J CELL PHYSIOL, V234, P19911, DOI 10.1002/jcp.28589
   Zhang MY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.884881
   Zhang XY, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00887 2
   Zhang YW, 2022, SCI CHINA LIFE SCI, V65, P1636, DOI 10.1007/s11427 021 2061 7
   Zhang Z, 2023, INFLAMM RES, V72, P2181, DOI 10.1007/s00011 023 01808 x
   Zhou L, 2016, J BONE MINER RES, V31, P964, DOI 10.1002/jbmr.2771
NR 57
TC 4
Z9 5
U1 1
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAR 30
PY 2024
VL 130
AR 111795
DI 10.1016/j.intimp.2024.111795
EA MAR 2024
PG 12
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA NQ9A5
UT WOS:001202025200001
PM 38447418
DA 2025 08 17
ER

PT J
AU Shi, SF
   Zhang, XL
   Zhu, C
   Chen, DS
   Guo, YY
AF Shi, Si Feng
   Zhang, Xian Long
   Zhu, Chen
   Chen, De Sheng
   Guo, Yong Yuan
TI Ultrasonically enhanced rifampin activity against internalized
   Staphylococcus aureus
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE ultrasound; osteoblast; Staphylococcus aureus; rifampin
ID ULTRASOUND MEDIATED DISRUPTION; LOW FREQUENCY ULTRASOUND; IN VIVO;
   ESCHERICHIA COLI; CELL MEMBRANES; PSEUDOMONAS AERUGINOSA; INTENSITY
   ULTRASOUND; ANTIBIOTIC ACTION; DRUG DELIVERY; PLASMID DNA
AB Staphylococcus aureus (S. aureus) is the principle causative agent of osteomyelitis, accounting for 80% of all human cases. S. aureus internalized in osteoblasts escapes immune response, including engulfment by phagocytes. It also escapes the action of a number of antibiotics. Ultrasound increases cell membrane permeability to a number of drugs. Following an internalization assay, we used low frequency, low power ultrasound combined with the antibiotic rifampin to target S. aureus internalized in human osteoblasts. Tryptic soy agar (TSA) was used to quantitate the antibacterial effect of rifampin combined with low frequency ultrasound. A Cell Counting Kit 8 (CCK 8) assay was used to evaluate cell viability following exposure to ultrasound. Our data revealed that rifampin successfully penetrates into osteoblasts and kills internalized S. aureus in osteoblasts, while low frequency ultrasound promotes this process. Ultrasound had a negative impact on the cell viability of osteoblasts; however, this damage was slight and reversible. Ultrasound enhanced antibiotic efficiency to bacteria internalized in the osteoblasts may contribute to the control of chronic infection to reduce recurrence.
C1 [Shi, Si Feng; Zhang, Xian Long; Zhu, Chen; Chen, De Sheng; Guo, Yong Yuan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Orthopaed Surg, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 6, Dept Orthopaed Surg, 600 Yi Shan Rd, Shanghai 200233, Peoples R China.
EM zhangxianlong20101@163.com
RI Zhu, Chen/GXN 0330 2022; Zhang, Xianlong/AAL 8407 2020
FU Characteristic Construction Foundation of the Sixth People's Hospital
FX This study was financially supported by the Characteristic Construction
   Foundation of the Sixth People's Hospital affiliated to Shanghai
   Jiaotong University.
CR Ananta E, 2005, J APPL MICROBIOL, V99, P271, DOI 10.1111/j.1365 2672.2005.02619.x
   Carmen JC, 2005, AM J INFECT CONTROL, V33, P78, DOI 10.1016/j.ajic.2004.08.002
   Carmen JC, 2004, J BIOMATER APPL, V18, P237, DOI 10.1177/0885328204040540
   Carmen John C., 2004, Journal of Infection and Chemotherapy, V10, P193
   Chang DC., 1992, Guide to electroporation and electrofusion, P9
   Chauhan VS, 2010, J MED MICROBIOL, V59, P755, DOI 10.1099/jmm.0.015859 0
   Chihara S, 2010, DM DIS MON, V56, P6, DOI 10.1016/j.disamonth.2009.07.001
   El Helou OC, 2010, EUR J CLIN MICROBIOL, V29, P961, DOI 10.1007/s10096 010 0952 9
   Ellington JK, 2006, J ORTHOP RES, V24, P87, DOI 10.1002/jor.20003
   Ellington JK, 2003, J BONE JOINT SURG BR, V85B, P918, DOI 10.1302/0301 620X.85B6.13509
   Garrigós C, 2010, ANTIMICROB AGENTS CH, V54, P5251, DOI 10.1128/AAC.00226 10
   Gracewski SM, 2005, J ACOUST SOC AM, V117, P1440, DOI 10.1121/1.1858211
   Guzmán HR, 2003, ULTRASOUND MED BIOL, V29, P1211, DOI 10.1016/S0301 5629(03)00899 8
   Guzmán HR, 2001, J ACOUST SOC AM, V110, P588, DOI 10.1121/1.1376131
   Guzmán HR, 2001, J ACOUST SOC AM, V110, P597, DOI 10.1121/1.1376130
   Huber PE, 2000, GENE THER, V7, P1516, DOI 10.1038/sj.gt.3301242
   Ishida I, 2007, J MED MICROBIOL, V56, P1042, DOI 10.1099/jmm.0.47029 0
   Iwanaga K, 2007, CANCER GENE THER, V14, P354, DOI 10.1038/sj.cgt.7701026
   Jin CC, 2010, J CLIN IMMUNOL, V30, P628, DOI 10.1007/s10875 010 9440 3
   Khanlari B, 2010, J ANTIMICROB CHEMOTH, V65, P1799, DOI 10.1093/jac/dkq182
   Kinoshita M, 2007, BIOCHEM BIOPH RES CO, V359, P860, DOI 10.1016/j.bbrc.2007.05.153
   Lee EK, 2004, IEEE T BIO MED ENG, V51, P82, DOI 10.1109/TBME.2003.820323
   Lefebvre M, 2010, INT J ANTIMICROB AG, V36, P542, DOI 10.1016/j.ijantimicag.2010.07.008
   Li YS, 2008, CANCER LETT, V266, P156, DOI 10.1016/j.canlet.2008.02.041
   Liu J, 1998, PHARMACEUT RES, V15, P918, DOI 10.1023/A:1011984817567
   Mehier Humbert S, 2005, J CONTROL RELEASE, V104, P213, DOI 10.1016/j.jconrel.2005.01.007
   Mitragotri S, 1996, PHARMACEUT RES, V13, P411, DOI 10.1023/A:1016096626810
   Ning RD, 2010, ACTA BIOCH BIOPH SIN, V42, P883, DOI 10.1093/abbs/gmq096
   Pitt WG, 2003, BIOTECHNOL PROGR, V19, P1038, DOI 10.1021/bp0340685
   Qian Z, 1999, J BIOMED MATER RES, V44, P198, DOI 10.1002/(SICI)1097 4636(199902)44:2<198::AID JBM10>3.0.CO;2 P
   Rapoport N, 1997, ARCH BIOCHEM BIOPHYS, V344, P114, DOI 10.1006/abbi.1997.0176
   Rediske AM, 1999, ANTIMICROB AGENTS CH, V43, P1211, DOI 10.1128/AAC.43.5.1211
   Rediske AM, 1999, LETT APPL MICROBIOL, V28, P81, DOI 10.1046/j.1365 2672.1999.00461.x
   Rediske AM, 1998, J GEN APPL MICROBIOL, V44, P283, DOI 10.2323/jgam.44.283
   Reilly SS, 2000, BONE, V26, P63, DOI 10.1016/S8756 3282(99)00239 2
   Runyan CM, 2006, J GEN APPL MICROBIOL, V52, P295, DOI 10.2323/jgam.52.295
   Saito K, 1999, EXP EYE RES, V68, P431, DOI 10.1006/exer.1998.0626
   Shi SF, 2012, EXP THER MED, V3, P367, DOI 10.3892/etm.2011.423
   Tachibana K, 2000, CANCER LETT, V149, P189, DOI 10.1016/S0304 3835(99)00358 4
   Wang L, 2010, BIOMATERIALS, V31, P1691, DOI 10.1016/j.biomaterials.2009.11.053
   Webb Lawrence X, 2007, J Surg Orthop Adv, V16, P73
   Williams RG, 1997, J BIOMATER APPL, V12, P20, DOI 10.1177/088532829701200102
   Wright JA, 2010, INT J MED MICROBIOL, V300, P193, DOI 10.1016/j.ijmm.2009.10.003
   Wyber JA, 1997, PHARMACEUT RES, V14, P750, DOI 10.1023/A:1012198321879
NR 44
TC 9
Z9 9
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
J9 EXP THER MED
JI Exp. Ther. Med.
PD JAN
PY 2013
VL 5
IS 1
BP 257
EP 262
DI 10.3892/etm.2012.758
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 052YK
UT WOS:000312236400047
PM 23251279
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Guo, J
   Bot, I
   de Nooijer, R
   Hoffman, SJ
   Stroup, GB
   Biessen, EAL
   Benson, GM
   Groot, PHE
   Van Eck, M
   Van Berkel, TJC
AF Guo, Jian
   Bot, Ilze
   de Nooijer, Ramon
   Hoffman, Sandra J.
   Stroup, George B.
   Biessen, Erik A. L.
   Benson, G. Martin
   Groot, Pieter H. E.
   Van Eck, Miranda
   Van Berkel, Theo J. C.
TI Leucocyte cathepsin K affects atherosclerotic lesion composition and
   bone mineral density in low density lipoprotein receptor deficient mice
SO CARDIOVASCULAR RESEARCH
LA English
DT Article
ID REDUCES ATHEROSCLEROSIS; MOLECULAR CLONING; GENE; EXPRESSION;
   OSTEOCLASTS; CELLS; PYCNODYSOSTOSIS; IDENTIFICATION; OSTEOPETROSIS;
   PROGRESSION
AB Cathepsin K (CatK), an established drug target for osteoporosis, has been reported to be upregulated in atherosclerotic lesions. Due to its proteolytic activity, CatK may influence the atherosclerotic lesion composition and stability. In this study, we investigated the potential role of leucocyte CatK in atherosclerotic plaque remodelling.
   To assess the biological role of leucocyte CatK, we used the technique of bone marrow transplantation to selectively disrupt CatK in the haematopoietic system. Total bone marrow progenitor cells from CatK(+/+), CatK(+/ ), and CatK( / ) mice were transplanted into X ray irradiated low density lipoprotein receptor knockout (LDLr / ) mice. The selective silencing of leucocyte CatK resulted in phenotypic changes in bone formation with an increased total bone mineral density in the CatK( / ) chimeras and an effect of gene dosage. The absence of leucocyte CatK resulted in dramatically decreased collagen and increased macrophage content of the atherosclerotic lesions while lesion size was not affected. The atherosclerotic lesions also demonstrated less elastic lamina fragmentation and a significant increase in the apoptotic and necrotic area in plaques of mice transplanted with CatK( / ) bone marrow.
   Leucocyte CatK is an important determinant of atherosclerotic plaque composition, vulnerability, and bone remodelling, rendering CatK an attractive target for pharmaceutical modulation in atherosclerosis and osteoporosis.
C1 [Guo, Jian; Bot, Ilze; de Nooijer, Ramon; Biessen, Erik A. L.; Van Eck, Miranda; Van Berkel, Theo J. C.] Leiden Univ, Gorlaeus Labs, LACDR, Div Biopharmaceut, NL 2333 CC Leiden, Netherlands.
   [Bot, Ilze] Leiden Univ, Med Ctr, Dept Cardiol, NL 2333 CC Leiden, Netherlands.
   [Hoffman, Sandra J.; Stroup, George B.] GlaxoSmithKline Inc, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA.
   [Benson, G. Martin; Groot, Pieter H. E.] GlaxoSmithKline Inc, Atherosclerosis Dept, Stevenage, Herts, England.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University   Excl LUMC;
   GlaxoSmithKline; Glaxosmithkline USA; GlaxoSmithKline; Glaxosmithkline
   United Kingdom
RP Bot, I (通讯作者)，Leiden Univ, Gorlaeus Labs, LACDR, Div Biopharmaceut, Einsteinweg 55, NL 2333 CC Leiden, Netherlands.
EM i.bot@lacdr.leidenuniv.nl
RI Van Berkel, Theo/ABD 7677 2021; van Eck, Miranda/LTC 5020 2024
OI Bot, Ilze/0000 0002 1242 1959
FU GSK Pharmaceuticals; Netherlands Heart Foundation [2001T041, M93.001];
   Netherlands Organization for Scientific Research [916.86.046]
FX This work was supported by GSK Pharmaceuticals (J.G.), the Netherlands
   Heart Foundation [grant numbers 2001T041 (M. V. E.), M93.001 (R. de N.)]
   and by the Netherlands Organization for Scientific Research [grant
   number 916.86.046 (I. B.)].
CR Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   DeVries Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078
   Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Jaffer FA, 2007, CIRCULATION, V115, P2292, DOI 10.1161/CIRCULATIONAHA.106.660340
   Johnson MR, 1996, GENOME RES, V6, P1050, DOI 10.1101/gr.6.11.1050
   LI YP, 1995, J BONE MINER RES, V10, P1197
   Lutgens E, 2006, CIRCULATION, V113, P98, DOI 10.1161/CIRCULATIONAHA.105.561449
   Lutgens SPM, 2006, J PATHOL, V210, P334, DOI 10.1002/path.2054
   Platt MO, 2007, AM J PHYSIOL HEART C, V292, pH1479, DOI 10.1152/ajpheart.00954.2006
   Rantakokko J, 1996, FEBS LETT, V393, P307, DOI 10.1016/0014 5793(96)00907 6
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Samokhin AO, 2008, ATHEROSCLEROSIS, V200, P58, DOI 10.1016/j.atherosclerosis.2007.12.047
   SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014 5793(94)01349 6
   Sukhova GK, 2003, J CLIN INVEST, V111, P897, DOI 10.1172/JCI200314915
   Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503
   Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181
   Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452
   TEZUKA K, 1994, J BIOL CHEM, V269, P1106
   VanEck M, 1997, ARTERIOSCL THROM VAS, V17, P3117, DOI 10.1161/01.ATV.17.11.3117
   Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262, DOI 10.1161/01.ATV.20.5.1262
   Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396
NR 25
TC 28
Z9 30
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0008 6363
EI 1755 3245
J9 CARDIOVASC RES
JI Cardiovasc. Res.
PD FEB 1
PY 2009
VL 81
IS 2
BP 278
EP 285
DI 10.1093/cvr/cvn311
PG 8
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 395IU
UT WOS:000262518600009
PM 19015136
OA Bronze
DA 2025 08 17
ER

PT J
AU Cheng, TL
   Lai, CH
   Shieh, SJ
   Jou, YB
   Yeh, JL
   Yang, AL
   Wang, YH
   Wang, CZ
   Chen, CH
   Shi, GY
   Ho, ML
   Wu, HL
AF Cheng, Tsung Lin
   Lai, Chao Han
   Shieh, Shyh Jou
   Jou, Yin Bo
   Yeh, Jwu Lai
   Yang, Ai Lun
   Wang, Yan Hsiung
   Wang, Chau Zen
   Chen, Chung Hwan
   Shi, Guey Yueh
   Ho, Mei Ling
   Wu, Hua Lin
TI Myeloid thrombomodulin lectin like domain inhibits osteoclastogenesis
   and inflammatory bone loss
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DIFFERENTIATION FACTOR; REPLACEMENT THERAPY; KAPPA B; PROTEIN;
   OSTEOPOROSIS; EXPRESSION; HMGB1; ACTIVATION; MONOCYTES; RECEPTOR
AB Osteoclastogenesis is an essential process during bone metabolism which can also be promoted by inflammatory signals. Thrombomodulin (TM), a transmembrane glycoprotein, exerts anti inflammatory activities such as neutralization of proinflammatory high mobility group box 1 (HMGB1) through TM lectin like domain. This study aimed to identify the role of myeloid TM (i.e., endogenous TM expression on the myeloid lineage) in osteoclastogenesis and inflammatory bone loss. Using human peripheral blood mononuclear cells and mouse bone marrow derived macrophages, we observed that the protein levels of TM were dramatically reduced as these cells differentiated into osteoclasts. In addition, osteoclastogenesis and extracellular HMGB1 accumulation were enhanced in primary cultured monocytes from myeloid specific TM deficient mice (LysMcre/TMflox/flox) and from TM lectin like domain deleted mice (TMLeD/LeD) compared with their respective controls. Micro computerized tomography scans showed that ovariectomy induced bone loss was more pronounced in TMLeD/LeD mice compared with controls. Finally, the inhibiting effects of recombinant TM lectin like domain (rTMD1) on bone resorption in vitro, and bone loss in both the ovariectomized model and collagen antibody induced arthritis model has been detected. These findings suggested that the myeloid TM lectin like domain may inhibit osteoclastogenesis by reducing HMGB1 signaling, and rTMD1 may hold therapeutic potential for inflammatory bone loss.
C1 [Cheng, Tsung Lin; Wang, Chau Zen; Ho, Mei Ling] Kaohsiung Med Univ, Coll Med, Dept Physiol, Kaohsiung, Taiwan.
   [Cheng, Tsung Lin; Wang, Yan Hsiung; Wang, Chau Zen; Chen, Chung Hwan; Ho, Mei Ling] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan.
   [Lai, Chao Han; Shi, Guey Yueh; Wu, Hua Lin] Natl Cheng Kung Univ, Cardiovasc Res Ctr, Tainan 701, Taiwan.
   [Lai, Chao Han; Shieh, Shyh Jou] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Surg, Tainan 70101, Taiwan.
   [Shieh, Shyh Jou] Natl Cheng Kung Univ, Int Res Ctr Wound Repair & Regenerat iWRR, Tainan 701, Taiwan.
   [Jou, Yin Bo; Shi, Guey Yueh; Wu, Hua Lin] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 70101, Taiwan.
   [Yeh, Jwu Lai] Kaohsiung Med Univ, Coll Med, Dept Pharmacol, Kaohsiung, Taiwan.
   [Yeh, Jwu Lai; Ho, Mei Ling] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan.
   [Yang, Ai Lun] Univ Taipei, Grad Inst Exercise Sci, Taipei, Taiwan.
   [Wang, Yan Hsiung] Kaohsiung Med Univ, Coll Dent Med, Sch Dent, Kaohsiung, Taiwan.
   [Chen, Chung Hwan] Kaohsiung Med Univ, Coll Med, Dept Orthoped, Kaohsiung, Taiwan.
   [Chen, Chung Hwan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung, Taiwan.
   [Chen, Chung Hwan] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Orthoped, Kaohsiung, Taiwan.
   [Ho, Mei Ling] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 80424, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; National Cheng Kung University; National
   Cheng Kung University; National Cheng Kung University Hospital; National
   Cheng Kung University; National Cheng Kung University; Kaohsiung Medical
   University; Kaohsiung Medical University; University of Taipei;
   Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University Hospital; Kaohsiung
   Medical University; Kaohsiung Municipal Ta Tung Hospital; National Sun
   Yat Sen University
RP Wu, HL (通讯作者)，Natl Cheng Kung Univ, Cardiovasc Res Ctr, Tainan 701, Taiwan.; Wu, HL (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan 70101, Taiwan.
EM halnwu@mail.ncku.edu.tw
RI Ho, Mei Ling/D 5515 2009; Yeh, Jwu Lai/A 1535 2010; Chen,
   Chung Hwan/D 4036 2009; Wang, Chau Zen/D 4868 2009; Wang,
   Yan Hsiung/ABD 4004 2020; Lai, Chao Han/JAX 5678 2023
OI Cheng, Tsung Lin/0000 0001 7080 8652; Yeh, Jwu Lai/0000 0001 7101 5865;
   Ho, Mei Ling/0000 0001 8064 8488; Chen, Chung Hwan/0000 0001 8941 4792;
   Wang, Yan Hsiung/0000 0001 8161 7472; Lai, Chao Han/0000 0002 1382 1495;
   
FU Ministry of Science and Technology (Taipei, Taiwan) [NSC
   102 2325 B 006 002, MOST 104 2320 B 037 026]; Ministry of Education,
   Taiwan, ROC; Top University Project; Kaohsiung Medical University "Aim
   for the Top Universities Grant" [KMU TP104B10, KMU TP104B13]
FX This work was supported, in part, by the Ministry of Science and
   Technology (Taipei, Taiwan; grants NSC 102 2325 B 006 002   for Hua Lin
   Wu, and MOST 104 2320 B 037 026   for Tsung Lin Cheng). This research
   was, in part, supported by the Ministry of Education, Taiwan, ROC., The
   Aim for the Top University Project to the National Cheng Kung
   University, and by Kaohsiung Medical University "Aim for the Top
   Universities Grant, grant No. KMU TP104B10 and KMU TP104B13". The
   authors thank the Center for Research Resources and Development in
   Kaohsiung Medical University for the assistance in mu CT analysis.
CR Abeyama K, 2005, J CLIN INVEST, V115, P1267, DOI 10.1172/JCI200522782
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338
   Cheng TL, 2015, J INVEST DERMATOL, V135, P1668, DOI 10.1038/jid.2015.32
   Cheng TL, 2013, J INVEST DERMATOL, V133, P1638, DOI 10.1038/jid.2013.8
   Cheng TL, 2011, J INVEST DERMATOL, V131, P2486, DOI 10.1038/jid.2011.230
   Conway EM, 2012, SEMIN IMMUNOPATHOL, V34, P107, DOI 10.1007/s00281 011 0282 8
   Conway EM, 2002, J EXP MED, V196, P565, DOI 10.1084/jem.20020077
   DITTMAN WA, 1990, BLOOD, V75, P329
   ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003 4819 102 3 319
   GANDO S, 1995, THROMB RES, V80, P519, DOI 10.1016/0049 3848(95)00207 3
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo reports/kvf198
   Grahnemo L, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0703 5
   Greenlee MC, 2008, CURR DRUG TARGETS, V9, P130
   Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222
   Huang HC, 2003, J BIOL CHEM, V278, P46750, DOI 10.1074/jbc.M305216200
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Ito T, 2008, ARTERIOSCL THROM VAS, V28, P1825, DOI 10.1161/ATVBAHA.107.150631
   Kao YC, 2010, MOL CELL BIOL, V30, P4767, DOI 10.1128/MCB.01021 09
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai CH, 2013, ANN SURG, V258, P1103, DOI 10.1097/SLA.0b013e31827df7cb
   LAU KHW, 1987, CLIN CHEM, V33, P458
   Lee SK, 2006, BONE, V38, P678, DOI 10.1016/j.bone.2005.10.011
   Ma CY, 2012, J IMMUNOL, V188, P6328, DOI 10.4049/jimmunol.1102266
   MCCACHREN SS, 1991, BLOOD, V78, P3128
   Montagnani A, 2011, AGING CLIN EXP RES, V23, P84, DOI 10.1007/BF03351073
   Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Naylor AJ, 2012, ARTHRITIS RHEUM US, V64, P3334, DOI 10.1002/art.34556
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Schairer C, 2000, JAMA J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485
   Seeman E, 2003, OSTEOPOROSIS INT, V14, pS2, DOI 10.1007/s00198 002 1340 9
   Shi CS, 2008, BLOOD, V112, P3661, DOI 10.1182/blood 2008 03 142760
   Shi CS, 2005, CIRCULATION, V111, P1627, DOI 10.1161/01.CIR.0000160364.05405.B5
   Sohn RH, 2005, BLOOD, V105, P3910, DOI 10.1182/blood 2004 03 0928
   StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212
   Toyosaki Maeda T, 2001, ARTHRITIS RES, V3, P306, DOI 10.1186/ar320
   van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456 008 9093 5
   Van de Wouwer M, 2006, J THROMB HAEMOST, V4, P1813, DOI 10.1111/j.1538 7836.2006.02033.x
   VERHAEGHE J, 1990, HORM RES, V34, P245, DOI 10.1159/000181834
   Weiler H, 2003, J THROMB HAEMOST, V1, P1515, DOI 10.1046/j.1538 7836.2003.00306.x
   Wu QY, 2016, J BONE MINER METAB, V34, P500, DOI 10.1007/s00774 015 0700 4
   Yanai H, 2013, P NATL ACAD SCI USA, V110, P20699, DOI 10.1073/pnas.1320808110
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang Y, 2015, SCI REP UK, V5, DOI 10.1038/srep13575
   Zhou H, 2001, J BIOL CHEM, V276, P14916, DOI 10.1074/jbc.M011554200
   Zhou Z, 2008, J BONE MINER RES, V23, P1084, DOI 10.1359/JBMR.080234
NR 50
TC 16
Z9 18
U1 0
U2 16
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUN 17
PY 2016
VL 6
AR 28340
DI 10.1038/srep28340
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DO7YF
UT WOS:000377998300001
PM 27311356
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kang, KL
   Kim, EC
   Park, JB
   Heo, JS
   Choi, Y
AF Kang, Kyung Lhi
   Kim, Eun Cheol
   Park, Joon Bong
   Heo, Jung Sun
   Choi, Yumi
TI HIGH FREQUENCY, LOW INTENSITY PULSED ULTRASOUND ENHANCES ALVEOLAR BONE
   HEALING OF EXTRACTION SOCKETS IN RATS: A PILOT STUDY
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Low intensity pulsed ultrasound; High frequency; Tooth extraction socket
   healing; Alveolar bone formation in rats
ID DIFFERENTIATION; PROLIFERATION; STIMULATION; OSTEOGENESIS; OSTEOBLASTS;
   EXPRESSION; SITES; CBFA1; LIPUS
AB Most studies of the beneficial effects of low intensity pulsed ultrasound (LIPUS) on bone healing have used frequencies between 1.0 and 1.5 MHz. However, after consideration of ultrasound wave characteristics and depth of target tissue, higher frequency LIPUS may have been more effective on superficially positioned alveolar bone. We investigated this hypothesis by applying LIPUS (frequency, 3.0 MHz; intensity, 30 mW/cm(2)) on shaved right cheeks over alveolar bones of tooth extraction sockets in rats for 10 min/d for 2 wk after tooth extraction; the control group (left cheek of the same rats) did not receive LIPUS treatment. Compared with the control group, the LIPUS group manifested more new bone growth inside the sockets on histomorphometric analysis (maximal difference 5 2.5 fold on the seventh day after extraction) and higher expressions of osteogenesisrelated mRNAs and proteins than the control group did. These findings indicate that 3.0 MHz LIPUS could enhance alveolar bone formation and calcification in rats. (C) 2016 World Federation for Ultrasound in Medicine & Biology.
C1 [Kang, Kyung Lhi; Park, Joon Bong; Choi, Yumi] Kyung Hee Univ, Sch Dent, Dept Periodontol, Seoul 05278, South Korea.
   [Kang, Kyung Lhi; Kim, Eun Cheol; Park, Joon Bong; Heo, Jung Sun] Kyung Hee Univ, Sch Dent, Inst Oral Biol, Seoul 05278, South Korea.
   [Kim, Eun Cheol] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, Seoul 05278, South Korea.
   [Kim, Eun Cheol] Kyung Hee Univ, Res Ctr Tooth & Periodontal Tissue Regenerat MRC, Seoul 05278, South Korea.
   [Heo, Jung Sun] Kyung Hee Univ, Sch Dent, Dept Maxillofacial Biomed Engn, Seoul 05278, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung
   Hee University; Kyung Hee University
RP Kang, KL (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Periodontol, Dent Hosp Gangdong, 892 Dongnam Ro, Seoul 05278, South Korea.
EM periokkl@khu.ac.kr
RI Kim, Cheorl Ho/T 6753 2019
FU Kyung Hee University [KHU 20120473]; Technological Development
   Commercialization grant   Small and Medium Business Administration
   (SMBA) of Korea [S2080517]; National Research Foundation of Korea (NRF)
   grant   Korean government (MSIP) [2012 R1 A5 A2051384]
FX This work was supported by a grant from Kyung Hee University in 2012
   (KHU 20120473), a Technological Development Commercialization grant
   funded by the Small and Medium Business Administration (SMBA) of Korea
   (S2080517) and a National Research Foundation of Korea (NRF) grant
   funded by the Korean government (MSIP) (2012 R1 A5 A2051384).
CR Al Daghreer S, 2014, ULTRASOUND MED BIOL, V40, P1187, DOI 10.1016/j.ultrasmedbio.2013.12.016
   [Anonymous], 2004, J JAPAN SOC ORAL IMP
   Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   Chung SL, 2011, ULTRASOUND MED BIOL, V37, P1120, DOI 10.1016/j.ultrasmedbio.2011.04.017
   Ebrahim S, 2014, CAN J SURG, V57, pE105, DOI 10.1503/cjs.010113
   Engelmann J, 2012, ULTRASOUND MED BIOL, V38, P1470, DOI 10.1016/j.ultrasmedbio.2012.03.020
   Fávaro Pípi E, 2010, ULTRASOUND MED BIOL, V36, P2057, DOI 10.1016/j.ultrasmedbio.2010.07.012
   Franceschi RT, 2009, CELLS TISSUES ORGANS, V189, P144, DOI 10.1159/000151747
   Götz W, 2008, CLIN ORAL IMPLAN RES, V19, P1016, DOI 10.1111/j.1600 0501.2008.01569.x
   Gu XQ, 2014, ASIAN PAC J TROP MED, V7, P325, DOI 10.1016/S1995 7645(14)60049 3
   Hannemann PFW, 2014, ARCH ORTHOP TRAUM SU, V134, P1093, DOI 10.1007/s00402 014 2014 8
   Hu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095168
   Inubushi T, 2008, J PERIODONTOL, V79, P1984, DOI [10.1902/jop.2008.080081, 10.1902/jop.2008.080081 ]
   Ishihara Y, 2014, J CRANIO MAXILL SURG, V42, P185, DOI 10.1016/j.jcms.2013.05.002
   Katano M, 2011, EXP ANIM TOKYO, V60, P385, DOI 10.1538/expanim.60.385
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kusuyama J, 2014, J BIOL CHEM, V289, P10330, DOI 10.1074/jbc.M113.546382
   Li L, 2012, BIOCHEM BIOPH RES CO, V418, P296, DOI 10.1016/j.bbrc.2012.01.014
   Lim K, 2013, BIOMED RES INT UK, V2013, DOI 10.1155/2013/269724
   Liu Q, 2012, BRIT J ORAL MAX SURG, V50, P244, DOI 10.1016/j.bjoms.2011.03.001
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Maeda T, 2013, J PROSTHODONT RES, V57, P93, DOI 10.1016/j.jpor.2012.11.001
   Miura K, 2014, EUR J ORTHODONT, V36, P419, DOI 10.1093/ejo/cjt066
   Montalti CS, 2013, BRAZ J PHYS THER, V17, P343, DOI 10.1590/S1413 35552012005000101
   NIYIBIZI C, 1994, EUR J BIOCHEM, V224, P943, DOI 10.1111/j.1432 1033.1994.00943.x
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Rutten S, 2008, BONE, V43, P348, DOI 10.1016/j.bone.2008.04.010
   Tajali SB, 2012, AM J PHYS MED REHAB, V91, P349, DOI 10.1097/PHM.0b013e31822419ba
   Takebe H, 2014, CLIN ORAL IMPLAN RES, V25, P735, DOI 10.1111/clr.12136
   Tanaka Shiho, 2007, J Oral Implantol, V33, P321, DOI 10.1563/1548 1336(2007)33[321:CONFBD]2.0.CO;2
   Tobita K, 2012, J ORTHOP SCI, V17, P470, DOI 10.1007/s00776 012 0233 9
   Toy E, 2014, AUST ORTHOD J, V30, P176
   Tsai C L, 1992, Chin J Physiol, V35, P21
   Ueno D, 2011, J PERIODONTOL, V82, P829, DOI 10.1902/jop.2010.100160
   Urita A, 2013, J HAND SURG AM, V38A, P498, DOI 10.1016/j.jhsa.2012.11.032
   VERMEULEN AHM, 1989, J HISTOCHEM CYTOCHEM, V37, P1503, DOI 10.1177/37.10.2789247
   Warden SJ, 2003, SPORTS MED, V33, P95, DOI 10.2165/00007256 200333020 00002
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Xie LK, 2011, INT J ORAL MAX SURG, V40, P730, DOI 10.1016/j.ijom.2011.03.016
   Yang Min Ho, 2010, Int J Stem Cells, V3, P74
NR 41
TC 8
Z9 9
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD FEB
PY 2016
VL 42
IS 2
BP 493
EP 502
DI 10.1016/j.ultrasmedbio.2015.10.022
PG 10
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA DA3XX
UT WOS:000367735800017
PM 26653935
DA 2025 08 17
ER

PT J
AU Charbord, P
   Livne, E
   Gross, G
   Häupl, T
   Neves, NM
   Marie, P
   Bianco, P
   Jorgensen, C
AF Charbord, Pierre
   Livne, Erella
   Gross, Gerhard
   Haeupl, Thomas
   Neves, Nuno M.
   Marie, Pierre
   Bianco, Paolo
   Jorgensen, Christian
TI Human Bone Marrow Mesenchymal Stem Cells: A Systematic Reappraisal Via
   the Genostem Experience
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Differentiation; Stem cell; Bone; Cartilage; Tendon; Smooth muscle;
   Regenerative medicine
ID STROMAL CELLS; OSTEOGENIC DIFFERENTIATION; SELF RENEWAL; IDENTIFICATION;
   EXPRESSION; CULTURE; REPAIR
AB Genostem (acronym for "Adult mesenchymal stem cells engineering for connective tissue disorders. From the bench to the bed side") has been an European consortium of 30 teams working together on human bone marrow Mesenchymal Stem Cell (MSC) biological properties and repair capacity. Part of Genostem activity has been dedicated to the study of basic issues on undifferentiated MSCs properties and on signalling pathways leading to the differentiation into 3 of the connective tissue lineages, osteoblastic, chondrocytic and tenocytic. We have evidenced that native bone marrow MSCs and stromal cells, forming the niche of hematopoietic stem cells, were the same cellular entity located abluminally from marrow sinus endothelial cells. We have also shown that culture amplified, clonogenic and highly proliferative MSCs were bona fide stem cells, sharing with other stem cell types the major attributes of self renewal and of multipotential priming to the lineages to which they can differentiate (osteoblasts, chondrocytes, adipocytes and vascular smooth muscle cells/pericytes). Extensive transcription profiling and in vitro and in vivo assays were applied to identify genes involved in differentiation. Thus we have described novel factors implicated in osteogenesis (FHL2, ITGA5, Fgf18), chondrogenesis (FOXO1A) and tenogenesis (Smad8). Another part of Genostem activity has been devoted to studies of the repair capacity of MSCs in animal models, a prerequisite for future clinical trials. We have developed novel scaffolds (chitosan, pharmacologically active microcarriers) useful for the repair of both bone and cartilage. Finally and most importantly, we have shown that locally implanted MSCs effectively repair bone, cartilage and tendon.
C1 [Charbord, Pierre] Hop Bicetre, INSERM, U972, Le Kremlin Bicetre, France.
   [Livne, Erella] Technion Israel Inst Technol, Fac Med, Haifa, Israel.
   [Neves, Nuno M.] Univ Minho, European Inst Excellence Tissue Engn & Regenerat, Dept Polymer Engn, Res Grp Biomat Biodegradables & Biomimet 3Bs, Guimaraes, Portugal.
   [Neves, Nuno M.] IBB, PT Govt Associated Lab, Guimaraes, Portugal.
   [Marie, Pierre] Univ Paris Diderot, INSERM, U606, Paris, France.
   [Bianco, Paolo] Univ La Sapienza & Biomed Sci Pk San Raffaele, Dept Expt Med, Rome, Italy.
   [Jorgensen, Christian] Hop St Eloi INM, INSERM, U844, Montpellier, France.
   [Gross, Gerhard] Helmholtz Ctr Infect Res HZI, Braunschweig, Germany.
   [Haeupl, Thomas] Charite, Lab Tissue Engn, Dept Rheumatol & Clin Immunol, D 13353 Berlin, Germany.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre
     APHP; Hopital Universitaire Antoine Beclere   APHP; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite Paris
   Saclay; Technion Israel Institute of Technology; Rappaport Faculty of
   Medicine; Universidade do Minho; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Sapienza
   University Rome; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Montpellier; CHU de Montpellier;
   Helmholtz Association; Helmholtz Center for Infection Research; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Charbord, P (通讯作者)，Hop Bicetre, INSERM, U972, Le Kremlin Bicetre, France.
EM pcharbord@noos.fr
RI Neves, Nuno/B 4685 2008
OI Neves, Nuno/0000 0003 3041 0687; UMinho, 3B's Research
   Group/0000 0002 5195 3456; charbord, pierre/0000 0002 2254 3300
FU European Community [503161]
FX Work supported by the European Community (Key action 1.2.4 3 Integrated
   Project Genostem, contract No 503161).
CR Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Boyer Martin I, 2005, J Hand Ther, V18, P80, DOI 10.1197/j.jht.2005.01.009
   BOYER MI, 2005, J HAND THER, V18, P86, DOI DOI 10.1197/J.JHT.2005.01.009
   Correlo VM, 2007, MACROMOL BIOSCI, V7, P354, DOI 10.1002/mabi.200600233
   Costa Pinto AR, 2009, BIOMACROMOLECULES, V10, P2067, DOI 10.1021/bm9000102
   Costa Pinto AR, 2008, TISSUE ENG PT A, V14, P1049, DOI [10.1089/ten.tea.2007.0153, 10.1089/tea.2007.0153]
   Delorme Bruno, 2007, V140, P67
   Delorme B, 2008, BLOOD, V111, P2631, DOI 10.1182/blood 2007 07 099622
   Delorme B, 2009, STEM CELLS, V27, P1142, DOI 10.1002/stem.34
   Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364
   Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935
   Dimitriou H, 2008, CYTOTHERAPY, V10, P125, DOI 10.1080/14653240701851332
   Djouad F, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2153
   Djouad F, 2009, CLONING STEM CELLS, V11, P407, DOI 10.1089/clo.2009.0013
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   HAMIDOUCHE Z, 2009, P NATL ACAD SCI US
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Hatzfeld A, 2007, LEUKEMIA, V21, P714, DOI 10.1038/sj.leu.2404589
   Hoffmann A, 2006, J CLIN INVEST, V116, P940, DOI 10.1172/JCI22689
   Huang S, 2009, BIOESSAYS, V31, P546, DOI 10.1002/bies.200800189
   Jones PH, 2007, CELL STEM CELL, V1, P371, DOI 10.1016/j.stem.2007.09.014
   Kaltz N, 2008, STEM CELLS, V26, P2419, DOI 10.1634/stemcells.2008 0304
   Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Mrugala D, 2008, ANN RHEUM DIS, V67, P288, DOI 10.1136/ard.2007.076620
   Mrugala D, 2009, CLONING STEM CELLS, V11, P61, DOI 10.1089/clo.2008.0070
   Noël D, 2008, EXP CELL RES, V314, P1575, DOI 10.1016/j.yexcr.2007.12.022
   Ogawa M, 2006, BLOOD, V108, P2893, DOI 10.1182/blood 2006 04 016600
   Oliveira JT, 2008, TISSUE ENG PT A, V14, P1651, DOI 10.1089/ten.tea.2007.0307
   Román I, 2007, BIOMATERIALS, V28, P2718, DOI 10.1016/j.biomaterials.2007.02.011
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Slack JMW, 2007, NAT REV MOL CELL BIO, V8, P369, DOI 10.1038/nrm2146
   Snedeker JG, 2009, CELLS TISSUES ORGANS, V190, P111, DOI 10.1159/000189211
   Snedeker JG, 2009, TISSUE ENG PART C ME, V15, P485, DOI 10.1089/ten.tec.2008.0612
   Snedeker JG, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2393153
   Song L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005 0604
   Srouji S, 2009, CALCIFIED TISSUE INT, V84, P138, DOI 10.1007/s00223 008 9202 x
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Towler DA, 2006, J CLIN INVEST, V116, P863, DOI 10.1172/JCI28320
   Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012
   Zipori D, 2005, STEM CELLS, V23, P719, DOI 10.1634/stemcells.2005 0030
NR 45
TC 60
Z9 67
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD MAR
PY 2011
VL 7
IS 1
BP 32
EP 42
DI 10.1007/s12015 010 9125 6
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 709TV
UT WOS:000286465200003
PM 20198518
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Song, M
   Baek, SH
   Heo, GE
   Lee, JH
AF Song, Min
   Baek, Seung Han
   Heo, Go Eun
   Lee, Jeong Hoon
TI Inferring Drug Protein Side Effect Relationships from Biomedical Text
SO GENES
LA English
DT Article
DE Biomedical Text Mining; semantic relatedness; Inference of
   Drug Protein Side Effect Relation
ID NF KAPPA B; BONE RESORPTION; LARGE SCALE; P38 MAPK; KINASE; ACTIVATION;
   DIFFERENTIATION; OSTEOCLAST; EXTRACTION; SORAFENIB
AB Background: Although there are many studies of drugs and their side effects, the underlying mechanisms of these side effects are not well understood. It is also difficult to understand the specific pathways between drugs and side effects. Objective: The present study seeks to construct putative paths between drugs and their side effects by applying text mining techniques to free text of biomedical studies, and to develop ranking metrics that could identify the most likely paths. Materials and Methods: We extracted three types of relationships drug protein, protein protein, and protein side effect from biomedical texts by using text mining and predefined relation extraction rules. Based on the extracted relationships, we constructed whole drug protein side effect paths. For each path, we calculated its ranking score by a new ranking function that combines corpus  and ontology based semantic similarity as well as co occurrence frequency. Results: We extracted 13 plausible biomedical paths connecting drugs and their side effects from cancer related abstracts in the PubMed database. The top 20 paths were examined, and the proposed ranking function outperformed the other methods tested, including co occurrence, COALS, and UMLS by P@5 P@20. In addition, we confirmed that the paths are novel hypotheses that are worth investigating further. Discussion: The risk of side effects has been an important issue for the US Food and Drug Administration (FDA). However, the causes and mechanisms of such side effects have not been fully elucidated. This study extends previous research on understanding drug side effects by using various techniques such as Named Entity Recognition (NER), Relation Extraction (RE), and semantic similarity. Conclusion: It is not easy to reveal the biomedical mechanisms of side effects due to a huge number of possible paths. However, we automatically generated predictable paths using the proposed approach, which could provide meaningful information to biomedical researchers to generate plausible hypotheses for the understanding of such mechanisms.
C1 [Song, Min; Heo, Go Eun] Yonsei Univ, Dept Lib & Informat Sci, Seoul 03722, South Korea.
   [Baek, Seung Han] Yonsei Univ, Inst Convergence, Seoul 03722, South Korea.
   [Lee, Jeong Hoon] POSTECH, Dept Creat IT Engn, Pohang 37673, South Korea.
C3 Yonsei University; Yonsei University; Pohang University of Science &
   Technology (POSTECH)
RP Song, M (通讯作者)，Yonsei Univ, Dept Lib & Informat Sci, Seoul 03722, South Korea.
EM min.song@yonsei.ac.kr; seunghan.baek@yonsei.ac.kr;
   goeun.heo@yonasei.ac.kr; jhlee@dblab.postech.ac.kr
RI ; Lee, Jeong Hoon/AAF 2400 2020; song, min/KPA 7030 2024
OI Baek, Seung Han/0000 0002 8722 0027; Song, Min/0000 0003 3255 1600; 
FU Next Generation Information Computing Development Program through the
   National Research Foundation of Korea (NRF)   Ministry of Science, ICT
   [NRF 2017M3C4A7065887]
FX This research was supported by Next Generation Information Computing
   Development Program through the National Research Foundation of Korea
   (NRF), funded by the Ministry of Science, ICT (No.
   NRF 2017M3C4A7065887).
CR [Anonymous], 2011, 1 INT WORKSH KNOWL D
   Atias N, 2011, J COMPUT BIOL, V18, P207, DOI 10.1089/cmb.2010.0255
   Baeza Raja B, 2004, MOL BIOL CELL, V15, P2013, DOI 10.1091/mbc.E03 08 0585
   Barabási AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Berger SI, 2009, BIOINFORMATICS, V25, P2466, DOI 10.1093/bioinformatics/btp465
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brasier AR, 2006, CARDIOVASC TOXICOL, V6, P111, DOI 10.1385/CT:6:2:111
   Cami A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002774
   Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140
   Chakravorty M, 2009, INT J BIOCHEM CELL B, V41, P1502, DOI 10.1016/j.biocel.2008.12.017
   Chen B, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002574
   Dash R.C., 2003, Archives of Pathology Laboratory Medicine, V127, P896, DOI [10.5858/2003 127 896 hacbai, DOI 10.5858/2003 127 896 HACBAI]
   De DD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073409
   Edwards JP, 2010, INT IMMUNOPHARMACOL, V10, P1220, DOI 10.1016/j.intimp.2010.07.002
   Eleftherohorinou H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008068
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526
   Feng JY, 2010, P NATL ACAD SCI USA, V107, P17791, DOI 10.1073/pnas.1009078107
   Garla VN, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471 2105 13 261
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954
   He B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027506
   He J, 2012, CANCER RES, V72, P6393, DOI 10.1158/0008 5472.CAN 12 2664
   Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang LC, 2011, BMC GENOMICS, V12, DOI 10.1186/1471 2164 12 S5 S11
   Ji GP, 2010, BIOCHEM BIOPH RES CO, V391, P547, DOI 10.1016/j.bbrc.2009.11.095
   Jurgens D., 2013, P ACL 2010 SYST DEM, P30
   Kuhn M, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2009.98
   Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082
   Lee S, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 S2 S2
   Li BQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033393
   Li J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000450
   Li YQ, 2000, CELL SIGNAL, V12, P751, DOI 10.1016/S0898 6568(00)00120 0
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lounkine E, 2012, NATURE, V486, P361, DOI 10.1038/nature11159
   Manning CD, 2014, PROCEEDINGS OF 52ND ANNUAL MEETING OF THE ASSOCIATION FOR COMPUTATIONAL LINGUISTICS: SYSTEM DEMONSTRATIONS, P55, DOI 10.3115/v1/p14 5010
   McInnes Bridget T, 2009, AMIA Annu Symp Proc, V2009, P431
   Mutt V., 2013, GASTROINTESTINAL HOR, V11
   Olson CM, 2007, INFECT IMMUN, V75, P270, DOI 10.1128/IAI.01412 06
   Pauwels E, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 169
   Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200
   Ramanan VK, 2012, TRENDS GENET, V28, P323, DOI 10.1016/j.tig.2012.03.004
   Rebholz Schuhmann D, 2012, NAT REV GENET, V13, P829, DOI 10.1038/nrg3337
   Rohde D. L., 2006, Commun. ACM, V8, P116
   Schulze Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171 2985(97)80025 3
   Sharma P, 2006, LIPIDS HEALTH DIS, V5, DOI 10.1186/1476 511X 5 1
   Sohn S, 2011, J AM MED INFORM ASSN, V18, pI144, DOI 10.1136/amiajnl 2011 000351
   Song M, 2015, J BIOMED INFORM, V57, P320, DOI 10.1016/j.jbi.2015.08.008
   Sun L., 2009, P 2009 C EMPIRICAL M, V2, P638, DOI 10.3115/1699571.1699596
   Tao HR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023199
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thompson P, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 397
   WALDUM HL, 1991, GASTROEN CLIN BIOL, V15, pC65
   Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389 3403.2002
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535 7163.MCT 08 0013
   XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326
   Xu R, 2014, J BIOMED INFORM, V51, P191, DOI 10.1016/j.jbi.2014.05.013
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
NR 58
TC 7
Z9 7
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD FEB
PY 2019
VL 10
IS 2
AR 159
DI 10.3390/genes10020159
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA HO2KE
UT WOS:000460742800088
PM 30791472
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Samal, S
   Panda, GP
   Shyamal, S
   Das, K
   Dash, M
AF Samal, Sasmita
   Panda, Gyanendra Prasad
   Shyamal, Sharmishtha
   Das, Kapilash
   Dash, Mamoni
TI Surface Engineered Osteoblast Extracellular Vesicles Serve as an
   Efficient Carrier for Drug and Small RNA to Actively Target Osteosarcoma
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE Extracellular Vesicles (EVs); Cargo delivery; Co delivery; Nanocarriers;
   Active targeting; Folate conjugation
ID DELIVERY; EXOSOMES; CELL; MICROENVIRONMENT; STRATEGIES; THERAPY
AB Osteosarcoma (OS) is a rare malignant tumor that affects soft tissue and has high rates of lung metastasis and mortality. The primary treatments for OS include preoperative chemotherapy, surgical resection of the lesion, and postoperative chemotherapy. However, OS chemotherapy presents critical challenges related to treatment toxicity and multiple drug resistance. To address these challenges, nanotechnology has developed nanosystems that release drugs directly to OS cells, reducing the drug's toxicity. Extracellular vesicles (EVs) are nanosized lipid bilayer bound vesicles that act as cell derived vehicles and drug delivery systems for several cancers. This study aims to utilize EVs for OS management by co delivering Hdac1 siRNA and zoledronic acid (zol). The EVs' surface is modified with folic acid (FA) and their targeting ability is compared to that of native EVs. The results showed that the EVs' targeting ability depends on the parent cell source, and FA conjugation further enhanced it. Furthermore, EVs were used as the carrier for co loading drug (zol) and small RNA (Hdac 1). This approach of using surface engineered EVs as carriers for cargo loading and delivery can be a promising strategy for osteosarcoma management.
C1 [Samal, Sasmita; Panda, Gyanendra Prasad; Shyamal, Sharmishtha; Das, Kapilash; Dash, Mamoni] BR Inst Life Sci BR ILS, Bhubaneswar 751023, Odisha, India.
   [Samal, Sasmita] KIIT Univ, Sch Biotechnol, Bhubaneswar 751024, Odisha, India.
   [Shyamal, Sharmishtha] ICMR Natl Inst Reprod Biol & Child Hlth, Mumbai 400012, India.
C3 Kalinga Institute of Industrial Technology (KIIT); Indian Council of
   Medical Research (ICMR); ICMR   National Institute for Research in
   Reproductive & Child Health (NIRRCH)
RP Dash, M (通讯作者)，BR Inst Life Sci BR ILS, Bhubaneswar 751023, Odisha, India.
EM mamoni.dash@ils.res.in
RI Dash, Mamoni/H 5450 2013
OI Dash, Mamoni/0000 0001 6930 6495
FU Ramalingaswami Fellowship 2016 17 [BT/HRD/35/02/2006]; Department of
   Biotechnology (DBT), Government of India [BT/PR36474/NNT/28/1701/2020];
   BRIC Institute of Life Sciences (ILS), Council of Scientific and
   Industrial Research (CSIR), New Delhi, Government of India; DBTR BioCARe
   Scientist Grant (2023 2024), Department of Biotechnology (DBT),
   Government of India [BT/PR50903/BIC/101/1307/2023]
FX Ramalingaswami Fellowship 2016 17 (D.O.NO.BT/HRD/35/02/2006), Department
   of Biotechnology (DBT), Government of India, Grant No.
   BT/PR36474/NNT/28/1701/2020 for the funding, BRIC Institute of Life
   Sciences (ILS), Council of Scientific and Industrial Research (CSIR),
   New Delhi, Government of India. Sharmishtha Shyamal is supported by
   DBTR BioCARe Scientist Grant (2023 2024), Department of Biotechnology
   (DBT), Government of India, Grant No: BT/PR50903/BIC/101/1307/2023.
CR Amiryaghoubi N, 2022, COLLOID SURFACE B, V220, DOI 10.1016/j.colsurfb.2022.112911
   Arami H, 2015, CHEM SOC REV, V44, P8576, DOI 10.1039/c5cs00541h
   Barik D, 2021, J PHARM SCI US, V110, P3757, DOI 10.1016/j.xphs.2021.08.028
   Bhome R, 2018, CANCER LETT, V420, P228, DOI 10.1016/j.canlet.2018.02.002
   Dash P, 2023, MACROMOL BIOSCI, V23, DOI 10.1002/mabi.202300211
   Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
   Evers MJW, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202101202
   Feng CX, 2021, BIOACT MATER, V6, P963, DOI 10.1016/j.bioactmat.2020.09.014
   Ghafouri Fard S, 2021, BIOMED PHARMACOTHER, V135, DOI 10.1016/j.biopha.2021.111217
   Gill J, 2021, NAT REV CLIN ONCOL, V18, P609, DOI 10.1038/s41571 021 00519 8
   Gomes da Silva LC, 2012, ACCOUNTS CHEM RES, V45, P1163, DOI 10.1021/ar300048p
   Holm J, 2020, BBA PROTEINS PROTEOM, V1868, DOI 10.1016/j.bbapap.2020.140466
   Hu B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0207 x
   Huang X, 2020, COLLOID SURFACE B, V190, DOI 10.1016/j.colsurfb.2020.110891
   JEFFREE GM, 1975, BRIT J CANCER, V32, P87, DOI 10.1038/bjc.1975.136
   Jhaveri J. R., 2024, BIORXIV, DOI [10.1101/2023.10.23.563628, DOI 10.1101/2023.10.23.563628]
   Ji ZY, 2023, MEDCOMM, V4, DOI 10.1002/mco2.308
   Karmali PP, 2011, EXPERT OPIN DRUG DEL, V8, P343, DOI 10.1517/17425247.2011.554818
   Koi Y, 2020, CANCER SCI, V111, P2104, DOI 10.1111/cas.14393
   Kosaka N, 2012, J BIOL CHEM, V287, P1397, DOI 10.1074/jbc.M111.288662
   Kubczak M, 2021, ADV DRUG DELIVER REV, V179, DOI 10.1016/j.addr.2021.114038
   Lee JW, 2022, J CONTROL RELEASE, V351, P713, DOI 10.1016/j.jconrel.2022.09.040
   Li QC, 2023, THERANOSTICS, V13, P4266, DOI 10.7150/thno.84971
   Lin H, 2020, J RECEPT SIG TRANSD, V40, P49, DOI 10.1080/10799893.2020.1713807
   Liu K, 2019, BRIT J DERMATOL, V181, P854, DOI 10.1111/bjd.17984
   Lotfy A, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03287 7
   Ma SN, 2023, RSC ADV, V13, P11269, DOI 10.1039/d3ra00300k
   Ma XD, 2023, ACS APPL NANO MATER, V6, P12425, DOI 10.1021/acsanm.3c02125
   Malekian F, 2023, J PHYSIOL LONDON, V601, P4853, DOI 10.1113/JP282799
   Meazza C, 2016, EXPERT REV ANTICANC, V16, P543, DOI 10.1586/14737140.2016.1168697
   Mehryab F, 2020, ACTA BIOMATER, V113, P42, DOI 10.1016/j.actbio.2020.06.036
   Nawaz FZ, 2022, TRENDS ENDOCRIN MET, V33, P159, DOI 10.1016/j.tem.2021.12.003
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978 1 4419 0284 9_1
   Rayamajhi S, 2020, J MATER CHEM B, V8, P4552, DOI 10.1039/d0tb00744g
   Samal S., 2022, BIOMIMETIC BIOMATERI, P29
   Samal S, 2021, INT J NANOMED, V16, P3509, DOI 10.2147/IJN.S307843
   Scaranti M, 2020, NAT REV CLIN ONCOL, V17, P349, DOI 10.1038/s41571 020 0339 5
   Song YC, 2012, J MATER CHEM, V22, P12568, DOI 10.1039/c2jm31582c
   Straessler KM, 2013, CANCER CELL, V23, P215, DOI 10.1016/j.ccr.2012.12.019
   Ta H, 2009, CANCER METAST REV, V28, P247, DOI 10.1007/s10555 009 9186 7
   Théry C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Tian T, 2018, BIOMATERIALS, V150, P137, DOI 10.1016/j.biomaterials.2017.10.012
   Welsh JA, 2024, J EXTRACELL VESICLES, V13, DOI 10.1002/jev2.12404
   Wood RK, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104100
   Wu KZ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.805978
   Yu LF, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419 023 06159 3
   Zhang M, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.799588
   Zhao JT, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1111855
   Zhou L, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109964
NR 49
TC 3
Z9 3
U1 3
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD AUG 16
PY 2024
VL 10
IS 12
BP 7466
EP 7481
DI 10.1021/acsbiomaterials.4c00952
EA AUG 2024
PG 16
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA O7I5E
UT WOS:001293309900001
PM 39150495
DA 2025 08 17
ER

PT J
AU Ilas, DC
   Churchman, SM
   Baboolal, T
   Giannoudis, PV
   Aderinto, J
   McGonagle, D
   Jones, E
AF Ilas, Dragos C.
   Churchman, Sarah M.
   Baboolal, Thomas
   Giannoudis, Peter, V
   Aderinto, Joseph
   McGonagle, Dennis
   Jones, Elena
TI The simultaneous analysis of mesenchymal stem cells and early osteocytes
   accumulation in osteoarthritic femoral head sclerotic bone
SO RHEUMATOLOGY
LA English
DT Article
DE OA; hip; bone; mesenchymal stem cells; osteocytes
ID HYPOMORPHIC CONDITIONAL DELETION; SUBCHONDRAL BONE; MARROW LESIONS;
   E11/PODOPLANIN; EXPRESSION; UNIT
AB Objective. OA subchondral bone is a key target for therapy development. Osteocytes, the most abundant bone cell, critically regulate bone formation and resorption. Their progenitors, mesenchymal stem cells (MSCs), display altered behaviour in osteoarthritic subchondral bone. This study investigated the relationships between native osteocytes and native MSCs in osteoarthritic femoral heads.
   Methods. To avoid culture manipulations, a bone treatment procedure was developed to simultaneously obtain pure osteocyte enriched fragments and matched native CD45( )CD271(+) MSCs. Gene expression in osteocytes and MSCs was compared between healthy and OA bone and selected molecules were examined by immunohistochemistry in relation to OA tissue pathology. Cell sorting and standard trilineage differentiation assays were employed to test OA MSC functionality.
   Results. Native osteocyte enrichment was confirmed histologically and by higher level osteocyte maturation transcripts expression, compared with purified MSCs. Compared with healthy bone, native OA osteocytes expressed 9  and 4 fold more early/embedding osteocyte molecules E11 and MMP14, and 6 fold more osteoprotegerin (P<0.01). CD271(+) MSCs accumulated in the regions of bone sclerosis (9 fold, P<0.0001) in close juxtaposition to trabeculae densely populated with morphologically immature E11 positive osteocytes (medians of 76% vs 15% in non sclerotic areas, P<0.0001), and osteoblasts. Gene expression of OA MSCs indicated their bone formation bias, with retained multipotentiality following culture expansion.
   Conclusions. In human late stage OA, osteogenically committed MSCs and adjacent immature osteocytes exhibit a marked accumulation in sclerotic areas. This hitherto unappreciated MSC early osteocyte axis could be key to understanding bone abnormalities in OA and represents a potential target for novel therapy development in early disease.
C1 [Ilas, Dragos C.; Churchman, Sarah M.; Baboolal, Thomas; Giannoudis, Peter, V; McGonagle, Dennis; Jones, Elena] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England.
   [Aderinto, Joseph] Leeds Teaching Hosp NHS Trust, Dept Orthopaed, Leeds, W Yorkshire, England.
C3 University of Leeds; University of Leeds
RP Jones, E (通讯作者)，St James Univ Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Room 5 23 Clin Sci Bldg, Leeds LS9 7TF, W Yorkshire, England.
EM e.jones@leeds.ac.uk
RI Giannoudis, Peter/AAA 3617 2020; Baboolal, Thomas/IWE 3593 2023; Jones,
   Elena/AAL 2818 2021; Churchman, Sarah/L 1828 2013
OI Ilas, Dragos/0000 0001 6404 6620; Jones, Elena/0000 0001 9365 2283; 
FU National Institute for Health Research (NIHR) infrastructure at Leeds
FX The research is supported by the National Institute for Health Research
   (NIHR) infrastructure at Leeds. The views expressed are those of the
   author(s) and not necessarily those of the NHS, the NIHR or the
   Department of Health.
CR Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Campbell TM, 2016, ARTHRITIS RHEUMATOL, V68, P1648, DOI 10.1002/art.39622
   Churchman SM, 2012, ARTHRITIS RHEUM US, V64, P2632, DOI 10.1002/art.34434
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Henrotin Y, 2012, OSTEOPOROSIS INT, V23, pS847, DOI 10.1007/s00198 012 2162 z
   Jaiprakash A, 2012, INT J BIOL SCI, V8, P406, DOI 10.7150/ijbs.4221
   Jia HR, 2018, ARTHRITIS RHEUMATOL, V70, P230, DOI 10.1002/art.40351
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Muratovic D, 2018, BONE, V108, P193, DOI 10.1016/j.bone.2018.01.012
   Pathak JL, 2016, CALCIFIED TISSUE INT, V98, P596, DOI 10.1007/s00223 016 0116 8
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Prideaux M, 2016, CURR OPIN PHARMACOL, V28, P24, DOI 10.1016/j.coph.2016.02.003
   Staines KA, 2018, OSTEOARTHR CARTILAGE, V26, pS61, DOI 10.1016/j.joca.2018.02.131
   Staines KA, 2017, J CELL PHYSIOL, V232, P3006, DOI 10.1002/jcp.25999
   Suri S, 2012, BONE, V51, P204, DOI 10.1016/j.bone.2011.10.010
   Teichtahl AJ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0466 4
   Tormin A, 2011, BLOOD, V117, P5067, DOI 10.1182/blood 2010 08 304287
   Xu L, 2012, SEMIN ARTHRITIS RHEU, V42, P105, DOI 10.1016/j.semarthrit.2012.03.009
   Zhang KQ, 2006, MOL CELL BIOL, V26, P4539, DOI 10.1128/MCB.02120 05
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 21
TC 22
Z9 23
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462 0324
EI 1462 0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD OCT
PY 2019
VL 58
IS 10
BP 1777
EP 1783
DI 10.1093/rheumatology/kez130
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA JF2ZS
UT WOS:000491255500013
PM 31165896
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Watterson, SH
   Liu, QJ
   Bertrand, MB
   Batt, DG
   Li, L
   Pattoli, MA
   Skala, S
   Cheng, LH
   Obermeier, MT
   Moore, R
   Yang, Z
   Vickery, R
   Elzinga, PA
   Discenza, L
   D'Arienzo, C
   Gillooly, KM
   Taylor, TL
   Pulicicchio, C
   Zhang, YF
   Heimrich, E
   McIntyre, KW
   Ruan, Q
   Westhouse, RA
   Catlett, IM
   Zheng, NY
   Chaudhry, C
   Dai, J
   Galella, MA
   Tebben, AJ
   Pokross, M
   Li, JQ
   Zhao, RL
   Smith, D
   Rampulla, R
   Allentoff, A
   Wallace, MA
   Mathur, A
   Salter Cid, L
   Macor, JE
   Carter, PH
   Fura, A
   Burke, JR
   Tino, JA
AF Watterson, Scott H.
   Liu, Qingjie
   Bertrand, Myra Beaudoin
   Batt, Douglas G.
   Li, Ling
   Pattoli, Mark A.
   Skala, Stacey
   Cheng, Lihong
   Obermeier, Mary T.
   Moore, Robin
   Yang, Zheng
   Vickery, Rodney
   Elzinga, Paul A.
   Discenza, Lorell
   D'Arienzo, Celia
   Gillooly, Kathleen M.
   Taylor, Tracy L.
   Pulicicchio, Claudine
   Zhang, Yifan
   Heimrich, Elizabeth
   McIntyre, Kim W.
   Ruan, Qian
   Westhouse, Richard A.
   Catlett, Ian M.
   Zheng, Naiyu
   Chaudhry, Charu
   Dai, Jun
   Galella, Michael A.
   Tebben, Andrew J.
   Pokross, Matt
   Li, Jianqing
   Zhao, Rulin
   Smith, Daniel
   Rampulla, Richard
   Allentoff, Alban
   Wallace, Michael A.
   Mathur, Arvind
   Salter Cid, Luisa
   Macor, John E.
   Carter, Percy H.
   Fura, Aberra
   Burke, James R.
   Tino, Joseph A.
TI Discovery of Branebrutinib (BMS 986195): A Strategy for Identifying a
   Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo
   Inactivation of Bruton's Tyrosine Kinase (BTK)
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID B CELL; ACTIVATION; IBRUTINIB; ACALABRUTINIB; ARTHRITIS; RESPONSES;
   DESIGN; MICE
AB Bruton's tyrosine kinase (BTK), a non receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical role in the downstream signaling pathways for the Fc gamma receptor in monocytes, the Fc epsilon receptor in granulocytes, and the RANK receptor in osteoclasts. As a result, pharmacological inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as rheumatoid arthritis and lupus. This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose. With excellent in vivo efficacy and a very desirable tolerability profile, Sa (branebrutinib, BMS 986195) has advanced into clinical studies.
C1 [Watterson, Scott H.; Liu, Qingjie; Bertrand, Myra Beaudoin; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.] Bristol Myers Squibb Res & Dev, POB 4000, Princeton, NJ 08543 USA.
C3 Bristol Myers Squibb
RP Watterson, SH (通讯作者)，Bristol Myers Squibb Res & Dev, POB 4000, Princeton, NJ 08543 USA.
EM scott.watterson@bms.com
RI ; yang, zheng/HGC 7753 2022; zhang, yifan/ABB 5853 2021; Zheng,
   Naiyu/P 3170 2017; liu, Qingjie/LMM 9454 2024
OI Zheng, Naiyu/0000 0002 5121 9024; Catlett, Ian/0000 0001 6220 2626; 
CR Ahmad S., 2016, PCT Int. Appl. Patent, Patent No. [2016065236 A1, 2016065236, WO 2016065236]
   Barf T, 2017, J PHARMACOL EXP THER, V363, P240, DOI 10.1124/jpet.117.242909
   Batt D. G., 2014, Substituted Carbazolecarboxamide Derivatives as BTK Inhibitors and Their Preparation and Use for the Treatment of Diseases, Patent No. [WO 2014210085, 2014210085]
   Brown JR, 2016, HAEMATOLOGICA, V101, P295, DOI 10.3324/haematol.2015.140806
   Burke J. R., 2017, ARTHRITIS RHERNA S10, V69
   Byrd JC, 2014, NEW ENGL J MED, V371, P213, DOI 10.1056/NEJMoa1400376
   Catlett I. M., 2017, ARTHRITIS RHEUMA S10, V69
   Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367
   Crawford JJ, 2018, J MED CHEM, V61, P2227, DOI 10.1021/acs.jmedchem.7b01712
   Dahal UP, 2013, CHEM RES TOXICOL, V26, P1739, DOI 10.1021/tx400301q
   De Lucca GV, 2016, J MED CHEM, V59, P7915, DOI 10.1021/acs.jmedchem.6b00722
   Di Paolo JA, 2011, NAT CHEM BIOL, V7, P41, DOI 10.1038/NCHEMBIO.481
   Gillooly KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181782
   González Bello C, 2016, CHEMMEDCHEM, V11, P22, DOI 10.1002/cmdc.201500469
   JANSSON L, 1993, CLIN EXP IMMUNOL, V94, P459, DOI 10.1111/j.1365 2249.1993.tb08218.x
   Johnson DS, 2010, FUTURE MED CHEM, V2, P949, DOI 10.4155/FMC.10.21
   Jongstra Bilen J, 2008, J IMMUNOL, V181, P288, DOI 10.4049/jimmunol.181.1.288
   Kivitz AJ, 2016, ARTHRITIS RHEUMATOL, V68
   Kuehn HS, 2010, J CELL SCI, V123, P2576, DOI 10.1242/jcs.071043
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Lee SK, 2017, EUR J CLIN PHARMACOL, V73, P689, DOI 10.1007/s00228 017 2226 2
   Leproult E, 2011, J MED CHEM, V54, P1347, DOI 10.1021/jm101396q
   Liu Q., 2017, U.S. Patent, Patent No. [9,688,629, 9688629]
   Liu QJ, 2018, BIOORG MED CHEM LETT, V28, P3080, DOI 10.1016/j.bmcl.2018.07.041
   Liu QJ, 2015, BIOORG MED CHEM LETT, V25, P4265, DOI 10.1016/j.bmcl.2015.07.102
   Lonsdale R, 2018, CHEM SOC REV, V47, P3816, DOI 10.1039/c7cs00220c
   Mauro FR, 2018, EXPERT REV HEMATOL, V11, P601, DOI 10.1080/17474086.2018.1495557
   Mease PJ, 2008, J RHEUMATOL, V35, P1245
   Middendorp S, 2003, J IMMUNOL, V171, P5988, DOI 10.4049/jimmunol.171.11.5988
   Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600 065X.2008.00741.x
   Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113
   Nakayama S, 2009, DRUG METAB DISPOS, V37, P1970, DOI 10.1124/dmd.109.027797
   Norman P, 2016, EXPERT OPIN INV DRUG, V25, P891, DOI 10.1080/13543784.2016.1182499
   Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745
   Rankin AL, 2013, J IMMUNOL, V191, P4540, DOI 10.4049/jimmunol.1301553
   Ruiz Castillo P, 2016, CHEM REV, V116, P12564, DOI 10.1021/acs.chemrev.6b00512
   Rule S, 2018, EXPERT REV HEMATOL, V11, P749, DOI 10.1080/17474086.2018.1506327
   Shi Q, 2014, BIOORG MED CHEM LETT, V24, P2206, DOI 10.1016/j.bmcl.2014.02.075
   Smith PF, 2017, BRIT J CLIN PHARMACO, V83, P2367, DOI 10.1111/bcp.13351
   Squibb Bristol Myers Co, 2014, Patent No. [WO2014210087, 2014210087, WO 2014210087]
   STEINBERG BJ, 1982, J CLIN INVEST, V70, P587, DOI 10.1172/JCI110651
   Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31
   Thompson PA, 2018, EXPERT OPIN INV DRUG, V27, P31, DOI 10.1080/13543784.2018.1404027
   Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548
   TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952 7915(94)90151 1
   Uetrecht JP, 1999, CHEM RES TOXICOL, V12, P387, DOI 10.1021/tx980249i
   Wang M, 2018, LANCET, V391, P659, DOI 10.1016/S0140 6736(17)33108 2
   Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220
   Watterson SH, 2016, J MED CHEM, V59, P9173, DOI 10.1021/acs.jmedchem.6b01088
   Whyburn LR, 2003, INT IMMUNOL, V15, P383, DOI 10.1093/intimm/dxg034
   Xu DG, 2012, J PHARMACOL EXP THER, V341, P90, DOI 10.1124/jpet.111.187740
NR 51
TC 88
Z9 96
U1 0
U2 48
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD APR 11
PY 2019
VL 62
IS 7
BP 3228
EP 3250
DI 10.1021/acs.jmedchem.9b00167
PG 23
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA HT7TW
UT WOS:000464768300004
PM 30893553
OA hybrid
DA 2025 08 17
ER

PT J
AU Irie, K
   Ekuni, D
   Tomofuji, T
   Endo, Y
   Kasuyama, K
   Yaegaki, K
   Morita, M
AF Irie, Koichiro
   Ekuni, Daisuke
   Tomofuji, Takaaki
   Endo, Yasumasa
   Kasuyama, Kenta
   Yaegaki, Ken
   Morita, Manabu
TI Combined Effects of Hydrogen Sulfide and Lipopolysaccharide on
   Osteoclast Differentiation in Rats
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE Hydrogen sulfide; lipopolysaccharides; osteoclasts; toll like receptor
   2; toll like receptor 4; rats
ID PERIODONTAL DISEASE; METHYL MERCAPTAN; ORAL MALODOR; RECEPTOR;
   CHOLESTEROL; EXPRESSION; MIGRATION; CYTOKINES
AB Background: Lipopolysaccharide (LPS) stimulates osteoclast differentiation through toll like receptors (TLRs) 2 and 4, and hydrogen sulfide (H2S) induces osteoclast differentiation. If H2S activates TLRs, H2S may enhance the effects of LPS on osteoclast differentiation. The purpose of the present study is to examine the combined effects of sodium hydrogen sulfide (NaHS, an H2S donor drug) and LPS on osteoclast differentiation and TLR expression in rat periodontal tissue.
   Methods: Twenty eight male Wistar rats (8 weeks old) were divided into four groups (n = 7 per group): a control (no treatment) group and three experimental groups (NaHS group, LPS group, and a combination [NaHS + LPS] group). At 1 day after topical application of NaHS and/or Porphyromonas gingivalis LPS into the gingival sulcus of first molars, the number of tartrate resistant acid phosphate (TRAP) positive osteoclasts in the periodontal tissue was counted. Expression of TLR2 and TLR4 mRNAs and proteins in the gingival was also assessed.
   Results: The number of TRAP positive osteoclasts was significantly higher in the combination group than in any other group (P < 0.01). The combination group had 11.0 fold higher TLR4 mRNA levels than the control group. TLR4 protein levels were also higher in the combination group than in the NaHS or LPS group. However, the TLR2 mRNA and protein levels were not significantly different in the combination group and the LPS group.
   Conclusion: In rat periodontal tissue, NaHS and LPS had an additive effect on osteoclast differentiation through activation of the TLR4 pathway but not the TLR2 pathway. J Periodontol 2012;83:522 527.
C1 [Ekuni, Daisuke] Okayama Univ, Dept Prevent Dent, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, Okayama 7008558, Japan.
   [Yaegaki, Ken] Nippon Dent Univ Tokyo, Dept Oral Hlth, Tokyo, Japan.
C3 Okayama University; Nippon Dental University
RP Ekuni, D (通讯作者)，Okayama Univ, Dept Prevent Dent, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
EM dekuni7@md.okayama u.ac.jp
RI Yaegaki, Ken/AAU 6827 2020
CR Dai SP, 2010, J BIOL CHEM, V285, P4995, DOI 10.1074/jbc.M109.067454
   Ekuni D, 2005, J PERIODONTOL, V76, P43, DOI 10.1902/jop.2005.76.1.43
   Ekuni D, 2011, NEUROMOL MED, V13, P197, DOI 10.1007/s12017 011 8151 0
   Ekuni D, 2003, J PERIODONTAL RES, V38, P591, DOI 10.1034/j.1600 0765.2003.00694.x
   Ekuni D, 2009, AM J PATHOL, V175, P1398, DOI 10.2353/ajpath.2009.090108
   Fan HG, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/704706
   Florin T, 1992, Gastroenterol Clin Biol, V16, P104
   Hayashi SI, 2003, J IMMUNOL, V171, P5130, DOI 10.4049/jimmunol.171.10.5130
   Ii H, 2010, J PERIODONTOL, V81, P1691, DOI 10.1902/jop.2010.100116
   Irie K, 2008, J DENT RES, V87, P456, DOI 10.1177/154405910808700511
   Irie K, 2009, ARCH ORAL BIOL, V54, P723, DOI 10.1016/j.archoralbio.2009.05.006
   Kawamoto S, 2002, ARCH ORAL BIOL, V47, P55, DOI 10.1016/S0003 9969(01)00088 7
   Kawata K, 2006, BIOCHEM BIOPH RES CO, V345, P552, DOI 10.1016/j.bbrc.2006.04.109
   Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Liu GG, 2008, BIOCHEM BIOPH RES CO, V370, P651, DOI 10.1016/j.bbrc.2008.04.031
   Morita M, 2001, J PERIODONTOL, V72, P79, DOI 10.1902/jop.2001.72.1.79
   Morita M, 2001, J PERIODONTOL, V72, P74, DOI 10.1902/jop.2001.72.1.74
   NG W, 1984, J DENT RES, V63, P994, DOI 10.1177/00220345840630071701
   Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471 2172 5 3
   PERSSON S, 1992, ORAL MICROBIOL IMMUN, V7, P378, DOI 10.1111/j.1399 302X.1992.tb00641.x
   RIZZO AA, 1967, PERIODONTICS, V5, P233
   Sanbe T, 2007, J PERIODONTOL, V78, P2165, DOI 10.1902/jop.2007.070181
   SOLISGAFFAR MC, 1980, J PERIODONTOL, V51, P603, DOI 10.1902/jop.1980.51.10.603
   Song JJ, 2009, INT J PEDIATR OTORHI, V73, P821, DOI 10.1016/j.ijporl.2009.02.017
   Tomofuji T, 2005, J DENT RES, V84, P752, DOI 10.1177/154405910508400813
   Xing Q, 2011, J DENT RES, V90, P157, DOI 10.1177/0022034510379019
   YAEGAKI K, 1992, J PERIODONTOL, V63, P783, DOI 10.1902/jop.1992.63.9.783
   Zhang HL, 2007, AM J PHYSIOL LUNG C, V292, pL960, DOI 10.1152/ajplung.00388.2006
   Zhi L, 2007, J LEUKOCYTE BIOL, V81, P1322, DOI 10.1189/jlb.1006599
NR 30
TC 24
Z9 26
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD APR
PY 2012
VL 83
IS 4
BP 522
EP 527
DI 10.1902/jop.2011.110315
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 926LI
UT WOS:000302832100016
PM 21910595
DA 2025 08 17
ER

PT J
AU Petrie, TA
   Raynor, JE
   Dumbauld, DW
   Lee, TT
   Jagtap, S
   Templeman, KL
   Collard, DM
   García, AJ
AF Petrie, Timothy A.
   Raynor, Jenny E.
   Dumbauld, David W.
   Lee, Ted T.
   Jagtap, Subodh
   Templeman, Kellie L.
   Collard, David M.
   Garcia, Andres J.
TI Multivalent Integrin Specific Ligands Enhance Tissue Healing and
   Biomaterial Integration
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID CELL ADHESION; OSTEOBLAST DIFFERENTIATION; BONE FORMATION; RGD;
   FIBRONECTIN; TITANIUM; BINDING; OSSEOINTEGRATION; ORGANIZATION; PEPTIDES
AB Engineered biointerfaces covered with biomimetic motifs, including short bioadhesive ligands, are a promising material based strategy for tissue repair in regenerative medicine. Potentially useful coating molecules are ligands for the integrins, major extracellular matrix receptors that require both ligand binding and nanoscale clustering for maximal signaling efficiency. We prepared coatings consisting of well defined multimer constructs with a precise number of recombinant fragments of fibronectin (monomer, dimer, tetramer, and pentamer) to assess how nanoscale ligand clustering affects integrin binding, stem cell responses, tissue healing, and biomaterial integration. Clinical grade titanium was grafted with polymer brushes that presented monomers, dimers, trimers, or pentamers of the alpha(5)beta(1) integrin specific fibronectin III(7 to 10) domain (FNIII7 10). Coatings consisting of trimers and pentamers enhanced integrin mediated adhesion in vitro, osteogenic signaling, and differentiation in human mesenchymal stem cells more than did surfaces presenting monomers and dimers. Furthermore, ligand clustering promoted bone formation and functional integration of the implant into bone in rat tibiae. This study establishes that a material based strategy in which implants are coated with clustered bioadhesive ligands can promote robust implant tissue integration.
C1 [Petrie, Timothy A.; Dumbauld, David W.; Lee, Ted T.; Templeman, Kellie L.; Garcia, Andres J.] Georgia Inst Technol, Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.
   [Petrie, Timothy A.; Dumbauld, David W.; Lee, Ted T.; Templeman, Kellie L.; Garcia, Andres J.] Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
   [Raynor, Jenny E.; Jagtap, Subodh; Collard, David M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.
C3 University System of Georgia; Georgia Institute of Technology;
   University System of Georgia; Georgia Institute of Technology;
   University System of Georgia; Georgia Institute of Technology
RP García, AJ (通讯作者)，Georgia Inst Technol, Woodruff Sch Mech Engn, 315 Ferst Dr,Room 2314 IBB, Atlanta, GA 30332 USA.
EM andres.garcia@me.gatech.edu
FU NIH [R01 EB 004496, R01 GM 06591]; Medtronic Foundation
FX We thank H. Erickson for providing complementary DNA for fibronectin
   constructs and M. Mathews for implant machining. Funding: This work was
   supported by NIH grants R01 EB 004496 and R01 GM 06591. T.A. P.
   acknowledges support from the Medtronic Foundation. Author
   contributions: T.A.P., J.E.R., D.W.D., T.T.L., S.J., and K.L.T.
   contributed to collection of experimental data; T.A.P. and A.J.G.
   analyzed the data; T.A.P., D.M.C., and A.J.G. contributed to writing the
   paper. Competing interests: A.J.G. has consulted for Synthes Inc.
   Georgia Tech Research Corporation has applied for a U.S. patent on the
   use of FNIII<INF>7 10</INF> for orthopedic repair. The authors declare
   that they have no competing interests.
CR Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Barber TA, 2007, J BIOMED MATER RES A, V80A, P306, DOI 10.1002/jbm.a.30927
   Brinkerhoff CJ, 2005, TISSUE ENG, V11, P865, DOI 10.1089/ten.2005.11.865
   Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277
   Coussen F, 2002, J CELL SCI, V115, P2581
   Garanger E, 2007, ANTI CANCER AGENT ME, V7, P552, DOI 10.2174/187152007781668706
   García AJ, 2005, BIOMATERIALS, V26, P7525, DOI 10.1016/j.biomaterials.2005.05.029
   García AJ, 2005, J DENT RES, V84, P407, DOI 10.1177/154405910508400502
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593
   Globus RK, 2005, CALCIFIED TISSUE INT, V76, P39, DOI 10.1007/s00223 004 0309 4
   Globus RK, 1998, J CELL SCI, V111, P1385
   Hennessy KM, 2008, BIOMATERIALS, V29, P3075, DOI 10.1016/j.biomaterials.2008.04.014
   Huang JH, 2009, NANO LETT, V9, P1111, DOI 10.1021/nl803548b
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Irvine DJ, 2002, BIOPHYS J, V82, P120, DOI 10.1016/S0006 3495(02)75379 4
   Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805
   Keselowsky BG, 2005, BIOMATERIALS, V26, P413, DOI 10.1016/j.biomaterials.2004.02.050
   Keselowsky BG, 2005, P NATL ACAD SCI USA, V102, P5953, DOI 10.1073/pnas.0407356102
   Koo LY, 2002, J CELL SCI, V115, P1423
   Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388
   M P, 2005, NAT BIOTECHNOL, V23, P47
   Maheshwari G, 2000, J CELL SCI, V113, P1677
   MASSIA SP, 1991, J CELL BIOL, V114, P1089, DOI 10.1083/jcb.114.5.1089
   MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791
   MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531
   Moursi AM, 1997, J CELL SCI, V110, P2187
   Petrie TA, 2008, BIOMATERIALS, V29, P2849, DOI 10.1016/j.biomaterials.2008.03.036
   Petrie TA, 2006, BIOMATERIALS, V27, P5459, DOI 10.1016/j.biomaterials.2006.06.027
   Petrie TA, 2009, J CELL MOL MED, V13, P2602, DOI 10.1111/j.1582 4934.2008.00476.x
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Raynor JE, 2007, ADV MATER, V19, P1724, DOI 10.1002/adma.200602129
   Reyes CD, 2007, BIOMATERIALS, V28, P3228, DOI 10.1016/j.biomaterials.2007.04.003
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   Schliephake H, 2002, CLIN ORAL IMPLAN RES, V13, P312, DOI 10.1034/j.1600 0501.2002.130312.x
   Tamura Y, 2001, J BONE MINER RES, V16, pS483
   Villard V, 2006, J PEPT SCI, V12, P206, DOI 10.1002/psc.707
   Vogel V, 2009, CURR OPIN CELL BIOL, V21, P38, DOI 10.1016/j.ceb.2009.01.002
NR 38
TC 141
Z9 172
U1 1
U2 66
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 18
PY 2010
VL 2
IS 45
AR 45ra60
DI 10.1126/scitranslmed.3001002
PG 6
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 735RT
UT WOS:000288435500004
PM 20720217
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yin, S
   Peng, YZ
   Lin, YR
   Wu, HZ
   Wang, BQ
   Wang, XF
   Chen, WX
   Liu, TY
   Peng, HQ
   Li, XP
   Xu, JK
   Wang, M
AF Yin, Sheng
   Peng, Yizhi
   Lin, Yingrui
   Wu, Hongzheng
   Wang, Bingqi
   Wang, Xiaofan
   Chen, Wanxin
   Liu, Tianyao
   Peng, Huanqie
   Li, Xianping
   Xu, Jiake
   Wang, Min
TI Bacterial heat shock protein: A new crosstalk between T lymphocyte and
   macrophage via JAK2/STAT1 pathway in bloodstream infection
SO MICROBIOLOGICAL RESEARCH
LA English
DT Article
DE Stenotrophomonas maltophilia; Mucosa associated invariant T; Bloodstream
   infection; Macrophages; Fludarabine
ID INTERNATIONAL CONSENSUS DEFINITIONS; SEPSIS; INHIBITION; CELLS
AB Bloodstream infection (BSI) refers to the infection of blood by pathogens. Severe immune response to BSI can lead to sepsis, a systemic infection leading to multiple organ dysfunction, coupled with drug resistance, mortality, and limited clinical treatment options. This work aims to further investigate the new interplay between bacterial exocrine regulatory protein and host immune cells in the context of highly drug  resistant malignant BSI. Whether interfering with related regulatory signaling pathways can reverse the inflammatory disorder of immune cells. In depth analysis of single  cell sequencing results in Septic patients for potential immunodeficiency factors. Analysis of key proteins enriched by host cells and key pathways using proteomics. Cell models and animal models validate the pathological effects of DnaK on T cells, MAITs, macrophages, and osteoclasts. The blood of patients was analyzed for the immunosuppression of T cells and MAITs. We identified that S. maltophilia  DnaK was enriched in immunodeficient T cells. The activation of the JAK2/STAT1 axis initiated the exhaustion of T cells. Septic patients with Gram negative bacterial infections exhibited deficiencies in MAITs, which correspond to IFN gamma. Cellular and animal experiments confirmed that DnaK could facilitate MAIT depletion and M1 polarization of macrophages. Additionally, Fludarabine mitigated M1 polarization of blood, liver, and spleen in mice. Interestingly, DnaK also repressed osteoclastogenesis of macrophages stimulated by RANKL. S.maltophilia  DnaK prompts the activation of the JAK2/STAT1 axis in T cells and the M1 polarization of macrophages. Targeting the DnaK's crosstalk can be a potentially effective approach for treating the inflammatory disorder in the broad spectrum drug  resistant BSI.
C1 [Yin, Sheng; Peng, Yizhi; Lin, Yingrui; Wu, Hongzheng; Wang, Bingqi; Wang, Xiaofan; Chen, Wanxin; Liu, Tianyao; Peng, Huanqie; Li, Xianping; Wang, Min] Cent South Univ, Xiangya Hosp 2, Dept Lab Med, Changsha 410011, Hunan, Peoples R China.
   [Peng, Yizhi] Cent South Univ, Hunan Canc Hosp, Dept Lab Med, Affiliated Canc Hosp,Xiangya Sch Med, Changsha 410031, Hunan, Peoples R China.
   [Yin, Sheng; Xu, Jiake] Univ Western Australia, Sch Biomed Sci, Perth, WA 6009, Australia.
   [Wang, Min] Cent South Univ, Dept Lab Med, Xiangya Hosp 2, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
C3 Central South University; Central South University; University of
   Western Australia; Central South University
RP Wang, M (通讯作者)，Cent South Univ, Dept Lab Med, Xiangya Hosp 2, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
EM wangmin0000@csu.edu.cn
RI ; Wang, Mingzhe/HGE 1901 2022; Wu, Hongzheng/JGD 7255 2023
OI Xu, Jiake/0000 0003 2021 8309; 
CR AlQranei MS, 2021, BMC IMMUNOL, V22, DOI 10.1186/s12865 021 00409 9
   [Anonymous], 2020, Sepsis: Data & Reports
   Charpentier JC, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964 021 00766 3
   Chen XS, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107791
   Chen Z, 2010, IMMUNOL LETT, V131, P11, DOI 10.1016/j.imlet.2010.04.003
   Clark DJ, 2019, ELIFE, V8, DOI 10.7554/eLife.45789
   Criado Marrero M, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0532
   Delano MJ, 2016, IMMUNOL REV, V274, P330, DOI 10.1111/imr.12499
   Fernando SM, 2018, CAN MED ASSOC J, V190, pE1058, DOI 10.1503/cmaj.170149
   Frank DA, 1999, NAT MED, V5, P444, DOI 10.1038/7445
   Funk SS, 2017, ORTHOP CLIN N AM, V48, P199, DOI 10.1016/j.ocl.2016.12.007
   Furuyama N, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/1490732
   Garrity Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100 7113.2000
   Ghazaei C, 2017, J MED MICROBIOL, V66, P259, DOI 10.1099/jmm.0.000429
   Grimm G, 2010, BONE, V47, P388, DOI 10.1016/j.bone.2010.04.602
   Hirata CL, 2019, ARCH BIOCHEM BIOPHYS, V677, DOI 10.1016/j.abb.2019.108159
   Huang JM, 2022, INFLAMM RES, V71, P81, DOI 10.1007/s00011 021 01524 4
   Jadhav G, 2016, SCI REP UK, V6, DOI 10.1038/srep25964
   Jeffery HC, 2016, J HEPATOL, V64, P1118, DOI 10.1016/j.jhep.2015.12.017
   Jensen IJ, 2020, ELIFE, V9, DOI 10.7554/eLife.55800
   Jiao Y, 2021, CRIT CARE, V25, DOI 10.1186/s13054 021 03775 3
   Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899
   Juno JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01076
   Kawakami T, 2013, IMMUNITY, V39, P996, DOI 10.1016/j.immuni.2013.11.007
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lamkanfi M, 2010, INT J BIOCHEM CELL B, V42, P21, DOI 10.1016/j.biocel.2009.09.013
   Lira Junior R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00086
   Liu JJ, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018 022 04490 0
   Liu L, 2020, COMB CHEM HIGH T SCR, V23, P369, DOI 10.2174/1386207323666200401121204
   Marshall JC, 2014, TRENDS MOL MED, V20, P195, DOI 10.1016/j.molmed.2014.01.007
   Minasyan H, 2019, SCAND J TRAUMA RESUS, V27, DOI 10.1186/s13049 019 0596 4
   Mukhopadhyay S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171689
   Naylor DJ, 2001, BIOCHEM SOC SYMP, V68, P45, DOI 10.1042/bss0680045
   Osorio EY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.846246
   Patoli D, 2020, J CLIN INVEST, V130, P5858, DOI 10.1172/JCI130996
   Qiu XR, 2021, J LEUKOCYTE BIOL, V110, P1253, DOI 10.1002/JLB.5MA0721 825R
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rol ML, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2016 015734
   Singer M, 2016, JAMA J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Stapels DAC, 2014, P NATL ACAD SCI USA, V111, P13187, DOI 10.1073/pnas.1407616111
   Terashima A, 2019, SEMIN IMMUNOPATHOL, V41, P619, DOI 10.1007/s00281 019 00755 2
   Toubal A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17307 0
   van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593
   Verykokakis M, 2018, CURR OPIN IMMUNOL, V51, P39, DOI 10.1016/j.coi.2018.01.006
   Viscoli C, 2016, VIRULENCE, V7, P248, DOI 10.1080/21505594.2016.1152440
   Voillet V, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98487
   Vulczak A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174255
   Wang M, 2021, MOL IMMUNOL, V130, P37, DOI 10.1016/j.molimm.2020.12.019
   Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298
   Xu JK, 2000, J BONE MINER RES, V15, P2178, DOI 10.1359/jbmr.2000.15.11.2178
   Zhao TC, 2020, ONCOL LETT, V20, P1127, DOI 10.3892/ol.2020.11647
NR 51
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944 5013
EI 1618 0623
J9 MICROBIOL RES
JI Microbiol. Res.
PD MAY
PY 2024
VL 282
AR 127626
DI 10.1016/j.micres.2024.127626
EA FEB 2024
PG 19
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA KZ3A0
UT WOS:001183739500001
PM 38330817
DA 2025 08 17
ER

PT J
AU Cochis, A
   Barberi, J
   Ferraris, S
   Miola, M
   Rimondini, L
   Vernè, E
   Yamaguchi, S
   Spriano, S
AF Cochis, Andrea
   Barberi, Jacopo
   Ferraris, Sara
   Miola, Marta
   Rimondini, Lia
   Verne, Enrica
   Yamaguchi, Seiji
   Spriano, Silvia
TI Competitive Surface Colonization of Antibacterial and Bioactive
   Materials Doped with Strontium and/or Silver Ions
SO NANOMATERIALS
LA English
DT Article
DE antibacterial activity; cytotoxicity; silver; strontium; competition for
   the surface; bone
ID TITANIUM SURFACES; STAPHYLOCOCCUS AUREUS; BACTERIAL ADHERENCE; OXIDE
   LAYER; NANOPARTICLES; MECHANISM; INFECTION; ADHESION; CELLS; INTEGRATION
AB Nowadays, there is a large amount of research aimed at improving the multifunctional behavior of the biomaterials for bone contact, including the concomitant ability to induce apatite formation (bioactivity), fast and effective osteoblasts colonization, and antibacterial activity. The aim of this study is to develop antibacterial and bioactive surfaces (Ti6Al4V alloy and a silica based bioactive glass) by chemical doping with strontium and/or silver ions. The surfaces were characterized by Scanning Electron Microscopy equipped with Energy Dispersive X ray Spectroscopy (SEM EDS), X ray photoelectron spectroscopy (XPS), and Transmission Electron Microscopy (TEM). To better focus on the cells bacteria competition for the implant surface, in addition to the standard assays for the evaluation of the bacteria adhesion (ISO22196) and for single cell cultures or biofilm formation, an innovative set of co cultures of cells and bacteria is here proposed to simulate a competitive surface colonization. The results suggest that all the bioactive tested materials were cytocompatible toward the bone progenitor cells representative for the self healing process, and that the doped ones were effective in reducing the surface colonization from a pathogenic drug resistant strain of Staphylococcus aureus. The co cultures experiments demonstrated that the doped surfaces were able to protect the adhered osteoblasts from the bacteria colonization as well as prevent the infection prior to the surface colonization by the osteoblasts.
C1 [Cochis, Andrea; Rimondini, Lia] Univ Piemonte Orientale, Dept Hlth Sci, I 28100 Novara, Italy.
   [Cochis, Andrea; Rimondini, Lia] Ctr Translat Res Autoimmune & Allerg Dis CAAD, Interdisciplinary Res Ctr Autoimmune Dis, I 28100 Novara, Italy.
   [Barberi, Jacopo; Ferraris, Sara; Miola, Marta; Verne, Enrica; Spriano, Silvia] Politecn Torino, Dept Appl Sci & Technol, I 10129 Turin, Italy.
   [Barberi, Jacopo; Ferraris, Sara; Miola, Marta; Verne, Enrica; Spriano, Silvia] Politecn Torino, PolitoBIOMedLab, Interdipartimental Lab, I 10129 Turin, Italy.
   [Yamaguchi, Seiji] Chubu Univ, Coll Life & Hlth Sci, Dept Biomed Sci, 1200 Matsumoto, Kasugai, Aichi 4878501, Japan.
C3 University of Eastern Piedmont Amedeo Avogadro; Polytechnic University
   of Turin; Polytechnic University of Turin; Chubu University
RP Spriano, S (通讯作者)，Politecn Torino, Dept Appl Sci & Technol, I 10129 Turin, Italy.; Spriano, S (通讯作者)，Politecn Torino, PolitoBIOMedLab, Interdipartimental Lab, I 10129 Turin, Italy.
EM andrea.cochis@med.uniupo.it; jacopo.barberi@polito.it;
   sara.ferraris@polito.it; marta.miola@polito.it;
   lia.rimondini@med.uniupo.it; enrica.verne@polito.it;
   sy esi@isc.chubu.ac.jp; silvia.spriano@polito.it
RI ; Barberi, Jacopo/JVO 4259 2024; Cochis, Andrea/U 5264 2018; Spriano,
   Silvia/AFS 3873 2022; RIMONDINI, LIA/K 5961 2016
OI MIOLA, MARTA/0000 0002 1440 6146; Spriano, Silvia/0000 0002 7367 9777;
   Cochis, Andrea/0000 0003 2455 8239; Verne, Enrica/0000 0002 8649 4739;
   BARBERI, JACOPO/0000 0002 9649 5401; RIMONDINI, LIA/0000 0002 7785 2282
FU MAECI Italy (GLOBAL project)
FX This research was funded by MAECI Italy (GLOBAL project).
CR Albers CE, 2013, NANOTOXICOLOGY, V7, P30, DOI 10.3109/17435390.2011.626538
   [Anonymous], 2011, ISO 22196:2011
   Cochis A, 2016, BIOMATERIALS, V80, P80, DOI 10.1016/j.biomaterials.2015.11.042
   Cochis A, 2017, J MATER CHEM B, V5, P8366, DOI 10.1039/c7tb01965c
   Collette J, 2010, OSTEOPOROSIS INT, V21, P233, DOI 10.1007/s00198 009 0940 z
   Ferraris S, 2018, SURF COAT TECH, V344, P177, DOI 10.1016/j.surfcoat.2018.03.020
   Ferraris S, 2016, MAT SCI ENG C MATER, V61, P965, DOI 10.1016/j.msec.2015.12.062
   Ferraris S, 2014, APPL SURF SCI, V311, P279, DOI 10.1016/j.apsusc.2014.05.056
   Ferraris S, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00103
   FITZGERALD RH, 1985, AM J MED, V78, P225, DOI 10.1016/0002 9343(85)90389 4
   Flemming HC, 2010, NAT REV MICROBIOL, V8, P623, DOI 10.1038/nrmicro2415
   GRISTINA AG, 1987, SCIENCE, V237, P1588, DOI 10.1126/science.3629258
   Guida A, 2003, J MATER SCI LETT, V22, P1401, DOI 10.1023/A:1025794927195
   Harrison JJ, 2010, NAT PROTOC, V5, P1236, DOI 10.1038/nprot.2010.71
   Higgins J.P., 2011, COCHRANE HDB SYSTEMA, V5
   Huotari K, 2015, ACTA ORTHOP, V86, P321, DOI 10.3109/17453674.2015.1035173
   Jamal M., 2015, RRJMB, V4, P1, DOI DOI 10.1099/JMM.0.000040
   Jung WK, 2008, APPL ENVIRON MICROB, V74, P2171, DOI 10.1128/AEM.02001 07
   Kaiser JP, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951 016 0244 3
   Kedziora A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020444
   Kunutsor SK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139166
   Lee JH, 2010, ACTA BIOMATER, V6, P4422, DOI 10.1016/j.actbio.2010.05.021
   Li HB, 1997, J AM SOC MASS SPECTR, V8, P781, DOI 10.1016/S1044 0305(97)84130 X
   Lin YG, 2008, J WUHAN UNIV TECHNOL, V23, P475, DOI 10.1007/s11595 006 4475 2
   Martinez Perez M, 2017, BONE JOINT RES, V6, P315, DOI 10.1302/2046 3758.65.BJR 2016 0226.R2
   McConda DB, 2016, BIOFOULING, V32, P627, DOI 10.1080/08927014.2016.1172572
   Miola M, 2017, J MATER SCI, V52, P5133, DOI 10.1007/s10853 017 0750 1
   Miola M, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/5/055014
   Nielsen SP, 2004, BONE, V35, P583, DOI 10.1016/j.bone.2004.04.026
   Noronha VT, 2017, DENT MATER, V33, P1110, DOI 10.1016/j.dental.2017.07.002
   Parnsamut C, 2015, GENET MOL RES, V14, P3650, DOI 10.4238/2015.April.17.15
   Simoes M, 2010, LWT FOOD SCI TECHNOL, V43, P573, DOI 10.1016/j.lwt.2009.12.008
   Subbiahdoss G, 2009, ACTA BIOMATER, V5, P1399, DOI 10.1016/j.actbio.2008.12.011
   van der Zande M, 2012, ACS NANO, V6, P7427, DOI 10.1021/nn302649p
   Veerachamy S, 2014, P I MECH ENG H, V228, P1083, DOI 10.1177/0954411914556137
   Wekwejt M., 2018, EUR J MED TECHNOL, V4, P19
   Xie HJ, 2019, ARTIF CELL NANOMED B, V47, P260, DOI 10.1080/21691401.2018.1552594
   Yamaguchi S, 2019, COATINGS, V9, DOI 10.3390/coatings9090561
   Yue CX, 2015, J BIOMED MATER RES A, V103, P3590, DOI 10.1002/jbm.a.35502
   Zhang RZ, 2015, NANOMED NANOTECHNOL, V11, P1949, DOI 10.1016/j.nano.2015.07.016
   Zhang XM, 2017, EXP THER MED, V14, P1126, DOI 10.3892/etm.2017.4610
   Zhao YH, 2012, APPL SURF SCI, V258, P8867, DOI 10.1016/j.apsusc.2012.05.106
NR 42
TC 51
Z9 54
U1 0
U2 21
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 4991
J9 NANOMATERIALS BASEL
JI Nanomaterials
PD JAN
PY 2020
VL 10
IS 1
AR 120
DI 10.3390/nano10010120
PG 19
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA KQ3KO
UT WOS:000516825600120
PM 31936394
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jin, WB
   Zhao, RY
   Wang, R
   Choi, SR
   Ploessl, K
   Alexoff, D
   Wu, ZH
   Zhu, L
   Kung, HF
AF Jin, Wenbin
   Zhao, Ruiyue
   Wang, Ran
   Choi, Seok Rye
   Ploessl, Karl
   Alexoff, David
   Wu, Zehui
   Zhu, Lin
   Kung, Hank F.
TI Theranostic Agent Targeting Bone Metastasis: A Novel
   [<SUP>68</SUP>Ga]Ga/[<SUP>177</SUP>Lu]Lu DOTA HBED bisphosphonate
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID GALLIUM(III) COMPLEXES; THERAPY; DOTA; BIODISTRIBUTION; LU 177 BPAMD;
   DOSIMETRY; GA 68
AB Bone metastasis in cancer patients is a major disease advancement for various types of cancer. Previously, [Ga 68]Ga HBED CC bisphosphonate ([Ga 68]Ga P15 041) showed excellent bone uptake and efficient detection of bone metastasis in patients. To accommodate different alpha  or beta( ) emitting metals for radionuclide therapy, a novel DOTA HBED CC bisphosphonate (P15 073, 1) was prepared and the corresponding [Ga 68]Ga 1 and [Lu 177]Lu 1 were successfully synthesized in high yields and purity. Gallium 68 conjugation to HBED CC at room temperature and lutetium 177 conjugation to DOTA at 95 degrees C were verified in model compounds through secondary mass confirmation. These bisphosphonates, [Ga 68]Ga 1 and [Lu 177]Lu 1, displayed high binding affinity to hydroxyapatite in vitro. After an iv injection, it showed excellent uptake in the spine of normal mice, and micro PET/CT imaging of nude mice model of bone metastasis showed high bone uptake in tumor tissue. The results indicated that [Ga 68]Ga/[Lu 177]Lu 1 holds promise as a theranostic radioligand agent for managing cancer bone metastases.
C1 [Jin, Wenbin; Wang, Ran; Zhu, Lin] Beijing Normal Univ, Coll Chem, Beijing 100875, Peoples R China.
   [Zhao, Ruiyue] Guangzhou Med Univ, Affiliated Hosp 1, Dept Nucl Med, Guangzhou 510120, Guangdong, Peoples R China.
   [Jin, Wenbin; Zhu, Lin] Inst Biomed Engn, Shenzhen Bay Lab, Shenzhen 518000, Guangdong, Peoples R China.
   [Wu, Zehui; Kung, Hank F.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
   [Choi, Seok Rye; Ploessl, Karl; Alexoff, David; Kung, Hank F.] Five Eleven Pharma Inc, Philadelphia, PA 19104 USA.
C3 Beijing Normal University; Guangzhou Medical University; Shenzhen Bay
   Laboratory; University of Pennsylvania
RP Zhu, L (通讯作者)，Beijing Normal Univ, Coll Chem, Beijing 100875, Peoples R China.; Zhu, L (通讯作者)，Inst Biomed Engn, Shenzhen Bay Lab, Shenzhen 518000, Guangdong, Peoples R China.; Kung, HF (通讯作者)，Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.; Kung, HF (通讯作者)，Five Eleven Pharma Inc, Philadelphia, PA 19104 USA.
EM zhulin@bnu.edu.cn; kunghf@pennmedicine.upenn.edu
RI Wang, Ran/AAP 1920 2020
OI Ploessl, Karl/0000 0001 7896 5900
FU Guangzhou Medical University [2022A1515110941]; Guangdong Regional Joint
   Fund [202201020558]; Science and Technology Program of Guangzhou; Plan
   on Enhancing Scientific Research in Guangzhou Medical University; Five
   Eleven Pharma, Inc.
FX This study was supported by the Guangdong Regional Joint Fund
   (2022A1515110941), the Science and Technology Program of Guangzhou
   (202201020558), and the Plan on Enhancing Scientific Research in
   Guangzhou Medical University. Five Eleven Pharma, Inc. was the sponsor
   of this study.
CR Afshar Oromieh A, 2016, J NUCL MED, V57, p79S, DOI 10.2967/jnumed.115.170720
   Banerjee S, 2015, CHEM REV, V115, P2934, DOI 10.1021/cr500171e
   Clézardin P, 2021, PHYSIOL REV, V101, P797, DOI 10.1152/physrev.00012.2019
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Dai JL, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.4
   Doot RK, 2020, NUCL MED BIOL, V86 87, P1, DOI 10.1016/j.nucmedbio.2020.04.002
   Feeley BT, 2006, J BONE MINER RES, V21, P1571, DOI 10.1359/JBMR.060706
   Fernández R, 2021, J NUCL MED, V62, P1126, DOI 10.2967/jnumed.120.255851
   Guleria M, 2019, CANCER BIOTHER RADIO, V34, P67, DOI 10.1089/cbr.2018.2605
   Guo R, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.766851
   Hennrich U, 2019, PHARMACEUTICALS BASE, V12, DOI 10.3390/ph12030114
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Holub J, 2015, CONTRAST MEDIA MOL I, V10, P122, DOI 10.1002/cmmi.1606
   Hu KZ, 2022, ACTA PHARM SIN B, V12, P867, DOI 10.1016/j.apsb.2021.09.032
   Jang A, 2023, THER ADV MED ONCOL, V15, DOI 10.1177/17588359231157632
   Khawar A, 2019, EJNMMI RES, V9, DOI 10.1186/s13550 019 0566 x
   Kubícek V, 2010, INORG CHEM, V49, P10960, DOI 10.1021/ic101378s
   Kuznik A, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172773
   LEPLATTE.F, 1967, J AM CHEM SOC, V89, P837
   Liepe K, 2003, J NUCL MED, V44, P953
   MacPherson DS, 2019, DALTON T, V48, P14547, DOI 10.1039/c9dt03039e
   Makarem A, 2019, J ORG CHEM, V84, P7501, DOI 10.1021/acs.joc.9b00832
   Meckel M, 2013, NUCL MED BIOL, V40, P823, DOI 10.1016/j.nucmedbio.2013.04.012
   Pfannkuchen N, 2017, PHARMACEUTICALS BASE, V10, DOI 10.3390/ph10020045
   Price EW, 2014, CHEM SOC REV, V43, P260, DOI 10.1039/c3cs60304k
   Qiu L, 2023, CLIN NUCL MED, V48, P489, DOI 10.1097/RLU.0000000000004634
   Sartor O, 2021, NEW ENGL J MED, V385, P1091, DOI 10.1056/NEJMoa2107322
   Seesaghur A, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen 2022 069214
   Sharma S, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00046
   Toegel S, 2008, EUR J PHARM BIOPHARM, V68, P406, DOI 10.1016/j.ejpb.2007.05.015
   Wang QX, 2023, MOL PHARMACEUT, V20, P1788, DOI 10.1021/acs.molpharmaceut.2c00978
   Yousefnia H, 2016, J RADIOANAL NUCL CH, V307, P1243, DOI 10.1007/s10967 015 4225 z
   Yousefnia H, 2015, APPL RADIAT ISOTOPES, V104, P128, DOI 10.1016/j.apradiso.2015.06.033
   Zha ZH, 2020, MOL PHARMACEUT, V17, P1674, DOI 10.1021/acs.molpharmaceut.0c00103
NR 34
TC 4
Z9 4
U1 7
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 7
PY 2024
VL 67
IS 6
BP 4793
EP 4803
DI 10.1021/acs.jmedchem.3c02372
EA MAR 2024
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA MI2Y0
UT WOS:001181197300001
PM 38450559
DA 2025 08 17
ER

PT J
AU Au, MT
   Ni, JG
   Tang, KM
   Wang, W
   Zhang, LL
   Wang, HT
   Zhao, FY
   Li, Z
   Luo, P
   Lau, LCM
   Chan, PK
   Luo, CT
   Zhou, B
   Zhu, L
   Zhang, CY
   Jiang, TS
   Lauwers, M
   Chan, JFW
   Yuan, SF
   Wen, CY
AF Au, Man Ting
   Ni, Junguo
   Tang, Kaiming
   Wang, Wei
   Zhang, Lanlan
   Wang, Hantang
   Zhao, Fangyi
   Li, Zhan
   Luo, Peng
   Lau, Lawrence Chun Man
   Chan, Ping Keung
   Luo, Cuiting
   Zhou, Bo
   Zhu, Lin
   Zhang, Charlie Yuli
   Jiang, Tianshu
   Lauwers, Marianne
   Chan, Jasper Fuk Woo
   Yuan, Shuofeng
   Wen, Chunyi
TI Blockade of endothelin receptors mitigates SARS CoV 2 induced
   osteoarthritis
SO NATURE MICROBIOLOGY
LA English
DT Article
ID POSTTRAUMATIC OSTEOARTHRITIS; CARTILAGE; RAT; INFECTION; BONE
AB Joint pain and osteoarthritis can occur as coronavirus disease 2019 (COVID 19) sequelae after infection. However, little is known about the damage to articular cartilage. Here we illustrate knee joint damage after wild type, Delta and Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) infection in vivo. Rapid joint injury with cystic lesions at the osteochondral junction was observed in two patients with post COVID osteoarthritis and recapitulated in a golden Syrian hamster model. SARS CoV 2 activated endothelin 1 signalling increased vascular permeability and caused viral spike proteins leakage into the subchondral bone. Osteoclast activation, chondrocyte dropout and cyst formation were confirmed histologically. The US Food and Drug Administration approved endothelin receptor antagonist, macitentan, mitigated cystic lesions and preserved chondrocyte number in the acute phase of viral infection in hamsters. Delayed macitentan treatment at post acute infection phase alleviated chondrocyte senescence and restored subchondral bone loss. It is worth noting that it could also attenuate viral spike induced joint pain. Our work suggests endothelin receptor blockade as a novel therapeutic strategy for post COVID arthritis.
   Endothelin 1 activation after SARS CoV 2 infection leads to vascular permeability, chondrocyte senescence, osteoclast activation and cyst formation in affected joints of hamsters, which can be alleviated using macitentan. Joint injury was also seen in two patients after COVID 19 infection.
C1 [Au, Man Ting; Ni, Junguo; Wang, Wei; Zhang, Lanlan; Wang, Hantang; Zhao, Fangyi; Li, Zhan; Zhang, Charlie Yuli; Jiang, Tianshu; Lauwers, Marianne; Wen, Chunyi] Hong Kong Polytech Univ, Dept Biomed Engn, Hong Kong, Peoples R China.
   [Tang, Kaiming; Luo, Peng; Luo, Cuiting; Chan, Jasper Fuk Woo; Yuan, Shuofeng] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Microbiol,State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.
   [Lau, Lawrence Chun Man; Chan, Ping Keung] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
   [Zhou, Bo] Southern Univ Sci & Technol, Dept Biochem, Sch Med, Shenzhen, Peoples R China.
   [Zhu, Lin] Hong Kong Baptist Univ, State Key Lab Environm & Biol Anal, Hong Kong, Peoples R China.
   [Chan, Jasper Fuk Woo; Yuan, Shuofeng] Univ Hong Kong, Shenzhen Hosp, Dept Infect Dis & Microbiol, Shenzhen, Peoples R China.
   [Chan, Jasper Fuk Woo; Yuan, Shuofeng] Ctr Virol Vaccinol & Therapeut, Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China.
   [Wen, Chunyi] Hong Kong Polytech Univ, Res Inst Smart Ageing, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University; University of Hong Kong; University of
   Hong Kong; Southern University of Science & Technology; Hong Kong
   Baptist University; University of Hong Kong; Hong Kong Polytechnic
   University
RP Wen, CY (通讯作者)，Hong Kong Polytech Univ, Dept Biomed Engn, Hong Kong, Peoples R China.; Yuan, SF (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Microbiol,State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China.; Yuan, SF (通讯作者)，Univ Hong Kong, Shenzhen Hosp, Dept Infect Dis & Microbiol, Shenzhen, Peoples R China.; Yuan, SF (通讯作者)，Ctr Virol Vaccinol & Therapeut, Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China.; Wen, CY (通讯作者)，Hong Kong Polytech Univ, Res Inst Smart Ageing, Hong Kong, Peoples R China.
EM yuansf@hku.hk; chunyi.wen@polyu.edu.hk
RI Zhao, Fangyi/MEQ 2940 2025; Yuan, Shuofeng/AEI 9788 2022; Lau, Lawrence
   Chun Man/AAJ 4908 2020; Zhu, Lin/ADP 1657 2022; Zhang,
   Lanlan/HJA 9960 2022; ZHOU, Bo/NMK 1785 2025; Lau, Lawrence
   C.M./AAJ 4908 2020; Luo, Peng/C 5323 2017; Luo, Peng/I 4790 2019; CHAN,
   Ping Keung/KXR 7531 2024
OI Jiang, Tianshu/0000 0003 1128 0450; Lauwers,
   Marianne/0000 0002 7034 7881; Zhu, Lin/0000 0002 2801 3626; Lau,
   Lawrence Chun Man/0000 0002 2245 9627; Wang, Wei/0000 0001 8487 444X;
   Tang, Kaiming/0000 0001 7310 6744; Luo, Peng/0000 0002 8215 2045; Yuan,
   Shuofeng/0000 0001 7996 1119; Au, Man Ting/0000 0003 1786 6006; 
FU Food and Health Bureau of the Government of the Hong Kong Special
   Administrative Region | Health and Medical Research Fund (HMRF)
   [16172691, 07210107]; Health and Medical Research Fund; Food and Health
   Bureau, The Government of the Hong Kong Special Administrative Region
   [151061/20M, PolyU15100821M, 15100324, C7060 21G, T11 709/21 N]; General
   Research Fund (PolyU); Research Grants Council of the Hong Kong Special
   Administrative Region; National Natural Science Foundation of China
   (NSFC) [N_PolyU 520/20, N_HKU767/22, MHP/011/20]; Research Grants
   Council (RGC); Hong Kong Polytechnic University (HKPU) Project of
   Strategic Importance (ZE2C); Innovation and Technology Commission
   [2021YFC0866100, 2023YFC3041600, 32322087, 32300134]; National Key
   Research and Development Program of China [I2022A006]; PolyU SZRI Seed
   Fund
FX This work was supported by Health and Medical Research Fund (16172691#
   to C.W. and 07210107# to S.Y.), the Food and Health Bureau, The
   Government of the Hong Kong Special Administrative Region; General
   Research Fund (PolyU 151061/20M, PolyU15100821M, 15100324 to C.W.),
   Collaborative Research Fund (C7060 21G and C7002 23Y to S.Y.) and
   Theme Based Research Scheme (T11 709/21 N to S.Y.), the Research Grants
   Council of the Hong Kong Special Administrative Region; The National
   Natural Science Foundation of China (NSFC) and the Research Grants
   Council (RGC) (NFSC/RGC) schemes (N_PolyU 520/20 to C.W. and N_HKU767/22
   to S.Y.); The Innovation and Technology Fund Mainland Hong Kong Joint
   Funding Scheme (ITF MHKJFS) (MHP/011/20 to C.W.); the Hong Kong
   Polytechnic University (HKPU) Project of Strategic Importance (ZE2C to
   C.W.); Health@InnoHK, Innovation and Technology Commission, the
   Government of the Hong Kong Special Administrative Region; National Key
   Research and Development Program of China (2021YFC0866100 and
   2023YFC3041600 to S.Y.); National Natural Science Foundation of China
   (32322087 and 32300134 to S.Y.); and PolyU SZRI Seed Fund (I2022A006 to
   C.W.). We thank D. Chan from the HKU, L. Rong from Sun Yat Sen
   University and M. Yang from the HKPU for the cell lines used in this
   study. We also thank E. Lau and M. Yuen from the University Research
   Facility in Life Sciences of the HKPU for providing technical support of
   micro MRI scanning and high resolution microscopy. We likewise thank J.
   Liu and Y. Zhang from the Department of Biomedical Engineering of HKPU
   for providing imaging assistance for micro MRI and mu CT scanning.
CR Abraham GR, 2022, J MOL CELL CARDIOL, V167, P92, DOI 10.1016/j.yjmcc.2022.03.007
   Atar MÖ, 2019, J BACK MUSCULOSKELET, V32, P549, DOI 10.3233/BMR 181326
   Au M, 2020, OSTEOARTHR CARTILAGE, V28, P1559, DOI 10.1016/j.joca.2020.08.006
   Bonin RP, 2014, MOL PAIN, V10, DOI 10.1186/1744 8069 10 26
   Bussani R, 2023, J PATHOL, V259, P254, DOI 10.1002/path.6035
   Camell CD, 2021, SCIENCE, V373, DOI 10.1126/science.abe4832
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140 6736(20)30154 9
   Chen WQ, 2014, P NATL ACAD SCI USA, V111, P6040, DOI 10.1073/pnas.1318859111
   Chu H, 2020, LANCET MICROBE, V1, pE14, DOI 10.1016/S2666 5247(20)30004 5
   De Melo JD, 1998, PAIN, V77, P261, DOI 10.1016/S0304 3959(98)00098 0
   De Melo JD, 1998, J CARDIOVASC PHARM, V31, pS518, DOI 10.1097/00005344 199800001 00149
   Dupont A, 2021, ARTERIOSCL THROM VAS, V41, P1760, DOI 10.1161/ATVBAHA.120.315595
   Evangelou K, 2022, EUR RESPIR J, V60, DOI 10.1183/13993003.02951 2021
   Gioia U, 2023, NAT CELL BIOL, V25, P550, DOI 10.1038/s41556 023 01096 x
   Hayer S, 2021, ANN RHEUM DIS, V80, P714, DOI 10.1136/annrheumdis 2020 219247
   Hirosue A, 2012, AGING CELL, V11, P553, DOI 10.1111/j.1474 9726.2012.00809.x
   Honge BL, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr 2020 241375
   Hoong CWS, 2021, INT J INFECT DIS, V104, P363, DOI 10.1016/j.ijid.2021.01.031
   Imhof AK, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3372
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Joo YB, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1977 9
   Kaufman GN, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3338
   Kerschan Schindl K, 2023, J BONE MINER RES, V38, P943, DOI 10.1002/jbmr.4822
   Khodorova A, 2009, J PAIN, V10, P4, DOI 10.1016/j.jpain.2008.09.009
   Kikinis R., 2014, Intraoperative Imaging and Image Guided Therapy, P277, DOI DOI 10.1007/978 1 4614 7657 319
   Kocyigit BF, 2021, RHEUMATOL INT, V41, P2031, DOI 10.1007/s00296 021 04998 x
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475
   Kuschner Z, 2021, JACEP OPEN, V2, DOI 10.1002/emp2.12452
   Lampsas S, 2022, CURR MED CHEM, V29, P3790, DOI 10.2174/0929867328666211026124033
   Lee S, 2021, NATURE, V599, P283, DOI 10.1038/s41586 021 03995 1
   Lei YY, 2021, CIRC RES, V128, P1323, DOI 10.1161/CIRCRESAHA.121.318902
   Lopez Leon S, 2021, SCI REP UK, V11, DOI [10.21203/rs.3.rs 266574/v1, 10.1038/s41598 021 95565 8, 10.1101/2021.01.27.21250617]
   Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 161
   Ma CH, 2015, BRAZ J MED BIOL RES, V48, P863, DOI 10.1590/1414 431X20154407
   Méndez R, 2022, THORAX, V77, P400, DOI 10.1136/thoraxjnl 2020 216797
   Mi BB, 2021, INT J BIOL SCI, V17, P1277, DOI 10.7150/ijbs.56657
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976 0105.177703
   Ono K, 2020, RMD OPEN, V6, DOI 10.1136/rmdopen 2020 001350
   Patterson BK, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.746021
   Qiao W, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30195 w
   Queiroz CM Jr, 2023, LIFE SCI, V324, DOI 10.1016/j.lfs.2023.121750
   Roy Beaudry M, 2003, ARTHRITIS RHEUM, V48, P2855, DOI 10.1002/art.11247
   Siva C, 2003, AM FAM PHYSICIAN, V68, P83
   Slouma M, 2023, INFECTION, V51, P37, DOI 10.1007/s15010 022 01858 z
   Son K., 2023, EUR RESPIR J, V61, DOI [DOI 10.1183/13993003.00970 2022, 10.4209/aaqr.2017.08.0288]
   Stein SR, 2022, NATURE, V612, P758, DOI 10.1038/s41586 022 05542 y
   Swank Z, 2023, CLIN INFECT DIS, V76, pE487, DOI 10.1093/cid/ciac722
   Taha SI, 2021, EUR CYTOKINE NETW, V32, P83, DOI 10.1684/ecn.2021.0471
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473 3099(20)30196 1
   Willems LH, 2022, THROMB RES, V209, P106, DOI 10.1016/j.thromres.2021.11.027
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan SF, 2022, SCIENCE, V377, P428, DOI 10.1126/science.abn8939
   Yuan SF, 2020, NAT MICROBIOL, V5, P1439, DOI 10.1038/s41564 020 00802 x
   Zhao Z, 2016, J INVEST MED, V64, P872, DOI 10.1136/jim 2015 000030
NR 54
TC 1
Z9 1
U1 3
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2058 5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
PD OCT
PY 2024
VL 9
IS 10
DI 10.1038/s41564 024 01802 x
EA SEP 2024
PG 28
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA H9U7Q
UT WOS:001310046300001
PM 39261580
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Hawkey, A
AF Hawkey, Adam
TI Low magnitude, high frequency signals could reduce bone loss during
   spaceflight
SO JBIS JOURNAL OF THE BRITISH INTERPLANETARY SOCIETY
LA English
DT Article
DE bone loss; vibration; exercise; microgravity; human spaceflight
ID VIBRATION; DEMINERALIZATION; OSTEOCLAST; STRENGTH; CHILDREN; DENSITY;
   WOMEN; HIP
AB The removal of gravitational loading results in a loss of homeostasis of the skeleton. This leads to significant losses of bone mass during long duration missions in space. Conventional exercise countermeasures, such as running and resistance training, have only limited effectiveness in reducing the rate at which bone is demineralised in microgravity. Bone loss, therefore, remains a major concern and if not annulled could be so severe as to jeopardise an extended human presence in space. In addition, current exercise regimes occupy valuable crew time, and astronauts often find the equipment cumbersome and uncomfortable to use. Recent studies suggest that exposing the body to short periods (<20mins) of low magnitude (<1g), high frequency (15 35Hz) signals (vibration) everyday could reduce, even prevent, bone loss during conditions such as osteoporosis on earth. The new vibration therapy treatment could also have several advantages over existing exercise countermeasures used in spaceflight due to it being very simple to operate, relatively inexpensive, and requiring only short periods of time 'training', unlike the complicated, expensive and time consuming devices currently used. This review highlights the detrimental effects that microgravity has on the strength and integrity of bone, how current countermeasures are ineffective at stemming this level of deterioration, and how new vibration techniques could significantly reduce space induced bone loss.
C1 Wolverhampton Univ, Res Ctr Sport Exercise & Performance, Walsall WS1 3BD, W Midlands, England.
C3 University of Wolverhampton
RP Hawkey, A (通讯作者)，Wolverhampton Univ, Res Ctr Sport Exercise & Performance, Gorway Rd, Walsall WS1 3BD, W Midlands, England.
CR Anderson M., 2002, KARGER GAZETTE, V65, P3
   Burger H, 1998, AM J EPIDEMIOL, V147, P871, DOI 10.1093/oxfordjournals.aje.a009541
   BW M D., 1960, AM J PHYS MED REHAB, V39, P219, DOI [10.1097/00002060 196012000 00001, DOI 10.1097/00002060 196012000 00001]
   CANN CE, 1990, TM102254 NASA
   Cardinale M, 2003, EXERC SPORT SCI REV, V31, P3, DOI 10.1097/00003677 200301000 00002
   DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003 4819 108 6 824
   Delecluse C, 2003, MED SCI SPORT EXER, V35, P1033, DOI 10.1249/01.MSS.0000069752.96438.B0
   Fewtrell MS, 2003, ARCH DIS CHILD, V88, P795, DOI 10.1136/adc.88.9.795
   Flieger J, 1998, CALCIFIED TISSUE INT, V63, P510, DOI 10.1007/s002239900566
   GRANTHAM N, 2006, SPORTS INJURY B
   Grigoriev A I, 1991, Physiologist, V34, pS44
   Hawkey A, 2003, INTERDISCIPL SCI REV, V28, P130, DOI 10.1179/030801803225010377
   Hawkey A, 2003, JBIS J BRIT INTERPLA, V56, P152
   HAWKEY A, 2006, SPACEFLIGHT, V48, P260
   HAWKEY A, 2004, P BUPA HLTH ADV C LO
   HAWKEY A, 2002, SPACEFLIGHT, V44, P44
   HAWKEY A, 2006, SPORT EXERCISE SCI, V3, P28
   HAWKEY A, 2006, BIOLIGST, V53, P183
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   ITUKCHEEWANONT P, 2005, P 84 M END SOC, V2, P49
   Johnston R., 1977, BIOMEDICAL RESULTS S
   KRIKALEV S, 2003, INTERDISCIPLINARY SC, V28, P135
   Lang T, 2004, J BONE MINER RES, V19, P1006, DOI 10.1359/JBMR.040307
   LeBlanc A., 2000, Journal of Musculoskeletal & Neuronal Interactions, V1, P157
   LOOKER AC, 1995, J BONE MINER RES, V10, P796
   MACK PB, 1967, AM J CLIN NUTR, V20, P1194, DOI 10.1093/ajcn/20.11.1194
   MACK PB, 1967, AMER J ROENTGENOL RA, V100, P503, DOI 10.2214/ajr.100.3.503
   Marx J, 2004, SCIENCE, V305, P1420, DOI 10.1126/science.305.5689.1420
   *NASA, 1966, SP121 NASA
   Osborn MJ, 1998, STRATEGY RES SPACE B
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   POLYAKOV VV, 2003, INTERDISCIPLINARY SC, V28, P135
   Rambaut PC., 1975, BIOMEDICAL RESULTS A, P303
   Rice AJ, 2004, J BONE MINER RES, V19, pS95
   RITTWEGER J, 2004, P AM SOC BON MIN RES
   RITTWEGER J, 2005, INT J SPORTS MED, V10, P1055
   Ronnestad BR, 2004, J STRENGTH COND RES, V18, P839
   Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01 0166com
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Rubin C, 2004, J BONE MINER RES, V19, P343, DOI 10.1359/JBMR.0301251
   SALMON A, 2000, HIST MIR 1986 2000, P52
   Turner RT, 2000, J APPL PHYSIOL, V89, P840, DOI 10.1152/jappl.2000.89.2.840
   Verschueren SMP, 2004, J BONE MINER RES, V19, P352, DOI 10.1359/JBMR.0301245
   VOSE GP, 1974, AM J ROENTGENOL, V121, P1
   Ward K, 2004, J BONE MINER RES, V19, P360, DOI 10.1359/JBMR.040129
   WHITEMAN T, 2007, J REGISTER EXERCISE, V8, P16
   *WHO, 1994, WHO TECHN REP SER, V843
   Zerath E, 1996, J APPL PHYSIOL, V81, P194, DOI 10.1152/jappl.1996.81.1.194
NR 48
TC 3
Z9 4
U1 0
U2 18
PU BRITISH INTERPLANETARY SOC
PI LONDON
PA 27 29 S LAMBETH RD, LONDON SW8 1SZ, ENGLAND
SN 0007 084X
J9 JBIS J BRIT INTERPLA
JI JBIS J. Br. Interplanet. Soc.
PD AUG
PY 2007
VL 60
IS 8
BP 278
EP 284
PG 7
WC Engineering, Aerospace; Astronomy & Astrophysics; Geosciences,
   Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Astronomy & Astrophysics; Geology
GA 188FZ
UT WOS:000247906200001
DA 2025 08 17
ER

PT J
AU Yang, Y
   Yu, T
   Tang, H
   Ren, ZH
   Li, QW
   Jia, J
   Chen, HY
   Fu, J
   Ding, SC
   Hao, Q
   Xu, D
   Song, LP
   Sun, B
   Sun, F
   Pei, J
AF Yang, Yong
   Yu, Tian
   Tang, Huan
   Ren, Zhihui
   Li, Qianwen
   Jia, Juan
   Chen, Hongyu
   Fu, Jun
   Ding, Shengchen
   Hao, Qiang
   Xu, Dan
   Song, Liping
   Sun, Bo
   Sun, Fei
   Pei, Jin
TI Ganoderma lucidum Immune Modulator Protein rLZ 8 Could Prevent
   and Reverse Bone Loss in Glucocorticoids Induced Osteoporosis Rat Model
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE rLZ 8; Ganoderma lucidum; osteoporosis; dexamethasone;
   glucocorticoids induced osteoporosis (GIOP)
ID LING ZHI 8; IMMUNOMODULATORY PROTEIN; LZ 8; MECHANISMS
AB Immune modulation has been recognized as an effective anti osteoporosis strategy since the pivotal role of the RANK/RANKL/OPG signaling in bone metabolism and remodeling was discovered. To investigate the potential preventive and/or therapeutic effects of immune modulator protein Ling Zhi 8 (LZ 8) on osteoporosis, the osteoporosis animal model was established in Wistar rats by intramuscular injection of dexamethasone (DEX), namely glucocorticoids induced osteoporosis (GIOP) rat model. To investigate the potential preventive effect of rLZ 8 on GIOP, we co treated the rats with DEX and rLZ 8 intraperitoneally during the GIOP modeling stage and analyze the bone mass measured by bone mineral content (BMC) and bone mineral density (BMD), as well as levels of phosphorus (Pi), calcium (Ca2+) and hydroxyproline (HOP) in femur of GIOP rats. Consistently, all results suggested that rLZ 8 could prevent bone loss in the femurs of GIOP rats. Through analyzing the trabeculae morphology and the trabeculae amount by H&E staining, we found rLZ 8 could also improve the structural deterioration in femurs of GIOP rats. In order to further verify the results and its mechanism obtained from bone analysis, multiple biomarkers, including minerals metabolism (Pi and Ca2+), bone formation markers (osteocalcin, ALP and IGF 1), bone resorption markers (TRACP5b, CTX 1 and HOP), cytokines (IL 1 beta, IL 6 and TNF alpha), oxidative stress indicators (GSH px, SOD and MDA) and hormone molecules (testosterone, estradiol, calcitonin and parathyroid hormone) have been detected in serum or urine of rats. Results of these biomarkers in serum or urine confirmed rLZ 8's protective effect in GIOP. Through analyzing the relative expression level of OPG and RANKL in femurs via western blot, we foundrLZ 8 could increase OPG/RANKL ratio which could impede osteoclastogenesis process. To test the potential therapeutic effect of rLZ 8 on successfully generated GIOP rats, we administrated rLZ 8 to rats for three weeks starting from the ending day of 7 weeks treatment of DEX. We found rLZ 8 could also reverse the bone loss in GIOP rats. Through the BWs and organ coefficient analysis, we found rLZ 8 has little toxicity to the rats. Our results suggested that rLZ 8 may be developed into promising anti osteoporosis drug with both preventive and therapeutic properties.
C1 [Yang, Yong; Yu, Tian; Tang, Huan; Ren, Zhihui; Li, Qianwen; Jia, Juan; Chen, Hongyu; Fu, Jun; Ding, Shengchen; Hao, Qiang; Xu, Dan; Song, Liping; Sun, Bo; Sun, Fei; Pei, Jin] Jilin Univ, Sch Pharmaceut Sci, Changchun, Peoples R China.
C3 Jilin University
RP Pei, J (通讯作者)，Jilin Univ, Sch Pharmaceut Sci, Changchun, Peoples R China.
EM peijin@jlu.edu.cn
RI tang, huan/LTZ 5374 2024; jia, jia/JKJ 5720 2023; Yang,
   Yong/LBZ 9282 2024; chen, hongyu/HHS 4314 2022
OI Yang, Yong/0000 0003 4115 0008; 
FU Science and Technology Development Project form Jilin Science and
   Technology Department [2018 0311072YY]; Jilin Province Development and
   Reform Commission [2014N149]; Jilin University [419080600013]
FX This research was funded by the Science and Technology Development
   Project form Jilin Science and Technology Department (2018 0311072YY),
   and Jilin Province Development and Reform Commission (2014N149). This
   research was also supported by Jilin University (Grant number
   419080600013).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Bonani M, 2017, TRANSPLANTATION, V101, P2139, DOI 10.1097/TP.0000000000001547
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Cör D, 2018, MOLECULES, V23, DOI 10.3390/molecules23030649
   Gillet C, 2017, ENDOCRINOLOGY, V158, P490, DOI 10.1210/en.2016 1687
   Guder C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00058
   HAAKFRENDSCHO M, 1993, CELL IMMUNOL, V150, P101, DOI 10.1006/cimm.1993.1182
   Hsu HY., 2013, Evid Based Complement Alternat Med, V2013, P513542, DOI DOI 10.1155/2013/513542
   Huang L, 2009, PROTEINS, V75, P524, DOI 10.1002/prot.22346
   KINO K, 1989, J BIOL CHEM, V264, P472
   Liang CY, 2012, ONCOL REP, V27, P1079, DOI 10.3892/or.2011.1593
   Liang Chongyang, 2009, Sheng Wu Gong Cheng Xue Bao, V25, P441
   Lin HJ, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/916531
   Lin TY, 2016, CANCER LETT, V375, P340, DOI 10.1016/j.canlet.2016.03.018
   Lin YL, 2009, J LEUKOCYTE BIOL, V86, P877, DOI 10.1189/jlb.0708441
   Liu MJ, 2011, J TRADIT CHIN MED, V31, P98, DOI 10.1016/S0254 6272(11)60020 4
   Lorentzon M, 2019, J INTERN MED, V285, P381, DOI 10.1111/joim.12873
   Loyd AL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01557
   Miyamoto I, 2009, EUR J PHARMACOL, V602, P1, DOI 10.1016/j.ejphar.2008.11.005
   Peugh J, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10176
   Tran PT, 2019, PHYTOMEDICINE, V55, P1, DOI 10.1016/j.phymed.2018.10.029
   Rizzoli R, 2015, NAT REV RHEUMATOL, V11, P98, DOI 10.1038/nrrheum.2014.188
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Takahashi M, 2010, LIFE SCI, V86, P24, DOI 10.1016/j.lfs.2009.10.020
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Vandewalle J, 2018, TRENDS ENDOCRIN MET, V29, P42, DOI 10.1016/j.tem.2017.10.010
   Wang TT, 2019, CURR DRUG TARGETS, V20, P1, DOI 10.2174/1389450119666180405094046
   Wheater G, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 201
   Wu CT, 2011, CARCINOGENESIS, V32, P1890, DOI 10.1093/carcin/bgr221
   Wu JR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114495
   Xue Q, 2008, J GEN APPL MICROBIOL, V54, P393, DOI 10.2323/jgam.54.393
NR 32
TC 22
Z9 23
U1 2
U2 30
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 19
PY 2020
VL 11
AR 731
DI 10.3389/fphar.2020.00731
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LW1IM
UT WOS:000538899200001
PM 32508652
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tsai, CH
   Liu, SC
   Chung, WH
   Wang, SW
   Wu, MH
   Tang, CH
AF Tsai, Chun Hao
   Liu, Shan Chi
   Chung, Wen Hui
   Wang, Shih Wei
   Wu, Min Huan
   Tang, Chih Hsin
TI Visfatin Increases VEGF Dependent Angiogenesis of Endothelial Progenitor
   Cells during Osteoarthritis Progression
SO CELLS
LA English
DT Article
DE osteoarthritis; visfatin; VEGF; miR 485 5p; angiogenesis
ID PROMOTES ANGIOGENESIS; IN VITRO; BONE; EXPRESSION; CARTILAGE;
   INFLAMMATION; OSTEOBLASTS; RESISTIN; THERAPY; TISSUE
AB Osteoarthritis (OA) pannus contains a network of neovascularization that is formed and maintained by angiogenesis, which is promoted by vascular endothelial growth factor (VEGF). Bone marrow derived endothelial progenitor cells (EPCs) are involved in VEGF induced vessel formation in OA. The adipokine visfatin stimulates the release of inflammatory cytokines during OA progression. In this study, we found significantly higher visfatin and VEGF serum concentrations in patients with OA compared with healthy controls. We describe how visfatin enhanced VEGF expression in human OA synovial fibroblasts (OASFs) and facilitated EPC migration and tube formation. Treatment of OASFs with PI3K and Akt inhibitors or siRNAs attenuated the effects of visfatin on VEGF synthesis and EPC angiogenesis. We also describe how miR 485 5p negatively regulated visfatin induced promotion of VEGF expression and EPC angiogenesis. In our OA rat model, visfatin shRNA was capable of inhibiting visfatin and rescuing EPC angiogenesis and pathologic changes. We detail how visfatin affected VEGF expression and EPC angiogenesis in OASFs by inhibiting miR 485 5p synthesis through the PI3K and Akt signaling pathways.
C1 [Tsai, Chun Hao] China Med Univ, Dept Sports Med, Coll Hlth Care, Taichung 404, Taiwan.
   [Tsai, Chun Hao] China Med Univ Hosp, Dept Orthoped Surg, Taichung 404, Taiwan.
   [Liu, Shan Chi] China Med Univ, Beigang Hosp, Dept Med Educ & Res, Touliu 651, Yunlin, Taiwan.
   [Chung, Wen Hui; Tang, Chih Hsin] China Med Univ, Sch Med, Dept Pharmacol, Taichung 404, Taiwan.
   [Wang, Shih Wei] Mackay Med Coll, Dept Med, New Taipei 252, Taiwan.
   [Wang, Shih Wei] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung 807, Taiwan.
   [Wu, Min Huan] Tunghai Univ, Phys Educ Off, Taichung 407, Taiwan.
   [Wu, Min Huan] Tunghai Univ, Sports Recreat & Hlth Management Continuing Studi, Taichung 807, Taiwan.
   [Tang, Chih Hsin] China Med Univ, Chinese Med Res Ctr, Taichung 404, Taiwan.
   [Tang, Chih Hsin] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung 41354, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital   Taiwan; China Medical University Taiwan;
   China Medical University Taiwan; Mackay Medical University; Kaohsiung
   Medical University; Tunghai University; Tunghai University; China
   Medical University Taiwan; Asia University Taiwan
RP Tang, CH (通讯作者)，China Med Univ, Sch Med, Dept Pharmacol, Taichung 404, Taiwan.; Wu, MH (通讯作者)，Tunghai Univ, Phys Educ Off, Taichung 407, Taiwan.; Wu, MH (通讯作者)，Tunghai Univ, Sports Recreat & Hlth Management Continuing Studi, Taichung 807, Taiwan.; Tang, CH (通讯作者)，China Med Univ, Chinese Med Res Ctr, Taichung 404, Taiwan.; Tang, CH (通讯作者)，Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung 41354, Taiwan.
EM ritsai8615@gmail.com; sdsaw.tw@yahoo.com.tw; sandy780717@gmail.com;
   shihwei@mmc.edu.tw; mhwu@thu.edu.tw; chtang@mail.cmu.edu.tw
RI 吳, 旻寰/ABG 2574 2020; Tang, Chih/O 5212 2015; Tsai, Chun Hao/H 3140 2013;
   Tang, Chih Hsin/O 5212 2015; Wang, Shih Wei/AAH 1967 2020
OI Wang, Shih Wei/0000 0001 7522 6352; Tsai, Chun Hao/0000 0002 4428 3132;
   Tang, Chih Hsin/0000 0002 7113 8352; 
FU Taiwan's Ministry of Science and Technology [MOST 108 2320 B 039 026 ,
   MOST 108 2320 B 039 064]; China Medical University [CMU 108 MF 66];
   China Medical University Hospital [DMR 109 159]
FX This study was supported by grants from Taiwan's Ministry of Science and
   Technology (MOST 108 2320 B 039 026 ; MOST 108 2320 B 039 064); China
   Medical University (CMU 108 MF 66) and China Medical University Hospital
   (DMR 109 159).
CR Al Modawi RN, 2019, MOL THER NUCL ACIDS, V17, P776, DOI 10.1016/j.omtn.2019.07.011
   Ammendola M, 2015, CURR STEM CELL RES T, V10, P181, DOI 10.2174/1574888X10666141126113622
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Benito MJ, 2005, ANN RHEUM DIS, V64, P1263, DOI 10.1136/ard.2004.025270
   Chen CY, 2017, J BONE MINER RES, V32, P34, DOI 10.1002/jbmr.2926
   Chen PC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133300
   Chen SS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1241 2
   Dehghan M, 2019, BIOMEDICINE TAIWAN, V9, P13, DOI 10.1051/bmdcn/2019090209
   Fioravanti A, 2015, INT J BIOMETEOROL, V59, P783, DOI 10.1007/s00484 014 0894 5
   Gao B, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0892 3
   Hamilton JL, 2016, J BONE MINER RES, V31, P911, DOI 10.1002/jbmr.2828
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Kiewisz J, 2016, ACTA BIOCHIM POL, V63, P475, DOI 10.18388/abp.2016_1284
   Kuo SJ, 2019, AGING US, V11, P4075, DOI 10.18632/aging.102038
   Kuo SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176052
   Lee HP, 2020, FOOD AGR IMMUNOL, V31, P193, DOI 10.1080/09540105.2020.1713055
   Lee HP, 2019, FOOD AGR IMMUNOL, V30, P1033, DOI 10.1080/09540105.2019.1660623
   Lee HP, 2019, J FUNCT FOODS, V52, P537, DOI 10.1016/j.jff.2018.11.040
   Li TM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050920
   Liao L, 2016, J BONE MINER METAB, V34, P485, DOI 10.1007/s00774 016 0743 1
   Liu JF, 2018, BIOCHEM PHARMACOL, V155, P537, DOI 10.1016/j.bcp.2018.07.024
   Liu SC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.453
   Liu SC, 2019, FOOD AGR IMMUNOL, V30, P620, DOI 10.1080/09540105.2019.1611745
   MacDonald IJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061505
   MacDonald IJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072012
   Mathiessen A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1229 9
   Nugent M, 2016, OSTEOARTHR CARTILAGE, V24, P573, DOI 10.1016/j.joca.2015.10.018
   Patel J, 2016, STEM CELL TRANSL MED, V5, P1302, DOI 10.5966/sctm.2016 0066
   Peplow PV, 2014, GROWTH FACTORS, V32, P83, DOI 10.3109/08977194.2014.904300
   Samakova A, 2019, PHYSIOL RES, V68, pS131, DOI 10.33549/physiolres.934345
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Su CM, 2018, BIOCHEM PHARMACOL, V154, P234, DOI 10.1016/j.bcp.2018.05.001
   Su CM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07952 9
   Su CM, 2015, J IMMUNOL, V195, P3355, DOI 10.4049/jimmunol.1403191
   Su CM, 2015, STEM CELLS, V33, P2243, DOI 10.1002/stem.2024
   Taipaleenmäki H, 2018, CURR OSTEOPOROS REP, V16, P1, DOI 10.1007/s11914 018 0417 0
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Tong KM, 2011, J CELL BIOCHEM, V112, P1431, DOI 10.1002/jcb.23059
   Tzeng HE, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1008 9
   Wang CQ, 2017, CANCER LETT, V385, P261, DOI 10.1016/j.canlet.2016.10.010
   Wang CJ, 2017, INT J MED SCI, V14, P213, DOI 10.7150/ijms.17469
   Wang MF, 2019, BIOCHEM PHARMACOL, V166, P23, DOI 10.1016/j.bcp.2019.05.005
   Wang SW, 2015, CARCINOGENESIS, V36, P104, DOI 10.1093/carcin/bgu218
   Wu KM, 2019, NUTR METAB, V16, DOI 10.1186/s12986 019 0356 5
   Wu MH, 2014, ONCOGENE, V33, P1725, DOI 10.1038/onc.2013.109
   Wu MH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010190
   Wu TJ, 2018, ENVIRON TOXICOL, V33, P1061, DOI 10.1002/tox.22618
   Xu ZY, 2018, INT J BIOL MACROMOL, V111, P440, DOI 10.1016/j.ijbiomac.2018.01.054
   Yang YC, 2019, ENVIRON TOXICOL, V34, P203, DOI 10.1002/tox.22674
   Yuan XL, 2014, OSTEOARTHR CARTILAGE, V22, P1077, DOI 10.1016/j.joca.2014.05.023
NR 50
TC 33
Z9 36
U1 0
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD MAY
PY 2020
VL 9
IS 5
DI 10.3390/cells9051315
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LW7RF
UT WOS:000539340200249
PM 32466159
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Nair, RR
   Avila, H
   Ma, XJ
   Wang, ZX
   Lennartz, M
   Darnay, BG
   Boyd, DD
   Yan, CH
AF Nair, Rajesh R.
   Avila, Hector
   Ma, Xujun
   Wang, Zhengxin
   Lennartz, Michelle
   Darnay, Bryant G.
   Boyd, Douglas D.
   Yan, Chunhong
TI A novel high throughput screening system identifies a small molecule
   repressive for matrix metalloproteinase 9 expression
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID IV COLLAGENASE EXPRESSION; KAPPA B BINDING; PROSTATE CANCER;
   GENE EXPRESSION; MATRIX METALLOPROTEINASES; MULTIPLE MYELOMA;
   BONE DISEASE; CELL LINES; TRANSCRIPTION; THERAPY
AB Aberrant gene expression is one of the driving forces for cancer progression and is considered an ideal target for chemical intervention. Although emerging bioluminescence reporter systems allow high throughput searches for small molecules regulatory for gene expression, frequent silencing of reporter genes by epigenetic mechanisms hinders wide application of this drug discovery strategy. Here we report a novel system that directs the integration of a promoter reporter construct to an open chromosomal location by Flp mediated homologous recombination, thereby overcoming reporter gene silencing. Using this system, we have screened more than 8000 compounds in the DIVERSet chemical library for repressors of a matrix metalloproteinase 9 (MMP 9) promoter and identified 5 methyl 2 (4 methylphenyl) 1H benzimidazole (MPBD) inhibitory for MMP 9 gene expression. Consistent with this effect, MPBD inhibits MMP 9 dependent invasion of UMSCC 1 oral cancer cells, preosteoclast migration, and receptor activator of nuclear factor kappa B ligand induced osteoclast activity over concentration ranges that repressed MMP 9 expression. Mechanistic studies indicated that MPBD antagonizes AP 1 function by inhibiting its transactivation activity. We conclude that the Flp mediated homologous recombination system to direct reporter integration into open chromatin regions represents a novel strategy allowing for the development of high throughput systems screening for lead compounds targeting aberrant gene expression in cancer.
C1 [Ma, Xujun; Lennartz, Michelle; Yan, Chunhong] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA.
   [Nair, Rajesh R.; Avila, Hector; Wang, Zhengxin; Boyd, Douglas D.] Univ Texas MD Anderson Canc Ctr Houston, Dept Canc Biol, Houston, TX USA.
   [Darnay, Bryant G.] Univ Texas MD Anderson Canc Ctr Houston, Dept Expt Therapeut, Houston, TX USA.
C3 Albany Medical College; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; UTMD Anderson Cancer Center
RP Yan, CH (通讯作者)，Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave, Albany, NY 12208 USA.
EM yanc@mail.amc.edu
OI Yan, Chunhong/0000 0002 3974 7991
FU NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS
   [R01 DE10845] Funding Source: Medline
CR Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008 5472.CAN 05 2502
   Ash CS, 2000, HEAD NECK J SCI SPEC, V22, P794, DOI 10.1002/1097 0347(200012)22:8<794::AID HED8>3.0.CO;2 W
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025 06
   Briehn CA, 2003, CHEM EUR J, V9, P2110, DOI 10.1002/chem.200204689
   Brown JE, 2005, JNCI J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002
   Chenoweth DM, 2007, BIOORGAN MED CHEM, V15, P759, DOI 10.1016/j.bmc.2006.10.051
   Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100
   Dong Z, 2005, AM J PATHOL, V166, P1173, DOI 10.1016/S0002 9440(10)62337 1
   Dunstan CR, 2007, NAT CLIN PRACT ONCOL, V4, P42, DOI 10.1038/ncponc0688
   Fujimura T, 2005, J PHARMACOL SCI, V99, P342, DOI 10.1254/jphs.FP0050578
   Guise Theresa A, 2005, Clin Breast Cancer, V5 Suppl, pS46, DOI 10.3816/CBC.2005.s.004
   Hjertner O, 2005, CURR DRUG TARGETS, V6, P701, DOI 10.2174/1389450054863716
   Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100
   JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104
   Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496 5509.2004
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299
   Papavassiliou AG, 1998, MOL MED TODAY, V4, P358, DOI 10.1016/S1357 4310(98)01303 3
   Rangarajan M, 2000, BIOORGAN MED CHEM, V8, P2591, DOI 10.1016/S0968 0896(00)00188 7
   Rapisarda A, 2002, CANCER RES, V62, P4316
   Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407
   Shin M, 2002, BBA MOL CELL RES, V1589, P311, DOI 10.1016/S0167 4889(02)00195 7
   Shoemaker Robert H., 2002, Current Topics in Medicinal Chemistry, V2, P229, DOI 10.2174/1568026023394317
   SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328
   Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103
   Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546
   Van Valckenborgh E, 2004, AM J PATHOL, V165, P869, DOI 10.1016/S0002 9440(10)63349 4
   Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092 8674(00)81159 9
   Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103
   Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200
   Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03 0960fje
   Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948
   Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311 06
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 38
TC 18
Z9 23
U1 0
U2 7
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0026 895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD MAR
PY 2008
VL 73
IS 3
BP 919
EP 929
DI 10.1124/mol.107.042606
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 266OE
UT WOS:000253444900032
PM 18065684
DA 2025 08 17
ER

PT J
AU Akhtar, J
   Mallaredy, V
   Dandapat, J
   Maiti, P
   Sahoo, SK
   Singh, S
AF Akhtar, Jabed
   Mallaredy, Vandana
   Dandapat, Jagneshwar
   Maiti, Prasanta
   Sahoo, Sanjeeb K.
   Singh, Sujay
TI PEGylation of an osteoclast inhibitory peptide: Suitable
   candidate for the treatment of osteoporosis
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE TRAF 6 Inhibitory peptide; RANK; PEGylated peptide; Bioavailability
ID POLYETHYLENE GLYCOL; THERAPEUTIC PEPTIDES; SIGNAL TRANSDUCTION;
   BIODISTRIBUTION; DEFICIENCY; DENSITY; DRUGS; CELLS
AB Osteoporosis is a condition of bone loss due to excessive osteoclastic activity. Several protein factors, such as receptor activator of nuclear factor kappa B (RANK), receptor activator of nuclear factor kappa B ligand (RANKL), osteoprotegerin (OPG), have been identified that are important in the pathogenesis of osteoporosis. RANKL binds to RANK and activates the NF kappa B pathway by interaction of its cytoplasmic domain with an intracellular adapter protein, TNF receptor associated factors 6 (TRAF 6). This interaction can be inhibited by cell permeable peptides that prevent RANK TRAF 6 interaction. However, similar to the peptides/proteins used in clinical setting, the effective application of this TRAF 6 Inhibitory peptide as a therapeutic agent is marred by several limitations for instance short half life, rapid renal clearance and immunogenicity. In the present study, we have developed PEGylated TRAF 6 Inhibitory peptide by conjugating TRAF 6 Inhibitory peptide to linear PEG backbone that exhibits longer bioavailability in plasma in the animal model. Besides, it has an enhanced uptake at its site of action, i.e., bone marrow. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Sahoo, Sanjeeb K.] Inst Life Sci, Lab Nanomed, Bhubaneswar 751023, Odisha, India.
   [Akhtar, Jabed; Maiti, Prasanta; Singh, Sujay] IMGENEX India Pvt Ltd, Bhubaneswar, Odisha, India.
   [Dandapat, Jagneshwar] Utkal Univ, PG Dept Biotechnol, Bhubaneswar 751004, Orissa, India.
C3 Department of Biotechnology (DBT) India; Institute of Life Sciences
   India (ILS); Utkal University
RP Sahoo, SK (通讯作者)，Inst Life Sci, Lab Nanomed, Nalco Sq, Bhubaneswar 751023, Odisha, India.
EM sanjeebsahoo2005@gmail.com; ssingh@imgenex.com
RI ; Dandapat, Jagneshwar/AAQ 4708 2020; Mallaredy, Vandana/AAU 3000 2020;
   Sanjeeb, Sahoo/ABF 3419 2020
OI Sahoo, Sanjeeb/0000 0002 9096 6954; 
FU Department of Biotechnology, Government of India
   [BT/04(SBIRI)/48/2006 PID]
FX SKS and SS would like to thank the Department of Biotechnology,
   Government of India for providing Grant no. BT/04(SBIRI)/48/2006 PID.
   The first author is thankful to H.O.D. P.G. Department of Zoology, North
   Orissa University for his kind help and Mr. Susanta K. Behera, Mr.
   Biswajit Behera, Mr. Jajati Keshari Ray from IMGENEX India Pvt. Ltd. for
   helping in carrying out experiments in mice.
CR Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Darnay BG, 1999, ANN RHEUM DIS, V58, P2
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Delgado C, 1996, BRIT J CANCER, V73, P175, DOI 10.1038/bjc.1996.32
   EnoAmooquaye EA, 1996, BRIT J CANCER, V73, P1323, DOI 10.1038/bjc.1996.253
   Gaur U, 2000, INT J PHARM, V202, P1, DOI 10.1016/S0378 5173(99)00447 0
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100
   KATRE NV, 1987, P NATL ACAD SCI USA, V84, P1487, DOI 10.1073/pnas.84.6.1487
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   KURFURST MM, 1992, ANAL BIOCHEM, V200, P244, DOI 10.1016/0003 2697(92)90460 O
   Lien S, 2003, TRENDS BIOTECHNOL, V21, P556, DOI 10.1016/j.tibtech.2003.10.005
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   MAEDA H, 1992, BIOCONJUGATE CHEM, V3, P351, DOI 10.1021/bc00017a001
   McClung M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2167
   NIH Consensus Development Panel on Osteoporosis Prevention D and Therapy Conference CD, 2001, JAMA, V285, P785
   Parveen S, 2006, CLIN PHARMACOKINET, V45, P965, DOI 10.2165/00003088 200645100 00002
   Poblenz AT, 2007, BIOCHEM BIOPH RES CO, V359, P510, DOI 10.1016/j.bbrc.2007.05.151
   Sato AK, 2006, CURR OPIN BIOTECH, V17, P638, DOI 10.1016/j.copbio.2006.10.002
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Terauchi M, 2007, BMC CANCER, V7, DOI 10.1186/1471 2407 7 140
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359 6446(05)03575 0
   Veronese FM, 2009, MILESTONES DRUG THER, P1, DOI 10.1007/978 3 7643 8679 5
   Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142 9612(00)00193 9
   Veronese FM, 1999, FARMACO, V54, P497, DOI 10.1016/S0014 827X(99)00066 X
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   Weinstein RS, 1997, ENDOCRINOLOGY, V138, P4013, DOI 10.1210/en.138.9.4013
   Werle M, 2006, AMINO ACIDS, V30, P351, DOI 10.1007/s00726 005 0289 3
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
NR 30
TC 4
Z9 4
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD SEP 15
PY 2012
VL 434
IS 1 2
BP 429
EP 436
DI 10.1016/j.ijpharm.2012.06.012
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 975AQ
UT WOS:000306479400051
PM 22698865
DA 2025 08 17
ER

PT J
AU Herten, M
   Grassmann, JP
   Sager, M
   Benga, L
   Fischer, JC
   Jäger, M
   Betsch, M
   Wild, M
   Hakimi, M
   Jungbluth, P
AF Herten, M.
   Grassmann, J. P.
   Sager, M.
   Benga, L.
   Fischer, J. C.
   Jaeger, M.
   Betsch, M.
   Wild, M.
   Hakimi, M.
   Jungbluth, P.
TI Bone marrow concentrate for autologous transplantation in minipigs
   Characterization and osteogenic potential of mesenchymal stem cells
SO VETERINARY AND COMPARATIVE ORTHOPAEDICS AND TRAUMATOLOGY
LA English
DT Article
DE Mesenchymal stem cells; minipig; bone marrow concentrate; colony forming
   units
ID MONONUCLEAR CELLS; STROMAL CELLS; DIFFERENTIATION; PLATELETS; THERAPY
AB Autologous bone marrow plays an increasing role in the treatment of bone, cartilage and tendon healing disorders. Cell based therapies display promising results in the support of local regeneration, especially therapies using intra operative one step treatments with autologous progenitor cells. In the present study, bone marrow derived cells were concentrated in a point of care device and investigated for their mesenchymal stem cell (MSC) characteristics and their osteogenic potential.
   Bone marrow was harvested from the iliac crest of 16 minipigs. The mononucleated cells (MNC) were concentrated by gradient density centrifugation, cultivated, characterized by flow cytometry and stimulated into osteoblasts, adipocytes, and chondrocytes. Cell differentiation was investigated by histological and immunohistological staining of relevant lineage markers. The proliferation capacity was determined via colony forming units of fibroblast and of osteogenic alkaline phosphatase positive cells.
   The MNC could be enriched 3.5 fold in nucleated cell concentrate in comparison to bone marrow. Flow cytometry analysis revealed a positive signal for the MSC markers. Cells could be differentiated into the three lines confirming the MSC character. The cellular osteogenic potential correlated significantly with the percentage of newly formed bone in vivo in a porcine metaphyseal long bone defect model.
   This study demonstrates that bone marrow concentrate from minipigs display cells with, MSC character and their osteogenic differentiation potential can be used for osseous defect repair in autologous transplantations.
C1 [Herten, M.] Univ Dusseldorf, Univ Hosp, Dept Orthopaed, D 40225 Dusseldorf, Germany.
   [Grassmann, J. P.; Wild, M.; Hakimi, M.; Jungbluth, P.] Univ Dusseldorf, Univ Hosp, Dept Trauma & Hand Surg, D 40225 Dusseldorf, Germany.
   [Sager, M.; Benga, L.; Betsch, M.] Univ Dusseldorf, Univ Hosp, Cent Anim Res Facil, D 40225 Dusseldorf, Germany.
   [Fischer, J. C.] Univ Dusseldorf, Univ Hosp, Inst Transplantat Diagnost & Cell Therapeut, D 40225 Dusseldorf, Germany.
   [Jaeger, M.] Univ Duisburg Essen, Univ Hosp, Dept Orthopaed, Essen, Germany.
C3 Heinrich Heine University Dusseldorf; Heinrich Heine University
   Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine
   University Dusseldorf; University of Duisburg Essen
RP Grassmann, JP (通讯作者)，Univ Dusseldorf, Univ Hosp, Dept Trauma & Handsurg, Moorenstr 5, D 40225 Dusseldorf, Germany.
EM Jan.Grassmann@med.uni duesseldorf.de
RI Jungbluth, Pascal/L 6703 2017; Betsch, Marcel/IRZ 3828 2023; Fischer,
   Johannes/NDS 1544 2025; Benga, Laurentiu/X 9301 2019; Herten,
   Monika/J 1547 2015
OI Jager, Marcus/0000 0001 9516 1058; Fischer,
   Johannes/0000 0002 2079 1845; Wild, Michael/0000 0002 6306 4867; 
CR Agay D, 2010, EXP HEMATOL, V38, P945, DOI 10.1016/j.exphem.2010.06.008
   BENNETT JH, 1991, J CELL SCI, V99, P131
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   CASTROMALASPINA H, 1980, BLOOD, V56, P289
   Chang C, 2008, CYTOTHERAPY, V10, P796, DOI 10.1080/14653240802461924
   CONNOLLY JF, 1991, CLIN ORTHOP RELAT R, P259
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Hakimi M, 2010, INJURY, V41, P717, DOI 10.1016/j.injury.2009.12.005
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Hermann PC, 2007, CELL TRANSPLANT, V16, P1059, DOI 10.3727/000000007783472363
   Hernigou P, 2005, J BONE JOINT SURG AM, V87A, P1430, DOI 10.2106/JBJS.D.02215
   Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79
   Jäger M, 2010, ORTHOPADE, V39, P449, DOI [10.1007/s00132 009 1583 7, 10.4081/or.2010.e20]
   Jäger M, 2011, J ORTHOP RES, V29, P173, DOI 10.1002/jor.21230
   Janicki P, 2011, EUR CELLS MATER, V21, P488, DOI 10.22203/eCM.v021a37
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Jungbluth P, 2010, EUR J MED RES, V15, P196
   Jungbluth P, 2010, J ORTHOP RES, V28, P1448, DOI 10.1002/jor.21152
   Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood 2004 04 1488
   Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   Massberg S, 2006, J EXP MED, V203, P1221, DOI 10.1084/jem.20051772
   Muschler GF, 2001, J ORTHOP RES, V19, P117, DOI 10.1016/S0736 0266(00)00010 3
   OWEN ME, 1987, J CELL SCI, V87, P731
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Seeger FH, 2007, EUR HEART J, V28, P766, DOI 10.1093/eurheartj/ehl509
   Solchaga LA, 2011, METHODS MOL BIOL, V698, P253, DOI 10.1007/978 1 60761 999 4_20
   Thoesen MS, 2006, AM J VET RES, V67, P1655, DOI 10.2460/ajvr.67.10.1655
   Turan RG, 2011, CIRC J, V75, P683, DOI 10.1253/circj.CJ 10 0817
   WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212
   Wheeler DL, 2005, J CRANIOFAC SURG, V19, P85
   Yoo JU, 1998, J BONE JOINT SURG AM, V80A, P1745, DOI 10.2106/00004623 199812000 00004
   Young RG, 1998, J ORTHOPAED RES, V16, P406, DOI 10.1002/jor.1100160403
NR 38
TC 13
Z9 14
U1 0
U2 7
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D 70469 STUTTGART, GERMANY
SN 0932 0814
EI 2567 6911
J9 VET COMP ORTHOPAED
JI Vet. Comp. Orthop. Traumatol.
PY 2013
VL 26
IS 1
BP 34
EP 41
DI 10.3415/VCOT 11 11 0165
PG 8
WC Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences; Zoology
GA 089HH
UT WOS:000314901100007
PM 23171924
DA 2025 08 17
ER

PT J
AU Brunsen, A
   Ritz, U
   Mateescu, A
   Höfer, I
   Frank, P
   Menges, B
   Hofmann, A
   Rommens, PM
   Knoll, W
   Jonas, U
AF Brunsen, A.
   Ritz, U.
   Mateescu, A.
   Hoefer, I.
   Frank, P.
   Menges, B.
   Hofmann, A.
   Rommens, P. M.
   Knoll, W.
   Jonas, U.
TI Photocrosslinkable dextran hydrogel films as substrates for osteoblast
   and endothelial cell growth
SO JOURNAL OF MATERIALS CHEMISTRY
LA English
DT Article
ID TISSUE ENGINEERING APPLICATIONS; CONTROLLED DRUG DELIVERY;
   EXTRACELLULAR MATRIX; IN VITRO; POLY(ETHYLENE GLYCOL); BONE FORMATION;
   CROSS LINKING; THIN FILMS; STEM CELLS; SCAFFOLDS
AB Functional hydrogel films on solid supports are versatile materials with large potential for cell growth and tissue engineering. Here, we report on a modular approach to generate functional hydrogel composite films for endothelial and osteoblast cell co culture. The polymer network of the parent hydrogel was formed by a dextran derivative (BP CMD), which contained carboxymethyl (CM) groups for further chemical functionalization and benzophenone (BP) moieties as a photocrosslinkable unit. BP CMD could be synthesized by three different routes, first with the benzophenone unit attached via an amide bond, or second by an ether bond, or third as an ion pair between the benzophenone ammonium salt and the carboxylate groups on the dextran backbone. For composite formation, BP functionalized silica nanoparticles, as well as gelatin particles were mixed with BP CMD and permanently fixed in the hydrogel matrix by photocrosslinking for mechanical reinforcement and to facilitate cell growth. In the last preparation step the BMP 2 growth factor was covalently coupled to the polymer backbone, which enhanced osteoblast and endothelial cell growth. The swelling behavior and successful BMP 2 immobilization of the hydrogel composite films were investigated with surface plasmon resonance and optical waveguide mode spectroscopy coupled with fluorescence detection. This modular approach allows independent selection and optimization of each component in the hydrogel composite for a wide range of potential applications for targeted cell growth, as successfully shown here with osteoblast endothelial cell co culture for bone tissue regeneration.
C1 [Brunsen, A.; Menges, B.; Jonas, U.] Max Planck Inst Polymer Res, D 55128 Mainz, Germany.
   [Brunsen, A.] Tech Univ Darmstadt, Dept Chem, LOEWE Soft Control, D 64287 Darmstadt, Germany.
   [Ritz, U.; Hofmann, A.; Rommens, P. M.] Johannes Gutenberg Univ Mainz, Dept Trauma Surg, Ctr Musculoskeletal Surg, BiomaTiCS Grp Mainz,Univ Med Ctr, Mainz, Germany.
   [Mateescu, A.; Jonas, U.] FORTH, IESL, Bioorgan Mat Chem Lab, Iraklion 71110, Crete, Greece.
   [Hoefer, I.; Frank, P.; Jonas, U.] Univ Siegen, D 57076 Siegen, Germany.
   [Knoll, W.] Austrian Inst Technol GmbH, AIT, A 1220 Vienna, Austria.
C3 Max Planck Society; Technical University of Darmstadt; Johannes
   Gutenberg University of Mainz; Foundation for Research & Technology  
   Hellas (FORTH); Universitat Siegen; Austrian Institute of Technology
   (AIT)
RP Brunsen, A (通讯作者)，Max Planck Inst Polymer Res, Ackermannweg 10, D 55128 Mainz, Germany.
RI Ritz, Ulrike/N 6871 2016; Hofmann, Alexander/C 3943 2013;
   Andrieu Brunsen, Annette/ABD 6949 2020; Höfer, Isabel/K 1396 2019;
   Jonas, Ulrich/E 4492 2010
OI Jonas, Ulrich/0000 0002 2161 4541; Andrieu Brunsen,
   Annette/0000 0002 3850 3047; Menges, Bernhard/0000 0002 3949 4146
FU European Commission through the ESMI   European Soft Matter
   Infrastructure project [262348]; Studienstiftung des Deutschen Volkes
FX The authors would like to acknowledge financial support by the European
   Commission through the ESMI   European Soft Matter Infrastructure
   project (grand agreement number 262348) and for an individual fellowship
   (A.B.) by the Studienstiftung des Deutschen Volkes. We want to thank
   Benoit Loppinet for the local ESMI project coordination and helpful
   discussions, Coenraad van den Broom for the silica nanoparticle
   synthesis, Robert Roskamp for the synthesis of 4 aminomethyl
   benzophenone, Manfred Wagner and Petra Kindervater for the help with the
   NMR spectroscopy, Helma Burg for AFM measurements, and Maren Muller for
   the Cryo SEM experiments.
CR Alajati A, 2008, NAT METHODS, V5, P439, DOI [10.1038/nmeth.1198, 10.1038/NMETH.1198]
   Anac I, 2010, MACROMOL CHEM PHYS, V211, P1018, DOI 10.1002/macp.200900533
   Anderson EH, 2004, MACROMOL BIOSCI, V4, P766, DOI 10.1002/mabi.200300125
   Andersson O, 2009, BIOMACROMOLECULES, V10, P142, DOI 10.1021/bm801029b
   Bagal DS, 2007, BIOSENS BIOELECTRON, V22, P3072, DOI 10.1016/j.bios.2007.01.008
   Bajpai AK, 2008, PROG POLYM SCI, V33, P1088, DOI 10.1016/j.progpolymsci.2008.07.005
   Beines PW, 2007, LANGMUIR, V23, P2231, DOI 10.1021/la063264t
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534 200206000 00033
   Brom C.R., 2010, J MATER CHEM, V20, P4827
   Brunsen A, 2012, J MAGN MAGN MATER, V324, P1488, DOI 10.1016/j.jmmm.2011.11.039
   Bryant SJ., 2006, SCAFFOLDING TISSUE E, P71
   Burdick JA, 2002, BIOMATERIALS, V23, P4315, DOI 10.1016/S0142 9612(02)00176 X
   Cenni E, 2011, ACTA PHARMACOL SIN, V32, P21, DOI 10.1038/aps.2010.143
   CHIRILA TV, 1993, BIOMATERIALS, V14, P26, DOI 10.1016/0142 9612(93)90072 A
   Chiu HC, 1999, J BIOMAT SCI POLYM E, V10, P591, DOI 10.1163/156856299X00504
   Chupa JM, 2000, BIOMATERIALS, V21, P2315, DOI 10.1016/S0142 9612(00)00158 7
   Cruise GM, 1999, CELL TRANSPLANT, V8, P293, DOI 10.1177/096368979900800310
   Drury JL, 2005, J BIOMECH ENG T ASME, V127, P220, DOI 10.1115/1.1865194
   Elbert DL, 1996, ANNU REV MATER SCI, V26, P365, DOI 10.1146/annurev.ms.26.080196.002053
   English AE, 1997, J CHEM PHYS, V107, P1645, DOI 10.1063/1.474516
   Ferreira L, 2005, BIOMATERIALS, V26, P4707, DOI 10.1016/j.biomaterials.2004.11.051
   Ferreira LS, 2007, BIOMATERIALS, V28, P2706, DOI 10.1016/j.biomaterials.2007.01.021
   Flanagan TC, 2006, BIOMATERIALS, V27, P2233, DOI 10.1016/j.biomaterials.2005.10.031
   Gianneli M, 2008, SOFT MATTER, V4, P1443, DOI 10.1039/b801468j
   GIESCHE H, 1994, J EUR CERAM SOC, V14, P189, DOI 10.1016/0955 2219(94)90087 6
   Grellier M, 2009, TRENDS BIOTECHNOL, V27, P562, DOI 10.1016/j.tibtech.2009.07.001
   Heinze T, 2005, MACROMOL SYMP, V223, P13, DOI 10.1002/masy.200550502
   Heinze T, 2006, ADV POLYM SCI, V205, P199, DOI 10.1007/12_100
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hofmann A, 2008, BIOMATERIALS, V29, P4217, DOI 10.1016/j.biomaterials.2008.07.024
   Hoshikawa A, 2006, TISSUE ENG, V12, P2333, DOI 10.1089/ten.2006.12.2333
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Huynh R, 1998, ANGEW MAKROMOL CHEM, V254, P61
   Hynd MR, 2007, J BIOMAT SCI POLYM E, V18, P1223, DOI 10.1163/156856207782177909
   Ifkovits JL, 2007, TISSUE ENG, V13, P2369, DOI 10.1089/ten.2007.0093
   Ishihara M, 2001, WOUND REPAIR REGEN, V9, P513, DOI 10.1046/j.1524 475x.2001.00513.x
   JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003 2697(91)90424 R
   Junk MJN, 2010, LANGMUIR, V26, P12253, DOI 10.1021/la101185q
   Junk MJN, 2010, LANGMUIR, V26, P7262, DOI 10.1021/la903396v
   Kan T, 2004, BIOORG MED CHEM LETT, V14, P1983, DOI 10.1016/j.bmcl.2004.01.067
   Knoll W, 1998, ANNU REV PHYS CHEM, V49, P569, DOI 10.1146/annurev.physchem.49.1.569
   Ko HCH, 2007, EUR CELLS MATER, V14, P1
   Kraehenbuehl TP, 2011, NAT METHODS, V8, P731, DOI 10.1038/nmeth.1671
   Liu VA, 2002, BIOMED MICRODEVICES, V4, P257, DOI 10.1023/A:1020932105236
   Liu YX, 2009, BIOMATERIALS, V30, P196, DOI 10.1016/j.biomaterials.2008.09.041
   Longo GS, 2011, MACROMOLECULES, V44, P147, DOI 10.1021/ma102312y
   Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142 9612(00)00196 4
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   Namkung S, 2007, J BIOMAT SCI POLYM E, V18, P901, DOI 10.1163/156856207781367701
   Nicodemus GD, 2008, TISSUE ENG PT B REV, V14, P149, DOI 10.1089/ten.teb.2007.0332
   Nilsson KPR, 2003, NAT MATER, V2, P419, DOI 10.1038/nmat899
   OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Pampaloni Francesco, 2009, Recent Pat Biotechnol, V3, P103
   Park KH, 2005, BIOTECHNOL LETT, V27, P227, DOI 10.1007/s10529 004 8297 z
   Raccis R, 2011, SOFT MATTER, V7, P7042, DOI 10.1039/c0sm01438a
   RATCLIFF MA, 1971, J ORG CHEM, V36, P3112
   Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027
   Risbud M, 2000, J BIOSCIENCES, V25, P25, DOI 10.1007/BF02985178
   Rodrigues MR, 2007, J CARBOHYD CHEM, V26, P439, DOI 10.1080/07328300701737912
   Roskamp R. F., 2009, M PLANCK I POLYM CHE
   Rouwkema J, 2009, TISSUE ENG PT A, V15, P2015, DOI 10.1089/ten.tea.2008.0318
   Schwartz VB, 2012, ADV FUNCT MATER, V22, P2376, DOI 10.1002/adfm.201102980
   Shoichet MS, 2010, MACROMOLECULES, V43, P581, DOI 10.1021/ma901530r
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021 9797(68)90272 5
   Suh JKF, 2000, BIOMATERIALS, V21, P2589
   Sun GM, 2011, P NATL ACAD SCI USA, V108, P20976, DOI 10.1073/pnas.1115973108
   Sun G, 2011, BIOMATERIALS, V32, P95, DOI 10.1016/j.biomaterials.2010.08.091
   Taboas JM, 2003, BIOMATERIALS, V24, P181, DOI 10.1016/S0142 9612(02)00276 4
   TIEN PK, 1977, REV MOD PHYS, V49, P361, DOI 10.1103/RevModPhys.49.361
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Wallace C, 2005, J BIOMED MATER RES A, V72A, P19, DOI 10.1002/jbm.a.30199
   Wang Y, 2009, ANAL CHEM, V81, P9625, DOI 10.1021/ac901662e
   Wilder J, 1998, PHYS REV E, V57, P6865, DOI 10.1103/PhysRevE.57.6865
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
NR 75
TC 25
Z9 28
U1 0
U2 82
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0959 9428
J9 J MATER CHEM
JI J. Mater. Chem.
PY 2012
VL 22
IS 37
BP 19590
EP 19604
DI 10.1039/c2jm34006b
PG 15
WC Chemistry, Physical; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA 996OK
UT WOS:000308099900028
DA 2025 08 17
ER

PT J
AU Ma, SY
   Li, SJ
   Zhang, YC
   Nie, JM
   Cao, J
   Li, A
   Li, Y
   Pei, DD
AF Ma, Shaoyang
   Li, Sijia
   Zhang, Yuchen
   Nie, Jiaming
   Cao, Jiao
   Li, Ang
   Li, Ye
   Pei, Dandan
TI BMSC Derived Exosomal CircHIPK3 Promotes Osteogenic Differentiation of
   MC3T3 E1 Cells via Mitophagy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteogenesis; exosome; mitophagy; circRNA; stem cells
ID MESENCHYMAL STEM CELLS; CIRCULAR RNAS; OSTEOPOROSIS; ACTIVATION;
   AUTOPHAGY; MIGRATION; STRESS
AB Exosome based therapy is emerging as a promising strategy to promote bone regeneration due to exosomal bioactive cargos, among which circular RNA (circRNA) has recently been recognized as the key effector. The role of exosomal circRNA derived from bone marrow mesenchymal stem cells (BMSCs) has not been well defined. The present study aimed to clarify the regulatory function and molecular mechanism of BMSC derived exosomal circRNA in osteogenesis. Exosomes derived from bone marrow mesenchymal stem cells (BMSC Exos) were isolated and identified. BMSC Exos' pro osteogenic effect on MC3T3 E1 cells was validated by alkaline phosphatase (ALP) activity and Alizarin Red staining. Through bioinformatic analysis and molecular experiments, circHIPK3 was selected and verified as the key circRNA of BMSC Exos to promote osteoblast differentiation of MC3T3 E1 cells. Mechanistically, circHIPK3 acted as an miR 29a 5p sponge and functioned in mitophagy via targeting miR 29a 5p and PINK1. Additionally, we showed that the mitophagy level of MC3T3 E1 cells were mediated by BMSC Exos, which promoted the osteogenic differentiation. Collectively, our results revealed an important role for BMSC derived exosomal circHIPK3 in osteogenesis. These findings provide a potentially effective therapeutic strategy for bone regeneration.
C1 [Ma, Shaoyang; Li, Sijia; Zhang, Yuchen; Nie, Jiaming; Cao, Jiao; Li, Ang; Li, Ye; Pei, Dandan] Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710000, Peoples R China.
C3 Xi'an Jiaotong University
RP Li, Y; Pei, DD (通讯作者)，Xi An Jiao Tong Univ, Coll Stomatol, Key Lab Shaanxi Prov Craniofacial Precis Med Res, Xian 710000, Peoples R China.
EM maxine0309@whu.edu.cn; peidandan@xjtu.edu.cn
RI Pei, Dandan/C 8539 2019; 李, 晔/IYS 5760 2023; Li, Ang/AAV 6381 2021;
   Zhang, Yuchen/ABL 9720 2022
OI Li, Ye/0000 0002 1624 8831; Nie, Jiaming/0009 0003 2474 8128
CR Chen L, 2021, FREE RADICAL BIO MED, V163, P356, DOI 10.1016/j.freeradbiomed.2020.12.235
   Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580 020 0243 y
   Ding K, 2018, BIOCHEM BIOPH RES CO, V503, P863, DOI 10.1016/j.bbrc.2018.06.088
   Fang JH, 2018, HEPATOLOGY, V68, P1459, DOI 10.1002/hep.29920
   Fang SH, 2020, DRUG DES DEV THER, V14, P4579, DOI 10.2147/DDDT.S258024
   Fei DD, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.687258
   Guo BB, 2015, J BIOL CHEM, V290, P3455, DOI 10.1074/jbc.M114.605253
   Hasanain M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.219
   He MY, 2022, STEM CELL TRANSL MED, V11, P987, DOI 10.1093/stcltm/szac049
   Huang XQ, 2019, J CELL PHYSIOL, V234, P21450, DOI 10.1002/jcp.28866
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341
   Klimczak A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4285215
   Krell J, 2016, GENOME RES, V26, P331, DOI 10.1101/gr.191759.115
   Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893
   Lee SY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02656 4
   Li GY, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/3319056
   Li XB, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0976 0
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   Liu AQ, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120718
   Liu CX, 2022, CELL, V185, P2016, DOI 10.1016/j.cell.2022.04.021
   Ma SY, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864 019 6338 1
   Mao GP, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02431 5
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Onishi M, 2021, EMBO J, V40, DOI 10.15252/embj.2020104705
   Ouyang ZX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 2161 5
   Pei DD, 2018, ADV SCI, V5, DOI 10.1002/advs.201800873
   Qian DY, 2017, BIOMED PHARMACOTHER, V90, P492, DOI 10.1016/j.biopha.2017.03.051
   Qin YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050712
   Shao Q, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.12048
   Sun XY, 2016, ONCOTARGET, V7, P53558, DOI 10.18632/oncotarget.10669
   Sun ZJ, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/6852661
   Suzuki H, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl151
   Tang S, 2021, ACTA HISTOCHEM, V123, DOI 10.1016/j.acthis.2021.151796
   Tsai TL, 2017, STEM CELL REP, V8, P387, DOI 10.1016/j.stemcr.2017.01.004
   Wan MC, 2021, ACTA BIOMATER, V136, P137, DOI 10.1016/j.actbio.2021.09.039
   Wang YX, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1041 z
   Wang ZK, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.953916
   Wu H, 2017, J CELL MOL MED, V21, P1228, DOI 10.1111/jcmm.13056
   Xia W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26302 y
   Xu YR, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01394 8
   Yan YM, 2017, MOL THER, V25, P465, DOI 10.1016/j.ymthe.2016.11.019
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yao XH, 2021, CANCER LETT, V512, P38, DOI 10.1016/j.canlet.2021.04.030
   Zhang DD, 2021, CELL DEATH DIFFER, V28, P283, DOI 10.1038/s41418 020 0600 6
   Zhang JY, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0391 3
   Zhang Y, 2016, CELL REP, V15, P611, DOI 10.1016/j.celrep.2016.03.058
   Zhao YY, 2022, MOL NEUROBIOL, V59, P6771, DOI 10.1007/s12035 022 03006 y
   Zheng YF, 2017, J PERIODONTOL, V88, P906, DOI 10.1902/jop.2017.170078
   Zhou XC, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14051012
   Zhu JM, 2019, THERANOSTICS, V9, P6901, DOI 10.7150/thno.37357
   Zhuang ZY, 2022, FASEB J, V36, DOI 10.1096/fj.202200832R
NR 52
TC 24
Z9 28
U1 11
U2 60
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2023
VL 24
IS 3
AR 2785
DI 10.3390/ijms24032785
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 8W1SH
UT WOS:000931099600001
PM 36769123
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Rahnama, M
   Jastrzebska Jamrogiewicz, I
   Jamrogiewicz, R
AF Rahnama, Mansur
   Jastrzebska Jamrogiewicz, Izabela
   Jamrogiewicz, Rafal
TI Influence of Hormone Replacement Therapy on Osteoprotegerin and Receptor
   Activator of Nuclear Factor Kappa B Ligand Concentrations in Menopausal
   Women
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
ID BONE MINERAL DENSITY; OSTEOCLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN;
   OPG; DISEASE; RANKL; PATHWAY; SYSTEM; MEN; OSTEOPOROSIS
AB The study was designed to compare the levels of the receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in the serum and saliva of menopausal women and verify whether there is a correlation between concentrations of these cytokines and bone mineral density (BMD) of the femur and mandible. Blood and saliva samples were collected from a group of 60 women during menopause30 untreated (control group) and 30 treated with hormone replacement therapy (HRT) (research group). Densitometry was conducted on the femoral bone and mandible. BMD in the research group was significantly higher than in the control group. The OPG concentration was slightly higher in the research group. The concentration of RANKL was slightly higher in the control group. Differences in RANKL/OPG between groups were not high enough to be statistically significant. Analysis of the RANKL in saliva revealed a significantly higher concentration of this factor in the control group. Observed beneficial effects of HRT on bone tissue may be exerted through the RANKL/OPG ratio, but further research is required to clearly confirm this thesis.
C1 [Rahnama, Mansur; Jastrzebska Jamrogiewicz, Izabela; Jamrogiewicz, Rafal] Med Univ Lublin, Chair & Dept Oral Surg, PL 20081 Lublin, Poland.
C3 Medical University of Lublin
RP Rahnama, M (通讯作者)，Med Univ Lublin, Chair & Dept Oral Surg, PL 20081 Lublin, Poland.
EM rahnama@plusnet.pl
RI Rahnama, Mansur/OCK 5076 2025
OI Jagielak, Maciej/0000 0002 2357 9831
CR Flórez Moreno GA, 2013, AM J ORTHOD DENTOFAC, V143, P92, DOI 10.1016/j.ajodo.2012.08.026
   Bai P, 2011, RESP RES, V12, DOI 10.1186/1465 9921 12 157
   Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348
   Belibasakis GN, 2012, J CLIN PERIODONTOL, V39, P239, DOI 10.1111/j.1600 051X.2011.01810.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cochran DL, 2008, J PERIODONTOL, V79, P1569, DOI 10.1902/jop.2008.080233
   Cyprysiak G., 2001, NOWA STOMATOLOGIA, V2, P33
   EI Sharkawy H, 2010, J PERIODONTOL, V81, P1635, DOI 10.1902/jop.2010.090628
   Giganti MG, 2012, J BIOL REG HOMEOS AG, V26, P671
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756 3282(99)00162 3
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hou JM, 2012, ACTA PHARMACOL SIN, V33, P1277, DOI 10.1038/aps.2012.83
   Hsu YH, 2006, HUM GENET, V118, P568, DOI 10.1007/s00439 005 0062 4
   Khosla S, 2002, OSTEOPOROSIS INT, V13, P394, DOI 10.1007/s001980200045
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lappin DF, 2007, J CLIN PERIODONTOL, V34, P271, DOI 10.1111/j.1600 051X.2007.01048.x
   Lerner UH, 2004, CRIT REV ORAL BIOL M, V15, P64, DOI 10.1177/154411130401500202
   Li YQ, 2012, ACTA PHARMACOL SIN, V33, P66, DOI 10.1038/aps.2011.136
   Lorens RS, 2006, TERAPIA, V14, P58
   Miller BE, 2000, MENOPAUSE, V7, P318, DOI 10.1097/00042192 200007050 00006
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   Price PA, 2001, ARTERIOSCL THROM VAS, V21, P1610, DOI 10.1161/hq1001.097102
   Rogers A, 2005, J CLIN ENDOCR METAB, V90, P6323, DOI 10.1210/jc.2005 0794
   Saidenberg Kermanac'h N, 2004, BONE, V35, P1200, DOI 10.1016/j.bone.2004.07.004
   Samelson EJ, 2008, J CLIN ENDOCR METAB, V93, P1789, DOI 10.1210/jc.2007 2492
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stanosz S, 2009, METABOLISM, V58, P1, DOI 10.1016/j.metabol.2008.07.016
   Stern A, 2007, EUR J ENDOCRINOL, V156, P555, DOI 10.1530/EJE 06 0753
   Trouvin AP, 2010, CLIN INTERV AGING, V5, P345, DOI 10.2147/CIA.S10153
   von Tirpitz C, 2003, EUR J GASTROEN HEPAT, V15, P1165, DOI 10.1097/00042737 200311000 00003
   Wong DT, 2006, J AM DENT ASSOC, V137, P313, DOI 10.14219/jada.archive.2006.0180
   Xiong JH, 2012, J BONE MINER RES, V27, P499, DOI 10.1002/jbmr.1547
   Xu H, 2007, J CLIN DENSITOM, V10, P165, DOI 10.1016/j.jocd.2007.01.006
   Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518
NR 35
TC 7
Z9 9
U1 0
U2 16
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1079 9907
EI 1557 7465
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD SEP 1
PY 2013
VL 33
IS 9
BP 485
EP 492
DI 10.1089/jir.2012.0149
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA 210HL
UT WOS:000323821600002
PM 23745763
DA 2025 08 17
ER

PT J
AU Yuca, H
   Senocak, TÇ
   Yigit, O
   Albayrak, MG
   Güvenalp, Z
AF Yuca, Hafize
   Senocak, Taha Cagri
   Yigit, Oktay
   Albayrak, Muhammet Gokhan
   Guvenalp, Zuhal
TI Semi quantitative analysis on sea buckthorn phenolic rich extract
   coating bone like open porous NiTi based alloy
SO HELIYON
LA English
DT Article
DE Sea buckthorn; Nickel titanium based alloy; Bone implant; Phenolics;
   HPLC
ID SHAPE MEMORY ALLOY; TRANSFORMATION BEHAVIOR; SURFACE; MICROSTRUCTURE;
   CYTOTOXICITY; OSTEOGENESIS; FABRICATION; OSTEOCLAST
AB This study investigates the feasibility of coating Ni Ti alloy with sea buckthorn extract via a hydrothermal method for targeted delivery of beneficial phenolic compounds to bone tissue. The qualitative analysis confirmed the presence of flavonoids and tannins in sea buckthorn extract, supporting its osteogenic potential. The microhardness of the NiTi alloy substrate was suitable for biomedical applications, and successful coating was achieved without compromising its properties. NiTi alloy samples were coated with 18.1, 20.1, and 12.4 mg of extract, respectively. Comprehensive evaluations confirmed the successful integration of the extract onto the alloy's surface. The coated system exhibited sustained release properties over five days, with the highest release occurring on the first day (on average 32.1 % for the first peak and 72.1 % for the second peak), as determined by HPLC analysis. The findings demonstrate the potential of this novel approach in developing dual functionality implants for bone health promotion. Overall, this study underscores the promising potential of Ni Ti alloy coated with sea buckthorn extract as a targeted drug delivery system for bone tissue.
C1 [Yuca, Hafize; Guvenalp, Zuhal] Ataturk Univ, Fac Pharm, Dept Pharmacognosy, TR 25240 Erzurum, Turkiye.
   [Yuca, Hafize; Guvenalp, Zuhal] Ataturk Univ, Med & Aromat Plant & Drug Res Ctr, TR 25240 Erzurum, Turkiye.
   [Senocak, Taha Cagri] Ataturk Univ, Engn Fac, Dept Met & Mat Engn, TR 25240 Erzurum, Turkiye.
   [Yigit, Oktay] Firat Univ, Technol Fac, Dept Met & Mat Engn, TR 23119 Elazig, Turkiye.
   [Yigit, Oktay] Michigan State Univ, Coll Engn, Dept Chem Engn & Mat Sci, Lansing, MI 48912 USA.
   [Albayrak, Muhammet Gokhan] Firat Univ, Engn Fac, Dept Met & Mat Engn, TR 23119 Elazig, Turkiye.
C3 Ataturk University; Ataturk University; Ataturk University; Firat
   University; Michigan State University; Firat University
RP Yuca, H (通讯作者)，Ataturk Univ, Fac Pharm, TR 25240 Erzurum, Turkiye.
EM hafize.yuca@atauni.edu.tr
RI ; Senocak, Taha Cagri/A 4801 2018; Yuca, Hafize/O 7037 2019; yiğit,
   oktay/W 1374 2018; Albayrak, Muhammet/W 1418 2018
OI SENOCAK, TAHA CAGRI/0000 0002 0043 5253; YUCA,
   Hafize/0000 0002 0857 4776; 
CR Agrawala P. K., 2002, Indian Journal of Experimental Biology, V40, P525
   Alam Zeb Alam Zeb, 2004, Journal of Biological Sciences, V4, P687
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Barras CDJ, 2000, EUR J VASC ENDOVASC, V19, P564, DOI 10.1053/ejvs.2000.1111
   Baytop T., 1999, Turkiye'de Bitkiler ile Tedavi Gecmiste ve Bugun
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bram M, 2002, MAT SCI ENG A STRUCT, V337, P254, DOI 10.1016/S0921 5093(02)00028 X
   Breeland G., 2022, Embryology, bone ossification
   Chu CL, 2004, MAT SCI ENG A STRUCT, V366, P114, DOI 10.1016/j.msea.2003.08.118
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Folin O, 1912, J BIOL CHEM, V12, P239
   Frenzel J, 2004, J ALLOY COMPD, V385, P214, DOI 10.1016/j.jallcom.2004.05.002
   Gil FJ, 2004, J MATER SCI MATER M, V15, P1181, DOI 10.1007/s10856 004 5669 9
   Hafez HS, 2011, AM J ORTHOD DENTOFAC, V140, P298, DOI 10.1016/j.ajodo.2010.05.025
   Jin S, 2013, COLLOID SURFACE B, V101, P343, DOI 10.1016/j.colsurfb.2012.06.029
   Kaya M, 2010, MATER SCI TECH LOND, V26, P522, DOI 10.1179/174328409X410809
   Kilic M, 2017, KOVOVE MATER, V55, P97, DOI 10.4149/km_2017_2_97
   Kilic M, 2019, MATER TEST, V61, P1140, DOI 10.3139/120.111439
   Lee JS, 2017, CHEM MATER, V29, P4375, DOI 10.1021/acs.chemmater.7b00802
   Park KH, 2022, NUTRIENTS, V14, DOI 10.3390/nu14173604
   Pons Faudoa FP, 2019, BIOMED MICRODEVICES, V21, DOI 10.1007/s10544 019 0389 6
   Rokaya D, 2019, SCI ADV MATER, V11, P1474, DOI 10.1166/sam.2019.3536
   Sakar M.K., 1991, Phytochemical Analyzes
   Salvetr P, 2017, KOVOVE MATER, V55, P379, DOI 10.4149/km_2017_6_379
   Sheykholeslami SOR, 2018, METALL MATER TRANS A, V49A, P5878, DOI 10.1007/s11661 018 4847 1
   SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49
   Tuncer K, 2021, J MECH BEHAV BIOMED, V119, DOI 10.1016/j.jmbbm.2021.104496
   Wu SL, 2008, J ALLOY COMPD, V449, P139, DOI 10.1016/j.jallcom.2006.01.144
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   YI HC, 1990, J MATER SCI, V25, P1159
   Yuan B, 2004, MAT SCI ENG A STRUCT, V382, P181, DOI 10.1016/j.msea.2004.04.068
   Yuca H, 2022, CHEM PAP, V76, P913, DOI 10.1007/s11696 021 01904 4
   Yusop AHM, 2023, BIOCYBERN BIOMED ENG, V43, P42, DOI 10.1016/j.bbe.2022.11.002
   Zhang JF, 2009, PHYTOMEDICINE, V16, P521, DOI 10.1016/j.phymed.2009.01.003
   Zhao Y, 2005, ACTA MATER, V53, P337, DOI 10.1016/j.actamat.2004.09.029
   Zhou Y, 2013, SURF COAT TECH, V228, pS2, DOI 10.1016/j.surfcoat.2012.11.002
NR 36
TC 2
Z9 2
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405 8440
J9 HELIYON
JI Heliyon
PD JUL 30
PY 2024
VL 10
IS 14
AR e34594
DI 10.1016/j.heliyon.2024.e34594
EA JUL 2024
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA ZC8Q6
UT WOS:001273188700001
PM 39114081
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kim, YR
   Kim, JH
AF Kim, Young Rok
   Kim, Jung Hyun
TI Hypertrophic Osteopathy Concurrent with an Aberrant Right Subclavian
   Artery in a Dog
SO VETERINARY SCIENCES
LA English
DT Article
DE aberrant right subclavian artery; dog; hypertrophic osteopathy; vascular
   ring anomaly
ID TRANSITIONAL CELL CARCINOMA; FOREIGN BODY; OSTEOARTHROPATHY; INFECTION;
   PNEUMONIA
AB Simple Summary Hypertrophic osteopathy (HO) is a rare bone disease characterized by abnormal new bone formation and soft tissue swelling in the limbs. In veterinary medicine, HO is mainly linked to different underlying disorders, and its development mechanisms are unclear. In this case, report, the only remarkable finding was an aberrant right subclavian artery (ARSA), which is a rare form of vascular ring anomaly in dogs, identified by computed tomographic angiography. This anomalous vessel induced mild dilation of the esophagus above it. Although ARSAs may be a possible cause of HO, the owner declined surgical correction because of potential complications after surgery. After palliative treatment with nonsteroidal anti inflammatory drugs (NSAIDs) for pain relief, intermittent lameness improved; however, no significant changes were observed in HO during the follow up period.Abstract A 13 year old spayed female cocker spaniel was presented with a 2 month history of swelling in several digits and intermittent hindlimb lameness. Radiographs revealed marked soft tissue swelling and periosteal new bone formation without cortical bone destruction, characteristic of hypertrophic osteopathy (HO), in the distal parts of all extremities except for the right forelimb. However, no notable findings were detected in thoracic radiographs. An ultrasonography indicated cranial bladder wall thickening, which resolved following antibiotic therapy. Computed tomographic angiography identified a potential underlying cause as an aberrant right subclavian artery (ARSA) originating from the aortic arch, compressing the esophagus and causing mild esophageal cranial dilation to the aberrant vessel. No other intrathoracic or neoplastic lesions were observed. Gastrointestinal symptoms, such as regurgitation, were absent. Although an ARSA was likely the cause of HO, surgical correction was declined by the owner. To the best of our knowledge, this is the first reported case of HO concurrent with ARSA in dogs.
C1 [Kim, Young Rok; Kim, Jung Hyun] Konkuk Univ, Coll Vet Med, Dept Vet Internal Med, Seoul 05029, South Korea.
C3 Konkuk University
RP Kim, JH (通讯作者)，Konkuk Univ, Coll Vet Med, Dept Vet Internal Med, Seoul 05029, South Korea.
EM junghyun@konkuk.ac.kr
RI ; Kim, Jung Hyun/D 2980 2011
OI Kim, Young Rok/0000 0003 3958 3533; 
CR Anderson TP, 2004, JAVMA J AM VET MED A, V224, P1464, DOI 10.2460/javma.2004.224.1464
   Bhamrah PS, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.7379
   Budreckis DM, 2015, J VET INTERN MED, V29, P828, DOI 10.1111/jvim.12578
   CAYWOOD DD, 1985, J AM VET MED ASSOC, V186, P698
   Cetinkaya MA, 2011, VET MED CZECH, V56, P595, DOI 10.17221/4437 VETMED
   Chiang YC, 2007, J VET MED SCI, V69, P209, DOI 10.1292/jvms.69.209
   Cho HS, 2020, IRAN J VET RES, V21, P61, DOI 10.22099/IJVR.2019.33804.5012
   Dunn ME, 2007, J SMALL ANIM PRACT, V48, P99, DOI 10.1111/j.1748 5827.2006.00159.x
   Foster WK, 2006, JAVMA J AM VET MED A, V228, P1366, DOI 10.2460/javma.228.9.1366
   Fulkerson C M., 2019, Withrow MacEwen's Small Animal Clinical Oncology, V6th, P645
   Gomes SA, 2020, J AM ANIM HOSP ASSOC, V56, P7, DOI 10.5326/JAAHA MS 6955
   Guyot H, 2011, CAN VET J, V52, P1308
   HALLIWELL WH, 1974, J AM VET MED ASSOC, V165, P911
   Henjes CR, 2011, BMC VET RES, V7, DOI 10.1186/1746 6148 7 57
   HESSELINK JW, 1990, J AM VET MED ASSOC, V196, P760
   Huang CH, 2010, J AM ANIM HOSP ASSOC, V46, P346, DOI 10.5326/0460346
   Khatat SE, 2020, J FELINE MED SURG OP, V6, DOI 10.1177/2055116920962433
   Kim J, 2017, J VET MED SCI, V79, P1052, DOI 10.1292/jvms.17 0031
   Makungu Modesta, 2007, Veterinarski Arhiv, V77, P463
   Miller R., 2015, Vet Record, V3, DOI [10.1136/vetreccr 2014 000138, DOI 10.1136/VETRECCR 2014 000138]
   Mochizuki Y, 2021, VET SCI, V8, DOI 10.3390/vetsci8060104
   Peeters D, 2001, J VET INTERN MED, V15, P407, DOI 10.1892/0891 6640(2001)015<0407:ROPLAH>2.3.CO;2
   Schorn C, 2021, BMC VET RES, V17, DOI 10.1186/s12917 021 03101 7
   Suzuki Ryohei, 2018, JFMS Open Rep, V4, p2055116918764589, DOI 10.1177/2055116918764589
   Ueno H, 2016, J DIABETES INVEST, V7, P812, DOI 10.1111/jdi.12492
   van der Merwe LL, 2008, VET J, V176, P294, DOI 10.1016/j.tvjl.2007.02.032
   Watrous BJ, 2002, VET RADIOL ULTRASOUN, V43, P545, DOI 10.1111/j.1740 8261.2002.tb01046.x
   WATSON ADJ, 1973, VET REC, V93, P240, DOI 10.1136/vr.93.9.240
   Withers SS, 2015, VET COMP ONCOL, V13, P157, DOI 10.1111/vco.12026
   WYLIE KB, 1993, J AM VET MED ASSOC, V202, P1986
   Yoon H, 2018, VET RADIOL ULTRASOUN, V59, pE44, DOI 10.1111/vru.12483
   Yoon HY, 2011, CAN VET J, V52, P1115
NR 32
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2306 7381
J9 VET SCI
JI Vet. Sci.
PD JUN
PY 2024
VL 11
IS 6
AR 263
DI 10.3390/vetsci11060263
PG 8
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA WR0Q4
UT WOS:001256485800001
PM 38922010
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sotozono, Y
   Ikoma, K
   Kido, M
   Onishi, O
   Minami, M
   Wada, H
   Yamada, S
   Matsuda, KI
   Tanaka, M
   Takahashi, K
AF Sotozono, Yasutaka
   Ikoma, Kazuya
   Kido, Masamitsu
   Onishi, Okihiro
   Minami, Masataka
   Wada, Hiroaki
   Yamada, Shunji
   Matsuda, Ken Ichi
   Tanaka, Masaki
   Takahashi, Kenji
TI Sweep imaging with Fourier transform as a tool with MRI for evaluating
   the effect of teriparatide on cortical bone formation in an
   ovariectomized rat model
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Osteoporosis; Teriparatide; Sweep imaging with Fourier transform
ID HUMAN PARATHYROID HORMONE; ONCE WEEKLY TERIPARATIDE; POSTMENOPAUSAL
   WOMEN; TURNOVER; OSTEOPOROSIS; HISTOMORPHOMETRY; PREVENTION; POROSITY;
   MARKERS
AB Background Teriparatide (TPTD) is a drug for osteoporosis that promotes bone formation and improves bone quality. However, the effects of TPTD on cortical bone are not well understood. Sweep imaging with Fourier transform (SWIFT) has been reported as a useful tool for evaluating bound water of cortical bone, but it has yet to be used to investigate the effects of TPTD on cortical bone. This study aimed to evaluate the consequences of the effect of TPTD on cortical bone formation using SWIFT. Methods Twelve week old female Sprague Dawley rats (n = 36) were reared after ovariectomy to create a postmenopausal osteoporosis model. They were divided into two groups: the TPTD and non TPTD groups. Rats were euthanized at 4, 12, and 24 weeks after initiating TPTD treatment. Tibial bones were evaluated using magnetic resonance imaging (MRI) and bone histomorphometry. In MRI, proton density weighted imaging (PDWI) and SWIFT imaging were performed. The signal to noise ratio (SNR) was calculated for each method. The same area evaluated by MRI was then used to calculate the bone formation rate by bone histomorphometry. Measurements were compared using the Mann Whitney U test, and a P value of < 0.05 was considered significant. Results PDWI SNR was not significantly different between the two groups at any time point (P = 0.589, 0.394, and 0.394 at 4, 12, and 24 weeks, respectively). Contrarily, SWIFT SNR was significantly higher in the TPTD group than in the non TPTD group at 4 weeks after initiating treatment, but it was not significantly different at 12 and 24 weeks (P = 0.009, 0.937, and 0.818 at 4, 12, and 24 weeks, respectively). The bone formation rate assessed by histomorphometry was significantly higher in the TPTD group than in the non TPTD group at all timepoints (P < 0.05, all weeks). In particular, at 4 weeks, the bone formation rate was markedly higher in the TPTD group than in the non TPTD group (P = 0.028, 1.98 +/  0.33 vs. 0.09 +/  0.05 mu m(3)/mu m(2)/day). Conclusions SWIFT could detect increased signals of bound water, reflecting the effect of TPTD on the cortical bone. The signal detected by SWIFT reflects a marked increase in the cortical bone formation rate.
C1 [Sotozono, Yasutaka; Ikoma, Kazuya; Kido, Masamitsu; Onishi, Okihiro; Minami, Masataka; Wada, Hiroaki; Takahashi, Kenji] Kyoto Prefectural Univ Med, Dept Orthopaed, Grad Sch Med Sci, 465 Kajii Cho, Kyoto, Japan.
   [Yamada, Shunji; Matsuda, Ken Ichi; Tanaka, Masaki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Anat & Neurobiol, Kyoto, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine
RP Ikoma, K (通讯作者)，Kyoto Prefectural Univ Med, Dept Orthopaed, Grad Sch Med Sci, 465 Kajii Cho, Kyoto, Japan.
EM kazuya@koto.kpu m.ac.jp
FU Japan Society for the Promotion of Science (JSPS) KAKENHI [21 K090232];
   Grants in Aid for Scientific Research [21K06412, 21K09232] Funding
   Source: KAKEN
FX This work was supported by Japan Society for the Promotion of Science
   (JSPS) KAKENHI [Grant Number 21 K090232].
CR Al Badr W, 2009, SAUDI J KIDNEY DIS T, V20, P12
   Chavassieux P, 2015, J CLIN ENDOCR METAB, V100, P4662, DOI 10.1210/jc.2015 2957
   CULLUM ID, 1989, BRIT J RADIOL, V62, P587, DOI 10.1259/0007 1285 62 739 587
   Du J, 2013, NMR BIOMED, V26, P489, DOI 10.1002/nbm.2906
   Fujita T, 1999, OSTEOPOROSIS INT, V9, P296, DOI 10.1007/s001980050151
   GAMBERT SR, 1995, ENDOCRIN METAB CLIN, V24, P317, DOI 10.1016/S0889 8529(18)30044 6
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Holzer G, 2009, J BONE MINER RES, V24, P468, DOI 10.1359/JBMR.081108
   Horch RA, 2010, MAGN RESON MED, V64, P680, DOI 10.1002/mrm.22459
   HORI M, 1988, BONE MINER, V3, P193
   Idiyatullin D, 2006, J MAGN RESON, V181, P342, DOI 10.1016/j.jmr.2006.05.014
   Ito M, 2014, OSTEOPOROSIS INT, V25, P1163, DOI 10.1007/s00198 013 2596 y
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kishi T, 1998, BONE, V22, P515, DOI 10.1016/S8756 3282(98)00045 3
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Melton LJ, 1997, J BONE MINER RES, V12, P1083, DOI 10.1359/jbmr.1997.12.7.1083
   Minami M, 2018, J MAGN RESON IMAGING, V48, P389, DOI 10.1002/jmri.25955
   Müller R, 1998, BONE, V23, P59, DOI 10.1016/S8756 3282(98)00068 4
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   ROBINSON RA, 1952, J BONE JOINT SURG AM, V34 A, P389, DOI 10.2106/00004623 195234020 00013
   ROCKOFF SD, 1969, CALC TISS RES, V3, P163, DOI 10.1007/BF02058659
   Sugimoto T, 2014, OSTEOPOROSIS INT, V25, P1173, DOI 10.1007/s00198 013 2516 1
   Sukenari T, 2015, J MAGN RESON IMAGING, V42, P128, DOI 10.1002/jmri.24765
   Weiger M, 2011, MAGN RESON MED, V66, P379, DOI 10.1002/mrm.22799
   WRONSKI TJ, 1994, BONE, V15, P51, DOI 10.1016/8756 3282(94)90891 5
   Zebaze R, 2017, BONE, V99, P80, DOI 10.1016/j.bone.2017.03.042
NR 28
TC 2
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD JAN 3
PY 2022
VL 23
IS 1
AR 16
DI 10.1186/s12891 021 04970 7
PG 10
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA YA0QJ
UT WOS:000738048500024
PM 34980094
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ju, WW
   Zhang, GF
   Zhang, X
   Wang, JT
   Wu, T
   Li, HF
AF Ju, Wenwen
   Zhang, Guangfeng
   Zhang, Xu
   Wang, Jingting
   Wu, Tong
   Li, Huafeng
TI Involvement of MiRNA 211 5p and Arhgap11a Interaction During Osteogenic
   Differentiation of MC3T3 E1 Cells
SO FRONTIERS IN SURGERY
LA English
DT Article
DE osteogenic differentiation; MC3T3 E1 cell; microRNA; miR 211 5p;
   Arhgap11a
ID MESENCHYMAL STEM CELLS; DRUG DELIVERY SYSTEMS; OSTEOBLAST
   DIFFERENTIATION; BONE; OSTEOPOROSIS; EXPRESSION; RUNX2
AB Objective: MicroRNAs (miRNAs) are well recognized for their abilities to regulate gene expression post transcriptionally in plants and animals. Recently, miRNA messenger RNA (mRNA) regulatory relationships have been confirmed during biological processes, including osteogenic differentiation. This study aimed to find out more candidate miRNA mRNA pairs involved in the osteogenic differentiation of MC3T3 E1 cells.
   Methods: An MC3T3 E1 based microarray dataset (accessioned as GSE46400) downloaded from the Gene Expression Omnibus included MC3T3 E1 cells with or without 14 day osteoblast differentiation osteoblast induction. Multiple miRNA mRNA prediction databases were searched by differentially expressed genes (DEGs) to obtain pairs of a miRNA DEG regulatory network. The MC3T3 E1 cells were cultured and incubated in the osteogenic differentiation medium for 14 days. The expressions of candidate miRNAs and mRNAs were determined by real time quantitative PCR(RT qPCR) in MC3T3 E1 cells. The miRNA mRNA interactions were verified by dual luciferase reporter gene assays and experiments using mimics miRNA or their inhibitors.
   Results: We identified 715 upregulated DEGs and 603 downregulated DEGs between MC3T3 E1 cells with and without osteoblast induction by analyzing the raw data of the GSE46400 dataset. There were 7 overlapped miRNA mRNA pairs identified during osteogenic differentiation of MC3T3 E1 cells, including mmu miR 204 5p Arhgap11a, mmu miR 211 5p Arhgap11a, mmu miR 24 3p H2afx, mmu miR 3470b Chek2, mmu miR 3470b Dlgap5, mmu miR 466b 3p Chek1, and mmu miR 466c 3p Chek1. The Arhgap11a, H2afx, Chek2, Dlgap5, and Chek1 were hub genes downregulated in MC3T3 E1 cells after osteogenic differentiation, verified by RT qPCR results. The RT qPCR also determined declined expressions of miR 204 5p and miR 24 3p concomitant with elevated expressions of miR 211 5p, miR 3470b, miR 466b 3p, and miR 466c 3p in the MC3T3 E1 cells, with osteoblast induction compared with undifferentiated MC3T3 E1 cells. Dual luciferase reporter gene assays demonstrated Arhgap11a as the target of miR 211 5p. MiR 211 5p upregulation by its mimic increased Arhgap11a expression in MC3T3 E1 cells.
   Conclusion: Our study characterizes miR 211 5p targeting Arhgap11a promotes the osteogenic differentiation of MC3T3 E1 cells, which provides novel targets to promote the osteogenesis process during bone repair.
C1 [Ju, Wenwen; Wang, Jingting; Li, Huafeng] Qiqihar Med Univ, Affiliated Hosp 3, Dept Endocrinol 1, Qiqihar, Peoples R China.
   [Zhang, Guangfeng] Qiqihar Med Univ, Dept Magnet Resonance Imaging MRI, Affiliated Hosp 3, Qiqihar, Peoples R China.
   [Zhang, Xu] Zhongshan City Peoples Hosp, Dept Endocrinol, Zhongshan, Peoples R China.
   [Wu, Tong] Qiqihar Med Univ, Mental & Hlth Coll, Qiqihar, Peoples R China.
C3 Qiqihar Medical University; Qiqihar Medical University; Sun Yat Sen
   University; Qiqihar Medical University
RP Li, HF (通讯作者)，Qiqihar Med Univ, Affiliated Hosp 3, Dept Endocrinol 1, Qiqihar, Peoples R China.
EM microma196a@126.com
RI wang, jingting/MXL 9999 2025
FU Basic Scientific Research Operational Expenses Scientific Research
   Projects of Heilongjiang Provincial Colleges and Universities
   [2019 KYYWF 1239]
FX This study received support from the Basic Scientific Research
   Operational Expenses Scientific Research Projects of Heilongjiang
   Provincial Colleges and Universities (2019 KYYWF 1239).
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Branchi V, 2019, INT J COLORECTAL DIS, V34, P1455, DOI 10.1007/s00384 019 03339 6
   Carbone EJ, 2017, NANOMED NANOTECHNOL, V13, P37, DOI 10.1016/j.nano.2016.08.015
   Chen SC, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm 21 2113
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Fan B, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.720645
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   Fischer BM, 2013, AM J PHYSIOL LUNG C, V304, pL394, DOI 10.1152/ajplung.00091.2012
   FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715
   Gu CY, 2021, MOL CANCER, V20, DOI 10.1186/s12943 021 01380 0
   Guo BB, 2020, BRIT J HAEMATOL, V188, P272, DOI 10.1111/bjh.16152
   Hu XY, 2016, STEM CELLS, V34, P1846, DOI 10.1002/stem.2391
   Iaquinta MR, 2021, THERANOSTICS, V11, P6573, DOI 10.7150/thno.55664
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Komori T, 2017, ADV EXP MED BIOL, V962, P83, DOI 10.1007/978 981 10 3233 2_6
   Laçin N, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102 865020190030000006
   Lawson Campbell D, 2018, Small GTPases, V9, P290, DOI 10.1080/21541248.2016.1220350
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Liu H, 2019, J BIOCHEM, V166, P495, DOI 10.1093/jb/mvz065
   Lu XQ, 2019, MED SCI MONITOR, V25, P9524, DOI 10.12659/MSM.918333
   Luo Y, 2018, J CELL PHYSIOL, V233, P6929, DOI 10.1002/jcp.26596
   Mens MMJ, 2018, STEM CELL REV REP, V14, P309, DOI 10.1007/s12015 018 9808 y
   Narayanan A, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116676
   Obata A, 2012, ACS APPL MATER INTER, V4, P5684, DOI 10.1021/am301614a
   Omori H, 2021, CANCERS, V13, DOI 10.3390/cancers13143491
   Pang Ming, 2021, Hua Xi Kou Qiang Yi Xue Za Zhi, V39, P547, DOI 10.7518/hxkq.2021.05.008
   Qadir A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030565
   Rath B, 2008, J BIOMECH, V41, P1095, DOI 10.1016/j.jbiomech.2007.11.024
   Reid IR, 2020, NAT REV ENDOCRINOL, V16, P333, DOI 10.1038/s41574 020 0339 7
   Sawamoto K, 2020, CURR OSTEOPOROS REP, V18, P515, DOI 10.1007/s11914 020 00620 4
   Tevlek A, 2018, ARTIF CELL NANOMED B, V46, P1145, DOI 10.1080/21691401.2018.1481081
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang H, 2022, BIOENGINEERED, V13, P5709, DOI 10.1080/21655979.2021.2017626
   Wang XL, 2015, CURR PHARM DESIGN, V21, P1575, DOI 10.2174/1381612821666150115152841
   Wehner C, 2020, BMC ORAL HEALTH, V20, DOI 10.1186/s12903 020 01089 4
   Wei JW, 2015, REV ENDOCR METAB DIS, V16, P93, DOI 10.1007/s11154 014 9307 7
   Wu YX, 2020, MOL CELL BIOCHEM, V475, P161, DOI 10.1007/s11010 020 03868 7
   Yan XR, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964 021 00797 w
   Yu C, 2018, CARDIOVASC RES, V114, P168, DOI 10.1093/cvr/cvx180
   Zhang BB, 2020, EXP THER MED, V20, P3633, DOI 10.3892/etm.2020.9106
   Zhang W, 2018, ONCOTARGET, V9, P3690, DOI [10.18632/oncotarget.24286, 10.18632/oncotarget.23196]
   Zhang Y, 2018, INT J BIOL SCI, V14, P508, DOI 10.7150/ijbs.23318
   Zhao JJ, 2020, MOL MED REP, V22, P2537, DOI 10.3892/mmr.2020.11303
   Zhou S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128846
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 47
TC 1
Z9 1
U1 1
U2 39
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 875X
J9 FRONT SURG
JI Front. Surg.
PD APR 15
PY 2022
VL 9
AR 857170
DI 10.3389/fsurg.2022.857170
PG 12
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 3D9AF
UT WOS:000829586000001
PM 35495761
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, W
   Ren, YG
   Liu, H
AF Huang, Wei
   Ren, Yangguang
   Liu, Hui
TI Vasohibin 1 inhibits Adriamycin resistance in osteosarcoma cells via the
   protein kinase B signaling pathway
SO ONCOLOGY LETTERS
LA English
DT Article
DE vasohibin 1; osteosarcoma; Adriamycin resistance; P glycoprotein;
   protein kinase B
ID COLORECTAL CANCER; ENHANCES RESISTANCE; ANGIOGENESIS; EXPRESSION;
   REGULATOR; CARCINOMA; APOPTOSIS; GROWTH
AB Vasohibin (VASH) 1 functions as a negative feedback modulator of angiogenesis in vascular endothelial cells. Mesenchymal VASH1 has been demonstrated to be negatively associated with tumor progression, however studies regarding VASH1 in tumor cells and its functions remain limited. The function of VASH1 in osteosarcoma remains unknown. In the present study, it was confirmed that osteosarcoma cells express decreased levels of VASH1 compared with that expressed by human osteoblast cells. 143B cells with decreased VASH1 expression revealed increased Adriamycin (ADR) resistance compared with U 2OS cells with increased VASH1 expression. Subsequent to manipulating VASH1 expression via transfection, results revealed that overexpression of VASH1 in 143B cells inhibited P glycoprotein (P gp) expression and ADR resistance significantly; silencing VASH1 in U 2OS cells enhanced P gp expression and ADR resistance significantly. Research into the molecular mechanism was performed and the results identified that protein kinase B (AKT) and extracellular signal related kinase signal pathways were both stimulated by VASH1, but only AKT inhibitor LY294002 was identified to efficiently counteract increases in P gp expression that had been induced by silencing of VASH1 in U 2OS cells. ADR resistance promoted by silencing VASH1 in U 2OS cells was also counteracted by LY294002. In conclusion, the present study confirmed the low expression of VASH1 in osteosarcoma cells. It was identified that VASH1 was able to inhibit drug resistance in osteosarcoma cells through regulation of P gp via the AKT signal pathway. This demonstrated a negative regulation function of VASH1 in osteosarcoma, deepened understanding of the function of VASH1 in tumors and suggests a basis for further studies in to the functions of VASH1.
C1 [Huang, Wei] Shanxian Cent Hosp Shandong Prov, Dept Orthoped, Heze 274300, Shandong, Peoples R China.
   [Ren, Yangguang] First Peoples Hosp Jining City, Dept Hand & Foot Surg, Jining 272000, Shandong, Peoples R China.
   [Liu, Hui] Shanxian Cent Hosp Shandong Prov, Clin Lab, 1 Wenhua Rd, Heze 274300, Shandong, Peoples R China.
RP Liu, H (通讯作者)，Shanxian Cent Hosp Shandong Prov, Clin Lab, 1 Wenhua Rd, Heze 274300, Shandong, Peoples R China.
EM liuhui 0530@163.com
RI Yang, Guoqing/Q 7238 2017
CR Coch L, 2014, HEPATOLOGY, V60, P633, DOI 10.1002/hep.26995
   Colabufo NA, 2013, BIOORGAN MED CHEM, V21, P1324, DOI 10.1016/j.bmc.2012.12.021
   Esser L, 2017, J BIOL CHEM, V292, P446, DOI 10.1074/jbc.M116.755884
   He SL, 2017, ONCOL LETT, V13, P587, DOI 10.3892/ol.2016.5461
   Kern J, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 284
   Kitajima T, 2014, ANTICANCER RES, V34, P5321
   Liu RH, 2017, CELL PHYSIOL BIOCHEM, V41, P451, DOI 10.1159/000456598
   Liu S, 2015, ONCOTARGET, V6, P7880, DOI 10.18632/oncotarget.3493
   Miyashita H, 2011, PHARMACEUTICALS, V4, P782, DOI 10.3390/ph4060782
   Miyashita H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046459
   Sobhan Mohammad Reza, 2017, Asian Pac J Cancer Prev, V18, P549
   Takahashi Y, 2015, INT J ONCOL, V47, P2057, DOI 10.3892/ijo.2015.3193
   Tandia M, 2017, CANCER CHEMOTH PHARM, V79, P759, DOI 10.1007/s00280 017 3268 y
   Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152
   Wu YLD, 2017, TRANSL ONCOL, V10, P221, DOI 10.1016/j.tranon.2016.12.008
   Xiao XL, 2016, INT J ONCOL, V48, P2608, DOI 10.3892/ijo.2016.3488
   Yan YC, 2014, MED ONCOL, V31, DOI 10.1007/s12032 013 0816 0
   Yang K, 2016, ONCOTARGETS THER, V9, P7285, DOI 10.2147/OTT.S108929
   Zhang T, 2014, MED ONCOL, V31, DOI 10.1007/s12032 014 0963 y
   Zhao GN, 2012, MED ONCOL, V29, P3325, DOI 10.1007/s12032 012 0313 x
   Zhao M, 2016, MOL MED REP, V14, P4741, DOI 10.3892/mmr.2016.5806
NR 21
TC 5
Z9 5
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD APR
PY 2018
VL 15
IS 4
BP 5983
EP 5988
DI 10.3892/ol.2018.8074
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GD9HA
UT WOS:000430822500258
PM 29556314
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, JH
   Liu, YZ
   Yin, LJ
   Chen, L
   Huang, J
   Liu, Y
   Zhang, RX
   Zhou, LY
   Yang, QJ
   Luo, JY
   Zuo, GW
   Deng, ZL
   He, BC
AF Wang, Jin Hua
   Liu, Ying Zi
   Yin, Liang Jun
   Chen, Liang
   Huang, Jun
   Liu, Yang
   Zhang, Ran Xi
   Zhou, Long Yang
   Yang, Qiu Jun
   Luo, Jin Yong
   Zuo, Guo wei
   Deng, Zhong Liang
   He, Bai Cheng
TI BMP9 and COX 2 form an important regulatory loop in BMP9 induced
   osteogenic differentiation of mesenchymal stem cells
SO BONE
LA English
DT Article
DE BMP9; COX 2; Osteogenic differentiation; Mesenchymal stem cells;
   BMP/Smad signaling
ID BONE MORPHOGENETIC PROTEINS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   OSTEOBLAST DIFFERENTIATION; RECOMBINANT ADENOVIRUSES; MULTILINEAGE
   CELLS; TISSUE; CYCLOOXYGENASE 2; GROWTH; SYSTEM; REPAIR
AB Mesenchymal stem cells (MSCs) can self renew and differentiate into osteogenic, chondrogenic, adipogenic and myogenic lineages. It's reported that bone morphogenetic protein 9 (BMP9) is one of the most potent osteogenic BMPs to initiate the commitment of MSCs to osteoblast lineage. Cyclooxygenase 2 (COX 2) is critical for bone fracture healing and osteogenic differentiation in MSCs. However, the relationship between COX 2 and BMP9 in osteogenesis remains unknown. Herein, we investigate the role of COX 2 in BMP9 induced osteogenesis in MSCs. We demonstrate that COX 2 is up regulated as a target of BMP9 in MSCs. Both COX 2 inhibitor (NS 398) and COX 2 knockdown siRNAs can effectively decrease alkaline phosphatase (ALP) activities induced by BMP9 in MSCs. NS 398 also down regulates BMP9 induced expression of osteopontin and osteocalcin, so does the matrix mineralization. The in vivo studies indicate that knockdown of COX 2 attenuates BMP9 induced ectopic bone formation. In perinatal limb culture assay, NS 398 is shown to reduce the hypertropic chondrocyte zone and ossification induced by BMP9. Mechanistically, knockdown of COX 2 significantly inhibits the BMP9 up regulated expression of Runx2 and Dlx 5 in MSCs, which can be rescued by exogenous expression of COX 2. Furthermore, knockdown of COX 2 apparently reduces BMP9 induced BMPR Smad reporter activity, the phosphorylation of Smad1/5/8, and the expression of Smad6 and Smad7 in MSCs. NS 398 blocks the expression of BMP9 mediated by BMP9 recombinant adenovirus. Taken together, our findings suggest that COX 2 plays an important role in BMP9 induced osteogenic differentiation in MSCs; BMP9 and COX 2 may form an important regulatory loop to orchestrate the osteogenic differentiation in MSCs. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Wang, Jin Hua] Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing, Peoples R China.
   [Wang, Jin Hua] Chongqing Med Univ, Affiliated Hosp Stomatol, Chongqing 400016, Peoples R China.
   [Liu, Ying Zi; Yin, Liang Jun; Chen, Liang; Liu, Yang; Deng, Zhong Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Orthoped Surg, Chongqing 400016, Peoples R China.
   [Liu, Ying Zi; Huang, Jun; Zhang, Ran Xi; Zhou, Long Yang; Yang, Qiu Jun; He, Bai Cheng] Key Lab Biochem & Mol Pharmacol Chongqing, Chongqing, Peoples R China.
   [Liu, Ying Zi; Huang, Jun; Zhang, Ran Xi; Zhou, Long Yang; Yang, Qiu Jun; He, Bai Cheng] Chongqing Med Univ, Sch Pharm, Dept Pharmacol, Chongqing 400016, Peoples R China.
   [Luo, Jin Yong; Zuo, Guo wei] Chongqing Med Univ, Chinese Minist Educ, Key Lab Diagnost Med, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University
RP He, BC (通讯作者)，Chongqing Med Univ, Sch Pharm, Dept Pharmacol, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM hebaicheng99@yahoo.com
RI ; Huang, Junmeng/MIQ 2629 2025; Zhang, Xingyun/AFM 3848 2022
OI Yin, Liang jun/0000 0002 9244 4965; 
FU Natural Science Foundation of China (NSFC) [81071462]; Chongqing Science
   & Technology Commission (CSTC) [2011BB5129]
FX We thank Dr. Di Chen of the University of Rochester Medical Center for
   providing the BMP/Smad binding elements reporter plasmids (p12 x
   SBE Luc). This work was supported in part by research grants from the
   Natural Science Foundation of China (NSFC, 81071462 to BCH), Chongqing
   Science & Technology Commission (CSTC, 2011BB5129 to BCH).
CR Amoh Y, 2005, P NATL ACAD SCI USA, V102, P17734, DOI 10.1073/pnas.0508440102
   Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   Bleuming SA, 2007, CANCER RES, V67, P8149, DOI 10.1158/0008 5472.CAN 06 4659
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Damrongsri D, 2006, CLIN ORAL IMPLAN RES, V17, P38, DOI 10.1111/j.1600 0501.2005.01187.x
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097 4644(20000901)78:3<476::AID JCB12>3.0.CO;2 5
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HO ML, 1995, CLIN ORTHOP RELAT R, P270
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132
   Jane JA, 2002, MOL THER, V6, P464, DOI 10.1006/mthe.2002.0691
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   Kodach LL, 2008, GASTROENTEROLOGY, V134, P1332, DOI 10.1053/j.gastro.2008.02.059
   Li GH, 2005, J BONE MINER RES, V20, P1611, DOI 10.1359/JBMR.050513
   López Coviella I, 2000, SCIENCE, V289, P313, DOI 10.1126/science.289.5477.313
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Maroni P, 2011, BREAST CANCER RES TR, V129, P433, DOI 10.1007/s10549 010 1240 1
   Milano F, 2007, GASTROENTEROLOGY, V132, P2412, DOI 10.1053/j.gastro.2007.03.026
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Peng Y, 2003, J CELL BIOCHEM, V90, P1149, DOI 10.1002/jcb.10744
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Reddi AH, 2009, CYTOKINE GROWTH F R, V20, P341, DOI 10.1016/j.cytogfr.2009.10.015
   Ringe J, 2008, J TISSUE ENG REGEN M, V2, P136, DOI 10.1002/term.75
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Takahashi K, 2013, ARCH ORAL BIOL, V58, P690, DOI 10.1016/j.archoralbio.2012.10.018
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Thanan R, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/165879
   Truksa J, 2006, P NATL ACAD SCI USA, V103, P10289, DOI 10.1073/pnas.0603124103
   Vuolteenaho K, 2008, BASIC CLIN PHARMACOL, V102, P10, DOI 10.1111/j.1742 7843.2007.00149.x
   Wang K, 2011, J CANCER RES CLIN, V137, P1687, DOI 10.1007/s00432 011 1047 4
   Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097 2765(01)00421 X
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Yamada Y, 2013, STEM CELLS, V31, P572, DOI 10.1002/stem.1300
   Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhao YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043383
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 53
TC 59
Z9 66
U1 1
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2013
VL 57
IS 1
BP 311
EP 321
DI 10.1016/j.bone.2013.08.015
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 235TC
UT WOS:000325742600041
PM 23981660
DA 2025 08 17
ER

PT J
AU Hernandez Unzueta, I
   Benedicto, A
   Telleria, U
   Sanz, E
   Márquez, J
AF Hernandez Unzueta, Iera
   Benedicto, Aitor
   Telleria, Uxue
   Sanz, Eduardo
   Marquez, Joana
TI Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel
   Adjuvant Agent to Treat Prostate Cancer
SO NUTRIENTS
LA English
DT Article
DE prostate cancer; cancer nutrition; adjuvant; chemotherapy; resistance;
   tumor microenvironment; fibroblast; osteoblast
ID ENDOPLASMIC RETICULUM STRESS; TUMOR MICROENVIRONMENT; CELL DEATH; GREEN
   TEA; COLORECTAL CANCER; RESISTANCE; APOPTOSIS; AUTOPHAGY; THERAPY;
   GROWTH
AB Prostate cancer is one of the most common cancers among men. Although many patients respond favorably to first line treatments, castration and chemotherapy resistance arises after a few years, leading to metastasis. Thus, new approaches are being investigated using natural supplements to reinforce current therapies. Ocoxin is a plant based mixture with antitumor properties that have been proved in several cancers. Here, we evaluated the cytotoxic capacity of this compound itself and combined with Docetaxel, Enzalutamide and Olaparib as an adjuvant agent. We observed that Ocoxin reduced tumor cell viability; slowed down cell cycles; altered the expression of genes involved in DNA replication, cell cycles and the p53 signaling pathway; and reduced migratory capacity after stimulation with cancer associated fibroblasts (CAFs) and osteoblasts in vitro and reduced tumor volume in vivo. The combination of the nutritional supplement with chemotherapy showed a higher cytotoxic effect than chemotherapy alone and reverted chemoresistance conferred by CAFs and osteoblasts. Moreover, the adjuvant therapy also improved the outcome in vivo compared to the treatment with solo chemotherapy, where mice developed smaller tumors and less angiogenesis. Therefore, Ocoxin arises as a good candidate for further studies in combination with current treatments for prostate cancer patients.
C1 [Hernandez Unzueta, Iera; Benedicto, Aitor; Telleria, Uxue; Marquez, Joana] Univ Basque Country, Med & Nursing Fac, Cell Biol & Histol Dept, Leioa 48940, Spain.
   [Sanz, Eduardo] Catalysis SL, Res & Dev, Madrid 28016, Spain.
C3 University of Basque Country
RP Hernandez Unzueta, I; Márquez, J (通讯作者)，Univ Basque Country, Med & Nursing Fac, Cell Biol & Histol Dept, Leioa 48940, Spain.
EM iera.hernandez@ehu.eus
OI Telleria Gonzalez, Uxue/0000 0001 7254 9877; Benedicto,
   Aitor/0000 0002 3026 7190; MARQUEZ CLAVIJO, JOANA/0000 0002 6429 615X
FU Catalysis S.L
FX This research was partly funded by Catalysis S.L.
CR Aggarwal BB, 2007, J CELL BIOCHEM, V102, P580, DOI 10.1002/jcb.21500
   Al Janabi H, 2021, CANCER RES, V81, P5399, DOI 10.1158/0008 5472.CAN 21 2708
   Al Mahtab M, 2015, INDIAN J CANCER, V52, P443, DOI 10.4103/0019 509X.176699
   Andersen MK, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32549 1
   Bai BK, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.738235
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140 6736(00)04046 0
   Benedicto A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020686
   Casado Vela J, 2009, PROTEIN EXPRES PURIF, V66, P15, DOI 10.1016/j.pep.2009.02.007
   Cha HR, 2020, CANCER RES, V80, P1615, DOI 10.1158/0008 5472.CAN 19 2948
   Crocetto F, 2021, NUTRIENTS, V13, DOI 10.3390/nu13113750
   de Bono J, 2020, NEW ENGL J MED, V382, P2091, DOI 10.1056/NEJMoa1911440
   Dror CM, 2021, FUTURE ONCOL, V17, P2413, DOI 10.2217/fon 2020 1245
   Dutta A, 2018, J TOXICOL US, V2018, DOI 10.1155/2018/8978731
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Farzaei MH, 2016, CURR PHARM DESIGN, V22, P4201, DOI 10.2174/1381612822666160601100823
   Fernández A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264
   Fontana F, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020460
   Fujiki H, 2012, CANCER LETT, V324, P119, DOI 10.1016/j.canlet.2012.05.012
   Ramos MIF, 2021, MOL CLIN ONCOL, V14, DOI 10.3892/mco.2020.2167
   Gao SY, 2014, ASIAN PAC J CANCER P, V15, P6437, DOI 10.7314/APJCP.2014.15.15.6437
   Garodia Prachi, 2007, J Soc Integr Oncol, V5, P25, DOI 10.2310/7200.2006.029
   Haider MT, 2014, BONE, V66, P240, DOI 10.1016/j.bone.2014.06.023
   Han IH, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008126
   Hensel J, 2016, UROLOGY, V92, P6, DOI 10.1016/j.urology.2015.12.039
   Hernandez Unzueta I, 2019, PANCREAS, V48, P555, DOI 10.1097/MPA.0000000000001277
   Hernandez Unzueta I, 2017, ONCOL LETT, V13, P4002, DOI 10.3892/ol.2017.6016
   Hoang DT, 2017, ONCOTARGET, V8, P3724, DOI 10.18632/oncotarget.12554
   Hussain M, 2020, NEW ENGL J MED, V383, P2345, DOI 10.1056/NEJMoa2022485
   Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598
   Kaidarova DR, 2019, ONCOL LETT, V18, P5644, DOI 10.3892/ol.2019.10868
   Kallifatidis G, 2016, SEMIN CANCER BIOL, V40 41, P160, DOI 10.1016/j.semcancer.2016.06.003
   Kanehisa M, 2023, NUCLEIC ACIDS RES, V51, pD587, DOI 10.1093/nar/gkac963
   Kanehisa M, 2022, PROTEIN SCI, V31, P47, DOI 10.1002/pro.4172
   Karpisheh V, 2021, LIFE SCI, V284, DOI 10.1016/j.lfs.2021.119132
   Kwon JTW, 2021, ENDOCR RELAT CANCER, V28, pT95, DOI 10.1530/ERC 21 0149
   Lecumberri E, 2013, CLIN NUTR, V32, P894, DOI 10.1016/j.clnu.2013.03.008
   Li TL, 2013, AUTOPHAGY, V9, P1057, DOI 10.4161/auto.24632
   Li ZH, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 03166 2
   Lin SC, 2018, CURR OSTEOPOROS REP, V16, P642, DOI 10.1007/s11914 018 0480 6
   Litwin MS, 2017, JAMA J AM MED ASSOC, V317, P2532, DOI 10.1001/jama.2017.7248
   Ma J, 2022, CANCERS, V14, DOI 10.3390/cancers14102406
   Ma J, 2020, FOOD CHEM TOXICOL, V135, DOI 10.1016/j.fct.2019.110991
   Márquez J, 2016, ONCOL REP, V35, P1265, DOI 10.3892/or.2015.4486
   Martori C, 2022, CANCERS, V14, DOI 10.3390/cancers14020440
   Massagué J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038
   Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859
   Merseburger AS, 2016, ADV THER, V33, P1072, DOI 10.1007/s12325 016 0351 4
   Mo PL, 2010, J BIOL CHEM, V285, P26908, DOI 10.1074/jbc.M110.132597
   Muñoz Guardiola P, 2021, AUTOPHAGY, V17, P1349, DOI 10.1080/15548627.2020.1761651
   Nagireddy S, 2021, ADV EXP MED BIOL, V1329, P295, DOI 10.1007/978 3 030 73119 9_16
   Nisar S, 2022, BIOMED PHARMACOTHER, V154, DOI 10.1016/j.biopha.2022.113610
   Obradovic AZ, 2020, CLIN CANCER RES, V26, P3182, DOI 10.1158/1078 0432.CCR 19 3372
   Pandiella Alonso A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092661
   Patel Seema, 2016, Journal of Dietary Supplements, V13, P245, DOI 10.3109/19390211.2015.1008614
   Pietrovito L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030787
   Pereira PP, 2018, ARCH ESP UROL, V71, P306
   Prenen H, 2019, CELL MOL LIFE SCI, V76, P1447, DOI 10.1007/s00018 018 2997 3
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008 5472.CAN 09 3537
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Ruiz Lorente R., 2020, Adenocarcinoma, V11, P276, DOI [10.4236/jct.2020.115023, DOI 10.4236/JCT.2020.115023]
   Sadeghi S, 2019, EUR J MED CHEM, V178, P131, DOI 10.1016/j.ejmech.2019.05.067
   Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568 019 0238 1
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Salehi B, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071483
   Sánchez BG, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 0769 2
   Schatten H, 2018, ADV EXP MED BIOL, V1095, P1, DOI 10.1007/978 3 319 95693 0_1
   Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002 9440(10)64255 1
   Sekhoacha M, 2022, MOLECULES, V27, DOI 10.3390/molecules27175730
   Shanmugam MK, 2011, NUTR CANCER, V63, P161, DOI 10.1080/01635581.2011.523502
   Shevach J, 2019, CURR UROL REP, V20, DOI 10.1007/s11934 019 0924 2
   Shiao SL, 2016, CANCER LETT, V380, P340, DOI 10.1016/j.canlet.2015.12.022
   Shirakami Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23092284
   Shumsky A, 2019, MOL CLIN ONCOL, V10, P463, DOI 10.3892/mco.2019.1809
   Silk N, 2021, J XENOBIOTICS, V11, P16, DOI 10.3390/jox11010002
   Singla RK, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.745177
   Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363
   Stearns ME, 2011, TRANSL ONCOL, V4, P147, DOI 10.1593/tlo.10286
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Termini D, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111536
   Thirugnanam S, 2008, ONCOL REP, V20, P1387, DOI 10.3892/or_00000157
   Tummala R, 2017, MOL CANCER THER, V16, P2770, DOI 10.1158/1535 7163.MCT 17 0030
   Vellky JE, 2020, NEOPLASIA, V22, P566, DOI 10.1016/j.neo.2020.09.002
   Wang C, 2022, CANCER LETT, V525, P9, DOI 10.1016/j.canlet.2021.10.027
   Wang KL, 2022, METABOLITES, V12, DOI 10.3390/metabo12060535
   Wang N, 2014, J BONE MINER RES, V29, P2688, DOI 10.1002/jbmr.2300
   Wang PW, 2015, J NUTR BIOCHEM, V26, P408, DOI 10.1016/j.jnutbio.2014.11.017
   Wang XN, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030283
   Wang XN, 2010, CELL CYCLE, V9, P4542, DOI 10.4161/cc.9.22.13790
   Wu JB, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964 014 0066 6
   Xia Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22327 5
   Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712
   Zhang TY, 2017, ONCOTARGET, V8, P110052, DOI 10.18632/oncotarget.22123
   Zhang ZD, 2020, CANCER CELL, V38, P279, DOI 10.1016/j.ccell.2020.06.005
NR 93
TC 4
Z9 4
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD MAY 29
PY 2023
VL 15
IS 11
AR 2536
DI 10.3390/nu15112536
PG 24
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA I8EL3
UT WOS:001005061100001
PM 37299500
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kaijzel, EL
   Snoeks, TJA
   Buijs, JT
   van der Pluijm, G
   Löwik, CWGM
AF Kaijzel, Eric L.
   Snoeks, Thomas J. A.
   Buijs, Jeroen T.
   van der Pluijm, Gabri
   Lowik, Clemens W. G. M.
TI Multimodal imaging and treatment of bone metastasis
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Optical imaging; Bioluminescence; Fluorescence; Bone metastasis;
   Bisphosphonates; Bone morphogenetic protein 7; Computed tomography
ID PROSTATE CANCER PROGRESSION; BREAST CANCER; FLUORESCENT PROTEIN; DRUG
   DISCOVERY; QUANTUM DOTS; MOUSE MODEL; MECHANISMS; DISEASE; CELLS; LIGHT
AB The role of molecular imaging in pre clinical research is continuously evolving. Particularly in small animal models in biomedical research, optical imaging technologies are frequently used to visualize normal as well as aberrant cellular processes at a molecular genetic or cellular level of function. Also in cancer metastasis research, whole body bioluminescent and fluorescent imaging techniques have become indispensable tools that allow non invasive and real time imaging of gene expression, tumor progression and metastasis, and response to therapeutic intervention. In this paper, we discuss the use of optical imaging strategies either alone or in combination with CT  to study intrabone tumor growth, tumor progression and to monitor efficacy of therapeutic agents in metastatic bone disease.
C1 [Kaijzel, Eric L.; Snoeks, Thomas J. A.; Buijs, Jeroen T.; van der Pluijm, Gabri; Lowik, Clemens W. G. M.] Leiden Univ, Dept Endocrinol, Med Ctr, NL 2333 ZA Leiden, Netherlands.
   [Buijs, Jeroen T.; van der Pluijm, Gabri] Leiden Univ, Dept Urol, Med Ctr, NL 2333 ZA Leiden, Netherlands.
C3 Leiden University   Excl LUMC; Leiden University; Leiden University
   Medical Center (LUMC); Leiden University; Leiden University Medical
   Center (LUMC); Leiden University   Excl LUMC
RP Kaijzel, EL (通讯作者)，Leiden Univ, Dept Endocrinol, Med Ctr, C4 R,Room 89,Albinusdreef 2, NL 2333 ZA Leiden, Netherlands.
EM E.L.Kaijzel@lumc.nl
RI Buijs, Jeroen/E 6082 2011; Snoeks, Thomas/E 9742 2010; Kaijzel,
   Eric/GZN 2333 2022
OI Kaijzel, Eric/0000 0003 3118 9910; van der Pluijm,
   Gabri/0000 0002 1351 1884; Buijs, Jeroen/0000 0001 5816 9739; Snoeks,
   Thomas/0000 0003 3866 346X
FU EC FP6 [LSHB CT 2004 503569]; DiMI [LSHB CT 2005 512146]; PRIMA
   [FP6 504587]; PROMET [LSHC CT 2006 018858]
FX This work was supported in part by EC FP6 projects EMIL
   (LSHB CT 2004 503569), DiMI (LSHB CT 2005 512146), PRIMA (FP6 504587)
   and PROMET (LSHC CT 2006 018858)
CR ARGUELLO F, 1988, CANCER RES, V48, P6876
   Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008 5472.CAN 06 2490
   Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168
   Cai WB, 2006, NANO LETT, V6, P669, DOI 10.1021/nl052405t
   Chaudhari AJ, 2005, PHYS MED BIOL, V50, P5421, DOI 10.1088/0031 9155/50/23/001
   Chen XY, 2004, CANCER RES, V64, P8009, DOI 10.1158/0008 5472.CAN 04 1956
   Choy G, 2003, BIOTECHNIQUES, V35, P1022, DOI 10.2144/03355rr02
   Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10
   Claxton K, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8310
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336
   Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008 5472.CAN 05 3560
   Doubrovin M, 2004, BIOCONJUGATE CHEM, V15, P1376, DOI 10.1021/bc0498572
   Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140 6736(07)60781 8
   El Deiry WS, 2006, J CLIN ONCOL, V24, P3261, DOI 10.1200/JCO.2006.06.5623
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gross S, 2006, CURR OPIN CHEM BIOL, V10, P334, DOI 10.1016/j.cbpa.2006.06.028
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078 0432.CCR 06 1007
   Hastings JW, 1996, GENE, V173, P5, DOI 10.1016/0378 1119(95)00676 1
   Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717
   Inoue Y, 2008, MOL IMAGING, V7, P21, DOI 10.2310/7290.2008.0003
   Kalikin LM, 2003, CANCER BIOL THER, V2, P656
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920
   Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602
   Klerk CPW, 2007, BIOTECHNIQUES, V43, P7, DOI 10.2144/000112515
   KOK P, 2007, P SOC PHOTO OPT INS, V6509, P1
   Kozloff KM, 2007, J BONE MINER RES, V22, P1208, DOI 10.1359/JBMR.070504
   Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499
   Lenkinski RE, 2003, ACAD RADIOL, V10, P1159, DOI 10.1016/S1076 6332(03)00253 8
   Lipshutz GS, 2001, MOL THER, V3, P284, DOI 10.1006/mthe.2001.0267
   Love C, 2003, RADIOGRAPHICS, V23, P341, DOI 10.1148/rg.232025103
   Luker GD, 2002, J VIROL, V76, P12149, DOI 10.1128/JVI.76.23.12149 12161.2002
   Lyons SK, 2005, J PATHOL, V205, P194, DOI 10.1002/path.1697
   Mahmood U, 2003, MOL CANCER THER, V2, P489
   Mansfield JR, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2032458
   Marì C, 1999, Q J NUCL MED, V43, P259
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403
   Ntziachristos V, 2005, NAT BIOTECHNOL, V23, P313, DOI 10.1038/nbt1074
   Paget S., 1889, Cancer Metastasis Rev, V133, P571, DOI DOI 10.1016/S0140 6736(00)49915 0
   Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Rudin M, 2003, NAT REV DRUG DISCOV, V2, P123, DOI 10.1038/nrd1007
   Rudin M, 2005, MOL IMAGING BIOL, V7, P5, DOI 10.1007/s11307 004 0954 z
   Schellenberger EA, 2003, NEOPLASIA, V5, P187, DOI 10.1016/S1476 5586(03)80050 7
   Seoane J, 2006, CARCINOGENESIS, V27, P2148, DOI 10.1093/carcin/bgl068
   Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043
   Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037
   Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110
   Shcherbo D, 2007, NAT METHODS, V4, P741, DOI 10.1038/NMETH1083
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378 1119(91)90270 L
   Troy Tamara, 2004, Mol Imaging, V3, P9, DOI 10.1162/153535004773861688
   van der Pluijm G, 2000, CANCER TREAT REV, V26, P11, DOI 10.1053/ctrv.1999.0143
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077
   Waarsing JH, 2004, BONE, V34, P163, DOI 10.1016/j.bone.2003.08.012
   Wang L, 2004, P NATL ACAD SCI USA, V101, P16745, DOI 10.1073/pnas.0407752101
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933
   Weissleder R, 2008, NATURE, V452, P580, DOI 10.1038/nature06917
   Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103 123
   Wetterwald A, 2002, AM J PATHOL, V160, P1143, DOI 10.1016/S0002 9440(10)64934 6
   Yang M, 2006, CLIN CANCER RES, V12, P2602, DOI 10.1158/1078 0432.CCR 05 2050
   Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523
   Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937
   Zacharakis G, 2005, IEEE T MED IMAGING, V24, P878, DOI 10.1109/TMI.2004.843254
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201 1148
   Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200
   Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888
   Zhang HL, 2003, CLIN EXP METASTAS, V20, P153, DOI 10.1023/A:1022621622063
NR 74
TC 24
Z9 26
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD APR
PY 2009
VL 26
IS 4
BP 371
EP 379
DI 10.1007/s10585 008 9217 8
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 418UI
UT WOS:000264174500009
PM 18941911
OA hybrid
DA 2025 08 17
ER

PT J
AU Verrotti, A
   Agostinelli, S
   Coppola, G
   Parisi, P
   Chiarelli, F
AF Verrotti, A.
   Agostinelli, S.
   Coppola, G.
   Parisi, P.
   Chiarelli, F.
TI A 12 month longitudinal study of calcium metabolism and bone turnover
   during valproate monotherapy
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE bone turnover; calcium metabolism; idiopathic generalized epilepsy;
   valproate
ID TERM ANTICONVULSANT THERAPY; MINERAL DENSITY; CHILDREN; CARBAMAZEPINE;
   EPILEPSY; MARKERS
AB Background and purpose: Treatment with valproate (VPA) can cause changes in bone mineral metabolism, but the real influences and the underlying pathologic mechanisms are still unclear and under discussion. The aim of this study was to examine the changes on calcium metabolism and bone turnover in post pubertal male patients with newly diagnosed idiopathic generalized epilepsy (IGE) before (baseline evaluation) and 12 months after VPA monotherapy (second evaluation).
   Methods: Participants included 20 post pubertal males with IGE, aged 16.5 22.1 years. Also 20 post pubertal sex  and age matched healthy controls were evaluated. Physical activity, calcium and vitamin D intake were determined. Laboratory samples were obtained to measure biochemical parameters of bone metabolism and bone turnover: serum calcium, phosphate, magnesium, 25 hydroxyvitamin D, 1,25 dihydroxyvitamin D, intact parathyroid hormone, total alkaline phosphatase, bone alkaline phosphatase (bone ALP), osteocalcin (OC), carboxy terminal propeptide of type I procollagen (PICP) and carboxy terminal telopeptide of type I collagen (ICTP).
   Results: At baseline evaluation, there were no significant differences between controls and patients parameters. At second evaluation, patients showed both markers of bone formation and resorption significantly higher than baseline values (bone ALP: 51.2 +/  9.9 vs. 57.3 +/  9.3 U/l, P < 0.01; OC: 8.1 +/  1.1 vs. 10.4 +/  1.5 mu g/l, P < 0.01; PICP: 138.7 +/  16.4 vs. 152.6 +/  17.1 mu g/l, P < 0.01; ICTP: 3.8 +/  0.8 vs. 5.9 +/  0.6 mu g/l, P < 0.01).
   Conclusions: Valproate monotherapy in epileptic post pubertal males causes a significant increase of bone turnover.
C1 [Verrotti, A.; Agostinelli, S.; Chiarelli, F.] Chieti Univ Hosp, Dept Pediat, I 66100 Chieti, Italy.
   [Coppola, G.] Naples Univ Hosp, Dept Child Neuropsychiat, Naples, Italy.
   [Parisi, P.] II Fac Sapienza Univ, Chair Paediat, Rome, Italy.
C3 Sapienza University Rome
RP Verrotti, A (通讯作者)，Chieti Univ Hosp, Dept Pediat, Via Vestini 5, I 66100 Chieti, Italy.
EM averrott@unich.it
RI Parisi, Pasquale/JBS 0369 2023; Coppola, Giangennaro/AAC 1111 2019
OI , Alberto/0000 0002 3670 6115; Coppola, Giangennaro/0000 0002 9574 0081;
   
CR [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528 1157.1989.tb05316.x
   Babayigit A, 2006, PEDIATR NEUROL, V35, P177, DOI 10.1016/j.pediatrneurol.2006.03.004
   Baer MT, 1997, AM J CLIN NUTR, V65, P1042, DOI 10.1093/ajcn/65.4.1042
   Boluk A, 2004, PHARMACOL RES, V50, P93, DOI 10.1016/j.phrs.2003.11.011
   Dai SM, 2004, ANN RHEUM DIS, V63, P1379, DOI 10.1136/ard.2003.018481
   DENT CE, 1970, BRIT MED J, V4, P69, DOI 10.1136/bmj.4.5727.69
   Drezner MK, 2004, EPILEPSY BEHAV, V5, pS41, DOI 10.1016/j.yebeh.2003.11.028
   Ecevit CG, 2004, PEDIATR NEUROL, V31, P279, DOI 10.1016/j.pediatrneurol.2004.03.021
   Elwakkad ASE, 2008, EPILEPSY RES, V80, P47, DOI 10.1016/j.eplepsyres.2008.03.008
   Engel J, 2001, EPILEPSIA, V42, P796, DOI 10.1046/j.1528 1157.2001.10401.x
   Kim SH, 2007, EPILEPSY BEHAV, V10, P291, DOI 10.1016/j.yebeh.2006.11.007
   Koyama N, 2002, BIOCHEM BIOPH RES CO, V292, P937, DOI 10.1006/bbrc.2002.6753
   Kumandas S, 2006, J PEDIATR ENDOCR MET, V19, P529
   LIFSHITZ F, 1973, J PEDIATR US, V83, P612, DOI 10.1016/S0022 3476(73)80223 9
   Nicolaidou P, 2006, J CHILD NEUROL, V21, P205, DOI 10.2310/7010.2006.00050
   Öner N, 2004, J PAEDIATR CHILD H, V40, P470, DOI 10.1111/j.1440 1754.2004.00431.x
   Pack AM, 2008, NEUROLOGY, V70, P1586, DOI 10.1212/01.wnl.0000310981.44676.de
   Pack AM, 2004, EPILEPSY BEHAV, V5, pS24, DOI 10.1016/j.yebeh.2003.11.029
   Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445
   Sheth RD, 2008, EPILEPSIA, V49, P125, DOI 10.1111/j.1528 1167.2007.01253.x
   SHETH RD, 1995, J PEDIATR US, V127, P256, DOI 10.1016/S0022 3476(95)70304 7
   TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170
   Tekgul H, 2006, J CHILD NEUROL, V21, P411, DOI 10.1177/08830738060210050101
   Tsukahara H, 2002, PEDIATR INT, V44, P247, DOI 10.1046/j.1442 200X.2002.01561.x
   VALIMAKI MJ, 1994, J BONE MINER RES, V9, P631
   Verrotti A, 2002, EPILEPSIA, V43, P1488, DOI 10.1046/j.1528 1157.2002.13002.x
   VERROTTI A, 1989, EUR J PEDIATR, V149, P146, DOI 10.1007/BF01995874
   Voudris K, 2002, SEIZURE EUR J EPILEP, V11, P377, DOI 10.1053/seiz.2002.0671
NR 28
TC 33
Z9 36
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1351 5101
EI 1468 1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD FEB
PY 2010
VL 17
IS 2
BP 232
EP 237
DI 10.1111/j.1468 1331.2009.02773.x
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 544DP
UT WOS:000273633000013
PM 19682062
DA 2025 08 17
ER

PT J
AU Liang, W
   Ding, PB
   Qian, JY
   Li, G
   Lu, EH
   Zhao, ZM
AF Liang, Wei
   Ding, Pengbing
   Qian, Jiaying
   Li, Guan
   Lu, Enhang
   Zhao, Zhenmin
TI Polarized M2 macrophages induced by mechanical stretching modulate bone
   regeneration of the craniofacial suture for midfacial hypoplasia
   treatment
SO CELL AND TISSUE RESEARCH
LA English
DT Article
DE Trans sutural distraction osteogenesis; Mechanical stretching; M2
   macrophage; Suture derived stem cell; Osteoblast
ID LEUKEMIA ASSOCIATED MACROPHAGES; DISTRACTION OSTEOGENESIS; MAXILLARY
   COMPLEX; CYCLIC STRAIN; CELLS; MORPHOLOGY; IMMUNE; DIFFERENTIATION;
   TOPOGRAPHY; EXPRESSION
AB The underlying mechanism of the trans sutural distraction osteogenesis (TSDO) technique as an effective treatment that improves the symptoms of midfacial hypoplasia syndromes is not clearly understood. Increasing findings in the orthopedics field indicate that macrophages are mechanically sensitive and their phenotypes can respond to mechanical cues. However, how macrophages respond to mechanical stretching and consequently influence osteoblast differentiation of suture derived stem cells (SuSCs) remains unclear, particularly during the TSDO process. In the present study, we established a TSDO rat model to determine whether and how macrophages were polarized in response to stretching and consequently affected bone regeneration of the suture frontal edge. Notably, after performing immunofluorescence, RNA sequencing, and micro computed tomography, it was demonstrated that macrophages are first recruited by various chemokines factors and polarized to the M2 phenotype upon optimal stretching. The latter in turn regulates SuSC activity and facilitates bone regeneration in sutures. Moreover, when the activated M2 macrophages were suppressed by pharmacological manipulation, new bone microarchitecture could rarely be detected under mechanical stretching and the expansion of the sutures was clear. Additionally, macrophages achieved M2 polarization in response to the optimal mechanical stretching (10%, 0.5 Hz) and strongly facilitated SuSC osteogenic differentiation and human umbilical vein endothelial cell angiogenesis using an indirect co culture system in vitro. Collectively, this study revealed the mechanical stimulation immune response bone regeneration axis and clarified at least in part how sutures achieve bone regeneration in response to mechanical force.
C1 [Liang, Wei; Ding, Pengbing; Qian, Jiaying; Li, Guan; Lu, Enhang; Zhao, Zhenmin] Peking Univ, Dept Plast Surg, Hosp 3, Beijing 100191, Peoples R China.
C3 Peking University
RP Zhao, ZM (通讯作者)，Peking Univ, Dept Plast Surg, Hosp 3, Beijing 100191, Peoples R China.
EM zzmbysy@sina.com
OI Lu, Enhang/0000 0001 5782 9328
FU National Natural Science Funder of China [81571925]; Key Clinical
   Projects of Peking University Third Hospital [BYSY2018061]
FX This project was supported by the National Natural Science Funder of
   China (No. 81571925) and the Key Clinical Projects of Peking University
   Third Hospital (No. BYSY2018061).
CR Adams S, 2019, ANN BIOMED ENG, V47, P2213, DOI 10.1007/s10439 019 02302 4
   Ballotta V, 2014, BIOMATERIALS, V35, P4919, DOI 10.1016/j.biomaterials.2014.03.002
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Chen K, 2020, NANOSCALE, V12, P9359, DOI 10.1039/d0nr01625j
   Chen SY, 2015, J IMMUNOL, V194, P2919, DOI 10.4049/jimmunol.1400451
   Chen XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0279 5
   Chen ZT, 2017, ACS NANO, V11, P4494, DOI 10.1021/acsnano.6b07808
   Cho SW, 2014, P NATL ACAD SCI USA, V111, P1545, DOI 10.1073/pnas.1315153111
   Chu SY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09402 8
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duan RQ, 2021, MAT SCI ENG C MATER, V122, DOI 10.1016/j.msec.2021.111948
   Garg K, 2013, BIOMATERIALS, V34, P4439, DOI 10.1016/j.biomaterials.2013.02.065
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Gruden G, 2005, J AM SOC NEPHROL, V16, P688, DOI 10.1681/ASN.2004030251
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Guihard P, 2015, AM J PATHOL, V185, P765, DOI 10.1016/j.ajpath.2014.11.008
   Han YD, 2018, BIOCHEM BIOPH RES CO, V497, P305, DOI 10.1016/j.bbrc.2018.02.076
   Ikegame M, 2019, J HISTOCHEM CYTOCHEM, V67, P107, DOI 10.1369/0022155418793588
   Jaggy M, 2015, NANO LETT, V15, P7146, DOI 10.1021/acs.nanolett.5b03359
   James AW, 2010, PLAST RECONSTR SURG, V125, P1352, DOI 10.1097/PRS.0b013e3181d62980
   Juban G, 2017, FEBS LETT, V591, P3007, DOI 10.1002/1873 3468.12703
   Katebi N, 2012, ORTHOD CRANIOFAC RES, V15, P148, DOI 10.1111/j.1601 6343.2012.01547.x
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Lee J, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801106
   Li WL, 2020, J CELL PHYSIOL, V235, P5972, DOI 10.1002/jcp.29522
   Liang W, 2021, DRUG DES DEV THER, V15, P905, DOI 10.2147/DDDT.S299641
   Lin TH, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0730 z
   Loi F, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0276 5
   Martino MM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11051
   Matheson LA, 2006, J BIOMED MATER RES A, V76A, P52, DOI 10.1002/jbm.a.30448
   Matheson LA, 2006, BIOMATERIALS, V27, P226, DOI 10.1016/j.biomaterials.2005.05.070
   Matheson LA, 2006, BIOCHEM CELL BIOL, V84, P763, DOI 10.1139/O06 093
   Matsumoto T, 1996, J BIOMECH ENG T ASME, V118, P420, DOI 10.1115/1.2796026
   McWhorter FY, 2015, CELL MOL LIFE SCI, V72, P1303, DOI 10.1007/s00018 014 1796 8
   McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110
   Miyazaki H, 2001, BIO MED MATER ENG, V11, P301
   Morinobu M, 2003, J BONE MINER RES, V18, P1706, DOI 10.1359/jbmr.2003.18.9.1706
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Pugin J, 1998, AM J PHYSIOL LUNG C, V275, pL1040, DOI 10.1152/ajplung.1998.275.6.L1040
   Sasaki A, 2002, J ORAL MAXIL SURG, V60, P667, DOI 10.1053/joms.2002.33117
   Shan SZ, 2019, FASEB J, V33, P13254, DOI 10.1096/fj.201900799RR
   Shi MC, 2017, BIOMATERIALS, V144, P176, DOI 10.1016/j.biomaterials.2017.08.027
   Sun LG, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9842075
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takeshita N, 2017, J BONE MINER METAB, V35, P40, DOI 10.1007/s00774 016 0737 z
   Timberlake AT, 2019, P NATL ACAD SCI USA, V116, P15116, DOI 10.1073/pnas.1902041116
   Tong HZ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 37326 8
   Tong HZ, 2015, PLAST RECONSTR SURG, V136, P144, DOI 10.1097/PRS.0000000000001375
   Tong HZ, 2015, J CRANIOFAC SURG, V26, P402, DOI 10.1097/SCS.0000000000001263
   Wosik J, 2018, BIOPHYS J, V114, P2001, DOI 10.1016/j.bpj.2018.03.002
   Wu TF, 2017, INT J DEV BIOL, V61, P495, DOI 10.1387/ijdb.170051gc
   Xing ZQ, 2010, DIS MODEL MECH, V3, P451, DOI 10.1242/dmm.003186
   Xu Y, 2007, PLAST RECONSTR SURG, V119, P819, DOI 10.1097/01.prs.0000255540.91987.a0
   Yang F., 2020, CANCER RES, V80, P3677, DOI DOI 10.1158/0008 5472.CAN 20 0034
   Yang X, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412910
   Yilmaz E, 2019, PEDIATR NEUROL, V99, P7, DOI 10.1016/j.pediatrneurol.2019.01.018
   Ying W, 2013, JOVE J VIS EXP, DOI 10.3791/50323
NR 59
TC 23
Z9 29
U1 1
U2 30
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0302 766X
EI 1432 0878
J9 CELL TISSUE RES
JI Cell Tissue Res.
PD DEC
PY 2021
VL 386
IS 3
BP 585
EP 603
DI 10.1007/s00441 021 03533 5
EA SEP 2021
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA WY6RC
UT WOS:000701279300001
PM 34568957
DA 2025 08 17
ER

PT J
AU Sheng, N
   Xing, F
   Zhang, QY
   Tan, J
   Nie, R
   Huang, K
   Li, HX
   Jiang, YL
   Tan, B
   Xiang, Z
   Xie, HQ
AF Sheng, Ning
   Xing, Fei
   Zhang, Qing Yi
   Tan, Jie
   Nie, Rong
   Huang, Kai
   Li, He Xi
   Jiang, Yan Lin
   Tan, Bo
   Xiang, Zhou
   Xie, Hui Qi
TI A pleiotropic SIS based hydrogel with immunomodulation via NLRP3
   inflammasome inhibition for diabetic bone regeneration
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Bone regeneration; Small intestinal submucosa; BMP 4; Hydrogel;
   Extracellular Matrix; Diabetes mellitus
ID M2 MACROPHAGE POLARIZATION; GRAPHENE OXIDE; SCAFFOLDS; MATRIX
AB As a progressive inflammatory disease, diabetes mellitus significantly changes the immuno microenvironment, causing an elevation in M1 macrophages and inflammatory mediators. This inflammation condition possesses a negative impact on the cellular function of osteoblasts and vascular endothelial cells, resulting in impaired bone defect repair involving both angiogenesis and osteogenesis. In our study, a good biocompatible hydrogel, GB@SIS, was successfully fabricated for bone repair under diabetic conditions. This hydrogel consists of a porcine small intestinal submucosal (SIS) extracellular matrix with thermosensitivity, bionic structure, and proangiogenic properties, and BMP 4 loaded on graphene oxide (GO) can be sustainably released from the hydrogel. In vitro studies have shown that the composite hydrogel possesses a good ability to promote angiogenesis and enhance osteogenesis. Additionally, the hydrogel was also able to promote macrophage conversion from M1 to M2 macrophages, which subsequently results in the release of osteogenesis related factors, specifically BMP 2. In a diabetic rat model with critical size cranial defects, the GB@SIS hydrogel modulates the inflammatory microenvironment and significantly accelerates the process of bone repair. Subsequent investigations have revealed that the GB@SIS hydrogel exerts immunomodulatory effects via the suppression of the NLRP3 signaling pathway and the elevation of adhesion related protein expression. In conclusion, the GB@SIS hydrogel demonstrates promising osteogenic characteristics as a biomaterial, exhibiting bone immunomodulatory properties that hold potential for its application in bone regeneration therapy specifically for diabetic patients.
C1 [Sheng, Ning; Xing, Fei; Zhang, Qing Yi; Tan, Jie; Nie, Rong; Huang, Kai; Li, He Xi; Jiang, Yan Lin; Xiang, Zhou; Xie, Hui Qi] Sichuan Univ, Dept Orthoped Surg, Chengdu, Peoples R China.
   [Sheng, Ning; Xing, Fei; Zhang, Qing Yi; Tan, Jie; Nie, Rong; Huang, Kai; Li, He Xi; Jiang, Yan Lin; Xiang, Zhou; Xie, Hui Qi] Sichuan Univ, West China Hosp, Orthoped Res Inst, Lab Stem Cell & Tissue Engn,State Key Lab Biothe, Chengdu, Peoples R China.
   [Jiang, Yan Lin; Xie, Hui Qi] Frontier Med Ctr, Tianfu Jincheng Lab, Chengdu 610212, Peoples R China.
   [Tan, Bo] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Orthoped Surg, Chengdu, Peoples R China.
   [Tan, Jie] Huazhong Univ Sci Technol Union, Shenzhen Hosp, Dept Spine Surg, Shenzhen 518052, Guangdong, Peoples R China.
C3 Sichuan University; Sichuan University; Tianfu Jincheng Laboratory;
   University of Electronic Science & Technology of China; Sichuan
   Provincial People's Hospital; Huazhong University of Science &
   Technology
RP Xiang, Z; Xie, HQ (通讯作者)，Sichuan Univ, Dept Orthoped Surg, Chengdu, Peoples R China.; Xiang, Z; Xie, HQ (通讯作者)，Sichuan Univ, West China Hosp, Orthoped Res Inst, Lab Stem Cell & Tissue Engn,State Key Lab Biothe, Chengdu, Peoples R China.
EM xiaoning_sheng@163.com; xingfeihuaxi@163.com; zhangqingyi@outlook.com;
   tanjie900101@126.com; nierong0808@163.com; huangkai.97@foxmail.com;
   lisshx@126.com; jiangyanlinhappy@163.com; tanboo8@163.com;
   xiangzhou@scu.edu.cn; xiehuiqi@scu.edu.cn
RI Huang, Kaiyin/AAP 6059 2020; Xie, Huiqi/GNP 6902 2022; fei,
   xing/AAC 2383 2022; Tan, Jie/IVV 5250 2023; Nie,
   Charlotte/HSE 7359 2023; sheng, 盛宁/KYR 0222 2024; Jiang,
   Yanlin/LSK 7102 2024
OI Sheng, Ning/0000 0002 9146 8762; Xing, Fei/0000 0002 9485 2946
FU The "1.3.5" Project for Disciplines of Excellence, West China Hospital,
   Sichuan University [ZYJC18002]; Frontiers Medical Center, Tianfu
   Jincheng Laboratory Foundation [TFJC2023010002]; Key Research and
   Development Program of Sichuan Provincial Department of Science and
   Technology [2022YFS0097]; National Natural Science Foundation of China
   [82202705]
FX This work has been jointly supported by the "1.3.5" Project for
   Disciplines of Excellence, West China Hospital, Sichuan University
   (ZYJC18002) ; the Frontiers Medical Center, Tianfu Jincheng Laboratory
   Foundation (TFJC2023010002) ; Key Research and Development Program of
   Sichuan Provincial Department of Science and Technology (Grant No.
   2022YFS0097) and National Natural Science Foundation of China (82202705)
   .
CR Andree B, 2013, TISSUE ENG PART B RE, V19, P279, DOI [10.1089/ten.teb.2012.0583, 10.1089/ten.TEB.2012.0583]
   Azzarello J, 2007, BIOMED MATER, V2, P55, DOI 10.1088/1748 6041/2/2/001
   Bai L, 2018, BIOMATERIALS, V162, P154, DOI 10.1016/j.biomaterials.2018.02.010
   Banerjee P, 2015, ECOTOX ENVIRON SAFE, V119, P47, DOI 10.1016/j.ecoenv.2015.04.022
   Böni Schnetzler M, 2019, SEMIN IMMUNOPATHOL, V41, P501, DOI 10.1007/s00281 019 00745 4
   Camargo WA, 2017, TISSUE ENG PART B RE, V23, P471, DOI [10.1089/ten.teb.2016.0370, 10.1089/ten.TEB.2016.0370]
   Chen M, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02628 8
   Cheng KM, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.918483
   Dai JZ, 2017, CELL PHYSIOL BIOCHEM, V43, P247, DOI 10.1159/000480367
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Elmadbouh I, 2021, CELLS BASEL, V10, DOI 10.3390/cells10102640
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Hartog A, 2013, EXP BIOL MED, V238, P798, DOI 10.1177/1535370213480740
   Heng BC, 2023, ADV SCI, V10, DOI 10.1002/advs.202204502
   Ji YH, 2019, J BIOMED MATER RES A, V107, P689, DOI 10.1002/jbm.a.36582
   Jiao Y, 2021, CRIT CARE, V25, DOI 10.1186/s13054 021 03775 3
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   La WG, 2014, INT J NANOMED, V9, P107, DOI 10.2147/IJN.S50742
   Li YZ, 2022, BIOACT MATER, V18, P213, DOI 10.1016/j.bioactmat.2022.03.021
   Li YW, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01400 z
   Liu C, 2015, RSC ADV, V5, P30727, DOI 10.1039/c5ra02355f
   Liu D, 2019, CLIN SCI, V133, P565, DOI 10.1042/CS20180600
   Lv L, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800675
   Martínez VG, 2017, CLIN CANCER RES, V23, P7388, DOI 10.1158/1078 0432.CCR 17 1004
   Narayanan KB, 2021, FOOD CHEM, V342, DOI 10.1016/j.foodchem.2020.128385
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Pecci A, 2018, GENE, V664, P152, DOI 10.1016/j.gene.2018.04.048
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635
   Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590 021 00886 5
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Sheng N, 2023, MATER TODAY BIO, V23, DOI 10.1016/j.mtbio.2023.100835
   Song YL, 2023, ADV SCI, V10, DOI 10.1002/advs.202304023
   Sun H, 2022, DIABETES RES CLIN PR, V183, DOI 10.1016/j.diabres.2021.109119
   Sun X, 2021, BIOACT MATER, V6, P757, DOI 10.1016/j.bioactmat.2020.08.030
   Sun Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12866
   Tan J, 2022, COMPOS PART B ENG, V243, DOI 10.1016/j.compositesb.2022.110149
   Teng YY, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.902894
   Tian HC, 2014, BIOMATERIALS, V35, P2120, DOI 10.1016/j.biomaterials.2013.11.058
   Witherel CE, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2021.120667
   Wu ZR, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200298
   Xu X, 2023, BIOACT MATER, V25, P701, DOI 10.1016/j.bioactmat.2022.07.006
   Zhang F, 2021, FASEB J, V35, DOI 10.1096/fj.202002374R
   Zhang JM, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10329
   Zhang JC, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.808212
   Zhang QY, 2023, COMPOS PART B ENG, V254, DOI 10.1016/j.compositesb.2023.110550
   Zhang XW, 2022, BIOACT MATER, V10, P15, DOI 10.1016/j.bioactmat.2021.09.014
   Zhu HM, 2023, DIABETOLOGIA, V66, P288, DOI 10.1007/s00125 022 05809 z
NR 47
TC 20
Z9 21
U1 28
U2 95
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD JAN 15
PY 2024
VL 480
AR 147985
DI 10.1016/j.cej.2023.147985
EA DEC 2023
PG 18
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA EE4E7
UT WOS:001137222100001
DA 2025 08 17
ER

PT J
AU Sen, S
   Diercke, K
   Zingler, S
   Lux, CJ
   Erber, R
AF Sen, S.
   Diercke, K.
   Zingler, S.
   Lux, C. J.
   Erber, R.
TI Compression Induces Ephrin A2 in PDL Fibroblasts via c fos
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE Eph family receptors; tooth movement; cellular mechanotransduction;
   mitogen activated protein kinase 1; periodontal ligament; serum response
   element
ID PERIODONTAL LIGAMENT FIBROBLASTS; DEPENDENT UP REGULATION; TYROSINE
   KINASE; OSTEOBLASTIC CELLS; ACTIVATION; EXPRESSION; PROTEIN; STRESS;
   OSTEOGENESIS; AP 1
AB Ephrin A2 EphA2 and ephrin B2 EphB4 interactions have been implicated in the regulation of bone remodeling. We previously demonstrated a potential role for members of the Eph ephrin family of receptor tyrosine kinases for bone remodeling during orthodontic tooth movement: compression dependent upregulation of ephrin A2 in fibroblasts of the periodontal ligament (PDL) attenuated osteogenesis in osteoblasts of the alveolar bone. However, factors affecting the regulation of ephrin A2 expression upon the application of compressive forces remained unclear. Here, we report a mechano dependent pathway of ephrin A2 induction in PDL fibroblasts (PDLFs) involving extracellular signal regulated kinases (ERK) 1/2 and c fos. PDLF subjected to compressive forces (30.3 g/cm(2)) upregulated c fos and ephrin A2 mRNA and protein expression and displayed increased ERK1/2 phosphorylation. Inhibition of the MAP kinase kinase (MEK)/ERK1/2 pathway using the specific MEK inhibitor U0126 significantly reduced ephrin A2 messenger RNA upregulation upon compression. Silencing of c fos using a small interfering RNA approach led to a significant inhibition of ephrin A2 induction upon the application of compressive forces. Interestingly, ephrin A2 stimulation of PDLF induced c fos expression and led also to the induction of ephrin A2 expression. Using a reporter gene construct in murine 3T3 cells, we found that ephrin A2 was able to stimulate serum response element (SRE) dependent luciferase activity. As the regulation of c fos is SRE dependent, ephrin A2 might induce c fos via SRE activation. Taken together, we provide evidence for an ERK1/2  and c fos dependent regulation of ephrin A2 in compressed PDLF and suggest a novel pathway for ephrin A2 induction emanating from ephrin A2 itself. We showed previously that ephrin A2 at compression sites might contribute to tooth movement by inhibiting osteogenic differentiation. The regulatory pathway of ephrin A2 induction during tooth movement identified in this study might be accessible for pharmacological interventions.
C1 [Sen, S.; Diercke, K.; Zingler, S.; Lux, C. J.; Erber, R.] Heidelberg Univ, Sch Dent, Dept Orthodont & Dentofacial Orthopaed, D 69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Erber, R (通讯作者)，Heidelberg Univ, Sch Dent, Dept Orthodont & Dentofacial Orthopaed, Neuenheimer Feld 400, D 69120 Heidelberg, Germany.
EM ralf.erber@med.uni heidelberg.de
RI Sen, Sinan/V 7915 2019; Erber, Ralf/AAF 3002 2020
OI Sen, Sinan/0000 0001 5907 5398; Lux, Christopher J./0000 0002 6995 5572
FU Dres. Majic Schlez Foundation; University of Heidelberg
FX This investigation was supported by a grant from the Dres.
   Majic Schlez Foundation to S.S. and by a grant from the "FRONTIER
   Innovationsfonds" of the University of Heidelberg. We thank Annette Kohl
   for expert technical assistance. The authors declare no potential
   conflicts of interest with respect to the authorship and/or publication
   of this article.
CR Buchwalter G, 2004, GENE, V324, P1, DOI 10.1016/j.gene.2003.09.028
   Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409
   Diercke K, 2011, J DENT RES, V90, P1108, DOI 10.1177/0022034511413926
   Diercke K, 2011, J BIOL CHEM, V286, P37651, DOI 10.1074/jbc.M110.166900
   Fitzgerald JB, 2008, J BIOL CHEM, V283, P6735, DOI 10.1074/jbc.M708670200
   Glantschnig H, 1996, EUR J CLIN INVEST, V26, P544, DOI 10.1046/j.1365 2362.1996.165312.x
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804
   Husse B, 2007, AM J PHYSIOL REG I, V293, pR1898, DOI 10.1152/ajpregu.00804.2006
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Kawarizadeh A, 2005, J DENT RES, V84, P902, DOI 10.1177/154405910508401006
   Kletsas D, 2002, J CELL PHYSIOL, V190, P313, DOI 10.1002/jcp.10052
   Kook SH, 2009, J CELL BIOCHEM, V106, P1060, DOI 10.1002/jcb.22085
   Korff T, 2008, BLOOD, V112, P73, DOI 10.1182/blood 2007 12 128835
   Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898 6568(00)00096 6
   Li J, 2007, MOL CELL BIOCHEM, V304, P45, DOI 10.1007/s11010 007 9484 8
   Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604
   Obi S, 2009, J APPL PHYSIOL, V106, P203, DOI 10.1152/japplphysiol.00197.2008
   Peake MA, 2003, FEBS LETT, V537, P117, DOI 10.1016/S0014 5793(03)00108 X
   Peverali FA, 2001, MOL MED, V7, P68, DOI 10.1007/BF03401840
   Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758
   Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185
   Yokoyama K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073210
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 24
TC 16
Z9 21
U1 0
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD MAR
PY 2015
VL 94
IS 3
BP 464
EP 472
DI 10.1177/0022034514567197
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CC2CB
UT WOS:000350151400010
PM 25604255
OA Green Published
DA 2025 08 17
ER

PT J
AU Hayer, S
   Niederreiter, B
   Kalkgruber, M
   Wanic, K
   Maissner, J
   Smolen, JS
   Aletaha, D
   Blüml, S
   Redlich, K
AF Hayer, S.
   Niederreiter, B.
   Kalkgruber, M.
   Wanic, K.
   Maissner, J.
   Smolen, J. S.
   Aletaha, D.
   Blueml, S.
   Redlich, K.
TI Analysis of combined deficiency of interleukin 1 and 6 versus single
   deficiencies in TNF  mediated arthritis and systemic bone loss
SO BONE & JOINT RESEARCH
LA English
DT Article
DE Experimental arthritis; Cytokine; Inflammatory joint damage;
   Inflammatory systemic bone loss
ID TUMOR NECROSIS FACTOR; RHEUMATOID ARTHRITIS; OSTEOCLAST FORMATION;
   MURINE MODEL; MICE; INFLAMMATION; COMBINATION; THERAPY; DAMAGE; CELLS
AB Aims
   Insufficient treatment response in rheumatoid arthritis (RA) patients requires novel treatment strategies to halt disease progression. The potential benefit of combination of cytokine inhibitors in RA is still unclear and needs further investigation. To explore the impact of combined deficiency of two major cytokines, namely interleukin (IL) 1 and IL 6, in this study double deficient mice for IL 1 alpha beta and IL 6 were investigated in different tumour necrosis factor (TNF) driven inflammatory bone disorders, namely peripheral arthritis and sacroiliitis, as well as systemic bone loss.
   Methods
   Disease course, histopathological features of arthritis, and micro CT (mu CT) bone analysis of local and systemic bone loss were assessed in 15 week old IL1( / )IL6( / )hTNFtg in comparison to IL1( / )hTNFtg, IL6( / )hTNFtg, and hTNFtg mice. mu CT bone analysis of single deficient and wild type mice was also performed.
   Results
   Combined deficiency of IL 1/IL 6 markedly ameliorated TNF mediated arthritis and bilateral sacroiliitis, but without additive benefits compared to single IL 1 deficiency. This finding confirms the important role of IL 1 and the marginal role of IL 6 in TNF driven pathways of local joint damage, but questions the efficacy of potential combinatorial therapies of IL 1 and IL 6 in treatment of RA. In contrast, combined deficiency of IL 1/IL 6 led to an additive protective effect on TNF driven systemic bone loss compared to single IL 1 and IL 6 deficiency. This finding clearly indicates a common contribution of both IL 1 and IL 6 in TNF driven systemic bone loss, and points to a discrepancy of cytokine dependency in local and systemic TNF driven mechanisms of inflammatory arthritis.
   Conclusion
   Combinatorial treatments in RA might provide different benefits to inflammatory local arthritis and systemic comorbidities.
C1 [Hayer, S.; Niederreiter, B.; Kalkgruber, M.; Wanic, K.; Maissner, J.; Smolen, J. S.; Aletaha, D.; Blueml, S.; Redlich, K.] Med Univ Vienna, Vienna, Austria.
   [Smolen, J. S.] Med Univ Vienna, Div Rheumatol, Vienna, Austria.
   [Aletaha, D.] Med Univ Vienna, Div Rheumatol, Vienna, Austria.
   [Blueml, S.] Med Univ Vienna, Div Rheumatol, Dept Internal Med 3, Vienna, Austria.
   [Redlich, K.] Med Univ Vienna, Div Rheumatol, Dept Med 2, Dept Internal Med 3, Vienna, Austria.
   [Redlich, K.] Karl Landsteiner Inst Rheumatol & Clin Immunol, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna; Medical University of Vienna; Medical University
   of Vienna
RP Hayer, S (通讯作者)，Med Univ Vienna, Vienna, Austria.
EM silvia.hayer@meduniwien.ac.at
RI ; Smolen, Josef/ADI 7087 2022
OI Hayer, Silvia/0000 0003 1334 5668; Wanic, Konrad/0000 0003 2995 7781;
   Bluml, Stephan/0000 0002 2758 4400
CR Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461
   Alves CH, 2016, CLIN REV ALLERG IMMU, V51, P27, DOI 10.1007/s12016 015 8522 7
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Blüml S, 2015, ANN RHEUM DIS, V74, P227, DOI 10.1136/annrheumdis 2013 203486
   Blüml S, 2014, SEMIN IMMUNOPATHOL, V36, P531, DOI 10.1007/s00281 014 0442 8
   Blüml S, 2012, INT IMMUNOL, V24, P275, DOI 10.1093/intimm/dxs047
   Blüml S, 2010, ARTHRITIS RHEUM US, V62, P1608, DOI 10.1002/art.27399
   Fardellone P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103361
   Genovese MC, 2004, ARTHRITIS RHEUM US, V50, P1412, DOI 10.1002/art.20221
   González Chávez SA, 2020, BONE JOINT RES, V9, P36, DOI 10.1302/2046 3758.91.BJR 2019 0055.R2
   Hayer S, 2007, ARTHRITIS RHEUM US, V56, P79, DOI 10.1002/art.22313
   Hayer S, 2021, ANN RHEUM DIS, V80, P714, DOI 10.1136/annrheumdis 2020 219247
   Hayer S, 2019, J BONE MINER RES, V34, P1632, DOI 10.1002/jbmr.3748
   Hayer S, 2010, ANN RHEUM DIS, V69, P1403, DOI 10.1136/ard.2010.129148
   HOLMDAHL R, 1989, CLIN EXP RHEUMATOL, V7, pS51
   Horai R, 1998, J EXP MED, V187, P1463, DOI 10.1084/jem.187.9.1463
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Koenders MI, 2005, AM J PATHOL, V167, P141, DOI 10.1016/S0002 9440(10)62961 6
   Ota N, 2001, J HUM GENET, V46, P267, DOI 10.1007/s100380170077
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Polzer K, 2010, ANN RHEUM DIS, V69, P284, DOI 10.1136/ard.2008.104786
   Redlich K, 2004, ARTHRITIS RHEUM, V50, P1001, DOI 10.1002/art.20194
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Rotta D, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.613720
   Saferding V, 2017, J AUTOIMMUN, V82, P74, DOI 10.1016/j.jaut.2017.05.006
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   Smolen JS, 2020, ANN RHEUM DIS, V79, P685, DOI 10.1136/annrheumdis 2019 216655
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Weinblatt M, 2007, ANN RHEUM DIS, V66, P228, DOI 10.1136/ard.2006.055111
   Zwerina J, 2007, P NATL ACAD SCI USA, V104, P11742, DOI 10.1073/pnas.0610812104
NR 30
TC 5
Z9 5
U1 0
U2 1
PU BRITISH EDITORIAL SOC BONE & JOINT SURGERY
PI LONDON
PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND
SN 2046 3758
J9 BONE JOINT RES
JI Bone Jt. Res.
PD JUL
PY 2022
VL 11
IS 7
BP 484
EP 493
DI 10.1302/2046 3758.117.BJR 2021 0481.R1
PG 10
WC Cell & Tissue Engineering; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA 2Z5ZW
UT WOS:000826656700007
PM 35801532
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nagase, S
   Ohyama, M
   Hashimoto, Y
   Small, M
   Kuwayama, T
   Deacon, S
AF Nagase, Shinichi
   Ohyama, Michiyo
   Hashimoto, Yoshitaka
   Small, Maria
   Kuwayama, Tomohiro
   Deacon, Steve
TI Pharmacodynamic Effects on Biochemical Markers of Bone Turnover and
   Pharmacokinetics of the Cathepsin K Inhibitor, ONO 5334, in an Ascending
   Multiple Dose, Phase 1 Study
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE Cathepsin K inhibitor; osteoporosis; phase 1; pharmacodynamics;
   biochemical markers of bone turnover; ONO 5334
ID POSTMENOPAUSAL WOMEN; ALENDRONATE THERAPY; MATRIX DEGRADATION;
   OSTEOPOROSIS; PYCNODYSOSTOSIS; OSTEOPETROSIS; DEFICIENCY; ODANACATIB;
   DENSITY; ACID
AB Selective inhibitors of cathepsin K, which has a major role in the degradation of bone collagen, are potential new treatments for osteoporosis. The pharrnacokinetics and the pharmacodynamic effects on biochemical markers of bone turnover of the new cathepsin K inhibitor, ONO 5334, were investigated in a multiple ascending dose, phase 1 study. A total of 120 healthy postmenopausal women were enrolled, and doses of 10 to 600 mg once daily and 50 and 300 mg twice daily were evaluated in 15  and 28 day multiple dosing cohorts. Plasma ONO 5334 concentration reached steady state within 2 days. Twenty four hours after the last dose in the 15 day multiple dose cohort, 100, 300, and 600 mg once daily reduced urinary C terminal telopeptide of type I collagen by a mean (+/  standard deviation) 44.9% +/  13.6%, 84.5% +/  4.4%, and 92.5% +/  1.3%, respectively. The 28 day cohort showed similar effects. There were far smaller effects on bone specific alkaline phosphatase (B ALP), tartrate resistant acid phosphatase 5b (TRAP5b), or osteocalcin (OC) (measured after 28 days). ONO 5334 was well tolerated up to 600 mg/d and for up to 28 days of multiple dosing. Multiple dosing with ONO 5334 100 mg resulted in considerable suppression of bone resorption markers with no appreciable effects on bone formation markers (B ALP, OC) or osteoclast number (TRAP5b).
C1 [Nagase, Shinichi; Small, Maria; Kuwayama, Tomohiro; Deacon, Steve] ONO PHARMA UK LTD, Clin Dev, London W1H 7AA, England.
   [Ohyama, Michiyo] Ono Pharmaceut Co Ltd, Clin Dev Planning, Osaka, Japan.
   [Hashimoto, Yoshitaka] Ono Pharmaceut Co, Pharmacokinet Res Grp, Ibaraki, Japan.
C3 Ono Pharmaceutical Co Ltd; Ono Pharmaceutical Co Ltd; Ono Pharmaceutical
   Co Ltd
RP Nagase, S (通讯作者)，ONO PHARMA UK LTD, Clin Dev, 11th Floor,Marble Arch Tower,55 Bryanston St, London W1H 7AA, England.
EM s nagase@ono uk.co.uk
RI Hashimoto, Yoshitaka/AAH 8503 2020
FU Ono Pharmaceutical Co., Ltd.
FX The study was sponsored by Ono Pharmaceutical Co., Ltd. and managed
   through the company's European office (ONO PHARMA UK LTD). No author is
   a fellow of the American College of Clinical Pharmacology. Shinichi
   Nagase, Michiyo Ohyama, Yoshitaka Hashimoto, Maria Small, Tomohiro
   Kuwayama, and Steve Deacon are employees of Ono Pharmaceutical Co., Ltd.
   or its European office, ONO PHARMA UK LTD.
CR Adami S, AM SOC BON MIN RES 2
   [Anonymous], DAT FIL INH ON COMP
   BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Bone HG, 2010, J BONE MINER RES, V25, P937, DOI 10.1359/jbmr.091035
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236
   Goh SK, 2007, J BONE JOINT SURG BR, V89B, P349, DOI 10.1302/0301 620X.89B3.18146
   Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654
   Nishi Y, 1999, J BONE MINER RES, V14, P1902, DOI 10.1359/jbmr.1999.14.11.1902
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   *ON PHARM CO LTD, DAT FIL INH EFF ONO
   *ON PHARM CO LTD, DAT FIL PHAS 1 3 PAR
   Pennypacker BL, 2010, J BONE MINER RES
   Reid DM, 2006, CLIN DRUG INVEST, V26, P63, DOI 10.2165/00044011 200626020 00002
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Stoch SA, 2009, CLIN PHARMACOL THER, V86, P175, DOI 10.1038/clpt.2009.60
   Tanaka M, AM SOC BON MIN RES 2
   Yamada H, AM SOC BON MIN RES 2
NR 19
TC 21
Z9 22
U1 0
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0091 2700
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD MAR
PY 2012
VL 52
IS 3
BP 306
EP 318
DI 10.1177/0091270011399080
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 898PZ
UT WOS:000300755600002
PM 21719717
DA 2025 08 17
ER

PT J
AU Liu, HL
   Zhang, XL
   Zhong, XL
   Li, ZH
   Cai, SA
   Yang, PZ
   Ou, CW
   Chen, MS
AF Liu, Hailin
   Zhang, Xiuli
   Zhong, Xinglong
   Li, Zehua
   Cai, Shaoai
   Yang, Pingzhen
   Ou, Caiwen
   Chen, Minsheng
TI Puerarin inhibits vascular calcification of uremic rats
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Puerarin; Vascular calcification; Chronic kidney disease; Inflammation
ID ANTIINFLAMMATORY THERAPIES; INFLAMMATION; HYPERTROPHY; ACTIVATION;
   CALCIUM; CYCLE
AB The risk of cardiovascular events in patients with chronic kidney disease is tremendously increased due to vascular calcification. Local vascular inflammation significantly promotes vascular calcification. A previous study has shown that puerarin inhibits calcification of mouse vascular smooth muscle cells (VSMCs) in vitro, but whether puerarin can inhibit vascular calcification in vivo and the underlying mechanisms remain unclear. In this study, we found that rat VSMCs treated with calcifying medium showed more mineral deposition, and this effect was inhibited by puerarin in a dose dependent manner, as detected by alizarin red staining and calcium content assay. Puerarin also prevented the trans differentiation of VSMCs into osteoblast like cells, indicated by down regulation of bone related genes including Runx2 and BMP2. In vivo study of uremic rats induced by renal nephrectomy further confirmed the inhibitory effect of puerarin on vascular calcification in uremic rats. Puerarin treatment significantly prevented mineral deposition in rat aortas and down regulated the expression of Runx2 and BMP2. Furthermore, we detected the levels of pro inflammatory cytokines including IL 1 beta, IL 6, IL 18 and TNF alpha in vitro and in vivo. The levels of IL 1 beta were remarkably increased in both calcified VSMCs and aortas of uremic rats, while puerarin treatment markedly decreased the expression of IL 1 beta. In addition, we found that puerarin reduced IL 1 beta possibly through targeting NLRP3/Caspasel/IL 1 beta and NF kappa B signaling pathways and inhibiting the generation of reactive oxygen species. Taken together, we demonstrated that puerarin has the capability of inhibiting vascular calcification in uremic rats by inhibiting inflammation.
C1 [Liu, Hailin; Zhang, Xiuli; Zhong, Xinglong; Li, Zehua; Yang, Pingzhen; Ou, Caiwen; Chen, Minsheng] Southern Med Univ, Zhujiang Hosp, Heart Ctr, Dept Cardiol,Lab Heart Ctr, Guangzhou 510282, Guangdong, Peoples R China.
   [Liu, Hailin; Zhang, Xiuli; Zhong, Xinglong; Li, Zehua; Yang, Pingzhen; Ou, Caiwen; Chen, Minsheng] Guangdong Prov Biomed Engn Technol Res Ctr Cardio, Guangzhou, Guangdong, Peoples R China.
   [Liu, Hailin; Zhang, Xiuli; Zhong, Xinglong; Li, Zehua; Yang, Pingzhen; Ou, Caiwen; Chen, Minsheng] Sino Japanese Cooperat Platform Translat Res Hear, Guangzhou, Guangdong, Peoples R China.
   [Cai, Shaoai] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China.
C3 Southern Medical University   China; Guangzhou Medical University
RP Yang, PZ; Ou, CW; Chen, MS (通讯作者)，Southern Med Univ, Zhujiang Hosp, Heart Ctr, Dept Cardiol,Lab Heart Ctr, Guangzhou 510282, Guangdong, Peoples R China.
EM y.pingzhen@yahoo.com; oucaiwen@smu.edu.cn; gzminsheng@vip.163.com
RI Zhang, Jidong/JCF 0839 2023; Li, Ze Hua/P 2281 2017; Ou,
   Caiwen/HNO 9226 2023
OI Chen, Minsheng/0000 0002 8271 268X; Zhang, XiuLi/0000 0002 2478 356X; 
FU Natural Science Foundation of China [31771099, U1501222, 31771060,
   81871504, 31671025]; Guangdong Natural Science Foundation [201704020143,
   201707010203]
FX This work was supported by the Natural Science Foundation of China
   [grant numbers 31771099, U1501222, 31771060, 81871504 and 31671025]; and
   the Guangdong Natural Science Foundation [grant numbers 201704020143 and
   201707010203].
CR Bäck M, 2015, NAT REV CARDIOL, V12, P199, DOI 10.1038/nrcardio.2015.5
   Benz K, 2018, INT J NEPHROL, V2018, DOI 10.1155/2018/4310379
   Bessueille L, 2015, CELL MOL LIFE SCI, V72, P2475, DOI 10.1007/s00018 015 1876 4
   Byon CH, 2016, REDOX BIOL, V9, P244, DOI 10.1016/j.redox.2016.08.015
   Cai SA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00540
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Demer LL, 2014, ARTERIOSCL THROM VAS, V34, P715, DOI 10.1161/ATVBAHA.113.302070
   Hénaut L, 2016, EXPERT OPIN THER TAR, V20, P89, DOI 10.1517/14728222.2015.1081685
   Hou ML, 2016, MOL CELL BIOCHEM, V420, P151, DOI 10.1007/s11010 016 2778 y
   Hou N, 2017, N S ARCH PHARMACOL, V390, P535, DOI 10.1007/s00210 017 1353 8
   Ji L, 2016, PHARMACOL REP, V68, P1054, DOI 10.1016/j.pharep.2016.06.007
   Kong YL, 2018, LAB INVEST, V98, P1320, DOI 10.1038/s41374 018 0076 x
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Liu B, 2015, BIOCHEM BIOPH RES CO, V464, P908, DOI 10.1016/j.bbrc.2015.07.065
   Lu Q, 2014, AM J CHINESE MED, V42, P337, DOI 10.1142/S0192415X14500220
   Moe SM, 2005, BLOOD PURIFICAT, V23, P64, DOI 10.1159/000082013
   Nadra I, 2005, CIRC RES, V96, P1248, DOI 10.1161/01.RES.0000171451.88616.c2
   Nakahara T, 2017, JACC CARDIOVASC IMAG, V10, P582, DOI 10.1016/j.jcmg.2017.03.005
   Ridker PM, 2014, EUR HEART J, V35, P1782, DOI 10.1093/eurheartj/ehu203
   Shanahan CM, 2007, CIRCULATION, V116, P2782, DOI 10.1161/CIRCULATIONAHA.107.749655
   Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Shao JS, 2010, HYPERTENSION, V55, P579, DOI 10.1161/HYPERTENSIONAHA.109.134205
   Song Y, 2017, EUR J PHARMACOL, V794, P45, DOI 10.1016/j.ejphar.2016.11.029
   Tamura K, 2007, EUR J PHARMACOL, V558, P159, DOI 10.1016/j.ejphar.2006.12.006
   Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061
   Webster AC, 2017, LANCET, V389, P1238, DOI 10.1016/S0140 6736(16)32064 5
   Yuan Y, 2016, EXP THER MED, V11, P415, DOI 10.3892/etm.2015.2910
   Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083
   Zhu LH, 2010, FREE RADICAL BIO MED, V48, P471, DOI 10.1016/j.freeradbiomed.2009.10.040
NR 30
TC 36
Z9 38
U1 1
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JUL 15
PY 2019
VL 855
BP 235
EP 243
DI 10.1016/j.ejphar.2019.05.023
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HZ5CW
UT WOS:000468869300026
PM 31085237
DA 2025 08 17
ER

PT J
AU Mistry, PK
   Liu, J
   Yang, M
   Nottoli, T
   McGrath, J
   Jain, D
   Zhang, KT
   Keutzer, J
   Chuang, WL
   Mehal, WZ
   Zhao, HY
   Lin, AP
   Mane, S
   Liu, XA
   Peng, YZ
   Li, JH
   Agrawal, M
   Zhu, LL
   Blair, HC
   Robinson, LJ
   Iqbal, J
   Sun, L
   Zaidi, M
AF Mistry, Pramod K.
   Liu, Jun
   Yang, Mei
   Nottoli, Timothy
   McGrath, James
   Jain, Dhanpat
   Zhang, Kate
   Keutzer, Joan
   Chuang, Wei Lein
   Mehal, Wajahat Z.
   Zhao, Hongyu
   Lin, Aiping
   Mane, Shrikant
   Liu, Xuan
   Peng, Yuan Z.
   Li, Jian H.
   Agrawal, Manasi
   Zhu, Ling Ling
   Blair, Harry C.
   Robinson, Lisa J.
   Iqbal, Jameel
   Sun, Li
   Zaidi, Mone
TI Glucocerebrosidase gene deficient mouse recapitulates Gaucher disease
   displaying cellular and molecular dysregulation beyond the macrophage
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE osteopenia; osteoblast; glucosylsphingosine; T cells; PKC
ID STORAGE DISORDERS; BONE DISEASE; THERAPY; GLUCOSYLCERAMIDE; TYPE 1;
   MICE; IDENTIFICATION; PATHOGENESIS; SPHINGOSINE; PHENOTYPE
AB In nonneuronopathic type 1 Gaucher disease (GD1), mutations in the glucocerebrosidase gene (GBA1) gene result in glucocerebrosidase deficiency and the accumulation of its substrate, glucocerebroside (GL 1), in the lysosomes of mononuclear phagocytes. This prevailing macrophage centric view, however, does not explain emerging aspects of the disease, including malignancy, autoimmune disease, Parkinson disease, and osteoporosis. We conditionally deleted the GBA1 gene in hematopoietic and mesenchymal cell lineages using an Mx1 promoter. Although this mouse fully recapitulated human GD1, cytokine measurements, microarray analysis, and cellular immunophenotyping together revealed widespread dysfunction not only of macrophages, but also of thymic T cells, dendritic cells, and osteoblasts. The severe osteoporosis was caused by a defect in osteoblastic bone formation arising from an inhibitory effect of the accumulated lipids LysoGL 1 and GL 1 on protein kinase C. This study provides direct evidence for the involvement in GD1 of multiple cell lineages, suggesting that cells other than macrophages may be worthwhile therapeutic targets.
C1 [Mistry, Pramod K.; Liu, Jun; Yang, Mei; McGrath, James] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06562 USA.
   [Mistry, Pramod K.; Mehal, Wajahat Z.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06562 USA.
   [Nottoli, Timothy] Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06562 USA.
   [McGrath, James] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06562 USA.
   [Jain, Dhanpat] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06562 USA.
   [Zhang, Kate; Keutzer, Joan; Chuang, Wei Lein] Genzyme, Framingham, MA 02134 USA.
   [Zhao, Hongyu; Lin, Aiping] Yale Univ, Sch Publ Hlth, New Haven, CT 06562 USA.
   [Mane, Shrikant] Yale Univ, Sch Med, Keck Ctr Genom, New Haven, CT 06562 USA.
   [Liu, Xuan; Peng, Yuan Z.; Li, Jian H.; Agrawal, Manasi; Zhu, Ling Ling; Iqbal, Jameel; Sun, Li; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
   [Blair, Harry C.; Robinson, Lisa J.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA.
   [Blair, Harry C.; Robinson, Lisa J.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15261 USA.
   [Blair, Harry C.; Robinson, Lisa J.] Pittsburgh Vet Affairs Med Ctr, Pittsburgh, PA 15261 USA.
C3 Yale University; Yale University; Yale University; Yale University; Yale
   University; Sanofi Aventis; Genzyme Corporation; Sanofi USA; Yale
   University; Yale University; Icahn School of Medicine at Mount Sinai;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Mistry, PK (通讯作者)，Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06562 USA.
EM pramod.mistry@yale.edu
RI ; Zhao, Hongyu/KTH 9411 2024; mane, shrikant/HTM 1453 2023
OI Zaidi, Mone/0000 0001 5911 9522; Agrawal, Manasi/0000 0003 4729 1485;
   Zhao, Hongyu/0000 0003 1195 9607; 
FU National Institute of Diabetes, Digestive and Kidney Diseases
   [K24DK066306]; Gaucher Generation Program; National Gaucher Foundation;
   National Institutes of Health [AG23176, DK80490, DK70526]; American
   Federation of Aging Research
FX P.K.M. is supported by National Institute of Diabetes, Digestive and
   Kidney Diseases Grant K24DK066306, a Gaucher Generation Program grant,
   and a grant from the National Gaucher Foundation. M.Z. and L. S. are
   supported by National Institutes of Health Grants AG23176, DK80490, and
   DK70526. J.I. was supported by the American Federation of Aging
   Research.
CR Aerts JM, 2008, ACTA PAEDIATR, V97, P7, DOI 10.1111/j.1651 2227.2007.00641.x
   Campeau PM, 2009, BLOOD, V114, P3181, DOI 10.1182/blood 2009 02 205708
   Cox TM, 2001, J INHERIT METAB DIS, V24, P106
   Elleder M, 2006, J INHERIT METAB DIS, V29, P707, DOI 10.1007/s10545 006 0411 z
   Elstein D, 1997, BAILLIERE CLIN HAEM, V10, P793, DOI 10.1016/S0950 3536(97)80041 8
   Enquist IB, 2006, P NATL ACAD SCI USA, V103, P13819, DOI 10.1073/pnas.0606016103
   Ginzburg L, 2004, SEMIN CELL DEV BIOL, V15, P417, DOI 10.1016/j.semcdb.2004.03.003
   Grabowski GA, 2008, LANCET, V372, P1263, DOI 10.1016/S0140 6736(08)61522 6
   HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164
   Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429
   KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125
   Lukina E, 2010, BLOOD, V116, P893, DOI 10.1182/blood 2010 03 273151
   Mistry PK, 2002, MOL GENET METAB, V77, P91, DOI 10.1016/S1096 7192(02)00122 1
   Mizukami H, 2002, J CLIN INVEST, V109, P1215, DOI 10.1172/JCI200214530
   Pastores GM, 2007, CLIN THER, V29, P1645, DOI 10.1016/j.clinthera.2007.08.006
   Ryu J, 2006, EMBO J, V25, P5840, DOI 10.1038/sj.emboj.7601430
   SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968
   Sidransky E, 2005, MOL GENET METAB, V84, P302, DOI 10.1016/j.ymgme.2004.11.007
   Sidransky E, 2004, MOL GENET METAB, V83, P6, DOI 10.1016/j.ymgme.2004.08.015
   Sidransky E, 1997, BAILLIERE CLIN HAEM, V10, P725, DOI 10.1016/S0950 3536(97)80036 4
   Sims KB, 2008, CLIN GENET, V73, P430, DOI 10.1111/j.1399 0004.2008.00978.x
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   Taddei TH, 2010, J INHERIT METAB DIS, V33, P291, DOI 10.1007/s10545 010 9070 1
   Taddei TH, 2009, AM J HEMATOL, V84, P208, DOI 10.1002/ajh.21362
   Wenstrup RJ, 2004, BLOOD, V104, P1253, DOI 10.1182/blood 2003 11 3854
   Xu YH, 2003, AM J PATHOL, V163, P2093, DOI 10.1016/S0002 9440(10)63566 3
NR 26
TC 182
Z9 202
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 9
PY 2010
VL 107
IS 45
BP 19473
EP 19478
DI 10.1073/pnas.1003308107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 677MZ
UT WOS:000283997800063
PM 20962279
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, NY
   Song, JQ
   Zhu, GL
   Shi, XT
   Wang, YJ
AF Li, Nanying
   Song, Juqing
   Zhu, Guanglin
   Shi, Xuetao
   Wang, Yingjun
TI Alendronate conjugated nanoparticles for calcification targeting
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Poly(lactic co glycolic acid); Nanoparticle; Dopamine;
   Calcification targeting
ID IN VITRO; VASCULAR CALCIFICATION; BREAST CANCER; DRUG CARRIER;
   POLYDOPAMINE; OSTEOBLAST; CHEMISTRY; GROWTH
AB In this article, the synthesis of a novel calcification targeting nanoparticle (NP) is reported, which is realized through dopamine self polymerization on the poly(lactic co glycolic acid) (PLGA) particle surface and subsequent alendronate conjugation. Cell viability and proliferation tests confirmed that such particle has low cytotoxicity and good biocompatibility. Experiments were designed to observe whether the synthesized NPs can pass through an obstructive hydrogel and directly bind themselves to hydroxyapatite (HA) NPs (mimicking calcified spots) and HA porous scaffolds (mimicking calcified tissues); and the result was positive, indicating ingenious targeting of NPs on calcifications. The calcification targeting NPs are expected to be with promising applications on calcification related disease diagnoses and therapies. (C) 2016 Published by Elsevier B.V.
C1 [Li, Nanying; Song, Juqing; Zhu, Guanglin; Wang, Yingjun] S China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510641, Guangdong, Peoples R China.
   [Li, Nanying; Song, Juqing; Zhu, Guanglin; Shi, Xuetao] S China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510641, Guangdong, Peoples R China.
C3 South China University of Technology; South China University of
   Technology
RP Wang, YJ (通讯作者)，S China Univ Technol, Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510641, Guangdong, Peoples R China.; Shi, XT (通讯作者)，S China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510641, Guangdong, Peoples R China.
EM mrshixuetao@gmail.com; imwangyj@163.com
RI Shi, Xuetao/D 5180 2012
FU National Basic Research Program of China [2012CB619100]; National
   Natural Science Foundation of China [51232002, 51502095]; 111 project
   [B13039]
FX This study was financially supported by grants from the National Basic
   Research Program of China (2012CB619100), the National Natural Science
   Foundation of China (51232002, 51502095) and the 111 project (B13039).
CR Abedin M, 2004, ARTERIOSCL THROM VAS, V24, P1161, DOI 10.1161/01.ATV.0000133194.94939.42
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Brannon Peppas L, 2012, ADV DRUG DELIVER REV, V64, P206, DOI 10.1016/j.addr.2012.09.033
   Cao YZ, 2013, ACS APPL MATER INTER, V5, P4438, DOI 10.1021/am4008598
   Cheng YY, 2004, PEDIATR BLOOD CANCER, V42, P410, DOI 10.1002/pbc.20019
   Cognet L, 2003, P NATL ACAD SCI USA, V100, P11350, DOI 10.1073/pnas.1534635100
   EGAWA S, 1992, BRIT J UROL, V69, P169, DOI 10.1111/j.1464 410X.1992.tb15490.x
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205
   Hu HY, 2010, CARBON, V48, P2347, DOI 10.1016/j.carbon.2010.03.014
   Jiang JH, 2010, J MEMBRANE SCI, V364, P194, DOI 10.1016/j.memsci.2010.08.017
   Jono S, 2006, J BONE MINER METAB, V24, P176, DOI 10.1007/s00774 005 0668 6
   Kiyozuka Y, 2001, ANTICANCER RES, V21, P1723
   Ku SH, 2010, BIOMATERIALS, V31, P9431, DOI 10.1016/j.biomaterials.2010.08.071
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Liu R, 2013, ACS APPL MATER INTER, V5, P9167, DOI 10.1021/am402585y
   Liu SQ, 2012, ADV MATER, V24, P6484, DOI 10.1002/adma.201202225
   Luo RF, 2013, COLLOID SURFACE B, V106, P66, DOI 10.1016/j.colsurfb.2013.01.033
   Merrell MA, 2007, EUR J PHARMACOL, V559, P21, DOI 10.1016/j.ejphar.2006.11.064
   Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523 1755.2005.00333.x
   Montet X, 2006, NEOPLASIA, V8, P214, DOI 10.1593/neo.05769
   Mu L, 2003, J CONTROL RELEASE, V86, P33, DOI 10.1016/S0168 3659(02)00320 6
   Panahifar A, 2013, ACS APPL MATER INTER, V5, P5219, DOI 10.1021/am4010495
   Panzavolta S, 2009, J INORG BIOCHEM, V103, P101, DOI 10.1016/j.jinorgbio.2008.09.012
   Persy V, 2006, ARTERIOSCL THROM VAS, V26, P2110, DOI 10.1161/01.ATV.0000236200.02726.f7
   Pisano ED, 2005, NEW ENGL J MED, V353, P1773, DOI 10.1056/NEJMoa052911
   Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005
   Roy I, 2003, J AM CHEM SOC, V125, P7860, DOI 10.1021/ja0343095
   Shields J P, 1995, Am J Card Imaging, V9, P62
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Wang C, 2009, TALANTA, V77, P1358, DOI 10.1016/j.talanta.2008.09.018
   Wu Z, 2009, J MAGN RESON IMAGING, V29, P177, DOI 10.1002/jmri.21617
   Yadav V., 2013, Angew. Chem, V125, P11203
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
NR 36
TC 25
Z9 26
U1 1
U2 123
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD JUN 1
PY 2016
VL 142
BP 344
EP 350
DI 10.1016/j.colsurfb.2016.03.015
PG 7
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA DK8IE
UT WOS:000375169600041
PM 26970822
DA 2025 08 17
ER

PT J
AU Ma, ZX
   Qiu, LH
   Li, JY
   Wu, Z
   Liang, S
   Zhao, YH
   Yang, JM
   Hu, M
   Li, YJ
AF Ma, Zhaoxia
   Qiu, Lihua
   Li, Jinyan
   Wu, Zhen
   Liang, Shu
   Zhao, Yunhui
   Yang, Jinmei
   Hu, Min
   Li, Yanjiao
TI Construction a novel osteoporosis model in immune deficient mice with
   natural ageing
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Osteoporosis; NOD/SCID mice; Naturally aging; Micro CT scanning;
   Real time RT PCR; Western blotting
ID OXIDATIVE STRESS; MINERALIZATION; THERAPY; HEALTH
AB Osteoporosis (OP) predominantly affects elderly individuals. Stem cells show potential for treating OP. However, animal models with normal immune function can eliminate implanted human cells. This study utilized naturally aging NOD/SCID mice, which exhibit immunodeficiency, to create a human osteoporosis model. This approach helps to minimize the premature immune clearance of transplanted allogeneic or xenogeneic cells in preclinical studies, allowing for a more accurate replication of the clinical pharmacological and pharmacokinetic processes involved in stem cell interventions for osteoporosis. NOD/SCID mice were fed until 12, 32, and 43 weeks of age, respectively, and then euthanized. We harvested lumbar vertebra for Micro Computed Tomography (Micro CT) scanning and pathological examination. Additionally, we performed biomechanical testing of lumbar vertebra to assess the severity of osteoporosis. We utilized real time RT PCR to assess gene expression changes associated with bone metabolism, aging, inflammation, oxidative stress, and the Tgf beta 1/Smad3 signaling pathway. In addition, the protein expression levels of P16, Tgf beta 1 and Smad3 were detected using Western Blotting (WB). In comparison to 12 week old mice, the 32 week old and 43 week old mice displayed significantly sparser and fractured trabeculae in their lumbar vertebra, lower bone mineral density (BMD), and changes in bone micro  structural parameters (**PP < 0.01, ***PP < 0.001). Additionally, compared to 12 week old mice, the 32 week old and 43 week old mice exhibited decreased expression of osteogenic genes (Alp, Alp , Opg, , Sp7, , Col1a1), increased expression of osteoclastic gene ( Rankl ), the number of TRAP positive osteoclasts significantly increased in 32  week old and 43 week old mice compared to 12 week old mice. The expression of genes related to aging and inflammatory (P16, P16 , Il 1 beta, , Tnf alpha) increases with advancing age (*PP < 0.05, **PP < 0.01, ***PP < 0.001). The expression of oxidative stress related genes ( Sod1 , Sod2, , Foxo3, , Nrf2), as well as Tgf beta 1 and Smad3 decreased with age (*PP < 0.05, **PP < 0.01, ***PP < 0.001). As age increases, the levels of P16 protein increase, Tgf beta 1 and Smad3 proteins decrease. Our study successfully replicated osteoporosis models in NOD/SCID mice at both 32 and 43 weeks, with the latter exhibiting more severe osteoporosis. This condition seems to be driven by factors such as aging, inflammation, oxidative stress, and the Tgf beta 1/Smad3 signaling pathway.
C1 [Ma, Zhaoxia; Qiu, Lihua; Li, Jinyan; Liang, Shu; Hu, Min; Li, Yanjiao] Kunming Univ, Yunnan Key Lab Basic Res Bone & Joint Dis, Kunming 650214, Yunnan, Peoples R China.
   [Wu, Zhen] Shenzhen Zhendej Pharmaceut Res & Dev Co Ltd, Shenzhen 518048, Guangdong, Peoples R China.
   [Zhao, Yunhui; Yang, Jinmei] Yunnan Jici Inst Regenerat Med Co Ltd, Kunming 650101, Yunnan, Peoples R China.
C3 Kunming University
RP Hu, M; Li, YJ (通讯作者)，Kunming Univ, Yunnan Key Lab Basic Res Bone & Joint Dis, Kunming 650214, Yunnan, Peoples R China.
EM huminynkm@163.com; YanjiaoLi1688@126.com
FU Yunnan Basic Research Project [202201AT070019]; Yunnan Key Laboratory of
   Basic Research for Bone and Joint Diseases [202205AG070075]
FX This work was supported by Yunnan Basic Research Project
   (202201AT070019) and the Yunnan Key Laboratory of Basic Research for
   Bone and Joint Diseases (202205AG070075) .
CR Aggarwal R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039365
   Aguila HL, 2005, IMMUNOL REV, V208, P7, DOI 10.1111/j.0105 2896.2005.00333.x
   Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816
   Aparici M, 2022, BIOCHEM PHARMACOL, V204, DOI 10.1016/j.bcp.2022.115226
   Camacho RE, 2007, EXP HEMATOL, V35, P1219, DOI 10.1016/j.exphem.2007.05.002
   Cao GD, 2023, LIFE SCI, V328, DOI 10.1016/j.lfs.2023.121877
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JX, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1007579
   Chen XR, 2021, BONE RES, V9, DOI 10.1038/s41413 020 00128 8
   Dam C, 2020, CLIN ORAL IMPLAN RES, V31, P264, DOI 10.1111/clr.13565
   Dias IR, 2018, CURR OSTEOPOROS REP, V16, P182, DOI 10.1007/s11914 018 0431 2
   Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025
   Eastell R, 2002, P NUTR SOC, V61, P173, DOI 10.1079/PNS2002160
   Ezzat S, 2019, J CELL BIOCHEM, V120, P2560, DOI 10.1002/jcb.27552
   Farr JN, 2019, J BONE MINER RES, V34, P1407, DOI 10.1002/jbmr.3729
   Filaire E, 2012, JOINT BONE SPINE, V79, P341, DOI 10.1016/j.jbspin.2012.03.007
   Fisher S, 2016, J AM ASSOC LAB ANIM, V55, P811
   Gao X, 2014, INT J CLIN EXP PATHO, V7, P5123
   Geng QH, 2019, INT J BIOL SCI, V15, P58, DOI 10.7150/ijbs.25783
   Hecker L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008182
   Kim HN, 2018, CURR TOP DEV BIOL, V127, P149, DOI 10.1016/bs.ctdb.2017.10.004
   Kim Sang Woo, 2013, Lab Anim Res, V29, P174, DOI 10.5625/lar.2013.29.3.174
   Kim S, 2024, MICROSC RES TECHNIQ, V87, P695, DOI 10.1002/jemt.24457
   Kimball JS, 2021, J BONE JOINT SURG AM, V103, P1451, DOI 10.2106/JBJS.20.00989
   Li J, 2023, AGING CELL, V22, DOI 10.1111/acel.13912
   Lin LS, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.814949
   Lin XS, 2019, ORTHOP SURG, V11, P143, DOI 10.1111/os.12427
   Liu KW, 2023, COMMUN BIOL, V6, DOI 10.1038/s42003 023 05635 y
   Liu LY, 2024, LIFE SCI, V345, DOI 10.1016/j.lfs.2024.122592
   Ma XL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030692
   Ovadya Y, 2014, BIOGERONTOLOGY, V15, P627, DOI 10.1007/s10522 014 9529 9
   Permuy M, 2019, J BONE MINER METAB, V37, P573, DOI 10.1007/s00774 019 01007 x
   Reinwald S, 2008, J BONE MINER RES, V23, P1353, DOI 10.1359/JBMR.080516
   Rudiansyah M, 2022, LIFE SCI, V306, DOI 10.1016/j.lfs.2022.120717
   Saito M, 2015, BONE, V81, P573, DOI 10.1016/j.bone.2015.09.006
   Solling AS, 2021, J BONE MINER RES, V36, P1245, DOI 10.1002/jbmr.4305
   Srivastava M, 2002, CLIN GERIATR MED, V18, P529, DOI 10.1016/S0749 0690(02)00022 8
   Sui BD, 2016, STEM CELL TRANSL MED, V5, P1238, DOI 10.5966/sctm.2015 0347
   Sun XD, 2016, CHEM BIOL INTERACT, V244, P9, DOI 10.1016/j.cbi.2015.11.027
   Tao ZS, 2024, REDOX REP, V29, DOI 10.1080/13510002.2024.2333096
   Tomczyk Warunek A, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25074075
   Velarde MC, 2012, AGING US, V4, P3, DOI 10.18632/aging.100423
   Wang Q, 2022, INT J CLIN PRACT, V2022, DOI 10.1155/2022/4593443
   Wang WZ, 2021, BIOCHEM BIOPH RES CO, V582, P64, DOI 10.1016/j.bbrc.2021.10.033
   Wang YL, 2019, EXP THER MED, V17, P3644, DOI 10.3892/etm.2019.7339
   Watanabe K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/140165
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Yang RL, 2020, AGING CELL, V19, DOI 10.1111/acel.13095
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang Y, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1709 y
   Zhang YW, 2024, AGEING RES REV, V94, DOI 10.1016/j.arr.2024.102196
   Zhang YW, 2024, GUT MICROBES, V16, DOI 10.1080/19490976.2023.2295432
   Zhou YL, 2024, INT IMMUNOPHARMACOL, V132, DOI 10.1016/j.intimp.2024.112027
NR 54
TC 1
Z9 1
U1 6
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 26
PY 2024
VL 735
AR 150820
DI 10.1016/j.bbrc.2024.150820
EA OCT 2024
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA J6J3D
UT WOS:001338104500001
PM 39406026
OA hybrid
DA 2025 08 17
ER

PT J
AU Gaspar Elsas, MI
   Queto, T
   Masid de Brito, D
   Vieira, BM
   de Luca, B
   Cunha, FQ
   Xavier Elsas, P
AF Gaspar Elsas, Maria Ignez
   Queto, Tulio
   Masid de Brito, Daniela
   Vieira, Bruno Marques
   de Luca, Bianca
   Cunha, Fernando Queiroz
   Xavier Elsas, Pedro
TI α Galactosylceramide suppresses murine eosinophil production through
   interferon γ dependent induction of NO synthase and CD95
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID KILLER T CELLS; INVARIANT NKT CELLS; BONE MARROW; UP REGULATION;
   INKT CELLS; MICE; ASTHMA; LIGAND; PHARMACOLOGY; INFLAMMATION
AB Background and Purpose Galactosylceramide ( GalCer), a pleiotropic immunomodulator with therapeutic potential in neoplastic, autoimmune and allergic diseases, activates invariant natural killer T cells throughCD1 restricted receptors for  GalCer on antigen presenting cells, inducing cytokine secretion. However the haemopoietic effects of  GalCer remain little explored.
   Experimental Approach GalCer induced modulation of eosinophil production in IL 5 stimulated bone marrow cultures was examined in wild type (BALB/c, C57BL/6) mice and their mutants lacking CD1, inducible NOS (iNOS), CD95 and IFN , along with the effects of lymphocytes; IFN ; caspase and iNOS inhibitors; non steroidal anti inflammatory drugs (NSAIDs) and LTD4; and dexamethasone.
   Key Results GalCer (10( 6) 10( 8)M) suppressed IL 5 stimulated eosinopoiesis by inducing apoptosis.  GalCer pretreatment in vivo (100gkg( 1), i.v.) suppressed colony formation by GM CSF stimulated bone marrow progenitors in semi solid cultures.  GalCer and dexamethasone synergistically promoted eosinophil maturation. Suppression of eosinophil production by  GalCer was prevented by aminoguanidine and was undetectable in bone marrow lacking iNOS, CD95, CD28; or CD1d. Separation on Percoll gradients and depletion of CD3+ cells made bone marrow precursors unresponsive to  GalCer. Responsiveness was restored with splenic lymphocytes. Experiments with (i) IFN  deficient bone marrow, alone or co cultured with spleen T cells from wild type, but not from CD1d deficient, donors; (ii) IFN  neutralization; and (iii) recombinant IFN , showed that these effects of  GalCer were mediated by IFN . Effects of  GalCer on eosinophil production were blocked by LTD4 and NSAIDs.
   Conclusions and Implications GalCer activation of IFN  secreting, CD1d restricted lymphocytes induced iNOS CD95 dependent apoptosis in developing eosinophils. This pathway is initiated by endogenous regulatory lymphocytes, antagonised by LTD4, NSAIDs and aminoguanidine, and modified by dexamethasone.
C1 [Gaspar Elsas, Maria Ignez; Queto, Tulio; Vieira, Bruno Marques; de Luca, Bianca] Fiocruz MS, Dept Pediat, Inst Nacl Saude Mulher Crianca & Adolescente Fern, BR 21045900 Rio De Janeiro, Brazil.
   [Masid de Brito, Daniela; Vieira, Bruno Marques] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Dept Immunol, BR 21941590 Rio De Janeiro, Brazil.
   [Cunha, Fernando Queiroz; Xavier Elsas, Pedro] Fac Med USP FMRP USP, Dept Pharmacol, Ribeirao Preto, Brazil.
C3 Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro
RP Xavier Elsas, P (通讯作者)，Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Dept Immunol, CCS Bloco I,Room I 2 066, BR 21941590 Rio De Janeiro, Brazil.
EM pxelsas@yahoo.com.br
RI Cunha, Fernando/M 3090 2014; Vieira, Bruno/IXN 7645 2023; Xavier Elsas,
   Pedro/Q 9070 2019
OI Xavier Elsas, Pedro/0000 0003 3057 6062; Vieira,
   Bruno/0000 0002 0697 4311; Cunha, Fernando Queiroz/0000 0003 4755 1670; 
FU CNPq; CAPES; FAPERJ from FAPERJ; CNPq [470377/2011 9]; FAPERJ
   [E 26/111.555/2010, E 26/103.138/2011]
FX This work was supported by CNPq fellowships (Research Productivity
   Fellowships to P. X. E. and M. I. G. E.); CAPES PhD fellowships to T. Q.
   and B. L.; and by FAPERJ fellowship (Doutorado Nota Dez) from FAPERJ to
   T. Q.; funding for the experimental work came from CNPq Grant
   470377/2011 9 to P. X. E., including funding to B. M. V. for technical
   assistance; grants from FAPERJ (E 26/111.555/2010 and E 26/103.138/2011)
   to P. X. E. The authors acknowledge the technical support provided by
   Monica Barradas, Daniela Masid de Brito and Cassio Luiz C. Almeida da
   Silva in the early phases of this study.
CR Adams EJ, 2014, CURR OPIN IMMUNOL, V26, P1, DOI 10.1016/j.coi.2013.09.005
   Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451
   Benoit AC, 2007, VACCINE, V25, P7754, DOI 10.1016/j.vaccine.2007.08.062
   Berkers CR, 2005, TRENDS PHARMACOL SCI, V26, P252, DOI 10.1016/j.tips.2005.03.005
   Bjordahl RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042635
   Bourgeois EA, 2011, EUR J IMMUNOL, V41, P299, DOI 10.1002/eji.201040647
   Chuang YH, 2011, J IMMUNOL, V186, P4687, DOI 10.4049/jimmunol.1003659
   Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117
   De Libero G, 2012, TRENDS IMMUNOL, V33, P103, DOI 10.1016/j.it.2012.01.005
   desLuca B, 2013, THESCIENTIFICWORLDJO, V2013
   Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404, DOI 10.1165/ajrcmb.17.4.2691
   Elsas MICG, 2000, BRIT J PHARMACOL, V130, P1362, DOI 10.1038/sj.bjp.0703403
   Elsas PX, 2008, BRIT J PHARMACOL, V153, P528, DOI 10.1038/sj.bjp.0707586
   Fujita H, 2009, J IMMUNOL, V183, P254, DOI 10.4049/jimmunol.0800520
   Gaspar Elsas MI, 2009, CLIN EXP ALLERGY, V39, P1187, DOI 10.1111/j.1365 2222.2009.03289.x
   Gaspar Elsas MIC, 2000, BRIT J PHARMACOL, V129, P1453
   Hachem P, 2005, EUR J IMMUNOL, V35, P2793, DOI 10.1002/eji.200535268
   Iwamura Chiaki, 2007, Allergol Int, V56, P1, DOI 10.2332/allergolint.R 06 136
   Jones CP, 2004, NITRIC OXIDE BIOL CH, V11, P184, DOI 10.1016/j.niox.2004.08.001
   JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011
   Jyonouchi S, 2014, CLIN EXP ALLERGY, V44, P58, DOI 10.1111/cea.12201
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476 5381.2010.00872.x]
   Kim HY, 2009, J IMMUNOL, V182, P3252, DOI 10.4049/jimmunol.0803339
   Kim JO, 2004, J ALLERGY CLIN IMMUN, V114, P1332, DOI 10.1016/j.jaci.2004.09.004
   Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030
   Konishi J, 2004, HUM IMMUNOL, V65, P1377, DOI 10.1016/j.humimm.2004.09.003
   LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688
   Li LP, 2012, J IMMUNOL, V188, P4681, DOI 10.4049/jimmunol.1102628
   Lintomen L, 2002, BRIT J PHARMACOL, V135, P1315, DOI 10.1038/sj.bjp.0704580
   Liu K, 2005, J EXP MED, V202, P1507, DOI 10.1084/jem.20050956
   Masid de Brito D, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/403970
   Masid de Brito D, 2014, LIFE SCI, V94, P74, DOI 10.1016/j.lfs.2013.11.006
   MATHEWS WR, 1982, BIOCHEM PHARMACOL, V31, P2129, DOI 10.1016/0006 2952(82)90435 X
   Matsuda H, 2005, AM J RESP CELL MOL, V33, P22, DOI 10.1165/rcmb.2004 0010OC
   Matsuda JL, 2008, CURR OPIN IMMUNOL, V20, P358, DOI 10.1016/j.coi.2008.03.018
   Maximiano ES, 2005, INT IMMUNOPHARMACOL, V5, P857, DOI 10.1016/j.intimp.2005.01.001
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476 5381.2010.00873.x
   Molano A, 2006, DRUG DISCOV TODAY, V3, P193
   ONEILL R, 1971, J ROY STAT SOC B, V33, P218
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Queto T, 2010, J LEUKOCYTE BIOL, V87, P885, DOI 10.1189/jlb.1108709
   Queto T, 2010, AM J RESP CRIT CARE, V181, P429, DOI 10.1164/rccm.200905 0800OC
   Rauch Isabella, 2013, JAKSTAT, V2, pe23820, DOI 10.4161/jkst.23820
   Rosenberg HF, 2007, J ALLERGY CLIN IMMUN, V119, P1303, DOI 10.1016/j.jaci.2007.03.048
   SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139
   Sonoda KH, 1999, J EXP MED, V190, P1215, DOI 10.1084/jem.190.9.1215
   Umetsu DT, 2010, J ALLERGY CLIN IMMUN, V125, P975, DOI 10.1016/j.jaci.2010.02.006
   Xavier Elsas P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/474132
   Yamamura T, 2007, J NEUROIMMUNOL, V191, P8, DOI 10.1016/j.jneuroim.2007.09.014
NR 49
TC 6
Z9 6
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JUL
PY 2015
VL 172
IS 13
SI SI
BP 3313
EP 3325
DI 10.1111/bph.13126
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CL1HN
UT WOS:000356693500011
PM 25752588
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Liu, JY
   Zhang, XN
   Xiao, CS
   Chen, XS
AF Liu, Jiaying
   Zhang, Xiaonong
   Xiao, Chunsheng
   Chen, Xuesi
TI A Drug Mineralized Hydrogel Orchestrated by Spontaneous Dynamic
   Mineralization
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE alendronate sodium; biomineralization; bone repair; drug mineralized
   hydrogel; dynamic mineralization process
ID BONE; BIOMINERALIZATION; ACID; BISPHOSPHONATES; NANOPARTICLES;
   OSTEOPOROSIS; SYSTEMS
AB Fabrication of mineralized materials through the nature mimicking dynamic biomineralization process has attracted great interest but remains a huge challenge till now. Here, a drug mineralized hydrogel (DMH) with spontaneous dynamic mineralization behaviors is reported, which highly mimics the dynamic mineralization process of natural tissues. The hydrogel is facilely fabricated via directly mixing sodium hyaluronate (HA) with alendronate sodium (ADA) and CaCl2 in deionized water. The resultant hydrogel possesses a white to semi transparent transition and a soft to hard transition during incubation at 37 degrees C. Mechanism studies reveal that the spontaneous dynamic change of the hydrogel is ascribed to the HA regulated dynamic mineralization of ADA/Ca2+ complexes, where amorphous ADA/Ca2+ complexes will gradually transform into mineral crystals with the prolongation of incubation time. Owing to the dynamic transformation process, the DMH shows excellent injectability and moldability at the initial stage. More importantly, the DMH exhibits a sustained release behavior of ADA in vitro, superior adhesiveness with bone, biodegradability, and good biocompatibility. As a result, the developed DMH demonstrates promising uses for accelerating bone repair in a rat cranial defect model. Overall, the research provides a general strategy to prepare drug mineralized hydrogels with spontaneous dynamic mineralization behaviors, which may find potential uses in various biomedical fields.
   The drug mineralized hydrogel (DMH) is prepared by simple mixing of alendronate sodium (ADA), Ca2+, and sodium hyaluronate (HA). The obtained hydrogel undergoes a spontaneous dynamic mineralization process characterized by a phase transformation from loosely amorphous to densely mineral structure and an in situ mechanical reinforcement property. The resultant DMH shows sustained release of ADA drug and promising use for accelerating bone repair.image
C1 [Liu, Jiaying; Xiao, Chunsheng; Chen, Xuesi] Univ Sci & Technol China, Sch Appl Chem & Engn, Hefei 230026, Anhui, Peoples R China.
   [Liu, Jiaying; Zhang, Xiaonong; Xiao, Chunsheng; Chen, Xuesi] Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Jilin, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Chinese Academy of Sciences; Changchun Institute of Applied
   Chemistry, CAS
RP Xiao, CS; Chen, XS (通讯作者)，Univ Sci & Technol China, Sch Appl Chem & Engn, Hefei 230026, Anhui, Peoples R China.; Xiao, CS; Chen, XS (通讯作者)，Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Jilin, Peoples R China.
EM xiaocs@ciac.ac.cn; xschen@ciac.ac.cn
RI Liu, Jiaying/HIR 7522 2022; Xiao, Chunsheng/E 3506 2012; Chen,
   Xuesi/ABB 5039 2020
FU National Natural Science Foundation of China; Jilin Provincial
   International Cooperation Key Laboratory of Biomedical Polymers
   [20210504001GH]; Department of Science and Technology of Jilin Province
   [20230204086YY];  [52222307];  [51833010]
FX This work was financially supported by the National Natural Science
   Foundation of China (52222307 and 51833010) and Jilin Provincial
   International Cooperation Key Laboratory of Biomedical Polymers
   (20210504001GH). This study was also supported by grant from the
   Department of Science and Technology of Jilin Province (grant number:
   20230204086YY).
CR Alvarez E, 2013, CRYSTENGCOMM, V15, P9899, DOI 10.1039/c3ce41346b
   Athanasiadou D, 2021, NAT REV CHEM, V5, P93, DOI 10.1038/s41570 020 00242 5
   Begum G, 2012, CHEM COMMUN, V48, P8216, DOI 10.1039/c2cc32756b
   BROWN WE, 1976, ANNU REV MATER SCI, V6, P213, DOI 10.1146/annurev.ms.06.080176.001241
   Burdick JA, 2005, BIOMACROMOLECULES, V6, P386, DOI 10.1021/bm049508a
   Chen W, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01764 1
   Dey A, 2010, NAT MATER, V9, P1010, DOI [10.1038/nmat2900, 10.1038/NMAT2900]
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.71, 10.1038/natrevmats.2016.21]
   Dong ZL, 2018, J AM CHEM SOC, V140, P2165, DOI 10.1021/jacs.7b11036
   Elsharkawy S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04319 0
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Faivre D, 2015, ANGEW CHEM INT EDIT, V54, P4728, DOI 10.1002/anie.201408900
   Filippidi E, 2017, SCIENCE, V358, P502, DOI 10.1126/science.aao0350
   FLEISCH H, 1969, NATURE, V223, P211, DOI 10.1038/223211a0
   Gal A, 2017, CHEM COMMUN, V53, P7740, DOI 10.1039/c7cc03639f
   Geng YN, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003 020 01606 9
   González Vázquez A, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120540
   Gordon LM, 2011, NATURE, V469, P194, DOI 10.1038/nature09686
   Guven MN, 2018, ACS OMEGA, V3, P8638, DOI 10.1021/acsomega.8b01103
   Han SY, 2011, J MATER CHEM, V21, P7996, DOI 10.1039/c1jm10466g
   Jiang W, 2022, BIOACT MATER, V12, P169, DOI 10.1016/j.bioactmat.2021.10.017
   Kahil K, 2021, J AM CHEM SOC, V143, P21100, DOI 10.1021/jacs.1c09174
   Kim S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 20953 7
   Kirsch T, 2012, CONNECT TISSUE RES, V53, P438, DOI 10.3109/03008207.2012.730081
   Lee JK, 2023, ADV SCI, V10, DOI 10.1002/advs.202205336
   Lin ZF, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201808439
   Liu HM, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000727
   Liu JY, 2020, ADV SCI, V7, DOI 10.1002/advs.202002243
   Liu JY, 2023, CHEM COMMUN, V59, P10169, DOI 10.1039/d3cc02527f
   Mao LB, 2022, J AM CHEM SOC, DOI 10.1021/jacs.2c07296
   Masica DL, 2010, J AM CHEM SOC, V132, P12252, DOI 10.1021/ja1001086
   Meng YZ, 2009, TISSUE ENG PT A, V15, P355, DOI 10.1089/ten.tea.2007.0371
   Okesola BO, 2021, ACS NANO, V15, P11202, DOI 10.1021/acsnano.0c09814
   Palmer LC, 2008, CHEM REV, V108, P4754, DOI 10.1021/cr8004422
   Rauner N, 2017, NATURE, V543, P407, DOI 10.1038/nature21392
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sánchez Fernández MJ, 2021, J MATER CHEM B, V9, P5848, DOI 10.1039/d1tb00502b
   Schoeppler V, 2018, ADV MATER, V30, DOI 10.1002/adma.201803855
   Sivasubramanian M, 2013, CARBOHYD POLYM, V97, P643, DOI 10.1016/j.carbpol.2013.05.018
   Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101
   Song Q, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav9075
   Tzanavaras PD, 2005, ANAL CHIM ACTA, V547, P98, DOI 10.1016/j.aca.2005.02.026
   Wang B, 2021, ACS APPL MATER INTER, V13, P32673, DOI 10.1021/acsami.1c06058
   Wang HY, 2015, ADV MATER, V27, P3717, DOI 10.1002/adma.201501558
   Wang XF, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010068
   Wang YQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10761 5
   Weiner S, 2011, ANNU REV MATER RES, V41, P21, DOI 10.1146/annurev matsci 062910 095803
   Xian SK, 2021, SMALL, V17, DOI 10.1002/smll.202005165
   Yao SS, 2017, ADV MATER, V29, DOI 10.1002/adma.201605903
   Yuan WH, 2020, BIOACT MATER, V5, P819, DOI 10.1016/j.bioactmat.2020.06.002
   Zhang KY, 2019, SMALL, V15, DOI 10.1002/smll.201900242
   Zhang KY, 2018, ADV SCI, V5, DOI 10.1002/advs.201800875
   Zhao J, 2022, ADV SCI, V9, DOI 10.1002/advs.202203031
NR 53
TC 10
Z9 11
U1 24
U2 172
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD MAR
PY 2024
VL 34
IS 12
DI 10.1002/adfm.202311844
EA DEC 2023
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA LO3P1
UT WOS:001118459200001
DA 2025 08 17
ER

PT J
AU Li, XA
   Li, YS
   Li, LJ
   Xie, X
   Yang, Y
   Deng, ZH
   Zeng, C
   Lei, GH
AF Li, Xuan'An
   Li, Yu Sheng
   Li, Liang Jun
   Xie, Xi
   Yang, Ye
   Deng, Zheng Han
   Zeng, Chao
   Lei, Guang Hua
TI Overactivated autophagy contributes to steroid induced avascular
   necrosis of the femoral head
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE autophagy; dexamethasone; osteoblast; steroid induced avascular necrosis
   of the femoral head
ID DOUBLE EDGED SWORD; INDUCED APOPTOSIS; OSTEONECROSIS
AB Steroid induced avascular necrosis of the femoral head (SANFH) is a mainly bilateral complication of steroid therapy that involves extensive necrosis, and frequently occurs in young and middle aged individuals, with a high disability rate. Autophagy is an intracellular lysosomal degradation process occurring in numerous diseases. However, the effect of dexamethasone (DXM) induced autophagy on osteoblasts is unclear. The aim of the present study was to investigate the effects of autophagy on SANFH. In the present study, femoral head of SANFH patients was collected, and the autophagy in the samples was evaluated. In addition, cell proliferation, membrane integrity and differentiation of osteoblasts were also detected to confirm the effect of DXM on a mouse osteoblasts cell MC3T3 E1 in vitro. Beclin 1 and microtubule associated protein 1 light chain 3 were used as the markers of autophagy, while the autophagy inhibitor 3 methyladenine (3 MA) was used to investigate the role of autophagy in DXM challenged osteoblasts. Immunohistochemistry results demonstrated that Beclinl was markedly increased in the femoral head of SANFH patients. Furthermore, the treatment of osteoblasts with DXM decreased cell viability, increased lactate dehydrogenase activity in the cell culture supernatant, and reduced the alkaline phosphatase activity and bone morphogenetic protein 2 expression in osteoblasts in vitro. By contrast, 3 MA treatment attenuated the cell injury induced by DXM. The present study indicates that overactivated autophagy may be an important factor contributing to SANFH, and autophagy may be a potential target for the prevention of SANFH.
C1 [Li, Xuan'An; Li, Yu Sheng; Li, Liang Jun; Xie, Xi; Yang, Ye; Deng, Zheng Han; Zeng, Chao; Lei, Guang Hua] Cent S Univ, Dept Orthopaed, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
C3 Central South University
RP Lei, GH (通讯作者)，Cent S Univ, Dept Orthopaed, Xiangya Hosp, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM lgh9640@sina.cn
RI ; Deng, Zhenhan/AAB 4968 2021
OI Deng, Zhenhan/0000 0003 0522 8269; 
FU National Natural Science Foundation of China [81201420, 81272034,
   81472130, 81402224, 81501923]; Provincial Science Foundation of Hunan
   [14JJ3032, 2015JJ3139]; Scientific Research Project of the Development
   and Reform Commission of Hunan Province [(2013) 1199]; Scientific
   Research Project of Science and Technology Office of Hunan Province
   [2013SK2018]; Health and Family Planning Commission of Hunan Province
   [B2014 12]; Administration of Traditional Chinese Medicine of Hunan
   Province [2015116]; China Scholarship Council [201606375101]; Doctoral
   Scientific Fund Project of the Ministry of Education of China
   [20120162110036]
FX This study was supported by grants from the National Natural Science
   Foundation of China (nos. 81201420, 81272034, 81472130, 81402224 and
   81501923), the Provincial Science Foundation of Hunan (nos. 14JJ3032 and
   2015JJ3139), the Scientific Research Project of the Development and
   Reform Commission of Hunan Province [no. (2013) 1199], the Scientific
   Research Project of Science and Technology Office of Hunan Province (no.
   2013SK2018), the Health and Family Planning Commission of Hunan Province
   (B2014 12), the Administration of Traditional Chinese Medicine of Hunan
   Province (no. 2015116), the China Scholarship Council (student ID:
   201606375101), and the Doctoral Scientific Fund Project of the Ministry
   of Education of China (no. 20120162110036).
CR Ayoub I, 2016, NEW ENGL J MED, V374, P991, DOI 10.1056/NEJMc1600141
   Chen WQ, 2014, NEURAL REGEN RES, V9, P1210, DOI 10.4103/1673 5374.135329
   Cohen J, 2016, CRIT CARE MED, V44, P1034, DOI 10.1097/CCM.0000000000001633
   Ding HY, 2015, BIOCHEM BIOPH RES CO, V460, P157, DOI 10.1016/j.bbrc.2015.02.161
   Fukushima W, 2010, CLIN ORTHOP RELAT R, V468, P2715, DOI 10.1007/s11999 010 1292 x
   Hao C, 2016, SCI REP UK, V6, DOI 10.1038/srep22599
   Huang SL, 2016, EXP THER MED, V11, P177, DOI 10.3892/etm.2015.2883
   Kerachian MA, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3062
   Kozlov N, 2015, MINERVA ANESTESIOL, V81, P901
   Li B, 2016, MOL MED REP, V13, P1413, DOI 10.3892/mmr.2015.4673
   Li M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030332
   Liu JT, 2016, MED ONCOL, V33, DOI 10.1007/s12032 015 0721 9
   Liu S, 2016, BIOCHEM PHARMACOL, V106, P82, DOI 10.1016/j.bcp.2016.03.002
   Mackie SL, 2015, ANN RHEUM DIS, V74, P2188, DOI 10.1136/annrheumdis 2015 207395
   Mont MA, 2015, J BONE JOINT SURG AM, V97A, P1604, DOI 10.2106/JBJS.O.00071
   Póvoa P, 2012, CURR OPIN INFECT DIS, V25, P199, DOI 10.1097/QCO.0b013e32834f44c7
   Shen C, 2015, OSTEOARTHR CARTILAGE, V23, P2279, DOI 10.1016/j.joca.2015.06.020
   Tai S, 2016, INT J CARDIOL, V211, P1, DOI 10.1016/j.ijcard.2016.02.128
   Troncoso R, 2014, CELL CYCLE, V13, P2281, DOI 10.4161/cc.29272
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Yang L, 2016, J MOL ENDOCRINOL, V56, P291, DOI 10.1530/JME 15 0267
   Yang MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097242
   Zarzynska JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/710345
   Zhao Y, 2014, EUR REV MED PHARMACO, V18, P3573
   Zhao Y, 2014, MOL MED REP, V9, P923, DOI 10.3892/mmr.2014.1915
NR 25
TC 11
Z9 13
U1 2
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUL
PY 2017
VL 14
IS 1
BP 367
EP 372
DI 10.3892/etm.2017.4508
PN A
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FA7RU
UT WOS:000405645400055
PM 28672940
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Laiguillon, MC
   Houard, X
   Bougault, C
   Gosset, M
   Nourissat, G
   Sautet, A
   Jacques, C
   Berenbaum, F
   Sellam, J
AF Laiguillon, Marie Charlotte
   Houard, Xavier
   Bougault, Carole
   Gosset, Marjolaine
   Nourissat, Geoffroy
   Sautet, Alain
   Jacques, Claire
   Berenbaum, Francis
   Sellam, Jeremie
TI Expression and function of visfatin (Nampt), an adipokine enzyme
   involved in inflammatory pathways of osteoarthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID COLONY ENHANCING FACTOR; RHEUMATOID ARTHRITIS; NICOTINAMIDE
   PHOSPHORIBOSYLTRANSFERASE; ARTICULAR CHONDROCYTES; CARTILAGE;
   OSTEOBLASTS; INHIBITION; DECREASES; INDUCTION; SYNOVITIS
AB Introduction: Visfatin is an adipokine that may be involved in intertissular joint communication in osteoarthritis (OA). With a homodimeric conformation, it exerts nicotinamide phosphoribosyltransferase (Nampt) enzymatic activity, essential for nicotinamide adenine dinucleotide biosynthesis. We examined the tissular origin and conformation of visfatin/Nampt in human OA joints and investigated the role of visfatin/Nampt in chondrocytes and osteoblasts by studying Nampt enzymatic activity.
   Methods: Synovium, cartilage and subchondral bone from human OA joints were used for protein extraction or incubated for 24 hours in serum free media (conditioned media), and synovial fluid was obtained from OA patients. Visfatin/Nampt expression in tissular extracts and conditioned media was evaluated by western blot and enzyme linked immunosorbent assay (ELISA), respectively. Nampt activity was assessed in OA synovium by colorimetric assay. Primary cultures of murine chondrocytes and osteoblasts were stimulated with visfatin/Nampt and pretreated or not with APO866, a pharmacologic inhibitor of Nampt activity. The effect on cytokines, chemokines, growth factors and hypertrophic markers expression was examined by quantitative reverse transcriptase polymerase chain reaction and/or ELISA.
   Results: In tissular explants, conditioned media and synovial fluid, visfatin/Nampt was found as a homodimer, corresponding to the enzymatically active conformation. All human OA joint tissues released visfatin/Nampt (synovium: 628 +/  106 ng/g tissue; subchondral bone: 195 +/  26 ng/g tissue; cartilage: 152 +/  46 ng/g tissue), with significantly higher level for synovium (P < 0.0005). Nampt activity was identified ex vivo in synovium. In vitro, visfatin/Nampt significantly induced the expression of interleukin 6, keratinocyte chemoattractant and monocyte chemoattractant protein 1 in chondrocytes and osteoblasts. APO866 decreased the mRNA and protein levels of these pro inflammatory cytokines in the two cell types (up to 94% and 63% inhibition, respectively). Levels of growth factors (vascular endothelial growth factor, transforming growth factor beta) and hypertrophic genes were unchanged with treatment.
   Conclusion: Visfatin/Nampt is released by all human OA tissues in a dimeric enzymatically active conformation and mostly by the synovium, which displays Nampt activity. The Nampt activity of visfatin is involved in chondrocyte and osteoblast activation, so targeting this enzymatic activity to disrupt joint tissue interactions may be novel in OA therapy.
C1 [Laiguillon, Marie Charlotte; Houard, Xavier; Bougault, Carole; Nourissat, Geoffroy; Jacques, Claire; Berenbaum, Francis; Sellam, Jeremie] Univ Paris 06, INSERM, UMRS 938, F 75012 Paris, France.
   [Gosset, Marjolaine] Paris Descartes Univ, EA 2496, F 92120 Montrouge, France.
   [Nourissat, Geoffroy; Sautet, Alain] Univ Paris 06, Dept Orthopaed Surg & Traumatol, St Antoine Hosp, AP HP, F 75012 Paris, France.
   [Berenbaum, Francis; Sellam, Jeremie] St Antoine Hosp, AP HP, Dept Rheumatol, F 75012 Paris, France.
   [Berenbaum, Francis; Sellam, Jeremie] Inflammat Immunopathol Biotherapy Dept DHU I2B, F 75012 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Sorbonne Universite; Universite Paris Cite; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Saint Antoine   APHP; Assistance Publique Hopitaux Paris (APHP);
   Sorbonne Universite; Hopital Universitaire Saint Antoine   APHP
RP Berenbaum, F (通讯作者)，Univ Paris 06, INSERM, UMRS 938, 184 Rue Faubourg St Antoine, F 75012 Paris, France.
EM francis.berenbaum@sat.aphp.fr
RI ; Houard, Xavier/MYQ 5371 2025; Berenbaum, Francis/AAO 5690 2020;
   Gosset, Marjolaine/AGH 8358 2022
OI JACQUES, Claire/0000 0002 2741 5340; Gosset,
   Marjolaine/0000 0002 4875 7892; berenbaum, francis/0000 0001 8252 7815;
   Bougault, Carole/0000 0002 3221 0585
CR ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Bakker A, 2003, METH MOLEC MED, V80, P19
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Blaise R, 2009, ARTHRITIS RHEUM US, V60, P428, DOI 10.1002/art.24250
   Brentano F, 2007, ARTHRITIS RHEUM, V56, P2829, DOI 10.1002/art.22833
   Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267
   Chauffier K, 2012, JOINT BONE SPINE, V79, P604, DOI 10.1016/j.jbspin.2011.12.013
   Chen WP, 2010, CLIN CHEM LAB MED, V48, P1141, DOI 10.1515/CCLM.2010.230
   Duan YH, 2012, RHEUMATOL INT, V32, P985, DOI 10.1007/s00296 010 1731 8
   Evans L, 2011, ARTHRITIS RHEUM, V1002, P30338
   Gabay O, 2009, CURR RHEUMATOL REV, V5, P226, DOI 10.2174/157339709790192440
   Garten A, 2010, BIOCHEM BIOPH RES CO, V391, P376, DOI 10.1016/j.bbrc.2009.11.066
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   Gómez R, 2011, NAT REV RHEUMATOL, V7, P528, DOI 10.1038/nrrheum.2011.107
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Gosset M, 2008, ARTHRITIS RHEUM US, V58, P1399, DOI 10.1002/art.23431
   Hasmann M, 2003, CANCER RES, V63, P7436
   Imai S, 2009, CELL BIOCHEM BIOPHYS, V53, P65, DOI 10.1007/s12013 008 9041 4
   Jacques C, 2012, J BIOL CHEM, V287, P15100, DOI 10.1074/jbc.M112.350215
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Khan JA, 2006, NAT STRUCT MOL BIOL, V13, P582, DOI 10.1038/nsmb1105
   Kitani T, 2003, FEBS LETT, V544, P74, DOI 10.1016/S0014 5793(03)00476 9
   Klein Wieringa IR, 2011, ANN RHEUM DIS, V70, P851, DOI 10.1136/ard.2010.140046
   Körner A, 2007, J CLIN ENDOCR METAB, V92, P4783, DOI 10.1210/jc.2007 1304
   Loeser RF, 2012, ARTHRITIS RHEUM US, V64, P1697, DOI 10.1002/art.34453
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Luk T, 2008, J LEUKOCYTE BIOL, V83, P804, DOI 10.1189/jlb.0807581
   Mahjoub M, 2012, OSTEOPOROSIS INT, V23, pS841, DOI 10.1007/s00198 012 2161 0
   Meier FMP, 2012, J BIOL CHEM, V287, P28378, DOI 10.1074/jbc.M111.312884
   Moschen AR, 2007, J IMMUNOL, V178, P1748, DOI 10.4049/jimmunol.178.3.1748
   Mutabaruka MS, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2925
   Otero M, 2006, ANN RHEUM DIS, V65, P1198, DOI 10.1136/ard.2005.046540
   Romacho T, 2009, DIABETOLOGIA, V52, P2455, DOI 10.1007/s00125 009 1509 2
   SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431
   Sanchez C, 2009, OSTEOARTHR CARTILAGE, V17, P473, DOI 10.1016/j.joca.2008.09.007
   Scanzello CR, 2012, BONE, V51, P249, DOI 10.1016/j.bone.2012.02.012
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Wang T, 2006, NAT STRUCT MOL BIOL, V13, P661, DOI 10.1038/nsmb1114
   Wosikowski K, 2002, CANCER RES, V62, P1057
   Yammani RR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3705
   Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432 1327.2000.01187.x
NR 42
TC 92
Z9 98
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2014
VL 16
IS 1
AR R38
DI 10.1186/ar4467
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA AG1BA
UT WOS:000335148700037
PM 24479481
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ansari, SA
   Alkeraim, HY
   Mahmood, A
   Alfayez, M
   Ahmed, S
   Ansari, IA
   Almehizia, AA
   Al Rasheed, LS
   Alkahtani, HM
AF Ansari, Siddique Akber
   Alkeraim, Hatoon Youssef
   Mahmood, Amer
   Alfayez, Musaad
   Ahmed, Sarfaraz
   Ansari, Irfan Aamer
   Almehizia, Abdulrahman A.
   Al Rasheed, Lamees S.
   Alkahtani, Hamad M.
TI Effect of N phenylbenzenesulfonamide targeting CNR2 over human bone
   marrow mesenchymal stem cell population and osteoblast/ adipocyte
   differentiation
SO PROCESS BIOCHEMISTRY
LA English
DT Article
DE N phenyl benzene sulfonamide; Cannabinoid receptors; HBMSCs; Osteoblast;
   Adipocyte; ALP
ID CANNABINOID RECEPTOR; CB2; DOCKING; PROTEIN; IDENTIFICATION;
   PHARMACOLOGY; GLIDE; MODEL; MASS
AB Cannabinoids receptor type 2 (CNR2) signaling using selective receptor compounds encourages the expression of osteogenic genes and enhances mineralization. The effect of six newly synthesized Cannabinoid receptors type 2 (CB2) selective compounds over the viability of human bone marrow mesenchymal stem cells (h BMMSCs) and their osteogenic and adipogenic potential study was carried out. Human mesenchymal stem cells (MSCs) were treated with 0.5 & mu;M of compounds 1 6 to induce lineage differentiation (adipogenic, osteogenic). The cells were analyzed using differentiation assays, lipid droplets and mineralized matrix was stained with "Niel red and Alizarin Red, further performed reverse transcription polymerase chain reaction (RT PCR) for lineage specific markers expression." Treatment with synthesized compounds N (4 (dimethyl amino) benzyl)  4 methyl N phenylbenzenesulfonamide (1), N (4 (dimethyl amino) benzyl) N phenyl benzamide (3) and N (4 tert  butylbenzyl) 4 methyl N phenylbenzenesulfonamide (5), increased both lipid droplets formation and Alkaline Phosphatase (ALP) activity. Treatment of N (4 (dimethylamino) benzyl) N phenylbenzene sulfonamide (2), and 4 methyl N phenyl N (4 (trifluoromethyl) benzyl) benzene sulfonamide (4) was found to enhance the adipogenic differentiation of (h BMSCs) and inhibit osteogenic differentiation. A Reduction in adipocyte differentiation upon exposure to N (4 tert butylbenzyl) N phenylbenzene sulfonamide (6) was noted. Conversely, enhanced mineral deposition was accompanied by increased alkaline phosphatase (ALP) activity in osteogenic differentiation. Taken together, these newly synthesized selective compounds work in favor of adipocyte formation except for 6 which reduces lipid droplets accumulation and enhanced calcium deposition. "In conclusion, compounds 1, 3, 5 and 6 demonstrated a positive effect over osteoblast formation compared to control." As per molecular docking study, compounds 1, 2 and 3 are the most active derivative will serve as anti osteoporosis drug discovery.
C1 [Ansari, Siddique Akber; Almehizia, Abdulrahman A.; Al Rasheed, Lamees S.; Alkahtani, Hamad M.] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, POB 2454, Riyadh 11451, Saudi Arabia.
   [Alkeraim, Hatoon Youssef; Mahmood, Amer; Alfayez, Musaad] King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, POB 2454, Riyadh 11451, Saudi Arabia.
   [Ahmed, Sarfaraz] King Saud Univ, Coll Pharm, Dept Pharmacognosy, POB 2457, Riyadh 11451, Saudi Arabia.
   [Ansari, Irfan Aamer] Univ Turin, Dept Drug Sci & Technol, I 10124 Turin, Italy.
C3 King Saud University; King Saud University; King Saud University;
   University of Turin
RP Ansari, SA (通讯作者)，King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, POB 2454, Riyadh 11451, Saudi Arabia.
EM sansari@ksu.edu.sa
RI AHMED, SARFARAZ/HLX 5216 2023; Alkahtani, Hamad/K 5313 2018; Mahmood,
   Amer/A 9514 2011; Alrasheed, Lamees/JCD 7362 2023; Almehizia,
   Abdulrahman/AAL 5543 2020; Ansari, Siddique Akber/M 4412 2017; Ansari,
   Irfan Aamer/HTT 2735 2023
OI Ansari, Irfan Aamer/0000 0001 5375 0006; Mahmood,
   Amer/0000 0002 9199 0120
FU King Saud University, Riyadh, Saudi Arabia [RSPD2023R744]
FX This research project was supported by the Researcher Supporting Project
   number (RSPD2023R744) , King Saud University, Riyadh, Saudi Arabia.
CR Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059
   Al Nbaheen M, 2013, STEM CELL REV REP, V9, P32, DOI 10.1007/s12015 012 9365 8
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Chen JZ, 2006, J MED CHEM, V49, P625, DOI 10.1021/jm050655g
   Damale MG, 2019, RSC ADV, V9, P26176, DOI 10.1039/c9ra03281a
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747 0285.2007.00483.x
   Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161
   Hua T, 2020, CELL, V180, P655, DOI 10.1016/j.cell.2020.01.008
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2010, CALCIFIED TISSUE INT, V87, P285, DOI 10.1007/s00223 010 9378 8
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101
   Li XT, 2020, TRENDS PHARMACOL SCI, V41, P665, DOI 10.1016/j.tips.2020.06.010
   Liu GD, 2022, J MED CHEM, V65, P8289, DOI 10.1021/acs.jmedchem.2c00170
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Ouyang Q, 2013, ACS MED CHEM LETT, V4, P387, DOI 10.1021/ml3004236
   Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163 7258(97)82001 3
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rayalam S., 2011, Adipose Tissue Biol., P195, DOI [10.1007/978 1 4614 0965 6_7, DOI 10.1007/978 1 4614 0965 6_7]
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026
   Rossi F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081919
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822 013 9644 8
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602 592
   Smith M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136546
   Sophocleous A, 2017, AGING CELL, V16, P1051, DOI 10.1111/acel.12638
   Sophocleous A, 2011, ENDOCRINOLOGY, V152, P2141, DOI 10.1210/en.2010 0930
   Sun YX, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/874982
   Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511
   Yang P, 2012, J MED CHEM, V55, P9973, DOI 10.1021/jm301212u
NR 33
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1359 5113
EI 1873 3298
J9 PROCESS BIOCHEM
JI Process Biochem.
PD OCT
PY 2023
VL 133
BP 121
EP 131
DI 10.1016/j.procbio.2023.08.009
EA AUG 2023
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA S8NY4
UT WOS:001073693000001
DA 2025 08 17
ER

PT J
AU Fu, WQ
   Im, YG
   Kim, B
   Kim, OS
   Yang, Y
   Song, JA
   Liu, DY
   Zhu, SY
   Kang, JS
   Kim, O
AF Fu, Wenqi
   Im, Yeong Gwan
   Kim, Byunggook
   Kim, Ok Su
   Yang, Ying
   Song, Jianan
   Liu, Danyang
   Zhu, Siyu
   Kang, Jae Seok
   Kim, Okjoon
TI 625 nm Light Irradiation Prevented MC3T3 E1 Cells from Accumulation of
   Misfolded Proteins via ROS and ATP Production
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE light emitting diode irradiation (LEDI); binding immunoglobulin protein
   (BiP); reactive oxygen species (ROS); adenosine triphosphate (ATP);
   endoplasmic reticulum (ER) stress; bone
ID ENDOPLASMIC RETICULUM STRESS; OXIDATIVE STRESS; THERAPY LLLT;
   ACTIVATION; APOPTOSIS; NEURONS; PATHWAY
AB Osteoblasts must acquire a considerable capacity for folding unfolded and misfolded proteins (MPs) to produce large amounts of extracellular matrix proteins and maintain bone homeostasis. MP accumulation contributes to cellular apoptosis and bone disorders. Photobiomodulation therapy has been used to treat bone diseases, but the effects of decreasing MPs with photobiomodulation remain unclear. In this study, we explored the efficacy of 625 nm light emitting diode irradiation (LEDI) to reduce MPs in tunicamycin (TM) induced MC3T3 E1 cells. Binding immunoglobulin protein (BiP), an adenosine triphosphate (ATP) dependent chaperone, is used to evaluate the capacity of folding MPs. The results revealed that pretreatment with 625 nm LEDI (Pre IR) induced reactive oxygen species (ROS) production, leading to the increased chaperone BiP through the inositol requiring enzyme 1 (IRE1)/X box binding protein 1s (XBP 1s) pathway, and then restoration of collagen type I (COL I) and osteopontin (OPN) expression relieving cell apoptosis. Furthermore, the translocation of BiP into the endoplasmic reticulum (ER) lumen might be followed by a high level of ATP production. Taken together, these results suggest that Pre IR could be beneficial to prevent MP accumulation through ROS and ATP in TM induced MC3T3 E1cells.
C1 [Fu, Wenqi; Yang, Ying; Song, Jianan; Liu, Danyang; Zhu, Siyu; Kang, Jae Seok; Kim, Okjoon] Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Gwangju 61186, South Korea.
   [Im, Yeong Gwan; Kim, Byunggook] Chonnam Natl Univ, Sch Dent, Dept Oral Med, Gwangju 61186, South Korea.
   [Kim, Ok Su] Chonnam Natl Univ, Sch Dent, Dept Periodontol, Gwangju 61186, South Korea.
C3 Chonnam National University; Chonnam National University; Chonnam
   National University
RP Kim, O (通讯作者)，Chonnam Natl Univ, Sch Dent, Dept Oral Pathol, Gwangju 61186, South Korea.
EM js3894@jnu.ac.kr
RI Zhu, Siyu/KCJ 5186 2024; Liu, Danyang/AAI 2312 2019
OI Liu, Danyang/0000 0003 3875 1822; Im, Yeong Gwan/0000 0003 2703 1475;
   Kim, OkJoon/0000 0002 6347 1411; , YING/0000 0002 8234 6421; Kim,
   OkSu/0000 0001 8528 9314; 
FU National Research Foundation of Korea (NRF) grant   Korea government
   (MSIT) [2022R1F1A1068614]
FX This research was funded by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT), grant number
   2022R1F1A1068614.
CR Banerjee A, 2011, J BIOL CHEM, V286, P29127, DOI 10.1074/jbc.M110.169771
   Brocchieri L, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471 2148 8 19
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Carroll JD, 2014, DENT MATER, V30, P465, DOI 10.1016/j.dental.2014.02.006
   Chakrabarti A, 2011, BIOTECHNOL BIOENG, V108, P2777, DOI 10.1002/bit.23282
   Chinese Human Liver Proteome Profiling Consortium, 2012, J PROTEOME RES, V9, P79
   Cho H, 2022, J MOL HISTOL, V53, P75, DOI 10.1007/s10735 021 10034 w
   Gao XJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423 0127 16 4
   Gardner BM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013169
   Georges Kalouche C.B, 2016, BIOCHIM BIOPHYS ACTA, V1863, P2322
   Ha TK, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201900130
   Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   He Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24173064
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Hino S, 2010, J BONE MINER METAB, V28, P131, DOI 10.1007/s00774 009 0117 z
   Horiuchi K, 2016, CELL MOL LIFE SCI, V73, P2851, DOI 10.1007/s00018 016 2178 1
   Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826
   Huang YY, 2013, J BIOPHOTONICS, V6, P829, DOI 10.1002/jbio.201200157
   Husa M, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4415
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Jiang M, 2022, J PERIODONTAL RES, V57, P915, DOI 10.1111/jre.13031
   Kim HP, 2014, BIOMOL THER, V22, P491, DOI 10.4062/biomolther.2014.083
   Kopp MC, 2019, NAT STRUCT MOL BIOL, V26, P1053, DOI 10.1038/s41594 019 0324 9
   Kudo T, 2008, CELL DEATH DIFFER, V15, P364, DOI 10.1038/sj.cdd.4402276
   Kulkarni S, 2019, LASER MED SCI, V34, P685, DOI 10.1007/s10103 018 2641 3
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249 1259.2001
   Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200
   Oakes SA, 2015, ANNU REV PATHOL MECH, V10, P173, DOI 10.1146/annurev pathol 012513 104649
   Osborne NN, 2017, MITOCHONDRION, V36, P29, DOI 10.1016/j.mito.2016.11.009
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sarmadi S, 2019, J LASERS MED SCI, V10, P330, DOI 10.15171/jlms.2019.53
   Sato AY, 2015, BONE, V73, P60, DOI 10.1016/j.bone.2014.12.012
   SATOH M, 1993, EXP CELL RES, V205, P76, DOI 10.1006/excr.1993.1060
   Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011
   Shim SM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan0630
   Sun Q, 2018, J PHOTOCH PHOTOBIO B, V186, P31, DOI 10.1016/j.jphotobiol.2018.05.015
   Tauffenberger A, 2021, NEUROCHEM RES, V46, P77, DOI 10.1007/s11064 020 03208 7
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041
   Wittkowske C, 2016, FRONT BIOENG BIOTECH, V4, DOI 10.3389/fbioe.2016.00087
NR 42
TC 3
Z9 3
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY 25
PY 2023
VL 24
IS 11
AR 9257
DI 10.3390/ijms24119257
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA J0KS1
UT WOS:001006586800001
PM 37298212
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Martu, MA
   Maftei, GA
   Luchian, I
   Stefanescu, OM
   Scutariu, MM
   Solomon, SM
AF Martu, Maria Alexandra
   Maftei, George Alexandru
   Luchian, Ionut
   Stefanescu, Ovidiu Mihail
   Scutariu, Mihaela Monica
   Solomon, Sorina Mihaela
TI The Effect of Acknowledged and Novel Anti Rheumatic Therapies on
   Periodontal Tissues A Narrative Review
SO PHARMACEUTICALS
LA English
DT Article
DE periodontal disease; rheumatoid arthritis; cytokines; treatment; DMARDs;
   gene therapy; host modulation; inflammation
ID PRO RESOLVING MEDIATORS; RHEUMATOID ARTHRITIS; INFLAMMATORY ARTHRITIS;
   MATRIX METALLOPROTEINASES; BONE DESTRUCTION; DOUBLE BLIND; DISEASE;
   STRATEGIES; ASSOCIATION; PARAMETERS
AB Rheumatoid arthritis (RA) and periodontal disease (PD) are chronic complex inflammatory diseases with several common susceptibility factors, especially genetic and environmental risk factors. Although both disorders involve a perturbation of the immune inflammatory response at multiple levels, one major difference between the two is the different locations in which they develop. RA is triggered by an exaggerated autoimmune response that targets joints, while periodontal disease occurs as a consequence of the subgingival periodontopathogenic microbiota. Current treatment models in both pathologies involve the stratification of patients to allow therapeutic individualization according to disease stage, complexity, progression, lifestyle, risk factors, and additional systemic diseases. Therapeutic guidelines for RA comprise of five main classes of drugs: non steroidal anti inflammatory drugs (NSAIDs), analgesics, glucocorticoids, and disease modifying anti rheumatic drugs (DMARDs): biologic and non biologic. Although various treatment options are available, a definitive treatment remains elusive, therefore research is ongoing in this area. Several alternatives are currently being tested, such as matrix metalloproteinases (MMP) inhibitors, toll like receptors (TLR) blockers, pro resolution mediators, anti hypoxia inducing factors, stem cell therapy, NLRP3 inhibitors and even natural derived compounds. Although the link between PD and rheumatoid arthritis has been investigated by multiple microbiology and immunology studies, the precise influence and causality is still debated in the literature. Furthermore, the immunomodulatory effect of anti rheumatic drugs on the periodontium is still largely unknown. In this narrative review, we explore the mechanisms of interaction and the potential influence that anti rheumatoid medication, including novel treatment options, has on periodontal tissues and whether periodontal health status and treatment can improve the prognosis of an RA patient.
C1 [Martu, Maria Alexandra; Luchian, Ionut; Solomon, Sorina Mihaela] Grigore T Popa Univ Med & Pharm, Periodontol Dept, Fac Dent Med, 16 Univ Str, Iasi 700115, Romania.
   [Maftei, George Alexandru] Grigore T Popa Univ Med & Pharm, Oral Pathol Dept, Fac Med Dent, 16 Univ Str, Iasi 700115, Romania.
   [Stefanescu, Ovidiu Mihail] Grigore T Popa Univ Med & Pharm, Dento Alveolar Surg & Anesthesiol Dept, Fac Dent Med, 16 Univ Str, Iasi 700115, Romania.
   [Scutariu, Mihaela Monica] Grigore T Popa Univ Med & Pharm, Fac Dent Med, Orodent Diagnost Dept, 16 Univ Str, Iasi 700115, Romania.
C3 Grigore T Popa University of Medicine & Pharmacy; Grigore T Popa
   University of Medicine & Pharmacy; Grigore T Popa University of Medicine
   & Pharmacy; Grigore T Popa University of Medicine & Pharmacy
RP Luchian, I (通讯作者)，Grigore T Popa Univ Med & Pharm, Periodontol Dept, Fac Dent Med, 16 Univ Str, Iasi 700115, Romania.; Maftei, GA (通讯作者)，Grigore T Popa Univ Med & Pharm, Oral Pathol Dept, Fac Med Dent, 16 Univ Str, Iasi 700115, Romania.
EM maria alexandra.martu@umfiasi.ro; george alexandru.maftei@umfiasi.ro;
   ionut.luchian@umfiasi.ro; ovidiu.stefanescu@umfiasi.ro;
   mihaela.scutariu@umfiasi.ro; sorina.solomon@umfiasi.ro
RI Luchian, Alexandru Ionut/HTP 5703 2023; Martu, Maria/X 5409 2018;
   Solomon, Sorina Mihaela/AHI 8331 2022; Martu, Maria
   Alexandra/X 5409 2018; Solomon, Sorina Mihaela/AHI 8331 2022;
   Stefanescu, Ovidiu/ABG 2886 2020; Scutariu, Monica
   Mihaela/MTF 9532 2025; Mihaela Monica, Scutariu/MTF 9532 2025; Maftei,
   George/MSW 7130 2025
OI Martu, Maria Alexandra/0000 0002 5092 5234; Maftei,
   George/0000 0003 4207 5337; Solomon, Sorina Mihaela/0000 0002 9588 6910;
   Luchian, Ionut/0000 0003 0017 9672; Mihaela Monica,
   Scutariu/0000 0001 9167 6302; 
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   Abdelrahman M.A., 2019, The Egyptian Journal of Internal Medicine, V31, P965
   Abdolmaleki F, 2020, CLIN REV ALLERG IMMU, V58, P82, DOI 10.1007/s12016 019 08754 9
   Agossa K., 2015, Clinical Anti Inflammatory Anti Allergy Drugs, V2, P3, DOI [10.2174/221270380201160517185229, DOI 10.2174/221270380201160517185229]
   Alam J, 2017, BIOMED PHARMACOTHER, V92, P615, DOI 10.1016/j.biopha.2017.05.055
   Alamgeer, 2020, PHYTOMEDICINE, V66, DOI 10.1016/j.phymed.2019.153134
   Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Aljohani S, 2018, J CRANIO MAXILL SURG, V46, P1515, DOI 10.1016/j.jcms.2018.05.046
   Alvarado R, 2017, FASEB J, V31, P85, DOI 10.1096/fj.201500093R
   Angelini J, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071002
   Angiolilli C, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1638 4
   Vieira GHA, 2021, J PERIODONTOL, V92, P1460, DOI 10.1002/JPER.20 0455
   Araki Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050905
   Arkema EV, 2010, J RHEUMATOL, V37, P1800, DOI 10.3899/jrheum.091398
   Baker KF, 2018, ANN RHEUM DIS, V77, P175, DOI 10.1136/annrheumdis 2017 211555
   Balta MG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01682
   Barden AE, 2016, PROSTAG LEUKOTR ESS, V107, P24, DOI 10.1016/j.plefa.2016.03.004
   Bartold PM, 2018, PERIODONTOL 2000, V78, P7, DOI 10.1111/prd.12237
   Baschant U, 2012, NAT REV RHEUMATOL, V8, P645, DOI 10.1038/nrrheum.2012.166
   Beck JD, 2019, J DENT RES, V98, P1053, DOI 10.1177/0022034519846113
   Brasil Oliveira Rebeca, 2020, Eur J Dent, V14, P496, DOI 10.1055/s 0040 1713954
   Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394
   Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140 6736(17)31491 5
   Calderaro DC, 2017, REV BRAS REUMATOL, V57, P238, DOI [10.1016/j.rbr.2016.10.002, 10.1016/j.rbre.2016.11.011]
   Cantley MD, 2017, BONE, V95, P162, DOI 10.1016/j.bone.2016.11.028
   Cazalis J, 2009, INFLAMMATION, V32, P130, DOI 10.1007/s10753 009 9111 9
   Checchi V, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144923
   Chen MX, 2021, J CLIN PERIODONTOL, V48, P1165, DOI 10.1111/jcpe.13506
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Choulaki C, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0775 2
   Ciccarelli F, 2015, CURR MED CHEM, V22, P596, DOI 10.2174/0929867321666141106125051
   Corbet M., 2020, ES 62 SUPPRESSION AR, DOI [10.1101/2020.10.08.331942, DOI 10.1101/2020.10.08.331942]
   Cox JH, 2010, ARTHRITIS RHEUM US, V62, P3645, DOI 10.1002/art.27757
   Crofford LJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4174
   de Molon RS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184541
   de Smit MJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052529
   Diniz Freitas M, 2018, J CLIN PERIODONTOL, V45, P570, DOI 10.1111/jcpe.12882
   Dionigi C, 2020, J CLIN PERIODONTOL, V47, P1466, DOI 10.1111/jcpe.13370
   Dong XW, 2020, CELL MOL IMMUNOL, V17, P261, DOI 10.1038/s41423 019 0201 9
   Doonan J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01016
   Drosos AA, 2020, CLIN RHEUMATOL, V39, P1363, DOI 10.1007/s10067 020 05001 x
   Drosos AA, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081237
   Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672
   EI Sharkawy H, 2010, J PERIODONTOL, V81, P1635, DOI 10.1902/jop.2010.090628
   Elashiry M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126459
   Fang QH, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3830212
   Fields GB, 2019, CELLS BASEL, V8, DOI 10.3390/cells8090984
   Franco C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020440
   Fu Q, 2018, MOL MED REP, V18, P3619, DOI 10.3892/mmr.2018.9422
   García S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3211
   Garlet GP, 2007, CLIN EXP IMMUNOL, V147, P128, DOI 10.1111/j.1365 2249.2006.03260.x
   Godoy LD, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600744
   GOLUB LM, 1995, J CLIN PERIODONTOL, V22, P100
   Golub LM, 2020, PERIODONTOL 2000, V82, P186, DOI 10.1111/prd.12315
   Golub LM, 2016, INT DENT J, V66, P127, DOI 10.1111/idj.12221
   Grabiec AM, 2018, CRIT REV MICROBIOL, V44, P336, DOI 10.1080/1040841X.2017.1373063
   Grabiec AM, 2012, ANN RHEUM DIS, V71, P424, DOI 10.1136/ard.2011.154211
   Guo C, 2018, CLIN EXP IMMUNOL, V194, P231, DOI 10.1111/cei.13167
   Han JC, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110848
   Harrington R, 2020, J INFLAMM RES, V13, P519, DOI 10.2147/JIR.S219586
   Hasegawa T, 2021, OSTEOPOROSIS INT, V32, P2323, DOI 10.1007/s00198 021 05995 3
   Hasegawa T, 2017, JOINT BONE SPINE, V84, P379, DOI 10.1016/j.jbspin.2016.05.010
   Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05 4724fje
   Hazlewood GS., 2020, Cochrane Database Syst Rev, V3, pCD013562, DOI [10.1002/14651858.CD013562, DOI 10.1002/14651858.CD013562]
   Hemmings FJ, 2001, RHEUMATOLOGY, V40, P537, DOI 10.1093/rheumatology/40.5.537
   Hussain SB, 2020, SEMIN ARTHRITIS RHEU, V50, P414, DOI 10.1016/j.semarthrit.2020.01.009
   Ikeda Y, 2021, OXYGEN BASEL, V1, P22, DOI 10.3390/oxygen1010004
   Jacob A.M., 2018, International Journal of Oral Health Sciences, V8, P6, DOI [10.4103/ijohs.ijohs_62_17, DOI 10.4103/IJOHS.IJOHS_62_17]
   Jäger E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17749 6
   Jain P, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13081175
   Jajoo NS, 2020, CLIN REV BONE MINER, V18, P18, DOI 10.1007/s12018 020 09271 6
   Jang Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010434
   Kaneko K, 2016, ARTHRITIS RHEUMATOL, V68, P521, DOI 10.1002/art.39414
   Kerschbaumer A, 2020, ANN RHEUM DIS, V79, P744, DOI 10.1136/annrheumdis 2019 216656
   Kobayashi T, 2019, BMC RHEUMATOL, V3, DOI 10.1186/s41927 019 0062 y
   Komerik N, 2005, ORAL DIS, V11, P303, DOI 10.1111/j.1601 0825.2005.01122.x
   Kozak M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9124045
   Kuritani M, 2018, BIOL PHARM BULL, V41, P637, DOI 10.1248/bpb.b18 00026
   Kussmann M, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2021 001737
   Laronha H, 2020, CELLS BASEL, V9, DOI 10.3390/cells9051076
   Li K, 2020, PHARMACOL THERAPEUT, V207, DOI 10.1016/j.pharmthera.2019.107465
   Li RB, 2017, INT J RHEUM DIS, V20, P1887, DOI 10.1111/1756 185X.13240
   Li YY, 2018, EXP GERONTOL, V105, P118, DOI 10.1016/j.exger.2017.10.027
   Liu PW, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106570
   Lopez Santalla M, 2021, EBIOMEDICINE, V69, DOI 10.1016/j.ebiom.2021.103427
   Mao GP, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1004 0
   Martu MA, 2018, ROM J ORAL REHABIL, V10, P161
   Martu MA, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10020226
   Mayer Y, 2013, J PERIODONTOL, V84, P136, DOI 10.1902/jop.2012.120009
   Mayer Y, 2009, J PERIODONTOL, V80, P1414, DOI 10.1902/jop.2009.090015
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Meng XL, 2022, J ETHNOPHARMACOL, V283, DOI 10.1016/j.jep.2021.114657
   Mercado FB, 2001, J PERIODONTOL, V72, P779, DOI 10.1902/jop.2001.72.6.779
   Mikuls TR, 2014, ARTHRITIS RHEUMATOL, V66, P1090, DOI 10.1002/art.38348
   Monnet E, 2020, ANN RHEUM DIS, V79, P316, DOI 10.1136/annrheumdis 2019 216487
   Monsarrat P, 2016, J CLIN PERIODONTOL, V43, P390, DOI 10.1111/jcpe.12534
   Mousavi MJ, 2021, AUTOIMMUN HIGHLIGHTS, V12, DOI 10.1186/s13317 020 00145 x
   Mustonen AM, 2021, CURR RHEUMATOL REP, V23, DOI 10.1007/s11926 021 01007 9
   O'Rourke VJ, 2017, AUST DENT J, V62, P14, DOI 10.1111/adj.12448
   Oh BR, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1357 2
   Okuma S, 2020, CANCERS, V12, DOI 10.3390/cancers12051209
   Özdemir RBÖ, 2020, IMMUNOL LETT, V227, P34, DOI 10.1016/j.imlet.2020.08.006
   Park JK, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02258 0
   Pers JO, 2008, J PERIODONTOL, V79, P1645, DOI [10.1902/jop.2008.070616, 10.1902/jop.2008.070616 ]
   Pilipchuk SP, 2015, DENT MATER, V31, P317, DOI 10.1016/j.dental.2015.01.006
   Piperigkou Z, 2018, METHODS MOL BIOL, V1731, P325, DOI 10.1007/978 1 4939 7595 2_27
   Preshaw PM, 2018, PERIODONTOL 2000, V76, P131, DOI 10.1111/prd.12148
   Preshaw PM, 2004, J PERIODONTOL, V75, P1068, DOI 10.1902/jop.2004.75.8.1068
   Punceviciene E, 2021, CLIN RHEUMATOL, V40, P3153, DOI 10.1007/s10067 021 05661 3
   Qiao YQ, 2020, JOINT BONE SPINE, V87, P556, DOI 10.1016/j.jbspin.2020.04.024
   Reddig A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071431
   Romano F, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8110515
   Romero Sánchez C, 2017, CURR RHEUMATOL REV, V13, P139, DOI 10.2174/1573397113666170407161520
   Saas P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.593300
   Samarpita S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2097 2
   Santos Sierra S, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11091291
   Savioli C, 2012, JCR J CLIN RHEUMATOL, V18, P180, DOI 10.1097/RHU.0b013e31825828be
   Schmickler J, 2017, J PERIODONTOL, V88, P368, DOI 10.1902/jop.2016.160355
   Serhan CN, 2018, J CLIN INVEST, V128, P2657, DOI 10.1172/JCI97943
   Serhan CN, 2017, FASEB J, V31, P1273, DOI [10.1096/fj.201601222R, 10.1096/fj.201601222r]
   Sfetcu L, 2021, MEDICINA LITHUANIA, V57, DOI 10.3390/medicina57050447
   Shiloah J, 2014, J PERIODONTAL RES, V49, P102, DOI 10.1111/jre.12085
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Speer EM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196352
   Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541
   Sun J, 2021, CLIN ORAL INVEST, V25, P4975, DOI 10.1007/s00784 021 03807 w
   Tada M, 2017, RHEUMATOL INT, V37, P999, DOI 10.1007/s00296 017 3720 7
   Takemoto T, 2020, CLIN EXP RHEUMATOL, V38, P933
   Takeuchi T, 2019, ANN RHEUM DIS, V78, P899, DOI 10.1136/annrheumdis 2018 214827
   Treuter E, 2017, FEBS LETT, V591, P2959, DOI 10.1002/1873 3468.12850
   Van Dyke TE, 2017, MOL ASPECTS MED, V58, P21, DOI 10.1016/j.mam.2017.04.006
   Venkataraman Archana, 2015, N Y State Dent J, V81, P30
   Wada TT, 2014, BIOCHEM BIOPH RES CO, V444, P682, DOI 10.1016/j.bbrc.2014.01.195
   Wang LP, 2020, DRUG DISCOV TODAY, V25, P1919, DOI 10.1016/j.drudis.2020.09.001
   Wolfe RM, 2017, IMMUNOL ALLERGY CLIN, V37, P283, DOI 10.1016/j.iac.2017.01.005
   Xie J, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1492 3
   Xue ML, 2014, RHEUMATOLOGY, V53, P2270, DOI 10.1093/rheumatology/keu254
   Yang Keum Han, 2017, [Journal of Dental Hygiene Science, 치위생과학회지], V17, P81, DOI 10.17135/jdhs.2017.17.1.81
   Yao Q, 2018, TRENDS PHARMACOL SCI, V39, P766, DOI 10.1016/j.tips.2018.06.003
   Young David A, 2019, F1000Res, V8, DOI 10.12688/f1000research.17471.1
   Ziebolz D, 2018, J PERIODONTOL, V89, P1310, DOI 10.1002/JPER.17 0616
NR 141
TC 26
Z9 26
U1 1
U2 22
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD DEC
PY 2021
VL 14
IS 12
AR 1209
DI 10.3390/ph14121209
PG 20
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA XX9QT
UT WOS:000736621300001
PM 34959607
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU abranyi Balogh, P
   Greiner, I
   Keglevich, G
AF abranyi Balogh, Peter
   Greiner, Istvan
   Keglevich, Gyoergy
TI A Mechanistic Study on the Formation of Dronic Acids
SO MOLECULES
LA English
DT Article
DE dronic acid; carboxylic acid; phosphorus trichloride; phosphorous acid;
   solvents; mechanism; calculations
ID RATIONAL SYNTHESIS; BISPHOSPHONATES; BONE
AB Dronic acid derivatives, important drugs against bone diseases, may be synthesized from the corresponding substituted acetic acid either by reaction with phosphorus trichloride in methanesulfonic acid as the solvent or by using also phosphorous acid as the P reactant if sulfolane is applied as the medium. The energetics of the two protocols were evaluated by high level quantum chemical calculations on the formation of fenidronic acid and benzidronic acid. The second option, involving (HO)(2)P O PCl2 as the nucleophile, was found to be more favorable over the first variation, comprising Cl2P O SO2Me as the real reagent, especially for the case of benzidronate.
C1 [abranyi Balogh, Peter] Med Chem Res Grp, Res Ctr Nat Sci, H 1117 Budapest, Hungary.
   [Greiner, Istvan] Gedeon Richter Plc, H 1475 Budapest, Hungary.
   [Keglevich, Gyoergy] Budapest Univ Technol & Econ, Dept Organ Chem & Technol, H 1521 Budapest, Hungary.
C3 HUN REN; HUN REN Research Centre for Natural Sciences; Gedeon Richter
   Chemistry Works; Budapest University of Technology & Economics
RP abranyi Balogh, P (通讯作者)，Med Chem Res Grp, Res Ctr Nat Sci, H 1117 Budapest, Hungary.; Keglevich, G (通讯作者)，Budapest Univ Technol & Econ, Dept Organ Chem & Technol, H 1521 Budapest, Hungary.
EM abranyi balogh.peter@ttk.mta.hu; i.greiner@richter.hu;
   keglevich.gyorgy@vbk.bme.hu
RI ; Ábrányi Balogh, Péter/B 9474 2013; Abranyi Balogh, Peter/B 9474 2013
OI Greiner, Istvan/0000 0002 5336 2828; Keglevich,
   Gyorgy/0000 0002 5366 472X; Abranyi Balogh, Peter/0000 0002 9284 5160
FU National Research, Development and Innovation Office [K134318]; Janos
   Bolyai Research Scholarship of the Hungarian Academy of Sciences
FX This project was supported by the National Research, Development and
   Innovation Office (K134318) and Janos Bolyai Research Scholarship of the
   Hungarian Academy of Sciences for P.A B.
CR Cheer SM, 2001, DRUGS, V61, P799, DOI 10.2165/00003495 200161060 00010
   Chesnut CH, 2006, DRUGS, V66, P1351, DOI 10.2165/00003495 200666100 00004
   Coukell AJ, 1998, DRUG AGING, V12, P149, DOI 10.2165/00002512 199812020 00007
   Dunn CJ, 2001, DRUGS, V61, P685, DOI 10.2165/00003495 200161050 00013
   Engineering ToolBox, 2010, REL PERM DIEL CONST
   Fifen JJ, 2014, J PHYS CHEM A, V118, P11090, DOI 10.1021/jp508968z
   Garadnay S., 2012, Chem. Abs, V157
   Grün A, 2015, LETT DRUG DES DISCOV, V12, P78
   Gruen A, 2014, LETT ORG CHEM, V11, P368
   Hudson HR, 2012, MINI REV MED CHEM, V12, P313, DOI 10.2174/138955712799829285
   Keglevich G, 2013, CURR ORG SYNTH, V10, P640
   Keglevich G, 2012, LETT DRUG DES DISCOV, V9, P345, DOI 10.2174/157018012799859963
   Keglevich G, 2011, TETRAHEDRON LETT, V52, P2744, DOI 10.1016/j.tetlet.2011.03.093
   Kovács R, 2014, HETEROATOM CHEM, V25, P186, DOI 10.1002/hc.21155
   Mardirossian N, 2017, MOL PHYS, V115, P2315, DOI 10.1080/00268976.2017.1333644
   Nagy DI, 2019, LETT DRUG DES DISCOV, V16, P238, DOI 10.2174/1570180815666180626122630
   Nagy DI, 2018, LETT DRUG DES DISCOV, V15, P713, DOI 10.2174/1570180814666171027160324
   Nagy DI, 2018, SYNTHETIC COMMUN, V48, P663, DOI 10.1080/00397911.2017.1410894
   Nagy DI, 2017, CURR ORG CHEM, V21, P1567, DOI 10.2174/1385272821666170417122441
   Nagy DI, 2017, HETEROATOM CHEM, V28, DOI 10.1002/hc.21370
   Nagy DI, 2016, MOLECULES, V21, DOI 10.3390/molecules21081046
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Sharpe M, 2001, DRUGS, V61, P999, DOI 10.2165/00003495 200161070 00010
   Tilstam U, 2012, ORG PROCESS RES DEV, V16, P1273, DOI 10.1021/op300108w
   Wickleder M.S., 2013, COMPREHENSIVE INORGA, V2nd, P491, DOI [10.1016/B978 0 08 097774 4.00222 9, DOI 10.1016/B978 0 08 097774 4.00222 9]
NR 26
TC 2
Z9 2
U1 1
U2 14
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1420 3049
J9 MOLECULES
JI Molecules
PD DEC
PY 2021
VL 26
IS 24
AR 7587
DI 10.3390/molecules26247587
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XY3RD
UT WOS:000736893000001
PM 34946669
OA Green Published, Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Jo, HG
   Baek, CY
   Kim, D
   Lee, DH
   Song, HS
AF Jo, Hee Geun
   Baek, Chae Yun
   Kim, Donghwan
   Lee, Donghun
   Song, Ho Sueb
TI Stem of Sorbus commixta Hedl. Extract Inhibits Cartilage
   Degradation and Arthritic Pain in Experimental Model via
   Anti Inflammatory Activity
SO NUTRIENTS
LA English
DT Article
DE East Asian herbal medicine; osteoarthritis; sorbus commixta;
   anti inflammatory; network pharmacology; cartilage degradation
ID TRADITIONAL CHINESE MEDICINE; OSTEOARTHRITIS; MECHANISMS
AB Osteoarthritis (OA) is a widespread joint disease that affects millions of people worldwide. Conventional treatments for OA, including non steroidal anti inflammatory drugs (NSAIDs) and steroids, have a risk of various adverse events, including liver, gastrointestinal, cardiovascular, and kidney disease, which are unsatisfactory in their effectiveness. In this study, Sorbus commixta Hedl. Stem extracts (SCE) were evaluated in animal models as potential inhibitors for the progression of OA. Sorbus commixta Hedl., which was found to have substantial anti inflammatory and antioxidant activities in earlier investigations, has shown potential as a candidate for OA treatment. To mimic human OA symptoms, male rats were injected using sodium iodoacetate (MIA) in their knee joints. SCE significantly reduced MIA induced weight bearing loss in rats after the MIA injection and alleviated cartilage degradation and subchondral bone injury caused by MIA. In addition, SCE administration reduced levels of TNF alpha and IL 1 beta such as pro inflammatory cytokines in serum, as well as the levels of matrix metalloproteinases (MMPs) such as MMP 1,  3,  8 and  13 in the joint cartilage. SCE significantly inhibited the writhing responses in acetic acid administered mice and was used to quantify pain. In lipopolysaccharide (LPS) activated RAW264.7, SCE suppressed NO production and reduced the expression of TNF alpha, PGE2, IL 6, IL 1 beta, MMP1, MMP3, MMP8, and MMP 13. Our study showed that SCE alleviated inflammation and cartilage degradation in arthritis through its anti inflammatory activities on multiple targets.
C1 [Jo, Hee Geun; Baek, Chae Yun; Lee, Donghun] Gachon Univ, Dept Herbal Pharmacol, Coll Korean Med, 1342 Seongnamdae Ro, Seongnam 13120, South Korea.
   [Jo, Hee Geun] Naturalis Inc, 6 Daewangpangyo Ro, Seongnam Si 13549, South Korea.
   [Kim, Donghwan; Song, Ho Sueb] Gachon Univ, Coll Korean Med, Dept Acupuncture & Moxibust Med, 1342 Seongnamdae Ro, Seongnam 13120, South Korea.
C3 Gachon University; Gachon University
RP Lee, DH (通讯作者)，Gachon Univ, Dept Herbal Pharmacol, Coll Korean Med, 1342 Seongnamdae Ro, Seongnam 13120, South Korea.; Song, HS (通讯作者)，Gachon Univ, Coll Korean Med, Dept Acupuncture & Moxibust Med, 1342 Seongnamdae Ro, Seongnam 13120, South Korea.
EM jho3366@hanmail.net; cyning20@gachon.ac.kr; dlee@gachon.ac.kr;
   hssong70@gachon.ac.kr
RI ; Jo, Hee Geun/ISV 0083 2023
OI Lee, Donghun/0000 0003 1075 0713; Jo, Hee Geun/0000 0002 1805 4387; Kim,
   Dong Hwan/0000 0001 5734 2181
FU National Research Foundation of Korea (NRF)   Korea government (MSIT)
   [2020R1A2C1013956]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MSIT) (No.
   2020R1A2C1013956).
CR Arra M, 2023, OSTEOARTHR CARTILAGE, V31, P1012, DOI 10.1016/j.joca.2023.04.003
   Bae JT, 2007, ARCH PHARM RES, V30, P1116, DOI 10.1007/BF02980246
   Conaghan PG, 2019, NAT REV RHEUMATOL, V15, P355, DOI 10.1038/s41584 019 0221 y
   de Almeida LGN, 2022, PHARMACOL REV, V74, P712, DOI 10.1124/pharmrev.121.000349
   De Roover A, 2023, OSTEOARTHR CARTILAGE, V31, P1303, DOI 10.1016/j.joca.2023.06.005
   Eitner A, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00349
   Gregori D, 2018, JAMA J AM MED ASSOC, V320, P2564, DOI 10.1001/jama.2018.19319
   Grillet B, 2023, NAT REV RHEUMATOL, V19, P363, DOI 10.1038/s41584 023 00966 w
   Hadzic E, 2023, EXPERT OPIN THER TAR, V27, P111, DOI 10.1080/14728222.2023.2185133
   Huang XJ, 2018, BIOMED PHARMACOTHER, V107, P433, DOI 10.1016/j.biopha.2018.07.161
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Im NK, 2016, J NAT PROD, V79, P412, DOI 10.1021/acs.jnatprod.5b01088
   Jenei Lanzl Z, 2019, CELL SIGNAL, V53, P212, DOI 10.1016/j.cellsig.2018.10.005
   Jo HG, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15051361
   Jo HG, 2022, PHARMACOL RES, V185, DOI 10.1016/j.phrs.2022.106460
   Jo HG, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.800571
   Knights AJ, 2023, CURR OPIN RHEUMATOL, V35, P128, DOI 10.1097/BOR.0000000000000923
   Kusakabe T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010371
   Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584 020 00518 6
   Latourte A, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 209757
   Leifer VP, 2022, OSTEOARTHR CARTILAGE, V30, P10, DOI 10.1016/j.joca.2021.05.007
   Leopoldino AO, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013273
   Leung YY, 2017, OSTEOARTHR CARTILAGE, V25, P1420, DOI 10.1016/j.joca.2017.04.001
   Li L, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 3120 0
   Li WH, 2023, AGEING RES REV, V89, DOI 10.1016/j.arr.2023.101981
   Li XZ, 2020, CHIN MED UK, V15, DOI 10.1186/s13020 020 00363 5
   Luo Y, 2020, AM J CHINESE MED, V48, P1, DOI 10.1142/S0192415X20500019
   Mahmoudian A, 2021, NAT REV RHEUMATOL, V17, P621, DOI 10.1038/s41584 021 00673 4
   Nejadhosseinian M, 2022, FRONT NUTR, V9, DOI 10.3389/fnut.2022.1026450
   Oo WM, 2022, CLIN GERIATR MED, V38, P397, DOI 10.1016/j.cger.2021.11.010
   Panossian A, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1199516
   Pigeolet M, 2021, LANCET, V397, P1059, DOI 10.1016/S0140 6736(21)00208 7
   Ren JL, 2023, TRENDS ENDOCRIN MET, V34, P146, DOI 10.1016/j.tem.2023.01.005
   Roberts E, 2016, ANN RHEUM DIS, V75, P552, DOI 10.1136/annrheumdis 2014 206914
   Sanchez Lopez E, 2022, NAT REV RHEUMATOL, V18, P258, DOI 10.1038/s41584 022 00749 9
   Sun WC, 2022, INT J MOL MED, V50, DOI 10.3892/ijmm.2022.5190
   Tong LP, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00226 9
   Tudorachi NB, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10060985
   Vincent TL, 2020, LANCET RHEUMATOL, V2, pE633, DOI 10.1016/S2665 9913(20)30279 4
   Wan JT, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.663978
   Wang MN, 2020, J PAIN RES, V13, P1421, DOI 10.2147/JPR.S247827
   Wang Q, 2022, PHYTOMEDICINE, V100, DOI 10.1016/j.phymed.2022.154029
   Wang Z, 2022, PHYTOMEDICINE, V105, DOI 10.1016/j.phymed.2022.154347
   Weng QL, 2023, BRIT J SPORT MED, V57, P990, DOI 10.1136/bjsports 2022 105898
   Yang G, 2014, IMMUNOPHARM IMMUNOT, V36, P70, DOI 10.3109/08923973.2013.866956
   Yang GM, 2023, ARTHRIT CARE RES, V75, P2489, DOI 10.1002/acr.25158
   Yang M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189884
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01330 w
   Yu H, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23094642
   Yu T, 2011, J ETHNOPHARMACOL, V134, P493, DOI 10.1016/j.jep.2010.12.032
   Zádori ZS, 2023, PHARMACOL THERAPEUT, V241, DOI 10.1016/j.pharmthera.2022.108327
   Zhang PH, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02785 y
NR 52
TC 11
Z9 12
U1 1
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6643
J9 NUTRIENTS
JI Nutrients
PD SEP
PY 2023
VL 15
IS 17
AR 3774
DI 10.3390/nu15173774
PG 17
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA R4PL9
UT WOS:001064180900001
PM 37686806
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ingle, BM
   Machado, ABC
   Pereda, CA
   Eastell, R
AF Ingle, BM
   Machado, ABC
   Pereda, CA
   Eastell, R
TI Monitoring alendronate and estradiol therapy with quantitative
   ultrasound and bone mineral density
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article
DE subcutaneous estradiol; bisphosphonates; bone mineral density;
   quantitative ultrasound
ID HORMONE REPLACEMENT THERAPY; X RAY ABSORPTIOMETRY; POSTMENOPAUSAL WOMEN;
   VERTEBRAL DEFORMITY; SALMON CALCITONIN; RANDOMIZED TRIAL; FRACTURE;
   MASS; DISCRIMINATION; OSTEOPOROSIS
AB Few studies have compared quantitative ultrasound with bone mineral density (BMD) in monitoring response to therapy in osteoporosis. The aim of our study was to compare finger ultrasound variables and BMD for monitoring alendronate and estradiol therapy in postmenopausal women. We recruited 26 women aged 50 to 79 yr (mean: 65 yr) with osteoporosis; 18 patients received 10 mg/d of alendronate and 500 mg/d of calcium carbonate and 8 patients received 500 mg/d of calcium carbonate only. We recruited 21 hysterectornized postmenopausal women who were randomized to treatment or control. The treatment group received a 25 mg estradiol implant, which was replaced every 6 mo. The control group had a sham procedure. In the alendronate group, there were significant changes at I yr at the lumbar spine 3 < 0.05), bone transmission time Q), < 0.01), and pure speed of sound (p < 0.001) and the changes continued into the second year. In the estradiol implant group, there were significant changes at I yr at the lumbar spine (p < 0.001), the femoral neck (p < 0.05), and the pure speed of sound (p < 0.01). For alendronate, the signal to noise ratio was similar between the lumbar spine and bone transmission time (1.8 and 1.4) and greater than for the pure speed of sound and femoral neck (0.8 and 0.7); for estradiol, the signal to noise ratio was similar between the lumbar spine and femoral neck (2.0 and 1.5) and greater than for the pure speed of sound and bone transmission time (1.1 and 0.6). These results indicated that changes in finger ultrasound are similar in clinical utility to dual energy X ray absorptiometry measurements at the femoral neck for the monitoring of antiresorptive treatments for osteoporosis.
C1 Univ Sheffield, Div Clin Sci, Med Sect, Bone Metab Grp, Sheffield S5 7AU, S Yorkshire, England.
C3 University of Sheffield
RP Eastell, R (通讯作者)，No Gen Hosp, Ctr Clin Sci, Bone Metab Grp, Div Clin Sci, Sheffield S5 7AU, S Yorkshire, England.
EM r.eastell@sheffield.ac.uk
RI Pereda, Claudia Alejandra/IXX 3171 2023; Eastell, Richard/G 5851 2011
OI Pereda, Claudia/0000 0002 9713 8641
CR Balikian P, 1998, J CLIN DENSITOM, V1, P19, DOI 10.1385/JCD:1:1:19
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Drake WM, 2002, OSTEOPOROSIS INT, V13, P249, DOI 10.1007/s001980200022
   Genant HK, 1996, J BONE MINER RES, V11, P707
   Giorgino R, 1996, J BONE MINER RES, V11, pM639
   GLUER CC, 1994, CALCIFIED TISSUE INT, V55, P46, DOI 10.1007/BF00310168
   Gluer CC, 1997, J BONE MINER RES, V12, P1280, DOI 10.1359/jbmr.1997.12.8.1280
   GONNELLI S, 1993, CURR THER RES CLIN E, V54, P458, DOI 10.1016/S0011 393X(05)80652 6
   Gonnelli S, 1996, OSTEOPOROSIS INT, V6, P303, DOI 10.1007/BF01623389
   Gonnelli S, 1995, OSTEOPOROSIS INT, V5, P413, DOI 10.1007/BF01626601
   Gonnelli S, 2002, J ENDOCRINOL INVEST, V25, P389, DOI 10.1007/BF03344023
   Gonnelli S, 2002, OSTEOPOROSIS INT, V13, P415, DOI 10.1007/s001980200048
   Hadji P, 2000, AM J OBSTET GYNECOL, V182, P529, DOI 10.1067/mob.2000.104204
   HANS D, 1995, BONE, V16, P295, DOI 10.1016/8756 3282(94)00041 7
   Krieg MA, 1999, OSTEOPOROSIS INT, V9, P483, DOI 10.1007/s001980050174
   Machado ABD, 1999, J BONE MINER RES, V14, P602
   Mauloni M, 2000, MENOPAUSE, V7, P402, DOI 10.1097/00042192 200011000 00006
   Mikhail MB, 1999, OSTEOPOROSIS INT, V9, P24, DOI 10.1007/s001980050112
   Pereda CA, 2002, BJOG INT J OBSTET GY, V109, P812, DOI 10.1016/S1470 0328(02)01177 1
   PLUSKIEWICZ W, 2000, BONE S3, V26, P395
   Pols HAP, 1999, OSTEOPOROSIS INT, V9, P461, DOI 10.1007/PL00004171
   ROSS P, 1995, BONE, V16, P325, DOI 10.1016/8756 3282(94)00045 X
   Sahota O, 2000, OSTEOPOROSIS INT, V11, P52, DOI 10.1007/s001980050006
   SCHOTT AM, 1995, J BONE MINER RES, V10, P243
   Tucci JR, 1996, AM J MED, V101, P488, DOI 10.1016/S0002 9343(96)00282 3
   Wüster C, 2000, J BONE MINER RES, V15, P1603, DOI 10.1359/jbmr.2000.15.8.1603
NR 26
TC 23
Z9 23
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1094 6950
EI 1559 0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD FAL
PY 2005
VL 8
IS 3
BP 278
EP 286
DI 10.1385/JCD:8:3:278
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 969TQ
UT WOS:000232258100005
PM 16055957
DA 2025 08 17
ER

PT J
AU Nagahara, Y
   Shimazawa, M
   Tanaka, H
   Ono, Y
   Noda, Y
   Ohuchi, K
   Tsuruma, K
   Katsuno, M
   Sobue, G
   Hara, H
AF Nagahara, Yuki
   Shimazawa, Masamitsu
   Tanaka, Hirotaka
   Ono, Yoko
   Noda, Yasuhiro
   Ohuchi, Kazuki
   Tsuruma, Kazuhiro
   Katsuno, Masahisa
   Sobue, Gen
   Hara, Hideaki
TI Glycoprotein nonmetastatic melanoma protein B ameliorates skeletal
   muscle lesions in a SOD1<SUP>G93A</SUP> mouse model of amyotrophic
   lateral sclerosis
SO JOURNAL OF NEUROSCIENCE RESEARCH
LA English
DT Article
DE glycoprotein nonmetastatic melanoma protein B; GPNMB; amyotrophic
   lateral sclerosis; ALS; skeletal muscle; neuromuscular junction;
   transgenic mouse; sporadic ALS
ID HEPATOCYTE GROWTH FACTOR; CRITICAL LIMB ISCHEMIA; INTRAMUSCULAR
   GENE TRANSFER; MOTOR NEURON DEGENERATION; OSTEOBLAST DIFFERENTIATION;
   BUERGERS DISEASE; TRANSGENIC MICE; PLASMID DNA; IN VITRO; OSTEOACTIVIN
AB Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of motor neurons and subsequent muscular atrophy. The quality of life of patients with ALS is significantly improved by ameliorating muscular symptoms. We previously reported that glycoprotein nonmetastatic melanoma protein B (GPNMB; osteoactivin) might serve as a target for ALS therapy. In the present study, superoxide dismutase 1/glycine residue 93 changed to alanine (SOD1(G93A)) transgenic mice were used as a model of ALS. Expression of the C terminal fragment of GPNMB was increased in the skeletal muscles of SOD1(G93A) mice and patients with sporadic ALS. SOD1(G93A)/GPNMB transgenic mice were generated to determine whether GPNMB expression ameliorates muscular symptoms. The weight and cross sectional area of the gastrocnemius muscle, number and cross sectional area of myofibers, and denervation of neuromuscular junctions were ameliorated in SOD1(G93A)/GPNMB vs. SOD1(G93A) mice. Furthermore, direct injection of a GPNMB expression plasmid into the gastrocnemius muscle of SOD1(G93A) mice increased the numbers of myofibers and prevented myofiber atrophy. These findings suggest that GPNMB directly affects skeletal muscle and prevents muscular pathology in SOD1(G93A) mice and may therefore serve as a target for therapy of ALS. (c) 2015 Wiley Periodicals, Inc.
C1 [Nagahara, Yuki; Shimazawa, Masamitsu; Tanaka, Hirotaka; Ono, Yoko; Noda, Yasuhiro; Ohuchi, Kazuki; Tsuruma, Kazuhiro; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu 5011196, Japan.
   [Katsuno, Masahisa; Sobue, Gen] Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4648601, Japan.
C3 Gifu Pharmaceutical University; Nagoya University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1 25 4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu pu.ac.jp
RI Tanaka, Hirotaka/KLE 0935 2024; KATSUNO, MASAHISA/I 7502 2014
OI Hara, Hideaki/0000 0003 2046 9001
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [25460103]; Grants in Aid for Scientific Research [25460103] Funding
   Source: KAKEN
FX The authors thank the patients and their families who participated in
   this study. This study was supported by grants from the Ministry of
   Education, Culture, Sports, Science and Technology, Japan : a
   Grant in Aid for Scientific Research (c) (25460103).
CR Abdelmagid SM, 2008, EXP CELL RES, V314, P2334, DOI 10.1016/j.yexcr.2008.02.006
   Ahmadi M, 2010, INVEST OPHTH VIS SCI, V51, P3494, DOI 10.1167/iovs.09 5030
   Audouard E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050509
   Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114
   BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901
   Boyer JG, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00356
   Chung JS, 2007, J IMMUNOL, V179, P5778, DOI 10.4049/jimmunol.179.9.5778
   Chung JS, 2009, EUR J IMMUNOL, V39, P965, DOI 10.1002/eji.200838990
   Da Cruz S, 2012, CELL METAB, V15, P778, DOI 10.1016/j.cmet.2012.03.019
   Dion PA, 2009, NAT REV GENET, V10, P769, DOI 10.1038/nrg2680
   Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004
   Frey D, 2000, J NEUROSCI, V20, P2534
   Furochi Harumi, 2007, J Med Invest, V54, P248, DOI 10.2152/jmi.54.248
   Furochi H, 2007, FEBS LETT, V581, P5743, DOI 10.1016/j.febslet.2007.11.036
   Gifondorwa DJ, 2007, J NEUROSCI, V27, P13173, DOI 10.1523/JNEUROSCI.4057 07.2007
   Gifondorwa DJ, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/170426
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Henry TD, 2011, GENE THER, V18, P788, DOI 10.1038/gt.2011.21
   Hoashi T, 2010, FASEB J, V24, P1616, DOI 10.1096/fj.09 151019
   Hu XF, 2013, J CELL BIOCHEM, V114, P2729, DOI 10.1002/jcb.24621
   Huang C, 2012, J CLIN INVEST, V122, P107, DOI 10.1172/JCI59130
   Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741 5214(98)70022 9
   Kim HJ, 2013, NATURE, V495, P467, DOI 10.1038/nature11922
   Kim JM, 2003, GENE THER, V10, P1543, DOI 10.1038/sj.gt.3302042
   Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044
   Kuan CT, 2006, CLIN CANCER RES, V12, P1970, DOI 10.1158/1078 0432.CCR 05 2797
   Léger B, 2006, FASEB J, V20, P583, DOI 10.1096/fj.05 5249fje
   Li W, 2007, EXP NEUROL, V203, P457, DOI 10.1016/j.expneurol.2006.08.028
   Lu QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046998
   Matsuki A, 2004, BIOCHEM BIOPH RES CO, V315, P59, DOI 10.1016/j.bbrc.2004.01.026
   Nikawa T, 2004, FASEB J, V18, P522, DOI 10.1096/fj.03 0419fje
   Ogawa T, 2005, AM J PHYSIOL CELL PH, V289, pC697, DOI 10.1152/ajpcell.00565.2004
   Onaga M, 2003, J HEPATOL, V39, P779, DOI 10.1016/S0168 8278(03)00361 1
   Ono Y, 2014, NEUROSCI LETT, V559, P174, DOI 10.1016/j.neulet.2013.12.005
   Osawa K, 2010, J GENE MED, V12, P937, DOI 10.1002/jgm.1515
   Rastogi S, 2011, AM J PHYSIOL HEART C, V300, pH1501, DOI 10.1152/ajpheart.00636.2010
   Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200
   Ripoll VM, 2008, GENE, V413, P32, DOI 10.1016/j.gene.2008.01.014
   Rose AAN, 2007, MOL CANCER RES, V5, P1001, DOI 10.1158/1541 7786.MCR 07 0119
   Rose AAN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012093
   Sakowski SA, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750 1326 7 44
   Schgoer W, 2009, CIRC RES, V105, P994, DOI 10.1161/CIRCRESAHA.109.199513
   Selim AA, 2003, CRIT REV EUKAR GENE, V13, P265, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.180
   Sheng MHC, 2008, FEBS LETT, V582, P1451, DOI 10.1016/j.febslet.2008.03.030
   Shigematsu H, 2011, INT ANGIOL, V30, P140
   Shimazawa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015307
   Singh M, 2010, CRIT REV EUKAR GENE, V20, P341, DOI 10.1615/CritRevEukarGeneExpr.v20.i4.50
   Sunyach C, 2012, NEUROPHARMACOLOGY, V62, P2346, DOI 10.1016/j.neuropharm.2012.02.013
   Takata M, 2013, BRIT J PHARMACOL, V170, P341, DOI 10.1111/bph.12277
   Tanaka H, 2012, SCI REP UK, V2, DOI 10.1038/srep00573
   Taniyama Y, 2001, GENE THER, V8, P181, DOI 10.1038/sj.gt.3301379
   Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078 0432.CCR 05 2018
   Utsunomiya K, 2012, BIOSCI BIOTECH BIOCH, V76, P2225, DOI 10.1271/bbb.120515
   Warita H, 1998, NEUROSCI LETT, V246, P153, DOI 10.1016/S0304 3940(98)00245 6
   WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111
   Wijesekera LC, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750 1172 4 3
   Williams MD, 2010, MELANOMA RES, V20, P184, DOI 10.1097/CMR.0b013e3283364a08
   Wong M, 2010, HUM MOL GENET, V19, P2284, DOI 10.1093/hmg/ddq106
   Wootz H, 2010, NEUROBIOL DIS, V37, P58, DOI 10.1016/j.nbd.2009.09.006
   Yoo YE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037258
   Yuan QY, 2012, LIFE SCI, V90, P695, DOI 10.1016/j.lfs.2012.03.003
   Zhang Qinglin, 2006, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V20, P1147
NR 62
TC 27
Z9 31
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0360 4012
EI 1097 4547
J9 J NEUROSCI RES
JI J. Neurosci. Res.
PD OCT
PY 2015
VL 93
IS 10
BP 1552
EP 1566
DI 10.1002/jnr.23619
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA CP7VQ
UT WOS:000360097600009
PM 26140698
DA 2025 08 17
ER

PT J
AU Varkas, G
   Jans, L
   Cypers, H
   Van Praet, L
   Carron, P
   Elewaut, D
   Van den Bosch, F
AF Varkas, G.
   Jans, L.
   Cypers, H.
   Van Praet, L.
   Carron, P.
   Elewaut, D.
   Van den Bosch, F.
TI Six Week Treatment of Axial Spondyloarthritis Patients With an Optimal
   Dose of Nonsteroidal Antiinflammatory Drugs: Early Response to Treatment
   in Signal Intensity on Magnetic Resonance Imaging of the Sacroiliac
   Joints
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID PLACEBO CONTROLLED TRIAL; ANKYLOSING SPONDYLITIS; RADIOGRAPHIC
   PROGRESSION; RESEARCH CONSORTIUM; DOUBLE BLIND; EFFICACY; INFLIXIMAB;
   INFLAMMATION; SAFETY; MULTICENTER
AB Objective. To evaluate the early effect of full dose nonsteroidal antiinflammatory drugs (NSAIDs) on the extent and intensity of bone marrow edema of the sacroiliac (SI) joints on magnetic resonance imaging (MRI) in axial spondyloarthritis (SpA).
   Methods. A single center, 6 week study of a cohort of consecutive patients with clinically suspected axial SpA was conducted. A total of 117 patients were screened. Forty patients who were diagnosed as having axial SpA and had presented with a positive MRI of the SI joints as defined by the Assessment of SpondyloArthritis international Society (ASAS) criteria were considered for a followup MRI after 6 weeks of an optimal dose of NSAIDs. Twenty patients completed the study. Disease activity was monitored by determining the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score every 2 weeks and the Bath Ankylosing Spondylitis Functional Index score at baseline and week 6. NSAID intake was assessed by the ASAS NSAID index. Primary end points were improvement in bone marrow edema of the SI joints on MRI and BASDAI response at week 6.
   Results. Approximately one third of eligible patients newly diagnosed as having axial SpA were unable to continue the full dose NSAID schedule. The median NSAID index was 97% in patients who completed the study. There was a reduction of 1.1 units (10.5%) in mean Spondyloarthritis Research Consortium of Canada (SPARCC) scores at week 6 in comparison to baseline (P=0.032). Overall, only 30% of the patients (6 of 20) had a minimal clinically important difference of 2.5 in SPARCC score. However, 80% of the patients displayed high intensity lesions on STIR images at baseline, which decreased significantly at week 6 (P=0.011). There was a significant decrease in the relative intensity of the region of interest (P=0.007) and a mean decrease of 0.6 in the BASDAI score per 2 weeks of therapy (P=0.001). Only 29.4% of the patients met the BASDAI criteria for 50% improvement (BASDAI50) at week 6.
   Conclusion. Our findings indicate a high level of dropout among patients receiving full dose NSAID therapy in daily practice. In those who tolerated NSAID therapy, there was no clinically relevant decrease in SPARCC scores and low BASDAI50 response. However, we found a decrease in signal intensity of bone marrow edema of the SI joints as an early response to 6 weeks of optimal NSAID therapy in patients newly presenting with axial SpA.
C1 [Varkas, G.; Cypers, H.; Elewaut, D.] Univ Ghent VIB, Inflammat Res Inst, Ghent, Belgium.
   [Varkas, G.; Jans, L.; Cypers, H.; Van Praet, L.; Carron, P.; Elewaut, D.; Van den Bosch, F.] Ghent Univ Hosp, B 9000 Ghent, Belgium.
C3 Ghent University; Flanders Institute for Biotechnology (VIB); Ghent
   University; Ghent University Hospital
RP Van den Bosch, F (通讯作者)，Ghent Univ Hosp, Dept Rheumatol, Pintelaan 185, B 9000 Ghent, Belgium.
EM Filip.vandenbosch@ugent.be
RI ; Elewaut, Dirk/K 6831 2014
OI Elewaut, Dirk/0000 0002 7468 974X; 
FU Ghent University Hospital (Clinical Research Funding grant); Het Fonds
   voor Wetenschappelijk Reuma Onderzoek
FX Supported by Ghent University Hospital (Clinical Research Funding grant)
   and Het Fonds voor Wetenschappelijk Reuma Onderzoek (to Dr. Varkas).
CR Appel H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2035
   Barkham N, 2009, ARTHRITIS RHEUM US, V60, P946, DOI 10.1002/art.24408
   Bellow M, 2000, ANN RHEUM DIS, V59, P135, DOI 10.1136/ard.59.2.135
   Braun J, 2003, ARTHRITIS RHEUM US, V48, P2224, DOI 10.1002/art.11104
   Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140 6736(02)08215 6
   Dougados M, 1999, RHEUMATOLOGY, V38, P235, DOI 10.1093/rheumatology/38.3.235
   Dougados M, 2014, ARTHRITIS RHEUMATOL, V66, P2091, DOI 10.1002/art.38721
   Dougados M, 2011, ANN RHEUM DIS, V70, P249, DOI 10.1136/ard.2010.133488
   Jarrett SJ, 2009, ANN RHEUM DIS, V68, P1466, DOI 10.1136/ard.2008.092213
   Kroon F, 2012, ANN RHEUM DIS, V71, P1623, DOI 10.1136/annrheumdis 2012 201370
   Lambert RGW, 2007, ARTHRITIS RHEUM, V56, P4005, DOI 10.1002/art.23044
   Landewé RBM, 2005, J RHEUMATOL, V32, P2050
   Maksymowych WP, 2012, J RHEUMATOL, V39, P1666, DOI 10.3899/jrheum.120131
   Maksymowych WP, 2005, ARTHRIT RHEUM ARTHR, V53, P703, DOI 10.1002/art.21445
   Marzo Ortega H, 2009, ANN RHEUM DIS, V68, P1721, DOI 10.1136/ard.2008.097931
   Poddubnyy D, 2012, ARTHRITIS RHEUM US, V64, P1388, DOI 10.1002/art.33465
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P1520, DOI 10.1136/ard.2009.110767
   Sieper J, 2014, ANN RHEUM DIS, V73, P101, DOI 10.1136/annrheumdis 2012 203201
   Sieper J, 2013, ANN RHEUM DIS, V72, P815, DOI 10.1136/annrheumdis 2012 201766
   van Onna M, 2015, SCAND J RHEUMATOL, V44, P129, DOI 10.3109/03009742.2014.933247
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
NR 22
TC 29
Z9 31
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD MAR
PY 2016
VL 68
IS 3
BP 672
EP 678
DI 10.1002/art.39474
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DF3ON
UT WOS:000371254300016
PM 26473982
DA 2025 08 17
ER

PT J
AU Donate Correa, J
   Domínguez Pimentel, V
   Muros de Fuentes, M
   Mora Fernández, C
   Martín Núñez, E
   Cazaña Pérez, V
   Navarro González, JF
AF Donate Correa, Javier
   Dominguez Pimentel, Virginia
   Muros de Fuentes, Mercedes
   Mora Fernandez, Carmen
   Martin Nunez, Ernesto
   Cazana Perez, Violeta
   Navarro Gonzalez, Juan F.
TI Beneficial Effects of Selective Vitamin D Receptor Activation by
   Paricalcitol in Chronic Kidney Disease
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Cardiovascular disease; inflammation; paricalcitol; vitamin D analogues;
   vitamin D receptor
ID CALCIUM SENSING RECEPTOR; D RESPONSE ELEMENTS; 1,25 DIHYDROXYVITAMIN
   D 3; HEMODIALYSIS PATIENTS; SECONDARY HYPERPARATHYROIDISM;
   PARATHYROID HORMONE; MORTALITY RISK; CELL PROLIFERATION; TARGETED
   KNOCKOUT; RENAL FUNCTION
AB In chronic kidney disease patients, active vitamin D level progressively declines in the course of the disease. This phenomenon is accompanied by elevation of parathyroid hormone, resulting in secondary hyperparathyroidism (SHPT), increased phosphorus levels, and hypocalcemia. All these disorders are associated with high rates of cardiovascular morbidity and mortality in these patients. Many vitamin D analogs have been approved for the treatment of SHPT in renal patients. Currently, new and more selective vitamin D receptor activators (VDRAs) have been introduced in this therapy with the aim of reducing SHPT without the hypercalcemia and hyperphosphatemia associated with the use of nonselective VDRAs. In addition, amelioration in hypertension, albuminuria, insulin resistance, and inflammation have been suggested as consequences of vitamin D receptor (VDR) activation. In this work, we summarize the beneficial effects attributed to paricalcitol, the only selective, new generation VDRA, currently available in Europe and the USA, with proven efficacy in the control of SHPT both in hemodialysis (HD) and pre dialysis patients. Paricalcitol exerts less calcemic and phosphatemic effects than other VDRAs and prevents deleterious bone resorption. Moreover, paricalcitol based therapy has been related to beneficial effects that could favor survival rates in chronic kidney disease patients. These benefits include anti inflammatory and antithrombotic effects, the inhibition of vascular smooth muscle cell proliferation, the renin angiotensin system, vascular calcification, and regression of left ventricular hypertrophy, which could reduce the risk of cardiovascular mortality.
C1 [Donate Correa, Javier; Mora Fernandez, Carmen; Martin Nunez, Ernesto; Cazana Perez, Violeta; Navarro Gonzalez, Juan F.] Univ Hosp Nuestra Senora de Candelaria, Res Unit, Santa Cruz De Tenerife 38010, Spain.
   [Donate Correa, Javier; Muros de Fuentes, Mercedes; Mora Fernandez, Carmen; Navarro Gonzalez, Juan F.] Univ Hosp Nuestra Senora de Candelaria, GEENDIAB Grp Espanol Estudio Nefropatia Diabet, Santa Cruz De Tenerife 38010, Spain.
   [Donate Correa, Javier; Muros de Fuentes, Mercedes; Mora Fernandez, Carmen; Navarro Gonzalez, Juan F.] Univ Hosp Nuestra Senora de Candelaria, REDINREN RD12 0021 0019, Santa Cruz De Tenerife 38010, Spain.
   [Dominguez Pimentel, Virginia; Navarro Gonzalez, Juan F.] Univ Hosp Nuestra Senora de Candelaria, Serv Nephrol, Santa Cruz De Tenerife 38010, Spain.
   [Muros de Fuentes, Mercedes] Univ Hosp Nuestra Senora de Candelaria, Clin Anal Serv, Santa Cruz De Tenerife 38010, Spain.
RP Navarro González, JF (通讯作者)，Univ Hosp Nuestra Senora de Candelaria, Serv Nephrol, Santa Cruz De Tenerife 38010, Spain.
EM jnavgon@gobiernodecanarias.org
RI ; Martín Núñez, Ernesto/AAA 3544 2021; Navarro Gonzalez, Juan
   F./M 7375 2014; Martin Nunez, Ernesto/AAA 3544 2021; DONATE CORREA,
   JAVIER/AAB 2936 2020; Navarro González, Juan/M 7375 2014;
   Mora Fernandez, Carmen/R 8288 2019
OI Cazana Perez, Violeta/0000 0001 9698 7265; Navarro Gonzalez, Juan
   F./0000 0002 5015 7474; Dominguez Pimentel,
   Virginia/0009 0002 9597 0378; DONATE CORREA, JAVIER/0000 0001 7389 7347;
   Martin Nunez, Ernesto/0000 0003 0341 0956; Mora Fernandez,
   Carmen/0000 0003 1570 6332
CR Alborzi P, 2008, HYPERTENSION, V52, P249, DOI 10.1161/HYPERTENSIONAHA.108.113159
   Andress D, 2007, DRUGS, V67, P1999, DOI 10.2165/00003495 200767140 00003
   Andress DL, 2006, KIDNEY INT, V69, P33, DOI 10.1038/sj.ki.5000045
   Bacchetta J, 2013, J BONE MINER RES, V28, P46, DOI 10.1002/jbmr.1740
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Canaff L, 2002, J BIOL CHEM, V277, P30337, DOI 10.1074/jbc.M201804200
   Canalejo R, 2010, J AM SOC NEPHROL, V21, P1125, DOI 10.1681/ASN.2009040427
   Cardús A, 2006, KIDNEY INT, V69, P1377, DOI 10.1038/sj.ki.5000304
   Cardus A, 2007, J BONE MINER RES, V22, P860, DOI 10.1359/JBMR.070305
   Cardus A, 2009, ATHEROSCLEROSIS, V204, P85, DOI 10.1016/j.atherosclerosis.2008.08.020
   Carrillo López N, 2008, NEPHROL DIAL TRANSPL, V23, P3479, DOI 10.1093/ndt/gfn338
   Coyne DW, 2013, NEPHROL DIAL TRANSPL, V28, P2260, DOI 10.1093/ndt/gft227
   Denda M, 1996, AM J KIDNEY DIS, V28, P596, DOI 10.1016/S0272 6386(96)90473 4
   Dobnig H, 2008, ARCH INTERN MED, V168, P1340, DOI 10.1001/archinte.168.12.1340
   Donate Correa J, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/670475
   Eleftheriadis T, 2012, IRAN J KIDNEY DIS, V6, P129
   Finch JL, 1999, J AM SOC NEPHROL, V10, P980
   Freundlich M, 2014, AM J HYPERTENS, V27, P720, DOI 10.1093/ajh/hpt177
   Fryer RM, 2007, NEPHRON PHYSIOL, V106, P76, DOI 10.1159/000104875
   Guerrero F, 2012, NEPHROL DIAL TRANSPL, V27, P2206, DOI 10.1093/ndt/gfr555
   Hansen D, 2011, KIDNEY INT, V80, P841, DOI 10.1038/ki.2011.226
   Helming L, 2005, BLOOD, V106, P4351, DOI 10.1182/blood 2005 03 1029
   Sánchez JGH, 2011, NEFROLOGIA, V31, P697, DOI 10.3265/Nefrologia.pre2011.Aug.11030
   Hewison M, 2003, J IMMUNOL, V170, P5382, DOI 10.4049/jimmunol.170.11.5382
   Hirata M, 2003, NEPHROL DIAL TRANSPL, V18, P1770, DOI 10.1093/ndt/gfg296
   Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P37, DOI 10.1093/ndt/17.suppl_10.37
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   Holick MF, 2005, SEMIN DIALYSIS, V18, P266, DOI 10.1111/j.1525 139X.2005.18402.x
   Izquierdo MJ, 2012, BMC NEPHROL, V13, DOI 10.1186/1471 2369 13 159
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Ketteler M, 2012, NEPHROL DIAL TRANSPL, V27, P3270, DOI 10.1093/ndt/gfs018
   Kifor O, 2001, AM J PHYSIOL RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291
   Kim HW, 2006, NEPHRON CLIN PRACT, V102, pC21, DOI 10.1159/000088295
   KIZAKI M, 1991, BLOOD, V77, P1238
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI0215219
   Lo WK, 2006, CONTRIB NEPHROL, V150, P152, DOI 10.1159/000093515
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471 4914(02)02294 3
   MCGONIGLE RJS, 1981, P EUR DIAL TRANS, V18, P579
   Moe SM, 2001, AM J KIDNEY DIS, V38, P792, DOI 10.1053/ajkd.2001.27697
   MULLER K, 1992, CYTOKINE, V4, P506, DOI 10.1016/1043 4666(92)90012 G
   Nakane M, 2006, J STEROID BIOCHEM, V98, P72, DOI 10.1016/j.jsbmb.2005.07.007
   Navarro González JF, 2013, J CLIN PHARMACOL, V53, P421, DOI 10.1002/jcph.19
   Navarro González JF, 2009, CLIN J AM SOC NEPHRO, V4, P1646, DOI 10.2215/CJN.02420409
   Nemere I, 2012, ENDOCRINOLOGY, V153, P1609, DOI 10.1210/en.2011 1850
   Nemere I, 2010, J BIOL CHEM, V285, P31859, DOI 10.1074/jbc.M110.116954
   Noonan W, 2008, NEPHROL DIAL TRANSPL, V23, P3824, DOI 10.1093/ndt/gfn375
   Panizo S, 2013, NEPHROL DIAL TRANSPL, V28, P2735, DOI 10.1093/ndt/gft268
   Panizo S, 2009, CIRC RES, V104, P1041, DOI 10.1161/CIRCRESAHA.108.189001
   Park CW, 1999, AM J KIDNEY DIS, V33, P73, DOI 10.1016/S0272 6386(99)70260 X
   Parker J, 2010, MATURITAS, V65, P225, DOI 10.1016/j.maturitas.2009.12.013
   PATEL SR, 1995, J CLIN INVEST, V96, P50, DOI 10.1172/JCI118061
   Penna G, 2000, J IMMUNOL, V164, P2405, DOI 10.4049/jimmunol.164.5.2405
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   RUSSELL J, 1986, ENDOCRINOLOGY, V119, P2864, DOI 10.1210/endo 119 6 2864
   Seibert Eric, 2005, Hemodial Int, V9 Suppl 1, pS25, DOI 10.1111/j.1542 4758.2005.01167.x
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   SHVIL Y, 1990, J AM SOC NEPHROL, V1, P99
   SILVER J, 1985, P NATL ACAD SCI USA, V82, P4270, DOI 10.1073/pnas.82.12.4270
   Slatopolsky E, 1996, J CLIN INVEST, V97, P2534, DOI 10.1172/JCI118701
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Sochorová K, 2009, CLIN IMMUNOL, V133, P69, DOI 10.1016/j.clim.2009.06.011
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   SZABO A, 1989, KIDNEY INT, V35, P1049, DOI 10.1038/ki.1989.89
   Tan XY, 2008, J AM SOC NEPHROL, V19, P1741, DOI 10.1681/ASN.2007060666
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Thadhani R, 2012, JAMA J AM MED ASSOC, V307, P674, DOI 10.1001/jama.2012.120
   Timms PM, 2002, QJM INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787
   van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016/j.jsbmb.2005.06.002
   Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605
   Wang AY, 2013, J AM SOC NE IN PRESS
   Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127
   Wanner C, 2002, KIDNEY INT, V61, pS99, DOI 10.1046/j.1523 1755.61.s80.18.x
   Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451
   Wu Wong JR, 2007, KIDNEY INT, V72, P237, DOI 10.1038/sj.ki.5002428
   Yang L, 2012, CELL IMMUNOL, V279, P160, DOI 10.1016/j.cellimm.2012.10.002
   YU XP, 1991, J BIOL CHEM, V266, P7588
NR 82
TC 7
Z9 9
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389 4501
EI 1873 5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PY 2014
VL 15
IS 7
BP 703
EP 709
DI 10.2174/1389450115666140417120902
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AI8LT
UT WOS:000337168100005
PM 24745821
DA 2025 08 17
ER

PT J
AU Naruphontjirakul, P
   Tsigkou, O
   Li, SW
   Porter, AE
   Jones, JR
AF Naruphontjirakul, Parichart
   Tsigkou, Olga
   Li, Siwei
   Porter, Alexandra E.
   Jones, Julian R.
TI Human mesenchymal stem cells differentiate into an osteogenic lineage in
   presence of strontium containing bioactive glass nanoparticles
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bioactive glass; Bone marrow derived human stem cells; Nanoparticles;
   Strontium; Osteogenic
ID MESOPOROUS SILICA NANOPARTICLES; TRANSCRIPTION FACTOR OSTERIX; TERM
   BISPHOSPHONATE THERAPY; BONE MARROW; IN VITRO; OSTEOBLAST
   DIFFERENTIATION; GENE EXPRESSION; 45S5 BIOGLASS(R); CELLULAR UPTAKE;
   IONIC PRODUCTS
AB While bioactive glass and ions released during its dissolution are known to stimulate osteoblast cells, the effect bioactive glass has on human stem cells is not clear. Here, we show that spherical monodispersed strontium containing bioactive nanoparticles (Sr BGNPs) of composition 90.6 mol% SiO2, 5.0 mol% CaO, 4.4% mol% SrO (4.4%Sr BGNPs) and 88.8 mol% SiO2, 1.8 mol% CaO, and 9.4 mol% SrO (9.4%Sr BGNPs) stimulate bone marrow derived human stem cell (hMSC) differentiation down an osteogenic pathway without osteogenic supplements. The particles were synthesised using a modified Stober process and had diameters of 90 +/  10 nm. Previous work on similar particles that did not contain Sr (80 mol% SiO2, 20 mol% CaO) showed stem cells did not differentiate when exposed to the particles. Here, both compositions of the Sr BGNPs (up to concentration of 250 mu g/mL) stimulated the early , mid , and late stage markers of osteogenic differentiation and accelerated mineralisation in the absence of osteogenic supplements. Sr ions play a key role in osteogenic stem cell differentiation. Sr BGNP dissolution products did not adversely affect hMSC viability and no significant differences in viability were measured between each particle composition. Confocal and transmission electron microscopy (TEM) demonstrated that monodispersed Sr BGNPs were internalised and localised within vesicles in the cytoplasm of hMSCs. Degradation of particles inside the cells was observed, whilst maintaining effective cations (Ca and Sr) in their silica network after 24 h in culture. The uptake of Sr BGNPs by hMSCs was reduced by inhibitors of specific routes of endocytosis, indicating that the Sr BGNPs uptake by hMSCs was probably via mixed endocytosis mechanisms. Sr BGNPs have potential as injectable therapeutic devices for bone regeneration or treatment of conditions such as osteoporosis, because of their ability deliver a sustained release of osteogenic inorganic cations, e.g. calcium (Ca) or and strontium (Sr), through particle degradation locally to cells.
   Statement of Significance
   Here, we show that 90 nm spherical strontium containing bioactive nanoparticles of stimulate bone marrow derived human stem cell (hMSC) differentiation down an osteogenic pathway without the use of osteogenic supplements. While bioactive glass and its dissolution products are known to promote excellent bone regeneration in vivo and to stimulate osteoblast cells to produce bone matrix in vitro, their effect on human stem cells is not clear. Previously our nanoparticles that contained only SiO2 and CaO did not provoke human bone marrow or adipose derived stem cell differentiation. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Naruphontjirakul, Parichart; Li, Siwei; Porter, Alexandra E.; Jones, Julian R.] Imperial Coll London, Dept Mat, South Kensington Campus, London SW7 2AZ, England.
   [Tsigkou, Olga] Univ Manchester, Sch Mat, Manchester M1 3BB, Lancs, England.
   [Naruphontjirakul, Parichart] King Mongkuts Univ Technol Thonburi, Biol Engn Program, Fac Engn, Bangkok 10140, Thailand.
C3 Imperial College London; University of Manchester; King Mongkuts
   University of Technology Thonburi
RP Jones, JR (通讯作者)，Imperial Coll London, Dept Mat, South Kensington Campus, London SW7 2AZ, England.
EM julian.r.jones@imperial.ac.uk
RI Naruphontjirakul, Parichart/G 7577 2019; Li, Siwei/AHI 0154 2022; Jones,
   Julian/B 1007 2012; Tsigkou, Olga/ABA 4244 2021
OI naruphontjirakul, parichart/0000 0001 9998 6700; Jones,
   Julian/0000 0002 2647 8024; Li, Siwei/0000 0002 1042 0012
FU Royal Thai Government; EPSRC [EP/M004414/1]; Engineering and Physical
   Sciences Research Council [EP/M004414/1] Funding Source: researchfish;
   EPSRC [EP/M004414/1] Funding Source: UKRI
FX The research work is supported by the Royal Thai Government and EPSRC
   (EP/M004414/1). Raw data available on request from
   rdm enquiries@imperial.ac.uk.
CR Abrahamsen B, 2014, OSTEOPOROSIS INT, V25, P757, DOI 10.1007/s00198 013 2469 4
   Adjei IM, 2014, ADV EXP MED BIOL, V811, P73, DOI 10.1007/978 94 017 8739 0_5
   Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev bioeng 071811 150124, 10.1146/annurev.bioeng 071811 150124]
   Amaral M, 2002, BIOMATERIALS, V23, P4897, DOI 10.1016/S0142 9612(02)00249 1
   Autefage H, 2015, P NATL ACAD SCI USA, V112, P4280, DOI 10.1073/pnas.1419799112
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bielby RC, 2005, TISSUE ENG, V11, P479, DOI 10.1089/ten.2005.11.479
   Bohner M, 2010, MATER TODAY, V13, P24, DOI 10.1016/S1369 7021(10)70014 6
   Boivin G., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P538
   Bolland M. J., 2016, BMJ BRIT MED J, V354, P1
   Bolland MJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen 2014 005787
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Bosetti M, 2005, BIOMATERIALS, V26, P3873, DOI 10.1016/j.biomaterials.2004.09.059
   Brennan TC, 2009, BRIT J PHARMACOL, V157, P1291, DOI 10.1111/j.1476 5381.2009.00305.x
   Burge R.T., 2001, Journal of Medical Economics, V4, P51
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cacciotti I, 2017, J MATER SCI, V52, P8812, DOI 10.1007/s10853 017 1010 0
   Cauley JA, 2014, NAT REV ENDOCRINOL, V10, P338, DOI 10.1038/nrendo.2014.51
   Cesareo R, 2010, INT J WOMENS HEALTH, V2, P1
   Choi MH, 2011, J PERIODONTAL IMPLAN, V41, P167, DOI 10.5051/jpis.2011.41.4.167
   Chung TH, 2007, BIOMATERIALS, V28, P2959, DOI 10.1016/j.biomaterials.2007.03.006
   Coelho MJ, 2000, BIOMATERIALS, V21, P1095, DOI 10.1016/S0142 9612(99)00192 1
   Cooper C, 2014, OSTEOPOROSIS INT, V25, P737, DOI 10.1007/s00198 013 2582 4
   Coulombe J, 2004, BIOCHEM BIOPH RES CO, V323, P1184, DOI 10.1016/j.bbrc.2004.08.209
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Datta N, 2006, P NATL ACAD SCI USA, V103, P2488, DOI 10.1073/pnas.0505661103
   de Oliveira PT, 2004, BIOMATERIALS, V25, P403, DOI 10.1016/S0142 9612(03)00539 8
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Gan Q, 2012, BIOMED MICRODEVICES, V14, P259, DOI 10.1007/s10544 011 9604 9
   Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401
   Gao GF, 2014, BIOTECHNOL J, V9, P1304, DOI 10.1002/biot.201400305
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gorustovich AA, 2010, J BIOMED MATER RES A, V92A, P232, DOI 10.1002/jbm.a.32355
   Hench L. L., 2015, BIOMEDICAL GLASSES, V1, P1, DOI [10.1515/bglass 2015 0001, DOI 10.1515/BGLASS 2015 0001]
   Hench L.L., 1971, Journal of Biomedical Materials Research Symposium, V36, P117, DOI DOI 10.1002/JBM.820050611
   Hench LL, 2002, J INORG MATER, V17, P897
   Houreh AB, 2017, J MATER SCI, V52, P8928, DOI 10.1007/s10853 017 0946 4
   Huang DM, 2005, FASEB J, V19, P2014, DOI 10.1096/fj.05 4288fje
   Hurtel Lemaire AS, 2009, J BIOL CHEM, V284, P575, DOI 10.1074/jbc.M801668200
   Isaac J, 2011, EUR CELLS MATER, V21, P130, DOI 10.22203/eCM.v021a11
   Jin A, 2017, BONE JOINT RES, V6, P602, DOI 10.1302/2046 3758.610.BJR 2016 0321.R1
   Jones JR, 2016, INT J APPL GLASS SCI, V7, P423, DOI 10.1111/ijag.12252
   Kafshgari MH, 2015, CURR DRUG DELIV, V12, P63, DOI 10.2174/1567201811666140821110631
   Kargozar S, 2018, J BIOMED MATER RES B, V106, P61, DOI 10.1002/jbm.b.33814
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Keogh MB, 2010, CELL TISSUE RES, V340, P169, DOI 10.1007/s00441 010 0939 y
   Kharwadkar N, 2017, BONE JOINT RES, V6, P144, DOI 10.1302/2046 3758.63.BJR 2016 0125.R1
   Kim YJ, 2006, GENE, V366, P145, DOI 10.1016/j.gene.2005.08.021
   Labbaf S, 2011, BIOMATERIALS, V32, P1010, DOI 10.1016/j.biomaterials.2010.08.082
   Leach JK, 2006, BIOMATERIALS, V27, P3249, DOI 10.1016/j.biomaterials.2006.01.033
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Lian J B, 1995, Iowa Orthop J, V15, P118
   LIEVREMONT M, 1982, ACTA ANAT, V114, P268
   Linares J, 2014, ACS APPL MATER INTER, V6, P13697, DOI 10.1021/am5031598
   Lloyd AA, 2017, P NATL ACAD SCI USA, V114, P8722, DOI 10.1073/pnas.1704460114
   Luong THN, 2011, NANOMEDICINE UK, V6, P961, DOI [10.2217/nnm.11.26, 10.2217/NNM.11.26]
   Ma S, 2017, SCI REP UK, V7, DOI 10.1038/srep43399
   Mao LX, 2017, ACTA BIOMATER, V61, P217, DOI 10.1016/j.actbio.2017.08.015
   Marie PJ, 2010, MOL INTERV, V10, P305, DOI 10.1124/mi.10.5.7
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Naruphontjirakul P., 2016, BIOMEDICAL GLASSES, P72, DOI DOI 10.1515/BGLASS 2016 0009
   Naruphontjiralcul P, 2018, ACTA BIOMATER, V66, P67, DOI 10.1016/j.actbio.2017.11.008
   Navas Moreno M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04066 0
   Ni PY, 2011, INT J NANOMED, V6, P3065, DOI 10.2147/IJN.S25297
   O'Donnell S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005326.pub2
   Oh N, 2014, INT J NANOMED, V9, P51, DOI 10.2147/IJN.S26592
   Ojansivu M, 2018, EUR CELLS MATER, V35, P54, DOI 10.22203/eCM.v035a05
   Ojansivu M, 2015, ACTA BIOMATER, V21, P190, DOI 10.1016/j.actbio.2015.04.017
   Pilmane M, 2017, MAT SCI ENG C MATER, V78, P1222, DOI 10.1016/j.msec.2017.05.042
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pournaqi F, 2017, BIOLOGICALS, V45, P78, DOI 10.1016/j.biologicals.2016.09.010
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Reginster JY, 2012, OSTEOPOROSIS INT, V23, P1115, DOI 10.1007/s00198 011 1847 z
   Reginster JY, 2002, CURR PHARM DESIGN, V8, P1907, DOI 10.2174/1381612023393639
   Reilly GC, 2007, BIOMATERIALS, V28, P4091, DOI 10.1016/j.biomaterials.2007.05.038
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Santocildes Romero ME, 2015, J TISSUE ENG REGEN M, V9, P619, DOI 10.1002/term.2003
   SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003 4819 115 11 837
   Setzer B, 2009, BIOMATERIALS, V30, P979, DOI 10.1016/j.biomaterials.2008.10.054
   Shamsi M, 2017, MAT SCI ENG C MATER, V78, P114, DOI 10.1016/j.msec.2017.02.165
   Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213
   Silver IA, 2001, BIOMATERIALS, V22, P175, DOI 10.1016/S0142 9612(00)00173 3
   stefanic M, 2018, J EUR CERAM SOC, V38, P887, DOI 10.1016/j.jeurceramsoc.2017.08.005
   Stigbrand T, 1984, Prog Clin Biol Res, V166, P3
   Sudo K, 2007, STEM CELLS, V25, P1610, DOI 10.1634/stemcells.2006 0504
   Sundelacruz S, 2015, SCI REP UK, V5, DOI 10.1038/srep18279
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Tanabe S, 2008, J BIOCHEM, V144, P399, DOI 10.1093/jb/mvn082
   Thiagarajan L, 2017, STEM CELL TRANSL MED, V6, P2146, DOI 10.1002/sctm.17 0137
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   Tsigkou O, 2014, ADV HEALTHC MATER, V3, P115, DOI 10.1002/adhm.201300126
   Tsigkou O, 2009, BIOMATERIALS, V30, P3542, DOI 10.1016/j.biomaterials.2009.03.019
   Twine NA, 2014, BONE, V67, P23, DOI 10.1016/j.bone.2014.06.027
   Vichery C, 2016, MATERIALS, V9, DOI 10.3390/ma9040288
   Wu SH, 2011, CHEM COMMUN, V47, P9972, DOI 10.1039/c1cc11760b
   Wu XCA, 2014, J AM CHEM SOC, V136, P7726, DOI 10.1021/ja503010a
   Xue YM, 2015, J MATER CHEM B, V3, P3831, DOI 10.1039/c5tb00204d
   Xynos ID, 2000, BIOCHEM BIOPH RES CO, V276, P461, DOI 10.1006/bbrc.2000.3503
   Xynos ID, 2001, J BIOMED MATER RES, V55, P151, DOI 10.1002/1097 4636(200105)55:2<151::AID JBM1001>3.0.CO;2 D
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yu M, 2017, ACS APPL MATER INTER, V9, P8460, DOI 10.1021/acsami.6b13874
   Zhang J, 2009, J TISSUE ENG REGEN M, V3, P63, DOI 10.1002/term.135
   Zhang W, 2018, MAT SCI ENG C MATER, V89, P245, DOI 10.1016/j.msec.2018.04.012
   Zhang W, 2016, ACS APPL MATER INTER, V8, P30747, DOI 10.1021/acsami.6b10378
   Zhao SC, 2015, ACTA BIOMATER, V12, P270, DOI 10.1016/j.actbio.2014.10.015
NR 112
TC 79
Z9 82
U1 3
U2 97
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD MAY
PY 2019
VL 90
BP 373
EP 392
DI 10.1016/j.actbio.2019.03.038
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA IA9UL
UT WOS:000469902300031
PM 30910622
DA 2025 08 17
ER

PT J
AU Gregorini, M
   Sileno, G
   Pattonieri, EF
   Corradetti, V
   Abelli, M
   Ticozzelli, E
   Scudeller, L
   Grignano, MA
   Esposito, P
   Bogliolo, L
   Giacomoni, A
   Rampino, T
AF Gregorini, M.
   Sileno, G.
   Pattonieri, E. F.
   Corradetti, V.
   Abelli, M.
   Ticozzelli, E.
   Scudeller, L.
   Grignano, M. A.
   Esposito, P.
   Bogliolo, L.
   Giacomoni, A.
   Rampino, T.
TI Understanding Bone Damage After Kidney Transplantation: A Retrospective
   Monocentric Cross Sectional Analysis
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 40th National Congress of the Italian Society of Organ Transplantation
   (SITO)
CY OCT 26 28, 2016
CL Rome, ITALY
SP Italian Soc Organ Transplantat
ID MINERAL DENSITY; IMMUNOSUPPRESSANT RAPAMYCIN; MYCOPHENOLATE MOFETIL;
   DIFFERENTIATION; OSTEOPENIA; FRACTURES; OSTEOPOROSIS; TACROLIMUS;
   MANAGEMENT; RECIPIENTS
AB Background. Kidney transplantation (KT) immunosuppression may induce bone tissue damage with bone mineral density (BMD) loss increasing bone fractures risk. Steroid therapy is considered the major player, but others factors are still under review.
   Patients and Methods. We designed an observational retrospective cohort study to evaluate bone damage after KT. The prevalence of osteopenia, osteoporosis, bone fractures, and the associated risk factors were investigated. The following parameters were recorded before transplantation and at the last follow up: demographic indexes, cumulative steroid dose (CSD), dialytic and transplantologic age, previous nephropathy, femoral and lumbar BMD, fractures, immunosuppressors, calcemia, phosphoremia, rejection episodes, estimated glomerular filtration rate, and parathyroid hormone and vitamin D levels. Stata software (Stata Corporation, College Station, Texas, United States) was used for the statistical analysis, to perform the Fisher's exact test, Kruskal Wallis test, Student t test, as well as univariate and multivariate analyses.
   Results. The analyzed cohort was composed of 297 patients (65.3% males and 34.7% females). Sixty percent of KT patients had normal BMD, 24% had osteopenia, and 15% had osteoporosis. Twelve percent were victims of bone fractures (8.4% minor, 2% femoral, and 1.7% vertebral). A significant correlation (P <.05) was observed for both osteopenia and osteoporosis with menopause, transplantologic age, CSD, previous glomerulonephritis, and mammalian target of rapamycin (mTOR) inhibitors treatment (imTOR).
   Conclusion. This study confirms the correlation between CSD (both before and after transplantation) and post  transplantation bone damage. It also shows that a large fraction of these patients had normal BMD related with a low steroid dose in our protocols. This correlation between imTOR assumption and osteoporosis deserves attention and warrants further in vitro analyses to be performed.
C1 [Gregorini, M.; Sileno, G.; Pattonieri, E. F.; Corradetti, V.; Grignano, M. A.; Esposito, P.; Rampino, T.] Fdn IRCCS Policlin San Matteo, Unit Nephrol Dialysis & Transplantat, Viale Golgi 19, I 27100 Pavia, Italy.
   [Gregorini, M.] Univ Pavia, Dept Internal Med & Therapeut, Pavia, Italy.
   [Abelli, M.; Ticozzelli, E.] Fdn IRCCS Policlin San Matteo, Unit Gen Surg 2, Pavia, Italy.
   [Scudeller, L.] Fdn IRCCS Policlin San Matteo Pavia, Clin Epidemiol Unit, Pavia, Italy.
   [Bogliolo, L.] Fdn IRCCS Policlin San Matteo Pavia, Unit Reumatol, Pavia, Italy.
   [Giacomoni, A.] Grande Osped Metropolitano Niguarda, Dept Surg, Niguarda Transplant Ctr, Milan, Italy.
   [Pattonieri, E. F.; Corradetti, V.] Univ Pavia, Dept Clin & Surg Sci, Pavia, Italy.
C3 IRCCS Fondazione San Matteo; University of Pavia; IRCCS Fondazione San
   Matteo; IRCCS Fondazione San Matteo; IRCCS Fondazione San Matteo;
   Ospedale Niguarda Ca' Granda; University of Pavia
RP Pattonieri, EF (通讯作者)，Fdn IRCCS Policlin San Matteo, Unit Nephrol Dialysis & Transplantat, Viale Golgi 19, I 27100 Pavia, Italy.
EM ef.pattonieri@gmail.com
RI rampino, teresa/AFI 8315 2022; Esposito, Pasquale/NGR 5196 2025;
   Rampino, Teresa/AFI 8315 2022; Scudeller, Luigia/K 9625 2014; Gregorini,
   Marilena/AFO 2242 2022; GREGORINI, MARILENA/AFO 2242 2022; CORRADETTI,
   VALERIA/P 7882 2015; PATTONIERI, ELEONORA FRANCESCA/LMO 1248 2024;
   Sileno, Giuseppe/AAC 3150 2021; Grignano, Maria Antonietta/AAA 9194 2019
OI rampino, teresa/0000 0002 5311 9174; Esposito,
   Pasquale/0000 0002 0834 5586; Scudeller, Luigia/0000 0001 7240 9567;
   fontana, iris/0000 0002 6360 8852; PATTONIERI, ELEONORA
   FRANCESCA/0000 0001 7870 2094; GREGORINI, MARILENA/0000 0003 1440 6872;
   Bogliolo, Laura/0000 0002 1661 0482; Sileno,
   Giuseppe/0000 0003 0597 1669; Grignano, Maria
   Antonietta/0000 0003 1439 7662
CR Adey DB, 2013, ADV CHRONIC KIDNEY D, V20, P427, DOI 10.1053/j.ackd.2013.06.008
   Akaberi S, 2008, AM J TRANSPLANT, V8, P2647, DOI 10.1111/j.1600 6143.2008.02423.x
   ALMOND MK, 1994, NEPHRON, V66, P52, DOI 10.1159/000187765
   Bouquegneau A, 2016, CLIN J AM SOC NEPHRO, V11, P1282, DOI 10.2215/CJN.11371015
   BRYER HP, 1995, J BONE MINER RES, V10, P132
   Dissanayake IR, 1998, TRANSPLANTATION, V65, P275
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   JOFFE I, 1993, CALCIFIED TISSUE INT, V53, P45, DOI 10.1007/BF01352014
   Kazama JJ, 2013, KIDNEY INT SUPPL, V3, P446, DOI 10.1038/kisup.2013.93
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kirino S, 2004, J BONE MINER METAB, V22, P554, DOI 10.1007/s00774 004 0523 1
   Lundquist AL, 2016, CURR OPIN NEPHROL HY, V25, P120, DOI 10.1097/MNH.0000000000000203
   Marcén R, 2007, TRANSPL P, V39, P2256, DOI 10.1016/j.transproceed.2007.07.073
   Marcén R, 2006, TRANSPLANTATION, V81, P826, DOI 10.1097/01.tp.0000203557.36884.e3
   Messa P, 2010, J NEPHROL, V23, pS175
   MOVSOWITZ C, 1988, ENDOCRINOLOGY, V123, P2571, DOI 10.1210/endo 123 5 2571
   Nair SS, 2014, AM J TRANSPLANT, V14, P943, DOI 10.1111/ajt.12652
   Naylor KL, 2014, TRANSPLANTATION, V98, P1279, DOI 10.1097/TP.0000000000000284
   Nikkel LE, 2015, BMJ BRIT MED J, V351, DOI 10.1136/bmj.h6246
   Nikkel LE, 2009, TRANSPLANTATION, V87, P1846, DOI 10.1097/TP.0b013e3181a6bbda
   Ogawa T, 1998, BIOCHEM BIOPH RES CO, V249, P226, DOI 10.1006/bbrc.1998.9118
   Pichette V, 1996, AM J KIDNEY DIS, V28, P105, DOI 10.1016/S0272 6386(96)90138 9
   Rossini M, 2016, REUMATISMO, V68, P1, DOI 10.4081/reumatismo.2016.870
   Rubert Mercedes, 2015, Bone Rep, V2, P74, DOI 10.1016/j.bonr.2015.05.003
   Shui C, 2002, CALCIFIED TISSUE INT, V71, P437, DOI 10.1007/s00223 001 1138 3
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411
   Trabulus S, 2003, NEFROLOGIA, V23, P127
   Tutal E, 2013, TRANSPL P, V45, P1562, DOI 10.1016/j.transproceed.2012.12.027
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Westenfeld R, 2011, NEPHROL DIAL TRANSPL, V26, P4115, DOI 10.1093/ndt/gfr214
   Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303
   WOLPAW T, 1994, TRANSPLANTATION, V58, P1186, DOI 10.1097/00007890 199412270 00008
NR 32
TC 19
Z9 20
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0041 1345
EI 1873 2623
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2017
VL 49
IS 4
BP 650
EP 657
DI 10.1016/j.transproceed.2017.02.023
PG 8
WC Immunology; Surgery; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Immunology; Surgery; Transplantation
GA EU3TO
UT WOS:000400954100008
PM 28457365
DA 2025 08 17
ER

PT J
AU Yumoto, K
   Eber, MR
   Wang, JC
   Cackowski, FC
   Decker, AM
   Lee, E
   Nobre, AR
   Aguirre Ghiso, JA
   Jung, YH
   Taichman, RS
AF Yumoto, Kenji
   Eber, Matthew R.
   Wang, Jingcheng
   Cackowski, Frank C.
   Decker, Ann M.
   Lee, Eunsohl
   Nobre, Ana Rita
   Aguirre Ghiso, Julio A.
   Jung, Younghun
   Taichman, Russell S.
TI Axl is required for TGF β2 induced dormancy of prostate cancer cells in
   the bone marrow
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH FACTOR BETA; RECEPTOR TYROSINE KINASES; TGF BETA;
   TUMOR SUPPRESSOR; DRUG RESISTANCE; DOWN REGULATION; METASTASIS;
   EXPRESSION; SURVIVAL; AXIS
AB Disseminated prostate cancer (PCa) cells in the marrow survive for years without evidence of proliferation, while maintaining the capacity to develop into metastatic lesions. These dormant disseminated tumor cells (DTCs) may reside in close proximity to osteoblasts, while expressing high levels of Axl, one of the tyrosine kinase receptors for growth arrest specific 6 (Gas6). Yet how Axl regulates DTC proliferation in marrow remains undefined. Here, we explored the impact of the loss of Axl in PCa cells (PC3 and DU145) on the induction of their dormancy when they are co cultured with a pre osteoblastic cell line, MC3T3 E1. MC3T3 E1 cells dramatically decrease the proliferation of PCa cells, however this suppressive effect of osteoblasts is significantly reduced by the reduction of Axl expression in PCa cells. Interestingly, expression of both TGF beta and its receptors were regulated by Axl expression in PCa cells, while specific blockade of TGF beta signaling limited the ability of the osteoblasts to induce dormancy of PCa cells. Finally, we found that both Gas6 and Axl are required for TGF beta 2 mediated cell growth suppression. Taken together, these data suggest that a loop between the Gas6/Axl axis and TGF beta 2 signaling plays a significant role in the induction of PCa cell dormancy.
C1 [Yumoto, Kenji; Eber, Matthew R.; Wang, Jingcheng; Cackowski, Frank C.; Decker, Ann M.; Lee, Eunsohl; Jung, Younghun; Taichman, Russell S.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Eber, Matthew R.] Wake Forest Univ, Sch Med, Dept Canc Biol & Comprehens Canc, Winston Salem, NC 27109 USA.
   [Cackowski, Frank C.] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA.
   [Nobre, Ana Rita; Aguirre Ghiso, Julio A.] Icahn Sch Med Mt Sinai, Div Hematol & Oncol Otolaryngol & Oncol Sci, Head & Neck Canc Basic Res,Dept Med, NCI Designated Tisch Canc Inst Mt Sinai,Dept Otol, New York, NY 10029 USA.
C3 University of Michigan System; University of Michigan; Wake Forest
   University; University of Michigan System; University of Michigan; Icahn
   School of Medicine at Mount Sinai
RP Taichman, RS (通讯作者)，Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
EM rtaich@umich.edu
RI ; AguirreGhiso, Julio/KXR 3097 2024; Taichman, Russell/NOF 9711 2025
OI Nobre, Ana Rita/0000 0002 5509 904X; 
FU University of Michigan MCubed Project; National Cancer Institute
   [CA093900, CA163124, U54CA143803, CA143055, CA009357]; Department of
   Defense [W81XW 15 1 0413, W81XWH 14 1 0403]; Prostate Cancer Foundation;
   National Cancer Institute [P01CA093900, T32CA009357] Funding Source: NIH
   RePORTER; National Institute of Dental and Craniofacial Research
   [T32DE007057] Funding Source: NIH RePORTER
FX This work is directly supported by the University of Michigan MCubed
   Project, the National Cancer Institute (CA093900, CA163124, U54CA143803,
   CA143055, CA009357), the Department of Defense (W81XW 15 1 0413 and
   W81XWH 14 1 0403), and the Prostate Cancer Foundation. R.S. Taichman
   receives support as the Major McKinley Ash Colligate Professor. We wish
   to thank Taocong Jin for diligent assistance with Q PCR work.
CR Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622 199601000 00009
   Chéry L, 2014, ONCOTARGET, V5, P9939, DOI 10.18632/oncotarget.2480
   Chowdhury Sanjib, 2009, Mol Cell Pharmacol, V1, P57
   Copland JA, 2003, ONCOGENE, V22, P8053, DOI 10.1038/sj.onc.1206835
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001 117
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035
   Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847
   Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097 0215(19970516)71:4<573::AID IJC11>3.3.CO;2 1
   Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555 006 9006 2
   Joseph J, 2012, MOL CANCER RES, V10, P282, DOI 10.1158/1541 7786.MCR 11 0404
   Jung YH, 2012, NEOPLASIA, V14, P429, DOI 10.1596/neo.111740
   Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840
   Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260
   Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mishra S, 2014, ONCOGENE, V33, P4097, DOI 10.1038/onc.2013.374
   Morrissey C, 2007, J CELL BIOCHEM, V101, P873, DOI 10.1002/jcb.21214
   Muraoka Cook RS, 2005, CLIN CANCER RES, V11, p937S
   Nakamura T, 2015, ONCOTARGET, V6, P1008, DOI 10.18632/oncotarget.2826
   Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043
   Pardali K, 2007, BBA REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004
   Pedersen Elisabeth A, 2012, Front Biosci (Schol Ed), V4, P1
   Reichl P, 2015, HEPATOLOGY, V61, P930, DOI 10.1002/hep.27492
   Rothlin CV, 2010, CURR OPIN IMMUNOL, V22, P740, DOI 10.1016/j.coi.2010.10.001
   Ruppender N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130565
   Sathiakumar N, 2011, PROSTATE CANCER P D, V14, P177, DOI 10.1038/pcan.2011.7
   Sawabu T, 2007, MOL CARCINOGEN, V46, P155, DOI 10.1002/mc.20211
   Sharifi N, 2007, J MOL ENDOCRINOL, V39, P329, DOI 10.1677/JME 07 0084
   Sharifi N, 2007, PROSTATE, V67, P301, DOI 10.1002/pros.20526
   Shiozawa Y., 2016, ONCOTARGET, DOI 10.18632/oncotarget.9251
   SHIOZAWA Y, 2011, THE JOURNAL OF CLINI, V121, P1298, DOI DOI 10.1172/JCI43414
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Song XZ, 2011, CANCER AM CANCER SOC, V117, P734, DOI 10.1002/cncr.25483
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Taichman RS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061873
   Tsou WI, 2014, J BIOL CHEM, V289, P25750, DOI 10.1074/jbc.M114.569020
   WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460 2075.1995.tb07214.x
   Williams RH, 1996, CLIN CANCER RES, V2, P635
   Yan HYH, 2015, CANCER RES, V75, P5283, DOI 10.1158/0008 5472.CAN 15 2282 T
   Yumoto K, 2014, CLIN CANCER RES, V20, P3384, DOI 10.1158/1078 0432.CCR 13 0897
   Yumoto K, 2014, CYTOM PART A, V85A, P548, DOI 10.1002/cyto.a.22434
   Zhang Q, 2005, MOL ENDOCRINOL, V19, P2390, DOI 10.1210/me.2005 0096
NR 46
TC 123
Z9 134
U1 2
U2 12
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 7
PY 2016
VL 6
AR 36520
DI 10.1038/srep36520
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EB0OH
UT WOS:000387042800001
PM 27819283
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, FF
   Okawa, H
   Kamano, Y
   Niibe, K
   Kayashima, H
   Osathanon, T
   Pavasant, P
   Saeki, M
   Yatani, H
   Egusa, H
AF Wang, Fangfang
   Okawa, Hiroko
   Kamano, Yuya
   Niibe, Kunimichi
   Kayashima, Hiroki
   Osathanon, Thanaphum
   Pavasant, Prasit
   Saeki, Makio
   Yatani, Hirofumi
   Egusa, Hiroshi
TI Controlled Osteogenic Differentiation of Mouse Mesenchymal Stem Cells by
   Tetracycline Controlled Transcriptional Activation of Amelogenin
SO PLOS ONE
LA English
DT Article
ID BONE SIALOPROTEIN BSP; IN VITRO; OSTEOBLAST DIFFERENTIATION; RECOMBINANT
   AMELOGENIN; PERIODONTAL LIGAMENT; OSTERIX EXPRESSION; CALCIUM PHOSPHATE;
   MATRIX PROTEINS; GENE EXPRESSION; STROMAL CELLS
AB Regenerative dental therapies for bone tissues rely on efficient targeting of endogenous and transplanted mesenchymal stem cells (MSCs) to guide bone formation. Amelogenin is the primary component of Emdogain, which is used to regenerate periodontal defects; however, the mechanisms underlying the therapeutic effects on alveolar bone remain unclear. The tetracycline (Tet) dependent transcriptional regulatory system is a good candidate to investigate distinct roles of genes of interest during stem cell differentiation. Here, we investigated amelogenin dependent regulation of osteogenesis in MSCs by establishing a Tet controlled transcriptional activation system. Clonal mouse bone marrow derived MSCs were lentivirally transduced with the Tet repressor (TetR) expression vector followed by drug selection to obtain MSCs constitutively expressing TetR (MSCs TetR). Expression vectors that contained the Tet operator and amelogenin coding (Amelx) cDNA fragments were constructed using the Gateway system and lentivirally introduced into MSCs TetR to generate a Tet regulation system in MSCs (MSCs TetR/Amelx). MSCs TetR/Amelx significantly overexpressed the Amelx gene and protein in the presence of the tetracycline derivative doxycycline. Concomitant expression of osterix, bone sialoprotein (BSP), osteopontin, and osteocalcin was modulated by addition or removal of doxycycline under osteogenic guidance. During osteogenic induction, MSCs TetR/Amelx treated with doxycycline showed significantly increased gene expression of osterix, type I collagen, BSP, and osteocalcin in addition to increased alkaline phosphatase activity and mineralized nodule formation. Enhanced extracellular matrix calcification was observed when forced Amelx expression commenced at the early stage but not at the intermediate or late stages of osteogenesis. These results suggest that a Tet controlled Amelx gene regulation system for mouse MSCs was successfully established, in which transcriptional activation of Amelx was associated with enhanced osteogenic differentiation, especially in the early stage of biomineralization.
C1 [Wang, Fangfang; Okawa, Hiroko; Kayashima, Hiroki; Yatani, Hirofumi; Egusa, Hiroshi] Osaka Univ, Grad Sch Dent, Dept Fixed Prosthodont, Suita, Osaka, Japan.
   [Okawa, Hiroko; Kamano, Yuya; Niibe, Kunimichi; Egusa, Hiroshi] Tohoku Univ, Grad Sch Dent, Div Mol & Regenerat Prosthodont, Sendai, Miyagi 980, Japan.
   [Osathanon, Thanaphum; Pavasant, Prasit] Chulalongkorn Univ, Fac Dent, Res Unit Mineralized Tissue, Bangkok, Thailand.
   [Saeki, Makio] Niigata Univ, Grad Sch Med & Dent Sci, Div Dent Pharmacol, Niigata, Japan.
C3 University of Osaka; Tohoku University; Chulalongkorn University;
   Niigata University
RP Egusa, H (通讯作者)，Osaka Univ, Grad Sch Dent, Dept Fixed Prosthodont, Suita, Osaka, Japan.
EM egu@dent.tohoku.ac.jp
RI Wang, Fang Fang/GPF 6144 2022; Egusa, Hiroshi/AFT 9694 2022
OI Osathanon, Thanaphum/0000 0003 1649 6357; Egusa,
   Hiroshi/0000 0002 0200 8132
FU Japan Society for the Promotion of Science; National Research Council of
   Thailand; Grants in Aid for Scientific Research [24792151] Funding
   Source: KAKEN
FX This investigation was supported in part by a Grant in Aid for the
   2013 2015 Bilateral Joint Research Projects from the Japan Society for
   the Promotion of Science (http://www.jsps.go.jp/english/index.html) (HE)
   and the National Research Council of Thailand (http://www.nrct.go.th/)
   (PP) (no numbers for the grants).
CR BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459
   Boabaid F, 2004, J PERIODONTOL, V75, P1126, DOI 10.1902/jop.2004.75.8.1126
   Bonucci E, 2012, FRONT BIOSCI LANDMRK, V17, P100, DOI 10.2741/3918
   BROOKES SJ, 1995, ARCH ORAL BIOL, V40, P1, DOI 10.1016/0003 9969(94)00135 X
   Crane NJ, 2006, BONE, V39, P434, DOI 10.1016/j.bone.2006.02.059
   Deshpande AS, 2010, J BIOL CHEM, V285, P19277, DOI 10.1074/jbc.M109.079939
   Egusa H, 2005, J BIOL CHEM, V280, P23691, DOI 10.1074/jbc.M413796200
   Egusa H, 2007, TISSUE ENG, V13, P2589, DOI 10.1089/ten.2007.0080
   Egusa H, 2014, STEM CELLS DEV, V23, P2156, DOI 10.1089/scd.2013.0344
   Egusa H, 2013, TISSUE ENG PT A, V19, P770, DOI [10.1089/ten.tea.2012.0164, 10.1089/ten.TEA.2012.0164]
   Egusa H, 2012, J PROSTHODONT RES, V56, P229, DOI 10.1016/j.jpor.2012.10.001
   Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001
   Egusa H, 2011, BONE, V49, P264, DOI 10.1016/j.bone.2011.04.003
   FINCHAM AG, 1994, J STRUCT BIOL, V112, P103, DOI 10.1006/jsbi.1994.1011
   Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401
   Gibson CW, 2008, CRIT REV EUKAR GENE, V18, P345, DOI 10.1615/CritRevEukarGeneExpr.v18.i4.30
   Grandin HM, 2012, TISSUE ENG PART B RE, V18, P181, DOI [10.1089/ten.TEB.2011.0365, 10.1089/ten.teb.2011.0365]
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Haze A, 2009, J CELL MOL MED, V13, P1110, DOI 10.1111/j.1582 4934.2009.00700.x
   Hu JC, 2011, BIOCHEM BIOPH RES CO, V408, P437, DOI 10.1016/j.bbrc.2011.04.042
   Kafri T, 2000, MOL THER, V1, P516, DOI 10.1006/mthe.2000.0083
   Kaku M, 2015, J PROSTHODONT RES, V59, P96, DOI 10.1016/j.jpor.2015.02.001
   Kaku M, 2014, J PROSTHODONT RES, V58, P193, DOI 10.1016/j.jpor.2014.08.003
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   LAU EC, 1989, GENOMICS, V4, P162, DOI 10.1016/0888 7543(89)90295 4
   Lee DS, 2014, STEM CELLS, V32, P2467, DOI 10.1002/stem.1733
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Mahamid J, 2008, P NATL ACAD SCI USA, V105, P12748, DOI 10.1073/pnas.0803354105
   Margolis HC, 2006, J DENT RES, V85, P775, DOI 10.1177/154405910608500902
   Margolis HC, 2010, AMELOGENINS MULTIFAC, P133
   Masaki C, 2015, J PROSTHODONT RES, V59, P220, DOI 10.1016/j.jpor.2015.04.005
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Matsuzawa M, 2009, J PERIODONTAL RES, V44, P289, DOI 10.1111/j.1600 0765.2008.01091.x
   Naidoo J, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/595410
   Nakano M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e40
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Olivares Navarrete R, 2014, EUR CELLS MATER, V28, P1
   Piper SL, 2012, J ORTHOP RES, V30, P1879, DOI 10.1002/jor.22162
   ROBINSON C, 1988, CARIES RES, V22, P321, DOI 10.1159/000261131
   Sasaki JI, 2015, J BIOMED MATER RES A, V103, P622, DOI 10.1002/jbm.a.35212
   Sasaki JI, 2012, INTEGR BIOL UK, V4, P1207, DOI 10.1039/c2ib20027a
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shimizu E, 2005, J PERIODONTOL, V76, P1482, DOI 10.1902/jop.2005.76.9.1482
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Sun Y, 2007, ACTA BIOCH BIOPH SIN, V39, P235, DOI 10.1111/j.1745 7270.2007.00258.x
   Swanson EC, 2006, EUR J ORAL SCI, V114, P239, DOI 10.1111/j.1600 0722.2006.00321.x
   Tanimoto K, 2012, CELLS TISSUES ORGANS, V196, P411, DOI 10.1159/000335912
   TERMINE JD, 1980, J BIOL CHEM, V255, P9760
   Veïs A, 2000, J BIOL CHEM, V275, P41263, DOI 10.1074/jbc.M002308200
   Viswanathan HL, 2003, J PERIODONTOL, V74, P1423, DOI 10.1902/jop.2003.74.10.1423
   Warotayanont R, 2008, BIOCHEM BIOPH RES CO, V367, P1, DOI 10.1016/j.bbrc.2007.12.048
   Wen X, 2011, BIOMATERIALS, V32, P6478, DOI 10.1016/j.biomaterials.2011.05.045
   Zhou BY, 2007, STEM CELLS, V25, P779, DOI 10.1634/stemcells.2006 0128
NR 54
TC 14
Z9 15
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 28
PY 2015
VL 10
IS 12
AR e0145677
DI 10.1371/journal.pone.0145677
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CZ9XO
UT WOS:000367451400070
PM 26709694
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Totoli, GGC
   Bighetti Trevisan, RL
   Freitas, GP
   Adolpho, LF
   Almeida, ALG
   Barbosa, ACL
   Ramos, JIR
   Beloti, MM
   Rosa, AL
AF Totoli, Gabriela Guaraldo Campos
   Bighetti Trevisan, Rayana Longo
   Freitas, Gileade Pereira
   Adolpho, Leticia Faustino
   Almeida, Adriana Luisa Golcalves
   Loyola Barbosa, Ana Carolina
   Ramos, Jaqueline Isadora Reis
   Beloti, Marcio Mateus
   Rosa, Adalberto Luiz
TI Association of mesenchymal stem cells derived from bone marrow and
   adipose tissue enhances bone repair in rat calvarial defects
SO REGENERATIVE MEDICINE
LA English
DT Article
DE adipose tissue; bone; bone marrow; cell therapy; stem cells
ID STROMAL CELLS; THERAPY; CD44
AB Plain language summaryWe evaluated the bone repair induced by cells that can develop into different types of cells (stem cells) derived from fat and spongy tissue inside the large bones and injected into defects created in rat skulls. Cells derived from both tissues developed into fat cells and bone forming cells. The combination of cells from fat and spongy tissue exhibited cooperative effects to increase bone repair with an advantage when cells from spongy tissue were injected prior to cells from fat. Our findings may contribute to stablish new therapies based on the use of cells to treat large bone defects.
   Aim: We evaluated the bone repair induced by MSCs from adipose tissue (AT MSCs) and bone marrow (BM MSCs) injected into rat calvarial defects at two time points. Methods & results: Both cell populations expressed MSC surface markers and differentiated into adipocytes and osteoblasts. mu CT showed that the combination of cells from distinct sources exhibited synergistic effects to increase bone repair with an advantage when BM MSCs were injected prior to AT MSCs. The higher osteogenic potential of these MSC combinations was demonstrated using an in vitro coculture system where BM MSCs and AT MSCs association induced higher ALP activity in MC3T3 E1 cells. Conclusion: Our findings may drive new approaches to treat bone defects and shed light on the complexity of the mechanisms involved in bone regeneration.
C1 [Totoli, Gabriela Guaraldo Campos; Bighetti Trevisan, Rayana Longo; Adolpho, Leticia Faustino; Almeida, Adriana Luisa Golcalves; Loyola Barbosa, Ana Carolina; Ramos, Jaqueline Isadora Reis; Beloti, Marcio Mateus; Rosa, Adalberto Luiz] Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, BR 14040904 Ribeirao Preto, SP, Brazil.
   [Freitas, Gileade Pereira] Univ Fed Goias, Sch Dent, BR 74605020 Goiania, GO, Brazil.
C3 Universidade de Sao Paulo; Universidade Federal de Goias
RP Rosa, AL (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, BR 14040904 Ribeirao Preto, SP, Brazil.
EM adalrosa@forp.usp.br
RI Rosa, Adalberto Luiz/A 6314 2008; Longo Bighetti Trevisan,
   Rayana/L 9482 2017; Guaraldo, Gabriela/AAF 1538 2021; Freitas,
   Gileade/G 8468 2016; Rosa, Adalberto/A 6314 2008; Trevisan,
   Rayana/L 9482 2017; Pereira Freitas, Gileade/G 8468 2016; Beloti,
   Marcio/AAX 4014 2020; Barbosa, Ana Carolina/JCF 7030 2023; Beloti,
   Marcio/E 7473 2012; Adolpho, Letícia/AAO 6338 2021
OI Rosa, Adalberto Luiz/0000 0002 6495 2778; Barbosa, Ana Carolina
   Loyola/0000 0001 8711 6791; Longo Bighetti Trevisan,
   Rayana/0000 0002 0228 3652; Pereira Freitas,
   Gileade/0000 0002 1674 4667; Goncalves de Almeida, Adriana
   Luisa/0000 0001 9360 3027; Beloti, Marcio/0000 0003 0149 7189; Guaraldo,
   Gabriela/0000 0002 4472 0291; Ramos, Jaqueline/0000 0003 3904 4206;
   Adolpho, Leticia/0000 0002 1952 5136
CR Abuna RPF, 2016, J CELL PHYSIOL, V231, P204, DOI 10.1002/jcp.25073
   Adolpho LF, 2022, REGEN MED, V17, P341, DOI 10.2217/rme 2021 0178
   Airuddin SS, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111624
   Belluomo, 2022, ACTA BIOMATER
   Blanco B, 2016, EUR J HAEMATOL, V97, P528, DOI 10.1111/ejh.12765
   Bose S, 2022, ACTA BIOMATER, V142, P174, DOI 10.1016/j.actbio.2022.02.001
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Cao HM, 2016, HAEMATOLOGICA, V101, P26, DOI 10.3324/haematol.2015.135921
   Chan YH, 2021, STEM CELL REV REP, V17, P1810, DOI 10.1007/s12015 021 10172 4
   Chen SL, 2015, INT J CLIN EXP PATHO, V8, P14596
   COOK SD, 1994, J BONE JOINT SURG AM, V76A, P827, DOI 10.2106/00004623 199406000 00006
   Cordeiro JM, 2022, BIOMATER ADV, V139, DOI 10.1016/j.bioadv.2022.212976
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Freitas GP, 2021, GENE THER, V28, P748, DOI 10.1038/s41434 021 00248 8
   Freitas GP, 2020, BIO PROTOCOL, V10, DOI 10.21769/BioProtoc.3534
   Freitas GP, 2019, REGEN MED, V14, P1107, DOI 10.2217/rme 2019 0036
   Freitas GP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50067 6
   Freitas GP, 2017, CALCIFIED TISSUE INT, V101, P312, DOI 10.1007/s00223 017 0282 3
   Fujii Y, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0783 7
   Gorodetsky R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105302
   Lynn JV, 2022, ANN PLAS SURG, V89, P459, DOI 10.1097/SAP.0000000000003301
   Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410
   Melief SM, 2013, STEM CELL TRANSL MED, V2, P455, DOI 10.5966/sctm.2012 0184
   Fideles SOM, 2019, J CELL BIOCHEM, V120, P11842, DOI 10.1002/jcb.28463
   Souza ATP, 2018, CYTOTHERAPY, V20, P1267, DOI 10.1016/j.jcyt.2018.06.010
   Qian H, 2012, J BIOL CHEM, V287, P25795, DOI 10.1074/jbc.M112.339622
   Raposio E, 2016, ORTHOP TRAUMATOL SUR, V102, P909, DOI 10.1016/j.otsr.2016.07.006
   Souza ATP, 2021, J BONE MINER METAB, V39, P163, DOI 10.1007/s00774 020 01152 8
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Yuan S, 2022, NANOMED NANOTECHNOL, V41, DOI 10.1016/j.nano.2022.102521
NR 30
TC 8
Z9 8
U1 0
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746 0751
EI 1746 076X
J9 REGEN MED
JI Regen. Med.
PD MAY
PY 2023
VL 18
IS 5
DI 10.2217/rme 2022 0219
EA APR 2023
PG 12
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering
GA G0FZ4
UT WOS:000975247800001
PM 37125511
DA 2025 08 17
ER

PT J
AU Tóth, F
   Gáll, JM
   Tozsér, J
   Hegedus, C
AF Toth, Ferenc
   Gall, Jozsef M.
   Tozser, Jozsef
   Hegedus, Csaba
TI Effect of inducible bone morphogenetic protein 2 expression on the
   osteogenic differentiation of dental pulp stem cells in vitro
SO BONE
LA English
DT Article
DE Bone morphogenetic protein 2; Gene therapy; Osteogenic differentiation;
   Noggin; Tet on
ID GENE EXPRESSION; ODONTOBLAST DIFFERENTIATION; BREAST CANCER;
   DOXYCYCLINE; THERAPY; GROWTH; PROLIFERATION; TETRACYCLINE; REGENERATION;
   STRATEGIES
AB Bone morphogenetic protein 2 (BMP 2) is a member of the transforming growth factor beta superfamily, it is known to be a factor involved in skeletal development and capable of inducing in vitro osteogenic differentiation of mesenchymal stem cells (MSCs). Dental pulp stem cells (DPSCs) isolated from extracted third molar teeth are an ideal resource for bone tissue engineering and regeneration applications, due to their convenient isolation, safe cryopreservation, and easy maintenance in cell cultures. The aims of this study were to deliver BMP 2 under control of the tetracycline inducible (tet on) promoter into dental pulp stem cells and to examine whether these BMP 2 expressing cell lines are capable of promoting osteogenic differentiation in vitro. BMP 2 gene was cloned into the lentiviral transfer plasmid pTet IFIES EGFP and used to establish the DPSC BMP 2 cell line. DPSC, DPSC GFP (mock) and DPSC BMP 2 cell lines were cultured in growth medium or osteogenic medium in the presence or absence of 100 ng/ml doxycycline. To assess differentiation, alkaline phosphatase activity, calcium accumulation and gene transcription levels of different genes involved in osteogenic differentiation (BMP 2, Runx2, alkaline phosphatase, and noggin) were measured. Doxycycline induced BMP 2 expression induced the differentiation of DPSCs into the preosteoblastic stage but could not favor the further maturation into osteoblasts and osteocytes. We found that while Runx2 gene transcription was continuously upregulated in doxycycline treated DPSC BMP 2 cells, the alkaline phosphatase activity and the accumulation of minerals were reduced. As a result of the increased BMP 2 expression, the transcription level of the BMP antagonist noggin was also upregulated, and probably caused the observed effects regarding alkaline phosphatase (ALP) activity and mineral deposition. Our study shows that this system is effective in controlling transgene expression in DPSC cell line. Exploration of all known factors affecting osteogenic differentiation and their interactions is of major importance for the field of regenerative medicine. As the metabolic reaction to the upregulated transgene transcription appears to be cell line specific, a wrongly selected target gene and/or regulation system could have adverse effects on differentiation.
C1 [Toth, Ferenc; Hegedus, Csaba] Univ Debrecen, Fac Dent, Dept Biomat & Prosthet Dent, POB 400, H 4002 Debrecen, Hungary.
   [Gall, Jozsef M.] Univ Debrecen, Fac Informat, Dept Appl Math & Probabil Theory, Debrecen, Hungary.
   [Tozser, Jozsef] Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, Debrecen, Hungary.
C3 University of Debrecen; University of Debrecen; University of Debrecen
RP Tóth, F (通讯作者)，Univ Debrecen, Fac Dent, Dept Biomat & Prosthet Dent, POB 400, H 4002 Debrecen, Hungary.
EM ferenc.toth@dental.unideb.hu; gall.jozsef@inf.unideb.hu;
   tozser@med.unideb.hu; hegedus.csaba.prof@dental.unideb.hu
RI Tozser, Jozsef/JCD 7848 2023
OI Toth, Ferenc/0000 0002 1170 6274
FU Department of Medical Chemistry, Faculty of Medicine, University of
   Debrecen [GINOP 2.3.2 15 2016 00020 TUMORDNS]; European Union; European
   Regional Development Fund; Higher Education Institutional Excellence
   Programme of the Ministry of Human Capacities in Hungary; 
   [GINOP 2.3.2 15 2016 00011];  [GINOP 2.3.2 15 2016 00022]
FX We thank the Department of Medical Chemistry, Faculty of Medicine,
   University of Debrecen, GINOP 2.3.2 15 2016 00020 TUMORDNS grant and
   Endre Kokai for The Opera Phenix equipment and Harmony 4.8 software
   access, and Zsuzsanna Polgar for help with imaging and image analysis.
   The work is supported by the GINOP 2.3.2 15 2016 00011 and
   GINOP 2.3.2 15 2016 00022 projects. The projects are co financed by the
   European Union and the European Regional Development Fund. This work was
   also financed in part by the Higher Education Institutional Excellence
   Programme of the Ministry of Human Capacities in Hungary, within the
   framework of the Biotechnology thematic program of the University of
   Debrecen.
CR Agrawal V, 2017, J BIOMED MATER RES B, V105, P904, DOI 10.1002/jbm.b.33599
   Aksel H, 2017, J ENDODONT, V43, P930, DOI 10.1016/j.joen.2017.01.036
   Albuquerque MTP, 2014, J DENT RES, V93, P1222, DOI 10.1177/0022034514549809
   Alhadlaq A, 2005, J BONE JOINT SURG AM, V87A, P936, DOI 10.2106/JBJS.D.02104
   Atalayin C, 2016, BRAZ ORAL RES, V30
   Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003
   Couble ML, 2000, CALCIFIED TISSUE INT, V66, P129, DOI 10.1007/PL00005833
   d'Aquino R, 2008, STEM CELL REV, V4, P21, DOI 10.1007/s12015 008 9013 5
   Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776 004 0815 2
   De Biase P, 2005, INJURY, V36, P43, DOI 10.1016/j.injury.2005.07.034
   Fajardo M, 2009, CLIN ORTHOP RELAT R, V467, P3071, DOI 10.1007/s11999 009 0981 9
   Fisher JN, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9352598
   Gafni Y, 2004, MOL THER, V9, P587, DOI 10.1016/j.ymthe.2003.12.009
   Gersbach CA, 2006, GENE THER, V13, P873, DOI 10.1038/sj.gt.3302725
   GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547
   Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958 1669(94)90067 1
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Goverdhana S., 1999, CLIN ORTHOP RELAT R, pS68
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hendy GN, 2005, HORM METAB RES, V37, P375, DOI 10.1055/s 2005 870152
   Hrubi E, 2018, HUM CELL, V31, P139, DOI 10.1007/s13577 018 0202 5
   Ide H, 1997, CANCER RES, V57, P5022
   Jimi E, 2010, JPN DENT SCI REV, V46, P33, DOI 10.1016/j.jdsr.2009.10.003
   Kadar K, 2009, J PHYSIOL PHARMACOL, V60, P167
   Kerenyi Farkas, 2016, Fogorv Sz, V109, P29
   Khojasteh A, 2013, OR SURG OR MED OR PA, V116, pE405, DOI 10.1016/j.oooo.2012.01.044
   Kim HS, 2005, INVEST OPHTH VIS SCI, V46, P840, DOI 10.1167/iovs.04 0929
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Lin P, 2012, STEM CELL TRANSL MED, V1, P886, DOI 10.5966/sctm.2012 0086
   Lowenstein PR, 2005, MOL THER, V12, P185, DOI 10.1016/j.ymthe.2005.06.439
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Ma JL, 2014, STEM CELL TRANSL MED, V3, P98, DOI 10.5966/sctm.2013 0126
   Moutsatsos I. K., 2001, EXOGENOUSLY REGULATE, P449, DOI [10.1006/mthe.2001.0291, DOI 10.1006/MTHE.2001.0291]
   Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291
   Muthukuru M, 2013, J PERIODONTOL, V84, P656, DOI 10.1902/jop.2012.120338
   Noël D, 2004, STEM CELLS, V22, P74, DOI 10.1634/stemcells.22 1 74
   Park JB, 2011, J CRANIOFAC SURG, V22, P1839, DOI 10.1097/SCS.0b013e31822e8216
   Peng HR, 2004, MOL THER, V9, P885, DOI 10.1016/j.ymthe.2004.02.023
   Pouliot F, 2003, CANCER RES, V63, P277
   Rosen V, 2006, ANN NY ACAD SCI, V1068, P19, DOI 10.1196/annals.1346.005
   Shuen WH, 2015, CANCER GENE THER, V22, P207, DOI 10.1038/cgt.2015.9
   Takeda T, 2008, J DENT RES, V87, P676, DOI 10.1177/154405910808700716
   Takeda Kawaguchi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115392
   Tamaoki N, 2010, J DENT RES, V89, P773, DOI 10.1177/0022034510366846
   Tasli PN, 2014, APPL BIOCHEM BIOTECH, V172, P3016, DOI 10.1007/s12010 013 0706 0
   Toniatti C, 2004, GENE THER, V11, P649, DOI 10.1038/sj.gt.3302251
   Wang YY, 2013, CYTOTECHNOLOGY, V65, P223, DOI 10.1007/s10616 012 9479 5
   Yang W, 2012, J DENT RES, V91, P58, DOI 10.1177/0022034511424409
   Ye L, 2009, INT J MOL MED, V24, P591, DOI 10.3892/ijmm_00000269
   Zhang QC, 2014, BIOMACROMOLECULES, V15, P84, DOI 10.1021/bm401309u
NR 51
TC 26
Z9 30
U1 0
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAR
PY 2020
VL 132
AR 115214
DI 10.1016/j.bone.2019.115214
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA KH3EL
UT WOS:000510529200016
PM 31884130
OA hybrid
DA 2025 08 17
ER

PT J
AU Chen, PQ
   Jerome, CP
   Burr, DB
   Turner, CH
   Ma, YL
   Rana, A
   Sato, M
AF Chen, Peiqi
   Jerome, Christopher P.
   Burr, David B.
   Turner, Charles H.
   Ma, Yanfei L.
   Rana, Asad
   Sato, Masahiko
TI Interrelationships between bone microarchitecture and strength in
   ovariectomized monkeys treated with teriparatide
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Proceedings Paper
CT 28th Annual Meeting of the
   American Society for Bone and Mineral Research
CY SEP 15 19, 2006
CL Philadelphia, PA
SP Amer Soc Bone & Mineral Res
DE teriparatide; bone microarchitecture; bone biopsy; histomorphometry;
   bone strength
ID PARATHYROID HORMONE 1 34; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL WOMEN;
   MINERAL DENSITY; CANCELLOUS BONE; ILIAC CREST; CYNOMOLGUS MONKEYS;
   LUMBAR VERTEBRAE; OSTEOPOROSIS; INCREASES
AB Bone microarchitecture measured at the iliac crest at 6 mo was confirmed to be a reasonable surrogate for, and a predictor of, architecture and strength of the femoral neck and lumbar vertebra after 18 mo of teriparatide treatment. However, the data taken together showed the importance of cortical bone volume for vertebra to assess pharmacological effects on bone quality.
   Introduction: Improvements in bone architecture with teriparatide treatment are suggested to contribute to fracture risk reduction in osteoporotic patients. Teriparatide significantly improves microarchitecture in the iliac crest of humans by stimulating bone modeling and remodeling processes that differ dramatically from those induced by antiresorptives. The relationship between improvements of bone microarchitecture and improvements of bone strength with teriparatide treatment has not yet been fully studied.
   Materials and Methods: Ovariectomized monkeys were administered vehicle (n = 20); teriparatide 1.0 mu g/kg/d (n = 19); or teriparatide 5.0 mu g/kg/d (n = 21) for 18 mo. Iliac crest biopsies were obtained at 6 and 15 mo after initiation of treatment. Animals were killed after 18 mo of treatment, and adjacent vertebrae or contralateral proximal femora were processed for biomechanical or histomorphometric analyses. Pearson correlation analyses were performed to assess the relationship between biomechanical and static histomorphometric parameters of lumbar vertebra, femoral neck, and iliac crest biopsies.
   Results: Static histomorphometric parameters of the 6  and 15 mo biopsies were significantly correlated with the vertebral and femoral neck parameters obtained at 18 mo of teriparatide treatment. Iliac crest biopsy parameters at 6 and 15 mo also correlated with vertebral and femoral neck strength at 18 mo. Static histomorphometry of the lumbar vertebra and femoral neck at 18 mo also significantly correlated with strength at these sites. However, cortical bone volume of the lumbar vertebrae had the strongest correlation with vertebral and femoral neck strength (r = 0.74 and 0.71, respectively).
   Conclusions: Teriparatide dose dependently improved cortical and trabecular microarchitecture of vertebra and femoral neck, as well as trabecular microarchitecture of the iliac crest. Bone microarchitecture at all sites was significantly correlated with lumbar vertebra and femoral neck strength. Cortical bone volume of vertebra had the strongest correlation with vertebral and femoral neck strength. Therefore, structural improvement seemed to be part of the mechanism for improved strength observed with teriparatide treatment. Trabecular bone architecture of the iliac crest at 6 mo also correlated with vertebral and femoral neck strength, as did femoral neck (cortical and trabecular) histomorphometry and trabecular histomorphometry of vertebra after 18 mo of treatment. Because clinical assessment of cortical bone volume is not readily possible for vertebra noninvasively, these findings confirm the importance of iliac crest biopsies to monitor skeletal health and show that biopsies are a reasonable surrogate to assess spine and femoral neck structure and function.
C1 Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.
   Think Bone Consulting Inc, Langley, WA USA.
   Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA.
C3 Eli Lilly; Lilly Research Laboratories; Indiana University System;
   Indiana University Indianapolis
RP Chen, PQ (通讯作者)，Eli Lilly & Co, Lilly Res Labs, DC 4108, Indianapolis, IN 46285 USA.
EM chenpe@lilly.com
CR Amling M, 1996, J BONE MINER RES, V11, P36, DOI 10.1002/jbmr.5650110107
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   Burr DB, 2001, J BONE MINER RES, V16, P157, DOI 10.1359/jbmr.2001.16.1.157
   Cendre E, 1999, OSTEOPOROSIS INT, V10, P353, DOI 10.1007/s001980050240
   CHALMERS J, 1966, J BONE JOINT SURG AM, VA 48, P299, DOI 10.2106/00004623 196648020 00008
   Chen PQ, 2006, J BONE MINER RES, V21, P1785, DOI 10.1359/JBMR.060802
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Delmas PD, 2000, BONE, V26, P553, DOI 10.1016/S8756 3282(00)00271 4
   DEMPSTER DW, 1993, OSTEOPOROSIS INT, V3, P90, DOI 10.1007/BF01623379
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Garnero P, 1999, BONE, V24, P603, DOI 10.1016/S8756 3282(99)00087 3
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   KESHAWARZ NM, 1984, METAB BONE DIS RELAT, V5, P223, DOI 10.1016/0221 8747(84)90063 8
   Lane NE, 2000, OSTEOPOROSIS INT, V11, P434, DOI 10.1007/s001980070111
   Li ZQ, 2001, STAT MED, V20, P3175, DOI 10.1002/sim.984
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   MOSEKILDE L, 1988, BONE, V9, P195, DOI 10.1016/8756 3282(88)90030 0
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   RECKER RR, 2006, OSTEOPOROS INT S2, V17, pS87
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   Sato M, 2000, OSTEOPOROSIS INT, V11, P871, DOI 10.1007/s001980070047
   Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112
   Thomsen JS, 2002, BONE, V30, P502, DOI 10.1016/S8756 3282(01)00702 5
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Turner CH, 2001, ADV EXP MED BIOL, V496, P165
   VESTERBY A, 1991, BONE, V12, P219, DOI 10.1016/8756 3282(91)90044 J
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
NR 31
TC 21
Z9 22
U1 0
U2 3
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2007
VL 22
IS 6
BP 841
EP 848
DI 10.1359/JBMR.070310
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 170QF
UT WOS:000246678300009
PM 17352652
DA 2025 08 17
ER

PT J
AU Yanagi, M
   Uehara, T
   Uchida, Y
   Kiyota, S
   Kinoshita, M
   Higaki, Y
   Akizawa, H
   Hanaoka, H
   Arano, Y
AF Yanagi, Mashiho
   Uehara, Tomoya
   Uchida, Yukie
   Kiyota, Sachiko
   Kinoshita, Mai
   Higaki, Yusuke
   Akizawa, Hiromichi
   Hanaoka, Hirofumi
   Arano, Yasushi
TI Chemical Design of <SUP>99m</SUP>Tc Labeled Probes for Targeting
   Osteogenic Bone Region
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG DELIVERY SYSTEM; CONJUGATED
   BISPHOSPHONATE; TC 99M; PERMEABILITY; RADIOPHARMACEUTICALS;
   INTERMEDIATE; SCINTIGRAPHY; PALLIATION; METASTASES
AB Radionuclide bone imaging using polynuclear Tc 99m complexes of bisphosphonates is the most common clinical practice in nuclear medicine. However, the improvement in the contrast between normal and osteogenic bone regions has been required. Herein we reported a new Tc 99m labeled compound considering the increased vascular permeability of osteogenic region. We selected penta D Asp as both a targeting motif to hydroxyapatite (HA) and a molecular size modifier, and two penta D Asp molecules were conjugated with the two carboxylate residues of ethylene dicysteine (EC) selected as the Tc 99m chelating moiety to prepare EC [(D Asp)(5)](2). The molecular size, HA binding, and pharmacokinetics of Tc 99m EC [(D Asp)(5)](2) in normal mice and model rats bearing osteogenic tumor were compared to those of Tc 99m MDP and Tc 99m EC with one (D Asp)(5) motif; Tc 99m EC (D Asp)(5). The molecular size of Tc 99m EC [(D Asp)(5)](2) was higher than that of Tc 99m MDP and Tc 99m EC (D Asp)(5) when determined by permeability of the Tc 99m compounds through a membrane filter (10kDa). The HA binding of Tc 99m EC [(D Asp)(5)](2) was higher than and similar to that of Tc 99m EC (D Asp)(5) and Tc 99m MDP. Tc 99m EC [(D Asp)(5)](2) exhibited significantly lower accumulation in normal bone of mice than did Tc 99m MDP. In osteogenic tumor bearing model rats, Tc 99m EC [(D Asp)(5)](2) accumulated in the osteogenic and normal bone region similar to and lower than Tc 99m MDP, respectively. Although further studies including the chain length of D Asp are required, these findings indicated that the present chemical design of Tc 99m labeled probe would be applicable to develop Tc 99m labeled probes for selective imaging of osteogenic bone region as well as develop therapeutic agents using therapeutic radionuclides such as Y 90, Lu 177, Re 186, or Re 188 and cytotoxic agents to osteogenic bone tumor region.
C1 [Yanagi, Mashiho; Uehara, Tomoya; Uchida, Yukie; Kiyota, Sachiko; Kinoshita, Mai; Higaki, Yusuke; Hanaoka, Hirofumi; Arano, Yasushi] Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2638675, Japan.
   [Akizawa, Hiromichi] Showa Pharmaceut Univ, Machida, Tokyo 1948543, Japan.
C3 Chiba University; Showa Pharmaceutical University
RP Uehara, T (通讯作者)，Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1 8 1 Inohana, Chiba 2638675, Japan.
EM tuehara@chiba u.jp
RI ; Arano, Yasushi/AFQ 8631 2022; Hanaoka, Hirofumi/T 6261 2019
OI Arano, Yasushi/0000 0001 6091 5382; 
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX This study was supported in part by a Grant in Aid for Young Scientists
   (B) and Special Funds for Education and Research (Development of SPECT
   Probes for Pharmaceutical Innovation) from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan.
CR Arano Y, 1997, BIOCONJUGATE CHEM, V8, P442, DOI 10.1021/bc970023b
   BLONDEAU P, 1967, CAN J CHEMISTRY, V45, P49, DOI 10.1139/v67 009
   Buckley O, 2007, NUCL MED COMMUN, V28, P521, DOI 10.1097/MNM.0b013e3281744440
   Chen W, 2000, MACROMOLECULES, V33, P9169, DOI 10.1021/ma000791p
   CURRY FE, 1983, AM J PHYSIOL, V245, pH495, DOI 10.1152/ajpheart.1983.245.3.H495
   Datta A, 2009, CANCER BIOTHER RADIO, V24, P123, DOI 10.1089/cbr.2008.0536
   FOGELMAN I, 1982, EUR J NUCL MED, V7, P506
   GREEN JM, 1993, J CHROMATOGR, V635, P203, DOI 10.1016/0021 9673(93)80362 C
   Hansen Algenstaedt N, 2005, EUR J CANCER, V41, P1073, DOI 10.1016/j.ejca.2004.12.034
   Hansen Algenstaedt N, 2006, ACTA ORTHOP, V77, P429, DOI 10.1080/17453670610046361
   IMAI S, 1986, EXP ANIM TOKYO, V35, P263, DOI 10.1538/expanim1978.35.3_263
   KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003 2697(70)90146 6
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Lamoureux F, 2008, INT J CANCER, V122, P751, DOI 10.1002/ijc.23187
   Love C, 2003, RADIOGRAPHICS, V23, P341, DOI 10.1148/rg.232025103
   Luyt LG, 1999, BIOCONJUGATE CHEM, V10, P470, DOI 10.1021/bc980134q
   Mayer Kuckuk P, 2006, BONE, V39, P965, DOI 10.1016/j.bone.2006.05.009
   Ogawa K, 2007, J NUCL MED, V48, P122
   Ogawa K, 2006, NUCL MED BIOL, V33, P513, DOI 10.1016/j.nucmedbio.2006.03.006
   Ogawa K, 2009, EUR J NUCL MED MOL I, V36, P115, DOI 10.1007/s00259 008 0925 8
   Ogawa K, 2006, J NUCL MED, V47, P2042
   Palma E, 2011, MOL BIOSYST, V7, P2950, DOI 10.1039/c1mb05242j
   Palma E, 2011, DALTON T, V40, P2787, DOI 10.1039/c0dt01396j
   PAPPENHEIMER JR, 1953, PHYSIOL REV, V33, P387, DOI 10.1152/physrev.1953.33.3.387
   PINKERTON TC, 1980, ANAL CHEM, V52, P1106, DOI 10.1021/ac50057a025
   Ryan PJ, 1997, SEMIN NUCL MED, V27, P291, DOI 10.1016/S0001 2998(97)80030 X
   Schmittmann G, 2000, J PHARM SCI, V89, P115, DOI 10.1002/(SICI)1520 6017(200001)89:1<115::AID JPS12>3.0.CO;2 7
   Sekido T, 2001, J DRUG TARGET, V9, P111, DOI 10.3109/10611860108997922
   Shukla G, 2009, CANCER BIOTHER RADIO, V24, P209, DOI 10.1089/cbr.2008.0551
   TANABE S, 1983, INT J APPL RADIAT IS, V34, P1585, DOI 10.1016/0020 708X(83)90003 0
   Uehara T, 2007, NUCL MED BIOL, V34, P79, DOI 10.1016/j.nucmedbio.2006.10.001
   Uehara T, 2010, BIOCONJUGATE CHEM, V21, P175, DOI 10.1021/bc900410q
   Verbeke K, 2002, BIOCONJUGATE CHEM, V13, P16, DOI 10.1021/bc0001600
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Yang DJ, 2003, RADIOLOGY, V226, P465, DOI 10.1148/radiol.2262011811
   YUAN F, 1995, CANCER RES, V55, P3752
NR 36
TC 11
Z9 11
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043 1802
EI 1520 4812
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL
PY 2013
VL 24
IS 7
BP 1248
EP 1255
DI 10.1021/bc400197f
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Chemistry
GA 187FV
UT WOS:000322103200014
PM 23758054
DA 2025 08 17
ER

PT J
AU Yoshida, M
   Mori, A
   Morimoto, S
   Kotani, E
   Oka, M
   Notoya, K
   Makino, H
   Ono, M
   Shirasaki, M
   Tada, N
   Fujita, H
   Ban, J
   Ikeda, Y
   Kawamoto, T
   Goto, M
   Kimura, H
   Baba, A
   Yasuma, T
AF Yoshida, Masato
   Mori, Akira
   Morimoto, Shinji
   Kotani, Etsuo
   Oka, Masahiro
   Notoya, Kohei
   Makino, Haruhiko
   Ono, Midori
   Shirasaki, Mikio
   Tada, Norio
   Fujita, Hisashi
   Ban, Junko
   Ikeda, Yukihiro
   Kawamoto, Tomohiro
   Goto, Mika
   Kimura, Hiroyuki
   Baba, Atsuo
   Yasuma, Tsuneo
TI Novel and potent calcium sensing receptor antagonists: Discovery of
   (5R) N [1 ethyl 1 (4 ethylphenyl)propyl] 2,7,7 trimethyl 5 phenyl
    4,5,6,7 tetrahydropyrazolo[1,5 a]pyrimidine 3 carboxamide
   monotosylate (TAK 075) as an orally active bone anabolic agent
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Orally active; Calcium sensing receptor antagonists; CaSR; Bone anabolic
   agents; PTH; TAK 075
ID PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES;
   RANDOMIZED TRIAL; OSTEOPOROSIS; RISK
AB The calcium sensing receptor antagonist (CaSR) has been recognized as a promising target of anabolic agents for treating osteoporosis. In the course of developing a new drug candidate for osteoporosis, we found tetrahydropyrazolopyrimidine derivative 1 to be an orally active CaSR antagonist that stimulated transient PTH secretion in rats. However, compound 1 showed poor physical and chemical stability. In order to work out this compound's chemical stability and further understand its in vivo efficacy, we focused on modifying the 2 position of the tetrahydropyrazolopyrimidine. As a result of chemical modification, we discovered (5R) N [1 ethyl 1 (4 ethylphenyl)propyl] 2,7,7 trimethyl 5 phenyl 4,5,6,7 tetrahydropyrazolo[1,5 a]pyrimidine 3 carboxamide monotosylate 10m (TAK 075), which showed improved solubility, chemical stability, and in vivo efficacy. Furthermore, we describe that evaluating the active metabolite is important during repeated treatment with short acting CaSR antagonists. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Yoshida, Masato; Mori, Akira; Morimoto, Shinji; Kotani, Etsuo; Oka, Masahiro; Notoya, Kohei; Makino, Haruhiko; Ono, Midori; Shirasaki, Mikio; Tada, Norio; Fujita, Hisashi; Ban, Junko; Ikeda, Yukihiro; Kawamoto, Tomohiro; Goto, Mika; Kimura, Hiroyuki; Baba, Atsuo; Yasuma, Tsuneo] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Yodogawa Ku, Osaka 5328686, Japan.
C3 Takeda Pharmaceutical Company Ltd
RP Yasuma, T (通讯作者)，Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Yodogawa Ku, 2 17 85 Jusohomachi, Osaka 5328686, Japan.
EM Yasuma_Tsuneo@takeda.co.jp
RI Goto, Mika/C 9980 2015
CR Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Carter PH, 2007, P NATL ACAD SCI USA, V104, P6846, DOI 10.1073/pnas.0605125104
   Chattopadhyay N, 2000, INT J BIOCHEM CELL B, V32, P789, DOI 10.1016/S1357 2725(00)00031 5
   Chen HG, 1996, TETRAHEDRON LETT, V37, P8129, DOI 10.1016/0040 4039(96)01890 4
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dobnig H, 2004, EXPERT OPIN PHARMACO, V5, P1153, DOI 10.1517/eoph.5.5.1153.31088
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Ettinger MP, 2003, ARCH INTERN MED, V163, P2237, DOI 10.1001/archinte.163.18.2237
   Fox J, 1997, BONE, V21, P163, DOI 10.1016/S8756 3282(97)00108 7
   Frolik CA, 2003, BONE, V33, P372, DOI 10.1016/S8756 3282(03)00202 3
   HUPPATZ JL, 1985, AUST J CHEM, V38, P221, DOI 10.1071/CH9850221
   Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028
   Lotinun S, 2002, ENDOCRINE, V17, P29, DOI 10.1385/ENDO:17:1:29
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pleiner Duxneuner J, 2009, CALCIFIED TISSUE INT, V84, P159, DOI 10.1007/s00223 009 9218 x
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Tarantino Umberto, 2007, Aging Clin Exp Res, V19, P7
   Yoshida M, 2011, J MED CHEM, V54, P1430, DOI 10.1021/jm101452x
   Yoshida M, 2010, BIOORGAN MED CHEM, V18, P8501, DOI 10.1016/j.bmc.2010.10.035
NR 19
TC 9
Z9 19
U1 0
U2 5
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAR 15
PY 2011
VL 19
IS 6
BP 1881
EP 1894
DI 10.1016/j.bmc.2011.02.001
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 732OO
UT WOS:000288196900005
PM 21353570
DA 2025 08 17
ER

PT J
AU Suzuki, S
   Morimoto, S
   Fujishiro, M
   Kawasaki, M
   Hayakawa, K
   Miyashita, T
   Ikeda, K
   Miyazawa, K
   Yanagida, M
   Takamori, K
   Ogawa, H
   Sekigawa, I
   Takasaki, Y
AF Suzuki, Satoshi
   Morimoto, Shinji
   Fujishiro, Maki
   Kawasaki, Mikiko
   Hayakawa, Kunihiro
   Miyashita, Tomoko
   Ikeda, Keigo
   Miyazawa, Keiji
   Yanagida, Mitsuaki
   Takamori, Kenji
   Ogawa, Hideoki
   Sekigawa, Iwao
   Takasaki, Yoshinari
TI Inhibition of the insulin like growth factor system is a potential
   therapy for rheumatoid arthritis
SO AUTOIMMUNITY
LA English
DT Article
DE Anti IGF 1R mAb; biologics; drug repositioning; insulin like growth
   factor; rheumatoid arthritis
ID FACTOR I RECEPTOR; BINDING PROTEINS; JAK/STAT PATHWAY; SYNOVIAL FLUID;
   ACTIVATION; EXPRESSION; ROLES; ALPHA
AB Objective: We have shown that connective tissue growth factor (CTGF) plays an important role in the pathogenesis of rheumatoid arthritis (RA). Insulin like growth factor binding proteins (IGFBPs) are modules of CTGF. IGFBPs bind IGF I and IGF II. IGF I plays a role in the regulation of immunity, bone metabolism and inflammation. Therefore, we investigated how the IGF system is associated with RA disease progression. Methods: Serum samples were collected from RA patients. IGF I and IGFBP 3 production were evaluated by enzyme linked immunosorbent assay, real time RT PCR and indirect immunofluorescence microscopy. Osteoclastogenesis was evaluated using tartrate resistant acid phosphatase staining, a bone resorption assay and osteoclast specific enzyme production. Angiogenesis was examined by a tube formation assay using human umbilical vein endothelial cells. Results: The serum concentrations of IGFBP 3 in RA patients were greater than those in normal controls. IGF I and IGFBP 3 were produced primarily by macrophages in the RA synovium. Furthermore, tumor necrosis factor a could induce aberrant IGF I and IGFBP 3 production in synovial fibroblasts. IGF I and IGFBP 3 promoted the induction of osteoclast generation and morphological changes, in combination with M colony stimulating factor and the receptor activator of NF kappa B ligand. In addition, IGF I and IGFBP 3 induced angiogenesis, as determined by the tube formation assay. These effects were neutralized by anti IGF IR monoclonal antibody (mAb). Conclusions: These results indicate that aberrant IGF I and IGFBP 3 production plays a role in abnormal osteoclastic activation and angiogenesis in RA. This work supports future clinical exploration of anti IGF IR mAb in drug repositioning as a new treatment for RA.
C1 [Suzuki, Satoshi; Morimoto, Shinji; Fujishiro, Maki; Kawasaki, Mikiko; Hayakawa, Kunihiro; Miyashita, Tomoko; Ikeda, Keigo; Yanagida, Mitsuaki; Takamori, Kenji; Ogawa, Hideoki; Sekigawa, Iwao] Juntendo Univ, Grad Sch Med, Inst Environm & Gender Specif Med, Urayasu, Chiba 2790021, Japan.
   [Suzuki, Satoshi; Miyashita, Tomoko; Takasaki, Yoshinari] Juntendo Univ, Sch Med, Dept Internal Med & Rheumatol, Tokyo 113, Japan.
   [Morimoto, Shinji; Ikeda, Keigo; Sekigawa, Iwao] Juntendo Univ, Urayasu Hosp, Dept Internal Med & Rheumatol, Urayasu, Chiba 2790021, Japan.
   [Miyazawa, Keiji] Kissei Pharmaceut Co Ltd, Cent Res Labs, Azumino, Ngano, Japan.
C3 Juntendo University; Juntendo University; Juntendo University; Kissei
   Pharmaceutical Co Ltd
RP Morimoto, S (通讯作者)，Juntendo Univ, Urayasu Hosp, Dept Internal Med & Rheumatol, 2 1 1 Tomioka, Urayasu, Chiba 2790021, Japan.
EM morimoto@juntendo.ac.jp
RI ; Hayakawa, Kunihiro/HCI 2493 2022; Ikeda, Keigo/I 4775 2019
OI Ikeda, Keigo/0000 0002 8032 7147; HAYAKAWA,
   Kunihiro/0000 0002 8053 746X; Suzuki, Satoshi/0000 0002 8172 2413
FU Institute for Environment and Gender Specific Medicine, Juntendo
   University Graduate School of Medicine; Grants in Aid for Scientific
   Research [26860265] Funding Source: KAKEN
FX This work was supported by grants from The Institute for Environment and
   Gender Specific Medicine, Juntendo University Graduate School of
   Medicine.
CR ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Collett Solberg PF, 2000, ENDOCRINE, V12, P121, DOI 10.1385/ENDO:12:2:121
   Ebong S, 2004, INVEST OPHTH VIS SCI, V45, P872, DOI 10.1167/iovs.03 0311
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Fernihough JK, 1996, ARTHRITIS RHEUM, V39, P1556, DOI 10.1002/art.1780390916
   FOURNIER T, 1995, J IMMUNOL, V155, P2123
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884
   Haruta K, 2012, INFLAMM RES, V61, P551, DOI 10.1007/s00011 012 0444 8
   Himpe E, 2009, BIOFACTORS, V35, P76, DOI 10.1002/biof.20
   Itoh Y, 2007, J IMMUNOL, V178, P3059, DOI 10.4049/jimmunol.178.5.3059
   Kawai M, 2012, ENDOCRIN METAB CLIN, V41, P323, DOI 10.1016/j.ecl.2012.04.013
   Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378 1119(02)00398 0
   KOCH AE, 1994, J IMMUNOL, V152, P4149
   La Cava A, 2004, J MOL MED, V82, P4, DOI 10.1007/s00109 003 0492 1
   LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143
   LUNDOLESEN K, 1970, ARTHRITIS RHEUM US, V13, P769, DOI 10.1002/art.1780130606
   Matsumoto T, 1996, J CLIN ENDOCR METAB, V81, P150, DOI 10.1210/jc.81.1.150
   MOCHIZUKI H, 1992, ENDOCRINOLOGY, V131, P1075, DOI 10.1210/en.131.3.1075
   Nakao K, 2005, BONE, V36, P884, DOI 10.1016/j.bone.2004.10.015
   Neidel J, 2001, CLIN EXP RHEUMATOL, V19, P81
   Nozawa K, 2013, ARTHRITIS RHEUM US, V65, P1477, DOI 10.1002/art.37902
   Nozawa K, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2863
   Paleolog EM, 2009, INT J EXP PATHOL, V90, P249, DOI 10.1111/j.1365 2613.2009.00640.x
   Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801
   ROONEY M, 1988, ARTHRITIS RHEUM US, V31, P956, DOI 10.1002/art.1780310803
   Salvi R, 2000, ARTHRITIS RES, V2, P504, DOI 10.1186/ar132
   Seccareccia E, 2012, GROWTH HORM IGF RES, V22, P193, DOI 10.1016/j.ghir.2012.09.003
   SEMBLE EL, 1985, J RHEUMATOL, V12, P237
   Takahashi T, 1999, CIRC RES, V85, P884
   Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206
   Ueland T, 2005, EUR J ENDOCRINOL, V152, P327, DOI 10.1530/eje.1.01874
   van der Heijde D, 2013, ARTHRITIS RHEUM US, V65, P559, DOI 10.1002/art.37816
   Walsh DA, 1998, AM J PATHOL, V152, P691
   Yadav A, 2005, J BIOL CHEM, V280, P31830, DOI 10.1074/jbc.M501316200
   Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200
NR 36
TC 19
Z9 23
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0891 6934
EI 1607 842X
J9 AUTOIMMUNITY
JI Autoimmunity
PD JUN
PY 2015
VL 48
IS 4
BP 251
EP 258
DI 10.3109/08916934.2014.976631
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA CI5LP
UT WOS:000354798100008
PM 25352179
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Cui, CY
   Liu, X
   Peng, MH
   Liu, Q
   Zhang, Y
AF Cui, Chun Yan
   Liu, Xiao
   Peng, Ming Hui
   Liu, Qing
   Zhang, Ying
TI Identification of key candidate genes and biological pathways in
   neuropathic pain
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Neuropathic pain; Hub genes; Robust rank aggregation; Microarray data
   analysis; Protein protein interaction (PPI) network; analysis
ID DORSAL ROOT GANGLION; CAVEOLIN 1; DISEASE; MECHANISMS; DISGENET;
   PROTEIN; SYSTEM
AB Background: Neuropathic pain is a common chronic pain, characterized by spontaneous pain and mechanical allodynia. The incidence of neuropathic pain is on the rise due to infections, higher rates of diabetes and stroke, and increased use of chemotherapy drugs in cancer patients. At present, due to its pathophysiological process and molecular mechanism remaining unclear, there is a lack of effective treatment and prevention methods in clinical practice. Now, we use bioinformatics technology to integrate and filter hub genes that may be related to the pathogenesis of neuropathic pain, and explore their possible molecular mechanism by functional annotation and pathway enrichment analysis. Methods: The expression profiles of GSE24982, GSE2884, GSE2636 and GSE30691 were downloaded from the Gene Expression Omnibus(GEO)database, and these datasets include 93 neuropathic pain Rattus norvegicus and 59 shame controls. After the four datasets were all standardized by quantiles, the differentially expressed genes (DEGs) between NPP Rattus norvegicus and the shame controls were finally identified by the robust rank aggregation (RRA) analysis method. In order to reveal the possible underlying biological function of DEGs, the Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway enrichment analysis of DEGs were performed. In addition, a Protein protein Interaction (PPI) network was also established. At the end of our study, a high throughput sequencing dataset GSE117526 was used to corroborate our calculation results.Results: Through RRA analysis of the above four datasets GSE24982, GSE2884, GSE2636, and GSE30691, we finally obtained 231 DEGs, including 183 up regulated genes and 47 down regulated genes. Arranging 231 DEGs in descending order according to |log2 fold change (FC)|, we found that the top 20 key genes include 14 up  regulated genes and 6 down regulated genes. The most down regulated hub gene abnormal expressed in NPP was Egf17 (P value = 0.008), Camk2n2 (P value = 0.002), and Lep (P value = 0.02), and the most up regulated hub gene abnormal expressed in NPP was Nefm (P value = 1.08E 06), Prx (P value = 2.68E 07), and Stip1 (P  value = 4.40E 07). In GO functional annotation analysis results, regulation of ion transmembrane transport (GO:0034765; P value = 1.45E 09) was the most remarkable enriched for biological process, synaptic membrane (GO:0097060; P value = 2.95E 08) was the most significantly enriched for cellular component, channel activity (GO:0015267; P value = 2.44E 06) was the most prominent enriched for molecular function. In KEGG pathway enrichment analysis results, the top three notable enrichment pathways were Neuroactive ligand receptor interaction (rno04080; P value = 3.46E 08), Calcium signaling pathway (rno04020; P value = 5.37E 05), and Osteoclast differentiation (rno04380; P value = 0.000459927). Cav1 and Lep appeared in the top 20 genes in both RRA analysis and PPI analysis, while Nefm appeared in RRA analysis and datasets GSE117526 validation analysis, so we finally identified these three genes as hub genes.Conclusions: Our research identified the hub genes and signal pathways of neuropathic pain, enriched the pathophysiological mechanism of neuropathic pain to some extent, and provided a possible basis for the targeted therapy of neuropathic pain.
C1 [Cui, Chun Yan; Liu, Xiao; Peng, Ming Hui; Liu, Qing; Zhang, Ying] Southwest Med Univ, Dept Pain, Hosp TCM, Luzhou 646000, Sichuan, Peoples R China.
   [Cui, Chun Yan; Liu, Xiao; Peng, Ming Hui; Liu, Qing; Zhang, Ying] Southwest Med Univ, Dept Anesthesiol, Hosp TCM, Luzhou 646000, Sichuan, Peoples R China.
   [Liu, Qing] Hejiang Tradit Chinese Med Hosp, Luzhou 646000, Sichuan, Peoples R China.
C3 Southwest Medical University; Southwest Medical University
RP Liu, Q; Zhang, Y (通讯作者)，Southwest Med Univ, Dept Pain, Hosp TCM, Luzhou 646000, Sichuan, Peoples R China.; Liu, Q; Zhang, Y (通讯作者)，Southwest Med Univ, Dept Anesthesiol, Hosp TCM, Luzhou 646000, Sichuan, Peoples R China.
EM 1105859368@qq.com; zhangying021210@163.com
CR Bannister K, 2020, ANNU REV PHARMACOL, V60, P257, DOI 10.1146/annurev pharmtox 010818 021524
   Barclay J, 2007, PAIN, V130, P225, DOI 10.1016/j.pain.2006.11.017
   Baron R, 2006, NAT CLIN PRACT NEURO, V2, P95, DOI 10.1038/ncpneuro0113
   Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474 4422(10)70143 5
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Berridge MJ, 2016, PHYSIOL REV, V96, P1261, DOI 10.1152/physrev.00006.2016
   Blizzard CA, 2013, J NEUROTRAUM, V30, P1908, DOI 10.1089/neu.2013.2850
   Boodhoo K, 2021, J MOL ENDOCRINOL, V66, P141, DOI 10.1530/JME 20 0256
   Bouras T, 2004, CANCER BIOL THER, V3, P931, DOI 10.4161/cbt.3.10.1147
   Cao C, 2022, NUCLEIC ACIDS RES, V50, pD1123, DOI 10.1093/nar/gkab957
   Chang KT, 2017, LIFE SCI, V187, P31, DOI 10.1016/j.lfs.2017.08.016
   Chen JL, 2020, AM J TRANSL RES, V12, P1714
   Esposito MF, 2019, PAIN MED, V20, pS23, DOI 10.1093/pm/pnz012
   Finnerup NB, 2016, PAIN, V157, P1599, DOI 10.1097/j.pain.0000000000000492
   Finnerup NB, 2021, PHYSIOL REV, V101, P259, DOI 10.1152/physrev.00045.2019
   Flint J, 2013, CURR BIOL, V23, pR265, DOI 10.1016/j.cub.2013.01.040
   Golubovic M, 2021, COMPUT BIOL MED, V132, DOI 10.1016/j.compbiomed.2021.104346
   Harrison C, 2018, NEUROMODULATION, V21, P225, DOI 10.1111/ner.12685
   Jia GL, 2020, J CELL PHYSIOL, V235, P2060, DOI 10.1002/jcp.29106
   Kim DS, 2001, NEUROREPORT, V12, P3401, DOI 10.1097/00001756 200110290 00050
   Kolde R, 2012, BIOINFORMATICS, V28, P573, DOI 10.1093/bioinformatics/btr709
   Lee YC, 2019, CURR PHARM DESIGN, V25, P4560, DOI 10.2174/1381612825666191210154535
   Li DL, 2021, PLANT PHYSIOL, V186, P1800, DOI 10.1093/plphys/kiab161
   Li J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01119
   Li X, 2013, MOL PAIN, V9, DOI 10.1186/1744 8069 9 65
   Liang YL, 2021, MOL NEUROBIOL, V58, P1185, DOI 10.1007/s12035 020 02180 1
   Lim G, 2009, J CLIN INVEST, V119, P295, DOI 10.1172/JCI36785
   Liu WL, 2022, J MOL NEUROSCI, V72, P1047, DOI 10.1007/s12031 022 01989 w
   Ma L, 2007, J BIOL CHEM, V282, P28980, DOI 10.1074/jbc.M702840200
   Mai LJ, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117885
   Moisset X, 2021, REV NEUROL FRANCE, V177, P843, DOI 10.1016/j.neurol.2021.07.011
   Nwosu ZC, 2016, MOL CANCER, V15, DOI 10.1186/s12943 016 0558 7
   Peters TJ, 2019, BIOINFORMATICS, V35, P560, DOI 10.1093/bioinformatics/bty675
   Piñero J, 2021, COMPUT STRUCT BIOTEC, V19, P2960, DOI 10.1016/j.csbj.2021.05.015
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Piñero J, 2015, DATABASE OXFORD, DOI 10.1093/database/bav028
   Ragoussis J, 2006, EXPERT REV MOL DIAGN, V6, P145, DOI 10.1586/14737159.6.2.145
   Reid IR, 2018, ENDOCR REV, V39, P938, DOI 10.1210/er.2017 00226
   Seo H, 2021, COMPUT BIOL MED, V135, DOI 10.1016/j.compbiomed.2021.104290
   Smith ES, 2018, J NEUROL, V265, P231, DOI 10.1007/s00415 017 8641 6
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Volonte D, 2020, CANCER METAST REV, V39, P397, DOI 10.1007/s10555 020 09875 w
   von Schack D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017670
   Yang JX, 2015, J NEUROSCI, V35, P36, DOI 10.1523/JNEUROSCI.1161 14.2015
   Yang QX, 2020, BRIEF BIOINFORM, V21, P1058, DOI 10.1093/bib/bbz049
   Zhang WQ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 015 0694 1
   Zhou SL, 2022, IEEE T PATTERN ANAL, V44, P5560, DOI 10.1109/TPAMI.2021.3075339
   Zhu T, 2003, CURR OPIN PLANT BIOL, V6, P418, DOI 10.1016/S1369 5266(03)00083 9
NR 48
TC 11
Z9 11
U1 4
U2 30
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010 4825
EI 1879 0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD NOV
PY 2022
VL 150
AR 106135
DI 10.1016/j.compbiomed.2022.106135
EA SEP 2022
PG 10
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA 5K4YH
UT WOS:000869732800004
PM 36166989
OA hybrid
DA 2025 08 17
ER

PT J
AU Sarkar, J
   Das, M
   Howlader, MSI
   Prateeksha, P
   Barthels, D
   Das, H
AF Sarkar, Jaganmay
   Das, Manjusri
   Howlader, Md Sariful Islam
   Prateeksha, Prateeksha
   Barthels, Derek
   Das, Hiranmoy
TI Epigallocatechin 3 gallate inhibits osteoclastic differentiation by
   modulating mitophagy and mitochondrial functions
SO CELL DEATH & DISEASE
LA English
DT Article
ID CARBAZOLE ALKALOIDS; AUTOPHAGY; DISEASE; NFATC1
AB A natural plant product, epigallocatechin 3 gallate (EGCG), was evaluated for its effectiveness in the regulation of osteoclastogenesis. We found that EGCG inhibited the osteoclast (OC) differentiation in vitro, and in primary bone marrow cells in a dose dependent manner. Quantitative RT PCR studies showed that the EGCG reduced the expression of OC differentiation markers. DCFDA, MitoSOX, and JC 1 staining revealed that the EGCG attenuated the reactive oxygen species (ROS), and mitochondrial membrane potential; and flux analysis corroborated the effect of EGCG. We further found that the EGCG inhibited mRNA and protein expressions of mitophagy related molecules. We confirmed that the OC differentiation was inhibited by EGCG by modulating mitophagy through AKT and p38MAPK pathways. Furthermore, in silico analysis revealed that the binding of RANK and RANKL was blocked by EGCG. Overall, we defined the mechanisms of osteoclastogenesis during arthritis for developing a new therapy using a natural compound besides the existing therapeutics.
C1 [Sarkar, Jaganmay; Das, Manjusri; Howlader, Md Sariful Islam; Prateeksha, Prateeksha; Barthels, Derek; Das, Hiranmoy] Texas Tech Univ, Hlth Sci Ctr, Jerry H Hodge Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.
C3 Texas Tech University System; Texas Tech University Health Sciences
   Center Amarillo
RP Das, H (通讯作者)，Texas Tech Univ, Hlth Sci Ctr, Jerry H Hodge Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.
EM hiranmoy.das@ttuhsc.edu
RI ; Das, Hiranmoy/R 7452 2019
OI Das, Hiranmoy/0000 0002 3343 0096; Sarkar, Dr.
   Jaganmay/0000 0003 1073 4537; 
FU National Institutes of Health [R01AR068279, STTR R42EY031196, STTR
   1R41AG057242]; Cancer Prevention and Research Institute of Texas (CPRIT)
   to the Imaging CoreTexas Tech University Health Sciences Center at
   Amarillo [RP200572]; National Eye Institute [R42EY031196] Funding
   Source: NIH RePORTER; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [R01AR068279] Funding Source: NIH
   RePORTER
FX We sincerely acknowledge our funding authority, National Institutes of
   Health R01AR068279 (NIAMS), STTR R42EY031196 (NEI), and STTR
   1R41AG057242 (NIA). We are thankful to Zijuan Liu, from TTUHSC core
   facility for her help in procuring confocal images. The core facility is
   being supported by a Core Facility Support Award (grant number RP200572)
   from the Cancer Prevention and Research Institute of Texas (CPRIT) to
   the Imaging Core, Texas Tech University Health Sciences Center at
   Amarillo. The funders had no role in the study design, data collection,
   analysis, decision to publish, or preparation of the manuscript.
CR Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008 5472.CAN 04 2840
   Aoki S, 2020, BIOCHEM BIOPH RES CO, V527, P874, DOI 10.1016/j.bbrc.2020.04.155
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen K, 2019, THERANOSTICS, V9, P1634, DOI 10.7150/thno.30206
   Chen ST, 2019, MOLECULES, V24, DOI 10.3390/molecules24010156
   Chowdhury A, 2016, BIOMED PHARMACOTHER, V78, P50, DOI 10.1016/j.biopha.2015.12.013
   Das M, 2012, CURR MOL MED, V12, P113, DOI 10.2174/156652412798889090
   Das M, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080908
   Deb M, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148 021 01125 2
   Guo YG, 2018, FITOTERAPIA, V127, P96, DOI 10.1016/j.fitote.2018.02.001
   Haileselassie B, 2019, J MOL CELL CARDIOL, V130, P160, DOI 10.1016/j.yjmcc.2019.04.006
   Hegarty VM, 2000, AM J CLIN NUTR, V71, P1003
   Hu CX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010144
   Ihenacho UK, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.660095
   Jacobs JP, 2010, ARTHRITIS RHEUM US, V62, P1921, DOI 10.1002/art.27470
   JOHNELL O, 1995, J BONE MINER RES, V10, P1802, DOI 10.1002/jbmr.5650101125
   Kawaguchi M, 2016, BIOCHEM BIOPH RES CO, V474, P188, DOI 10.1016/j.bbrc.2016.04.098
   Kim B, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10815
   Kim H, 2017, J BONE MINER RES, V32, P397, DOI 10.1002/jbmr.2974
   Kim MH, 2020, PHARM BASEL, P13
   Koentjoro B, 2017, SCI REP UK, V7, DOI 10.1038/srep44373
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   Laha D, 2019, AUTOPHAGY, V15, P2063, DOI 10.1080/15548627.2019.1596491
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liemburg Apers DC, 2015, ARCH TOXICOL, V89, P1209, DOI 10.1007/s00204 015 1520 y
   Lin RW, 2009, BIOCHEM BIOPH RES CO, V379, P1033, DOI 10.1016/j.bbrc.2009.01.007
   Liu YH, 2019, THERANOSTICS, V9, P4648, DOI 10.7150/thno.35414
   Ma YL, 2018, BIOORG CHEM, V76, P359, DOI 10.1016/j.bioorg.2017.12.016
   Maity J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04903 9
   Maity J, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101622
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marycz K, 2016, J CELL MOL MED, V20, P2384, DOI 10.1111/jcmm.12932
   Matta SK, 2015, INT J BIOCHEM CELL B, V66, P121, DOI 10.1016/j.biocel.2015.07.010
   Melser S, 2013, CELL METAB, V17, P719, DOI 10.1016/j.cmet.2013.03.014
   Meyer A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00536
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nakagawa H, 2002, BIOCHEM BIOPH RES CO, V292, P94, DOI 10.1006/bbrc.2002.6622
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Ng PY, 2019, BIOCHEM SOC T, V47, P639, DOI 10.1042/BST20180445
   Onishi M, 2021, EMBO J, V40, DOI 10.15252/embj.2020104705
   Otera H, 2010, J CELL BIOL, V191, P1141, DOI 10.1083/jcb.201007152
   Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556 018 0176 2
   Ploumi C, 2017, FEBS J, V284, P183, DOI 10.1111/febs.13820
   Salminen KA, 2011, PHYTOMEDICINE, V18, P533, DOI 10.1016/j.phymed.2010.08.012
   Sarkar J, 2016, BIOMED PHARMACOTHER, V84, P340, DOI 10.1016/j.biopha.2016.09.049
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Wang J, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431x20198092, 10.1590/1414 431X20198092]
   Wang TF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00433
   Wei RR, 2018, BIOORG CHEM, V77, P387, DOI 10.1016/j.bioorg.2018.01.032
   Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761
   Xu J, 2017, MOLECULES, V22, DOI 10.3390/molecules22081337
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 303
   Zhang Y, 2018, J BONE MINER RES, V33, P1114, DOI 10.1002/jbmr.3398
   Zhao HB, 2012, TRAFFIC, V13, P1307, DOI 10.1111/j.1600 0854.2012.01395.x
NR 55
TC 43
Z9 49
U1 5
U2 30
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 28
PY 2022
VL 13
IS 10
AR 908
DI 10.1038/s41419 022 05343 1
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 5U5FG
UT WOS:000876572000002
PM 36307395
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Donovan, J
   Abraham, D
   Norman, J
AF Donovan, Johanna
   Abraham, David
   Norman, Jill
TI Platelet derived growth factor signaling in mesenchymal cells
SO FRONTIERS IN BIOSCIENCE LANDMARK
LA English
DT Article
DE PDGF; PDGFR; Fibroblast; Vascular smooth muscle cell; Chondrocyte;
   Osteoblast; Osteoclast; Review
ID PROTEASE ACTIVATED LIGAND; PDGF BETA RECEPTOR; TGF BETA; STEM CELLS;
   FACTOR BB; PHOSPHOINOSITIDE 3 KINASE; AUTOPHOSPHORYLATION SITES; INDUCED
   PROLIFERATION; FUNCTION MUTATION; MIGRATION
AB Platelet derived growth factors (PDGFs) and their receptors are major mitogens for many cell types of mensenchymal origin, including fibroblasts and vascular smooth muscle cells (VSMCs). Their role in enhancing migratory and proliferative responses and extracellular matrix synthesis in these cells, make them key regulators of critical biological functions and in tissue diseases including tissue remodeling, scarring and fibrosis. The activities of the PDGFs have been extensively characterized at the molecular and cellular level and in in vivo model systems. This, in turn, has lead to an increasing number of PDGF based therapies designed to accelerate or combat defects in tissue repair. This review aims to summarize recent developments in the role of PDGF in key mesenchymal cell functions. Many of the current developments in this field have primarily focused on advancements in understanding cell differentiation, migration, proliferation and the development of emerging PDGF based therapies and hence will be primary focus of this review.
C1 [Donovan, Johanna; Abraham, David] UCL Med Sch, Ctr Rheumatol & Connect Tissue Dis, London NW3 2PF, England.
   [Norman, Jill] UCL Med Sch, Div Med, Ctr Nephrol, London NW3 2PF, England.
C3 University of London; University College London; University of London;
   University College London
RP Donovan, J (通讯作者)，UCL Med Sch, Ctr Rheumatol & Connect Tissue Dis, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.
EM johanna.donovan@ucl.ac.uk
RI Abraham, David/AGI 5959 2022
FU Arthritis Research UK [18420, 19427, 16379]; Rosetrees Trust;
   Scleroderma Society; Cancer Research UK; Versus Arthritis [19427]
   Funding Source: researchfish; Versus Arthritis [18420] Funding Source:
   researchfish
FX The authors would like to thank Arthritis Research UK (Grant no 18420,
   19427, 16379), The Rosetrees Trust and The Scleroderma Society for
   funding support.
CR Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   ANTONIADES HN, 1979, P NATL ACAD SCI USA, V76, P1809, DOI 10.1073/pnas.76.4.1809
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Asanbaeva A, 2008, BIOMECH MODEL MECHAN, V7, P263, DOI 10.1007/s10237 007 0096 8
   Ashraf A, 2009, PLAST RECONSTR SURG, V124, P1118, DOI 10.1097/PRS.0b013e3181b5a349
   BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092 8674(90)90448 N
   Behnia H., 2011, J CRANIOMAXILLOFAC S
   Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588
   Caplan A. I., 2011, J ORTHOP RES
   Cerutis DR, 2007, J PERIODONTOL, V78, P1136, DOI 10.1902/jop.2007.060442
   Chan MC, 2010, EMBO J, V29, P559, DOI 10.1038/emboj.2009.370
   Chang PC, 2010, GENE THER, V17, P95, DOI 10.1038/gt.2009.117
   Chen PY, 2009, J BIOL CHEM, V284, P15980, DOI 10.1074/jbc.M809399200
   Chen YT, 2011, KIDNEY INT, V80, P1170, DOI 10.1038/ki.2011.208
   Chiara F, 2004, J BIOL CHEM, V279, P42516, DOI 10.1074/jbc.M406051200
   Choi KH, 2010, CARDIOVASC RES, V85, P836, DOI 10.1093/cvr/cvp359
   Chung R, 2009, BONE, V44, P878, DOI 10.1016/j.bone.2009.01.377
   CLAESSONWELSH L, 1987, P NATL ACAD SCI USA, V84, P8796, DOI 10.1073/pnas.84.24.8796
   CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917
   Corselli M, 2010, ARTERIOSCL THROM VAS, V30, P1104, DOI 10.1161/ATVBAHA.109.191643
   Dahal Bhola K, 2011, Pulm Circ, V1, P259, DOI 10.4103/2045 8932.83448
   Davis BN, 2009, J BIOL CHEM, V284, P3728, DOI 10.1074/jbc.M808788200
   DEUEL TF, 1981, J BIOL CHEM, V256, P8896
   Díaz Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH 24.909
   Englesbe MJ, 2004, J VASC SURG, V39, P440, DOI 10.1016/j.jvs.2003.07.010
   FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454
   Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397
   Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007
   Fürst R, 2010, ATHEROSCLEROSIS, V211, P409, DOI 10.1016/j.atherosclerosis.2010.04.003
   Gebb SA, 2003, ADV EXP MED BIOL, V543, P117
   Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109 007 0258 2
   Gope ML, 2009, WOUND REPAIR REGEN, V17, P71, DOI 10.1111/j.1524 475X.2008.00443.x
   Guan SX, 2009, J INVEST DERMATOL, V129, P1909, DOI 10.1038/jid.2008.457
   Harper L, 2007, NEPHRON PHYSIOL, V107, pP45, DOI 10.1159/000107805
   Hee CK, 2011, AM J SPORT MED, V39, P1630, DOI 10.1177/0363546511404942
   Heldin CH, 2004, CYTOKINE GROWTH F R, V15, P195, DOI 10.1016/j.cytogfr.2004.03.001
   HELDIN CH, 1985, MOL CELL ENDOCRINOL, V39, P169, DOI 10.1016/0303 7207(85)90061 9
   HELDIN CH, 1985, J CELL SCI, P65
   Heldin CH, 1998, BBA REV CANCER, V1378, pF79, DOI 10.1016/S0304 419X(98)00015 8
   Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283
   Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721
   Jester JV, 2002, EXP EYE RES, V75, P645, DOI 10.1006/exer.2002.2066
   Jiang YL, 2006, ACTA BIOCH BIOPH SIN, V38, P29, DOI 10.1111/j.1745 7270.2006.00123.x
   Kaigler D, 2011, EXPERT OPIN BIOL TH, V11, P375, DOI 10.1517/14712598.2011.554814
   Karakiulakis G, 2007, J BIOL CHEM, V282, P908, DOI 10.1074/jbc.M602178200
   Kaur H, 2009, EXP EYE RES, V89, P432, DOI 10.1016/j.exer.2009.03.017
   KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092 8674(89)90510 2
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   King SJ, 2011, EMBO J, V30, P1705, DOI 10.1038/emboj.2011.82
   KOYAMA N, 1994, CIRC RES, V75, P682, DOI 10.1161/01.RES.75.4.682
   Krampert M, 2008, LAB INVEST, V88, P1204, DOI 10.1038/labinvest.2008.81
   Krausgrill B, 2009, CELL TRANSPLANT, V18, P847, DOI 10.3727/096368909X471134
   Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257
   Lee CK, 2007, CARDIOVASC RES, V74, P159, DOI 10.1016/j.cardiores.2007.01.012
   Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579
   Lin Z, 2008, J PERIODONTAL RES, V43, P440, DOI 10.1111/j.1600 0765.2008.01089.x
   Liu S, 2011, AGING CELL, V10, P661, DOI 10.1111/j.1474 9726.2011.00704.x
   Lo Re S., 2011, AM J RESP CRIT CARE
   Lohmeyer JA, 2011, LANGENBECK ARCH SURG, V396, P543, DOI 10.1007/s00423 011 0761 3
   LUBINUS M, 1994, J BIOL CHEM, V269, P9822
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Mogford JE, 2009, WOUND REPAIR REGEN, V17, P405, DOI 10.1111/j.1524 475X.2009.00481.x
   MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460 2075.1993.tb05879.x
   MURRAYRUST J, 1993, STRUCTURE, V1, P153, DOI 10.1016/0969 2126(93)90029 G
   Nass N, 2010, INT J BIOCHEM CELL B, V42, P749, DOI 10.1016/j.biocel.2010.01.012
   Nedeau AE, 2008, EXP CELL RES, V314, P2176, DOI 10.1016/j.yexcr.2008.04.007
   Nikolidakis D, 2009, BIOMATERIALS, V30, P94, DOI 10.1016/j.biomaterials.2008.09.022
   Nincheri P, 2010, CELL SIGNAL, V22, P1688, DOI 10.1016/j.cellsig.2010.06.009
   Niwa R, 2007, CURR OPIN GENET DEV, V17, P145, DOI 10.1016/j.gde.2007.02.004
   Olson LE, 2009, DEV CELL, V16, P303, DOI 10.1016/j.devcel.2008.12.003
   OSTMAN A, 1992, J CELL BIOL, V118, P509, DOI 10.1083/jcb.118.3.509
   Owens Gary K, 2007, Novartis Found Symp, V283, P174
   Plasari G, 2009, MOL CELL BIOL, V29, P6006, DOI 10.1128/MCB.01921 08
   Popova SN, 2004, DEV BIOL, V270, P427, DOI 10.1016/j.ydbio.2004.03.006
   Pountos I, 2010, J ORTHOP TRAUMA, V24, P552, DOI 10.1097/BOT.0b013e3181efa8fe
   RAINES EW, 1982, J BIOL CHEM, V257, P5154
   Raja S, 2009, INT J DENT HYG, V7, P82, DOI 10.1111/j.1601 5037.2009.00380.x
   Reddi AL, 2007, J BIOL CHEM, V282, P29336, DOI 10.1074/jbc.M701797200
   Rhee CK, 2011, RESPIRATION, V82, P273, DOI 10.1159/000327719
   Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960 9822(01)00442 0
   RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460 2075.1992.tb05484.x
   Rovida E, 2008, J HEPATOL, V48, P107, DOI 10.1016/j.jhep.2007.08.010
   Rzucidlo EM, 2007, J VASC SURG, V45, p25A, DOI 10.1016/j.jvs.2007.03.001
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sanz L, 2008, MICROVASC RES, V75, P308, DOI 10.1016/j.mvr.2007.11.007
   SCHAFER SJ, 1993, ARCH BIOCHEM BIOPHYS, V302, P431, DOI 10.1006/abbi.1993.1236
   Scheef EA, 2009, AM J PHYSIOL CELL PH, V296, pC724, DOI 10.1152/ajpcell.00409.2008
   Schneider L, 2009, J CELL BIOL, V185, P163, DOI 10.1083/jcb.200806019
   Sirois MG, 1997, CIRCULATION, V95, P669, DOI 10.1161/01.CIR.95.3.669
   Sorrell JM, 2009, TISSUE ENG PT A, V15, P1751, DOI 10.1089/ten.tea.2008.0254
   Sun WJ, 2007, GROWTH FACTORS, V25, P309, DOI 10.1080/08977190701803885
   Tamm M, 1998, AM J RESP CELL MOL, V19, P653, DOI 10.1165/ajrcmb.19.4.3058
   Thomopoulos S, 2010, ANN BIOMED ENG, V38, P225, DOI 10.1007/s10439 009 9844 5
   Tokunaga A, 2008, J BONE MINER RES, V23, P1519, DOI 10.1359/JBMR.080409
   Vercoutter Edouart AS, 2008, BIOMATERIALS, V29, P2280, DOI 10.1016/j.biomaterials.2008.01.020
   Vij N, 2008, MOL VIS, V14, P1020
   Walker TR, 1998, MOL PHARMACOL, V54, P1007, DOI 10.1124/mol.54.6.1007
   Wu NL, 2010, EXP DERMATOL, V19, pE173, DOI 10.1111/j.1600 0625.2009.01036.x
   YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0
   Zemskov EA, 2009, J BIOL CHEM, V284, P16693, DOI 10.1074/jbc.M109.010769
   Zymek P, 2006, J AM COLL CARDIOL, V48, P2315, DOI 10.1016/j.jacc.2006.07.060
NR 101
TC 74
Z9 81
U1 0
U2 17
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093 9946
EI 1093 4715
J9 FRONT BIOSCI LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2013
VL 18
BP 106
EP 119
DI 10.2741/4090
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 171UK
UT WOS:000320954800007
PM 23276912
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, CL
   Tsai, ML
   Wu, SN
AF Wang, Chung Lin
   Tsai, Mei Ling
   Wu, Sheng Nan
TI Evidence for Mitoxantrone induced Block of Inwardly Rectifying
   K<SUP>+</SUP> Channels Expressed in the Osteoclast Precursor RAW 264.7
   Cells Differentiated with Lipopolysaccharide
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Mitoxantrone; Inwardly rectifying K+ channel; Osteoclast progenitor
   cells; Membrane potential
ID EXTRACELLULAR CALCIUM; BKCA CHANNEL; ION CHANNELS; CURRENTS;
   NANOPARTICLES; CHEMOTHERAPY; INHIBITION; ACTIVATION; STIMULATE; RECEPTOR
AB Background/Aims: Mitoxanthrone (MX) is an anthracenedione antineoplastic agent. Whether this drug and other related compounds have any effects on ion currents in osteoclasts remains largely unclear. Methods: In this study, the effects of MX and other related compounds on inwardly rectifying K+ current (I K(IR)) were investigated in RAW 264.7 osteoclast precursor cells treated with lipopolysaccharide. Results: The I K(IR) in these cells are blocked by BaCl2 (1 mM). MX (1 100 mu M) decreased the amplitude of I K(IR) in a concentration dependent manner with an IC50 value of 6.4 mu M. MX also slowed the time course of I K(IR) inactivation elicited by large hyperpolarization. Doxorubicin (10 mu M), 17 beta estradiol (10 mu M) and tertiapin (1 mu M) decreased the I K(IR) amplitude in these cells. In bafilomycin A(1) treated cells, MX mediated block of I K(IR) still existed. In cell attached configuration, when the electrode was filled with MX (10 mu M), the activity of inwardly rectifying K+ (Kir) channels was decreased with no change in single channel conductance. MX mediated reduction of channel activity is accompanied by a shortening of mean open time. Under current clamp conditions, addition of MX resulted in membrane depolarization. Therefore, MX can interact with the Kir channels to decrease the I K(IR) amplitude and to depolarize the membrane in these cells. Conclusion: The block by this drug of Kir2.1 channels appears to be one of the important mechanisms underlying its actions on the resorptive activity of osteoclasts, if similar results occur in vivo. Targeting at Kir channels may be clinically useful as an adjunctive regimen to anti cancer drugs (e.g., MX or doxorubicin) in influencing the resorptive activity of osteoclasts. Copyright (C) 2012 S. Karger AG, Basel
C1 [Wang, Chung Lin; Tsai, Mei Ling; Wu, Sheng Nan] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 70101, Taiwan.
   [Wang, Chung Lin] Chung Jen Coll Nursing Hlth Sci & Management, Dept Nursing, Chiayi, Taiwan.
   [Wu, Sheng Nan] Natl Cheng Kung Univ, Coll Med, Dept Anat & Cell Biol, Tainan 70101, Taiwan.
   [Tsai, Mei Ling; Wu, Sheng Nan] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University
RP Wu, SN (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan.
EM snwu@mail.ncku.edu.tw
RI ; Wu, Sheng Nan/B 9224 2009
OI Wu, Sheng Nan/0000 0002 5208 3253; 
FU National Science Council, Taiwan [NSC 98 2320 B 006 MY3]
FX Part of the research leading to these results was aided by grants from
   the National Science Council (NSC 98 2320 B 006 MY3), Taiwan, through a
   contract awarded to S. N. W. The authors thank Hsien Ching Huang,
   Chia Chen Yeh and Pei Yu Wu for technical assistances in this work.
CR Abraham R, 2000, CANCER, V88, P790, DOI 10.1002/(SICI)1097 0142(20000215)88:4<790::AID CNCR9>3.0.CO;2 M
   Akchurin T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002104
   Azim HA, 2008, ANTI CANCER DRUG, V19, P645, DOI 10.1097/CAD.0b013e3282ff0f48
   Boudot C, 2010, BONE, V46, P1416, DOI 10.1016/j.bone.2010.01.383
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Eklund J, 2006, CANCER AM CANCER SOC, V106, P2459, DOI 10.1002/cncr.21880
   Espinosa L, 2002, J CELL SCI, V115, P3837, DOI 10.1242/jcs.00062
   HAMMERLAND LG, 1994, AM J PHYSIOL CELL PH, V267, pC1103, DOI 10.1152/ajpcell.1994.267.4.C1103
   Ho JW, 2012, MED HYPOTHESES, V78, P377, DOI 10.1016/j.mehy.2011.12.002
   Huang MH, 2006, STEROIDS, V71, P129, DOI 10.1016/j.steroids.2005.09.009
   Ihaka R., 1996, J Comput Graph Statist, V5, P299, DOI [10.2307/1390807, DOI 10.2307/1390807, DOI 10.1080/10618600.1996.10474713]
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jongsma HJ, 2001, CURR BIOL, V11, pR747, DOI 10.1016/S0960 9822(01)00437 7
   Kitamura H, 2000, J PHARMACOL EXP THER, V293, P196
   Kobayashi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028208
   Komarova SV, 2001, CURR PHARM DESIGN, V7, P637, DOI 10.2174/1381612013397799
   Lee CM, 2006, BRIT J CANCER, V94, P863, DOI 10.1038/sj.bjc.6603010
   Lee I, 2010, MOL CANCER THER, V9, P2951, DOI 10.1158/1535 7163.MCT 10 0511
   Liu TA, 2011, BBA BIOMEMBRANES, V1808, P1772, DOI 10.1016/j.bbamem.2011.02.016
   López Izquierdo A, 2011, J CARDIOVASC PHARM, V57, P407, DOI 10.1097/FJC.0b013e31820b7c03
   Ma YH, 2011, J MATER CHEM, V21, P9483, DOI 10.1039/c1jm10750j
   Ma YL, 2012, EUR J PHARM SCI, V45, P539, DOI 10.1016/j.ejps.2011.11.014
   Matsuda H, 2010, J PHYSIOL LONDON, V588, P4673, DOI 10.1113/jphysiol.2010.194480
   Newell EW, 2005, J PHYSIOL LONDON, V567, P869, DOI 10.1113/jphysiol.2005.092056
   Okamoto F, 2001, JPN J PHYSIOL, V51, P501, DOI 10.2170/jjphysiol.51.501
   Pan MH, 2008, J AGR FOOD CHEM, V56, P7502, DOI 10.1021/jf800820y
   Park EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027739
   Sakai H, 2006, J PHYSIOL LONDON, V576, P417, DOI 10.1113/jphysiol.2006.117176
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   SIMS SM, 1989, AM J PHYSIOL, V256, pC1277, DOI 10.1152/ajpcell.1989.256.6.C1277
   STEWART DJ, 1986, CANCER TREAT REP, V70, P1255
   Sung RJ, 2006, AM J PHYSIOL HEART C, V291, pH2597, DOI 10.1152/ajpheart.00393.2006
   Tiligada E, 2006, ENDOCR RELAT CANCER, V13, pS115, DOI 10.1677/erc.1.01272
   Wang GX, 1999, BRIT J PHARMACOL, V127, P321, DOI 10.1038/sj.bjp.0702547
   Wang YJ, 2007, BIOCHEM PHARMACOL, V73, P1347, DOI 10.1016/j.bcp.2006.12.029
   Weidema AF, 2000, BONE, V27, P5, DOI 10.1016/S8756 3282(00)00287 8
   Wu SN, 2011, J MEMBRANE BIOL, V241, P11, DOI 10.1007/s00232 011 9358 6
   Wu SN, 2001, J INVEST MED, V49, P522, DOI 10.2310/6650.2001.33629
   Zobel C, 2003, J PHYSIOL LONDON, V550, P365, DOI 10.1113/jphysiol.2002.036400
NR 39
TC 11
Z9 11
U1 0
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2012
VL 30
IS 3
BP 687
EP 701
DI 10.1159/000341449
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 989AW
UT WOS:000307533600017
PM 22854649
OA gold
DA 2025 08 17
ER

PT J
AU Yang, X
   Ding, Y
   Wang, XL
   Dai, HM
   Xu, HF
   Wu, B
   He, XY
   Zhang, YX
   Li, X
   Jin, YG
   Cui, CP
   Peng, J
   Cui, Y
   Zhang, LQ
AF Yang, Xi
   Ding, Yi
   Wang, Xiaolu
   Dai, Hongmiao
   Xu, Haifeng
   Wu, Bo
   He, Xiaoyang
   Zhang, Yuxuan
   Li, Xin
   Jin, Yiguang
   Cui, Chun Ping
   Peng, Jiang
   Cui, Yu
   Zhang, Lingqiang
TI An activatable near infrared fluorescent probe targeting CKIP 1 for
   monitoring osteoporosis in vivo
SO SENSORS AND ACTUATORS B CHEMICAL
LA English
DT Article
DE NIR fluorescent probe; CKIP 1; In vivo imaging; Osteoporosis
ID BONE FORMATION; CANCER; OSTEOBLASTS; DYES
AB Osteoporosis (OP) is characterized by decreased bone mass and strength. Patients with OP have a higher risk of bone fragility and fracture. Currently, bone mineral density (BMD) determined by radioactive scanning is one of the most critical parameters applied in the clinical diagnosis and monitoring of therapeutic response in osteoporosis. However, radioactive scanning exposes the potential risks of long time radiation damage. This calls for development of less toxic and highly sensitive molecular fluorescence imaging techniques. Currently, this is not possible because there are no effective indicators. Here, we found a negative correlation between osteoporosis and casein kinase 2 interacting protein 1 (CKIP 1, also known as PLEKHO1). This kinase was previously found to negatively regulate bone formation. Using this new biomarker, we designed an activatable near infrared (NIR) fluorescent probe targeting CKIP 1 mRNA (NPC) with the toe hold mediated strand displacement reaction and fuel amplification strategy. NIR fluorophore Cy5 and its quencher part BHQ3 were incorporated in the probe. The ratio of NPC probe and its fuel strand were also optimized. The designed detection system effectively visualized CKIP 1 at the cell level and in three different osteoporosis models. Results revealed that the NPC probe targeting CKIP 1 can be used to monitor changes in bone mass and therapy responses in vivo.
C1 [Yang, Xi; Ding, Yi; Wang, Xiaolu; Dai, Hongmiao; Wu, Bo; Cui, Chun Ping; Cui, Yu; Zhang, Lingqiang] Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 100850, Peoples R China.
   [Yang, Xi; Xu, Haifeng] Gen Hosp Xinjiang Mil Command, Urumqi 830000, Xinjiang, Peoples R China.
   [He, Xiaoyang; Jin, Yiguang] Beijing Inst Radiat Med, Beijing 100850, Peoples R China.
   [Zhang, Yuxuan; Peng, Jiang] Chinese Peoples Liberat Army Gen Hosp, Beijing Key Lab Regenerat Med Orthopaed, Lab Orthopaed, Dept Orthopaed, Beijing 100853, Peoples R China.
   [Li, Xin] Chinese Peoples Liberat Army Gen Hosp, Beijing Key Lab Chron Heart Failure Precis Med, Core Lab Translat Med, Beijing 100853, Peoples R China.
C3 Academy of Military Medical Sciences   China; Chinese People's
   Liberation Army General Hospital; Chinese People's Liberation Army
   General Hospital
RP Cui, Y; Zhang, LQ (通讯作者)，Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 100850, Peoples R China.
EM cuiyubmi@163.com; zhanglq@nic.bmi.ac.cn
RI Peng, Jiang/AAQ 1123 2021; Xu, Haifeng/AAR 2509 2020; WANG,
   Xiaolu/C 9563 2015; Jin, Yiguang/H 6742 2013; Wu, Bo/AAD 9842 2020
OI Cui, Chun Ping/0000 0003 0251 3259; 
CR Alkhybari EM, 2018, RADIAT PROT DOSIM, V182, P532, DOI 10.1093/rpd/ncy113
   Bernhard W, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08003 3
   Beyer T, 2020, CANCER IMAGING, V20, DOI 10.1186/s40644 020 00312 3
   Cunha L, 2014, DRUG DISCOV TODAY, V19, P936, DOI 10.1016/j.drudis.2014.01.003
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Gil HM, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102189
   Han B, 2018, MOL MED REP, V18, P2506, DOI 10.3892/mmr.2018.9222
   He XX, 2010, WIRES NANOMED NANOBI, V2, P349, DOI 10.1002/wnan.85
   Hernandez R, 2013, CURR MED CHEM, V20, P3594
   JERGAS M, 1993, ARTHRITIS RHEUM US, V36, P1649, DOI 10.1002/art.1780361203
   Joshi BP, 2018, CONTRAST MEDIA MOL I, DOI 10.1155/2018/2015237
   Kozloff K. M., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P353
   Lambers Floor M, 2012, Bonekey Rep, V1, P37, DOI 10.1038/bonekey.2012.28
   Li CY, 2020, ANGEW CHEM INT EDIT, V59, P247, DOI 10.1002/anie.201911803
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Ling SK, 2012, CIRCULATION, V126, P3028, DOI 10.1161/CIRCULATIONAHA.112.102780
   Liu J, 2017, AGING CELL, V16, P360, DOI 10.1111/acel.12566
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Luo SL, 2011, BIOMATERIALS, V32, P7127, DOI 10.1016/j.biomaterials.2011.06.024
   Martelli C, 2016, ONCOTARGET, V7, P48753, DOI 10.18632/oncotarget.9066
   Mizrahi DM, 2011, EUR J MED CHEM, V46, P5175, DOI 10.1016/j.ejmech.2011.08.040
   Muller Jochen, 2013, Recent Results Cancer Res, V187, P221, DOI 10.1007/978 3 642 10853 2_7
   Nisar S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02656 7
   Reginster JY, 2005, OSTEOPOROSIS INT, V16, pS1, DOI 10.1007/s00198 004 1752 9
   Shinn J, 2021, ARCH PHARM RES, V44, P165, DOI 10.1007/s12272 021 01313 x
   Syed AJ, 2021, CHEM SOC REV, V50, P5668, DOI 10.1039/d0cs01492c
   Vahrmeijer AL, 2013, NAT REV CLIN ONCOL, V10, P507, DOI 10.1038/nrclinonc.2013.123
   van Manen L, 2018, J SURG ONCOL, V118, P283, DOI 10.1002/jso.25105
   Wiedenmann J, 2009, IUBMB LIFE, V61, P1029, DOI 10.1002/iub.256
   Yang XL, 2016, J AM CHEM SOC, V138, P14076, DOI 10.1021/jacs.6b08794
   Yuan A, 2013, J PHARM SCI US, V102, P6, DOI 10.1002/jps.23356
   Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang K, 2019, ADV MATER, V31, DOI 10.1002/adma.201807888
   Zhang XC, 2016, PROG BIOPHYS MOL BIO, V122, P140, DOI 10.1016/j.pbiomolbio.2016.09.007
   Zhu SJ, 2018, THERANOSTICS, V8, P4141, DOI 10.7150/thno.27995
NR 36
TC 2
Z9 2
U1 1
U2 29
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
EI 0925 4005
J9 SENSOR ACTUAT B CHEM
JI Sens. Actuator B Chem.
PD NOV 1
PY 2021
VL 346
AR 130453
DI 10.1016/j.snb.2021.130453
EA JUL 2021
PG 11
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA UK1VD
UT WOS:000691762700004
DA 2025 08 17
ER

PT J
AU Chen, B
   Wang, WM
   Hu, ML
   Liang, YK
   Wang, N
   Li, CY
   Li, Y
AF Chen, Bo
   Wang, Wanmeng
   Hu, Meilin
   Liang, Yunkai
   Wang, Ning
   Li, Changyi
   Li, Ying
TI "Photo Thermo Electric" Dental Implant for Anti Infection and Enhanced
   Osteoimmunomodulation
SO ACS NANO
LA English
DT Article
DE dental implant; implant associated infection; osteoimmunomodulation;
   photothermal; photoelectric
ID BONE REGENERATION; TIO2; OSTEOGENESIS; PERFORMANCE; HYDROGEL; THERAPY;
   DAMAGE
AB The dental implant market has experienced explosive growth, owing to the widespread acceptance of implants as the core of oral rehabilitation. Clinically, achieving simultaneous anti infective effects and rapid osseointegration is a crucial but challenging task for implants. The demand for implants with long term broad spectrum antibacterial and immune osteogenic properties is growing. Existing methods are limited by a lack of safety, efficiency, short lasting anti infective ability, and inadequate consideration of the immunomodulatory effects on osteogenesis. Herein, a ZnO/black TiO2 x heterojunction surface structure was designed as a near infrared (NIR) light responsive nanofilm immobilized on a titanium (Ti) implant surface. This nanofilm introduces abundant oxygen vacancies and heterojunctions, which enhance the photothermal and photoelectric abilities of Ti implants under NIR illumination by narrowing the band gap and improving interfacial charge transfer. The "photo thermo electric" implant exhibits excellent broad spectrum antibacterial efficacy against three dental pathogenic bacteria (Porphyromonas gingivalis, Fusobacterium nucleatum, and Staphylococcus aureus, >99.4%) by destroying the bacterial membrane and increasing the production of intracellular reactive oxygen species. Additionally, the implant can effectively eliminate mature multispecies biofilms and kill bacteria inside the biofilms under NIR irradiation. Meanwhile, this implant can also induce the pro regenerative transformation of macrophages and promote osteoblast proliferation and differentiation. Moreover, in vivo results confirmed the superior antibacterial and osteoimmunomodulatory properties of this dental implant. RNA sequencing revealed that the underlying osteogenic mechanisms involve activation of the Wnt/beta catenin signaling pathway and bone development. Overall, this versatile "photo thermo electric" platform endows implants with anti infection and bone integration performance simultaneously, which holds great potential for dental implants.
C1 [Chen, Bo; Wang, Wanmeng; Hu, Meilin; Liang, Yunkai; Wang, Ning; Li, Changyi; Li, Ying] Tianjin Med Univ, Stomatol Hosp, Sch Dent, Tianjin 300070, Peoples R China.
   [Chen, Bo; Wang, Wanmeng; Hu, Meilin; Liang, Yunkai; Wang, Ning; Li, Changyi; Li, Ying] Tianjin Key Lab Oral Soft & Hard Tissues Restorat, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University
RP Li, CY; Li, Y (通讯作者)，Tianjin Med Univ, Stomatol Hosp, Sch Dent, Tianjin 300070, Peoples R China.; Li, CY; Li, Y (通讯作者)，Tianjin Key Lab Oral Soft & Hard Tissues Restorat, Tianjin 300070, Peoples R China.
EM lichangyi@tmu.edu.cn; yingli@tmu.edu.cn
RI Li, Changyi/H 4176 2018; chen, bo/AAC 7188 2022; wang,
   ning/AFX 9397 2022; Li, Ying/R 2373 2018
OI Li, Ying/0000 0003 2314 9599
FU National Natural Science Foundation of China [82171008]; Tianjin Science
   and Technology Planning Project [21JCYBJC01530, 21JCQNJC01830]; Science
   and Technology Development Fund of Tianjin Education Commission
   [2022KJ208]; Tianjin Health Research Project [TJWJ2021QN042]
FX This work was funded by the National Natural Science Foundation of
   China, grant number 82171008; the Tianjin Science and Technology
   Planning Project, grant numbers 21JCYBJC01530 and 21JCQNJC01830; the
   Science and Technology Development Fund of Tianjin Education Commission,
   grant number 2022KJ208; and the Tianjin Health Research Project, grant
   number TJWJ2021QN042. We sincerely acknowledge Baoji Lian Zhong Titanium
   Metal Material Co., Ltd., for the precious help in implant design and
   manufacture.
CR Adan C, 2023, SCI TOTAL ENVIRON, V894, DOI 10.1016/j.scitotenv.2023.165017
   Albrektsson T, 2022, CLIN IMPLANT DENT R, V24, P532, DOI 10.1111/cid.13102
   Almoshari Y, 2020, BIOMATERIALS, V261, DOI 10.1016/j.biomaterials.2020.120293
   Berglundh T, 2024, PERIODONTOL 2000, DOI 10.1111/prd.12549
   Biesinger MC, 2010, APPL SURF SCI, V257, P887, DOI 10.1016/j.apsusc.2010.07.086
   Camps Font O, 2018, J PERIODONTOL, V89, P1165, DOI 10.1002/JPER.18 0024
   Chen B, 2020, INT J NANOMED, V15, P2095, DOI 10.2147/IJN.S244349
   Chen D, 2023, ACS APPL MATER INTER, V15, P34378, DOI 10.1021/acsami.3c03446
   Chen WZ, 2017, BIOMATERIALS, V114, P82, DOI 10.1016/j.biomaterials.2016.10.055
   Chen XB, 2011, SCIENCE, V331, P746, DOI 10.1126/science.1200448
   Chen YC, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.860149
   Chen ZT, 2017, ACS NANO, V11, P4494, DOI 10.1021/acsnano.6b07808
   Chung IH, 2010, GENESIS, V48, P645, DOI 10.1002/dvg.20671
   Ding TX, 2023, SMALL, V19, DOI 10.1002/smll.202206265
   Fan WJ, 2016, CHEM COMMUN, V52, P5316, DOI 10.1039/c6cc00903d
   Gu JH, 2023, ACS BIOMATER SCI ENG, V9, P2615, DOI 10.1021/acsbiomaterials.2c01551
   Heyman O, 2022, J CLIN PERIODONTOL, V49, P1217, DOI 10.1111/jcpe.13631
   Hsu MN, 2020, MOL THER, V28, P441, DOI 10.1016/j.ymthe.2019.11.029
   Hu ZC, 2023, BIOACT MATER, V22, P1, DOI 10.1016/j.bioactmat.2022.08.025
   Jao Y, 2023, J DENT SCI, V18, P1453, DOI 10.1016/j.jds.2023.07.002
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Katoh M, 2008, CURR DRUG TARGETS, V9, P565, DOI 10.2174/138945008784911750
   Kim WJ, 2022, BIOMATER RES, V26, DOI 10.1186/s40824 022 00307 0
   Koutouzis T, 2019, PERIODONTOL 2000, V81, P152, DOI 10.1111/prd.12289
   Koutouzis T, 2017, J PERIODONTOL, V88, pE32, DOI 10.1902/jop.2016.160273
   Lausch AJ, 2013, ADV FUNCT MATER, V23, P4906, DOI 10.1002/adfm.201203760
   Li C, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202215906
   Li J, 2023, ADV MATER, V35, DOI 10.1002/adma.202300380
   Li X, 2022, BIOMATERIALS, V287, DOI 10.1016/j.biomaterials.2022.121683
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu BY, 2022, BIOACT MATER, V10, P269, DOI 10.1016/j.bioactmat.2021.09.009
   Liu XF, 2017, APPL CATAL B ENVIRON, V201, P119, DOI 10.1016/j.apcatb.2016.08.031
   Liu Y, 2023, APPL SURF SCI, V614, DOI 10.1016/j.apsusc.2022.156109
   Liu YX, 2020, MAT SCI ENG C MATER, V116, DOI 10.1016/j.msec.2020.111212
   Liu ZW, 2020, COLLOID SURFACE B, V188, DOI 10.1016/j.colsurfb.2020.110781
   Lv BC, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29455 6
   Maeda A, 2015, J BIOL CHEM, V290, P14004, DOI 10.1074/jbc.M114.628818
   Mamat MH, 2022, MATER CHEM PHYS, V288, DOI 10.1016/j.matchemphys.2022.126436
   Naldoni A, 2012, J AM CHEM SOC, V134, P7600, DOI 10.1021/ja3012676
   Ouyang L, 2021, REGEN THER, V18, P24, DOI 10.1016/j.reth.2021.03.003
   Peng H, 2022, ACS NANO, V16, P4756, DOI 10.1021/acsnano.2c00048
   Peng Huan, 2020, Proc Natl Acad Sci U S A, V117, P1951, DOI 10.1073/pnas.1913234117
   Qi MY, 2022, LWT FOOD SCI TECHNOL, V155, DOI 10.1016/j.lwt.2021.112990
   Shao JS, 2005, J CLIN INVEST, V115, P1210, DOI 10.1172/JCI200524140
   Silva JPD, 2023, ACS BIOMATER SCI ENG, V9, P5389, DOI 10.1021/acsbiomaterials.3c00491
   Sun FY, 2023, ADV MATER, V35, DOI 10.1002/adma.202210018
   Sun JJ, 2013, DEVELOPMENT, V140, P1034, DOI 10.1242/dev.085225
   Tao BL, 2023, MATER DESIGN, V233, DOI 10.1016/j.matdes.2023.112268
   Tian YJ, 2022, BIOACT MATER, V9, P428, DOI 10.1016/j.bioactmat.2021.07.033
   Tong LP, 2019, BIOMATERIALS, V193, P1, DOI 10.1016/j.biomaterials.2018.12.008
   Wang CQ, 2022, CHEM ENG J, V445, DOI 10.1016/j.cej.2022.136562
   Wang HJ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100142
   Wang MF, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800351
   Wang RM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 02828 6
   Wang Y, 2019, BIOSENS BIOELECTRON, V131, P163, DOI 10.1016/j.bios.2019.01.064
   Weng ZZ, 2022, BIOMATER SCI UK, V11, P76, DOI 10.1039/d2bm01460b
   Xu YC, 2020, CHEM ENG J, V379, DOI 10.1016/j.cej.2019.122295
   Xu YD, 2021, BIOACT MATER, V6, P1575, DOI 10.1016/j.bioactmat.2020.11.013
   Yang MG, 2022, ADV MATER, V34, DOI 10.1002/adma.202106314
   Yang MG, 2020, CARBON, V166, P350, DOI 10.1016/j.carbon.2020.05.036
   Yuan Z, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119479
   Zhang DZ, 2015, J ALLOY COMPD, V618, P551, DOI 10.1016/j.jallcom.2014.09.004
   Zhang LD, 2023, ADV SCI, V10, DOI 10.1002/advs.202203472
   Zhang M, 2022, PROBIOTICS ANTIMICRO, V14, P169, DOI 10.1007/s12602 021 09857 6
   Zhao HJ, 2020, CELL SIGNAL, V67, DOI 10.1016/j.cellsig.2019.109489
   Zhao YY, 2022, BIOMATERIALS, V288, DOI 10.1016/j.biomaterials.2022.121684
   Zhou SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27273 w
NR 67
TC 14
Z9 14
U1 41
U2 81
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD AUG 28
PY 2024
VL 18
IS 36
BP 24968
EP 24983
DI 10.1021/acsnano.4c05859
EA AUG 2024
PG 16
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA F4J0V
UT WOS:001300768900001
PM 39192736
DA 2025 08 17
ER

PT J
AU Lin, SK
   Wang, HW
   Shun, CT
   Yang, CN
   Hong, CY
   Lai, EHH
   Cheng, SJ
   Chen, MH
   Yang, H
   Lin, HY
   Wu, FY
   Kok, SH
AF Lin, Sze Kwan
   Wang, Han Wei
   Shun, Chia Tung
   Yang, Cheng Ning
   Hong, Chi Yuan
   Lai, Eddie Hsiang Hua
   Cheng, Shih Jung
   Chen, Mu Hsiung
   Yang, Hsiang
   Lin, Hung Ying
   Wu, Fang Yu
   Kok, Sang Heng
TI Sirtuin 6 ameliorates arthritis through modulating cyclic AMP responsive
   element binding protein/CCN1/cyclooxygenase 2 pathway in osteoblasts
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Sirtuin 6; Cyclic AMP responsive element binding protein; CCN1;
   Cyclooxygenase 2; Collagen induced arthritis
ID HYPOXIA INDUCED APOPTOSIS; RICH PROTEIN 61; RHEUMATOID ARTHRITIS;
   SYNOVIAL TISSUE; CCN1 CYR61; ACTIVATION; EXPRESSION; INFLAMMATION;
   INHIBITION; CELECOXIB
AB IntroductionCCN1 is an immediate early gene product pivotal for arthritis progression. We have previously shown that sirtuin 6 (SIRT6) inhibited hypoxia induced CCN1 expression in osteoblasts. Herein we examined the contribution of cyclic AMP responsive element binding protein (CREB)/CRE to this suppressive action and the influence of CCN1 on cyclooxygenase (COX) 2 synthesis.Materials and methodsMC3T3 E1 murine osteoblasts were cultured under normoxia (21% oxygen) or hypoxia (2% oxygen). Expressions of CCN1, phospho CREB (Ser133), COX2 and relevant kinases were assessed by Western blot. SIRT6 was overexpressed in cultured osteoblasts and arthritic joints by a lentiviral based technique. Activities of CCN1 gene promoter constructs were examined by luciferase reporter assay. Interaction between CREB and CCN1 promoter was assessed by chromatin immunoprecipitation (ChIP). Collagen induced arthritis (CIA) was established in 20 rats to evaluate the effects of SIRT6 therapy on osteoblastic expressions of phospho CREB, CCN1 and COX2.ResultsSIRT6 suppressed hypoxia enhanced CCN1 expression and CREB phosphorylation. Attenuation of calcium/calmodulin dependent protein kinase II (CaMKII) may be responsible for SIRT6 induced CREB inhibition. CRE at   286 bp upstream of the ATG start codon was essential for CCN1 expression under hypoxia and SIRT6 reduced hypoxia stimulated CREB/CRE interaction. Forced expression of CREB rescued SIRT6 suppressed CCN1 synthesis. CCN1 induced COX2 expression in osteoblasts. In rat CIA, the therapeutic effect of SIRT6 was accompanied by decreases in osteoblastic expressions of phospho CREB, CCN1 and COX2.ConclusionOur study indicated that the benefits of SIRT6 to inflammatory arthritis and bone resorption are at least partially derived from its modulation of CREB/CCN1/COX2 pathway in osteoblasts.
C1 [Lin, Sze Kwan; Wang, Han Wei; Hong, Chi Yuan; Lai, Eddie Hsiang Hua; Cheng, Shih Jung; Chen, Mu Hsiung; Yang, Hsiang; Lin, Hung Ying; Wu, Fang Yu; Kok, Sang Heng] Natl Taiwan Univ Hosp, Dept Dent, 1 Chang Te St, Taipei, Taiwan.
   [Lin, Sze Kwan; Yang, Cheng Ning; Hong, Chi Yuan; Lai, Eddie Hsiang Hua; Cheng, Shih Jung; Kok, Sang Heng] Natl Taiwan Univ, Sch Dent, Coll Med, Dept Dent, Taipei, Taiwan.
   [Wang, Han Wei] Natl Taiwan Univ, Grad Inst Clin Dent, Coll Med, Sch Dent, Taipei, Taiwan.
   [Shun, Chia Tung] Natl Taiwan Univ Hosp, Dept Forens Med & Pathol, Taipei, Taiwan.
   [Hong, Chi Yuan] Natl Taiwan Univ, Coll Bioresources & Agr, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University
RP Kok, SH (通讯作者)，Natl Taiwan Univ Hosp, Dept Dent, 1 Chang Te St, Taipei, Taiwan.; Kok, SH (通讯作者)，Natl Taiwan Univ, Sch Dent, Coll Med, Dept Dent, Taipei, Taiwan.
EM shkok@ntu.edu.tw
RI ; KOK, SANG HENG/AAJ 5497 2020; Shun, Chia Tung/M 1400 2019
OI SHUN, CHIA TUNG/0000 0002 0468 4468; 
FU National Science and Technology Council, Taiwan [MOST
   109 2314 B 002 034 MY3, MOST 111 2314 B 002 113]; National Taiwan
   University Hospital, Taipei, Taiwan [NTUH 109 S4494, NTUH 110 S4841,
   NTUH 109 S4746, NTUH 111 S0140]
FX The work was supported by Grants from National Science and Technology
   Council, Taiwan (MOST 109 2314 B 002 034 MY3 to SHK and MOST
   111 2314 B 002 113 to SKL) and National Taiwan University Hospital,
   Taipei, Taiwan (NTUH 109 S4494 and NTUH 110 S4841 to SHK and NTUH
   109 S4746 and NTUH 111 S0140 to SKL).
CR Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717
   Chen CY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00513 0
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140 6736(99)02332 6
   Emre Y, 2014, SEMIN IMMUNOPATHOL, V36, P253, DOI 10.1007/s00281 014 0420 1
   Erickson JR, 2008, CELL, V133, P462, DOI 10.1016/j.cell.2008.02.048
   Erickson JR, 2013, NATURE, V502, P372, DOI 10.1038/nature12537
   FALCHUK KH, 1970, AM J MED, V49, P223, DOI 10.1016/S0002 9343(70)80078 X
   Grimley R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039847
   Guclu E, 2022, MOL NEUROBIOL, V59, P7036, DOI 10.1007/s12035 022 03026 8
   He XJ, 2019, EBIOMEDICINE, V41, P538, DOI 10.1016/j.ebiom.2019.02.009
   Hong OY, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 16405 x
   Hou KL, 2017, BIOFACTORS, V43, P170, DOI 10.1002/biof.1320
   Jiang HM, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419 022 04632 z
   Kang RY, 1996, BRIT J RHEUMATOL, V35, P711
   Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052
   Kim SJ, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115497
   Kishimoto K, 2021, ARCH BIOCHEM BIOPHYS, V708, DOI 10.1016/j.abb.2021.108962
   Kok SH, 2015, J ENDODONT, V41, P1631, DOI 10.1016/j.joen.2015.05.008
   Kok SH, 2013, ARTHRITIS RHEUM US, V65, P639, DOI 10.1002/art.37807
   Kok SH, 2011, ARTHRITIS RHEUM US, V63, P1010, DOI 10.1002/art.27433
   Kushwah N, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.669701
   Kwon EJ, 2018, CONNECT TISSUE RES, V59, P245, DOI 10.1080/03008207.2017.1360293
   La Spina M, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/7658501
   Lee HS, 2013, ARTHRITIS RHEUM US, V65, P1776, DOI 10.1002/art.37963
   Lee YL, 2018, INT ENDOD J, V51, pe74, DOI 10.1111/iej.12742
   Li CM, 2010, EUR J PHARMACOL, V649, P100, DOI 10.1016/j.ejphar.2010.08.060
   Li YJ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.861334
   Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078 0432.CCR 04 2639
   Liu G, 2021, MED RES REV, V41, P1089, DOI 10.1002/med.21753
   Lu S, 2020, AGING US, V12, P7042, DOI 10.18632/aging.103062
   LUNDOLESEN K, 1970, ARTHRITIS RHEUM US, V13, P769, DOI 10.1002/art.1780130606
   McEvoy AN, 2004, ARTHRITIS RHEUM US, V50, P1132, DOI 10.1002/art.20157
   Mendes KL, 2017, CYTOKINE GROWTH F R, V38, P98, DOI 10.1016/j.cytogfr.2017.11.001
   Meyuhas R, 2008, MOL CANCER RES, V6, P1397, DOI 10.1158/1541 7786.MCR 07 2086
   Narazaki A, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07521 9
   Nishikawa K, 2021, EMBO REP, V22, DOI 10.15252/embr.202153035
   Noguchi M, 2005, EUR J PHARMACOL, V513, P229, DOI 10.1016/j.ejphar.2005.01.058
   OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888
   Pan Z, 2023, BIOMED PHARMACOTHER, V158, DOI 10.1016/j.biopha.2022.114095
   Schütze N, 2001, J CLIN PATHOL MOL PA, V54, P170, DOI 10.1136/mp.54.3.170
   Seo E, 2022, LIFE SCI, V310, DOI 10.1016/j.lfs.2022.121042
   Shahgaldi S, 2021, LIFE SCI, V282, DOI 10.1016/j.lfs.2021.119803
   Shi T, 2005, J BIOL CHEM, V280, P13560, DOI 10.1074/jbc.M414670200
   Siegle I, 1998, ARTHRITIS RHEUM US, V41, P122, DOI 10.1002/1529 0131(199801)41:1<122::AID ART15>3.3.CO;2 #
   Simon LS, 1999, JAMA J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921
   Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200
   Song MY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29472 5
   Wakisaka S, 1998, ANN RHEUM DIS, V57, P487, DOI 10.1136/ard.57.8.487
   Wei YJ, 2021, J PHYSIOL BIOCHEM, V77, P577, DOI 10.1007/s13105 021 00822 z
   Xiao CY, 2012, J BIOL CHEM, V287, P41903, DOI 10.1074/jbc.M112.415182
   Xiao JJ, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117660
   Xu T, 2016, GENE, V592, P179, DOI 10.1016/j.gene.2016.07.053
   Yang YY, 2022, J CELL PHYSIOL, V237, P3205, DOI 10.1002/jcp.30791
   Zhang RH, 2018, J CELL BIOCHEM, V119, P9141, DOI 10.1002/jcb.27176
   Zhang S, 2018, FREE RADICAL BIO MED, V115, P18, DOI 10.1016/j.freeradbiomed.2017.11.005
   Zhang Z, 2021, J BONE MINER RES, V36, P579, DOI 10.1002/jbmr.4207
NR 57
TC 1
Z9 2
U1 1
U2 12
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD NOV
PY 2023
VL 41
IS 6
BP 772
EP 784
DI 10.1007/s00774 023 01468 1
EA OCT 2023
PG 13
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA AZ9P9
UT WOS:001095054600001
PM 37898986
DA 2025 08 17
ER

PT J
AU Kim, ME
   Seon, JK
   Kang, JY
   Yoon, TR
   Lee, JS
   Kim, HK
AF Kim, Mi Eun
   Seon, Jong Keun
   Kang, Ju Yeon
   Yoon, Taek Rim
   Lee, Jun Sik
   Kim, Hyung Keun
TI Bone Forming Peptide 4 Induces Osteogenic Differentiation and VEGF
   Expression on Multipotent Bone Marrow Stromal Cells
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE bone morphogenetic proteins; bone forming peptides; osteogenic
   differentiation; bone formation; VEGF
ID REGENERATION; BMP 7
AB Bone morphogenetic proteins (BMPs) have been widely used as treatment for bone repair. However, clinical trials on fracture repair have challenged the effectiveness of BMPs and suggested that delivery of multipotent bone marrow stromal cells (BMSCs) might be beneficial. During bone remodeling and bone fracture repair, multipotent BMSCs differentiate into osteoblasts or chondrocytes to stimulate bone formation and regeneration. Stem cell based therapies provide a promising approach for bone formation. Extensive research has attempted to develop adjuvants as specific stimulators of bone formation for therapeutic use in patients with bone resorption. We previously reported for the first time bone forming peptides (BFPs) that induce osteogenesis and bone formation. BFPs are also a promising osteogenic factor for prompting bone regeneration and formation. Thus, the aim of the present study was to investigate the underlying mechanism of a new BFP 4 (FFKATEVHFRSIRST) in osteogenic differentiation and bone formation. This study reports that BFP 4 induces stronger osteogenic differentiation of BMSCs than BMP 7. BFP 4 also induces ALP activity, calcium concentration, and osteogenic factors (Runx2 and osteocalcin) in a dose dependent manner in BMSCs. Therefore, these results indicate that BFP 4 can induce osteogenic differentiation and bone formation. Thus, treatment of multipotent BMSCs with BFP 4 enhanced osteoblastic differentiation and displayed greater bone forming ability than BMP 7 treatment. These results suggest that BFP 4 stimulated cell therapy may be an efficient and cost effective complement to BMP 7 based clinical therapy for bone regeneration and formation.
C1 [Kim, Mi Eun; Lee, Jun Sik] Chosun Univ, Coll Nat Sci, Integrat Biol Sci, Dept Biol,Immunol Res Lab, Gwangju, South Korea.
   [Kim, Mi Eun; Lee, Jun Sik] Chosun Univ, Coll Nat Sci, BK21 Educ Res Grp Age Associated Disorder Control, Gwangju, South Korea.
   [Seon, Jong Keun; Kang, Ju Yeon; Yoon, Taek Rim; Kim, Hyung Keun] Chonnam Natl Univ Hosp, Korea Biomed Mat & Devices Innovat Res Ctr, Gwangju, South Korea.
   [Seon, Jong Keun; Kang, Ju Yeon; Yoon, Taek Rim; Kim, Hyung Keun] Chonnam Natl Univ, Hwasun Hosp, Ctr Joint Dis, Dept Orthopaed Surg, Jeonnam, South Korea.
C3 Chosun University; Chosun University; Chonnam National University;
   Chonnam National University Hospital; Chonnam National University
RP Lee, JS (通讯作者)，Chosun Univ, Coll Nat Sci, Integrat Biol Sci, Dept Biol,Immunol Res Lab, Gwangju, South Korea.; Lee, JS (通讯作者)，Chosun Univ, Coll Nat Sci, BK21 Educ Res Grp Age Associated Disorder Control, Gwangju, South Korea.; Kim, HK (通讯作者)，Chonnam Natl Univ Hosp, Korea Biomed Mat & Devices Innovat Res Ctr, Gwangju, South Korea.; Kim, HK (通讯作者)，Chonnam Natl Univ, Hwasun Hosp, Ctr Joint Dis, Dept Orthopaed Surg, Jeonnam, South Korea.
EM junsiklee@chosun.ac.kr; chemokines@naver.com
FU National Research Foundation of Korea (NRF) grant [2017R1A2B4008676,
   2018R1D1A1B07048920, NRF 2016M3A9E9941832, NRF 2020R1A2C1012984]
FX This research was supported by the National Research Foundation of Korea
   (NRF) grant (Nos. 2017R1A2B4008676, 2018R1D1A1B07048920,
   NRF 2016M3A9E9941832, and NRF 2020R1A2C1012984).
CR Chang SCN, 2009, ARTIF ORGANS, V33, P301, DOI 10.1111/j.1525 1594.2009.00728.x
   Chen WC, 2018, BIOCHEM PHARMACOL, V150, P254, DOI 10.1016/j.bcp.2018.02.021
   Douglas TEL, 2018, J DAIRY SCI, V101, P28, DOI 10.3168/jds.2017 13119
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Geng W, 2019, MOL MED REP, V20, P664, DOI 10.3892/mmr.2019.10257
   Hamamura K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184619
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Kim B, 2018, CELL SIGNAL, V49, P68, DOI 10.1016/j.cellsig.2018.06.001
   Kim HK, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.40
   Kim HK, 2012, BIOMATERIALS, V33, P7057, DOI 10.1016/j.biomaterials.2012.06.036
   Kumar G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205154
   Lee JS, 2018, STEM CELL RES, V26, P28, DOI 10.1016/j.scr.2017.11.016
   Lerner UH, 2019, J CLIN PERIODONTOL, V46, P33, DOI 10.1111/jcpe.13051
   Li JH, 2010, J BIOMED MATER RES A, V95A, P973, DOI 10.1002/jbm.a.32926
   Narasimhulu CA, 2020, CELLS BASEL, V9, DOI 10.3390/cells9020280
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Sangadala S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081900
   Shen BJ, 2010, J CELL BIOCHEM, V109, P406, DOI 10.1002/jcb.22412
   Veselá B, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00124
   Yang F, 2018, CELL PHYSIOL BIOCHEM, V46, P2561, DOI 10.1159/000489684
   Yang L, 2018, MOL OMICS, V14, P341, DOI 10.1039/c8mo00128f
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
NR 23
TC 10
Z9 11
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD OCT 6
PY 2021
VL 9
AR 734483
DI 10.3389/fbioe.2021.734483
PG 8
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA WL0KH
UT WOS:000710104800001
PM 34692657
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Luo, ZG
   Xiao, L
   Li, J
   Dong, BH
   Wang, CS
AF Luo, Zhenguo
   Xiao, Li
   Li, Jing
   Dong, Buhuai
   Wang, Chunsheng
TI Integrative analysis reveals driver long non coding RNAs in osteosarcoma
SO MEDICINE
LA English
DT Article
DE biomarkers; expression profiling; integrative analysis; long non coding
   RNA; osteosarcoma
ID CANCER GENOME; PROGRESSION; SURVIVAL; TUMOR; PROLIFERATION;
   TUMORIGENESIS; CHEMOTHERAPY; CONTRIBUTES; EXPRESSION; APOPTOSIS
AB Transcriptome profiling of osteosarcoma (OS) by next generation sequencing technology (NGS) has been broadly performed by previous researches, which uncovers a large number protein coding driver genes, facilitates our understanding of the molecular mechanisms of OS formation, progression and metastasis. Recently, more and more researchers realize the importance of long non coding RNAs (lncRNAs) on the development of OS. However, few studies focus on discovering driver lncRNAs.Here we collected somatic copy number alterations (SCNAs) and gene expression profiles of 84 samples from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) project. The RNA sequencing data detected 13,903 expressed lncRNAs, 157 of which were previously reported to be associated with cancer based on the annotations from Lnc2Cancer database.By analyzing the SNP array data, several significant SCNAs were detected, such as the amplifications on chromosomes 1q, 4q, 17p, 17q, and 19q, and deletions on 1q, 3q, 9p, 10q, and 15q. With the SCNA and gene expression profiles, we identified 167 driver genes by integrative analysis, including 162 novel driver lncRNAs, 2 lncRNAs reported to be associated with OS, and another 3 associated with other cancers. Furthermore, functional characterization and survival analysis revealed that RP11 241F15.10 may function as a tumor suppressor in OS, and loss of function may contribute to activation of Wnt signaling pathway.This study not only facilitates our understanding of the oncogenic or tumor suppressor role of lncRNAs in OS, but also provides potential therapies for the patients with OS with metastasis or relapse.
C1 [Luo, Zhenguo; Wang, Chunsheng] Xi An Jiao Tong Univ, Dept Orthoped, Affiliated Hosp 2, 157 Xiwu Rd, Xian 710004, Shannxi Provinc, Peoples R China.
   [Luo, Zhenguo; Xiao, Li; Dong, Buhuai] Xi An Jiao Tong Univ, Dept Anesthesiol, Honghui Hosp, Xian, Shannxi Provinc, Peoples R China.
   [Li, Jing] Fourth Hosp Xian, Dept Intens Care Unit, Xian, Shannxi Provinc, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University
RP Wang, CS (通讯作者)，Xi An Jiao Tong Univ, Dept Orthoped, Affiliated Hosp 2, 157 Xiwu Rd, Xian 710004, Shannxi Provinc, Peoples R China.
EM doctor_wcs@163.com
CR Arora RS, 2011, CANCER CAUSE CONTROL, V22, P681, DOI 10.1007/s10552 011 9740 9
   Bernthal NM, 2012, CANCER AM CANCER SOC, V118, P5888, DOI 10.1002/cncr.27651
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Chen SF, 2015, INT J ENV RES PUB HE, V12, P11178, DOI 10.3390/ijerph120911178
   Ding J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.84
   Fang ZY, 2016, CANCER LETT, V374, P62, DOI 10.1016/j.canlet.2016.01.033
   Gentile A, 2008, CANCER METAST REV, V27, P85, DOI 10.1007/s10555 007 9107 6
   He PH, 2016, AM J TRANSL RES, V8, P1780
   JAFFE N, 1974, NEW ENGL J MED, V291, P994, DOI 10.1056/NEJM197411072911902
   Jiang N, 2017, CANCER LETT, V405, P46, DOI 10.1016/j.canlet.2017.06.009
   Jiang Z, 2018, BIOCHEM BIOPH RES CO, V495, P238, DOI 10.1016/j.bbrc.2017.11.012
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Li M, 2016, DNA CELL BIOL, V35, P235, DOI 10.1089/dna.2015.3171
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Liu CB, 2016, AM J TRANSL RES, V8, P4095
   Liu GF, 2017, AM J CANCER RES, V7, P1450
   Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795
   Meyers PA, 2011, CANCER AM CANCER SOC, V117, P1736, DOI 10.1002/cncr.25744
   Mirabello L, 2011, CANCER CAUSE CONTROL, V22, P899, DOI 10.1007/s10552 011 9763 2
   Musselman JRB, 2012, INT J MOL EPIDEMIOL, V3, P286
   Ning SW, 2016, NUCLEIC ACIDS RES, V44, pD980, DOI 10.1093/nar/gkv1094
   Pasic I, 2010, CANCER RES, V70, P160, DOI 10.1158/0008 5472.CAN 09 1902
   Ravasi T, 2006, GENOME RES, V16, P11, DOI 10.1101/gr.4200206
   Razek A, 2012, RADIOL MED, V117, P96, DOI 10.1007/s11547 011 0709 2
   Razek AAKA, 2010, J NEURORADIOLOGY, V37, P37, DOI 10.1016/j.neurad.2009.08.006
   Razek AAKA, 2017, EUR J RADIOL, V89, P221, DOI 10.1016/j.ejrad.2017.02.015
   Rong L, 2017, BIOCHEM BIOPH RES CO, V484, P586, DOI 10.1016/j.bbrc.2017.01.141
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653
   Song W, 2018, ONCOL RES, V26, P261, DOI 10.3727/096504017X15031557924132
   Stiller CA, 2006, EUR J CANCER, V42, P2006, DOI 10.1016/j.ejca.2006.05.015
   Stiller CA, 2001, EUR J CANCER, V37, P760, DOI 10.1016/S0959 8049(01)00004 1
   Surov A, 2015, SKELETAL RADIOL, V44, P995, DOI 10.1007/s00256 015 2141 5
   Tian ZZ, 2015, INT J CLIN EXP PATHO, V8, P15138
   Tong GL, 2017, AM J TRANSL RES, V9, P4545
   Wang FQ, 2016, CELL PHYSIOL BIOCHEM, V40, P287, DOI 10.1159/000452545
   Wang Y, 2016, CANCER LETT, V382, P137, DOI 10.1016/j.canlet.2016.08.024
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Xie CH, 2016, TUMOR BIOL, V37, P15031, DOI 10.1007/s13277 016 5391 5
   Yang Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14421
   Zhou Q, 2016, ONCOTARGET, V7, P82620, DOI 10.18632/oncotarget.13012
NR 40
TC 8
Z9 9
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB
PY 2019
VL 98
IS 6
AR e14302
DI 10.1097/MD.0000000000014302
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA HQ6ZR
UT WOS:000462569300029
PM 30732148
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Song, HM
   Wei, YC
   Li, N
   Wu, B
   Xie, N
   Zhang, KM
   Wang, SZ
   Wang, HM
AF Song, Hong Mei
   Wei, Ying Chen
   Li, Nan
   Wu, Bin
   Xie, Na
   Zhang, Kun Mu
   Wang, Shi Zhong
   Wang, He Ming
TI Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK
   and RANKL in rabbits with steroid induced femoral head avascular
   necrosis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE steroid induced avascular necrosis of the femoral head; Wenyangbushen
   formula; vascular endothelial growth factor; OPG RANK RANKL signaling
   pathways
ID ENDOTHELIAL GROWTH FACTOR; INDUCED OSTEONECROSIS; RECEPTOR ACTIVATOR;
   GENE EXPRESSION; IN VITRO; BONE; OSTEOPROTEGERIN; HIP; RANKL/RANK/OPG;
   INHIBITION
AB The present study aimed to investigate the effects of Wenyangbushen formula on the mRNA and protein expression levels of vascular endothelial growth factor (VEGF), osteoprotegerin (OPG), receptor activator of nuclear factor (NF)  ligand (RANK), and RANK ligand (RANKL) in a rabbit model of steroid induced avascular necrosis of the femoral head (SANFH). The present study also aimed to examine the potential mechanism underlying the effect of this formula on the treatment of SANFH. A total of 136 New Zealand rabbits were randomly divided into five groups: Normal group, model group, and three groups treated with the traditional Chinese medicine (TCM), Wenyangbushen decoction, at a low, moderate and high dose, respectively. The normal group and positive control group were intragastrically administered with saline. The TCM groups were treated with Wenyangbushen decoction at the indicated dosage. Following treatment for 8 weeks, the mRNA and protein expression levels of VEGF, OPG, RANK and RANKL in the femoral head tissues were determined using reverse transcription quantitative polymerase chain reaction and western blot analyses, respectively. The data revealed that Wenyangbushen decoction effectively promoted the growth of bone cells, osteoblasts and chondrocytes, and prevented cell apoptosis in the SANFH. The mRNA and protein expression levels of OPG and VEGF were increased, while the levels of RANK and RANKL were reduced in the necrotic tissue of the model group, compared with those in the normal rabbits. Wenyangbushen treatment prevented these changes, manifested by an upregulation in the expression levels of VEGF and OPG, and downregulation in the expression levels of RANK and RANKL in a dose dependent manner. It was concluded that treatment with Wenyangbushen formula alleviated necrosis of the femoral head induced by steroids. It was observed to promote bone cell, osteoblast and chondrocyte growth, as well as prevent cell apoptosis. In addition, it upregulated the expression levels of OPG and VEGF, and inhibited the expression levels of RANK and RANKL. These results suggest the potential use of Wenyangbushen formula as a possible approach for the effective treatment of SANFH.
C1 [Song, Hong Mei; Wu, Bin; Zhang, Kun Mu] Fujian Tradit Chinese Med Univ, Affiliated Peoples Hosp 2, Dept Rehabil, Fuzhou 350003, Fujian, Peoples R China.
   [Song, Hong Mei; Wei, Ying Chen; Li, Nan; Wang, He Ming] Fujian Tradit Chinese Med Univ, Dept Orthoped, Fuzhou 350003, Fujian, Peoples R China.
   [Xie, Na] Harrison Int Peace Hosp, Qual Control Dept, Hengshui 053000, Hebei, Peoples R China.
   [Wang, Shi Zhong] Fujian Vocat Coll Bioengn, Fuzhou 350002, Fujian, Peoples R China.
RP Wang, HM (通讯作者)，Fujian Tradit Chinese Med Univ, Dept Orthoped, 1 Huatuo Rd, Fuzhou 350003, Fujian, Peoples R China.
EM 1365866912@qq.com; whm27@163.com
RI Wang, Heming/HKF 0311 2023
FU National Natural Science Foundation of China [81173283]; Fujian Province
   Educational Department [JA13156]
FX This study was supported by grants from the National Natural Science
   Foundation of China (grant. no. 81173283) and Project of Fujian Province
   Educational Department (grant. no. JA13156).
CR [Anonymous], EVID BASED COMPLEMEN, DOI [10.1155/2015/184802256481664305618, DOI 10.1155/2015/18480225648166]
   Bai YD, 2008, MED HYPOTHESES, V71, P256, DOI 10.1016/j.mehy.2008.03.021
   Beckmann R, 2014, SCI WORLD J, DOI 10.1155/2014/347813
   Bekler Halil, 2007, Acta Orthop Traumatol Turc, V41, P58
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen Wei Heng, 2011, Zhongguo Gu Shang, V24, P352
   Geusens P, 2012, THER ADV MUSCULOSKEL, V4, P225, DOI 10.1177/1759720X12438080
   Hofstaetter JG, 2009, OSTEOARTHR CARTILAGE, V17, P362, DOI 10.1016/j.joca.2008.07.013
   Kim HKW, 2006, J BONE MINER RES, V21, P1946, DOI 10.1359/JBMR.060905
   Lee YJ, 2012, J ORTHOP RES, V30, P21, DOI 10.1002/jor.21492
   Mandelin J, 2003, J BONE JOINT SURG BR, V85B, P1196, DOI 10.1302/0301 620X.85B8.13311
   Seamon J, 2012, ARTHRITIS, DOI 10.1155/2012/601763
   Sheng H, 2013, INT J CLIN EXP PATHO, V6, P1046
   Shiotani A, 2002, ANAT REC, V268, P137, DOI 10.1002/ar.10121
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steffen RT, 2010, J BONE JOINT SURG BR, V92B, P787, DOI 10.1302/0301 620X.92B6.23377
   Tong PJ, 2011, CALCIFIED TISSUE INT, V89, P271, DOI 10.1007/s00223 011 9516 y
   Varoga D, 2009, CLIN ORTHOP RELAT R, V467, P3273, DOI 10.1007/s11999 009 1076 3
   Wang G, 2010, J INT MED RES, V38, P1060, DOI 10.1177/147323001003800333
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
   Yang L, 2009, J ORTHOP RES, V27, P169, DOI 10.1002/jor.20733
   Yeh LCC, 1999, MOL CELL ENDOCRINOL, V153, P113, DOI 10.1016/S0303 7207(99)00076 3
   Zhong XY, 2015, MOL MED REP, V12, P1699, DOI 10.3892/mmr.2015.3566
NR 24
TC 14
Z9 20
U1 0
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2015
VL 12
IS 6
BP 8155
EP 8161
DI 10.3892/mmr.2015.4478
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CZ6CT
UT WOS:000367189500044
PM 26496816
OA Bronze
DA 2025 08 17
ER

PT J
AU Nabeshima, Y
   Washida, M
   Tamura, M
   Maeno, A
   Ohnishi, M
   Shiroishi, T
   Imura, A
   Razzaque, MS
   Nabeshima, Y
AF Nabeshima, Yoko
   Washida, Miwa
   Tamura, Masaru
   Maeno, Akiteru
   Ohnishi, Mutsuko
   Shiroishi, Toshihiko
   Imura, Akihiro
   Razzaque, M. Shawkat
   Nabeshima, Yo ichi
TI Calpain 1 inhibitor BDA 410 ameliorates α klotho deficiency phenotypes
   resembling human aging related syndromes
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH FACTOR 23; VITAMIN D; VASCULAR CALCIFICATION;
   PARATHYROID HORMONE; PHOSPHATE TOXICITY; MOUSE MODEL; MECHANISMS;
   RECEPTOR; FGF23; 1,25 DIHYDROXYVITAMIN D
AB Taking good care of elderly is a major challenge of our society, and thus identification of potential drug targets to reduce age associated disease burden is desirable. alpha klotho( / ) (alpha kl) is a short lived mouse model that displays multiple phenotypes resembling human aging related syndromes. Such ageing phenotype of alpha kl( / ) mice is associated with activation of a proteolytic enzyme, Calpain 1. We hypothesized that uncontrolled activation of calpain 1 might be causing age related phenotypes in alpha kl deficient mice. We found that daily administration of BDA 410, a calpain 1 inhibitor, strikingly ameliorated multiple aging related phenotypes. Treated mice showed recovery of reproductive ability, increased body weight, reduced organ atrophy, and suppression of ectopic calcifications, bone mineral density reduction, pulmonary emphysema and senile atrophy of skin. We also observed ectopic expression of FGF23 in calcified arteries of alpha kl( / ) mice, which might account for the clinically observed association of increased FGF23 level with increased risk of cardiovascular mortality. These findings allow us to propose that modulation of calpain 1 activity is a potential therapeutic option for delaying age associated organ pathology, particularly caused by the dysregulation of mineral ion homeostasis.
C1 [Nabeshima, Yoko; Washida, Miwa; Imura, Akihiro; Nabeshima, Yo ichi] Fdn Biomed Res & Innovat, Inst Biomed Res & Innovat, Lab Mol Life Sci, 2 2 Minatojima Minamimachi Chuo Ku, Kobe, Hyogo 6500047, Japan.
   [Tamura, Masaru; Maeno, Akiteru; Shiroishi, Toshihiko] Natl Inst Genet, Mammalian Genet Lab, Genet Strains Res Ctr, Mishima, Shizuoka 4118540, Japan.
   [Ohnishi, Mutsuko; Razzaque, M. Shawkat] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Razzaque, M. Shawkat] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA.
C3 Institute for Biomedical Research & Innovation (IBRI); Research
   Organization of Information & Systems (ROIS); National Institute of
   Genetics (NIG)   Japan; Harvard University; Harvard School of Dental
   Medicine; Harvard University; Harvard University Medical Affiliates;
   Forsyth Institute
RP Nabeshima, Y (通讯作者)，Fdn Biomed Res & Innovat, Inst Biomed Res & Innovat, Lab Mol Life Sci, 2 2 Minatojima Minamimachi Chuo Ku, Kobe, Hyogo 6500047, Japan.
EM nabemr@lmls kobe.org
RI Tamura, Masaru/D 1416 2017; Razzaque, Mohammed/K 4282 2019
FU Ministry of Education, Culture, Sports, Science and Technology
   [22229003]; Grants in Aid for Scientific Research [22229003] Funding
   Source: KAKEN
FX We are grateful to all staff of the animal facility center RIKEN CDB,
   Dr. Rene St Arnaud for supplying cyp27b1<SUP> / </SUP> mice, and
   Mitsubishi Tanabe Pharma Corporation Tokyo, Japan for supplying BDA 410.
   We thank K. Yurugi for technical assistance and Drs. T. Tsuruyama, T.
   Tanaka, R. Maeda, Y. Hashimoto, N. Nakamura, and K. Kobayashi for
   helpful suggestions and critical discussions. This work was supported by
   a grant in aid for Scientific Research (S) (22229003, to Y.N.) from the
   Ministry of Education, Culture, Sports, Science and Technology.
CR Alonso L, 2006, J CELL SCI, V119, P391, DOI 10.1242/jcs02793
   Bhattacharyya N, 2012, TRENDS ENDOCRIN MET, V23, P610, DOI 10.1016/j.tem.2012.07.002
   Calleja Agius J, 2007, Menopause Int, V13, P60, DOI 10.1258/175404507780796325
   Campbell RL, 2012, BIOCHEM J, V447, P335, DOI 10.1042/BJ20120921
   Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135
   De Franceschi L, 2013, FASEB J, V27, P750, DOI 10.1096/fj.12 217836
   Demay MB, 2006, ANN NY ACAD SCI, V1068, P204, DOI 10.1196/annals.1346.026
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Johnson CS, 2006, ANTICANCER RES, V26, P2543
   Johnson CS, 2002, CANCER METAST REV, V21, P147, DOI 10.1023/A:1020836226594
   Kendrick J, 2011, AM J KIDNEY DIS, V58, P826, DOI 10.1053/j.ajkd.2011.07.020
   Koh N, 2001, BIOCHEM BIOPH RES CO, V280, P1015, DOI 10.1006/bbrc.2000.4226
   Komaba H, 2012, NAT REV NEPHROL, V8, P484, DOI 10.1038/nrneph.2012.116
   Kovesdy CP., 2013, Nephrol Dial Transplant
   Kuizon BD, 1999, J BONE MINER RES, V14, P1680, DOI 10.1359/jbmr.1999.14.10.1680
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636
   Li XR, 2007, MOL BIOCHEM PARASIT, V155, P26, DOI 10.1016/j.molbiopara.2007.05.004
   London GM, 1997, KIDNEY INT, V51, P1678, DOI 10.1038/ki.1997.233
   Manya H, 2002, J BIOL CHEM, V277, P35503, DOI 10.1074/jbc.M206033200
   Mathew S, 2008, J AM SOC NEPHROL, V19, P1092, DOI 10.1681/ASN.2007070760
   Medici D, 2008, J CELL BIOL, V182, P459, DOI 10.1083/jcb.200803024
   Mellgren RL, 2007, J BIOL CHEM, V282, P35868, DOI 10.1074/jbc.M706929200
   MILLINER DS, 1990, KIDNEY INT, V38, P931, DOI 10.1038/ki.1990.293
   Moe SM, 2005, KIDNEY INT, V67, P2295, DOI 10.1111/j.1523 1755.2005.00333.x
   Nakatani T, 2009, FASEB J, V23, P433, DOI 10.1096/fj.08 114397
   Narvaez CJ, 2001, STEROIDS, V66, P301, DOI 10.1016/S0039 128X(00)00202 6
   Ohnishi M, 2010, FASEB J, V24, P3562, DOI 10.1096/fj.09 152488
   Ohnishi M, 2009, KIDNEY INT, V75, P1166, DOI 10.1038/ki.2009.24
   Proudfoot D, 2006, NEPHROLOGY, V11, P455, DOI 10.1111/j.1440 1797.2006.00660.x
   Quarles LD, 2012, EXP CELL RES, V318, P1040, DOI 10.1016/j.yexcr.2012.02.027
   Razzaque MS, 2011, CLIN SCI, V120, P91, DOI 10.1042/CS20100377
   Razzaque MS, 2006, TRENDS MOL MED, V12, P298, DOI 10.1016/j.molmed.2006.05.002
   Razzaque MS, 2006, FASEB J, V20, P720, DOI 10.1096/fj.05 5432fje
   Rostand SG, 1999, KIDNEY INT, V56, P383, DOI 10.1046/j.1523 1755.1999.00575.x
   Sage AP, 2010, NAT REV CARDIOL, V7, P528, DOI 10.1038/nrcardio.2010.115
   Sato A, 2007, P NATL ACAD SCI USA, V104, P2361, DOI 10.1073/pnas.0607882104
   Sergeev IN, 2009, BIOCHEM BIOPH RES CO, V384, P18, DOI 10.1016/j.bbrc.2009.04.078
   Sergeev IN, 2005, J STEROID BIOCHEM, V97, P145, DOI 10.1016/j.jsbmb.2005.06.007
   Shao JS, 2010, HYPERTENSION, V55, P579, DOI 10.1161/HYPERTENSIONAHA.109.134205
   Stubbs JR, 2007, J AM SOC NEPHROL, V18, P2116, DOI 10.1681/ASN.2006121385
   Subramanian V, 2012, J CARDIOVASC PHARM, V59, P66, DOI 10.1097/FJC.0b013e318235d5ea
   Trinchese F, 2008, J CLIN INVEST, V118, P2796, DOI 10.1172/JCI34254
   Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003 0048
   Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315
   Ureña P, 1999, KIDNEY INT, V55, P2141, DOI 10.1046/j.1523 1755.1999.00461.x
   Wallin R, 2001, MED RES REV, V21, P274, DOI 10.1002/med.1010.abs
   WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165 6147(94)90090 6
   Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683
NR 50
TC 21
Z9 24
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD AUG 1
PY 2014
VL 4
AR 5847
DI 10.1038/srep05847
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AM5ZR
UT WOS:000339940500001
PM 25080854
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Andrade, RC
   Boroni, M
   Amazonas, MK
   Vargas, FR
AF Andrade, Raissa Coelho
   Boroni, Mariana
   Amazonas, Marion Kielmanowicz
   Vargas, Fernando Regla
TI New drug candidates for osteosarcoma: Drug repurposing based on gene
   expression signature
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Osteosarcoma; Microarray expression data; Gene expression signature;
   Drug repurposing; Afatinib
ID STEM CELLS; BIOLOGY; TUMOR
AB Osteosarcoma (OS) is an aggressive bone malignancy and the third most common cancer in adolescence. Since the late 1970s, OS therapy and prognosis had only modest improvements, making it appealing to explore new tools that could help ameliorate the treatment. We present a meta analysis of the gene expression signature of primary OS, and propose small molecules that could reverse this signature. The meta analysis was performed using GEO microarray series. We first compared gene expression from eleven primary OS against osteoblasts to obtain the differentially expressed genes (DEGs). We later filtered those DEGs by verifying which ones had a concordant direction of differential expression in a validation group of 82 OS samples versus 30 bone marrow mesenchymal stem cells (BM MSC) samples. A final gene expression signature of 266 genes (98 up and 168 down regulated) was obtained. The L1000CDS(2) engine was used for drug repurposing. The top molecules predicted to reverse the signature were afatinib (PubChem CID 10184653), BRD K95196255 (PubChem CID 3242434), DG 041 (PubChem CID 11296282) and CA 074 Me (PubChem CID 23760717). Afatinib (Gilotrif (TM)) is currently used for metastatic non small cell lung cancer with EGFR mutations, and in vitro evidence shows antineoplastic potential in OS cells. The other three molecules have reports of antineoplastic effects, but are not currently FDA approved. Further studies are necessary to establish the potential of these drugs in OS treatment. We believe our results can be an important contribution for the investigation of new therapeutic genetic targets and for selecting new drugs to be tested for OS.
C1 [Andrade, Raissa Coelho; Amazonas, Marion Kielmanowicz; Vargas, Fernando Regla] Oswaldo Cruz Fdn FIOCRUZ, Birth Defects Epidemiol Lab, Av. Brasil 4365 Pavilhao Leonidas deane Sala 617, Rio De Janeiro, Brazil.
   [Andrade, Raissa Coelho; Vargas, Fernando Regla] State Rio Janeiro UNIRIO, Fed Univ, Genet & Mol Biol Dept, Rio De Janeiro, Brazil.
   [Boroni, Mariana] Brazilian Natl Canc Inst INCA, Div Expt & Translat Res, Bioinformat & Computat Biol Lab, Rio De Janeiro, Brazil.
   [Boroni, Mariana] Univ Campinas UNICAMP, Expt Med Res Cluster EMRC, Campinas, Brazil.
C3 Fundacao Oswaldo Cruz; National Cancer Institute (Inca); Universidade
   Estadual de Campinas
RP Vargas, FR (通讯作者)，Oswaldo Cruz Fdn FIOCRUZ, Birth Defects Epidemiol Lab, Av. Brasil 4365 Pavilhao Leonidas deane Sala 617, Rio De Janeiro, Brazil.; Vargas, FR (通讯作者)，State Rio Janeiro UNIRIO, Fed Univ, Genet & Mol Biol Dept, Rio De Janeiro, Brazil.
EM fernando.vargas@ioc.fiocruz.br
RI Vargas, Fernando/V 1934 2019; Boroni, Mariana/AAQ 2019 2020
OI Andrade, Raissa/0000 0001 6363 6215; 
FU Inova Fiocruz
FX We thank Nicole de Miranda Scherer, Daniel Andrade Moreira and Jessica
   Goncalves Vieira da Cruz for the orientations during the computational
   analyses. We also thank Inova Fiocruz for the financial support. This
   work is dedicated to the memory of Nilton Barreto dos Santos, dear
   friend and great scientist.
CR Abarrategi A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3631764
   [Anonymous], 2017, Pediatric Cancer in Africa: A Case Based Guide to Diagnosis and Management, DOI [DOI 10.1007/978 3 319 17936 0, 10.1007/978 3 319 17936 0]
   Ballatori SE, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2016.1
   Barbaric D, 2006, LEUKEMIA RES, V30, P1355, DOI 10.1016/j.leukres.2006.03.009
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Bougeard G, 2015, J CLIN ONCOL, V33, P2345, DOI 10.1200/JCO.2014.59.5728
   Brown HK, 2018, CALCIFIED TISSUE INT, V102, P174, DOI 10.1007/s00223 017 0372 2
   Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431
   Chen SF, 2015, INT J ENV RES PUB HE, V12, P11178, DOI 10.3390/ijerph120911178
   Cho SY, 2004, J BIOL CHEM, V279, P16050, DOI 10.1074/jbc.M305758200
   Collier CD, 2016, J ORTHOP RES, V34, pS1, DOI [10.1002/jor.23247.S1, DOI 10.1002/JOR.23247.S1]
   Cruz Ramos M, 2020, J CANCER RES CLIN, V146, P1693, DOI 10.1007/s00432 020 03220 y
   Duan QN, 2016, NPJ SYST BIOL APPL, V2, DOI 10.1038/npjsba.2016.15
   Dungo RT, 2013, DRUGS, V73, P1503, DOI 10.1007/s40265 013 0111 6
   Ertel A, 2006, MOL CANCER, V5, DOI 10.1186/1476 4598 5 55
   Fagone P, 2017, SCI REP UK, V7, DOI 10.1038/srep44564
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Guillem Llobat P, 2016, ONCOTARGET, V7, P32462, DOI 10.18632/oncotarget.8655
   Huang ZX, 2014, INDIAN J OTOLARYNGOL, V66, pS120, DOI 10.1007/s12070 011 0359 7
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Karatzas E, 2019, METHODS MOL BIOL, V1903, P149, DOI 10.1007/978 1 4939 8955 3_9
   Keenan AB, 2018, CELL SYST, V6, P13, DOI 10.1016/j.cels.2017.11.001
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kingsmore KM, 2020, NAT REV RHEUMATOL, V16, P32, DOI 10.1038/s41584 019 0337 0
   Kwon OS, 2019, ARCH PHARM RES, V42, P879, DOI 10.1007/s12272 019 01176 3
   Leek Jt T.L., 2020, R PACKAGE
   Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401
   Liu WH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0363 x
   Longhi A, 2008, J CLIN ONCOL, V26, P5368, DOI 10.1200/JCO.2007.14.9104
   Lu Y, 2015, ONCOL LETT, V10, P2123, DOI 10.3892/ol.2015.3535
   Makielski KM, 2019, VET SCI, V6, DOI 10.3390/vetsci6020048
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   Musa A., 2017, BRIEFINGS BIOINF, V19, DOI [10.1093/bib/bbw112bbw11, DOI 10.1093/BIB/BBW112BBW11]
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   NIH, LINCS DAT PORT CELLS
   Otoukesh B, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935 018 0654 4
   Patel N, 2015, J ORTHOP RES, V33, P1474, DOI 10.1002/jor.22795
   Pezzulo AA, 2019, J CLIN INVEST, V129, P744, DOI 10.1172/JCI123524
   Prater Stephanie., 2019, Cancer, Osteosarcoma
   Ribi S, 2015, ONCOTARGET, V6, P7727, DOI 10.18632/oncotarget.3115
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roberts RD, 2019, CANCER AM CANCER SOC, V125, P3514, DOI 10.1002/cncr.32351
   Ruan Hang, 2015, Horiz Cancer Res, V56, P23
   Shehata M, 2008, CLIN CANCER RES, V14, P5050, DOI 10.1158/1078 0432.CCR 07 4994
   Simpson E, 2018, JAAPA J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d
   Sinatro A.L., 2018, OSTEOSARCOMA MOL ETI
   Smeland S, 2019, EUR J CANCER, V109, P36, DOI 10.1016/j.ejca.2018.11.027
   Sudhan DR, 2016, INT J CANCER, V138, P2665, DOI 10.1002/ijc.29992
   Sudhan DR, 2015, PHARMACOL THERAPEUT, V155, P105, DOI 10.1016/j.pharmthera.2015.08.007
   Tirtei E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28072
   Turanli B, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00420
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Wang P, 2016, ONCOTARGET, V7, P55343, DOI 10.18632/oncotarget.10533
   Wang Zichen, 2016, F1000Res, V5, P1574, DOI 10.12688/f1000research.9110.1
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yang W, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/s12872 015 0056 7
   Zhang KC, 2017, THERANOSTICS, V7, P213, DOI 10.7150/thno.16044
   Zhang SY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21300 5
   Zhu YJ, 2019, THERANOSTICS, V9, P3526, DOI 10.7150/thno.32796
NR 61
TC 10
Z9 10
U1 0
U2 12
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010 4825
EI 1879 0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD JUL
PY 2021
VL 134
AR 104470
DI 10.1016/j.compbiomed.2021.104470
EA MAY 2021
PG 10
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA TI2LA
UT WOS:000672620700003
PM 34004576
DA 2025 08 17
ER

PT J
AU Jhun, J
   Lee, J
   Byun, JK
   Kim, EK
   Woo, JW
   Lee, JH
   Kwok, SK
   Ju, JH
   Park, KS
   Kim, HY
   Park, SH
   Cho, ML
AF Jhun, JooYeon
   Lee, Jennifer
   Byun, Jae Kyeong
   Kim, Eun Kyung
   Woo, Jung Won
   Lee, Jae Ho
   Kwok, Seung Ki
   Ju, Ji Hyeon
   Park, Kyung Su
   Kim, Ho Youn
   Park, Sung Hwan
   Cho, Mi La
TI Red Ginseng Extract Ameliorates Autoimmune Arthritis via Regulation of
   STAT3 Pathway, Th17/Treg Balance, and Osteoclastogenesis in Mice and
   Human
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; NF KAPPA B; PANAX GINSENG; OXIDATIVE STRESS;
   CELL DEVELOPMENT; COMPOUND K; SUPPRESSION; ACTIVATION; IL 17
AB Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic joint inflammation. Red ginseng is a steamed and dried Panax ginseng C.A. Meyer, which has been used as alternative medicine for thousands of years. This study was undertaken to investigate the effects of red ginseng extracts (RGE) on autoimmune arthritis in mice and humans and to delineate the underlying mechanism. RGE was orally administered three times a week to mice with arthritis. Oral administration of RGE markedly ameliorated clinical arthritis score and histologically assessed joint inflammation in mice with CIA. A significant reduction in STAT3 phosphorylation and a decrease in the number of Th17 cells were observed with RGE treatment. There was also a marked reduction in RANKL induced osteoclastogenesis with treatment of RGE. The inhibitory effect of RGE on Th17 differentiation and osteoclastogenesis observed in mice was also confirmed in the subsequent experiments performed using human peripheral blood mononuclear cells. Our findings provide the first evidence that RGE can regulate Th17 and reciprocally promote Treg cells by inhibiting the phosphorylation of STAT3. Therefore, RGE can ameliorate arthritis in mice with CIA by targeting pathogenic Th17 and osteoclast differentiation, suggesting a novel therapy for treatment of RA.
C1 [Jhun, JooYeon; Lee, Jennifer; Byun, Jae Kyeong; Kim, Eun Kyung; Woo, Jung Won; Lee, Jae Ho; Kwok, Seung Ki; Ju, Ji Hyeon; Park, Kyung Su; Kim, Ho Youn; Park, Sung Hwan; Cho, Mi La] Catholic Univ Korea, Catholic Res Inst Med Sci, Rheumatism Res Ctr, Seoul, South Korea.
   [Lee, Jennifer; Lee, Jae Ho; Kwok, Seung Ki; Ju, Ji Hyeon; Park, Kyung Su; Kim, Ho Youn; Park, Sung Hwan; Cho, Mi La] Catholic Univ Korea, Sch Med, Div Rheumatol, Dept Internal Med,Seoul St Marys Hosp, Seoul 137701, South Korea.
   [Cho, Mi La] Catholic Univ Korea, Coll Med, Conversant Res Consortium Immunol Dis, Seoul 137040, South Korea.
C3 Catholic University of Korea; Catholic University of Korea; Seoul St.
   Mary's Hospital; Catholic University of Korea
RP Park, SH (通讯作者)，Catholic Univ Korea, Catholic Res Inst Med Sci, Rheumatism Res Ctr, Seoul, South Korea.
EM rapark@catholic.ac.kr; iammila@catholic.ac.kr
RI Jung, SeungHyun/HTS 1049 2023
FU National Research Foundation of Korea (NRF)   Ministry of Education,
   Science, and Technology [NRF 2013R1A2A2A01007720]; Korea Health
   Technology R & D Project, Ministry for Health & Welfare, Republic of
   Korea [HI09C1555]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF), funded by the Ministry
   of Education, Science, and Technology (NRF 2013R1A2A2A01007720) and by a
   Grant of the Korea Health Technology R & D Project, Ministry for Health
   & Welfare, Republic of Korea (Grant no HI09C1555). The English in this
   document has been checked by at least two professional editors, both
   native speakers of English. For a certificate, please see:
   http://www.textcheck.com/certificate/LVMKBG.
CR Bae J, 2012, J GINSENG RES, V36, P375, DOI 10.5142/jgr.2012.36.4.375
   Cho E, 2013, J ETHNOPHARMACOL, V145, P294, DOI 10.1016/j.jep.2012.11.006
   Choi YS, 2013, RHEUMATOL INT, V33, P1981, DOI 10.1007/s00296 013 2664 9
   Coon JT, 2002, DRUG SAFETY, V25, P323, DOI 10.2165/00002018 200225050 00003
   Egan PJ, 2008, ARTHRITIS RHEUM US, V58, P3720, DOI 10.1002/art.24075
   Ernst E, 2010, J GINSENG RES, V34, P259, DOI 10.5142/jgr.2010.34.4.259
   Fay J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2102
   He L, 2012, BONE, V50, P1207, DOI 10.1016/j.bone.2012.03.022
   Hitchon CA, 2004, ARTHRITIS RES THER, V6, P265, DOI 10.1186/ar1447
   Hong YJ, 2012, J ETHNOPHARMACOL, V144, P225, DOI 10.1016/j.jep.2012.08.009
   Jung HJ, 2012, J PHARM PHARMACOL, V64, P756, DOI 10.1111/j.2042 7158.2012.01460.x
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Kim HA, 2007, INT IMMUNOPHARMACOL, V7, P1286, DOI 10.1016/j.intimp.2007.05.006
   Kim HJ, 2011, J GINSENG RES, V35, P129, DOI 10.5142/jgr.2011.35.2.129
   Kim KR, 2010, BIOL PHARM BULL, V33, P604, DOI 10.1248/bpb.33.604
   Koenders MI, 2006, ANN RHEUM DIS, V65, P29, DOI 10.1136/ard.2006.058529
   Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139
   Liu HP, 2013, EUR J IMMUNOL, V43, P1716, DOI 10.1002/eji.201242889
   Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Nakae S, 2003, J IMMUNOL, V171, P6173, DOI 10.4049/jimmunol.171.11.6173
   Park JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051377
   Park S, 2011, FOOD CHEM TOXICOL, V49, P1367, DOI 10.1016/j.fct.2011.03.021
   Ramesh T, 2012, NUTR RES, V32, P718, DOI 10.1016/j.nutres.2012.08.005
   Shen T, 2011, J GINSENG RES, V35, P200, DOI 10.5142/jgr.2011.35.2.200
   Stamp LK, 2012, RHEUMATOLOGY, V51, P1796, DOI 10.1093/rheumatology/kes193
   Surh YJ, 2001, J KOREAN MED SCI, V16, pS38, DOI 10.3346/jkms.2001.16.S.S38
   Wruck CJ, 2011, ANN RHEUM DIS, V70, P844, DOI 10.1136/ard.2010.132720
   Wu Q, 2012, J ETHNOPHARMACOL, V144, P782, DOI 10.1016/j.jep.2012.09.046
   Xiang YZ, 2008, PHYTOTHER RES, V22, P851, DOI 10.1002/ptr.2384
   Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995
   Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001
   Zúñiga LA, 2013, IMMUNOL REV, V252, P78, DOI 10.1111/imr.12036
NR 33
TC 32
Z9 37
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962 9351
EI 1466 1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2014
VL 2014
AR 351856
DI 10.1155/2014/351856
PG 13
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA AN0KV
UT WOS:000340274400001
PM 25147435
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Nicoli, F
   Dito, G
   Guabello, G
   Longhi, M
   Corbetta, S
AF Nicoli, Federico
   Dito, Giorgia
   Guabello, Gregorio
   Longhi, Matteo
   Corbetta, Sabrina
TI Hypercalciuria in Postmenopausal Women With Reduced Bone Mineral Density
   Is Associated With Different Mineral Metabolic Profiles: Effects of
   Treatment With Thiazides and Anti resorptives
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE hypercalciuria; osteoporosis; PTH parathyroid hormone; calcium;
   phosphate; hyperparathyroidism
ID HYPERPARATHYROIDISM; MECHANISMS
AB Hypercalciuria may represent a challenge during the workup for osteoporosis management. The present study aimed: (1) to describe the phenotype associated with hypercalciuria in vitamin D sufficient (serum 25 hydroxyvitamin D (25OHD) > 20 ng/ml) patients with osteopenia/osteoporosis; (2) to analyze the effects of thiazides and anti resorptive drugs on urine calcium excretion (UCa), mineral metabolic markers, and bone mineral density. Seventy seven postmenopausal women with hypercalciuria (Uca > 4.0 mg/kg body weight/24 h on two determinations) were retrospectively evaluated in a real life setting. Median UCa was 5.39 (4.75 6.70) mg/kg/24 h. Kidney stones occurred in 32.9% of patients, who had median UCa similar to that of patients without kidney stones. Clustering analysis considering the three variables, such as serum calcium, phosphate, and parathormone (PTH), identified two main clusters of hypercalciuric patients. Cluster 1 (n = 13) included patients with a primary hyperparathyroidism like profile, suggesting a certain degree of autonomous PTH secretion from parathyroid glands. Within cluster 2 (n = 61), two subgroups were recognized, cluster 2A (n = 18) that included patients with relatively increased PTH and normophosphatemia, and cluster 2B (n = 43) that included patients with the normal mineral profile. After a follow up of 33.4 +/  19.6 months, 49 patients treated with thiazidic diuretics (TZD) were reevaluated; 20 patients were treated with hydrochlorothiazide (HCT; 12.5 37.5 mg/day), 29 with indapamide (IND; 1.50 3.75 mg/day). Any significant difference could be detected in all the parameters both basal and treated conditions between patients treated with HCT or IND. TZD induced a mean 39% reduction in UCa and 63.3% of patients obtained Uca < 4.0 mg/kg/24 h, independent of their mineral metabolic profile. Moreover, TZD induced a significant decrease in PTH levels. TZD treated patients normalizing UCa experienced an increase in bone mineral densities when concomitantly treated with anti resorptives, while any gain could be observed in TZD treated patients with persistent hypercalciuria. Finally, multiple regression analysis showed that UCa reduction was at least in part related to denosumab treatment. In conclusion, in postmenopausal osteoporotic women, hypercalciuria is associated with kidney stones in about one third of patients and with a wide range of impaired PTH secretion, determining a diagnostic challenge. TZD efficiently reduces UCa and normalization contributes to increasing anti resorptives positive effect on bone mineral density.
C1 [Nicoli, Federico] Univ Milan, Dept Biotechnol & Translat Med, Milan, Italy.
   [Nicoli, Federico; Dito, Giorgia; Corbetta, Sabrina] IRCCS Ist Ortoped Galeazzi, Endocrinol & Diabetol Serv, Milan, Italy.
   [Guabello, Gregorio; Longhi, Matteo] IRCCS Ist Ortoped Galeazzi, Rheumatol Unit, Milan, Italy.
   [Corbetta, Sabrina] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy.
C3 University of Milan; IRCCS Istituto Ortopedico Galeazzi; IRCCS Istituto
   Ortopedico Galeazzi; University of Milan
RP Corbetta, S (通讯作者)，IRCCS Ist Ortoped Galeazzi, Endocrinol & Diabetol Serv, Milan, Italy.; Corbetta, S (通讯作者)，Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy.
EM sabrina.corbetta@unimi.it
RI Nicoli, Federico/O 3625 2019; Corbetta, Sabrina/H 5457 2011
CR Alon US, 2018, PEDIATR ENDOCR REV P, V15, P291, DOI 10.17458/per.vol15.2018.a.DiureticsMineralBoneMetabolism
   Arcidiacono T, 2014, AM J NEPHROL, V40, P499, DOI 10.1159/000369833
   Bergwitz C, 2019, PFLUG ARCH EUR J PHY, V471, P149, DOI 10.1007/s00424 018 2184 2
   Cesareo R, 2018, NUTRIENTS, V10, DOI 10.3390/nu10050546
   Corbetta S, 2005, J ENDOCRINOL INVEST, V28, P122, DOI 10.1007/BF03345354
   Eisner BH, 2009, J ENDOUROL, V23, P191, DOI 10.1089/end.2008.0567
   Eller Vainicher C, 2013, EUR J ENDOCRINOL, V169, P225, DOI 10.1530/EJE 13 0102
   Gordon RJ, 2020, J CLIN ENDOCR METAB, V105, P2392, DOI 10.1210/clinem/dgaa217
   Hammer Oyvind, 2001, Palaeontologia Electronica, V4, pUnpaginated
   Hou JH, 2016, CURR OPIN NEPHROL HY, V25, P308, DOI 10.1097/MNH.0000000000000239
   Letavernier E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030366
   Levey AS, 2014, AM J KIDNEY DIS, V63, P820, DOI 10.1053/j.ajkd.2013.12.006
   Li DF, 2020, J TRANSL MED, V18, DOI 10.1186/s12967 020 02270 7
   Marcocci C, 2015, J ENDOCRINOL INVEST, V38, P577, DOI 10.1007/s40618 015 0261 3
   Mingione A, 2015, CURR CANCER DRUG TAR, V15, P563, DOI 10.2174/1568009615666150602143041
   Minisola S, 2018, BEST PRACT RES CL EN, V32, P791, DOI 10.1016/j.beem.2018.09.001
   Moriyama Manabu T, 2011, Clin Calcium, V21, P1522, DOI CliCa111015221529
   Nijenhuis T, 2005, J CLIN INVEST, V115, P1651, DOI 10.1172/JCI24134
   Palmieri S, 2015, J CLIN ENDOCR METAB, V100, P2734, DOI 10.1210/jc.2014 4548
   Ryan LE, 2012, CURR OSTEOPOROS REP, V10, P286, DOI 10.1007/s11914 012 0120 5
   Saponaro F, 2020, J ENDOCRINOL INVEST, V43, P677, DOI 10.1007/s40618 019 01162 y
   Saponaro F, 2020, J CLIN ENDOCR METAB, V105, pE2789, DOI 10.1210/clinem/dgaa233
   Verdelli C, 2017, EUR J ENDOCRINOL, V176, pR39, DOI 10.1530/EJE 16 0430
   Vezzoli G, 2019, UROLITHIASIS, V47, P23, DOI 10.1007/s00240 018 1096 0
NR 24
TC 6
Z9 9
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2296 858X
J9 FRONT MED LAUSANNE
JI Front. Med.
PD DEC 15
PY 2021
VL 8
AR 780087
DI 10.3389/fmed.2021.780087
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA YI3ME
UT WOS:000743755000001
PM 34977081
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huynh, NCN
   Everts, V
   Pavasant, P
   Ampornaramveth, RS
AF Huynh, Nam Cong Nhat
   Everts, Vincent
   Pavasant, Prasit
   Ampornaramveth, Ruchanee Salingcarnboriboon
TI Inhibition of Histone Deacetylases Enhances the Osteogenic
   Differentiation of Human Periodontal Ligament Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE HDAC INHIBITOR; HISTONE DEACETYLASE; OSTEOGENIC DIFFERENTIATION;
   PERIODONTAL LIGAMENT CELL; TRICHOSTATIN A
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOCALCIN GENE;
   RUNX2 ACTIVITY; STROMAL CELLS; IN VITRO; EXPRESSION; ACETYLATION;
   INDUCTION; INTERACTS
AB One of the characteristics of periodontal ligament (PDL) cells is their plasticity. Yet, the underlying mechanisms responsible for this phenomenon are unknown. One possible mechanism might be related to epigenetics, since histone deacetylases (HDACs) have been shown to play a role in osteoblast differentiation. This study was aimed to investigate the role of HDACs in osteogenic differentiation of human PDL (hPDL) cells. HDAC inhibitor trichostatin A (TSA) had no effect on cell viability as was assessed by MTT assay. Osteogenic and adipogenic differentiation was analyzed by gene expression, ALP activity and mineral deposition. Western blotting was used to investigate the effect of TSA on histone acetylation and protein expression. In the presence of the HDAC inhibitor osteogenic differentiation was induced; osteoblast related gene expression was increased significantly. ALP activity and mineral nodule formation were also enhanced. Inhibition of HDACs did not induce differentiation into the adipocyte lineage. hPDL highly expressed HDACs of both class I (HDAC 1, 2, 3) and class II (HDAC 4, 6). During osteogenic differentiation HDAC 3 expression gradually decreased. This was apparent in the absence and presence of the inhibitor. The level of acetylated Histone H3 was increased during osteogenic differentiation. Inhibition of HDAC activity induced hyperacetylation of Histone H3, therefore, demonstrating Histone H3 as a candidate target molecule for HDAC inhibition. In conclusion, hPDL cells express a distinguished series of HDACs and these enzymes appear to be involved in osteogenic differentiation. This finding suggests a potential application of TSA for bone regeneration therapy by hPDL cells. J. Cell. Biochem. 117: 1384 1395, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Huynh, Nam Cong Nhat; Pavasant, Prasit] Chulalongkorn Univ, Fac Dent, Mineralized Tissue Res Unit, Bangkok, Thailand.
   [Huynh, Nam Cong Nhat; Ampornaramveth, Ruchanee Salingcarnboriboon] Chulalongkorn Univ, Fac Dent, Dept Microbiol, DRU Oral Microbiol, Bangkok, Thailand.
   [Everts, Vincent] Univ Amsterdam, Acad Ctr Dent Amsterdam ACTA, Dept Oral Cell Biol, Gustav Mahlerlaan 3004, NL 1081 LA Amsterdam, Netherlands.
   [Everts, Vincent] Vrije Univ Amsterdam, Res Inst MOVE, Gustav Mahlerlaan 3004, NL 1081 LA Amsterdam, Netherlands.
   [Pavasant, Prasit] Chulalongkorn Univ, Fac Dent, Dept Anat, Bangkok, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; University of
   Amsterdam; Academic Center for Dentistry Amsterdam; Vrije Universiteit
   Amsterdam; Vrije Universiteit Amsterdam; Academic Center for Dentistry
   Amsterdam; Chulalongkorn University
RP Ampornaramveth, RS (通讯作者)，Chulalongkorn Univ, Fac Dent, Dept Microbiol, DRU Oral Microbiol, Bangkok, Thailand.
EM ruchanee.a@chula.ac.th
RI ; Ampornaramveth, Ruchanee/U 1638 2019
OI Huynh, Nam/0000 0003 4718 7813; 
FU Higher Education Commission of Thailand, National Research University
   (NRU) [WCU 58 033 AS]; Research Chair Grant, Thailand National Science
   and Technology Development Agency (NSTDA); Ratchadapiseksomphot
   Endowment Fund of Chulalongkorn University [RES560530156 HR]
FX Grant sponsor: Higher Education Commission of Thailand, National
   Research University (NRU); Grant number: # WCU 58 033 AS; Grant sponsor:
   The 2012 Research Chair Grant, Thailand National Science and Technology
   Development Agency (NSTDA); Grant sponsor: The Ratchadapiseksomphot
   Endowment Fund of Chulalongkorn University; Grant number:
   RES560530156 HR.
CR Avery JK, 2006, ESSENTIALS ORAL HIST, P121
   Baertschi S, 2014, J BIOL CHEM, V289, P24995, DOI 10.1074/jbc.M114.564997
   Bergomi M, 2011, J BIOMECH, V44, P34, DOI 10.1016/j.jbiomech.2010.08.019
   Boufker HI, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 298
   Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   Choi HD, 2011, J PERIODONTAL IMPLAN, V41, P30, DOI 10.5051/jpis.2011.41.1.30
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Chuenjitkuntaworn B, 2010, J BIOMED MATER RES A, V94A, P241, DOI 10.1002/jbm.a.32657
   Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541 7786.MCR 07 0324
   Fu Y, 2014, INT J BIOCHEM CELL B, V54, P68, DOI 10.1016/j.biocel.2014.07.003
   Grégoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882 06
   Haberland M, 2010, J BIOL CHEM, V285, P14663, DOI 10.1074/jbc.M109.081679
   Hesse E, 2010, J CELL BIOL, V191, P1271, DOI 10.1083/jcb.201009107
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Jensen ED, 2008, J BONE MINER RES, V23, P361, DOI 10.1359/JBMR.071104
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Kaneda T, 2006, BONE, V38, P420, DOI 10.1016/j.bone.2005.08.021
   Kim TI, 2013, BIOTECHNOL LETT, V35, P129, DOI 10.1007/s10529 012 0992 6
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Leupin O, 2007, J BONE MINER RES, V22, P1957, DOI 10.1359/JBMR.070804
   Lu J, 2011, P NATL ACAD SCI USA, V108, P21200, DOI 10.1073/pnas.1119181109
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   Osathanon T, 2015, ARCH ORAL BIOL, V60, P29, DOI 10.1016/j.archoralbio.2014.08.018
   Osathanon T, 2013, J BIOMED MATER RES A, V101, P358, DOI 10.1002/jbm.a.34332
   Paino F, 2014, STEM CELLS, V32, P279, DOI 10.1002/stem.1544
   Qiao YB, 2015, J BIOL CHEM, V290, P2508, DOI 10.1074/jbc.M114.603761
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Seto Edward, 2006, P61
   Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002 0122
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Silverstein RA, 2005, CURR GENET, V47, P1, DOI 10.1007/s00294 004 0541 5
   Toussirot É, 2010, JOINT BONE SPINE, V77, P395, DOI 10.1016/j.jbspin.2010.03.009
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805
   Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982 7992.2002
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Xu S, 2013, ACTA PHARMACOL SIN, V34, P699, DOI 10.1038/aps.2012.182
   Xu Y, 2009, TISSUE ENG PT A, V15, P3697, DOI [10.1089/ten.tea.2009.0213, 10.1089/ten.TEA.2009.0213]
   Xu YX, 2005, INT J MOL MED, V15, P169
   Yan CH, 2006, MOL CELL BIOL, V26, P6357, DOI 10.1128/MCB.00311 06
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Zhou Y, 2009, INT J PERIODONT REST, V29, P507
   Zhou Y, 2008, J PERIODONTOL, V79, P525, DOI [10.1902/jop.2008.070373, 10.1902/jop.2008.070373 ]
NR 48
TC 50
Z9 57
U1 0
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JUN
PY 2016
VL 117
IS 6
BP 1384
EP 1395
DI 10.1002/jcb.25429
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DI8HB
UT WOS:000373741000011
PM 27043246
DA 2025 08 17
ER

PT J
AU Beer, AJ
   Schwarzenböck, SM
   Zantl, N
   Souvatzoglou, M
   Maurer, T
   Watzlowik, P
   Kessler, H
   Wester, HJ
   Schwaiger, M
   Krause, BJ
AF Beer, Ambros J.
   Schwarzenboeck, Sarah M.
   Zantl, Niko
   Souvatzoglou, Michael
   Maurer, Tobias
   Watzlowik, Petra
   Kessler, Horst
   Wester, Hans Juergen
   Schwaiger, Markus
   Krause, Bernd Joachim
TI Non invasive assessment of inter and intrapatient variability of
   integrin expression in metastasized prostate cancer by PET
SO ONCOTARGET
LA English
DT Article
DE prostate cancer; integrins; alpha v beta 3; angiogenesis; PET
ID POSITRON EMISSION TOMOGRAPHY; ALPHA(V)BETA(3) INTEGRIN; ALPHA V BETA 3
   INTEGRIN; CELL MIGRATION; BREAST CANCER; RGD PEPTIDES; F 18 GALACTO RGD;
   OSTEOPONTIN; ACTIVATION; THERAPY
AB Purpose: Due to the high expression of the integrin alpha v beta 3 not only on endothelial cells, but also on mature osteoclasts and prostate cancer cells, imaging of osseous metastases with alpha v beta 3 targeted tracers seems promising. However, little is known about the patterns of alpha v beta 3 expression in metastasized prostate cancer lesions in vivo. Thus we evaluated the uptake of the alpha v beta 3 specific PET tracer [F 18]Galacto RGD for assessment of bone metastases in prostate cancer patients.
   Results: [F 18]Galacto RGD PET identified 58/74 bone lesions (detection rate of 78.4%) and lymph node metastases in 2/5 patients. The SUVmean was 2.12+/ 0.94 (range 0.70 4.38; tumor/blood 1.36+/ 0.53; tumor/muscle 2.82+/ 1.31) in bone lesions and 2.21+/ 1.18 (range 0.75 3.56) in lymph node metastases. Good visualization and detection of bone metastases was feasible due to a low background activity of the surrounding normal bone tissue.
   Methods: 12 patients with known metastasized prostate cancer according to conventional staging (including bone scintigraphy and contrast enhanced CT; median PSA 68.63 ng/ml, range 3.72 1935) were examined with PET after i.v. injection of [F 18] Galacto RGD. Two blinded nuclear medicine physicians evaluated the PET scans in consensus concerning lesion detectability. Volumes of interest were drawn in the PET scans over all metastases defined by conventional staging (maximum of 11 lesions/patient), over the left ventricle, liver and muscle and standardized uptake values (SUVs) were calculated.
   Conclusions: Our data show generally elevated uptake of [F 18] Galacto RGD in bone metastases from prostate cancer with a marked inter and intrapatient variability. While [F 18] Galacto RGD PET is inferior to bone scintigraphy for detection of osseous metastases, it might be valuable in patient screening and monitoring of alpha v beta 3 targeted therapies due to the high variability of alpha v beta 3 expression.
C1 [Beer, Ambros J.; Schwarzenboeck, Sarah M.; Souvatzoglou, Michael; Watzlowik, Petra; Schwaiger, Markus; Krause, Bernd Joachim] Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, D 81675 Munich, Germany.
   [Zantl, Niko; Maurer, Tobias] Tech Univ Munich, Klinikum Rechts Isar, Dept Urol, D 81675 Munich, Germany.
   [Kessler, Horst] Tech Univ Munich, Dept Chem, IAS, D 85747 Garching, Germany.
   [Kessler, Horst] Tech Univ Munich, Dept Chem, Ctr Integrated Prot Sci CIPSM, D 85747 Garching, Germany.
   [Wester, Hans Juergen] Tech Univ Munich, Inst Radiopharmaceut Chem, D 85748 Garching, Germany.
   [Beer, Ambros J.; Souvatzoglou, Michael] Univ Ulm, Dept Nucl Med, D 89081 Ulm, Germany.
   [Schwarzenboeck, Sarah M.; Krause, Bernd Joachim] Univ Rostock, Med Ctr, Dept Nucl Med, D 18057 Rostock, Germany.
   [Zantl, Niko] Klinikum Konstanz, Dept Urol, D 78464 Constance, Germany.
C3 Technical University of Munich; University of Munich; Technical
   University of Munich; Technical University of Munich; Technical
   University of Munich; Technical University of Munich; Ulm University;
   University of Rostock
RP Schwarzenböck, SM (通讯作者)，Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, D 81675 Munich, Germany.; Schwarzenböck, SM (通讯作者)，Univ Rostock, Med Ctr, Dept Nucl Med, D 18057 Rostock, Germany.
EM sarah.schwarzenboeck@med.uni rostock.de
RI Beer, Ambros/AAA 5539 2022; Kessler, Horst/C 1178 2010; Maurer,
   Tobias/R 7561 2017
OI Beer, Ambros/0000 0001 9042 7806; Maurer, Tobias/0000 0002 5660 7691
FU Sander Foundation
FX We thank the Cyclotron and PET team, especially Michael Herz, Brigitte
   Dzewas, Coletta Kruschke and Nicola Henke for excellent technical
   assistance and the Sander Foundation for financial support.
CR Alva A, 2012, INVEST NEW DRUG, V30, P749, DOI 10.1007/s10637 010 9573 5
   Beer AJ, 2006, J NUCL MED, V47, P763
   Beer AJ, 2005, J NUCL MED, V46, P1333
   Beer AJ, 2006, CLIN CANCER RES, V12, P3942, DOI 10.1158/1078 0432.CCR 06 0266
   Bradley DA, 2011, INVEST NEW DRUG, V29, P1432, DOI 10.1007/s10637 010 9420 8
   Cai HC, 2013, J LABELLED COMPD RAD, V56, P264, DOI 10.1002/jlcr.2999
   Cai Weibo, 2006, Anti Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530
   Cheng SL, 2000, J CELL BIOCHEM, V77, P265, DOI 10.1002/(SICI)1097 4644(20000501)77:2<265::AID JCB9>3.0.CO;2 6
   Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224
   Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733
   Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g
   Felding Habermann B, 2004, P NATL ACAD SCI USA, V101, P17210, DOI 10.1073/pnas.0407869101
   Felding Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355
   Felding Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853
   Gaertner FC, 2012, EUR J NUCL MED MOL I, V39, P126, DOI 10.1007/s00259 011 2028 1
   Ganguly KK, 2013, CELL ADHES MIGR, V7, P251, DOI 10.4161/cam.23840
   Haubner R, 2005, PLOS MED, V2, P244, DOI 10.1371/journal.pmed.0020070
   Haubner R, 2001, CANCER RES, V61, P1781
   Haubner R, 2004, BIOCONJUGATE CHEM, V15, P61, DOI 10.1021/bc034170n
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Liu SL, 2010, MOL IMAGING BIOL, V12, P530, DOI 10.1007/s11307 009 0284 2
   Liu ZF, 2009, EUR J NUCL MED MOL I, V36, P947, DOI 10.1007/s00259 008 1045 1
   Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172
   Mas Moruno C, 2010, ANTI CANCER AGENT ME, V10, P753, DOI 10.2174/187152010794728639
   McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429
   McGary EC, 2002, CANCER BIOL THER, V1, P459, DOI 10.4161/cbt.1.5.158
   Neubauer S, 2013, ANGEW CHEM INT EDIT, V52, P11656, DOI 10.1002/anie.201306376
   Notni J, 2013, NUCL MED BIOL, V40, P33, DOI 10.1016/j.nucmedbio.2012.08.006
   Putz E, 1999, CANCER RES, V59, P241
   ROSS FP, 1993, J BIOL CHEM, V268, P9901
   Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724
   Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454
   Sloan EK, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1398
   Sun YX, 2007, PROSTATE, V67, P61, DOI 10.1002/pros.20500
   Thalmann GN, 1999, CLIN CANCER RES, V5, P2271
   Weber WA, 1999, J NUCL MED, V40, P1771
   Weber WA, 2006, J CLIN ONCOL, V24, P3282, DOI 10.1200/JCO.2006.06.6068
   Zheng DQ, 1999, CANCER RES, V59, P1655
   Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200
NR 41
TC 18
Z9 18
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 10
PY 2016
VL 7
IS 19
BP 28151
EP 28159
DI 10.18632/oncotarget.8611
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA DO4HF
UT WOS:000377741700095
PM 27058620
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Polyzos, SA
   Anastasilakis, AD
   Litsas, I
   Efstathiadou, Z
   Kita, M
   Arsos, G
   Moralidis, E
   Papatheodorou, A
   Terpos, E
AF Polyzos, Stergios A.
   Anastasilakis, Athanasios D.
   Litsas, Ioannis
   Efstathiadou, Zoe
   Kita, Marina
   Arsos, Georgios
   Moralidis, Efstratios
   Papatheodorou, Athanasios
   Terpos, Evangelos
TI Profound hypocalcemia following effective response to zoledronic acid
   treatment in a patient with juvenile Paget's disease
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Juvenile Paget's disease; Hyperparathyroidism; Hypocalcemia; Paget's
   disease of bone; Zoledronic acid
ID CHRONIC IDIOPATHIC HYPERPHOSPHATASIA; BISPHOSPHONATE THERAPY; BONE
   TURNOVER; OSTEOPROTEGERIN; PAMIDRONATE; DISODIUM
AB Juvenile Paget's disease (JPD) is a rare, autosomal recessive osteopathy. Although it has phenotypic overlap with Paget's disease of bone (PDB), it is probably a distinct entity. Because of its rarity, optimal disease management has not yet been established by randomized controlled trials. However, clinical, biochemical, and radiographic improvement has been reported after treatment with antiresorptive agents, including calcitonin and bisphosphonates (BPs). Compared with other BPs, zoledronic acid (ZOL) has a higher affinity to bone mineral and is a stronger inhibitor of the enzyme farnesyl pyrophosphate synthase (the main target of nitrogen containing BPs), properties that explain the prolonged effect of ZOL on bone turnover and render it a therapeutic option for JPD, similar to PDB. We describe hereby, for the first time in the literature, the case of a patient with JPD who developed severe hypocalcemia and secondary hyperparathyroidism following effective treatment with ZOL.
C1 [Polyzos, Stergios A.; Litsas, Ioannis; Efstathiadou, Zoe; Kita, Marina] Hippokrateion Hosp, Dept Endocrinol, Thessaloniki 55134, Greece.
   [Anastasilakis, Athanasios D.] 424 Gen Mil Hosp, Dept Endocrinol, Thessaloniki, Greece.
   [Arsos, Georgios; Moralidis, Efstratios] Aristotle Univ Thessaloniki, Dept Nucl Med, Ippokrat Gen Hosp, GR 54006 Thessaloniki, Greece.
   [Papatheodorou, Athanasios] 251 Gen AF Hosp, Dept Med Res, Athens, Greece.
   [Terpos, Evangelos] Univ Athens, Sch Med, Dept Clin Therapeut, GR 11527 Athens, Greece.
C3 Aristotle University of Thessaloniki; National & Kapodistrian University
   of Athens
RP Polyzos, SA (通讯作者)，Hippokrateion Hosp, Dept Endocrinol, 13 Simou Lianidi, Thessaloniki 55134, Greece.
EM stergios@endo.gr
RI ; Polyzos, Stergios/H 2844 2019; Terpos, Evangelos/AAD 3667 2019;
   Efstathiadou, Zoe/AAI 4427 2021; Anastasilakis, Athanasios/AAF 7669 2020
OI Efstathiadou, Zoe/0000 0002 7345 7912; Anastasilakis,
   Athanasios/0000 0002 9624 6296; ARSOS, GEORGIOS/0000 0002 3491 2783;
   Moralidis, Efstratios/0000 0002 0640 4765; Terpos,
   Evangelos/0000 0001 5133 1422; Polyzos, Stergios/0000 0001 9232 4042
CR Avramidis A, 2008, J BONE MINER METAB, V26, P635, DOI 10.1007/s00774 008 0852 6
   Cundy T, 2002, HUM MOL GENET, V11, P2119, DOI 10.1093/hmg/11.18.2119
   Cundy T, 2005, NEW ENGL J MED, V353, P918, DOI 10.1056/NEJMoa050893
   Cundy T, 2004, J BONE MINER RES, V19, P703, DOI 10.1359/JBMR.040127
   Demir E, 2000, J PEDIATR ENDOCR MET, V13, P217
   Devogelaer JP, 2008, OSTEOPOROSIS INT, V19, P1109, DOI 10.1007/s00198 008 0629 8
   DOYLE FH, 1974, BRIT J RADIOL, V47, P9, DOI 10.1259/0007 1285 47 553 9
   Heaney RP, 2003, J AM COLL NUTR, V22, P142, DOI 10.1080/07315724.2003.10719287
   Khan SA, 1996, J BONE MINER RES, V11, P178
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Papapetrou PD, 2009, HORM INT J ENDOCRINO, V8, P96, DOI 10.14310/horm.2002.1226
   Polyzos SA, 2009, HORM METAB RES, V41, P846, DOI 10.1055/s 0029 1233491
   Polyzos SA, 2009, EXPERT REV ENDOCRINO, V4, P424
   Polyzos SA, 2009, SUPPORT CARE CANCER, V17, P1329, DOI 10.1007/s00520 009 0704 5
   Ralston SH, 2008, BEST PRACT RES CL RH, V22, P101, DOI 10.1016/j.berh.2007.11.005
   Reid IR, 2005, NEW ENGL J MED, V353, P898, DOI 10.1056/NEJMoa044241
   Shankar S, 2006, J BONE MINER RES, V21, pP22, DOI 10.1359/JBMR.06S204
   Simsek S, 2007, J CLIN ENDOCR METAB, V92, P1897, DOI 10.1210/jc.2006 0479
   SINGER F, 1994, J BONE MINER RES, V9, P733
   SPINDLER A, 1992, J RHEUMATOL, V19, P642
   Stewart GO, 1999, BONE, V24, P139, DOI 10.1016/S8756 3282(98)00163 X
   Stuckey BGA, 2001, J BONE MINER RES, V16, P1719, DOI 10.1359/jbmr.2001.16.9.1719
   Tau C, 2004, BONE, V35, P210, DOI 10.1016/j.bone.2004.03.013
   Whitson HE, 2006, BONE, V39, P954, DOI 10.1016/j.bone.2006.04.032
   Whyte MP, 2002, NEW ENGL J MED, V347, P175, DOI 10.1056/NEJMoa013096
NR 26
TC 24
Z9 24
U1 0
U2 2
PU SPRINGER TOKYO
PI TOKYO
PA 1 11 11 KUDAN KITA, CHIYODA KU, TOKYO, 102 0073, JAPAN
SN 0914 8779
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PY 2010
VL 28
IS 6
BP 706
EP 712
DI 10.1007/s00774 010 0198 8
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 701XV
UT WOS:000285859400013
PM 20533067
DA 2025 08 17
ER

PT J
AU Karlsson, J
   Atefyekta, S
   Andersson, M
AF Karlsson, Johan
   Atefyekta, Saba
   Andersson, Martin
TI Controlling drug delivery kinetics from mesoporous titania thin films by
   pore size and surface energy
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE mesoporous titania; controlled drug delivery; release kinetics;
   alendronate; QCM D
ID IMPLANT FIXATION; SILICA FILMS; BONE; BISPHOSPHONATES; ADSORPTION
AB The osseointegration capacity of bone anchoring implants can be improved by the use of drugs that are administrated by an inbuilt drug delivery system. However, to attain superior control of drug delivery and to have the ability to administer drugs of varying size, including proteins, further material development of drug carriers is needed. Mesoporous materials have shown great potential in drug delivery applications to provide and maintain a drug concentration within the therapeutic window for the desired period of time. Moreover, drug delivery from coatings consisting of mesoporous titania has shown to be promising to improve healing of bone anchoring implants. Here we report on how the delivery of an osteoporosis drug, alendronate, can be controlled by altering pore size and surface energy of mesoporous titania thin films. The pore size was varied from 3.4 nm to 7.2 nm by the use of different structure directing templates and addition of a swelling agent. The surface energy was also altered by grafting dimethylsilane to the pore walls. The drug uptake and release profiles were monitored in situ using quartz crystal microbalance with dissipation (QCM D) and it was shown that both pore size and surface energy had a profound effect on both the adsorption and release kinetics of alendronate. The QCM D data provided evidence that the drug delivery from mesoporous titania films is controlled by a binding diffusion mechanism. The yielded knowledge of release kinetics is crucial in order to improve the in vivo tissue response associated to therapeutic treatments.
C1 [Karlsson, Johan; Atefyekta, Saba; Andersson, Martin] Chalmers Univ Technol, Dept Chem & Biol Engn, S 41296 Gothenburg, Sweden.
C3 Chalmers University of Technology
RP Karlsson, J (通讯作者)，Chalmers Univ Technol, Dept Chem & Chem Engn, Kemivagen 10, S 41296 Gothenburg, Sweden.
EM johan.karlsson@chalmers.se
RI ; Karlsson, Johan/JJE 1282 2023
OI , Martin/0000 0003 1523 4697; Karlsson, Johan/0000 0001 6008 6692; 
FU Materials Sciences Area of Advance at Chalmers University of Technology
FX The financial support for this work was provided from the Materials
   Sciences Area of Advance at Chalmers University of Technology. We
   acknowledge the Maxlab synchrotron facility in Lund, Sweden, for giving
   us the opportunity and assistance to perform synchrotron SAXS
   measurements. We also thank Professor Anette Larsson and Professor
   Fredrik Hook at Chalmers University of Technology for their inputs to
   this work.
CR Abtahi J, 2013, J DENT RES, V92, P279, DOI 10.1177/0022034512472335
   Alberius PCA, 2002, CHEM MATER, V14, P3284, DOI 10.1021/cm011209u
   Almanza Workman AM, 2003, THIN SOLID FILMS, V423, P77, DOI 10.1016/S0040 6090(02)00997 5
   Andersson M, 2005, CHEM MATER, V17, P1409, DOI 10.1021/cm0485761
   Andreatta G, 2008, LANGMUIR, V24, P6072, DOI 10.1021/la800049x
   Besson S, 2003, J MATER CHEM, V13, P404, DOI 10.1039/b206698j
   Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521 4095(199905)11:7<579::AID ADMA579>3.0.CO;2 R
   Colilla M, 2008, INT J NANOMED, V3, P403
   Coquil T, 2009, J APPL PHYS, V106, DOI 10.1063/1.3182826
   Crepaldi EL, 2003, J AM CHEM SOC, V125, P9770, DOI 10.1021/ja030070g
   Galli S, 2014, CLIN IMPLANT DENT RE
   Galli S, 2014, ACTA BIOMATER, V10, P5193, DOI 10.1016/j.actbio.2014.08.011
   Grandfield K, 2013, NANOSCALE, V5, P4302, DOI 10.1039/c3nr00826f
   Grosso D, 2004, ADV FUNCT MATER, V14, P309, DOI 10.1002/adfm.200305036
   Harmankaya N, 2013, ACTA BIOMATER, V9, P7064, DOI 10.1016/j.actbio.2013.02.040
   Höök F, 2002, COLLOID SURFACE B, V24, P155, DOI 10.1016/S0927 7765(01)00236 3
   Ivanova A, 2014, J AM CHEM SOC, V136, P5930, DOI 10.1021/ja411292u
   Izquierdo Barba I, 2008, J NANOMATER, V2008, DOI 10.1155/2008/106970
   Joos U, 2006, INT J ORAL MAX SURG, V35, P783, DOI 10.1016/j.ijom.2006.03.013
   Karlsson J, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 014 5337 7
   Karlsson J, 2014, NANO LETT, V14, P4220, DOI [10.1021/nl1501564f, 10.1021/nl501564f]
   Karlsson J, 2012, ACTA BIOMATER, V8, P4438, DOI 10.1016/j.actbio.2012.07.035
   Kimmel DB, 2007, J DENT RES, V86, P1022, DOI 10.1177/154405910708601102
   Lian HY, 2011, J PHYS CHEM C, V115, P6581, DOI 10.1021/jp110852p
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   McMaster WA, 2012, ACS APPL MATER INTER, V4, P4717, DOI 10.1021/am301093k
   Mendes VC, 2007, BIOMATERIALS, V28, P4748, DOI 10.1016/j.biomaterials.2007.07.020
   Puleo DA, 1999, BIOMATERIALS, V20, P2311, DOI 10.1016/S0142 9612(99)00160 X
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937
   Schuster E, 2014, BIOPHYS J, V106, P253, DOI 10.1016/j.bpj.2013.11.2959
   Soler Illia GJAA, 2012, NANOSCALE, V4, P2549, DOI 10.1039/c2nr11817c
   Song SW, 2005, LANGMUIR, V21, P9568, DOI 10.1021/la051167e
   Ukmar T, 2011, J CONTROL RELEASE, V155, P409, DOI 10.1016/j.jconrel.2011.06.038
   Vallet Regí M, 2007, ANGEW CHEM INT EDIT, V46, P7548, DOI 10.1002/anie.200604488
   Wang SB, 2009, MICROPOR MESOPOR MAT, V117, P1, DOI 10.1016/j.micromeso.2008.07.002
   Wermelin K, 2008, BONE, V42, P365, DOI 10.1016/j.bone.2007.10.013
   Wu B, 2007, J PHYS CHEM C, V111, P1131, DOI 10.1021/jp0665291
   Wu QL, 2011, LANGMUIR, V27, P9557, DOI 10.1021/la201388n
   Wu QL, 2011, J PHYS CHEM C, V115, P11925, DOI 10.1021/jp2021193
   Xia W, 2012, J BIOMED MATER RES B, V100B, P82, DOI 10.1002/jbm.b.31925
   Xu M, 2011, NANOSCALE, V3, P3329, DOI 10.1039/c1nr10477b
   Yan WQ, 1997, J BIOMED MATER RES, V37, P267, DOI 10.1002/(SICI)1097 4636(199711)37:2<267::AID JBM17>3.3.CO;2 C
   Yang PP, 2008, BIOMATERIALS, V29, P4341, DOI 10.1016/j.biomaterials.2008.07.042
   Zhu M, 2014, ACS APPL MATER INTER, V6, P5456, DOI 10.1021/am405013t
NR 45
TC 26
Z9 27
U1 0
U2 58
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 4425
EP 4436
DI 10.2147/IJN.S83005
PG 12
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA CM3JO
UT WOS:000357578300001
PM 26185444
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Mao, YJ
   Chen, Y
   Li, WF
   Wang, Y
   Qiu, JJ
   Fu, YX
   Guan, JZ
   Zhou, PH
AF Mao, Yingji
   Chen, Yu
   Li, Weifeng
   Wang, Ying
   Qiu, Jingjing
   Fu, Yingxiao
   Guan, Jianzhong
   Zhou, Pinghui
TI Physiology Inspired Multilayer Nanofibrous Membranes Modulating
   Endogenous Stem Cell Recruitment and Osteo Differentiation for Staged
   Bone Regeneration
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE bone regeneration; cell recruitment; drug delivery; osteogenesis; tissue
   engineering
ID SCAFFOLD; OLIGODEOXYNUCLEOTIDE; REPAIR; HYDROXYAPATITE; BIOMATERIALS;
   OSTEOBLASTS; PROMOTES; DELIVERY; FRACTURE; ROLES
AB Bone regeneration involves a cascade of sophisticated, multiple staged cellular and molecular events, where early phase stem cell recruitment mediated by chemokines and late phase osteo differentiation induced by pro osteogenic factors play the crucial roles. Herein, enlightened by a bone physiological and regenerative mechanism, the multilayer nanofibrous membranes (PLLA@SDF 1 alpha@MT01) consisting of PLLA/MT01 micro sol electrospun nanofibers as intima and PLLA/PEG/SDF 1 alpha electrospun nanofibers as adventitia are fabricated through micro sol electrospinning and manual multi layer stacking technologies. In vitro releasing profiles show that PLLA@SDF 1 alpha@MT01 represents the rapid release of stromal cell derived SDF 1 alpha (SDF 1 alpha) in the outer layers, while with long term sustained release of MT01 in the inner layer. Owing to interconnected porosity like the natural bone extracellular matrix and improved hydrophilia, PLLA@SDF 1 alpha@MT01 manifests good biocompatibility both in vitro and in vivo. Furthermore, PLLA@SDF 1 alpha@MT01 can promote bone marrow mesenchymal stem cells (BMSCs) migration by amplifying the SDF 1 alpha/CXCR4 axis and stimulating BMSCs osteo differentiation via activating the MAPK pathway in vitro. PLLA@SDF 1 alpha@MT01, with a programmed dual delivery system, exhibits the synergetic promotion of bone regeneration and vascularization by emulating key characteristics of the staged bone repair in vivo. Overall, PLLA@SDF 1 alpha@MT01 that mimics the endogenous cascades of bone regeneration can enrich the physiology mimetic staged regenerative strategy and represent a promising tissue engineered scaffold for the bone defect.
C1 [Mao, Yingji; Chen, Yu; Li, Weifeng; Wang, Ying; Fu, Yingxiao; Guan, Jianzhong; Zhou, Pinghui] Bengbu Med Coll, Sch Life Sci, Affiliated Hosp 1, Dept Orthoped, Bengbu 233030, Peoples R China.
   [Mao, Yingji; Qiu, Jingjing; Guan, Jianzhong; Zhou, Pinghui] Bengbu Med Coll, Anhui Prov Key Lab Tissue Transplantat, Bengbu 233030, Peoples R China.
   [Chen, Yu; Wang, Ying] Bengbu Med Coll, Affiliated Hosp 1, Dept Plast Surg, Bengbu 233004, Peoples R China.
C3 Bengbu Medical University; Bengbu Medical University; Bengbu Medical
   University
RP Guan, JZ; Zhou, PH (通讯作者)，Bengbu Med Coll, Sch Life Sci, Affiliated Hosp 1, Dept Orthoped, Bengbu 233030, Peoples R China.; Guan, JZ; Zhou, PH (通讯作者)，Bengbu Med Coll, Anhui Prov Key Lab Tissue Transplantat, Bengbu 233030, Peoples R China.
EM guanjianzhong@bbmc.edu.cn; zphdoctor@126.com
RI ; Mao, Yingji/AAW 7766 2020; Qiu, Jingjing/E 9248 2015; LI,
   WEI/ISS 1208 2023
OI Mao, Yingji/0000 0001 9737 1526; Chen, Yu/0000 0001 7672 6762; 
FU Anhui Educational Committee [KJ2020ZD51, KJ2021ZD0089]; Natural Science
   Foundation of Anhui Province [1908085MH276, 2008085QH362]; 512 Talents
   Development Project of Bengbu Medical College [by51202302, by51202309];
   Distinguished Young Scholars of First Affiliated Hospital of Bengbu
   Medical College [2021byyfyjq01]; Science Research Project of Bengbu
   Medical College [2021bypd006]
FX Y.M. and Y.C. contributed equally to this work. This work was supported
   by the Key Program of the Anhui Educational Committee (No. KJ2020ZD51
   and KJ2021ZD0089), the Project of Natural Science Foundation of Anhui
   Province (No. 1908085MH276 and 2008085QH362), 512 Talents Development
   Project of Bengbu Medical College (No. by51202302 and by51202309),
   Distinguished Young Scholars of First Affiliated Hospital of Bengbu
   Medical College (2021byyfyjq01), and Science Research Project of Bengbu
   Medical College (2021bypd006).
CR Betz OB, 2007, GENE THER, V14, P1039, DOI 10.1038/sj.gt.3302956
   Chen L, 2021, BIOACT MATER, V6, P361, DOI 10.1016/j.bioactmat.2020.08.022
   Cheng L, 2020, SMALL, V16, DOI 10.1002/smll.202005433
   Cheng LY, 2016, BIOMATERIALS, V83, P169, DOI 10.1016/j.biomaterials.2016.01.002
   Coffman JE, 2018, BIOCONJUGATE CHEM, V29, P1544, DOI 10.1021/acs.bioconjchem.8b00090
   Feng ZY, 2011, INT J MOL SCI, V12, P2543, DOI 10.3390/ijms12042543
   Fujio M, 2011, BONE, V49, P693, DOI 10.1016/j.bone.2011.06.024
   Gao XM, 2021, ACS APPL MATER INTER, V13, P97, DOI 10.1021/acsami.0c15945
   Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011
   Gil Albarova J, 2012, ACTA BIOMATER, V8, P3777, DOI 10.1016/j.actbio.2012.06.019
   Hanagata N, 2017, INT J NANOMED, V12, P515, DOI 10.2147/IJN.S114477
   Hanagata N, 2012, INT J NANOMED, V7, P2181, DOI 10.2147/IJN.S30197
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Hosogane N, 2010, INT J BIOCHEM CELL B, V42, P1132, DOI 10.1016/j.biocel.2010.03.020
   Hou X, 2012, INT J MOL SCI, V13, P7902, DOI 10.3390/ijms13077902
   Jackson DE, 2003, FEBS LETT, V540, P7, DOI 10.1016/S0014 5793(03)00224 2
   Kane R, 2013, MATER TODAY, V16, P418, DOI 10.1016/j.mattod.2013.11.001
   Keshavarz S, 2019, BBA MOL CELL RES, V1866, P296, DOI 10.1016/j.bbamcr.2018.11.013
   Kortesidis A, 2005, BLOOD, V105, P3793, DOI 10.1182/blood 2004 11 4349
   Li B, 2020, ACS BIOMATER SCI ENG, V6, P6737, DOI 10.1021/acsbiomaterials.0c00972
   Li L, 2019, MAT SCI ENG C MATER, V98, P1241, DOI 10.1016/j.msec.2019.01.075
   Liang YJ, 2019, GENE, V684, P1, DOI 10.1016/j.gene.2018.10.042
   Liu XZ, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121037
   Liu Y, 2016, SMALL, V12, P4611, DOI 10.1002/smll.201600626
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Lopes D, 2018, BIOMATERIALS, V185, P240, DOI 10.1016/j.biomaterials.2018.09.028
   Lv XK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081262
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Martin V, 2018, MAT SCI ENG C MATER, V82, P363, DOI 10.1016/j.msec.2017.04.038
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Qiu ZP, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00154 y
   Qu YJ, 2020, SMALL, V16, DOI 10.1002/smll.202002750
   Rezaeinia H, 2020, MAT SCI ENG C MATER, V115, DOI 10.1016/j.msec.2020.111115
   Santoro M, 2016, ADV DRUG DELIVER REV, V107, P206, DOI 10.1016/j.addr.2016.04.019
   Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023
   Shen YQ, 2012, INT J MOL SCI, V13, P2877, DOI 10.3390/ijms13032877
   Shuai CJ, 2021, BIOACT MATER, V6, P490, DOI 10.1016/j.bioactmat.2020.09.001
   Sidharthan DS, 2022, BIOTECHNOL J, V17, DOI 10.1002/biot.202100570
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Sukegawa A, 2012, TISSUE ENG PT A, V18, P934, DOI [10.1089/ten.tea.2011.0380, 10.1089/ten.TEA.2011.0380]
   Sun TF, 2021, BIOACT MATER, V6, P4163, DOI 10.1016/j.bioactmat.2021.04.013
   Wang MQ, 2021, BIOACT MATER, V6, P1318, DOI 10.1016/j.bioactmat.2020.10.022
   Wang WZ, 2019, COLLOID SURFACE B, V181, P963, DOI 10.1016/j.colsurfb.2019.06.065
   Wei BG, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab044
   Wells JM, 2018, NATURE, V557, P322, DOI 10.1038/s41586 018 0073 7
   Wu L, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119555
   Xiao M, 2019, EXP CELL RES, V381, P39, DOI 10.1016/j.yexcr.2019.04.036
   Yang WJ, 2020, J ADV RES, V24, P191, DOI 10.1016/j.jare.2020.04.009
   Yang Y, 2016, ACTA BIOMATER, V46, P112, DOI 10.1016/j.actbio.2016.09.035
   Yu WW, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01844 x
   Zhang HL, 2021, J BONE MINER METAB, V39, P126, DOI 10.1007/s00774 020 01122 0
   Zhang M, 2016, MED SCI MONITOR, V22, P1309, DOI 10.12659/MSM.898194
   Zhang YW, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2022.112700
   Zhu GY, 2021, BIOACT MATER, V6, P4110, DOI 10.1016/j.bioactmat.2021.03.043
   Zhuang YP, 2021, ADV DRUG DELIVER REV, V176, DOI 10.1016/j.addr.2021.113885
   Zou ZY, 2021, BIOACT MATER, V6, P1839, DOI 10.1016/j.bioactmat.2020.11.021
NR 56
TC 32
Z9 37
U1 8
U2 105
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD NOV
PY 2022
VL 11
IS 21
AR 2201457
DI 10.1002/adhm.202201457
EA SEP 2022
PG 16
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA 5W1EI
UT WOS:000849044700001
PM 36027596
DA 2025 08 17
ER

PT J
AU Kiechl, S
   Wittmann, J
   Giaccari, A
   Knoflach, M
   Willeit, P
   Bozec, A
   Moschen, AR
   Muscogiuri, G
   Sorice, GP
   Kireva, T
   Summerer, M
   Wirtz, S
   Luther, J
   Mielenz, D
   Billmeier, U
   Egger, G
   Mayr, A
   Oberhollenzer, F
   Kronenberg, F
   Orthofer, M
   Penninger, JM
   Meigs, JB
   Bonora, E
   Tilg, H
   Willeit, J
   Schett, G
AF Kiechl, Stefan
   Wittmann, Juergen
   Giaccari, Andrea
   Knoflach, Michael
   Willeit, Peter
   Bozec, Aline
   Moschen, Alexander R.
   Muscogiuri, Giovanna
   Sorice, Gian Pio
   Kireva, Trayana
   Summerer, Monika
   Wirtz, Stefan
   Luther, Julia
   Mielenz, Dirk
   Billmeier, Ulrike
   Egger, Georg
   Mayr, Agnes
   Oberhollenzer, Friedrich
   Kronenberg, Florian
   Orthofer, Michael
   Penninger, Josef M.
   Meigs, James B.
   Bonora, Enzo
   Tilg, Herbert
   Willeit, Johann
   Schett, Georg
TI Blockade of receptor activator of nuclear factor κB (RANKL) signaling
   improves hepatic insulin resistance and prevents development of diabetes
   mellitus
SO NATURE MEDICINE
LA English
DT Article
ID CARDIOVASCULAR DISEASE; IKK BETA; OSTEOPROTEGERIN; RISK; LIGAND;
   OBESITY; LIVER; INFLAMMATION; OSTEOBLASTS; METABOLISM
AB Hepatic insulin resistance is a driving force in the pathogenesis of type 2 diabetes mellitus (T2DM) and is tightly coupled with excessive storage of fat and the ensuing inflammation within the liver(1 3). There is compelling evidence that activation of the transcription factor nuclear factor kappa B (NF kappa B) and downstream inflammatory signaling pathways systemically and in the liver are key events in the etiology of hepatic insulin resistance and p cell dysfunction, although the molecular mechanisms involved are incompletely understood(3 6). We here test the hypothesis that receptor activator of NE kappa B ligand (RANKL), a prototypic activator of NF kappa B, contributes to this process using both an epidemiological and experimental approach. In the prospective population based Bruneck Study, a high serum concentration of soluble RANKL emerged as a significant (P < 0.001) and independent risk predictor of T2DM manifestation. In close agreement, systemic or hepatic blockage of RANKL signaling in genetic and nutritional mouse models of T2DM resulted in a marked improvement of hepatic insulin sensitivity and amelioration or even normalization of plasma glucose concentrations and glucose tolerance. Overall, this study provides evidence for a role of RANKL signaling in the pathogenesis of T2DM. If so, translation to the clinic may be feasible given current pharmacological strategies to lower RANKL activity to treat osteoporosis.
C1 [Kiechl, Stefan; Knoflach, Michael; Willeit, Peter; Willeit, Johann] Med Univ Innsbruck, Dept Neurol, A 6020 Innsbruck, Austria.
   [Wittmann, Juergen; Mielenz, Dirk] Univ Erlangen Nurnberg, Dept Internal Med 3, Div Mol Immunol, D 91054 Erlangen, Germany.
   [Giaccari, Andrea; Muscogiuri, Giovanna; Sorice, Gian Pio] Univ Cattolica Sacro Cuore, Div Endocrinol & Metab Dis, Policlin A Gemelli, Rome, Italy.
   [Giaccari, Andrea] Fdn Don C Gnocchi, Milan, Italy.
   [Willeit, Peter] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
   [Bozec, Aline; Kireva, Trayana; Luther, Julia; Schett, Georg] Univ Erlangen Nurnberg, Dept Internal Med 3, D 91054 Erlangen, Germany.
   [Moschen, Alexander R.; Tilg, Herbert] Med Univ Innsbruck, Div Endocrinol Gastroenterol & Metab, Dept Med 1, A 6020 Innsbruck, Austria.
   [Summerer, Monika; Kronenberg, Florian] Med Univ Innsbruck, Div Genet Epidemiol Mol & Clin Pharmacol, Dept Med Genet, A 6020 Innsbruck, Austria.
   [Wirtz, Stefan; Billmeier, Ulrike] Univ Erlangen Nurnberg, Dept Internal Med 1, D 91054 Erlangen, Germany.
   [Egger, Georg; Oberhollenzer, Friedrich] Bruneck Hosp, Dept Internal Med, Brunico, Italy.
   [Mayr, Agnes] Bruneck Hosp, Dept Lab Med, Brunico, Italy.
   [Orthofer, Michael; Penninger, Josef M.] Austrian Acad Sci, IMBA, Inst Mol Biotechnol, A 1010 Vienna, Austria.
   [Meigs, James B.] Harvard Univ, Dept Internal Med, Boston, MA 02115 USA.
   [Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA.
   [Bonora, Enzo] Univ & Hosp Trust Verona, Div Endocrinol Diabet & Metab Dis, Verona, Italy.
C3 Medical University of Innsbruck; University of Erlangen Nuremberg;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   IRCCS Fondazione Don Carlo Gnocchi Onlus; University of Cambridge;
   University of Erlangen Nuremberg; Medical University of Innsbruck;
   Medical University of Innsbruck; University of Erlangen Nuremberg;
   Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of
   Molecular Biotechnology (IMBA); Harvard University; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital;
   University of Verona; Azienda Ospedaliera Universitaria Integrata Verona
RP Kiechl, S (通讯作者)，Med Univ Innsbruck, Dept Neurol, A 6020 Innsbruck, Austria.
EM stefan.kiechl@i med.ac.at; georg.schett@uk erlangen.de
RI ; Penninger, Josef/I 6860 2013; Bonora, Enzo/AAA 5300 2022; Tilg,
   Herbert/AEO 9569 2022; Summerer, Monika/JAZ 1817 2023; Moschen,
   Alexander/ABF 2267 2021; Giaccari, Andrea/ACI 3719 2022; Sorice,
   Gian/L 1270 2018; Muscogiuri, Giovanna/K 5817 2016; Kronenberg,
   Florian/B 1736 2008; Meigs, James/P 3927 2019; Willeit,
   Peter/HCI 7091 2022; Kiechl, Stefan/GQP 0351 2022
OI Moschen, Alexander R/0000 0003 3598 7848; Willeit,
   Peter/0000 0002 1866 7159; Penninger, Josef/0000 0002 8194 3777;
   Knoflach, Michael/0000 0001 5576 6562; , Agnes Mayr/0000 0001 9363 873X;
   BONORA, Enzo/0000 0003 1074 5164; Wirtz, Stefan/0000 0001 6936 7431;
   Wittmann, Jurgen/0000 0003 0404 8186; Kronenberg,
   Florian/0000 0003 2229 1120; Muscogiuri, Giovanna/0000 0002 8809 4931; 
FU Deutsche Forschungsgemeinschaft [SPP1468 IMMUNOBONE]; Bundesministerium
   fur Bildung und Forschung (Bundesministerium fur Bildung und Forschung
   project ANCYLOSS); European Union; Innovative Medicines Initiative
   funded project BTCure; National Institute of Diabetes and Digestive and
   Kidney Diseases [K24 DK080140]; Genomics of Lipid associated Disorders
   of the Austrian Genome Research Programme GEN AU; 'Pustertaler Verein
   zur Pravention von Herz  und Hirngefasserkrankungen; Gesundheitsbetrieb
   Bruneck; Assessorat fur Gesundheitswesen, Familie und Soziales, Bolzand;
   Umberto Di Mario Prize by the Societa Italiana di Diabetologia;
   Fondazione Don Gnocchi; Universita Cattolica del Sacro Cuore (Fondi
   Ateneo Linea D.3.2 Sindrome Metabolica); Italian Ministry of Education,
   University and Research [PRIN 2010JS3PMZ_011]; Christian Doppler
   Research Society; Italian Ministry of Education, University and
   Research; University of Verona; European Research Council; Austrian
   Academy of Sciences; National Bank Foundation; Era of Hope/US Department
   of Defense
FX This study was supported by the Deutsche Forschungsgemeinschaft
   (SPP1468 IMMUNOBONE to G.S.), the Bundesministerium fur Bildung und
   Forschung (Bundesministerium fur Bildung und Forschung project ANCYLOSS
   to G.S.), the European Union (Masterswitch to G.S.), the Innovative
   Medicines Initiative funded project BTCure (to G.S.), the National
   Institute of Diabetes and Digestive and Kidney Diseases (K24 DK080140 to
   J.B.M.), the Genomics of Lipid associated Disorders of the Austrian
   Genome Research Programme GEN AU (to EK.), the 'Pustertaler Verein zur
   Pravention von Herz  und Hirngefasserkrankungen; the 'Gesundheitsbetrieb
   Bruneck' and the Assessorat fur Gesundheitswesen, Familie und Soziales,
   Bolzand. G.M. is recipient of the Umberto Di Mario Prize by the Societa
   Italiana di Diabetologia 2011. A.G. was supported by grants from
   Fondazione Don Gnocchi, Universita Cattolica del Sacro Cuore (Fondi
   Ateneo Linea D.3.2 Sindrome Metabolica) and the Italian Ministry of
   Education, University and Research (PRIN 2010JS3PMZ_011). A.M. and H.T.
   were supported by the Christian Doppler Research Society. E.B. is
   recipient of grants from the Italian Ministry of Education, University
   and Research and the University of Verona. J.M.P. holds an advanced
   European Research Council grant and is supported by the Austrian Academy
   of Sciences, a Grant by the National Bank Foundation and Era of Hope/US
   Department of Defense. We thank B. Enrich for technical support.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185
   BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0
   Brennan Speranza TC, 2012, J CLIN INVEST, V122, P4172, DOI 10.1172/JCI63377
   Cai DS, 2012, AGING US, V4, P98, DOI 10.18632/aging.100431
   Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166
   Collin Osdoby P, 2004, CIRC RES, V95, P1046, DOI 10.1161/01.RES.0000149165.99974.12
   Donath MY, 2005, DIABETES, V54, pS108, DOI 10.2337/diabetes.54.suppl_2.S108
   Goto H, 2011, CYTOKINE, V56, P662, DOI 10.1016/j.cyto.2011.09.005
   Huang W, 2010, DIABETES, V59, P347, DOI 10.2337/db09 0016
   Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955
   Jiang JJ, 2001, BIOCHEM BIOPH RES CO, V289, P1088, DOI 10.1006/bbrc.2001.6100
   Kanazawa I, 2011, BONE, V48, P720, DOI 10.1016/j.bone.2010.12.020
   Kiechl S, 2004, CIRCULATION, V109, P2175, DOI 10.1161/01.CIR.0000127957.43874.BB
   Kiechl Stefan, 2006, Expert Rev Cardiovasc Ther, V4, P801, DOI 10.1586/14779072.4.6.801
   Kiechl S, 2007, CIRCULATION, V116, P385, DOI 10.1161/CIRCULATIONAHA.106.686774
   Kindle L, 2006, J BONE MINER RES, V21, P193, DOI 10.1359/JBMR.051027
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lieb W, 2010, ARTERIOSCL THROM VAS, V30, P1849, DOI 10.1161/ATVBAHA.109.199661
   Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947
   Liu LS, 2012, J ENDODONT, V38, P943, DOI 10.1016/j.joen.2012.03.010
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324
   Mazzone T, 2008, LANCET, V371, P1800, DOI 10.1016/S0140 6736(08)60768 0
   Meng QY, 2011, J BIOL CHEM, V286, P32324, DOI 10.1074/jbc.M111.254417
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   Nathan DM, 2010, NEW ENGL J MED, V362, P1533, DOI 10.1056/NEJMe1002322
   Nishikawa M, 2008, HUM GENE THER, V19, P1009, DOI 10.1089/hum.2008.020
   Schett G, 2004, JAMA J AM MED ASSOC, V291, P1108, DOI 10.1001/jama.291.9.1108
   Secchiero P, 2006, AM J PATHOL, V169, P2236, DOI 10.2353/ajpath.2006.060398
   Semb AG, 2009, ARTERIOSCL THROM VAS, V29, P975, DOI 10.1161/ATVBAHA.109.184101
   Sheng L, 2012, NAT MED, V18, P943, DOI 10.1038/nm.2756
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059
   Targher G, 2010, NEW ENGL J MED, V363, P1341, DOI 10.1056/NEJMra0912063
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Venuraju SM, 2010, J AM COLL CARDIOL, V55, P2049, DOI 10.1016/j.jacc.2010.03.013
   Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599
   Ziolkowska M, 2002, ARTHRITIS RHEUM US, V46, P1744, DOI 10.1002/art.10388
NR 40
TC 217
Z9 247
U1 0
U2 48
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD MAR
PY 2013
VL 19
IS 3
BP 358
EP 363
DI 10.1038/nm.3084
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 105BN
UT WOS:000316040700030
PM 23396210
DA 2025 08 17
ER

PT J
AU Buitrago, JAR
   Landström, M
   Wolf Watz, M
AF Buitrago, Jhon A. Rodriguez
   Landstrom, Marene
   Wolf Watz, Magnus
TI Human transforming growth factor β type I receptor in complex with
   kinase inhibitor SB505124
SO ACTA CRYSTALLOGRAPHICA SECTION F STRUCTURAL BIOLOGY COMMUNICATIONS
LA English
DT Article
DE TGF beta type I receptor; inhibition; intracellular domain; prostate
   cancer; osteoblast differentiation
ID TGF BETA; MOLPROBITY
AB The crystal structure of the intracellular domain of transforming growth factor beta type I receptor (T beta R1) in complex with the competitive inhibitor SB505124 is presented. The study provides insights into the structure and function of T beta R1 in complex with SB505124, and as such offers molecular level understanding of the inhibition of this critical signalling pathway. The potential of SB505124 as an avenue for therapy in cancer treatment is discussed on basis of the results.
C1 [Buitrago, Jhon A. Rodriguez] Umea Univ, Dept Chem, Linnaeus Vag 10, S 90185 Umea, Sweden.
   [Buitrago, Jhon A. Rodriguez; Landstrom, Marene; Wolf Watz, Magnus] Umea Univ, Dept Med Biosci, S 90185 Umea, Sweden.
C3 Umea University; Umea University
RP Buitrago, JAR (通讯作者)，Umea Univ, Dept Chem, Linnaeus Vag 10, S 90185 Umea, Sweden.; Buitrago, JAR; Wolf Watz, M (通讯作者)，Umea Univ, Dept Med Biosci, S 90185 Umea, Sweden.
EM rodriguez.jhon@umu.se; magnus.wolf watz@umu.se
FU Medical Faculty at Umea University [FS 506 21]; Swedish Research Council
   [2023 02370_VR]; Swedish Cancer Society [23 2902 Pj 01H]; Swedish
   Research Council [2023 02370] Funding Source: Swedish Research Council
FX This study was finically supported by grants from the Medical Faculty at
   Umea University to ML (FS 506 21), from the Swedish Research Council to
   MWW (2021 04513_VR) and ML (2023 02370_VR) and from the Swedish Cancer
   Society to ML (23 2902 Pj 01H).
CR Agirre J, 2023, ACTA CRYSTALLOGR D, V79, P449, DOI 10.1107/S2059798323003595
   Almuraikhi N, 2023, CELL BIOCHEM FUNCT, V41, P564, DOI 10.1002/cbf.3812
   Berman H. M., ACTA CRYSTALLOGR D, VD58, P899
   Boguslawska J, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121619
   Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Derynck Rik., 2007, TGF BETA FAMILY
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Goldberg FW, 2009, J MED CHEM, V52, P7901, DOI 10.1021/jm900807w
   Guo W., 2024, Ther. Pat., V34, P99
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Jones E, 2009, EXPERT OPIN THER TAR, V13, P227, DOI [10.1517/14728220802705696 , 10.1517/14728220802705696]
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Keegan RM, 2008, ACTA CRYSTALLOGR D, V64, P119, DOI 10.1107/S0907444907037195
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Krissinel E, 2022, ACTA CRYSTALLOGR D, V78, P1079, DOI 10.1107/S2059798322007987
   Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58
   Liebschner D., 2019, ACTA CRYSTALLOGR D, VD75, P861
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Mu YB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1332
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Ogunjimi AA, 2012, CELL SIGNAL, V24, P476, DOI 10.1016/j.cellsig.2011.09.027
   Pettersen EF, 2021, PROTEIN SCI, V30, P70, DOI 10.1002/pro.3943
   Sapitro J, 2010, MOL VIS, V16, P1880
   Tickle I. J., 2018, STARANISO
   Vonrhein C, 2011, ACTA CRYSTALLOGR D, V67, P293, DOI 10.1107/S0907444911007773
   Wasilko DJ, 2009, PROTEIN EXPRES PURIF, V65, P122, DOI 10.1016/j.pep.2009.01.002
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
NR 32
TC 0
Z9 0
U1 1
U2 1
PU INT UNION CRYSTALLOGRAPHY
PI CHESTER
PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND
EI 2053 230X
J9 ACTA CRYSTALLOGR F
JI Acta Crystallogr. F Struct. Biol. Commun.
PD NOV
PY 2024
VL 80
BP 314
EP 319
DI 10.1107/S2053230X24010094
PN 11
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biophysics; Crystallography
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Crystallography
GA O7X7V
UT WOS:001373216800004
PM 39441620
OA hybrid
DA 2025 08 17
ER

PT J
AU Egusa, H
   Kayashima, H
   Miura, J
   Uraguchi, S
   Wang, FF
   Okawa, H
   Sasaki, JI
   Saeki, M
   Matsumoto, T
   Yatani, H
AF Egusa, Hiroshi
   Kayashima, Hiroki
   Miura, Jiro
   Uraguchi, Shinya
   Wang, Fangfang
   Okawa, Hiroko
   Sasaki, Jun Ichi
   Saeki, Makio
   Matsumoto, Takuya
   Yatani, Hirofumi
TI Comparative Analysis of Mouse Induced Pluripotent Stem Cells and
   Mesenchymal Stem Cells During Osteogenic Differentiation In Vitro
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID BONE MORPHOGENETIC PROTEINS; MARROW STROMAL POPULATIONS; OSTEOBLAST
   DIFFERENTIATION; 3 DIMENSIONAL CULTURE; GRAFT SUBSTITUTES; APATITE
   FORMATION; ENGINEERED BONE; MINERALIZATION; GENE; AMELOBLASTIN
AB Induced pluripotent stem cells (iPSCs) can differentiate into mineralizing cells and are, therefore, expected to be useful for bone regenerative medicine; however, the characteristics of iPSC derived osteogenic cells remain unclear. Here, we provide a direct in vitro comparison of the osteogenic differentiation process in mesenchymal stem cells (MSCs) and iPSCs from adult C57BL/6J mice. After 30 days of culture in osteogenic medium, both MSCs and iPSCs produced robustly mineralized bone nodules that contained abundant calcium phosphate with hydroxyapatite crystal formation. Mineral deposition was significantly higher in iPSC cultures than in MSC cultures. Scanning electron microscopy revealed budding matrix vesicles in early osteogenic iPSCs; subsequently, the vesicles propagated to exhibit robust mineralization without rich fibrous structures. Early osteogenic MSCs showed deposition of many matrix vesicles in abundant collagen fibrils that became solid mineralized structures. Both cell types demonstrated increased expression of osteogenic marker genes, such as runx2, osterix, dlx5, bone sialoprotein (BSP), and osteocalcin, during osteogenesis; however, real time reverse transcription polymerase chain reaction array analysis revealed that osteogenesis related genes encoding mineralization associated molecules, bone morphogenetic proteins, and extracellular matrix collagens were differentially expressed between iPSCs and MSCs. These data suggest that iPSCs are capable of differentiation into mature osteoblasts whose associated hydroxyapatite has a crystal structure similar to that of MSC associated hydroxyapatite; however, the transcriptional differences between iPSCs and MSCs could result in differences in the mineral and matrix environments of the bone nodules. Determining the biological mechanisms underlying cell specific differences in mineralization during in vitro iPSC osteogenesis may facilitate the development of clinically effective engineered bone.
C1 [Egusa, Hiroshi; Kayashima, Hiroki; Uraguchi, Shinya; Wang, Fangfang; Okawa, Hiroko; Sasaki, Jun Ichi; Yatani, Hirofumi] Osaka Univ, Grad Sch Dent, Dept Fixed Prosthodont, Div Oromaxillofacial Regenerat, Suita, Osaka, Japan.
   [Egusa, Hiroshi] Tohoku Univ, Grad Sch Dent, Div Mol & Regenerat Prosthodont, Sendai, Miyagi 9808575, Japan.
   [Miura, Jiro] Osaka Univ, Dent Hosp, Div Interdisciplinary Dent, Suita, Osaka, Japan.
   [Saeki, Makio] Niigata Univ, Grad Sch Med & Dent Sci, Div Dent Pharmacol, Niigata, Japan.
   [Matsumoto, Takuya] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biomat, Okayama 7008530, Japan.
C3 University of Osaka; Tohoku University; University of Osaka; Niigata
   University; Okayama University
RP Egusa, H (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Mol & Regenerat Prosthodont, Aoba Ku, 4 1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM egu@dent.tohoku.ac.jp
RI ; Miura, Jiro/AAF 8083 2021; Egusa, Hiroshi/AFT 9694 2022; Sasaki,
   Jun Ichi/JFA 6687 2023; Wang, Fang Fang/GPF 6144 2022; Miura,
   Jiro/A 2037 2014
OI Sasaki, Jun Ichi/0000 0002 0330 0397; Egusa,
   Hiroshi/0000 0002 0200 8132; Miura, Jiro/0000 0002 0000 025X
FU Japan Society for the Promotion of Science [24659858, 25253102,
   25293395]; Grants in Aid for Scientific Research [25462957, 25242041,
   25293395, 26861634, 25253102, 24659858] Funding Source: KAKEN
FX The authors thank Takao Sakata and Tomoki Nishida (Osaka University
   Research Center for ultra high voltage electron microscopy) for
   technical assistance in electron microscope observations. This
   investigation was supported by Grants in Aid for Exploratory Research
   (24659858, H. E.) and for Scientific Research (A: 25253102, H.Y. and H.
   E.; and B: 25293395, H. E.) from the Japan Society for the Promotion of
   Science.
CR ANDERSON HC, 1995, CLIN ORTHOP RELAT R, P266
   Anguera MC, 2012, CELL STEM CELL, V11, P75, DOI 10.1016/j.stem.2012.03.008
   Arpornmaeklong P, 2009, STEM CELLS DEV, V18, P955, DOI 10.1089/scd.2008.0310
   Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097 4644(19990301)72:3<396::AID JCB9>3.3.CO;2 Y
   Ayala Peña VB, 2013, EXP CELL RES, V319, P2028, DOI 10.1016/j.yexcr.2013.05.006
   Bigdeli N, 2010, TISSUE ENG PT A, V16, P3427, DOI 10.1089/ten.tea.2010.0112
   Bilousova G, 2011, STEM CELLS, V29, P206, DOI 10.1002/stem.566
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Boskey A, 2007, BIOMATERIALS, V28, P2465, DOI 10.1016/j.biomaterials.2006.11.043
   Brinckmann J, 2005, TOP CURR CHEM, V247, P1, DOI 10.1007/b103817
   Brown SE, 2009, CELLS TISSUES ORGANS, V189, P256, DOI 10.1159/000151746
   Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Coen G, 2009, VIRCHOWS ARCH, V454, P263, DOI 10.1007/s00428 008 0724 4
   De Long WG, 2007, J BONE JOINT SURG AM, V89A, P649, DOI 10.2106/JBJS.F.00465
   DEUTSCH D, 1991, J BIOL CHEM, V266, P16021
   Egusa H, 2005, J BIOL CHEM, V280, P23691, DOI 10.1074/jbc.M413796200
   Egusa H, 2007, TISSUE ENG, V13, P2589, DOI 10.1089/ten.2007.0080
   Egusa H, 2013, TISSUE ENG PT A, V19, P770, DOI [10.1089/ten.tea.2012.0164, 10.1089/ten.TEA.2012.0164]
   Egusa H, 2012, J PROSTHODONT RES, V56, P229, DOI 10.1016/j.jpor.2012.10.001
   Egusa H, 2012, J PROSTHODONT RES, V56, P151, DOI 10.1016/j.jpor.2012.06.001
   Egusa Hiroshi, 2012, Clin Calcium, V22, P67, DOI CliCa12016773
   Egusa H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012743
   Egusa H, 2009, BIOMATERIALS, V30, P4676, DOI 10.1016/j.biomaterials.2009.05.032
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Eyre DR, 2005, TOP CURR CHEM, V247, P207, DOI 10.1007/b103828
   Gentleman E, 2009, NAT MATER, V8, P763, DOI [10.1038/NMAT2505, 10.1038/nmat2505]
   Gothard D, 2010, TISSUE ENG PART C ME, V16, P583, DOI [10.1089/ten.tec.2009.0462, 10.1089/ten.TEC.2009.0462]
   Greenwald AS, 2001, J BONE JOINT SURG AM, V83A, P98, DOI 10.2106/00004623 200100022 00007
   Hatakeyama J, 2009, J DENT RES, V88, P318, DOI 10.1177/0022034509334749
   Hayashi T, 2012, CELL TRANSPLANT, V21, P591, DOI 10.3727/096368911X605529
   Iizuka S, 2011, MOL CELL BIOL, V31, P783, DOI 10.1128/MCB.00912 10
   Itskovitz Eldor J, 2000, MOL MED, V6, P88, DOI 10.1007/BF03401776
   Jahnen Dechent W, 2008, J MOL MED, V86, P379, DOI 10.1007/s00109 007 0294 y
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kao CL, 2010, STEM CELLS DEV, V19, P247, DOI 10.1089/scd.2009.0186
   Kärner E, 2007, STEM CELLS DEV, V16, P39, DOI 10.1089/scd.2006.0010
   Kawaguchi J, 2005, BONE, V36, P758, DOI 10.1016/j.bone.2004.07.019
   Kawaguchi Jitsutaro, 2006, V330, P135
   Kim YK, 2010, BIOMATERIALS, V31, P6618, DOI 10.1016/j.biomaterials.2010.04.060
   Kokabu S, 2012, MOL ENDOCRINOL, V26, P87, DOI 10.1210/me.2011 1168
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Krebsbach PH, 1996, J BIOL CHEM, V271, P4431
   Li F, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471 2121 13 35
   Li F, 2010, J CELL BIOCHEM, V109, P643, DOI 10.1002/jcb.22440
   Liu GZ, 2009, J CELL BIOL, V185, P67, DOI 10.1083/jcb.200810137
   Liu Y, 2011, BIOMATERIALS, V32, P1291, DOI 10.1016/j.biomaterials.2010.10.018
   Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014
   Mao ZK, 2001, GENE, V279, P181, DOI 10.1016/S0378 1119(01)00749 1
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Matsumoto M, 2013, DENT MATER, V29, P287, DOI 10.1016/j.dental.2012.11.003
   MCCULLOCH CAG, 1991, BLOOD, V77, P1906
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Okamoto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043800
   Purpura KA, 2004, STEM CELLS, V22, P39, DOI 10.1634/stemcells.22 1 39
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Sasaki JI, 2010, TISSUE ENG PT A, V16, P2497, DOI [10.1089/ten.tea.2009.0523, 10.1089/ten.TEA.2009.0523]
   Sasaki JI, 2012, INTEGR BIOL UK, V4, P1207, DOI 10.1039/c2ib20027a
   Sato T, 1968, J Electron Microsc (Tokyo), V17, P158
   Schäfer C, 2003, J CLIN INVEST, V112, P357, DOI [10.1172/JCI17202, 10.1172/JCI200317202]
   Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   SCHOETERS GER, 1988, CELL TISSUE KINET, V21, P363, DOI 10.1111/j.1365 2184.1988.tb00794.x
   Shimko DA, 2004, TISSUE ENG, V10, P1386, DOI 10.1089/ten.2004.10.1386
   Shivali G, 2012, PHYTOCHEM ANALYSIS, V23, P171, DOI 10.1002/pca.1339
   Spahr A, 2006, EUR J ORAL SCI, V114, P504, DOI 10.1111/j.1600 0722.2006.00403.x
   Suga H, 2011, NATURE, V480, P57, DOI 10.1038/nature10637
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tashiro K, 2009, STEM CELLS, V27, P1802, DOI 10.1002/stem.108
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vater C, 2011, ACTA BIOMATER, V7, P463, DOI 10.1016/j.actbio.2010.07.037
   Wutzl A, 2006, J BIOMED MATER RES A, V77A, P75, DOI 10.1002/jbm.a.30615
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
NR 76
TC 48
Z9 51
U1 0
U2 35
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD SEP 15
PY 2014
VL 23
IS 18
BP 2156
EP 2169
DI 10.1089/scd.2013.0344
PG 14
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA AP1LZ
UT WOS:000341832900004
PM 24625139
OA Green Published
DA 2025 08 17
ER

PT J
AU Sermijn, E
   Strobbe, T
   Vandekerckhove, L
   Libbrecht, L
   Colle, I
   Schoonjans, R
   Vogelaers, D
AF Sermijn, E.
   Strobbe, T.
   Vandekerckhove, L.
   Libbrecht, L.
   Colle, I
   Schoonjans, R.
   Vogelaers, D.
TI CALCIPHYLAXIS: A RARE COMPLICATION IN ALCOHOLIC LIVER DISEASE
SO ACTA CLINICA BELGICA
LA English
DT Article
DE Calciphylaxis; alcoholic cirrhosis
ID CHRONIC RENAL FAILURE; CALCIFIC UREMIC ARTERIOLOPATHY; VASCULAR
   CALCIFICATION; GLYCOPROTEIN/FETUIN A; HYPERBARIC OXYGEN; RISK FACTORS;
   CASE SERIES; INHIBITION; MORTALITY; THERAPY
AB Calciphylaxis, or calcific uremic arteriolopathy (CUA) is a rare but well described entity in patients with end stage renal disease (ESRD) and/or hyperparathyroidism. CUA is characterized by systemic acute calcification of the small and intermediate dermal vasculature that can lead to epidermal ischemia, ulceration, and necrosis. Cutaneous lesions of calciphylaxis characteristically begin as tender, violaceous, livedoid discolorations. The mechanisms of disease remain poorly understood although abnormal bone and mineral metabolism and hyperparathyroidism can contribute to CUA. Therapeutic strategies are of unproven benefit and mortality remains high.
   Calciphylaxis has also been extremely rarely reported in patients without ESRD and/or hyperparathyroidism. We report an unusual case of calciphylaxis in a patient With alcoholic liver cirrhosis and normal renal function, without any alteration in the phosphocalcic and parathyroid hormone (PTH) metabolisms.
C1 [Sermijn, E.; Strobbe, T.; Vandekerckhove, L.; Libbrecht, L.; Colle, I; Vogelaers, D.] UZ Gent, Ghent, Belgium.
   [Schoonjans, R.] AZ Zusters van Barmhartigheid, Ronse, Belgium.
C3 Ghent University; Ghent University Hospital
RP Sermijn, E (通讯作者)，UZ Gent, Ghent, Belgium.
EM erica.sermijn@ugent.be
RI Vandekerckhove, Linos/J 6420 2013
OI Vandekerckhove, Linos/0000 0002 8600 1631
CR ADROGUE HJ, 1981, AM J NEPHROL, V1, P177, DOI 10.1159/000166536
   Angelis M, 1997, SURGERY, V122, P1083, DOI 10.1016/S0039 6060(97)90212 9
   Bardin T, 2003, CURR OPIN RHEUMATOL, V15, P48, DOI 10.1097/00002281 200301000 00009
   Basile C, 2002, J NEPHROL, V15, P676
   Bleibel W, 2006, AM J KIDNEY DIS, V48, P659, DOI 10.1053/j.ajkd.2006.05.031
   Budisavljevic MN, 1996, J AM SOC NEPHROL, V7, P978
   Cicone JS, 2004, AM J KIDNEY DIS, V43, P1104, DOI 10.1053/j.ajkd.2004.03.018
   Essary LR, 2000, AM J CLIN PATHOL, V113, P280, DOI 10.1309/AGLF X21H Y37W 50KL
   Fine A, 2002, KIDNEY INT, V61, P2210, DOI 10.1046/j.1523 1755.2002.00375.x
   Heiss A, 2003, J BIOL CHEM, V278, P13333, DOI 10.1074/jbc.M210868200
   Janigan DT, 2000, AM J KIDNEY DIS, V35, P588, DOI 10.1016/S0272 6386(00)70003 5
   Kalabay L, 2002, EUR J GASTROEN HEPAT, V14, P389, DOI 10.1097/00042737 200204000 00009
   Kalajian AH, 2009, ARCH DERMATOL, V145, P451, DOI 10.1001/archdermatol.2008.602
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047
   Mathew S, 2008, J AM SOC NEPHROL, V19, P1509, DOI 10.1681/ASN.2007080902
   Mathur RV, 2001, POSTGRAD MED J, V77, P557, DOI 10.1136/pmj.77.911.557
   Mazhar AR, 2001, KIDNEY INT, V60, P324, DOI 10.1046/j.1523 1755.2001.00803.x
   Norris B, 2005, CLIN NUCL MED, V30, P725, DOI 10.1097/01.rlu.0000182215.97219.72
   Podymow T, 2001, NEPHROL DIAL TRANSPL, V16, P2176, DOI 10.1093/ndt/16.11.2176
   Schäfer C, 2003, J CLIN INVEST, V112, P357, DOI [10.1172/JCI17202, 10.1172/JCI200317202]
   Weenig RH, 2007, J AM ACAD DERMATOL, V56, P569, DOI 10.1016/j.jaad.2006.08.065
NR 22
TC 5
Z9 5
U1 0
U2 2
PU ACTA CLINICA BELGICA
PI GHENT
PA UNIV HOSPITAL GENT, DE PINTELAAN 185, RENAL DIVISION, B 9000 GHENT,
   BELGIUM
SN 0001 5512
J9 ACTA CLIN BELG
JI Acta Clin. Belg.
PD MAR APR
PY 2013
VL 68
IS 2
BP 116
EP 119
DI 10.2143/ACB.2863
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 152QT
UT WOS:000319546900009
PM 23967720
DA 2025 08 17
ER

PT J
AU Laine, SK
   Alm, JJ
   Virtanen, SP
   Aro, HT
   Laitala Leinonen, TK
AF Laine, Salla K.
   Alm, Jessica J.
   Virtanen, Sanna P.
   Aro, Hannu T.
   Laitala Leinonen, Tiina K.
TI MicroRNAs miR 96, miR 124, and miR 199a regulate gene expression in
   human bone marrow derived mesenchymal stem cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE ADIPOGENESIS; CHONDROGENESIS; MESENCHYMAL STEM CELLS; microRNA;
   OSTEOGENESIS
ID OSTEOGENIC DIFFERENTIATION; ADIPOGENIC DIFFERENTIATION; STROMAL CELLS;
   PROLIFERATION; CHONDROGENESIS
AB MicroRNAs are small non coding RNAs that control gene expression at the post transcriptional level by binding to 3' untranslated regions (3' UTR) of their target mRNAs. They present a promising tool to delineate the molecular mechanisms regulating differentiation of human mesenchymal stromal cells (hMSCs) and to improve the controlled differentiation of hMSCs in therapeutic applications. Here we show that three microRNAs, miR 96, miR 124, and miR 199a, were differentially expressed during osteogenic, adipogenic, and chondrogenic induction of human bone marrow derived MSCs. miR 96 expression was increased during osteogenesis and adipogenesis, but not during chondrogenesis. miR 124 was exclusively expressed in adipocytes, whereas miR 199a was upregulated in osteoblasts and chondrocytes. Furthermore, functional studies with synthetic miRNA precursors and inhibitors demonstrated that miR 96, miR 124, and miR 199a regulated the expression of genes important for hMSC differentiation, such as aggrecan, transcription factor SOX9, and fatty acid binding protein 4 (FABP4). Modulation of miR 96, miR 124, and miR 199a expression may thus be useful in specific targeting of hMSC differentiation, for e.g., MSC based therapies. J. Cell. Biochem. 113: 26872695, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Laine, Salla K.; Virtanen, Sanna P.; Laitala Leinonen, Tiina K.] Univ Turku, Dept Cell Biol & Anat, Inst Biomed, Skeletal Biol Consortium, FI 20520 Turku, Finland.
   [Alm, Jessica J.; Aro, Hannu T.] Univ Turku, Orthopaed Res Unit, Dept Orthopaed Surg & Traumatol, FI 20520 Turku, Finland.
   [Alm, Jessica J.; Aro, Hannu T.] Turku Univ Hosp, FIN 20520 Turku, Finland.
C3 University of Turku; University of Turku; University of Turku
RP Laine, SK (通讯作者)，Univ Turku, Dept Cell Biol & Anat, Inst Biomed, Skeletal Biol Consortium, Kiinamyllynkatu 10, FI 20520 Turku, Finland.
EM sksuom@utu.fi
OI Aro, Hannu/0000 0003 3118 9144; Alm, Jessica/0000 0002 2066 9073
FU Academy of Finland [116307]; Academy of Finland (AKA) [116307] Funding
   Source: Academy of Finland (AKA)
FX Grant sponsor: Academy of Finland; Grant number: 116307.
CR Abdallah BM, 2009, J CELL PHYSIOL, V218, P9, DOI 10.1002/jcp.21572
   Akiyama H, 2008, MOD RHEUMATOL, V18, P213, DOI 10.1007/s10165 008 0048 x
   Akiyama H, 2011, J BONE MINER METAB, V29, P390, DOI 10.1007/s00774 011 0273 9
   Alm JJ, 2010, J ORTHOP RES, V28, P1634, DOI 10.1002/jor.21167
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bork S, 2011, J CELL PHYSIOL, V226, P2226, DOI 10.1002/jcp.22557
   Cheng LC, 2009, NAT NEUROSCI, V12, P399, DOI 10.1038/nn.2294
   Dudek KA, 2010, J BIOL CHEM, V285, P24381, DOI 10.1074/jbc.M110.111328
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Farrell BC, 2011, INT J DEV NEUROSCI, V29, P31, DOI 10.1016/j.ijdevneu.2010.10.001
   Goff LA, 2008, EXP HEMATOL, V36, P1354, DOI 10.1016/j.exphem.2008.05.004
   Grandjean V, 2009, DEVELOPMENT, V136, P3647, DOI 10.1242/dev.041061
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Hung C, 2006, SCAND J SURG, V95, P81, DOI 10.1177/145749690609500202
   Karbiener M, 2009, BIOCHEM BIOPH RES CO, V390, P247, DOI 10.1016/j.bbrc.2009.09.098
   Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106
   Kim YJ, 2012, J CELL PHYSIOL, V227, P183, DOI 10.1002/jcp.22716
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Kim YJ, 2009, J BONE MINER RES, V24, P816, DOI 10.1359/JBMR.081230
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092 8674(93)90529 Y
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Martinez Sanchez A, 2012, J BIOL CHEM, V287, P916, DOI 10.1074/jbc.M111.302430
   Miyaki S, 2010, GENE DEV, V24, P1173, DOI 10.1101/gad.1915510
   Miyaki S, 2009, ARTHRITIS RHEUM US, V60, P2723, DOI 10.1002/art.24745
   Nakamachi Y, 2009, ARTHRITIS RHEUM US, V60, P1294, DOI 10.1002/art.24475
   Pais H, 2010, RNA, V16, P489, DOI 10.1261/rna.1701210
   PROCKOP DJ, 1997, SCIENCE, V276, P71, DOI [DOI 10.1126/SCIENCE.276.5309.71, 10.1126/science.276.5309.71]
   Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102
   Reilly GC, 2007, BIOMATERIALS, V28, P4091, DOI 10.1016/j.biomaterials.2007.05.038
   Robins JC, 2005, BONE, V37, P313, DOI 10.1016/j.bone.2005.04.040
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schoolmeesters A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005605
   Skarn M, 2011, STEM CELLS DEV
   Suomi S, 2008, GENE REGUL SYST BIO, V2, P177
   Tomé M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167
   Tuddenham L, 2006, FEBS LETT, V580, P4214, DOI 10.1016/j.febslet.2006.06.080
   Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213
   Wagner W, 2007, STEM CELL REV, V3, P239, DOI 10.1007/s12015 007 9001 1
   Yang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021679
   Yang Z, 2011, STEM CELLS DEV, V20, P259, DOI 10.1089/scd.2010.0072
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018 002 8490 y
NR 44
TC 101
Z9 122
U1 0
U2 43
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG
PY 2012
VL 113
IS 8
BP 2687
EP 2695
DI 10.1002/jcb.24144
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 959TB
UT WOS:000305334900015
PM 22441842
DA 2025 08 17
ER

PT J
AU Mahardawi, B
   Tompkins, KA
   Mattheos, N
   Arunjaroensuk, S
   Pimkhaokham, A
AF Mahardawi, Basel
   Tompkins, Kevin A.
   Mattheos, Nikos
   Arunjaroensuk, Sirida
   Pimkhaokham, Atiphan
TI Periosteum derived Micrografts for bone regeneration
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Alveolar bone grafting; bone regeneration; dental implants;
   osteogenesis; periosteum
ID EXTRACTION SOCKETS; OSTEOBLAST DIFFERENTIATION; BIOACTIVE GLASS; TOOTH
   EXTRACTION; GENE EXPRESSION; GROWTH FACTOR; STEM CELL; IN VITRO;
   AUGMENTATION; SUBSTITUTES
AB Bone regeneration is currently one of the most widely researched topics in regenerative medicine. Several bone grafting materials have been introduced and compared. However, the limitations of the currently available grafts have led researchers to investigate new materials to be used. In contrast, the periosteum performs endogenous bone regeneration as seen in physiological bone fracture repair, and transplanted periosteum has been used to induce bone regeneration in animal models. Although many of the introduced bone grafting materials have not been clinically evaluated, the use of the periosteum for bone regeneration has been documented in several clinical situations. Recently, the Micrograft concept, which was initially used to treat burn patients, where the tissue sample is cut into smaller pieces to expand the area that they can cover, has been applied to oral periosteal tissue for inclusion in scaffolds for bone defect healing, and was evaluated in various clinical bone augmentation procedures. This article first presents a brief overview of some of the commonly used bone grafts and their limitations. Next, it provides background information on the periosteum, including its histology and the cell biology and signaling involved in its osteogenic effect, periosteum derived Micrografts, their osteogenic potential, and their recent clinical applications for bone augmentation.
C1 [Mahardawi, Basel; Mattheos, Nikos; Arunjaroensuk, Sirida; Pimkhaokham, Atiphan] Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Bangkok, Thailand.
   [Tompkins, Kevin A.] Chulalongkorn Univ, Fac Dent, Off Res Affairs, Bangkok, Thailand.
   [Mattheos, Nikos] Karolinska Inst, Dept Dent Med, Stockholm, Sweden.
   [Pimkhaokham, Atiphan] Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, 34 Henri Dunant Rd, Bangkok 10330, Thailand.
C3 Chulalongkorn University; Chulalongkorn University; Karolinska
   Institutet; Chulalongkorn University
RP Pimkhaokham, A (通讯作者)，Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, 34 Henri Dunant Rd, Bangkok 10330, Thailand.
EM atiphan.p@chula.ac.th
RI Mahardawi, Basel/AEA 9773 2022; Pimkhaokham, Atiphan/AAQ 4177 2021;
   Mattheos, Nikos/C 8614 2011
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   Akbarzadeh Baghban Alireza, 2009, Iran Endod J, V4, P125
   Akiyama M, 2021, BMC RES NOTES, V14, DOI 10.1186/s13104 021 05825 z
   Akiyama Mari, 2018, Open Biomed Eng J, V12, P75, DOI 10.2174/1874120701812010075
   Al Nawas B, 2014, EUR J ORAL IMPLANTOL, V7, pS219
   Apriawan Tedy, 2022, Surg Neurol Int, V13, P140, DOI 10.25259/SNI_62_2022
   Astarita C, 2020, J INT MED RES, V48, DOI 10.1177/0300060520914794
   Bahney CS, 2019, J ORTHOP RES, V37, P35, DOI 10.1002/jor.24170
   Baino F, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00202
   Becker W, 1998, J PERIODONTOL, V69, P414, DOI 10.1902/jop.1998.69.4.414
   Bernardo MP, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 05207 w
   Bilkay U, 2008, J CRANIOFAC SURG, V19, P453, DOI 10.1097/SCS.0b013e318052fe3d
   Camargo PM, 2000, ORAL SURG ORAL MED O, V90, P581, DOI 10.1067/moe.2000.110035
   Cao Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0244 5
   Ceccarelli G, 2017, MOLECULES, V22, DOI 10.3390/molecules22122109
   Ceccarelli G, 2016, J CELL PHYSIOL, V231, P607, DOI 10.1002/jcp.25104
   Chacko Neelathil Lisa, 2014, J Int Oral Health, V6, P20
   Chang H, 2012, STEM CELL TRANSL MED, V1, P480, DOI 10.5966/sctm.2011 0056
   d'Aquino R., 2016, J Transl Sci, V2, P125, DOI [10.15761/jts.1000128, DOI 10.15761/JTS.1000128]
   De Bari C, 2006, ARTHRITIS RHEUM, V54, P1209, DOI 10.1002/art.21753
   de Lageneste OD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03124 z
   Debnath S, 2018, NATURE, V562, P133, DOI 10.1038/s41586 018 0554 8
   Deng BP, 2015, EXP THER MED, V10, P31, DOI 10.3892/etm.2015.2457
   Donzelli E, 2007, ARCH ORAL BIOL, V52, P64, DOI 10.1016/j.archoralbio.2006.07.007
   Dwek JR, 2010, SKELETAL RADIOL, V39, P319, DOI 10.1007/s00256 009 0849 9
   El Chaar ES, 2013, IMPLANT DENT, V22, P120, DOI 10.1097/ID.0b013e3182859869
   Eskow AJ, 2014, J PERIODONTOL, V85, P514, DOI 10.1902/jop.2013.130178
   Fei YR, 2011, J BIOL CHEM, V286, P40575, DOI 10.1074/jbc.M111.274910
   Ferrarotti F, 2018, J CLIN PERIODONTOL, V45, P841, DOI 10.1111/jcpe.12931
   Ferraz EP, 2015, J DENT, V43, P110, DOI 10.1016/j.jdent.2014.10.010
   Ferretti Concetta, 2014, World J Stem Cells, V6, P266, DOI 10.4252/wjsc.v6.i3.266
   Foolen J, 2008, J ORTHOP RES, V26, P1263, DOI 10.1002/jor.20586
   Froum S, 2002, J PERIODONTOL, V73, P94, DOI 10.1902/jop.2002.73.1.94
   Froum SJ, 2013, INT J PERIODONT REST, V33, P269, DOI 10.11607/prd.1614
   Giuliani A, 2013, STEM CELL TRANSL MED, V2, P316, DOI 10.5966/sctm.2012 0136
   Haugen HJ, 2019, J CLIN PERIODONTOL, V46, P92, DOI 10.1111/jcpe.13058
   Hing KA, 2005, INT J APPL CERAM TEC, V2, P184, DOI 10.1111/j.1744 7402.2005.02020.x
   Huh JY, 2005, ORAL SURG ORAL MED O, V100, P296, DOI 10.1016/j.tripleo.2004.12.015
   Jin Y, 2020, PEERJ, V8, DOI 10.7717/peerj.10374
   Joshi Chaitanya Pradeep, 2016, J Indian Soc Periodontol, V20, P429, DOI 10.4103/0972 124X.188335
   Kamm T, 2015, HNO, V63, P481, DOI 10.1007/s00106 015 0031 8
   Kangwannarongkul T, 2018, INT J ORAL MAX IMPL, V33, P541, DOI 10.11607/jomi.6234
   Kawakami S, 2021, INT J IMPLANT DENT, V7, DOI 10.1186/s40729 020 00288 6
   Kawakami S, 2019, INT J ORAL MAX IMPL, V34, P651, DOI 10.11607/jomi.7021
   Kemppainen J, 2014, CONNECT TISSUE RES, V55, P146, DOI 10.3109/03008207.2014.923851
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kumar V, 2022, CLEFT PALATE CRAN J, V59, P833, DOI 10.1177/10556656211025197
   Kunert Keil C, 2015, MAT SCI ENG C MATER, V46, P177, DOI 10.1016/j.msec.2014.10.033
   Lee DW, 2009, INT J ORAL MAX IMPL, V24, P609
   Lim SM, 2005, BIOTECHNOL LETT, V27, P607, DOI 10.1007/s10529 005 3625 5
   Lupi SM, 2018, CASE REP DENT, V2018, DOI 10.1155/2018/3023096
   Mahardawi B, 2023, INT J ORAL MAX SURG, V52, P604, DOI 10.1016/j.ijom.2022.10.014
   Mahardawi B, 2023, INT J ORAL MAX SURG, V52, P132, DOI 10.1016/j.ijom.2022.04.018
   Maragos P, 2002, INT J PERIODONT REST, V22, P493
   Matthews BG, 2021, ELIFE, V10, DOI 10.7554/eLife.58534
   Matthews BG, 2014, J BONE MINER RES, V29, P1283, DOI 10.1002/jbmr.2140
   Minamizato T, 2018, INT J ORAL MAX SURG, V47, P125, DOI 10.1016/j.ijom.2017.02.1279
   Miron RJ, 2016, CLIN ORAL IMPLAN RES, V27, P668, DOI 10.1111/clr.12647
   NAKAHARA H, 1990, BONE, V11, P181, DOI 10.1016/8756 3282(90)90212 H
   Nisar Numaan, 2020, J Dent Res Dent Clin Dent Prospects, V14, P139, DOI 10.34172/joddd.2020.028
   Norton MR, 2003, CLIN ORAL IMPLAN RES, V14, P775, DOI 10.1046/j.0905 7161.2003.00952.x
   Norton MR, 2002, INT J ORAL MAX IMPL, V17, P249
   Ortinau LC, 2019, CELL STEM CELL, V25, P784, DOI 10.1016/j.stem.2019.11.003
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Reich KM, 2011, ORAL DIS, V17, P33, DOI 10.1111/j.1601 0825.2010.01699.x
   RITSILA VA, 1994, CLIN ORTHOP RELAT R, P259
   Rizzi SC, 2001, J BIOMED MATER RES, V55, P475, DOI 10.1002/1097 4636(20010615)55:4<475::AID JBM1039>3.0.CO;2 Q
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   Baena RRY, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00087
   Schliephake H, 2015, CLIN IMPLANT DENT R, V17, P247, DOI 10.1111/cid.12114
   Schroeder JE, 2011, INJURY, V42, P609, DOI 10.1016/j.injury.2011.03.029
   Serino G, 2008, CLIN ORAL IMPLAN RES, V19, P26, DOI 10.1111/j.1600 0501.2007.01311.x
   Song E, 2006, BIOMATERIALS, V27, P2951, DOI 10.1016/j.biomaterials.2006.01.015
   SQUIER CA, 1990, J ANAT, V171, P233
   Sun JS, 2002, BIOMATERIALS, V23, P3377, DOI 10.1016/S0142 9612(02)00038 8
   Suwanwela J, 2017, INT J ORAL MAX IMPL, V32, P611, DOI 10.11607/jomi.5052
   Tanabe Shihori, 2014, World J Stem Cells, V6, P24, DOI 10.4252/wjsc.v6.i1.24
   Tong CK, 2011, CELL BIOL INT, V35, P221, DOI 10.1042/CBI20100326
   Turhani D, 2005, INT J ORAL MAX SURG, V34, P543, DOI 10.1016/j.ijom.2004.10.023
   Valta MP, 2006, ENDOCRINOLOGY, V147, P2171, DOI 10.1210/en.2005 1502
   Wang T, 2017, J CELL PHYSIOL, V232, P913, DOI 10.1002/jcp.25641
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Wong RWK, 2006, J ORAL MAXIL SURG, V64, P770, DOI 10.1016/j.joms.2006.01.008
   Wood RA, 2012, J PERIODONTOL, V83, P329, DOI 10.1902/jop.2011.110270
   Wu D, 2019, BMC ORAL HEALTH, V19, DOI 10.1186/s12903 019 0970 7
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zhao R, 2021, MOLECULES, V26, DOI 10.3390/molecules26103007
   Zhao XY, 2017, MAT SCI ENG C MATER, V78, P658, DOI 10.1016/j.msec.2017.03.186
   Zimmermann G, 2011, INJURY, V42, pS16, DOI 10.1016/j.injury.2011.06.199
NR 89
TC 4
Z9 5
U1 1
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD JUL 4
PY 2023
VL 64
IS 4
BP 400
EP 412
DI 10.1080/03008207.2023.2206489
EA MAY 2023
PG 13
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA K8LY7
UT WOS:000990142200001
PM 37195000
DA 2025 08 17
ER

PT J
AU Ivanyuk, A
   Segarra, NG
   Buclin, T
   Klein, A
   Jacquier, D
   Newman, CJ
   Bloetzer, C
AF Ivanyuk, Anton
   Segarra, Nuria Garcia
   Buclin, Thierry
   Klein, Andrea
   Jacquier, David
   Newman, Christopher J.
   Bloetzer, Clemens
TI Myoglobinuria in two patients with Duchenne muscular dystrophy after
   treatment with zoledronate: a case report and call for caution
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Duchenne muscular dystrophy; myoglobinuria; bisphosphonates; zoledronate
ID BISPHOSPHONATE THERAPY; DOUBLE BLIND; OSTEOPOROSIS; RHABDOMYOLYSIS;
   ALENDRONATE; CHILDREN; BOYS
AB Rhabdomyolysis with myoglobinuria is a recognized complication of dystrophinopathies. It can be triggered by infections, exercise or volatile anesthetics. To our knowledge, it has never been reported in boys with Duchenne muscular dystrophy (DMD) after the administration of bisphosphonates. We report two patients with DMD who presented an apparent transient rhabdomyolysis with myoglobinuria after zoledronate administration. Possible mechanisms could involve hypophosphatemia, a known dose dependent side effect of bisphosphonates, and/or direct myotoxicity of biphosphonates. Physicians and families should be aware of rhabdomyolysis with myoglobinuria as a potential uncommon side effect of bisphosphonates in DMD, in particular of zoledronate. (C) 2018 Published by Elsevier B.V.
C1 [Ivanyuk, Anton; Buclin, Thierry] CHU Vaudois, Serv Clin Pharmacol, Lausanne Univ Hosp, Bugnon 17, CH 1011 Lausanne, Switzerland.
   [Segarra, Nuria Garcia] CHU Vaudois, Ctr Mol Dis, Lausanne Univ Hosp, Div Genet Med, Pierre Decker 2, CH 1011 Lausanne, Switzerland.
   [Klein, Andrea; Jacquier, David; Newman, Christopher J.; Bloetzer, Clemens] CHU Vaudois, Paediat Neurol & Neurorehabil Unit, Lausanne Univ Hosp, Pierre Decker 5, CH 1011 Lausanne, Switzerland.
   [Klein, Andrea] UKBB, Pediat Neurol, Univ Childrens Hosp Basel, Basel, Switzerland.
   [Klein, Andrea] Inselspital Bern, Bern, Switzerland.
   [Bloetzer, Clemens] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland.
C3 University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV);
   University of Basel; University of Bern
RP Ivanyuk, A (通讯作者)，CHU Vaudois, Serv Clin Pharmacol, Lausanne Univ Hosp, Bugnon 17, CH 1011 Lausanne, Switzerland.
EM anton.ivanyuk@chuv.ch
RI ; Newman, Christopher John/Y 1822 2019; Buclin, Thierry/P 1640 2014;
   Newman, Christopher/Y 1822 2019; Jacquier, David/AAJ 5733 2020
OI Jacquier, David/0000 0002 6173 2905; Newman, Christopher
   John/0000 0002 9874 6681; Klein, Andrea/0000 0003 2733 5911; Buclin,
   Thierry/0000 0003 0639 5536; 
CR Bell JM, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010899.pub2
   Bishop N, 2014, J CLIN DENSITOM, V17, P275, DOI 10.1016/j.jocd.2014.01.004
   Buckner JL, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/928385
   Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474 4422(09)70271 6
   Buyse GM, 2015, LANCET, V385, P1748, DOI 10.1016/S0140 6736(15)60025 3
   Easthope Mowatt Y, 2010, NEUROMUSCULAR DISORD, V20, pS7, DOI 10.1016/j.nmd.2010.07.272
   George S, 2015, J CLIN ENDOCR METAB, V100, P4163, DOI 10.1210/jc.2015 2680
   Gordon KE, 2011, PEDIATRICS, V127, pE353, DOI 10.1542/peds.2010 1666
   Hawker GA, 2005, ARCH PHYS MED REHAB, V86, P284, DOI 10.1016/j.apmr.2004.04.021
   HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092 8674(87)90579 4
   Houston C, 2014, MUSCLE NERVE, V49, P506, DOI 10.1002/mus.23948
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Mah JK, 2014, NEUROMUSCULAR DISORD, V24, P482, DOI 10.1016/j.nmd.2014.03.008
   Matzno S, 2009, J PHARM PHARMACOL, V61, P781, DOI [10.1211/jpp/61.06.0011, 10.1211/jpp.61.06.0011]
   McDonald CM, 2017, LANCET, V390, P1489, DOI 10.1016/S0140 6736(17)31611 2
   Merck & Co.  Inc., 2012, FOS PRESCR INF
   Sbrocchi AM, 2012, OSTEOPOROSIS INT, V23, P2703, DOI 10.1007/s00198 012 1911 3
   Schaefer M, 2010, P END SOC 92 ANN M J
   SINGHAL PC, 1992, AM J MED, V92, P458, DOI 10.1016/0002 9343(92)90740 3
   Srinivasan R, 2016, MUSCLE NERVE, V54, P79, DOI 10.1002/mus.24991
   Syed YY, 2016, DRUGS, V76, P1699, DOI 10.1007/s40265 016 0657 1
   Uppsala Monitoring Center, WHO GLOB IND CAS SAF
   Vierucci F, 2017, CURR OPIN RHEUMATOL, V29, P535, DOI 10.1097/BOR.0000000000000423
   Ward LM, 2016, OSTEOPOROSIS INT, V27, P2147, DOI 10.1007/s00198 016 3515 9
NR 24
TC 10
Z9 11
U1 0
U2 3
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 8966
EI 1873 2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT
PY 2018
VL 28
IS 10
BP 865
EP 867
DI 10.1016/j.nmd.2018.08.004
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA GZ1KF
UT WOS:000449126300008
PM 30217487
DA 2025 08 17
ER

PT J
AU O'Connor, JP
   Capo, JT
   Tan, V
   Cottrell, JA
   Manigrasso, MB
   Bontempo, N
   Parsons, JR
AF O'Connor, J. Patrick
   Capo, John T.
   Tan, Virak
   Cottrell, Jessica A.
   Manigrasso, Michaele B.
   Bontempo, Nicholas
   Parsons, J. Russell
TI A comparison of the effects of ibuprofen and rofecoxib on rabbit fibula
   osteotomy healing
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RATS; INDOMETHACIN; ANGIOGENESIS;
   PREVENTION; PHARMACOKINETICS; INHIBITION; METABOLISM; EXCRETION;
   CELECOXIB
AB Background and purpose Non steroidal anti inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) activity, which is the rate limiting enzyme in the synthesis of prostaglandins. Previous studies have indicated that NSAID therapy, and in particular NSAIDs that specifically target the inflammatory cyclooxygenase (COX 2), impair bone healing. We compared the effects of ibuprofen and rofecoxib on fibula osteotomy healing in rabbits to determine whether nominal, continuous inhibition of COX 2 with rofecoxib would differentially affect fracture healing more than cyclical inhibition of COX 2 using ibuprofen, which inhibits COX 1 and COX 2 and has a short half life in vivo.
   Methods Bilateral fibula osteotomies were done in 67 skeletally mature male New Zealand white rabbits. The rabbits were treated with placebo, rofecoxib (12.5 mg once a day), or ibuprofen (50 mg 3 times a day) for 28 days after surgery. Plasma ibuprofen levels were measured by HPLC analysis. Bone healing was assessed by histomorphometry at 3 and 6 weeks after osteotomy, and at 6 and 12 weeks by torsional mechanical testing.
   Results Plasma ibuprofen levels peaked and declined between successive doses. Fracture callus morphology was abnormal in the rofecoxib treated rabbits and torsional mechanical testing showed that fracture healing was impaired. Ibuprofen treatment caused persistence of cartilage within the fracture callus and reduced peak torque at 6 weeks after osteotomy as compared to the fibulas from the placebo treated rabbits. In the specimens allowed to progress to possible healing, non union was seen in 5 of the 26 fibulas from the rofecoxib treated animals as compared to 1 of 24 in the placebo group and 1 of 30 in the ibuprofen treatment group.
   Interpretation Continuous COX 2 inhibition as modeled by rofecoxib treatment appears to be more deleterious to fracture repair than cyclical cyclooxygenase inhibition as modeled by ibuprofen treatment. Ibuprofen treatment appeared to delay bone healing based upon the persistence of cartilage within the fracture callus and diminished shear modulus. Despite the ibuprofen induced delay, rofecoxib treatment produced worse fracture (osteotomy) healing than ibuprofen treatment.
C1 [O'Connor, J. Patrick] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.
   Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Orthopaed, Newark, NJ 07103 USA.
   Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.
   Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Dept Orthopaed, Newark, NJ 07103 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers University System; Rutgers University New Brunswick;
   Rutgers University Biomedical & Health Sciences; Rutgers University
   System; Rutgers University New Brunswick; Rutgers University Biomedical
   & Health Sciences
RP O'Connor, JP (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.
EM oconnojp@umdnj.edu
FU Wyeth Consumer Healthcare
FX This work was supported by a grant from Wyeth Consumer Healthcare to
   JPOC. We thank Kenneth Bono, Matthew P. Wolenski, Stephen P. Jacobsen,
   Jules Hip Flores, Markus F. Meyenhofer, David J. Svach, Celestine
   Nnaeto, Rebecca Wilusz, Dovid Moradi, and Kristin Francisco for their
   technical assistance in performing these studies. We are also grateful
   to Dr Robert Donnelly for his advice in the use of the Dionix HPLC
   system.
CR ALLEN HL, 1980, ACTA ORTHOP SCAND, V51, P595, DOI 10.3109/17453678008990848
   ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131 199505000 00006
   Baron R., 1983, Bone histomorphometry: Techniques and interpretation, P13
   Brideau C, 1996, INFLAMM RES, V45, P68, DOI 10.1007/BF02265118
   Burd TA, 2003, J BONE JOINT SURG BR, V85B, P700, DOI 10.1302/0301 620X.85B5.13970
   Burd TA, 2001, J BONE JOINT SURG AM, V83A, P1783, DOI 10.2106/00004623 200112000 00003
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Halpin RA, 2000, DRUG METAB DISPOS, V28, P1244
   Hausman MR, 2001, BONE, V29, P560, DOI 10.1016/S8756 3282(01)00608 1
   KELLER J, 1993, ACTA ORTHOP SCAND, V64, P59, DOI 10.3109/17453679308994530
   Maniatopoulos C, 1986, Int J Oral Maxillofac Implants, V1, P31
   Murnaghan M, 2006, J BONE JOINT SURG AM, V88A, P140, DOI 10.2106/JBJS.F.00454
   O'Connor JP, 2008, DRUG TODAY, V44, P693, DOI 10.1358/dot.2008.44.9.1251573
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Paulson SK, 2000, DRUG METAB DISPOS, V28, P514
   Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711
   Seno H, 2002, CANCER RES, V62, P506
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Steinmeyer J, 2000, ARTHRITIS RES, V2, P379, DOI 10.1186/ar116
   Teng XW, 2003, J CHROMATOGR B, V796, P225, DOI 10.1016/j.jchromb.2003.07.010
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   WILLIAMS KM, 1991, AGENTS ACTIONS, V34, P381, DOI 10.1007/BF01988732
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
NR 24
TC 49
Z9 51
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1745 3674
EI 1745 3682
J9 ACTA ORTHOP
JI Acta Orthop.
PY 2009
VL 80
IS 5
BP 597
EP 605
DI 10.3109/17453670903316769
PG 9
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 530SE
UT WOS:000272611800018
PM 19916696
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bukhari, SNA
   Hussain, F
   Thu, HE
   Hussain, Z
AF Bukhari, Syed Nasir Abbas
   Hussain, Fahad
   Thu, Hnin Ei
   Hussain, Zahid
TI Synergistic effects of combined therapy of curcumin and Fructus
   Ligustri Lucidi for treatment of osteoporosis: cellular and
   molecular evidence of enhanced bone formation
SO JOURNAL OF INTEGRATIVE MEDICINE JIM
LA English
DT Article
DE Osteoporosis; Curcumin; Fructus Ligustri Lucidi; Combined herbal
   therapy; Cell proliferation; Cell differentiation; Bone formation
ID MORPHOGENETIC PROTEIN 2; ALKALINE PHOSPHATASE; EURYCOMA LONGIFOLIA;
   IN VITRO; MINERALIZATION; CELLS; DIFFERENTIATION; OSTEOPONTIN;
   ANTIOXIDANT; OSTEOCALCIN
AB Objective: The present study explored the effects of the combined herbal therapy consisting of curcumin (CUR) and Fructus Ligustri Lucidi (FLL) on aspects of bone regeneration.
   Methods: Prior to analyzing the ability of this novel combined herbal therapy to promote aspects of bone regeneration, its cytotoxicity was determined using MC3T3 E1 cells (pre osteoblast model). Cell proliferation was evaluated using phase contrast microscopy and cell differentiation was estimated using alkaline phosphatase activity. The effect of the combined herbal therapy (CUR + FLL) was also assessed in terms of mineralization in the extracellular matrix (ECM) of cultured cells. Further, to explore the molecular mechanisms of bone formation, time dependent expression of bone regulating protein biomarkers was also evaluated.
   Results: Combined herbal therapy (CUR + FLL) significantly upregulated the viability, proliferation and differentiation of MC3T3 E1 cells compared to the monotherapy of CUR or FLL. The magnitude of ECM mineralization (calcium deposition) was also higher in MC3T3 E1 cells treated with combined therapy. The time dependent expression of bone forming protein biomarkers revealed that the tendency of expression of these bone regulating proteins was remarkably higher in cells treated with combined therapy.
   Conclusion: The co administration of CUR and FLL had superior promotion of elements of bone regeneration in cultured cells, thus could be a promising alternative herbal therapy for the management of bone erosive disorders such as osteoporosis.
   Please cite this article as: Bukhari SNA, Hussain F, Thu HE, Hussain Z. Synergistic effects of combined therapy of curcumin and Fructus Ligustri Lucidi for treatment of osteoporosis: cellular and molecular evidence of enhanced bone formation. J Integr Med. 2019; 17(1): 38 45. (C) 2018 Shanghai Changhai Hospital. Published by Elsevier B.V. All rights reserved.
C1 [Bukhari, Syed Nasir Abbas] Aljouf Univ, Coll Pharm, Dept Pharmaceut Chem, Aljouf 2014, Sakaka, Saudi Arabia.
   [Hussain, Fahad] Univ Lahore, IMBB, Lahore 55150, Pakistan.
   [Thu, Hnin Ei] Lincoln Univ Coll, Fac Dent, Dept Pharmacol & Dent Therapeut, Petaling Jaya 47301, Selangor, Malaysia.
   [Hussain, Zahid] Univ Teknol MARA UiTM, Fac Pharm, Dept Pharmaceut, Puncak Alam Campus, Bandar Puncak Alam 42300, Selangor, Malaysia.
C3 Al Jouf University; University of Lahore; Lincoln University College;
   Universiti Teknologi MARA
RP Hussain, Z (通讯作者)，Univ Teknol MARA UiTM, Fac Pharm, Dept Pharmaceut, Puncak Alam Campus, Bandar Puncak Alam 42300, Selangor, Malaysia.
EM zahidh85@yahoo.com
RI ; Thu, Hnin Ei/AFR 8954 2022; Bukhari, Syed/R 3825 2017; HUSSAIN,
   ZAHID/AAX 8822 2020; Bukhari, Syed Nasir Abbas/R 3825 2017
OI Hussain, Zahid/0000 0002 6978 3133; Thu, Hnin Ei/0000 0002 9665 7650;
   Bukhari, Syed Nasir Abbas/0000 0001 8125 7972
CR Ahn MS, 2004, KOREAN J FOOD CULTUR, V19, P170
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   Gao LL, 2015, NAT PROD RES, V29, P493, DOI 10.1080/14786419.2014.954114
   Hussain F, 2017, ASIAN PAC J TROP BIO, V7, P950, DOI 10.1016/j.apjtb.2017.09.015
   Hussain Z, 2017, BIOMED PHARMACOTHER, V93, P596, DOI 10.1016/j.biopha.2017.06.087
   Hussain Z, 2017, MAT SCI ENG C MATER, V77, P1316, DOI 10.1016/j.msec.2017.03.226
   Hussain Z, 2017, COLLOID SURFACE B, V150, P223, DOI 10.1016/j.colsurfb.2016.11.036
   Jin H., 2008, J JILIN I CHEM TECHN, V25, P35
   Kaunitz Andrew M, 2009, J Fam Pract, V58, pS1
   Ko Chun Hay, 2010, Chin Med, V5, P39, DOI 10.1186/1749 8546 5 39
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Leboime A, 2010, JOINT BONE SPINE, V77, pS107, DOI 10.1016/S1297 319X(10)70004 X
   Lee YS, 2011, INT IMMUNOPHARMACOL, V11, P712, DOI 10.1016/j.intimp.2011.01.018
   Liu JL, 2015, BIO MED MATER ENG, V26, pS2041, DOI 10.3233/BME 151509
   Liu JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099920
   Luppen CA, 2003, J BIOL CHEM, V278, P44995, DOI 10.1074/jbc.M306730200
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Miao Q, 2012, INT J MOL SCI, V13, P56, DOI 10.3390/ijms13010056
   Moran JM, 2012, INT J MOL SCI, V13, P16104, DOI 10.3390/ijms131216104
   Ohba S, 2007, BIOCHEM BIOPH RES CO, V357, P854, DOI 10.1016/j.bbrc.2007.03.173
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Raida M, 2006, INT J MOL MED, V18, P735
   Sakamoto W, 2005, BBA MOL BASIS DIS, V1740, P12, DOI 10.1016/j.bbadis.2005.03.004
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
   Thu H., 2016, INT J PHARM PHARM SC, V8, P199, DOI [10.22159/ijpps.2016v8i11.14518, DOI 10.22159/ijpps.2016v8i11.14518]
   Thu HE, 2017, CHIN J NAT MEDICINES, V15, P71, DOI 10.1016/S1875 5364(17)30010 9
   Thu HE, 2017, J ETHNOPHARMACOL, V195, P143, DOI 10.1016/j.jep.2016.10.085
   Tsutsumi K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086834
   WEINREB M, 1990, J BONE MINER RES, V5, P831
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Zhang Y, 2006, BIOL PHARM BULL, V29, P291, DOI 10.1248/bpb.29.291
   Zhang Y, 2008, BRIT J NUTR, V99, P494, DOI 10.1017/S0007114507801589
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
NR 35
TC 26
Z9 29
U1 1
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095 4964
J9 J INTEGR MED JIM
JI J. Integr. Med. JIM
PD JAN
PY 2019
VL 17
IS 1
BP 38
EP 45
DI 10.1016/j.joim.2018.08.003
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA HG5XX
UT WOS:000455055500008
PM 30139656
DA 2025 08 17
ER

PT J
AU Li, D
   Shao, LP
   Zhou, HY
   Jiang, W
   Zhang, W
   Xu, Y
AF Li, Dan
   Shao, Leping
   Zhou, Haiyan
   Jiang, Wei
   Zhang, Wei
   Xu, Yan
TI The efficacy of cinacalcet combined with conventional therapy on bone
   and mineral metabolism in dialysis patients with secondary
   hyperparathyroidism: a meta analysis
SO ENDOCRINE
LA English
DT Article
DE Cinacalcet; Dialysis; KDOQI; Secondary hyperparathyroidism
ID HEMODIALYSIS PATIENTS; VASCULAR CALCIFICATION; VITAMIN D; DISEASE; HCL;
   CALCIUM; SENSIPAR/MIMPARA; CALCIMIMETICS; HYDROCHLORIDE; CALCITRIOL
AB Cinacalcet, the first calcimimetic to be approved for the treatment of secondary hyperparathyroidism (SHPT) in the chronic kidney disease patients, offers a novel therapeutic approach to SHPT. The aim of this meta analysis is to access the efficacy and safety of cinacalcet on bone and mineral metabolism disorders in the dialysis patients with SHPT. Randomized controlled trials on cinacalcet combined with vitamin D and/or phosphate binders in the dialysis patients with SHPT were identified in Pubmed, Sciencedirect, and the Cochrane library. Data were analyzed with RevMan software. We compared the proportion of patients achieving the biochemical targets recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and the incidence of adverse events between the cinacalcet and control groups. Six trials involving 2,548 patients were included. A greater proportion of patients in the cinacalcet group compared with the conventional group achieved the KDOQI targets. The relative risks (RRs) were parathyroid hormone (PTH) (RR = 3.51, 95 % CI: 2.38 5.17), calcium (RR = 2.04, 95 % CI: 1.76 2.37), phosphorus (RR = 1.15, 95 % CI: 0.83 1.60), and calcium phosphorus product (Ca x P) (RR = 1.41, 95 % CI: 1.18 1.69), the number of patients simultaneously achieving the KDOQI targets for PTH + Ca x P was also greater (RR = 3.89, 95 % CI: 2.36 6.41), with p < 0.001 for each. The most common adverse events were nausea, vomiting, diarrhea, and hypocalcemia, which had a higher incidence in the cinacalcet group, but were usually mild to moderate in severity and transient. Compared with conventional therapy, treatment with cinacalcet results in more patients achieving KDOQI targets and offers an effective and safety therapeutic option for controlling mineral and bone disorders in the dialysis patients with SHPT.
C1 [Li, Dan; Shao, Leping; Zhou, Haiyan; Jiang, Wei; Zhang, Wei; Xu, Yan] Qingdao Univ, Dept Nephrol, Coll Med, Affiliated Hosp, Qingdao 266071, Shandong, Peoples R China.
C3 Qingdao University
RP Xu, Y (通讯作者)，Qingdao Univ, Dept Nephrol, Coll Med, Affiliated Hosp, 16 Jiangsu Rd, Qingdao 266071, Shandong, Peoples R China.
EM xuyan67@126.com
RI Xu, Yan/IQS 1405 2023; Sun, Haoyang/KHD 3534 2024
FU Natural Science Foundation of China [81170688]
FX This research received a research grant from Natural Science Foundation
   of China (No. 81170688). All authors have no conflict of financial
   interest.
CR Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Boer Rob, 2012, J Med Econ, V15, P509, DOI 10.3111/13696998.2012.664799
   Brown AJ, 2007, J STEROID BIOCHEM, V103, P578, DOI 10.1016/j.jsbmb.2006.12.089
   Cano NJM, 2007, J AM SOC NEPHROL, V18, P2583, DOI 10.1681/ASN.2007020184
   Chertow GM, 2012, HEMODIAL INT, V16, P188, DOI 10.1111/j.1542 4758.2011.00642.x
   Chonchol M, 2009, AM J KIDNEY DIS, V53, P197, DOI 10.1053/j.ajkd.2008.09.021
   Conzo G, 2012, ENDOCRINE, V42, P606, DOI 10.1007/s12020 012 9648 5
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Danese MD, 2008, CLIN J AM SOC NEPHRO, V3, P1423, DOI 10.2215/CJN.01060308
   Duntas LH, 2011, ENDOCRINE, V39, P199, DOI 10.1007/s12020 011 9452 7
   Eandi M, 2010, PHARMACOECONOMICS, V28, P1041, DOI 10.2165/11538600 000000000 00000
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   El Shafey EM, 2011, THER APHER DIAL, V15, P547, DOI 10.1111/j.1744 9987.2011.00994.x
   Fishbane S, 2008, CLIN J AM SOC NEPHRO, V3, P1718, DOI 10.2215/CJN.01040308
   Garside R, 2007, NEPHROL DIAL TRANSPL, V22, P1428, DOI 10.1093/ndt/gfl774
   Greenbaum LA, 2005, PEDIATR NEPHROL, V20, P622, DOI 10.1007/s00467 004 1792 6
   Jean G, 2007, CLIN NEPHROL, V68, P63
   Ketteler M., 2011, NEPHROL DIAL TRANSPL, V0, P1
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Komaba H, 2010, CLIN J AM SOC NEPHRO, V5, P2305, DOI 10.2215/CJN.02110310
   Lien YHH, 2005, NEPHROL DIAL TRANSPL, V20, P1232, DOI 10.1093/ndt/gfh829
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Lucchi L, 2011, ARTIF ORGANS, V35, P1186, DOI 10.1111/j.1525 1594.2011.01270.x
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Muscheites J, 2008, PEDIATR NEPHROL, V23, P1823, DOI 10.1007/s00467 008 0810 5
   Nagano N, 2006, PHARMACOL THERAPEUT, V109, P339, DOI 10.1016/j.pharmthera.2005.06.019
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Ogata H., 2008, NDT PLUS S3, V1, P9
   Peacock M, 2011, J CLIN ENDOCR METAB, V96, pE9, DOI 10.1210/jc.2010 1221
   Peacock M, 2009, J CLIN ENDOCR METAB, V94, P4860, DOI 10.1210/jc.2009 1472
   Raposo JF, 2012, ENDOCRINE, V41, P309, DOI 10.1007/s12020 011 9521 y
   Seeherunvong W, 2006, PEDIATR NEPHROL, V21, P1434, DOI 10.1007/s00467 006 0204 5
   Shigematsu T, 2009, AM J NEPHROL, V29, P230, DOI 10.1159/000156717
   Spasovski GB, 2007, INT UROL NEPHROL, V39, P1209, DOI 10.1007/s11255 007 9276 9
   Steddon SJ, 2005, NEPHRON CLIN PRACT, V99, pC1, DOI 10.1159/000081787
   Sterrett JR, 2007, CLIN NEPHROL, V68, P10
   Uhlig K, 2010, AM J KIDNEY DIS, V55, P773, DOI 10.1053/j.ajkd.2010.02.340
   Ureña P, 2009, NEPHROL DIAL TRANSPL, V24, P2852, DOI 10.1093/ndt/gfp144
   Verberckmoes SC, 2007, KIDNEY INT, V71, P298, DOI 10.1038/sj.ki.5002028
   Yajima A, 2008, THER APHER DIAL, V12, pS38, DOI 10.1111/j.1744 9987.2008.00630.x
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
   Zitt E, 2011, WIEN KLIN WOCHENSCHR, V123, P45, DOI 10.1007/s00508 010 1515 x
NR 44
TC 18
Z9 18
U1 0
U2 55
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355 008X
EI 1559 0100
J9 ENDOCRINE
JI Endocrine
PD FEB
PY 2013
VL 43
IS 1
BP 68
EP 77
DI 10.1007/s12020 012 9711 2
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 064IY
UT WOS:000313069600013
PM 22669774
DA 2025 08 17
ER

PT J
AU Danesin, R
   Brun, P
   Roso, M
   Delaunay, F
   Samouillan, V
   Brunelli, K
   Iucci, G
   Ghezzo, F
   Modesti, M
   Castagliuolo, I
   Dettin, M
AF Danesin, Roberta
   Brun, Paola
   Roso, Martina
   Delaunay, Florian
   Samouillan, Valerie
   Brunelli, Katya
   Iucci, Giovanna
   Ghezzo, Francesca
   Modesti, Michele
   Castagliuolo, Ignazio
   Dettin, Monica
TI Self Assembling peptide enriched electrospun polycaprolactone scaffolds
   promote the h osteoblast adhesion and modulate
   differentiation associated gene expression
SO BONE
LA English
DT Article
DE Self assembling peptides; Polycaprolactone; RGD; Electrospinning;
   h osteoblasts
ID LOCAL DELIVERY; STROMAL CELLS; IN VITRO; PROLIFERATION; BIOMATERIALS;
   COLLAGEN
AB Electrospun polycaprolactone (PCL) is able to support the adhesion and growth of h osteoblasts and to delay their degradation rate to a greater extent with respect to other polyesters. The drawbacks linked to its employment in regenerative medicine arise from its hydrophobic nature and the lack of biochemical signals linked to it. This work reports on the attempt to add five different self assembling (SA) peptides to PCL solutions before electrospinning. The hybrid scaffolds obtained had regular fibers (SEM analysis) whose diameters were similar to those of the extracellular matrix, more stable hydrophilic (contact angle measurement) surfaces, and an amorphous phase constrained by peptides (DSC analysis). They appeared to have a notable capacity to promote the h osteoblast adhesion and differentiation process by increasing the gene expression of alkaline phosphatase, bone sialoprotein, and osteopontin. Adding an Arg Gly Asp (RGD) motif to a self assembling sequence was found to enhance cell adhesion, while the same motif condensed with a scrambled sequence did not, indicating that there is a cooperative effect between RGD and 3D architecture created by the self assembling peptides. The study demonstrates that self assembling peptide scaffolds are still able to promote beneficial effects on h osteoblasts even after they have been included in electrospun polycaprolactone. The possibility of linking biochemical messages to self assembling peptides could lead the way to a 3D decoration of fibrous scaffolds. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Danesin, Roberta; Roso, Martina; Brunelli, Katya; Ghezzo, Francesca; Modesti, Michele; Dettin, Monica] Univ Padua, Dept Ind Engn, I 35131 Padua, Italy.
   [Brun, Paola; Castagliuolo, Ignazio] Univ Padua, Dept Mol Med, I 35121 Padua, Italy.
   [Delaunay, Florian; Samouillan, Valerie] Univ Toulouse 3, Carnot Inst, CIRIMAT, UMR 5085, F 31062 Toulouse 09, France.
   [Iucci, Giovanna] Univ Roma Tre, Dept Phys E Amaldi, I 00146 Rome, Italy.
C3 University of Padua; University of Padua; Universite de Toulouse;
   Universite Federale Toulouse Midi Pyrenees (ComUE); Universite Toulouse
   III   Paul Sabatier; Institut National Polytechnique de Toulouse; Centre
   National de la Recherche Scientifique (CNRS); Roma Tre University
RP Dettin, M (通讯作者)，Univ Padua, Dept Ind Engn, Via Marzolo 9, I 35131 Padua, Italy.
EM roberta.danesin@unipd.it; paola.brun.1@unipd.it; martina.roso@unipd.it;
   florian.delaunay@gmail.com; vsamou@cict.fr; katya.brunelli@unipd.it;
   iucci@uniroma3.it; francesca.ghezzo@unipd.it; michele.modesti@unipd.it;
   ignazio.castagliuolo@unipd.it; monica.dettin@unipd.it
RI Samouillan, Valerie/KIB 7176 2024; CASTAGLIUOLO, IGNAZIO/K 9963 2016;
   castagliuolo, ignazio/K 9963 2016; Brun, Paola/A 3380 2016
OI CASTAGLIUOLO, IGNAZIO/0000 0001 9888 7030; Modesti,
   Michele/0000 0002 5805 5587; Brun, Paola/0000 0002 3279 9000; IUCCI,
   Giovanna/0000 0002 6478 3759; SAMOUILLAN, Valerie/0000 0003 0571 3985;
   roso, martina/0000 0001 6430 2751
FU MIUR
FX The authors would like to thank Dr. Elena Bozza for her assistance in
   preparing the scaffolds and Dr. Linda Inverso for the review of the
   manuscript. This work has been in part supported by Grant of the MIUR
   (PRIN 2005, ex60%2010).
CR Bacakova L, 2011, BIOTECHNOL ADV, V29, P739, DOI 10.1016/j.biotechadv.2011.06.004
   Bagno A, 2007, BONE, V41, P704, DOI 10.1016/j.bone.2007.06.008
   Brun P, 2011, ACTA BIOMATER, V7, P2526, DOI 10.1016/j.actbio.2011.02.025
   BUCCI C, 1966, PHYS REV, V148, P816, DOI 10.1103/PhysRev.148.816
   Chapekar MS, 2000, J BIOMED MATER RES, V53, P617, DOI 10.1002/1097 4636(2000)53:6<617::AID JBM1>3.3.CO;2 3
   Choi JS, 2008, BIOMATERIALS, V29, P2899, DOI 10.1016/j.biomaterials.2008.03.031
   Fonseca CP, 2007, INT J ELECTROCHEM SC, V2, P52
   Gambaretto R, 2008, BIOPOLYMERS, V89, P906, DOI 10.1002/bip.21030
   Gelain F, 2011, ACS NANO, V5, P227, DOI 10.1021/nn102461w
   Gelain F, 2010, J CONTROL RELEASE, V145, P231, DOI 10.1016/j.jconrel.2010.04.026
   GUMMOW RJ, 1994, SOLID STATE IONICS, V69, P59, DOI 10.1016/0167 2738(94)90450 2
   Huang Y, 2008, APPL SURF SCI, V255, P257, DOI 10.1016/j.apsusc.2008.06.192
   Iucci G, 2011, J APPL POLYM SCI, V122, P3574, DOI 10.1002/app.34768
   Li WJ, 2006, TISSUE ENG, V12, P1775, DOI 10.1089/ten.2006.12.1775
   Li WJ, 2002, J BIOMED MATER RES, V60, P613, DOI 10.1002/jbm.10167
   Li WJ, 2005, BIOMATERIALS, V26, P599, DOI 10.1016/j.biomaterials.2004.03.005
   Li WJ, 2003, J BIOMED MATER RES A, V67A, P1105, DOI 10.1002/jbm.a.10101
   Luensmann Doerte, 2008, Cont Lens Anterior Eye, V31, P179, DOI 10.1016/j.clae.2008.05.004
   Ma ZW, 2005, TISSUE ENG, V11, P1149, DOI 10.1089/ten.2005.11.1149
   Mahmoud ZN, 2011, BIOMATERIALS, V32, P3712, DOI 10.1016/j.biomaterials.2010.12.002
   Miller RE, 2010, OSTEOARTHR CARTILAGE, V18, P1608, DOI 10.1016/j.joca.2010.09.004
   Misawa H, 2006, CELL TRANSPLANT, V15, P903, DOI 10.3727/000000006783981369
   Moulder J., 1995, Handbook of X ray photoelectron spectroscopy: a reference book of standard spectra for identification and interpretation of XPS data
   Ortiz J, 2012, J BIOMED MATER RES A, V100A, P1770, DOI 10.1002/jbm.a.34103
   Ozeki M, 2011, J BIOMATER APPL, V25, P663, DOI 10.1177/0885328209356328
   Prabhakaran MP, 2009, ACTA BIOMATER, V5, P2884, DOI 10.1016/j.actbio.2009.05.007
   Samouillan V, 2002, BIOMACROMOLECULES, V3, P531, DOI 10.1021/bm015655m
   Segers VFM, 2007, DRUG DISCOV TODAY, V12, P561, DOI 10.1016/j.drudis.2007.05.003
   Segers VFM, 2007, CIRCULATION, V116, P1683, DOI 10.1161/CIRCULATIONAHA.107.718718
   Singh S, 2007, J NANOSCI NANOTECHNO, V7, P2596, DOI 10.1166/jnn.2007.909
   Thomas V, 2006, J NANOSCI NANOTECHNO, V6, P487, DOI 10.1166/jnn.2006.097
   Tzaphlidou M, 2005, MICRON, V36, P593, DOI 10.1016/j.micron.2005.05.009
   Venugopal J, 2005, CELL BIOL INT, V29, P861, DOI 10.1016/j.cellbi.2005.03.026
   Wang YX, 2004, PHARM RES DORDR, V21, P1362, DOI 10.1023/B:PHAM.0000036909.41843.18
   Williamson MR, 2004, BIOMATERIALS, V25, P459, DOI 10.1016/S0142 9612(03)00536 2
   Yoshimoto H, 2003, BIOMATERIALS, V24, P2077, DOI 10.1016/S0142 9612(02)00635 X
NR 36
TC 35
Z9 35
U1 0
U2 52
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2012
VL 51
IS 5
BP 851
EP 859
DI 10.1016/j.bone.2012.08.119
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 015FX
UT WOS:000309432900003
PM 22926428
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Tian, A
   Zhai, JJ
   Peng, Y
   Zhang, L
   Teng, MH
   Liao, J
   Sun, X
   Liang, X
AF Tian, Ai
   Zhai, Jun jiang
   Peng, Yan
   Zhang, Li
   Teng, Min hua
   Liao, Jian
   Sun, Xu
   Liang, Xing
TI Osteoblast Response to Titanium Surfaces Coated with Strontium
   Ranelate Loaded Chitosan Film
SO INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS
LA English
DT Article
DE chitosan; drug releasing membrane; osteoblast; strontium ranelate;
   titanium surface coating
ID CALCIUM SENSING RECEPTOR; IN VITRO; POSTMENOPAUSAL WOMEN; OSTEOPOROTIC
   RATS; DENTAL IMPLANTS; BONE; OSSEOINTEGRATION; DIFFERENTIATION;
   FIXATION; DELIVERY
AB Purpose: Improving the peri implant bone quality has notable clinical value in cases of osteoporosis following implant insertion. Materials and Methods: In this study, strontium ranelate loaded chitosan film was produced on a titanium surface in different concentrations of strontium ranelate (SR) (0, 2, 20, 40, and 80 mmol/L of the strontium ion [Sr2+]) with the expectation of utilizing the bone healing enhancement effect of Sr2+. The physicochemical properties of SR loaded chitosan films were characterized by x ray diffraction (XRD), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR). The release/dissolution mechanism was tested by inductively coupled plasma optical emission spectrometry (ICP OES), and in vitro cell responses were evaluated using primary osteoblasts (POBs) in terms of cell proliferation, alkaline phosphatase (ALP) activity, and quantitative analysis of key osteoblastic gene expression. Results: XRD and FTIR observation showed that only a few SRs reacted chemically with chitosan through hydrogen bonds or conjugate action. The initial burst release (70% to 85%) of Sr2+ occurred in the first 3 days and was followed by a slower release stage. At a low concentration (2 mmol/L or 20 mmol/L), SR loaded chitosan film promoted cell responses of POBs with enhanced proliferation, ALP activity, and expression levels of bone morphogenetic protein 2 (BMP 2), runt related transcription factor 2 (Runx 2), ALP, and osteocalcin, but at a high concentration (40 mmol/L or 80 mmol/L), it inhibited POB growth. Conclusion: These results indicated that SR loaded chitosan film on a titanium surface promotes osteoblast proliferation and differentiation in a dose dependent manner, which may represent a new approach in the treatment of a titanium implant.
C1 [Tian, Ai] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Peoples R China.
   [Tian, Ai] Zhe Jiang Univ, Stomatol Hosp, Coll Med, Dept Prosthodont, Hangzhou, Zhejiang, Peoples R China.
   [Zhai, Jun jiang] Chengdu First Peoples Hosp, Chengdu Integrated TCM, Dept Prosthodont, Chengdu, Sichuan, Peoples R China.
   [Zhai, Jun jiang] Chengdu First Peoples Hosp, Western Med Hosp, Chengdu, Sichuan, Peoples R China.
   [Peng, Yan] Chongqing Med Univ, Affiliated Hosp Stomatol, Dept Prosthodont, Chongqing, Peoples R China.
   [Zhang, Li; Teng, Min hua; Sun, Xu; Liang, Xing] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.
   [Liao, Jian] GuiYang Med Univ, Affiliated Hosp, Dept Prosthodont, Guiyang, Peoples R China.
C3 Sichuan University; Zhejiang University; Chongqing Medical University;
   Sichuan University; Guizhou Medical University
RP Liang, X (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, 14 3rd Sect Renmin South Rd, Chengdu, Peoples R China.
EM xingliangdent@vip.163.com
RI ; sun, xu/JCN 6491 2023
OI LIAO, JIAN/0000 0003 3519 4485; 
FU Sichuan Science and Technology Support Program [2013SZ0070]; Guizhou
   Science and Technology Support Program [[2014]2026]
FX This research was supported by Sichuan Science and Technology Support
   Program (Grant No. 2013SZ0070); Guizhou Science and Technology Support
   Program (Grant No. [2014]2026). The authors reported no conflicts of
   interest related to this study.
CR Andreadis ST, 2006, TRENDS BIOTECHNOL, V24, P331, DOI 10.1016/j.tibtech.2006.05.001
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Capuccini C, 2008, ACTA BIOMATER, V4, P1885, DOI 10.1016/j.actbio.2008.05.005
   Caudrillier A, 2010, MOL PHARMACOL, V78, P569, DOI 10.1124/mol.109.063347
   Caverzasio J, 2008, BONE, V42, P1131, DOI 10.1016/j.bone.2008.02.010
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Dahl SG, 2001, BONE, V28, P446, DOI 10.1016/S8756 3282(01)00419 7
   Dayer R, 2010, OSTEOPOROSIS INT, V21, P957, DOI 10.1007/s00198 009 1031 x
   Devine DM, 2013, J BIOMED MATER RES B, V101B, P591, DOI 10.1002/jbm.b.32861
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Giro G, 2011, J ORAL MAXIL SURG, V69, P1911, DOI 10.1016/j.joms.2011.01.028
   Klokkevold PR, 1996, J PERIODONTOL, V67, P1170, DOI 10.1902/jop.1996.67.11.1170
   Kumar MNVR, 2000, REACT FUNCT POLYM, V46, P1
   Li YF, 2010, BIOMATERIALS, V31, P9006, DOI 10.1016/j.biomaterials.2010.07.112
   Li YF, 2010, J ORTHOP RES, V28, P578, DOI 10.1002/jor.21050
   Meunier PJ, 2009, OSTEOPOROSIS INT, V20, P1663, DOI 10.1007/s00198 008 0825 6
   MUZZARELLI RAA, 1993, BIOMATERIALS, V14, P925, DOI 10.1016/0142 9612(93)90134 N
   Park JW, 2013, CLIN ORAL IMPLAN RES, V24, P706, DOI 10.1111/j.1600 0501.2012.02444.x
   Park JW, 2012, J BIOMED MATER RES A, V100A, P1477, DOI 10.1002/jbm.a.34085
   Park JW, 2012, CLIN ORAL IMPLAN RES, V23, P294, DOI 10.1111/j.1600 0501.2010.02144.x
   Park JW, 2010, ACTA BIOMATER, V6, P2843, DOI 10.1016/j.actbio.2010.01.017
   Qi MC, 2004, INT J ORAL MAX SURG, V33, P279, DOI 10.1006/ijom.2002.0398
   Qi MC, 2012, BONE, V50, P119, DOI 10.1016/j.bone.2011.10.011
   Qiu K, 2006, BIOMATERIALS, V27, P1277, DOI 10.1016/j.biomaterials.2005.08.006
   Rao SB, 1997, J BIOMED MATER RES, V34, P21, DOI 10.1002/(SICI)1097 4636(199701)34:1<21::AID JBM4>3.0.CO;2 P
   Reginster JY, 2005, J CLIN ENDOCR METAB, V90, P2816, DOI 10.1210/jc.2004 1774
   Reginster JY, 2003, DRUG TODAY, V39, P89, DOI 10.1358/dot.2003.39.2.799416
   Shibli JA, 2008, INT J ORAL MAX SURG, V37, P321, DOI 10.1016/j.ijom.2007.11.019
   SKORYNA S, 1984, TRACE SUBST ENV HLTH, V18, P3
   Syddall Holly E, 2012, Arch Osteoporos, V7, P37, DOI 10.1007/s11657 012 0069 0
   Takezawa T, 2007, J BIOTECHNOL, V131, P76, DOI 10.1016/j.jbiotec.2007.05.033
   Verberckmoes SC, 2003, KIDNEY INT, V64, P534, DOI 10.1046/j.1523 1755.2003.00123.x
   Wang LC, 2007, J MATER SCI MATER M, V18, P1125, DOI 10.1007/s10856 007 0159 5
   Yamazaki M, 1999, ORAL SURG ORAL MED O, V87, P411, DOI 10.1016/S1079 2104(99)70239 8
   Zhu LL, 2007, BIOCHEM BIOPH RES CO, V355, P307, DOI 10.1016/j.bbrc.2007.01.120
NR 35
TC 16
Z9 18
U1 0
U2 46
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0882 2786
EI 1942 4434
J9 INT J ORAL MAX IMPL
JI Int. J. Oral Maxillofac. Implants
PD NOV DEC
PY 2014
VL 29
IS 6
BP 1446
EP 1453
DI 10.11607/jomi.3806
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AW2MI
UT WOS:000346121900028
PM 25397808
DA 2025 08 17
ER

PT J
AU Aveic, S
   Davtalab, R
   Vogt, M
   Weber, M
   Buttler, P
   Tonini, GP
   Fischer, H
AF Aveic, Sanja
   Davtalab, Roswitha
   Vogt, Michael
   Weber, Michael
   Buttler, Patricia
   Tonini, Gian Paolo
   Fischer, Horst
TI Calcium phosphate scaffolds with defined interconnecting channel
   structure provide a mimetic 3D niche for bone marrow metastasized tumor
   cell growth
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bone marrow niche; Metastatic cancer; In vitro model; beta TCP; 3D
   scaffolds; Interconnecting channels
ID MESENCHYMAL STROMAL CELLS; NEUROBLASTOMA CELLS; DIFFERENTIATION;
   HEMATOPOIESIS; OSTEOBLASTS; LINEAGE
AB Metastasis of tumor cells in the bone marrow (BM) is a multi step and highly dynamic process during which cells succumb important phenotypic changes. Behavior of disseminated tumor cells in BM is strictly regulated by three dimensional (3D) cell cell and cell matrix interactions. In this study, we explored whether the beta tricalcium phosphate (beta TCP) scaffolds with a tailored interconnecting channel structure could enable appropriate 3D mimetic BM microenvironment for the growth of metastatic neuroblastoma cells. The scaffolds provided the mechanical support for human mesenchymal stromal cells (hMSC) allowing them to proliferate, differentiate towards osteoblasts, and produce the deposits of extra cellular matrix inside the interconnected channels. The in vitro microenvironment shaped by stromal cells was then tailored by neuroblastoma tumor cells. Immunohistological analyses confirmed the organization of tumor cells into the forms of spheres only when co cultured with hMSC derived osteoblasts. The growing rate of tumor cells in 3D conditions was less marked comparing to the one of the cells grown as 2D monolayer as confirmed by decreased Ki 67 expression. Instead, the 3D culturing of neuroblastoma cells inside supportive stroma promoted cell quiescence as sustained by increased p27 level. A balance between cell proliferation, survival, and differentiation was more evident for tumor cells grown inside the 3D scaffolds, thus mirroring better the situation that occurs in vivo where the cells do not follow the exponential growth rate. We conclude that the proposed 3D beta TCP scaffold type provides a mimetic 3D in vitro niche suitable for studying behavior of BM metastasized tumor cells.
   Statement of Significance
   Bone marrow (BM) niche is a favorite target of metastatic neuroblastoma cells. To better address the molecular mechanisms that sustain spatiotemporal organization of neuroblastoma cells in the marrow we mimicked the three dimensional (3D) assembly of stromal and tumor cells inside beta tricalcium phosphate (beta TCP) scaffolds. beta TCP scaffolds with a tailored interconnecting channel structure provided mechanical support to mesenchymal stromal cells allowing them to differentiate towards osteoblasts and to produce extracellular matrix. A dynamic cell matrix interplay favored the characteristic rosette like growth of metastatic neuroblastoma cells and triggered their quiescence. With our study, we confirmed the potential of beta TcP scaffolds with reproduced BM niche as a cost effective in vitro model for the growth of disseminated tumor cells, and for related biological and pharmacological surveys. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Aveic, Sanja; Tonini, Gian Paolo] Fdn Ist Ric Pediat Citta Speranza, Neuroblastoma Lab, Padua, Italy.
   [Aveic, Sanja; Davtalab, Roswitha; Weber, Michael; Fischer, Horst] RWTH Aachen Univ Hosp, Dept Dent Mat & Biomat Res, Aachen, Germany.
   [Vogt, Michael] RWTH Aachen Univ Hosp, Interdisciplinary Ctr Clin Res, Aachen, Germany.
   [Buttler, Patricia] RWTH Aachen Univ Hosp, Dept Operat Dent Periodontol & Prevent Dent, Aachen, Germany.
C3 Fondazione Citta della Speranza; RWTH Aachen University; RWTH Aachen
   University Hospital; RWTH Aachen University; RWTH Aachen University
   Hospital; RWTH Aachen University; RWTH Aachen University Hospital
RP Aveic, S (通讯作者)，Fdn Ist Ric Pediat Citta Speranza, Neuroblastoma Lab, Padua, Italy.; Aveic, S (通讯作者)，RWTH Aachen Univ Hosp, Dept Dent Mat & Biomat Res, Aachen, Germany.
EM s.aveic@irpcds.org
RI ; Aveic, Sanja/J 9456 2014; Vogt, Michael/HMW 0022 2023; Fischer,
   Horst/G 8449 2011
OI Fischer, Horst/0000 0003 0990 5028; Aveic, Sanja/0000 0002 3886 4360;
   Vogt, Michael/0000 0003 3535 5293; 
FU Italian Neuroblastoma Foundation "Fondazione Italiana per la Lotta al
   Neuroblastoma" [13_02/IRP]
FX This work was financially supported by The Italian Neuroblastoma
   Foundation "Fondazione Italiana per la Lotta al Neuroblastoma"; project
   number 13_02/IRP.
CR Abbasi MR, 2017, CLIN CANCER RES, V23, P4224, DOI 10.1158/1078 0432.CCR 16 2082
   Alisi A, 2013, INT J MOL SCI, V14, P24706, DOI 10.3390/ijms141224706
   Aveic S, 2018, EUR J PHARMACOL, V818, P435, DOI 10.1016/j.ejphar.2017.11.016
   Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   Barthes J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/921905
   Benien P, 2014, FUTURE ONCOL, V10, P1311, DOI 10.2217/fon.13.274
   Bertillot F, 2017, METHODS MOL BIOL, V1612, P269, DOI 10.1007/978 1 4939 7021 6_20
   Braham MVJ, 2018, TISSUE ENG PART C ME, V24, P300, DOI [10.1089/ten.tec.2017.0467, 10.1089/ten.TEC.2017.0467]
   Braham MVJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1434465
   Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Campos DFD, 2015, TISSUE ENG PT A, V21, P740, DOI [10.1089/ten.tea.2014.0231, 10.1089/ten.TEA.2014.0231]
   Capulli M, 2014, ARCH BIOCHEM BIOPHYS, V561, P3, DOI 10.1016/j.abb.2014.05.003
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785
   Cuiffo BG, 2012, CELL ADHES MIGR, V6, P220, DOI 10.4161/cam.20875
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Feng Xu, 2009, Curr Chem Biol, V3, P189
   Ferreira MSV, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045 016 0234 9
   Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465
   Gauthaman K, 2011, TISSUE ENG PT A, V17, P71, DOI [10.1089/ten.tea.2010.0224, 10.1089/ten.TEA.2010.0224]
   Ghajar CM, 2015, NAT REV CANCER, V15, P238, DOI 10.1038/nrc3910
   Granchi D, 2011, BONE, V48, P152, DOI 10.1016/j.bone.2010.06.028
   Huang XB, 2016, INT J MOL MED, V38, P1141, DOI 10.3892/ijmm.2016.2712
   Kapalczynska M, 2018, ARCH MED SCI, V14, P910, DOI 10.5114/aoms.2016.63743
   Kolahi K. S., 2010, REV SYST BIOL MED, P625
   Li LT, 2015, MOL MED REP, V11, P1566, DOI 10.3892/mmr.2014.2914
   Lindner M, 2014, J BIOMED MATER RES A, V102, P3677, DOI 10.1002/jbm.a.35038
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luksch R, 2016, CRIT REV ONCOL HEMAT, V107, P163, DOI 10.1016/j.critrevonc.2016.10.001
   Martin YD, 2015, CELL REP, V13, P2456, DOI 10.1016/j.celrep.2015.11.025
   Matsuoka F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055082
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   MORTON AJ, 1992, MOL BRAIN RES, V13, P53, DOI 10.1016/0169 328X(92)90044 C
   Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315
   Neuss S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023195
   PAPAC RJ, 1994, CANCER AM CANCER SOC, V74, P2403, DOI 10.1002/1097 0142(19941101)74:9<2403::AID CNCR2820740904>3.0.CO;2 F
   Qiao H, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0008 9
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rödling L, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04808 0
   ROSS RA, 1985, CANCER RES, V45, P1628
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Sen KS, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800343
   Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960
   Shiozawa Y, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.57
   Sieber S., 2017, J TISSUE ENG REGEN M, P479
   SMITH SR, 1994, BRIT J HAEMATOL, V88, P445, DOI 10.1111/j.1365 2141.1994.tb05056.x
   Taichman RS, 1998, STEM CELLS, V16, P7, DOI 10.1002/stem.160007
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008 5472.CAN 10 1040
   Verma D, 2010, PHILOS T R SOC A, V368, P2083, DOI 10.1098/rsta.2010.0013
   Voigt A, 2000, CELL ADHES COMMUN, V7, P423, DOI 10.3109/15419060009109023
   Wu JY, 2009, J BONE MINER RES, V24, P759, DOI [10.1359/JBMR.090225, 10.1359/jbmr.090225]
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
NR 55
TC 17
Z9 17
U1 0
U2 32
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD APR 1
PY 2019
VL 88
BP 527
EP 539
DI 10.1016/j.actbio.2019.02.030
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA HS2KG
UT WOS:000463688900041
PM 30797105
DA 2025 08 17
ER

PT J
AU Oike, A
   Iwata, S
   Hirayama, A
   Ono, Y
   Nagasato, Y
   Kawabata, Y
   Takai, S
   Sanematsu, K
   Wada, N
   Shigemura, N
AF Oike, Asami
   Iwata, Shusuke
   Hirayama, Ayaka
   Ono, Yurika
   Nagasato, Yuki
   Kawabata, Yuko
   Takai, Shingo
   Sanematsu, Keisuke
   Wada, Naohisa
   Shigemura, Noriatsu
TI Bisphosphonate affects the behavioral responses to HCl by disrupting
   farnesyl diphosphate synthase in mouse taste bud and tongue epithelial
   cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GTP BINDING PROTEIN; RISEDRONATE TREATMENT; MOLECULAR MECHANISMS;
   EMBRYONIC LETHALITY; MEVALONATE PATHWAY; ADHESION; RENEWAL; GROWTH;
   CHOLESTEROL; SUPPRESSION
AB Little is known about the molecular mechanisms underlying drug induced taste disorders, which can cause malnutrition and reduce quality of life. One of taste disorders is known adverse effects of bisphosphonates, which are administered as anti osteoporotic drugs. Therefore, the present study evaluated the effects of risedronate (a bisphosphonate) on taste bud cells. Expression analyses revealed that farnesyl diphosphate synthase (FDPS, a key enzyme in the mevalonate pathway) was present in a subset of mouse taste bud and tongue epithelial cells, especially type III sour sensitive taste cells. Other mevalonate pathway associated molecules were also detected in mouse taste buds. Behavioral analyses revealed that mice administered risedronate exhibited a significantly enhanced aversion to HCl but not for other basic taste solutions, whereas the taste nerve responses were not affected by risedronate. Additionally, the taste buds of mice administered risedronate exhibited significantly lower mRNA expression of desmoglein 2, an integral component of desmosomes. Taken together, these findings suggest that risedronate may interact directly with FDPS to inhibit the mevalonate pathway in taste bud and tongue epithelial cells, thereby affecting the expression of desmoglein 2 related with epithelial barrier function, which may lead to alterations in behavioral responses to HCl via somatosensory nerves.
C1 [Oike, Asami; Iwata, Shusuke; Hirayama, Ayaka; Ono, Yurika; Nagasato, Yuki; Takai, Shingo; Sanematsu, Keisuke; Shigemura, Noriatsu] Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Fukuoka, Japan.
   [Oike, Asami; Wada, Naohisa] Kyushu Univ, Grad Sch Dent Sci, Sect Interdisciplinary Dent, Fukuoka, Japan.
   [Iwata, Shusuke; Sanematsu, Keisuke; Shigemura, Noriatsu] Kyushu Univ, Res & Dev Ctr F Sense Devices, Fukuoka, Japan.
   [Kawabata, Yuko] Kyushu Univ, Fac Dent Sci, Dept Cell Biol Aging Sci & Pharmacol, Div Oral Biol Sci, Fukuoka, Japan.
   [Sanematsu, Keisuke] Kyushu Univ, Fac Dent Sci, Oral Hlth Brain Hlth Total Hlth Res Ctr, Fukuoka, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; Kyushu
   University; Kyushu University
RP Shigemura, N (通讯作者)，Kyushu Univ, Grad Sch Dent Sci, Sect Oral Neurosci, Fukuoka, Japan.; Shigemura, N (通讯作者)，Kyushu Univ, Res & Dev Ctr F Sense Devices, Fukuoka, Japan.
EM shigemura@dent.kyushu u.ac.jp
RI Wada, Naohisa/AGC 2734 2022
OI Iwata, Shusuke/0000 0001 8655 3471; Wada, Naohisa/0009 0000 1377 1160
FU JSPS KAKENHI [JP18K17016, JP19H03818, JP20K18458, JP21H05006,
   JP22K09905, JP22K19672]; JST SPRING [JPMJSP2136]; Grants in Aid for
   Scientific Research [22K09905, 21K09818, 22K09915] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI grants (JP18K17016, JP19H03818,
   JP20K18458, JP21H05006, JP22K09905 and JP22K19672) and JST SPRING grants
   (JPMJSP2136). The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   Allis TJ, 2012, FACIAL PLAST SURG CL, V20, P93, DOI [10.3205/cto000077, 10.1016/j.fsc.2011.10.011]
   Bartl R, 2023, Osteoporosis in Clinical Practice
   BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Borah B, 2006, BONE, V39, P345, DOI 10.1016/j.bone.2006.01.161
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Caraglia M, 2005, CURR DRUG TARGETS, V6, P301, DOI 10.2174/1389450053765833
   Chandrashekar J, 2006, NATURE, V444, P288, DOI 10.1038/nature05401
   Chandrashekar J, 2009, SCIENCE, V326, P443, DOI 10.1126/science.1174601
   Cho YK, 1998, CHEM SENSES, V23, P735, DOI 10.1093/chemse/23.6.735
   Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573
   Cozin M, 2011, J ORAL MAXIL SURG, V69, P2564, DOI 10.1016/j.joms.2011.03.005
   Delmas PD, 2007, J CLIN ENDOCR METAB, V92, P1296, DOI 10.1210/jc.2006 1526
   Donetti E, 2014, ORAL DIS, V20, P466, DOI 10.1111/odi.12154
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   FARBMAN AI, 1980, CELL TISSUE KINET, V13, P349, DOI 10.1111/j.1365 2184.1980.tb00474.x
   Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171 9335(99)80074 0
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hager EJ, 2007, J INHERIT METAB DIS, V30, P888, DOI 10.1007/s10545 007 0776 7
   Hamamichi R, 2006, NEUROSCIENCE, V141, P2129, DOI 10.1016/j.neuroscience.2006.05.061
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hirose F, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 58991 8
   JONES PBB, 1987, LANCET, V2, P637
   Kataoka S, 2008, CHEM SENSES, V33, P243, DOI 10.1093/chemse/bjm083
   Kharazmi M, 2012, J ORAL MAXIL SURG, V70, P830, DOI 10.1016/j.joms.2011.03.046
   Kim RH, 2011, J DENT RES, V90, P810, DOI 10.1177/0022034511402995
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   McClung MR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115407
   Michlig S, 2007, J COMP NEUROL, V502, P1003, DOI 10.1002/cne.21354
   Murata Y, 2003, CHEM SENSES, V28, P237, DOI 10.1093/chemse/28.3.237
   Naik BS, 2010, EUR J INTERN MED, V21, P240, DOI 10.1016/j.ejim.2010.01.017
   Ohashi K, 2003, J BIOL CHEM, V278, P42936, DOI 10.1074/jbc.M307228200
   Papamitsou T, 2020, MEDICINA LITHUANIA, V56, DOI 10.3390/medicina56020051
   Pastar I, 2016, J CELL PHYSIOL, V231, P2452, DOI 10.1002/jcp.25357
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092 8674(92)90164 8
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092 8674(92)90163 7
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Schlegel N, 2010, AM J PHYSIOL GASTR L, V298, pG774, DOI 10.1152/ajpgi.00239.2009
   Shigemura N, 2004, ENDOCRINOLOGY, V145, P839, DOI 10.1210/en.2003 0602
   Shigemura N, 2016, INT REV CEL MOL BIO, V323, P71, DOI 10.1016/bs.ircmb.2015.12.004
   Shigemura N, 2013, J NEUROSCI, V33, P6267, DOI 10.1523/JNEUROSCI.5599 12.2013
   SIMON SA, 1993, MICROSC RES TECHNIQ, V26, P196, DOI 10.1002/jemt.1070260303
   Spindler V, 2015, INFLAMM BOWEL DIS, V21, P2349, DOI 10.1097/MIB.0000000000000486
   Sukumaran SK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07746 z
   Takai S, 2015, FASEB J, V29, P2268, DOI 10.1096/fj.14 265355
   Tozawa R, 1999, J BIOL CHEM, V274, P30843, DOI 10.1074/jbc.274.43.30843
   Wakchoure S, 2006, CLIN CANCER RES, V12, P2862, DOI 10.1158/1078 0432.CCR 05 2766
   Wilke M., 2014, J Bone Oncol, V3, P10, DOI [10.1016/j.jbo.2014.02.001, DOI 10.1016/J.JBO.2014.02.001]
   Wong GT, 1999, J NEUROSCI, V19, P5802, DOI 10.1523/JNEUROSCI.19 14 05802.1999
   Yoshida R, 2010, P NATL ACAD SCI USA, V107, P935, DOI 10.1073/pnas.0912048107
   ZHANG D, 1995, J CELL SCI, V108, P2285
   Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325
   Zhang J, 2015, PROTEIN CELL, V6, P254, DOI 10.1007/s13238 014 0131 3
NR 57
TC 3
Z9 3
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 8
PY 2022
VL 12
IS 1
DI 10.1038/s41598 022 25755 5
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA G9LC6
UT WOS:000992275200039
PM 36481783
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, YM
   Wang, ZY
   Zhang, LY
   Zhou, DM
   Sun, Y
   Wang, PJ
   Ju, SG
   Chen, P
   Li, J
   Fu, JX
AF Zhang, Yangmin
   Wang, Ziyan
   Zhang, Liying
   Zhou, Dongming
   Sun, Yu
   Wang, Panjun
   Ju, Songguang
   Chen, Ping
   Li, Jun
   Fu, Jinxiang
TI Impact of connexin 43 coupling on survival and migration of multiple
   myeloma cells
SO ARCHIVES OF MEDICAL SCIENCE
LA English
DT Article
DE multiple myeloma; gap junction intercellular communication; migration;
   cellular signaling
ID MESENCHYMAL STEM CELLS; BONE MARROW MICROENVIRONMENT; GAP JUNCTIONS;
   BREAST CANCER; INTERCELLULAR COMMUNICATION; EXPRESSION; DISEASE;
   DIFFERENTIATION; OSTEOBLASTS; CONNECTIONS
AB Introduction: Gap junctions (GJs) represent the best known intercellular communication (IC) system and are membrane spanning channels that facilitate intercellular communication by allowing small signaling molecules to pass from cell to cell. In this study, we constructed an amino terminus of human Cx43 (Cx43NT GFP), verified the overexpression of Cx43 NT in HUVEC cells and explored the impact of gap junctions (GJs) on multiple myeloma (MM).
   Material and methods: The levels of phosphorylated Cx43(s368) and the change of MAPK pathway associated molecules (ERK1/2, JNK, p38, NF kappa B) were also investigated in our cell models. Cx43 mRNA and proteins were detected in both MM cell lines and mesenchymal stem cells (MSCs). Dye transfer assays demonstrated that gap junction intercellular communication (GJIC) occurring via Cx43 situated between MM and MSCs or MM and HUVECCx43NT is functional.
   Results: Our results present evidence for a channel dependent modulator action of connexin 43 on the migratory activity of MM cells toward MSCs or HUVECCx43 N was higher than those of spontaneous migration (p < 0.05) and protection them from apoptosis in the presence of dexamethasone via cytokines secretion. In the meantime, the migration of MM cells involves an augmented response of p38 and JNK signaling pathway of carboxyl tail of the protein.
   Conclusions: Our data suggest that GJIC between MM and MSCs is one of the essential factors in tumor cell proliferation and drug sensitivity, and is implicated in MM pathogenesis.
C1 [Zhang, Yangmin; Wang, Ziyan; Zhang, Liying; Zhou, Dongming; Sun, Yu; Wang, Panjun; Chen, Ping; Li, Jun; Fu, Jinxiang] Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou 215004, Jiangsu, Peoples R China.
   [Ju, Songguang] Soochow Univ, Med Coll, Dept Immunol, Suzhou, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP Fu, JX (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Hematol, Suzhou 215004, Jiangsu, Peoples R China.
EM fujinxiang@suda.edu.cn
RI Wang, Ziyan/HII 8458 2022; Ju, Songguang/G 9204 2015
CR Al Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725
   Andrews SW, 2013, BRIT J BIOMED SCI, V70, P110, DOI 10.1080/09674845.2013.11669945
   Attar Schneider O, 2016, MOL CARCINOGEN, V55, P1343, DOI 10.1002/mc.22378
   Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood 2011 09 380410
   Behrens J, 2010, EUR J CELL BIOL, V89, P828, DOI 10.1016/j.ejcb.2010.06.003
   Belting M, 2008, J CELL BIOL, V183, P1187, DOI 10.1083/jcb.200810038
   Cancelas JA, 2000, BLOOD, V96, P498
   Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268
   Ciovacco WA, 2009, BONE, V44, P80, DOI 10.1016/j.bone.2008.08.117
   Civitelli R, 2008, ARCH BIOCHEM BIOPHYS, V473, P188, DOI 10.1016/j.abb.2008.04.005
   Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621
   Cronier L, 2009, ANTIOXID REDOX SIGN, V11, P323, DOI 10.1089/ars.2008.2153
   Fowler JA, 2011, BONE, V48, P121, DOI 10.1016/j.bone.2010.06.029
   Fowler JA, 2009, DIS MODEL MECH, V2, P604, DOI 10.1242/dmm.003160
   Fu JX, 2017, ARCH MED SCI, V13, P236, DOI 10.5114/aoms.2017.64722
   Fu JX, 2010, ARCH MED SCI, V6, P496, DOI 10.5114/aoms.2010.14459
   Grek CL, 2016, CANCER LETT, V374, P117, DOI 10.1016/j.canlet.2016.02.008
   Hervé JC, 2007, PROG BIOPHYS MOL BIO, V94, P29, DOI 10.1016/j.pbiomolbio.2007.03.010
   Ilvesaro J, 2000, J BONE MINER RES, V15, P919, DOI 10.1359/jbmr.2000.15.5.919
   Kanczuga Koda L, 2006, J CLIN PATHOL, V59, P429, DOI 10.1136/jcp.2005.029272
   Keats JJ, 2006, LEUKEMIA LYMPHOMA, V47, P2289, DOI 10.1080/10428190600822128
   Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217
   Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922
   McLachlan E, 2007, J MEMBRANE BIOL, V218, P107, DOI 10.1007/s00232 007 9052 x
   McLeod TL, 2001, CELL COMMUN ADHES, V8, P441, DOI 10.3109/15419060109080767
   Mesnil M, 2005, BBA BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004
   Mitsiades CS, 2007, HEMATOL ONCOL CLIN N, V21, P1007, DOI 10.1016/j.hoc.2007.08.007
   Montecino Rodriguez E, 2000, BLOOD, V96, P917, DOI 10.1182/blood.V96.3.917.015k45_917_924
   Moreno AP, 2007, PROG BIOPHYS MOL BIO, V94, P107, DOI 10.1016/j.pbiomolbio.2007.03.004
   Naus CC, 2010, NAT REV CANCER, V10, P435, DOI 10.1038/nrc2841
   Nguyen TD, 2009, MOL IMMUNOL, V46, P2938, DOI 10.1016/j.molimm.2009.06.022
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Plotkin LI, 2013, BONE, V52, P157, DOI 10.1016/j.bone.2012.09.030
   Presley CA, 2005, CELL COMMUN ADHES, V12, P307, DOI 10.1080/15419060500514200
   Reagan MR, 2015, BONE, V75, P161, DOI 10.1016/j.bone.2015.02.021
   Sinyuk M, 2015, ONCOTARGET, V6, P31508, DOI 10.18632/oncotarget.5226
   Thuringer D, 2015, ONCOTARGET, V6, P28800, DOI 10.18632/oncotarget.4894
   Wong RCB, 2008, STEM CELL REV, V4, P283, DOI 10.1007/s12015 008 9038 9
   Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745
   Zhang XH, 2015, LEUKEMIA LYMPHOMA, V56, P211, DOI 10.3109/10428194.2014.913289
NR 40
TC 8
Z9 10
U1 0
U2 3
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA ST 2, POZNAN, 61 615, POLAND
SN 1734 1922
EI 1896 9151
J9 ARCH MED SCI
JI Arch. Med. Sci.
PY 2017
VL 13
IS 6
BP 1335
EP 1346
DI 10.5114/aoms.2017.71065
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA FM6BZ
UT WOS:000415133000010
PM 29181063
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Hatori, K
   Camargos, G
   Chatterjee, M
   Faot, F
   Sasaki, K
   Duyck, J
   Vandamme, K
AF Hatori, K.
   Camargos, G. V.
   Chatterjee, M.
   Faot, F.
   Sasaki, K.
   Duyck, J.
   Vandamme, K.
TI Single and combined effect of high frequency loading and bisphosphonate
   treatment on the bone micro architecture of ovariectomized rats
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone; Bisphosphonate; Ex vivo micro CT; High frequency loading;
   Ovariectomized rats
ID WHOLE BODY VIBRATION; MECHANICAL SIGNALS; CORTICAL BONE; ESTROGEN;
   ALENDRONATE; EXERCISE; MASS; OSTEOPOROSIS; TURNOVER; STRENGTH
AB Mechanical loading at high frequency affects bone. Whether this also applies to osteoporotic bone, combined or not with bisphosphonate therapy, was investigated in this animal study through imaging. An anabolic effect of high frequency loading on osteoporotic bone, however non synergistic with bisphosphonates, was found, thereby revealing its potential for treatment of osteoporosis.
   In an effort to elucidate the effect of high frequency (HF) loading on bone and to optimize its potential for treatment osteoporosis, this study aimed to investigate the effect of HF loading via whole body vibration (WBV), alone or in association with bisphosphonate treatment (alendronate ALN), on the micro architecture of ovariectomy (OVX) induced compromised bone.
   Eighty four female Wistar rats were ovariectomized (OVX) or sham operated (shOVX). OVX animals were treated either with ALN (3 days/week at a dose of 2 mg/kg) or with saline solution. Each group (shOVX, OVX, ALN) was further divided into subgroups relative to the loading status (sham WBV versus WBV) and the duration of experimental period (4 days versus 14 days). (Sham)WBV loading was applied for 10 min/day using 10 consecutive steps of HF loading (130, 135, 140, 145, 150, 130, 135, 140, 145, 150 Hz). Tibial bone structural responses to WBV and/or ALN treatment were analyzed using ex vivo micro computed tomography.
   The animal's hormonal status displayed a major impact on the trabecular and cortical bone structural parameters. Furthermore, mechanical treatment with HF WBV increased the cortical thickness and reduced the medullar area in OVX rats. However, OVX trabecular bone was not affected by HF stimuli. Finally, ALN prevented OVX associated bone loss, but the association of ALN with WBV did not lead to a synergistic bone response in OVX bone.
   HF WBV mechanical stimulation displayed an anabolic effect on osteoporotic cortical bone, confirming its therapeutic properties for enhancing compromised bone. Additionally, its association with bisphosphonates' administration did not produce any additive effect on the bone micro architecture in the present study.
C1 [Hatori, K.; Camargos, G. V.; Chatterjee, M.; Faot, F.; Duyck, J.; Vandamme, K.] Katholieke Univ Leuven, BIOMAT Res Grp, Dept Oral Hlth Sci, Leuven, Belgium.
   [Hatori, K.; Camargos, G. V.; Chatterjee, M.; Faot, F.; Duyck, J.; Vandamme, K.] Univ Hosp Leuven, Leuven, Belgium.
   [Hatori, K.; Sasaki, K.] Tohoku Univ, Grad Sch Dent, Div Adv Prosthet Dent, Sendai, Miyagi 980, Japan.
   [Camargos, G. V.] Univ Estadual Campinas, Dept Prosthodont & Periodontol, Piracicaba Dent Sch, Sao Paulo, Brazil.
   [Faot, F.] Univ Fed Pelotas, Sch Dent, Dept Restorat Dent, Prosthodont Div, Pelotas, RS, Brazil.
C3 KU Leuven; KU Leuven; University Hospital Leuven; Tohoku University;
   Universidade Estadual de Campinas; Universidade Federal de Pelotas
RP Vandamme, K (通讯作者)，Katholieke Univ Leuven, BIOMAT Res Grp, Dept Oral Hlth Sci, Leuven, Belgium.
EM Katleen.Vandamme@med.kuleuven.be
RI Duyck, Joke/AGN 7677 2022; Faot, Fernanda/AAF 8097 2020; De Villa
   Camargos Camargos, Germana/AAQ 1077 2020
OI Duyck, Joke/0000 0002 8698 1692; Faot, Fernanda/0000 0001 6889 7238; De
   Villa Camargos, Germana/0000 0002 7675 7048
FU Fund for Scientific Research Flanders (FWO Flanders); Brazilian Science
   Without Borders Program [246131/2012 8, 245450/2012 2]
FX The author would like to acknowledge Dr. A. Ivanova for the help with
   the statistical analysis. This work was supported by the Fund for
   Scientific Research Flanders (FWO Flanders postdoctoral researcher K.
   Vandamme) and by the Brazilian Science Without Borders Program
   (246131/2012 8 process, Phd student G.V. Camargos; 245450/2012 2
   process, Postdoctoral researcher F. Faot).
CR Adams JE, 2013, NAT REV ENDOCRINOL, V9, P28, DOI 10.1038/nrendo.2012.217
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyd SK, 2006, BONE, V39, P854, DOI 10.1016/j.bone.2006.04.017
   Brouwers JEM, 2010, J ORTHOP RES, V28, P62, DOI 10.1002/jor.20951
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Burghardt AJ, 2010, J BONE MINER RES, V25, P2282, DOI 10.1002/jbmr.157
   Chen BL, 2013, CALCIFIED TISSUE INT, V93, P481, DOI 10.1007/s00223 013 9765 z
   Chen BL, 2012, J ORTHOP RES, V30, P733, DOI 10.1002/jor.22004
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Feher A, 2010, BONE, V46, P203, DOI 10.1016/j.bone.2009.10.023
   Fuchs RK, 2007, BONE, V41, P290, DOI 10.1016/j.bone.2007.04.179
   Hoyland JA, 1999, J PATHOL, V188, P294
   Inada Masaki, 2010, Clin Calcium, V20, P1467, DOI CliCa101014671472
   Ishihara A, 1999, J ELECTRON MICROSC, V48, P465, DOI 10.1093/oxfordjournals.jmicro.a023703
   Iwamoto J, 2005, AGING CLIN EXP RES, V17, P157
   Iwamoto J, 2012, J MUSCULOSKEL NEURON, V12, P136
   Judex S, 2010, J MUSCULOSKEL NEURON, V10, P3
   Judex S, 2007, J BIOMECH, V40, P1333, DOI 10.1016/j.jbiomech.2006.05.014
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Lee K, 2003, NATURE, V424, P389, DOI 10.1038/424389a
   Lee KCL, 2004, EXERC SPORT SCI REV, V32, P64, DOI 10.1097/00003677 200404000 00005
   Lespessailles E, 2009, CALCIFIED TISSUE INT, V85, P146, DOI 10.1007/s00223 009 9269 z
   Lim SK, 1999, J BONE MINER RES, V14, P1189, DOI 10.1359/jbmr.1999.14.7.1189
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Ogawa T, 2011, CLIN ORAL IMPLAN RES, V22, P302, DOI 10.1111/j.1600 0501.2010.02020.x
   Ogawa T, 2011, J CLIN PERIODONTOL, V38, P180, DOI 10.1111/j.1600 051X.2010.01637.x
   Oxlund BS, 2003, BONE, V32, P69, DOI 10.1016/S8756 3282(02)00916 X
   Ozcivici E, 2010, NAT REV RHEUMATOL, V6, P50, DOI 10.1038/nrrheum.2009.239
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Pei LM, 2004, J CLIN INVEST, V113, P805, DOI 10.1172/JCI200421311
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rogers Maurice, 2011, Scottish Forestry, V65, P34
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Rubinacci A, 2008, CALCIFIED TISSUE INT, V82, P316, DOI 10.1007/s00223 008 9115 8
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Saxon LK, 2007, AM J PHYSIOL ENDOC M, V293, pE484, DOI 10.1152/ajpendo.00189.2007
   Saxon LK, 2006, BONE, V39, P1261, DOI 10.1016/j.bone.2006.06.030
   Saxon LK, 2005, BONE, V36, P185, DOI 10.1016/j.bone.2004.08.003
   Seeman E, 2007, OSTEOPOROSIS INT, V18, P123, DOI 10.1007/s00198 006 0296 6
   Sehmisch S, 2009, OSTEOPOROSIS INT, V20, P1999, DOI 10.1007/s00198 009 0892 3
   Shi HF, 2010, BONE, V46, P1299, DOI 10.1016/j.bone.2009.11.028
   Siris ES, 2009, AM J MED, V122, P3, DOI 10.1016/j.amjmed.2008.12.002
   Tezval M, 2011, CALCIFIED TISSUE INT, V88, P33, DOI 10.1007/s00223 010 9423 7
   van der Jagt OP, 2012, J BONE MINER METAB, V30, P40, DOI 10.1007/s00774 011 0293 5
   Waarsing JH, 2004, BONE, V34, P163, DOI 10.1016/j.bone.2003.08.012
NR 45
TC 22
Z9 26
U1 0
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JAN
PY 2015
VL 26
IS 1
BP 303
EP 313
DI 10.1007/s00198 014 2857 4
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AY6PZ
UT WOS:000347689400032
PM 25236876
DA 2025 08 17
ER

PT J
AU El Mashad, GM
   El Hawy, MA
   El Hefnawy, SM
   Mohamed, SM
AF El Mashad, Ghada Mohamed
   El Hawy, Mahmoud Ahmed
   El Hefnawy, Sally Mohamed
   Mohamed, Sanaa Mansour
TI Bone mineral density in children with idiopathic nephrotic syndrome
SO JORNAL DE PEDIATRIA
LA English
DT Article
DE Nephrotic syndrome; Bone mineral density; DXA scan
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; CORTICOSTEROIDS; MECHANISMS;
   MARKERS; ADOLESCENTS; INHIBITION; METABOLISM; THERAPY; GROWTH; HEALTH
AB Objectives: To assess bone mineral density (BMD) in children with idiopathic nephrotic syndrome (NS) and normal glomerular filtration rate (GFR).
   Methods: Cross sectional case control study carried out on 50 children: 25 cases of NS (16 steroid sensitive [SSNS] and nine steroid resistant [SRNS] under follow up in the pediatric nephrology unit of Menoufia University Hospital, which is tertiary care center, were compared to 25 healthy controls with matched age and sex. All of the participants were subjected to complete history taking, thorough clinical examination, laboratory investigations (serum creatinine, blood urea nitrogen [BUN], phosphorus [P], total and ionized calcium [[a], parathyroid hormone [PTH], and alkaline phosphatase [ALP]). Bone mineral density was measured at the lumbar spinal region (L2 L4) in patients group using dual energy X ray absorptiometry (DXA).
   Results: Total and ionized Ca were significantly lower while, serum P, ALP, and PTH were higher in SSNS and SRNS cases than the controls. Osteopenia was documented by DXA scan in 11 patients (44%) and osteoporosis in two patients (8%). Fracture risk was mild in six (24%), moderate in two (8%), and marked in three (12%) of patients.
   Conclusion: Bone mineralization was negatively affected by steroid treatment in children with NS. (C) 2016 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY NC ND license.
C1 [El Mashad, Ghada Mohamed; El Hawy, Mahmoud Ahmed; Mohamed, Sanaa Mansour] Menoufia Univ, Fac Med, Dept Pediat, Menoufia, Egypt.
   [El Hefnawy, Sally Mohamed] Menoufia Univ, Fac Med, Dept Biochem, Menoufia, Egypt.
C3 Egyptian Knowledge Bank (EKB); Menofia University; Egyptian Knowledge
   Bank (EKB); Menofia University
RP El Hawy, MA (通讯作者)，Menoufia Univ, Fac Med, Dept Pediat, Menoufia, Egypt.
EM mahmodelhawy18@yahoo.com
RI ; El Hefnawy, Sally/Y 8788 2019; El Hawy, Mahmoud/AAK 4407 2020
OI El Hawy, Mahmoud/0000 0002 3420 922X; elmashad,
   ghada/0000 0001 5147 8803; 
CR Aceto G, 2014, PEDIATR NEPHROL, V29, P2147, DOI 10.1007/s00467 014 2834 3
   Bakr AM, 2004, PEDIATR NEPHROL, V19, P1390, DOI 10.1007/s00467 004 1670 2
   Basiratnia M, 2006, IRAN J MED SCI, V31, P82
   Bishop N, 2014, J CLIN DENSITOM, V17, P275, DOI 10.1016/j.jocd.2014.01.004
   Canalis E, 2003, CURR OPIN RHEUMATOL, V15, P454, DOI 10.1097/00002281 200307000 00013
   Esmaeeili M, 2015, INT J PEDIATR MASSHA, V3, P103
   Fortes Cristina Maria Teixeira, 2014, J. Pediatr. (Rio J.), V90, P624, DOI 10.1016/j.jped.2014.04.008
   Gulati S, 2003, AM J KIDNEY DIS, V41, P1163, DOI 10.1016/S0272 6386(03)00348 2
   Hodson EM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001533.pub3
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Kos an C, 2012, W INDIAN MED J, V61, P627
   Leonard MB, 2004, NEW ENGL J MED, V351, P868, DOI 10.1056/NEJMoa040367
   Lestari N, 2015, PAEDIATR INDONES, V55, P194
   Moon RJ, 2014, BONE, V58, P108, DOI 10.1016/j.bone.2013.10.012
   Mushtaq T, 2002, ARCH DIS CHILD, V87, P93, DOI 10.1136/adc.87.2.93
   Niaudet P, 2009, PEDIAT NEPHROLOGY, P66792
   Panczyk Tomaszewska M, 2015, ADV EXP MED BIOL, V840, P21, DOI 10.1007/5584_2014_87
   Phan V, 2014, OSTEOPOROSIS INT, V25, P627, DOI 10.1007/s00198 013 2466 7
   Quintal Virginia S., 2014, J. Pediatr. (Rio J.), V90, P556, DOI 10.1016/j.jped.2014.03.001
   Ribeiro D, 2015, EUR J PEDIATR, V174, P911, DOI 10.1007/s00431 014 2479 z
   Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yang LJ, 2006, CLIN BIOCHEM, V39, P561, DOI 10.1016/j.clinbiochem.2005.11.015
   Yildurm ZK, 2008, J PEDIAT HEMATOL ONC, V30, P749, DOI 10.1097/MPH.0b013e318180bbc9
   Zhang SY, 2011, CONTRIB NEPHROL, V169, P94, DOI 10.1159/000313947
NR 25
TC 11
Z9 11
U1 0
U2 3
PU SOC BRASIL PEDIATRIA
PI RIO DE JANEIRO, RJ
PA RUA SANTA CLARA 292, RIO DE JANEIRO, RJ, CEP 22401 01, BRAZIL
SN 0021 7557
EI 1678 4782
J9 J PEDIAT BRAZIL
JI J. Pediatr.
PD MAR APR
PY 2017
VL 93
IS 2
BP 142
EP 147
DI 10.1016/j.jped.2016.05.010
PG 6
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA EQ3RU
UT WOS:000397991000006
PM 27821253
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bender, T
   Donáth, J
   Barna, I
   Gergely, P
   Poór, G
AF Bender, T.
   Donath, J.
   Barna, I.
   Gergely, P., Jr.
   Poor, Gy
TI The analgesic effect of pamidronate is not caused by the elevation of
   beta endorphin level in Paget's disease  : A controlled pilot study
SO NEUROENDOCRINOLOGY LETTERS
LA English
DT Article
DE beta endorphin; bisphosphonate; pamidronate; Paget's disease
ID PAIN; BISPHOSPHONATES; PLASMA; BONE
AB BACKGROUND: Although an analgesic effect is an essential component of the mode of action of bisphosphonates, its physiological mechanisms are still unclear. Beta endorphin release plays an important role in the analgesic effect of both calcitonin and raloxifene. As patients with Paget's disease receive large doses of bisphosphonates within relatively short time periods, we examined whether repeated pamidronate infusion therapy would cause measurable change in beta endorphin levels.
   MATERIALS & METHODS: Visual analog scale (VAS) scores of pain intensity, beta endorphin levels, and alkaline phosphatase activity of 11 patients with Paget's disease (7 with the mono  and 4 with the polyostotic form) were determined at baseline, as well as after 3 and 6 infusions (on Days 6 and 12 of treatment, respectively). Eleven untreated patients with Paget's disease (7 with the mono and 4 with the polyostotic form) served as controls.
   RESULTS: It was established that in the course of pamidronate infusion therapy BE levels remained constant, whereas the values in serum alkaline phosphatase and pain intensity scores were significantly reduced.
   CONCLUSIONS: Although high dose pamidronate therapy does mitigate pain substantially (as demonstrated by the reduction of VAS scores), its analgesic action is probably unrelated to the enhancement of beta endorphin release.
C1 Hosp Bros St John of God, Polyclin, Budapest, Hungary.
   Hungarian Acad Sci, Inst Expt Med, H 1051 Budapest, Hungary.
C3 HUN REN; HUN REN Institute of Experimental Medicine; Hungarian Academy
   of Sciences
RP Bender, T (通讯作者)，Budai Irgalmasrendi Korhaz, Arpad Fejedelem U7, H 1025 Budapest, Hungary.
EM bender@mail.datanet.hu
CR BARNA I, 1992, BRAIN RES, V593, P69, DOI 10.1016/0006 8993(92)91265 G
   Bonabello A, 2001, PAIN, V91, P269, DOI 10.1016/S0304 3959(00)00447 4
   El Shafei A, 2002, ANN RHEUM DIS, V61, P183, DOI 10.1136/ard.61.2.183
   Fisher JE, 2000, ENDOCRINOLOGY, V141, P4793, DOI 10.1210/en.141.12.4793
   FRANCESCHINI R, 1993, BIOMED PHARMACOTHER, V47, P305, DOI 10.1016/0753 3322(93)90079 Z
   Fulfaro F, 2005, J CHEMOTHERAPY, V17, P555, DOI 10.1179/joc.2005.17.5.555
   Gabis L, 2003, AM J PHYS MED REHAB, V82, P81, DOI 10.1097/00002060 200302000 00001
   Gennari C, 2002, BONE, V30, p67S
   Goldfarb AH, 1997, SPORTS MED, V24, P8, DOI 10.2165/00007256 199724010 00002
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Hosking D, 1996, BMJ BRIT MED J, V312, P491, DOI 10.1136/bmj.312.7029.491
   Huk OL, 2003, J ORTHOP RES, V21, P81, DOI 10.1016/S0736 0266(02)00099 2
   Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526 5900(03)00716 8
   Neele SJM, 2002, FERTIL STERIL, V77, P1110, DOI 10.1016/S0015 0282(02)03108 4
   Pappagallo M, 2003, J PAIN SYMPTOM MANAG, V26, P678, DOI 10.1016/S0885 3924(03)00201 X
   SZEKELY JI, 2000, PHARMAZIE S1, V56, P22
   Tucci J R, 2001, Endocr Pract, V7, P423
   Vaccarino AL, 1999, PEPTIDES, V20, P1527, DOI 10.1016/S0196 9781(99)00166 7
NR 18
TC 3
Z9 3
U1 0
U2 0
PU MAGHIRA & MAAS PUBLICATIONS
PI MUNSBACH
PA MAGHIRA & MAAS S A R L, 6C, RUE GABRIEL LIPPMANN, L 5365 MUNSBACH,
   LUXEMBOURG
SN 0172 780X
EI 2354 4716
J9 NEUROENDOCRINOL LETT
JI Neuroendocrinol. Lett.
PD AUG
PY 2006
VL 27
IS 4
BP 513
EP 515
PG 3
WC Endocrinology & Metabolism; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology
GA 119ST
UT WOS:000243034300016
PM 16891991
DA 2025 08 17
ER

PT J
AU Yang, W
   Li, HY
   Wu, YF
   Mi, RJ
   Liu, WZ
   Shen, X
   Lu, YX
   Jiang, YH
   Ma, MJ
   Shen, HY
AF Yang, W.
   Li, H. Y.
   Wu, Y. F.
   Mi, R. J.
   Liu, W. Z.
   Shen, X.
   Lu, Y. X.
   Jiang, Y. H.
   Ma, M. J.
   Shen, H. Y.
TI ac4C acetylation of RUNX2 catalyzed by NAT10 spurs osteogenesis of BMSCs
   and prevents ovariectomy induced bone loss
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; RIBOSOMAL RNA; POSTMENOPAUSAL WOMEN;
   DIFFERENTIATION; THERAPY; COMBINATION; INHIBITION; FRACTURES
AB N acetyltransferase 10 (NAT10) is the key enzyme for N4 acetylcytidine (ac4C) modification of mRNA, which participates in various cellular processes and is related to many diseases. Here, we explore the relationships among osteoblast differentiation, NAT10, and ac4C, and we found that NAT0 expression and the ac4C level of total RNA were decreased in the bone tissues of bilateral ovariectomized (OVX) mice and osteoporosis patients. Adenoviruses overexpressing NAT10 reversed bone loss, and Remodelin, an NAT10 inhibitor, enhanced the loss of bone mass in OVX mice. Moreover, bone marrow derived mesenchymal stem cells (BMSCs) with low level ac4C modification formed fewer calcium nodules in vitro with NAT10 silencing, whereas BMSCs with high level ac4C modification formed more calcium nodules with NAT10 overexpression. Moreover, we demonstrated that the ac4C level of runt related transcription factor 2 (RUNX2) mRNA was increased after BMSCs were cultured in osteogenic medium (OM) and decreased after NAT10 silencing. The RUNX2 mRNA half life and protein expression decreased after silencing NAT10 in BMSCs. Therefore, NAT10 based ac4C modification promotes the osteogenic differentiation of BMSCs by regulating the RUNX2 ac4C level. Because abnormal levels of NAT10 are probably one of the mechanisms responsible for osteoporosis, NAT10 is a new potential therapeutic target for this disease.
C1 [Yang, W.; Li, H. Y.; Shen, X.; Jiang, Y. H.; Ma, M. J.; Shen, H. Y.] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, 3025 Shennan Middle Rd, Shenzhen 518033, Guangdong, Peoples R China.
   [Wu, Y. F.; Mi, R. J.; Lu, Y. X.] Sun Yat Sen Univ, Affiliated Hosp 8, Ctr Biotherapy, Shenzhen 518033, Peoples R China.
   [Liu, W. Z.; Shen, H. Y.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou 510120, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Ma, MJ; Shen, HY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, 3025 Shennan Middle Rd, Shenzhen 518033, Guangdong, Peoples R China.
EM mamj8@mail.sysu.edu.cn; shenhuiy@mail.sysu.edu.cn
RI Wang, Yang/HJA 2356 2022
FU National Natural Science Foundation of China [81971518]; Key Realm R&D
   Programme of Guangdong Province [2019B020236001]; Shenzhen Key Medical
   Discipline Construction Fund [ZDSYS20190902092851024]; Natural Science
   Foundation of Guangdong Province [2018A030313232]; Health Welfare Fund
   Project of Futian District [FTWS2020078]
FX We thank American Journal Experts for providing the English lan guage
   editing service for this manuscript. We also thank Yuanqi Feng and
   Fengxin Gao for valuable comments on acRIP seq data anal ysis. All
   graphical abstracts were created with BioRender.com . This study was
   supported by the National Natural Science Foundation of China (81971518)
   , the Key Realm R&D Programme of Guangdong Province (2019B020236001) ,
   the Shenzhen Key Medical Discipline Construction Fund
   (ZDSYS20190902092851024) , the Natural Science Foundation of Guangdong
   Province (2018A030313232) , and the Health Welfare Fund Project of
   Futian District (FTWS2020078) .
CR Almalki SG, 2016, DIFFERENTIATION, V92, P41, DOI 10.1016/j.diff.2016.02.005
   Antebi B, 2014, CURR OSTEOPOROS REP, V12, P41, DOI 10.1007/s11914 013 0184 x
   Arango D, 2018, CELL, V175, P1872, DOI 10.1016/j.cell.2018.10.030
   Balmus G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03770 3
   Bian Q, 2012, MENOPAUSE, V19, P225, DOI 10.1097/gme.0b013e3182272ef1
   BRUENGER E, 1993, FASEB J, V7, P196, DOI 10.1096/fasebj.7.1.8422966
   Cai SY, 2017, BIOCHEM BIOPH RES CO, V483, P624, DOI 10.1016/j.bbrc.2016.12.092
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   Huang ZX, 2015, ONCOTARGETS THER, V8, P2675, DOI 10.2147/OTT.S92275
   Ito S, 2014, J BIOL CHEM, V289, P35724, DOI 10.1074/jbc.C114.602698
   Jing H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0231 0
   Jing H, 2017, FASEB J, V31, P4422, DOI 10.1096/fj.201700118R
   Kanis JA, 1997, OSTEOPOROSIS INT, V7, P108, DOI 10.1007/BF03194355
   KAWAI G, 1989, NUCL ACID S, V21, P61
   Kearns AE, 2008, ENDOCR REV, V29, P155, DOI 10.1210/er.2007 0014
   Kohli N, 2018, BONE, V110, P38, DOI 10.1016/j.bone.2018.01.015
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kumbhar BV, 2013, CELL BIOCHEM BIOPHYS, V66, P797, DOI 10.1007/s12013 013 9525 8
   Larrieu D, 2014, SCIENCE, V344, P527, DOI 10.1126/science.1252651
   Li JT, 2019, CELL DEATH DIFFER, V26, P2652, DOI 10.1038/s41418 019 0328 3
   Lin WC, 2008, DEV GROWTH DIFFER, V50, P321, DOI [10.1111/j.1440 169x.2008.01041.x, 10.1111/j.1440 169X.2008.01041.x]
   Liu HY, 2020, NUCLEIC ACIDS RES, V48, P3638, DOI 10.1093/nar/gkaa130
   Liu WJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1448 x
   Liu XF, 2018, NUCLEIC ACIDS RES, V46, P9601, DOI 10.1093/nar/gky777
   Liu XF, 2016, EMBO REP, V17, P349, DOI 10.15252/embr.201540505
   Marini F, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081329
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Sharma S, 2015, NUCLEIC ACIDS RES, V43, P2242, DOI 10.1093/nar/gkv075
   Shen GY, 2018, CELL PHYSIOL BIOCHEM, V47, P2307, DOI 10.1159/000491541
   Shen Q, 2009, EXP CELL RES, V315, P1653, DOI 10.1016/j.yexcr.2009.03.007
   Sotornik Ivo, 2016, Vnitr Lek, V62 Suppl 6, P84
   Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140 6736(07)61342 7
   Tang SA, 2019, STEM CELLS, V37, P270, DOI 10.1002/stem.2937
   Tang YC, 2008, CELL BIOL INT, V32, P1150, DOI 10.1016/j.cellbi.2008.06.005
   Tompkins BA, 2018, CIRC RES, V122, P1006, DOI 10.1161/CIRCRESAHA.117.312486
   Tschida BR, 2017, CANCER RES, V77, P6576, DOI 10.1158/0008 5472.CAN 17 2281
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   van Meurs JBJ, 2019, J BONE MINER RES, V34, P215, DOI 10.1002/jbmr.3662
   Yin B, 2019, STEM CELLS, V37, P115, DOI 10.1002/stem.2918
   Zhang P, 2016, J BONE MINER RES, V31, P391, DOI 10.1002/jbmr.2704
   Zhao XL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10929 3
NR 46
TC 78
Z9 84
U1 2
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162 2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD DEC 3
PY 2021
VL 26
BP 135
EP 147
DI 10.1016/j.omtn.2021.06.022
EA AUG 2021
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA XO4SC
UT WOS:000730176000012
PM 34513300
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yang, YL
   Tao, BL
   Gong, Y
   Chen, R
   Yang, WH
   Lin, CC
   Chen, MW
   Qin, L
   Jia, YL
   Cai, KY
AF Yang, Yulu
   Tao, Bailong
   Gong, Yi
   Chen, Rui
   Yang, Weihu
   Lin, Chuanchuan
   Chen, Maowen
   Qin, Lu
   Jia, Yile
   Cai, Kaiyong
TI Functionalization of Ti substrate
   withpH responsivenaringin ZnOnanoparticles for the reconstruction of
   large bony after osteosarcoma resection
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE antibacterial; anti osteosarcoma; Naringin; titanium; ZnO nanoparticles
ID ANTIBACTERIAL ACTIVITY; REACTIVE OXYGEN; OSTEOGENIC ACTIVITY; SIGNALING
   PATHWAY; CANCER CELLS; TUMOR GROWTH; IN VITRO; BACTERIA; ROS;
   NANOPARTICLES
AB After bone tumor resection, the large bony deficits are commonly reconstructed with Ti based metallic endoprosthesis, which provide immediate stable fixation and allow early ambulation and weight bearing. However, when used in osteosarcoma resection, Ti implant relative infection and tumor recurrence were recognized as the two critical factors for implantation failure. Hence, in this work, a novel zinc oxide nanoparticle decorating with naringin was prepared and immobilized onto Ti substrate. The drugs delivery profiles proved that in the bacterial infection and Warburg effect of osteosarcoma induced acidic condition, naringin and Zn(2+)can be released easily from the functional Ti substrate. The anti osteosarcoma and antibacterial assay showed the delivered naringin and Zn(2+)can induce a remarkable increase of oxidative stress in bacteria (Escherichia coliandStaphylococcus aureus) and osteosarcoma (Saos 2 cells) by producing reactive oxygen species (ROS). Accumulation of ROS results in damage of bacterial biofilm and bacterial membrane, leading to the leakage of bacterial RNA and DNA. Meanwhile, the increase of ROS induces osteosarcoma cell apoptosis by activating ROS/extracellular signal regulated kinase signaling pathway. Furthermore, in vitro cellular experiments, including cell viability, alkaline phosphatase activity, collagen secretion, extracellular matrix mineralization level, indicated that the functional Ti substrate exhibited great potential for osteoblasts proliferation and differentiation. Hence, this study provides a simple and promising strategy of developing multifunctional Ti based implants for the reconstruction of large bony after osteosarcoma resection.
C1 [Yang, Yulu; Tao, Bailong; Yang, Weihu; Lin, Chuanchuan; Chen, Maowen; Qin, Lu; Jia, Yile; Cai, Kaiyong] Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400044, Peoples R China.
   [Gong, Yi] Chongqing Canc Inst Hosp, Dept Hematol Oncol, Chongqing, Peoples R China.
   [Chen, Rui] Chongqing Canc Inst Hosp, Dept Pathol, Chongqing, Peoples R China.
   [Cai, Kaiyong] Southwest Univ, Chongqing Key Lab Soft Matter Mat Chem & Funct Mf, Chongqing, Peoples R China.
C3 Chongqing University; Southwest University   China
RP Yang, WH; Cai, KY (通讯作者)，Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400044, Peoples R China.
EM yangweihu@cqu.edu.cn; kaiyong_cai@cqu.edu.cn
RI ; Lin, Chuanchuan/LQK 1231 2024; Tao, Bailong/AAR 1533 2021; Cai,
   Kaiyong/G 1233 2011
OI tao, bailong/0000 0001 8619 5029; Yang, Weihu/0000 0002 8857 197X; Cai,
   Kaiyong/0000 0001 9029 680X
FU 2019 Fundamental Research Funds for the Central Universities ("medical
   and engineering fused" item) [2019CDYGYB015]; Fundamental Research Funds
   for the Central Universities [2018CDXYSW0023, 2019CDXYSG0004]; National
   Natural Science Foundation of China [21734002, 51825302]; State Key
   Project of Research and Development [2016YFC1100300, 2017YFB0702603]
FX 2019 Fundamental Research Funds for the Central Universities ("medical
   and engineering fused" item), Grant/Award Number: 2019CDYGYB015;
   Fundamental Research Funds for the Central Universities, Grant/Award
   Numbers: 2018CDXYSW0023, 2019CDXYSG0004; National Natural Science
   Foundation of China, Grant/Award Numbers: 21734002, 51825302; State Key
   Project of Research and Development, Grant/Award Numbers:
   2016YFC1100300, 2017YFB0702603
CR Avisetti DR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087050
   Bowen WH, 2018, TRENDS MICROBIOL, V26, P229, DOI 10.1016/j.tim.2017.09.008
   Camargo CA, 2012, ANTICANCER RES, V32, P129
   Céliz G, 2011, J APPL MICROBIOL, V111, P731, DOI 10.1111/j.1365 2672.2011.05070.x
   Chen JF, 2014, BASIC CLIN PHARMACOL, V114, P293, DOI 10.1111/bcpt.12153
   Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318
   Dhivya R., 2015, Adv. Mater. Lett., V6, P505, DOI [10.5185/amlett.2015.5766, DOI 10.5185/AMLETT.2015.5766]
   Farid MU, 2018, NANOSCALE, V10, P4475, DOI 10.1039/c8nr00189h
   Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Godet I, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12412 1
   Hu H, 2012, ACTA BIOMATER, V8, P904, DOI 10.1016/j.actbio.2011.09.031
   Hu Y, 2012, BIOMATERIALS, V33, P3515, DOI 10.1016/j.biomaterials.2012.01.040
   Huang P, 2017, COLLOID SURFACE B, V160, P628, DOI 10.1016/j.colsurfb.2017.10.012
   Hussain MS, 2018, J ORTHOP TRAUMA, V32, pE237, DOI 10.1097/BOT.0000000000001154
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Ishikawa K, 2002, BIOMATERIALS, V23, P423, DOI 10.1016/S0142 9612(01)00121 1
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jia XH, 2017, J MATER CHEM B, V5, P2459, DOI 10.1039/c6tb03084j
   Jin GD, 2014, BIOMATERIALS, V35, P7699, DOI 10.1016/j.biomaterials.2014.05.074
   Kanno S, 2005, BIOL PHARM BULL, V28, P527, DOI 10.1248/bpb.28.527
   Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475 2867 13 89
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kuang Y, 2019, COLLOID SURFACE B, V181, P461, DOI 10.1016/j.colsurfb.2019.05.078
   Li HJ, 2016, ACS NANO, V10, P6753, DOI 10.1021/acsnano.6b02326
   Li J, 2017, ACS NANO, V11, P11250, DOI 10.1021/acsnano.7b05620
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Liu JL, 2019, J ALLOY COMPD, V783, P898, DOI 10.1016/j.jallcom.2018.12.330
   Liu YQ, 2018, ACTA BIOMATER, V73, P531, DOI 10.1016/j.actbio.2018.04.014
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mao CY, 2017, ACS NANO, V11, P9010, DOI 10.1021/acsnano.7b03513
   Martinez Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Nayak S, 2013, BIOMATERIALS, V34, P2855, DOI 10.1016/j.biomaterials.2013.01.019
   Poillet Perez L, 2015, REDOX BIOL, V4, P184, DOI 10.1016/j.redox.2014.12.003
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Santamaria E, 2006, J SURG ONCOL, V94, P522, DOI 10.1002/jso.20490
   Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056
   Shen XK, 2019, BIOMATERIALS, V212, P1, DOI 10.1016/j.biomaterials.2019.05.008
   Shen XK, 2014, ACS APPL MATER INTER, V6, P16426, DOI 10.1021/am5049338
   Sirelkhatim A, 2015, NANO MICRO LETT, V7, P219, DOI 10.1007/s40820 015 0040 x
   Sultana ST, 2015, SCI REP UK, V5, DOI 10.1038/srep14908
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412
   Ta H. T., 2019, CANCER METAST REV, V28, P247
   Tan J, 2018, ACS APPL MATER INTER, V10, P42018, DOI 10.1021/acsami.8b15724
   Tao BL, 2020, CHEM ENG J, V390, DOI 10.1016/j.cej.2020.124621
   Tao BL, 2019, J BIOMED MATER RES A, V107, P2310, DOI 10.1002/jbm.a.36740
   Tao BL, 2019, COLLOID SURFACE B, V177, P242, DOI 10.1016/j.colsurfb.2019.02.014
   Tao BL, 2018, COLLOID SURFACE B, V170, P382, DOI 10.1016/j.colsurfb.2018.06.039
   Tao SC, 2016, SCI REP UK, V6, DOI 10.1038/srep26835
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Tsui VWK, 2008, PHYTOTHER RES, V22, P401, DOI 10.1002/ptr.2338
   Ueno T, 2016, BIOMATERIALS, V108, P177, DOI 10.1016/j.biomaterials.2016.08.050
   Van Acker H, 2017, TRENDS MICROBIOL, V25, P456, DOI 10.1016/j.tim.2016.12.008
   Wang MM, 2018, ACS APPL MATER INTER, V10, P41003, DOI 10.1021/acsami.8b07527
   Wang T, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951 016 0245 2
   Wang X, 2017, EUR J PHARM BIOPHARM, V113, P168, DOI 10.1016/j.ejpb.2016.12.034
   Westphal K, 2008, CANCER RES, V68, P2952, DOI 10.1158/0008 5472.CAN 07 2984
   Xiao FF, 2019, ACS NANO, V13, P1511, DOI 10.1021/acsnano.8b07251
   Xiong HM, 2013, ADV MATER, V25, P5329, DOI 10.1002/adma.201301732
   Yang R, 2008, CLIN CANCER RES, V14, P6396, DOI 10.1158/1078 0432.CCR 07 5113
   Yang YC, 2018, J BONE ONCOL, V10, P36, DOI 10.1016/j.jbo.2017.11.005
   ZEEGEN EN, 2004, CLIN ORTHOP RELAT R, V420, P239
   Zhang GZ, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957 4484/27/10/105204
   Zhang Y, 2013, CURR MOL MED, V13, P1633, DOI 10.2174/1566524013666131111130058
   Zhang YY, 2019, MATER LETT, V241, P18, DOI 10.1016/j.matlet.2019.01.033
   Zhao XL, 2014, CURR OPIN MICROBIOL, V21, P1, DOI 10.1016/j.mib.2014.06.008
   Zhao X, 2014, ASIAN PAC J TROP MED, V7, P639, DOI 10.1016/S1995 7645(14)60107 3
   Zibara K, 2017, J CELL COMMUN SIGNAL, V11, P57, DOI 10.1007/s12079 016 0362 6
   Zorov DB, 2006, BBA BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029
NR 72
TC 30
Z9 30
U1 3
U2 85
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV 1
PY 2020
VL 108
IS 11
BP 2190
EP 2205
DI 10.1002/jbm.a.36977
EA JUN 2020
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA NH7YK
UT WOS:000542144900001
PM 32363788
DA 2025 08 17
ER

PT J
AU Dong, L
   Wang, R
   Zhu, YA
   Wang, CM
   Diao, HJ
   Zhang, CY
   Zhao, JN
   Zhang, JF
AF Dong, Lei
   Wang, Rui
   Zhu, Yi an
   Wang, Chunming
   Diao, Huajia
   Zhang, Chenyu
   Zhao, Jianning
   Zhang, Junfeng
TI Antisense oligonucleotide targeting TNF α can suppress Co Cr Mo
   particle induced osteolysis
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE particle induced osteolysis; TNF alpha; antisense oligonucleotide;
   osteoclastogenesis
ID NECROSIS FACTOR ALPHA; KAPPA B; RECEPTOR ACTIVATOR; BONE LOSS;
   OSTEOPROTEGERIN; CELLS; POLYETHYLENE; MACROPHAGES; EXPRESSION; THERAPY
AB The most common cause of implant failure in joint replacement is aseptic loosening due to particle induced osteolysis. TNF alpha has been shown to be one of the key factors in the process of osteoclastogenesis. Anti TNF agents are useful in the treatment of joint inflammation related to osteolysis. This study investigated the effect of a single subcutaneous dose of an antisense oligonucleotide (ASO) on particle induced osteolysis. We utilized the murine calvaria osteolysis model in C57BL/J6 mice. Bone resorption was measured by the toluidine blue staining. Osteoclasts were detected by tartrate resistant acid phosphatase (TRAP) staining assay and were quantified by a TRAP quantification kit. Results show that bone resorption is 0.347 +/  0.09 mm(2) in mice with particle implantation, and decreased to 0.123 +/  0.05 mm(2) and 0.052 +/  0.02 mm(2) after ASO treatment with low and high doses, respectively. The number of osteoclasts in animal calvaria treated with ASO is reduced compared with that of untreated animals, and the quantification results indicate that about 90% of osteoclastogenesis is suppressed by the ASO. In addition, the osteoclastogenesis can be reestablished by the addition of TNF alpha. In conclusion, we demonstrate that the antisense oligonucleotide targeting to TNF alpha can suppress osteolysis induced by metal particles in a murine calvaria model. This new finding may be of value in the search for novel therapeutic methods for implant loosening. (c) 2008 Orthopaedic Research Society.
C1 [Dong, Lei; Wang, Rui; Zhu, Yi an; Wang, Chunming; Diao, Huajia; Zhang, Chenyu; Zhao, Jianning; Zhang, Junfeng] Nanjing Univ, Sch Med, State Key Lab Pharmaceut Biotechnol, Jinling Hosp, Nanjing 210093, Peoples R China.
   [Dong, Lei; Wang, Rui; Zhu, Yi an; Wang, Chunming; Diao, Huajia; Zhang, Chenyu; Zhao, Jianning; Zhang, Junfeng] Nanjing Univ, Sch Med, Dept Orthopaed, Jinling Hosp, Nanjing 210093, Peoples R China.
   [Wang, Rui; Zhao, Jianning] Second Mil Med Univ, Shanghai 200433, Peoples R China.
   [Zhang, Chenyu; Zhang, Junfeng] Nanjing Univ, Jiangsu Prov Diabet Ctr, Nanjing 210093, Peoples R China.
   [Zhang, Junfeng] Jiangsu Prov Lab Nanotechnol, Nanjing 210093, Peoples R China.
C3 Nanjing University; Nanjing University; Naval Medical University;
   Nanjing University
RP Zhang, JF (通讯作者)，Nanjing Univ, Sch Med, State Key Lab Pharmaceut Biotechnol, Jinling Hosp, Nanjing 210093, Peoples R China.
EM jfzhang@nju.edu.cn
RI , ZhangCY/JSK 5704 2023; Wang, Chunming/I 3392 2013; Dong,
   Lei/J 3516 2013; zhang, junfeng/JHT 7871 2023
OI Wang, Chunming/0000 0001 9185 9678; 
CR Aboul Fadl T, 2005, CURR MED CHEM, V12, P2193, DOI 10.2174/0929867054864859
   Algan SM, 1996, J ORTHOP RES, V14, P30, DOI 10.1002/jor.1100140107
   ASPENBERG P, 1998, CLIN ORTHOP RELAT R, V12, P75
   Benz EB, 2001, BIOMATERIALS, V22, P2835, DOI 10.1016/S0142 9612(01)00027 8
   Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Childs LM, 2001, J BONE JOINT SURG AM, V83A, P1789, DOI 10.2106/00004623 200112000 00004
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Desai SB, 2006, BEST PRACT RES CL RH, V20, P757, DOI 10.1016/j.berh.2006.06.002
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Hofbauer LC, 1999, EUR J ENDOCRINOL, V141, P195, DOI 10.1530/eje.0.1410195
   HOROWITZ SM, 1995, J BIOMED MATER RES, V29, P477, DOI 10.1002/jbm.820290407
   Ingham E, 2005, BIOMATERIALS, V26, P1271, DOI 10.1016/j.biomaterials.2004.04.035
   Ingham E, 2000, BIOMATERIALS, V21, P1005, DOI 10.1016/S0142 9612(99)00261 6
   JASTY M, 1992, Current Opinion in Rheumatology, V4, P204, DOI 10.1097/00002281 199204000 00012
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   KNOCHA M, 2005, BIOMATERIALS, V26, P1803
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kurtz SM, 1999, BIOMATERIALS, V20, P1659, DOI 10.1016/S0142 9612(99)00053 8
   LIU CC, 1987, J HISTOCHEM CYTOCHEM, V35, P1355, DOI 10.1177/35.12.3680930
   Myers KJ, 2003, J PHARMACOL EXP THER, V304, P411, DOI 10.1124/jpet.102.040329
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175
   Palmbos PL, 2002, J ORTHOP RES, V20, P483, DOI 10.1016/S0736 0266(01)00147 4
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Pushparaj PN, 2006, CLIN EXP PHARMACOL P, V33, P504, DOI 10.1111/j.1440 1681.2006.04399.x
   Ren WP, 2006, BIOMATERIALS, V27, P5161, DOI 10.1016/j.biomaterials.2006.04.004
   Rice R, 2003, DEV BIOL, V262, P75, DOI 10.1016/S0012 1606(03)00355 5
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P849, DOI 10.1002/jor.1100180602
   Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321
   Silva MJ, 2002, J BONE JOINT SURG AM, V84A, P1490, DOI 10.2106/00004623 200208000 00038
   Whitson HE, 2006, BONE, V39, P954, DOI 10.1016/j.bone.2006.04.032
NR 32
TC 30
Z9 35
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD AUG
PY 2008
VL 26
IS 8
BP 1114
EP 1120
DI 10.1002/jor.20607
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 327FD
UT WOS:000257714100011
PM 18327794
DA 2025 08 17
ER

PT J
AU Ferreira, DD
   Boratto, FA
   Cardoso, VN
   Serakides, R
   Fernandes, SO
   Ferreira, LAM
   Oliveira, MC
AF Ferreira, Diego dos Santos
   Boratto, Fernanda Alves
   Cardoso, Valbert Nascimento
   Serakides, Rogeria
   Fernandes, Simone Odilia
   Miranda Ferreira, Lucas Antonio
   Oliveira, Monica Cristina
TI Alendronate coated long circulating liposomes containing
   <SUP>99m</SUP>technetium ceftizoxime used to identify osteomyelitis
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE bone targeting; radiolabeled antibiotics; scintigraphic imaging; bone
   infection diagnosis
ID PH SENSITIVE LIPOSOMES; TC 99M LABELED CEFTIZOXIME; INFECTION;
   BISPHOSPHONATES; NANOCARRIERS; INFLAMMATION; DELIVERY
AB Osteomyelitis is a progressive destruction of bones caused by microorganisms.   Inadequate or absent treatment increases the risk of bone growth inhibition, fractures, and sepsis. Among the diagnostic techniques, functional images are the most sensitive in detecting osteomyelitis in its early stages. However, these techniques do not have adequate specificity. By contrast, radiolabeled antibiotics could improve selectivity, since they are specifically recognized by the bacteria. The incorporation of these radiopharmaceuticals in drug delivery systems with high affinity for bones could improve the overall uptake. In this work, long circulating and alendronate coated liposomes containing (99m)technetium radiolabeled ceftizoxime were prepared and their ability to identify infectious foci (osteomyelitis) in animal models was evaluated. The effect of the presence of PEGylated lipids and surface attached alendronate was evaluated. The bone targeted long circulating liposomal (99m)technetium ceftizoxime showed higher uptake in regions of septic inflammation than did the non long circulating and/or alendronate non coated liposomes, showing that both the presence of PEGylated lipids and alendronate coating are important to optimize the bone targeting. Scintigraphic images of septic or aseptic inflammation bearing Wistar rats, as well as healthy rats, were acquired at different time intervals after the intravenous administration of these liposomes. The target to non target ratio proved to be significantly higher in the osteomyelitis bearing animals for all investigated time intervals. Biodistribution studies were also performed after the intravenous administration of the formulation in osteomyelitis bearing animals. A significant amount of liposomes were taken up by the organs of the mononuclear phagocyte system (liver and spleen). Intense renal excretion was also observed during the entire experiment period. Moreover, the liposome uptake by the infectious focus was significantly high. These results show that long circulating and alendronate coated liposomes containing (99m)technetium radiolabeled ceftizoxime have a tropism for infectious foci.
C1 [Ferreira, Diego dos Santos; Boratto, Fernanda Alves; Miranda Ferreira, Lucas Antonio; Oliveira, Monica Cristina] Univ Fed Minas Gerais, Fac Pharm, Dept Pharmaceut Prod, BR 31270901 Belo Horizonte, MG, Brazil.
   [Cardoso, Valbert Nascimento; Fernandes, Simone Odilia] Univ Fed Minas Gerais, Fac Pharm, Dept Clin & Toxicol Anal, BR 31270901 Belo Horizonte, MG, Brazil.
   [Serakides, Rogeria] Univ Fed Minas Gerais, Sch Vet, BR 31270901 Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais
RP Oliveira, MC (通讯作者)，Univ Fed Minas Gerais, Fac Pharm, Dept Pharmaceut Prod, Ave Presidente Antonio Carlos,6627 Pampulha, BR 31270901 Belo Horizonte, MG, Brazil.
EM monicacristina@ufmg.br
RI fernandes, simone/AAU 8611 2020; Cardoso, Valbert/AAA 7240 2019;
   Oliveira, Monica/H 2080 2015; Serakides, Rogéria/C 7571 2016; Ferreira,
   Lucas/H 5762 2015; dos Santos Ferreira, Diego/O 7637 2014; oliveira,
   Monica/AAL 7682 2020
OI Oliveira, Monica/0000 0003 2594 9581; Cardoso,
   Valbert/0000 0001 7597 9602; dos Santos Ferreira,
   Diego/0000 0003 1505 7950; Antunes Fernandes, Simone
   Odilia/0000 0002 6139 5187; Ferreira, Lucas/0000 0003 2474 5536
FU FAPEMIG; CNPq; FINEP
FX The authors would like to thank FAPEMIG, CNPq, and FINEP for their
   financial support. Diego dos Santos Ferreira wishes to thank CNPq for
   his grant.
CR Anada T, 2009, BIOORG MED CHEM LETT, V19, P4148, DOI 10.1016/j.bmcl.2009.05.117
   [Anonymous], 2005, Braz. Arch. Biol. Technol, DOI [DOI 10.1590/S1516 89132005000700014, 10.1590/S1516 89132005000700014]
   Awasthi V, 1998, J NUCL MED, V39, P1089
   Benitez A, 2006, Q J NUCL MED MOL IM, V50, P147
   Bertrand N, 2014, ADV DRUG DELIVER REV, V66, P2, DOI 10.1016/j.addr.2013.11.009
   Boerman OC, 2001, INFLAMM RES, V50, P55, DOI 10.1007/s000110050725
   Crommelin DJA, 1999, J CONTROL RELEASE, V62, P245, DOI 10.1016/S0168 3659(99)00044 9
   Diniz SOF, 2008, NUCL MED COMMUN, V29, P830, DOI 10.1097/MNM.0b013e3283000514
   El Maghraby TAF, 2006, Q J NUCL MED MOL IM, V50, P167
   Erdogan S, 2000, J MICROENCAPSUL, V17, P459
   Gomes Barreto V, 2000, REV ESP MED NUCL, V19, P478
   Gratz S, 2001, J NUCL MED, V42, P1257
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Hung GU, 2000, SEMIN NUCL MED, V30, P147, DOI 10.1053/nm.2000.5415
   Kothari NA, 2001, RADIOL CLIN N AM, V39, P653, DOI 10.1016/S0033 8389(05)70304 3
   Kurniawan J, 2014, LANGMUIR, V30, P4997, DOI 10.1021/la500341c
   Lang S, 1996, RADIOLOGE, V36, P781, DOI 10.1007/s001170050140
   LITZINGER DC, 1994, BBA BIOMEMBRANES, V1190, P99, DOI 10.1016/0005 2736(94)90038 8
   Love Charito, 2004, J Nucl Med Technol, V32, P47
   Ferreira SMZMD, 2012, BIOORG MED CHEM LETT, V22, P4605, DOI 10.1016/j.bmcl.2012.05.105
   Mussi SV, 2013, EUR J PHARM SCI, V48, P282, DOI 10.1016/j.ejps.2012.10.025
   NEW RRC, 1990, LIPOSOMES PRACTICAL
   Oyen WJG, 1996, J NUCL MED, V37, P1392
   Palestro CJ, 2007, CELL MICROBIOL, V9, P2323, DOI 10.1111/j.1462 5822.2007.01013.x
   Phillips WT, 1999, ADV DRUG DELIVER REV, V37, P13, DOI 10.1016/S0169 409X(98)00108 2
   Pineda C, 2006, INFECT DIS CLIN N AM, V20, P789, DOI 10.1016/j.idc.2006.09.009
   Pinkerton NM, 2013, MOL PHARMACEUT, V10, P319, DOI 10.1021/mp300452g
   Rangger C, 2012, INT J NANOMED, V7, P5889, DOI 10.2147/IJN.S36847
   Rauscher A, 2014, NUCL MED BIOL, V41, pE66, DOI 10.1016/j.nucmedbio.2013.12.012
   Rennen HJJM, 2001, EUR J NUCL MED, V28, P241, DOI 10.1007/s002590000447
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Salerno M, 2010, CURR CANCER DRUG TAR, V10, P649, DOI 10.2174/156800910793605767
   Schott H, 2011, BIOORGAN MED CHEM, V19, P3520, DOI 10.1016/j.bmc.2011.04.015
   Signore A, 2002, BRAZ ARCH BIOL TECHN, V45, P15, DOI 10.1590/S1516 89132002000500004
   Carmo VAS, 2007, BRAZ ARCH BIOL TECHN, V50, P199, DOI 10.1590/S1516 89132007000600025
   Stahl P.H., 2002, HDB PHARM SALTS PROP
   Swami A, 2014, P NATL ACAD SCI USA, V111, P10287, DOI 10.1073/pnas.1401337111
   Torchilin VP, 2007, AAPS J, V9, pE128, DOI 10.1208/aapsj0902015
   Ulrich AS, 2002, BIOSCIENCE REP, V22, P129, DOI 10.1023/A:1020178304031
   Wang M, 2010, PHARMACOL RES, V62, P90, DOI 10.1016/j.phrs.2010.03.005
   Wareham David, 2005, Braz. arch. biol. technol., V48, P145
   Ziessman H A., 2014, Nuclear Medicine: The requisites
NR 43
TC 31
Z9 34
U1 0
U2 33
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178 2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 2441
EP 2450
DI 10.2147/IJN.S76168
PG 10
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Pharmacology & Pharmacy
GA CE2BJ
UT WOS:000351617300001
PM 25848262
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Chen, WS
   Xian, GY
   Gu, MH
   Pan, BQ
   Wu, XY
   Ye, YY
   Zheng, LL
   Zhang, ZJ
   Sheng, PY
AF Chen, Weishen
   Xian, Guoyan
   Gu, Minghui
   Pan, Baiqi
   Wu, Xiaoyu
   Ye, Yongyu
   Zheng, Linli
   Zhang, Ziji
   Sheng, Puyi
TI Autophagy inhibitors 3 MA and LY294002 repress osteoclastogenesis and
   titanium particle stimulated osteolysis
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID NF KAPPA B; PERI IMPLANT OSTEOLYSIS; BONE RESORPTION; RANKL;
   SUPPRESSION; EXPRESSION; DIFFERENTIATION; INVOLVEMENT; PATHWAY; CELLS
AB Aseptic loosening caused by peri implant osteolysis (PIO) is a common complication after joint replacement, and there is still no better treatment than revision surgery. The wear particle induced inflammation response, especially subsequent osteoclastic bone resorption, is responsible for PIO. As the importance of wear particles in inducing autophagy in cells around the prosthesis in PIO has been discovered, this might be a central process underlying aseptic loosening. However, the role of autophagy induced by wear particles in osteoclastogenesis during PIO remains unclear. In this study, we investigated the role of autophagy in osteoclastogenesis and verified it in a mouse calvarial osteolysis model. We found that osteoclasts were increased in the interface membranes of patients with aseptic loosening. In vitro, knocking down the Atg5 gene or using autophagy inhibitors (3 MA, LY294002) to inhibit autophagy was found to repress osteoclastogenesis and decrease expression of the osteoclast related genes TRAP, cathepsin K, and matrix metalloprotein 9 (MMP 9) with or without titanium (Ti) particles. In vivo, 3 MA and LY294002 repressed Ti particle stimulated osteolysis and osteoclastogenesis and reduced expression of the pro inflammatory factors TNF alpha, IL 1 beta, and IL 6. Our results suggest that 3 MA and LY294002 might be the potential medicines to prevent and treat PIO and aseptic loosening.
C1 [Chen, Weishen; Xian, Guoyan; Gu, Minghui; Pan, Baiqi; Wu, Xiaoyu; Ye, Yongyu; Zheng, Linli; Zhang, Ziji; Sheng, Puyi] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Joint Surg, Guangzhou 510080, Peoples R China.
   [Chen, Weishen; Xian, Guoyan; Gu, Minghui; Pan, Baiqi; Wu, Xiaoyu; Ye, Yongyu; Zheng, Linli; Zhang, Ziji; Sheng, Puyi] Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Orthopaed & Traumatol, Guangzhou 510080, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Zhang, ZJ; Sheng, PY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Dept Joint Surg, Guangzhou 510080, Peoples R China.; Zhang, ZJ; Sheng, PY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 1, Guangdong Prov Key Lab Orthopaed & Traumatol, Guangzhou 510080, Peoples R China.
EM zhangziji@mail.sysu.edu.cn; shengpy@mail.sysu.edu.cn
RI wu, 晓煜/HIK 3475 2022; Zhang, Ziji/MDT 9723 2025
OI Xian, Guoyan/0000 0002 1982 2392; Chen, Weishen/0000 0003 3469 842X
FU National Natural Science Foundation of China [81672149, 81802179,
   81972050]; Guangdong Basic and Applied Basic Research Foundation
   [2019A1515012185]; Fundamental Research Funds for the Central
   Universities of China [19ykpy64]
FX We thank Professor Chaohong Li (Zhongshan Medical School, Sun Yat sen
   University, Guangzhou, China) for providing our laboratory and
   equipment. This work was supported by the National Natural Science
   Foundation of China [grant numbers 81672149, 81802179, and 81972050];
   Guangdong Basic and Applied Basic Research Foundation [grant number
   2019A1515012185]; and the Fundamental Research Funds for the Central
   Universities of China [grant number 19ykpy64].
CR Anaraki PK, 2015, J BONE MINER RES, V30, P379, DOI 10.1002/jbmr.2350
   Bayliss LE, 2017, LANCET, V389, P1424, DOI 10.1016/S0140 6736(17)30059 4
   Camuzard O, 2019, J BONE JOINT SURG AM, V101, P466, DOI 10.2106/JBJS.18.00479
   Catalano A, 2018, BONE, V116, P42, DOI 10.1016/j.bone.2018.07.010
   Chen LL, 2013, TISSUE ENG PT A, V19, P2226, DOI [10.1089/ten.tea.2012.0469, 10.1089/ten.TEA.2012.0469]
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   El Kholy K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01300
   Feng W, 2017, SCI REP UK, V7, DOI 10.1038/srep41411
   Feng YL, 2018, INT J MOL MED, V41, P202, DOI 10.3892/ijmm.2017.3208
   Goodman SB, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0962
   Goodman SB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122091
   Gu Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.275
   Heymann D, 2010, BONE CANC
   Hou JM, 2012, ACTA PHARMACOL SIN, V33, P1277, DOI 10.1038/aps.2012.83
   Hu XY, 2017, ACTA BIOMATER, V48, P479, DOI 10.1016/j.actbio.2016.11.022
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Laha D, 2019, AUTOPHAGY, V15, P2063, DOI 10.1080/15548627.2019.1596491
   Li D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0862 9
   Li HY, 2011, NAT NANOTECHNOL, V6, P645, DOI [10.1038/NNANO.2011.153, 10.1038/nnano.2011.153]
   Li ZQ, 2016, AM J PHYSIOL ENDOC M, V310, pE355, DOI 10.1152/ajpendo.00309.2015
   Liu NC, 2016, BIOCHEM BIOPH RES CO, V473, P133, DOI 10.1016/j.bbrc.2016.03.065
   Liu Y, 2019, J CELL PHYSIOL, V234, P13832, DOI 10.1002/jcp.28063
   Martin TJ, 2015, REV ENDOCR METAB DIS, V16, P131, DOI 10.1007/s11154 014 9308 6
   Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556 018 0092 5
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116
   Piemontese M, 2016, SCI REP UK, V6, DOI 10.1038/srep24262
   Pierrefite Carle V, 2015, AGEING RES REV, V24, P206, DOI 10.1016/j.arr.2015.08.004
   Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
   Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016
   Qian YB, 2015, HIP INT, V25, P581, DOI 10.5301/hipint.5000281
   Sabokbar A, 2016, CLIN REV ALLERG IMMU, V51, P16, DOI 10.1007/s12016 015 8523 6
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Sharkey PF, 2014, J ARTHROPLASTY, V29, P1774, DOI 10.1016/j.arth.2013.07.024
   Terkawi MA, 2019, ACTA BIOMATER, V89, P242, DOI 10.1016/j.actbio.2019.03.028
   Wang DW, 2012, AUTOPHAGY, V8, P954, DOI 10.4161/auto.19927
   Wang H, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2125656
   Wang LL, 2018, ACTA BIOMATER, V73, P488, DOI 10.1016/j.actbio.2018.04.013
   Wang S, 2020, INT J BIOL SCI, V16, P2675, DOI 10.7150/ijbs.46627
   Wang ZH, 2017, ACTA BIOMATER, V48, P489, DOI 10.1016/j.actbio.2016.11.020
   Wang ZH, 2015, AUTOPHAGY, V11, P2358, DOI 10.1080/15548627.2015.1106779
   Wang ZH, 2015, ACTA BIOMATER, V24, P352, DOI 10.1016/j.actbio.2015.06.024
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Xian GY, 2020, J BIOMED MATER RES A, V108, P1792, DOI 10.1002/jbm.a.36938
   Xiao Y, 2018, INFLAMMATION, V41, P614, DOI 10.1007/s10753 017 0717 z
   Xie H, 2011, CARDIOVASC RES, V92, P296, DOI 10.1093/cvr/cvr200
   Yang GP, 2018, INFLAMMATION, V41, P1498, DOI 10.1007/s10753 018 0795 6
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
NR 50
TC 29
Z9 34
U1 0
U2 47
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD JUL 21
PY 2021
VL 9
IS 14
BP 4922
EP 4935
DI 10.1039/d1bm00691f
EA MAY 2021
PG 14
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA TI6SU
UT WOS:000655985100001
PM 34052845
DA 2025 08 17
ER

PT J
AU Thadhani, R
   Wolf, M
AF Thadhani, Ravi
   Wolf, Myles
TI Vitamin D in patients with kidney disease: Cautiously optimistic
SO ADVANCES IN CHRONIC KIDNEY DISEASE
LA English
DT Article
DE vitamin D; hemodialysis survival; cardiovascular disease
ID STAGE RENAL DISEASE; 1,25 DIHYDROXYVITAMIN D 3; CARDIOVASCULAR DISEASE;
   25 HYDROXYVITAMIN D 3 1 ALPHA HYDROXYLASE; HEMODIALYSIS PATIENTS;
   PARATHYROID HORMONE; D INSUFFICIENCY; UNITED STATES; CALCIFICATION;
   HYPERTROPHY
AB Nephrologists are well aware of the therapeutic effects of activated vitamin D in managing secondary hyperparathyroidism. Beyond bone and mineral metabolism, however, we are now beginning to appreciate the effects of activating the vitamin D receptor (VDR) in other cell types. Our group and others recently found a survival advantage associated with injectable vitamin D therapy in hemodialysis populations. The observational nature of these studies, however, subjects them to the possibility that confounding and bias may have accounted for their results. Therefore, it is unclear if indeed a survival benefit exists, if harm is incurred with this therapy or if activation of the VDR in cell types other than bone, intestine, and the parathyroid gland are applicable to our patients with kidney disease. The range of studies being planned include those targeting the cardiovascular effects of VDR activation, further understanding of the prevalence and consequences of vitamin D deficiency in patients with kidney disease, trials to examine the effects of VDR activation on intermediate cardiovascular and noncardiovascular endpoints, and trials targeting mortality endpoints. If consistent with the recent observations, these studies may provide nephrologists with an intervention to alter the otherwise poor outcomes in patients with kidney disease. (c) 2007 by the National Kidney Foundation, Inc.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr D Receptor Activat Res, Boston, MA 02114 USA.
   Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Renal Unit, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital; Harvard
   Medical School
RP Thadhani, R (通讯作者)，Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr D Receptor Activat Res, Bullfinch 127,55 Fruit St, Boston, MA 02114 USA.
EM rthadhani@partners.org
FU NIDDK NIH HHS [DK71674] Funding Source: Medline
CR Achinger SG, 2005, KIDNEY INT, V67, pS37, DOI 10.1111/j.1523 1755.2005.09506.x
   Bas A, 2006, J BONE MINER RES, V21, P484, DOI 10.1359/JBMR.051211
   Brown AJ, 2001, AM J KIDNEY DIS, V38, pS3, DOI 10.1053/ajkd.2001.28111
   Cole SR, 2005, AM J EPIDEMIOL, V162, P471, DOI 10.1093/aje/kwi216
   Dusso AS, 2003, KIDNEY INT, V63, pS6, DOI 10.1046/j.1523 1755.63.s85.3.x
   Foley RN, 2000, J AM SOC NEPHROL, V11, P912, DOI 10.1681/ASN.V115912
   FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22
   GALLIENI M, 1995, AM J PHYSIOL RENAL, V268, pF746, DOI 10.1152/ajprenal.1995.268.4.F746
   González EA, 2004, AM J NEPHROL, V24, P503, DOI 10.1159/000081023
   Hayashi SY, 2006, NEPHROL DIAL TRANSPL, V21, P125, DOI 10.1093/ndt/gfi075
   Hyppönen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140 6736(01)06580 1
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   LaClair RE, 2005, AM J KIDNEY DIS, V45, P1026, DOI 10.1053/j.ajkd.2005.02.029
   Levin A, 2005, KIDNEY INT, V68, P1973, DOI 10.1111/j.1523 1755.2005.00651.x
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI0215219
   Makibayashi K, 2001, AM J PATHOL, V158, P1733, DOI 10.1016/S0002 9440(10)64129 6
   Mathieu C, 2002, TRENDS MOL MED, V8, P174, DOI 10.1016/S1471 4914(02)02294 3
   Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542
   Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360
   NYOMBA BL, 1984, ENDOCRINOLOGY, V115, P191, DOI 10.1210/endo 115 1 191
   O'Herrin JK, 2002, AM J NEPHROL, V22, P515, DOI 10.1159/000065289
   Park CW, 1999, AM J KIDNEY DIS, V33, P73, DOI 10.1016/S0272 6386(99)70260 X
   Rostand SG, 1999, KIDNEY INT, V56, P383, DOI 10.1046/j.1523 1755.1999.00575.x
   Somjen D, 2005, CIRCULATION, V111, P1666, DOI 10.1161/01.CIR.0000160353.27927.70
   Stack AG, 2002, AM J KIDNEY DIS, V40, P1202, DOI 10.1053/ajkd.2002.36881
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Thadhani R, 2006, CLIN J AM SOC NEPHRO, V1, P1117, DOI 10.2215/CJN.00080106
   van Etten E, 2000, TRANSPLANTATION, V69, P1932, DOI 10.1097/00007890 200005150 00032
   Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755
   Wolisi GO, 2005, SEMIN DIALYSIS, V18, P307, DOI 10.1111/j.1525 139X.2005.18407.x
   Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582
   Zaslavsky LMA, 2005, J DIABETES COMPLICAT, V19, P194, DOI 10.1016/j.jdiacomp.2004.12.001
   Zehnder D, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133621
   Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888
   Zittermann A, 2005, BRIT J NUTR, V94, P483, DOI 10.1079/BJN20051544
   Zittermann A, 2003, J AM COLL CARDIOL, V41, P105, DOI 10.1016/S0735 1097(02)02624 4
   Zittermann A, 2006, PROG BIOPHYS MOL BIO, V92, P39, DOI 10.1016/j.pbiomolbio.2006.02.001
NR 38
TC 13
Z9 15
U1 0
U2 0
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1548 5595
EI 1548 5609
J9 ADV CHRONIC KIDNEY D
JI Adv. Chronic Kidney Dis.
PD JAN
PY 2007
VL 14
IS 1
BP 22
EP 26
DI 10.1053/j.ackd.2006.10.009
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 126LB
UT WOS:000243513300005
PM 17200040
DA 2025 08 17
ER

PT J
AU Cao, B
   Chai, CX
   Zhao, SS
AF Cao, Bo
   Chai, Chunxiang
   Zhao, Sishun
TI Protective effect of Edaravone against hypoxia induced cytotoxicity in
   osteoblasts MC3T3 E1 cells
SO IUBMB LIFE
LA English
DT Article
DE Edaravone; osteoporosis; hypoxia; reactive oxygen species; apoptosis
ID BONE; MECHANISMS; DISEASE; MODEL
AB Edaravone is a newly developed clinical medicine for the treatment of acute cerebral infarction. Reduced blood supply to bones (hypoxia) has been involved in the pathological development of osteoporosis. In this study, we investigated the effect of Edaravone and its latent mechanism on hypoxia induced cell toxicity in MC3T3 E1 cells. Cell viability was determined by the 3 (4,5 dimethyl thiazol 2yl) 2,5 diphenyl tetrazolium bromide (MTT) assay. Intracellular reactive oxygen species (ROS) and nitric oxide (NO) were determined by the fluorescence dyes 2,7 dichlorofluorescein diacetate (DCFH DA) and 4 amino 5 methylamino 2,7 difluorofluorescein diacetate (DAF FM DA), respectively. mRNA and proteins were determined by real time polymerase chain reaction and Western blot analysis, respectively. Edaravone significantly restored the hypoxia induced reduction of MC3T3 E1 cell viability and inhibited lactate dehydrogenase release. In addition, we found that Edaravone inhibits the generation of ROS and NO. Hoechst staining results indicated that the nuclear condensation characteristic of apoptosis was increased in MC3T3 E1 cells after hypoxia exposure, which was significantly suppressed by Edaravone treatment. Mechanistically, we found that Edaravone markedly reduced the expression of cleaved caspase 3 and blunted the release of cytochrome c. These findings strongly suggested that Edaravone suppresses hypoxia induced cytotoxicity in MC3T3 E1 cells. The pleiotropic effects of Edaravone on hypoxia exposure in osteoblasts suggest potential antiosteoporosis mechanisms of Edaravone. (c) 2015 IUBMB Life, 67(12):928 933, 2015
C1 [Cao, Bo; Chai, Chunxiang; Zhao, Sishun] Weifang Med Sch, Affiliated Hosp, Emergency Dept, Weifang City 261031, Shandong, Peoples R China.
C3 Shandong Second Medical University
RP Zhao, SS (通讯作者)，Weifang Med Sch, Affiliated Hosp, 2428 YuHe Rd, Weifang City 261031, Shandong, Peoples R China.
EM sszhao335@yeah.net
RI Cao, Bo/D 1983 2017
CR Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Bridgeman G, 1996, J ANAT, V188, P611
   Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839
   Chen DF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052948
   Chowdhury AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073672
   Griffith JF, 2011, SKELETAL RADIOL, V40, P517, DOI 10.1007/s00256 011 1122 6
   Higashi Yukihito, 2006, Recent Pat Cardiovasc Drug Discov, V1, P85
   Ishikawa A, 2007, NEUROSCI RES, V59, P406, DOI 10.1016/j.neures.2007.08.008
   Jiao SS, 2015, P NATL ACAD SCI USA, V112, P5225, DOI 10.1073/pnas.1422998112
   Lambeth JD, 2007, FREE RADICAL BIO MED, V43, P332, DOI 10.1016/j.freeradbiomed.2007.03.027
   Li CY, 2002, AM J PHYSIOL CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001
   Li Q., ENV TOXICOL IN PRESS
   Lim LS, 2009, AM J PREV MED, V36, P366, DOI 10.1016/j.amepre.2009.01.013
   London GM, 2012, J NEPHROL, V25, P619, DOI 10.5301/jn.5000187
   London GM, 2011, KIDNEY BLOOD PRESS R, V34, P203, DOI 10.1159/000327004
   Lu GY, 2007, EUR POLYM J, V43, P3807, DOI 10.1016/j.eurpolymj.2007.06.016
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Nakamura T, 2008, STROKE, V39, P463, DOI 10.1161/STROKEAHA.107.486654
   Nanes MS, 2014, SEMIN NUCL MED, V44, P439, DOI 10.1053/j.semnuclmed.2014.06.006
   Otomo E, 2003, CEREBROVASC DIS, V15, P222, DOI 10.1159/000069318
   Pasco JA, 2006, J WOMENS HEALTH, V15, P295, DOI 10.1089/jwh.2006.15.295
   Rajesh KG, 2003, AM J PHYSIOL HEART C, V285, pH2171, DOI 10.1152/ajpheart.00143.2003
   Reczek CR, 2015, CURR OPIN CELL BIOL, V33, P8, DOI 10.1016/j.ceb.2014.09.010
   Ren YX, 2015, INT J NEUROSCI, V125, P555, DOI 10.3109/00207454.2014.959121
   Sanders KM, 2007, TRANSL RES, V150, P215, DOI 10.1016/j.trsl.2007.03.012
   Sheng BY, 2009, CHINESE SCI BULL, V54, P1725, DOI 10.1007/s11434 009 0239 7
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Takizawa Y, 2009, PEDIATR RES, V65, P636, DOI 10.1203/PDR.0b013e3181a16a9f
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   Wang GB, 2013, NEUROSCI LETT, V543, P72, DOI 10.1016/j.neulet.2013.02.067
   Watanabe K, 2003, REDOX REP, V8, P151, DOI 10.1179/135100003225001520
   Watanabe T, 2004, YAKUGAKU ZASSHI, V124, P99, DOI 10.1248/yakushi.124.99
NR 32
TC 8
Z9 10
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1521 6543
EI 1521 6551
J9 IUBMB LIFE
JI IUBMB Life
PD DEC
PY 2015
VL 67
IS 12
BP 928
EP 933
DI 10.1002/iub.1436
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CZ7GT
UT WOS:000367268600005
PM 26596678
OA Bronze
DA 2025 08 17
ER

PT J
AU Gan, K
   Xu, LX
   Feng, XK
   Zhang, QD
   Wang, F
   Zhang, MJ
   Tan, WF
AF Gan, Ke
   Xu, Lingxiao
   Feng, Xiaoke
   Zhang, Qiande
   Wang, Fang
   Zhang, Miaojia
   Tan, Wenfeng
TI Celastrol attenuates bone erosion in collagen Induced arthritis mice and
   inhibits osteoclast differentiation and function in RANKL induced
   RAW264.7
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Celastrol; Osteodast; Collagen Induced arthritis
ID WILFORDII HOOK F; RHEUMATOID ARTHRITIS; T CELLS; AUTOIMMUNE ARTHRITIS;
   DOUBLE BLIND; PATHOGENESIS; INFLAMMATION; MECHANISMS; EXTRACT; DAMAGE
AB Recently, the traditional Chinese medicine Tripterygium wilfordii Hook f (TwHF) of the Celastraceae family has attracted increasing attention for its potential therapeutic application in patients with rheumatoid arthritis (RA). It is well accepted that TwHF exerts the antirheumatic activity and mainly depends on its potent anti inflammatory property. To further explore the therapeutic potential of the well defined TwHF derived single compound celastrol in RA, we study the therapeutic efficacy of celastrol on bone erosion in collagen induced arthritis (CIA) mice and delineate its effects on osteodast differentiation and functions in RANKL induced osteodast precursors RAW264.7 cell line. In CIA mice, daily injection of celastrol (beginning on day 28 after arthritis induction) markedly suppressed arthritis, and reduced bone damage in the joints as demonstrated by histology and bone micro computed tomography (Cr). The effects were accompanied by reductions of osteoclast cells in joints, serum tartrate resistant acid phosphatase (TRAP) 5b, and expression of osteoclastic genes (Trap, Ctsk, Ctr, Mmp 9) and transcriptional factors (c Fos, c Jun and NFATc1). When RAW264.7 cells were treated with RANKL, celastrol inhibited the formation of TRAP + multinucleated cells and the bone resorbing activity in dose dependent manners. Furthermore, celastrol reduced the RANKL induced expression of osteodastic genes and transcriptional factors, as well as phosphorylation of NF kB and mitogen activated protein kinases (MAPK). These findings show that celastrol could directly inhibit osteodast formation and function, suggesting a novel therapeutic strategy of celastrol for managing RA, especially in preventing bone destruction. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Gan, Ke; Xu, Lingxiao; Zhang, Miaojia; Tan, Wenfeng] Nanjing Med Univ, Dept Rheumatol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Gan, Ke] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Tradit Chinese Med, Nanjing, Jiangsu, Peoples R China.
   [Feng, Xiaoke; Zhang, Qiande] Nanjing Med Univ, Integrat Med Inst, Nanjing, Jiangsu, Peoples R China.
   [Wang, Fang] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing University of Chinese Medicine;
   Nanjing Medical University; Nanjing Medical University
RP Tan, WF (通讯作者)，Nanjing Med Univ, Dept Rheumatol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM tw2006@njmu.edu.cn
OI , Gan/0000 0001 6458 3098
FU National Natural Science Foundation of China (NSFC) [30701129, 30901332,
   81172845, 81273294, 81403240, 81401352]; National Natural Science
   Foundation of Jiangsu province [BK2011851, BK2012875, BK20140956,
   BK20141021]; Special Project Of Clinical Medicine from Jiangsu province
   [BL2013034]; Youth Natural Science Foundation of Nanjing University of
   Chinese Medicine [13XZR12]; Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD); Asia Pacific League of
   Associations for Rheumatology (APLAR); International League of
   Associations for Rheumatology (ILAR)
FX The authors are grateful for useful advice and suggestions from Dr.
   Pojen Chen. Support for this work was obtained from the National Natural
   Science Foundation of China (NSFC): 30701129 (W.T.), 30901332 (F.W.),
   81172845 (W.T.), 81273294 (M.Z.), 81403240 (KG.), and 81401352 (L.X.),
   National Natural Science Foundation of Jiangsu province: BK2011851
   (W.T.), BK2012875 (M.Z.), BK20140956 (K.G.), and BK20141021 (L.X.), the
   Special Project Of Clinical Medicine from Jiangsu province: BL2013034
   (M.Z.), the Youth Natural Science Foundation of Nanjing University of
   Chinese Medicine: 13XZR12 (K.G.), a project funded by the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD), and scholarship from Asia Pacific League of Associations for
   Rheumatology (APLAR) and International League of Associations for
   Rheumatology (ILAR) (W.T.).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Aschenberg S, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4235
   Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brinker AM, 2007, PHYTOCHEMISTRY, V68, P732, DOI 10.1016/j.phytochem.2006.11.029
   Burmester GR, 2014, NAT REV RHEUMATOL, V10, P77, DOI 10.1038/nrrheum.2013.168
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021
   Danks L, 2013, J BIOCHEM, V154, P29, DOI 10.1093/jb/mvt049
   Dimitroulas T, 2013, AUTOIMMUN REV, V12, P958, DOI 10.1016/j.autrev.2013.03.015
   Goldbach Mansky R, 2009, ANN INTERN MED, V151, P229, DOI 10.7326/0003 4819 151 4 200908180 00005
   Ho LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 294
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kim DY, 2009, EUR J PHARMACOL, V612, P98, DOI 10.1016/j.ejphar.2009.03.078
   Lv QW, 2014, ANN RHEUM DIS, V73, pE57, DOI 10.1136/annrheumdis 2014 205973
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Nanjundaiah SM, 2012, J BIOL CHEM, V287, P22216, DOI 10.1074/jbc.M112.356816
   O'Shea JJ, 2013, NAT REV RHEUMATOL, V9, P173, DOI 10.1038/nrrheum.2013.7
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schramm C, 2004, ARTHRITIS RES THER, V6, pR114, DOI 10.1186/ar1039
   Smolen JS, 2012, NAT REV RHEUMATOL, V8, P235, DOI 10.1038/nrrheum.2012.23
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167
   Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411
   TAO XL, 1989, CHINESE MED J PEKING, V102, P327
   Venkatesha SH, 2012, BIOORGAN MED CHEM, V20, P5229, DOI 10.1016/j.bmc.2012.06.050
NR 29
TC 58
Z9 71
U1 0
U2 46
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD FEB
PY 2015
VL 24
IS 2
BP 239
EP 246
DI 10.1016/j.intimp.2014.12.012
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA CC2OD
UT WOS:000350183600015
PM 25529994
DA 2025 08 17
ER

PT J
AU Kirkwood, KL
   Li, F
   Rogers, JE
   Otremba, J
   Coatney, DD
   Kreider, JM
   D'Silva, NJ
   Chakravarty, S
   Dugar, S
   Higgins, LS
   Protter, AA
   Medicherla, S
AF Kirkwood, Keith L.
   Li, Fei
   Rogers, Jill E.
   Otremba, Jodie
   Coatney, Derek D.
   Kreider, Jaclynn M.
   D'Silva, Nisha J.
   Chakravarty, Sarvajit
   Dugar, Sundeep
   Higgins, Linda S.
   Protter, Andrew A.
   Medicherla, Satyanarayana
TI A p38α selective mitogen activated protein kinase inhibitor prevents
   periodontal bone loss
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID KAPPA B LIGAND; P38 MAP KINASE; RECEPTOR ACTIVATOR; TNF ALPHA;
   ACTINOBACILLUS ACTINOMYCETEMCOMITANS; PORPHYROMONAS GINGIVALIS; RANKL
   EXPRESSION; IL 6 EXPRESSION; OSTEOPROTEGERIN; CYTOKINES
AB In the oral microbial environment, Gram negative bacterial derived lipopolysaccharide (LPS) can initiate inflammatory bone loss as seen in periodontal diseases. p38 Mitogen activated protein kinase (MAPK) signaling is critical to inflammatory cytokine and LPS induced cytokine expression, which may contribute toward periodontal bone loss. The purpose of this proof of principle study was to evaluate the ability of an orally active p38 alpha MAPK inhibitor (SD 282) to reduce periopathogenic LPS induced alveolar bone loss in an experimental rat model. Five groups of Sprague Dawley rats received one of the following treatments: LPS injected to the palatal gingiva adjacent to the maxillary molars three times per week for 8 weeks, LPS plus two doses of SD 282 (15 or 45 mg/kg) twice daily by oral gavage, or control groups given drug vehicle (1% polyethylene glycol) or SD 282 (45 mg/kg) only. Baseline and 8 week alveolar bone loss was assessed by microcomputed tomography (mu CT) and histological examination. LPS induced severe bone loss over this time period, whereas control groups were unchanged from baseline measurements. Both doses of SD 282 showed significant protection from LPS induced bone loss. Bone area and volumetric analysis of maxillas by mu CT indicated significant loss of bone volume with LPS treatment, which was blocked with the p38 inhibitor. Histological examination indicated significantly fewer tartate resistant acid phosphatase positive osteoclasts and a significant decrease in interleukin (IL) 6, IL 1 beta, and tumor necrosis factor alpha expression in p38 inhibitor treated groups compared with LPS groups by immunostaining. Results from this in vivo study suggest that orally active p38 MAPK inhibitors can reduce LPS induced inflammatory cytokine production and osteoclast formation and protect against LPS stimulated alveolar bone loss.
C1 Univ Michigan, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   Univ Michigan, Orthoped Res Lab, Ann Arbor, MI 48109 USA.
   Scios Inc, Fremont, CA USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Scios
RP Kirkwood, KL (通讯作者)，Univ Michigan, Dept Periodont & Oral Med, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM klkirk@umich.edu
RI Kirkwood, Keith/L 4728 2018; D'Silva, Nisha/B 4734 2013; Dugar,
   Siddharth/ABF 1545 2020
OI Kirkwood, Keith/0000 0003 4519 8973; 
FU NIAMS NIH HHS [P30AR46024] Funding Source: Medline
CR Adams JL, 2001, PROGR MED CHEM, V38, P1, DOI 10.1016/S0079 6468(08)70091 2
   Assuma R, 1998, J IMMUNOL, V160, P403
   Aubin J E, 2000, Medscape Womens Health, V5, P5
   Baker PJ, 2000, MICROBES INFECT, V2, P1181, DOI 10.1016/S1286 4579(00)01272 7
   CHEN YM, 1998, J BASIC SCI ENG, V6, P367
   Crotti T, 2003, J PERIODONTAL RES, V38, P380, DOI 10.1034/j.1600 0765.2003.00615.x
   Dai JC, 2006, BONE, V38, P509, DOI 10.1016/j.bone.2005.10.007
   Ejeil AL, 2003, J PERIODONTOL, V74, P196, DOI 10.1902/jop.2003.74.2.196
   Graves DT, 2003, J PERIODONTOL, V74, P391, DOI 10.1902/jop.2003.74.3.391
   Graves DT, 1999, CLIN INFECT DIS, V28, P482, DOI 10.1086/515178
   Greenwald RA, 1999, J RHEUMATOL, V26, P1650
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847
   Holtmann H, 1999, MOL CELL BIOL, V19, P6742
   Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200
   Kirkwood K, 2003, BIOCHEM PHARMACOL, V66, P1809, DOI 10.1016/S0006 2952(03)00450 7
   KIRKWOOD K, 2006, IN PRESS PERIODONTOL
   Kostenuik PJ, 2004, BONE, V34, P656, DOI 10.1016/j.bone.2003.12.006
   LEE HJ, 1995, J CLIN PERIODONTOL, V22, P885, DOI 10.1111/j.1600 051X.1995.tb01788.x
   Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162 3109(00)00206 X
   Madianos PN, 2005, J CLIN PERIODONTOL, V32, P57, DOI 10.1111/j.1600 051X.2005.00821.x
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Medicherla S, 2006, J PHARMACOL EXP THER, V318, P132, DOI 10.1124/jpet.105.098020
   Mercado FB, 2003, J CLIN PERIODONTOL, V30, P761, DOI 10.1034/j.1600 051X.2003.00371.x
   PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600 0765.1991.tb01649.x
   Patil C, 2006, ORAL MICROBIOL IMMUN, V21, P392, DOI 10.1111/j.1399 302X.2006.00314.x
   Patil C, 2004, IMMUNOL INVEST, V33, P213, DOI 10.1081/IMM 120034231
   Reddi K, 1996, J PERIODONTAL RES, V31, P120, DOI 10.1111/j.1600 0765.1996.tb00473.x
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   ROGERS JE, 2006, IN PRESS J PERIODONT
   Rossa C Jr, 2005, MATRIX BIOL, V24, P478, DOI 10.1016/j.matbio.2005.06.006
   Rossa C, 2006, J INTERF CYTOK RES, V26, P719, DOI 10.1089/jir.2006.26.719
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Slots J, 1999, PERIODONTOL 2000, V20, P82, DOI 10.1111/j.1600 0757.1999.tb00159.x
   STASHENKO P, 1991, J PERIODONTOL, V62, P504, DOI 10.1902/jop.1991.62.8.504
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   TSAI CC, 1995, J PERIODONTOL, V66, P852, DOI 10.1902/jop.1995.66.10.852
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   Wilensky A, 2005, J PERIODONTOL, V76, P1282, DOI 10.1902/jop.2005.76.8.1282
   WILLIAMS RC, 1990, NEW ENGL J MED, V322, P373, DOI 10.1056/NEJM199002083220606
   WILSON ME, 1992, INFECT IMMUN, V60, P1806, DOI 10.1128/IAI.60.5.1806 1812.1992
NR 41
TC 53
Z9 57
U1 0
U2 3
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD JAN
PY 2007
VL 320
IS 1
BP 56
EP 63
DI 10.1124/jpet.106.112466
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 119ER
UT WOS:000242995600007
PM 17041006
DA 2025 08 17
ER

PT J
AU Liu, D
   Xu, W
   Tang, Y
   Cao, JX
   Chen, R
   Wu, DW
   Chen, HP
   Su, B
   Xu, JF
AF Liu, Di
   Xu, Wen
   Tang, Yuan
   Cao, Jingxue
   Chen, Ran
   Wu, Dingwei
   Chen, Hongpeng
   Su, Bo
   Xu, Jinfu
TI Nebulization of risedronate alleviates airway obstruction and
   inflammation of chronic obstructive pulmonary diseases via suppressing
   prenylation dependent RAS/ERK/NF κB and RhoA/ROCK1/MLCP signaling
SO RESPIRATORY RESEARCH
LA English
DT Article
DE Pulmonary disease; Chronic obstructive; Risedronic acid; Inflammation;
   Animal models
ID LIQUID CHROMATOGRAPHIC DETERMINATION; MYOSIN PHOSPHATASE; SMOOTH MUSCLE;
   ALL CAUSE; MACROPHAGES; MORTALITY; SUBUNIT; KINASES; CELLS
AB Background: Chronic obstructive pulmonary disease (COPD) is a progressive disorder that causes airway obstruction and lung inflammation. The first line treatment of COPD is the bronchodilators of beta 2 agonists and antimuscarinic drugs, which can help control the airway obstruction, but the long term use might render the drug tolerance. Bisphosphonates are widely used in osteoclast mediated bone diseases treatment for decades. For drug repurposing, can delivery of a third generation of nitrogen containing bisphosphonate, risedronate (RIS) ameliorate the progression of COPD? Methods: COPD rats or mice models have been established through cigarette smoking and elastase injection, and then the animals are received RIS treatment via nebulization. Lung deposition of RIS was primarily assessed by high performance liquid chromatography (HPLC). The respiratory parameters of airway obstruction in COPD rats and mice were documented using plethysmography method and resistance compliance system. Results: High lung deposition and bioavailability of RIS was monitored with 88.8% of RIS input dose. We found that RIS could rescue the lung function decline of airspace enlargement and mean linear intercept in the COPD lung. RIS could curb the airway obstruction by suppressing 60% of the respiratory resistance and elevating the airway's dynamic compliance, tidal volume and mid expiratory flow. As an inhibitor of farnesyl diphosphate synthase (FDPS), RIS suppresses FDPS mediated RAS and RhoA prenylation to obstruct its membrane localization in airway smooth muscle cells (ASMCs), leading to the inhibition of downstream ERK MLCK and ROCK1 MLCP pathway to cause ASMCs relaxation. Additionally, RIS nebulization impeded pro inflammatory cell accumulation, particularly macrophages infiltration in alveolar parenchyma. The NF kappa B, tumor necrosis factor alpha, IL 1 beta, IL 8, and IL 6 declined in microphages following RIS nebulization. Surprisingly, nebulization of RIS could overcome the tolerance of beta 2 agonists in COPD rats by increasing the expression of beta 2 receptors. Conclusions: Nebulization of RIS could alleviate airway obstruction and lung inflammation in COPD, providing a novel strategy for treating COPD patients, even those with beta 2 agonists tolerance.
C1 [Liu, Di; Tang, Yuan; Cao, Jingxue; Chen, Ran; Su, Bo] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Cent Lab, Shanghai, Peoples R China.
   [Liu, Di] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Radiat Oncol, Shanghai, Peoples R China.
   [Xu, Wen; Xu, Jinfu] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
   [Tang, Yuan] Bengbu Med Coll, Basic Med Coll, Bengbu, Peoples R China.
   [Cao, Jingxue] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Radiol, Shanghai, Peoples R China.
   [Wu, Dingwei; Chen, Hongpeng] Zhejiang Xianju Pharmaceut Co Ltd, Xianju, Peoples R China.
   [Su, Bo] Bengbu Med Coll, Sch Life Sci, Bengbu, Peoples R China.
C3 Tongji University; Tongji University; Tongji University; Bengbu Medical
   University; Tongji University; Bengbu Medical University
RP Su, B (通讯作者)，Tongji Univ, Shanghai Pulm Hosp, Sch Med, Cent Lab, Shanghai, Peoples R China.; Xu, JF (通讯作者)，Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Resp & Crit Care Med, Shanghai, Peoples R China.
EM Su_bo_s@hotmail.com; jfxu@tongji.edu.cn
RI ; Xu, Jin fu/AAC 6980 2020
OI Xu, Jin fu/0000 0002 8039 8973; 
CR Almeida M, 2014, PATHOBIOLOGY, V81, P261, DOI 10.1159/000358306
   Ammit AJ, 2000, AM J RESP CRIT CARE, V161, P257, DOI 10.1164/ajrccm.161.1.9901005
   Berzat AC, 2006, METHOD ENZYMOL, V407, P575, DOI 10.1016/S0076 6879(05)07046 1
   Bloom DE, 2012, PGDA WORKING PAPERS
   Eapen MS, 2017, EXPERT REV RESP MED, V11, P827, DOI 10.1080/17476348.2017.1360769
   Elkady OA, 2021, AAPS PHARMSCITECH, V22, DOI 10.1208/s12249 021 02078 8
   FURST P, 1990, J CHROMATOGR, V499, P557, DOI 10.1016/S0021 9673(00)97000 6
   GOLD REPORTS, 2022 GOLD REPORTS GL
   Goldklang MP, 2016, C98 AIRWAY REMODELIN, pA6176
   Grassie ME, 2011, ARCH BIOCHEM BIOPHYS, V510, P147, DOI 10.1016/j.abb.2011.01.018
   Guido G, 2009, CLIN CASES MINER BON, V6, P114
   Hirota N, 2013, CHEST, V144, P1026, DOI 10.1378/chest.12 3073
   Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Ito M, 2004, MOL CELL BIOCHEM, V259, P197, DOI 10.1023/B:MCBI.0000021373.14288.00
   IWAKI K, 1990, J CHROMATOGR, V504, P359, DOI 10.1016/S0021 9673(01)89539 X
   Jiang XF, 2012, FASEB J, V26, P1995, DOI 10.1096/fj.11 193870
   Karal A, 2022, INT J INNOV RES REV, V6, P58
   Kim Hee Jin, 2018, Exp Mol Med, V50, P1, DOI 10.1038/s12276 018 0179 x
   Matsumura F, 2008, BIOCHEM BIOPH RES CO, V369, P149, DOI 10.1016/j.bbrc.2007.12.090
   Murthy KS, 2006, ANNU REV PHYSIOL, V68, P345, DOI 10.1146/annurev.physiol.68.040504.094707
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140 6736(14)61682 2
   Nazinigouba O., 2014, J Pulm Respir Med
   Odendall C, 2012, CELL HOST MICROBE, V12, P657, DOI 10.1016/j.chom.2012.09.011
   Raherison C, 2018, BMC PULM MED, V18, DOI 10.1186/s12890 018 0684 7
   Rangasamy T, 2009, AM J PHYSIOL LUNG C, V296, pL888, DOI 10.1152/ajplung.90369.2008
   Riddick N, 2008, J CELL BIOCHEM, V103, P1158, DOI 10.1002/jcb.21488
   Seshacharyulu P, 2019, ONCOGENE, V38, P5265, DOI 10.1038/s41388 019 0791 9
   Shah NJ, 2021, INTRO BASICS PHARM T, P533
   Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003
   Tashkin D, 2009, REV PORT PNEUMOL, V15, P137, DOI 10.1016/S0873 2159(15)30121 5
   Tetley TD, 2002, CHEST, V121, p156S, DOI 10.1378/chest.121.5_suppl.156S
   Tomlinson MJ, 2013, J TISSUE ENG, V4, DOI 10.1177/2041731412472690
   Ueno M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7332
   Vaes AW, 2014, EUR RESPIR J, V44, P1199, DOI 10.1183/09031936.00023214
   Van Hoecke L, 2017, JOVE J VIS EXP, DOI 10.3791/55398
   Vi L, 2015, J BONE MINER RES, V30, P1090, DOI 10.1002/jbmr.2422
   Wang C, 2018, LANCET, V391, P1706, DOI [10.1016/S0140 6736(18)30841 9, 10.1016/s0140 6736(18)30841 9]
   Wang YJ, 2018, INT J CHRONIC OBSTR, V13, P3341, DOI 10.2147/COPD.S176122
   Yim RP, 2013, PAEDIATR RESPIR REV, V14, P195, DOI 10.1016/j.prrv.2012.11.002
NR 40
TC 5
Z9 8
U1 2
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1465 993X
J9 RESP RES
JI Respir. Res.
PD DEC 28
PY 2022
VL 23
IS 1
AR 380
DI 10.1186/s12931 022 02274 5
PG 14
WC Respiratory System
WE Science Citation Index Expanded (SCI EXPANDED)
SC Respiratory System
GA 7K3GJ
UT WOS:000905173800001
PM 36575527
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xiao, YB
   Donnelly, H
   Sprott, M
   Luo, JJ
   Jayawarna, V
   Lemgruber, L
   Tsimbouri, PM
   Meek, RMD
   Salmeron Sanchez, M
   Dalby, MJ
AF Xiao, Yinbo
   Donnelly, Hannah
   Sprott, Mark
   Luo, Jiajun
   Jayawarna, Vineetha
   Lemgruber, Leandro
   Tsimbouri, P. Monica
   Meek, R. M. Dominic
   Salmeron Sanchez, Manuel
   Dalby, Matthew J.
TI Material driven fibronectin and vitronectin assembly enhances BMP 2
   presentation and osteogenesis
SO MATERIALS TODAY BIO
LA English
DT Article
DE Mesenchymal stem cells; Polymer organized extracellular matrix;
   Vitronectin; Fibronectin; Bone morphogenetic protein 2; Osteogenesis
ID BONE MORPHOGENETIC PROTEINS; GROWTH FACTOR; EXTRACELLULAR MATRIX;
   ADVERSE EVENTS; SURFACE CHEMISTRIES; CELL; BINDING; ALPHA(5)BETA(1);
   ADHESION; ALPHA V BETA 3
AB Mesenchymal stem cell (MSC) based tissue engineering strategies are of interest in the field of bone tissue regenerative medicine. MSCs are commonly investigated in combination with growth factors (GFs) and bio materials to provide a regenerative environment for the cells. However, optimizing how biomaterials interact with MSCs and efficiently deliver GFs, remains a challenge. Here, via plasma polymerization, tissue culture plates are coated with a layer of poly (ethyl acrylate) (PEA), which is able to spontaneously permit fibronectin (FN) to form fibrillar nanonetworks. However, vitronectin (VN), another important extracellular matrix (ECM) protein forms multimeric globules on the polymer, thus not displaying functional groups to cells. Interestingly, when FN and VN are co absorbed onto PEA surfaces, VN can be entrapped within the FN fibrillar nanonetwork in the monomeric form providing a heterogeneous, open ECM network. The combination of FN and VN promote MSC adhesion and leads to enhanced GF binding; here we demonstrate this with bone morphogenetic protein 2 (BMP2). Moreover, MSC differentiation into osteoblasts is enhanced, with elevated expression of osteopontin (OPN) and osteocalcin (OCN) quantified by immunostaining, and increased mineralization observed by von Kossa staining. Osteogenic intracellular signalling is also induced, with increased activity in the SMAD pathway. The study emphasizes the need of recapitulating the complexity of native ECM to achieve optimal cell material interactions.
C1 [Xiao, Yinbo; Donnelly, Hannah; Sprott, Mark; Tsimbouri, P. Monica; Dalby, Matthew J.] Univ Glasgow, Inst Mol Cell & Syst Biolog, Coll Med Vet & Life Sci, Ctr Cellular Microenvironm, Joseph Black Bldg, Glasgow City G12 8QQ, Scotland.
   [Luo, Jiajun; Jayawarna, Vineetha; Salmeron Sanchez, Manuel] Univ Glasgow, Ctr Cellular Microenvironm, Sch Engn, Div Biomed Engn, Glasgow City G12 8QQ, Scotland.
   [Lemgruber, Leandro] Univ Glasgow, Inst Infect Immun & Inflammat, Coll Med, Glasgow Imaging Facil, Glasgow City G12, Scotland.
   [Meek, R. M. Dominic] Queen Elizabeth Univ Hosp, Dept Trauma & Orthopaed, Glasgow City G51, Scotland.
C3 University of Glasgow; University of Glasgow; University of Glasgow;
   Queen Elizabeth University Hospital (QEUH)
RP Xiao, YB; Dalby, MJ (通讯作者)，Univ Glasgow, Inst Mol Cell & Syst Biolog, Coll Med Vet & Life Sci, Ctr Cellular Microenvironm, Joseph Black Bldg, Glasgow City G12 8QQ, Scotland.
EM y.xiao.1@research.gla.ac.uk; Matthew.Dalby@glasgow.ac.uk
RI Lemgruber, Leandro/KHW 3949 2024; Sprott, Mark/AAF 3771 2019; Tsimbouri,
   Penelope/F 4373 2010; Salmeron Sanchez, Manuel/E 4680 2010; Meek,
   Dominic/AAF 5057 2020; Dalby, Matthew/G 2426 2012
OI Luo, Jiajun/0000 0003 4735 102X; Dalby, Matthew/0000 0002 0528 3359;
   Sprott, Mark/0000 0002 1990 9498; Donnelly, Hannah/0000 0002 5154 9971; 
FU EPSRC [EP/P001114/1]; China Scholarship Council [201908060063];
   Engineering and Physical Sciences Research Council [EP/P001114/1]
   Funding Source: researchfish
FX This work was supported by an EPSRC Programme Grant (EP/P001114/1) . YB.
   acknowledges the support from China Scholarship Council (#201908060063)
   . X ray photoelectron spectroscopy was conducted by the National EPSRC
   XPS Users'Service (NEXUS) , Newcastle.
CR Alba Perez A, 2020, MAT SCI ENG C MATER, V113, DOI 10.1016/j.msec.2020.110966
   [Anonymous], 2011, The Extracellular Matrix: an Overview, DOI DOI 10.1007/978 3 642 16555 9
   Barrias CC, 2009, BIOMATERIALS, V30, P307, DOI 10.1016/j.biomaterials.2008.09.048
   BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503
   Cantini M, 2017, ADV BIOSYST, V1, DOI 10.1002/adbi.201700047
   Chen LN, 2018, MATER TODAY, V21, P38, DOI 10.1016/j.mattod.2017.07.002
   Cheng ZA, 2019, ADV SCI, V6, DOI 10.1002/advs.201800361
   Cipitria A, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700052
   Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955 0674(03)00096 6
   Crouzier T, 2011, ADV MATER, V23, pH111, DOI 10.1002/adma.201004637
   Dalby MJ, 2018, NAT REV MATER, V3, DOI 10.1038/natrevmats.2017.91
   Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014
   Donnelly H, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2018.0388
   Dumic Cule I, 2018, INT ORTHOP, V42, P2619, DOI 10.1007/s00264 018 4153 y
   Fourel L, 2016, J CELL BIOL, V212, P693, DOI 10.1083/jcb.201508018
   Gamell C, 2008, J CELL SCI, V121, P3960, DOI 10.1242/jcs.031286
   Garrison KR, 2007, HEALTH TECHNOL ASSES, V11, P1
   González García C, 2013, COLLOID SURFACE B, V111, P618, DOI 10.1016/j.colsurfb.2013.07.016
   Gugutkov D, 2010, J BIOMED MATER RES A, V92A, P322, DOI 10.1002/jbm.a.32374
   Gupta MC, 2005, CYTOKINE GROWTH F R, V16, P347, DOI 10.1016/j.cytogfr.2005.02.004
   Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955 0674(93)90036 P
   Harrington R. E., 2020, BIOMATERIALS SCI, P1431, DOI DOI 10.1016/B978 0 12 816137 1.00091 X
   Horzum U, 2014, METHODSX, V1, P56, DOI 10.1016/j.mex.2014.06.004
   Hudalla GA, 2011, INTEGR BIOL UK, V3, P832, DOI 10.1039/c1ib00021g
   Hussey GS, 2018, NAT REV MATER, V3, P159, DOI 10.1038/s41578 018 0023 x
   Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009
   Ivankovic Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515
   Kanchanawong P, 2010, NATURE, V468, P580, DOI 10.1038/nature09621
   Kechagia JZ, 2019, NAT REV MOL CELL BIO, V20, P457, DOI 10.1038/s41580 019 0134 2
   Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537
   Kisiel M, 2013, BIOMATERIALS, V34, P704, DOI 10.1016/j.biomaterials.2012.10.015
   Leavesley DI, 2013, IUBMB LIFE, V65, P807, DOI 10.1002/iub.1203
   Li TJ, 2020, BIOACT MATER, V5, P1044, DOI 10.1016/j.bioactmat.2020.06.021
   Lin MP, 2015, BIOMACROMOLECULES, V16, P973, DOI 10.1021/bm501873g
   Llopis Hernández V, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600188
   Martino MM, 2015, ADV DRUG DELIVER REV, V94, P41, DOI 10.1016/j.addr.2015.04.007
   Martino MM, 2014, SCIENCE, V343, P885, DOI 10.1126/science.1247663
   Martino MM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002614
   Martino MM, 2010, FASEB J, V24, P4711, DOI 10.1096/fj.09 151282
   Mecham R.P, 2011, CELL BIOL EXTRACELLU, DOI [10.1016/0092 8674(92)90608 f, DOI 10.1016/0092 8674(92)90608 F]
   Mitchell AC, 2016, ACTA BIOMATER, V30, P1, DOI 10.1016/j.actbio.2015.11.007
   Morgan MR, 2009, IUBMB LIFE, V61, P731, DOI 10.1002/iub.200
   MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867
   Moulisová V, 2017, BIOMATERIALS, V126, P61, DOI 10.1016/j.biomaterials.2017.02.024
   Oliver Cervelló L, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001757
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Pireaux J. J., 1993, J ELECT SPECTROS REL, V62, P371
   Posa F, 2021, BIOMATERIALS, V267, DOI 10.1016/j.biomaterials.2020.120484
   Roca Cusachs P, 2009, P NATL ACAD SCI USA, V106, P16245, DOI 10.1073/pnas.0902818106
   Salmerón Sánchez M, 2011, BIOMATERIALS, V32, P2099, DOI 10.1016/j.biomaterials.2010.11.057
   Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517
   Sprott MR, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801469
   Su Y.C., 2018, VITRONECTIN, Vsecond, DOI [10.1016/B978 0 12 810420 0.00033 X, DOI 10.1016/B978 0 12 810420 0.00033 X]
   Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445
   Toromanov G, 2015, ACS BIOMATER SCI ENG, V1, P927, DOI 10.1021/acsbiomaterials.5b00147
   Toromanov G, 2010, POLYMER, V51, P2329, DOI 10.1016/j.polymer.2010.03.041
   Woo EJ, 2013, CLIN ORTHOP RELAT R, V471, P1707, DOI 10.1007/s11999 012 2684 x
   Woo EJ, 2012, SPINE J, V12, P894, DOI 10.1016/j.spinee.2012.09.052
   Woo EJ, 2012, J ORAL MAXIL SURG, V70, P765, DOI 10.1016/j.joms.2011.09.008
   Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040
NR 62
TC 12
Z9 12
U1 2
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD DEC
PY 2022
VL 16
AR 100367
DI 10.1016/j.mtbio.2022.100367
EA JUL 2022
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 3Y1HR
UT WOS:000843481000005
PM 35937570
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Bhattarai, G
   Poudel, SB
   Kook, SH
   Lee, JC
AF Bhattarai, Govinda
   Poudel, Sher Bahadur
   Kook, Sung Ho
   Lee, Jeong Chae
TI Resveratrol prevents alveolar bone loss in an experimental rat model of
   periodontitis
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Resveratrol; Lipopolysaccharide; Periodontitis; HO 1; Nrf2
ID MATRIX METALLOPROTEINASE INDUCER; OXIDATIVE STRESS; REACTIVE OXYGEN;
   EPITHELIAL CELLS; DISEASE; ACTIVATION; EXPRESSION; THERAPY; PATHWAY;
   DIFFERENTIATION
AB Resveratrol is an antioxidant and anti inflammatory polyphenol. Periodontitis is induced by oral pathogens, where a systemic inflammatory response accompanied by oxidative stress is the major event initiating disease. We investigated how resveratrol modulates cellular responses and the mechanisms related to this modulation in lipopolysaccharide (LPS) stimulated human gingival fibroblasts (hGFs). We also explored whether resveratrol protects rats against alveolar bone loss in an experimental periodontitis model. Periodontitis was induced around the first upper molar of the rats by applying ligature infused with LPS. Stimulating hGFs with 5 mu g/mI LPS augmented the expression of cyclooxygenase 2, matrix metalloproteinase (MMP) 2, MMP 9, and Toll like receptor 4. LPS treatment also stimulated the production of reactive oxygen species (ROS) and the phosphorylation of several protein kinases in the cells. However, the expression of heme oxygenase 1 (HO 1) and nuclear factor E2 related factor 2 (Nrf2) was inhibited by the addition of LPS. Resveratrol treatment almost completely inhibited all of these changes in LPS stimulated cells. Specifically, resveratrol alone augmented HO 1 induction via Nrf2 mediated signaling. Histological and micro CT analyses revealed that administration of resveratrol (5 mg/kg body weight) improved ligature/LPS mediated alveolar bone loss in rats. Resveratrol also attenuated the production of inflammation related proteins, the formation of osteoclasts, and the production of circulating ROS in periodontitis rats. Furthermore, resveratrol suppressed LPS mediated decreases in HO 1 and Nrf2 levels in the inflamed periodontal tissues. Collectively, our findings suggest that resveratrol protects rats from periodontitic tissue damage by inhibiting inflammatory responses and by stimulating antioxidant defense systems.
   Statement of significance
   The aims of this study were to investigate how resveratrol modulates cellular responses and the mechanisms related to this modulation in lipopolysaccharide (LPS) stimulated human gingival fibroblasts (hGFs) and protects rats against alveolar bone disruption in an experimental periodontitis model. Our findings suggest that resveratrol protects rats from periodontitic tissue damage by inhibiting inflammatory responses and by stimulating antioxidant defense systems. On the basis of our experiment studies, we proposed that resveratrol could be used as novel bioactive materials or therapeutic drug for the treatment of periodontitis or other inflammatory bone diseases like osteoporosis, arthritis etc. Furthermore, it could be also used for the modification or coating of implant materials as an antiinflammatory molecules which will help to accelerate bone formation. There are a few of reports suggesting antioxidant and anti inflammatory potentials of resveratrol. However, our results highlight the cellular mechanisms by which resveratrol inhibits LPS mediated cellular damages using human originated gingival fibroblasts and also support the potential of resveratrol to suppress periodontitis mediated tissue damages. We believe that the present findings might improve a clinical approach of using of resveratrol on human, although further detailed experiments will be needed. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Bhattarai, Govinda; Poudel, Sher Bahadur; Kook, Sung Ho; Lee, Jeong Chae] Chonbuk Natl Univ, Cluster Craniofacial Dev & Regenerat Res, Inst Oral Biosci, Program BK21, Jeonju 561756, South Korea.
   [Bhattarai, Govinda; Poudel, Sher Bahadur; Kook, Sung Ho; Lee, Jeong Chae] Chonbuk Natl Univ, Sch Dent, Jeonju 561756, South Korea.
   [Kook, Sung Ho; Lee, Jeong Chae] Chonbuk Natl Univ, Dept Bioact Mat Sci, Jeonju 561756, South Korea.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University
RP Lee, JC (通讯作者)，Chonbuk Natl Univ, Inst Oral Biosci, Jeonju 561756, South Korea.
EM leejc88@jbnu.ac.kr
RI Poudel, Sher/V 3282 2019
OI Poudel, Sher Bahadur/0000 0003 3733 4648
FU Basic Science Research Program through the National Research Foundation
   of Korea (KRF)   Ministry of Science, ICT and Future Planning
   [NRF 2013R1A2A2A01967207]; KRF [NRF 2014R1A1A2008488]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (KRF) funded by the
   Ministry of Science, ICT and Future Planning (NRF 2013R1A2A2A01967207).
   A grant from the KRF endowed to Dr. Govinda Bhattarai
   (NRF 2014R1A1A2008488) supported a part of this study.
CR Rubiolo JA, 2008, EUR J PHARMACOL, V591, P66, DOI 10.1016/j.ejphar.2008.06.067
   Bullon P, 2011, FREE RADICAL BIO MED, V50, P1336, DOI 10.1016/j.freeradbiomed.2011.02.018
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600 0765.2007.00989.x
   Carvalho RD, 2013, ARCH ORAL BIOL, V58, P50, DOI 10.1016/j.archoralbio.2012.04.020
   Casati MZ, 2013, J PERIODONTOL, V84, pE58, DOI 10.1902/jop.2013.120746
   Chapple ILC, 2007, PERIODONTOL 2000, V43, P160, DOI 10.1111/j.1600 0757.2006.00178.x
   Chapple ILC, 1997, J CLIN PERIODONTOL, V24, P287, DOI 10.1111/j.1600 051X.1997.tb00760.x
   Corotti MV, 2009, ARCH ORAL BIOL, V54, P764, DOI 10.1016/j.archoralbio.2009.04.013
   Cottart CH, 2010, MOL NUTR FOOD RES, V54, P7, DOI 10.1002/mnfr.200900437
   Csiszar A, 2011, ANN NY ACAD SCI, V1215, P117, DOI 10.1111/j.1749 6632.2010.05848.x
   D'Aiuto F, 2010, J DENT RES, V89, P1241, DOI 10.1177/0022034510375830
   Das Samarjit, 2007, Inflammation & Allergy Drug Targets, V6, P168, DOI 10.2174/187152807781696464
   Dong W, 2009, J PERIODONTAL RES, V44, P125, DOI 10.1111/j.1600 0765.2008.01105.x
   Durbin SM, 2014, J BONE MINER METAB, V32, P38, DOI 10.1007/s00774 013 0469 2
   FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607
   Garcia Contreras R, 2015, BIOMATERIALS, V57, P33, DOI 10.1016/j.biomaterials.2015.03.059
   He T, 2015, MOL CELL ENDOCRINOL, V402, P13, DOI 10.1016/j.mce.2014.12.010
   Jakus PB, 2013, J NUTR BIOCHEM, V24, P819, DOI 10.1016/j.jnutbio.2012.04.017
   Kantarci A, 2006, PERIODONTOL 2000, V40, P144, DOI 10.1111/j.1600 0757.2005.00145.x
   King GN, 2002, J PERIODONTOL, V73, P925, DOI 10.1902/jop.2002.73.8.925
   Kook SH, 2015, MOL CELL BIOCHEM, V402, P213, DOI 10.1007/s11010 015 2329 y
   Kook SH, 2014, J PERIODONTOL, V85, P645, DOI 10.1902/jop.2013.130252
   Lamont RJ, 1998, MICROBIOL MOL BIOL R, V62, P1244, DOI 10.1128/MMBR.62.4.1244 1263.1998
   Liu L, 2010, J PERIODONTAL RES, V45, P541, DOI 10.1111/j.1600 0765.2010.01269.x
   Luo W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051008
   Marcaccini AM, 2010, J CLIN PERIODONTOL, V37, P180, DOI 10.1111/j.1600 051X.2009.01512.x
   Marcaccini AM, 2009, CLIN CHIM ACTA, V409, P117, DOI 10.1016/j.cca.2009.09.012
   Marchetti C, 2015, IMMUNOBIOLOGY, V220, P1030, DOI 10.1016/j.imbio.2015.02.003
   Minagawa T, 2015, J PERIODONTAL RES, V50, P586, DOI 10.1111/jre.12238
   Nagaol Y., 2014, HEPAT MON, V12
   Nakamura H, 2013, J BONE MINER RES, V28, P1457, DOI 10.1002/jbmr.1866
   Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Rai Balwant, 2008, J Oral Sci, V50, P53, DOI 10.2334/josnusd.50.53
   Rodini CO, 2008, J MOL HISTOL, V39, P275, DOI 10.1007/s10735 008 9163 4
   Shin SM, 2009, MOL PHARMACOL, V76, P884, DOI 10.1124/mol.109.058479
   Takayama S, 2001, J DENT RES, V80, P2075, DOI 10.1177/00220345010800121001
   Tamaki N, 2014, FREE RADICAL BIO MED, V75, P222, DOI 10.1016/j.freeradbiomed.2014.07.034
   Toker H, 2008, J PERIODONTOL, V79, P1089, DOI [10.1902/jop.2008.070462, 10.1902/jop.2008.070462 ]
   Tomofuji T, 2009, JPN DENT SCI REV, V45, P46, DOI 10.1016/j.jdsr.2008.12.002
   Ungvari Z, 2011, EXERC SPORT SCI REV, V39, P128, DOI 10.1097/JES.0b013e3182141f80
   Waddington RJ, 2000, ORAL DIS, V6, P138
   Wang HD, 2013, BRIT J PHARMACOL, V170, P796, DOI 10.1111/bph.12301
   Wang W, 2014, ACTA BIOMATER, V10, P4983, DOI 10.1016/j.actbio.2014.08.022
   WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011
   Zhang YQ, 2015, CLIN NUTR, V34, P752, DOI 10.1016/j.clnu.2014.08.014
   Zhang Z, 2014, MOL MED REP, V10, P101, DOI 10.3892/mmr.2014.2226
   Zhen L, 2015, ACTA PHARMACOL SIN, V36, P221, DOI 10.1038/aps.2014.131
NR 48
TC 197
Z9 216
U1 8
U2 113
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN 1
PY 2016
VL 29
BP 398
EP 408
DI 10.1016/j.actbio.2015.10.031
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DA0MA
UT WOS:000367490000037
PM 26497626
DA 2025 08 17
ER

PT J
AU Otis, V
   Sarret, P
   Gendron, L
AF Otis, V.
   Sarret, P.
   Gendron, L.
TI SPINAL ACTIVATION OF DELTA OPIOID RECEPTORS ALLEVIATES CANCER RELATED
   BONE PAIN
SO NEUROSCIENCE
LA English
DT Article
DE delta opioid receptor; bone cancer; MRMT 1 cells; allodynia; complete
   Freund's adjuvant; pain
ID RAT MODEL; INTRATHECAL D ALA2 D LEU5 ENKEPHALIN; METHIONINE ENKEPHALIN;
   CHRONIC INFLAMMATION; INDUCED HYPERALGESIA; NEUROPATHIC PAIN; MURINE
   MODEL; TUMOR GROWTH; MORPHINE; MU
AB Over the past few years, significant progress has been made in cancer therapy. Indeed, the lifespan of cancer patients has significantly increased. Although patients live longer, cancer related pain remains a daily problem affecting their quality of life, especially when metastases reach the bone. In patients coping with cancer induced bone pain, morphine and NSAIDs, often used in combination with other medications, are the most commonly used drugs to alleviate pain. However, these drugs have dose limiting side effects. Morphine and other routinely used opioids are mu opioid receptor (MOPR) agonists. The MOPR is responsible for most opioid related adverse effects. In the present study, we revealed potent analgesic effects of an intrathecally administered selective delta opioid receptor (DOPR) agonist, deltorphin II, in a recently developed rat bone cancer model. Indeed, we found that deltorphin II dose dependently reversed mechanical allodynia 14 days post surgery in this cancer pain model, which is based on the implantation of mammary MRMT 1 cells in the femur. This effect was DOPR mediated as it was completely blocked by naltrindole, a selective DOPR antagonist. Using the complete Freund's adjuvant model of inflammatory pain, we further demonstrated that deltorphin II was equipotent at alleviating inflammatory and cancer pain (i.e. similar ED50 values). Altogether, the present results show, for the first time, that activation of spinal DOPRs causes significant analgesia at doses sufficient to reduce inflammatory pain in a rat bone cancer pain model. Our results further suggest that DOPR represents a potential target for the development of novel analgesic therapies to be used in the treatment of cancer related pain. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Otis, V.; Sarret, P.; Gendron, L.] Univ Sherbrooke, Fac Med & Sci Sante, Dept Physiol & Biophys, Sherbrooke, PQ J1H 5N4, Canada.
   [Sarret, P.; Gendron, L.] Univ Sherbrooke, Fac Med & Sci Sante, Inst Pharmacol Sherbrooke, Sherbrooke, PQ J1H 5N4, Canada.
C3 University of Sherbrooke; University of Sherbrooke
RP Gendron, L (通讯作者)，Univ Sherbrooke, Fac Med & Sci Sante, Dept Physiol & Biophys, 3001,12ieme Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
EM Louis.Gendron@USherbrooke.ca
OI Sarret, Philippe/0000 0002 7627 701X; Gendron, Louis/0000 0002 2058 8863
FU Canadian Institutes of Health Research (CIHR) [MOP 84538, MOP 106574];
   Cancer Research Society (CRS); Fonds de la Recherche en Sante du Quebec
   (FRSQ)
FX The authors are thankful to Karine Belleville who provided technical
   help and advice on the bone cancer model. This work was primarily
   supported by grant MOP 84538 from the Canadian Institutes of Health
   Research (CIHR) to LG, but also by grant MOP 106574 from the CIHR
   awarded to PS and LG and by a grant from the Cancer Research Society
   (CRS) awarded to PS. LG is the recipient of a Fonds de la Recherche en
   Sante du Quebec (FRSQ) Junior 1 salary support, and PS is a CIHR Young
   Investigator.
CR Baamonde A, 2005, N S ARCH PHARMACOL, V372, P213, DOI 10.1007/s00210 005 0013 6
   Brainin Mattos J, 2006, PAIN, V122, P174, DOI 10.1016/j.pain.2006.01.032
   Cahill CM, 2003, PAIN, V101, P199, DOI 10.1016/S0304 3959(02)00333 0
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165 0270(94)90144 9
   Christo PJ, 2008, ANN NY ACAD SCI, V1138, P278, DOI 10.1196/annals.1414.033
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   de Wit R, 2001, J PAIN SYMPTOM MANAG, V22, P911, DOI 10.1016/S0885 3924(01)00354 2
   Debruyne D, 2010, ANTICANCER RES, V30, P9
   DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149 7634(05)80090 9
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Donovan Rodriguez T, 2004, NEUROSCI LETT, V360, P29, DOI 10.1016/j.neulet.2004.01.048
   Doré Savard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013774
   Fraser GL, 2000, J PHARMACOL EXP THER, V295, P1135
   Gavériaux Ruff C, 2008, EUR J NEUROSCI, V27, P2558, DOI 10.1111/j.1460 9568.2008.06223.x
   Gendron L, 2007, NEUROSCIENCE, V150, P807, DOI 10.1016/j.neuroscience.2007.09.060
   Gendron L, 2007, NEUROSCIENCE, V144, P263, DOI 10.1016/j.neuroscience.2006.08.077
   Gendron L, 2006, J NEUROSCI, V26, P953, DOI 10.1523/JNEUROSCI.3598 05.2006
   Halvorson KG, 2006, CLIN J PAIN, V22, P587, DOI 10.1097/01.ajp.0000210902.67849.e6
   Holdridge SV, 2007, EUR J PAIN, V11, P685, DOI 10.1016/j.ejpain.2006.10.008
   Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306 4522(00)00110 X
   Honore P, 2000, PAIN MED, V1, P303, DOI 10.1046/j.1526 4637.2000.00047.x
   Hurley RW, 2000, J NEUROSCI, V20, P1249, DOI 10.1523/JNEUROSCI.20 03 01249.2000
   Jaglowski JR, 2005, CANCER CHEMOTH PHARM, V56, P97, DOI 10.1007/s00280 004 0929 4
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   King T, 2007, PAIN, V132, P154, DOI 10.1016/j.pain.2007.06.026
   Kirou Mauro AN, 2009, J PAIN SYMPTOM MANAG, V37, P77, DOI 10.1016/j.jpainsymman.2007.12.014
   KRAMES ES, 1986, PAIN, V24, P205, DOI 10.1016/0304 3959(86)90043 6
   Kuniyasu H, 2010, GUT, V59, P348, DOI 10.1136/gut.2009.178376
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Martin M, 2003, EUR J NEUROSCI, V17, P701, DOI 10.1046/j.1460 9568.2003.02482.x
   Martin Kleiner I, 2003, INT IMMUNOPHARMACOL, V3, P707, DOI 10.1016/S1567 5769(03)00058 4
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304 3959(01)00437 7
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Mercadante S, 2003, J PAIN SYMPTOM MANAG, V26, P769, DOI 10.1016/S0885 3924(03)00258 6
   Mercadante S, 1998, CANCER TREAT REV, V24, P425, DOI 10.1016/S0305 7372(98)90005 6
   Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470 2045(09)70350 X
   Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304 3959(01)00324 4
   Mika J, 2001, EUR J PHARMACOL, V415, P31, DOI 10.1016/S0014 2999(01)00814 7
   Morinville A, 2004, J NEUROSCI, V24, P5549, DOI 10.1523/JNEUROSCI.2719 03.2004
   Morinville A, 2004, PAIN, V109, P266, DOI 10.1016/j.pain.2004.01.011
   MOULIN DE, 1985, PAIN, V23, P213, DOI 10.1016/0304 3959(85)90099 5
   Nadal X, 2006, EUR J NEUROSCI, V23, P830, DOI 10.1111/j.1460 9568.2006.04569.x
   ONOFRIO BM, 1983, LANCET, V1, P1386
   Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254
   Petrillo P, 2003, J PHARMACOL EXP THER, V307, P1079, DOI 10.1124/jpet.103.055590
   PORRECA F, 1987, J PHARMACOL EXP THER, V241, P393
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140 6736(99)01310 0
   Ruiz Garcia V, 2008, BMJ BRIT MED J, V337, DOI 10.1136/bmj.a3104
   Schulman KL, 2007, CANCER AM CANCER SOC, V109, P2334, DOI 10.1002/cncr.22678
   Silverman SM, 2009, PAIN PHYSICIAN, V12, P679
   STEWART PE, 1994, J PHARMACOL EXP THER, V268, P701
   Urch C, 2004, PALLIATIVE MED, V18, P267, DOI 10.1191/0269216304pm887ra
   Wacnik PW, 2003, PAIN, V101, P175, DOI 10.1016/S0304 3959(02)00312 3
   Yamamoto J, 2008, NEUROSCIENCE, V151, P843, DOI 10.1016/j.neuroscience.2007.11.025
   Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658
NR 57
TC 29
Z9 37
U1 1
U2 8
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306 4522
EI 1873 7544
J9 NEUROSCIENCE
JI Neuroscience
PD JUN 2
PY 2011
VL 183
BP 221
EP 229
DI 10.1016/j.neuroscience.2011.03.052
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 765ZQ
UT WOS:000290748300021
PM 21458544
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Mistry, PK
   Liu, J
   Sun, L
   Chuang, WL
   Yuen, T
   Yang, RH
   Lu, P
   Zhang, KT
   Li, JH
   Keutzer, J
   Stachnik, A
   Mennone, A
   Boyer, JL
   Jain, D
   Brady, RO
   New, MI
   Zaidi, M
AF Mistry, Pramod K.
   Liu, Jun
   Sun, Li
   Chuang, Wei Lien
   Yuen, Tony
   Yang, Ruhua
   Lu, Ping
   Zhang, Kate
   Li, Jianhua
   Keutzer, Joan
   Stachnik, Agnes
   Mennone, Albert
   Boyer, James L.
   Jain, Dhanpat
   Brady, Roscoe O.
   New, Maria I.
   Zaidi, Mone
TI Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE macrophage; knockout mice; S1P
ID ACID BETA GLUCOSIDASE; NONLYSOSOMAL GLUCOSYLCERAMIDASE; DEFICIENT MICE;
   PHENOTYPE; GLUCOSYLSPHINGOSINE; MUTATIONS; THERAPY; MARKERS; GBA1; CELL
AB The inherited deficiency of the lysosomal glucocerebrosidase (GBA) due to mutations in the GBA gene results in Gaucher disease (GD). A vast majority of patients present with nonneuronopathic, type 1 GD (GD1). GBA deficiency causes the accumulation of two key sphingolipids, glucosylceramide (GL 1) and glucosylsphingosine (LysoGL 1), classically noted within the lysosomes of mononuclear phagocytes. How metabolites of GL 1 or LysoGL 1 produced by extralysosomal glucocerebrosidase GBA2 contribute to the GD1 pathophysiology is not known. We recently recapitulated hepatosplenomegaly, cytopenia, hypercytokinemia, and the bone formation defect of human GD1 through conditional deletion of Gba in Mx1 Cre(+):GD1 mice. Here we show that the deletion of Gba2 significantly rescues the GD1 clinical phenotype, despite enhanced elevations in GL 1 and LysoGL 1. Most notably, the reduced bone volume and bone formation rate are normalized. These results suggest that metabolism of GL 1 or LysoGL 1 into downstream bioactive lipids is a major contributor to the bone formation defect. Direct testing revealed a strong inhibition of osteoblast viability by nanomolar concentrations of sphingosine, but not of ceramide. These findings are consistent with toxicity of high circulating sphingosine levels in GD1 patients, which decline upon enzyme replacement therapy; serum ceramide levels remain unchanged. Together, complementary results from mice and humans affected with GD1 not only pinpoint sphingosine as being an osteoblast toxin, but also set forth Gba2 as a viable therapeutic target for the development of inhibitors to ameliorate certain disabling consequences of GD1.
C1 [Mistry, Pramod K.; Liu, Jun; Yang, Ruhua; Mennone, Albert; Boyer, James L.; Jain, Dhanpat] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA.
   [Sun, Li; Yuen, Tony; Lu, Ping; Li, Jianhua; Stachnik, Agnes; New, Maria I.; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
   [Sun, Li; Yuen, Tony; Lu, Ping; Li, Jianhua; Stachnik, Agnes; Zaidi, Mone] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
   [Chuang, Wei Lien; Zhang, Kate; Keutzer, Joan] Genzyme Sanofi, Framingham, MA 01701 USA.
   [Brady, Roscoe O.] NINDS, NIH, Bethesda, MD 20824 USA.
C3 Yale University; Icahn School of Medicine at Mount Sinai; Icahn School
   of Medicine at Mount Sinai; Sanofi Aventis; Sanofi France; National
   Institutes of Health (NIH)   USA; NIH National Institute of Neurological
   Disorders & Stroke (NINDS)
RP Mistry, PK (通讯作者)，Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA.
EM pramod.mistry@yale.edu; maria.new@mssm.edu; mone.zaidi@mountsinai.org
OI Zaidi, Mone/0000 0001 5911 9522; Yuen, Tony/0009 0001 6000 8827
FU National Institutes of Arthritis, Musculoskeletal and Skin Diseases [AR
   65932]; National Institutes of Health [AG23176, DK80490, AG40132,
   DK66306]; Silvio O. Conte Digestive Diseases Research Core Center
   [DK34989]; Children's Hormone Foundation; Genzyme; Sanofi Company;
   Center of Excellence Grant in Clinical Translational Research
FX We thank David W. Russell (University of Texas Southwestern Medical
   Center) for providing Gba2<SUP> / </SUP> mice. This study was supported
   in large part by National Institutes of Arthritis, Musculoskeletal and
   Skin Diseases Grant AR 65932 (to M.Z. and P.K.M.). This work was also
   supported by National Institutes of Health Grants AG23176, DK80490, and
   AG40132 (to M.Z. and L.S.); National Institutes of Health Grant DK66306
   (to P.K.M.); Silvio O. Conte Digestive Diseases Research Core Center
   Grant DK34989 (to J.L.B. and A.M.); and the Children's Hormone
   Foundation (M.I.N.). P.K.M. is also supported by a Genzyme, a Sanofi
   Company, Center of Excellence Grant in Clinical Translational Research.
CR [Anonymous], COLD SPRING HARB PER
   Aureli M, 2012, J INHERIT METAB DIS, V35, P1081, DOI 10.1007/s10545 012 9478 x
   Boot RG, 2007, J BIOL CHEM, V282, P1305, DOI 10.1074/jbc.M610544200
   Brady RO, 2010, J BIOL CHEM, V285, P41216, DOI 10.1074/jbc.X110.197954
   Dekker N, 2011, BLOOD, V118, pE118, DOI 10.1182/blood 2011 05 352971
   Elleder M, 2006, J INHERIT METAB DIS, V29, P707, DOI 10.1007/s10545 006 0411 z
   Enquist IB, 2006, P NATL ACAD SCI USA, V103, P13819, DOI 10.1073/pnas.0606016103
   Gonzalez Carmona MA, 2012, LIVER INT, V32, P1354, DOI 10.1111/j.1478 3231.2012.02841.x
   Grabowski GA, 2012, HEMATOL AM SOC HEMAT, P13, DOI 10.1182/asheducation 2012.1.13
   Haider S, 2013, P NATL ACAD SCI USA, V110, P2605, DOI 10.1073/pnas.1221133110
   Hammer MB, 2013, AM J HUM GENET, V92, P245, DOI 10.1016/j.ajhg.2012.12.012
   Harzer K, 2012, BIOCHEM BIOPH RES CO, V423, P308, DOI 10.1016/j.bbrc.2012.05.117
   Lachmann RH, 2004, QJM INT J MED, V97, P199, DOI 10.1093/qjmed/hch036
   Liu J, 2012, P NATL ACAD SCI USA, V109, P10018, DOI 10.1073/pnas.1200941109
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Martin E, 2013, AM J HUM GENET, V92, P238, DOI 10.1016/j.ajhg.2012.11.021
   Mistry PK, 2010, P NATL ACAD SCI USA, V107, P19473, DOI 10.1073/pnas.1003308107
   Mizukami H, 2002, J CLIN INVEST, V109, P1215, DOI 10.1172/JCI200214530
   New MI, 2013, P NATL ACAD SCI USA, V110, P2611, DOI 10.1073/pnas.1300057110
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Overkleeft HS, 1998, J BIOL CHEM, V273, P26522, DOI 10.1074/jbc.273.41.26522
   SASAGASAKO N, 1994, J BIOCHEM, V115, P113, DOI 10.1093/oxfordjournals.jbchem.a124284
   Sidransky E, 2012, DISCOV MED, V14, P273
   Sims KB, 2008, CLIN GENET, V73, P430, DOI 10.1111/j.1399 0004.2008.00978.x
   Sun L, 2006, CELL, V125, P247, DOI 10.1016/j.cell.2006.01.051
   van Dussen L, 2011, J CLIN ENDOCR METAB, V96, P2194, DOI 10.1210/jc.2011 0162
   Xu YH, 2003, AM J PATHOL, V163, P2093, DOI 10.1016/S0002 9440(10)63566 3
   YAMAGUCHI Y, 1994, J BIOCHEM TOKYO, V116, P704, DOI 10.1093/oxfordjournals.jbchem.a124584
   Yildiz Y, 2006, J CLIN INVEST, V116, P2985, DOI 10.1172/JCI29224
   Yildiz Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 151
   Yuen T, 2012, BIOCHEM BIOPH RES CO, V422, P573, DOI 10.1016/j.bbrc.2012.05.027
   Zhu LL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047058
   Zu Heringdorf Dagmar Meyer, 2013, Handb Exp Pharmacol, P239, DOI 10.1007/978 3 7091 1368 4_13
NR 33
TC 88
Z9 97
U1 0
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 1
PY 2014
VL 111
IS 13
BP 4934
EP 4939
DI 10.1073/pnas.1400768111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AD9IX
UT WOS:000333579700061
PM 24639522
OA Green Published
DA 2025 08 17
ER

PT J
AU Dai, BY
   Li, QQ
   Song, XX
   Ge, YX
   Wu, J
   Zhang, KJ
   Wang, C
   Zhang, YF
   Teng, HJ
   Li, CJ
   Jiang, Q
AF Dai, Bingyang
   Li, Qiangqiang
   Song, Xiaoxiao
   Ge, Yuxiang
   Wu, Jing
   Zhang, Kaijia
   Wang, Chao
   Zhang, Yifeng
   Teng, Huajian
   Li, Chaojun
   Jiang, Qing
TI Knockdown of Ggps1 in chondrocyte expedites fracture healing by
   accelerating the progression of endochondral ossification in mice
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Geranylgeranyl diphosphate synthase 1; Endochondral ossification;
   Intramembranous ossification; Bone fracture
ID BONE FORMATION; CELL DIFFERENTIATION; MOUSE MODEL; FACTOR SOX9;
   EXPRESSION; STATINS; CARTILAGE; GENE; CHONDROGENESIS; RESORPTION
AB Bone fracture healing is achieved through the proliferation and differentiation of stem cells, while bone marrow stem cells (BMSCs) contribute to endochondral ossification. During fracture healing, mesenchymal progenitor cells first form a cartilaginous blastema that becomes vascularized to recruit precursor cells of osteoblasts through the bone morphogenetic protein 2 (Bmp2)/Smad dependent Runx2 pathway. Statins deplete geranylgeranyl diphosphate (GGPP), which participates in the regulation of BMSCs differentiation, through the inhibition of 3 hydroxy 3 methylglutaryl (HMG) CoA reductase, leading to impaired protein geranylgeranylation, which strongly impacts the bone synthesis induced by Bmp2. Accordingly, we would like to investigate the role of geranylgeranyl diphosphate synthase 1 (Ggps1) in bone fracture via endochondral ossification in mice. We used a Cre loxP system, namely the tamoxifen inducible Collagen 2 CreER(T2) Ggps1 (fl/fl), to eliminate specifically the Ggps1 activity in chondrocytes of 8 10 week old mice. We found that the endochondral bone formation, calcification and vasculogenesis of the bony callus were accelerated in fractures in Ggps1( / )mice. Together, the results of this study confirm that the specific deletion of Ggps1, using the Collagen 2 CreER(T2) mice, will accelerate the fracture healing process by activating the Bmp2/Smad dependent Runx2 pathway. In addition, we managed to improve the fracture healing process by inhibiting the Ggps1 activity and its related products with statin drugs.
C1 [Dai, Bingyang; Song, Xiaoxiao; Ge, Yuxiang; Zhang, Kaijia; Wang, Chao; Jiang, Qing] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Sports Med & Adult Reconstruct Surg, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
   [Dai, Bingyang; Song, Xiaoxiao; Ge, Yuxiang; Zhang, Kaijia; Wang, Chao; Teng, Huajian; Jiang, Qing] Nanjing Univ, Model Anim Res Ctr, Lab Bone & Joint Dis, Nanjing 210093, Jiangsu, Peoples R China.
   [Li, Qiangqiang; Jiang, Qing] Nanjing Med Univ, Drum Tower Hosp, Dept Sports Med & Adult Reconstruct Surg, Clin Coll, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
   [Li, Chaojun] Nanjing Univ, MOE Key Lab Model Animals Dis Study, MARC, Nanjing 210093, Jiangsu, Peoples R China.
   [Li, Chaojun] Nanjing Univ, Sch Med, Nanjing 210093, Jiangsu, Peoples R China.
   [Wu, Jing; Zhang, Yifeng] Nanjing Univ, Sch Med, Nanjing 210093, Jiangsu, Peoples R China.
C3 Nanjing University; Nanjing University; Nanjing University; Nanjing
   Medical University; Nanjing University; Nanjing University; Nanjing
   University
RP Jiang, Q (通讯作者)，Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Sports Med & Adult Reconstruct Surg, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.; Teng, HJ; Jiang, Q (通讯作者)，Nanjing Univ, Model Anim Res Ctr, Lab Bone & Joint Dis, Nanjing 210093, Jiangsu, Peoples R China.; Jiang, Q (通讯作者)，Nanjing Med Univ, Drum Tower Hosp, Dept Sports Med & Adult Reconstruct Surg, Clin Coll, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.; Li, CJ (通讯作者)，Nanjing Univ, MOE Key Lab Model Animals Dis Study, MARC, Nanjing 210093, Jiangsu, Peoples R China.; Li, CJ (通讯作者)，Nanjing Univ, Sch Med, Nanjing 210093, Jiangsu, Peoples R China.
EM tenghj@nicemice.cn; licj@nju.edu.cn; qingj@nju.edu.cn
RI ; Wu, Jing/NOE 3383 2025; Yi, Chenlong/HGU 3846 2022; Jiang,
   Qing/JXM 6827 2024
OI Li, Chaojun/0000 0001 9474 7321; Dai, Bingyang/0000 0002 6193 8516; 
FU National Natural Science Foundation of China [81271945, 81420108021]
FX This work was supported by the project of the National Natural Science
   Foundation of China (81271945) and the National Natural Science
   Foundation of China (81420108021).
CR Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792
   BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115
   Bradley EW, 2011, CRIT REV EUKAR GENE, V21, P101, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.10
   Chen M, 2007, GENESIS, V45, P44, DOI 10.1002/dvg.20261
   Chen PF, 2016, BIOMATERIALS, V81, P1, DOI 10.1016/j.biomaterials.2015.12.006
   DODGE GR, 1989, J CLIN INVEST, V83, P647, DOI 10.1172/JCI113929
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   FROMMER J, 1971, J DENT RES, V50, P1260, DOI 10.1177/00220345710500052801
   Fukui T, 2012, J BONE MINER RES, V27, P1118, DOI 10.1002/jbmr.1558
   Garrett IR, 2002, ARTHRITIS RES, V4, P237, DOI 10.1186/ar413
   Hecht J, 2007, GENE EXPR PATTERNS, V7, P102, DOI 10.1016/j.modgep.2006.05.014
   Ito T, 2002, ATHEROSCLEROSIS, V165, P51, DOI 10.1016/S0021 9150(02)00194 6
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P3, DOI 10.1211/jpp.58.1.0002
   Jia Z, 2015, J CONTROL RELEASE, V200, P23, DOI 10.1016/j.jconrel.2014.12.028
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   KONG RYC, 1993, EUR J BIOCHEM, V213, P99, DOI 10.1111/j.1432 1033.1993.tb17739.x
   Kumar D, 2009, MOL CELL BIOL, V29, P4262, DOI 10.1128/MCB.01779 08
   Li CY, 2011, BONE, V49, P1178, DOI 10.1016/j.bone.2011.08.012
   Li FF, 2011, J BONE MINER RES, V26, P2899, DOI 10.1002/jbmr.504
   Marsh D, 1998, CLIN ORTHOP RELAT R, pS22
   McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018 005 5298 6
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mungo DV, 2002, J ORTHOP RES, V20, P159, DOI 10.1016/S0736 0266(01)00065 1
   Nagaoka Y, 2015, J DENT RES, V94, P594, DOI 10.1177/0022034514564187
   Niu YB, 2015, MOL MED REP, V11, P4468, DOI 10.3892/mmr.2015.3249
   SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Sverdrup FM, 2010, OSTEOARTHR CARTILAGE, V18, P948, DOI 10.1016/j.joca.2010.03.015
   Tsubaki M, 2011, CYTOKINE, V54, P100, DOI 10.1016/j.cyto.2011.01.005
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Valcourt U, 2002, J BIOL CHEM, V277, P33545, DOI 10.1074/jbc.M202086200
   van der Kraan PM, 2009, OSTEOARTHR CARTILAGE, V17, P1539, DOI 10.1016/j.joca.2009.06.008
   Wang GY, 2007, DEV BIOL, V306, P612, DOI 10.1016/j.ydbio.2007.03.520
   Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113
   Woods A, 2005, J BIOL CHEM, V280, P11626, DOI 10.1074/jbc.M409158200
   Woods A, 2007, J BIOL CHEM, V282, P23500, DOI 10.1074/jbc.M700680200
   Wu DC, 2009, J AM SOC NEPHROL, V20, P554, DOI 10.1681/ASN.2008040445
   Yuasa M, 2015, J CLIN INVEST, V125, P3723, DOI 10.1172/JCI84059
   Yuasa M, 2015, J CLIN INVEST, V125, P3117, DOI 10.1172/JCI80313
   Zehentner BK, 1999, J BONE MINER RES, V14, P1734, DOI 10.1359/jbmr.1999.14.10.1734
   Zhang YJ, 2014, PHARMACOL RES, V88, P53, DOI 10.1016/j.phrs.2013.12.009
NR 43
TC 6
Z9 6
U1 0
U2 23
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAR
PY 2018
VL 36
IS 2
BP 133
EP 147
DI 10.1007/s00774 017 0824 9
PG 15
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA FX7OS
UT WOS:000426280600001
PM 28357594
DA 2025 08 17
ER

PT J
AU Chang, YH
   Liu, HW
   Chu, TY
   Wen, YT
   Tsai, RK
   Ding, DC
AF Chang, Yu Hsun
   Liu, Hwan Wun
   Chu, Tang Yuan
   Wen, Yao Tseng
   Tsai, Rong Kung
   Ding, Dah Ching
TI Cisplatin Impaired Adipogenic Differentiation of Adipose Mesenchymal
   Stem Cells
SO CELL TRANSPLANTATION
LA English
DT Article
DE Adipose stem cells; Chemotherapy; Cisplatin; Differentiation;
   Adipogenesis
ID ACUTE KIDNEY INJURY; P300; CHEMOTHERAPY; MECHANISMS; PATHWAYS; DELIVERY;
   THERAPY; BINDING; KINASE; CANCER
AB Adipose tissue derived mesenchymal stem cells (ADSCs) are derived from adipose tissue and can be induced in vitro to differentiate into osteoblasts, chondroblasts, myocytes, neurons, and other cell types. Cisplatin is a commonly used chemotherapy drug for cancer patients. However, the effects of cisplatin on ADSCs remain elusive. This study found that a high concentration of cisplatin affects the viability of ADSCs. First, the IC50 concentration of cisplatin was evaluated. Proliferation of ADSCs, as assessed by the XTT method, decreased immediately after treatment with various concentrations of cisplatin. ADSCs maintained mesenchymal stem cell surface markers after cisplatin treatment, as determined by flow cytometry. Upon differentiation by adding specific reagents, a significant decrease in adipogenic differentiation (by Oil red O staining) and osteogenic differentiation (by Alizarin red staining), and significant chondrogenic differentiation ( by Alcian blue staining) were found after cisplatin treatment. Quantitative RT PCR was also used in evaluating expression of specific genes to confirm differentiation. Finally, ADSCs from one donor who had received cisplatin showed significantly decreased adipogenic differentiation but increased osteogenic differentiation compared with ADSCs derived from one healthy donor. In conclusion, cisplatin affects the viability, proliferation, and differentiation of ADSCs both in vitro and in vivo via certain signaling pathways, such as p53 and Fas/FasL. The differentiation abilities of ADSCs should be evaluated before their transplantation for repairing cisplatin induced tissue damage.
C1 [Chang, Yu Hsun] Buddhist Tzu Chi Gen Hosp, Dept Pediat, Hualien, Taiwan.
   [Chang, Yu Hsun; Chu, Tang Yuan; Ding, Dah Ching] Buddhist Tzu Chi Gen Hosp, Dept Res, Lab Stem Cell Res, Hualien, Taiwan.
   [Liu, Hwan Wun] Buddhist Tzu Chi Gen Hosp, Dept Occupat Med, Hualien, Taiwan.
   [Chu, Tang Yuan; Ding, Dah Ching] Buddhist Tzu Chi Gen Hosp, Dept Obstet & Gynecol, 707 Chung Yang Rd,Sect 3, Hualien, Taiwan.
   [Wen, Yao Tseng; Tsai, Rong Kung] Buddhist Tzu Chi Gen Hosp, Eye Res Inst, Hualien, Taiwan.
   [Ding, Dah Ching] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan.
C3 Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Buddhist
   Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Buddhist Tzu Chi
   General Hospital; Hualien Tzu Chi Hospital; Buddhist Tzu Chi General
   Hospital; Hualien Tzu Chi Hospital; Buddhist Tzu Chi General Hospital;
   Hualien Tzu Chi Hospital; Tzu Chi University
RP Ding, DC (通讯作者)，Buddhist Tzu Chi Gen Hosp, Dept Obstet & Gynecol, 707 Chung Yang Rd,Sect 3, Hualien, Taiwan.
EM dah1003@yahoo.com.tw
RI Chu, Ta Ya/F 2755 2011; DING, DAH CHING/Y 3592 2019
OI Chu, Tang Yuan/0000 0003 2717 2681
FU Intramural Research Project of Buddhist Tzu Chi General Hospital [TCRD
   104 07]
FX This work was supported by grants from the Intramural Research Project
   of Buddhist Tzu Chi General Hospital (TCRD 104 07). Y. H.C.: conception
   of the study, experimental design and execution of experiments, and
   manuscript writing; H. W.L., T. Y.C., T. Y.W., and R. K.T.: critical
   discussion of the data and manuscript; D. C.D.: experimental design and
   manuscript writing. The authors declare no conflicts of interests.
CR Ackova DG, 2016, RECENT PAT ANTI CANC, V11, P98, DOI 10.2174/1574892811666151111142721
   Badri KR, 2008, MOL CELL BIOL, V28, P6358, DOI 10.1128/MCB.00333 08
   Barabas K, 2008, VET COMP ONCOL, V6, P1, DOI 10.1111/j.1476 5829.2007.00142.x
   Boulikas T, 2004, ONCOL REP, V11, P559
   Brozovic A, 2010, CRIT REV TOXICOL, V40, P347, DOI 10.3109/10408441003601836
   Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006
   Chai Y, 2013, ANAL QUANT CYTOL, V35, P171
   Chang YH, 2016, CELL TRANSPLANT, V25, P937, DOI 10.3727/096368915X690288
   Dai R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6737345
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   Desoize B, 2002, CRIT REV ONCOL HEMAT, V42, P1, DOI 10.1016/S1040 8428(02)00017 3
   Ding DC, 2013, J BIOMED SCI, V20, DOI 10.1186/1423 0127 20 59
   DONALDSON SS, 1979, CANCER, V43, P2036, DOI 10.1002/1097 0142(197905)43:5+<2036::AID CNCR2820430712>3.0.CO;2 7
   Ebadi M, 2014, NUTRIENTS, V6, P5280, DOI 10.3390/nu6115280
   Ehrhart N, 2002, AM J VET RES, V63, P703, DOI 10.2460/ajvr.2002.63.703
   Elhusseini FM, 2016, J STEM CELLS REGEN, V12, pP36
   Eliopoulos N, 2010, AM J PHYSIOL RENAL, V299, pF1288, DOI 10.1152/ajprenal.00671.2009
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Furumatsu T, 2005, J BIOL CHEM, V280, P35203, DOI 10.1074/jbc.M502409200
   Gan Y, 2016, CANCER BIOL THER, V17, P741, DOI 10.1080/15384047.2016.1178425
   Gu HJ, 2015, EXP CELL RES, V339, P112, DOI 10.1016/j.yexcr.2015.08.005
   Ho IL, 2015, SCI REP UK, V5, DOI 10.1038/srep16948
   Iioka T, 2003, J BONE MINER RES, V18, P1419, DOI 10.1359/jbmr.2003.18.8.1419
   Jun JH, 2010, J BIOL CHEM, V285, P36410, DOI 10.1074/jbc.M110.142307
   Kalinina NI, 2011, ACTA NATURAE, V3, P30, DOI 10.32607/20758251 2011 3 4 30 37
   Khan H, 2016, CURR STEM CELL RES T
   Kim JH, 2012, AM J PHYSIOL RENAL, V302, pF1141, DOI 10.1152/ajprenal.00060.2011
   Li CJ, 2015, J CELL PHYSIOL, V230, P2671, DOI 10.1002/jcp.24983
   Li KH, 2010, STEM CELLS DEV, V19, P1267, DOI 10.1089/scd.2009.0196
   Liang W, 2011, CYTOTECHNOLOGY, V63, P523, DOI 10.1007/s10616 011 9374 5
   Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981
   Lin TM, 2005, STEM CELLS DEV, V14, P92, DOI 10.1089/scd.2005.14.92
   Maredziak M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2152435
   Mirzaei H, 2016, CURR MED CHEM, V23, P455, DOI 10.2174/0929867323666151217122033
   Moghadasali R, 2014, CYTOTHERAPY, V16, P734, DOI 10.1016/j.jcyt.2014.01.004
   Morigi M, 2010, STEM CELLS, V28, P513, DOI 10.1002/stem.293
   Ni WM, 2015, J HISTOCHEM CYTOCHEM, V63, P842, DOI 10.1369/0022155415599039
   Nicolay NH, 2016, SCI REP UK, V6, DOI 10.1038/srep20035
   Omar HA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151649
   Ong WK, 2013, INT J BIOCHEM CELL B, V45, P1083, DOI 10.1016/j.biocel.2013.02.013
   Sahu BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134139
   Schwarz S, 2014, INT J ORAL SCI, V6, P154, DOI 10.1038/ijos.2014.23
   Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426
   Sheashaa H, 2016, EXP THER MED, V11, P1573, DOI 10.3892/etm.2016.3109
   Shen Q, 2009, J CLIN INVEST, V119, P3462, DOI 10.1172/JCI37412
   Shi CM, 2016, ONCOTARGET, V7, P40830, DOI 10.18632/oncotarget.8518
   Stine KC, 2014, J ORTHOP RES, V32, P464, DOI 10.1002/jor.22527
   Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200
   West CC, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0302 7
   Xu SF, 2014, CURR ONCOL, V21, pE658, DOI 10.3747/co.21.1956
   Yang HJ, 2014, CELLS TISSUES ORGANS, V199, P373, DOI 10.1159/000369969
   Yasuda K, 2012, CYTOTHERAPY, V14, P1089, DOI 10.3109/14653249.2012.693157
   Zhang LN, 2015, STEM CELLS DEV, V24, P2841, DOI 10.1089/scd.2015.0027
   Zhang LR, 2015, INT J MOL MED, V36, P957, DOI 10.3892/ijmm.2015.2324
NR 54
TC 11
Z9 12
U1 1
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0963 6897
EI 1555 3892
J9 CELL TRANSPLANT
JI Cell Transplant.
PY 2017
VL 26
IS 6
BP 1077
EP 1087
DI 10.3727/096368917X694886
PG 11
WC Cell & Tissue Engineering; Medicine, Research & Experimental;
   Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Transplantation
GA EX3NL
UT WOS:000403139000011
PM 28155807
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, QY
   Yang, YZ
   Yuan, XM
   Luo, F
   Ling, Y
   Chen, CM
   Huang, Y
   Huang, RY
   Ma, WK
   Yao, XM
AF Wang, Qiuyi
   Yang, Yuzheng
   Yuan, Xuemei
   Luo, Feng
   Ling, Yi
   Chen, Changming
   Huang, Ying
   Huang, Runyue
   Ma, Wukai
   Yao, Xueming
TI Jinwu Jiangu Capsule alleviates rheumatoid arthritis symptoms by
   regulating the ADCY10 and cAMP/RANKL pathways
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Jinwu Jiangu Capsule; Rheumatoid arthritis; Synovial fibroblasts;
   Collagen induced arthritis; RNA sequencing
ID DISEASE; RANKL
AB Ethnopharmacological relevance: Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects joints and damages other tissues, including the heart, kidneys, lungs, digestive system, eyes, skin and nervous system. Jinwu Jiangu Capsule (JWJG) is effective in tonifying kidneys, activating blood circulation, and dispelling wind and dampness. Meanwhile, it produces favorable clinical results in relieving joint pain and reducing inflammation. However, precise therapeutic effect and mechanisms of JWJG on RA remain unclear. Aim of the study: The traditional Chinese medicine JWJG exhibits certain properties in anti inflammation and pain relief for RA treatment. This study aimed to investigate the efficacy of JWJG and elucidate its underlying mechanisms in RA treatment. Materials and methods: A collagen induced arthritis (CIA) rat model was administered JWJG orally at varying doses for 28 days, alongside control and positive control groups treated with saline and leflunomide, respectively. Indicators including joint swelling, bone loss, histopathological changes, Th17/Treg lymphocyte differentiation, and inflammatory factor expression were assessed. RNA sequencing of synovial tissues identified JWJG influenced genes and pathways. RASFs treated with ADCY10 lentivirus, PKA agonist, or AR plasmid underwent additional JWJG containing serum or beta  sitosterol treatment to monitor ADCY10, RANKL, and cAMP pathway alterations. Results: JWJG administration significantly reduced joint swelling, bone loss, and inflammation, balanced Th17/ Treg, and suppressed TNF alpha, IL 1 beta, IL 6, and RANKL levels. In RASFs, JWJG downregulated ADCY10, cAMP, and phospho PKA/CREB, thereby inhibiting osteoclast differentiation. Meanwhile, beta  sitosterol decreased AR levels, which suppressed ADCY10 and RANKL expression. JWJG treatment could directly/indirectly inhibit ADCY10 reduced cAMP/RANKL, inflammation, and osteoclastogenesis, enhancing RA symptomatology comparable to leflunomide. It demonstrated superior regulation of Th17/Treg ratios and cytokine suppression, with potential to substantially improve RA patients' quality of life. Conclusions: JWJG inhibited ADCY10, decreased cAMP/RANKL, and impeded inflammation and osteoclastogenesis, with a notable improvement in RA symptoms comparable to leflunomide. It can be introduced as a potential new therapeutic strategy for preventing or even reversing bone damage and improving the quality of life for RA patients.
C1 [Wang, Qiuyi; Yang, Yuzheng; Yuan, Xuemei; Luo, Feng; Ling, Yi; Chen, Changming; Huang, Ying; Ma, Wukai; Yao, Xueming] Guizhou Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Rheumatol Immunol, 83 Feishan st, Guiyang 550001, Guizhou, Peoples R China.
   [Huang, Runyue] Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome Chinese Med, 11 Dade Rd, Guiyang 550001, Guizhou, Peoples R China.
   [Yao, Xueming] Dept Liupanshui Hosp Tradit Chinese Med, Liupanshui 553000, Guizhou Provinc, Peoples R China.
C3 Guizhou University of Traditional Chinese Medicine; Guangzhou University
   of Chinese Medicine
RP Ma, WK; Yao, XM (通讯作者)，Guizhou Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Rheumatol Immunol, 83 Feishan st, Guiyang 550001, Guizhou, Peoples R China.; Huang, RY (通讯作者)，Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome Chinese Med, 11 Dade Rd, Guiyang 550001, Guizhou, Peoples R China.
EM ryhuang@gzucm.edu.cn; fsmymwk@163.com; yxming19@foxmail.com
RI ; Yao, Xue ming/HDM 5818 2022; Chen, CM/G 3339 2010
OI chen, changming/0000 0001 9635 0272; 
FU University of Traditional Chinese Medicine National and Provincial
   Science and Technology Innovation Talent Team Cultivation Project
   (Guizhou University of Traditional Chinese Medicine TD) [[2022] 004];
   Traditional Chinese Medicine and ethnic medicine Science and technology
   research project of Guizhou Administration of Traditional Chinese
   Medicine [QZYY 2024 009]; Guizhou University of Traditional Chinese
   Medicine [2023 36]; "Three Navigation" Talent Training Project of the
   Second Affiliated Hospital of Guizhou University of Traditional Chinese
   Medicine [SHRC KY2024022]
FX This work was supported by the National Natural Science Foundation of
   China: 82160869; Guizhou Provincial Basic Research Program (Natural
   Science) Qiankehe Basics ZK [2023] General 412; Guizhou University of
   Traditional Chinese Medicine National and Provincial Science and
   Technology Innovation Talent Team Cultivation Project (Guizhou
   University of Traditional Chinese Medicine TD NO. [2022]004; Traditional
   Chinese Medicine and ethnic medicine Science and technology research
   project of Guizhou Administration of Traditional Chinese Medicine,
   QZYY 2024 009; Guizhou University of Traditional Chinese Medicine,
   Guikehe Academic New Miao [2023 36] ; The "Three Navigation" Talent
   Training Project of the Second Affiliated Hospital of Guizhou University
   of Traditional Chinese Medicine [SHRC KY2024022] .
CR Altermann E, 2005, BMC GENOMICS, V6, DOI 10.1186/1471 2164 6 60
   Amin MA, 2017, SEMIN IMMUNOPATHOL, V39, P385, DOI 10.1007/s00281 017 0631 3
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166 4328(01)00297 2
   Chemin K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00353
   Chuang SC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186490
   Cisneros IE, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.593146
   Delion M, 2016, J PATHOL, V240, P50, DOI 10.1002/path.4753
   Ding N, 2020, BMB REP, V53, P154, DOI 10.5483/BMBRep.2020.53.3.147
   England BR, 2018, BMJ BRIT MED J, V361, DOI 10.1136/bmj.k1036
   Hanlon MM, 2022, CLIN EXP IMMUNOL, V208, P167, DOI 10.1093/cei/uxab021
   He M, 2022, CELLS BASEL, V11, DOI 10.3390/cells11193012
   Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065
   Kim JM, 2013, J CELL PHYSIOL, V228, P617, DOI 10.1002/jcp.24171
   Kondo N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010922
   Li T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.818677
   Liu Y, 2016, J MOL HISTOL, V47, P475, DOI 10.1007/s10735 016 9689 9
   Ma Wu kai, 2016, Zhongguo Zhong Xi Yi Jie He Za Zhi, V36, P624
   Mawukai Zhong Qin, 2010, Effect of the Jinwu Jiangu Decoction for Rheumatoid Arthritis with Methotrexate Resistance
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Neumann E, 2010, TRENDS MOL MED, V16, P458, DOI 10.1016/j.molmed.2010.07.004
   Orr C, 2017, NAT REV RHEUMATOL, V13, P463, DOI 10.1038/nrrheum.2017.115
   Pandolfi F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155238
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 3 r25
   Ruilian Z, 2022, COMPUT MATH METHOD M, V2022, DOI 10.1155/2022/2011625
   Scherer HU, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102400
   Schinocca C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.637829
   Selimov Pavel, 2023, Folia Med (Plovdiv), V65, P53, DOI 10.3897/folmed.65.e72448
   Shlobin NA, 2021, NEUROSURG REV, V44, P1957, DOI 10.1007/s10143 020 01412 1
   Urso K, 2019, BONE, V127, P104, DOI 10.1016/j.bone.2019.06.002
   Wang LF, 2021, CELL SIGNAL, V78, DOI 10.1016/j.cellsig.2020.109847
   Wang QY, 2021, ACTA BIOCHIM POL, V68, P641, DOI 10.18388/abp.2020_5514
   Wang Y, 2017, BIOCHEM PHARMACOL, V138, P119, DOI 10.1016/j.bcp.2017.05.006
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Yang Y, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1541 4
   Zhao F, 2020, J BIOL REG HOMEOS AG, V34, P221, DOI 10.23812/19 367 L
   Zuo TT, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.908986
NR 38
TC 2
Z9 2
U1 5
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD FEB 10
PY 2025
VL 338
AR 119099
DI 10.1016/j.jep.2024.119099
EA NOV 2024
PN 3
PG 18
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA M9G8B
UT WOS:001360550100001
PM 39542189
DA 2025 08 17
ER

PT J
AU Lu, S
   Fang, C
AF Lu, Shuai
   Fang, Chao
TI Isosakuranetin inhibits subchondral osteoclastogenesis for attenuating
   osteoarthritis via suppressing NF κB/CXCL2 axis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Osteoarthritis; Isosakuranetin; Osteoclastogenesis; Subchondral bone;
   Articular cartilage
ID ARTICULAR CARTILAGE; NERVE GROWTH; BONE MARROW; RAT MODEL; PAIN;
   ANGIOGENESIS; PATHOGENESIS; RESORPTION; COMPONENTS; CHANNELS
AB As the most predominant form of arthritis, osteoarthritis (OA) is featured with irreversible progress and involvement of the whole joint. Since OA onset, abnormal mechanical load initiates excessive osteoclastogenesis, evolving a rapid turnover of subchondral bone, cyst creation, synovitis, cartilage degradation, and ultimately resulting in joint failure. Additionally, aberrant vascularization and nociceptive pain are invoked by osteoclastinduced angiogenesis and sensory innervation in the subchondral bone. Rhizoma anemarrhenae (Zhimu) has been extensively demonstrated to show multiple pharmacological effects including anti inflammation, antiaging, and immunomodulation. Herein, Broussonin a (BRA), Markogein (MAN), and Isosakuranetin (ISN) derived from Rhizoma anemarrhenae, were initially discovered for their affinity with Bone marrow mononuclear cell (BMMC) membranes using the Cell membrane chromatography/Time of flight mass spectrometry (CMC/ TOFMS) method, while only ISN exerted a significant inhibitory effect on RANKL induced osteoclastogenesis in BMMC in vitro. Intriguingly, we disclosed that ISN blunted the overactivation of Tartrate resistant acid phosphatase positive (TRAP+) osteoclasts in subchondral bone in OA mice, as indicated by enhanced bone volume/ total volume (BV/TV), trabecular number (Tb.N), and trabeculae thickness (Tb.Th), as well as diminished trabecular pattern factor (Tb.pf). Treatment with ISN also impaired aberrant angiogenesis and nociceptive reaction in the subchondral bone marrow. Moreover, ISN hindered the loss of articular cartilage proteoglycan and lowered the Osteoarthritis Research Society International (OARSI) grade, boosting the expression amount of Aggrecan (ACAN) and Collagen II (COL II) positive cells while reducing Matrix metalloproteinase 13 (MMP 13) positive cells. For mechanisms, We verified that ISN hampered subchondral osteoclastogenesis by blocking nuclear factor kappa light chain enhancer of activated B cells (NF kappa B) signaling and C X C Motif Chemokine Ligand 2 (CXCL2) stimulation. Taken together, we reveal that ISN impedes the progression of OA by preventing hyperactivated subchondral osteoclastogenesis via suppressing the NF kappa B/CXCL2 axis.
C1 [Fang, Chao] Univ Sci & Technol China, Affiliated Hosp 1, USTC, Div Life Sci & Med,Dept Orthoped, Hefei 230001, Peoples R China.
   [Lu, Shuai] Shanghai Fengxian Dist Cent Hosp, Dept Orthoped, Shanghai 201499, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS
RP Fang, C (通讯作者)，Univ Sci & Technol China, Affiliated Hosp 1, USTC, Div Life Sci & Med,Dept Orthoped, Hefei 230001, Peoples R China.
EM fcch2820@163.com
FU Doctoral Research Initiation Foundation of the First Affiliated Hospital
   of USTC [RC2021133]
FX <BOLD>This research was supported by the Doctoral Research Initiation
   Foundation of the First Affiliated Hospital of USTC (RC2021133) . We
   thank the Experimental Center of The First Affiliated Hospital of USTC
   for providing experimental reagents and instruments. </BOLD> Chao Fang
   was the overall principal supervisor who designed the study. Chao Fang
   revised the manuscript and received financial support. Shuai Lu carried
   out the experiments and wrote the manuscript. Chao Fang and Shuai Lu
   collected the data and generated the figures and ta bles. All authors
   critically reviewed the article and approved the final manuscript.
CR Abdelkafy A, 2012, ARTHROSC TEC, V1, pE149, DOI 10.1016/j.eats.2012.05.008
   Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Aso K, 2020, OSTEOARTHR CARTILAGE, V28, P1245, DOI 10.1016/j.joca.2020.05.010
   Bae SH, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122684
   Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011
   Barton KI, 2017, J ORTHOP RES, V35, P454, DOI 10.1002/jor.23322
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Cabahug Zuckerman P, 2016, J BONE MINER RES, V31, P1356, DOI 10.1002/jbmr.2807
   Chen XF, 2014, ANAL CHEM, V86, P4748, DOI 10.1021/ac500287e
   Chen XF, 2012, J CHROMATOGR A, V1242, P67, DOI 10.1016/j.chroma.2012.04.034
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Deveza LA, 2018, RHEUMATOLOGY, V57, P34, DOI 10.1093/rheumatology/kex417
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Fang C, 2022, ACTA PHARMACOL SIN, V43, P1299, DOI 10.1038/s41401 021 00747 9
   Funck Brentano T, 2011, CYTOKINE GROWTH F R, V22, P91, DOI 10.1016/j.cytogfr.2011.04.003
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Gu YQ, 2020, ACTA PHARM SIN B, V10, P1856, DOI 10.1016/j.apsb.2020.01.019
   Guo LY, 2020, CLIN EXP HYPERTENS, V42, P428, DOI 10.1080/10641963.2019.1693585
   Han SL, 2018, PHYTOCHEM ANALYSIS, V29, P341, DOI 10.1002/pca.2756
   Hu HX, 2023, ADV SCI, V10, DOI 10.1002/advs.202304722
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Hu Y, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00147 z
   Hunt MA, 2020, OSTEOARTHR CARTILAGE, V28, P267, DOI 10.1016/j.joca.2019.12.003
   Hunter DJ, 2020, LANCET, V396, P1711, DOI 10.1016/S0140 6736(20)32230 3
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Jia SS, 2017, PHARMACOLOGY, V100, P201, DOI 10.1159/000478986
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Jung H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091449
   Kang GD, 2017, INT IMMUNOPHARMACOL, V43, P179, DOI 10.1016/j.intimp.2016.12.021
   Katz JN, 2021, JAMA J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Kwoh CK, 2013, NAT REV RHEUMATOL, V9, P7, DOI 10.1038/nrrheum.2012.217
   Lan Ying C., 2013, Journal of Jiangxi University of Traditional, Chin. Med.
   Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584 020 00518 6
   Li JD, 2023, THERANOSTICS, V13, P931, DOI 10.7150/thno.78639
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Liu Y, 2023, RHEUMATOLOGY, V62, P1436, DOI 10.1093/rheumatology/keac539
   Loeser RF, 2016, NAT REV RHEUMATOL, V12, P412, DOI 10.1038/nrrheum.2016.65
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Marcu KB, 2010, CURR DRUG TARGETS, V11, P599, DOI 10.2174/138945010791011938
   Moon SM, 2018, BIOMED PHARMACOTHER, V97, P264, DOI 10.1016/j.biopha.2017.10.130
   Neogi T, 2010, ANN RHEUM DIS, V69, P841, DOI 10.1136/ard.2009.110114
   Oláh T, 2022, ADV SCI, V9, DOI 10.1002/advs.202201692
   Romeo SG, 2019, NAT CELL BIOL, V21, P430, DOI 10.1038/s41556 019 0304 7
   Shen XB, 2022, BIOORG CHEM, V119, DOI 10.1016/j.bioorg.2021.105546
   Shen Z, 2024, APOPTOSIS, V29, P1810, DOI 10.1007/s10495 024 01973 2
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Sowers MF, 2003, OSTEOARTHR CARTILAGE, V11, P387, DOI 10.1016/S1063 4584(03)00080 3
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Su SX, 2021, J NEUROSCI, V41, P2457, DOI 10.1523/JNEUROSCI.1551 20.2020
   Su WP, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135446
   Suri S, 2012, BONE, V51, P204, DOI 10.1016/j.bone.2011.10.010
   Taheri S, 2023, OSTEOARTHR CARTILAGE, V31, P49, DOI 10.1016/j.joca.2022.10.002
   Takegahara N, 2024, EXP MOL MED, V56, P264, DOI 10.1038/s12276 024 01157 7
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Walsh DA, 2010, RHEUMATOLOGY, V49, P1852, DOI 10.1093/rheumatology/keq188
   Wang H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.940555
   Wang KD, 2022, ANN RHEUM DIS, V81, P544, DOI 10.1136/annrheumdis 2021 221380
   Wang YJ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.723988
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu PC, 2022, J ETHNOPHARMACOL, V293, DOI 10.1016/j.jep.2022.115269
   Yao H, 2023, PHYTOMEDICINE, V118, DOI 10.1016/j.phymed.2023.154967
   Yao Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392 023 01330 w
   Ye YJ, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1117489
   Yu Y., 2024, Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, V177
   Zhang H, 2023, SCI ADV, V9, DOI 10.1126/sciadv.abo7868
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhou F, 2022, J ORTHOP TRANSL, V32, P69, DOI 10.1016/j.jot.2021.11.002
   Zhu JX, 2020, ELIFE, V9, DOI 10.7554/eLife.57656
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
NR 75
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC 25
PY 2024
VL 143
AR 113321
DI 10.1016/j.intimp.2024.113321
EA OCT 2024
PN 1
PG 13
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA J0M3X
UT WOS:001334096800001
PM 39388890
OA hybrid
DA 2025 08 17
ER

PT J
AU Yu, M
   Lei, B
   Gao, CB
   Yan, J
   Ma, PX
AF Yu, Meng
   Lei, Bo
   Gao, Chuanbo
   Yan, Jin
   Ma, Peter X.
TI Optimizing surface engineered ultra small gold nanoparticles for highly
   efficient miRNA delivery to enhance osteogenic differentiation of bone
   mesenchymal stromal cells
SO NANO RESEARCH
LA English
DT Article
DE ultra small gold nanoparticles; surface engineering; microRNA (miRNA)
   delivery; bone mesenchymal stromal cells; osteogenic differentiation
ID SIRNA DELIVERY; DRUG DELIVERY; GENE DELIVERY; MICRORNA DELIVERY; RENAL
   CLEARANCE; QUANTUM DOTS; THERAPY; REGENERATION; TOXICITY;
   POLYETHYLENIMINE
AB Regulation of osteogenic differentiation of bone mesenchymal stromal cells (BMSCs) plays a critical role in bone regeneration. As small non coding RNAs, microRNAs (miRNAs) play an important role in stem cell differentiation through regulating target mRNA expression. Unfortunately, highly efficient and safe delivery of miRNAs to BMSCs to regulate their osteogenic differentiation remains challenging. Conventional inorganic nanocrystals have shown increased toxicity owing to their larger size precluding renal clearance. Here, we developed novel, surface engineered, ultra small gold nanoparticles (USAuNPs, < 10 nm) for use as highly efficient miR 5106 delivery systems to enable regulation of BMSC differentiation. We exploited the effects of AuNPs coated layer by layer with polyethylenimine (PEI) and liposomes (Lipo) to enhance miR 5106 delivery activity and subsequent BMSC differentiation capacity. The PEI  and Lipo coated AuNPs (Au@PEI@Lipo) showed negligible cytotoxicity, good miRNA 5106 binding affinity, highly efficient delivery of miRNAs to BMSCs, and long term miRNA expression (21 days). Additionally, compared with commercial Lipofectamine 3000 and 25 kD PEI, the optimized Au@PEI@Lipo miR 5106 nanocomplexes significantly enhanced BMSC differentiation into osteoblast like cells through activation of the Sox9 transcription factor. Our findings reveal a promising strategy for the rational design of ultra small inorganic nanoparticles as highly efficient miRNA delivery platforms for tissue regeneration and disease therapy.
C1 [Yu, Meng; Lei, Bo; Gao, Chuanbo; Yan, Jin] Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710054, Peoples R China.
   [Lei, Bo] Xi An Jiao Tong Univ, State Key Lab Mfg Syst Engn, Xian 710054, Peoples R China.
   [Lei, Bo] Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710054, Peoples R China.
   [Ma, Peter X.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Macromol Sci & Engn Ctr, Ann Arbor, MI 48109 USA.
   [Ma, Peter X.] Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Lei, B (通讯作者)，Xi An Jiao Tong Univ, Frontier Inst Sci & Technol, Xian 710054, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, State Key Lab Mfg Syst Engn, Xian 710054, Peoples R China.; Lei, B (通讯作者)，Xi An Jiao Tong Univ, State Key Lab Mech Behav Mat, Xian 710054, Peoples R China.; Ma, PX (通讯作者)，Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.; Ma, PX (通讯作者)，Univ Michigan, Macromol Sci & Engn Ctr, Ann Arbor, MI 48109 USA.; Ma, PX (通讯作者)，Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.
EM rayboo@xjtu.edu.cn; mapx@umich.edu
RI Gao, Chuanbo/D 6121 2011; X, Peter/E 4895 2011; Lei, Bo/B 9463 2009
OI Gao, Chuanbo/0000 0003 3429 3473; 
FU State Key Laboratory for Mechanical Behavior of Materials; Scientific
   Research Starting Foundation from Xi'an Jiaotong University
   [DW011798N3000010]; Fundamental Research Funds for the Central
   Universities [XJJ2014090]; Natural Science Basic Research Plan in
   Shaanxi Province of China [2015JQ5165]; National Natural Science
   Foundation of China [51502237]
FX We acknowledge the valuable comments of potential reviewers. This work
   was supported by State Key Laboratory for Mechanical Behavior of
   Materials, the Scientific Research Starting Foundation from Xi'an
   Jiaotong University (No. DW011798N3000010), the Fundamental Research
   Funds for the Central Universities (No. XJJ2014090), the Natural Science
   Basic Research Plan in Shaanxi Province of China (No. 2015JQ5165), and
   National Natural Science Foundation of China (No. 51502237).
CR Almeida JPM, 2014, NANOMED NANOTECHNOL, V10, P503, DOI 10.1016/j.nano.2013.09.011
   Arote R, 2007, BIOMATERIALS, V28, P735, DOI 10.1016/j.biomaterials.2006.09.028
   Austin LA, 2014, ARCH TOXICOL, V88, P1391, DOI 10.1007/s00204 014 1245 3
   Bishop CJ, 2015, ACTA BIOMATER, V11, P393, DOI 10.1016/j.actbio.2014.09.020
   Boanini E, 2014, BIOMATERIALS, V35, P5619, DOI 10.1016/j.biomaterials.2014.03.053
   Bozzuto G, 2015, INT J NANOMED, V10, P975, DOI 10.2147/IJN.S68861
   Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340
   Conde J, 2015, ADV DRUG DELIVER REV, V81, P169, DOI 10.1016/j.addr.2014.09.003
   Ding Y, 2014, MOL THER, V22, P1075, DOI 10.1038/mt.2014.30
   Dong HF, 2015, ACS APPL MATER INTER, V7, P11015, DOI 10.1021/acsami.5b02803
   Dreaden EC, 2014, ACS NANO, V8, P8374, DOI 10.1021/nn502861t
   Ehlerding EB, 2016, ADV SCI, V3, DOI 10.1002/advs.201500223
   Elbakry A, 2009, NANO LETT, V9, P2059, DOI 10.1021/nl9003865
   Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613
   Gao CB, 2012, NANOSCALE, V4, P2875, DOI 10.1039/c2nr30300k
   Ghosh R, 2013, BIOMATERIALS, V34, P807, DOI 10.1016/j.biomaterials.2012.10.023
   Huang XQ, 2011, BLOOD, V117, P2157, DOI 10.1182/blood 2010 08 302711
   Kai ZS, 2010, NAT STRUCT MOL BIOL, V17, P5, DOI 10.1038/nsmb.1762
   Karmali PP, 2011, EXPERT OPIN DRUG DEL, V8, P343, DOI 10.1517/17425247.2011.554818
   Lee Y, 2011, J CONTROL RELEASE, V155, P3, DOI 10.1016/j.jconrel.2010.09.009
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Link S, 1999, J PHYS CHEM B, V103, P4212, DOI 10.1021/jp984796o
   Longmire M, 2008, NANOMEDICINE UK, V3, P703, DOI 10.2217/17435889.3.5.703
   Oliveira JM, 2006, BIOMATERIALS, V27, P6123, DOI 10.1016/j.biomaterials.2006.07.034
   Pattni BS, 2015, CHEM REV, V115, P10938, DOI 10.1021/acs.chemrev.5b00046
   Peng B, 2015, ADV DRUG DELIVER REV, V88, P108, DOI 10.1016/j.addr.2015.05.014
   Rana S, 2012, ADV DRUG DELIVER REV, V64, P200, DOI 10.1016/j.addr.2011.08.006
   Shen JL, 2014, ADV HEALTHC MATER, V3, P1629, DOI 10.1002/adhm.201400103
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Sun Q, 2015, J AM CHEM SOC, V137, P6000, DOI 10.1021/jacs.5b01435
   Tian HY, 2012, ADV HEALTHC MATER, V1, P337, DOI 10.1002/adhm.201200033
   Valencia Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Wang B, 2013, ACCOUNTS CHEM RES, V46, P761, DOI 10.1021/ar2003336
   Wang HY, 2015, ADV DRUG DELIVER REV, V81, P142, DOI 10.1016/j.addr.2014.10.031
   Wang WW, 2013, CURR PHARM BIOTECHNO, V14, P46
   Wang XL, 2015, CURR PHARM DESIGN, V21, P1575, DOI 10.2174/1381612821666150115152841
   Wang Y. D., 2013, U.S. Patent, Patent No. [8,529,928, 8529928]
   Xiong MP, 2007, BIOMATERIALS, V28, P4889, DOI 10.1016/j.biomaterials.2007.07.043
   Yang JP, 2015, CHEM REV, V115, P5274, DOI 10.1021/cr500542t
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yu MX, 2015, ACS NANO, V9, P6655, DOI 10.1021/acsnano.5b01320
   Zhang XD, 2012, BIOMATERIALS, V33, P4628, DOI 10.1016/j.biomaterials.2012.03.020
   Zhang XD, 2011, INT J NANOMED, V6, P2071, DOI 10.2147/IJN.S21657
   Zhang XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10376
   Zhu Y, 2013, BIOMACROMOLECULES, V14, P342, DOI 10.1021/bm301523p
NR 46
TC 69
Z9 69
U1 3
U2 159
PU TSINGHUA UNIV PRESS
PI BEIJING
PA TSINGHUA UNIV, RM A703, XUEYAN BLDG, BEIJING, 100084, PEOPLES R CHINA
SN 1998 0124
EI 1998 0000
J9 NANO RES
JI Nano Res.
PD JAN
PY 2017
VL 10
IS 1
BP 49
EP 63
DI 10.1007/s12274 016 1265 9
PG 15
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA EF1DT
UT WOS:000390066000005
DA 2025 08 17
ER

PT J
AU Park, KL
   Oh, DG
   Kim, YO
   Song, KS
   Ahn, DW
AF Park, Kyeong Lok
   Oh, Da Gyo
   Kim, Young Ok
   Song, Kyeong Seob
   Ahn, Do Whan
TI Rosiglitazone suppresses RANKL induced NFATc1 autoamplification by
   disrupting the physical interaction between NFATc1 and PPAR
SO FEBS OPEN BIO
LA English
DT Article
DE NFATc1; osteoclastogenesis; physical interaction; PPAR; rosiglitazone
ID ACTIVATED RECEPTOR GAMMA; MEDIATED OSTEOCLAST DIFFERENTIATION; RESISTANT
   ACID PHOSPHATASE; FACTOR KAPPA B; T CELLS; TRANSCRIPTION FACTOR;
   NUCLEAR FACTOR; SIGNALING PATHWAY; REGULATES OSTEOCLASTOGENESIS;
   TERMINAL DIFFERENTIATION
AB Receptor activator of nuclear factor B ligand (RANKL) is required for initiation of osteoclastogenesis, with the signaling pathway including the NF kB, c Fos, and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) transcription factors. Because NFATc1 expression is autoamplified, we investigated the molecular mechanism by which peroxisome proliferator activated receptor gamma (PPAR) activation by the thiazolidinedione drug rosiglitazone decreases NFATc1 expression during RANKL stimulation. Western blotting demonstrated that rosiglitazone attenuated the increase in NFATc1 protein level induced by RANKL without affecting that of PPAR. Immunofluorescence data indicated that rosiglitazone tended to suppress RANKL induced NFATc1 nuclear translocation, partly by reducing calcineurin activity, as reflected by the observed decrease in nuclear NFATc1 abundance. On coimmunoprecipitation, the intensity of the physical interaction between NFATc1 and PPAR was unexpectedly higher in the RANKL stimulated group than in the control, but rosiglitazone reduced this to basal levels. Furthermore, RANKL failed to elevate mRNA expression of NFATc1 after PPAR knockdown. ChIP assay indicated that rosiglitazone significantly reduced the binding of NFATc1 to its own promoter despite RANKL stimulation. These findings suggest that PPAR activation by rosiglitazone blocks NFATc1 from binding to its own promoter, thereby reducing RANKL induced NFATc1 autoamplification.
C1 [Park, Kyeong Lok] Kosin Univ, Gospel Hosp, Dept Dent, Busan, South Korea.
   [Oh, Da Gyo; Song, Kyeong Seob; Ahn, Do Whan] Kosin Univ, Gospel Hosp, Dept Physiol, 34 Amnam Dong, Busan 49267, South Korea.
   [Kim, Young Ok] Kosin Univ, Gospel Hosp, Dept Pathol, Busan, South Korea.
RP Ahn, DW (通讯作者)，Kosin Univ, Gospel Hosp, Dept Physiol, 34 Amnam Dong, Busan 49267, South Korea.
EM dwahn@kosin.ac.kr
FU Kosin University College of Medicine
FX This work was supported by a grant from the MRC 2012 program of Kosin
   University College of Medicine.
CR Ali AA, 2005, ENDOCRINOLOGY, V146, P1226, DOI 10.1210/en.2004 0735
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Balkan W, 2009, GENE, V446, P90, DOI 10.1016/j.gene.2009.06.013
   Bao YX, 2008, MOL CELL BIOCHEM, V317, P189, DOI 10.1007/s11010 008 9848 8
   Cho ES, 2012, MOL CELLS, V33, P173, DOI 10.1007/s10059 012 2240 z
   Chung SW, 2003, MOL PHARMACOL, V64, P1169, DOI 10.1124/mol.64.5.1169
   Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074 7613(02)00329 1
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Fretz JA, 2008, MOL ENDOCRINOL, V22, P737, DOI 10.1210/me.2007 0333
   Fukunaga T, 2015, J BONE MINER RES, V30, P508, DOI 10.1002/jbmr.2364
   Hasegawa H, 2010, J BIOL CHEM, V285, P25448, DOI 10.1074/jbc.M109.068742
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hounoki H, 2008, BONE, V42, P765, DOI 10.1016/j.bone.2007.11.016
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451
   Mandal CC, 2016, J BIOL CHEM, V291, P1148, DOI 10.1074/jbc.M115.668939
   Mbalaviele G, 2000, J BIOL CHEM, V275, P14388, DOI 10.1074/jbc.275.19.14388
   Okamoto H, 2005, CLIN EXP RHEUMATOL, V23, P323
   Okazaki R, 1999, ENDOCRINOLOGY, V140, P5060, DOI 10.1210/en.140.11.5060
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Ricote M, 2007, BBA MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013
   Sander TL, 2006, ENDOTHELIUM J ENDOTH, V13, P181, DOI 10.1080/10623320600760308
   Song KS, 2013, ACTA PHYSIOL, V208, P245, DOI 10.1111/apha.12104
   Sorocéanu MA, 2004, J ENDOCRINOL, V183, P203, DOI 10.1677/joe.1.05723
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Takeuchi A, 1998, J IMMUNOL, V160, P209
   Wagner N, 2009, CARDIOVASC RES, V83, P61, DOI 10.1093/cvr/cvp106
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Wen XY, 2010, J BIOL CHEM, V285, P29981, DOI 10.1074/jbc.M110.110908
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yang CR, 2010, SHOCK, V33, P662, DOI 10.1097/SHK.0b013e3181cc0738
   Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541
NR 36
TC 3
Z9 4
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2211 5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD OCT
PY 2018
VL 8
IS 10
BP 1584
EP 1593
DI 10.1002/2211 5463.12513
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA GV5TK
UT WOS:000446166100002
PM 30338210
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kim, H
   Baek, JK
   Park, SB
   Kim, JD
   Son, HJ
   Park, GH
   Eo, HJ
   Park, JH
   Jung, HS
   Jeong, JB
AF Kim, Ha Na
   Baek, Jueng Kyu
   Park, Su Bin
   Kim, Jeong Dong
   Son, Ho Jun
   Park, Gwang Hun
   Eo, Hyun Ji
   Park, Jae Ho
   Jung, Hyuk Sang
   Jeong, Jin Boo
TI Anti inflammatory effect of Vaccinium oldhamii stems through
   inhibition of NF κB and MAPK/ATF2 signaling activation in LPS stimulated
   RAW264.7 cells
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Anti inflammation; Anti osteoclastogenesis; Inflammatory diseases;
   Vaccinium oldhamii
ID CARBONIC ANHYDRASE II; NITRIC OXIDE; BONE LOSS; OSTEOCLAST
   DIFFERENTIATION; OXIDATIVE STRESS; INFLAMMATION; COX 2;
   CYCLOOXYGENASE 2; EXPRESSION; RECEPTOR
AB Background Vaccinium oldhamii (V. oldhamii) has been reported to exert a variety of the pharmacological properties such as anti oxidant activity, anti cancer activity, and inhibitory activity of alpha amylase and acetylcholinesterase. However, the anti inflammatory activity of V. oldhamii has not been studied. In this study, we aimed to investigate anti inflammatory activity of the stem extracts from V. oldhamii, and to elucidate the potential mechanisms in LPS stimulated RAW264.7 cells. Methods Cell viability was evaluated by MTT assay. The determination of NO and PGE2 production was performed using Griess reagent and Prostaglandin E 2 ELISA Kit, respectively. The change of mRNA or protein level was evaluated by RT PCR and Western blot. Results Among VOS, VOL and VOF, the inhibitory effect of NO and PGE(2) production induced by LPS was highest in VOS treatment. Thus, VOS was selected for the further study. VOS dose dependently blocked LPS induced NO and PGE(2) production by inhibiting iNOS and COX 2 expression, respectively. VOS inhibited the expression of pro inflammatory cytokines such as IL 1 beta, IL 6 and TNF alpha. In addition, VOS suppressed TRAP activity and attenuated the expression of the osteoclast specific genes such as NFATc1, c FOS, TRAP, MMP 9, cathepsin K, CA2, OSCAR and ATPv06d2. VOS inhibited LPS induced NF kappa B signaling activation through blocking I kappa B alpha degradation and p65 nuclear accumulation. VOS inhibited MAPK signaling activation by attenuating the phosphorylation of ERK1/2, p38 and JNK. Furthermore, VOS inhibited ATF2 phosphorylation and blocked ATF2 nuclear accumulation. Conclusions These results indicate that VOS may exert anti inflammatory activity by inhibiting NF kappa B and MAPK/ATF2 signaling. From these findings, VOS has potential to be a candidate for the development of chemopreventive or therapeutic agents for the inflammatory diseases.
C1 [Kim, Ha Na; Baek, Jueng Kyu; Park, Su Bin; Kim, Jeong Dong; Jeong, Jin Boo] Andong Natl Univ, Dept Med Plant Resources, Andong 36729, South Korea.
   [Son, Ho Jun; Park, Gwang Hun; Eo, Hyun Ji] Natl Inst Forest Sci, Forest Med Resources Res Ctr, Yeongju 36040, South Korea.
   [Park, Jae Ho] Jungwon Univ, Dept Pharmaceut Sci, Geosan 28024, Chungbuk, South Korea.
   [Jung, Hyuk Sang] Kyung Hee Univ, Coll Korean Med, Dept Anat, Seoul 02447, South Korea.
   [Jeong, Jin Boo] Andong Natl Univ, Inst Agr Sci & Technol, Andong 36729, South Korea.
C3 Gyeongkuk National University; National Institute of Forest Science
   (NIFOS), Republic of South Korea; Korea Forest Research Institute
   (KFRI); Jungwon University; Kyung Hee University; Gyeongkuk National
   University
RP Jeong, JB (通讯作者)，Andong Natl Univ, Dept Med Plant Resources, Andong 36729, South Korea.; Jeong, JB (通讯作者)，Andong Natl Univ, Inst Agr Sci & Technol, Andong 36729, South Korea.
EM jjb0403@anu.ac.kr
RI ; Jeong, Jin Boo/AGH 6556 2022
OI Jeong, Jin Boo/0000 0002 0936 341X; 
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [NRF 2016R1D1A3B03931713,
   NRF 2018R1A6A1A03024862]
FX This work was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education (NRF 2016R1D1A3B03931713 and NRF 2018R1A6A1A03024862). Two
   funding bodies provided financial support for this study. The founding
   sponsor had no role in the study design, performance, data collection
   and analysis, decision to publish, or preparation/writing of the
   manuscript.
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Aldini R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108112
   Aparna V, 2012, CHEM BIOL DRUG DES, V80, P434, DOI 10.1111/j.1747 0285.2012.01418.x
   Arulselvan P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5276130
   Baba T, 2016, MICROBES ENVIRON, V31, P186, DOI 10.1264/jsme2.ME16011
   Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004
   BLOTMAN F, 1982, INT J IMMUNOPHARMACO, V4, P119, DOI 10.1016/0192 0561(82)90059 5
   Chang HH, 2017, KIDNEY BLOOD PRESS R, V42, P919, DOI 10.1159/000485082
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Choi J, 2004, PLANTA MED, V70, P1027, DOI 10.1055/s 2004 832642
   Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567 5769(01)00086 8
   Coon D, 2007, J ENDODONT, V33, P432, DOI 10.1016/j.joen.2006.12.001
   Dandekar R., 2015, J PHARMACOGN PHYTOCH, V4, P149
   David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099
   Fujisaki K, 2007, LIFE SCI, V80, P1311, DOI 10.1016/j.lfs.2006.12.037
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Guan FQ, 2014, BIOMED REP, V2, P760, DOI 10.3892/br.2014.314
   Habermann B, 2007, ACTA ORTHOP, V78, P221, DOI 10.1080/17453670710013717
   Herrera BS, 2011, J PERIODONTOL, V82, P1608, DOI 10.1902/jop.2011.100768
   Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Inoue K, 2014, J BONE MINER RES, V29, P1823, DOI 10.1002/jbmr.2229
   Kellinsalmi M, 2007, EUR J PHARMACOL, V572, P102, DOI 10.1016/j.ejphar.2007.06.030
   Kitade H, 1996, HEPATOLOGY, V23, P797, DOI 10.1053/jhep.1996.v23.pm0008666334
   Krishnan K, 2014, INFLAMMOPHARMACOLOGY, V22, P373, DOI 10.1007/s10787 014 0218 8
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Lee JH, 2004, ARCH PHARM RES, V27, P53, DOI 10.1007/BF02980046
   Lee JW, 2009, CYTOTECHNOLOGY, V61, P125, DOI 10.1007/s10616 010 9253 5
   Li L, 2016, EUR J PHARMACOL, V777, P17, DOI 10.1016/j.ejphar.2016.02.057
   Li L, 2015, EUR J PHARMACOL, V765, P115, DOI 10.1016/j.ejphar.2015.08.032
   Libby P, 2006, AM J CLIN NUTR, V83, p456S
   Nakagawa Hayato, 2012, Patholog Res Int, V2012, P172894, DOI 10.1155/2012/172894
   Nemeth K, 2011, J IMMUNOL, V186, P13, DOI 10.4049/jimmunol.1002483
   Nilforoushan D, 2009, NITRIC OXIDE BIOL CH, V21, P27, DOI 10.1016/j.niox.2009.04.002
   Oh Soonja, 2009, [Korean Journal of Plant Reources., 한국자원식물학회지], V22, P71
   Ono K, 2003, BONE, V33, P798, DOI 10.1016/S8756 3282(03)00264 3
   Park EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027739
   Park HeeWook Park HeeWook, 2005, Korean Journal of Pharmacognosy, V36, P191
   Park JY, 2005, CLIN CHIM ACTA, V351, P185, DOI 10.1016/j.cccn.2004.09.013
   Ravipati AS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 173
   Reifen R, 2015, J NUTR BIOCHEM, V26, P1632, DOI 10.1016/j.jnutbio.2015.08.006
   Saeed NM, 2012, TOXICOL APPL PHARM, V264, P84, DOI 10.1016/j.taap.2012.07.020
   SEIBERT K, 1994, RECEPTOR, V4, P17
   Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787 007 0013 x
   Silva RO, 2014, FUND CLIN PHARMACOL, V28, P455, DOI 10.1111/fcp.12049
   Sostres C, 2010, BEST PRACT RES CL GA, V24, P121, DOI 10.1016/j.bpg.2009.11.005
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev immunol 020711 075008
   Tsuda Hirotoshi, 2013, Plants (Basel), V2, P57, DOI 10.3390/plants2010057
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Wyss Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896 6273(02)00794 8
   Yang Eun Jin, 2009, Interdiscip Toxicol, V2, P245, DOI 10.2478/v10102 009 0022 2
   Yu T, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/950472
   Zhang MX, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193309
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 60
TC 10
Z9 10
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472 6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD NOV 4
PY 2019
VL 19
IS 1
AR 291
DI 10.1186/s12906 019 2720 4
PG 14
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA JK4FO
UT WOS:000494799200001
PM 31684931
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Price, U
   Le, HOT
   Powell, SE
   Schmid, MJ
   Marx, DB
   Zhang, Y
   Wang, D
   Narayana, N
   Reinhardt, RA
AF Price, U.
   Le, H O T.
   Powell, S. E.
   Schmid, M. J.
   Marx, D. B.
   Zhang, Y.
   Wang, D.
   Narayana, N.
   Reinhardt, R. A.
TI Effects of local simvastatin alendronate conjugate in preventing
   periodontitis bone loss
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE bisphosphonate; bone; periodontitis; statin
ID MUCOPERIOSTEAL FLAP SURGERY; ALVEOLAR BONE;
   ACTINOBACILLUS ACTINOMYCETEMCOMITANS; BISPHOSPHONATE ALENDRONATE;
   SYSTEMIC ALENDRONATE; RESORPTIVE PHASE; DRUG DELIVERY; RAT; MODEL;
   LIPOPOLYSACCHARIDE
AB Background and Objective: Local host modulation therapy is an emerging approach to prevent disease progression in sites with moderate periodontitis. The combination of simvastatin and alendronate would be an intriguing host modulatory strategy because of the bone anabolic properties of simvastatin and the antiresorptive/ bone targeting characteristics of alendronate. The objective of this study was to evaluate the effects of local administration of a simvastatin alendronate beta cyclodextrin (SIM ALN CD) conjugate for preventing experimental periodontitis bone loss.
   Material and Methods: Twenty four mature female Sprague Dawley rats were treated with three, 12 mu L injections, administered one week apart, bilaterally into the palatal/ interproximal gingiva. The injections contained: (i) a conjugate of 0.5 mg of SIM and 3.75 mg of ALN CD in H2O; (ii) H2O alone; or (iii) no treatment. One week later, the same sites were subjected to induction of experimental periodontitis by three injections (i. e. one injection administered every other day for five d) of 0.01 mg of Escherichia coli endotoxin [lipopolysaccharide (LPS)] in phosphate buffered saline (PBS) or PBS alone. After an additional week, the rats were killed, the palates were harvested and interproximal bone volume and adjacent thickness were calculated using microcomputed tomography. Subsequently, specimens were decalcified, and interproximal histologic sections were stained with hematoxylin and eosin for evaluation of alveolar crest osteoclasts and surrounding inflammation. Values were compared among treatment groups using analysis of variance and the Kruskal Wallis test.
   Results: Interproximal bone volume was reduced by LPS injections (p <= 0.04), yet when experimental periodontitis was preceded by treatment with SIM ALN  CD, more bone was preserved than after treatment with carrier alone (p = 0.007). While LPS caused a significant loss in bone thickness over the palatal roots (p <= 0.04), the injection protocol (PBS) also caused a significant loss of palatal bone thickness (p <= 0.03). However, prophylactic SIM ALN CD injections resulted in no further loss of bone thickness during experimental periodontitis. LPS injections gave histologic evidence of increased osteoclasts and subsulcular inflammation, both of which were reduced when preceded by treatment with SIM ALN CD (p <= 0.0002).
   Conclusion: The primary conclusion of this study was that locally applied SIMALN  CD has the potential to prevent episodes of periodontitis bone loss.
C1 [Price, U.; Le, H O T.; Reinhardt, R. A.] Univ Nebraska Med Ctr, Coll Dent, Dept Surg Specialties, Lincoln, NE USA.
   [Powell, S. E.] Univ Nebraska Med Ctr, Dept Growth & Dev, Coll Dent, Lincoln, NE USA.
   [Schmid, M. J.] Univ Nebraska Med Ctr, Res Adm, Coll Dent, Lincoln, NE USA.
   [Marx, D. B.] Univ Nebraska, Dept Stat, Lincoln, NE USA.
   [Zhang, Y.; Wang, D.] Univ Nebraska Med Ctr, Dept Pharmaceut Sci, Coll Pharm, Omaha, NE USA.
   [Narayana, N.] Univ Nebraska Med Ctr, Dept Oral Biol, Coll Dent, Lincoln, NE USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska Lincoln; University of Nebraska System;
   University of Nebraska Medical Center; University of Nebraska Lincoln;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska Lincoln; University of Nebraska System;
   University of Nebraska Lincoln; University of Nebraska System;
   University of Nebraska Medical Center; University of Nebraska System;
   University of Nebraska Lincoln; University of Nebraska Medical Center
RP Reinhardt, RA (通讯作者)，UNMC Coll Dent, 40th & Holdrege, Lincoln, NE 68583 USA.
EM rareinha@unmc.edu
FU UNMC Surgical Specialties and Growth and Development Postgraduate Funds;
   Windsweep Farm Fund; UneMed Corporation
FX This research was supported by the UNMC Surgical Specialties and Growth
   and Development Postgraduate Funds, the Windsweep Farm Fund, and an
   innovation grant from UneMed Corporation. The authors thank Phyllis Kumm
   for processing histologic specimens and Susan McCoy for preparation of
   the manuscript. Drs Wang and Reinhardt have patent applications for
   synthesis of the cyclodextrin alendronate conjugates. There are no other
   conflicts of interest related to this study.
CR Ayukawa Y, 2009, ORAL SURG ORAL MED O, V107, P336, DOI 10.1016/j.tripleo.2008.07.013
   Barros SP, 2003, J DENT RES, V82, P791, DOI 10.1177/154405910308201006
   Bashutski JD, 2010, NEW ENGL J MED, V363, P2396, DOI 10.1056/NEJMoa1005361
   Binderman I, 2000, J PERIODONTOL, V71, P1236, DOI 10.1902/jop.2000.71.8.1236
   Bradley JD, 2007, J PERIODONTAL RES, V42, P267, DOI 10.1111/j.1600 0765.2006.00943.x
   Coimbra LS, 2011, J PERIODONTOL, V82, P767, DOI 10.1902/jop.2010.100555
   Cunha Cruz J, 2006, J PERIODONTOL, V77, P1061, DOI 10.1902/jop.2006.050280
   Dumitrescu AL, 2004, J CLIN PERIODONTOL, V31, P596, DOI 10.1111/j.1600 051X.2004.00528.x
   Greenstein G, 2006, J PERIODONTOL, V77, P565, DOI 10.1902/jop.2006.050140
   Herrera D, 2002, J CLIN PERIODONTOL, V29, P136, DOI 10.1034/j.1600 051X.29.s3.8.x
   Kador PF, 2011, J PERIODONTOL, V82, P926, DOI 10.1902/jop.2010.100442
   Kaynak D, 2000, J PERIODONTOL, V71, P790, DOI 10.1902/jop.2000.71.5.790
   Killeen AC, 2012, J PERIODONTOL, V83, P1463, DOI 10.1902/jop.2012.110683
   Komatsu K, 2008, J PERIODONTAL RES, V43, P194, DOI 10.1111/j.1600 0765.2007.01012.x
   Krayer Joe W, 2010, Dent Clin North Am, V54, P13, DOI 10.1016/j.cden.2009.08.010
   Küçük D, 2011, INT J ORAL MAX SURG, V40, P1395, DOI 10.1016/j.ijom.2011.08.004
   Lee YJ, 2008, BIOMATERIALS, V29, P1940, DOI 10.1016/j.biomaterials.2007.12.045
   Lee Y, 2011, MOL PHARMACEUT, V8, P1035, DOI 10.1021/mp200045p
   Liu XM, 2008, BIOMATERIALS, V29, P1686, DOI 10.1016/j.biomaterials.2007.12.023
   Marques MR, 2005, ARCH ORAL BIOL, V50, P421, DOI 10.1016/j.archoralbio.2004.08.014
   Menezes AMA, 2005, J PERIODONTOL, V76, P1901, DOI 10.1902/jop.2005.76.11.1901
   Meraw SJ, 1999, J PERIODONTOL, V70, P1228, DOI 10.1902/jop.1999.70.10.1228
   Meraw SJ, 1999, J PERIODONTOL, V70, P151, DOI 10.1902/jop.1999.70.2.151
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nezic L, 2009, BASIC CLIN PHARMACOL, V104, P185, DOI 10.1111/j.1742 7843.2008.00302.x
   Nyan M, 2010, J BIOMED MATER RES B, V93B, P65, DOI 10.1002/jbm.b.31559
   Özec I, 2007, J CRANIOFAC SURG, V18, P546
   Park CH, 2007, J PERIODONTOL, V78, P273, DOI 10.1902/jop.2007.060252
   Pradeep AR, 2012, J PERIODONTOL, V83, P1472, DOI 10.1902/jop.2012.110716
   Pradeep AR, 2012, J PERIODONTOL, V83, P1322, DOI 10.1902/jop.2012.110292
   Pradeep A R., 2012, J. Periodontol
   Pradeep AR, 2010, J PERIODONTOL, V81, P214, DOI 10.1902/jop.2009.090429
   Raja S, 2009, INT J DENT HYG, V7, P82, DOI 10.1111/j.1601 5037.2009.00380.x
   Ramamurthy NS, 2002, J PERIODONTAL RES, V37, P1, DOI 10.1034/j.1600 0765.2002.00342.x
   REDDY MS, 1995, J PERIODONTOL, V66, P211, DOI 10.1902/jop.1995.66.3.211
   Rogers JE, 2007, J PERIODONTOL, V78, P550, DOI 10.1902/jop.2007.060321
   Rutledge J, 2011, J PERIODONTOL, V82, P597, DOI 10.1902/jop.2010.100214
   Sama AA, 2004, CLIN ORTHOP RELAT R, P135, DOI 10.1097/01.blo.0000137825.50462.c5
   SLOTS J, 1984, J DENT RES, V63, P412, DOI 10.1177/00220345840630031101
   SOCRANSKY SS, 1992, J PERIODONTOL, V63, P322, DOI 10.1902/jop.1992.63.4s.322
   Srisubut S, 2007, ORAL SURG ORAL MED O, V104, pE11, DOI 10.1016/j.tripleo.2007.04.022
   Stein D, 2005, J PERIODONTOL, V76, P1861, DOI 10.1902/jop.2005.76.11.1861
   Tokunaga K, 2011, J PERIODONTAL RES, V46, P655, DOI 10.1111/j.1600 0765.2011.01386.x
   WEINREB M, 1994, J PERIODONTAL RES, V29, P35, DOI 10.1111/j.1600 0765.1994.tb01088.x
   Wikesjo Ulf M E, 2007, Oral Maxillofac Surg Clin North Am, V19, P535, DOI 10.1016/j.coms.2007.07.004
   WILLIAMS RC, 1988, J PERIODONTAL RES, V23, P225, DOI 10.1111/j.1600 0765.1988.tb01363.x
   Wu Z, 2008, INT J ORAL MAX SURG, V37, P170, DOI 10.1016/j.ijom.2007.06.018
   Yaffe A, 1997, J PERIODONTOL, V68, P884, DOI 10.1902/jop.1997.68.9.884
   Yaffe A, 1999, J PERIODONTOL, V70, P893, DOI 10.1902/jop.1999.70.8.893
NR 50
TC 25
Z9 29
U1 0
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD OCT
PY 2013
VL 48
IS 5
BP 541
EP 548
DI 10.1111/jre.12036
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 210GD
UT WOS:000323817500001
PM 23278592
DA 2025 08 17
ER

PT J
AU Fouque, D
   Roth, H
   Darne, B
   Jean Bouchet, L
   Daugas, E
   Drueke, TB
   Hannedouche, T
   Jean, G
   London, GM
AF Fouque, Denis
   Roth, Hubert
   Darne, Bernadette
   Jean Bouchet, Louis
   Daugas, Eric
   Drueke, Tilman B.
   Hannedouche, Thierry
   Jean, Guillaume
   London, Gerard M.
CA French Phosphorus Calcium Observ
TI Achievement of Kidney Disease: Improving Global Outcomes mineral and
   bone targets between 2010 and 2014 in incident dialysis patients in
   France: the Photo Graphe3 study
SO CLINICAL KIDNEY JOURNAL
LA English
DT Article
DE calcium; haemodialysis; KDIGO; parathyroid hormone; phosphate; survival
ID INDEPENDENT RISK FACTOR; HEMODIALYSIS PATIENTS; METABOLISM; MORTALITY;
   PHOSPHATE; CALCIUM; DEFINITION; GUIDELINES; PHOSPHORUS; SURVIVAL
AB Background: Abnormal serum phosphate, calcium and parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD) undergoing haemodialysis have been associated with poor survival. The French Phosphorus and Calcium Observatory (Photo Graphe (R) 3) aimed to estimate the percentage of CKD patients achieving the three Kidney Disease: Improving Global Outcomes (KDIGO) targets about optimal serum phosphate, calcium and PTH over a 3.5 year follow up period.
   Methods: This was a prospective, multicentre, epidemiological observational study conducted with nephrologists in France, selected using a clustering approach. Eligible patients were adults undergoing intermittent haemodialysis or haemodiafiltration therapy started within the preceding 12 months. Data about clinical events, serum biochemistry and treatment were collected once every 6 months for 2.5 years and 12 months thereafter.
   Results: Overall, 9010 incident patients were included (men, 63%; median age, 71 years) of whom 7515 (83.4%) were treated by haemodialysis and 1495 (16.6%) by haemodiafiltration. None had a history of fracture or revascularization while 89 (1%) patients had a history of parathyroidectomy >6 months. Overall, 874 (10%) patients received a kidney graft, 2183 (24%) died and 1148 (13%) were lost to follow up. The proportion achieving the three KDIGO targets increased significantly from 11% to 16% (P < 0.0001) until Year 2, but remained stable afterwards. The percentage of incident dialysis patients with normal serum phosphate (P < 0.0001) or normal serum calcium (P < 0.0001) levels increased significantly over time, while no significant change was observed for those with controlled PTH.
   Conclusion: Less than 20% of patients achieved the KDIGO recommendations although their proportion increased slightly over time.
C1 [Fouque, Denis] UCBL, Univ Lyon, CH Lyon Sud, Dept Nephrol,Inserm Carmen,CENS, Lyon, France.
   [Roth, Hubert] Univ J Fourier, Ctr Rech Nutr Humaine Rhone Alpes, Pole Rech CHU Grenoble, Inserm Bioenerget U1055, Grenoble, France.
   [Darne, Bernadette] Monitoring Force Grp, Maisons Laffitte, France.
   [Jean Bouchet, Louis] Ctr Traitement Malad Renales St Augustin, Bordeaux, France.
   [Daugas, Eric] HU Paris Nord Site Bichat, Paris, France.
   [Drueke, Tilman B.] UVSQ, Univ Paris Sud, Univ Paris Saclay, Inserm U1018,CESP, Villejuif, France.
   [Hannedouche, Thierry] Hop Univ Strasbourg, Fac Med, Serv Nephrol, Strasbourg, France.
   [Jean, Guillaume] NephoCare Tassin Charcot, Sainte Foy Les Lyon, France.
   [London, Gerard M.] Hop Manhes, Fleury Merogis, France.
C3 CHU Lyon; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite Claude Bernard Lyon 1; Communaute Universite
   Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux
   Paris (APHP); Universite Paris Cite; Hopital Universitaire Bichat Claude
   Bernard   APHP; Universite Paris Saclay; Institut National de la Sante
   et de la Recherche Medicale (Inserm); CHU Strasbourg; Universites de
   Strasbourg Etablissements Associes; Universite de Strasbourg
RP Fouque, D (通讯作者)，UCBL, Univ Lyon, CH Lyon Sud, Dept Nephrol,Inserm Carmen,CENS, Lyon, France.
EM denis.fouque@univ lyon1.fr
RI ; fouque, denis/C 5338 2014; Fouque, Denis/C 5338 2014
OI Jean, guillaume/0000 0003 4757 9956; fouque, denis/0000 0002 9707 7199;
   DAUGAS, Eric/0000 0001 7256 7979; ROTH, Hubert/0000 0002 1980 3220
CR Abe M, 2013, NUTRIENTS, V5, P1002, DOI 10.3390/nu5031002
   Alseiari M, 2016, AM J KIDNEY DIS, V67, P417, DOI 10.1053/j.ajkd.2015.09.016
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Bover J, 2009, J RENAL CARE, V35, P19, DOI 10.1111/j.1755 6686.2009.00049.x
   Cannata Andía JB, 2016, NEPHROL DIAL TRANSPL, V31, P541, DOI 10.1093/ndt/gfv055
   Danese MD, 2015, NEPHROL DIAL TRANSPL, V30, P1336, DOI 10.1093/ndt/gfv034
   del Pozo Fernández C, 2013, NEFROLOGIA, V33, P675, DOI 10.3265/Nefrologia.pre2013.Jun.11980
   Dhingra R, 2007, ARCH INTERN MED, V167, P879, DOI 10.1001/archinte.167.9.879
   Djukanovic L, 2016, NEPHRON, V132, P168, DOI 10.1159/000443848
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Floege J, 2011, NEPHROL DIAL TRANSPL, V26, P1948, DOI 10.1093/ndt/gfq219
   Fouque D, 2013, NEPHROL DIAL TRANSPL, V28, P360, DOI 10.1093/ndt/gfs404
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Goldsmith DJA, 2010, NEPHROL DIAL TRANSPL, V25, P3823, DOI 10.1093/ndt/gfq513
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Kalantar Zadeh K, 2013, PATIENT PREFER ADHER, V7, DOI 10.2147/PPA.S43486
   Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kim Gheun Ho, 2014, Electrolyte Blood Press, V12, P35, DOI 10.5049/EBP.2014.12.2.35
   Lee SA, 2016, OSTEOPOROSIS INT, V27, P2717, DOI 10.1007/s00198 016 3636 1
   Fernandez Martín JL, 2015, NEPHROL DIAL TRANSPL, V30, P1542, DOI 10.1093/ndt/gfv099
   Merle E, 2016, KIDNEY INT, V89, P666, DOI 10.1016/j.kint.2015.12.001
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2008, CLIN J AM SOC NEPHRO, V3, pS127, DOI 10.2215/CJN.04331206
   Natoli JL, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 88
   Palomares I, 2013, BLOOD PURIFICAT, V36, P122, DOI 10.1159/000353418
   Pelletier S, 2010, NEPHROL DIAL TRANSPL, V25, P3062, DOI 10.1093/ndt/gfq128
   Pelletier S, 2010, NEPHROL THER, V6, P11, DOI 10.1016/j.nephro.2009.09.001
   Souberbielle JCP, 2010, KIDNEY INT, V77, P93, DOI 10.1038/ki.2009.374
   Tangri N, 2011, AM J KIDNEY DIS, V57, P415, DOI 10.1053/j.ajkd.2010.08.037
   Tentori F, 2015, CLIN J AM SOC NEPHRO, V10, P98, DOI 10.2215/CJN.12941213
   Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198
NR 32
TC 11
Z9 12
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2048 8505
EI 2048 8513
J9 CLIN KIDNEY J
JI Clin. Kidney J.
PD FEB
PY 2018
VL 11
IS 1
BP 73
EP 79
DI 10.1093/ckj/sfx101
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA GA2IF
UT WOS:000428143700014
PM 29423206
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Lazarus, DD
   Doyle, EG
   Bernier, SG
   Rogers, AB
   Labenski, MT
   Wakefield, JD
   Karp, RM
   Clark, EJ
   Lorusso, J
   Hoyt, JG
   Thompson, CD
   Hannig, G
   Westlin, WF
AF Lazarus, D. D.
   Doyle, E. G.
   Bernier, S. G.
   Rogers, A. B.
   Labenski, M. T.
   Wakefield, J. D.
   Karp, R. M.
   Clark, E. J.
   Lorusso, J.
   Hoyt, J. G.
   Thompson, C. D.
   Hannig, G.
   Westlin, W. F.
TI An inhibitor of methionine aminopeptidase type 2, PPI 2458, ameliorates
   the pathophysiological disease processes of rheumatoid arthritis
SO INFLAMMATION RESEARCH
LA English
DT Article
DE arthritis; aminopeptidase; osteoclast
ID STREPTOCOCCAL CELL WALL; COLLAGEN INDUCED ARTHRITIS; ENDOTHELIAL
   GROWTH FACTOR; TUMOR NECROSIS FACTOR; ANGIOGENESIS INHIBITOR; SYNOVIAL
   FIBROBLASTS; OSTEOCLAST FORMATION; ANTIRHEUMATIC DRUGS; INDUCED
   POLYARTHRITIS; PSORIATIC ARTHRITIS
AB Objective: To elucidate the role of methionine aminopeptidase type 2 (MetAP 2) in the clinical pathology of rheumatoid arthritis, arthritis was induced in rats by administration of peptidoglycan polysaccharide (PG PS).
   Design: The inhibitor of MetAP 2, PPI 2458, was administered orally at 5 mg/kg every other day during 3 distinct phases of the disease. In vitro studies were performed to clarify in vivo findings.
   Results: Ankle swelling was completely alleviated by MetAP 2 inhibition. Inhibition of MetAP 2 in blood and tissues correlated with protection against PG PS induced arthritis. Histopathology of the tarsal joints improved following PPI 2458 administration, including a significant improvement of bone structure. In in vitro studies, osteoclast formation and activity were inhibited by PPI 2458, a mechanism not previously attributed to MetAP 2 inhibition.
   Conclusions: The important role that MetAP 2 has in the pathophysiological disease processes of PG PS arthritis provides a strong rationale for evaluating PPI 2458 as a disease modifying antirheumatic treatment for rheumatoid arthritis.
C1 [Westlin, W. F.] Avila Therapeut, Waltham, MA 02453 USA.
   [Lazarus, D. D.; Doyle, E. G.; Bernier, S. G.; Karp, R. M.; Clark, E. J.; Lorusso, J.; Hannig, G.; Westlin, W. F.] PRAECIS Pharmaceut Incorp, Dept Preclin Res, Waltham, MA 02451 USA.
   [Labenski, M. T.; Wakefield, J. D.; Hoyt, J. G.; Thompson, C. D.] PRAECIS Pharmaceut Incorp, Dept Analyt Pharmacol, Waltham, MA 02451 USA.
   [Rogers, A. B.] MIT, Div Comparat Med, Cambridge, MA 02139 USA.
   [Lazarus, D. D.] GPC Biotech Inc, Waltham, MA 02451 USA.
   [Labenski, M. T.] Arizona State Univ, Tempe, AZ 85069 USA.
   [Wakefield, J. D.] Microbia Inc, Cambridge, MA 02141 USA.
   [Hoyt, J. G.] Infin Pharmaceut Inc, Cambridge, MA 02139 USA.
   [Thompson, C. D.] Merck Pharmaceut Co, West Point, PA 19486 USA.
C3 Massachusetts Institute of Technology (MIT); Arizona State University;
   Arizona State University Tempe; Ironwood Pharmaceuticals, Inc.; Infinity
   Pharmaceuticals, Inc.; Merck & Company
RP Westlin, WF (通讯作者)，Avila Therapeut, 100 Beaver St, Waltham, MA 02453 USA.
EM wwestlin@avilatx.com
OI Thompson, Charles/0000 0002 6206 7345
CR ABE J, 1994, CANCER RES, V54, P3407
   Adamopoulos IE, 2006, J PATHOL, V208, P35, DOI 10.1002/path.1891
   Adarichev VA, 2003, J IMMUNOL, V170, P2283, DOI 10.4049/jimmunol.170.5.2283
   ALLEN JB, 1983, ARTHRITIS RHEUM, V26, P560, DOI 10.1002/art.1780260418
   BALFOUR RB, 1996, METHODS, V9, P233
   Bernier SG, 2004, P NATL ACAD SCI USA, V101, P10768, DOI 10.1073/pnas.0404105101
   Bhargava P, 1999, CLIN CANCER RES, V5, P1989
   Brahn E, 2001, ARTHRITIS RHEUM, V44, pS271
   Brahn E, 2003, ARTHRITIS RHEUM, V48, pS347
   CHERWINSKI HM, 1995, INFLAMM RES, V44, P317, DOI 10.1007/BF01796261
   Cho ML, 2002, ARTHRITIS RHEUM, V46, P1202, DOI 10.1002/art.10215
   CROMARTIE WJ, 1977, J EXP MED, V146, P1585, DOI 10.1084/jem.146.6.1585
   de Bandt M, 2000, ARTHRITIS RHEUM, V43, P2056
   De Klerck B, 2004, ARTHRITIS RES THER, V6, pR220, DOI 10.1186/ar1167
   den Broeder AA, 2002, RHEUMATOLOGY, V41, P638, DOI 10.1093/rheumatology/41.6.638
   Fassbender H G, 1988, Scand J Rheumatol Suppl, V76, P1
   Feldmann M, 1996, J INFLAMM, V47, P90
   Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074 5521(97)90198 8
   INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0
   Jackson JR, 1997, J RHEUMATOL, V24, P1253
   Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439
   Jobanputra P, 2004, RHEUMATOLOGY, V43, P206, DOI 10.1093/rheumatology/keh003
   Kiely PDW, 2002, RHEUMATOLOGY, V41, P631, DOI 10.1093/rheumatology/41.6.631
   KUSAKA M, 1994, BRIT J CANCER, V69, P212, DOI 10.1038/bjc.1994.41
   Lethbridge Çejku M, 2003, MED CARE, V41, P1367, DOI 10.1097/01.MLR.0000100582.52451.AC
   Li P, 2004, J BONE MINER RES, V19, P207, DOI 10.1359/JBMR.0301233
   Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419
   Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198
   MCBURNEY MW, 1975, CANCER RES, V35, P586
   Michaud K, 2003, ARTHRITIS RHEUM US, V48, P2750, DOI 10.1002/art.11439
   MOORE TL, 1989, J RHEUMATOL, V16, P1069
   Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301
   Nagashima M, 2000, RHEUMATOLOGY, V39, P1255, DOI 10.1093/rheumatology/39.11.1255
   Nagashima M, 1999, CLIN EXP IMMUNOL, V116, P360
   OBYRNE EM, 1991, AGENTS ACTIONS, V34, P239, DOI 10.1007/BF01993291
   Orchard TR, 1998, GUT, V42, P387, DOI 10.1136/gut.42.3.387
   PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135
   Rantakokko K, 1997, CLIN EXP RHEUMATOL, V15, P399
   Salvarani C, 2002, CLIN EXP RHEUMATOL, V20, pS71
   Sartor R. Balfour, 1996, Methods (Orlando), V9, P233, DOI 10.1006/meth.1996.0030
   Schimmer RC, 1997, J IMMUNOL, V159, P4103
   Schrijver IA, 2000, ARTHRITIS RHEUM US, V43, P2160, DOI 10.1002/1529 0131(200010)43:10<2160::AID ANR3>3.0.CO;2 T
   Schrijver IA, 2001, RHEUMATOLOGY, V40, P438, DOI 10.1093/rheumatology/40.4.438
   Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099
   Sokka T, 2002, J RHEUMATOL, V29, P2521
   Uknis AB, 2001, INFLAMM RES, V50, P149, DOI 10.1007/s000110050739
   van der Heijden IM, 2000, ARTHRITIS RHEUM US, V43, P593, DOI 10.1002/1529 0131(200003)43:3<593::AID ANR16>3.0.CO;2 1
   Van der Heijden IM, 2000, ARTHRITIS RHEUM, V43, P1061
   VANLENT PLEM, 1993, AM J PATHOL, V143, P1226
   Wu YL, 2005, ARTHRITIS RHEUM US, V52, P3257, DOI 10.1002/art.21354
   YANASE T, 1993, CANCER RES, V53, P2566
   Yelin E, 2004, ARTHRITIS RHEUM, V50, P2317, DOI 10.1002/art.20298
NR 52
TC 14
Z9 25
U1 0
U2 6
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023 3830
EI 1420 908X
J9 INFLAMM RES
JI Inflamm. Res.
PD JAN
PY 2008
VL 57
IS 1
BP 18
EP 27
DI 10.1007/s00011 007 7075 5
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA 253TO
UT WOS:000252540700004
PM 18209961
DA 2025 08 17
ER

PT J
AU Redondo, A
   Bagué, S
   Bernabeu, D
   Ortiz Cruz, E
   Valverde, C
   Alvarez, R
   Martinez Trufero, J
   Lopez Martin, JA
   Correa, R
   Cruz, J
   Lopez Pousa, A
   Santos, A
   del Muro, XG
   Martin Broto, J
AF Redondo, Andres
   Bague, Silvia
   Bernabeu, Daniel
   Ortiz Cruz, Eduardo
   Valverde, Claudia
   Alvarez, Rosa
   Martinez Trufero, Javier
   Lopez Martin, Jose A.
   Correa, Raquel
   Cruz, Josefina
   Lopez Pousa, Antonio
   Santos, Aurelio
   Garcia del Muro, Xavier
   Martin Broto, Javier
TI Malignant bone tumors (other than Ewing's): clinical practice guidelines
   for diagnosis, treatment and follow up by Spanish Group for Research on
   Sarcomas (GEIS)
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Bone tumors; Bone sarcomas; Clinical guideline; Diagnosis; Treatment
ID GIANT CELL TUMOR; HIGH GRADE OSTEOSARCOMA; PHASE II TRIAL;
   PEDIATRIC ONCOLOGY GROUP; SKULL BASE CHORDOMA; NONMETASTATIC
   OSTEOSARCOMA; PROGNOSTIC FACTORS; NEOADJUVANT CHEMOTHERAPY; LOCAL
   RECURRENCE; DEDIFFERENTIATED CHONDROSARCOMA
AB Primary malignant bone tumors are uncommon and heterogeneous malignancies. This document is a guideline developed by the Spanish Group for Research on Sarcoma with the participation of different specialists involved in the diagnosis and treatment of bone sarcomas. The aim is to provide practical recommendations with the intention of helping in the clinical decision making process. The diagnosis and treatment of bone tumors requires a multidisciplinary approach, involving as a minimum pathologists, radiologists, surgeons, and radiation and medical oncologists. Early referral to a specialist center could improve patients' survival. The multidisciplinary management of osteosarcoma, chondrosarcoma, chordoma, giant cell tumor of bone and other rare bone tumors is reviewed in this guideline. Ewing's sarcoma will be the focus of a separate guideline because of its specific biological, clinical and therapeutic features. Each statement has been accompanied by the level of evidence and grade of recommendation on the basis of the available data. Surgical excision is the mainstay of treatment of a localized bone tumor, with various techniques available depending on the histologic type, grade and location of the tumor. Chemotherapy plays an important role in some chemosensitive subtypes (such as high grade osteosarcoma). In other subtypes, historically considered chemoresistant (such as chordoma or giant cell tumor of bone), new targeted therapies have emerged recently, with a very significant efficacy in the case of denosumab. Radiation therapy is usually necessary in the treatment of chordoma and sometimes of other bone tumors.
C1 [Redondo, Andres; Bernabeu, Daniel; Ortiz Cruz, Eduardo] Hosp La Paz, Paseo Castellama 261, Madrid 28046, Spain.
   [Bague, Silvia] Hosp Santa Creu & Sant Pau, Carrer St Quinti 89, Barcelona 08026, Spain.
   [Valverde, Claudia] Hosp Valle De Hebron, Passeig Vall dHebron 119 129, Barcelona 08035, Spain.
   [Alvarez, Rosa] Hosp Gregorio Maranon, C Dr Esquerdo 46, Marid 28007, Spain.
   [Martinez Trufero, Javier] Hosp Miguel Servet, Paseo Isabel la Catolica 1 3, Zaragoza 50009, Spain.
   [Lopez Martin, Jose A.] Hosp 12 Octubre, Ctra Andalucia,Km 5 4, E 28041 Madrid, Spain.
   [Correa, Raquel] Hosp Virgen de la Victoria, Campus Teatinos S N, Malaga 29010, Spain.
   [Cruz, Josefina] Hosp Univ Canarias, Carretera Ofra S N, San Cristobal De Laguna 38320, Santa Cruz De T, Spain.
   [Lopez Pousa, Antonio] Hosp Santa Creu & Sant Pau, C Mas Casanovas 90, Barcelona 08041, Spain.
   [Santos, Aurelio; Martin Broto, Javier] Hosp Virgen del Rocio, Ave Manuel Siurot S N, Seville 41013, Spain.
   [Garcia del Muro, Xavier] Inst Catala Oncol Hosp, Avinguda GranVia Hosp 199 203, Barcelona, Spain.
C3 Hospital Universitario La Paz; Hospital of Santa Creu i Sant Pau;
   Hospital Universitari Vall d'Hebron; General University Gregorio Maranon
   Hospital; Miguel Servet University Hospital; Hospital Universitario 12
   de Octubre; Universidad de la Laguna; University Hospital of the Canary
   Islands; Hospital of Santa Creu i Sant Pau; Virgen del Rocio University
   Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   Institut Catala d'Oncologia
RP Redondo, A (通讯作者)，Hosp La Paz, Paseo Castellama 261, Madrid 28046, Spain.
EM andres.redondos@uam.es
RI LOPEZ MARTIN, JOSE/A 2376 2010; Alvarez, Rosa/MZR 5280 2025;
   Lopez Martin, Jose A./A 2376 2010; Martín Broto, Javier/AAI 2313 2019;
   Redondo, Andres/HZJ 4224 2023; Martinez Trufero, Javier/AAE 6915 2021
OI ALVAREZ, ROSA/0000 0003 0935 8298; Lopez Pousa,
   Antonio/0000 0003 1066 3951; Lopez Martin, Jose A./0000 0001 7530 3207;
   Martinez Trufero, Javier/0000 0002 0997 2573; Martin Broto,
   Javier/0000 0001 7350 6916; Redondo Sanchez, Andres/0000 0002 7257 5642;
   
CR Amichetti M, 2009, NEUROSURG REV, V32, P403, DOI 10.1007/s10143 009 0194 4
   Ares C, 2009, INT J RADIAT ONCOL, V75, P1111, DOI 10.1016/j.ijrobp.2008.12.055
   Ashford RU, 2006, J BONE JOINT SURG BR, V88B, P1207, DOI 10.1302/0301 620X.88B9.17680
   BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097 0142(19931201)72:11<3227::AID CNCR2820721116>3.0.CO;2 C
   Bacci G, 2008, J SURG ONCOL, V98, P415, DOI 10.1002/jso.21140
   Balke M, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 462
   Barrientos Ruiz I, 2017, CLIN ORTHOP RELAT R, V475, P511, DOI 10.1007/s11999 016 5090 y
   Baumann BC, 2015, INT J RADIAT ONCOL, V93, pE641, DOI 10.1016/j.ijrobp.2015.07.2184
   Baumert BG, 2001, INT J RADIAT ONCOL, V49, P1439, DOI 10.1016/S0360 3016(00)01422 X
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bernstein Molho R, 2012, CANCER CHEMOTH PHARM, V70, P855, DOI 10.1007/s00280 012 1968 x
   Bertrand TE, 2016, CLIN ORTHOP RELAT R, V474, P677, DOI 10.1007/s11999 015 4359 x
   Bielack SS, 1999, J CLIN ONCOL, V17, P1164, DOI 10.1200/JCO.1999.17.4.1164
   Bielack SS, 2009, J CLIN ONCOL, V27, P557, DOI 10.1200/JCO.2008.16.2305
   Bompas E, 2015, ANN ONCOL, V26, P2168, DOI 10.1093/annonc/mdv300
   Casali PG, 2014, ANN ONCOL, V25, P113, DOI 10.1093/annonc/mdu256
   Chakarun CJ, 2013, RADIOGRAPHICS, V33, P197, DOI 10.1148/rg.331125089
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Chen Z, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/4639575
   Costelloe CM, 2013, AM J ROENTGENOL, V200, P3, DOI 10.2214/AJR.12.8488
   Delaney TF, 2014, J SURG ONCOL, V110, P115, DOI 10.1002/jso.23617
   DeLaney TF, 2009, INT J RADIAT ONCOL, V74, P732, DOI 10.1016/j.ijrobp.2008.08.058
   ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106
   Ferrari S, 2003, J CLIN ONCOL, V21, P710, DOI 10.1200/JCO.2003.03.141
   Ferrari S, 2012, J CLIN ONCOL, V30, P2112, DOI 10.1200/JCO.2011.38.4420
   Ferrer Santacreu EM, 2012, J ONCOL, V2012, DOI 10.1155/2012/437958
   Fidler MM, 2015, BRIT J CANCER, V112, P1857, DOI 10.1038/bjc.2015.159
   Fletcher CDM, 2013, WHO CLASSIFICATION T, V4th, P244
   Fox E, 2012, ONCOLOGIST, V17, P321, DOI 10.1634/theoncologist.2010 0265
   Frezza AM, 2015, EUR J CANCER, V51, P374, DOI 10.1016/j.ejca.2014.11.007
   George S, 2009, J CLIN ONCOL, V27, P3154, DOI 10.1200/JCO.2008.20.9890
   Goorin AM, 2003, J CLIN ONCOL, V21, P1574, DOI 10.1200/JCO.2003.08.165
   Grignani G, 2012, ANN ONCOL, V23, P508, DOI 10.1093/annonc/mdr151
   Grimer RJ, 2007, EUR J CANCER, V43, P2060, DOI 10.1016/j.ejca.2007.06.016
   Hart JL, 2014, SEMIN DIAGN PATHOL, V31, P30, DOI 10.1053/j.semdp.2014.01.003
   Imran H, 2009, J BONE JOINT SURG AM, V91A, P604, DOI 10.2106/JBJS.H.00449
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Kivioja AH, 2008, ACTA ORTHOP, V79, P86, DOI 10.1080/17453670710014815
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P1181, DOI 10.1007/s11999 010 1560 9
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Littrell LA, 2004, RADIOGRAPHICS, V24, P1397, DOI 10.1148/rg.245045009
   Marina NM, 2016, LANCET ONCOL, V17, P1396, DOI 10.1016/S1470 2045(16)30214 5
   Martin Broto J, 2014, ACTA ONCOL, V53, P1173, DOI 10.3109/0284186X.2014.910313
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Mineo TC, 1998, CHEST, V113, P1402, DOI 10.1378/chest.113.5.1402
   Mitchell AD, 2000, J BONE JOINT SURG BR, V82B, P55, DOI 10.1302/0301 620X.82B1.9020
   Mori T, 2016, J SURG ONCOL, V114, P495, DOI 10.1002/jso.24322
   Müller U, 2016, ACTA RADIOL, V57, P225, DOI 10.1177/0284185115574156
   Navid F, 2008, CANCER, V113, P419, DOI 10.1002/cncr.23586
   Ortiz EJ, 2005, CLIN ORTHOP RELAT R, P116, DOI 10.1097/01.blo.0000155375.88317.6c
   Osasan S, 2016, ANTICANCER RES, V36, P4391, DOI 10.21873/anticanres.10982
   Pakos EE, 2011, J BONE JOINT SURG BR, V93B, P1271, DOI 10.1302/0301 620X.93B9.27166
   Palmerini E, 2014, AM J CLIN ONCOL CANC, V37, P528, DOI 10.1097/COC.0b013e31827defa1
   Papagelopoulos Panayiotis J, 2002, Am J Orthop (Belle Mead NJ), V31, P253
   PICCI P, 1994, J CLIN ONCOL, V12, P2699, DOI 10.1200/JCO.1994.12.12.2699
   Puri A, 2014, CLIN ORTHOP RELAT R, V472, P1568, DOI 10.1007/s11999 013 3385 9
   Reddy KIA, 2015, BONE JOINT J, V97B, P115, DOI 10.1302/0301 620X.97B1.33924
   Ressler S, 2009, ANTICANCER RES, V29, P2579
   Rothermundt C, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2333 y
   Roux S, 2002, AM J CLIN PATHOL, V117, P210
   Sahgal A, 2015, NEURO ONCOLOGY, V17, P889, DOI 10.1093/neuonc/nou347
   Saylors RL, 2001, J CLIN ONCOL, V19, P3463, DOI 10.1200/JCO.2001.19.15.3463
   Schwarz R, 2009, CANCER TREAT RES, V152, P147, DOI 10.1007/978 1 4419 0284 9_7
   Serra M, 2006, INT J ONCOL, V29, P1459
   Shi WY, 2013, AM J CLIN ONCOL CANC, V36, P505, DOI 10.1097/COC.0b013e3182568fb6
   Sobin LH, 2009, TNM CLASSIFICATION M, P153
   Somerfield MPJ., 2000, CLASS PAP CURR COMME, V4, P881
   Stacchiotti S, 2013, ANN ONCOL, V24, P1931, DOI 10.1093/annonc/mdt117
   Stacchiotti S, 2012, J CLIN ONCOL, V30, P914, DOI 10.1200/JCO.2011.35.3656
   Stacchiotti S, 2010, ANN SURG ONCOL, V17, P211, DOI 10.1245/s10434 009 0740 x
   Stokke J, 2015, PEDIATR BLOOD CANCER, V62, P1616, DOI 10.1002/pbc.25514
   Thomas D, 2010, LANCET ONCOL, V11, P815, DOI 10.1016/S1470 2045(10)70170 4
   Traina F, 2015, J BONE JOINT SURG AM, V97A, DOI 10.2106/JBJS.N.00661
   Tse LF, 2008, BONE, V42, P68, DOI 10.1016/j.bone.2007.08.038
   Verstraete KL, 2000, EUR J RADIOL, V34, P229, DOI 10.1016/S0720 048X(00)00202 3
   WINKLER K, 1988, J CLIN ONCOL, V6, P329, DOI 10.1200/JCO.1988.6.2.329
   Wojcik JB, 2014, AM J SURG PATHOL, V38, P1538, DOI 10.1097/PAS.0000000000000265
   Wu JS, 2008, RADIOLOGY, V248, P962, DOI 10.1148/radiol.2483071742
   Yakushiji T, 2009, J MAGN RESON IMAGING, V29, P895, DOI 10.1002/jmri.21703
   Yang YJ, 2004, ARCH PATHOL LAB MED, V128, P759
   Zhang QY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003661
NR 81
TC 41
Z9 43
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344 5704
EI 1432 0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD DEC
PY 2017
VL 80
IS 6
BP 1113
EP 1131
DI 10.1007/s00280 017 3436 0
PG 19
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA FM8RQ
UT WOS:000415357600008
PM 29038849
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Matsushita, M
   Ozaki, Y
   Hasegawa, Y
   Terada, F
   Tabata, N
   Shiheido, H
   Yanagawa, H
   Oikawa, T
   Matsuo, K
   Du, WL
   Yamada, T
   Hozumi, M
   Ichikawa, D
   Hattori, Y
AF Matsushita, Maiko
   Ozaki, Yoshie
   Hasegawa, Yuka
   Terada, Fukiko
   Tabata, Noriko
   Shiheido, Hirokazu
   Yanagawa, Hiroshi
   Oikawa, Tsukasa
   Matsuo, Koichi
   Du, Wenlin
   Yamada, Taketo
   Hozumi, Masashi
   Ichikawa, Daiju
   Hattori, Yutaka
TI A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on
   High Risk Myeloma Cells and Osteoclasts
SO PLOS ONE
LA English
DT Article
ID REFRACTORY MULTIPLE MYELOMA; 2013 UPDATE; NUCLEOPHOSMIN; TARGET;
   LENALIDOMIDE; POMALIDOMIDE; MANAGEMENT; LEUKEMIA; CANCER; STRATIFICATION
AB Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the C max was 2.1 mu M at 1 h after the injection of TC11, with 1.2 h as the half life. TC11 significantly inhibited the differentiation and function of tartrate resistant acid phosphatase (TRAP) positive multinucleated osteoclasts in mouse osteoclast cultures using M CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by alpha tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.
C1 [Matsushita, Maiko; Ozaki, Yoshie; Hasegawa, Yuka; Terada, Fukiko; Hozumi, Masashi; Ichikawa, Daiju; Hattori, Yutaka] Keio Univ, Fac Pharm, Tokyo, Japan.
   [Tabata, Noriko; Shiheido, Hirokazu; Yanagawa, Hiroshi] Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 223, Japan.
   [Oikawa, Tsukasa; Matsuo, Koichi] Keio Univ, Sch Med, Tokyo, Japan.
   [Du, Wenlin; Yamada, Taketo] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan.
C3 Keio University; Keio University; Keio University; Keio University
RP Hattori, Y (通讯作者)，Keio Univ, Fac Pharm, Tokyo, Japan.
EM hattori yt@pha.keio.ac.jp
RI Matsuo, Koichi/AFP 4369 2022; Matsuo, Koichi/K 5695 2012; Wenlin,
   Du/JPL 4333 2023; Oikawa, Tsukasa/B 7718 2013
OI Hattori, Yutaka/0000 0003 1080 9738; Matsuo, Koichi/0000 0002 1490 8955;
   Oikawa, Tsukasa/0000 0003 2694 2699; Shiheido,
   Hirokazu/0000 0002 1415 2019
FU Private University Strategic Research Base Development Program of MEXT
   (Ministry of Education, Culture, Sports, Science and Technology) of
   Japan; Keio Gijuku Academic development Funds; Japan Leukemia Research
   Fund
FX This work was supported in part by a Grant in Aid for Scientific
   Research (Y. Hattori, MM) and a grant from the Private University
   Strategic Research Base Development Program (Y. Hattori) of MEXT (the
   Ministry of Education, Culture, Sports, Science and Technology) of
   Japan, Keio Gijuku Academic development Funds (Y. Hattori) and Japan
   Leukemia Research Fund (Y. Hattori, MM). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparartion of the manuscript.
CR Avet Loiseau H, 2012, J CLIN ONCOL, V30, P1949, DOI 10.1200/JCO.2011.36.5726
   Balusu R, 2011, BLOOD, V118, P3096, DOI 10.1182/blood 2010 09 309674
   Bergsagel PL, 2013, BLOOD, V121, P884, DOI 10.1182/blood 2012 05 432203
   Bird JM, 2011, BRIT J HAEMATOL, V154, P32, DOI 10.1111/j.1365 2141.2011.08573.x
   Chang H, 2010, LEUKEMIA LYMPHOMA, V51, P2084, DOI 10.3109/10428194.2010.524325
   Chesi M, 2013, INT J HEMATOL, V97, P313, DOI 10.1007/s12185 013 1291 2
   Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646
   Du WL, 2007, BLOOD, V109, P3042, DOI 10.1182/blood 2006 02 003103
   Ebert BL, 2011, SEMIN ONCOL, V38, P621, DOI 10.1053/j.seminoncol.2011.04.010
   Estey EH, 2013, AM J HEMATOL, V88, P317, DOI 10.1002/ajh.23404
   Falini B, 2009, LEUKEMIA, V23, P1731, DOI 10.1038/leu.2009.124
   Falini B, 2011, BLOOD REV, V25, P247, DOI 10.1016/j.blre.2011.06.001
   Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885
   Hattori Y, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.13
   Ito T, 2011, CELL MOL LIFE SCI, V68, P1569, DOI 10.1007/s00018 010 0619 9
   Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319
   Lacy MQ, 2011, CURR HEMATOL MALIG R, V6, P120, DOI 10.1007/s11899 011 0077 y
   Lee HH, 2007, PROTEINS, V69, P672, DOI 10.1002/prot.21504
   Li J, 2006, J BIOL CHEM, V281, P16536, DOI 10.1074/jbc.M601386200
   Lindstrom M.S., 2011, BIOCHEM RES INT, V2011, P195
   Lopez Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119
   Mateos MV, 2011, BLOOD, V118, P4547, DOI 10.1182/blood 2011 04 345801
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McCurdy AR, 2013, THER ADV HEMATOL, V4, P211, DOI 10.1177/2040620713480155
   Modi ND, 2012, LEUKEMIA, V26, P589, DOI 10.1038/leu.2011.282
   NAMBA M, 1989, IN VITRO CELL DEV B, V25, P723
   Oikawa T, 2012, J CELL BIOL, V197, P553, DOI 10.1083/jcb.201111116
   Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092 8674(00)00093 3
   Pan BQ, 2012, PHARMACOL THERAPEUT, V136, P56, DOI 10.1016/j.pharmthera.2012.07.004
   Perez EA, 2009, MOL CANCER THER, V8, P2086, DOI 10.1158/1535 7163.MCT 09 0366
   Qi W, 2008, ONCOGENE, V27, P4210, DOI 10.1038/onc.2008.54
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Rajkumar SV, 2013, AM J HEMATOL, V88, P225, DOI 10.1002/ajh.23390
   Sawyer JR, 2011, CANCER GENET NY, V204, P3, DOI 10.1016/j.cancergencyto.2010.11.002
   Shiheido H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038878
   Siegel DS, 2012, SEMIN HEMATOL, V49, pS3, DOI 10.1053/j.seminhematol.2012.05.005
   Spagnuolo PA, 2010, BLOOD, V115, P4824, DOI 10.1182/blood 2009 09 243055
   Terpos E, 2013, ONCOTARGETS THER, V6, P531, DOI 10.2147/OTT.S34498
   Weinhold N, 2010, GENE CHROMOSOME CANC, V49, P333, DOI 10.1002/gcc.20745
   Zangari M, 2012, CANCER TREAT REV, V38, P968, DOI 10.1016/j.ctrv.2011.12.007
   Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood 2011 05 356063
NR 41
TC 9
Z9 9
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JAN 24
PY 2015
VL 10
IS 1
AR e0116135
DI 10.1371/journal.pone.0116135
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CC4PT
UT WOS:000350336000008
PM 25617756
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Tsubaki, M
   Kato, C
   Nishinobo, M
   Ogaki, M
   Satou, T
   Ito, T
   Kusunoki, T
   Fujiwara, K
   Yamazoe, Y
   Nishida, S
AF Tsubaki, Masanobu
   Kato, Chisato
   Nishinobo, Minori
   Ogaki, Mitsuhiko
   Satou, Takao
   Ito, Tatsuki
   Kusunoki, Takashi
   Fujiwara, Kimiko
   Yamazoe, Yuzuru
   Nishida, Shozo
TI Nitrogen containing bisphosphonate, YM529/ONO 5920, inhibits macrophage
   inflammatory protein 1α expression and secretion in mouse myeloma cells
SO CANCER SCIENCE
LA English
DT Article
ID MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; CAUSES APOPTOSIS; PROTEIN
   1 ALPHA; BONE DISEASE; SURVIVAL; CANCER; RECRUITMENT; OSTEOCLASTS;
   MECHANISMS; CCR1
AB Macrophage inflammatory protein 1 alpha (MIP 1 alpha) is detected at high concentrations in patients with multiple myeloma, and it is thought to play an important role in the etiology of multiple myeloma and osteolysis. Thus, we investigated whether or not YM529/ONO 5920, a new bisphosphonate, inhibited MIP 1 alpha mRNA expression in, and MIP 1 alpha secretion from, mouse myeloma cells. When the cells were stimulated by lipopolysaccharide, increased MIP 1 alpha mRNA expression and MIP 1 alpha secretion were observed. YM529/ONO 5920 inhibited MIP 1 alpha mRNA expression and MIP 1 alpha secretion in a concentration dependent manner. A transient increase in the phosphorylation of extracellular regulated kinase 1/2 (ERK1/2) and Akt was observed after lipopolysaccharide stimulation. After YM529/ONO 5920 was given, there was no transient increase in the phosphorylation of ERK1/2 or Akt. These results indicated that YM529/ONO 5920 inhibited the expression and secretion of MIP 1 alpha through blocking the signaling pathway of the Ras/mitogen activated protein kinase kinase/ERK and Ras/phosphatidylinositol 3 kinase/Akt. Accordingly, YM529/ONO 5920 appears to have promise for use in effective future therapy for osteolysis and myeloma cell growth that depends on MIP 1 alpha.
C1 Kinki Univ, Sch Pharm, Div Pharmacotherapy, Higashiosaka, Osaka 5778502, Japan.
   Kinki Univ, Sch Med, Dept Pathol, Okayama, Osaka 5898511, Japan.
   Kinki Univ, Sch Med, Dept Otolaryngol, Osakasayama, Osaka 5898511, Japan.
   Kinki Univ Hosp, Dept Pharm, Osakasayama, Osaka 5898511, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University); Kindai University (Kinki University); Kindai University
   (Kinki University)
RP Nishida, S (通讯作者)，Kinki Univ, Sch Pharm, Div Pharmacotherapy, Higashiosaka, Osaka 5778502, Japan.
EM nishida@phar.kindai.ac.jp
RI 正寛, 椿/JDF 1457 2023; Kusunoki, Takashi/AAE 5512 2019
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Caraglia M, 2006, ENDOCR RELAT CANCER, V13, P7, DOI 10.1677/erc.1.01094
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   Choi SJ, 2000, BLOOD, V96, P671
   Ciesielski CJ, 2002, EUR J IMMUNOL, V32, P2037, DOI 10.1002/1521 4141(200207)32:7<2037::AID IMMU2037>3.0.CO;2 I
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gordon S, 2002, BRIT J HAEMATOL, V119, P475, DOI 10.1046/j.1365 2141.2002.03824.x
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood 2002 08 2640
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092 8674(02)00827 9
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Nishida S, 2003, LIFE SCI, V73, P2655, DOI 10.1016/S0024 3205(03)00664 7
   Oba Y, 2005, EXP HEMATOL, V33, P272, DOI 10.1016/j.exphem.2004.11.015
   Roodman GD, 2002, J BONE MINER RES, V17, P1921, DOI 10.1359/jbmr.2002.17.11.1921
   Segawa H, 2005, LEUKEMIA RES, V29, P451, DOI 10.1016/j.leukres.2004.10.004
   Shipman CM, 1998, CANCER RES, V58, P5294
   Terpos E, 2003, BRIT J HAEMATOL, V123, P106, DOI 10.1046/j.1365 2141.2003.04561.x
   Winding B, 2000, J CANCER RES CLIN, V126, P631, DOI 10.1007/PL00008475
   Xu HM, 2003, J BIOL CHEM, V278, P36334, DOI 10.1074/jbc.M305698200
   Yamagishi S, 2004, AM J PATHOL, V165, P1865, DOI 10.1016/S0002 9440(10)63239 7
   Yu XF, 2004, J BONE MINER RES, V19, P2065, DOI 10.1359/JBMR.040910
NR 24
TC 16
Z9 17
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1347 9032
EI 1349 7006
J9 CANCER SCI
JI Cancer Sci.
PD JAN
PY 2008
VL 99
IS 1
BP 152
EP 158
DI 10.1111/j.1349 7006.2007.00651.x
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 239FD
UT WOS:000251503300021
PM 17979996
OA Green Published
DA 2025 08 17
ER

PT J
AU Huang, Q
   Hao, LY
   Xie, J
   Zhang, CL
   Lin, Y
AF Huang, Qian
   Hao, Liying
   Xie, Jing
   Zhang, Chaoliang
   Lin, Yunfeng
TI Morphologically Controlled Synthesis of Hydroxyapatite and Its
   Bioactivity on Osteoblast Cells
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE Hydroxyapatite; Osteoblast; Controlled Synthesis; In Vitro Study
ID HYDROTHERMAL SYNTHESIS; HOLLOW MICROSPHERES; PROTEIN ADSORPTION;
   TITANIUM SURFACE; DRUG RELEASE; CALCIUM; NANOSTRUCTURES; BIOCERAMICS;
   TEMPLATE; GROWTH
AB Surface morphology has great influence on bioactivity of materials. It is important to understand biological responses of materials via structured surface design, which is essential for development of bioactive bone repair materials. Herein, different morphologies of hydroxyapatite were obtained by soft templates in a hydrothermal process. The morphology of the hydroxyapatite was modified from nanorods to flake like and dandelion like shapes by using cetyltrimethyl ammonium bromide, ammonium tartrate and trisodium citrate, respectively. After characterized these obtained materials, cell proliferation, adhesion and staining experiments were then carried out to evaluate the biocompatibility of the obtained materials. As a result, the rod like shaped hydroxyapatite showed the best cellular biocompatibility and cell proliferation. Possible reaction mechanisms between the cells and materials were also proposed in this study.
C1 [Huang, Qian; Hao, Liying; Xie, Jing; Zhang, Chaoliang; Lin, Yunfeng] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
C3 Sichuan University
RP Lin, Y (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
RI Huang, Qian/A 4019 2017; Lin, Yunfeng/H 3393 2011; Xie, Jing/P 6112 2014
OI Lin, Yunfeng/0000 0003 1224 6561; Xie, Jing/0000 0001 8156 0322
FU National Natural Science Foundation of China [81470721, 31170929];
   Sichuan Province Science and technology support program [2014SZ0019 3]
FX This work was funded by Funding of National Natural Science Foundation
   of China (81470721, 31170929), Funding of Sichuan Province Science and
   technology support program (2014SZ0019 3).
CR Bharath G, 2014, RSC ADV, V4, P37446, DOI 10.1039/c4ra06929c
   BLAKESLEE KC, 1971, J AM CERAM SOC, V54, P559, DOI 10.1111/j.1151 2916.1971.tb12207.x
   Cai YR, 2007, CHEM MATER, V19, P3081, DOI 10.1021/cm070298t
   Cheng ZH, 1998, J CHEM SOC FARADAY T, V94, P1501
   Cölfen H, 2010, NAT MATER, V9, P960, DOI 10.1038/nmat2911
   Corami A, 2007, J HAZARD MATER, V146, P164, DOI 10.1016/j.jhazmat.2006.12.003
   Dorozhkin SV, 2002, ANGEW CHEM INT EDIT, V41, P3130, DOI 10.1002/1521 3773(20020902)41:17<3130::AID ANIE3130>3.0.CO;2 1
   Eliaz N, 2007, J BIOMED MATER RES A, V80A, P621, DOI 10.1002/jbm.a.30944
   Fisher MB, 2013, TISSUE ENG PART B RE, V19, P1, DOI [10.1089/ten.TEB.2012.0723, 10.1089/ten.teb.2012.0723]
   Gopi D, 2013, B MATER SCI, V36, P799, DOI 10.1007/s12034 013 0540 6
   Guo XH, 2011, NEW J CHEM, V35, P663, DOI 10.1039/c0nj00708k
   He G, 2014, CELL PROLIFERAT, V47, P258, DOI 10.1111/cpr.12105
   HENCH LL, 1991, J AM CERAM SOC, V74, P1487, DOI 10.1111/j.1151 2916.1991.tb07132.x
   Hutchens SA, 2006, BIOMATERIALS, V27, P4661, DOI 10.1016/j.biomaterials.2006.04.032
   Jiang SD, 2012, J PHYS CHEM C, V116, P4484, DOI 10.1021/jp211648x
   JORIS SJ, 1971, J PHYS CHEM US, V75, P3172, DOI 10.1021/j100689a025
   Kikuchi M, 2001, BIOMATERIALS, V22, P1705, DOI 10.1016/S0142 9612(00)00305 7
   Komlev VS, 2002, BIOMATERIALS, V23, P3449, DOI 10.1016/S0142 9612(02)00049 2
   Lin KL, 2013, ACS APPL MATER INTER, V5, P8008, DOI 10.1021/am402089w
   Liu JB, 2003, CERAM INT, V29, P629, DOI 10.1016/S0272 8842(02)00210 9
   Liu XH, 2011, NAT MATER, V10, P398, DOI [10.1038/NMAT2999, 10.1038/nmat2999]
   Ma MG, 2009, EUR J INORG CHEM, P5522, DOI 10.1002/ejic.200900839
   Ma YJ, 2014, J INORG MATER, V29, P284, DOI 10.3724/SP.J.1077.2014.13271
   Tari NE, 2011, MATER CHEM PHYS, V131, P132, DOI 10.1016/j.matchemphys.2011.07.078
   TheinHan WW, 2013, BONE RES, V1, P371, DOI 10.4248/BR201304008
   Wang P, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.17
   Wang YJ, 2006, MATER LETT, V60, P1484, DOI 10.1016/j.matlet.2005.11.053
   Wang YS, 2009, J COLLOID INTERF SCI, V339, P69, DOI 10.1016/j.jcis.2009.07.023
   Wu Y, 2011, BIOMATERIALS, V32, P951, DOI 10.1016/j.biomaterials.2010.10.001
   Yang H, 2013, RSC ADV, V3, P23184, DOI 10.1039/c3ra44839h
   Yang H, 2013, MATER CHEM PHYS, V141, P488, DOI 10.1016/j.matchemphys.2013.05.048
   Yang LX, 2012, CERAM INT, V38, P495, DOI 10.1016/j.ceramint.2011.07.033
   Yang PP, 2008, BIOMATERIALS, V29, P4341, DOI 10.1016/j.biomaterials.2008.07.042
   Zhao XY, 2013, CRYSTENGCOMM, V15, P7926, DOI 10.1039/c3ce41255e
   Zhao XY, 2013, CRYSTENGCOMM, V15, P206, DOI 10.1039/c2ce26315g
NR 35
TC 5
Z9 5
U1 1
U2 32
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 1533 4880
EI 1533 4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD JUL
PY 2016
VL 16
IS 7
BP 6978
EP 6985
DI 10.1166/jnn.2016.11387
PG 8
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA EB1HM
UT WOS:000387100400050
DA 2025 08 17
ER

PT J
AU Schwaneck, EC
   Streit, A
   Krone, M
   Hartmann, S
   Müller Richter, U
   Kübler, AC
   Gadeholt, O
   Schmalzing, M
   Tony, HP
   Brands, RC
AF Schwaneck, E. C.
   Streit, A.
   Krone, M.
   Hartmann, S.
   Mueller Richter, U.
   Kuebler, A. C.
   Gadeholt, O.
   Schmalzing, M.
   Tony, H.  P.
   Brands, R. C.
TI Osteoporosis therapy in patients with inflammatory rheumatic diseases
   and osteonecrosis of the jaw
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA English
DT Article
DE Antiresorptive therapy; MRONJ; BONJ; Bisphosphonates; Dental care
ID BISPHOSPHONATE RELATED OSTEONECROSIS; MEDICATION RELATED OSTEONECROSIS;
   AVASCULAR NECROSIS; RISK; ARTHRITIS; COMORBIDITIES; ASSOCIATION;
   PREVALENCE; MECHANISMS
AB Background and objectives The aim of the present study was to assess the prevalence of medication related osteonecrosis of the jaw (MRONJ) in osteoporosis patients suffering from inflammatory rheumatic diseases, as well as to assess the prevalence of relevant dental, behavioral, and medical risk factors for MRONJ. Materials and methods A total of 198 patients with inflammatory rheumatic diseases and osteoporosis therapy were recruited from a tertiary rheumatological/immunological referral center between June 2015 and September 2016. They were assessed using a structured interview. A maxillofacial surgeon later examined patients complaining of possible symptoms of osteonecrosis. In cases of osteonecrosis, dental records were obtained and evaluated. Preventive measures taken and dental as well as other clinical risk factors were evaluated. Results Of the 198 patients, three suffered from osteonecrosis of the jaw, none of whom had any history of malignant disease or radiation therapy, resulting in a prevalence of 1.5%. Of these three patients, only one was given bisphosphonates intravenously (i.v.), whereas all three had been treated orally. All three diagnoses of MRONJ had been previously known to the patients and their maxillofacial surgeons. Two of the patients had rheumatoid arthritis, and one patient suffered from large vessel vasculitis. Long anti osteoporotic treatment duration, low functional status, and low bone density of the femur were significantly associated with MRONJ development. Conclusion Inflammatory rheumatic diseases constitute a risk factor for MRONJ in patients treated with bisphosphonates for osteoporosis. Patients should be counseled accordingly and should be offered dental screening and regular dental check ups.
C1 [Schwaneck, E. C.; Streit, A.; Gadeholt, O.; Schmalzing, M.; Tony, H.  P.] Univ Hosp Wurzburg, Dept Rheumatol & Immunol, Oberdurrbacher Str 6, D 97080 Wurzburg, Germany.
   [Krone, M.] Univ Wurzburg, Inst Hyg & Microbiol, Wurzburg, Germany.
   [Hartmann, S.; Mueller Richter, U.; Kuebler, A. C.; Brands, R. C.] Univ Hosp Wurzburg, Dept Oral & Maxillofacial Plast Surg, Wurzburg, Germany.
C3 University of Wurzburg; University of Wurzburg; University of Wurzburg
RP Schwaneck, EC (通讯作者)，Univ Hosp Wurzburg, Dept Rheumatol & Immunol, Oberdurrbacher Str 6, D 97080 Wurzburg, Germany.
EM Schwaneck_E@ukw.de
RI Krone, Manuel/AFA 9276 2022; Gadeholt, Ottar/AAM 1030 2021; Kübler,
   Alexander/ABA 9297 2021
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Bieniek J, 2016, CLIN INTERV AGING, V11, P453, DOI 10.2147/CIA.S101369
   Bonomi M, 2010, MED ONCOL, V27, P224, DOI 10.1007/s12032 009 9195 y
   Di Fede O, 2016, ORAL DIS, V22, P543, DOI 10.1111/odi.12490
   Dougados M, 2016, CURR OPIN RHEUMATOL, V28, P282, DOI 10.1097/BOR.0000000000000267
   Dougados M, 2014, ANN RHEUM DIS, V73, P62, DOI 10.1136/annrheumdis 2013 204223
   Fleisher KE, 2013, J ORAL MAXIL SURG, V71, P513, DOI 10.1016/j.joms.2012.07.049
   Hong SO, 2017, CLIN ORAL INVEST, V21, P1905, DOI 10.1007/s00784 016 1973 2
   Jansen JP, 2011, SEMIN ARTHRITIS RHEU, V40, P275, DOI 10.1016/j.semarthrit.2010.06.001
   Jarnbring F, 2015, BRIT J ORAL MAX SURG, V53, P1007, DOI 10.1016/j.bjoms.2015.10.006
   Jeong HG, 2017, IMAGNG SCI DENT, V47, P41, DOI 10.5624/isd.2017.47.1.45
   Kos M, 2010, J CRANIO MAXILL SURG, V38, P255, DOI 10.1016/j.jcms.2009.06.005
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   Lo JC, 2010, J ORAL MAXIL SURG, V68, P243, DOI 10.1016/j.joms.2009.03.050
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mönkkönen H, 2007, LIFE SCI, V81, P1066, DOI 10.1016/j.lfs.2007.08.007
   Pischon N, 2016, J PERIODONTOL, V87, P763, DOI 10.1902/jop.2016.150475
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Poxleitner P, 2017, DTSCH ARZTEBL INT, V114, P63, DOI 10.3238/arztebl.2017.0063
   Räikkönen J, 2009, BRIT J PHARMACOL, V157, P427, DOI 10.1111/j.1476 5381.2009.00160.x
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Richter A, 2016, ANN RHEUM DIS, V75, P1667, DOI 10.1136/annrheumdis 2015 207838
   Ringe JD, 2010, RHEUMATOL INT, V30, P863, DOI 10.1007/s00296 009 1311 y
   Rogers SN, 2015, BRIT J ORAL MAX SURG, V53, P176, DOI 10.1016/j.bjoms.2014.11.008
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Smitten AL, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2404
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Walter C, 2010, HEAD FACE MED, V6, DOI 10.1186/1746 160X 6 11
   Wang CC, 2016, J WOMENS HEALTH, V25, P738, DOI 10.1089/jwh.2015.5617
NR 32
TC 3
Z9 3
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 0340 1855
EI 1435 1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
PD MAR
PY 2020
VL 79
IS 2
SI SI
BP 203
EP 209
DI 10.1007/s00393 019 0606 y
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA KR9VH
UT WOS:000517960600012
PM 30796524
DA 2025 08 17
ER

PT J
AU Kita, M
   Ohishi, N
   Washida, K
   Kondo, M
   Koyama, T
   Yamada, K
   Uemura, D
AF Kita, M
   Ohishi, N
   Washida, K
   Kondo, M
   Koyama, T
   Yamada, K
   Uemura, D
TI Symbioimine and neosymbioimine, amphoteric iminium metabolites from the
   symbiotic marine dinoflagellate Symbiodinium sp.*
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE symbioimine; neosymbioimine; iminium metabolite; inhibition of
   osteoclasts differentiation; COX 2
ID ZOOXANTHELLATOXIN A; OSTEOCLAST DIFFERENTIATION; POLYHYDROXY METABOLITE;
   LACTONE; TOXIN
AB Two amphoteric iminium metabolites, symbioimine (1) and neosymbioimine (2), were isolated from a cultivated symbiotic marine dinoflagellate Symbiodinium sp. Compounds I and 2 have a characteristic 6,6,6 tricyclic iminium ring structure and an aryl sulfate moiety. The plausible biogenetic pathway of I and 2 can be explained by an intramolecular Diels Alder reaction followed by imine cyclization. Symbioimine (1) inhibited the differentiation of RAW264 cells into osteoclasts (EC50 = 44 mu M), and significantly inhibited cyclooxygenase 2 activity at 10 mu M. Thus, symbioimine is a potent anti resorptive and anti inflammatory drug. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Nagoya Univ, Grad Sch Sci, Dept Chem, Nagoya, Aichi 4648602, Japan.
   Nagoya Univ, Grad Sch Sci, Res Ctr Mat Sci, Nagoya, Aichi 4648602, Japan.
C3 Nagoya University; Nagoya University
RP Uemura, D (通讯作者)，Nagoya Univ, Grad Sch Sci, Dept Chem, Nagoya, Aichi 4648602, Japan.
EM uemura@chem3.chem.nagoya u.ac.jp
CR BLANK RJ, 1985, SCIENCE, V229, P656, DOI 10.1126/science.229.4714.656
   Chou T, 1996, TETRAHEDRON LETT, V37, P4027, DOI 10.1016/0040 4039(96)00753 8
   Chou T, 1996, TETRAHEDRON LETT, V37, P4023, DOI 10.1016/0040 4039(96)00752 6
   Gerwick WH, 2001, ALKALOIDS, V57, P75, DOI 10.1016/S0099 9598(01)57003 0
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   HU TM, 1995, J CHEM SOC CHEM COMM, P2159, DOI 10.1039/c39950002159
   Kita M, 2005, CHEM LETT, V34, P454, DOI 10.1246/cl.2005.454
   Kita M, 2004, J AM CHEM SOC, V126, P4794, DOI 10.1021/ja049277f
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lu CK, 2001, TETRAHEDRON LETT, V42, P1713, DOI 10.1016/S0040 4039(00)02331 5
   NAKAMURA H, 1995, J AM CHEM SOC, V117, P550, DOI 10.1021/ja00106a071
   NAKAMURA H, 1995, TETRAHEDRON LETT, V36, P7255, DOI 10.1016/0040 4039(95)01503 A
   NAKAMURA H, 1993, J ORG CHEM, V58, P313, DOI 10.1021/jo00054a009
   Onodera K, 2003, TETRAHEDRON, V59, P1067, DOI 10.1016/S0040 4020(02)01630 7
   Onodera KI, 2004, BIOSCI BIOTECH BIOCH, V68, P955, DOI 10.1271/bbb.68.955
   Reddy BS, 2000, CANCER RES, V60, P293
   ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348
   Sammakia T, 2005, J AM CHEM SOC, V127, P6504, DOI 10.1021/ja043506g
   SEKI T, 1995, TETRAHEDRON LETT, V36, P7093, DOI 10.1016/0040 4039(95)01434 J
   Shimizu Y, 2003, CURR OPIN MICROBIOL, V6, P236, DOI 10.1016/S1369 5274(03)00064 X
   Shimizu Y, 1996, ANNU REV MICROBIOL, V50, P431, DOI 10.1146/annurev.micro.50.1.431
   SHIMIZU Y, 1993, CHEM REV, V93, P1685, DOI 10.1021/cr00021a002
   SODA H, 1998, P NATL ACAD SCI USA, V95, P3597
   Takada N, 2001, TETRAHEDRON LETT, V42, P3495, DOI 10.1016/S0040 4039(01)00478 6
   Takada N, 2001, TETRAHEDRON LETT, V42, P3491, DOI 10.1016/S0040 4039(01)00480 4
   TORIGOE K, 1988, J AM CHEM SOC, V110, P7876, DOI 10.1021/ja00231a048
   TRENCH RK, 1981, PURE APPL CHEM, V53, P819, DOI 10.1351/pac198153040819
   UEMURA D, 1995, J AM CHEM SOC, V117, P1155, DOI 10.1021/ja00108a043
   UMERA D, 1991, ANTITUMOR POLYETHERS, V4, P1
   VANE J, 1994, NATURE, V367, P215, DOI 10.1038/367215a0
   Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563
   Watanabe R, 2002, TETRAHEDRON LETT, V43, P6501, DOI 10.1016/S0040 4039(02)01495 8
NR 32
TC 51
Z9 60
U1 0
U2 10
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD SEP 1
PY 2005
VL 13
IS 17
BP 5253
EP 5258
DI 10.1016/j.bmc.2005.05.064
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 957AP
UT WOS:000231341900030
PM 16009558
DA 2025 08 17
ER

PT J
AU Ahmad, T
   Byun, H
   Lee, J
   Perikamana, SKM
   Shin, YM
   Kim, EM
   Shin, H
AF Ahmad, Taufiq
   Byun, Hayeon
   Lee, Jinkyu
   Perikamana, Sajeesh Kumar Madhurakat
   Shin, Young Min
   Kim, Eun Mi
   Shin, Heungsoo
TI Stem cell spheroids incorporating fibers coated with adenosine and
   polydopamine as a modular building blocks for bone tissue engineering
SO BIOMATERIALS
LA English
DT Article
DE AP FF; Adenosine ligand; A2bR signaling; Osteogenic differentiation;
   Spheroids; Bone microenvironment; Stem cell delivery; Bone tissue
   engineering
ID OSTEOGENIC DIFFERENTIATION; MORPHOGENETIC PROTEIN 2; REGENERATIVE
   MEDICINE; FACTOR DELIVERY; OSTEOBLASTS; SCAFFOLDS; ORGANOGENESIS;
   OPPORTUNITIES; PROLIFERATION; BIOMATERIALS
AB Although stem cell spheroids offer great potential as functional building blocks for bottom up bone tissue engineering, delivery of bioactive signals remain challenging. Here, we engineered adenosine ligand modified fiber fragments to create a 3D cell instructive microenvironment for bone. Briefly, the Poly(? lactic acid) (PLLA) nanofiber sheet was partially degraded into fragmented fibers (FFs) through aminolysis and adenosine was stably incorporated via one step polydopamine coating. The SEM and XPS analysis demonstrated that polydopamine assisted adenosine coating efficiency was significantly increased, which led to high coating efficiency of adenosine and its significant retention. The engineered fibers were then assembled into stable spheroids with human adipose derived stem cells (hADSCs). The adenosine in the spheroids effectively stimulated A2bR (1.768 +/  0.08) signaling, which further significantly induced the expression of osteogenic markers such as Runx2 (3.216 +/  0.25), OPN (4.136 +/  0.14), OCN (10.16 +/  0.34), and OSX (2.27 +/  0.11) with improved mineral deposition (1.375 +/  0.05 mu g per spheroid). In contrast, the adipogenic differentiation of hADSCs was significantly suppressed within the engineered spheroids. Transplantation of engineered spheroids strongly induced osteogenic differentiation of hADSCs in ectopic subcutaneous tissue. Finally, the bone regeneration was significantly enhanced by implanting AP FF group (59.97 +/  18.33%) as compared to P FF (27.96 +/  11.14) and defect only (7.97 +/  3.76%). We propose that stem cell spheroids impregnated with engineered fibers enabling adenosine delivery could be promising building blocks for a bottom up approach to create large tissues for regeneration of damaged bone.
C1 [Ahmad, Taufiq; Byun, Hayeon; Lee, Jinkyu; Perikamana, Sajeesh Kumar Madhurakat; Shin, Young Min; Kim, Eun Mi; Shin, Heungsoo] Hanyang Univ, Dept Bioengn, 222 Wangsimni Ro, Seoul 04763, South Korea.
   [Ahmad, Taufiq; Byun, Hayeon; Lee, Jinkyu; Perikamana, Sajeesh Kumar Madhurakat; Kim, Eun Mi; Shin, Heungsoo] BK21 Plus Future Biopharmaceut Human Resources Tr, 222 Wangsimni Ro, Seoul 04763, South Korea.
C3 Hanyang University
RP Shin, H (通讯作者)，Hanyang Univ, Dept Bioengn, 222 Wangsimni Ro, Seoul 04763, South Korea.
EM hshin@hanyang.ac.kr
RI Lee, Jinkyu/GXV 5369 2022; Ahmad, Taufiq/AAC 2885 2019; Kim,
   Eun/AAO 2742 2021
OI Ahmad, Taufiq/0000 0001 8435 4962; Shin, Young Min/0000 0002 8818 454X;
   Kim, Eun Mi/0000 0002 7131 9049
FU National Research Foundation of Republic of Korea   Korean government
   [NRF 2019R1A2C2084965, NRF 2018M3C1B7021994]
FX This research was supported by National Research Foundation of Republic
   of Korea grant funded by the Korean government (Grant Nos.
   NRF 2019R1A2C2084965 and NRF 2018M3C1B7021994).
CR Costa MA, 2011, J CELL PHYSIOL, V226, P1353, DOI 10.1002/jcp.22458
   Ahmad T, 2018, J IND ENG CHEM, V67, P80, DOI 10.1016/j.jiec.2018.06.017
   Ahmad T, 2018, ACTA BIOMATER, V74, P464, DOI 10.1016/j.actbio.2018.05.035
   Ahmad T, 2017, ACTA BIOMATER, V64, P161, DOI 10.1016/j.actbio.2017.10.022
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   [Anonymous], ARXIV150300178
   Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Ashammakhi N, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801048
   Azevedo HS, 2015, ADV DRUG DELIVER REV, V94, P63, DOI 10.1016/j.addr.2015.08.003
   Bernhard A, 2013, OSTEOPOROSIS INT, V24, P2671, DOI 10.1007/s00198 013 2374 x
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74
   Bodle JC, 2011, TISSUE ENG PART B RE, V17, P195, DOI [10.1089/ten.TEB.2010.0738, 10.1089/ten.teb.2010.0738]
   Bratt Leal AM, 2011, BIOMATERIALS, V32, P48, DOI 10.1016/j.biomaterials.2010.08.113
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Chen F, 2016, LANGMUIR, V32, P12119, DOI 10.1021/acs.langmuir.6b03294
   Cheng NC, 2012, BIOMATERIALS, V33, P1748, DOI 10.1016/j.biomaterials.2011.11.049
   Copeland KL, 2013, J PHYS CHEM B, V117, P14001, DOI 10.1021/jp408027j
   Cui X, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2016.0877
   Dang M, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0025 8
   Dang PN, 2016, ACS BIOMATER SCI ENG, V2, P30, DOI 10.1021/acsbiomaterials.5b00277
   Dang PN, 2016, STEM CELL TRANSL MED, V5, P206, DOI 10.5966/sctm.2015 0115
   Ding Y H, 2016, Biosurf Biotribol, V2, P121, DOI 10.1016/j.bsbt.2016.11.001
   Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573
   Elbert DL, 2011, CURR OPIN BIOTECH, V22, P674, DOI 10.1016/j.copbio.2011.04.001
   Fan HL, 2015, SOFT MATTER, V11, P4621, DOI 10.1039/c5sm00732a
   Gharibi B, 2011, J BONE MINER RES, V26, P2112, DOI 10.1002/jbmr.424
   Grapin Botton A, 2016, DIABETES OBES METAB, V18, P33, DOI 10.1111/dom.12720
   Guven S, 2015, TRENDS BIOTECHNOL, V33, P269, DOI 10.1016/j.tibtech.2015.02.003
   Ham Jack, 2012, Front Endocrinol (Lausanne), V3, P113
   Han YS, 2010, JOINT BONE SPINE, V77, P27, DOI 10.1016/j.jbspin.2009.05.013
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Hwang NS, 2008, ADV DRUG DELIVER REV, V60, P199, DOI 10.1016/j.addr.2007.08.036
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Kang HM, 2017, BIOMATERIALS, V149, P12, DOI 10.1016/j.biomaterials.2017.09.035
   Kang HM, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600691
   Kang SM, 2012, ADV FUNCT MATER, V22, P2949, DOI 10.1002/adfm.201200177
   Kao R, 2012, ENDOCRINE, V42, P622, DOI 10.1007/s12020 012 9717 9
   Kazemzadeh Narbat M, 2015, J DRUG TARGET, V23, P580, DOI 10.3109/1061186X.2015.1058803
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Leferink A, 2014, ADV MATER, V26, P2592, DOI 10.1002/adma.201304539
   Li CM, 2006, BIOMATERIALS, V27, P3115, DOI 10.1016/j.biomaterials.2006.01.022
   Lim JJ, 2011, ACTA BIOMATER, V7, P986, DOI 10.1016/j.actbio.2010.10.009
   Lin HS, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa663b
   Lopez CD, 2019, ADV DRUG DELIVER REV, V146, P240, DOI 10.1016/j.addr.2018.06.010
   Lu TL, 2013, INT J NANOMED, V8, P337, DOI 10.2147/IJN.S38635
   Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Mehta G, 2012, J CONTROL RELEASE, V164, P192, DOI 10.1016/j.jconrel.2012.04.045
   Midha S, 2019, J TISSUE ENG REGEN M, V13, P925, DOI 10.1002/term.2847
   Mu Q, 2014, ANALYST, V139, P93, DOI 10.1039/c3an01592k
   Nichol JW, 2009, SOFT MATTER, V5, P1312, DOI 10.1039/b814285h
   Nijhuis AWG, 2013, TISSUE ENG PART C ME, V19, P610, DOI [10.1089/ten.tec.2012.0313, 10.1089/ten.TEC.2012.0313]
   Onoe H, 2015, DRUG DISCOV TODAY, V20, P236, DOI 10.1016/j.drudis.2014.10.018
   Oryan A, 2017, CELLS TISSUES ORGANS, V204, P59, DOI 10.1159/000469704
   Ovsianikov A, 2018, TRENDS BIOTECHNOL, V36, P348, DOI 10.1016/j.tibtech.2018.01.005
   Perikamana SKM, 2015, ACS APPL MATER INTER, V7, P8798, DOI 10.1021/acsami.5b01340
   Ryu JH, 2018, ACS APPL MATER INTER, V10, P7523, DOI 10.1021/acsami.7b19865
   Samorezov JE, 2015, ADV DRUG DELIVER REV, V84, P45, DOI 10.1016/j.addr.2014.11.018
   Sasai Y, 2013, CELL STEM CELL, V12, P520, DOI 10.1016/j.stem.2013.04.009
   Scott MA, 2012, STEM CELLS DEV, V21, P655, DOI 10.1089/scd.2011.0517
   Shih YRV, 2014, P NATL ACAD SCI USA, V111, P990, DOI 10.1073/pnas.1321717111
   Tian HJ, 2017, CYTOKINE GROWTH F R, V34, P73, DOI 10.1016/j.cytogfr.2017.01.002
   Tiruvannamalai Annamalai R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084287
   Vavken J, 2016, EUR SPINE J, V25, P3979, DOI 10.1007/s00586 015 3870 9
   Winkler T, 2018, BONE JOINT RES, V7, P232, DOI 10.1302/2046 3758.73.BJR 2017 0270.R1
   Yang ZG, 2017, ACM T INTERNET TECHN, V17, DOI 10.1145/3015463
   Yu X, 2014, ANGEW CHEM INT EDIT, V53, P12600, DOI 10.1002/anie.201404947
   Zhang C, 2017, ACS APPL MATER INTER, V9, P34356, DOI 10.1021/acsami.7b11092
NR 68
TC 65
Z9 66
U1 1
U2 106
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2020
VL 230
AR 119652
DI 10.1016/j.biomaterials.2019.119652
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA KE7QQ
UT WOS:000508746600024
PM 31787333
DA 2025 08 17
ER

PT J
AU Sahu, S
   Sahoo, S
   Sullivan, T
   O'Sullivan, TN
   Turan, S
   Albaugh, ME
   Burkett, S
   Tran, B
   Salomon, DS
   Kozlov, SV
   Koehler, KR
   Jolly, MK
   Sharan, SK
AF Sahu, Sounak
   Sahoo, Sarthak
   Sullivan, Teresa
   O'Sullivan, T. Norene
   Turan, Sevilay
   Albaugh, Mary E.
   Burkett, Sandra
   Tran, Bao
   Salomon, David S.
   V. Kozlov, Serguei
   Koehler, Karl R.
   Jolly, Mohit Kumar
   Sharan, Shyam K.
TI Spatiotemporal modulation of growth factors directs the generation of
   multilineage mouse embryonic stem cell derived mammary organoids
SO DEVELOPMENTAL CELL
LA English
DT Article
ID HORMONE RELATED PROTEIN; GLAND DEVELOPMENT; SKIN APPENDAGE; EXPRESSION;
   DERIVATION; UNIQUE; GENE; BMP; DIFFERENTIATION; IDENTIFICATION
AB Ectodermal appendages, such as the mammary gland (MG), are thought to have evolved from hair  associated apocrine glands to serve the function of milk secretion. Through the directed differentiation of mouse embryonic stem cells (mESCs), here, we report the generation of multilineage ESC  derived mammary organoids (MEMOs). We adapted the skin organoid model, inducing the dermal mesenchyme to transform into mammary  specific mesenchyme via the sequential activation of Bone Morphogenetic Protein 4 (BMP4) and Parathyroid Hormone  related Protein (PTHrP) and inhibition of hedgehog (HH) signaling. Using single cell RNA sequencing, we identified gene expression profiles that demonstrate the presence of mammary specific epithelial cells, fibroblasts, and adipocytes. MEMOs undergo ductal morphogenesis in Matrigel and can reconstitute the MG in vivo. Further, we demonstrate that the loss of function in placode regulators LEF1 and TBX3 in mESCs results in impaired skin and MEMO generation. In summary, our MEMO model robust tool for studying the development of ectodermal appendages, and it provides a foundation for regenerative medicine and disease modeling.
C1 [Sahu, Sounak; Sullivan, Teresa; Albaugh, Mary E.; Burkett, Sandra; Salomon, David S.; Sharan, Shyam K.] NCI, Ctr Canc Res, Mouse Canc Genet Program MCGP, Frederick, MD 21702 USA.
   [Sahoo, Sarthak; Jolly, Mohit Kumar] Indian Inst Sci, Dept Bioengn, Bengaluru 560012, India.
   [O'Sullivan, T. Norene; V. Kozlov, Serguei; Sharan, Shyam K.] NCI, Ctr Adv Preclin Res CAPR, Frederick, MD 21702 USA.
   [Turan, Sevilay; Albaugh, Mary E.; Tran, Bao; V. Kozlov, Serguei] Leidos Biomed Sci Inc, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
   [Koehler, Karl R.] Harvard Med Sch, Dept Otolaryngol Head & Neck Surg, Boston, MA 02115 USA.
   [Koehler, Karl R.] Boston Childrens Hosp, Dept Otolaryngol, Dept Plast & Oral Surg, Boston, MA 02115 USA.
   [Koehler, Karl R.] Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Cancer Institute
   (NCI); Indian Institute of Science (IISC)   Bangalore; National
   Institutes of Health (NIH)   USA; NIH National Cancer Institute (NCI);
   National Institutes of Health (NIH)   USA; NIH National Cancer Institute
   (NCI); Frederick National Laboratory for Cancer Research; Harvard
   University; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Boston Children's Hospital; Harvard
   University; Harvard University Medical Affiliates; Boston Children's
   Hospital
RP Sharan, SK (通讯作者)，NCI, Ctr Canc Res, Mouse Canc Genet Program MCGP, Frederick, MD 21702 USA.; Sharan, SK (通讯作者)，NCI, Ctr Adv Preclin Res CAPR, Frederick, MD 21702 USA.
EM sharans@mail.nih.gov
RI Sahu, Sounak/ABA 5942 2020; Kozlov, Sergii/Y 8735 2019; Jolly,
   Mohit/A 1826 2014
OI Sahu, Sounak/0000 0001 7290 6651; 
FU Intramural Research Program, Center for Cancer Research, National Cancer
   Institute, US National Institutes of Health [SB/S2/RJN 049/2018];
   Science and Engineering Research Board (SERB) , Department of Science
   and Technology (DST) , Government of India; National Institute of
   Arthritis, Musculoskeletal, and Skin Disease (NIAMS) , US National
   Institutes of Health [R01AR075018]
FX We thank Drs. J. Acharya, I. Daar, J. Keller, A. Mishra, E. Sterneck,
   and L. Tessarollo for their critical comments on the manuscript. We
   thank all the members of the Sharan lab, J. Lee and A.P. Le from the
   Koehler lab, and Drs. Senthil Muthuswamy (NCI) and Geoffrey Wahl (Salk
   Institute) for suggestions on this project. We acknowledge support from
   Jyoti Shetty from CCR Single  cell sequencing core facility, Dr. S.
   Lockett from Optical Microscopy and Analysis Lab, Y. Zhao from CCR
   Bioinformatics core, Dr. E. Conner from CCR Sequencing core, and J.
   Carrell and M. Karwan from CCR Flow cytometry core. All figures in this
   manuscript were prepared using Adobe Illustrator v6, and the
   illustrations were made using a paid subscription to Biorender.com . The
   Sharan laboratory is funded by the Intramural Research Program, Center
   for Cancer Research, National Cancer Institute, US National Institutes
   of Health. M.K.J. is supported by Infosys Foundation, Bangalore, India,
   and by the Ramanujan Fellowship (SB/S2/RJN 049/2018) supported by
   Science and Engineering Research Board (SERB) , Department of Science
   and Technology (DST) , Government of India. K.R.K. is supported by the
   National Institute of Arthritis, Musculoskeletal, and Skin Disease
   (NIAMS) , US National Institutes of Health (R01AR075018) .
CR Alghadeer A, 2023, DEV CELL, V58, P2163, DOI 10.1016/j.devcel.2023.07.013
   Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797 311
   Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299
   Biggs LC, 2014, SEMIN CELL DEV BIOL, V25, P11, DOI 10.1016/j.semcdb.2014.01.007
   Boulanger CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062019
   Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147
   Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899
   Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347
   Coletta RD, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 4
   Dai XQ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03023 7
   Danesh SM, 2009, GENE EXPR PATTERNS, V9, P255, DOI 10.1016/j.gep.2009.04.002
   Davenport TG, 2003, DEVELOPMENT, V130, P2263, DOI 10.1242/dev.00431
   Dekkers JF, 2019, NAT PROTOC, V14, P1756, DOI 10.1038/s41596 019 0160 8
   Dimitrov D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30755 0
   Duarte AA, 2018, NAT METHODS, V15, P134, DOI 10.1038/nmeth.4535
   Englund E, 2016, ONCOGENE, V35, P5585, DOI 10.1038/onc.2016.98
   Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003
   Foley J, 2001, DEVELOPMENT, V128, P513
   Giraddi RR, 2018, CELL REP, V24, P1653, DOI 10.1016/j.celrep.2018.07.025
   Gritli Linde A, 2007, DEV CELL, V12, P99, DOI 10.1016/j.devcel.2006.12.006
   Han BC, 2015, CELL REP, V13, P1046, DOI 10.1016/j.celrep.2015.09.063
   Hatsell SJ, 2006, DEVELOPMENT, V133, P3661, DOI 10.1242/dev.02542
   Hayashi R, 2022, NATURE, V605, P126, DOI 10.1038/s41586 022 04613 4
   Hebbard L, 2000, J CELL SCI, V113, P2619
   Henry S, 2021, J MAMMARY GLAND BIOL, V26, P43, DOI 10.1007/s10911 021 09486 3
   Hens J, 2009, DEV DYNAM, V238, P2713, DOI 10.1002/dvdy.22097
   Hens JR, 2007, DEVELOPMENT, V134, P1221, DOI 10.1242/dev.000182
   Jamieson PR, 2017, DEVELOPMENT, V144, P1065, DOI 10.1242/dev.145045
   Kanaya N, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0618 9
   Kessenbrock K, 2017, P NATL ACAD SCI USA, V114, P3121, DOI 10.1073/pnas.1701464114
   Koehler KR, 2017, NAT BIOTECHNOL, V35, P583, DOI 10.1038/nbt.3840
   Koehler KR, 2013, NATURE, V500, P217, DOI 10.1038/nature12298
   KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957
   Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125
   Lawson Devon A, 2015, Cold Spring Harb Protoc, V2015, DOI 10.1101/pdb.prot078071
   Lee JY, 2020, NATURE, V582, P399, DOI 10.1038/s41586 020 2352 3
   Lee J, 2018, CELL REP, V22, P242, DOI 10.1016/j.celrep.2017.12.007
   Liu YE, 2007, ONCOGENE, V26, P2115, DOI 10.1038/sj.onc.1210000
   Lu CP, 2016, SCIENCE, V354, DOI 10.1126/science.aah6102
   Lu CP, 2012, CELL, V150, P136, DOI 10.1016/j.cell.2012.04.045
   Mailleux AA, 2002, DEVELOPMENT, V129, P53
   McCauley HA, 2017, DEVELOPMENT, V144, P958, DOI 10.1242/dev.140731
   Mikkola ML, 2007, SEMIN CELL DEV BIOL, V18, P225, DOI 10.1016/j.semcdb.2007.01.007
   Mikkola ML, 2006, J MAMMARY GLAND BIOL, V11, P187, DOI 10.1007/s10911 006 9029 x
   Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901 785
   NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424
   Oftedal OT, 2013, J MAMMARY GLAND BIOL, V18, P105, DOI 10.1007/s10911 013 9290 8
   Oftedal OT, 2002, J MAMMARY GLAND BIOL, V7, P225, DOI 10.1023/A:1022896515287
   Oshima K, 2010, CELL, V141, P704, DOI 10.1016/j.cell.2010.03.035
   Qu Y, 2017, STEM CELL REP, V8, P205, DOI 10.1016/j.stemcr.2016.12.023
   Romagnoli M, 2019, STEM CELL REP, V12, P831, DOI 10.1016/j.stemcr.2019.02.008
   Sahu S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 11224 6
   Sahu S, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101485
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   SMITH BH, 1969, AM J CLIN PATHOL, V51, P610
   Spike BT, 2012, CELL STEM CELL, V10, P183, DOI 10.1016/j.stem.2011.12.018
   Spina E, 2021, SEMIN CELL DEV BIOL, V114, P83, DOI 10.1016/j.semcdb.2020.12.012
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Tanaka J, 2022, NAT CELL BIOL, V24, P1595, DOI 10.1038/s41556 022 01007 6
   Tanaka J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06469 7
   Tucker JA, 2008, DEV CELL, V14, P108, DOI 10.1016/j.devcel.2007.11.004
   VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691
   Veltmaat JM, 2004, DEV DYNAM, V229, P349, DOI 10.1002/dvdy.10441
   Wansbury O, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2928
   Watson CJ, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.169862
   Widelitz RB, 2007, SEMIN CELL DEV BIOL, V18, P255, DOI 10.1016/j.semcdb.2007.02.005
   Wong ESM, 2010, METHOD ENZYMOL, V476, P265, DOI 10.1016/S0076 6879(10)76015 8
   Wysolmerski JJ, 2012, J CLIN ENDOCR METAB, V97, P2947, DOI 10.1210/jc.2012 2142
   Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020
   Zvelebil M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3403
NR 71
TC 6
Z9 6
U1 4
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1534 5807
EI 1878 1551
J9 DEV CELL
JI Dev. Cell
PD JAN 22
PY 2024
VL 59
IS 2
DI 10.1016/j.devcel.2023.12.003
EA JAN 2024
PG 21
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA JA5N0
UT WOS:001170445800001
PM 38159568
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Koulaouzidis, G
   Henein, M
AF Koulaouzidis, George
   Henein, Michael
TI Coronary Calcification and Hormones
SO ANGIOLOGY
LA English
DT Article
DE coronary calcification; hormones; adiponectin; leptin; resistin;
   visfatin; oestrogen; testosterone; parathyroid hormone; growth hormone;
   ghrelin; renin angiotensin; osteoprotegerin; osteopontin; insulin;
   insulin resistance; fetuin A
ID PLASMA ADIPONECTIN LEVELS; CONVERTING ENZYME GENE; SERUM FETUIN A;
   ARTERY CALCIFICATION; INSULIN RESISTANCE; VASCULAR CALCIFICATION;
   REPLACEMENT THERAPY; HEART DISEASE; OSTEOPROTEGERIN LEVELS;
   SMOOTH MUSCLE
AB The pathogenesis of coronary artery calcification and its role in atherogenesis has not been completely understood but is a new focus of interest in experimental and clinical research. Various bioactive substances, including hormones, have been implicated in the process of arterial calcification. This review considers the relationship between coronary artery calcification and hormones. These hormones may become therapeutic targets for the prevention of arterial calcification.
C1 [Koulaouzidis, George] Guys & St Thomas Hosp, Ctr Cardiothorac, London SE1 9RT, England.
   [Henein, Michael] Umea Univ, Ctr Heart, Umea, Sweden.
   [Henein, Michael] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
C3 Guy's & St Thomas' NHS Foundation Trust; Umea University; Umea
   University
RP Koulaouzidis, G (通讯作者)，St Thomas Hosp, Westminster Bridge Rd, London SE1 7EH, England.
EM geokoul@hotmail.com
RI ; Koulaouzidis, George/IWM 6475 2023
OI Koulaouzidis, George/0000 0001 8340 9423; 
CR Akhrass F, 2003, J CLIN ENDOCR METAB, V88, P5611, DOI 10.1210/jc.2003 031008
   Alexandersen P, 2006, CLIMACTERIC, V9, P108, DOI 10.1080/13697130600647743
   Anand DV, 2006, J AM COLL CARDIOL, V47, P1850, DOI 10.1016/j.jacc.2005.12.054
   Arad Y, 2001, ARTERIOSCL THROM VAS, V21, P2051, DOI 10.1161/hq1201.100257
   Arad Y, 1998, CORONARY ARTERY DIS, V9, P513, DOI 10.1097/00019501 199809080 00007
   Aryan M, 2009, J BONE MINER METAB, V27, P591, DOI 10.1007/s00774 009 0078 2
   Ashley DT, 2010, METABOLISM
   Avignon A, 2007, DIABETES CARE, V30, P2934, DOI 10.2337/dc07 0992
   Barreto DV, 2005, KIDNEY INT, V67, P1576, DOI 10.1111/j.1523 1755.2005.00239.x
   Barrett Connor E, 2005, MENOPAUSE, V12, P40, DOI 10.1097/00042192 200512010 00009
   Behre CJ, 2007, SCAND J CLIN LAB INV, V67, P449, DOI 10.1080/00365510601158717
   Beltowski J, 2006, ATHEROSCLEROSIS, V189, P47, DOI 10.1016/j.atherosclerosis.2006.03.003
   Bogazzi F, 2007, J CLIN ENDOCR METAB, V92, P4271, DOI 10.1210/jc.2007 1213
   BOSKEY AL, 1993, BONE MINER, V22, P147, DOI 10.1016/S0169 6009(08)80225 5
   Broedl UC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004733
   Browner WS, 2001, J CLIN ENDOCR METAB, V86, P631, DOI 10.1210/jc.86.2.631
   Budoff MJ, 2005, J WOMENS HEALTH, V14, P410, DOI 10.1089/jwh.2005.14.410
   Budoff MJ, 2001, AM J CARDIOL, V88, p46E
   Christian RC, 2002, J CLIN ENDOCR METAB, V87, P1062, DOI 10.1210/jc.87.3.1062
   Chung CP, 2009, LUPUS, V18, P799, DOI 10.1177/0961203309103582
   Dabelea D, 2003, DIABETES, V52, P2833, DOI 10.2337/diabetes.52.11.2833
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   DOHERTY TM, 1994, CALCIFIED TISSUE INT, V54, P224, DOI 10.1007/BF00301683
   Doherty TM, 1999, AM HEART J, V137, P806, DOI 10.1016/S0002 8703(99)70403 5
   Elkeles RS, 2008, EUR HEART J, V29, P2244, DOI 10.1093/eurheartj/ehn279
   Filippatos TD, 2010, CURR VASC PHARM
   FITZPATRICK LA, 1994, J CLIN INVEST, V94, P1597, DOI 10.1172/JCI117501
   Greenland P, 2004, JAMA J AM MED ASSOC, V291, P210, DOI 10.1001/jama.291.2.210
   Greif M, 2009, ARTERIOSCL THROM VAS, V29, P781, DOI 10.1161/ATVBAHA.108.180653
   GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033 0620(95)80012 3
   Guzman RJ, 2007, J VASC SURG, V45, p57A, DOI 10.1016/j.jvs.2007.02.049
   Haddad RM, 2007, MAYO CLIN PROC, V82, P29
   Henein M Y., 2010, Int J Cardiol
   Hernandes FR, 2007, CLIN NEPHROL, V67, P89
   Herrmann BL, 2009, EXP CLIN ENDOCR DIAB, V117, P417, DOI 10.1055/s 0029 1214386
   Hofbauer LC, 2001, ARTHRITIS RHEUM US, V44, P253, DOI 10.1002/1529 0131(200102)44:2<253::AID ANR41>3.0.CO;2 S
   Hulley S, 2002, JAMA J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58
   Iribarren C, 2007, J CLIN ENDOCR METAB, V92, P729, DOI 10.1210/jc.2006 1138
   Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21
   Jung HH, 2006, NEPHROL DIAL TRANSPL, V21, P1915, DOI 10.1093/ndt/gfl118
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kepez A, 2009, INT J CARDIOVAS IMAG, V25, P187, DOI 10.1007/s10554 008 9369 2
   Kiechl S, 2004, CIRCULATION, V109, P2175, DOI 10.1161/01.CIR.0000127957.43874.BB
   Kilpatrick ES, 2007, DIABETES CARE, V30, P707, DOI 10.2337/dc06 1982
   Kirkpantur A, 2009, ARTIF ORGANS, V33, P844, DOI 10.1111/j.1525 1594.2009.00814.x
   Kobayashi S, 2008, CLIN J AM SOC NEPHRO, V3, P1289, DOI 10.2215/CJN.00010108
   Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230
   Kondos GT, 2003, CIRCULATION, V107, P2571, DOI 10.1161/01.CIR.0000068341.61180.55
   Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50
   Kurnatowska I, 2011, NEPHRON CLIN PRACT, V117, pC297, DOI 10.1159/000321169
   Kwon HM, 2000, J KOREAN MED SCI, V15, P485, DOI 10.3346/jkms.2000.15.5.485
   Lawlor DA, 2005, J CLIN ENDOCR METAB, V90, P5677, DOI 10.1210/jc.2005 0825
   Lee KK, 2009, AM HEART J, V157, P939, DOI 10.1016/j.ahj.2009.02.006
   Li GH, 2000, CIRCULATION, V101, P2949, DOI 10.1161/01.CIR.101.25.2949
   Li GZ, 2005, REGUL PEPTIDES, V129, P167, DOI 10.1016/j.regpep.2005.02.015
   Lorant DP, 2010, DIABETES CARE
   Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5
   Mackey RH, 2005, ARCH INTERN MED, V165, P510, DOI 10.1001/archinte.165.5.510
   Malkin CJ, 2010, HEART, V96, P1821, DOI 10.1136/hrt.2010.195412
   Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513
   Marso SP, 2008, DIABETES CARE, V31, P989, DOI 10.2337/dc07 2024
   Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508
   MATTU RK, 1995, CIRCULATION, V91, P270, DOI 10.1161/01.CIR.91.2.270
   Maurovich Horvat P, 2010, MED SCI MONITOR, V16, pMT59
   McLaughlin VV, 1997, AM HEART J, V134, P1115, DOI 10.1016/S0002 8703(97)70033 4
   McRobb L, 2009, ENDOCRINOLOGY, V150, P841, DOI 10.1210/en.2008 0760
   Mehrotra R, 2005, KIDNEY INT, V67, P1070, DOI 10.1111/j.1523 1755.2005.00172.x
   Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306
   Mesquita M, 2009, CLIN CHEM LAB MED, V47, P339, DOI 10.1515/CCLM.2009.075
   Mikami S, 2008, HYPERTENS RES, V31, P1163, DOI 10.1291/hypres.31.1163
   Mikkola TS, 2002, CARDIOVASC RES, V53, P605, DOI 10.1016/S0008 6363(01)00466 7
   Mori K, 2010, CORONARY ARTERY DIS, V21, P281, DOI 10.1097/MCA.0b013e32832fe5d5
   Morony S, 2008, CIRCULATION, V117, P411, DOI 10.1161/CIRCULATIONAHA.107.707380
   Nsengimana J, 2007, FUTUR CARDIOL, V3, P587, DOI 10.2217/14796678.3.6.587
   OBRIEN ER, 1994, ARTERIOSCLER THROMB, V14, P1648, DOI 10.1161/01.ATV.14.10.1648
   Oei HHS, 2005, ATHEROSCLEROSIS, V182, P169, DOI 10.1016/j.atherosclerosis.2005.01.040
   Oh DK, 2007, DIABETES OBES METAB, V9, P282, DOI 10.1111/j.1463 1326.2006.00610.x
   Ohmori R, 2003, ATHEROSCLEROSIS, V170, P333, DOI 10.1016/S0021 9150(03)00298 3
   Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19
   Omland T, 2008, J AM COLL CARDIOL, V51, P627, DOI 10.1016/j.jacc.2007.09.058
   Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433 200312000 00003
   Ouyang P, 2009, ATHEROSCLEROSIS, V204, P255, DOI 10.1016/j.atherosclerosis.2008.08.037
   Pfohl M, 1998, J AM COLL CARDIOL, V31, P987, DOI 10.1016/S0735 1097(98)00044 8
   Pischon T, 2006, CLIN CHEM, V52, P797, DOI 10.1373/clinchem.2006.067819
   Pischon T, 2004, JAMA J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730
   Poulakou MV, 2008, IN VIVO, V22, P537
   Qasim A, 2008, J AM COLL CARDIOL, V52, P231, DOI 10.1016/j.jacc.2008.04.016
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Reilly MP, 2005, CIRCULATION, V111, P932, DOI 10.1161/01.CIR.0000155620.10387.43
   Reilly MP, 2004, J CLIN ENDOCR METAB, V89, P3872, DOI 10.1210/jc.2003 031676
   Rennenberg RJMW, 2010, J CELL MOL MED, V14, P2203, DOI 10.1111/j.1582 4934.2010.01139.x
   Rho YH, 2010, ARTHRITIS RHEUM US, V62, P1259, DOI 10.1002/art.27376
   Rodrigues TC, 2010, BRAZ J MED BIOL RES, V43, P1084, DOI 10.1590/S0100 879X2010007500109
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Rumberger JA, 1999, MAYO CLIN PROC, V74, P243, DOI 10.4065/74.3.243
   Saddi Rosa P, 2010, DIABETOL METAB SYNDR, V2, DOI 10.1186/1758 5996 2 21
   Schauer IE, 2010, DIABETES
   Schisterman EF, 2002, J WOMEN HEALTH GEN B, V11, P631, DOI 10.1089/152460902760360577
   Schulze MB, 2005, DIABETES, V54, P534, DOI 10.2337/diabetes.54.2.534
   Schurgin S, 2001, DIABETES CARE, V24, P335, DOI 10.2337/diacare.24.2.335
   Shahar E, 2008, PREV MED, V47, P38, DOI 10.1016/j.ypmed.2007.12.013
   Shaw LJ, 2003, RADIOLOGY, V228, P826, DOI 10.1148/radiol.2283021006
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Streeten Elizabeth A, 2008, Endocr Pract, V14, P155
   Suliman ME, 2008, ADV CLIN CHEM, V46, P217, DOI 10.1016/S0065 2423(08)00406 X
   Tanaka M, 2010, J ATHEROSCLER THROMB, V17, P1033, DOI 10.5551/jat.5116
   Ueland T, 2004, J AM COLL CARDIOL, V44, P1970, DOI 10.1016/j.jacc.2004.06.076
   Uz Ö, 2009, TURK KARDIYOL DERN A, V37, P397
   Van Campenhout A, 2009, ATHEROSCLEROSIS, V204, P321, DOI 10.1016/j.atherosclerosis.2008.09.033
   Venuraju SM, 2010, J AM COLL CARDIOL, V55, P2049, DOI 10.1016/j.jacc.2010.03.013
   Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166
   Wallace AM, 2001, CIRCULATION, V104, P3052, DOI 10.1161/hc5001.101061
   Watson KE, 2000, J CARDIOVASC RISK, V7, P93
   Weikert C, 2008, J CLIN ENDOCR METAB, V93, P2647, DOI 10.1210/jc.2007 2735
   Westenfeld R, 2009, J AM SOC NEPHROL, V20, P1264, DOI 10.1681/ASN.2008060572
   Wolk R, 2004, J AM COLL CARDIOL, V44, P1819, DOI 10.1016/j.jacc.2004.07.050
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Yu N, 2010, CLIN ENDOCRINOL, V73, P30, DOI 10.1111/j.1365 2265.2009.03766.x
   Zeadin M, 2009, ARTERIOSCL THROM VAS, V29, P2069, DOI 10.1161/ATVBAHA.109.195255
   Zhang Bin, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P1002
NR 120
TC 5
Z9 6
U1 0
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0003 3197
EI 1940 1574
J9 ANGIOLOGY
JI Angiology
PD OCT
PY 2011
VL 62
IS 7
BP 554
EP 564
DI 10.1177/0003319711399418
PG 11
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 831KM
UT WOS:000295729400007
PM 21421627
DA 2025 08 17
ER

PT J
AU Feder, D
   Mohd Pahmi, SH
   Adibi, H
   Guddat, LW
   Schenk, G
   McGeary, RP
   Hussein, WM
AF Feder, Daniel
   Mohd Pahmi, Siti Hajar
   Adibi, Hadi
   Guddat, Luke W.
   Schenk, Gerhard
   McGeary, Ross P.
   Hussein, Waleed M.
TI Optimization of an α aminonaphthylmethylphosphonic acid inhibitor of
   purple acid phosphatase using rational structure based design approaches
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Purple acid phosphatase; Tartrate resistant acid phosphatase;
   Metallohydrolases; Chemotherapeutics; Osteoporosis; Drug Development
ID BIOCHEMICAL CHARACTERIZATION; CRYSTAL STRUCTURES; RECOMBINANT HUMAN;
   OSTEOPOROSIS; BISPHOSPHONATES; LEADS; MICE; IDENTIFICATION;
   LOCALIZATION; PREVENTION
AB Purple acid phosphatases (PAPs) are ubiquitous binuclear metallohydrolases that have been isolated from various animals, plants and some types of fungi. In humans and mice, elevated PAP activity in osteoclasts is associated with osteoporosis, making human PAP an attractive target for the development of anti osteoporotic drugs. Based on previous studies focusing on phosphonate scaffolds, as well as a new crystal structure of a PAP in complex with a derivative of a previously synthesized & alpha; aminonaphthylmethylphosphonic acid, phos phonates 24 40 were designed as new PAP inhibitor candidates. Subsequent docking studies predicted that all of these compounds are likely to interact strongly with the active site of human PAP and most are likely to interact strongly with the active site of pig PAP. The seventeen candidates were synthesized with good yields and nine of them (26 28, 30, 33 36 and 38) inhibit in the sub micromolar to nanomolar range against pig PAP, with 28 and 35 being the most potent mammalian PAP inhibitors reported with Ki values of 168 nM and 186 nM, respec tively. This study thus paves the way for the next stage of drug development for phosphonate inhibitors of PAPs as anti osteoporotic agents.
C1 [Feder, Daniel; Mohd Pahmi, Siti Hajar; Adibi, Hadi; Guddat, Luke W.; Schenk, Gerhard; McGeary, Ross P.; Hussein, Waleed M.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.
   [Adibi, Hadi] Kermanshah Univ Med Sci, Hlth Inst, Pharmaceut Sci Res Ctr, Kermanshah, Iran.
   [Schenk, Gerhard] Univ Queensland, Sustainable Minerals Inst, Brisbane, Qld 4072, Australia.
   [Schenk, Gerhard] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia.
   [Hussein, Waleed M.] Helwan Univ, Fac Pharm, Pharmaceut Organ Chem Dept, Helwan, Egypt.
C3 University of Queensland; Kermanshah University of Medical Sciences;
   University of Queensland; University of Queensland; Egyptian Knowledge
   Bank (EKB); Helwan University
RP Hussein, WM (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.
EM w.hussein@uq.edu.au
RI Guddat, Luke/AAI 2930 2021; Hussein, Waleed/AAK 7916 2021; Schenk,
   Gerhard/AFJ 8595 2022
FU Australian Research Council [DP0986292, DP150104358]
FX The authors declare the following financial interests/personal
   relationships which may be considered as potential competing interests:
   Gerhard Schenk reports financial support was provided by Australian
   Research Council. Gerhard Schenk reports financial support was provided
   by Australian Research Council. The X ray data were obtained at the
   Australian Synchrotron on beamline MX1. The assistance of Tom
   Caradoc Davies and Alan Riboldi Tunnicliffe during data collection is
   much appreciated. We thank Dr. Tri Le for assistance with NMR studies
   and Mr. Graham MacFarlane for MS measurements. This work was funded by
   Australian Research Council (DP0986292) and (DP150104358).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Alimoradi N, 2017, J ENZYM INHIB MED CH, V32, P20, DOI 10.1080/14756366.2016.1230109
   Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103
   BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167 4838(86)90310 9
   Bernhardt PV, 2004, BIOCHEMISTRY US, V43, P10387, DOI 10.1021/bi0490338
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Bonnick SL, 2006, AM J MED, V119, p25S, DOI 10.1016/j.amjmed.2005.12.020
   Boonen S, 2007, BONE, V40, pS26, DOI 10.1016/j.bone.2007.03.003
   Boorsma CE, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12623 w
   Bozzo GG, 2004, BIOCHEM J, V377, P419, DOI 10.1042/BJ20030947
   CAMPBELL HD, 1978, BIOCHEM BIOPH RES CO, V82, P615, DOI 10.1016/0006 291X(78)90919 1
   Cashikar AG, 1997, PLANT PHYSIOL, V114, P907, DOI 10.1104/pp.114.3.907
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   CRANS DC, 1992, BIOCHEMISTRY US, V31, P11731, DOI 10.1021/bi00162a009
   DELANO WL, 2002, PYMOL
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   EkRylander B, 1997, BIOCHEM J, V321, P305, DOI 10.1042/bj3210305
   Elliott ME, 2004, EPILEPSY BEHAV, V5, pS16, DOI 10.1016/j.yebeh.2003.11.027
   Elliott TW, 2006, J BRAZIL CHEM SOC, V17, P1558, DOI 10.1590/S0103 50532006000800011
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Ensrud KE, 2019, JAMA J AM MED ASSOC, V322, P2017, DOI 10.1001/jama.2019.15781
   Fang H, 2007, HETEROATOM CHEM, V18, P9, DOI 10.1002/hc.20227
   Faridoon, 2012, BIOORG MED CHEM LETT, V22, P2555, DOI 10.1016/j.bmcl.2012.01.123
   Feder D, 2021, CHEMMEDCHEM, V16, P3342, DOI 10.1002/cmdc.202100486
   Feder D, 2020, PLANT SCI, V294, DOI 10.1016/j.plantsci.2020.110445
   Feder D, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111611
   Feder D, 2019, CHEMBIOCHEM, V20, P1536, DOI 10.1002/cbic.201900077
   Feder D, 2012, CHEM BIOL DRUG DES, V80, P665, DOI 10.1111/cbdd.12001
   Flanagan JU, 2006, GENE, V377, P12, DOI 10.1016/j.gene.2006.02.031
   Funhoff EG, 2001, BIOCHEMISTRY US, V40, P11614, DOI 10.1021/bi010766r
   Guddat LW, 1999, STRUCT FOLD DES, V7, P757, DOI 10.1016/S0969 2126(99)80100 2
   Guillemin F, 2013, OSTEOPOROSIS INT, V24, P3001, DOI 10.1007/s00198 013 2408 4
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hayman AR, 2000, J HISTOCHEM CYTOCHEM, V48, P219, DOI 10.1177/002215540004800207
   Hayman AR, 2003, J BONE MINER RES, V18, P1905, DOI 10.1359/jbmr.2003.18.10.1905
   Hollberg K, 2002, EXP CELL RES, V279, P227, DOI 10.1006/excr.2002.5612
   Hussein WM, 2019, MEDCHEMCOMM, V10, P61, DOI 10.1039/c8md00491a
   Hussein WM, 2018, EUR J MED CHEM, V157, P462, DOI 10.1016/j.ejmech.2018.08.004
   Hussein WM, 2009, J ORG CHEM, V74, P1473, DOI 10.1021/jo802651p
   Hwang CH, 2004, CHEM COMMUN, P816, DOI 10.1039/b316984g
   Janckila AJ, 2002, CLIN CHIM ACTA, V320, P49, DOI 10.1016/S0009 8981(02)00026 8
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Kuang RB, 2009, PLANT PHYSIOL, V151, P199, DOI 10.1104/pp.109.143180
   Liebschner D, 2017, ACTA CRYSTALLOGR D, V73, P148, DOI 10.1107/S2059798316018210
   Ljusberg J, 1999, BIOCHEM J, V343, P63, DOI 10.1042/0264 6021:3430063
   Marshall K, 1997, ARCH BIOCHEM BIOPHYS, V345, P230, DOI 10.1006/abbi.1997.0250
   Mauck KF, 2006, MAYO CLIN PROC, V81, P662, DOI 10.4065/81.5.662
   McGeary RP, 2014, EUR J MED CHEM, V76, P132, DOI 10.1016/j.ejmech.2014.02.008
   McGeary RP, 2009, BIOORG MED CHEM LETT, V19, P163, DOI 10.1016/j.bmcl.2008.10.125
   McNicholas S, 2011, ACTA CRYSTALLOGR D, V67, P386, DOI 10.1107/S0907444911007281
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Mitic N, 2005, ARCH BIOCHEM BIOPHYS, V439, P154, DOI 10.1016/j.abb.2005.05.013
   Mitic N, 2006, CHEM REV, V106, P3338, DOI 10.1021/cr050318f
   Mohd Pahmi SH, 2011, BIOORG MED CHEM LETT, V21, P3092, DOI 10.1016/j.bmcl.2011.03.024
   Park JH, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1514 4
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Reithmeier A, 2018, CHEM BIOL DRUG DES, V92, P1255, DOI 10.1111/cbdd.13187
   Reithmeier A, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3616 7
   Roberts HC, 2007, CALCIFIED TISSUE INT, V80, P400, DOI 10.1007/s00223 007 9032 2
   Schenk G., J BIOL INORG CHEM
   Schenk G, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472 6807 8 6
   Schenk G, 2013, COORDIN CHEM REV, V257, P473, DOI 10.1016/j.ccr.2012.03.020
   SCHINDELMEISER J, 1989, PATHOL RES PRACT, V185, P184
   SCHLOSNAGLE DC, 1974, J BIOL CHEM, V249, P7574
   Selleck C, 2017, CHEM EUR J, V23, P4778, DOI 10.1002/chem.201700866
   Silverman SL, 2011, OSTEOPOROSIS INT, V22, P21, DOI 10.1007/s00198 010 1274 6
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041
   Sträter N, 2005, J MOL BIOL, V351, P233, DOI 10.1016/j.jmb.2005.04.014
   STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774
   Thomsen R, 2006, J MED CHEM, V49, P3315, DOI 10.1021/jm051197e
   Tran HT, 2010, PLANT SCI, V179, P14, DOI 10.1016/j.plantsci.2010.04.005
   TROY K, 1985, AM J HEMATOL, V19, P237, DOI 10.1002/ajh.2830190305
   Twitchett MB, 2002, INORG CHEM, V41, P5787, DOI 10.1021/ic020037f
   Valizadeh M, 2004, ARCH BIOCHEM BIOPHYS, V424, P154, DOI 10.1016/j.abb.2004.01.008
   Walker Jennie, 2020, Nurs Older People, V32, P34, DOI 10.7748/nop.2019.e1153
   WISSNER A, 1985, J MED CHEM, V28, P1365, DOI 10.1021/jm00147a045
   Wu X, 2016, OSTEOPOROSIS INT, V27, P3083, DOI 10.1007/s00198 016 3763 8
   Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 158
   ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V159, P68, DOI 10.1016/0006 291X(89)92405 4
   Zenger S, 2011, CLIN EXP METASTAS, V28, P65, DOI 10.1007/s10585 010 9358 4
   Zhang LH, 2017, AUSTRALAS PHYS ENG S, V40, P603, DOI 10.1007/s13246 017 0566 y
NR 84
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN 5
PY 2023
VL 254
AR 115383
DI 10.1016/j.ejmech.2023.115383
EA APR 2023
PG 19
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA K0RR2
UT WOS:001013611200001
PM 37087894
DA 2025 08 17
ER

PT J
AU Wei, LJ
   Diao, Y
   Qi, J
   Khokhlov, A
   Feng, H
   Yan, X
   Li, Y
AF Wei, Lijun
   Diao, Yan
   Qi, Jing
   Khokhlov, Alexander
   Feng, Hui
   Yan, Xing
   Li, Yu
TI Effect of Change in Spindle Structure on Proliferation Inhibition of
   Osteosarcoma Cells and Osteoblast under Simulated Microgravity during
   Incubation in Rotating Bioreactor
SO PLOS ONE
LA English
DT Article
ID APOPTOSIS
AB In order to study the effect of microgravity on the proliferation of mammalian osteosarcoma cells and osteoblasts, the changes in cell proliferation, spindle structure, expression of MAD2 or BUB1, and effect of MAD2 or BUB1 on the inhibition of cell proliferation is investigated by keeping mammalian osteosarcoma cells and osteoblasts under simulated microgravity in a rotating wall vessel (2D RWVS) bioreactor. Experimental results indicate that the effect of microgravity on proliferation inhibition, incidence of multipolar spindles, and expression of MAD2 or BUB1 increases with the extension of treatment time. And multipolar cells enter mitosis after MAD2 or BUB1 is knocked down, which leads to the decrease in DNA content, and decrease the accumulation of cells within multipolar spindles. It can therefore be concluded that simulated microgravity can alter the structure of spindle microtubules, and stimulate the formation of multipolar spindles together with multicentrosomes, which causes the overexpression of SAC proteins to block the abnormal cells in metaphase, thereby inhibiting cell proliferation. By clarifying the relationship between cell proliferation inhibition, spindle structure and SAC changes under simulated microgravity, the molecular mechanism and morphology basis of proliferation inhibition induced by microgravity is revealed, which will give experiment and theoretical evidence for the mechanism of space bone loss and some other space medicine problems.
C1 [Wei, Lijun; Diao, Yan; Qi, Jing; Feng, Hui; Yan, Xing; Li, Yu] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150006, Peoples R China.
   [Khokhlov, Alexander] Moscow MV Lomonosov State Univ, Sch Biol, Moscow, Russia.
C3 Harbin Institute of Technology; Lomonosov Moscow State University
RP Li, Y (通讯作者)，Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150006, Peoples R China.
EM liyugene@hit.edu.cn
RI ; Khokhlov, Alexander/G 3905 2013; Li, YiXue/JRW 6306 2023
OI Khokhlov, Alexander/0000 0001 7454 7023; 
FU National Science Foundation of China [30970686]; Opening Foundation of
   the State Key Laboratory for Space Medicine Fundamentals and Application
   [SMFA09K03]; Natural Science Foundation of Heilongjiang Province
   [D200879]; Natural Scientific Research Innovation Foundation of Harbin
   Institute of Technology [HIT.NSRIF.2008.14]
FX This work is funded by National Science Foundation of China (30970686),
   Opening Foundation of the State Key Laboratory for Space Medicine
   Fundamentals and Application (SMFA09K03), Natural Science Foundation of
   Heilongjiang Province (D200879), and Natural Scientific Research
   Innovation Foundation of Harbin Institute of Technology
   (HIT.NSRIF.2008.14). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962 8924(00)01872 9
   Buravkova LB, 2001, ACTA ASTRONAUT, V48, P647, DOI 10.1016/S0094 5765(01)00023 6
   Dai ZQ, 2007, CELL PROLIFERAT, V40, P671, DOI 10.1111/j.1365 2184.2007.00461.x
   ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639
   Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098 2264(200002)27:2<183::AID GCC10>3.0.CO;2 P
   GUIGNANDON A, 1995, CELL STRUCT FUNCT, V20, P369, DOI 10.1247/csf.20.369
   Hughes Fulford M, 2003, ADV SPACE RES SERIES, V32, P1585, DOI 10.1016/S0273 1177(03)90399 1
   Kossmehl P, 2003, ENDOCRINOLOGY, V144, P4172, DOI 10.1210/en.2002 0171
   Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007
   Lewis ML, 2004, J GRAVIT SPACE BIO B, V1, P3
   Liedert A, 2004, BIOCHEM BIOPH RES CO, V319, P951, DOI 10.1016/j.bbrc.2004.05.087
   Malmanche N, 2006, FEBS LETT, V580, P2888, DOI 10.1016/j.febslet.2006.03.081
   RIJKEN PJ, 1991, J CELL SCI, V100, P491
   RIJKEN PJ, 1991, AVIAT SPACE ENVIR MD, V62, P32
   SiTu ZQ, 2004, CELL CULTURE, P163
   Sun CR, 2006, J HARBIN MED U, V1, P70
   [谭映军 Tan Yingjun], 2011, [航天医学与医学工程, Space Medicine & Medical Engineering], V24, P13
   Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034
   Vassy J, 2003, ADV SPACE RES SERIES, V32, P1595, DOI 10.1016/S0273 1177(03)90400 5
   Wang SL, 2008, J PRACT MED, V6, P915
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wu C, 2011, PLOS ONE, V7, P1
   Xiong JH, 2003, ACTA ZOOL SINICA, V1, P98
   [Zhang Shu 张舒], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P4530
   Zhang XY, 2000, CHIN J AEROSPACE MED, V11, P432
   [Zheng Hongxia 郑红霞], 2010, [航天医学与医学工程, Space Medicine & Medical Engineering], V23, P416
   Zhong JJ, 2006, J XINJIANG MED U, V8, P669
NR 27
TC 14
Z9 15
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2013
VL 8
IS 10
AR e76710
DI 10.1371/journal.pone.0076710
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 232NS
UT WOS:000325501300083
PM 24116140
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Katakami, N
   Nishimura, T
   Hidaka, Y
   Hata, A
   Nishino, K
   Mori, M
   Hirashima, T
   Takase, N
   Kaneda, T
   Ohnishi, H
   Morita, S
   Hatachi, Y
AF Katakami, Nobuyuki
   Nishimura, Takashi
   Hidaka, Yu
   Hata, Akito
   Nishino, Kazumi
   Mori, Masahide
   Hirashima, Tomonori
   Takase, Naoto
   Kaneda, Toshihiko
   Ohnishi, Hisashi
   Morita, Satoshi
   Hatachi, Yukimasa
TI Randomized phase II study of zoledronate dosing every four versus eight
   weeks in patients with bone metastasis from lung cancer (Hanshin Cancer
   Group0312)
SO LUNG CANCER
LA English
DT Article
DE Zoledronate; Bone metastasis; Lung cancer; Randomized phase 2; Dosing
   schedule; Every four vs eight weeks
ID ATYPICAL FEMORAL FRACTURE; SKELETAL RELATED EVENTS; LONG TERM;
   MULTIPLE MYELOMA; PLUS CISPLATIN; DOUBLE BLIND; BREAST; ACID; TRIAL;
   BISPHOSPHONATES
AB Background: Zoledronic acid (ZA) reduces the incidence of skeletal related events (SREs) in patients with bone metastases from solid tumors. However, the optimal dosing interval of ZA for patients with lung cancer is uncertain. Methods: We conducted a randomized, open label, feasibility phase 2 trial at eight Japanese hospitals. Patients with bone metastases from lung cancer were randomly assigned to receive either 4 mg of ZA every four weeks (4wk ZA) or every eight weeks (8wk ZA). The primary endpoint was the time to the first SRE and the rate and types of SREs after one year. SREs were defined as pathologic bone fracture, bone radiation therapy or surgery, and spinal cord compression. Secondary endpoints were the SRE incidence at six months, pain assessment, changes in analgesic consumption, serum N telopeptide, toxicity, and overall survival. Results: Between November 2012 and October 2018, 109 patients were randomly assigned to the 4wk ZA group (54 patients) and the 8wk ZA group (55 patients). The number of patients who received chemotherapy or molecular targeted agents was 30 and 23 and 18 and 16 in the 4wk ZA and 8wk ZA groups, respectively. The median time to the first SRE could not be calculated because of a low SRE. The time to the first SRE of all patients did not differ between the groups (P = 0.715, HR = 1.18, 95% CI = 0.48, 2.9). The SRE rate of all patients after 12 months was 17.6% (95% CI = 8.4, 30.9%) in the 4wk ZA and 23.3% (95% CI = 11.8, 38.6%) in the 8wk ZA group, without significant differences between the groups. There was no difference in any secondary endpoint between groups, and these endpoints did not differ among treatment modalities. Conclusions: An eight week ZA interval does not increase the SRE risk for patients with bone metastasis from lung cancer and could be considered clinically.
C1 [Katakami, Nobuyuki; Takase, Naoto; Hatachi, Yukimasa] Takarazuka City Hosp, Takarazuka, Japan.
   [Nishimura, Takashi] Kyoto Katsura Hosp, Kyoto, Japan.
   [Hidaka, Yu; Morita, Satoshi] Kyoto Univ, Sch Med, Kyoto, Japan.
   [Hata, Akito] Kobe Minimally Invas Canc Ctr, Kobe, Japan.
   [Nishino, Kazumi] Osaka Int Canc Inst, Osaka, Japan.
   [Mori, Masahide] Natl Hosp Org Osaka Toneyama Med Ctr, Osaka, Japan.
   [Hirashima, Tomonori] Osaka Habikino Med Ctr, Osaka, Japan.
   [Kaneda, Toshihiko] Kobe City Med Ctr West Hosp, Kobe, Japan.
   [Ohnishi, Hisashi] Akashi Med Ctr, Akashi, Japan.
   [Katakami, Nobuyuki; Hata, Akito] Kobe City Med Ctr Gen Hosp, Kobe, Japan.
   [Katakami, Nobuyuki] Takarazuka City Hosp, 4 5 1 Kohama Takarazuka, Takarazuka 6650827, Japan.
C3 Kyoto University; Kobe City Medical Center General Hospital; Kobe City
   Medical Center General Hospital
RP Katakami, N (通讯作者)，Takarazuka City Hosp, 4 5 1 Kohama Takarazuka, Takarazuka 6650827, Japan.
EM nkatakami1954@gmail.com
CR Amadori D, 2013, LANCET ONCOL, V14, P663, DOI 10.1016/S1470 2045(13)70174 8
   Body J.J., EUR J CANCER
   Body JJ, 2010, J BONE MINER RES, V25, P440, DOI 10.1359/jbmr.090810
   Clemons M, 2021, EUR J CANCER, V142, P132, DOI 10.1016/j.ejca.2020.08.019
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Galvano A, 2019, J BONE ONCOL, V18, DOI 10.1016/j.jbo.2019.100252
   Hanna N, 2006, J CLIN ONCOL, V24, P2038, DOI 10.1200/JCO.2005.04.8595
   Hayashi K, 2014, ANTICANCER RES, V34, P1245
   Henk H, 2012, CURR MED RES OPIN, V28, P1119, DOI 10.1185/03007995.2012.689254
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hortobagyi G.N., JAMA ONCOL
   Katakami N., J THORAC ONCOL
   Kubota K, 2015, ANN ONCOL, V26, P1401, DOI 10.1093/annonc/mdv190
   Morgan GJ, 2012, BLOOD, V119, P5374, DOI 10.1182/blood 2011 11 392522
   Noda K., 2002, NEW ENGL J MED, V346
   Paz Ares LG, 2013, J CLIN ONCOL, V31, P2895, DOI 10.1200/JCO.2012.47.1102
   Peter R, 2004, BMJ BRIT MED J, V328, P335, DOI 10.1136/bmj.328.7435.335
   Poon M, 2013, CLIN ONCOL UK, V25, P435, DOI 10.1016/j.clon.2013.03.003
   Puhaindran ME, 2011, J BONE JOINT SURG AM, V93A, P1235, DOI 10.2106/JBJS.J.01199
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Scagliotti GV, 2012, J THORAC ONCOL, V7, P1823, DOI 10.1097/JTO.0b013e31826aec2b
   Stopeck A.T., J CLIN
   von Moos R, 2013, SUPPORT CARE CANCER, V21, P1773, DOI 10.1007/s00520 013 1755 1
   Yang SP, 2017, ONCOLOGIST, V22, P438, DOI 10.1634/theoncologist.2016 0192
NR 29
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169 5002
EI 1872 8332
J9 LUNG CANCER
JI Lung Cancer
PD AUG
PY 2023
VL 182
AR 107261
DI 10.1016/j.lungcan.2023.107261
EA JUN 2023
PG 14
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Respiratory System
GA L1FD0
UT WOS:001020773200001
PM 37307753
DA 2025 08 17
ER

PT J
AU Gilde, F
   Fourel, L
   Guillot, R
   Pignot Paintrand, I
   Okada, T
   Fitzpatrick, V
   Boudou, T
   Albiges Rizo, C
   Picart, C
AF Gilde, Flora
   Fourel, Laure
   Guillot, Raphael
   Pignot Paintrand, Isabelle
   Okada, Takaharu
   Fitzpatrick, Vincent
   Boudou, Thomas
   Albiges Rizo, Corinne
   Picart, Catherine
TI Stiffness dependent cellular internalization of matrix bound BMP 2 and
   its relation to Smad and non Smad signaling
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Growth factor; Biomaterial; Surface; Internalization; Bone morphogenetic
   protein
ID BONE MORPHOGENETIC PROTEINS; POLYELECTROLYTE MULTILAYER FILM;
   GROWTH FACTORS; OSTEOBLAST DIFFERENTIATION; PLASMA MEMBRANE; STEM CELLS;
   ENDOCYTOSIS; CAVEOLAE; REGENERATION; DYNAMIN
AB Surface coatings delivering BMP are a promising approach to render biomaterials osteoinductive. In contrast to soluble BMPs which can interact with their receptors at the dorsal side of the cell, BMPs presented as an insoluble cue physically bound to a biomimetic matrix, called here matrix bound (bBMP 2), are presented to cells by their ventral side. To date, BMP 2 internalization and signaling studies in cell biology have always been performed by adding soluble (sBMP 2) to cells adhered on cell culture plates or glass slides, which will be considered here as a "reference" condition. However, whether and how matrix bound BMP 2 can be internalized by cells and its relation to canonical (SMAD) and non canonical signaling (ALP) remain open questions. In this study, we investigated the uptake and processing of BMP 2 by C2C12 myoblasts. This BMP 2 was presented either embedded in polyelectrolyte multilayer films (matrix bound presentation) or as soluble form. Using fluorescently labeled BMP 2, we showed that the amount of matrix bound BMP 2 internalized is dependent on the level of crosslinking of the polyelectrolyte films. Cav 1 mediated internalization is related to both SMAD and ALP signaling, while clathrin mediated is only related to ALP signaling. BMP 2 internalization was independent of the presentation mode (sBMP 2 versus bBMP 2) for low crosslinked films (soft, EDC10) in striking contrast with high crosslinked (stiff, EDC70) films where internalization was much lower and slower for bBMP 2. As anticipated, internalization of sBMP 2 barely depended on the underlying matrix. Taken together, these results indicate that BMP 2 internalization can be tuned by the underlying matrix and activates downstream BMP 2 signaling, which is key for the effective formation of bone tissue.
   Statement of Significance
   The presentation of growth factors from material surfaces currently presents significant challenges in academic research, clinics and industry. Being able to deliver efficiently these growth factors by a biomaterial will open new perspectives for regenerative medicine.
   However, to date, very little is known about how matrix bound growth factors are delivered to cells, especially whether they are internalized and how they are signaling to drive key differentiation events. These initial steps are crucial as they will guide the subsequent processes leading to tissue regeneration. In this work, we investigate the uptake and processing by cells of BMP 2 ligands embedded in polyelectrolyte multilayer films in comparison to soluble BMP 2. We show that BMP 2 responsive cells can internalize matrix bound BMP 2 and that internalization is dependent on the cross linking level of the polyelectrolyte films. In addition, we show that internalization is mediated by both clathrin  and caveolin dependent pathways. While inhibiting clathrin dependent endocytosis affects only non canonical signaling, blocking caveolin 1 dependent endocytosis reduces both canonical and non canonical BMP signaling. The signaling pathways found for matrix bound BMP 2 are similar to those found for soluble BMP 2. These results highlight that BMP 2 presented by a biomaterial at the ventral side of the cell can trigger major endocytic and associated signaling pathways leading to bone regeneration. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Gilde, Flora; Guillot, Raphael; Pignot Paintrand, Isabelle; Fitzpatrick, Vincent; Boudou, Thomas; Picart, Catherine] MINATEC, CNRS UMR LMGP 5628, 3 Parvis Louis Neel, F 38016 Grenoble, France.
   [Gilde, Flora; Guillot, Raphael; Pignot Paintrand, Isabelle; Fitzpatrick, Vincent; Boudou, Thomas; Picart, Catherine] Univ Grenoble Alpes, Grenoble Inst Technol, 3 Parvis Louis Neel, F 38016 Grenoble, France.
   [Fourel, Laure; Albiges Rizo, Corinne] Inst Adv Biosci, Inst Albert Bonniot, INSERM U1209, Site Sante,BP170, F 38042 Grenoble 9, France.
   [Fourel, Laure; Albiges Rizo, Corinne] CNRS, Inst Albert Bonniot, UMR5309, Site Sante,BP170, F 38042 Grenoble 9, France.
   [Fourel, Laure; Albiges Rizo, Corinne] Univ Grenoble Alpes, Inst Albert Bonniot, Site Sante,BP170, F 38042 Grenoble 9, France.
   [Okada, Takaharu] Natl Inst Mat Sci, Biomat Unit, Int Ctr Mat Nanoarchitecton WPI MANA, 1 1 Namiki, Tsukuba, Ibaraki 3050044, Japan.
C3 Communaute Universite Grenoble Alpes; Institut National Polytechnique de
   Grenoble; Centre National de la Recherche Scientifique (CNRS);
   Communaute Universite Grenoble Alpes; Institut National Polytechnique de
   Grenoble; Universite Grenoble Alpes (UGA); Communaute Universite
   Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la
   Sante et de la Recherche Medicale (Inserm); Communaute Universite
   Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la
   Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes;
   Universite Grenoble Alpes (UGA); National Institute for Materials
   Science
RP Picart, C (通讯作者)，MINATEC, CNRS UMR LMGP 5628, 3 Parvis Louis Neel, F 38016 Grenoble, France.; Picart, C (通讯作者)，Univ Grenoble Alpes, Grenoble Inst Technol, 3 Parvis Louis Neel, F 38016 Grenoble, France.; Albiges Rizo, C (通讯作者)，Inst Adv Biosci, Site Sante,BP170, F 38042 Grenoble 9, France.
EM Corinne.albiges rizo@ujf grenoble.fr; catherine.picart@grenoble inp.fr
RI Fourel, Laure/M 3061 2013; Fitzpatrick, Vincent/HLH 2342 2023;
   Albiges Rizo, Corinne/M 2568 2013; Boudou, Thomas/A 9089 2013; PICART,
   Catherine/C 9132 2011; PAINTRAND, Isabelle/G 5054 2011
OI ALBIGES RIZO, Corinne/0000 0002 6333 4150; Boudou,
   Thomas/0000 0002 6821 2937; PAINTRAND, Isabelle/0000 0002 7266 4952;
   Fitzpatrick, Vincent/0000 0002 0556 1179; PICART,
   Catherine/0000 0003 0130 1000
FU European Commission; ERC [GA 259370]; FRM; Ligue Nationale contre le
   Cancer for Equipe labellisee Ligue
FX The authors thank D. Logeart Avramoglou for providing the C2C12 A5
   transfected cells, A. Ho Shui Ling for her help in the preparation of
   the samples and Prof Takao Aoyagi for supporting T. Okada's research
   stay in Grenoble. We are grateful to O.Destaing, F Bruckert and J
   Eyckmans for fruitful discussions and comments on the manuscript. This
   work was supported by the European Commission, FP7 via an ERC Starting
   grant to CP (BIOMIM, GA 259370), by the FRM (CAR) and by the Ligue
   Nationale contre le Cancer for Equipe labellisee Ligue 2014 (CAR). The
   groups of C.P. and C.A.R. belong to the CNRS consortium CellTiss.
CR Abbatiello S. E., 1997, PROT SOC M BOST MA, P99
   Alborzinia H, 2013, J CELL SCI, V126, P117, DOI 10.1242/jcs.109777
   Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652
   Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432 0436.2001.680412.x
   Belair DG, 2014, CHEM COMMUN, V50, P15651, DOI 10.1039/c4cc04317k
   Boerckel JD, 2011, BIOMATERIALS, V32, P5241, DOI 10.1016/j.biomaterials.2011.03.063
   Bonor J, 2012, J CELL PHYSIOL, V227, P2880, DOI 10.1002/jcp.23032
   Bragdon B, 2012, BONE, V50, P189, DOI 10.1016/j.bone.2011.10.016
   Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467
   CANTOR CR, 1998, BIOPHYS CHEM
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chen YG, 2009, CELL RES, V19, P58, DOI 10.1038/cr.2008.315
   Cheng JPX, 2016, TRENDS CELL BIOL, V26, P177, DOI 10.1016/j.tcb.2015.10.010
   Crouzier T, 2011, BIOMATERIALS, V32, P7543, DOI 10.1016/j.biomaterials.2011.06.062
   Crouzier T, 2011, ADV MATER, V23, pH111, DOI 10.1002/adma.201004637
   Crouzier T, 2009, SMALL, V5, P598, DOI 10.1002/smll.200800804
   Dai JW, 1997, J GEN PHYSIOL, V110, P1, DOI 10.1085/jgp.110.1.1
   Dave PC, 2014, NAT MATER, V13, P532, DOI 10.1038/nmat3997
   Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975
   Dierich A, 2007, ADV MATER, V19, P693, DOI 10.1002/adma.200601271
   Du J, 2011, P NATL ACAD SCI USA, V108, P9466, DOI 10.1073/pnas.1106467108
   Fourel L, 2016, J CELL BIOL, V212, P693, DOI 10.1083/jcb.201508018
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Gilde F, 2012, BIOMACROMOLECULES, V13, P3620, DOI 10.1021/bm3010808
   Gonnord P, 2012, SEMIN CELL DEV BIOL, V23, P154, DOI 10.1016/j.semcdb.2011.11.002
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Gribova V, 2013, ACTA BIOMATER, V9, P6468, DOI 10.1016/j.actbio.2012.12.015
   Grossier JP, 2014, EMBO J, V33, P35, DOI 10.1002/embj.201385284
   Guillot R, 2013, BIOMATERIALS, V34, P5737, DOI 10.1016/j.biomaterials.2013.03.067
   Hartung A, 2006, MOL CELL BIOL, V26, P7791, DOI 10.1128/MCB.00022 06
   Haxaire K, 2003, BIOPOLYMERS, V72, P149, DOI 10.1002/bip.10342
   Heining E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025163
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Jortikka L, 1997, CELL SIGNAL, V9, P47, DOI 10.1016/S0898 6568(96)00094 0
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kelley R, 2009, J CELL BIOL, V184, P597, DOI 10.1083/jcb.200808064
   Kisiel M, 2012, J CONTROL RELEASE, V162, P646, DOI 10.1016/j.jconrel.2012.08.004
   Leikina E, 2013, J CELL BIOL, V200, P109, DOI 10.1083/jcb.201207012
   Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002
   Marom B, 2011, J BIOL CHEM, V286, P19287, DOI 10.1074/jbc.M110.210377
   Martino MM, 2014, SCIENCE, V343, P885, DOI 10.1126/science.1247663
   Mueller TD, 2012, FEBS LETT, V586, P1846, DOI 10.1016/j.febslet.2012.02.043
   Nassoy P, 2012, TRENDS CELL BIOL, V22, P381, DOI 10.1016/j.tcb.2012.04.007
   Nickel J, 2009, CYTOKINE GROWTH F R, V20, P367, DOI 10.1016/j.cytogfr.2009.10.022
   Nohe A, 2005, J CELL SCI, V118, P643, DOI 10.1242/jcs.01402
   Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200
   Paarmann P, 2016, INT J BIOCHEM CELL B, V76, P51, DOI 10.1016/j.biocel.2016.04.010
   Patterson J, 2010, BIOMATERIALS, V31, P6772, DOI 10.1016/j.biomaterials.2010.05.047
   Phillippi JA, 2008, STEM CELLS, V26, P127, DOI 10.1634/stemcells.2007 0520
   Rauch C, 2002, AM J PHYSIOL CELL PH, V283, pC235, DOI 10.1152/ajpcell.00234.2001
   Reddi AH, 2009, CYTOKINE GROWTH F R, V20, P341, DOI 10.1016/j.cytogfr.2009.10.015
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961
   ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092 8674(92)90143 Z
   Saldanha S, 2013, J CELL PHYSIOL, V228, P1060, DOI 10.1002/jcp.24253
   Saleem M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7249
   Schmidmaier G, 2008, INJURY, V39, pS37, DOI 10.1016/S0020 1383(08)70014 7
   Schwab EH, 2015, NANO LETT, V15, P1526, DOI 10.1021/acs.nanolett.5b00315
   Shekaran A, 2014, BIOMATERIALS, V35, P5453, DOI 10.1016/j.biomaterials.2014.03.055
   Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007
   Simic P, 2007, EMBO REP, V8, P327, DOI 10.1038/sj.embor.7400943
   Sinha B, 2011, CELL, V144, P402, DOI 10.1016/j.cell.2010.12.031
   Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377
   van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962 8924(98)01490 1
   Von Einem S, 2011, GROWTH FACTORS, V29, P63, DOI 10.3109/08977194.2011.561798
   WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
NR 71
TC 29
Z9 33
U1 1
U2 44
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2016
VL 46
BP 55
EP 67
DI 10.1016/j.actbio.2016.09.014
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA ED3WG
UT WOS:000388778600005
PM 27633320
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Vanneste, F
   Faure, A
   Varache, M
   Menendez Miranda, M
   Dyon Tafani, V
   Dussurgey, S
   Errazuriz Cerda, E
   La Padula, V
   Alcouffe, P
   Carriere, M
   Gref, R
   Laurent, F
   Josse, J
   Ladavière, C
AF Vanneste, Florian
   Faure, Allison
   Varache, Mathieu
   Menendez Miranda, Mario
   Dyon Tafani, Virginie
   Dussurgey, Sebastien
   Errazuriz Cerda, Elisabeth
   La Padula, Veronica
   Alcouffe, Pierre
   Carriere, Marie
   Gref, Ruxandra
   Laurent, Frederic
   Josse, Jerome
   Ladaviere, Catherine
TI LipoParticles: a lipid membrane coating onto polymer particles to
   enhance the internalization in osteoblast cells
SO NANOSCALE
LA English
DT Article
ID HYBRID NANOPARTICLES; SILICA NANOPARTICLES; PROMISING PLATFORM;
   DELIVERY; PLGA; LIPOSOMES; CHITOSAN; BIOCOMPATIBILITY; STABILIZATION;
   CYCLODEXTRIN
AB LipoParticles, core shell assemblies consisting of a polymer core coated by a lipid membrane, are promising carriers for drug delivery applications with intracellular targets. This is of great interest since it is actually challenging to treat infections involving intracellular bacteria such as bone and joint infections where the bacteria are hidden in osteoblast cells. The present work reports for the first time to the best of our knowledge the proof of enhanced internalization of particles in osteoblast cells thanks to a lipid coating of particles (= LipoParticles). The ca. 300 nm sized assemblies were elaborated by reorganization of liposomes (composed of DPPC/DPTAP 10/90 mol/mol) onto the surface of poly(lactic co glycolic acid) (PLGA) particles, and were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and zetametry. Optimization of these assemblies was also performed by adding poly(ethylene glycol) (PEG) chains on their surface (corresponding to a final formulation of DPPC/DPTAP/DPPE PEG5000 8/90/2 mol/mol/mol). Interestingly, this provided them colloidal stability after their 20 fold dilution in PBS or cell culture medium, and made possible their freeze drying without forming aggregates after their re hydration. Their non cytotoxicity towards a human osteoblast cell line (MG63) was also demonstrated. The enhanced internalization of LipoParticles in this MG63 cell line, in comparison with PLGA particles, was proven by observations with a confocal laser scanning microscope, as well as by flow cytometry assays. Finally, this efficient internalization of LipoParticles in MG63 cells was confirmed by TEM on ultrathin sections, which also revealed localization close to intracellular Staphylococcus aureus.
   LipoParticles, core shell assemblies consisting of a polymer core coated by a lipid membrane, are promising carriers for drug delivery applications with intracellular targets.
C1 [Vanneste, Florian; Varache, Mathieu; Alcouffe, Pierre; Ladaviere, Catherine] Univ Claude Bernard Lyon 1, Univ Lyon, Univ Jean Monnet, INSA Lyon,UMR 5223,Ingn Mat Polymeres,CNRS, F 69622 Lyon, France.
   [Faure, Allison; Dyon Tafani, Virginie; Laurent, Frederic; Josse, Jerome] Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Int Rech Infectiol CIRI, Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France.
   [Menendez Miranda, Mario; Gref, Ruxandra] Univ Paris Sud, Inst Sci Mol Orsay ISMO, F 91405 Orsay, France.
   [Dussurgey, Sebastien] Univ Claude Bernard Lyon 1, Struct Federat Rech Biosci, UMS344 US8, Inserm,CNRS,ENS Lyon, Lyon, France.
   [Errazuriz Cerda, Elisabeth] Univ Claude Bernard Lyon 1, Ctr Imagerie Quantitat Lyon Est CIQLE, Lyon, France.
   [La Padula, Veronica] Univ Claude Bernard Lyon 1, Ctr Technol Microstruct, Villeurbanne, France.
   [Carriere, Marie] Univ Grenoble Alpes, CEA, CNRS, IRIG,SyMMES,CIBEST, F 38000 Grenoble, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS   Institute of
   Chemistry (INC); Institut National des Sciences Appliquees de Lyon  
   INSA Lyon; Universite Jean Monnet; Institut National de la Sante et de
   la Recherche Medicale (Inserm); Universite Claude Bernard Lyon 1; Ecole
   Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante
   et de la Recherche Medicale (Inserm); Centre National de la Recherche
   Scientifique (CNRS); Universite Claude Bernard Lyon 1; Universite Paris
   Saclay; Ecole Normale Superieure de Lyon (ENS de LYON); Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   Claude Bernard Lyon 1; Centre National de la Recherche Scientifique
   (CNRS); Universite Claude Bernard Lyon 1; Universite Claude Bernard Lyon
   1; Centre National de la Recherche Scientifique (CNRS); CEA; Communaute
   Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)
RP Ladavière, C (通讯作者)，Univ Claude Bernard Lyon 1, Univ Lyon, Univ Jean Monnet, INSA Lyon,UMR 5223,Ingn Mat Polymeres,CNRS, F 69622 Lyon, France.; Josse, J (通讯作者)，Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Int Rech Infectiol CIRI, Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France.
EM jerome.josse@univ lyon1.fr
RI Varache, Mathieu/O 6979 2016; Carrière, Marie/F 2149 2011; Gref,
   Ruxandra/F 1487 2011; carriere, marie/F 2149 2011; Varache,
   Mathieu/AAH 8980 2019
OI Varache, Mathieu/0000 0001 7166 2253; Menendez Miranda,
   Mario/0000 0002 2992 1351; carriere, marie/0000 0001 8446 6462;
   Dussurgey, Sebastien/0000 0002 6025 0509; DYON TAFANI,
   VIRGINIE/0009 0007 7191 9064
FU This work was financially supported by grants from the French Agence
   Nationale de la Recherche (ANR 2016 ANTIDOTE). The authors thank Marion
   Decossas (CBMN UMR 5248, Bordeaux) for cryo TEM observations of
   LipoParticles, and the scientific illustrator The D [ANR 2016 ANTIDOTE,
   CBMN UMR 5248]; French Agence Nationale de la Recherche
FX This work was financially supported by grants from the French Agence
   Nationale de la Recherche (ANR 2016 ANTIDOTE). The authors thank Marion
   Decossas (CBMN UMR 5248, Bordeaux) for cryo TEM observations of
   LipoParticles, and the scientific illustrator The Drawing Scientist
   (<URI>https://www.thedrawingscientist.com</URI>) for reviewing and
   optimizing the figures and graphical abstract presented in this paper.
CR Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017
   Alsaab HO, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122728
   Alshehri A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22166 3
   Ayad C, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13030377
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022 2836(65)80093 6
   Barratt G., 2001, POLYM BIOMATERIALS R
   Bathfield M, 2008, MACROMOLECULES, V41, P8346, DOI 10.1021/ma801567c
   Bershteyn A, 2008, SOFT MATTER, V4, P1787, DOI 10.1039/b804933e
   Bourguignon T, 2021, INT J PHARMACEUT, V610, DOI 10.1016/j.ijpharm.2021.121202
   Braun T, 2016, CYTOM PART A, V89A, P301, DOI 10.1002/cyto.a.22792
   Bugnicourt L, 2019, J COLLOID INTERF SCI, V534, P105, DOI 10.1016/j.jcis.2018.08.098
   Bugnicourt L, 2017, J CONTROL RELEASE, V256, P121, DOI 10.1016/j.jconrel.2017.04.018
   Caster JM, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1416
   Cenni E., 2012, J BIOMAT SCI POLYM E, P1
   Chan JM, 2010, P NATL ACAD SCI USA, V107, P2213, DOI 10.1073/pnas.0914585107
   Chaudhury A, 2012, INT J PHARMACEUT, V430, P167, DOI 10.1016/j.ijpharm.2012.04.036
   Corsi K, 2003, BIOMATERIALS, V24, P1255, DOI 10.1016/S0142 9612(02)00507 0
   Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043
   El Say KM, 2017, INT J PHARMACEUT, V528, P675, DOI 10.1016/j.ijpharm.2017.06.052
   Elmowafy Enas M., 2019, Journal of Pharmaceutical Investigation, V49, P347, DOI 10.1007/s40005 019 00439 x
   Guimaraes D, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120571
   Harush Frenkel O, 2008, BIOMACROMOLECULES, V9, P435, DOI 10.1021/bm700535p
   Hitzman CJ, 2006, J PHARM SCI US, V95, P1114, DOI 10.1002/jps.20591
   Jadon RS, 2019, J DRUG DELIV SCI TEC, V51, P475, DOI 10.1016/j.jddst.2019.03.039
   Josse J, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00085
   Krishnamurthy S, 2015, BIOMATER SCI UK, V3, P923, DOI 10.1039/c4bm00427b
   Lacour W, 2016, ADV HEALTHC MATER, V5, P2032, DOI 10.1002/adhm.201600091
   Large DE, 2021, ADV DRUG DELIVER REV, V176, DOI 10.1016/j.addr.2021.113851
   Li B, 2012, INT J NANOMED, V7, P187, DOI 10.2147/IJN.S27864
   Li X, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.01027
   Liu JW, 2009, J AM CHEM SOC, V131, P1354, DOI 10.1021/ja808018y
   Liu P, 2022, MOLECULES, V27, DOI 10.3390/molecules27041372
   Ma TT, 2014, COLLOID SURFACE B, V117, P512, DOI 10.1016/j.colsurfb.2014.02.039
   Mandal B, 2013, NANOMED NANOTECHNOL, V9, P474, DOI 10.1016/j.nano.2012.11.010
   Marro FC, 2021, J ANTIMICROB CHEMOTH, V76, P3091, DOI 10.1093/jac/dkab301
   Messerschmidt SKE, 2009, J CONTROL RELEASE, V137, P69, DOI 10.1016/j.jconrel.2009.03.010
   Mornet S, 2005, NANO LETT, V5, P281, DOI 10.1021/nl048153y
   Nsairat H, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e09394
   Ozturk OncelM. O., 2019, Biomimetic Lipid Membranes: Fundamentals, Applications, and Commercialization, P193, DOI [DOI 10.1007/978 3 030 11596 88, DOI 10.1007/978 3 030 11596 8_8]
   Pancani E, 2018, PART PART SYST CHAR, V35, DOI 10.1002/ppsc.201700457
   Park K, 2019, J CONTROL RELEASE, V304, P125, DOI 10.1016/j.jconrel.2019.05.003
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0392 8
   Persano F, 2021, NANO EXPRESS, V2, DOI 10.1088/2632 959X/abeb4b
   Provost A, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 53528 0
   Przybylo M, 2016, EUR J PHARM SCI, V85, P39, DOI 10.1016/j.ejps.2016.01.028
   Rabinovich M., 2007, MRS P, V1019
   Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794
   Shi SF, 2012, INT J NANOMED, V7, P5593, DOI 10.2147/IJN.S34348
   Shukla R, 2023, CELL, V186, DOI 10.1016/j.cell.2023.07.038
   Shulkin P M, 1984, J Microencapsul, V1, P73, DOI 10.3109/02652048409031539
   Stark B, 2010, EUR J PHARM SCI, V41, P546, DOI 10.1016/j.ejps.2010.08.010
   Tan SW, 2013, NANOSCALE, V5, P860, DOI 10.1039/c2nr32880a
   Tande AJ, 2014, CLIN MICROBIOL REV, V27, P302, DOI 10.1128/CMR.00111 13
   Thevenot J, 2008, J PHYS CHEM B, V112, P13812, DOI 10.1021/jp805865r
   Thevenot J, 2007, BIOMACROMOLECULES, V8, P3651, DOI 10.1021/bm700753q
   Troutier AL, 2005, LANGMUIR, V21, P9901, DOI 10.1021/la050796l
   Troutier AL, 2005, LANGMUIR, V21, P1305, DOI 10.1021/la047659t
   Troutier AL, 2007, ADV COLLOID INTERFAC, V133, P1, DOI 10.1016/j.cis.2007.02.003
   Troutier Thuilliez AL, 2009, SOFT MATTER, V5, P4739, DOI 10.1039/b911260j
   Un K, 2012, BIOMATERIALS, V33, P8131, DOI 10.1016/j.biomaterials.2012.07.030
   van den Hoven JM, 2012, INT J PHARMACEUT, V438, P209, DOI 10.1016/j.ijpharm.2012.08.046
   Vega E, 2012, INT J NANOMED, V7, P1357, DOI 10.2147/IJN.S28481
   Ventola C Lee, 2017, P T, V42, P742
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Xu XW, 2014, RSC ADV, V4, P46481, DOI 10.1039/c4ra06863g
   Yi YF, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556 276X 9 560
   Yoo J, 2020, ACS BIOMATER SCI ENG, V6, P6053, DOI 10.1021/acsbiomaterials.0c01228
NR 67
TC 3
Z9 3
U1 1
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD NOV 16
PY 2023
VL 15
IS 44
BP 18015
EP 18032
DI 10.1039/d3nr03267a
EA NOV 2023
PG 18
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA X5FQ4
UT WOS:001091570100001
PM 37916389
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Williams, LJ
   Henry, MJ
   Berk, M
   Dodd, S
   Jacka, FN
   Kotowicz, MA
   Nicholson, GC
   Pasco, JA
AF Williams, Lana J.
   Henry, Margaret J.
   Berk, Michael
   Dodd, Seetal
   Jacka, Felice N.
   Kotowicz, Mark A.
   Nicholson, Geoffrey C.
   Pasco, Julie A.
TI Selective serotonin reuptake inhibitor use and bone mineral density in
   women with a history of depression
SO INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE bone mineral density; depression; selective serotonin reuptake
   inhibitors
ID OLDER WOMEN; GEELONG OSTEOPOROSIS; PHYSICAL ACTIVITY; RISK; FRACTURES;
   ANTIDEPRESSANTS; 5 HYDROXYTRYPTAMINE; QUESTIONNAIRE; TRANSPORTER;
   EXPRESSION
AB Selective serotonin reuptake inhibitors (SSRIs) are a first line treatment for depression. They have been reported to regulate serotonin signalling in bone cells and may influence bone metabolism. This study aimed to investigate the effect of SSRIs on bone mineral density (BMD) in a sample of women with a lifetime history of depression. In this community based study of 607 women, a history of depression was ascertained using the structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders (DSM) IV TR research version, non patient edition. BMD was measured at the posterior anterior (PA) spine, hip, total body and forearm using dual energy absorptiometry, and medication use and lifestyle factors were self reported. Among 177 women with a lifetime history of depression, current users of bisphosphonates, glucocorticoids, hormone therapy and antidepressants other than SSRIs were excluded. Of the remaining 128 (median age 51.5 years, range 30 74), 26 (20.3%) reported current SSRI use. After controlling for age, weight, height and smoking history, BMD among SSRI users was 5.6% lower at the femoral neck (P=0.03), 6.2% lower at the trochanter (P=0.04) and 4.4% lower at the mid forearm (P=0.03) than nonusers. No differences in BMD were detected at other sites. Although the mechanism remains unclear, these observations are consistent with a role for the serotonergic system in regulating bone metabolism.
C1 [Williams, Lana J.; Henry, Margaret J.; Berk, Michael; Dodd, Seetal; Jacka, Felice N.; Kotowicz, Mark A.; Nicholson, Geoffrey C.; Pasco, Julie A.] Univ Melbourne, Assoc MAPS, Dept Clin & Biomed Sci, Geelong, Vic 3220, Australia.
C3 University of Melbourne
RP Williams, LJ (通讯作者)，Univ Melbourne, Assoc MAPS, Dept Clin & Biomed Sci, POB 281, Geelong, Vic 3220, Australia.
EM lanaw@barwonhealth.org.au
RI Nicholson, Geoffrey/F 1901 2010; Ackland, Julie/C 8607 2012; Berk,
   Michael/M 7891 2013; Jacka, Felice/D 9424 2012; Kotowicz,
   Mark/AAI 4135 2021; Rogers, Margaret/ABI 1852 2020; Jacka,
   Felice/ABE 6322 2020; Berk, Michael/AGH 9427 2022
OI Nicholson, Geoffrey/0000 0002 0152 1153; Kotowicz,
   Mark/0000 0002 8094 1411; Berk, Michael/0000 0002 5554 6946; Jacka,
   Felice/0000 0002 9825 0328; Williams, Lana/0000 0002 1377 1272; Rogers,
   Margaret Joy/0000 0002 1233 6754; 
CR [Anonymous], 1996, DIETARY QUESTIONNAIR
   BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936
   Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606
   Berk M, 1997, J PSYCHOSOM RES, V43, P529, DOI 10.1016/S0022 3999(97)00139 6
   Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756 3282(01)00593 2
   Cauley JA, 2005, OSTEOPOROSIS INT, V16, P1525, DOI 10.1007/s00198 005 1866 8
   Diem SJ, 2007, ARCH INTERN MED, V167, P1240, DOI 10.1001/archinte.167.12.1240
   Ensrud KE, 2003, ARCH INTERN MED, V163, P949, DOI 10.1001/archinte.163.8.949
   Gustafsson BI, 2005, J BONE MINER RES, V20, pS113
   Gustafsson BI, 2006, J CELL BIOCHEM, V98, P139, DOI 10.1002/jcb.20734
   Gustafsson BI, 2006, J CELL BIOCHEM, V97, P1283, DOI 10.1002/jcb.20733
   Haney EM, 2007, ARCH INTERN MED, V167, P1246, DOI 10.1001/archinte.167.12.1246
   Henry MJ, 2000, J CLIN DENSITOM, V3, P261, DOI 10.1385/JCD:3:3:261
   Hubbard R, 2003, AM J EPIDEMIOL, V158, P77, DOI 10.1093/aje/kwg114
   Jacka F.N., 2007, J. Men's Health & Gend., V4, P292
   Jacka FN, 2005, MENOPAUSE, V12, P88, DOI 10.1097/00042192 200512010 00015
   Kinjo Mitsuyo, 2005, Am J Med, V118, P1414
   Liu B, 1998, LANCET, V351, P1303, DOI 10.1016/S0140 6736(97)09528 7
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Michelson D, 1996, NEW ENGL J MED, V335, P1176, DOI 10.1056/NEJM199610173351602
   PASCO JA, 2007, IN PRESS J AFFECT DI
   Richards JB, 2007, ARCH INTERN MED, V167, P188, DOI 10.1001/archinte.167.2.188
   Sogaard AJ, 2005, OSTEOPOROSIS INT, V16, P887, DOI 10.1007/s00198 004 1784 1
   Vaswani M, 2003, PROG NEURO PSYCHOPH, V27, P85, DOI 10.1016/S0278 5846(02)00338 X
   VOORRIPS LE, 1991, MED SCI SPORT EXER, V23, P974, DOI 10.1249/00005768 199108000 00015
   Warden SJ, 2005, MOL CELL ENDOCRINOL, V242, P1, DOI 10.1016/j.mce.2005.06.005
   Warden SJ, 2005, ENDOCRINOLOGY, V146, P685, DOI 10.1210/en.2004 1259
   Westbroek I, 2001, J BIOL CHEM, V276, P28961, DOI 10.1074/jbc.M101824200
   Whooley MA, 1999, ARCH INTERN MED, V159, P484, DOI 10.1001/archinte.159.5.484
   Yazici KM, 2003, PSYCHIAT RES, V117, P271, DOI 10.1016/S0165 1781(03)00017 9
NR 30
TC 93
Z9 101
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0268 1315
EI 1473 5857
J9 INT CLIN PSYCHOPHARM
JI Int. Clin. Psychopharmacol.
PD MAR
PY 2008
VL 23
IS 2
BP 84
EP 87
DI 10.1097/YIC.0b013e3282f2b3bb
PG 4
WC Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Psychiatry
GA 266OD
UT WOS:000253444800003
PM 18301122
DA 2025 08 17
ER

PT J
AU Bejhed, RS
   Kharazmi, M
   Hallberg, P
AF Bejhed, Rebecca S.
   Kharazmi, Mohammad
   Hallberg, Par
TI Identification of Risk Factors for Bisphosphonate Associated Atypical
   Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance
   Database
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE bisphosphonates; osteonecrosis; atypical fracture; adverse drug
   reaction; drug safety; pharmacovigilance; risk factor
ID MEDICATION RELATED OSTEONECROSIS; BONE; PREVENTION; ONJ
AB BACKGROUND: Atypical femoral fractures (AFs) and osteonecrosis of the jaw (ONJ) are well known adverse drug reactions (ADRs) associated with bisphosphonates. To prevent these ADRs and to aid in the search for pathogenic mechanisms, knowledge of risk factors can be helpful. Objective: To identify risk factors for bisphosphonate related ONJ and AF. Methods: In this case control study of reports of bisphosphonate related ADRs from February 16, 1984, to October 16, 2013, in the Swedish national database of ADRs, we compared characteristics for cases of ONJ (n = 167) and AF (n = 55) with all other bisphosphonate related ADRs (n = 565) with regard to demographic variables, clinical characteristics, and concomitant drug treatments. We adjusted for multiple comparisons with Bonferroni correction. Results: Time to onset of ADRs differed statistically significantly between cases of AF and controls (2156 vs 111 days). For ONJ versus controls, differences were statistically significant for time to onset (1240 vs 111 days), intravenous administration (40% vs 20%), dental procedures (49% vs 0.2%) and prostheses (5% vs 0%), cancer disease (44% vs 12%), multiple myeloma (21% vs 1%), rheumatoid arthritis (14% vs 5%), and treatment with antineoplastic agents and oxycodone. Conclusion: These results lend further evidence to previously identified risk factors for ONJthat is, intravenous bisphosphonate administration; invasive dental procedures and dental prostheses; cancer disease, in particular multiple myeloma; and possibly, long term bisphosphonate treatment. A putative further risk factor is rheumatoid arthritis. Only long term bisphosphonate treatment was more common among AF cases. The lack of overlap of risk factors between ONJ and AF suggests different pathogenic mechanisms.
C1 [Bejhed, Rebecca S.] Uppsala Univ, Angstrom Lab, Uppsala, Sweden.
   [Kharazmi, Mohammad] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden.
   [Kharazmi, Mohammad] Cent Hosp Vasteras, Vasteras, Sweden.
   [Hallberg, Par] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
C3 Uppsala University; Uppsala University; Vasteras Central Hospital;
   Uppsala University
RP Hallberg, P (通讯作者)，Uppsala Univ, Univ Uppsala Hosp, Dept Med Sci, Clin Pharmacol, SE 75185 Uppsala, Sweden.
EM par.hallberg@medsci.uu.se
OI Hallberg, Par/0000 0003 3465 3280; Stjernberg Bejhed,
   Rebecca/0000 0001 8641 7146
FU Swedish Dental Society
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study has
   been supported by the Swedish Dental Society.
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Berenson JR, 1999, ANNU REV MED, V50, P237
   Bertulyte I, 2014, J PHARMACOL PHARMACO, V5, P100, DOI 10.4103/0976 500X.130051
   Bertulyte I, 2012, PHARMACOEPIDEM DR S, V21, P441
   Compston J, 2011, OSTEOPOROSIS INT, V22, P2951, DOI 10.1007/s00198 011 1804 x
   Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Girgis CM, 2011, THER ADV MUSCULOSKEL, V3, P301, DOI 10.1177/1759720X11416270
   Gordi T, 2004, CLIN THER, V26, P780, DOI 10.1016/S0149 2918(04)90078 1
   HUTCHINGS HA, 1994, EUR RESPIR J, V7, P715, DOI 10.1183/09031936.94.07040715
   Jarnbring F, 2015, BRIT J ORAL MAX SURG, V53, P1007, DOI 10.1016/j.bjoms.2015.10.006
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kajizono M, 2015, BIOL PHARM BULL, V38, P1850, DOI 10.1248/bpb.b15 00385
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Lescaille G, 2013, J RHEUMATOL, V40, P781, DOI 10.3899/jrheum.120810
   Lesclous P, 2009, BONE, V45, P843, DOI 10.1016/j.bone.2009.07.011
   Madrid C, 2010, ORAL ONCOL, V46, P468, DOI 10.1016/j.oraloncology.2010.03.016
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Otto S, 2012, J CRANIO MAXILL SURG, V40, P303, DOI 10.1016/j.jcms.2011.05.003
   Otto S, 2011, J CRANIO MAXILL SURG, V39, P272, DOI 10.1016/j.jcms.2010.05.009
   RIGGS BL, 1992, NEW ENGL J MED, V327, P620
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Schilcher J, 2014, NEW ENGL J MED, V371, P974, DOI 10.1056/NEJMc1403799
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Shkolnikova J, 2013, ANZ J SURG, V83, P175, DOI 10.1111/ans.12018
   The Uppsala Monitoring Centre, US WHO UMC SYST STAN
   Then C, 2012, ONKOLOGIE, V35, P658, DOI 10.1159/000343950
   Unnanuntana Aasis, 2013, J Bone Joint Surg Am, V95, P1, DOI 10.2106/JBJS.L.00568
   Wester K, 2007, PHARMACOEPIDEM DR S, V16, P173, DOI 10.1002/pds.1263
   Yazdi PM, 2015, OR SURG OR MED OR PA, V119, P416, DOI 10.1016/j.oooo.2014.12.024
NR 35
TC 16
Z9 20
U1 0
U2 24
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060 0280
EI 1542 6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD AUG
PY 2016
VL 50
IS 8
BP 616
EP 624
DI 10.1177/1060028016649368
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DS6TK
UT WOS:000380915500002
PM 27179251
DA 2025 08 17
ER

PT J
AU Xie, KX
   Kong, S
   Li, FX
   Zhang, YL
   Wang, J
   Zhao, WD
AF Xie, Kexin
   Kong, Shan
   Li, Fuxing
   Zhang, Yulin
   Wang, Jing
   Zhao, Weidong
TI Bioinformatics Based Study to Investigate Potential Differentially
   Expressed Genes and miRNAs in Pediatric Sepsis
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Computational Biology; Hu Paraneoplastic Encephalomyelitis Antigens;
   MicroRNAs; Sepsis
ID ACUTE LUNG INJURY; NF KAPPA B; POLYMICROBIAL SEPSIS; OXIDATIVE STRESS;
   HUMAN TLR8; INFLAMMATION; INHIBITION; ACTIVATION; MORTALITY;
   IDENTIFICATION
AB Background: Sepsis is an extremely common health issue with a considerable mortality rate in children. Our understanding about the pathogenic mechanisms of sepsis is limited. The aim of this study was to identify the differential expression genes (DEGs) in pediatric sepsis through comprehensive analysis, and to provide specific insights for the clinical sepsis therapies in children.
   Material/Methods: Three pediatric gene expression profiles (GSE25504, GSE26378, GSE26440) were downloaded from the Gene Expression Omnibus (GEO) database. The difference expression genes (DEGs) between pediatric sepsis and normal control group were screened with the GEO2R online tool. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the DEGs were performed. Cytoscape with CytoHubba were used to identify the hub genes. Finally, NetworkAnalyst was used to construct the targeted microRNAs (miRNAs) of the hub genes.
   Results: Totally, 160 overlapping upward genes and 61 downward genes were identified. In addition, 5 KEGG pathways, including hematopoietic cell lineage, Staphylococcus aureus infection, starch and sucrose metabolism, osteoclast differentiation, and tumor necrosis factor (TNF) signaling pathway, were significantly enriched using a database for labeling, visualization, and synthetic discovery. In combination with the results of the protein protein interaction (PPI) network and CytoHubba, 9 hub genes including ITGAM, TLR8, IL1 beta, MMP9, MPO, FPR2, ELANE, SPI1, and C3AR1 were selected. Combined with DEG miRNAs visualization, 5 miRNAs, including has miR 204 5p, has miR 211 5p, has miR 590 5p, and has miR 21 5p, were predicted as possibly the key miRNAs.
   Conclusions: Our findings will contribute to identification of potential biomarkers and novel strategies for pediatric sepsis treatment.
C1 [Xie, Kexin; Kong, Shan; Li, Fuxing; Zhang, Yulin; Zhao, Weidong] Dali Univ, Lab Dept, Dali, Yunnan, Peoples R China.
   [Wang, Jing] Dali Univ, Sch Clin Med, Dali, Yunnan, Peoples R China.
C3 Dali University; Dali University
RP Zhao, WD (通讯作者)，Dali Univ, Lab Dept, Dali, Yunnan, Peoples R China.
EM wdzhao@dall.edu.cn
RI Zhao, Wei/JLM 5784 2023
OI Li, Fuxing/0000 0002 8441 7879
FU National Science Foundation of China [81960363]; Doctoral Scientific
   Research Foundation of Dali University [KYBS201721]; Foundation of
   Yunnan Provincial Department of Education [2019Y0284]
FX This work was supported by grant no. 81960363 founded by the National
   Science Foundation of China, and by the Doctoral Scientific Research
   Foundation of Dali University (no. KYBS201721), and by the Foundation of
   Yunnan Provincial Department of Education (no. 2019Y0284)
CR Ames SG, 2018, PEDIATR CRIT CARE ME, V19, P390, DOI 10.1097/PCC.0000000000001502
   Avery JT, 2019, MAMM GENOME, V30, P245, DOI 10.1007/s00335 019 09819 y
   Bergstrom B, 2015, J IMMUNOL, V195, P1100, DOI 10.4049/jimmunol.1403176
   Bojic S, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/5064684
   Çakmak HA, 2020, BALK MED J, V37, P60, DOI 10.4274/balkanmedj.galenos.2020.2020.1.94
   Cervantes JL, 2013, J LEUKOCYTE BIOL, V94, P1231, DOI 10.1189/jlb.0413206
   Chen L, 2020, HUM MOL GENET
   Chen L, 2018, ADV CLIN CHEM, V85, P91, DOI 10.1016/bs.acc.2018.02.005
   CHERRUAULT Y, 1991, INT J BIOMED COMPUT, V27, P215, DOI 10.1016/0020 7101(91)90064 L
   Della Giustina A, 2020, NUTRITION, V70, DOI 10.1016/j.nut.2018.12.003
   Fagerholm SC, 2006, BLOOD, V108, P3379, DOI 10.1182/blood 2006 03 013557
   Fischer J, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979 020 00177 x
   Florentino D, 2020, NEUROCHEM INT, V135, DOI 10.1016/j.neuint.2020.104712
   Ge Y, 2019, CYTOKINE GROWTH F R, V45, P24, DOI 10.1016/j.cytogfr.2018.12.004
   Geng RX, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/3215958
   Gobbetti T, 2014, P NATL ACAD SCI USA, V111, P18685, DOI 10.1073/pnas.1410938111
   Goodwin AJ, 2015, CRIT CARE, V19, DOI 10.1186/s13054 015 1162 8
   Grabowski P, 2019, MOL CELL PROTEOMICS, V18, P760, DOI 10.1074/mcp.RA118.001141
   He CH, 2017, LANCET GLOB HEALTH, V5, pE186, DOI [10.1016/s2214 109x(16)30334 5, 10.1016/S2214 109X(16)30334 5]
   Hu QY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03099
   Huang PX, 2020, BRAIN PATHOL, V30, P495, DOI 10.1111/bpa.12798
   Jiang Wei Wei, 2018, Zhongguo Dang Dai Er Ke Za Zhi, V20, P578
   Jin LY, 2014, MOL MED REP, V10, P631, DOI 10.3892/mmr.2014.2299
   Jordakieva G, 2020, WIEN KLIN WOCHENSCHR
   Karpurapu M, 2011, BLOOD, V118, P5255, DOI 10.1182/blood 2011 03 341123
   Krüger A, 2015, EMBO REP, V16, P1656, DOI 10.15252/embr.201540861
   Kurtoglu EL, 2019, TURK J GASTROENTEROL, V30, P745, DOI 10.5152/tjg.2019.18276
   Larkin CM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196478
   Li BJ, 2017, MOL MED REP, V16, P5085, DOI 10.3892/mmr.2017.7217
   Li R, 2019, J LAW MED ETHICS, V47, P369, DOI 10.1177/1073110519876165
   Li XY, 2014, LIFE SCI, V102, P139, DOI 10.1016/j.lfs.2014.03.010
   Liu CH, 2016, INFLAMMATION, V39, P900, DOI 10.1007/s10753 016 0322 6
   Ma J, 2019, INFLAMMATION, V42, P637, DOI 10.1007/s10753 018 0921 5
   Napier BA, 2016, J EXP MED, V213, P2365, DOI 10.1084/jem.20160027
   Prout AJ, 2018, J PEDIATR US, V199, P194, DOI 10.1016/j.jpeds.2018.03.056
   Rao LB, 2020, CYTOKINE, V128, DOI 10.1016/j.cyto.2020.155000
   Saravanan R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05242 0
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Sohn YK, 2020, BIOTECHNOL BIOENG
   Stanski NL, 2020, AM J RESP CRIT CARE, V201, P848, DOI 10.1164/rccm.201911 2187OC
   Tsai S, 2019, SURG ONCOL CLIN N AM, V28, P685, DOI 10.1016/j.soc.2019.06.004
   Wang S, 2019, INFLAMMATION
   Wang Xiangdong, 2011, J Clin Bioinforma, V1, P1, DOI 10.1186/2043 9113 1 1
   Wang XH, 2018, J MOL HISTOL, V49, P411, DOI 10.1007/s10735 018 9781 4
   Weiss SL, 2020, INTENS CARE MED, V46, P10, DOI 10.1007/s00134 019 05878 6
   Yan P, 2018, PEERJ, V6, DOI 10.7717/peerj.6092
   Ye BX, 2018, CANCER LETT, V416, P42, DOI 10.1016/j.canlet.2017.12.017
   Yehya N, 2018, CRIT CARE MED, V46, pE9, DOI 10.1097/CCM.0000000000002754
   Yu GL, 2018, J PHARMACOL EXP THER, V364, P311, DOI 10.1124/jpet.117.245688
   Zhang HJ, 2018, BIOMED PHARMACOTHER, V103, P869, DOI 10.1016/j.biopha.2018.04.092
   Zhang HJ, 2016, STEM CELL REP, V6, P940, DOI 10.1016/j.stemcr.2016.05.002
   Zhang L, 2018, CURR MED SCI, V38, P997, DOI 10.1007/s11596 018 1975 1
   Zhou HT, 2018, J IMMUNOL, V200, P1771, DOI 10.4049/jimmunol.1701285
NR 53
TC 14
Z9 16
U1 1
U2 16
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
EI 1643 3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JUN 23
PY 2020
VL 26
AR e923881
DI 10.12659/MSM.923881
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA MA7PU
UT WOS:000542105200001
PM 32575108
OA Green Published
DA 2025 08 17
ER

PT J
AU Teng, ZW
   Zhu, Y
   Lin, D
   Hao, QG
   Yue, QN
   Yu, XC
   Sun, S
   Jiang, LH
   Lu, S
AF Teng, Zhaowei
   Zhu, Yun
   Lin, Da
   Hao, Qinggang
   Yue, Qiaoning
   Yu, Xiaochao
   Sun, Shuo
   Jiang, Lihong
   Lu, Sheng
TI Deciphering the chromatin spatial organization landscapes during BMMSC
   differentiation
SO JOURNAL OF GENETICS AND GENOMICS
LA English
DT Article
DE Bone marrow mesenchymal stem cells; Differentiation; Hi C; ATAC seq;
   Single nucleotide polymorphisms; Genome wide association studies
ID GENOME WIDE ASSOCIATION; GENE REGULATION; BONE; TRANSCRIPTION;
   REORGANIZATION; OSTEOPOROSIS; ARCHITECTURE; EXPRESSION; PRINCIPLES;
   FRACTURES
AB The differentiation imbalance in bone marrow mesenchymal stem cells (BMMSCs) is critical for the development of bone density diseases as the population ages. BMMSCs are precursor cells for osteoblasts and adipocytes; however, the chromatin organization landscapes during BMMSC differentiation remain elusive. In this study, we systematically delineate the four dimensional genome and dynamic epigenetic atlas of BMMSCs by RNA sequencing, assay for transposase accessible chromatin sequencing, and high throughput chromosome conformation capture. The structure analyses reveal 17.5% common and 28.5% 30% specific loops among BMMSCs, osteoblasts, and adipocytes. The subsequent correlation of genome wide association studies and expression quantitative trait locus (eQTL) data with multi omics analysis reveal 274 genes and 3634 single nucleotide polymorphisms (SNPs) associated with bone degeneration and osteoporosis (OP). We hypothesize that SNP mutations affect transcription factor (TF) binding sites, thereby affecting changes in gene expression. Furthermore, 26 motifs, 260 TFs, and 291 SNPs are identified to affect the eQTL. Among these genes, DAAM2, TIMP2, and TMEM241 are found to be essential for diseases such as bone degeneration and OP and may serve as potential drug targets.Copyright (c) 2023, The Authors. Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, and Genetics Society of China. Published by Elsevier Limited and Science Press. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Teng, Zhaowei; Lu, Sheng] Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Dept Orthoped, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China.
   [Teng, Zhaowei; Jiang, Lihong] First Peoples Hosp Yunnan Prov, Key Lab Yunnan Prov Innovat Applicat Tradit Chines, Kunming 650032, Yunnan, Peoples R China.
   [Teng, Zhaowei] First Peoples Hosp Yunnan Prov, Clin Med Res Ctr, Kunming 650032, Yunnan, Peoples R China.
   [Zhu, Yun; Yue, Qiaoning; Yu, Xiaochao; Sun, Shuo] Kunming Med Univ, Affiliated Hosp 6, Yuxi 653100, Yunnan, Peoples R China.
   [Lin, Da] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.
   [Hao, Qinggang] Yunnan Univ, Ctr Life Sci, Sch Life Sci, Kunming 650504, Yunnan, Peoples R China.
C3 Kunming University of Science & Technology; Kunming University of
   Science & Technology; Kunming University of Science & Technology;
   Kunming Medical University; Huazhong Agricultural University; Yunnan
   University
RP Teng, ZW; Lu, S (通讯作者)，Kunming Univ Sci & Technol, Peoples Hosp Yunnan Prov 1, Dept Orthoped, Affiliated Hosp, Kunming 650032, Yunnan, Peoples R China.; Teng, ZW; Jiang, LH (通讯作者)，First Peoples Hosp Yunnan Prov, Key Lab Yunnan Prov Innovat Applicat Tradit Chines, Kunming 650032, Yunnan, Peoples R China.; Teng, ZW (通讯作者)，First Peoples Hosp Yunnan Prov, Clin Med Res Ctr, Kunming 650032, Yunnan, Peoples R China.
EM tengzhaowei2003@163.com; lihongjiangchinay@163.com; gwklsprof@163.com
RI hao, qinggang/KLZ 6651 2024; Lin, Da/JRZ 0235 2023
FU National Natural Science Foundation of China [31960136]; Yunnan health
   training project for high level talents; Yunnan Key Laboratory of
   Innovative Application of Traditional Chinese Medicine [202105AG070032];
   Kunming University of Science and Technology & the First People's
   Hospital of Yunnan Province Joint Special Project on Medical Research
   [KUSTKH2022002Z]; Yunnan Orthopedics and Sports Rehabilitation Clinical
   Medical Research [2022YJZX  GK04]; 2023 Project of Yunnan Basic Research
   [202201AT070079, 202201AT070285]
FX We would like to acknowledge the assistance of Prof. Gang Cao (Huazhong
   Agricultural University) and his colleagues for their advice regarding
   the analysis of DLO Hi C data. We would like to thank Chengling Liu and
   Leilei Zhan (Medical Research Center, Wuhan GeneCreate Biological
   Engineering Co., Ltd.) for their assistance with sequenced data
   analysis. We sincerely thank Ms. Jin Liu for her contribution to
   themanuscript. This work was supported in part by the National Natural
   Science Foundation of China, grant no. 31960136, and the Yunnan health
   training project for high level talents. Yunnan Key Laboratory of
   Innovative Application of Traditional Chinese Medicine, grant no.
   202105AG070032. Kunming University of Science and Technology & the First
   People's Hospital of Yunnan Province Joint Special Project on Medical
   Research, grant no. KUSTKH2022002Z, and 2021 Center of Yunnan
   Orthopedics and Sports Rehabilitation Clinical Medical Research, grant
   no. 2022YJZX  GK04, and the 2023 Project of Yunnan Basic Research, grant
   no. 202201AT070079 and 202201AT070285.
CR Adachi JD, 2010, MAYO CLIN PROC, V85, P806, DOI 10.4065/mcp.2010.0082
   Alonso N, 2018, ANN RHEUM DIS, V77, P378, DOI 10.1136/annrheumdis 2017 212469
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Bailey TL, 2011, BIOINFORMATICS, V27, P1653, DOI 10.1093/bioinformatics/btr261
   Barutcu AR, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 015 0768 0
   Battulin N, 2015, GENOME BIOL, V16, DOI 10.1186/s13059 015 0642 0
   Bertero A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09483 5
   Bonora G, 2014, CURR OPIN GENET DEV, V27, P92, DOI 10.1016/j.gde.2014.05.002
   Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Chandra T, 2015, CELL REP, V10, P471, DOI 10.1016/j.celrep.2014.12.055
   Chen JF, 2019, CELLS BASEL, V8, DOI 10.3390/cells8111318
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Chen T, 2009, J BIOL CHEM, V284, P6683, DOI 10.1074/jbc.M807753200
   Cheng AX, 2010, J BONE MINER RES, V25, P2404, DOI 10.1002/jbmr.174
   Chesi A., 2015, HUM MOL GENET
   Chesi A, 2017, J BONE MINER RES, V32, P1274, DOI 10.1002/jbmr.3097
   Choi KM, 2008, J BIOSCI BIOENG, V105, P586, DOI 10.1263/jbb.105.586
   Cole Zoe A, 2008, Curr Rheumatol Rep, V10, P92, DOI 10.1007/s11926 008 0017 6
   Crane E, 2015, NATURE, V523, P240, DOI 10.1038/nature14450
   Cremer T, 2006, CURR OPIN CELL BIOL, V18, P307, DOI 10.1016/j.ceb.2006.04.007
   Damcott CM, 2004, METABOLISM, V53, P303, DOI 10.1016/j.metabol.2003.10.010
   Dixon JR, 2015, NATURE, V518, P331, DOI 10.1038/nature14222
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Durand NC, 2016, CELL SYST, V3, P95, DOI 10.1016/j.cels.2016.07.002
   Fraser J, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20156492
   Gozo MC, 2013, CELL DEATH DIFFER, V20, P1031, DOI 10.1038/cdd.2013.34
   Guo Y, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000806
   Gupta S, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 2 r24
   Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200
   Hong P, 2020, GENES BASEL, V11, DOI 10.3390/genes11030289
   Hsu YH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000977
   Hwang JY, 2013, J MED GENET, V50, P212, DOI 10.1136/jmedgenet 2012 101156
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Karasik D, 2010, J BONE MINER RES, V25, P1555, DOI 10.1002/jbmr.38
   KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248
   Kharazmi M, 2019, CALCIFIED TISSUE INT, V105, P51, DOI 10.1007/s00223 019 00546 9
   Kou I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019641
   Kulkarni AK, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01484
   Letarouilly JG, 2019, GENOMICS, V111, P793, DOI 10.1016/j.ygeno.2018.05.001
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Liang X, 2018, BONE, V116, P301, DOI 10.1016/j.bone.2018.08.021
   Lieberman Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Lin D, 2018, NAT GENET, V50, P754, DOI 10.1038/s41588 018 0111 2
   Liu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005027
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Mccoy TH, 2019, JBMR PLUS, V3, P23, DOI 10.1002/jbm4.10063
   Miele A, 2008, MOL BIOSYST, V4, P1046, DOI 10.1039/b803580f
   Morris JA, 2019, NAT GENET, V51, P258, DOI 10.1038/s41588 018 0302 x
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Nora EP, 2013, BIOESSAYS, V35, P818, DOI 10.1002/bies.201300040
   Panula J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 105
   PECK WA, 1993, AM J MED, V94, P646
   Pope BD, 2014, NATURE, V515, P402, DOI 10.1038/nature13986
   Rao SSP, 2014, CELL, V159, P1665, DOI 10.1016/j.cell.2014.11.021
   Rhie SK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12079 8
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   SCHRODER HM, 1993, CLIN ORTHOP RELAT R, P166
   Stains JP, 2003, GENOME BIOL, V4, DOI 10.1186/gb 2003 4 7 222
   Sud A, 2017, NAT REV CANCER, V17, P692, DOI 10.1038/nrc.2017.82
   Sun SW, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.06.14
   Taylor Kira C, 2016, Bone Rep, V5, P233, DOI 10.1016/j.bonr.2016.08.005
   Trajanoska K, 2018, BMJ BRIT MED J, V362, DOI 10.1136/bmj.k3225
   Wan J, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475 2840 9 13
   Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01261 5
   Wilson D.E., 1993, J CLIN INVEST
   Xu WZ, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859 021 04408 w
   Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471 4914(02)02340 7
   Zhang C, 2019, J CELL PHYSIOL, V234, P2491, DOI 10.1002/jcp.26776
   Zheng HF, 2015, NATURE, V526, P112, DOI 10.1038/nature14878
NR 70
TC 8
Z9 8
U1 1
U2 13
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1673 8527
EI 1873 5533
J9 J GENET GENOMICS
JI J. Genet. Genomics
PD APR
PY 2023
VL 50
IS 4
BP 264
EP 275
DI 10.1016/j.jgg.2023.01.009
EA APR 2023
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA F7CK7
UT WOS:000983883000001
PM 36720443
OA hybrid
DA 2025 08 17
ER

PT J
AU Yang, P
   Wang, LP
   Peng, RT
   Almehizia, AA
   Tong, Q
   Myint, KZ
   Ouyang, Q
   Alqarni, MH
   Wang, LR
   Xie, XQ
AF Yang, Peng
   Wang, Lipinig
   Peng, Rentian
   Almehizia, Abdulrahman A.
   Tong, Qin
   Myint, Kyaw Zeyar
   Ouyang, Qin
   Alqarni, Mohammed Hamed
   Wang, Lirong
   Xie, Xiang Qun
TI Novel Triaryl Sulfonamide Derivatives as Selective Cannabinoid Receptor
   2 Inverse Agonists and Osteoclast Inhibitors: Discovery, Optimization,
   and Biological Evaluation
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID CB2 RECEPTOR; ENDOCANNABINOID SYSTEM; SIGNAL TRANSDUCTION; LIGAND;
   ATTENUATION; ANTAGONIST; BINDS
AB Cannabinoid receptors have gained increasing attention as drug targets for developing potential therapeutic ligands. Here, we report the discovery and optimization of triaryl sulfonamides as a novel series possessing significant CB2 receptor affinity and selectivity. Four sets of triaryl ligands were designed and synthesized for further structural modifications and led to the identification of eight compounds as potent and selective CB2 inverse agonists with high binding affinity (CB2 K i < 10 nM). Especially, compound 57 exhibited the strongest binding affinity on the CB2 receptor (CB2 K i of 0.5 nM) and the best selectivity over the CB1 receptor (selectivity index of 2594). Importantly, 57 also showed potent inhibitory activity on osteoclast formation, and it was confirmed by a cell viability assay that the inhibition effects were not derived from the cytotoxicity. Finally, 3D QSAR studies confirmed our SAR findings that three bulky groups play an important role for CB2 receptor binding affinity.
C1 [Yang, Peng; Wang, Lipinig; Peng, Rentian; Almehizia, Abdulrahman A.; Tong, Qin; Myint, Kyaw Zeyar; Ouyang, Qin; Alqarni, Mohammed Hamed; Wang, Lirong; Xie, Xiang Qun] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
   [Yang, Peng; Wang, Lipinig; Peng, Rentian; Almehizia, Abdulrahman A.; Tong, Qin; Myint, Kyaw Zeyar; Ouyang, Qin; Alqarni, Mohammed Hamed; Wang, Lirong; Xie, Xiang Qun] Univ Pittsburgh, Sch Pharm, Computat Chem Genom Screening Ctr, Pittsburgh, PA 15260 USA.
   [Yang, Peng; Wang, Lipinig; Peng, Rentian; Almehizia, Abdulrahman A.; Tong, Qin; Myint, Kyaw Zeyar; Ouyang, Qin; Alqarni, Mohammed Hamed; Wang, Lirong; Xie, Xiang Qun] Univ Pittsburgh, Drug Discovery Inst, Pittsburgh, PA 15260 USA.
   [Wang, Lirong; Xie, Xiang Qun] Univ Pittsburgh, Pittsburgh Chem Methods & Lib Dev CMLD Ctr, Pittsburgh, PA 15260 USA.
   [Xie, Xiang Qun] Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15260 USA.
   [Xie, Xiang Qun] Univ Pittsburgh, Dept Biol Struct, Pittsburgh, PA 15260 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Xie, XQ (通讯作者)，Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
EM xix15@pitt.edu
RI Almehizia, Abdulrahman/AAL 5543 2020; Yang, Peng/HPH 5119 2023; Alqarni,
   Mohammed H./AGY 9343 2022; qin, tong/JEZ 6348 2023; Alqarni,
   Mohammed/AGY 9343 2022
OI Almehizia, Abdulrahman/0000 0001 8711 3873; Alqarni, Mohammed
   H./0000 0002 7061 9111; Yang, Peng/0000 0002 2613 941X; 
FU NIH [R01DA025612, R21HL109654, P50 GM067082]; National Natural Science
   Foundation of China [NSFC81090410, NSFC90913018]
FX The authors from the University of Pittsburgh gratefully acknowledge the
   financial support for our laboratory from the NIH R01DA025612 and
   R21HL109654 and P50 GM067082. The authors also acknowledge the
   collaborative support from the National Natural Science Foundation of
   China (NSFC81090410, NSFC90913018).
CR Anandarajah AP, 2008, ANN RHEUM DIS, V67, P296, DOI 10.1136/ard.2007.076091
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902
   Chen JZ, 2006, J MED CHEM, V49, P625, DOI 10.1021/jm050655g
   COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218
   DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919
   FELDER CC, 1995, MOL PHARMACOL, V48, P443
   Feng RT, 2008, MOL CANCER THER, V7, P1494, DOI 10.1158/1535 7163.MCT 08 0183
   Feng RT, 2007, BLOOD, V109, P2130, DOI 10.1182/blood 2006 07 027458
   Francisco MEY, 2002, J MED CHEM, V45, P2708, DOI 10.1021/jm010498v
   Gertsch J, 2008, P NATL ACAD SCI USA, V105, P9099, DOI 10.1073/pnas.0803601105
   Guindon J, 2011, BRIT J PHARMACOL, V163, P1447, DOI 10.1111/j.1476 5381.2011.01327.x
   Hegde VL, 2008, MOL PHARMACOL, V74, P20, DOI 10.1124/mol.108.047035
   Hillard CJ, 2008, CURR PHARM DESIGN, V14, P2347, DOI 10.2174/138161208785740054
   Hohmann AG, 2002, CHEM PHYS LIPIDS, V121, P173, DOI 10.1016/S0009 3084(02)00154 8
   Huffman JW, 1999, CURR MED CHEM, V6, P705
   Huffman JW, 2005, BIOORGAN MED CHEM, V13, P89, DOI 10.1016/j.bmc.2004.09.050
   Idris AI, 2010, CALCIFIED TISSUE INT, V87, P285, DOI 10.1007/s00223 010 9378 8
   Iwamura H, 2001, J PHARMACOL EXP THER, V296, P420
   Izzo AA, 2008, GUT, V57, P1140, DOI 10.1136/gut.2008.148791
   Karsak M, 2007, SCIENCE, V316, P1494, DOI 10.1126/science.1142265
   Kimball ES, 2006, AM J PHYSIOL GASTR L, V291, pG364, DOI 10.1152/ajpgi.00407.2005
   Lunn CA, 2006, J PHARMACOL EXP THER, V316, P780, DOI 10.1124/JPET.105.093500
   Marriott KSC, 2008, CURR TOP MED CHEM, V8, P187
   MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0
   MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006 2952(95)00109 D
   Muñoz Luque J, 2008, J PHARMACOL EXP THER, V324, P475, DOI 10.1124/jpet.107.131896
   MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0
   Myint KZ, 2010, INT J MOL SCI, V11, P3846, DOI 10.3390/ijms11103846
   Oesch S, 2009, J PHARM PHARMACOL, V61, P839, DOI 10.1211/jpp/61.07.0002
   Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2
   Palazuelos J, 2008, J BIOL CHEM, V283, P13320, DOI 10.1074/jbc.M707960200
   Palmer SL, 2002, CHEM PHYS LIPIDS, V121, P3, DOI 10.1016/S0009 3084(02)00143 3
   Raitio KH, 2005, CURR MED CHEM, V12, P1217, DOI 10.2174/0929867053764617
   Rinaldi Carmona M, 1998, J PHARMACOL EXP THER, V284, P644
   Ross RA, 1999, BRIT J PHARMACOL, V126, P665, DOI 10.1038/sj.bjp.0702351
   SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437
   Xi ZX, 2011, NAT NEUROSCI, V14, P1160, DOI 10.1038/nn.2874
   Xie XQ, 1996, J BIOL CHEM, V271, P10640, DOI 10.1074/jbc.271.18.10640
   Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511
   Xu J, 2012, J MED CHEM, V55, P3122, DOI 10.1021/jm201540h
   Yang P, 2012, J MED CHEM, V55, P9973, DOI 10.1021/jm301212u
   Yang P, 2012, FUTURE MED CHEM, V4, P187, DOI [10.4155/FMC.11.179, 10.4155/fmc.11.179]
   Zhang YX, 2011, INT IMMUNOPHARMACOL, V11, P1303, DOI 10.1016/j.intimp.2011.04.013
NR 44
TC 38
Z9 45
U1 0
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAR 14
PY 2013
VL 56
IS 5
BP 2045
EP 2058
DI 10.1021/jm3017464
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 108PQ
UT WOS:000316308300022
PM 23406429
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Okawa, Y
   Hideshima, T
   Steed, P
   Vallet, S
   Hall, S
   Huang, K
   Rice, J
   Barabasz, A
   Foley, B
   Ikeda, H
   Raje, N
   Kiziltepe, T
   Yasui, H
   Enatsu, S
   Anderson, KC
AF Okawa, Yutaka
   Hideshima, Teru
   Steed, Paul
   Vallet, Sonia
   Hall, Steven
   Huang, Ken
   Rice, John
   Barabasz, Amy
   Foley, Brianna
   Ikeda, Hiroshi
   Raje, Noopur
   Kiziltepe, Tanyel
   Yasui, Hiroshi
   Enatsu, Sotaro
   Anderson, Kenneth C.
TI SNX 2112, a selective Hsp90 inhibitor, potently inhibits tumor cell
   growth, angiogenesis, and osteoclastogenesis in multiple myeloma and
   other hematologic tumors by abrogating signaling via Akt and ERK
SO BLOOD
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; SMALL MOLECULE INHIBITOR; ANTITUMOR ACTIVITY;
   DRUG RESISTANCE; SOLID TUMORS; PHASE I; ACTIVATION;
   HEAT SHOCK PROTEIN 90; BONE; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN
AB Heat shock protein 90 (Hsp90) acts as a molecular chaperone required for maintaining the conformational stability of client proteins regulating cell proliferation, survival, and apoptosis. Here we investigate the biologic significance of Hsp90 inhibition in multiple myeloma (MM) and other hematologic tumors using an orally available novel small molecule inhibitor SNX 2112, which exhibits unique activities relative to 17 allyamino 17 demethoxy geldanamycin (17 AAG). SNX 2112 triggers growth inhibition and is more potent than 17 AAG against MM and other malignancies. It induces apoptosis via caspase 8,  9,  3, and poly (ADP ribose) polymerase cleavage. SNX 2112 inhibits cytokine inducedAkt and extracellular signal related kinase (ERK) activation and also overcomes the growth advantages conferred by interleukin 6, insulin like growth factor 1, and bone marrow stromal cells. Importantly, SNX 2112 inhibits tube formation by human umbilical vein endothelial cells via abrogation of eNOS/Akt pathway and markedly inhibits osteoclast formation via down regulation of ERK/c fos and PU.1. Finally, SNX 2112, delivered by its prodrug SNX 5422, inhibits MM cell growth and prolongs survival in a xenograft murine model. Our results indicate that blockade of Hsp90 by SNX 2112 not only inhibitsMMcell growth but also acts in the bone marrow microenvironment to block angiogenesis and osteoclastogenesis. Taken together, our data provide the framework for clinical studies of SNX 2112 to improve patient outcome in MM and other hematologic malignancies. (Blood. 2009; 113:846 855)
C1 [Okawa, Yutaka; Hideshima, Teru; Vallet, Sonia; Ikeda, Hiroshi; Raje, Noopur; Kiziltepe, Tanyel; Yasui, Hiroshi; Enatsu, Sotaro; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
   [Okawa, Yutaka; Hideshima, Teru; Vallet, Sonia; Ikeda, Hiroshi; Raje, Noopur; Kiziltepe, Tanyel; Yasui, Hiroshi; Enatsu, Sotaro; Anderson, Kenneth C.] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Myeloma Ctr, Boston, MA 02115 USA.
   [Okawa, Yutaka] Jikei Univ, Sch Med, Dept Internal Med, Div Clin Oncol & Hematol, Tokyo, Japan.
   [Steed, Paul; Hall, Steven; Huang, Ken; Rice, John; Barabasz, Amy; Foley, Brianna] Serenex, Durham, NC USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard University; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute; Jikei University
RP Anderson, KC (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, LeBow Inst Myeloma Therapeut, Mayer 557,44 Binney St, Boston, MA 02115 USA.
EM yutaka_okawa@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu
RI ; Rice, John/AAO 4080 2021; Anderson, Kenneth/ACP 5073 2022; Vallet,
   Sonia/AHE 3935 2022
OI Vallet, Sonia/0000 0003 0146 8089; Yasui, Hiroshi/0000 0003 0905 6855; 
FU National Institutes of Health [IP50 CA10070 01, PO 1 CA78378, RO 1
   CA50947]; Multiple Myeloma Research Foundation; LeBow Family Fund
FX This study was supported by the National Institutes of Health
   Specialized Programs of Research Excellence (grants IP50 CA10070 01,
   PO 1 CA78378, and RO 1 CA50947), the Multiple Myeloma Research
   Foundation (T.H., K.C.A.), and the LeBow Family Fund to Cure Myeloma
   (K.C.A.).
CR Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burrows F, 2004, CELL CYCLE, V3, P1530, DOI 10.4161/cc.3.12.1277
   Chandarlapaty S, 2008, CLIN CANCER RES, V14, P240, DOI 10.1158/1078 0432.CCR 07 1667
   Cysyk RL, 2006, CHEM RES TOXICOL, V19, P376, DOI 10.1021/tx050237e
   Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Dunn FB, 2002, J NATL CANCER I, V94, P1194
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Francis LK, 2006, CLIN CANCER RES, V12, P6826, DOI 10.1158/1078 0432.CCR 06 1331
   García Cardeña G, 1998, NATURE, V392, P821, DOI 10.1038/33934
   Georgakis Georgios V, 2005, Future Oncol, V1, P273
   Grem JL, 2005, J CLIN ONCOL, V23, P1885, DOI 10.1200/JCO.2005.12.085
   Hall, 2007, CANCER RES, V67, P4177
   Hayashi T, 2002, MOL CANCER THER, V1, P851
   Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833
   HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140 6736(92)93150 L
   Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758
   Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913
   Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood 2005 03 1158
   Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535 6108(04)00050 9
   Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664
   Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822
   Neckers Len, 2005, Expert Opin Emerg Drugs, V10, P137, DOI 10.1517/14728214.10.1.137
   Ogata A, 1997, CLIN CANCER RES, V3, P1017
   Patterson J, 2008, CANCER CHEMOTH PHARM, V61, P923, DOI 10.1007/s00280 007 0546 0
   Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738
   Podar K, 2007, BLOOD, V109, P1669, DOI 10.1182/blood 2006 08 042747
   Rajkumar SV, 2001, BRIT J HAEMATOL, V113, P565, DOI 10.1046/j.1365 2141.2001.02690.x
   Ramanathan RK, 2005, CLIN CANCER RES, V11, P3385, DOI 10.1158/1078 0432.CCR 04 2322
   Richardson PG, 2007, J CLIN ONCOL, V25
   Richardson Paul, 2004, Curr Treat Options Oncol, V5, P227, DOI 10.1007/s11864 004 0014 6
   Roodman GD, 2004, BLOOD CELL MOL DIS, V32, P290, DOI 10.1016/j.bcmd.2004.01.001
   Sausville EA, 2003, CURR CANCER DRUG TAR, V3, P377, DOI 10.2174/1568009033481831
   Solit DB, 2002, CLIN CANCER RES, V8, P986
   Steed R, 2006, EJC SUPPL, V4, P165
   Sun JX, 2004, ARTERIOSCL THROM VAS, V24, P2238, DOI 10.1161/01.ATV.0000147894.22300.4c
   Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200
   Takahashi S, 2003, J BIOL CHEM, V278, P9339, DOI 10.1074/jbc.M212651200
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   Vacca A, 1999, BLOOD, V93, P3064
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Yasui H, 2006, BRIT J HAEMATOL, V132, P385, DOI 10.1111/j.1365 2141.2005.05860.x
   Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109 004 0549 9
   Ziche M, 2000, J NEURO ONCOL, V50, P139, DOI 10.1023/A:1006431309841
NR 50
TC 194
Z9 205
U1 1
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JAN 22
PY 2009
VL 113
IS 4
BP 846
EP 855
DI 10.1182/blood 2008 04 151928
PG 10
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 397EW
UT WOS:000262646200013
PM 18948577
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Shahrara, S
   Castro Rueda, HP
   Haines, GK
   Koch, AE
AF Shahrara, Shiva
   Castro Rueda, Hernan P.
   Haines, G. Kenneth
   Koch, Alisa E.
TI Differential expression of the FAK family kinases in rheumatoid
   arthritis and osteoarthritis synovial tissues
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID FOCAL ADHESION KINASE; ADJUVANT INDUCED ARTHRITIS; OSTEOCLASTIC
   BONE RESORPTION; ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA;
   PHOSPHATIDYLINOSITOL 3 KINASE; ALPHA(V)BETA(3) INTEGRIN; POSSIBLE
   INVOLVEMENT; SIGNAL TRANSDUCTION; CELL ADHESION
AB The focal adhesion kinase (FAK) family kinases, including FAK and proline rich kinase 2 (Pyk)2, are the predominant mediators of integrin alpha v beta 3 signaling events that play an important role in cell adhesion, osteoclast pathology, and angiogenesis, all processes important in rheumatoid arthritis (RA). Using immunohistochemical and western blot analysis, we studied the distribution of phospho (p) FAK, pPyk2, pSrc, pPaxillin and pPL gamma. in the synovial tissue (ST) from patients with RA, osteoarthritis (OA) and normal donors (NDs) as well as in RA ST fibroblasts and peripheral blood differentiated macrophages (PB M Phi s) treated with tumor necrosis factor alpha (TNF alpha) or interleukin 1 beta (IL1 beta). RA and OA STs showed a greater percentage of pFAK on lining cells and M Phi s compared with ND ST. RA ST fibroblasts expressed pFAK at baseline, which increased with TNF alpha or IL1 beta stimulation. Pyk2 and Src were phosphorylated more on RA versus OA and ND lining cells and MFs. pPyk2 was expressed on RA ST fibrobasts but not in MFs at baseline, however it was upregulated upon TNF alpha or IL1 beta activation in both cell types. pSrc was expressed in RA ST fibroblasts and MFs at baseline and was further increased by TNF alpha or IL1 beta stimulation. pPaxillin and pPLC. were upregulated in RA versus OA and ND lining cells and sublining M Phi s. Activation of the FAK family signaling cascade on RA and OA lining cells may be responsible for cell adhesion and migration into the diseased STs. Therapies targeting this novel signaling pathway may be beneficial in RA.
C1 [Shahrara, Shiva; Castro Rueda, Hernan P.; Koch, Alisa E.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA.
   [Haines, G. Kenneth] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA.
   [Haines, G. Kenneth] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06511 USA.
   [Koch, Alisa E.] Chicago Hlth Care Syst, Vet Adm, Chicago, IL 60611 USA.
   [Koch, Alisa E.] Vet Adm, Ann Arbor, MI 48109 USA.
   [Koch, Alisa E.] Univ Michigan, Ctr Med, Ann Arbor, MI 48109 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine; Yale University; University of
   Michigan System; University of Michigan
RP Koch, AE (通讯作者)，Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA.
EM aekoch@med.umich.edu
RI Koch, Alisa/B 6894 2011
FU NHLBI NIH HHS [R01 HL058695, HL58695] Funding Source: Medline; NIAID NIH
   HHS [AI40987, R01 AI040987] Funding Source: Medline; NIAMS NIH HHS
   [AR48267, AR049353, R01 AR048267, K01 AR049353] Funding Source: Medline
CR ALTMAN R, 1991, ARTHRITIS RHEUM, V34, P505, DOI 10.1002/art.1780340502
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Andreev J, 1999, MOL CELL BIOL, V19, P2338
   Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898 6568(99)00076 5
   Badger AM, 2000, ARTHRITIS RHEUM, V43, P175, DOI 10.1002/1529 0131(200001)43:1<175::AID ANR22>3.0.CO;2 S
   Baig S, 2002, BIOCHEM SOC T, V30, P883, DOI 10.1042/bst0300883
   Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109
   Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284
   Chang JS, 1999, FEBS LETT, V460, P161, DOI 10.1016/S0014 5793(99)01338 1
   CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995
   CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148
   Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209
   Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945 053X(97)90008 1
   HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637
   HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0
   Itonaga I, 2000, J PATHOL, V192, P97
   KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132
   Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952
   Kohno M, 2001, J RHEUMATOL, V28, P2591
   Maru Y, 2001, BBA MOL CELL RES, V1540, P147, DOI 10.1016/S0167 4889(01)00127 6
   Matsumoto Y, 2002, J IMMUNOL, V168, P5824, DOI 10.4049/jimmunol.168.11.5824
   Miyazaki Tsuyoshi, 2006, Mod Rheumatol, V16, P68
   Morel J, 2004, JOINT BONE SPINE, V71, P503, DOI 10.1016/j.jbspin.2004.03.004
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361
   Nishikawa M, 2003, ARTHRITIS RHEUM US, V48, P2670, DOI 10.1002/art.11227
   Okigaki M, 2003, P NATL ACAD SCI USA, V100, P10740, DOI 10.1073/pnas.1834348100
   POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678
   Ruth JH, 2003, LAB INVEST, V83, P579, DOI 10.1097/01.LAB.0000062854.30195.52
   Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181
   SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680
   Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079 6107(98)00052 2
   Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189
   Shahrara S, 2005, ARTHRITIS RHEUM, V52, P1907, DOI 10.1002/art.21033
   Shahrara S, 2003, ARTHRITIS RHEUM US, V48, P3568, DOI 10.1002/art.11344
   Shahrara S, 2006, J IMMUNOL, V177, P5077, DOI 10.4049/jimmunol.177.8.5077
   Sweeney SE, 2004, CURR OPIN RHEUMATOL, V16, P231, DOI 10.1097/00002281 200405000 00011
   TANAKA S, 1995, J CELL BIOCHEM, V58, P424, DOI 10.1002/jcb.240580405
   Tokuhira M, 2000, ARTHRITIS RHEUM, V43, P1122, DOI 10.1002/1529 0131(200005)43:5<1122::AID ANR23>3.0.CO;2 7
   TURNER CE, 1994, J CELL SCI, V107, P1583
   Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357 2725(98)00062 4
   Tvorogov D, 2005, J CELL SCI, V118, P601, DOI 10.1242/jcs.01643
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413
   Xiong WC, 2003, FRONT BIOSCI LANDMRK, V8, pD1219, DOI 10.2741/1117
   Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021
   Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756 3282(02)00834 7
NR 49
TC 64
Z9 73
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478 6354
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2007
VL 9
IS 5
AR R112
DI 10.1186/ar2318
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 252TB
UT WOS:000252468400035
PM 17963503
OA Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Aguilera Correa, JJ
   Gisbert Garzarán, M
   Mediero, A
   Fernández Aceñero, MJ
   de Pablo Velasco, D
   Lozano, D
   Esteban, J
   Vallet Regí, M
AF Aguilera Correa, J. J.
   Gisbert Garzaran, M.
   Mediero, A.
   Fernandez Acenero, M. J.
   de Pablo Velasco, D.
   Lozano, D.
   Esteban, J.
   Vallet Regi, M.
TI Antibiotic delivery from bone targeted mesoporous silica nanoparticles
   for the treatment of osteomyelitis caused by methicillin resistant
   Staphylococcus aureus
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Osteomyelitis; Biofilm; Methicillin resistant Staphylococcus aureus;
   Mesoporous silica nanoparticles; Bone targeting; Drug delivery
ID PSEUDOMONAS AERUGINOSA; SUSTAINED RELEASE; BIOFILM FORMATION;
   MOXIFLOXACIN; GELATIN; EFFICACY; PROLIFERATION; OSTEOBLASTS; DIAGNOSIS;
   CULTURES
AB Osteomyelitis is a hard to treat infection of the bone and bone marrow that is mainly caused by Staphy lococcus aureus, with an increasing incidence of methicillin resistant S. aureus (MRSA). Owing to the ag gressiveness of these bacteria in colonizing and destroying the bone, systemic antibiotic treatments fail to eradicate the infection. Instead, it normally entails surgery to remove the dead or infected bone. In this work, we report bone targeted mesoporous silica nanoparticles for the treatment of osteomyelitis. The nanoparticles have been engineered with a functional gelatine/colistin coating able to hamper pre mature release from the mesopores while effectively disaggregating the bacterial biofilm. Because an tibiotic resistance is a global emergency, we have designed two sets of identical nanoparticles, carrying each of them a clinically relevant antibiotic, that have demonstrated to have synergistic effect. The bone  targeted nanoparticles have been thoroughly evaluated in vitro and in vivo , obtaining a notable reduction of the amount of bacteria in the bone in just 24 h after only one dose, and paving the way for localized, nanoparticle mediated treatment of MRSA caused osteomyelitis. Statement of significance In this work, we propose the use of bone targeted mesoporous silica nanoparticles to address S. aureus  caused osteomyelitis that render synergistic therapeutic effect via multidrug delivery. Because the bac terial biofilm is responsible for an aggressive surgical approach and prolonged antibiotic treatment, the nanoparticles have been functionalized with a functional coating able to both disaggregate the biofilm, hamper premature antibiotic release and protect the intact bone. These engineered nanoparticles are able to effectively target bone tissue both in vitro and in vivo , showing high biocompatibility and elevated an tibacterial effect. (c) 2022 The Author(s). Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
C1 [Aguilera Correa, J. J.; Gisbert Garzaran, M.; Lozano, D.; Vallet Regi, M.] Univ Complutense Madrid, Inst Invest Sanitaria Hosp 12 Octubre & 12, Dept Quim Ciencias Farmaceut, Plaza Ramon Y Cajal S N, Madrid 28029, Spain.
   [Aguilera Correa, J. J.; Esteban, J.] CIBER Enfermedades Infecciosas CIBERINFEC, Madrid 28029, Spain.
   [Mediero, A.] UAM, Bone & Joint Unit, IIS Fdn Jimenez Diaz, Ave Reyes Catolicos 2, Madrid 228037, Spain.
   [Fernandez Acenero, M. J.; de Pablo Velasco, D.] UCM, Pathol Dept, San Carlos Clin Hosp, Madrid, Spain.
   [Gisbert Garzaran, M.; Lozano, D.; Vallet Regi, M.] CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid 28029, Spain.
   [Esteban, J.] UAM, IIS Fdn Jimenez Diaz, Clin Microbiol Dept, Ave Reyes Catolicos 2, Madrid 28037, Spain.
C3 Complutense University of Madrid; Fundacion Jimenez Diaz; Autonomous
   University of Madrid; Complutense University of Madrid; CIBER   Centro
   de Investigacion Biomedica en Red; CIBERBBN; Fundacion Jimenez Diaz;
   Autonomous University of Madrid
RP Esteban, J; Vallet Regí, M (通讯作者)，Univ Complutense Madrid, Inst Invest Sanitaria Hosp 12 Octubre & 12, Dept Quim Ciencias Farmaceut, Plaza Ramon Y Cajal S N, Madrid 28029, Spain.
EM jesteban@fjd.es
RI Aguilera Correa, John/T 1515 2018; LOZANO, DANIEL/AAN 6416 2020;
   Mediero, Aranzazu/AAA 8362 2020; Esteban, Jaime/S 6554 2018;
   Vallet Regí, Maria/M 3378 2014; Gisbert Garzarán, Miguel/S 2443 2016;
   Lozano, Daniel/B 5081 2017; Gisbert Garzaran, Miguel/S 2443 2016
OI Aguilera Correa, John Jairo/0000 0002 4002 1944; Esteban,
   Jaime/0000 0002 8971 3167; De Pablo Velasco, David/0000 0003 0286 6089;
   Lozano, Daniel/0000 0001 5902 9201; Gisbert Garzaran,
   Miguel/0000 0001 9815 0354; Mediero, Aranzazu/0000 0002 5368 574X
FU European Research Council [ERC 2015 AdG 694160]; Instituto de Salud
   Carlos III [CP15/00053]
FX The authors acknowledge the financial support from the European Research
   Council through ERC 2015 AdG 694160 (VERDI) grant. AM is funded by
   grants from Instituto de Salud Carlos III through the "Miguel Servet"
   program (CP15/00053). We also wish to acknowledge Roger Plaut from
   United States Food & Drugs Administration for providing us the
   bioluminescent MRSA (SAP231), Maria del Mar Gonzalez Garcia Parreno from
   IIS  Fundacion Jimenez Diaz for her help with the use of the confocal
   laser scanning microscope, and Beatriz Toirac Chavez and Antonia
   Jimenez Morales from Carlos III University of Madrid for manufacturing
   the Ti 6Al 4V implants used in the in vivo model of this study. Parts of
   this work were previously presented at the 32nd European Congress of
   Clinical Microbiology and Infectious Diseases, and 25th Spanish Congress
   of Clinical Microbiology and Infectious Diseases. Graphical abstract,
   Scheme 1 , and some icons from Figs. S4, S5 and S6 have been created
   with BioRender.com.
CR Abdelgawad ME, 2014, BONE, V67, P181, DOI 10.1016/j.bone.2014.07.012
   Aguilar Colomer A, 2017, J ANTIBIOT, V70, P259, DOI 10.1038/ja.2016.154
   Aguilera Correa JJ, 2022, ACTA BIOMATER, V137, P218, DOI 10.1016/j.actbio.2021.10.014
   Aguilera Correa JJ, 2019, ACS OMEGA, V4, P11815, DOI 10.1021/acsomega.9b00898
   Aguilera Correa JJ, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6119 4
   Aiken SS, 2015, SURG INFECT, V16, P54, DOI 10.1089/sur.2013.162
   [Anonymous], 2021, Global Antimicrobial Resistance and Use Surveillance System (GLASS)
   Auñón A, 2020, J ORTHOP RES, V38, P588, DOI 10.1002/jor.24496
   Balas F, 2008, ACTA BIOMATER, V4, P514, DOI 10.1016/j.actbio.2007.11.009
   Balfour JAB, 1999, DRUGS, V57, P363
   BASSI L, 1973, J INFECT DIS, V128, P736, DOI 10.1093/infdis/128.6.736
   Benetton SA, 1998, TALANTA, V47, P639, DOI 10.1016/S0039 9140(98)00111 8
   Bentley KLD, 2017, J BONE MINER RES, V32, P985, DOI 10.1002/jbmr.3055
   Birt MC, 2017, J ORTHOP, V14, P45, DOI 10.1016/j.jor.2016.10.004
   Brandl K, 2017, AM J PHYSIOL GASTR L, V312, pG413, DOI 10.1152/ajpgi.00361.2016
   Brinkman CL, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01822 16
   de Mesy Bentley Karen L, 2018, JBJS Case Connect, V8, pe8, DOI 10.2106/JBJS.CC.17.00154
   DeLeon S, 2014, INFECT IMMUN, V82, P4718, DOI 10.1128/IAI.02198 14
   Devlin H, 2021, INT J NANOMED, V16, P1929, DOI 10.2147/IJN.S293190
   Doadrio AL, 2015, INT J PHARMACEUT, V492, P207, DOI 10.1016/j.ijpharm.2015.07.046
   Esteban J, 2008, J CLIN MICROBIOL, V46, P488, DOI 10.1128/JCM.01762 07
   EUCAST, 2000, CLIN MICROBIOL INFEC, V6, P570
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Forsblom E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122824
   Fritz JM, 2008, PHYSICIAN SPORTSMED, V36, P50, DOI 10.3810/psm.2008.12.11
   Fu C, 2017, RSC ADV, V7, P8886, DOI 10.1039/c6ra26020a
   del Pozo EG, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879 018 3550 6
   Gisbert Garzaran M, 2017, RSC ADV, V7, P132, DOI 10.1039/c6ra26771h
   Gisbert Garzarán M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12010083
   González MJ, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx053
   Gounani Z, 2019, COLLOID SURFACE B, V175, P498, DOI 10.1016/j.colsurfb.2018.12.035
   Greimel F, 2017, DRUG DES DEV THER, V11, P1729, DOI 10.2147/DDDT.S138888
   Grela E, 2018, ACTA HISTOCHEM, V120, P303, DOI 10.1016/j.acthis.2018.03.007
   Hakki SS, 2010, J TRACE ELEM MED BIO, V24, P243, DOI 10.1016/j.jtemb.2010.03.003
   Herigstad B, 2001, J MICROBIOL METH, V44, P121, DOI 10.1016/S0167 7012(00)00241 4
   Hernandes C., 2013, American Journal of Plant Sciences, V4, P850, DOI 10.4236/ajps.2013.44104
   Honda M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15068 4
   Jacobsen A, 2019, PEERJ, V7, DOI 10.7717/peerj.7040
   Kasugai S, 2000, J BONE MINER RES, V15, P936, DOI 10.1359/jbmr.2000.15.5.936
   Kim AY, 2017, CELL TRANSPLANT, V26, P115, DOI 10.3727/096368916X693338
   Klinger Strobel M, 2017, INT J ANTIMICROB AG, V49, P472, DOI 10.1016/j.ijantimicag.2017.01.005
   Kremers HM, 2015, J BONE JOINT SURG AM, V97A, P837, DOI 10.2106/JBJS.N.01350
   Kruppke B, 2020, MOLECULES, V25, DOI 10.3390/molecules25215103
   Kuang ZP, 2021, GENES DIS, V8, P193, DOI 10.1016/j.gendis.2019.09.014
   Leber AL, 2016, CLINICAL MICROBIOLOGY PROCEDURES HANDBOOK, 4TH EDITION, DOI 10.1128/9781555818814.ch5.16
   Lee S, 2013, INT J NANOMED, V8, P147, DOI 10.2147/IJN.S39534
   Lee SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136075
   Lee YJ, 2016, QUANT IMAG MED SURG, V6, P184, DOI 10.21037/qims.2016.04.01
   Leijtens B, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879 017 2429 2
   Liao YT, 2017, J MATER CHEM B, V5, P7008, DOI 10.1039/c7tb01217a
   Libraty DH, 2012, NEW ENGL J MED, V366, P481, DOI 10.1056/NEJMc1111493
   Liu JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099920
   Loughran AJ, 2014, MICROBIOLOGYOPEN, V3, P897, DOI 10.1002/mbo3.214
   Lu J, 2010, SMALL, V6, P1794, DOI 10.1002/smll.201000538
   Malincarne L, 2006, J ANTIMICROB CHEMOTH, V57, P950, DOI 10.1093/jac/dkl091
   Manzano M, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201902634
   Marriott I, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00101
   Martínez Carmona M, 2016, RSC ADV, V6, P50923, DOI 10.1039/c6ra07763c
   Masters EA, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0061 z
   Mateo C, 2007, ENZYME MICROB TECH, V40, P1451, DOI 10.1016/j.enzmictec.2007.01.018
   Minardi D, 2008, J CHEMOTHERAPY, V20, P195, DOI 10.1179/joc.2008.20.2.195
   Momodu I.I., 2022, Osteomyelitis
   MOORE SG, 1990, RADIOLOGY, V175, P219, DOI 10.1148/radiology.175.1.2315484
   Mootz JM, 2015, MOL MICROBIOL, V96, P388, DOI 10.1111/mmi.12943
   Nation RL, 2009, CURR OPIN INFECT DIS, V22, P535, DOI 10.1097/QCO.0b013e328332e672
   Ng AY, 2018, JBMR PLUS, V2, P328, DOI 10.1002/jbm4.10058
   Nie BE, 2022, BIOACT MATER, V16, P134, DOI 10.1016/j.bioactmat.2022.02.003
   Ocaña JA, 2000, ANALYST, V125, P2322, DOI 10.1039/b005991i
   Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301
   Okoliegbe IN, 2021, ANTIBIOTICS BASEL, V10, DOI 10.3390/antibiotics10080967
   Oostingh GJ, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743 8977 8 8
   Paris JL, 2015, ACS NANO, V9, P11023, DOI 10.1021/acsnano.5b04378
   Peeters E, 2009, J ANTIMICROB CHEMOTH, V64, P801, DOI 10.1093/jac/dkp253
   Plaut RD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059232
   Potempa J., 2004, Handbook of Proteolytic Enzymes, P389, DOI [10.1016/B978 0 12 079611 3.50104 X, DOI 10.1016/B978 0 12 079611 3.50104 X]
   Ragelle H, 2017, EXPERT OPIN DRUG DEL, V14, P851, DOI 10.1080/17425247.2016.1244187
   Riss T.L., 2004, Assay Guidance Manual
   Rohanizadeh R, 2008, J MATER SCI MATER M, V19, P1173, DOI 10.1007/s10856 007 3154 y
   Rothstein DM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a027011
   Juan RS, 2010, ANTIMICROB AGENTS CH, V54, P5161, DOI 10.1128/AAC.00027 10
   Silago V, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01618 5
   Singh Seema, 2017, J Lab Physicians, V9, P317, DOI 10.4103/JLP.JLP_8_17
   Sobolewska B, 2013, CURR EYE RES, V38, P662, DOI 10.3109/02713683.2012.746991
   Soranoglou V, 2017, INT J ANTIMICROB AG, V50, P186, DOI 10.1016/j.ijantimicag.2017.01.041
   SRITHARAN M, 1993, METHOD FIND EXP CLIN, V15, P107
   Stepanovic S, 2007, APMIS, V115, P891, DOI 10.1111/j.1600 0463.2007.apm_630.x
   Subramaniam S, 2019, ANTIBIOTICS BASEL, V8, DOI 10.3390/antibiotics8020039
   Sugioka K, 2018, INVEST OPHTH VIS SCI, V59, P5098, DOI 10.1167/iovs.18 24925
   Sunyer R, 2016, SCIENCE, V353, P1157, DOI 10.1126/science.aaf7119
   TALIAFERRO WH, 1951, J INFECT DIS, V89, P143, DOI 10.1093/infdis/89.2.143
   Tam K, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3 0039 2018
   Turner NA, 2019, NAT REV MICROBIOL, V17, P203, DOI 10.1038/s41579 018 0147 4
   Uhljar LÉ, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13040556
   Vallet Regi M, 2001, CHEM MATER, V13, P308, DOI 10.1021/cm0011559
   Vandenesch F, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00012
   Vivero Escoto JL, 2010, SMALL, V6, P1952, DOI 10.1002/smll.200901789
   Wang Q, 2017, SCI REP UK, V7, DOI [10.1038/s41598 017 13141 5, 10.1038/srep41808]
   Weinstein MelvinP., 2018, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
   Xu JH, 2013, MICROPOR MESOPOR MAT, V182, P165, DOI 10.1016/j.micromeso.2013.08.050
   Yuan XW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01196
   Zhang BK, 2021, NANOMED NANOTECHNOL, V37, DOI 10.1016/j.nano.2021.102420
   Zhou XJ, 2018, J MATER CHEM B, V6, P740, DOI 10.1039/c7tb01246b
   Zimmerli W, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01746 18
   Zou Z, 2013, LANGMUIR, V29, P12804, DOI 10.1021/la4022646
NR 104
TC 32
Z9 33
U1 5
U2 45
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2022
VL 154
BP 608
EP 625
DI 10.1016/j.actbio.2022.10.039
EA DEC 2022
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 7N8GD
UT WOS:000907572600008
PM 36341887
OA Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Zheng, Z
   Yu, CY
   Wei, H
AF Zheng, Zhi
   Yu, Cuiyun
   Wei, Hua
TI Injectable Hydrogels as Three Dimensional Network Reservoirs for
   Osteoporosis Treatment
SO TISSUE ENGINEERING PART B REVIEWS
LA English
DT Article
DE injectable hydrogels; osteoporosis; drugs; stem cells; nucleic acids
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION;
   EXTRACELLULAR MATRIX; BONE REGENERATION; IN VITRO; THERMOSENSITIVE
   HYDROGEL; DRUG DELIVERY; GENE THERAPY; OSTEOBLAST DIFFERENTIATION;
   CARTILAGE FORMATION
AB Despite tremendous progresses made in the field of tissue engineering over the past several decades, it remains a significant challenge for the treatment of osteoporosis (OP) due to the lack of appropriate carriers to improve the bioavailability of therapeutic agents and the unavailability of artificial bone matrix with desired properties for the replacement of damaged bone regions. Encouragingly, the development of injectable hydrogels for the treatment of OP has attracted increasing attention in recent years because they can serve either as a reservoir for various therapeutic species or as a perfect filler for bone injuries with irregular shapes. However, the relationship between the complicated pathological mechanism of OP and the properties of diverse polymeric materials lacks elucidation, which clearly hampers the clinical application of injectable hydrogels for the efficient treatment of OP. To clarify this relationship, this article summarized both localized and systematic treatment of OP using an injectable hydrogel based strategy. Specifically, the pathogenesis of OP and the limitations of current treatment approaches were first analyzed. We further focused on the use of hydrogels loaded with various therapeutic substances following a classification standard of the encapsulated cargoes for OP treatment with an emphasis on the application and precautions of each category. A concluding remark on existing challenges and future directions of this rapidly developing research area was finally made.
   Impact statement
   Effective osteoporosis (OP) treatment remains a significant challenge due substantially to the unavailability of appropriate drug carriers and artificial matrices with desired properties to promote bone repair and replace damaged regions. For this purpose, this review focused on the development of diverse injectable hydrogel systems for the delivery of various therapeutic agents, including drugs, stem cells, and nucleic acids, for effective increase in bone mass and favorable osteogenesis. The summarized important guidelines are believed to promote clinical development and translation of hydrogels for the efficient treatment of OP and OP related bone damages toward improved life quality of millions of patients.
C1 Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang, Peoples R China.
   Univ South China, Sch Pharmaceut Sci, Hengyang, Peoples R China.
C3 University of South China; University of South China
RP Yu, CY; Wei, H (通讯作者)，Univ South China, Sch Pharmaceut Sci, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang 421001, Peoples R China.
EM yucuiyunusc@hotmail.com; weih@usc.edu.cn
RI 魏, 华/JXN 6629 2024
OI Zheng, Zhi/0000 0002 8050 5396
FU Outstanding Youth Fund of National Natural Science Foundation of China
   [81471777]; Natural Science Foundation of Hunan province [2017JJ1024];
   Health Department of Hunan Province 225 Talent Project; Chuanshan Talent
   Program of the University of South China; Hunan Provincial Innovation
   Foundation for Postgraduate [CX20200911]
FX The authors acknowledge the sponsorship from the Outstanding Youth Fund
   of National Natural Science Foundation of China (81471777), Natural
   Science Foundation of Hunan province (2017JJ1024), the Health Department
   of Hunan Province 225 Talent Project to C.Y. Yu, the Chuanshan Talent
   Program of the University of South China to C.Y., and the financial
   support by Hunan Provincial Innovation Foundation for Postgraduate
   (CX20200911).
CR Akhtar MF, 2016, SAUDI PHARM J, V24, P554, DOI 10.1016/j.jsps.2015.03.022
   Alexander A, 2013, J CONTROL RELEASE, V172, P715, DOI 10.1016/j.jconrel.2013.10.006
   Amsden B, 1998, MACROMOLECULES, V31, P8382, DOI 10.1021/ma980765f
   Annabi N, 2016, ADV MATER, V28, P40, DOI 10.1002/adma.201503255
   Annabi N, 2013, BIOMATERIALS, V34, P5496, DOI 10.1016/j.biomaterials.2013.03.076
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Asatrian G, 2015, STEM CELLS CLONING, V8, P39, DOI 10.2147/SCCAA.S48423
   Baldari S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102087
   Barati D, 2016, J CONTROL RELEASE, V223, P126, DOI 10.1016/j.jconrel.2015.12.031
   Basu A, 2016, ADV DRUG DELIVER REV, V107, P192, DOI 10.1016/j.addr.2016.07.004
   Bikram M, 2007, ANN BIOMED ENG, V35, P796, DOI 10.1007/s10439 007 9263 4
   Bin Imran A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6124
   Black DM, 2019, ENDOCR REV, V40, P333, DOI 10.1210/er.2018 00001
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Blocki A, 2015, BIOMATERIALS, V53, P12, DOI 10.1016/j.biomaterials.2015.02.075
   Brazel CS, 2000, EUR J PHARM BIOPHARM, V49, P47, DOI 10.1016/S0939 6411(99)00058 2
   Brunader R, 2002, AM FAM PHYSICIAN, V65, P1357
   Bülhoff M, 2019, ACTA ORTHOP TRAUMATO, V53, P170, DOI 10.1016/j.aott.2019.03.011
   Carthew J, 2020, ACTA BIOMATER, V101, P249, DOI 10.1016/j.actbio.2019.11.016
   Castaño IM, 2016, SCI REP UK, V6, DOI 10.1038/srep27941
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Chen S, 2017, STEM CELL REP, V8, P773, DOI 10.1016/j.stemcr.2017.01.028
   Chen X, 2015, BIOMATERIALS, V53, P239, DOI 10.1016/j.biomaterials.2015.02.071
   Choi B, 2015, ACTA BIOMATER, V12, P30, DOI 10.1016/j.actbio.2014.10.013
   Conde J, 2016, NAT MATER, V15, P353, DOI [10.1038/NMAT4497, 10.1038/nmat4497]
   Huynh CT, 2016, NANOMEDICINE UK, V11, P1535, DOI 10.2217/nnm 2016 0088
   Conrad B, 2018, TISSUE ENG PT A, V24, P1631, DOI [10.1089/ten.tea.2018.0011, 10.1089/ten.TEA.2018.0011]
   da Silva LP, 2016, ACS APPL MATER INTER, V8, P33464, DOI 10.1021/acsami.6b11684
   Daly AC, 2018, BIOMATERIALS, V162, P34, DOI 10.1016/j.biomaterials.2018.01.057
   Deeks ED, 2018, DRUG AGING, V35, P163, DOI 10.1007/s40266 018 0525 7
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Diab T, 2012, J MECH BEHAV BIOMED, V11, P123, DOI 10.1016/j.jmbbm.2011.11.007
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.71, 10.1038/natrevmats.2016.21]
   Dirckx N, 2019, NAT REV ENDOCRINOL, V15, P651, DOI 10.1038/s41574 019 0246 y
   Dosier CR, 2015, TISSUE ENG PT A, V21, P156, DOI [10.1089/ten.tea.2014.0057, 10.1089/ten.TEA.2014.0057]
   Dua R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149121
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Ehrbar M, 2004, CIRC RES, V94, P1124, DOI 10.1161/01.RES.0000126411.29641.08
   Elviri L, 2017, EXPERT OPIN DRUG DEL, V14, P897, DOI 10.1080/17425247.2017.1247803
   Ezquer FE, 2017, CELL ADHES MIGR, V11, P110, DOI 10.1080/19336918.2016.1197480
   Fan CX, 2019, ADV MATER, V31, DOI 10.1002/adma.201902900
   Fathi A, 2014, BIOMATERIALS, V35, P5425, DOI 10.1016/j.biomaterials.2014.03.026
   Fatin Rouge N, 2004, BIOPHYS J, V86, P2710, DOI 10.1016/S0006 3495(04)74325 8
   Feinberg AW, 2015, ANNU REV BIOMED ENG, V17, P243, DOI 10.1146/annurev bioeng 071114 040632
   Feng Q, 2016, BIOMATERIALS, V101, P217, DOI 10.1016/j.biomaterials.2016.05.043
   Fisher SA, 2017, J AM CHEM SOC, V139, P7416, DOI 10.1021/jacs.7b00513
   Frith JE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02486 0
   Gaharwar AK, 2013, ADV MATER, V25, P3329, DOI 10.1002/adma.201300584
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Ghobril C, 2015, CHEM SOC REV, V44, P1820, DOI 10.1039/c4cs00332b
   Ghosh SS, 2000, J HEPATOL, V32, P238, DOI 10.1016/S0168 8278(00)80429 8
   Gibbs DMR, 2016, J TISSUE ENG REGEN M, V10, P187, DOI 10.1002/term.1968
   Golpanian S, 2016, PHYSIOL REV, V96, P1127, DOI 10.1152/physrev.00019.2015
   Gonzalez Fernandez T, 2016, TISSUE ENG PT A, V22, P776, DOI [10.1089/ten.tea.2015.0576, 10.1089/ten.TEA.2015.0576]
   Gu DY, 2017, EXPERT OPIN DRUG DEL, V14, P879, DOI 10.1080/17425247.2017.1245290
   Hannafon F, 2014, J GERONTOL NURS, V40, P10, DOI 10.3928/00989134 20140204 01
   Hare JM, 2012, JAMA J AM MED ASSOC, V308, P2369, DOI 10.1001/jama.2012.25321
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hassan MQ, 2015, BONE, V81, P746, DOI 10.1016/j.bone.2015.05.026
   Henriksen K, 2010, EXPERT OPIN BIOL TH, V10, P1617, DOI 10.1517/14712598.2010.526104
   Hernández González AC, 2020, CARBOHYD POLYM, V229, DOI 10.1016/j.carbpol.2019.115514
   Hu XY, 2017, CARBOHYD POLYM, V155, P242, DOI 10.1016/j.carbpol.2016.08.077
   Huang QT, 2017, CHEM SOC REV, V46, P6255, DOI 10.1039/c6cs00052e
   Huettner N, 2018, TRENDS BIOTECHNOL, V36, P372, DOI 10.1016/j.tibtech.2018.01.008
   Ingavle GC, 2019, BIOMATERIALS, V197, P119, DOI 10.1016/j.biomaterials.2019.01.005
   Inoue K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06446 0
   Jiang HX, 2016, ULTRASON SONOCHEM, V32, P398, DOI 10.1016/j.ultsonch.2016.04.008
   Jiang TY, 2018, ACS NANO, V12, P9693, DOI 10.1021/acsnano.8b03800
   Jiang YJ, 2014, BIOMATERIALS, V35, P4969, DOI 10.1016/j.biomaterials.2014.03.001
   Jin HL, 2018, ACS NANO, V12, P3295, DOI 10.1021/acsnano.7b08148
   Kates SL, 2016, INJURY, V47, pS65, DOI 10.1016/S0020 1383(16)30015 8
   Kelly SH, 2017, ADV DRUG DELIVER REV, V114, P3, DOI 10.1016/j.addr.2017.04.009
   Kettenberger U, 2017, J TISSUE ENG REGEN M, V11, P1974, DOI 10.1002/term.2094
   Khang G, 2015, J TISSUE ENG REGEN M, V9, P265, DOI 10.1002/term.1625
   Kharkar PM, 2013, CHEM SOC REV, V42, P7335, DOI 10.1039/c3cs60040h
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim HD, 2017, ACS APPL MATER INTER, V9, P21639, DOI 10.1021/acsami.7b04114
   Kim J, 2007, BIOMATERIALS, V28, P1830, DOI 10.1016/j.biomaterials.2006.11.050
   Kim YW, 2019, MAT SCI ENG C MATER, V95, P86, DOI 10.1016/j.msec.2018.10.045
   Klotz BJ, 2016, TRENDS BIOTECHNOL, V34, P394, DOI 10.1016/j.tibtech.2016.01.002
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Kotobuki N, 2008, CELL TRANSPLANT, V17, P705, DOI 10.3727/096368908786092793
   Kuijpers AJ, 1999, MACROMOLECULES, V32, P3325, DOI 10.1021/ma981929v
   Kylmäoja E, 2016, CURR STEM CELL RES T, V11, P626, DOI 10.2174/1574888X10666151019115724
   Larrañeta E, 2018, CARBOHYD POLYM, V181, P1194, DOI 10.1016/j.carbpol.2017.12.015
   Laurila R, 2013, INT J CLIN EXP PATHO, V6, P1400
   Hong LTA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00583 8
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Lee JH, 2015, TISSUE ENG PT A, V21, P2262, DOI [10.1089/ten.tea.2014.0659, 10.1089/ten.TEA.2014.0659]
   Lee JH, 2019, PROG RETIN EYE RES, V68, P31, DOI 10.1016/j.preteyeres.2018.08.003
   Lei YG, 2010, BIOMATERIALS, V31, P9106, DOI 10.1016/j.biomaterials.2010.08.016
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li H, 2015, CELL DEATH DIFFER, V22, P1935, DOI 10.1038/cdd.2015.99
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li LP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9682757
   Li X, 2014, BIOMATERIALS, V35, P5679, DOI 10.1016/j.biomaterials.2014.03.067
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Li ZB, 2014, MAT SCI ENG C MATER, V45, P620, DOI 10.1016/j.msec.2014.06.003
   Liao IC, 2013, ADV FUNCT MATER, V23, P5833, DOI 10.1002/adfm.201300483
   Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004
   Lin H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1350 6
   Lindsay R, 2016, OSTEOPOROSIS INT, V27, P2395, DOI 10.1007/s00198 016 3534 6
   Liu LL, 2018, INT J BIOL MACROMOL, V108, P376, DOI 10.1016/j.ijbiomac.2017.11.128
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Liu YP, 2017, ACS APPL MATER INTER, V9, P23428, DOI 10.1021/acsami.7b05740
   Lou JZ, 2018, BIOMATERIALS, V154, P213, DOI 10.1016/j.biomaterials.2017.11.004
   Lu SC, 2018, BIOMATERIALS, V179, P29, DOI 10.1016/j.biomaterials.2018.06.032
   Luger D, 2017, CIRC RES, V120, P1598, DOI 10.1161/CIRCRESAHA.117.310599
   Ma D, 2012, NAT CHEM, V4, P503, DOI [10.1038/NCHEM.1326, 10.1038/nchem.1326]
   Ma X, 2016, COLLOID SURFACE B, V143, P81, DOI 10.1016/j.colsurfb.2016.03.025
   Ma ZW, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477 3155 12 23
   Manaka T, 2011, BIOMATERIALS, V32, P9642, DOI 10.1016/j.biomaterials.2011.08.026
   Matzkin EG, 2019, J AM ACAD ORTHOP SUR, V27, pE902, DOI 10.5435/JAAOS D 18 00600
   Mayfield AE, 2014, BIOMATERIALS, V35, P133, DOI 10.1016/j.biomaterials.2013.09.085
   McGoldrick R, 2017, PLAST RECONSTR SURG, V140, P1169, DOI 10.1097/PRS.0000000000003840
   Militz M, 2010, CHIRURG, V81, P310, DOI 10.1007/s00104 009 1842 5
   Moya Ortega MD, 2012, INT J PHARMACEUT, V428, P152, DOI 10.1016/j.ijpharm.2012.02.038
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Naahidi S, 2017, BIOTECHNOL ADV, V35, P530, DOI 10.1016/j.biotechadv.2017.05.006
   Nafee N, 2018, J DRUG TARGET, V26, P563, DOI 10.1080/1061186X.2017.1390670
   Nagai N, 2018, INT J NANOMED, V13, P5215, DOI 10.2147/IJN.S173216
   Nguyen MK, 2018, ACTA BIOMATER, V75, P105, DOI 10.1016/j.actbio.2018.06.007
   Ning ZY, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201900020
   Ohnishi H, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/1/014110
   Park JB, 2012, EXP THER MED, V4, P303, DOI 10.3892/etm.2012.590
   Park SH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06911 8
   Park TY, 2020, J CONTROL RELEASE, V321, P602, DOI 10.1016/j.jconrel.2020.02.047
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939 6411(00)00090 4
   Peppas Nicholas A, 2014, J Control Release, V190, P31
   Perez RA, 2014, TISSUE ENG PT A, V20, P103, DOI [10.1089/ten.tea.2013.0198, 10.1089/ten.TEA.2013.0198]
   Plotkin LI, 2019, ADV PROTEIN CHEM STR, V116, P237, DOI 10.1016/bs.apcsb.2019.01.002
   Posadowska U, 2015, INT J PHARMACEUT, V485, P31, DOI 10.1016/j.ijpharm.2015.03.003
   Poudel AJ, 2018, CARBOHYD POLYM, V194, P69, DOI 10.1016/j.carbpol.2018.04.035
   Qi C, 2018, BIOMATERIALS, V163, P89, DOI 10.1016/j.biomaterials.2018.02.016
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Ramamoorth M, 2015, J CLIN DIAGN RES, V9, pGE1, DOI 10.7860/JCDR/2015/10443.5394
   Reginster JY, 2015, OSTEOPOROSIS INT, V26, P1667, DOI 10.1007/s00198 015 3109 y
   Reichert JC, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/6/065001
   Rizzi SC, 2005, BIOMACROMOLECULES, V6, P1226, DOI 10.1021/bm049614c
   Rocha Braz MGM, 2016, ARCH ENDOCRIN METAB, V60, P391, DOI 10.1590/2359 3997000000178
   Rodell CB, 2015, BIOCONJUGATE CHEM, V26, P2279, DOI 10.1021/acs.bioconjchem.5b00483
   Rodling L, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701403
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Saeed H, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0254 3
   Saini P, 2016, ADV DRUG DELIVER REV, V107, P47, DOI 10.1016/j.addr.2016.06.014
   Saravanan S, 2019, INT J BIOL MACROMOL, V121, P38, DOI 10.1016/j.ijbiomac.2018.10.014
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   Segredo Morales E, 2018, INT J PHARMACEUT, V543, P160, DOI 10.1016/j.ijpharm.2018.03.034
   Seib FP, 2013, ADV FUNCT MATER, V23, P58, DOI 10.1002/adfm.201201238
   Shafaghi R, 2019, MAT SCI ENG C MATER, V104, DOI 10.1016/j.msec.2019.109941
   Shang JJ, 2018, SOFT MATTER, V14, P8401, DOI 10.1039/c8sm01728j
   Shekaran A, 2014, BIOMATERIALS, V35, P5453, DOI 10.1016/j.biomaterials.2014.03.055
   Sheyn D, 2016, MOL THER, V24, P318, DOI 10.1038/mt.2015.211
   Shigemitsu H, 2017, ACCOUNTS CHEM RES, V50, P740, DOI 10.1021/acs.accounts.7b00070
   Shirani A, 2019, ACS APPL MATER INTER, V11, P43500, DOI 10.1021/acsami.9b14904
   Singh NK, 2014, J CONTROL RELEASE, V193, P214, DOI 10.1016/j.jconrel.2014.04.056
   Slaughter BV, 2009, ADV MATER, V21, P3307, DOI 10.1002/adma.200802106
   Solling ASK, 2018, THER ADV MUSCULOSKEL, V10, P105, DOI 10.1177/1759720X18775936
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Storrie H, 2006, ADV DRUG DELIVER REV, V58, P500, DOI 10.1016/j.addr.2006.03.004
   Su CY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26432 2
   Sui L, 2018, BIOMATERIALS, V177, P88, DOI 10.1016/j.biomaterials.2018.05.038
   Sukarto A, 2012, BIOMACROMOLECULES, V13, P2490, DOI 10.1021/bm300733n
   Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409
   Svedbom A, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0137 0
   Swan VJD, 2010, ADV THER, V27, P917, DOI 10.1007/s12325 010 0081 y
   Tan J, 2016, OSTEOPOROSIS INT, V27, P757, DOI 10.1007/s00198 015 3230 y
   Tanaka KSE, 2010, BIOORG MED CHEM LETT, V20, P1355, DOI 10.1016/j.bmcl.2010.01.006
   Tang AM, 2016, NANOSCALE, V8, P10570, DOI 10.1039/c6nr00843g
   Tang SC, 2016, ACTA BIOMATER, V43, P292, DOI 10.1016/j.actbio.2016.07.011
   Thambi T, 2016, MACROMOL RAPID COMM, V37, P1881, DOI 10.1002/marc.201600371
   van Beek ER, 1998, BONE, V23, P437, DOI 10.1016/S8756 3282(98)00120 3
   Vanecek V, 2013, EUR SPINE J, V22, P2777, DOI 10.1007/s00586 013 2991 2
   Vishwakarma A, 2016, TRENDS BIOTECHNOL, V34, P470, DOI 10.1016/j.tibtech.2016.03.009
   Wang H, 2017, SCI REP UK, V7, DOI 10.1038/srep40011
   Wang LL, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601041
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang XN, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249 020 1619 1
   Wang XZ, 2018, BIOMATERIALS, V179, P164, DOI 10.1016/j.biomaterials.2018.06.039
   Wang YC, 2017, BIOMATERIALS, V139, P127, DOI 10.1016/j.biomaterials.2017.06.001
   Wegman F, 2011, EUR CELLS MATER, V21, P230, DOI 10.22203/eCM.v021a18
   Wegman F, 2014, J TISSUE ENG REGEN M, V8, P763, DOI 10.1002/term.1571
   Wei H, 2015, BIOMATER SCI UK, V3, P1050, DOI 10.1039/c4bm00417e
   Wojda SJ, 2020, J ORTHOP RES, V38, P536, DOI 10.1002/jor.24502
   Yamamoto M, 2000, J CONTROL RELEASE, V64, P133, DOI 10.1016/S0168 3659(99)00129 7
   Yan HJ, 2018, BIOMATERIALS, V161, P190, DOI 10.1016/j.biomaterials.2018.01.041
   Yang XY, 2010, J BIOMED MATER RES A, V95A, P1170, DOI 10.1002/jbm.a.32936
   Yang YS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10809 6
   Yang YH, 2018, ACTA BIOMATER, V69, P71, DOI 10.1016/j.actbio.2017.12.043
   Yavropoulou MP, 2019, EXPERT OPIN PHARMACO, V20, P1201, DOI 10.1080/14656566.2019.1615882
   Youngblood RL, 2018, MOL THER, V26, P2087, DOI 10.1016/j.ymthe.2018.07.022
   Yu L, 2011, BIOMACROMOLECULES, V12, P1290, DOI 10.1021/bm101572j
   Yu P, 2020, J MATER CHEM B, V8, P270, DOI 10.1039/c9tb02049g
   Zanotto G, 2019, J ORTHOP RES, V37, P2307, DOI 10.1002/jor.24414
   Zeng HC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15000
   Zeng YZ, 2019, ACTA BIOMATER, V93, P152, DOI 10.1016/j.actbio.2019.01.060
   Zhang JF, 2011, RNA BIOL, V8, P829, DOI 10.4161/rna.8.5.16043
   Zhang KY, 2018, ADV SCI, V5, DOI 10.1002/advs.201800875
   Zhang XS, 2018, CHEM COMMUN, V54, DOI 10.1039/c8cc06685j
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhang YS, 2017, SCIENCE, V356, DOI 10.1126/science.aaf3627
   Zhang YF, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00622
   Zhao C, 2019, ACS APPL MATER INTER, V11, P8749, DOI 10.1021/acsami.8b19094
   Zhao FL, 2015, NANOMATERIALS BASEL, V5, P2054, DOI 10.3390/nano5042054
   Zhao Y, 2014, ADV MATER, V26, P436, DOI 10.1002/adma.201303387
   Zheng LP, 2018, BIOMACROMOLECULES, V19, P3874, DOI 10.1021/acs.biomac.8b01001
   Zheng Z, 2019, INFLAMMATION, V42, P606, DOI 10.1007/s10753 018 0918 0
   Zheng Z, 2018, LYMPHAT RES BIOL, V16, P498, DOI 10.1089/lrb.2018.0015
   Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044
   Zimmermann CE, 2011, TISSUE ENG PT A, V17, P1147, DOI [10.1089/ten.tea.2009.0577, 10.1089/ten.TEA.2009.0577]
NR 211
TC 28
Z9 29
U1 3
U2 84
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3368
EI 1937 3376
J9 TISSUE ENG PART B RE
JI Tissue Eng. Part B Rev.
PD OCT 1
PY 2021
VL 27
IS 5
BP 430
EP 454
DI 10.1089/ten.teb.2020.0168
EA NOV 2020
PG 25
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering;
   Materials Science
GA WL2JV
UT WOS:000593335000001
PM 33086984
DA 2025 08 17
ER

PT J
AU Allen, MR
   Iwata, K
   Sato, M
   Burr, DB
AF Allen, Matthew R.
   Iwata, Ken
   Sato, Masahiko
   Burr, David B.
TI Raloxifene enhances vertebral mechanical properties independent of bone
   density
SO BONE
LA English
DT Article
DE bisphosphonates; SERMS; osteoporosis; microdamage; biomechanics
ID POSTMENOPAUSAL WOMEN; FRACTURE RISK; RANDOMIZED TRIAL; MINERAL DENSITY;
   BIOMECHANICAL PROPERTIES; OSTEOPOROTIC FRACTURES; COLLAGEN; RISEDRONATE;
   REDUCTION; THERAPY
AB Anti remodeling agents produce similar reductions in vertebral fracture risk despite large differences in BMD changes suggesting the mechanism of fracture risk reduction may differ among these agents. Forty eight intact (non ovariectomized) skeletally mature female beagle dogs were treated orally for 12 months with clinically relevant doses of risedronate (RIS, 0.10 mg/kg/day), alendronate (ALN, 0.2 mg/kg/day), raloxifene (RAL, 0.50 mg/kg/day), or saline (VEH, 1 ml/kg/day). After sacrifice, the following measurements were made on vertebral bone: areal (aBMD) and volumetric (vBMD) bone mineral densities, tissue mineralization by ash content, static and dynamic histomorphometric parameters, microdamage, and extrinsic and intrinsic measures of biomechanical strength, stiffness and energy to fracture. At these doses, RAL suppressed bone turnover ( 20%) significantly less than the bisphosphonates ( 66 and  71%) and did not produce significant differences in aBMD, vBMD, BV/TV or percent ash compared to VEH treated animals. Microdamage accumulation in RAL treated animals was not significantly different than VEH; both RIS and ALN had significantly higher crack surface density compared to VEH. Stiffness was significantly higher than VEH in all treatment groups. Ultimate load divided by aBMD, a measure of strength independent of BMD, was significantly higher only in RAL treated animals compared to VEH (+16%, P = 0.015). Based on these data, we conclude that raloxifene produces improvements in bone mechanical properties in ways that do not involve increases in BMD. (c) 2006 Elsevier Inc. All rights reserved.
C1 Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
   Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN 46202 USA.
   Indiana Univ Purdue Univ, Ft Wayne, IN 46805 USA.
   Lilly Res Labs, Indianapolis, IN 46285 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis; Purdue University
   System; Indiana University Purdue University Fort Wayne; Eli Lilly;
   Lilly Research Laboratories
RP Allen, MR (通讯作者)，Indiana Univ, Sch Med, Dept Anat & Cell Biol, MS 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM matallen@iupui.edu
RI Allen, Matthew/A 8799 2015
OI Allen, Matthew/0000 0002 1174 9004
FU NCRR NIH HHS [C06 RR 10601 01] Funding Source: Medline; NIAMS NIH HHS
   [5R01 AR 047838 03, 5T32 AR 007581 09] Funding Source: Medline
CR Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boxberger J., 2004, T ORTHOP RES SOC, P29
   Burrows MT, 1917, J UROLOGY, V1, P3, DOI 10.1016/S0022 5347(17)74226 7
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cummings SR, 2002, AM J MED, V112, P281, DOI 10.1016/S0002 9343(01)01124 X
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   DeLaet CEDH, 1997, BRIT MED J, V315, P221, DOI 10.1136/bmj.315.7102.221
   Delmas PD, 2004, BONE, V34, P599, DOI 10.1016/j.bone.2003.12.022
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hernandez CJ, 2005, BONE, V37, P825, DOI 10.1016/j.bone.2005.07.019
   HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523
   Huja SS, 1999, J BIOMECH, V32, P1243, DOI 10.1016/S0021 9290(99)00047 0
   Jackson S, 2002, BJOG INT J OBSTET GY, V109, P339
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   Khastgir G, 2001, OSTEOPOROSIS INT, V12, P465, DOI 10.1007/s001980170091
   Li ZQ, 2001, STAT MED, V20, P3175, DOI 10.1002/sim.984
   MARTIN B, 2005, T ORTHOP RES SOC, V30
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Moro L, 1997, EUR J CLIN CHEM CLIN, V35, P29
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Paschalis EP, 2003, J BONE MINER RES, V18, P955, DOI 10.1359/jbmr.2003.18.6.955
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Sarkar S, 2002, J BONE MINER RES, V17, P1, DOI 10.1359/jbmr.2002.17.1.1
   TANG S, 2005, T ORTHOP RES SOC, V30
   Vashishth D., 2004, T ORTHOP RES SOC, P29
   Viguet Carrin S, 2005, J BONE MINER RES, V20, pS115
   Wang X, 2002, BONE, V31, P1, DOI 10.1016/S8756 3282(01)00697 4
   Watts NB, 2004, J CLIN DENSITOM, V7, P255, DOI 10.1385/JCD:7:3:255
   Wu P., 2003, Trans Orthop Res Soc, V28, P404
NR 30
TC 78
Z9 96
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD NOV
PY 2006
VL 39
IS 5
BP 1130
EP 1135
DI 10.1016/j.bone.2006.05.007
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 099HP
UT WOS:000241584500022
PM 16814622
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Chakarun, CJ
   Forrester, DM
   Gottsegen, CJ
   Patel, DB
   White, EA
   Matcuk, GR
AF Chakarun, Corey J.
   Forrester, Deborah M.
   Gottsegen, Christopher J.
   Patel, Dakshesh B.
   White, Eric A.
   Matcuk, George R., Jr.
TI Giant Cell Tumor of Bone: Review, Mimics, and New Developments in
   Treatment
SO RADIOGRAPHICS
LA English
DT Article
ID LONG BONES; BENIGN; AFIP; CURETTAGE; JOINT; CYST
AB Giant cell tumor (GCT) of bone is generally a benign tumor composed of mononuclear stromal cells and characteristic multinucleated giant cells that exhibit osteoclastic activity. It usually develops in long bones but can occur in unusual locations. The typical appearance is a lytic lesion with a well defined but nonsclerotic margin that is eccentric in location, extends near the articular surface, and occurs in patients with closed physes. However, GCT may have aggressive features, including cortical expansion or destruction with a soft tissue component. Fluid fluid levels, consistent with secondary formation of aneurysmal bone cysts, are seen in 14% of cases. GCT can mimic or be mimicked by other benign or malignant lesions at both radiologic evaluation and histologic analysis. Rarely, GCT is associated with histologically benign lung metastases or undergoes malignant degeneration. In the past, the mainstay of treatment was surgical, primarily consisting of curettage with cement placement, with recurrence rates of 15% 25%. Recurrence is suggested by development of progressive lucency at the cement bone interface. Other complications include pathologic fracture and postoperative infection. Denosumab, a monoclonal antibody that targets the osteoclastic activity of GCT, has produced 90% tumor necrosis in early studies, results indicative of promise as a potential adjuvant therapy.
C1 [Chakarun, Corey J.; Forrester, Deborah M.; Gottsegen, Christopher J.; Patel, Dakshesh B.; White, Eric A.; Matcuk, George R., Jr.] Univ So Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90033 USA.
C3 University of Southern California
RP Matcuk, GR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Radiol, 1500 San Pablo St,2nd Floor Imaging, Los Angeles, CA 90033 USA.
EM matcuk@usc.edu
RI ; Patel, Dakshesh/HGU 5666 2022; Matcuk, George/H 3350 2019
OI White, Eric/0000 0003 2457 9320; Gottsegen,
   Christopher/0000 0003 4610 8757; Patel, Dakshesh/0000 0002 6828 6610;
   Matcuk, George/0000 0002 2858 0794; 
CR Anchan C, 2008, INT J SHOULDER SURG, V2, P68, DOI 10.4103/0973 6042.42582
   Arnold RT, 2011, RADIOGRAPHICS, V31, P93, DOI 10.1148/rg.311105048
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Bandyopadhyay R, 2010, J CANCER RES THER, V6, P106, DOI 10.4103/0973 1482.63552
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Biscaglia R, 2000, CANCER, V88, P2022, DOI 10.1002/(SICI)1097 0142(20000501)88:9<2022::AID CNCR6>3.0.CO;2 Y
   Blackley HR, 1999, J BONE JOINT SURG AM, V81A, P811, DOI 10.2106/00004623 199906000 00008
   Collins M, 2003, POETRY WALES, V38, P32
   Cooper A S., 1818, Surgical Essays, P178
   DAHLIN DC, 1985, AM J ROENTGENOL, V144, P955, DOI 10.2214/ajr.144.5.955
   Deheshi BM, 2007, CLIN ORTHOP RELAT R, P96, DOI 10.1097/BLO.0b013e31805d85e4
   Desai D, 2010, OPEN DENT J, V4, P211, DOI 10.2174/1874210601004010211
   Dhillon Mandeep S, 2007, Indian J Orthop, V41, P154, DOI 10.4103/0019 5413.32049
   Dominkus M, 2006, INT ORTHOP, V30, P499, DOI 10.1007/s00264 006 0204 x
   Farsad K, 2009, RADIOGRAPHICS, V29, P1525, DOI 10.1148/rg.295085215
   FELDMAN F, 1980, SKELETAL RADIOL, V5, P119, DOI 10.1007/BF00347334
   Helms CA, 2007, FUNDAMENTALS DIAGNOS, V3rd, P1070
   Hoch B, 2007, SKELETAL RADIOL, V36, P973, DOI 10.1007/s00256 007 0310 x
   Kafchitsas K, 2010, ANTICANCER RES, V30, P3795
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P1181, DOI 10.1007/s11999 010 1560 9
   Kwon JW, 2007, AM J ROENTGENOL, V189, P246, DOI 10.2214/AJR.06.1472
   Lichtinger TK, 2004, ARCH ORTHOP TRAUM SU, V124, P715, DOI 10.1007/s00402 004 0753 7
   Liu H S, 1998, Changgeng Yi Xue Za Zhi, V21, P37
   Malawer MM, 1999, CLIN ORTHOP RELAT R, P176
   Mendenhall WM, 2006, AM J CLIN ONCOL CANC, V29, P96, DOI 10.1097/01.coc.0000195089.11620.b7
   Miller IJ, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746 1596 5 62
   Murphey MD, 2001, RADIOGRAPHICS, V21, P1283, DOI 10.1148/radiographics.21.5.g01se251283
   Nahal A, 2010, CURR ONCOL, V17, P71
   Novais EN, 2011, J HAND SURG AM, V36A, P1610, DOI 10.1016/j.jhsa.2011.06.032
   Okamoto Y, 2003, MED PEDIATR ONCOL, V41, P454, DOI 10.1002/mpo.10258
   Rastogi Shishir, 2007, Indian J Orthop, V41, P109, DOI 10.4103/0019 5413.32040
   SHANKMAN S, 1988, SKELETAL RADIOL, V17, P46, DOI 10.1007/BF00361455
   Sherwani RK, 2008, INT J SHOULDER SURG, V2, P59, DOI 10.4103/0973 6042.42579
   SIM FH, 1977, J BONE JOINT SURG AM, V59, P1052, DOI 10.2106/00004623 197759080 00009
   STEWART MJ, 1950, J BONE JOINT SURG AM, V32 A, P439, DOI 10.2106/00004623 195032020 00028
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   TORNBERG DN, 1975, J BONE JOINT SURG AM, VA 57, P420, DOI 10.2106/00004623 197557030 00026
   Turcotte RE, 2002, CLIN ORTHOP RELAT R, P248
   Turcotte RE, 2006, ORTHOP CLIN N AM, V37, P35, DOI 10.1016/j.ocl.2005.08.005
   Unni KK, 1996, DAHLINS BONE TUMORS, P263
   Varshney A, 2010, J FOOT ANKLE SURG, V49, DOI 10.1053/j.jfas.2010.04.010
   YALE JF, 1995, J AM PODIAT MED ASSN, V85, P708, DOI 10.7547/87507315 85 11 708
   Yu Xiu chun, 2010, Orthop Surg, V2, P211, DOI 10.1111/j.1757 7861.2010.00089.x
   Zhen W, 2004, J BONE JOINT SURG BR, V86B, P212, DOI 10.1302/0301 620X.86B2.14362
NR 44
TC 243
Z9 257
U1 0
U2 20
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0271 5333
J9 RADIOGRAPHICS
JI Radiographics
PD JAN FEB
PY 2013
VL 33
IS 1
BP 197
EP 211
DI 10.1148/rg.331125089
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 073NA
UT WOS:000313748500018
PM 23322837
DA 2025 08 17
ER

PT J
AU Bouchareb, R
   Lebeche, D
AF Bouchareb, Rihab
   Lebeche, Djamel
TI Isolation of Mouse Interstitial Valve Cells to Study the Calcification
   of the Aortic Valve In Vitro
SO JOVE JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID DISEASE
AB The calcification of aortic valve cells is the hallmark of aortic stenosis and is associated with valve cusp fibrosis. Valve interstitial cells (VICs) play an important role in the calcification process in aortic stenosis through the activation of their dedifferentiation program to osteoblast like cells. Mouse VICs are a good in vitro tool for the elucidation of the signaling pathways driving the mineralization of the aortic valve cell. The method described herein, successfully used by these authors, explains how to obtain freshly isolated cells. A two step collagenase procedure was performed with 1 mg/mL and 4.5 mg/mL. The first step is crucial to remove the endothelial cell layer and avoid any contamination. The second collagenase incubation is to facilitate the migration of VICs from the tissue to the plate. In addition, an immunofluorescence staining procedure for the phenotype characterization of the isolated mouse valve cells is discussed. Furthermore, the calcification assay was performed in vitro by using the calcium reagent measurement procedure and alizarin red staining. The use of mouse valve cell primary culture is essential for testing new pharmacological targets to inhibit cell mineralization in vitro.
C1 [Bouchareb, Rihab; Lebeche, Djamel] Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, New York, NY 10029 USA.
   [Lebeche, Djamel] Icahn Sch Med Mt Sinai, Diabet Obes & Metab Inst, Dept Med, New York, NY 10029 USA.
   [Lebeche, Djamel] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai
RP Bouchareb, R (通讯作者)，Icahn Sch Med Mt Sinai, Cardiovasc Res Ctr, New York, NY 10029 USA.
EM rihab.bouchareb@mssm.edu
CR Bossé Y, 2008, J AM COLL CARDIOL, V51, P1327, DOI 10.1016/j.jacc.2007.12.031
   Bouchareb R, 2019, EUR HEART J, V40, P1362, DOI 10.1093/eurheartj/ehy696
   Bouchareb R, 2014, J MOL CELL CARDIOL, V67, P49, DOI 10.1016/j.yjmcc.2013.12.009
   Drexler HG, 2002, CYTOTECHNOLOGY, V39, P75, DOI 10.1023/A:1022913015916
   Hinton RB, 2011, ANNU REV PHYSIOL, V73, P29, DOI 10.1146/annurev physiol 012110 142145
   JANSSEN JW, 1991, EUR J CLIN CHEM CLIN, V29, P197
   Lerman DA, 2015, EUR CARDIOL REV, V10, P108, DOI 10.15420/ecr.2015.10.2.108
   Marquis Gravel G, 2016, CIRCULATION, V134, P1766, DOI 10.1161/CIRCULATIONAHA.116.023997
   Ortlepp JR, 2006, J HEART VALVE DIS, V15, P502
   Richards J, 2013, AM J PATHOL, V182, P1922, DOI 10.1016/j.ajpath.2013.01.037
   Rostagno C, 2019, WORLD J CARDIOL, V11, P71, DOI 10.4330/wjc.v11.i2.71
   Rutkovskiy A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006339
   Simionescu DT, 2012, J HEALTHC ENG, V3, P179, DOI 10.1260/2040 2295.3.2.179
   Spitzer Ernest, 2019, Card Fail Rev, V5, P99, DOI 10.15420/cfr.2018.41.2
   Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735 1097(96)00563 3
NR 15
TC 6
Z9 6
U1 0
U2 3
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940 087X
J9 JOVE J VIS EXP
JI J. Vis. Exp.
PD MAY
PY 2021
IS 171
AR e62419
DI 10.3791/62419
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA SN5PC
UT WOS:000658340400061
PM 34028451
DA 2025 08 17
ER

PT J
AU Petersen, KK
   Olesen, AE
   Simonsen, O
   Arendt Nielsen, L
AF Petersen, Kristian Kjaer
   Olesen, Anne Estrup
   Simonsen, Ole
   Arendt Nielsen, Lars
TI Mechanistic pain profiling as a tool to predict the efficacy of 3 week
   nonsteroidal anti inflammatory drugs plus paracetamol in patients with
   painful knee osteoarthritis
SO PAIN
LA English
DT Article
DE Osteoarthritis; Mechanistic pain profiling; Nonsteroidal
   anti inflammatory drug; Temporal summation of pain
ID CHRONIC POSTOPERATIVE PAIN; TEMPORAL SUMMATION; CENTRAL SENSITIZATION;
   NEUROPATHIC PAIN; CONTROLLED TRIAL; COX 2 INHIBITOR; IBUPROFEN; HIP;
   ETORICOXIB; RECOMMENDATIONS
AB Joint inflammation is present in a subpopulation of knee osteoarthritis (OA) patients. Proinflammatory cytokines are known to sensitize the peripheral and central pain pathways. This can be mechanistically assessed by pressure pain thresholds and temporal summation of pain (TSP). Nonsteroidal anti inflammatory drugs (NSAIDs) combined with paracetamol are recommended as OA treatment. The current study hypothesized that evidence of central sensitization would predict poor responses to peripherally directed therapies in knee OA and therefore aimed to investigate the value of mechanistic pain profiling for predicting pain outcome of treatment with NSAIDs plus paracetamol. One hundred thirty two patients received ibuprofen 1200 mg/daily, paracetamol 3 g/daily, and pantoprazole 20 mg/daily for 3 weeks. Before administration, cuff pain detection, tolerance threshold, and TSP were assessed. Worst pain within the last 24 hours and pain during activity (visual analogue scales) were assessed before and after treatment. Facilitated TSP was found at baseline in the nonresponders to the 3 weeks treatment as compared to responders for both the 30% and 50% pain alleviation criteria (P < 0.02). Linear regression models identified facilitated TSP (P < 0.01) and low clinical pain scores (P < 0.001) as independent factors for prediction of poor pain alleviation by the treatment. In conclusion, this study found that mechanistic pain profiling can predict pain alleviation of NSAIDs and paracetamol. Facilitated TSP and low clinical pain scores before treatment are independent predictors of poor pain alleviation after NSAIDs and paracetamol. This study adds to the growing evidence that a subgroup of knee OA patients with manifested central sensitization may require special management attention.
C1 [Petersen, Kristian Kjaer; Arendt Nielsen, Lars] Aalborg Univ, Fac Med, Dept Hlth Sci & Technol, SMI, Fredrik Bajers Vej 7 D3, DK 9220 Aalborg, Denmark.
   [Petersen, Kristian Kjaer] Aalborg Univ, Fac Med, Dept Hlth Sci & Technol, Ctr Neuroplast & Pain,SMI, Aalborg, Denmark.
   [Olesen, Anne Estrup; Simonsen, Ole] Aalborg Univ, Dept Clin Med, Aalborg, Denmark.
   [Olesen, Anne Estrup] Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, Mech Sense, Aalborg, Denmark.
   [Simonsen, Ole] Aalborg Univ Hosp, Dept Orthoped Surg, Aalborg, Denmark.
C3 Aalborg University; Aalborg University; Aalborg University; Aalborg
   University; Aalborg University Hospital; Aalborg University; Aalborg
   University Hospital
RP Petersen, KK (通讯作者)，Aalborg Univ, Fac Med, Dept Hlth Sci & Technol, SMI, Fredrik Bajers Vej 7 D3, DK 9220 Aalborg, Denmark.
EM KKP@HST.AAU.DK
RI Olesen, Anne/B 3127 2016; Petersen, Kristian Kjaer Staal/Q 4311 2017;
   Arendt Nielsen, Lars/T 4885 2018; Petersen, Kristian/Q 4311 2017;
   Olesen, Anne Estrup/B 3127 2016
OI Petersen, Kristian Kjaer Staal/0000 0003 4506 000X; Arendt Nielsen,
   Lars/0000 0003 0892 1579; Olesen, Anne Estrup/0000 0001 9365 1918
FU Innovation Fund Denmark [136 2014 5]; Aalborg University Talent
   Management Programme [771126]; Shionogi Science Program; TaNeDS Europe
   grant; Danish National Research Foundation [DNRF121]
FX The authors thank The Innovation Fund Denmark (j.no. 136 2014 5), The
   Aalborg University Talent Management Programme (j.no. 771126), The
   Shionogi Science Program, and the TaNeDS Europe grant for providing the
   opportunity to conduct the study. Center for Neuroplasticity and Pain
   (CNAP) is supported by the Danish National Research Foundation
   (DNRF121). Project nurse Tina Jensen and patient hotel manager Vibeke
   Bergmann Engers at Aalborg University Hospital, Aalborg, Denmark, are
   acknowledged for their continued support and practical assistance in
   conducting the study.
CR Ahn DK, 2007, PAIN, V132, P23, DOI 10.1016/j.pain.2007.01.015
   Arendt Nielsen L, 2018, EUR J PAIN, V22, P216, DOI 10.1002/ejp.1140
   Arendt Nielsen L, 2015, EUR J PAIN, V19, P1406, DOI 10.1002/ejp.651
   Arendt Nielsen L, 2017, PAIN, V158, pS66, DOI 10.1097/j.pain.0000000000000812
   Arendt Nielsen L, 2016, PAIN, V157, P1634, DOI 10.1097/j.pain.0000000000000562
   Arendt Nielsen L, 2010, PAIN, V149, P573, DOI 10.1016/j.pain.2010.04.003
   BANNWARTH B, 1995, BRIT J CLIN PHARMACO, V40, P266, DOI 10.1111/j.1365 2125.1995.tb05783.x
   Bjordal JM, 2004, BMJ BRIT MED J, V329, P1317, DOI 10.1136/bmj.38273.626655.63
   Brazier D, 2017, CLIN DRUG INVEST, V37, P1025, DOI 10.1007/s40261 017 0549 5
   Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110
   Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781
   Dimitroulas T, 2014, SEMIN ARTHRITIS RHEU, V44, P145, DOI 10.1016/j.semarthrit.2014.05.011
   Doherty M, 2011, ANN RHEUM DIS, V70, P1534, DOI 10.1136/ard.2011.154047
   Dworkin RH, 2011, OSTEOARTHR CARTILAGE, V19, P483, DOI 10.1016/j.joca.2011.02.020
   Edwards RR, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1124 6
   Eitner A, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00349
   Eitner A, 2017, PAIN, V158, P1743, DOI 10.1097/j.pain.0000000000000972
   Finan PH, 2013, ARTHRITIS RHEUM US, V65, P363, DOI 10.1002/art.34646
   Freynhagen R, 2006, CURR MED RES OPIN, V22, P1911, DOI 10.1185/030079906X132488
   Graham GG, 2013, INFLAMMOPHARMACOLOGY, V21, P201, DOI 10.1007/s10787 013 0172 x
   Graven Nielsen T, 2012, ARTHRITIS RHEUM US, V64, P2907, DOI 10.1002/art.34466
   Graven Nielsen T, 2015, PAIN, V156, P2193, DOI 10.1097/j.pain.0000000000000294
   Graven Nielsen T, 2010, NAT REV RHEUMATOL, V6, P599, DOI 10.1038/nrrheum.2010.107
   Har Even R, 2014, J CLIN PHARMACOL, V54, P1023, DOI 10.1002/jcph.307
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Izumi M, 2017, PAIN, V158, P323, DOI 10.1097/j.pain.0000000000000764
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Kongtharvonskul J, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 015 0115 7
   Kosek E, 2000, PAIN, V88, P69, DOI 10.1016/S0304 3959(00)00310 9
   Kosek E, 2016, PAIN, V157, P1382, DOI 10.1097/j.pain.0000000000000507
   Kurien T, 2018, J PAIN, V19, P1329, DOI 10.1016/j.jpain.2018.05.011
   Lin HY, 2010, INT J RHEUM DIS, V13, P144, DOI 10.1111/j.1756 185X.2010.01468.x
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   Moss P, 2018, CLIN J PAIN, V34, P15, DOI 10.1097/AJP.0000000000000504
   O'Leary H, 2018, PAIN, V159, P1877, DOI 10.1097/j.pain.0000000000001288
   Ohtori S, 2012, YONSEI MED J, V53, P801, DOI 10.3349/ymj.2012.53.4.801
   Ong CKS, 2010, ANESTH ANALG, V110, P1170, DOI 10.1213/ANE.0b013e3181cf9281
   Petersen KK, 2018, CLIN J PAIN, V34, P193, DOI 10.1097/AJP.0000000000000528
   Petersen KK, 2015, CLIN J PAIN, V31, P1, DOI 10.1097/AJP.0000000000000146
   Petersen KK, 2016, PAIN, V157, P1400, DOI 10.1097/j.pain.0000000000000531
   Petersen KK, 2015, PAIN, V156, P55, DOI 10.1016/j.pain.0000000000000022
   Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001
   Puopolo A, 2007, OSTEOARTHR CARTILAGE, V15, P1348, DOI 10.1016/j.joca.2007.05.022
   Reinold H, 2005, J CLIN INVEST, V115, P673
   Renner B, 2010, N S ARCH PHARMACOL, V381, P127, DOI 10.1007/s00210 009 0482 0
   Riis A, 2014, BONE JOINT J, V96B, P1498, DOI 10.1302/0301 620X.96B11.33726
   Roos Ewa M, 2003, Health Qual Life Outcomes, V1, P64, DOI 10.1186/1477 7525 1 64
   Schaible HG, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0470 8
   Schett G, 2013, ANN RHEUM DIS, V71, P403
   Schnitzer TJ, 2015, OSTEOARTHR CARTILAGE, V23, pS8, DOI 10.1016/j.joca.2014.10.003
   Siebuhr AS, 2014, OSTEOARTHR CARTILAGE, V22, P44, DOI 10.1016/j.joca.2013.10.020
   Vaegter HB, 2017, CLIN J PAIN, V33, P475, DOI 10.1097/AJP.0000000000000428
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140 6736(12)61729 2
   Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140
   WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539 199377020 00026
   Wylde V, 2017, EUR J PAIN, V21, P357, DOI 10.1002/ejp.929
   Yarnitsky D, 2015, PAIN, V156, pS24, DOI 10.1097/01.j.pain.0000460343.46847.58
   Yue Y, 2018, PAIN MED, V19, P355, DOI 10.1093/pm/pnx157
   Zhang W, 2007, OSTEOARTHR CARTILAGE, V15, P981, DOI 10.1016/j.joca.2007.06.014
NR 59
TC 57
Z9 58
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304 3959
EI 1872 6623
J9 PAIN
JI Pain
PD FEB
PY 2019
VL 160
IS 2
BP 486
EP 492
DI 10.1097/j.pain.0000000000001427
PG 7
WC Anesthesiology; Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anesthesiology; Neurosciences & Neurology
GA HQ4PQ
UT WOS:000462394100019
PM 30371559
OA Green Published
DA 2025 08 17
ER

PT J
AU Chu, J
   Shi, PP
   Yan, WX
   Fu, JP
   Yang, Z
   He, CM
   Deng, XY
   Liu, HP
AF Chu, Jing
   Shi, Panpan
   Yan, Wenxia
   Fu, Jinping
   Yang, Zhi
   He, Chengmin
   Deng, Xiaoyuan
   Liu, Hanping
TI PEGylated graphene oxide mediated quercetin modified collagen hybrid
   scaffold for enhancement of MSCs differentiation potential and diabetic
   wound healing
SO NANOSCALE
LA English
DT Article
ID ACELLULAR DERMAL MATRIX; PHOTOTHERMAL THERAPY; NANO GRAPHENE;
   STEM CELLS; IN VIVO; BIOMEDICAL APPLICATIONS; RAMAN SPECTROSCOPY; HUMAN
   FIBROBLASTS; DRUG DELIVERY; MECHANISM
AB Nanoscale delivery based on polyethylene glycol (PEG) ylated graphene oxide (GO PEG) merits attention for biomedical applications owing to its functional surface modification, superior solubility/biocompatibility and controllable drug release capability. However, impaired skin regeneration in applications of these fascinating nanomaterials in diabetes is still limited, and critical issues need to be addressed regarding insufficient collagen hyperplasia and inadequate blood supply. Therefore, a high performance tissue engineering scaffold with biocompatible and biodegradable properties is essential for diabetic wound healing. Natural and artificial acellular dermal matrix (ADM) scaffolds with spatially organized collagen fibers can provide a suitable architecture and environment for cell attachment and proliferation. Here, a novel collagen nanomaterial drug hybrid scaffold was constructed from GO PEG mediated quercetin (GO PEG/Que) modified ADM (ADM GO PEG/Que). The resulting unique and versatile hybrid scaffold exhibited multiple advantages, including the following: a biocompatible, cell adhesive surface for accelerating mesenchymal stem cell (MSC) attachment and proliferation; superior stability and adjustability of the conduction potential of quercetin for inducing the differentiation of MSCs into adipocytes and osteoblasts; and a biodegradable nanofiber interface for promoting collagen deposition and angiogenesis in diabetic wound repair. This study provides new prospects for the design of innovative GO PEG based collagen hybrid scaffolds for application in efficient therapeutic drug delivery, stem cell based therapies, tissue engineering and regenerative medicine.
C1 [Chu, Jing; Shi, Panpan; Yan, Wenxia; Fu, Jinping; Yang, Zhi; He, Chengmin; Deng, Xiaoyuan; Liu, Hanping] South China Normal Univ, Coll Biophoton, MOE Key Lab Laser Life Sci, Guangzhou, Guangdong, Peoples R China.
C3 South China Normal University
RP Deng, XY; Liu, HP (通讯作者)，South China Normal Univ, Coll Biophoton, MOE Key Lab Laser Life Sci, Guangzhou, Guangdong, Peoples R China.
EM xydeng12@126.com; liuhp@scnu.edu.cn
OI Yang, Zhi/0000 0001 6614 4523; , Wenxia/0000 0002 3386 1750
FU National Natural Science Foundation of China [81671729]; Guangzhou
   Municipal Science and Technology Project, China [201804010051]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81671729) and the Guangzhou Municipal Science and Technology
   Project, China (No. 201804010051). We give special thanks to Xiao Wang
   from the Biomedical Translational Research Institute, Jinan University
   for the supply of TPEF SHG microscopy and flow cytometry.
CR Avitabile S, 2015, J INVEST DERMATOL, V135, P2862, DOI 10.1038/jid.2015.278
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Castleberry SA, 2016, ADV MATER, V28, P1809, DOI 10.1002/adma.201503565
   Chang H. L., 2010, J CLIN INVEST, V120, P3340
   Chen RN, 2004, BIOMATERIALS, V25, P2679, DOI 10.1016/j.biomaterials.2003.09.070
   Dave SH, 2016, ACS NANO, V10, P7515, DOI 10.1021/acsnano.6b02391
   Dembereldorj U, 2012, J MATER CHEM, V22, P23845, DOI 10.1039/c2jm34853e
   Escande C, 2013, DIABETES, V62, P1084, DOI 10.2337/db12 1139
   Feng LZ, 2013, SMALL, V9, P1989, DOI 10.1002/smll.201202538
   Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
   Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001
   He S., 2012, ACS APPL MATER INTER, V4, P6317
   Huang J, 2012, SMALL, V8, P2577, DOI 10.1002/smll.201102743
   Huang J, 2010, NANOSCALE, V2, P2733, DOI 10.1039/c0nr00473a
   Liu Z, 2008, J AM CHEM SOC, V130, P10876, DOI 10.1021/ja803688x
   Mirza RE, 2014, DIABETES, V63, P1103, DOI 10.2337/db13 0927
   Moore K, 1997, BRIT J DERMATOL, V137, P188, DOI 10.1046/j.1365 2133.1997.18041895.x
   Nowicki Michael T, 2008, Drug Metab Lett, V2, P11
   Ravichandran R, 2012, BIOMATERIALS, V33, P846, DOI 10.1016/j.biomaterials.2011.10.030
   Sharma A, 2006, J INVEST DERMATOL, V126, P2323, DOI 10.1038/sj.jid.5700428
   SPANHEIMER RG, 1988, DIABETES, V37, P371, DOI 10.2337/diabetes.37.4.371
   Volarevic V, 2011, STEM CELLS, V29, P5, DOI 10.1002/stem.556
   Vyas VS, 2016, ADV MATER, V28, P8749, DOI 10.1002/adma.201603006
   Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097 2765(00)00088 5
   Wang QN, 2015, BIOMATERIALS, V53, P659, DOI 10.1016/j.biomaterials.2015.03.011
   Wen HY, 2012, SMALL, V8, P760, DOI 10.1002/smll.201101613
   Wiseman RL, 2010, MOL CELL, V38, P291, DOI 10.1016/j.molcel.2010.04.001
   Xing Q, 2014, ADV FUNCT MATER, V24, P3027, DOI 10.1002/adfm.201303460
   Xu WG, 2013, SMALL, V9, P1206, DOI 10.1002/smll.201203097
   Yang K, 2016, ADV DRUG DELIVER REV, V105, P228, DOI 10.1016/j.addr.2016.05.015
   Yang K, 2013, NAT PROTOC, V8, P2392, DOI 10.1038/nprot.2013.146
   Yang K, 2013, SMALL, V9, P1492, DOI 10.1002/smll.201201417
   Yang K, 2012, ADV MATER, V24, P1868, DOI 10.1002/adma.201104964
   Yang K, 2011, ACS NANO, V5, P516, DOI 10.1021/nn1024303
   Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u
   Yao X, 2013, BIOMATERIALS, V34, P9001, DOI 10.1016/j.biomaterials.2013.08.013
   Zhang W, 2011, BIOMATERIALS, V32, P8555, DOI 10.1016/j.biomaterials.2011.07.071
   Zhang WD, 2012, ADV MATER, V24, P5391, DOI 10.1002/adma.201202678
   Zhang XJ, 2009, BIOMATERIALS, V30, P2666, DOI 10.1016/j.biomaterials.2009.01.018
   Zhou T, 2014, BIOMATERIALS, V35, P4185, DOI 10.1016/j.biomaterials.2014.01.044
   Zhu YW, 2010, ADV MATER, V22, P3906, DOI 10.1002/adma.201001068
NR 41
TC 104
Z9 105
U1 1
U2 192
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040 3364
EI 2040 3372
J9 NANOSCALE
JI Nanoscale
PD MAY 28
PY 2018
VL 10
IS 20
BP 9547
EP 9560
DI 10.1039/c8nr02538j
PG 14
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA GH2VO
UT WOS:000433260300015
PM 29745944
DA 2025 08 17
ER

PT J
AU Du, K
   Chen, GH
   Bai, X
   Chen, L
   Hu, SQ
   Li, YH
   Wang, GZ
   He, JW
   Lai, SJ
AF Du, Kun
   Chen, Guan He
   Bai, Xue
   Chen, Li
   Hu, Shen Qiang
   Li, Yan Hong
   Wang, Guo Ze
   He, Jing Wei
   Lai, Song Jia
TI Dynamics of transcriptome and chromatin accessibility revealed
   sequential regulation of potential transcription factors during the
   brown adipose tissue whitening in rabbits
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE BAT; rabbits; ATAC seq; epigenetics; whitening
ID LIPID METABOLISM; PPAR GAMMA; FAT; CELL; LIPOLYSIS; BINDING; BEIGE;
   BETA; MICE; ADIPOGENESIS
AB Brown adipose tissue (BAT) represents a valuable target for treating obesity in humans. BAT losses of thermogenic capacity and gains a "white adipose tissue like (WAT like) " phenotype (BAT whitening) under thermoneutral environments, which could lead to potential low therapy responsiveness in BAT based obesity treatments. However, the epigenetic mechanisms of BAT whitening remain largely unknown. In this study, BATs were collected from rabbits at day0 (D0), D15, D85, and 2 years (Y2). RNA sequencing (RNA seq) and the assay for transposase accessible chromatin with high throughput sequencing (ATAC seq) were performed to investigate transcriptome and chromatin accessibility of BATs at the four whitening stages, respectively. Our data showed that many genes and chromatin accessible regions (refer to as "peaks ") were identified as significantly changed during BAT whitening in rabbits. The BAT selective genes downregulated while WAT selective genes upregulated from D0 to Y2, and the de novo lipogenesis related genes reached the highest expression levels at D85. Both the highly expressed genes and accessible regions in Y2 were significantly enriched in immune response related signal pathways. Analysis of different relationships between peaks and their nearby genes found an increased proportion of the synchronous changes between chromatin accessibility and gene expression during BAT whitening. The synergistic changes between the chromatin accessibility of promoter and the gene expression were found in the key adipose genes. The upregulated genes which contained increased peaks were significantly enriched in the PI3K Akt signaling pathway, steroid biosynthesis, TGF beta signaling pathway, osteoclast differentiation, and dilated cardiomyopathy. Moreover, the footprinting analysis suggested that sequential regulation of potential transcription factors (TFs) mediated the loss of thermogenic phenotype and the gain of a WAT like phenotype of BAT. In conclusion, our study provided the transcriptional and epigenetic frameworks for understanding BAT whitening in rabbits for the first time and might facilitate potential insights into BAT based obesity treatments.
C1 [Du, Kun; Chen, Guan He; Bai, Xue; Chen, Li; Hu, Shen Qiang; Li, Yan Hong; Lai, Song Jia] Sichuan Agr Univ, Farm Anim Genet Resources Explorat & Innovat Key L, Chengdu, Peoples R China.
   [Wang, Guo Ze] Guizhou Med Univ, Sch Publ Hlth, Key Lab Environm Pollut Monitoring & Dis Control, Minist Educ, Guiyang, Peoples R China.
   [He, Jing Wei] Sichuan Anim Husb Stn, Chengdu, Peoples R China.
C3 Sichuan Agricultural University; Guizhou Medical University
RP Lai, SJ (通讯作者)，Sichuan Agr Univ, Farm Anim Genet Resources Explorat & Innovat Key L, Chengdu, Peoples R China.
EM laisj5794@163.com
RI Wang, Guoze/HNO 9644 2023
FU earmarked fund for China Agriculture Research System;  [CARS 44 A 2]
FX Funding This work was supported by the earmarked fund for China
   Agriculture Research System (CARS 44 A 2).
CR Abdelatty AM, 2021, ANIMAL, V15, DOI 10.1016/j.animal.2021.100348
   Ackermann AM, 2016, MOL METAB, V5, P233, DOI 10.1016/j.molmet.2016.01.002
   Altshuler Keylin S, 2016, CELL METAB, V24, P402, DOI 10.1016/j.cmet.2016.08.002
   Anderson DH, 2006, PROG LIPID RES, V45, P102, DOI 10.1016/j.plipres.2005.12.003
   Angueira AR, 2020, CELL REP, V30, P2869, DOI 10.1016/j.celrep.2020.02.023
   Auclair M, 2021, AM J PHYSIOL ENDOC M, V320, pE219, DOI 10.1152/ajpendo.00131.2020
   Bai ZQ, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002176
   Bentsen M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18035 1
   Bertrand Gaday C, 2016, FEBS LETT, V590, P982, DOI 10.1002/1873 3468.12129
   Brown J, 2017, BIOINFORMATICS, V33, P3137, DOI 10.1093/bioinformatics/btx373
   Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/nmeth.2688, 10.1038/NMETH.2688]
   Chen S, 2022, EUR J NUTR, V61, P2015, DOI 10.1007/s00394 021 02769 9
   Chen YC, 2022, CELL BIOL TOXICOL, V38, P741, DOI 10.1007/s10565 021 09608 x
   Cohen P, 2014, CELL, V156, P304, DOI 10.1016/j.cell.2013.12.021
   Comeglio P, 2018, J ENDOCRINOL, V238, P107, DOI 10.1530/JOE 17 0557
   Dai W, 2021, MOL METAB, V53, DOI 10.1016/j.molmet.2021.101300
   de Jong JMA, 2019, NAT METAB, V1, P830, DOI 10.1038/s42255 019 0101 4
   DERRY DM, 1972, DEV BIOL, V27, P204, DOI 10.1016/0012 1606(72)90098 X
   Ding CM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03754 3
   Du K, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10111176
   Duan YH, 2019, FASEB J, V33, P10019, DOI 10.1096/fj.201900665RR
   Fischer AW, 2017, AM J PHYSIOL ENDOC M, V312, pE72, DOI 10.1152/ajpendo.00284.2016
   Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001
   Fox KE, 2006, J BIOL CHEM, V281, P40341, DOI 10.1074/jbc.M605077200
   Fujimoto Y, 2013, ENDOCRINOLOGY, V154, P3577, DOI 10.1210/en.2013 1203
   Gao H, 2014, CELL METAB, V19, P981, DOI 10.1016/j.cmet.2014.03.032
   Gao P, 2020, DIABETES, V69, P165, DOI 10.2337/db19 0526
   Giroud M, 2021, DIABETOLOGIA, V64, P1850, DOI 10.1007/s00125 021 05470 y
   Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783
   Gu ZG, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864 018 4625 x
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   HARDMAN MJ, 1971, J PHYSIOL LONDON, V213, P175, DOI 10.1113/jphysiol.1971.sp009375
   HARRIS WH, 1986, CAN J PHYSIOL PHARM, V64, P561, DOI 10.1139/y86 093
   Hiraike Y, 2017, NAT CELL BIOL, V19, P1081, DOI 10.1038/ncb3590
   Hu SQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00196
   Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kong XX, 2014, CELL, V158, P69, DOI 10.1016/j.cell.2014.04.049
   Kotzbeck P, 2018, J LIPID RES, V59, P784, DOI 10.1194/jlr.M079665
   Kwon EY, 2012, BMC GENOMICS, V13, DOI 10.1186/1471 2164 13 450
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Laurila PP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad0015
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li Y, 2022, CELL, V185, P949, DOI 10.1016/j.cell.2022.02.004
   Lidell ME, 2013, NAT MED, V19, P631, DOI 10.1038/nm.3017
   Lim S, 2012, NAT PROTOC, V7, P606, DOI 10.1038/nprot.2012.013
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Martin M., 2011, EMBnet.Journal, V17, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]
   Milet C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 16543 7
   Miranda CS, 2020, NUTRITION, V78, DOI 10.1016/j.nut.2020.110791
   Monteiro MC, 2011, STEM CELLS, V29, P1837, DOI 10.1002/stem.737
   Mottillo EP, 2014, J LIPID RES, V55, P2276, DOI 10.1194/jlr.M050005
   Müller S, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00387
   Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005
   Paulus A, 2017, METHODS, V130, P105, DOI 10.1016/j.ymeth.2017.05.001
   Pettersson AML, 2015, DIABETOLOGIA, V58, P2115, DOI 10.1007/s00125 015 3673 x
   Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583
   Qiang L, 2012, CELL, V150, P620, DOI 10.1016/j.cell.2012.06.027
   Quinlan Aaron R, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi1112s47
   Ramírez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365
   Richard MA, 2020, BIOCHEM J, V477, P1261, DOI 10.1042/BCJ20190464
   Ross Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Roy D, 2017, J BIOL CHEM, V292, P14827, DOI [10.1074/jbc.M117.783043, 10.1074/jbc.m117.783043]
   Schlein C, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108624
   Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182
   Shimizu I, 2014, J CLIN INVEST, V124, P2099, DOI 10.1172/JCI71643
   Skop V, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.065
   Stine RR, 2016, MOL METAB, V5, P57, DOI 10.1016/j.molmet.2015.11.001
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev biochem 052110 115718
   Tarasov A, 2015, BIOINFORMATICS, V31, P2032, DOI 10.1093/bioinformatics/btv098
   Wang FX, 2020, DEV CELL, V54, P742, DOI 10.1016/j.devcel.2020.07.003
   Wang GZ, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944 018 0915 1
   Wang GZ, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944 020 01219 5
   Wang XL, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2022.101561
   Wrann CD, 2012, ADIPOCYTE, V1, P168, DOI 10.4161/adip.20574
   Xie HH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5247
   Yadav H, 2011, CELL METAB, V14, P67, DOI 10.1016/j.cmet.2011.04.013
   Yamashita Y, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061686
   Yao DW, 2020, ANIMALS BASEL, V10, DOI 10.3390/ani10101871
   Yau WW, 2019, AUTOPHAGY, V15, P131, DOI 10.1080/15548627.2018.1511263
   Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb 2008 9 9 r137
   Zheng QT, 2017, P NATL ACAD SCI USA, V114, pE9474, DOI 10.1073/pnas.1707853114
   Zhou ZQ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax8096
NR 86
TC 6
Z9 6
U1 1
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD SEP 26
PY 2022
VL 10
AR 981661
DI 10.3389/fcell.2022.981661
PG 15
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 5Q7JC
UT WOS:000874002000001
PM 36225319
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu Wong, JR
   Tian, J
   Nakane, M
   Ma, JL
   Fey, TA
   Kroeger, P
   Fryer, RM
   Reinhart, GA
AF Wu Wong, JR
   Tian, J
   Nakane, M
   Ma, JL
   Fey, TA
   Kroeger, P
   Fryer, RM
   Reinhart, GA
TI Cardiovascular disease in chronic kidney failure: The role of VDR
   activators
SO CURRENT OPINION IN INVESTIGATIONAL DRUGS
LA English
DT Article
DE cardiovascular disease; chronic kidney disease; clinical studies;
   vitamin D analogs; vitamin D receptor
ID VITAMIN D RECEPTOR; CORONARY ARTERY DISEASE; SMOOTH MUSCLE CELLS;
   SECONDARY HYPERPARATHYROIDISM; 1,25 DIHYDROXYVITAMIN D 3;
   PARATHYROID HORMONE; D ANALOGS; CALCIFICATION; HEMODIALYSIS; RISK
AB Vitamin D 3 is modified by vitamin D 3 25 hydroxylase in the liver, and by 25 hydroxyvitamin D 3 1 alpha hydroxylase (CYP27B1) in the kidney, to form the active metabolite 1 alpha,25 dihydroxyvitamin D 3. Several vitamin D receptor (VDR) activators, including paricalcitol and calcitriol, are currently available for the treatment of hyperparathyroidism secondary to chronic kidney disease (CKD). CKD patients encounter a much higher risk of cardiovascular disease than do members of the general public, and recent clinical observations have shown that VDR activator therapy provides survival benefit for CKD patients in the rank order of paricalcitol > calcitriol > no VDR activator therapy, independent of parathyroid hormone, phosphorus and calcium. One possible explanation for this observation is that VDR activators exert a positive impact on cardiovascular functions. Studies in animals with disrupted genes involved in the vitamin D signaling pathway have provided some interesting data. For example, in mice lacking VDR or CYP27B1, it was found that in addition to the expected phenotype (hypocalcemia, secondary hyperparathyroidism and osteomalacia), expression of renin or atrial natriuretic peptide was elevated. The mice also developed hypertension and cardiac hypertrophy. Gene expression profiling studies have revealed that VDR may play a role in regulating smooth muscle cell (SMC) proliferation, thrombosis, fibrinolysis and vessel relaxation. Paricalcitol and calcitriol are equally potent at suppressing plasminogen activator inhibitor 1 synthesis and inhibiting cellular proliferation in human coronary artery SMCs. The effect of VDR activators on the modulation of renin expression and vascular functions may be factors that contribute to reduced mortality and morbidity risk in VDR activator treated CKD patients. In this review, we discuss recent preclinical and clinical data regarding the role of VDR and its ligands in the cardiovascular system.
RP R4CM,AP52,200 Abbott Pk Rd, Abbott Pk, IL 60064 USA.
EM ruth.r.wuwong@abbott.com
CR Aihara K, 2004, J BIOL CHEM, V279, P35798, DOI 10.1074/jbc.M404865200
   Amann K, 2003, NEPHROL DIAL TRANSPL, V18, P631, DOI 10.1093/ndt/gfg059
   Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140 6736(00)02456 9
   Brown AJ, 2002, NEPHROL DIAL TRANSPL, V17, P10, DOI 10.1093/ndt/17.suppl_10.10
   Carlberg C, 2001, STEROIDS, V66, P213, DOI 10.1016/S0039 128X(00)00150 1
   Chen NX, 2002, KIDNEY INT, V62, P1724, DOI 10.1046/j.1523 1755.2002.00625.x
   CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945
   Dobrez DG, 2004, NEPHROL DIAL TRANSPL, V19, P1174, DOI 10.1093/ndt/gfh123
   Doherty TM, 1997, CIRCULATION, V96, P1477, DOI 10.1161/01.CIR.96.5.1477
   Doherty TM, 2004, ENDOCR REV, V25, P629, DOI 10.1210/er.2003 0015
   Fraga C, 2002, HISTOCHEM CELL BIOL, V117, P547, DOI 10.1007/s00418 002 0413 3
   Hirata M, 2003, NEPHROL DIAL TRANSPL, V18, P1770, DOI 10.1093/ndt/gfg296
   Jono S, 1998, CIRCULATION, V98, P1302, DOI 10.1161/01.CIR.98.13.1302
   Koyama T, 1998, BLOOD, V92, P160, DOI 10.1182/blood.V92.1.160.413k16_160_167
   Levin ER, 1998, NEW ENGL J MED, V339, P321
   Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102 1235
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI0215219
   Martin KJ, 2004, SEMIN NEPHROL, V24, P456, DOI 10.1016/j.semnephrol.2004.06.013
   MITSUHASHI T, 1991, J CLIN INVEST, V87, P1889, DOI 10.1172/JCI115213
   Nakai S, 2004, THER APHER DIAL, V8, P3
   *NAT KIDN FDN, 2003, ANN INTERN MED, V139, P136
   OConnell TD, 1997, AM J PHYSIOL HEART C, V272, pH1751
   Ohsawa M, 2000, CIRCULATION, V102, P2867
   Park CW, 1999, AM J KIDNEY DIS, V33, P73, DOI 10.1016/S0272 6386(99)70260 X
   Parker T G, 1995, New Horiz, V3, P288
   Reddan DN, 2003, J AM SOC NEPHROL, V14, P2373, DOI 10.1097/01.ASN.0000083900.92829.F5
   RITZ E, 1995, AM J KIDNEY DIS, V26, P808, DOI 10.1016/0272 6386(95)90448 4
   Ruef J, 1999, THROMB HAEMOSTASIS, V82, P109, DOI 10.1055/s 0037 1614638
   Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513
   SIGMUND CD, 1990, J BIOL CHEM, V265, P19916
   Silver J, 2002, AM J PHYSIOL RENAL, V283, pF367, DOI 10.1152/ajprenal.00061.2002
   SIMPSON RU, 1985, J BIOL CHEM, V260, P8882
   Slatopolsky E, 1999, KIDNEY INT, V56, pS14, DOI 10.1046/j.1523 1755.1999.07304.x
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755
   Weiner DE, 2004, J AM SOC NEPHROL, V15, P1307, DOI 10.1097/01.ASN.0000123691.46138.E2
   WOLISI GO, 2005, IN PRESS SEMIN NEPHR, V25
   WU J, 1995, AM J PHYSIOL ENDOC M, V268, pE1108, DOI 10.1152/ajpendo.1995.268.6.E1108
   Wu SX, 1996, AM J PHYSIOL RENAL, V271, pF203, DOI 10.1152/ajprenal.1996.271.1.F203
   Wu Wong J Ruth, 2004, Curr Opin Investig Drugs, V5, P320
   WUWONG JR, 2005, IN PRESS ATHEROSCLER
   Xiang W, 2005, AM J PHYSIOL ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004
   Young EW, 2005, J AM SOC NEPHROL, V16
   Zebrack JS, 2003, J AM COLL CARDIOL, V42, P57, DOI 10.1016/S0735 1097(03)00564 3
NR 45
TC 19
Z9 24
U1 0
U2 2
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1472 4472
EI 2040 3429
J9 CURR OPIN INVEST DR
JI Curr. Opin. Investig. Drugs
PD MAR
PY 2006
VL 7
IS 3
BP 206
EP 213
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 021WS
UT WOS:000236017200002
PM 16555680
DA 2025 08 17
ER

PT J
AU García García, P
   Ruiz, M
   Reyes, R
   Delgado, A
   Évora, C
   Riancho, JA
   Rodríguez Rey, JC
   Pérez Campo, FM
AF Garcia Garcia, Patricia
   Ruiz, Mario
   Reyes, Ricardo
   Delgado, Araceli
   Evora, Carmen
   Antonio Riancho, Jost
   Carlos Rodriguez Rey, Jost
   Maria Perez Campo, Flor
TI Smurf1 Silencing Using a LNA ASOs/Lipid Nanoparticle System to
   Promote Bone Regeneration
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Mesenchymal stem cells; Bone regeneration; LNA ASO; GapmeR; Smurf1;
   Osteogenesis; BMP
ID MESENCHYMAL STEM CELLS; MORPHOGENETIC PROTEIN 2; STROMAL CELLS;
   OSTEOBLAST DIFFERENTIATION; ANTISENSE OLIGONUCLEOTIDES; BMP 2 DELIVERY;
   GROWTH FACTOR; GENE TRANSFER; PROLIFERATION; OSTEOGENESIS
AB Despite the great advance of bone tissue engineering in the last few years, repair of bone defects remains a major problem. Low cell engraftment and dose dependent side effects linked to the concomitant administration of bone morphogenetic proteins (BMPs) are the main problems currently hindering the clinical use of mesenchymal stem cell (MSC) based therapies in this field. We have managed to bypass these drawbacks by combining the silencing the Smurf1 ubiquitin ligase in MSCs with the use of a scaffold that sustainably releases low doses of BMP 2. In this system, Smurf1 silencing is achieved by using GapmeRs, a clinically safe method that avoids the use of viral vectors, facilitating its translation to the clinic. Here, we show that a single transient transfection with a small quantity of a Smurf1 specific GapmeR is able to induce a significant level of silencing of the target gene, enough to prime MSCs for osteogenic differentiation. Smurf1 silencing highly increases MSCs responsiveness to BMP 2, allowing a dramatic reduction of the dose needed to achieve the desired therapeutic effect. The combination of these primed cells with alginate scaffolds designed to sustainably and locally release low doses of BMP 2 to the defect microenvironment is able to induce the formation of a mature bone matrix both in an osteoporotic rat calvaria system and in a mouse ectopic model. Importantly, this approach also enhances osteogenic differentiation in MSCs from osteoporotic patients, characterized by a reduced bone forming potential, even at low BMP doses, underscoring the regenerative potential of this system. Stem Cells Translational Medicine 2019
C1 [Garcia Garcia, Patricia; Delgado, Araceli; Evora, Carmen] Univ La Laguna, Inst Biomed Technol ITB, Dept Chem Engn & Pharmaceut Technol, San Cristobal la Laguna, Spain.
   [Ruiz, Mario; Carlos Rodriguez Rey, Jost; Maria Perez Campo, Flor] Univ Cantabria, Fac Med, Dept Mol Biol, IDIVAL, Santander, Spain.
   [Reyes, Ricardo] Univ La Laguna, Inst Biomed Technol ITB, Dept Biochem Microbiol Cellular Biol & Genet, San Cristobal la Laguna, Spain.
   [Antonio Riancho, Jost] Univ Cantabria, Dept Internal Med, IDIVAL, Hosp U M Valdecilla, Santander, Spain.
C3 Universidad de la Laguna; Universidad de Cantabria; Universidad de la
   Laguna; Hospital Universitario Marques de Valdecilla (HUMV); Universidad
   de Cantabria
RP Pérez Campo, FM (通讯作者)，Fac Med, Dept Biochem & Mol Biol, Avda Cardenal Herrera Oria S N, Santander 39011, Cantabria, Spain.
EM f.perezcampo@unican.es
RI García García, Patricia/GVS 2023 2022; Reyes, Ricardo/M 1121 2014;
   Delgado, Araceli/K 9419 2014; Evora, Carmen/K 9994 2014
OI Perez Campo, Flor Maria/0000 0002 9872 7990; Reyes,
   Ricardo/0000 0002 1765 3257; Delgado, Araceli/0000 0001 7045 6933;
   Rodriguez Rey, Jose/0000 0002 8369 3118; Evora,
   Carmen/0000 0002 9347 4672; Garcia Garcia, Patricia/0000 0003 4801 4404
FU Spanish Ministerio de Economia y competitividad [RTI2018097324];
   Instituto de Investigacion Marques de Valdecilla (IDIVAL) [INNVAL
   17/15]; Palex Medical S.A.
FX This research was supported by a grant from the Spanish Ministerio de
   Economia y competitividad (Project RTI2018097324), a grant from the
   Instituto de Investigacion Marques de Valdecilla (IDIVAL, INNVAL 17/15),
   and Palex Medical S.A.
CR Baxter MA, 2004, STEM CELLS, V22, P675, DOI 10.1634/stemcells.22 5 675
   Benglis D, 2008, NEUROSURGERY, V62, P423, DOI 10.1227/01.neu.0000326030.24220.d8
   Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen HT, 2012, J CELL MOL MED, V16, DOI 10.1111/j.1582 4934.2011.01335.x
   Chen NF, 2010, J NEUROSURG SPINE, V12, P40, DOI 10.3171/2009.4.SPINE0876
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Crooke ST, 2018, CELL METAB, V27, P714, DOI 10.1016/j.cmet.2018.03.004
   Dang PN, 2017, STEM CELL TRANSL MED, V6, P1644, DOI 10.1002/sctm.16 0222
   del Real A, 2017, EPIGENETICS US, V12, P113, DOI 10.1080/15592294.2016.1271854
   del Rosario C, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/4/045008
   Delgado Calle J, 2011, BONE, V49, P830, DOI 10.1016/j.bone.2011.06.006
   Dmitriev AE, 2011, SPINE J, V11, P500, DOI 10.1016/j.spinee.2011.05.002
   El Bialy I, 2017, PHARM RES DORDR, V34, P1152, DOI 10.1007/s11095 017 2147 x
   Even J, 2012, J AM ACAD ORTHOP SUR, V20, P547, DOI 10.5435/JAAOS 20 09 547
   Fafián Labora J, 2015, SCI REP UK, V5, DOI 10.1038/srep16765
   Fan JB, 2016, STEM CELL TRANSL MED, V5, P539, DOI 10.5966/sctm.2015 0249
   Fierro FA, 2011, STEM CELLS, V29, P1727, DOI 10.1002/stem.720
   Fluiter K, 2009, MOL BIOSYST, V5, P838, DOI 10.1039/b903922h
   Ganguly P, 2017, CELL TRANSPLANT, V26, P1520, DOI 10.1177/0963689717721201
   Granero Moltó F, 2009, STEM CELLS, V27, P1887, DOI 10.1002/stem.103
   Hamann A, 2019, J BIOL ENG, V13, DOI 10.1186/s13036 019 0140 0
   He XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060473
   Heggebö J, 2014, ORTHOP REV, V6, P65, DOI 10.4081/or.2014.5242
   Hernández A, 2012, ACTA BIOMATER, V8, P781, DOI 10.1016/j.actbio.2011.10.008
   Honda Y, 2013, SCI REP UK, V3, DOI 10.1038/srep03420
   Hsu WK, 2008, SPINE J, V8, P419, DOI 10.1016/j.spinee.2008.01.008
   Ishikawa H, 2007, ACTA ORTHOP, V78, P285, DOI 10.1080/17453670710013816
   Jackson AL, 2010, NAT REV DRUG DISCOV, V9, P57, DOI 10.1038/nrd3010
   James AW, 2016, TISSUE ENG PART B RE, V22, P284, DOI [10.1089/ten.TEB.2015.0357, 10.1089/ten.teb.2015.0357]
   Jeon O, 2007, BIOMATERIALS, V28, P2763, DOI 10.1016/j.biomaterials.2007.02.023
   Kakiuchi Kiyota S, 2014, TOXICOL SCI, V138, P234, DOI 10.1093/toxsci/kft278
   Kawai M, 2003, HUM GENE THER, V14, P1547, DOI 10.1089/104303403322495052
   Kean TJ, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/732742
   Kim D, 2006, STEM CELLS, V24, P1798, DOI 10.1634/stemcells.2005 0480
   Krause U, 2010, P NATL ACAD SCI USA, V107, P4147, DOI 10.1073/pnas.0914360107
   Levin AA, 2019, NEW ENGL J MED, V380, P57, DOI 10.1056/NEJMra1705346
   Liu LZ, 2012, BONE, V51, P633, DOI 10.1016/j.bone.2012.06.010
   Martínez Sanz E, 2011, J CONTROL RELEASE, V152, P232, DOI 10.1016/j.jconrel.2011.02.003
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708
   Pérez Campo FM, 2017, J BONE MINER METAB, V35, P150, DOI 10.1007/s00774 016 0753 z
   Pountos I, 2010, J ORTHOP TRAUMA, V24, P552, DOI 10.1097/BOT.0b013e3181efa8fe
   Rentsch C, 2014, BIOMATTER, V4, pe2799, DOI 10.4161/biom.27993
   Reyes R, 2018, DRUG DELIV, V25, P750, DOI 10.1080/10717544.2018.1446473
   Rodríguez Évora M, 2013, EUR J PHARM SCI, V49, P873, DOI 10.1016/j.ejps.2013.06.008
   Rodríguez Évora M, 2014, BIOMACROMOLECULES, V15, P1311, DOI 10.1021/bm401854d
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Scarfì S, 2016, WORLD J STEM CELLS, V8, P1, DOI 10.4252/wjsc.v8.i1.1
   Schroeder A, 2010, J INTERN MED, V267, P9, DOI 10.1111/j.1365 2796.2009.02189.x
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Singh K, 2011, SPINE, V36, P192, DOI 10.1097/BRS.0b013e3181cdd396
   Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841
   Stein CA, 2017, MOL THER, V25, P1069, DOI 10.1016/j.ymthe.2017.03.023
   STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393
   Sun YX, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00466 4
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305
   Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293
   Zigdon Giladi H, 2015, WORLD J STEM CELLS, V7, P630, DOI 10.4252/wjsc.v7.i3.630
NR 62
TC 20
Z9 20
U1 1
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2157 6564
EI 2157 6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD DEC
PY 2019
VL 8
IS 12
BP 1306
EP 1317
DI 10.1002/sctm.19 0145
EA OCT 2019
PG 12
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA JP6XZ
UT WOS:000491108000001
PM 31631568
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Abid, S
   Lee, MJ
   Rodich, B
   Hook, JS
   Moreland, JG
   Towler, D
   Maalouf, NM
   Keller, A
   Ratti, G
   Jain, R
AF Abid, Shadaan
   Lee, MinJae
   Rodich, Bailey
   Hook, Jessica S.
   Moreland, Jessica G.
   Towler, Dwight
   Maalouf, Naim M.
   Keller, Ashley
   Ratti, Gregory
   Jain, Raksha
TI Evaluation of an association between RANKL and OPG with bone disease in
   people with cystic fibrosis
SO JOURNAL OF CYSTIC FIBROSIS
LA English
DT Article
DE Cystic fibrosis; Osteoporosis; Receptor activator of NF; ? B;
   Osteoprotegerin; Dual energy x ray absorptiometry; tion; genetic
   factors; malnutrition; low vitamin D levels; glucocorti
ID OSTEOPROTEGERIN; OSTEOPOROSIS; MARKERS; SYSTEM; CELLS; CFTR
AB Background: As people with Cystic Fibrosis (CF) live longer, extra pulmonary complications such as CFrelated bone disease (CFBD) are becoming increasingly important. The etiology of CFBD is poorly understood but is likely multifactorial. Bones undergo continuous remodeling via pathways including RANK (receptor activator of NF  kappa B)/sRANKL (soluble ligand)/OPG (osteoprotegerin). We sought to examine the association between sRANKL (stimulant of osteoclastogenesis) and OPG levels (inhibitor of osteoclast formation) and CFBD to investigate their potential utility as biomarkers of bone turnover in people with CF.Methods: We evaluated sRANKL and OPG in plasma from people with CF and healthy controls (HC) and compared levels in those with CF to bone mineral density results. We used univariable and multivariable analysis to account for factors that may impact sRANKL and OPG.Results: We found a higher median [IQR] sRANKL 10,896pg/mL [5,781 24,243] CF; 2,406pg.mL [659.50  5,042] HC; p = 0.0 0 09), lower OPG 56.68pg/mL [36.28 124.70] CF; 583.20pg/mL [421.30 675.10] HC; p < 0.0 0 01), and higher RANKL/OPG in people with CF no BD than in HC ( p < 0.0 0 01). Furthermore, we found a higher RANKL/OPG ratio 407.50pg/mL [214.40 602.60] CFBD; 177.70pg/mL [131.50 239.70] CF no BD; p = 0.007) in people with CFBD versus CF without bone disease. This difference persisted after adjusting for variables thought to impact bone health.Conclusions: The current screening recommendations of imaging for CFBD may miss important markers of bone turnover such as the RANKL/OPG ratio. These findings support the investigation of therapies that modulate the RANK/RANKL/OPG pathway as potential therapeutic targets for bone disease in CF.(c) 2022 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
C1 [Abid, Shadaan; Towler, Dwight; Maalouf, Naim M.; Keller, Ashley; Ratti, Gregory; Jain, Raksha] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA.
   [Lee, MinJae] Univ Texas Southwestern Med Ctr Dallas, Dept Populat & Data Sci, Div Biostat, Dallas, TX USA.
   [Rodich, Bailey] Baylor Scott & White, Dept Anesthesiol, Temple, TX USA.
   [Hook, Jessica S.; Moreland, Jessica G.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA.
   [Jain, Raksha] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center; Baylor Scott & White Health; University of Texas System;
   University of Texas Southwestern Medical Center; University of Texas
   System; University of Texas Southwestern Medical Center
RP Jain, R (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
EM raksha.jain@utsouthwestern.edu
RI Lee, MinJae/AAK 1972 2020; Abid, Shadaan/B 2660 2015
OI Moreland, Jessica/0000 0001 8487 9494; Hook,
   Jessica/0000 0001 8344 8211; Lee, MinJae/0000 0002 4329 506X; Maalouf,
   Naim/0000 0002 0997 283X; Towler, Dwight/0000 0003 2107 7923; Ratti,
   Gregory/0000 0001 6286 5921
FU NIH/NCATS UT Southwestern CTSA Lifespan award [LS 2018 001]; CF
   Foundation [JAIN19A0 I, JAIN20Y7]
FX NIH/NCATS UT Southwestern CTSA Lifespan award (LS 2018 001) (R.J., D.T.,
   J.M.) and CF Foundation pilot award (JAIN19A0 I) (R.J.) and STATnet
   award (JAIN20Y7)(R.J., M.L.) for funding support.
CR Ali R, 2019, LUPUS, V28, P1233, DOI 10.1177/0961203319867129
   Ambroszkiewicz J, 2013, ADV MED SCI POLAND, V58, P338, DOI 10.2478/ams 2013 0011
   [Anonymous], 2022, DENOSUMAB PRESCRIBIN
   Aris RM, 2005, J CLIN ENDOCR METAB, V90, P1888, DOI 10.1210/jc.2004 1629
   Ashcroft AJ, 2003, IMMUNITY, V19, P849, DOI 10.1016/S1074 7613(03)00326 1
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Chen JS, 2012, NAT REV ENDOCRINOL, V8, P81, DOI 10.1038/nrendo.2011.146
   Conway SP, 2000, THORAX, V55, P798, DOI 10.1136/thorax.55.9.798
   Delion M, 2016, J PATHOL, V240, P50, DOI 10.1002/path.4753
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Ionescu AA, 2000, AM J RESP CRIT CARE, V162, P789, DOI 10.1164/ajrccm.162.3.9910118
   Lam GY, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 94883 1
   Le Heron L, 2010, J CYST FIBROS, V9, P69, DOI 10.1016/j.jcf.2009.11.005
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   Ott SM, 1998, CLIN CHEST MED, V19, P555, DOI 10.1016/S0272 5231(05)70100 3
   Paccou J, 2010, CALCIFIED TISSUE INT, V86, P1, DOI 10.1007/s00223 009 9316 9
   Poubelle PE, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2137
   Putman MS, 2019, J CYST FIBROS, V18, pS56, DOI 10.1016/j.jcf.2019.08.017
   Shead EF, 2007, THORAX, V62, P650, DOI 10.1136/thx.2006.075887
   Shead EF, 2010, J CYST FIBROS, V9, P93, DOI 10.1016/j.jcf.2009.11.007
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stalvey MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080098
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   van Tuyl LHD, 2010, ANN RHEUM DIS, V69, P1623, DOI 10.1136/ard.2009.121764
   Vega D, 2007, J CLIN ENDOCR METAB, V92, P4514, DOI 10.1210/jc.2007 0646
   Velard F, 2015, EUR RESPIR J, V45, P845, DOI 10.1183/09031936.00174014
   Velard F, 2014, AM J RESP CRIT CARE, V189, P746, DOI 10.1164/rccm.201312 2144LE
NR 29
TC 6
Z9 6
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1569 1993
EI 1873 5010
J9 J CYST FIBROS
JI J. Cyst. Fibros
PD JAN
PY 2023
VL 22
IS 1
BP 140
EP 145
DI 10.1016/j.jcf.2022.08.011
EA MAR 2023
PG 6
WC Respiratory System
WE Science Citation Index Expanded (SCI EXPANDED)
SC Respiratory System
GA A5ZI3
UT WOS:000955898500001
PM 36041886
OA Bronze
DA 2025 08 17
ER

PT J
AU Hamm, P
   Beckmann, D
   Worschech, R
   Braun, A
   Gutmann, M
   Korb Pap, A
   Luehmann, T
   Pap, T
   Meinel, L
AF Hamm, Prisca
   Beckmann, Denise
   Worschech, Rafael
   Braun, Alexandra
   Gutmann, Marcus
   Korb Pap, Adelheid
   Luehmann, Tessa
   Pap, Thomas
   Meinel, Lorenz
TI Transglutaminase catalyzed covalent anti myostatin peptide depots
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Solid phase peptide synthesis; Transglutaminase; Drug depot;
   Extracellular matrix; Myostatin inhibition
ID GROWTH FACTOR I; DELIVERY; FIBRONECTIN; EXTRACTION
AB Nature realizes protein and peptide depots by catalyzing covalent bonds with the extracellular matrix (ECM) of tissues. We are translating this natural blueprint for the sustained delivery of a myostatin inhibiting peptide (Anti Myo), resulting in an enzyme depot established from injectable solutions. For that, we fused Anti Myo to the D domain of insulin like growth factor I, a transglutaminase (TG) substrate. TG catalyzed the covalent binding of the D domain to ECM proteins, such as laminin and fibronectin, on bioengineered ECM and in mice. ECM decorated with Anti Myo suppressed myostatin activity and pathway activation and reduced the differentiation of preconditioned bone marrow derived macrophages into osteoclasts in vitro.
C1 [Hamm, Prisca; Worschech, Rafael; Braun, Alexandra; Gutmann, Marcus; Luehmann, Tessa; Meinel, Lorenz] Univ Wurzburg, Inst Pharm & Food Chem, D 97074 Wurzburg, Germany.
   [Beckmann, Denise; Korb Pap, Adelheid; Pap, Thomas] Univ Hosp Munster, Inst Musculoskeletal Med, Domagkstr 3, D 48149 Munster, Germany.
   [Meinel, Lorenz] Helmholtz Inst RNA Based Infect Res HIRI, D 97070 Wurzburg, Germany.
C3 University of Wurzburg; University of Munster
RP Meinel, L (通讯作者)，Univ Wurzburg, Inst Pharm & Food Chem, D 97074 Wurzburg, Germany.; Pap, T (通讯作者)，Univ Hosp Munster, Inst Musculoskeletal Med, Domagkstr 3, D 48149 Munster, Germany.
EM thomas.pap@unimuenster.de; lorenz.meinel@uni wuerzburg.de
RI Meinel, Lorenz/D 9997 2015; Lühmann, Tessa/E 1209 2015
FU German Federal Ministry of Education and Research (BMBF) [16GW0334K]
FX We sincerely thank Dr. Andreas Schlosser and Stephanie Lamer (Rudolf
   Virchow Zentrum, University of Wurzburg, Germany) for their support in
   mass spectrometry analysis. The project was funded within the framework
   "BICRA" (#16GW0334K) by the German Federal Ministry of Education and
   Research (BMBF) .
CR Baig MH, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.876078
   BARRY ELR, 1988, J BIOL CHEM, V263, P10464
   Braun AC, 2017, PHARM RES DORDR, V34, P58, DOI 10.1007/s11095 016 2038 6
   Caló E, 2015, EUR POLYM J, V65, P252, DOI 10.1016/j.eurpolymj.2014.11.024
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Dankbar B, 2015, NAT MED, V21, P1085, DOI 10.1038/nm.3917
   Dodt K, 2020, ACS BIOMATER SCI ENG, V6, P5240, DOI 10.1021/acsbiomaterials.0c00691
   Gander B, 2001, CHIMIA, V55, P212
   Gresham RCH, 2021, BIOACT MATER, V6, P1945, DOI 10.1016/j.bioactmat.2020.12.012
   Gutmann M, 2019, ACS BIOMATER SCI ENG, V5, P215, DOI 10.1021/acsbiomaterials.8b00865
   Haas D, 2022, BIOCONJUGATE CHEM, V33, P97, DOI 10.1021/acs.bioconjchem.1c00495
   Han H., 2011, Google Patents
   Hughes CS, 2019, NAT PROTOC, V14, P68, DOI 10.1038/s41596 018 0082 x
   Lee H., 2018, Emerging Areas in Bioengineering, P607
   Mangala LS, 2005, MOL CANCER, V4, DOI 10.1186/1476 4598 4 33
   Meinel L, 2004, J BIOMED MATER RES A, V71A, P25, DOI 10.1002/jbm.a.30117
   Meinel L, 2001, J CONTROL RELEASE, V70, P193, DOI 10.1016/S0168 3659(00)00352 7
   Omosule CL, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.662908
   Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i
   Sivaramakrishnan M, 2013, BBA MOL CELL RES, V1833, P3176, DOI 10.1016/j.bbamcr.2013.09.002
   Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02 01 0048
   Wallner C., 2016, Journal of Dermatology Research and Therapy, V1
   Wu F, 2018, ACS BIOMATER SCI ENG, V4, P819, DOI 10.1021/acsbiomaterials.7b01016
NR 24
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939 6411
EI 1873 3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD OCT
PY 2024
VL 203
AR 114462
DI 10.1016/j.ejpb.2024.114462
EA AUG 2024
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA F3Q5W
UT WOS:001309004500001
PM 39197542
OA hybrid
DA 2025 08 17
ER

PT J
AU Lin, L
   Li, S
   Hu, S
   Yu, W
   Jiang, B
   Mao, C
   Li, G
   Yang, R
   Miao, X
   Jin, M
   Gu, Y
   Lu, E
AF Lin, L.
   Li, S.
   Hu, S.
   Yu, W.
   Jiang, B.
   Mao, C.
   Li, G.
   Yang, R.
   Miao, X.
   Jin, M.
   Gu, Y.
   Lu, E.
TI UCHL1 Impairs Periodontal Ligament Stem Cell Osteogenesis in
   Periodontitis
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE periodontal diseases; cell differentiation; deubiquitinating enzymes;
   mitophagy; Smad proteins; bone regeneration
ID TERMINAL HYDROLASE L1; REGENERATION
AB Periodontitis comprises a series of inflammatory responses resulting in alveolar bone loss. The suppression of osteogenesis of periodontal ligament stem cells (PDLSCs) by inflammation is responsible for impaired alveolar bone regeneration, which remains an ongoing challenge for periodontitis therapy. Ubiquitin C terminal hydrolase L1 (UCHL1) belongs to the family of deubiquitinating enzymes, which was found to play roles in inflammation previously. In this study, the upregulation of UCHL1 was identified in inflamed PDLSCs isolated from periodontitis patients and in healthy PDLSCs treated with tumor necrosis factor alpha or interleukin 1 beta, and the higher expression level of UCHL1 was accompanied with the impaired osteogenesis of PDLSCs. Then UCHL1 was inhibited in PDLSCs using the lentivirus or inhibitor, and the osteogenesis of PDLSCs suppressed by inflammation was rescued by UCHL1 inhibition. Mechanistically, the negative effect of UCHL1 on the osteogenesis of PDLSCs was attributable to its negative regulation of mitophagy dependent bone morphogenetic protein 2/Smad signaling pathway in periodontitis associated inflammation. Furthermore, a ligature induced murine periodontitis model was established, and the specific inhibitor of UCHL1 was administrated to periodontitis mice. The histological results showed increased active osteoblasts on alveolar bone surface and enhanced alveolar bone regeneration when UCHL1 was inhibited in periodontitis mice. Besides, the therapeutic effects of UCHL1 inhibition on ameliorating periodontitis were verified, as indicated by less bone loss and reduced inflammation. Altogether, our study proved UCHL1 to be a key negative regulator of the osteogenesis of PDLSCs in periodontitis and suggested that UCHL1 inhibition holds promise for alveolar bone regeneration in periodontitis treatment.
C1 [Lin, L.; Li, S.; Hu, S.; Yu, W.; Jiang, B.; Mao, C.; Li, G.; Yang, R.; Jin, M.; Gu, Y.; Lu, E.] Shanghai Jiao Tong Univ, Renji Hosp, Dept Stomatol, Sch Med, 160 Pujian Rd, Shanghai 200127, Peoples R China.
   [Miao, X.; Gu, Y.] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Shanghai Inst Biol Sci,Key Lab Tissue Microenviro, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; University
   of Chinese Academy of Sciences, CAS; Shanghai Institute of Nutrition &
   Health, CAS
RP Jin, M; Gu, Y; Lu, E (通讯作者)，Shanghai Jiao Tong Univ, Renji Hosp, Dept Stomatol, Sch Med, 160 Pujian Rd, Shanghai 200127, Peoples R China.
EM jinmin@renji.com; guyutingxm@126.com; lueryi222@outlook.com
RI ; 金, 敏/ITW 0589 2023; Jin, Min/ITW 0589 2023
OI Lu, Eryi/0000 0002 0045 2571; Mao, Chuanyuan/0000 0002 3649 5944; Jin,
   Min/0000 0003 0073 4816
FU National Natural Science Foundation of China [52171075, 81900565,
   82000567]; Science and Technology Commission of Shanghai Municipality
   [21DZ2294700, 201409006300, 21ZR1439400, 19ZR 1430900]; Research Fund of
   Key Laboratory of Tissue Microenvironment and Tumor of Shanghai
   Institute of Nutrition and Health of Chinese Academy of Sciences
   [202007]; Opening Project of Shanghai Key Laboratory of Orthopaedic
   Implant [KFKT2021001]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: The work was
   supported by National Natural Science Foundation of China (grant numbers
   52171075, 81900565, 82000567), Science and Technology Commission of
   Shanghai Municipality (grant numbers 21DZ2294700, 201409006300,
   21ZR1439400, 19ZR 1430900), the Research Fund of Key Laboratory of
   Tissue Microenvironment and Tumor of Shanghai Institute of Nutrition and
   Health of Chinese Academy of Sciences (grant number 202007), and the
   Opening Project of Shanghai Key Laboratory of Orthopaedic Implant (grant
   number KFKT2021001).
CR Ausländer D, 2018, NAT METHODS, V15, P57, DOI [10.1038/NMETH.4505, 10.1038/nmeth.4505]
   Cerqueira FM, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101676
   Deas DE, 2016, PERIODONTOL 2000, V71, P128, DOI 10.1111/prd.12114
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Gao HB, 2017, BIOCHEM BIOPH RES CO, V492, P96, DOI 10.1016/j.bbrc.2017.08.027
   Giannobile WV, 2019, J CLIN PERIODONTOL, V46, P6, DOI 10.1111/jcpe.13130
   Graham SH, 2017, AGEING RES REV, V34, P30, DOI 10.1016/j.arr.2016.09.011
   Gu YT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0532 y
   Ham SJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4574
   Khalid S, 2020, FREE RADICAL BIO MED, V153, P103, DOI 10.1016/j.freeradbiomed.2020.04.008
   Kimura Y, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00019
   Lampert MA, 2019, AUTOPHAGY, V15, P1182, DOI 10.1080/15548627.2019.1580095
   Lee SY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02656 4
   Li X, 2021, DRUG DISCOV TODAY, V26, P1226, DOI 10.1016/j.drudis.2021.03.002
   Liang QY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12997
   Lin QS, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101254
   Liu JN, 2022, J LEUKOCYTE BIOL, V111, P1185, DOI 10.1002/JLB.1MA1220 853RR
   Nuñez J, 2019, PERIODONTOL 2000, V79, P107, DOI 10.1111/prd.12250
   Onishi M, 2021, EMBO J, V40, DOI 10.15252/embj.2020104705
   Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556 018 0176 2
   Park JC, 2011, J CLIN PERIODONTOL, V38, P721, DOI 10.1111/j.1600 051X.2011.01716.x
   Pei DD, 2018, ADV SCI, V5, DOI 10.1002/advs.201800873
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Reinicke AT, 2019, J IMMUNOL, V203, P1730, DOI 10.4049/jimmunol.1801133
   Sakurai M, 2006, J CELL SCI, V119, P162, DOI 10.1242/jcs.02716
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shang LL, 2021, J LEUKOCYTE BIOL, V110, P539, DOI 10.1002/JLB.3MR0321 766R
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Takami Y, 2007, ARTERIOSCL THROM VAS, V27, P2184, DOI 10.1161/ATVBAHA.107.142505
   Tassi SA, 2017, J PERIODONTAL RES, V52, P793, DOI 10.1111/jre.12455
   Tsuchida S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071476
   Wu XL, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02399 2
   Xia XH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02888 x
   Xu XY, 2019, STEM CELL TRANSL MED, V8, P392, DOI 10.1002/sctm.18 0181
   Zhang ZH, 2021, CELL BIOL INT, V45, P2107, DOI 10.1002/cbin.11662
   Zhang ZY, 2021, J LEUKOCYTE BIOL, V110, P565, DOI 10.1002/JLB.4MR0421 750R
   Zhou M, 2021, BIOACT MATER, V6, P1676, DOI 10.1016/j.bioactmat.2020.11.018
NR 37
TC 32
Z9 35
U1 7
U2 57
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JAN
PY 2023
VL 102
IS 1
BP 61
EP 71
DI 10.1177/00220345221116031
EA SEP 2022
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 7F7XB
UT WOS:000853962700001
PM 36112902
DA 2025 08 17
ER

PT S
AU Xie, L
   Tintani, F
   Wang, X
   Li, FF
   Zhen, GH
   Qiu, T
   Wan, M
   Crane, J
   Chen, QM
   Cao, X
AF Xie, Liang
   Tintani, Francis
   Wang, Xiao
   Li, Fengfeng
   Zhen, Gehua
   Qiu, Tao
   Wan, Mei
   Crane, Janet
   Chen, Qianming
   Cao, Xu
BE Zaidi, M
TI Systemic neutralization of TGF β attenuates osteoarthritis
SO MARROW 2016, VOL 1376
SE Annals of the New York Academy of Sciences
LA English
DT Article; Book Chapter
DE osteoarthritis; subchondral bone; cartilage; TGF beta; antibody
ID GROWTH FACTOR BETA; MESENCHYMAL STEM CELLS; BONE MARROW LESIONS; MURINE
   KNEE JOINT; SUBCHONDRAL BONE; ARTICULAR CARTILAGE; OSTEOPHYTE FORMATION;
   RHEUMATOID ARTHRITIS; ANGIOGENESIS; INHIBITION
AB Osteoarthritis (OA) is a major source of pain and disability worldwide with no effective medical therapy due to poor understanding of its pathogenesis. Transforming growth factor beta (TGF beta) has been reported to play a role in subchondral bone pathology and articular cartilage degeneration during the progression of OA. In this study, we demonstrated that systemic use of a TGF beta neutralizing antibody (1D11) attenuates OA progression by targeting subchondral bone pathological features in rodent OA models. Systemic administration of 1D11 preserves the subchondral bone microarchitecture, preventing articular cartilage degeneration by inhibition of excessive TGF beta activity, in both subchondral bone and the circulation. Moreover, the aberrant increases in the numbers of blood vessels, nestin(+) mesenchymal stromal/stemcells, and osterix(+) osteoblast progenitors were normalized by 1D11 systemic injection. Thus, systemic neutralization of excessive TGF beta ligands effectively prevented OA progression in animal models, with promising clinical implications for OA treatment.
C1 [Xie, Liang; Tintani, Francis; Wang, Xiao; Li, Fengfeng; Zhen, Gehua; Qiu, Tao; Wan, Mei; Crane, Janet; Cao, Xu] Johns Hopkins Univ, Inst Cell Engn, Dept Orthopaed Surg, Baltimore, MD USA.
   [Xie, Liang; Chen, Qianming] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, 14,Sec 3,Renminnan Rd, Chengdu 610041, Sichuan, Peoples R China.
C3 Johns Hopkins University; Sichuan University
RP Chen, QM (通讯作者)，Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, 14,Sec 3,Renminnan Rd, Chengdu 610041, Sichuan, Peoples R China.; Cao, X (通讯作者)，Johns Hopkins Med Inst, Orthopaed Surg, 720 Rutland Ave,Ross Bldg, Baltimore, MD 21205 USA.
EM qmchen@scu.edu.cn; xcao11@jhmi.edu
RI ; Xie, Liang/AAR 7725 2021; Crane, Janet/LNP 7603 2024; Wang,
   Xiao/AAL 8698 2020; qiu, tao/LLL 6919 2024
OI Crane, Janet/0000 0001 7713 0936; Chen, Qianming/0000 0002 5371 4432;
   Wang, Xiao/0000 0001 6395 706X; 
FU NIAMS NIH HHS [K08 AR064833, R01 AR063943] Funding Source: Medline;
   NIDDK NIH HHS [R01 DK057501, T32 DK007751] Funding Source: Medline;
   Intramural NIH HHS [Z01 DK057501] Funding Source: Medline
CR ARNOLDI C C, 1972, Journal of Bone and Joint Surgery British Volume, V54B, P409
   Ashraf S, 2008, CURR OPIN RHEUMATOL, V20, P573, DOI 10.1097/BOR.0b013e3283103d12
   Bakker AC, 2001, OSTEOARTHR CARTILAGE, V9, P128, DOI 10.1053/joca.2000.0368
   Berenbaum F, 2011, OSTEOARTHR CARTILAGE, V19, P361, DOI 10.1016/j.joca.2011.01.019
   Burr DB, 2003, RHEUM DIS CLIN N AM, V29, P675, DOI 10.1016/S0889 857X(03)00061 9
   Cao X, 2011, NAT MED, V17, P1344, DOI 10.1038/nm.2499
   Cunha SI, 2011, BLOOD, V117, P6999, DOI 10.1182/blood 2011 01 330142
   Davidson ENB, 2007, OSTEOARTHR CARTILAGE, V15, P597, DOI 10.1016/j.joca.2007.02.005
   Davidson ENB, 2006, ANN RHEUM DIS, V65, P1414, DOI 10.1136/ard.2005.045971
   Edwards JR, 2010, J BONE MINER RES, V25, P2419, DOI 10.1002/jbmr.139
   Fox AJS, 2009, SPORTS HEALTH, V1, P461, DOI 10.1177/1941738109350438
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Guiducci S, 2011, ANN RHEUM DIS, V70, P2011, DOI 10.1136/ard.2011.150607
   HAHN M, 1992, BONE, V13, P327, DOI 10.1016/8756 3282(92)90078 B
   Hawker GA, 2011, OSTEOARTHR CARTILAGE, V19, P366, DOI 10.1016/j.joca.2011.01.021
   Hootman JM, 2006, ARTHRITIS RHEUM US, V54, P226, DOI 10.1002/art.21562
   Hulth A, 1996, J ORTHOPAED RES, V14, P547, DOI 10.1002/jor.1100140408
   Hunter DJ, 2006, ARTHRITIS RHEUM US, V54, P1529, DOI 10.1002/art.21789
   Hunter DJ, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2601
   Imhof H, 1999, Top Magn Reson Imaging, V10, P180, DOI 10.1097/00002142 199906000 00002
   Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004
   Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Lotz M, 2012, OSTEOARTHR CARTILAGE, V20, P192, DOI 10.1016/j.joca.2011.11.015
   LOTZ M, 1990, J IMMUNOL, V144, P4189
   Madry H, 2010, KNEE SURG SPORT TR A, V18, P419, DOI 10.1007/s00167 010 1054 z
   Mapp PI, 2008, OSTEOARTHR CARTILAGE, V16, P61, DOI 10.1016/j.joca.2007.05.017
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564
   Ono N, 2014, DEV CELL, V29, P330, DOI 10.1016/j.devcel.2014.03.014
   Pickarski M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 197
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Poole A.R., 2001, Arthritis and allied conditions. A Textbook of rheumatology, P226
   Poole AR, 2002, ANN RHEUM DIS, V61, P78, DOI 10.1136/ard.61.suppl_2.ii78
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   Scharstuhl A, 2003, ARTHRITIS RHEUM US, V48, P3442, DOI 10.1002/art.11328
   Scharstuhl A, 2002, J IMMUNOL, V169, P507, DOI 10.4049/jimmunol.169.1.507
   Schlaak JF, 1996, CLIN EXP RHEUMATOL, V14, P155
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2
   Shen J, 2013, ARTHRITIS RHEUM US, V65, P3107, DOI 10.1002/art.38122
   Stein V, 2012, RHEUMATOL INT, V32, P1197, DOI 10.1007/s00296 010 1749 y
   Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354
   Suri S, 2012, BONE, V51, P204, DOI 10.1016/j.bone.2011.10.010
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Tchetina EV, 2011, ARTHRITIS, DOI 10.1155/2011/683970
   van Beuningen HM, 2000, OSTEOARTHR CARTILAGE, V8, P25, DOI 10.1053/joca.1999.0267
   VANBEUNINGEN HM, 1994, LAB INVEST, V71, P279
   Wan M, 2012, STEM CELLS, V30, P2498, DOI 10.1002/stem.1208
   Wang MN, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4133
   Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018 004 4144 6
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xie L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/762098
   Xu X, 2015, J BONE MINER RES, V30, P2033, DOI 10.1002/jbmr.2550
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 59
TC 63
Z9 66
U1 0
U2 30
PU BLACKWELL SCIENCE PUBL
PI OXFORD
PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND
SN 0077 8923
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2016
VL 1376
BP 53
EP 64
DI 10.1111/nyas.13000
PG 12
WC Cell Biology
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA BF6YH
UT WOS:000383803800005
PM 26837060
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Lorenz, S
   Frenzel, R
   Paschke, R
   Breitwieser, GE
   Miedlich, SU
AF Lorenz, Stephan
   Frenzel, Romy
   Paschke, Ralf
   Breitwieser, Gerda E.
   Miedlich, Susanne U.
TI Functional desensitization of the extracellular calcium sensing receptor
   is regulated via distinct mechanisms:: Role of G protein coupled
   receptor kinases, protein kinase C and β arrestins
SO ENDOCRINOLOGY
LA English
DT Article
ID AGONIST INDUCED INTERNALIZATION; PHOSPHORYLATION; ACTIVATION; FILAMIN;
   CA2+; EXPRESSION; BINDS; 1A
AB The extracellular calcium sensing receptor (CaR) senses small fluctuations of the extracellular calcium (Ca e(2+)) concentration and translates them into potent changes in parathyroid hormone secretion. Dissecting the regulatory mechanisms of CaR mediated signal transduction may provide insights into the physiology of the receptor and identify new molecules as potential drug targets for the treatment of osteoporosis and/or hyperparathyroidism. CaR can be phosphorylated by protein kinase C (PKC) and G protein coupled receptor kinases (GRKs), and has been shown to bind to beta arrestins, potentially contributing to desensitization of CaR, although the mechanisms by which CaR mediated signal transduction is terminated are not known. We used a PKC phosphorylation site deficient CaR, GRK and beta arrestin overexpression or down regulation to delineate CaR mediated desensitization. Fluorescence activated cell sorting was used to determine whether receptor internalization contributed to desensitization. Overexpression of GRK 2 or 3 reduced Ca e(2+) dependent inositol phosphate accumulation by more than 70%, whereas a GRK2 mutant deficient in G alpha(q) binding (D110A) was without major effect. Overexpression of GRK 4   6 did not reduce Ca e(2+) dependent inositol phosphate accumulation. Overexpression of beta arrestin 1 or 2 revealed a modest inhibitory effect on Ca e(2+) dependent inositol phosphate production ( 20   30%), which was not observed for the PKC phosphorylation site deficient CaR. Agonist dependent receptor internalization ( 10   15%) did not account for the described effects. Thus, we conclude that PKC phosphorylation of CaR contributes to beta arrestin dependent desensitization of CaR coupling to G proteins. In contrast, GRK 2 predominantly interferes with G protein mediated inositol 1,4,5 trisphosphate formation by binding to G alpha(q).
C1 Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   Univ Leipzig, Dept Med 2, D 04109 Leipzig, Germany.
   Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Leipzig University; Geisinger Medical Center
RP Miedlich, SU (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Bulfinch 327,55 Fruit St, Boston, MA 02114 USA.
EM smiedlich@partners.org
RI ; Lorenz, Stephan/ABD 6137 2021
OI Lorenz, Stephan/0000 0002 6678 355X; 
FU NIGMS NIH HHS [R01 GM077563, GM58578] Funding Source: Medline
CR Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200
   Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267
   Barak LS, 2003, ASSAY DRUG DEV TECHN, V1, P339, DOI 10.1089/15406580360545152
   Brown E M, 2000, Rev Endocr Metab Disord, V1, P307, DOI 10.1023/A:1026570518919
   Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808
   Dhami GK, 2004, J BIOL CHEM, V279, P16614, DOI 10.1074/jbc.M314090200
   Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200
   Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712
   Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200
   Hjälm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200
   Iacovelli L, 2003, J BIOL CHEM, V278, P12433, DOI 10.1074/jbc.M203992200
   Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102
   Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237
   Mundell SJ, 2003, J NEUROCHEM, V84, P294, DOI 10.1046/j.1471 4159.2003.01515.x
   Mundell SJ, 2001, J NEUROCHEM, V78, P546, DOI 10.1046/j.1471 4159.2001.00421.x
   Nagano N, 2005, J PHARMACOL SCI, V97, P355, DOI 10.1254/jphs.FMJ04007X6
   Naik S, 2005, J BIOL CHEM, V280, P8722, DOI 10.1074/jbc.M413014200
   Namkung Y, 2004, J BIOL CHEM, V279, P49533, DOI 10.1074/jbc.M408319200
   Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015
   Penela P, 2003, CELL SIGNAL, V15, P973, DOI 10.1016/S0898 6568(03)00099 8
   Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383
   Pi M, 2005, MOL ENDOCRINOL, V19, P1078, DOI 10.1210/me.2004 0450
   Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742 4658.2005.04728.x
   Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102
   Rodland KD, 2004, CELL CALCIUM, V35, P291, DOI 10.1016/j.ceca.2003.10.011
   Spurney RF, 1998, J BIOL CHEM, V273, P28496, DOI 10.1074/jbc.273.43.28496
   Tu CL, 2004, CELL CALCIUM, V35, P265, DOI 10.1016/j.ceca.2003.10.019
   Voigt C, 2004, J ENDOCRINOL, V182, P173, DOI 10.1677/joe.0.1820173
   Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515
   Ward DT, 2004, CELL CALCIUM, V35, P217, DOI 10.1016/j.ceca.2003.10.017
   Wonerow P, 2000, CLIN ENDOCRINOL, V53, P461, DOI 10.1046/j.1365 2265.2000.01119.x
   Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200
NR 32
TC 52
Z9 60
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD MAY
PY 2007
VL 148
IS 5
BP 2398
EP 2404
DI 10.1210/en.2006 1035
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 158RG
UT WOS:000245810600050
PM 17255208
DA 2025 08 17
ER

PT J
AU Kamiya, Y
   Kikuchi, T
   Goto, H
   Okabe, I
   Takayanagi, Y
   Suzuki, Y
   Sawada, N
   Okabe, T
   Suzuki, Y
   Kondo, S
   Hayashi, J
   Mitani, A
AF Kamiya, Yosuke
   Kikuchi, Takeshi
   Goto, Hisashi
   Okabe, Iichiro
   Takayanagi, Yuhei
   Suzuki, Yuki
   Sawada, Noritaka
   Okabe, Teppei
   Suzuki, Yuki
   Kondo, Shun
   Hayashi, Jun ichiro
   Mitani, Akio
TI IL 35 and RANKL Synergistically Induce Osteoclastogenesis in RAW264
   Mouse Monocytic Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE interleukin 35; osteoimmunology; inflammatory bone destruction
ID RHEUMATOID ARTHRITIS; RECEPTOR ACTIVATOR; SERUM LEVELS; INTERLEUKIN 35;
   IL 27; PROTEIN; DIFFERENTIATION; EXPRESSION; REGULATORS; THERAPY
AB Interleukin (IL) 35 is an immunosuppressive cytokine mainly produced by regulatory T cells. IL 35 mediates immunological functions by suppressing the inflammatory immune response. However, the role of IL 35 in bone destructive diseases remains unclear, especially in terms of osteoclastogenesis. Therefore, the current study investigated the synergistic effect of IL 35 on osteoclastogenesis that is involved the pathogeneses of periodontitis and rheumatoid arthritis. Osteoclastic differentiation and osteoclastogenesis of RAW264 (RAW) cells induced by receptor activator of nuclear factor (NF) kappa B ligand (RANKL) and IL 35 were evaluated by tartrate resistant acid phosphate staining, hydroxyapatite resorption assays, and quantitative polymerase chain reaction. The effect of IL 35 on RANKL stimulated signaling pathways was assessed by Western blot analysis. Costimulation of RAW cells by RANKL and IL 35 induced osteoclastogenesis significantly compared with stimulation by RANKL alone. Phosphorylations of extracellular signal regulated kinase (ERK) and p38 mitogen activated protein kinase tended to be increased by RANKL and IL 35 compared with RANKL or IL 35 alone. Additionally, the osteoclastogenesis induced by RANKL and IL 35 was suppressed by inhibition of ERK. In this study, IL 35 and RANKL induced osteoclastogenesis synergistically. Previous reports have shown that IL 35 suppresses the differentiation of osteoclasts. Therefore, IL 35 might play dual roles of destruction and protection in osteoclastogenesis.
C1 [Kamiya, Yosuke; Kikuchi, Takeshi; Goto, Hisashi; Okabe, Iichiro; Takayanagi, Yuhei; Suzuki, Yuki; Sawada, Noritaka; Okabe, Teppei; Suzuki, Yuki; Kondo, Shun; Hayashi, Jun ichiro; Mitani, Akio] Aichi Gakuin Univ, Sch Dent, Dept Periodontol, Chikusa Ku, 2 11 Suemori Dori, Nagoya, Aichi 4648651, Japan.
C3 Aichi Gakuin University
RP Kikuchi, T (通讯作者)，Aichi Gakuin Univ, Sch Dent, Dept Periodontol, Chikusa Ku, 2 11 Suemori Dori, Nagoya, Aichi 4648651, Japan.
EM k yosuke@dpc.agu.ac.jp; tkikuchi@dpc.agu.ac.jp; hisashi@dpc.agu.ac.jp;
   iichiro@dpc.agu.ac.jp; ag173d14@dpc.agu.ac.jp; yukip@dpc.agu.ac.jp;
   ag173d11@dpc.agu.ac.jp; ag183d03@dpc.agu.ac.jp; ag193d11@dpc.agu.ac.jp;
   ag193d07@dpc.agu.ac.jp; jun1row@dpc.agu.ac.jp; minita@dpc.agu.ac.jp
OI Suzuki, Yuki/0000 0003 3660 6867; Hayashi,
   Jun ichiro/0000 0001 9742 5184; Kamiya, Yosuke/0000 0002 5433 6998;
   Mitani, Akio/0000 0001 5427 411X; Kikuchi, Takeshi/0000 0003 0310 5302
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
   Japan [26861824]; Grants in Aid for Scientific Research [26861824]
   Funding Source: KAKEN
FX This research was funded by a Grant in Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology
   (MEXT) of Japan, grant number 26861824.
CR [Anonymous], 2013, NAT MED, V19, P379, DOI 10.1038/nm.3163
   Catalan Dibene J, 2018, J INTERF CYTOK RES, V38, P423, DOI 10.1089/jir.2018.0089
   Chen C, 2014, ASIAN PAC J ALLERGY, V32, P211, DOI 10.12932/AP0403.32.3.2014
   Ciccarelli F, 2015, CURR MED CHEM, V22, P596, DOI 10.2174/0929867321666141106125051
   Collison LW, 2008, IMMUNOL REV, V226, P248, DOI 10.1111/j.1600 065X.2008.00704.x
   Collison LW, 2012, NAT IMMUNOL, V13, P290, DOI 10.1038/ni.2227
   De Martinis M, 2020, CURR MED CHEM, V27, P6356, DOI 10.2174/0929867326666190730113123
   Hunter CA, 2005, NAT REV IMMUNOL, V5, P521, DOI 10.1038/nri1648
   Jin Y, 2017, EXP THER MED, V14, P5605, DOI 10.3892/etm.2017.5255
   Jing L, 2019, J DENT RES, V98, P813, DOI 10.1177/0022034519847443
   Jones LL, 2011, IMMUNOL RES, V51, P5, DOI 10.1007/s12026 011 8209 y
   Kalaitzoglou E, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0672 6
   Kartner N, 2010, J BIOL CHEM, V285, P37476, DOI 10.1074/jbc.M110.123281
   Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Kuo J, 2011, CLIN VACCINE IMMUNOL, V18, P1125, DOI 10.1128/CVI.00052 11
   Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105 2896.2004.00214.x
   Li H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113698
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Li Y, 2016, OSTEOPOROSIS INT, V27, P1537, DOI 10.1007/s00198 015 3410 9
   Li YM, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/136329
   Liu Di xin, 2015, Shanghai Kou Qiang Yi Xue, V24, P455
   Logar DB, 2007, J BONE MINER METAB, V25, P219, DOI 10.1007/s00774 007 0753 0
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Mitani A, 2015, J PERIODONTOL, V86, P301, DOI 10.1902/jop.2014.140293
   Mori G., 2013, Clin. Develop. Immunol, V2013, DOI DOI 10.1155/2013/720504
   Nakano S, 2015, RHEUMATOLOGY, V54, P1498, DOI 10.1093/rheumatology/keu528
   Niedbala W, 2007, EUR J IMMUNOL, V37, P3021, DOI 10.1002/eji.200737810
   Ning XW, 2015, TOHOKU J EXP MED, V237, P77, DOI 10.1620/tjem.237.77
   Okabe I, 2017, J CELL BIOCHEM, V118, P739, DOI 10.1002/jcb.25726
   Peng MZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01417
   Peng S, 2010, INT J MOL SCI, V11, P222, DOI 10.3390/ijms11010222
   Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074 7613(02)00324 2
   Quan GH, 2015, INT J MOL SCI, V16, P29496, DOI 10.3390/ijms161226179
   Raj SC, 2018, CONTEMP CLIN DENT, V9, P293, DOI 10.4103/ccd.ccd_51_18
   RALPH P, 1977, J IMMUNOL, V119, P950
   Sakkas LI, 2018, IMMUNOL RES, V66, P305, DOI 10.1007/s12026 018 8998 3
   Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005
   Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217
   Takeda H, 2014, INFLAMMATION, V37, P657, DOI 10.1007/s10753 013 9782 0
   Thiolat A, 2014, CYTOKINE, V69, P87, DOI 10.1016/j.cyto.2014.05.015
   Tomcik M, 2015, RHEUMATOLOGY, V54, P2273, DOI 10.1093/rheumatology/kev260
   Yago T, 2018, CENT EUR J IMMUNOL, V43, P148, DOI 10.5114/ceji.2018.77384
   Yago T, 2009, J CELL BIOCHEM, V108, P947, DOI 10.1002/jcb.22326
   Yokota K, 2014, ARTHRITIS RHEUMATOL, V66, P121, DOI 10.1002/art.38218
NR 48
TC 11
Z9 12
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2020
VL 21
IS 6
AR 2069
DI 10.3390/ijms21062069
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LJ0UU
UT WOS:000529890200165
PM 32197293
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Liu, L
   Jin, RR
   Duan, JM
   Yang, L
   Cai, ZY
   Zhu, WC
   Nie, Y
   He, J
   Xia, CC
   Gong, QY
   Song, B
   Anderson, JM
   Ai, H
AF Liu, Li
   Jin, Rongrong
   Duan, Jimei
   Yang, Li
   Cai, Zhongyuan
   Zhu, Wencheng
   Nie, Yu
   He, Jing
   Xia, Chunchao
   Gong, Qiyong
   Song, Bin
   Anderson, James M.
   Ai, Hua
TI Bioactive iron oxide nanoparticles suppress osteoclastogenesis and
   ovariectomy induced bone loss through regulating the TRAF6 p62 CYLD
   signaling complex
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Iron oxide nanoparticles (IONPs); Osteoclastogenesis; Osteoporosis; p62;
   TRAF6
ID MR CONTRAST AGENTS; DIFFERENTIATION; DELIVERY; THERAPY; TRAF6; CYLD
AB Iron oxide nanoparticles (IONPs) have been widely used as contrast agents for magnetic resonance imaging (MRI) and other biomedical applications in both clinical and preclinical cases. In the present study, we show that two clinically used IONPs, ferumoxytol and ferucarbotran, have an intrinsic inhibitory effect on receptor activator NF kappa B ligand (RANKL) induced osteoclastogenesis of bone marrow derived monocytes/macrophages (BMMs). IONPs significantly inhibited the formation of tartrate resistant acid phosphatase (TRAP) positive multinuclear osteoclasts and functional actin ring structures. More importantly, the inhibitory effect was also verified in vivo by its capacity to rescue the bone loss of ovariectomized (OVX) mice after intravenous injection with IONPs. Mechanistically, we found that IONPs trigger the upregulation of p62 which result in recruitment of CYLD and enhanced deubiquitination of TRAF6, a master controller of RANKL signaling. The downstream activation of NF kappa B and MAPK signals was accordingly attenuated, ultimately leading to reduced expression of osteoclatogenesis related genes. Taken together, clinically used IONPs can inhibit osteoclastogenesis through regulating TRAF6 p62 CYLD signaling complex, and they may be considered as alternative options for treatment of osteoporosis.
   Statement of Significance
   Nanoparticles have been developed as drug delivery systems for treatment of osteoporosis, mostly an age related health problem with risk of fractures. In this work, we show that two clinically used iron oxide nanoparticles (IONPs) ferumoxytol and ferucarbotran themselves can significantly reduce the osteoporosis of ovariectomized (OVX) mice through inhibiting Osteoclastogenesis. We found that IONPs trigger the upregulation of p62 which result in recruitment of CYLD and enhanced deubiquitination of TRAF6, a master controller of RANKL signaling. The downstream activation of NF kappa B and MAPK signals was accordingly attenuated, leading to reduced expression of osteoclatogenesis related genes. Taken together, clinically used IONPs inhibit osteoclastogenesis through regulating TRAF6 p62 CYLD signaling complex, and they may be considered as alternative options for treatment of osteoporosis. (C) 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Liu, Li; Jin, Rongrong; Duan, Jimei; Yang, Li; Cai, Zhongyuan; Zhu, Wencheng; Nie, Yu; He, Jing; Xia, Chunchao; Ai, Hua] Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
   [Xia, Chunchao; Gong, Qiyong; Song, Bin; Ai, Hua] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu 610041, Peoples R China.
   [Anderson, James M.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.
   [Anderson, James M.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.
   [Zhu, Wencheng] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
C3 Sichuan University; Sichuan University; University System of Ohio; Case
   Western Reserve University; University System of Ohio; Case Western
   Reserve University; Chinese Academy of Sciences; Center for Excellence
   in Molecular Cell Science, CAS
RP Jin, RR (通讯作者)，Sichuan Univ, Natl Engn Res Ctr Biomat, Chengdu 610064, Peoples R China.
EM jinrr2015@scu.edu.cn; huaai@scu.edu.cn
RI xia, chunchao/AAM 1686 2021; Gong, Qiyong/W 3052 2019; Song,
   Bin/KFS 0206 2024; He, Jing/JTT 9706 2023; Zhu, Wencheng/IZE 0813 2023
OI Gong, Qiyong/0000 0002 5912 4871; Song, Bin/0000 0002 7269 2101; 
FU Innovative Research Groups of the National Natural Science Foundation of
   China [81621003]; National Key Basic Research Program of China
   [2013CB933903]; Sichuan Province Science and Technology Program
   [2019JDRC0103]; China Postdoctoral Science Foundation [2015M572475];
   Sino German Cooperation group [GZ1512]; National Natural Science
   Foundation of China [81873921]
FX This work was supported by Innovative Research Groups of the National
   Natural Science Foundation of China (81621003), National Key Basic
   Research Program of China (2013CB933903), Sichuan Province Science and
   Technology Program (No. 2019JDRC0103), China Postdoctoral Science
   Foundation Funded Project (2015M572475), Sino German Cooperation group
   (GZ1512) and National Natural Science Foundation of China (81873921).
CR Ang E, 2009, J CELL PHYSIOL, V220, P450, DOI 10.1002/jcp.21787
   Arami H, 2015, CHEM SOC REV, V44, P8576, DOI 10.1039/c5cs00541h
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bellin MF, 2006, EUR J RADIOL, V60, P314, DOI 10.1016/j.ejrad.2006.06.021
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bulte JWM, 2004, NMR BIOMED, V17, P484, DOI 10.1002/nbm.924
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Cheng H, 2017, DRUG DISCOV TODAY, V22, P1336, DOI 10.1016/j.drudis.2017.04.021
   Choi SY, 2015, INT J NANOMED, V10, P4383, DOI 10.2147/IJN.S78775
   Dadfar SM, 2019, ADV DRUG DELIVER REV, V138, P302, DOI 10.1016/j.addr.2019.01.005
   Gera S, 2017, CURR DRUG DELIV, V14, P904, DOI 10.2174/1567201813666161230142123
   Guo MM, 2015, PROTEOMICS, V15, P3169, DOI 10.1002/pmic.201400431
   Ha SW, 2018, ACTA BIOMATER, V82, P184, DOI 10.1016/j.actbio.2018.10.018
   Heo DN, 2014, ACS NANO, V8, P12049, DOI 10.1021/nn504329u
   Hu Y, 2018, CHEM SOC REV, V47, P1874, DOI 10.1039/c7cs00657h
   Jin RR, 2019, BIOMATERIALS, V203, P23, DOI 10.1016/j.biomaterials.2019.02.026
   Jin RR, 2014, CURR OPIN PHARMACOL, V18, P18, DOI 10.1016/j.coph.2014.08.002
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Liu G, 2011, SMALL, V7, P2742, DOI 10.1002/smll.201100825
   Lv YD, 2015, EXP THER MED, V9, P143, DOI 10.3892/etm.2014.2071
   Rawat P, 2016, INT J PHARMACEUT, V506, P253, DOI 10.1016/j.ijpharm.2016.04.049
   Raynal I, 2004, INVEST RADIOL, V39, P56, DOI 10.1097/01.rli.0000101027.57021.28
   Storey P, 2014, J MAGN RESON IMAGING, V39, P1401, DOI 10.1002/jmri.24320
   Sun Y, 2016, ACS NANO, V10, P5759, DOI 10.1021/acsnano.5b07828
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Xiong JH, 2018, BONE, V112, P1, DOI 10.1016/j.bone.2018.04.001
   Xu Y, 2015, BIOMATERIALS, V58, P63, DOI 10.1016/j.biomaterials.2015.04.016
   Yang L, 2015, NANOSCALE, V7, P625, DOI 10.1039/c4nr05061d
   Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/nnano.2016.168, 10.1038/NNANO.2016.168]
NR 34
TC 48
Z9 49
U1 2
U2 87
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD FEB
PY 2020
VL 103
BP 281
EP 292
DI 10.1016/j.actbio.2019.12.022
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA KM6DD
UT WOS:000514227900022
PM 31866569
DA 2025 08 17
ER

PT J
AU Dahiya, A
   Chaudhari, VS
   Bose, S
AF Dahiya, Aditi
   Chaudhari, Vishal Sharad
   Bose, Susmita
TI Bone Healing via Carvacrol and Curcumin Nanoparticle on 3D Printed
   Scaffolds
SO SMALL
LA English
DT Article
DE 3D printing; bone tissue engineering; carvacrol; curcumin; lipid
   nanoparticles
ID TRICALCIUM PHOSPHATE SCAFFOLDS; DELIVERY; STRESS
AB Carvacrol is a potent antimicrobial and anti inflammatory agent, while curcumin possesses antioxidant, anti inflammatory, and anticancer properties. These phytochemicals have poor solubility, bioavailability, and stability in their free form. Nanoencapsulation can reduce these limitations with enhanced translational capability. Integrating nanocarriers with 3D printed calcium phosphate (CaP) scaffolds presents a novel strategy for bone regeneration. Carvacrol and curcumin loaded nanoparticles (CC NP) synthesized with melt emulsification produced negatively charged, monodispersed particles with a hydrodynamic diameter of similar to 127 nm. Their release from the scaffold shows a biphasic release under physiological and acidic conditions. At pH 5.0, the CC NP exhibits a 53% release of curcumin and nearly 100% release of carvacrol, compared to 19% and 36% from their respective drug solutions. At pH 7.4, similar to 40% of curcumin and 76% of carvacrol releases, highlighting their pH sensitive release mechanism. In vitro studies demonstrate a 1.4 fold increase in osteoblast cell viability with CC NP treatment. CC NP exhibit cytotoxic effects against osteosarcoma cells, reducing cell viability by similar to 2.9 fold. The antibacterial efficacy of CC NP evaluated against Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) exhibiting 98% antibacterial efficacy. This approach enhances therapeutic outcomes and minimizes the potential side effects associated with conventional treatments, paving the way for innovative applications in regenerative medicine.
C1 [Dahiya, Aditi; Chaudhari, Vishal Sharad; Bose, Susmita] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
   [Dahiya, Aditi; Bose, Susmita] Washington State Univ, Dept Chem, Pullman, WA 99164 USA.
C3 Washington State University; Washington State University
RP Bose, S (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.; Bose, S (通讯作者)，Washington State Univ, Dept Chem, Pullman, WA 99164 USA.
EM sbose@wsu.edu
RI Chaudhari, Vishal/JBS 7647 2023
OI Dahiya, Aditi/0000 0001 5009 3952; Chaudhari, Vishal
   Sharad/0000 0002 2755 4412
FU National Institute of Dental and Craniofacial Research (NIDCR) of the
   NIH [R01 DE029204 01]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS) of the National Institute of
   Health, USA [R56 AR06636106]
FX The authors wish to express their gratitude for the funding received
   from The National Institute of Dental and Craniofacial Research (NIDCR)
   of the NIH Grant Number R01 DE029204 01 (PI: Bose) and the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of
   the National Institute of Health, USA under Award Number R56 AR06636106
   (PI: Bose). The views expressed in this content are those of the authors
   alone and may not reflect the official stance of the National Institutes
   of Health. The authors acknowledge the Franceschi Microscopy & Imaging
   Center at Washington State University for their assistance.
CR Bachmeier BE, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061716
   Bannwarth C, 2021, WIRES COMPUT MOL SCI, V11, DOI 10.1002/wcms.1493
   Behzadi S, 2017, CHEM SOC REV, V46, P4218, DOI 10.1039/c6cs00636a
   Bhattacharjee A, 2023, J MATER CHEM B, V11, P4725, DOI 10.1039/d2tb02547g
   Bhawana, 2011, J AGR FOOD CHEM, V59, P2056, DOI 10.1021/jf104402t
   Bose S, 2023, COLLOID SURFACE B, V231, DOI 10.1016/j.colsurfb.2023.113563
   Bose S, 2022, JOM US, V74, P3349, DOI 10.1007/s11837 022 05366 1
   Bose S, 2021, ACTA BIOMATER, V126, P63, DOI 10.1016/j.actbio.2021.02.034
   Bose S, 2020, TRENDS BIOTECHNOL, V38, P404, DOI 10.1016/j.tibtech.2019.11.005
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Cao J, 2020, TRENDS CANCER, V6, P580, DOI 10.1016/j.trecan.2020.02.003
   Chaudhari, 2024, Gingerolzinc complex loaded 3Dprinted calcium phosphate for controlled release application. Drug Delivery and Translational Research, P1
   Chaudhari VS, 2023, J DRUG DELIV SCI TEC, V90, DOI 10.1016/j.jddst.2023.105169
   Chen IJ, 2013, BIOORGAN MED CHEM, V21, P7898, DOI 10.1016/j.bmc.2013.10.003
   Chiu KW, 2023, LIFE BASEL, V13, DOI 10.3390/life13030744
   Cieza A, 2020, LANCET, V396, P2006, DOI 10.1016/S0140 6736(20)32340 0
   Dahiya A, 2023, J MED CHEM, V67, P2745, DOI 10.1021/acs.jmedchem.3c01884
   Dai CS, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11030459
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Giovagnorio F, 2023, ANTIBIOTICS BASEL, V12, DOI 10.3390/antibiotics12111621
   Gong XP, 2020, J COMPUT CHEM, V41, DOI 10.1002/jcc.26133
   Grimme S, 2019, J CHEM THEORY COMPUT, V15, P2847, DOI 10.1021/acs.jctc.9b00143
   Hajibonabi Aida, 2023, OpenNano, DOI 10.1016/j.onano.2023.100170
   Ismail NI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102454
   Jafarinezhad Z, 2019, FOOD SCI NUTR, V7, P3581, DOI 10.1002/fsn3.1210
   Ji ZY, 2023, MEDCOMM, V4, DOI 10.1002/mco2.308
   Jimi E, 2019, CELLS BASEL, V8, DOI 10.3390/cells8121636
   Ke DX, 2018, ADDIT MANUF, V22, P111, DOI 10.1016/j.addma.2018.04.020
   Kostelecka K, 2024, CANCERS, V16, DOI 10.3390/cancers16081611
   Kushram P, 2024, ACS APPL MATER INTER, V16, P48955, DOI 10.1021/acsami.4c05588
   Lee Y, 2023, EXP MOL MED, V55, P2085, DOI 10.1038/s12276 023 01086 x
   Lv ZH, 2023, ADV MATER, V35, DOI 10.1002/adma.202206545
   Mamun MM, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.687660
   Moukengue B, 2022, CANCERS, V14, DOI 10.3390/cancers14143503
   Sampaio LA, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.702487
   Santoro M, 2016, ADV DRUG DELIVER REV, V107, P206, DOI 10.1016/j.addr.2016.04.019
   Sarkar N, 2020, ACS APPL MATER INTER, V12, P13644, DOI 10.1021/acsami.9b22474
   Sarkar N, 2019, ACS APPL MATER INTER, V11, P17184, DOI 10.1021/acsami.9b01218
   Son HE, 2018, LIFE SCI, V193, P34, DOI 10.1016/j.lfs.2017.12.008
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Szwed Georgiou A, 2023, ACS BIOMATER SCI ENG, V9, P5222, DOI 10.1021/acsbiomaterials.3c00609
   Tarafder S, 2013, J TISSUE ENG REGEN M, V7, P631, DOI 10.1002/term.555
   Vu AA, 2022, ACS APPL BIO MATER, V5, P1120, DOI 10.1021/acsabm.1c01181
   Vu AA, 2020, ACS APPL MATER INTER, V12, P52383, DOI 10.1021/acsami.0c14993
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Xu LT, 2022, ADV NANOBIOMED RES, V2, DOI 10.1002/anbr.202100109
   Xue NN, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15070879
   Yeh YC, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00286
   Yetisgin AA, 2020, MOLECULES, V25, DOI 10.3390/molecules25092193
   Yuan Z, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25010671
   Zhang MZ, 2023, ACS NANO, V17, P4433, DOI 10.1021/acsnano.2c09855
   Zhang SO, 2022, ANTI CANCER AGENT ME, V22, P1714, DOI 10.2174/1871520621666210901111932
   Zhang WS, 2021, ADV SCI, V8, DOI 10.1002/advs.202003937
   Zhang YH, 2023, RESEARCH CHINA, V6, DOI 10.34133/research.0255
   Zhao HK, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00658 5
   Zoi V, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091086
NR 58
TC 9
Z9 9
U1 12
U2 21
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD DEC
PY 2024
VL 20
IS 50
AR 2405642
DI 10.1002/smll.202405642
EA OCT 2024
PG 13
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA S3E1J
UT WOS:001343110900001
PM 39463050
OA hybrid
DA 2025 08 17
ER

PT J
AU Liao, WZ
   Ni, C
   Ge, RY
   Li, YF
   Jiang, SY
   Yang, WR
   Yan, FH
AF Liao, Wenzheng
   Ni, Can
   Ge, Ruiyang
   Li, Yanfen
   Jiang, Shaoyun
   Yang, Wenrong
   Yan, Fuhua
TI Nel like Molecule Type 1 Combined with Gold Nanoparticles Modulates
   Macrophage Polarization, Osteoclastogenesis, and Oral Microbiota in
   Periodontitis
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE Nell 1; goldnanoparticles; periodontitis; macrophages; polarization;
   osteoclastogenesis; microbiota
ID RAW 264.7 CELLS; OSTEOGENIC DIFFERENTIATION; IN VIVO; IMMUNE;
   PLASTICITY; RESOLUTION; RECEPTORS; RESPONSES; TARGETS
AB The disruption of host microbe homeostasis and uncontrolled inflammatory response have been considered as vital causes for developing periodontitis, subsequently leading to an imbalance between the bone and immune system and the collapse of bone homeostasis. Consequently, strategies to modulate the immune response and bone metabolization have become a promising approach to prevent and treat periodontitis. In this study, we investigated the cooperative effects of Nel like molecule type 1 (Nell 1) and gold nanoparticles (AuNPs) on macrophage polarization, osteoclast differentiation, and the corresponding functions in an experimental model of periodontitis in rats. Nell 1 combined AuNPs in in vitro studies were found to reduce the production of inflammatory factors (TNF alpha, p < 0.0001; IL 6, p = 0.0012), modulate the ratio of M2/M1 macrophages by inducing macrophage polarization into the M2 phenotype, and inhibit cell fusion, maturation, and activity of osteoclasts. Furthermore, the local application of Nell 1 combined AuNPs in in vivo studies resulted in alleviation of damages to the periodontal and bone tissues, modulation of macrophage polarization and the activity of osteoclasts, and alteration of the periodontal microbiota, in which the relative abundance of the probiotic Bifidobacterium increased (p < 0.05). These findings reveal that Nell 1 combined AuNPs could be a promising drug candidate for the prevention and treatment of periodontitis. However, Nell 1 combined AuNPs did not show organ toxicity or impair the integrity of intestinal epithelium but alter the gut microbiota, leading to the dysbiosis of gut microbiota. The adverse impact of changes in gut microbiota needs to be further investigated. Nonetheless, this study provides a novel perspective and direction for the biological safety assessment of biomaterials in oral clinical applications.
C1 [Liao, Wenzheng; Ni, Can; Li, Yanfen; Yan, Fuhua] Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp, Inst Stomatol,Med Sch, Nanjing 210008, Peoples R China.
   [Ge, Ruiyang] Zunyi Med Univ, Hosp Stomatol, Dept Periodontol, Zunyi 563099, Peoples R China.
   [Jiang, Shaoyun] Peking Univ, Stomatol Ctr, Guangdong Prov High level Clin Key Specialty, Shenzhen Hosp, Shenzhen 5180036, Guangdong, Peoples R China.
   [Jiang, Shaoyun] Guangdong Prov Engn Res Ctr Oral Dis Diag & Treatm, Shenzhen 5180036, Guangdong, Peoples R China.
   [Jiang, Shaoyun] Shenzhen Clin Res Ctr Oral Dis, Shenzhen 5180036, Guangdong, Peoples R China.
   [Yang, Wenrong] Deakin Univ, Ctr Chem & Biotechnol, Sch Life & Environm Sci, Geelong, Vic 3216, Australia.
C3 Nanjing University; Zunyi Medical University; Peking University; Deakin
   University
RP Yan, FH (通讯作者)，Nanjing Univ, Nanjing Stomatol Hosp, Affiliated Hosp, Inst Stomatol,Med Sch, Nanjing 210008, Peoples R China.; Yang, WR (通讯作者)，Deakin Univ, Ctr Chem & Biotechnol, Sch Life & Environm Sci, Geelong, Vic 3216, Australia.
EM wenrong.yang@deakin.edu.au; yanfh@nju.edu.cn
RI Yang, Wenrong/A 4837 2011; yang, wenrong/AEG 3650 2022
OI yang, wenrong/0000 0001 8815 1951; Yan, Fuhua/0000 0002 6963 3530
FU National Natural Science Foundation of China [82001051]; National
   Natural Science Foundation Project of China [JSDW202246]; Jiangsu
   Provincial Medical Key Discipline Cultivation Unit [BE2022670]; Jiangsu
   Province Key Research and Development Program
FX This study was supported by the National Natural Science Foundation
   Project of China (No. 82001051), Jiangsu Provincial Medical Key
   Discipline Cultivation Unit (JSDW202246), and Jiangsu Province Key
   Research and Development Program (BE2022670). We also thank BioRender
   for providing drawing elements, which helped visualize our research.
CR Abdelkader Y, 2023, ADV DRUG DELIVER REV, V200, DOI 10.1016/j.addr.2023.114992
   Berghaus LJ, 2010, COMP IMMUNOL MICROB, V33, P443, DOI 10.1016/j.cimid.2009.07.001
   Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587 019 0209 9
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bustamante M, 2020, PROBIOTICS ANTIMICRO, V12, P325, DOI 10.1007/s12602 019 9521 4
   Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]
   Cao RY, 2021, J MOL HISTOL, V52, P671, DOI 10.1007/s10735 021 09976 y
   Chamberlain LM, 2009, J BIOMED MATER RES A, V88A, P858, DOI 10.1002/jbm.a.31930
   Curtis MA, 2020, PERIODONTOL 2000, V83, P14, DOI 10.1111/prd.12296
   Ebersole JL, 2017, PERIODONTOL 2000, V75, P52, DOI 10.1111/prd.12222
   Facchin BM, 2022, INFLAMM RES, V71, P741, DOI 10.1007/s00011 022 01584 0
   Freire MO, 2013, PERIODONTOL 2000, V63, P149, DOI 10.1111/prd.12034
   Gao W, 2019, ACTA BIOMATER, V85, P203, DOI 10.1016/j.actbio.2018.12.046
   Guo MM, 2015, PROTEOMICS, V15, P3169, DOI 10.1002/pmic.201400431
   Hajishengallis G, 2020, PERIODONTOL 2000, V84, P14, DOI 10.1111/prd.12331
   Hao YP, 2022, ACS APPL MATER INTER, V14, P16006, DOI 10.1021/acsami.2c00877
   Hascoët E, 2023, BONE RES, V11, DOI 10.1038/s41413 023 00257 w
   James AW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8362
   Kinane DF., 2017, NAT REV DIS PRIM, V3, P1, DOI DOI 10.1038/NRDP.2017.38
   Kus Liskiewicz M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010952
   Kwak JH, 2015, BIOMATERIALS, V57, P73, DOI 10.1016/j.biomaterials.2015.03.063
   Li CS, 2020, BIOMATERIALS, V226, DOI 10.1016/j.biomaterials.2019.119541
   Li JJ, 2019, ACS NANO, V13, P5002, DOI 10.1021/acsnano.9b01002
   Lin PY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168900
   Lin ZS, 2023, FOOD CHEM, V404, DOI 10.1016/j.foodchem.2022.134643
   Ma JS, 2010, NITRIC OXIDE BIOL CH, V23, P214, DOI 10.1016/j.niox.2010.06.005
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Marchesan J, 2018, NAT PROTOC, V13, P2247, DOI 10.1038/s41596 018 0035 4
   Mei L, 2022, ACS APPL MATER INTER, V14, P20538, DOI 10.1021/acsami.1c23713
   Mikhailova EO, 2021, J FUNCT BIOMATER, V12, DOI 10.3390/jfb12040070
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Nambara K, 2016, LANGMUIR, V32, P12559, DOI 10.1021/acs.langmuir.6b02064
   Naot D, 2008, BONE, V43, P813, DOI 10.1016/j.bone.2008.07.003
   Ng AY, 2018, JBMR PLUS, V2, P328, DOI 10.1002/jbm4.10058
   Ni C, 2019, BIOMATERIALS, V206, P115, DOI 10.1016/j.biomaterials.2019.03.039
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084
   Pan WY, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0064 z
   Peilin W, 2023, MATER TODAY BIO, V21, DOI 10.1016/j.mtbio.2023.100700
   Qian J, 2022, J DENT RES, V101, P559, DOI 10.1177/00220345211049781
   Qiao D, 2023, ACTA BIOMATER, V162, P135, DOI 10.1016/j.actbio.2023.03.027
   Ribeiro AA, 2022, MOL ORAL MICROBIOL, V37, P256, DOI 10.1111/omi.12389
   Sharma VK, 2022, MATER TODAY BIO, V13, DOI 10.1016/j.mtbio.2022.100204
   Shen J, 2013, TISSUE ENG PT A, V19, P2390, DOI [10.1089/ten.tea.2012.0519, 10.1089/ten.TEA.2012.0519]
   Shi ZH, 2023, BIOENG TRANSL MED, V8, DOI 10.1002/btm2.10466
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Sun XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763334
   Sun Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778078
   Teles F, 2022, PERIODONTOL 2000, V89, P190, DOI 10.1111/prd.12435
   Ting K, 1999, J BONE MINER RES, V14, P80, DOI 10.1359/jbmr.1999.14.1.80
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Veis DJ, 2023, ANNU REV PATHOL MECH, V18, P257, DOI 10.1146/annurev pathmechdis 031521 040919
   Wang M, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.106346
   Wang NN, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.983608
   Wang YP, 2022, BIOMATERIALS, V285, DOI 10.1016/j.biomaterials.2022.121538
   Wisitrasameewong W, 2017, J DENT RES, V96, P685, DOI 10.1177/0022034517690490
   Wu ZR, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200298
   Yadid M, 2019, NANO LETT, V19, P2198, DOI 10.1021/acs.nanolett.9b00472
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Zhang B, 2021, J PERIODONTAL RES, V56, P991, DOI 10.1111/jre.12912
   Zhang SY, 2022, ACTA PHARM SIN B, V12, P3124, DOI 10.1016/j.apsb.2022.02.008
   Zhang YH, 2017, THERANOSTICS, V7, P1214, DOI 10.7150/thno.17252
   Zheng W., 2022, Recent Advancements in Microbial Diversity, P99, DOI [10.1016/B978 0 12 822368 0.00006 2, DOI 10.1016/B978 0 12 822368 0.00006 2]
   Zhou J, 2021, BIOMED ENG ONLINE, V20, DOI 10.1186/s12938 021 00954 9
   Zhou J, 2018, INT J NANOMED, V13, P555, DOI 10.2147/IJN.S150897
   Zhu ST, 2019, INT J NANOMED, V14, P5017, DOI 10.2147/IJN.S204628
   Zhu SQ, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951 018 0415 5
NR 68
TC 9
Z9 9
U1 7
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD FEB 9
PY 2024
VL 16
IS 7
BP 8442
EP 8458
DI 10.1021/acsami.3c17862
EA FEB 2024
PG 17
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA IQ4T3
UT WOS:001164558700001
PM 38335323
DA 2025 08 17
ER

PT J
AU Agas, D
   Gabai, V
   Sufianov, AA
   Shneider, A
   Sabbieti, MG
AF Agas, Dimitrios
   Gabai, Vladimir
   Sufianov, Albert A.
   Shneider, Alexander
   Sabbieti, Maria Giovanna
TI P62/SQSTM1 enhances osteogenesis and attenuates inflammatory signals in
   bone marrow microenvironment
SO GENERAL AND COMPARATIVE ENDOCRINOLOGY
LA English
DT Article
DE P62; p62 DNA plasmid; Bone marrow; Mesenchymal stem cells
ID MESENCHYMAL STEM CELLS; TGF BETA; OSTEOBLAST DIFFERENTIATION;
   MORPHOGENETIC PROTEIN 2; AUTOPHAGY; P62; PTH; EXPRESSION; RECEPTOR;
   NICHE
AB Bone marrow derived mesenchymal/stromal stem cells (MSCs) became a major focus of research since the anti inflammatory features and the osteogenic commitment of these cells can prevent the inflamm aging and various form of osteopenia in humans and animals. We previously showed that p62/SQSTM1 plasmid can prompt release of anti inflammatory cytokines/chemokines by MSC when injected in adult mice. Furthermore, it can enhance osteoblastogenesis at the expense of adipogenesis and ameliorate bone density and bone remodeling. On the other hand, absence of p62 partially exhausted MSC pool caused expansion of fat cells within bone marrow and pro inflammatory mediator's accumulation. Given the critical function of p62 as molecular hub of MSC dynamics, here, using MSCs from p62 knockout adult mice, we investigated the effect of this protein on MSC survival and bone forming molecule cascades. We found that the main osteogenic routes are impaired in absence of p62. In particular, lack of p62 can suppress Smads activation, and Osterix and CREBs expression, thus significantly modifying the schedule of MSCs differentiation. MSCs obtained from p62 /  mice have also demonstrate an amplified NFcB/ Smad1/5/8 colocalization along with NFcB activation in the nucleus, which precludes Smads binding to target promoters. Considering the "teamwork" of TGFll, PTH and BMP2 on MSC homeostatic behavior, we consider that p62 exerts an essential role as a hub protein. Lastly, ex vivo pulsing p62 deficient MSCs, which then will be administered to a patient as a cell therapy, may be considered as a treatment for bone and bone marrow disorders.
C1 [Agas, Dimitrios; Sabbieti, Maria Giovanna] Univ Camerino, Sch Biosci & Vet Med, Camerino, MC, Italy.
   [Gabai, Vladimir; Shneider, Alexander] CureLab Oncol Inc, Dedham, MA USA.
   [Sufianov, Albert A.] Fed Ctr Neurosurg, Tyumen, Russia.
   [Sufianov, Albert A.] Sechenov First Moscow State Med Univ, Moscow, Russia.
   [Shneider, Alexander] Ariel Univ, Dept Mol Biol, Ariel, Israel.
   [Shneider, Alexander] Peter Great St Petersburg Polytech Univ, Inst Biomed Syst & Biotechnol, St Petersburg, Russia.
C3 University of Camerino; Sechenov First Moscow State Medical University;
   Ariel University; Peter the Great St. Petersburg Polytechnic University
RP Agas, D (通讯作者)，Univ Camerino, Sch Biosci & Vet Med, Camerino, MC, Italy.
EM dimitrios.agas@unicam.it; giovanna.sabbieti@unicam.it
RI ; Agas, Dimitrios/AAO 9214 2021; Sufianov, Albert/C 4799 2017
OI Agas, Dimitrios/0000 0002 7809 3601; Sabbieti, Maria
   Giovanna/0000 0002 0838 5748; 
FU UNICAM Noemi Avi colli funds
FX Partial financial support was received by the UNICAM Noemi Avi colli
   funds.
CR Agas Dimitrios, 2022, Adv Exp Med Biol, V1376, P61, DOI 10.1007/5584_2021_666
   Agas D, 2021, J CELL PHYSIOL, V236, P6101, DOI 10.1002/jcp.30296
   Agas D, 2020, J CELL PHYSIOL, V235, P7516, DOI 10.1002/jcp.29654
   Agas D, 2017, J ENDOCRINOL, V232, P309, DOI 10.1530/JOE 16 0538
   Agas D, 2015, CYTOKINE GROWTH F R, V26, P347, DOI 10.1016/j.cytogfr.2014.12.004
   Agas D, 2013, AM J PHYSIOL ENDOC M, V305, pE1185, DOI 10.1152/ajpendo.00290.2013
   Atfi A, 2010, NAT CELL BIOL, V12, P205, DOI 10.1038/ncb0310 205
   Augello A, 2010, HUM GENE THER, V21, P1226, DOI 10.1089/hum.2010.173
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   Davis SW, 2007, DEV BIOL, V305, P145, DOI 10.1016/j.ydbio.2007.02.001
   Deshpande S, 2013, J SURG RES, V185, P278, DOI 10.1016/j.jss.2013.06.063
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Eliseev RA, 2006, EXP CELL RES, V312, P40, DOI 10.1016/j.yexcr.2005.09.016
   Eyckmans J, 2010, J CELL MOL MED, V14, P1845, DOI 10.1111/j.1582 4934.2009.00807.x
   Haas AR, 1999, DIFFERENTIATION, V64, P77, DOI 10.1046/j.1432 0436.1999.6420077.x
   Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125
   Hu XB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13095
   Itasaki N, 2010, DEV DYNAM, V239, P16, DOI 10.1002/dvdy.22009
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Josephson AM, 2019, P NATL ACAD SCI USA, V116, P6995, DOI 10.1073/pnas.1810692116
   Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008 5472.CAN 08 4401
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kwon J, 2012, EMBO REP, V13, P150, DOI 10.1038/embor.2011.246
   Lacava G, 2019, J CELL PHYSIOL, V234, P16338, DOI 10.1002/jcp.28299
   Lee J, 2012, J BIOL CHEM, V287, P4033, DOI 10.1074/jbc.M111.280065
   Lepperdinger G, 2011, CURR OPIN IMMUNOL, V23, P518, DOI 10.1016/j.coi.2011.05.007
   Marchetti L, 2006, J CELL BIOCHEM, V97, P1379, DOI 10.1002/jcb.20746
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Naganawa T, 2008, J CELL BIOCHEM, V103, P1975, DOI 10.1002/jcb.21589
   Nallet Staub F, 2015, DEV CELL, V32, P640, DOI 10.1016/j.devcel.2015.01.011
   Nuschke A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt530
   Ozeki N, 2016, EXP CELL RES, V347, P24, DOI 10.1016/j.yexcr.2016.07.002
   Pun NT, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00456 6
   Qiu T, 2010, NAT CELL BIOL, V12, P224, DOI 10.1038/ncb2022
   RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Sabbieti MG, 2017, CURR STEM CELL REP, V3, P210, DOI 10.1007/s40778 017 0091 7
   Sabbieti MG, 2015, ONCOTARGET, V6, P3590, DOI 10.18632/oncotarget.2884
   Sabbieti MG, 2009, J CELL PHYSIOL, V219, P143, DOI 10.1002/jcp.21661
   Sbrana FV, 2016, STEM CELL REV REP, V12, P621, DOI 10.1007/s12015 016 9690 4
   Schuettpelz LG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00204
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055 8068.2004
   Sobue T, 2002, J BONE MINER RES, V17, P502, DOI 10.1359/jbmr.2002.17.3.502
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yamazaki M, 2009, J BIOL CHEM, V284, P35987, DOI 10.1074/jbc.M109.070540
   Yin X, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0058 7
   Zhang RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020780
   Zhu W, 2006, BONE, V39, P61, DOI 10.1016/j.bone.2005.12.018
NR 56
TC 4
Z9 4
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0016 6480
EI 1095 6840
J9 GEN COMP ENDOCR
JI Gen. Comp. Endocrinol.
PD MAY 1
PY 2022
VL 320
AR 114009
DI 10.1016/j.ygcen.2022.114009
EA FEB 2022
PG 11
WC Endocrinology & Metabolism; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Zoology
GA 2Q3HV
UT WOS:000820318900004
PM 35227727
DA 2025 08 17
ER

PT J
AU Davies, OG
   Cox, SC
   Williams, RL
   Tsaroucha, D
   Dorrepaal, RM
   Lewis, MP
   Grover, LM
AF Davies, O. G.
   Cox, S. C.
   Williams, R. L.
   Tsaroucha, D.
   Dorrepaal, R. M.
   Lewis, M. P.
   Grover, L. M.
TI Annexin enriched osteoblast derived vesicles act as an extracellular
   site of mineral nucleation within developing stem cell cultures
SO SCIENTIFIC REPORTS
LA English
DT Article
ID AMORPHOUS CALCIUM PHOSPHATE; VI COLLAGEN; BONE; EXOSOMES; PROTEIN;
   REGENERATION; CARTILAGE; TRANSFORMATION; STIMULATION; ASSOCIATION
AB The application of extracellular vesicles (EVs) as natural delivery vehicles capable of enhancing tissue regeneration could represent an exciting new phase in medicine. We sought to define the capacity of EVs derived from mineralising osteoblasts (MO EVs) to induce mineralisation in mesenchymal stem cell (MSC) cultures and delineate the underlying biochemical mechanisms involved. Strikingly, we show that the addition of MO EVs to MSC cultures significantly (P < 0.05) enhanced the expression of alkaline phosphatase, as well as the rate and volume of mineralisation beyond the current gold standard, BMP2. Intriguingly, these effects were only observed in the presence of an exogenous phosphate source. EVs derived from non mineralising osteoblasts (NMO EVs) were not found to enhance mineralisation beyond the control. Comparative label free LC MS/MS profiling of EVs indicated that enhanced mineralisation could be attributed to the delivery of bridging collagens, primarily associated with osteoblast communication, and other non collagenous proteins to the developing extracellular matrix. In particular, EV associated annexin calcium channelling proteins, which form a nucleational core with the phospholipid rich membrane and support the formation of a pre apatitic mineral phase, which was identified using infrared spectroscopy. These findings support the role of EVs as early sites of mineral nucleation and demonstrate their value for promoting hard tissue regeneration.
C1 [Davies, O. G.; Lewis, M. P.] Univ Loughborough, Sch Sport Exercise & Hlth Sci, Epinal Way, Loughborough LE11 3TU, Leics, England.
   [Davies, O. G.; Cox, S. C.; Williams, R. L.; Tsaroucha, D.; Grover, L. M.] Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
   [Dorrepaal, R. M.] Univ Coll Dublin, UCD Sch Biosyst & Food Engn, Dublin 4, Ireland.
C3 Loughborough University; University of Birmingham; University College
   Dublin
RP Davies, OG (通讯作者)，Univ Loughborough, Sch Sport Exercise & Hlth Sci, Epinal Way, Loughborough LE11 3TU, Leics, England.; Davies, OG (通讯作者)，Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
EM O.G.Davies@lboro.ac.uk
RI Grover, Liam/F 2713 2011; Williams, Richard/N 3398 2014
OI Grover, Liam/0000 0002 9774 7412; Dorrepaal, Ronan/0000 0002 1429 5570;
   Williams, Richard/0000 0002 6384 7079; Davies, Owen/0000 0003 0808 8695;
   Cox, Sophie/0000 0003 4746 0322
FU EPSRC E TERM; European Research Council (ERC) [335508 BioWater];
   Engineering and Physical Sciences Research Council [EP/I017801/1]
   Funding Source: researchfish; Medical Research Council [MC_PC_16037]
   Funding Source: researchfish; EPSRC [EP/I017801/1] Funding Source: UKRI;
   MRC [MC_PC_16037] Funding Source: UKRI
FX The authors would like to acknowledge M. Platt (Loughborough University)
   for his expertise and assistance with IZON qNano tunable resistive pulse
   sensing and C. Bursa (University of Birmingham) for her practical
   assistance with AFM. The work was directly funded by an EPSRC E TERM
   Landscape fellowship personally awarded to Dr. Owen Davies. R.M.
   Dorrepaal was funded by the European Research Council (ERC) under the
   starting grant programme ERC 2013 StG call Proposal No. 335508 BioWater.
CR ANDERSON HC, 1967, J CELL BIOL, V35, P81, DOI 10.1083/jcb.35.1.81
   Armstrong JPK, 2017, ACS NANO, V11, P69, DOI 10.1021/acsnano.6b07607
   Basu J, 2016, EXPERT OPIN BIOL TH, V16, P489, DOI 10.1517/14712598.2016.1131976
   Bernardi P., 2007, V45, P481
   BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022 5320(67)80034 0
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Brown RJ, 2011, PROTEOMICS, V11, P4660, DOI 10.1002/pmic.201100058
   BROWN WE, 1957, J AM CHEM SOC, V79, P5318, DOI 10.1021/ja01576a068
   Cary RL, 2013, J BONE MINER RES, V28, P1599, DOI 10.1002/jbmr.1890
   Chen NX, 2008, J BONE MINER RES, V23, P1798, DOI 10.1359/JBMR.080604
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Cui L, 2016, BONE, V87, P147, DOI 10.1016/j.bone.2016.04.007
   Deng LL, 2015, BONE, V79, P37, DOI 10.1016/j.bone.2015.05.022
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Fais S, 2016, ACS NANO, V10, P3886, DOI 10.1021/acsnano.5b08015
   Genge BR, 2007, J BIOL CHEM, V282, P26035, DOI 10.1074/jbc.M701057200
   Giannoudis PV, 2013, INJURY, V44, pS1, DOI 10.1016/S0020 1383(13)70002 0
   Gillette JM, 2004, J CELL SCI, V117, P441, DOI 10.1242/jcs.00909
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405 367
   Golub EE, 2009, BBA GEN SUBJECTS, V1790, P1592, DOI 10.1016/j.bbagen.2009.09.006
   Habraken W, 2016, MATER TODAY, V19, P69, DOI 10.1016/j.mattod.2015.10.008
   Heathman TRJ, 2015, REGEN MED, V10, P49, DOI [10.2217/RME.14.73, 10.2217/rme.14.73]
   Henkel J, 2013, BONE RES, V1, P216, DOI 10.4248/BR201303002
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   Herr AB, 2009, J BIOL CHEM, V284, P19781, DOI 10.1074/jbc.R109.013219
   HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710
   Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071
   Hustedt Joshua W., 2014, Yale Journal of Biology and Medicine, V87, P549
   Huynh N, 2016, J DENT RES, V95, P673, DOI 10.1177/0022034516633189
   Izu Y, 2016, CELL TISSUE RES, V364, P623, DOI 10.1007/s00441 015 2345 y
   Kaminska A, 1996, POLYM DEGRAD STABIL, V51, P19, DOI 10.1016/0141 3910(95)00159 X
   Kanada M, 2015, P NATL ACAD SCI USA, V112, pE1433, DOI 10.1073/pnas.1418401112
   Kim M, 2011, BMB REP, V44, P619, DOI 10.5483/BMBRep.2011.44.10.619
   Kohara Y, 2016, ANN ANAT, V208, P58, DOI 10.1016/j.aanat.2016.07.003
   Kohara Y, 2015, J ANAT, V226, P478, DOI 10.1111/joa.12296
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Laulagnier K, 2004, BIOCHEM J, V380, P161, DOI 10.1042/BJ20031594
   Mahamid J, 2010, P NATL ACAD SCI USA, V107, P6316, DOI 10.1073/pnas.0914218107
   MAILLARD C, 1992, ENDOCRINOLOGY, V130, P1599, DOI 10.1210/en.130.3.1599
   MAJESKA RJ, 1975, BIOCHIM BIOPHYS ACTA, V391, P51, DOI 10.1016/0005 2744(75)90151 5
   Malhotra V, 2015, ANNU REV CELL DEV BI, V31, P109, DOI 10.1146/annurev cellbio 100913 013002
   Morgan JM, 2011, J CELL BIOCHEM, V112, P3354, DOI 10.1002/jcb.23265
   Ong SG, 2015, CIRC RES, V117, P7, DOI 10.1161/CIRCRESAHA.115.306593
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Qin YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050712
   REY C, 1991, CALCIFIED TISSUE INT, V49, P383, DOI 10.1007/BF02555847
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   SAUER GR, 1988, J BIOL CHEM, V263, P13718
   SELA J, 1992, BONE MINER, V17, P163, DOI 10.1016/0169 6009(92)90729 W
   Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734
   SUAREZ F, 1993, J BONE MINER RES, V8, P1201
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   Tatara AM, 2016, J BONE JOINT SURG AM, V98, P1132, DOI 10.2106/JBJS.16.00299
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Valapala M, 2011, J BIOL CHEM, V286, P30911, DOI 10.1074/jbc.M111.271155
   van der Goot FG, 2006, TRENDS CELL BIOL, V16, P514, DOI 10.1016/j.tcb.2006.08.003
   Wang LJ, 2008, CHEM REV, V108, P4628, DOI 10.1021/cr0782574
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Wu LNY, 1997, J BIOL CHEM, V272, P4404, DOI 10.1074/jbc.272.7.4404
   WUTHIER RE, 1975, CALC TISS RES, V19, P197, DOI 10.1007/BF02564004
   Xiao Z., 2006, CELL PHYSL, V2010, P325
   Yáñez Mó M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
   Yim N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12277
   Zhang JY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0417 0
   Zhang W, 2003, J AM CERAM SOC, V86, P1052, DOI 10.1111/j.1151 2916.2003.tb03422.x
NR 66
TC 49
Z9 53
U1 0
U2 21
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD OCT 3
PY 2017
VL 7
AR 12639
DI 10.1038/s41598 017 13027 6
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FI6WZ
UT WOS:000412138800075
PM 28974747
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Goia Socol, M
   Duncea, I
   Goia Socol, MA
   Hazi, G
   Leucuta, DC
   Tomoaia, G
   Suteu, M
   Georgescu, CE
AF Goia Socol, Monica
   Duncea, Ileana
   Goia Socol, Mihai Andrei
   Hazi, Georgeta
   Leucuta, Daniel Corneliu
   Tomoaia, Gheorghe
   Suteu, Mihai
   Georgescu, Carmen Emanuela
TI Experimental diabetic conditions in primary human osteoblastic cell
   cultures and effects on osteoblast derived cathepsin K
SO ROMANIAN BIOTECHNOLOGICAL LETTERS
LA English
DT Article
DE type 1 diabetes mellitus; insulin; glucose; systemic hormones;
   osteoblasts; cathepsin K
ID ENVIRONMENT; RESORPTION; EXPRESSION; BONE
AB The mechanisms underlying bone pathology in type 1 diabetes are still under research. Dysregulation of osteoblast derived cathepsin K production in type 1 diabetes mellitus could contribute, partly, to the onset of osteopenia associated to this disease. This study aimed to assess the expression of cathepsin K gene and the activity of this enzyme in primary human osteoblastic cell cultures exposed for 24 hours to various concentrations of glucose and insulin, simulating dysglycemic states encountered in patients with type 1 diabetes. RNA was isolated from the cell lysates, reverse transcription was performed and gene expression was assessed by quantitative polymerase chain reaction (qPCR). Cathepsin K activity was determined quantitatively from supernatants. The expression of cathepsin K gene was increased in low glucose and decreased in severe hyperglycemia. A significant inversely proportional association was observed between cathepsin K activity and glucose (Spearman coefficient= 0.71, 95% CI  0.83  0.26). In a multiple regression model, statistically significant positive associations were observed between cathepsin K and insulin (p=0.017) and between cathepsin K and the interaction glucose insulin (p=0.017). The inversely proportional relationship between cathepsin K and glucose and the positive one between cathepsin K and insulin may be important in the case of insulin therapy induced hypoglycemia which, if occurred repeatedly, may result in increased bone resorption.
C1 [Goia Socol, Monica; Duncea, Ileana; Goia Socol, Mihai Andrei; Suteu, Mihai; Georgescu, Carmen Emanuela] Iuliu Hatieganu Univ Med & Pharm, Dept Endocrinol, Cluj Napoca, Romania.
   [Goia Socol, Monica; Duncea, Ileana; Hazi, Georgeta; Georgescu, Carmen Emanuela] Cluj Cty Emergency Hosp, Endocrinol Clin, Cluj Napoca, Romania.
   [Goia Socol, Mihai Andrei] Cluj Cty Emergency Hosp, Ctr Diabet, Cluj Napoca, Romania.
   [Leucuta, Daniel Corneliu] Iuliu Hatieganu Univ Med & Pharm, Dept Med Informat & Biostat, Cluj Napoca, Romania.
   [Tomoaia, Gheorghe] Iuliu Hatieganu Univ Med & Pharm, Dept Orthoped & Traumatol, Cluj Napoca, Romania.
C3 Iuliu Hatieganu University of Medicine & Pharmacy; Iuliu Hatieganu
   University of Medicine & Pharmacy; Iuliu Hatieganu University of
   Medicine & Pharmacy
RP Goia Socol, M (通讯作者)，Iuliu Hatieganu Univ Med & Pharm, Dept Endocrinol, Cluj Napoca, Romania.
EM socol.monica@umfcluj.ro
RI ; Leucuța, Daniel/E 3625 2014; Leucuta, Daniel/E 3625 2014
OI Suteu, Mihai/0000 0002 3518 8889; Leucuta, Daniel/0000 0003 4218 8622
FU European Social Fund [POSDRU 107/1.5/S/78702]; Ministry of Education and
   Research grant [PN II ID PCE 2011 3 0879]
FX Our work was supported by the European Social Fund POSDRU
   107/1.5/S/78702 project and the Ministry of Education and Research grant
   PN II ID PCE 2011 3 0879 projects.
CR [Anonymous], 2012, R: a language and environment for statistical computing
   Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   García Hernández A, 2012, BONE, V50, P276, DOI 10.1016/j.bone.2011.10.032
   Gaster M, 2002, DIABETES, V51, P921, DOI 10.2337/diabetes.51.4.921
   GOIA SOCOL M, 2013, ANN ROMANIAN SOC CEL, V18, P75
   Hie M, 2007, BONE, V41, P1045, DOI 10.1016/j.bone.2007.08.030
   Ilmer M, 2009, TISSUE ENG PT A, V15, P2397, DOI 10.1089/ten.tea.2008.0427
   Lecaille F, 2008, BIOCHIMIE, V90, P208, DOI 10.1016/j.biochi.2007.08.011
   LEEHEY DJ, 1995, DIABETES, V44, P929, DOI 10.2337/diabetes.44.8.929
   Mandelin J, 2006, BONE, V38, P769, DOI 10.1016/j.bone.2005.10.017
   Motyl K, 2009, BIOL PROCED ONLINE, V11, P296, DOI 10.1007/s12575 009 9000 5
   Mulari MTK, 2004, CALCIFIED TISSUE INT, V75, P253, DOI 10.1007/s00223 004 0172 3
   Pepene CE, 2001, BONE, V29, P540, DOI 10.1016/S8756 3282(01)00607 X
   Thorvaldson L, 2008, CYTOKINE, V43, P93, DOI 10.1016/j.cyto.2008.03.013
   Wongdee K, 2011, WORLD J DIABETES, V2, P41, DOI 10.4239/wjd.v2.i3.41
   Xu F, 2013, J HUAZHONG U SCI MED, V33, P244, DOI 10.1007/s11596 013 1105 z
   Zayzafoon M, 2002, J BIOL CHEM, V277, P37212, DOI 10.1074/jbc.M200129200
   Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097 4644(20001101)79:2<301::AID JCB130>3.0.CO;2 0
NR 19
TC 0
Z9 0
U1 0
U2 3
PU ARS DOCENDI
PI BUCHAREST
PA SOS PANDURI 90, SECT 5, BUCHAREST, RO 050663, ROMANIA
SN 1224 5984
J9 ROM BIOTECH LETT
JI Rom. Biotech. Lett.
PD SEP OCT
PY 2014
VL 19
IS 5
BP 9755
EP 9762
PG 8
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA AT6QY
UT WOS:000345064900013
DA 2025 08 17
ER

PT J
AU Tang, H
   Mattheos, N
   Yao, Y
   Jia, Y
   Ma, L
   Gong, P
AF Tang, H.
   Mattheos, N.
   Yao, Y.
   Jia, Y.
   Ma, L.
   Gong, P.
TI In vivo osteoprotegerin gene therapy preventing bone loss induced
   by periodontitis
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE aggressive periodontitis; animal model; cytokines; genetics; host
   modulation therapy; periodontal therapy
ID LIGAMENT CELLS; STIMULATE OSTEOCLASTOGENESIS; PORPHYROMONAS GINGIVALIS;
   RECEPTOR ACTIVATOR; VITRO MODEL; RANKL; OPG; DISEASE; MECHANISMS;
   EXPRESSION
AB ObjectiveThe objective of this study was to investigate the effects of osteoprotegerin (OPG) gene therapy on alveolar bone resorption caused by experimental periodontitis in rats, thus forming a foundation for potential clinical applications of OPG gene therapy in the treatment of periodontitis and peri implantitis.
   Material and MethodsTo study the effects of OPG on alveolar bone protection, an experimental periodontitis model was used by placing a bacterial plaque retentive silk ligature in the gingival sulcus around the maxillary second molar tooth, injection of Porphyromonas gingivalis and high carbohydrate diet. A total of 30 Sprague Dawley rats were randomly divided into three groups, with 10 rats in each group: group I (control) was treated with 10L normal saline injection; group II with 10L mock vector; and group III with 10L local OPG gene transfer by transfection with in vitro constructed pcDNA3.1 human OPG (pcDNA3.1 hOPG). A subperiosteal injection was done adjacent to the second molars on days 0, 7, 14 and 21. Four weeks later, all animals were killed and radiographic, histological and immunohistochemical examinations were performed. Statistical analysis included ANOVA and LSD Bonferroni test.
   ResultsGroup III (OPG gene therapy) had significantly enhanced (p<0.05) integrated optical density of OPG, had significantly decreased alveolar bone resorption volume and active osteoclast number (p<0.05) through descriptive histological examination when compared with the other two groups at week 4.
   ConclusionLocal recombinant OPG plasmid mediated gene therapy suppresses osteoclastogenesis in vivo and inhibits alveolar bone height reduction caused by experimental periodontitis in rats. OPG gene therapy may be beneficial in preventing progressive periodontal bone loss.
C1 [Tang, H.; Yao, Y.; Jia, Y.; Ma, L.; Gong, P.] Sichuan Univ, West China Hosp Stomatol, Chengdu 610041, Sichuan, Peoples R China.
   [Tang, H.; Mattheos, N.] Univ Hong Kong, Prince Philip Dent Hosp, Hong Kong, Hong Kong, Peoples R China.
C3 Sichuan University; University of Hong Kong
RP Gong, P (通讯作者)，Sichuan Univ, West China Hosp Stomatol, 14,Block 3,Renmin Nan Rd, Chengdu 610041, Sichuan, Peoples R China.
EM gp602002@163.com
RI ; Mattheos, Nikos/C 8614 2011
OI Mattheos, Nikos/0000 0001 7358 7496; 
FU National Natural Science Foundation [81170995]; National 973 Projects
   [2012CB619100]; State Key Clinical Specialty of Implant Dentistry
   Project
FX This work was supported by a National Natural Science Foundation
   Projects grant NO. 81170995, a National 973 Projects NO. 2012CB619100
   and State Key Clinical Specialty of Implant Dentistry Project. No
   competing financial interests exist.
CR Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Anandarajah AP, 2006, J CELL BIOCHEM, V97, P226, DOI 10.1002/jcb.20674
   [Anonymous], J BIOMEDICINE BIOTEC
   Aoki S, 2010, J BONE MINER RES, V25, P1907, DOI 10.1002/jbmr.89
   Belibasakis GN, 2012, J CLIN PERIODONTOL, V39, P239, DOI 10.1111/j.1600 051X.2011.01810.x
   Bhatavadekar NB, 2009, J CLIN PERIODONTOL, V36, P124, DOI 10.1111/j.1600 051X.2008.01354.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bozic D, 2012, J CLIN PERIODONTOL, V39, P80, DOI 10.1111/j.1600 051X.2011.01794.x
   Brown Julie M, 2004, Cancer Treat Res, V118, P149
   Buduneli N, 2009, J PERIODONTOL, V80, P1274, DOI 10.1902/jop.2009.090106
   Cantley MD, 2011, J PERIODONTAL RES, V46, P697, DOI 10.1111/j.1600 0765.2011.01392.x
   Chen R, 2008, J PERIODONTAL RES, V43, P237, DOI 10.1111/j.1600 0765.2007.01021.x
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Crotti T, 2003, J PERIODONTAL RES, V38, P380, DOI 10.1034/j.1600 0765.2003.00615.x
   de Moraes GN, 2011, ANAL BIOCHEM, V415, P203, DOI 10.1016/j.ab.2011.04.032
   Dereka XE, 2010, INFLAMMATION, V33, P200, DOI 10.1007/s10753 009 9174 7
   Deshmukh J, 2011, INT J DENT CLIN, V28, P48
   Ditto AJ, 2009, EXPERT OPIN DRUG DEL, V6, P1149, DOI 10.1517/17425240903241796
   Diz P, 2012, J AM DENT ASSOC, V143, P981, DOI 10.14219/jada.archive.2012.0323
   Giannobile WV, 2008, J PERIODONTOL, V79, P1592, DOI 10.1902/jop.2008.080174
   Goater JJ, 2002, J ORTHOPAED RES, V20, P169, DOI 10.1016/S0736 0266(01)00083 3
   Gruber R, 2010, WIEN MED WOCHENSCHR, V160, P438, DOI 10.1007/s10354 010 0809 y
   Horowitz MC, 2010, BONE, V47, P472, DOI 10.1016/j.bone.2010.06.011
   Jin QM, 2007, J PERIODONTOL, V78, P1300, DOI 10.1902/jop.2007.070073
   Kanzaki H, 2006, GENE THER, V13, P678, DOI 10.1038/sj.gt.3302707
   Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210
   Kanzaki H, 2001, J DENT RES, V80, P887, DOI 10.1177/00220345010800030801
   Kook SH, 2011, J CELL BIOCHEM, V112, P2891, DOI 10.1002/jcb.23205
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lamont RJ, 1998, MICROBIOL MOL BIOL R, V62, P1244, DOI 10.1128/MMBR.62.4.1244 1263.1998
   Li Bin bin, 2005, Beijing Da Xue Xue Bao Yi Xue Ban, V37, P536
   Mahamed DA, 2005, DIABETES, V54, P1477, DOI 10.2337/diabetes.54.5.1477
   Mayahara K, 2012, ARCH ORAL BIOL, V57, P1377, DOI 10.1016/j.archoralbio.2012.07.009
   Meulman T, 2011, J PERIODONTAL RES, V46, P629, DOI 10.1111/j.1600 0765.2011.01385.x
   Michalowicz BS, 2000, J PERIODONTOL, V71, P1699, DOI 10.1902/jop.2000.71.11.1699
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Neves JS, 2009, ARCH ORAL BIOL, V54, P651, DOI 10.1016/j.archoralbio.2009.04.001
   Oka H, 2012, J PERIODONTOL, V83, P506, DOI 10.1902/jop.2011.110301
   Park JK, 2013, RHEUMATOLOGY, V52, P1529, DOI 10.1093/rheumatology/ket184
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Research Science and Therapy Committee of American Academy of Periodontology, 2005, J Periodontol, V76, P850
   Rifkin DB, 2010, J CELL BIOL, V190, P949, DOI 10.1083/jcb.201008116
   Rios HF, 2011, J PERIODONTOL, V82, P1223, DOI 10.1902/jop.2011.100710
   Schwartz Z, 1997, PERIODONTOL 2000, V14, P158, DOI 10.1111/j.1600 0757.1997.tb00196.x
   Sedghizadeh PP, 2008, J ORAL MAXIL SURG, V66, P767, DOI 10.1016/j.joms.2007.11.035
   SHI ZR, 1988, J HISTOCHEM CYTOCHEM, V36, P317, DOI 10.1177/36.3.3278057
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stein SH, 2011, J PERIODONTAL RES, V46, P483, DOI 10.1111/j.1600 0765.2011.01364.x
   Suzuki Y, 2001, RHEUMATOLOGY, V40, P673, DOI 10.1093/rheumatology/40.6.673
   Tamma Roberto, 2012, Inflammation & Allergy Drug Targets, V11, P196
   Tat Steeve Kwan, 2009, Keio Journal of Medicine, V58, P29
   Taubman MA, 2007, J CLIN PERIODONTOL, V34, P367, DOI 10.1111/j.1600 051X.2007.01065.x
   Tenenbaum HC, 2002, J PERIODONTOL, V73, P813, DOI 10.1902/jop.2002.73.7.813
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Tokuyama Naoto, 2010, Clin Calcium, V20, P1532, DOI CliCa101015321538
   Toshio T, 1995, J BONE MINER METAB, V13, P71
   Weinberg MA, 1999, J CLIN PERIODONTOL, V26, P335, DOI 10.1034/j.1600 051X.1999.260601.x
   Winn SR, 2000, ADV DRUG DELIVER REV, V42, P121, DOI 10.1016/S0169 409X(00)00057 0
   Wu Yafei, 2003, Sichuan Da Xue Xue Bao Yi Xue Ban, V34, P742
   YAMAMOTO T, 1980, J BIOL CHEM, V255, P2612
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Yu HC, 2010, J BONE MINER RES, V25, P1128, DOI 10.1002/jbmr.9
   ZAIDI M, 1988, Q J EXP PHYSIOL CMS, V73, P471, DOI 10.1113/expphysiol.1988.sp003168
   Zhang L, 2012, INT ENDOD J, V45, P68, DOI 10.1111/j.1365 2591.2011.01949.x
   Zhao N, 2012, ORTHOD CRANIOFAC RES, V15, P10, DOI 10.1111/j.1601 6343.2011.01532.x
NR 66
TC 16
Z9 17
U1 1
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD AUG
PY 2015
VL 50
IS 4
BP 434
EP 443
DI 10.1111/jre.12224
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA CM4ZY
UT WOS:000357696900002
PM 25203865
DA 2025 08 17
ER

PT J
AU Cantarini, L
   Vitale, A
   Magnotti, F
   Lucherini, OM
   Caso, F
   Frediani, B
   Galeazzi, M
   Rigante, D
AF Cantarini, Luca
   Vitale, Antonio
   Magnotti, Flora
   Lucherini, Orso Maria
   Caso, Francesco
   Frediani, Bruno
   Galeazzi, Mauro
   Rigante, Donato
TI Weekly oral alendronate in mevalonate kinase deficiency
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Article
DE Mevalonate kinase deficiency; Autoinflammatory disorder; Alendronate
ID PERIODIC FEVER SYNDROME; HYPERIMMUNOGLOBULINEMIA D; HYPER IGD;
   CLODRONATE; PREVENTION; ACTIVATION; MUTATION; REGISTRY; MODEL; LPS
AB Background: Mevalonate kinase deficiency (MKD) is caused by mutations in the MVK gene, encoding the second enzyme of mevalonate pathway, which results in subsequent shortage of downstream compounds, and starts in childhood with febrile attacks, skin, joint, and gastrointestinal symptoms, sometimes induced by vaccinations.
   Methods: For a history of early onset corticosteroid induced reduction of bone mineral density in a 14 year old boy with MKD, who also had presented three bone fractures, we administered weekly oral alendronate, a drug widely used in the management of osteoporosis and other high bone turnover diseases, which blocks mevalonate and halts the prenylation process.
   Results: All of the patient's MKD clinical and laboratory abnormalities were resolved after starting alendronate treatment.
   Conclusions: This observation appears enigmatic, since alendronate should reinforce the metabolic block characterizing MKD, but is crucial because of the ultimate improvement shown by this patient. The anti inflammatory properties of bisphosphonates are a new question for debate among physicians across various specialties, and requires further biochemical and clinical investigation.
C1 [Cantarini, Luca; Vitale, Antonio; Magnotti, Flora; Lucherini, Orso Maria; Caso, Francesco; Frediani, Bruno; Galeazzi, Mauro] Univ Siena, Policlin Scotte, Rheumatol Unit, Interdepartmental Res Ctr System Autoimmune & Au, Siena, Italy.
   [Rigante, Donato] Univ Cattolica Sacro Cuoro, Inst Pediat, Rome, Italy.
C3 University of Siena; Catholic University of the Sacred Heart
RP Cantarini, L (通讯作者)，Univ Siena, Policlin Scotte, Rheumatol Unit, Interdepartmental Res Ctr System Autoimmune & Au, Siena, Italy.
EM cantariniluca@hotmail.com
RI Rigante, Donato/AAE 2660 2019; Magnotti, Flora/G 7309 2019; Caso,
   Francesco/AAC 9809 2020; Cantarini, Luca/K 5658 2014; Benetti,
   Elisa/AAI 6682 2021
OI Cantarini, Luca/0000 0002 7352 1275; Lucherini, Orso
   Maria/0000 0002 3314 0814; Magnotti, Flora/0000 0002 3803 9934; Caso,
   Francesco/0000 0002 8928 2520; Rigante, Donato/0000 0001 7032 7779; 
CR ADAMI S, 1986, CALCIFIED TISSUE INT, V39, P226, DOI 10.1007/BF02555208
   ATTARDOPARRINELLO G, 1987, ARCH INTERN MED, V147, P1629, DOI 10.1001/archinte.147.9.1629
   Barrera P, 2000, ARTHRITIS RHEUM US, V43, P1951, DOI 10.1002/1529 0131(200009)43:9<1951::AID ANR5>3.0.CO;2 K
   Bodar EJ, 2007, BLOOD, V109, P2416, DOI 10.1182/blood 2005 10 039578
   Bonetti PO, 2003, EUR HEART J, V24, P225, DOI 10.1016/S0195 668X(02)00419 0
   Deng X, 2006, TOXICOL APPL PHARM, V213, P64, DOI 10.1016/j.taap.2005.09.005
   Houten SM, 2003, EUR J HUM GENET, V11, P196, DOI 10.1038/sj.ejhg.5200933
   Kuijk LM, 2008, MOL IMMUNOL, V45, P2158, DOI 10.1016/j.molimm.2007.12.008
   Mandey SHL, 2006, ARTHRITIS RHEUM US, V54, P3690, DOI 10.1002/art.22194
   Marcuzzi A, 2008, PEDIATR RES, V64, P177, DOI 10.1203/PDR.0b013e3181761870
   Marcuzzi A, 2011, APOPTOSIS, V16, P882, DOI 10.1007/s10495 011 0621 1
   Milhavet F, 2008, HUM MUTAT, V29, P803, DOI 10.1002/humu.20720
   Miziorko HM, 2011, ARCH BIOCHEM BIOPHYS, V505, P131, DOI 10.1016/j.abb.2010.09.028
   Mönkkönen J, 1998, LIFE SCI, V62, pPL95, DOI 10.1016/S0024 3205(97)01178 8
   Rigante D, 2007, ARTHRITIS RHEUM US, V56, P658, DOI 10.1002/art.22409
   Rigante D, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/485103
   SANSONI P, 1995, J BONE MINER RES, V10, P1719
   Shikama Y, 2010, TOXICOL LETT, V199, P123, DOI 10.1016/j.toxlet.2010.08.013
   Simon A, 2004, NEUROLOGY, V62, P994, DOI 10.1212/01.WNL.0000115390.33405.F7
   ter Haar N, 2013, ANN RHEUM DIS, V72, P678, DOI 10.1136/annrheumdis 2011 201268
   van der Hilst JCH, 2008, MEDICINE, V87, P301, DOI 10.1097/MD.0b013e318190cfb7
   VANDERMEER JWM, 1984, LANCET, V1, P1087
   Zanin V, 2012, INFLAMM RES, V61, P1363, DOI 10.1007/s00011 012 0537 4
NR 23
TC 15
Z9 15
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750 1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD DEC 20
PY 2013
VL 8
AR 196
DI 10.1186/1750 1172 8 196
PG 4
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA AB8CM
UT WOS:000332017700002
PM 24360083
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Carluccio, M
   Zuccarini, M
   Ziberi, S
   Giuliani, P
   Morabito, C
   Mariggiò, MA
   Lonardo, MT
   Adinolfi, E
   Orioli, E
   Di Iorio, P
   Caciagli, F
   Ciccarelli, R
AF Carluccio, Marzia
   Zuccarini, Mariachiara
   Ziberi, Sihana
   Giuliani, Patricia
   Morabito, Caterina
   Mariggio, Maria A.
   Lonardo, Maria Teresa
   Adinolfi, Elena
   Orioli, Elisa
   Di Iorio, Patrizia
   Caciagli, Francesco
   Ciccarelli, Renata
TI Involvement of P2X7 Receptors in the Osteogenic Differentiation of
   Mesenchymal Stromal/Stem Cells Derived from Human Subcutaneous Adipose
   Tissue
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Subcutaneous adipose tissue derived stromal stem cells; Osteogenic
   differentiation; Regenerative medicine; ATP analogues; P2X7 receptors
ID STEM CELLS; P2X(7) RECEPTOR; EXPRESSION; ACTIVATION; MINERALIZATION;
   NUCLEOTIDES; OSTEOBLASTS; MECHANISMS; PROMOTE; DEATH
AB The ionotropic P2X7 receptor (P2X7R) is involved in bone homeostasis but its role in osteogenesis is controversial. Thus, we investigated the expression of P2X7R and the effects exerted by its modulation in mesenchymal stromal cells from human subcutaneous adipose tissue (S ASCs), which have potential therapeutic application in bone regenerative medicine. We found that undifferentiated S ASCs expressed P2X7R and its functional splice variants P2X7AR and P2X7BR. Cell stimulation by P2X7R agonist BzATP (100 mu M) neither modified proliferation nor caused membrane pore opening while increasing intracellular Ca2+ levels and migration. The P2X7R antagonist A438079 reversed these effects. However, 25 100 mu M BzATP, administered to S ASCs undergoing osteogenic differentiation, dose dependently decreased extracellular matrix mineralization and expression of osteogenic transcription factors Runx2, alkaline phosphatase and osteopontin. These effects were not coupled to cell proliferation reduction or to cell death increase, but were associated to decrease in P2X7AR and P2X7BR expression. In contrast, expression of P2X7R, especially P2X7BR isoform, significantly increased during the osteogenic process. Noteworthy, the antagonist A438079, administered alone, at first restrained cell differentiation, enhancing it later. Accordingly, A438079 reversed BzATP effects only in the second phase of S ASCs osteogenic differentiation. Apyrase, a diphosphohydrolase converting ATP/ADP into AMP, showed a similar behavior. Altogether, findings related to A438079 or apyrase effects suggest an earlier and prevailing pro osteogenic activity by endogenous ATP and a later one by adenosine derived from endogenous ATP metabolism. Conversely, P2X7R pharmacological stimulation by BzATP, mimicking the effects of high ATP levels occurring during tissue injuries, depressed receptor expression/activity impairing MSC osteogenic differentiation.
C1 [Carluccio, Marzia; Zuccarini, Mariachiara; Ziberi, Sihana; Giuliani, Patricia; Di Iorio, Patrizia; Caciagli, Francesco; Ciccarelli, Renata] Univ G dAnnunzio, Sect Pharmacol, Dept Med Oral & Biotechnol Sci, Via Vestini 29, I 66100 Chieti, Italy.
   [Carluccio, Marzia; Zuccarini, Mariachiara; Ziberi, Sihana; Giuliani, Patricia; Morabito, Caterina; Mariggio, Maria A.; Di Iorio, Patrizia; Caciagli, Francesco; Ciccarelli, Renata] Univ G dAnnunzio, Aging Res Ctr & Translat Med, Chieti, Italy.
   [Carluccio, Marzia; Ziberi, Sihana; Morabito, Caterina; Mariggio, Maria A.; Ciccarelli, Renata] StemTeCh Grp, Chieti, Italy.
   [Morabito, Caterina; Mariggio, Maria A.] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
   [Lonardo, Maria Teresa] Madre Giuseppina Vanin Hosp, Rome, Italy.
   [Adinolfi, Elena; Orioli, Elisa] Univ Ferrara, Dept Morphol Surg end Expt Med, Ferrara, Italy.
C3 G d'Annunzio University of Chieti Pescara; G d'Annunzio University of
   Chieti Pescara; G d'Annunzio University of Chieti Pescara; University of
   Ferrara
RP Ciccarelli, R (通讯作者)，Univ G dAnnunzio, Sect Pharmacol, Dept Med Oral & Biotechnol Sci, Via Vestini 29, I 66100 Chieti, Italy.; Ciccarelli, R (通讯作者)，Univ G dAnnunzio, Aging Res Ctr & Translat Med, Chieti, Italy.; Ciccarelli, R (通讯作者)，StemTeCh Grp, Chieti, Italy.
EM renata.ciccarelli@unich.it
RI ZUCCARINI, MARIACHIARA/I 8642 2018; Adinolfi, Elena/F 9169 2010;
   Mariggio, Maria/HJA 7815 2022; Ciccarelli, Renata/HTN 2298 2023
OI Adinolfi, Elena/0000 0001 8129 9929; 
FU University of Chieti Pescara
FX This work was supported by funds for research to RC and PDI from the
   University of Chieti Pescara.
CR Adinolfi E, 2015, CANCER RES, V75, P635, DOI 10.1158/0008 5472.CAN 14 1259
   Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09 153601
   Agrawal A, 2017, BONE, V95, P91, DOI 10.1016/j.bone.2016.11.011
   Agrawal A, 2015, J MOL ENDOCRINOL, V54, pR75, DOI 10.1530/JME 14 0226
   Ali S, 2018, PURINERG SIGNAL, V14, P371, DOI 10.1007/s11302 018 9618 3
   Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014 2999(99)00350 7
   Burnstock G, 2014, EXP PHYSIOL, V99, P16, DOI 10.1113/expphysiol.2013.071951
   Caprara GA, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00493
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Cheewatrakoolpong B, 2005, BIOCHEM BIOPH RES CO, V332, P17, DOI 10.1016/j.bbrc.2005.04.087
   Ciciarello M, 2013, STEM CELLS DEV, V22, P1097, DOI 10.1089/scd.2012.0432
   D'Alimonte I, 2017, STEM CELLS DEV, V26, P843, DOI 10.1089/scd.2016.0190
   Di Virgilio F, 2018, TRENDS CELL BIOL, V28, P392, DOI 10.1016/j.tcb.2018.01.005
   Dufrane D, 2017, CELL TRANSPLANT, V26, P1496, DOI 10.1177/0963689717721203
   Egusa H, 2012, J PROSTHODONT RES, V56, P229, DOI 10.1016/j.jpor.2012.10.001
   Feng YH, 2006, J BIOL CHEM, V281, P17228, DOI 10.1074/jbc.M602999200
   Forostyak O, 2016, STEM CELL RES, V16, P622, DOI 10.1016/j.scr.2016.03.010
   Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285
   Gangadharan V, 2015, AM J PHYSIOL CELL PH, V308, pC41, DOI 10.1152/ajpcell.00037.2014
   Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846
   Gartland A, 2012, FRONT BIOSCI LANDMRK, V17, P16, DOI 10.2741/3912
   Gharibi B, 2011, J BONE MINER RES, V26, P2112, DOI 10.1002/jbmr.424
   Giuliani AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107224
   He WJ, 2013, FASEB J, V27, P3446, DOI 10.1096/fj.13 231233
   Jiang LH, 2017, CELL MOL LIFE SCI, V74, P3697, DOI 10.1007/s00018 017 2545 6
   Jiang LH, 2017, J CELL PHYSIOL, V232, P287, DOI 10.1002/jcp.25484
   Jiang LH, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00055
   Jorgensen NR, 2015, CURR MED CHEM, V22, P902, DOI 10.2174/0929867321666141215094749
   Kotova PD, 2018, CELL CALCIUM, V71, P1, DOI 10.1016/j.ceca.2017.11.001
   Lavoie JR, 2013, BIOCHIMIE, V95, P2212, DOI 10.1016/j.biochi.2013.06.017
   Lazarowski ER, 2012, PURINERG SIGNAL, V8, P359, DOI 10.1007/s11302 012 9304 9
   Lenertz LY, 2015, GENE, V570, P1, DOI 10.1016/j.gene.2015.06.031
   Li SY, 2015, MOL MED REP, V12, P4320, DOI 10.3892/mmr.2015.3999
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mackenzie AB, 2005, J BIOL CHEM, V280, P33968, DOI 10.1074/jbc.M502705200
   Miyazaki T, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.385369
   Nakamura E, 2000, AM J PHYSIOL CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510
   Noronha Matos JB, 2016, J CELL PHYSIOL, V231, P1852, DOI 10.1002/jcp.25303
   Noronha Matos JB, 2014, FASEB J, V28, P5208, DOI 10.1096/fj.14 257923
   Orriss IR, 2006, BONE, V39, P300, DOI 10.1016/j.bone.2006.02.063
   Orriss IR, 2017, J ENDOCRINOL, V233, P341, DOI 10.1530/JOE 17 0042
   Orriss IR, 2012, BONE, V51, P389, DOI 10.1016/j.bone.2012.06.013
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269
   Sluyter R, 2017, ADV EXP MED BIOL, V1051, P17, DOI 10.1007/5584_2017_59
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Tamajusuku ASK, 2010, J CELL BIOCHEM, V109, P983, DOI 10.1002/jcb.22478
   Wagner W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002213
   Xing S, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00294
NR 49
TC 18
Z9 20
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD AUG
PY 2019
VL 15
IS 4
BP 574
EP 589
DI 10.1007/s12015 019 09883 6
PG 16
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA IJ0QW
UT WOS:000475605700009
PM 30955192
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Dong, XL
   Leung, PC
   Che, CT
   Wong, MS
AF Zhang, Yan
   Dong, Xiao Li
   Leung, Ping Chung
   Che, Chun Tao
   Wong, Man Sau
TI Fructus ligustri lucidi extract improves calcium balance and modulates
   the calciotropic hormone level and vitamin D dependent gene expression
   in aged ovariectomized rats
SO MENOPAUSE THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE fructus ligustri lucidi; dietary calcium; ovariectomized; calcium
   balance; vitamin D
ID 1,25 DIHYDROXYVITAMIN D 3; BONE TURNOVER; D RECEPTOR; POSTMENOPAUSAL
   WOMEN; ESTROGEN DEFICIENCY; ABSORPTION; ENZYMES; MARKERS; ACID; MICE
AB Objective: Fructus ligustri lucidi (FLL) is a widely used herb in China that is classically included in antiaging formulas for the treatment of age related symptoms. Our laboratory previously showed that FLL could regulate calcium balance in young ovariectomized (OVX) rats. In the present study, we aimed to determine whether FLL could regulate calcium balance in aged OVX rats and to study the potential mechanisms that mediate its action in vivo.
   Design: Aged OVX rats were orally administered an ethanol extract of FLL and its vehicle and fed with diets containing different levels of calcium [low calcium diet (LCD), 0.1% Ca; medium calcium diet (MCD), 0.6% Ca; and high calcium diet (HCD), 1.2% Ca] for 12 weeks.
   Results: Significant reductions in urinary and fecal calcium excretion were found in the FLL treated animals, resulting in a significant induction of calcium retention in rats fed with the MCD and HCD. FLL treatment significantly increased the serum 1,25 dihydroxyvitamin D 3 level and slightly decreased the serum parathyroid hormone level in OVX rats fed with the MCD and HCD. When OVX rats were challenged by LCD, the inductions of serum parathyroid hormone and 1,25 dihydroxyvitamin D3 were decreased by FLL administration. FLL treatment significantly up regulated duodenal vitamin D receptor and calcium transport protein I mRNA expression in rats fed with the HCD. FLL treatment reduced the expression of renal vitamin D receptor and 25 hydroxyvitamin D 24 hydroxylase mRNA in OVX rats fed with the LCD and MCD.
   Conclusions: Twelve weeks of FLL treatment could reduce calcium loss, modulate the parathyroid hormone vitamin D axis, and increase vitamin D dependent calcium transport in aged OVX rats, suggesting that FLL might be useful as an alternative medicine for improving calcium balance in postmenopausal women.
C1 [Dong, Xiao Li; Wong, Man Sau] Hong Kong Polytech Univ, Inst Mol Technol Drug Discovery & Synth, Cent Lab, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
   [Zhang, Yan; Wong, Man Sau] Hong Kong Polytech Univ, Shenzhen Res Inst, State Key Lab Chinese Med & Mol Pharmacol, Shenzhen, Peoples R China.
   [Dong, Xiao Li] Qingdao Univ, Coll Med, Dept Med Psychol & Psychiat, Qingdao 266071, Peoples R China.
   [Leung, Ping Chung] Chinese Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Che, Chun Tao] Chinese Univ Hong Kong, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University; Hong Kong Polytechnic University;
   Qingdao University; Chinese University of Hong Kong; Chinese University
   of Hong Kong
RP Wong, MS (通讯作者)，Hong Kong Polytech Univ, Inst Mol Technol Drug Discovery & Synth, Cent Lab, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
EM bcmswong@polyu.edu.hk
RI ; Che, Chun Tao/AAV 2795 2020; Dong, Xiaoli/ACK 2017 2022; Wong, Man
   Sau/F 2059 2015
OI DONG, XIAOLI/0000 0002 7372 0450; Wong, Man Sau/0000 0002 0729 8618
CR Anderson PH, 2004, J STEROID BIOCHEM, V89 90, P111, DOI 10.1016/j.jsbmb.2004.03.089
   Anderson PH, 2003, J MOL ENDOCRINOL, V31, P123, DOI 10.1677/jme.0.0310123
   Armbrecht HJ, 2003, ARCH BIOCHEM BIOPHYS, V420, P194, DOI 10.1016/j.abb.2003.09.025
   Armbrecht HJ, 1999, BIOCHEM BIOPH RES CO, V255, P731, DOI 10.1006/bbrc.1999.0271
   Boonen S, 2004, OSTEOPOROSIS INT, V15, P511, DOI 10.1007/s00198 004 1621 6
   Bown D., 1995, ENCY HERBS THEIR USE
   Brown AJ, 2005, ARCH BIOCHEM BIOPHYS, V437, P51, DOI 10.1016/j.abb.2005.02.007
   CAI J, 2006, J FUJIAN COLL TCM, V16, P34
   Ding Y.Q., 2006, J PREVENTIVE MED CHI, V24, P247
   Gennari C, 2001, Public Health Nutr, V4, P547
   Greer FR, 2006, PEDIATRICS, V117, P578, DOI 10.1542/peds.2005 2822
   Hao S. C., 1997, J TIANJIN NORMAL U N, V17, P49
   Haung W., 2003, Modern J Integr Tradition Chin Western Med, V12, P772
   Healy KD, 2005, ARCH BIOCHEM BIOPHYS, V433, P466, DOI 10.1016/j.abb.2004.10.001
   Holloway L, 2007, BRIT J NUTR, V97, P365, DOI 10.1017/S000711450733674X
   Khosla S, 1997, J CLIN ENDOCR METAB, V82, P1522, DOI 10.1210/jc.82.5.1522
   LEDGER GA, 1994, J CLIN ENDOCR METAB, V79, P211, DOI 10.1210/jc.79.1.211
   Li ML, 1994, CHINA J CHINESE MAT, V19, P504
   Li YC, 1998, ENDOCRINOLOGY, V139, P847, DOI 10.1210/en.139.3.847
   LIANG SM, 1991, ZHONG YAO FANG JI XU, P656
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Liu HX, 2003, J PHARMACEUT BIOMED, V32, P479, DOI 10.1016/S0731 7085(03)00235 8
   MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002 9343(92)90682 2
   Mitamura R, 2006, EUR J NUTR, V45, P242, DOI 10.1007/s00394 006 0592 0
   *NAT RES COUNC, 1996, GUID CAR US LAB AN
   Neuprez A, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471 2458 7 64
   Nordin BEC, 2004, AM J CLIN NUTR, V80, P998, DOI 10.1093/ajcn/80.4.998
   O'Loughlin PD, 1998, J PHYSIOL LONDON, V511, P313, DOI 10.1111/j.1469 7793.1998.313bi.x
   Omdahl JL, 2002, ANNU REV NUTR, V22, P139, DOI 10.1146/annurev.nutr.22.120501.150216
   Pharmacopoeia Commission of the Ministry of Public Health, 2005, CHIN PHARM 1
   Portale AA, 2000, PEDIATR NEPHROL, V14, P620
   Song YR, 2004, J NUTR, V134, P1857, DOI 10.1093/jn/134.8.1857
   ten Bolscher M, 1999, J BONE MINER RES, V14, P1197, DOI 10.1359/jbmr.1999.14.7.1197
   TOSHIMASA S, 1992, J BIOL CHEM, V267, P13757
   [王涛 Wang Tao], 2003, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V14, P403
   Wong MS, 2000, J NUTR, V130, P1147, DOI 10.1093/jn/130.5.1147
   Zhang Y, 2006, BIOL PHARM BULL, V29, P291, DOI 10.1248/bpb.29.291
   ZHANG Y, 2007, AM J PHYSIOL, V292, pF723
   [张岩 ZHANG Yan], 2006, [中草药, Chinese Traditional and Herbal Drugs], V37, P558
NR 39
TC 36
Z9 41
U1 1
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106 3621 USA
SN 1072 3714
J9 MENOPAUSE
JI Menopause J. N. Am. Menopause Soc.
PD MAY JUN
PY 2008
VL 15
IS 3
BP 558
EP 565
DI 10.1097/gme.0b013e31814fad27
PG 8
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 298MU
UT WOS:000255692600026
PM 18327153
DA 2025 08 17
ER

PT J
AU Moschetta, M
   Di Pietro, G
   Ria, R
   Gnoni, A
   Mangialardi, G
   Guarini, A
   Ditonno, P
   Musto, P
   D'Auria, F
   Ricciardi, MR
   Dammacco, F
   Ribatti, D
   Vacca, A
AF Moschetta, Michele
   Di Pietro, Giulia
   Ria, Roberto
   Gnoni, Antonio
   Mangialardi, Giuseppe
   Guarini, Attilio
   Ditonno, Paolo
   Musto, Pellegrino
   D'Auria, Fiorella
   Ricciardi, Maria Rosaria
   Dammacco, Franco
   Ribatti, Domenico
   Vacca, Angelo
TI Bortezomib and zoledronic acid on angiogenic and vasculogenic activities
   of bone marrow macrophages in patients with multiple myeloma
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Angiogenesis; Bortezomib; Macrophages; Multiple myeloma; Vasculogenesis;
   Zoledronic acid
ID PROTEASOME INHIBITOR PS 341; FACTOR KAPPA B; SQUAMOUS CELL CARCINOMA;
   ENDOTHELIAL CELLS; HEMATOLOGIC MALIGNANCIES; CLINICAL USE; IN VIVO;
   CANCER; GROWTH; BISPHOSPHONATES
AB Bone marrow neovascularisation supports plasma cell tumour progression in patients with multiple myeloma (MM), and is partially sustained by bone marrow macrophages through their angiogenic and vasculogenic activities. As such, macrophages may be a target for antivascular treatment in MM. Here, we show that bortezomib (BZ) and zoledronic acid (ZOL) display distinct and synergistic inhibitory effects on cell proliferation, adhesion, migration and expression of angiogenic cytokines (i.e.: VEGF, bFGF, HGF and PDGF). Similar effects were found on capillarogenic Organisation and expression of vascular markers in cells which became vasculogenic. VEGFR2 and ERK1/2 phosphoactivation as well as NF kappa B activity were also inhibited. Overall these data provide evidence that the exposure of bone marrow macrophages in MM during the treatment with ZOL and BZ, alone and or in combination, impacts their angiogenic and vasculogenic properties, suggesting that these cells may be considered as a target of both drugs in MM patients. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Moschetta, Michele; Di Pietro, Giulia; Ria, Roberto; Gnoni, Antonio; Mangialardi, Giuseppe; Dammacco, Franco; Vacca, Angelo] Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I 70124 Bari, Italy.
   [Guarini, Attilio] Inst Oncol Giovanni Paolo II, Hematol Unit, I 70100 Bari, Italy.
   [Ditonno, Paolo] Di Venere Hosp, Hematol Unit, I 74100 Bari, Italy.
   [Musto, Pellegrino; D'Auria, Fiorella] Ctr Riferimento Oncol Basilicata IRCCS CROB, Hematol & Bone Marrow Transplantat Unit, I 85023 Potenza, Italy.
   [Ricciardi, Maria Rosaria] Univ Roma La Sapienza, Div Hematol, Dept Cellular Biotechnol & Hematol, I 00100 Rome, Italy.
   [Ribatti, Domenico] Univ Bari, Sch Med, Dept Human Anat & Histol, I 70124 Bari, Italy.
C3 Universita degli Studi di Bari Aldo Moro; IRCCS CROB; Sapienza
   University Rome; Universita degli Studi di Bari Aldo Moro
RP Vacca, A (通讯作者)，Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, Policlin Piazza Giulio Cesare 11, I 70124 Bari, Italy.
EM a.vacca@dimo.uniba.it
RI Dammacco, Franco/ABG 5728 2020; DITONNO, PAOLO/AAG 5684 2020; RICCIARDI,
   Maria Rosaria/Z 5810 2019; Tataranni, Tiziana/C 4839 2013; Ria,
   Roberto/I 4263 2015; D'Auria, Fiorella/K 8483 2016; Vacca,
   Angelo/AAC 9558 2022; Ricciardi, Maria/Z 5810 2019; Guarini,
   Attilio/AAK 3156 2020
OI RICCIARDI, Maria Rosaria/0000 0002 8772 3521; Tataranni,
   Tiziana/0000 0002 2140 4456; guarini, attilio/0000 0002 9304 6651; Ria,
   Roberto/0000 0002 1515 0090; Musto, Pellegrino/0000 0003 3277 6594;
   DITONNO, PAOLO/0000 0002 5187 7756; Vacca, Angelo/0000 0002 4567 8216;
   D'Auria, Fiorella/0000 0002 3030 1651; 
FU Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan); Ministry
   of Education, University and Research; Ministry of Health, Progetto
   Oncologia
FX This work was supported by Associazione Italiana per la Ricerca sul
   Cancro (AIRC, Milan), the Ministry of Education, University and Research
   (MUR, PRIN Projects 2008), and the Ministry of Health, Progetto
   Oncologia 2006, Humanitas Mirasole S.P.A., Rome, Italy. The sponsors of
   this study are public or non profit organisations that support science
   in general. They had no role in gathering, analysing or interpreting the
   data.
CR Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Clézardin P, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.37420
   Coluccia AML, 2008, BLOOD, V112, P1346, DOI 10.1182/blood 2007 10 116590
   Cusack JC, 2001, CANCER RES, V61, P3535
   Dhillon S, 2008, DRUGS, V68, P507, DOI 10.2165/00003495 200868040 00010
   Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   DURIE BGM, 1986, SEMIN ONCOL, V13, P300
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170
   Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200
   Kawasaki K, 2008, J CELL BIOL, V181, P131, DOI 10.1083/jcb.200709127
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   LeBlanc R, 2002, CANCER RES, V62, P4996
   Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008 5472.CAN 04 0852
   Major PP, 2000, CANCER, V88, P6, DOI 10.1002/(SICI)1097 0142(20000101)88:1<6::AID CNCR3>3.3.CO;2 4
   Mystakidou K, 2005, J PAIN PALLIAT CARE, V19, P41, DOI 10.1300/J354v19n03_07
   Orlowski RZ, 2005, BLOOD, V105, P3058, DOI 10.1182/blood 2004 07 2911
   Pajonk F, 2001, RADIAT RES, V156, P447, DOI 10.1667/0033 7587(2001)156[0447:TPICBA]2.0.CO;2
   Palumbo A, 2008, BLOOD, V111, P3968, DOI 10.1182/blood 2007 10 117457
   Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood 2004 07 2909
   Podar K, 2004, CANCER RES, V64, P7500, DOI 10.1158/0008 5472.CAN 04 0124
   Podar K, 2007, BEST PRACT RES CL HA, V20, P597, DOI 10.1016/j.beha.2007.08.002
   RAIKKONEN J, 2009, BRIT J PHARM
   Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456
   RIBATTI D, 2009, LEUKEMIA
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008 5472.CAN 05 1195
   Sarkar FH, 2008, FRONT BIOSCI LANDMRK, V13, P2950, DOI 10.2741/2900
   Scavelli C, 2008, ONCOGENE, V27, P663, DOI 10.1038/sj.onc.1210691
   Scavelli C, 2007, MOL CANCER THER, V6, P3256, DOI 10.1158/1535 7163.MCT 07 0311
   Sun XF, 2007, HISTOL HISTOPATHOL, V22, P1387, DOI 10.14670/HH 22.1387
   Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419
   Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood 2003 04 1338
   Vacca A, 2003, HAEMATOLOGICA, V88, P176
   Yang HH, 2003, CLIN LYMPHOMA, V4, P119, DOI 10.3816/CLM.2003.n.022
   2003, BRIT J HAEMATOL, V121, P749
NR 41
TC 58
Z9 67
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959 8049
EI 1879 0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JAN
PY 2010
VL 46
IS 2
BP 420
EP 429
DI 10.1016/j.ejca.2009.10.019
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 550JE
UT WOS:000274123300029
PM 19914061
DA 2025 08 17
ER

PT J
AU Massey, AS
   Pentlavalli, S
   Cunningham, R
   McCrudden, CM
   McErlean, EM
   Redpath, P
   Ali, AA
   Annett, S
   McBride, JW
   McCaffrey, J
   Robson, T
   Migaud, ME
   McCarthy, HO
AF Massey, Ashley S.
   Pentlavalli, Sreekanth
   Cunningham, Richard
   McCrudden, Cian M.
   McErlean, Emma M.
   Redpath, Philip
   Ali, Ahlam A.
   Annett, Stephanie
   McBride, John W.
   McCaffrey, Joanne
   Robson, Tracy
   Migaud, Marie E.
   McCarthy, Helen O.
TI Potentiating the Anticancer Properties of Bisphosphonates by
   Nanocomplexation with the Cationic Amphipathic Peptide, RALA
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE alendronate; prostate cancer; bisphosphonates; cell penetrating
   peptides; self assembling nanoparticles
ID ZOLEDRONIC ACID; NANOPARTICLES; METASTASES; INHIBITORS; MECHANISM;
   GROWTH
AB Bisphosphonates (BPs) are a class of bone resorptive drug with a high affinity for the hydroxyapatite structure of bone matrices that are used for the treatment of osteoporosis. However, clinical application is limited by a common toxicity, BP related osteonecrosis of the jaw. There is emerging evidence that BPs possess anticancer potential, but exploitation of these antiproliferative properties is limited by their toxicities. We previously reported the utility of a cationic amphipathic fusogenic peptide, RALA, to traffic anionic nucleic acids into various cell types in the form of cationic nanoparticles. We hypothesized that complexation with RALA could similarly be used. to conceal a BP's hydroxyapatite affinity, and to enhance bioavailability, thereby improving anticancer efficacy. Incubation of RALA with alendronate, etidronate, risedronate, or zoledronate provoked spontaneous electrostatic formation of cationic nanoparticles that did not exceed 100 nm in diameter and that were stable over a range of temperatures and for up to 6 h. The nanoparticles demonstrated a pH responsiveness, possibly indicative of a conformational change, that could facilitate release of the BP cargo in the endosomal environment. RALA/BP nanoparticles were more potent anticancer agents than their free BP counterparts in assays investigating the viability of PC3 prostate cancer and MDA MB 231 breast cancer cells. Moreover, RALA complexation potentiated the tumor growth delay activity of alendronate in a PC3 xenograft model of prostate cancer. Taken together, these findings further validate the use of BPs as repurposed anticancer agents.
C1 [Massey, Ashley S.; Pentlavalli, Sreekanth; Cunningham, Richard; McCrudden, Cian M.; McErlean, Emma M.; Redpath, Philip; Ali, Ahlam A.; Annett, Stephanie; McBride, John W.; McCaffrey, Joanne; Robson, Tracy; Migaud, Marie E.; McCarthy, Helen O.] Queens Univ Belfast, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
C3 Queens University Belfast
RP McCarthy, HO (通讯作者)，Queens Univ Belfast, Sch Pharm, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM h.mccarthy@qub.ac.uk
RI migaud, marie/C 9026 2015; McErlean, Emma/AAS 5412 2020
OI McCarthy, Helen/0000 0002 1254 3745; Ali, Ahlam/0009 0000 3244 8609;
   Robson, Tracy/0000 0003 4262 6872; McErlean, Emma/0000 0001 6841 2712;
   Pentlavalli, Sreekanth/0000 0002 8513 1215
FU Royal Pharmaceutical Society of Great Britain; EPSRC [EP/H031065/1];
   Engineering and Physical Sciences Research Council [EP/I016104/1,
   EP/H031065/1] Funding Source: researchfish; EPSRC [EP/H031065/1,
   EP/I016104/1] Funding Source: UKRI
FX A.S.M. was funded by the Royal Pharmaceutical Society of Great Britain.
   R.C. was funded by the EPSRC EP/H031065/1.
CR Aft R, 2012, CRIT REV ONCOL HEMAT, V82, P233, DOI 10.1016/j.critrevonc.2011.05.009
   Bagwe RP, 2006, LANGMUIR, V22, P4357, DOI 10.1021/la052797j
   Banerjee A, 2011, INORG CHEM, V50, P11667, DOI 10.1021/ic201652h
   Chebbi I, 2010, INT J PHARMACEUT, V383, P116, DOI 10.1016/j.ijpharm.2009.09.011
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Rodríguez Lozano FJ, 2015, J CRANIO MAXILL SURG, V43, P855, DOI 10.1016/j.jcms.2015.04.012
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Konate K, 2010, BIOCHEMISTRY US, V49, P3393, DOI 10.1021/bi901791x
   Mani J, 2012, PROSTATE CANCER P D, V15, P250, DOI 10.1038/pcan.2012.9
   Marra M, 2011, NANOMED NANOTECHNOL, V7, P955, DOI 10.1016/j.nano.2011.03.004
   McCarthy HO, 2014, J CONTROL RELEASE, V189, P141, DOI 10.1016/j.jconrel.2014.06.048
   Metcalf S, 2011, FUTURE ONCOL, V7, P1325, DOI [10.2217/FON.11.113, 10.2217/fon.11.113]
   Milen M, 2010, SYNTHETIC COMMUN, V40, P2291, DOI 10.1080/00397910903226166
   Ottewell PD, 2010, INT J CANCER, V126, P522, DOI 10.1002/ijc.24756
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Rubino MT, 2011, CHEMMEDCHEM, V6, P1258, DOI 10.1002/cmdc.201000540
   Salzano G, 2011, INT J PHARMACEUT, V403, P292, DOI 10.1016/j.ijpharm.2010.10.046
   Singh S. K., 2008, BEILSTEIN J ORG CHEM, V4, P42
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Vassiliou V, 2009, ANTI CANCER AGENT ME, V9, P326, DOI 10.2174/1871520610909030326
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 25
TC 32
Z9 34
U1 1
U2 39
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD APR
PY 2016
VL 13
IS 4
BP 1217
EP 1228
DI 10.1021/acs.molpharmaceut.5b00670
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DI5PH
UT WOS:000373550600003
PM 26954700
DA 2025 08 17
ER

PT J
AU Toffoli, A
   Parisi, L
   Bianchi, MG
   Lumetti, S
   Bussolati, O
   Macaluso, GM
AF Toffoli, Andrea
   Parisi, Ludovica
   Bianchi, Massimiliano G.
   Lumetti, Simone
   Bussolati, Ovidio
   Macaluso, Guido M.
TI Thermal treatment to increase titanium wettability induces selective
   proteins adsorption from blood serum thus affecting osteoblasts adhesion
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Dental implants; Titanium; Wettability; Blood serum; Fibronectin;
   Osteoblasts; Adhesion
ID IMPLANT SURFACES; BONE APPOSITION; FOCAL CONTACTS; FIBRONECTIN;
   BIOCOMPATIBILITY; INTEGRATION
AB Objectives: To investigate how a thermal treatment to increase titanium wettability influences proteins adsorption from blood serum and osteoblasts responses.
   Methods: Titanium discs with machined or micro rough profiles were thermally treated to obtain hydrophilic surfaces. The adsorption kinetics of two representative serum proteins were determined by Bradford assay, while the stable protein adsorption pattern from blood serum was investigated by SDS PAGE and Western Blot analysis. Subsequently, MC3T3 E1 cells were cultured on titanium for 24h and assayed for adhesion and morphology.
   Results: Thermally induced hydrophilicity dramatically improved the capacity of titanium to selectively adsorb fibronectin and fibrinogen from blood serum, without evident influence on other representative serum proteins. The selective adsorption of fibronectin was linked to the improved capacity of MC3T3 E1 cells to adhere and spread on hydrophilic surfaces.
   Significance: We identified a potential method to improve selective protein adsorption on titanium by enhancing implant surface wettability through a thermal treatment. Selective fibronectin adsorption was further indicated as the responsible for improved osteoblasts adhesion. Targeting specific cell response by selective protein adsorption appears to be crucial to conceive even more performant therapies.
C1 [Toffoli, Andrea; Parisi, Ludovica; Lumetti, Simone; Macaluso, Guido M.] Univ Parma, Ctr Univ Odontoiatria, Via Gramsci 14, I 43126 Parma, PR, Italy.
   [Toffoli, Andrea; Parisi, Ludovica; Bianchi, Massimiliano G.; Lumetti, Simone; Bussolati, Ovidio; Macaluso, Guido M.] Dipartimento Med & Chirurg, Via Gramsci 14, I 43126 Parma, PR, Italy.
   [Macaluso, Guido M.] CNR, Ist Mat Elettron & Magnetismo, Parco Area Sci 37 A, I 43124 Parma, PR, Italy.
C3 University of Parma; University Hospital of Parma; University of Parma;
   University Hospital of Parma; Consiglio Nazionale delle Ricerche (CNR);
   Istituto dei Materiali per l'Elettronica ed il Magnetismo (IMEM CNR)
RP Parisi, L (通讯作者)，Univ Parma, Ctr Univ Odontoiatria, Dipartimento Med & Chirurg, Via Gramsci 14, I 43126 Parma, PR, Italy.
EM andrea.toffoli@unipr.it; ludovica.parisi@unipr.it;
   massimiliano.bianchi@unipr.it; simone.lumetti@unipr.it;
   ovidio.bussolati@unipr.it; guidomaria.macaluso@unipr.it
RI Macaluso, Guido/D 5317 2013; Salvaterra Toffoli, Andrea/GLT 1295 2022;
   Bussolati, Ovidio/B 7589 2013
OI BIANCHI, Massimiliano/0000 0002 4179 6573; Salvaterra Toffoli,
   Andrea/0000 0003 1641 7743
CR Aita H, 2009, BIOMATERIALS, V30, P1015, DOI 10.1016/j.biomaterials.2008.11.004
   ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
   Ballester Beltrán J, 2011, SOFT MATTER, V7, P10803, DOI 10.1039/c1sm06102j
   Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521
   Bornstein MM, 2008, CLIN ORAL IMPLAN RES, V19, P233, DOI 10.1111/j.1600 0501.2007.01473.x
   Buser D, 2004, J DENT RES, V83, P529, DOI 10.1177/154405910408300704
   Chehroudi B, 2010, J BIOMED MATER RES A, V93A, P724, DOI 10.1002/jbm.a.32587
   Chen LN, 2018, MATER TODAY, V21, P38, DOI 10.1016/j.mattod.2017.07.002
   Doyle AD, 2009, J CELL BIOL, V184, P481, DOI 10.1083/jcb.200810041
   Galli C, 2016, ACTA BIOMATER, V42, P147, DOI 10.1016/j.actbio.2016.07.035
   Garland A, 2012, PROG SURF SCI, V87, P1, DOI 10.1016/j.progsurf.2012.02.001
   Ghassemi A, 2018, IMPLANT DENT, V27, P405, DOI 10.1097/ID.0000000000000773
   Gittens RA, 2014, ACTA BIOMATER, V10, P2907, DOI 10.1016/j.actbio.2014.03.032
   Gittens RA, 2013, ACTA BIOMATER, V9, P6268, DOI 10.1016/j.actbio.2012.12.002
   Hasan A, 2018, LANGMUIR, V34, P3494, DOI 10.1021/acs.langmuir.7b03152
   Karoussis IK, 2004, CLIN ORAL IMPLAN RES, V15, P8, DOI 10.1111/j.1600 0501.2004.00983.x
   Kohavi D, 2013, CLIN ORAL IMPLAN RES, V24, P1002, DOI 10.1111/j.1600 0501.2012.02508.x
   Kopf BS, 2015, J BIOMED MATER RES A, V103, P2661, DOI 10.1002/jbm.a.35401
   Lee YJ, 2012, J PERIODONTAL IMPLAN, V42, P81, DOI 10.5051/jpis.2012.42.3.81
   Lorenzetti M, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/4/045012
   MacDonald DE, 2002, BIOMATERIALS, V23, P1269, DOI 10.1016/S0142 9612(01)00317 9
   MacDonald DE, 2004, BIOMATERIALS, V25, P3135, DOI 10.1016/j.biomaterials.2003.10.029
   McFarland CD, 2000, J BIOMED MATER RES, V49, P200, DOI 10.1002/(SICI)1097 4636(200002)49:2<200::AID JBM7>3.3.CO;2 C
   Ogawa T, 2003, INT J ORAL MAX IMPL, V18, P200
   Parisi L, 2017, J MATER SCI MATER M, V28, DOI 10.1007/s10856 017 5931 6
   Parisi L, 2019, J ORAL SCI
   Parisi L, 2019, MATERIALS, V12, DOI 10.3390/ma12050812
   Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661
   Schwarz F, 2008, J CLIN PERIODONTOL, V35, P64, DOI 10.1111/j.1600 051X.2007.01159.x
   Shorouq M., 2015, INT J SCI RES, P1212
   SINGER II, 1982, J CELL BIOL, V92, P398, DOI 10.1083/jcb.92.2.398
   Smeets R, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6285620
   Vogler EA, 2012, BIOMATERIALS, V33, P1201, DOI 10.1016/j.biomaterials.2011.10.059
NR 33
TC 64
Z9 64
U1 2
U2 70
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD FEB
PY 2020
VL 107
AR 110250
DI 10.1016/j.msec.2019.110250
PG 7
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA JU0RI
UT WOS:000501386500023
PM 31761226
DA 2025 08 17
ER

PT J
AU Tarnowski, M
   Koryciak Komarska, H
   Czekaj, P
   Sebesta, R
   Czekaj, TM
   Urbanek, K
   Likus, W
   Malinowska Kolodziej, I
   Plewka, D
   Nowaczyk Dura, G
   Wiaderkiewicz, R
   Sieron, AL
AF Tarnowski, Madej
   Koryciak Komarska, Halina
   Czekaj, Piotr
   Sebesta, Ryszard
   Czekaj, Tomasz M.
   Urbanek, Ksymena
   Likus, Wirginia
   Malinowska Kolodziej, Izabela
   Plewka, Danuta
   Nowaczyk Dura, Grazyna
   Wiaderkiewicz, Ryszard
   Sieron, Aleksander L.
TI The comparison of multipotential for differentiation of progenitor
   mesenchymal like stem cells obtained from livers of young and old rats
SO FOLIA HISTOCHEMICA ET CYTOBIOLOGICA
LA English
DT Article
DE cell differentiation; differentiation markers; liver stem cells; notch
   signalling; progenitors
ID BONE MARROW CELLS; STROMAL CELLS; OVAL CELLS; HEPATOCYTES; MICE;
   PROLIFERATION; DEFECTS; ORIGIN; MSCS; SHH
AB The presence of stem cells differentiating to hepatocytes and cholangiocytes has been previously reported in livers of young rats. Here, we have isolated, cultured, and characterized mesenchymal stem cells (MSCs) from livers of young and old rats and tested their multipotential for differentiation. The mesenchymal stem cells in liver sections were identified by the presence of markers, respectively for primary stem cells Thy 1 and CD34, for differentiation to early cholangiocytes GST and CK19, and for differentiation to hepatocytes GST alpha and CK18. Ki67 was detected as the cell proliferation marker. Cells isolated from livers of either age group were tested in a culture for their viability following storage and were characterized for the presence of most of the markers detected in cells in situ. The results revealed age dependent changes in the number of recovered primary MSCs. In both age groups we have observed cells changing under differentiating conditions to liver cell lineages, such as cholangiocytes and hepatocytes, as well as to non liver cells such as adipocytes, astrocytes, neuroblasts, and osteoblasts. Our data revealed that from the livers of rats 20 months and older the primary MSCs could be isolated and expanded; however, they were significantly fewer, even though their differentiation multipotential was preserved. The mechanism involved in the differentiation of liver MSCs seemed to depend on a constellation of signals in Notch signalling pathways. Thus, our results support the idea of potential use of liver as a source of MSCs, not only for liver reconstruction but also for cell therapy in general.
C1 Med Univ Silesia, Dept Gen & Mol Biol & Genet, PL 40752 Katowice, Poland.
   Med Univ Silesia, Dept Histol & Embriol, PL 40752 Katowice, Poland.
   Med Univ Silesia, Ctr Excellence Res & Teach Mol Biol Matrix N, Dept Physiol, Katowice, Poland.
C3 Medical University of Silesia; Medical University of Silesia; Medical
   University of Silesia
RP Sieron, AL (通讯作者)，Med Univ Silesia, Dept Gen & Mol Biol & Genet, Medykow 18, Bldg C 1, PL 40752 Katowice, Poland.
EM histem2@slam.katowice.pl; alsieron@slam.katowice.pl
RI ; Tarnowski, Maciej/J 6292 2014; Sieron, Aleksander/G 1700 2013; Czekaj,
   Tomasz/F 5129 2015; Malinowska, Izabela/A 4816 2013
OI Sieron, Aleksander L./0000 0002 3894 9508; Tarnowski,
   Maciej/0000 0002 3869 5077; Czekaj, Piotr/0000 0002 0376 5629; Plewka,
   Danuta/0000 0002 5408 1489; Likus, Wirginia/0000 0002 4738 6102; 
CR Alvarez Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069
   Buján J, 2006, WOUND REPAIR REGEN, V14, P216, DOI 10.1111/j.1743 6109.2006.00113.x
   Buján J, 2005, HISTOL HISTOPATHOL, V20, P891, DOI 10.14670/HH 20.891
   Cheng LP, 2004, NAT NEUROSCI, V7, P510, DOI 10.1038/nn1221
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   DABEVA MD, 1993, AM J PATHOL, V143, P1606
   Evarts RP, 1996, CARCINOGENESIS, V17, P2143, DOI 10.1093/carcin/17.10.2143
   Gordon GJ, 2000, AM J PATHOL, V157, P771, DOI 10.1016/S0002 9440(10)64591 9
   Gordon GJ, 2000, AM J PATHOL, V156, P607, DOI 10.1016/S0002 9440(10)64765 7
   Hoffman RM, 2007, EXPERT OPIN BIOL TH, V7, P289, DOI 10.1517/14712598.7.3.289
   Jensen CH, 2004, AM J PATHOL, V164, P1347, DOI 10.1016/S0002 9440(10)63221 X
   Kondo T, 2005, P NATL ACAD SCI USA, V102, P4789, DOI 10.1073/pnas.0408239102
   Lechner A, 2003, AM J PHYSIOL ENDOC M, V284, pE259, DOI 10.1152/ajpendo.00393.2002
   LEMIRE JM, 1991, AM J PATHOL, V139, P535
   Lemmer ER, 1998, J HEPATOL, V29, P450, DOI 10.1016/S0168 8278(98)80064 0
   Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60
   Muller Borer BJ, 2007, P NATL ACAD SCI USA, V104, P3877, DOI 10.1073/pnas.0700416104
   Ning HX, 2006, DIFFERENTIATION, V74, P510, DOI 10.1111/j.1432 0436.2006.00081.x
   Ogura T, 1996, DEVELOPMENT, V122, P537
   Overturf K, 1997, AM J PATHOL, V151, P1273
   Peister A, 2004, GENE THER, V11, P224, DOI 10.1038/sj.gt.3302163
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood 2003 09 3070
   Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168
   Pochampally RR, 2004, P NATL ACAD SCI USA, V101, P9282, DOI 10.1073/pnas.0401558101
   Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902
   Tarnowski M, 2006, MED SCI MONITOR, V12, pRA154
   Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730
   Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135
   Tsukui T, 1999, P NATL ACAD SCI USA, V96, P11376, DOI 10.1073/pnas.96.20.11376
   Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100
   Zheng B, 2006, TISSUE ENG, V12, P1891, DOI 10.1089/ten.2006.12.1891
NR 32
TC 10
Z9 12
U1 0
U2 9
PU VIA MEDICA
PI GDANSK
PA UL SWIETOKRZYSKA 73, 80 180 GDANSK, POLAND
SN 0239 8508
EI 1897 5631
J9 FOLIA HISTOCHEM CYTO
JI Folia Histochem. Cytobiol.
PY 2007
VL 45
IS 3
BP 245
EP 254
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 230LA
UT WOS:000250876800015
PM 17951175
DA 2025 08 17
ER

PT J
AU Chang, SH
   Hsiao, HY
   Chen, YH
   Cheng, MH
   Liu, JW
   Huang, HJ
   Chou, YT
   Amer, TAM
   Vijayaraghavan, P
   Palanisamy, S
   Wang, YM
   Lu, TT
AF Chang, Shih Hao
   Hsiao, Hui Yi
   Chen, Yi Hong
   Cheng, Ming Huei
   Liu, Jia Wei
   Huang, Hsiao Jo
   Chou, Yu Ting
   Amer, Tarik Abdelkareem Mostafa
   Vijayaraghavan, Priya
   Palanisamy, Sathyadevi
   Wang, Yun Ming
   Lu, Tsai Te
TI Conjugation of bone grafts with NO delivery dinitrosyl iron complexes
   promotes synergistic osteogenesis and angiogenesis in rat calvaria bone
   defects
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID NITRIC OXIDE; HARVESTING TECHNIQUES; CALCIUM PHOSPHATE; AUTOGENOUS BONE;
   HYDROXYAPATITE; NEUROGENESIS; EXTRACTION; RESORPTION; RELEASE; IMPACT
AB Craniofacial/jawbone deformities remain a significant clinical challenge in restoring facial/dental functions and esthetics. Despite the reported therapeutics for clinical bone tissue regeneration, the bioavailability issue of autografts and limited regeneration efficacy of xenografts/synthetic bone substitutes, however, inspire continued efforts towards functional conjugation and improvement of bioactive bone graft materials. Regarding the potential of nitric oxide (NO) in tissue engineering, herein, functional conjugation of NO delivery dinitrosyl iron complex (DNIC) and osteoconductive bone graft materials was performed to optimize the spatiotemporal control over the delivery of NO and to activate synergistic osteogenesis and angiogenesis in rat calvaria bone defects. Among three types of biomimetic DNICs, [Fe 2(mu SCH2CH2COOH)(2)(NO)(4)] (DNIC COOH) features a steady kinetics for cellular uptake by MC3T3 E1 osteoblast cells followed by intracellular assembly of protein bound DNICs and release of NO. This steady kinetics for intracellular delivery of NO by DNIC COOH rationalizes its biocompatibility and wide spectrum cell proliferation effects on MC3T3 E1 osteoblast cells and human umbilical vein endothelial cells (HUVECs). Moreover, the bridging [SCH2CH2COOH]( ) thiolate ligands in DNIC COOH facilitate its chemisorption to deproteinized bovine bone mineral (DBBM) and physisorption onto TCP (beta tricalcium phosphate), respectively, which provides a mechanism to control the kinetics for the local release of loaded DNIC COOH. Using rats with calvaria bone defects as an in vivo model, DNIC DBBM/DNIC TCP promotes the osteogenic and angiogenic activity ascribed to functional conjugation of osteoconductive bone graft materials and NO delivery DNIC COOH. Of importance, the therapeutic efficacy of DNIC DBBM/DNIC TCP on enhanced compact bone formation after treatment for 4 and 12 weeks supports the potential for clinical application to regenerative medicine.
C1 [Chang, Shih Hao; Huang, Hsiao Jo] Linkou Chang Gung Mem Hosp, Dept Periodont, Taoyuan 33305, Taiwan.
   [Chang, Shih Hao] Chang Gung Univ, Grad Inst Dent & Craniofacial Sci, Taoyuan 33302, Taiwan.
   [Chang, Shih Hao; Hsiao, Hui Yi; Cheng, Ming Huei; Liu, Jia Wei; Huang, Hsiao Jo] Linkuo Chang Gung Mem Hosp, Ctr Tissue Engn, Taoyuan 33305, Taiwan.
   [Hsiao, Hui Yi; Cheng, Ming Huei; Liu, Jia Wei] Linkou Chang Gung Mem Hosp, Div Reconstruct Microsurg, Dept Plast & Reconstruct Surg, Taoyuan 33305, Taiwan.
   [Hsiao, Hui Yi] Chang Gung Univ, Dept Biomed Sci, Taoyuan 33302, Taiwan.
   [Chen, Yi Hong; Palanisamy, Sathyadevi; Lu, Tsai Te] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 30013, Taiwan.
   [Chou, Yu Ting; Amer, Tarik Abdelkareem Mostafa; Wang, Yun Ming] Natl Yang Ming Chiao Tung Univ, Inst Mol Med & Bioengn, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Hsinchu 300, Taiwan.
   [Vijayaraghavan, Priya] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Wang, Yun Ming] Natl Yang Ming Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS, Hsinchu 300, Taiwan.
   [Lu, Tsai Te] Natl Tsing Hua Univ, Dept Chem, Hsinchu 30013, Taiwan.
   [Lu, Tsai Te] Chung Yuan Christian Univ, Dept Chem, Taoyuan 32023, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial
   Hospital; Chang Gung University; National Tsing Hua University; National
   Yang Ming Chiao Tung University; Kaohsiung Medical University; National
   Yang Ming Chiao Tung University; National Tsing Hua University; Chung
   Yuan Christian University
RP Hsiao, HY (通讯作者)，Linkuo Chang Gung Mem Hosp, Ctr Tissue Engn, Taoyuan 33305, Taiwan.; Hsiao, HY (通讯作者)，Linkou Chang Gung Mem Hosp, Div Reconstruct Microsurg, Dept Plast & Reconstruct Surg, Taoyuan 33305, Taiwan.; Hsiao, HY (通讯作者)，Chang Gung Univ, Dept Biomed Sci, Taoyuan 33302, Taiwan.; Lu, TT (通讯作者)，Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu 30013, Taiwan.; Wang, YM (通讯作者)，Natl Yang Ming Chiao Tung Univ, Inst Mol Med & Bioengn, Dept Biol Sci & Technol, Coll Biol Sci & Technol, Hsinchu 300, Taiwan.; Wang, YM (通讯作者)，Natl Yang Ming Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices IDS, Hsinchu 300, Taiwan.; Lu, TT (通讯作者)，Natl Tsing Hua Univ, Dept Chem, Hsinchu 30013, Taiwan.; Lu, TT (通讯作者)，Chung Yuan Christian Univ, Dept Chem, Taoyuan 32023, Taiwan.
EM ivyhsiao@gmail.com; ymwang@mail.nctu.edu.tw; ttlu@mx.nthu.edu.tw
RI Lu, Tsai Te/AAX 6063 2020; HSIAO, HUI YI/K 5428 2017; Chou,
   Yu Ting/IYT 3589 2023; Hsiao, Ivy/K 5428 2017; Vijayaraghavan,
   Priya/AAY 3027 2021
OI HSIAO, HUI YI/0000 0003 3170 2112; Vijayaraghavan,
   Priya/0000 0003 3956 9870; 
FU National Science and Technology Council, Taiwan [MOST
   109 2628 M 007 003 MY3]; National Tsing Hua University, Taiwan
   [109Q2711E1, 110Q2513E1]; Chang Gung Medical Research Program
   [CMRPG3J1841]; Chang Gung Memorial Hospital, Linkou, Taiwan; "Center for
   Intelligent Drug Systems and Smart Bio devices (IDS2B)" project from The
   Featured Areas Research Center Program within Ministry of Education
   (MOE) in Taiwan; "Smart Platform of Dynamic Systems Biology for
   Therapeutic Development" project from The Featured Areas Research Center
   Program within Ministry of Education (MOE) in Taiwan
FX We gratefully acknowledge the financial support from the National
   Science and Technology Council, Taiwan (MOST 109 2628 M 007 003 MY3),
   from National Tsing Hua University, Taiwan (Grant No. 109Q2711E1 and
   110Q2513E1), from Chang Gung Medical Research Program (CMRPG3J1841), and
   from Chang Gung Memorial Hospital, Linkou, Taiwan. The authors would
   like to gratefully acknowledge the financial support by the "Center for
   Intelligent Drug Systems and Smart Bio devices (IDS2B)" and "Smart
   Platform of Dynamic Systems Biology for Therapeutic Development" project
   from The Featured Areas Research Center Program within the framework of
   the Higher Education Sprout Project by the Ministry of Education (MOE)
   in Taiwan. The authors would like to thank Laboratory Animal Center,
   Chang Gung Memorial Hospital, Linkou, for the molecular imaging and
   technical support. We thank Ms Hsiu Ni Huang (Instrumentation Center,
   National Taiwan Normal University) for the help with the EPR experiments
   and Dr En Hui Liu (Center for Nanotechnology, Materials Science, and
   Microsystems, NTHU) for technical support with the SEM and EDS
   experiments.
CR Abou Elella AMKE, 2002, CAN J GASTROENTEROL, V16, P791, DOI 10.1155/2002/986305
   Al Ahmady HH, 2018, J CRANIO MAXILL SURG, V46, P1593, DOI 10.1016/j.jcms.2018.05.049
   Baltzis D, 2014, ADV THER, V31, P817, DOI 10.1007/s12325 014 0140 x
   Beaucage Kim L, 2016, Bone Rep, V5, P70, DOI 10.1016/j.bonr.2016.04.002
   Borrelli MR, 2020, J CRANIOFAC SURG, V31, P15, DOI 10.1097/SCS.0000000000005840
   Broggini N, 2015, J BIOMED MATER RES B, V103, P1478, DOI 10.1002/jbm.b.33319
   Cardozo VF, 2014, INT J PHARMACEUT, V473, P20, DOI 10.1016/j.ijpharm.2014.06.051
   Chappuis V, 2013, J DENT RES, V92, p195S, DOI 10.1177/0022034513506713
   Chen YC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810101
   Chen YJ, 2019, MOL PHARMACEUT, V16, P4241, DOI 10.1021/acs.molpharmaceut.9b00586
   Choi YK, 2016, NAT MED, V22, P1335, DOI 10.1038/nm.4188
   Chung CW, 2022, ACS APPL MATER INTER, V14, P6343, DOI 10.1021/acsami.1c20802
   Delloye C, 2007, J BONE JOINT SURG BR, V89B, P574, DOI 10.1302/0301 620X.89B5.19039
   Di LZ, 2014, ADV ORTHOP, V2014, DOI 10.1155/2014/791539
   Discepoli N, 2013, J CLIN PERIODONTOL, V40, P638, DOI 10.1111/jcpe.12074
   El Fiqi A, 2022, COLLOID SURFACE B, V217, DOI 10.1016/j.colsurfb.2022.112650
   Fiamengui JF, 2013, CLEFT PALATE CRAN J, V50, P597, DOI 10.1597/11 193
   Fricker S P, 1999, Expert Opin Investig Drugs, V8, P1209, DOI 10.1517/13543784.8.8.1209
   de Frutos AG, 2020, SPINE J, V20, P1899, DOI 10.1016/j.spinee.2020.07.014
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Gauthier O, 1999, J BIOMED MATER RES, V47, P28, DOI 10.1002/(SICI)1097 4636(199910)47:1<28::AID JBM4>3.0.CO;2 P
   Ghorbani F, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01863 y
   Götz W, 2012, ANN ANAT, V194, P171, DOI 10.1016/j.aanat.2011.10.002
   He WF, 2022, FASEB J, V36, DOI 10.1096/fj.202101577RR
   Hsiao HY, 2019, DALTON T, V48, P9431, DOI 10.1039/c9dt00777f
   Huang HW, 2018, J BIOL INORG CHEM, V23, P775, DOI 10.1007/s00775 018 1569 1
   Huang SS, 2020, ACS APPL MATER INTER, V12, P28952, DOI 10.1021/acsami.0c04080
   Ignarro L.J., 2000, NITRIC OXIDE BIOL PA
   Jensen SS, 2009, J BIOMED MATER RES B, V90B, P171, DOI 10.1002/jbm.b.31271
   Jiang YQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc3513
   Kalyanaraman H, 2018, NITRIC OXIDE BIOL CH, V76, P62, DOI 10.1016/j.niox.2018.03.007
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Laurent Q, 2021, JACS AU, V1, P710, DOI 10.1021/jacsau.1c00128
   Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867
   Majumder S, 2014, NITRIC OXIDE BIOL CH, V36, P76, DOI 10.1016/j.niox.2013.12.002
   Marçal FF, 2019, OR SURG OR MED OR PA, V128, P621, DOI 10.1016/j.oooo.2019.07.001
   Miron RJ, 2011, J DENT RES, V90, P1428, DOI 10.1177/0022034511422718
   Miron RJ, 2013, CLIN IMPLANT DENT R, V15, P481, DOI 10.1111/j.1708 8208.2012.00440.x
   Park J, 2020, NAT NANOTECHNOL, V15, P690, DOI 10.1038/s41565 020 0701 x
   Pokidova OV, 2020, DALTON T, V49, P12674, DOI 10.1039/d0dt02452j
   Rangaswami H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001423
   Saulacic N, 2015, CLIN ORAL IMPLAN RES, V26, P383, DOI 10.1111/clr.12357
   Schairer DO, 2012, VIRULENCE, V3, P271, DOI 10.4161/viru.20328
   Sharmin F, 2019, J BIOMED MATER RES B, V107, P1002, DOI 10.1002/jbm.b.34193
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Sung YC, 2019, NAT NANOTECHNOL, V14, P1160, DOI 10.1038/s41565 019 0570 3
   Wagner JM, 2019, J MOL MED, V97, P1439, DOI 10.1007/s00109 019 01822 9
   Waller T, 2020, CLIN ORAL IMPLAN RES, V31, P517, DOI 10.1111/clr.13588
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Wu CR, 2021, JACS AU, V1, P998, DOI 10.1021/jacsau.1c00160
   Xie HX, 2016, CERAM INT, V42, P2386, DOI 10.1016/j.ceramint.2015.10.036
   Xu TP, 2022, SMALL, V18, DOI 10.1002/smll.202200314
   Yan JL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02425 z
   Yang L, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800155
   Yang QH, 2020, SMALL, V16, DOI 10.1002/smll.201906814
   Yang YH, 2021, SMALL, V17, DOI 10.1002/smll.202006598
   Ye J, 2021, ACS NANO, V15, P13692, DOI 10.1021/acsnano.1c04974
   Hong YH, 2022, ACS APPL MATER INTER, V14, P3849, DOI 10.1021/acsami.1c21409
   Zhang PJ, 2020, ACS APPL MATER INTER, V12, P18319, DOI 10.1021/acsami.0c01792
   Zhao YD, 2000, BIOCHEMISTRY US, V39, P10848, DOI 10.1021/bi9929296
   Zhao YZ, 2022, J CONTROL RELEASE, V350, P93, DOI 10.1016/j.jconrel.2022.08.018
NR 61
TC 5
Z9 6
U1 2
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD AUG 24
PY 2023
VL 11
IS 33
BP 8007
EP 8019
DI 10.1039/d3tb00587a
EA JUL 2023
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA X7P5S
UT WOS:001041460900001
PM 37530140
DA 2025 08 17
ER

PT J
AU Hsu, CP
   Maddox, J
   Block, G
   Bartley, Y
   Yu, ZG
AF Hsu, Cheng Pang
   Maddox, Judy
   Block, Geoffrey
   Bartley, Yessenia
   Yu, Zhigang
TI Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and
   Safety of a Single Dose of Romosozumab
SO JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE biologics; clinical trial; pharmacodynamics; pharmacokinetics and drug
   metabolism; renal disease
ID POSTMENOPAUSAL WOMEN; SCLEROSTIN; OSTEOPOROSIS; FRACTURE; DISEASE; RISK
AB We evaluated the pharmacokinetics, pharmacodynamics, and safety of a single subcutaneous dose of romosozumab 210 mg, a monoclonal antibody against sclerostin, in an open label, parallel group study in participants with severe (stage 4) renal impairment (RI; n = 8) or end stage renal disease requiring hemodialysis (ESRD RH; n = 8), or healthy participants with normal renal function (n = 8). Compared with the group with normal renal function, the mean romosozumab exposure was 31% and 43% higher as measured by maximum observed serum concentration and area under the concentration time curve, respectively, in the severe RI group and similar to those in the ESRD RH group. For all 3 groups, the maximum mean percent increase in procollagen type 1 N terminal propeptide and decrease in serum C telopeptide levels from baseline were observed on day 15. Changes in procollagen type 1 N terminal propeptide and serum C telopeptide were of similar patterns in all 3 groups. The single dose of romosozumab 210 mg was well tolerated. Adverse events (AEs) were reported for 13 patients (7 patients with severe RI and 6 with ESRD RH), with no deaths, AEs, or serious AEs leading to withdrawal. The incidence of subjects with postbaseline transient decreases in serum calcium (severe RI, n = 1; ESRD RH, n = 5) and increases in intact parathyroid hormone (severe RI, n = 7; ESRD RH, n = 7; healthy, n = 3) were greater in severe RI and ESRD RH groups than in the healthy group. All reported events of hypocalcemia (severe RI, n = 1; ESRD RH, n = 4) were asymptomatic. These results support the use of romosozumab without dose adjustment in patients with severe RI or ESRD RH.
C1 [Hsu, Cheng Pang; Maddox, Judy; Bartley, Yessenia; Yu, Zhigang] Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
   [Block, Geoffrey] US Renal Care Inc, Plano, TX USA.
C3 Amgen
RP Hsu, CP (通讯作者)，Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.
EM chengh@amgen.com
FU Amgen Inc.; Astellas Pharma Inc.; UCB Pharma
FX The study was funded by Amgen Inc., Astellas Pharma Inc., and UCB
   Pharma.
CR Akaberi S, 2008, AM J TRANSPLANT, V8, P2647, DOI 10.1111/j.1600 6143.2008.02423.x
   Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523 1755.2000.00178.x
   Brandenburg VM, 2013, BMC NEPHROL, V14, DOI 10.1186/1471 2369 14 219
   Cejka D, 2014, J CLIN ENDOCR METAB, V99, P248, DOI 10.1210/jc.2013 2786
   Cejka D, 2012, NEPHROL DIAL TRANSPL, V27, P226, DOI 10.1093/ndt/gfr270
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   de Oliveira RB, 2013, NEPHROL DIAL TRANSPL, V28, P2510, DOI 10.1093/ndt/gft234
   Drüeke TB, 2011, CLIN J AM SOC NEPHRO, V6, P700, DOI 10.2215/CJN.01370211
   Dukas L, 2005, OSTEOPOROSIS INT, V16, P1683, DOI 10.1007/s00198 005 1903 7
   EVENITY®, 2019, EVENITY ROM AQQG US
   EVENITY®, 2019, EVENITY ROM EU SUMM
   Gallant KMH, 2017, CURR OSTEOPOROS REP, V15, P214, DOI 10.1007/s11914 017 0368 x
   Graciolli FG, 2017, KIDNEY INT, V91, P1436, DOI 10.1016/j.kint.2016.12.029
   Kiyosumi R, 2020, NEPHROL DIAL TRANSPL, V35, P1722
   Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890
   Levey AS, 2006, ANN INTERN MED, V145, P247, DOI 10.7326/0003 4819 145 4 200608150 00004
   Lewiecki EM, 2018, J CLIN ENDOCR METAB, V103, P3183, DOI 10.1210/jc.2017 02163
   Miller P, 2020, ANN RHEUM DIS, V79, P185, DOI 10.1136/annrheumdis 2020 eular.4539
   Nishizawa Y, 2008, J BONE MINER METAB, V26, P265, DOI 10.1007/s00774 007 0826 0
   Padhi D, 2011, J BONE MINER RES, V26, P19, DOI 10.1002/jbmr.173
   Paglialunga S, 2017, EXPERT REV CLIN PHAR, V10, P273, DOI 10.1080/17512433.2017.1274651
   Pelletier S, 2013, CLIN J AM SOC NEPHRO, V8, P819, DOI 10.2215/CJN.07670712
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
NR 25
TC 17
Z9 18
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0091 2700
EI 1552 4604
J9 J CLIN PHARMACOL
JI J. Clin. Pharmacol.
PD SEP
PY 2022
VL 62
IS 9
BP 1132
EP 1141
DI 10.1002/jcph.2050
EA APR 2022
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 3I2TN
UT WOS:000777079700001
PM 35304747
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Docheva, D
   Padula, D
   Popov, C
   Mutschler, W
   Clausen Schaumann, H
   Schieker, M
AF Docheva, Denitsa
   Padula, Daniela
   Popov, Cvetan
   Mutschler, Wolf
   Clausen Schaumann, Hauke
   Schieker, Matthias
TI Researching into the cellular shape, volume and elasticity of
   mesenchymal stem cells, osteoblasts and osteosarcoma cells by atomic
   force microscopy
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE bone; mesenchymal stem cells (MSCs); osteoblasts (OBs); osteosarcoma;
   atomic force microscopy (AFM); Young's modulus; cytoskeleton; focal
   adhesion
ID BONE MARROW; VISCOELASTIC PROPERTIES; ADHESION; FIBROBLASTS; MORPHOLOGY;
   SENESCENCE; MECHANICS; EXPANSION; CULTURES; TENSION
AB Within the bone lie several different cell types, including osteoblasts (OBs) and mesenchymal stem cells (MSCs). The MSCs are ideal targets for regenerative medicine of bone due to their differentiation potential towards OBs. Human MSCs exhibit two distinct morphologies: rapidly self renewing cells (RS) and flat cells (FC) with very low proliferation rates. Another cell type found in pathological bone conditions is osteosarcoma. In this study, we compared the topographic and morphometric features of RS and FC cells, human OBs and MG63 osteosarcoma cells by atomic force microscopy (AFM). The results demonstrated clear differences: FC and hOB cells showed similar ruffled topography, whereas RS and MG63 cells exhibited smoother surfaces. Furthermore, we investigated how selected substrates influence cell morphometry. We found that RS and MG63 cells were flatter on fibrous substrates such as polystyrene and collagen I, but much more rounded on glass, the smoothest surface. In contrast, cells with large area, namely FC and hOB cells, did not exhibit pronounced changes in flatness with regards to the different substrates. They were, however, remarkably flatter in comparison to RS and MG63 cells. We could explain the differences in flatness by the extent of adhesion. Indeed, FC and hOB cells showed much higher content of focal adhesions. Finally, we used the AFM to determine the cellular Young's modulus. RS, FC and hOB cells showed comparable stiffness on the three different substrates, while MG63 cells demonstrated the unique feature of increased elasticity on collagen I. In summary, our results show, for the first time, a direct comparison between the morphometric and biophysical features of different human cell types derived from normal and pathological bone. Our study manifests the opinion that along with RNA, proteomic and functional research, morphological and biomechanical characterization of cells also reveals novel cell features and interrelationships.
C1 [Docheva, Denitsa; Padula, Daniela; Popov, Cvetan; Mutschler, Wolf; Schieker, Matthias] Univ Munich, Dept Surg, D 80336 Munich, Germany.
   [Padula, Daniela; Clausen Schaumann, Hauke] Munich Univ Appl Sci, Fac 06, Munich, Germany.
   [Clausen Schaumann, Hauke] Univ Munich, Ctr NanoSci, Munich, Germany.
C3 University of Munich; University of Munich; University of Munich
RP Schieker, M (通讯作者)，Univ Munich, Dept Surg, Nussbaumstr 20, D 80336 Munich, Germany.
EM Matthias.Schieker@med.uni muenchen.de
RI Popov, Cvetan/K 3851 2016; Schieker, Matthias/A 9583 2015; Schieker,
   Matthias/J 6511 2015; Docheva, Denitsa/R 1259 2018; Clausen Schaumann,
   Hauke/W 1830 2017
OI Popov, Cvetan/0000 0001 6578 6153; Schieker,
   Matthias/0000 0002 1230 3653; Docheva, Denitsa/0000 0002 7588 1290;
   Clausen Schaumann, Hauke/0000 0002 9413 0310
CR Andersen L Klembt, 2005, Eur Cell Mater, V10, P61
   Annaz B, 2004, J MICROSC OXFORD, V215, P100, DOI 10.1111/j.0022 2720.2004.01354.x
   Bacáková L, 2001, J BIOMED MATER RES, V54, P567
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Blonder J, 2006, EXPERT REV PROTEOMIC, V3, P483, DOI 10.1586/14789450.3.5.483
   Böcker W, 2007, J GENE MED, V9, P585, DOI 10.1002/jgm.1049
   BURGER W, 2005, DIGITALE BILDVERARBE, P429
   BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957 4484/6/1/001
   Clausen Schaumann H, 2000, CURR OPIN CHEM BIOL, V4, P524, DOI 10.1016/S1367 5931(00)00126 5
   Cohen MM, 2006, AM J MED GENET A, V140A, P2646, DOI 10.1002/ajmg.a.31368
   Collinsworth AM, 2002, AM J PHYSIOL CELL PH, V283, pC1219, DOI 10.1152/ajpcell.00502.2001
   Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   Costa KD, 2003, DIS MARKERS, V19, P139, DOI 10.1155/2004/482680
   Danti S, 2007, MACROMOL BIOSCI, V7, P589, DOI 10.1002/mabi.200600271
   Darling EM, 2006, OSTEOARTHR CARTILAGE, V14, P571, DOI 10.1016/j.joca.2005.12.003
   Darling EM, 2007, BIOPHYS J, V92, P1784, DOI 10.1529/biophysj.106.083097
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Docheva D, 2007, J CELL MOL MED, V11, P21, DOI 10.1111/j.1582 4934.2007.00001.x
   Domke J, 1998, LANGMUIR, V14, P3320, DOI 10.1021/la9713006
   Domke J, 2000, COLLOID SURFACE B, V19, P367, DOI 10.1016/S0927 7765(00)00145 4
   DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097 0142(19950101)75:1+<203::AID CNCR2820751308>3.0.CO;2 V
   Engel A, 2000, NAT STRUCT BIOL, V7, P715, DOI 10.1038/78929
   Franz CM, 2005, J CELL SCI, V118, P5315, DOI 10.1242/jcs.02653
   Haga H, 2000, ULTRAMICROSCOPY, V82, P253, DOI 10.1016/S0304 3991(99)00157 6
   HALLIDAY D, 2002, FUNDAMENTALS PHYS, P359
   HERTZ H, 1881, J REINE ANGEW MATH, V92, DOI [DOI 10.1515/CRLL.1882.92.156, 10.1515/crll.1882.92.156, DOI 10.1515/9783112342404 004]
   HOWARD J, 2001, MECH MOTOR PROTEINS, P148
   Huang GTJ, 2006, J ENDODONT, V32, P1066, DOI 10.1016/j.joen.2006.05.009
   Hutter JL, 2005, J MICROSC OXFORD, V219, P61, DOI 10.1111/j.1365 2818.2005.01497.x
   Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904
   Kidoaki S, 2007, J BIOMED MATER RES A, V81A, P803, DOI 10.1002/jbm.a.31114
   Krampera M, 2006, BONE, V39, P678, DOI 10.1016/j.bone.2006.04.020
   KUCHLING H, 2004, TASCHENBUCH PHYS, P625
   Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103
   Matzke R, 2001, NAT CELL BIOL, V3, P607, DOI 10.1038/35078583
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   Meyer U, 1998, J MATER SCI MATER M, V9, P301, DOI 10.1023/A:1008894612021
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Prockop DJ, 2001, CYTOTHERAPY, V3, P393, DOI 10.1080/146532401753277229
   Puech PH, 2006, ULTRAMICROSCOPY, V106, P637, DOI 10.1016/j.ultramic.2005.08.003
   Radmacher M, 2007, METHOD CELL BIOL, V83, P347, DOI 10.1016/S0091 679X(07)83015 9
   Rodríguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234
   Rotsch C, 2000, BIOPHYS J, V78, P520, DOI 10.1016/S0006 3495(00)76614 8
   Santos NC, 2004, BIOPHYS CHEM, V107, P133, DOI 10.1016/j.bpc.2003.09.001
   Schieker M, 2004, J ANAT, V204, P133, DOI 10.1111/j.1469 7580.2004.00252.x
   Schieker M., 2006, EUROPEAN J TRAUMA, V32, P114, DOI DOI 10.1007/S00068 006 6047 8
   Schieker M, 2007, J ANAT, V210, P592, DOI 10.1111/j.1469 7580.2007.00716.x
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Settleman J, 2004, MOL CELL, V14, P148, DOI 10.1016/S1097 2765(04)00207 2
   Shin D, 1999, J ORTHOP RES, V17, P880, DOI 10.1002/jor.1100170613
   Simon A, 2006, MICRON, V37, P1, DOI 10.1016/j.micron.2005.06.006
   Smith JR, 2004, STEM CELLS, V22, P823, DOI 10.1634/stemcells.22 5 823
   Sneddon I. N., 1965, INT J ENG SCI, V3, P47, DOI DOI 10.1016/0020 7225(65)90019 4
   Takai E, 2005, ANN BIOMED ENG, V33, P963, DOI 10.1007/s10439 005 3555 3
   Tataria M, 2006, J PEDIATR SURG, V41, P624, DOI 10.1016/j.jpedsurg.2005.12.001
   Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005 0620
   Valabrega G, 2003, BRIT J CANCER, V88, P396, DOI 10.1038/sj.bjc.6600735
   Wang YK, 2003, J BIOL CHEM, V278, P21886, DOI 10.1074/jbc.M300092200
   Yeo EJ, 2000, EXP GERONTOL, V35, P553, DOI 10.1016/S0531 5565(00)00108 X
   Yourek G, 2007, ASAIO J, V53, P219, DOI 10.1097/MAT.0b013e31802deb2d
   Zamir E, 2001, J CELL SCI, V114, P3583
NR 62
TC 173
Z9 202
U1 2
U2 65
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD APR
PY 2008
VL 12
IS 2
BP 537
EP 552
DI 10.1111/j.1582 4934.2007.00138.x
PG 16
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 289NG
UT WOS:000255060600013
PM 18419596
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Belsing, TZ
   Tofteng, C
   Langdahl, BL
   Charles, P
   Feldt Rasmussen, U
AF Belsing, Tina Z.
   Tofteng, Charlotte
   Langdahl, Bente L.
   Charles, Peder
   Feldt Rasmussen, Ulla
TI Can bone loss be reversed by antithyroid drug therapy in premenopausal
   women with Graves' disease?
SO NUTRITION & METABOLISM
LA English
DT Article
ID THYROID STIMULATING HORMONE; TSH RECEPTOR ANTIBODIES; MINERAL DENSITY;
   FRACTURE RISK; HYPERTHYROID PATIENTS; NEGATIVE CORRELATION; LONGITUDINAL
   CHANGES; THYROTOXIC PATIENTS; HUMAN OSTEOBLAST; TURNOVER
AB Context: Hyperthyroidism can lead to reduced bone mineral density (BMD) and increased fracture risk particularly in postmenopausal women, but the mechanism behind is still unclear.
   Objective: Prospective examination of the influence of thyroid hormones and/or thyroid autoantibodies on BMD in premenopause.
   Design: We have examined 32 premenopausal women with untreated active Graves' disease from time of diagnosis, during 18 months of antithyroid drug therapy (ATD) and additionally 18 months after discontinuing ATD. Variables of thyroid metabolism, calcium homeostasis and body composition were measured every 3 months. BMD of lumbar spine and femoral neck were measured at baseline, 18 +/  3 and 36 +/  3 months. Data were compared to base line, a sex and age matched control group and a group of patients with Hashimoto's thyroiditis treated with non suppressive doses of levothyroxine.
   Results: The study showed significantly (p < 0.002) lower BMD in the thyrotoxic state compared to the control group with subsequent significant improvement during 18 +/  3 months of ATD compared to baseline (p < 0.001). However, during the following 18 months after stopping ATD femoral neck BMD decreased again unrelated to age (more than 0.4% per year, p < 0,002). The wellestablished effect of thyrotoxicosis on calcium homeostasis was confirmed. The positive predictor for best BMD was TSH receptor antibodies (TRAb) while free T4 correlated negatively in the thyrotoxic female Graves' patients (p < 0.02 and p < 0.003). In healthy controls and patients with treated Graves' disease both TSH and T4 correlated negatively to the bone mass (BMC) (p < 0.003).
   Conclusion: The results indicated a clinically relevant impact of thyroid function on bone modulation also in premenopausal women with Graves' disease, and further indicated the possibility for a direct action of TRAb on bones.
C1 [Belsing, Tina Z.; Tofteng, Charlotte; Feldt Rasmussen, Ulla] Rigshosp, Natl Univ Hosp, Dept Endocrinol, DK 2100 Copenhagen, Denmark.
   [Langdahl, Bente L.; Charles, Peder] Aarhus Univ Hosp, Dept Endocrinol, DK 8000 Aarhus, Denmark.
C3 University of Copenhagen; Copenhagen University Hospital;
   Rigshospitalet; Aarhus University
RP Feldt Rasmussen, U (通讯作者)，Rigshosp, Natl Univ Hosp, Dept Endocrinol, DK 2100 Copenhagen, Denmark.
EM ufeldt@rh.dk
RI Feldt Rasmussen, Ulla/AAB 9218 2021
FU Agnes and Knut Morks Fund; Jacob Madsen and Olga Madsens Fund; Novo
   Nordic Foundation; Danish Hospital Foundation for Medical Research of
   Copenhagen; Faroe Islands and Greenland, Christenson Ceson Family Fund;
   Hernoe Family Fund; Danish Medical Association; Arvid Nilsson's and the
   Clinical Research Foundation; University of Copenhagen
FX Lisbeth Kirkegaard, Betty Fischer and Mathilde Brandt are thanked for
   excellent technical assistance in handling the patient samples, DXA
   scans and measurements of thyroid hormones, thyroid autoantibodies
   (TRAb) and calcium. We also thank Dr. pharm. Mimi Hoier Madsen for
   measuring anti thyroperoxidase (anti TPO), and Brahms Diagnostic for
   providing the TRAB (R) and anti TPO kits. This work received financial
   support from Agnes and Knut Morks Fund, Jacob Madsen and Olga Madsens
   Fund, the Novo Nordic Foundation, Danish Hospital Foundation for Medical
   Research of Copenhagen, The Faroe Islands and Greenland,
   Christenson Ceson Family Fund, Hernoe Family Fund, The Danish Medical
   Association Research Fund, Arvid Nilsson's and the Clinical Research
   Foundation, University of Copenhagen.
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Abu EO, 1997, BONE, V21, P137, DOI 10.1016/S8756 3282(97)00097 5
   Acotto CG, 2004, J CLIN DENSITOM, V7, P201, DOI 10.1385/JCD:7:2:201
   [Anonymous], 2003, THYROID, V13, P3
   Bassett JHD, 2007, MOL ENDOCRINOL, V21, P1095, DOI 10.1210/me.2007 0033
   Brandi L, 2002, NEPHROL DIAL TRANSPL, V17, P829, DOI 10.1093/ndt/17.5.829
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   DAUGAARD H, 1988, AM J PHYSIOL, V254, pE740, DOI 10.1152/ajpendo.1988.254.6.E740
   DEGROOT LJ, 2000, THYROID ITS DIS
   DIAMOND T, 1994, ANN INTERN MED, V120, P8, DOI 10.7326/0003 4819 120 1 199401010 00002
   ERIKSEN EF, 1985, BONE, V6, P421, DOI 10.1016/8756 3282(85)90218 2
   Feldt Rasmussen U, 1991, Autoimmunity, V9, P245, DOI 10.3109/08916939109007650
   Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003 4819 130 9 199905040 00016
   Grimnes G, 2008, THYROID, V18, P1147, DOI 10.1089/thy.2008.0158
   Hanson J, 1997, J BONE MINER RES, V12, P1316, DOI 10.1359/jbmr.1997.12.8.1316
   Jodar E, 1997, J CLIN ENDOCR METAB, V82, P1989, DOI 10.1210/jc.82.6.1989
   Jodar E, 1997, CLIN ENDOCRINOL, V47, P279, DOI 10.1046/j.1365 2265.1997.2261041.x
   Karga H, 2004, CLIN ENDOCRINOL, V61, P466, DOI 10.1111/j.1365 2265.2004.02110.x
   Karga H, 2010, J BONE MINER METAB, V28, P35, DOI 10.1007/s00774 009 0098 y
   Klefter O, 2009, EUR J ENDOCRINOL, V161, P213, DOI 10.1530/EJE 09 0160
   Kumeda Y, 2000, J CLIN ENDOCR METAB, V85, P4157, DOI 10.1210/jc.85.11.4157
   Langdahl BL, 1996, BONE, V19, P557, DOI 10.1016/S8756 3282(96)00247 5
   LEE MS, 1990, J CLIN ENDOCR METAB, V70, P766, DOI 10.1210/jcem 70 3 766
   Leslie WD, 2008, BONE, V43, P667, DOI 10.1016/j.bone.2008.06.001
   Majima T, 2006, OSTEOPOROSIS INT, V17, P1103, DOI 10.1007/s00198 006 0091 4
   Massart C, 2001, CLIN CHIM ACTA, V304, P39, DOI 10.1016/S0009 8981(00)00385 5
   Morimura T, 2005, ENDOCRINOLOGY, V146, P2077, DOI 10.1210/en.2004 1432
   Morris MS, 2007, BONE, V40, P1128, DOI 10.1016/j.bone.2006.12.001
   MOSEKILDE L, 1977, ACTA ENDOCRINOL COP, V85, P515, DOI 10.1530/acta.0.0850515
   MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889 8529(18)30338 4
   Nielsen P K, 1994, Adv Perit Dial, V10, P99
   ROSEN CJ, 1992, J CLIN ENDOCR METAB, V75, P1531, DOI 10.1210/jc.75.6.1531
   Sampath TK, 2007, J BONE MINER RES, V22, P849, DOI 10.1359/JBMR.070302
   Schott M, 2000, HORM METAB RES, V32, P429, DOI 10.1055/s 2007 978666
   Siddiqi A, 1997, J CLIN ENDOCR METAB, V82, P753, DOI 10.1210/jc.82.3.753
   STEIGER P, 1995, CALCIFIED TISSUE INT, V57, P469, DOI 10.1007/BF00301953
   Sun L, 2006, ANN NY ACAD SCI, V1068, P309, DOI 10.1196/annals.1346.033
   Tsai JA, 2004, CALCIFIED TISSUE INT, V74, P486, DOI 10.1007/s00223 003 0108 3
   Vestergaard P, 2005, CALCIFIED TISSUE INT, V77, P139, DOI 10.1007/s00223 005 0068 x
   Vestergaard P, 2000, THYROID, V10, P341, DOI 10.1089/thy.2000.10.341
   Vestergaard P, 2003, THYROID, V13, P585, DOI 10.1089/105072503322238854
   Vestling L, 2002, IEEE MICROW WIREL CO, V12, P249, DOI 10.1109/LMWC.2002.801134
   Von Recklinghausen F., 1891, FIBROSE ODER DEFORMI, P1
   WAKASUGI M, 1993, CLIN ENDOCRINOL, V38, P283, DOI 10.1111/j.1365 2265.1993.tb01007.x
   WAKASUGI M, 1994, THYROID, V4, P179, DOI 10.1089/thy.1994.4.179
   Zimmermann Belsing T, 1998, CLIN ENDOCRINOL, V49, P589, DOI 10.1046/j.1365 2265.1998.00627.x
NR 46
TC 19
Z9 23
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743 7075
J9 NUTR METAB
JI Nutr. Metab.
PD SEP 1
PY 2010
VL 7
AR 72
DI 10.1186/1743 7075 7 72
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA 658LU
UT WOS:000282492300001
PM 20807449
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hawkes, CP
   Li, D
   Hakonarson, H
   Meyers, KE
   Thummel, KE
   Levine, MA
AF Hawkes, Colin Patrick
   Li, Dong
   Hakonarson, Hakon
   Meyers, Kevin E.
   Thummel, Kenneth E.
   Levine, Michael A.
TI CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D
   Inactivation in Patients With CYP24A1 Mutations
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID IDIOPATHIC INFANTILE HYPERCALCEMIA; DRUG INDUCED OSTEOMALACIA; THERAPY;
   KETOCONAZOLE; HEPATOTOXICITY; TUBERCULOSIS; GENE; D 3
AB Context: The P450 enzyme CYP24A1 is the principal inactivator of vitamin D metabolites. Biallelic loss of function mutations in CYP24A1 are associated with elevated serum levels of 1,25 dihydroxyvitamin D 3 with consequent hypercalcemia and hypercalciuria and represent the most common form of idiopathic infantile hypercalcemia (IIH). Current management strategies for this condition include a low calcium diet, reduced dietary vitamin D intake, and limited sunlight exposure. CYP3A4 is a P450 enzyme that inactivates many drugs and xenobiotics and may represent an alternative pathway for inactivation of vitamin D metabolites.
   Objective: Our goal was to determine if rifampin, a potent inducer of CYP3A4, can normalize mineral metabolism in patients with IIH due to mutations in CYP24A1.
   Methods: We treated two patients with IIH with daily rifampin (10 mg/kg/d, up to a maximum of 600 mg). Serum calcium, phosphorus, parathyroid hormone (PTH), liver, and adrenal function and vitamin D metabolites, as well as urinary calcium excretion, were monitored during treatment of up to 13 months.
   Results: Prior to treatment, both patients had hypercalcemia, hypercalciuria, and nephrocalcinosis with elevated serum 1,25 dihydroxyvitamin D 3 and suppressed serum PTH. Daily treatment with rifampin was well tolerated and led to normalization or improvement in all clinical and biochemical parameters.
   Conclusion: These observations suggest that rifampin induced overexpression of CYP3A4 provides an alternative pathway for inactivation of vitamin D metabolites in patients who lack CYP24A1 function.
C1 [Hawkes, Colin Patrick; Levine, Michael A.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
   [Hawkes, Colin Patrick] Natl Childrens Res Ctr, Dublin D12 V004, Ireland.
   [Li, Dong; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Gen, Philadelphia, PA 19104 USA.
   [Meyers, Kevin E.] Childrens Hosp Philadelphia, Div Nephrol, Philadelphia, PA 19104 USA.
   [Meyers, Kevin E.; Levine, Michael A.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Thummel, Kenneth E.] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98155 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; National Children's Research Centre (NCRC); University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; University of Washington;
   University of Washington Seattle
RP Levine, MA (通讯作者)，Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
EM levinem@chop.edu
RI Hakonarson, Hakon/ABZ 4865 2022; Hawkes, Colin/D 4223 2013; Levine,
   Michael/JED 8261 2023
OI Levine, Michael/0000 0003 0036 7809; Hawkes, Colin/0000 0001 6484 0445; 
FU National Institute of Diabetes and Digestive and Kidney Diseases [R01
   DK079970]; National Institutes of General Medical Sciences
   [R01GM063666]; National Center for Research Resources [UL1TR000003];
   National Center for Advancing Translational Sciences, National
   Institutes of Health; National Children's Research Centre, Dublin,
   Ireland
FX This work was supported in part by Grant R01 DK079970 from the National
   Institute of Diabetes and Digestive and Kidney Diseases (to M.A.L.); by
   Grant R01GM063666 from the National Institutes of General Medical
   Sciences (to K.E.T.); by Grant UL1TR000003 from the National Center for
   Research Resources and the National Center for Advancing Translational
   Sciences, National Institutes of Health; and by a PhD grant from the
   National Children's Research Centre, Dublin, Ireland (to C.P.H.). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIH.
CR Boeree MJ, 2015, AM J RESP CRIT CARE, V191, P1058, DOI 10.1164/rccm.201407 1264OC
   Bolland Mark J, 2008, Ann Clin Microbiol Antimicrob, V7, P3, DOI 10.1186/1476 0711 7 3
   BRESLAU NA, 1992, J CLIN ENDOCR METAB, V75, P1446, DOI 10.1210/jc.75.6.1446
   Castinetti F, 2014, J CLIN ENDOCR METAB, V99, P1623, DOI 10.1210/jc.2013 3628
   CREERY RDG, 1954, LANCET, V2, P110
   Dauber A, 2012, J CLIN ENDOCR METAB, V97, pE268, DOI 10.1210/jc.2011 1972
   Gigante M, 2016, NEPHRON, V133, P193, DOI 10.1159/000446663
   Kaufmann M, 2011, J BIOL CHEM, V286, P28729, DOI 10.1074/jbc.M111.236679
   KOLARS JC, 1992, J CLIN INVEST, V90, P1871, DOI 10.1172/JCI116064
   KYRIAZOPOULOU V, 1984, J CLIN ENDOCR METAB, V59, P1204, DOI 10.1210/jcem 59 6 1204
   Li D, 2016, J CLIN ENDOCR METAB, V101, P2196, DOI 10.1210/jc.2016 1211
   LIGHTWOOD R, 1953, LANCET, V265, P255
   Nesterova G, 2013, CLIN J AM SOC NEPHRO, V8, P649, DOI 10.2215/CJN.05360512
   Nguyen M, 2010, J PEDIATR US, V157, P296, DOI 10.1016/j.jpeds.2010.02.025
   Niwa T, 2005, BIOL PHARM BULL, V28, P1805, DOI 10.1248/bpb.28.1805
   Pentikis HS, 2007, PHARMACOTHERAPY, V27, P1361, DOI 10.1592/phco.27.10.1361
   Roizen J, ASBMR S BON OM TRANS
   Saukkonen JJ, 2006, AM J RESP CRIT CARE, V174, P935, DOI 10.1164/rccm.200510 1666ST
   Sayers J, 2015, CLIN KIDNEY J, V8, P453, DOI 10.1093/ckj/sfv028
   Schlingmann KP, 2011, NEW ENGL J MED, V365, P410, DOI 10.1056/NEJMoa1103864
   Tebben PJ, 2012, J CLIN ENDOCR METAB, V97, pE423, DOI 10.1210/jc.2011 1935
   Villarino ME, 1997, AM J RESP CRIT CARE, V155, P1735, DOI 10.1164/ajrccm.155.5.9154885
   Wang ZC, 2013, J BONE MINER RES, V28, P1101, DOI 10.1002/jbmr.1839
   Wang ZC, 2012, MOL PHARMACOL, V81, P498, DOI 10.1124/mol.111.076356
   Wang ZC, 2011, ANAL BIOCHEM, V418, P126, DOI 10.1016/j.ab.2011.06.043
   Wingard JR, 2005, CLIN INFECT DIS, V41, P308, DOI 10.1086/431595
   Xu Y, 2006, MOL PHARMACOL, V69, P56, DOI 10.1124/mol.105.017392
   Zanger UM, 2005, TOXICOL MECH METHOD, V15, P121, DOI 10.1080/15376520590918847
   Zhou SF, 2008, CURR DRUG METAB, V9, P310, DOI 10.2174/138920008784220664
NR 29
TC 60
Z9 61
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAY 1
PY 2017
VL 102
IS 5
BP 1440
EP 1446
DI 10.1210/jc.2016 4048
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA EW6IX
UT WOS:000402614700002
PM 28324001
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Takeuchi, K
   Abe, M
   Hiasa, M
   Oda, A
   Amou, H
   Kido, S
   Harada, T
   Tanaka, O
   Miki, H
   Nakamura, S
   Nakano, A
   Kagawa, K
   Yata, K
   Ozaki, S
   Matsumoto, T
AF Takeuchi, Kyoko
   Abe, Masahiro
   Hiasa, Masahiro
   Oda, Asuka
   Amou, Hiroe
   Kido, Shinsuke
   Harada, Takeshi
   Tanaka, Osamu
   Miki, Hirokazu
   Nakamura, Shingen
   Nakano, Ayako
   Kagawa, Kumiko
   Yata, Kenichiro
   Ozaki, Shuji
   Matsumoto, Toshio
TI TGF β Inhibition Restores Terminal Osteoblast Differentiation to
   Suppress Myeloma Growth
SO PLOS ONE
LA English
DT Article
ID INFLAMMATORY PROTEIN (MIP) 1 ALPHA; BONE MORPHOGENETIC PROTEIN 2; MARROW
   STROMAL CELLS; I RECEPTOR KINASE; RESISTANCE CAM DR; OSTEOLYTIC LESIONS;
   VICIOUS CYCLE; ACTIVATION; ADHESION; CANCER
AB Background: Multiple myeloma (MM) expands almost exclusively in the bone marrow and generates devastating bone lesions, in which bone formation is impaired and osteoclastic bone resorption is enhanced. TGF beta, a potent inhibitor of terminal osteoblast (OB) differentiation, is abundantly deposited in the bone matrix, and released and activated by the enhanced bone resorption in MM. The present study was therefore undertaken to clarify the role of TGF beta and its inhibition in bone formation and tumor growth in MM.
   Methodology/Principal Findings: TGF beta suppressed OB differentiation from bone marrow stromal cells and MC3T3 E1 preosteoblastic cells, and also inhibited adipogenesis from C3H10T1/2 immature mesenchymal cells, suggesting differentiation arrest by TGF beta. Inhibitors for a TGF beta type I receptor kinase, SB431542 and Ki26894, potently enhanced OB differentiation from bone marrow stromal cells as well as MC3T3 E1 cells. The TGF beta inhibition was able to restore OB differentiation suppressed by MM cell conditioned medium as well as bone marrow plasma from MM patients. Interestingly, TGF beta inhibition expedited OB differentiation in parallel with suppression of MM cell growth. The anti MM activity was elaborated exclusively by terminally differentiated OBs, which potentiated the cytotoxic effects of melphalan and dexamethasone on MM cells. Furthermore, TGF beta inhibition was able to suppress MM cell growth within the bone marrow while preventing bone destruction in MM bearing animal models.
   Conclusions/Significance: The present study demonstrates that TGF beta inhibition releases stromal cells from their differentiation arrest by MM and facilitates the formation of terminally differentiated OBs, and that terminally differentiated OBs inhibit MM cell growth and survival and enhance the susceptibility of MM cells to anti MM agents to overcome the drug resistance mediated by stromal cells. Therefore, TGF beta appears to be an important therapeutic target in MM bone lesions.
C1 [Takeuchi, Kyoko; Abe, Masahiro; Oda, Asuka; Amou, Hiroe; Kido, Shinsuke; Harada, Takeshi; Tanaka, Osamu; Miki, Hirokazu; Nakamura, Shingen; Nakano, Ayako; Kagawa, Kumiko; Yata, Kenichiro; Matsumoto, Toshio] Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 770, Japan.
   [Hiasa, Masahiro] Univ Tokushima, Grad Sch Oral Sci, Dept Biomat & Bioengn, Tokushima 770, Japan.
   [Ozaki, Shuji] Tokushima Univ Hosp, Div Transfus Med, Tokushima, Japan.
C3 Tokushima University; Tokushima University; Tokushima University
RP Takeuchi, K (通讯作者)，Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 770, Japan.
EM masabe@clin.med.tokushima u.ac.jp
RI 日浅, 雅博/S 1537 2019; Nakamura, Shingen/GPX 5438 2022; Abe,
   Masahiro/AAJ 3032 2021; Tanaka, Osamu/AAS 9252 2020
OI HIASA, MASAHIRO/0000 0002 4830 6274; 
FU Ministry of Education, Culture, Science and Sports of Japan; Ministry of
   Health, Labor and Welfare of Japan [17 16]
FX This work was supported in part by Grants in aid for Scientific Research
   (A) to T. M. and (C) to M. A., and for the 21st Century Center of
   Excellence Program from the Ministry of Education, Culture, Science and
   Sports of Japan, and a Grant in aid for Cancer Research (17 16) to M. A.
   from the Ministry of Health, Labor and Welfare of Japan. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   [Anonymous], J BONE MINERAL RES
   Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Choi SJ, 2001, J CLIN INVEST, V108, P1833, DOI 10.1172/JCI13116
   Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658
   Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776 004 0815 2
   Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood 2007 03 077685
   Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349 7006.2006.00357.x
   Giuliani N, 2007, CANCER RES, V67, P7665, DOI 10.1158/0008 5472.CAN 06 4666
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Guise TA, 2003, CLIN ORTHOP RELAT R, pS32, DOI 10.1097/01.blo.0000093055.96273.69
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Hashimoto T, 2004, BRIT J HAEMATOL, V125, P38, DOI 10.1111/j.1365 2141.2004.04864.x
   Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782
   Hiraga T, 2001, CANCER RES, V61, P4418
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Isufi I, 2007, J INTERF CYTOK RES, V27, P543, DOI 10.1089/jir.2007.0009
   Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315
   Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood 2007 11 124164
   Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067
   Matsumoto T, 2006, ANN NY ACAD SCI, V1068, P319, DOI 10.1196/annals.1346.035
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006 291X(89)92795 2
   Oshima T, 2005, BLOOD, V106, P3160, DOI 10.1182/blood 2004 12 4940
   OURSLER MJ, 1994, J BONE MINER RES, V9, P443
   Ozaki S, 2007, INT J HEMATOL, V86, P180, DOI 10.1532/IJH97.07030
   Pennisi A, 2006, BLOOD, V108, p154A
   Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359 6101(96)00048 2
   PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024
   PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P49, DOI 10.1002/jbmr.5650050109
   Qiang YW, 2008, BLOOD
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Spinella Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756 3282(01)00580 4
   Strobl H, 1999, MICROBES INFECT, V1, P1283, DOI 10.1016/S1286 4579(99)00256 7
   Suzawa M, 1999, ENDOCRINOLOGY, V140, P2125, DOI 10.1210/en.140.5.2125
   Tanaka Y, 2007, CLIN CANCER RES, V13, P816, DOI 10.1158/1078 0432.CCR 06 2258
   Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101
   Tassone P, 2005, BLOOD, V106, P713, DOI 10.1182/blood 2005 01 0373
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Yaccoby S, 2004, CANCER RES, V64, P2016, DOI 10.1158/0008 5472.CAN 03 1131
   Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood 2006 09 047712
   Yata K, 2004, LEUKEMIA, V18, P1891, DOI 10.1038/sj.leu.2403513
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
   Zangari M, 2006, CLIN LYMPHOMA MYELOM, V7, P109, DOI 10.3816/CLM.2006.n.047
NR 49
TC 109
Z9 118
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2010
VL 5
IS 3
AR e9870
DI 10.1371/journal.pone.0009870
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 574DS
UT WOS:000275969500009
PM 20360846
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Joshi, J
   Mahajan, G
   Kothapalli, CR
AF Joshi, Jyotsna
   Mahajan, Gautam
   Kothapalli, Chandrasekhar R.
TI Three dimensional collagenous niche and azacytidine selectively promote
   time dependent cardiomyogenesis from human bone marrow derived MSC
   spheroids
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE 5 azacytidine; atomic force microscopy; collagen gels; human bone
   marrow derived MSCs; myocardial infarction; Wnt signaling
ID MESENCHYMAL STEM CELLS; CARDIOMYOCYTES IN VITRO; CARDIAC REGENERATION;
   MYOCARDIAL REGENERATION; HEART DISEASE; THERAPY; DIFFERENTIATION;
   BIOMATERIALS; EXPRESSION; STIFFNESS
AB Endogenous adult cardiac regenerative machinery is not capable of replacing the lost cells following myocardial infarction, often leading to permanent alterations in structure function mechanical properties. Regenerative therapies based on delivering autologous stem cells within an appropriate 3D milieu could meet such demand, by enabling homing and directed differentiation of the transplanted cells into lost specialized cell populations. Since type I collagen is the predominant cardiac tissue matrix protein, we here optimized the 3D niche which could promote time dependent evolution of cardiomyogenesis from human bone marrow derived mesenchymal stem cells (BM MSC). 3D collagen gel physical and mechanical characteristics were assessed using SEM and AFM, respectively, while the standalone and combined effects of collagen concentration, culture duration, and 5 azacytidine (aza) dose on the phenotype and genotype of MSC spheroids were quantified using immunofluorescence labeling and RT PCR analysis. Increasing collagen concentration led to a significant increase in Young's modulus (p<0.01) but simultaneous decrease in the mean pore size, resulting in stiffer gels. Spheroid formation significantly modulated MSC differentiation and genotype, mostly due to better cell cell interactions. Among the aza dosages tested, 10M appears to be optimal, while 3mg/ml gels resulted in significantly lower cell viability compared to 1 or 2mg/ml gels. Stiffer gels (2 and 3mg/ml) and exposure to 10M aza upregulated early and late cardiac marker expressions in a time dependent fashion. On the other hand, cell cell signaling within the MSC spheroids seem to have a strong role in influencing mature cardiac markers expression, since neither aza nor gel stiffness seem to significantly improve their expression. Western blot analysis suggested that canonical Wnt/ catenin signaling pathway might be primarily mediating the observed benefits of aza on cardiac differentiation of MSC spheroids. In conclusion, 2mg/ml collagen and 10M aza appears to offer optimal 3D microenvironment in terms of cell viability and time dependent evolution of cardiomyogenesis from human BM MSCs, with significant applications in cardiac tissue engineering and stem cell transplantation for regenerating lost cardiac tissue.
C1 [Joshi, Jyotsna; Mahajan, Gautam; Kothapalli, Chandrasekhar R.] Cleveland State Univ, Dept Chem & Biomed Engn, 2121 Euclid Ave,FH 460, Cleveland, OH 44115 USA.
C3 University System of Ohio; Cleveland State University
RP Kothapalli, CR (通讯作者)，Cleveland State Univ, Dept Chem & Biomed Engn, 2121 Euclid Ave,FH 460, Cleveland, OH 44115 USA.
EM c.kothapalli@csuohio.edu
RI Mahajan, Gautam/AAE 1388 2020
OI Mahajan, Gautam/0000 0001 9892 0996
FU NSF CBET [1337859]; NSF DMR [1126126]; Direct For Mathematical &
   Physical Scien; Division Of Materials Research [1126126] Funding Source:
   National Science Foundation; Div Of Chem, Bioeng, Env, & Transp Sys;
   Directorate For Engineering [1337859] Funding Source: National Science
   Foundation
FX NSF CBET, Grant number: 1337859 Cellular and Molecular Medicine
   Specialization fellowship at CSU; NSF DMR, Grant number: 1126126
CR Arnal Pastor M, 2013, REGENERATIVE MEDICINE AND TISSUE ENGINEERING, P275, DOI 10.5772/56076
   Arshi A, 2013, SCI TECHNOL ADV MAT, V14, DOI 10.1088/1468 6996/14/2/025003
   Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107
   Bayomy AF, 2012, LIFE SCI, V91, P823, DOI 10.1016/j.lfs.2012.08.034
   Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680
   Carvalho PH, 2013, ARQ BRAS CARDIOL, V100, P82, DOI 10.1590/S0066 782X2012005000114
   Cesarz Z, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9176357
   Chen QZ, 2008, MAT SCI ENG R, V59, P1, DOI 10.1016/j.mser.2007.08.001
   Cho J, 2009, J BIOL CHEM, V284, P36647, DOI 10.1074/jbc.M109.019109
   Doppler SA, 2013, J THORAC DIS, V5, P683, DOI 10.3978/j.issn.2072 1439.2013.08.71
   Forte G, 2012, TISSUE ENG PT A, V18, P1837, DOI [10.1089/ten.tea.2011.0707, 10.1089/ten.TEA.2011.0707]
   Gishto A, 2015, J BIOMED MATER RES A, V103, P693, DOI 10.1002/jbm.a.35217
   Gnecchi M, 2012, VASC PHARMACOL, V57, P48, DOI 10.1016/j.vph.2012.04.002
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   Hafez P, 2016, CELL BIOL INT, V40, P55, DOI 10.1002/cbin.10536
   Hazeltine Laurie B, 2012, Int J Cell Biol, V2012, P508294, DOI 10.1155/2012/508294
   Hosoda T, 2012, AM J CARDIOVASC DIS, V2, P58
   Hou J, 2013, CELL BIOL INT, V37, P1291, DOI 10.1002/cbin.10161
   Jadczyk T, 2013, BRIT J PHARMACOL, V169, P247, DOI 10.1111/j.1476 5381.2012.01965.x
   Joshi J, 2015, CURR PHARM DESIGN, V21, P2006, DOI 10.2174/1381612821666150302153138
   Karam JP, 2012, BIOMATERIALS, V33, P5683, DOI 10.1016/j.biomaterials.2012.04.028
   Karantalis V, 2012, AM J PHYSIOL HEART C, V303, pH256, DOI 10.1152/ajpheart.00221.2012
   Koyanagi M, 2007, CIRC RES, V101, P1139, DOI 10.1161/CIRCRESAHA.107.151381
   Lakshmanan R, 2012, EXPERT OPIN BIOL TH, V12, P1623, DOI 10.1517/14712598.2012.721770
   Lee B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111896
   Li ZQ, 2011, POLYMERS BASEL, V3, P740, DOI 10.3390/polym3020740
   Lopez Garcia MDC, 2010, BIO MED MATER ENG, V20, P361, DOI 10.3233/BME 2010 0649
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Martin Rendon E, 2008, VOX SANG, V95, P137, DOI 10.1111/j.1423 0410.2008.01076.x
   McMullen NM, 2007, CAN J PHYSIOL PHARM, V85, P1, DOI 10.1139/Y06 105
   Parenteau Bareil R, 2010, MATERIALS, V3, P1863, DOI 10.3390/ma3031863
   PELOUCH V, 1993, MOL CELL BIOCHEM, V129, P101, DOI 10.1007/BF00926359
   Perino MG, 2008, J MOL CELL CARDIOL, V45, P475, DOI 10.1016/j.yjmcc.2008.05.002
   Peterkin T, 2005, SEMIN CELL DEV BIOL, V16, P83, DOI 10.1016/j.semcdb.2004.10.003
   Piryaei A, 2015, CELL BIOL INT, V39, P519, DOI 10.1002/cbin.10421
   Potapova IA, 2008, AM J PHYSIOL HEART C, V295, pH2257, DOI 10.1152/ajpheart.00219.2008
   Qiu YL, 2015, AM J PHYSIOL HEART C, V308, pH990, DOI 10.1152/ajpheart.00935.2014
   Ruan Zhong Bao, 2010, Indian J Med Sci, V64, P402
   Russo V, 2014, BIOMATERIALS, V35, P3956, DOI 10.1016/j.biomaterials.2014.01.075
   Sart S, 2014, TISSUE ENG PART B RE, V20, P365, DOI [10.1089/ten.TEB.2013.0537, 10.1089/ten.teb.2013.0537]
   Sehnert AJ, 2002, NAT GENET, V31, P106, DOI 10.1038/ng875
   Seo HH, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0348 6
   Simmers P, 2015, TISSUE ENG PT A, V21, P1455, DOI [10.1089/ten.tea.2014.0363, 10.1089/ten.TEA.2014.0363]
   Thiene G, 2010, CARDIOVASC PATHOL, V19, P1, DOI 10.1016/j.carpath.2009.08.002
   Valiente Alandi I, 2016, J MOL CELL CARDIOL, V91, P228, DOI 10.1016/j.yjmcc.2016.01.011
   Wang F, 2010, ADV DRUG DELIVER REV, V62, P784, DOI 10.1016/j.addr.2010.03.001
   Yang YL, 2009, BIOPHYS J, V97, P2051, DOI 10.1016/j.bpj.2009.07.035
   Young JL, 2014, SCI REP UK, V4, DOI 10.1038/srep06425
   Zimmermann WH, 2006, CARDIOVASC RES, V71, P419, DOI 10.1016/j.cardiores.2006.03.023
NR 49
TC 33
Z9 42
U1 1
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0006 3592
EI 1097 0290
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD AUG
PY 2018
VL 115
IS 8
BP 2013
EP 2026
DI 10.1002/bit.26714
PG 14
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA GM8PK
UT WOS:000438494300012
PM 29665002
DA 2025 08 17
ER

PT J
AU Dachs, E
   Piedrafita, L
   Hereu, M
   Esquerda, JE
   Calderó, J
AF Dachs, E.
   Piedrafita, L.
   Hereu, M.
   Esquerda, J. E.
   Caldero, J.
TI CHRONIC TREATMENT WITH LITHIUM DOES NOT IMPROVE NEUROMUSCULAR PHENOTYPE
   IN A MOUSE MODEL OF SEVERE SPINAL MUSCULAR ATROPHY
SO NEUROSCIENCE
LA English
DT Article
DE lithium; spinal muscular atrophy; SMN Delta 7 mouse; spinal cord;
   skeletal muscle; GSK 3 beta
ID AMYOTROPHIC LATERAL SCLEROSIS; MOTOR NEURON PROTEIN; INCREASES SMN
   EXPRESSION; CENTRAL NERVOUS SYSTEM; WNT SIGNALING PATHWAY;
   SKELETAL MUSCLE; DISEASE PROGRESSION; 2,4 DIAMINOQUINAZOLINE
   DERIVATIVES; SELECTIVE VULNERABILITY; NEUROTROPHIC FACTOR
AB Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by defective levels of the survival motor neuron (SMN) protein. SMA causes spinal motoneuron (MN) loss, and progressive muscle weakness and paralysis. Currently, there is no effective therapy to cure this disease. Although different strategies focused on increasing the expression of functional SMN protein have been assayed, numerous SMN independent therapeutic approaches have been demonstrated to have potential effectiveness in improving the SMA phenotype in mouse models and clinical trials. Recent works have shown that compounds which inhibit GSK 3 beta activity are effective in promoting MN survival and ameliorating lifespan in models of MN diseases including SMA. Taking into account the reported neuroprotective actions of lithium (Li) through the inhibition of GSK 3 beta in different studies, we tested here its potential efficiency as a therapeutic agent in a mouse model of severe SMA (SMN Delta 7 mice). We show that the chronic treatment with Li initiated before the appearance of disease symptoms, although inhibited GSK 3 beta, did not improve the median survival, motor behavior, and spinal MN loss linked to SMA. Li administration did not either ameliorate the microglial and astroglial reaction in the spinal cord or the depletion of glutamatergic synapses on MNs observed in SMN Delta 7 animals. Moreover, Li treatment did not mitigate muscle atrophy or calcitonin gene related peptide (CGRP) downregulation in the neuromuscular junctions linked to the disease. However, a significant reduction in apoptotic cell death found in the skeletal muscle of SMA mice was observed after Li treatment. (c) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Caldero, J.] Univ Lleida, Fac Med, Dept Expt Med, Unitat Neurobiol Cellular, Lleida 25198, Catalonia, Spain.
   Inst Recerca Biomed Lleida IRBLLEIDA, Lleida 25198, Catalonia, Spain.
C3 Universitat de Lleida; Institut de Recerca Biomedica   IRB Lleida
RP Calderó, J (通讯作者)，Univ Lleida, Fac Med, Dept Expt Med, Unitat Neurobiol Cellular, Av Rovira Roure 80, Lleida 25198, Catalonia, Spain.
EM jordi.caldero@mex.udl.cat
RI Dachs Cabanas, Elisabet/F 7636 2015; Caldero, Jordi/A 7373 2010;
   Dachs Cabanas, Elisabet/F 7636 2015; Esquerda, Josep/A 7377 2010;
   Llorens, Lídia/C 6394 2011; Esquerda, Josep E/A 7377 2010; Calderó,
   Jordi/A 7373 2010
OI Dachs Cabanas, Elisabet/0000 0001 6969 0626; Caldero,
   Jordi/0000 0003 1972 0115; Piedrafita Llorens,
   Lidia/0000 0001 8151 7447; Esquerda, Josep E/0000 0003 1413 2103; 
FU Ministerio de Ciencia y Tecnologia; Ministerio de Economia y
   Competitividad; FEDER [SAF2009 07166, SAF2011 22908;, SAF2012 31831]
FX We thank Ronald W. Oppenheim for critical reading of the manuscript and
   for helpful comments and suggestions. We also thank Olga Tarabal and
   Anna Casanovas for useful discussions, Montse Ortega for her technical
   assistance, and Francisco Correa, Neus Montull, Claudia Cervero, Laercio
   Moreira Cardoso and Maria Caldero for their help in some experiments of
   this study. This work was supported by grants from the Ministerio de
   Ciencia y Tecnologia and Ministerio de Economia y Competitividad
   financed jointly with FEDER (SAF2009 07166; SAF2011 22908;
   SAF2012 31831).
CR Aggarwal SP, 2010, LANCET NEUROL, V9, P481, DOI 10.1016/S1474 4422(10)70068 5
   Ahmad S, 2012, HUM MOL GENET, V21, P2745, DOI 10.1093/hmg/dds102
   Ahn SW, 2012, J NEUROL SCI, V320, P1, DOI 10.1016/j.jns.2012.05.038
   Andreassi C, 2004, EUR J HUM GENET, V12, P59, DOI 10.1038/sj.ejhg.5201102
   Avila AM, 2007, J CLIN INVEST, V117, P659, DOI 10.1172/JCI29562
   Azzouz M, 2004, J CLIN INVEST, V114, P1726, DOI 10.1172/JCI200422922
   Baughan TD, 2009, HUM MOL GENET, V18, P1600, DOI 10.1093/hmg/ddp076
   Benkhelifa Ziyyat S, 2013, MOL THER, V21, P282, DOI 10.1038/mt.2012.261
   Bhat RV, 2004, J NEUROCHEM, V89, P1313, DOI 10.1111/j.1471 4159.2004.02422.x
   Biondi O, 2008, J NEUROSCI, V28, P953, DOI 10.1523/JNEUROSCI.3237 07.2008
   Biondi O, 2010, J NEUROSCI, V30, P11288, DOI 10.1523/JNEUROSCI.1764 10.2010
   Bosch Marcé M, 2011, HUM MOL GENET, V20, P1844, DOI 10.1093/hmg/ddr067
   Bowerman M, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 24
   Bowerman M, 2010, HUM MOL GENET, V19, P1468, DOI 10.1093/hmg/ddq021
   Brahe C, 2005, EUR J HUM GENET, V13, P256, DOI 10.1038/sj.ejhg.5201320
   Brichta L, 2003, HUM MOL GENET, V12, P2481, DOI 10.1093/hmg/ddg256
   Burghes AHM, 2009, NAT REV NEUROSCI, V10, P597, DOI 10.1038/nrn2670
   Butchbach MER, 2010, HUM MOL GENET, V19, P454, DOI 10.1093/hmg/ddp510
   Calderó J, 2010, NEUROSCIENCE, V165, P1353, DOI 10.1016/j.neuroscience.2009.11.034
   Caspi M, 2008, ONCOGENE, V27, P3546, DOI 10.1038/sj.onc.1211026
   Chalecka Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745
   Chang JG, 2001, P NATL ACAD SCI USA, V98, P9808, DOI 10.1073/pnas.171105098
   Chen PC, 2012, ACS CHEM NEUROSCI, V3, P5, DOI 10.1021/cn200085z
   Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039
   Chen YC, 2012, NEUROL RES, V34, P390, DOI 10.1179/1743132812Y.0000000027
   Chen YC, 2012, BIOCHEM BIOPH RES CO, V420, P397, DOI 10.1016/j.bbrc.2012.03.006
   Chiò A, 2010, NEUROLOGY, V75, P619, DOI 10.1212/WNL.0b013e3181ed9e7c
   Chuang DM, 2007, BIOL PSYCHIAT, V62, P4, DOI 10.1016/j.biopsych.2007.04.008
   Chuang DM, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00015
   Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399 5618.2002.01179.x
   Cifuentes Diaz C, 2001, J CELL BIOL, V152, P1107, DOI 10.1083/jcb.152.5.1107
   CLARKE PGH, 1995, METHOD CELL BIOL, V46, P277
   Coady TH, 2010, J NEUROSCI, V30, P126, DOI 10.1523/JNEUROSCI.4489 09.2010
   Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205
   Corti S, 2008, J CLIN INVEST, V118, P3316, DOI 10.1172/JCI35432
   Corti S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004108
   Corti S, 2010, BRAIN, V133, P465, DOI 10.1093/brain/awp318
   Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896 6273(03)00195 8
   Dachs E, 2011, J NEUROPATH EXP NEUR, V70, P444, DOI 10.1097/NEN.0b013e31821cbd8b
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499
   Dominguez E, 2011, HUM MOL GENET, V20, P681, DOI 10.1093/hmg/ddq514
   Dou HY, 2005, J NEUROSCI, V25, P8375, DOI 10.1523/JNEUROSCI.2164 05.2005
   El Khodor BF, 2008, EXP NEUROL, V212, P29, DOI 10.1016/j.expneurol.2008.02.025
   Feldkötter M, 2002, AM J HUM GENET, V70, P358, DOI 10.1086/338627
   Feng HL, 2008, NEUROSCIENCE, V155, P567, DOI 10.1016/j.neuroscience.2008.06.040
   Ferrucci M, 2010, NEUROBIOL DIS, V37, P370, DOI 10.1016/j.nbd.2009.10.017
   FIDZIANSKA A, 1990, BRAIN, V113, P433, DOI 10.1093/brain/113.2.433
   Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105
   Foust KD, 2010, NAT BIOTECHNOL, V28, P271, DOI 10.1038/nbt.1610
   Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515
   FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092 8674(95)90534 0
   Gill A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006489
   Glascock JJ, 2012, BIOCHEM BIOPH RES CO, V417, P376, DOI 10.1016/j.bbrc.2011.11.121
   Gogliotti RG, 2012, J NEUROSCI, V32, P3818, DOI 10.1523/JNEUROSCI.5775 11.2012
   Gowing G, 2011, NEUROTHERAPEUTICS, V8, P591, DOI 10.1007/s13311 011 0068 7
   Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200
   Guettier Sigrist S, 2002, MUSCLE NERVE, V25, P700, DOI 10.1002/mus.10081
   Haddad H, 2003, MUSCLE NERVE, V28, P432, DOI 10.1002/mus.10455
   Harwood AJ, 2003, BIOCHEM PHARMACOL, V66, P179, DOI 10.1016/S0006 2952(03)00187 4
   Hashimoto R, 2002, NEUROPHARMACOLOGY, V43, P1173, DOI 10.1016/S0028 3908(02)00217 4
   Hashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022 3042.2001.00728.x
   Hayhurst M, 2012, DEV BIOL, V368, P323, DOI 10.1016/j.ydbio.2012.05.037
   Hu JH, 2003, J NEUROCHEM, V85, P432, DOI 10.1046/j.1471 4159.2003.01670.x
   Hua YM, 2010, GENE DEV, V24, P1634, DOI 10.1101/gad.1941310
   Huo KM, 2012, MOL CELL NEUROSCI, V51, P32, DOI 10.1016/j.mcn.2012.07.002
   Inestrosa NC, 2012, J NEUROIMMUNE PHARM, V7, P788, DOI 10.1007/s11481 012 9417 5
   Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755
   Jablonka S, 2000, HUM MOL GENET, V9, P341, DOI 10.1093/hmg/9.3.341
   Kariya S, 2008, HUM MOL GENET, V17, P2552, DOI 10.1093/hmg/ddn156
   Kinali M, 2002, NEUROLOGY, V59, P609, DOI 10.1212/WNL.59.4.609
   Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
   Koh SH, 2007, EXP NEUROL, V205, P336, DOI 10.1016/j.expneurol.2007.03.004
   Koh SH, 2005, EUR J NEUROSCI, V22, P301, DOI 10.1111/j.1460 9568.2005.04191.x
   Kong LL, 2009, J NEUROSCI, V29, P842, DOI 10.1523/JNEUROSCI.4434 08.2009
   Lee AJH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046353
   Lee YI, 2011, DEV BIOL, V356, P432, DOI 10.1016/j.ydbio.2011.05.667
   Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797 265
   LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092 8674(95)90460 3
   Lesbordes JC, 2003, HUM MOL GENET, V12, P1233, DOI 10.1093/hmg/ddg143
   Ling KKY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015457
   Lorson CL, 2010, HUM MOL GENET, V19, pR111, DOI 10.1093/hmg/ddq147
   Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27
   Lunn MR, 2008, LANCET, V371, P2120, DOI 10.1016/S0140 6736(08)60921 6
   Luo J, 2010, FRONT NEUROSCI SWITZ, V4, DOI 10.3389/fnins.2010.00041
   Lutz CM, 2011, J CLIN INVEST, V121, P3029, DOI 10.1172/JCI57291
   Mailman MD, 2002, GENET MED, V4, P20, DOI 10.1097/00125817 200201000 00004
   Makhortova NR, 2011, NAT CHEM BIOL, V7, P544, DOI [10.1038/NCHEMBIO.595, 10.1038/nchembio.595]
   Manji HK, 1999, BIOL PSYCHIAT, V46, P929, DOI 10.1016/S0006 3223(99)00165 1
   Markowitz JA, 2012, PEDIATR NEUROL, V46, P1, DOI 10.1016/j.pediatrneurol.2011.09.001
   Mattis VB, 2009, HUM MOL GENET, V18, P3906, DOI 10.1093/hmg/ddp333
   Mentis GZ, 2011, NEURON, V69, P453, DOI 10.1016/j.neuron.2010.12.032
   Merlini L, 2003, J CHILD NEUROL, V18, P537, DOI 10.1177/08830738030180080501
   Miller RG, 2011, NEUROLOGY, V77, P973, DOI 10.1212/WNL.0b013e31822dc7a5
   Miller RG, 2001, J NEUROL SCI, V191, P127, DOI 10.1016/S0022 510X(01)00632 3
   Monani UR, 2000, HUM MOL GENET, V9, P333, DOI 10.1093/hmg/9.3.333
   Monani UR, 2005, NEURON, V48, P885, DOI 10.1016/j.neuron.2005.12.001
   Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200
   Murray LM, 2008, HUM MOL GENET, V17, P949, DOI 10.1093/hmg/ddm367
   Murray LM, 2013, NEUROBIOL DIS, V49, P57, DOI 10.1016/j.nbd.2012.08.019
   Mutsaers CA, 2011, HUM MOL GENET, V20, P4334, DOI 10.1093/hmg/ddr360
   Narver HL, 2008, ANN NEUROL, V64, P465, DOI 10.1002/ana.21449
   Nicole S, 2003, J CELL BIOL, V161, P571, DOI 10.1083/jcb.200210117
   Nizzardo M, 2011, EXP NEUROL, V229, P214, DOI 10.1016/j.expneurol.2011.01.017
   Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102
   Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642
   Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756 199806220 00031
   Nonaka S, 1998, J PHARMACOL EXP THER, V286, P539
   Oprea GE, 2008, SCIENCE, V320, P524, DOI 10.1126/science.1155085
   Pane M, 2008, NEUROMUSCULAR DISORD, V18, P536, DOI 10.1016/j.nmd.2008.05.004
   Park GH, 2010, J NEUROSCI, V30, P12005, DOI 10.1523/JNEUROSCI.2208 10.2010
   Passini MA, 2011, TRENDS MOL MED, V17, P259, DOI 10.1016/j.molmed.2011.01.002
   Passini MA, 2010, J CLIN INVEST, V120, P1253, DOI 10.1172/JCI41615
   Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092 8674(00)81632 3
   Pizzasegola C, 2009, AMYOTROPH LATERAL SC, V10, P221, DOI 10.1080/17482960902803440
   Pruss RM, 2010, FUTURE MED CHEM, V2, P1429, DOI 10.4155/FMC.10.228
   Rajendra TK, 2007, J CELL BIOL, V176, P831, DOI 10.1083/jcb.200610053
   Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100
   Riessland M, 2010, HUM MOL GENET, V19, P1492, DOI 10.1093/hmg/ddq023
   Rigo F, 2012, J CELL BIOL, V199, P21, DOI 10.1083/jcb.201207087
   Rose FF, 2009, HUM MOL GENET, V18, P997, DOI 10.1093/hmg/ddn426
   Ruggiu M, 2012, MOL CELL BIOL, V32, P126, DOI 10.1128/MCB.06077 11
   Ruiz R, 2010, J NEUROSCI, V30, P849, DOI 10.1523/JNEUROSCI.4496 09.2010
   Schreml J, 2013, EUR J HUM GENET, V21, P643, DOI 10.1038/ejhg.2012.222
   Shababi M, 2011, HUM GENE THER, V22, P135, DOI 10.1089/hum.2010.114
   Shin JH, 2007, MOL PHARMACOL, V71, P965, DOI 10.1124/mol.106.030676
   Simon CM, 2010, HUM MOL GENET, V19, P973, DOI 10.1093/hmg/ddp562
   Singh J, 2008, ACS CHEM BIOL, V3, P711, DOI 10.1021/cb800120t
   Sumner Charlotte J, 2006, NeuroRx, V3, P235, DOI 10.1007/BF03207053
   Sumner CJ, 2009, HUM MOL GENET, V18, P3145, DOI 10.1093/hmg/ddp253
   Tews DS, 1996, NEUROMUSCULAR DISORD, V6, P265, DOI 10.1016/0960 8966(96)00018 1
   Thurmond J, 2008, J MED CHEM, V51, P449, DOI 10.1021/jm061475p
   Torres Benito L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026164
   Tsai LK, 2008, J MOL MED, V86, P1243, DOI 10.1007/s00109 008 0388 1
   Tsai LK, 2012, NEURAL PLAST, V2012, DOI 10.1155/2012/456478
   Tsai LK, 2012, NEUROBIOL DIS, V45, P272, DOI 10.1016/j.nbd.2011.06.021
   Valori CF, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000830
   Wada A, 2005, J PHARMACOL SCI, V99, P307, DOI 10.1254/jphs.CRJ05009X
   Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299
   Wei H, 2001, NEUROSCIENCE, V106, P603, DOI 10.1016/S0306 4522(01)00311 6
   Wirth B, 2006, HUM GENET, V119, P422, DOI 10.1007/s00439 006 0156 7
   Wolstencroft EC, 2005, HUM MOL GENET, V14, P1199, DOI 10.1093/hmg/ddi131
   Wyatt TJ, 2010, EXPERT OPIN BIOL TH, V10, P1587, DOI 10.1517/14712598.2010.529895
   Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111
   Yoshioka W, 2009, J TOXICOL SCI, V34, P519, DOI 10.2131/jts.34.519
   Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200
NR 145
TC 10
Z9 10
U1 0
U2 15
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306 4522
EI 1873 7544
J9 NEUROSCIENCE
JI Neuroscience
PD OCT 10
PY 2013
VL 250
BP 417
EP 433
DI 10.1016/j.neuroscience.2013.07.026
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA 223YC
UT WOS:000324847400039
PM 23876328
DA 2025 08 17
ER

PT J
AU Liu, D
   Huang, Y
   Li, B
   Jia, CQ
   Liang, F
   Fu, Q
AF Liu, Da
   Huang, Ying
   Li, Bin
   Jia, Changqing
   Liang, Feng
   Fu, Qin
TI Carvedilol promotes neurological function, reduces bone loss and
   attenuates cell damage after acute spinal cord injury in rats
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE acute spinal cord injury; apoptosis; carvedilol; inflammatory response;
   osteoporosis; oxidative stress
ID NECROSIS FACTOR ALPHA; OSTEOCLAST DIFFERENTIATION; OXIDATIVE DAMAGE;
   MINERAL DENSITY; OSTEOPROTEGERIN; EXPRESSION; APOPTOSIS;
   METHYLPREDNISOLONE; RECEPTOR; LIGAND
AB Acute spinal cord injury (SCI) leads to permanent functional deficits via mechanical injury and secondary mechanisms, but the therapeutic strategy for SCI is limited. Carvedilol has been shown to possess multiple biological and pharmacological properties. The of the present study was to investigate the possible protective effect of carvedilol in SCI rats. An acute SCI rat model was established and neurological function was tested. After carvedilol (10mg/kg, oral gavage) treatment for 21days, the status of osteoporosis, neuron damage, astrocyte activation, inflammation, oxidative stress and apoptosis were evaluated in rats. Carvedilol significantly improved locomotor activity that was decreased by SCI. In addition, carvedilol promoted bone growth by regulating the expression of nuclear factor B ligand (receptor activator of nuclear factor B ligand; RANKL) and osteoprotegerin (OPG), inactivating osteoclasts and thereby increasing bone mineral density in tibias. In addition, carvedilol reduced SCI induced neural damage, increased neuron number and reduced astrocyte activation in the spinal cord. Furthermore, the production and mRNA expression of tumour necrosis factor , interleukin (IL) 1 and IL 6 were significantly reduced, reduced glutathione content and superoxide dismutase activity were markedly increased and malondialdehyde content was markedly decreased in the spinal cords of carvedilol treated rats. These results indicate that carvedilol exhibits anti inflammatory and anti oxidative effects in SCI rats. In addition, the expression of Fas and Fas ligand was reduced by carvedilol treatment, which, in turn, reduced cleaved caspase 3 expression and finally decreased the number of apoptotic cells in the spinal cord. In conclusion, carvedilol promotes neurological function, reduces bone loss and attenuates cell damage after acute SCI in rats.
C1 [Liu, Da; Li, Bin; Jia, Changqing; Liang, Feng; Fu, Qin] China Med Univ, Dept Orthopaed Surg, Shengjing Hosp, Shenyang 110004, Peoples R China.
   [Huang, Ying] China Med Univ, Dept Ultrasound, Shengjing Hosp, Shenyang 110004, Peoples R China.
C3 China Medical University; China Medical University
RP Fu, Q (通讯作者)，China Med Univ, Dept Orthopaed Surg, Shengjing Hosp, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM cmu2hfuqin@163.com
FU National Natural Science Foundation of China [81371552]; Natural Science
   Foundation of Liaoning Province [2013021054, 2013021020]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No.: 81371552) and the Natural Science Foundation
   of Liaoning Province (No. 2013021054 and 2013021020).
CR Abdel Raheem MH, 2014, HORM METAB RES
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Baud'huin M, 2013, CYTOKINE GROWTH F R, V24, P401, DOI 10.1016/j.cytogfr.2013.06.001
   Beattie MS, 2002, PROG BRAIN RES, V137, P37
   Bracken M.B., 2010, Cochrane Database Syst. Rev, V2000, P1, DOI DOI 10.1002/14651858.CD001046
   BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001
   Budh CN, 2007, CLIN REHABIL, V21, P89, DOI 10.1177/0269215506070313
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Rodrigues MAC, 2013, CHEM BIOL INTERACT, V206, P90, DOI 10.1016/j.cbi.2013.08.015
   Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306 4522(00)00538 8
   Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197 73
   Dauty M, 2000, BONE, V27, P305, DOI 10.1016/S8756 3282(00)00326 4
   de Araújo RF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066391
   Desclaux M, 2015, J NEUROSCI RES, V93, P43, DOI 10.1002/jnr.23468
   Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826 200109000 00002
   Garland DE, 2004, J SPINAL CORD MED, V27, P202, DOI 10.1080/10790268.2004.11753748
   Gerndt SJ, 1997, J TRAUMA, V42, P279, DOI 10.1097/00005373 199702000 00017
   Gifre L, 2014, CLIN REHABIL, V28, P361, DOI 10.1177/0269215513501905
   Guo JD, 2014, MOL CELL BIOCHEM, V390, P215, DOI 10.1007/s11010 014 1972 z
   Hadley MN, 2002, NEUROSURGERY, V50, pS63
   HALL ED, 1993, RES P ARNMD, V71, P81
   Helge EW, 2014, SCAND J MED SCI SPOR, V24, P98, DOI 10.1111/sms.12239
   Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001
   Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074 7613(01)00151 0
   Jiang SH, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/431580
   Karalija A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041086
   Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335
   Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422
   Kim YH, 2012, TOXICOL MECH METHOD, V22, P488, DOI 10.3109/15376516.2012.678406
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021 9681(75)90057 0
   Krizsan Agbas D, 2014, J NEUROTRAUM, V31, P846, DOI 10.1089/neu.2013.3115
   Kumar A, 2009, PHARMACOL BIOCHEM BE, V92, P25, DOI 10.1016/j.pbb.2008.10.005
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lazo MG, 2001, SPINAL CORD, V39, P208, DOI 10.1038/sj.sc.3101139
   Li B, 2006, INT J CARDIOL, V111, P247, DOI 10.1016/j.ijcard.2005.08.065
   Li Z, 2010, INDIAN J BIOCHEM BIO, V47, P359
   Liu QW, 2013, INDIAN J PHARMACOL, V45, P458, DOI 10.4103/0253 7613.117729
   Morsy MA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/105214
   Onose G, 2009, SPINAL CORD, V47, P716, DOI 10.1038/sc.2009.52
   Oudega M, 2013, EXP NEUROL, V250, P151, DOI 10.1016/j.expneurol.2013.09.013
   Qian T, 2005, SPINAL CORD, V43, P199, DOI 10.1038/sj.sc.3101681
   Qin WP, 2010, ANN NY ACAD SCI, V1211, P66, DOI 10.1111/j.1749 6632.2010.05806.x
   Qin Weiping, 2010, Curr Osteoporos Rep, V8, P212, DOI 10.1007/s11914 010 0029 9
   Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166 2236(97)01139 9
   Sayer Faisal T, 2006, Spine J, V6, P335, DOI 10.1016/j.spinee.2005.11.001
   Schulte M, 2007, CELL DEATH DIFFER, V14, P1040, DOI 10.1038/sj.cdd.4402101
   Scott A, 2008, SPORTS MED, V38, P139, DOI 10.2165/00007256 200838020 00004
   Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387
   Sun L, 2013, J SPINAL CORD MED, V36, P616, DOI 10.1179/2045772312Y.0000000020
   Taoka Y, 2000, J NEUROTRAUM, V17, P219, DOI 10.1089/neu.2000.17.219
   Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478
   Warden SJ, 2002, OSTEOPOROSIS INT, V13, P586, DOI 10.1007/s001980200077
   Wu YX, 2014, NEUROSCI LETT, V580, P7, DOI 10.1016/j.neulet.2013.11.055
   Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471 4159.2006.04312.x
   Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369
   Yang LQ, 2004, SPINE, V29, P966, DOI 10.1097/00007632 200405010 00004
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yin X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038381, 10.1371/journal.pone.0051853]
   Yu WR, 2011, ACTA NEUROPATHOL, V122, P747, DOI 10.1007/s00401 011 0882 3
   Zhou Y, 2014, CELL MOL NEUROBIOL, V34, P1151, DOI 10.1007/s10571 014 0090 5
NR 63
TC 12
Z9 12
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0305 1870
EI 1440 1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD FEB
PY 2015
VL 42
IS 2
BP 202
EP 212
DI 10.1111/1440 1681.12345
PG 11
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA AY8PE
UT WOS:000347814900011
PM 25424914
DA 2025 08 17
ER

PT J
AU Oliveira, JM
   Kotobuki, N
   Marques, AP
   Pirraco, RP
   Benesch, J
   Hirose, M
   Costa, SA
   Mano, JF
   Ohgushi, H
   Reis, RL
AF Oliveira, Joaquim M.
   Kotobuki, Noriko
   Marques, Alexandra P.
   Pirraco, Rogerio P.
   Benesch, Johan
   Hirose, Motohiro
   Costa, Silgia A.
   Mano, Joao F.
   Ohgushi, Hajime
   Reis, Rui L.
TI Surface engineered carboxymethylchitosan/poly(amidoamine) dendrimer
   nanoparticles for intracellular targeting
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; IN VITRO CYTOTOXICITY; OSTEOBLAST LIKE CELLS;
   STARCH BASED POLYMERS; OSTEOGENIC DIFFERENTIATION;
   O CARBOXYMETHYLCHITOSAN; CHEMICAL MODIFICATION; FLUORESCENT PROBES;
   PAMAM DENDRIMERS; DEXAMETHASONE
AB Novel highly branched biodegradable macromolecular systems have been developed by grafting carboxymethylchitosan (CMCht) onto low generation poly(amidoamine) (PAMAM) dendrimers. Such structures organize into sphere like nanoparticles that are proposed to be used as carriers to deliver bioactive molecules aimed at controlling the behavior of stem cells, namely their proliferation and differentiation. The nanoparticles did not exhibit significant cytotoxicity in the range of concentrations below 1 mg mL( 1), and fluorescent probe labeled nanoparticles were found to be internalized with highly efficiency by both human osteoblast like cells and rat bone marrow stromal cells, under fluorescence activated cell sorting and fluorescence microscopy analyses. Dexamethasone (Dex) has been incorporated into CMCht/PAMAM dendrimer nanoparticles and release rates were determined by high performance liquid chromatography. Moreover, the biochemical data demonstrates that the Dex loaded CMCht/PAMAM dendrimer nanoparticles promote the osteogenic differentiation of rat bone marrow stromal cells, in vitro. The nanoparticles exhibit interesting physicochemical and biological properties and have great potential to be used in fundamental cell biology studies as well as in a variety of biomedical applications, including tissue engineering and regenerative medicine.
C1 [Oliveira, Joaquim M.; Marques, Alexandra P.; Pirraco, Rogerio P.; Benesch, Johan; Costa, Silgia A.; Mano, Joao F.; Reis, Rui L.] Univ Minho, Dept Polymer Engn, IBB,PT Govt Associated Lab,Dept Polymer Engn, Res Grp Biomat Biodegradables & Biomimet 3Bs, P 4710057 Braga, Portugal.
   [Kotobuki, Noriko; Hirose, Motohiro; Ohgushi, Hajime] Natl Inst Adv Ind Sci & Technol, RICE, Amagasaki, Hyogo 6610974, Japan.
C3 Universidade do Minho; National Institute of Advanced Industrial Science
   & Technology (AIST)
RP Oliveira, JM (通讯作者)，Univ Minho, Dept Polymer Engn, IBB,PT Govt Associated Lab,Dept Polymer Engn, Res Grp Biomat Biodegradables & Biomimet 3Bs, Campus Gualtar, P 4710057 Braga, Portugal.
EM rgreis@dep.uminho.pt
RI Benesch, Johan/C 6593 2014; Pirraco, Rogerio/O 8122 2015; Reis,
   Rui/A 8938 2008; Oliveira, Joaquim/H 8636 2012; Mano, Joao/A 4418 2009;
   Mano, João/A 4418 2009; Benesch, Johan/AAH 3246 2021; da Costa, Silgia
   Aparecida/M 5901 2015; Hirose, Motohiro/M 4959 2018; Oliveira, Joaquim
   Miguel/H 8636 2012; Da Costa, Silgia/M 5901 2015; Reis, Rui
   L./A 8938 2008; Marques, Alexandra/B 1238 2012
OI Benesch, Johan/0000 0003 3991 7433; Pirraco,
   Rogerio/0000 0001 5521 950X; Mano, Joao/0000 0002 2342 3765; da Costa,
   Silgia Aparecida/0000 0001 8331 538X; Hirose,
   Motohiro/0000 0001 9010 0125; Oliveira, Joaquim
   Miguel/0000 0001 7052 8837; Reis, Rui L./0000 0002 4295 6129; Marques,
   Alexandra/0000 0002 3222 0310; UMinho, 3B's Research
   Group/0000 0002 5195 3456
CR Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   BERESFORD JN, 1994, ARCH ORAL BIOL, V39, P941, DOI 10.1016/0003 9969(94)90077 9
   Blum JS, 2004, J ORTHOP RES, V22, P411, DOI 10.1016/j.orthres.2003.08.006
   Brothers HM, 1998, J CHROMATOGR A, V814, P233, DOI 10.1016/S0021 9673(98)00419 1
   Chen XG, 2003, CARBOHYD POLYM, V53, P355, DOI 10.1016/S0144 8617(03)00051 1
   CHOKSAKULNIMITR S, 1995, J CONTROL RELEASE, V34, P233, DOI 10.1016/0168 3659(95)00007 U
   D'Emanuele A, 2004, J CONTROL RELEASE, V95, P447, DOI 10.1016/j.jconrel.2003.12.006
   Domanski DM, 2004, BIOELECTROCHEMISTRY, V63, P189, DOI 10.1016/j.bioelechem.2003.09.023
   Domanski DM, 2004, BIOELECTROCHEMISTRY, V63, P193, DOI 10.1016/j.bioelechem.2003.09.024
   Eijken M, 2006, MOL CELL ENDOCRINOL, V248, P87, DOI 10.1016/j.mce.2005.11.034
   Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359 6446(01)01757 3
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142 9612(02)00445 3
   Gao HJ, 2005, P NATL ACAD SCI USA, V102, P9469, DOI 10.1073/pnas.0503879102
   HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009 8981(90)90031 M
   Hata N, 2004, J BIOSCI BIOENG, V97, P233, DOI 10.1016/S1389 1723(04)70197 8
   Hayashi R, 2004, EUR J PHARMACOL, V500, P51, DOI 10.1016/j.ejphar.2004.07.011
   Huang M, 2004, PHARM RES DORDR, V21, P344, DOI 10.1023/B:PHAM.0000016249.52831.a5
   Huo X, 2004, WORLD J GASTROENTERO, V10, P1666, DOI 10.3748/wjg.v10.i11.1666
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jevprasesphant R, 2004, J CONTROL RELEASE, V97, P259, DOI 10.1016/j.jconrel.2004.03.022
   Jevprasesphant R, 2003, PHARM RES DORDR, V20, P1543, DOI 10.1023/A:1026166729873
   Jorgensen NR, 2004, STEROIDS, V69, P219, DOI 10.1016/j.steroids.2003.12.005
   KALLARD E, 1993, BIOL REPROD, V48, P143
   Kallinteri P, 2002, BIOMATERIALS, V23, P4819, DOI 10.1016/S0142 9612(02)00233 8
   Kitamura S, 2004, ARTIF ORGANS, V28, P72, DOI 10.1111/j.1525 1594.2004.07325.x
   Kotobuki N, 2005, TISSUE ENG, V11, P663, DOI 10.1089/ten.2005.11.663
   Kotobuki N, 2004, ARTIF ORGANS, V28, P33, DOI 10.1111/j.1525 1594.2004.07320.x
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Li J, 2007, POLYM DEGRAD STABIL, V92, P515, DOI 10.1016/j.polymdegradstab.2006.04.028
   Luo D, 2000, NAT BIOTECHNOL, V18, P893, DOI 10.1038/78523
   Luo D, 2002, MACROMOLECULES, V35, P3456, DOI 10.1021/ma0106346
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168 3659(99)00246 1
   Marques AP, 2005, MAT SCI ENG C BIO S, V25, P215, DOI 10.1016/j.msec.2005.01.013
   Marques AP, 2002, BIOMATERIALS, V23, P1471, DOI 10.1016/S0142 9612(01)00272 1
   Ogston N, 2002, STEROIDS, V67, P895, DOI 10.1016/S0039 128X(02)00054 5
   Prinzen L, 2007, NANO LETT, V7, P93, DOI 10.1021/nl062226r
   Ryu JS, 1997, BIOTECHNOL BIOENG, V55, P565, DOI 10.1002/(SICI)1097 0290(19970805)55:3<565::AID BIT14>3.0.CO;2 F
   Sakharov DV, 2003, FEBS LETT, V537, P6, DOI 10.1016/S0014 5793(03)00063 2
   Sashiwa H, 2002, CARBOHYD POLYM, V49, P195, DOI 10.1016/S0144 8617(01)00322 8
   Sashiwa H, 2002, CARBOHYD POLYM, V47, P201, DOI 10.1016/S0144 8617(01)00167 9
   Sato H, 1996, ADV DRUG DELIVER REV, V19, P445, DOI 10.1016/0169 409X(96)00013 0
   Söntjens SHM, 2006, BIOMACROMOLECULES, V7, P310, DOI 10.1021/bm050663e
   Sun JJ, 2007, CHINESE MED J PEKING, V120, P2284, DOI 10.1097/00029330 200712020 00025
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   TANG MX, 1996, BIOCONJUG CHEM, V4, P372
   Thompson KJ, 2002, J CELL SCI, V115, P2165
   Tomalia DA, 2005, PROG POLYM SCI, V30, P294, DOI 10.1016/j.progpolymsci.2005.01.007
   Tomalia DA, 2005, PROG POLYM SCI, V30, P217, DOI 10.1016/j.progpolymsci.2005.03.003
   TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381
   Tomalia DA, 2005, MATER TODAY, V8, P34, DOI 10.1016/S1369 7021(05)00746 7
   Trevors JT, 2003, J BIOCHEM BIOPH METH, V57, P87, DOI 10.1016/S0165 022X(03)00076 9
   Tsai MA, 1998, BIOPHYS J, V74, P3282, DOI 10.1016/S0006 3495(98)78035 X
   Uchimura E, 2003, CALCIFIED TISSUE INT, V73, P575, DOI 10.1007/s00223 002 1052 3
   VORGIAS CE, 1988, BIOSCIENCE REP, V8, P193, DOI 10.1007/BF01116464
   Wiesmann HP, 2003, J ORAL MAXIL SURG, V61, P1455, DOI 10.1016/j.joms.2003.05.001
   Yan AH, 2006, ADV MATER, V18, P2373, DOI 10.1002/adma.200600838
   Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119
   Zhu AP, 2006, CARBOHYD POLYM, V63, P89, DOI 10.1016/j.carbpol.2005.08.006
   Zhu AP, 2005, COLLOID SURFACE B, V43, P143, DOI 10.1016/j.colsurfb.2005.04.009
NR 59
TC 53
Z9 62
U1 1
U2 49
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD JUN 24
PY 2008
VL 18
IS 12
BP 1840
EP 1853
DI 10.1002/adfm.200800165
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 324MT
UT WOS:000257523400015
DA 2025 08 17
ER

PT J
AU Chen, DF
   Zeng, HP
   Du, SH
   Li, H
   Zhou, JH
   Li, YW
   Wang, TT
   Hua, ZC
AF Chen, D. F.
   Zeng, H. P.
   Du, S. H.
   Li, H.
   Zhou, J. H.
   Li, Y. W.
   Wang, T. T.
   Hua, Z. C.
TI Extracts from plastrum testudinis promote proliferation of rat
   bone marrow derived mesenchymal stem cells
SO CELL PROLIFERATION
LA English
DT Article
ID POLYUNSATURATED FATTY ACIDS; FIBROBLAST GROWTH FACTOR; IN VITRO;
   GENE EXPRESSION; STROMAL CELLS; MORPHOGENETIC PROTEIN 2;
   DIFFERENTIATION; DEXAMETHASONE; OSTEOBLASTS; PROGENITORS
AB Objectives: The purpose of this study is to identify active components of PT involved in promoting proliferation of MSCs and to investigate its mechanism. PT was extracted with petroleum ether, ethyl acetate, ethanol and water respectively. Materials and methods: Evidence provided by MTT, HE stain, BrdUrd, PCNA immunoreactivity and cell cycle indicated that Plastrum Testudinis Extracted with ethyl acetate (PTE) is the only active components responsible for increasing MSCs proliferation. Results: This finding leads us to identify the chemical component of PTE. Steroid, fatty acids and their esters components in PTE were determined by GC MS and HPLC. The mechanism of PTE action may be associated with the up regulation of BMP4. Conclusions: Our findings give novel insights into the promoting effects of Plastrum Testudinis on proliferation of MSCs and help to identify the chemical component and to clarify the mechanism of its pharmacological activities.
C1 Guangzhou Univ Tradit Chinese Med, Dept Anat, Guangzhou 510405, Guangdong, Peoples R China.
   Nanjing Univ, Dept Biochem, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Peoples R China.
   S China Univ Technol, Fac Chem, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Nanjing University; South
   China University of Technology
RP Chen, DF (通讯作者)，Guangzhou Univ Tradit Chinese Med, Dept Anat, 12 Jichang Rd, Guangzhou 510405, Guangdong, Peoples R China.
EM CDF27212@21cn.com; zenghp@scnu.edu.cn
RI Jianwen, Zhao/A 1171 2014; wang, tingting/AAK 2640 2020
OI Chen, Dongfeng/0000 0003 1263 2374; zeng, heping/0000 0002 9025 9643
CR Abeywardena MY, 2001, CARDIOVASC RES, V52, P361, DOI 10.1016/S0008 6363(01)00406 0
   Akino K, 2003, WOUND REPAIR REGEN, V11, P354, DOI 10.1046/j.1524 475X.2003.11507.x
   Almeida JP, 2005, J PERIODONTOL, V76, P272, DOI 10.1902/jop.2005.76.2.272
   Atmani H, 2003, J CELL BIOCHEM, V89, P364, DOI 10.1002/jcb.10507
   Bousserouel S, 2004, EUR J BIOCHEM, V271, P4462, DOI 10.1111/j.1432 1033.2004.04385.x
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169
   Castaneda S, 2005, BLOOD CELL MOL DIS, V35, P217, DOI 10.1016/j.bcmd.2005.06.007
   Cavaglieri CR, 2003, LIFE SCI, V73, P1683, DOI 10.1016/S0024 3205(03)00490 9
   Chen DF, 2005, FEBS J, V272, P141
   Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097 4652(199910)181:1<67::AID JCP7>3.0.CO;2 C
   Cornet F, 2004, MOL CELL BIOCHEM, V265, P79, DOI 10.1023/B:MCBI.0000044309.43612.3b
   Das UN, 2002, NUTRITION, V18, P178, DOI 10.1016/S0899 9007(01)00719 5
   Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580
   Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711
   Li XD, 2005, OSTEOPOROSIS INT, V16, P101, DOI 10.1007/s00198 004 1649 7
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Nano JL, 2003, PROSTAG LEUKOTR ESS, V69, P207, DOI 10.1016/S0952 3278(03)00083 8
   Nugent AP, 2005, EUR J CLIN NUTR, V59, P742, DOI 10.1038/sj.ejcn.1602132
   OGATA T, 1993, P NATL ACAD SCI USA, V99, P19
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Pennisi E, 2004, SCIENCE, V303, P951
   PENNISI E, 1998, SCIENCE, V279, P72
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rocchi P, 2005, ONCOL REP, V13, P1139
   Roynette CE, 2004, CLIN NUTR, V23, P139, DOI 10.1016/j.clnu.2003.07.005
   State Pharmacopoeia Commission of the People's Republic of China, 2000, PHARM PEOPL REP CHIN, V1, P15
   Takagi M, 2003, CYTOTECHNOLOGY, V43, P89, DOI 10.1023/B: CYTO.0000039911.46200.61
   Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777
   Urist MR, 1997, J BONE MINER RES, V12, P343, DOI 10.1359/jbmr.1997.12.3.343
   van den Bos C, 1997, Hum Cell, V10, P45
   Walsh S, 2001, RHEUMATOLOGY, V40, P74, DOI 10.1093/rheumatology/40.1.74
   WOODS AL, 1991, HISTOPATHOLOGY, V19, P21, DOI 10.1111/j.1365 2559.1991.tb00890.x
   Yang L, 2003, CHINESE MED J PEKING, V116, P1357
NR 37
TC 48
Z9 60
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD APR
PY 2007
VL 40
IS 2
BP 196
EP 212
DI 10.1111/j.1365 2184.2007.00431.x
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 144KH
UT WOS:000244794400005
PM 17472727
OA Green Published
DA 2025 08 17
ER

PT J
AU Singh, RK
   Kim, TH
   Patel, KD
   Kim, JJ
   Kim, HW
AF Singh, Rajendra K.
   Kim, Tae Hyun
   Patel, Kapil D.
   Kim, Jung Ju
   Kim, Hae Won
TI Development of biocompatible apatite nanorod based drug delivery system
   with in situ fluorescence imaging capacity
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID MESOPOROUS SILICA NANOPARTICLES; HYDROXYAPATITE NANOCOMPOSITES;
   CITRIC ACID; LUMINESCENT; PHOTOLUMINESCENCE; NANOCRYSTALS; ALENDRONATE;
   PARTICLES; EFFICIENT; PROBE
AB Biocompatible and multifunctional nanocarriers significantly improve the therapeutic and diagnostic efficacy of the cargo molecules. Here we report a novel biocompatible apatite nanocrystal based delivery system with in situ imaging capacity. A nanorod (40 nm x 10 nm) produced by a citrate involved sol gel process expressed a strong blue emission at 427 nm under fluorescence microscopy. The CO2 center dot  radical impurities present in the apatite crystal lattice account for the fluorescent behavior. The fluorescent nanorods exhibited excellent cell viability (over 90% up to similar to 100 mu g ml( 1) concentration for both osteoblasts and osteoclasts). The nanorods loaded alendronate drug at a high efficiency (10%) and released over 3 days, while enabling in situ fluorescence imaging within the cells. The fluorescent apatite was further hybridized onto the surface of mesoporous nanospheres, aimed at improving the drug delivery capacity. Small interfering RNA (siRNA) gene, encoding Plekho 1, was effectively loaded to the hybrid nanocarrier, and was sustainably released over 5 days. The siRNA loaded nanocarrier exhibited excellent osteoblastic uptake (96% efficiency) and gene silencing effect, suppressing Plekho 1 down to similar to 18%, while preserving intracellular fluorescence signals. Taken as a whole, the self fluorescent nature of apatite nanorods is believed to find potential and versatile applications as biocompatible drug delivery and in situ imaging systems.
C1 [Singh, Rajendra K.; Kim, Tae Hyun; Patel, Kapil D.; Kim, Jung Ju; Kim, Hae Won] Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 330714, South Korea.
   [Singh, Rajendra K.; Kim, Tae Hyun; Patel, Kapil D.; Kim, Jung Ju; Kim, Hae Won] Dankook Univ, Dept Nanobiomed Sci, Cheonan 330714, South Korea.
   [Singh, Rajendra K.; Kim, Tae Hyun; Patel, Kapil D.; Kim, Jung Ju; Kim, Hae Won] Dankook Univ, PLUS NBM Global Res Ctr Regenerat Med BK21, Cheonan 330714, South Korea.
   [Kim, Hae Won] Dankook Univ, Sch Dent, Dept Biomat Sci, Cheonan 330714, South Korea.
C3 Dankook University; Dankook University; Dankook University; Dankook
   University
RP Kim, HW (通讯作者)，Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 330714, South Korea.
EM kimhw@dku.edu
RI Singh, Rajendra/O 9797 2016; Singh, Rajendra K/O 9797 2016; Kim,
   Young/T 8521 2019; Patel, Kapil D/F 3874 2012; Patel, Kapil/F 3874 2012
OI Singh, Rajendra K/0000 0003 3127 3346; Patel, Kapil
   D/0000 0002 0393 9166; 
FU Priority Research Centers Program, National Research Foundation, South
   Korea [2009 0093829]
FX This study was supported by a grant from Priority Research Centers
   Program (2009 0093829), National Research Foundation, South Korea.
CR Al Deeb SK, 2004, TALANTA, V64, P695, DOI 10.1016/j.talanta.2004.03.044
   Al Kattan A, 2010, J PHYS CHEM C, V114, P2918, DOI 10.1021/jp910923g
   ANGELOV S, 1986, J PHYS CHEM SOLIDS, V47, P409, DOI 10.1016/0022 3697(86)90032 6
   Blasse G., 1994, A General Introduction to Luminescent Materials, DOI [10.1007/978 3 642 79017 1_1, DOI 10.1007/978 3 642 79017 1_1]
   Boanini E, 2008, BIOMATERIALS, V29, P790, DOI 10.1016/j.biomaterials.2007.10.040
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Cai YR, 2008, J MATER CHEM, V18, P3775, DOI 10.1039/b805407j
   Chang Q, 2011, ADV MATER RES SWITZ, V152 153, P1248, DOI 10.4028/www.scientific.net/AMR.152 153.1248
   Chen F, 2011, BIOMATERIALS, V32, P9031, DOI 10.1016/j.biomaterials.2011.08.032
   Chu CL, 2002, J MATER SCI LETT, V21, P1793, DOI 10.1023/A:1020997510289
   Derfus AM, 2004, NANO LETT, V4, P11, DOI 10.1021/nl0347334
   Donners JJJM, 2003, ADV MATER, V15, P313, DOI 10.1002/adma.200390076
   Dorozhkin SV, 2010, ACTA BIOMATER, V6, P715, DOI 10.1016/j.actbio.2009.10.031
   Feldmann C, 2003, ADV FUNCT MATER, V13, P511, DOI 10.1002/adfm.200301005
   Fox K, 2012, CHEMPHYSCHEM, V13, P2495, DOI 10.1002/cphc.201200080
   Green WH, 1997, SCIENCE, V276, P1826, DOI 10.1126/science.276.5320.1826
   Hu YY, 2011, CHEM MATER, V23, P2481, DOI 10.1021/cm200355n
   Huang Y, 2012, NANOSCALE, V4, P2484, DOI 10.1039/c2nr12072k
   Huh S, 2003, CHEM MATER, V15, P4247, DOI 10.1021/cm0210041
   Kim EJ, 2007, J AM CERAM SOC, V90, P2795, DOI 10.1111/j.1551 2916.2007.01791.x
   Kumar CSSR, 2011, ADV DRUG DELIVER REV, V63, P789, DOI 10.1016/j.addr.2011.03.008
   Kwon S, 2013, J TISSUE ENG, V4, DOI 10.1177/2041731413503357
   Lee DE, 2012, CHEM SOC REV, V41, P2656, DOI 10.1039/c2cs15261d
   Li CF, 2009, POWDER TECHNOL, V192, P1, DOI 10.1016/j.powtec.2008.11.001
   Lin CK, 2006, CHEM MATER, V18, P458, DOI 10.1021/cm052109h
   Lopez Macipe A, 1998, ADV MATER, V10, P49, DOI 10.1002/(SICI)1521 4095(199801)10:1<49::AID ADMA49>3.0.CO;2 R
   Matsunaga K, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.104106
   Na HK, 2012, SMALL, V8, P1752, DOI 10.1002/smll.201200028
   Palazzo B, 2007, ADV FUNCT MATER, V17, P2180, DOI 10.1002/adfm.200600361
   Rauschmann MA, 2005, BIOMATERIALS, V26, P2677, DOI 10.1016/j.biomaterials.2004.06.045
   Rhee SH, 1999, BIOMATERIALS, V20, P2155, DOI 10.1016/S0142 9612(99)00118 0
   Rimola A, 2008, J AM CHEM SOC, V130, P16181, DOI 10.1021/ja806520d
   Ropp R.C., 1991, Luminescence and the Solid State
   Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242
   Talhavini M, 1998, J PHOTOCH PHOTOBIO A, V114, P65, DOI 10.1016/S1010 6030(97)00307 9
   Tanaka K, 2001, J AM CHEM SOC, V123, P2530, DOI 10.1021/ja0035708
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Tasciotti E, 2008, NAT NANOTECHNOL, V3, P151, DOI 10.1038/nnano.2008.34
   Vallet Regí M, 2004, PROG SOLID STATE CH, V32, P1, DOI 10.1016/j.progsolidstchem.2004.07.001
   Wu HC, 2010, ADV FUNCT MATER, V20, P67, DOI 10.1002/adfm.200901108
   Yang YK, 2007, NAT PROTOC, V2, P1740, DOI 10.1038/nprot.2007.246
   Yu M, 2005, CHEM MATER, V17, P1783, DOI 10.1021/cm0479537
   Zhang CM, 2008, J PHYS CHEM C, V112, P2183, DOI 10.1021/jp710046x
   Zhang CM, 2010, BIOMATERIALS, V31, P3374, DOI 10.1016/j.biomaterials.2010.01.044
   Zhang CM, 2009, LANGMUIR, V25, P13591, DOI 10.1021/la9019684
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhou H, 2011, ACTA BIOMATER, V7, P2769, DOI 10.1016/j.actbio.2011.03.019
   Zondervan R, 2004, J PHYS CHEM A, V108, P1657, DOI 10.1021/jp037222e
NR 48
TC 41
Z9 42
U1 0
U2 66
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2014
VL 2
IS 14
BP 2039
EP 2050
DI 10.1039/c3tb21156h
PG 12
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA AD2VT
UT WOS:000333094700014
PM 32261639
DA 2025 08 17
ER

PT J
AU Jiang, S
   Zheng, Z
   Yuan, B
   Yan, RS
   Yao, QJ
   Chen, HR
   Zhang, YX
   Lei, Y
   Liang, HD
AF Jiang, Shan
   Zheng, Ziang
   Yuan, Bo
   Yan, Rushan
   Yao, Qijun
   Chen, Haoran
   Zhang, Yongxun
   Lei, Yue
   Liang, Haidong
TI MFAP2 induces epithelial mesenchymal transformation of osteosarcoma
   cells by activating the Notch1 pathway
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Microfibril associated protein 2 (MFAP2); epithelial mesenchymal
   transformation; osteosarcoma (OS); Notch1 pathway; neoplasm invasiveness
ID TRANSITION EMT; BETA CATENIN; E CADHERIN; PROGRESSION
AB Background: Osteosarcoma (OS) is a malignancy originating from mesenchymal tissue. Microfibrilassociated protein 2 (MFAP2) plays a crucial role in cancer, notably promoting epithelial mesenchymal transition (EMT). However, its involvement in OS remains unexplored. Methods: MFAP2 was silenced in U2OS cells using shRNA targeting MFAP2 (sh MFAP2) and validated by quantitative real time polymerase chain reaction (qRT PCR). We extracted gene chip data of MFAP2 from multiple databases (GSE28424, GSE42572, and GSE126209). Correlation analyses between MFAP2 and the Notch1 pathway identified through the gene set variation analysis (GSVA) enrichment analysis were conducted using the Pearson correlation method. Cellular behaviors (viability, migration, and invasion) were assessed via the Cell Counting Kit 8 (CCK 8), wound healing, and Transwell assays. EMT markers (N cadherin, vimentin, and (3 catenin) and Notch1 levels were examined by western blotting and qRT PCR. Cell morphology was observed microscopically to evaluate EMT. Finally, the role of MFAP2 in OS was validated through a xenograft tumor model. Results: OS cell lines exhibited higher MFAP2 mRNA expression than normal osteoblasts. MFAP2 knockdown in U2OS cells significantly reduced viability, migration, and invasion, along with downregulation of N cadherin and vimentin, as well as upregulation of (3 catenin. MFAP2 significantly correlated with the Notch1 pathway in OS and its knockdown inhibited Notch1 protein expression. Furthermore, Notch1 activation reversed the inhibitory effects of MFAP2 knockdown on the malignant characteristic of U2OS cells. Additionally, MFAP2 knockdown inhibited tumor growth, expression levels of EMT markers, and Notch1 expression in OS tumor tissues. Conclusions: Our study revealed that MFAP2 was an upstream regulator of the Notch1 signaling pathway to promote EMT in OS. These findings suggested MFAP2 as a potential OS therapy target.
C1 [Jiang, Shan; Zheng, Ziang; Yuan, Bo; Yan, Rushan; Yao, Qijun; Chen, Haoran; Zhang, Yongxun; Lei, Yue; Liang, Haidong] Dalian Med Univ, Hosp 2, Dept Bone & Soft Tissue Repair & Reconstruct Surg, 467,Zhongshan Rd, Dalian 116000, Peoples R China.
C3 Dalian Medical University
RP Liang, HD (通讯作者)，Dalian Med Univ, Hosp 2, Dept Bone & Soft Tissue Repair & Reconstruct Surg, 467,Zhongshan Rd, Dalian 116000, Peoples R China.
EM johnlhddmu@outlook.com
RI Yuan, Bo/HDN 6321 2022; 郑, 子昂/JAX 9358 2023; yao, qijun/GZL 9566 2022
FU Cultivating Scientific Research Project of the Second Hospital of Dalian
   Medical University [dy2yynpy202219]
FX This work was supported by The Cultivating Scientific Research Project
   of the Second Hospital of Dalian Medical University (No. dy2yynpy202219)
   . The authors expressed gratitude to Yangzhou University for providing
   us with the experimental platform.
CR Amirouche A, 2021, NEW MICROB NEW INFEC, V41, DOI 10.1016/j.nmni.2021.100874
   Cao YY, 2023, CANCER CELL INT, V23, DOI 10.1186/s12935 023 02859 0
   Capobianco E, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1188641
   Chaw SY, 2012, ORAL ONCOL, V48, P997, DOI 10.1016/j.oraloncology.2012.05.011
   Chen ZH, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923808
   Combs MD, 2013, J BIOL CHEM, V288, P28869, DOI 10.1074/jbc.M113.497727
   Craft CS, 2018, MATRIX BIOL, V71 72, P100, DOI 10.1016/j.matbio.2018.03.006
   Dong SY, 2020, CANCER MANAG RES, V12, P12557, DOI 10.2147/CMAR.S274986
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580 018 0080 4
   Gao YA, 2021, AGING US, V13, P2668, DOI 10.18632/aging.202314
   Haider C, 2019, HEPATOLOGY, V69, P222, DOI 10.1002/hep.30166
   He Y, 2019, EXP THER MED, V18, P1884, DOI 10.3892/etm.2019.7765
   Jiang YF, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 34689 5
   Kim H, 2020, CELLS BASEL, V9, DOI 10.3390/cells9040861
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liu P, 2018, MED SCI MONITOR, V24, P2098, DOI 10.12659/MSM.906945
   Liu WP, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/7841279
   Liu YX, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 022 03862 1
   Loh CY, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101118
   Miao K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16936 9
   Miyamoto A, 2006, J BIOL CHEM, V281, P10089, DOI 10.1074/jbc.M600298200
   Qian XQ, 2020, INT J MED SCI, V17, P1215, DOI 10.7150/ijms.44683
   Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0295 3
   Shao SJ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.774988
   Sheng GH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.780264
   Sun XY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116200
   Wang JK, 2018, ONCOTARGETS THER, V11, P4001, DOI 10.2147/OTT.S160831
   Xu WZ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1002036
   Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580 020 0237 9
   Yao LW, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389 020 0198 z
   Yu XB, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578 021 00600 w
   Zhang KX, 2021, AGING US, V13, P21090, DOI 10.18632/aging.203261
   Zhao X, 2021, BIOMED ENG ONLINE, V20, DOI 10.1186/s12938 021 00860 0
   Zhou BH, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00934 y
   Zhu GJ, 2018, ONCOL LETT, V15, P3472, DOI 10.3892/ol.2018.7751
NR 35
TC 4
Z9 4
U1 0
U2 3
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218 676X
EI 2219 6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD JUN 30
PY 2024
VL 13
IS 6
DI 10.21037/tcr 23 2035
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA A5O8A
UT WOS:001283029400011
PM 38988940
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Flood, J
AF Flood, Joseph
TI The Role of Acetaminophen in the Treatment of Osteoarthritis
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; UPPER GASTROINTESTINAL
   COMPLICATIONS; KNEE OSTEOARTHRITIS; DOUBLE BLIND; STANDING COMMITTEE;
   ANALGESIC USE; TASK FORCE; PARACETAMOL; METAANALYSIS; EFFICACY
AB The major clinical guidelines recommend the use of acetaminophen (acetyl para aminophenol [APAP]) for the treatment of mild to moderate symptoms of osteoarthritis (OA) and only recommend the use of nonsteroidal anti inflammatory drugs (NSAIDs) after APAP failure. This recommendation is based on the efficacy of APAP in treating OA and its relatively benign side effect profile compared with NSAIDs. NSAIDs are associated with a high risk of adverse events, particularly those of the gastrointestinal (GI) tract. A large number of studies in OA have compared APAP with a variety of selective and nonselective NSAIDs and typically found greater efficacy with NSAIDs. This advantage, however, is mainly the result of increased efficacy in patients with more severe disease, and is viewed as a relatively small analgesic advantage in some studies and meta analyses. Many of these same studies have reported little or no difference in safety between APAP and NSAIDs, but these results are typically based on short term studies. Results from meta analyses on the safety of NSAIDs almost unanimously confirm elevated risk of GI complications. The analgesic mechanism of APAP is still not well understood. However, the notion that APAP has no anti inflammatory effect has been challenged in recent years with increasing data that suggest it may have an effect on inflammation distinct from that seen with NSAIDs. A variety of mechanistic hypotheses have been proposed. (Am J Manag Care. 2010;16:S48 S54)
C1 Ohio State Univ, Coll Med & Publ Hlth, Dept Internal Med, Columbus, OH 43215 USA.
C3 University System of Ohio; Ohio State University
RP Flood, J (通讯作者)，Ohio State Univ, Coll Med & Publ Hlth, Dept Internal Med, 500 E Main St,Ste 230, Columbus, OH 43215 USA.
EM jjflood@columbusrr.com
FU McNeil Consumer Healthcare
FX Financial support for this work was provided by McNeil Consumer
   Healthcare.
CR Altman RD, 2000, ARTHRITIS RHEUM US, V43, P1905
   [Anonymous], 2008, NICE clinical guideline, V59
   Barrett BJ, 1996, AM J KIDNEY DIS, V28, pS14, DOI 10.1016/S0272 6386(96)90563 6
   BJORKMAN R, 1995, ACTA ANAESTH SCAND, V39, P3
   Bjornsson GA, 2003, BRIT J CLIN PHARMACO, V55, P405, DOI 10.1046/j.1365 2125.2003.01779.x
   BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289
   Botting RM, 2000, CLIN INFECT DIS, V31, pS202, DOI 10.1086/317520
   BRADLEY JD, 1992, J RHEUMATOL, V19, P1950
   BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203
   Brandt KD, 2006, RHEUMATOLOGY, V45, P1389, DOI 10.1093/rheumatology/kel100
   Case JP, 2003, ARCH INTERN MED, V163, P169, DOI 10.1001/archinte.163.2.169
   Fored CM, 2001, NEW ENGL J MED, V345, P1801, DOI 10.1056/NEJMoa010323
   Forman JP, 2007, ARCH INTERN MED, V167, P394, DOI 10.1001/archinte.167.4.394
   Golden Harvey E, 2004, Am J Ther, V11, P85, DOI 10.1097/00045391 200403000 00002
   Hersch M, 2008, PHARMACOTHERAPY, V28, P1205, DOI 10.1592/phco.28.10.1205
   Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742
   Kis B, 2005, AM J PHYSIOL REG I, V288, pR897, DOI 10.1152/ajpregu.00613.2004
   KONTUREK SJ, 1982, GUT, V23, P536, DOI 10.1136/gut.23.6.536
   Lee C, 2004, ARTHRIT RHEUM ARTHR, V51, P746, DOI 10.1002/art.20698
   Lewis JD, 2005, GASTROENTEROLOGY, V129, P1865, DOI 10.1053/j.gastro.2005.08.051
   Lewis SC, 2002, BRIT J CLIN PHARMACO, V54, P320, DOI 10.1046/j.1365 2125.2002.01636.x
   LIGUMSKY M, 1986, ISRAEL J MED SCI, V22, P807
   Martel Pelletier J, 2008, BEST PRACT RES CL RH, V22, P351, DOI 10.1016/j.berh.2008.02.001
   Miceli Richard C, 2004, ANN RHEUM DIS, V63, P923, DOI 10.1136/ard.2003.017236
   Mrozek S, 2009, ANN FR ANESTH, V28, P448, DOI 10.1016/j.annfar.2009.01.018
   MURRELL GAC, 1995, BIOCHEM BIOPH RES CO, V206, P15, DOI 10.1006/bbrc.1995.1003
   Ofman JJ, 2002, J RHEUMATOL, V29, P804
   Pelletier JP, 1996, OSTEOARTHR CARTILAGE, V4, P77, DOI 10.1016/S1063 4584(96)80009 4
   Pelletier JP, 2001, ARTHRITIS RHEUM US, V44, P1237, DOI 10.1002/1529 0131(200106)44:6<1237::AID ART214>3.0.CO;2 F
   Pincus T, 2004, ANN RHEUM DIS, V63, P931, DOI 10.1136/ard.2003.020313
   Pincus T, 2001, ARTHRITIS RHEUM US, V44, P1587, DOI 10.1002/1529 0131(200107)44:7<1587::AID ART282>3.0.CO;2 X
   Rahme E, 2002, ARTHRITIS RHEUM US, V46, P3046, DOI 10.1002/art.10604
   Rainsford K. D., 2006, Inflammopharmacology, V14, P150, DOI 10.1007/s10787 006 1389 8
   Rexrode KM, 2001, JAMA J AM MED ASSOC, V286, P315, DOI 10.1001/jama.286.3.315
   Rodríguez LAG, 2001, EPIDEMIOLOGY, V12, P570
   Rostom A, 2000, J RHEUMATOL, V27, P2203
   ROSTOM A, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002296
   Schnitzer TJ, 2005, J RHEUMATOL, V32, P1093
   Shen H, 2006, RHEUMATOLOGY, V45, P765, DOI 10.1093/rheumatology/kei253
   SKJELBRED P, 1984, CURR THER RES CLIN E, V35, P377
   SKJELBRED P, 1979, EUR J CLIN PHARMACOL, V15, P27, DOI 10.1007/BF00563555
   Smith HS, 2009, PAIN PHYSICIAN, V12, P269
   Swierkosz Tomasz A, 2002, Med Sci Monit, V8, pBR496
   Takeba Y, 2001, J RHEUMATOL, V28, P2176
   TASKIRAN D, 1994, BIOCHEM BIOPH RES CO, V200, P142, DOI 10.1006/bbrc.1994.1426
   Towheed TE, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004257.pub2
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
   Zhang W, 2005, ANN RHEUM DIS, V64, P669, DOI 10.1136/ard.2004.028886
   Zhang W, 2004, ANN RHEUM DIS, V63, P901, DOI 10.1136/ard.2003.018531
   Zoppi M., 1995, EUR J PAIN, V16, P42
NR 50
TC 40
Z9 49
U1 0
U2 5
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088 0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD MAR
PY 2010
VL 16
IS 2
SU S
BP S48
EP S54
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
   General & Internal
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; General & Internal Medicine
GA 715HP
UT WOS:000286874200003
PM 20297877
DA 2025 08 17
ER

PT J
AU Spivey, TL
   De Giorgi, V
   Zhao, YD
   Bedognetti, D
   Pos, Z
   Liu, QZ
   Tomei, S
   Ascierto, ML
   Uccellini, L
   Reinboth, J
   Chouchane, L
   Stroncek, DF
   Wang, E
   Marincola, FM
AF Spivey, Tara L.
   De Giorgi, Valeria
   Zhao, Yingdong
   Bedognetti, Davide
   Pos, Zoltan
   Liu, Qiuzhen
   Tomei, Sara
   Ascierto, Maria Libera
   Uccellini, Lorenzo
   Reinboth, Jennifer
   Chouchane, Lotfi
   Stroncek, David F.
   Wang, Ena
   Marincola, Francesco M.
TI The stable traits of melanoma genetics: an alternate approach to target
   discovery
SO BMC GENOMICS
LA English
DT Article
DE Melanoma; Melanoma genetics; Cancer; Tumor microenvironment
ID COMPARATIVE GENOMIC HYBRIDIZATION; COLORECTAL CANCER; PROGNOSTIC
   RELEVANCE; ACQUIRED RESISTANCE; MALIGNANT MELANOMA; ANTIGEN EXPRESSION;
   TISSUE MICROARRAY; CELL CARCINOMA; T CELLS; TUMORS
AB Background: The weight that gene copy number plays in transcription remains controversial; although in specific cases gene expression correlates with copy number, the relationship cannot be inferred at the global level. We hypothesized that genes steadily expressed by 15 melanoma cell lines (CMs) and their parental tissues (TMs) should be critical for oncogenesis and their expression most frequently influenced by their respective copy number.
   Results: Functional interpretation of 3,030 transcripts concordantly expressed (Pearson's correlation coefficient p value < 0.05) by CMs and TMs confirmed an enrichment of functions crucial to oncogenesis. Among them, 968 were expressed according to the transcriptional efficiency predicted by copy number analysis (Pearson's correlation coefficient p value < 0.05). We named these genes, "genomic delegates" as they represent at the transcriptional level the genetic footprint of individual cancers. We then tested whether the genes could categorize 112 melanoma metastases. Two divergent phenotypes were observed: one with prevalent expression of cancer testis antigens, enhanced cyclin activity, WNT signaling, and a Th17 immune phenotype (Class A). This phenotype expressed, therefore, transcripts previously associated to more aggressive cancer. The second class (B) prevalently expressed genes associated with melanoma signaling including MITF, melanoma differentiation antigens, and displayed a Th1 immune phenotype associated with better prognosis and likelihood to respond to immunotherapy. An intermediate third class (C) was further identified. The three phenotypes were confirmed by unsupervised principal component analysis.
   Conclusions: This study suggests that clinically relevant phenotypes of melanoma can be retraced to stable oncogenic properties of cancer cells linked to their genetic back bone, and offers a roadmap for uncovering novel targets for tailored anti cancer therapy.
C1 [Spivey, Tara L.; De Giorgi, Valeria; Bedognetti, Davide; Liu, Qiuzhen; Tomei, Sara; Ascierto, Maria Libera; Uccellini, Lorenzo; Reinboth, Jennifer; Wang, Ena; Marincola, Francesco M.] NIH, Infect Dis & Immunogenet Sect IDIS, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
   [Spivey, Tara L.] NIH, Clin Res Training Program CRTP, Bethesda, MD 20892 USA.
   [Spivey, Tara L.] Rush Univ, Med Ctr, Rush Med Coll, Chicago, IL 60612 USA.
   [Zhao, Yingdong] NCI, Biometr Res Branch, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA.
   [Bedognetti, Davide; Ascierto, Maria Libera] Univ Genoa, Dept Internal Med DiMI, I 16132 Genoa, Italy.
   [Bedognetti, Davide] Natl Canc Res Inst Genoa, Genoa, Italy.
   [Bedognetti, Davide] Dept Oncol Biol & Genet, Genoa, Italy.
   [Pos, Zoltan] Semmelweis Univ, Dept Genet Cell & Immunobiol, H 1089 Budapest, Hungary.
   [Tomei, Sara] Univ Pisa, Dept Oncol, Pisa, Italy.
   [Ascierto, Maria Libera] Univ Genoa, Ctr Excellence Biomed Res CEBR, Genoa, Italy.
   [Chouchane, Lotfi] Weill Cornell Med Coll Qatar, Doha, Qatar.
   [Stroncek, David F.] NIH, Cell Proc Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
   [Uccellini, Lorenzo] Univ Milan, Inst Infect & Trop Dis, L Sacco Hosp, Milan, Italy.
   [Reinboth, Jennifer] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA.
   [Reinboth, Jennifer] Univ Wurzburg, Dept Biochem, Bioctr, D 97074 Wurzburg, Germany.
   [Marincola, Francesco M.] NIH, Infect Dis & Immunogenet Sect IDIS, Dept Transfus Med, Ctr Human Immunol CHI, Bethesda, MD 20892 USA.
   [Spivey, Tara L.; De Giorgi, Valeria; Bedognetti, Davide; Liu, Qiuzhen; Tomei, Sara; Ascierto, Maria Libera; Uccellini, Lorenzo; Reinboth, Jennifer; Wang, Ena; Marincola, Francesco M.] NIH, Infect Dis & Immunogenet Sect IDIS, Dept Transfus Med, Trans NIH Ctr Human Immunol CHI, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH)   USA; NIH Clinical Center (CC);
   National Institutes of Health (NIH)   USA; Rush University; National
   Institutes of Health (NIH)   USA; NIH National Cancer Institute (NCI);
   NIH Division of Cancer Treatment & Diagnosis; University of Genoa;
   Semmelweis University; University of Pisa; University of Genoa; Qatar
   Foundation (QF); Weill Cornell Medical College Qatar; National
   Institutes of Health (NIH)   USA; NIH Clinical Center (CC); University
   of Milan; Luigi Sacco Hospital; Genelux Corporation; University of
   Wurzburg; National Institutes of Health (NIH)   USA; National Institutes
   of Health (NIH)   USA; NIH National Heart Lung & Blood Institute (NHLBI)
RP De Giorgi, V (通讯作者)，NIH, Infect Dis & Immunogenet Sect IDIS, Dept Transfus Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
EM degiorgiv@mail.nih.gov; FMarincola@mail.cc.nih.gov
RI Pós, Zoltán/C 3623 2014; Bedognetti, Davide/GLQ 9410 2022; Chouchane,
   Lotfi/ABF 1360 2020; Ascierto, Maria/A 9239 2012; Pos,
   Zoltan/C 3623 2014; Bedognetti, Davide/ADI 1011 2022; De Giorgi,
   Valeria/D 4582 2017
OI Pos, Zoltan/0000 0002 2574 7616; Bedognetti, Davide/0000 0002 5857 773X;
   Ascierto, Maria Libera/0009 0008 8904 1613
FU NIH; Pfizer Inc.
FX Tara Spivey's research fellowship was made possible through the Clinical
   Research Training Program, a public private partnership supported
   jointly by the NIH and Pfizer Inc. (via a grant to the foundation for
   NIH from Pfizer Inc.).
CR Ascierto ML, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 146
   ASCIERTO ML, 2011, BREAST CANC RES TREA
   Ascierto PA, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 32
   Ascierto PA, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 38
   Bacolod MD, 2010, J MOL DIAGN, V12, P552, DOI 10.2353/jmoldx.2010.100098
   Basil CF, 2006, CANCER RES, V66, P2953, DOI 10.1158/0008 5472.CAN 05 3433
   Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115
   Bolli M, 2002, ANN SURG, V236, P785, DOI 10.1097/00000658 200212000 00011
   Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733
   Chen Z, 2008, CYTOKINE, V41, P71, DOI 10.1016/j.cyto.2007.09.009
   Chinnaiyan AM, 2010, PROG MOL BIOL TRANSL, V95, P55, DOI 10.1016/B978 0 12 385071 3.00004 6
   Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039
   Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148
   Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600 0463.2007.apm_855.xml.x
   Dienstmann R, 2011, ANTI CANCER AGENT ME, V11, P285, DOI 10.2174/187152011795347469
   Dissanayake SK, 2007, J BIOL CHEM, V282, P17259, DOI 10.1074/jbc.M700075200
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Garbe C, 2011, ONCOLOGIST, V16, P5, DOI 10.1634/theoncologist.2010 0190
   Gast A, 2010, GENE CHROMOSOME CANC, V49, P733, DOI 10.1002/gcc.20785
   Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065
   Jin P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471 2164 5 55
   Kawakami Y, 1997, Int Rev Immunol, V14, P173, DOI 10.3109/08830189709116851
   Kawakami Y, 1998, J IMMUNOTHER, V21, P237, DOI 10.1097/00002371 199807000 00001
   Kocher T, 2002, INT J CANCER, V100, P702, DOI 10.1002/ijc.10540
   Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752
   Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065 2776(08)60911 6
   Marincola FM, 2011, IMMUNOLOGIC SIGNATURES OF REJECTION, P1, DOI 10.1007/978 1 4419 7219 4
   Marincola FM, 2003, TRENDS IMMUNOL, V24, P335, DOI 10.1016/S1471 4906(03)00116 9
   Pagès F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Roschke AV, 2003, CANCER RES, V63, P8634
   SABATINO M, 2008, CANCER RES, V68, P222
   Simon R, 2007, CANCER INFORM, V3, P11
   Squire JA, 2002, HEAD NECK J SCI SPEC, V24, P874, DOI 10.1002/hed.10122
   Thompson SL, 2011, CHROMOSOME RES, V19, P433, DOI 10.1007/s10577 010 9179 y
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008 5472.CAN 10 2907
   van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600 065X.2002.18806.x
   Wang E, 2004, CANCER RES, V64, P7279, DOI 10.1158/0008 5472.CAN 04 1597
   Wang E, 2008, TRENDS IMMUNOL, V29, P256, DOI 10.1016/j.it.2008.03.002
   Wang Ena, 2004, J Transl Med, V2, P34, DOI 10.1186/1479 5876 2 34
   Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002
   Weaver BAA, 2009, J CELL BIOL, V185, P934, DOI 10.1083/jcb.200905098
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535 6108(02)00045 4
   Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250
   Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937
   Zhu J, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 172
NR 46
TC 31
Z9 32
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2164
J9 BMC GENOMICS
JI BMC Genomics
PD APR 26
PY 2012
VL 13
AR 156
DI 10.1186/1471 2164 13 156
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 949HR
UT WOS:000304567800001
PM 22537248
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Pessina, A
   Sisto, F
   Coccè, V
   Cavicchini, L
   Ciusani, E
   Gribaldo, L
   Bonomi, A
AF Pessina, Augusto
   Sisto, Francesca
   Cocce, Valentina
   Cavicchini, Loredana
   Ciusani, Emilio
   Gribaldo, Laura
   Bonomi, Arianna
TI A mesenchymal stromal cell line resistant to paclitaxel that
   spontaneously differentiates into osteoblast like cells
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE Drug sensitivity; Mesenchymal stem cells; Osteogenesis; Paclitaxel
   resistance; SR 4987
ID BONE MARROW; STEM CELLS; IN VITRO; TAXOL RESISTANCE; SR 4987 CELLS;
   ADULT MOUSE; ESTABLISHMENT; OSTEOGENESIS; INHIBITION; MECHANISMS
AB The mesenchymal stromal cell line SR 4987 has been established in our laboratory from the bone marrow of BDF/1 mice. Recent information on mesenchymal stem cells biology and the need to deal with well characterized cell lines suggest to critically consider the existent data on this cell line by updating them with new investigations on growth parameters, in vitro plasticity, and drug sensitivity to anti cancer, anti inflammatory, and a histone deacetylase inhibitor. SR 4987 cells show a population doubling time of 24.5 +/  5.4 h, a plating efficiency of 2.87 +/  1.19%, and under stimulation maintain only in part their multipotency by differentiating towards chondro osteogenic lineages but not into adipogenic. Surprisingly, these mesenchymal stromal cells differentiate spontaneously into osteoblast like cells and this is significantly stimulated by valproic acid. SR 4987 cells show a dramatic resistance to paclitaxel (PTX) with a resistance index of 39.6 times (evaluated versus MOLT 4 leukemia) and of 68.2 (versus HT 29 colorectal carcinoma). SR 4987 resistance is reversed by verapamil and correlates with high expression of P glycoprotein that is down modulated by PTX. Taken together, our results indicated that SR 4987 line is a very interesting cell model useful to investigate both drug sensitivity resistance and physiopathological aspects related to mesenchymal cell function.
C1 [Pessina, Augusto; Sisto, Francesca; Cocce, Valentina; Cavicchini, Loredana; Bonomi, Arianna] Univ Milan, Dept Publ Hlth Microbiol Virol, I 20133 Milan, Italy.
   [Ciusani, Emilio] Fdn IRCCS Ist Neurol Besta, Milan, Italy.
   [Gribaldo, Laura] Commiss European Communities, Joint Res Ctr, IHCP, I 21020 Ispra, Italy.
C3 University of Milan; Fondazione IRCCS Istituto Neurologico Carlo Besta;
   European Commission Joint Research Centre; EC JRC ISPRA Site
RP Pessina, A (通讯作者)，Univ Milan, Dept Publ Hlth Microbiol Virol, Via Pascal 36, I 20133 Milan, Italy.
EM augusto.pessina@unimi.it
RI ; Ciusani, Emilio/J 9822 2016
OI SISTO, FRANCESCA/0000 0003 0166 2164; Ciusani,
   Emilio/0000 0002 7285 123X
CR Burns BS, 2001, CLIN ORTHOP RELAT R, P259
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700
   FOGH J, 1975, HUMAN TUMOR CELLS IN, P115, DOI [DOI 10.1007/978 1 4757 1647 45, DOI 10.1007/978 1 4757 1647 4_5, 10.1007/978 1 4757 1647 45]
   FRIEDENSTEIN AJ, 1966, J EMBRYOL EXP MORPH, V16, P381
   Gribaldo Laura, 1999, Drug Metabolism and Drug Interactions, V15, P279
   HAYNESWORTH SE, 1992, BONE, V13, P69, DOI 10.1016/8756 3282(92)90363 2
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kellinsalmi M, 2007, EUR J PHARMACOL, V572, P102, DOI 10.1016/j.ejphar.2007.06.030
   McAteer JA., 1994, BASIC CELL CULTURE, P93
   MINOWADA J, 1972, J NATL CANCER I, V49, P891
   Mossman T, 1983, J IMMUNOL METHODS, V65, P55, DOI DOI 10.1016/0022 1759(83)90303 4
   Opavsky R, 2001, J BIOL CHEM, V276, P38795, DOI 10.1074/jbc.M105241200
   Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934
   Parekh H, 1997, BIOCHEM PHARMACOL, V53, P461, DOI 10.1016/S0006 2952(97)83383 7
   Pessina A, 1999, LIFE SCI, V65, P513, DOI 10.1016/S0024 3205(99)00272 6
   Pessina A, 2004, BIOCHEM BIOPH RES CO, V323, P315, DOI 10.1016/j.bbrc.2004.08.088
   Pessina A, 1995, METHOD MOL CELL BIOL, V5, P230
   PESSINA A, 1992, CYTOTECHNOLOGY, V8, P93, DOI 10.1007/BF02525491
   Pessina A, 1998, CELL MOL BIOL, V44, P933
   Pessina A., 1994, Indian Journal of Experimental Biology, V32, P113
   Pessina A, 1997, EXP HEMATOL, V25, P536
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rosland GV, 2009, CANCER RES, V69, P5331, DOI 10.1158/0008 5472.CAN 08 4630
   SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0
   Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912
   Takagi M, 1999, CYTOTECHNOLOGY, V31, P225, DOI 10.1023/A:1008098313067
   Takagi M, 2005, J BIOSCI BIOENG, V99, P189, DOI 10.1263/jbb.99.189
   Tallheden T, 2003, J BONE JOINT SURG AM, V85A, P93, DOI 10.2106/00004623 200300002 00012
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   ULMANEN M, 2002, ADV SKELETAL RECONST, P53
   Wang Y, 2006, CLIN EXP PHARMACOL P, V33, P696, DOI 10.1111/j.1440 1681.2006.04432.x
   Yamaza T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002615
NR 35
TC 10
Z9 10
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742 2091
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD JUN
PY 2011
VL 27
IS 3
BP 169
EP 180
DI 10.1007/s10565 010 9179 x
PG 12
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Toxicology
GA 757PO
UT WOS:000290100400002
PM 21190129
DA 2025 08 17
ER

PT J
AU Heuschkel, MA
   Babler, A
   Heyn, J
   van der Vorst, EPC
   Steenman, M
   Gesper, M
   Kappel, B
   Magne, D
   Gouëffic, Y
   Kramann, R
   Jahnen Dechent, W
   Marx, N
   Quillard, T
   Goettsch, C
AF Heuschkel, Marina A.
   Babler, Anne
   Heyn, Jonas
   van der Vorst, Emiel P. C.
   Steenman, Marja
   Gesper, Maren
   Kappel, Ben A.
   Magne, David
   Goueffic, Yann
   Kramann, Rafael
   Jahnen Dechent, Willi
   Marx, Nikolaus
   Quillard, Thibaut
   Goettsch, Claudia
TI Distinct role of mitochondrial function and protein kinase C in intimal
   and medial calcification in vitro
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE vascular calcification; vascular smooth muscle cells; drug repurposing;
   mitochondrial function; matrix mineralization; protein kinase C
ID SMOOTH MUSCLE CELL; VASCULAR CALCIFICATION; CARDIOVASCULAR
   CALCIFICATION; DIFFERENTIATION; CALCIUM; CYTOSKELETON; ACTIVATION;
   MECHANISMS; TNAP
AB IntroductionVascular calcification (VC) is a major risk factor for cardiovascular morbidity and mortality. Depending on the location of mineral deposition within the arterial wall, VC is classified as intimal and medial calcification. Using in vitro mineralization assays, we developed protocols triggering both types of calcification in vascular smooth muscle cells (SMCs) following diverging molecular pathways. Materials and methods and resultsHuman coronary artery SMCs were cultured in osteogenic medium (OM) or high calcium phosphate medium (CaP) to induce a mineralized extracellular matrix. OM induces osteoblast like differentiation of SMCs a key process in intimal calcification during atherosclerotic plaque remodeling. CaP mimics hyperphosphatemia, associated with chronic kidney disease a risk factor for medial calcification. Transcriptomic analysis revealed distinct gene expression profiles of OM and CaP calcifying SMCs. OM and CaP treated SMCs shared 107 differentially regulated genes related to SMC contraction and metabolism. Real time extracellular efflux analysis demonstrated decreased mitochondrial respiration and glycolysis in CaP treated SMCs compared to increased mitochondrial respiration without altered glycolysis in OM treated SMCs. Subsequent kinome and in silico drug repurposing analysis (Connectivity Map) suggested a distinct role of protein kinase C (PKC). In vitro validation experiments demonstrated that the PKC activators prostratin and ingenol reduced calcification triggered by OM and promoted calcification triggered by CaP. ConclusionOur direct comparison results of two in vitro calcification models strengthen previous observations of distinct intracellular mechanisms that trigger OM and CaP induced SMC calcification in vitro. We found a differential role of PKC in OM and CaP calcified SMCs providing new potential cellular and molecular targets for pharmacological intervention in VC. Our data suggest that the field should limit the generalization of results found in in vitro studies using different calcification protocols.
C1 [Heuschkel, Marina A.; Heyn, Jonas; Gesper, Maren; Kappel, Ben A.; Marx, Nikolaus; Goettsch, Claudia] Rhein Westfal TH Aachen, Med Fac, Dept Internal Med Cardiol 1, Aachen, Germany.
   [Babler, Anne; Kramann, Rafael] Rhein Westfal TH Aachen, Inst Expt Med & Syst Biol, Univ Hosp, Aachen, Germany.
   [van der Vorst, Emiel P. C.] Rhein Westfal TH Aachen, Interdisciplinary Ctr Clin Res, Inst Mol Cardiovasc Res, Aachen, Germany.
   [van der Vorst, Emiel P. C.] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Pathol, Med Ctr, Maastricht, Netherlands.
   [van der Vorst, Emiel P. C.] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Prevent IPEK, Munich, Germany.
   [van der Vorst, Emiel P. C.] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany.
   [Steenman, Marja; Quillard, Thibaut] INSERM, Inst Thorax, CNRS, UMR 1087, Nantes, France.
   [Steenman, Marja; Quillard, Thibaut] Nantes Univ, Nantes, France.
   [Magne, David] Univ Claude Bernard Lyon 1, ICBMS UMR CNRS 5246, Villeurbanne, France.
   [Goueffic, Yann] Grp Hosp Paris St Joseph, Vasc Ctr, Dept Vasc Surg, Paris, France.
   [Kramann, Rafael] Rhein Westfal TH Aachen, Dept Nephrol & Clin Immunol, Univ Hosp, Aachen, Germany.
   [Kramann, Rafael] Erasmus MC, Dept Internal Med Nephrol & Transplantat, Rotterdam, Netherlands.
   [Jahnen Dechent, Willi] Rhein Westfal TH Aachen, Biointerface Lab, Helmholtz Inst Biomed Engn, Aachen, Germany.
   [Quillard, Thibaut] Nantes Univ Med, PHY Os Lab, INSERM, UMR 1238, Nantes, France.
C3 RWTH Aachen University; RWTH Aachen University; RWTH Aachen University
   Hospital; RWTH Aachen University; Maastricht University; University of
   Munich; Munich Heart Alliance; German Centre for Cardiovascular
   Research; Centre National de la Recherche Scientifique (CNRS); Nantes
   Universite; CHU de Nantes; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Nantes Universite; Institut National des
   Sciences Appliquees de Lyon   INSA Lyon; Universite Claude Bernard Lyon
   1; Centre National de la Recherche Scientifique (CNRS); CNRS   Institute
   of Chemistry (INC); Universite Paris Cite; Hopital Paris Saint Joseph;
   RWTH Aachen University; RWTH Aachen University Hospital; Erasmus
   University Rotterdam; Erasmus MC; Helmholtz Association; RWTH Aachen
   University; Nantes Universite; CHU de Nantes; Institut National de la
   Sante et de la Recherche Medicale (Inserm)
RP Goettsch, C (通讯作者)，Rhein Westfal TH Aachen, Med Fac, Dept Internal Med Cardiol 1, Aachen, Germany.
EM cgoettsch@ukaachen.de
RI Steenman, Marja/D 3618 2015; Quillard, Thibaut/K 8150 2015; Goettsch,
   Claudia/AAD 9658 2019; Jahnen Dechent, Willi/A 7608 2011; Kramann,
   Rafael/K 7995 2013; Babler, Anne/AAA 7250 2021; Kappel, Ben/H 3983 2019
OI Steenman, Marja/0000 0003 4547 4448; Magne, David/0000 0002 6511 9390;
   van der Vorst, Emiel/0000 0001 5771 6278; Kappel, Ben
   Arpad/0000 0001 9065 9412; Jahnen Dechent, Willi/0000 0003 1315 4407;
   Kramann, Rafael/0000 0003 4048 6351; 
FU "Deutsche Forschungsgemein schaft" (DFG, German Research Foundation);
   European Union [GO1801/5 1, 322900939]; European Research Area Network
   on Cardiovascular Diseases (ERA NET CVD JTC2017, Microexploration
   project) [722609]; Interdisciplinary Center for Clinical Research within
   the faculty of Medicine at the RWTH Aachen University [BMBF 01KL1801];
   Fondation de l'Avenir (Paris, France); University Hospital of Nantes
   (Nantes, France); Federation Francaise de Cardiologie (Paris, France)
FX This work was funded by the "Deutsche Forschungsgemein schaft" (DFG,
   German Research Foundation) [GO1801/5 1 to CG and Transregional
   Collaborative Research Centre (TRR 219; Project ID 322900939) to CG,
   WJ D, RK, and NM], a research grant from the European Union's Horizon
   2020 research and innovation program under the Marie Sklodowska Curie
   grant agreement No. 722609, INTRICARE (to CG, WJ D, and NM), and a grant
   from the European Research Area Network on Cardiovascular Diseases
   (ERA NET CVD JTC2017, Microexploration project; BMBF 01KL1801) to CG and
   DM. EvdV received financial support from the Interdisciplinary Center
   for Clinical Research within the faculty of Medicine at the RWTH Aachen
   University. TQ received financial support from the Fondation de l'Avenir
   (Paris, France), the University Hospital of Nantes (Nantes, France), and
   the Federation Francaise de Cardiologie (Paris, France).
CR Al Mahi N, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 43935 8
   Alesutan I, 2020, J MOL MED, V98, P985, DOI 10.1007/s00109 020 01925 8
   Alves RDAM, 2014, BMC GENOMICS, V15, DOI 10.1186/1471 2164 15 965
   Bardeesi ASA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1190 z
   BONUCCI E, 1973, AM J PATHOL, V71, P167
   Borland SJ, 2017, CARDIOVASC RES, V113, P1639, DOI 10.1093/cvr/cvx178
   Chirumamilla CS, 2019, METHODS MOL BIOL, V1930, P99, DOI 10.1007/978 1 4939 9036 8_13
   Claudia G, 2022, CARDIOVASC RES, V118, P84, DOI 10.1093/cvr/cvaa299
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Espitia O, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191976
   Fakhry M, 2017, BBA MOL BASIS DIS, V1863, P643, DOI 10.1016/j.bbadis.2016.12.003
   Fink BD, 2017, AM J PHYSIOL CELL PH, V313, pC146, DOI 10.1152/ajpcell.00086.2017
   Galea GL, 2014, J BIOL CHEM, V289, P25509, DOI 10.1074/jbc.M114.580365
   Galindez G, 2021, NAT COMPUT SCI, V1, P33, DOI 10.1038/s43588 020 00007 6
   Gesper M, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.648259
   Goettsch C, 2016, J CLIN INVEST, V126, P1323, DOI 10.1172/JCI80851
   Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Han YC, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100483
   Harja E, 2009, FASEB J, V23, P1081, DOI 10.1096/fj.08 120345
   Herrmann J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062204
   Heuschkel MA, 2020, CELLS BASEL, V9, DOI 10.3390/cells9102164
   Hruska KA, 2008, KIDNEY INT, V74, P148, DOI 10.1038/ki.2008.130
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hutcheson JD, 2016, NAT MATER, V15, P335, DOI 10.1038/nmat4519
   Hutcheson JD, 2015, SEMIN CELL DEV BIOL, V46, P68, DOI 10.1016/j.semcdb.2015.09.004
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Kapustin AN, 2015, CIRC RES, V116, P1312, DOI 10.1161/CIRCRESAHA.116.305012
   Kim GH, 2014, KIDNEY RES CLIN PRAC, V33, P52, DOI 10.1016/j.krcp.2013.12.003
   Lacolley P, 2012, CARDIOVASC RES, V95, P194, DOI 10.1093/cvr/cvs135
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Lee K, 2014, BIOCHEM BIOPH RES CO, V453, P793, DOI 10.1016/j.bbrc.2014.10.026
   Lee SJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082685
   Libby P, 2002, NAT MED, V8, P1257, DOI 10.1038/nm1102 1257
   Lin CS, 2012, CARDIOVASC RES, V95, P346, DOI 10.1093/cvr/cvs189
   Liu J, 2010, J TISSUE ENG REGEN M, V4, P329, DOI 10.1002/term.242
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140 6736(12)61728 0
   Ma WF, 2022, ATHEROSCLEROSIS, V340, P12, DOI 10.1016/j.atherosclerosis.2021.11.025
   Ma WQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03162 w
   Malyala S, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006719
   Moe SM, 2008, J AM SOC NEPHROL, V19, P213, DOI 10.1681/ASN.2007080854
   Nakura A, 2011, BONE, V48, P476, DOI 10.1016/j.bone.2010.09.238
   Nidorf SM, 2020, NEW ENGL J MED, V383, P1838, DOI 10.1056/NEJMoa2021372
   Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003
   Park S, 2018, DIABETES METAB J, V42, P270, DOI 10.4093/dmj.2018.0101
   Phadwal K, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.611922
   Rashdan NA, 2020, J BONE MINER RES, V35, P357, DOI 10.1002/jbmr.3888
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Rogers MA, 2017, CIRC RES, V121, P220, DOI 10.1161/CIRCRESAHA.116.310293
   Rukov JL, 2016, AM J PHYSIOL RENAL, V310, pF477, DOI 10.1152/ajprenal.00472.2015
   Salabei JK, 2014, NAT PROTOC, V9, P421, DOI 10.1038/nprot.2014.018
   Shioi S., 2003, ARTERIOSCL THROM VAS, V15, P9
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Steenman M, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 22292 y
   Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070
   Strubbe Rivera JO, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80398 8
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Travis JA, 2001, CIRC RES, V88, P77, DOI 10.1161/01.RES.88.1.77
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Villa Bellosta R, 2018, ARTERIOSCL THROM VAS, V38, P2137, DOI 10.1161/ATVBAHA.118.311444
   Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950
   Wickham H., 2016, ggplot2: Elegant Graphics for Data Analysis
   Wirka RC, 2019, NAT MED, V25, P1280, DOI 10.1038/s41591 019 0512 5
   Zhang HL, 2020, ELIFE, V9, DOI 10.7554/eLife.60827
   Zhu Dongxing, 2012, Front Endocrinol (Lausanne), V3, P95, DOI 10.3389/fendo.2012.00095
NR 65
TC 5
Z9 5
U1 1
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2297 055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD SEP 20
PY 2022
VL 9
AR 959457
DI 10.3389/fcvm.2022.959457
PG 18
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 5Q8TY
UT WOS:000874098500001
PM 36204585
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Paley, CA
   Bennett, MI
   Johnson, MI
AF Paley, Carole A.
   Bennett, Michael I.
   Johnson, Mark I.
TI Acupuncture for Cancer Induced Bone Pain?
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID DORSAL HORN; AURICULAR ACUPUNCTURE; RAT MODEL; COMPLEMENTARY/ALTERNATIVE
   MEDICINE; BRAIN; ELECTROACUPUNCTURE; STIMULATION; ANALGESIA; MODULATION;
   MECHANISMS
AB Bone pain is the most common type of pain in cancer. Bony metastases are common in advanced cancers, particularly in multiple myeloma, breast, prostate or lung cancer. Current pain relieving strategies include the use of opioid based analgesia, bisphosphonates and radiotherapy. Although patients experience some pain relief, these interventions may produce unacceptable side effects which inevitably affect the quality of life. Acupuncture may represent a potentially valuable adjunct to existing strategies for pain relief and it is known to be relatively free of harmful side effects. Although acupuncture is used in palliative care settings for all types of cancer pain the evidence base is sparse and inconclusive and there is very little evidence to show its effectiveness in relieving cancer induced bone pain (CIBP). The aim of this critical review is to consider the known physiological effects of acupuncture and discuss these in the context of the pathophysiology of malignant bone pain. The aim of future research should be to produce an effective protocol for treating CIBP with acupuncture based on a sound, evidence based rationale. The physiological mechanisms presented in this review suggest that this is a realistic objective.
C1 [Paley, Carole A.; Johnson, Mark I.] Leeds Metropolitan Univ, Fac Hlth, Leeds LS1 3HE, W Yorkshire, England.
   [Paley, Carole A.] Airedale Dist Gen Hosp, Keighley, W Yorkshire, England.
   [Paley, Carole A.; Bennett, Michael I.; Johnson, Mark I.] Leeds Pallium Res Grp, Leeds, W Yorkshire, England.
   [Bennett, Michael I.] Univ Lancaster, Int Observ End Life Care, Lancaster, England.
C3 Leeds Beckett University; University of Leeds; Lancaster University
RP Paley, CA (通讯作者)，Leeds Metropolitan Univ, Fac Hlth, Leeds LS1 3HE, W Yorkshire, England.
EM biodynamics.physiotherapy@tesco.net
RI Bennett, Michael/A 1620 2009; Paley, Carole Anne/HMV 0264 2023; Paley,
   Carole/AAM 2469 2020
OI Bennett, Michael/0000 0002 8369 8349; Paley, Carole
   Anne/0000 0002 6335 2666; 
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458 05.2005
   Bingel U, 2006, PAIN, V120, P8, DOI 10.1016/j.pain.2005.08.027
   Bingel U, 2008, PHYSIOLOGY, V23, P371, DOI 10.1152/physiol.00024.2008
   CAMPBELL A, 1999, ACUPUNCT MED, V17, P124, DOI DOI 10.1136/AIM.17.2.124
   CAMPBELL A, 1999, ACUPUNCT MED, V17, P113
   Campbell Anthony, 2006, Acupunct Med, V24, P118
   Carlsson Christer, 2002, Acupunct Med, V20, P82
   Ceccherelli F, 2002, J ALTERN COMPLEM MED, V8, P341, DOI 10.1089/10755530260128032
   Chan Gunn C., 1989, Acupuncture in Medicine, V6, P50
   Clohisy DR, 2003, CANCER AM CANCER SOC, V97, P866, DOI 10.1002/cncr.11144
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   Diel IJ, 2006, EJC SUPPL, V4, P1, DOI 10.1016/j.ejcsup.2006.07.001
   Dillon M, 1999, PALLIATIVE MED, V13, P253, DOI 10.1191/026921699667999073
   Donovan Rodriguez T, 2005, ANESTHESIOLOGY, V102, P132, DOI 10.1097/00000542 200501000 00022
   Ernst E, 2007, SUPPORT CARE CANCER, V15, P565, DOI 10.1007/s00520 006 0174 y
   Ernst E, 2003, PALLIATIVE MED, V17, P704, DOI 10.1191/0269216303pm816oa
   Ernst E, 2003, EUR J CANCER, V39, P2273, DOI 10.1016/S0959 8049(03)00604 X
   Eustachi A, 2009, INTEGR CANCER THER, V8, P56, DOI 10.1177/1534735408327996
   Filshie J, 2005, EJC SUPPL, V3, P107, DOI 10.1016/S1359 6349(05)80267 8
   Filshie J, 2001, Acupunct Med, V19, P117
   FILSHIE J, 1990, ACUPUNCT MED, V8, P38
   Filshie Jacqueline, 2005, Acupunct Med, V23, P171
   Filshie Jacqueline, 2006, Acupunct Med, V24, P172
   Freeman MD, 2009, J BRACHIAL PLEX PERI, V4, DOI 10.1186/1749 7221 4 2
   Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815 04.2005
   Goblirsch MJ, 2005, J CELL BIOCHEM, V96, P682, DOI 10.1002/jcb.20589
   Gori L, 2007, EVID BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Guo HF, 1996, MOL BRAIN RES, V43, P157, DOI 10.1016/S0169 328X(96)00170 2
   HAN JS, 1986, ASIA PAC J PHARMACOL, V1, P17
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166 2236(02)00006 1
   Harding C, 2009, BJU INT, V103, P186, DOI 10.1111/j.1464 410X.2008.07884.x
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097 0193(2000)9:1<13::AID HBM2>3.0.CO;2 F
   Langevin HM, 2007, J ALTERN COMPLEM MED, V13, P355, DOI 10.1089/acm.2007.6351
   Langevin HM, 2006, HISTOCHEM CELL BIOL, V125, P487, DOI 10.1007/s00418 005 0138 1
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee HJ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756 9966 28 102
   Leknes S, 2008, NAT REV NEUROSCI, V9, P314, DOI 10.1038/nrn2333
   Leng G, 1999, PALLIATIVE MED, V13, P163, DOI 10.1191/026921699676243035
   Lewith GT, 2005, EVID BASED COMPL ALT, V2, P315, DOI 10.1093/ecam/neh110
   Lipton Allan, 2004, J Support Oncol, V2, P205
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304 3959(02)00102 1
   Lund Irene, 2006, Acupunct Med, V24, P13
   *MACM CANC REL, 2002, DIR COMPL THER SERV
   MacPherson H, 2001, Acupunct Med, V19, P93
   MacPherson H, 2008, NEUROSCI LETT, V434, P144, DOI 10.1016/j.neulet.2008.01.058
   Mann F., 2000, Reinventing acupuncture: A new concept of ancient medicine, V2nd
   Mantyh P, 2006, EJC SUPPL, V4, P4, DOI 10.1016/j.ejcsup.2006.07.003
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006 8993(77)90161 5
   Mercadante S, 1997, PAIN, V69, P1, DOI 10.1016/S0304 3959(96)03267 8
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Qaseem A, 2009, ANN INTERN MED, V150, P148
   RAMPES H, 1999, ACUPUNCTURE SCI APPR, P128
   Sandkuhler J, 1997, J NEUROSCI, V17, P6483
   Sandkühler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304 3959(00)00424 3
   Sevcik MA, 2005, PAIN, V115, P128, DOI 10.1016/j.pain.2005.02.022
   Shimoyama M, 2005, PAIN, V114, P221, DOI 10.1016/j.pain.2004.12.018
   Suzuki R, 2005, NEUROSIGNALS, V14, P175, DOI 10.1159/000087656
   Thompson JW, 2005, OXFORD TXB PALLIATIV, P421
   Urch CE, 2005, J PAIN, V6, P837, DOI 10.1016/j.jpain.2005.08.005
   Urch CE, 2003, PAIN, V106, P347, DOI 10.1016/j.pain.2003.08.002
   Usichenko TI, 2008, ANAESTHESIA, V63, P1343, DOI 10.1111/j.1365 2044.2008.05632.x
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   White A, 2001, Acupunct Med, V19, P84
   White A., 2008, An introduction to western medical acupuncture
   Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133
   Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   ZHOU ZF, 1981, SCI SINICA, V24, P1166
   2009, ACUPUNCTURE CANC PAI
NR 75
TC 22
Z9 26
U1 0
U2 31
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2011
VL 2011
BP 1
EP 8
DI 10.1093/ecam/neq020
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 802PO
UT WOS:000293523700001
PM 21799687
OA hybrid, Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Bique, AM
   Kaivosoja, E
   Mikkonen, M
   Paulasto Kröckel, M
AF Bique, Anna Maria
   Kaivosoja, Emilia
   Mikkonen, Marko
   Paulasto Krockel, Mervi
TI Choice of osteoblast model critical for studying the effects of
   electromagnetic stimulation on osteogenesis in vitro
SO ELECTROMAGNETIC BIOLOGY AND MEDICINE
LA English
DT Article
DE Cell proliferation and differentiation; extremely low frequency
   electromagnetic fields; MC3T3 E1 murine osteoblast like cell line;
   osteoblast mineralization; osteoblast phenotype; pulsed electromagnetic
   fields; SaOS 2 osteosarcoma cell line
ID MESENCHYMAL STEM CELLS; HUMAN BONE MARROW; HUMAN OSTEOPROGENITOR CELLS;
   UMBILICAL CORD BLOOD; FIELD STIMULATION; OSTEOSARCOMA CELLS;
   GENE EXPRESSION; REPRESENTATIVE MODELS; RAT OSTEOBLASTS; MC3T3 E1 CELLS
AB The clinical benefits of electromagnetic field (EMF) therapy in enhancing osteogenesis have been acknowledged for decades, but agreement regarding the underlying mechanisms continues to be sought. Studies have shown EMFs to promote osteoblast like cell proliferation, or contrarily, to induce differentiation and enhance mineralization. Typically these disparities have been attributed to methodological differences. The present paper argues the possibility that the chosen osteoblast model impacts stimulation outcome. Phenotypically immature cells, particularly at low seeding densities, appear to be prone to EMF amplified proliferation. Conversely, mature cells at higher densities seem to be predisposed to earlier onset differentiation and mineralization. This suggests that EMFs augment ongoing processes in cell populations. To test this hypothesis, mature SaOS 2 cells and immature MC3T3 E1 cells at various densities, with or without osteoinduction, were exposed to sinusoidal 50 Hz EMF. The exposure stimulated the proliferation of MC3T3 E1 and inhibited the proliferation of SaOS 2 cells. Baseline alkaline phosphatase (ALP) expression of SaOS 2 cells was high and rapidly further increased with EMF exposure, whereas ALP effects in MC3T3 E1 cells were not seen until the second week. Thus both cell types responded differently to EMF stimulation, corroborating the hypothesis that the phenotypic maturity and culture stage of cells influence stimulation outcome.
C1 [Bique, Anna Maria; Kaivosoja, Emilia; Mikkonen, Marko; Paulasto Krockel, Mervi] Aalto Univ, Dept Elect Engn & Automat, Sch Elect Engn, Espoo, Finland.
C3 Aalto University
RP Bique, AM (通讯作者)，Tietotie 3, Espoo 02150, Finland.
EM maria.bique@aalto.fi
RI Mikkonen, Marko/AAC 5403 2020; Peltola, Emilia/L 9969 2013
OI Peltola, Emilia/0000 0002 8868 9273
CR Aaron RK, 1996, J ORTHOP RES, V14, P582, DOI 10.1002/jor.1100140412
   Barnaba S, 2013, PHYSIOTHER RES INT, V18, P109, DOI 10.1002/pri.1536
   BASSETT CAL, 1974, ANN NY ACAD SCI, V238, P242, DOI 10.1111/j.1749 6632.1974.tb26794.x
   Benayahu D, 2002, J CELL BIOCHEM, V84, P108, DOI 10.1002/jcb.1270
   Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243
   Borsje MA, 2010, ANGLE ORTHOD, V80, P498, DOI 10.2319/060809 318.1
   Carvalho RS, 1998, J CELL BIOCHEM, V70, P376, DOI 10.1002/(SICI)1097 4644(19980901)70:3<376::AID JCB11>3.0.CO;2 J
   Chang WHS, 2004, BIOELECTROMAGNETICS, V25, P457, DOI 10.1002/bem.20016
   Cheng GZ, 2011, NITRIC OXIDE BIOL CH, V25, P316, DOI 10.1016/j.niox.2011.05.009
   CLOVER J, 1994, BONE, V15, P585, DOI 10.1016/8756 3282(94)90305 0
   Czekanska EM, 2014, J BIOMED MATER RES A, V102, P2636, DOI 10.1002/jbm.a.34937
   De Mattei M, 1999, BIOELECTROMAGNETICS, V20, P177, DOI 10.1002/(SICI)1521 186X(1999)20:3<177::AID BEM4>3.0.CO;2 #
   Declercq H, 2004, BIOMATERIALS, V25, P757, DOI 10.1016/S0142 9612(03)00580 5
   DEHAAS WG, 1980, J BONE JOINT SURG BR, V62, P465, DOI 10.1302/0301 620X.62B4.6968752
   Diniz P, 2002, BIOELECTROMAGNETICS, V23, P398, DOI 10.1002/bem.10032
   Diniz P, 2002, NITRIC OXIDE BIOL CH, V7, P18, DOI 10.1016/S1089 8603(02)00004 6
   Emes Y, 2013, LASER MED SCI, V28, P901, DOI 10.1007/s10103 012 1165 5
   Esmail MY, 2012, ELECTROMAGN BIOL MED, V31, P375, DOI 10.3109/15368378.2012.662196
   Esposito M, 2012, IN VIVO, V26, P299
   FRIEDENBERG ZB, 1966, J BONE JOINT SURG AM, VA 48, P915, DOI 10.2106/00004623 196648050 00009
   Fu YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091581
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Grace KLR, 1998, ORTHOPEDICS, V21, P297
   Hannay G, 2005, BIOELECTROMAGNETICS, V26, P670, DOI 10.1002/bem.20166
   Hinsenkamp M, 1978, Acta Orthop Belg, V44, P671
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   JUKKOLA A, 1993, J BONE MINER RES, V8, P651
   Kaivosoja E, 2015, J TISSUE ENG REGEN M, V9, P31, DOI 10.1002/term.1612
   Kamolmatyakul S., 2008, Songklanakarin Journal of Science and Technology, V30, P25
   Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005 0342
   Ledda M, 2015, TISSUE ENG PART C ME, V21, P207, DOI [10.1089/ten.TEC.2014.0216, 10.1089/ten.tec.2014.0216]
   Li KC, 2014, ARCH ORAL BIOL, V59, P921, DOI 10.1016/j.archoralbio.2014.05.015
   Lim K., 2013, BIOMED RES INT, V2013, P14
   Liu CX, 2013, BIOELECTROMAGNETICS, V34, P453, DOI 10.1002/bem.21791
   Lohmann CH, 2000, J ORTHOP RES, V18, P637, DOI 10.1002/jor.1100180417
   Mareschi K, 2001, HAEMATOLOGICA, V86, P1099
   Martino CF, 2008, BIOELECTROMAGNETICS, V29, P125, DOI 10.1002/bem.20372
   McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534 5807(04)00075 9
   McLeod KJ, 2000, RADIAT RES, V153, P706, DOI 10.1667/0033 7587(2000)153[0706:SOADRI]2.0.CO;2
   Miyagi N, 2000, BIOELECTROMAGNETICS, V21, P112, DOI 10.1002/(SICI)1521 186X(200002)21:2<112::AID BEM6>3.0.CO;2 H
   MURRAY E, 1987, J BONE MINER RES, V2, P231
   NORTON LA, 1982, CLIN ORTHOP RELAT R, P280
   Ongaro A, 2014, BIOELECTROMAGNETICS, V35, P426, DOI 10.1002/bem.21862
   Pautke C, 2004, ANTICANCER RES, V24, P3743
   Prideaux M, 2014, CALCIFIED TISSUE INT, V95, P183, DOI 10.1007/s00223 014 9879 y
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   RODAN SB, 1987, CANCER RES, V47, P4961
   Saldaña L, 2011, ACTA BIOMATER, V7, P4210, DOI 10.1016/j.actbio.2011.07.019
   Schwartz Z, 2008, J ORTHOP RES, V26, P1250, DOI 10.1002/jor.20591
   Schwartz Z, 2009, ANN BIOMED ENG, V37, P437, DOI 10.1007/s10439 008 9628 3
   Selvarnurugan N, 2007, J ORTHOP RES, V25, P1213, DOI 10.1002/jor.20409
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   Soda A, 2008, J MED INVESTIG, V55, P267, DOI 10.2152/jmi.55.267
   Sollazzo V, 1999, ELECTRICITY AND MAGNETISM IN BIOLOGY AND MEDICINE, P453
   Sollazzo V, 2010, CLIN ORTHOP RELAT R, V468, P2260, DOI 10.1007/s11999 010 1341 5
   Song MY, 2014, BIOELECTROMAGNETICS, V35, P479, DOI 10.1002/bem.21867
   Spreafico A, 2006, PROTEOMICS, V6, P3520, DOI 10.1002/pmic.200500858
   Sun LY, 2010, BIOELECTROMAGNETICS, V31, P209, DOI 10.1002/bem.20550
   Sun LY, 2009, BIOELECTROMAGNETICS, V30, P251, DOI 10.1002/bem.20472
   Team RC, 2014, R PROJECT STAT COMPU
   Thomas CH, 2002, P NATL ACAD SCI USA, V99, P1972, DOI 10.1073/pnas.032668799
   Torricelli P, 2003, BIOMED PHARMACOTHER, V57, P57, DOI 10.1016/S0753 3322(02)00329 3
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   Yang W, 2008, ELECTROMAGN BIOL MED, V27, P298, DOI 10.1080/15368370802289604
   Yang Y, 2010, BIOELECTROMAGNETICS, V31, P277, DOI 10.1002/bem.20560
   Zhong C, 2012, PHYS THER, V92, P1208, DOI 10.2522/ptj.20110224
   Zhou J, 2014, BIOELECTROMAGNETICS, V35, P30, DOI 10.1002/bem.21794
   Zhou J, 2011, BONE, V49, P753, DOI 10.1016/j.bone.2011.06.026
NR 70
TC 14
Z9 15
U1 0
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1536 8378
EI 1536 8386
J9 ELECTROMAGN BIOL MED
JI Electromagn. Biol. Med.
PY 2016
VL 35
IS 4
BP 353
EP 364
DI 10.3109/15368378.2016.1138124
PG 12
WC Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Biophysics
GA DV5AU
UT WOS:000382938600006
PM 27355896
DA 2025 08 17
ER

PT J
AU Attivi, D
   Kosmalski, G
   Zeghmouli, C
   Gibaud, S
AF Attivi, David
   Kosmalski, Gaetan
   Zeghmouli, Claire
   Gibaud, Stephane
TI Effect of intravenous hydration in patients receiving bisphosphonate
   therapy
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
LA English
DT Article
DE Biphosphonate; Cancer; Hypercalcaemia; Renal toxicity; Side effect
ID CANCER PATIENTS; HYPERCALCEMIA; SAFETY; ZOLEDRONATE; FUROSEMIDE;
   MECHANISMS; EFFICACY; MYELOMA
AB Background Patients with advanced cancers are at high risk for bone metastases, which accelerate bone resorption and skeletal complications. Therefore, bisphosphonates, which are strong inhibitors of bone resorption, are widely used to prevent pathological fractures, pain and tumour induced hypercalcaemia. Intravenous infusion of bisphosphonate is associated with dose  and infusion rate dependent adverse renal effects. Objective The present study investigated the effect of hydration on bisphosphonate efficacy and safety. Settings The 600 bed CHOV Hospital (NeufchA cent teau, France) and the Universit, de Lorraine (Nancy, France). Methods Patients who received pamidronate or zoledronic acid treatments were identified: 50 patients [16 of whom were hydrated and 34 of whom were non hydrated]. Data on serum calcium levels, creatinine clearance and clinical tolerance were collected. Main outcome measure The impact of hydration on these parameters was analysed between day 1 and day 7. Results Bisphosphonate normalized calcaemia and hydration did not induce further reduction of calcium levels. Patient kidneys were significantly preserved by hydration in both groups (median clearance: +6.2 %), whereas dehydrated patients had lower creatinine clearance (median clearance:  1.1 %). Hydration did not influence other clinical or biological parameters tested. Conclusion Hydration plays an important role in the treatment of hypercalcaemia by pamidronate and zoledronic acid: it enhances kidney protection (i.e., creatinine clearance).
C1 [Attivi, David; Kosmalski, Gaetan; Zeghmouli, Claire] CHOV, F 88300 Neufchateau, France.
   [Gibaud, Stephane] Univ Lorraine, Fac Pharm, Equipe CITHEFOR EA3452, F 54000 Nancy, France.
   [Gibaud, Stephane] Univ Lorraine, Pharm Clin, Fac Pharm, F 54000 Nancy, France.
C3 Universite de Lorraine; Universite de Lorraine
RP Gibaud, S (通讯作者)，Univ Lorraine, Fac Pharm, Equipe CITHEFOR EA3452, 5 Rue Albert Lebrun, F 54000 Nancy, France.
EM stephane.gibaud@univ lorraine.fr
RI GIBAUD, Stephane/F 2650 2010
OI GIBAUD, Stephane/0000 0003 3594 0601
CR Ali SM, 2001, J CLIN ONCOL, V19, P3434, DOI 10.1200/JCO.2001.19.14.3434
   Bodmer M, 2007, NEPHROL DIAL TRANSPL, V22, P2366, DOI 10.1093/ndt/gfm209
   BOUNAMEAUX HM, 1983, LANCET, V1, P471
   FISKEN RA, 1980, Q J MED, V49, P405
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Green JR, 1997, PHARMACOL TOXICOL, V80, P225, DOI 10.1111/j.1600 0773.1997.tb01964.x
   Henley D, 2005, INTERN MED J, V35, P726, DOI 10.1111/j.1445 5994.2005.00949.x
   LeGrand SB, 2008, ANN INTERN MED, V149, P259, DOI 10.7326/0003 4819 149 4 200808190 00007
   Lühe A, 2008, TOXICOL IN VITRO, V22, P899, DOI 10.1016/j.tiv.2008.01.006
   Lumachi F, 2009, ANTICANCER RES, V29, P1551
   Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523 1755.2003.00071.x
   Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104
   Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806
   Tralongo P, 2004, ONCOLOGY BASEL, V67, P112, DOI 10.1159/000080996
   [U.S. Food and Drug Administration FDA], 2009, DRUG SAF NEWSL, V2, P16
NR 17
TC 2
Z9 3
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2210 7703
EI 2210 7711
J9 INT J CLIN PHARM NET
JI Int. J. Clin. Phar,.
PD DEC
PY 2014
VL 36
IS 6
BP 1277
EP 1281
DI 10.1007/s11096 014 9994 x
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AT6DB
UT WOS:000345028100025
PM 25208980
DA 2025 08 17
ER

PT J
AU Ronco, C
   Cozzolino, M
AF Ronco, Claudio
   Cozzolino, Mario
TI Mineral metabolism abnormalities and vitamin D receptor activation in
   cardiorenal syndromes
SO HEART FAILURE REVIEWS
LA English
DT Article
DE Cardiorenal syndromes; Cardiovascular disease; Chronic kidney disease;
   Mineral and bone disorder; Vitamin D
ID CHRONIC KIDNEY DISEASE; STAGE RENAL DISEASE; PARATHYROID HORMONE LEVELS;
   HEART FAILURE; SECONDARY HYPERPARATHYROIDISM; CARDIOVASCULAR DISEASE;
   HEMODIALYSIS PATIENTS; 1,25 DIHYDROXYVITAMIN D 3; MYOCARDIAL INFARCTION;
   D SUPPLEMENTATION
AB Over the last decade, it has become increasingly clear that the cardiovascular and renal systems are interdependent. Primary disorders of either system have been shown to disturb the other system. As a result, a class of cardiorenal syndromes (CRS) has been identified wherein a vicious cycle is established as an acute/chronic dysfunction of either the kidney or the heart exacerbates the loss of function in the other organ. Progressive loss of kidney function observed in patients with CRS (mostly types 2 and 4) leads to reduced production of calcitriol (active vitamin D) and an imbalance in calcium and phosphorus levels, which are correlated with increased rates of cardiovascular events and mortality. In addition, hypocalcemia can lead to prolonged and excessive secretion of parathyroid hormone (PTH), eventually leading to development of secondary hyperparathyroidism. Therefore, based on this important mechanism of organ damage, one of the major goals of therapy for patients with CRS is to restore regulatory control of PTH. Although administration of calcitriol increases serum calcium levels and reduces PTH levels, it is also associated with elevated serum levels of calcium phosphorus product. Therefore, compounds that selectively activate vitamin D receptors, potentially reducing calcium x phosphate toxicity, are likely to enhance cardiorenal protection and provide significant clinical benefit.
C1 [Ronco, Claudio] Osped San Bortolo ULSS 6, Int Renal Res Inst, Dept Nephrol Dialysis & Transplantat, I 36100 Vicenza, Italy.
   [Cozzolino, Mario] Univ Milan, Dept Med Surg & Dent, San Paolo Hosp, Div Renal, Milan, Italy.
C3 ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Milan; San
   Paolo Polo Universitaria Hospital
RP Ronco, C (通讯作者)，Osped San Bortolo ULSS 6, Int Renal Res Inst, Dept Nephrol Dialysis & Transplantat, Viale Rodolfi 37, I 36100 Vicenza, Italy.
EM cronco@goldnet.it
RI Cozzolino, Mario/AAB 9965 2022
OI Ronco, Claudio/0000 0002 6697 4065; Cozzolino, Mario/0000 0002 8494 6252
CR Alsafwah S, 2007, CLIN MED RES, V5, P238, DOI 10.3121/cmr.2007.737
   Andress D, 2007, DRUGS, V67, P1999, DOI 10.2165/00003495 200767140 00003
   Artaza JN, 2009, CLIN J AM SOC NEPHRO, V4, P1515, DOI 10.2215/CJN.02260409
   BAKER LRI, 1989, KIDNEY INT, V35, P661, DOI 10.1038/ki.1989.36
   Berl T, 2006, CLIN J AM SOC NEPHRO, V1, P8, DOI 10.2215/CJN.00730805
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Bodyak N, 2007, P NATL ACAD SCI USA, V104, P16810, DOI 10.1073/pnas.0611202104
   Bongartz LG, 2005, EUR HEART J, V26, P11, DOI 10.1093/eurheartj/ehi020
   Bover J, 2009, J RENAL CARE, V35, P19, DOI 10.1111/j.1755 6686.2009.00049.x
   Brancaccio D, 2002, NEPHROL DIAL TRANSPL, V17, P201, DOI 10.1093/ndt/17.2.201
   Breidthardt T, 2009, KIDNEY INT, V75, P253, DOI 10.1038/ki.2008.591
   Brown AJ, 2002, NEPHROL DIAL TRANSPL, V17, P10, DOI 10.1093/ndt/17.suppl_10.10
   Cozzolino M, 2009, CLIN NEPHROL, V71, P593
   Cozzolino M, 2008, AM J NEPHROL, V28, P339, DOI 10.1159/000111827
   de Zeeuw D, 2010, LANCET, V376, P1543, DOI 10.1016/S0140 6736(10)61032 X
   Dusso A, 2010, J STEROID BIOCHEM, V121, P193, DOI 10.1016/j.jsbmb.2010.03.064
   Fraser A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013882
   Geisberg C, 2006, CLEV CLIN J MED, V73, P485, DOI 10.3949/ccjm.73.5.485
   Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174
   Hage FG, 2009, J AM COLL CARDIOL, V53, P2129, DOI 10.1016/j.jacc.2009.02.047
   Herzog CA, 2002, NEPHROL DIAL TRANSPL, V17, P7, DOI 10.1093/ndt/17.1.7
   Hruska KA, 2008, KIDNEY INT, V74, P148, DOI 10.1038/ki.2008.130
   Isakova T, 2009, KIDNEY INT, V76, P705, DOI 10.1038/ki.2009.246
   Jean G, 2009, NEPHROL DIAL TRANSPL, V24, P3799, DOI 10.1093/ndt/gfp370
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Joy MS, 2007, J MANAGE CARE PHARM, V13, P397, DOI 10.18553/jmcp.2007.13.5.397
   Kaneko TM, 2007, CLIN ORTHOP RELAT R, P188, DOI 10.1097/BLO.0b013e318031465b
   Kerr DNS, 1997, CARDIOVASC RES, V36, P293, DOI 10.1016/S0008 6363(97)00243 5
   Ketteler M, 2009, NEPHROL DIAL TRANSPL, V24, P2618, DOI 10.1093/ndt/gfp323
   Kochupillai N, 2008, INDIAN J MED RES, V127, P256
   Kooienga L, 2009, AM J KIDNEY DIS, V53, P408, DOI 10.1053/j.ajkd.2008.09.020
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI 10.1172/JCI0215219
   Liu LCY, 2010, EUR HEART J, V31, P1054
   Locatelli F, 2002, NEPHROL DIAL TRANSPL, V17, P723, DOI 10.1093/ndt/17.5.723
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   Malluche HH, 2002, KIDNEY INT, V62, P367, DOI 10.1046/j.1523 1755.2002.00450.x
   Mancuso P, 2008, J CARDIOVASC PHARM, V51, P559, DOI 10.1097/FJC.0b013e3181761906
   Marchais SJ, 1999, NEPHROL DIAL TRANSPL, V14, P2178, DOI 10.1093/ndt/14.9.2178
   Matias PJ, 2010, CLIN J AM SOC NEPHRO, V5, P905, DOI 10.2215/CJN.06510909
   McAlister FA, 2004, CIRCULATION, V109, P1004, DOI 10.1161/01.CIR.0000116764.53225.A9
   Melamed ML, 2008, ARTERIOSCL THROM VAS, V28, P1179, DOI 10.1161/ATVBAHA.108.165886
   Mittalhenkle A, 2004, AM J KIDNEY DIS, V44, P672, DOI 10.1053/j.ajkd.2004.07.001
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004 0002
   Nemerovski CW, 2009, PHARMACOTHERAPY, V29, P691, DOI 10.1592/phco.29.6.691
   Nickolas TL, 2006, J AM SOC NEPHROL, V17, P3223, DOI 10.1681/ASN.2005111194
   Pfeifer M, 2001, J CLIN ENDOCR METAB, V86, P1633, DOI 10.1210/jc.86.4.1633
   Rix M, 1999, KIDNEY INT, V56, P1084, DOI 10.1046/j.1523 1755.1999.00617.x
   Ronco C, 2008, J AM COLL CARDIOL, V52, P1527, DOI 10.1016/j.jacc.2008.07.051
   Ronco C, 2010, EUR HEART J, V31, P703, DOI 10.1093/eurheartj/ehp507
   Ronco C, 2009, CURR OPIN CRIT CARE, V15, P384, DOI 10.1097/MCC.0b013e32832e971b
   Ronco C, 2009, BLOOD PURIFICAT, V27, P114, DOI 10.1159/000167018
   Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754, DOI 10.1093/ajcn/83.4.754
   Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275
   Smith Katherine R, 2009, Nephrol Nurs J, V36, P49
   Snijder MB, 2007, J INTERN MED, V261, P558, DOI 10.1111/j.1365 2796.2007.01778.x
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523 1755.2003.00878.x
   Staeva Vieira TP, 2002, J IMMUNOL, V168, P1181, DOI 10.4049/jimmunol.168.3.1181
   Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536
   Thomas R, 2008, PRIMARY CARE, V35, P329, DOI 10.1016/j.pop.2008.01.008
   Tian J, 2007, NEPHROL DIAL TRANSPL, V22, P321, DOI 10.1093/ndt/gfl595
   Tishkoff DX, 2008, ENDOCRINOLOGY, V149, P558, DOI 10.1210/en.2007 0805
   US Renal Data System, 2004, USRDS 2004 ANN DAT R
   Vitamin D., 2008, ALTERN MED REV, V13, P153
   Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127
   Watson KE, 1997, CIRCULATION, V96, P1755, DOI 10.1161/01.CIR.96.6.1755
   Wolf M, 2007, J STEROID BIOCHEM, V103, P487, DOI 10.1016/j.jsbmb.2006.11.009
   Zhao GX, 2010, DIABETES CARE, V33, P344, DOI 10.2337/dc09 0924
   Zittermann A, 2008, EUR J HEART FAIL, V10, P321, DOI 10.1016/j.ejheart.2008.01.013
NR 70
TC 25
Z9 26
U1 0
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1382 4147
J9 HEART FAIL REV
JI Heart Fail. Rev.
PD MAR
PY 2012
VL 17
IS 2
SI SI
BP 211
EP 220
DI 10.1007/s10741 011 9232 8
PG 10
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 917BD
UT WOS:000302146100008
PM 21327712
DA 2025 08 17
ER

PT J
AU Wibowo, I
   Utami, N
   Anggraeni, T
   Barlian, A
   Putra, RE
   Indriani, AD
   Masadah, R
   Ekawardhani, S
AF Wibowo, Indra
   Utami, Nuruliawaty
   Anggraeni, Tjandra
   Barlian, Anggraini
   Putra, Ramadhani Eka
   Indriani, Annisa Devi
   Masadah, Rina
   Ekawardhani, Savira
TI Propolis Can Improve Caudal Fin Regeneration in Zebrafish (Danio
   rerio) Induced by The Combined Administration of Alloxan and Glucose
SO ZEBRAFISH
LA English
DT Article
DE zebrafish; ethanolic extract of propolis; alloxan; hyperglycemia; caudal
   fin; regeneration
ID PANCREATIC BETA CELLS; OXIDATIVE STRESS; SONIC HEDGEHOG;
   DIABETES MELLITUS; POLYOL PATHWAY; EXPRESSION; MECHANISMS; GENES; MODEL;
   HYPERGLYCEMIA
AB Hyperglycemia, a primary symptom in diabetes mellitus, is associated with difficulties in wound healing and regeneration. This condition is due to the length of the inflammatory phase and free radicals. Furthermore, there is evidence that molecular pathogenesis is involved in impaired wound healing in diabetics. As an animal model, zebrafish have many shared orthologous genes with human that are involved in protein regulation of wound healing and regeneration. Little is known about natural drugs that may be used to treat complications of wound healing in diabetes. Propolis, however, is known to consist of various organic compounds such as phenols and flavonoids with antioxidant and anti inflammatory activities. This research aims to study propolis' effect on caudal fin regeneration and relative expression of several genes belonging to Hedgehog, bone morphogenetic protein (BMP), and Wnt signaling hyperglycemic (HG) zebrafish. GC MS analysis and antioxidant activity testing were performed on ethanolic extract of propolis (EEP). Caudal fin regeneration was analyzed using ImageJ; blood glucose levels were measured; and relative gene expression analysis of shha, igf2a, bmp2b, and col1a2 was performed by the real time polymerase chain reaction method with the beta actin housekeeping gene. Impairment of caudal fin regeneration in zebrafish hyperglycemia was characterized by a low percentage of regeneration and decreased relative gene expression. EEP at 15 ppm could increase the percentage of caudal fin regeneration and the expression of shha, igf2a, bmp2b, and col1a2. Based on the results, it appears that phenols and flavonoids from the EEP can improve the caudal fin regeneration of HG zebrafish.
C1 [Wibowo, Indra; Utami, Nuruliawaty; Anggraeni, Tjandra; Barlian, Anggraini; Putra, Ramadhani Eka; Indriani, Annisa Devi] Bandung Inst Technol ITB, Sch Life Sci & Technol, Bandung, Indonesia.
   [Putra, Ramadhani Eka] Inst Teknol Sumatera, Biol Studi Program, Jalan Terusan Ryacudu, Way Hui, Indonesia.
   [Masadah, Rina] Hasanuddin Univ, Dept Pathol Anat, Fac Med, Makassar, Indonesia.
   [Ekawardhani, Savira] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Parasitol Div, Jalan Eyckman 38, Bandung 40161, Indonesia.
C3 Institute Technology of Bandung; Universitas Hasanuddin; Universitas
   Padjadjaran
RP Ekawardhani, S (通讯作者)，Univ Padjadjaran, Fac Med, Dept Biomed Sci, Parasitol Div, Jalan Eyckman 38, Bandung 40161, Indonesia.
EM savira@unpad.ac.id
RI Wibowo, Indra/JMR 0034 2023; ekawardhani, savira/GSN 9432 2022; Utami,
   Nuruliawaty/F 3024 2019; PUTRA, RAMADHANI EKA/JGE 3498 2023; Barlian,
   Anggraini/GOH 2578 2022
OI Ekawardhani, Savira/0000 0002 8904 7811; Wibowo,
   Indra/0000 0001 7197 2075; Utami, Nuruliawaty/0000 0001 7720 2450; 
FU IPUPT Desentralisasi DIKTI Grant; BPPDN DIKTI Scholarship; Riset
   Kolaborasi; PPKI; Insinas
FX This research was partly supported by grants (to IW), IPUPT
   Desentralisasi DIKTI Grant, Riset Kolaborasi, BPPDN DIKTI Scholarship
   and grants (to SE) PPKI 2019, and Insinas 2020.
CR Abo Salem OM, 2009, PAK J PHARM SCI, V22, P205
   Ai Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
   AKIMENKO MA, 1995, DEVELOPMENT, V121, P347
   Amir O., 2012, ULCERS, V2012
   Azevedo AS, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471 213X 12 24
   Bankova V, 2005, J ETHNOPHARMACOL, V100, P114, DOI 10.1016/j.jep.2005.05.004
   Barroso Poliana Ribeiro, 2012, Inflammopharmacology, V20, P289, DOI 10.1007/s10787 011 0105 5
   Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20
   Bijlsma MF, 2009, J CELL MOL MED, V13, P2053, DOI 10.1111/j.1582 4934.2008.00491.x
   Boyer F, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/534873
   Brem H, 2007, J CLIN INVEST, V117, P1219, DOI 10.1172/JCI32169
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Capiotti KM, 2014, COMP BIOCHEM PHYS B, V171, P58, DOI 10.1016/j.cbpb.2014.03.005
   Catrina SB, 2004, DIABETES, V53, P3226, DOI 10.2337/diabetes.53.12.3226
   Chung SSM, 2003, J AM SOC NEPHROL, V14, pS233, DOI 10.1097/01.ASN.0000077408.15865.06
   Clayton W., 2009, Clin Diabetes, V27, P52, DOI DOI 10.2337/DIACLIN.27.2.52
   Coughlan MT, 2009, J AM SOC NEPHROL, V20, P742, DOI 10.1681/ASN.2008050514
   Dey Lucy, 2002, Altern Med Rev, V7, P45
   Dorey K, 2010, DEVELOPMENT, V137, P3731, DOI 10.1242/dev.037689
   Dunlop M, 2000, KIDNEY INT, V58, pS3, DOI 10.1046/j.1523 1755.2000.07702.x
   Eames SC, 2010, ZEBRAFISH, V7, P205, DOI 10.1089/zeb.2009.0640
   Ebeling P, 1998, FEBS LETT, V436, P301, DOI 10.1016/S0014 5793(98)01149 1
   Fuliang HU, 2005, PHARMACOL RES, V51, P147, DOI 10.1016/j.phrs.2004.06.011
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   Gleeson M, 2007, ACTA DIABETOL, V44, P157, DOI 10.1007/s00592 007 0257 3
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   Gregoris E, 2010, FOOD CHEM TOXICOL, V48, P76, DOI 10.1016/j.fct.2009.09.018
   Hasan A.E.Z., 2013, JURNAL TEKNOLOGI IND, V23, P7
   Ho Jun Kim, 2002, J Vet Sci, V3, P247
   Hwang JM, 2008, MOL CELL BIOCHEM, V311, P179, DOI 10.1007/s11010 008 9708 6
   Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975
   Intine RV., 2013, JOVE J VIS EXP, V72, P1
   Iovine MK, 2007, NAT CHEM BIOL, V3, P613, DOI 10.1038/nchembio.2007.36
   Kakoolaki S, 2013, BASIC CLIN NEUROSCI, V4, P153
   Kanbur R., 2009, SPATIAL INEQUALITY D
   Kitamura H, 2013, ADIPOCYTE, V2, P227, DOI 10.4161/adip.25608
   Kubisch HM, 1997, DIABETES, V46, P1563, DOI 10.2337/diabetes.46.10.1563
   Lan CCE, 2013, DIABETES, V62, P2530, DOI 10.2337/db12 1714
   Lattanzio V, 2001, J AGR FOOD CHEM, V49, P5817, DOI 10.1021/jf010255b
   Le H, 2008, WOUND REPAIR REGEN, V16, P768, DOI 10.1111/j.1524 475X.2008.00430.x
   Lipinski B, 2001, J DIABETES COMPLICAT, V15, P203, DOI 10.1016/S1056 8727(01)00143 X
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Löndahl M, 2010, DIABETES CARE, V33, P998, DOI 10.2337/dc09 1754
   Lorenzi M, 2007, EXP DIABETES RES, DOI 10.1155/2007/61038
   Maes J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043850
   Matsushige K, 1996, PHYTOMEDICINE, V3, P203, DOI 10.1016/S0944 7113(96)80037 7
   McLennan SV, 2008, WOUND REPAIR REGEN, V16, P706, DOI 10.1111/j.1524 475X.2008.00421.x
   Michalak A, 2006, POL J ENVIRON STUD, V15, P523
   Modak M, 2007, J CLIN BIOCHEM NUTR, V40, P163, DOI 10.3164/jcbn.40.163
   Naziroglu M, 2001, BIOL TRACE ELEM RES, V79, P149, DOI 10.1385/BTER:79:2:149
   Nelson EA, 2006, DIABETIC MED, V23, P348, DOI 10.1111/j.1464 5491.2006.01785.x
   Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229
   Olsen AS, 2010, WOUND REPAIR REGEN, V18, P532, DOI 10.1111/j.1524 475X.2010.00613.x
   Orsolic N, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472 6882 12 117
   Ozturk H, 2007, RENAL FAILURE, V29, P249, DOI 10.1080/08860220601166289
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Park S, 2015, NUTRIENTS, V7, P8987, DOI 10.3390/nu7115445
   Paul CC., 2015, Integrative Obesity and Diabetes, V3, P71, DOI DOI 10.3923/IJBC.2015.92.109
   Poss FD, 2000, DEV BIOL, V222, P347, DOI 10.1006/dbio.2000.9722
   Quint E, 2002, P NATL ACAD SCI USA, V99, P8713, DOI 10.1073/pnas.122571799
   Reinisalo M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/340520
   Sarras MP Jr, 2013, WOUND REPAIR REGEN, V21, P320, DOI 10.1111/wrr.12027
   Schebesta M, 2006, THESCIENTIFICWORLDJO, V6, P38, DOI 10.1100/tsw.2006.326
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Seven PT., 2012, EFFECTS PROPOLIS ANI
   Shapiro Karen, 2002, J Am Pharm Assoc (Wash), V42, P217, DOI 10.1331/108658002763508515
   Shin EunJi Shin EunJi, 2012, African Journal of Pharmacy and Pharmacology, V6, P2922
   SHKUMAT MS, 2013, J MED BIOL SCI, V6, P1
   Simkin J, 2015, REGENERATION, V2, P93, DOI 10.1002/reg2.36
   Thomas CC, 2015, MED CLIN N AM, V99, P1, DOI 10.1016/j.mcna.2014.08.015
   Trusheva B, 2011, NAT PROD RES, V25, P606, DOI 10.1080/14786419.2010.488235
   Tseng YC, 2009, AM J PHYSIOL REG I, V297, pR275, DOI 10.1152/ajpregu.00180.2009
   Tu S, 2011, DEV CELL, V20, P725, DOI 10.1016/j.devcel.2011.04.013
   Unnikrishnan R, 2016, NAT REV ENDOCRINOL, V12, P357, DOI 10.1038/nrendo.2016.53
   VOLPERT R, 1993, Z NATURFORSCH C, V48, P851
   Wali AF., 2015, BIOMED RES INT, P1
   Wilson JM, 2009, J AM ASSOC LAB ANIM, V48, P785
   Wong SL, 2015, NAT MED, V21, P815, DOI 10.1038/nm.3887
   Wu CJ, 2008, J DENT SCI, V3, P13
   Yan B, 2014, J IMMUNOL, V192, P5998, DOI 10.4049/jimmunol.1301645
   Yan CL, 2010, AM J PATHOL, V176, P2247, DOI 10.2353/ajpath.2010.090048
NR 82
TC 8
Z9 8
U1 2
U2 28
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1545 8547
EI 1557 8542
J9 ZEBRAFISH
JI Zebrafish
PD AUG 1
PY 2021
VL 18
IS 4
BP 274
EP 281
DI 10.1089/zeb.2020.1969
EA JUL 2021
PG 8
WC Developmental Biology; Zoology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology; Zoology
GA UC1HE
UT WOS:000676014400001
PM 34297614
DA 2025 08 17
ER

PT J
AU Qi, HW
   Wang, BQ
   Wang, MJ
   Xie, HF
   Chen, C
AF Qi, Haowen
   Wang, Bingqing
   Wang, Mingjuan
   Xie, Haifeng
   Chen, Chen
TI A pH/ROS responsive antioxidative and antimicrobial GelMA hydrogel for
   on demand drug delivery and enhanced osteogenic differentiation in vitro
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Smart hydrogel; On demand drug delivery; Boronate complex;
   Antibacterial; Oxidative stress; Osteogenesis
ID BONE REGENERATION; HYALURONIC ACID; TISSUE; PROANTHOCYANIDINS;
   MICROENVIRONMENT; CHITOSAN; SCAFFOLDS; MECHANISM
AB Long term inflammation, including those induced by bacterial infections, contributes to the superfluous accumulation of reactive oxygen species (ROS), further aggravating this condition, decreasing the local pH, and adversely affecting bone defect healing. Conventional drug delivery scaffold materials struggle to meet the demands of this complex and dynamic microenvironment. In this work, a smart gelatin methacryloyl (GelMA) hydrogel was synthesized for the dual delivery of proanthocyanidin and amikacin based on the unique pH and ROS responsiveness of boronate complexes. Fourier transform infrared spectroscopy (FTIR) and X ray photoelectron spectroscopy (XPS) demonstrated the co crosslinking of two boronate complexes with GelMA. The addition of the boronate complexes improved the mechanical properties, swelling ratio, degradation kinetics and antioxidative properties of the hydrogel. The hydrogel exhibited pH and ROS responses and a synergistic control over the drug release. Proanthocyanidin was responsively released to protect mouse osteoblast precursor cells from oxidative stress and promote their osteogenic differentiation. The hydrogel responded to pH changes and released sufficient amikacin in a timely manner, thereby exerting an efficient antimicrobial effect. Overall, the hydrogel delivery system exhibited a promising strategy for solving infectious and inflammatory problems in bone defects and promoting early stage bone healing.
C1 [Qi, Haowen; Wang, Bingqing; Xie, Haifeng] Nanjing Med Univ, Affiliated Stomatol Hosp, Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Dept Prosthodont,State Key Lab Cultivat Base Res P, Nanjing 210029, Peoples R China.
   [Wang, Mingjuan; Chen, Chen] Nanjing Med Univ, Affiliated Stomatol Hosp, Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Dept Endodont,State Key Lab Cultivat Base Res Prev, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Xie, HF (通讯作者)，Nanjing Med Univ, Affiliated Stomatol Hosp, Jiangsu Prov Engn Res Ctr Stomatol Translat Med, Dept Prosthodont,State Key Lab Cultivat Base Res P, Nanjing 210029, Peoples R China.
EM xhf 1980@126.com
RI ; Xie, Haifeng/AAR 2559 2021
OI Qi, Haowen/0009 0003 0055 6236; Chen, Chen/0000 0002 2989 180X; Wang,
   Bingqing/0000 0003 4370 879X; 
FU Key R & D Program of Jiangsu Province (Social Development) Project
   [BE2022797]; Jiangsu Province Capability Improvement Project through
   Science, Technology and Education Jiangsu Provincial Research Hospital
   Cultivation Unit [YJXYYJSDW4]; Jiangsu Provincial Medical Innovation
   Center [CXZX202227]
FX This work was supported by Key R & D Program of Jiangsu Province (Social
   Development) Project [grant BE2022797] ; Jiangsu Province Capability
   Improvement Project through Science, Technology and Education Jiangsu
   Provincial Research Hospital Cultivation Unit (YJXYYJSDW4) , Jiangsu
   Provincial Medical Innovation Center (CXZX202227) .
CR Albright V, 2017, ACTA BIOMATER, V61, P66, DOI 10.1016/j.actbio.2017.08.012
   Arai Y, 2020, J CONTROL RELEASE, V328, P596, DOI 10.1016/j.jconrel.2020.09.023
   Chen JT, 2023, CHEM ENG J, V471, DOI 10.1016/j.cej.2023.144537
   Chen L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9102012
   Chen QX, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202201067
   Chen XT, 2023, J MATER CHEM B, V11, P2663, DOI 10.1039/d2tb02407a
   Choi EJ, 2022, J IMMUNOL RES, V2022, DOI 10.1155/2022/6284124
   Choi JB, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11030617
   Craig WA, 2001, CLIN INFECT DIS, V33, pS233, DOI 10.1086/321854
   Dudaric L, 2015, FOOD RES INT, V77, P290, DOI 10.1016/j.foodres.2015.10.017
   Farmer EE, 2013, ANNU REV PLANT BIOL, V64, P429, DOI 10.1146/annurev arplant 050312 120132
   Feng JN, 2018, FOOD CHEM, V239, P612, DOI 10.1016/j.foodchem.2017.06.052
   Frasconi M, 2010, ANAL CHEM, V82, P2512, DOI 10.1021/ac902944k
   Fu Y, 2021, MATER HORIZ, V8, P1618, DOI 10.1039/d0mh01985b
   Gibbs DMR, 2016, J TISSUE ENG REGEN M, V10, P187, DOI 10.1002/term.1968
   Gourlay G, 2022, PLANT CELL ENVIRON, V45, P362, DOI 10.1111/pce.14242
   Han L, 2017, J MATER CHEM B, V5, P731, DOI 10.1039/c6tb02348g
   Han S, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51614 x
   Han W, 2023, INT J BIOL MACROMOL, V227, P373, DOI 10.1016/j.ijbiomac.2022.12.037
   Hande Y., 2011, Advances in Materials Physics and Chemistry, V1, DOI [10.4236/ampc.2011.12009, DOI 10.4236/AMPC.2011.12009]
   He BB, 2022, BIOACT MATER, V17, P234, DOI 10.1016/j.bioactmat.2022.01.034
   He ZC, 2023, CARBOHYD POLYM, V299, DOI 10.1016/j.carbpol.2022.120180
   Henkel J, 2013, BONE RES, V1, P216, DOI 10.4248/BR201303002
   Hong GY, 2021, APPL SURF SCI, V570, DOI 10.1016/j.apsusc.2021.151144
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142 9612(00)00121 6
   Jorgensen C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.606781
   Kanellakopoulou K, 2009, INT J ANTIMICROB AG, V33, P354, DOI 10.1016/j.ijantimicag.2008.09.008
   KELLY MT, 1976, ANTIMICROB AGENTS CH, V9, P440, DOI 10.1128/AAC.9.3.440
   Kong HJ, 2003, MACROMOLECULES, V36, P4582, DOI 10.1021/ma034137w
   Lee DH, 2006, CELL BIOL TOXICOL, V22, P39, DOI 10.1007/s10565 006 0018 z
   Li N, 2019, CHEM ENG J, V371, P618, DOI 10.1016/j.cej.2019.04.017
   Li YP, 2012, ANGEW CHEM INT EDIT, V51, P2864, DOI 10.1002/anie.201107144
   Liang C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 12163 z
   Lin ZJ, 2021, BIOACT MATER, V6, P2315, DOI 10.1016/j.bioactmat.2021.01.018
   Liu Y, 2022, ACTA BIOMATER, V146, P37, DOI 10.1016/j.actbio.2022.03.046
   Liu Z, 2017, ACCOUNTS CHEM RES, V50, P2185, DOI 10.1021/acs.accounts.7b00179
   Maiuolo J, 2021, NUTRIENTS, V13, DOI 10.3390/nu13113834
   Mantena SK, 2006, FREE RADICAL BIO MED, V40, P1603, DOI 10.1016/j.freeradbiomed.2005.12.032
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Maryanovich M, 2013, TRENDS CELL BIOL, V23, P129, DOI 10.1016/j.tcb.2012.09.007
   Maxwell A, 2021, LIFE SCI, V284, DOI 10.1016/j.lfs.2021.119883
   Okamoto T, 2014, J BONE MINER METAB, V32, P393, DOI 10.1007/s00774 013 0516 z
   Patterson J, 2010, BIOMATERIALS, V31, P6772, DOI 10.1016/j.biomaterials.2010.05.047
   Rama M, 2023, POLYM BULL, V80, P7341, DOI 10.1007/s00289 022 04442 5
   Raut A, 2022, CRIT REV ANAL CHEM, V52, P375, DOI 10.1080/10408347.2020.1803042
   Reis M, 2021, DENT MATER, V37, P1633, DOI 10.1016/j.dental.2021.08.013
   RISTUCCIA AM, 1985, THER DRUG MONIT, V7, P12, DOI 10.1097/00007691 198503000 00003
   Sandor M, 2002, BBA GEN SUBJECTS, V1570, P63, DOI 10.1016/S0304 4165(02)00153 8
   Shen XK, 2019, COLLOID SURFACE B, V180, P39, DOI 10.1016/j.colsurfb.2019.04.033
   Shin YC, 2015, CARBON, V95, P1051, DOI 10.1016/j.carbon.2015.09.028
   Paiva KBS, 2014, ARCH BIOCHEM BIOPHYS, V561, P74, DOI 10.1016/j.abb.2014.07.034
   Stubelius A, 2019, ACCOUNTS CHEM RES, V52, P3108, DOI 10.1021/acs.accounts.9b00292
   Tan WW, 2023, CARBOHYD POLYM, V312, DOI 10.1016/j.carbpol.2023.120824
   Tang JH, 2020, INT J NANOMED, V15, P1643, DOI 10.2147/IJN.S231339
   Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397
   Vieira VMP, 2017, CHEM SCI, V8, P6981, DOI 10.1039/c7sc03301j
   Walters G, 2018, J TISSUE ENG REGEN M, V12, pE1662, DOI 10.1002/term.2593
   Wang H, 2023, BIOACT MATER, V21, P324, DOI 10.1016/j.bioactmat.2022.08.029
   Wang RF, 2021, ACS FOOD SCI TECHNOL, V1, P35, DOI 10.1021/acsfoodscitech.0c00021
   Wang SS, 2014, CHEM SCI, V5, P1135, DOI 10.1039/c3sc52986j
   Wang YC, 2020, EXTREME MECH LETT, V39, DOI 10.1016/j.eml.2020.100797
   Wang YH, 2018, MATERIALS, V11, DOI 10.3390/ma11081345
   Wei D, 2015, J MATER CHEM B, V3, P2753, DOI 10.1039/c5tb00129c
   Wu MH, 2022, MATER TODAY BIO, V17, DOI 10.1016/j.mtbio.2022.100458
   Xu K, 2023, BIOMATERIALS, V301, DOI 10.1016/j.biomaterials.2023.122268
   Xu XF, 2011, APPL SURF SCI, V257, P10520, DOI 10.1016/j.apsusc.2011.07.033
   Xue X, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009432
   Zhang M, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120543
   Zhang Z, 2023, CHEM ENG J, V472, DOI 10.1016/j.cej.2023.145061
   Zhao XD, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202009442
   Zhou QY, 2022, APPL SURF SCI, V602, DOI 10.1016/j.apsusc.2022.154400
   Zhu GY, 2021, BIOACT MATER, V6, P4110, DOI 10.1016/j.bioactmat.2021.03.043
NR 72
TC 14
Z9 14
U1 14
U2 43
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAY 25
PY 2024
VL 657
AR 124134
DI 10.1016/j.ijpharm.2024.124134
EA APR 2024
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA SO3N1
UT WOS:001235354600001
PM 38643810
DA 2025 08 17
ER

PT J
AU Min, KK
   Neupane, S
   Adhikari, N
   Sohn, WJ
   An, SY
   Kim, JY
   An, CH
   Lee, Y
   Kim, YG
   Park, JW
   Lee, JM
   Kim, JY
   Suh, JY
AF Min, Kyung Kon
   Neupane, Sanjiv
   Adhikari, Nirpesh
   Sohn, Wern Joo
   An, Seo Young
   Kim, Ji Youn
   An, Chang Hyeon
   Lee, Youngkyun
   Kim, Yong Gun
   Park, Jin Woo
   Lee, Jae Mok
   Kim, Jae Young
   Suh, Jo Young
TI Effects of resveratrol on bone healing capacity in the mouse tooth
   extraction socket
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE bone formation; drug efficacy; resveratrol; tooth extraction
ID MORPHOGENETIC PROTEIN 2; CELLS; RAT; DIFFERENTIATION; REGENERATION;
   GROWTH; SUPPLEMENTATION
AB Background and Objective After tooth extraction, the extraction socket undergoes several steps of soft and hard tissue healing. The healing process of the extraction socket is modulated by a range of signaling factors and biochemical agents. It has been reported that resveratrol, a polyphenolic compound, exhibits various biological effects, including anti inflammatory, anti carcinogenic, antioxidant, and anti aging effects, and protects cardiovascular and bone tissues. In this study, we examined the cellular effects of resveratrol on human periodontal ligament (hPDL) cells and osteoblast like (MC3T3 E1) cells and evaluated the bone healing capacity of tooth extraction sockets in mice. Material and Methods Resveratrol was applied to hPDL and MC3T3 E1 cells to detect cell proliferation and alkaline phosphatase (ALP) activity, and qPCR was employed to understand the gene expression level in vitro. For in vivo experiment, six week old C57BL/6 male mice were randomly divided into control (n = 15) and experimental (n = 15) groups and maxillary first molars were extracted by surgery. Experimental groups received 50 mu M resveratrol on extraction sockets and analyzed the degree of new bone formation. Results Treatment of hPDL and MC3T3 E1 cells with resveratrol increased the cell proliferation and ALP activity and enhanced the expression of ALP, BMP 2, BMP 4, and OC genes. Resveratrol enhanced new bone formation in the lingual extraction socket in mice. Conclusion These results suggest that resveratrol increases the cellular physiology of PDL and osteoblast including their proliferation and differentiation and may play an important role in bone healing capacity after tooth extraction.
C1 [Min, Kyung Kon; Kim, Yong Gun; Park, Jin Woo; Lee, Jae Mok; Suh, Jo Young] Kyungpook Natl Univ, Sch Dent, Dept Periodontol, IHBR, Daegu, South Korea.
   [Neupane, Sanjiv; Adhikari, Nirpesh; Lee, Youngkyun; Kim, Jae Young] Kyungpook Natl Univ, Sch Dent, Dept Biochem, IHBR, 2177 Dalgubeol Daero, Daegu 41940, South Korea.
   [Sohn, Wern Joo] Daegu Haany Univ, Premajor Cosmet & Pharmaceut, Gyongsan, South Korea.
   [An, Seo Young; An, Chang Hyeon] Kyungpook Natl Univ, Sch Dent, Dept Oral & Maxillofacial Radiol, IHBR, Daegu, South Korea.
   [Kim, Ji Youn] Gachon Univ, Dept Dent Hyg, Incheon, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Daegu Haany University; Kyungpook National University (KNU);
   Gachon University
RP Kim, JY (通讯作者)，Kyungpook Natl Univ, Sch Dent, Dept Biochem, IHBR, 2177 Dalgubeol Daero, Daegu 41940, South Korea.; Suh, JY (通讯作者)，Kyungpook Natl Univ, Sch Dent, Dept Periodontol, 2177 Dalgubeol Daero, Daegu 41940, South Korea.
EM jykim91@knu.ac.kr; jysuh@knu.ac.kr
RI ; Adhikari, Nirpesh/KEJ 4658 2024; Neupane, Sanjiv/I 3470 2018; Kim,
   Ji Youn/A 5779 2017
OI ADHIKARI, NIRPESH/0000 0002 8922 2114; 
FU National Research Foundation of Korea [2017M3A9E4047243,
   2017R1A5A2015391, 2018R1A2A3075600]; Ministry of Education, Science and
   Technology, Republic of Korea
FX National Research Foundation of Korea, Grant/Award Number:
   2017M3A9E4047243, 2017R1A5A2015391 and 2018R1A2A3075600; Ministry of
   Education, Science and Technology, Republic of Korea
CR AMLER MH, 1969, ORAL SURG ORAL MED O, V27, P309, DOI 10.1016/0030 4220(69)90357 0
   An SY, 2017, HISTOCHEM CELL BIOL, V148, P435, DOI 10.1007/s00418 017 1584 2
   Araújo MG, 2005, J CLIN PERIODONTOL, V32, P212, DOI 10.1111/j.1600 051X.2005.00642.x
   Arifin WN, 2017, MALAYS J MED SCI, V24, P101, DOI 10.21315/mjms2017.24.5.11
   Aubin J E, 2001, Rev Endocr Metab Disord, V2, P81, DOI 10.1023/A:1010011209064
   Bhattarai G, 2016, ACTA BIOMATER, V29, P398, DOI 10.1016/j.actbio.2015.10.031
   Boissy P, 2005, CANCER RES, V65, P9943, DOI 10.1158/0008 5472.CAN 05 0651
   Cecchinato V, 2007, BIOCHEM PHARMACOL, V74, P1568, DOI 10.1016/j.bcp.2007.08.001
   Devlin H, 2002, INT J ORAL MAX SURG, V31, P641, DOI 10.1054/ijom.2002.0292
   Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828
   Durbin SM, 2014, J BONE MINER METAB, V32, P38, DOI 10.1007/s00774 013 0469 2
   Fiorellini JP, 2005, J PERIODONTOL, V76, P605, DOI 10.1902/jop.2005.76.4.605
   Gabbay KH, 2010, J BIOL CHEM, V285, P19510, DOI 10.1074/jbc.M110.110247
   Gambini J, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/837042
   GUGLIELMOTTI MB, 1985, J ORAL MAXIL SURG, V43, P359, DOI 10.1016/0278 2391(85)90257 5
   Habauzit Veronique, 2008, Phytochemistry Reviews, V7, P313, DOI 10.1007/s11101 007 9078 9
   Habold C, 2011, J BONE MINER METAB, V29, P15, DOI 10.1007/s00774 010 0187 y
   Hahn Jack, 2003, Implant Dent, V12, P170
   Juhasz B, 2010, EXP CLIN CARDIOL, V15, pE134
   Kanyama M, 2003, ARCH ORAL BIOL, V48, P723, DOI 10.1016/S0003 9969(03)00153 5
   Kim HS, 2006, DIABETES RES CLIN PR, V74, P41, DOI 10.1016/j.diabres.2006.03.034
   Lee AMC, 2014, NUTRIENTS, V6, P5871, DOI 10.3390/nu6125871
   Lekic PC, 2001, ANAT REC, V262, P193
   LIN WL, 1994, ANAT REC, V240, P492, DOI 10.1002/ar.1092400407
   Liu P, 1999, CALCIFIED TISSUE INT, V65, P173, DOI 10.1007/s002239900678
   Liu ZP, 2005, J MED FOOD, V8, P14, DOI 10.1089/jmf.2005.8.14
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Momken I, 2011, FASEB J, V25, P3646, DOI 10.1096/fj.10 177295
   Mukherjee S, 2010, DOSE RESPONSE, V8, P478, DOI 10.2203/dose response.09 015.Mukherjee
   PIETROKO.J, 1971, J PROSTHET DENT, V26, P119, DOI 10.1016/0022 3913(71)90041 2
   Reynders P, 1999, J ORTHOP TRAUMA, V13, P121, DOI 10.1097/00005131 199902000 00009
   Ribeiro FV, 2017, J PERIODONTOL, V88, P788, DOI 10.1902/jop.2017.170025
   Sadi G, 2016, PHARM BIOL, V54, P1156, DOI 10.3109/13880209.2015.1056311
   Samsami kor M, 2015, ARCH MED RES, V46, P280, DOI 10.1016/j.arcmed.2015.05.005
   Schropp L, 2003, INT J PERIODONT REST, V23, P313
   Simon Deepti, 2004, Indian J Dent Res, V15, P133
   Su JL, 2007, J BIOL CHEM, V282, P19385, DOI 10.1074/jbc.M702452200
   Takaoka M., 1940, J FAC SCIHOKKAIDO IM, VIII, P1, DOI DOI 10.1246/NIKKASHI1921.60.1261
   Tseng PC, 2011, J BONE MINER RES, V26, P2552, DOI 10.1002/jbmr.460
NR 39
TC 23
Z9 25
U1 3
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD APR
PY 2020
VL 55
IS 2
BP 247
EP 257
DI 10.1111/jre.12710
EA DEC 2019
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA KV3LI
UT WOS:000500254300001
PM 31797379
DA 2025 08 17
ER

PT J
AU Zhang, WF
   Li, MQ
   Zhao, Z
   Xu, JS
   Liu, JL
   Feng, P
   Zhang, B
   Huang, ZH
   Kong, QQ
   Lin, YF
AF Zhang, Weifei
   Li, Mengqing
   Zhao, Zhen
   Xu, Jiangshan
   Liu, Junlin
   Feng, Pin
   Zhang, Bin
   Huang, Zhangheng
   Kong, Qing Quan
   Lin, Yunfeng
TI Tetrahedral Framework Nucleic Acid Loaded Retinoic Acid Promotes
   Osteosarcoma Stem Cell Clearance
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE osteosarcoma stem cell; tetrahedral framework nucleicacid; retinoic
   acid; ATRA; Wnt signalingpathway
ID CANCER STEMNESS; DNA; METASTASIS
AB Metastatic osteosarcoma is a commonly seen malignant tumor in adolescents, with a five year survival rate of approximately 20% and a lack of treatment options. Osteosarcoma cancer stem cells are considered to be important drivers of the metastasis of osteosarcoma, and therefore their clearance is considered a promising strategy for treating metastatic osteosarcoma. In the relevant literature, retinoic acid (ATRA) is considered effective for eliminating osteosarcoma stem cells, but it has some inherent disadvantages, including poor solubility, difficulty in entering cells, and structural instability. Tetrahedral framework nucleic acids (tFNAs) are a type of nanoparticles that can carry small molecule drugs into cells to exert therapeutic effects. Therefore, we designed and synthesized a nanoparticle named T ATRA by using tFNAs to load ATRA and studied its effect in a nude mouse model. T ATRA is more effective than ATRA in the clearance of osteosarcoma stem cells and in inhibiting osteosarcoma cell metastasis via the Wnt signaling pathway, thus prolonging the survival time of nude mice with osteosarcoma.
C1 [Zhang, Weifei; Zhao, Zhen; Kong, Qing Quan] Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Weifei; Zhao, Zhen; Kong, Qing Quan] Sichuan Univ, West China Hosp, Orthoped Res Inst, Chengdu 610041, Sichuan, Peoples R China.
   [Li, Mengqing] Peking Univ, Shenzhen Hosp, Dept Pathol, Shenzhen 518036, Guangdong, Peoples R China.
   [Xu, Jiangshan; Lin, Yunfeng] Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Liu, Junlin; Feng, Pin; Zhang, Bin; Kong, Qing Quan] Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Orthoped Surg, Chengdu 610041, Sichuan, Peoples R China.
   [Huang, Zhangheng] Wenzhou Med Univ, Dept Orthopaed Spine Surg, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
   [Lin, Yunfeng] Sichuan Prov Engn Res Ctr Oral Biomat, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Peking University; Sichuan
   University; Wenzhou Medical University
RP Kong, QQ (通讯作者)，Sichuan Univ, West China Hosp, Dept Orthoped Surg, Chengdu 610041, Sichuan, Peoples R China.; Kong, QQ (通讯作者)，Sichuan Univ, West China Hosp, Orthoped Res Inst, Chengdu 610041, Sichuan, Peoples R China.; Lin, YF (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Natl Ctr Stomatol, State Key Lab Oral Dis,Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China.; Kong, QQ (通讯作者)，Hosp Chengdu Off Peoples Govt Tibetan Autonomous R, Dept Orthoped Surg, Chengdu 610041, Sichuan, Peoples R China.; Huang, ZH (通讯作者)，Wenzhou Med Univ, Dept Orthopaed Spine Surg, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.; Lin, YF (通讯作者)，Sichuan Prov Engn Res Ctr Oral Biomat, Chengdu 610041, Sichuan, Peoples R China.
EM hzh1319330149@sina.com; kqqspine@126.com; yunfenglin@scu.edu.cn
RI zhang, weifei/AEG 8653 2022; Huang, Zhangheng/HHD 0371 2022; Lin,
   Yunfeng/H 3393 2011; Kong, qingquan/IXN 4311 2023; Bin,
   Zhang/Y 5353 2019
OI Lin, Yunfeng/0000 0003 1224 6561; 
FU National Natural Science Foundation of China [82372447, 82202747];
   Science and Technology Major Project of Tibetan Autonomous Region of
   China [XZ202201ZD0001G]; Science and Technology Project of Tibet
   Autonomous Region [XZ202303ZY0007G]; The 1<middle dot>3<middle dot>5
   Project for Disciplines of Excellence, West China Hospital, Sichuan
   University [ZYJC21026, ZYJC21077]; Science, Technology, and Innovation
   Commission of Shenzhen Municipality [RCBS20210706092253060,
   JCYJ20220531093814033]
FX This work was supported by The National Natural Science Foundation of
   China (82372447 and 82202747), Science and Technology Major Project of
   Tibetan Autonomous Region of China (XZ202201ZD0001G), Science and
   Technology Project of Tibet Autonomous Region (XZ202303ZY0007G),
   1<middle dot>3<middle dot>5 Project for Disciplines of Excellence, West
   China Hospital, Sichuan University (ZYJC21026 and ZYJC21077), and
   Science, Technology, and Innovation Commission of Shenzhen Municipality
   (RCBS20210706092253060 and JCYJ20220531093814033). Thanks are also due
   to Liying Hao (State Key Laboratory of Oral Diseases, West China
   Hospital of Stomatology, Sichuan University) for help in AFM
   characterization.
CR Bai L, 2024, ADV FUNCT MATER, V34, DOI 10.1002/adfm.202314789
   Bhal S, 2023, MED ONCOL, V40, DOI 10.1007/s12032 022 01905 7
   Borges GSM, 2021, EXPERT OPIN DRUG DEL, V18, P1335, DOI 10.1080/17425247.2021.1919619
   Borlongan MC, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1125174
   Cai ZW, 2023, ACS NANO, V17, P22668, DOI 10.1021/acsnano.3c06999
   Cao J, 2023, BIOMED PHARMACOTHER, V165, DOI 10.1016/j.biopha.2023.115096
   Chang TY, 2024, INT J BIOL SCI, V20, P880, DOI 10.7150/ijbs.90817
   Chen Y, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392 024 01736 0
   Chen ZY, 2023, AM J CHINESE MED, V51, P1041, DOI 10.1142/S0192415X23500489
   Chu XJ, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392 024 01851 y
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008 5472.CAN 06 3126
   Clarke MF, 2019, NEW ENGL J MED, V380, P2237, DOI 10.1056/NEJMra1804280
   Ge YC, 2024, ADV SCI, V11, DOI 10.1002/advs.202308701
   Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394
   Gorshtein G, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.679955
   Guarrera L, 2023, J EXP CLIN CANC RES, V42, DOI 10.1186/s13046 023 02869 w
   Gui KK, 2019, BIOMED PHARMACOTHER, V111, P751, DOI 10.1016/j.biopha.2018.11.118
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   He C, 2023, SMALL, V19, DOI 10.1002/smll.202302575
   Jun H, 2023, ACS NANO, V17, P12336, DOI 10.1021/acsnano.3c01503
   Kielbik M, 2023, BBA REV CANCER, V1878, DOI 10.1016/j.bbcan.2023.189003
   Li HB, 2022, EBIOMEDICINE, V82, DOI 10.1016/j.ebiom.2022.104142
   Li Yanjing, 2021, Nanomicro Lett, V13, P86, DOI 10.1007/s40820 021 00614 6
   Li Y, 2024, BONE RES, V12, DOI 10.1038/s41413 024 00319 7
   Liang L, 2014, ANGEW CHEM INT EDIT, V53, P7745, DOI 10.1002/anie.201403236
   Liang YL, 2023, SMALL, V19, DOI 10.1002/smll.202205511
   Lin YF, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00199 9
   Liu M, 2024, BBA REV CANCER, V1879, DOI 10.1016/j.bbcan.2023.189050
   Liu S, 2024, THERANOSTICS, V14, P622, DOI 10.7150/thno.88759
   Liu XY, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08967 2
   Lu L, 2018, EUR J PHARM SCI, V112, P186, DOI 10.1016/j.ejps.2017.11.017
   Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50
   Martins Neves SR, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24098401
   Mirabello L, 2009, CANCER AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121
   Nasab NT, 2023, J BIOCHEM MOL TOXIC, V37, DOI 10.1002/jbt.23486
   Qi C, 2024, INT J ORAL SCI, V16, DOI 10.1038/s41368 024 00290 3
   Qin XY, 2018, P NATL ACAD SCI USA, V115, P4969, DOI 10.1073/pnas.1802279115
   Seeman NC, 1998, ANGEW CHEM INT EDIT, V37, P3220, DOI 10.1002/(SICI)1521 3773(19981217)37:23<3220::AID ANIE3220>3.0.CO;2 C
   Shao XJ, 2019, ACTA PHARMACOL SIN, V40, P1343, DOI 10.1038/s41401 019 0262 4
   Sharma S, 2024, BIOMACROMOLECULES, V25, P5650, DOI 10.1021/acs.biomac.4c00847
   Shi SR, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0077 4
   Tian TR, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00212 1
   Tian T, 2023, NEONATOLOGY, V120, P441, DOI 10.1159/000530352
   Tu YC, 2024, INT J NANOMED, V19, P3641, DOI 10.2147/IJN.S459288
   Wang J, 2021, ANGEW CHEM INT EDIT, V60, P10766, DOI 10.1002/anie.202101474
   Wang KL, 2011, ANGEW CHEM INT EDIT, V50, P6098, DOI 10.1002/anie.201008053
   Wang Q, 2024, BIOMATERIALS, V306, DOI 10.1016/j.biomaterials.2024.122497
   Wang QG, 2024, ADV SCI, V11, DOI 10.1002/advs.202306622
   Wang W, 2023, ASIAN J PHARM SCI, V18, DOI 10.1016/j.ajps.2023.100846
   Wang Y, 2022, NANO LETT, V22, P1759, DOI 10.1021/acs.nanolett.1c05003
   Yan R, 2023, ACS NANO, V17, P8767, DOI 10.1021/acsnano.3c02102
   Yang YT, 2024, BIOACT MATER, V39, P191, DOI 10.1016/j.bioactmat.2024.05.017
   Yedjou C, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756 8722 3 28
   Yu LQ, 2024, ONCOL REP, V51, DOI 10.3892/or.2024.8719
   Zhang H, 2020, NANO LETT, V20, P8399, DOI 10.1021/acs.nanolett.0c03671
   Zhang T, 2022, ADV MATER, DOI 10.1002/adma.202107820
   Zhang T, 2020, NAT PROTOC, V15, P2728, DOI 10.1038/s41596 020 0355 z
   Zhang WF, 2022, CELL BIOL INT, V46, P336, DOI 10.1002/cbin.11752
   Zhang WF, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/9941733
   Zhao D, 2022, INT J ORAL SCI, V14, DOI 10.1038/s41368 022 00171 7
   Zhao YX, 2023, SMALL, V19, DOI 10.1002/smll.202302326
   Zhuo BB, 2021, J BONE ONCOL, V31, DOI 10.1016/j.jbo.2021.100403
NR 62
TC 1
Z9 1
U1 14
U2 29
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD OCT 19
PY 2024
VL 16
IS 43
BP 58452
EP 58463
DI 10.1021/acsami.4c14440
EA OCT 2024
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA K6O6U
UT WOS:001338407500001
PM 39425646
DA 2025 08 17
ER

PT J
AU Jadresic, M
   Kuna, SK
   Brzac, HT
   Baretic, M
   Huic, D
AF Jadresic, Marina
   Kuna, Sanja Kusacic
   Brzac, Hrvojka Tomic
   Baretic, Maja
   Huic, Drazen
TI PARATHYROID CARCINOMA: ULTRASONOGRAPHIC AND CLINICAL EXPERIENCE
SO ACTA CLINICA CROATICA
LA English
DT Article
DE Parathyroid carcinoma; Atypical parathyroid adenoma;
   Hyperparathyroidism; Neck ultrasound
ID CHRONIC RENAL FAILURE; PRIMARY HYPERPARATHYROIDISM; GENE; MUTATIONS;
   ADENOMA
AB   Parathyroid cancer is an extremely rare malignancy that usually leads to hyperparathyroidism. The aim of this report is to present clinical and ultrasonographic features of tumors in six patients (5 females; mean age 53.2 years) treated for parathyroid carcinoma at the Department of Nuclear Medicine during 20 years. Most patients presented with hypercalcemia, and one of them had a previous history of long term secondary hyperparathyroidism and was treated with hemodialysis. All patients had significantly reduced bone density, and two of them presented with typical 'brown' tumors involving long bones of lower extremities. After initial treatment, all patients except for the youngest female patient were in long term remission with normal serum calcium and parathyroid hormone levels. Preoperative imaging procedures such as ultrasound with targeted fine needle aspiration biopsy and Tc99m sestamibi scan helped determine the location and extent of the disease, but definitive diagnosis was made after the surgery. Parathyroid cancer is a rare form of malignant tumor that is difficult to diagnose preoperatively due to similar clinical features with benign causes of hyperparathyroidism such as hyperplasia and adenomas, especially atypical ones that require regular follow up. Complete surgical resection provides the best chance of cure, although metastatic disease is possible.
C1 [Kuna, Sanja Kusacic; Brzac, Hrvojka Tomic; Huic, Drazen] Zagreb Univ Hosp Ctr, Clin Dept Nucl Med & Radiat Protect, Kispaticeva 12, HR 10000 Zagreb, Croatia.
   [Jadresic, Marina] Zadar Gen Hosp, Dept Oncol & Nucl Med, Zadar, Croatia.
   [Baretic, Maja] Zagreb Univ Hosp Ctr, Dept Internal Med, Div Endocrinol & Diabet, Zagreb, Croatia.
   [Kuna, Sanja Kusacic; Baretic, Maja; Huic, Drazen] Univ Zagreb, Sch Med, Zagreb, Croatia.
C3 University of Zagreb; UNIVERSITY ZAGREB HOSPITAL; University of Zadar;
   University of Zagreb; UNIVERSITY ZAGREB HOSPITAL; University of Zagreb
RP Kuna, SK (通讯作者)，Zagreb Univ Hosp Ctr, Clin Dept Nucl Med & Radiat Protect, Kispaticeva 12, HR 10000 Zagreb, Croatia.
EM sanja.kusacickuna@gmail.com
RI Baretić, Maja/ITU 6886 2023
CR Adam MA, 2010, ONCOLOGIST, V15, P61, DOI 10.1634/theoncologist.2009 0185
   Agarwal G, 2006, LANGENBECK ARCH SURG, V391, P623, DOI 10.1007/s00423 006 0095 8
   Alvelos MI, 2011, GENET RES INT, V2011, DOI 10.4061/2011/275802
   Baretic M, 2014, WORLD J CLIN CASES, V2, P151, DOI 10.12998/wjcc.v2.i5.151
   Baser H, 2013, J Med Cases, V4, P357
   BERLAND Y, 1982, CLIN NEPHROL, V18, P154
   Cetani F, 2019, ENDOCR RELAT CANCER, V26, pR441, DOI 10.1530/ERC 19 0135
   Cheon M, 2011, NUCL MED MOLEC IMAG, V45, P276, DOI 10.1007/s13139 011 0103 y
   Colovic Z, 2020, ACTA CLIN CROAT, V59, P96, DOI 10.20471/acc.2020.59.s1.12
   CRYNS VL, 1994, NEW ENGL J MED, V330, P757, DOI 10.1056/NEJM199403173301105
   Do Cao C, 2015, ANN ENDOCRINOL PARIS, V76, P165, DOI 10.1016/j.ando.2015.03.016
   Fang C, 2018, ULTRASOUND, V26, P110, DOI 10.1177/1742271X18758516
   Ferraro V, 2019, BMC ENDOCR DISORD, V19, DOI 10.1186/s12902 019 0368 1
   Gokkaya N, 2016, GYNECOL ENDOCRINOL, V32, P783, DOI 10.1080/09513590.2016.1188916
   Haber RS, 2002, CLIN ENDOCRINOL, V57, P241, DOI 10.1046/j.1365 2265.2002.01583.x
   Harari A, 2011, J CLIN ENDOCR METAB, V96, P3679, DOI 10.1210/jc.2011 1571
   Haven CJ, 2007, CLIN ENDOCRINOL, V67, P370, DOI 10.1111/j.1365 2265.2007.02894.x
   Hu Y, 2018, INT J ENDOCRINOL, V2018, DOI 10.1155/2018/3745239
   IRELAND JP, 1985, J CLIN PATHOL, V38, P1114, DOI 10.1136/jcp.38.10.1114
   Kulkarni P S, 2004, Indian J Cancer, V41, P51
   Li YL, 2016, ENDOCR RELAT CANCER, V23, pR229, DOI 10.1530/ERC 16 0059
   Miki H, 1996, SURGERY, V120, P897, DOI 10.1016/S0039 6060(96)80101 2
   Nam M, 2017, ACTA RADIOL, V58, P670, DOI 10.1177/0284185116666418
   Posada Gonzalez Maria, 2014, Surg Res Pract, V2014, P731481, DOI 10.1155/2014/731481
   Fernandes JMP, 2018, INT J SURG CASE REP, V42, P214, DOI 10.1016/j.ijscr.2017.11.030
   Quaglino F, 2020, INT J ENDOCRINOL, V2020, DOI 10.1155/2020/7048185
   Quartey Benjamin, 2011, World J Oncol, V2, P138, DOI 10.4021/wjon311w
   SHANE E, 1982, ENDOCR REV, V3, P218, DOI 10.1210/edrv 3 2 218
   Shane E, 2001, J CLIN ENDOCR METAB, V86, P485, DOI 10.1210/jc.86.2.485
   Sharretts JM, 2010, SEMIN ONCOL, V37, P580, DOI 10.1053/j.seminoncol.2010.10.013
   Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237
   Spinelli C, 2000, J ENDOCRINOL INVEST, V23, P255, DOI 10.1007/BF03343718
   Sungu N, 2018, INDIAN J PATHOL MICR, V61, P22, DOI 10.4103/IJPM.IJPM_85_17
   Ullah Ekram, 2012, Indian J Endocrinol Metab, V16, P1040, DOI 10.4103/2230 8210.103037
   Wei CH, 2012, CURR TREAT OPTION ON, V13, P11, DOI 10.1007/s11864 011 0171 3
   Wilkins BJ, 2009, HEAD NECK PATHOL, V3, P140, DOI 10.1007/s12105 009 0115 4
NR 36
TC 0
Z9 0
U1 0
U2 1
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR 10000, CROATIA
SN 0353 9466
EI 1333 9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PY 2023
VL 62
IS 4
BP 585
EP 594
DI 10.20471/acc.2023.62.04.2
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA G4V9X
UT WOS:001316645800002
PM 39866755
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Mahendra, A
   Yang, XY
   Abnouf, S
   Adolacion, JRT
   Park, D
   Soomro, S
   Roszik, J
   Coarfa, C
   Romain, G
   Wanzeck, K
   Bridges, SL
   Aggarwal, A
   Qiu, P
   Agarwal, SK
   Mohan, C
   Varadarajan, N
AF Mahendra, Ankit
   Yang, Xingyu
   Abnouf, Shaza
   Adolacion, Jay R. T.
   Park, Daechan
   Soomro, Sanam
   Roszik, Jason
   Coarfa, Cristian
   Romain, Gabrielle
   Wanzeck, Keith
   Bridges, S. Louis, Jr.
   Aggarwal, Amita
   Qiu, Peng
   Agarwal, Sandeep K.
   Mohan, Chandra
   Varadarajan, Navin
TI Beyond Autoantibodies: Biologic Roles of Human Autoreactive B Cells in
   Rheumatoid Arthritis Revealed by RNA Sequencing
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID FIBROBLAST LIKE SYNOVIOCYTES; TUMOR NECROSIS FACTOR; SYNOVIAL FLUID;
   EXPRESSION; AMPHIREGULIN; INFLAMMATION; IDENTIFICATION; ACTIVATION;
   INDUCTION; CYTOKINES
AB Objective. To obtain the comprehensive transcriptome profile of human citrulline specific B cells from patients with rheumatoid arthritis (RA).
   Methods. Citrulline  and hemagglutinin specific B cells were sorted by flow cytometry using peptide streptavidin conjugates from the peripheral blood of RA patients and healthy individuals. The transcriptome profile of the sorted cells was obtained by RNA sequencing, and expression of key protein molecules was evaluated by aptamer based SOMAscan assay and flow cytometry. The ability of these proteins to effect differentiation of osteoclasts and proliferation and migration of synoviocytes was examined by in vitro functional assays.
   Results. Citrulline specific B cells, in comparison to citrulline negative B cells, from patients with RA differentially expressed the interleukin 15 receptor alpha (IL 15R alpha) gene as well as genes related to protein citrullination and cyclic AMP signaling. In analyses of an independent cohort of cyclic citrullinated peptide seropositive RA patients, the expression of IL 151R alpha protein was enriched in citrulline specific B cells from the patients' peripheral blood, and surprisingly, all B cells from RA patients were capable of producing the epidermal growth factor ligand amphiregulin (AREG). Production of AREG directly led to increased migration and proliferation of fibroblast like synoviocytes, and, in combination with anti citrullinated protein antibodies, led to the increased differentiation of osteoclasts.
   Conclusion. To the best of our knowledge, this is the first study to document the whole transcriptome profile of autoreactive B cells in any autoimmune disease. These data identify several genes and pathways that may be targeted by repurposing several US Food and Drug Administration approved drugs, and could serve as the foundation for the comparative assessment of B cell profiles in other autoimmune diseases.
C1 [Mahendra, Ankit; Abnouf, Shaza; Adolacion, Jay R. T.; Soomro, Sanam; Romain, Gabrielle; Mohan, Chandra; Varadarajan, Navin] Univ Houston, Houston, TX 77204 USA.
   [Yang, Xingyu; Qiu, Peng] Georgia Inst Technol, Atlanta, GA 30332 USA.
   [Park, Daechan] Ajou Univ, Suwon, South Korea.
   [Roszik, Jason] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Coarfa, Cristian; Agarwal, Sandeep K.] Baylor Coll Med, Houston, TX 77030 USA.
   [Wanzeck, Keith; Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Aggarwal, Amita] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India.
C3 University of Houston System; University of Houston; University System
   of Georgia; Georgia Institute of Technology; Ajou University; University
   of Texas System; UTMD Anderson Cancer Center; Baylor College of
   Medicine; University of Alabama System; University of Alabama
   Birmingham; Sanjay Gandhi Postgraduate Institute of Medical Sciences
RP Varadarajan, N (通讯作者)，Univ Houston, Dept Chem & Biomol Engn, 4726 Calhoun Rd, Houston, TX 77204 USA.
EM nvaradar@central.uh.edu
RI Mohan, Chandra/GPX 8233 2022; Varadarajan, Navin/HTT 3904 2023
OI Varadarajan, Navin/0000 0001 7524 8228; Roszik,
   Janos/0000 0002 4561 6170
FU Cancer Prevention and Research Institute of Texas [RP130570, RP180466];
   United States Department of Defense [CA160591]; Melanoma Research
   Alliance [509800]; National Science Foundation [1705464]; NIH
   [R01 CA 174385]; Owens Foundation; Welch Foundation [E 1774]; University
   of Alabama at Birmingham
FX Supported by the Cancer Prevention and Research Institute of Texas
   (RP130570 and RP180466), the United States Department of Defense
   (Congressionally Directed Medical Research Program CA160591), the
   Melanoma Research Alliance (509800), the National Science Foundation
   (1705464), the NIH (grant R01 CA 174385), the Owens Foundation, the
   Welch Foundation (E 1774), and the University of Alabama at Birmingham
   RADAR fund.
CR Albaba Dania, 2015, Microarrays (Basel), V4, P424, DOI 10.3390/microarrays4030424
   ARNETT FC, 1988, ARTHRITIS RHEUM US, V31, P315, DOI 10.1002/art.1780310302
   Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Baslund B, 2005, ARTHRITIS RHEUM US, V52, P2686, DOI 10.1002/art.21249
   Berasain C, 2014, SEMIN CELL DEV BIOL, V28, P31, DOI 10.1016/j.semcdb.2014.01.005
   Bolin Celeste, 2012, Genes Cancer, V3, P117, DOI 10.1177/1947601912458284
   Boross P, 2006, SPRINGER SEMIN IMMUN, V28, P339, DOI 10.1007/s00281 006 0049 9
   Chang M, 2011, NAT IMMUNOL, V12, P1002, DOI 10.1038/ni.2090
   Dörner T, 2009, NAT REV RHEUMATOL, V5, P433, DOI 10.1038/nrrheum.2009.141
   Eyre S, 2012, NAT GENET, V44, P1336, DOI 10.1038/ng.2462
   Hamel KM, 2014, ARTHRITIS RHEUMATOL, V66, P60, DOI 10.1002/art.38207
   Harada M, 2015, J IMMUNOL, V194, P1039, DOI 10.4049/jimmunol.1400562
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Kerkman PF, 2016, ANN RHEUM DIS, V75, P1170, DOI 10.1136/annrheumdis 2014 207182
   Khare S, 2010, CRIT REV IMMUNOL, V30, P463, DOI 10.1615/CritRevImmunol.v30.i5.50
   Kokkonen H, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3237
   Kurkó J, 2013, CLIN REV ALLERG IMMU, V45, P170, DOI 10.1007/s12016 012 8346 7
   Lal P, 2011, ARTHRITIS RHEUM US, V63, P3681, DOI 10.1002/art.30596
   Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596
   Liu FL, 2014, RHEUMATOLOGY, V53, P260, DOI 10.1093/rheumatology/ket350
   Diaz ACM, 2012, ARTHRITIS, DOI 10.1155/2012/943156
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Moalli F, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/830421
   Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734
   Nagafuchi Y, 2016, SCI REP UK, V6, DOI 10.1038/srep29338
   Nutt SL, 2007, NAT REV IMMUNOL, V7, P923, DOI 10.1038/nri2204
   Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810
   Roumenina LT, 2006, BIOCHEMISTRY US, V45, P4093, DOI 10.1021/bi052646f
   Santiago Raber ML, 2001, J IMMUNOL, V167, P4067, DOI 10.4049/jimmunol.167.7.4067
   Savio AS, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0516 3
   Schreeder DM, 2010, J IMMUNOL, V185, P23, DOI 10.4049/jimmunol.1000832
   Swanson CD, 2012, J IMMUNOL, V188, P3513, DOI 10.4049/jimmunol.1102693
   Takemura S, 2001, J IMMUNOL, V167, P4710, DOI 10.4049/jimmunol.167.8.4710
   Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072
   Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood 2002 10 3161
   TETTA C, 1990, ANN RHEUM DIS, V49, P665, DOI 10.1136/ard.49.9.665
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Toubi E, 2007, ANN RHEUM DIS, V66, P818, DOI 10.1136/ard.2006.062505
   van der Linden MPM, 2009, ARTHRITIS RHEUM US, V60, P2232, DOI 10.1002/art.24716
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Vieth B, 2017, BIOINFORMATICS, V33, P3486, DOI 10.1093/bioinformatics/btx435
   Wagner CA, 2015, ANN RHEUM DIS, V74, P579, DOI 10.1136/annrheumdis 2013 203915
   Waldmann Thomas A, 2013, J Investig Dermatol Symp Proc, V16, pS28, DOI 10.1038/jidsymp.2013.8
   Wang S, 2013, BBA GENE REGUL MECH, V1829, P1126, DOI 10.1016/j.bbagrm.2013.07.003
   Werner M, 2010, IMMUNOL REV, V237, P55, DOI 10.1111/j.1600 065X.2010.00934.x
   Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018 008 7440 8
   WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840
   Yamane S, 2008, J INFLAMM LOND, V5, DOI 10.1186/1476 9255 5 5
   Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020
NR 52
TC 21
Z9 24
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD APR
PY 2019
VL 71
IS 4
BP 529
EP 541
DI 10.1002/art.40772
PG 13
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA HT3HK
UT WOS:000464454700006
PM 30407753
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Yao, JY
   Wu, XJ
   Qiao, XJ
   Zhang, DQ
   Zhang, L
   Ma, JA
   Cai, XJ
   Bostrom, KI
   Yao, YC
AF Yao, Jiayi
   Wu, Xiuju
   Qiao, Xiaojing
   Zhang, Daoqin
   Zhang, Li
   Ma, Jocelyn A.
   Cai, Xinjiang
   Bostrom, Kristina, I
   Yao, Yucheng
TI Shifting osteogenesis in vascular calcification
SO JCI INSIGHT
LA English
DT Article
ID ENDOTHELIAL MESENCHYMAL TRANSITION; SMALL MOLECULE INHIBITORS; COLLAGEN
   PROMOTER; CRE RECOMBINASE; TRANSGENIC MICE; BONE; EXPRESSION; CELLS;
   DIFFERENTIATION; PATHWAY
AB Transitions between cell fates commonly occur in development and disease. However, reversing an unwanted cell transition in order to treat disease remains an unexplored area. Here, we report a successful process of guiding ill fated transitions toward normalization in vascular calcification. Vascular calcification is a severe complication that increases the all cause mortality of cardiovascular disease but lacks medical therapy. The vascular endothelium is a contributor of osteoprogenitor cells to vascular calcification through endothelial mesenchymal transitions, in which endothelial cells (ECs) gain plasticity and the ability to differentiate into osteoblast like cells. We created a high throughput screening and identified SB216763, an inhibitor of glycogen synthase kinase 3 (GSK3), as an inducer of osteoblastic endothelial transition. We demonstrated that SB216763 limited osteogenic differentiation in ECs at an early stage of vascular calcification. Lineage tracing showed that SB216763 redirected osteoblast like cells to the endothelial lineage and reduced late stage calcification. We also found that deletion of GSK3 beta in osteoblasts recapitulated osteoblastic endothelial transition and reduced vascular calcification. Overall, inhibition of GSK3 ss promoted the transition of cells with osteoblastic characteristics to endothelial differentiation, thereby ameliorating vascular calcification.
C1 [Yao, Jiayi; Wu, Xiuju; Qiao, Xiaojing; Zhang, Daoqin; Zhang, Li; Ma, Jocelyn A.; Cai, Xinjiang; Bostrom, Kristina, I; Yao, Yucheng] Univ Calif Los Angeles UCLA, Div Cardiol, Dept Med, David Geffen Sch Med, Los Angeles, CA USA.
   [Bostrom, Kristina, I] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California Los Angeles
RP Yao, YC (通讯作者)，Univ Calif Los Angeles, Div Cardiol, David Geffen Sch Med, Box 951679, Los Angeles, CA 90095 USA.
EM yyao@mednet.ucla.edu
RI ; Cai, Xinjiang/F 4843 2010
OI Yao, Jiayi/0000 0001 9235 2406; Ma, Jocelyn/0000 0002 3259 2333; ,
   Xiuju/0000 0002 7499 0137; Cai, Xinjiang/0000 0001 8933 7133
FU NIH [NS79353, HL139675, HL30568, HL81397]; National Heart Lung and Blood
   Institute [R01HL139675, R01HL081397] Funding Source: NIH RePORTER;
   National Institute of Neurological Disorders and Stroke [R01NS079353]
   Funding Source: NIH RePORTER
FX Funding for this work was provided in part by NIH grants NS79353 (to
   YY), HL139675 (to YY), HL30568 (to KIB), and HL81397 (to KIB). We thank
   Robert Damoiseaux at UCLA for the chemical compound screen.
CR Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096 9136(199712)14:5+<S7::AID DIA522>3.3.CO;2 I
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Boitano AE, 2010, SCIENCE, V329, P1345, DOI 10.1126/science.1191536
   Boström KI, 2016, ATHEROSCLEROSIS, V253, P124, DOI 10.1016/j.atherosclerosis.2016.08.046
   Boström KI, 2011, CIRC RES, V108, P446, DOI 10.1161/CIRCRESAHA.110.236596
   Boström KI, 2016, VASC PHARMACOL, V84, P8, DOI 10.1016/j.vph.2016.05.014
   Cao N, 2016, SCIENCE, V352, P1216, DOI 10.1126/science.aaf1502
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen Neal X, 2003, Curr Diab Rep, V3, P28, DOI 10.1007/s11892 003 0049 2
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   Corada M, 2014, ARTERIOSCL THROM VAS, V34, P2372, DOI 10.1161/ATVBAHA.114.303218
   Corada M, 2010, DEV CELL, V18, P938, DOI 10.1016/j.devcel.2010.05.006
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Dudley AC, 2008, CANCER CELL, V14, P201, DOI 10.1016/j.ccr.2008.06.017
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Guihard PJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167936
   Hotta R, 2009, STEM CELLS, V27, P2896, DOI 10.1002/stem.208
   Hruska KA, 2009, SEMIN NEPHROL, V29, P156, DOI 10.1016/j.semnephrol.2009.01.008
   Huh JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054551
   Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kim JE, 2004, AM J PATHOL, V165, P1875, DOI 10.1016/S0002 9440(10)63240 3
   Kitajima K, 2016, EXP HEMATOL, V44, P68, DOI 10.1016/j.exphem.2015.09.007
   Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359 6101(96)00027 5
   Kovacic JC, 2012, CIRCULATION, V125, P1795, DOI 10.1161/CIRCULATIONAHA.111.040352
   Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017
   Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978
   Li WL, 2013, CELL STEM CELL, V13, P270, DOI 10.1016/j.stem.2013.08.002
   Li WL, 2013, CELL RES, V23, P81, DOI 10.1038/cr.2012.182
   Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0
   Lüscher TF, 2003, CIRCULATION, V108, P1655, DOI 10.1161/01.CIR.0000089189.70578.E2
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Majewska E, 2017, NEUROCHEM RES, V42, P918, DOI 10.1007/s11064 016 2044 4
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Niiyama Hiroshi, 2009, J Vis Exp, DOI 10.3791/1035
   Ranchoux B, 2015, CIRCULATION, V131, P1006, DOI 10.1161/CIRCULATIONAHA.114.008750
   Rayasam GV, 2009, BRIT J PHARMACOL, V156, P885, DOI 10.1111/j.1476 5381.2008.00085.x
   ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421
   Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027
   Sage AP, 2010, NAT REV CARDIOL, V7, P528, DOI 10.1038/nrcardio.2010.115
   Saijilafu, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3690
   Shao ES, 2009, BLOOD, V114, P2197, DOI 10.1182/blood 2009 01 199166
   Szabo Rogers H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149604
   Tang RN, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475 2840 11 113
   Willems E, 2011, CIRC RES, V109, P360, DOI 10.1161/CIRCRESAHA.111.249540
   Wrana J L, 2000, Sci STKE, V2000, pre1, DOI 10.1126/stke.2000.23.re1
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Wu KK, 2007, ATHEROSCLEROSIS, V191, P241, DOI 10.1016/j.atherosclerosis.2006.08.030
   Yamamizu K, 2010, J CELL BIOL, V189, P325, DOI 10.1083/jcb.200904114
   Yao JY, 2017, J CELL BIOL, V216, P3369, DOI 10.1083/jcb.201612122
   Yao JY, 2015, CIRC RES, V117, P758, DOI 10.1161/CIRCRESAHA.115.306751
   Yao YC, 2013, CIRC RES, V113, P495, DOI 10.1161/CIRCRESAHA.113.301792
   Yao YC, 2010, CIRC RES, V107, P485, DOI 10.1161/CIRCRESAHA.110.219071
   Zhang DQ, 2021, ARTERIOSCL THROM VAS, V41, P931, DOI 10.1161/ATVBAHA.120.315571
NR 55
TC 18
Z9 18
U1 0
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD MAY 24
PY 2021
VL 6
IS 10
AR e143023
DI 10.1172/jci.insight.143023
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA SG5UU
UT WOS:000653507400006
PM 33848269
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huh, JE
   Seo, DM
   Baek, YH
   Choi, DY
   Park, DS
   Lee, JD
AF Huh, Jeong Eun
   Seo, Dong Min
   Baek, Yong Hyeon
   Choi, Do Young
   Park, Dong Suk
   Lee, Jae Dong
TI Biphasic positive effect of formononetin on metabolic activity of human
   normal and osteoarthritic subchondral osteoblasts
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Formononetin; Osteoarthritis; Subchondral osteoblasts; Osteogenic;
   Inflammatory mediators
ID ESTROGEN REPLACEMENT THERAPY; BONE COLLAGEN METABOLISM;
   GROWTH FACTOR BETA; PROSTAGLANDIN E 2; CANCELLOUS BONE;
   INTERLEUKIN 1 BETA; PHYTOESTROGENS; ISOFLAVONES; EXPRESSION; MECHANISM
AB Osteoarthritis is a multifactorial disease characterized by loss of articular cartilage and subchondral plate thickening. Therefore, biochemical analysis of the underlying bone tissue has provided important information for treatment of osteoarthritis. In this study, we determined the potential role of formononetin, a phytoestrogen isolated from Astragalus membranaceus to alter the expression of metabolic markers and cytokine production of human normal osteoblasts (Obs) and osteoarthritis subchondral osteoblasts (OA Obs). Human OA Obs and normal Obs were cultured for 3 days, 7 days or 14 days in the present medium only or were treated with various doses of formononetin. Cells were analyzed for viability by WST 8 assay, alkaline phosphatase (ALP) activity, osteogenic markers (osteocalcin (OCN) and type I collagen (Coil)) and cytokines (interleukin 6 (IL 6), vascular endothelial growth factor (VEGF), bone morphogenic protein 2 (BMP 2)). The level of IL 6, VEGF, BMP 2. OCN and Coil was increased in OA Obs compared with normal Obs. Formononetin dose dependently decreased ALP, IL 6, VEGF, BMP 2, OCN and Col l in OA Obs, while markedly increased ALP, VEGF, BMP 2, OCN and Coil in normal Obs. Interestingly, formononetin markedly increased the expression of VEGF and BMP 2 for 3 days of culture and significantly increased OCN and Col l at 14 days in human normal Obs. The remodeling effect of formononetin on osteogenic markers and cytokines of inflammatory mediators was more striking in OA Obs as well. Taken together, these results could suggest that formononetin has biphasic positive effects on normal Obs and OA Obs by modifying their biological synthetic capacities. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved.
C1 [Seo, Dong Min; Choi, Do Young; Lee, Jae Dong] Kyung Hee Univ, Coll Oriental Med, Dept Acupuncture & Moxibust, Seoul 130701, South Korea.
   [Huh, Jeong Eun] Kyung Hee Univ, Oriental Med Res Ctr Bone & Joint Dis, Seoul 134727, South Korea.
   [Baek, Yong Hyeon; Park, Dong Suk] Kyung Hee Univ, EW Neo Med Ctr, Dept Acupuncture & Moxibust, Seoul 134727, South Korea.
C3 Kyung Hee University; Kyung Hee University; Korea Institute of Oriental
   Medicine (KIOM); Kyung Hee University
RP Lee, JD (通讯作者)，Kyung Hee Univ, Coll Oriental Med, Dept Acupuncture & Moxibust, 1 Hoegidong, Seoul 130701, South Korea.
EM jehuh2551@hanmail.net
FU Korean Government [NRF 2009 353 20091611]
FX This work was supported by the National Research Foundation of Korea
   Grant funded by the Korean Government [NRF 2009 353 20091611].
CR Atkinson C, 2004, AM J CLIN NUTR, V79, P326
   Bailey AJ, 2002, INT J BIOCHEM CELL B, V34, P176, DOI 10.1016/S1357 2725(01)00107 8
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Branca F, 2005, FORUM NUTR, V57, P100, DOI 10.1159/000083773
   Cantatore FP, 2004, CLIN RHEUMATOL, V23, P490, DOI 10.1007/s10067 004 0928 1
   Chang H, 2003, BIOMED ENVIRON SCI, V16, P83
   Chen XJ, 2006, AM J CHINESE MED, V34, P1015, DOI 10.1142/S0192415X0600448X
   Choi SI, 2007, OSTEOARTHR CARTILAGE, V15, P1086, DOI 10.1016/j.joca.2007.02.015
   Claassen H, 2008, CELL TISSUE RES, V333, P71, DOI 10.1007/s00441 008 0616 6
   Cotter A, 2003, NUTR REV, V61, P346, DOI 10.1301/nr.2003.oct.346 351
   DEQUEKER J, 1993, ARTHRITIS RHEUM, V36, P1702, DOI 10.1002/art.1780361209
   Ham KD, 2004, J BONE MINER RES, V19, P823, DOI 10.1359/JBMR.040309
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Hilal G, 1998, ARTHRITIS RHEUM, V41, P891, DOI 10.1002/1529 0131(199805)41:5<891::AID ART17>3.0.CO;2 X
   Hilal G, 2001, J BONE MINER RES, V16, P713, DOI 10.1359/jbmr.2001.16.4.713
   Hilal G, 1999, ARTHRITIS RHEUM, V42, P2112, DOI 10.1002/1529 0131(199910)42:10<2112::AID ANR11>3.0.CO;2 N
   Jarred RA, 2002, CANCER EPIDEM BIOMAR, V11, P1689
   Kim C, 2003, ARCH PHARM RES, V26, P917, DOI 10.1007/BF02980200
   Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353
   Lajeunesse D, 2003, Mod Rheumatol, V13, P7, DOI 10.3109/s101650300001
   Mansell JP, 1997, BRIT J RHEUMATOL, V36, P16
   Mansell JP, 1998, J CLIN INVEST, V101, P1596, DOI 10.1172/JCI867
   Martel Pelletier J., 2005, Arthritis and Allied Conditioned:A textbook of Rheumatology, P2199
   Massicotte F, 2002, OSTEOARTHR CARTILAGE, V10, P491, DOI 10.1053/joca.2002.0528
   Nestel P, 2007, ATHEROSCLEROSIS, V192, P184, DOI 10.1016/j.atherosclerosis.2006.04.033
   Olson EJ, 2008, BONE, V42, P907, DOI 10.1016/j.bone.2007.12.007
   Ososki AL, 2003, PHYTOTHER RES, V17, P845, DOI 10.1002/ptr.1364
   PELLETIER JP, 2001, ARTHRITIS ALLIED CON, P2195
   RADIN EL, 1986, CLIN ORTHOP RELAT R, P34
   Sanchez C, 2005, OSTEOARTHR CARTILAGE, V13, P979, DOI 10.1016/j.joca.2005.03.008
   Sanchez C, 2004, OSTEOARTHR CARTILAGE, V12, P801, DOI 10.1016/j.joca.2004.06.011
   Sanchez C, 2008, ARTHRITIS RHEUM US, V58, P442, DOI 10.1002/art.23159
   Wu Fabao, 2004, Zhong Yao Cai, V27, P232
NR 33
TC 36
Z9 41
U1 0
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD APR
PY 2010
VL 10
IS 4
BP 500
EP 507
DI 10.1016/j.intimp.2010.01.012
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 588II
UT WOS:000277062500018
PM 20138155
DA 2025 08 17
ER

PT J
AU Medina Huertas, R
   Manzano Moreno, FJ
   De Luna Bertos, E
   Ramos Torrecillas, J
   García Martínez, O
   Ruiz, C
AF Medina Huertas, Rosa
   Javier Manzano Moreno, Francisco
   De Luna Bertos, Elvira
   Ramos Torrecillas, Javier
   Garcia Martinez, Olga
   Ruiz, Concepcion
TI The effects of low level diode laser irradiation on differentiation,
   antigenic profile, and phagocytic capacity of osteoblast like cells
   (MG 63)
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Alkaline phosphatase; Biostimulatory effect; Low level laser therapy;
   Osteoblast; Antigenic expression; Phagocytic capacity
ID DIFFERENT GROWTH FACTORS; IGF I; THERAPY; PROLIFERATION; TGF BETA 1;
   OSTEOGENESIS; MODULATION; EXPRESSION; PHENOTYPE; MECHANISM
AB Previous in vivo and in vitro studies have reported that low level diode laser therapy induces a biostimulatory effect, such as cell proliferation. The aim of the present study was to evaluate whether the laser irradiation of osteoblast like cells (MG 63) can modify alkaline phosphatase activity (ALP), antigenic profile, and phagocytic capacity. The MG 63 cell line was exposed to diode laser (ezLase) of 940 nm at 1 1.5 W/cm(2) and 3 4 J. ALP was evaluated by a spectrophotometric technique and antigenic expression analysis (CD 54, CD80, CD86, HLA DR), and phagocytic activity was analyzed by flow cytometry. At 24 h, the treated groups showed an increased ALP, and the highest increase versus controls (P = 0.002) was at the dose of 1 W/cm(2) and 3 J; this modulation of the antigenic profile translated into a reduced expression of CD54, CD86, and HLA DR and a slightly decreased phagocytic capacity with respect to the nonirradiated control group at the different intensities and fluencies assayed. These results demonstrate that laser therapy can exert a biostimulatory effect on osteoblastic cells at different levels, which may be clinically useful in the regeneration of bone tissue.
C1 [Medina Huertas, Rosa; De Luna Bertos, Elvira; Ramos Torrecillas, Javier; Garcia Martinez, Olga; Ruiz, Concepcion] Univ Granada, Fac Hlth Sci, Grp BIO277, E 18071 Granada, Spain.
   [Medina Huertas, Rosa; Javier Manzano Moreno, Francisco; De Luna Bertos, Elvira; Ramos Torrecillas, Javier; Garcia Martinez, Olga; Ruiz, Concepcion] Inst Invest Biosanitaria, Granada 18071, Spain.
   [Javier Manzano Moreno, Francisco] Univ Granada, Sch Dent, Grp BIO277, E 18071 Granada, Spain.
C3 University of Granada; Instituto de Investigacion Biosanitaria IBS
   Granada; University of Granada
RP Ruiz, C (通讯作者)，Univ Granada, Fac Hlth Sci, Grp BIO277, E 18071 Granada, Spain.
EM crr@ugr.es
RI Ramos Torrecillas, Javier/F 3746 2012; Ruiz, Concepcion/L 2808 2014;
   Manzano Moreno, Francisco/B 1771 2015; Concepcion, Ruiz/L 2808 2014; De
   Luna Bertos, Elvira/F 8544 2016; García Martínez, Olga/L 2782 2014;
   Garcia Martinez, Olga/L 2782 2014
OI Ramos Torrecillas, Javier/0000 0002 6631 7866; Concepcion,
   Ruiz/0000 0003 4332 6812; De Luna Bertos, Elvira/0000 0002 4381 5942;
   Garcia Martinez, Olga/0000 0003 1912 4639
FU CEI BIOTIC (Ministerio de Ciencia e Innovacion) [CEI2013 MP 20]; Junta
   de Andalucia [BIO277]; Department of Nursing (University of Granada)
FX This study was supported by the grant CEI2013 MP 20 from CEI BIOTIC
   (Ministerio de Ciencia e Innovacion), research group BIO277 (Junta de
   Andalucia), and Department of Nursing (University of Granada).
CR Alves ACA, 2013, LASER MED SCI, V28, P529, DOI 10.1007/s10103 012 1102 7
   Babilas P, 2010, HAUTARZT, V63, P59
   da Silva APRB, 2012, LASER MED SCI, V27, P777, DOI 10.1007/s10103 011 0968 0
   Bouvet Gerbettaz S, 2009, LASER SURG MED, V41, P291, DOI 10.1002/lsm.20759
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002 0023
   Chen YJ, 2004, J ORTHOP RES, V22, P526, DOI 10.1016/j.orthres.2003.10.005
   da Silva JP, 2010, PHOTOMED LASER SURG, V28, P17, DOI 10.1089/pho.2008.2372
   Davies LB, 2014, LASER MED SCI, V29, P195, DOI 10.1007/s10103 013 1304 7
   De Luna Bertos E, 2013, SCI WORLD J, DOI 10.1155/2013/809891
   de Oliveira PT, 2007, J BIOMED MATER RES A, V80A, P554, DOI 10.1002/jbm.a.30955
   Díaz Rodríguez L, 2012, BIOL RES NURS, V14, P98, DOI 10.1177/1099800411398933
   Eduardo CD, 2010, LASER MED SCI, V25, P781, DOI 10.1007/s10103 010 0812 y
   Eingartner C, 1999, INT ORTHOP, V23, P253, DOI 10.1007/s002640050365
   Garavello I, 2004, HISTOL HISTOPATHOL, V19, P43, DOI 10.14670/HH 19.43
   García Martínez O, 2012, J ORAL MAXIL SURG, V70, P1558, DOI 10.1016/j.joms.2011.06.199
   Hashmi JT, 2010, LASER SURG MED, V42, P450, DOI 10.1002/lsm.20950
   Ing SW, 2011, NUTR REV, V69, P123, DOI 10.1111/j.1753 4887.2011.00376.x
   Manzano Moreno FJ, 2013, CLIN ORAL INVEST, V17, P1349, DOI 10.1007/s00784 012 0811 4
   Kamali F, 2007, J PHOTOCH PHOTOBIO B, V88, P11, DOI 10.1016/j.jphotobiol.2007.04.010
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Khadra M, 2004, CLIN ORAL IMPLAN RES, V15, P325, DOI 10.1111/j.1600 0501.2004.00994.x
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Huertas RM, 2014, BIOL RES NURS, V16, P191, DOI 10.1177/1099800413482695
   Nogueira GT, 2012, LASER MED SCI, V27, P1189, DOI 10.1007/s10103 011 1035 6
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Pejcic A, 2010, PHOTOMED LASER SURG, V28, P69, DOI 10.1089/pho.2008.2301
   Peplow PV, 2011, PHOTOMED LASER SURG, V29, P285, DOI 10.1089/pho.2010.2846
   Pérez E, 2006, BIOSCIENCE REP, V26, P281, DOI 10.1007/s10540 006 9022 z
   Posten W, 2005, DERMATOL SURG, V31, P334, DOI 10.1097/00042728 200503000 00016
   Pyo SJ, 2013, LASER MED SCI, V28, P543, DOI 10.1007/s10103 012 1109 0
   Reyes Botella C, 2002, CELL PHYSIOL BIOCHEM, V12, P353, DOI 10.1159/000067905
   Reyes Botella C, 2002, CELL PHYSIOL BIOCHEM, V12, P359, DOI 10.1159/000067906
   Ruiz C, 2007, J BONE MINER METAB, V25, P286, DOI 10.1007/s00774 007 0767 7
   Ruiz C, 2003, CELL PHYSIOL BIOCHEM, V13, P309, DOI 10.1159/000074546
   Sandrini E, 2005, J BIOMED MATER RES B, V73B, P392, DOI 10.1002/jbm.b.30241
   Saygun I, 2012, PHOTOMED LASER SURG, V30, P149, DOI 10.1089/pho.2011.3079
   Stanley KT, 2006, J BONE MINER RES, V21, P29, DOI 10.1359/JBMR.051004
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Vandrovcová M, 2011, PHYSIOL RES, V60, P403, DOI 10.33549/physiolres.932045
   Wang FS, 2002, J BONE JOINT SURG BR, V84B, P457, DOI 10.1302/0301 620X.84B3.11609
NR 40
TC 29
Z9 30
U1 0
U2 7
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD JUL
PY 2014
VL 29
IS 4
BP 1479
EP 1484
DI 10.1007/s10103 014 1557 9
PG 6
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA AK7ZB
UT WOS:000338645800022
PM 24619140
DA 2025 08 17
ER

PT J
AU Hosseini, E
   Ghasemzadeh, M
   Kamalizad, M
   Schwarer, AP
AF Hosseini, Ehteramolsadat
   Ghasemzadeh, Mehran
   Kamalizad, Maedeh
   Schwarer, Anthony P.
TI Ex vivo expansion of CD3<SUP>depleted</SUP> cord blood MNCs in the
   presence of bone marrow stromal cells; an appropriate strategy to
   provide functional NK cells applicable for cellular therapy
SO STEM CELL RESEARCH
LA English
DT Article
DE BMSCs; CD3(depleted) mononuclear cells; Cytotoxicity; NK cell;
   Osteoblastic cells; Umbilical cord blood
ID NATURAL KILLER CELLS; MESENCHYMAL STEM CELLS; HLA E POLYMORPHISMS;
   CYTOLYTIC ACTIVITY; SERUM FREE; IN VITRO; IMMUNOTHERAPY; CANCER;
   TRANSPLANTATION; GENERATION
AB Considering umbilical cord blood (UCB) as a rich source of hematopoietic stemcells, we introduced a cost effective approach to expand CD3(depleted) UCB MNCs into functional NK cells. CD3(depleted) UCB MNCs were expanded in the presence or absence of a feeder [ bone marrow stem cells (BMSCs) or osteoblasts], with or without cytokines and their differentiation into NK cells was determined by flow cytometry. NK cell function was quantified by LAMP 1/CD107a expression, TNF alpha/IFN gamma release, and LDH release/PI staining in targets. Higher expansion of NK cells was observed after two weeks in the presence of BMSCs and cytokines (104 +/  15) compared to osteoblasts and cytokines (84 +/  29, p <0.05). On day 14, CD3depleted UCB MNCs in the presence of BMSCs and cytokines showed lower expression of CD3, CD19, CD14, CD15 and CD69 as well as higher expression of CD2 and CD7, which were suggestive of cell differentiation into mature NK cell lineage. Strong cytotoxicity of expanded cells was also identified with higher LDH release and PI% in targets. Significant upregulation of LAMP 1 with decreased release of IFN gamma and TNF a from effectors were observed. We demonstrate an effective expansion of UCB NK cells that maintained their functional capabilities applicable for cellular therapies. (C) 2017 The Authors. Published by Elsevier B. V.
C1 [Hosseini, Ehteramolsadat; Ghasemzadeh, Mehran; Kamalizad, Maedeh] High Inst Res & Educ Transfus Med, Blood Transfus Res Ctr, Iranian Blood Transfus Org Bldg,Hemmat ExpressWay, Tehran 146651157, Iran.
   [Schwarer, Anthony P.] Monash Univ, Eastern Sch, Dept Hematol & Oncol, Melbourne, Vic, Australia.
C3 Monash University
RP Hosseini, E (通讯作者)，High Inst Res & Educ Transfus Med, Blood Transfus Res Ctr, Iranian Blood Transfus Org Bldg,Hemmat ExpressWay, Tehran 146651157, Iran.
EM e.hosseini10@yahoo.com.au
RI Ghasemzadeh, Mehran/G 5445 2016; Hosseini, Ehteramolsadat/G 5499 2016
OI Ghasemzadeh, Mehran/0000 0003 1128 5649; Hosseini,
   Ehteramolsadat/0000 0002 6807 0908
CR Alici E, 2007, EXP HEMATOL, V35, P1839, DOI 10.1016/j.exphem.2007.08.006
   Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008
   Arai S, 2005, EXPERT OPIN BIOL TH, V5, P163, DOI 10.1517/14712598.5.2.163
   Balakumaran A, 2015, BLOOD, V125, P793, DOI 10.1182/blood 2014 06 566810
   Basse PH, 2002, MOL BIOTECHNOL, V21, P161, DOI 10.1385/MB:21:2:161
   Berg M, 2009, CYTOTHERAPY, V11, P341, DOI 10.1080/14653240902807034
   Boissel L, 2008, BIOL BLOOD MARROW TR, V14, P1031, DOI 10.1016/j.bbmt.2008.06.016
   Cerboni C, 2007, BLOOD, V110, P606, DOI 10.1182/blood 2006 10 052720
   Childs RW, 2013, HEMATOL AM SOC HEMAT, P234, DOI 10.1182/asheducation 2013.1.234
   Condiotti R, 2001, EXP HEMATOL, V29, P104, DOI 10.1016/S0301 472X(00)00617 2
   Freud AG, 2006, IMMUNOL REV, V214, P56, DOI 10.1111/j.1600 065X.2006.00451.x
   Frias AM, 2008, EXP HEMATOL, V36, P61, DOI 10.1016/j.exphem.2007.08.031
   Friedman R, 2007, BIOL BLOOD MARROW TR, V13, P1477, DOI 10.1016/j.bbmt.2007.08.048
   Ghasemzadeh M, 2016, LEUKEMIA RES, V43, P58, DOI 10.1016/j.leukres.2015.12.002
   Hosseini E, 2015, EXP HEMATOL, V43, P149, DOI 10.1016/j.exphem.2014.11.007
   Hosseini E, 2013, LEUKEMIA RES, V37, P516, DOI 10.1016/j.leukres.2013.01.011
   Hosseini E, 2012, IRAN J ALLERGY ASTHM, V11, P15, DOI 011.01/ijaai.1521
   Imai C, 2005, BLOOD, V106, P376, DOI 10.1182/blood 2004 12 4797
   Kao IT, 2007, STEM CELLS DEV, V16, P1043, DOI 10.1089/scd.2007.0033
   Klingemann HG, 2005, CYTOTHERAPY, V7, P16, DOI 10.1080/14653240510018000
   Klingemann HG, 2004, CYTOTHERAPY, V6, P15, DOI 10.1080/14653240310004548
   Luevano M, 2012, CELL MOL IMMUNOL, V9, P310, DOI 10.1038/cmi.2012.17
   Luhm J, 2002, J HEMATOTH STEM CELL, V11, P651, DOI 10.1089/15258160260194794
   McKenna DH, 2007, TRANSFUSION, V47, P520, DOI 10.1111/j.1537 2995.2006.01145.x
   McKenna David H, 2012, Methods Mol Biol, V882, P491, DOI 10.1007/978 1 61779 842 9_28
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Olson JA, 2010, BLOOD, V115, P4293, DOI 10.1182/blood 2009 05 222190
   RABINOWICH H, 1994, J IMMUNOL, V152, P517
   RABINOWICH H, 1994, J IMMUNOL, V153, P3504
   Rafii S, 1997, LEUKEMIA LYMPHOMA, V27, P375, DOI 10.3109/10428199709058305
   Shiozawa Y, 2008, ACTA HAEMATOL BASEL, V120, P134, DOI 10.1159/000178144
   Shook DR, 2011, TISSUE ANTIGENS, V78, P409, DOI 10.1111/j.1399 0039.2011.01796.x
   Siegler U, 2005, LEUKEMIA, V19, P2215, DOI 10.1038/sj.leu.2403985
   Srivastava S, 2008, CYTOTHERAPY, V10, P775, DOI 10.1080/14653240802648181
   Sutlu T, 2009, J INTERN MED, V266, P154, DOI 10.1111/j.1365 2796.2009.02121.x
   Taichman RS, 1998, STEM CELLS, V16, P7, DOI 10.1002/stem.160007
   Taichman RUSSELL S., 2000, Hematology, V4, P421
   Tanaka H, 2003, EUR J HAEMATOL, V71, P29, DOI 10.1034/j.1600 0609.2003.00081.x
   Winchester B G, 2001, Eur J Paediatr Neurol, V5 Suppl A, P11, DOI 10.1053/ejpn.2000.0428
   Woll PS, 2005, J IMMUNOL, V175, P5095, DOI 10.4049/jimmunol.175.8.5095
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
NR 41
TC 19
Z9 19
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873 5061
EI 1876 7753
J9 STEM CELL RES
JI Stem Cell Res.
PD MAR
PY 2017
VL 19
BP 148
EP 155
DI 10.1016/j.scr.2017.01.010
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA EP5WW
UT WOS:000397450700023
PM 28171825
OA gold
DA 2025 08 17
ER

PT J
AU Zhao, L
   Liu, S
   Wang, Y
   Zhang, QY
   Zhao, WJ
   Wang, ZJ
   Yin, M
AF Zhao, Lu
   Liu, Sha
   Wang, Yin
   Zhang, Qiaoyan
   Zhao, Wenjuan
   Wang, Zejian
   Yin, Ming
TI Effects of Curculigoside on Memory Impairment and Bone Loss via
   Anti Oxidative Character in APP/PS1 Mutated Transgenic Mice
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; ALZHEIMERS DISEASE; OXIDATIVE STRESS; AMYLOID BETA;
   POSTMENOPAUSAL OSTEOPOROSIS; LIPID PEROXIDATION; NITRIC OXIDE;
   DIFFERENTIATION; ORCHIOIDES; OSTEOBLASTS
AB Alzheimer's disease (AD) and osteoporosis are two closely related multifactorial progressively degenerative diseases that predominantly affect aged people. These two diseases share many common risk factors, including old age, being female, smoking, excessive drinking, low estrogen, and vitamin D3 levels. Additionally, oxidative damage and the dysfunction of the antioxidant system play important roles in the pathogenesis of osteoporosis and AD. A beta not only leads to impaired memory but also plays a crucial role in the demineralization process of bone tissues of older people and women with menopause. Curculigoside can promote calcium deposition and increase the levels of ALP and Runx2 in osteoblasts under oxidative stress via anti oxidative character. Therefore, we investigated the effects of CUR on the spatial learning and memory by the Morris water maze and brain immunohistochemistry, and bone microstructure and material properties of femurs by micro computed tomography and mechanical testing in APP/PS1 mutated transgenic mice. Oral administration of CUR can significantly enhance learning performance and ameliorate bone loss in APP/PS1 mutated transgenic mice, and the mechanism may be related to its antioxidant effect. Based on these results, CUR has real potential as a new natural resource for developing medicines or dietary supplements for the prevention and treatment of the two closely linked multifactorial progressive degenerative disorders, AD and osteoporosis.
C1 [Zhao, Lu; Zhao, Wenjuan; Wang, Zejian; Yin, Ming] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China.
   [Wang, Yin] PLA 455 Hosp, Shanghai, Peoples R China.
   [Liu, Sha] Chengdu Med Coll, Sch Pharm, Dept Pharmacol, Chengdu, Sichuan, Peoples R China.
   [Zhang, Qiaoyan] Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Chengdu Medical College; Naval Medical
   University
RP Wang, ZJ (通讯作者)，Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200030, Peoples R China.
EM wangzejian@sjtu.edu.cn; myin@sjtu.edu.cn
RI Liu, Suling/N 2796 2013
FU National Natural Science Foundation of China [81274152]; natural science
   foundation of Shanghai science and Technology Commission, China
   [13ZR1449600]; scientific research fund of Shanghai City Health Planning
   Commission, China [2013299]
FX This study was supported by the grants from the National Natural Science
   Foundation of China (Grant No. 81274152), the natural science foundation
   of Shanghai science and Technology Commission, China (Grant No.
   13ZR1449600), and the scientific research fund of Shanghai City Health
   Planning Commission, China (Grant No. 2013299).
CR Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Belkacemi A, 2012, FREE RADICAL BIO MED, V52, P593, DOI 10.1016/j.freeradbiomed.2011.11.020
   Tung BT, 2015, EXP GERONTOL, V64, P1, DOI 10.1016/j.exger.2015.02.004
   CALABRESE V, 2014, EXPT PHARM DRUG DISC, V5, P120
   Cao Q, 2014, BIOMATERIALS, V35, P8273, DOI 10.1016/j.biomaterials.2014.06.020
   Chen G, 2015, BIOL PHARM B
   Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307
   Garnero P, 2014, BONE, V66, P46, DOI 10.1016/j.bone.2014.05.016
   Gouras GK, 2014, NEUROTHERAPEUTICS, P1
   Jagger CJ, 2005, ENDOCRINOLOGY, V146, P113, DOI 10.1210/en.2004 1058
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jiao L, 2009, PHYTOMEDICINE, V16, P874, DOI 10.1016/j.phymed.2009.01.005
   Kang Z, 2014, NEUROSCIENCE, V267, P232, DOI 10.1016/j.neuroscience.2014.02.050
   Lakshmi V, 2003, J ETHNOPHARMACOL, V89, P181, DOI 10.1016/S0378 8741(03)00160 0
   Lalonde R, 2012, REV NEUROSCIENCE, V23, P363, DOI 10.1515/revneuro 2012 0041
   LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092 8674(89)90833 7
   Li SF, 2014, BONE, V61, P164, DOI 10.1016/j.bone.2014.01.010
   Lin TW, 2015, NEUROBIOL LEARN MEM, V118, P189, DOI 10.1016/j.nlm.2014.12.005
   Liraz O, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750 1326 8 16
   Liu Lei, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P1419, DOI 10.3736/jcim20121214
   Liu MM, 2014, STEM CELLS DEV, V23, P146, DOI 10.1089/scd.2013.0261
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Melville KM, 2014, J BONE MINER RES, V29, P370, DOI 10.1002/jbmr.2082
   Mlakar SJ, 2012, MENOPAUSE, V19, P368, DOI 10.1097/gme.0b013e31822d5b10
   Morley JE, 2014, BIOCHEM PHARMACOL, V88, P479, DOI 10.1016/j.bcp.2013.12.018
   MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0
   Ozgocmen S, 2007, ARCH MED RES, V38, P196, DOI 10.1016/j.arcmed.2006.09.010
   Ozgocmen S, 2007, MOL CELL BIOCHEM, V295, P45, DOI 10.1007/s11010 006 9270 z
   PECK WA, 1993, AM J MED, V94, P646
   Salminen A, 2008, AGEING RES REV, V7, P83, DOI 10.1016/j.arr.2007.09.002
   Sato Y, 2004, J NEUROL SCI, V223, P107, DOI 10.1016/j.jns.2004.03.033
   Shen GS, 2014, CALCIFIED TISSUE INT, V94, P632, DOI 10.1007/s00223 014 9845 8
   Steeve KT, 2004, CYTOKINE GROWTH F R, V15, P49, DOI 10.1016/j.cytogfr.2003.10.005
   Tian Z, 2012, FOOD CHEM TOXICOL, V50, P4010, DOI 10.1016/j.fct.2012.08.006
   Toth P., 2015, Aging Cell
   Wang Y, 2012, ACTA BIOCH BIOPH SIN, V44, P431, DOI 10.1093/abbs/gms014
   Wang YK, 2010, J ETHNOPHARMACOL, V132, P233, DOI 10.1016/j.jep.2010.08.008
   [吴琼 WU Qiong], 2007, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V24, P6
   Wu XY, 2012, MOLECULES, V17, P10108, DOI 10.3390/molecules170910108
   Xia WF, 2013, J BONE MINER RES, V28, P2122, DOI 10.1002/jbmr.1954
   Zhao Y, 2013, OXIDATIVE STRESS AND, V2013
NR 42
TC 29
Z9 38
U1 0
U2 33
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 17
PY 2015
VL 10
IS 7
AR e0133289
DI 10.1371/journal.pone.0133289
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CN1RV
UT WOS:000358198700121
PM 26186010
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Bock, N
   Woodruff, MA
   Steck, R
   Hutmacher, DW
   Farrugia, BL
   Dargaville, TR
AF Bock, Nathalie
   Woodruff, Maria A.
   Steck, Roland
   Hutmacher, Dietmar W.
   Farrugia, Brooke L.
   Dargaville, Tim R.
TI Composites for Delivery of Therapeutics: Combining Melt Electrospun
   Scaffolds with Loaded Electrosprayed Microparticles
SO MACROMOLECULAR BIOSCIENCE
LA English
DT Article
DE drug delivery; electrospraying; microstructures; polymer drug
   interactions; tissue engineering
ID POLY(LACTIC CO GLYCOLIC ACID) MICROSPHERES; TOPOGRAPHICAL CONTROL;
   NANOFIBER SCAFFOLDS; PROTEIN DELIVERY; MOLECULAR WEIGHT; DRUG DELIVERY;
   TISSUE; RELEASE; BONE; DEGRADATION
AB A novel strategy is reported to produce biodegradable microfiber scaffolds layered with high densities of microparticles encapsulating a model protein. Direct electrospraying on highly porous melt electrospun scaffolds provides a reproducible scaffold coating throughout the entire architecture. The burst release of protein is significantly reduced due to the immobilization of microparticles on the surface of the scaffold and release mechanisms are dependent on protein polymer interactions. The composite scaffolds have a positive biological effect in contact with precursor osteoblast cells up to 18 days in culture. The scaffold design achieved with the techniques presented here endorses these new composite scaffolds as promising templates for growth factor delivery.
C1 [Bock, Nathalie; Woodruff, Maria A.; Steck, Roland; Hutmacher, Dietmar W.; Farrugia, Brooke L.; Dargaville, Tim R.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld 4059, Australia.
C3 Queensland University of Technology (QUT)
RP Bock, N (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Kelvin Grove, Qld 4059, Australia.
EM n.bock@qut.edu.au
RI Farrugia, Brooke/J 1292 2012; Steck, Roland/J 1076 2012; Hutmacher,
   Dietmar/AEO 9578 2022; Woodruff, Maria/J 1247 2012
OI Hutmacher, Dietmar Werner/0000 0001 5678 2134; Steck,
   Roland/0000 0002 8791 1709; Bock, Nathalie/0000 0001 9331 4698;
   Farrugia, Brooke/0000 0003 1303 4165; Woodruff,
   Maria/0000 0002 4909 5288; Dargaville, Tim/0000 0003 4665 9508
FU Wound Management Innovation CRC; Australian Research Council
   [LP100200084, LP110200082]; QUT; Australian Research Council
   [LP110200082, LP100200084] Funding Source: Australian Research Council
FX The authors would like to thank Dr. Rachel Hancock (QUT) for biological
   sample preparation for SEM analysis. N.B. acknowledges the financial
   support from QUT in the form of an Australian Postgraduate Award
   scholarship, and top up from the Deputy Vice Chancellor. B. F.
   acknowledges support from the Wound Management Innovation CRC. M. A. W.
   acknowledges support from the Australian Research Council LP100200084.
   This work was supported by the Australian Research Council
   (LP110200082).
CR [Anonymous], 2005, NAT MATER, DOI DOI 10.1038/nmat1421
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Bhaskar S, 2010, SMALL, V6, P404, DOI 10.1002/smll.200901306
   Blackwood KA, 2012, INT J POLYM SCI, V2012, DOI 10.1155/2012/174942
   Blanco MD, 2006, INT J PHARMACEUT, V326, P139, DOI 10.1016/j.ijpharm.2006.07.030
   Bock N, 2012, PROG POLYM SCI, V37, P1510, DOI 10.1016/j.progpolymsci.2012.03.002
   Bock N, 2011, POLYMERS BASEL, V3, P131, DOI 10.3390/polym3010131
   Boury F, 1997, J CONTROL RELEASE, V45, P75, DOI 10.1016/S0168 3659(96)01547 7
   Brown TD, 2012, BIOINTERPHASES, V7, DOI 10.1007/s13758 011 0013 7
   Brown TD, 2011, ADV MATER, V23, P5651, DOI 10.1002/adma.201103482
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Castelli F, 2000, THERMOCHIM ACTA, V346, P153, DOI 10.1016/S0040 6031(99)00391 3
   Chen FM, 2009, BIOMATERIALS, V30, P5215, DOI 10.1016/j.biomaterials.2009.06.009
   Chew SY, 2005, BIOMACROMOLECULES, V6, P2017, DOI 10.1021/bm0501149
   Chung HJ, 2007, ADV DRUG DELIVER REV, V59, P249, DOI 10.1016/j.addr.2007.03.015
   CLARK P, 1987, DEVELOPMENT, V99, P439
   Crotts G, 1997, J CONTROL RELEASE, V44, P123, DOI 10.1016/S0168 3659(96)01511 8
   Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142 9612(97)00144 0
   Dalton PD, 2013, BIOMATER SCI UK, V1, P171, DOI 10.1039/c2bm00039c
   Diekman BO, 2010, TISSUE ENG PT A, V16, P523, DOI [10.1089/ten.tea.2009.0398, 10.1089/ten.TEA.2009.0398]
   Dunne M, 2000, BIOMATERIALS, V21, P1659, DOI 10.1016/S0142 9612(00)00040 5
   Farrugia BL, 2013, BIOFABRICATION, V5, DOI 10.1088/1758 5082/5/2/025001
   Freiberg S, 2004, INT J PHARMACEUT, V282, P1, DOI 10.1016/j.ijpharm.2004.04.013
   Hadjiargyrou M, 2008, EXPERT OPIN DRUG DEL, V5, P1093, DOI 10.1517/17425247.5.10.1093 
   HAUSBERGER AG, 1995, J PHARMACEUT BIOMED, V13, P747, DOI 10.1016/0731 7085(95)01276 Q
   Hildebrand T, 1997, J MICROSC OXFORD, V185, P67, DOI 10.1046/j.1365 2818.1997.1340694.x
   Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421
   Ionescu LC, 2010, BIOMATERIALS, V31, P4113, DOI 10.1016/j.biomaterials.2010.01.098
   Jaworek A, 2009, J ELECTROSTAT, V67, P435, DOI 10.1016/j.elstat.2008.12.019
   JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146
   Kang JD, 2011, SPINE J, V11, P517, DOI 10.1016/j.spinee.2011.03.022
   King TW, 2000, J BIOMED MATER RES, V51, P383, DOI 10.1002/1097 4636(20000905)51:3<383::AID JBM12>3.0.CO;2 D
   Lee SH, 2007, ADV DRUG DELIVER REV, V59, P339, DOI 10.1016/j.addr.2007.03.016
   Lemoine D, 1996, BIOMATERIALS, V17, P2191, DOI 10.1016/0142 9612(96)00049 X
   Li SM, 1996, J CONTROL RELEASE, V40, P41, DOI 10.1016/0168 3659(95)00138 7
   Lu W, 1995, PDA J Pharm Sci Technol, V49, P13
   Mannion RJ, 2011, SPINE J, V11, P527, DOI 10.1016/j.spinee.2010.07.005
   Miyaki M, 1999, COLLOID SURFACE A, V153, P603, DOI 10.1016/S0927 7757(98)00623 2
   Murugan R, 2006, TISSUE ENG, V12, P435, DOI 10.1089/ten.2006.12.435
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Pareta R, 2005, J MATER SCI MATER M, V16, P919, DOI 10.1007/s10856 005 4426 z
   PARK TG, 1995, BIOMATERIALS, V16, P1123, DOI 10.1016/0142 9612(95)93575 X
   Porter JR, 2009, BIOTECHNOL PROGR, V25, P1539, DOI 10.1002/btpr.246
   Reneker DH, 2007, ADV APPL MECH, V41, P43, DOI 10.1016/S0065 2156(07)41002 X
   Seyednejad H, 2011, J CONTROL RELEASE, V152, P168, DOI 10.1016/j.jconrel.2010.12.016
   Shenoy SL, 2005, POLYMER, V46, P3372, DOI 10.1016/j.polymer.2005.03.011
   Siepmann J, 2005, BIOMACROMOLECULES, V6, P2312, DOI 10.1021/bm050228k
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Szentivanyi A, 2011, ADV DRUG DELIVER REV, V63, P209, DOI 10.1016/j.addr.2010.12.002
   Tessmar JK, 2007, ADV DRUG DELIVER REV, V59, P274, DOI 10.1016/j.addr.2007.03.020
   Valo H, 2009, SMALL, V5, P1791, DOI 10.1002/smll.200801907
   van de Weert M, 2000, PHARM RES DORDR, V17, P1159, DOI 10.1023/A:1026498209874
   Vaquette C, 2013, ACTA BIOMATER, V9, P4599, DOI 10.1016/j.actbio.2012.08.015
   Vaquette C, 2012, CELL TISSUE RES, V347, P815, DOI 10.1007/s00441 011 1318 z
   Vaquette C, 2011, ACTA BIOMATER, V7, P2544, DOI 10.1016/j.actbio.2011.02.036
   Vasita R, 2006, EXPERT REV MED DEVIC, V3, P29, DOI 10.1586/17434440.3.1.29
   Venugopal J, 2008, J BIOMED MATER RES B, V84B, P34, DOI 10.1002/jbm.b.30841
   von Burkersroda F, 2002, BIOMATERIALS, V23, P4221, DOI 10.1016/S0142 9612(02)00170 9
   Wang F, 2009, BIOMACROMOLECULES, V10, P2609, DOI 10.1021/bm900541u
   Wunderlich Bernhard, 2005, Thermal Analysis of Polymeric Materials
   Xie JW, 2008, MACROMOL RAPID COMM, V29, P1775, DOI 10.1002/marc.200800381
   Ye ML, 2010, J CONTROL RELEASE, V146, P241, DOI 10.1016/j.jconrel.2010.05.011
NR 62
TC 23
Z9 23
U1 1
U2 34
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 5187
EI 1616 5195
J9 MACROMOL BIOSCI
JI Macromol. Biosci.
PD FEB
PY 2014
VL 14
IS 2
BP 202
EP 214
DI 10.1002/mabi.201300276
PG 13
WC Biochemistry & Molecular Biology; Materials Science, Biomaterials;
   Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Materials Science; Polymer Science
GA AB7GN
UT WOS:000331957700006
PM 24106032
DA 2025 08 17
ER

PT J
AU Martin Rendon, E
   Sweeney, D
   Lu, F
   Girdlestone, J
   Navarrete, C
   Watt, SM
AF Martin Rendon, E.
   Sweeney, D.
   Lu, F.
   Girdlestone, J.
   Navarrete, C.
   Watt, S. M.
TI 5 azacytidine treated human mesenchymal stem/progenitor cells derived
   from umbilical cord, cord blood and bone marrow do not generate
   cardiomyocytes in vitro at high frequencies
SO VOX SANGUINIS
LA English
DT Article
DE 5 azacytidine; bone marrow; cord blood; mesenchymal stem/progenitor
   cells; umbilical cord
ID HEMATOPOIETIC STEM CELLS; PROGENITOR CELLS; ELECTROPHYSIOLOGICAL
   PROPERTIES; ENDOTHELIAL CELLS; TRANSDIFFERENTIATION; TRANSPLANTATION;
   PHENOTYPE; THERAPY; DIFFERENTIATION; PROTECTION
AB Background and Objectives Mesenchymal stem/progenitor cells (MSCs) are multipotent progenitors that differentiate into such lineages as bone, fat, cartilage and stromal cells that support haemopoiesis. Bone marrow MSCs can also contribute to cardiac repair, although the mechanism for this is unclear. Here, we examine the potential of MSCs from different sources to generate cardiomyocytes in vitro, as a means for predicting their therapeutic potential after myocardial infarction.
   Materials and Methods Mesenchymal stem/progenitor cells were isolated from the perivascular tissue and Wharton's jelly of the umbilical cord and from cord blood. Their immunophenotype and differentiation potential to generate osteoblasts, chondrocytes, adipocytes and cardiomyoxcytes in vitro was compared with those of bone marrow MSCs.
   Results Mesenchymal stem/progenitor cells isolated from umbilical cord and cord blood were phenotypically similar to bone marrow MSCs, the exception being in the expression of CD106, which was absent on umbilical cord MSCs, and CD146 that was highly expressed in cord blood MSCs. They have variable abilities to give rise to osteoblasts, chondrocytes and adipocytes, with bone marrow MSCs being the most robust. While a small proportion (similar to 0.07%) of bone marrow MSCs could generate cardiomyocyte like cells in vitro, those from umbilical cord and cord blood did not express cardiac markers either spontaneously or after treatment with 5 azacytidine.
   Conclusion Although MSCs may be useful for such clinical applications as bone or cartilage repair, the results presented here indicate that such cells do not generate cardiomyocytes frequently enough for cardiac repair. Their efficacy in heart repair is likely to be due to paracrine mechanisms.
C1 [Martin Rendon, E.; Sweeney, D.; Lu, F.; Watt, S. M.] John Radcliffe Hosp, NHS Blood & Transplant, Stem Cell Res Lab, Oxford OX3 9BQ, England.
   [Martin Rendon, E.; Lu, F.; Watt, S. M.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England.
   [Lu, F.] Univ Hong Kong, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.
   [Girdlestone, J.; Navarrete, C.] Colindale Ctr, NHS Blood & Transplant, Histocompatibil & Immunogenet Res Grp, London, England.
   [Girdlestone, J.; Navarrete, C.] UCL, Dept Immunol & Cellular Pathol, London, England.
C3 University of Oxford; University of Oxford; University of Hong Kong;
   University of London; University College London
RP Martin Rendon, E (通讯作者)，John Radcliffe Hosp, NHS Blood & Transplant, Stem Cell Res Lab, Oxford OX3 9BQ, England.
EM enca.rendon@ndcls.ox.ac.uk
RI Martin Rendon, Enca/K 6457 2016; Watt, Suzanne/AAV 4908 2021
OI Girdlestone, John/0000 0001 7422 9674
CR Augello A, 2007, ARTHRITIS RHEUM US, V56, P1175, DOI 10.1002/art.22511
   Badorff C, 2003, CIRCULATION, V107, P1024, DOI 10.1161/01.CIR.0000051460.85800.BB
   Balana B, 2006, CELL RES, V16, P949, DOI 10.1038/sj.cr.7310116
   Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chen SL, 2004, AM J CARDIOL, V94, P92, DOI 10.1016/j.amjcard.2004.03.034
   Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698
   Dai WD, 2005, TRANSPL IMMUNOL, V15, P91, DOI 10.1016/j.trim.2005.09.004
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076
   Gnecchi M, 2005, NAT MED, V11, P367, DOI 10.1038/nm0405 367
   Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05 5211com
   Gratwohl A, 2003, LEUKEMIA, V17, P941, DOI 10.1038/sj.leu.2402896
   Gronthos S, 2003, J CELL SCI, V116, P1827, DOI 10.1242/jcs.00369
   Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006 0686
   Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Joannides A, 2003, J HEMATOTH STEM CELL, V12, P681, DOI 10.1089/15258160360732704
   Kadivar M, 2006, BIOCHEM BIOPH RES CO, V340, P639, DOI 10.1016/j.bbrc.2005.12.047
   Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC
   Krabbe C, 2005, APMIS, V113, P831, DOI 10.1111/j.1600 0463.2005.apm_3061.x
   Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117
   Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB
   Lagostena L, 2005, CARDIOVASC RES, V66, P482, DOI 10.1016/j.cardiores.2005.01.018
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lechner V, 2007, ZBL CHIR, V132, P358, DOI 10.1055/s 2007 981247
   Lee OKS, 2004, J CELL BIOCHEM, V93, P917, DOI 10.1002/jcb.20241
   Lévesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289
   Li CD, 2007, CELL TISSUE RES, V330, P437, DOI 10.1007/s00441 007 0504 5
   Liu Xiao Dan, 2007, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V15, P1019
   Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298
   Manca MF, 2008, CYTOTHERAPY, V10, P54, DOI 10.1080/14653240701732763
   Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912
   Martin Rendon E, 2007, STEM CELLS, V25, P1003, DOI 10.1634/stemcells.2006 0398
   McCulloch EA, 2003, LEUKEMIA, V17, P1042, DOI 10.1038/sj.leu.2402948
   Metcalf D, 2001, BIOMED PHARMACOTHER, V55, P75, DOI 10.1016/S0753 3322(00)00021 4
   Mirotsou M, 2007, P NATL ACAD SCI USA, V104, P1643, DOI 10.1073/pnas.0610024104
   Mohyeddin Bonab M, 2007, ARCH IRAN MED, V10, P467
   Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446
   Nishiyama N, 2007, STEM CELLS, V25, P2017, DOI 10.1634/stemcells.2006 0662
   Noiseux N, 2006, MOL THER, V14, P840, DOI 10.1016/j.ymthe.2006.05.016
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Parekkadan B, 2007, TISSUE ENG, V13, P2465, DOI 10.1089/ten.2007.0054
   Potier E, 2007, BONE, V40, P1078, DOI 10.1016/j.bone.2006.11.024
   RIDER DA, 2008, STEM CELLS
   Ringdén O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004 0166
   Silva GV, 2005, CIRCULATION, V111, P150, DOI 10.1161/01.CIR.0000151812.86142.45
   Stuckey DJ, 2006, STEM CELLS, V24, P1968, DOI 10.1634/stemcells.2006 0074
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii 247
   Wagner W, 2005, EXP HEMATOL, V33, P1402, DOI 10.1016/j.exphem.2005.07.003
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Watt SM, 2000, BLOOD, V95, P3113
   Ye NS, 2006, STEM CELLS DEV, V15, P665, DOI 10.1089/scd.2006.15.665
   Yeh ETH, 2003, CIRCULATION, V108, P2070, DOI 10.1161/01.CIR.0000099501.52718.70
   Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210
   ZWART I, 2008, J NEUROSC RES
NR 60
TC 139
Z9 173
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0042 9007
EI 1423 0410
J9 VOX SANG
JI Vox Sang.
PY 2008
VL 95
IS 2
BP 137
EP 148
DI 10.1111/j.1423 0410.2008.01076.x
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 324EC
UT WOS:000257499500009
PM 18557828
DA 2025 08 17
ER

PT J
AU Niehage, C
   Steenblock, C
   Pursche, T
   Bornhäuser, M
   Corbeil, D
   Hoflack, B
AF Niehage, Christian
   Steenblock, Charlotte
   Pursche, Theresia
   Bornhaeuser, Martin
   Corbeil, Denis
   Hoflack, Bernard
TI The Cell Surface Proteome of Human Mesenchymal Stromal Cells
SO PLOS ONE
LA English
DT Article
ID PLASMA MEMBRANE PROTEINS; EMBRYONIC STEM CELLS; BONE MARROW; OSTEOBLAST
   DIFFERENTIATION; GENE EXPRESSION; MONOLAYER CULTURES; PROGENITOR CELL;
   DENDRITIC CELLS; RECEPTOR CD97; LIGAND CD55
AB Background: Multipotent human mesenchymal stromal cells (hMSCs) are considered as promising biological tools for regenerative medicine. Their antibody based isolation relies on the identification of reliable cell surface markers.
   Methodology/Principal Findings: To obtain a comprehensive view of the cell surface proteome of bone marrow derived hMSCs, we have developed an analytical pipeline relying on cell surface biotinylation of intact cells using cell impermeable, cleavable sulfo NHS SS biotin to enrich the plasma membrane proteins and mass spectrometry for identification with extremely high confidence. Among the 888 proteins identified, we found approximate to 200 bona fide plasma membrane proteins including 33 cell adhesion molecules and 26 signaling receptors. In total 41 CD markers including 5 novel ones (CD97, CD112, CD239, CD276, and CD316) were identified. The CD markers are distributed homogenously within plastic adherent hMSC populations and their expression is modulated during the process of adipogenesis or osteogenesis. Moreover, our in silico analysis revealed a significant difference between the cell surface proteome of hMSCs and that of human embryonic stem cells reported previously.
   Conclusions/Significance: Collectively, our analytical methods not only provide a basis for further studies of mechanisms maintaining the multipotency of hMSCs within their niches and triggering their differentiation after signaling, but also a toolbox for a refined antibody based identification of hMSC populations from different tissues and their isolation for therapeutic intervention.
C1 [Niehage, Christian; Steenblock, Charlotte; Pursche, Theresia; Corbeil, Denis; Hoflack, Bernard] Tech Univ Dresden, Ctr Biotechnol, D 8027 Dresden, Germany.
   [Bornhaeuser, Martin] Univ Hosp Dresden, Dept Hematol & Oncol, Dresden, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Carl
   Gustav Carus University Hospital
RP Niehage, C (通讯作者)，Tech Univ Dresden, Ctr Biotechnol, D 8027 Dresden, Germany.
EM bernard.hoflack@biotec.tu dresden.de
RI Steenblock, Charlotte/C 9038 2018; Corbeil, Denis/L 2340 2019; HOFLACK,
   Bernard/AAZ 6668 2020
OI Corbeil, Denis/0000 0003 1181 3659; Steenblock,
   Charlotte/0000 0002 9635 4860
FU Deutsche Forschungsgemeinschaft [TRR 83, SFB655 B2, SFB655 B3, HO
   2584/2 1, HO 2584/1 1, HO 2584/6 1, HO 2584/8 1]; Bundesministerium fur
   Bildung und Forschung [0313815B]; Dresden University of Technology
   [HWP 1207]
FX This work was supported in part by grants from Deutsche
   Forschungsgemeinschaft (TRR 83)(BH), SFB655 B2 (MB), SFB655 B3 (DC), HO
   2584/2 1 (BH), HO 2584/1 1 (BH), HO 2584/6 1 (BH), HO 2584/8 1 (BH),
   Bundesministerium fur Bildung und Forschung (0313815B, BH) and Dresden
   University of Technology (HWP 1207, BH). No additional external funding
   was received for this study. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood 2004 04 1559
   Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029
   Battula VL, 2009, HAEMATOL HEMATOL J, V94, P173, DOI 10.3324/haematol.13740
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Crop M, 2009, TRANSPL INT, V22, P365, DOI 10.1111/j.1432 2277.2008.00786.x
   Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dormeyer W, 2008, J PROTEOME RES, V7, P2936, DOI 10.1021/pr800056j
   Foster LJ, 2005, STEM CELLS, V23, P1367, DOI 10.1634/stemcells.2004 0372
   Freund D, 2006, STEM CELLS DEV, V15, P815, DOI 10.1089/scd.2006.15.815
   Freund D, 2010, CYTOTHERAPY, V12, P131, DOI 10.3109/14653240903476438
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
   Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048
   GREGORY CA, 2005, SCI STKE, pPE37
   Gu B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015795
   Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Im GI, 2005, OSTEOARTHR CARTILAGE, V13, P845, DOI 10.1016/j.joca.2005.05.005
   Jeong JA, 2007, PROTEOMICS, V7, P4181, DOI 10.1002/pmic.200700502
   Kaltz N, 2010, EXP CELL RES, V316, P2609, DOI 10.1016/j.yexcr.2010.06.002
   Kettner S, 2007, MOL CELL BIOL, V27, P7718, DOI 10.1128/MCB.00180 07
   Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005 0008
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lee HJ, 2009, ARTHRITIS RHEUM US, V60, P2325, DOI 10.1002/art.24786
   Lee KD, 2004, HEPATOLOGY, V40, P1275, DOI 10.1002/hep.20469
   Leemans JC, 2004, J IMMUNOL, V172, P1125, DOI 10.4049/jimmunol.172.2.1125
   Liu F, 2008, J BONE MINER METAB, V26, P312, DOI 10.1007/s00774 007 0842 0
   Liu Y, 2005, ONCOL REP, V14, P1413
   LURIA EA, 1971, TRANSFUSION, V11, P345, DOI 10.1111/j.1537 2995.1971.tb04426.x
   Miao ZN, 2006, CELL BIOL INT, V30, P681, DOI 10.1016/j.cellbi.2006.03.009
   Montzka K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471 2202 10 16
   Pal R, 2009, J TISSUE ENG REGEN M, V3, P163, DOI 10.1002/term.143
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pozzobon M, 2009, STEM CELLS DEV, V18, P497, DOI 10.1089/scd.2008.0003
   Qiu HB, 2008, J PROTEOME RES, V7, P1904, DOI 10.1021/pr700651b
   Rabilloud T, 2009, ELECTROPHORESIS, V30, pS174, DOI 10.1002/elps.200900050
   Roche S, 2009, PROTEOMICS, V9, P223, DOI 10.1002/pmic.200800035
   Salasznyk RM, 2005, STEM CELLS DEV, V14, P354, DOI 10.1089/scd.2005.14.354
   Sanchez Fernandez MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003537
   Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522 2683(20000401)21:6<1054::AID ELPS1054>3.3.CO;2 #
   Santos TM, 2010, TRANSPL P, V42, P563, DOI 10.1016/j.transproceed.2010.01.032
   Schindler J, 2006, J NEURAL TRANSM, V113, P995, DOI 10.1007/s00702 006 0508 4
   Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471 2407 4 73
   Song L, 2006, STEM CELLS, V24, P1707, DOI 10.1634/stemcells.2005 0604
   Steinert M, 2002, AM J PATHOL, V161, P1657, DOI 10.1016/S0002 9440(10)64443 4
   van Pel M, 2008, HAEMATOL HEMATOL J, V93, P1137, DOI 10.3324/haematol.12838
   Wagner W, 2006, EXP HEMATOL, V34, P536, DOI 10.1016/j.exphem.2006.01.002
   Wang ZY, 2004, BLOOD, V103, P100, DOI 10.1182/blood 2003 04 1063
   Xu ZW, 2010, CELL MOL IMMUNOL, V7, P11, DOI 10.1038/cmi.2009.108
   Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128
   Zhang AX, 2007, MOL CELL BIOCHEM, V304, P167, DOI 10.1007/s11010 007 9497 3
   Zhang GB, 2008, IMMUNOLOGY, V123, P538, DOI 10.1111/j.1365 2567.2007.02723.x
   Zhao YX, 2004, ANAL CHEM, V76, P1817, DOI 10.1021/ac0354037
NR 56
TC 84
Z9 102
U1 1
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 26
PY 2011
VL 6
IS 5
AR e20399
DI 10.1371/journal.pone.0020399
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 769XS
UT WOS:000291052200060
PM 21637820
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Kiso, H
   Takahashi, K
   Saito, K
   Togo, Y
   Tsukamoto, H
   Huang, BY
   Sugai, M
   Shimizu, A
   Tabata, Y
   Economides, AN
   Slavkin, HC
   Bessho, K
AF Kiso, Honoka
   Takahashi, Katsu
   Saito, Kazuyuki
   Togo, Yumiko
   Tsukamoto, Hiroko
   Huang, Boyen
   Sugai, Manabu
   Shimizu, Akira
   Tabata, Yasuhiko
   Economides, Aris N.
   Slavkin, Harold C.
   Bessho, Kazuhisa
TI Interactions between BMP 7 and USAG 1 (Uterine Sensitization Associated
   Gene 1) Regulate Supernumerary Organ Formations
SO PLOS ONE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 7; TOOTH MORPHOGENESIS; DENTAL MESENCHYME;
   CELL DEATH; MOUSE; EXPRESSION; KIDNEY; TEETH; ANTAGONIST; RECEPTOR
AB Bone morphogenetic proteins (BMPs) are highly conserved signaling molecules that are part of the transforming growth factor (TGF) beta superfamily, and function in the patterning and morphogenesis of many organs including development of the dentition. The functions of the BMPs are controlled by certain classes of molecules that are recognized as BMP antagonists that inhibit BMP binding to their cognate receptors. In this study we tested the hypothesis that USAG 1 (uterine sensitization associated gene 1) suppresses deciduous incisors by inhibition of BMP 7 function. We learned that USAG 1 and BMP 7 were expressed within odontogenic epithelium as well as mesenchyme during the late bud and early cap stages of tooth development. USAG 1 is a BMP antagonist, and also modulates Wnt signaling. USAG 1 abrogation rescued apoptotic elimination of odontogenic mesenchymal cells. BMP signaling in the rudimentary maxillary incisor, assessed by expressions of Msx1 and Dlx2 and the phosphorylation of Smad protein, was significantly enhanced. Using explant culture and subsequent subrenal capsule transplantation of E15 USAG 1 mutant maxillary incisor tooth primordia supplemented with BMP 7 demonstrated in USAG 1(+/ ) as well as USAG 1( / ) rescue and supernumerary tooth development. Based upon these results, we conclude that USAG 1 functions as an antagonist of BMP 7 in this model system. These results further suggest that the phenotypes of USAG 1 and BMP 7 mutant mice reported provide opportunities for regenerative medicine and dentistry.
C1 [Kiso, Honoka; Takahashi, Katsu; Saito, Kazuyuki; Togo, Yumiko; Tsukamoto, Hiroko; Bessho, Kazuhisa] Kyoto Univ, Dept Oral & Maxillofacial Surg, Grad Sch Med, Sakyo Ku, Kyoto, Japan.
   [Huang, Boyen] James Cook Univ, Dept Paediat Dent, Sch Med & Dent, Cairns, Australia.
   [Sugai, Manabu] Kyoto Univ Hosp, Translat Res Ctr, Sakyo Ku, Kyoto 606, Japan.
   [Shimizu, Akira] Osaka Univ, Host Def Lab, World Premier Int Immunol Frontier Res Ctr, Suita, Osaka, Japan.
   [Tabata, Yasuhiko] Kyoto Univ, Dept Biomat, Inst Frontier Med Sci, Kyoto, Japan.
   [Economides, Aris N.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
   [Slavkin, Harold C.] Univ So Calif, Ctr Craniofacial Mol Biol, Div Biomed Sci, Ostrow Sch Dent, Los Angeles, CA 90033 USA.
C3 Kyoto University; James Cook University; Kyoto University; University of
   Osaka; Kyoto University; Regeneron; University of Southern California
RP Takahashi, K (通讯作者)，Kyoto Univ, Dept Oral & Maxillofacial Surg, Grad Sch Med, Sakyo Ku, Shogoin Kawahara Cho, Kyoto, Japan.
EM takahask@kuhp.kyoto u.ac.jp
RI ; Huang, Boyen/AAR 3348 2020; Huang, Boyen/I 7768 2014
OI Economides, Aris/0000 0002 6508 8942; Biresaw, Samuel
   Shiferaw/0000 0001 5508 8511; Sugai, Manabu/0000 0003 1668 7647; Huang,
   Boyen/0000 0002 1246 7447
FU A STEP (Adaptable & Seamless Technology Transfer Program through
   Target driven RD) FS stage [AS231Z01061G, AS242Z02645Q];  [22592213]; 
   [25463081]; Grants in Aid for Scientific Research [25463081, 25293069,
   26670155, 24390073] Funding Source: KAKEN
FX This work was supported by Grant in Aid for Scientific Research(C):
   22592213 and 25463081 and A STEP (Adaptable & Seamless Technology
   Transfer Program through Target driven R&D) FS stage: AS231Z01061G and
   AS242Z02645Q. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Ahrens Hans., 1913, Anatomische Hefte, V48, P167
   Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125
   Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265
   Bei M, 2000, DEVELOPMENT, V127, P4711
   Brown A, 2006, BIODRUGS, V20, P243, DOI 10.2165/00063030 200620040 00005
   Charles C, 2011, DEVELOPMENT, V138, P4063, DOI 10.1242/dev.069195
   DANFORTH CH, 1958, GENETICS, V43, P139
   Darwin C., 1871, P475
   DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795
   FITZGERALD LR, 1973, ARCH ORAL BIOL, V18, P381, DOI 10.1016/0003 9969(73)90162 3
   Fujimori S, 2010, DEV BIOL, V348, P97, DOI 10.1016/j.ydbio.2010.09.009
   Fujita K, 1958, J STOMATOL SOC JPN, V25, P97
   Ganan Y, 1996, DEVELOPMENT, V122, P2349
   Godin RE, 1998, DEVELOPMENT, V125, P3473
   Graham A, 1996, MOL CELL NEUROSCI, V8, P76, DOI 10.1006/mcne.1996.0046
   GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0
   Hovorakova M, 2011, J EXP ZOOL PART B, V316B, P347, DOI 10.1002/jez.b.21408
   Huang B, 2013, ORAL DIS, V19, P144, DOI 10.1111/j.1601 0825.2012.01963.x
   Järvinen E, 2006, P NATL ACAD SCI USA, V103, P18627, DOI 10.1073/pnas.0607289103
   KAUFMAN MH, 1995, J ANAT, V186, P607
   Keränen SVE, 1999, DEV GENES EVOL, V209, P495, DOI 10.1007/s004270050282
   Klein OD, 2006, DEV CELL, V11, P181, DOI 10.1016/j.devcel.2006.05.014
   Klopcic B, 2007, EUR J CELL BIOL, V86, P781, DOI 10.1016/j.ejcb.2007.03.005
   KOLLAR EJ, 1972, AM ZOOL, V12, P125
   Kollar EJ, 1972, DEV ASPECTS ORAL BIO, P125
   Lagronova Churava S, 2013, J EXP ZOOL PART B, V320B, P307, DOI 10.1002/jez.b.22502
   Li TT, 2004, CURR OPIN NEPHROL HY, V13, P417, DOI 10.1097/01.mnh.0000133974.24935.fe
   Liu F, 2010, J DENT RES, V89, P909, DOI 10.1177/0022034510370090
   LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808
   Maas R, 1997, CRIT REV ORAL BIOL M, V8, P4, DOI 10.1177/10454411970080010101
   Millen KJ, EPSTEINS INBORN ERRO, V3, DOI [10.1093/med/9780199934522.003.0137, DOI 10.1093/MED/9780199934522.003.0137]
   Mitsiadis TA, 2003, DEVELOPMENT, V130, P4451, DOI 10.1242/dev.00631
   Mitsiadis TA, 2008, DEV BIOL, V313, P887, DOI 10.1016/j.ydbio.2007.10.055
   Miyazaki Y, 2003, KIDNEY INT, V63, P835, DOI 10.1046/j.1523 1755.2003.00834.x
   Munne PM, 2010, EVOL DEV, V12, P383, DOI 10.1111/j.1525 142X.2010.00425.x
   Munne PM, 2009, DEVELOPMENT, V136, P393, DOI 10.1242/dev.025064
   Murashima Suginami A, 2008, BIOCHEM BIOPH RES CO, V369, P1012, DOI 10.1016/j.bbrc.2008.02.135
   Murashima Suginami A, 2007, BIOCHEM BIOPH RES CO, V359, P549, DOI 10.1016/j.bbrc.2007.05.148
   Mustonen T, 2003, DEV BIOL, V259, P123, DOI 10.1016/S0012 1606(03)00157 X
   Nadiri A, 2004, J HISTOCHEM CYTOCHEM, V52, P103, DOI 10.1177/002215540405200110
   Nakamura T, 2008, J BIOL CHEM, V283, P4825, DOI 10.1074/jbc.M708388200
   Ohazama A, 2008, INBORN ERRORS DEV MO, P245
   Ohazama A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004092
   Ohazama A, 2009, DEVELOPMENT, V136, P897, DOI 10.1242/dev.027979
   Ooe T, 1969, Okajimas Folia Anat Jpn, V46, P243
   Peterková R, 2005, ARCH ORAL BIOL, V50, P219, DOI 10.1016/j.archoralbio.2004.10.020
   Peterková R, 2002, CONNECT TISSUE RES, V43, P120, DOI 10.1080/03008200290000745
   Peterková R, 2000, J CRAN GENET DEV BIO, V20, P158
   Pispa J, 2004, DEV DYNAM, V231, P432, DOI 10.1002/dvdy.20138
   Plikus MV, 2005, EVOL DEV, V7, P440, DOI 10.1111/j.1525 142X.2005.05048.x
   Prochazka J, 2010, P NATL ACAD SCI USA, V107, P15497, DOI 10.1073/pnas.1002784107
   Rose C., 1895, Oester ungar ViertjschrZhik, V11, P45
   Sakata Goto T, 2012, BONE, V50, P69, DOI 10.1016/j.bone.2011.09.049
   SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494 348
   Schneider M, 2008, J MOL MED, V86, P507, DOI 10.1007/s00109 007 0301 3
   Schulze C., 1970, THOMAS ORAL PATHOLOG, P112
   Slavkin HC, 1972, DEVELOPMENTAL ASPECT, P165
   Slavkin HC, 1979, DEV CRANIOFACIAL BIO
   Slavkin HC, 2012, BIRTH DISCIPLINE CRA
   SOFAER JA, 1969, J EMBRYOL EXP MORPH, V22, P181
   Tabata Y, 1998, ADV DRUG DELIVER REV, V31, P287, DOI 10.1016/S0169 409X(97)00125 7
   Tabata Y, 1999, BIOMATERIALS, V20, P2169, DOI 10.1016/S0142 9612(99)00121 0
   Takahashi K, 1998, DEVELOPMENT, V125, P1627
   Takahashi K., 2013, Gene Therapy Tools and Potential Applications, DOI [10.5772/52529, DOI 10.5772/52529, 10.5772/52529.]
   Tanaka M, 2008, KIDNEY INT, V73, P181, DOI 10.1038/sj.ki.5002626
   Thesleff I, 1996, ANAT REC, V245, P151
   Thomas BL, 2000, DEVELOPMENT, V127, P217
   Thomas BL, 1997, DEVELOPMENT, V124, P4811
   Tucker AS, 2004, DEV BIOL, V268, P185, DOI 10.1016/j.ydbio.2003.12.019
   VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092 8674(93)90678 J
   Wang XP, 2009, DEVELOPMENT, V136, P1939, DOI 10.1242/dev.033803
   Wang YH, 1999, DEV DYNAM, V216, P320, DOI 10.1002/(SICI)1097 0177(199912)216:4/5<320::AID DVDY2>3.0.CO;2 H
   Wawersik S, 1999, DEV BIOL, V207, P176, DOI 10.1006/dbio.1998.9153
   Yamamoto H, 2005, ARCH ORAL BIOL, V50, P189, DOI 10.1016/j.archoralbio.2004.11.010
   Yanagita M, 2006, J CLIN INVEST, V116, P70, DOI 10.1172/JCI25445
   Yanagita M, 2005, CYTOKINE GROWTH F R, V16, P309, DOI 10.1016/j.cytogfr.2005.02.007
   Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075
   Yusof W Z, 1990, J Can Dent Assoc, V56, P147
   Zhang QH, 2003, DEV DYNAM, V227, P78, DOI 10.1002/dvdy.10289
   Zhang ZY, 2009, SCIENCE, V323, P1232, DOI 10.1126/science.1167418
   ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700
   Zouvelou V, 2009, J EXP ZOOL PART B, V312B, P361, DOI 10.1002/jez.b.21262
   Zuzarte Luis V, 2005, SEMIN CELL DEV BIOL, V16, P261, DOI 10.1016/j.semcdb.2004.12.004
NR 83
TC 33
Z9 37
U1 1
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 9
PY 2014
VL 9
IS 5
AR e96938
DI 10.1371/journal.pone.0096938
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AI4LX
UT WOS:000336838000082
PM 24816837
OA Green Submitted, Green Published, gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Han, YD
   Zhang, LH
   Xing, YL
   Zhang, LC
   Chen, XJ
   Tang, PF
   Chen, ZB
AF Han, Yudi
   Zhang, Lihai
   Xing, Yaling
   Zhang, Licheng
   Chen, Xiaojuan
   Tang, Peifu
   Chen, Zhongbin
TI Autophagy relieves the function inhibition and apoptosis promoting
   effects on osteoblast induced by glucocorticoid
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE osteoblast; autophagy; apoptosis; glucocorticoids; osteoporosis
ID BONE; DEXAMETHASONE; METABOLISM; MECHANISMS; FRACTURE; PATHWAY
AB Autophagy may be a major mechanism by which osteoblasts (OBs) protect against the negative effects of chronic glucocorticoid (GC) usage. OBs are closely associated with the remodeling that occurs in GC induced osteoporosis (GIO). In osteocytes, in response to stress induced by GCs, several pathways are activated, including cell necrosis, apoptosis and autophagy. However, the role of autophagy in OBs following treatment with excess GCs has not been addressed. In the current study, confocal microscopy observation of green fluorescent protein microtubule associated protein 1 light chain 3 beta (LC3) punctuate, and western blotting for LC3II and Beclin 1 were performed for detection of autophagy in the MC3T3 E1 osteoblastic cell line. Flow cytometry and western blotting were used for the examination of apoptosis and expression of BAX apoptosis regulator (Bax)/apoptosis regulator Bcl 2 (Bcl 2). The expression of genes associated with osteoblastic function, runt related transcription factor 2, alpha 1 type 1 collagen and osteocalcin, were measured by reverse transcription quantitative polymerase chain reaction. The results indicated that autophagy was induced in OBs during dexamethasone (Dex) treatment in a dose dependent manner. The level of autophagy did not continue to increase over time, but peaked at 48 h and then decreased gradually. Subsequently, flow cytometry was used to demonstrate that inhibition of autophagy induced apoptosis in OBs under Dex treatment, and was associated with the upregulation of Bax and the downregulation of Bcl 2 protein expression. Furthermore, the data suggested that the inhibition of autophagy also suppressed the expression of osteoblastic genes. By contrast, the stimulation of autophagy maintained the gene expression level under Dex treatment. The data revealed that autophagy is an important regulator of osteoblastic apoptosis through its interaction with Bax/Bcl 2, and maintains the osteoblastic function of MC3T3 E1 cells following GC exposure. In addition, these results indicated that the suppression of autophagy in OBs under chronic GC therapy may increase the prevalence of GIO and fragility fractures.
C1 [Han, Yudi; Zhang, Lihai; Zhang, Licheng; Tang, Peifu] Chinese Peoples Liberat Army Gen Hosp, Dept Orthopaed, 28 Fuxing Rd, Beijing 100853, Peoples R China.
   [Xing, Yaling; Chen, Xiaojuan; Chen, Zhongbin] Beijing Inst Radiat Med, Dept Electromagnet & Laser Biol, Div Infect & Immun, 27 Taiping Rd, Beijing 100850, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Academy of Military
   Medical Sciences   China
RP Tang, PF (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Orthopaed, 28 Fuxing Rd, Beijing 100853, Peoples R China.; Chen, ZB (通讯作者)，Beijing Inst Radiat Med, Dept Electromagnet & Laser Biol, Div Infect & Immun, 27 Taiping Rd, Beijing 100850, Peoples R China.
EM pftang301@163.com; chenzb@bmi.ac.cn
FU China, National High tech R&D Program (863 Program) [SS2012AA041604];
   National Natural Science Foundation of China [31271000]
FX This study was funded by two grants from China, National High tech R&D
   Program (863 Program) (grant no. SS2012AA041604) and National Natural
   Science Foundation of China (grant no. 31271000).
CR Alm JJ, 2012, TISSUE ENG PART C ME, V18, P658, DOI [10.1089/ten.tec.2011.0675, 10.1089/ten.TEC.2011.0675]
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97
   Chipuk JE, 2012, CELL, V148, P988, DOI 10.1016/j.cell.2012.01.038
   Czaja MJ, 2010, AM J PHYSIOL CELL PH, V298, pC973, DOI 10.1152/ajpcell.00527.2009
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev genet 102808 114910
   Hong JM, 2011, J BONE MINER RES, V26, P657, DOI 10.1002/jbmr.241
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08 01 0080
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Jia JJ, 2011, FASEB J, V25, P3366, DOI 10.1096/fj.11 182519
   Jiang M, 2012, KIDNEY INT, V82, P1271, DOI 10.1038/ki.2012.261
   Jilka RL, 2014, J BONE MINER RES, V29, P103, DOI 10.1002/jbmr.2007
   Jung HS, 2008, CELL METAB, V8, P318, DOI 10.1016/j.cmet.2008.08.013
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037030
   Li JH, 2011, J VIROL, V85, P6319, DOI 10.1128/JVI.02627 10
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473
   Martinet W, 2009, CLIN SCI, V116, P697, DOI 10.1042/CS20080508
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mizushima N, 2009, CURR TOP MICROBIOL, V335, P71, DOI 10.1007/978 3 642 00302 8_3
   Naves MA, 2011, CELL BIOL INT, V35, P1147, DOI 10.1042/CBI20100731
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Rangaraju S, 2010, J NEUROSCI, V30, P11388, DOI 10.1523/JNEUROSCI.1356 10.2010
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Xia HF, 2014, FEBS LETT, V588, P574, DOI 10.1016/j.febslet.2013.12.026
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Yang YH, 2013, APOPTOSIS, V18, P1363, DOI 10.1007/s10495 013 0867 x
   Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867
NR 42
TC 38
Z9 53
U1 1
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
EI 1791 244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD FEB
PY 2018
VL 41
IS 2
BP 800
EP 808
DI 10.3892/ijmm.2017.3270
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FT5VV
UT WOS:000423222200022
PM 29207032
OA Green Submitted, Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Bolam, SM
   O'Regan Brown, A
   Konar, S
   Callon, KE
   Coleman, B
   Dalbeth, N
   Monk, AP
   Musson, DS
   Cornish, J
   Munro, JT
AF Bolam, Scott M.
   O'Regan Brown, Arama
   Konar, Subhajit
   Callon, Karen E.
   Coleman, Brendan
   Dalbeth, Nicola
   Monk, A. Paul
   Musson, David S.
   Cornish, Jillian
   Munro, Jacob T.
TI Cytotoxicity of tranexamic acid to tendon and bone in vitro: Is there a
   safe dosage?
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article
DE Arthroscopy; Intra articular drugs; Tranexamic acid; Toxicity;
   Orthopaedics; Peri articular tissues
ID TOTAL KNEE ARTHROPLASTY; CRUCIATE LIGAMENT RECONSTRUCTION; REDUCING
   BLOOD LOSS; HIP ARTHROPLASTY; REPLACEMENT; HEMARTHROSIS; EFFICACY
AB Introduction Tranexamic acid (TXA) has been shown to be effective at reducing peri operative blood loss and haemarthrosis in arthroplasty and arthroscopic soft tissue reconstructions. Intra articular application, as an injection or peri articular wash, is becoming increasingly common. Recent studies have shown TXA has the potential to be cytotoxic to cartilage, but its effects on human tendon and bone remain poorly understood. The aim of this study was to investigate whether TXA has any detrimental effects on tendon derived cells and osteoblast like cells and determine whether there is a safe dosage for clinical application. Materials and methods Primary tendon derived cells and osteoblast like cells were harvested from hamstring tendons and trabecular bone explants, respectively, and analysed in vitro with a range of TXA concentrations (0 to 100 mg/ml) at time points: 3 and 24 h. The in vitro toxic effect of TXA was investigated using viability assays (alamarBlue), functional assays (collagen deposition), fluorescent microscopy and live/apoptosis/necrosis staining for cell death mechanisms in 2D monolayer and 3D collagen gel cell culture. Results There was a significant (P < 0.05) decrease in tendon derived cell and osteoblast like cell numbers following treatment with TXA >= 50 mg/ml after 3 h and >= 20 mg/ml after 24 h. In tendon derived cells, increasing concentrations > 35 mg/ml resulted in significantly (P < 0.05) reduced collagen deposition. Fluorescence imaging confirmed atypical cellular morphologies with increasing TXA concentrations and reduced cell numbers. The mechanism of cell death was demonstrated to be occurring through apoptosis. Conclusions Topical TXA treatment demonstrated dose  and time dependent cytotoxicity to tendon derived cells and osteoblast like cells with concentrations 20 mg/ml and above in isolated 2D and 3D in vitro culture. On the basis of these findings, concentrations of less than 20 mg/ml are expected to be safe. Orthopaedic surgeons should show caution when considering topical TXA treatments, particularly in soft tissue and un cemented arthroplasty procedures.
C1 [Bolam, Scott M.; O'Regan Brown, Arama; Konar, Subhajit; Callon, Karen E.; Dalbeth, Nicola; Musson, David S.; Cornish, Jillian; Munro, Jacob T.] Univ Auckland, Fac Med & Heath Sci, Auckland, New Zealand.
   [Bolam, Scott M.; Monk, A. Paul; Munro, Jacob T.] Auckland City Hosp, Dept Orthopaed Surg, Auckland, New Zealand.
   [Coleman, Brendan] Middlemore Hosp, Dept Orthopaed Surg, Auckland, New Zealand.
   [Monk, A. Paul] Univ Auckland, Auckland Bioengn Inst, Auckland, New Zealand.
C3 University of Auckland; Auckland City Hospital; University of Auckland
RP Bolam, SM (通讯作者)，Univ Auckland, Fac Med & Heath Sci, Auckland, New Zealand.; Bolam, SM (通讯作者)，Auckland City Hosp, Dept Orthopaed Surg, Auckland, New Zealand.
EM s.bolam@auckland.ac.nz
RI ; konar, subhajit/KIG 5569 2024; Bolam, Scott/GNW 5631 2022
OI Bolam, Scott/0000 0002 0197 307X; Musson, David/0000 0003 2109 8791;
   konar, subhajit/0000 0003 1476 7395
FU Maurice & Phyllis Paykel Trust [193119]
FX We would like to acknowledge the financial support of the Maurice &
   Phyllis Paykel Trust (#193119).
CR Aggarwal AK, 2016, J ARTHROPLASTY, V31, P1442, DOI 10.1016/j.arth.2015.12.033
   AHLBERG A, 1976, ACTA ORTHOP SCAND, V47, P486, DOI 10.3109/17453677608988725
   Ambra LF, 2019, KNEE SURG SPORT TR A, V27, P931, DOI 10.1007/s00167 017 4746 9
   Bahl V, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749 799X 8 5
   Baranowsky A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010449
   Bolam SM, 2021, KNEE SURG SPORT TR A, V29, P1862, DOI 10.1007/s00167 020 06219 7
   Busse P, 2019, BONE JOINT RES, V8, P41, DOI 10.1302/2046 3758.82.BJR 2018 0099.R1
   Chen YC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004656
   Chhana A, 2014, ANN RHEUM DIS, V73, P1737, DOI 10.1136/annrheumdis 2013 204657
   Chiang ER, 2019, ARTHROSCOPY, V35, P2127, DOI 10.1016/j.arthro.2019.02.018
   Cuellar JM, 2014, SPINE, V39, pE1132, DOI 10.1097/BRS.0000000000000488
   Demol J, 2011, EUR CELLS MATER, V21, P272, DOI 10.22203/eCM.v021a21
   Dyba J, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.3629.3629
   Gandhi Rajiv, 2013, BMC Res Notes, V6, P184, DOI 10.1186/1756 0500 6 184
   Goderecci R, 2019, EUR J MED RES, V24, DOI 10.1186/s40001 019 0373 x
   Goyal N, 2017, J ARTHROPLASTY, V32, P28, DOI 10.1016/j.arth.2016.07.004
   Karaaslan F, 2015, AM J SPORT MED, V43, P2720, DOI 10.1177/0363546515599629
   Lamberti PM, 2002, CLIN ORTHOP RELAT R, P414
   Maniar RN, 2012, CLIN ORTHOP RELAT R, V470, P2605, DOI 10.1007/s11999 012 2310 y
   Mao ZY, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1293 3
   Matthews Brya G, 2014, Bonekey Rep, V3, P560, DOI 10.1038/bonekey.2014.55
   McLean M, 2019, BONE JOINT RES, V8, P11, DOI 10.1302/2046 3758.81.BJR 2018 0181.R1
   Morrison RJM, 2017, BONE JOINT RES, V6, P499, DOI 10.1302/2046 3758.68.BJR 2017 0005.R1
   Murkin JM, 2010, ANESTH ANALG, V110, P350, DOI 10.1213/ANE.0b013e3181c92b23
   Musson DS, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1089 x
   Musson DS, 2015, TISSUE ENG PT A, V21, P1539, DOI [10.1089/ten.tea.2014.0128, 10.1089/ten.TEA.2014.0128]
   Nilsson IM., 1980, J CLIN PATHOL S, V14
   Panteli M, 2013, KNEE, V20, P300, DOI 10.1016/j.knee.2013.05.014
   Parker JD, 2018, BONE JOINT J, V100B, P404, DOI 10.1302/0301 620X.100B3.BJJ 2017 1135.R1
   Poeran Jashvant, 2014, BMJ, V349, pg4829, DOI 10.1136/bmj.g4829
   Quedado J, 2016, AM J ORTHOPSYCHIAT, V45, P439
   Sa Ngasoongsong P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/164206
   Sa ngasoongsong P, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471 2474 14 340
   Seo JG, 2013, KNEE SURG SPORT TR A, V21, P1869, DOI 10.1007/s00167 012 2079 2
   Siegel MG, 2019, ARTHROSCOPY, V35, P2973, DOI 10.1016/j.arthro.2019.09.007
   Tuttle JR., 2015, AM J ORTHOP BELLE ME, V44, P497
   Tzatzairis TK, 2016, J ARTHROPLASTY, V31, P2465, DOI 10.1016/j.arth.2016.04.036
   VERSTRAETE M, 1985, DRUGS, V29, P236, DOI 10.2165/00003495 198529030 00003
   Wagenbrenner M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123880
   Zhang H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006916
   Zhang Y, 2016, ORTHOPADE, V45, P616, DOI 10.1007/s00132 016 3252 y
NR 41
TC 11
Z9 13
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD MAY 15
PY 2022
VL 17
IS 1
AR 273
DI 10.1186/s13018 022 03167 5
PG 10
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 1G5FX
UT WOS:000795874400003
PM 35570313
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ory, B
   Moriceau, G
   Trichet, V
   Blanchard, F
   Berreur, M
   Redini, F
   Rogers, M
   Heymann, D
AF Ory, B.
   Moriceau, G.
   Trichet, V.
   Blanchard, F.
   Berreur, M.
   Redini, F.
   Rogers, M.
   Heymann, D.
TI Farnesyl diphosphate synthase is involved in the resistance to
   zoledronic acid of osteosarcoma cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE osteosarcoma; bisphosphonate; zoledronic acid; metabolic resistance;
   farnesyl diphosphate synthase
ID NITROGEN CONTAINING BISPHOSPHONATES; HIGH GRADE OSTEOSARCOMA;
   SOFT TISSUE TUMORS; MULTIDRUG RESISTANCE; IN VITRO; DRUG RESISTANCE;
   EXPRESSION; BONE; CHEMOTHERAPY; MECHANISMS
AB We recently demonstrated original anti tumor effects of zoledronic acid (Zol) on osteosarcoma cell lines independently of their p53 and Rb status. The present study investigated the potential Zol resistance acquired by osteosarcoma cells after prolonged treatment. After 12 weeks of culture in the presence of 1 mu m Zol, the effects of high doses of Zol (10 100 mu m) were compared between the untreated rat (OSRGA, ROS) and human (MG63, SAOS2) osteosarcoma cells and Zol pretreated cells in terms of cell proliferation, cell cycle analysis, migration assay and cytoskeleton organization. Long term treatment with 1 mu m Zol reduced the sensitivity of osteosarcoma cells to high concentrations of Zol. Furthermore, the Zol resistant cells were sensitive to conventional anti cancer agents demonstrating that this resistance process is independent of the multidrug resistance phenotype. However, as similar experiments performed in the presence of clodronate and pamidronate evidenced that this drug resistance was restricted to the nitrogen containing bisphosphonates, we then hypothesized that this resistance could be associated with a differential expression of farnesyl diphos phate synthase (FPPS) also observed in human osteosarcoma samples. The transfection of Zol resistant cells with FPPS siRNA strongly increased their sensitivity to Zol. This study demonstrates for the first time the induction of metabolic resistance after prolonged Zol treatment of osteosarcoma cells confirming the therapeutic potential of Zol for the treatment of bone malignant pathologies, but points out the importance of the treatment regimen may be important in terms of duration and dose to avoid the development of drug metabolic resistance.
C1 [Heymann, D.] INSERM, ERI 7, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822,Fac Med, F 44035 Nantes 1, France.
   [Ory, B.; Moriceau, G.; Trichet, V.; Blanchard, F.; Berreur, M.; Redini, F.; Heymann, D.] Univ Nantes, Nantes Atlantique Univ, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, Nantes, France.
   [Rogers, M.] Univ Aberdeen, Inst Med Sci, Bone & Musculoskeletal Res Program, Aberdeen, Scotland.
   [Heymann, D.] Hosp Nantes, Nantes, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Nantes Universite; University of Aberdeen; Nantes Universite; CHU de
   Nantes
RP Heymann, D (通讯作者)，INSERM, ERI 7, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822,Fac Med, 1 Rue Gaston Veil, F 44035 Nantes 1, France.
EM dominique.heymann@univ nantes.fr
RI ; Trichet, Valérie/L 1553 2015; REDINI, Francoise/K 7981 2015; Heymann,
   Dominique/AAC 6014 2019; ory, benjamin/K 8231 2015; Blanchard,
   Frederic/K 8018 2015
OI ory, benjamin/0000 0002 2622 7356; Trichet, Valerie/0000 0003 4183 9032;
   Heymann, Dominique/0000 0001 7777 0669; Blanchard,
   Frederic/0000 0003 1055 2573; Rogers, Michael/0000 0002 1818 9249
CR Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507
   Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097 0215(19991022)84:5<489::AID IJC7>3.0.CO;2 D
   Beretta GL, 2004, BIOCHEM PHARMACOL, V68, P283, DOI 10.1016/j.bcp.2004.03.022
   BIEDLER JL, 1970, CANCER RES, V30, P1174
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877
   Doggrell SA, 2001, EXPERT OPIN INV DRUG, V10, P1755, DOI 10.1517/13543784.10.9.1755
   ENDO A, 1992, J LIPID RES, V33, P1569
   Evdokiou A, 2003, BONE, V33, P216, DOI 10.1016/S8756 3282(03)00223 0
   Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125
   GOTTESMAN MM, 1994, COLD SPRING HARB SYM, V59, P677, DOI 10.1101/SQB.1994.059.01.078
   GREM JL, 1988, JNCI J NATL CANCER I, V80, P626, DOI 10.1093/jnci/80.9.626
   Heymann D, 2005, BONE, V37, P74, DOI 10.1016/j.bone.2005.02.020
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   Ifergan I, 2003, CANCER AM CANCER SOC, V98, P1958, DOI 10.1002/cncr.11741
   JASMIN C, 1982, SEM HOP PARIS, V58, P1684
   KLEIN B, 1977, INT J CANCER, V20, P112, DOI 10.1002/ijc.2910200118
   Kruh GD, 2003, ONCOGENE, V22, P7262, DOI 10.1038/sj.onc.1206932
   LINK MP, 1991, CLIN ORTHOP RELAT R, P8
   Lourda M, 2007, INT J CANCER, V120, P611, DOI 10.1002/ijc.22327
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Gomes CMF, 2006, NUCL MED BIOL, V33, P831, DOI 10.1016/j.nucmedbio.2006.07.011
   Mensah Osman EJ, 2007, CANCER AM CANCER SOC, V109, P957, DOI 10.1002/cncr.22479
   Notarnicola M, 2004, ONCOLOGY BASEL, V67, P351, DOI 10.1159/000082918
   Ortiz Gómez A, 2006, EUKARYOT CELL, V5, P1057, DOI 10.1128/EC.00034 06
   Ory B, 2007, MOL PHARMACOL, V71, P333, DOI 10.1124/mol.106.028837
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   Ory B, 2007, CURR MED CHEM, V14, P1381, DOI 10.2174/092986707780831159
   Ozben T, 2006, FEBS LETT, V580, P2903, DOI 10.1016/j.febslet.2006.02.020
   Papapoulos SE, 2006, J BONE MINER RES, V21, pP88, DOI 10.1359/JBMR.06S216
   Provisor AJ, 1997, J CLIN ONCOL, V15, P76, DOI 10.1200/JCO.1997.15.1.76
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   ROSEN G, 1976, CANCER AM CANCER SOC, V37, P1, DOI 10.1002/1097 0142(197601)37:1<1::AID CNCR2820370102>3.0.CO;2 3
   Russell RGG, 2007, PEDIATRICS, V119, pS150, DOI 10.1542/peds.2006 2023H
   Salomo M, 2003, BRIT J HAEMATOL, V122, P202, DOI 10.1046/j.1365 2141.2003.04437.x
   Sandberg AA, 2003, CANCER GENET CYTOGEN, V145, P1, DOI 10.1016/S0165 4608(03)00105 5
   Serra M, 2006, INT J ONCOL, V29, P1459
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Sonnemann J, 2001, ANTI CANCER DRUG, V12, P459, DOI 10.1097/00001813 200106000 00007
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   TSURUO T, 1981, CANCER RES, V41, P1967
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097 0215(19990118)80:2<199::AID IJC7>3.0.CO;2 4
   Zhou H, 2003, J PEDIAT HEMATOL ONC, V25, P27, DOI 10.1097/00043426 200301000 00007
NR 50
TC 31
Z9 33
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2008
VL 12
IS 3
BP 928
EP 941
DI 10.1111/j.1582 4934.2008.00141.x
PG 14
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 304JG
UT WOS:000256105200013
PM 18494934
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU El Maraghy, SA
   Mehana, NA
AF El Maraghy, Shohda A.
   Mehana, Noha Ali
TI Modulatory effects of L arginine and soy enriched diet on bone
   homeostasis abnormalities in streptozotocin induced diabetic rats
SO CHEMICO BIOLOGICAL INTERACTIONS
LA English
DT Article
DE L Arginine; Soy enriched diet; Osteoporosis; Diabetes mellitus; PTH
ID ESTROGEN RECEPTOR MODULATORS; HORMONE REPLACEMENT THERAPY; NITRIC OXIDE
   PRODUCTION; AMINO ACIDS; IGF I; OSTEOPROTEGERIN LIGAND; POSTMENOPAUSAL
   WOMEN; OXIDATIVE STRESS; INSULIN; CELLS
AB Diabetes mellitus is a complex syndrome which is responsible for numerous complications affecting the whole body. Osteoporosis is regarded as one of the chronic complications of diabetes mellitus that results from reduced bone formation and increased resorption. In this context, we searched for dietary supplements that preserve diabetic bone loss. Parathyroid hormone (PTH) has been suggested as a possible mechanism affecting bone homeostasis in streptozotocin (STZ) induced diabetic rats. The osteoprotective effects of L arginine and soy enriched diet were also investigated. Male Wistar rats were allocated into four groups; normal control, untreated STZ diabetic rats and STZ diabetic rats treated with either L arginine (10 mg/kg/day) or fed soy enriched diet (200 g/kg diet) for 12 weeks. L Arginine and soy enriched diet normalized serum PTH level and increased serum osteocalcin level; bone osteocalcin, osteoprotegerin and runt related transcription factor2 mRNA levels compared to diabetic rats. A decrease in serum pyridinoline, C terminal telopeptides of type I collagen, cathepsin k levels and bone cathepsin k mRNA level was observed in both treated groups. Both treatments increased serum insulin and insulin like growth factor 1 levels and decreased urinary calcium excretion. In conclusion, L arginine and soy enriched diet are effective in prevention of osteoporosis associated with diabetes mellitus. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [El Maraghy, Shohda A.; Mehana, Noha Ali] Cairo Univ, Fac Pharm, Dept Biochem, Giza, Egypt.
C3 Egyptian Knowledge Bank (EKB); Cairo University
RP El Maraghy, SA (通讯作者)，Fac Pharm, 23 Kasr El Aini St, Cairo, Egypt.
EM Shohda.elmaraghy@pharma.cu.edu.eg
CR Ahmad AM, 2003, J CLIN ENDOCR METAB, V88, P2860, DOI 10.1210/jc.2002 021787
   Ahmad T, 2008, GROWTH HORM IGF RES, V18, P404, DOI 10.1016/j.ghir.2008.02.003
   Arjmandi BH, 1998, AM J CLIN NUTR, V68, p1364S, DOI 10.1093/ajcn/68.6.1364S
   Arjmandi BH, 2003, J CLIN ENDOCR METAB, V88, P1048, DOI 10.1210/jc.2002 020849
   Azadbakht L, 2009, J RENAL NUTR, V19, P479, DOI 10.1053/j.jrn.2009.06.002
   Baecker N, 2005, J BONE MINER RES, V20, P471, DOI 10.1359/JBMR.041121
   Baker VL, 2000, OBSTET GYNECOL SURV, V55, pS21, DOI 10.1097/00006254 200007001 00001
   Ben Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409
   Bikle Daniel D, 2012, Curr Mol Pharmacol, V5, P135
   Bourrin S, 2000, ENDOCRINOLOGY, V141, P3149, DOI 10.1210/en.141.9.3149
   Boyle JP, 2001, DIABETES CARE, V24, P1936, DOI 10.2337/diacare.24.11.1936
   Broadhead GK, 2011, J BIOL CHEM, V286, P8786, DOI 10.1074/jbc.M110.149724
   Burke GL, 2000, J NUTR, V130, p664S, DOI 10.1093/jn/130.3.664S
   CASPARY WF, 1973, DIGESTION, V9, P248, DOI 10.1159/000197452
   Chevalley T, 1998, BONE, V23, P103, DOI 10.1016/S8756 3282(98)00081 7
   Cohen RA, 2010, J CARDIOVASC PHARM, V55, P308, DOI 10.1097/FJC.0b013e3181d89670
   Conconi MT, 2001, FARMACO, V56, P755, DOI 10.1016/S0014 827X(01)01126 0
   del Pino Montes J, 2004, CALCIFIED TISSUE INT, V75, P526, DOI 10.1007/s00223 004 0118 9
   Demonty I, 2003, NUTR REV, V61, P189, DOI 10.1301/nr.2003.jun.189 203
   FADDA GZ, 1989, KIDNEY INT, V36, P773, DOI 10.1038/ki.1989.262
   Flynn NE, 2002, BIOMED PHARMACOTHER, V56, P427, DOI 10.1016/S0753 3322(02)00273 1
   Fowlkes JL, 2008, ENDOCRINOLOGY, V149, P1697, DOI 10.1210/en.2007 1408
   GRILL V, 1992, METABOLISM, V41, P28, DOI 10.1016/0026 0495(92)90186 E
   Guerra Menéndez L, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 271
   HAGENFELDT L, 1989, ACTA PAEDIATR SCAND, V78, P278, DOI 10.1111/j.1651 2227.1989.tb11070.x
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Irwin R, 2006, ENDOCRINOLOGY, V147, P5760, DOI 10.1210/en.2006 0700
   Kaneto H, 2005, INT J BIOCHEM CELL B, V37, P1595, DOI 10.1016/j.biocel.2005.04.003
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kostenuik PJ, 2001, ENDOCRINOLOGY, V142, P4295, DOI 10.1210/en.142.10.4295
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lardon J, 2004, VIRCHOWS ARCH, V444, P61, DOI 10.1007/s00428 003 0930 z
   Li YQ, 2012, ACTA PHARMACOL SIN, V33, P66, DOI 10.1038/aps.2011.136
   Liu DM, 2006, DIABETES, V55, P1043, DOI 10.2337/diabetes.55.04.06.db05 1089
   Mancini L, 2000, BIOCHEM BIOPH RES CO, V274, P477, DOI 10.1006/bbrc.2000.3164
   Maxwell AJ, 2001, J APPL PHYSIOL, V90, P933, DOI 10.1152/jappl.2001.90.3.933
   McKinnon CM, 2001, DIABETOLOGIA, V44, P1203, DOI 10.1007/s001250100628
   Mezei O, 2003, J NUTR, V133, P1238
   MONCADA S, 1993, NEW ENGL J MED, V329, P2002
   Motyl K, 2009, BIOL PROCED ONLINE, V11, P296, DOI 10.1007/s12575 009 9000 5
   Motyl KJ, 2009, J CELL PHYSIOL, V218, P575, DOI 10.1002/jcp.21626
   Nakasaki M, 2008, BONE, V43, P869, DOI 10.1016/j.bone.2008.07.241
   Okazaki R, 1997, J CLIN ENDOCR METAB, V82, P2915, DOI 10.1210/jc.82.9.2915
   Park CY, 2012, NUTRIENTS, V4, P1610, DOI 10.3390/nu4111610
   Pennisi P, 2009, J ENDOCRINOL INVEST, V32, P546, DOI 10.1007/BF03346505
   Percival MD, 1999, BIOCHEMISTRY US, V38, P13574, DOI 10.1021/bi991028u
   Picherit C, 2001, BRIT J NUTR, V85, P307, DOI 10.1079/BJN2000252
   PIEPER GM, 1995, J CARDIOVASC PHARM, V25, P397, DOI 10.1097/00005344 199503000 00008
   PIEPER GM, 1995, DIABETES, V44, P1106, DOI 10.2337/diabetes.44.9.1106
   Preisinger E, 2009, Z RHEUMATOL, V68, P534, DOI 10.1007/s00393 009 0445 3
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rosen CJ, 2008, J BONE MINER RES, V23, P1881, DOI 10.1359/JBMR.081001
   Russell G, 2001, Novartis Found Symp, V232, P251
   Russell G., 2001, NOVART FDN SYMP, V232, P267
   Salt IP, 2003, J BIOL CHEM, V278, P18791, DOI 10.1074/jbc.M210618200
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Stilgren LS, 2004, BONE, V35, P256, DOI 10.1016/j.bone.2004.03.012
   Sugimoto E, 2000, BIOCHEM PHARMACOL, V59, P471, DOI 10.1016/S0006 2952(99)00351 2
   SUGIMOTO T, 1990, KIDNEY INT, V37, P1522, DOI 10.1038/ki.1990.144
   Vasilijevic A, 2007, J PHYSIOL LONDON, V584, P921, DOI 10.1113/jphysiol.2007.140277
   VERHAEGHE J, 1990, HORM RES, V34, P245, DOI 10.1159/000181834
   VISSER JJ, 1994, MED HYPOTHESES, V43, P339, DOI 10.1016/0306 9877(94)90113 9
   Wang WW, 2010, MOL CELL BIOCHEM, V338, P115, DOI 10.1007/s11010 009 0344 6
   Wong C, 2002, SURGERY, V132, P998, DOI 10.1067/msy.2002.128558
   Wu GY, 2000, J NUTR, V130, P2626, DOI 10.1093/jn/130.11.2626
   Young ME, 1997, BIOCHEM J, V322, P223, DOI 10.1042/bj3220223
NR 68
TC 12
Z9 14
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009 2797
EI 1872 7786
J9 CHEM BIOL INTERACT
JI Chem. Biol. Interact.
PD MAR 5
PY 2015
VL 229
BP 9
EP 16
DI 10.1016/j.cbi.2015.01.009
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA CE7VU
UT WOS:000352050800002
PM 25617479
DA 2025 08 17
ER

PT J
AU Sekar, D
AF Sekar, Durairaj
TI Implications of microRNA 21 and its involvement in the treatment of
   different type of arthritis
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE miRNAs; miR 21; Arthritis; Rheumatoid arthritis; Osteoarthritis; mRNA
ID RHEUMATOID ARTHRITIS; HUMAN CHONDROCYTES; EXPRESSION; MIR 21; DICER;
   ACTIVATION; TARGETS; BURDEN; RATS
AB Arthritis is a kind of autoimmune disease, which includes many circumstances that affect joints, the tissues surrounding the joints, and other connective tissues. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the common arthritis seen in many populations. Researchers have made extensive studies on all types of arthritis, novel drugs are being developed by many laboratories, but yet no treatment option is available for these diseases and need new insight into the molecular pathways and pathophysiology of all types of arthritis. MicroRNAs (miRNAs), a class of non coding RNAs, have shown to be played a plenty of roles in both a suppressive and a promoting role in disease pathogenesis and progression. Among the classes of microRNAs, miR 21 is a widespread miRNA commonly upregulated in many diseases and suggesting that it plays an important role in cell proliferation, apoptosis, and invasion. It is highly expressed in osteoclast precursors and the pro osteoclastogenic nature of miR 21 makes it a promising candidate as a therapeutic target to treat bone related disorders. Up to now, there are few papers that demonstrate the role of miR 21 in arthritis and related bone disorders and the number of studies related to different types of arthritis is sparse. Therefore, the main thrust of this paper is to provide an overview of the current clinical evidence and significance of miR 21 in arthritis and bone related inflammation disorders. We summarize the important research findings surrounding the role of miR 21 and its involvement in the treatment of different types of arthritis.
C1 [Sekar, Durairaj] Saveetha Univ, Saveetha Denatal Coll & Hosp, Dent Res Cell & Biomed Res Unit, Saveetha Inst Med & Tech Sci SIMATS, Chennai 600077, Tamil Nadu, India.
   [Sekar, Durairaj] Saveetha Univ, Saveetha Denatal Coll & Hosp, Lab Anim Ctr, Saveetha Inst Med & Tech Sci SIMATS, Chennai 600077, Tamil Nadu, India.
C3 Saveetha Institute of Medical & Technical Science; Saveetha Institute of
   Medical & Technical Science
RP Sekar, D (通讯作者)，Saveetha Univ, Saveetha Denatal Coll & Hosp, Dent Res Cell & Biomed Res Unit, Saveetha Inst Med & Tech Sci SIMATS, Chennai 600077, Tamil Nadu, India.; Sekar, D (通讯作者)，Saveetha Univ, Saveetha Denatal Coll & Hosp, Lab Anim Ctr, Saveetha Inst Med & Tech Sci SIMATS, Chennai 600077, Tamil Nadu, India.
EM duraimku@gmail.com
RI ; Sekar, Durairaj/H 6184 2019
OI sekar, Durairaj/0000 0002 0722 8636; 
CR Balzano F, 2017, INT J MED SCI, V14, P622, DOI 10.7150/ijms.18972
   Chen JQ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174585
   CHEN Y, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/9279078
   Churov AV, 2015, AUTOIMMUN REV, V14, P1029, DOI 10.1016/j.autrev.2015.07.005
   Ciancio G, 2017, CLIN EXP RHEUMATOL, V35, P113
   Ding F, 2019, EUR REV MED PHARMACO, V23, P3984, DOI 10.26355/eurrev_201905_17828
   Dong LY, 2014, J CELL MOL MED, V18, P2213, DOI 10.1111/jcmm.12353
   Dudics S, 2018, INT J MOL SCI, V19
   Elmesmari A, 2016, RHEUMATOLOGY, V55, P2056, DOI 10.1093/rheumatology/kew272
   Fogel O, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1829 7
   Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102
   Hoshikawa N, 2020, MOL THER NUCL ACIDS, V19, P199, DOI 10.1016/j.omtn.2019.11.011
   Hu SL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01747
   Huang RY, 2019, EXPERT REV MOL DIAGN, V19, P363, DOI 10.1080/14737159.2019.1599716
   Iliopoulos D, 2011, EUR J IMMUNOL, V41, P1754, DOI 10.1002/eji.201040646
   Jin SW, 2018, ANN RHEUM DIS, V77, P1644, DOI 10.1136/annrheumdis 2018 213511
   Kobayashi T, 2008, P NATL ACAD SCI USA, V105, P1949, DOI 10.1073/pnas.0707900105
   Li HW, 2016, EXP THER MED, V11, P2531, DOI 10.3892/etm.2016.3188
   Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071568
   Liu XG, 2019, EUR REV MED PHARMACO, V23, P96, DOI 10.26355/eurrev_201908_18635
   Ma SX, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2145 y
   Madhyastha R, 2019, J NAT MED TOKYO, V73, P59, DOI 10.1007/s11418 018 1237 3
   Matthews GL, 2013, RHEUM DIS CLIN N AM, V39, P177, DOI 10.1016/j.rdc.2012.10.006
   Miyaki S, 2012, NAT REV RHEUMATOL, V8, P543, DOI 10.1038/nrrheum.2012.128
   Mizoguchi F, 2010, J CELL BIOCHEM, V109, P866, DOI 10.1002/jcb.22228
   Motta F, 2020, J TRANSL AUTOIMMUN, V3, DOI 10.1016/j.jtauto.2020.100050
   Neto MF, 2017, ARTHRITIS, DOI 10.1155/2017/6365857
   Priyanka P, 2018, GENE REP, V11, P229, DOI 10.1016/j.genrep.2018.03.015
   Reginster JY, 2002, RHEUMATOLOGY, V41, P3, DOI 10.1093/rheumatology/41.suppl_1.3
   Sambamoorthi U, 2017, EXPERT REV PHARM OUT, V17, P53, DOI 10.1080/14737167.2017.1281744
   Smigielska Czepiel K, 2014, GENES IMMUN, V15, P115, DOI 10.1038/gene.2013.69
   Song J, 2014, J ORTHOP RES, V32, P1628, DOI 10.1002/jor.22718
   Song J, 2013, BIOCHEM BIOPH RES CO, V431, P210, DOI 10.1016/j.bbrc.2012.12.133
   Thysen S, 2015, DIS MODEL MECH, V8, P17, DOI 10.1242/dmm.016881
   Tsezou A, 2014, OSTEOARTHR CARTILAGE, V22, P2017, DOI 10.1016/j.joca.2014.07.024
   Wang HL, 2012, TRANSL RES, V160, P198, DOI 10.1016/j.trsl.2012.04.002
   Wang XB, 2019, RHEUMATOLOGY, V58, P1485, DOI 10.1093/rheumatology/kez102
   Wu XN, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009131
   Yang SS, 2016, J RHEUMATOL, V43, P1312, DOI 10.3899/jrheum.151253
   Yuan Y, 2016, BONE JOINT RES, V5, P523, DOI 10.1302/2046 3758.510.BJR 2016 0074.R2
   Zhang JB, 2016, MOL CARCINOGEN, V55, P732, DOI 10.1002/mc.22317
   Zhang YK, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.152
   Zhu H, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1160 7
   Zou QF, 2019, EUR REV MED PHARMACO, V23, P3105, DOI 10.26355/eurrev_201904_17594
NR 44
TC 17
Z9 18
U1 0
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300 8177
EI 1573 4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD FEB
PY 2021
VL 476
IS 2
BP 941
EP 947
DI 10.1007/s11010 020 03960 y
EA NOV 2020
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA QF6AI
UT WOS:000584370100001
PM 33136235
DA 2025 08 17
ER

PT J
AU Chen, G
   Sircar, K
   Aprikian, A
   Potti, A
   Goltzman, D
   Rabbani, SA
AF Chen, Gaoping
   Sircar, Kanishka
   Aprikian, Armen
   Potti, Anil
   Goltzman, David
   Rabbani, Shafaat A.
TI Expression of RANKL/RANK/OPG in primary and metastatic human prostate
   cancer as markers of disease stage and functional regulation
SO CANCER
LA English
DT Article
DE prostate cancer; bone metastasis; RANK; RANKL; OPG
ID FACTOR KAPPA B; RECEPTOR ACTIVATOR; OSTEOCLAST DIFFERENTIATION;
   OSTEOPROTEGERIN LIGAND; IN VITRO; PROGNOSTIC IMPLICATIONS;
   BREAST CARCINOMA; BONE METASTASES; TUMOR GROWTH; CELLS
AB BACKGROUND. Late stage prostate cancer patients are refractory to hormone therapy and exhibit a high propensity to develop skeletal metastasis. In this regard, the role of a novel cytokine system belonging to the tumor necrosis factor (TNF) family that is critical for osteoclastic osteolysis and that consists of receptor activator of NF kappa B ligand (RANKL), its receptor (RANK), and decoy receptor osteoprotegerin (OPG) is of potential interest.
   METHODS. Reverse transcriptase polymerase chain reaction (RT PCR) and immunohistochemical analysis was used to examine the expression of RANKL, RANK, and OPG in human prostate cancer cell lines and in 89 archival samples of primary and metastatic (lymph nodes, skeleton) prostate cancer patients. Expression of these proteins was correlated with clinicopathogic parameters of the prostate cancer.
   RESULTS. Expression of RANKL/RANK/OPG was low in normal but markedly higher in prostate cancer cell lines. Analysis of surgical biopsy specimens showed the expression of RANKL (31%), RANK (38%), and OPG (19%) in primary carcinoma. The expression frequency was significantly higher (RANKL [44%], RANK [49%], and OPG [73%]) in metastatic prostate cancer. OPG (83%) production was more common in skeletal as compared with lymph node metastases (46%), whereas the expression of RANKL expression was less discordant in bone (47%) and lymph node metastases (36%). The increased expression of RANKL/RANK/ OPG observed correlated with Gleason score, TNM stage, androgen status, and serum prostate specific antigen (PSA) levels in the prostate cancer patients.
   CONCLUSIONS. Expression of RANKL/RANK/OPG correlates with more aggressive, advanced, metastatic prostate carcinoma to suggest their role as diagnostic, prognostic, and therapeutic targets for prostate cancer.
C1 McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada.
   McGill Univ, Ctr Hlth, Dept Pathol, Montreal, PQ H3A 1A1, Canada.
   McGill Univ, Ctr Hlth, Dept Urol, Montreal, PQ H3A 1A1, Canada.
   Duke Univ, Med Ctr, Div Hematol, Durham, NC USA.
   Duke Univ, Med Ctr, Div Oncol & Transplantat, Durham, NC USA.
C3 McGill University; McGill University; McGill University; Duke
   University; Duke University
RP Rabbani, SA (通讯作者)，McGill Univ, Ctr Hlth, Dept Med, 687 Pine Ave W,Room H4 61, Montreal, PQ H3A 1A1, Canada.
EM shafaat.rabbani@mcgill.ca
RI Sircar, Kanishka/E 4106 2012
OI rabbani, shafaat/0000 0001 5594 3899
CR Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Body JJ, 2003, CANCER AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138
   Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090 4295(00)01122 5
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260
   Chen GP, 2004, CANCER AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518
   Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008 5472.CAN 04 2033
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Fisher JL, 2003, J BONE MINER RES, V18, pS63
   Fiumara P, 2001, BLOOD, V98, P2784, DOI 10.1182/blood.V98.9.2784
   Granchi D, 2004, INT J CANCER, V111, P829, DOI 10.1002/ijc.20308
   Grimaud E, 2003, AM J PATHOL, V163, P2021, DOI 10.1016/S0002 9440(10)63560 2
   Guan M, 2005, J CLIN PATHOL, V58, P1175, DOI 10.1136/jcp.2005.026955
   Holen I, 2002, CANCER RES, V62, P1619
   Holen I, 2005, BREAST CANCER RES TR, V92, P207, DOI 10.1007/s10549 005 2419 8
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Huang L, 2003, J CLIN PATHOL MOL PA, V56, P116, DOI 10.1136/mp.56.2.116
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Ito R, 2003, VIRCHOWS ARCH, V443, P146, DOI 10.1007/s00428 003 0845 8
   Jemal A, 2005, CA CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jung K, 2004, INT J CANCER, V111, P783, DOI 10.1002/ijc.20314
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Kiefer JA, 2004, CLIN EXP METASTAS, V21, P381, DOI 10.1007/s10585 004 2869 0
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013
   Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697
   Mizutani Y, 2004, CANCER AM CANCER SOC, V101, P1794, DOI 10.1002/cncr.20550
   Morony S, 2005, ENDOCRINOLOGY, V146, P3235, DOI 10.1210/en.2004 1583
   Morony S, 2001, CANCER RES, V61, P4432
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Ray MR, 2005, J BONE MINER RES, V20, pS117
   Segawa N, 2002, INT J UROL, V9, P545, DOI 10.1046/j.1442 2042.2002.00514.x
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sordillo EM, 2003, CANCER AM CANCER SOC, V97, P802, DOI 10.1002/cncr.11134
   Tada T, 2005, INT J CANCER, V116, P253, DOI 10.1002/ijc.21008
   Yorke R, 2003, EUR J CANCER, V39, P2099, DOI 10.1016/S0959 8049(03)00434 9
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
NR 40
TC 190
Z9 210
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0008 543X
EI 1097 0142
J9 CANCER AM CANCER SOC
JI Cancer
PD JUL 15
PY 2006
VL 107
IS 2
BP 289
EP 298
DI 10.1002/cncr.21978
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 062QO
UT WOS:000238959800010
PM 16752412
DA 2025 08 17
ER

PT J
AU Kura, JR
   Cheung, B
   Conover, CF
   Wnek, RD
   Reynolds, MC
   Buckley, KH
   Soto, BM
   Otzel, DM
   Aguirre, JI
   Yarrow, JF
AF Kura, Jayachandra R.
   Cheung, Bosco
   Conover, Christine F.
   Wnek, Russell D.
   Reynolds, Michael C.
   Buckley, Kinley H.
   Soto, Benjamin M.
   Otzel, Dana M.
   Aguirre, J. Ignacio
   Yarrow, Joshua F.
TI Passive bicycle training stimulates epiphyseal bone formation and
   restores bone integrity independent of locomotor recovery in a rat
   spinal cord injury model
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE bone; disuse; exercise; musculoskeletal; unloading
ID MINERAL DENSITY; ELECTRICAL STIMULATION; FUNCTIONAL ADAPTATION; PROXIMAL
   TIBIA; DISTAL FEMUR; FRACTURE; MUSCLE; RISK; GUIDELINES; CHILDREN
AB It is unknown whether activity based physical therapy (ABPT) modalities that mobilize the paralyzed limbs improve bone integrity at the highly fracture prone epiphyseal regions of the distal femur and proximal tibia following severe spinal cord injury (SCI). In this study, 4 mo old skeletally mature littermate matched male Sprague Dawley rats received either SHAM surgery or severe contusion SCI. At 1 wk postsurgery, SCI rats were stratified to undergo no ABPT, two 20 min bouts/day of quadrupedal bodyweight supported treadmill training (qBWSTT), or hindlimb passive isokinetic bicycle (cycle) training, 5 days/wk for another 3 wk. We assessed locomotor recovery and plantar flexor muscle mass, tracked cancellous and cortical bone microstructure at the distal femoral and proximal tibial epiphyses using in vivo microcomputed tomography (microCT), and evaluated bone turnover at the tibial epiphysis with histomorphometry. All SCI animals displayed persistent hindlimb paralysis and pervasive muscle atrophy. Over the initial 2 wk, which included 1 wk of no exercise and 1 wk of ABPT acclimation, a similar magnitude of bone loss developed in all SCI groups. Thereafter, cancellous bone loss and cortical bone decrements increased in the SCI no ABPT group. qBWSTT attenuated this trabecular bone loss but did not prevent the ongoing cortical bone deficits. In comparison, twice daily cycle training increased the number and activity of osteoblasts versus other SCI groups and restored all bone microstructural parameters to SHAM levels at both epiphyseal sites. These data indicate that a novel passive isokinetic cycle training regimen reversed cancellous and cortical bone deterioration at key epiphyseal sites after experimental SCI via osteoblast mediated bone anabolic mechanisms, independent of locomotor recovery or increased muscle mass. NEW & NOTEWORTHY This study was the first to assess how quadrupedal bodyweight supported treadmill training or passive isokinetic bicycle (cycle) training impacts bone recovery at the distal femoral and proximal tibial epiphyses in a rat model of severe contusion spinal cord injury. Our results demonstrate that passive isokinetic cycle training completely restored cancellous and cortical bone microstructural parameters at these sites via osteoblast mediated bone anabolic actions, independent of locomotor recovery or increased plantar flexor muscle mass.
C1 [Kura, Jayachandra R.; Cheung, Bosco; Conover, Christine F.; Wnek, Russell D.; Reynolds, Michael C.; Buckley, Kinley H.; Soto, Benjamin M.; Otzel, Dana M.; Yarrow, Joshua F.] North Florida South Georgia Vet Hlth Syst, Malcom Randall Dept Vet Affairs Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA.
   [Aguirre, J. Ignacio] Univ Florida, Coll Vet Med, Dept Physiol Sci, Gainesville, FL USA.
   [Yarrow, Joshua F.] Univ Florida, Coll Med, Div Endocrinol Diabet & Metab, Gainesville, FL 32611 USA.
   [Yarrow, Joshua F.] VA Eastern Colorado Hlth Care Syst, Eastern Colorado Geriatr Res Educ & Clin Serv, Rocky Mt Reg VA Med Ctr, Aurora, CO 80045 USA.
   [Yarrow, Joshua F.] Univ Colorado, Dept Med, Div Geriatr Med, Anschutz Med Campus, Aurora, CO 80045 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; University of
   Colorado System; University of Colorado Anschutz Medical Campus
RP Yarrow, JF (通讯作者)，North Florida South Georgia Vet Hlth Syst, Malcom Randall Dept Vet Affairs Med Ctr, Brain Rehabil Res Ctr, Gainesville, FL 32608 USA.; Yarrow, JF (通讯作者)，Univ Florida, Coll Med, Div Endocrinol Diabet & Metab, Gainesville, FL 32611 USA.; Yarrow, JF (通讯作者)，VA Eastern Colorado Hlth Care Syst, Eastern Colorado Geriatr Res Educ & Clin Serv, Rocky Mt Reg VA Med Ctr, Aurora, CO 80045 USA.; Yarrow, JF (通讯作者)，Univ Colorado, Dept Med, Div Geriatr Med, Anschutz Med Campus, Aurora, CO 80045 USA.
EM joshua.yarrow@va.gov
RI ; Aguirre, J./AAX 2217 2021
OI Yarrow, Joshua/0000 0002 2727 8649; 
FU Department of Veterans Affairs Office of Research and Development,
   Rehabilitation Research and Development Service [1I01RX002447,
   1I21RX002185]; PECASE [B9280 O]; American Physiological Society (APS)
   Undergraduate Summer Research Fellowship; North Florida/South Georgia
   Veterans Healthcare System; VA Eastern Colorado Health Care System
FX This work was supported by the Department of Veterans Affairs Office of
   Research and Development, Rehabilitation Research and Development
   Service Merit Award 1I01RX002447, SPiRE Award 1I21RX002185, and PECASE
   No. B9280 O (to J.F.Y.), by an American Physiological Society (APS)
   Undergraduate Summer Research Fellowship (to J.R.K.), and by resources
   provided by the North Florida/South Georgia Veterans Healthcare System
   and the VA Eastern Colorado Health Care System.
CR BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Beck DT, 2014, J BONE MINER RES, V29, P2405, DOI 10.1002/jbmr.2265
   Bergholt NL, 2019, CARTILAGE, V10, P370, DOI 10.1177/1947603518764262
   Bose PK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00258
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   CHURCHES AE, 1982, CLIN ORTHOP RELAT R, P265
   Cirnigliaro CM, 2017, OSTEOPOROSIS INT, V28, P747, DOI 10.1007/s00198 016 3798 x
   Cirnigliaro CM, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10375
   Coupaud S, 2009, J MUSCULOSKEL NEURON, V9, P288
   Dauty M, 2000, BONE, V27, P305, DOI 10.1016/S8756 3282(00)00326 4
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Eazer J, 2024, JBMR PLUS, V8, DOI 10.1093/jbmrpl/ziad019
   Edwards WB, 2014, OSTEOPOROSIS INT, V25, P1005, DOI 10.1007/s00198 013 2557 5
   Eser P, 2005, ARCH PHYS MED REHAB, V86, P498, DOI 10.1016/j.apmr.2004.09.006
   Eser P, 2004, BONE, V34, P869, DOI 10.1016/j.bone.2004.01.001
   Frisbie J H, 1997, J Spinal Cord Med, V20, P66
   Frotzler A, 2015, SPINAL CORD, V53, P701, DOI 10.1038/sc.2015.74
   Giangregorio LM, 2005, SPINAL CORD, V43, P649, DOI 10.1038/sj.sc.3101774
   Giangregorio LM, 2006, APPL PHYSIOL NUTR ME, V31, P283, DOI 10.1139/H05 036
   Gifre L, 2014, CLIN REHABIL, V28, P361, DOI 10.1177/0269215513501905
   GOLDSTEIN SA, 1991, J BIOMECH, V24, P135, DOI 10.1016/0021 9290(91)90384 Y
   GOODSHIP AE, 1979, J BONE JOINT SURG AM, V61, P539, DOI 10.2106/00004623 197961040 00008
   Haider IT, 2018, OSTEOPOROSIS INT, V29, P2703, DOI 10.1007/s00198 018 4733 0
   HARRIGAN TP, 1993, J BIOMECH, V26, P183, DOI 10.1016/0021 9290(93)90048 J
   Javaheri B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax8301
   Jepsen KJ, 2015, J BONE MINER RES, V30, P951, DOI 10.1002/jbmr.2539
   Johnston TE, 2008, J SPINAL CORD MED, V31, P215, DOI 10.1080/10790268.2008.11760715
   Kwon BK, 2002, SPINE, V27, P1504, DOI 10.1097/00007632 200207150 00005
   Lauer RT, 2011, SPINAL CORD, V49, P917, DOI 10.1038/sc.2011.19
   Lazo MG, 2001, SPINAL CORD, V39, P208, DOI 10.1038/sj.sc.3101139
   Lin T, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.28
   Liu M, 2008, SPINAL CORD, V46, P488, DOI 10.1038/sj.sc.3102169
   Lynskey JV, 2008, J REHABIL RES DEV, V45, P229, DOI 10.1682/JRRD.2007.03.0047
   MINAIRE P, 1974, CALC TISS RES, V17, P57, DOI 10.1007/BF02547214
   Morse L, 2008, OSTEOPOROSIS INT, V19, P645, DOI 10.1007/s00198 007 0494 x
   Morse LR, 2009, OSTEOPOROSIS INT, V20, P385, DOI 10.1007/s00198 008 0671 6
   Nishiyama KK, 2010, BONE, V46, P155, DOI 10.1016/j.bone.2009.09.023
   NSCISC, 2024, Annual Statistical Report Complete Public Version for the Spinal Cord Injury Model Systems
   OCONNOR JA, 1982, J BIOMECH, V15, P767, DOI 10.1016/0021 9290(82)90092 6
   Otzel DM, 2019, CALCIFIED TISSUE INT, V104, P79, DOI 10.1007/s00223 018 0471 8
   Otzel DM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061701
   SCOTT GC, 1990, J BIOMECH, V23, P127, DOI 10.1016/0021 9290(90)90347 6
   Sutor TW, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020608
   Vestergaard P, 1998, SPINAL CORD, V36, P790, DOI 10.1038/sj.sc.3100648
   Voor MJ, 2012, J NEUROTRAUM, V29, P1676, DOI 10.1089/neu.2011.2037
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   Williams JA, 2022, BONE REP, V16, DOI 10.1016/j.bonr.2022.101592
   Williams JA, 2022, J MUSCULOSKEL NEURON, V22, P212
   Williams JA, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2019.100233
   Willoughby DS, 2000, ARCH PHYS MED REHAB, V81, P157
   Yarrow JF, 2014, J MUSCULOSKEL NEURON, V14, P255
   Yarrow JF., 2020, Encyclopedia of bone biology, V1st, P429
   Yarrow JF, 2023, MED SCI SPORT EXER, V55, P813, DOI 10.1249/MSS.0000000000003101
   Yarrow JF, 2021, J APPL PHYSIOL, V131, P1288, DOI 10.1152/japplphysiol.00444.2021
   Yarrow JF, 2020, J NEUROSCI RES, V98, P843, DOI 10.1002/jnr.24564
   Yarrow JF, 2017, J NEUROTRAUM, V34, P2972, DOI 10.1089/neu.2016.4814
   Yarrow JF, 2012, MENOPAUSE, V19, P1267, DOI 10.1097/gme.0b013e318255657f
   Zehnder Y, 2004, OSTEOPOROSIS INT, V15, P180, DOI 10.1007/s00198 003 1529 6
NR 58
TC 0
Z9 0
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI Rockville
PA 6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES
SN 8750 7587
EI 1522 1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD SEP 1
PY 2024
VL 137
IS 3
BP 676
EP 688
DI 10.1152/japplphysiol.00299.2024
PG 13
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA G0U0W
UT WOS:001313862000002
PM 39088645
DA 2025 08 17
ER

PT J
AU Zhang, DW
   Cheng, Y
   Zhang, JC
   Wang, XL
   Wang, NL
   Yao, XS
AF Zhang, Dawei
   Cheng, Yan
   Zhang, Jinchao
   Wang, Xinluan
   Wang, Naili
   Yao, Xinsheng
TI Cytotoxic effects of flavonol glycosides and nonflavonoid constituents
   of Epimedium koreanum on primary osteoblasts
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Epimedium koreanum Nakai; flavonol glycosides; nonflavonoid
   constituents; osteoblasts; cytotoxicity
ID HORMONE REPLACEMENT THERAPY; IN VITRO; CELLS; EXTRACT; PROLIFERATION;
   SAGITTATUM; NAKAI; RATS
AB Seven flavonol glycosides and four nonflavonoid compounds were isolated from Epimedium koreanum Nakai (Berberidaceae), and their effects on the proliferation of rat osteoblast like (ROB) cells were evaluated with a mitochondrial activity assay. Both flavonol glycosides and nonflavonoid compounds strongly inhibited the proliferation of primary ROB cells at most concentrations (2.0 x 10( 5) mol/L similar to 1.0 x 10( 8) mol/L), and a simple structure function relationship was also found in these compounds. Considering the antiosteoporotic effect of flavonoids in vivo, these results suggest that the flavonoids may enhance the development of osteoblasts through their active metabolites, and the mechanism between proliferation and differentiation of osteoblasts needs to be further studied to fully evaluate the mechanism of E. koreanum in the treatment of osteoporosis.
C1 [Zhang, Dawei; Cheng, Yan; Wang, Xinluan; Wang, Naili; Yao, Xinsheng] Shenyang Pharmaceut Univ, Dept Nat Prod Chem, Shenyang 110016, Peoples R China.
   [Zhang, Dawei; Wang, Xinluan; Wang, Naili; Yao, Xinsheng] Tradit Chinese Med & Nat Med Shenzhen, Key Lab Res & Dev, Shenzhen, India.
   [Zhang, Jinchao] Hebei Univ, Coll Chem & Environm Sci, Dept Chem, Baoding, India.
C3 Shenyang Pharmaceutical University; Hebei University
RP Yao, XS (通讯作者)，Shenyang Pharmaceut Univ, Dept Nat Prod Chem, POB 81,103 Wenhua Rd, Shenyang 110016, Peoples R China.
EM yaoxinsheng@vip.tom.com
RI Zhang, Dawei/AAE 8366 2020
CR Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   CARMENT A, 1987, AUSTR J LAW SOC, V4, P7
   Chen KM, 2004, PHARMAZIE, V59, P61
   Chen TL, 1999, CALCIFIED TISSUE INT, V64, P304, DOI 10.1007/s002239900624
   Davison S, 2003, CLIN ENDOCRINOL, V58, P249, DOI 10.1046/j.1365 2265.2003.01774.x
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hidaka S, 1997, CALCIFIED TISSUE INT, V61, P239, DOI 10.1007/s002239900329
   Huang HF, 1997, AM J CHINESE MED, V25, P351, DOI 10.1142/S0192415X97000391
   JI H, 2001, CHIN J OSTEOPOROSIS, V7, P4
   Jiang Yong nan, 2002, Zhongguo Zhongyao Zazhi, V27, P221
   Katzburg S, 1999, BONE, V25, P667, DOI 10.1016/S8756 3282(99)00225 2
   LI T, 2000, CHIN J OSTEOPOROSIS, V6, P55
   Liu HC, 2001, J FORMOS MED ASSOC, V100, P383
   Meng FH, 2005, PHYTOMEDICINE, V12, P189, DOI 10.1016/j.phymed.2004.03.007
   Meng FH, 2005, PHARM BIOL, V43, P92, DOI 10.1080/13880200590903435
   MIZUNO M, 1988, PHYTOCHEMISTRY, V27, P3641, DOI 10.1016/0031 9422(88)80783 0
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Pinkerton JV, 1999, ENDOCR REV, V20, P308, DOI 10.1210/er.20.3.308
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Sun Pengyue, 1998, Yaoxue Xuebao, V33, P919
   WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
   Zhang DW, 2008, PHYTOMEDICINE, V15, P55, DOI 10.1016/j.phymed.2007.04.002
   ZHANG G, 1999, CHIN J OSTEOPOROSIS, V5, P51
NR 24
TC 4
Z9 8
U1 0
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1388 0209
J9 PHARM BIOL
JI Pharm. Biol.
PD MAR
PY 2008
VL 46
IS 3
BP 185
EP 190
DI 10.1080/13880200701735478
PG 6
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA 271CM
UT WOS:000253766500007
OA Bronze
DA 2025 08 17
ER

PT J
AU He, S
   Duan, CY
   Wang, S
   Yu, Y
   Chan, YK
   Shi, XY
   Huang, JH
   Wang, ST
   Peng, SJ
   Deng, Y
AF He, Shuai
   Duan, Chunyan
   Wang, Song
   Yu, Yue
   Chan, Yau Kei
   Shi, Xiuyuan
   Huang, Jiahu
   Wang, Shouteng
   Peng, Shaojun
   Deng, Yi
TI Fusion Peptide Engineered Polyetheretherketone Implants with
   Photo Assisted Anti Pathogen and Enhanced Angiogenesis for in vivo
   Osseointegrative Fixation
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Orthopedic Implant; Polyetheretherketone; Antibacterial; Angiogenesis;
   Osseointegration
ID SILVER NANOPARTICLES; ANTIBACTERIAL ACTIVITY; OSTEOBLAST FUNCTIONS;
   TOXICITY MECHANISMS; VEGF; OSTEOGENESIS; ADHESION; VITRO; GOLD
AB Owing to its superior mechanical and physicochemical characteristics, polyetheretherketone (PEEK) is considered a potent orthopedic material. Yet, poor bactericidal, osseointegrative and angiogenic properties of bioinert PEEK collectively hamper its clinical adoption. Herein, we present a strategy for developing multifunctional hierarchical coatings bearing a synthetic fusion peptide and polydopamine/silver nanoparticles (pDA/AgNPs) bio heterojunctions (bio HJs), in an attempt to empower PEEK with triple modal abilities, which prevents bacterial infection, enhances ossification and promotes re vascularization for physiological osseointegrative fixation. By harnessing the adhesion of bioinspired pDA, AgNPs are facilely immobilized onto peripheral surface and incorporated into interior cavity of micro/nano porous sulfonated PEEK (SP) to form hierarchical pDA/ AgNPs heterostructures. The bio HJs coatings exhibit robust and repeatable bacteria eradicating ability, assisted by near infrared illumination, due to the synergistic effects of the metal ion/photothermal therapy. The fusion peptide engineered PEEK exhibits osteogenesis activity in terms of promoting osteoblast proliferation, spreading, boosting the synthesis and secretion of osteogenesis related genes. Besides, the fusion peptide engineered PEEK also has the ability to promote HUVECs growth, reproduction, and tube formation, facilitating the synthesis and secretion of angiogenesis associated genes. Moreover, the results of the in vivo experiments further corroborate the in vivo osteointegration and angiogenic abilities of materials. Expectantly, the multifunctional coatings with the presented triple therapeutic effects represent a prospective clinical solution to address the current clinical challenges associated with the use of PEEK implants.
C1 [He, Shuai; Yu, Yue; Wang, Shouteng; Deng, Yi] Sichuan Univ, Sch Chem Engn, Chengdu 610065, Peoples R China.
   [Deng, Yi] Sichuan Univ, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.
   [Duan, Chunyan] Southwest Med Univ, Sch Basic Med Sci, Luzhou 646000, Peoples R China.
   [Wang, Song; Huang, Jiahu] Affiliated Hosp Southwest Med Univ, Dept Spine Surg, Luzhou 646000, Peoples R China.
   [Peng, Shaojun] Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Inst Translat Med, Zhuhai 519000, Guangdong, Peoples R China.
   [Deng, Yi] Univ Hong Kong, Dept Mech Engn, Hong Kong 999077, Peoples R China.
   [Chan, Yau Kei] Univ Hong Kong, Dept Ophthalmol, Hong Kong 999077, Peoples R China.
   [Shi, Xiuyuan] Imperial Coll London, Dept Mat, London SW72AZ, England.
C3 Sichuan University; Sichuan University; Southwest Medical University;
   Jinan University; University of Hong Kong; University of Hong Kong;
   Imperial College London
RP Deng, Y (通讯作者)，Sichuan Univ, Sch Chem Engn, Chengdu 610065, Peoples R China.; Peng, SJ (通讯作者)，Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Inst Translat Med, Zhuhai 519000, Guangdong, Peoples R China.
EM shaojunpeng@ext.jnu.edu.cn; dengyibandeng@scu.edu.cn
OI Yu, Yue/0000 0002 7338 6202; CHAN, Yau Kei/0000 0002 1044 2668
FU National Natural Science Foundation of China [81961160736, 81801848,
   8217070298]; Natural Science Foundation of Sichuan [2022NSFSC0361];
   Sichuan Science and Technology Program [2021YJ0049]; Chengdu
   International Science and Technology Cooperation Foundation
   [2020 GH03 00005 HZ, 2017 GH02 00025 HZ]; State Key Laboratory of
   Polymer Materials Engineering [sklpme2019 2 05]; Young Elite Scientist
   Sponsorship Program by CAST; Youth Science and Technology Academic
   Leader Training Program of (Sichuan University); Sichuan
   University Luzhou City Special Funding for Strategic Cooperation
   [2020CDLZ 5]; Luzhou Municipal People's Government Southwest Medical
   University Strategic Cooperation Project [2020LZXNYDJ43]
FX This work is jointly funded by the National Natural Science Foundation
   of China (81961160736, 81801848, 8217070298) , Natural Science
   Foundation of Sichuan (2022NSFSC0361) , Sichuan Science and Technology
   Program (2021YJ0049) , Chengdu International Science and Technology
   Cooperation Foundation (2020 GH03 00005 HZ, 2017 GH02 00025 HZ) , State
   Key Laboratory of Polymer Materials Engineering (sklpme2019 2 05) ,
   Young Elite Scientist Sponsorship Program by CAST, Youth Science and
   Technology Academic Leader Training Program of (Sichuan University) ,
   Sichuan University Luzhou City Special Funding for Strategic Cooperation
   (2020CDLZ 5) , Luzhou Municipal People's Government Southwest Medical
   University Strategic Cooperation Project (2020LZXNYDJ43) . The authors
   also thank Hui Wang, Daichuan Ma, Daibing Luo (Analytical & Testing
   Center, Sichuan University) for their help in SEM, XRD and UV vis
   characterizations and the support from Dong Yu, Han Kang in Life Science
   Core Facilities (College of Life Sciences, Sichuan University) with
   Digital scanning system (Wislcap WS 10 and Olympus VS200) and
   Fluorescence microscope (Nikon Eclipse TI U) .
CR Asharani PV, 2010, ADV FUNCT MATER, V20, P1233, DOI 10.1002/adfm.200901846
   Cai GQ, 2020, COMPOS PART B ENG, V186, DOI 10.1016/j.compositesb.2020.107802
   Chen JJ, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120446
   Chen Y, 2020, J CONTROL RELEASE, V328, P251, DOI 10.1016/j.jconrel.2020.08.055
   Deng Y, 2013, MATER LETT, V104, P8, DOI 10.1016/j.matlet.2013.03.145
   Dennes TJ, 2009, J AM CHEM SOC, V131, P3456, DOI 10.1021/ja810075c
   Dong TS, 2020, ACS APPL MATER INTER, V12, P14971, DOI 10.1021/acsami.0c02304
   Eliaz N, 2009, ACTA BIOMATER, V5, P3178, DOI 10.1016/j.actbio.2009.04.005
   Fan L, 2020, ACS APPL MATER INTER, V12, P22225, DOI 10.1021/acsami.0c06091
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Fu JN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27217 4
   Gao P, 2020, BIOACT MATER, V5, P680, DOI 10.1016/j.bioactmat.2020.04.019
   Derami HG, 2021, ADV MATER, V33, DOI 10.1002/adma.202008809
   Han HS, 2020, ADV SCI, V7, DOI 10.1002/advs.202000800
   Huang ZZ, 2017, J HAZARD MATER, V321, P37, DOI 10.1016/j.jhazmat.2016.08.075
   Ivask A, 2014, ACS NANO, V8, P374, DOI 10.1021/nn4044047
   Jakus AE, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7704
   Kelly CN, 2021, BIOMATERIALS, V279, DOI 10.1016/j.biomaterials.2021.121206
   Kim T, 2018, ACS NANO, V12, P5615, DOI 10.1021/acsnano.8b01362
   Le Ouay B, 2015, NANO TODAY, V10, P339, DOI 10.1016/j.nantod.2015.04.002
   Lee H, 2007, SCIENCE, V318, P426, DOI 10.1126/science.1147241
   Leslie Barbick JE, 2011, BIOMATERIALS, V32, P5782, DOI 10.1016/j.biomaterials.2011.04.060
   Li JH, 2018, ADV SCI, V5, DOI 10.1002/advs.201700678
   Li M, 2022, BIOACT MATER, V8, P309, DOI 10.1016/j.bioactmat.2021.07.002
   Li M, 2019, ADV SCI, V6, DOI 10.1002/advs.201900599
   Liu MY, 2016, NANOSCALE, V8, P16819, DOI 10.1039/c5nr09078d
   LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416
   Mas Moruno C, 2014, ACS APPL MATER INTER, V6, P6525, DOI 10.1021/am5001213
   Meng XC, 2021, J ORTHOP TRANSL, V26, P67, DOI 10.1016/j.jot.2020.02.010
   Metavarayuth Kamolrat, 2021, Biomater Transl, V2, P165, DOI 10.12336/biomatertransl.2021.02.006
   Mitra I, 2021, MATER TODAY, V45, P20, DOI 10.1016/j.mattod.2020.11.021
   Mo S, 2020, CHEM ENG J, V392, DOI 10.1016/j.cej.2019.123736
   Morimoto J, 2012, ANGEW CHEM INT EDIT, V51, P3423, DOI 10.1002/anie.201108118
   Mourya V.K., 2010, Adv. Mat. Lett, V1, P11, DOI [DOI 10.5185/AMLETT.2010.3108, 10.5185/amlett.2010.3108]
   Neoh KG, 2012, BIOMATERIALS, V33, P2813, DOI 10.1016/j.biomaterials.2012.01.018
   Niyonshuti II, 2020, ACS APPL MATER INTER, V12, P40067, DOI 10.1021/acsami.0c10517
   Ouyang LP, 2016, BIOMATERIALS, V83, P115, DOI 10.1016/j.biomaterials.2016.01.017
   Parthiban SP, 2017, ACTA BIOMATER, V51, P330, DOI 10.1016/j.actbio.2017.01.046
   Poinard B, 2018, ACS APPL MATER INTER, V10, P21125, DOI 10.1021/acsami.8b04799
   Qiu M, 2019, J HAZARD MATER, V367, P339, DOI 10.1016/j.jhazmat.2018.12.096
   Rizzello L, 2014, CHEM SOC REV, V43, P1501, DOI 10.1039/c3cs60218d
   Rout SK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02742 3
   Morones Ramirez JR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006276
   Sang S, 2021, CHEM ENG J, V420, DOI 10.1016/j.cej.2021.130059
   Service RF, 2000, SCIENCE, V289, P1498, DOI 10.1126/science.289.5484.1498
   Tan L, 2018, ADV MATER, V30, DOI 10.1002/adma.201801808
   Tao ZS, 2021, J ORTHOP TRANSL, V27, P67, DOI 10.1016/j.jot.2020.10.006
   Wang CY, 2018, J BIOMAT SCI POLYM E, V29, P1595, DOI 10.1080/09205063.2018.1477316
   Wang LX, 2014, BIOMATERIALS, V35, P6758, DOI 10.1016/j.biomaterials.2014.04.085
   Wang S, 2020, NANOSCALE, V12, P11936, DOI 10.1039/d0nr02327b
   Wang YL, 2016, NANOSCALE, V8, P11143, DOI 10.1039/c6nr01114d
   Wang Z, 2020, SMALL, V16, DOI 10.1002/smll.201907042
   Wei PF, 2019, ACS APPL MATER INTER, V11, P30596, DOI 10.1021/acsami.9b10219
   Xin HQ, 2021, CHEM ENG J, V424, DOI 10.1016/j.cej.2021.130380
   Xu AX, 2016, J MATER CHEM B, V4, P1878, DOI 10.1039/c5tb02782a
   Xu QB, 2017, CARBOHYD POLYM, V177, P187, DOI 10.1016/j.carbpol.2017.08.129
   Yang H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18891 x
   Yuan B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4704
   Zhang F, 2008, BIOMATERIALS, V29, P4751, DOI 10.1016/j.biomaterials.2008.08.043
   Zhang JC, 2021, CHEM ENG J, V422, DOI 10.1016/j.cej.2021.130094
   Zhang XY, 2020, CHEM ENG J, V382, DOI 10.1016/j.cej.2019.122849
   Zhao Y, 2013, BIOMATERIALS, V34, P9264, DOI 10.1016/j.biomaterials.2013.08.071
NR 62
TC 32
Z9 33
U1 9
U2 168
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD OCT 15
PY 2022
VL 446
AR 137453
DI 10.1016/j.cej.2022.137453
EA JUN 2022
PN 5
PG 16
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA 2M5ZI
UT WOS:000817777300002
DA 2025 08 17
ER

PT J
AU Priya, PS
   Nayak, SPRR
   Margesan, T
   Chitra, V
   Almutairi, MH
   Almutairi, BO
   Kumaradoss, KM
   Namasivayam, SKR
   Arockiaraj, J
AF Priya, P. Snega
   Nayak, S. P. Ramya Ranjan
   Margesan, Thirumal
   Chitra, Vellapandian
   Almutairi, Mikhlid H.
   Almutairi, Bader O.
   Kumaradoss, Kathiravan Muthu
   Namasivayam, S. Karthick Raja
   Arockiaraj, Jesu
TI Investigating the osteoprotective effects of quercetin and rutin from
   Terminalia chebula in glucocorticoid induced osteoporosis in vitro cell
   line and in vivo zebrafish model
SO SOUTH AFRICAN JOURNAL OF BOTANY
LA English
DT Article
DE Network pharmacology; Quercetin; Rutin; Osteoporosis; Terminalia chebula
ID OXIDATIVE STRESS; OSTEOGENESIS; EMBRYOS; INHIBITION; EXTRACT
AB Terminalia chebula, called as king of traditional Tibetan medicine, contains bioactive compounds such as quercetin and rutin, which have been implicated in bone health. Osteoporosis, characterized by bone density decline, poses a significant health concern. Exploring natural agents like quercetin and rutin could offer novel therapeutic avenues. A network pharmacology guided approach on quercetin and rutin combination from Terminalia chebula against glucocorticoid induced osteoporosis in vitro and in vivo models was studied in this present investigation. Bioactive compounds from T. chebula were identified, and their potential targets were assessed using network pharmacology. Quercetin and rutin were selected for further study based on their interaction with osteoporosis related targets. In vitro studies utilized osteoblast like UMR 106 cells to evaluate cell proliferation, differentiation, and mineralization. In vivo experiments were conducted using zebrafish larvae to assess embryotoxicity, bone development, oxidative stress, and mRNA expression related to osteoporosis. Quercetin, and rutin, individually and in combination, demonstrated enhanced cell proliferation, osteoblastic differentiation, and mineralization in UMR 106 cells. In zebrafish larvae, the combination showed improved survival rates, hatching rates, and reduced developmental abnormalities compared to Dex treated larvae. Moreover, the combination significantly attenuated oxidative stress, reduced apoptosis, increased alkaline phosphatase activity, enhanced calcium deposition, and regulated the RANK/RANKL/OPG pathway, indicative of osteoprotective effects against glucocorticoid induced osteoporosis. The study highlights the potential of quercetin and rutin, particularly in combination, as promising candidates for the treatment of glucocorticoid induced osteoporosis. Their multifaceted effects on osteoporosis, demonstrated through in vitro and in vivo experiments, suggest a comprehensive therapeutic approach targeting various aspects of osteoporosis pathophysiology. (c) 2024 SAAB. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
C1 [Priya, P. Snega; Nayak, S. P. Ramya Ranjan; Arockiaraj, Jesu] SRM Inst Sci & Technol, Fac Sci & Humanities, Dept Biotechnol, Kattankulatur 603203, Tamil Nadu, India.
   [Margesan, Thirumal] SRM Inst Sci & Technol, SRM Coll Pharm, Dept Pharmacognosy, Kattankulathur 603203, Tamil Nadu, India.
   [Chitra, Vellapandian] SRM Inst Sci & Technol, SRM Coll Pharm, Dept Pharmacol, Kattankulathur 603203, Tamil Nadu, India.
   [Almutairi, Mikhlid H.; Almutairi, Bader O.] King Saud Univ, Coll Sci, Dept Zool, POB 2455, Riyadh 11451, Saudi Arabia.
   [Kumaradoss, Kathiravan Muthu] SRM Inst Sci & Technol, SRM Coll Pharm, Dept Pharmaceut Chem, Kattankulathur 603203, Tamil Nadu, India.
   [Namasivayam, S. Karthick Raja] Saveetha Inst Med & Tech Sci SIMATS, Ctr Appl Res, Saveetha Sch Engn, Chennai 602105, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai; SRM Institute of Science
   & Technology Chennai; SRM Institute of Science & Technology Chennai;
   King Saud University; SRM Institute of Science & Technology Chennai;
   Saveetha Institute of Medical & Technical Science; Saveetha School of
   Engineering
RP Arockiaraj, J (通讯作者)，SRM Inst Sci & Technol, Fac Sci & Humanities, Dept Biotechnol, Kattankulatur 603203, Tamil Nadu, India.; Kumaradoss, KM (通讯作者)，SRM Inst Sci & Technol, SRM Coll Pharm, Dept Pharmaceut Chem, Kattankulathur 603203, Tamil Nadu, India.; Namasivayam, SKR (通讯作者)，Saveetha Inst Med & Tech Sci SIMATS, Ctr Appl Res, Saveetha Sch Engn, Chennai 602105, Tamil Nadu, India.
EM kathirak@srmist.edu.in; karthickrajanamasivayams.sse@saveetha.com;
   jesuaroa@srmist.edu.in
RI ; M, Thirumal/ABO 2824 2022; Almutairi, Bader/ABX 0720 2022; Karthick
   Raja Namasivayam, Dr.S./B 9625 2011
OI , Dr.S. Karthick Raja Namasivayam/0000 0003 2894 1905; 
FU Department of Science and Tech nology (DST) [RSP2025R414]; King Saud
   University, Riyadh, Saudi Arabia
FX Acknowledgment Ms. P. Snega Priya acknowledges Department of Science and
   Tech nology (DST) , Govt. of India for awarding her with INSPIRE
   fellowship to complete her Ph.D degree. The authors extend their sincere
   appre ciation to Researchers Supporting Project Number (RSP2025R414) ,
   King Saud University, Riyadh, Saudi Arabia.
CR AbuZahra HM, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10101593
   Adeyemi JA, 2015, COMP BIOCHEM PHYS C, V172, P7, DOI 10.1016/j.cbpc.2015.04.001
   Ahmed OM, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2710607
   Ahmed S, 2021, J ETHNOPHARMACOL, V273, DOI 10.1016/j.jep.2021.113829
   Anastasilaki E, 2023, HORM INT J ENDOCRINO, V22, P611, DOI 10.1007/s42000 023 00491 1
   Arafa EA, 2023, BIOMED PHARMACOTHER, V161, DOI 10.1016/j.biopha.2023.114461
   Bag Anwesa, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P244, DOI 10.1016/S2221 1691(13)60059 3
   Basaran E, 2022, EUR J PHARM SCI, V172, DOI 10.1016/j.ejps.2022.106153
   Bernar A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010723
   Cai ZH, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/7019792
   Chen JR, 2017, MOLECULES, V22, DOI 10.3390/molecules22122068
   Choi SS, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10111696
   Derakhshanian H, 2013, CAN J PHYSIOL PHARM, V91, P380, DOI 10.1139/cjpp 2012 0190
   Deveci H., 2017, Med. Sci. | Int. Med. J., V1, DOI [10.5455/medscience.2017.06.8597, DOI 10.5455/MEDSCIENCE.2017.06.8597]
   Dietrich K, 2021, J BONE MINER RES, V36, P436, DOI 10.1002/jbmr.4256
   Fardet L, 2011, RHEUMATOLOGY, V50, P1982, DOI 10.1093/rheumatology/ker017
   Favus MJ, 2010, NEW ENGL J MED, V363, P2027, DOI 10.1056/NEJMct1004903
   Gandhi NM, 2005, MOL CELL BIOCHEM, V277, P43, DOI 10.1007/s11010 005 4819 9
   Hu Y, 2022, LIFE BASEL, V12, DOI 10.3390/life12070980
   Iova GM, 2021, MOLECULES, V26, DOI 10.3390/molecules26051332
   Jia YJ, 2022, FOOD CHEM, V396, DOI 10.1016/j.foodchem.2022.133685
   KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756 3282(94)90821 4
   Kim HL, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10238698
   Krithiga G, 2011, B MATER SCI, V34, P589, DOI 10.1007/s12034 011 0075 7
   Lee HH, 2020, J KOREAN NEUROSURG S, V63, P433, DOI 10.3340/jkns.2019.0097
   Li M, 2016, J ETHNOPHARMACOL, V185, P120, DOI 10.1016/j.jep.2016.03.023
   Liu WJ, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112871
   Liu XW, 2021, EUR J HISTOCHEM, V65, DOI 10.4081/ejh.2021.3195
   Luo SY, 2016, J ORTHOP TRANSL, V4, P35, DOI 10.1016/j.jot.2015.07.002
   Naik GH, 2004, PHYTOMEDICINE, V11, P530, DOI 10.1016/j.phymed.2003.08.001
   Parashar R., 2020, Journal of Pharmacognosy and Phytochemistry, V9, P1690
   Peng CH, 2021, TZU CHI MED J, V33, P212, DOI 10.4103/tcmj.tcmj_233_20
   Piemontese M, 2016, AM J PHYSIOL ENDOC M, V311, pE587, DOI 10.1152/ajpendo.00219.2016
   Priya PS, 2023, PROCESS BIOCHEM, V134, P63, DOI 10.1016/j.procbio.2023.09.019
   Priya PS, 2023, J DRUG DELIV SCI TEC, V81, DOI 10.1016/j.jddst.2023.104278
   Priya PS, 2023, SCI TOTAL ENVIRON, V864, DOI 10.1016/j.scitotenv.2022.160968
   Qi WD, 2022, MOLECULES, V27, DOI 10.3390/molecules27196545
   Ruangsuriya J, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906 020 02892 w
   Saleem A, 2002, J ETHNOPHARMACOL, V81, P327, DOI 10.1016/S0378 8741(02)00099 5
   Semwal R, 2021, PHYTOCHEM LETT, V46, P119, DOI 10.1016/j.phytol.2021.10.006
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Sharma K, 2023, FREE RADICAL BIO MED, V194, P99, DOI 10.1016/j.freeradbiomed.2022.11.026
   Singh M, 2022, COMP BIOCHEM PHYS C, V262, DOI 10.1016/j.cbpc.2022.109463
   Song XL, 2020, J MOL MODEL, V26, DOI 10.1007/s00894 020 04356 x
   Sromová V, 2023, CELLS BASEL, V12, DOI 10.3390/cells12212576
   Sudhakaran G, 2023, LIFE SCI, V335, DOI 10.1016/j.lfs.2023.122280
   Tonelli F, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00489
   Wang XL, 2011, PHYTOMEDICINE, V18, P868, DOI 10.1016/j.phymed.2011.01.022
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Wu MH, 2011, ENVIRON TOXICOL CHEM, V30, P2335, DOI 10.1002/etc.634
   Xiao HH, 2014, J STEROID BIOCHEM, V143, P141, DOI 10.1016/j.jsbmb.2014.02.019
   Xie LB, 2024, J ETHNOPHARMACOL, V321, DOI 10.1016/j.jep.2023.117480
   Xu PC, 2022, J ETHNOPHARMACOL, V293, DOI 10.1016/j.jep.2022.115269
   Yang LJ, 2011, J ETHNOPHARMACOL, V135, P553, DOI 10.1016/j.jep.2011.03.056
   Yurteri A, 2023, JOINT DIS RELAT SURG, V34, P365, DOI 10.52312/jdrs.2023.870
   Zhang YH, 2021, J ETHNOPHARMACOL, V277, DOI 10.1016/j.jep.2021.114249
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
   Zou Y, 2017, J APPL TOXICOL, V37, P842, DOI 10.1002/jat.3432
NR 58
TC 3
Z9 3
U1 2
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0254 6299
EI 1727 9321
J9 S AFR J BOT
JI S. Afr. J. Bot.
PD DEC
PY 2024
VL 175
BP 712
EP 722
DI 10.1016/j.sajb.2024.10.060
EA NOV 2024
PG 11
WC Plant Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences
GA M6O6F
UT WOS:001358712000001
DA 2025 08 17
ER

PT J
AU Mattarello, MJ
   Benedini, S
   Fiore, C
   Camozzi, V
   Sartorato, P
   Luisetto, G
   Armanini, D
AF Mattarello, MJ
   Benedini, S
   Fiore, C
   Camozzi, V
   Sartorato, P
   Luisetto, G
   Armanini, D
TI Effect of licorice on PTH levels in healthy women
SO STEROIDS
LA English
DT Article
DE aldosterone; calcium; licorice; PTH; estrogenic activity;
   25 hydroxycholecalciferol
ID MINERALOCORTICOID ACTION; PARATHYROID HORMONE; SERUM TESTOSTERONE; ACID;
   DERIVATIVES; GLABRIDIN; MECHANISM; GLABRENE
AB Licorice has been considered a medicinal plant for thousands of years. Its most common side effect is hypokalemic hypertension, which is secondary to a block of 11 beta hydroxysteroid dehydrogenase type 2 at the level of the kidney, leading to an enhanced mineralocorticoid effect of cortisol. This effect is due to glycyrrhetinic acid, which is the main constituent of the root, but other components are also present, including isoflavans, which have estrogenlike activity, and are thus involved in the modulation of bone metabolism. We investigated nine healthy women 22 26 years old, in the luteal phase of the cycle. They were given 3.5 g of a commercial preparation of licorice (containing 7.6%, w/w of glycyrrhizic acid) daily for 2 months. Plasma renin activity (PRA), aldosterone, cortisol, serum parathyroid hormone (PTH), 1,25 dihydroxy Vitamin D (1,2501 11)), 25 hydroxycholecalciferol (250HD), estradiol, FHS, LH, alkaline phosphatase (ALP), calcium, phosphate and creatinine, urinary calcium and phosphate and mineralometry were measured. PTH, 250HD and urinary calcium increased significantly from baseline values after 2 months of therapy, while 1,250HD and ALP did not change during treatment. All these parameters returned to pretreatment levels 1 month after discontinuation of licorice. PRA and aldosterone were depressed during therapy, while blood pressure and plasma cortisol remained unchanged. Conclusions: licorice can increase serum PTH and urinary calcium levels from baseline value in healthy women after only 2 months of treatment. The effect of licorice on calcium metabolism is probably influenced by several components of the root, which show aldosterone like, estrogen like and antiandrogen activity. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Padua, Dept Med & Surg Sci Endocrinol, I 35100 Padua, Italy.
C3 University of Padua
RP Univ Padua, Dept Med & Surg Sci Endocrinol, Via Osped 105, I 35100 Padua, Italy.
EM decio.armanini@unipd.it
RI Camozzi, Valentina/Q 9833 2016; Benedini, Stefano/F 7483 2013
OI Camozzi, Valentina/0000 0002 1634 951X; Armanini,
   Decio/0000 0002 6433 5155; Benedini, Stefano/0000 0003 0957 5049
CR [Anonymous], ACTA OBSTETRICIA GYN
   Armanini D, 2004, STEROIDS, V69, P763, DOI 10.1016/j.steroids.2004.09.005
   Armanini D, 1999, NEW ENGL J MED, V341, P1158, DOI 10.1056/NEJM199910073411515
   ARMANINI D, 1989, J ENDOCRINOL INVEST, V12, P303, DOI 10.1007/BF03349993
   ARMANINI D, 1983, CLIN ENDOCRINOL, V19, P609, DOI 10.1111/j.1365 2265.1983.tb00038.x
   Armanini D, 2002, EXP CLIN ENDOCR DIAB, V110, P257, DOI 10.1055/s 2002 34587
   Armanini D, 1996, J ENDOCRINOL INVEST, V19, P624, DOI 10.1007/BF03349029
   BERNARDI M, 1994, LIFE SCI, V55, P863, DOI 10.1016/0024 3205(94)90042 6
   Cooper MS, 2003, J CLIN ENDOCR METAB, V88, P3874, DOI 10.1210/jc.2003 022025
   Cooper MS, 2002, J BONE MINER RES, V17, P979, DOI 10.1359/jbmr.2002.17.6.979
   DUARTE B, 1988, J CLIN ENDOCR METAB, V66, P584, DOI 10.1210/jcem 66 3 584
   EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140 6736(88)90742 8
   Francis RM, 1999, CLIN ENDOCRINOL, V50, P411
   FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584
   KASPERK CH, 1989, ENDOCRINOLOGY, V124, P1576, DOI 10.1210/endo 124 3 1576
   LATIF S A, 1990, Steroids, V55, P52, DOI 10.1016/0039 128X(90)90024 6
   Ploeger B, 2001, DRUG METAB REV, V33, P125, DOI 10.1081/DMR 100104400
   Reed MJ, 2004, MATURITAS, V48, pS4, DOI 10.1016/j.maturitas.2004.02.013
   RESNICK LM, 1987, J HYPERTENS, V5, pS99
   ROSSI E, 1995, AM J HYPERTENS, V8, P884, DOI 10.1016/0895 7061(95)00182 O
   Rubin MR, 2002, INT J FERTIL WOMEN M, V47, P103
   SAKAMOTO K, 1988, ENDOCRINOL JAPON, V35, P333
   Somjen D, 2004, J STEROID BIOCHEM, V91, P241, DOI 10.1016/j.jsbmb.2004.04.008
   TAKEUCHI T, 1991, AM J CHINESE MED, V19, P73, DOI 10.1142/S0192415X91000119
   Tamir S, 2000, CANCER RES, V60, P5704
   Tamir S, 2001, J STEROID BIOCHEM, V78, P291, DOI 10.1016/S0960 0760(01)00093 0
NR 26
TC 13
Z9 16
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039 128X
EI 1878 5867
J9 STEROIDS
JI Steroids
PD MAY
PY 2006
VL 71
IS 5
BP 403
EP 408
DI 10.1016/j.steroids.2006.01.005
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 040GI
UT WOS:000237366600009
PM 16513152
DA 2025 08 17
ER

PT J
AU Petrie, TA
   Raynor, JE
   Reyes, CD
   Burns, KL
   Collard, DM
   García, AJ
AF Petrie, Timothy A.
   Raynor, Jenny E.
   Reyes, Catherine D.
   Burns, Kellie L.
   Collard, David M.
   Garcia, Andres J.
TI The effect of integrin specific bioactive coatings on tissue healing and
   implant osseointegration
SO BIOMATERIALS
LA English
DT Article
DE bone; fibronectin; cell adhesion; RGD; FAK; integrins
ID TOTAL JOINT ARTHROPLASTY; IN VIVO EVALUATION; BONE FORMATION;
   CELL ADHESION; OSTEOBLAST DIFFERENTIATION; BIOMATERIAL SURFACES;
   TITANIUM IMPLANTS; BINDING; ALPHA V BETA 3; HYDROXYAPATITE
AB Implant osseointegration, defined as bone apposition and functional fixation, is a requisite for clinical success in orthopaedic and dental applications, many of which are restricted by implant loosening. Modification of implants to present bioactive motifs such as the RGD cell adhesive sequence from fibronectin (FN) represents a promising approach in regenerative medicine. However, these biomimetic strategies have yielded only marginal enhancements in tissue healing in vivo. In this study, clinical grade titanium implants were grafted with a non fouling oligo(ethylene glycol) substituted polymer coating functionalized with controlled densities of ligands of varying specificity for target integrin receptors. Biomaterials presenting the alpha(5)beta(1) integrin specific FN fragment FNIII7 10 enhanced osteoblastic differentiation in bone marrow stromal cells compared to unmodified titanium and RGD presenting surfaces. Importantly, FNIII7 10 functionalized titanium significantly improved functional implant osseointegration compared to RGD functionalized and unmodified titanium in vivo. This study demonstrates that bioactive coatings that promote integrin binding specificity regulate marrow derived progenitor osteoblastic differentiation and enhance healing responses and functional integration of biomedical implants. This work identifies an innovative strategy for the rational design of biomaterials for regenerative medicine. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Petrie, Timothy A.; Reyes, Catherine D.; Burns, Kellie L.; Garcia, Andres J.] Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.
   [Petrie, Timothy A.; Reyes, Catherine D.; Burns, Kellie L.; Garcia, Andres J.] Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
   [Raynor, Jenny E.; Collard, David M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.
C3 University System of Georgia; Georgia Institute of Technology;
   University System of Georgia; Georgia Institute of Technology;
   University System of Georgia; Georgia Institute of Technology
RP García, AJ (通讯作者)，Georgia Inst Technol, George W Woodruff Sch Mech Engn, 315 Ferst Dr,Room 2314 IBB, Atlanta, GA 30332 USA.
EM andres.garcia@me.gatech.edu
FU NIBIB NIH HHS [R01 EB004496, R01 EB 004496] Funding Source: Medline
CR *AM AC ORTH SURG, 2003, ARTHR TOT JOINT REPL
   Anderson JM, 2001, ANNU REV MATER RES, V31, P81, DOI 10.1146/annurev.matsci.31.1.81
   [Anonymous], 1999, NAT ARTHR ACT PLAN P
   Barber TA, 2007, J BIOMED MATER RES A, V80A, P306, DOI 10.1002/jbm.a.30927
   Bauer TW, 1999, SKELETAL RADIOL, V28, P483, DOI 10.1007/s002560050552
   Bauer TW, 1999, SKELETAL RADIOL, V28, P423, DOI 10.1007/s002560050541
   Carron CP, 2000, J ENDOCRINOL, V165, P587, DOI 10.1677/joe.0.1650587
   Cheng SL, 2000, J CELL BIOCHEM, V77, P265, DOI 10.1002/(SICI)1097 4644(20000501)77:2<265::AID JCB9>3.0.CO;2 6
   Cheng SL, 2001, CALCIFIED TISSUE INT, V68, P87, DOI 10.1007/BF02678146
   Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Elmengaard B, 2005, BIOMATERIALS, V26, P3521, DOI 10.1016/j.biomaterials.2004.09.039
   Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404
   Gallant ND, 2005, MOL BIOL CELL, V16, P4329, DOI 10.1091/mbc.E05 02 0170
   García AJ, 2005, BIOMATERIALS, V26, P7525, DOI 10.1016/j.biomaterials.2005.05.029
   Hanks SK, 2003, FRONT BIOSCI LANDMRK, V8, pD982, DOI 10.2741/1114
   Hubbell JA, 2004, NAT BIOTECHNOL, V22, P828, DOI 10.1038/nbt0704 828
   Hutchinson JH, 2003, J MED CHEM, V46, P4790, DOI 10.1021/jm030306r
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Kanagaraja S, 1996, BIOMATERIALS, V17, P2225, DOI 10.1016/0142 9612(95)00311 8
   Keselowsky BG, 2005, BIOMATERIALS, V26, P413, DOI 10.1016/j.biomaterials.2004.02.050
   Keselowsky BG, 2005, P NATL ACAD SCI USA, V102, P5953, DOI 10.1073/pnas.0407356102
   Langer R, 2004, NATURE, V428, P487, DOI 10.1038/nature02388
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Nakamura I, 1999, J CELL SCI, V112, P3985
   Petrie TA, 2006, BIOMATERIALS, V27, P5459, DOI 10.1016/j.biomaterials.2006.06.027
   Pilliar RM, 2005, ORTHOP CLIN N AM, V36, P113, DOI 10.1016/j.ocl.2004.08.001
   Rammelt S, 2007, J ORTHOP RES, V25, P1052, DOI 10.1002/jor.20403
   Raynor JE, 2007, ADV MATER, V19, P1724, DOI 10.1002/adma.200602129
   Reyes CD, 2007, BIOMATERIALS, V28, P3228, DOI 10.1016/j.biomaterials.2007.04.003
   Reyes CD, 2003, J BIOMED MATER RES A, V67A, P328, DOI 10.1002/jbm.a.10122
   Schliephake H, 2002, CLIN ORAL IMPLAN RES, V13, P312, DOI 10.1034/j.1600 0501.2002.130312.x
   Siebers MC, 2007, CLIN ORAL IMPLAN RES, V18, P354, DOI 10.1111/j.1600 0501.2006.01314.x
   Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772
   Wang H, 2006, BIOMATERIALS, V27, P4192, DOI 10.1016/j.biomaterials.2006.03.034
NR 35
TC 185
Z9 216
U1 3
U2 70
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2008
VL 29
IS 19
BP 2849
EP 2857
DI 10.1016/j.biomaterials.2008.03.036
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 304YL
UT WOS:000256144900003
PM 18406458
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Capobianco, E
   Mora, A
   La Sala, D
   Roberti, A
   Zaki, N
   Badidi, E
   Taranta, M
   Cinti, C
AF Capobianco, Enrico
   Mora, Antonio
   La Sala, Dario
   Roberti, Annalisa
   Zaki, Nazar
   Badidi, Elarbi
   Taranta, Monia
   Cinti, Caterina
TI Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating
   Human Multi Drug Resistant Osteosarcoma HosDXR150 Cell Line
SO PLOS ONE
LA English
DT Article
ID INCREASED EXPRESSION; GROWTH; TUMORIGENESIS; METHYLATION; MECHANISMS;
   CHROMATIN; FACTOR 1; RELAPSE; VIEWS; GENE
AB Understanding the molecular mechanisms underlying multi drug resistance (MDR) is one of the major challenges in current cancer research. A phenomenon which is common to both intrinsic and acquired resistance, is the aberrant alteration of gene expression in drug resistant cancers. Although such dysregulation depends on many possible causes, an epigenetic characterization is considered a main driver. Recent studies have suggested a direct role for epigenetic inactivation of genes in determining tumor chemo sensitivity. We investigated the effects of the inhibition of DNA methyltransferase (DNMT) and hystone deacethylase (HDAC), considered to reverse the epigenetic aberrations and lead to the re expression of de novo methylated genes in MDR osteosarcoma (OS) cells. Based on our analysis of the HosDXR150 cell line, we found that in order to reduce cell proliferation, co treatment of MDR OS cells with DNMT (5 Aza dC, DAC) and HDAC (Trichostatin A, TSA) inhibitors is more effective than relying on each treatment alone. In re expressing epigenetically silenced genes induced by treatments, a very specific regulation takes place which suggests that methylation and de acetylation have occurred either separately or simultaneously to determine MDR OS phenotype. In particular, functional relationships have been reported after measuring differential gene expression, indicating that MDR OS cells acquired growth and survival advantage by simultaneous epigenetic inactivation of both multiple p53 independent apoptotic signals and osteoblast differentiation pathways. Furthermore, co treatment results more efficient in inducing the re expression of some main pathways according to the computed enrichment, thus emphasizing its potential towards representing an effective therapeutic option for MDR OS.
C1 [Capobianco, Enrico; Mora, Antonio] CNR, Inst Clin Physiol, Lab Integrat Syst Med, I 56100 Pisa, Italy.
   [Capobianco, Enrico] Univ Miami, Ctr Computat Sci, Miami, FL USA.
   [Mora, Antonio; Zaki, Nazar; Badidi, Elarbi] United Arab Emirates Univ, Coll Informat Technol, Al Ain, U Arab Emirates.
   [La Sala, Dario; Roberti, Annalisa; Taranta, Monia; Cinti, Caterina] CNR, Inst Clin Physiol, Expt Oncol Unit, Siena, Italy.
   [La Sala, Dario] Policlin Univ, Dept Expt Biomed & Clin Neurosci, Palermo, Italy.
   [Roberti, Annalisa] Univ Penn, Perelman Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica
   (IFC CNR); University of Miami; United Arab Emirates University;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica
   (IFC CNR); University of Palermo; University of Pennsylvania
RP Cinti, C (通讯作者)，CNR, Inst Clin Physiol, Expt Oncol Unit, Siena, Italy.
EM ccinti@ifc.cnr.it
RI ; Cinti, Caterina/HLX 2432 2023; Badidi, Elarbi/ISS 7621 2023; Taranta,
   Monia/IUO 4735 2023; Zaki, Nazar/F 1972 2013; Roberti,
   Annalisa/AAB 4278 2021; Mora, Antonio/ABA 2676 2020; Zaki,
   Nazar/ABC 1680 2020
OI Taranta, Monia/0009 0005 4245 2448; Mora, Antonio/0000 0003 1344 1131;
   Cinti, Caterina/0000 0001 8049 0369; Badidi, Elarbi/0000 0001 9121 8766;
   Zaki, Nazar/0000 0002 6259 9843; Roberti, Annalisa/0000 0001 8442 7228; 
FU Consiglio Nazionale delle Ricerche (CNR); Regione Toscana; Bando Unico
   Ricerca e Sviluppo Programma Operativo Regionale; Competitivita
   Regionale e Occupazione; Fondo Europeo di Sviluppo Regionale,; POR CReO
FX This work was supported by funding of Consiglio Nazionale delle Ricerche
   (CNR) and of Regione Toscana, Bando Unico Ricerca e Sviluppo Programma
   Operativo Regionale, Competitivita Regionale e Occupazione, Fondo
   Europeo di Sviluppo Regionale, POR CReO FESR 2007 2013, Project acronym
   Title: ACTILA. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014 4827(03)00342 2
   Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168 9525(99)01971 X
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Cain Jason E., 2013, Sarcoma, V2013, P608964, DOI 10.1155/2013/608964
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Cote GM, 2013, CURR TREAT OPTION ON, V14, P454, DOI 10.1007/s11864 013 0239 3
   Cui JC, 2011, B CANCER, V98, pE62, DOI 10.1684/bdc.2011.1400
   Dario LS, 2008, REV RECENT CLIN TRIA, V3, P192, DOI 10.2174/157488708785700320
   Engel MA, 2010, CURR MED CHEM, V17, P3303
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Grimer RJ, 2002, J BONE JOINT SURG BR, V84B, P395, DOI 10.1302/0301 620X.84B3.12019
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kempf Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Kresse SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048262
   La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487
   Lafleur EA, 2003, IL 12 INHIBITS METAS, P3175
   LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Patel DJ, 2013, ANNU REV BIOCHEM, V82, P81, DOI 10.1146/annurev biochem 072711 165700
   Perissinotto E, 2005, CLIN CANCER RES, V11, P490
   Roberti A, 2006, J CELL PHYSIOL, V207, P571, DOI 10.1002/jcp.20515
   Scotlandi K, 1996, AM J PATHOL, V149, P1209
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Teodoridis JM, 2004, BIOCHEM SOC T, V32, P916, DOI 10.1042/BST0320916
   Terabe M, 2006, CANCER RES, V66, P3869, DOI 10.1158/0008 5472.CAN 05 3421
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   Uchibori M, 2006, INT J ONCOL, V28, P33
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008
NR 33
TC 41
Z9 44
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 22
PY 2014
VL 9
IS 4
AR e95596
DI 10.1371/journal.pone.0095596
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AG2IS
UT WOS:000335240300058
PM 24756038
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Law, S
   Panwar, P
   Li, J
   Aguda, AH
   Jamroz, A
   Guido, RVC
   Brömme, D
AF Law, Simon
   Panwar, Preety
   Li, Jody
   Aguda, Adeleke H.
   Jamroz, Andrew
   Guido, Rafael V. C.
   Bromme, Dieter
TI A composite docking approach for the identification and characterization
   of ectosteric inhibitors of cathepsin K
SO PLOS ONE
LA English
DT Article
ID CYSTEINE PROTEASES; MOLECULAR DOCKING; SCORING FUNCTIONS; DRUG DESIGN;
   PROTEIN; OSTEOPOROSIS; DEGRADATION; OSTEOCLASTS; EXPRESSION; DISCOVERY
AB Cathepsin K (CatK) is a cysteine protease that plays an important role in mammalian intra and extracellular protein turnover and is known for its unique and potent collagenase activity. Through studies on the mechanism of its collagenase activity, selective ectosteric sites were identified that are remote from the active site. Inhibitors targeting these ectosteric sites are collagenase selective and do not interfere with other proteolytic activities of the enzyme. Potential ectosteric inhibitors were identified using a computational approach to screen the druggable subset of and the entire 281,987 compounds comprising Chemical Repository library of the National Cancer Institute Developmental Therapeutics Program (NCI DTP). Compounds were scored based on their affinity for the ectosteric site. Here we compared the scores of three individual molecular docking methods with that of a composite score of all three methods together. The composite docking method was up to five fold more effective at identifying potent collagenase inhibitors (IC50 < 20 mu M) than the individual methods. Of 160 top compounds tested in enzymatic assays, 28 compounds revealed blocking of the collagenase activity of CatK at 100 mu M. Two compounds exhibited IC50 values below 5 mu M corresponding to a molar protease: inhibitor concentration of < 1:12. Both compounds were subsequently tested in osteoclast bone resorption assays where the most potent inhibitor, 10 [2 [bis(2 hydroxyethyl) amino] ethyl] 7,8 diethylbenzo[g] pteridine 2,4 dione, (NSC 374902), displayed an inhibition of bone resorption with an IC50 value of approximately 300 nM and no cell toxicity effects.
C1 [Law, Simon; Aguda, Adeleke H.; Bromme, Dieter] Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC, Canada.
   [Law, Simon; Panwar, Preety; Li, Jody; Jamroz, Andrew; Bromme, Dieter] Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada.
   [Panwar, Preety; Li, Jody; Jamroz, Andrew; Bromme, Dieter] Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC, Canada.
   [Guido, Rafael V. C.] Univ Sao Paulo, Inst Fis Sao Carlos, Ctr Inovacao Biodiversidade & Farmacos, Sao Carlos, SP, Brazil.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia; Universidade de Sao Paulo
RP Brömme, D (通讯作者)，Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC, Canada.; Brömme, D (通讯作者)，Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada.; Brömme, D (通讯作者)，Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC, Canada.
EM dbromme@dentistry.ubc.ca
RI ; Guido, Rafael/A 7450 2009
OI Aguda, Adeleke/0000 0001 5187 3264; Law, Simon Sau
   Yin/0000 0002 9650 2958; Jamroz, Andrew/0000 0002 6199 1667; Guido,
   Rafael/0000 0002 7187 0818
FU Canadian Institutes of Health Research [MOP 89974, MOP 125866]; Natural
   Sciences & Engineering Research Council of Canada [RGPIN 326803 13];
   Canada Research Chair
FX The present work was supported by the Canadian Institutes of Health
   Research [grant numbers MOP 89974, MOP 125866] (CIHR:
   http://www.cihr irsc.gc.ca/e/193.html), the Natural Sciences &
   Engineering Research Council of Canada [grant number RGPIN 326803 13]
   (NSERC: http://www.nserc crsng.gc.ca/index_eng.asp), and a Canada
   Research Chair award (to D.B.). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   Alonso H, 2006, MED RES REV, V26, P531, DOI 10.1002/med.20067
   [Anonymous], 2004, NCI YEAST ANT DRUG S
   Brömme D, 2016, EXPERT OPIN DRUG DIS, V11, P457, DOI 10.1517/17460441.2016.1160884
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   Brömme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179
   Brömme D, 2009, EXPERT OPIN INV DRUG, V18, P585, DOI [10.1517/13543780902832661, 10.1517/13543780902832661 ]
   Carta G, 2007, J CHEM INF MODEL, V47, P1564, DOI 10.1021/ci600471m
   Corsino P, 2009, J BIOL CHEM, V284, P29945, DOI 10.1074/jbc.M109.055251
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Du X, 2013, J BIOL CHEM, V288, P34871, DOI 10.1074/jbc.M113.510008
   Dunstan MS, 2011, J MED CHEM, V54, P6597, DOI 10.1021/jm200416e
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77
   Feng BY, 2007, J MED CHEM, V50, P2385, DOI 10.1021/jm061317y
   Ferrara P, 2004, J MED CHEM, V47, P3032, DOI 10.1021/jm030489h
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   Grinter SZ, 2014, MOLECULES, V19, P10150, DOI 10.3390/molecules190710150
   Halgren TA, 2009, J CHEM INF MODEL, V49, P377, DOI 10.1021/ci800324m
   Houston DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121424
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656
   Linnevers CJ, 1997, PROTEIN SCI, V6, P919
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Lutgens SPM, 2007, FASEB J, V21, P3029, DOI 10.1096/fj.06 7924com
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Ntie Kang F, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193 1801 2 353
   PAN YP, 2002, ABSTR PAP AM CHEM 1, V224, P29531
   Panwar P, 2017, MATRIX BIOL
   Panwar P, 2017, J BONE MINER RES
   Panwar P, 2016, BRIT J PHARMACOL, V173, P396, DOI 10.1111/bph.13383
   Rastelli G, 2002, BIOORGAN MED CHEM, V10, P1437, DOI 10.1016/S0968 0896(01)00410 2
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822 013 9644 8
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sharma V, 2015, BIOCHEM J, V465, P163, DOI 10.1042/BJ20140809
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Spitzer R, 2012, J COMPUT AID MOL DES, V26, P687, DOI 10.1007/s10822 011 9533 y
   Sullivan K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147230
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Valasani KR, 2014, J CHEM INF MODEL, V54, P902, DOI 10.1021/ci5000196
   Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569
   Yamashita DS, 1997, J AM CHEM SOC, V119, P11351, DOI 10.1021/ja972204u
   Yasuda Y, 2004, J BIOL CHEM, V279, P36761, DOI 10.1074/jbc.M403986200
NR 46
TC 8
Z9 8
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2017
VL 12
IS 10
AR e0186869
DI 10.1371/journal.pone.0186869
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FL2ZD
UT WOS:000414088900027
PM 29088253
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, R
   Mu, XD
   Liu, DW
   Chen, CD
   Meng, BW
   Qu, Y
   Liu, J
   Wang, RC
   Li, CJ
   Mao, XL
   Wang, QT
   Zhang, QB
AF Zhang, Rong
   Mu, Xiaodan
   Liu, Dawei
   Chen, Chider
   Meng, Bowen
   Qu, Yan
   Liu, Jin
   Wang, Runci
   Li, Chuanjie
   Mao, Xueli
   Wang, Qintao
   Zhang, Qingbin
TI Apoptotic vesicles rescue impaired mesenchymal stem cells and their
   therapeutic capacity for osteoporosis by restoring miR 145a 5p
   deficiency
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Apoptotic vesicles; Mesenchymal stem cells; Osteoporosis; miR 145a 5p;
   TGF beta/Smad signaling; Wnt/beta catenin signaling
ID BONE LOSS; EXTRACELLULAR VESICLES; POSTMENOPAUSAL WOMEN; ESTROGEN
   DEFICIENCY; MULTIPLE MYELOMA; DIFFERENTIATION; MECHANISMS; IMMUNE;
   OSTEOBLASTS; EXPRESSION
AB Apoptotic vesicles (apoVs) play a vital role in various physiological and pathological conditions. However, we have yet to fully understand their precise biological effects in rescuing impaired mesenchymal stem cells (MSCs). Here, we proved that systemic infusion of MSCs derived from wild type (WT) mice rather than from ovariectomized (OVX) mice effectively improved the osteopenia phenotype and rescued the impaired recipient MSCs in osteoporotic mice. Meanwhile, apoVs derived from WT MSCs (WT apoVs) instead of OVX apoVs efficiently restored the impaired biological function of OVX MSCs and their ability to improve osteoporosis. Mechanistically, the reduced miR 145a 5p expression hindered the osteogenic differentiation and immunomodulatory capacity of OVX MSCs by affecting the TGF beta/Smad 2/3 Wnt/beta catenin signaling axis, resulting in the development of osteoporosis. WT apoVs directly transferred miR 145a 5p to OVX MSCs, which were then reused to restore their impaired biological functions. The differential expression of miR 145a 5p is responsible for the distinct efficacy between the two types of apoVs. Overall, our findings unveil the remarkable potential of apoVs, as a novel nongenetic engineering approach, in rescuing the biological function and therapeutic capability of MSCs derived from patients. This discovery offers a new avenue for exploring apoVs based stem cell engineering and expands the application scope of stem cell therapy, contributing to the maintenance of bone homeostasis through a previously unrecognized mechanism.
C1 [Zhang, Rong; Li, Chuanjie; Zhang, Qingbin] Guangzhou Med Univ, Sch & Hosp Stomatol, Guangdong Engn Res Ctr Oral Restorat & Reconstruct, Dept Temporomandibular Joint, Guangzhou 510180, Guangdong, Peoples R China.
   [Zhang, Rong; Li, Chuanjie; Zhang, Qingbin] Guangzhou Med Univ, Guangzhou Key Lab Basic & Appl Res Oral Regenerat, Guangzhou 510180, Guangdong, Peoples R China.
   [Zhang, Rong; Liu, Dawei; Chen, Chider; Liu, Jin; Wang, Runci; Mao, Xueli] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA.
   [Zhang, Rong] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
   [Mu, Xiaodan] Capital Med Univ, Beijing Friendship Hosp, Dept Stomatol, Beijing 100050, Peoples R China.
   [Liu, Dawei] Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, Beijing 100081, Peoples R China.
   [Meng, Bowen; Qu, Yan; Mao, Xueli] Sun Yat Sen Univ, Hosp Stomatol, Ctr Craniofacial Stem Cell Res, Guanghua Sch Stomatol,Guangdong Prov Key Lab Stoma, Guangzhou 510055, Guangdong, Peoples R China.
   [Liu, Jin] Sichuan Univ, Lab Aging Res, Chengdu 610041, Sichuan, Peoples R China.
   [Liu, Jin] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Qintao] Air Force Med Univ, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Qintao] Air Force Med Univ, Natl Clin Res Ctr Oral Dis, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Qintao] Air Force Med Univ, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Sch Stomatol, Dept Periodontol, Xian 710032, Shaanxi, Peoples R China.
C3 Guangzhou Medical University; Guangzhou Medical University; University
   of Pennsylvania; Capital Medical University; Peking University; Sun Yat
   Sen University; Sichuan University; Sichuan University; Air Force
   Medical University; Air Force Medical University; Air Force Medical
   University
RP Zhang, QB (通讯作者)，Guangzhou Med Univ, Sch & Hosp Stomatol, Guangdong Engn Res Ctr Oral Restorat & Reconstruct, Dept Temporomandibular Joint, Guangzhou 510180, Guangdong, Peoples R China.; Zhang, QB (通讯作者)，Guangzhou Med Univ, Guangzhou Key Lab Basic & Appl Res Oral Regenerat, Guangzhou 510180, Guangdong, Peoples R China.; Wang, QT (通讯作者)，Air Force Med Univ, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.; Wang, QT (通讯作者)，Air Force Med Univ, Natl Clin Res Ctr Oral Dis, Xian 710032, Shaanxi, Peoples R China.; Wang, QT (通讯作者)，Air Force Med Univ, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Sch Stomatol, Dept Periodontol, Xian 710032, Shaanxi, Peoples R China.
EM wangqintao@aliyun.com; qingbinzhang@gzhmu.edu.cn
RI Zhang, Qingbin/D 5688 2011
OI Wang, Runci/0000 0001 9536 2845
FU National Natural Science Foundation of China
FX Not applicable.
CR Aghebati Maleki L, 2019, J CELL PHYSIOL, V234, P8570, DOI 10.1002/jcp.27833
   Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007
   Arjmand B, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00430
   Atkin Smith GK, 2017, TRENDS CELL BIOL, V27, P151, DOI 10.1016/j.tcb.2016.08.011
   Atkin Smith GK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8439
   Ayala Cuellar AP, 2019, BIOMOL THER, V27, P25, DOI 10.4062/biomolther.2017.260
   Beier EE, 2015, J BIOL CHEM, V290, P18216, DOI 10.1074/jbc.M114.629204
   Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998
   Bolland MJ, 2011, BMJ BRIT MED J, V342, DOI 10.1136/bmj.d2040
   Caruso S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01486
   Chen H, 2015, SCI REP UK, V5, DOI 10.1038/srep08718
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Cheng WZ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03181 8
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571 020 0403 1
   Dong L, 2020, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12044
   Dou G, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2987
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Eichholz KF, 2020, STEM CELL TRANSL MED, V9, P1431, DOI 10.1002/sctm.19 0405
   Eirin A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.660851
   El Nakeep S, 2022, CURR STEM CELL RES T, V17, P727, DOI 10.2174/1574888X16666210910112403
   Fang SJ, 2015, INT J MOL SCI, V16, P8227, DOI 10.3390/ijms16048227
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Fu Y, 2021, BIOENGINEERED, V12, P7714, DOI 10.1080/21655979.2021.1982323
   Fu Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03883 6
   Fuchs E, 2020, CELL STEM CELL, V27, P532, DOI 10.1016/j.stem.2020.09.011
   Gao YG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176081
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Genc B, 2019, ADV EXP MED BIOL, V1084, P145, DOI 10.1007/5584_2018_247
   Goradel NH, 2018, J CELL BIOCHEM, V119, P95, DOI 10.1002/jcb.26169
   Grant LR, 2019, BIOCHEM SOC T, V47, P509, DOI 10.1042/BST20180080
   Guerrero F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089179
   Gugjoo MB, 2020, RECENT PATENTS INFLA, V14, P3, DOI 10.2174/1872213X14666200130100236
   Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Hao LY, 2016, CELL PHYSIOL BIOCHEM, V38, P1267, DOI 10.1159/000443074
   He XY, 2021, CELL MOL BIOL LETT, V26, DOI 10.1186/s11658 021 00291 8
   Horiguchi M, 2021, INT J MOL SCI, V22
   Hu CX, 2018, J CELL MOL MED, V22, P1428, DOI 10.1111/jcmm.13492
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Huang ZQ, 2024, J EXTRACELL VESICLES, V13, DOI 10.1002/jev2.12428
   Huybrechts Y, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00165
   Iantomasi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043772
   Iaquinta MR, 2021, THERANOSTICS, V11, P6573, DOI 10.7150/thno.55664
   Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Leder BZ, 2017, CURR OSTEOPOROS REP, V15, P110, DOI 10.1007/s11914 017 0353 4
   Lee KS, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12152
   Leong JY, 2020, ACS NANO, V14, P5298, DOI 10.1021/acsnano.9b04926
   Li KN, 2021, EMBO J, V40, DOI 10.15252/embj.2020107135
   Li MJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.573511
   Li Y, 2018, CURR STEM CELL RES T, V13, P362, DOI 10.2174/1574888X13666180403163456
   Liang B, 2022, CELL MOL BIOL LETT, V27, DOI 10.1186/s11658 022 00371 3
   Liao L, 2016, STEM CELLS, V34, P1054, DOI 10.1002/stem.2274
   Lin RY, 2023, SMALL, V19, DOI 10.1002/smll.202301671
   Liu CX, 2020, FOOD FUNCT, V11, P10817, DOI [10.1039/d0fo00787k, 10.1039/D0FO00787K]
   Liu DW, 2018, CELL RES, V28, P918, DOI 10.1038/s41422 018 0070 2
   Liu XZ, 2020, TOXICOLOGY, V431, DOI 10.1016/j.tox.2019.152353
   Liu Y, 2014, J DENT RES, V93, P1124, DOI 10.1177/0022034514552675
   Liu Y, 2012, INT J BIOCHEM CELL B, V44, P2044, DOI 10.1016/j.biocel.2012.08.003
   Liu ZY, 2020, J INVEST MED, V68, P45, DOI 10.1136/jim 2019 001010
   Ma L, 2023, BIOACT MATER, V19, P626, DOI 10.1016/j.bioactmat.2022.04.022
   Ma L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0091 4
   Marini F, 2023, OSTEOPOROSIS INT, V34, P213, DOI 10.1007/s00198 022 06523 7
   Min AJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/186904
   Nagata S, 2018, ANNU REV IMMUNOL, V36, P489, DOI 10.1146/annurev immunol 042617 053010
   Nair N, 2020, BBA MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.06.003
   Ota K, 2013, ENDOCRINOLOGY, V154, P3745, DOI 10.1210/en.2013 1272
   Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472
   Qu Y, 2022, ACTA BIOMATER, V149, P258, DOI 10.1016/j.actbio.2022.07.009
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Rudiansyah M, 2022, LIFE SCI, V306, DOI 10.1016/j.lfs.2022.120717
   Ryoo GH, 2020, BIOCHEM BIOPH RES CO, V531, P508, DOI 10.1016/j.bbrc.2020.07.083
   Santavanond Jascinta P, 2021, Subcell Biochem, V97, P61, DOI 10.1007/978 3 030 67171 6_4
   Serena C, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148 020 00843 3
   Song NJ, 2015, MOL CELL BIOCHEM, V410, P55, DOI 10.1007/s11010 015 2537 5
   Sun KM, 2016, BIOMED PHARMACOTHER, V83, P1105, DOI 10.1016/j.biopha.2016.08.025
   Sun XD, 2016, CHEM BIOL INTERACT, V244, P9, DOI 10.1016/j.cbi.2015.11.027
   Tabatabaei Mahdis Sadat, 2022, Methods Mol Biol, V2508, P115, DOI 10.1007/978 1 0716 2376 3_10
   Taipaleenmäki H, 2018, CURR OSTEOPOROS REP, V16, P1, DOI 10.1007/s11914 018 0417 0
   Wang J, 2021, ACS NANO, V15, P14360, DOI 10.1021/acsnano.1c03517
   Wang L, 2013, STEM CELLS, V31, P1383, DOI 10.1002/stem.1388
   Wang LT, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24065814
   Wang MJ, 2015, AM J RHINOL ALLERGY, V29, pE152, DOI 10.2500/ajra.2015.29.4241
   Wang RC, 2023, BIOACT MATER, V25, P472, DOI 10.1016/j.bioactmat.2022.07.026
   Wang XS, 2019, CELL MOL LIFE SCI, V76, P4043, DOI 10.1007/s00018 019 03199 x
   Wang YN, 2015, INT J CLIN EXP PATHO, V8, P6828
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Xu CL, 2014, J IMMUNOL, V192, P103, DOI 10.4049/jimmunol.1302164
   Xu XB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180992
   Yang N, 2013, J BONE MINER RES, V28, P559, DOI 10.1002/jbmr.1798
   Yang RL, 2015, IMMUNITY, V43, P251, DOI 10.1016/j.immuni.2015.07.017
   Yin JQ, 2019, NAT BIOMED ENG, V3, P90, DOI 10.1038/s41551 018 0325 8
   Yu Q, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.812262
   Yuan XR, 2022, RHEUMATOL IMMUNOL RE, V3, P61, DOI 10.2478/rir 2022 0011
   Yudhawati R, 2023, Int J Mol Sci., V24
   Zeng J, 2020, NAT MED, V26, P535, DOI 10.1038/s41591 020 0790 y
   Zhang T, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110287
   Zhang X, 2022, J EXTRACELL VESICLES, V11, DOI 10.1002/jev2.12240
   Zhang YM, 2023, INT J NANOMED, V18, P3285, DOI 10.2147/IJN.S409588
   Zheng CX, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12109
   Zhou M, 2022, J CONTROL RELEASE, V351, P394, DOI 10.1016/j.jconrel.2022.09.045
   Zhu HL, 2012, J CLIN IMMUNOL, V32, P514, DOI 10.1007/s10875 011 9647 y
NR 106
TC 5
Z9 6
U1 2
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD SEP 20
PY 2024
VL 22
IS 1
AR 580
DI 10.1186/s12951 024 02829 2
PG 21
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA G6D6Q
UT WOS:001317525500001
PM 39304875
OA gold
DA 2025 08 17
ER

PT J
AU Haffner Luntzer, M
   Ignatius, A
AF Haffner Luntzer, M.
   Ignatius, A.
TI ANIMAL MODELS FOR STUDYING METAPHYSEAL BONE FRACTURE HEALING
SO EUROPEAN CELLS & MATERIALS
LA English
DT Article
DE Fracture healing; animal models; metaphyseal fractures; bone
   regeneration
ID INTENSITY PULSED ULTRASOUND; WHOLE BODY VIBRATION; CANCELLOUS BONE;
   PARATHYROID HORMONE; SHEEP MODEL; OSTEOPOROTIC FRACTURES; RAT MODELS;
   ESTROGEN; DEFECTS; STRONTIUM
AB An estimated 2 million osteoporotic fractures occur annually in the US, resulting in a dramatic reduction in quality of life for affected patients and a high economic burden for society. Osteoporotic fractures are frequently located in metaphyseal bone regions. They are often associated with healing complications, because of the reduced healing capacity of the diseased bone tissue, the poor primary stability of the fracture fixation in the fragile bone, and the high frequency of comorbidities in these patients. Therefore, osteoporotic fractures require optimised treatment strategies to ensure proper bone healing. Preclinical animal models can help understanding of the underlying mechanisms and development of new therapies. However, whereas diaphyseal fracture models are widely available, appropriate animal models for metaphyseal fracture healing are scarce, although essential for translational research. This review covers large and small animal models for metaphyseal fracture healing. General requirements for suitable animal models are presented, as well as advantages and disadvantages of the current models. Furthermore, differences and similarities between metaphyseal and diaphyseal bone fracture healing are discussed. Both large  and small animal models are available for studying metaphyseal fracture healing, which mainly differ in fracture location and geometry as well as stabilisation techniques. Most common used fracture sites are distal femur and proximal tibia. Each model found in the literature has certain advantages and disadvantages; however, many lack standardisation resulting in a high variability or poor mimicking of the clinical situation. Therefore, further refinement of animal models is needed especially to study osteoporotic metaphyseal fracture healing.
C1 [Haffner Luntzer, M.; Ignatius, A.] Univ Med Ctr Ulm, Inst Orthopaed Res & Biomech, Ulm, Germany.
C3 Ulm University
RP Haffner Luntzer, M (通讯作者)，Helmholtzstr 4, D 89081 Ulm, Germany.
EM melanie.haffner luntzer@uni ulm.de
RI ; Haffner Luntzer, Melanie/L 3562 2019; Ignatius, Anita/M 6012 2013
OI Haffner Luntzer, Melanie/0000 0002 3333 2613; 
FU German Research Foundation [CRC1149];  [251293561];  [INST 40/599 1]; 
   [INST 40/4912]
FX This work was conducted in the context of the Collaborative Research
   Centre CRC1149 supported from the German Research Foundation (project
   number 251293561: INST 40/599 1 and INST 40/4912).
CR Agholme F, 2014, J ORTHOP RES, V32, P471, DOI 10.1002/jor.22525
   Agholme F, 2011, BONE, V48, P988, DOI 10.1016/j.bone.2011.02.008
   Alagboso FI, 2019, EUR CELLS MATER, V37, P444, DOI 10.22203/eCM.v037a27
   Alt V, 2016, INJURY, V47, pS1, DOI 10.1016/S0020 1383(16)30001 8
   Alt V, 2013, ACTA BIOMATER, V9, P7035, DOI 10.1016/j.actbio.2013.02.002
   An YHH, 1998, CLIN ORTHOP RELAT R, P300
   Aonuma H, 2011, J NEPAL MED ASSOC, V51, P171
   Aonuma H, 2014, J BONE MINER METAB, V32, P232, DOI 10.1007/s00774 013 0492 3
   ASHAMMAKHI N, 1994, CLIN MATER, V17, P113, DOI 10.1016/0267 6605(94)90133 3
   Aspenberg P, 2008, ACTA ORTHOP, V79, P111, DOI 10.1080/17453670710014851
   Beil FT, 2010, J TRAUMA, V69, P1259, DOI 10.1097/TA.0b013e3181c4544d
   Bernhardsson M, 2018, ACTA ORTHOP, V89, P674, DOI 10.1080/17453674.2018.1523771
   Bernhardsson M, 2015, ACTA ORTHOP, V86, P745, DOI 10.3109/17453674.2015.1075705
   Bernhardsson M, 2015, INJURY, V46, P990, DOI 10.1016/j.injury.2015.02.011
   Bindl R, 2013, J ORTHOP RES, V31, P1851, DOI 10.1002/jor.22416
   Blokhuis TJ, 2017, INJURY, V48, pS91, DOI 10.1016/j.injury.2017.04.021
   Chen WT, 2015, ACTA ORTHOP, V86, P238, DOI 10.3109/17453674.2014.1003127
   Chen WJ, 2004, J BONE MINER METAB, V22, P303, DOI 10.1007/s00774 004 0487 6
   Choy MHV, 2020, FASEB J, V34, P4234, DOI 10.1096/fj.201901595R
   Claes L, 2017, UNFALLCHIRURG, V120, P14, DOI 10.1007/s00113 016 0280 3
   Claes L, 2011, OSTEOLOGIE, V20, P29
   Claes L, 2011, J ORTHOP RES, V29, P425, DOI 10.1002/jor.21227
   Claes L, 2009, ARCH ORTHOP TRAUM SU, V129, P923, DOI 10.1007/s00402 008 0692 9
   Fan W, 2008, BONE, V42, P81, DOI 10.1016/j.bone.2007.08.048
   Haffner Luntzer M, 2020, J ORTHOP RES, V38, P2131, DOI 10.1002/jor.24677
   Haffner Luntzer M, 2017, EUR J MED RES, V22, DOI 10.1186/s40001 017 0264 y
   Han DY, 2015, AM J TRANSL RES, V7, P2279
   Han N, 2012, CHINESE MED J PEKING, V125, P676, DOI 10.3760/cma.j.issn.0366 6999.2012.04.022
   Handolin L, 2007, J MATER SCI MATER M, V18, P1239, DOI 10.1007/s10856 006 0096 8
   Heiss C, 2010, J BIOMAT SCI POLYM E, V21, P1345, DOI 10.1163/092050609X12517190417759
   HINSENKAMP M, 1984, ORTHOPEDICS, V7, P1309, DOI 10.3928/0147 7447 19840801 13
   Histing T, 2011, BONE, V49, P591, DOI 10.1016/j.bone.2011.07.007
   Histing T, 2012, J SURG RES, V178, P715, DOI 10.1016/j.jss.2012.04.007
   JARRY L, 1971, CAN J SURG, V14, P127
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Kampschulte M, 2016, MICROVASC RES, V105, P7, DOI 10.1016/j.mvr.2015.10.005
   Kauschke V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113531
   Kawano Tetsuya, 2017, Osteoporos Sarcopenia, V3, P185, DOI 10.1016/j.afos.2017.11.001
   Kolios L, 2010, PHYTOTHER RES, V24, P1796, DOI 10.1002/ptr.3176
   Kolios L, 2010, CALCIFIED TISSUE INT, V86, P23, DOI 10.1007/s00223 009 9318 7
   Kolios L, 2009, PLANTA MED, V75, P459, DOI 10.1055/s 0029 1185380
   Komrakova M, 2015, CALCIFIED TISSUE INT, V97, P391, DOI 10.1007/s00223 015 0019 0
   Komrakova M, 2013, CALCIFIED TISSUE INT, V92, P509, DOI 10.1007/s00223 013 9706 x
   Komrakova M, 2011, J ENDOCRINOL, V211, P157, DOI 10.1530/JOE 11 0096
   Komrakova M, 2011, J ENDOCRINOL, V209, P9, DOI 10.1530/JOE 10 0353
   Komrakova M, 2010, BONE, V47, P480, DOI 10.1016/j.bone.2010.05.013
   Li WL, 2017, J INT MED RES, V45, P1200, DOI 10.1177/0300060517707075
   Lips KS, 2014, J MUSCULOSKEL NEURON, V14, P173
   Lips KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077259
   Mackert GA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189356
   Marmor Meir, 2015, J Orthop Trauma, V29 Suppl 12, pS53, DOI 10.1097/BOT.0000000000000469
   Martínez ME, 1999, CALCIFIED TISSUE INT, V64, P280, DOI 10.1007/s002239900619
   Matos MA, 2007, ACTA CIR BRAS, V22, P115, DOI 10.1590/S0102 86502007000200007
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   Meunier A, 2006, ARCH ORTHOP TRAUM SU, V126, P433, DOI 10.1007/s00402 006 0160 3
   Morgan EF, 2008, BONE, V43, P1031, DOI 10.1016/j.bone.2008.07.251
   Morse A, 2020, CALCIFIED TISSUE INT, V106, P172, DOI 10.1007/s00223 019 00615 z
   Nikolaou VS, 2009, INJURY, V40, P663, DOI 10.1016/j.injury.2008.10.035
   Nishizuka T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104603
   Nozaka K, 2008, BONE, V42, P90, DOI 10.1016/j.bone.2007.08.041
   Oheim R, 2017, INJURY, V48, P841, DOI 10.1016/j.injury.2017.02.009
   Oheim R, 2016, INJURY, V47, pS3, DOI 10.1016/S0020 1383(16)30002 X
   Oheim R, 2013, J ORTHOP RES, V31, P1067, DOI 10.1002/jor.22327
   PENG Z, 1994, BONE, V15, P523, DOI 10.1016/8756 3282(94)90276 3
   Ray S, 2018, BIOMATERIALS, V157, P1, DOI 10.1016/j.biomaterials.2017.11.049
   Ray S, 2016, INJURY, V47, pS52, DOI 10.1016/S0020 1383(16)30013 4
   Sandberg OH, 2015, BONE JOINT RES, V4, P170, DOI 10.1302/2046 3758.410.2000414
   Sandberg O, 2017, J ORTHOP RES, V35, P793, DOI 10.1002/jor.23316
   Sandberg O, 2015, ACTA ORTHOP, V86, P243, DOI 10.3109/17453674.2014.973328
   Sandberg O, 2014, BONE, V63, P15, DOI 10.1016/j.bone.2014.02.008
   Sandberg O, 2012, ACTA ORTHOP, V83, P305, DOI 10.3109/17453674.2012.693018
   Sandberg OH, 2016, ACTA ORTHOP, V87, P459, DOI 10.1080/17453674.2016.1205172
   Saul D, 2018, J APPL PHYSIOL, V124, P118, DOI 10.1152/japplphysiol.01126.2016
   Stuermer EK, 2010, LANGENBECK ARCH SURG, V395, P163, DOI 10.1007/s00423 008 0436 x
   Stuermer EK, 2014, BONE, V64, P187, DOI 10.1016/j.bone.2014.04.008
   Stuermer EK, 2010, CALCIFIED TISSUE INT, V87, P168, DOI 10.1007/s00223 010 9381 0
   Tätting L, 2017, ACTA ORTHOP, V88, P223, DOI 10.1080/17453674.2016.1274587
   Tätting L, 2018, BONE JOINT RES, V7, P620, DOI 10.1302/2046 3758.712.BJR 2017 0366.R2
   Thormann U, 2014, INJURY, V45, P487, DOI 10.1016/j.injury.2013.10.033
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Tsiridis E, 2007, J ORTHOP RES, V25, P1193, DOI 10.1002/jor.20420
   Tu JW, 2014, BONE, V69, P12, DOI 10.1016/j.bone.2014.08.016
   UHTHOFF HK, 1987, J ORTHOP RES, V5, P14, DOI 10.1002/jor.1100050104
   UHTHOFF HK, 1981, CLIN ORTHOP RELAT R, P295
   Wong RMY, 2019, EUR CELLS MATER, V37, P420, DOI 10.22203/eCM.v037a25
NR 85
TC 12
Z9 13
U1 2
U2 27
PU AO RESEARCH INSTITUTE DAVOS ARI
PI DAVOS
PA CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND
SN 1473 2262
J9 EUR CELLS MATER
JI Eur. Cells Mater.
PD JUL SEP
PY 2020
VL 40
BP 172
EP 188
DI 10.22203/eCM.v040a11
PG 17
WC Cell & Tissue Engineering; Engineering, Biomedical; Materials Science,
   Biomaterials; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science; Orthopedics
GA PA1LO
UT WOS:000595381300002
PM 33119886
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, JW
   Cui, YT
   Zhang, B
   Sun, SY
   Xu, H
   Yao, MK
   Wu, DK
   Wang, YB
AF Wang, Jingwei
   Cui, Yutao
   Zhang, Bin
   Sun, Shouye
   Xu, Hang
   Yao, Mingkai
   Wu, Dankai
   Wang, Yanbing
TI Polydopamine Modified functional materials promote bone regeneration
SO MATERIALS & DESIGN
LA English
DT Article
DE Bone defect; Polydopamine; Biomaterial; Bone regeneration
ID SURFACE MODIFICATION; POLY(DOPAMINE) ASSISTED IMMOBILIZATION;
   HYDROXYAPATITE NANOPARTICLE; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST
   FUNCTIONS; ELECTROSPUN FIBERS; CERAMIC SCAFFOLDS; TITANIUM ALLOY;
   CELL ADHESION; ANTIBACTERIAL
AB With the increasing incidence of bone defects in clinical practice, the demand for bone grafts or substitutes has become more urgent. Polydopamine (PDA) coated bone tissue engineering materials offer a promising alternative in such cases. PDA coating is characterized by a solid coating formed by polymerization of dopamine under alkaline and oxygen containing conditions, which can provide implants good hydrophilicity through the active functional groups contained in the structure. More importantly, the strong adhesion of the coating can provide an anchor between bone implant materials and drugs to achieve functional modification of the implant surface to enhance bone regeneration. In this review, the different effects of dopamine derivatives and their polymerization in current research were summarized. The mechanisms underlying the effects of PDA in promoting bone regeneration have also discussed in detail, providing a theoretical basis for the clinical application of PDA. Finally, a series of PDA coated materials for the promotion of bone repair have been summarized and discussed. This review provides cutting edge design ideas for PDA based biomaterials and highlights promising treatment strategies for bone defects.
C1 [Wang, Jingwei; Cui, Yutao; Sun, Shouye; Xu, Hang; Wu, Dankai; Wang, Yanbing] Second Hosp Jilin Univ, Orthopaed Med Ctr, Changchun 130041, Peoples R China.
   [Yao, Mingkai] 964th Hosp PLA Joint Logist Support Force, Traumatol Dept, Changchun 130062, Peoples R China.
   [Zhang, Bin] 964th Hosp PLA Joint Logist Support Force, Dept Spinal Surg, Changchun 130062, Peoples R China.
C3 Jilin University
RP Wu, DK; Wang, YB (通讯作者)，Second Hosp Jilin Univ, Orthopaed Med Ctr, Changchun 130041, Peoples R China.; Yao, MK (通讯作者)，964th Hosp PLA Joint Logist Support Force, Traumatol Dept, Changchun 130062, Peoples R China.
EM yaomk77@126.com; wudk@jlu.edu.cn; wangyanbing@jlu.edu.cn
RI Wu, Dankai/JFJ 8040 2023
FU Project of Jilin Provincial Science and Technology Department
   [20230402009GH]; Industrial Technology Research and Development Project
   of Jilin Provincial Development and Reform Commission [2023C040 3]; The
   13th Five  Year Plan of Science and Technology Research of Jilin
   Provincial Education Department [JJKH20180108KJ]
FX This study was supported by the project of Jilin Provincial Science and
   Technology Department (20230402009GH) ; Industrial Technology Research
   and Development Project of Jilin Provincial Development and Reform
   Commission (2023C040 3) ; The 13th Five  Year Plan of Science and
   Technology Research of Jilin Provincial Education Department
   (JJKH20180108KJ) .
CR Agilan P, 2021, COLLOID SURFACE A, V629, DOI 10.1016/j.colsurfa.2021.127489
   Albu AM, 2019, MAT SCI ENG C MATER, V98, P461, DOI 10.1016/j.msec.2019.01.014
   Bachir AI, 2014, CURR BIOL, V24, P1845, DOI 10.1016/j.cub.2014.07.011
   Bai HT, 2020, MATER DESIGN, V189, DOI 10.1016/j.matdes.2020.108513
   Baldwin F, 2020, MOLECULES, V25, DOI 10.3390/molecules25071583
   Ball V, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00109
   Barati D, 2020, ANN BIOMED ENG, V48, P1971, DOI 10.1007/s10439 020 02522 z
   Brink O, 2021, INJURY, V52, pS23, DOI 10.1016/j.injury.2020.11.013
   Carvalho AL, 2016, J MATER CHEM B, V4, P5385, DOI 10.1039/c6tb00841k
   Chen G, 2013, J BIOMED MATER RES A, V101, P44, DOI 10.1002/jbm.a.34298
   Chen JL, 2016, RSC ADV, V6, P104025, DOI 10.1039/c6ra20673e
   Chen TJ, 2021, MAT SCI ENG C MATER, V126, DOI 10.1016/j.msec.2021.112109
   Chen YW, 2018, MAT SCI ENG C MATER, V91, P679, DOI 10.1016/j.msec.2018.06.005
   Cheng J, 2015, J BIOACT COMPAT POL, V30, P289, DOI 10.1177/0883911515569918
   Cheng YL, 2016, J MATER CHEM B, V4, P6307, DOI 10.1039/c6tb01377e
   Chiang TI, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70262 0
   Chien CY, 2013, J BIOMED MATER RES A, V101, P740, DOI 10.1002/jbm.a.34376
   Cui YT, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100409
   Daley EJ, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10212
   Feng P, 2021, J MATER RES TECHNOL, V15, P3375, DOI 10.1016/j.jmrt.2021.09.137
   Fu CA, 2021, INT J NANOMED, V16, P6693, DOI 10.2147/IJN.S328390
   Gao T, 2021, MATER LETT, V287, DOI 10.1016/j.matlet.2021.129308
   Ghimire A, 2019, ACS CENTRAL SCI, V5, P1929, DOI 10.1021/acscentsci.9b00870
   Guarise C, 2021, MAT SCI ENG C MATER, V128, DOI 10.1016/j.msec.2021.112286
   Guarise C, 2018, BIOFOULING, V34, P719, DOI 10.1080/08927014.2018.1491555
   Hanami K, 2013, BONE, V56, P1, DOI 10.1016/j.bone.2013.04.019
   He RZ, 2022, COLLOID SURFACE B, V216, DOI 10.1016/j.colsurfb.2022.112582
   He S, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0169
   He Y, 2018, ACTA BIOMATER, V80, P412, DOI 10.1016/j.actbio.2018.09.036
   Hu XF, 2010, BIOMATERIALS, V31, P8854, DOI 10.1016/j.biomaterials.2010.08.006
   Huang YZ, 2018, MAT SCI ENG C MATER, V84, P12, DOI 10.1016/j.msec.2017.11.002
   Hung HS, 2020, ACS APPL MATER INTER, V12, P44393, DOI 10.1021/acsami.0c05747
   Jia ZJ, 2016, ACS APPL MATER INTER, V8, P28495, DOI 10.1021/acsami.6b10473
   Jia ZJ, 2016, BIOMATERIALS, V75, P203, DOI 10.1016/j.biomaterials.2015.10.035
   Jin H, 2021, ACS BIOMATER SCI ENG, V7, P2177, DOI 10.1021/acsbiomaterials.1c00462
   Kim H, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14091633
   Kim HH, 2014, INT J BIOL MACROMOL, V70, P516, DOI 10.1016/j.ijbiomac.2014.06.052
   Kim S.E., 2016, Biomedical Materials, V11
   Kim SE, 2014, CARBOHYD POLYM, V114, P123, DOI 10.1016/j.carbpol.2014.08.005
   Kim SE, 2014, CARBOHYD POLYM, V99, P700, DOI 10.1016/j.carbpol.2013.08.053
   Kwon Gi Wan, 2017, Biomater Res, V21, P11, DOI 10.1186/s40824 017 0097 3
   Lee DJ, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.20
   Lee JE, 2019, POLYMERS BASEL, V11, DOI 10.3390/polym11050798
   Lee YJ, 2013, BIOMATERIALS, V34, P5059, DOI 10.1016/j.biomaterials.2013.03.051
   Li H, 2021, ADV COLLOID INTERFAC, V295, DOI 10.1016/j.cis.2021.102489
   Li YT, 2019, J MATER CHEM B, V7, P3546, DOI 10.1039/c8tb03245a
   Li ZL, 2021, CARBOHYD POLYM, V267, DOI 10.1016/j.carbpol.2021.118224
   Lin BP, 2015, SURF COAT TECH, V281, P82, DOI 10.1016/j.surfcoat.2015.09.033
   Lin H, 2020, MACROMOL MATER ENG, V305, DOI 10.1002/mame.202000064
   Lin QX, 2020, COLLOID SURFACE B, V196, DOI 10.1016/j.colsurfb.2020.111304
   Liu FF, 2021, INT J BIOL MACROMOL, V167, P1338, DOI 10.1016/j.ijbiomac.2020.11.088
   Liu FF, 2020, J ADV RES, V21, P91, DOI 10.1016/j.jare.2019.10.002
   Liu JW, 2016, RSC ADV, V6, P107001, DOI 10.1039/c6ra19698e
   Liu X, 2019, ROY SOC OPEN SCI, V6, DOI 10.1098/rsos.191028
   Liu Y, 2021, BLOOD, V138, P2051, DOI 10.1182/blood.2020010419
   Liu ZG, 2018, ACS BIOMATER SCI ENG, V4, P1852, DOI 10.1021/acsbiomaterials.8b00243
   Liu ZG, 2014, MAT SCI ENG C MATER, V44, P44, DOI 10.1016/j.msec.2014.07.063
   Long Q, 2020, RSC ADV, V10, P28397, DOI 10.1039/d0ra02388d
   Long XL, 2020, POLYM CHEM UK, V11, P4995, DOI 10.1039/d0py00774a
   Lu GG, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30243 5
   Lu ZH, 2020, MAT SCI ENG C MATER, V117, DOI 10.1016/j.msec.2020.111359
   Lynge ME, 2015, NANOMEDICINE UK, V10, P2725, DOI 10.2217/nnm.15.89
   Miao YL, 2019, J MATER CHEM B, V7, P3250, DOI 10.1039/c8tb03361g
   Nordberg A, 2010, ACS APPL MATER INTER, V2, P654, DOI 10.1021/am100002s
   Orlacchio R, 2022, MOLECULES, V27, DOI 10.3390/molecules27072137
   Rezaei H, 2021, BIOTECHNOL APPL BIOC, V68, P185, DOI 10.1002/bab.1911
   Rim NG, 2012, COLLOID SURFACE B, V91, P189, DOI 10.1016/j.colsurfb.2011.10.057
   Ruan YY, 2022, COLLOID SURFACE B, V216, DOI 10.1016/j.colsurfb.2022.112528
   Shi DJ, 2019, J BIOMED MATER RES A, V107, P1615, DOI 10.1002/jbm.a.36678
   Shim KS, 2017, POLYMERS BASEL, V9, DOI 10.3390/polym9070297
   Shin YM, 2017, J MATER CHEM B, V5, P8725, DOI 10.1039/c7tb01758h
   Shuai CJ, 2019, CHEM ENG J, V374, P304, DOI 10.1016/j.cej.2019.03.273
   Soumya S, 2012, J MATER CHEM, V22, P1904, DOI 10.1039/c1jm14038h
   Su JH, 2020, MAT SCI ENG C MATER, V113, DOI 10.1016/j.msec.2020.110983
   Sun AA, 2021, DRUG DELIV, V28, P1649, DOI 10.1080/10717544.2021.1960924
   Sun XJ, 2020, J BIOMATER APPL, V34, P891, DOI 10.1177/0885328219886185
   Taylor EL, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116391
   Tolabi H, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1008360
   Wan T, 2019, J MATER SCI, V54, P11179, DOI 10.1007/s10853 018 03264 z
   Wang CX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 019 1529 x
   Wang GD, 2021, NANOTECHNOLOGY, V32, DOI 10.1088/1361 6528/abe439
   Wang H, 2019, ACS APPL MATER INTER, V11, P7615, DOI 10.1021/acsami.8b21558
   Wang JW, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.952670
   Wang LF, 2021, BIOMATER SCI UK, V9, P7565, DOI 10.1039/d1bm01119g
   Wang LF, 2021, CELL SIGNAL, V78, DOI 10.1016/j.cellsig.2020.109847
   Wang MY, 2021, MAT SCI ENG C MATER, V129, DOI 10.1016/j.msec.2021.112376
   Wang N., 2020, Colloids and Surfaces a Physicochemical and Engineering Aspects, V602
   Wang X, 2020, MAT SCI ENG C MATER, V109, DOI 10.1016/j.msec.2019.110544
   Wang X, 2018, RSC ADV, V8, P15575, DOI 10.1039/c8ra01960f
   Wang X, 2016, BIOMATER SCI UK, V4, P678, DOI 10.1039/c5bm00482a
   Wang YL, 2019, CLIN IMPLANT DENT R, V21, P977, DOI 10.1111/cid.12819
   Wang ZM, 2017, BIOFABRICATION, V9, DOI 10.1088/1758 5090/aa7fdc
   Wang ZL, 2016, ACS APPL MATER INTER, V8, P26559, DOI 10.1021/acsami.6b08733
   Wu CT, 2014, ACTA BIOMATER, V10, P428, DOI 10.1016/j.actbio.2013.10.013
   Wu LP, 2021, ACS APPL MATER INTER, V13, P39142, DOI 10.1021/acsami.1c12412
   Wu M, 2019, CERAM INT, V45, P3033, DOI 10.1016/j.ceramint.2018.10.149
   Wu RQ, 2022, AM J SPORT MED, V50, P757, DOI 10.1177/03635465211066948
   Wu Y., 2021, Frontiers in Bioengineering and Biotechnology, V9
   Wu ZZ, 2022, COLLOID SURFACE B, V211, DOI 10.1016/j.colsurfb.2021.112296
   Xie CM, 2016, ACS BIOMATER SCI ENG, V2, P920, DOI 10.1021/acsbiomaterials.6b00015
   Xu K, 2021, APPL MATER TODAY, V24, DOI 10.1016/j.apmt.2021.101155
   Xu MC, 2016, NANOSCALE, V8, P13790, DOI 10.1039/c6nr01952h
   Xu MC, 2013, BIOMATER SCI UK, V1, P933, DOI 10.1039/c3bm60028a
   Xu Y, 2023, INT J BIOL MACROMOL, V229, P443, DOI 10.1016/j.ijbiomac.2022.12.303
   Xu Z., 2019, Molecules, V24
   Xue X, 2022, BIOACT MATER, V12, P327, DOI 10.1016/j.bioactmat.2021.10.029
   Yan HH, 2020, ACS BIOMATER SCI ENG, V6, P634, DOI 10.1021/acsbiomaterials.9b01601
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Yang WF, 2018, J BIOMED NANOTECHNOL, V14, P294, DOI 10.1166/jbn.2018.2495
   Yang XL, 2019, J BIOMATER APPL, V34, P284, DOI 10.1177/0885328219845962
   Yang YX, 2021, MATERIALS, V14, DOI 10.3390/ma14081849
   Yang YH, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202104636
   Yao MY, 2021, BIOMATER SCI UK, V9, P3319, DOI 10.1039/d0bm01785j
   Yao QQ, 2018, J TISSUE ENG REGEN M, V12, P1519, DOI 10.1002/term.2681
   Yeh CH, 2015, MATERIALS, V8, P4299, DOI 10.3390/ma8074299
   Yin HM, 2019, APPL SURF SCI, V481, P987, DOI 10.1016/j.apsusc.2019.03.193
   Yu B, 2017, ADV ENG MATER, V19, DOI 10.1002/adem.201600708
   Yu Y, 2021, COLLOID SURFACE B, V198, DOI 10.1016/j.colsurfb.2020.111492
   Yuan N, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9867819
   Yuan Z, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119479
   Yuan Z, 2018, J MATER CHEM B, V6, P8090, DOI 10.1039/c8tb01918e
   Zain NM, 2014, APPL SURF SCI, V322, P169, DOI 10.1016/j.apsusc.2014.09.179
   Zhang DT, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120783
   Zhang FX, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121169
   Zhang HJ, 2021, BIOMATER SCI UK, V9, P960, DOI 10.1039/d0bm01840f
   Zhang J, 2018, NANOMED NANOTECHNOL, V14, P965, DOI 10.1016/j.nano.2018.01.017
   Zhang JW, 2019, MATER LETT, V251, P161, DOI 10.1016/j.matlet.2019.05.046
   Zhang K, 2018, LANGMUIR, V34, P15544, DOI 10.1021/acs.langmuir.8b03357
   Zhang SW, 2016, MAT SCI ENG C MATER, V69, P496, DOI 10.1016/j.msec.2016.06.044
   Zhang WB, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.172310
   Zhang XSY, 2020, BIOMED MATER, V15, DOI 10.1088/1748 605X/ab4c78
   Zhang XJ, 2020, CERAM INT, V46, P14796, DOI 10.1016/j.ceramint.2020.03.004
   Zhang YG, 2017, COLLOID SURFACE B, V159, P337, DOI 10.1016/j.colsurfb.2017.07.093
   Zhang ZJ, 2021, BIOMATERIALS, V274, DOI 10.1016/j.biomaterials.2021.120853
   Zhao XY, 2017, MAT SCI ENG C MATER, V78, P658, DOI 10.1016/j.msec.2017.03.186
   Zhou W, 2020, ACTA BIOMATER, V101, P128, DOI 10.1016/j.actbio.2019.10.023
   Zhou ZW, 2020, SURF INTERFACES, V19, DOI 10.1016/j.surfin.2020.100501
   Zhu J, 2022, MOL MED, V28, DOI 10.1186/s10020 022 00453 0
   Zhu QH, 2022, RSC ADV, V12, P13209, DOI 10.1039/d2ra00910b
   Zhu Y, 2019, J MATER CHEM B, V7, P2019, DOI 10.1039/c8tb03379j
NR 140
TC 30
Z9 30
U1 15
U2 79
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD FEB
PY 2024
VL 238
AR 112655
DI 10.1016/j.matdes.2024.112655
EA JAN 2024
PG 17
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA IC2S7
UT WOS:001164065200001
OA gold
DA 2025 08 17
ER

PT J
AU Jiang, WT
   Xu, T
   Yuan, SS
   Wei, YP
   Song, ZM
   Li, QQ
   She, SP
   Wang, XK
   Wang, C
   Yang, G
   Cao, J
   Sun, F
   Shi, M
   Li, SQ
   Liu, ZT
   Mo, YQ
   Lv, P
   Zhang, Y
   Wang, Y
   Hu, WJ
AF Jiang, Wenting
   Xu, Tao
   Yuan, Shasha
   Wei, Yiping
   Song, Zhanming
   Li, Qingqing
   She, Shaoping
   Wang, Xuekang
   Wang, Cui
   Yang, Gang
   Cao, Jie
   Sun, Fei
   Shi, Meng
   Li, Siqi
   Liu, Zhongtian
   Mo, Yaqian
   Lv, Ping
   Zhang, Yu
   Wang, Ying
   Hu, Wenjie
TI Critical roles for CCR2 and the therapeutic potential of cenicriviroc in
   periodontitis: A pre clinical study
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE CCR2; cenicriviroc; monocytes/macrophages; periodontitis; targeted
   therapy
ID MONOCYTE CHEMOATTRACTANT PROTEIN 1; BONE RESORPTION; IMMUNE; MCP 1;
   OSTEOIMMUNOLOGY; PATHOGENESIS; CHEMOKINES; EXPRESSION; DISEASE
AB Aim: CCR2 plays important roles in many inflammatory and bone metabolic diseases, but its specific role in periodontitis is unknown. In the present study, we aimed to explore the role of CCR2 in the progression of periodontitis and evaluate the effect of cenicriviroc (CVC) on periodontitis.
   Materials and Methods: The expression of CCR2 was studied in patients with periodontitis and in ligation induced murine model of periodontitis. The role of CCR2 in promoting inflammation and bone resorption in periodontitis was evaluated in Ccr2( / ) mice and wild type mice. The effect of CVC in the prevention and treatment of periodontitis was evaluated by systemic and local medication. Microcomputed tomography, haematoxylin and eosin staining, tartrate resistant acid phosphatase staining, quantitative real time polymerase chain reaction, enzyme linked immunosorbent assay, and flow cytometry were used for histomorphology, molecular biology, and cytology analysis, respectively.
   Results: In this study, we demonstrated that CCR2 was highly expressed in human and murine periodontitis and that CCR2 deficiency was associated with decreased inflammatory monocyte and macrophage infiltration and inflammatory mediators, osteoclast number and alveolar bone resorption. Prevention and treatment with CVC significantly reduced the severity of periodontitis, regardless of whether it was administered systemically or locally.
   Conclusions: CCR2 plays an important role in the development and progression of periodontitis, and CVC is a potential drug for the prevention and treatment of periodontitis.
C1 [Jiang, Wenting; Yuan, Shasha; Wei, Yiping; Wang, Cui; Yang, Gang; Cao, Jie; Sun, Fei; Li, Siqi; Hu, Wenjie] Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol,Beij, Natl Clin Res Ctr Oral Dis,Natl Ctr Stomatol,Dept, Beijing 100081, Peoples R China.
   [Xu, Tao] Peking Univ, Sch & Hosp Stomatol,Dept Emergency, Natl Engn Lab Digital & Mat Technol Stomatol,Natl, Natl Clin Res Ctr Oral Dis,Beijing Key Lab Digita, Beijing, Peoples R China.
   [Song, Zhanming; Li, Qingqing; Wang, Xuekang; Liu, Zhongtian; Mo, Yaqian; Lv, Ping; Zhang, Yu; Wang, Ying] Peking Univ, Sch Basic Med Sci, Dept Immunol, Beijing 100191, Peoples R China.
   [Song, Zhanming; Li, Qingqing; Wang, Xuekang; Liu, Zhongtian; Mo, Yaqian; Lv, Ping; Zhang, Yu; Wang, Ying] Peking Univ, NHC Key Lab Med Immunol, Beijing 100191, Peoples R China.
   [She, Shaoping] Peking Univ, Peoples Hosp, Beijing Key Lab Hepatitis C & Immunotherapy Liver, Hepatol Inst, Beijing, Peoples R China.
   [Shi, Meng] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Lv, Ping; Wang, Ying] Peking Univ, Ctr Human Dis Genom, Beijing, Peoples R China.
   [Hu, Wenjie] Peking Univ, NHC Res Ctr Engn & Technol Computerized Dent, Beijing, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University; Peking University; Capital Medical University; Peking
   University; Peking University
RP Hu, WJ (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol,Beij, Natl Clin Res Ctr Oral Dis,Natl Ctr Stomatol,Dept, Beijing 100081, Peoples R China.; Wang, Y (通讯作者)，Peking Univ, Sch Basic Med Sci, Dept Immunol, Beijing 100191, Peoples R China.; Wang, Y (通讯作者)，Peking Univ, NHC Key Lab Med Immunol, Beijing 100191, Peoples R China.
EM yw@bjmu.edu.cn; huwenjie@pkuss.bjmu.edu.cn
RI ; Yang, Gang/B 2616 2008; Liu, Zhongtian/ABE 5037 2021
OI Wei, Yiping/0000 0002 8517 3757; WANG, YING/0000 0001 5224 6692; 
FU Peking University Clinical Scientist Program [BMU2019LCKXJ010];
   Foundation for Clinical Characteristics Application Research
   [Z161100000516042]; National Natural Science Foundation of China
   [81970536]
FX Peking University Clinical Scientist Program, Grant/Award Number:
   BMU2019LCKXJ010; Foundation for Clinical Characteristics Application
   Research, Grant/Award Number: Z161100000516042; National Natural Science
   Foundation of China, Grant/Award Number: 81970536
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Abusleme L, 2017, ORAL DIS, V23, P854, DOI 10.1111/odi.12598
   Almubarak A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00330
   Ambade A, 2019, HEPATOLOGY, V69, P1105, DOI 10.1002/hep.30249
   Anstee QM, 2020, CONTEMP CLIN TRIALS, V89, DOI 10.1016/j.cct.2019.105922
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Boström EA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134608
   Ferreira SB, 2011, J DENT RES, V90, P632, DOI 10.1177/0022034510395021
   Festing Michael F W, 2002, ILAR J, V43, P244
   Friedman SL, 2018, HEPATOLOGY, V67, P1754, DOI 10.1002/hep.29477
   Gamonal J, 2001, J PERIODONTAL RES, V36, P194, DOI 10.1034/j.1600 0765.2001.360309.x
   Garlet GP, 2003, J PERIODONTAL RES, V38, P210, DOI 10.1034/j.1600 0765.2003.02012.x
   Gunpinar S, 2017, ORAL DIS, V23, P763, DOI 10.1111/odi.12658
   Gupta M, 2013, CYTOKINE, V61, P892, DOI 10.1016/j.cyto.2012.12.012
   Hajishengallis G, 2020, PERIODONTOL 2000, V84, P14, DOI 10.1111/prd.12331
   Hajishengallis G, 2016, SEMIN IMMUNOL, V28, P146, DOI 10.1016/j.smim.2016.02.002
   HANAZAWA S, 1993, INFECT IMMUN, V61, P5219, DOI 10.1128/IAI.61.12.5219 5224.1993
   Huang WX, 2019, CLIN SCI, V133, P135, DOI 10.1042/CS20180679
   Jakubzick CV, 2017, NAT REV IMMUNOL, V17, P349, DOI 10.1038/nri.2017.28
   Jurdzinski KT, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148 020 00982 7
   Kinane DF., 2017, NAT REV DIS PRIM, V3, P1, DOI DOI 10.1038/NRDP.2017.38
   Koide M, 2010, PERIODONTOL 2000, V54, P235, DOI 10.1111/j.1600 0757.2010.00355.x
   Krenkel O, 2018, HEPATOLOGY, V67, P1270, DOI 10.1002/hep.29544
   Lalezari J, 2011, JAIDS J ACQ IMM DEF, V57, P118, DOI 10.1097/QAI.0b013e318213c2c0
   Lam RS, 2014, J IMMUNOL, V193, P2349, DOI 10.4049/jimmunol.1400853
   Lira Junior R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00086
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Papathanasiou E, 2020, J DENT RES, V99, P1425, DOI 10.1177/0022034520945209
   Pradeep AR, 2009, ARCH ORAL BIOL, V54, P503, DOI 10.1016/j.archoralbio.2009.02.007
   Preshaw PM, 2018, PERIODONTOL 2000, V76, P131, DOI 10.1111/prd.12148
   Raghu H, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210426
   Repeke CE, 2010, BONE, V46, P1122, DOI 10.1016/j.bone.2009.12.030
   Serbina NV, 2008, ANNU REV IMMUNOL, V26, P421, DOI 10.1146/annurev.immunol.26.021607.090326
   Shi M, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00124
   Sima C, 2013, PERIODONTOL 2000, V63, P80, DOI 10.1111/prd.12032
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Thompson M, 2016, AIDS, V30, P869, DOI 10.1097/QAD.0000000000000988
   Wang LX, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01788 6
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   YU XH, 1995, J PERIODONTOL, V66, P80, DOI 10.1902/jop.1995.66.1.80
NR 40
TC 8
Z9 8
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD NOV
PY 2022
VL 49
IS 11
BP 1203
EP 1216
DI 10.1111/jcpe.13699
EA AUG 2022
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 5I9HP
UT WOS:000835827700001
PM 35817437
DA 2025 08 17
ER

PT J
AU Yu, WW
   Liu, YY
   Bi, XT
   Yang, ZJ
   Sun, XH
   Shen, YQ
AF Yu, Wenwen
   Liu, Yuyan
   Bi, Xueting
   Yang, Zhujun
   Sun, Xinhua
   Shen, Yuqin
TI miR 34a Improves the Proliferation and Osteogenic Differentiation of
   MG63 Cells Under Short Term Mechanical Force Loading
SO JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING
LA English
DT Article
DE miR 34a; Short Term Tension; Short Term Compression; OTM; Proliferation;
   Osteogenic Differentiation
ID ORTHODONTIC TOOTH MOVEMENT; STEM CELLS; BONE RESORPTION; IN VIVO;
   OSTEOBLAST DIFFERENTIATION; EARLY RESPONSES; EXPRESSION; COLLAGEN;
   SIGNALS; STRETCH
AB Poor alveolar bone conditions remain challenging for orthodontic tooth movement. Recently, endogenous miR 34a has been reported as an important factor of bone anabolism. However, the association of miR 34a with mechanical stimuli remains elusive. In this study, we investigated the effects of miR 34a on osteogenesis proliferation and differentiation under short term mechanical force loading. The process of orthodontic tooth movement (OTM) in vivo elevated the expression levels of miR 34a and osteogenic differentiation genes, Runx2 and Coli. An apparent promotion of miR 34a expression, as well as MG63 proliferation and osteogenic differentiation, was demonstrated under short term tension in vitro, and this was in contrast to that in compression conditions in vitro. The PCR assay revealed that the miR 34a achieved high expression by using Lipofectamine(2000) mediated transfection. Under mechanical tension and compression, gain of function tests exhibited that miR 34a improved MG63 proliferation and osteogenic differentiation. Thus, these results showed that mechanical force loading in vivo and in vitro induced different expression levels of miR 34a and osteogenesis, and the forced expression of miR 34a played a positive role in osteogenesis under mechanical tension and compression in vitro. This novel regulatory pathway of miR 34a provides new insights into the molecular therapy of mechanotransdunction mediated bone remodeling.
C1 [Yu, Wenwen; Liu, Yuyan; Yang, Zhujun; Sun, Xinhua] Jilin Univ, Sch & Hosp Stomatol, Dept Orthodont, Changchun 130021, Jilin, Peoples R China.
   [Bi, Xueting; Shen, Yuqin] Jilin Univ, Sch & Hosp Stomatol, Dept Periodont, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Sun, XH (通讯作者)，Jilin Univ, Sch & Hosp Stomatol, Dept Orthodont, Changchun 130021, Jilin, Peoples R China.; Shen, YQ (通讯作者)，Jilin Univ, Sch & Hosp Stomatol, Dept Periodont, Changchun 130021, Jilin, Peoples R China.
RI Yu, Wenwen/LCE 3187 2024
FU National Natural Science Foundation of China [81371153]; Medical Support
   Program of the Jilin university [470110000423]; Medical Support Program
   of the Jilin province [20170311032YY]
FX This research was supported by grants from the National Natural Science
   Foundation of China (No. 81371153), the Medical Support Program of the
   Jilin university (No. 470110000423), and Medical Support Program of the
   Jilin province (No. 20170311032YY).
CR Agostini M, 2014, ONCOTARGET, V5, P872, DOI 10.18632/oncotarget.1825
   Brooks PJ, 2009, ANGLE ORTHOD, V79, P1108, DOI 10.2319/121508 638R.1
   Bumann A, 1997, EUR J ORTHODONT, V19, P29, DOI 10.1093/ejo/19.1.29
   Burr DB, 1996, BONE, V18, P405, DOI 10.1016/8756 3282(96)00028 2
   Cao YJ, 2015, INT J MOL MED, V36, P760, DOI 10.3892/ijmm.2015.2275
   Chang ML, 2017, J CELL PHYSIOL, V232, P3762, DOI 10.1002/jcp.25856
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Chen N, 2016, J DENT RES, V95, P1425, DOI 10.1177/0022034516657043
   Chen YH, 2015, GENE, V566, P13, DOI 10.1016/j.gene.2015.03.055
   Taddei SRD, 2012, J BIOMECH, V45, P2729, DOI 10.1016/j.jbiomech.2012.09.006
   Ding J, 2003, BIOSCI BIOTECH BIOCH, V67, P314, DOI 10.1271/bbb.67.314
   Fan C, 2016, STEM CELL REP, V7, P236, DOI 10.1016/j.stemcr.2016.06.010
   Fang SJ, 2015, INT J MOL SCI, V16, P8227, DOI 10.3390/ijms16048227
   Grilli A, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920 015 0106 0
   Hesse E, 2010, J BIOMED MATER RES A, V94A, P442, DOI 10.1002/jbm.a.32696
   Hou JH, 2014, KOREAN J ORTHOD, V44, P320, DOI 10.4041/kjod.2014.44.6.320
   Hua Yong Mei, 2008, Hua Xi Kou Qiang Yi Xue Za Zhi, V26, P189
   Ichimura A, 2010, MOL PHARMACOL, V77, P1016, DOI 10.1124/mol.109.063321
   Iwawaki Y, 2015, J BIOSCI BIOENG, V120, P456, DOI 10.1016/j.jbiosc.2015.02.006
   Kaller M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010462
   Kim TW, 1999, AM J ORTHOD DENTOFAC, V115, P645, DOI 10.1016/S0889 5406(99)70290 8
   KING GJ, 1991, AM J ORTHOD DENTOFAC, V99, P456, DOI 10.1016/S0889 5406(05)81579 3
   Krishnan V., 2006, AM J ORTHOD DENTOFAC, V129, p469., DOI [10.1016/j.ajodo.2005.10.007, DOI 10.1016/J.AJODO.2005.10.007]
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   KUITERT RB, 1989, ACTA MORPHOL NEER SC, V26, P191
   Li J, 2015, BONE, V78, P130, DOI 10.1016/j.bone.2015.05.003
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Liu J, 2006, BIOCHEM BIOPH RES CO, V348, P1167, DOI 10.1016/j.bbrc.2006.07.175
   Liu L, 2017, CELL BIOL INT, V41, P112, DOI 10.1002/cbin.10704
   Owan I, 1997, AM J PHYSIOL CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810
   Pavlin D, 2001, CONNECT TISSUE RES, V42, P135, DOI 10.3109/03008200109014255
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122
   Sakai Y, 2009, J DENT RES, V88, P345, DOI 10.1177/0022034509334649
   Sun F, 2014, J DENT RES, V93, P589, DOI 10.1177/0022034514531146
   Sun ZY, 2015, SCI REP UK, V5, DOI 10.1038/srep08077
   Tamura M, 2013, MOL MED REP, V8, P1807, DOI 10.3892/mmr.2013.1713
   Wan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050090
   Wang H, 2016, SCI REP UK, V6, DOI 10.1038/srep23170
   Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057
   Wise GE, 2008, J DENT RES, V87, P414, DOI 10.1177/154405910808700509
   YAMASAKI K, 1980, J DENT RES, V59, P1635, DOI 10.1177/00220345800590101301
   Yan YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035709
   Yuan HF, 2015, EXP MOL PATHOL, V98, P158, DOI 10.1016/j.yexmp.2015.01.002
   Zahrowski JJ, 2007, AM J ORTHOD DENTOFAC, V131, P311, DOI 10.1016/j.ajodo.2006.09.035
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
NR 46
TC 2
Z9 3
U1 0
U2 35
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381 0751 USA
SN 2157 9083
EI 2157 9091
J9 J BIOMATER TISS ENG
JI J. Biomater. Tissue Eng.
PD FEB
PY 2018
VL 8
IS 2
BP 248
EP 257
DI 10.1166/jbt.2018.1730
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GC2JU
UT WOS:000429609000013
DA 2025 08 17
ER

PT J
AU Xie, BC
   Wu, JH
   Li, YM
   Wu, XJ
   Zeng, ZW
   Zhou, CH
   Xu, DH
   Wu, LH
AF Xie, Baocheng
   Wu, Jiahuan
   Li, Yongmei
   Wu, Xuejun
   Zeng, Zhanwei
   Zhou, Chenhui
   Xu, Daohua
   Wu, Longhuo
TI Geniposide Alleviates Glucocorticoid Induced Inhibition of Osteogenic
   Differentiation in MC3T3 E1 Cells by ERK Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE geniposide; osteogenic differentiation; glucocorticoid; osteoporosis;
   ERK pathway; GLP 1 receptor
ID TRANSCRIPTION FACTOR OSTERIX; OSTEOBLAST DIFFERENTIATION; INDUCED
   OSTEOPOROSIS; PEPTIDE 1 RECEPTOR; PROLIFERATION; EXPRESSION; ACTIVATION;
   UPDATE; KINASE; RATS
AB Glucocorticoid (GC) therapy is the leading cause of secondary osteoporosis and the therapeutic and preventative drugs for GC induced osteoporosis are limited. In this study, we investigated the protective effects of geniposide on dexamethasone (DEX) induced osteogenic inhibition in MC3T3 E1 cells. The results showed that there was no obvious toxicity on MC3T3 E1 cells when geniposide was used at the doses ranging from 1 to 75 mu M. In DEX treated MC3T3 E1 cells, geniposide promoted the alkaline phosphatase (ALP) activity and the mineralization. In addition, geniposide also significantly increased the mRNA and protein expression of osteopontin (OPN), Runt related transcription factor 2 (Runx2), and Osterix (Osx) in DEX treated MC3T3 E1 cells. Furthermore, geniposide activated ERK pathway in DEX treated MC3T3 E1 cells. The ERK activation inhibitor U0126 and glucagon like peptide 1 (GLP 1) receptor antagonist exendin 9 39 abolished the geniposide induced activation of ERK and inhibited the protective effect of geniposide. Taken together, our study revealed that geniposide alleviated GC induced osteogenic suppression in MC3T3 E1 cells. The effect of geniposide was at least partially associated with activating ERK signaling pathway via GLP 1 receptor. Geniposide might be a potential therapeutic agent for GC induced osteoporosis.
C1 [Xie, Baocheng; Wu, Jiahuan; Xu, Daohua] Guangdong Med Univ, Marine Biomed Res Inst, Publ Serv Platform South China Sea R&D Marine Bio, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Peoples R China.
   [Xie, Baocheng; Wu, Jiahuan; Li, Yongmei; Wu, Xuejun; Zeng, Zhanwei; Xu, Daohua] Guangdong Med Univ, Dept Pharmacol, Inst Tradit Chinese Med & New Pharm Dev, Dongguan, Peoples R China.
   [Zhou, Chenhui] Guangdong Med Univ, Sch Nursing, Dongguan, Peoples R China.
   [Wu, Longhuo] Gannan Med Univ, Coll Pharm, Ganzhou, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University; Guangdong
   Medical University; Gannan Medical University
RP Xu, DH (通讯作者)，Guangdong Med Univ, Marine Biomed Res Inst, Publ Serv Platform South China Sea R&D Marine Bio, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang, Peoples R China.; Xu, DH (通讯作者)，Guangdong Med Univ, Dept Pharmacol, Inst Tradit Chinese Med & New Pharm Dev, Dongguan, Peoples R China.; Wu, LH (通讯作者)，Gannan Med Univ, Coll Pharm, Ganzhou, Peoples R China.
EM daohuax108@163.com; longhwu@hotmail.com
RI Xie, Baocheng/GQQ 8354 2022
OI Xie, baocheng/0000 0002 7109 402X
FU National Natural Science Foundation of China [81660371]; Scientific
   Research Fund of Jiangxi Provincial Education Department [GJJ180792];
   Innovative Teamwork Project of Gannan Medical University [TD201707];
   Scientific Research Fund of The Public Service Platform of South China
   Sea for R&D Marine Biomedicine Resources
FX The work was supported by the National Natural Science Foundation of
   China (81660371), Scientific Research Fund of The Public Service
   Platform of South China Sea for R&D Marine Biomedicine Resources,
   Scientific Research Fund of Jiangxi Provincial Education Department
   (GJJ180792), and Innovative Teamwork Project of Gannan Medical
   University (TD201707).
CR Aoyama E, 2014, INT J MOL MED, V34, P475, DOI 10.3892/ijmm.2014.1787
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Bultink IEM, 2013, EXPERT OPIN PHARMACO, V14, P185, DOI 10.1517/14656566.2013.761975
   Chen YM, 2015, EUR J PHARMACOL, V768, P21, DOI 10.1016/j.ejphar.2015.09.029
   Compston J, 2018, ENDOCRINE, V61, P7, DOI 10.1007/s12020 018 1588 2
   Deng R, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00105
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Gong N, 2014, NEUROPHARMACOLOGY, V84, P31, DOI 10.1016/j.neuropharm.2014.04.007
   Güler Yüksel M, 2018, CALCIFIED TISSUE INT, V102, P592, DOI 10.1007/s00223 017 0335 7
   Hsu E, 2017, CURR OPIN ENDOCRINOL, V24, P411, DOI 10.1097/MED.0000000000000368
   Huang BS, 2017, CELL PHYSIOL BIOCHEM, V43, P705, DOI 10.1159/000480657
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kanis JA, 2009, NAT REV RHEUMATOL, V5, P425, DOI 10.1038/nrrheum.2009.139
   Kim YJ, 2006, GENE, V366, P145, DOI 10.1016/j.gene.2005.08.021
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kuo WH, 2005, TOXICOL APPL PHARM, V208, P155, DOI 10.1016/j.taap.2005.02.013
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Li FH, 2016, J ETHNOPHARMACOL, V185, P77, DOI 10.1016/j.jep.2016.03.025
   Li N, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00854
   Liu CY, 2017, CELL BIOL INT, V41, P544, DOI 10.1002/cbin.10758
   Lu W, 2018, CLIN EXP DERMATOL, V43, P667, DOI 10.1111/ced.13409
   Ma J, 2018, EXP MOL PATHOL, V105, P252, DOI 10.1016/j.yexmp.2018.08.011
   Meng JR, 2016, STEM CELL REP, V6, P579, DOI 10.1016/j.stemcr.2016.02.002
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Poulsen RC, 2011, ENDOCRINOLOGY, V152, P503, DOI 10.1210/en.2010 1087
   Sun P, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/284314
   Tu QS, 2006, BIOCHEM BIOPH RES CO, V341, P1257, DOI 10.1016/j.bbrc.2006.01.092
   van der Goes MC, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4686
   Wang R, 2017, PHYTOTHER RES, V31, P631, DOI 10.1002/ptr.5775
   Wang Y, 2018, INT IMMUNOPHARMACOL, V65, P284, DOI 10.1016/j.intimp.2018.09.049
   Wu XL, 2017, EXP CELL RES, V360, P281, DOI 10.1016/j.yexcr.2017.09.018
   Xu B, 2017, ACTA PHARMACOL SIN, V38, P688, DOI 10.1038/aps.2016.168
   Yao DD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.107
   YAO KL, 1994, J BONE MINER RES, V9, P231
   Ye QF, 2016, EXP THER MED, V11, P1499, DOI 10.3892/etm.2016.3034
   Zhang P, 2012, INT J MOL MED, V29, P1083, DOI 10.3892/ijmm.2012.934
   Zhang Y, 2016, MOL CELL ENDOCRINOL, V430, P89, DOI 10.1016/j.mce.2016.04.020
   Zhang YS, 2017, ANTIVIR THER, V22, P599, DOI 10.3851/IMP3152
NR 42
TC 33
Z9 35
U1 0
U2 38
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 18
PY 2019
VL 10
AR 411
DI 10.3389/fphar.2019.00411
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HU1LN
UT WOS:000465034000001
PM 31057410
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Botvin, VV
   Sukhinina, E
   Fetisova, AA
   Wagner, D
   Vedyashkina, MY
   Pryadko, A
   Pershina, AG
   Surmeneva, MA
   Kholkin, AL
   Surmenev, RA
AF Botvin, Vladimir V.
   Sukhinina, Ekaterina, V
   Fetisova, Anastasia A.
   Wagner, Dmitry, V
   Vedyashkina, Maria Y.
   Pryadko, Artyom
   Pershina, Alexandra G.
   Surmeneva, Maria A.
   Kholkin, Andrei L.
   Surmenev, Roman A.
TI Changes in gene expression profile of normal human fibroblasts on P
   (VDF TrFE) scaffolds highly doped with Fe3O4 CA nanoparticles under
   alternating magnetic field stimulation
SO EUROPEAN POLYMER JOURNAL
LA English
DT Article
DE P(VDF TrFE) scaffolds; Magnetite nanoparticles; Human fibroblasts;
   Mesenchymal stem cells; Proliferation; Transcriptome analysis
ID POLY(VINYLIDENE FLUORIDE); SIGNALING PATHWAY; GROWTH FACTOR; STEM CELLS;
   IN VITRO; DIFFERENTIATION; P(VDF TRFE); NANOFIBERS; PHASES; OSTEOGENESIS
AB The design of novel hybrid magnetoactive scaffolds based on biocompatible piezopolymers and magnetic nanoparticles is of interest for medicine, mainly for tissue regeneration, because application of an external either static or alternating magnetic field to cells that settled on a magnetoactive scaffold offers an opportunity for remote control of cellular functions. This study describes fabrication of electrospun magnetoactive poly(vinylidene fluoride co trifluoroethylene) [P(VDF TrFE)] scaffolds highly doped with 20 wt% of magnetite nanoparticles modified with citric acid (Fe3O4 CA). The electrospun P(VDF TrFE)/Fe3O4 CA scaffolds have defect free morphology with a fiber diameter of approximately 1 mu m and contain both an electroactive beta phase (predominantly) and a lesser amount of an gamma phase. A high content of uniformly distributed Fe3O4 CA nanoparticles within P(VDF TrFE) fibrous scaffolds resulted in a high saturation magnetization of 12.1 emu/g and ferrimagnetic behavior of the composite P(VDF TrFE)/Fe3O4 CA scaffolds. They were proved to be biocompatible with normal human cells: normal human fibroblasts and human mesenchymal stem cells adhered to the scaffold and retained their viability. According to high throughput RNA sequencing data, the adhesion of fibroblasts to the scaffolds upregulated genes related to key stages of tissue regeneration such as coagulation (genes THBD and SERPINB2) and wound healing (IL24, PDGFB, F3, and PLAU) and affected TGF beta, BMP, and Wnt signaling pathways. Alternating magnetic field exposure of the magnetoactive P(VDF TrFE)/Fe3O4 CA scaffolds with fibroblasts settled on the surface activated extracellular and intracellular cell signaling pathways.
C1 [Botvin, Vladimir V.; Fetisova, Anastasia A.; Surmeneva, Maria A.; Surmenev, Roman A.] Natl Res Tomsk Polytech Univ, Int Res & Dev Ctr Piezo and Magnetoelect Mat, Res Sch Chem & Appl Biomed Sci, Tomsk 634050, Russia.
   [Sukhinina, Ekaterina, V; Pershina, Alexandra G.] Siberian State Med Univ, Ctr Biosci & Bioengn, Tomsk 634050, Russia.
   [Sukhinina, Ekaterina, V; Vedyashkina, Maria Y.; Pershina, Alexandra G.] Natl Res Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Tomsk 634050, Russia.
   [Wagner, Dmitry, V] Natl Res Tomsk State Univ, Tomsk 634050, Russia.
   [Pryadko, Artyom; Surmeneva, Maria A.; Surmenev, Roman A.] Natl Res Tomsk Polytech Univ, Phys Mat Sci & Composite Mat Ctr, Res Sch Chem & Appl Biomed Sci, Tomsk 634050, Russia.
   [Kholkin, Andrei L.] Univ Aveiro, Aveiro Inst Mat, Dept Phys, P 3810193 Aveiro, Portugal.
   [Kholkin, Andrei L.] Univ Aveiro, Aveiro Inst Mat, CICECO, P 3810193 Aveiro, Portugal.
C3 Tomsk Polytechnic University; Siberian State Medical University; Tomsk
   Polytechnic University; Tomsk State University; Tomsk Polytechnic
   University; Universidade de Aveiro; Universidade de Aveiro
RP Botvin, VV; Surmenev, RA (通讯作者)，Natl Res Tomsk Polytech Univ, Int Res & Dev Ctr Piezo and Magnetoelect Mat, Res Sch Chem & Appl Biomed Sci, Tomsk 634050, Russia.; Pershina, AG (通讯作者)，Siberian State Med Univ, Ctr Biosci & Bioengn, Tomsk 634050, Russia.; Pershina, AG (通讯作者)，Natl Res Tomsk Polytech Univ, Res Sch Chem & Appl Biomed Sci, Tomsk 634050, Russia.; Surmenev, RA (通讯作者)，Natl Res Tomsk Polytech Univ, Phys Mat Sci & Composite Mat Ctr, Res Sch Chem & Appl Biomed Sci, Tomsk 634050, Russia.; Kholkin, AL (通讯作者)，Univ Aveiro, Aveiro Inst Mat, Dept Phys, P 3810193 Aveiro, Portugal.; Kholkin, AL (通讯作者)，Univ Aveiro, Aveiro Inst Mat, CICECO, P 3810193 Aveiro, Portugal.
EM v.v.botvin@gmail.com; allysyz@mail.ru; kholkin@ua.pt; rsurmenev@mail.ru
RI Pershina, Alexandra/C 3053 2015; Vedyashkina, Maria/MCY 4568 2025;
   Kholkin, Andrei/G 5834 2010; Sukhinina, Ekaterina/AGR 0843 2022;
   Fetisova, Anastasia/JNS 7737 2023; Wagner, Dmitry/A 5659 2014
OI Fetisova, Anastasia/0009 0009 5032 4584; 
FU Russian Science Foundation [22 73 00228]; Ministry of Science and Higher
   Education of Russia [075 15 2021 588]
FX The authors thank the central laboratories of Tomsk Polytechnic
   University (Analytical Center) for the XPS measurements. Financial
   support from the Russian Science Foundation (grant number 22 73 00228,
   synthesis and characterization of materials) and from the Ministry of
   Science and Higher Education of Russia (grant agreement #075 15 2021 588
   of 1 June 2021, biological study) is acknowledged. The authors thank
   Albert Muslimov for MSCs isolation and Prof. Dmitry Kuprash for carrying
   out the RNA sequencing at the Center for Precision Genome Editing and
   Genetic Technologies for Biomedicine, Pirogov Medical University.
CR Abalymov AA, 2020, MACROMOL MATER ENG, V305, DOI 10.1002/mame.202000308
   Akhmetshina A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1734
   Ardeshirylajimi A, 2018, ASAIO J, V64, P253, DOI 10.1097/MAT.0000000000000631
   Arrigoni A, 2020, RSC ADV, V10, P37779, DOI 10.1039/d0ra05478j
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Biernacka A, 2011, GROWTH FACTORS, V29, P196, DOI 10.3109/08977194.2011.595714
   Botvin V, 2023, POLYMERS BASEL, V15, DOI 10.3390/polym15143135
   Botvin VV, 2024, POLYMER, V296, DOI 10.1016/j.polymer.2024.126765
   Botvin VV, 2022, POLYM ENG SCI, V62, P1593, DOI 10.1002/pen.25947
   Cai XM, 2017, RSC ADV, V7, P15382, DOI 10.1039/c7ra01267e
   Cambier S, 2023, CELL MOL IMMUNOL, V20, P217, DOI 10.1038/s41423 023 00974 6
   Castro N, 2020, SENSORS BASEL, V20, DOI 10.3390/s20123340
   Chan BP, 2008, EUR SPINE J, V17, pS467, DOI 10.1007/s00586 008 0745 3
   Charoenlarp P, 2017, INFLAMM REGEN, V37, DOI 10.1186/s41232 017 0043 8
   Chernova E, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12234321
   Cojocaru FD, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232416190
   Costa Almeida R, 2018, J TISSUE ENG REGEN M, V12, P240, DOI 10.1002/term.2405
   Cunha Cunha C. C., 2013, Am. J. Biomed. Eng, V2 2, P263, DOI [10.5923/j.ajbe.20120206.05 10.5923/j.ajbe.20120206.05, DOI 10.5923/J.AJBE.20120206.05]
   D'Amora U, 2017, BIOACT MATER, V2, P138, DOI 10.1016/j.bioactmat.2017.04.003
   Daly KA, 2011, STEM CELLS BIOL REG, P353, DOI 10.1007/978 1 61779 322 6_19
   Dave K, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110078
   Dheyab MA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 67869 8
   Esmaeili E, 2019, J CELL PHYSIOL, V234, P13617, DOI 10.1002/jcp.28040
   Farag MM, 2023, J MATER SCI, V58, P527, DOI 10.1007/s10853 022 08102 x
   Fernandes MM, 2019, ACS APPL MATER INTER, V11, P45265, DOI 10.1021/acsami.9b14001
   Gaharwar AK, 2020, NAT REV MATER, V5, P686, DOI 10.1038/s41578 020 0209 x
   Gao XY, 2020, ADV MATER TECHNOL US, V5, DOI 10.1002/admt.201900716
   Gilroy DA, 2017, MRS COMMUN, V7, P367, DOI 10.1557/mrc.2017.41
   Gomes MR, 2022, BIOMATER ADV, V137, DOI 10.1016/j.bioadv.2022.212808
   Gomes RN, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00153 z
   Guillot Ferriols M, 2020, MAT SCI ENG C MATER, V117, DOI 10.1016/j.msec.2020.111281
   Hadadian Y, 2022, ACS OMEGA, V7, P15996, DOI 10.1021/acsomega.2c01136
   Hao SS, 2017, BIOMATERIALS, V140, P16, DOI 10.1016/j.biomaterials.2017.06.013
   Hashimoto Y, 2007, ELECTR ENG JPN, V160, P46, DOI 10.1002/eej.20203
   He Y, 2019, FASEB J, V33, P6069, DOI 10.1096/fj.201802195R
   Hermenegildo B, 2019, COLLOID SURFACE B, V181, P1041, DOI 10.1016/j.colsurfb.2019.06.023
   HSIEH HJ, 1991, AM J PHYSIOL, V260, pH642, DOI 10.1152/ajpheart.1991.260.2.H642
   Hu C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf0787
   Hu XC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084440
   Huang F, 2024, BIOL RES, V57, DOI 10.1186/s40659 023 00481 y
   Huang HM, 2006, CLIN ORTHOP RELAT R, P201, DOI 10.1097/01.blo.0000203464.35561.be
   Jenkins TL, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0076 5
   Jere SW, 2017, CYTOKINE GROWTH F R, V38, P73, DOI 10.1016/j.cytogfr.2017.10.001
   Kandasamy G, 2015, INT J PHARMACEUT, V496, P191, DOI 10.1016/j.ijpharm.2015.10.058
   Kapat K, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909045
   Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587 019 0201 4
   Kim DW, 2007, J KOREAN PHYS SOC, V51, P719, DOI 10.3938/jkps.51.719
   Kim EC, 2017, J PERIODONTAL IMPLAN, V47, P273, DOI 10.5051/jpis.2017.47.5.273
   Kim EC, 2015, BIOELECTROMAGNETICS, V36, P267, DOI 10.1002/bem.21903
   Kim M, 2020, APL MATER, V8, DOI 10.1063/5.0011686
   Kim W, 2012, TALANTA, V94, P348, DOI 10.1016/j.talanta.2012.03.001
   Kopyl S, 2021, MATER TODAY BIO, V12, DOI 10.1016/j.mtbio.2021.100149
   Li J, 2019, APPL SURF SCI, V463, P626, DOI 10.1016/j.apsusc.2018.08.266
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu SQ, 2023, CELL, V186, P2127, DOI 10.1016/j.cell.2023.03.031
   Liu WW, 2020, ACS APPL MATER INTER, V12, P51885, DOI 10.1021/acsami.0c10957
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796
   Marquez AL, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14030467
   Martins P, 2014, PROG POLYM SCI, V39, P683, DOI 10.1016/j.progpolymsci.2013.07.006
   Mayeen A, 2019, DALTON T, V48, P16961, DOI 10.1039/c9dt02856k
   Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550
   Niculescu AG, 2022, METHODS, V199, P16, DOI 10.1016/j.ymeth.2021.04.018
   Panseri S, 2012, J BIOMED MATER RES A, V100A, P2278, DOI 10.1002/jbm.a.34167
   Penn JW, 2012, INT J BURNS TRAUMA, V2, P18
   Perez JE, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01488 5
   Pryadko AS, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14030529
   Raja IS, 2022, MATER DESIGN, V216, DOI 10.1016/j.matdes.2022.110580
   Ribeiro C, 2016, COLLOID SURFACE B, V140, P430, DOI 10.1016/j.colsurfb.2015.12.055
   Ribeiro S, 2020, ACS APPL BIO MATER, V3, P4239, DOI 10.1021/acsabm.0c00315
   Russo V, 2022, CELLS BASEL, V11, DOI 10.3390/cells11020266
   Rustad KC, 2013, DIFFERENTIATION, V86, P87, DOI 10.1016/j.diff.2013.02.003
   Sabbatini L, 2014, POLYMER SURFACE CHARACTERIZATION, P73
   Sadeghzadeh H, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03426 0
   Sadtler K, 2016, SCIENCE, V352, P366, DOI 10.1126/science.aad9272
   Sapir Yulia, 2014, Methods Mol Biol, V1181, P83, DOI 10.1007/978 1 4939 1047 2_8
   Sapir Y, 2012, BIOMATERIALS, V33, P4100, DOI 10.1016/j.biomaterials.2012.02.037
   Saveleva MS, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00179
   Shlapakova LE, 2024, MATER TODAY BIO, V25, DOI 10.1016/j.mtbio.2024.100950
   Shu CQ, 2023, ADV SCI, V10, DOI 10.1002/advs.202206875
   Shuai CJ, 2022, BIOMATER RES, V26, DOI 10.1186/s40824 022 00278 2
   Shuai CJ, 2020, MATER DESIGN, V185, DOI 10.1016/j.matdes.2019.108275
   Simoes RD, 2009, POLYM ENG SCI, V49, P2150, DOI 10.1002/pen.21455
   Singh D, 2017, PHYS CHEM CHEM PHYS, V19, P7743, DOI 10.1039/c7cp00275k
   Singh RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091584
   Sokolova AI, 2019, MICROSC RES TECHNIQ, V82, P544, DOI 10.1002/jemt.23198
   Song H, 2022, MATER HORIZ, V9, P3031, DOI 10.1039/d2mh00693f
   Tang BL, 2018, ACS APPL MATER INTER, V10, P7841, DOI 10.1021/acsami.7b19385
   Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577
   Testa Anta M, 2019, NANOSCALE ADV, V1, P2086, DOI 10.1039/c9na00064j
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Wagner DV, 2023, INVENTIONS BASEL, V8, DOI 10.3390/inventions8010026
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xia Y, 2018, BIOMATERIALS, V183, P151, DOI 10.1016/j.biomaterials.2018.08.040
   Xie J, 2016, ACTA BIOMATER, V29, P365, DOI 10.1016/j.actbio.2015.10.007
   Xu Qianqian, 2021, Adv Mater, V33, pe2008452, DOI 10.1002/adma.202008452
   Xu XF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.719562
   Xue JJ, 2019, CHEM REV, V119, P5298, DOI 10.1021/acs.chemrev.8b00593
   Yu L, 2009, POLYMER, V50, P2133, DOI 10.1016/j.polymer.2009.03.003
   Yun HM, 2016, BIOMATERIALS, V85, P88, DOI 10.1016/j.biomaterials.2016.01.035
   Zheng LS, 2018, J TISSUE ENG REGEN M, V12, P2029, DOI 10.1002/term.2737
   Zou ML, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.713605
NR 104
TC 0
Z9 0
U1 4
U2 12
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0014 3057
EI 1873 1945
J9 EUR POLYM J
JI Eur. Polym. J.
PD NOV 15
PY 2024
VL 220
AR 113492
DI 10.1016/j.eurpolymj.2024.113492
EA OCT 2024
PG 11
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA J2H0S
UT WOS:001335318200001
DA 2025 08 17
ER

PT J
AU Marycz, K
   Smieszek, A
   Jelen, M
   Chrzastek, K
   Grzesiak, J
   Meissner, J
AF Marycz, Krzysztof
   Smieszek, Agnieszka
   Jelen, Marta
   Chrzastek, Klaudia
   Grzesiak, Jakub
   Meissner, Justyna
TI THE EFFECT OF THE BIOACTIVE SPHINGOLIPIDS S1P AND C1P ON MULTIPOTENT
   STROMAL CELLS   NEW OPPORTUNITIES IN REGENERATIVE MEDICINE
SO CELLULAR & MOLECULAR BIOLOGY LETTERS
LA English
DT Article
DE Mesenchymal stem cells; Sphingolipids; Sphingosine 1 phosphate;
   Ceramide 1 phosphate; Osteogenic differentiation; Regenerative medicine;
   Bone marrow stem cells; Adipose stem cells
ID MESENCHYMAL STEM CELLS; 1 PHOSPHATE STIMULATES PROLIFERATION; BONE
   MORPHOGENETIC PROTEIN 2; SPHINGOSINE 1 PHOSPHATE; OSTEOGENIC
   DIFFERENTIATION; CERAMIDE 1 PHOSPHATE; CERAMIDE 1 PHOSPHATE;
   MICROVESICLES; MIGRATION; SPHINGOSINE 1 PHOSPHATE
AB Sphingosine 1 phosphate (S1P) and ceramide 1 phosphate (C1P) belong to a family of bioactive sphingolipids that act as important extracellular signaling molecules and chemoattractants. This study investigated the influence of S1P and C1P on the morphology, proliferation activity and osteogenic properties of rat multipotent stromal cells derived from bone marrow (BMSCs) and subcutaneous adipose tissue (ASCs). We show that S1P and C1P can influence mesenchymal stem cells (MSCs), each in a different manner. S1P stimulation promoted the formation of cellular aggregates of BMSCs and ASCs, while C1P had an effect on the regular growth pattern and expanded intercellular connections, thereby increasing the proliferative activity. Although osteogenic differentiation of MSCs was enhanced by the addition of S1P, the effectiveness of osteoblast differentiation was more evident in BMSCs, particularly when biochemical and molecular marker levels were considered. The results of the functional osteogenic differentiation assay, which includes an evaluation of the efficiency of extracellular matrix mineralization (SEM EDX), revealed the formation of numerous mineral aggregates in BMSC cultures stimulated with S1P. Our data demonstrated that in an appropriate combination, the bioactive sphingolipids S1P and C1P may find wide application in regenerative medicine, particularly in bone regeneration with the use of MSCs.
C1 [Marycz, Krzysztof; Smieszek, Agnieszka] Wroclaw Res Ctr EIT, PL 54066 Wroclaw, Poland.
   [Marycz, Krzysztof; Smieszek, Agnieszka; Jelen, Marta; Chrzastek, Klaudia; Grzesiak, Jakub; Meissner, Justyna] Univ Environm & Life Sci Wroclaw, Fac Biol, PL 50631 Wroclaw, Poland.
C3 Wroclaw University of Environmental & Life Sciences
RP Marycz, K (通讯作者)，Wroclaw Res Ctr EIT, Stablowicka 147, PL 54066 Wroclaw, Poland.
EM krzysztof.marycz@up.wroc.pl
RI Smieszek, Agnieszka/A 4887 2017; Grzesiak, Jakub/ABB 6774 2020; Marycz,
   Krzysztof/A 2249 2017; Śmieszek, Agnieszka/A 4887 2017
OI Smieszek, Agnieszka/0000 0002 7314 9821; Meissner,
   Justyna/0000 0002 8667 908X; Chrzastek, Klaudia/0000 0003 1264 6987; 
CR Anderson DG, 2004, SCIENCE, V305, P1923, DOI 10.1126/science.1099987
   Bauer S, 2008, ACTA BIOMATER, V4, P1576, DOI 10.1016/j.actbio.2008.04.004
   Berthiaume F, 2011, ANNU REV CHEM BIOMOL, V2, P403, DOI 10.1146/annurev chembioeng 061010 114257
   Bhakta G, 2013, ACTA BIOMATER, V9, P9098, DOI 10.1016/j.actbio.2013.07.008
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798
   Calise S, 2012, BBA MOL CELL RES, V1823, P439, DOI 10.1016/j.bbamcr.2011.11.016
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932
   Das A, 2014, J BIOMED MATER RES A, V102, P1210, DOI 10.1002/jbm.a.34779
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208
   Gangoiti P, 2012, BIOCHIMIE, V94, P597, DOI 10.1016/j.biochi.2011.09.009
   García Olmo D, 2005, DIS COLON RECTUM, V48, P1416, DOI 10.1007/s10350 005 0052 6
   Garcia Olmo D, 2009, DIS COLON RECTUM, V52, P79, DOI 10.1007/DCR.0b013e3181973487
   Gomez Munoz A., 2012, J MEMB SCI TECHNOL, V2, P107
   Gómez Muñoz A, 2010, ADV EXP MED BIOL, V688, P118
   Grzesiak J, 2011, INT J MORPHOL, V29, P1012, DOI 10.4067/S0717 95022011000300059
   Gupta PK, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt116
   Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097 4652(199603)166:3<585::AID JCP13>3.0.CO;2 6
   Herrera MB, 2010, J CELL MOL MED, V14, P1605, DOI 10.1111/j.1582 4934.2009.00860.x
   Hinkovska Galcheva V, 2010, ADV EXP MED BIOL, V688, P131
   Hung SC, 2002, STEM CELLS, V20, P249, DOI 10.1634/stemcells.20 3 249
   Ishii M, 2013, BBA MOL CELL BIOL L, V1831, P223, DOI 10.1016/j.bbalip.2012.06.002
   Ishii M, 2010, J EXP MED, V207, P2793, DOI 10.1084/jem.20101474
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jo CH, 2014, STEM CELLS, V32, P1254, DOI 10.1002/stem.1634
   Jorgensen Christian, 2011, Regen Med, V6, P44, DOI 10.2217/rme.11.80
   Kaveh K, 2011, J ANIM VET ADV, V10, P2317, DOI 10.3923/javaa.2011.2317.2330
   Kim C, 2013, STEM CELLS, V31, P500, DOI 10.1002/stem.1291
   Krzak Ros J, 2013, PRZEM CHEM, V92, P1101
   Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559
   Marycz K., 2014, ACTA VET HUNG, V22, P1
   Marycz K, 2013, BIOMED MATER, V8, DOI 10.1088/1748 6041/8/6/065004
   Mason C, 2008, REGEN MED, V3, P1, DOI 10.2217/17460751.3.1.1
   Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076
   Moon MH, 2015, MOL MED REP, V11, P1031, DOI 10.3892/mmr.2014.2810
   Orozco L, 2013, TRANSPLANTATION, V95, P1535, DOI 10.1097/TP.0b013e318291a2da
   Patel DM, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/496218
   Pelled G, 2002, CURR PHARM DESIGN, V8, P1917, DOI 10.2174/1381612023393666
   Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f
   Quint P, 2013, J BIOL CHEM, V288, P5398, DOI 10.1074/jbc.M112.413583
   Ratajczak J, 2006, LEUKEMIA, V20, P1487, DOI 10.1038/sj.leu.2404296
   Ratajczak J, 2013, STEM CELLS DEV, V22, P422, DOI 10.1089/scd.2012.0268
   Schneider G, 2013, MOL CANCER RES, V11, P793, DOI 10.1158/1541 7786.MCR 12 0600
   Sefcik LS, 2008, BIOMATERIALS, V29, P2869, DOI 10.1016/j.biomaterials.2008.03.017
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Tocci Angelo, 2003, Hematol J, V4, P92, DOI 10.1038/sj.thj.6200232
   Toonkel RL, 2013, AM J RESP CRIT CARE, V188, P133, DOI 10.1164/rccm.201207 1204PP
   Woo EJ, 2013, CLIN ORTHOP RELAT R, V471, P1707, DOI 10.1007/s11999 012 2684 x
   Woo EJ, 2012, SPINE J, V12, P894, DOI 10.1016/j.spinee.2012.09.052
   Wrzeszcz K, 2013, PRZEM CHEM, V92, P1018
NR 57
TC 22
Z9 23
U1 1
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1425 8153
EI 1689 1392
J9 CELL MOL BIOL LETT
JI Cell. Mol. Biol. Lett.
PD SEP
PY 2015
VL 20
IS 3
BP 510
EP 533
DI 10.1515/cmble 2015 0029
PG 24
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CO4VP
UT WOS:000359159200010
PM 26110483
OA gold
DA 2025 08 17
ER

PT J
AU Yuan, A
   Woo, SB
AF Yuan, Anna
   Woo, Sook Bin
TI Adverse drug events in the oral cavity
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
LA English
DT Article
ID STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; SQUAMOUS CELL
   CARCINOMA; INDUCED GINGIVAL HYPERPLASIA; BISPHOSPHONATE RELATED
   OSTEONECROSIS; TOPICAL CALCINEURIN INHIBITORS; RENAL TRANSPLANT
   RECIPIENT; COA REDUCTASE INHIBITORS; OF THE LITERATURE; LICHEN PLANUS
AB Adverse reactions to medications are common and may have a variety of clinical presentations in the oral cavity. Targeted therapies and the new biologic agents have revolutionized the treatment of cancers, autoimmune diseases, and inflammatory and rheumatologic diseases but have also been associated with adverse events in the oral cavity. Some examples include osteonecrosis, seen with not only bisphosphonates but also antiangiogenic agents, and the distinctive ulcers caused by mammalian target of rapamycin inhibitors. As newer therapeutic agents are approved, it is likely that more adverse drug events will be encountered. This review describes the most common clinical presentations of oral mucosal reactions to medications, namely, xerostomia, lichenoid reactions, ulcers, bullous disorders, pigmentation, fibrovascular hyperplasia, white lesions, dysesthesia, osteonecrosis, infection, angioedema, and malignancy. Oral health care providers should be familiar with such events, as they will encounter them in their practice.
C1 [Yuan, Anna; Woo, Sook Bin] Brigham & Womens Hosp, Div Oral Med, Boston, MA 02115 USA.
   [Yuan, Anna; Woo, Sook Bin] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Brigham &
   Women's Hospital; Harvard University; Harvard School of Dental Medicine
RP Yuan, A (通讯作者)，Brigham & Womens Hosp, Div Oral Med & Dent, 75 Francis St, Boston, MA 02115 USA.
EM annayuan@post.harvard.edu
OI Yuan, Anna/0000 0001 5619 5175
CR Abou Elhamd KEA, 2009, EUR ARCH OTO RHINO L, V266, P1327, DOI 10.1007/s00405 008 0785 7
   Agrillo A, 2012, EUR REV MED PHARMACO, V16, P952
   Ahdout J, 2010, J AM ACAD DERMATOL, V62, P874, DOI 10.1016/j.jaad.2009.04.048
   Al Akhrass F, 2011, MED MYCOL, V49, P400, DOI 10.3109/13693786.2010.533391
   Al Mohaya M, 2007, J ORAL PATHOL MED, V36, P570, DOI 10.1111/j.1600 0714.2007.00557.x
   Alfreijat M, 2013, J COMMUNITY HOSP INT, V3, DOI 10.3402/jchimp.v3i3 4.21047
   ALJABRE SHM, 1994, J AM ACAD DERMATOL, V30, P671, DOI 10.1016/S0190 9622(09)80125 4
   Allegra A, 2012, HEMATOL ONCOL, V30, P41, DOI 10.1002/hon.1000
   Alonso JCM, 2005, CONTACT DERMATITIS, V53, P121, DOI 10.1111/j.0105 1873.2005.0650h.x
   Apostolou T, 2004, TRANSPLANTATION, V77, P1911, DOI 10.1097/01.TP.0000123078.89315.93
   Arora B, 2004, ANN ONCOL, V15, P358, DOI 10.1093/annonc/mdh068
   Artico G, 2011, AN BRAS DERMATOL, V86, P152, DOI 10.1590/S0365 05962011000700040
   Arya R, 2011, NEUROLOGY, V76, P1338, DOI 10.1212/WNL.0b013e3182152844
   Asarch A, 2009, J AM ACAD DERMATOL, V61, P104, DOI 10.1016/j.jaad.2008.09.032
   Auquier Dunant A, 2002, ARCH DERMATOL, V138, P1019, DOI 10.1001/archderm.138.8.1019
   Ayangco L, 2003, DERMATOL CLIN, V21, P195, DOI 10.1016/S0733 8635(02)00062 1
   Baecklund E, 2006, ARTHRITIS RHEUM US, V54, P3774, DOI 10.1002/art.22277
   Bagán JV, 2004, ORAL DIS, V10, P401, DOI 10.1111/j.1601 0825.2004.01024.x
   Bagg A, 2013, SEMIN DIAGN PATHOL, V30, P102, DOI 10.1053/j.semdp.2012.08.005
   Bakkour W, 2012, DERMATOLOGY THER, V2, DOI 10.1007/s13555 012 0003 9
   Baricevic M, 2013, WIEN KLIN WOCHENSCHR, V125, P408, DOI 10.1007/s00508 013 0382 7
   Beaven AW, 2007, DRUG TODAY, V43, P461, DOI 10.1358/dot.2007.43.7.1119723
   Becker JC, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 7
   Berger TG, 2006, J AM ACAD DERMATOL, V54, P818, DOI 10.1016/j.jaad.2006.01.054
   Blaya M, 2011, NEW ENGL J MED, V365, pE20, DOI 10.1056/NEJMicm1014268
   Boer CC, 2010, BONE MARROW TRANSPL, V45, P705, DOI 10.1038/bmt.2009.237
   Bongartz T, 2006, JAMA J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275
   Bostanci N, 2006, J CLIN PERIODONTOL, V33, P771, DOI 10.1111/j.1600 051X.2006.00990.x
   Boulinguez S, 2000, BRIT J DERMATOL, V143, P1261, DOI 10.1046/j.1365 2133.2000.03898.x
   Breathnach S M, 1995, Australas J Dermatol, V36, P121, DOI 10.1111/j.1440 0960.1995.tb00953.x
   BROWN RS, 1991, J ORAL PATHOL MED, V20, P201, DOI 10.1111/j.1600 0714.1991.tb00419.x
   Burns BV, 1998, J LARYNGOL OTOL, V112, P485, DOI 10.1017/S002221510014085X
   Byun JW, 2014, AM J DERMATOPATH, V36, P684, DOI 10.1097/DAD.0b013e3182919e3a
   Casamiquela KM, 2013, J DRUGS DERMATOL, V12, P223
   Chiappinelli J A, 1992, Quintessence Int, V23, P539
   Choonhakarn C, 1999, J AM ACAD DERMATOL, V40, P645, DOI 10.1016/S0190 9622(99)70459 7
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   de Oliveira MA, 2011, ORAL ONCOL, V47, P998, DOI 10.1016/j.oraloncology.2011.08.009
   Deepak P, 2013, J GASTROINTEST LIVER, V22, P269
   Delabaye I, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3058
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140 6736(06)69446 4
   Dixit Gaurav, 2012, J Assoc Physicians India, V60, P56
   Dorchin M, 2013, IRAN J PEDIATR HEMAT, V3, P138
   DOWNHAM TF, 1978, JAMA J AM MED ASSOC, V240, P1138, DOI 10.1001/jama.1978.03290110036005
   DREIZEN S, 1992, POSTGRAD MED, V91, P349
   Edwards D, 2013, OR SURG OR MED OR PA, V115, pE36, DOI 10.1016/j.oooo.2012.08.001
   Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140 6736(00)02799 9
   EISENBERG E, 1981, ORAL SURG ORAL MED O, V51, P409, DOI 10.1016/0030 4220(81)90151 1
   Ena P, 2004, J Dermatolog Treat, V15, P253, DOI 10.1080/09546630410015556
   Epstein JB, 2002, BONE MARROW TRANSPL, V30, P785, DOI 10.1038/sj.bmt.1703716
   Estilo CL, 2008, J CLIN ONCOL, V26, P4037, DOI 10.1200/JCO.2007.15.5424
   Femiano F, 2011, ORAL SURG ORAL MED O, V112, pE15, DOI 10.1016/j.tripleo.2011.01.039
   Fessa C, 2012, AM J CLIN DERMATOL, V13, P417, DOI 10.2165/11634590 000000000 00000
   FICARRA G, 1990, ORAL SURG ORAL MED O, V70, P748, DOI 10.1016/0030 4220(90)90014 J
   Fiorentino DF, 2007, ARCH DERMATOL, V143, P233, DOI 10.1001/archderm.143.2.233
   Fischer G, 2007, J REPROD MED, V52, P329
   Fischer TC, 2003, AM J MED, V114, P77, DOI 10.1016/S0002 9343(02)01311 6
   Fleissig Y, 2012, OR SURG OR MED OR PA, V113, pE1, DOI 10.1016/j.tripleo.2011.06.023
   Garrigue V, 2001, TRANSPLANTATION, V72, P968, DOI 10.1097/00007890 200109150 00043
   Giancola F, 2013, Ann Stomatol (Roma), V4, P20
   GIANSANTI JS, 1971, ORAL SURG ORAL MED O, V31, P66, DOI 10.1016/0030 4220(71)90035 1
   Goffin E, 1998, CLIN NEPHROL, V50, P197
   Fernández CG, 2010, EUR J DERMATOL, V20, P127, DOI 10.1684/ejd.2010.0818
   Gómez Traseira C, 2013, RECENT PATENTS INFLA, V7, P268, DOI 10.2174/1872213X113079990018
   Gonzalez Arriagada Wilfredo Alejandro, 2013, Gen Dent, V61, pe15
   Grinspan D, 1966, Bull Soc Fr Dermatol Syphiligr, V73, P898
   GROSSMAN ME, 1995, J AM ACAD DERMATOL, V33, P675, DOI 10.1016/0190 9622(95)91307 6
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Gupta S, 2009, J EUR ACAD DERMATOL, V23, P1207, DOI 10.1111/j.1468 3083.2009.03124.x
   HALEVY S, 1993, J AM ACAD DERMATOL, V29, P249, DOI 10.1016/0190 9622(93)70176 T
   Hampson JP, 2005, PHARM WORLD SCI, V27, P279, DOI 10.1007/s11096 005 7115 6
   Han YQ, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00156
   Hanakawa H, 2013, ACTA MED OKAYAMA, V67, P265
   HEALY CM, 1995, J ORAL PATHOL MED, V24, P46, DOI 10.1111/j.1600 0714.1995.tb01129.x
   Heikkilä H, 2000, J AM ACAD DERMATOL, V42, P883, DOI 10.1016/S0190 9622(00)90262 7
   HENKIN RI, 1994, DRUG SAFETY, V11, P318, DOI 10.2165/00002018 199411050 00004
   Hernández G, 2001, ORAL SURG ORAL MED O, V92, P526, DOI 10.1067/moe.2001.116152
   Hershman DL, 2011, BREAST CANCER RES TR, V125, P767, DOI 10.1007/s10549 010 1278 0
   HERTZ RS, 1980, J AM DENT ASSOC, V100, P713, DOI 10.14219/jada.archive.1980.0235
   HEYDENREICH G, 1977, ACTA MED SCAND, V202, P61
   Hilas O, 2007, AM J HEALTH SYST PH, V64, P273, DOI 10.2146/ajhp060071
   Hoefert S, 2010, ORAL SURG ORAL MED O, V110, P463, DOI 10.1016/j.tripleo.2010.04.049
   Hom KA, 2012, INT J PEDIATR OTORHI, V76, P14, DOI 10.1016/j.ijporl.2011.07.016
   Hoshida Y, 2007, J RHEUMATOL, V34, P322
   Hung SL, 2006, PHARMACOGENET GENOM, V16, P297, DOI 10.1097/01.fpc.0000199500.46842.4a
   Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102
   Iacopino AM, 1997, J PERIODONTOL, V68, P73, DOI 10.1902/jop.1997.68.1.73
   Ichikawa A, 2013, EUR J HAEMATOL, V91, P20, DOI 10.1111/ejh.12116
   Inamadar AC, 2002, BRIT J DERMATOL, V147, P1025, DOI 10.1046/j.1365 2133.2002.49886.x
   Insert P, 2009, INSERT P LIPITOR ATO
   Jain V K, 1991, Ann Dent, V50, P9
   Kalantzis A, 2005, ORAL SURG ORAL MED O, V100, P52, DOI 10.1016/j.tripleo.2004.08.020
   Kandil AO, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748 717X 5 49
   Kataoka M, 2000, J CELL PHYSIOL, V182, P351, DOI 10.1002/(SICI)1097 4652(200003)182:3<351::AID JCP5>3.3.CO;2 L
   Katsenos S, 2012, ARCH BRONCONEUMOL, V48, P218, DOI [10.1016/j.arbr.2012.03.004, 10.1016/j.arbres.2012.01.007]
   Kikuchi K, 2010, HEAD NECK PATHOL, V4, P305, DOI 10.1007/s12105 010 0202 6
   Kleinegger CL, 2000, ORAL SURG ORAL MED O, V90, P189, DOI 10.1067/moe.2000.106340
   Koch FP, 2011, ORAL MAXILLOFAC SURG, V15, P63, DOI 10.1007/s10006 010 0224 y
   Kollmannsberger C, 2011, ONCOLOGIST, V16, P543, DOI 10.1634/theoncologist.2010 0263
   KORSTANJE MJ, 1995, CLIN EXP DERMATOL, V20, P10, DOI 10.1111/j.1365 2230.1995.tb01275.x
   Kragelund C, 2010, J ORAL PATHOL MED, V39, P497, DOI 10.1111/j.1600 0714.2010.00897.x
   Kragelund C, 2009, J ORAL PATHOL MED, V38, P63, DOI 10.1111/j.1600 0714.2008.00702.x
   Kulkantrakorn K, 2012, PAIN PRACT, V12, P202, DOI 10.1111/j.1533 2500.2011.00479.x
   Langeland T, 2005, BRIT J DERMATOL, V152, P183, DOI 10.1111/j.1365 2133.2004.06315.x
   Lauritano D, 2014, INT J ORAL SCI, V6, P27, DOI 10.1038/ijos.2013.93
   Lavanya N, 2011, J Oral Maxillofac Pathol, V15, P127, DOI 10.4103/0973 029X.84474
   Le QT, 2011, J CLIN ONCOL, V29, P2808, DOI 10.1200/JCO.2010.32.4095
   LEE L, 1994, ORAL SURG ORAL MED O, V78, P607, DOI 10.1016/0030 4220(94)90173 2
   Lee WJ, 2009, BRIT J DERMATOL, V161, P1045, DOI 10.1111/j.1365 2133.2009.09290.x
   Lehloenya RJ, 2012, J ANTIMICROB CHEMOTH, V67, P2535, DOI 10.1093/jac/dks225
   Leombruno JP, 2009, ANN RHEUM DIS, V68, P1136, DOI 10.1136/ard.2008.091025
   Lerman MA, 2010, J AM DENT ASSOC, V141, P867, DOI 10.14219/jada.archive.2010.0285
   Lerman MA, 2009, ORAL SURG ORAL MED O, V107, P8, DOI 10.1016/j.tripleo.2008.07.022
   Li CC, 2012, HEAD NECK PATHOL, V6, P290, DOI 10.1007/s12105 011 0325 4
   Liebhaber MI, 1999, CHEST, V115, P886, DOI 10.1378/chest.115.3.886
   Lim DS, 2002, DERMATOLOGY, V205, P169, DOI 10.1159/000063899
   Lipworth AD, 2009, ONCOLOGY BASEL, V77, P257, DOI 10.1159/000258880
   Lisi P, 2004, J AM ACAD DERMATOL, V50, P648, DOI 10.1016/S0190 9622(03)02787 7
   Lo Muzio L, 2013, CLIN ORAL INVEST, V17, P333, DOI 10.1007/s00784 012 0767 4
   Logan R, 2009, CANCER CHEMOTH PHARM, V63, P239, DOI 10.1007/s00280 008 0732 8
   Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c
   Lowell Goldsmith SK, 2012, FITZPATRICKS DERMATO
   Lowndes S, 2002, ANN ONCOL, V13, P1948, DOI 10.1093/annonc/mdf350
   Mabrouk D, 2010, ANN PHARMACOTHER, V44, P1770, DOI 10.1345/aph.1P309
   Macario Barrel A, 2001, ANN DERMATOL VENER, V128, P1327
   Mahajan VK, 2005, INT J DERMATOL, V44, P796, DOI 10.1111/j.1365 4632.2004.02454.x
   Mahendra Aneet, 2006, Indian J Dermatol Venereol Leprol, V72, P391
   Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140 6736(02)07873 X
   Mann BS, 2005, CLIN CANCER RES, V11, P5671, DOI 10.1158/1078 0432.CCR 05 0354
   Marsot Dupuch K, 2004, EUR RADIOL, V14, pE155, DOI 10.1007/s00330 003 2045 y
   Martins F, 2013, ORAL ONCOL, V49, P293, DOI 10.1016/j.oraloncology.2012.11.008
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Mattsson U, 2010, ORAL SURG ORAL MED O, V110, pE19, DOI 10.1016/j.tripleo.2010.02.030
   Matz H, 1997, DERMATOLOGY, V195, P48, DOI 10.1159/000245685
   Mawardi H, 2011, BONE MARROW TRANSPL, V46, P884, DOI 10.1038/bmt.2011.77
   McCartan B E, 1997, Oral Dis, V3, P58
   MedFacts.com, 2013, MEDFACTS MET COV ADV
   Mignogna MD, 2009, ANN PHARMACOTHER, V43, P546, DOI [10.1345/aph.1L592, 10.1345/aph.1K592]
   Mocciaro F, 2011, J CROHNS COLITIS, V5, P173, DOI 10.1016/j.crohns.2011.01.003
   Mockenhaupt M, 2008, J INVEST DERMATOL, V128, P35, DOI 10.1038/sj.jid.5701033
   Morton RS, 1999, J PERIODONTOL, V70, P1464, DOI 10.1902/jop.1999.70.12.1464
   Moss AC, 2007, GASTROENTEROLOGY, V132, P829, DOI DOI 10.1053/J.GASTR0.2007.01.014]
   Naithani R, 2009, INDIAN PEDIATR, V46, P68
   Naranjo J, 2007, TRANSPL P, V39, P612, DOI 10.1016/j.transproceed.2006.12.028
   Nebeker JR, 2004, ANN INTERN MED, V140, P795, DOI 10.7326/0003 4819 140 10 200405180 00009
   Nisly S.A., 2013, J PHARM TECHNOL, V29, P149, DOI 10.1177/875512251302900309
   Niwa Y, 2003, BRIT J DERMATOL, V149, P960, DOI 10.1111/j.1365 2133.2003.05735.x
   OKADA N, 1993, BRIT J DERMATOL, V129, P403, DOI 10.1111/j.1365 2133.1993.tb03166.x
   Okui T, 2010, MOL CANCER THER, V9, P2960, DOI 10.1158/1535 7163.MCT 10 0489
   Otto S, 2013, J CRANIO MAXILL SURG, V41, P694, DOI 10.1016/j.jcms.2013.05.038
   Özkaya E, 2013, J AM ACAD DERMATOL, V69, DOI 10.1016/j.jaad.2012.08.019
   Özkaya Bayazit E, 2003, J AM ACAD DERMATOL, V49, P1003, DOI 10.1016/S0190 9622(03)01588 3
   Park SB, 2013, CA CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Pascual JC, 2006, INT J DERMATOL, V45, P1471, DOI 10.1111/j.1365 4632.2006.03171.x
   Perez Alvarez R, 2013, CURR OPIN RHEUMATOL, V25, P56, DOI 10.1097/BOR.0b013e32835b1366
   Piboonniyom SO, 2005, ORAL SURG ORAL MED O, V99, P696, DOI 10.1016/j.tripleo.2004.07.013
   Pinheiro RS, 2011, J CLIN PATHOL, V64, P1083, DOI 10.1136/jclinpath 2011 200187
   Pionetti C H, 2003, Allergol Immunopathol (Madr), V31, P291, DOI 10.1157/13052436
   Pradhan S, 2009, J NEPAL MED ASSOC, V48, P149, DOI 10.31729/jnma.232
   Irazabal MP, 2013, ANN PHARMACOTHER, V47, pE16, DOI 10.1345/aph.1R637
   PRICE EJ, 1995, DRUG SAFETY, V12, P283, DOI 10.2165/00002018 199512040 00008
   Pua VSC, 2006, AUSTRALAS J DERMATOL, V47, P57, DOI 10.1111/j.1440 0960.2006.00225.x
   Rachner TD, 2013, MAYO CLIN PROC, V88, P418, DOI 10.1016/j.mayocp.2013.01.002
   Rafii MS, 2005, NEUROLOGY, V65, P1906, DOI 10.1212/01.wnl.0000190262.59672.4c
   Reddy Ramana Bv, 2013, J Oral Maxillofac Pathol, V17, P431, DOI 10.4103/0973 029X.125214
   REINHARDT LA, 1983, CUTIS, V31, P98
   Robledo Sierra J, 2013, ORAL DIS, V19, P313, DOI 10.1111/odi.12009
   ROGER D, 1994, CLIN EXP DERMATOL, V19, P88, DOI 10.1111/j.1365 2230.1994.tb01128.x
   ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404
   Ruggiero SL, 2009, ANNU REV MED, V60, P85, DOI 10.1146/annurev.med.60.063007.134350
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Ruscin J Mark, 2006, Am J Geriatr Pharmacother, V4, P325
   Salvana EMT, 2009, CLIN MICROBIOL REV, V22, P274, DOI 10.1128/CMR.00040 08
   Samonis G, 2000, ONCOL REP, V7, P1389
   Schalock PC, 2005, J AM ACAD DERMATOL, V52, P705, DOI 10.1016/j.jaad.2004.11.074
   SCHINCAGLIA GP, 1992, J ORAL PATHOL MED, V21, P181, DOI 10.1111/j.1600 0714.1992.tb00098.x
   Schlosser BJ, 2010, DERMATOL THER, V23, P251, DOI 10.1111/j.1529 8019.2010.01322.x
   Schubert M M, 1991, Curr Opin Dent, V1, P384
   Scully C, 2004, CRIT REV ORAL BIOL M, V15, P221, DOI 10.1177/154411130401500405
   SCULLY C, 1994, CRIT REV ORAL BIOL M, V5, P125, DOI 10.1177/10454411940050020101
   Sebök B, 2004, ACTA DERM VENEREOL, V84, P229, DOI 10.1080/00015550310006851
   Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713
   Seymour RA, 1996, J CLIN PERIODONTOL, V23, P165, DOI 10.1111/j.1600 051X.1996.tb02072.x
   Shino M, 2011, AM J OTOLARYNG, V32, P624, DOI 10.1016/j.amjoto.2010.11.014
   SIEGEL MA, 1991, J AM DENT ASSOC, V122, P75, DOI 10.14219/jada.archive.1991.0284
   Siponen M, 2010, ORAL SURG ORAL MED O, V110, P319, DOI 10.1016/j.tripleo.2010.04.001
   Smidt Hansen T, 2013, J ORAL MAXIL SURG, V71, P1532, DOI 10.1016/j.joms.2013.03.019
   Sonis S, 2010, CANCER AM CANCER SOC, V116, P210, DOI 10.1002/cncr.24696
   Sonis Stephen T, 2010, Curr Opin Support Palliat Care, V4, P26, DOI 10.1097/SPC.0b013e328335fb76
   Southward J, 2009, ANN PHARMACOTHER, V43, P772, DOI 10.1345/aph.1L527
   Stoopler Eric T, 2003, Dent Clin North Am, V47, P517, DOI 10.1016/S0011 8532(03)00018 1
   Subramanian S, 2011, INFLAMM BOWEL DIS, V17, P99, DOI 10.1002/ibd.21370
   Sugerman PB, 2000, CLIN DERMATOL, V18, P533, DOI 10.1016/S0738 081X(00)00142 5
   Susser WS, 1999, J AM ACAD DERMATOL, V40, P367, DOI 10.1016/S0190 9622(99)70488 3
   TADINI G, 1991, ARCH DERMATOL, V127, P267, DOI 10.1001/archderm.127.2.267
   Tennis P, 2011, BRIT J DERMATOL, V165, P465, DOI 10.1111/j.1365 2133.2011.10363.x
   Thornhill MH, 2006, J ORAL PATHOL MED, V35, P233, DOI 10.1111/j.1600 0714.2006.00406.x
   Treister NS, 2004, ORAL SURG ORAL MED O, V97, P718, DOI 10.1016/j.tripleo.2003.11.006
   Triantos D, 1997, CLIN INFECT DIS, V25, P1392, DOI 10.1086/516131
   Trujillo M J, 2001, Allergol Immunopathol (Madr), V29, P133
   Tuccori M, 2011, DRUG SAFETY, V34, P849, DOI 10.2165/11593120 000000000 00000
   Vahabi Surena, 2014, Journal of Basic and Clinical Physiology and Pharmacology, V25, P167, DOI 10.1515/jbcpp 2013 0003
   VANDENHAUTE V, 1989, DERMATOLOGICA, V179, P10, DOI 10.1159/000248091
   Vassileva S, 1998, CLIN DERMATOL, V16, P379, DOI 10.1016/S0738 081X(98)00008 X
   Villa A, 2011, AUST DENT J, V56, P290, DOI 10.1111/j.1834 7819.2011.01347.x
   Wahiduzzaman M, 2008, Dermatol Online J, V14, P14
   Weller R, 1996, CLIN EXP DERMATOL, V21, P121, DOI 10.1111/j.1365 2230.1996.tb00033.x
   Weng RR, 2011, AM J HEALTH SYST PH, V68, P585, DOI 10.2146/ajhp100276
   Westbrook P, 1997, J PERIODONTOL, V68, P645, DOI 10.1902/jop.1997.68.7.645
   Westbury LW, 1997, J PERIODONTOL, V68, P84, DOI 10.1902/jop.1997.68.1.84
   Wijeratne C, 1996, AM J PSYCHIAT, V153, P735
   Wimmer CD, 2013, TRANSPL INT, V26, P999, DOI 10.1111/tri.12165
   WOLF ME, 1993, INT J CLIN PHARM TH, V31, P365
   WOLF R, 1994, DERMATOLOGY, V189, P1, DOI 10.1159/000246749
   Woo SB, 1996, BONE MARROW TRANSPL, V17, P1127
   Woo SB, 2009, ORAL ONCOL, V45, P740, DOI 10.1016/j.oraloncology.2008.10.001
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zavras AI, 2013, J AM DENT ASSOC, V144, P1014, DOI 10.14219/jada.archive.2013.0228
NR 220
TC 89
Z9 105
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 2212 4403
EI 1528 395X
J9 OR SURG OR MED OR PA
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol.
PD JAN
PY 2015
VL 119
IS 1
BP 35
EP 47
DI 10.1016/j.oooo.2014.09.009
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AY1FB
UT WOS:000347338000015
PM 25442252
OA hybrid
DA 2025 08 17
ER

PT J
AU Wong, CC
   Yeh, YY
   Chen, CH
   Manga, YB
   Jheng, PR
   Lu, CX
   Chuang, EY
AF Wong, Chin Chean
   Yeh, Yi Yen
   Chen, Chih Hwa
   Manga, Yankuba B.
   Jheng, Pei Ru
   Lu, Chu Xuan
   Chuang, Er Yuan
TI Effectiveness of treating segmental bone defects with a synergistic
   co delivery approach with platelet rich fibrin and tricalcium phosphate
SO MATERIALS SCIENCE & ENGINEERING C MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE PRF; TCP; Bone graft substitute; Bone regeneration
ID ALKALINE PHOSPHATASE; STEM CELLS; ALLOGRAFT; DIFFERENTIATION;
   RECONSTRUCTION; PROLIFERATION; REGENERATION; CONCENTRATE; INCREASES;
   SCAFFOLDS
AB Several studies have applied tricalcium phosphate (TCP) or autografts in bone tissue engineering to enhance the clinical regeneration of bone. Unfortunately, there are several drawbacks related to the use of autografts, including a risk of infection, blood loss, limited quantities, and donor site morbidities. Platelet rich fibrin (PRF) is a natural extracellular matrix (ECM) biomaterial that possesses bioactive factors, which can generally be used in regenerative medicine. The goal of the present investigation was to develop osteoconductive TCP incorporated with bioactive PRF for bio synergistic bone regeneration and examine the potential biological mechanisms and applications. Our in vitro results showed that PRF plus TCP had excellent biosafety and was favorable for initiating osteoblast cell attachment, slow release of bioactive factors, cell proliferation, cell migration, and ECM formation that potentially impacted bone repair. In a rabbit femoral segmental bone defect model, regeneration of bone was considerably augmented in defects locally implanted by PRF plus TCP according to radiographic and histologic examinations. Notably, the outcomes of this investigation suggest that the combination of PRF and TCP possesses novel synergistic and bio inspired functions that facilitate bone regeneration.
C1 [Wong, Chin Chean; Chen, Chih Hwa] Taipei Med Univ, Dept Orthoped, Shuang Ho Hosp, New Taipei, Taiwan.
   [Wong, Chin Chean; Chen, Chih Hwa] Taipei Med Univ, Coll Med, Sch Med, Dept Orthoped, Taipei, Taiwan.
   [Wong, Chin Chean; Chen, Chih Hwa] Taipei Med Univ, Res Ctr Biomed Devices, Taipei, Taiwan.
   [Wong, Chin Chean; Chen, Chih Hwa] Taipei Med Univ, Coll Med, Int PhD Program Cell Therapy & Regenerat Med, Taipei, Taiwan.
   [Yeh, Yi Yen; Manga, Yankuba B.; Jheng, Pei Ru; Lu, Chu Xuan; Chuang, Er Yuan] Taipei Med Univ, Coll Biomed Engn, Sch Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan.
   [Chuang, Er Yuan] Taipei Med Univ, Cell Physiol & Mol Image Res Ctr, Wan Fang Hosp, Taipei, Taiwan.
C3 Taipei Medical University; Shuang Ho Hospital; Taipei Medical
   University; Taipei Medical University; Taipei Medical University; Taipei
   Medical University; Taipei Medical University; Taipei Municipal WanFang
   Hospital
RP Chuang, EY (通讯作者)，Taipei Med Univ, Coll Biomed Engn, Sch Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan.
EM eychuang@tmu.edu.tw
OI Manga, Yankuba B./0000 0002 8750 3721
FU Taiwanese Ministry of Science and Technology [108 2320 B 038 061 MY3,
   108 2221 E 038 017 MY3, 109 2314 B 038]; Taipei Medical
   University Shuang Ho Hospital [108 TMU SHH 16]
FX This research work was financially supported by the Taiwanese Ministry
   of Science and Technology (grant nos.: 108 2320 B 038 061 MY3,
   108 2221 E 038 017 MY3 and 109 2314 B 038) and by Taipei Medical
   University Shuang Ho Hospital (108 TMU SHH 16) .
CR AHO AJ, 1994, CLIN ORTHOP RELAT R, P200
   Ariizumi T., 2019, J BIOMATER NANOBIOTE, V10, P159, DOI [10.4236/jbnb.2019.103009, DOI 10.4236/JBNB.2019.103009]
   Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623 200310000 00010
   Bansal S, 2017, Indian J Dent Sci, V9, pS49, DOI [10.4103/IJDS.IJDS5517, DOI 10.4103/IJDS.IJDS5517]
   Bohner M, 2004, BIOMATERIALS, V25, P3569, DOI 10.1016/j.biomaterials.2003.10.032
   Bothe F, 2018, ACTA BIOMATER, V76, P135, DOI 10.1016/j.actbio.2018.06.026
   Chang YC, 2011, AUST DENT J, V56, P365, DOI 10.1111/j.1834 7819.2011.01362.x
   Chen T, 2020, MAT SCI ENG C MATER, V116, DOI 10.1016/j.msec.2020.111148
   Choukroun J, 2006, ORAL SURG ORAL MED O, V101, P299, DOI 10.1016/j.tripleo.2005.07.012
   Doi K, 2020, RSC ADV, V10, P22684, DOI 10.1039/d0ra03202f
   Dong, BIOACT MATER, V6, P3839
   Ehrler DM, 2000, CLIN ORTHOP RELAT R, P38
   Fellah BH, 2007, KEY ENG MATER, V330 332, P1063, DOI 10.4028/www.scientific.net/KEM.330 332.1063
   Ma FB, 2020, MAT SCI ENG C MATER, V116, DOI 10.1016/j.msec.2020.111217
   Fenelon M, 2021, MAT SCI ENG C MATER, V124, DOI 10.1016/j.msec.2021.112032
   Fernández Medina T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246243
   Gazdag, 1995, J Am Acad Orthop Surg, V3, P1
   Ghanaati, 2018, SJIJOGF DENT, V1, P80
   Golafshan N, 2021, MAT SCI ENG C MATER, V120, DOI 10.1016/j.msec.2020.111611
   Grecu AF, 2019, MEDICINA LITHUANIA, V55, DOI 10.3390/medicina55050141
   H. Food Drug Administration, 2005, FED REGISTER, V70, P21947
   Haleem AM, 2010, CARTILAGE, V1, P253, DOI 10.1177/1947603510366027
   Heo JH, 2018, TISSUE ENG REGEN MED, V15, P793, DOI 10.1007/s13770 018 0167 1
   Kargarpour Z, 2020, J PERIODONTOL, V91, P413, DOI 10.1002/JPER.19 0109
   Knabe C, 2017, BIOMATERIALS, V123, P48, DOI 10.1016/j.biomaterials.2017.01.035
   Kobayashi E, 2016, CLIN ORAL INVEST, V20, P2353, DOI 10.1007/s00784 016 1719 1
   Lee D, 2019, CHEM ENG J, V365, P30, DOI 10.1016/j.cej.2019.02.020
   Lei LH, 2020, J PERIODONTOL, V91, P462, DOI 10.1002/JPER.19 0290
   Li M, 2017, MAT SCI ENG C MATER, V75, P149, DOI 10.1016/j.msec.2017.02.042
   Li N, 2019, CHEM ENG J, V371, P618, DOI 10.1016/j.cej.2019.04.017
   Li XJ, 2019, MOL MED REP, V19, P943, DOI 10.3892/mmr.2018.9714
   LI XQ, 1991, ACTA ANAT, V140, P236
   Matassi F, 2011, CLIN CASES MINER BON, V8, P21
   Meng ZL, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1235 5
   Mikai A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197028
   Miron RJ, 2019, J PERIODONTOL, V90, P817, DOI 10.1002/JPER.18 0553
   Miron RJ, 2018, ACTA BIOMATER, V75, P35, DOI 10.1016/j.actbio.2018.05.021
   Miron RJ, 2017, TISSUE ENG PART B RE, V23, P83, DOI [10.1089/ten.TEB.2016.0233, 10.1089/ten.teb.2016.0233]
   Miron RJ, 2013, CLIN ORAL INVEST, V17, P981, DOI 10.1007/s00784 012 0764 7
   Moya JS, 2016, SCI REP UK, V6, DOI 10.1038/srep31478
   Murphy CM, 2010, BIOMATERIALS, V31, P461, DOI 10.1016/j.biomaterials.2009.09.063
   Nair A, 2010, TISSUE ENG PART C ME, V16, P23, DOI [10.1089/ten.tec.2009.0094, 10.1089/ten.TEC.2009.0094]
   Parmaksiz M, 2021, MAT SCI ENG C MATER, V124, DOI 10.1016/j.msec.2021.112065
   Qian ZY, 2020, ACS APPL MATER INTER, V12, P55659, DOI 10.1021/acsami.0c17142
   Quirynen M., 2019, M J I J O O IMPLANTS, V34
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Shirakata Y., 2021, CLIN ORAL INVEST, P1
   Shuai CJ, 2021, ACS SUSTAIN CHEM ENG, V9, P1814, DOI 10.1021/acssuschemeng.0c08009
   SIFFERT RS, 1951, J EXP MED, V93, P415, DOI 10.1084/jem.93.5.415
   Sumida R, 2019, EXP THER MED, V18, P358, DOI 10.3892/etm.2019.7560
   Taylor BL, 2020, REGEN ENG TRANSL MED, V6, P241, DOI 10.1007/s40883 018 0084 9
   Trivisonno A, 2019, STEM CELL TRANSL MED, V8, P1265, DOI 10.1002/sctm.19 0166
   Uetanabaro LC, 2020, INT J ORAL MAX IMPL, V35, P70, DOI 10.11607/jomi.7745
   Vadalà G, 2008, J TISSUE ENG REGEN M, V2, P515, DOI 10.1002/term.121
   Volkov AV, 2020, MAT SCI ENG C MATER, V114, DOI 10.1016/j.msec.2020.110991
   Wang XS, 2019, ACS APPL MATER INTER, V11, P9223, DOI 10.1021/acsami.8b22041
   Wang ZX, 2015, TISSUE ENG PT A, V21, P2346, DOI [10.1089/ten.tea.2015.0071, 10.1089/ten.TEA.2015.0071]
   Wong CC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093221
   Woo HN, 2021, BIOACT MATER, V6, P3328, DOI 10.1016/j.bioactmat.2021.03.012
   Wu CL, 2012, AUST DENT J, V57, P207, DOI 10.1111/j.1834 7819.2012.01686.x
   Yang YW, 2021, BIOACT MATER, V6, P1230, DOI 10.1016/j.bioactmat.2020.10.017
   Yang ZM, 2016, ONCOL LETT, V12, P1445, DOI 10.3892/ol.2016.4777
   Yaszemski MJ, 1996, BIOMATERIALS, V17, P175, DOI 10.1016/0142 9612(96)85762 0
   Zhang FY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15580 6
   Zhao FJ, 2020, CHEM ENG J, V402, DOI 10.1016/j.cej.2020.126203
   Zhao YH, 2013, BIOMATERIALS, V34, P5506, DOI 10.1016/j.biomaterials.2013.03.079
   Zhao YZ, 2021, MAT SCI ENG C MATER, V122, DOI 10.1016/j.msec.2021.111877
NR 68
TC 11
Z9 11
U1 2
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD OCT
PY 2021
VL 129
AR 112364
DI 10.1016/j.msec.2021.112364
EA AUG 2021
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA WA3VO
UT WOS:000702816800003
PM 34579883
DA 2025 08 17
ER

PT J
AU Gao, L
   Cai, GP
   Shi, XJ
AF Gao, Lei
   Cai, Guoping
   Shi, Xiaojun
TI β Ecdysterone Induces Osteogenic Differentiation in Mouse Mesenchymal
   Stem Cells and Relieves Osteoporosis
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE beta ecdysterone; mesenchymal stem cell; osteogenic differentiation;
   estrogen receptors; osteoporosis
ID ACID INDUCED OSTEOPOROSIS; BONE MARROW CULTURE; OSTEOBLAST
   DIFFERENTIATION; PATHWAY; GENE; CBFA1; RATS
AB The effect on bone tissue of beta ecdysterone, a type of ecdysteroid found in many plants, has not been previously investigated. In this study, we found that beta ecdysterone treatment significantly induced alkaline phosphatase (ALP) activity in mesenchymal stem cells in a dose dependent manner. Real time polymerase chain reaction (PCR) showed that Runx2, osteocalcin, and type I collagen expression also increased. ICI182780, a specific estrogen receptor antagonist, inhibited the upregulation of ALP activity. Moreover, beta ecdysterone promoted estrogen receptor (ER) reporter gene activity; however, ICI182780 reversed its effect, suggesting that beta ecdysterone has stimulatory effects on osteogenic differentiation via the Ell. Furthermore, beta ecdysterone alleviated osteoporosis symptoms in a mouse model without obvious side effects. Therefore beta ecdysterone may be a promising candidate drug for the treatment of osteoporosis.
C1 [Gao, Lei; Cai, Guoping] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.
   [Gao, Lei; Cai, Guoping; Shi, Xiaojun] Tsinghua Univ, Grad Sch Shenzhen, Div Life Sci, Shenzhen 518055, Peoples R China.
C3 Tsinghua University; Tsinghua University; Tsinghua Shenzhen
   International Graduate School
RP Cai, GP (通讯作者)，Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China.
EM gaolei1107@hotmail.com; shixj@sz.tsinghua.edu.cn
RI Gao, Liang/O 6598 2014
CR AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107
   Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020
   Ji XH, 2000, J BONE MINER METAB, V18, P132, DOI 10.1007/s007740050103
   Jia TL, 2003, BIOCHEM PHARMACOL, V65, P709, DOI 10.1016/S0006 2952(02)01585 X
   Jordan VC, 2003, J MED CHEM, V46, P1081, DOI 10.1021/jm020450x
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Liao EY, 2003, ENDOCR RES, V29, P23, DOI 10.1081/ERC 120018674
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   OTAKA T, 1980, NATURE, V285, P43
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Liao QC, 2007, ACTA PHARMACOL SIN, V28, P1597, DOI 10.1111/j.1745 7254.2007.00632.x
   Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756 3282(97)00276 7
   Song C.L., 2002, CHINESE J OSTEOPOROS, V8, P266
   Spinella Jaegle S, 2001, J CELL SCI, V114, P2085
   Tou JCL, 2005, EXP BIOL MED, V230, P31
   Wei M, 2007, AM J CHINESE MED, V35, P663, DOI 10.1142/S0192415X07005156
   WEI PL, 2005, J CELL BIOCHEM, V94, P307
   WU X, 2006, CHIN J CLIN REHABIL, V19, P72
   Xu Peng, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P1785
   YOSHIDA T, 1971, BIOCHEM PHARMACOL, V20, P3263, DOI 10.1016/0006 2952(71)90431 X
NR 27
TC 40
Z9 49
U1 0
U2 8
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2 12 15 SHIBUYA, SHIBUYA KU, TOKYO, 150 0002, JAPAN
SN 0918 6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD DEC
PY 2008
VL 31
IS 12
BP 2245
EP 2249
DI 10.1248/bpb.31.2245
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 376SZ
UT WOS:000261204600013
PM 19043207
OA Bronze
DA 2025 08 17
ER

PT J
AU Tran, NMP
   Dang, NTN
   Nguyen, NTP
   Nguyen, LVH
   Quyen, TN
   Tran, PA
   Lee, BT
   Hiep, NT
AF Nam Minh Phuong Tran
   Nhi Thao Ngoc Dang
   Nghi Thi Phuong Nguyen
   Long Vuong Hoang Nguyen
   Tran Ngoc Quyen
   Tran, Phong A.
   Lee, Byong Taek
   Nguyen Thi Hiep
TI Fabrication of injectable bone substitute loading porous
   simvastatin loaded poly(lactic co glycolic acid) microspheres
SO INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS
LA English
DT Article
DE Biphasic calcium phosphate; drug delivery system; injectable bone
   substitute; poly(lactic co glycolic acid) microspheres; simvastatin
ID PLGA MICROSPHERES; IN VITRO; CALCIUM CITRATE; OPERATIVE TIME;
   CITRIC ACID; SCAFFOLD; VIVO; BIOMATERIALS; OSTEOGENESIS; COMPOSITES
AB An injectable bone substitute (IBS) with well controlled release mechanism of simvastatin (SIM) was fabricated from SIM loaded porous poly(lactic co glycolic acid) microspheres (PLGA MSs), biphasic calcium phosphates (BCP) and CaCO3 nano powder as the solid phase and gelatin, citric acid and hydroxypropyl methylcellulose as the liquid phase. The ratios of PLGA MSs and BCP were varied to obtain IBS with optimal mechanical properties, biocompatibility and bioactivity. In vitro test with MG 63 pre osteoblast cells showed that IBS with higher amount of PLGA MSs yield better cell adhesion and proliferation. In vivo study on rabbit femoral defect also suggested that the IBS promoted osteogenesis.
C1 [Nam Minh Phuong Tran; Nhi Thao Ngoc Dang; Nghi Thi Phuong Nguyen; Long Vuong Hoang Nguyen; Nguyen Thi Hiep] Vietnam Natl Univ Ho Chi Minh City VNU HCM, Int Univ, Dept Biomed Engn, Tissue Engn & Regenerat Med Lab, Ho Chi Minh City, Vietnam.
   [Tran Ngoc Quyen] Vietnam Acad Sci & Technol, Inst Appl Mat Sci, Ho Chi Minh City, Vietnam.
   [Tran Ngoc Quyen] Grad Univ Sci & Technol Viet Nam, Vietnam Acad Sci & Technol, Ho Chi Minh City, Vietnam.
   [Tran, Phong A.] Queensland Univ Technol, Brisbane, Qld, Australia.
   [Lee, Byong Taek] Soonchunhyang Univ, Coll Med, Dept Biomed Engn & Mat, Cheonan, South Korea.
C3 Vietnam National University Ho Chi Minh City (VNUHCM) System; Vietnam
   Academy of Science & Technology (VAST); Vietnam Academy of Science &
   Technology (VAST); Queensland University of Technology (QUT);
   Soonchunhyang University
RP Hiep, NT (通讯作者)，Int Univ, Dept Biomed Engn, Vietnam Natl Univ Ho Chi Minh City, Quarter 6,Ward Linh Trung, Ho Chi Minh City 700000, Vietnam.
EM nthiep@hcmiu.edu.vn
RI ; Tran, Phong/I 4039 2017; Lee, YongTaek/B 8483 2009; Thu Huong,
   Nguyen/AAG 7775 2020; Tran, Nam/LJK 6374 2024
OI Nguyen, Long/0000 0002 6851 6818; Nguyen, Nghi/0000 0002 9544 5250;
   Tran, Phong/0000 0003 2820 7399; Nguyen, Thi Hiep/0000 0002 5843 4392;
   Minh phuong Tran, Nam/0000 0003 3446 2230; Lee,
   Byong Taek/0000 0001 9072 0033; Nguyen, Long
   Vuong Hoang/0000 0003 0669 0842
FU Vietnam National University   Ho Chi Minh City [1161/Q D DHQG KHCN];
   Office of Naval Research (ONR) [N62909 14 1 N011 P00001]
FX The facility for this research was supported by Vietnam National
   University   Ho Chi Minh City [grant number: 1161/Q D DHQG KHCN]. The
   labor was supported by Office of Naval Research (ONR) [grant number:
   N62909 14 1 N011 P00001].
CR Bao TQ, 2011, J MATER SCI, V46, P2510, DOI 10.1007/s10853 010 5101 4
   Daley BJ, 2015, J AM COLL SURGEONS, V220, P550, DOI 10.1016/j.jamcollsurg.2014.12.040
   Djagny KB, 2001, CRIT REV FOOD SCI, V41, P481, DOI 10.1080/20014091091904
   Fellah BH, 2006, J ORTHOP RES, V24, P628, DOI 10.1002/jor.20125
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Ghadam AGJ, 2013, IRAN J CHEM CHEM ENG, V32, P27
   Grimandi G, 1998, J BIOMED MATER RES, V39, P660, DOI 10.1002/(SICI)1097 4636(19980315)39:4<660::AID JBM22>3.0.CO;2 9
   Ignjatovic NL, 2007, ACTA BIOMATER, V3, P927, DOI 10.1016/j.actbio.2007.04.001
   Jang DW, 2012, SCI TECHNOL ADV MAT, V13, DOI 10.1088/1468 6996/13/3/035009
   Ju Hj M. V., 2007, INT J PHARMACEUT, V12, P340
   Khairoun I, 2002, J BIOMED MATER RES, V60, P633, DOI 10.1002/jbm.10132
   Khan FS, 2014, ADV MATER SCI ENG, V2014, DOI 10.1155/2014/921815
   Kim HW, 2005, J MATER SCI MATER M, V16, P189, DOI 10.1007/s10856 005 6679 y
   Lee YT, 2007, MATER CHEM PHYS, V104, P249, DOI 10.1016/j.matchemphys.2007.02.009
   Li JF, 2016, BIOENGINEERED, V7, P376, DOI 10.1080/21655979.2016.1226656
   Li Y, 2015, J ORTHOP TRANSL, V3, P95, DOI 10.1016/j.jot.2015.05.002
   Liu H, 2006, ACTA BIOMATER, V2, P557, DOI 10.1016/j.actbio.2006.03.007
   Low KL, 2010, J BIOMED MATER RES B, V94B, P273, DOI 10.1002/jbm.b.31619
   MARKS DC, 1992, LEUKEMIA RES, V16, P1165, DOI 10.1016/0145 2126(92)90114 M
   Masaeli R, 2016, MAT SCI ENG C MATER, V69, P171, DOI 10.1016/j.msec.2016.06.033
   Masaeli R, 2016, IRAN J PHARM RES, V15, P205
   Nath SD, 2014, J BIOMATER APPL, V28, P1151, DOI 10.1177/0885328213499272
   Nath SD, 2013, INT J PHARMACEUT, V443, P87, DOI 10.1016/j.ijpharm.2012.12.037
   Nguyen TH., 2016, J. Biomed. Sci. Eng, V9, P419, DOI [10.4236/jbise.2016.99037, DOI 10.4236/JBISE.2016.99037]
   Nguyen TH, 2010, J MATER SCI MATER M, V21, P1969, DOI 10.1007/s10856 010 4048 y
   Piskin E, 2009, J BIOMED MATER RES A, V90A, P1137, DOI 10.1002/jbm.a.32157
   Sadiasa A, 2013, J DRUG TARGET, V21, P719, DOI 10.3109/1061186X.2013.811512
   Schmitt M, 2002, BIOMATERIALS, V23, P2789, DOI 10.1016/S0142 9612(02)00015 7
   Short HL, 2017, J PEDIATR SURG, V52, P1561, DOI 10.1016/j.jpedsurg.2017.03.044
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Thai VV, 2010, J MATER SCI MATER M, V21, P1867, DOI 10.1007/s10856 010 4058 9
   Nguyen TH, 2013, J BIOMATER APPL, V28, P514, DOI 10.1177/0885328212462257
   Nguyen TH, 2013, J BIOMED MATER RES A, V101, P797, DOI 10.1002/jbm.a.34382
   Thi Hiep Nguyen, 2010, Journal of Biomedical Science & Engineering, V3, P1117, DOI 10.4236/jbise.2010.312145
   Wang CY, 2010, J TAIWAN INST CHEM E, V41, P203, DOI 10.1016/j.jtice.2009.08.006
   Wang DA, 2005, TISSUE ENG, V11, P201, DOI 10.1089/ten.2005.11.201
   Wong RWK, 2003, BRIT J ORAL MAX SURG, V41, P244, DOI 10.1016/S0266 4356(03)00081 0
   Yamaguchi I, 2003, COLLOID SURFACE A, V214, P111, DOI 10.1016/S0927 7757(02)00365 5
   Yokoyama A, 2002, BIOMATERIALS, V23, P1091, DOI 10.1016/S0142 9612(01)00221 6
   Yoon ST, 2002, CLIN ORTHOP RELAT R, P33
   Zhang HX, 2015, J BIOMED MATER RES A, V103, P3250, DOI 10.1002/jbm.a.35463
   Zhang W, 2012, ASIAN PAC J TROP MED, V5, P310, DOI 10.1016/S1995 7645(12)60045 5
NR 42
TC 1
Z9 2
U1 2
U2 55
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO 0154 OSLO, NORWAY
SN 0091 4037
EI 1563 535X
J9 INT J POLYM MATER PO
JI Int. J. Polym. Mater. Polym. Biomat.
PD APR 12
PY 2020
VL 69
IS 6
BP 351
EP 362
DI 10.1080/00914037.2019.1566726
PG 12
WC Materials Science, Biomaterials; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science; Polymer Science
GA KG3JE
UT WOS:000509837900002
DA 2025 08 17
ER

PT J
AU Li, YF
   Qiao, ZF
   Yu, FL
   Hu, HT
   Huang, YD
   Xiang, Q
   Zhang, QH
   Yang, Y
   Zhao, YP
AF Li, Yangfan
   Qiao, Zhifen
   Yu, Fenglin
   Hu, Huiting
   Huang, Yadong
   Xiang, Qi
   Zhang, Qihao
   Yang, Yan
   Zhao, Yueping
TI Transforming Growth Factor β3/Chitosan Sponge (TGF β3/CS) Facilitates
   Osteogenic Differentiation of Human Periodontal Ligament Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE transforming growth factor beta 3; chitosan sponge; human periodontal
   ligament cells; osteogenic differentiation
ID BONE REGENERATION; CHONDROGENIC DIFFERENTIATION; OSTEOBLAST
   DIFFERENTIATION; INDUCTION; MEMBRANES; PROLIFERATION; SCAFFOLDS;
   HYDROGEL; MODEL; BETA
AB Periodontal disease is the main reason for tooth loss in adults. Tissue engineering and regenerative medicine are advanced technologies used to manage soft and hard tissue defects caused by periodontal disease. We developed a transforming growth factor beta 3/chitosan sponge (TGF beta 3/CS) to repair periodontal soft and hard tissue defects. We investigated the proliferation and osteogenic differentiation behaviors of primary human periodontal ligament stem cells (hPDLSCs) to determine the bioactivity and potential application of TGF beta 3 in periodontal disease. We employed calcein AM/propidium iodide (PI) double labeling or cell membranes (CM) Dil labeling coupled with fluorescence microscopy to trace the survival and function of cells after implantation in vitro and in vivo. The mineralization of osteogenically differentiated hPDLSCs was confirmed by measuring alkaline phosphatase (ALP) activity and calcium content. The levels of COL I, ALP, TGF beta RI, TGF beta RII, and Pp38/t p38 were assessed by western blotting to explore the mechanism of bone repair prompted by TGF beta 3. When hPDLSCs were implanted with various concentrations of TGF beta 3/CS (62.5 500 ng/mL), ALP activity was the highest in the TGF beta 3 (250 ng/mL) group after 7 d (p < 0.05 vs. control). The calcium content in each group was increased significantly after 21 and 28 d (p < 0.001 vs. control). The optimal result was achieved by the TGF beta 3 (500 ng/mL) group. These results showed that TGF beta 3/CS promotes osteogenic differentiation of hPDLSCs, which may involve the p38 mitogen activated protein kinase (MAPK) signaling pathway. TGF beta 3/CS has the potential for application in the repair of incomplete alveolar bone defects.
C1 [Li, Yangfan; Qiao, Zhifen; Yu, Fenglin; Huang, Yadong; Xiang, Qi; Zhang, Qihao; Yang, Yan] Jinan Univ, Inst Biomed, Guangzhou 510632, Guangdong, Peoples R China.
   [Li, Yangfan; Qiao, Zhifen; Yu, Fenglin; Huang, Yadong; Xiang, Qi; Zhang, Qihao; Yang, Yan] Jinan Univ, Guangdong Prov Key Lab Bioengn Med, Guangzhou 510632, Guangdong, Peoples R China.
   [Hu, Huiting; Zhao, Yueping] Jinan Univ, Dept Stomatol, Coll Med, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Jinan University; Jinan University
RP Xiang, Q (通讯作者)，Jinan Univ, Inst Biomed, Guangzhou 510632, Guangdong, Peoples R China.; Xiang, Q (通讯作者)，Jinan Univ, Guangdong Prov Key Lab Bioengn Med, Guangzhou 510632, Guangdong, Peoples R China.
EM lyfvlyf421@163.com; zfq525525@163.com; yukylinyu@163.com;
   huhuiting94@126.com; tydhuang@jnu.edu.cn; txiangqi@jnu.edu.cn;
   tqhzhang@jnu.edu.cn; yangyan107@jnu.edu.cn; ypzhao6026@gmail.com
OI Xiang, QI/0000 0002 7833 5746
FU Administration of Ocean and Fisheries of Guangdong Province
   [GDME 2018C013, 17]; Guangzhou Science and Technology Program key
   projects [201803010044]; Science and technology program of Tianhe
   District, Guangzhou City [201704YG066]
FX This research was funded by Administration of Ocean and Fisheries of
   Guangdong Province, grant number GDME 2018C013. This research was funded
   by Administration of Ocean and Fisheries of Guangdong Province, grant
   number Yuecainong, 2017, no.17. This research was funded by Guangzhou
   Science and Technology Program key projects, grant number 201803010044.
   This research was funded by Science and technology program of Tianhe
   District, Guangzhou City, grant number 201704YG066.D
CR Aisenbrey EA, 2019, BIOMATERIALS, V190, P51, DOI 10.1016/j.biomaterials.2018.10.028
   Akintoye SO, 2018, ORAL DIS, V24, P49, DOI 10.1111/odi.12761
   Al Askar M, 2018, SAUDI DENT J, V30, P256, DOI 10.1016/j.sdentj.2018.05.004
   Bottino MC, 2012, DENT MATER, V28, P703, DOI 10.1016/j.dental.2012.04.022
   Chen FM, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0288 1
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Deng MY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0693 0
   Douglas TEL, 2018, J DAIRY SCI, V101, P28, DOI 10.3168/jds.2017 13119
   EzEldeen M, 2019, J DENT RES, V98, P406, DOI 10.1177/0022034519828701
   Feldman DS, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9040065
   Ge B, 2019, ARCH ORAL BIOL, V99, P126, DOI 10.1016/j.archoralbio.2019.01.007
   Gjerde C, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0951 9
   Goker F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143551
   Grafe I, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022202
   Guerrero J, 2018, ACTA BIOMATER, V77, P142, DOI 10.1016/j.actbio.2018.07.004
   Gupta Akshat, 2019, J Oral Biol Craniofac Res, V9, P91, DOI 10.1016/j.jobcr.2018.11.001
   Hameed MH, 2019, J PROSTHODONT, V28, P421, DOI 10.1111/jopr.13028
   Iviglia G, 2019, J FUNCT BIOMATER, V10, DOI 10.3390/jfb10010003
   Jing H, 2019, FASEB J, V33, P5641, DOI 10.1096/fj.201802137RRR
   Kim SH, 2009, J PERIODONTOL, V80, P1815, DOI 10.1902/jop.2009.090249
   Klar RM, 2014, BIOMATERIALS, V35, P2773, DOI 10.1016/j.biomaterials.2013.12.062
   Kloss FR, 2018, CLIN ORAL IMPLAN RES, V29, P1163, DOI 10.1111/clr.13380
   Laidmäe I, 2018, J MATER SCI MATER M, V29, DOI 10.1007/s10856 018 6192 8
   Larsson L, 2016, J DENT RES, V95, P255, DOI 10.1177/0022034515618887
   Lee HL, 2016, STEM CELLS, V34, P711, DOI 10.1002/stem.2231
   Lin CY, 2013, BIOMATERIALS, V34, P9401, DOI 10.1016/j.biomaterials.2013.08.051
   Liu YM, 2019, ASIAN J PHARM SCI, V14, P511, DOI 10.1016/j.ajps.2018.09.007
   McDermott AM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7756
   Meguid EA, 2018, J CELL PHYSIOL, V233, P1825, DOI 10.1002/jcp.25940
   Menon AH, 2018, CARBOHYD POLYM, V195, P356, DOI 10.1016/j.carbpol.2018.04.115
   Moioli EK, 2008, BONE, V42, P332, DOI 10.1016/j.bone.2007.10.004
   Paolella F, 2019, J BIOMED MATER RES A, V107, P2774, DOI 10.1002/jbm.a.36780
   Rakhmatia YD, 2013, J PROSTHODONT RES, V57, P3, DOI 10.1016/j.jpor.2012.12.001
   Reynolds MA, 2015, J PERIODONTOL, V86, pS105, DOI 10.1902/jop.2015.140378
   Ripamonti U, 2008, J CELL MOL MED, V12, P1029, DOI 10.1111/j.1582 4934.2008.00126.x
   Ripamonti U, 2019, J PERIODONTAL RES, V54, P10, DOI 10.1111/jre.12596
   Ripamonti U, 2015, BIOMATERIALS, V49, P90, DOI 10.1016/j.biomaterials.2015.01.058
   Ripamonti U, 2014, BIOMATERIALS, V35, P9407, DOI 10.1016/j.biomaterials.2014.07.053
   Safari S, 2018, WORLD J STEM CELLS, V10, P66, DOI 10.4252/wjsc.v10.i6.66
   Sasaki H, 2018, AM J SPORT MED, V46, P2402, DOI 10.1177/0363546518782973
   Shanbhag S, 2017, J TISSUE ENG REGEN M, V11, P2935, DOI 10.1002/term.2198
   Shimabukuro Y, 2011, J CELL PHYSIOL, V226, P809, DOI 10.1002/jcp.22406
   Soldatos NK, 2017, QUINTESSENCE INT, V48, P131, DOI 10.3290/j.qi.a37133
   Urban IA, 2019, J CLIN PERIODONTOL, V46, P319, DOI 10.1111/jcpe.13061
   Wang LY, 2018, INT J MOL MED, V41, P829, DOI 10.3892/ijmm.2017.3294
   Yang Q, 2017, INT J NANOMED, V12, P6721, DOI 10.2147/IJN.S141888
   Yu W, 2018, BIOMED PHARMACOTHER, V98, P9, DOI 10.1016/j.biopha.2017.11.144
   Zang SQ, 2014, CARBOHYD POLYM, V113, P240, DOI 10.1016/j.carbpol.2014.07.018
   Zhu YY, 2019, J PERIODONTOL, V90, P400, DOI 10.1002/JPER.18 0251
NR 49
TC 22
Z9 24
U1 1
U2 20
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT 2
PY 2019
VL 20
IS 20
AR 4982
DI 10.3390/ijms20204982
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JQ3AZ
UT WOS:000498822800014
PM 31600954
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Veale, DJ
   Ritchlin, C
   FitzGerald, O
AF Veale, DJ
   Ritchlin, C
   FitzGerald, O
TI Immunopathology of psoriasis and psoriatic arthritis
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID SYNOVIAL MEMBRANE; OSTEOCLAST DIFFERENTIATION; RHEUMATOID ARTHRITIS;
   BONE RESORPTION; T LYMPHOCYTES; CELL; EXPRESSION; CYTOKINE; JOINT;
   SUSCEPTIBILITY
AB Psoriatic arthritis (PsA) is characterised by several unique clinical features that differentiate it from rheumatoid arthritis (RA). Attempts to identify immunopothological mechanisms, some shared with psoriasis, that underlie these differences from RA have been most challenging. Recent research studies, however, highlight novel findings in PsA at the molecular, cellular, and tissue levels that form the basis far a new understanding of this relatively common form of inflammatory arthritis. In particular, the availability of new, biological antitumour necrosis factor a therapies have allowed further insight into the immunopathology of psoriasis and PsA. This brief review focuses on immunohistological studies in psoriatic skin, PsA synovium, and bone to demonstrate how these data advance our knowledge of disease pathogenesis.
C1 St Vincents Univ, Dublin, Ireland.
   Univ Rochester, Sch Med, Rochester, NY USA.
C3 University of Rochester
RP St Vincents Univ Hosp, Dept Rheumatol, Elm Pk, Dublin 4, Ireland.
EM d.veale@st vincents.ie
RI ; Veale, David/F 5670 2010
OI ritchlin, christopher/0000 0002 2602 1219; Veale,
   Douglas/0000 0003 2802 4971
CR Antoni C, 2002, ARTHRIT RHEUM ARTHR, V47, P506, DOI 10.1002/art.10671
   Asumalahti K, 2001, HUM MOL GENET, V10, P301
   Balding J, 2003, ARTHRITIS RHEUM, V48, P1408, DOI 10.1002/art.10935
   Bengtsson ÅK, 2002, CRIT REV IMMUNOL, V22, P201
   Bhushan M, 2000, BRIT J DERMATOL, V142, P1171, DOI 10.1046/j.1365 2133.2000.03544.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BRAVERMAN IM, 1974, J INVEST DERMATOL, V62, P493, DOI 10.1111/1523 1747.ep12681007
   BRAVERMAN IM, 1977, J INVEST DERMATOL, V68, P53, DOI 10.1111/1523 1747.ep12485169
   CHANG JCC, 1994, P NATL ACAD SCI USA, V91, P9282, DOI 10.1073/pnas.91.20.9282
   Chaudhari U, 2001, LANCET, V357, P1842, DOI 10.1016/S0140 6736(00)04954 0
   Costello P, 1999, J RHEUMATOL, V26, P1117
   Costello PJ, 2001, J IMMUNOL, V166, P2878, DOI 10.4049/jimmunol.166.4.2878
   Creamer D., 2002, Angiogenesis, V5, P231, DOI 10.1023/A:1024515517623
   Creamer D, 1997, BRIT J DERMATOL, V137, P851, DOI 10.1111/j.1365 2133.1997.tb01543.x
   Curran SA, 2004, J IMMUNOL, V172, P1935, DOI 10.4049/jimmunol.172.3.1935
   Danning CL, 2000, ARTHRITIS RHEUM US, V43, P1244, DOI 10.1002/1529 0131(200006)43:6<1244::AID ANR7>3.0.CO;2 2
   EEDY DJ, 1991, J INVEST DERMATOL, V96, P434, DOI 10.1111/1523 1747.ep12469898
   Fearon U, 2003, J RHEUMATOL, V30, P260
   Fearon U, 2001, CLIN EXP DERMATOL, V26, P333, DOI 10.1046/j.1365 2230.2001.00792.x
   Fearon U, 1999, ANN NY ACAD SCI, V878, P619, DOI 10.1111/j.1749 6632.1999.tb07743.x
   Fraser A, 2003, ARTHRITIS RHEUM, V48, P3085, DOI 10.1002/art.11331
   GLADMAN DD, 1986, J RHEUMATOL, V13, P586
   Gonzalez S, 2000, J INVEST DERMATOL, V115, P824, DOI 10.1046/j.1523 1747.2000.00133.x
   Gottlieb AB, 2003, ARCH DERMATOL, V139, P1627, DOI 10.1001/archderm.139.12.1627
   GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595 442
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Kane D, 2003, ARTHRITIS RHEUM, V48, P1676, DOI 10.1002/art.10988
   Kane David, 2004, Curr Rheumatol Rep, V6, P292, DOI 10.1007/s11926 004 0041 0
   Kupper TS, 2003, NEW ENGL J MED, V349, P1987, DOI 10.1056/NEJMp038164
   Kuroda K, 2001, J INVEST DERMATOL, V116, P713, DOI 10.1046/j.1523 1747.2001.01316.x
   Laloux L, 2001, ANN RHEUM DIS, V60, P316, DOI 10.1136/ard.60.4.316
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409
   Markhan T, 2003, BR J DERMATOL S59, V143, P40
   Massey HM, 1999, BRIT J HAEMATOL, V106, P167
   Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140 6736(00)02530 7
   Mease PJ, 2003, RHEUM DIS CLIN N AM, V29, P495, DOI 10.1016/S0889 857X(03)00047 4
   MULHERIN D, 1995, J RHEUMATOL, V22, P1211
   Nair, 2002, AM J HUM GENET, V70, P1074
   Nair RP, 2000, AM J HUM GENET, V66, P1833, DOI 10.1086/302932
   Nickoloff BJ, 2000, J DERMATOL SCI, V24, P212, DOI 10.1016/S0923 1811(00)00120 1
   PAUKKONEN K, 1992, ARCH DERMATOL RES, V284, P375, DOI 10.1007/BF00372065
   Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153
   Pitzalis C, 1996, ARTHRITIS RHEUM, V39, P137, DOI 10.1002/art.1780390118
   Reece RJ, 1999, ARTHRITIS RHEUM, V42, P1481, DOI 10.1002/1529 0131(199907)42:7<1481::AID ANR23>3.0.CO;2 E
   RESNICK DNG, 1989, PSORIATRIC ARTHRITIS
   Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989
   Ritchlin C, 1998, J RHEUMATOL, V25, P1544
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Tassiulas I, 1999, HUM IMMUNOL, V60, P479, DOI 10.1016/S0198 8859(99)00034 8
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   VALDIMARSSON H, 1995, IMMUNOL TODAY, V16, P145, DOI 10.1016/0167 5699(95)80132 4
   VEALE D, 1993, BRIT J RHEUMATOL, V32, P413
   VEALE D, 1993, ARTHRITIS RHEUM, V36, P893, DOI 10.1002/art.1780360705
   VEALE D, 1995, BRIT J DERMATOL, V132, P32, DOI 10.1111/j.1365 2133.1995.tb08621.x
   VEALE DJ, 1994, ANN RHEUM DIS, V53, P450, DOI 10.1136/ard.53.7.450
   Winchester R, 1988, Scand J Rheumatol Suppl, V74, P89
   ZARIC D, 1981, SCAND J RHEUMATOL, V10, P249, DOI 10.3109/03009748109095307
NR 59
TC 111
Z9 124
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD MAR
PY 2005
VL 64
SU 2
BP 26
EP 29
DI 10.1136/ard.2004.031740
PG 4
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 902CL
UT WOS:000227328900007
PM 15708930
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Wang, H
   Jia, TH
   Zacharias, N
   Gong, W
   Du, HX
   Wooley, PH
   Yang, SY
AF Wang, H.
   Jia, T H
   Zacharias, N.
   Gong, W.
   Du, H X
   Wooley, P. H.
   Yang, S Y
TI Combination gene therapy targeting on interleukin 1β and RANKL for wear
   debris induced aseptic loosening
SO GENE THERAPY
LA English
DT Article
DE osteoclastogenesis; periprosthetic osteolysis; synergetic effects
ID TOTAL HIP ARTHROPLASTY; NF KAPPA B; INDUCED OSTEOLYSIS; RECEPTOR
   ACTIVATOR; MURINE MODEL; DEFECTIVE INTERLEUKIN 1; OSTEOCLAST;
   OSTEOPETROSIS; INFLAMMATION; MACROPHAGES
AB This study investigated the efficacy of a combination gene therapy to repress interleukin 1 (IL 1) and receptor activator of nuclear factor NF kappa B ligand (RANKL) for the treatment of particulate debris induced aseptic loosening, and tried to explore the molecular mechanism of the exogenous gene modifications on osteoclastogenesis. RAW cells activated by titanium particles were transduced with DFG IL 1 Ra (retroviral vector encoding IL 1 receptor antagonist) and AAV OPG (adeno associated viral vectors osteoprotegerin) individually or in combination for 4 weeks. Pro inflammatory cytokines in culture media were determined by enzyme linked imnnunosorbent assay, and gene expressions of RANK, IL 1 beta, c Fos, TRAF6, JNK1 and CPK were examined using real time PCR. An established knee implant failure mouse model was employed to evaluate the efficacy of the in vivo double gene therapy. The surgical implantation of a titanium alloy pin into the proximal tibia was followed by monthly challenge with titanium debris. Pen implant gene transfers of IL 1Ra and OPG (respectively or in combination) were given 3 weeks after surgery. The combination of OPG and IL 1Ra gene transfer exhibited strong synergetic effects in blockage of inflammation and osteoclastogenesis at 8 weeks after gene modification. The combination therapy reversed pen implant bone resorption and restored implant stability when compared with either single gene transduction. Real time PCR data indicated that the action of IL 1Ra gene therapy may be mediated via the JNK1 pathway, while the reduction of osteoclastogenesis by OPG gene modification may be regulated by c Fos expression. In addition, both gene modifications resulted in significant diminishment of TRAF6 expression. Gene Therapy (2013) 20, 128 135; doi:10.1038/gt.2012.1; published online 9 February 2012
C1 [Wang, H.; Wooley, P. H.; Yang, S Y] Via Christi Wichita Hosp Inc, Orthopaed Res Inst, Wichita, KS 67214 USA.
   [Wang, H.; Jia, T H; Gong, W.; Du, H X] Shandong Univ, Dept Orthopaed, Jinan Cent Hosp, Jinan 250100, Peoples R China.
   [Zacharias, N.; Wooley, P. H.; Yang, S Y] Wichita State Univ, Dept Biol Sci, Wichita, KS 67208 USA.
C3 Shandong University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; Wichita State University
RP Yang, SY (通讯作者)，Via Christi Wichita Hosp Inc, Orthopaed Res Inst, 929 N St Francis St, Wichita, KS 67214 USA.
EM shang you_yang@via christi.org
RI Yang, Shang You/ADX 1056 2022
OI Yang, Shang You/0000 0002 8835 5302; Strong, Nora/0000 0003 0540 2124
FU National Institutes Health [5R03AR054929]; Kansas Bioscience Authority;
   Graduate School of Shandong University, China
FX The authors wish to thank Ms Zhengs Song and Ms Tala Sandid for their
   excellent technical assistance. This study was supported in part by the
   National Institutes Health (5R03AR054929 S YY) and Scholarship Funding
   from Kansas Bioscience Authority (S YY and PHW). Hao Wang was supported
   by a Fellowship for Oversea Study from Graduate School of Shandong
   University, China. This work was supported by an NIH grant No
   5R03AR054929 to S YY.
CR AMSTUTZ HC, 1992, CLIN ORTHOP RELAT R, P7
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CHIBA J, 1994, CLIN ORTHOP RELAT R, P304
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gallo J, 2008, PHYSIOL RES, V57, P339, DOI 10.33549/physiolres.931140
   GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   Jacobs JJ, 2001, CLIN ORTHOP RELAT R, P71
   Keener JD, 2003, J BONE JOINT SURG AM, V85A, P1066, DOI 10.2106/00004623 200306000 00013
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Leibbrandt A, 2009, ADV EXP MED BIOL, V647, P130, DOI 10.1007/978 0 387 89520 8_9
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Maloney WJ, 1996, AAOS INSTR COURS LEC, V45, P171
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Neale SD, 1999, ACTA ORTHOP SCAND, V70, P452, DOI 10.3109/17453679909000980
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Troen BR, 2006, ANN NY ACAD SCI, V1068, P165, DOI 10.1196/annals.1346.018
   Tsutsumi R, 2008, J ORTHOP RES, V26, P1340, DOI 10.1002/jor.20620
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Yang S, 2002, INFLAMM RES, V51, P342, DOI 10.1007/PL00000313
   Yang SY, 2007, J ORTHOP RES, V25, P603, DOI 10.1002/jor.20342
   Yang SY, 2004, GENE THER, V11, P483, DOI 10.1038/sj.gt.3302192
   Yang SY, 2002, ARTHRITIS RHEUM, V46, P2514, DOI 10.1002/art.10527
   Yuan HP, 2011, J CLIN PERIODONTOL, V38, P1029, DOI 10.1111/j.1600 051X.2011.01780.x
   Zhang K, 2009, INFLAMM RES, V58, P837, DOI 10.1007/s00011 009 0051 5
   Zhang L, 2010, GENE THER, V17, P1262, DOI 10.1038/gt.2010.64
   Zhang T, 2009, BIOMATERIALS, V30, P6102, DOI 10.1016/j.biomaterials.2009.07.032
NR 33
TC 16
Z9 17
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969 7128
EI 1476 5462
J9 GENE THER
JI Gene Ther.
PD FEB
PY 2013
VL 20
IS 2
BP 128
EP 135
DI 10.1038/gt.2012.1
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 091UD
UT WOS:000315074400003
PM 22318091
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xu, GQ
   Shen, XK
   Dai, LL
   Ran, QC
   Ma, PP
   Cai, KY
AF Xu, Gaoqiang
   Shen, Xinkun
   Dai, Liangliang
   Ran, Qichun
   Ma, Pingping
   Cai, Kaiyong
TI Reduced bacteria adhesion on octenidine loaded mesoporous silica
   nanoparticles coating on titanium substrates
SO MATERIALS SCIENCE AND ENGINEERING C MATERIALS FOR BIOLOGICAL
   APPLICATIONS
LA English
DT Article
DE Titanium substrates; Mesoporous silica nanoparticles; Octenidine;
   Antibacterial property; Osteoblasts
ID THERAPY IN VITRO; OSTEOGENIC DIFFERENTIATION; OSTEOBLAST FUNCTIONS;
   DIHYDROCHLORIDE; RELEASE; BIOMATERIALS; MECHANISMS; OXIDATION
AB Bacterial infection is one of the most severe postoperative complications leading to implantation failure. The early bacterial stage (4 6 h) was proved to be the "decisive period" for long term bacteria related infection. Thus, to endow potential early antibacterial capacity for a titanium (Ti) based implant, an effective antiseptic agent of octenidine dihydrochloride (OCT) was effectively loaded on the mesoporous silica nanoparticles (MSNs) incorporated titania coating which was fabricated by an electrophoretic enhanced micro arc oxidation technique. The surface characteristic of the coatings were characterized by various methods (SEM, AFM, XPS, XRD, etc.), and its corrosion resistance was also examined by the potentiodynamic polarization curves. The composite coating without OCT loading not only displayed good cytocompatibility but also exhibited certain anti bacterial property. After loading with OCT, its antibacterial efficiency of the titanium substrates with composite coating was greatly enhanced without compromising their cytocompatibility. The study provides an approach for the fabrication of anti bacterial Ti implant for potential orthopedic application. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Xu, Gaoqiang; Shen, Xinkun; Dai, Liangliang; Ran, Qichun; Ma, Pingping; Cai, Kaiyong] Chongqing Univ, Coll Bioengn, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400030, Peoples R China.
C3 Chongqing University
RP Cai, KY (通讯作者)，Chongqing Univ, Coll Bioengn, Chongqing 400030, Peoples R China.
EM kaiyong_cai@cqu.edu.cn
RI Cai, Kaiyong/G 1233 2011; dai, liangliang/JCE 1715 2023; dai,
   liangliang/M 1284 2016
OI dai, liangliang/0000 0002 2041 9357; Cai, Kaiyong/0000 0001 9029 680X
FU National Natural Science Foundation of China [51173216]; State Key
   Project of Research and Development [2016YFC1100300]; Natural Science
   Foundation of Chongqing Municipal Government [CSTC2013kjrc ljrcpy0004,
   CSTC2013jjB50004]; National Key Technology R&D Program of the Ministry
   of Science and Technology [2012BAI18B04]
FX The work was financially supported by National Natural Science
   Foundation of China (51173216), State Key Project of Research and
   Development (Grant No. 2016YFC1100300), Natural Science Foundation of
   Chongqing Municipal Government (CSTC2013kjrc ljrcpy0004,
   CSTC2013jjB50004), National Key Technology R&D Program of the Ministry
   of Science and Technology (2012BAI18B04).
CR Adabi M., 2016, Artificial Cells, Nanomedicine, and Biotechnology, V44, P1049
   An YH, 1998, J BIOMED MATER RES, V43, P338, DOI 10.1002/(SICI)1097 4636(199823)43:3<338::AID JBM16>3.0.CO;2 B
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142 9612(99)00242 2
   Bai Y, 2011, APPL SURF SCI, V257, P7010, DOI 10.1016/j.apsusc.2011.03.058
   Bauer S, 2013, PROG MATER SCI, V58, P261, DOI 10.1016/j.pmatsci.2012.09.001
   Cai KY, 2011, CHEM COMMUN, V47, P7719, DOI 10.1039/c1cc11855b
   Campoccia D, 2013, BIOMATERIALS, V34, P8533, DOI 10.1016/j.biomaterials.2013.07.089
   Campoccia D, 2013, BIOMATERIALS, V34, P8018, DOI 10.1016/j.biomaterials.2013.07.048
   Chen QZ, 2015, MAT SCI ENG R, V87, P1, DOI 10.1016/j.mser.2014.10.001
   Dai LL, 2014, LANGMUIR, V30, P7867, DOI 10.1021/la501924p
   Hetrick EM, 2006, CHEM SOC REV, V35, P780, DOI 10.1039/b515219b
   Hu HJ, 2010, SURF COAT TECH, V204, P3265, DOI 10.1016/j.surfcoat.2010.03.028
   Hu Y, 2010, ADV MATER, V22, P4146, DOI 10.1002/adma.201000854
   Hübner NO, 2010, SKIN PHARMACOL PHYS, V23, P244, DOI 10.1159/000314699
   Inzunza D, 2014, J BIOMED MATER RES A, V102, P37, DOI 10.1002/jbm.a.34673
   Izquierdo Barba I, 2015, ACTA BIOMATER, V15, P20, DOI 10.1016/j.actbio.2014.12.023
   Jenull S, 2015, J WOUND CARE, V24, P280, DOI 10.12968/jowc.2015.24.6.280
   Jia ZJ, 2016, BIOMATERIALS, V75, P203, DOI 10.1016/j.biomaterials.2015.10.035
   Kazemzadeh Narbat M, 2013, BIOMATERIALS, V34, P5969, DOI 10.1016/j.biomaterials.2013.04.036
   Koburger T, 2010, J ANTIMICROB CHEMOTH, V65, P1712, DOI 10.1093/jac/dkq212
   Lemire JA, 2013, NAT REV MICROBIOL, V11, P371, DOI 10.1038/nrmicro3028
   Liu P, 2012, MATER LETT, V75, P118, DOI 10.1016/j.matlet.2012.02.016
   Liu YT, 2014, J MATER CHEM B, V2, P7927, DOI 10.1039/c4tb00822g
   Luo Z, 2013, ACS NANO, V7, P10271, DOI 10.1021/nn404676w
   Mestres G, 2012, ACTA BIOMATER, V8, P1169, DOI 10.1016/j.actbio.2011.11.021
   Mohedano M, 2015, MATER DESIGN, V86, P735, DOI 10.1016/j.matdes.2015.07.132
   Moritz S, 2014, INT J PHARMACEUT, V471, P45, DOI 10.1016/j.ijpharm.2014.04.062
   Müller G, 2014, SKIN PHARMACOL PHYS, V27, P1, DOI 10.1159/000350172
   Neoh KG, 2012, BIOMATERIALS, V33, P2813, DOI 10.1016/j.biomaterials.2012.01.018
   Niazi H, 2014, ACS APPL MATER INTER, V6, P5538, DOI 10.1021/am405938n
   Obermeier A, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866 015 0523 4
   Odatsu T, 2015, J BIOMED MATER RES A, V103, P2797, DOI 10.1002/jbm.a.35412
   Qin H, 2014, BIOMATERIALS, V35, P9114, DOI 10.1016/j.biomaterials.2014.07.040
   Shen XK, 2016, J MATER CHEM B, V4, P1423, DOI 10.1039/c5tb01956g
   Shie MY, 2011, ACTA BIOMATER, V7, P2604, DOI 10.1016/j.actbio.2011.02.023
   Tavakol S, 2014, J NANOPART RES, V16, DOI 10.1007/s11051 014 2622 9
   Thevenot Paul, 2008, Curr Top Med Chem, V8, P270, DOI 10.2174/156802608783790901
   Tian YX, 2014, ACTA BIOMATER, V10, P4505, DOI 10.1016/j.actbio.2014.06.002
   Weckbach S, 2012, ARCH ORTHOP TRAUM SU, V132, P15, DOI 10.1007/s00402 011 1386 2
   Xu GQ, 2015, SURF COAT TECH, V272, P58, DOI 10.1016/j.surfcoat.2015.04.024
   Xu ZB, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/506782
   Yerokhin AL, 1999, SURF COAT TECH, V122, P73, DOI 10.1016/S0257 8972(99)00441 7
   Zhang ZX, 2011, J BIOMED MATER RES B, V97B, P224, DOI 10.1002/jbm.b.31804
   Zhao L, 2014, COLLOID SURFACE B, V119, P115, DOI 10.1016/j.colsurfb.2014.05.002
   Zhou XJ, 2015, ACS APPL MATER INTER, V7, P15777, DOI 10.1021/acsami.5b02636
NR 45
TC 36
Z9 37
U1 1
U2 114
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928 4931
EI 1873 0191
J9 MAT SCI ENG C MATER
JI Mater. Sci. Eng. C Mater. Biol. Appl.
PD JAN 1
PY 2017
VL 70
BP 386
EP 395
DI 10.1016/j.msec.2016.08.050
PN 1
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA EC3SP
UT WOS:000388046900048
PM 27770907
DA 2025 08 17
ER

PT J
AU Gu, JN
   Zheng, YZ
   Yang, HM
   Li, YY
   Liu, SW
   Wu, YQ
   Ren, LZ
   Yu, Y
   Long, YL
AF Gu, Jingna
   Zheng, Yizhou
   Yang, Hongmei
   Li, Yanyang
   Liu, Shuowen
   Wu, Yequn
   Ren, Lingzhi
   Yu, Yang
   Long, Yongling
TI Cistanche deserticola polysaccharide regulated the gut
   microbiota SCFAs Th17/Treg cell axis and ameliorated the inflammation of
   postmenopausal osteoporosis
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Postmenopausal osteoporosis; Inflammation; Gut microbiota; Short chain
   fatty acids; Th17/Treg cell balance
ID BONE LOSS
AB Chronic inflammation plays a critical role in the pathogenesis of postmenopausal osteoporosis (PMO). Short chain fatty acids (SCFAs) produced by the gut microbiota (GM) have emerged as key regulators of the inflammatory response. Cistanche deserticola polysaccharide (CDP), derived from the traditional Chinese medicine Cistanche deserticola, possesses potent anti inflammatory properties. However, the precise mechanism by which CDP modulates inflammation in PMO via the gut bone axis remains elusive. In this study, we elucidated that CDP could effectively restore GM composition, ameliorate intestinal mucosal damage, elevate SCFA levels, rebalance the Th17/Treg cells equilibrium, attenuate the accumulation of proinflammatory cytokines, potentially facilitate osteoblast differentiation, potentially suppress osteoclastogenesis, and enhance bone microarchitecture in PMO mice. Collectively, our findings provided compelling evidence that CDP alleviated PMO associated inflammation, potentially mediated through the intricate interplay between GM derived SCFAs and the Th17/Treg cells.
C1 [Gu, Jingna; Zheng, Yizhou; Yang, Hongmei; Li, Yanyang; Liu, Shuowen; Wu, Yequn; Ren, Lingzhi; Yu, Yang; Long, Yongling] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.
C3 Guangzhou University of Chinese Medicine
RP Yu, Y; Long, YL (通讯作者)，Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.
EM yuyang@gzucm.edu.cn; longyongling2023@163.com
RI Yizhou, Zheng/AAP 6728 2020; Li, Yanyang/ISU 4152 2023
OI Zheng, Yizhou/0000 0002 8246 5009
FU Natural Science Foundation of Guangdong Province, China [2214050007586]
FX This study was funded by the Natural Science Foundation of Guangdong
   Province, China (Grant number: 2214050007586) . In addition, we thanks
   Dr. Shijie Li from the Clinical Medical College of Acupuncture
   Moxibustion and Rehabilitation at the Guangzhou University of Chinese
   Medicine for providing technical help on polysaccharide preparation,
   also thanks to Dr. Huang Yusheng from the Lingnan Medical Research
   Center of Guangzhou University of Chinese Medicine for his help in
   providing instruments and equipment for animal experiments. The figure
   in graphic abstract was created using Bio  render (https://biorender.com
   /) .
CR Asarat M, 2016, IMMUNOL INVEST, V45, P205, DOI 10.3109/08820139.2015.1122613
   Baccaro LF, 2015, CLIN INTERV AGING, V10, DOI 10.2147/CIA.S54614
   Boulangé CL, 2016, GENOME MED, V8, DOI 10.1186/s13073 016 0303 2
   Campos Perez W, 2021, BBA MOL CELL BIOL L, V1866, DOI 10.1016/j.bbalip.2021.158900
   Chen XQ, 2017, BIOCHEM PHARMACOL, V142, P111, DOI 10.1016/j.bcp.2017.06.136
   Chin N, 2022, MICROBIOME, V10, DOI 10.1186/s40168 022 01355 3
   Choi M, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100595
   Committee P., 2020, Pharmacopoeia of the People's Republic of China
   Farooqui KJ, 2021, DIABETES METAB SYND, V15, P927, DOI 10.1016/j.dsx.2021.04.017
   Fu ZF, 2020, INT J BIOL MACROMOL, V149, P732, DOI 10.1016/j.ijbiomac.2020.01.216
   Gao Y, 2021, AGING US, V13, P15320, DOI 10.18632/aging.203090
   Gill PA, 2018, ALIMENT PHARM THER, V48, P15, DOI 10.1111/apt.14689
   Huang CL, 2022, CELLS BASEL, V11, DOI 10.3390/cells11111851
   Huang Z, 2020, CURR OSTEOPOROS REP, V18, P23, DOI 10.1007/s11914 020 00559 6
   Kim H, 2021, CELLS BASEL, V10, DOI 10.3390/cells10010089
   Kim YG, 2014, ARCH ORAL BIOL, V59, P897, DOI 10.1016/j.archoralbio.2014.05.009
   Le Goff B, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8659302
   Liu WX, 2015, INT REV IMMUNOL, V34, P332, DOI 10.3109/08830185.2014.952414
   Lucas S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 017 02490 4
   Luu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 08711 2
   Matsuoka K, 2015, SEMIN IMMUNOPATHOL, V37, P47, DOI 10.1007/s00281 014 0454 4
   Omenetti S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00639
   Song L, 2019, MOL MED REP, V19, P4743, DOI 10.3892/mmr.2019.10155
   Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140 6736(07)61342 7
   Wan XY, 2023, NEUROPHARMACOLOGY, V228, DOI 10.1016/j.neuropharm.2023.109466
   Wan XY, 2022, NEUROPHARMACOLOGY, V213, DOI 10.1016/j.neuropharm.2022.109139
   Wang NN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00988
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Xiao W, 2021, J FUNCT FOODS, V81, DOI 10.1016/j.jff.2021.104464
   Zha L, 2018, BIOMED PHARMACOTHER, V102, P369, DOI 10.1016/j.biopha.2018.03.080
   Zhang B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01412
   Zhang Y, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/7812099
   Zhao RQ, 2013, EUR J CLIN INVEST, V43, P1195, DOI 10.1111/eci.12158
NR 33
TC 5
Z9 7
U1 13
U2 58
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1756 4646
EI 2214 9414
J9 J FUNCT FOODS
JI J. Funct. Food.
PD OCT
PY 2023
VL 109
AR 105811
DI 10.1016/j.jff.2023.105811
EA SEP 2023
PG 13
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA U9FN3
UT WOS:001087789000001
OA gold
DA 2025 08 17
ER

PT J
AU Deng, X
   Tamai, R
   Endo, Y
   Kiyoura, Y
AF Deng, Xue
   Tamai, Riyoko
   Endo, Yasuo
   Kiyoura, Yusuke
TI Alendronate augments interleukin 1β release from macrophages infected
   with periodontal pathogenic bacteria through activation of caspase 1
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Bisphosphonates (BPs); Porphyromonas gingivalis; Tannerella forsythia;
   Interleukin 1 beta (IL 1 beta); Tumor necrosis factor alpha (TNF alpha);
   Alendronate; Clodronate; Pam(3)CSK(4); Lipid A; Caspase 1
ID NECROSIS FACTOR ALPHA; ACUTE PHASE RESPONSE; NOD LIKE RECEPTORS;
   IN VITRO; PORPHYROMONAS GINGIVALIS; BONE RESORPTION;
   HISTIDINE DECARBOXYLASE; IL 1 BETA SECRETION; MEVALONATE PATHWAY;
   MONONUCLEAR CELLS
AB Nitrogen containing bisphosphonates (NBPs) are anti bone resorptive drugs with inflammatory side effects that include osteomyelitis and osteonecrosis of the jaw. Oral bacteria have been considered to be a trigger for these NBP associated jaw bone diseases. The present study examined the effects of alendronate (a typical NBP) and clodronate (a non NBP) on the production of proinflammatory cytokines by macrophages infected with Porphyromonas gingivalis and Tannerella forsythia, which are important pathogens of periodontal diseases. Pretreatment with alendronate augmented IL 1 beta, but not TNF alpha, production by macrophages infected with P gingivalis or T. forsythia. This augmentation of IL 1 beta production was inhibited by clodronate. Furthermore, caspase 1, a promoter of IL 1 beta production, was activated by treatment with alendronate, and caspase 1 inhibitor reduced the production of IL 1 beta induced by alendronate and P gingivalis. These results suggest that NBPs augment periodontal pathogenic bacteria induced IL 1 beta release via caspase 1 activation, and this phenomenon may contribute to the development of NBP associated inflammatory side effects including jaw osteomyelitis. Co treatment with clodronate may prevent and/or reduce these inflammatory effects induced by NBPs. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Deng, Xue; Tamai, Riyoko; Kiyoura, Yusuke] Ohu Univ, Sch Dent, Div Oral Bacteriol, Dept Oral Med Sci, Fukushima 9638611, Japan.
   [Endo, Yasuo] Tohoku Univ, Dept Mol Regulat, Grad Sch Dent, Aoba Ku, Sendai, Miyagi 9808575, Japan.
C3 Tohoku University
RP Kiyoura, Y (通讯作者)，Ohu Univ, Sch Dent, Div Oral Bacteriol, Dept Oral Med Sci, 31 1 Misumido,Tomitamachi, Fukushima 9638611, Japan.
EM y kiyoura@den.ohu u.ac.jp
RI Tamai, Riyoko/B 7998 2013
OI Tamai, Riyoko/0000 0002 2782 2763
FU Japan Society for the Promotion of Science [19890201]; Ohu University
   School of Dentistry; Grants in Aid for Scientific Research [19890201]
   Funding Source: KAKEN
FX This work was supported by a Grant in Aid for Scientific Research from
   the Japan Society for the Promotion of Science (No. 19890201) and a
   Grant in Aid for Scientific Research from the Ohu University School of
   Dentistry.
CR ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671
   Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Ballester I, 2007, BRIT J PHARMACOL, V151, P206, DOI 10.1038/sj.bjp.0707227
   Chun YHP, 2005, J PERIODONTAL RES, V40, P87, DOI 10.1111/j.1600 0765.2004.00771.x
   Crabtree TD, 2001, INFECT IMMUN, V69, P2123, DOI 10.1128/IAI.69.4.2123 2129.2001
   Craig RG, 2003, J PERIODONTOL, V74, P1007, DOI 10.1902/jop.2003.74.7.1007
   Darveau RP, 1997, PERIODONTOL 2000, V14, P12, DOI 10.1111/j.1600 0757.1997.tb00190.x
   Deng X, 2007, INT IMMUNOPHARMACOL, V7, P152, DOI 10.1016/j.intimp.2006.09.009
   Deng X, 2006, TOXICOL APPL PHARM, V213, P64, DOI 10.1016/j.taap.2005.09.005
   Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Endo Y, 1999, BRIT J PHARMACOL, V126, P903, DOI 10.1038/sj.bjp.0702367
   ENDO Y, 1993, CALCIFIED TISSUE INT, V52, P248, DOI 10.1007/BF00298728
   FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   FLEISCH HA, 1997, ANAL MED, V29, P56
   Franchi L, 2008, CELL MICROBIOL, V10, P1, DOI 10.1111/j.1462 5822.2007.01059.x
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Gauldie J, 2007, BIOCHEM SOC T, V35, P661, DOI 10.1042/BST0350661
   Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009
   GROSSI SG, 1994, J PERIODONTOL, V65, P260, DOI 10.1902/jop.1994.65.3.260
   GROSSI SG, 1995, J PERIODONTOL, V66, P23, DOI 10.1902/jop.1995.66.1.23
   Hajishengallis G, 2002, CLIN DIAGN LAB IMMUN, V9, P403, DOI 10.1128/CDLI.9.2.403 411.2002
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hsu LC, 2008, P NATL ACAD SCI USA, V105, P7803, DOI 10.1073/pnas.0802726105
   Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Kunzmann V, 2000, BLOOD, V96, P384
   Lamont RJ, 1998, MICROBIOL MOL BIOL R, V62, P1244, DOI 10.1128/MMBR.62.4.1244 1263.1998
   LIN JH, 1994, J PHARM SCI US, V83, P1741, DOI 10.1002/jps.2600831218
   Lipton A, 2004, ONCOLOGIST, V9, P38, DOI 10.1634/theoncologist.9 90004 38
   MACAROL V, 1994, AM J OPHTHALMOL, V118, P220, DOI 10.1016/S0002 9394(14)72902 2
   Makkonen N, 1999, EUR J PHARM SCI, V8, P109, DOI 10.1016/S0928 0987(98)00065 7
   MALEFYT RD, 1991, J EXP MED, V174, P1209
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097 2765(02)00599 3
   MONKKONEN J, 1990, PHARMACOL TOXICOL, V65, P294
   Mundy, 1999, Expert Opin Investig Drugs, V8, P2009, DOI 10.1517/13543784.8.12.2009
   Ogawa T, 1996, FEMS IMMUNOL MED MIC, V14, P1, DOI 10.1111/j.1574 695X.1996.tb00261.x
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097 0142(20000615)88:12+<2961::AID CNCR12>3.0.CO;2 L
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Sauty A, 1996, BONE, V18, P133, DOI 10.1016/8756 3282(95)00448 3
   Scannapieco FA, 1999, J PERIODONTOL, V70, P793, DOI 10.1902/jop.1999.70.7.793
   SIRIS ES, 1993, LANCET, V341, P436, DOI 10.1016/0140 6736(93)93029 Z
   STOUFI ED, 1987, J CLIN IMMUNOL, V7, P235, DOI 10.1007/BF00915729
   Sugawara S, 1998, BRIT J PHARMACOL, V125, P735, DOI 10.1038/sj.bjp.0702151
   Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0
   Tanner A, 1998, J CLIN PERIODONTOL, V25, P85, DOI 10.1111/j.1600 051X.1998.tb02414.x
   Taxman DJ, 2006, J IMMUNOL, V177, P4252, DOI 10.4049/jimmunol.177.7.4252
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0
   Yarom N, 2007, OSTEOPOROSIS INT, V18, P1363, DOI 10.1007/s00198 007 0384 2
NR 58
TC 29
Z9 30
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0041 008X
EI 1096 0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD FEB 15
PY 2009
VL 235
IS 1
BP 97
EP 104
DI 10.1016/j.taap.2008.11.005
PG 8
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA 409YL
UT WOS:000263541600012
PM 19063908
DA 2025 08 17
ER

PT J
AU Zhao, JH
   Luo, YP
   Zhang, L
   Chen, YF
   Chen, YX
   Wu, XH
   Aierken, A
   Duolikun, D
   Wang, TL
   Zhou, ZF
   Liu, ZQ
   Zheng, LP
AF Zhao, Jinhui
   Luo, Yiping
   Zhang, Lei
   Chen, Yunfeng
   Chen, Yixing
   Wu, Xinhui
   Aierken, Aihemaitijiang
   Duolikun, Dilixiati
   Wang, Tianlong
   Zhou, Zifei
   Liu, Zhiqing
   Zheng, Longpo
TI Mild Hyperthermia Accelerates Bone Repair by Dynamically Regulating
   iNOS/Arg1 Balance in the Early Stage
SO ADVANCED SCIENCE
LA English
DT Article
DE bone repair; iNOS/Arg1 balance; macrophage; mild hyperthermia
ID ANGIOGENESIS; REGENERATION; OSTEOGENESIS; MACROPHAGES; STRATEGIES;
   IMMUNITY; TISSUES
AB Mild hyperthermia therapy has garnered interest as an adjunctive treatment for bone repair. However, its optimal timing, duration, and underlying mechanisms remain unclear. In this study, how mild hyperthermia supports bone repair during the early stages is assesed. These findings reveal that mild hyperthermia accelerates bone regeneration by dynamically regulating inducible nitric oxide synthase/arginase 1 (iNOS/Arg1) balance. This process involves macrophage polarization to the M1 phenotype through iNOS activation, followed by a rapid transition to the M2 phenotype through Arg1 activation after 3 days of sustained mild hyperthermia. RNA Seq reveals that a single day of mild hyperthermia induced immune alterations aligned with the early inflammatory phase of bone repair, characterized by osteoclast activation, cell recruitment, and neovascularization, thereby preparing for the transition to the repair phase. Experiments involving subcutaneous abscesses, subcutaneous embedding, and critical cranial bone defects further confirm that early mild hyperthermia treatment dynamically regulates macrophage phenotypes. This regulation enhances early antibacterial activity, promotes angiogenesis, and facilitates the transition from inflammation to repair, ultimately accelerating bone defect repair. This study is the first to elucidate the dual temporal effects of early mild hyperthermia on immune regulation, offering insights into the optimal timing and duration of photothermal therapy following bone repair surgery.
C1 [Zhao, Jinhui; Luo, Yiping; Zhang, Lei; Chen, Yunfeng; Chen, Yixing; Wu, Xinhui; Aierken, Aihemaitijiang; Duolikun, Dilixiati; Wang, Tianlong; Zhou, Zifei; Liu, Zhiqing; Zheng, Longpo] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai 200072, Peoples R China.
   [Zheng, Longpo] Shanghai Trauma Emergency Ctr, Shanghai 200072, Peoples R China.
   [Zheng, Longpo] Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Sch Med, Orthoped Intelligent Minimally Invas Diag & Treatm, Shanghai 200072, Peoples R China.
C3 Tongji University; Tongji University
RP Wang, TL; Zhou, ZF; Liu, ZQ; Zheng, LP (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai 200072, Peoples R China.; Zheng, LP (通讯作者)，Shanghai Trauma Emergency Ctr, Shanghai 200072, Peoples R China.; Zheng, LP (通讯作者)，Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Sch Med, Orthoped Intelligent Minimally Invas Diag & Treatm, Shanghai 200072, Peoples R China.
EM wtlong@tongji.edu.cn; 1805202@tongji.edu.cn; liu_zhiqingkm19@126.com;
   zheng@tongji.edu.cn
RI 刘, 志清/KCL 6754 2024; zheng, longpo/GWV 5230 2022; Zhou,
   Zifei/LEN 2353 2024
OI Wang, Tian Long/0000 0002 5869 5517; 
FU National Natural Science Foundation of China; Shanghai Science and
   Technology Innovation Action Plan [23S31905700]; National Key R&D
   Program of China [2022YFE0123500]; Natural Science Foundation of
   Shanghai Municipality [21ZR1450000, 22S31903300];  [82372395]
FX J.Z., Y.L., and L.Z. contributed equally to this work. This work was
   financially supported by the National Natural Science Foundation of
   China (Grant No. 82372395), Shanghai Science and Technology Innovation
   Action Plan (Grant No. 23S31905700), National Key R&D Program of China
   (Grant No. 2022YFE0123500) and Natural Science Foundation of Shanghai
   Municipality (Grant Nos. 21ZR1450000 and 22S31903300).
CR Bixel MG, 2024, NAT COMMUN, V15, DOI 10.1038/s41467 024 48579 5
   Cao S, 2024, ANN RHEUM DIS, V83, P72, DOI 10.1136/ard 2022 223626
   Chen ZT, 2016, MATER TODAY, V19, P304, DOI 10.1016/j.mattod.2015.11.004
   Chen ZT, 2015, BIOMATERIALS, V61, P126, DOI 10.1016/j.biomaterials.2015.04.044
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1
   Einhorn TA, 2005, J ORTHOP TRAUMA, V19, pS4, DOI 10.1097/00005131 200511101 00002
   El Kasmi KC, 2008, NAT IMMUNOL, V9, P1399, DOI 10.1038/ni.1671
   Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843
   Fan L, 2023, ADV SCI, V10, DOI 10.1002/advs.202205692
   Giobbe GG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13605 4
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Guo XY, 2023, ACS APPL MATER INTER, V15, P21965, DOI 10.1021/acsami.3c02964
   Ho Shui Ling A, 2018, BIOMATERIALS, V180, P143, DOI 10.1016/j.biomaterials.2018.07.017
   Humphrey JD, 2014, NAT REV MOL CELL BIO, V15, P802, DOI 10.1038/nrm3896
   Jia B, 2021, BIOACT MATER, V6, P1588, DOI 10.1016/j.bioactmat.2020.11.007
   Jin CY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01965 4
   Kieler M, 2021, FEBS J, V288, P3694, DOI 10.1111/febs.15715
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li B, 2022, SMALL, V18, DOI 10.1002/smll.202202691
   Li JL, 2023, ACS NANO, V17, P1036, DOI 10.1021/acsnano.2c07439
   Li JT, 2022, RESEARCH CHINA, V2022, DOI 10.34133/2022/9869518
   Liang Y. P., 2023, ADV HEALTHC MATER, V12
   Lin WM, 2024, SCI ADV, V10, DOI 10.1126/sciadv.adl6343
   Liu Q., 2023, ADV FUNCT MATER, V33
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Liu ZQ, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202304158
   Longoni A, 2022, ADV SCI, V9, DOI 10.1002/advs.202103284
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031
   Meizlish ML, 2024, SCI ADV, V10, DOI 10.1126/sciadv.adk6906
   Meng Q., 2024, ADV MATER, V36
   Menger MM, 2022, ANGIOGENESIS, V25, P279, DOI 10.1007/s10456 022 09832 x
   Miao YL, 2019, BIOMATER SCI UK, V7, P4046, DOI 10.1039/c9bm01072f
   Molgora M, 2020, CELL, V182, P886, DOI 10.1016/j.cell.2020.07.013
   Norgaard R, 2006, ANN NY ACAD SCI, V1067, P443, DOI 10.1196/annals.1354.063
   Park HG, 2005, CELL MOL LIFE SCI, V62, P10, DOI 10.1007/s00018 004 4208 7
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Richter RF, 2023, BIOACT MATER, V28, P402, DOI 10.1016/j.bioactmat.2023.06.001
   Sayed S, 2019, MAT SCI ENG C MATER, V105, DOI 10.1016/j.msec.2019.110027
   Shi HX, 2023, THERANOSTICS, V13, P3245, DOI 10.7150/thno.84759
   Shoulders H, 2019, TRANSL RES, V203, P1, DOI 10.1016/j.trsl.2018.07.006
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Sun XN, 2024, ADV SCI, V11, DOI 10.1002/advs.202306937
   Thakur T, 2016, J BIOMED MATER RES A, V104, P879, DOI 10.1002/jbm.a.35621
   Wang LT, 2022, NANO TODAY, V43, DOI 10.1016/j.nantod.2022.101401
   Wang TL, 2024, SCI ADV, V10, DOI 10.1126/sciadv.adi6799
   Wang YL, 2016, CLIN IMPLANT DENT R, V18, P618, DOI 10.1111/cid.12343
   Wu MH, 2024, THERANOSTICS, V14, P4014, DOI 10.7150/thno.97335
   Wu MH, 2023, SMALL, V19, DOI 10.1002/smll.202300111
   Xu YQ, 2024, ACS APPL MATER INTER, V16, P3215, DOI 10.1021/acsami.3c17888
   Xue X, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202202470
   You J., 2024, ADV HEALTHC MATER
   Zhao JH, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2022.112719
   Zhao T, 2024, BIOACT MATER, V40, P19, DOI 10.1016/j.bioactmat.2024.05.025
   Zheng Y., 2022, 51, V32
   Zhu YM, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 39349 w
NR 56
TC 1
Z9 1
U1 29
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD FEB
PY 2025
VL 12
IS 8
DI 10.1002/advs.202409882
EA DEC 2024
PG 18
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA Y5L5U
UT WOS:001388417500001
PM 39738868
OA gold
DA 2025 08 17
ER

PT J
AU Benso, B
   Franchin, M
   Massarioli, AP
   Paschoal, JAR
   Alencar, SM
   Franco, GCN
   Rosalen, PL
AF Benso, Bruna
   Franchin, Marcelo
   Massarioli, Adna Prado
   Rizzato Paschoal, Jonas Augusto
   Alencar, Severino Matias
   Nobre Franco, Gilson Cesar
   Rosalen, Pedro Luiz
TI Anti Inflammatory, Anti Osteoclastogenic and Antioxidant Effects of
   Malva sylvestris Extract and Fractions: In Vitro and In
   Vivo Studies
SO PLOS ONE
LA English
DT Article
ID RANKL INDUCED OSTEOCLASTOGENESIS; PAW EDEMA; FREE RADICALS; RAT;
   INFLAMMATION; INHIBITION; DECREASES; IL 1 BETA; MECHANISM; MIGRATION
AB Given their medical importance, natural products represent a tremendous source of drug discovery. The aim of this study was to investigate Malva sylvestris L. extract and fractions and their pharmacological activities followed by chemical identification. The aqueous fraction (AF) was identified as the bioactive fraction in the in vitro and in vivo assays. The AF controlled the neutrophil migration to the peritoneal cavity by 66%, inhibited the antiedematogenic activity by 58.8%, and controlled IL 1 beta cytokine expression by 54%. The in vitro viability tests showed a concentration dependent effect, where the MSE and fractions at concentrations under 10 mu g/ mL were non toxic to cells. Transcriptional factors of carbonic anhydrase II (CAII), cathepsin K (Ctsk) and tartrate resistant acid phosphatase (TRAP) were analyzed by qPCR in RAW 264.7 cell lines. The gene expression analysis showed that the AF was the only treatment that could downregulate all the study genes: CAII, Ctsk and TRAP (p<0.05). TRAP staining was used to evaluate osteoclast formation. AF treatments reduced the number of osteoclastogenesis 2.6 fold compared to the vehicle control group. Matrix metalloproteinase 9 (MMP 9) activity decreased 75% with the AF treatment. Moreover, the bioactive fraction had the ability to regulate the oxidation pathway in the ABTS (2,2 Azino bis (3 ethylbenzthiazoline 6 sulfonic acid) assay with an activity equivalent to 1.30 mu mol Trolox/g and DPPH (2,2 diphenyl 1 picrylhydrazyl) radicals 1.01 g/L. Positive ion ESI mass spectrometry for molecular ions at m/z 611 and 633 confirmed rutin as the major compound in the AF. The AF of M. sylvestris presented anti inflammatory, controlled osteoclastogenic mechanisms and antioxidant abilities in different in vitro and in vivo methods. In addition, we suggest that given its multi target activity the bioactive fraction may be a good candidate in the therapy of chronic inflammatory diseases.
C1 [Benso, Bruna; Franchin, Marcelo; Rosalen, Pedro Luiz] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Piracicaba, SP, Brazil.
   [Benso, Bruna] Univ Austral Chile, Fac Med, Sch Dent, Valdivia, Chile.
   [Massarioli, Adna Prado; Alencar, Severino Matias] Univ Sao Paulo, Dept Agri Food Ind Food & Nutr, Luiz de Queiroz Coll Agr, Piracicaba, SP, Brazil.
   [Rizzato Paschoal, Jonas Augusto] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Chem & Phys, Ribeirao Preto, SP, Brazil.
   [Nobre Franco, Gilson Cesar] Univ Estadual Ponta Grossa, Dept Gen Biol, Lab Physiol & Pathophysiol, Ponta Grossa, PR, Brazil.
C3 Universidade Estadual de Campinas; Universidad Austral de Chile;
   Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade
   Estadual de Ponta Grossa
RP Benso, B; Rosalen, PL (通讯作者)，Univ Estadual Campinas, Piracicaba Dent Sch, Dept Physiol Sci, Piracicaba, SP, Brazil.; Benso, B (通讯作者)，Univ Austral Chile, Fac Med, Sch Dent, Valdivia, Chile.
EM bruna.benso@uach.cl; rosalen@fop.unicamp.br
RI Alencar, Severino/B 7743 2012; Franchin, Marcelo/M 7636 2017;
   Massarioli, Adna/I 4840 2013; Rosalen, Pedro/I 3718 2012; Matias de
   Alencar, Severino/B 7743 2012; Franco, Gilson/F 9312 2012; Paschoal,
   Jonas/F 4260 2012; Benso, Bruna/L 1010 2015
OI Rosalen, Pedro Luiz/0000 0003 0812 4027; Matias de Alencar,
   Severino/0000 0002 6637 7973; Franchin, Marcelo/0000 0001 5613 2756;
   Massarioli, Adna/0000 0002 2747 0788; Paschoal,
   Jonas/0000 0002 7372 0936; Benso, Bruna/0000 0002 4425 5174
FU Sao Paulo Research Foundation (FAPESP) [2011/23980 5]
FX This work was funded by Grant #2011/23980 5, Sao Paulo Research
   Foundation (FAPESP). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The authors are grateful to the Sao Paulo Research
   Foundation (FAPESP) (Grant #2011/23980 5) for financial support. We also
   would like to thank Dr. Helen Lowry for the very careful review of the
   English in this work.
CR Al Mamun MA, 2015, BIOL RES, V48, DOI 10.1186/s40659 015 0043 6
   Barros L, 2010, FOOD CHEM TOXICOL, V48, P1466, DOI 10.1016/j.fct.2010.03.012
   Bocci V, 2013, CURR MED CHEM, V20, P3397, DOI 10.2174/0929867311320270005
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Bruna Benso, 2015, PLOS ONE
   Cataldo DD, 2003, CELL MOL BIOL, V49, P875
   Choi KS, 2014, ARCH BIOCHEM BIOPHYS, V559, P38, DOI 10.1016/j.abb.2014.05.016
   Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899 9007(96)00000 8
   Coxon A, 2002, ARTHRITIS RHEUM, V46, P2604, DOI 10.1002/art.10546
   Cragg GM, 2014, J NAT PROD, V77, P703, DOI 10.1021/np5000796
   Crotti TN, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/281287
   Dal Secco D, 2006, NITRIC OXIDE BIOL CH, V15, P77, DOI 10.1016/j.niox.2006.02.004
   Franchin M, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/907041
   Franchin M, 2012, J ETHNOPHARMACOL, V143, P709, DOI 10.1016/j.jep.2012.07.040
   Franco GCN, 2011, EXP CELL RES, V317, P1454, DOI 10.1016/j.yexcr.2011.03.014
   Gasparetto JC, 2012, J PHARM PHARMACOL, V64, P172, DOI 10.1111/j.2042 7158.2011.01383.x
   Georgakopoulou EA, 2014, ORAL DIS, V20, P127, DOI 10.1111/odi.12132
   Hardy RS, 2014, ANN NY ACAD SCI, V1318, P18, DOI 10.1111/nyas.12389
   Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316 341.1996
   Ishtiaq Muhammad, 2007, Pak J Biol Sci, V10, P2241, DOI 10.3923/pjbs.2007.2241.2256
   Javanmardi J, 2003, FOOD CHEM, V83, P547, DOI 10.1016/S0308 8146(03)00151 1
   Kauss T, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2372
   Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371
   Kim HS, 2012, INT J MOL MED, V29, P169, DOI 10.3892/ijmm.2011.822
   Koeberle A, 2014, DRUG DISCOV TODAY, V19, P1871, DOI 10.1016/j.drudis.2014.08.006
   Kohli P, 2009, BRIT J PHARMACOL, V158, P960, DOI 10.1111/j.1476 5381.2009.00290.x
   LEVY L, 1969, LIFE SCI PT 1 PHYSI, V8, P601, DOI 10.1016/0024 3205(69)90021 6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Morris Christopher J, 2003, Methods Mol Biol, V225, P115
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Ohshiba T, 2003, BRIT J CANCER, V88, P1318, DOI 10.1038/sj.bjc.6600858
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Posadas I, 2004, BRIT J PHARMACOL, V142, P331, DOI 10.1038/sj.bjp.0705650
   Prudente AS, 2013, FOOD CHEM TOXICOL, V58, P324, DOI 10.1016/j.fct.2013.04.042
   Rainsford K. D., 2007, V42, P3
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891 5849(98)00315 3
   Seleem D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157188
   Shim KS, 2011, J MED FOOD, V14, P1439, DOI 10.1089/jmf.2010.1502
   Syggelos SA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/230805
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tiveron AP, 2012, INT J MOL SCI, V13, P8943, DOI 10.3390/ijms13078943
   van den Berg WB, 2001, SEMIN ARTHRITIS RHEU, V30, P7, DOI 10.1053/sarh.2001.23704
   WARD PA, 1974, ANN NY ACAD SCI, V221, P290, DOI 10.1111/j.1749 6632.1974.tb28228.x
   WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544
   Wu CL, 2015, BIOCHEM PHARMACOL, V93, P59, DOI 10.1016/j.bcp.2014.10.019
   Yan B, 2014, J IMMUNOL, V192, P5998, DOI 10.4049/jimmunol.1301645
   Zhang F, 2011, BIOCHIMIE, V93, P296, DOI 10.1016/j.biochi.2010.10.001
NR 48
TC 31
Z9 31
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2016
VL 11
IS 9
AR e0162728
DI 10.1371/journal.pone.0162728
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DW8GC
UT WOS:000383891900015
PM 27643502
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Cossío, PI
   Macián, AC
   Ceballos, JLP
   Nicas, JP
   Pérez, JLG
AF Infante Cossio, Pedro
   Cabezas Macian, Antonio
   Perez Ceballos, Jose Luis
   Palomino Nicas, Julian
   Gutierrez Perez, Jose Luis
TI Bisphosphonate related osteonecrosis of the jaw in patients with
   multiple myeloma
SO MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
LA English
DT Article
DE bisphosphonates; osteonecrosis; jaws; multiple myeloma; cancer; oral
   complications
AB Purpose: To review the main clinical radiographic, therapeutic, and preventive aspects of osteonecrosis related to intravenous bisphosphonate therapy in patients with multiple myeloma.
   Materials and methods: Between 2005 and 2006, we studied four patients with previous diagnosis of multiple myeloma treated with intravenous zoledronic acid, presenting nonhealing extraction sockets and intraoral exposed bone. We assessed the location of lesions, the relation with previous history of dento alveolar surgery procedures, the clinical features, the treatments carried out, and the outcomes achieved.
   Results: All the patients were treated with chlorhexidine mouthwashes and oral amoxycilin clavulanic acid for long periods of time. Two patients did not respond to the conservative management and needed surgical bone debridement.
   Conclusions: Dental extractions seem to contribute the development of osteonecrosis of the jaw in patients with multiple myeloma treated with intravenous bisphosphonate therapy. Whereas the pathologic mechanisms are not known, these patients should undergo frequent check ups before, during, and after bisphosphonate therapy. The management must be symptomatic and palliative, including systemic antibiotics, control of pain, and chlorhexidine mouthwashes during long periods of time.
C1 [Infante Cossio, Pedro; Gutierrez Perez, Jose Luis] Univ Seville, Hosp Univ Virgen del Rocio, Fac Odontol, Serv Cirugia Oral & Maxilofacial, Seville, Spain.
   [Palomino Nicas, Julian] Hosp Univ Virgen del Rocio, Unidad Enfermedades Infecciosas, Seville 41013, Spain.
C3 University of Sevilla; Virgen del Rocio University Hospital; Virgen del
   Rocio University Hospital
RP Cossío, PI (通讯作者)，Hosp Univ Virgen del Rocio, Serv Cirugia Oral & Maxillofacial, Av Manuel Siurot, Seville 41013, Spain.
EM pinfante@us.es
RI Moreno Perez, Jose Luis/Y 1142 2019; Infante Cossio, Pedro/F 4451 2019
OI Infante Cossio, Pedro/0000 0002 2770 8573
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Calvo Villas JM, 2006, MED CLIN BARCELONA, V127, P576, DOI 10.1016/S0025 7753(06)72338 7
   Clarke BM, 2007, OTOLARYNG HEAD NECK, V136, P396, DOI 10.1016/j.otohns.2006.11.008
   Dimitrakopoulos I, 2006, INT J ORAL MAX SURG, V35, P588, DOI 10.1016/j.ijom.2006.02.022
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   FERNANDEZ NP, 2006, MED ORAL PATOL ORAL, V11, pE396
   Leite AF, 2006, ORAL SURG ORAL MED O, V102, P14, DOI 10.1016/j.tripleo.2005.10.045
   Jimenez Soriano Yolanda, 2005, Med Oral Patol Oral Cir Bucal, V10 Suppl 2, pE88
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2005, ORAL SURG ORAL MED O, V99, P135, DOI 10.1016/j.tripleo.2004.10.001
   Mortensen M, 2007, LARYNGOSCOPE, V117, P30, DOI 10.1097/01.mlg.0000240885.64568.9e
   Pastor Zuazaga Daniel, 2006, Med Oral Patol Oral Cir Bucal, V11, pE76
   Ruggiero SL, 2006, ORAL SURG ORAL MED O, V102, P433, DOI 10.1016/j.tripleo.2006.06.004
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Schwartz HC, 2005, J ORAL MAXIL SURG, V63, P1555, DOI 10.1016/j.joms.2005.06.003
NR 19
TC 10
Z9 11
U1 0
U2 3
PU MEDICINA ORAL S L
PI VALENCIA
PA CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN
SN 1698 6946
J9 MED ORAL PATOL ORAL
JI Med. Oral Patol. Oral Cir. Bucal
PD JAN
PY 2008
VL 13
IS 1
BP E52
EP E57
AR 10489929
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 352NW
UT WOS:000259504900012
PM 18167482
DA 2025 08 17
ER

PT J
AU van Boven, JFM
   Stuurman Bieze, AGG
   Hiddink, EG
   Postma, MJ
   Vegter, S
AF van Boven, Job F. M.
   Stuurman Bieze, Ada G. G.
   Hiddink, Eric G.
   Postma, Maarten J.
   Vegter, Stefan
TI Medication Monitoring and Optimization: A Targeted Pharmacist Program
   for Effective and Cost Effective Improvement of Chronic Therapy
   Adherence
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
ID RANDOMIZED CONTROLLED TRIAL; PHARMACEUTICAL CARE; OSTEOPOROSIS
   MEDICATION; ASTHMA; INTERVENTION; NONADHERENCE; BISPHOSPHONATES;
   DATABASE; DISEASE; STROKE
AB BACKGROUND: Community pharmacies provide a promising platform for monitoring and improving therapy adherence and providing pharmaceutical care. Structured methods and appropriate software are important tools to increase pharmacist effectiveness and improve health outcomes. In 2006, the Medication Monitoring and Optimization (MeMO) program was introduced in several community pharmacies in the Netherlands. MeMO facilitates targeted and continuous patient centered pharmaceutical care around chronic medication, such as for osteoporosis, cardiovascular disease, and asthma/chronic obstructive pulmonary disease (COPD).
   OBJECTIVES: To describe the MeMO program and summarize findings from publications on its effectiveness, patient satisfaction, and cost effectiveness.
   METHODS: In the first part of this article, the MeMO program is extensively described. In the second part, a review of the evidence of effectiveness, cost effectiveness, and patient satisfaction of the MeMO program is provided. Evidence is based on 5 previously published articles.
   RESULTS: The MeMO program starts with structured counseling sessions with patients at the initiation and follow up of chronic therapies. This process is followed by a continuous phase in which patients' therapy adherence is monitored on a monthly basis, using standardized search algorithms in the pharmacy database. When the algorithm detects a patient's discontinuation of therapy, tailored interventions are used to improve adherence and optimize pharmacotherapy. For osteoporosis patients, treatment discontinuation with bisphosphonates after 1 year dropped from 31.7% to 16.1% (P<0.001). This program was shown to be cost effective in patients initiating osteoporotic therapy. Future scenarios with lower drug prices (e.g., from generic prescribing) result in cost savings for the MeMO program. For lipid lowering drugs, the MeMO program has been shown to lower therapy discontinuation after 1 year from 25.9% to 13.6% (P<0.001). By extrapolating these results to patients' lifetimes, the intervention was estimated to be cost effective, with gains for primary prevention of cardiovascular events, and even cost saving in secondary prevention. Results from the ongoing MeMO asthma/COPD program are promising, showing marked improvements in therapy control and quality of life for asthma and COPD patients. Almost all patients participating in MeMO programs are satisfied with the pharmacy team and have gained knowledge of the effectiveness and administration of their medications and the importance of therapy adherence.
   CONCLUSION: The MeMO program is an effective and structured method to improve patients' adherence to chronic medication in the field of osteoporosis, lipid lowering drugs, and asthma/COPD and is well received by patients. By targeting the program toward nonadherent and high risk patients, the program showed favorable cost effectiveness. Copyright (C) 2014, Academy of Managed Care Pharmacy. All rights reserved.
C1 [van Boven, Job F. M.; Hiddink, Eric G.; Postma, Maarten J.; Vegter, Stefan] Univ Groningen, Dept Pharm, Unit PharmacoEpidemiol & PharmacoEcon, NL 9713 AV Groningen, Netherlands.
   [Stuurman Bieze, Ada G. G.; Hiddink, Eric G.] Hlth Base Fdn, Houten, Netherlands.
   [Hiddink, Eric G.] PharmaPartners, Oosterhout, Netherlands.
C3 University of Groningen
RP van Boven, JFM (通讯作者)，Univ Groningen, Dept Pharm, Unit PharmacoEpidemiol & PharmacoEcon PE2, Antonius Deusinglaan 1, NL 9713 AV Groningen, Netherlands.
EM j.f.m.van.boven@rug.nl
RI van Boven, Job/K 7942 2019; Postma, Mark/E 1561 2018
OI van Boven, Job/0000 0003 2368 2262; Postma, Maarten/0000 0002 6306 3653;
   
FU Royal Dutch Association for the Advancement of Pharmacy (KNMP)
FX No funding was received for this study. Vegter has received grants from
   the Royal Dutch Association for the Advancement of Pharmacy (KNMP), and
   Postma is on several pharmacy advisory boards. Stuurman Bieze and
   Hiddink are employees of the Health Base Foundation, which developed the
   MeMO intervention program.
CR Amarenco P, 2006, NEW ENGL J MED, V355, P549
   [Anonymous], PHARMACOEPIDEMIOLOGY
   Boland MRS, 2013, VALUE HEALTH, V16, pA329, DOI 10.1016/j.jval.2013.08.043
   Boonen LHHM, 2010, ADV HEALTH ECON HEAL, V22, P53, DOI 10.1108/S0731 2199(2010)0000022006
   Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140 6736(02)09327 3
   de Bruin M, 2010, HEALTH PSYCHOL, V29, P421, DOI 10.1037/a0020335
   deGier JJ, 1996, PHARM WORLD SCI, V18, P241
   García Cárdenas V, 2013, RESP MED, V107, P1346, DOI 10.1016/j.rmed.2013.05.014
   Hiddink EG, 2011, PHARM WEEKBLAD WETEN, V5, P147
   Hiligsmann M, 2010, HEALTH POLICY, V96, P170, DOI 10.1016/j.healthpol.2010.01.014
   Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012
   Mayor S, 2013, BMJ BRIT MED J, V347, DOI 10.1136/bmj.f4586
   Murphy AC, 2012, THORAX, V67, P751, DOI 10.1136/thoraxjnl 2011 201096
   OSBORNE ML, 1995, J CLIN EPIDEMIOL, V48, P1393, DOI 10.1016/0895 4356(95)00065 8
   Pont LG, 2002, EUR J CLIN PHARMACOL, V57, P819, DOI 10.1007/s00228 001 0395 4
   SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001
   Stuurman Bieze AGG, 2014, OSTEOPOROSIS INT, V25, P1807, DOI 10.1007/s00198 014 2659 8
   Stuurman Bieze AGG, 2013, ANN PHARMACOTHER, V47, P1448, DOI 10.1177/1060028013501146
   Stuurman Bieze AG, 2005, PHARM WORLD SCI, V27, P385, DOI 10.1007/s11096 005 7113 8
   Stuurman Bieze AG, 2010, PHARM WEEKBLAD WETEN, V4, P128
   Stuurman Bieze AG, 2014, PHARM WEEKBLAD WETEN, pa1413
   Stuurman Bieze AGG, 2004, PHARM WORLD SCI, V26, P289, DOI 10.1023/B:PHAR.0000042926.99705.61
   Tommelein E, 2014, BRIT J CLIN PHARMACO, V77, P756, DOI 10.1111/bcp.12242
   van Boven JFM, 2013, INT J CLIN PHARM NET, V35, P1075, DOI 10.1007/s11096 013 9829 1
   van Boven JFM, 2011, VALUE HEALTH, V14, pA310, DOI 10.1016/j.jval.2011.08.428
   van Boven JFM, 2014, RESP MED, V108, P103, DOI 10.1016/j.rmed.2013.08.044
   van Boven JFM, 2013, J BONE MINER METAB, V31, P562, DOI 10.1007/s00774 013 0440 2
   van den Boogaard CHA, 2006, CURR MED RES OPIN, V22, P1757, DOI 10.1185/030079906X132370
   van der Molen Thys, 2003, Health Qual Life Outcomes, V1, P13, DOI 10.1186/1477 7525 1 13
   Vegter S, 2013, HDB FARMACEUTISCHE P
   Vegter S, 2014, J MANAG CARE SPEC PH, V20, P722, DOI 10.18553/jmcp.2014.20.7.722
   Vegter S, 2011, AM J MANAG CARE, V17, P609
NR 32
TC 48
Z9 50
U1 1
U2 33
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314 3134 USA
SN 2376 0540
EI 2376 1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD AUG
PY 2014
VL 20
IS 8
BP 786
EP 792
DI 10.18553/jmcp.2014.20.8.786
PG 7
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA AL9PP
UT WOS:000339473500003
PM 25062071
OA Green Published
DA 2025 08 17
ER

PT J
AU Qiao, MX
   Xu, ZY
   Pei, XB
   Liu, YH
   Wang, J
   Chen, JY
   Zhu, Z
   Wan, QB
AF Qiao, Mingxin
   Xu, Zhengyi
   Pei, Xibo
   Liu, Yanhua
   Wang, Jian
   Chen, Junyu
   Zhu, Zhou
   Wan, Qianbing
TI Nano SIM@ZIF 8 modified injectable High intensity biohydrogel with
   bidirectional regulation of osteogenesis and Anti adipogenesis for bone
   repair
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Metal  organic frameworks; Hyperlipidemia; Synergetic osteogenesis;
   Injectable hydrogel; Bone tissue engineering
ID COMPOSITE NANOFIBERS; OSTEOBLAST PROMOTION; EXTRACELLULAR MATRIX;
   CALCIUM SUPPLEMENT; PPAR GAMMA; IN VITRO; DIFFERENTIATION; SIMVASTATIN;
   WNT; HYDROGELS
AB Hyperlipidemia negatively affects osteogenesis, thereby impairing bone healing. However, few biomaterials have been developed for bone tissue engineering to solve this problem. Herein, the preparation of specific biomaterials that can promote osteogenesis and suppress adipogenesis holds great promise for reconstructive bone defect treatment. In this study, we propose the construction of a nano simvastatin laden zeolitic imidazolate framework 8 (nano SIM@ZIF 8) modified injectable high intensity biohydrogel, composed of poly (ethylene glycol) diacrylate (PEGDA) and sodium alginate (SA) to form nano SIM@ZIF 8/PEGDA/SA (defined as nSZPS), which can stimulate osteogenic differentiation and inhibit adipogenic differentiation. The characterization and drug loading efficiency of the nanoparticles were examined to confirm the successful synthesis of nano SIM@ZIF8. Within the PEGDA/SA delivery platform, nSZPS showed excellent injectability and mechanical strength through rheological and mechanical tests. Moreover, owing to the sustained release of SIM and bioactive Zn ions, nSZPS not only possessed excellent biocompatibility but also significantly enhanced the osteogenic differentiation ability and inhibited the adipogenic efficacy of BMSCs in vitro. Furthermore, nSZPS showed excellent osseointegration and lipid lowering abilities in healing bone defects of hyperlipidemic rats by decreasing PPAR gamma expression and increasing RUNX2 expression in vivo. In addition, the bidirectional regulatory mechanisms of nSZPS in bone defects may be closely related to the mutual regulation of the PPAR gamma and Wnt/beta CATENIN pathways. In summary, this nano SIM@ZIF 8 modified injectable high intensity biohydrogel might be a promising strategy for complex bone regeneration, especially in hyperlipidemic microenvironments.
C1 [Qiao, Mingxin; Xu, Zhengyi; Pei, Xibo; Liu, Yanhua; Wang, Jian; Chen, Junyu; Zhu, Zhou; Wan, Qianbing] Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Qiao, Mingxin; Xu, Zhengyi; Pei, Xibo; Liu, Yanhua; Wang, Jian; Chen, Junyu; Zhu, Zhou; Wan, Qianbing] Sichuan Univ, West China Hosp Stomatol, Dept Prosthodont, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Zhu, Z; Wan, QB (通讯作者)，Sichuan Univ, West China Hosp Stomatol, Dept Prosthodont, Chengdu 610041, Peoples R China.
EM jujoy1202@163.com; champion@scu.edu.cn
RI Pei, Xibo/JGD 3532 2023; Xu, Zheng Yi/ABC 5388 2021; Wang,
   Jian/JWO 7247 2024; Zhu, Zhou/JUF 7436 2023; wang, jian/GVS 0711 2022
OI Pei, Xibo/0000 0003 0386 8262; Wan, Qianbing/0000 0002 0028 5881;
   Zhengyi, Xu/0000 0001 5852 9167; Wang, Jian/0000 0002 5137 0330; Zhu,
   Zhou/0000 0003 3324 483X; 
FU National Natural Science Foundation of China [81970984, 82101076,
   81771122, 82071164, 81970985]; Postdoctoral Research Foundation of China
   [2020M683334]
FX Acknowledgements This work was supported by the National Natural Science
   Foundation of China (Nos. 81970984, 82101076, 81771122, 82071164,
   81970985) , Postdoctoral Research Foundation of China (Grant No.
   2020M683334) .
CR Abdelhamid HN, 2021, CHEM ENG J, V426, DOI 10.1016/j.cej.2021.131733
   Ahn C, 2018, ACS NANO, V12, P9126, DOI 10.1021/acsnano.8b03264
   Bajaj MS, 2016, STEM CELL RES, V17, P646, DOI 10.1016/j.scr.2016.11.015
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Chen BJ, 2020, CHEM ENG J, V396, DOI 10.1016/j.cej.2020.125335
   Chen R, 2021, J MATER CHEM B, V9, P1107, DOI 10.1039/d0tb02553d
   Chen WH, 2018, ACS NANO, V12, P7538, DOI 10.1021/acsnano.8b03417
   Christodoulides C, 2009, TRENDS ENDOCRIN MET, V20, P16, DOI 10.1016/j.tem.2008.09.002
   Chung SW, 2016, AM J SPORT MED, V44, P1153, DOI 10.1177/0363546515627816
   Dabiri SMH, 2021, SMALL, V17, DOI 10.1002/smll.202103192
   Dai BY, 2021, BIOACT MATER, V6, P2511, DOI 10.1016/j.bioactmat.2021.01.027
   Deng YH, 2019, BIOMATERIALS, V192, P569, DOI 10.1016/j.biomaterials.2018.11.036
   Fan JB, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120445
   Gao XM, 2021, ACS APPL MATER INTER, V13, P97, DOI 10.1021/acsami.0c15945
   Guler E, 2021, INT J BIOL MACROMOL, V190, P244, DOI 10.1016/j.ijbiomac.2021.08.196
   Guo JX, 2021, CHEM ENG J, V405, DOI 10.1016/j.cej.2020.126584
   Guo YC, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf9635
   Hong CS, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1800979
   Ingavle GC, 2019, BIOMATERIALS, V197, P119, DOI 10.1016/j.biomaterials.2019.01.005
   Jiménez M, 2019, J MATER CHEM B, V7, P1974, DOI 10.1039/c8tb02738b
   Jing W, 2019, J BIOMED MATER RES A, V107, P1443, DOI 10.1002/jbm.a.36659
   Kadriu B, 2018, MOL PSYCHIATR, V23, P1626, DOI 10.1038/mp.2017.109
   Kim H, 2020, ACS NANO, V14, P6519, DOI 10.1021/acsnano.9b08216
   Kim S, 2021, MOL CELLS, V44, P1, DOI 10.14348/molcells.2020.0143
   Kunwar P, 2019, ADV OPT MATER, V7, DOI 10.1002/adom.201900656
   Leach JK, 2018, ACS BIOMATER SCI ENG, V4, P1115, DOI 10.1021/acsbiomaterials.6b00741
   Leutner M, 2019, ANN RHEUM DIS, V78, P1706, DOI 10.1136/annrheumdis 2019 215714
   Li GHY, 2020, INT J EPIDEMIOL, V49, P1221, DOI 10.1093/ije/dyz145
   Li LB, 2020, CHEM ENG J, V386, DOI 10.1016/j.cej.2019.123945
   Li SN, 2019, CHEM ENG J, V378, DOI 10.1016/j.cej.2019.122175
   Liu W., CHEM ENG J, V424, DOI 10.1016/j.cej.2021.13032
   Liu YH, 2020, ACS APPL MATER INTER, V12, P36978, DOI 10.1021/acsami.0c12090
   Marcusa DP, 2021, JAMA CARDIOL, V6, P582, DOI 10.1001/jamacardio.2020.6184
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Park CS, 2018, BIOSENS BIOELECTRON, V105, P151, DOI 10.1016/j.bios.2018.01.018
   Pham QP, 2008, BIOMATERIALS, V29, P2729, DOI 10.1016/j.biomaterials.2008.02.025
   Pobloth AM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam8828
   Qu J, 2019, CHEM ENG J, V362, P548, DOI 10.1016/j.cej.2019.01.028
   Rezk AI, 2018, CHEM ENG J, V350, P812, DOI 10.1016/j.cej.2018.05.185
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Shi JL, 2019, ACS APPL MATER INTER, V11, P28858, DOI 10.1021/acsami.9b07991
   Stillman Z, 2020, POLYM CHEM UK, V11, P568, DOI 10.1039/c9py01206k
   Sun QQ, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119473
   Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137
   Tao BL, 2020, CHEM ENG J, V390, DOI 10.1016/j.cej.2020.124621
   Tao S, 2021, J CONTROL RELEASE, V329, P121, DOI 10.1016/j.jconrel.2020.11.059
   Wang JW, 2020, THERANOSTICS, V10, P8591, DOI 10.7150/thno.45142
   Wang YB, 2020, ACS NANO, V14, P13056, DOI 10.1021/acsnano.0c04518
   Wei PR, 2021, CHEM ENG J, V422, DOI 10.1016/j.cej.2021.130051
   Wong FSY, 2019, BIOMATERIALS, V201, P53, DOI 10.1016/j.biomaterials.2019.01.032
   Wu C, 2014, MAT SCI ENG C MATER, V44, P262, DOI 10.1016/j.msec.2014.08.040
   Xue YY, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001369
   Yamamuro T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 17985 w
   Zhai XY, 2018, ADV SCI, V5, DOI 10.1002/advs.201700550
   Zhang JK, 2018, INT J BIOL SCI, V14, P449, DOI 10.7150/ijbs.24158
   Zhang M, 2018, EUR REV MED PHARMACO, V22, P2896, DOI 10.26355/eurrev_201805_14992
   Zhang Q, 2020, CLIN INTERV AGING, V15, P1649, DOI 10.2147/CIA.S266722
   Zhang X, 2017, ACS APPL MATER INTER, V9, P25171, DOI 10.1021/acsami.7b07800
   Zhang ZC, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120905
   Zheng HQ, 2016, J AM CHEM SOC, V138, P962, DOI 10.1021/jacs.5b11720
   Zheng J, 2020, J BONE MINER RES, V35, P1224, DOI 10.1002/jbmr.3989
   Zhong LN, 2020, NANOSCALE, V12, P24437, DOI 10.1039/d0nr06297a
   Zhu Z, 2020, NANO RES, V13, P511, DOI 10.1007/s12274 020 2642 y
   Zou M, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001502
NR 65
TC 42
Z9 45
U1 23
U2 282
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD APR 15
PY 2022
VL 434
AR 134583
DI 10.1016/j.cej.2022.134583
EA JAN 2022
PG 16
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA ZY8LB
UT WOS:000772831300002
DA 2025 08 17
ER

PT J
AU Hamano, T
   Fujii, N
   Matsui, I
   Nakano, C
   Inoue, K
   Tomida, K
   Mikami, S
   Okada, N
   Tsubakihara, Y
   Rakugi, H
   Isaka, Y
AF Hamano, Takayuki
   Fujii, Naohiko
   Matsui, Isao
   Nakano, Chikako
   Inoue, Kazunori
   Tomida, Kodo
   Mikami, Satoshi
   Okada, Noriyuki
   Tsubakihara, Yoshiharu
   Rakugi, Hiromi
   Isaka, Yoshitaka
TI Guideline Practice Gap in the Management of Predialysis Chronic Kidney
   Disease Mineral Bone Disorder in Japan
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Active vitamin D; Chronic kidney disease mineral bone disorder; Diabetes
   mellitus; 25 hydroxyvitamin D; Proteinuria; Secondary
   hyperparathyroidism
ID VITAMIN D ANALOG; RENAL INSUFFICIENCY; SERUM CALCIUM; PROGRESSION;
   ASSOCIATION; PHOSPHORUS; MORTALITY; PODOCYTE; METABOLISM; ACTIVATION
AB No study has reported the current status of the management of chronic kidney disease mineral bone disorder (CKD MBD) in Japan. Using the Osaka Vitamin D Study in CKD (OVIDS CKD), we examined the prevalence of patients with serum calcium, phosphate, parathyroid hormone (PTH), or 25 hydroxyvitamin D levels outside the target of KDOQI guidelines. Eighty four percent of the patients had 25 hydroxyvitamin D <30 ng/mL. Significant determinants of poor vitamin D status were female gender, diabetes, high PTH, and high urinary protein (2+ or greater). The percentage of patients with intact PTH higher than the target was 8% in CKD stage 3a, while between 20 22% in stages 3b to 5. The patients indicated for ergocalciferol were 7, 18, and 19% in stages 3a, 3b, and 4, respectively, and those indicated for active vitamin D were 21% in stage 5. Since neither ergocalciferol nor cholecalciferol is available in 2011 in Japan, we have no choice but to prescribe alfacalcidol or calcitriol; however, the percent of patients receiving these drugs was only 1, 4, 8, and 14% in stages 3a, 3b, 4, and 5, respectively, indicating that PTH and vitamin D status are not well controlled in Japan. In contrast, more than 80% of the patients met the target of serum calcium and phosphate. Contrary to expectations, nearly 20% of the patients had hypophosphatemia in stage 3 and 5, possibly because of strict protein restriction. Given these results, nephrologists should consider prescribing active vitamin D, especially for females and patients with diabetes, massive proteinuria, or secondary hyperparathyroidism.
C1 [Hamano, Takayuki; Matsui, Isao; Nakano, Chikako; Inoue, Kazunori; Rakugi, Hiromi; Isaka, Yoshitaka] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka 5650871, Japan.
   [Tomida, Kodo] Kansai Rousai Hosp, Dept Internal Med, Amagasaki, Hyogo, Japan.
   [Fujii, Naohiko] Hyogo Prefectural Hosp Nishinomiya, Dept Nephrol, Nishinomiya, Hyogo, Japan.
   [Okada, Noriyuki; Tsubakihara, Yoshiharu] Osaka Gen Med Ctr, Dept Hypertens & Nephrol, Osaka, Japan.
   [Mikami, Satoshi] Higashi Kohri Hosp, Dept Internal Med, Osaka, Japan.
C3 University of Osaka
RP Hamano, T (通讯作者)，Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Box A8,2 2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM hamatea@medone.med.osaka u.ac.jp
RI ; Hamano, TAKAYUKI/AAZ 4837 2021; Rakugi, Hiromi/ADM 3795 2022; Fujii,
   Naohiko/ABG 8766 2021; Inoue, Kazunori/ABB 7715 2022
OI Tsubakihara, Yoshiharu/0000 0001 9703 9443; Matsui,
   Isao/0000 0001 8378 6130; Rakugi, Hiromi/0000 0001 6508 4338; 
FU Chugai Pharmaceutical Co., Ltd.; Grants in Aid for Scientific Research
   [21390222] Funding Source: KAKEN
FX Takayuki Hamano received a speaker's fee and Isao Matsui received grants
   from Chugai Pharmaceutical Co., Ltd. The other authors have no conflict
   of interests.
CR CRIVELLO JF, 1988, ARCH BIOCHEM BIOPHYS, V262, P471, DOI 10.1016/0003 9861(88)90398 0
   de Zeeuw D, 2010, LANCET, V376, P1543, DOI 10.1016/S0140 6736(10)61032 X
   Deb DK, 2010, KIDNEY INT, V77, P1000, DOI 10.1038/ki.2010.22
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Fishbane S, 2009, AM J KIDNEY DIS, V54, P647, DOI 10.1053/j.ajkd.2009.04.036
   Imai E, 2010, CLIN EXP NEPHROL, V14, P558, DOI 10.1007/s10157 010 0328 6
   Kazama JJ, 2007, THER APHER DIAL, V11, pS44, DOI 10.1111/j.1744 9987.2007.00516.x
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kosmadakis G, 2008, KIDNEY INT, V73, P360, DOI 10.1038/sj.ki.5002666
   Kovesdy CP, 2008, KIDNEY INT, V73, P1296, DOI 10.1038/ki.2008.64
   Kovesdy CP, 2008, ARCH INTERN MED, V168, P397, DOI 10.1001/archinternmed.2007.110
   Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523 1755.1998.00044.x
   Kriz W, 2002, MICROSC RES TECHNIQ, V57, P189, DOI 10.1002/jemt.10072
   Lash JP, 2009, CLIN J AM SOC NEPHRO, V4, P1302, DOI 10.2215/CJN.00070109
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Levin A, 2008, AM J KIDNEY DIS, V52, P661, DOI 10.1053/j.ajkd.2008.06.023
   Matsui I, 2009, NEPHROL DIAL TRANSPL, V24, P2354, DOI 10.1093/ndt/gfp117
   Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034
   Matsusaka T, 2005, J AM SOC NEPHROL, V16, P1013, DOI 10.1681/ASN.2004080720
   McKinney K, 2008, CLIN ENDOCRINOL, V69, P535, DOI 10.1111/j.1365 2265.2008.03233.x
   Mizobuchi M, 2007, J AM SOC NEPHROL, V18, P1796, DOI 10.1681/ASN.2006091028
   Nakai S, 2008, THER APHER DIAL, V12, P49, DOI 10.1111/j.1744 9987.2007.00540.x
   Nakajima H, 2004, J AM SOC NEPHROL, V15, P276, DOI 10.1097/01.ASN.0000109672.83594.02
   Norris KC, 2006, J AM SOC NEPHROL, V17, P2928, DOI 10.1681/ASN.2005101101
   Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244
   Schwarz S, 2006, CLIN J AM SOC NEPHRO, V1, P825, DOI 10.2215/CJN.02101205
   Slatopolsky E, 1999, KIDNEY INT, V56, pS46, DOI 10.1046/j.1523 1755.1999.07305.x
   Tanaka H, 2009, BONE, V45, P949, DOI 10.1016/j.bone.2009.07.016
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
NR 29
TC 13
Z9 14
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD JUN
PY 2011
VL 15
SU 1
SI SI
BP 2
EP 8
DI 10.1111/j.1744 9987.2011.00918.x
PG 7
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 789VG
UT WOS:000292544600002
PM 21595844
DA 2025 08 17
ER

PT J
AU Lin, JJ
   Ning, T
   Jia, SC
   Li, KJ
   Huang, YC
   Liu, Q
   Lin, JH
   Zhang, XT
AF Lin, Jian Jing
   Ning, Tong
   Jia, Shi Cheng
   Li, Ke Jia
   Huang, Yong Can
   Liu, Qiang
   Lin, Jian Hao
   Zhang, Xin Tao
TI Evaluation of genetic response of mesenchymal stem cells to nanosecond
   pulsed electric fields by whole transcriptome sequencing
SO WORLD JOURNAL OF STEM CELLS
LA English
DT Article
DE Nanosecond pulsed electric fields; Whole transcriptome sequencing;
   Mesenchymal stem cells; Genetic response; Stem cell engineering
ID DIFFERENTIATION; STIMULATION
AB BACKGROUND Mesenchymal stem cells (MSCs) modulated by various exogenous signals have been applied extensively in regenerative medicine research. Notably, nanosecond pulsed electric fields (nsPEFs), characterized by short duration and high strength, significantly influence cell phenotypes and regulate MSCs differentiation via multiple pathways. Consequently, we used transcriptomics to study changes in messenger RNA (mRNA), long noncoding RNA (lncRNA), microRNA (miRNA), and circular RNA expression during nsPEFs application. AIM To explore gene expression profiles and potential transcriptional regulatory mechanisms in MSCs pretreated with nsPEFs. METHODS The impact of nsPEFs on the MSCs transcriptome was investigated through whole transcriptome sequencing. MSCs were pretreated with 5 pulse nsPEFs (100 ns at 10 kV/cm, 1 Hz), followed by total RNA isolation. Each transcript was normalized by fragments per kilobase per million. Fold change and difference significance were applied to screen the differentially expressed genes (DEGs). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to elucidate gene functions, complemented by quantitative polymerase chain reaction verification. RESULTS In total, 263 DEGs were discovered, with 92 upregulated and 171 downregulated. DEGs were predominantly enriched in epithelial cell proliferation, osteoblast differentiation, mesenchymal cell differentiation, nuclear division, and wound healing. Regarding cellular components, DEGs are primarily involved in condensed chromosome, chromosomal region, actin cytoskeleton, and kinetochore. From aspect of molecular functions, DEGs are mainly involved in glycosaminoglycan binding, integrin binding, nuclear steroid receptor activity, cytoskeletal motor activity, and steroid binding. Quantitative real time polymerase chain reaction confirmed targeted transcript regulation. CONCLUSION Our systematic investigation of the wide ranging transcriptional pattern modulated by nsPEFs revealed the differential expression of 263 mRNAs, 2 miRNAs, and 65 lncRNAs. Our study demonstrates that nsPEFs may affect stem cells through several signaling pathways, which are involved in vesicular transport, calcium ion transport, cytoskeleton, and cell differentiation.
C1 [Lin, Jian Jing; Jia, Shi Cheng; Zhang, Xin Tao] Peking Univ, Dept Sports Med & Rehabil, Shenzhen Hosp, Shenzhen 518036, Guangdong, Peoples R China.
   [Ning, Tong] Shandong Univ, Hosp 2, Inst Med Sci, Cheeloo Coll Med, Jinan 250033, Shandong, Peoples R China.
   [Li, Ke Jia] Peking Univ, Coll Future Technol, Dept Biomed Engn, Beijing 100871, Peoples R China.
   [Huang, Yong Can] Peking Univ, Shenzhen Engn Lab Orthopaed Regenerat Technol, Shenzhen Hosp, Shenzhen 518036, Guangdong, Peoples R China.
   [Liu, Qiang; Lin, Jian Hao] Peking Univ, Peoples Hosp, Arthrit Clin & Res Ctr, Beijing 100044, Peoples R China.
   [Zhang, Xin Tao] Peking Univ, Dept Sports Med & Rehabil, Shenzhen Hosp, 1120 Lianhua Rd, Shenzhen 518036, Guangdong, Peoples R China.
C3 Peking University; Shandong University; Peking University; Peking
   University; Peking University; Peking University
RP Zhang, XT (通讯作者)，Peking Univ, Dept Sports Med & Rehabil, Shenzhen Hosp, 1120 Lianhua Rd, Shenzhen 518036, Guangdong, Peoples R China.
EM zhangxintao@sina.com
RI Huang, Yong Can/AFQ 2454 2022; Shicheng, Jia/IAQ 5476 2023
FU National Natural Science Foundation, China [82272568, 81902247,
   32201013]; Natural Science Foundation of Shandong Province, China
   [ZR2021QH275]; Natural Science Foundation of Jinan City, China
   [202225070]; Guangdong Basic and Applied Basic Research Foundation,
   China [2022A1515220056]
FX Supported by the National Natural Science Foundation, China, No.
   82272568, 81902247, and 32201013; Natural Science Foundation of Shandong
   Province, China, No. ZR2021QH275; Natural Science Foundation of Jinan
   City, China, No. 202225070; and Guangdong Basic and Applied Basic
   Research Foundation, China, No. 2022A1515220056.
CR Aaron RK, 2004, CLIN ORTHOP RELAT R, P21, DOI 10.1097/01.blo.0000118699.26862.41
   ANDREWS M J, 1978, Journal of Biological Physics, V6, P69, DOI 10.1007/BF02311220
   Bicer M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10121696
   Bonora M, 2021, INT REV CEL MOL BIO, V362, P111, DOI 10.1016/bs.ircmb.2021.05.003
   Cao YY, 2018, J CELL BIOCHEM, V119, P8450, DOI 10.1002/jcb.27069
   Chen J, 2021, J ONCOL, V2021, DOI 10.1155/2021/5572402
   Chen Y, 2021, AGING US, V13, P9991, DOI 10.18632/aging.202759
   Chermnykh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041003
   Choi DH, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121156
   Chumnarnsilpa S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9254
   Fan LT, 2019, J ORTHOP RES, V37, P1387, DOI 10.1002/jor.24224
   Guo WB, 2016, ACS NANO, V10, P5086, DOI 10.1021/acsnano.6b00200
   Heilig AK, 2022, ELIFE, V11, DOI 10.7554/eLife.71845
   Hess R, 2012, BIOMATERIALS, V33, P8975, DOI 10.1016/j.biomaterials.2012.08.056
   Kasprzycka W, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011236
   Kim JA, 2016, TISSUE ENG REGEN MED, V13, P57, DOI 10.1007/s13770 015 9066 x
   Klemm SL, 2019, NAT REV GENET, V20, P207, DOI 10.1038/s41576 018 0089 8
   Koga T, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 44817 9
   Kusuyama J, 2014, J BIOL CHEM, V289, P10330, DOI 10.1074/jbc.M113.546382
   Li DW, 2021, EMBO REP, V22, DOI 10.15252/embr.202051644
   Li KJ, 2022, SCI CHINA LIFE SCI, V65, P927, DOI 10.1007/s11427 021 1983 y
   Li KJ, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01821 5
   Liu Y, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.992961
   Ma SY, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1091360
   Manser M, 2017, SCI REP UK, V7, DOI 10.1038/srep43345
   Mao Z, 2020, SMALL, V16, DOI 10.1002/smll.201904047
   McKinney JM, 2022, ACTA BIOMATER, V141, P315, DOI 10.1016/j.actbio.2021.12.034
   Morotomi Yano K, 2011, ARCH BIOCHEM BIOPHYS, V515, P99, DOI 10.1016/j.abb.2011.09.002
   Muratori C, 2017, J BIOL CHEM, V292, P19381, DOI 10.1074/jbc.M117.803049
   Nguyen HT, 2013, J NEURAL ENG, V10, DOI 10.1088/1741 2560/10/4/046011
   Ning T, 2019, EUR CELLS MATER, V38, P79, DOI 10.22203/eCM.v038a07
   Ning T, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1133 0
   Pakhomov AG, 2015, BBA BIOMEMBRANES, V1848, P958, DOI 10.1016/j.bbamem.2014.12.026
   Pchelintseva E, 2018, J CELL PHYSIOL, V233, P3755, DOI 10.1002/jcp.26120
   Pooley RD, 2008, J CELL SCI, V121, P3413, DOI 10.1242/jcs.032847
   Qian JJ, 2020, CANCER LETT, V495, P1, DOI 10.1016/j.canlet.2020.09.015
   Roth CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154555
   Safaei Z, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1047851
   Scarlett SS, 2009, BBA BIOMEMBRANES, V1788, P1168, DOI 10.1016/j.bbamem.2009.02.006
   Stacey M, 2011, BIOELECTROCHEMISTRY, V82, P131, DOI 10.1016/j.bioelechem.2011.06.002
   Thrivikraman G, 2018, BIOMATERIALS, V150, P60, DOI 10.1016/j.biomaterials.2017.10.003
   Uusküla Reimand L, 2022, SCI ADV, V8, DOI 10.1126/sciadv.add4920
   Vadlamani RA, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2019.0079
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Wang X, 2022, NATURE AGING, V2, P155, DOI 10.1038/s43587 021 00164 x
   Xie YH, 2022, CELL STEM CELL, V29, P70, DOI 10.1016/j.stem.2021.09.009
   Yang YH, 2018, ACTA BIOMATER, V69, P71, DOI 10.1016/j.actbio.2017.12.043
   Yang ZG, 2020, NAT BIOMED ENG, V4, P69, DOI 10.1038/s41551 019 0485 1
   Yao CG, 2009, IEEE T DIELECT EL IN, V16, P1259, DOI 10.1109/TDEI.2009.5293936
   Zhang JB, 2022, BIOFABRICATION, V14, DOI 10.1088/1758 5090/ac5935
   Zhang Y, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1044773
   Zhou P, 2018, BIOELECTROCHEMISTRY, V124, P7, DOI 10.1016/j.bioelechem.2018.06.009
NR 52
TC 1
Z9 1
U1 1
U2 7
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1948 0210
J9 WORLD J STEM CELLS
JI World J. Stem Cells
PD MAR 26
PY 2024
VL 16
IS 3
DI 10.4252/wjsc.v16.i3.305
PG 20
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA NC2L1
UT WOS:001198181700004
PM 38577234
OA hybrid
DA 2025 08 17
ER

PT J
AU Block, GA
   Zeig, S
   Sugihara, J
   Chertow, GM
   Chi, EM
   Turner, SA
   Bushinsky, DA
AF Block, Geoffrey A.
   Zeig, Steven
   Sugihara, Jared
   Chertow, Glenn M.
   Chi, Eric M.
   Turner, Stewart A.
   Bushinsky, David A.
CA TARGET Investigators
TI Combined therapy with cinacalcet and low doses of vitamin D sterols in
   patients with moderate to severe secondary hyperparathyroidism
SO NEPHROLOGY DIALYSIS TRANSPLANTATION
LA English
DT Article
DE cinacalcet; KDOQI (TM); PTH; secondary hyperparathyroidism; vitamin D
ID INTACT PARATHYROID HORMONE; HEMODIALYSIS PATIENTS; GENE EXPRESSION;
   CALCIUM; DIALYSIS; D 2; HYDROCHLORIDE; CALCIMIMETICS; PTH
AB Background. Adequate control of all four KDOQI(TM) biochemical targets for chronic kidney disease, bone and mineral disorder (CKD MBD), which include parathyroid hormone (PTH), calcium (Ca), phosphorus (P) and Ca x P, remains difficult and is accomplished in < 6% of patients receiving haemodialysis. The objective of the current study was to determine whether treatment with cinacalcet combined with low doses of vitamin D sterols improves control of both PTH and Ca x P among haemodialysis patients with secondary hyperparathyroidism (sHPT).
   Methods. This multicentre, open label study enrolled haemodialysis subjects (N = 444) with moderate to severe sHPT (mean serum biPTH > 160 430 pg/mL) (similar to iPTH 300 800 pg/mL or ng/L). Cinacalcet was titrated sequentially (30 180 mg/day) during an 8 week dose titration phase to achieve biPTH <= 160 pg/mL (similar to iPTH 300 pg/mL or ng/L) and efficacy was assessed over 8 weeks. At week 2 of the study, subjects receiving vitamin D sterols had doses reduced to the equivalent of 2 mcg of paricalcitol three times a week or 6 mcg/week. Among the efficacy endpoints were the proportion of subjects with mean biPTH <= 160 pg/mL (similar to iPTH 300 pg/mL or ng/L), with mean Ca x P <= 55 mg(2)/dL(2) (4.4 mmol(2)/L 2) and with both simultaneously during the assessment phase.
   Results. The majority of subjects (n = 375) reached the assessment phase of the study and were included in efficacy analyses; 39 subjects withdrew due to adverse events. Sixty two percent of subjects achieved the biPTH target, 83% achieved the Ca x P target and 54% reached both targets. Treatment reduced biPTH by 35% (P < 0.0001), calcium by 11% (P < 0.0001), phosphorus by 7% (P < 0.0001) and Ca x P by 17% (P < 0.0001). The proportion of subjects with values for biPTH, for Ca x P and for both biPTH and Ca x P within the target range during the assessment phase did not differ between subjects who received cinacalcet together with vitamin D sterols, and those who received cinacalcet alone.
   Conclusion. Among subjects with moderate to severe sHPT undergoing haemodialysis, combined therapy with cinacalcet and low doses of vitamin D sterols improved achievement of the biochemical targets for CKD MBD recommended by the KDOQI (TM) guidelines.
C1 [Block, Geoffrey A.] Denver Nephrologists, Denver, CO 80230 USA.
   [Zeig, Steven] Pines Clin Res, Pembroke Pines, FL USA.
   [Sugihara, Jared] St Francis Med Ctr, Honolulu, HI USA.
   [Chertow, Glenn M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Chi, Eric M.; Turner, Stewart A.] Amgen Inc, Thousand Oaks, CA 91320 USA.
   [Bushinsky, David A.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
C3 University of California System; University of California San Francisco;
   Amgen; University of Rochester
RP Block, GA (通讯作者)，Denver Nephrologists, 130 Rampart Way Suite 300B, Denver, CO 80230 USA.
EM gablock@denverneph.net
RI ; Block, Geoffrey/AAV 8070 2021
OI Sekkarie, Mohamed/0000 0002 9859 6257; Chertow,
   Glenn/0000 0002 7599 0534
CR Bleyer AJ, 1999, AM J KIDNEY DIS, V33, P694, DOI 10.1016/S0272 6386(99)70221 0
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Brown AJ, 2002, J LAB CLIN MED, V139, P279, DOI 10.1067/mlc.2002.122819
   Chertow GM, 2006, CLIN J AM SOC NEPHRO, V1, P305, DOI 10.2215/CJN.00870805
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Fujimori A, 2004, THER APHER DIAL, V8, P474, DOI 10.1111/j.1774 9987.2004.00189.x
   GALLIENI M, 1992, KIDNEY INT, V42, P1191, DOI 10.1038/ki.1992.404
   Heaney RP, 1997, J CLIN ENDOCR METAB, V82, P4111, DOI 10.1210/jc.82.12.4111
   Levi R, 2006, J AM SOC NEPHROL, V17, P107, DOI 10.1681/ASN.2005070679
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   Manley HJ, 2004, NEPHROL DIAL TRANSPL, V19, P1842, DOI 10.1093/ndt/gfh280
   Martin KJ, 2005, KIDNEY INT, V68, P1236, DOI 10.1111/j.1523 1755.2005.00517.x
   Martin KJ, 1998, J AM SOC NEPHROL, V9, P1427
   NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Tan AU, 1997, KIDNEY INT, V51, P317, DOI 10.1038/ki.1997.39
   Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 21
TC 73
Z9 78
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0931 0509
EI 1460 2385
J9 NEPHROL DIAL TRANSPL
JI Nephrol. Dial. Transplant.
PD JUL
PY 2008
VL 23
IS 7
BP 2311
EP 2318
DI 10.1093/ndt/gfn026
PG 8
WC Transplantation; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Transplantation; Urology & Nephrology
GA 322ZK
UT WOS:000257413600034
PM 18310602
OA Bronze
DA 2025 08 17
ER

PT J
AU Khalil, H
   Williams, RJ
   Stenbeck, G
   Henderson, B
   Meghji, S
   Nair, SP
AF Khalil, Hesham
   Williams, Rachel J.
   Stenbeck, Gudrun
   Henderson, Brian
   Meghji, Sajeda
   Nair, Sean P.
TI Invasion of bone cells by Staphylococcus epidermidis
SO MICROBES AND INFECTION
LA English
DT Article
DE Staphylococcus epidermidis; invasion; bone cells
ID FIBRONECTIN BINDING PROTEIN; TOTAL HIP ARTHROPLASTY; CULTURED
   OSTEOBLASTS; AUREUS; INTERNALIZATION; OSTEOMYELITIS; JOINT; MECHANISMS;
   ARTHRITIS; ADHESION
AB Bone implants infected with Staphylococcus epidermidis often require surgical intervention because of the failure of antibiotic treatment. The reasons why such infections are resistant to therapy are poorly understood. We have previously reported that another bacterium, Staphylococcus aureus, can invade bone cells and thereby evade antimicrobial therapy. In this study we have investigated the hypothesis that S.epidermidis can also invade bone cells and may therefore explain the difficulties of treating infections with this organism. We found that S. epidermidis was capable of invading bone cells but that there were significant strain dependent differences in this capacity. A recombinant protein encompassing the D1 D4 repeat region of S. aureus fibronectin binding protein B completely, inhibited internalization of S. aureus but failed to block internalization of S. epidermidis. Similarly a blocking antibody to alpha 5 ss 1 integrin inhibited internalization of S. aureus by bone cells but had no effect on the uptake of S. epidermidis. Therefore unlike S. aureus, S. epidermidis does not gain entrance into bone cells through a fibronectin bridge between the alpha 5 ss 1 integrin and a bacterial adhesin. Crown Copyright (c) 2007 Published by Elsevier Masson SAS. All rights reserved.
C1 UCL, Div Microbial Dis, Eastman Dent Inst, London WC1X 8LD, England.
   UCL, Bone & Mineral Ctr, London WC1E 6JJ, England.
C3 University of London; University College London; University of London;
   University College London
RP Nair, SP (通讯作者)，UCL, Div Microbial Dis, Eastman Dent Inst, 256 Grays Inn Rd, London WC1X 8LD, England.
EM snair@eastman.ucl.ac.uk
RI Almoallim, Hesham/H 7795 2014; Nair, Sean/C 9562 2009
OI Almoallim, Hesham/0000 0002 1455 1095; 
CR Ahmed S, 2001, INFECT IMMUN, V69, P2872, DOI 10.1128/IAI.69.5.2872 2877.2001
   BARASCH A, 1993, ORAL SURG ORAL MED O, V75, P391, DOI 10.1016/0030 4220(93)90157 Y
   BREMELL T, 1990, ARTHRITIS RHEUM US, V33, P1739, DOI 10.1002/art.1780331120
   BREMELL T, 1992, INFECT IMMUN, V60, P2976, DOI 10.1128/IAI.60.7.2976 2985.1992
   Carek PJ, 2001, AM FAM PHYSICIAN, V63, P2413
   Christel Pascal, 1994, Current Opinion in Rheumatology, V6, P161, DOI 10.1097/00002281 199403000 00008
   Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897
   DAROUICHE RO, 1994, ANTIMICROB AGENTS CH, V38, P1059, DOI 10.1128/AAC.38.5.1059
   DEWIT D, 1993, BRIT J RHEUMATOL, V32, P339
   DUPONT JA, 1986, CLIN ORTHOP RELAT R, P122
   Ellington JK, 1999, MICROB PATHOGENESIS, V26, P317, DOI 10.1006/mpat.1999.0272
   FEHRING TK, 1994, CLIN ORTHOP RELAT R, P229
   Francois P, 1999, J BIOMAT SCI POLYM E, V10, P1207, DOI 10.1163/156856299X00027
   Galdbart JO, 1999, J CLIN MICROBIOL, V37, P1306, DOI 10.1128/JCM.37.5.1306 1312.1999
   Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075
   Jevon M, 1999, INFECT IMMUN, V67, P2677, DOI 10.1128/IAI.67.5.2677 2681.1999
   Lachiewicz PF, 1996, J BONE JOINT SURG AM, V78A, P749, DOI 10.2106/00004623 199605000 00015
   MACK D, 1992, INFECT IMMUN, V60, P2048, DOI 10.1128/IAI.60.5.2048 2057.1992
   McCrea KW, 2000, MICROBIOL SGM, V146, P1535, DOI 10.1099/00221287 146 7 1535
   Nilsson M, 1998, INFECT IMMUN, V66, P2666, DOI 10.1128/IAI.66.6.2666 2673.1998
   NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042 6822(67)90105 5
   Reilly SS, 2000, BONE, V26, P63, DOI 10.1016/S8756 3282(99)00239 2
   Schierholz JM, 2001, J HOSP INFECT, V49, P87, DOI 10.1053/jhin.2001.1052
   SEIBOLD R, 1991, CLIN THER, V13, P457
   Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462 5822.1999.00011.x
   Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423
   Williams RJ, 2002, INFECT IMMUN, V70, P6805, DOI 10.1128/IAI.70.12.6805 6810.2002
NR 27
TC 65
Z9 72
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286 4579
J9 MICROBES INFECT
JI Microbes Infect.
PD APR
PY 2007
VL 9
IS 4
BP 460
EP 465
DI 10.1016/j.micinf.2007.01.002
PG 6
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA 160RK
UT WOS:000245959800006
PM 17331787
OA Bronze
DA 2025 08 17
ER

PT J
AU Krause, DS
   Fulzele, K
   Catic, A
   Sun, CC
   Dombkowski, D
   Hurley, MP
   Lezeau, S
   Attar, E
   Wu, JY
   Lin, HY
   Divieti Pajevic, P
   Hasserjian, RP
   Schipani, E
   Van Etten, RA
   Scadden, DT
AF Krause, Daniela S.
   Fulzele, Keertik
   Catic, Andre
   Sun, Chia Chi
   Dombkowski, David
   Hurley, Michael P.
   Lezeau, Sanon
   Attar, Eyal
   Wu, Joy Y.
   Lin, Herbert Y.
   Divieti Pajevic, Paola
   Hasserjian, Robert P.
   Schipani, Ernestina
   Van Etten, Richard A.
   Scadden, David T.
TI Differential regulation of myeloid leukemias by the bone marrow
   microenvironment
SO NATURE MEDICINE
LA English
DT Article
ID CHRONIC MYELOGENOUS LEUKEMIA; STEM CELLS; MICE; PROGENITOR; ENGRAFTMENT;
   EXPRESSION; INDUCTION; RECEPTOR; HORMONE; MLL AF9
AB Like their normal hematopoietic stem cell counterparts, leukemia stem cells (LSCs) in chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) are presumed to reside in specific niches in the bone marrow microenvironment (BMM)(1) and may be the cause of relapse following chemotherapy(2). Targeting the niche is a new strategy to eliminate persistent and drug resistant LSCs. CD44 (refs. 3,4) and interleukin 6 (ref. 5) have been implicated previously in the LSC niche. Transforming growth factor beta 1 (TGF beta 1) is released during bone remodeling(6) and plays a part in maintenance of CML LSCs7, but a role for TGF beta 1 from the BMM has not been defined. Here, we show that alteration of the BMM by osteoblastic cell specific activation of the parathyroid hormone (PTH) receptor(8,9) attenuates BCR ABL1 oncogene induced CML like myeloproliferative neoplasia (MPN)(10) but enhances MLL AF9 oncogene induced AML(11) in mouse transplantation models, possibly through opposing effects of increased TGF beta 1 on the respective LSCs. PTH treatment caused a 15 fold decrease in LSCs in wild type mice with CML like MPN and reduced engraftment of immune deficient mice with primary human CML cells. These results demonstrate that LSC niches in CML and AML are distinct and suggest that modulation of the BMM by PTH may be a feasible strategy to reduce LSCs, a prerequisite for the cure of CML.
C1 [Krause, Daniela S.; Catic, Andre; Hurley, Michael P.; Lezeau, Sanon; Scadden, David T.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
   [Krause, Daniela S.; Catic, Andre; Hurley, Michael P.; Lezeau, Sanon; Scadden, David T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [Krause, Daniela S.; Catic, Andre; Hurley, Michael P.; Lezeau, Sanon; Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
   [Krause, Daniela S.; Catic, Andre; Hurley, Michael P.; Lezeau, Sanon; Scadden, David T.] Harvard Stem Cell Inst, Cambridge, MA USA.
   [Krause, Daniela S.; Dombkowski, David; Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   [Fulzele, Keertik; Wu, Joy Y.; Divieti Pajevic, Paola] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Sun, Chia Chi; Lin, Herbert Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
   [Attar, Eyal; Scadden, David T.] Massachusetts Gen Hosp, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA.
   [Schipani, Ernestina] Indiana Univ Sch Med, Div Endocrinol, Indianapolis, IN 46202 USA.
   [Van Etten, Richard A.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   University; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard University; Harvard University
   Medical Affiliates; Massachusetts General Hospital; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital;
   Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Indiana University System; Indiana University
   Bloomington; Tufts Medical Center
RP Scadden, DT (通讯作者)，Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
EM rvanetten@tuftsmedicalcenter.org; dscadden@mgh.harvard.edu
RI ; Pajevic, Paola/M 3236 2019
OI Catic, Andre/0000 0002 3572 7598; Krause, Daniela
   S./0000 0003 3603 1119; Divieti Pajevic, Paola/0000 0001 9853 9837
FU Ellison Medical Foundation; US National Institute on Aging
   [K01AG036744];  [K08 CA138916 02];  [T32 CA009216];  [AR060221]; 
   [R21AR060689];  [R01 CA090576];  [R01 HL089747];  [R01 HL044851];  [R01
   CA148180]; National Cancer Institute [R01CA090576] Funding Source: NIH
   RePORTER
FX The authors thank A. Legedza and D. Neuberg for advice on statistical
   analysis and H. H. Chen for helpful discussions. This work was supported
   by grants K08 CA138916 02 and T32 CA009216 to D. S. K., grant AR060221
   to K. F. and P. D. P., grant R21AR060689 to E. S., grants R01 CA090576
   and R01 HL089747 to R. A. V., grants R01 HL044851 and R01 CA148180 and a
   grant from The Ellison Medical Foundation to D.T.S. A.C. was supported
   by US National Institute on Aging grant K01AG036744.
CR Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902
   GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394
   Guo J, 2010, CELL METAB, V11, P161, DOI 10.1016/j.cmet.2009.12.007
   Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732
   Heaney NB, 2010, BLOOD, V115, P2241, DOI 10.1182/blood 2008 06 164582
   Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103
   Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350
   Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483
   Krause DS, 2007, TRENDS MOL MED, V13, P470, DOI 10.1016/j.molmed.2007.09.003
   Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489
   Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980
   Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399
   Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442
   Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734
   Ohishi M, 2009, AM J PATHOL, V174, P2160, DOI 10.2353/ajpath.2009.081026
   Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103
   Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012
   Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
NR 25
TC 205
Z9 227
U1 0
U2 29
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1078 8956
EI 1546 170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2013
VL 19
IS 11
BP 1513
EP +
DI 10.1038/nm.3364
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 251IF
UT WOS:000326920300029
PM 24162813
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Flammier, S
   Peyruchaud, O
   Bourguillault, F
   Duboeuf, F
   Davignon, JL
   Norman, DD
   Isaac, S
   Marotte, H
   Tigyi, G
   Machuca Gayet, I
   Coury, F
AF Flammier, Sacha
   Peyruchaud, Olivier
   Bourguillault, Fanny
   Duboeuf, Francois
   Davignon, Jean Luc
   Norman, Derek D.
   Isaac, Sylvie
   Marotte, Hubert
   Tigyi, Gabor
   Machuca Gayet, Irma
   Coury, Fabienne
TI Osteoclast Derived Autotaxin, a Distinguishing Factor for Inflammatory
   Bone Loss
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID TUMOR NECROSIS FACTOR; LYSOPHOSPHATIDIC ACID; RHEUMATOID ARTHRITIS;
   LYSOPHOSPHOLIPASE D; MINERAL DENSITY; EXPRESSION; ALPHA; EROSION;
   DAMAGE; RANKL
AB Objective The severity of rheumatoid arthritis (RA) correlates directly with bone erosions arising from osteoclast (OC) hyperactivity. Despite the fact that inflammation may be controlled in patients with RA, those in a state of sustained clinical remission or low disease activity may continue to accrue erosions, which supports the need for treatments that would be suitable for long lasting inhibition of OC activity without altering the physiologic function of OCs in bone remodeling. Autotaxin (ATX) contributes to inflammation, but its role in bone erosion is unknown.
   Methods ATX was targeted by inhibitory treatment with pharmacologic drugs and also by conditional inactivation of the ATX gene Ennp2 in murine OCs (Delta ATX (c)(tsk)). Arthritic and erosive diseases were studied in human tumor necrosis factor transgenic (hTNF(+/ )) mice and mice with K/BxN serum transfer induced arthritis. Systemic bone loss was also analyzed in mice with lipopolysaccharide (LPS) induced inflammation and estrogen deprivation. Joint inflammation and bone erosion were assessed by histology and micro computed tomography. The role of ATX in RA was also examined in OC differentiation and activity assays.
   Results OCs present at sites of inflammation overexpressed ATX. Pharmacologic inhibition of ATX in hTNF(+/ ) mice, as compared to vehicle treated controls, significantly mitigated focal bone erosion (36% decrease; P < 0.05) and systemic bone loss (43% decrease; P < 0.05), without affecting synovial inflammation. OC derived ATX was revealed to be instrumental in OC bone resorptive activity and was up regulated by the inflammation elicited in the presence of TNF or LPS. Specific loss of ATX in OCs from mice subjected to ovariectomy significantly protected against the systemic bone loss and erosion that had been induced with LPS and K/BxN serum treatments (30% reversal of systemic bone loss [P < 0.01]; 55% reversal of erosion [P < 0.001]), without conferring bone protective properties. Conclusion Our results identify ATX as a novel OC factor that specifically controls inflammation induced bone erosions and systemic bone loss. Therefore, ATX inhibition offers a novel therapeutic approach for potentially preventing bone erosion in patients with RA.
C1 [Flammier, Sacha; Peyruchaud, Olivier; Bourguillault, Fanny; Duboeuf, Francois; Machuca Gayet, Irma; Coury, Fabienne] INSERM UMR 1033 LYOS, Lyon, France.
   [Flammier, Sacha; Peyruchaud, Olivier; Bourguillault, Fanny; Duboeuf, Francois; Machuca Gayet, Irma; Coury, Fabienne] Univ Lyon 1, Lyon, France.
   [Davignon, Jean Luc] Univ Paul Sabatier Toulouse III, CHU Purpan, CPTP, INSERM CNRS U1043, Toulouse, France.
   [Davignon, Jean Luc] Pierre Paul Riquet Hosp, Toulouse, France.
   [Norman, Derek D.; Tigyi, Gabor] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.
   [Isaac, Sylvie; Coury, Fabienne] Lyon Sud Hosp, Pierre Benite, France.
   [Marotte, Hubert] Univ Lyon, SAINBIOSE, INSERM, U1059,LBTO, St Etienne, France.
   [Marotte, Hubert] Univ Hosp St Etienne, St Etienne, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Claude Bernard Lyon 1; CHU de Toulouse; Universite de
   Toulouse; Universite Toulouse III   Paul Sabatier; Centre National de la
   Recherche Scientifique (CNRS); Institut National de la Sante et de la
   Recherche Medicale (Inserm); CHU de Toulouse; University of Tennessee
   System; University of Tennessee Health Science Center; CHU Lyon;
   Institut National de la Sante et de la Recherche Medicale (Inserm); CHU
   de St Etienne
RP Machuca Gayet, I; Coury, F (通讯作者)，Fac Med Lyon Est, INSERM UMR1033, Rue Guillaume Paradin, F 69372 Lyon 08, France.
EM irma.machuca gayet@inserm.fr; fabienne.coury lucas@chu lyon.fr
RI ; Coury, Fabienne/MSW 4864 2025; Tigyi, Gabor/LZF 2742 2025; MAROTTE,
   Hubert/AFR 6908 2022; Davignon, Jean Luc/C 5726 2009
OI DAVIGNON, Jean Luc/0000 0002 8365 6552; Marotte,
   Hubert/0000 0003 1177 9497; Tigyi, Gabor/0000 0001 5371 171X; Machuca 
   Gayet, irma/0000 0002 3010 9774; coury, fabienne/0000 0002 9175 8620;
   francois, duboeuf/0000 0002 7819 0153; Peyruchaud,
   Olivier/0000 0002 5393 4945
FU Agence Nationale de la Recherche [ANR 15CE14 0010 01]; Fondation ARC
   pour la Recherche sur le Cancer [PJA20151203151]; INSERM; Ligue Contre
   le Cancer; Pfizer
FX Supported by the Agence Nationale de la Recherche (project
   ANR 15CE14 0010 01), Fondation ARC pour la Recherche sur le Cancer
   (grant PJA20151203151), INSERM, Ligue Contre le Cancer, and Pfizer.
CR Benesch MGK, 2015, ENDOCR RELAT CANCER, V22, P593, DOI 10.1530/ERC 15 0045
   Benesch MGK, 2014, FASEB J, V28, P2655, DOI 10.1096/fj.13 248641
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Brown AK, 2008, ARTHRITIS RHEUM US, V58, P2958, DOI 10.1002/art.23945
   Cohen G, 2007, ANN RHEUM DIS, V66, P358, DOI 10.1136/ard.2006.057497
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Danks L, 2016, ANN RHEUM DIS, V75, P1187, DOI 10.1136/annrheumdis 2014 207137
   David M, 2014, J BIOL CHEM, V289, P6551, DOI 10.1074/jbc.M113.533232
   David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741
   Deodhar A, 2010, ARTHRIT CARE RES, V62, P569, DOI 10.1002/acr.20004
   Desroy N, 2017, J MED CHEM, V60, P3580, DOI 10.1021/acs.jmedchem.7b00032
   Ferry G, 2003, J BIOL CHEM, V278, P18162, DOI 10.1074/jbc.M301158200
   Fotopoulou S, 2010, DEV BIOL, V339, P451, DOI 10.1016/j.ydbio.2010.01.007
   Georgess D, 2014, MOL BIOL CELL, V25, P380, DOI 10.1091/mbc.E13 07 0363
   Giganti A, 2008, J BIOL CHEM, V283, P7776, DOI 10.1074/jbc.M708705200
   Goldring SR, 2004, ARTHRITIS RHEUM US, V50, P2044, DOI 10.1002/art.20383
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Gupte R, 2011, CHEMMEDCHEM, V6, P922, DOI 10.1002/cmdc.201000425
   Kanda H, 2008, NAT IMMUNOL, V9, P415, DOI 10.1038/ni1573
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460 2075.1991.tb04978.x
   Lapierre DM, 2010, J BIOL CHEM, V285, P25792, DOI 10.1074/jbc.M110.109322
   Leblanc R, 2014, BLOOD, V124, P3141, DOI 10.1182/blood 2014 04 568683
   Lee JM, 2012, J IMMUNOL, V189, P5284, DOI 10.4049/jimmunol.1003738
   McMichael BK, 2010, J BIOL CHEM, V285, P26641, DOI 10.1074/jbc.M110.119909
   Miyabe Y, 2013, ARTHRITIS RHEUM US, V65, P2037, DOI 10.1002/art.37991
   Molenaar ETH, 2004, ARTHRITIS RHEUM, V50, P36, DOI 10.1002/art.11481
   Monach PA, 2008, CURR PROTOC IMMUNOL, V15, P1
   Moolenaar Wouter H, 2012, Cell, V148, P378, DOI 10.1016/j.cell.2012.01.013
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Nakanaga K, 2010, J BIOCHEM, V148, P13, DOI 10.1093/jb/mvq052
   Nikitopoulou I, 2012, J EXP MED, V209, P923, DOI 10.1084/jem.20112012
   Nishioka T, 2016, SCI REP UK, V6, DOI 10.1038/srep23433
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Quan LD, 2016, PHARM RES DORDR, V33, P186, DOI 10.1007/s11095 015 1776 1
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Schett G, 2005, NAT CLIN PRACT RHEUM, V1, P47, DOI 10.1038/ncprheum0036
   Umezu Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026
   van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419 05
   Wu JM, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 71
   Zhao CQ, 2008, MOL PHARMACOL, V73, P587, DOI 10.1124/mol.107.038216
NR 41
TC 17
Z9 20
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD NOV
PY 2019
VL 71
IS 11
BP 1801
EP 1811
DI 10.1002/art.41005
EA SEP 2019
PG 11
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA JH5OA
UT WOS:000488579200001
PM 31162832
OA Green Submitted, Green Accepted
DA 2025 08 17
ER

PT J
AU Byham Gray, L
   Drasher, T
   Deckman, K
   Graham, D
   Liftman, C
   Roberto, L
   Peiffer, P
   Denmark, R
AF Byham Gray, Laura
   Drasher, Tammy
   Deckman, Karen
   Graham, Diane
   Liftman, Carol
   Roberto, Linda
   Peiffer, Phyllis
   Denmark, Robert
TI Effect of Aggressive Osteodystrophy Management on Clinical Outcomes in
   Stage 5 Chronic Kidney Disease
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID PHOSPHATE BINDER CHOICE; SECONDARY HYPERPARATHYROIDISM; DIALYSIS
   PATIENTS; VITAMIN D; HEMODIALYSIS PATIENTS; MORTALITY RISK;
   BONE DISEASE; RENAL OSTEODYSTROPHY; PRACTICE PATTERNS; CALCIUM
AB Objective: The study investigated whether the type of bone disease management (aggressive versus conventional) had an impact on clinical outcomes, namely bone health measures (e.g., biointact parathyroid hormone [BiPTH], serum corrected calcium [cCa] level, serum phosphorus [phos] level, and corrected calcium phosphorus product [cCaPO(4)]).
   Design and Setting: Retrospective chart review of 173 closed medical records of maintenance hemodialysis patients on thrice weekly therapy from January 1, 2005, through December 31, 2005. Two Conventional Management (i.e., control group) and three Aggressive Management (i.e., treatment group) dialysis facilities were enrolled.
   Results: There was a significant interaction for group assignment and BiPTH levels (F = 4.12, P = .01), with the Aggressive Group trending toward lower BiPTH levels than the Conventional Group. The Conventional Group experienced a significantly lower mean annualized serum cCa level (F = 8.85, P = .003), and used non calcium based binders significantly more (P < .0005) than the Aggressive Group. In terms of serum phos level, the Aggressive Group had a significantly lower (F = 2.73, P = .05) value than the Conventional Group. No significant differences were reported for cCaPO4 product (F = 1.87, P = .17). The percentage of the total sample that achieved target range for all bone health measures included 29.8% (n = 50).
   Conclusions: The study demonstrated that aggressive bone disease management appears to be as effective as traditional interventions in the treatment of mineral and bone metabolism disorders in chronic kidney disease. (C) 2009 by the National Kidney Foundation, Inc.
C1 [Byham Gray, Laura] Univ Med & Dent New Jersey, Sch Hlth Related Profess, Univ Educ Ctr, Dept Nutr Sci, Stratford, NJ 08084 USA.
   [Drasher, Tammy] Dialysis Clin Inc, N Billerica, MA USA.
   [Deckman, Karen] Dialysis Corp Amer, Vineland, NJ USA.
   [Graham, Diane] Milton S Hershey Med Ctr, Dialysis Unit, Hershey, PA USA.
   [Liftman, Carol] DaVita, Franklin Dialysis Ctr, Philadelphia, PA USA.
   [Roberto, Linda] Fresenius Med Care Mt Airy, Philadelphia, PA USA.
   [Peiffer, Phyllis] Wellspan Dialysis, York, PA USA.
   [Denmark, Robert] Univ Med & Dent New Jersey, Sch Hlth Related Profess, Newark, NJ 07103 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Pennsylvania State University; Penn
   State Health; DaVita; Rutgers University System; Rutgers University New
   Brunswick; Rutgers University Biomedical & Health Sciences
RP Byham Gray, L (通讯作者)，Univ Med & Dent New Jersey, Sch Hlth Related Profess, Univ Educ Ctr, Dept Nutr Sci, Room 2111,40 E Laurel Rd, Stratford, NJ 08084 USA.
EM laura.byham gray@umdnj.edu
FU National Kidney Foundation
FX This work was supported by a Council on Renal Nutrition Research Grant
   of the National Kidney Foundation.
CR Barreto FC, 2008, KIDNEY INT, V73, P771, DOI 10.1038/sj.ki.5002769
   BLEYER A, 1999, AM J KIDNEY, P694
   Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2000, AM J KIDNEY DIS, V35, P1226, DOI 10.1016/S0272 6386(00)70064 3
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Block GA, 2005, KIDNEY INT, V68, P1815, DOI 10.1111/j.1523 1755.2005.00600.x
   Block GA, 2008, NEPHROL DIAL TRANSPL, V23, P2311, DOI 10.1093/ndt/gfn026
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   de Francisco ALM, 2004, CLIN THER, V26, P1976, DOI 10.1016/j.clinthera.2004.12.011
   Drüeke TB, 2008, KIDNEY INT, V73, P674, DOI 10.1038/sj.ki.5002800
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Floege J, 2008, NEPHROL DIAL TRANSPL, V23, P3050, DOI 10.1093/ndt/gfn393
   GALLIENI M, 1992, KIDNEY INT, V42, P1191, DOI 10.1038/ki.1992.404
   Giachelli CM, 2004, J AM SOC NEPHROL, V15, P2959, DOI 10.1097/01.ASN.0000145894.57533.C4
   Goodman WG, 2005, SEMIN DIALYSIS, V18, P296, DOI 10.1111/j.1525 139X.2005.18405.x
   Goodman WG, 2004, SEMIN DIALYSIS, V17, P209, DOI 10.1111/j.0894 0959.2004.17308.x
   Heaney RP, 1997, J CLIN ENDOCR METAB, V82, P4111, DOI 10.1210/jc.82.12.4111
   Hruska KA, 2007, SEMIN DIALYSIS, V20, P309, DOI 10.1111/j.1525 139X.2007.00300.x
   Kalantar Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514
   Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009
   Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512
   MALLUCHE HH, 1990, KIDNEY INT, V38, pS48
   Manley HJ, 2004, NEPHROL DIAL TRANSPL, V19, P1842, DOI 10.1093/ndt/gfh280
   Manns B, 2006, AM J KIDNEY DIS, V48, P159, DOI 10.1053/j.ajkd.2006.03.044
   Martin CJ, 2003, J RENAL NUTR, V13, P133, DOI 10.1053/jren.2003.50015
   McCann L, 2005, J RENAL NUTR, V15, P265, DOI 10.1053/j.jrn.2005.01.002
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Peter WLS, 2008, AM J KIDNEY DIS, V51, P445, DOI 10.1053/j.ajkd.2007.12.002
   Pisoni RL, 2005, CONTRIB NEPHROL, V149, P58, DOI 10.1159/000085458
   Rix M, 1999, KIDNEY INT, V56, P1084, DOI 10.1046/j.1523 1755.1999.00617.x
   Souberbielle JC, 2006, CLIN CHIM ACTA, V366, P81, DOI 10.1016/j.cca.2005.10.010
   Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868
   Tentori F, 2008, AM J KIDNEY DIS, V52, P519, DOI 10.1053/j.ajkd.2008.03.020
   Weisinger JR, 2006, CLIN J AM SOC NEPHRO, V1, P1300, DOI 10.2215/CJN.01510506
   Winkelmayer WC, 2008, AM J KIDNEY DIS, V51, P362, DOI 10.1053/j.ajkd.2008.01.004
   Young EW, 2004, AM J KIDNEY DIS, V44, pS34, DOI 10.1053/j.ajkd.2004.08.009
NR 38
TC 0
Z9 0
U1 1
U2 8
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 1051 2276
EI 1532 8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD JUL
PY 2009
VL 19
IS 4
BP 321
EP 333
DI 10.1053/j.jrn.2009.01.018
PG 13
WC Nutrition & Dietetics; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics; Urology & Nephrology
GA 464HH
UT WOS:000267495500009
PM 19464927
OA Bronze
DA 2025 08 17
ER

PT J
AU Leena, RS
   Vairamani, M
   Selvamurugan, N
AF Leena, R. S.
   Vairamani, M.
   Selvamurugan, N.
TI Alginate/Gelatin scaffolds incorporated with Silibinin loaded Chitosan
   nanoparticles for bone formation in vitro
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Silibinin; Chitosan nanoparticles; Alginate; Gelatin; Bone tissue
   engineering
ID MARROW STROMAL CELLS; OSTEOBLAST DIFFERENTIATION; PHYSICOCHEMICAL
   PROPERTIES; EXTRACELLULAR MATRIX; COMPOSITE SCAFFOLDS; LINEAGE
   PROGRESSION; POROUS GELATIN; KAPPA B; EXPRESSION; MICRORNAS
AB Silibinin is a plant derived flavonolignan known for its multiple biological properties, but its role in the promotion of bone formation has not yet been well studied. Moreover, the delivery of Silibinin is hindered by its complex hydrophobic nature, which limits its bioavailability. Hence, in this study, we fabricated a drug delivery system using chitosan nanoparticles loaded with Silibinin at different concentrations (20 mu M, 50 mu M, and 100 mu M). They were then incorporated into scaffOlds containing Alginate and Gelatin (Alg/Gel) for the sustained and prolonged release of Silibinin. The Silibinin loaded chitosan nanoparticles (SCN) were prepared using the ionic gelation technique, and the scaffolds (Alg/Gel SCN) were synthesized by the conventional method of freeze drying. The scaffolds were subjected to physicochemical and material characterization studies. The addition of SCN did not affect the porosity of the scaffolds, yet increased the protein adsorption, degradation rates, and bio mineralization. These scaffolds were biocompatible with mouse mesenchymal stem cells. The scaffolds loaded with 50 mu M Silibinin promoted osteoblast differentiation, which was determined at cellular and molecular levels. Recent studies indicated the role of microRNAs (miRNAs) in osteogenesis and we found that the Silibinin released from scaffolds regulated miRNAs that control the bone morphogenetic protein pathway. Hence, our results suggest the potential for sustained and prolonged release of Silibinin to promote bone formation and, thus, these Alg/Gel SCN scaffolds may be candidates for bone tissue engineering applications. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Leena, R. S.; Vairamani, M.; Selvamurugan, N.] SRM Univ, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
C3 SRM Institute of Science & Technology Chennai
RP Selvamurugan, N (通讯作者)，SRM Univ, Sch Bioengn, Dept Biotechnol, Kattankulathur 603203, Tamil Nadu, India.
EM selvamn2@yahoo.com
RI ; Selvamurugan, Nagarajan/P 7894 2016
OI Saleth, Leena Regi/0000 0001 5075 1820; Selvamurugan,
   Nagarajan/0000 0003 3713 1920
FU SRM University; Council for Scientific and Industrial Research, India
   [60(110)/13/EMR II]
FX We thank K. Balagangadharan and M. Vishal for their technical help
   during the manuscript preparation. This work was supported in part by
   the SRM University and a research grant from the Council for Scientific
   and Industrial Research, India [Grant No. 60(110)/13/EMR II to N.S].
CR Asti A, 2014, INT J ARTIF ORGANS, V37, P187, DOI [10.5301/ijao.5000307, 10.530/ijao.5000307]
   Bakhshandeh B, 2012, BIOTECHNOL LETT, V34, P1579, DOI 10.1007/s10529 012 0934 3
   Balakrishnan B, 2014, ACTA BIOMATER, V10, P3650, DOI 10.1016/j.actbio.2014.04.031
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Boskey AL, 1998, BONE, V23, P187, DOI 10.1016/S8756 3282(98)00092 1
   Boskey AL, 1998, J CELL BIOCHEM, P83, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<83::AID JCB12>3.0.CO;2 F
   Chapekar MS, 2000, J BIOMED MATER RES, V53, P617, DOI 10.1002/1097 4636(2000)53:6<617::AID JBM1>3.3.CO;2 3
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cho JK, 2012, J PHARM SCI US, V101, P2382, DOI 10.1002/jps.23137
   Costa Pinto AR, 2011, TISSUE ENG PART B RE, V17, P331, DOI 10.1089/ten.teb.2010.0704
   Dounighi NM, 2012, J VENOM ANIM TOXINS, V18, P44
   GERSTENFELD LC, 1990, ANAT RECORD, V228, P93, DOI 10.1002/ar.1092280113
   Gohulkumar M, 2014, MAT SCI ENG C MATER, V41, P274, DOI 10.1016/j.msec.2014.04.056
   Guo ST, 2014, BIOTECHNOL ADV, V32, P778, DOI 10.1016/j.biotechadv.2013.10.002
   Gupta DK, 2010, INDIAN J ORTHOP, V44, P84, DOI 10.4103/0019 5413.58611
   Harley B.A., 2008, BIOPHYS J, V95
   Hayrapetyan A, 2015, TISSUE ENG PART B RE, V21, P75, DOI [10.1089/ten.teb.2014.0119, 10.1089/ten.TEB.2014.0119]
   He J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013558
   Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421
   Jalota S, 2008, MAT SCI ENG C BIO S, V28, P129, DOI 10.1016/j.msec.2007.10.058
   Jayakumar R, 2010, CARBOHYD POLYM, V79, P1, DOI 10.1016/j.carbpol.2009.08.026
   Jia LJ, 2010, COLLOID SURFACE B, V80, P213, DOI 10.1016/j.colsurfb.2010.06.008
   Kamath MS, 2014, INT J NANOMED, V9, P183, DOI 10.2147/IJN.S49460
   Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959
   Kavya KC, 2013, INT J BIOL MACROMOL, V59, P255, DOI 10.1016/j.ijbiomac.2013.04.023
   Kim JL, 2012, EXP BIOL MED, V237, P417, DOI 10.1258/ebm.2011.011376
   Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351
   Komori T., 2009, Regulation of Osteoblast Differentiation by Runx2, P43, DOI [10.1007/978 1 4419 1050 9_5, DOI 10.1007/978 1 4419 1050 9_5]
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kvasnicka F, 2003, J CHROMATOGR A, V990, P239, DOI 10.1016/S0021 9673(02)01971 4
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Mishra B, 2010, NANOMED NANOTECHNOL, V6, P9, DOI 10.1016/j.nano.2009.04.008
   Moorthi A, 2013, INT J BIOL MACROMOL, V56, P181, DOI 10.1016/j.ijbiomac.2013.02.017
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Pan T, 2016, J MATER SCI TECHNOL, V32, P889, DOI 10.1016/j.jmst.2016.01.007
   Pooja D, 2014, INT J BIOL MACROMOL, V69, P267, DOI 10.1016/j.ijbiomac.2014.05.035
   Qi LF, 2004, CARBOHYD RES, V339, P2693, DOI 10.1016/j.carres.2004.09.007
   Raghavan R.N., 2016, TRENDS BIOMATER ARTI, V30
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Rosellini E, 2009, J BIOMED MATER RES A, V91A, P447, DOI 10.1002/jbm.a.32216
   Rowley JA, 1999, BIOMATERIALS, V20, P45, DOI 10.1016/S0142 9612(98)00107 0
   Sadeghipari M., 2016, J MATER SCI MATER EL, V27, P1
   Sainitya R, 2015, INT J BIOL MACROMOL, V80, P481, DOI 10.1016/j.ijbiomac.2015.07.016
   Salamone F, 2012, TRANSL RES, V159, P477, DOI 10.1016/j.trsl.2011.12.003
   Saravanan S, 2016, INT J BIOL MACROMOL, V93, P1354, DOI 10.1016/j.ijbiomac.2016.01.112
   Singh RP, 2005, EUR J CANCER, V41, P1969, DOI 10.1016/j.ejca.2005.03.033
   Sowjanya JA, 2013, COLLOID SURFACE B, V109, P294, DOI 10.1016/j.colsurfb.2013.04.006
   Sriram M, 2015, INT J BIOL MACROMOL, V74, P404, DOI 10.1016/j.ijbiomac.2014.12.034
   Srivastava S.K., 2013, MITOCHONDRIA TARGETS, P187
   Srivastava SK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/848710
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Sun HL, 2010, BIOMATERIALS, V31, P1133, DOI 10.1016/j.biomaterials.2009.10.030
   Szpalski C, 2012, TISSUE ENG PART B RE, V18, P258, DOI [10.1089/ten.TEB.2011.0440, 10.1089/ten.teb.2011.0440]
   Tan JM, 2014, J NANOMATER, V2014, DOI 10.1155/2014/862148
   Tripathi A, 2012, INT J BIOL MACROMOL, V50, P294, DOI 10.1016/j.ijbiomac.2011.11.013
   Velasco MA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/729076
   Vimalraj S, 2016, INT J BIOL MACROMOL, V93, P1457, DOI 10.1016/j.ijbiomac.2015.12.083
   Vimalraj S, 2015, INT J BIOL MACROMOL, V79, P490, DOI 10.1016/j.ijbiomac.2015.05.017
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Vimalraj S, 2014, INT J BIOL MACROMOL, V66, P194, DOI 10.1016/j.ijbiomac.2014.02.030
   Vishal M, 2017, J CELL PHYSIOL, V232, P371, DOI 10.1002/jcp.25434
   Wilson CJ, 2005, TISSUE ENG, V11, P1, DOI 10.1089/ten.2005.11.1
   Woo JT, 2010, J ORAL BIOSCI, V52, P15
   Wu LB, 2004, BIOMATERIALS, V25, P5821, DOI 10.1016/j.biomaterials.2004.01.038
   Wu X, 2010, ACTA BIOMATER, V6, P1167, DOI 10.1016/j.actbio.2009.08.041
   Xu Lian, 2015, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V29, P1288
   Xu PF, 2013, INT J PHARMACEUT, V454, P21, DOI 10.1016/j.ijpharm.2013.06.053
   Yang CM, 2009, J TISSUE ENG REGEN M, V3, P601, DOI 10.1002/term.201
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Ying XZ, 2013, EUR J PHARMACOL, V721, P225, DOI 10.1016/j.ejphar.2013.09.031
   Zhang Y, 2012, J BIOL CHEM, V287, P21926, DOI 10.1074/jbc.M112.340398
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhao D, 2015, MOL CELL BIOCHEM, V400, P87, DOI 10.1007/s11010 014 2265 2
NR 73
TC 78
Z9 84
U1 0
U2 41
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
EI 1873 4367
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD OCT 1
PY 2017
VL 158
BP 308
EP 318
DI 10.1016/j.colsurfb.2017.06.048
PG 11
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA FL3FP
UT WOS:000414108600036
PM 28711017
DA 2025 08 17
ER

PT J
AU Chen, ZT
   Han, SW
   Shi, MC
   Liu, GQ
   Chen, ZF
   Chang, J
   Wu, CT
   Xiao, Y
AF Chen, Zetao
   Han, Shengwei
   Shi, Mengchao
   Liu, Guanqi
   Chen, Zhuofan
   Chang, Jiang
   Wu, Chengtie
   Xiao, Yin
TI Immunomodulatory effects of mesoporous silica nanoparticles on
   osteogenesis: From nanoimmunotoxicity to nanoimmunotherapy
SO APPLIED MATERIALS TODAY
LA English
DT Article
DE Nanoimmunotoxicity; Nanoimmunotherapy; Mesoporous silica anoparticle;
   Osteogenesis; Autophagy
ID NF KAPPA B; IMMUNE RESPONSE; OSTEOBLAST DIFFERENTIATION; SIGNALING
   PATHWAY; COLLOIDAL SILICA; STEM CELLS; AUTOPHAGY; BIOMATERIALS;
   INFLAMMATION; REGENERATION
AB The immune reaction towards nanomaterials has long been concerned for the safety issue. A concept "nanoimmunotoxicity" was generated accordingly to describe this deleterious immunomodulatory effects. In additional to the detrimental effects, immune response has also been proved to be an essential component of the biomaterials  mediated reconstruction of a functional tissue. In this study, we investigate the immunomodualtory effects of mesoporous silica nanoparticles (MSNs) on macrophages and the effects of the generated osteoimmune environment on bone marrow mesenchymal stromal cells. It is found that macrophages could uptake MSNs and elicited significant effects on inhibiting the inflammatory response, which could be due to the inhibition of Wnt5A/Ca2+ pathway and the activation of autophagy. Interestingly, the modulated immune environment enhanced the osteogenic differentiation of bone marrow mesenchymal stromal cells, leading to the increase of mineralized nodules and alkaline phosphatase activity. This suggests that the immunomodulatory effects of nanomaterials are not always detrimental, but can be beneficial for tissue regeneration. In addition to the detrimental effects, the positive effects of nanomaterial mediated immune response should be emphasized. The concept "nanoimmumotherpy" was proposed accordingly, and the paradigm on design nanomaterials should be shifted from "inert" to "immunomoluatory" to modulate an immune environment favourable for tissue regeneration and therapy. (c) 2017 Elsevier Ltd. All rights reserved.
C1 [Chen, Zetao; Liu, Guanqi; Chen, Zhuofan; Xiao, Yin] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
   [Chen, Zetao; Liu, Guanqi; Chen, Zhuofan; Xiao, Yin] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
   [Shi, Mengchao; Chang, Jiang; Wu, Chengtie] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai 200050, Peoples R China.
   [Han, Shengwei] Nanjing Univ, Med Sch, Nanjing Stomatol Hosp, Nanjing 210008, Jiangsu, Peoples R China.
   [Shi, Mengchao; Xiao, Yin] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4059, Australia.
   [Chen, Zetao; Han, Shengwei; Shi, Mengchao; Liu, Guanqi; Chen, Zhuofan; Chang, Jiang; Wu, Chengtie; Xiao, Yin] Australia China Ctr Tissue Engn & Regenerat Med, Brisbane, Qld, Australia.
C3 Sun Yat Sen University; Chinese Academy of Sciences; Shanghai Institute
   of Ceramics, CAS; Nanjing University; Queensland University of
   Technology (QUT)
RP Wu, CT; Xiao, Y (通讯作者)，Australia China Ctr Tissue Engn & Regenerat Med, Brisbane, Qld, Australia.
EM chengtiewu@mail.sic.ac.cn; yin.xiao@qut.edu.au
RI Chen, Kuan Hung/LIC 4398 2024; Shi, Mengchao/T 7940 2018; Xiao,
   Yin/AAM 4033 2020; Chen, Zetao/AAG 5530 2020
OI Xiao, Yin/0000 0003 1785 3491; 
FU National Key Research and Development Program of China [2016YFB0700803];
   Science and Technology Commission of Shanghai Municipality
   [17540712300]; National Natural Science Foundation of China [81701024];
   Fundamental Research Funds for the Central Universities [17ykpy70]; ITI
   Research Grant [1267_2017]; Guangdong Province Higher Vocational
   Colleges & Schools Pearl River Scholar Funded Scheme; 100 Top Talents
   Program of Sun Yat sen University
FX This work was supported by the National Key Research and Development
   Program of China [grant number 2016YFB0700803], Science and Technology
   Commission of Shanghai Municipality [grant number 17540712300], the
   National Natural Science Foundation of China [grant number 81701024],
   the Fundamental Research Funds for the Central Universities [grant
   number 17ykpy70], ITI Research Grant [grant number 1267_2017], Guangdong
   Province Higher Vocational Colleges & Schools Pearl River Scholar Funded
   Scheme (2017), and the 100 Top Talents Program of Sun Yat sen University
   (Z.C.).
CR [Anonymous], SCIENTIFICA CAIRO
   [Anonymous], 2017, SMALL
   Augustine R, 2017, APPL MATER TODAY, V7, P91, DOI 10.1016/j.apmt.2017.01.010
   Bhattacharjee P, 2016, APPL MATER TODAY, V5, P52, DOI 10.1016/j.apmt.2016.09.007
   Bryers JD, 2012, BIOTECHNOL BIOENG, V109, P1898, DOI 10.1002/bit.24559
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927
   Chen Y, 2013, ADV MATER, V25, P3144, DOI 10.1002/adma.201205292
   Chen ZT, 2017, ACS NANO, V11, P4494, DOI 10.1021/acsnano.6b07808
   Chen ZT, 2017, NANOSCALE, V9, P706, DOI 10.1039/c6nr06421c
   Chen ZT, 2014, BIOMATERIALS, V35, P8553, DOI 10.1016/j.biomaterials.2014.06.038
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   Dong M, 2016, BIOL TRACE ELEM RES, V173, P306, DOI 10.1007/s12011 016 0686 3
   Franz S, 2011, BIOMATERIALS, V32, P6692, DOI 10.1016/j.biomaterials.2011.05.078
   George SJ, 2008, ARTERIOSCL THROM VAS, V28, P400, DOI 10.1161/ATVBAHA.107.160952
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gu HJ, 2011, BIOMATERIALS, V32, P7023, DOI 10.1016/j.biomaterials.2011.06.003
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Han PP, 2013, BIOMATER SCI UK, V1, P379, DOI 10.1039/c2bm00108j
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065
   Hirota K., 2012, Endocytosis of particle formulations by macrophages and its application to clinical treatment
   Huang P, 2017, BIOMATERIALS, V125, P23, DOI 10.1016/j.biomaterials.2017.02.018
   Huang P, 2017, J AM CHEM SOC, V139, P1275, DOI 10.1021/jacs.6b11846
   Kerativitayanan P, 2015, ADV HEALTHC MATER, V4, P1600, DOI 10.1002/adhm.201500272
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee S, 2013, INT J NANOMED, V8, P147, DOI 10.2147/IJN.S39534
   Lee S, 2011, BIOMATERIALS, V32, P9434, DOI 10.1016/j.biomaterials.2011.08.042
   Liu K, 2015, AUTOPHAGY, V11, P271, DOI 10.1080/15548627.2015.1009787
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Ma C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172499
   Macias Ceja DC, 2017, BRIT J PHARMACOL, V174, P2501, DOI 10.1111/bph.13860
   Maye P, 2004, J BIOL CHEM, V279, P24659, DOI 10.1074/jbc.M311724200
   McMahon RE, 2013, J BIOMED MATER RES B, V101B, P387, DOI 10.1002/jbm.b.32823
   Mokarram N, 2014, ANN BIOMED ENG, V42, P338, DOI 10.1007/s10439 013 0941 0
   Moyano DF, 2012, J AM CHEM SOC, V134, P3965, DOI 10.1021/ja2108905
   Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008
   Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Shi MC, 2016, ACTA BIOMATER, V30, P334, DOI 10.1016/j.actbio.2015.11.033
   Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600 065X.2011.01088.x
   Syed S, 2013, CURR ALLERGY ASTHM R, V13, P50, DOI 10.1007/s11882 012 0302 3
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Varanasi VG, 2012, J ORAL IMPLANTOL, V38, P325, DOI 10.1563/AAID JOI D 11 00108
   Walsh MC, 2006, ANNU REV IMMUNOL, V24, P33, DOI 10.1146/annurev.immunol.24.021605.090646
   Williams DF, 2009, BIOMATERIALS, V30, P5897, DOI 10.1016/j.biomaterials.2009.07.027
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Zhang ML, 2012, J BIOMED MATER RES A, V100A, P2979, DOI 10.1002/jbm.a.34246
   Zhao Y, 2014, J BIOL CHEM, V289, P21028, DOI 10.1074/jbc.M113.546523
NR 49
TC 52
Z9 54
U1 2
U2 150
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352 9407
J9 APPL MATER TODAY
JI Appl. Mater. Today
PD MAR
PY 2018
VL 10
BP 184
EP 193
DI 10.1016/j.apmt.2017.12.003
PG 10
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA FX2IA
UT WOS:000425881700019
DA 2025 08 17
ER

PT J
AU De Wilde, A
   Heberden, C
   Chaumaz, G
   Bordat, C
   Lieberherr, M
AF De Wilde, Anne
   Heberden, Christine
   Chaumaz, Gilles
   Bordat, Christian
   Lieberherr, Michele
TI Signaling networks from Gβ1 subunit to transcription factors and actin
   remodeling via a membrane located ERβ related protein in the rapid
   action of daidzein in osteoblasts
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID ESTROGEN RECEPTOR ALPHA; ELEMENT BINDING PROTEIN; KINASE C ALPHA;
   PLASMA MEMBRANE; NONGENOMIC ACTIONS; COUPLED RECEPTORS; DNA SYNTHESIS;
   ACTIVATION; ESTRADIOL; PATHWAY
AB Although estrogen replacement has been the main therapy to prevent and treat osteoporosis, there are concerns about its safety. Phytoestrogens have attracted attention to their potential impacts in osteoporosis prevention and treatment. Among phytoestrogens, the isoflavone daidzein (Dz) acts on transcription via the intracellular estrogen receptors (ER), mainly ER beta, in osteoblasts, but mimics only part of the estrogen effects. Since estradiol also exerts rapid effects in osteoblasts, we investigated the multistep processes involved in the rapid actions of low (1 100 pM) doses of daidzein. Dz bound to a membrane moiety, related to ER beta since the calcium response to Dz was blocked by an anti ER beta antibody directed against the C terminus, but not by a double stranded siRNA specific for ER beta. This protein was coupled to a pertussis toxin (PTX) sensitive C beta 1 subunit whose transducer was PLC beta 2, which triggered a rapid (5 sec) mobilization of calcium from the endoplasmic reticulum. Dz phosphorylated within 15 sec ERK1/2 whose phosphorylation involved two routes: G beta 1/PLC beta 2/PKC/c Raf 1/MEK1/2 and G beta 1/PI3K/cSrc/c Raf 1/MEK1/2 as shown using several inhibitors. Dz induced rapid (1 min) changes in the actin cytoskeleton via the two routes. The rapid (20 sec) phosphorylation of Elk 1 and CREB by Dz involved G beta 1 and ERK1/2. All the processes were insensitive to the estradiol antagonist ICI 182,780. In conclusion, the rapid effects of Dz seem to be biologically relevant for the function of osteoblast in bone since the isoflavone activates transcription factors linked to early genes controlling cellular proliferation and differentiation, and modulates actin cytoskeleton which controls cell adhesion, division, or secretion.
C1 INRA, LNSA, F 78350 Jouy En Josas, France.
   CNRS, UMR 8104, Paris, France.
C3 Universite Paris Saclay; INRAE; Universite Paris Cite; Centre National
   de la Recherche Scientifique (CNRS); CNRS   National Institute for
   Biology (INSB); Institut National de la Sante et de la Recherche
   Medicale (Inserm)
RP Lieberherr, M (通讯作者)，INRA, LNSA, Batiment 230, F 78350 Jouy En Josas, France.
EM michele.lieberherr@jouy.inra.fr
RI de Wilde, Anne/IUP 7159 2023
CR Abrahám IM, 2004, ENDOCRINOLOGY, V145, P3055, DOI 10.1210/en.2003 1676
   AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200
   Ansonoff MA, 1998, ENDOCRINOLOGY, V139, P3050, DOI 10.1210/en.139.7.3050
   Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269
   Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105
   Benten WPM, 2001, ENDOCRINOLOGY, V142, P1669, DOI 10.1210/en.142.4.1669
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004 0486
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Carpenter CL, 2000, CRIT CARE MED, V28, pN94, DOI 10.1097/00003246 200004001 00011
   Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099
   Cato AC., 2002, SCI STKE, V2002, pRE9, DOI DOI 10.1126/STKE.2002.138.RE9
   Dang ZC, 2005, TRENDS ENDOCRIN MET, V16, P207, DOI 10.1016/j.tem.2005.05.001
   De Wilde A, 2004, J CELL PHYSIOL, V200, P253, DOI 10.1002/jcp.20008
   Doolan CM, 2003, MOL CELL ENDOCRINOL, V199, P87, DOI 10.1016/S0303 7207(02)00303 9
   Dopp E, 1999, J STEROID BIOCHEM, V68, P57, DOI 10.1016/S0960 0760(98)00158 7
   Dos Santos EG, 2002, ENDOCRINOLOGY, V143, P930
   Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432 1033.1997.t01 1 00010.x
   Farhat MY, 1996, BIOCHEM PHARMACOL, V51, P571, DOI 10.1016/S0006 2952(95)02159 0
   Harvey BJ, 2002, STEROIDS, V67, P483, DOI 10.1016/S0039 128X(01)00169 6
   Hennessy BA, 2005, MOL CELL ENDOCRINOL, V229, P39, DOI 10.1016/j.mce.2004.10.001
   Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959
   KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Le Mellay V, 1999, J CELL BIOCHEM, V75, P138, DOI 10.1002/(SICI)1097 4644(19991001)75:1<138::AID JCB14>3.0.CO;2 I
   LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902
   LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365
   Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898 6568(01)00192 9
   Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007
   LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394
   LUST WD, 1976, ANAL BIOCHEM, V72, P8, DOI 10.1016/0003 2697(76)90500 5
   Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443
   Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200
   Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165 6147(00)01678 3
   Marino M, 2001, J CELL PHYSIOL, V188, P170, DOI 10.1002/jcp.1105
   Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460 2075.1996.tb00471.x
   MIKSICEK RJ, 1995, P SOC EXP BIOL MED, V208, P44
   Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603
   NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092 8674(95)90407 7
   Nethrapalli IS, 2005, ENDOCRINOLOGY, V146, P56, DOI 10.1210/en.2004 1106
   Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626
   Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805
   Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002 0253
   Razandi M, 2004, MOL ENDOCRINOL, V18, P2854, DOI 10.1210/me.2004 0115
   Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200
   Roberson ED, 1999, J NEUROSCI, V19, P4337
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756 3282(01)00643 3
   Singh M, 2000, J NEUROSCI, V20, P1694
   Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116
   Sylvia VL, 2001, J CELL BIOCHEM, V81, P413, DOI 10.1002/1097 4644(20010601)81:3<413::AID JCB1055>3.0.CO;2 M
   Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004 1064
   Toran Allerand CD, 2002, J NEUROSCI, V22, P8391
   Wade CNB, 2003, ENDOCRINOLOGY, V144, P832, DOI 10.1210/en.2002 220899
   Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165 6147(00)01468 1
   Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699
   WONG G, 1974, NATURE, V252, P713, DOI 10.1038/252713a0
   Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710
   Zagar Y, 2004, J BIOL CHEM, V279, P2403, DOI 10.1074/jbc.M309132200
NR 63
TC 21
Z9 23
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2006
VL 209
IS 3
BP 786
EP 801
DI 10.1002/jcp.20767
PG 16
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA 101QD
UT WOS:000241754600030
PM 16972265
DA 2025 08 17
ER

PT J
AU Cho, DC
   Kim, KT
   Jeon, Y
   Sung, JK
AF Cho, Dae Chul
   Kim, Kyoung Tae
   Jeon, Younghoon
   Sung, Joo Kyung
TI A synergistic bone sparing effect of curcumin and alendronate in
   ovariectomized rat
SO ACTA NEUROCHIRURGICA
LA English
DT Article
DE Alendronate; Curcumin; Micro computed tomography; Osteoporosis;
   Ovariectomy; Rat
ID RECEPTOR ACTIVATOR; MINERAL DENSITY; OSTEOPOROSIS; BISPHOSPHONATES;
   FRACTURES; LIGAND; OSTEOCLASTOGENESIS; MECHANISMS; TURNOVER; THERAPY
AB The purpose of this study was to evaluate the therapeutic effects of combination therapy with curcumin and alendronate on bone remodeling after ovariectomy in rats.
   Eighty female Sprague Dawley rats underwent either a sham operation (the sham group) or bilateral ovariectomy (OVX). The ovariectomized animals were randomly distributed amongst four groups: untreated OVX group, curcumin administered group, alendronate administered group, and the combination therapy group. At 8 and 12 weeks after surgery, rats from each of the groups were euthanized. Serum biochemical markers of bone turnover, including osteocalcin and alkaline phosphatase (ALP), and the telopeptide fragment of type I collagen C terminus (CTX) were analyzed. Bone histomorphometric parameters of the 4th lumbar vertebrae were determined by micro computed tomography (CT). In addition, mechanical strength was determined by a three point bending test.
   Serum biochemical markers of bone turnover in the experiment groups (curcumin administered group, alendronate administered group, and the combination therapy group) were significantly lower than in the untreated OVX group (p < 0.05). The combination therapy group had lower ALP and CTX 1 concentrations at 12 weeks, which were statistically significant compared with the curcumin only and the alendronate only group (p < 0.05). The combination therapy group had a significant increase in BMD at 8 weeks and Cr.BMD at 12 weeks compared with the curcumin only group (p = 0.005 and p = 0.013, respectively). The three point bending test showed that the 4th lumbar vertebrae of the combination therapy group had a significantly greater maximal load value compared to that of the curcumin only and the alendronate only group (p < 0.05).
   The present study demonstrated that combination therapy with a high dose of curcumin and a standard dose of alendronate has therapeutic advantages over curcumin or alendronate monotherapy, in terms of the synergistic antiresorptive effect on bone remodeling, and improving bone mechanical strength.
C1 [Sung, Joo Kyung] Kyungpook Natl Univ Hosp, Dept Neurosurg, Taegu 700721, South Korea.
   [Cho, Dae Chul; Kim, Kyoung Tae; Sung, Joo Kyung] Kyungpook Natl Univ, Dept Neurosurg, Sch Med, Taegu, South Korea.
   [Jeon, Younghoon] Kyungpook Natl Univ, Dept Anesthesiol & Pain Med, Sch Med, Taegu, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   Hospital (KNUH); Kyungpook National University (KNU); Kyungpook National
   University (KNU)
RP Sung, JK (通讯作者)，Kyungpook Natl Univ Hosp, Dept Neurosurg, 50 Samduk 2 Ga, Taegu 700721, South Korea.
EM jodc60484@yahoo.co.kr
OI Jeon, Younghoon/0000 0002 7168 4214
FU Biomedical Reserach Institute grant, Kyungpook National University
   Hospital
FX This work was supported by Biomedical Reserach Institute grant,
   Kyungpook National University Hospital (2011).
CR Adachi JD, 2001, OSTEOPOROSIS INT, V12, P903, DOI 10.1007/s001980170017
   Bell NH, 2003, J CLIN INVEST, V111, P1120, DOI 10.1172/JCI200318358
   Bharti AC, 2004, J IMMUNOL, V172, P5940, DOI 10.4049/jimmunol.172.10.5940
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Canpolat S, 2010, J PHYSIOL BIOCHEM, V66, P23, DOI 10.1007/s13105 010 0008 8
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Folwarczna J, 2010, PHARMACOL REP, V62, P900, DOI 10.1016/S1734 1140(10)70350 9
   French DL, 2008, PHYTOMEDICINE, V15, P1069, DOI 10.1016/j.phymed.2008.06.007
   Joe B, 2004, CRIT REV FOOD SCI, V44, P97, DOI 10.1080/10408690490424702
   Kashii M, 2008, J BONE MINER METAB, V26, P24, DOI 10.1007/s00774 007 0782 8
   Notoya M, 2006, EUR J PHARMACOL, V534, P55, DOI 10.1016/j.ejphar.2006.01.028
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Oh S, 2008, MOL CELLS, V26, P486
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   Ozaki K, 2000, BIOCHEM PHARMACOL, V59, P1577, DOI 10.1016/S0006 2952(00)00277 X
   Park SK, 2011, BIOORG MED CHEM LETT, V21, P3573, DOI 10.1016/j.bmcl.2011.04.106
   Park SB, 2010, J KOREAN NEUROSURG S, V48, P309, DOI 10.3340/jkns.2010.48.4.309
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Sakai S, 2012, BONE, V50, P1054, DOI 10.1016/j.bone.2012.02.005
   Salari P, 2012, J PHARM PHARM SCI, V15, P305, DOI 10.18433/J3RK5J
   Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010
   Szulc P, 2003, JOINT BONE SPINE, V70, P157, DOI 10.1016/S1297 319X(03)00033 2
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Yang KY, 2007, J CHROMATOGR B, V853, P183, DOI 10.1016/j.jchromb.2007.03.010
   Yang MW, 2011, PHYTOMEDICINE, V18, P205, DOI 10.1016/j.phymed.2010.05.011
NR 26
TC 23
Z9 25
U1 0
U2 16
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4 6, PO BOX 89, A 1201 WIEN, AUSTRIA
SN 0001 6268
J9 ACTA NEUROCHIR
JI Acta Neurochir.
PD DEC
PY 2012
VL 154
IS 12
BP 2215
EP 2223
DI 10.1007/s00701 012 1516 9
PG 9
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Surgery
GA 040XJ
UT WOS:000311359500012
PM 23053289
DA 2025 08 17
ER

PT J
AU Bai, LJ
   Zhang, XL
   Shen, W
   Wang, P
   Yin, X
   Liu, JN
   Xu, HL
   Liu, B
   Man, ZT
   Li, W
AF Bai, Liangjie
   Zhang, Xiaolei
   Shen, Wei
   Wang, Peng
   Yin, Xin
   Liu, Jianing
   Xu, Hailun
   Liu, Bing
   Man, Zhentao
   Li, Wei
TI Multifunctional Scaffold Comprising Metal Organic Framework, Hydrogel,
   and Demineralized Bone Matrix for the Treatment of Steroid Induced
   Femoral Head Necrosis
SO SMALL
LA English
DT Article
DE angiogenesis; deferoxamine; inflammation; osteogenesis; oxidative stress
ID OSTEOBLAST DIFFERENTIATION; OXIDATIVE STRESS; OSTEONECROSIS; APOPTOSIS;
   INFLAMMATION; METABOLISM; ACTIVATION; THERAPY; ZINC
AB Overproduction of reactive oxygen species (ROS) results in oxidative stress, a critical factor in the pathogenesis of steroid induced osteonecrosis of the femoral head (SONFH). Excess ROS not only hinders the osteogenic differentiation of bone marrow derived mesenchymal stem cells (BMSCs) but also impairs mitochondrial structure and function, resulting in irreversible cellular damage. Herein, a biomimetic multifunctional scaffold comprising Zn modified metal organic framework 818 (Zn MOF 818) loaded with deferoxamine (DFO), gelatin methacryloyl (GelMA) hydrogel, and demineralized bone matrix (DBM) is shown to scavenge excess ROS, promote angiogenesis, and regulate immunity. Introduced Zn significantly enhances the superoxide dismutase  and catalase like activities of MOF 818, which increases ROS scavenging efficiency. Zn MOF 818 disrupts the vicious intracellular cycle of mitochondrial dysfunction and ROS accumulation by enhancing mitophagy, stabilizing mitochondrial function, and upregulating antioxidant genes. Additionally, Zn MOF 818 facilitates the polarization of macrophages toward the M2 phenotype and alleviates inflammation, creating an advantageous immune microenvironment for osteogenic differentiation of BMSCs. The release of DFO, an activator of the HIF 1 alpha pathway, and Zn2+ from Zn MOF 818, along with the secretion of various cytokines from DBM (such as bone morphogenetic proteins and vascular endothelial growth factors), enhances angiogenesis and osteogenesis. This scaffold targets multiple factors concurrently, offering a promising new approach for treating SONFH.
C1 [Bai, Liangjie; Zhang, Xiaolei; Wang, Peng; Xu, Hailun; Man, Zhentao; Li, Wei] Shandong First Med Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250021, Shandong, Peoples R China.
   [Shen, Wei] Shandong Univ, Linyi Peoples Hosp, Dept Neurol, Linyi 276007, Shandong, Peoples R China.
   [Yin, Xin] Shandong Univ, Linyi Peoples Hosp, Dept Joint Surg, Linyi 276007, Shandong, Peoples R China.
   [Liu, Jianing] Shandong First Med Univ, Shandong Prov Hosp, Dept Cent Lab, Jinan 250021, Peoples R China.
   [Liu, Bing] Shandong First Med Univ, Dept Oral & Maxillofacial Surg, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Shandong University; Shandong First
   Medical University & Shandong Academy of Medical Sciences; Shandong
   First Medical University & Shandong Academy of Medical Sciences
RP Man, ZT; Li, W (通讯作者)，Shandong First Med Univ, Shandong Prov Hosp, Dept Joint Surg, Jinan 250021, Shandong, Peoples R China.; Liu, B (通讯作者)，Shandong First Med Univ, Dept Oral & Maxillofacial Surg, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China.
EM liubing@sdfmu.edu.cn; manzhentao@sdfmu.edu.cn; liwei@sdfmu.edu.cn
FU National Natural Science Foundation of China [52002223, 81672185,
   52201299, 81702152]; Key Technology Research and Development Program of
   Shandong (Major Science and Technology Innovation Project)
   [2020CXGC010502]; Taishan Scholar Foundation of Shandong Province
   [tsqn202211348]; National key research and development plan
   [2023YFB4606705]; Shandong Province Natural Science Foundation
   [ZR2022MH222, ZR2022QE192, ZR2023MH209]
FX This work was supported by National Natural Science Foundation of China
   (Nos. 52002223, 81672185, 52201299, and 81702152), Key Technology
   Research and Development Program of Shandong (Major Science and
   Technology Innovation Project) (2020CXGC010502), Taishan Scholar
   Foundation of Shandong Province (No. tsqn202211348), The national key
   research and development plan (2023YFB4606705) and the Shandong Province
   Natural Science Foundation (Grant Nos. ZR2022MH222, ZR2022QE192, and
   ZR2023MH209).
CR Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Bao B, 2003, AM J PHYSIOL ENDOC M, V285, pE1095, DOI 10.1152/ajpendo.00545.2002
   Bosco G, 2018, J ENZYM INHIB MED CH, V33, P1501, DOI 10.1080/14756366.2018.1485149
   Chao DY, 2022, J AM CHEM SOC, V144, P23438, DOI 10.1021/jacs.2c09663
   Curi R, 2017, CLIN SCI, V131, P1329, DOI 10.1042/CS20170220
   Deng S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01787
   Fan KL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03903 8
   Fei DD, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.687258
   Gao J, 2018, CELL DEATH DIFFER, V25, P229, DOI 10.1038/cdd.2017.144
   Gessi S, 2010, CURR PHARM DESIGN, V16, P3540, DOI 10.2174/138161210793797915
   Gruskin E, 2012, ADV DRUG DELIVER REV, V64, P1063, DOI 10.1016/j.addr.2012.06.008
   Gu YP, 2020, AGEING RES REV, V59, DOI 10.1016/j.arr.2020.101036
   Han XY, 2021, BIOACT MATER, V6, P1639, DOI 10.1016/j.bioactmat.2020.11.019
   Hinsenkamp M, 2015, INT ORTHOP, V39, P137, DOI 10.1007/s00264 014 2562 0
   Holt DJ, 2012, ADV DRUG DELIVER REV, V64, P1123, DOI 10.1016/j.addr.2012.04.002
   Huang F, 2024, J AM CHEM SOC, V146, P3186, DOI 10.1021/jacs.3c11059
   Huang SL, 2016, EXP THER MED, V11, P177, DOI 10.3892/etm.2015.2883
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kong N, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00196 y
   Korbecki J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910701
   Lan DM, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.938520
   Lee J, 2009, CHEM SOC REV, V38, P1450, DOI 10.1039/b807080f
   Lee SY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02656 4
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017 00064
   Li QF, 2020, RSC ADV, V10, P16537, DOI 10.1039/c9ra10563h
   Li ZY, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.680328
   Liang H, 2017, ACS APPL MATER INTER, V9, P1352, DOI 10.1021/acsami.6b15124
   Liang S, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115712
   Lin CS, 2013, HISTOL HISTOPATHOL, V28, P1109, DOI 10.14670/HH 28.1109
   Lin H, 2008, BIOMATERIALS, V29, P1189, DOI 10.1016/j.biomaterials.2007.11.032
   Lin PH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10010016
   Liu Q, 2019, J AM CHEM SOC, V141, P488, DOI 10.1021/jacs.8b11230
   Ma M, 2022, BONE JOINT RES, V11, P26, DOI 10.1302/2046 3758.111.BJR 2021 0467.R1
   Mamidi N, 2023, BIOMACROMOLECULES, V25, P2075, DOI 10.1021/acs.biomac.3c00279
   Mobarra Naser, 2016, Int J Hematol Oncol Stem Cell Res, V10, P239
   Mu S, 2017, MOL MED REP, V16, P9579, DOI 10.3892/mmr.2017.7810
   Naik PP, 2019, CELL MOL LIFE SCI, V76, P27, DOI 10.1007/s00018 018 2922 9
   Natalio F, 2012, NAT NANOTECHNOL, V7, P530, DOI [10.1038/nnano.2012.91, 10.1038/NNANO.2012.91]
   Ngo MT, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120207
   Park SH, 2022, ADV SCI, V9, DOI 10.1002/advs.202200872
   Petek D, 2019, EFORT OPEN REV, V4, P85, DOI 10.1302/2058 5241.4.180036
   Plum LM, 2010, INT J ENV RES PUB HE, V7, P1342, DOI 10.3390/ijerph7041342
   Qin L, 2006, BONE, V39, P863, DOI 10.1016/j.bone.2006.04.018
   Shyngys M, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.603608
   Sun XJ, 2021, PHARM BIOL, V59, P1326, DOI 10.1080/13880209.2021.1979595
   Sung YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0730 7
   Swarup I, 2018, J ARTHROPLASTY, V33, P2893, DOI 10.1016/j.arth.2018.04.016
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van der Stok J, 2017, BONE JOINT RES, V6, P423, DOI 10.1302/2046 3758.67.BJR 2017 0027.R1
   Vo MT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11164 2
   Wang J, 2023, AUTOPHAGY, V19, P2409, DOI 10.1080/15548627.2023.2186112
   Wang WD, 2024, J ORTHOP SURG RES, V19, DOI 10.1186/s13018 024 04775 z
   Wilson N, 2023, TRENDS CELL BIOL, V33, P788, DOI 10.1016/j.tcb.2023.02.004
   Wong SK, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00430
   Xiao JS, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201604872
   Xu Y, 2020, AUTOPHAGY, V16, P3, DOI 10.1080/15548627.2019.1603547
   Yan YF, 2019, BIOMATERIALS, V190, P97, DOI 10.1016/j.biomaterials.2018.10.033
   Yang GC, 2016, CANCER LETT, V378, P80, DOI 10.1016/j.canlet.2016.05.007
   Yu CJ, 2014, NANOSCALE, V6, P9618, DOI 10.1039/c3nr06896j
   Yu K, 2023, CHEM ENG J, V451, DOI 10.1016/j.cej.2022.138321
   Zadegan SA, 2017, EUR SPINE J, V26, P958, DOI 10.1007/s00586 016 4858 9
   Zheng ML, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12091675
   Zhou BX, 2023, BIOMATER RES, V27, DOI 10.1186/s40824 023 00422 6
NR 63
TC 10
Z9 10
U1 34
U2 57
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613 6810
EI 1613 6829
J9 SMALL
JI Small
PD JAN
PY 2025
VL 21
IS 3
DI 10.1002/smll.202407758
EA NOV 2024
PG 19
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA U1T9Q
UT WOS:001360574500001
PM 39575484
OA Bronze
DA 2025 08 17
ER

PT J
AU Hamdani, G
   Gabet, Y
   Rachmilewitz, D
   Karmeli, F
   Bab, I
   Dresner Pollak, R
AF Hamdani, Gilad
   Gabet, Yankel
   Rachmilewitz, Daniel
   Karmeli, Fanny
   Bab, Itai
   Dresner Pollak, Rivka
TI Dextran sodium sulfate induced colitis causes rapid bone loss in mice
SO BONE
LA English
DT Article
DE DSS; Colitis; Osteopenia; Mice
ID INFLAMMATORY BOWEL DISEASE; EXPERIMENTAL MURINE COLITIS;
   NECROSIS FACTOR ALPHA; MINERAL DENSITY; CROHNS DISEASE; INTESTINAL
   INFLAMMATION; IN VITRO; OSTEOPROTEGERIN; METABOLISM; CELLS
AB Introduction: Osteopenia is a common complication of human inflammatory bowel disease (IBD) We. evaluated the contribution of colonic inflammation to osteopenia and its mechanism in a murine colitis model.
   Methods: Colitis was induced by adding dextran sodium sulfate (DSS) to the drinking water for 2 weeks to nine week old Balb/C male mice. 5% DSS was added on the first week and was reduced to 2.5% on the second week. Age  and sex matched Balb/C mice served as the control group. Indices of femoral bone mass and architecture were determined by micro computed tomography (mu CT). Bone formation parameters and osteoclast number were determined by dynamic histomorphometry. The degree of colonic inflammation was assessed by a clinical disease activity index, and Colonic mucosal myeloperoxidase activity.
   Results: DSS treated mice exhibited a significantly lower bone mass compared to controls as indicated by decreased trabecular bone volume (BV/TV) of 32%. This reduction was accompanied by decreased trabecular number (23%) and connectivity density (37%) compared to the controls. No changes were observed in cortical bone indices. Osteopenia resulted from Suppressed bone formation, as indicated by decreased trabecular double labeled Surface (dL%) of 90%, mineralizing Surface (MS) of 62%, and bone formation rate (BFR) of 67%, and increased bone resorption as indicated by a 34% increase in osteoclast number in DSS treated mice compared to the controls. Myeloperoxidase activity inversely correlated with trabecular BV/TV (r= 0.67, p=0.02), trabecular number (r= 0.86, p=0.0008) and connectivity density (r= 0.63, p=0.03). Myeloperoxidase activity inversely correlated with the bone formation indices: dL%, MS, and BFR (r= 0.79, p=0.007, r=  0.84, p=0.002, r= 0.83, p=0.003, respectively).
   Conclusions: DSS induced colitis is associated with reduced femoral bone mass and altered micro architecture, which results from Suppressed bone formation and increased bone resorption. The decrease in indices of bone mass, structure and formation are directly linked to the degree of colonic mucosal inflammation. DSS induced colitis can be used to Study pharmacological interventions for bone loss in colitis. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Karmeli, Fanny; Dresner Pollak, Rivka] Hadassah Hebrew Univ, Med Ctr, Dept Med, Endocrinol & Metab Serv, IL 91120 Jerusalem, Israel.
   [Rachmilewitz, Daniel] Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Gabet, Yankel; Bab, Itai] Hebrew Univ Jerusalem, Bone Lab, Jerusalem, Israel.
   [Hamdani, Gilad] Hebrew Univ Jerusalem, Hadassah Med Sch, IL 91010 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew
   University of Jerusalem; Hebrew University of Jerusalem
RP Dresner Pollak, R (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Med, Endocrinol & Metab Serv, POB 12000, IL 91120 Jerusalem, Israel.
EM rivkap@hadassah.org.il
RI Dresner Pollak, Rivka/JEP 6550 2023; Gabet, Yankel/I 6244 2019
OI Gabet, Yankel/0000 0002 7494 0631; 
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Ashcroft AJ, 2003, IMMUNITY, V19, P849, DOI 10.1016/S1074 7613(03)00326 1
   Bernstein CN, 2000, ANN INTERN MED, V133, P795, DOI 10.7326/0003 4819 133 10 200011210 00012
   Bernstein CN, 2005, INFLAMM BOWEL DIS, V11, P325, DOI 10.1097/01.MIB.0000164015.60795.ca
   Bernstein CN, 2003, GASTROENTEROLOGY, V124, P795, DOI 10.1053/gast.2003.50106
   Bernstein M, 2005, AM J GASTROENTEROL, V100, P2031, DOI 10.1111/j.1572 0241.2005.50219.x
   Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952 7915(99)00032 1
   Byrne FR, 2005, GUT, V54, P78, DOI 10.1136/gut.2003.035113
   Cohen SL, 2004, INFLAMM BOWEL DIS, V10, P557, DOI 10.1097/00054725 200409000 00009
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   COOPER HS, 1993, LAB INVEST, V69, P238
   CROUCHER PI, 1993, OSTEOPOROSIS INT, V3, P236, DOI 10.1007/BF01623826
   Dresner Pollak R, 2004, GASTROENTEROLOGY, V127, P792, DOI 10.1053/j.gastro.2004.06.013
   Dresner Pollak R, 2008, GASTROENTEROLOGY, V134, P259, DOI 10.1053/j.gastro.2007.10.025
   FRIES W, 1994, DIGESTION, V55, P229, DOI 10.1159/000201152
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hyams JS, 1997, J PEDIATR GASTR NUTR, V24, P289, DOI 10.1097/00005176 199703000 00011
   Jahnsen J, 2004, SCAND J GASTROENTERO, V39, P145, DOI 10.1080/00365520310007873
   Karlsson A, 2008, INT IMMUNOPHARMACOL, V8, P20, DOI 10.1016/j.intimp.2007.10.007
   Kumar R, 2002, CURR OPIN NEPHROL HY, V11, P547, DOI 10.1097/00041552 200209000 00011
   Lin CL, 1996, GASTROENTEROLOGY, V111, P1263, DOI 10.1053/gast.1996.v111.pm8898640
   Melgar S, 2005, AM J PHYSIOL GASTR L, V288, pG1328, DOI 10.1152/ajpgi.00467.2004
   Melgar S, 2008, INT IMMUNOPHARMACOL, V8, P836, DOI 10.1016/j.intimp.2008.01.036
   Melgar S, 2007, AM J PHYSIOL GASTR L, V292, pG165, DOI 10.1152/ajpgi.00152.2006
   Moschen AR, 2005, GUT, V54, P479, DOI 10.1136/gut.2004.044370
   Negri AL, 2004, J BONE MINER METAB, V22, P514, DOI 10.1007/s00774 004 0516 0
   Ogata Y, 1999, J IMMUNOL, V162, P2754
   OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016 5085(90)90290 H
   Paganelli M, 2007, INFLAMM BOWEL DIS, V13, P416, DOI 10.1002/ibd.20039
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Rachmilewitz D, 2002, GASTROENTEROLOGY, V122, P1428, DOI 10.1053/gast.2002.32994
   Steiner PD, 2001, BONE, V29, P344, DOI 10.1016/S8756 3282(01)00506 3
   Sylvester FA, 2002, J BONE MINER RES, V17, P695, DOI 10.1359/jbmr.2002.17.4.695
   Talbott SM, 1998, J NUTR, V128, P640, DOI 10.1093/jn/128.3.640
   Uno JK, 2006, GASTROENTEROLOGY, V131, P497, DOI 10.1053/j.gastro.2006.05.020
   Van Staa TP, 2003, GASTROENTEROLOGY, V125, P1591, DOI 10.1053/j.gastro.2003.09.027
   Vidal K, 2004, AM J PHYSIOL GASTR L, V287, pG836, DOI 10.1152/ajpgi.00428.2003
   Xiao ZS, 1998, AM J PHYSIOL ENDOC M, V275, pE700, DOI 10.1152/ajpendo.1998.275.4.E700
   Yoshihara K, 2006, GUT, V55, P334, DOI 10.1136/gut.2005.076000
NR 40
TC 40
Z9 46
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD NOV
PY 2008
VL 43
IS 5
BP 945
EP 950
DI 10.1016/j.bone.2008.06.018
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 365ZK
UT WOS:000260448500021
PM 18675386
DA 2025 08 17
ER

PT J
AU Barradas, AMC
   Yuan, HP
   van der Stok, J
   Quang, BL
   Fernandes, H
   Chaterje, A
   Hogenes, MCH
   Shultz, K
   Donahue, LR
   van Blitterswijk, C
   de Boer, J
AF Barradas, Ana M. C.
   Yuan, Huipin
   van der Stok, Johan
   Bach Le Quang
   Fernandes, Hugo
   Chaterje, Anindita
   Hogenes, Marieke C. H.
   Shultz, Kathy
   Donahue, Leah Rae
   van Blitterswijk, Clemens
   de Boer, Jan
TI The influence of genetic factors on the osteoinductive potential of
   calcium phosphate ceramics in mice
SO BIOMATERIALS
LA English
DT Article
DE Calcium phosphate; BMP (bone morphogenetic protein); Osteoblast; Bone
ID BONE MORPHOGENETIC PROTEIN 2; INBRED STRAINS; HYDROXYAPATITE;
   VARIABILITY; INDUCTION; GROWTH; ANGIOGENESIS; MACROPHAGE; RECEPTOR;
   CARRIER
AB The efficacy of calcium phosphate (Cap) ceramics in healing large bone defects is, in general, not as high as that of autologous bone grafting. Recently, we reported that CaP ceramics with osteoinductive properties were as efficient in healing an ilium defect of a sheep as autologous bone graft was, which makes this subclass of CaP ceramics a powerful alternative for bone regeneration. Although osteoinduction by CaP ceramics has been shown in several large animal models it is sporadically reported in mice. Because the lack of a robust mouse model has delayed understanding of the mechanism, we screened mice from 11 different inbred mouse strains for their responsiveness to subcutaneous implantation of osteoinductive tricalcium phosphate (TCP). In only two strains (FVB and 129S2) the ceramic induced bone formation, and in particularly, in FVB mice, bone was found in all the tested mice. We also demonstrated that other CaP ceramics induced bone formation at the same magnitude as that observed in other animal models. Furthermore, VEGF did not significantly increase TCP induced bone formation. The mouse model here described can accelerate research of osteoinductive mechanisms triggered by CaP ceramics and potentially the development of therapies for bone regeneration. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Barradas, Ana M. C.; Yuan, Huipin; Fernandes, Hugo; Chaterje, Anindita; van Blitterswijk, Clemens; de Boer, Jan] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Tissue Regenerat, NL 7522 NB Enschede, Netherlands.
   [Yuan, Huipin] Progentix Orthobiol BV, Bilthoven, Netherlands.
   [van der Stok, Johan] Univ Med Ctr Rotterdam, Erasmus MC, Dept Orthopaed, Orthoped Res Lab, Rotterdam, Netherlands.
   [Bach Le Quang; Shultz, Kathy; Donahue, Leah Rae] Jackson Lab, Bar Harbor, ME 04609 USA.
   [Hogenes, Marieke C. H.] E Netherlands, Pathol Lab, NL 7512 AD Enschede, Netherlands.
C3 University of Twente; Erasmus University Rotterdam; Erasmus MC; Jackson
   Laboratory
RP de Boer, J (通讯作者)，Univ Twente, MIRA Inst Biomed Technol & Tech Med, Dept Tissue Regenerat, Drienerlolaan 5, NL 7522 NB Enschede, Netherlands.
EM j.deboer@utwente.nl
RI ; Fernandes, Hugo/H 6192 2014
OI Quang Bach, Le/0000 0002 1001 4751; Barradas, Ana/0000 0003 4221 8879;
   Fernandes, Hugo/0000 0002 4574 7648; de Boer, Jan/0000 0001 9188 9324;
   van Blitterswijk, Clemens/0000 0003 2371 4615
FU TeRM Smart Mix Program of the Netherlands Ministry of Economic Affairs;
   Netherlands Ministry of Education, Culture and Science
FX The authors gratefully acknowledge the financial support of the TeRM
   Smart Mix Program of the Netherlands Ministry of Economic Affairs and
   the Netherlands Ministry of Education, Culture and Science. We also wish
   to acknowledge Annette Gijsbers Bruggink and collaborators (Biobank, UMC
   Utrecht) and Liliana Teixeira, Joyce Doom and Karolina
   Janeczek Portalska for technical assistance.
CR Andrikopoulos P, 2011, J BIOL CHEM, V286, P37919, DOI 10.1074/jbc.M111.251777
   Baird Evan O, 2009, J Orthop Surg Res, V4, P12, DOI 10.1186/1749 799X 4 12
   Barradas AMC, 2011, EUR CELLS MATER, V21, P407, DOI 10.22203/eCM.v021a31
   Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756 3282(96)00047 6
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Crouzier T, 2011, BIOMATERIALS, V32, P7543, DOI 10.1016/j.biomaterials.2011.06.062
   Cullen N, 2009, J HEAD TRAUMA REHAB, V24, P69, DOI 10.1097/HTR.0b013e31819a8fcc
   de Bruijn JD, 2008, WOODHEAD PUBL MATER, P199, DOI 10.1533/9781845694227.1.199
   Fellah BH, 2010, J BIOMED MATER RES A, V93A, P1588, DOI 10.1002/jbm.a.32663
   Ghanaati S, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/1/015005
   Habibovic P, 2005, BIOMATERIALS, V26, P3565, DOI 10.1016/j.biomaterials.2004.09.056
   Harada Y, 1996, J BIOMED MATER RES, V31, P19, DOI 10.1002/(SICI)1097 4636(199605)31:1<19::AID JBM3>3.3.CO;2 L
   Hartman EHM, 2004, BIOMATERIALS, V25, P5831, DOI 10.1016/j.biomaterials.2004.01.039
   Honda Y, 2006, BIOCHEM BIOPH RES CO, V345, P1155, DOI 10.1016/j.bbrc.2006.05.013
   Hulsart Billström G, 2011, ACTA BIOMATER, V7, P3042, DOI 10.1016/j.actbio.2011.04.021
   Jung HJ, 2010, J BIOL CHEM, V285, P25867, DOI 10.1074/jbc.M110.135632
   Kan LX, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/309287
   KLEIN CPAT, 1989, BIOMATERIALS, V10, P59
   Koyama N, 2011, BRIT J ORAL MAX SURG, V49, P314, DOI 10.1016/j.bjoms.2010.05.010
   Li JZ, 2003, GENE THER, V10, P1735, DOI 10.1038/sj.gt.3302075
   Li SH, 2003, TISSUE ENG, V9, P535, DOI 10.1089/107632703322066714
   Li X, 2001, BONE, V29, P134, DOI 10.1016/S8756 3282(01)00497 5
   Manigrasso MB, 2008, CALCIFIED TISSUE INT, V82, P465, DOI 10.1007/s00223 008 9144 3
   Marusic A, 1999, BONE, V25, P25, DOI 10.1016/S8756 3282(99)00095 2
   Matsushita N, 2004, J BIOMED MATER RES A, V70A, P450, DOI 10.1002/jbm.a.30102
   Mukhopadhyay D, 1996, BIOCHEM BIOPH RES CO, V229, P733, DOI 10.1006/bbrc.1996.1873
   Odgaard A, 1997, BONE, V20, P315, DOI 10.1016/S8756 3282(97)00007 0
   Potter BK, 2010, J BONE JOINT SURG AM, V92A, P74, DOI 10.2106/JBJS.J.00776
   Ripamonti U, 1999, S AFR J SCI, V95, P335
   RIPAMONTI U, 1993, MATRIX, V13, P491, DOI 10.1016/S0934 8832(11)80115 0
   Ripamonti U, 2010, BIOMATERIALS, V31, P6400, DOI 10.1016/j.biomaterials.2010.04.037
   Sakuma Y, 2000, J BONE MINER RES, V15, P218, DOI 10.1359/jbmr.2000.15.2.218
   Shehab D, 2002, J NUCL MED, V43, P346
   Shen WG, 2007, CELL BIOL INT, V31, P126, DOI 10.1016/j.cellbi.2006.09.017
   Takahashi Y, 2005, BIOMATERIALS, V26, P4856, DOI 10.1016/j.biomaterials.2005.01.012
   Thomsen P, 2001, CURR OPIN SOLID ST M, V5, P163, DOI 10.1016/S1359 0286(01)00004 3
   YAMASAKI H, 1992, BIOMATERIALS, V13, P308, DOI 10.1016/0142 9612(92)90054 R
   Yang RN, 2011, J ZHEJIANG UNIV SC B, V12, P582, DOI 10.1631/jzus.B1000204
   Yang ZJ, 1996, BIOMATERIALS, V17, P2131, DOI 10.1016/0142 9612(96)00044 0
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Yuan HP, 2002, J MATER SCI MATER M, V13, P1271, DOI 10.1023/A:1021191432366
   Yuan HP, 1998, J MATER SCI MATER M, V9, P723, DOI 10.1023/A:1008950902047
   Yuan HP, 2006, TISSUE ENG, V12, P1607, DOI 10.1089/ten.2006.12.1607
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zelzer E, 2005, CURR TOP DEV BIOL, V65, P169
NR 45
TC 49
Z9 53
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2012
VL 33
IS 23
BP 5696
EP 5705
DI 10.1016/j.biomaterials.2012.04.021
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 963CG
UT WOS:000305597100004
PM 22594974
DA 2025 08 17
ER

PT J
AU Jamal, M
   Lewandowski, SL
   Lawton, ML
   Huang, GTJ
   Ikonomou, L
AF Jamal, Mohamed
   Lewandowski, Sara L.
   Lawton, Matthew L.
   Huang, George T J
   Ikonomou, Laertis
TI Derivation and characterization of putative craniofacial mesenchymal
   progenitor cells from human induced pluripotent stem cells
SO STEM CELL RESEARCH
LA English
DT Article
ID CRANIAL NEURAL CREST; SONIC HEDGEHOG; IN VITRO; DIFFERENTIATION;
   INHIBITION; INDUCTION; DEFECTS; APOPTOSIS; FATE; VIVO
AB The introduction and widespread adoption of induced pluripotent stem cell (iPSC) technology has opened new avenues for craniofacial regenerative medicine. Neural crest cells (NCCs) are the precursor population to many craniofacial structures, including dental and periodontal structures, and iPSC derived NCCs may, in the near future, offer an unlimited supply of patient specific cells for craniofacial repair interventions.
   Here, we used an established protocol involving simultaneous Wnt signaling activation and TGF beta signaling inhibition to differentiate three human iPSC lines to cranial NCCs. We then derived a mesenchymal progenitor cell (NCC MPCs) population with chondrogenic and osteogenic potential from cranial NCCs and investigated their similarity to widely studied human postnatal dental or periodontal stem/progenitor cells. NCC MPCs were quite distinct from both their precursor cells (NCCs) and bone marrow mesenchymal stromal cells, a stromal population of mesodermal origin. Despite their similarity with dental stem/progenitor cells, NCC MPCs were clearly differentiated by a core set of 43 genes, including ACKR3 (CXCR7), whose expression (both at transcript and protein level) appear to be specific to NCC MPCs.
   Altogether, our data demonstrate the feasibility of craniofacial mesenchymal progenitor derivation from human iPSCs through a neural crest intermediate and set the foundation for future studies regarding their full differentiation repertoire and their in vivo existence.
C1 [Jamal, Mohamed; Lewandowski, Sara L.; Lawton, Matthew L.; Ikonomou, Laertis] Boston Univ, Ctr Regenerat Med, 670 Albany St,Room 211, Boston, MA 02118 USA.
   [Jamal, Mohamed; Lewandowski, Sara L.; Lawton, Matthew L.; Ikonomou, Laertis] Boston Med Ctr, 670 Albany St,Room 211, Boston, MA 02118 USA.
   [Ikonomou, Laertis] Boston Univ, Sch Med, Pulm Ctr, Boston, MA 02118 USA.
   [Huang, George T J] Univ Tennessee, Dept Biosci Res, Coll Dent, Hlth Sci Ctr, Memphis, TN USA.
   [Jamal, Mohamed] Mohammed Bin Rashid Univ Med & Hlth Sci, Hamdan Bin Mohammed Coll Dent Med, Endodont Dept, Dubai, U Arab Emirates.
C3 Boston University; Boston Medical Center; Boston University; University
   of Tennessee System; University of Tennessee Health Science Center
RP Ikonomou, L (通讯作者)，Boston Univ, Ctr Regenerat Med, 670 Albany St,Room 211, Boston, MA 02118 USA.; Ikonomou, L (通讯作者)，Boston Med Ctr, 670 Albany St,Room 211, Boston, MA 02118 USA.
EM laertis@bu.edu
RI Ikonomou, Laertis/D 4579 2009; Lewandowski, Sara/J 2988 2017; Ahmed,
   Mohamed/AAG 2265 2021
OI Ikonomou, Laertis/0000 0003 0993 6713; Lawton, Matthew
   Luke/0000 0002 7244 1337; Jamal, Mohamed/0000 0001 5865 7943
FU CTSA grant [UL1 TR001430]; NIH [1UL1TR001430, R24HL123828, U01TR001810,
   R01 HL111574, R01 HL124280]; National Institutes of Health [R01
   DE019156]; Foundation for Endodontics, American Association of
   Endodontists grant; Boston University Clinical and Translational Science
   Institute training grant [TL1TR001410]; Evans Junior Faculty Research
   Merit Award
FX We thank Adam Gower and Eduard Drizik of the Boston University
   Microarray and Sequencing Resource Core Facility for Affymetrix array
   processing and bioinformatics support (CTSA grant UL1 TR001430). We are
   grateful to Brian R. Tilton of the BUSM Flow Cytometry Core for
   technical assistance, supported by NIH Grant 1UL1TR001430, and Drs. Greg
   Miller and Marianne James of the CReM, supported by grants R24HL123828
   and U01TR001810. We thank Dr. Darrell N. Kotton for helpful comments on
   the manuscript and Dr. Mina Mina, from UConn Health Center, for
   insightful discussions. This work was supported in part by grants from
   the National Institutes of Health (R01 DE019156 to GT JH). MJ is
   supported by a Foundation for Endodontics, American Association of
   Endodontists grant, SLL is supported by a Boston University Clinical and
   Translational Science Institute training grant (TL1TR001410), and LI is
   supported by NIH grants R01 HL111574 and R01 HL124280 and an Evans
   Junior Faculty Research Merit Award.
CR Ahlgren SC, 1999, CURR BIOL, V9, P1304, DOI 10.1016/S0960 9822(00)80052 4
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Beverdam A, 2001, DEVELOPMENT, V128, P3975
   Brainarray, 2017, DESCRIPTION CUSTOMIZ
   Brettschneider J, 2008, TECHNOMETRICS, V50, P241, DOI 10.1198/004017008000000334
   Chai Y, 2000, DEVELOPMENT, V127, P1671
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Creuzet S, 2002, DEVELOPMENT, V129, P4301
   Dai M. H., 2005, NUCLEIC ACIDS RES, V33, P9
   de Crozé N, 2011, P NATL ACAD SCI USA, V108, P155, DOI 10.1073/pnas.1010740107
   Delloye Bourgeois C, 2014, BIOCHEM BIOPH RES CO, V452, P655, DOI 10.1016/j.bbrc.2014.08.134
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dupin E, 2014, BIRTH DEFECTS RES C, V102, P187, DOI 10.1002/bdrc.21080
   Fukuta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112291
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb 2004 5 10 r80
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hackland JOS, 2017, STEM CELL REP, V9, P1043, DOI 10.1016/j.stemcr.2017.08.008
   Ho KS, 2002, CURR OPIN NEUROBIOL, V12, P57, DOI 10.1016/S0959 4388(02)00290 8
   Hu D, 1999, DEVELOPMENT, V126, P4873
   Huang M., 2016, SCI REP, V6, P9
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Janebodin K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027526
   Jiang XH, 2009, STEM CELLS DEV, V18, P1059, DOI 10.1089/scd.2008.0362
   Kurmann AA, 2015, CELL STEM CELL, V17, P527, DOI 10.1016/j.stem.2015.09.004
   Lee G, 2009, NATURE, V461, P402, DOI 10.1038/nature08320
   Leucht P, 2008, DEVELOPMENT, V135, P2845, DOI 10.1242/dev.023788
   Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092 8674(01)00369 5
   Machon O, 2015, BMC DEV BIOL, V15, DOI 10.1186/s12861 015 0093 6
   Menendez L, 2013, NAT PROTOC, V8, P203, DOI 10.1038/nprot.2012.156
   Menendez L, 2011, P NATL ACAD SCI USA, V108, P19240, DOI 10.1073/pnas.1113746108
   Mica Y, 2013, CELL REP, V3, P1140, DOI 10.1016/j.celrep.2013.03.025
   Milet C, 2012, DEV BIOL, V366, P22, DOI 10.1016/j.ydbio.2012.01.013
   Mumme M, 2016, LANCET, V388, P1985, DOI 10.1016/S0140 6736(16)31658 0
   Nuti N, 2016, STEM CELL REV REP, V12, P511, DOI 10.1007/s12015 016 9661 9
   Osafune K, 2008, NAT BIOTECHNOL, V26, P313, DOI 10.1038/nbt1383
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Quintana AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180856
   Rada Iglesias A, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0360
   Rada Iglesias A, 2012, CELL STEM CELL, V11, P633, DOI 10.1016/j.stem.2012.07.006
   Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588
   Roessler E, 2009, HUM GENET, V125, P393, DOI 10.1007/s00439 009 0628 7
   Schwend T, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471 213X 9 59
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shao MY, 2015, J MOL CELL BIOL, V7, P441, DOI 10.1093/jmcb/mjv052
   Sharpe PT, 2016, DEVELOPMENT, V143, P2273, DOI 10.1242/dev.134189
   Signore IA, 2016, BIRTH DEFECTS RES A, V106, P814, DOI 10.1002/bdra.23546
   Simoes Costa M, 2015, DEVELOPMENT, V142, P242, DOI 10.1242/dev.105445
   Simoes Costa M, 2014, GENOME RES, V24, P281, DOI 10.1101/gr.161182.113
   Sonoyama W, 2008, J ENDODONT, V34, P166, DOI 10.1016/j.joen.2007.11.021
   Wang WD, 2011, DEV BIOL, V360, P173, DOI 10.1016/j.ydbio.2011.09.019
   Wu ZF, 2015, INT J CLIN EXP MED, V8, P7220
NR 52
TC 10
Z9 10
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873 5061
EI 1876 7753
J9 STEM CELL RES
JI Stem Cell Res.
PD DEC
PY 2018
VL 33
BP 100
EP 109
DI 10.1016/j.scr.2018.10.015
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA HD6IH
UT WOS:000452639700018
PM 30340089
OA Green Accepted, gold
DA 2025 08 17
ER

PT J
AU Krambs, JR
   Abou Ezzi, G
   Yao, JC
   Link, DC
AF Krambs, Joseph Ryan
   Abou Ezzi, Grazia
   Yao, Juo Chin
   Link, Daniel C.
TI Canonical signaling by TGF family members in mesenchymal stromal cells
   is dispensable for hematopoietic niche maintenance under basal and
   stress conditions
SO PLOS ONE
LA English
DT Article
ID GROWTH FACTOR BETA; BONE MARROW; G CSF; PHOSPHATIDYLINOSITOL 3 KINASE;
   INEFFECTIVE ERYTHROPOIESIS; II RECEPTOR; STEM CELLS; DIFFERENTIATION;
   ACTIVATION; EXPRESSION
AB Mesenchymal stromal cells are an important component of the bone marrow hematopoietic niche. Prior studies showed that signaling from members of the transforming growth factor (TGF) superfamily in mesenchymal stromal cells is required for normal niche development. Here, we assessed the impact of TGF family signaling on niche maintenance and stress responses by deleting Smad4 in mesenchymal stromal cells at birth, thereby abrogating canonical TGF signaling. No alteration in the number or spatial organization of CXCL12 abundant reticular (CAR) cells, osteoblasts, or adipocytes was observed in Osx Cre, Smad4(fl/fl) mice, and expression of key niche factors was normal. Basal hematopoiesis and stress erythropoiesis responses to acute hemolytic anemia were normal. TGF beta potently inhibits stromal CXCL12 expression in vitro; however, G CSF induced decreases in bone marrow CXCL12 expression and subsequent hematopoietic stem/progenitor cell mobilization were normal in Osx Cre, Tgfbr2(fl/fl) mice, in which all TGF beta signaling in mesenchymal stromal is lost. Finally, although a prior study showed that TGF beta enhances recovery from myeloablative therapy, hematopoietic recovery following single or multiple doses of 5 flurauracil were normal in Osx Cre, Tgfbr2(fl/fl) mice. Collectively, these data suggest that TGF family member signaling in mesenchymal stromal cells is dispensable for hematopoietic niche maintenance under basal and stress conditions.
C1 [Krambs, Joseph Ryan; Abou Ezzi, Grazia; Yao, Juo Chin; Link, Daniel C.] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Link, DC (通讯作者)，Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA.
EM danielclink@wusti.edu
OI Krambs, Joseph/0000 0002 5364 5430; Yao, Juo Chin/0000 0002 2041 9867;
   Link, Daniel/0000 0002 3170 7581
FU National Institutes of Health [RO1HL131655]; National Cancer Institute
   [F31CA247136]; NCI Cancer Center Support Grant [P30 CA091842]
FX This study was supported by the National Institutes of Health grant
   RO1HL131655 (DCL) and by the National Cancer Institute grant F31CA247136
   (JRK). The Siteman Cancer Center is supported in part by an NCI Cancer
   Center Support Grant #P30 CA091842.
   https://grants.nih.gov/grants/oer.htm.The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdulkadyrov KM, 2014, BRIT J HAEMATOL, V165, P814, DOI 10.1111/bjh.12835
   Abou Ezzi G, 2019, STEM CELL REPORTS
   Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254
   Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200
   Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200
   Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27
   Brenet F, 2013, J EXP MED, V210, P623, DOI 10.1084/jem.20121610
   BURT DW, 1992, BIOCHEM BIOPH RES CO, V184, P590, DOI 10.1016/0006 291X(92)90630 4
   Carrancio S, 2014, BRIT J HAEMATOL, V165, P870, DOI 10.1111/bjh.12838
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Christopher MJ, 2008, J BONE MINER RES, V23, P1765, DOI 10.1359/JBMR.080612
   Christopher MJ, 2009, BLOOD, V114, P1331, DOI 10.1182/blood 2008 10 184754
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Dominici M, 2009, BLOOD, V114, P2333, DOI 10.1182/blood 2008 10 183459
   DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795
   Dussiot M, 2014, NAT MED, V20, P398, DOI 10.1038/nm.3468
   Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01 08 0398
   Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413
   Frey RS, 1997, CANCER RES, V57, P628
   Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008 5472.CAN 06 3851
   Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926
   Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161
   HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117
   Herpin A, 2004, DEV COMP IMMUNOL, V28, P461, DOI 10.1016/j.dci.2003.09.007
   Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345
   Iancu Rubin C, 2013, EXP HEMATOL, V41, P155, DOI 10.1016/j.exphem.2012.12.002
   IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kaygusuz MA, 2006, LIFE SCI, V80, P67, DOI 10.1016/j.lfs.2006.08.023
   Khurana S, 2014, STEM CELLS, V32, P3012, DOI 10.1002/stem.1794
   Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612
   Levéen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560
   Lévesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994
   LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027
   MULDER KM, 1992, J BIOL CHEM, V267, P5029
   Omatsu Y, 2010, IMMUNITY, V33, P387, DOI 10.1016/j.immuni.2010.08.017
   Peters SB, 2017, BONE, V97, P54, DOI 10.1016/j.bone.2016.12.017
   Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328
   SPARKS RL, 1992, J CELL PHYSIOL, V150, P568, DOI 10.1002/jcp.1041500318
   Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016
   Suragani RNVS, 2014, BLOOD, V123, P3864, DOI 10.1182/blood 2013 06 511238
   Suragani RNVS, 2014, NAT MED, V20, P408, DOI 10.1038/nm.3512
   Tikhonova AN, 2019, NATURE, V572, pE6, DOI 10.1038/s41586 019 1394 x
   Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001
   Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008 5472.CAN 05 1522
   WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wright N, 2003, BLOOD, V102, P1978, DOI 10.1182/blood 2002 10 3190
   Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029
   Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366
   Yu VWC, 2015, J EXP MED, V212, P759, DOI 10.1084/jem.20141843
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhou BO, 2017, NAT CELL BIOL, V19, P891, DOI 10.1038/ncb3570
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 60
TC 6
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2020
VL 15
IS 5
AR e0233751
DI 10.1371/journal.pone.0233751
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA LU1WS
UT WOS:000537552800164
PM 32470079
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Watanabe, M
   Yahagi, T
   Shirayama, T
   Miyake, K
   Kotani, H
   Ogawa, T
   Matsuzaki, K
AF Watanabe, Misaki
   Yahagi, Tadahiro
   Shirayama, Takahiro
   Miyake, Katsunori
   Kotani, Hitoshi
   Ogawa, Takuya
   Matsuzaki, Keiichi
TI Effects of a Whole Plant Extract of Scutellaria rubropunctata
   var. rubropunctata on Bone Metabolism with Estrogen Receptor
   Activation
SO PLANTS BASEL
LA English
DT Article
DE estrogen receptor; osteoporosis; osteogenesis; Scutellaria rubropunctata
   var. rubropunctata
ID GROWTH FACTOR BETA; BAZEDOXIFENE/CONJUGATED ESTROGENS; OSTEOBLAST
   DIFFERENTIATION; COMPLEX; THERAPY; PHOSPHATASE; MODULATION; RALOXIFENE;
   FRACTURES; INDUCTION
AB We screened natural resources for estrogen receptor (ER) activating and bone metabolism promoting activities with the aim of finding potential treatments for osteoporosis. A screen of 1531 extracts from Ryukyu Arc plants using a luciferase reporter assay identified an 80% MeOH extract of Scutellaria rubropunctata var. rubropunctata (SRE) with dose dependent ER transcription promoting activity. Importantly, SRE had no proliferative effect on human breast cancer cells. SRE enhanced the ALP activity of pre osteoblast MC3T3 E1 cells after 72 h in culture and slightly enhanced mineralization at 14 and 21 d. SRE did not significantly affect the TRAP activity of RAW264.7 cells. Gene expression analysis in MC3T3 E1 cells by quantitative real time PCR revealed that SRE upregulated the mRNA levels of Runx2, Osterix (Osx), Osteopontin (Opn), Osteocalcin (Ocn), Smad1, Smad4, and Smad5 at 72 h, and those of Runx2, Osx, S mad1, Smad4, and Smad5 at 21 d of osteogenic induction. Analysis of the expression levels of osteogenic markers suggested that SRE may promote osteogenic differentiation by acting at the early stage of differentiation rather than at the late stage of differentiation. These results indicate that SRE activates ER and induces osteoblast differentiation by activating Runx2 and Osx through the BMP/Smad pathway, suggesting that SRE may be useful for the prevention and treatment of postmenopausal osteoporosis.
C1 [Watanabe, Misaki; Yahagi, Tadahiro; Shirayama, Takahiro; Matsuzaki, Keiichi] Nihon Univ, Sch Pharm, Lab Pharmacognosy, 7 7 1 Narashinodai, Funabashi, Chiba 2748555, Japan.
   [Miyake, Katsunori] Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432 1 Horinouchi, Hachioji, Tokyo 1920392, Japan.
   [Kotani, Hitoshi] Shimane Univ, Fac Med, 1060 Nishikawatsu cho, Matsue, Shimane 6908504, Japan.
   [Ogawa, Takuya] Int Univ Hlth & Welf, Sch Pharm, 2600 1 Kitakanemaru, Ohtawara, Tochigi 3248501, Japan.
C3 Nihon University; Tokyo University of Pharmacy & Life Sciences; Shimane
   University; International University of Health & Welfare
RP Yahagi, T; Matsuzaki, K (通讯作者)，Nihon Univ, Sch Pharm, Lab Pharmacognosy, 7 7 1 Narashinodai, Funabashi, Chiba 2748555, Japan.
EM yahagi.tadahiro@nihon u.ac.jp; matsuzaki.keiichi@nihon u.ac.jp
RI ; Ogawa, Takuya/JCE 2176 2023
OI Yahagi, Tadahiro/0000 0002 6373 4613; OGAWA, Takuya/0000 0001 9194 3079;
   Matsuzaki, Keiichi/0000 0002 4589 1981; Miyake,
   Katsunori/0000 0001 6199 8781
FU JSPS KAKENHI [JP18K14938, JP22K06670]; Grants in Aid for Scientific
   Research [22K06670] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI Grants (JP18K14938 and
   JP22K06670) and a grant for novel research project in the School of
   Pharmacy, Nihon University (2016).
CR Beral Valerie, 2003, Lancet, V362, P419
   Bitto A, 2008, BRIT J PHARMACOL, V155, P896, DOI 10.1038/bjp.2008.305
   Bodine PVN, 1998, ENDOCRINOLOGY, V139, P2048, DOI 10.1210/en.139.4.2048
   Bord S, 2001, BONE, V29, P216, DOI 10.1016/S8756 3282(01)00501 4
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burger HG, 2002, RECENT PROG HORM RES, V57, P257, DOI 10.1210/rp.57.1.257
   Cos P, 2003, PLANTA MED, V69, P589, DOI 10.1055/s 2003 41122
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fakhry Maya, 2013, World J Stem Cells, V5, P136, DOI 10.4252/wjsc.v5.i4.136
   FINKELMAN RD, 1992, P NATL ACAD SCI USA, V89, P12190, DOI 10.1073/pnas.89.24.12190
   GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003 4819 117 12 1016
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hannafon F, 2014, J GERONTOL NURS, V40, P10, DOI 10.3928/00989134 20140204 01
   Heino TJ, 2002, J CELL BIOCHEM, V85, P185, DOI 10.1002/jcb.10109
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   Kousteni S, 2007, MOL CELL BIOL, V27, P1516, DOI 10.1128/MCB.01550 06
   Krege JH, 2012, BONE, V50, P161, DOI 10.1016/j.bone.2011.10.018
   Lindsay R, 2009, FERTIL STERIL, V92, P1045, DOI 10.1016/j.fertnstert.2009.02.093
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Lobo RA, 2009, FERTIL STERIL, V92, P1025, DOI 10.1016/j.fertnstert.2009.03.113
   MAJESKA RJ, 1994, J BONE JOINT SURG AM, V76A, P713, DOI 10.2106/00004623 199405000 00013
   Moustakas A, 2001, J CELL SCI, V114, P4359
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Ohashi H., 2017, WILD FLOWERS JAPAN, V5
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   OURSLER MJ, 1991, ENDOCRINOLOGY, V129, P3313, DOI 10.1210/endo 129 6 3313
   OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304
   Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675
   Pickar JH, 2009, FERTIL STERIL, V92, P1018, DOI 10.1016/j.fertnstert.2009.05.094
   Pinkerton JV, 2009, MENOPAUSE, V16, P1116, DOI 10.1097/gme.0b013e3181a7df0d
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Rotem C, 2007, GYNECOL ENDOCRINOL, V23, P117, DOI 10.1080/09513590701200900
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Stovall DW, 2007, MENOPAUSE, V14, P510, DOI 10.1097/GME.0b013e318031a83d
   van Die MD, 2009, J ALTERN COMPLEM MED, V15, P853, DOI 10.1089/acm.2008.0447
   Wang ZL, 2018, PHARM BIOL, V56, P465, DOI 10.1080/13880209.2018.1492620
   Warren MP, 2009, MENOPAUSE, V16, P1083, DOI 10.1097/gme.0b013e3181baa9cc
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
NR 40
TC 2
Z9 2
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 2223 7747
J9 PLANTS BASEL
JI Plants Basel
PD AUG
PY 2022
VL 11
IS 16
AR 2075
DI 10.3390/plants11162075
PG 15
WC Plant Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences
GA 4B3YC
UT WOS:000845716300001
PM 36015379
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Kumar, P
   Gao, QH
   Ning, Y
   Wang, Z
   Krebsbach, PH
   Polverini, PJ
AF Kumar, Pawan
   Gao, Qinghong
   Ning, Yu
   Wang, Zhuo
   Krebsbach, Paul H.
   Polverini, Peter J.
TI Arsenic trioxide enhances the therapeutic efficacy of radiation
   treatment of oral squamous carcinoma while protecting bone
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID ACUTE PROMYELOCYTIC LEUKEMIA; ENDOTHELIAL GROWTH FACTOR; PROTEIN KINASE
   PATHWAY; IN VITRO; CELL APOPTOSIS; ACTIVATION; P38; CANCER;
   ANGIOGENESIS; AS2O3
AB Therapeutic radiation is commonly used in the treatment of squamous cell carcinoma of the oral cavity and pharynx. Despite the proven efficacy of this form of anticancer therapy, high dose radiation treatment is invariably associated with numerous unwanted side effects. This is particularly true for bone, in which radiation treatment often leads to osteoradionecrosis. The aim of this study was to investigate if treatment with arsenic trioxide (AS(2)O(3)) could enhance the antitumor effect of radiotherapy whereas minimizing the destructive effects of radiation on bone. As2O3 treatment induced a dose dependent (1 20 mu mol/L) inhibition of endothelial and tumor cell (OSCC 3 and UM SCC 74A) survival and significantly enhanced radiation induced endothelial cell and tumor cell death. In contrast, As2O3 treatment (0.5   7.5 mu mol/L) induced the proliferation of osteoblasts and also protected osteoblasts against radiation induced cell death. Furthermore, As2O3 treatment was able to significantly enhance radiation induced inhibition of endothelial cell tube formation and tumor cell colony formation. To test the effectiveness of As2O3 and radiation treatment in vivo, we used a severe combined immunodeficiency mouse model that has a bone ossicle and tumor growing side by side subcutaneously. Animals treated with As2O3 and radiation showed a significant inhibition of tumor growth, tumor angiogenesis, and tumor metastasis to the lungs as compared with As2O3 treatment or radiation treatment alone. In contrast, As2O3 treatment protected bone ossicles from radiation induced bone loss. These results suggest a novel strategy to enhance the therapeutic efficacy of radiation treatment while protecting bone from the adverse effects of therapeutic radiation.
C1 [Kumar, Pawan; Gao, Qinghong; Ning, Yu; Wang, Zhuo; Krebsbach, Paul H.; Polverini, Peter J.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Kumar, P (通讯作者)，Univ Michigan, Sch Dent, Dept Biol & Mat Sci, 1011 N Univ Ave,Room 5205, Ann Arbor, MI 48109 USA.
EM pksuri@umich.edu
RI Polverini, Peter/AAJ 8392 2020; gao, qing/LDG 6497 2024; Krebsbach,
   Paul/AAC 4765 2021; Kumar, Pawan/H 7777 2013
FU NCI NIH HHS [5 P50 CA097248] Funding Source: Medline
CR Agis H, 1999, ANN HEMATOL, V78, P329, DOI 10.1007/s002770050523
   Barchowsky A, 1999, TOXICOL APPL PHARM, V159, P65, DOI 10.1006/taap.1999.8723
   Chen GQ, 1997, BLOOD, V89, P3345
   Chen GQ, 1996, BLOOD, V88, P1052
   Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097 4652(199811)177:2<324::AID JCP14>3.0.CO;2 9
   Döbróssy L, 2005, CANCER METAST REV, V24, P9, DOI 10.1007/s10555 005 5044 4
   Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097 4644(20000901)78:3<476::AID JCB12>3.0.CO;2 5
   Gal TJ, 2000, ARCH OTOLARYNGOL, V126, P1124, DOI 10.1001/archotol.126.9.1124
   GREEN N, 1969, RADIOLOGY, V93, P635, DOI 10.1148/93.3.635
   Griffin RJ, 2005, INT J RADIAT ONCOL, V61, P1516, DOI 10.1016/j.ijrobp.2004.12.058
   Hayashi T, 2002, MOL CANCER THER, V1, P851
   HOWLAND WJ, 1975, RADIOLOGY, V117, P677, DOI 10.1148/117.3.677
   Jereczek Fossa BA, 2002, CANCER TREAT REV, V28, P65, DOI 10.1053/ctrv.2002.0254
   Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211
   Kao YH, 2003, CHEM RES TOXICOL, V16, P460, DOI 10.1021/tx025652a
   Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890 199704270 00003
   Kumar P, 2005, LAB INVEST, V85, P756, DOI 10.1038/labinvest.3700272
   Kumar P, 2004, J BIOL CHEM, V279, P43352, DOI 10.1074/jbc.M405777200
   Kumar P, 2007, CANCER RES, V67, P1193, DOI 10.1158/0008 5472.CAN 06 2265
   Lew YS, 1999, CANCER RES, V59, P6033
   Lowe LC, 2005, BIOCHEM BIOPH RES CO, V329, P772, DOI 10.1016/j.bbrc.2005.02.032
   Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6 suppl_2 22
   Nöth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014 4827(03)00386 0
   PROBERT JC, 1975, RADIOLOGY, V114, P155, DOI 10.1148/114.1.155
   Roboz GJ, 2000, BLOOD, V96, P1525, DOI 10.1182/blood.V96.4.1525.h8001525_1525_1530
   Schneider A, 2003, J ORTHOP RES, V21, P859, DOI 10.1016/S0736 0266(03)00042 1
   Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354
   Shim MJ, 2002, J BIOCHEM MOL BIOL, V35, P377
   Simeonova PP, 2002, J BIOL CHEM, V277, P2945, DOI 10.1074/jbc.M109136200
   Soucy NV, 2003, TOXICOL SCI, V76, P271, DOI 10.1093/toxsci/kfg231
   Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200
   Waxman S, 2001, ONCOLOGIST, V6, P3, DOI 10.1634/theoncologist.6 suppl_2 3
   Wu J, 2003, HORM METAB RES, V35, P751
   Zhu XH, 1999, J NATL CANCER I, V91, P772, DOI 10.1093/jnci/91.9.772
NR 34
TC 36
Z9 46
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2008
VL 7
IS 7
BP 2060
EP 2069
DI 10.1158/1535 7163.MCT 08 0287
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 330SW
UT WOS:000257964100033
PM 18645016
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, YL
   Chen, XY
   Xiong, YQ
   Xu, XQ
   Xie, CD
   Min, M
   Liang, DM
   Chen, C
   Mao, HJ
AF Li, Yalan
   Chen, Xiaoyue
   Xiong, Yiqing
   Xu, Xueqiang
   Xie, Caidie
   Min, Min
   Liang, Dongmei
   Chen, Cheng
   Mao, Huijuan
TI BRCC36 regulates β catenin ubiquitination to alleviate vascular
   calcification in chronic kidney disease
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Chronic kidney disease; Vascular calcification; Ubiquitin proteasome
   degradation; BRCC36; beta catenin
ID SMOOTH MUSCLE CELLS; OSTEOGENIC DIFFERENTIATION; PIOGLITAZONE
AB BackgroundThe prevalence of vascular calcification (VC) in chronic kidney disease (CKD) patients remains substantial, but currently, there are no effective pharmaceutical therapies available. BRCA1/BRCA2 containing complex subunit 36 (BRCC36) has been implicated in osteoblast osteogenic conversion; however, its specific role in VC remains to be fully elucidated. The aim of this study was to investigate the role and underlying mechanisms of BRCC36 in VC.MethodsThe association between BRCC36 expression and VC was examined in radial arteries from patients with CKD, high adenine induced CKD mice, and vascular smooth muscle cells (VSMCs). Western blotting, real time polymerase chain reaction, immunofluorescence, and immunohistochemistry were used to analyse gene expression. Gain  and loss of function experiments were performed to comprehensively investigate the effects of BRCC36 on VC. Coimmunoprecipitation and TOPFlash luciferase assays were utilized to further investigate the regulatory effects of BRCC36 on the Wnt/beta catenin pathway.ResultsBRCC36 expression was downregulated in human calcified radial arteries, calcified aortas from CKD mice, and calcified VSMCs. VSMC specific BRCC36 overexpression alleviated calcium deposition in the vasculature, whereas BRCC36 depletion aggravated VC progression. Furthermore, BRCC36 inhibited the osteogenic differentiation of VSMCs in vitro. Rescue experiments revealed that BRCC36 exerts the protective effects on VC partly by regulating the Wnt/beta catenin signalling pathway. Mechanistically, BRCC36 inhibited the Wnt/beta catenin pathway by decreasing the K63 linked ubiquitination of beta catenin. Additionally, pioglitazone attenuated VC partly through upregulating BRCC36 expression.ConclusionsOur research results emphasize the critical role of the BRCC36 beta catenin axis in VC, suggesting that BRCC36 or beta catenin may be promising therapeutic targets to prevent the progression of VC in CKD patients.
C1 [Li, Yalan; Chen, Xiaoyue; Xiong, Yiqing; Xu, Xueqiang; Min, Min; Liang, Dongmei; Mao, Huijuan] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Nephrol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
   [Chen, Cheng] Yangzhou Polytech Coll, Dept Med Sci, 458 West Wenchang Rd, Yangzhou 225009, Peoples R China.
   [Xie, Caidie] Nanjing Univ Chinese Med, Second Hosp Nanjing, Dept Gen Med, 1 1 Zhongfu Rd, Nanjing 210003, Peoples R China.
C3 Nanjing Medical University; Yangzhou Polytechnic Institute; Nanjing
   University of Chinese Medicine
RP Mao, HJ (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Nephrol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.; Chen, C (通讯作者)，Yangzhou Polytech Coll, Dept Med Sci, 458 West Wenchang Rd, Yangzhou 225009, Peoples R China.
EM yishixingtaicc@163.com; maohuijuan72@njmu.edu.cn
FU National Natural Science Foundation of China
FX Thanks to all participants involved in this research. The figures are
   created with www.BioRender.com.
CR Adelnia H, 2023, ACS NANO, V17, P18775, DOI 10.1021/acsnano.3c03041
   Aierken Y, 2024, CARDIOVASC DIABETOL, V23, DOI 10.1186/s12933 024 02224 z
   Al Huseini I, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007405
   Ballester Servera C, 2024, ANTIOXIDANTS BASEL, V13, DOI 10.3390/antiox13050523
   Cai LX, 2019, IRAN J BASIC MED SCI, V22, P173, DOI 10.22038/IJBMS.2018.29498.7123
   Chen JY, 2024, NAT COMMUN, V15, DOI 10.1038/s41467 024 44726 0
   Chen JY, 2022, AM J PHYSIOL LUNG C, V322, pL737, DOI 10.1152/ajplung.00447.2021
   Chen ZF, 2024, CELL COMMUN SIGNAL, V22, DOI 10.1186/s12964 024 01566 1
   Cui L, 2020, FREE RADICAL BIO MED, V161, P23, DOI 10.1016/j.freeradbiomed.2020.09.028
   Dawson J, 2018, CIRCULATION, V138, P1221, DOI 10.1161/CIRCULATIONAHA.118.036147
   Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097 2765(03)00424 6
   Gao HL, 2024, MOL CANCER, V23, DOI 10.1186/s12943 024 02005 y
   Gao M, 2017, MOL MED REP, V16, P6208, DOI 10.3892/mmr.2017.7308
   González Salvatierra S, 2023, CARDIOVASC DIABETOL, V22, DOI 10.1186/s12933 023 02043 8
   Górriz JL, 2015, CLIN J AM SOC NEPHRO, V10, P654, DOI 10.2215/CJN.07450714
   Han YC, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100483
   Hao QY, 2024, GUT MICROBES, V16, DOI 10.1080/19490976.2024.2351532
   Kim JS, 2023, CELL MOL IMMUNOL, V20, P189, DOI 10.1038/s41423 022 00971 1
   Lanzer P, 2021, J AM COLL CARDIOL, V78, P1145, DOI 10.1016/j.jacc.2021.06.049
   Lee J, 2024, DIABETES METAB J, V48, P83, DOI 10.4093/dmj.2022.0363
   Lee SH, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33202 2
   Legchenko E, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao0303
   Lin YB, 2024, CELL MOL BIOL LETT, V29, DOI 10.1186/s11658 024 00583 9
   Liu D, 2022, AUTOPHAGY, V18, P2001, DOI 10.1080/15548627.2022.2055286
   Liu JW, 2024, CANCER SCI, V115, P1196, DOI 10.1111/cas.16090
   Ma Q, 2022, CIRCULATION, V146, P1444, DOI 10.1161/CIRCULATIONAHA.121.058901
   Na JR, 2024, EBIOMEDICINE, V105, DOI 10.1016/j.ebiom.2024.105211
   Ouyang L, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146985
   Schunk SJ, 2021, NAT REV NEPHROL, V17, P172, DOI 10.1038/s41581 020 00343 w
   Shen H, 2024, CIRCULATION, V150, P132, DOI 10.1161/CIRCULATIONAHA.123.066430
   Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013
   Villa Bellosta R, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012423
   Walden M, 2019, NATURE, V570, P194, DOI 10.1038/s41586 019 1232 1
   Wang CR, 2023, NAT METAB, V5, P1765, DOI 10.1038/s42255 023 00883 y
   Wang HY, 2024, ADV SCI, V11, DOI 10.1002/advs.202304263
   Wang YD, 2024, CLIN TRANSL MED, V14, DOI 10.1002/ctm2.1754
   Wang ZX, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 29191 x
   Xie CD, 2022, EXP CELL RES, V413, DOI 10.1016/j.yexcr.2022.113051
   Xiong L, 2024, BONE RES, V12, DOI 10.1038/s41413 024 00335 7
   Xu PB, 2024, NATURE, V627, DOI 10.1038/s41586 024 07112 w
   Yalcinkaya M, 2023, CIRCULATION, V148, P1764, DOI 10.1161/CIRCULATIONAHA.123.065344
   Yang L, 2022, CIRC RES, V130, P213, DOI 10.1161/CIRCRESAHA.121.319745
   Ye YZ, 2022, KIDNEY INT, V102, P1259, DOI 10.1016/j.kint.2022.07.034
   Zhang HT, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.10909
   Zhang K, 2017, ARTERIOSCL THROM VAS, V37, P1933, DOI 10.1161/ATVBAHA.117.309161
   Zhang TT, 2025, J ADV RES, V68, P445, DOI 10.1016/j.jare.2024.02.020
NR 46
TC 2
Z9 3
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD SEP 3
PY 2024
VL 22
IS 1
AR 820
DI 10.1186/s12967 024 05605 w
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA E8P1S
UT WOS:001305555700001
PM 39227917
OA gold
DA 2025 08 17
ER

PT J
AU Niimi, H
   Ohsugi, Y
   Katagiri, S
   Watanabe, K
   Hatasa, M
   Shimohira, T
   Tsuchiya, Y
   Maekawa, S
   Hirota, T
   Kadokura, H
   Yokose, S
   Iwata, T
   Aoki, A
AF Niimi, Hiromi
   Ohsugi, Yujin
   Katagiri, Sayaka
   Watanabe, Kazuki
   Hatasa, Masahiro
   Shimohira, Tsuyoshi
   Tsuchiya, Yosuke
   Maekawa, Shogo
   Hirota, Tomomitsu
   Kadokura, Hiroshi
   Yokose, Satoshi
   Iwata, Takanori
   Aoki, Akira
TI Effects of Low Level Er:YAG Laser Irradiation on Proliferation and
   Calcification of Primary Osteoblast Like Cells Isolated From Rat
   Calvaria
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Er; YAG laser; osteoblast like cell; microarray; proliferation;
   calcification; gene expression
ID BONE NODULE FORMATION; LIGHT THERAPY LLLT; DIFFERENTIATION INVOLVEMENT;
   EXPRESSION; TRANSCRIPTION; PROTEINS; GENE; FREQUENCY; RUNX2; DLX5
AB Several reports have shown that the photo bio modulation of cells by various lasers has favorable biological effects. However, the effects of low level Er:YAG laser irradiation on osteoblasts remain unclear. The purpose of this study was to evaluate the effects of low level Er:YAG laser irradiation on proliferation and osteogenic differentiation of primary osteoblast like cells isolated from the calvariae of 3 5 day old Wistar rats. Cells were irradiated by Er:YAG laser at energy fluences of 2.2, 3.3, and 4.3 J/cm(2), respectively. After irradiation, cell surface temperatures were measured and cell proliferation was evaluated by flow cytometry and CCK 8. Calcification was evaluated by measuring areas of Alizarin red S staining after 7, 14, and 21 days culture in osteoinductive medium. Gene expression in non irradiated and laser irradiated cells was evaluated by qPCR at 3, 6, and 12 h, as well as 1, 3, 7, and 14 days after irradiation. Microarray analysis was performed to comprehensively evaluate the gene expression of non irradiated and irradiated cells at 3.3 J/cm(2)at 6 h after irradiation. No pronounced increase of cell surface temperature was induced by irradiation. Irradiation did not affect osteoblast like cell proliferation. Osteoblast like cell calcification was significantly increased 7 days after Er:YAG laser irradiation at 3.3 J/cm(2).Bglapexpression was significantly increased in cells irradiated at 3.3 J/cm(2)6 h post irradiation. Microarray analysis showed that irradiation at 3.3 J/cm(2)caused an upregulation of inflammation related genes and downregulation ofWisp2. Gene set enrichment analysis also clarified enrichment of inflammation related and Notch signaling gene sets. In conclusion, low level Er:YAG laser irradiation at 3.3 J/cm(2)enhanced calcification of primary osteoblast like cells via enhancedBglapexpression and enriched Notch signaling.
C1 [Niimi, Hiromi; Ohsugi, Yujin; Katagiri, Sayaka; Watanabe, Kazuki; Hatasa, Masahiro; Shimohira, Tsuyoshi; Tsuchiya, Yosuke; Maekawa, Shogo; Iwata, Takanori; Aoki, Akira] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Periodontol, Tokyo, Japan.
   [Hirota, Tomomitsu] Jikei Univ, Res Ctr Med Sci, Div Mol Genet, Sch Med, Tokyo, Japan.
   [Kadokura, Hiroshi; Yokose, Satoshi] Meikai Univ, Sch Dent, Dept Restorat & Biomat Sci, Div Endodont & Operat Dent, Saitama, Japan.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Jikei University; Meikai University
RP Katagiri, S; Aoki, A (通讯作者)，Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Periodontol, Tokyo, Japan.
EM katagiri.peri@tmd.ac.jp; aoperi@tmd.ac.jp
RI ; Maekawa, Shogo/AAX 6288 2021
OI MAEKAWA, SHOGO/0000 0002 6207 7826; Ohsugi, Yujin/0000 0002 2843 173X
FU Japan Society for the Promotion of Science [16K11825, 20K09971,
   17K11982, 19K18989, 20K18501]; Grants in Aid for Scientific Research
   [20K09971, 20K18501, 19K18989, 17K11982, 16K11825] Funding Source: KAKEN
FX This work was supported by the Japan Society for the Promotion of
   Science (16K11825 and 20K09971 to AA, 17K11982 to SK, 19K18989 to SM,
   and 20K18501 to YO).
CR Aleksic V, 2010, LASER MED SCI, V25, P559, DOI 10.1007/s10103 010 0761 5
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   ANISOWICZ A, 1991, J IMMUNOL, V147, P520
   Aoki A, 2015, PERIODONTOL 2000, V68, P217, DOI 10.1111/prd.12080
   Arisu HD, 2006, LASER MED SCI, V21, P175, DOI 10.1007/s10103 006 0398 6
   Avci P, 2013, SEMIN CUTAN MED SURG, V32, P41
   Carroll JD, 2014, DENT MATER, V30, P465, DOI 10.1016/j.dental.2014.02.006
   Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258
   Fukuhara E, 2006, CALCIFIED TISSUE INT, V79, P443, DOI 10.1007/s00223 006 0072 9
   Goto N, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8035759
   Grassi FR, 2011, J BIOL REG HOMEOS AG, V25, P603
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gu GL, 2006, CELL TISSUE RES, V323, P263, DOI 10.1007/s00441 005 0066 3
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274
   Jang H, 2012, PHOTOMED LASER SURG, V30, P405, DOI 10.1089/pho.2012.3240
   Kawaki H, 2011, BONE, V49, P975, DOI 10.1016/j.bone.2011.06.033
   Kawane T, 2014, J BONE MINER RES, V29, P1960, DOI 10.1002/jbmr.2240
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Komori T, 2020, MOL CELLS, V43, P168, DOI 10.14348/molcells.2019.0244
   Kong S, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700157
   Kumar A, 2013, J BIOMED MATER RES A, V101, P2925, DOI 10.1002/jbm.a.34603
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Lin GL, 2011, J CELL BIOCHEM, V112, P3491, DOI 10.1002/jcb.23287
   Liu BY, 2019, CELL TISSUE BANK, V20, P173, DOI 10.1007/s10561 019 09751 0
   Meller D, 2000, INVEST OPHTH VIS SCI, V41, P2922
   Mikami R, 2018, LASER SURG MED, V50, P340, DOI 10.1002/lsm.22775
   Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nassif A, 2014, BONE, V66, P96, DOI 10.1016/j.bone.2014.06.003
   Newberry EP, 1998, BIOCHEMISTRY US, V37, P16360, DOI 10.1021/bi981878u
   Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200
   Noda M, 2016, LASER SURG MED, V48, P955, DOI 10.1002/lsm.22560
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Ohsugi Y, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800245
   Ozawa Y, 1998, BONE, V22, P347, DOI 10.1016/S8756 3282(97)00294 9
   Pourzarandian A, 2004, PHOTOMED LASER SURG, V22, P342, DOI 10.1089/1549541041797913
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rizzi CF, 2006, LASER SURG MED, V38, P704, DOI 10.1002/lsm.20371
   Rosa N, 2015, MED ENG PHYS, V37, P719, DOI 10.1016/j.medengphy.2015.05.015
   Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681
   Shimizu N, 2007, LASER SURG MED, V39, P551, DOI 10.1002/lsm.20521
   Shimohira T., PHOTOBIOMOD PHOTOMED
   Shippy R, 2006, NAT BIOTECHNOL, V24, P1123, DOI 10.1038/nbt1241
   Shirakabe K, 2001, GENES CELLS, V6, P851, DOI 10.1046/j.1365 2443.2001.00466.x
   Stein A, 2005, PHOTOMED LASER SURG, V23, P161, DOI 10.1089/pho.2005.23.161
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Ueda Y, 2003, J CLIN LASER MED SUR, V21, P271, DOI 10.1089/104454703322564479
   Woodruff LD, 2004, PHOTOMED LASER SURG, V22, P241, DOI 10.1089/1549541041438623
   Yokose S, 1996, ENDOCRINOLOGY, V137, P469, DOI 10.1210/en.137.2.469
   Yokose S, 2013, J Bio Integ, V3, P53, DOI DOI 10.32176/BIOINTEG.3.1_53
NR 56
TC 25
Z9 26
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUN 23
PY 2020
VL 8
AR 459
DI 10.3389/fcell.2020.00459
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA MK3XY
UT WOS:000548717500001
PM 32656208
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Roviello, G
   Michelet, MRG
   D'Angelo, A
   Nobili, S
   Mini, E
AF Roviello, G.
   Michelet, M. R. Gatta
   D'Angelo, A.
   Nobili, S.
   Mini, E.
TI Role of novel hormonal therapies in the management of non metastatic
   castration resistant prostate cancer: a literature based meta analysis
   of randomized trials
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Prostate cancer; Enzalutamide; Apalutamide; Darolutamide
ID METASTASIS FREE SURVIVAL; BONE METASTASIS; ANDROGEN RECEPTOR; MEN;
   BICALUTAMIDE; GUIDELINES; DENOSUMAB; HISTORY; ANTIGEN; PHASE 3
AB Background Novel hormonal therapies have been recently investigated in non metastatic castration resistant prostate cancer (CRPC). We performed a meta analysis to assess the efficacy and safety of novel hormonal therapies in non metastatic CRPC. Materials and methods The primary outcome was metastasis free survival (MFS). The secondary endpoints were overall survival (OS), time to PSA progression and safety. We planned a subgroup analysis according to the PSA doubling time (> 6 vs < 6 months), Eastern Cooperative Oncology Group (ECOG) performance status (1 vs 0) and concomitant use of bone targeting agent (yes vs no). Results Pooled analysis of novel hormonal therapies revealed significantly increased MFS compared with placebo (hazard ratio (HR): HR = 0.32, 95% CI 0.25 0.41; p < 0.00001). The subgroup analysis showed a statistically significant MFS advantage in favour of men with the lower ECOG performance status. Other secondary endpoints favoured the novel hormonal therapies. The relative risk (RR) of grade >= 3 adverse events and >= 3 hypertension was 1.31 and 1.39, respectively. Conclusions This study confirmed the efficacy and safety of the novel hormonal therapies in non metastatic CRPC.
C1 [Roviello, G.; Nobili, S.; Mini, E.] Univ Florence, Dept Hlth Sci, Viale Pieraccini 6, I 50139 Florence, Italy.
   [Michelet, M. R. Gatta] Univ Florence, Sch Human Hlth Sci, Largo Brambilla 3, I 50134 Florence, Italy.
   [D'Angelo, A.] Univ Bath, Dept Biol & Biochem, Bath B2 7AY, Avon, England.
C3 University of Florence; University of Florence; University of Bath
RP Roviello, G (通讯作者)，Univ Florence, Dept Hlth Sci, Viale Pieraccini 6, I 50139 Florence, Italy.
EM giandomenicoroviello@hotmail.it
RI Nobili, Stefania/AAA 5917 2019; D'Angelo, Alberto/AAC 7434 2021;
   Roviello, Giandomenico/AAA 5310 2019
OI Roviello, Giandomenico/0000 0001 5504 8237; D'Angelo,
   Alberto/0000 0001 8417 9172; 
CR Afshar Mehran, 2015, Urol Oncol, V33, DOI 10.1016/j.urolonc.2015.05.003
   Anantharaman A, 2017, EXPERT REV ANTICANC, V17, P625, DOI 10.1080/14737140.2017.1333903
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197 2456(86)90046 2
   DINUNNO V, 2019, CLIN GENITOURIN CANC
   Esther J, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864 019 0611 z
   Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671
   Francini E, 2014, EXPERT REV ANTICANC, V14, P1135, DOI 10.1586/14737140.2014.949677
   Freedland SJ, 2012, UROLOGY, V80, P293, DOI 10.1016/j.urology.2012.04.007
   Higgins JPT, 2003, BMJ BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Horwich A, 2013, ANN ONCOL, V24, P1141, DOI 10.1093/annonc/mds624
   Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536
   Iacovelli R, 2015, EUR J CANCER, V51, P1970, DOI 10.1016/j.ejca.2015.06.106
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197 2456(95)00134 4
   Lodde M, 2010, UROLOGY, V76, P1189, DOI 10.1016/j.urology.2009.12.057
   Mason MD, 2007, JNCI J NATL CANCER I, V99, P765, DOI 10.1093/jnci/djk178
   Moher D, 2010, INT J SURG, V8, P336, DOI [10.1371/journal.pmed.1000097, 10.1186/2046 4053 4 1, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.i4086]
   Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Neppl Huber C, 2012, ANN ONCOL, V23, P1325, DOI 10.1093/annonc/mdr414
   Petrioli R, 2015, WORLD J CLIN ONCOL, V6, P99, DOI 10.5306/wjco.v6.i5.99
   Roviello G, 2018, MED ONCOL, V35, DOI 10.1007/s12032 018 1081 z
   Roviello G, 2016, EUR J CANCER, V61, P111, DOI 10.1016/j.ejca.2016.04.002
   Scher HI, 1997, J CLIN ONCOL, V15, P2928, DOI 10.1200/JCO.1997.15.8.2928
   Siegel RL, 2018, CA CANCER J CLIN, V68, P329, DOI 10.3322/caac.21460
   Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Smith MR, 2011, CANCER AM CANCER SOC, V117, P2077, DOI 10.1002/cncr.25762
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Suzuki H, 2008, J UROLOGY, V180, P921, DOI 10.1016/j.juro.2008.05.045
   Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Xie WL, 2017, J CLIN ONCOL, V35, P3097, DOI 10.1200/JCO.2017.73.9987
NR 34
TC 17
Z9 18
U1 0
U2 11
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 1699 048X
EI 1699 3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD JUL
PY 2020
VL 22
IS 7
BP 1033
EP 1039
DI 10.1007/s12094 019 02228 2
EA OCT 2019
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA MN9WJ
UT WOS:000490205600001
PM 31617061
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Qiu, S
   Wu, XA
   Geng, DC
   Pan, WZ
   Li, Z
   Wang, G
   Li, D
   Li, C
   Feng, S
   Zhu, L
   Xu, YZ
   Gao, FL
AF Qiu, Shang
   Wu, Xiunan
   Geng, Dechun
   Pan, Wenzhen
   Li, Zheng
   Wang, Gang
   Li, Daen
   Li, Cheng
   Feng, Shuo
   Zhu, Liang
   Xu, Yaozeng
   Gao, Fenglei
TI H2O2/NIR sensitive "two step" nano theranostic system based hollow
   mesoporous copper sulfide/hyaluronic acid/JWH133 as an optimally
   designed delivery system for multidimensional treatment of RA
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE RA; Cannabinoid receptors; Cannabinoid; Inflammation; Drug delivery
ID CANNABINOID RECEPTOR 2; FIBROBLAST LIKE SYNOVIOCYTES;
   RHEUMATOID ARTHRITIS; SYNOVIAL FIBROBLASTS; BONE; CB2; INFLAMMATION;
   EXPRESSION; CELL
AB Cannabinoid receptors are widely distributed in many cells in Rheumatoid arthritis RA and strengthening factor to boost the development of RA diseases. Here, the hollow mesoporous copper sulfide (CuS) was used as the carrier skeleton and the cannabinoid type 2 (CB2) receptor agonist JWH133 was efficiently loaded inside of CuS through adsorption, then the outer layer was modified with hyaluronic acid (HA) to prevent the leakage of in ternal drugs. After the CuS JWH133@HA nano carrier reached the target area, HA responsive cracked under RA microenvironment to realize the first step of accurate drug delivery of JWH133, and the thermally responsive CuS under near infrared (NIR) promoted the release of internal drugs. Then, JWH133 specifically combined CB2 receptors on the surface of macrophage, synovial cells and osteoblasts to realize the second step of drug delivery. The inflammatory factors secreted by cells are significantly inhibited, and the activity of osteoblasts was significantly enhanced. Therapeutic effect by CuS JWH133@HA of RA was well verified by decreasing levels of inflammation in vivo and improvement of inflamed and swollen joints of mice. The CuS JWH133@HA nano  composite showed satisfactory multidimensional therapeutic effect of RA in vitro and in vivo, which provided a novel idea for RA treatment.
C1 [Qiu, Shang; Wu, Xiunan; Li, Zheng; Wang, Gang; Li, Daen; Gao, Fenglei] Xuzhou Med Univ, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou 221002, Jiangsu, Peoples R China.
   [Qiu, Shang; Li, Cheng; Feng, Shuo; Zhu, Liang] Xuzhou Med Univ, Dept Orthoped, Affiliated Hosp, Xuzhou 221002, Jiangsu, Peoples R China.
   [Geng, Dechun; Xu, Yaozeng] Soochow Univ, Dept Orthopaed, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
   [Pan, Wenzhen] Pingyin Peoples Hosp, Dept Orthoped, Jinan 250000, Shandong, Peoples R China.
C3 Xuzhou Medical University; Xuzhou Medical University; Soochow University
     China
RP Gao, FL (通讯作者)，Xuzhou Med Univ, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou 221002, Jiangsu, Peoples R China.
EM jsxzgfl@sina.com
RI wu, xiunan/KZU 6761 2024; Geng, Dechun/LMO 1733 2024
OI Gao, Fenglei/0000 0002 9367 8368; Li, Zheng/0009 0002 0564 2371; 
FU Jiangsu Outstanding Youth Fund [BK20220062]; Youth Medical Science and
   Technology Innovation Project of Xuzhou Health Commission
   [XWKYHT20210577]; Key University Science Research Project of Jiangsu
   Province [21KJA350003]; Priority Academic Program Development of Jiangsu
   Higher Education Institutions (PAPD); Special Project of Diagnosis and
   Treatment Technology for Key Clinical Dis eases in Suzhou [LCZX20200];
   Development Foundation of Xuzhou Medical University [XYFY2021001];
   Xuzhou Science and Technology Project [KC19019]
FX The authors gratefully acknowledge financial support from the Jiangsu
   Outstanding Youth Fund (BK20220062) , Youth Medical Science and
   Technology Innovation Project of Xuzhou Health Commission
   (XWKYHT20210577) , Key University Science Research Project of Jiangsu
   Province (21KJA350003) , the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD) , Special Project of
   Diagnosis and Treatment Technology for Key Clinical Dis eases in Suzhou
   (LCZX20200) , Development Foundation of Xuzhou Medical University
   (XYFY2021001) , Xuzhou Science and Technology Project (KC19019) .
CR Bai JX, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109025
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Baumann H, 1998, AM J PATHOL, V152, P641
   Boutet MA, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102758
   Bryk M, 2021, PHARMACOL REP, V73, P681, DOI 10.1007/s43440 021 00270 y
   Butoescu N, 2009, EUR J PHARM BIOPHARM, V73, P205, DOI 10.1016/j.ejpb.2009.06.009
   Cassano D, 2018, BIOCONJUGATE CHEM, V29, P4, DOI 10.1021/acs.bioconjchem.7b00664
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Choi KY, 2019, ADV MATER, V31, DOI 10.1002/adma.201803549
   Deane KD, 2021, ARTHRITIS RHEUMATOL, V73, P181, DOI 10.1002/art.41417
   Ding DD, 2022, ADV SCI, V9, DOI 10.1002/advs.202200974
   England BR, 2021, ANN RHEUM DIS, V80, P286, DOI 10.1136/annrheumdis 2020 218282
   Fechtner S, 2019, CLIN EXP RHEUMATOL, V37, P1026
   Fechtner S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01027
   Feng QH, 2017, ACTA BIOMATER, V49, P402, DOI 10.1016/j.actbio.2016.11.035
   Fraher D, 2021, MOL CELL ENDOCRINOL, V529, DOI 10.1016/j.mce.2021.111267
   Fukuda S, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 275
   González Naranjo P, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115672
   Gouveia VM, 2018, NANOMEDICINE UK, V13, P1037, DOI 10.2217/nnm 2017 0377
   Gui H, 2015, IMMUNOBIOLOGY, V220, P817, DOI 10.1016/j.imbio.2014.12.012
   Gui H, 2014, RHEUMATOLOGY, V53, P802, DOI 10.1093/rheumatology/ket447
   Hashiesh HM, 2021, EUR J PHARMACOL, V909, DOI 10.1016/j.ejphar.2021.174398
   Heinemann JC, 2015, LIFE SCI, V138, P18, DOI 10.1016/j.lfs.2014.11.027
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hou L, 2017, ACTA BIOMATER, V54, P307, DOI 10.1016/j.actbio.2017.03.005
   Huang RQ, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121088
   Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968 0896(99)00219 9
   Ichise Y, 2020, CELLS BASEL, V9, DOI 10.3390/cells9071689
   Ilchovska D, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102741
   Li Q, 2019, ACS APPL MATER INTER, V11, P417, DOI 10.1021/acsami.8b19667
   Lowin T, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 02892 1
   Madzovska Malagurski I, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/3/035015
   Mateen S, 2016, CLIN CHIM ACTA, V455, P161, DOI 10.1016/j.cca.2016.02.010
   Mitragotri S, 2011, ARCH PHARM RES, V34, P1887, DOI 10.1007/s12272 011 1109 9
   Mor A, 2005, CLIN IMMUNOL, V115, P118, DOI 10.1016/j.clim.2004.12.009
   Mura S, 2013, NAT MATER, V12, P991, DOI [10.1038/NMAT3776, 10.1038/nmat3776]
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Pandey S, 2018, PHARM RES DORDR, V35, DOI 10.1007/s11095 018 2478 2
   Qi JC, 2022, COLLOID SURFACE B, V212, DOI 10.1016/j.colsurfb.2022.112339
   Rajesh M, 2008, BRIT J PHARMACOL, V153, P347, DOI 10.1038/sj.bjp.0707569
   Mesa XMR, 2021, CANNABIS CANNABINOID, V6, P196, DOI 10.1089/can.2020.0183
   Schett G, 2021, NAT REV RHEUMATOL, V17, P135, DOI 10.1038/s41584 020 00543 5
   Shimozono S, 2013, NATURE, V496, P363, DOI 10.1038/nature12037
   Suto T, 2022, RHEUMATOLOGY, V61, P4535, DOI 10.1093/rheumatology/keac124
   Timmen M., 2020, SCI REP UK, V10, P1
   Tobeiha M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6910312
   Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Tortora C, 2020, J PEDIATR GASTR NUTR, V71, P633, DOI 10.1097/MPG.0000000000002863
   Uemura Y., 2015, JAP J CLIN PATH, V63, P1357
   Wang P, 2021, BIOACT MATER, V6, P916, DOI 10.1016/j.bioactmat.2020.09.017
   Wang Q, 2016, J CONTROL RELEASE, V230, P64, DOI 10.1016/j.jconrel.2016.03.035
   Yang XZ, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12854
   Yuan F, 2012, ADV DRUG DELIVER REV, V64, P1205, DOI 10.1016/j.addr.2012.03.006
   Yuan YH, 2019, J MATER SCI TECHNOL, V35, P2727, DOI 10.1016/j.jmst.2019.04.028
   Zhang MZ, 2021, J COLLOID INTERF SCI, V594, P493, DOI 10.1016/j.jcis.2021.03.050
   Zhang X, 2019, ACS NANO, V13, P5306, DOI 10.1021/acsnano.8b09786
   Zhao QM, 2019, J MATER CHEM B, V7, P2284, DOI 10.1039/c8tb03377c
   Zhou W, 2021, ACS OMEGA, V6, P6861, DOI 10.1021/acsomega.0c06057
NR 59
TC 11
Z9 12
U1 3
U2 43
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD JAN 15
PY 2023
VL 225
BP 298
EP 309
DI 10.1016/j.ijbiomac.2022.11.019
EA DEC 2022
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 7Z8RT
UT WOS:000915821000001
PM 36372104
DA 2025 08 17
ER

PT J
AU Zeng, L
   Wu, GZ
   Goh, KJ
   Lee, YM
   Ng, CC
   Ben You, A
   Wang, JH
   Jia, DY
   Hao, AJ
   Yu, Q
   Li, BJ
AF Zeng, Li
   Wu, Guang Zhi
   Goh, Kim Jee
   Lee, Yew Mun
   Ng, Chuo Chung
   Ben You, Ang
   Wang, Jianhe
   Jia, Deyong
   Hao, Aijun
   Yu, Qiang
   Li, Baojie
TI Saturated Fatty Acids Modulate Cell Response to DNA Damage: Implication
   for Their Role in Tumorigenesis
SO PLOS ONE
LA English
DT Article
AB DNA damage triggers a network of signaling events that leads to cell cycle arrest or apoptosis. This DNA damage response acts as a mechanism to prevent cancer development. It has been reported that fatty acids (FAs) synthesis is increased in many human tumors while inhibition of fatty acid synthase (FASN) could suppress tumor growth. Here we report that saturated fatty acids (SFAs) play a negative role in DNA damage response. Palmitic acid, as well as stearic acid and myristic acid, compromised the induction of p21 and Bax expression in response to double stranded breaks and ssDNA, while inhibition or knockdown of FASN enhanced these cellular events. SFAs appeared to regulate p21 and Bax expression via Atr p53 dependent and independent pathways. These effects were only observed in primary mouse embryonic fibroblasts and osteoblasts, but not in immortalized murine NIH3T3, or transformed HCT116 and MCF 7 cell lines. Accordingly, SFAs showed some positive effects on proliferation of MEFs in response to DNA damage. These results suggest that SFAs, by negatively regulating the DNA damage response pathway, might promote cell transformation, and that increased synthesis of SFAs in precancer/cancer cells might contribute to tumor progression and drug resistance.
C1 [Zeng, Li; Wu, Guang Zhi; Goh, Kim Jee; Lee, Yew Mun; Ng, Chuo Chung; Ben You, Ang; Wang, Jianhe; Li, Baojie] Natl Univ Singapore, Inst Mol & Cell Biol, Canc & Dev Biol Div, Singapore 117548, Singapore.
   [Wu, Guang Zhi] Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China.
   [Jia, Deyong; Hao, Aijun] Shandong Univ, Fac Med, Key Lab Expt Teratol, Minist Educ, Jinan, Peoples R China.
   [Yu, Qiang] Genome Inst Singapore, Lab Mol Pharmacol, Singapore, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR   Institute of
   Molecular & Cell Biology (IMCB); National University of Singapore; Jilin
   University; Shandong University; Agency for Science Technology &
   Research (A*STAR); A*STAR   Genome Institute of Singapore (GIS)
RP Zeng, L (通讯作者)，Natl Univ Singapore, Inst Mol & Cell Biol, Canc & Dev Biol Div, 10 Kent Ridge Crescent, Singapore 117548, Singapore.
EM libj@imcb.a star.edu.sg
RI ; Lee, Yew Mun/G 8891 2017; Jia, Deyong/GQP 9611 2022
OI Jia, Deyong/0000 0003 2034 0363; Yu, Qiang/0000 0003 2132 8278; Lee, Yew
   Mun/0000 0002 8360 7689; 
FU Agency for Science, Technology, and Research, Signapore; Ministry of
   Education, China [NCET 04 0624]
FX The study was supported by Agency for Science, Technology, and Research,
   Signapore (BL) and New Century Excellent Talents Program in University
   (NCET 04 0624), Ministry of Education, China (AH).
CR Aja S, 2008, AM J PHYSIOL REG I, V294, pR352, DOI 10.1152/ajpregu.00862.2006
   Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268
   Beeharry N, 2003, MUTAT RES FUND MOL M, V530, P27, DOI 10.1016/S0027 5107(03)00134 9
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Chajès V, 2006, CANCER RES, V66, P5287, DOI 10.1158/0008 5472.CAN 05 1489
   CHALBOS D, 1987, J BIOL CHEM, V262, P9923
   Dowell P, 2005, ANNU REV BIOCHEM, V74, P515, DOI 10.1146/annurev.biochem.73.011303.074027
   Fraser DA, 1999, RHEUMATOLOGY, V38, P948, DOI 10.1093/rheumatology/38.10.948
   Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485
   Greaves J, 2007, J CELL BIOL, V176, P249, DOI 10.1083/jcb.200610151
   Grishko V, 2005, FREE RADICAL BIO MED, V38, P755, DOI 10.1016/j.freeradbiomed.2004.11.023
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092 8674(00)81683 9
   Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   Key T, 2007, BRIT MED J, V335, P897, DOI 10.1136/bmj.39373.676204.BE
   Kiffmeyer T, 2007, Cancer Treat Res, V134, P275
   KLEIN S, 1992, AM J PHYSIOL, V262, pE631, DOI 10.1152/ajpendo.1992.262.5.E631
   Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008 5472.CAN 05 4673
   KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379
   Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897
   Li BJ, 2004, GENE DEV, V18, P1824, DOI 10.1101/gad.1223504
   Li JN, 2001, CANCER RES, V61, P1493
   Malhotra V, 2003, CANCER BIOL THER, V2, pS2
   MEDES G, 1953, CANCER RES, V13, P27
   Menendez JA, 2004, MOL CARCINOGEN, V41, P164, DOI 10.1002/mc.20054
   Menendez JA, 2004, INT J ONCOL, V24, P591
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Ogino S, 2007, HUM PATHOL, V38, P842, DOI 10.1016/j.humpath.2006.11.018
   Pandian SS, 1999, J ROY COLL SURG EDIN, V44, P352
   Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704
   Pizer ES, 1996, CANCER RES, V56, P745
   Prentice RL, 2007, JNCI J NATL CANCER I, V99, P1534, DOI 10.1093/jnci/djm159
   Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555
   Schmid B, 2005, BIOCHEM BIOPH RES CO, V328, P1073, DOI 10.1016/j.bbrc.2005.01.067
   Slade RF, 2003, ANTICANCER RES, V23, P1235
   Van de Sande T, 2002, CANCER RES, V62, P642
   vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023
   Walley AJ, 2006, HUM MOL GENET, V15, pR124, DOI 10.1093/hmg/ddl215
   Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712
   Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600
   Zeng L, 2005, J BIOL CHEM, V280, P29374, DOI 10.1074/jbc.M503016200
   Zhang XH, 2007, J CELL SCI, V120, P4134, DOI 10.1242/jcs.015834
   Zhou WB, 2003, CANCER RES, V63, P7330
NR 43
TC 61
Z9 63
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2008
VL 3
IS 6
AR e2329
DI 10.1371/journal.pone.0002329
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 396TO
UT WOS:000262614300024
PM 18523653
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Nahleh, Z
   Abrams, J
   Bhargaval, A
   Nirmal, K
   Graff, JJ
AF Nahleh, Zeina
   Abrams, Judith
   Bhargaval, Ashish
   Nirmal, Kavita
   Graff, John J.
TI Outcome of Patients With Early Breast Cancer Receiving
   Nitrogen Containing Bisphosphonates: A Comparative Analysis From the
   Metropolitan Detroit Cancer Surveillance System
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Alendronate; Ibandronate; MDCSS; Risedronate
ID ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; ADJUVANT CLODRONATE; BONE LOSS;
   FOLLOW UP; METASTASES; INHIBITION; MECHANISMS; REDUCTION; APOPTOSIS
AB Background: Preclinical data suggest that bisphosphonates exhibit antitumor activity. However, clinical studies indicated conflicting results. In this study, we compared the overall survival (OS) of postmenopausal patients with non metastatic invasive breast cancer who received any of the second generation nitrogen containing bisphosphonates for osteopenia or osteoporosis, with the survival of those who did not. Patients and Methods: We conducted a retrospective study at the Wayne State University/Karmanos Cancer institute (KCI) in Detroit, Michigan and extracted data from the Metropolitan Detroit Cancer Surveillance System (MDCSS), a Surveillance, Epidemiology and End Results (SEER) registry. Patients > 50 years of age with stage I, II, or III invasive breast cancer between the years 2000 through 2003 were included. Information regarding medications was extracted from the patients' medical records. Results: A total of 696 women with stage I Ill breast cancer were included. Ninety seven women (14%) used nitrogen containing bisphosphonates. The difference in OS between bisphosphonate users and nonusers was not statistically significant (P = .32) at 3 years. Alter adjusting for differences between the groups in age, stage of disease, hormone receptor status, endocrine therapy, vitamin D, and calcium use, there was a marginally significant (P = .07) difference in survival; bisphosphonate users had poorer survival than nonusers. Conclusion: Our results indicate that the use of nitrogen containing bisphosptionates is not associated with improved OS in patients with nonmetastatic breast cancer, even after adjusting for known prognostic factors, but with a marginally worse OS. Further research is awaited to clarify the role of bisphosphonates in the adjuvant setting.
C1 [Nahleh, Zeina] Wayne State Univ, Karmanos Canc Inst, Div Hematol Oncol, Breast Oncol Multidisciplinary Team,Sch Med, Detroit, MI 48201 USA.
   [Abrams, Judith] Wayne State Univ, Sch Med, Ctr Urban & African Amer Hlth, Detroit, MI 48201 USA.
   [Bhargaval, Ashish] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA.
   [Graff, John J.] Wayne State Univ, Karmanos Canc Inst, Dept Family Med, Epidemiol Sect,Sch Med, Detroit, MI 48201 USA.
C3 Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne
   State University; Wayne State University; Wayne State University;
   Barbara Ann Karmanos Cancer Institute
RP Nahleh, Z (通讯作者)，Wayne State Univ, Karmanos Canc Inst, Div Hematol Oncol, Breast Oncol Multidisciplinary Team,Sch Med, 4100 John R,4HWCRC, Detroit, MI 48201 USA.
EM nahlehz@karmanos.org
FU NCI NIH HHS [HHSN261201000028C] Funding Source: Medline
CR Brufsky AM, 2009, CLIN BREAST CANCER, V9, P77, DOI 10.3816/CBC.2009.n.015
   Bundred NJ, 2008, CANCER AM CANCER SOC, V112, P1001, DOI 10.1002/cncr.23259
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   EIDTMANN H, 2008, 31 ANN SAN ANT BREAS
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Ha TC, 2007, BRIT J CANCER, V96, P1796, DOI 10.1038/sj.bjc.6603661
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Park IH, 2009, BMC CANCER, V9, DOI 10.1186/1471 2407 9 154
   Paterson AHG, 2005, ACTA ONCOL, V44, P80, DOI 10.1080/02841860410002879
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saarto T, 2004, ACTA ONCOL, V43, P650, DOI 10.1080/02841860410032885
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Schenk N, 2007, EJC SUPPL, V5, P186, DOI 10.1016/S1359 6349(07)70770 X
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SMITH I, 2009, 32 ANN SAN ANT BREAS
   VANHOLTENVERZAN.NI, 1997, MEDICINA B AIRES, V57, P109
   vanHoltenVerzantvoort ATM, 1996, EUR J CANCER, V32A, P450, DOI 10.1016/0959 8049(95)00564 1
NR 23
TC 1
Z9 1
U1 0
U2 4
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1526 8209
EI 1938 0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD DEC
PY 2010
VL 10
IS 6
BP 459
EP 464
DI 10.3816/CBC.2010.n.060
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 689GP
UT WOS:000284915800006
PM 21147689
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Rahmanian, M
   Seyfoori, A
   Dehghan, MM
   Eini, L
   Naghib, SM
   Gholami, H
   Mohajeri, SF
   Mamaghani, KR
   Majidzadeh A, K
AF Rahmanian, Mehdi
   Seyfoori, Amir
   Dehghan, Mohammad Mehdi
   Eini, Leila
   Naghib, Seyed Morteza
   Gholami, Hossein
   Mohajeri, Saeed Farzad
   Mamaghani, Kaveh Rahimi
   Majidzadeh A, Keivan
TI Multifunctional gelatin tricalcium phosphate porous nanocomposite
   scaffolds for tissue engineering and local drug delivery: In
   vitro and in vivo studies
SO JOURNAL OF THE TAIWAN INSTITUTE OF CHEMICAL ENGINEERS
LA English
DT Article
DE Nanocomposite; Cancer; Drug loaded scaffold; Tissue engineering; Bone
   metastatic tumor
ID BIOMIMETIC COMPOSITE SCAFFOLD; NANOSTRUCTURED MONTICELLITE; BONE;
   HYDROXYAPATITE; CYTOTOXICITY; FORMALDEHYDE; NANOFIBERS; RELEASE
AB Bone is known as the most prevalent, metastatic site of breast cancer; however, it's mechanism details are unknown, so developing a suitable scaffold for bone defect regeneration and sustain drug release after tumor resection can considerably inhibit the tumor recurrence after a while. Here, synthesized gelatin/beta tricalcium phosphate (beta TCP) nanocomposite scaffold loaded with zoledronic acid (ZA) drug with different beta TCP concentrations, crosslinker and varying drug doses were investigated to highlight their effect on biological properties of the scaffold contained bone cells. The scanning electron microscopy (SEM) illustrated porous structure (50 200 mu m) of gelatin reinforced with beta TCP spherical nanoparticles (around 90 nm diameter) that could be a proper matrix for bone cells proliferation. In vitro biological analysis by cytotoxicity assay (MTT test) as well as osteoblast cell line (G292) attachment test showed that the scaffolds were biocompatible and non toxic. Also, higher beta TCP nanoparticle concentration enhanced the rate of cell proliferation on the scaffold. Further investigations indicated that the type of cell seeding into porous scaffolds should be considered as a significant parameter in cell behavior on the scaffold. The better cell attachment was observed in agarose gel wells in comparison with the petri dish one. Nanocomposite samples were loaded with ZA drug and its effects on the cell proliferation were investigated in vitro and in vivo as well. Histopathological results showed that the new bone formation was established more than 75% in the whole area of the defect after 3 and 4 months. For the first time, nanoscaled beta TCP/gelatin composite was proposed as a potential for controlled drug release and local resected tumor treatment. All findings besides in vitro and in vivo analyses, recommend gelatin/nano beta tricalcium phosphate/drug scaffolds as a promising three dimensional environment for repairing the resected bone tissue in primary or metastatic bone sites. (C) 2019 Taiwan Institute of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
C1 [Rahmanian, Mehdi; Seyfoori, Amir; Eini, Leila; Naghib, Seyed Morteza; Majidzadeh A, Keivan] ACECR, Motamed Canc Inst, Breast Canc Res Ctr, Biomat & Tissue Engn Dept, Tehran, Iran.
   [Dehghan, Mohammad Mehdi] Univ Tehran, Fac Vet Med, Dept Surg & Radiol, Tehran, Iran.
   [Naghib, Seyed Morteza; Mamaghani, Kaveh Rahimi] IUST, Sch Adv Technol, Nanotechnol Dept, POB 16846 13114, Tehran, Iran.
   [Gholami, Hossein; Mohajeri, Saeed Farzad] Univ Tehran, Inst Biomed Res, Tehran, Iran.
C3 Academic Center for Education, Culture & Research (ACECR); University of
   Tehran; Iran University Science & Technology; University of Tehran
RP Majidzadeh A, K (通讯作者)，ACECR, Motamed Canc Inst, Breast Canc Res Ctr, Biomat & Tissue Engn Dept, Tehran, Iran.
EM kmajidzadeh@mrcjd.ac.ir
RI ; gholami, Hossein/AAA 3788 2022; Dehghan, Mohammad Mehdi/D 4670 2009;
   Naghib, Seyed/S 8817 2018; Farzad Mohajeri, Saeed/AAE 4062 2019;
   Seyfoori, Amir/AAH 6657 2019; Rahimi Mamaghani, Kaveh/IUP 0463 2023
OI Majidzadeh A, Keivan/0000 0002 8811 0997; Naghib, Seyed
   Morteza/0000 0003 4612 030X; Farzad Mohajeri, Saeed/0000 0003 4694 347X;
   Seyfoori, Amir/0000 0001 7745 2396; Rahimi Mamaghani,
   Kaveh/0000 0002 0012 0331; Aminianfar, Hossein/0000 0001 7858 1798; 
CR Andrade Renato, 2016, J Exp Orthop, V3, P31
   Bakhtiari L, 2010, CERAM INT, V36, P2421, DOI 10.1016/j.ceramint.2010.07.012
   Belfrage O, 2012, BMC MUSCULOSKEL DIS, V13, P1
   Ben David D, 2011, J CRANIO MAXILL SURG, V39, P364, DOI 10.1016/j.jcms.2010.09.001
   Chen P, 2019, MAT SCI ENG C MATER, V97, P325, DOI 10.1016/j.msec.2018.12.027
   Dudas JR, 2006, ANN PLAS SURG, V56, P543, DOI 10.1097/01.sap.0000210629.17727.bd
   Fu YT, 2015, BONE, V78, P15, DOI 10.1016/j.bone.2015.04.034
   Gong T, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.29
   Gooneh Farahani S, 2019, EXPERT OPIN DRUG DEL, V16, P79, DOI 10.1080/17425247.2019.1556257
   Hu M, 2018, J TAIWAN INST CHEM E, V85, P91, DOI 10.1016/j.jtice.2017.12.021
   Huang L, 2018, J TAIWAN INST CHEM E, V83, P184, DOI 10.1016/j.jtice.2017.12.006
   Kalantari E, 2019, MAT SCI ENG C MATER, V98, P1087, DOI 10.1016/j.msec.2018.12.140
   Kalantari E, 2018, CERAM INT, V44, P14704, DOI 10.1016/j.ceramint.2018.05.098
   Kalantari E, 2018, CERAM INT, V44, P12731, DOI 10.1016/j.ceramint.2018.04.076
   Kalantari E, 2017, J SOL GEL SCI TECHN, V84, P87, DOI 10.1007/s10971 017 4461 5
   Kalkhoran AHZ, 2018, BIOMED PHYS ENG EXPR, V4, DOI 10.1088/2057 1976/aad745
   Kalkhoran AHZ, 2018, EUR J PHARM SCI, V111, P303, DOI 10.1016/j.ejps.2017.09.038
   Kebede MA, 2018, J TAIWAN INST CHEM E, V92, P91, DOI 10.1016/j.jtice.2018.01.034
   Koshkaki MR, 2013, IRAN POLYM J, V22, P653, DOI 10.1007/s13726 013 0164 0
   Kuttappan S, 2016, INT J BIOL MACROMOL, V93, P1390, DOI 10.1016/j.ijbiomac.2016.06.043
   Lin FH, 1998, BIOMATERIALS, V19, P905, DOI 10.1016/S0142 9612(97)00202 0
   Liu DH, 2019, CHEM ENG J, V362, P269, DOI 10.1016/j.cej.2019.01.015
   Ozturk OH, 2007, CELL BIOL INT, V31, P1069, DOI 10.1016/j.cellbi.2007.02.004
   Pathi SP, 2011, BIOMATERIALS, V32, P5112, DOI 10.1016/j.biomaterials.2011.03.055
   Rahmanian M, 2017, J CERAM SCI TECHNOL, V8, P505, DOI 10.4416/JCST2017 00029
   Roseti L, 2017, MAT SCI ENG C MATER, V78, P1246, DOI 10.1016/j.msec.2017.05.017
   Serra IR, 2015, MAT SCI ENG C MATER, V55, P592, DOI 10.1016/j.msec.2015.05.072
   Seyfoori A, 2019, J TAIWAN INST CHEM E, V96, P503, DOI 10.1016/j.jtice.2018.10.018
   Sharifi E, 2016, MAT SCI ENG C MATER, V59, P533, DOI 10.1016/j.msec.2015.09.037
   Sobral JM, 2011, ACTA BIOMATER, V7, P1009, DOI 10.1016/j.actbio.2010.11.003
   Teotia AK, 2016, ACS APPL MATER INTER, V8, P10775, DOI 10.1021/acsami.6b02145
   Wendt D, 2003, BIOTECHNOL BIOENG, V84, P205, DOI 10.1002/bit.10759
   Yang YY, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aa87f2
   Zhang XH, 2012, MATER LETT, V73, P172, DOI 10.1016/j.matlet.2012.01.049
   Zhu W, 2015, ACTA BIOMATER, V14, P164, DOI 10.1016/j.actbio.2014.12.008
NR 35
TC 31
Z9 32
U1 1
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1876 1070
EI 1876 1089
J9 J TAIWAN INST CHEM E
JI J. Taiwan Inst. Chem. Eng.
PD AUG
PY 2019
VL 101
BP 214
EP 220
DI 10.1016/j.jtice.2019.04.028
PG 7
WC Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA IG5KA
UT WOS:000473840800021
DA 2025 08 17
ER

PT J
AU Karanxha, L
   Park, SJ
   Son, WJ
   Nör, JE
   Min, KS
AF Karanxha, Lorena
   Park, Su Jung
   Son, Won Jun
   Nor, Jacques E.
   Min, Kyung San
TI Combined Effects of Simvastatin and Enamel Matrix Derivative on
   Odontoblastic Differentiation of Human Dental Pulp Cells
SO JOURNAL OF ENDODONTICS
LA English
DT Article
DE Combination; enamel matrix derivative; extracellular signal regulated
   kinase; simvastatin; odontoblastic
ID OSTEOBLASTIC DIFFERENTIATION; TOOTH DEVELOPMENT; BONE FORMATION;
   STEM CELLS; IN VITRO; EXPRESSION; PROTEINS; SIALOPHOSPHOPROTEIN;
   PROLIFERATION; OSTEOGENESIS
AB Introduction: We previously reported that simvastatin and enamel matrix derivative (EMD) have a dentinogenic effect. However, there is little information about the combined effects of these 2 agents on odontoblastic differentiation. The aim of this study was to investigate the effects of combined treatment with simvastatin and EMD on odontoblastic differentiation of human dental pulp cells (hDPCs). This study further explored the role of extracellular signal regulated kinase (ERK) as a target and mediator of the differentiation induced by simvastatin in hDPCs. Methods: The odontoblastic differentiation was analyzed by alkaline phosphatase activity, real time polymerase chain reaction (PCR) for odontoblastic/osteoblastic markers (ie, dentin sialophosphoprotein, dentin matrix protein 1, and osteonectin), and alizarin red S staining. We also explored the role of ERK signaling as a mediator of simvastatin by Western blotting and real time PCR. The expression of osteoblast specific transcription factors was detected by reverse transcription PCR. Results: The alkaline phosphatase activity and the expression of odontoblastic markers (ie, dentin sialophosphoprotein and dentin matrix protein 1) increased in simvastatin/EMD treated cells. Mineralized nodule formation increased in EMD  and simvastatin/EMD treated cells. Notably, the combined use of both simvastatin and EMD resulted in more potent differentiation than that observed after a single therapy. Simvastatin activated ERK phosphorylation and treatment with ERK inhibitor blocked the messenger RNA expression of odontoblastic markers. However, in simvastatin/EMD treated cells, the expression of these genes did not decrease significantly. Compared with other groups, the EMD  and simvastatin/EMD treated group showed a greater expression of osterix. Conclusions: Simvastatin promotes odontoblastic differentiation of hDPCs via the ERK signaling pathway. In addition, simvastatin induced differentiation is facilitated by co treatment with EMD. Collectively, these results suggest a new strategy to induce odontoblastic differentiation of hDPCs. (J Endod 2013;39:76 82)
C1 [Karanxha, Lorena; Park, Su Jung] Wonkwang Univ, Sch Dent, Dept Conservat Dent, Iksan, South Korea.
   [Son, Won Jun] Seoul Natl Univ, Sch Dent, Dept Conservat Dent, Seoul, South Korea.
   [Nor, Jacques E.] Univ Michigan, Sch Dent, Dept Cariol Restorat Sci Endodont, Angiogenesis Res Lab, Ann Arbor, MI 48109 USA.
   [Nor, Jacques E.] Univ Michigan, Coll Engn, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Nor, Jacques E.] Univ Michigan, Sch Med, Dept Otolaryngol, Ann Arbor, MI USA.
   [Min, Kyung San] Chonbuk Natl Univ, Sch Dent, Dept Conservat Dent, Jeonju 562756, South Korea.
C3 Wonkwang University; Seoul National University (SNU); University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; Jeonbuk National University
RP Min, KS (通讯作者)，Chonbuk Natl Univ, Sch Dent, Dept Conservat Dent, 664 14 Deokjin, Jeonju 562756, South Korea.
EM endomin@gmail.com
RI ; Min, Kyung San/ABC 3852 2020; Nor, Jacques/AAJ 6139 2021
OI Min, Kyung San/0000 0002 1928 3384; 
FU Basic Science Research Program though the National Research Foundation
   of Korea (NRF); Ministry of Education, Science and Technology
   [2011 0013825]; National Institute of Dental and Craniofacial Research
   [R01DE021410] Funding Source: NIH RePORTER
FX Supported by Basic Science Research Program though the National Research
   Foundation of Korea (NRF) funded by the Ministry of Education, Science
   and Technology (no. 2011 0013825).
CR Baek KH, 2005, J KOREAN MED SCI, V20, P438, DOI 10.3346/jkms.2005.20.3.438
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Chen S, 2009, J DENT RES, V88, P904, DOI 10.1177/0022034509342873
   D'Souza RN, 1999, DEVELOPMENT, V126, P2911
   DSOUZA RN, 1995, J DENT RES, V74, P702, DOI 10.1177/00220345950740021301
   Gestrelius S, 2000, Clin Oral Investig, V4, P120, DOI 10.1007/s007840050127
   Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P658, DOI 10.1111/j.1600 051X.1997.tb00247.x
   Hargreaves KM, 2011, PATHWAYS PULP, P604
   Heijl L, 1997, J CLIN PERIODONTOL, V24, P705, DOI 10.1111/j.1600 051X.1997.tb00253.x
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Jepsen S, 1997, J ENDODONT, V23, P378, DOI 10.1016/S0099 2399(97)80187 2
   Jiang SY, 2011, CELL PROLIFERAT, V44, P372, DOI 10.1111/j.1365 2184.2011.00762.x
   Kim IS, 2011, J PERIODONTAL RES, V46, P204, DOI 10.1111/j.1600 0765.2010.01329.x
   Kim SH, 2007, J BIOMED MATER RES A, V80A, P826, DOI 10.1002/jbm.a.30945
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lai EHH, 2012, J ENDODONT, V38, P757, DOI 10.1016/j.joen.2012.02.023
   Lee SY, 2012, J ENDODONT, V38, P405, DOI 10.1016/j.joen.2011.12.025
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   Lu YB, 2007, DEV BIOL, V303, P191, DOI 10.1016/j.ydbio.2006.11.001
   Min KS, 2008, ORAL SURG ORAL MED O, V105, P654, DOI 10.1016/j.tripleo.2007.11.011
   Min KS, 2010, J ENDODONT, V36, P447, DOI 10.1016/j.joen.2009.11.021
   Min KS, 2009, J ENDODONT, V35, P847, DOI 10.1016/j.joen.2009.03.014
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Nakamura Y, 2004, CALCIFIED TISSUE INT, V75, P243, DOI 10.1007/s00223 003 0153 y
   Nakamura Y, 2002, INT ENDOD J, V35, P407, DOI 10.1046/j.1365 2591.2002.00556.x
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nakashima M, 2005, J ENDODONT, V31, P711, DOI 10.1097/01.don.0000164138.49923.e5
   Narukawa M, 2007, ACTA BIOCH BIOPH SIN, V39, P1, DOI 10.1111/j.1745 7270.2007.00250.x
   Okamoto Y, 2009, J ENDODONT, V35, P367, DOI 10.1016/j.joen.2008.11.024
   Papagerakis P, 2002, BONE, V30, P377, DOI 10.1016/S8756 3282(01)00683 4
   Pelaez D, 2012, BIOCHEM BIOPH RES CO, V417, P1286, DOI 10.1016/j.bbrc.2011.12.131
   SCHRODER U, 1985, J DENT RES, V64, P541, DOI 10.1177/002203458506400407
   Song CL, 2003, BIOCHEM BIOPH RES CO, V308, P458, DOI 10.1016/S0006 291X(03)01408 6
   Suzuki S, 2012, ARCH ORAL BIOL, V57, P1165, DOI 10.1016/j.archoralbio.2012.03.005
   Weishaupt P, 2008, ORAL SURG ORAL MED O, V106, P304, DOI 10.1016/j.tripleo.2008.02.033
NR 35
TC 41
Z9 43
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0099 2399
EI 1878 3554
J9 J ENDODONT
JI J. Endod.
PD JAN
PY 2013
VL 39
IS 1
BP 76
EP 82
DI 10.1016/j.joen.2012.10.013
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 068PO
UT WOS:000313378900014
PM 23228261
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhang, WL
   Rong, HR
   Liang, JG
   Mao, C
   Li, ZC
   Dai, ZW
   Li, DB
   Guo, WX
   Chen, SY
   Wang, ZW
   Wei, JS
AF Zhang, Weilin
   Rong, Hongrui
   Liang, Jinguo
   Mao, Chao
   Li, Zhencong
   Dai, Zhiwen
   Li, Dingbin
   Guo, Weixiong
   Chen, Siyuan
   Wang, Zhongwei
   Wei, Jinsong
TI Chitosan modified with PAP as a promising delivery system for melatonin
   in the treatment of osteoporosis: targeting the divalent metal
   transporter 1
SO JOURNAL OF BIOLOGICAL ENGINEERING
LA English
DT Article
DE Osteoporosis; Melatonin; Chitosan
ID HYDROGEL; BONE; DMT1; SKIN
AB The demands for novel and efficient therapies have gradually increased with the rising concerns of osteoporosis (OP). The most popular method in promoting bone regeneration during osteoporotic conditions consists of loading bioactive materials with different drugs to treat osteoporotic bones by either promoting the process of osteogenesis, or by inhibiting the activity of osteoclasts. By analyzing single cell sequencing results, we found that divalent metal transporter 1 (DMT1) played a role in OP. Based on our previous results, we found that melatonin (MT) suppressed expression of DMT1 induced by high glucose during OP, so we determined the efficacy of MT for the treatment of OP. However, the clinical effects of MT on OP were unsatisfactory. To enhance its biological efficacy, we combined MT with porous gelatin chitosan (chitosan) and the conductive material, PLA b AP b PLA (PAP), then determined how MT incorporation in chitosan@PAP nanoparticles affected the ability to promote MC3T3 E1 osteogenesis and mineralization, both in vitro and in vivo. The results confirmed the effect of MT on DMT1. We then prepared and characterized composites prepared as nanofibers, and determined the efficacy of MT combined with chitosan PAP modified hydrogels as a slow release system in a femur model of osteoporosis mice, with associated properties suitable for bone tissue engineering. The results indicated that MT loaded chitosan@PAP nanospheres showed favorable osteogenic functions, both in vivo and in vitro, providing a practical solution for bone regeneration for OP patients.
C1 [Zhang, Weilin; Rong, Hongrui; Liang, Jinguo; Mao, Chao; Li, Zhencong; Dai, Zhiwen; Li, Dingbin; Guo, Weixiong; Chen, Siyuan; Wang, Zhongwei; Wei, Jinsong] Guangdong Med Univ, Dept Spinal Degenerat & Deform Surg, Affiliated Hosp, Zhanjiang 524001, Peoples R China.
C3 Guangdong Medical University
RP Wang, ZW; Wei, JS (通讯作者)，Guangdong Med Univ, Dept Spinal Degenerat & Deform Surg, Affiliated Hosp, Zhanjiang 524001, Peoples R China.
EM zhongwei.wang@gdmu.edu.cn; jinsong.wei@gdmu.edu.cn
RI Li, Zhencong/JAI 9720 2023; CHEN, SIYUAN/GVT 4628 2022; Liang,
   Jinguo/KQU 1798 2024
FU Project initiated by high level talent research in Affiliated Hospital
   of Guangdong Medical University [GCC2022007, GCC2022044]
FX This research was funded by the Project initiated by high level talent
   research in Affiliated Hospital of Guangdong Medical University (NO.
   GCC2022007 and NO. GCC2022044).
CR Abourehab MAS, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810975
   Amstrup AK, 2013, OSTEOPOROSIS INT, V24, P2919, DOI 10.1007/s00198 013 2404 8
   Arendt J, 2007, J PINEAL RES, V43, P106, DOI 10.1111/j.1600 079X.2007.00457.x
   Balagangadharan K, 2017, INT J BIOL MACROMOL, V104, P1372, DOI 10.1016/j.ijbiomac.2016.12.046
   Cipolla Neto J, 2018, ENDOCR REV, V39, P990, DOI 10.1210/er.2018 00084
   Da W, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00667
   Di WL, 1997, NEW ENGL J MED, V336, P1028, DOI 10.1056/NEJM199704033361418
   Gyanewali S, 2021, INT J PHARMACEUT, V608, DOI 10.1016/j.ijpharm.2021.121060
   Huang RY, 2020, J ORAL IMPLANTOL, V46, P562, DOI 10.1563/aaid joi D 19 00208
   Ignjatovic N, 2016, MAT SCI ENG C MATER, V60, P357, DOI 10.1016/j.msec.2015.11.061
   Johnston CB, 2020, MED CLIN N AM, V104, P873, DOI 10.1016/j.mcna.2020.06.004
   Kendler DL, 2021, J BONE ONCOL, V28, DOI 10.1016/j.jbo.2021.100361
   Kikwai L, 2002, J CONTROL RELEASE, V83, P307, DOI 10.1016/S0168 3659(02)00202 X
   Lalanne S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031490
   Lampropoulou Adamidou K, 2014, J ORTHOP RES, V32, P1646, DOI 10.1002/jor.22712
   Lane JM, 2000, CLIN ORTHOP RELAT R, P139
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lei C, 2023, BIOMATERIALS, V296, DOI 10.1016/j.biomaterials.2023.122066
   Li DW, 2020, BIOMATER SCI UK, V8, P3138, DOI 10.1039/d0bm00376j
   Li T, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12548
   Liu F, 2017, INT J MED SCI, V14, P275, DOI 10.7150/ijms.17860
   Ma HD, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/9067610
   Middleton JC, 2000, BIOMATERIALS, V21, P2335, DOI 10.1016/S0142 9612(00)00101 0
   Norouzi M, 2016, DRUG DISCOV TODAY, V21, P1835, DOI 10.1016/j.drudis.2016.07.006
   Oryan A, 2017, INT J BIOL MACROMOL, V104, P1003, DOI 10.1016/j.ijbiomac.2017.06.124
   Othman SI, 2021, INT J BIOL MACROMOL, V190, P417, DOI 10.1016/j.ijbiomac.2021.08.154
   Parajuli D, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14163433
   Pearson RG, 2011, OSTEOARTHR CARTILAGE, V19, P324, DOI 10.1016/j.joca.2010.12.005
   Sui BD, 2017, THERANOSTICS, V7, P1225, DOI 10.7150/thno.18181
   Wang XD, 2019, MOL MED, V25, DOI 10.1186/s10020 019 0107 0
   Wright NC, 2014, J BONE MINER RES, V29, P2520, DOI 10.1002/jbmr.2269
   Yu P, 2021, J CONTROL RELEASE, V338, P486, DOI 10.1016/j.jconrel.2021.08.056
   Zhang WL, 2015, INT J MED SCI, V12, P441, DOI 10.7150/ijms.11986
   Zhu M, 2021, OSTEOPOROSIS INT, V32, P2493, DOI 10.1007/s00198 021 06024 z
NR 34
TC 4
Z9 4
U1 4
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754 1611
J9 J BIOL ENG
JI J. Biol. Eng.
PD APR 15
PY 2024
VL 18
IS 1
AR 27
DI 10.1186/s13036 024 00422 7
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA NT0F0
UT WOS:001202579700001
PM 38622739
OA gold
DA 2025 08 17
ER

PT J
AU Khan, AA
   Bilezikian, JP
   Brandi, ML
   Clarke, BL
   Gittoes, NJ
   Pasieka, JL
   Rejnmark, L
   Shoback, DM
   Potts, JT
   Guyatt, GH
   Mannstadt, M
AF Khan, Aliya A.
   Bilezikian, John P.
   Brandi, Maria Luisa
   Clarke, Bart L.
   Gittoes, Neil J.
   Pasieka, Janice L.
   Rejnmark, Lars
   Shoback, Dolores M.
   Potts, John T.
   Guyatt, Gordon H.
   Mannstadt, Michael
TI Evaluation and Management of Hypoparathyroidism Summary Statement and
   Guidelines from the Second International Workshop
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PTH; VIT D; FGF23; CELL; TISSUE SIGNALING ENDOCRINE PATHWAYS;
   PARATHYROID RELATED DISORDERS; DISORDERS OF CALCIUM; PHOSPHATE
   METABOLISM
ID QUALITY OF LIFE; CALCIUM SENSING RECEPTOR; PARATHYROID HORMONE 1 34;
   BASAL GANGLIA CALCIFICATION; BONE MINERAL DENSITY; VITAMIN D DEFICIENCY;
   LONG TERM TREATMENT; FOLLOW UP; POSTSURGICAL HYPOPARATHYROIDISM;
   IDIOPATHIC HYPOPARATHYROIDISM
AB This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence based recommendations. The HypoPT task forces included four teams with a total of 50 international experts including representatives from the sponsoring societies. A methodologist (GG) and his team supported the taskforces and conducted the systematic reviews. A formal process following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and the systematic reviews provided the structure for seven of the guideline recommendations. The task force used a less structured approach based on narrative reviews for 20 non GRADEd recommendations. Clinicians may consider postsurgical HypoPT permanent if it persists for >12 months after surgery. To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total thyroidectomy (strong recommendation, moderate quality evidence). PTH > 10 pg/mL (1.05 pmol/L) virtually excludes long term HypoPT. In individuals with nonsurgical HypoPT, genetic testing may be helpful in the presence of a positive family history of nonsurgical HypoPT, in the presence of syndromic features, or in individuals younger than 40 years. HypoPT can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataracts, seizures, cardiac arrhythmias, ischemic heart disease, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory indices. In patients with chronic HypoPT, the panel suggests conventional therapy with calcium and active vitamin D metabolites as first line therapy (weak recommendation, low quality evidence). When conventional therapy is deemed unsatisfactory, the panel considers the use of PTH. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Khan, Aliya A.] McMaster Univ, Dept Med, Div Endocrinol & Metab, Hamilton, ON, Canada.
   [Bilezikian, John P.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA.
   [Brandi, Maria Luisa] FIRMO Fdn, Florence, Italy.
   [Clarke, Bart L.] Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN USA.
   [Gittoes, Neil J.] Queen Elizabeth Hosp, Ctr Endocrinol Diabet & Metab, Birmingham, England.
   [Pasieka, Janice L.] Univ Calgary, Cumming Sch Med, Dept Surg & Oncol, Calgary, AB, Canada.
   [Rejnmark, Lars] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark.
   [Shoback, Dolores M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA USA.
   [Potts, John T.; Mannstadt, Michael] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA.
   [Potts, John T.; Mannstadt, Michael] Harvard Med Sch, Boston, MA USA.
   [Guyatt, Gordon H.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
C3 McMaster University; Columbia University; Mayo Clinic; University of
   Birmingham; University of Calgary; Aarhus University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA
   Medical Center; University of California System; University of
   California San Francisco; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   Medical School; McMaster University
RP Khan, AA (通讯作者)，McMaster Univ, Div Endocrinol & Metab, Dept Med, Hamilton, ON L8S 4L8, Canada.
EM aliya@mcmaster.ca
RI Guyatt, Gordon/ACB 1302 2022; Mannstadt, Michael/AAO 1124 2020
OI Pasieka, Janice L/0000 0003 2753 4988
FU Takeda; Amolyt; Ascendis; Calcilytix
FX We acknowledge unrestricted financial support from Amolyt, Ascendis,
   Calcilytix, and Takeda. They had no input into the planning or design of
   the project, the conduct of the reviews, evaluation of the data, or the
   writing or review of themanuscript, its contents, conclusions, or
   recommendations contained herein.
CR ABUGASSA S, 1993, J CLIN ENDOCR METAB, V76, P1617, DOI 10.1210/jc.76.6.1617
   ACETO T, 1966, J CLIN ENDOCR METAB, V26, P487, DOI 10.1210/jcem 26 5 487
   Aggarwal S, 2013, EUR J ENDOCRINOL, V168, P895, DOI 10.1530/EJE 12 0946
   Al Azem H, 2012, BEST PRACT RES CL EN, V26, P517, DOI 10.1016/j.beem.2012.01.004
   Alikasifoglu A, 2005, CLIN PEDIATR, V44, P267, DOI 10.1177/000992280504400312
   Allas S., 2021, J ENDOCR SOC, V5, pA254, DOI [10.1210/jendso/bvab048.516, DOI 10.1210/JENDSO/BVAB048.516, 10.1210/JENDSO/BVAB048.516]
   Almquist M, 2018, BRIT J SURG, V105, P1313, DOI 10.1002/bjs.10843
   Ardawi MSM, 1997, EUR J ENDOCRINOL, V137, P402, DOI 10.1530/eje.0.1370402
   Arlt W, 2002, EUR J ENDOCRINOL, V146, P215, DOI 10.1530/eje.0.1460215
   Astor MC, 2016, J CLIN ENDOCR METAB, V101, P3045, DOI 10.1210/jc.2016 1477
   Barczynski M, 2007, LANGENBECK ARCH SURG, V392, P693, DOI 10.1007/s00423 007 0165 6
   Bjornsdottir S, 2022, J BONE MINER RES, V37, P2602, DOI 10.1002/jbmr.4675
   Bollerslev J, 2021, ANN ENDOCRINOL PARIS, V82, P151, DOI 10.1016/j.ando.2020.02.003
   Bollerslev J, 2015, EUR J ENDOCRINOL, V173, pEG1, DOI 10.1530/EJE 15 0628
   Brandi ML, 2016, J CLIN ENDOCR METAB, V101, P2273, DOI 10.1210/jc.2015 3907
   Brod M, 2021, QUAL LIFE RES, V30, P277, DOI 10.1007/s11136 020 02607 1
   Brod M, 2020, PATIENT, V13, P151, DOI 10.1007/s40271 019 00388 5
   BRONSKY D, 1968, PEDIATRICS, V42, P606
   Brown EM, 2009, ENDOCRIN METAB CLIN, V38, P437, DOI 10.1016/j.ecl.2009.01.001
   Brown Spandana J, 2017, Methodist Debakey Cardiovasc J, V13, P49, DOI 10.14797/mdcj 13 2 49
   Büttner M, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa597
   Bulloch Marilyn N, 2012, J Pharm Pract, V25, P352, DOI 10.1177/0897190012442070
   BUNCE GE, 1990, ANNU REV NUTR, V10, P233, DOI 10.1146/annurev.nu.10.070190.001313
   CAPLAN RH, 1993, J REPROD MED, V38, P914
   Carr AA, 2014, J AM COLL SURGEONS, V219, P757, DOI 10.1016/j.jamcollsurg.2014.06.003
   Cayo AK, 2012, SURGERY, V152, P1059, DOI 10.1016/j.surg.2012.08.030
   Chawla H, 2017, J CLIN ENDOCR METAB, V102, P251, DOI 10.1210/jc.2016 3292
   Chen K, 2019, J MED ECON, V22, P1141, DOI 10.1080/13696998.2019.1624081
   Chen QX, 2003, J CLIN ENDOCR METAB, V88, P4655, DOI 10.1210/jc.2003 030470
   CHOPRA D, 1978, J CLIN ENDOCR METAB, V46, P869, DOI 10.1210/jcem 46 6 869
   Clarke BL, 2017, ENDOCRINE, V55, P282, DOI 10.1007/s12020 016 1141 0
   Cusano NE, 2019, CURR OPIN RHEUMATOL, V31, P381, DOI 10.1097/BOR.0000000000000618
   Cusano NE, 2014, J CLIN ENDOCR METAB, V99, P3694, DOI 10.1210/jc.2014 2267
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P2356, DOI 10.1210/jc.2013 1239
   DAHLMAN T, 1994, ACTA OBSTET GYN SCAN, V73, P393, DOI 10.3109/00016349409006250
   Demirel N, 2009, ANN TROP PAEDIATR, V29, P149, DOI 10.1179/146532809X440770
   Donzuso G, 2019, NEUROL SCI, V40, P2251, DOI 10.1007/s10072 019 03998 x
   EASTELL R, 1985, BRIT MED J, V291, P955, DOI 10.1136/bmj.291.6500.955
   FORMAN MB, 1980, CLIN ENDOCRINOL, V12, P385, DOI 10.1111/j.1365 2265.1980.tb02725.x
   FUJIYAMA K, 1995, J CLIN ENDOCR METAB, V80, P2135, DOI 10.1210/jc.80.7.2135
   Gafni RI., 2021, J ENDOCR SOC, V5, pA269, DOI [10.1210/jendso/bvab048.545, DOI 10.1210/JENDSO/BVAB048.545]
   Gosmanova EO, 2021, ADV THER, V38, P1876, DOI 10.1007/s12325 021 01658 1
   Gosmanova EO, 2021, REV ENDOCR METAB DIS, V22, P297, DOI 10.1007/s11154 020 09613 1
   Goswami R, 2004, EUR J ENDOCRINOL, V150, P9, DOI 10.1530/eje.0.1500009
   Goswami R, 2012, CLIN ENDOCRINOL, V77, P200, DOI 10.1111/j.1365 2265.2012.04353.x
   Habibullah M, 2018, J IMMUNOL, V201, P3175, DOI 10.4049/jimmunol.1701527
   Hadker N, 2014, ENDOCR PRACT, V20, P671, DOI 10.4158/EP13328.OR
   Hartogsohn EAR, 2020, CLIN ENDOCRINOL, V93, P261, DOI 10.1111/cen.14212
   Hatswell B L, 2015, Bone Rep, V3, P15, DOI 10.1016/j.bonr.2015.05.005
   Hepsen S, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00759 8
   Holten Andersen L, 2019, J BONE MINER RES, V34, P2075, DOI 10.1002/jbmr.3824
   Hough TA, 2004, P NATL ACAD SCI USA, V101, P13566, DOI 10.1073/pnas.0405516101
   Husebye ES, 2018, NEW ENGL J MED, V378, P1132, DOI 10.1056/NEJMra1713301
   IRELAND AW, 1968, ARCH INTERN MED, V122, P408, DOI 10.1001/archinte.122.5.408
   Ish Shalom S, 2021, J BONE MINER RES, V36, P1060, DOI 10.1002/jbmr.4274
   Karpf DB, 2020, J BONE MINER RES, V35, P1430, DOI 10.1002/jbmr.4016
   Khan A. A., 2018, PRIMER METABOLIC BON, P173, DOI [10.1002/9781119266594.ch23, DOI 10.1002/9781119266594.CH23]
   Khan AA., 2022, J BONE MINER RES, DOI [DOI 10.1002/JBMR.4716, 10.1002/jbmr.4716]
   Khan A, 2015, EUR J ENDOCRINOL, V172, P527, DOI 10.1530/EJE 14 0877
   Khan AA, 2023, J BONE MINER RES, V38, P14, DOI 10.1002/jbmr.4726
   Khan AA, 2022, J CLIN ENDOCR METAB, V107, pE372, DOI 10.1210/clinem/dgab577
   Khan AA, 2021, ENDOCRINE, V72, P553, DOI 10.1007/s12020 021 02629 w
   Khan AA, 2019, EUR J ENDOCRINOL, V180, pP1, DOI 10.1530/EJE 18 0609
   Khan AA, 2019, EUR J ENDOCRINOL, V180, pR37, DOI 10.1530/EJE 18 0541
   Kim SH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232842
   Kim SM, 2015, THYROID, V25, P830, DOI 10.1089/thy.2014.0500
   Kovacs CS, 2016, PHYSIOL REV, V96, P449, DOI 10.1152/physrev.00027.2015
   Lecerf P, 2012, SURGERY, V152, P863, DOI 10.1016/j.surg.2012.03.011
   Leidig Bruckner G, 2016, HORM METAB RES, V48, P806, DOI 10.1055/s 0042 118181
   Levy I, 2015, J CLIN ENDOCR METAB, V100, P4106, DOI 10.1210/jc.2015 2257
   Li YX, 1996, J CLIN INVEST, V97, P910, DOI 10.1172/JCI118513
   Linglart A, 2011, J CLIN ENDOCR METAB, V96, P3308, DOI 10.1210/jc.2011 1359
   Lopes MP, 2016, ARCH ENDOCRIN METAB, V60, P532, DOI 10.1590/2359 3997000000221
   Mannstadt M., 2022, J BONE MINER RES, DOI [10.1002/jbmr.4667, DOI 10.1002/JBMR.4667]
   Mannstadt M, 2019, J CLIN ENDOCR METAB, V104, P5133, DOI 10.1210/jc.2019 01010
   Mannstadt M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.55
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Martin S, 2019, ADV THER, V36, P1999, DOI 10.1007/s12325 019 00999 2
   Matarazzo P, 2014, J PEDIATR ENDOCR MET, V27, P53, DOI 10.1515/jpem 2013 0159
   Mendonça ML, 2013, BMC ENDOCR DISORD, V13, DOI 10.1186/1472 6823 13 1
   Meola A, 2018, J ENDOCRINOL INVEST, V41, P1221, DOI 10.1007/s40618 018 0857 5
   MIHARA M, 1995, INTERNAL MED, V34, P666, DOI 10.2169/internalmedicine.34.666
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   Modi S, 2014, EUR J ENDOCRINOL, V170, P777, DOI 10.1530/EJE 14 0075
   MORI S, 1992, INTERNAL MED, V31, P820, DOI 10.2169/internalmedicine.31.820
   Noda H, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10367
   Palermo A, 2018, J CLIN ENDOCR METAB, V103, P271, DOI 10.1210/jc.2017 01555
   Pasieka JL., 2022, JBMR
   Phillips CG, 2008, J NEUROSCI, V28, P12062, DOI 10.1523/JNEUROSCI.4134 08.2008
   Piranavan P, 2019, J CLIN ENDOCR METAB, V104, P550, DOI 10.1210/jc.2018 01151
   de León Ballesteros GP, 2019, WORLD J SURG, V43, P1728, DOI 10.1007/s00268 019 04987 z
   Puliani G, 2021, J CLIN ENDOCR METAB, V106, pE2215, DOI 10.1210/clinem/dgab038
   Raue F, 2011, CLIN ENDOCRINOL, V75, P760, DOI 10.1111/j.1365 2265.2011.04142.x
   Roberts MS, 2019, J BONE MINER RES, V34, P1609, DOI 10.1002/jbmr.3747
   Rubin MR, 2016, J CLIN ENDOCR METAB, V101, P2742, DOI 10.1210/jc.2015 4135
   Rubin MR, 2010, BONE, V46, P190, DOI 10.1016/j.bone.2009.09.020
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   Saha S, 2017, J BONE MINER METAB, V35, P405, DOI 10.1007/s00774 016 0767 6
   Sakane EN, 2019, J CLIN ENDOCR METAB, V104, P5795, DOI 10.1210/jc.2019 00698
   Santonati A, 2015, J CLIN ENDOCR METAB, V100, P3590, DOI 10.1210/jc.2015 1855
   Saraff V, 2018, HORM RES PAEDIAT, V89, P271, DOI 10.1159/000479867
   Schnatz PF, 2002, OBSTET GYNECOL SURV, V57, P365, DOI 10.1097/00006254 200206000 00022
   Seely EW, 1997, AM J OBSTET GYNECOL, V176, P214, DOI 10.1016/S0002 9378(97)80039 7
   SEEMAN E, 1982, J CLIN INVEST, V69, P1302, DOI 10.1172/JCI110570
   SEKI K, 1991, AM J OBSTET GYNECOL, V164, P1248, DOI 10.1016/0002 9378(91)90694 M
   Shani H, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.092
   Shimizu M, 2016, J BONE MINER RES, V31, P1405, DOI 10.1002/jbmr.2811
   SHUKLA S, 1990, J AM GERIATR SOC, V38, P884, DOI 10.1111/j.1532 5415.1990.tb05704.x
   Sikjaer T, 2014, OSTEOPOROSIS INT, V25, P1717, DOI 10.1007/s00198 014 2677 6
   Sikjaer T, 2016, J BONE MINER RES, V31, P1440, DOI 10.1002/jbmr.2812
   Sikjaer T, 2013, J BONE MINER RES, V28, P2232, DOI 10.1002/jbmr.1964
   Sikjaer T, 2012, J BONE MINER RES, V27, P781, DOI 10.1002/jbmr.1493
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Silva BC, 2017, OSTEOPOROSIS INT, V28, P463, DOI 10.1007/s00198 016 3750 0
   Starr JR, 2020, OSTEOPOROSIS INT, V31, P327, DOI 10.1007/s00198 019 05177 2
   Tabacco G, 2019, J CLIN ENDOCR METAB, V104, P2748, DOI 10.1210/jc.2018 02430
   Takahashi Hiroshi, 1994, Nippon Ganka Gakkai Zasshi, V98, P142
   Tay YKD, 2019, J CLIN ENDOCR METAB, V104, P5601, DOI 10.1210/jc.2019 00893
   Truong MT, 2008, LARYNGOSCOPE, V118, P1966, DOI 10.1097/MLG.0b013e318180276f
   Tuli G, 2020, ENDOCRINE, V67, P457, DOI 10.1007/s12020 019 02128 z
   Underbjerg L, 2018, CLIN ENDOCRINOL, V88, P838, DOI 10.1111/cen.13593
   Underbjerg L, 2019, CLIN ENDOCRINOL, V90, P592, DOI 10.1111/cen.13927
   Underbjerg L, 2018, J BONE MINER RES, V33, P822, DOI 10.1002/jbmr.3368
   Underbjerg L, 2015, J BONE MINER RES, V30, P1738, DOI 10.1002/jbmr.2501
   Underbjerg L, 2014, J BONE MINER RES, V29, P2504, DOI 10.1002/jbmr.2273
   Underbjerg L, 2013, J BONE MINER RES, V28, P2277, DOI 10.1002/jbmr.1979
   Vadiveloo T, 2019, CLIN ENDOCRINOL, V90, P285, DOI 10.1111/cen.13895
   Vadiveloo T, 2018, J BONE MINER RES, V33, P478, DOI 10.1002/jbmr.3329
   van Uum S., 2022, J BONE MINER RES, DOI 10.1002/jbmr.4698
   Vokes TJ, 2018, J CLIN ENDOCR METAB, V103, P722, DOI 10.1210/jc.2017 01471
   Wang B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221173
   Wilde D, 2020, JBMR PLUS, V4, DOI 10.1002/jbm4.10245
   Winer KK, 2008, J CLIN ENDOCR METAB, V93, P3389, DOI 10.1210/jc.2007 2552
   Winer KK, 2021, BONE, V149, DOI 10.1016/j.bone.2021.115977
   Winer KK, 2018, J PEDIATR US, V203, P391, DOI 10.1016/j.jpeds.2018.08.010
   Winer KK, 2014, J PEDIATR US, V165, P556, DOI 10.1016/j.jpeds.2014.04.060
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2010, J CLIN ENDOCR METAB, V95, P2680, DOI 10.1210/jc.2009 2464
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Winer KK, 1996, JAMA J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
   Yao L., 2022, JBMR, DOI [10.1002/jbmr.4687, DOI 10.1002/JBMR.4687]
   Yao L, 2022, J BONE MINER RES, V37, P2642, DOI 10.1002/jbmr.4673
   Yao L, 2022, J BONE MINER RES, V37, P2654, DOI 10.1002/jbmr.4676
NR 144
TC 74
Z9 80
U1 2
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2022
VL 37
IS 12
BP 2568
EP 2585
DI 10.1002/jbmr.4691
EA NOV 2022
PG 18
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 8L1RC
UT WOS:000883107600001
PM 36054621
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhu, CL
   Pongkitwitoon, S
   Qiu, JC
   Thomopoulos, S
   Xia, YN
AF Zhu, Chunlei
   Pongkitwitoon, Suphannee
   Qiu, Jichuan
   Thomopoulos, Stavros
   Xia, Younan
TI Design and Fabrication of a Hierarchically Structured Scaffold for
   Tendon to Bone Repair
SO ADVANCED MATERIALS
LA English
DT Article
DE hierarchically structured scaffolds; inverse opals; regenerative
   medicine; tendon to bone insertion; tissue engineering
ID MESENCHYMAL STEM CELLS; ROTATOR CUFF; NANOFIBER SCAFFOLDS;
   DIFFERENTIATION; CALCIFICATION; OSTEOGENESIS; MINERALIZATION;
   BIOMATERIALS; MECHANISMS; GRADIENTS
AB A hierarchically structured scaffold is designed and fabricated for facilitating tendon to bone repair. The scaffold is composed of three regions with distinct functions: (i) an array of channels to guide the in growth of cells and aligned deposition of collagen fibers, as well as integration of the scaffold with the tendon side, (ii) a region with a gradient in mineral composition to facilitate stress transfer between tendon and bone, and (iii) a mineralized inverse opal region to promote the integration of the scaffold with the underlying bone. Cell culture experiments confirm that adipose derived stromal cells are able to infiltrate and proliferate through the entire thickness of the scaffold without compromised cell viability. The seeded stem cells exhibit directed differentiation into tenocytes and osteoblasts along the mineral gradient as a response to the gradient in Young's modulus. This novel scaffold holds great promise to promote the formation of a functional tendon to bone attachment by offering a structurally and compositionally appropriate microenvironment for healing.
C1 [Zhu, Chunlei; Qiu, Jichuan; Xia, Younan] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.
   [Zhu, Chunlei; Qiu, Jichuan; Xia, Younan] Emory Univ, Atlanta, GA 30332 USA.
   [Pongkitwitoon, Suphannee; Thomopoulos, Stavros] Columbia Univ, Dept Orthopaed Surg, New York, NY 10032 USA.
   [Thomopoulos, Stavros] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA.
   [Xia, Younan] Georgia Inst Technol, Sch Chem & Biomol Engn, Sch Chem & Biochem, Atlanta, GA 30332 USA.
C3 University System of Georgia; Georgia Institute of Technology; Emory
   University; Columbia University; Columbia University; University System
   of Georgia; Georgia Institute of Technology
RP Xia, YN (通讯作者)，Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA.; Xia, YN (通讯作者)，Emory Univ, Atlanta, GA 30332 USA.; Xia, YN (通讯作者)，Georgia Inst Technol, Sch Chem & Biomol Engn, Sch Chem & Biochem, Atlanta, GA 30332 USA.
EM younan.xia@bme.gatech.edu
RI Qiu, Jichuan/T 6424 2019; Xia, Younan/E 8499 2011
OI Qiu, Jichuan/0000 0002 9993 8220; 
FU National Institutes of Health [R01 AR060820]; Georgia Institute of
   Technology
FX C.Z. and S.P. contributed equally to this work. This work was supported
   in part by a grant from the National Institutes of Health (R01 AR060820)
   and startup funds from the Georgia Institute of Technology (to Y.X.).
   Adipose derived stromal cells were taken post mortem from Sprague Dawley
   rats used for other studies following protocols approved by the
   Institutional Animal Care and Use Committee (IACUC) of Columbia
   University.
CR Bensimon Brito A, 2016, BMC DEV BIOL, V16, DOI 10.1186/s12861 016 0102 4
   Chen FM, 2016, PROG POLYM SCI, V53, P86, DOI 10.1016/j.progpolymsci.2015.02.004
   Choi SW, 2010, LANGMUIR, V26, P12126, DOI 10.1021/la101519b
   Dai R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6737345
   Deymier Black AC, 2015, J BIOMECH ENG T ASME, V137, DOI 10.1115/1.4031571
   Dickhut A, 2009, J CELL PHYSIOL, V219, P219, DOI 10.1002/jcp.21673
   Dormer NH, 2010, ANN BIOMED ENG, V38, P2121, DOI 10.1007/s10439 010 0033 3
   Galatz LM, 2004, J BONE JOINT SURG AM, V86A, P219, DOI 10.2106/00004623 200402000 00002
   Galatz LM, 2006, J ORTHOP RES, V24, P541, DOI 10.1002/jor.20067
   Gan TX, 2013, FASEB J, V27
   Gao X, 2016, ACS APPL MATER INTER, V8, P3499, DOI 10.1021/acsami.5b12413
   Genin GM, 2017, NAT MATER, V16, P607, DOI 10.1038/nmat4906
   Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640
   Gersbach CA, 2006, GENE THER, V13, P873, DOI 10.1038/sj.gt.3302725
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Guo J, 2016, EXP CELL RES, V341, P1, DOI 10.1016/j.yexcr.2016.01.007
   Hu YZ, 2015, BIOPHYS J, V108, P431, DOI 10.1016/j.bpj.2014.09.049
   Kalantari F, 2007, MODERN PATHOL, V20, P357, DOI 10.1038/modpathol.3800747
   Kim HL, 2015, MAT SCI ENG C MATER, V54, P20, DOI 10.1016/j.msec.2015.04.033
   Lee J, 2013, BIOMATERIALS, V34, P8140, DOI 10.1016/j.biomaterials.2013.07.074
   Li YH, 2015, SCI REP UK, V5, DOI 10.1038/srep13149
   Lipner J, 2014, J MECH BEHAV BIOMED, V40, P59, DOI 10.1016/j.jmbbm.2014.08.002
   Lipner J, 2015, TISSUE ENG PT A, V21, P2766, DOI [10.1089/ten.tea.2015.0101, 10.1089/ten.TEA.2015.0101]
   Liu WY, 2014, ACS APPL MATER INTER, V6, P2842, DOI 10.1021/am405418g
   Loghem Jani Van, 2015, J Clin Aesthet Dermatol, V8, P38
   Lu HH, 2013, ANNU REV BIOMED ENG, V15, P201, DOI 10.1146/annurev bioeng 071910 124656
   Lu HH, 2010, ANN BIOMED ENG, V38, P2142, DOI 10.1007/s10439 010 0046 y
   Mack E, 2007, CYTOM PART A, V71A, P404, DOI 10.1002/cyto.a.20391
   Macrí Pellizzeri L, 2015, TISSUE ENG PT A, V21, P1633, DOI [10.1089/ten.TEA.2014.0251, 10.1089/ten.tea.2014.0251]
   Nonoyama T, 2016, ADV MATER, V28, P6740, DOI 10.1002/adma.201601030
   Patel S, 2016, ANN NY ACAD SCI, V1383, P97, DOI 10.1111/nyas.13267
   Pongkitwitoon S, 2016, SCI REP UK, V6, DOI 10.1038/srep34791
   Rossetti L, 2017, NAT MATER, V16, P664, DOI [10.1038/NMAT4863, 10.1038/nmat4863]
   Russell JN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073849
   Schwartz AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048630
   Screen HRC, 2004, P I MECH ENG H, V218, P109, DOI 10.1243/095441104322984004
   Seidi A, 2011, ACTA BIOMATER, V7, P1441, DOI 10.1016/j.actbio.2011.01.011
   Shen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077613
   Shukunami C, 2006, DEV BIOL, V298, P234, DOI 10.1016/j.ydbio.2006.06.036
   Wegner KA, 2017, J HISTOCHEM CYTOCHEM, V65, P479, DOI 10.1369/0022155417718541
   Wopenka B, 2008, APPL SPECTROSC, V62, P1285, DOI 10.1366/000370208786822179
   Wright J, 2001, MODERN PATHOL, V14, P717, DOI 10.1038/modpathol.3880378
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Yang PJ, 2009, TISSUE ENG PART B RE, V15, P127, DOI 10.1089/ten.teb.2008.0371
   Zhang H, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2919718
   Zhang XZ, 2012, J SHOULDER ELB SURG, V21, P266, DOI 10.1016/j.jse.2011.11.016
   Zhang YS, 2017, ADV MATER, V29, DOI 10.1002/adma.201701115
NR 47
TC 111
Z9 124
U1 10
U2 435
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935 9648
EI 1521 4095
J9 ADV MATER
JI Adv. Mater.
PD APR 19
PY 2018
VL 30
IS 16
AR 1707306
DI 10.1002/adma.201707306
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA GD4FX
UT WOS:000430460100025
PM 29534316
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hasebe, A
   Tashima, H
   Ide, T
   Iijima, M
   Yoshimoto, N
   Ting, K
   Kuroda, S
   Niimi, T
AF Hasebe, Ai
   Tashima, Hiroki
   Ide, Teruhiko
   Iijima, Masumi
   Yoshimoto, Nobuo
   Ting, Kang
   Kuroda, Shun'ichi
   Niimi, Tomoaki
TI Efficient Production and Characterization of Recombinant Human NELL1
   Protein in Human Embryonic Kidney 293 F Cells
SO MOLECULAR BIOTECHNOLOGY
LA English
DT Article
DE NELL 1; Osteoblast differentiation; Bone regeneration; Extracellular
   matrix
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; BONE REGENERATION;
   CALVARIAL DEFECTS; EXPRESSION; CRANIOSYNOSTOSIS; GENE; MICE;
   GLYCOSYLATION; VITRONECTIN
AB NELL1 is a secretory protein that induces osteogenic differentiation and bone formation by osteoblastic cells. Because of its potent osteoinductive activity, NELL1 may be useful for bone regeneration therapy. However, at present, we have little knowledge regarding NELL1 receptors and NELL1 mediated signaling pathways. We have previously produced NELL1 using an insect's cell expression system; however, the protein was relatively unstable and was degraded by proteases released from dead cells. In the present study, NELL1 protein was expressed in human embryonic kidney 293 F cells. Stable cell lines expressing NELL1 fused to a C terminal hexahistidine tag were obtained by G418 selection of transfected cells. Cells grown in serum free medium showed high levels of NELL1 protein production (approximately 4 mg/l cell culture) for up to 6 months. NELL1 protein was purified from culture medium using a one step nickel chelate affinity chromatography protocol. Purified NELL1 protein immobilized onto culture dishes induced the expression of both early and late osteogenic markers on mouse mesenchymal C3H10T1/2 cells. When NELL1 expressing 293 F cells were grown on gelatin coated glass cover slips, recombinant NELL1 was deposited in the extracellular matrix after detachment of cells. These results suggest that NELL1 acts as an extracellular matrix component. Recombinant NELL1 formed multimers and was glycosylated. An abundant source of functionally active NELL1 protein will be useful for more advanced studies, such as the development of novel techniques for bone regeneration.
C1 [Hasebe, Ai; Tashima, Hiroki; Ide, Teruhiko; Iijima, Masumi; Yoshimoto, Nobuo; Kuroda, Shun'ichi; Niimi, Tomoaki] Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan.
   [Ting, Kang] Univ Calif Los Angeles, Dent & Craniofacial Res Inst, Los Angeles, CA 90095 USA.
C3 Nagoya University; University of California System; University of
   California Los Angeles
RP Kuroda, S (通讯作者)，Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.
EM skuroda@agr.nagoya u.ac.jp; tniimi@agr.nagoya u.ac.jp
RI Kuroda, Shun'Ichi/KVY 1906 2024
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [18108003, 23510255]; Grants in Aid for Scientific Research [18108003,
   23710143, 23510255] Funding Source: KAKEN
FX This work was partially supported by a Grant in aid (nos. 18108003,
   23510255) for Scientific Research from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan.
CR Aghaloo T, 2007, MOL THER, V15, P1872, DOI 10.1038/sj.mt.6300270
   Aghaloo T, 2006, AM J PATHOL, V169, P903, DOI 10.2353/ajpath.2006.051210
   Aghaloo T, 2010, J ORAL MAXIL SURG, V68, P300, DOI 10.1016/j.joms.2009.03.066
   Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951
   Bokui N, 2008, FEBS LETT, V582, P365, DOI 10.1016/j.febslet.2007.12.006
   Cowan CM, 2007, J BONE MINER RES, V22, P918, DOI 10.1359/JBMR.070312
   Cowan CM, 2006, BONE, V38, P48, DOI 10.1016/j.bone.2005.06.023
   Desai J, 2006, HUM MOL GENET, V15, P1329, DOI 10.1093/hmg/ddl053
   ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.bi.56.070187.002433
   Fleury D, 2008, PROTEIN EXPRES PURIF, V60, P74, DOI 10.1016/j.pep.2008.03.023
   Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151
   Klees RF, 2005, MOL BIOL CELL, V16, P881, DOI 10.1091/mbc.e04 08 0695
   Klees RF, 2008, EXP CELL RES, V314, P763, DOI 10.1016/j.yexcr.2007.12.007
   KUAN SF, 1989, J BIOL CHEM, V264, P19271
   Kundu AK, 2006, BIOCHEM BIOPH RES CO, V347, P347, DOI 10.1016/j.bbrc.2006.06.110
   Kuroda S, 1999, BIOCHEM BIOPH RES CO, V265, P79, DOI 10.1006/bbrc.1999.1638
   Li WM, 2010, TISSUE ENG PT A, V16, P2861, DOI 10.1089/ten.tea.2009.0550
   Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020
   Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017
   Siu RK, 2011, TISSUE ENG PT A, V17, P1123, DOI [10.1089/ten.tea.2010.0486, 10.1089/ten.TEA.2010.0486]
   SOTTILE J, 1991, BIOCHEMISTRY US, V30, P6556, DOI 10.1021/bi00240a028
   Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945 053X(00)00072 X
   Ting K, 1999, J BONE MINER RES, V14, P80, DOI 10.1359/jbmr.1999.14.1.80
   Tsai KS, 2010, J BIOMED MATER RES A, V94A, P673, DOI 10.1002/jbm.a.32693
   Xue J, 2011, BONE, V48, P485, DOI 10.1016/j.bone.2010.10.166
   Zhang X, 2010, J DENT RES, V89, P865, DOI 10.1177/0022034510376401
   Zhang XL, 2006, LAB INVEST, V86, P633, DOI 10.1038/labinvest.3700430
   Zhang XL, 2011, J BONE MINER RES, V26, P777, DOI 10.1002/jbmr.267
   Zhang XL, 2002, J CLIN INVEST, V110, P861, DOI 10.1172/JCI200215375
   Zhang XL, 2003, J BONE MINER RES, V18, P2126, DOI 10.1359/jbmr.2003.18.12.2126
NR 30
TC 14
Z9 19
U1 0
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1073 6085
J9 MOL BIOTECHNOL
JI Mol. Biotechnol.
PD MAY
PY 2012
VL 51
IS 1
BP 58
EP 66
DI 10.1007/s12033 011 9440 4
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 920CW
UT WOS:000302380500007
PM 21814724
DA 2025 08 17
ER

PT J
AU Drüeke, TB
AF Drueeke, Tilman B.
TI Cinacalcet Treatment in Dialysis Patients with Secondary
   Hyperparathyroidism: Effects and Open Issues
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Aortic calcification; Atherosclerosis; Calcimimetics; CKD MBD; iPTH;
   Parathyroid hyperplasia; Secondary hyperparathyroidism
ID PARATHYROID HORMONE LEVELS; EXTRAOSSEOUS CALCIFICATIONS; MINERAL
   METABOLISM; DECREASES; MORTALITY; CALCIUM; DISEASE; HCL
AB The recent introduction of calcimimetics, a novel class of therapeutic agents, has led to a change in the treatment strategy of secondary hyperparathyroidism in patients with end stage renal disease. In initial acute studies in chronic hemodialysis patients, the calcimimetic cinacalcet was shown to reduce plasma intact parathyroid hormone within hours, followed by a rapid, profound decrease in plasma calcium and a minor decrease in plasma phosphorus. Subsequent reports showed that the long term administration of cinacalcet to such patients proved to be superior to standard therapy in controlling secondary uremic hyperparathyroidism, in that it was able to induce a decrease in both plasma intact parathyroid hormone and the calcium x phosphorus product, in contrast to the effects of active vitamin D sterols. This allowed the achievement of the guideline treatment targets proposed by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative in a much larger proportion of dialysis patients than standard therapy did. Moreover, the effect of cinacalcet is long lasting. An important question is that of cinacalcet's effects on patient outcomes, which is still lacking. A similar lack of information exists for most other treatment modalities given to correct the mineral and bone disorder of chronic kidney disease. A post hoc analysis of four clinical trials combined done in hemodialysis patients showed that randomization to cinacalcet led to significant reductions in the risk of parathyroidectomy, fracture, and cardiovascular hospitalization. To obtain a definitive answer to this question, including patient survival, we will have to wait for the results of prospective, randomized controlled trials. In pre clinical studies performed in rats with chronic renal failure, the administration of the calcimimetic NPS R 568 at the time of uremia induction allowed the prevention of parathyroid hyperplasia, and the reversal of already established hyperplasia as well. Perhaps more important from the clinical point of view, NPS R 568 also appeared to allow reversal of osteitis fibrosa in uremic rats and reduction of aortic calcification and atherosclerosis in uremic rats and mice. In conclusion, the clinical introduction of cinacalcet allows for better control of secondary hyperparathyroidism in dialysis patients as compared to standard therapy, based on surrogate biochemical markers. Hopefully, in the future this improvement will be shown to be associated with better patient outcomes for the treatment of fractures and cardiovascular morbidity and mortality.
C1 Hop Necker Enfants Malad, INSERM, Unit & Nephrol 845, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker Enfants Malades   APHP
RP Drüeke, TB (通讯作者)，Hop Necker Enfants Malad, INSERM, Unit & Nephrol 845, Paris, France.
EM tilman.drueke@inserm.fr
RI DRUEKE, Tilman/B 4958 2010
OI Drueke, Tilman B./0000 0002 0700 7681
FU Amgen, Genzyme; SHIRE
FX T Drueke has received grant support and honoraria from Amgen, Genzyme
   and SHIRE.
CR Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Cunningham J, 2005, KIDNEY INT, V68, P1793, DOI 10.1111/j.1523 1755.2005.00596.x
   Arenas MD, 2007, NEPHROL DIAL TRANSPL, V22, P1639, DOI 10.1093/ndt/gfl840
   Drueke T, 2007, NEPHROL DIAL TRANSPL, V22, P1828, DOI 10.1093/ndt/gfm177
   Fukagawa M, 2008, NEPHROL DIAL TRANSPL, V23, P328, DOI 10.1093/ndt/gfm534
   Goodman WG, 2000, KIDNEY INT, V58, P436, DOI 10.1046/j.1523 1755.2000.00183.x
   IVANOVSKI O, 2006, J AM SOC NEPHROL, V17, pA690
   Lopez I, 2008, KIDNEY INT, V73, P300, DOI 10.1038/sj.ki.5002675
   Lopez I, 2006, J AM SOC NEPHROL, V17, P795, DOI 10.1681/ASN.2005040342
   Malluche HH, 2008, CLIN NEPHROL, V69, P269
   Rodriguez ME, 2007, AM J PHYSIOL RENAL, V292, pF1390, DOI 10.1152/ajprenal.00262.2006
   Stevens LA, 2004, J AM SOC NEPHROL, V15, P770, DOI 10.1097/01.ASN.0000113243.24155.2F
   Torres PU, 2006, KIDNEY INT, V70, P240, DOI 10.1038/sj.ki.5001658
   Wada M, 1998, KIDNEY INT, V53, P448, DOI 10.1046/j.1523 1755.1998.00782.x
NR 15
TC 2
Z9 2
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD OCT
PY 2008
VL 12
SU 1
BP S2
EP S12
DI 10.1111/j.1744 9987.2008.00624.x
PG 11
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 410GZ
UT WOS:000263566800002
PM 19032522
DA 2025 08 17
ER

PT J
AU White, HD
   Ahmad, AM
   Durham, BH
   Joshi, AA
   Fraser, WD
   Vora, JP
AF White, H. D.
   Ahmad, A. M.
   Durham, B. H.
   Joshi, A. A.
   Fraser, W. D.
   Vora, J. P.
TI Effect of Oral Phosphate and Alendronate on Bone Mineral Density When
   Given as Adjunctive Therapy to Growth Hormone Replacement in Adult
   Growth Hormone Deficiency
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PARATHYROID HORMONE; BODY COMPOSITION; POSTMENOPAUSAL OSTEOPOROSIS;
   CIRCADIAN RHYTHM; IONIZED CALCIUM; PTH SENSITIVITY; RENAL PHOSPHATE;
   IN VIVO; METABOLISM; GH
AB Background: Adult GH deficiency (AGHD) is associated with osteoporosis, which occurs as the result of reduced sensitivity of the bone and kidney to the effect of PTH.
   Aim: The aim of the study was to examine the effect of oral phosphate and alendronate therapy on PTH sensitivity, bone turnover, and bone mineral density (BMD) in AGHD patients.
   Methods: Forty four AGHD patients were hospitalized for 24 h, and half hourly blood and 3 hourly urine samples were collected for PTH, nephrogenous cAMP (marker of renal PTH activity), procollagen type I amino terminal propeptide, and type I collagen beta C telopeptide. Patients were randomized to one of six groups: patients who were previously naive to GH were randomized to receive GH replacement (GHR) alone, GHR + alendronate, or GHR + phosphate sandoz, whereas patients already receiving GHR were randomized to continue GHR alone, GHR + alendronate, or GHR + phosphate sandoz. Study visits were repeated after 1, 3, 6, and 12 months in the previously GH naive group and after 12 months in the previously GH replaced group. BMD was measured at 0 and 12 months.
   Results: Patients receiving GHR + phosphate had greater increases in nephrogenous cAMP and bone markers than patients receiving GHR alone (P < 0.01), and this was associated with greater increases in BMD (P < 0.01). In the GHR + alendronate groups, type I collagen beta C telopeptide decreased (P < 0.001), and BMD increases were greater than in those receiving GHR alone (P < 0.05). The greatest increases in BMD were seen in patients receiving GHR + phosphate.
   Conclusions: Phosphate and alendronate therapy given in combination with GHR confer advantage in terms of BMD increase. Phosphate appears to exert its effect by increasing PTH target organ action, whereas alendronate acts primarily through reduction in bone resorption. (J Clin Endocrinol Metab 96: 726 736, 2011)
C1 [White, H. D.; Ahmad, A. M.; Joshi, A. A.; Vora, J. P.] Royal Liverpool Univ Hosp, Dept Endocrinol & Diabet, Liverpool L7 8XP, Merseyside, England.
   [Durham, B. H.; Fraser, W. D.] Univ Liverpool, Inst Aging & Chron Dis, Dept Musculoskeletal Biol, Liverpool L69 3GA, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool
RP White, HD (通讯作者)，Wrexham Maelor Hosp, Gladstone Ctr, Dept Endocrinol & Diabet, Wrexham LL13 7TD, Wales.
EM h.white@ukf.net
FU Eli Lilly (Indianapolis, IN); Pfizer (Ann Arbor, MI)
FX We are grateful to all the nursing and clerical staff on the Metabolic
   Bone Unit, Royal Liverpool University Hospital, for all their help and
   support. We also thank Roche (Lewes, UK), for the provision of bone
   marker kits, and Eli Lilly (Indianapolis, IN) and Pfizer (Ann Arbor, MI)
   for their support.
CR Ahmad AM, 2004, AM J PHYSIOL ENDOC M, V286, pE986, DOI 10.1152/ajpendo.00325.2003
   Ahmad AM, 2003, J CLIN ENDOCR METAB, V88, P2860, DOI 10.1210/jc.2002 021787
   Ahmad AM, 2003, BONE, V32, P170, DOI 10.1016/S8756 3282(02)00952 3
   Ahmad AM, 2001, CLIN ENDOCRINOL, V54, P709, DOI 10.1046/j.1365 2265.2001.01275.x
   Altman D G, 1982, Stat Med, V1, P59, DOI 10.1002/sim.4780010109
   Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379
   Biermasz NR, 2001, J CLIN ENDOCR METAB, V86, P3079, DOI 10.1210/jc.86.7.3079
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Boonen S, 1996, GERONTOLOGY, V42, P330, DOI 10.1159/000213811
   DELMAS PD, 1995, BONE, V16, P603, DOI 10.1016/8756 3282(95)00113 R
   DREZNER MK, 1976, METABOLISM, V25, P1103, DOI 10.1016/0026 0495(76)90018 4
   el Hajj Fuleihan G, 1997, J CLIN ENDOCR METAB, V82, P281, DOI DOI 10.1210/JC.82.1.281
   Estepa JC, 1999, J BONE MINER RES, V14, P1848, DOI 10.1359/jbmr.1999.14.11.1848
   FINKELSTEIN JW, 1972, J CLIN ENDOCR METAB, V35, P665, DOI 10.1210/jcem 35 5 665
   FRASER DR, 1973, NATURE NEW BIOL, V241, P163, DOI 10.1038/newbio241163a0
   Fraser WD, 1998, OSTEOPOROSIS INT, V8, P121, DOI 10.1007/BF02672507
   FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29
   GARDNER MD, 1981, ANN CLIN BIOCHEM, V18, P106, DOI 10.1177/000456328101800210
   IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem 73 5 1081
   JOHANSEN JS, 1990, J CLIN ENDOCR METAB, V70, P916, DOI 10.1210/jcem 70 4 916
   Joseph F, 2008, J BONE MINER RES, V23, P721, DOI 10.1359/JBMR.071117
   JUBIZ W, 1972, J CLIN INVEST, V51, P2040, DOI 10.1172/JCI107010
   KELLY PA, 1993, RECENT PROG HORM RES, V48, P123
   KILAV R, 1995, J CLIN INVEST, V96, P327, DOI 10.1172/JCI118038
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   LIEBERMAN SA, 1994, J BONE MINER RES, V9, P1723
   MCCLOSKEY EV, 1988, CLIN SCI, V74, P607, DOI 10.1042/cs0740607
   MOJON A, 1992, CHRONOBIOL INT, V9, P403, DOI 10.3109/07420529209064552
   NAVEHMANY T, 1995, J CLIN INVEST, V96, P1786, DOI 10.1172/JCI118224
   NETELENBOS JC, 1991, J CLIN ENDOCR METAB, V72, P223, DOI 10.1210/jcem 72 1 223
   OGLE GD, 1992, PEDIATR NEPHROL, V6, P483, DOI 10.1007/BF00874021
   REEVE J, 1981, METAB BONE DIS RELAT, V3, P23, DOI 10.1016/S0221 8747(81)80019 7
   ROSEN T, 1993, ACTA ENDOCRINOL COP, V129, P201, DOI 10.1530/acta.0.1290201
   RUDMAN D, 1985, J AM GERIATR SOC, V33, P800, DOI 10.1111/j.1532 5415.1985.tb04195.x
   Samadfam R, 2007, ENDOCRINOLOGY, V148, P2778, DOI 10.1210/en.2006 1475
   SILVERBERG SJ, 1986, J BONE MINER RES, V1, P383
   VALK NK, 1995, CLIN ENDOCRINOL, V43, P317, DOI 10.1111/j.1365 2265.1995.tb02038.x
   WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140 6736(75)92736 1
   White HD, 2005, J CLIN ENDOCR METAB, V90, P3371, DOI 10.1210/jc.2004 1650
   White HD, 2004, CLIN ENDOCRINOL, V60, P516, DOI 10.1111/j.1365 2265.2004.02010.x
   White HD, 2010, ANN CLIN BIOCHEM, V47, P212, DOI 10.1258/acb.2010.009178
   WUSTER C, 1991, KLIN WOCHENSCHR, V69, P769, DOI 10.1007/BF01797616
NR 42
TC 6
Z9 7
U1 0
U2 11
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815 5817 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD MAR
PY 2011
VL 96
IS 3
BP 726
EP 736
DI 10.1210/jc.2010 1929
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 730GA
UT WOS:000288020600042
PM 21252245
OA Bronze
DA 2025 08 17
ER

PT J
AU Jardim, DL
   Silva, AGE
   Pompeo, ASFL
   Sarkis, AS
   Cardoso, APG
   Sasse, AD
   Fay, AP
   Soares, A
   Pompeo, ACL
   Carneiro, A
   Kann, AG
   Fogassa, C
   De Freitas, CH Jr
   Chade, DC
   Herchenhorn, D
   De Almeida, DVP
   Da Rosa, DAR
   Wiermann, EG
   Schutz, FAB
   Kater, FR
   De Moura, F
   Korkes, F
   Meyer, F
   De Oliveira, FNG
   Sabino, F
   Almeida, GL
   Avanco, G
   Guimaraes, GC
   Lemos, GC
   Carvalhal, GF
   Kim, H
   Morbeck, IP
   Campagnari, JC
   Rinck, JA Jr
   Da Ponte, JRT
   Da Trindade, KM
   Atem, L
   Borges, L
   Nogueira, LM
   Batista, LTEA
   Maia, MC
   Sadi, MV
   Rocha, MAA
   Luz, MD
   Smaletz, O
   Lages, PSM
   Matuda, RMK
   Dos Reis, RB
   Indio, RF
   Fernandes, RD
   Cavallero, SR
   Souza, VC
   Busato, WB Jr
   Alfer, WA Jr
   Maluf, F
AF Jardim, Denis L.
   Silva, Adriano Goncalves e
   Pompeo, Alexandre Saad Fere Lima
   Sarkis, Alvaro Sadek
   Cardoso, Ana Paula Garcia
   Sasse, Andre Deeke
   Fay, Andre Poisl
   Soares, Andrey
   Pompeo, Antonio Carlos Lima
   Carneiro, Arie
   Kann, Ariel Galapo
   Fogassa, Camilla
   De Freitas Jr, Celso Heitor
   Chade, Daher Cezar
   Herchenhorn, Daniel
   De Almeida, Daniel Vargas Pivato
   Da Rosa, Diogo Augusto Rodrigues
   Wiermann, Evanius Garcia
   Schutz, Fabio Augusto Barros
   Kater, Fabio Roberto
   De Moura, Fernando
   Korkes, Fernando
   Meyer, Fernando
   De Oliveira, Fernando Nunes Galvao
   Sabino, Fernando
   Almeida, Gilberto Laurino
   Avanco, Guilherme
   Guimaraes, Gustavo Cardoso
   Lemos, Gustavo Caserta
   Carvalhal, Gustavo Franco
   Kim, Hanna
   Morbeck, Igor Protzner
   Campagnari, Joao Carlos
   Rinck Jr, Jose Augusto
   Da Ponte, Jose Ricardo Tuma
   Da Trindade, Karine Martins
   Atem, Leonardo
   Borges, Leonardo
   Nogueira, Lucas Mendes
   Batista, Lucas Teixeira e Aguiar
   Maia, Manuel Caitano
   Sadi, Marcus Vinicius
   Rocha, Maria Alzira Almeida
   Luz, Murilo De Almeida
   Smaletz, Oren
   Lages, Paulo Sergio Moraes
   Matuda, Raquel Midori Koga
   Dos Reis, Rodolfo Borges
   Indio, Rodrigo Frota
   Fernandes, Roni De Carvalho
   Cavallero, Sandro Roberto
   Souza, Vinicius Carrera
   Busato Jr, Wilson
   Alfer Jr, Wladimir
   Maluf, Fernando
TI ?Non metastatic, Castration resistant Prostate Cancer: Diagnostic and
   Treatment Recommendations by an Expert Panel from Brazil?
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Prostate cancer; Non metastatic; Castration resistant prostate cancer;
   Practice guidelines; Androgen receptor signalling inhibitors
ID METASTASIS FREE SURVIVAL; MEN; ENZALUTAMIDE; APALUTAMIDE; CONSENSUS;
   ANTIGEN; PATIENT
AB A panel of Brazilian experts convened in order to provide recommendations regarding staging methods, antineoplastic therapy, osteoclast targeted therapy, and patient follow up in non metastatic, castration  resistant prostate cancer. Key points include the reliance on prostate specific antigen doubling time for treat ment decisions, the absence of a clear preference between conventional and novel imaging techniques, and the increasing role of novel androgen receptor signaling inhibitors.Introduction: Non metastatic, castration resistant prostate cancer (nmCRPC) is an important clinical stage of prostate cancer, prior to morbidity and mortality from clinical metastases. In particular, the introduction of novel androgen  receptor signaling inhibitors (ARSi) has changed the therapeutic landscape in nmCRPC. Given recent developments in this field, we update our recommendations for the management of nmCRPC. Methods: A panel of 51 invited medical oncologists and urologists convened in May of 2021 with the aim of discussing and providing recommendations regard ing the most relevant issues concerning staging methods, antineoplastic therapy, osteoclast targeted therapy, and patient follow up in nmCRPC. Panel members considered the available evidence and their practical experience to address the 73 multiple choice questions presented. Results: Key recommendations and findings include the reliance on prostate specific antigen doubling time for treatment decisions, the absence of a clear preference between conven tional and novel (i.e., positron emission tomography based) imaging techniques, the increasing role of ARSis in various settings, the general view that ARSis have similar efficacy. Panelists highlighted the slight preference for darolutamide, when safety is of greater concern, and a continued need to develop high level evidence to guide the intensity of follow up in this subset of prostate cancer. Discussion: Despite the limitations associated with a consensus panel, the topics addressed are relevant in current practice, and the recommendations can help practicing clinicians to provide state of the art treatment to patients with nmCRPC in Brazil and other countries with similar healthcare settings.
C1 [Silva, Adriano Goncalves e] Hosp Sirio Libanes, Soc Beneficente Senhoras, Sao Paulo, SP, Brazil.
   [Pompeo, Alexandre Saad Fere Lima] Inst Canc & Transplante, Curitiba, PR, Brazil.
   [Pompeo, Alexandre Saad Fere Lima; De Freitas Jr, Celso Heitor] Hosp Beneficencia Portuguesa, Dept Uro Oncol, Sao Paulo, SP, Brazil.
   [Pompeo, Alexandre Saad Fere Lima] Grp Uro Oncol Hcor, Sao Paulo, SP, Brazil.
   [Sarkis, Alvaro Sadek] Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil.
   [Cardoso, Ana Paula Garcia; Soares, Andrey; Carneiro, Arie; Fogassa, Camilla; Rocha, Maria Alzira Almeida] Hosp Israelita Albert Einstein, Dept Oncol, Sao Paulo, SP, Brazil.
   [Sasse, Andre Deeke] Grp Sonhe, Campinas, SP, Brazil.
   [Fay, Andre Poisl] PUCRS Sch Med, Porto Alegre, RS, Brazil.
   [Fay, Andre Poisl] Grp Oncoclin, Sao Paulo, SP, Brazil.
   [Soares, Andrey; Herchenhorn, Daniel; Da Rosa, Diogo Augusto Rodrigues; De Oliveira, Fernando Nunes Galvao; Sabino, Fernando; Da Trindade, Karine Martins; Maia, Manuel Caitano] Latin Amer Cooperat Oncol Grp LACOG, Genitourinary Grp, Porto Alegre, RS, Brazil.
   [Pompeo, Antonio Carlos Lima] Soc Brasileira Urol, Sao Paulo, SP, Brazil.
   [Kann, Ariel Galapo] Hosp Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil.
   [Chade, Daher Cezar] Univ Sao Paulo, Inst Cancer Estado Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Herchenhorn, Daniel; Indio, Rodrigo Frota] Rede Or, Rio De Janeiro, RJ, Brazil.
   [De Almeida, Daniel Vargas Pivato; Lages, Paulo Sergio Moraes; Matuda, Raquel Midori Koga] Grp Oncoclin, Brasilia, DF, Brazil.
   [Da Rosa, Diogo Augusto Rodrigues] Grp Oncoclin, Rio De Janeiro, RJ, Brazil.
   [Wiermann, Evanius Garcia] Inst Oncol Parana, Curitiba, PR, Brazil.
   [Schutz, Fabio Augusto Barros; Kater, Fabio Roberto; De Moura, Fernando; Guimaraes, Gustavo Cardoso; Kim, Hanna; Campagnari, Joao Carlos; Luz, Murilo De Almeida; Maluf, Fernando] Hosp Beneficencia Portuguesa, Dept Oncol, Sao Paulo, SP, Brazil.
   [Korkes, Fernando] Fac Med ABC, Grp Urooncol, Santo Andre, SP, Brazil.
   [Korkes, Fernando; Lemos, Gustavo Caserta; Borges, Leonardo; Alfer Jr, Wladimir; Maluf, Fernando] Hosp Israelita Albert Einstein, Dept Urol, Sao Paulo, SP, Brazil.
   [Meyer, Fernando] Soc Brasileira Urol, Curitiba, PR, Brazil.
   [Meyer, Fernando] Hosp Univ Cajuru, Curitiba, PR, Brazil.
   [Meyer, Fernando] Pontificia Univ Catol Parana PUCPR, Curitiba, PR, Brazil.
   [De Oliveira, Fernando Nunes Galvao] Clin Oncol Grp CAM CLION, Salvador, BA, Brazil.
   [Sabino, Fernando] Hosp Santa Lucia, Brasilia, DF, Brazil.
   [Sabino, Fernando] Hosp Univ Brasilia, Brasilia, DF, Brazil.
   [Almeida, Gilberto Laurino] Univ Vale Itajai UNIVALI, Itajai, SC, Brazil.
   [Avanco, Guilherme] Hosp Nove Julho, Sao Paulo, SP, Brazil.
   [Carvalhal, Gustavo Franco] Pontificia Univ Catol Rio Grande do Sul, Porto Alegre, RS, Brazil.
   [Carvalhal, Gustavo Franco] Hosp Moinhos Vento, Porto Alegre, RS, Brazil.
   [Morbeck, Igor Protzner] Univ Catol Brasilia, Brasflia, DF, Brazil.
   [Campagnari, Joao Carlos] Clin Urol & Nefrol, Sao Paulo, SP, Brazil.
   [Rinck Jr, Jose Augusto] A C Camargo Canc Ctr, Sao Paulo, SP, Brazil.
   [Da Ponte, Jose Ricardo Tuma] Hosp Ophir Loyola, Belem, PA, Brazil.
   [Da Trindade, Karine Martins; Atem, Leonardo] Rede Or, Fortaleza, CE, Brazil.
   [Nogueira, Lucas Mendes] Univ Fed Minas Gerais UFMG, Hosp Clin, Belo Horizonte, MG, Brazil.
   [Batista, Lucas Teixeira e Aguiar] Univ Fed Bahia, Salvador, BA, Brazil.
   [Batista, Lucas Teixeira e Aguiar] Hosp Cardio Pulm, Salvador, BA, Brazil.
   [Maia, Manuel Caitano] Hosp Porto Dias, Dept Med Oncol, Belem, PA, Brazil.
   [Sadi, Marcus Vinicius] Univ Fed Sao Paulo UNIFESP, Sao Paulo, SP, Brazil.
   [Luz, Murilo De Almeida] Hosp Erasto Gaertner, Curitiba, PR, Brazil.
   [Dos Reis, Rodolfo Borges] Fac Med Ribeirao Preto USP FMRP, Ribeirao Preto, SP, Brazil.
   [Fernandes, Roni De Carvalho] Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, SP, Brazil.
   [Fernandes, Roni De Carvalho] Irmandade Santa Casa Misericordia Sao Paulo Hosp, Sao Paulo, SP, Brazil.
   [Cavallero, Sandro Roberto] Ctr Tratamento Oncol CTO, Belem, PA, Brazil.
   [Cavallero, Sandro Roberto] Hosp Adventista Belem HAB, Belem, PA, Brazil.
   [Souza, Vinicius Carrera] Inst Or Ensino & Pesquisa, Salvador, BA, Brazil.
   [Souza, Vinicius Carrera] Rede Or, Salvador, BA, Brazil.
C3 Hospital Sirio Libanes; Universidade de Sao Paulo; Hospital Israelita
   Albert Einstein; Pontificia Universidade Catolica Do Rio Grande Do Sul;
   Universidade de Sao Paulo; Faculdade de Medicina do ABC; Hospital
   Israelita Albert Einstein; Universidade de Brasilia; Universidade do
   Vale do Itajai; A.C.Camargo Cancer Center; Universidade Federal de Minas
   Gerais; Universidade Federal da Bahia; Universidade Federal de Sao Paulo
   (UNIFESP); Faculdade de Ciencias Medicas Santa Casa de Sao Paulo
RP Maluf, F (通讯作者)，Beneficencia Portuguesa Sao Paulo Hosp, Clin Oncol Dept, Rua Martiniano Carvalho 951, BR 01321001 Sao Paulo, SP, Brazil.
EM maluffc@uol.com.br
RI Pompeo, Antonio/E 2557 2012; GUIMARAES, GUSTAVO/H 3595 2012; Kann,
   Ariel/NTQ 3404 2025; Reis, Rodolfo/F 5877 2014; Sasse,
   Andre/B 3375 2009; NOGUEIRA, LUCAS/F 7887 2010; Monteiro,
   Fernando/S 8402 2019; Sasse, Andre/P 7272 2019; Rinck, José/D 2340 2014;
   Nogueira, Lucas/F 7887 2010; Korkes, Fernando/W 6570 2019; Rocha,
   Alexandra/LRT 8268 2024; Carneiro, Arie/AAW 4703 2021
OI Sasse, Andre/0000 0002 3038 3933; Soares, Andrey/0000 0003 4980 6729;
   Monteiro, Fernando/0000 0002 6621 8251; Nogueira,
   Lucas/0000 0002 3612 6524; Almeida, Daniel/0000 0001 9467 5049; Silva,
   Carlos/0000 0002 1549 6833; /0000 0002 7462 3679
FU Bayer
FX This study was funded by Bayer.
CR Basch E, 2014, J CLIN ONCOL, V32, P3436, DOI 10.1200/JCO.2013.54.8404
   Brasil. Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2019, EST 2020 INC CANC BR
   Buck SAJ, 2021, DRUG RESIST UPDATE, V56, DOI 10.1016/j.drup.2021.100761
   Cornford P, 2021, EUR UROL, V79, P263, DOI 10.1016/j.eururo.2020.09.046
   Crawford ED, 2020, CAN J UROL, V27, P10352
   Esther J., 2020, CANCER TREAT RES COM, V24
   Fendler WP, 2019, CLIN CANCER RES, V25, P7448, DOI 10.1158/1078 0432.CCR 19 1050
   Fizazi K, 2020, NEW ENGL J MED, V383, P1040, DOI 10.1056/NEJMoa2001342
   Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671
   Graff JN, 2015, ONCOLOGY NY, V29, P416
   Gupta R, 2020, EXPERT REV ANTICANC, V20, P513, DOI 10.1080/14737140.2020.1772759
   Heidegger I, 2020, UROL ONCOL SEMIN ORI, V38, P129, DOI 10.1016/j.urolonc.2019.11.007
   Hird AE, 2020, CLIN GENITOURIN CANC, V18, P343, DOI 10.1016/j.clgc.2020.02.005
   Hofman MS, 2020, LANCET, V395, P1208, DOI 10.1016/S0140 6736(20)30314 7
   Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536
   Khalaf DJ, 2019, LANCET ONCOL, V20, P1730, DOI 10.1016/S1470 2045(19)30688 6
   Kumar J, 2020, UROL ONCOL SEMIN ORI, V38, P826, DOI 10.1016/j.urolonc.2020.03.022
   Liede A, 2013, J CLIN ONCOL, V31
   Maluf F, 2021, INT BRAZ J UROL, V47, P359, DOI [10.1590/S1677 5538.IBJU.2020.0249, 10.1590/s1677 5538.ibju.2020.0249]
   Mateo J, 2019, EUR UROL, V75, P285, DOI 10.1016/j.eururo.2018.07.035
   Mori K, 2020, INT J CLIN ONCOL, V25, P1892, DOI 10.1007/s10147 020 01777 9
   National Comprehensive Cancer NetworkNCCN Practice Guidelines in Oncology, 2022, PROSTATE CANCER, V1
   Perera M, 2020, EUR UROL, V77, P403, DOI 10.1016/j.eururo.2019.01.049
   Saad F, 2018, LANCET ONCOL, V19, P1404, DOI 10.1016/S1470 2045(18)30456 X
   Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
   Scher HI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139440
   Small EJ, 2019, ANN ONCOL, V30, P1813, DOI 10.1093/annonc/mdz397
   Smith MR, 2021, EUR J CANCER, V154, P138, DOI 10.1016/j.ejca.2021.06.010
   Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546
   Smith MR, 2013, J CLIN ONCOL, V31, P3800, DOI 10.1200/JCO.2012.44.6716
   Smith MR, 2011, CANCER AM CANCER SOC, V117, P2077, DOI 10.1002/cncr.25762
   Smith MR, 2005, J CLIN ONCOL, V23, P2918, DOI 10.1200/JCO.2005.01.529
   Sternberg CN, 2020, NEW ENGL J MED, V382, P2197, DOI 10.1056/NEJMoa2003892
   Sung H, 2021, CA CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Pereira FMT, 2021, JCO GLOB ONCOL, V7, P545, DOI 10.1200/GO.20.00507
   Tombal B, 2019, LANCET ONCOL, V20, P556, DOI 10.1016/S1470 2045(18)30898 2
   Wenzel M, 2022, PROSTATE CANCER P D, V25, P139, DOI 10.1038/s41391 021 00395 4
NR 37
TC 0
Z9 0
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219 3931 USA
SN 1558 7673
EI 1938 0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD APR
PY 2023
VL 21
IS 2
BP e58
EP e69
DI 10.1016/j.clgc.2022.09.005
EA MAR 2023
PG 12
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Urology & Nephrology
GA D2EP0
UT WOS:000966907900001
PM 36266221
DA 2025 08 17
ER

PT J
AU Müller, A
   Bölzner, C
   Eidner, T
   Smolenski, UC
   Hein, GE
AF Mueller, A.
   Boelzner, C.
   Eidner, T.
   Smolenski, U. C.
   Hein, G. E.
TI Factors modifying collagen catabolism in patients with ankylosing
   spondylitis
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE ankylosing spondylitis; osteoporosis; collagen crosslinks; inflammation;
   NSAIDs
ID PYRIDINIUM CROSS LINKS; BONE MINERAL DENSITY; NONSTEROIDAL
   ANTIINFLAMMATORY DRUGS; BIOCHEMICAL MARKERS; RHEUMATOID ARTHRITIS;
   DISEASE ACTIVITY; OSTEOPOROSIS; TURNOVER; DEGRADATION; METABOLISM
AB Objective: We quantified the total excretion of the collagen crosslinks (CL) pyridinofine (PYD) and deoxypyridinoline (DPD) in 108 ankylosing spondylitis (AS) patients (29 f, 79 in) in correlation to different characteristics of disease to evaluate different mechanism contributing to development of osteoporosis in AS.
   Methods: PYD and DPD were measured by HPLC.
   Results: AS patients show a highly significant positive correlation between PYD and inflammatory activity In cases involving peripheral joints, significantly higher CL levels in urine were found. Patients with syndesmophytes excreted significantly more CL vs. those without. In the more advanced stages of sacroiliitis (stage III and IV), CL levels tended to be higher. Among those patients treated with NSAIDs, a tendency to decreased levels of DPD and consecutive raised levels of the quotient PYD/DPD were observed.
   No significant correlation was found between restricted spine mobility or duration of disease and amount of excreted CL.
   Conclusions: Our investigations show that the inflammatory process, the involvement of the peripheral joints, the presence of syndesmophytes and the stage of sacroiliitis all have an influence on the extent of collagen degradation in AS patients. NSAIDs do not increase but appear to reduce collagen I catabolism.
C1 Rheum & Osteol FZL, Inst Physiotherapy, Dept Internal Med Rheumatol & Osteol, Res Lab, D 07740 Jena, Germany.
   Univ Jena, Inst Physiotherapy, Dept Orthopaed, Jena, Germany.
C3 Friedrich Schiller University of Jena
RP Müller, A (通讯作者)，Rheum & Osteol FZL, Inst Physiotherapy, Dept Internal Med Rheumatol & Osteol, Res Lab, Erlanger Allee 101, D 07740 Jena, Germany.
EM andreas.mueller@med.uni jena.de; gert.hein@med.uni jena.de
CR Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Bronson WD, 1998, J RHEUMATOL, V25, P929
   Capaci K, 2003, YONSEI MED J, V44, P379, DOI 10.3349/ymj.2003.44.3.379
   Dernis E, 2002, CLIN EXP RHEUMATOL, V20, pS185
   El Maghraoui A, 2004, JOINT BONE SPINE, V71, P291, DOI 10.1016/j.jbspin.2003.06.002
   Eyre DR, 1995, ACTA ORTHOP SCAND, V66, P166, DOI 10.3109/17453679509157685
   Gratacós J, 1999, ARTHRITIS RHEUM, V42, P2319, DOI 10.1002/1529 0131(199911)42:11<2319::AID ANR9>3.0.CO;2 G
   Hein G, 1997, CLIN RHEUMATOL, V16, P167, DOI 10.1007/BF02247846
   MacDonald AG, 1997, BRIT J RHEUMATOL, V36, P50
   Mackay K, 1998, ARTHRITIS RHEUM US, V41, P2263, DOI 10.1002/1529 0131(199812)41:12<2263::AID ART23>3.3.CO;2 9
   MARHOFFER W, 1995, ANN RHEUM DIS, V54, P556, DOI 10.1136/ard.54.7.556
   Morton DJ, 1998, J BONE MINER RES, V13, P1924, DOI 10.1359/jbmr.1998.13.12.1924
   Muller A, 1996, RHEUMATOL INT, V16, P23, DOI 10.1007/BF01419951
   Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889 8529(02)00055 5
   RISTELI L, 1993, ANN MED, V25, P385, DOI 10.3109/07853899309147301
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Toussirot E, 1999, RHEUMATOLOGY, V38, P21, DOI 10.1093/rheumatology/38.1.21
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
   WILL R, 1989, LANCET, V2, P1483
   Yilmaz N, 2000, CLIN RHEUMATOL, V19, P92, DOI 10.1007/s100670050024
NR 21
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0949 2321
EI 2047 783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD NOV 5
PY 2007
VL 12
IS 11
BP 568
EP 572
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 231JW
UT WOS:000250944000005
PM 18024266
DA 2025 08 17
ER

PT J
AU Liu, B
   Chen, F
   Wu, Y
   Wang, XL
   Feng, M
   Li, Z
   Zhou, MJ
   Wang, YC
   Wu, LQ
   Liu, XH
   Liang, DS
AF Liu, Bo
   Chen, Fei
   Wu, Yong
   Wang, Xiaolin
   Feng, Mai
   Li, Zhuo
   Zhou, Miaojin
   Wang, Yanchi
   Wu, Lingqian
   Liu, Xionghao
   Liang, Desheng
TI Enhanced tumor growth inhibition by mesenchymal stem cells derived from
   iPSCs with targeted integration of interleukin24 into rDNA loci
SO ONCOTARGET
LA English
DT Article
DE rDNA locus; gene targeting; MSCs derived from iPSCs; IL24; anti tumor
ID DIFFERENTIATION ASSOCIATED GENE 7/INTERLEUKIN 24; PROTECTIVE SIGNALING
   PATHWAYS; ATTENUATE LIMB ISCHEMIA; BREAST CANCER CELLS; STROMAL CELLS;
   IN VIVO; MELANOMA DIFFERENTIATION; MDA 7/IL 24 THERAPY; GENE; CARCINOMA
AB Induced pluripotent stem cells (iPSCs) are a promising source of mesenchymal stem cells (MSCs) for clinical applications. In this study, we transformed human iPSCs using a non viral vector carrying the IL24 transgene pHrn IL24. PCR and southern blotting confirmed IL24 integration into the rDNA loci in four of 68 iPSC clones. We then differentiated a high expressing IL24 iPSC clone into MSCs (IL24 iMSCs) that showed higher expression of IL24 in culture supernatants and in cell lysates than control iMSCs. IL24 iMSCs efficiently differentiated into osteoblasts, chondrocytes and adipocytes. Functionally, IL24 iMSCs induced in vitro apoptosis in B16 F10 melanoma cells more efficiently than control iMSCs when co cultured in Transwell assays. In vivo tumor xenograft studies in mice demonstrated that IL24 iMSCs inhibited melanoma growth more than control iMSCs did. Immunofluorescence and histochemical analysis showed larger necrotic areas and cell nuclear aggregation in tumors with IL24 iMSCs than control iMSCs, indicating that IL24 iMSCs inhibited tumor growth by inducing apoptosis. These findings demonstrate efficient transformation of iPSCs through gene targeting with non viral vectors into a rDNA locus. The ability of these genetically modified MSCs to inhibit in vivo melanoma growth is suggestive of the clinical potential of autologous cell therapy in cancer.
C1 [Liu, Bo; Chen, Fei; Wu, Yong; Wang, Xiaolin; Feng, Mai; Li, Zhuo; Zhou, Miaojin; Wang, Yanchi; Wu, Lingqian; Liu, Xionghao; Liang, Desheng] Cent S Univ, State Key Lab Med Genet, Changsha, Hunan, Peoples R China.
   [Liu, Bo; Chen, Fei; Wu, Yong; Wang, Xiaolin; Feng, Mai; Li, Zhuo; Zhou, Miaojin; Wang, Yanchi; Wu, Lingqian; Liu, Xionghao; Liang, Desheng] Cent S Univ, Sch Life Sci, Changsha, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Liu, XH; Liang, DS (通讯作者)，Cent S Univ, State Key Lab Med Genet, Changsha, Hunan, Peoples R China.; Liu, XH; Liang, DS (通讯作者)，Cent S Univ, Sch Life Sci, Changsha, Hunan, Peoples R China.
EM liuxionghao@sklmg.edu.cn; liangdesheng@sklmg.edu.cn
RI Wang, Yanchi/KVB 7923 2024; Liang, Desheng/ABH 2349 2021; 周,
   妙金/GZL 4967 2022; Liu, Xionghao/X 8424 2019; wang,
   xiaolin/HZK 6809 2023; chen, fei/GQP 1145 2022; Chen, Fei/GQP 1145 2022
OI Chen, Fei/0000 0003 2413 214X
FU National Natural Science Foundation of China [81272540, 81271944,
   31571313]; National Key Research and Development Program of China
   [2016YFC0905100]; Natural Science Foundation of Hunan Province of China
   [11JJ4023]
FX The present research was supported by The National Natural Science
   Foundation of China (81272540, 81271944, 31571313), The National Key
   Research and Development Program of China (2016YFC0905100) and The
   Natural Science Foundation of Hunan Province of China (11JJ4023).
CR Azab B, 2012, J CELL PHYSIOL, V227, P2145, DOI 10.1002/jcp.22947
   Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107
   Beers J, 2012, NAT PROTOC, V7, P2029, DOI 10.1038/nprot.2012.130
   Belmar Lopez C, 2013, BMC MED, V11, DOI 10.1186/1741 7015 11 139
   Bhutia SK, 2013, INT J CANCER, V133, P2726, DOI 10.1002/ijc.28289
   Dash R, 2010, CYTOKINE GROWTH F R, V21, P381, DOI 10.1016/j.cytogfr.2010.08.004
   Diederichs S, 2014, STEM CELLS DEV, V23, P1594, DOI 10.1089/scd.2013.0477
   Eulitt PJ, 2010, CANCER BIOL THER, V10, P1290, DOI 10.4161/cbt.10.12.13497
   Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008 5472.CAN 05 3127
   Gao P, 2010, CANCER LETT, V290, P157, DOI 10.1016/j.canlet.2009.08.031
   Germano IM, 2010, CANCER GENE THER, V17, P664, DOI 10.1038/cgt.2010.31
   Ginn SL, 2013, J GENE MED, V15, P65, DOI 10.1002/jgm.2698
   Gopalan B, 2007, MOL CANCER, V6, DOI 10.1186/1476 4598 6 11
   Hamed HA, 2010, MOL THER, V18, P1130, DOI 10.1038/mt.2010.29
   Heeschen C, 2004, CIRCULATION, V109, P1615, DOI 10.1161/01.CIR.0000124476.32871.E3
   Hingtgen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040234
   Hu GW, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt546
   Hu YJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/135189
   Huo W, 2013, ONCOL REP, V30, P986, DOI 10.3892/or.2013.2507
   Jiang HP, 1995, ONCOGENE, V11, P2477
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921
   Kidd S, 2010, CYTOTHERAPY, V12, P615, DOI 10.3109/14653241003631815
   Lebedeva IV, 2008, CANCER RES, V68, P7439, DOI 10.1158/0008 5472.CAN 08 0072
   Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116
   Li YJ, 2015, ONCOTARGET, V6, P36943, DOI 10.18632/oncotarget.6046
   Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312
   Liu X, 2007, J THROMB HAEMOST, V5, P347, DOI 10.1111/j.1538 7836.2007.02355.x
   Liu XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037071
   Loebinger MR, 2009, CANCER RES, V69, P4134, DOI 10.1158/0008 5472.CAN 08 4698
   Maestroni GJM, 1999, CELL MOL LIFE SCI, V55, P663, DOI 10.1007/s000180050322
   Menezes ME, 2015, ONCOTARGET, V6, P36928, DOI 10.18632/oncotarget.6047
   Menezes ME, 2014, ADV EXP MED BIOL, V818, P127, DOI 10.1007/978 1 4471 6458 6_6
   Menon LG, 2007, STEM CELLS, V25, P520, DOI 10.1634/stemcells.2006 0257
   Miller JC, 2011, NAT BIOTECHNOL, V29, P143, DOI 10.1038/nbt.1755
   Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276
   Otsu K, 2009, BLOOD, V113, P4197, DOI 10.1182/blood 2008 09 176198
   Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62
   Qiao L, 2008, CANCER LETT, V269, P67, DOI 10.1016/j.canlet.2008.04.032
   Qiao L, 2008, CELL RES, V18, P500, DOI 10.1038/cr.2008.40
   SAKAI K, 1995, GENOMICS, V26, P521, DOI 10.1016/0888 7543(95)80170 Q
   Sarkar S, 2015, ONCOTARGET, V6, P10712, DOI 10.18632/oncotarget.3544
   Sasportas LS, 2009, P NATL ACAD SCI USA, V106, P4822, DOI 10.1073/pnas.0806647106
   Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359 6101(02)00074 6
   Sauane M, 2008, P NATL ACAD SCI USA, V105, P9763, DOI 10.1073/pnas.0804089105
   Shou P, 2016, ONCOGENE, V35, P5953, DOI 10.1038/onc.2016.128
   Suzuki K, 2011, MOL MED, V17, P579, DOI 10.2119/molmed.2010.00157
   Valero V, 2011, CANCER GENE THER, V18, P510, DOI 10.1038/cgt.2011.20
   Wei N, 2010, HUM GENE THER, V21, P855, DOI 10.1089/hum.2009.207
   Weir C, 2008, HEART LUNG CIRC, V17, P395, DOI 10.1016/j.hlc.2008.01.006
   Wu Y, 2014, BIOCHEM BIOPH RES CO, V446, P261, DOI 10.1016/j.bbrc.2014.02.099
   Xin H, 2007, STEM CELLS, V25, P1618, DOI 10.1634/stemcells.2006 0461
   Xue JF, 2009, PROG BIOCHEM BIOPHYS, V36, P1429, DOI 10.3724/SP.J.1206.2009.00255
   Zhang X, 2013, CURR CANCER DRUG TAR, V13, P92, DOI 10.2174/156800913804486665
   Zhou YT, 2015, DIS MODEL MECH, V8, P1625, DOI 10.1242/dmm.021857
NR 55
TC 29
Z9 33
U1 0
U2 24
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 20
PY 2017
VL 8
IS 25
BP 40791
EP 40803
DI 10.18632/oncotarget.16584
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EY8YG
UT WOS:000404283700070
PM 28388559
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Gaudenzi, C
   Schioppa, T
   Passari, M
   Zucchi, G
   Tiberio, L
   Vahidi, Y
   Scutera, S
   Musso, T
   Sozzani, S
   Del Prete, A
   Salvi, V
   Bosisio, D
AF Gaudenzi, Carolina
   Schioppa, Tiziana
   Passari, Mauro
   Zucchi, Giovanni
   Tiberio, Laura
   Vahidi, Yasmin
   Scutera, Sara
   Musso, Tiziana
   Sozzani, Silvano
   Del Prete, Annalisa
   Salvi, Valentina
   Bosisio, Daniela
TI Extracellular microRNAs induce dendritic cell dependent joint
   inflammation and potentiate osteoclast differentiation via TLR7/ 8
   engagement
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE let7b 5p; miR574 5p; miR21 5p; miR203a 3p; Tumor Necrosis Factor (TNF);
   Th1 polarization; Rheumatoid Arthritis (RA)
ID ARTHRITIS; INSIGHTS
AB Objectives: Monocyte derived dendritic cells (DCs) are key players in the induction of inflammation, autoreactive T cell activation and loss of tolerance in rheumatoid arthritis (RA), but the precise mechanisms underlying their activation remain elusive. Here, we hypothesized that extracellular microRNAs released in RA synovial fluids may represent a novel, physiological stimulus triggering unwanted immune response via TLR8 expressing DC stimulation. Methods: Human monocyte derived DCs were stimulated with a mixture of GU rich miRNAs upregulated in RA tissues and released in synovial fluids (Ex miRNAs). Activation of DCs was assessed in terms of NF kappa B activation by Western blot, cytokine production by ELISA, T cell proliferation and polarization by allogeneic mixed lymphocyte reaction. DC differentiation into osteoclasts was evaluated in terms of tartrate resistant acid phosphatase production and formation of resorption pits in dentine slices. Induction of joint inflammation in vivo was evaluated using a murine model of DC induced arthritis. TLR7/8 involvement was assessed by specific inhibitors. Results: Ex miRNAs activate DCs to secrete TNF alpha, induce joint inflammation, start an early autoimmune response and potentiate the differentiation of DCs into aggressive osteoclasts. Conclusions: This work represents a proof of concept that the pool of extracellular miRNAs overexpressed in RA joints can act as a physiological activator of inflammation via the stimulation of TLR8 expressed by human DCs, which in turn exert arthritogenic functions. In this scenario, pharmacological inhibition of TLR8 might offer a new therapeutic option to reduce inflammation and osteoclast mediated bone destruction in RA.
C1 [Gaudenzi, Carolina; Schioppa, Tiziana; Passari, Mauro; Tiberio, Laura; Vahidi, Yasmin; Del Prete, Annalisa; Salvi, Valentina; Bosisio, Daniela] Univ Brescia, Dept Mol & Translat Med, Viale Europa 11, I 25123 Brescia, Italy.
   [Schioppa, Tiziana; Del Prete, Annalisa] IRCCS Humanitas Res Hosp, Milan, Italy.
   [Zucchi, Giovanni; Sozzani, Silvano] Sapienza Univ Rome, Lab Affiliated Inst Pasteur Italia, Dept Mol Med, Rome, Italy.
   [Scutera, Sara; Musso, Tiziana] Univ Turin, Dept Publ Hlth & Pediat Sci, Turin, Italy.
   [Sozzani, Silvano] IRCCS Neuromed, Pozzilli, IS, Italy.
C3 University of Brescia; Sapienza University Rome; University of Turin;
   IRCCS Neuromed
RP Bosisio, D (通讯作者)，Univ Brescia, Dept Mol & Translat Med, Viale Europa 11, I 25123 Brescia, Italy.
EM daniela.bosisio@unibs.it
RI Salvi, Valentina/Y 8757 2019; SCUTERA, SARA/AAU 6455 2020; GAUDENZI,
   CAROLINA/KBB 4509 2024; Schioppa, Tiziana/AAB 4961 2021; Bosisio,
   Daniela/AAL 3792 2020; Gaudenzi, Carolina/KBB 4509 2024; Sozzani,
   Silvano/C 1447 2009; Del Prete, Annalisa/Z 1368 2019; Vahidi,
   Yasmin/LEN 1550 2024
OI Zucchi, Giovanni/0009 0001 8772 2473; SCUTERA, SARA AGATA
   CATERINA/0000 0002 7431 0875; GAUDENZI, CAROLINA/0000 0003 1731 8747;
   Vahidi, Yasmin/0000 0002 2984 4093; Sozzani,
   Silvano/0000 0002 3144 8743; 
FU Italian Ministry of the University and Research [MUR PRIN
   20178ALPCM_005]; National Center for Gene Therapy and Drugs based on RNA
   Technology by Unione Europea NextGenerationEU [PNRR CN3]; Associazione
   Italiana per la Ricerca sul Cancro [IG 20776]; University of Brescia
FX This research was funded by the Italian Ministry of the University and
   Research (MUR PRIN 20178ALPCM_005 to DB), PNRR CN3 (National Center for
   Gene Therapy and Drugs based on RNA Technology financed by Unione
   Europea NextGenerationEU to SS), Associazione Italiana per la Ricerca
   sul Cancro (IG 20776 to SS), University of Brescia (Fondi Locali to DB,
   VS, ADP). These funders were not involved in the study design,
   collection, analysis, interpretation of data, the writing of this
   article or the decision to submit it for publication.
CR Bosisio D, 2019, CANCER LETT, V452, P59, DOI 10.1016/j.canlet.2019.03.021
   Chen X, 2012, TRENDS CELL BIOL, V22, P125, DOI 10.1016/j.tcb.2011.12.001
   Foers AD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094910
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hegewald AB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585282
   Hu ZY, 2018, CELL CHEM BIOL, V25, P1286, DOI 10.1016/j.chembiol.2018.07.004
   Kim SJ, 2016, ARTHRITIS RHEUMATOL, V68, P1099, DOI 10.1002/art.39544
   Leung BP, 2002, J IMMUNOL, V169, P7071, DOI 10.4049/jimmunol.169.12.7071
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Rivollier A, 2004, BLOOD, V104, P4029, DOI 10.1182/blood 2004 01 0041
   Salvi V, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.150542
   Salvi V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00015
   Salvi V, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98204
   Seenprachawong K, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00543
   Shimizu T, 2017, CURR OPIN STRUC BIOL, V47, P52, DOI 10.1016/j.sbi.2017.05.010
   Stanczyk J, 2011, ARTHRITIS RHEUM US, V63, P373, DOI 10.1002/art.30115
   Vlach J, 2021, J PHARMACOL EXP THER, V376, P397, DOI 10.1124/jpet.120.000275
   Yu MB, 2017, RHEUMATOL INT, V37, P1043, DOI 10.1007/s00296 017 3671 z
   Zhang L, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102438
NR 19
TC 5
Z9 7
U1 1
U2 8
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896 8411
EI 1095 9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD MAY
PY 2024
VL 145
AR 103189
DI 10.1016/j.jaut.2024.103189
EA MAR 2024
PG 7
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA PQ4A1
UT WOS:001215522100001
PM 38442677
DA 2025 08 17
ER

PT J
AU Pan, T
   Song, WJ
   Gao, HC
   Li, TJ
   Cao, XD
   Zhong, SZ
   Wang, YJ
AF Pan, Ting
   Song, Wenjing
   Gao, Huichang
   Li, Tianjie
   Cao, Xiaodong
   Zhong, Shizhen
   Wang, Yingjun
TI miR 29b Loaded Gold Nanoparticles Targeting to the Endoplasmic Reticulum
   for Synergistic Promotion of Osteogenic Differentiation
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE miR 29b; gold nanoparticles; osteogenic dffferentiation; human
   mesenchymal stem cells; miRNA delivery
ID MESENCHYMAL STEM CELLS; ANIMAL DEVELOPMENT; BONE REGENERATION; POSITIVE
   REGULATION; MICRORNA DELIVERY; STROMAL CELLS; GENE THERAPY; IN VITRO;
   GROWTH; STRATEGIES
AB Precise control of stem cells, such as human bone marrow derived mesenchymal stem cells (hMSCs), is critical for the development of effective cellular therapies for tissue engineering and regeneration medicine. Emerging evidence suggests that several miRNAs act as key regulators of diverse biological processes, including differentiation of various stem cells. In this study, we have described a delivery system for miR 29b using PEI capped gold nanoparticles (AuNPs) to synergistically promote osteoblastic differentiation. The cell proliferation assay revealed that AuNPs and AuNPs/miR 29b exert negligible cytotoxicity to hMSCs and MC3T3 E1 cells. With the assistance of AuNPs as a delivery vector, miR 29b could efficiently enter the cytoplasm and regulate osteogenesis. AuNPs/miR 29b more effectively promoted osteoblast differentiation and mineralization through induced the expression of osteogenesis genes (RUNX2, OPN, OCN, ALP) for the long term, compared to the widely used commercial transfection reagent, Lipofectamine. With no obvious cytotoxicity, PEI capped AuNPs showed great potential as an adequate miRNA vector for osteogenesis differentiation. Interestingly, we observed loading of AuNPs as well as AuNPs/miR 29b into the lumen of the endoplasmic reticulum (ER). Our findings collectively suggest that AuNPs, together with miR 29b, exert a synergistic promotory effect on osteogenic differentiation of hMSCs and MC3T3 E1 cells.
C1 [Pan, Ting; Gao, Huichang; Li, Tianjie; Cao, Xiaodong; Wang, Yingjun] South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510641, Guangdong, Peoples R China.
   [Pan, Ting; Song, Wenjing; Gao, Huichang; Li, Tianjie; Cao, Xiaodong; Wang, Yingjun] Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Guangdong, Peoples R China.
   [Song, Wenjing] South China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510006, Guangdong, Peoples R China.
   [Zhong, Shizhen] Southern Med Univ, Sch Basic Med Sci, Guangzhou 510515, Guangdong, Peoples R China.
C3 South China University of Technology; South China University of
   Technology; Southern Medical University   China
RP Wang, YJ (通讯作者)，South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510641, Guangdong, Peoples R China.; Song, WJ; Wang, YJ (通讯作者)，Natl Engn Res Ctr Tissue Restorat & Reconstruct, Guangzhou 510006, Guangdong, Peoples R China.; Song, WJ (通讯作者)，South China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510006, Guangdong, Peoples R China.
EM phsongwj@scut.edu.cn; imwangyj@163.com
RI cao, xiaodong/E 5641 2011
FU National Basic Research Program of China [2012CB619100]; National
   Natural Science Foundation of China [51232002]; 111 Project [B13039]
FX This study was financially supported by grants from the National Basic
   Research Program of China (Grant 2012CB619100), the National Natural
   Science Foundation of China (Grant 51232002), and the 111 Project (Grant
   B13039).
CR Alvarez Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Bahadur KCR, 2014, NANOTECHNOL REV, V3, P269, DOI 10.1515/ntrev 2013 0026
   Bamaby S. N., 2014, P NATL ACAD SCI USA, V111, P9739
   Beavers KR, 2015, ADV DRUG DELIVER REV, V88, P123, DOI 10.1016/j.addr.2014.12.006
   Bigall NC, 2011, ADV MATER, V23, P5645, DOI 10.1002/adma.201103505
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chen RR, 2003, PHARM RES DORDR, V20, P1103, DOI 10.1023/A:1025034925152
   Choi CKK, 2015, J AM CHEM SOC, V137, P7337, DOI 10.1021/jacs.5b01457
   Cinque L, 2015, NATURE, V528, P272, DOI 10.1038/nature16063
   Dhore CR, 2001, ARTERIOSCL THROM VAS, V21, P1998, DOI 10.1161/hq1201.100229
   Elbaz J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3000
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Frank O, 2002, J CELL BIOCHEM, V85, P737, DOI 10.1002/jcb.10174
   Gao J, 2011, J CELL BIOCHEM, V112, P1844, DOI 10.1002/jcb.23106
   Giatsidis G, 2013, PLAST RECONSTR SURG, V131, P1425, DOI 10.1097/PRS.0b013e31828bd153
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Heo DN, 2014, J MATER CHEM B, V2, P1584, DOI 10.1039/c3tb21246g
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Kim J, 2014, BIOMATERIALS, V35, P9058, DOI 10.1016/j.biomaterials.2014.07.036
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liu DD, 2010, CHINESE SCI BULL, V55, P1013, DOI 10.1007/s11434 010 0046 1
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Luo ZW, 2015, BIOMATERIALS, V52, P463, DOI 10.1016/j.biomaterials.2015.01.001
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   Mentink A, 2013, BIOMATERIALS, V34, P4592, DOI 10.1016/j.biomaterials.2013.03.001
   Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963
   Oh N, 2014, ACS NANO, V8, P6232, DOI 10.1021/nn501668a
   Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966
   Peng B, 2015, ADV DRUG DELIVER REV, V88, P108, DOI 10.1016/j.addr.2015.05.014
   Phillips JE, 2007, BIOMATERIALS, V28, P211, DOI 10.1016/j.biomaterials.2006.07.032
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Song WJ, 2010, SMALL, V6, P239, DOI 10.1002/smll.200901513
   Suh JS, 2013, BIOMATERIALS, V34, P4347, DOI 10.1016/j.biomaterials.2013.02.039
   Tellado SF, 2015, ADV DRUG DELIVER REV, V94, P126, DOI 10.1016/j.addr.2015.03.004
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang ZX, 2004, J MATER CHEM, V14, P578, DOI 10.1039/b314328g
   Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070
   Wu LC, 2013, ACS NANO, V7, P365, DOI 10.1021/nn3043397
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhang C, 2014, ACS NANO, V8, P1130, DOI 10.1021/nn406039p
   Zhang DW, 2014, MAT SCI ENG C MATER, V42, P70, DOI 10.1016/j.msec.2014.04.042
   Zhang R, 2012, INT J BIOCHEM CELL B, V44, P224, DOI 10.1016/j.biocel.2011.10.019
   Zhang Y, 2013, J CONTROL RELEASE, V172, P962, DOI 10.1016/j.jconrel.2013.09.015
NR 47
TC 66
Z9 68
U1 2
U2 118
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD AUG 3
PY 2016
VL 8
IS 30
BP 19217
EP 19227
DI 10.1021/acsami.6b02969
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA DS7MT
UT WOS:000380968300006
PM 27399270
DA 2025 08 17
ER

PT J
AU Dewar, AL
   Zannettino, ACW
   Hughes, TP
   Lyons, AB
AF Dewar, AL
   Zannettino, ACW
   Hughes, TP
   Lyons, AB
TI Inhibition of c fms by imatinib   Expanding the spectrum of treatment
SO CELL CYCLE
LA English
DT Article
DE imatinib; gleevec; c fms; bone remodelling; arthritis
ID COLONY STIMULATING FACTOR; TYROSINE KINASE INHIBITOR; GASTROINTESTINAL
   STROMAL TUMOR; GROWTH FACTOR RECEPTORS; STEM CELL FACTOR; OP OP MOUSE;
   RHEUMATOID ARTHRITIS; CSF 1 RECEPTOR; INFLAMMATORY ARTHRITIS;
   SIGNAL TRANSDUCTION
AB Imatinib is a selective protein tyrosine kinase inhibitor currently used in the treatment of chronic myeloid leukaemia (CML). It specifically suppresses the growth of bcr abl expressing CML progenitor cells by blocking the ATP binding site of the kinase domain of bcr abl. Imatinib also inhibits the c abl, platelet derived growth factor receptor ( PDGFR), abl related gene and stem cell factor receptor, c kit, protein tyrosine kinases. It is through inhibition of c kit that imatinib is also used clinically in the treatment of gastrointestinal stromal tumours. We have recently demonstrated that imatinib also specifically targets the macrophage colony stimulating factor receptor, c fms, at therapeutic concentrations. Although this finding has important implications with regard to potential side effects in patients currently receiving imatinib therapy, these results suggest that imatinib may also be useful in the treatment of diseases where c fms is implicated. This includes breast and ovarian cancer and inflammatory conditions such as rheumatoid arthritis. We also speculate that imatinib may be used in diseases where bone destruction occurs due to excessive osteoclast activity, such as in the haematologic malignancy, multiple myeloma.
C1 Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia.
   Hanson Inst, Div Haematol, Adelaide, SA 5000, Australia.
C3 Institute Medical & Veterinary Science Australia; Hanson Institute
RP Dewar, AL (通讯作者)，Inst Med & Vet Sci, Div Haematol, Frome Rd, Adelaide, SA 5000, Australia.
EM andrea.dewar@imvs.sa.gov.au
RI ; Hughes, Tim/AAO 9975 2021
OI Zannettino, Andrew/0000 0002 6646 6167; Lyons, Alan/0000 0002 8508 5853;
   
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357 2725(99)00076 X
   Bischof RJ, 2000, CLIN EXP IMMUNOL, V119, P361
   Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
   Campbell IK, 2000, J LEUKOCYTE BIOL, V68, P144
   Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952
   Carsons SE, 2000, J RHEUMATOL, V27, P2798
   CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917
   Clavel G, 2003, JOINT BONE SPINE, V70, P321, DOI 10.1016/S1297 319X(03)00088 5
   Croucher PI, 1998, BRIT J HAEMATOL, V103, P902, DOI 10.1046/j.1365 2141.1998.01082.x
   Demetri GD, 2001, SEMIN ONCOL, V28, P19, DOI 10.1053/sonc.2001.29181
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Dewar AL, 2005, IMMUNOL CELL BIOL, V83, P48, DOI 10.1111/j.1440 1711.2004.01296.x
   Dewar AL, 2003, LEUKEMIA, V17, P1713, DOI 10.1038/sj.leu.2403071
   Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596 561
   Eklund KK, 2003, ANN MED, V35, P362, DOI 10.1080/07853890310001339
   FELIX R, 1990, J BONE MINER RES, V5, P781
   FILDERMAN AE, 1992, CANCER RES, V52, P3661
   FIRESTEIN GS, 1988, J EXP MED, V168, P1573, DOI 10.1084/jem.168.5.1573
   Fixe P, 1998, CYTOKINE, V10, P32, DOI 10.1006/cyto.1997.0249
   Fujikawa Y, 1996, ENDOCRINOLOGY, V137, P4058, DOI 10.1210/en.137.9.4058
   HATTERSLEY G, 1991, BIOCHEM BIOPH RES CO, V177, P526, DOI 10.1016/0006 291X(91)92015 C
   Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932
   Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404
   KACINSKI BM, 1991, ONCOGENE, V6, P941
   Kacinski BM, 1997, MOL REPROD DEV, V46, P71, DOI 10.1002/(SICI)1098 2795(199701)46:1<71::AID MRD11>3.0.CO;2 6
   Miyachi K, 2003, CLIN RHEUMATOL, V22, P329, DOI 10.1007/s10067 003 0716 3
   Pandiella A, 2003, BRIT J HAEMATOL, V123, P858, DOI 10.1046/j.1365 2141.2003.04706.x
   Pollard JW, 1997, MOL REPROD DEV, V46, P54, DOI 10.1002/(SICI)1098 2795(199701)46:1<54::AID MRD9>3.0.CO;2 Q
   Pollard JW, 1997, MOL REPROD DEV, V46, P60
   Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525 1373.1999.d01 1.x
   Sapi E, 2004, EXP BIOL MED, V229, P1
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Toy EP, 2001, GYNECOL ONCOL, V80, P194, DOI 10.1006/gyno.2000.6070
   Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704
   WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828
   WILLIAMS WV, 1992, SEMIN ARTHRITIS RHEU, V21, P317, DOI 10.1016/0049 0172(92)90025 9
   YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460 2075.1987.tb02655.x
   YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0
NR 39
TC 45
Z9 59
U1 0
U2 2
PU LANDES BIOSCIENCE
PI GEORGETOWN
PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA
SN 1538 4101
J9 CELL CYCLE
JI Cell Cycle
PD JUL
PY 2005
VL 4
IS 7
BP 851
EP 853
DI 10.4161/cc.4.7.1788
PG 3
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 952EX
UT WOS:000230986600001
PM 15917650
DA 2025 08 17
ER

PT J
AU Askin, A
   Korkmaz, M
   Bayram, K
   Koçyigit, H
   Demirdal, S
   Kizilay, A
   Tosun, Ö
AF Askin, Ayhan
   Korkmaz, Merve
   Bayram, Korhan
   Kocyigit, Hikmet
   Demirdal, Secil
   Kizilay, Ayten
   Tosun, Ozgur
TI ATYPICAL SACRAL AND ILIAC BONE INSUFFICIENCY FRACTURES IN A PATIENT
   RECEIVING LONG TERM BISPHOSPHONATE THERAPY
SO TURKISH JOURNAL OF GERIATRICS TURK GERIATRI DERGISI
LA English
DT Article
DE Fractures; Stress; Ilium; Sacrum; Osteoporosis; Aged; Diphosphonates
AB Insufficiency fractures are a type of stress fracture occurring in bones with low resistance. The most common cause of insufficiency fractures is postmenopausal osteoporosis. Corticosteroid use, radiotherapy, rheumatoid arthritis, Paget disease, osteomalacia, long term use of bisphosphonates, hyperparathyroidism, diabetes mellitus, primary biliary cirrhosis, renal osteodystrophy are among the other risk factors. These fractures are generally overlooked because the symptomatology is similar to the clinical signs of osteodegenerative diseases, which are common in the elderly, particularly without a history of trauma.
   A 73 year old female patient was admitted to our outpatient clinic with a increase in low back pain intensity and difficulty in walking 3 months ago without a history of any trauma. She had a waddling gait with painful movements of both hips. Lumbar range of motion was normal but painful. On laboratory examination 25(OH) vitamin D3 level was low. Pelvic magnetic resonance imaging showed widespread bone marrow edema at both sacral wings and left iliac bone and signal recordings corresponding to insufficiency fractures in this region.
   Herein we present a case of an osteoporosis patient with sacral and iliac bone fractures that were treated conservatively.
C1 [Askin, Ayhan; Korkmaz, Merve; Bayram, Korhan; Kocyigit, Hikmet; Demirdal, Secil; Kizilay, Ayten] Katip Celebi Univ, Ataturk Training & Res Hosp, Phys Med & Rehabil, Izmir, Turkey.
   [Tosun, Ozgur] Katip Celebi Univ, Ataturk Training & Res Hosp, Radiol, Izmir, Turkey.
C3 Izmir Ataturk Training & Research Hospital; Izmir Katip Celebi
   University; Izmir Katip Celebi University; Izmir Ataturk Training &
   Research Hospital
RP Askin, A (通讯作者)，Katip Celebi Univ, Ataturk Training & Res Hosp, Phys Med & Rehabil, Izmir, Turkey.
EM ayhanaskin@hotmail.com
RI AŞKIN, AYHAN/A 7699 2015; Tosun, Ozgur/G 2279 2011; KIZILAY,
   Ahmet/R 6871 2019; bayram, korhan baris/HLG 9611 2023; Askin,
   Ayhan/A 7699 2015; Tosun, Özgür/G 2279 2011; bayram,
   korhan/HLG 9611 2023; Kocyigit, Hikmet/ABD 5244 2020
OI Tosun, Ozgur/0000 0001 6755 2131; bayram, korhan
   baris/0000 0002 5054 5784; Askin, Ayhan/0000 0001 9445 4430; 
CR Al faham Z, 2014, J NUCL MED TECHNOL, V42, P240, DOI 10.2967/jnmt.114.137547
   Ayalon O, 2013, BULL HOSP JT DIS, V71, P301
   Babayev M, 2000, AM J PHYS MED REHAB, V79, P404, DOI 10.1097/00002060 200007000 00014
   Baldwin MJ, 2014, INT MED CASE REP J, V7, P93, DOI 10.2147/IMCRJ.S60133
   CharyValckenaere I, 1997, REV RHUM, V64, P542
   DESMET AA, 1985, AM J ROENTGENOL, V145, P601, DOI 10.2214/ajr.145.3.601
   GOTISGRAHAM I, 1994, J BONE JOINT SURG BR, V76B, P882, DOI 10.1302/0301 620X.76B6.7983111
   Imai K, 2007, J BONE MINER METAB, V25, P333, DOI 10.1007/s00774 007 0771 y
   Kannus P, 2005, OSTEOPOROSIS INT, V16, P1304, DOI 10.1007/s00198 005 1941 1
   Kim Do Hoon, 2012, J Bone Metab, V19, P159, DOI 10.11005/jbm.2012.19.2.159
   Lee YJ, 2008, J KOREAN NEUROSURG S, V44, P166, DOI 10.3340/jkns.2008.44.3.166
   Longhino V, 2011, CLIN CASES MINER BON, V8, P19
   Murthy NS, 2012, RADIOL CLIN N AM, V50, P799, DOI 10.1016/j.rcl.2012.04.009
   Soubrier M, 2003, JOINT BONE SPINE, V70, P209, DOI 10.1016/S1297 319X(03)00024 1
   Tsiridis E, 2006, OSTEOPOROSIS INT, V17, P1716, DOI 10.1007/s00198 006 0175 1
NR 15
TC 1
Z9 1
U1 0
U2 3
PU GUNES KITABEVI LTD STI
PI ANKARA
PA M RAUF INAN SOK NO 3, ANKARA, SIHHIYE 06410, TURKEY
SN 1304 2947
EI 1307 9948
J9 TURK J GERIATR
JI Turk. J. Geriatr.
PY 2015
VL 18
IS 2
BP 171
EP 175
PG 5
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA CN4CY
UT WOS:000358378200013
DA 2025 08 17
ER

PT J
AU Kusuyama, J
   Seong, C
   Makarewicz, NS
   Ohnishi, T
   Shima, K
   Semba, I
   Bandow, K
   Matsuguchi, T
AF Kusuyama, Joji
   Seong, Changhwan
   Makarewicz, Nathan S.
   Ohnishi, Tomokazu
   Shima, Kaori
   Semba, Ichiro
   Bandow, Kenjiro
   Matsuguchi, Tetsuya
TI Low intensity pulsed ultrasound (LIPUS) maintains osteogenic potency by
   it the increased expression and stability of Nanog through spleen
   tyrosine kinase (Syk) activation
SO CELLULAR SIGNALLING
LA English
DT Article
DE Mesenchymal stem cell; Differentiation; Osteoblast; Osteogenesis;
   Passage
ID MESENCHYMAL STEM CELLS; MULTILINEAGE DIFFERENTIATION; SELF RENEWAL; ATP
   RELEASE; BONE; PHOSPHORYLATION; PROLIFERATION; PLURIPOTENCY; INHIBITION;
   REORGANIZATION
AB Mesenchymal stem cells (MSCs) are a powerful tool for cell based, clinical therapies like bone regeneration. Therapeutic use of cell transplantation requires many cells, however, the expansion process needed to produce large quantities of cells reduces the differentiation potential of MSCs. Here, we examined the protective effects of low intensity pulsed ultrasound (LIPUS) on the maintenance of osteogenic potency. Primary osteoblastic cells were serially passaged between 2 and 12 times with daily LIPUS treatment. We found that LIPUS stimulation maintains osteogenic differentiation capacity in serially passaged cells, as characterized by improved matrix mineralization and Osteocalcin mRNA expression. Decreased expression of Nanog, Sox2, and Msx2, and increased expression of Pparg2 from serial passaging was recovered in LIPUS stimulated cells. We found that LIPUS stimulation not only increased but also sustained expression of Nanog in primary osteoblasts and ST2 cells, a mouse mesenchymal stromal cell line. Nanog overexpression in serially passaged cells mimicked the recuperative effects of LIPUS on osteogenic potency, highlighting the important role of Nanog in LIPUS stimulation. Additionally, we found that spleen tyrosine kinase (Syk) is an important signaling molecule to induce Nanog expression in LIPUS stimulated cells. Syk activation was regulated by both Rho associated kinase 1 (ROCK1) and extracellular ATP in a paracrine manner. Interestingly, the LIPUS induced increase in Nanog mRNA expression was regulated by ATP P2X4 Syk Y323 activation, while the improvement of Nanog protein stability was controlled by the ROCK1 Syk Y525/526 pathway. Taken together, these results indicate that LIPUS stimulation recovers and maintains the osteogenic potency of serially passaged cells through a Syk Nanog axis.
C1 [Kusuyama, Joji; Seong, Changhwan; Ohnishi, Tomokazu; Matsuguchi, Tetsuya] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Oral Biochem, Field Dev Med, 8 35 1 Sakuragaoka, Kagoshima 8908544, Japan.
   [Kusuyama, Joji; Makarewicz, Nathan S.] Harvard Med Sch, Dept Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, One Joslin Pl, Boston, MA 02215 USA.
   [Seong, Changhwan] Kagoshima Univ, Grad Sch Med & Dent Sci, Field Oral & Maxillofacial Rehabil, Dept Oral & Maxillofacial Surg, 8 35 1 Sakuragaoka, Kagoshima 8908544, Japan.
   [Shima, Kaori; Semba, Ichiro] Kagoshima Univ, Grad Sch Med & Dent Sci, Field Oncol, Dept Oral Pathol, 8 35 1 Sakuragaoka, Kagoshima 8908544, Japan.
   [Bandow, Kenjiro] Meikai Univ, Sch Dent, Dept Oral Biol & Tissue Engn, 1 1 Keyakidai, Saitama 3500283, Japan.
C3 Kagoshima University; Harvard University; Harvard University Medical
   Affiliates; Joslin Diabetes Center, Inc.; Harvard Medical School;
   Kagoshima University; Kagoshima University; Meikai University
RP Kusuyama, J (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Oral Biochem, Field Dev Med, 8 35 1 Sakuragaoka, Kagoshima 8908544, Japan.
EM joji.kusuyama@joslin.harvard.edu
RI Shima, Kaori/HTO 3717 2023; Matsuguchi, Tetsuya/HGU 0412 2022; Kusuyama,
   Joji/AAQ 7547 2020
OI Bandow, Kenjiro/0000 0002 1362 3034; Semba, Ichiro/0000 0002 4588 2380;
   Makarewicz, Nathan/0000 0001 8255 7563; Kusuyama,
   Joji/0000 0003 4054 1939; 
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [15K20375]; Kanzawa Medical Research Foundation; Nakatomi Foundation;
   Japan Foundation for Aging and Health; Teijin Pharma; Grants in Aid for
   Scientific Research [15K20375] Funding Source: KAKEN
FX We thank Ms. Yoko Amita and Ms. Yuka Kajiya for their secretarial
   assistance. This work was supported by grants from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (15K20375 to
   JK), the Kanzawa Medical Research Foundation (to JK), the Nakatomi
   Foundation (to JK), and the Japan Foundation for Aging and Health (to
   JK), and Teijin Pharma, which supplied the LIPUS device.
CR Andalib Mohammad Nahid, 2016, Biomater Res, V20, P11
   Apoorva F, 2018, CELL REP, V23, P499, DOI 10.1016/j.celrep.2018.03.069
   Bijli KM, 2008, J BIOL CHEM, V283, P14674, DOI 10.1074/jbc.M802094200
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471 2121 7 14
   Boyle Sarah T, 2016, Small GTPases, V7, P139, DOI 10.1080/21541248.2016.1173771
   Brumbaugh J, 2014, STEM CELL REP, V2, P18, DOI 10.1016/j.stemcr.2013.12.005
   Carsetti L, 2009, CELL SIGNAL, V21, P1187, DOI 10.1016/j.cellsig.2009.03.007
   Cha Y, 2010, STEM CELLS, V28, P1476, DOI 10.1002/stem.470
   Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403
   Costa V, 2018, J CELL PHYSIOL, V233, P1558, DOI 10.1002/jcp.26058
   Coughlin TR, 2015, CALCIFIED TISSUE INT, V96, P65, DOI 10.1007/s00223 014 9928 6
   Di Battista JA, 2014, INFLAMM RES, V63, P907, DOI 10.1007/s00011 014 0764 y
   Forst AL, 2016, J AM SOC NEPHROL, V27, P848, DOI 10.1681/ASN.2014111144
   Gharibi B, 2014, STEM CELLS, V32, P2256, DOI 10.1002/stem.1709
   Goetzke R, 2018, CELL MOL LIFE SCI, V75, P3297, DOI 10.1007/s00018 018 2830 z
   Haga JH, 2002, ANN BIOMED ENG, V30, P1262, DOI 10.1114/1.1528613
   Han SM, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.28
   Hazama R, 2009, GENES CELLS, V14, P871, DOI 10.1111/j.1365 2443.2009.01317.x
   Hensel K, 2011, ULTRASOUND MED BIOL, V37, P2105, DOI 10.1016/j.ultrasmedbio.2011.09.007
   Hoey DA, 2012, STEM CELLS, V30, P2561, DOI 10.1002/stem.1235
   Horiuchi R, 2012, EXP CELL RES, V318, P1726, DOI 10.1016/j.yexcr.2012.05.021
   Jarvis MF, 2009, NEUROPHARMACOLOGY, V56, P208, DOI 10.1016/j.neuropharm.2008.06.067
   Kim SH, 2014, STEM CELL RES, V13, P1, DOI 10.1016/j.scr.2014.04.001
   Kim YM, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0594 2
   Knight MN, 2013, ADV WOUND CARE, V2, P306, DOI 10.1089/wound.2012.0420
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Komori T, 2011, J CELL BIOCHEM, V112, P750, DOI 10.1002/jcb.22994
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 60
   Kuo YC, 2015, STEM CELLS, V33, P429, DOI 10.1002/stem.1860
   Kusuyama J., 2019, J CELL BIOCH
   Kusuyama J, 2018, J CELL PHYSIOL, V233, P2549, DOI 10.1002/jcp.26130
   Kusuyama J, 2017, MOL BIOL CELL, V28, P1326, DOI 10.1091/mbc.E16 10 0716
   Kusuyama J, 2016, J LIPID RES, V57, P1806, DOI 10.1194/jlr.M067207
   Kusuyama J, 2014, J BIOL CHEM, V289, P10330, DOI 10.1074/jbc.M113.546382
   Kwon HJ, 2016, SCI REP UK, V6, DOI 10.1038/srep39302
   Ling P, 2017, ADV EDUC MARK ADMIN, P1, DOI 10.4018/978 1 5225 1738 2.ch001
   Liu DD, 2013, ACS APPL MATER INTER, V5, P13295, DOI 10.1021/am404276r
   Liu XQ, 2014, THROMB RES, V134, P1066, DOI 10.1016/j.thromres.2014.08.025
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Manaka S, 2015, FEBS LETT, V589, P310, DOI 10.1016/j.febslet.2014.12.013
   Mócsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765
   Moretto Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107
   Nakao J, 2014, BONE, V58, P17, DOI 10.1016/j.bone.2013.09.018
   Ramakrishna S, 2011, STEM CELLS DEV, V20, P1512, DOI 10.1089/scd.2010.0410
   Razzouk S, 2012, J PERIODONTOL, V83, P547, DOI 10.1902/jop.2011.110384
   Reséndiz JC, 2003, MOL PHARMACOL, V63, P639, DOI 10.1124/mol.63.3.639
   Romano CL, 2009, ULTRASOUND MED BIOL, V35, P529, DOI 10.1016/j.ultrasmedbio.2008.09.029
   Saha S, 2006, J CELL PHYSIOL, V206, P126, DOI 10.1002/jcp.20441
   Saunders A, 2013, STEM CELLS, V31, P1227, DOI 10.1002/stem.1384
   Schuh CMAP, 2014, CYTOTHERAPY, V16, P1666, DOI 10.1016/j.jcyt.2014.07.005
   Schymeinsky J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001132
   Sisakhtnezhad S, 2017, EUR J CELL BIOL, V96, P13, DOI 10.1016/j.ejcb.2016.11.003
   Song Guanbin, 2007, Molecular & Cellular Biomechanics, V4, P201
   Speich HE, 2008, AM J PHYSIOL CELL PH, V295, pC1045, DOI 10.1152/ajpcell.90644.2007
   Sun DH, 2013, STEM CELLS, V31, P1170, DOI 10.1002/stem.1356
   Suurväli J, 2017, BIOMED J, V40, P245, DOI 10.1016/j.bj.2017.06.010
   Tsai CC, 2012, MOL CELL, V47, P169, DOI 10.1016/j.molcel.2012.06.020
   Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777
   Wei CC, 2014, CELL TRANSPLANT, V23, P505, DOI 10.3727/096368914X678328
   White UA, 2010, MOL CELL ENDOCRINOL, V318, P10, DOI 10.1016/j.mce.2009.08.023
   Yang YHK, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0876 3
   Yoon DS, 2011, CELL PROLIFERAT, V44, P428, DOI 10.1111/j.1365 2184.2011.00770.x
   Yu TC, 2010, AM J PHYSIOL CELL PH, V298, pC457, DOI 10.1152/ajpcell.00342.2009
   Zhang H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0805 5
   Zhang J, 2000, J BIOL CHEM, V275, P35442, DOI 10.1074/jbc.M004549200
   Zhang SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046853
NR 66
TC 7
Z9 7
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898 6568
EI 1873 3913
J9 CELL SIGNAL
JI Cell. Signal.
PD OCT
PY 2019
VL 62
AR 109345
DI 10.1016/j.cellsig.2019.109345
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA IQ3RP
UT WOS:000480669100018
PM 31228531
DA 2025 08 17
ER

PT J
AU Harten, RD
   Svach, DJ
   Schmeltzer, R
   Uhrich, KE
AF Harten, RD
   Svach, DJ
   Schmeltzer, R
   Uhrich, KE
TI Salicylic acid derived poly(anhydride esters) inhibit bone resorption
   and formation in vivo
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE salicylic acid; poly(anhydride ester); bone formation; bone resorption;
   bone defect
ID OSTEOCLAST LIKE CELLS; FETAL RAT CALVARIAE; PROSTAGLANDIN E 2;
   ANTIBIOTIC DELIVERY; ANTIPLAQUE AGENTS; DRUG DELIVERY; RELEASE;
   OSTEOMYELITIS; MECHANISM; POLYMER
AB The objective of this study was to investigate the effects of a novel polymer that biodegrades into salicylic acid (SA) on the healing of critical sized long bone defects. Microspheres of the homopolymer, or a copolymer containing 50% less of the SA, were packed into 5 mm mid diaphyseal defects in rat femurs. Control animals received collagen sponge implants. After 4 and 8 weeks of implantation, bone healing was evaluated using microradiography and quantitative histomorphometry. Four weeks postsurgery, significantly less new bone was formed in both of the polymer groups (p < 0.038). Reduced bone loss was also noted with the polymers at this time, although it was not statistically significant. However, at 8 weeks postsurgery, a statistically significant reduction in bone loss was observed in both of the polymer groups compared with controls (p < 0.0072). Both polymers seemed to elicit identical tissue responses because there were no differences detected between the homopolymer and copolymer materials at either time point. These results indicate that locally released SA can significantly reduce both bone loss and bone formation in this animal model. (C) 2005 Wiley Periodicals, Inc.
C1 Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Orthopaed, Newark, NJ 07103 USA.
   Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick
RP Harten, RD (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Orthopaed, Newark, NJ 07103 USA.
EM hartenr@synthes.com
RI Uhrich, Kathryn/I 2099 2013
OI Uhrich, Kathryn/0000 0001 7273 7528
CR An YHH, 1998, CLIN ORTHOP RELAT R, P300
   BERGSMA JE, 1995, BIOMATERIALS, V16, P25, DOI 10.1016/0142 9612(95)91092 D
   Berkland C, 2004, J CONTROL RELEASE, V94, P129, DOI 10.1016/j.jconrel.2003.09.011
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   Campo CJ, 1999, POLYM BULL, V42, P61, DOI 10.1007/s002890050435
   CHYUN YS, 1984, PROSTAG OTH LIPID M, V27, P97, DOI 10.1016/0090 6980(84)90223 5
   CLARK MT, 1986, J MED CHEM, V29, P25, DOI 10.1021/jm00151a004
   COBURN RA, 1981, J MED CHEM, V24, P1245, DOI 10.1021/jm00142a023
   DEKEL S, 1981, J BONE JOINT SURG BR, V63, P178, DOI 10.1302/0301 620X.63B2.7217138
   Erdmann L, 2000, BIOMATERIALS, V21, P2507, DOI 10.1016/S0142 9612(00)00118 6
   Erdmann L, 2000, BIOMATERIALS, V21, P1941, DOI 10.1016/S0142 9612(00)00073 9
   FARBER BF, 1993, J BIOMED MATER RES, V27, P599, DOI 10.1002/jbm.820270506
   Friess W, 2002, PHARM DEV TECHNOL, V7, P235, DOI 10.1081/PDT 120003491
   Fujita D, 2003, PROSTAG LEUKOTR ESS, V68, P351, DOI 10.1016/S0952 3278(03)00027 9
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Glassman SD, 1998, SPINE, V23, P834, DOI 10.1097/00007632 199804010 00020
   Gruber R, 2002, BONE, V30, P726, DOI 10.1016/S8756 3282(02)00697 X
   Heckman JD, 1999, J BONE JOINT SURG AM, V81A, P1717, DOI 10.2106/00004623 199912000 00009
   Keila S, 2001, J ENDOCRINOL, V168, P131, DOI 10.1677/joe.0.1680131
   Kenawy ER, 2002, J CONTROL RELEASE, V81, P57, DOI 10.1016/S0168 3659(02)00041 X
   Lader CS, 1998, ENDOCRINOLOGY, V139, P3157, DOI 10.1210/en.139.7.3157
   LAURENCIN CT, 1993, J ORTHOPAED RES, V11, P256, DOI 10.1002/jor.1100110213
   Li LC, 2002, ADV DRUG DELIVER REV, V54, P963
   Lin SS, 1999, CLIN ORTHOP RELAT R, P240
   Mitchell ME, 2001, AVIAT SPACE ENVIR MD, V72, P790
   MORI S, 1992, CALCIFIED TISSUE INT, V50, P80, DOI 10.1007/BF00297302
   Muller E, 1998, J INFECT DIS, V177, P501, DOI 10.1086/517386
   Nelson CL, 2002, J ORTHOP RES, V20, P643, DOI 10.1016/S0736 0266(01)00133 4
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Özalp Y, 2002, J MICROENCAPSUL, V19, P83, DOI 10.1080/02652040110065404
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Park ES, 1998, J CONTROL RELEASE, V52, P179, DOI 10.1016/S0168 3659(97)00223 X
   PLOTQUIN D, 1991, PROSTAG LEUKOTR ESS, V43, P13, DOI 10.1016/0952 3278(91)90126 P
   PRUDENCIO A, 2004, 31 ANN M CONTR REL S
   RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1654, DOI 10.1210/endo 126 3 1654
   Saito N, 2003, BIOMATERIALS, V24, P2287, DOI 10.1016/S0142 9612(03)00040 1
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Storm PB, 2002, J NEURO ONCOL, V56, P209, DOI 10.1023/A:1015003232713
   Tielinen L, 2002, BIOMATERIALS, V23, P3817, DOI 10.1016/S0142 9612(02)00105 9
   UEDA K, 1980, J PEDIATR US, V97, P834, DOI 10.1016/S0022 3476(80)80282 4
   UHRICH KE, 1995, MACROMOLECULES, V28, P2184, DOI 10.1021/ma00111a012
   Weinreb M, 1999, AM J PHYSIOL ENDOC M, V276, pE376, DOI 10.1152/ajpendo.1999.276.2.E376
   WINET H, 1993, J BIOMED MATER RES, V27, P667, DOI 10.1002/jbm.820270514
   Woodiel FN, 1996, J BONE MINER RES, V11, P1249
   YEAGY B, 2003, AM ASS PHARM SCI J, V5
   ZHOU ZF, 1993, BIOMAT ARTIF CELL IM, V21, P71
NR 46
TC 36
Z9 51
U1 0
U2 6
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1549 3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD MAR 15
PY 2005
VL 72A
IS 4
BP 354
EP 362
DI 10.1002/jbm.a.30184
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 903ZD
UT WOS:000227463400002
PM 15678485
DA 2025 08 17
ER

PT J
AU Habacher, G
   Malik, R
   Lait, PJP
   Coghill, LM
   Middleton, RP
   Warren, WC
   Lyons, LA
AF Habacher, Gabriele
   Malik, Richard
   Lait, Philippa J. P.
   Coghill, Lyndon M.
   Middleton, Rondo P.
   Warren, Wesley C.
   Lyons, Leslie A.
TI Feline precision medicine using whole exome sequencing identifies a
   novel frameshift mutation for vitamin D dependent rickets type 2
SO JOURNAL OF FELINE MEDICINE AND SURGERY
LA English
DT Article
DE Animal models; Felis catus; whole exome sequencing; rickets; precision
   medicine
ID D RESISTANT RICKETS; GENE; DOG
AB ObjectivesA 14 week old female domestic longhair kitten presented with shifting lameness and disproportionately smaller size compared with a co housed littermate. MethodsHematology and serum biochemical testing were conducted to investigate causes for delayed growth, and radiographs of the appendicular skeleton were obtained. ResultsThe afflicted kitten had marked hypocalcemia, mild hypophosphatemia and substantial elevations in alkaline phosphatase activity, as well as pathognomonic radiographic findings consistent with rickets. Skeletal changes and hypocalcemia prompted testing of concentrations of parathyroid hormone (PTH) and vitamin D metabolites. Endocrine testing demonstrated significant increases in serum concentrations of PTH and 1,25 dihydroxycholecalciferol (calcitriol), supporting a diagnosis of vitamin D dependent rickets type 2. Provision of analgesia, supraphysiologic doses of calcitriol and calcium carbonate supplementation achieved normalization of the serum calcium concentration and restoration of normal growth, although some skeletal abnormalities persisted. Once skeletally mature, ongoing calcitriol supplementation was not required. Whole exome sequencing (WES) was conducted to identify the underlying DNA variant. A cytosine deletion at cat chromosome position B4:76777621 in VDR (ENSFCAT00000029466:c.106delC) was identified and predicted to cause a stop codon in exon 2 (p.Arg36Glufs*18), disrupting >90% of the receptor. The variant was unique and homozygous in this patient and absent in the sibling and approximately 400 other cats for which whole genome and whole exome data were available. Conclusions and relevanceA unique, heritable form of rickets was diagnosed in a domestic longhair cat. WES identified a novel frameshift mutation affecting the gene coding for the vitamin D3 receptor, determining the likely causal genetic variant. Precision medicine techniques, including whole exome and whole genome sequencing, can be a standard of care in cats to identify disease etiologies, and to target therapeutics and personalize treatment.
C1 [Habacher, Gabriele] CVS UK Ltd, Raddenstiles Vet Surg, Exmouth, England.
   [Malik, Richard] Univ Sydney, Ctr Vet Educ, Sydney, NSW, Australia.
   [Lait, Philippa J. P.] Univ Bristol, Langford Vets, Bristol, England.
   [Coghill, Lyndon M.] Univ Missouri, Coll Vet Med, Dept Vet Pathobiol, Columbia, MO 65211 USA.
   [Middleton, Rondo P.] Nestle Purina Res, St Louis, MO USA.
   [Warren, Wesley C.] Univ Missouri, Inst Data Sci & Informat, Sch Med, Div Anim Sci,Coll Agr,Dept Surg, Columbia, MO 65211 USA.
   [Lyons, Leslie A.] Univ Missouri, Coll Vet Med, Dept Vet Med & Surg, E109 Vet Med Bldg,1520 E Rollins St, Columbia, MO 65211 USA.
C3 University of Sydney; University of Bristol; University of Missouri
   System; University of Missouri Columbia; Nestle SA; Nestle Research
   Center; University of Missouri System; University of Missouri Columbia;
   University of Missouri System; University of Missouri Columbia
RP Lyons, LA (通讯作者)，Univ Missouri, Coll Vet Med, Dept Vet Med & Surg, E109 Vet Med Bldg,1520 E Rollins St, Columbia, MO 65211 USA.
EM lyonsla@missouri.edu
RI ; Malik, Richard/I 2009 2019
OI Lyons, Leslie/0000 0002 1628 7726; 
CR Buckley RM, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008926
   Cartwright JA, 2018, J VET INTERN MED, V32, P764, DOI 10.1111/jvim.15052
   Christakos S, 2010, ENDOCRIN METAB CLIN, V39, P243, DOI 10.1016/j.ecl.2010.02.002
   Clarke KE, 2021, J SMALL ANIM PRACT, V62, P935, DOI 10.1111/jsap.13401
   Cunningham F, 2019, NUCLEIC ACIDS RES, V47, pD745, DOI 10.1093/nar/gky1113
   Duplan F, 2020, J FELINE MED SURG OP, V6, DOI 10.1177/2055116920910278
   Finch NC, 2016, J FELINE MED SURG, V18, P387, DOI 10.1177/1098612X16643248
   Geisen V, 2009, J VET INTERN MED, V23, P196, DOI [10.1111/j.1939 1676.2008.0220.x, 10.1111/j.1939 1676.2008.00220.x]
   Godfrey DR, 2005, J SMALL ANIM PRACT, V46, P440, DOI 10.1111/j.1748 5827.2005.tb00343.x
   Grahn RA, 2012, J FELINE MED SURG, V14, P587, DOI 10.1177/1098612X12446637
   HOW KL, 1994, GEN COMP ENDOCR, V96, P12, DOI 10.1006/gcen.1994.1154
   HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209
   Kopke MA, 2022, J VET INTERN MED, V36, P1800, DOI 10.1111/jvim.16509
   Landrum MJ, 2018, NUCLEIC ACIDS RES, V46, pD1062, DOI 10.1093/nar/gkx1153
   LeVine DN, 2009, J VET INTERN MED, V23, P1278, DOI 10.1111/j.1939 1676.2009.0405.x
   Levine MA, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00315
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059 016 0974 4
   Mechica JB, 1997, J CLIN ENDOCR METAB, V82, P3892, DOI 10.1210/jc.82.11.3892
   Miyamoto K, 1997, MOL ENDOCRINOL, V11, P1165, DOI 10.1210/me.11.8.1165
   Norman T., 1996, PRINCIPLES BONE BIOL, P1398
   OMIM, 277440 OMIM
   OMIM, 601769 OMIM
   Phillips AM, 2011, J FELINE MED SURG, V13, P526, DOI 10.1016/j.jfms.2011.05.010
   Pineda C, 2013, J FELINE MED SURG, V15, P866, DOI 10.1177/1098612X13478264
   Rodney AR, 2023, FRONT VET SCI, V10, DOI 10.3389/fvets.2023.1079019
   Rodney AR, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 86200 7
   RUT AR, 1994, CLIN ENDOCRINOL, V41, P581, DOI 10.1111/j.1365 2265.1994.tb01822.x
   Schreiner CA, 2003, J AM VET MED ASSOC, V222, P337, DOI 10.2460/javma.2003.222.337
   Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264
   Tanner E, 2005, J FELINE MED SURG, V7, P307, DOI 10.1016/j.jfms.2005.01.003
   Teshima T, 2019, BMC VET RES, V15, DOI 10.1186/s12917 019 1784 1
   Tomsa C, 1999, J SMALL ANIM PRACT, V40, P533, DOI 10.1111/j.1748 5827.1999.tb03015.x
   Zhu WJ, 1998, J BONE MINER RES, V13, P259, DOI 10.1359/jbmr.1998.13.2.259
NR 33
TC 2
Z9 2
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1098 612X
EI 1532 2750
J9 J FELINE MED SURG
JI J. Feline Med. Surg.
PD MAY
PY 2023
VL 25
IS 5
AR 1098612X231165630
DI 10.1177/1098612X231165630
PG 8
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA K4MI1
UT WOS:001016191800001
PM 37387221
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wang, CD
   Xiao, F
   Gan, YK
   Yuan, WE
   Zhai, ZJ
   Jin, T
   Chen, XD
   Zhang, XL
AF Wang, Chuandong
   Xiao, Fei
   Gan, Yaokai
   Yuan, Weien
   Zhai, Zhanjing
   Jin, Tuo
   Chen, Xiaodong
   Zhang, Xiaoling
TI Improving Bone Regeneration Using Chordin siRNA Delivered by
   pH Responsive and Non Toxic Polyspermine Imidazole 4,5 Imine
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Human bone marrow mesenchymal stem cells; Chordin; Bone morphogenetic
   protein 2; Polyspermine imidazole 4; 5 imine; Osteogenesis
ID MORPHOGENETIC PROTEIN ANTAGONISTS; MESENCHYMAL STEM CELLS; IN VIVO;
   OSTEOBLAST DIFFERENTIATION; HUMAN FRACTURES; BMP INHIBITORS; EXPRESSION;
   GENE; POLYETHYLENIMINE; REPAIR
AB Background/Aims: Bone nonunion remains a challenge for orthopaedists. The technological advancements that have been made in precisely silencing target genes have provided promising methods to address this challenge. Methods: We detected the expression levels of the bone morphogenetic protein (BMP) inhibitors Chordin, Gremlin and Noggin using real time PCR in bone mesenchymal stem cells (BMSCs) isolated from patients with normal fracture healing and those with bone nonunion. Moreover, we detected the expression of Chordin, Gremlin and Noggin during the osteogenic differentiation of human BMSCs (hBMSCs) using real time PCR and Western blot. We delivered Chordin siRNA to hBMSCs using a previously reported cationic polymer, polyspermine imidazole 4,5 imine (PSI), as a pH responsive and non cytotoxic transfection agent. The apoptosis and cellular uptake efficiency were analysed by flow cytometry. Results: We identified Chordin as the most appropriate potential therapeutic target gene for enhancing the osteogenic differentiation of hBMSCs. Chordin knockdown rescued the osteogenic capacity of hBMSCs isolated from patients with bone nonunion. Highly efficient knockdown of Chordin was achieved in hBMSCs using PSI. Chordin knockdown promoted hBMSC osteogenesis and bone regeneration in vitro and in vivo. Conclusions: Our results suggest that Chordin is a potential target for improving osteogenesis and bone nonunion therapy and that responsive and non toxic cationic polyimines such as PSI are therapeutically feasible carriers for the packaging and delivery of Chordin siRNA to hBMSCs. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Wang, Chuandong; Xiao, Fei; Chen, Xiaodong; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Xin Hua Hosp, Sch Med SJTUSM, Dept Orthoped Surg, Shanghai, Peoples R China.
   [Yuan, Weien; Jin, Tuo] Shanghai Jiao Tong Univ, Sch Pharm, 800 Dongchuan Rd, Shanghai, Peoples R China.
   [Gan, Yaokai; Zhai, Zhanjing] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implant, Dept Orthopaed Surg,Sch Med, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Zhang, XL (通讯作者)，Shanghai Jiao Tong Univ, Xin Hua Hosp, Sch Med SJTUSM, Dept Orthoped Surg, Shanghai, Peoples R China.
EM xlzhang@shsmu.edu.cn
RI ; Chen, Xiao Dong/ADG 8612 2022; Zhang, Xiaoling/J 1666 2016
OI Zhang, Xiaoling/0000 0002 0134 1347; 
FU National Natural Science Foundation of China [81772347, 81572123];
   Science and Technology Commission of Shanghai Municipality [15411951100,
   16430723500]; Shanghai Municipal Education Commission Gaofeng Clinical
   Medicine Grant Support [20161314]; Shanghai Shen Kang hospital
   development center [16CR2036B]; China Postdoctoral Science Foundation
   [2017M621501]
FX This work was supported by grants from National Natural Science
   Foundation of China (No. 81772347, 81572123), Science and Technology
   Commission of Shanghai Municipality (No. 15411951100, 16430723500),
   Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant
   Support (No. 20161314) and Shanghai Shen Kang hospital development
   center (No. 16CR2036B), China Postdoctoral Science Foundation (No.
   2017M621501).
CR Abdallah Basem M., 2008, V455, P89, DOI 10.1007/978 1 59745 104 8_6
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   Bonnet ME, 2008, PHARM RES DORDR, V25, P2972, DOI 10.1007/s11095 008 9693 1
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Chen C, 2012, J CELL BIOCHEM, V113, P3672, DOI 10.1002/jcb.24240
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chrastil J, 2013, SPINE, V38, pE1020, DOI 10.1097/BRS.0b013e3182982f8e
   Conway JD, 2014, ORTHOPEDICS, V37, pE1049, DOI 10.3928/01477447 20141124 50
   Dean DB, 2010, J ANAT, V216, P625, DOI 10.1111/j.1469 7580.2010.01214.x
   Duan SY, 2012, INT J NANOMED, V7, P3813, DOI 10.2147/IJN.S33101
   Duan SY, 2012, ANGEW CHEM INT EDIT, V51, P7938, DOI 10.1002/anie.201201793
   Gao YL, 2016, CELL PHYSIOL BIOCHEM, V38, P319, DOI 10.1159/000438632
   Hinsenkamp M, 2015, INT ORTHOP, V39, P137, DOI 10.1007/s00264 014 2562 0
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang J, 2016, CELL PHYSIOL BIOCHEM, V39, P1177, DOI 10.1159/000447824
   Kapilov Buchman Y, 2015, BIOCONJUGATE CHEM, V26, P880, DOI 10.1021/acs.bioconjchem.5b00100
   Kloen P, 2012, BONE, V51, P59, DOI 10.1016/j.bone.2012.03.032
   Kwong FNK, 2009, J ORTHOP RES, V27, P752, DOI 10.1002/jor.20794
   Meinhardt H, 2015, DEV BIOL, V405, P137, DOI 10.1016/j.ydbio.2015.05.025
   Ndong JD, 2014, NAT MED, V20, P904, DOI 10.1038/nm.3583
   Niikura T, 2006, J ORTHOP RES, V24, P1463, DOI 10.1002/jor.20182
   Sánchez Duffhues G, 2015, BONE, V80, P43, DOI 10.1016/j.bone.2015.05.025
   Tsialogiannis E, 2009, EXPERT OPIN THER TAR, V13, P123, DOI 10.1517/14728220802637725 
   Walsh DW, 2010, TRENDS CELL BIOL, V20, P244, DOI 10.1016/j.tcb.2010.01.008
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Xiang SN, 2012, BIOMATERIALS, V33, P6520, DOI 10.1016/j.biomaterials.2012.05.044
   Yamamoto K, 2015, P NATL ACAD SCI USA, V112, P6152, DOI 10.1073/pnas.1420713112
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
   Yu YY, 2010, BONE, V46, P841, DOI 10.1016/j.bone.2009.11.005
   Zhang CQ, 2017, CELL PHYSIOL BIOCHEM, V43, P2155, DOI 10.1159/000484295
   Zhao XY, 2014, CYTOKINE GROWTH F R, V25, P35, DOI 10.1016/j.cytogfr.2013.12.010
   Zhou W, 2017, CELL PHYSIOL BIOCHEM, V42, P551, DOI 10.1159/000477605
   Zou L, 2017, CELL PHYSIOL BIOCHEM, V41, P2161, DOI 10.1159/000475570
NR 35
TC 17
Z9 17
U1 0
U2 18
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 46
IS 1
BP 133
EP 147
DI 10.1159/000488416
PG 15
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GE3SU
UT WOS:000431134000012
PM 29587276
OA gold
DA 2025 08 17
ER

PT J
AU Bharadwaj, S
   Liu, GH
   Shi, YG
   Wu, RP
   Yang, B
   He, TC
   Fan, YX
   Lu, XY
   Zhou, XB
   Liu, H
   Atala, A
   Rohozinski, J
   Zhang, YY
AF Bharadwaj, Shantaram
   Liu, Guihua
   Shi, Yingai
   Wu, Rongpei
   Yang, Bin
   He, Tongchuan
   Fan, Yuxin
   Lu, Xinyan
   Zhou, Xiaobo
   Liu, Hong
   Atala, Anthony
   Rohozinski, Jan
   Zhang, Yuanyuan
TI Multipotential Differentiation of Human Urine Derived Stem Cells:
   Potential for Therapeutic Applications in Urology
SO STEM CELLS
LA English
DT Article
DE Urine; Bladder; Stem cells; Telomerase; Differentiation; Smooth muscle;
   Urothelial cells
ID BONE MORPHOGENETIC PROTEINS; BMP 9 INDUCED OSTEOGENIC DIFFERENTIATION;
   SMALL INTESTINAL SUBMUCOSA; SMOOTH MUSCLE CELLS; OSTEOBLAST
   DIFFERENTIATION; GROWTH FACTOR; TISSUE; MARROW; TARGET; PLAYS
AB We sought to biologically characterize and identify a subpopulation of urine derived stem cells (USCs) with the capacity for multipotent differentiation. We demonstrated that single USCs can expand to a large population with 60 70 population doublings. Nine of 15 individual USC clones expressed detectable levels of telomerase and have long telomeres. These cells expressed pericyte and mesenchymal stem cell markers. Upon induction with appropriate media in vitro, USCs differentiated into bladder associated cell types, including functional urothelial and smooth muscle cell lineages. When the differentiated USCs were seeded onto a scaffold and subcutaneously implanted into nude mice, multilayered tissue like structures formed consisting of urothelium and smooth muscle. Additionally, USCs were able to differentiate into endothelial, osteogenic, chondrogenic, adipogenic, skeletal myogenic, and neurogenic lineages but did not form teratomas during the 1 month study despite telomerase activity. USCs may be useful in cell based therapies and tissue engineering applications, including urogenital reconstruction. STEM Cells 2013;
C1 [Bharadwaj, Shantaram; Liu, Guihua; Shi, Yingai; Wu, Rongpei; Yang, Bin; Atala, Anthony; Rohozinski, Jan; Zhang, Yuanyuan] Wake Forest Sch Med, Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA.
   [Wu, Rongpei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510275, Guangdong, Peoples R China.
   [Yang, Bin] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Urol, Shanghai 200092, Peoples R China.
   [He, Tongchuan] Univ Chicago, Med Ctr, Dept Surg, Mol Oncol Lab, Chicago, IL 60637 USA.
   [Fan, Yuxin] Baylor Coll Med, Dept Pediat, John Welsh Cardiovasc Diagnost Lab, Houston, TX 77030 USA.
   [Lu, Xinyan] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Clin Cytogenet Lab, Houston, TX 77030 USA.
   [Zhou, Xiaobo] Methodist Hosp, Res Inst, Radiol Translat Biol Dept, Houston, TX 77030 USA.
   [Liu, Hong] Univ Oklahoma, Ctr Bioengn, Norman, OK 73019 USA.
   [Liu, Hong] Univ Oklahoma, Sch Elect & Comp Engn, Norman, OK 73019 USA.
   [Rohozinski, Jan] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA.
C3 Wake Forest University; Sun Yat Sen University; Tongji University;
   University of Chicago; University of Chicago Medical Center; Baylor
   College of Medicine; Baylor College of Medicine; Houston Methodist;
   University of Oklahoma System; University of Oklahoma   Norman;
   University of Oklahoma System; University of Oklahoma   Norman; Baylor
   College of Medicine
RP Zhang, YY (通讯作者)，Wake Forest Sch Med, Wake Forest Inst Regenerat Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM yzhang@wakehealth.edu
RI ; guihua, liu/B 1060 2012; Atala, Anthony/J 3052 2013
OI Atala, Anthony/0000 0001 8186 2160; Rohozinski, Jan/0000 0001 7872 2984
FU NIDDK NIH HHS [R21 DK071791] Funding Source: Medline
CR Atala A, 2006, LANCET, V367, P1241, DOI 10.1016/S0140 6736(06)68438 9
   Baddour JA, 2012, BIRTH DEFECTS RES C, V96, P1, DOI 10.1002/bdrc.21006
   Bharadwaj S, 2011, TISSUE ENG PT A, V17, P2123, DOI [10.1089/ten.tea.2010.0637, 10.1089/ten.TEA.2010.0637]
   Bodin A, 2010, BIOMATERIALS, V31, P8889, DOI 10.1016/j.biomaterials.2010.07.108
   Brack AS, 2012, CELL STEM CELL, V10, P504, DOI 10.1016/j.stem.2012.04.001
   Bryan TM, 1998, EXP CELL RES, V239, P370, DOI 10.1006/excr.1997.3907
   Chen KL, 2010, P NATL ACAD SCI USA, V107, P3346, DOI 10.1073/pnas.0909367106
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623 200308000 00017
   Cross WR, 2005, AM J PHYSIOL RENAL, V289, pF459, DOI 10.1152/ajprenal.00040.2005
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092 8674(00)81664 5
   Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298
   Kang Q, 2009, STEM CELLS DEV, V18, P545, DOI 10.1089/scd.2008.0130
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kropp BP, 1999, J UROLOGY, V162, P1779, DOI 10.1016/S0022 5347(05)68237 7
   Li WL, 2012, STEM CELLS, V30, P61, DOI 10.1002/stem.768
   Liu Y, 2009, BIOMATERIALS, V30, P3865, DOI 10.1016/j.biomaterials.2009.04.008
   Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739
   Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22 3 377
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   PRYOR JP, 1991, FERTIL STERIL, V56, P725
   Raya Rivera A, 2011, LANCET, V377, P1175, DOI 10.1016/S0140 6736(10)62354 9
   Sharff KA, 2009, J BIOL CHEM, V284, P649, DOI 10.1074/jbc.M806389200
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Smith JA, 2012, AGING DIS, V3, P260
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tian H, 2010, TISSUE ENG PT A, V16, P1769, DOI [10.1089/ten.tea.2009.0625, 10.1089/ten.TEA.2009.0625]
   TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168 9525(91)90378 4
   Vidal MA, 2012, STEM CELLS DEV, V21, P273, DOI 10.1089/scd.2010.0589
   Wu SF, 2011, J UROLOGY, V186, P640, DOI 10.1016/j.juro.2011.03.152
   Wu SF, 2011, BIOMATERIALS, V32, P1317, DOI 10.1016/j.biomaterials.2010.10.006
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang W, 2010, PLOS ONE, V5
   Zhang YY, 2008, J UROLOGY, V180, P2226, DOI 10.1016/j.juro.2008.07.023
   Zhang Y, 2008, J UROLOGY, V180, P10, DOI 10.1016/j.juro.2008.04.068
   Zhang YY, 2000, J UROLOGY, V164, P928, DOI 10.1016/S0022 5347(05)67220 5
NR 43
TC 245
Z9 288
U1 0
U2 72
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD SEP
PY 2013
VL 31
IS 9
BP 1840
EP 1856
DI 10.1002/stem.1424
PG 17
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 229II
UT WOS:000325255700011
PM 23666768
OA Bronze
DA 2025 08 17
ER

PT J
AU Savarino, L
   Benetti, D
   Baldini, N
   Tarabusi, C
   Greco, M
   Aloisi, R
   Frascarelli, S
   Fantozzi, R
   Dianzani, C
   Mian, M
AF Savarino, L
   Benetti, D
   Baldini, N
   Tarabusi, C
   Greco, M
   Aloisi, R
   Frascarelli, S
   Fantozzi, R
   Dianzani, C
   Mian, M
TI A preliminary in vitro and in vivo study of the effects of
   new anthraquinones on neutrophils and bone remodeling
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE anthraquinones; superoxide; bone remodeling; microradiography; X ray
   diffraction
ID DEBRIS INDUCED OSTEOLYSIS; NECROSIS FACTOR ALPHA; KNEE REPLACEMENTS;
   TOTAL HIP; WEAR; SUPEROXIDE; OSTEOCLASTS; DIACEREIN; MODEL; RHEIN
AB Osteolysis, that is, progressive periprosthetic bone loss, is responsible for approximately 70% of aseptic loosening and implant failure. Usually, it is due to a granulomatous reaction wear induced, leading to macrophage and osteoclast mediated bone resorption. At present, there is no established prophylaxis or treatment for this process. For this purpose, as a preliminary investigation, we aimed to study the effects in two directions, inhibition of proinflammatory signals, and bone remodeling activity, of two newly synthesized anthraquinone molecules [NN' Diethylamino2,6 anthraquinone disulfonamide (GR375) and N,N' (pethoxyphenyl) 2,6 anthraquinone disulfon amide (GR377)]. Among the pro inflammatory signals, the ability of the two anthraquinones to interfere with the production of superoxide anion (O 2( )), which was assumed as a marker of reactive oxygen species (ROS), was evaluated in an in vitro cell model by testing phagocytes, such as human neutrophils, challenged by the chemotactic agent N formylmethionyl leucyl phenylalanine (FMLP). Both compounds inhibited O 2( ) production, in a dose dependent way, without exerting scavenger effects. An in vivo model was applied to investigate their effect on bone remodeling. Fifty four female Wistar rats were divided into eight groups of six animals each, and a 4 week treatment was applied in two phases. A 25 mg/kg/os dose in the first phase and 12.5 6.25mg/kg/os doses in the second one were employed. The tibia trabecular bone at the secondary spongiosa level was analyzed, and trabecular bone volume (%TBV), trabecular thickness (TbTh), and apatite lattice parameters were measured. At the highest doses of GR375 and GR377 the %TBV and the TbTh increased by 33.2, 34.6%, and 3.6 and 9.1%, respectively, whereas crystallographic parameters were not significantly different from the untreated group. Our results suggest a simultaneous antiinflammatory and antiosteoclastic activity of both drugs that encourages to perform further research. If it will be confirmed, they could be proposed in a variety of bone diseases, in particular, when acute inflammation is associated to osteolytic processes and, eventually, in the prevention and treatment of periprosthetic osteolysis. (c) 2005 Wiley Periodicals, Inc.
C1 Ist Ortoped Rizzoli, Lab Pathophysiol Orthopaed Implants, I 40136 Bologna, Italy.
   Gunther Res SRL, Pisa, Italy.
   Univ Pisa, Dept Human & Environm Sci, Pisa, Italy.
   Univ Turin, Dept Anat Pharmacol & Forens Med, Turin, Italy.
C3 IRCCS Istituto Ortopedico Rizzoli; University of Pisa; University of
   Turin
RP Savarino, L (通讯作者)，Ist Ortoped Rizzoli, Lab Pathophysiol Orthopaed Implants, Via Barbaino 1 10, I 40136 Bologna, Italy.
EM lucia.savarino@ior.it
RI ; Baldini, Nicola/J 4806 2016
OI savarino, lucia/0000 0002 3177 3546; Baldini,
   Nicola/0000 0003 2228 3833; Fantozzi, Roberto/0000 0003 1129 2021;
   Dianzani, Chiara/0000 0002 2246 3183
CR Archibeck M J, 2001, Instr Course Lect, V50, P185
   Bauer TW, 2002, CLIN ORTHOP RELAT R, P138, DOI 10.1097/01.blo.00000038467.05771.90
   Childs LM, 2002, J BONE MINER RES, V17, P192, DOI 10.1359/jbmr.2002.17.2.192
   Childs LM, 2001, J BONE MINER RES, V16, P338, DOI 10.1359/jbmr.2001.16.2.338
   De Sanctis V, 2000, CALCIFIED TISSUE INT, V67, P128, DOI 10.1007/s002230001122
   Dianzani C, 2001, J LEUKOCYTE BIOL, V69, P1013
   Douni E, 2004, ARTHRITIS RES THER, V6, pR65, DOI 10.1186/ar1028
   FANTOZZI R, 1986, AGENTS ACTIONS, V18, P155, DOI 10.1007/BF01988009
   Goodman SB, 1998, CLIN ORTHOP RELAT R, P25
   Goodman SB, 1998, J BONE JOINT SURG BR, V80B, P531, DOI 10.1302/0301 620X.80B3.8158
   Hukkanen M, 1997, J BONE JOINT SURG BR, V79B, P467, DOI 10.1302/0301 620X.79B3.7469
   Hwa SY, 2001, J RHEUMATOL, V28, P825
   Martel Pelletier J, 1998, J RHEUMATOL, V25, P753
   MIAN M, 1989, INT J TISSUE REACT, V11, P117
   Mian M, 1996, CLIN EXP RHEUMATOL, V14, P619
   MIAN M, 1987, J PHARM PHARMACOL, V39, P845, DOI 10.1111/j.2042 7158.1987.tb05131.x
   Millett PJ, 2002, J BONE JOINT SURG AM, V84A, P236, DOI 10.2106/00004623 200202000 00011
   Rangan GK, 1999, AM J PHYSIOL RENAL, V277, pF779, DOI 10.1152/ajprenal.1999.277.5.F779
   Saleh KJ, 2004, CLIN ORTHOP RELAT R, P138, DOI 10.1097/01.blo.0000142288.66246.4d
   SAVARINO L, 1995, J BIOMED MATER RES, V29, P701, DOI 10.1002/jbm.820290605
   SAVARINO L, 1993, BIOMATERIALS, V14, P900, DOI 10.1016/0142 9612(93)90131 K
   Schmalzried TP, 1999, J BONE JOINT SURG AM, V81A, P115, DOI 10.2106/00004623 199901000 00016
   STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765
   Tamura T, 2002, EUR J PHARMACOL, V448, P81, DOI 10.1016/S0014 2999(02)01898 8
   Ulrich Vinther M, 2002, J BONE JOINT SURG AM, V84A, P1405, DOI 10.2106/00004623 200208000 00017
   Wagner C, 2004, SHOCK, V22, P108, DOI 10.1097/01.shk.0000132488.71875.15
   Wang ML, 2002, J ARTHROPLASTY, V17, P335, DOI 10.1054/arth.2002.30416
   Wozniak W, 2004, ACTA ORTHOP SCAND, V75, P549, DOI 10.1080/00016470410001402
   Yang S, 1998, CALCIFIED TISSUE INT, V63, P346, DOI 10.1007/s002239900538
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhang XP, 2001, J BONE MINER RES, V16, P660, DOI 10.1359/jbmr.2001.16.4.660
NR 31
TC 5
Z9 6
U1 0
U2 1
PU WILEY LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1549 3296
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD NOV 1
PY 2005
VL 75A
IS 2
BP 324
EP 332
DI 10.1002/jbm.a.30426
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 974GE
UT WOS:000232578500010
PM 16088894
OA Bronze
DA 2025 08 17
ER

PT J
AU Choi, JY
   Kim, HJ
   Lee, YC
   Cho, YO
   Seong, HS
   Cho, M
   Kim, SG
AF Choi, Je Yong
   Kim, Hylin Jon
   Lee, Yong Chan
   Cho, Young Ouck
   Seong, Ha Soo
   Cho, Michael
   Kim, Seong Gon
TI Inhibition of bone healing by pamidronate in calvarial bony defects
SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND
   ENDODONTOLOGY
LA English
DT Article
ID NITROGEN CONTAINING BISPHOSPHONATES; IN VITRO; MEVALONATE PATHWAY;
   RESORPTION; VIVO; DIFFERENTIATION; PROLIFERATION; APOPTOSIS; NECROSIS;
   RATS
AB Objective. Pamidronate has been studied as a therapeutic drug for various osteopenic diseases. However, avascular osteonecrosis in the jawbone has been recently reported in patients receiving pamidronate. The objective of this study was to examine the effect of pamidronate on bone regeneration in a controlled animal model.
   Materials and methods. To determine the effect of parmidronate on bone healing in a local bony defect area, a rabbit calvarial bony defect model was used and poly L lactide co glycolide (PLGA) used as a drug carrier material. Four defect groups were made in each rabbit calvaria and the defects were treated as follows: untreated bony defect (group 1), PLGA only (group 2), 2 mg of pamidronate with PLGA (group 3), and 3 mg of pamidronate with PLGA (group 4). Bone healing was evaluated by radiography and histology at 1, 2, 4, 6, and 8 weeks after surgery.
   Results. In radiographic analysis, radiopacity was lower in pamidronate groups than non operated rabbit calvarial bone at all observation points (P <.05). In histological analysis, the initial bone formation at I week was not different among groups, but it was much lower in the pamidronate groups than in the control or PLGA group after 2 weeks. Newly formed bone at I week underwent avascular necrosis after 2 weeks in both pamidronate groups. Avascular necrosis was not observed until 8 weeks in both topically applied pamidronate groups.
   Conclusion. Collectively, pamidronate inhibits bone healing in rabbit calvarial bony defect and it may explain the avascular necrosis of the jaws in patients receiving pamidronate.
C1 Hallym Univ, Dept Oral & Maxillofacial Surg, Anyang 431070, Kyungki Do, South Korea.
   Hallym Univ, Dept Otolaryngol, Anyang 431070, Kyungki Do, South Korea.
   Kyungpook Natl Univ, Sch Med, Dept Biochem, Taejon, South Korea.
   Childrens Hosp Philadelphia, Dept Plast & Reconstruct Surg, Philadelphia, PA 19104 USA.
C3 Hallym University; Hallym University; Kyungpook National University
   (KNU); University of Pennsylvania; Pennsylvania Medicine; Childrens
   Hospital of Philadelphia
RP Kim, SG (通讯作者)，Hallym Univ, Sacred Heart Hosp, Dept Oral & Maxillofacial Surg, 896 Pyungchon Dong, Anyang 431070, Kyungki Do, South Korea.
EM epker@chollian.net
RI ; Kim, Seong Gon/AAF 7553 2020
OI Kim, Seong Gon/0000 0001 5088 2732; 
CR Abildgaard N, 1998, EUR J HAEMATOL, V61, P128
   Bagan JV, 2006, ORAL ONCOL, V42, P327, DOI 10.1016/j.oraloncology.2005.08.001
   D'Aoust P, 2000, CELL TISSUE RES, V302, P353, DOI 10.1007/s004419900165
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fleisch H., 2002, PRINCIPLES BONE BIOL, V2nd, P1361
   Fournier P, 2002, CANCER RES, V62, P6538
   FRAME JW, 1980, J ORAL SURG, V38, P176
   GROSSMAN SA, 1992, J NEUROSURG, V76, P640, DOI 10.3171/jns.1992.76.4.0640
   Heikkilä P, 2002, ANTI CANCER DRUG, V13, P245, DOI 10.1097/00001813 200203000 00006
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rodan Gideon A., 2002, Current Molecular Medicine (Hilversum), V2, P571, DOI 10.2174/1566524023362104
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Sim BKL, 1997, CANCER RES, V57, P1329
   Sparidans RW, 1999, J CHROMATOGR B, V730, P95, DOI 10.1016/S0378 4347(99)00196 6
   Starck W J, 1995, Int J Oral Maxillofac Implants, V10, P74
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Van Offel JF, 2002, ANN RHEUM DIS, V61, P925, DOI 10.1136/ard.61.10.925
   ZIZIC TM, 1985, AM J MED, V79, P596, DOI 10.1016/0002 9343(85)90057 9
NR 24
TC 18
Z9 22
U1 0
U2 4
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1079 2104
EI 1528 395X
J9 ORAL SURG ORAL MED O
JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
PD MAR
PY 2007
VL 103
IS 3
BP 321
EP 328
DI 10.1016/j.tripleo.2006.06.057
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 153NH
UT WOS:000245441700008
PM 17321441
DA 2025 08 17
ER

PT J
AU Landersdorfer, CB
   Kinzig, M
   Bulitta, JB
   Hennig, FF
   Holzgrabe, U
   Sörgel, F
   Gusinde, J
AF Landersdorfer, Cornelia B.
   Kinzig, Martina
   Bulitta, Juergen B.
   Hennig, Friedrich F.
   Holzgrabe, Ulrike
   Soergel, Fritz
   Gusinde, Johannes
TI Bone Penetration of Amoxicillin and Clavulanic Acid Evaluated by
   Population Pharmacokinetics and Monte Carlo Simulation
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID STAPHYLOCOCCUS AUREUS; CORTICAL BONE; CANINE BONE; OSTEOMYELITIS;
   INTERNALIZATION; LEVOFLOXACIN; OSTEOBLASTS; INFECTIONS; VOLUNTEERS;
   ABSORPTION
AB Amoxicillin (amoxicilline) clavulanic acid has promising activity against pathogens that cause bone infections. We present the first evaluation of the bone penetration of a beta lactam by population pharmacokinetics and pharmacodynamic profiling via Monte Carlo simulations. Twenty uninfected patients undergoing total hip replacement received a single intravenous infusion of 2,000 mg/200 mg amoxicillin clavulanic acid before surgery. Blood and bone specimens were collected. Bone samples were pulverized under liquid nitrogen with a cryogenic mill, including an internal standard. The drug concentrations in serum and total bone were analyzed by liquid chromatography tandem mass spectrometry. We used NONMEM and S ADAPT for population pharmacokinetic analysis and a target time of the non protein bound drug concentration above the MIC for >= 50% of the dosing interval for near maximal bactericidal activity in serum. The median of the ratio of the area under the curve (AUC) for bone/AUC for serum was 20% (10th to 90th percentile for between subject variability [variability], 16 to 25%) in cortical bone and 18% (variability, 11 to 29%) in cancellous bone for amoxicillin and 15% (variability, 11 to 21%) in cortical bone and 10% (variability, 5.1 to 21%) in cancellous bone for clavulanic acid. Analysis in S ADAPT yielded similar results. The equilibration half lives between serum and bone were 12 min for amoxicillin and 14 min for clavulanic acid. For a 30 min infusion of 2,000 mg/200 mg amoxicillin clavulanic acid every 4 h, amoxicillin achieved robust (>= 90%) probabilities of target attainment (PTAs) for MICs of <= 12 mg/liter in serum and 2 to 3 mg/liter in bone and population PTAs above 95% against methicillin susceptible Staphylococcus aureus in bone and serum. The AUC of amoxicillin clavulanic acid was 5 to 10 times lower in bone than in serum, and amoxicillin clavulanic acid achieved a rapid equilibrium and favorable population PTAs against pathogens commonly encountered in bone infections.
C1 [Landersdorfer, Cornelia B.; Kinzig, Martina; Bulitta, Juergen B.; Soergel, Fritz] IBMP Inst Biomed & Pharmaceut Res, D 90562 Nurnberg, Germany.
   [Hennig, Friedrich F.; Gusinde, Johannes] Univ Erlangen Nurnberg, Dept Surg, Erlangen, Germany.
   [Holzgrabe, Ulrike] Univ Wurzburg, Inst Pharm & Food Chem, Wurzburg, Germany.
   [Soergel, Fritz] Univ Duisburg Essen, Dept Pharmacol, Essen, Germany.
C3 University of Erlangen Nuremberg; University of Wurzburg; University of
   Duisburg Essen
RP Sörgel, F (通讯作者)，IBMP Inst Biomed & Pharmaceut Res, Paul Ehrlich Str 19, D 90562 Nurnberg, Germany.
EM ibmp@osn.de
RI ; Bulitta, Jurgen/P 3355 2018; Landersdorfer, Cornelia/I 4103 2019
OI Landersdorfer, Cornelia/0000 0003 0928 4743; Bulitta,
   Jurgen/0000 0001 7352 3097; Holzgrabe, Ulrike/0000 0002 0364 7278; 
CR ADAM D, 1987, ANTIMICROB AGENTS CH, V31, P935, DOI 10.1128/AAC.31.6.935
   Ahmed S, 2001, INFECT IMMUN, V69, P2872, DOI 10.1128/IAI.69.5.2872 2877.2001
   AKIMOTO Y, 1982, J ORAL MAXIL SURG, V40, P287, DOI 10.1016/0278 2391(82)90220 8
   ALLEN GD, 1988, BIOPHARM DRUG DISPOS, V9, P127, DOI 10.1002/bod.2510090202
   ARANCIBIA A, 1980, ANTIMICROB AGENTS CH, V17, P199, DOI 10.1128/AAC.17.2.199
   Baqain ZH, 2004, BRIT J ORAL MAX SURG, V42, P506, DOI 10.1016/j.bjoms.2004.06.010
   BAUER RJ, 2007, S ADAPT MCPEM USERS
   BEAL SL, 1999, NONMEM USERS GUIDES
   Blumer JL, 2005, PEDIATRICS, V116, P927, DOI 10.1542/peds.2004 2294
   Boselli E, 2002, J CHEMOTHERAPY, V14, P361, DOI 10.1179/joc.2002.14.4.361
   BREILH D, 2003, J CHEMOTHER, V15, P314
   Bulitta JB, 2007, ANTIMICROB AGENTS CH, V51, P2497, DOI 10.1128/AAC.01477 06
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cotran R.S., 1994, Robbins Pathological Basis of Disease
   Craig WA, 1998, CLIN INFECT DIS, V26, P1, DOI 10.1086/516284
   DALY RC, 1982, ANTIMICROB AGENTS CH, V22, P461, DOI 10.1128/AAC.22.3.461
   Djabarouti S, 2004, J CHROMATOGR B, V799, P165, DOI 10.1016/j.jchromb.2003.10.031
   Drusano GL, 2000, ANTIMICROB AGENTS CH, V44, P2046, DOI 10.1128/AAC.44.8.2046 2051.2000
   Drusano GL, 2004, NAT REV MICROBIOL, V2, P289, DOI 10.1038/nrmicro862
   Drusano GL, 2002, ANTIMICROB AGENTS CH, V46, P586, DOI 10.1128/AAC.46.2.586 589.2002
   Figueiredo R, 2008, J ORAL MAXIL SURG, V66, P943, DOI 10.1016/j.joms.2008.01.045
   GISBY J, 1994, J ANTIMICROB CHEMOTH, V34, P755, DOI 10.1093/jac/34.5.755
   GRIMER RJ, 1986, CHEMOTHERAPY, V32, P185, DOI 10.1159/000238414
   Guyton AC., 1996, TXB MED PHYSL
   HALL BB, 1983, J BONE JOINT SURG AM, V65, P526, DOI 10.2106/00004623 198365040 00016
   Hardman J.G., 1996, Goodman and Gilman's The Pharmacological Basis of Therapeutics, V9th
   Hoban DJ, 2003, INT J ANTIMICROB AG, V21, P425, DOI 10.1016/S0924 8579(03)00038 4
   HOFFKEN G, 1985, J ANTIMICROB CHEMOTH, V16, P763
   HORBER FF, 1986, ANTIMICROB AGENTS CH, V29, P614, DOI 10.1128/AAC.29.4.614
   Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075
   HUGHES S, 1978, CLIN ORTHOP RELAT R, P332
   Hughes S P, 1992, Acta Orthop Belg, V58 Suppl 1, P217
   HUGHES SPF, 1985, J ANTIMICROB CHEMOTH, V15, P517, DOI 10.1093/jac/15.5.517
   Jevon M, 1999, INFECT IMMUN, V67, P2677, DOI 10.1128/IAI.67.5.2677 2681.1999
   Keaveny T.M., 2001, BONE MECH HDB
   Landersdorfer CB, 2009, CLIN PHARMACOKINET, V48, P89, DOI 10.2165/0003088 200948020 00002
   Landersdorfer CB, 2009, ANTIMICROB AGENTS CH, V53, P2074, DOI 10.1128/AAC.01056 08
   Lew DP, 1997, NEW ENGL J MED, V336, P999, DOI 10.1056/NEJM199704033361406
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Lipsky BA, 1997, CLIN INFECT DIS, V24, P643, DOI 10.1093/clind/24.4.643
   LUNKE RJ, 1981, ANTIMICROB AGENTS CH, V19, P851, DOI 10.1128/AAC.19.5.851
   Malincarne L, 2006, J ANTIMICROB CHEMOTH, V57, P950, DOI 10.1093/jac/dkl091
   MEISSNER A, 1989, INFECTION, V17, P146, DOI 10.1007/BF01644014
   MEISSNER A, 1990, J ANTIMICROB CHEMOTH, V26, P69, DOI 10.1093/jac/26.suppl_D.69
   MORRIS MA, 1982, MICROVASC RES, V23, P188, DOI 10.1016/0026 2862(82)90064 4
   Mouton JW, 2008, J ANTIMICROB CHEMOTH, V61, P235, DOI 10.1093/jac/dkm476
   Mouton JW, 2005, J ANTIMICROB CHEMOTH, V55, P601, DOI 10.1093/jac/dki079
   Mutschler E, 1999, ANATOMIE PHYSL PATHO
   NILSSONEHLE I, 1985, J ANTIMICROB CHEMOTH, V16, P491, DOI 10.1093/jac/16.4.491
   PIGNATELLI M, 1981, DENT CADMOS, V49, P17
   PIOTROVSKIJ VK, 1994, PHARMACEUT RES, V11, P1346, DOI 10.1023/A:1018911032009
   Sanchez  Garces MA, 2004, MED ORAL PATOL ORAL, V9, P63
   SJOVALL J, 1986, BRIT J CLIN PHARMACO, V21, P171, DOI 10.1111/j.1365 2125.1986.tb05172.x
   WEISMEIER K, 1989, J ANTIMICROB CHEMOTH, V24, P93, DOI 10.1093/jac/24.suppl_B.93
   WITTMANN DH, 1980, INFECTION, V8, P330, DOI 10.1007/BF01640931
NR 55
TC 31
Z9 31
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 0066 4804
EI 1098 6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2009
VL 53
IS 6
BP 2569
EP 2578
DI 10.1128/AAC.01119 08
PG 10
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA 448DY
UT WOS:000266244500047
PM 19307356
OA Green Published
DA 2025 08 17
ER

PT J
AU Bradley, JD
   Cleverly, DG
   Burns, AM
   Helm, NB
   Schmid, MJ
   Marx, DB
   Cullen, DM
   Reinhardt, RA
AF Bradley, J. D.
   Cleverly, D. G.
   Burns, A. M.
   Helm, N. B.
   Schmid, M. J.
   Marx, D. B.
   Cullen, D. M.
   Reinhardt, R. A.
TI Cyclooxygenase 2 inhibitor reduces simvastatin induced bone
   morphogenetic protein 2 and bone formation in vivo
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE bone formation rate; bone morphogenetic protein 2; cyclooxygenase 2;
   simvastatin
ID MC3T3 E1 CELLS; OSTEOBLAST DIFFERENTIATION; STATINS; EXPRESSION;
   PROSTAGLANDIN E2; GROWTH; NSAID; RATS
AB Simvastatin, a cholesterol lowering drug, also stimulates oral bone growth when applied topically, without systemic side effects. However, the mechanisms involved in vivo are not known. We hypothesized that bone morphogenetic protein 2, nitric oxide synthase, and cyclooxygenase 2 are involved, based on prior in vitro evidence.
   A rat bilateral mandible model, where 0.5 mg of simvastatin in methylcellulose gel was placed on one side and gel alone on the other, was used to quantify nitric oxide, cyclooxygenase 2 and bone morphogenetic protein 2 (via tissue extraction, enzyme activity or immunoassay), and to analyze the bone formation rate (via undecalcified histomorphometry). Cyclooxygenase 2 and nitric oxide synthase inhibitors (NS 398 and L NAME, respectively) were administered intraperitoneally.
   Simvastatin was found to stimulate local bone morphogenetic protein 2, nitric oxide and the regional bone formation rate (p < 0.05), whereas NS 398 inhibited bone morphogenetic protein 2 and reduced the bone formation rate (p < 0.05).
   These data suggest an association between simvastatin induced bone morphogenetic protein 2 and bone formation in the mandibular microenvironment, and the negative effect of cyclooxygenase 2 inhibitors on bone growth.
C1 Univ Nebraska, Med Ctr, Coll Dent, Dept Surg Special, Lincoln, NE 68583 USA.
   Univ Nebraska, Med Ctr, Coll Dent, Dept Oral Biol, Lincoln, NE 68583 USA.
   Univ Nebraska, Dept Biometry, Lincoln, NE 68583 USA.
   Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA.
C3 University of Nebraska System; University of Nebraska Lincoln;
   University of Nebraska Medical Center; University of Nebraska System;
   University of Nebraska Lincoln; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Lincoln; Creighton
   University
RP Reinhardt, RA (通讯作者)，Univ Nebraska, Med Ctr, Coll Dent, Dept Surg Special, 40th & Holdrege, Lincoln, NE 68583 USA.
EM rareinha@unmc.edu
FU NIDCR NIH HHS [R15 DE015096, DE 015096] Funding Source: Medline
CR Arikawa T, 2004, J CELL PHYSIOL, V200, P400, DOI 10.1002/jcp.20031
   Chen JC, 2004, EXP CELL RES, V301, P305, DOI 10.1016/j.yexcr.2004.05.039
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   HAKEDA Y, 1985, BIOCHEM BIOPH RES CO, V126, P340, DOI 10.1016/0006 291X(85)90611 4
   Handy RLC, 1998, BRIT J PHARMACOL, V123, P1119, DOI 10.1038/sj.bjp.0701735
   Harder AT, 2003, J CLIN PHARMACOL, V43, P807, DOI 10.1177/0091270003256061
   Iwaniec U. T., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P469
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Martin GJ, 1999, SPINE, V24, P2188, DOI 10.1097/00007632 199911010 00003
   MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228
   McFarlane SI, 2002, J CLIN ENDOCR METAB, V87, P1451, DOI 10.1210/jc.87.4.1451
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Oxlund H, 2001, CALCIFIED TISSUE INT, V69, P299, DOI 10.1007/s00223 001 2027 5
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Paya M, 1997, BRIT J PHARMACOL, V120, P1445, DOI 10.1038/sj.bjp.0701073
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Stein D, 2005, J PERIODONTOL, V76, P1861, DOI 10.1902/jop.2005.76.11.1861
   Sugiyama M, 2000, BIOCHEM BIOPH RES CO, V271, P688, DOI 10.1006/bbrc.2000.2697
   Takiguchi T, 1999, J PERIODONTAL RES, V34, P431
   Tang CH, 2005, J BIOL CHEM, V280, P22907, DOI 10.1074/jbc.M500130200
   Thylin MR, 2002, J PERIODONTOL, V73, P1141, DOI 10.1902/jop.2002.73.10.1141
   Vrotsos Y, 2003, CRIT REV EUKAR GENE, V13, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.170
   Wong RWK, 2005, BRIT J ORAL MAX SURG, V43, P46, DOI 10.1016/j.bjoms.2004.08.014
   YANG RS, 1993, CALCIFIED TISSUE INT, V52, P57, DOI 10.1007/BF00675627
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 28
TC 25
Z9 31
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JUN
PY 2007
VL 42
IS 3
BP 267
EP 273
DI 10.1111/j.1600 0765.2006.00943.x
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 160LX
UT WOS:000245943800010
PM 17451547
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Coe, LM
   Madathil, SV
   Casu, C
   Lanske, B
   Rivella, S
   Sitara, D
AF Coe, Lindsay M.
   Madathil, Sangeetha Vadakke
   Casu, Carla
   Lanske, Beate
   Rivella, Stefano
   Sitara, Despina
TI FGF 23 Is a Negative Regulator of Prenatal and Postnatal Erythropoiesis*
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Bone; Bone Marrow; Erythrocyte; Erythropoeisis; Hematopoiesis; Kidney;
   FGF 23; Anemia
ID CHRONIC KIDNEY DISEASE; GROWTH FACTOR 23; DOMINANT HYPOPHOSPHATEMIC
   RICKETS; FAMILIAL TUMORAL CALCINOSIS; HEMATOPOIETIC STEM CELLS;
   VITAMIN D METABOLISM; IN VIVO; PARATHYROID HORMONE; RENAL FAILURE; FGF23
AB Background: FGF 23, a bone derived hormone, regulates phosphate and vitamin D in the kidney. Results: Genetic and pharmacological manipulations of FGF 23 alter erythropoiesis and HSC frequency both in young adult age and embryonically. Conclusion: Fgf 23 regulates erythropoiesis through Epo and independent of vitamin D. Significance: These findings provide a new target for treating blood disorders associated with bone and renal defects.
   Abnormal blood cell production is associated with chronic kidney disease (CKD) and cardiovascular disease (CVD). Bone derived FGF 23 (fibroblast growth factor 23) regulates phosphate homeostasis and bone mineralization. Genetic deletion of Fgf 23 in mice (Fgf 23( / )) results in hypervitaminosis D, abnormal mineral metabolism, and reduced lymphatic organ size. Elevated FGF 23 levels are linked to CKD and greater risk of CVD, left ventricular hypertrophy, and mortality in dialysis patients. However, whether FGF 23 is involved in the regulation of erythropoiesis is unknown. Here we report that loss of FGF 23 results in increased hematopoietic stem cell frequency associated with increased erythropoiesis in peripheral blood and bone marrow in young adult mice. In particular, these hematopoietic changes are also detected in fetal livers, suggesting that they are not the result of altered bone marrow niche alone. Most importantly, administration of FGF 23 in wild type mice results in a rapid decrease in erythropoiesis. Finally, we show that the effect of FGF 23 on erythropoiesis is independent of the high vitamin D levels in these mice. Our studies suggest a novel role for FGF 23 in erythrocyte production and differentiation and suggest that elevated FGF 23 levels contribute to the pathogenesis of anemia in patients with CKD and CVD.
C1 [Coe, Lindsay M.; Madathil, Sangeetha Vadakke; Sitara, Despina] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA.
   [Casu, Carla; Rivella, Stefano] Weill Cornell Med Coll, Dept Pediat Hematol, New York, NY 10021 USA.
   [Lanske, Beate] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
   [Sitara, Despina] NYU, Sch Med, Dept Med, New York, NY 10016 USA.
C3 New York University; Cornell University; Weill Cornell Medicine; Harvard
   University; Harvard School of Dental Medicine; New York University
RP Sitara, D (通讯作者)，NYU, Coll Dent, 345 E 24th St,Rm 902C, New York, NY 10010 USA.
EM ds199@nyu.edu
RI ; Vadakke Madathil, Sangeetha/B 5340 2011; Rivella, Stefano/A 1597 2010;
   Vadakke Madathil, Sangeetha/B 5340 2011
OI SITARA, DESPINA/0000 0002 4836 5039; Rivella,
   Stefano/0000 0002 0938 6558; Vadakke Madathil,
   Sangeetha/0000 0002 4948 9412; Lanske, Beate/0000 0003 4638 804X; 
FU National Institutes of Health [P30DE020754]; American Heart Association
   [12SDG12080152]; American Society for Bone and Mineral Research Career
   Enhancement Award [A13 0052 001]; American Heart Association (AHA)
   [12SDG12080152] Funding Source: American Heart Association (AHA)
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant P30DE020754. This work was also supported by American Heart
   Association Scientist Development Grant 12SDG12080152 and American
   Society for Bone and Mineral Research Career Enhancement Award
   A13 0052 001 (to D. S.).
CR Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247
   Asari S, 2005, EXP HEMATOL, V33, P26, DOI 10.1016/j.exphem.2004.10.001
   Benet Pagès A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034
   Bernhardt WM, 2010, J AM SOC NEPHROL, V21, P2151, DOI 10.1681/ASN.2010010116
   Bogdanova A, 2013, INT J MOL SCI, V14, P9848, DOI 10.3390/ijms14059848
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Christensen JL, 2004, PLOS BIOL, V2, P368, DOI 10.1371/journal.pbio.0020075
   Colvin GA, 2007, J CELL PHYSIOL, V211, P386, DOI 10.1002/jcp.20945
   Damasiewicz MJ, 2011, NEPHROLOGY, V16, P261, DOI 10.1111/j.1440 1797.2011.01443.x
   Dzierzak E, 2008, NAT IMMUNOL, V9, P129, DOI 10.1038/ni1560
   Farrow EG, 2011, BEST PRACT RES CL RH, V25, P735, DOI 10.1016/j.berh.2011.10.020
   Farrow EG, 2011, P NATL ACAD SCI USA, V108, pE1146, DOI 10.1073/pnas.1110905108
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Fliser D, 2007, J AM SOC NEPHROL, V18, P2600, DOI 10.1681/ASN.2006080936
   Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104
   Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354
   Isakova T, 2011, JAMA J AM MED ASSOC, V305, P2432, DOI 10.1001/jama.2011.826
   Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881
   Koulnis M, 2011, JOVE J VIS EXP, V54, P1
   Kuznetsov SA, 2004, J CELL BIOL, V167, P1113, DOI 10.1083/jcb.200408079
   Larsson T, 2003, KIDNEY INT, V64, P2272, DOI 10.1046/j.1523 1755.2003.00328.x
   Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154
   LIPKIN GW, 1990, NEPHROL DIAL TRANSPL, V5, P920, DOI 10.1093/ndt/5.11.920
   Liu SG, 2003, J BIOL CHEM, V278, P37419, DOI 10.1074/jbc.M304544200
   Mirams M, 2004, BONE, V35, P1192, DOI 10.1016/j.bone.2004.06.014
   Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397
   Perwad F, 2007, AM J PHYSIOL RENAL, V293, pF1577, DOI 10.1152/ajprenal.00463.2006
   Plett PA, 2002, BLOOD, V100, P3545, DOI 10.1182/blood.V100.10.3545
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051
   Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081
   Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007
   Sitara D, 2006, AM J PATHOL, V169, P2161, DOI 10.2353/ajpath.2006.060329
   Sitara D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000154
   Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369
   Sugiyama D, 2011, THESCIENTIFICWORLDJO, V11, P1770, DOI 10.1100/2011/598097
   Taylor EN, 2011, AM HEART J, V161, P956, DOI 10.1016/j.ahj.2011.02.012
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664
   WU H, 1995, CELL, V83, P59, DOI 10.1016/0092 8674(95)90234 1
   Yoshiko Y, 2007, BONE, V40, P1565, DOI 10.1016/j.bone.2007.01.017
   Zeigler BM, 2010, DIS MODEL MECH, V3, P763, DOI 10.1242/dmm.004788
   Zhang F, 1996, EXP HEMATOL, V24, P1469
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 46
TC 115
Z9 120
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD APR 4
PY 2014
VL 289
IS 14
BP 9795
EP 9810
DI 10.1074/jbc.M113.527150
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AE2MK
UT WOS:000333807000030
PM 24509850
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Yan, XL
   Lan, Y
   Wang, XY
   He, WY
   Yao, HY
   Chen, DB
   Xiong, JX
   Gao, JA
   Li, ZA
   Yang, GA
   Li, XS
   Liu, YL
   Zhang, JY
   Liu, B
   Mao, N
AF Yan, Xin Long
   Lan, Yu
   Wang, Xiao Yan
   He, Wen Yan
   Yao, Hui Yu
   Chen, Dong Bo
   Xiong, Jia Xiang
   Gao, Jiao
   Li, Zhuan
   Yang, Guan
   Li, Xiu Sen
   Liu, Yuan Lin
   Zhang, Ji Yan
   Liu, Bing
   Mao, Ning
TI Migration of Dorsal Aorta Mesenchymal Stem Cells Induced by Mouse
   Embryonic Circulation
SO DEVELOPMENTAL DYNAMICS
LA English
DT Article
DE mesenchymal stem cells; dorsal aorta; aorta gonad mesonephros;
   migration; embryonic circulation; PDGF; MAPK
ID GONAD MESONEPHROS; BONE MARROW; STROMAL CELLS; PROGENITOR CELLS;
   TRANSGENIC MICE; YOLK SAC; MULTIPOTENT; DIFFERENTIATION; IDENTIFICATION;
   CHEMOKINE
AB Mesenchymal stem cells (MSCs) represent powerful tools for regenerative medicine for their differentiation and migration capacity. However, ontogeny and migration of MSCs in mammalian mid gestation conceptus is poorly understood. We identified canonical MSCs in the mouse embryonic day (E) 11.5 dorsal aorta (DA). They possessed homogenous immunophenotype (CD45( )CD31( )Flk 1( )CD44(+)CD29(+)), expressed perivascular markers (alpha SMA( )NG2(+)PDGFR beta(+)PDGFR alpha(+)), and had tri lineage differentiation potential (osteoblasts, adipocytes, and chondrocytes). Of interest, MSCs were also detected in E12.5 E13.5 embryonic circulation, 24 hr later than in DA, suggesting migration like hematopoietic stem cells. Functionally, E12.5 embryonic blood could trigger efficient migration of DA MSCs through platelet derived growth factor (PDGF) receptor , transforming growth factor beta receptor , but not basic fibroblast growth factor receptor  mediated signaling. Moreover, downstream JNK and AKT signaling pathway played important roles in embryonic blood or PDGF mediated migration of DA derived MSCs. Taken together, these results revealed that clonal MSCs developed in the mouse DA. More importantly, the embryonic circulation, in addition to its conventional transporting roles, could modulate migration of MSC during early embryogenesis. Developmental Dynamics 240: 65 74, 2011. (C) 2010 Wiley Liss, Inc.
C1 [Yan, Xin Long; Wang, Xiao Yan; Yao, Hui Yu; Gao, Jiao; Li, Xiu Sen; Liu, Yuan Lin; Mao, Ning] Inst Basic Med Sci, Dept Cell Biol, Beijing 100850, Peoples R China.
   [Lan, Yu; Yang, Guan] Inst Biotechnol, Genet Lab Dev & Dis, Beijing, Peoples R China.
   [Xiong, Jia Xiang] Third Mil Med Univ, Dept Physiol, Chongqing, Peoples R China.
   [Zhang, Ji Yan] Inst Basic Med Sci, Dept Mol Immunol, Beijing, Peoples R China.
   [Yan, Xin Long; He, Wen Yan; Chen, Dong Bo; Gao, Jiao; Li, Zhuan; Liu, Bing] Acad Mil Med Sci, Affiliated Hosp, Lab Oncol, Beijing, Peoples R China.
C3 Army Medical University; Academy of Military Medical Sciences   China
RP Mao, N (通讯作者)，Inst Basic Med Sci, Dept Cell Biol, Tai Ping Rd 27, Beijing 100850, Peoples R China.
EM bingliu17@yahoo.com; maoning@nic.bmi.ac.cn
RI ; He, Wenyan/JQW 2452 2023; leng, ling/GQH 2273 2022; Zhang,
   Jian/A 2564 2008; Lan, Yu/AAV 2236 2021; wang, xiaoyan/R 1523 2016; Liu,
   Bing/ABH 2370 2021; Yuanlin, Liu/ABE 5488 2021
OI Zhang, Jiyan/0000 0001 8011 8719; Yan, Xinlong/0000 0001 9967 5654
FU National Natural Science Foundation [30730043, 30871410, 30800426];
   National Key Basic Research Program of China [2005CB522705,
   2005CB522506, 2006CB943601]
FX Grant sponsor: National Natural Science Foundation; Grant numbers:
   30730043, 30871410, 30800426; Grant sponsor: National Key Basic Research
   Program of China; Grant numbers: 2005CB522705, 2005CB522506,
   2006CB943601.
CR Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Belema Bedada F, 2008, CELL STEM CELL, V2, P566, DOI 10.1016/j.stem.2008.03.003
   Boisset JC, 2010, NATURE, V464, P116, DOI 10.1038/nature08764
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Cossu G, 2003, CURR OPIN GENET DEV, V13, P537, DOI 10.1016/j.gde.2003.08.001
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Cumano A, 2007, ANNU REV IMMUNOL, V25, P745, DOI 10.1146/annurev.immunol.25.022106.141538
   de Bruijn MFTR, 2000, EMBO J, V19, P2465, DOI 10.1093/emboj/19.11.2465
   de Bruijn MFTR, 2002, IMMUNITY, V16, P673, DOI 10.1016/S1074 7613(02)00313 8
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Durand C, 2007, P NATL ACAD SCI USA, V104, P20838, DOI 10.1073/pnas.0706923105
   Durand C, 2006, HAEMATOLOGICA, V91, P1172
   Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078 0432.CCR 07 0731
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood 2005 11 010504
   Guo ZK, 2006, STEM CELLS, V24, P992, DOI 10.1634/stemcells.2005 0224
   He WY, 2010, HAEMATOL HEMATOL J, V95, P875, DOI 10.3324/haematol.2009.014241
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kissa K, 2010, NATURE, V464, P112, DOI 10.1038/nature08761
   Kumaravelu P, 2002, DEVELOPMENT, V129, P4891
   Lan Y, 2007, MOL CELL BIOL, V27, P7683, DOI 10.1128/MCB.00577 07
   Ledran MH, 2008, CELL STEM CELL, V3, P85, DOI 10.1016/j.stem.2008.06.001
   Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007 0054
   Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007 1122
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Mendes SC, 2005, DEVELOPMENT, V132, P1127, DOI 10.1242/dev.01615
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Minasi MG, 2002, DEVELOPMENT, V129, P2773
   Ohneda O, 1998, BLOOD, V92, P908
   Oostendorp RAJ, 2002, J CELL SCI, V115, P2099
   Oostendorp RAJ, 2002, BLOOD, V99, P1183, DOI 10.1182/blood.V99.4.1183
   Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142
   Phinney Donald G., 2008, V449, P171, DOI 10.1007/978 1 60327 169 1_12
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood 2004 09 3507
   Sun SK, 2003, STEM CELLS, V21, P527, DOI 10.1634/stemcells.21 5 527
   Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028
   Wang XY, 2008, BLOOD, V111, P2436, DOI 10.1182/blood 2007 07 099333
   Xu MJ, 1998, BLOOD, V92, P2032, DOI 10.1182/blood.V92.6.2032.418k29_2032_2040
NR 41
TC 6
Z9 13
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1058 8388
EI 1097 0177
J9 DEV DYNAM
JI Dev. Dyn.
PD JAN
PY 2011
VL 240
IS 1
BP 65
EP 74
DI 10.1002/dvdy.22490
PG 10
WC Anatomy & Morphology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Developmental Biology
GA 702IN
UT WOS:000285887900006
PM 21089075
OA Bronze
DA 2025 08 17
ER

PT J
AU Recker, RR
   Marin, F
   Ish Shalom, S
   Möricke, R
   Hawkins, F
   Kapetanos, G
   de la Peña, MP
   Kekow, J
   Farrerons, J
   Sanz, B
   Oertel, H
   Stepan, J
AF Recker, Robert R.
   Marin, Fernando
   Ish Shalom, Sophia
   Moericke, Ruediger
   Hawkins, Federico
   Kapetanos, Georgios
   de la Pena, Maria P.
   Kekow, Joern
   Farrerons, Jordi
   Sanz, Beatriz
   Oertel, Heide
   Stepan, Jan
TI Comparative Effects of Teriparatide and Strontium Ranelate on Bone
   Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal
   Women With Osteoporosis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Proceedings Paper
CT 35th European Symposium on Calcified Tissues
CY MAY 24 28, 2008
CL Barcelona, SPAIN
DE bone marker; bone biopsy; osteoporosis; strontium; teriparatide
ID PARATHYROID HORMONE 1 34; MINERAL DENSITY; THERAPY; ARCHITECTURE;
   ALENDRONATE; MECHANISMS; IMPROVES; NOMENCLATURE; 2 YEAR; MEN
AB We assessed the effects on bone remodeling and histomorphometry after daily subcutaneous injections of teriparatide (n = 39, 20 mu g/d) or oral strontium ranelate (SrR, n = 40, 2 g/d) in postmenopausal women with osteoporosis. Evaluable biopsies were obtained from 29 patients in the teriparatide group and 22 in the SrR group after 6 mo of treatment. The mean +/  SD mineralization surfaces as a percent of bone surfaces (MS/BS, %) at the trabecular level were 7.73 +/  1.48% for teriparatide and 5.25 +/  1.15% for SrR (p = 0.219) and at the endocortical level were 17.22 +/  3.06% and 9.70 +/  2.07%, respectively (p = 0.052). Cortical porosity was 5.40 +/  0.41% in the teriparatide and 4.14 +/  0.40% in the SrR group (p = 0.037). Teriparatide induced significant increases from baseline in bone formation and resorption markers, reaching statistical significance for amino terminal propeptide of type I collagen (PINP) after 1 mo (+57%, p < 0.001). SrR induced small, but statistically significant, reductions from baseline in PINP at 3 ( 14%, p = 0.005) and 6 mo ( 19%, p < 0.001) and in serum P C terminal telopeptide of type I collagen (beta CTX) at 1 and 3 mo ( 11%, for both,p < 0.05). There were more patients with adverse events after SrR (70%) than teriparatide (41%) treatment (p = 0.013). In conclusion, the changes in biochemical markers of bone formation confirmed bone forming activity of teriparatide but not of SrR treatment. The effects of SrR on bone remodeling and cell activity were modest, indicating that its effects on fracture reduction may be predominantly mediated through a different mechanism than that observed with anabolic or more potent antiresorptive agents. J Bone Miner Res 2009;24:1358 1368. Published online on March 30, 2009; doi: 10.1359/JBMR.090315
C1 [Recker, Robert R.] Creighton Univ, Sch Med, Osteoporosis Res Ctr, Omaha, NE 68131 USA.
   [Marin, Fernando; Sanz, Beatriz; Oertel, Heide] Lilly Res Ctr Ltd, Windlesham GU20 6PH, Surrey, England.
   [Ish Shalom, Sophia] Technion Israel Inst Technol, Fac Med, Bone & Mineral Metab Unit, Haifa, Israel.
   [Moericke, Ruediger] Endocrinol Clin Res Lab, Magdeburg, Germany.
   [Hawkins, Federico] Hosp 12 Octubre, E 28041 Madrid, Spain.
   [Kapetanos, Georgios] Aristotle Univ Thessaloniki, GR 54006 Thessaloniki, Greece.
   [de la Pena, Maria P.] Clin Med Monraz, Guadalajara, Jalisco, Mexico.
   [Kekow, Joern] Special Hosp, Vogelsang Gommern, Germany.
   [Farrerons, Jordi] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
   [Stepan, Jan] Charles Univ Prague, Fac Med, Prague, Czech Republic.
C3 Creighton University; Eli Lilly; Lilly Research Laboratories; Technion
   Israel Institute of Technology; Rappaport Faculty of Medicine; Hospital
   Universitario 12 de Octubre; Aristotle University of Thessaloniki;
   Hospital of Santa Creu i Sant Pau; Charles University Prague
RP Recker, RR (通讯作者)，Creighton Univ, Sch Med, Osteoporosis Res Ctr, 601 N 30th St,Suite 6730, Omaha, NE 68131 USA.
EM rrecker@creighton.edu
RI Stepan, Jan/A 7280 2013; MARIN, FERNANDO/HKO 8917 2023
OI Stepan, Jan/0000 0003 1541 8306; 
CR Ammann P, 2004, J BONE MINER RES, V19, P2012, DOI 10.1359/JBMR.040906
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Arlot ME, 2008, J BONE MINER RES, V23, P215, DOI 10.1359/JBMR.071012
   Blake GM, 2005, J BONE MINER RES, V20, P1901, DOI 10.1359/JBMR.050810
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Borah B, 2004, BONE, V34, P736, DOI 10.1016/j.bone.2003.12.013
   Brixen K, 2008, CALCIFIED TISSUE INT, V82, pS217
   Calvo MS, 1996, ENDOCR REV, V17, P333, DOI 10.1210/er.17.4.333
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Canalis E, 2007, NEW ENGL J MED, V357, P905, DOI 10.1056/NEJMra067395
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Durham BH, 2007, J BONE MINER RES, V22, pS336
   Eastell R, 2006, CURR MED RES OPIN, V22, P61, DOI 10.1185/030079905X75096
   Fuchs RK, 2008, OSTEOPOROSIS INT, V19, P1331, DOI 10.1007/s00198 008 0602 6
   GOLDNER JACQUES, 1938, AMER JOUR PATH, V14, P237
   Goltzman D, 2008, ARCH BIOCHEM BIOPHYS, V473, P218, DOI 10.1016/j.abb.2008.03.003
   Graeff C, 2007, J BONE MINER RES, V22, P1426, DOI 10.1359/jbmr.070603
   Hauge EM, 2001, BONE, V28, P556, DOI 10.1016/S8756 3282(01)00424 0
   HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756 3282(93)90190 L
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Hodsman AB, 2000, BONE, V27, P311, DOI 10.1016/S8756 3282(00)00316 1
   Jerome CP, 2001, BONE, V28, P150, DOI 10.1016/S8756 3282(00)00430 0
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   KESHAWARZ NM, 1984, METAB BONE DIS RELAT, V5, P223, DOI 10.1016/0221 8747(84)90063 8
   Lindsay R, 2006, J BONE MINER RES, V21, P366, DOI 10.1359/JBMR.051109
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Meunier PJ, 2002, J CLIN ENDOCR METAB, V87, P2060, DOI 10.1210/jc.87.5.2060
   Meunier PJ, 2004, NEW ENGL J MED, V350, P459, DOI 10.1056/NEJMoa022436
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   RECKER RR, 1988, J BONE MINER RES, V3, P133
   Reginster JY, 2002, OSTEOPOROSIS INT, V13, P925, DOI 10.1007/s001980200129
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
NR 43
TC 96
Z9 122
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2009
VL 24
IS 8
BP 1358
EP 1368
DI 10.1359/JBMR.090315
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 482CK
UT WOS:000268861300003
PM 19338452
OA Bronze
DA 2025 08 17
ER

PT J
AU Su, YW
   Fan, J
   Fan, CM
   Peymanfar, Y
   Zhang, YL
   Xian, CJ
AF Su, Yu Wen
   Fan, Jian
   Fan, Chia Ming
   Peymanfar, Yaser
   Zhang, Ya Li
   Xian, Cory J.
TI Roles of apoptotic chondrocyte derived CXCL12 in the enhanced
   chondroclast recruitment following methotrexate and/or dexamethasone
   treatment
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE chemotherapy; childhood cancer; chondrocytes; CXCL12; growth plate
ID CHEMOTHERAPY INDUCED DAMAGES; BONE GROWTH; LYMPHOBLASTIC LEUKEMIA;
   CELL LINE; MECHANISMS; PROMOTES; DIFFERENTIATION; ANGIOGENESIS;
   PATHOBIOLOGY; HYPERTROPHY
AB Intensive use of methotrexate (MTX) and/or dexamethasone (DEX) for treating childhood malignancies is known to cause chondrocyte apoptosis and growth plate dysfunction leading to bone growth impairments. However, mechanisms remain vague and it is unclear whether MTX and DEX combination treatment could have additive effects in the growth plate defects. In this study, significant cell apoptosis was induced in mature ATDC5 chondrocytes after treatment for 48 h with 10( 5) M MTX and/or 10( 6) M DEX treatment. PCR array assays with treated cells plus messenger RNA and protein expression confirmation analyses identified chemokine CXCL12 having the most prominent induction in each treatment group. Conditioned medium from treated chondrocytes stimulated migration of RAW264.7 osteoclast precursor cells and formation of osteoclasts, and these stimulating effects were inhibited by the neutralizing antibody for CXCL12. Additionally, while MTX and DEX combination treatment showed some additive effects on apoptosis induction, it did not have additive or counteractive effects on CXCL12 expression and its functions in enhancing osteoclastic recruitment and formation. In young rats treated acutely with MTX, there was increased expression of CXCL12 in the tibial growth plate, and more resorbing chondroclasts were found present at the border between the hypertrophic growth plate and metaphysis bone. Thus, the present study showed an association between induced chondrocyte apoptosis and stimulated osteoclastic migration and formation following MTX and/or DEX treatment, which could be potentially or at least partially linked molecularly by CXCL12 induction. This finding may contribute to an enhanced mechanistic understanding of bone growth impairments following MTX and/or DEX therapy.
C1 [Su, Yu Wen; Fan, Chia Ming; Peymanfar, Yaser; Zhang, Ya Li; Xian, Cory J.] Univ South Australia, UniSA Clin & Hlth Sci, Adelaide, SA 5001, Australia.
   [Fan, Jian; Xian, Cory J.] Tongji Univ, Dept Orthoped, Shanghai, Peoples R China.
C3 University of South Australia; Tongji University
RP Xian, CJ (通讯作者)，Univ South Australia, UniSA Clin & Hlth Sci, Adelaide, SA 5001, Australia.
EM Cory.Xian@unisa.edu.au
RI Xian, Cory/D 2646 2009; SU, Yu Wen/V 4948 2018; Peymanfar,
   Yaser/AHI 8022 2022; Zhang, Yali/HNR 3900 2023; Su, Yu Wen/V 4948 2018
OI Zhang, Yali/0000 0003 0107 4274; SU, Yu Wen/0000 0002 2067 5270;
   Peymanfar, Yaser/0000 0002 5793 0474; 
FU National Health and Medical Research Council of Australia [1127396];
   Channel 7 Children's Research Foundation [171494]; Natural Science
   Foundation of China [81671928]
FX This work was supported in part by grants from National Health and
   Medical Research Council of Australia (Grant No.: 1127396), Channel 7
   Children's Research Foundation (Grant No.: 171494), and Natural Science
   Foundation of China (Grant No.: 81671928).
CR Alblowi J, 2013, BONE, V53, P294, DOI 10.1016/j.bone.2012.12.006
   BALLARD PL, 1995, AM J OBSTET GYNECOL, V173, P254, DOI 10.1016/0002 9378(95)90210 4
   Boland K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.250
   Caetano Lopes J, 2009, AUTOIMMUN REV, V8, P250, DOI 10.1016/j.autrev.2008.07.038
   Chrysis D, 2003, J ENDOCRINOL, V176, P331, DOI 10.1677/joe.0.1760331
   Crofton PM, 2000, PEDIATR RES, V48, P490, DOI 10.1203/00006450 200010000 00012
   Diamond P, 2009, J BONE MINER RES, V24, P1150, DOI [10.1359/JBMR.090210, 10.1359/jbmr.090210]
   Fan C, 2011, CURR MOL MED, V11, P140, DOI 10.2174/156652411794859223
   Fan CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046915
   Georgiou KR, 2012, INT J EXP PATHOL, V93, P104, DOI 10.1111/j.1365 2613.2011.00800.x
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Haddy TB, 2001, ONCOLOGIST, V6, P278, DOI 10.1634/theoncologist.6 3 278
   Hassanshahi M, 2019, J CELL BIOCHEM, V120, P3220, DOI 10.1002/jcb.27589
   Hassanshahi M, 2019, J CELL PHYSIOL, V234, P16549, DOI 10.1002/jcp.28326
   Hassanshahi M, 2019, J CELL PHYSIOL, V234, P11276, DOI 10.1002/jcp.27785
   Hassanshahi M, 2017, ANGIOGENESIS, V20, P427, DOI 10.1007/s10456 017 9577 2
   Kikuta J, 2013, RHEUMATOLOGY, V52, P226, DOI 10.1093/rheumatology/kes259
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Li J, 2004, BRIT J HAEMATOL, V127, P326, DOI 10.1111/j.1365 2141.2004.05200.x
   Mackie EJ, 2011, J ENDOCRINOL, V211, P109, DOI 10.1530/JOE 11 0048
   Mitchell C, 2009, BRIT J HAEMATOL, V146, P424, DOI 10.1111/j.1365 2141.2009.07769.x
   Odgren PR, 2016, CONNECT TISSUE RES, V57, P161, DOI 10.3109/03008207.2016.1140752
   Olney RC, 2009, HORM RES, V72, P30, DOI 10.1159/000229761
   Pfeffer CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020448
   Shandala T, 2012, J CELL PHYSIOL, V227, P2889, DOI 10.1002/jcp.23034
   Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174
   Su YW, 2017, ANN NY ACAD SCI, V1403, P109, DOI 10.1111/nyas.13380
   Su YW, 2016, J BONE MINER RES, V31, P1258, DOI 10.1002/jbmr.2786
   Terry DE, 2000, ANAL BIOCHEM, V285, P211, DOI 10.1006/abio.2000.4761
   Veerman AJ, 2009, LANCET ONCOL, V10, P957, DOI 10.1016/S1470 2045(09)70228 1
   Viana MB, 2008, PEDIATR BLOOD CANCER, V50, P509, DOI 10.1002/pbc.21396
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Wang YM, 2014, J BONE MINER RES, V29, P1900, DOI 10.1002/jbmr.2196
   Wei L, 2006, J RHEUMATOL, V33, P1818
   Wei L, 2010, DEV BIOL, V341, P236, DOI 10.1016/j.ydbio.2010.02.033
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021
   Xian CJ, 2008, J CELL PHYSIOL, V214, P777, DOI 10.1002/jcp.21274
   Xian CJ, 2007, BONE, V41, P842, DOI 10.1016/j.bone.2007.07.021
   Xian CJ, 2007, ENDOCR REV, V28, P284, DOI 10.1210/er.2006 0049
   Yao YC, 2013, J CELL BIOCHEM, V114, P1223, DOI 10.1002/jcb.24467
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   Zaman F, 2019, FASEB J, V33, P4962, DOI 10.1096/fj.201801741R
   Zaman F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033168
   Zuscik MJ, 2008, J CLIN INVEST, V118, P429, DOI 10.1172/JCI34174
NR 46
TC 4
Z9 4
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2021
VL 236
IS 8
BP 5966
EP 5979
DI 10.1002/jcp.30278
EA JAN 2021
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA SC9AI
UT WOS:000607071100001
PM 33438203
DA 2025 08 17
ER

PT J
AU Méaux, MN
   Alioli, C
   Linglart, A
   Lemoine, S
   Vignot, E
   Bertholet Thomas, A
   Peyruchaud, O
   Flammier, S
   Machuca Gayet, I
   Bacchetta, J
AF Meaux, Marie Noelle
   Alioli, Candide
   Linglart, Agnes
   Lemoine, Sandrine
   Vignot, Emmanuelle
   Bertholet Thomas, Aurelia
   Peyruchaud, Olivier
   Flammier, Sacha
   Machuca Gayet, Irma
   Bacchetta, Justine
TI X Linked Hypophosphatemia, Not Only a Skeletal Disease But Also a
   Chronic Inflammatory State
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE X linked hypophosphatemia; obesity; inflammation; osteoclastogenesis;
   vitamin D
ID GROWTH FACTOR 23; VITAMIN D; YOUNG ADULTS; FGF23; CHILDREN;
   HYPERTENSION; THERAPY; AGE
AB Context X linked hypophosphatemia (XLH) is a rare genetic disease caused by a primary excess of fibroblast growth factor 23 (FGF23). FGF23 has been associated with inflammation and impaired osteoclastogenesis, but these pathways have not been investigated in XLH. Objective This work aimed to evaluate whether XLH patients display peculiar inflammatory profile and increased osteoclastic activity. Methods We performed a prospective, multicenter, cross sectional study analyzing transcript expression of 8 inflammatory markers (Il6, Il8, Il1 beta, CXCL1, CCL2, CXCR3, Il1R, Il6R) by real time quantitative polymerase chain reaction on peripheral blood mononuclear cells (PBMCs) purified from total blood samples extracted from patients and healthy control individuals. The effect of native/active vitamin D on osteoclast formation was also assessed in vitro from XLH patients' PBMCs. Results In total, 28 XLH patients (17 children, among them 6 undergoing standard of care [SOC] and 11 burosumab therapy) and 19 controls were enrolled. Expression of most inflammatory markers was significantly increased in PBMCs from XLH patients compared to controls. No differences were observed between the burosumab and SOC subgroups. Osteoclast formation was significantly impaired in XLH patients. XLH mature osteoclasts displayed higher levels of inflammatory markers, being however lower in cells derived from the burosumab subgroup (as opposed to SOC). Conclusion We describe for the first time a peculiar inflammatory profile in XLH. Since XLH patients have a propensity to develop arterial hypertension, obesity, and enthesopathies, and because inflammation can worsen these clinical outcomes, we hypothesize that inflammation may play a critical role in these extraskeletal complications of XLH.
C1 [Meaux, Marie Noelle; Bertholet Thomas, Aurelia; Flammier, Sacha; Bacchetta, Justine] CHU Lyon, Ctr Reference Malad Renales Rares Filieres Malad, Serv Nephrol Rhumatol & Dermatol Pediat,OSCAR, Ctr Reference Malad Rares Calcium & Phosphore, F 69500 Bron, France.
   [Meaux, Marie Noelle; Bertholet Thomas, Aurelia; Flammier, Sacha; Bacchetta, Justine] CHU Lyon, ERN ERKNet, F 69500 Bron, France.
   [Meaux, Marie Noelle; Alioli, Candide; Bertholet Thomas, Aurelia; Machuca Gayet, Irma; Bacchetta, Justine] Univ Claude Bernard Lyon 1, Fac Med Lyon Est, INSERM, UMR 1033, F 69008 Lyon, France.
   [Linglart, Agnes] Univ Paris Saclay, Ctr Reference Malad Rares Calcium & Phosphore, Serv endocrinol & diabete enfant,Plateforme exper, AP HP,Filiere Sante Malad Rares OSCARERNendoRARE, F 94270 Le Kremlin Bicetre, France.
   [Lemoine, Sandrine; Vignot, Emmanuelle] Hop Edouard Herriot, Dept Nephrol, Serv explorat Fonct renale, F 69003 Lyon, France.
   [Lemoine, Sandrine; Vignot, Emmanuelle; Bacchetta, Justine] Hop Edouard Herriot, Serv Rhumatol, F 69003 Lyon, France.
C3 CHU Lyon; CHU Lyon; Universite Claude Bernard Lyon 1; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Bicetre   APHP; Universite
   Paris Saclay; CHU Lyon; CHU Lyon
RP Méaux, MN (通讯作者)，Hop Femme Mere Enfant, Ctr Reference Malad Renales Rares, Ctr Reference Malad Rares Calcium & Phosphore, Serv Nephrol Rhumatol & Dermatol Pediat, Blvd Pinel, F 694500 Bron, France.
EM mn.meaux@gmail.com
RI ; Lemoine, Sandrine/AAL 4365 2021; Bacchetta, Justine/B 3842 2016;
   Linglart, Agnes/A 8047 2016; Linglart, agnes/A 8047 2016
OI Meaux, Marie Noelle/0000 0001 8418 1926; Peyruchaud,
   Olivier/0000 0002 5393 4945; Linglart, Agnes/0000 0003 3455 002X; Lab,
   Carmen/0000 0002 5935 3236; 
FU Kyowa Kirin; INSERM (Insfitut National de la Sante et de la Recherche
   Medicale); Universite Claude Bernard Lyon 1 (University Lyon);
   Cystinosis Research Foundation; ANR (Agence Nationale de la Recherche)
   grant [ANR 20 CE14 0036 01]; Agence Nationale de la Recherche (ANR)
   [ANR 20 CE14 0036] Funding Source: Agence Nationale de la Recherche
   (ANR)
FX The Hospices Civils de Lyon received a research grant from Kyowa Kirin
   for the HYPOCLAST study. The INSERM 1033 laboratory is supported by
   grants from INSERM (Insfitut National de la Sante et de la Recherche
   Medicale) and Universite Claude Bernard Lyon 1 (University Lyon to O.P.
   and I.M.G.  Recurent fundings 2022), the Cystinosis Research Foundation
   (to I.M.G. and J.B.), and an ANR (Agence Nationale de la Recherche)
   grant (BONETAX No. ANR 20 CE14 0036 01). The funders had no role in the
   design of the study; the collection, analyses, or interpretation of
   data; the writing of the manuscript, or the decision to publish the
   results.
CR Ali FN, 2014, J PEDIATR US, V165, P738, DOI 10.1016/j.jpeds.2014.06.027
   Allard L, 2015, CALCIFIED TISSUE INT, V97, P69, DOI 10.1007/s00223 015 0013 6
   Alon US, 2003, PEDIATR NEPHROL, V18, P155, DOI 10.1007/s00467 002 1044 6
   Amarasekara DS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e8
   Andrukhova O, 2014, EMBO MOL MED, V6, P744, DOI 10.1002/emmm.201303716
   Araujo EG, 2020, RHEUMATOLOGY, V59, pI10, DOI 10.1093/rheumatology/keaa039
   Ardeshirpour Laleh, 2007, Pediatr Endocrinol Rev, V5 Suppl 1, P584
   Bacchetta J, 2021, JOINT BONE SPINE, V88, DOI 10.1016/j.jbspin.2021.105208
   Bacchetta J, 2019, ACTA PAEDIATR, V108, P2253, DOI 10.1111/apa.14907
   Bacchetta J, 2020, METABOLISM, V103, DOI 10.1016/j.metabol.2019.01.006
   Beck Nielsen SS, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023 019 1014 8
   Bernardor J, 2021, CURR OSTEOPOROS REP, V19, P553, DOI 10.1007/s11914 021 00707 6
   Bernardor J, 2020, J BONE MINER RES, V35, P2265, DOI 10.1002/jbmr.4122
   Bertholet Thomas A, 2018, PEDIATR NEPHROL, V33, P1165, DOI 10.1007/s00467 018 3902 x
   Bloudeau L, 2023, PEDIATR NEPHROL, V38, P697, DOI 10.1007/s00467 022 05636 9
   Bosy Westphal A, 2021, OBES REV, V22, DOI 10.1111/obr.13190
   Briot K, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2021 001714
   Cannata Andía JB, 2021, CALCIFIED TISSUE INT, V108, P410, DOI 10.1007/s00223 020 00777 1
   Carpenter TO, 2018, NEW ENGL J MED, V378, P1987, DOI 10.1056/NEJMoa1714641
   Che H, 2016, EUR J ENDOCRINOL, V174, P325, DOI 10.1530/EJE 15 0661
   Chonchol M, 2016, J AM SOC NEPHROL, V27, P227, DOI 10.1681/ASN.2014101009
   Claramunt Taberner D, 2018, NEPHROL DIAL TRANSPL, V33, P1525, DOI 10.1093/ndt/gfx362
   Connor J, 2015, J CLIN ENDOCR METAB, V100, P3625, DOI 10.1210/JC.2015 2199
   Czaya B, 2019, KIDNEY INT, V96, P813, DOI 10.1016/j.kint.2019.05.018
   Dubourg LD, 2022, NEPHROL DIAL TRANSPL, V37, P2150, DOI 10.1093/ndt/gfab331
   Faraji Bellée CA, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00854
   Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122
   Freundlich M, 2021, PEDIATR NEPHROL, V36, P3007, DOI 10.1007/s00467 020 04843 6
   Goltzman D, 2018, FRONT HORM RES, V50, P1, DOI 10.1159/000486060
   Grabner A, 2015, CELL METAB, V22, P1020, DOI 10.1016/j.cmet.2015.09.002
   Grau L, 2020, KIDNEY360, V1, P648, DOI 10.34067/KID.0001692020
   Gutiérrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130
   Haffner D, 2019, NAT REV NEPHROL, V15, P435, DOI 10.1038/s41581 019 0152 5
   Hall JE, 2021, CARDIOVASC RES, V117, P1859, DOI 10.1093/cvr/cvaa336
   Han XB, 2016, FEBS LETT, V590, P53, DOI 10.1002/1873 3468.12040
   Hernández Frías O, 2019, PEDIATR NEPHROL, V34, P1077, DOI 10.1007/s00467 018 4180 3
   Herrou J, 2022, J CLIN ENDOCR METAB, V107, pE224, DOI 10.1210/clinem/dgab580
   Imel EA, 2019, LANCET, V393, P2416, DOI 10.1016/S0140 6736(19)30654 3
   Krick S, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00236 2018
   Lecoq AL., 2020, J ENDOCR SOC, V4
   Meaux MN., 2022, SUPPL DATA XLINKED H, DOI [10.6084/m9.figshare.21082699, DOI 10.6084/M9.FIGSHARE.21082699]
   Mendoza FA, 2012, CLIN J AM SOC NEPHRO, V7, P1155, DOI 10.2215/CJN.13281211
   Michels WM, 2010, CLIN J AM SOC NEPHRO, V5, P1003, DOI 10.2215/CJN.06870909
   Nakamura Y, 2017, ENDOCR J, V64, P283, DOI 10.1507/endocrj.EJ16 0199
   Nehgme R, 1997, J CLIN ENDOCR METAB, V82, P2450, DOI 10.1210/jc.82.8.2450
   Pierce CB, 2021, KIDNEY INT, V99, P948, DOI 10.1016/j.kint.2020.10.047
   Piketty ML, 2020, CLIN CHEM LAB MED, V58, pE267, DOI 10.1515/cclm 2020 0460
   Quinaux T, 2021, CELLS BASEL, V10, DOI 10.3390/cells10092498
   Rothenbuhler A, 2020, METABOLISM, V103, DOI 10.1016/j.metabol.2019.03.009
   Simic P, 2020, J CLIN INVEST, V130, P1513, DOI 10.1172/JCI131190
   Singh S, 2016, KIDNEY INT, V90, P985, DOI 10.1016/j.kint.2016.05.019
   Terkawi MA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031786
   Vervloet M, 2019, NAT REV NEPHROL, V15, P109, DOI 10.1038/s41581 018 0087 2
   Yin K, 2014, J INFLAMM RES, V7, P69, DOI 10.2147/JIR.S63898
   Zajac M, 2015, CROAT MED J, V56, P344, DOI 10.3325/cmj.2015.56.344
   Zhukouskaya V., 2019, J ENDOCR SOC, V3
   Zhukouskaya VV, 2020, ENDOCR CONNECT, V9, P144, DOI 10.1530/EC 19 0481
NR 57
TC 8
Z9 9
U1 0
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021 972X
EI 1945 7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD NOV 25
PY 2022
VL 107
IS 12
BP 3275
EP 3286
DI 10.1210/clinem/dgac543
EA SEP 2022
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 6S5TJ
UT WOS:000862377300001
PM 36112422
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Rockel, JS
   Grol, M
   Bernier, SM
   Leask, A
AF Rockel, Jason S.
   Grol, Matthew
   Bernier, Suzanne M.
   Leask, Andrew
TI Cyclic AMP regulates extracellular matrix gene expression and metabolism
   in cultured primary rat chondrocytes
SO MATRIX BIOLOGY
LA English
DT Article
DE Cyclic AMP; Chondrocytes; Extracellular matrix; Metabolism; Glycogen
   synthase kinase; Prostaglandin E 2
ID DEPENDENT PROTEIN KINASE; NECROSIS FACTOR ALPHA; TNF ALPHA; ARTICULAR
   CHONDROCYTES; RHEUMATOID ARTHRITIS; PROSTAGLANDIN E 2; RETINOIC ACID;
   BETA CATENIN; KAPPA B; CAMP
AB In osteo  and rheumatoid arthritis, the synovial fluid surrounding chondrocytes contains increased levels of prostaglandin E 2 (PGE(2)), an agent known to elevate intracellular cyclic AMP (cAMP). However, the effect of PGE(2)/cAMP on mRNA expression in chondrocytes is largely unknown. In this report, we assess the effect of the cell permeable cAMP analog adenosine 8 (4 chloro phenylthio) 3',5' cyclic monophosphate (CPT cAMP) and PGE(2) on mRNA expression in primary neonatal rat chondrocytes. CPT cAMP decreased type 11 collagen, link protein, parathyroid hormone/parathyroid hormone related peptide receptor and alkaline phosphatase, increased glyceraldehyde 3 phosphate dehydrogenase mRNA and lactate efflux, but did not alter type X collagen or aggrecan mRNA. The effect of CPT cAMP on type 11 collagen and link protein mRNAs and chondrocyte metabolism were attenuated by the transcriptional inhibitor actinomycin D, indicating that the ability of CPT cAMP to suppress mRNA expression was not due to alterations in mRNA stability, but were instead likely due to transcriptional mechanisms. CPT cAMP treatment induced GSK3 beta phosphorylation and beta catenin mediated transcriptional activity. Pharmacological inhibition of GSK3 beta paralleled the effects of CPT cAMP on type II collagen, link protein and chondrocyte metabolism, suggesting that the effect of CPT cAMP on chondrocytes may be GSK3 beta/beta catenin dependent. The effects of CPT cAMP on beta catenin mediated transcription, cell metabolism and mRNA expression were mimicked by the cAMP elevating agent PGE(2), providing a physiologically relevant context for our studies. Collectively, these results suggest that agents that elevate cAMP signaling may impair chondrocyte function in conditions such as arthritis. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Leask, Andrew] Univ Western Ontario, Schulich Sch Med & Dent, Div Oral Biol, London, ON N6A 5C1, Canada.
   [Rockel, Jason S.; Grol, Matthew; Bernier, Suzanne M.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, Canadian Inst Hlth,Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada.
C3 Western University (University of Western Ontario); Western University
   (University of Western Ontario)
RP Leask, A (通讯作者)，Univ Western Ontario, Schulich Sch Med & Dent, Div Oral Biol, London, ON N6A 5C1, Canada.
EM jsrockel@uwo.ca; matthew.grol@schulich.uwo.ca;
   andrew.leask@schulich.uwo.ca
RI Leask, Andrew/G 5217 2015; Grol, Matthew William/HOF 9774 2023; Grol,
   Matthew/HOF 9774 2023
OI Grol, Matthew William/0000 0001 6514 9066; 
FU Canadian Institutes of Health Research (CIHR) [14095, 81243]; Natural
   Sciences and Engineering Research Council
FX This study was supported by operating grants 14095 and 81243 (to S.
   Bernier and A. Leask, respectively) from the Canadian Institutes of
   Health Research (CIHR). J. Rockel is a recipient of a PGS D scholarship
   from the Natural Sciences and Engineering Research Council. M. Grol is a
   recipient of a Canadian Institutes of Health Research CGS masters
   scholarship. We thank Dr. S.Jeffery Dixon and J. Ryan Gillespie for
   their helpful insights.
CR Aoyama T, 2005, J BONE MINER RES, V20, P377, DOI 10.1359/JBMR.041122
   ASKEW GR, 1991, J BIOL CHEM, V266, P16834
   Attur M, 2008, J IMMUNOL, V181, P5082, DOI 10.4049/jimmunol.181.7.5082
   Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697 174
   BERNARD DW, 1991, J BIOL CHEM, V266, P710
   Chen XS, 2008, ARTHRITIS RHEUM US, V58, P3788, DOI 10.1002/art.23985
   CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   CURTIS AJ, 1992, BIOCHEM J, V288, P721, DOI 10.1042/bj2880721
   de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884
   DOSTMANN WRG, 1991, BIOCHEMISTRY US, V30, P8710, DOI 10.1021/bi00099a032
   Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380
   Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597
   Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097 2765(01)00253 2
   Fujita H, 2006, BRAIN RES, V1113, P10, DOI 10.1016/j.brainres.2006.06.079
   GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014 4827(92)90186 C
   GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110
   Hardy MM, 2002, ARTHRITIS RHEUM, V46, P1789, DOI 10.1002/art.10356
   Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149 4158.2000
   Kammermann JR, 1996, OSTEOARTHR CARTILAGE, V4, P23, DOI 10.1016/S1063 4584(96)80004 5
   Kennedy L, 2007, EXP CELL RES, V313, P952, DOI 10.1016/j.yexcr.2006.12.006
   Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106
   Kleiveland CR, 2008, EXP CELL RES, V314, P1831, DOI 10.1016/j.yexcr.2008.02.004
   Klooster AR, 2005, ARTHRITIS RES THER, V7, pR127, DOI 10.1186/ar1464
   Kohno H, 1997, J BONE MINER RES, V12, P847, DOI 10.1359/jbmr.1997.12.5.847
   Kou I, 2004, J BIOL CHEM, V279, P50942, DOI 10.1074/jbc.M406786200
   Kudirka JC, 2007, J CELL PHYSIOL, V213, P54, DOI 10.1002/jcp.21087
   Lee RB, 1997, BIOCHEM J, V321, P95, DOI 10.1042/bj3210095
   Liacini A, 2003, EXP CELL RES, V288, P208, DOI 10.1016/S0014 4827(03)00180 0
   Liu F, 2008, CELL SIGNAL, V20, P999, DOI 10.1016/j.cellsig.2007.11.011
   Long FX, 2001, DEVELOPMENT, V128, P541
   LORENZEN M, 1983, AM J PHYSIOL, V245, pF188, DOI 10.1152/ajprenal.1983.245.2.F188
   Mastbergen SC, 2005, OSTEOARTHR CARTILAGE, V13, P519, DOI 10.1016/j.joca.2005.02.004
   McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528
   Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193
   Pala D, 2008, J BIOL CHEM, V283, P9239, DOI 10.1074/jbc.M705175200
   Rockel JS, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2595
   Rockel JS, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2349
   Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110
   Sakuma Y, 2004, BONE, V34, P827, DOI 10.1016/j.bone.2003.12.007
   SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521
   Santhanagopal A, 2001, ENDOCRINOLOGY, V142, P4401, DOI 10.1210/en.142.10.4401
   Séguin CA, 2003, J CELL PHYSIOL, V197, P357, DOI 10.1002/jcp.10371
   Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738
   Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200
   Smith MD, 1997, J RHEUMATOL, V24, P365
   STURGE RA, 1978, ANN RHEUM DIS, V37, P315, DOI 10.1136/ard.37.4.315
   Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200
   Taskén K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003
   Taurin S, 2008, AM J PHYSIOL CELL PH, V294, pC1169, DOI 10.1152/ajpcell.00096.2008
   TOKUNAGA M, 1981, ANN RHEUM DIS, V40, P462, DOI 10.1136/ard.40.5.462
   Ugland H, 2008, MOL BIOL CELL, V19, P5082, DOI 10.1091/mbc.E08 01 0094
   Üstünel I, 2003, ANAT HISTOL EMBRYOL, V32, P356, DOI 10.1111/j.1439 0264.2003.00494.x
   Yang G, 2005, GENESIS, V42, P33, DOI 10.1002/gene.20120
   Yokoyama U, 2008, AM J PHYSIOL HEART C, V295, pH1547, DOI 10.1152/ajpheart.01317.2007
   Zambon AC, 2005, P NATL ACAD SCI USA, V102, P8561, DOI 10.1073/pnas.0503363102
   Zhu M, 2009, J BONE MINER RES, V24, P12, DOI [10.1359/jbmr.080901, 10.1359/JBMR.080901]
NR 57
TC 6
Z9 7
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0945 053X
EI 1569 1802
J9 MATRIX BIOL
JI Matrix Biol.
PD JUL
PY 2009
VL 28
IS 6
BP 354
EP 364
DI 10.1016/j.matbio.2009.05.005
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 506JC
UT WOS:000270770100007
PM 19505573
DA 2025 08 17
ER

PT J
AU Roshan Ghias, A
   Arnoldi, J
   Procter, P
   Pioletti, DP
AF Roshan Ghias, Alireza
   Arnoldi, Joerg
   Procter, Philip
   Pioletti, Dominique P.
TI In vivo assessment of local effects after application of bone screws
   delivering bisphosphonates into a compromised cancellous bone site
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Bone screws; Cancellous bone; Drug delivery; Biomechanics; Histology
ID TRABECULAR BONE; FIXATION; IMPLANTS; RATS; OSTEOPOROSIS; MECHANISMS;
   DENSITY; RABBITS; SURFACE; SYSTEM
AB Background: The primary stability of cancellous screw is difficult to obtain in bone of compromised quality and failure of screw fixation is common. To overcome this problem, it is proposed to locally deliver bisphosphonate from the screw. An in vivo validation of the increase in fixation of the cancellous screw is then needed in compromised bone.
   Methods: In this study, we used an overdrilling procedure, which enables consistent modeling of reduced screw stability comparable to compromised cancellous bone. Forty eight adult NZW rabbits were used in this study and all animals underwent bilateral femur implantation. One leg was implanted with the screw containing the bisphosphonate (biocoated group) while the other was used as control (control group) with the screw only. Mechanical testing and micro CT imaging were used to assess the effect of local drug delivery of Zoledronate on screws fixation at 5 time points.
   Findings: At the early time points (1, 5, and 10 days), no significant difference could be seen between the biocoated and control groups. At 6 weeks, the bone volume fraction was significantly higher in the trabecular region of the biocoated group. However, this increase did not have a significant effect on the pull out force. At the last time point, 11 weeks, both the bone volume fraction and the pull out force were significantly higher in the biocoated group.
   Interpretation: The results of this study suggest that, in compromised bone, local delivery of bisphosphonate enhances the stability of bone screws. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Roshan Ghias, Alireza; Pioletti, Dominique P.] Ecole Polytech Fed Lausanne, Lab Biomech Orthoped, Inst Bioengn, CH 1015 Lausanne, Switzerland.
   [Arnoldi, Joerg] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden.
   [Procter, Philip] Brunel Univ, Sch Engn & Design, Uxbridge UB8 3PH, Middx, England.
C3 Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne; University of Gothenburg; Brunel University
RP Pioletti, DP (通讯作者)，Ecole Polytech Fed Lausanne, Lab Biomech Orthoped, Inst Bioengn, Stn 15, CH 1015 Lausanne, Switzerland.
EM dominique.pioletti@epfl.ch
RI ; Procter, Philip/N 4714 2019; Pioletti, Dominique/C 5697 2008
OI Procter, Philip/0000 0002 3219 1177; Pioletti,
   Dominique/0000 0001 5535 5296
FU Stryker Osteosynthesis, Selzach, Switzerland
FX The FibMat (fibrinogen) coated screws were kindly provided by Dr Trine
   Vikinge, AddBIO AB, Linkoping Sweden. This study was partially funded by
   Stryker Osteosynthesis, Selzach, Switzerland.
CR Abtahi J, 2010, INT J ORAL MAX SURG, V39, P673, DOI 10.1016/j.ijom.2010.04.002
   Aspenberg P, 2009, ACTA ORTHOP, V80, P119, DOI 10.1080/17453670902807466
   Augat P, 2003, J BIOMED MATER RES A, V66A, P457, DOI 10.1002/jbm.a.10601
   Björkenheim JM, 2004, ACTA ORTHOP SCAND, V75, P741, DOI 10.1080/00016470410004120
   Castañeda S, 2008, J BONE MINER METAB, V26, P53, DOI 10.1007/s00774 007 0797 1
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   GRARDEL B, 1994, OSTEOPOROSIS INT, V4, P204, DOI 10.1007/BF01623240
   Hoshikawa A, 2003, BIOMATERIALS, V24, P4967, DOI 10.1016/S0142 9612(03)00422 8
   PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Pioletti Dominique P., 2008, Current Drug Delivery, V5, P59, DOI 10.2174/156720108783331041
   Riggs BL, 2004, J BONE MINER RES, V19, P1945, DOI 10.1359/JBMR.040916
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Schorlemmer S, 2003, J BONE MINER RES, V18, P2010, DOI 10.1359/jbmr.2003.18.11.2010
   Seebeck J, 2005, OSTEOPOROSIS INT, V16, pS107, DOI 10.1007/s00198 004 1777 0
   Stadelmann VA, 2008, BONE, V42, P358, DOI 10.1016/j.bone.2007.09.055
   Tengvall P, 2004, BIOMATERIALS, V25, P2133, DOI 10.1016/j.biomaterials.2003.08.049
   Turner A. Simon, 2001, European Cells & Materials, V1, P66
   Wermelin K, 2008, BONE, V42, P365, DOI 10.1016/j.bone.2007.10.013
   Wermelin K, 2008, J BIOMED MATER RES A, V86A, P220, DOI 10.1002/jbm.a.31583
NR 21
TC 16
Z9 21
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268 0033
J9 CLIN BIOMECH
JI Clin. Biomech.
PD DEC
PY 2011
VL 26
IS 10
BP 1039
EP 1043
DI 10.1016/j.clinbiomech.2011.06.004
PG 5
WC Engineering, Biomedical; Orthopedics; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Orthopedics; Sport Sciences
GA 859KP
UT WOS:000297875600011
PM 21696870
OA Green Published
DA 2025 08 17
ER

PT J
AU Luo, TYD
   Allen, MR
AF Luo, Tianyi D.
   Allen, Matthew R.
TI Short courses of dexamethasone abolish bisphosphonate induced reductions
   in bone toughness
SO BONE
LA English
DT Article
DE Zoledronic acid; Mechanical properties; Toughness; Remodeling
   suppression
ID MICRODAMAGE ACCUMULATION; BIOMECHANICAL PROPERTIES; 1 YEAR TREATMENT;
   ZOLEDRONIC ACID; RISEDRONATE; ALENDRONATE; FRACTURES; TURNOVER; SITES
AB Atypical femoral fractures, which display characteristics of brittle material failure, have been associated with potent remodeling suppression drugs. Given the millions of individuals treated with this class of drugs it is likely that other factors play a role in these fractures. Some evidence suggests that concomitant use of corticosteroids may contribute to the pathogenesis although data in this area is lacking. The goal of this study was to assess the combined role of bisphosphonates and dexamethasone on bone mechanical properties. Skeletally mature beagle dogs were either untreated controls, or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL + DEX Zoledronic acid (0.06 mg/kg) was given monthly via IV infusion for 9 months. DEX (5 mg) was administered daily for one week during each of the last three months of the 9 month experiment. Ribs were harvested and assessed for bone geometry, mechanical properties, and remodeling rate (n = 3 6 specimens per group). DEX significantly suppressed intracortical remodeling compared to vehicle controls while both ZOL and the combination of DEX + ZOL nearly abolished intracortical remodeling. ZOL treatment resulted in significantly lower bone toughness, determined from 3 point bending tests, compared to all other treatment groups while the toughness in ZOL + DEX animals was identical to those of untreated controls. These findings suggest that short courses of dexamethasone not only do not adversely affect toughness in the setting of bisphosphonates, but also actually reverse the adverse effects of its treatment. Understanding the mechanism for this tissue level effect could lead to novel approaches for reducing the risk of atypical femoral fractures. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Luo, Tianyi D.; Allen, Matthew R.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington
RP Allen, MR (通讯作者)，Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5035, Indianapolis, IN 46202 USA.
EM matallen@iupui.edu
RI Allen, Matthew/A 8799 2015
FU NIH [DE019686]
FX We would like to thank Carrie Pell and her staff for assistance with
   animal care, and Keith Condon for his assistance with histological
   processing. This work was supported by a grant from the NIH (DE019686  
   MRA).
CR Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   Allen MR, 2006, CALCIFIED TISSUE INT, V79, P255, DOI 10.1007/s00223 006 0031 5
   Allen M.S., 2012, ADV ECOSYSTEM APPROA, P1
   Allen MR, 2008, CALCIFIED TISSUE INT, V82, P354, DOI 10.1007/s00223 008 9131 8
   Allen MR, 2007, J BONE MINER RES, V22, P1759, DOI 10.1359/JBMR.070720
   Allen MR, 2006, BONE, V39, P872, DOI 10.1016/j.bone.2006.04.028
   Allen MR, 2010, J BONE MINER RES, V25, P98, DOI 10.1359/jbmr.090713
   Balooch G, 2007, ARTHRITIS RHEUM, V56, P3726, DOI 10.1002/art.22976
   Clemons MJ, 2006, J CLIN ONCOL, V24, P4895, DOI 10.1200/JCO.2006.05.9212
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259
   Giusti A, 2011, BONE, V48, P966, DOI 10.1016/j.bone.2010.12.033
   Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Jia JJ, 2011, FASEB J, V25, P3366, DOI 10.1096/fj.11 182519
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lenart BA, 2009, OSTEOPOROSIS INT, V20, P1353, DOI 10.1007/s00198 008 0805 x
   Mashiba T, 2000, J BONE MINER RES, V15, P613, DOI 10.1359/jbmr.2000.15.4.613
   Mashiba T, 2001, BONE, V28, P524, DOI 10.1016/S8756 3282(01)00414 8
   Nicolella DP, 2006, J BIOMECH, V39, P1735, DOI 10.1016/j.jbiomech.2005.04.032
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Tan S.H., 2010, OXYGEN PLASMA TREATM, P1
   Tang SY, 2009, OSTEOPOROSIS INT, V20, P887, DOI 10.1007/s00198 008 0754 4
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596
   Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155
   Yates CJ, 2011, J BONE MINER RES, V26, P1377, DOI 10.1002/jbmr.308
NR 27
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD SEP
PY 2013
VL 56
IS 1
BP 199
EP 203
DI 10.1016/j.bone.2013.06.004
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 189WS
UT WOS:000322299600027
PM 23774445
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Da Silva, D
   Crous, A
   Abrahamse, H
AF Da Silva, Daniella
   Crous, Anine
   Abrahamse, Heidi
TI Synergistic Effects of Photobiomodulation and Differentiation Inducers
   on Osteogenic Differentiation of Adipose Derived Stem Cells in
   Three Dimensional Culture
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE adipose derived stem cells; differentiation inducers; three dimensional
   cell culture; photobiomodulation; osteoporosis regenerative therapy
ID MECHANISMS; BONE
AB Osteoporosis, a common metabolic bone disorder, leads to increased fracture risk and significant morbidity, particularly in postmenopausal women and the elderly. Traditional treatments often fail to fully restore bone health and may cause side effects, prompting the exploration of regenerative therapies. Adipose derived stem cells (ADSCs) offer potential for osteoporosis treatment, but their natural inclination toward adipogenic rather than osteogenic differentiation poses a challenge. This study investigates a novel approach combining differentiation inducers (DIs), three dimensional (3D) hydrogel scaffolds, and photobiomodulation (PBM) to promote osteogenic differentiation of immortalised ADSCs. A dextran based 3D hydrogel matrix, supplemented with a DI cocktail of dexamethasone, beta glycerophosphate disodium, and ascorbic acid, was used to foster osteogenesis. PBM was applied using near infrared (825 nm), green (525 nm), and combined wavelengths at fluences of 3 J/cm2, 5 J/cm2, and 7 J/cm2 to enhance osteogenic potential. Flow cytometry identified osteoblast specific markers, while inverted light microscopy evaluated cellular morphology. Reactive oxygen species assays measured oxidative stress, and quantitative polymerase chain reaction (qPCR) revealed upregulated gene expression linked to osteogenesis. The findings demonstrate that integrating DIs, 3D hydrogels, and PBM effectively drives osteogenic differentiation in immortalised ADSCs. The PBM enhanced osteogenic marker expression, induced morphological changes, and upregulated gene activity, presenting a promising framework for bone regeneration. Future research should assess the stability and functionality of these differentiated cells and explore their applicability in preclinical models of bone injury or degeneration. This integrative approach demonstrated specific efficacy in promoting the osteogenic differentiation of ADSCs, highlighting its potential application in developing targeted treatments for osteoporosis.
C1 [Da Silva, Daniella; Crous, Anine; Abrahamse, Heidi] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, POB 17011, ZA 2028 Johannesburg, South Africa.
C3 University of Johannesburg
RP Abrahamse, H (通讯作者)，Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, POB 17011, ZA 2028 Johannesburg, South Africa.
EM 216040611@student.uj.ac.za; acrous@uj.ac.za; habrahamse@uj.ac.za
RI ; Da Silva, Daniella/AAL 5075 2020; Crous, Anine/AAL 6476 2020;
   Abrahamse, Heidi/U 7763 2019
OI Da Silva, Daniella/0000 0002 1588 2697; Abrahamse,
   Heidi/0000 0001 5002 827X
FU National Research Foundation of South Africa Thuthuka Instrument;
   Department of Science and Innovation [HLHA23X task ALC R007]; University
   Research Council [2022URC00513]; Department of Science and Innovation
   South African Research Chairs Initiative [DSI NRF/SARChI, 98337];
   University of Johannesburg Faculty of Health Sciences;  [TTK2205035996]
FX This work is supported by the National Research Foundation of South
   Africa Thuthuka Instrument, grant number TTK2205035996; the Department
   of Science and Innovation (DSI) funded African Laser Centre (ALC), grant
   number HLHA23X task ALC R007; the University Research Council, grant
   number 2022URC00513; the Department of Science and Innovation South
   African Research Chairs Initiative (DSI NRF/SARChI), grant number 98337,
   and the APC was funded by the University of Johannesburg Faculty of
   Health Sciences.
CR Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Çevik ZBY, 2023, J PHOTOCH PHOTOBIO B, V238, DOI 10.1016/j.jphotobiol.2022.112615
   Chen JQ, 2022, J PHOTOCH PHOTOBIO B, V233, DOI 10.1016/j.jphotobiol.2022.112472
   Chen XD, 1999, J BONE MINER RES, V14, P362, DOI 10.1359/jbmr.1999.14.3.362
   Choi JUA, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770143
   Cui Y, 2020, TRANSL ANDROL UROL, V9, P2082, DOI 10.21037/tau 20 607
   Da Silva D, 2023, REGEN THER, V24, P602, DOI 10.1016/j.reth.2023.11.003
   Dubey NK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082200
   Ganguly M, 2015, LASER SURG MED, V47, P711, DOI 10.1002/lsm.22407
   George S, 2018, J PHOTOCH PHOTOBIO B, V188, P60, DOI 10.1016/j.jphotobiol.2018.09.004
   Ghasemi M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312827
   Hamblin MR, 2018, PHOTOCHEM PHOTOBIOL, V94, P199, DOI 10.1111/php.12864
   Hoang DM, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01134 4
   Hoarau Véchot J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010181
   Hong YH, 2024, ANTIOXIDANTS BASEL, V13, DOI 10.3390/antiox13030312
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Hutchings G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113790
   Kaur G, 2010, BIOMATERIALS, V31, P1732, DOI 10.1016/j.biomaterials.2009.11.041
   Komori T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071694
   Lau CS, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25126805
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Liao X, 2018, PHOTOCHEM PHOTOBIOL, V94, P780, DOI 10.1111/php.12912
   Liu XZ, 2017, SPINE, V42, pE1342, DOI 10.1097/BRS.0000000000002266
   Lu TF, 2018, EXP THER MED, V16, P2399, DOI 10.3892/etm.2018.6445
   Marahleh A, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1121727
   Moraes DA, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0359 3
   Nasello G, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00336
   Neve A, 2013, J CELL PHYSIOL, V228, P1149, DOI 10.1002/jcp.24278
   Oliveira NK, 2019, DENT MATER, V35, P1740, DOI 10.1016/j.dental.2019.08.109
   Peng F, 2012, LASER MED SCI, V27, P645, DOI 10.1007/s10103 011 1005 z
   Pereira DR, 2022, BIOMATER ADV, V133, DOI 10.1016/j.msec.2021.112611
   Ruan YR, 2021, LASER MED SCI, V36, P55, DOI 10.1007/s10103 020 03002 5
   Serrage H, 2019, PHOTOCH PHOTOBIO SCI, V18, P1877, DOI 10.1039/c9pp00089e
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tarantino U, 2022, OSTEOPOROSIS INT, V33, P2467, DOI 10.1007/s00198 022 06482 z
   Tsao YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010159
   Tsuji Wakako, 2014, World J Stem Cells, V6, P312, DOI 10.4252/wjsc.v6.i3.312
   Wang JLS, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.584147
   Wang YG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07525 w
   Wang YG, 2016, SCI REP UK, V6, DOI 10.1038/srep33719
   Wiesmann Anne, 2006, Head Face Med, V2, P8, DOI 10.1186/1746 160X 2 8
   Wu XW, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/9477332
   Wu ZB, 2024, MEDCOMM, V5, DOI 10.1002/mco2.657
   Xu JH, 2015, AM J TRANSL RES, V7, P2527
   Zakrzewski W, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1165 5
   Zhang JX, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8810813
   Zhu YM, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0799 z
NR 48
TC 0
Z9 0
U1 3
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2024
VL 25
IS 24
AR 13350
DI 10.3390/ijms252413350
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA Q4W6I
UT WOS:001384705800001
PM 39769115
OA gold
DA 2025 08 17
ER

PT J
AU Asri, SFM
   Ramli, ESM
   Soelaiman, IN
   Noh, MAM
   Rashid, AHA
   Suhaimi, F
AF Asri, Siti Fadziyah Mohamad
   Ramli, Elvy Suhana Mohd
   Soelaiman, Ima Nirwana
   Noh, Muhamad Alfakry Mat
   Rashid, Abdul Hamid Abdul
   Suhaimi, Farihah
TI Piper sarmentosum Effects on 11β Hydroxysteroid Dehydrogenase
   Type 1 Enzyme in Serum and Bone in Rat Model of Glucocorticoid Induced
   Osteoporosis
SO MOLECULES
LA English
DT Article
DE glucocorticoid; osteoporosis; Piper sarmentosum; 11 beta hydroxysteroid
   dehydrogenase
ID OSTEOBLAST DIFFERENTIATION; AQUEOUS EXTRACT; INHIBITION; MECHANISMS;
   EXPRESSION; RECEPTOR; LEAVES; CELLS
AB Glucocorticoid induced osteoporosis is one of the common causes of secondary osteoporosis. Piper sarmentosum (Ps) extract possesses antioxidant and anti inflammatory activities. In this study, we determined the correlation between the effects of Ps leaf water extract with the regulation of 11 beta hydroxysteroid dehydrogenase (HSD) type 1 enzyme activity in serum and bone of glucocorticoid induced osteoporotic rats. Twenty four Sprague Dawley rats were grouped into following: G1: sham operated group administered with intramuscular vehicle olive oil and vehicle normal saline orally; G2: adrenalectomized (adrx) control group given intramuscular dexamethasone (120 mu g/kg/day) and vehicle normal saline orally; G3: adrx group given intramuscular dexamethasone (120 mu g/kg/day) and water extract of Piper sarmentosum (125 mg/kg/day) orally. After two months, the femur and serum were taken for ELISA analysis. Results showed that Ps leaf water extract significantly reduced the femur corticosterone concentration (p < 0.05). This suggests that Ps leaf water extract was able to prevent bone loss due to long term glucocorticoid therapy by acting locally on the bone cells by increasing the dehydrogenase action of 11 beta HSD type 1. Thus, Ps may have the potential to be used as an alternative medicine against osteoporosis and osteoporotic fracture in patients on long term glucocorticoid treatment.
C1 [Asri, Siti Fadziyah Mohamad; Ramli, Elvy Suhana Mohd; Suhaimi, Farihah] Univ Kebangsaan Malaysia, Fac Med, Dept Anat, Med Ctr, Jalan Yaacob Latif, Kuala Lumpur 56000, Malaysia.
   [Asri, Siti Fadziyah Mohamad] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Human Anat, Upm Serdang 43400, Selangor, Malaysia.
   [Soelaiman, Ima Nirwana] Univ Kebangsaan Malaysia, Fac Med, Dept Pharmacol, Med Ctr, Jalan Yaacob Latif, Kuala Lumpur 56000, Malaysia.
   [Noh, Muhamad Alfakry Mat] Univ Malaya, Med Ctr, Fac Med, Dept Anat, Kuala Lumpur 59100, Malaysia.
   [Rashid, Abdul Hamid Abdul] Univ Teknol MARA UiTM, Fac Med, Basic Med Sci Cluster, Anat Unit, Sungai Buloh Campus,Jalan Hosp, Sungai Buloh 47000, Selangor, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Putra Malaysia; Universiti
   Kebangsaan Malaysia; Universiti Malaya
RP Asri, SFM; Suhaimi, F (通讯作者)，Univ Kebangsaan Malaysia, Fac Med, Dept Anat, Med Ctr, Jalan Yaacob Latif, Kuala Lumpur 56000, Malaysia.; Asri, SFM (通讯作者)，Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Human Anat, Upm Serdang 43400, Selangor, Malaysia.
EM fadziyah@yahoo.com.my; elvysuhana@yahoo.com.my;
   imasoel@ppukm.ukm.edu.my; pae2300@yahoo.com; dahar_219@yahoo.com;
   farihah@ppukm.ukm.edu.my
RI MAT NOH, MUHAMAD ALFAKRI/B 9152 2010; Mohamad Asri, Siti
   Fadziyah/HHC 9722 2022; Soelaiman, Ima/C 4289 2017
OI Mohamad Asri, Siti Fadziyah/0000 0001 9033 5872; Mat Noh, Muhamad
   Alfakri/0000 0002 1693 556X
FU National University of Malaysia [UKM DLP 2011 065,
   UKM GGPM TKP 054 2010]
FX The authors are very thankful to the staff of the Laboratory of Anatomy
   and Pharmacology, Faculty of Medicine, National University of Malaysia
   for their technical assistance. This work was supported by the National
   University of Malaysia with grant UKM DLP 2011 065 and
   UKM GGPM TKP 054 2010.
CR Amran AA, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476 511X 9 44
   Ariffin SHZ, 2009, CANCER CELL INT, V9, DOI 10.1186/1475 2867 9 6
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Chapman K, 2013, PHYSIOL REV, V93, P1139, DOI 10.1152/physrev.00020.2012
   Chung S, 2011, BBA MOL BASIS DIS, V1812, P581, DOI 10.1016/j.bbadis.2011.02.003
   Cooper MS, 2000, BONE, V27, P375, DOI 10.1016/S8756 3282(00)00344 6
   Draper N, 2005, J ENDOCRINOL, V186, P251, DOI 10.1677/joe.1.06019
   EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140 6736(88)90742 8
   Eijken M, 2005, MOL ENDOCRINOL, V19, P621, DOI 10.1210/me.2004 0212
   Estai MA, 2011, IRAN J MED SCI, V36, P281
   Estai MA, 2011, J MED PLANTS RES, V5, P7132, DOI [10.5897/JMPRX11.006, 10.5897/JMPRx11.006]
   Estai MA, 2011, CLINICS, V66, P865, DOI 10.1590/S1807 59322011000500025
   Fadziyah MAS, 2016, INT J BASIC APPL SCI, V4, P18
   Herrmann M, 2011, OSTEOPOROSIS RESEARCH: ANIMAL MODELS, P57, DOI 10.1007/978 0 85729 293 3_6
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Homma M, 2001, METABOLISM, V50, P801, DOI 10.1053/meta.2001.24213
   Ima Nirwana S, 2002, Med J Malaysia, V57, P136
   Khalid Hussain Khalid Hussain, 2008, Natural Product Radiance, V7, P402
   Klein Gordon L, 2015, Osteoporos Sarcopenia, V1, P39, DOI 10.1016/j.afos.2015.07.008
   Lucinda LMF, 2010, FITOTERAPIA, V81, P982, DOI 10.1016/j.fitote.2010.06.014
   Mohd Zainudin M., 2013, EVID BASED COMPL ALT, V2013, P1
   Nirwana SI, 2012, BRIT J PHARM RES, V2, P168
   Orcel P, 2005, JOINT BONE SPINE, V72, P461, DOI 10.1016/j.jbspin.2005.09.002
   Peungvicha P, 1998, J ETHNOPHARMACOL, V60, P27, DOI 10.1016/S0378 8741(97)00127 X
   Rahman NNNA, 1999, J ETHNOPHARMACOL, V64, P249, DOI 10.1016/S0378 8741(98)00135 4
   Ramli ESM, 2012, IRAN J MED SCI, V37, P39
   Ramli ESM, 2013, CURR DRUG TARGETS, V14, P1675, DOI 10.2174/13894501113146660228
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Ridtitid W, 1998, J ETHNOPHARMACOL, V61, P135, DOI 10.1016/S0378 8741(98)00025 7
   Stewart PM, 1999, VITAM HORM, V57, P249
   Subramaniam Vimala, 2003, Malays J Nutr, V9, P41
   Suhana MRE, 2011, CLIN TER, V162, P313
   Sumazian Y, 2010, J MED PLANTS RES, V4, P881
   Tagawa N, 2007, BIOL PHARM BULL, V30, P403, DOI 10.1248/bpb.30.403
   Taves MD, 2011, AM J PHYSIOL ENDOC M, V301, pE11, DOI 10.1152/ajpendo.00100.2011
   Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003 0031
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Woitge HW, 2001, ENDOCRINOLOGY, V142, P1341, DOI 10.1210/en.142.3.1341
   Zakaria ZA, 2010, J ETHNOPHARMACOL, V128, P42, DOI 10.1016/j.jep.2009.12.021
   Zardooz H, 2010, PHYSIOL RES, V59, P973, DOI 10.33549/physiolres.931896
   Zhou DA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471 2474 15 239
NR 42
TC 12
Z9 12
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1420 3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2016
VL 21
IS 11
AR 1523
DI 10.3390/molecules21111523
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EE9AO
UT WOS:000389918200105
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Takahata, M
   Shimizu, T
   Yamada, S
   Yamamoto, T
   Hasegawa, T
   Fujita, R
   Kobayashi, H
   Endo, T
   Koike, Y
   Amizuka, N
   Todoh, M
   Okumura, JI
   Kajino, T
   Iwasaki, N
AF Takahata, Masahiko
   Shimizu, Tomohiro
   Yamada, Satoshi
   Yamamoto, Tomomaya
   Hasegawa, Tomoka
   Fujita, Ryo
   Kobayashi, Hideyuki
   Endo, Tsutomu
   Koike, Yoshinao
   Amizuka, Norio
   Todoh, Masahiro
   Okumura, Jun Ichiro
   Kajino, Tomomichi
   Iwasaki, Norimasa
TI Bone biopsy findings in patients receiving long term bisphosphonate
   therapy for glucocorticoid induced osteoporosis
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Rheumatoid arthritis; Glucocorticoid induced osteoporosis;
   Bisphosphonate; Bone quality; Bone fragility
ID FRACTURE; ALENDRONATE; PREVENTION; TISSUE; RISK; TERIPARATIDE;
   MECHANISMS; OSTEOCYTES; MICE
AB Introduction Bisphosphonates (BPs) have been shown to reduce the incidence of vertebral fractures during the first year or two of glucocorticoid (GC) treatments and are therefore recommended as a first line treatment for GC induced osteoporosis (GIO). However, there are theoretical concerns about the long term use of BPs in low turnover osteoporosis caused by chronic GC therapy. Materials and methods We analyzed the trabecular microarchitecture, bone metabolism, and material strength of iliac crest bone biopsy samples from 10 female patients with rheumatoid arthritis who received an average of 6.7 years of BP therapy for GIO (GIOBP group), compared with those of 10 age  and bone mineral density (BMD) matched non rheumatoid arthritis postmenopausal women (reference group). Results Patients in the GIOBP group had a significantly greater fracture severity index, as calculated from the number and the extent of vertebral fractures compared with the reference patients. Micro computed tomography analysis showed that the degree of mineralization and trabecular microarchitecture were significantly lower in the GIOBP group than in the reference patients. Patients in the GIOBP group exhibited lower bone contact stiffness, determined by micro indentation testing, than in the reference group. The contact stiffness of the bone was negatively correlated with the fracture severity index and the daily prednisolone dosage. Immunohistochemistry and serum bone turnover markers showed decreased osteoclastic activity, impaired mineralization, and an increased fraction of empty lacunae in the GIOBP group. Conclusion Our findings indicate that patients receiving long term BP for GIO are still at high risk for fragility fractures because of poor bone quality.
C1 [Takahata, Masahiko; Shimizu, Tomohiro; Fujita, Ryo; Kobayashi, Hideyuki; Endo, Tsutomu; Koike, Yoshinao; Iwasaki, Norimasa] Hokkaido Univ, Fac Med, Dept Orthopaed Surg, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.
   [Takahata, Masahiko; Shimizu, Tomohiro; Fujita, Ryo; Kobayashi, Hideyuki; Endo, Tsutomu; Koike, Yoshinao; Iwasaki, Norimasa] Hokkaido Univ, Grad Sch Med, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.
   [Yamamoto, Tomomaya; Hasegawa, Tomoka] Hokkaido Univ, Dept Dev Biol Hard Tissue, Div Oral Hlth Sci, Grad Sch Dent Med, Sapporo, Hokkaido, Japan.
   [Yamada, Satoshi; Amizuka, Norio; Todoh, Masahiro] Hokkaido Univ, Fac Engn, Div Mech & Aerosp Engn, Sapporo, Hokkaido, Japan.
   [Okumura, Jun Ichiro] Sapporo City Gen Hosp, Dept Orthoped Surg, Sapporo, Hokkaido, Japan.
   [Kajino, Tomomichi] Tonan Hosp, Dept Orthoped Surg, Sapporo, Hokkaido, Japan.
C3 Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido
   University; Sapporo City General Hospital
RP Takahata, M (通讯作者)，Hokkaido Univ, Fac Med, Dept Orthopaed Surg, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.; Takahata, M (通讯作者)，Hokkaido Univ, Grad Sch Med, Kita Ku, Kita 15 Nishi 7, Sapporo, Hokkaido 0608638, Japan.
EM takamasa@med.hokudai.ac.jp
RI Amizuka, Norio/G 1397 2012; Todoh, Masahiro/A 6602 2012; Takahata,
   Masahiko/E 1929 2012; Yamada, Satoshi/F 5951 2014
OI Yamada, Satoshi/0000 0002 6832 7857
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [25462357]; Grants in Aid for Scientific Research [25462357, 21K19585]
   Funding Source: KAKEN
FX This project was supported in part by a Grant in Aid for Scientific
   Research (C) from the Ministry of Education, Culture, Sports, Science,
   and Technology of Japan 25462357 (M. Takahata).
CR Amiche MA, 2016, OSTEOPOROSIS INT, V27, P1709, DOI 10.1007/s00198 015 3455 9
   Boivin G, 2008, BONE, V43, P532, DOI 10.1016/j.bone.2008.05.024
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Buckley L, 2017, ARTHRITIS RHEUMATOL, V69, P1521, DOI [10.1002/art.40137, 10.1002/acr.23279]
   COMPSTON JE, 1994, ANN RHEUM DIS, V53, P163, DOI 10.1136/ard.53.3.163
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Feng JQ, 2006, NAT GENET, V38, P1310, DOI 10.1038/ng1905
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Herrera S, 2017, BONE, V95, P175, DOI 10.1016/j.bone.2016.11.003
   Kanis JA, 2004, J BONE MINER RES, V19, P893, DOI 10.1359/JBMR.040134
   Lane NE, 2006, J BONE MINER RES, V21, P466, DOI 10.1359/JBMR.051103
   Lems WF, 2015, ENDOCRINE, V49, P628, DOI 10.1007/s12020 015 0639 1
   Mellibovsky L, 2015, J BONE MINER RES, V30, P1651, DOI 10.1002/jbmr.2497
   MELLISH RWE, 1987, ANN RHEUM DIS, V46, P830, DOI 10.1136/ard.46.11.830
   Nampei A, 2008, MOD RHEUMATOL, V18, P170, DOI 10.1007/s10165 008 0032 5
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Sambrook PN, 2003, J BONE MINER RES, V18, P919, DOI 10.1359/jbmr.2003.18.5.919
   Sosa DD, 2017, CALCIFIED TISSUE INT, V101, P34, DOI 10.1007/s00223 017 0256 5
   Takahata M, 2012, ARTHRITIS RHEUM US, V64, P3649, DOI 10.1002/art.34639
   Teitelbaum SL, 2011, ARTHRITIS RHEUM US, V63, P325, DOI 10.1002/art.30135
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Wang YK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012691
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Yamamoto T, 2016, ENDOCRINOLOGY, V157, P2604, DOI 10.1210/en.2015 2028
   Yao W, 2008, ARTHRITIS RHEUM, V58, P1674, DOI 10.1002/art.23454
NR 27
TC 8
Z9 8
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2022
VL 40
IS 4
BP 613
EP 622
DI 10.1007/s00774 022 01323 9
EA MAR 2022
PG 10
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 2R3RB
UT WOS:000780352700001
PM 35333984
DA 2025 08 17
ER

PT J
AU Sun, YH
   Wang, FC
   Wang, L
   Jiao, ZD
   Fang, J
   Li, JM
AF Sun, Yinghua
   Wang, Fuchao
   Wang, Li
   Jiao, Zhaode
   Fang, Jun
   Li, Jianmin
TI MicroRNA 433 regulates apoptosis by targeting PDCD4 in human
   osteosarcoma cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE miR 433; programmed cell death 4; apoptosis; osteosarcoma
ID CANCER CELLS; RESISTANCE; MIR 433; EXPRESSION
AB Osteosarcoma is the most common aggressive sarcoma of the bone in children and adolescents. It is characterized by a high level of genetic instability and recurrent DNA deletions and amplifications. microRNAs (miRNAs) play a key role in cancer initiation, progression and metastasis; however, the potential role of miRNAs in osteosarcoma remains largely unknown. In the present study, miR 433 was shown to be overexpressed in osteosarcoma tissues compared with normal human osteoblasts. Transfection of miR 433 mimics into osteosarcoma cell lines significantly decreased apoptosis by targeting programmed cell death 4, a tumor suppressor that is involved in apoptosis. In contrast, inhibition of miR 433 enhanced apoptosis. Furthermore, in vivo miR 433 overexpression inhibited the apoptosis of tumor cells and increased tumor growth. The results of the present study suggested that miR 433 is a potential molecular target for osteosarcoma therapy.
C1 [Sun, Yinghua; Wang, Fuchao; Wang, Li; Jiao, Zhaode; Fang, Jun] Weifang Med Univ, Yidu Cent Hosp, Dept Orthoped, Weifang 262500, Shandong, Peoples R China.
   [Li, Jianmin] Shandong Univ, Qilu Hosp, Dept Orthoped, 107 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
C3 Shandong Second Medical University; Shandong University
RP Li, JM (通讯作者)，Shandong Univ, Qilu Hosp, Dept Orthoped, 107 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
EM jianmin365@126.com
RI Sun, Yinghua/M 9926 2013
CR Aljubran AH, 2009, ANN ONCOL, V20, P1136, DOI 10.1093/annonc/mdn731
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Duong Linh M, 2013, J Registry Manag, V40, P59
   Ferguson WS, 2001, CANCER INVEST, V19, P292, DOI 10.1081/CNV 100102557
   Ghosh T, 2014, CELL REP, V7, P1779, DOI 10.1016/j.celrep.2014.05.029
   Gotanda K, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 369
   Guo LH, 2013, INT J MOL SCI, V14, P14171, DOI 10.3390/ijms140714171
   Kelly AD, 2013, GENOME MED, V5, DOI 10.1186/gm406
   Kumar RMR, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060877
   Lankat Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lin SM, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1075
   Lin X, 2013, LEUKEMIA, V27, P344, DOI 10.1038/leu.2012.224
   Lin Z., 2016, CANC RES CLIN ONCOL, V142, P239
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Luo FT, 2012, J BIOSCIENCES, V37, P965, DOI 10.1007/s12038 012 9257 8
   Mitra R, 2015, INT J CANCER, V137, P1516, DOI 10.1002/ijc.29512
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Treiber T, 2012, THROMB HAEMOSTASIS, V107, P605, DOI 10.1160/TH11 12 0836
   Wang GC, 2016, J BONE ONCOL, V5, P51, DOI 10.1016/j.jbo.2016.02.002
   Wang Q, 2014, TUMOR BIOL, V35, P12743, DOI 10.1007/s13277 014 2600 y
   Weiner Gorzel K, 2015, CANCER MED US, V4, P745, DOI 10.1002/cam4.409
   Zhang YM, 2015, BIOCHEM BIOPH RES CO, V459, P367, DOI 10.1016/j.bbrc.2015.02.101
   Zhao HE, 2013, ONCOL REP, V29, P1027, DOI 10.3892/or.2013.2234
   Zhou CS, 2016, CELL ONCOL, V39, P463, DOI 10.1007/s13402 016 0288 2
NR 28
TC 11
Z9 15
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2017
VL 14
IS 2
BP 2353
EP 2358
DI 10.3892/ol.2017.6441
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FE0IS
UT WOS:000407904600161
PM 28781674
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cuypers, LAB
   de Boer, L
   Wang, R
   Walboomers, XF
   Yang, F
   Zaat, SAJ
   Leeuwenburgh, SCG
AF Cuypers, Lizzy A. B.
   de Boer, Leonie
   Wang, Rong
   Walboomers, X. Frank
   Yang, Fang
   Zaat, Sebastian A. J.
   Leeuwenburgh, Sander C. G.
TI Antibacterial Activity of Zinc Doped Hydroxyapatite and
   Vancomycin Loaded Gelatin Nanoparticles against Intracellular
   Staphylococcus aureus in Human THP 1 Derived Macrophages
SO ACS APPLIED NANO MATERIALS
LA English
DT Article
DE nanoparticles; drug delivery; antibiotic; intracellular pathogens;
   vancomycin; zinc
ID PHARMACODYNAMIC EVALUATION; MODEL; ANTIBIOTICS; GENTAMICIN; OSTEOBLASTS;
   NANOSPHERES; PROTEIN; IONS
AB Treating bone infections with common antibiotics is challenging, since pathogens like Staphylococcus aureus can reside inside macrophages. To target these intracellular bacteria, we have proposed nanoparticles (NPs) as drug carriers. This study aims to investigate the efficacy of hydroxyapatite and gelatin NPs, selected in view of their bone mimicry and potential for targeted delivery, as carriers for the antibacterial agents zinc and vancomycin. Therefore, two distinct NPs are fabricated: zinc doped hydroxyapatite (ZnHA) and vancomycin loaded gelatin (VGel) NPs. The NPs are characterized based on morphology, size, chemical composition, cellular internalization, and intracellular bactericidal efficacy. Specifically, the intracellular bactericidal efficacy is tested using a validated coculture model of human THP 1 derived macrophages and phagocytosed S. aureus bacteria. Scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR) results show that the spherical NPs are synthesized successfully. These NPs are internalized by THP 1 cells and show >75% colocalization with lysosomes without compromising the viability of the THP 1 cells. Both ZnHA and VGel NPs substantially reduce the intracellular survival of S. aureus compared to the direct addition of dissolved zinc and vancomycin. Concluding, our NPs are highly effective drug delivery vehicles to kill intracellular S. aureus, which stress the potential of these NPs for future clinical translation.
C1 [Cuypers, Lizzy A. B.; Wang, Rong; Walboomers, X. Frank; Yang, Fang; Leeuwenburgh, Sander C. G.] Radboud Univ Nijmegen, Res Inst Med Innovat, Med Ctr, Dept Dent Regenerat Biomat, NL 6525 EX Nijmegen, Netherlands.
   [de Boer, Leonie; Zaat, Sebastian A. J.] Univ Amsterdam, Amsterdam Inst Immunol & Infect Dis, Med Ctr, NL 1105 AZ Amsterdam, Netherlands.
C3 Radboud University Nijmegen; University of Amsterdam
RP Leeuwenburgh, SCG (通讯作者)，Radboud Univ Nijmegen, Res Inst Med Innovat, Med Ctr, Dept Dent Regenerat Biomat, NL 6525 EX Nijmegen, Netherlands.
EM sander.leeuwenburgh@radboudumc.nl
RI ; Leeuwenburgh, S.C.G./L 4483 2015; Walboomers, X.Frank/B 3692 2013
OI Wang, Rong/0000 0002 6623 8439; Cuypers, Lizzy/0009 0004 9382 0856
FU Dutch Research Council (NWO VICI) [17835]
FX This work was financially supported by the Dutch Research Council
   (NWO VICI grant 17835).
CR Andrée L, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12193423
   Aramwit P, 2015, MATER EXPRESS, V5, P241, DOI 10.1166/mex.2015.1233
   Barcia Macay M, 2006, ANTIMICROB AGENTS CH, V50, P841, DOI 10.1128/AAC.50.3.841 851.2006
   Bhattacharjee A, 2019, MATERIALS, V12, DOI 10.3390/ma12111814
   Brinch KS, 2010, J ANTIMICROB CHEMOTH, V65, P1720, DOI 10.1093/jac/dkq159
   Chakraborty SP, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957 4484/21/10/105103
   Chen G. D., 2014, NANOPARTICLES MEETCE
   Cobb LH, 2020, J ORTHOP RES, V38, P2091, DOI 10.1002/jor.24689
   Crisan CM, 2021, APPL SCI BASEL, V11, DOI 10.3390/app11031120
   Cuypers LAB, 2023, OPEN CERAM, V16, DOI 10.1016/j.oceram.2023.100488
   Del Pino P, 2014, MATER HORIZ, V1, P301, DOI 10.1039/c3mh00106g
   DREVETS DA, 1994, INFECT IMMUN, V62, P2222, DOI 10.1128/IAI.62.6.2222 2228.1994
   Faya M, 2020, AMINO ACIDS, V52, P1439, DOI 10.1007/s00726 020 02903 7
   Fu Q, 2008, J BIOMATER APPL, V23, P37, DOI 10.1177/0885328207081350
   Goudouri OM, 2014, ACTA BIOMATER, V10, P3795, DOI 10.1016/j.actbio.2014.03.028
   Gudkov SV, 2021, FRONT PHYS LAUSANNE, V9, DOI 10.3389/fphy.2021.641481
   Hamza T, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866 014 0207 5
   Hamza T, 2013, EUR CELLS MATER, V25, P341, DOI 10.22203/eCM.v025a24
   Heras C, 2020, ACTA BIOMATER, V114, P395, DOI 10.1016/j.actbio.2020.07.044
   Hu YY, 2011, CHEM MATER, V23, P2481, DOI 10.1021/cm200355n
   Hussain S, 2018, NAT BIOMED ENG, V2, P95, DOI 10.1038/s41551 017 0187 5
   Ibrahim HM, 2022, CELLULOSE, V29, P5677, DOI 10.1007/s10570 022 04614 6
   Jiang YJ, 2020, ACS CENTRAL SCI, V6, P2267, DOI 10.1021/acscentsci.0c00893
   Jorge LS, 2010, BRAZ J INFECT DIS, V14, P310, DOI 10.1590/S1413 86702010000300020
   Lai HZ, 2015, ACS APPL MATER INTER, V7, P2046, DOI 10.1021/am507919m
   Li LL, 2014, ACS NANO, V8, P4975, DOI 10.1021/nn501040h
   Liu X, 2014, INT J NANOMED, V9, P1261, DOI 10.2147/IJN.S56298
   Madkhali OA, 2023, POLYMERS BASEL, V15, DOI 10.3390/polym15214327
   Maji R, 2019, MOL PHARMACEUT, V16, P4594, DOI 10.1021/acs.molpharmaceut.9b00713
   Marambio Jones C, 2010, J NANOPART RES, V12, P1531, DOI 10.1007/s11051 010 9900 y
   Mardziah CM, 2020, CERAM INT, V46, P13945, DOI 10.1016/j.ceramint.2020.02.192
   Mohamed W, 2014, EUR CELLS MATER, V28, P258, DOI 10.22203/eCM.v028a18
   Munir MT, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 94939 2
   Nguyen HA, 2006, J ANTIMICROB CHEMOTH, V57, P883, DOI 10.1093/jac/dkl079
   Nguyen HA, 2009, ANTIMICROB AGENTS CH, V53, P1434, DOI 10.1128/AAC.01145 08
   Ofudje EA, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01716
   Pedroni MA, 2024, J ORTHOP SCI, V29, P334, DOI 10.1016/j.jos.2022.11.022
   Perez Davila S, 2023, POLYMERS BASEL, V15, DOI 10.3390/polym15214250
   Qiu YH, 2020, INT J BIOL MACROMOL, V156, P640, DOI 10.1016/j.ijbiomac.2020.04.090
   Ribeiro AI, 2022, ACS APPL NANO MATER, V5, P3030, DOI 10.1021/acsanm.1c03891
   Singh R, 2009, EXP MOL PATHOL, V86, P215, DOI 10.1016/j.yexmp.2008.12.004
   Soe YM, 2021, CELL MICROBIOL, V23, DOI 10.1111/cmi.13317
   Song JK, 2015, MACROMOL BIOSCI, V15, P901, DOI 10.1002/mabi.201500005
   Song T, 2021, J MATER CHEM B, V9, P2469, DOI 10.1039/d0tb02648d
   Su K, 2015, BIOTECHNOL LETT, V37, P2139, DOI 10.1007/s10529 015 1907 0
   Tuntun SM, 2023, NEW J CHEM, V47, P2874, DOI 10.1039/d2nj04130h
   Uskokovic V, 2014, MAT SCI ENG C MATER, V37, P210, DOI 10.1016/j.msec.2014.01.008
   Van Bambeke F, 2004, ANTIMICROB AGENTS CH, V48, P2853, DOI 10.1128/AAC.48.8.2853 2860.2004
   van Zyl WF, 2015, APPL ENVIRON MICROB, V81, P5993, DOI 10.1128/AEM.01247 15
   Villa MM, 2015, J BIOMED MATER RES B, V103, P243, DOI 10.1002/jbm.b.33225
   Walter N, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10081064
   Wang C, 2023, BIOMATER SCI UK, V11, P432, DOI 10.1039/d2bm01489k
   Wang HA, 2014, ACTA BIOMATER, V10, P508, DOI 10.1016/j.actbio.2013.08.036
   Weiss KM, 2023, J BIOMED MATER RES B, V111, P295, DOI 10.1002/jbm.b.35151
   Xie SY, 2017, SCI REP UK, V7, DOI 10.1038/srep41104
   Xu J, 2012, J BIOMED MATER RES A, V100A, P738, DOI 10.1002/jbm.a.33270
   Yao CX, 2019, ENZYME MICROB TECH, V127, P50, DOI 10.1016/j.enzmictec.2019.04.011
   Yildirim M, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15010199
   Yin MZ, 2014, J NANOMATER, V2014, DOI 10.1155/2014/731897
   Yu Y, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01919
   Yue H, 2010, EUR J PHARM SCI, V41, P650, DOI 10.1016/j.ejps.2010.09.006
   Zhang XL, 2018, INT J NANOMED, V13, P5377, DOI 10.2147/IJN.S168959
   Zhao XX, 2013, ARCH TOXICOL, V87, P1037, DOI 10.1007/s00204 012 0827 1
NR 63
TC 2
Z9 2
U1 7
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
EI 2574 0970
J9 ACS APPL NANO MATER
JI ACS Appl. Nano Mater.
PD SEP 11
PY 2024
VL 7
IS 18
BP 21964
EP 21974
DI 10.1021/acsanm.4c03941
EA SEP 2024
PG 11
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA H2M4E
UT WOS:001310589400001
PM 39360166
OA hybrid
DA 2025 08 17
ER

PT J
AU Matsuo, T
   Sato, K
   Matsui, T
   Sawada, S
   Muramatsu, Y
   Kawanami, K
   Deie, M
AF Matsuo, Toshihiro
   Sato, Keiji
   Matsui, Takuya
   Sawada, Shigeyuki
   Muramatsu, Yoshitaka
   Kawanami, Katsuhisa
   Deie, Masataka
TI Inhibitory effects of low intensity pulsed ultrasound sonication on the
   proliferation of osteosarcoma cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE low intensity pulsed ultrasound; osteosarcoma; LM8; sonication;
   apoptosis
ID IN VITRO; OSTEOBLASTS; APOPTOSIS; BONE; MECHANISMS; EXPRESSION; CALLUS;
   LIPUS; AKT
AB To date, there is limited data on the biological effects of low intensity pulsed ultrasound (LIPUS) on primary malignant bone tumors. The purpose of the present study was to investigate the antitumor effects of LIPUS on osteosarcoma cells. The effects of LIPUS on cell viability, induction' of apoptosis, mitochondrial membrane potential and intracellular signaling molecules in the LM8 osteosarcoma cell line were investigated. LIPUS inhibited cell viability (P=0.0022) and mitochondrial membrane potential (P=0.0019) in LM8 cells. Flow cytometry analysis and terminal deoxynucleotidyl transferase dUTP nick end labeling staining revealed significantly higher numbers of apoptotic (P<0.0001) and necrotic cells (P=0.0091) compared with cells without treatment. LIPUS treatment significantly increased phosphorylated Akt (P<0.0001) and IKBa (P=0.0001) levels, and reduced phosphorylated mitogen activated protein kinase 7 (P<0.0001) and phosphorylated checkpoint kinase 1 (P=0.0008) levels. These results suggest that LIPUS is a non invasive adjuvant therapy that is able to inhibit cellular proliferation in osteosarcoma cells.
C1 [Matsuo, Toshihiro; Sato, Keiji; Sawada, Shigeyuki; Muramatsu, Yoshitaka; Kawanami, Katsuhisa; Deie, Masataka] Aichi Med Univ, Dept Orthopaed Surg, 1 1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
   [Matsui, Takuya] Aichi Med Univ, Dept Physiol, Nagakute, Aichi 4801195, Japan.
C3 Aichi Medical University; Aichi Medical University
RP Matsuo, T (通讯作者)，Aichi Med Univ, Dept Orthopaed Surg, 1 1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
EM matsuot@aichi med u.ac.jp
CR Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Bandow K, 2007, J CELL PHYSIOL, V211, P392, DOI 10.1002/jcp.20944
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742 4658.2009.07366.x
   Cochran M, 2013, ULTRASOUND MED BIOL, V39, P1102, DOI 10.1016/j.ultrasmedbio.2013.01.013
   Czerniak B, 2016, BONE TUMORS, P200
   Duan L, 2014, CANCER BIOL THER, V15, P1600, DOI 10.4161/15384047.2014.961876
   Durfee RA, 2016, RHEUMATOL THER, V3, P221, DOI 10.1007/s40744 016 0046 y
   El Mowafi H, 2005, INT ORTHOP, V29, P121, DOI 10.1007/s00264 004 0625 3
   ENNEKING WF, 1978, J BONE JOINT SURG AM, V60, P731, DOI 10.2106/00004623 197860060 00002
   Feril LB, 2005, CANCER LETT, V221, P145, DOI 10.1016/j.canlet.2004.08.034
   Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301 620X.82B5.9899
   Ham SJ, 1998, EUR J SURG ONCOL, V24, P584, DOI 10.1016/S0748 7983(98)93896 3
   Harrison A, 2016, ULTRASONICS, V70, P45, DOI 10.1016/j.ultras.2016.03.016
   HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623 199401000 00004
   Kondo T, 2009, J MED ULTRASON, V36, P61, DOI 10.1007/s10396 009 0212 8
   Muramatsu Y, 2017, IN VIVO, V31, P61, DOI 10.21873/invivo.11026
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   ROSEN G, 1979, CANCER AM CANCER SOC, V43, P2163, DOI 10.1002/1097 0142(197906)43:6<2163::AID CNCR2820430602>3.0.CO;2 S
   Rutten S, 2007, J TRAUMA, V62, P902, DOI 10.1097/01.ta.0000238663.33796.fb
   Sawai Y, 2012, ONCOL REP, V28, P481, DOI 10.3892/or.2012.1816
   Shi MF, 2016, ULTRASONICS, V64, P43, DOI 10.1016/j.ultras.2015.07.011
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Suzuki A, 2009, ACTA BIOCH BIOPH SIN, V41, P108, DOI 10.1093/abbs/gmn012
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   Waiwut P, 2011, MOL CELL BIOCHEM, V350, P169, DOI 10.1007/s11010 010 0695 z
   Xin ZC, 2016, TRANSL ANDROL UROL, V5, P255, DOI 10.21037/tau.2016.02.04
NR 27
TC 11
Z9 13
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2017
VL 14
IS 3
BP 3071
EP 3076
DI 10.3892/ol.2017.6472
PN A
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FF0NE
UT WOS:000408597600070
PM 28928844
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Pronai, W
   Rosenkranz, A
   Bock, A
   Klauser Braun, R
   Jäger, C
   Pendl, G
   Hemetsberger, M
   Lhotta, K
AF Pronai, Wolfgang
   Rosenkranz, Alexander R.
   Bock, Andreas
   Klauser Braun, Renate
   Jaeger, Christine
   Pendl, Gunther
   Hemetsberger, Margit
   Lhotta, Karl
TI Management of secondary hyperparathyroidism: practice patterns and
   outcomes of cinacalcet treatment with or without active vitamin D in
   Austria and Switzerland   the observational TRANSIT Study
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE Cinacalcet; Secondary hyperparathyroidism; Cinacalcet; Secondary
   hyperparathyroidism; Treatment pattern; Clinical practice; Observational
   study
AB Secondary hyperparathyroidism is a complex disorder requiring an individualized multicomponent treatment approach. This study was conducted to identify treatment combinations used in clinical practice in Austria and Switzerland and the potential to control this disorder. A total of 333 adult hemodialysis and peritoneal dialysis patients were analyzed. All patients received conventional care prior to initiation of a cinacalcet based regimen. During the study, treatment components, e.g. cinacalcet, active vitamin D analogues and phosphate binders, were adapted to individual patient requirements and treatment dynamics were documented. Overall, the mean intact parathyroid hormone (iPTH) increased from 64.2 pmol/l to 79.6 pmol/l under conventional therapy and decreased after cinacalcet initiation to 44.0 pmol/l after 12 months (mean decrease between baseline and 12 months  45%). Calcium remained within the normal range throughout the study and phosphorus ranged around the upper limit of normal. The Kidney Disease: Improving Global Outcomes (KDIGO) target achievement for iPTH increased from 44.5% of patients at baseline to 65.7% at 12 months, corrected calcium from 58.9% to 51.9% and phosphorus from 18.4% to 24.4%. On average, approximately 30% of patients adapted their regimen from one observation period to the next. The reasons for changing a given regimen were to attain or maintain any of the bone mineral markers within recommended targets and to avoid developments to extreme values. Some regional differences in practice patterns were identified. No new safety signals emerged. In conclusion, cinacalcet appears to be a necessary treatment component to achieve recommended targets. The detailed composition of the treatment mix should be adapted to patient requirements and reassessed on a regular basis.
C1 [Pronai, Wolfgang] Hosp Bros St John God, Dialysis Unit, Dept Internal Med, Johannes von Gott Pl 1, A 7001 Eisenstadt, Austria.
   [Rosenkranz, Alexander R.] Med Univ Graz, Clin Div Nephrol, Dept Internal Med, Graz, Austria.
   [Bock, Andreas] Kantonsspital Aarau, Nephrol Abt, Aarau, Switzerland.
   [Klauser Braun, Renate] Sozialmed Zentrum Ost Donauspital, Vienna, Austria.
   [Jaeger, Christine] Amgen GmbH, Vienna, Austria.
   [Pendl, Gunther] Amgen AG, Zug, Switzerland.
   [Hemetsberger, Margit] Hemetsberger Med Serv, Vienna, Austria.
   [Lhotta, Karl] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria.
C3 Medical University of Graz; Kantonsspital Aarau AG (KSA); Donauspital
RP Pronai, W (通讯作者)，Hosp Bros St John God, Dialysis Unit, Dept Internal Med, Johannes von Gott Pl 1, A 7001 Eisenstadt, Austria.
EM Wolfgang.Pronai@bbeisen.at
OI Hemetsberger, Margit/0000 0003 1877 6838
FU Amgen Austria GmbH, Vienna, Austria; Amgen Switzerland AG, Zug,
   Switzerland; Amgen Austria GmbH, Austria
FX The study was sponsored by Amgen Austria GmbH, Vienna, Austria, and
   Amgen Switzerland AG, Zug, Switzerland. Statistical analysis was
   conducted by QUALIS evaluation GmbH, Zurich, Switzerland, with financial
   support from Amgen Austria GmbH, Vienna, Austria. Hemetsberger medical
   services played a major role in developing the protocol, the statistical
   analysis plan, and the manuscript, as well as in data interpretation,
   with financial support from Amgen Austria GmbH, Austria.
CR Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Gutiérrez OM, 2010, CLIN J AM SOC NEPHRO, V5, P1710, DOI 10.2215/CJN.02640310
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Kramar R., OSTERREICHISCHES DIA
   Vervloet M, 2010, CLIN NEPHROL, V74, P198
   Wetmore JB, 2009, NAT CLIN PRACT NEPHR, V5, P24, DOI 10.1038/ncpneph0977
   Zitt E, 2011, WIEN KLIN WOCHENSCHR, V123, P45, DOI 10.1007/s00508 010 1515 x
NR 7
TC 3
Z9 5
U1 0
U2 3
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4 6, PO BOX 89, A 1201 WIEN, AUSTRIA
SN 0043 5325
EI 1613 7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD MAY
PY 2017
VL 129
IS 9 10
BP 317
EP 328
DI 10.1007/s00508 016 1153 z
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA EU9FJ
UT WOS:000401343300003
PM 28091752
OA Green Published
DA 2025 08 17
ER

PT J
AU Kane, A
   Dinh, H
   Campbell, L
   Cain, AK
   Hibbs, D
   Carter, D
AF Kane, Aidan
   Dinh, Hue
   Campbell, Leona
   Cain, Amy K.
   Hibbs, David
   Carter, Dee
TI Spectrum of activity and mechanisms of azole bisphosphonate synergy in
   pathogenic Candida
SO MICROBIOLOGY SPECTRUM
LA English
DT Article
DE Candida albicans; azole; drug synergy; bisphosphonate; zoledronate;
   fluconazole; Candida glabrata; mevalonate pathway
ID OXIDATIVE STRESS RESPONSE; MULTIDRUG RESISTANCE; IN VITRO; ZOLEDRONIC
   ACID; MURINE MODEL; GLABRATA; MEMBRANE; YEAST; EPIDEMIOLOGY;
   OSTEOPOROSIS
AB Candidiasis places a significant burden on human health and can range from common superficial vulvovaginal and oral infections to invasive diseases with high mortality. The most common Candida species implicated in human disease is Candida albicans, but other species like Candida glabrata are emerging. The use of azole antifungals for treatment is limited by increasing rates of resistance. This study explores repositioning bisphosphonates, which are traditionally used for osteoporosis, as antifungal synergists that can improve and revitalize the use of azoles. Risedronate, alendronate, and zoledronate (ZOL) were tested against isolates from six different species of Candida, and ZOL produced moderate antifungal activity and strong synergy with azoles like fluconazole (FLC), particularly in C. glabrata. FLC:ZOL combinations had increased fungicidal and antibiofilm activity compared to either drug alone, and the combination prevented the development of antifungal resistance. Mechanistic investigations demonstrated that the synergy was mediated by the depletion of squalene, resulting in the inhibition of ergosterol biosynthesis and a compromised membrane structure. In C. glabrata, synergy compromised the function of membrane bound multidrug transporters and caused an accumulation of reactive oxygen species, which may account for its acute sensitivity to FLC:ZOL. The efficacy of FLC:ZOL in vivo was confirmed in a Galleria mellonella infection model, where combinations improved the survival of larvae infected with C. albicans and C. glabrata to a greater extent than monotherapy with FLC or ZOL, and at reduced dosages. These findings demonstrate that bisphosphonates and azoles are a promising new combination therapy for the treatment of topical candidiasis.
C1 [Kane, Aidan; Campbell, Leona; Carter, Dee] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia.
   [Kane, Aidan; Campbell, Leona; Carter, Dee] Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW, Australia.
   [Dinh, Hue; Cain, Amy K.] Macquarie Univ, ARC Ctr Excellence Synthet Biol, Sch Nat Sci, Sydney, NSW, Australia.
   [Hibbs, David] Univ Sydney, Sch Pharm, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; Macquarie University; ARC
   Centre of Excellence in Synthetic Biology; University of Sydney
RP Carter, D (通讯作者)，Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia.; Carter, D (通讯作者)，Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW, Australia.
EM dee.carter@sydney.edu.au
RI ; cain, amy/K 8251 2012; Carter, Dee/C 1331 2010
OI Kane, Aidan/0000 0003 4927 0071; Carter, Dee/0000 0002 4638 0059; Cain,
   Amy/0000 0002 4230 6572; Dinh, Hue/0000 0003 3455 3394
FU USYD | Marie Bashir Institute, University of Sydney (Marie Bashir
   Institute)
FX The authors thank Catriona Halliday (Westmead Hospital, NSW, Australia),
   Kerry Weeks (Royal North Shore Hospital, NSW, Australia), and Tahereh
   Shokohi (Mazandaran University of Medical Science, Sari, Iran) for
   providing the clinical Candida isolates used in this study. We also
   thank Timothy Newsome, Nicolas Gracie, and Liam Howell (University of
   Sydney, NSW, Australia) for their microscopy resources and expertise.
CR Abe F, 2009, BIOCHEMISTRY US, V48, P8494, DOI 10.1021/bi900578y
   Arthington Skaggs BA, 2000, ANTIMICROB AGENTS CH, V44, P2081, DOI 10.1128/AAC.44.8.2081 2085.2000
   BALFOUR JA, 1992, DRUGS, V43, P259, DOI 10.2165/00003495 199243020 00010
   Barantsevich N, 2022, ANTIBIOTICS BASEL, V11, DOI 10.3390/antibiotics11060718
   Benedict K, 2019, CLIN INFECT DIS, V68, P1791, DOI 10.1093/cid/ciy776
   Buchacz K, 2016, J INFECT DIS, V214, P862, DOI 10.1093/infdis/jiw085
   Carbonare LD, 2010, DRUG HEALTHC PATIENT, V2, P121, DOI 10.2147/DHPS.S6285
   Cavalheiro M, 2018, FRONT MED LAUSANNE, V5, DOI 10.3389/fmed.2018.00028
   Chakravarti A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170649
   CLSI, BROTH DIL ANT SUSC Y
   Cuéllar Cruz M, 2009, MEM I OSWALDO CRUZ, V104, P649, DOI 10.1590/S0074 02762009000400020
   Cuéllar Cruz M, 2008, EUKARYOT CELL, V7, P814, DOI 10.1128/EC.00011 08
   Cuervo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077317
   Daneshnia F, 2023, LANCET MICROBE, V4, pe470, DOI 10.1016/S2666 5247(23)00067 8
   Denning DW, 2015, SCIENCE, V347, P1414, DOI 10.1126/science.aaa6097
   Devaux F, 2019, MICROBIOL SGM, V165, P1041, DOI 10.1099/mic.0.000807
   Deveau A, 2010, EUKARYOT CELL, V9, P569, DOI 10.1128/EC.00321 09
   Douglas LJ, 2003, TRENDS MICROBIOL, V11, P30, DOI 10.1016/S0966 842X(02)00002 1
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fidel PL Jr, 1999, CLIN MICROBIOL REV, V12, P80, DOI 10.1128/CMR.12.1.80
   Forrest GN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471 2334 10 152
   Frei A, 2022, JACS AU, V2, P2277, DOI 10.1021/jacsau.2c00308
   Garcia Cuesta Carla, 2014, J Clin Exp Dent, V6, pe576, DOI 10.4317/jced.51798
   Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P286, DOI 10.1016/j.ijantimicag.2003.07.019
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Goldman M, 2000, ANTIMICROB AGENTS CH, V44, P1585, DOI 10.1128/AAC.44.6.1585 1587.2000
   Hachem R, 2008, CANCER, V112, P2493, DOI 10.1002/cncr.23466
   Hendrych T, 2009, BBA BIOMEMBRANES, V1788, P717, DOI 10.1016/j.bbamem.2008.12.001
   Jamiu AT, 2020, MED MYCOL, V59, P14, DOI 10.1093/mmy/myaa031
   Kane A, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15040482
   Kane A, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.01753 20
   Krishnamurthy SS, 1999, FEMS MICROBIOL LETT, V173, P475, DOI 10.1111/j.1574 6968.1999.tb13541.x
   Kullberg BJ, 2015, NEW ENGL J MED, V373, P1445, DOI 10.1056/NEJMra1315399
   Lewis RE, 2001, PHARMACOTHERAPY, V21, p149S, DOI 10.1592/phco.21.12.149S.34505
   Li QQ, 2018, MOL MED REP, V17, P6585, DOI 10.3892/mmr.2018.8716
   Lima WG, 2019, BIOMED PHARMACOTHER, V111, P270, DOI 10.1016/j.biopha.2018.12.076
   Lu H, 2023, MBIO, V14, DOI 10.1128/mbio.02639 22
   Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801
   Mukhopadhyay K, 2004, ANTIMICROB AGENTS CH, V48, P1778, DOI 10.1128/AAC.48.5.1778 1787.2004
   Mukhopadhyay K, 2002, ANTIMICROB AGENTS CH, V46, P3695, DOI 10.1128/AAC.46.12.3695 3705.2002
   Nakayama H, 2000, ANTIMICROB AGENTS CH, V44, P2411, DOI 10.1128/AAC.44.9.2411 2418.2000
   Nishikawa JL, 2016, NATURE, V530, P485, DOI 10.1038/nature16963
   Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301
   OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676 2682.1988
   Orta Zavalza E, 2013, MOL MICROBIOL, V88, P1135, DOI 10.1111/mmi.12247
   Orwoll ES, 2010, J BONE MINER RES, V25, P2239, DOI 10.1002/jbmr.119
   Pappas PC, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.26
   Pappas Peter G, 2016, Clin Infect Dis, V62, pe1, DOI 10.1093/cid/civ933
   PARKINSON T, 1995, ANTIMICROB AGENTS CH, V39, P1696, DOI 10.1128/AAC.39.8.1696
   Perfect JR, 2017, NAT REV DRUG DISCOV, V16, P603, DOI 10.1038/nrd.2017.46
   Pierce CG, 2008, NAT PROTOC, V3, P1494, DOI 10.1038/nprot.2008.141
   POLAK A, 1993, MYCOSES, V36, P43, DOI 10.1111/j.1439 0507.1993.tb00686.x
   PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166 3542(90)90001 N
   Rodrigues CF, 2014, EUR J CLIN MICROBIOL, V33, P673, DOI 10.1007/s10096 013 2009 3
   Rodrigues ML, 2018, MBIO, V9, DOI 10.1128/mBio.01755 18
   Shahina Z, 2022, MICROBIOL SPECTR, V10, DOI 10.1128/spectrum.03183 22
   Silva S, 2012, FEMS MICROBIOL REV, V36, P288, DOI 10.1111/j.1574 6976.2011.00278.x
   Spanakis EK, 2010, MAYO CLIN PROC, V85, P1073, DOI 10.4065/mcp.2010.0447
   Spanova M, 2012, BBA MOL CELL BIOL L, V1821, P647, DOI 10.1016/j.bbalip.2012.01.015
   Sun LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172228
   Szczepaniak J, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00176
   Tavakkoli A, 2020, PHARMACOL THERAPEUT, V208, DOI 10.1016/j.pharmthera.2020.107483
   Thompson K, 2010, ADV EXP MED BIOL, V658, P11, DOI 10.1007/978 1 4419 1050 9_2
   Vandeputte P, 2005, ANTIMICROB AGENTS CH, V49, P4608, DOI 10.1128/AAC.49.11.4608 4615.2005
   Vazquez J A., 2011, Essentials of Clinical Mycology, P167
   Wangsanut T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810645
   Whaley SG, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02173
   White PL, 2004, J CLIN MICROBIOL, V42, P2101, DOI 10.1128/JCM.42.5.2101 2107.2004
   Yadav AK, 2011, MICROBIOL SGM, V157, P484, DOI 10.1099/mic.0.045054 0
   Yang G, 2015, ANTIMICROB AGENTS CH, V59, P7530, DOI 10.1128/AAC.01873 15
   Zameer S, 2020, BRAIN RES BULL, V161, P197, DOI 10.1016/j.brainresbull.2020.04.010
   Zhang YH, 2013, ACS MED CHEM LETT, V4, P423, DOI 10.1021/ml4000436
   Zoric N, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906 017 1773 5
NR 73
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
SN 2165 0497
J9 MICROBIOL SPECTR
JI Microbiol. Spectr.
PD JUN 4
PY 2024
VL 12
IS 6
DI 10.1128/spectrum.00121 24
EA MAY 2024
PG 25
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA TA2S4
UT WOS:001216723600001
PM 38695556
OA gold
DA 2025 08 17
ER

PT J
AU Wang, YJ
   He, G
   Tang, H
   Shi, YX
   Zhu, M
   Kang, X
   Bian, XT
   Lyu, JT
   Zhou, M
   Yang, MY
   Mu, MD
   Chen, W
   Zhou, BH
   Yuan, CS
   Zhang, JQ
   Tang, KL
AF Wang, Yunjiao
   He, Gang
   Tang, Hong
   Shi, Youxing
   Zhu, Min
   Kang, Xia
   Bian, Xuting
   Lyu, Jingtong
   Zhou, Mei
   Yang, Mingyu
   Mu, Miduo
   Chen, Wan
   Zhou, Binghua
   Yuan, Chengsong
   Zhang, Jiqiang
   Tang, Kanglai
TI Aspirin promotes tenogenic differentiation of tendon stem cells and
   facilitates tendinopathy healing through regulating the GDF7/Smad1/5
   signaling pathway
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE NSAIDs; stem cell differentiation; tendon injury healing
ID OSTEOGENIC DIFFERENTIATION; IDENTIFICATION; MODELS
AB Tendinopathy is a common musculoskeletal system disorder in sports medicine, but regeneration ability of injury tendon is limited. Tendon stem cells (TSCs) have shown the definitive treatment evidence for tendinopathy and tendon injuries due to their tenogenesis capacity. Aspirin, as the representative of nonsteroidal anti inflammatory drugs for its anti inflammatory and analgestic actions, has been commonly used in treating tendinopathy in clinical, but the effect of aspirin on tenogenesis of TSCs is unclear. We hypothesized that aspirin could promote injury tendon healing through inducing TSCs tenogenesis. The aim of the present study is to make clear the effect of aspirin on TSC tenogenesis and tendon healing in tendinopathy, and thus provide new treatment evidence and strategy of aspirin for clinical practice. First, TSCs were treated with aspirin under tenogenic medium for 3, 7, and 14 days. Sirius Red staining was performed to observe the TSC differentiation. Furthermore, RNA sequencing was utilized to screen out different genes between the induction group and aspirin treatment group. Then, we identified the filtrated molecules and compared their effect on tenogenesis and related signaling pathway. At last, we constructed the tendinopathy model and compared biomechanical changes after aspirin intake. From the results, we found that aspirin promoted tenogenesis of TSCs. RNA sequencing showed that growth differentiation factor 6 (GDF6), GDF7, and GDF11 were upregulated in induction medium with the aspirin group compared with the induction medium group. GDF7 increased tenogenesis and activated Smad1/5 signaling. In addition, aspirin increased the expression of TNC, TNMD, and Scx and biomechanical properties of the injured tendon. In conclusion, aspirin promoted TSC tenogenesis and tendinopathy healing through GDF7/Smad1/5 signaling, and this provided new treatment evidence of aspirin for tendinopathy and tendon injuries.
C1 [Wang, Yunjiao; He, Gang; Tang, Hong; Shi, Youxing; Zhu, Min; Kang, Xia; Bian, Xuting; Lyu, Jingtong; Zhou, Mei; Yang, Mingyu; Mu, Miduo; Chen, Wan; Zhou, Binghua; Yuan, Chengsong; Tang, Kanglai] Third Mil Med Univ, Southwest Hosp, State Key Lab Trauma Burn & Combined Injury, Dept Orthopead,Sports Med Ctr, Gaotanyan St 30, Chongqing 400038, Peoples R China.
   [Zhang, Jiqiang] Third Mil Med Univ, Dept Neurol, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University
RP Tang, KL (通讯作者)，Third Mil Med Univ, Southwest Hosp, State Key Lab Trauma Burn & Combined Injury, Dept Orthopead,Sports Med Ctr, Gaotanyan St 30, Chongqing 400038, Peoples R China.
EM tangkanglai@hotmail.com
RI Yang, Mingyu/IWM 2177 2023; wang, yunjiao/HLP 8098 2023; tang,
   kang/HNQ 2884 2023; Zhang, Jiqiang/B 4488 2008
OI Zhang, Jiqiang/0000 0002 1905 8750; yunjiao, wang/0000 0003 1108 7079
FU National Key Research and Development of China [2016YFC1100500];
   Chongqing Science and Technology Commission [cstc2015shmszx0471];
   National Natural Science Foundation of China [81230040, 81572133]; China
   National Funds for Distinguished Young Scientists [81601943]
FX National Key Research and Development of China, Grant/Award Number:
   2016YFC1100500; Chongqing Science and Technology Commission, Grant/Award
   Number: cstc2015shmszx0471; National Natural Science Foundation of
   China, Grant/Award Numbers: 81230040, 81572133; China National Funds for
   Distinguished Young Scientists, Grant/Award Number: 81601943
CR Antman EM, 2017, CIRCULATION, V135, P2062, DOI 10.1161/CIRCULATIONAHA.117.027288
   Aslan H, 2008, J CLIN INVEST, V118, P439, DOI 10.1172/JCI33944
   Bez M, 2018, MOL THER, V26, P1746, DOI 10.1016/j.ymthe.2018.04.020
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Chen SW, 2018, MED SCI MONITOR, V24, P1567, DOI 10.12659/MSM.908802
   Chen YJ, 2004, J ORTHOP RES, V22, P854, DOI 10.1016/j.orthres.2003.10.013
   Dirks RC, 2011, J MUSCULOSKEL NEURON, V11, P141
   Docheva D, 2015, ADV DRUG DELIVER REV, V84, P222, DOI 10.1016/j.addr.2014.11.015
   Etminan M, 2003, BMJ BRIT MED J, V327, P128, DOI 10.1136/bmj.327.7407.128
   Gaspar D, 2015, ADV DRUG DELIVER REV, V84, P240, DOI 10.1016/j.addr.2014.11.023
   Goncalves AI, 2018, NANOMED NANOTECHNOL, V14, P1149, DOI 10.1016/j.nano.2018.02.008
   Gray RT, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4142 y
   Hao W, 2018, EUR J PHARMACOL, V827, P198, DOI 10.1016/j.ejphar.2018.03.016
   Hart DA, 1999, CLIN ORTHOP RELAT R, P237
   Hou YH, 2017, ONCOTARGET, V8, P77424, DOI 10.18632/oncotarget.20495
   Lin JX, 2018, ACTA BIOMATER, V70, P1, DOI 10.1016/j.actbio.2018.01.012
   Liu JP, 2015, CELL PHYSIOL BIOCHEM, V35, P1831, DOI 10.1159/000373994
   Liu JP, 2013, BIOCHEM BIOPH RES CO, V435, P514, DOI 10.1016/j.bbrc.2012.11.083
   Mikic B, 2006, J ORTHOP RES, V24, P831, DOI 10.1002/jor.20092
   Mikic B, 2009, ANAT REC, V292, P396, DOI 10.1002/ar.20852
   Ni M, 2012, J ORTHOP RES, V30, P613, DOI 10.1002/jor.21559
   Nourissat G, 2015, NAT REV RHEUMATOL, V11, P223, DOI 10.1038/nrrheum.2015.26
   Rui YF, 2010, TISSUE ENG PT A, V16, P1549, DOI [10.1089/ten.tea.2009.0529, 10.1089/ten.TEA.2009.0529]
   Schweitzer R, 2001, DEVELOPMENT, V128, P3855
   Shen H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077613
   Stoll C, 2011, BIOMATERIALS, V32, P4806, DOI 10.1016/j.biomaterials.2011.03.026
   Sun J, 2018, BIOMATERIALS, V162, P22, DOI 10.1016/j.biomaterials.2018.02.008
   Wang YY, 2019, J CELL MOL MED, V23, P426, DOI 10.1111/jcmm.13946
   Wang YJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12650
   Warden SJ, 2007, BRIT J SPORT MED, V41, P232, DOI 10.1136/bjsm.2006.032342
   Yuan MT, 2018, INT J MOL MED, V42, P1967, DOI 10.3892/ijmm.2018.3801
   Zhang JY, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 10
NR 32
TC 32
Z9 34
U1 0
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2020
VL 235
IS 5
BP 4778
EP 4789
DI 10.1002/jcp.29355
EA OCT 2019
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA KK6JH
UT WOS:000491789200001
PM 31637734
DA 2025 08 17
ER

PT J
AU Tabler, JM
   Rice, CP
   Liu, KJ
   Wallingford, JB
AF Tabler, Jacqueline M.
   Rice, Christopher P.
   Liu, Karen J.
   Wallingford, John B.
TI A novel ciliopathic skull defect arising from excess neural crest
SO DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Cilia; Ciliopathy; Fuz; Fgf8; Neural crest; Craniofacial; Skull;
   Calvaria; Coronal suture; Greig cephalopolysyndactyly; Morphogenesis;
   Craniosynostosis; Wnt1; Mesp1; Mouse
ID PLANAR CELL POLARITY; DURA MATER; OSTEOBLAST DIFFERENTIATION; MESODERM
   BOUNDARY; MOUSE MODEL; HEDGEHOG; CRANIOSYNOSTOSIS; GENE; CILIOGENESIS;
   MECHANISMS
AB The skull is essential for protecting the brain from damage, and birth defects involving disorganization of skull bones are common. However, the developmental trajectories and molecular etiologies by which many craniofacial phenotypes arise remain poorly understood. Here, we report a novel skull defect in ciliopathic Fuz mutant mice in which only a single bone pair encases the forebrain, instead of the usual paired frontal and parietal bones. Through genetic lineage analysis, we show that this defect stems from a massive expansion of the neural crest derived frontal bone. This expansion occurs at the expense of the mesodermally derived parietal bones, which are either severely reduced or absent. A similar, though less severe, phenotype was observed in Gli3 mutant mice, consistent with a role for Gli3 in cilia mediated signaling. Excess crest has also been shown to drive defective palate morphogenesis in ciliopathic mice, and that defect is ameliorated by reduction of Fgf8 gene dosage. Strikingly, skull defects in Fuz mutant mice are also rescued by loss of one allele of fgf8, suggesting a potential route to therapy. In sum, this work is significant for revealing a novel skull defect with a previously un described developmental etiology and for suggesting a common developmental origin for skull and palate defects in ciliopathies. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Tabler, Jacqueline M.; Rice, Christopher P.; Wallingford, John B.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [Liu, Karen J.] Kings Coll London, Dept Craniofacial Dev & Stem Cell Biol, London WC2R 2LS, England.
C3 University of Texas System; University of Texas Austin; University of
   London; King's College London
RP Wallingford, JB (通讯作者)，Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.; Liu, KJ (通讯作者)，Kings Coll London, Dept Craniofacial Dev & Stem Cell Biol, London WC2R 2LS, England.
EM karen.liu@kcl.ac.uk; Wallingford@austin.utexas.edu
RI tabler, jacqueline/KYP 2896 2024; Liu, Karen/F 2870 2010; Rice,
   Christopher/JSL 3869 2023
OI Liu, Karen/0000 0002 2483 2165; 
FU NIDCR [F32DE023272]; BBSRC [BB/I021922/1]; Wellcome Trust Value in
   People Award; NIGMS; NHLBI; BBSRC [BB/I021922/1] Funding Source: UKRI;
   Biotechnology and Biological Sciences Research Council [BB/I021922/1]
   Funding Source: researchfish
FX We thank Basil Yannakoudakis and Hadeel Adel Al lami for generating mice
   in the Liu Lab, and Mitch Butler for critical reading of the manuscript.
   J. M. T. is supported by a National Research Service Award from the
   NIDCR F32DE023272. This work was supported by funding from the BBSRC
   (BB/I021922/1) to K. J. L., a Wellcome Trust Value in People Award to K.
   J. L. and J. M. T., and by grants from the NIGMS and the NHLBI to J. B.
   W. J. B. W. is an Early Career Scientist of the HHMI.
CR Chen P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087311
   Creuzet S, 2005, J ANAT, V207, P447, DOI 10.1111/j.1469 7580.2005.00485.x
   Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960 9822(07)00562 3
   Deckelbaum RA, 2012, DEVELOPMENT, V139, P1346, DOI 10.1242/dev.076729
   Fish JL, 2014, DEVELOPMENT, V141, P674, DOI 10.1242/dev.100107
   Gagan Jeffrey R., 2007, Birth Defects Research, V81, P297, DOI 10.1002/bdrc.20104
   Gray RS, 2009, NAT CELL BIOL, V11, P1225, DOI 10.1038/ncb1966
   Heydeck W, 2009, DEV DYNAM, V238, P3035, DOI 10.1002/dvdy.22130
   Holmes G, 2009, DEV BIOL, V328, P273, DOI 10.1016/j.ydbio.2009.01.026
   Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102
   Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169
   HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393 241
   Ilagan R, 2006, DEVELOPMENT, V133, P2435, DOI 10.1242/dev.02408
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   Johnson D, 2011, EUR J HUM GENET, V19, P369, DOI 10.1038/ejhg.2010.235
   KWEE ML, 1983, CLIN GENET, V24, P200
   Li S, 2007, AM J PHYSIOL CELL PH, V293, pC1834, DOI 10.1152/ajpcell.00135.2007
   Li SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014033
   Merrill AE, 2006, HUM MOL GENET, V15, P1319, DOI 10.1093/hmg/ddl052
   Moore K, 1999, J ULTRAS MED, V18, P783, DOI 10.7863/jum.1999.18.11.783
   Mossey P, 2003, BRIT DENT J, V195, P613, DOI 10.1038/sj.bdj.4810738
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   NAGY A, 2003, MANIPULATING MOUSE E
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Panigrahi Inusha, 2011, Indian J Hum Genet, V17, P48, DOI 10.4103/0971 6866.86171
   Park TJ, 2006, NAT GENET, V38, P303, DOI 10.1038/ng1753
   Quarto N, 2010, J BONE MINER RES, V25, P1680, DOI 10.1359/jbmr.091116
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Saga Y, 1999, DEVELOPMENT, V126, P3437
   Spector JA, 2002, PLAST RECONSTR SURG, V109, P645, DOI 10.1097/00006534 200202000 00035
   Spector JA, 2002, PLAST RECONSTR SURG, V109, P631, DOI 10.1097/00006534 200202000 00033
   Strecker S, 2013, GENESIS, V51, P246, DOI 10.1002/dvg.22360
   Tabler JM, 2013, DEV CELL, V25, P623, DOI 10.1016/j.devcel.2013.05.021
   Tokumaru AM, 1996, AM J NEURORADIOL, V17, P619
   Twigg SRF, 2015, HUM MOL GENET, V24, pR50, DOI 10.1093/hmg/ddv228
   Yannakoudakis BZ, 2013, RARE DIS, V1, DOI 10.4161/rdis.27109
   Yoshida T, 2005, J ANAT, V206, P437, DOI 10.1111/j.1469 7580.2005.00411.x
   Yoshida T, 2008, MECH DEVELOP, V125, P797, DOI 10.1016/j.mod.2008.06.007
NR 38
TC 29
Z9 32
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0012 1606
EI 1095 564X
J9 DEV BIOL
JI Dev. Biol.
PD SEP 1
PY 2016
VL 417
IS 1
BP 4
EP 10
DI 10.1016/j.ydbio.2016.07.001
PG 7
WC Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology
GA DU7VX
UT WOS:000382423800002
PM 27395007
OA Green Accepted, Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Silva, ML
   Tasso, L
   Azambuja, AA
   Figueiredo, MA
   Salum, FG
   da Silva, VD
   Cherubini, K
AF Silva, Miguel Luciano
   Tasso, Leandro
   Azambuja, Alan Arrieira
   Figueiredo, Maria Antonia
   Salum, Fernanda Goncalves
   da Silva, Vinicius Duval
   Cherubini, Karen
TI Effect of hyperbaric oxygen therapy on tooth extraction sites in rats
   subjected to bisphosphonate therapy histomorphometric and
   immunohistochemical analysis
SO CLINICAL ORAL INVESTIGATIONS
LA English
DT Article
DE Osteonecrosis; Bisphosphonates; Hyperbaric oxygen therapy; Bone
ID GROWTH FACTOR EXPRESSION; LEVEL LASER THERAPY; ZOLEDRONIC ACID;
   AVASCULAR OSTEONECROSIS; RECEPTOR ACTIVATOR; SURGICAL TREATMENT;
   MULTIPLE MYELOMA; INSPIRED OXYGEN; GENE EXPRESSION; CANCER PATIENTS
AB This study aimed to investigate the effect of hyperbaric oxygen therapy (HBOT) on tooth extraction sites in rats treated with bisphosphonate.
   Rats were treated with zoledronic acid, subjected to tooth extractions and allocated into groups: (1) 7 days of HBOT, (2) 14 days of HBOT, (3) 7 day control, and (4) 14 day control. The site of tooth extractions was analyzed by histomorphometry and immunohistochemistry.
   On macroscopic analysis, HBOT did not significantly affect bone exposure volume either at 7 or 14 days. On hematoxylin and eosin (H&E) analysis, the 14 day HBOT group showed less non vital bone compared to both controls and 7 day HBOT group. HBOT significantly lowered expression of vascular endothelial growth factor (VEGF), receptor activator NF kB ligand (RANKL), bone morphogenetic protein 2 (BMP 2), and osteoprotegerin (OPG) at 7 days, compared to control, whereas at 14 days, there was no significant difference for these variables.
   HBOT can reduce the amounts of non vital bone microscopically detected in tooth extraction sites of rats subjected to bisphosphonate therapy. The effect seems to occur in a dose dependent mode. Further studies are required to clarify the mechanisms accounting for this effect.
   Treatment of bisphosphonate related osteonecrosis of the jaw (BRONJ) has been a challenging task, where the effectiveness of HBOT is controversial. This study reports important effects of HBOT on the maxillae of rats subjected to bisphosphonate treatment, making an important contribution to the knowledge about the applicability of HBOT in BRONJ.
C1 [Silva, Miguel Luciano; Figueiredo, Maria Antonia; Salum, Fernanda Goncalves; Cherubini, Karen] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Coll Dent, Postgrad Program, Porto Alegre, RS, Brazil.
   [Tasso, Leandro] UCS, Pharmacol Lab, Postgrad Program Biotechnol, Caxias Do Sul, RS, Brazil.
   [Azambuja, Alan Arrieira] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Hosp Sao Lucas, Dept Oncol, Porto Alegre, RS, Brazil.
   [da Silva, Vinicius Duval] Pontifical Catholic Univ Rio Grande do Sul PUCRS, Hosp Sao Lucas, Dept Pathol, Porto Alegre, RS, Brazil.
   [Cherubini, Karen] Hosp Sao Lucas PUCRS, Serv Estomatol, Av Ipiranga 6690 231, BR 90610000 Porto Alegre, RS, Brazil.
C3 Pontificia Universidade Catolica Do Rio Grande Do Sul; Universidade de
   Caxias do Sul; Pontificia Universidade Catolica Do Rio Grande Do Sul;
   Pontificia Universidade Catolica Do Rio Grande Do Sul; Pontificia
   Universidade Catolica Do Rio Grande Do Sul
RP Cherubini, K (通讯作者)，Pontifical Catholic Univ Rio Grande do Sul PUCRS, Coll Dent, Postgrad Program, Porto Alegre, RS, Brazil.; Cherubini, K (通讯作者)，Hosp Sao Lucas PUCRS, Serv Estomatol, Av Ipiranga 6690 231, BR 90610000 Porto Alegre, RS, Brazil.
EM karen.cherubini@pucrs.br
RI da Silva, Vinicius/AAE 9220 2021; Cherubini, Karen/K 2572 2015
OI Cherubini, Karen/0000 0003 0913 477X
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Abrahamsen B, 2010, CURR OPIN RHEUMATOL, V22, P404, DOI 10.1097/BOR.0b013e32833ad677
   Allen MR, 2009, J ORAL MAXIL SURG, V67, P61, DOI 10.1016/j.joms.2009.01.007
   Altay MA, 2014, PHOTOMED LASER SURG, V32, P468, DOI 10.1089/pho.2014.3742
   Amenabar Jose M, 2006, J Oral Sci, V48, P139, DOI 10.2334/josnusd.48.139
   Antonini F, 2010, J CRANIOFAC SURG, V21, P1962, DOI 10.1097/SCS.0b013e3181f4ee4e
   Asano T, 2007, CIRC J, V71, P405, DOI 10.1253/circj.71.405
   Atalay B, 2011, LASER MED SCI, V26, P815, DOI 10.1007/s10103 011 0974 2
   Berti Couto SA, 2014, HEAD NECK J SCI SPEC, V36, P84, DOI 10.1002/hed.23260
   Biasotto M, 2006, ACTA ODONTOL SCAND, V64, P348, DOI 10.1080/00016350600844360
   Bocanegra Pérez MS, 2012, MED ORAL PATOL ORAL, V17, pE948, DOI 10.4317/medoral.17946
   Boff RC, 2014, ARCH ORAL BIOL, V59, P790, DOI 10.1016/j.archoralbio.2014.05.002
   Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006
   Cerimele F, 2003, AM J PATHOL, V163, P1321, DOI 10.1016/S0002 9440(10)63491 8
   Cetiner S, 2009, J BONE MINER METAB, V27, P435, DOI 10.1007/s00774 009 0047 9
   Chiu CT, 2010, J ORAL MAXIL SURG, V68, P1055, DOI 10.1016/j.joms.2009.12.030
   Colella G, 2009, J ORAL MAXIL SURG, V67, P2698, DOI 10.1016/j.joms.2009.07.097
   Cremers SCLM, 2005, CLIN PHARMACOKINET, V44, P551, DOI 10.2165/00003088 200544060 00001
   Curi MM, 2007, J ORAL MAXIL SURG, V65, P349, DOI 10.1016/j.joms.2005.12.051
   Danesh Sani SA, 2012, J CRANIOFAC SURG, V23, pE483, DOI 10.1097/SCS.0b013e3182668777
   Dias MD, 2008, UNDERSEA HYPERBAR M, V35, P53
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Ehler WJ, 1995, SPUMS J, V25, P86
   Fedele S, 2015, BRIT J ORAL MAX SURG, V53, P13, DOI 10.1016/j.bjoms.2014.09.001
   Fedele S, 2010, AM J MED, V123, P1060, DOI 10.1016/j.amjmed.2010.04.033
   Feldmeier J, 2003, UNDERSEA HYPERBAR M, V30, P1
   Feldmeier JJ, 2002, UNDERSEA HYPERBAR M, V29, P4
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fok TCO, 2008, ORAL SURG ORAL MED O, V105, P417, DOI 10.1016/j.tripleo.2007.07.015
   Freiberger JJ, 2007, J ORAL MAXIL SURG, V65, P1321, DOI 10.1016/j.joms.2007.03.019
   Freiberger JJ, 2009, J ORAL MAXIL SURG, V67, P96, DOI 10.1016/j.joms.2008.12.003
   Gill AL, 2004, QJM INT J MED, V97, P385, DOI 10.1093/qjmed/hch074
   Gordillo GM, 2008, CLIN EXP PHARMACOL P, V35, P957, DOI 10.1111/j.1440 1681.2008.04934.x
   GRATTON JP, 1995, BRIT J PHARMACOL, V114, P720, DOI 10.1111/j.1476 5381.1995.tb17198.x
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Gutta R, 2007, ORAL SURG ORAL MED O, V104, P186, DOI 10.1016/j.tripleo.2006.12.004
   Heras Rincon Ignacio, 2007, Med Oral Patol Oral Cir Bucal, V12, pE267
   Hewitt C, 2007, J ORAL PATHOL MED, V36, P319, DOI 10.1111/j.1600 0714.2007.00540.x
   Hinson AM, 2015, J ORAL MAXIL SURG, V73, P53, DOI 10.1016/j.joms.2014.07.012
   Iwase T, 1996, UNDERSEA HYPERBAR M, V23, P5
   Jiang S, 2008, J CELL BIOCHEM, V104, P580, DOI 10.1002/jcb.21647
   Kalns JE, 2003, WOUND REPAIR REGEN, V11, P139, DOI 10.1046/j.1524 475X.2003.11210.x
   Kang Thomas S, 2004, Arch Facial Plast Surg, V6, P31, DOI 10.1001/archfaci.6.1.31
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   KNIGHTON DR, 1990, ARCH SURG CHICAGO, V125, P97
   KNIGHTON DR, 1984, ARCH SURG CHICAGO, V119, P199
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Koch FP, 2012, CLIN ORAL INVEST, V16, P79, DOI 10.1007/s00784 010 0477 8
   Lam DK, 2007, J CAN DENT ASSOC, V73, P417
   Lee Cameron Y S, 2007, J Oral Implantol, V33, P371, DOI 10.1563/1548 1336(2007)33[371:UOPPIT]2.0.CO;2
   Lee JY, 2015, LASER MED SCI, V30, P635, DOI 10.1007/s10103 013 1382 6
   Lionco JD, 2006, THESIS
   LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Maahs MP, 2011, HEAD NECK J SCI SPEC, V33, P199, DOI 10.1002/hed.21422
   Magopoulos C, 2007, AM J OTOLARYNG, V28, P158, DOI 10.1016/j.amjoto.2006.08.004
   Martins MAT, 2012, ORAL ONCOL, V48, P79, DOI 10.1016/j.oraloncology.2011.08.010
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002 9610(05)81019 0
   Migliorati CA, 2005, J AM DENT ASSOC, V136, P1658, DOI 10.14219/jada.archive.2005.0108
   Milovanova TN, 2009, J APPL PHYSIOL, V106, P711, DOI 10.1152/japplphysiol.91054.2008
   Montebugnoli L, 2007, ORAL SURG ORAL MED O, V104, P473, DOI 10.1016/j.tripleo.2007.01.008
   Nastro E, 2007, ACTA HAEMATOL BASEL, V117, P181, DOI 10.1159/000097876
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Rugani P, 2015, CLIN ORAL INVEST, V19, P1329, DOI 10.1007/s00784 014 1384 1
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Rupel K, 2014, ORAL ONCOL, V50, P1049, DOI 10.1016/j.oraloncology.2014.08.016
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Sakurai A, 2003, INFECT IMMUN, V71, P6019, DOI 10.1128/IAI.71.10.6019 6026.2003
   Sheikh AY, 2000, ARCH SURG CHICAGO, V135, P1293, DOI 10.1001/archsurg.135.11.1293
   Shimura K, 2006, INT J HEMATOL, V84, P343, DOI 10.1532/IJH97.06110
   Shirota T, 2009, CLIN ORAL IMPLAN RES, V20, P1402, DOI 10.1111/j.1600 0501.2009.01801.x
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
   Thom SR, 2009, J APPL PHYSIOL, V106, P988, DOI 10.1152/japplphysiol.91004.2008
   Vairaktaris E, 2009, J ORAL MAXIL SURG, V67, P2009, DOI 10.1016/j.joms.2009.04.032
   Vasconcelos ACU, 2012, J ORAL PATHOL MED, V41, P702, DOI 10.1111/j.1600 0714.2012.01140.x
   Vescovi P, 2014, INT J DENT, V2014, DOI 10.1155/2014/107690
   Vescovi P, 2013, MED ORAL PATOL ORAL, V18, pE680, DOI 10.4317/medoral.18812
   Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510
   Wehrhan F, 2010, J TRANSL MED, V8, DOI 10.1186/1479 5876 8 96
   Williams DW, 2014, AM J PATHOL, V184, P3084, DOI 10.1016/j.ajpath.2014.07.010
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Wreford Brown CE, 2003, UNDERSEA HYPERBAR M, V30, P175
   Yamada J, 2009, J SURG RES, V151, P115, DOI 10.1016/j.jss.2008.01.031
   Zhang QX, 2008, J INVEST DERMATOL, V128, P2102, DOI 10.1038/jid.2008.53
NR 86
TC 14
Z9 15
U1 0
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D 69121 HEIDELBERG, GERMANY
SN 1432 6981
EI 1436 3771
J9 CLIN ORAL INVEST
JI Clin. Oral Investig.
PD JAN
PY 2017
VL 21
IS 1
BP 199
EP 210
DI 10.1007/s00784 016 1778 3
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EG9OL
UT WOS:000391388300023
PM 26955837
DA 2025 08 17
ER

PT J
AU Xie, J
   Li, Q
   Ding, X
   Gao, YY
AF Xie, Jing
   Li, Quan
   Ding, Xi
   Gao, Yunyun
TI GSK1059615 kills head and neck squamous cell carcinoma cells possibly
   via activating mitochondrial programmed necrosis pathway
SO ONCOTARGET
LA English
DT Article
DE HNSCC; PI3K AKT mTOR; GSK1059615; programmed necrosis
ID PERMEABILITY TRANSITION PORE; MOLECULAR TARGETED THERAPIES;
   COLORECTAL CANCER CELLS; NON APOPTOTIC DEATH; CYCLOPHILIN D; IN VITRO;
   AKT INHIBITOR; GROWTH; VIVO; OSTEOBLASTS
AB This study tested the anti head and neck squamous cell carcinoma (HNSCC) cell activity by GSK1059615, a novel PI3K and mTOR dual inhibitor. GSK1059615 inhibited survival and proliferation of established (SCC 9, SQ20B and A253 lines) and primary human HNSCC cells. GSK1059615 blocked PI3K AKT mTOR activation in HNSCC cells. Intriguingly, GSK1059615 treatment in HNSCC cells failed to provoke apoptosis, but induced programmed necrosis. The latter was tested by mitochondria depolarization, ANT 1 cyclophilin D mitochondrial association and lactate dehydrogenase (LDH) release. Reversely, mPTP blockers (sanglifehrin A, cyclosporin A and bongkrekic acid) or cyclophilin D shRNA dramatically alleviated GSK1059615 induced SCC 9 cell death. Further studies demonstrated that GSK1059615 i.p. injection suppressed SCC 9 tumor growth in nude mice, which was compromised with co administration with cyclosporin A. Thus, targeting PI3K AKT mTOR pathway by GSK1059615 possibly provokes programmed necrosis pathway to kill HNSCC cells.
C1 [Xie, Jing; Ding, Xi; Gao, Yunyun] Wenzhou Med Univ, Affiliated Hosp 1, Dept Stomatol, Wenzhou, Peoples R China.
   [Li, Quan] Soochow Univ, Affiliated Hosp 2, Ctr Stomatol, Suzhou, Peoples R China.
C3 Wenzhou Medical University; Soochow University   China
RP Xie, J (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Dept Stomatol, Wenzhou, Peoples R China.
EM xiejingwenzhou9@163.com
RI gao, yunyun/HSG 6108 2023
FU Wenzhou Science and Technology Bureau [Y20130260]
FX This work was generously supported by grants from the Wenzhou Science
   and Technology Bureau (Y20130260). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amornphimoltham P, 2005, CANCER RES, V65, P9953, DOI 10.1158/0008 5472.CAN 05 0921
   Baines CP, 2009, J MOL CELL CARDIOL, V46, P850, DOI 10.1016/j.yjmcc.2009.02.007
   Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200
   Bozec A, 2009, EXPERT OPIN EMERG DR, V14, P299, DOI 10.1517/14728210902997947
   Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118
   Carnero A, 2009, EXPERT OPIN INV DRUG, V18, P1265, DOI 10.1517/13543780903066798
   Chen B, 2013, BIOCHEM BIOPH RES CO, V437, P526, DOI 10.1016/j.bbrc.2013.06.103
   Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094
   Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200
   Dong YY, 2016, TUMOR BIOL, V37, P15053, DOI 10.1007/s13277 016 5403 5
   Freudlsperger C, 2011, EXPERT OPIN THER TAR, V15, P63, DOI 10.1517/14728222.2011.541440
   Fu ML, 2016, BIOCHEM BIOPH RES CO, V477, P527, DOI 10.1016/j.bbrc.2016.04.147
   Goerner M, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758 3284 2 8
   Guo F, 2016, BIOCHEM BIOPH RES CO, V474, P277, DOI 10.1016/j.bbrc.2016.04.077
   Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300 9084(02)01375 5
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535 7163.MCT 09 1012
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Javadov S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00076
   Ji F, 2015, BIOCHEM BIOPH RES CO, V458, P568, DOI 10.1016/j.bbrc.2015.02.007
   Ju TF, 2016, BIOCHEM BIOPH RES CO, V470, P728, DOI 10.1016/j.bbrc.2016.01.053
   Kai S, 2014, BIOCHEM BIOPH RES CO, V452, P768, DOI 10.1016/j.bbrc.2014.08.147
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li K.R., 2013, PLOS ONE, V8
   Li Y, 2016, BIOCHEM BIOPH RES CO, V477, P607, DOI 10.1016/j.bbrc.2016.06.100
   Liu Y, 2015, CANCER CHEMOTH PHARM, V76, P641, DOI 10.1007/s00280 015 2822 8
   Lu JH, 2014, MOL CELL BIOCHEM, V389, P17, DOI 10.1007/s11010 013 1922 1
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078 0432.CCR 11 2824
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365 2184.2012.00845.x
   Peng Y, 2015, BIOCHEM BIOPH RES CO, V465, P137, DOI 10.1016/j.bbrc.2015.07.147
   Qin LS, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046 015 0174 1
   Qiu Y, 2014, BIOCHEM BIOPH RES CO, V448, P15, DOI 10.1016/j.bbrc.2014.04.024
   Sano D, 2011, HEAD NECK J SCI SPEC, V33, P349, DOI 10.1002/hed.21455
   Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102
   Tang TS, 2005, P NATL ACAD SCI USA, V102, P2602, DOI 10.1073/pnas.0409402102
   Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495 006 0525 7
   VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012
   Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014
   Yang YL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055384, 10.1371/journal.pone.0054736, 10.1371/journal.pone.0067755]
   Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263
   Yu T, 2015, BIOCHEM BIOPH RES CO, V464, P286, DOI 10.1016/j.bbrc.2015.06.144
   Zhang LY, 2014, BIOCHEM BIOPH RES CO, V450, P697, DOI 10.1016/j.bbrc.2014.06.039
   Zhang YM, 2015, J INVEST DERMATOL, V135, P181, DOI 10.1038/jid.2014.326
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589
   Zhou CX, 2016, TUMOR BIOL, V37, P3135, DOI 10.1007/s13277 015 4134 3
NR 45
TC 39
Z9 41
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 1
PY 2017
VL 8
IS 31
BP 50814
EP 50823
DI 10.18632/oncotarget.15135
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA FC3CZ
UT WOS:000406717200047
PM 28881606
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kolomansky, A
   Kaye, I
   Ben Califa, N
   Gorodov, A
   Awida, Z
   Sadovnic, O
   Ibrahim, M
   Liron, T
   Hiram Bab, S
   Oster, HS
   Sarid, N
   Perry, C
   Gabet, Y
   Mittelman, M
   Neumann, D
AF Kolomansky, Albert
   Kaye, Irit
   Ben Califa, Nathalie
   Gorodov, Anton
   Awida, Zamzam
   Sadovnic, Ofer
   Ibrahim, Maria
   Liron, Tamar
   Hiram Bab, Sahar
   Oster, Howard S.
   Sarid, Nadav
   Perry, Chava
   Gabet, Yankel
   Mittelman, Moshe
   Neumann, Drorit
TI Anti CD20 Mediated B Cell Depletion Is Associated With Bone Preservation
   in Lymphoma Patients and Bone Mass Increase in Mice
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE rituximab; follicular lymphoma; anti CD20 antibodies; RANKL (receptor
   activator for nuclear factor k B ligand); B cell depletion; bone
   density; CD115
ID RECEPTOR ACTIVATOR; OSTEOCLAST PRECURSORS; ESTROGEN DEFICIENCY; MINERAL
   DENSITY; RANKL; DIFFERENTIATION; LIGAND; INTERLEUKIN 7; OSTEOPOROSIS;
   EXPRESSION
AB Immunotherapy with anti CD20 specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet been described. Here, we used cross sectional X ray imaging (CT/PET CT) to serially assess bone density in patients with follicular lymphoma receiving rituximab maintenance therapy. Remarkably, this treatment prevented the decline in bone mass observed in the control group of patients who did not receive active maintenance therapy. In accordance with these data, anti CD20 mediated B cell depletion in normal C57BL/6J female mice led to a significant increase in bone mass, as reflected by a 7.7% increase in bone mineral density (whole femur), and a similar to 5% increase in cortical as well as trabecular tissue mineral density. Administration of anti CD20 antibodies resulted in a significant decrease in osteoclastogenic signals, including RANKL, which correlated with a reduction in osteoclastogenic potential of bone marrow cells derived from B cell depleted animals. Taken together, our data suggest that in addition to its anti tumor activity, anti CD20 treatment has a favorable effect on bone mass. Our murine studies indicate that B cell depletion has a direct effect on bone remodeling.
C1 [Kolomansky, Albert; Ben Califa, Nathalie; Gorodov, Anton; Awida, Zamzam; Ibrahim, Maria; Neumann, Drorit] Tel Aviv Univ, Dept Cell & Dev Biol, Tel Aviv, Israel.
   [Kolomansky, Albert; Kaye, Irit; Oster, Howard S.; Mittelman, Moshe] Tel Aviv Sourasky Med Ctr, Dept Med A, Tel Aviv, Israel.
   [Kolomansky, Albert; Kaye, Irit; Ben Califa, Nathalie; Gorodov, Anton; Awida, Zamzam; Sadovnic, Ofer; Ibrahim, Maria; Liron, Tamar; Hiram Bab, Sahar; Oster, Howard S.; Sarid, Nadav; Perry, Chava; Gabet, Yankel; Mittelman, Moshe; Neumann, Drorit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Gorodov, Anton] Open Univ Israel, Raanana, Israel.
   [Sadovnic, Ofer] Tel Aviv Sourasky Med Ctr, Dept Radiol, Tel Aviv, Israel.
   [Liron, Tamar; Hiram Bab, Sahar; Gabet, Yankel] Tel Aviv Univ, Dept Anat & Anthropol, Tel Aviv, Israel.
   [Sarid, Nadav; Perry, Chava] Tel Aviv Sourasky Med Ctr, Inst Hematol, Tel Aviv, Israel.
C3 Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty
   of Medicine; Open University Israel; Tel Aviv University; Sackler
   Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv
   University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv
   Sourasky Medical Center
RP Neumann, D (通讯作者)，Tel Aviv Univ, Dept Cell & Dev Biol, Tel Aviv, Israel.; Neumann, D (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
EM histo6@tauex.tau.ac.il
RI Gabet, Yankel/I 6244 2019; Oster, Henrik/D 2335 2013
OI Gabet, Yankel/0000 0002 7494 0631; Neumann, Drorit/0000 0002 4805 7511;
   Oster, Henrik/0000 0002 1414 7068
FU Sackler Faculty of Medicine, Tel Aviv University; Israel Science
   Foundation (ISF) [1822/12, 343/17]; Cancer Biology Research Center, Tel
   Aviv University
FX This work was supported by the Schauder Memorial Endowment Fund, Sackler
   Faculty of Medicine, Tel Aviv University, by the Israel Science
   Foundation (ISF) Grant No. 1822/12 to YG, Grant No. 343/17 to DN and by
   a grant from the Dotan Hemato oncology Fund, the Cancer Biology Research
   Center, Tel Aviv University to DN, MM, and YG.
CR Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Avivi I, 2019, AGING CELL, V18, DOI 10.1111/acel.12959
   BENAYAHU D, 1993, BIOCHEM BIOPH RES CO, V194, P391, DOI 10.1006/bbrc.1993.1832
   Blin Wakkach C, 2004, J BONE MINER RES, V19, P1137, DOI 10.1359/JBMR.040318
   Choi Y, 2003, EXP MOL MED, V35, P385, DOI 10.1038/emm.2003.51
   Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521 4141(200107)31:7<2179::AID IMMU2179>3.0.CO;2 X
   Deshet Unger N, 2020, THERANOSTICS, V10, P8744, DOI 10.7150/thno.45845
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dubrovsky AM, 2018, CALCIFIED TISSUE INT, V102, P607, DOI 10.1007/s00223 018 0401 9
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Freedman A, 2012, AM J HEMATOL, V87, P988, DOI 10.1002/ajh.23313
   Fujiwara Y, 2016, J BIOL CHEM, V291, P24838, DOI 10.1074/jbc.M116.742452
   Gabet Y, 2010, BLOOD, V116, P3964, DOI 10.1182/blood 2010 01 263830
   Hein G, 2011, RHEUMATOL INT, V31, P269, DOI 10.1007/s00296 010 1560 9
   HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167 5699(89)90175 8
   Hiram Bab S, 2015, FASEB J, V29, P1890, DOI 10.1096/fj.14 259085
   Horowitz MC, 2010, BONE, V47, P472, DOI 10.1016/j.bone.2010.06.011
   Hu FL, 2017, J AUTOIMMUN, V76, P53, DOI 10.1016/j.jaut.2016.09.002
   Keren Z, 2011, BLOOD, V117, P3104, DOI 10.1182/blood 2010 09 307983
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625
   Manolagas SC, 2013, NAT REV ENDOCRINOL, V9, P699, DOI 10.1038/nrendo.2013.179
   Martin CE, 2017, IMMUNITY, V47, P171, DOI 10.1016/j.immuni.2017.07.005
   MASUZAWA T, 1994, J CLIN INVEST, V94, P1090, DOI 10.1172/JCI117424
   Meednu N, 2016, ARTHRITIS RHEUMATOL, V68, P805, DOI 10.1002/art.39489
   Pinto CM, 2013, LUPUS, V22, P1128, DOI 10.1177/0961203313502861
   Montecino Rodriguez E, 2001, NAT IMMUNOL, V2, P83, DOI 10.1038/83210
   Noh T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005438
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Pierpont TM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00163
   Ruegsegger P, 1996, CALCIFIED TISSUE INT, V58, P24, DOI 10.1007/s002239900006
   Sato T, 2001, J BONE MINER RES, V16, P2215, DOI 10.1359/jbmr.2001.16.12.2215
   Schwaiger BJ, 2017, BONE, V101, P62, DOI 10.1016/j.bone.2017.04.008
   Scott David L, 2010, Lancet, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Shahaf G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00077
   Svendsen P, 2017, LEUKEMIA LYMPHOMA, V58, P1105, DOI 10.1080/10428194.2016.1233543
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Toraldo G, 2003, P NATL ACAD SCI USA, V100, P125, DOI 10.1073/pnas.0136772100
   Toubi E, 2007, ANN RHEUM DIS, V66, P818, DOI 10.1136/ard.2006.062505
   Weber NK, 2014, AM J GASTROENTEROL, V109, P401, DOI 10.1038/ajg.2013.478
   Wheater G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201527
   Xu S, 2016, J BONE MINER RES, V31, P1320, DOI 10.1002/jbmr.2800
   Yao ZQ, 2017, J BIOL CHEM, V292, P10169, DOI 10.1074/jbc.M116.771816
   Yun TJ, 2001, J IMMUNOL, V166, P1482, DOI 10.4049/jimmunol.166.3.1482
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 46
TC 6
Z9 6
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 19
PY 2020
VL 11
AR 561294
DI 10.3389/fimmu.2020.561294
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA OI4NC
UT WOS:000583256400001
PM 33193330
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU El Ghannam, A
   Jahed, K
   Govindaswami, M
AF El Ghannam, Ahmed
   Jahed, Kiarash
   Govindaswami, Meera
TI Resorbable bioactive ceramic for treatment of bone infection
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE drug delivery; controlled release; silica calcium phosphate
   nanocomposite; osteomyelitis; vancomycin; in vitro
ID OSTEOBLAST GENE EXPRESSION; SI RICH NANOCOMPOSITE; DRUG DELIVERY SYSTEM;
   EXPERIMENTAL OSTEOMYELITIS; MORPHOGENETIC PROTEINS; CEMENT FORMULATIONS;
   METHYL METHACRYLATE; ANTIBIOTIC IMPLANT; GRAFT COPOLYMERS; WAR INJURIES
AB Polymethylmethacrylate (PMMA) beads have been widely used in the treatment of bone infection over the last three decades. Although PMMA does offer a mechanism to quickly and effectively administer a localized dose of antibiotic to the site of infection, its efficacy is limited by its nonresorbability and nonbioactivity. Resorbable bioactive silica calcium phosphate nanocomposite (SCPC75) was investigated as a novel controlled release carrier of vancomycin for the treatment of osteomyelitis. SCPC75 particles adsorbed significantly higher amount of vancomycin compared with PMMA. Moreover, SCPC75 provided a sustained release kinetics of therapeutic dose of vancomycin up to 35 days. The novel resorbable ceramic was able to release 95.5% of the adsorbed drug in an average dose of 12 mu g/mL/day over 480 h (35 days). In conjunction with the sustained drug release, a controlled dissolution rate that led to 40% mass loss of SCPC75 was observed. On the other hand, PMMA provided a sustained release of a therapeutic dose of vancomycin for 14 days after which minimal concentration of the drug was detected. Moreover, PMMA retained 32% of the drug adsorbed onto its surface. The SCPC vancomycin implant can serve a dual function: provide a sustained therapeutic dose of antibiotic to eradicate infection and stimulate bone cell differentiation and new bone formation. (C) 2010 Wiley Periodicals, Inc. J Biomed Mater Res 94A: 308 316, 2010
C1 [El Ghannam, Ahmed] Univ N Carolina, Dept Mech Engn & Engn Sci, Charlotte, NC 28223 USA.
   [Jahed, Kiarash] Univ Louisville, Sch Med, Dept Internal Med, Louisville, KY 40202 USA.
   [Govindaswami, Meera] Univ Kentucky, Ctr Oral Hlth Res, Lexington, KY 40536 USA.
C3 University of North Carolina; University of North Carolina Charlotte;
   University of Louisville; University of Kentucky
RP El Ghannam, A (通讯作者)，Univ N Carolina, Dept Mech Engn & Engn Sci, Charlotte, NC 28223 USA.
EM arelgha@uncc.edu
CR ANIKET, 2008, P ASME 2008 SUMM BIO
   Bingen E, 2006, MED MALADIES INFECT, V36, P439, DOI 10.1016/j.medmal.2006.07.016
   Busic Z, 2006, MIL MED, V171, P55
   CALHOUN JH, 1989, AM J SURG, V157, P443, DOI 10.1016/0002 9610(89)90597 7
   CALHOUN JH, 1997, CLIN ORTHOP RELAT R, V341, P206
   Chen AM, 1999, CLIN ORTHOP RELAT R, P239, DOI 10.1097/00003086 199909000 00031
   CIERNY G, 1984, ORTHOPEDICS, V7, P1557, DOI 10.3928/0147 7447 19841001 07
   CIERNY III G., 1985, CONT ORTHOP, V10, P17, DOI DOI 10.1097/01.BLO.0000088564.81746.62
   DAHNERS LE, 1987, CLIN ORTHOP RELAT R, V219, P278
   Deb S, 1999, J BIOMATER APPL, V14, P16, DOI 10.1177/088532829901400102
   El Ghannam A, 2006, J BIOMED MATER RES A, V76A, P386, DOI 10.1002/jbm.a.30517
   El Ghannam A, 2005, J BIOMED MATER RES B, V73B, P277, DOI 10.1002/jbm.b.30209
   El Ghannam A, 2004, J BIOMED MATER RES A, V71A, P377, DOI 10.1002/jbm.a.30128
   El Ghannam A, 2007, J ORAL MAXIL SURG, V65, P1495, DOI 10.1016/j.joms.2006.10.031
   El Ghannam AR, 2004, J BIOMED MATER RES A, V69A, P490, DOI 10.1002/jbm.a.30022
   ELGHANNAM A, J BIOMED A IN PRESS
   ELSON RA, 1977, J BONE JOINT SURG BR, V59, P200, DOI 10.1302/0301 620X.59B2.873980
   Gitelis Steven, 2002, J Orthop Surg (Hong Kong), V10, P53
   Gupta G, 2007, J BIOMED MATER RES B, V81B, P387, DOI 10.1002/jbm.b.30675
   Gupta G, 2007, J BIOMED MATER RES A, V80A, P486, DOI 10.1002/jbm.a.31005
   HAS B, 1995, INJURY, V26, P245, DOI 10.1016/0020 1383(95)90010 U
   Has B, 1993, Lijec Vjesn, V115, P148
   Humphrey JS, 1998, CLIN ORTHOP RELAT R, P218
   Janosi Kresimir, 1995, Croatian Medical Journal, V36, P104
   Jiranek WA, 2006, J BONE JOINT SURG AM, V88A, P2487, DOI 10.2106/JBJS.E.01126
   Kanellakopoulou K, 2000, DRUGS, V59, P1223, DOI 10.2165/00003495 200059060 00003
   Kilian O, 2002, CHIRURG, V73, P65, DOI 10.1007/s104 002 8031 1
   Kirby BJ, 2004, ELECTROPHORESIS, V25, P203, DOI 10.1002/elps.200305755
   Kirker Head CA, 2000, ADV DRUG DELIVER REV, V43, P65, DOI 10.1016/S0169 409X(00)00078 8
   Kuehn KD, 2005, ORTHOP CLIN N AM, V36, P17, DOI 10.1016/j.ocl.2004.06.010
   LEVIN PD, 1975, J BONE JOINT SURG BR, V57, P234, DOI 10.1302/0301 620X.57B2.234
   Lewis G, 2008, J BIOMED MATER RES B, V84B, P301, DOI 10.1002/jbm.b.30873
   Li RH, 2001, TRENDS BIOTECHNOL, V19, P255, DOI 10.1016/S0167 7799(01)01665 1
   LIU YK, 1987, J BIOMED MATER RES, V21, P247, DOI 10.1002/jbm.820210208
   Lovric Z, 2002, NATL MED J INDIA, V15, P111
   LOVRIC Z, 1994, J TRAUMA, V36, P248, DOI 10.1097/00005373 199402000 00019
   LOVRIC Z, 1994, CROAT MED J, V35, P253
   LYE KW, TISSUE EN B IN PRESS
   MADER JT, 2002, CLIN ORTHOP RELAT R, V403, P58, DOI DOI 10.1097/00003086 200210000 00011
   McKee MD, 2002, J ORTHOP TRAUMA, V16, P622, DOI 10.1097/00005131 200210000 00002
   Mehta S, 1996, J ORTHOPAED RES, V14, P749, DOI 10.1002/jor.1100140511
   Minari C, 2001, P I MECH ENG H, V215, P251, DOI 10.1243/0954411011533643
   Nguyen S, 2006, J BIOMED MATER RES B, V77B, P5, DOI 10.1002/jbm.b.30430
   Nguyen S, 2004, MACROMOL BIOSCI, V4, P262, DOI 10.1002/mabi.200300088
   OSTERMANN PAW, 1995, J BONE JOINT SURG BR, V77B, P93, DOI 10.1302/0301 620X.77B1.7822405
   OTSUKA M, 1995, J BIOMED MATER RES, V29, P33, DOI 10.1002/jbm.820290106
   PICKNELL B, 1977, J BONE JOINT SURG BR, V59, P302, DOI 10.1302/0301 620X.59B3.408356
   Pillai O, 2001, CURR OPIN CHEM BIOL, V5, P447, DOI 10.1016/S1367 5931(00)00227 1
   Price JS, 1996, J BIOMED MATER RES, V30, P281, DOI 10.1002/(SICI)1097 4636(199603)30:3<281::AID JBM2>3.0.CO;2 M
   Radin S, 1997, BIOMATERIALS, V18, P777, DOI 10.1016/S0142 9612(96)00190 1
   Rogers Foy JM, 1999, J INVEST SURG, V12, P263, DOI 10.1080/089419399272386
   Ruszczak Z, 2003, ADV DRUG DELIVER REV, V55, P1679, DOI 10.1016/j.addr.2003.08.007
   Schuh A, 2003, ZBL CHIR, V128, P674
   SHINSAKO K, 2008, J BIOMED MAT ENG, V18, P377
   Solberg BD, 1999, J ORTHOP TRAUMA, V13, P102, DOI 10.1097/00005131 199902000 00006
   Vázquez B, 2005, BIOMATERIALS, V26, P4309, DOI 10.1016/j.biomaterials.2004.10.042
   WAHING H, 1978, J BONE JOINT SURG BR, V60, P270
   Walenkamp GHIM, 1998, ACTA ORTHOP SCAND, V69, P518, DOI 10.3109/17453679808997790
   Webb JCJ, 2007, J BONE JOINT SURG BR, V89B, P851, DOI 10.1302/0301 620X.89B7.19148
   Wininger DA, 1996, ANTIMICROB AGENTS CH, V40, P2675, DOI 10.1128/AAC.40.12.2675
NR 60
TC 27
Z9 31
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JUL
PY 2010
VL 94A
IS 1
BP 308
EP 316
DI 10.1002/jbm.a.32705
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 606DC
UT WOS:000278400800033
PM 20186734
DA 2025 08 17
ER

PT J
AU Le Blanc, S
   Simann, M
   Jakob, F
   Schütze, N
   Schilling, T
AF Le Blanc, Solange
   Simann, Meike
   Jakob, Franz
   Schuetze, Norbert
   Schilling, Tatjana
TI Fibroblast growth factors 1 and 2 inhibit adipogenesis of human bone
   marrow stromal cells in 3D collagen gels
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Adipogenesis; Bone marrow stromal cells; Fibroblast growth factor; 3D;
   Matrix metalloproteinases; Tissue inhibitor of metalloproteinases
ID MESENCHYMAL STEM CELLS; IN VITRO; ADIPOCYTE DIFFERENTIATION; FACTOR
   RECEPTOR; ADIPOSE TISSUE; TYROSINE KINASE; KEY REGULATOR; MATRIX;
   HEPARIN; FGF
AB Multipotent human bone marrow stromal cells (hBMSCs) are the common progenitors of osteoblasts and adipocytes. A shift in hBMSC differentiation in favor of adipogenesis may contribute to the bone loss and marrow fat accumulation observed in aging and osteoporosis. Hence, the identification of factors modulating marrow adipogenesis is of great therapeutic interest. Fibroblast growth factors 1 (FGF1) and 2 (FGF2) play important roles in several cellular processes including differentiation. Their role in adipogenesis is, however, still unclear given the contradictory reports found in the literature. In this work, we investigated the effect of FGF signaling on hBMSC adipogenesis in a 3D collagen gel system to mimic the natural microenvironment. We successfully established adipogenic differentiation of hBMSC embedded in type I collagen gels. We found that exogenous FGF1 and FGF2 exerted an inhibitory effect on lipid droplet accumulation and gene expression of adipogenic markers, which was abolished by pharmacological blocking of FGF receptor (FGFR) signaling. FGF treatment also affected the expression of the matrix metalloproteinase 13 (MMP13) and the tissue inhibitor of metalloproteinases 1 (TIMP1), altering the MMP/TIMP balance, which modulates collagen processing and turnover. FGF1  and FGF2 mediated inhibition of differentiation was, however, not restricted to adipogenesis since FGF1 and FGF2 treatment also resulted in the inhibition of the osteogenic differentiation in collagen gels. We conclude that FGFR signaling inhibits the in vitro adipogenic commitment of hBMSCs, downregulating core differentiation markers and altering ECM composition. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Le Blanc, Solange; Simann, Meike; Jakob, Franz; Schuetze, Norbert; Schilling, Tatjana] Univ Wurzburg, Dept Orthoped, Orthoped Ctr Musculoskeletal Res, D 97074 Wurzburg, Germany.
C3 University of Wurzburg
RP Le Blanc, S (通讯作者)，Univ Wurzburg, Dept Orthoped, Orthoped Ctr Musculoskeletal Res, Brettreichstr 11, D 97074 Wurzburg, Germany.
EM s leblanc.klh@uni wuerzburg.de; m simann.klh@uni wuerzburg.de;
   f jakob.klh@uni wuerzburg.de; n schuetze.klh@uni wuerzburg.de;
   t schilling.klh@uni wuerzburg.de
RI Jakob, Franz/D 8526 2015
FU CONICYT BECAS CHILE [72100742]; German Research Foundation (DFG) [Schi
   1071/3 1]
FX The authors gratefully thank Prof. Heike Wailes and Dr. Jenny Reboredo
   for providing the collagen solution, Viola Zehe for her technical
   assistance and Dr. Julia Dotterweich for proofreading. SL was funded by
   CONICYT BECAS CHILE 72100742. This work was supported by the German
   Research Foundation (DFG) Grant Schi 1071/3 1.
CR Ahn HJ, 2009, FEBS LETT, V583, P2922, DOI 10.1016/j.febslet.2009.07.056
   Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594
   Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Caldwell MA, 1998, EXP NEUROL, V152, P1, DOI 10.1006/exnr.1998.6815
   Chan BP, 2007, BIOMATERIALS, V28, P4652, DOI 10.1016/j.biomaterials.2007.07.041
   Chun TH, 2006, CELL, V125, P577, DOI 10.1016/j.cell.2006.02.050
   Coutu DL, 2011, BLOOD, V117, P6801, DOI 10.1182/blood 2010 12 321539
   Cristancho AG, 2011, NAT REV MOL CELL BIO, V12, P722, DOI 10.1038/nrm3198
   DAMON DH, 1989, J CELL PHYSIOL, V138, P221, DOI 10.1002/jcp.1041380202
   Daya S, 2007, DIFFERENTIATION, V75, P360, DOI 10.1111/j.1432 0436.2006.00146.x
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Gimble JM, 2012, CLIN BIOCHEM, V45, P874, DOI 10.1016/j.clinbiochem.2012.03.006
   Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858
   Huang Z, 2010, CYTOKINE, V51, P305, DOI 10.1016/j.cyto.2010.06.002
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   Hutley L, 2004, DIABETES, V53, P3097, DOI 10.2337/diabetes.53.12.3097
   Imaizumi T, 1996, J DERMATOL SCI, V11, P134, DOI 10.1016/0923 1811(95)00431 9
   Itoh N, 2011, J BIOCHEM, V149, P121, DOI 10.1093/jb/mvq121
   Jonker JW, 2012, NATURE, V485, P391, DOI 10.1038/nature10998
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kakudo N, 2007, BIOCHEM BIOPH RES CO, V359, P239, DOI 10.1016/j.bbrc.2007.05.070
   Karlsen TA, 2011, J CELL BIOCHEM, V112, P684, DOI 10.1002/jcb.22978
   Koopman R, 2001, HISTOCHEM CELL BIOL, V116, P63
   Laestander C, 2014, CELL PROLIFERAT, V47, P3, DOI 10.1111/cpr.12084
   Lowe CE, 2011, J CELL SCI, V124, P2681, DOI 10.1242/jcs.079699
   Lu CL, 2010, BLOOD, V115, P221, DOI 10.1182/blood 2009 06 228494
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   Mauney J, 2010, MATRIX BIOL, V29, P3, DOI 10.1016/j.matbio.2009.09.003
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955
   MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Neubauer M, 2005, TISSUE ENG, V11, P1840, DOI 10.1089/ten.2005.11.1840
   Neubauer M, 2004, FEBS LETT, V577, P277, DOI 10.1016/j.febslet.2004.10.020
   Newell FS, 2006, FASEB J, V20, P2615, DOI 10.1096/fj.05 5710fje
   Nöth U, 2007, J BIOMED MATER RES A, V83A, P626, DOI 10.1002/jbm.a.31254
   Oh SA, 2012, TISSUE ENG PT A, V18, P1087, DOI [10.1089/ten.TEA.2011.0360, 10.1089/ten.tea.2011.0360]
   Ohta H, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00018
   Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292
   Panek RL, 1998, J PHARMACOL EXP THER, V286, P569
   Park JS, 2011, BIOMATERIALS, V32, P3921, DOI 10.1016/j.biomaterials.2011.02.019
   Patel NG, 2005, J CLIN ENDOCR METAB, V90, P1226, DOI 10.1210/jc.2004 1309
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Plant AL, 2009, BBA MOL CELL RES, V1793, P893, DOI 10.1016/j.bbamcr.2008.10.012
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Schilling T, 2008, J CELL BIOCHEM, V103, P413, DOI 10.1002/jcb.21415
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Steinert AF, 2012, STEM CELL TRANSL MED, V1, P237, DOI 10.5966/sctm.2011 0036
   Tang KT, 1996, J CELL BIOCHEM, V61, P152, DOI 10.1002/(SICI)1097 4644(19960401)61:1<152::AID JCB16>3.0.CO;2 Q
   Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev biochem 052110 115718
   Tsutsumi S, 2001, BIOCHEM BIOPH RES CO, V288, P413, DOI 10.1006/bbrc.2001.5777
   UHLRICH S, 1986, BIOCHEM BIOPH RES CO, V137, P1205, DOI 10.1016/0006 291X(86)90353 0
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb 2002 3 7 research0034
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Watt FM, 2013, NAT REV MOL CELL BIO, V14, P467, DOI 10.1038/nrm3620
   Widberg CH, 2009, AM J PHYSIOL ENDOC M, V296, pE121, DOI 10.1152/ajpendo.90602.2008
   Yoneno K, 2005, J BIOMED MATER RES A, V75A, P733, DOI 10.1002/jbm.a.30488
NR 61
TC 17
Z9 17
U1 1
U2 23
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD NOV 1
PY 2015
VL 338
IS 2
BP 136
EP 148
DI 10.1016/j.yexcr.2015.09.009
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CV6BA
UT WOS:000364354500002
PM 26384550
DA 2025 08 17
ER

PT J
AU Asano, T
   Suzutani, K
   Watanabe, A
   Honda, A
   Mori, N
   Yashiro, M
   Sato, S
   Kobayashi, H
   Watanabe, H
   Hazama, M
   Kanno, T
   Suzuki, E
   Ishii, S
   Migita, K
AF Asano, Tomoyuki
   Suzutani, Ken
   Watanabe, Aya
   Honda, Aki
   Mori, Natsumi
   Yashiro, Makiko
   Sato, Shuzo
   Kobayashi, Hiroko
   Watanabe, Hiroshi
   Hazama, Momoko
   Kanno, Takashi
   Suzuki, Eiji
   Ishii, Shiro
   Migita, Kiyoshi
TI The utility of FDG PET/CT imaging in the evaluation of multicentric
   reticulohistiocytosis: A case report
SO MEDICINE
LA English
DT Article
DE FDG PET; CT; multicentric reticulohistiocytosis; tumor necrosis factor ;
   ultrasonography
ID DISEASE
AB Introduction:Multicentric reticulohistiocytosis (MRH) is a rare histiocytic disorder that involves the skin, joints, and visceral organs.Case presentation:We report a 67 year old woman with MRH who presented with a 2 years history of polyarthralgia and skin nodules. Her symptoms were an inflammatory polyarthropathy with punched out lesions of the distal interphalangeal (DIP) joints of both hands. Doppler ultrasonography of the hands showed large bone erosions with power Doppler signals in the DIP joints. F 18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) demonstrated increased FDG uptake in cutaneous papules surrounding the affected joints, suggesting an inflammatory process. There was no evidence of malignancy. Biopsy samples of skin nodules exhibited dermal infiltration with CD68 positive histiocytes and multinucleated giant cells. The patient was diagnosed with MRH and treated with combination therapy comprising a steroid (prednisolone), tacrolimus, methotrexate, and infliximab, which resulted in clinical improvement. Following infliximab treatment, there was a significant decrease in a bone resorption marker (tartrate resistant acid phosphatase 5b: TRACP 5b), suggesting that tumor necrosis factor  targeting therapy may inhibit osteoclast formation and resorption activity in patients with MRH.Conclusion:MRH is a progressive destructive arthritic condition, and early diagnostic and therapeutic strategies are necessary to improve the outcome. FDG PET/CT and joint ultrasonography might be noninvasive imaging modalities that could help diagnose MRH.
C1 [Asano, Tomoyuki; Suzutani, Ken; Watanabe, Aya; Mori, Natsumi; Yashiro, Makiko; Sato, Shuzo; Kobayashi, Hiroko; Watanabe, Hiroshi; Migita, Kiyoshi] Fukushima Med Univ, Sch Med, Dept Rheumatol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
   [Honda, Aki] Fukushima Med Univ, Sch Med, Dept Dermatol, 1 Hikarigaoka, Fukushima, Japan.
   [Hazama, Momoko; Kanno, Takashi; Suzuki, Eiji] Ohta Nishinouhi Gen Hosp Fdn, Dept Rheumatol, Koriyama, Fukushima, Japan.
   [Ishii, Shiro] Fukushima Med Univ, Sch Med, Dept Radiol, Fukushima, Fukushima, Japan.
C3 Fukushima Medical University; Fukushima Medical University; Fukushima
   Medical University
RP Migita, K (通讯作者)，Fukushima Med Univ, Sch Med, Dept Rheumatol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan.
EM migita@fmu.ac.jp
RI Sato, Shuzo/AAC 7025 2019
OI Asano, Tomoyuki/0009 0005 6538 1881; Sato, Shuzo/0000 0002 8110 8261
CR Adamopoulos IE, 2006, HUM PATHOL, V37, P1176, DOI 10.1016/j.humpath.2006.04.007
   Bennàssar A, 2011, J DERMATOL, V38, P905, DOI 10.1111/j.1346 8138.2010.01146.x
   CAMPBELL DA, 1991, BAILLIERE CLIN RHEUM, V5, P301, DOI 10.1016/S0950 3579(05)80285 7
   Chen CH, 2006, JCR J CLIN RHEUMATOL, V12, P252, DOI 10.1097/01.rhu.0000239902.91768.f9
   Codriansky KA, 2008, ARTHRIT RHEUM ARTHR, V59, P444, DOI 10.1002/art.23320
   El Haddad B, 2011, RHEUMATOL INT, V31, P1235, DOI 10.1007/s00296 009 1287 7
   Gorman JD, 2000, ARTHRITIS RHEUM, V43, P930, DOI 10.1002/1529 0131(200004)43:4<930::AID ANR27>3.0.CO;2 A
   Goto H, 2003, ARTHRITIS RHEUM, V48, P3538, DOI 10.1002/art.11362
   Islam AD, 2013, CLIN REV ALLERG IMMU, V45, P281, DOI 10.1007/s12016 013 8362 2
   Liang GC, 1996, ARTHRITIS RHEUM, V39, P171, DOI 10.1002/art.1780390125
   Matejicka C, 2003, ARTHRITIS RHEUM, V48, P864, DOI 10.1002/art.10781
   NAKAJIMA Y, 1992, J RHEUMATOL, V19, P1643
   Nakamura H, 1997, ARTHRITIS RHEUM, V40, P2266, DOI 10.1002/art.1780401224
   Sellam J, 2005, CLIN EXP RHEUMATOL, V23, P97
   Selmi C, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926 015 0511 6
   Tajirian AL, 2006, CLIN DERMATOL, V24, P486, DOI 10.1016/j.clindermatol.2006.07.010
   Tariq S, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064 016 1874 5
   Treglia G, 2014, ACAD RADIOL, V21, P675, DOI 10.1016/j.acra.2014.01.008
   Trotta F, 2004, BEST PRACT RES CL RH, V18, P759, DOI 10.1016/j.berh.2004.06.002
   Zhuang HM, 2005, RADIOL CLIN N AM, V43, P121, DOI 10.1016/j.rcl.2004.07.005
NR 20
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2018
VL 97
IS 33
AR e11449
DI 10.1097/MD.0000000000011449
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA GR0ZS
UT WOS:000442255600002
PM 30113451
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Konittinen, YT
   Ma, J
   Lappalainen, R
   Laine, P
   Kitti, U
   Santavirta, S
   Teronen, O
AF Konittinen, YT
   Ma, J
   Lappalainen, R
   Laine, P
   Kitti, U
   Santavirta, S
   Teronen, O
TI Immunohistochemical evaluation of inflammatory mediators in failing
   implants
SO INTERNATIONAL JOURNAL OF PERIODONTICS & RESTORATIVE DENTISTRY
LA English
DT Article
ID NECROSIS FACTOR ALPHA; TOTAL HIP REPLACEMENT; ORAL IMPLANTS;
   GROWTH FACTOR; GIANT CELLS; TNF ALPHA; IN VITRO; CYTOKINES;
   PERIODONTITIS; TITANIUM
AB It was hypothesized that pen implant tissue around loosening dental implants may contain cytokines with a potential to regulate osteoclasts. Peri implant and/or gingival samples from loosened implants, chronic periodontitis (CP), and normal controls (n = 10 samples in each group) were analyzed using immunohistochemical staining to observe tumor necrosis factor alpha (TNF alpha), interleukin 1 alpha (IL 1 alpha), IL 6, platelet derived growth factor A (PDGF A), and transforming growth factor alpha (TGF alpha). These cytokines were found in foreign body giant cells, macrophages, fibroblasts, and epithelial cells. TNF alpha, IL 1 alpha, and IL 6 were increased (P < 05; unpaired t test) in peri implantitis and CP whereas PDGF A and TGF alpha were not. In conclusion, cytokines with a potential to activate osteoclasts were found in both peri implantitis and CP but the cytokine profiles differed in that IL 1 alpha was the most prevalent cytokine in the former and TNF alpha was the most common in the latter These cytokines may contribute to peri implant bone loss/loosening by stimulating formation and activity of osteoclasts and might be an amenable target for local therapies with cytokine modulators.
C1 Univ Helsinki, Cent Hosp, Biomedicum Helsinki, Dept Med Invartes Med, FIN 00029 Helsinki, Finland.
   ORTON Res Inst, Helsinki, Finland.
   Invalid Fdn, Orthopaed Hosp, Helsinki, Finland.
   Helsinki Cent Univ Hosp, Helsinki, Finland.
   Univ Kuopio, Dept Appl Phys, FIN 70211 Kuopio, Finland.
   Univ Helsinki, Biomedicum Anat, FIN 00014 Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; Helsinki University Central Hospital; University of Eastern
   Finland; University of Helsinki
RP Konittinen, YT (通讯作者)，Univ Helsinki, Cent Hosp, Biomedicum Helsinki, Dept Med Invartes Med, POB 700, FIN 00029 Helsinki, Finland.
EM yrjo.konttinen@helsinki.fi
OI Teronen, Olli/0000 0003 2211 9187
CR APSE P, 1989, J PERIODONTAL RES, V24, P96, DOI 10.1111/j.1600 0765.1989.tb00863.x
   el Askary A S, 1999, Implant Dent, V8, P173
   Esposito M, 1998, EUR J ORAL SCI, V106, P527, DOI 10.1046/j.0909 8836..t01 2 .x
   Gemmell E, 1998, J DENT RES, V77, P16, DOI 10.1177/00220345980770010101
   Goldring SR, 1996, CLIN ORTHOP RELAT R, P13
   Graves DT, 1999, CLIN INFECT DIS, V28, P482, DOI 10.1086/515178
   Hernandez Pando R, 2000, IMMUNOLOGY, V100, P352, DOI 10.1046/j.1365 2567.2000.00025.x
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110
   KJELDSEN M, 1993, J PERIODONTOL, V64, P1013, DOI 10.1902/jop.1993.64.11.1013
   Konttinen YT, 1996, CLIN EXP RHEUMATOL, V14, P255
   Konttinen YT., 1997, CURR ORTHOPAED, V11, P40
   Listgarten MA, 1999, J PERIODONTOL, V70, P431, DOI 10.1902/jop.1999.70.4.431
   Manlapaz M, 1996, J ORTHOP RES, V14, P465, DOI 10.1002/jor.1100140317
   MARIANO M, 1974, J PATHOL, V113, P1, DOI 10.1002/path.1711130102
   Oates T W, 1996, Curr Opin Periodontol, V3, P34
   Oringer RJ, 1998, CLIN ORAL IMPLAN RES, V9, P365, DOI 10.1034/j.1600 0501.1996.090602.x
   REITAMO S, 1980, HISTOPATHOLOGY, V4, P517, DOI 10.1111/j.1365 2559.1980.tb02946.x
   Rifas L, 1999, CALCIFIED TISSUE INT, V64, P1, DOI 10.1007/s002239900570
   Salcetti JM, 1997, INT J ORAL MAX IMPL, V12, P32
   SCHENA M, 1992, LEUKEMIA, V6, P120
   Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502
   Tervahartiala T, 2001, J DENT RES, V80, P1535, DOI 10.1177/00220345010800061101
   Wang JY, 1996, BIOMATERIALS, V17, P2233, DOI 10.1016/0142 9612(96)00072 5
   Williams RO, 1998, ARTHRITIS RHEUM, V41, P1806, DOI 10.1002/1529 0131(199810)41:10<1806::AID ART12>3.0.CO;2 9
   Xu JW, 2000, ANN RHEUM DIS, V59, P822, DOI 10.1136/ard.59.10.822
   Xu JW, 1998, RHEUMATOL INT, V17, P215, DOI 10.1007/s002960050037
   Xu JW, 1996, CLIN EXP RHEUMATOL, V14, P643
NR 27
TC 84
Z9 94
U1 0
U2 8
PU QUINTESSENCE PUBLISHING CO INC
PI HANOVER PARK
PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA
SN 0198 7569
J9 INT J PERIODONT REST
JI Int. J. Periodontics Restor. Dent.
PD APR
PY 2006
VL 26
IS 2
BP 135
EP 141
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 035EQ
UT WOS:000236983600003
PM 16642902
DA 2025 08 17
ER

PT J
AU Katsianou, M
   Papavassiliou, KA
   Zoi, I
   Gargalionis, AN
   Panagopoulos, D
   Themistocleous, MS
   Piperi, C
   Papavassiliou, AG
   Basdra, EK
AF Katsianou, Maira
   Papavassiliou, Kostas A.
   Zoi, Ilianna
   Gargalionis, Antonios N.
   Panagopoulos, Dimitrios
   Themistocleous, Marios S.
   Piperi, Christina
   Papavassiliou, Athanasios G.
   Basdra, Efthimia K.
TI Polycystin 1 modulates RUNX2 activation and osteocalcin gene
   expression via ERK signalling in a human craniosynostosis cell model
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE craniosynostosis; dolichocephaly; ERK; mechanosensation;
   mechanotransduction; osteoblast differentiation; osteocalcin; PC1;
   RUNX2; trigonocephaly
ID FORCE INDUCED CRANIOSYNOSTOSIS; SKELETAL; BIOLOGY; CILIA; CBFA1
AB Craniosynostosis refers to the premature fusion of one or more cranial sutures leading to skull shape deformities and brain growth restriction. Among the many factors that contribute to abnormal suture fusion, mechanical forces seem to play a major role. Nevertheless, the underlying mechanobiology related mechanisms of craniosynostosis still remain unknown. Understanding how aberrant mechanosensation and mechanotransduction drive premature suture fusion will offer important insights into the pathophysiology of craniosynostosis and result in the development of new therapies, which can be used to intervene at an early stage and prevent premature suture fusion. Herein, we provide evidence for the first time on the role of polycystin 1 (PC1), a key protein in cellular mechanosensitivity, in craniosynostosis, using primary cranial suture cells isolated from patients with trigonocephaly and dolichocephaly, two common types of craniosynostosis. Initially, we showed that PC1 is expressed at the mRNA and protein level in both trigonocephaly and dolichocephaly cranial suture cells. Followingly, by utilizing an antibody against the mechanosensing extracellular N terminal domain of PC1, we demonstrated that PC1 regulates runt related transcription factor 2 (RUNX2) activation and osteocalcin gene expression via extracellular signal regulated kinase (ERK) signalling in our human craniosynostosis cell model. Altogether, our study reveals a novel mechanotransduction signalling axis, PC1 ERK RUNX2, which affects osteoblastic differentiation in cranial suture cells from trigonocephaly and dolichocephaly patients.
C1 [Katsianou, Maira; Papavassiliou, Kostas A.; Zoi, Ilianna; Gargalionis, Antonios N.; Piperi, Christina; Papavassiliou, Athanasios G.; Basdra, Efthimia K.] Natl & Kapodistrian Univ Athens, Med Sch, Dept Biol Chem, Athens 11527, Greece.
   [Panagopoulos, Dimitrios; Themistocleous, Marios S.] Agia Sofia Childrens Hosp, Dept Neurosurg, Athens, Greece.
C3 National & Kapodistrian University of Athens; The Aghia Sophia
   Children's Hospital
RP Piperi, C; Papavassiliou, AG; Basdra, EK (通讯作者)，Natl & Kapodistrian Univ Athens, Med Sch, Dept Biol Chem, Athens 11527, Greece.
EM cpiperi@med.uoa.gr; papavas@med.uoa.gr; ebasdra@med.uoa.gr
RI ; Gargalionis, Antonios/P 8374 2019; Piperi, Christina/AAF 2009 2020;
   Papavassiliou, Kostas/AAA 6459 2021
OI Zoi, Ilianna/0000 0002 0435 2463; Piperi, Christina/0000 0002 2701 0618;
   Papavassiliou, Kostas/0000 0001 9620 745X; Themistocleous,
   Marios/0000 0003 3810 8001; Papavassiliou,
   Athanasios/0000 0001 5803 4527; BASDRA, EFTHIMIA/0000 0002 0913 9354
FU NIDDK [P30 DK090868]
FX The IgPKD1 antibody was a generous gift from Dr O.
   Ibraghimov Beskrovnaya and H. Husson (Genzyme Co., Boston, MA). Studies
   utilized resources (polycystin 1 CT2741 antibody) provided by the NIDDK
   sponsored Baltimore Polycystic Kidney Disease Research and Clinical Core
   Center, P30 DK090868.
CR BASDRA EK, 1995, BBA MOL CELL RES, V1268, P209, DOI 10.1016/0167 4889(95)00090 F
   Beederman M, 2014, GENES DIS, V1, P120, DOI 10.1016/j.gendis.2014.07.004
   Berrout J, 2012, BRAIN RES, V1436, P1, DOI 10.1016/j.brainres.2011.11.044
   Boulter C, 2001, P NATL ACAD SCI USA, V98, P12174, DOI 10.1073/pnas.211191098
   CARTER DH, 1991, J HISTOCHEM CYTOCHEM, V39, P599, DOI 10.1177/39.5.1707904
   Cohen MM Jr, 2000, J CRAN GENET DEV BIO, V20, P94
   Coussens AK, 2009, J CELL PHYSIOL, V218, P183, DOI 10.1002/jcp.21586
   Dalagiorgou G, 2017, CELL MOL LIFE SCI, V74, P921, DOI 10.1007/s00018 016 2394 8
   Dalagiorgou G, 2013, CELL MOL LIFE SCI, V70, P167, DOI 10.1007/s00018 012 1164 5
   Dalagiorgou G, 2010, INT J BIOCHEM CELL B, V42, P1610, DOI 10.1016/j.biocel.2010.06.017
   Davis C, 2010, PLAST RECONSTR SURG, V125, P1111, DOI 10.1097/PRS.0b013e3181d0abcf
   Dere R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009239
   Di Rocco F, 2009, J NEUROSURG PEDIATR, V4, P21, DOI 10.3171/2009.3.PEDS08355
   Distefano G, 2009, MOL CELL BIOL, V29, P2359, DOI 10.1128/MCB.01259 08
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Gargalionis AN, 2015, INT J CANCER, V136, P1515, DOI 10.1002/ijc.29140
   Garrocho Rangel A, 2018, MED ORAL PATOL ORAL, V23, pE421, DOI 10.4317/medoral.22328
   Greenwood J, 2014, GENET MED, V16, P302, DOI 10.1038/gim.2013.134
   Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521 1878(200002)22:2<138::AID BIES5>3.0.CO;2 4
   Hou B, 2009, BONE, V44, P1121, DOI 10.1016/j.bone.2009.02.018
   Ibraghimov Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641
   Katsianou M., 2021, J CELL MOL MED, V00, P1
   Katsianou MA, 2016, BBA CLIN, V6, P165, DOI 10.1016/j.bbacli.2016.04.006
   Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947
   Kolpakova Hart E, 2008, DEV BIOL, V321, P407, DOI 10.1016/j.ydbio.2008.07.005
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   LAJEUNIE E, 1995, AM J MED GENET, V55, P500, DOI 10.1002/ajmg.1320550422
   Lattanzi W, 2017, AM J MED GENET A, V173, P1406, DOI 10.1002/ajmg.a.38159
   Lee SW, 2006, J CELL BIOCHEM, V98, P981, DOI 10.1002/jcb.20773
   Maeno T, 2011, BONE, V49, P673, DOI 10.1016/j.bone.2011.07.023
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076
   Nauli SM, 2008, CIRCULATION, V117, P1161, DOI 10.1161/CIRCULATIONAHA.107.710111
   Neve A, 2011, CELL TISSUE RES, V343, P289, DOI 10.1007/s00441 010 1086 1
   Oppenheimer AJ, 2012, J CRANIOFAC SURG, V23, P573, DOI 10.1097/SCS.0b013e318241db3e
   Oppenheimer AJ, 2009, PLAST RECONSTR SURG, V124, P1840, DOI 10.1097/PRS.0b013e3181bf806c
   Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Papachroni KK, 2009, TRENDS MOL MED, V15, P208, DOI 10.1016/j.molmed.2009.03.001
   Papavassiliou KA, 2019, J CELL MOL MED, V23, P6215, DOI 10.1111/jcmm.14506
   Pneumaticos SG, 2010, J CELL MOL MED, V14, P2561, DOI 10.1111/j.1582 4934.2010.01062.x
   Ratisoontorn C, 2005, BONE, V36, P627, DOI 10.1016/j.bone.2005.01.010
   Retailleau K, 2014, J PHYSIOL LONDON, V592, P2453, DOI 10.1113/jphysiol.2014.271346
   Sharif Naeini R, 2009, CELL, V139, P587, DOI 10.1016/j.cell.2009.08.045
   Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096
   Streets AJ, 2009, J CELL SCI, V122, P1410, DOI 10.1242/jcs.045021
   Tahiri Y, 2017, PLAST RECONSTR SURG, V140, p177E, DOI 10.1097/PRS.0000000000003473
   Twigg SRF, 2015, AM J HUM GENET, V97, P359, DOI 10.1016/j.ajhg.2015.07.006
   Ursitti F, 2011, ACTA PAEDIATR, V100, P1185, DOI 10.1111/j.1651 2227.2011.02299.x
   Varela A, 2015, SCI REP UK, V5, DOI 10.1038/srep13461
   Wang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091730
   Wu B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171451
   Wu XW, 2019, INT J BIOL SCI, V15, P298, DOI 10.7150/ijbs.29183
   Xiao ZS, 2010, ANN NY ACAD SCI, V1192, P410, DOI 10.1111/j.1749 6632.2009.05239.x
   Yin L, 2008, BONE, V42, P631, DOI 10.1016/j.bone.2007.11.019
   Ziros PG, 2008, INT J BIOCHEM CELL B, V40, P1659, DOI 10.1016/j.biocel.2007.05.024
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
NR 57
TC 6
Z9 7
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD APR
PY 2021
VL 25
IS 7
BP 3216
EP 3225
DI 10.1111/jcmm.16391
EA MAR 2021
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA RK4SC
UT WOS:000624621500001
PM 33656806
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lee, JH
   Mandakhbayar, N
   El Fiqi, A
   Kim, HW
AF Lee, Jung Hwan
   Mandakhbayar, Nandin
   El Fiqi, Ahmed
   Kim, Hae Won
TI Intracellular co delivery of Sr ion and phenamil drug through mesoporous
   bioglass nanocarriers synergizes BMP signaling and tissue mineralization
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Co delivery; Therapeutic ion; BMP signaling activator; Bioglass
   nanocarrier; Multipotent stem cells; Hard tissue regeneration
ID DENTAL PULP CELLS; BIOACTIVE GLASS; STEM CELLS; BONE MARROW; ODONTOGENIC
   DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION;
   MECHANICAL PROPERTIES; COLLAGEN HYDROGELS; STRONTIUM
AB Inducing differentiation and maturation of resident multipotent stem cells (MSCs) is an important strategy to regenerate hard tissues in mal calcification conditions. Here we explore a co delivery approach of therapeutic molecules comprised of ion and drug through a mesoporous bioglass nanoparticle (MBN) for this purpose. Recently, MBN has offered unique potential as a nanocarrier for hard tissues, in terms of high mesoporosity, bone bioactivity (and possibly degradability), tunable delivery of biomolecules, and ionic modification. Herein Sr ion is structurally doped to MBN while drug Phenamil is externally loaded as a small molecule activator of BMP signaling, for the stimulation of osteo/odontogenesis and mineralization of human MSCs derived from dental pulp. The Sr doped MBN (85Si:10Ca:5Sr) sol gel processed presents a high mesoporosity with a pore size of similar to 6 nm. In particular, Sr ion is released slowly at a daily rate of similar to 3 ppm per mg nanoparticles for up to 7 days, a level therapeutically effective for cellular stimulation. The Sr MBN is internalized to most MSCs via an ATP dependent macropinocytosis within hours, increasing the intracellular levels of Sr, Ca and Si ions. Phenamil is loaded maximally similar to 30% into Sr MBN and then released slowly for up to 7 days. The co delivered molecules (Sr ion and Phenamil drug) have profound effects on the differentiation and maturation of cells, i.e., significantly enhancing expression of osteo/odontogenic genes, alkaline phosphatase activity, and mineralization of cells. Of note, the stimulation is a result of a synergism of Sr and Phenamil, through a Trb3 dependent BMP signaling pathway. This biological synergism is further evidenced in vivo in a mal calcification condition involving an extracted tooth implantation in dorsal subcutaneous tissues of rats. Six weeks post operation evidences the osseous dentinal hard tissue formation, which is significantly stimulated by the Sr/Phenamil delivery, based on histomorphometric and micro computed tomographic analyses. The bioactive nanoparticles releasing both Sr ion and Phenamil drug are considered to be a promising therapeutic nanocarrier platform for hard tissue regeneration. Furthermore, this novel ion/drug co delivery concept through nanoparticles can be extensively used for other tissues that require different therapeutic treatment.
   Statement of Significance
   This study reports a novel design concept in inorganic nanoparticle delivery system for hard tissues  theco delivery of therapeutic molecules comprised of ion (Sr) and drug (Phenamil) through a unique nanoparticle of mesoporous bioactive glass (MBN). The physico chemical and biological properties of MBN enabled an effective loading of both therapeutic molecules and a subsequently sustained/controlled release. The co delivered Sr and Phenamil demonstrated significant stimulation of adult stem cell differentiation in vitro and osseous/dentinal regeneration in vivo, through BMP signaling pathways. We consider the current combination of Sr ion with Phenamil is suited for the osteo/odontogenesis of stem cells for hard tissue regeneration, and further, this ion/drug co delivery concept can extend the applications to other areas that require specific cellular and tissue functions. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Lee, Jung Hwan; Mandakhbayar, Nandin; El Fiqi, Ahmed; Kim, Hae Won] Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 330714, South Korea.
   [Mandakhbayar, Nandin; El Fiqi, Ahmed; Kim, Hae Won] Dankook Univ, Dept Nanobiomed Sci, Cheonan 330714, South Korea.
   [Mandakhbayar, Nandin; El Fiqi, Ahmed; Kim, Hae Won] Dankook Univ, PLUS NBM Global Res Ctr Regenerat Med BK21, Cheonan 330714, South Korea.
   [El Fiqi, Ahmed] Natl Res Ctr, Glass Res Dept, Cairo 12622, Egypt.
   [Kim, Hae Won] Dankook Univ, Sch Dent, Dept Biomat Sci, Cheonan 330714, South Korea.
C3 Dankook University; Dankook University; Dankook University; Egyptian
   Knowledge Bank (EKB); National Research Centre (NRC); Dankook University
RP Kim, HW (通讯作者)，Dankook Univ, Inst Tissue Regenerat Engn ITREN, Cheonan 330714, South Korea.
EM kimhw@dku.edu
RI El Fiqi (Ph.D.), Associate Professor of Nano Biomaterials,
   Ahmed/N 1814 2018; Mandakhbayar, Nandin/D 9427 2014; Lee,
   Jung Hwan/AFK 0831 2022
OI El Fiqi, Ahmed/0000 0002 2344 1728; Mandakhbayar, Nandin
   Erdene/0000 0003 0273 377X; Lee, Jung Hwan/0000 0001 8678 5459; 
FU National Research Foundation of Korea (Global Research Laboratory
   Program) [2015032163]; National Research Foundation of Korea (Priority
   Research Centers Program) [2009 0093829]; National Research Foundation
   of Korea (Basic Research Program) [2015R1C1A1A01052127]
FX This research was supported by the National Research Foundation of Korea
   (Global Research Laboratory Program: 2015032163, Priority Research
   Centers Program: 2009 0093829, and Basic Research Program:
   2015R1C1A1A01052127). Special thanks to an illustrator 'Sa Beom Park'
   for the illustration of Fig. 8.
CR [Anonymous], [No title captured]
   Balmayor ER, 2015, ADV DRUG DELIVER REV, V94, P13, DOI 10.1016/j.addr.2015.04.022
   Boanini E, 2014, BIOMATERIALS, V35, P5619, DOI 10.1016/j.biomaterials.2014.03.053
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Bosetti M, 2005, BIOMATERIALS, V26, P3873, DOI 10.1016/j.biomaterials.2004.09.059
   Cheng TL, 2015, J TISSUE ENG, V6, DOI 10.1177/2041731415609448
   Choi YJ, 2013, MOL CELL BIOCHEM, V375, P59, DOI 10.1007/s11010 012 1528 z
   Corradetti B, 2016, J CONTROL RELEASE, V240, P242, DOI 10.1016/j.jconrel.2015.12.042
   De Godoy RF, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5387 5
   Dutta Dipannita, 2012, Cell Logist, V2, P203
   El Fiqi A, 2015, J MATER CHEM B, V3, P1321, DOI 10.1039/c4tb01634c
   El Fiqi A, 2015, ACS APPL MATER INTER, V7, P1140, DOI 10.1021/am5077759
   El Fiqi A, 2013, ACTA BIOMATER, V9, P9508, DOI 10.1016/j.actbio.2013.07.036
   El Fiqi A, 2012, NANOSCALE, V4, P7475, DOI 10.1039/c2nr31775c
   Fan JB, 2015, TISSUE ENG PT A, V21, P2053, DOI [10.1089/ten.tea.2014.0489, 10.1089/ten.TEA.2014.0489]
   Faraji AH, 2009, BIOORGAN MED CHEM, V17, P2950, DOI 10.1016/j.bmc.2009.02.043
   Gao Y, 2015, J MATER CHEM B, V3, P1245, DOI 10.1039/c4tb01452a
   Gold S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011360
   Gong WY, 2014, J ENDODONT, V40, P83, DOI 10.1016/j.joen.2013.08.018
   Hench LL, 2002, SCIENCE, V295, P1014, DOI 10.1126/science.1067404
   Hoppe A, 2011, BIOMATERIALS, V32, P2757, DOI 10.1016/j.biomaterials.2011.01.004
   Hosoya A, 2008, BONE, V42, P350, DOI 10.1016/j.bone.2007.09.054
   Inoue M., 2005, J Hard Tissue Biol, V14, P5
   Jebahi S., 2013, Annales Pharmaceutiques Francaises, V71, P234, DOI 10.1016/j.pharma.2013.05.003
   Jin GZ, 2015, TISSUE ENG REGEN MED, V12, P69, DOI 10.1007/s13770 014 0095 7
   Jin GZ, 2015, RSC ADV, V5, P26832, DOI 10.1039/c4ra16955g
   Jin GZ, 2014, TISSUE ENG REGEN MED, V11, P284, DOI 10.1007/s13770 014 0033 8
   Jones JR, 2013, ACTA BIOMATER, V9, P4457, DOI 10.1016/j.actbio.2012.08.023
   Kang MS, 2015, ACTA BIOMATER, V16, P103, DOI 10.1016/j.actbio.2014.12.028
   Kim GH, 2015, J BIOMATER APPL, V29, P854, DOI 10.1177/0885328214546884
   Kim JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149967
   Kim TH, 2016, ACTA BIOMATER, V29, P352, DOI 10.1016/j.actbio.2015.09.035
   Kokubo T, 2006, BIOMATERIALS, V27, P2907, DOI 10.1016/j.biomaterials.2006.01.017
   Krishnan V, 2016, DENT MATER, V32, P646, DOI 10.1016/j.dental.2016.02.002
   Lakhkar NJ, 2015, J TISSUE ENG, V6, DOI 10.1177/2041731415617741
   Landgraf L, 2015, BEILSTEIN J NANOTECH, V6, P300, DOI 10.3762/bjnano.6.28
   Lo KWH, 2014, TRENDS BIOTECHNOL, V32, P74, DOI 10.1016/j.tibtech.2013.12.002
   lohara K, 2004, J DENT RES, V83, P590
   Lundmark R, 2008, CURR BIOL, V18, P1802, DOI 10.1016/j.cub.2008.10.044
   Mao AS, 2015, P NATL ACAD SCI USA, V112, P14452, DOI 10.1073/pnas.1508520112
   Meiszterics K.S.A., 2011, 5 EUR C INT FED MED
   Mouriño V, 2012, J R SOC INTERFACE, V9, P401, DOI 10.1098/rsif.2011.0611
   Murphy S, 2010, J MATER SCI MATER M, V21, P2827, DOI 10.1007/s10856 010 4139 9
   Owens GJ, 2016, PROG MATER SCI, V77, P1, DOI 10.1016/j.pmatsci.2015.12.001
   Park KW, 2009, MOL CELL BIOL, V29, P3905, DOI 10.1128/MCB.00002 09
   Pashuck ET, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002717
   Perez RA, 2016, PROG MATER SCI, V82, P234, DOI 10.1016/j.pmatsci.2016.05.003
   Prescott RS, 2008, J ENDODONT, V34, P421, DOI 10.1016/j.joen.2008.02.005
   Qiu Y, 2015, NANOSCALE, V7, P6588, DOI 10.1039/c5nr00884k
   Saeki K, 2016, DENT MATER, V32, P240, DOI 10.1016/j.dental.2015.11.020
   Saranti A, 2006, J NON CRYST SOLIDS, V352, P390, DOI 10.1016/j.jnoncrysol.2006.01.042
   Saravanan S, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416680319
   Shalumon KT, 2013, J BIOMED NANOTECHNOL, V9, P430, DOI 10.1166/jbn.2013.1559
   Tao ZM, 2009, CHEM RES TOXICOL, V22, P1869, DOI 10.1021/tx900276u
   Torii I, 2001, IMMUNOLOGY, V103, P70, DOI 10.1046/j.1365 2567.2001.01218.x
   Tsigkou O, 2014, ADV HEALTHC MATER, V3, P115, DOI 10.1002/adhm.201300126
   Tsigkou O, 2009, BIOMATERIALS, V30, P3542, DOI 10.1016/j.biomaterials.2009.03.019
   Vrijens K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059045
   Wang J, 2011, BIOMATERIALS, V32, P7822, DOI 10.1016/j.biomaterials.2011.04.034
   Wang SN, 2014, ACTA BIOMATER, V10, P2792, DOI 10.1016/j.actbio.2014.02.013
   Wang SP, 2016, J CONTROL RELEASE, V240, P454, DOI 10.1016/j.jconrel.2016.04.018
   Wang XF, 2014, BIOMATERIALS, V35, P2720, DOI 10.1016/j.biomaterials.2013.12.029
   Wang YP, 2013, ARCH ORAL BIOL, V58, P1709, DOI 10.1016/j.archoralbio.2013.09.001
   Wu CT, 2014, J CONTROL RELEASE, V193, P282, DOI 10.1016/j.jconrel.2014.04.026
   Wu XL, 2015, MAT SCI ENG C MATER, V52, P242, DOI 10.1016/j.msec.2015.03.057
   Xia W, 2006, J CONTROL RELEASE, V110, P522, DOI 10.1016/j.jconrel.2005.11.002
   Yamaguchi S, 2014, ACTA BIOMATER, V10, P2282, DOI 10.1016/j.actbio.2014.01.026
   Yameen B, 2014, J CONTROL RELEASE, V190, P485, DOI 10.1016/j.jconrel.2014.06.038
   Yanes RE, 2013, SMALL, V9, P697, DOI 10.1002/smll.201201811
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yu HS, 2015, J BIOMATER APPL, V30, P338, DOI 10.1177/0885328215590108
   Zhang J, 2009, J TISSUE ENG REGEN M, V3, P63, DOI 10.1002/term.135
   Zhang J, 2015, J BIOMATER APPL, V29, P954, DOI 10.1177/0885328214550896
   Zhang YR, 2014, INT J ORAL SCI, V6, P61, DOI 10.1038/ijos.2014.21
   Zhang YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104527
   Zhang YY, 2010, BIOMATERIALS, V31, P8465, DOI 10.1016/j.biomaterials.2010.07.060
NR 76
TC 86
Z9 90
U1 2
U2 102
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD SEP 15
PY 2017
VL 60
BP 93
EP 108
DI 10.1016/j.actbio.2017.07.021
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FH8DG
UT WOS:000411421400008
PM 28713017
DA 2025 08 17
ER

PT J
AU She, F
   Wang, WB
   Wang, Y
   Tang, PF
   Wei, JQ
   Chen, H
   Zhang, BX
AF She, Fei
   Wang, Wenbo
   Wang, Yan
   Tang, Peifu
   Wei, Junqiang
   Chen, Hua
   Zhang, Boxun
TI Melatonin protects MG63 osteoblast  like cells from hydrogen peroxide 
   induced cytotoxicity by maintaining mitochondrial function
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE mitochondrial dysfunction; melatonin; hydrogen peroxide; cytotoxicity
ID OXIDATIVE DAMAGE; DNA; STRESS; OXYGEN; APOPTOSIS; RADICALS; NEURONS;
   HUMANS; MOUSE
AB Osteoporosis is a bone disease that has been connected with reactive oxygen species (ROS) induced cytotoxicity. Mitochondrial dysfunction may be involved in the mechanism underlying ROS induced cytotoxicity. It has been demonstrated that melatonin may exert cytoprotective effects by improving mitochondrial energetics and functions in several models of oxidative damage. In the present study, the MG63 osteoblast like cell line was exposed to different concentrations of hydrogen peroxide (H2O2; 0, 100, 200, 400 or 800 M) for 8 h, and 200 or 400 M H2O2 for various periods of time (0.5, 4, 8 or 12 h). Results showed that H2O2 significantly reduced cell viability, increased the release of lactate dehydrogenase, increased the levels of ROS and malondialdehyde, reduced the concentration of adenosine 5 triphosphate, disrupted the mitochondrial membrane potential (m) and decreased the mitochondrial DNA copy number in MG63 cells. However, pretreatment with melatonin effectively decreased all of these H2O2 induced changes in cytotoxicity and mitochondrial dysfunction in MG63 cells. The protective effects of melatonin may be attributed to its ability to maintain mitochondrial function in H2O2 treated cells. This study suggests that melatonin is a potential pharmacological agent for preventing ROS induced bone loss in diseases such as osteoporosis.
C1 [She, Fei; Wang, Yan; Tang, Peifu; Wei, Junqiang; Chen, Hua; Zhang, Boxun] Chinese Peoples Liberat Army, Gen Hosp, Dept Orthopaed Surg, Beijing 100853, Peoples R China.
   [Wang, Wenbo] Chinese Peoples Liberat Army, Gen Hosp, Dept Endocrinol, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital
RP Chen, H (通讯作者)，Chinese Peoples Liberat Army, Gen Hosp, Dept Orthopaed Surg, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM 157776860@qq.com; 940114371@qq.com
RI chen, hua/AAD 7881 2022
OI chen, hua/0000 0002 4410 6742
FU National Natural Science Foundation of China [81000803]
FX This study was partially supported by the National Natural Science
   Foundation of China (grant no. 81000803).
CR Arendt J, 2005, SLEEP MED REV, V9, P25, DOI 10.1016/j.smrv.2004.05.002
   ARMSTRONG SM, 1989, EXPERIENTIA, V45, P932, DOI 10.1007/BF01953050
   Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919
   Castroviejo Dario Acuna, 2002, Current Topics in Medicinal Chemistry, V2, P133, DOI 10.2174/1568026023394344
   Chen LJ, 2005, J PINEAL RES, V39, P34, DOI 10.1111/j.1600 079X.2005.00209.x
   Choi EM, 2013, J APPL TOXICOL, V33, P488, DOI 10.1002/jat.1784
   Choi EM, 2012, INFLAMMATION, V35, P1204, DOI 10.1007/s10753 012 9430 0
   Choi EM, 2009, EUR J PHARMACOL, V624, P45, DOI 10.1016/j.ejphar.2009.09.041
   Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600 079X.2000.280401.x
   Coto Montes A, 2010, OPEN BIOL J, V3, P39
   DEACON S, 1995, BRAIN RES, V688, P77, DOI 10.1016/0006 8993(95)96872 I
   Duan QH, 2006, J PINEAL RES, V41, P351, DOI 10.1111/j.1600 079X.2006.00374.x
   Escames G, 2010, CURR NEUROPHARMACOL, V8, P182, DOI 10.2174/157015910792246245
   Guerrero Juan M., 2002, Current Topics in Medicinal Chemistry, V2, P167, DOI 10.2174/1568026023394335
   Hardeland R, 2003, J PINEAL RES, V34, P17, DOI 10.1034/j.1600 079X.2003.02941.x
   Herrera F, 2007, J NEUROCHEM, V100, P736, DOI 10.1111/j.1471 4159.2006.04228.x
   Jimenez Jorge S, 2005, J PINEAL RES, V39, P77, DOI 10.1111/j.1600 079X.2005.00220.x
   Jou MJ, 2007, J PINEAL RES, V43, P389, DOI 10.1111/j.1600 079X.2007.00490.x
   Klongpanichapak S, 2007, J PINEAL RES, V43, P65, DOI 10.1111/j.1600 079X.2007.00444.x
   Lee HC, 2007, EXP BIOL MED, V232, P592
   León J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600 079X.2004.00181.x
   López A, 2009, J PINEAL RES, V46, P188, DOI 10.1111/j.1600 079X.2008.00647.x
   Park BG, 2005, TOXICOLOGY, V215, P115, DOI 10.1016/j.tox.2005.07.003
   Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968 0004(00)01674 1
   Rajaratnam SMW, 2004, J PHYSIOL LONDON, V561, P339, DOI 10.1113/jphysiol.2004.073742
   Reiter RJ, 2008, NEUROENDOCRINOL LETT, V29, P391
   Rosenstein RE, 2010, J PINEAL RES, V49, P1, DOI 10.1111/j.1600 079X.2010.00764.x
   Sandhu SK, 2011, J CLIN PATHOL, V64, P1042, DOI 10.1136/jcp.2010.077842
   Slominski A, 2005, ENDOCRINE, V27, P137, DOI 10.1385/ENDO:27:2:137
   Srinivasan V, 2009, GYNECOL ENDOCRINOL, V25, P779, DOI 10.3109/09513590903159649
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600 079X.2006.00407.x
   Vairetti M, 2005, J PINEAL RES, V38, P223, DOI 10.1111/j.1600 079X.2004.00193.x
   Xu SC, 2010, BRAIN RES, V1311, P189, DOI 10.1016/j.brainres.2009.10.062
   Xu SC, 2009, FEBS J, V276, P4224, DOI 10.1111/j.1742 4658.2009.07094.x
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
NR 35
TC 22
Z9 25
U1 4
U2 21
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2014
VL 9
IS 2
BP 493
EP 498
DI 10.3892/mmr.2013.1832
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AC7FU
UT WOS:000332694100017
PM 24297096
OA Bronze
DA 2025 08 17
ER

PT J
AU Naylor, KE
   Jacques, RM
   Paggiosi, M
   Gossiel, F
   Peel, NFA
   McCloskey, EV
   Walsh, JS
   Eastell, R
AF Naylor, K. E.
   Jacques, R. M.
   Paggiosi, M.
   Gossiel, F.
   Peel, N. F. A.
   McCloskey, E. V.
   Walsh, J. S.
   Eastell, R.
TI Response of bone turnover markers to three oral bisphosphonate therapies
   in postmenopausal osteoporosis: the TRIO study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bisphosphonate; Bone turnover markers; Postmenopausal osteoporosis;
   Variability
ID FRACTURE INTERVENTION TRIAL; BIOCHEMICAL MARKERS; MINERAL DENSITY;
   VERTEBRAL FRACTURES; ALENDRONATE THERAPY; RANDOMIZED TRIAL;
   ELDERLY WOMEN; DOUBLE BLIND; RISEDRONATE; RISK
AB We used bone turnover markers to identify women who responded to bisphosphonate treatment for osteoporosis. Response was more likely with alendronate and ibandronate than risedronate. There was a greater decrease in bone markers if baseline bone turnover markers were higher and if the patient took more than 80 % of her medication.
   Introduction Biochemical response to bisphosphonate therapy can be assessed using either a decrease in bone turnover marker beyond the least significant change (LSC) or a reduction to within a reference interval (RI). We compared the performance of these target responses and determined whether response was related to the type of bisphosphonate, compliance and baseline bone turnover markers.
   Methods Biochemical responses to three oral bisphosphonates were assessed in an open, controlled trial comprising 172 postmenopausal osteoporotic women (age 53 84 years), randomised to alendronate, ibandronate or risedronate, plus calcium and vitamin D supplementation for 2 years. The LSC for each marker was derived within the study population, whereas RIs were obtained from a control group of healthy premenopausal women (age 35 40 years).
   Results Over Over 70 % of women achieved a target response for serum CTX and PINP, irrespective of the approach used. The percentage decrease at 12 weeks was greater for women with baseline PINP above the RI  63 % (difference 13 %, 95 % CI 0 to 27.1, P = 0.049) and good compliance  67 % (difference 15.9 %, 95 % CI 6.3 to 25.5, P = 0.001). Responders had a greater increase in spine bone density compared to nonresponders; for example 6.2 vs. 2.3 % (difference 3.9 %, 95 % CI 1.6 to 6.3, P = 0.0011) for PINP LSC. The magnitude of change in bone markers was greater with ibandronate and alendronate than risedronate.
   Conclusions Both approaches to response identified similar proportions of women as responders. Nonresponders had smaller increases in BMD, and we suggest that biochemical assessment of response is a useful tool for the management of women with postmenopausal osteoporosis.
C1 [Naylor, K. E.; Paggiosi, M.; Gossiel, F.; McCloskey, E. V.; Walsh, J. S.; Eastell, R.] Univ Sheffield, Mellanby Ctr Bone Res, Acad Unit Bone Metab, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.
   [Jacques, R. M.] Univ Sheffield, Sch Hlth & Related Res, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.
   [Peel, N. F. A.] No Gen Hosp, Sheffield Teaching Hosp NHS Fdn Trust, Metab Bone Ctr, Sheffield S5 7AU, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; Northern General
   Hospital; University of Sheffield
RP Naylor, KE (通讯作者)，Univ Sheffield, Mellanby Ctr Bone Res, Acad Unit Bone Metab, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.
EM k.e.naylor@sheffield.ac.uk
RI McCloskey, Eugene/T 5197 2019; Eastell, Richard/G 5851 2011; Jacques,
   Richard/A 2410 2010
OI Paggiosi, Margaret/0000 0002 1030 0723; Walsh,
   Jennifer/0000 0002 7122 2650; Jacques, Richard/0000 0001 6710 5403
FU Warner Chilcott; Immunodiagnostics Systems; NIHR Clinical Research
   Facility; Medical Research Council [MR/K006312/1] Funding Source:
   researchfish; National Institute for Health Research [NF SI 0513 10073]
   Funding Source: researchfish; MRC [MR/K006312/1] Funding Source: UKRI
FX This study was funded by Warner Chilcott, the bone turnover marker
   measurements were funded by Immunodiagnostics Systems. Professor Richard
   Eastell (Academic Unit of Bone Metabolism, The University of Sheffield)
   is a National Institute for Health Research (NIHR) Senior Investigator.
   The authors approved the manuscript for publication and vouch for the
   completeness and accuracy of the data. The funder was involved in the
   design, but not in the conduct, analysis or reporting of the study.We
   are grateful to the data safety monitoring board, the Clinical Trials
   Research Unit, School of Health and Related Research, for data
   management and statistical support and the staff of the Academic Unit of
   Bone Metabolism for conducting the study. We would also like to
   acknowledge the Lay Advisory Panel for Bone Research and the
   participants of the TRIO study. We acknowledge the support of the NIHR
   Clinical Research Facility. The views expressed in this publication are
   those of the author(s) and not necessarily those of the National
   Institute for Health Research.
CR Adachi JD, 2005, AGING CLIN EXP RES, V17, P150
   [Anonymous], 2008, DEFINING ESTABLISHIN
   Arlot M, 2005, J BONE MINER RES, V20, P1244, DOI 10.1359/JBMR.050309
   Bauer DC, 2004, J BONE MINER RES, V19, P1250, DOI 10.1359/JBMR.040512
   Bauer DC, 2006, J BONE MINER RES, V21, P292, DOI 10.1359/JBMR.051018
   Baxter I, 2013, OSTEOPOROSIS INT, V24, P941, DOI 10.1007/s00198 012 2097 4
   Bergmann P, 2009, INT J CLIN PRACT, V63, P19, DOI 10.1111/j.1742 1241.2008.01911.x
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Caro JJ, 2004, OSTEOPOROSIS INT, V15, P1003, DOI 10.1007/s00198 004 1652 z
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Diez Perez A, 2012, OSTEOPOROSIS INT, V23, P2769, DOI 10.1007/s00198 012 2093 8
   Eastell R, 2006, CURR MED RES OPIN, V22, P61, DOI 10.1185/030079905X75096
   Eastell R, 2011, J BONE MINER RES, V26, P1662, DOI 10.1002/jbmr.342
   Emkey R, 2009, CLIN THER, V31, P751, DOI 10.1016/j.clinthera.2009.04.018
   Finigan J, 2013, OSTEOPOROSIS INT, V24, P2879, DOI 10.1007/s00198 013 2386 6
   Fink E, 2000, OSTEOPOROSIS INT, V11, P295, DOI 10.1007/PL00004183
   Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431
   Greenspan SL, 2002, ANN INTERN MED, V137, P875, DOI 10.7326/0003 4819 137 11 200212030 00008
   Hannon R, 1998, J BONE MINER RES, V13, P1124, DOI 10.1359/jbmr.1998.13.7.1124
   Hannon R, 2000, OSTEOPOROSIS INT, V11, P30, DOI 10.1007/s001980070004
   Ingle BM, 1999, OSTEOPOROSIS INT, V10, P408, DOI 10.1007/s001980050247
   Jacques RM, 2012, J BONE MINER RES, V27, P1627, DOI 10.1002/jbmr.1644
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Miller PD, 2008, CURR MED RES OPIN, V24, P207, DOI 10.1185/030079908X253889
   Naylor K, 2012, NAT REV RHEUMATOL, V8, P379, DOI 10.1038/nrrheum.2012.86
   Paggiosi MA, 2014, OSTEOPOROSIS INT, V25, P2729, DOI 10.1007/s00198 014 2817 z
   Reginster JY, 2000, OSTEOPOROSIS INT, V11, P83, DOI 10.1007/s001980050010
   Rogers A, 2009, BONE, V45, P1044, DOI 10.1016/j.bone.2009.07.089
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2006, ANN NY ACAD SCI, V1068, P367, DOI 10.1196/annals.1346.041
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   Vasikaran S, 2011, CLIN CHEM LAB MED, V49, P1271, DOI 10.1515/CCLM.2011.602
   Vasikaran SD, 2008, CRIT REV CL LAB SCI, V45, P221, DOI [10.1080/10408360801949442, 10.1080/10408360801949442 ]
NR 37
TC 124
Z9 139
U1 1
U2 12
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JAN
PY 2016
VL 27
IS 1
BP 21
EP 31
DI 10.1007/s00198 015 3145 7
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DC9FC
UT WOS:000369525500003
PM 25990354
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nabil, H
   Kummu, O
   Lehenkari, P
   Rysä, J
   Risteli, J
   Hakkola, J
   Hukkanen, J
AF Nabil, Heba
   Kummu, Outi
   Lehenkari, Petri
   Rysa, Jaana
   Risteli, Juha
   Hakkola, Jukka
   Hukkanen, Janne
TI Rifampicin induces the bone form of alkaline phosphatase in humans
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE alkaline phosphatase; bone; pregnane X receptor; pregnenolone 16&#945;
   &#8208; carbonitrile; rifampicin
ID PREGNANE X RECEPTOR; XENOBIOTIC RECEPTOR; GENE EXPRESSION; AORTIC
   CALCIFICATION; CYP24 EXPRESSION; MESSENGER RNA; INDUCTION; HORMONE;
   CELLS; HEPATITIS
AB Pregnane X receptor (PXR) is a xenobiotic sensing nuclear receptor that regulates drug metabolism in the liver and intestine. In our clinical trials on healthy volunteers to discover novel metabolic functions of PXR activation, we observed that rifampicin, a well established ligand for human PXR, 600 mg daily for a week, increased the plasma alkaline phosphatase (ALP) significantly compared with the placebo. Further analysis with lectin affinity electrophoresis revealed that especially the bone form of ALP was elevated. To investigate the mechanism(s) of bone ALP induction, we employed osteoblast lineage differentiated from human primary bone marrow derived mesenchymal stromal cells. Rifampicin treatment increased ALP activity and mRNA level of bone biomarker genes (ALP, MGP, OPN and OPG). PXR expression was detected in the cells, but the expression was very low compared with the human liver. To further investigate the potential role of PXR in the ALP induction, we treated mice and rats with a rodent PXR ligand pregnenolone 16 alpha carbonitrile (PCN). However, PCN treatment did not increase plasma ALP activity or bone ALP mRNA expression. In conclusion, rifampicin treatment induces the bone form of ALP in the serum of healthy human volunteers. Further studies are required to establish the mechanism of this novel finding.
C1 [Nabil, Heba; Kummu, Outi; Hakkola, Jukka] Univ Oulu, Res Unit Biomed, Oulu, Finland.
   [Nabil, Heba; Kummu, Outi; Lehenkari, Petri; Risteli, Juha; Hakkola, Jukka; Hukkanen, Janne] Univ Oulu, Med Res Ctr Oulu, Oulu, Finland.
   [Nabil, Heba; Kummu, Outi; Lehenkari, Petri; Risteli, Juha; Hakkola, Jukka; Hukkanen, Janne] Oulu Univ Hosp, Oulu, Finland.
   [Nabil, Heba; Kummu, Outi; Hakkola, Jukka; Hukkanen, Janne] Univ Oulu, Bioctr Oulu, Oulu, Finland.
   [Lehenkari, Petri; Risteli, Juha] Univ Oulu, Canc Res & Translat Med Res Unit, Oulu, Finland.
   [Rysa, Jaana] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland.
   [Risteli, Juha] Oulu Univ Hosp, Nordlab, Oulu, Finland.
   [Hukkanen, Janne] Univ Oulu, Res Unit Internal Med, POB 5000, FI 90014 Oulu, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; University of Oulu; University of Eastern Finland; University
   of Oulu; University of Oulu
RP Hukkanen, J (通讯作者)，Univ Oulu, Res Unit Internal Med, POB 5000, FI 90014 Oulu, Finland.
EM janne.hukkanen@oulu.fi
RI ; Hukkanen, Janne/C 7292 2013; Lehenkari, Petri/O 3009 2016
OI Kummu, Outi/0000 0003 0327 3496; Hukkanen, Janne/0000 0003 4981 0525;
   Hakkola, Jukka/0000 0001 5048 4363; Abdelfattah, Heba
   Nabil/0000 0003 3850 5488
FU Finnish Medical Foundation; Sydantutkimussaatio; Diabetestutkimussaatio;
   Pohjois Suomen Terveydenhuollon Tukisaatio
FX The Finnish Medical Foundation supported the research;
   Sydantutkimussaatio; Diabetestutkimussaatio; Pohjois Suomen
   Terveydenhuollon Tukisaatio
CR [Anonymous], 2012, Clinical and Research Information on Drug Induced Liver Injury Internet PubMed Internet
   Azuma K, 2010, J ENDOCRINOL, V207, P257, DOI 10.1677/JOE 10 0208
   Bervoets ARJ, 2003, AM J KIDNEY DIS, V41, P997, DOI 10.1016/S0272 6386(03)00197 5
   Bilski J, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9074601
   Cheung CL, 2013, J CLIN ENDOCR METAB, V98, P3856, DOI 10.1210/jc.2013 2024
   Das B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004912
   Diczfalusy U, 2011, BRIT J CLIN PHARMACO, V71, P183, DOI 10.1111/j.1365 2125.2010.03773.x
   Drechsler C, 2011, CLIN J AM SOC NEPHRO, V6, P1752, DOI 10.2215/CJN.10091110
   Fawley J, 2016, J SURG RES, V202, P225, DOI 10.1016/j.jss.2015.12.008
   HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009 8981(90)90031 M
   Hassani Nezhad Gashti F, 2020, CLIN PHARMACOL THER, V108, P856, DOI 10.1002/cpt.1871
   Hassani Nezhad Gashti F, 2018, BIOCHEM PHARMACOL, V148, P253, DOI 10.1016/j.bcp.2018.01.001
   Hautajärvi H, 2018, J CHROMATOGR B, V1100, P179, DOI 10.1016/j.jchromb.2018.09.028
   Holick MF, 2005, J CLIN INVEST, V115, P32, DOI 10.1172/JCI200523995
   Hossain A, 2008, CELL IMMUNOL, V253, P66, DOI 10.1016/j.cellimm.2008.05.001
   Hui M, 1997, CALCIFIED TISSUE INT, V60, P467, DOI 10.1007/s002239900264
   Hukkanen J, 2015, J PHYSIOL PHARMACOL, V66, P831
   Hukkanen J, 2012, EXPERT REV CLIN PHAR, V5, P569, DOI [10.1586/ecp.12.39, 10.1586/ECP.12.39]
   Iba K, 2004, J BONE MINER METAB, V22, P594, DOI 10.1007/s00774 004 0528 9
   Isefuku S, 2001, J ORTHOP RES, V19, P950, DOI 10.1016/S0736 0266(01)00022 5
   Ito Kunihiko, 2016, Kekkaku, V91, P509
   Johnson K, 2005, ARTERIOSCL THROM VAS, V25, P686, DOI 10.1161/01.ATV.0000154774.71187.f0
   KASONO K, 1988, BONE MINER, V4, P355
   Kim JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071417
   Krishnamoorthy G, 2009, INDIAN J PEDIATR, V76, P377, DOI 10.1007/s12098 009 0005 5
   KYEYUNENYOMBI E, 1991, ARCH BIOCHEM BIOPHYS, V291, P316, DOI 10.1016/0003 9861(91)90141 5
   LeCluyse EL, 2001, CHEM BIOL INTERACT, V134, P283, DOI 10.1016/S0009 2797(01)00163 6
   Leskelä HV, 2003, BIOCHEM BIOPH RES CO, V311, P1008, DOI 10.1016/j.bbrc.2003.10.095
   Leung C, 2016, PEDIATR INFECT DIS J, V35, P822, DOI 10.1097/INF.0000000000001169
   Magnusson P, 1997, J BONE MINER RES, V12, P210, DOI 10.1359/jbmr.1997.12.2.210
   MATSUURA S, 1990, BIOCHEM BIOPH RES CO, V168, P993, DOI 10.1016/0006 291X(90)91127 E
   Miki Y, 2005, MOL CELL ENDOCRINOL, V231, P75, DOI 10.1016/j.mce.2004.12.005
   Mornet E, 2000, HUM MUTAT, V15, P309, DOI 10.1002/(SICI)1098 1004(200004)15:4<309::AID HUMU2>3.0.CO;2 C
   MOSS DW, 1992, CLIN CHEM, V38, P2486
   Narisawa S, 2007, J BONE MINER RES, V22, P1700, DOI 10.1359/JBMR.070714
   Ndrepepa G., 2017, J Lab Precis Med, V2, P83, DOI DOI 10.21037/JLPM.2017.10.02
   NIJHAWAN R, 1990, INT J CLIN PHARM RES, V10, P319
   Okazaki T, 2003, EPILEPSIA, V44, P1128, DOI 10.1046/j.1528 1157.2003.15603.x
   OKESINA AB, 1991, J CLIN PATHOL, V44, P480, DOI 10.1136/jcp.44.6.480
   Orimo H, 2005, BONE, V36, P866, DOI 10.1016/j.bone.2005.02.010
   Orimo H, 2006, NUTR RES, V26, P227, DOI 10.1016/j.nutres.2006.05.004
   Oscarson M, 2007, PHARMACOGENET GENOM, V17, P907, DOI 10.1097/FPC.0b013e3280143dfc
   Pascussi JM, 2005, J CLIN INVEST, V115, P177, DOI 10.1172/JCI200521867
   Prince MI, 2002, GUT, V50, P436, DOI 10.1136/gut.50.3.436
   Rubinacci A, 1991, Minerva Endocrinol, V16, P187
   Rysä J, 2013, CLIN PHARMACOL THER, V93, P556, DOI 10.1038/clpt.2013.48
   Sharma U, 2014, INDIAN J CLIN BIOCHE, V29, P269, DOI 10.1007/s12291 013 0408 y
   Shioi A, 2002, CIRC RES, V91, P9, DOI 10.1161/01.RES.0000026421.61398.F2
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Stanik J, 2019, HORM RES PAEDIAT, V91, P1, DOI 10.1159/000497113
   STEELE MA, 1991, CHEST, V99, P465, DOI 10.1378/chest.99.2.465
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Tabb MM, 2003, J BIOL CHEM, V278, P43919, DOI 10.1074/jbc.M303136200
   Tveden Nyborg P, 2021, BASIC CLIN PHARMACOL, V128, P4, DOI 10.1111/bcpt.13492
   Urena P, 1996, J AM SOC NEPHROL, V7, P506
   Vasikaran S, 2011, OSTEOPOROSIS INT, V22, P391, DOI 10.1007/s00198 010 1501 1
   WEISS MJ, 1988, J BIOL CHEM, V263, P12002
   Xing YQ, 2020, ACTA PHARMACOL SIN B, V10, P197, DOI 10.1016/j.apsb.2019.06.012
   Xu Y, 2006, MOL PHARMACOL, V69, P56, DOI 10.1124/mol.105.017392
   Yang JH, 2010, CELL BIOCHEM FUNCT, V28, P334, DOI 10.1002/cbf.1668
   Yu ZQ, 2019, J BONE MINER METAB, V37, P944, DOI 10.1007/s00774 019 01001 3
   Zhou CC, 2006, J CLIN INVEST, V116, P1703, DOI 10.1172/JCI27793
NR 62
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1742 7835
EI 1742 7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD JAN
PY 2022
VL 130
SU 1
SI SI
BP 81
EP 94
DI 10.1111/bcpt.13586
EA MAY 2021
PG 14
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA XW2JE
UT WOS:000647836100001
PM 33851518
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Li, YT
   Li, N
   Zhao, XJ
   Zhang, B
   Yang, LL
   Liu, JJ
   Snooks, H
   Hu, CL
   Ma, XQ
AF Li, Yanting
   Li, Nan
   Zhao, Xiaojun
   Zhang, Bo
   Yang, Lingling
   Liu, Jingjing
   Snooks, Hunter
   Hu, Changling
   Ma, Xueqin
TI Beneficial effect of 2′ acetylacteoside on ovariectomized mice via
   modulating the function of bone resorption
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE 2 ' Acetylacteoside; Ovariectomized mice; Anti osteoporotic; RANK; TRAF6
ID NF KAPPA B; Y. C. MA; PHENYLETHANOID GLYCOSIDES; OSTEOPOROSIS;
   OSTEOCLAST; DIFFERENTIATION; ECHINACOSIDE; PREVENTION; INDUCTION;
   STRENGTH
AB 2' Acetylacteoside (2' AA), a bioactive constituent isolated from Cistanche deserticola, has been proven to possess a variety of important pharmacological effects, thus brought an increased amount of scientists' attention. As the extract of C. deserticola exhibited significant anti osteoporotic bioactivity in our previous study, we proposed that 2' AA maybe one of the responsibilities. As a result, 2' AA (10, 20 and 40 mg/kg body weight/day) exhibited significant anti osteoporotic effects on ovariectomized (OVX) mice after 12 weeks of oral administration, confirmed by the increased bone mineral density, enhanced bone strength and improved trabecular bone micro architecture including bone mineral content, tissue mineral content, trabecular number, and trabecular separation of OVX mice. Moreover, the properties of bone resorption markers including cathepsin K, TRAP and deoxypyridinoline were significantly suppressed, whereas the activities of bone formation index like ALP and BGP as well as the weights of the body, uterus, and vagina were seemingly not influenced by 2' AA intervention. Mechanistically, the above therapeutic effect of 2' AA on bone resorption of OVX mice operated maybe mainly through RANKL/RANK/TRAF6 mediated NF kappa B/NFATc1 pathway, which was confirmed by the down regulated expressions of RANK, TRAF6, I kappa B kinase beta, NF kappa B and NFATc1. Summarily, 2' AA exhibited significant antiosteoporotic activity and may be regarded as a promising anti osteoporotic candidate for future clinical trial.
C1 [Li, Yanting; Li, Nan; Zhao, Xiaojun; Zhang, Bo; Yang, Lingling; Liu, Jingjing; Ma, Xueqin] Ningxia Med Univ, Sch Pharm, Dept Pharmaceut Anal, Key Lab Hui Ethn Med Modernizat,Minist Educ, 1160 Shenli St, Yinchuan 750004, Ningxia, Peoples R China.
   [Snooks, Hunter; Hu, Changling] North Caroline A&T State Univ, Ctr Excellence Post Harvest Technol, Lab Funct Foods & Human Hlth, North Carolina Res Campus,500 Laureate Way, Kannapolis, NC 28081 USA.
C3 Ningxia Medical University
RP Ma, XQ (通讯作者)，Ningxia Med Univ, Sch Pharm, Dept Pharmaceut Anal, Key Lab Hui Ethn Med Modernizat,Minist Educ, 1160 Shenli St, Yinchuan 750004, Ningxia, Peoples R China.
EM maxueqin217@126.com
RI ; ma, xueqin/GWR 0125 2022; li, yanting/KJM 1976 2024; Hu,
   Changling/P 7012 2019
OI ma, Xueqin/0000 0003 4818 5967; 
FU National Natural Science Foundation of China [81860753, 81560684];
   Ningxia Natural Science Foundation [2019AAC03084]; Ningxia key research
   and invention program of science and technology cooperation of the East
   and the West [2017BY084, 2017BY079]; West Light Foundation of the
   Chinese Academy of Sciences Young Scientists of West 2017
FX This work was supported by the National Natural Science Foundation of
   China (No. 81860753, 81560684), Ningxia Natural Science Foundation (No.
   2019AAC03084), Ningxia key research and invention program of science and
   technology cooperation of the East and the West (No. 2017BY084,
   2017BY079), the West Light Foundation of the Chinese Academy of
   Sciences Young Scientists of West 2017.
CR Banu J, 2012, NUTR REV, V70, P22, DOI 10.1111/j.1753 4887.2011.00451.x
   De Lima C.G.G.A. Rachel, 2018, J ETHNOPHARMACOL, V224
   EINHORN TA, 1992, CALCIFIED TISSUE INT, V51, P333, DOI 10.1007/BF00316875
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gao YQ, 2017, DRUG CHEM TOXICOL, V40, P383, DOI 10.1080/01480545.2016.1242013
   He JB, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 016 0301 4
   Hu Xiao, 2014, Zhongguo Zhong Yao Za Zhi, V39, P1630
   Jolly JJ, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050963
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P737, DOI 10.1007/s00198 004 1734 y
   Kleerekoper M, 2006, OSTEOPOROSIS INT, V17, P1707, DOI 10.1007/s00198 006 0187 x
   Lee H., 2020, INT J MOL SCI, V21
   Li F, 2013, PHYTOMEDICINE, V20, P549, DOI 10.1016/j.phymed.2013.01.001
   Li Y, 2016, J PHARMACEUT BIOMED, V118, P167, DOI 10.1016/j.jpba.2015.10.038
   Liu JJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23051213
   Liu JJ, 2018, PHYTOMEDICINE, V42, P43, DOI 10.1016/j.phymed.2018.03.020
   Lomaga M.A., 1999, GENES DEV, V13
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Morikawa T, 2014, J NAT MED TOKYO, V68, P561, DOI 10.1007/s11418 014 0837 9
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Park CK, 2008, BIOCHEM PHARMACOL, V75, P2175, DOI 10.1016/j.bcp.2008.03.007
   Park K, 2014, INT J MOL MED, V33, P178, DOI 10.3892/ijmm.2013.1557
   Peng F, 2016, CHEM PHARM BULL, V64, P1024, DOI 10.1248/cpb.c16 00033
   Pharmacopoeia, 2015, ED COMM CHIN PHARM P, P178
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Rufus P, 2013, CURR DRUG TARGETS, V14, P1689, DOI 10.2174/1389450114666131220160357
   Soysa Niroshani Surangika, 2012, J Med Dent Sci, V59, P65
   Süntar I, 2013, CURR DRUG TARGETS, V14, P1611
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753
   van den Bergh J.P., 2012, NAT REV RHEUMATOL, V8, P163
   Wang T, 2012, AM J CHINESE MED, V40, P1123, DOI 10.1142/S0192415X12500838
   Yang L, 2019, INT J MOL SCI, V20, P12, DOI [10.3390/ijms20030569, DOI 10.3390/IJMS20030569]
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017
   Zhang B., 2019, FRONT PHARM, V10
   Zhang L, 2016, TROP J PHARM RES, V15, P1929, DOI 10.4314/tjpr.v15i9.17
   Zhao H., 2018, J IMMUNOL RES, V2018, P1, DOI DOI 10.1109/TMC.2018.2873015
   Zhao X, 2011, J ETHNOPHARMACOL, V137, P1083, DOI 10.1016/j.jep.2011.07.017
NR 40
TC 8
Z9 9
U1 1
U2 9
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD NOV
PY 2020
VL 131
AR 110747
DI 10.1016/j.biopha.2020.110747
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH6KI
UT WOS:000582699600112
PM 32932047
OA gold
DA 2025 08 17
ER

PT J
AU Zhu, SY
   Wang, PL
   Liao, CS
   Yang, YQ
   Yuan, CY
   Wang, S
   Dissanayaka, WL
   Heng, BC
   Zhang, CF
AF Zhu, S. Y.
   Wang, P. L.
   Liao, C. S.
   Yang, Y. Q.
   Yuan, C. Y.
   Wang, S.
   Dissanayaka, W. L.
   Heng, B. C.
   Zhang, C. F.
TI Transgenic expression of ephrinB2 in periodontal ligament stem cells
   (PDLSCs) modulates osteogenic differentiation via signaling crosstalk
   between ephrinB2 and EphB4 in PDLSCs and between PDLSCs and
   pre osteoblasts within co culture
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE co culture; ephrinB2; EphB4 signaling; osteoblasts; osteogenic
   differentiation; periodontal ligament stem cells
ID DEPENDENT UP REGULATION; REGENERATION; FIBROBLASTS; MINERALIZATION;
   ACTIVATION; DISEASE; TISSUES; TUMOR
AB Background and ObjectiveThe goal of periodontal therapy is to regenerate/reconstruct the damaged supporting tissues of diseased teeth and to facilitate recovery of their physiological functions. Combination of stem cell transplantation and gene therapy offers a viable method for accelerating periodontal repair and regeneration. In this study, the role of the ephrinB2/EphB4 signaling pathway in regulating osteogenic differentiation of periodontal ligament stem cells (PDLSCs) and crosstalk between PDLSCs and pre osteoblasts within co culture was investigated through ephrinB2 transgenic expression in PDLSCs.
   Material and MethodsPDLSCs isolated from premolar teeth of teenage patients undergoing orthodontic treatment were transfected with transgenic (hEfnB2 GFP Bsd) vector or empty vector (GFP Bsd). Vector PDLSCs, EfnB2 PDLSCs, MC3T3 E1 and co cultures of vector PDLSCs with MC3T3 E1, and EfnB2 PDLSCs with MC3T3 E1 were subjected to osteogenic induction. The osteogenic differentiation of EfnB2 PDLSCs, vector PDLSCs and co cultures were assessed by reverse transcription polymerase chain reaction, alkaline phosphatase (ALP) assay and Alizarin red S staining. Protein expression levels of ephrinB2, EphB4, phosphorylated ephrinB2 and EphB4 were analyzed by western blot, immunoprecipitation and co immunoprecipitation assays.
   ResultsALP assay and Alizarin red S staining demonstrated higher ALP activity and increased mineralization with EfnB2 PDLSCs vs. vector PDLSCs and with co culture of EfnB2 PDLSCs and MC3T3 E1 vs. vector PDLSCs and MC3T3 E1. Reverse transcription polymerase chain reaction revealed that the expression of human odonto/osteogenic markers were significantly enhanced in EfnB2 PDLSCs compared to vector PDLSCs, and that the expression of mouse odonto/osteogenic markers were significantly higher in co culture of EfnB2 PDLSCs with MC3T3 E1 vs. vector PDLSCs with MC3T3 E1. The EphB4 receptor was activated through phosphorylation during osteogenic differentiation.
   ConclusionOur data indicate that transgenic expression of ephrinB2 in PDLSCs could promote osteogenic differentiation via stimulation of the phosphorylation of ephrinB2 and EphB4, which regulates cell communication between PDLSCs and between PDLSCs and pre osteoblasts within co culture.
C1 [Zhu, S. Y.; Yuan, C. Y.; Wang, S.; Dissanayaka, W. L.; Heng, B. C.; Zhang, C. F.] Univ Hong Kong, Endodontol, Fac Dent, Pokfulam, Hong Kong, Peoples R China.
   [Zhu, S. Y.; Zhang, C. F.] HKU Shenzhen Inst Res & Innovat, Hong Kong, Peoples R China.
   [Zhu, S. Y.; Wang, P. L.] Xuzhou Stomatol Hosp, Dent Implant Ctr, Xuzhou, Peoples R China.
   [Liao, C. S.; Yang, Y. Q.] Univ Hong Kong, Orthodont, Fac Dent, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; The University of Hong
   Kong Shenzhen Institute of Research & Innovation; University of Hong
   Kong
RP Zhang, CF (通讯作者)，Univ Hong Kong Hosp, Fac Dent, Endodontol, Floor 3A,34 Hosp Rd, Sai Ying Pun, Hong Kong, Peoples R China.
EM zhangcf@hku.hk
RI ; wang, shuai/AEK 5112 2022; Yuan, Changyong/AAN 8724 2020; Heng,
   Boon/E 5462 2016; Dissanayaka, Waruna/K 1850 2016
OI Heng, Boon Chin/0000 0003 2541 3699; Wang, Shuai/0000 0002 2666 5233;
   Liao, Chongshan/0000 0001 7494 5515; Dissanayaka,
   Waruna/0000 0002 3621 4866
FU National Nature Science Foundation of China [81470735]
FX This work was supported by a grant from the National Nature Science
   Foundation of China (81470735) to C. Zhang.
CR Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466
   Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324
   Arthur A, 2009, J DENT RES, V88, P829, DOI 10.1177/0022034509342363
   Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180
   Bassir SH, 2016, J CELL PHYSIOL, V231, P50, DOI 10.1002/jcp.25067
   Chen FM, 2012, BIOMATERIALS, V33, P6320, DOI 10.1016/j.biomaterials.2012.05.048
   Chen R, 2008, J PERIODONTAL RES, V43, P237, DOI 10.1111/j.1600 0765.2007.01021.x
   Chen Y, 2016, J DENT RES, V95, P302, DOI 10.1177/0022034515610768
   Desvarieux M, 2003, STROKE, V34, P2120, DOI 10.1161/01.STR.0000085086.50957.22
   Diercke K, 2011, J DENT RES, V90, P1108, DOI 10.1177/0022034511413926
   Diercke K, 2011, J BIOL CHEM, V286, P37651, DOI 10.1074/jbc.M110.166900
   Evans CH, 2015, NAT REV RHEUMATOL, V11, P234, DOI 10.1038/nrrheum.2015.28
   Han J, 2014, J PERIODONTAL RES, V49, P333, DOI 10.1111/jre.12111
   Hou JH, 2014, KOREAN J ORTHOD, V44, P320, DOI 10.4041/kjod.2014.44.6.320
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Jung IH, 2014, TISSUE ENG PT A, V20, P2189, DOI [10.1089/ten.TEA.2013.0648, 10.1089/ten.tea.2013.0648]
   Kim I, 2002, FASEB J, V16, P1126, DOI 10.1096/fj.01 0805fje
   Kook SH, 2009, J CELL BIOCHEM, V106, P1060, DOI 10.1002/jcb.22085
   Lin Z, 2015, J PERIODONTOL, V86, pS134, DOI 10.1902/jop.2015.130689
   Mundy GR, 2006, CELL, V126, P441, DOI 10.1016/j.cell.2006.07.015
   Park JY, 2011, CELL TRANSPLANT, V20, P271, DOI 10.3727/096368910X519292
   Park JC, 2011, J CLIN PERIODONTOL, V38, P721, DOI 10.1111/j.1600 051X.2011.01716.x
   Park SY, 2015, TISSUE ENG PT A, V21, P451, DOI [10.1089/ten.tea.2014.0156, 10.1089/ten.TEA.2014.0156]
   Pennisi A, 2009, BLOOD, V114, P1803, DOI 10.1182/blood 2009 01 201954
   Reynolds MA, 2015, J PERIODONTOL, V86, pS105, DOI 10.1902/jop.2015.140378
   Sculean A, 2008, J CLIN PERIODONTOL, V35, P106, DOI 10.1111/j.1600 051X.2008.01263.x
   Sims NA, 2014, ARCH BIOCHEM BIOPHYS, V561, P22, DOI 10.1016/j.abb.2014.05.015
   Su F, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0023 3
   Takyar FM, 2013, J BONE MINER RES, V28, P912, DOI 10.1002/jbmr.1820
   Tierney EG, 2013, J CONTROL RELEASE, V165, P173, DOI 10.1016/j.jconrel.2012.11.013
   Tonna S, 2014, FASEB J, V28, P4482, DOI 10.1096/fj.14 254300
   Wang Hom Lay, 2005, Dent Clin North Am, V49, P637, DOI 10.1016/j.cden.2005.03.004
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 33
TC 22
Z9 25
U1 4
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JUN
PY 2017
VL 52
IS 3
BP 562
EP 573
DI 10.1111/jre.12424
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ET0MC
UT WOS:000399955500029
PM 27763659
DA 2025 08 17
ER

PT J
AU Williams, DF
AF Williams, David F.
TI Biocompatibility Pathways: Biomaterials Induced Sterile Inflammation,
   Mechanotransduction, and Principles of Biocompatibility Control
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE inflammasome; fibrosis; damage associated molecular patterns; medical
   devices; tissue engineering; nanotoxicology
ID POSTERIOR CAPSULAR OPACIFICATION; BONE MORPHOGENETIC PROTEIN 2;
   CATHETER RELATED THROMBOSIS; NLRP3 INFLAMMASOME; LEARNING CURVE;
   OSTEOBLAST DIFFERENTIATION; FIBRONECTIN ADSORPTION; SURFACE CHEMISTRY;
   TITANIUM IMPLANTS; STENT THROMBOSIS
AB This paper addresses a significant paradox in biomaterials science; biocompatibility phenomena have been experienced and described for over 50 years but without an agreed understanding of the framework of mechanisms that control the events that occur when a biomaterial is exposed to the tissues of the human body. The need for such an understanding has become more urgent as biomaterials are now used in wide ranging applications such as tissue engineering, drug and gene delivery, and imaging contrast agents. A detailed analysis of these phenomena, especially in terms of clinical outcomes rather than in vitro experiments, determines that two overarching mechanisms, mechanotransduction and sterile inflammation associated with damage associated molecular patterns, are responsible for the vast majority of phenomena. In contrast, interfacial interactions, for so long being assumed to play pivotal roles in biocompatibility, especially relating to protein adsorption, are actually relatively unimportant unless, through conformational changes, they are able to participate in 3D ECM development. Critical to this new view of biocompatibility is the fact that the combination of mechanotransduction and sterile inflammation, especially focusing on inflammasome activation and the immunology of the balance between inflammation and fibrosis, allows biomaterials science to encompass mechanisms of innate and adaptive immunity without recourse to the traditional implications of pathogen induced responses of the immune system. In this way, a system of biocompatibility pathways can be generated; these are able to explain a wide range of clinical biocompatibility challenges, including nanoparticle translocation and internalization, intraocular lens opacification, leukocyte dominated responses to metallic wear debris in joint replacement, stem cell differentiation of nanostructured hydrogels, tissue responses to incontinence meshes, and restenosis of intravascular stents. Perhaps even more importantly, the identification of these molecular pathways of biocompatibility offers prospects of the control of the host response by targeting specific points in these pathways, for example the inhibition of epithelial to mesenchymal transformation that can result in excessive fibrosis, and the inhibition of activation of the NLRP3 inflammasome following exposure to biomaterial induced stresses; this should lead to a more effective translation of biocompatibility understanding into better clinical outcomes.
C1 [Williams, David F.] Wake Forest Inst Regenerat Med, Richard H Dean Biomed Bldg,391 Technol Way, Winston Salem, NC 27101 USA.
C3 Wake Forest University
RP Williams, DF (通讯作者)，Wake Forest Inst Regenerat Med, Richard H Dean Biomed Bldg,391 Technol Way, Winston Salem, NC 27101 USA.
EM dfwillia@wakehealth.edu
CR Albrektsson T O, 1994, Periodontol 2000, V4, P58, DOI 10.1111/j.1600 0757.1994.tb00006.x
   Almany L, 2005, BIOMATERIALS, V26, P2467, DOI 10.1016/j.biomaterials.2004.06.047
   Ambesi A, 2014, J CELL SCI, V127, P3805, DOI 10.1242/jcs.150458
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Anderson J, 2011, SEMIN IMMUNOPATHOL, V33, P221, DOI 10.1007/s00281 011 0244 1
   Andorko JI, 2016, ACTA BIOMATER, V32, P24, DOI 10.1016/j.actbio.2015.12.026
   Andrade J D, 1973, Med Instrum, V7, P110
   ANDRADE JD, 1986, ADV POLYM SCI, V79, P1
   Antoniou SA, 2011, SURG LAPARO ENDO PER, V21, P1, DOI 10.1097/SLE.0b013e31820ad56c
   Awasthi N, 2009, ARCH OPHTHALMOL CHIC, V127, P555, DOI 10.1001/archophthalmol.2009.3
   Axelrad TW, 2009, CYTOKINE GROWTH F R, V20, P481, DOI 10.1016/j.cytogfr.2009.10.003
   Baier R E, 1969, J Biomed Mater Res, V3, P191, DOI 10.1002/jbm.820030115
   Bar Meir E, 2003, AUTOIMMUNITY, V36, P193, DOI 10.1080/08916931000148818
   Baujard Lamotte L, 2008, COLLOID SURFACE B, V63, P129, DOI 10.1016/j.colsurfb.2007.11.015
   Belmont PJ, 2014, J BONE JOINT SURG AM, V96A, P20, DOI 10.2106/JBJS.M.00018
   Berk BC, 2008, CIRCULATION, V117, P1082, DOI 10.1161/CIRCULATIONAHA.107.720730
   Beykal B, 2015, J COLLOID INTERF SCI, V460, P321, DOI 10.1016/j.jcis.2015.08.055
   Biggs MJP, 2010, NANOMED NANOTECHNOL, V6, P619, DOI 10.1016/j.nano.2010.01.009
   Boekhoven J, 2014, ADV MATER, V26, P1642, DOI 10.1002/adma.201304606
   Boerckel JD, 2011, BIOMATERIALS, V32, P5241, DOI 10.1016/j.biomaterials.2011.03.063
   BOSTMAN OM, 1992, CLIN ORTHOP RELAT R, P193, DOI 10.1097/00003086 199205000 00031
   Bozukova D, 2010, MAT SCI ENG R, V69, P63, DOI 10.1016/j.mser.2010.05.002
   BRASH JL, 1979, J POLYM SCI POL SYM, P377
   Brevig T, 2005, BIOMATERIALS, V26, P3039, DOI 10.1016/j.biomaterials.2004.09.006
   Brown BN, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.08.002
   Brun P, 2013, ACTA BIOMATER, V9, P6105, DOI 10.1016/j.actbio.2012.12.018
   Bueter CL, 2014, J IMMUNOL, V192, P5943, DOI 10.4049/jimmunol.1301695
   Byrne RA, 2015, EUR HEART J, V36, P3320, DOI 10.1093/eurheartj/ehv511
   Castillo Alesha B, 2010, Curr Osteoporos Rep, V8, P98, DOI 10.1007/s11914 010 0015 2
   Chakravorty N, 2012, ACTA BIOMATER, V8, P3516, DOI 10.1016/j.actbio.2012.05.008
   Champion JA, 2008, PHARM RES DORDR, V25, P1815, DOI 10.1007/s11095 008 9562 y
   Champion JA, 2009, PHARM RES DORDR, V26, P244, DOI 10.1007/s11095 008 9626 z
   Chatakun P, 2014, CELL MOL LIFE SCI, V71, P113, DOI 10.1007/s00018 013 1326 0
   Chaudhuri O, 2007, NATURE, V445, P295, DOI 10.1038/nature05459
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Chen HY, 2011, AM J PHYSIOL HEART C, V301, pH2254, DOI 10.1152/ajpheart.00240.2011
   Chen JN, 2013, J MECH BEHAV BIOMED, V20, P387, DOI 10.1016/j.jmbbm.2012.08.019
   Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009
   Chlupác J, 2014, PHYSIOL RES, V63, P167, DOI 10.33549/physiolres.932577
   Chrcanovic BR, 2016, J ORAL REHABIL, V43, P716, DOI 10.1111/joor.12415
   Christo SN, 2016, SCI REP UK, V6, DOI 10.1038/srep20635
   CLARK GCF, 1982, J BIOMED MATER RES, V16, P125, DOI 10.1002/jbm.820160205
   Collins C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4984
   Corbo C, 2016, NANOMEDICINE UK, V11, P81, DOI 10.2217/nnm.15.188
   Cosemans JMEM, 2013, CARDIOVASC RES, V99, P342, DOI 10.1093/cvr/cvt110
   Costa MA, 2005, CIRCULATION, V111, P2257, DOI 10.1161/01.CIR.0000163587.36485.A7
   Cox A, 2013, NAT REV UROL, V10, P78, DOI 10.1038/nrurol.2012.243
   Daemen J, 2007, CIRCULATION, V116, P316, DOI 10.1161/CIRCULATIONAHA.106.621342
   Daly KA, 2012, BIOMATERIALS, V33, P91, DOI 10.1016/j.biomaterials.2011.09.040
   Daniel J, 2012, J BONE JOINT SURG AM, V94A, P86, DOI 10.2106/JBJS.J.01612
   Darby IA, 2014, CLIN COSMET INV DERM, V7, P301, DOI 10.2147/CCID.S50046
   Das RK, 2014, BIOMATERIALS, V35, P5278, DOI 10.1016/j.biomaterials.2014.03.044
   Das RK, 2013, ACS NANO, V7, P3351, DOI 10.1021/nn4001325
   Davies PF, 2013, CARDIOVASC RES, V99, P315, DOI 10.1093/cvr/cvt101
   Deerenberg EB, 2015, HERNIA, V19, P89, DOI 10.1007/s10029 014 1321 x
   Delaunay C, 2010, ORTHOP TRAUMATOL SUR, V96, P894, DOI 10.1016/j.otsr.2010.05.008
   Delgado Calle J, 2014, CALCIFIED TISSUE INT, V94, P414, DOI 10.1007/s00223 013 9821 8
   Dennis AM, 2016, J PHYS CHEM LETT, V7, P2139, DOI 10.1021/acs.jpclett.6b00570
   Deschaseaux F, 2009, TRENDS MOL MED, V15, P417, DOI 10.1016/j.molmed.2009.07.002
   Di Cio S, 2016, ACTA BIOMATER, V30, P26, DOI 10.1016/j.actbio.2015.11.027
   Dmitriev AE, 2011, SPINE J, V11, P500, DOI 10.1016/j.spinee.2011.05.002
   Donati M, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003791
   Doshi N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010051
   Duncan R, 2013, ADV DRUG DELIVER REV, V65, P60, DOI 10.1016/j.addr.2012.08.012
   Ebo DG, 2006, ALLERGY, V61, P211, DOI 10.1111/j.1398 9995.2006.00982.x
   Egeberg A, 2016, ANN PLAS SURG, V77, P255, DOI 10.1097/SAP.0000000000000227
   Ereifej ES, 2013, J NEUROSCI METH, V217, P17, DOI 10.1016/j.jneumeth.2013.04.023
   Fairweather D, 2014, CLIN MED INSIGHTS CA, V8, P49, DOI 10.4137/CMC.S17068
   Fang RNH, 2016, ANNU REV CHEM BIOMOL, V7, P305, DOI 10.1146/annurev chembioeng 080615 034446
   Faundez A, 2016, INT ORTHOP, V40, P1309, DOI 10.1007/s00264 016 3149 8
   Fedorchak GR, 2014, PROG BIOPHYS MOL BIO, V115, P76, DOI 10.1016/j.pbiomolbio.2014.06.009
   Feldman N, 2015, AGEING RES REV, V24, P29, DOI 10.1016/j.arr.2015.01.003
   Fenoglio I, 2011, ADV DRUG DELIVER REV, V63, P1186, DOI 10.1016/j.addr.2011.08.001
   Fitts Michelle K, 2014, Open Urol Nephrol J, V7, P33
   Fox CS, 2015, J CARDIAC SURG, V30, P856, DOI 10.1111/jocs.12644
   Galili U, 2015, TISSUE ENG PART B RE, V21, P231, DOI [10.1089/ten.teb.2014.0392, 10.1089/ten.TEB.2014.0392]
   Gallo J, 2013, INNATE IMMUN LONDON, V19, P213, DOI 10.1177/1753425912451779
   Gámez B, 2014, J MOL ENDOCRINOL, V52, pR179, DOI 10.1530/JME 13 0294
   García AJ, 2005, BIOMATERIALS, V26, P7525, DOI 10.1016/j.biomaterials.2005.05.029
   García AJ, 2006, ADV POLYM SCI, P171, DOI 10.1007/12_071
   Gentleman MM, 2014, INT MATER REV, V59, P417, DOI 10.1179/1743280414Y.0000000038
   Ghosh S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2794
   Giger EV, 2013, J CONTROL RELEASE, V167, P175, DOI 10.1016/j.jconrel.2013.01.032
   Gill HS, 2012, TRENDS MOL MED, V18, P145, DOI 10.1016/j.molmed.2011.12.002
   Gingras AR, 2006, BIOCHEMISTRY US, V45, P1805, DOI 10.1021/bi052136l
   Goel SA, 2012, CARDIOVASC RES, V96, P363, DOI 10.1093/cvr/cvs276
   Goh ET, 2015, INT J MOL SCI, V16, P597, DOI 10.3390/ijms16010597
   Goldhahn J, 2012, CALCIFIED TISSUE INT, V90, P343, DOI 10.1007/s00223 012 9587 4
   Gonen Wadmany M, 2007, BIOMATERIALS, V28, P3876, DOI 10.1016/j.biomaterials.2007.05.005
   Gonzalez Rodriguez D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122097
   Gorbet MB, 2004, BIOMATERIALS, V25, P5681, DOI 10.1016/j.biomaterials.2004.01.023
   Goriainov V, 2014, ACTA BIOMATER, V10, P4043, DOI 10.1016/j.actbio.2014.06.004
   Grafahrend D, 2011, NAT MATER, V10, P67, DOI 10.1038/NMAT2904
   Greason KL, 2014, J CARDIAC SURG, V29, P303, DOI 10.1111/jocs.12323
   Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893
   Guo R, 2015, BIOMATERIALS, V73, P85, DOI 10.1016/j.biomaterials.2015.09.005
   Gustafson HH, 2015, NANO TODAY, V10, P487, DOI 10.1016/j.nantod.2015.06.006
   HANEIN D, 1993, LANGMUIR, V9, P1058, DOI 10.1021/la00028a030
   Harmankaya N, 2013, ACTA BIOMATER, V9, P7064, DOI 10.1016/j.actbio.2013.02.040
   Hayden RS, 2014, ADV FUNCT MATER, V24, P472, DOI 10.1002/adfm.201302210
   HAYNES CA, 1994, COLLOID SURFACE B, V2, P517, DOI 10.1016/0927 7765(94)80066 9
   Hazra S, 2012, INT J OPHTHALMOL CHI, V5, P59, DOI 10.3980/j.issn.2222 3959.2012.01.12
   Heuberger MP, 2005, BIOMATERIALS, V26, P1165, DOI 10.1016/j.biomaterials.2004.05.020
   Hielscher A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147600
   Higuchi A, 2014, PROG POLYM SCI, V39, P1348, DOI 10.1016/j.progpolymsci.2014.01.002
   Hirsh SL, 2013, COLLOID SURFACE B, V103, P395, DOI 10.1016/j.colsurfb.2012.10.039
   Hoenich NA, 2002, BIOMATERIALS, V23, P3853, DOI 10.1016/S0142 9612(02)00121 7
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   HORBETT TA, 1982, ADV CHEM SER, P233
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huebsch N, 2010, NAT MATER, V9, P518, DOI [10.1038/nmat2732, 10.1038/NMAT2732]
   HUETZ P, 1995, LANGMUIR, V11, P3145, DOI 10.1021/la00008a046
   Hughes PE, 1996, J BIOMECH, V29, P855, DOI 10.1016/0021 9290(95)00168 9
   HUISKES R, 1992, CLIN ORTHOP RELAT R, P124
   Humphrey JD, 2001, J BIOMECH ENG T ASME, V123, P638, DOI 10.1115/1.1406131
   Hunziker EB, 2012, BONE, V51, P98, DOI 10.1016/j.bone.2012.04.004
   Iskratsch T, 2014, NAT REV MOL CELL BIO, V15, P825, DOI 10.1038/nrm3903
   Jackson SP, 2009, J THROMB HAEMOST, V7, P17, DOI 10.1111/j.1538 7836.2009.03401.x
   Jacobs T, 2012, PLASMA CHEM PLASMA P, V32, P1039, DOI 10.1007/s11090 012 9394 8
   Jaffer IH, 2015, J THROMB HAEMOST, V13, pS72, DOI 10.1111/jth.12961
   Ji W, 2012, BIOMATERIALS, V33, P6604, DOI 10.1016/j.biomaterials.2012.06.018
   Jiang JH, 2016, AM J PATHOL, V186, P57, DOI 10.1016/j.ajpath.2015.09.006
   Jones L, 2013, INVEST OPHTH VIS SCI, V54, P37, DOI 10.1167/iovs.13 13215
   Jukema JW, 2012, NAT REV CARDIOL, V9, P53, DOI 10.1038/nrcardio.2011.132
   Kahraman G, 2014, BRIT J OPHTHALMOL, V98, P905, DOI 10.1136/bjophthalmol 2013 303841
   Kandahari AM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.14
   Karazisis D, 2016, INT J NANOMED, V11, P1367, DOI 10.2147/IJN.S101294
   Kerativitayanan P, 2015, ADV HEALTHC MATER, V4, P1600, DOI 10.1002/adhm.201500272
   Keung AJ, 2011, STEM CELLS, V29, P1886, DOI 10.1002/stem.746
   Killian ML, 2012, J SHOULDER ELB SURG, V21, P228, DOI 10.1016/j.jse.2011.11.002
   Kilpadi KL, 2001, J BIOMED MATER RES, V57, P258, DOI 10.1002/1097 4636(200111)57:2<258::AID JBM1166>3.0.CO;2 R
   Kim MC, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002926
   King WJ, 2012, ADV DRUG DELIVER REV, V64, P1239, DOI 10.1016/j.addr.2012.03.004
   Kissin M, 2000, J VASC SURG, V31, P69, DOI 10.1016/S0741 5214(00)70069 3
   Klein Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013
   Klinge U, 2014, HERNIA, V18, P571, DOI 10.1007/s10029 014 1220 1
   Kohane DS, 2007, BIOTECHNOL BIOENG, V96, P203, DOI 10.1002/bit.21301
   Kohane DS, 2006, J BIOMED MATER RES A, V77A, P351, DOI 10.1002/jbm.a.30654
   Koskinas KC, 2012, J AM COLL CARDIOL, V59, P1337, DOI 10.1016/j.jacc.2011.10.903
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Kusaka T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092634
   Kzhyshkowska J, 2015, J LEUKOCYTE BIOL, V98, P953, DOI 10.1189/jlb.5VMR0415 166R
   Landgraeber S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/185150
   Lara Castillo N, 2015, BONE, V76, P58, DOI 10.1016/j.bone.2015.03.019
   Le Guéhennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Leal Egaña A, 2012, J MATER CHEM, V22, P14330, DOI 10.1039/c2jm31174g
   Lee YK, 2015, INT J NANOMED, V10, P97, DOI 10.2147/IJN.S72998
   Leishman L, 2012, J CATARACT REFR SURG, V38, P1664, DOI 10.1016/j.jcrs.2012.04.040
   Lennerås M, 2015, CLIN IMPLANT DENT R, V17, pE486, DOI 10.1111/cid.12276
   Li BJ, 2015, BIOMATER SCI UK, V3, P73, DOI 10.1039/c3bm60326a
   Li JX, 2014, BIOTECHNOL ADV, V32, P727, DOI 10.1016/j.biotechadv.2013.12.009
   Li WA, 2016, BIOMATERIALS, V83, P249, DOI 10.1016/j.biomaterials.2016.01.026
   Li Y, 2015, NANOSCALE, V7, P2758, DOI 10.1039/c4nr05575f
   Li YSJ, 2005, J BIOMECH, V38, P1949, DOI 10.1016/j.jbiomech.2004.09.030
   Liao CY, 2014, RSC ADV, V4, P15759, DOI 10.1039/c3ra47381c
   Liu PH, 2015, BIOCHEM BIOPH RES CO, V468, P319, DOI 10.1016/j.bbrc.2015.10.105
   Long AT, 2016, J THROMB HAEMOST, V14, P427, DOI 10.1111/jth.13235
   Lozner EL, 1942, J CLIN INVEST, V21, P241, DOI 10.1172/JCI101295
   Lu YH, 2016, BIOMATERIALS, V90, P27, DOI 10.1016/j.biomaterials.2016.03.003
   Luensmann D, 2012, CONTACT LENS ANTERIO, V35, P53, DOI 10.1016/j.clae.2011.12.005
   Lüscher TF, 2007, CIRCULATION, V115, P1051, DOI 10.1161/CIRCULATIONAHA.106.675934
   Luna Gomes T, 2015, IMMUNOBIOLOGY, V220, P1101, DOI 10.1016/j.imbio.2015.05.004
   Lunov O, 2011, ACS NANO, V5, P9648, DOI 10.1021/nn203596e
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Maas C, 2008, J CLIN INVEST, V118, P3208, DOI [10.1172/JC135424, 10.1172/JCI35424]
   Mackenzie H, 2014, SURGERY, V156, P158, DOI 10.1016/j.surg.2014.03.008
   Malik AF, 2011, P NATL ACAD SCI USA, V108, P20095, DOI 10.1073/pnas.1105152108
   MARCUS AJ, 1995, THROMB HAEMOSTASIS, V74, P213
   MARGOLIS J, 1957, J PHYSIOL LONDON, V137, P95, DOI 10.1113/jphysiol.1957.sp005799
   Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006
   Martínez E, 2009, NANOMEDICINE UK, V4, P65, DOI 10.2217/17435889.4.1.65
   Mathieu V, 2014, J BIOMECH, V47, P3, DOI 10.1016/j.jbiomech.2013.09.021
   Matson JB, 2012, CHEM COMMUN, V48, P26, DOI 10.1039/c1cc15551b
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Mauck RL, 2015, ANN BIOMED ENG, V43, P529, DOI 10.1007/s10439 015 1249 z
   Mavrogenis AF, 2009, J MUSCULOSKEL NEURON, V9, P61
   Mazza E, 2015, J MECH BEHAV BIOMED, V48, P100, DOI 10.1016/j.jmbbm.2015.03.023
   Miller CJ, 2013, NAT REV GENET, V14, P733, DOI 10.1038/nrg3513
   Misawa Y, 2015, SURG TODAY, V45, P1205, DOI 10.1007/s00595 014 1104 0
   Mitchell MJ, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00044
   Mori H, 2016, EUR HEART J, V37, P1217, DOI 10.1093/eurheartj/ehw006
   Moshayedi P, 2014, BIOMATERIALS, V35, P3919, DOI 10.1016/j.biomaterials.2014.01.038
   Mosqueira D, 2014, ACS NANO, V8, P2033, DOI 10.1021/nn4058984
   Murphy DA, 2015, TRANSFUS MED REV, V29, P90, DOI 10.1016/j.tmrv.2014.12.001
   Murphy WL, 2014, NAT MATER, V13, P547, DOI [10.1038/NMAT3937, 10.1038/nmat3937]
   Murray J, 2013, BRIT J HAEMATOL, V162, P748, DOI 10.1111/bjh.12474
   Nagel T, 2010, BIOMECH MODEL MECHAN, V9, P359, DOI 10.1007/s10237 009 0182 1
   Nesbitt WS, 2009, NAT MED, V15, P665, DOI 10.1038/nm.1955
   Neth P, 2013, CARDIOVASC RES, V99, P294, DOI 10.1093/cvr/cvt096
   Nibourg LM, 2015, EXP EYE RES, V136, P100, DOI 10.1016/j.exer.2015.03.011
   Nie SQ, 2014, J MATER CHEM B, V2, P4911, DOI 10.1039/c4tb00555d
   Nikolsky E, 2005, AM J CARDIOL, V95, P709, DOI 10.1016/j.amjcard.2004.11.020
   Nunley RM, 2010, CLIN ORTHOP RELAT R, V468, P382, DOI 10.1007/s11999 009 1106 1
   Nygren H, 1997, J BIOMED MATER RES, V34, P487, DOI 10.1002/(SICI)1097 4636(19970315)34:4<487::AID JBM9>3.3.CO;2 6
   Ollerton A, 2012, J CATARACT REFR SURG, V38, P1827, DOI 10.1016/j.jcrs.2012.05.039
   Ong DS, 2015, NAT REV CARDIOL, V12, P325, DOI 10.1038/nrcardio.2015.32
   Ozaki E, 2015, J INFLAMM RES, V8, P15, DOI 10.2147/JIR.S51250
   Pacheco P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060989
   Page JM, 2015, BIOMATERIALS, V64, P33, DOI 10.1016/j.biomaterials.2015.06.026
   Palmieri A, 2007, NANOMED NANOTECHNOL, V3, P138, DOI 10.1016/j.nano.2007.03.004
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Park JW, 2011, ACTA BIOMATER, V7, P3222, DOI 10.1016/j.actbio.2011.04.015
   Park SJ, 2012, J AM COLL CARDIOL, V59, P2051, DOI 10.1016/j.jacc.2011.10.909
   Pashuck ET, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002717
   Patel DN, 2016, CURR OPIN UROL, V26, P302, DOI 10.1097/MOU.0000000000000288
   Paukkeri EL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155121
   Paul Clark MJ, 2012, PHARMACOL THERAPEUT, V135, P200, DOI 10.1016/j.pharmthera.2012.05.007
   Pennisi CP, 2011, COLLOID SURFACE B, V85, P189, DOI 10.1016/j.colsurfb.2011.02.028
   Petrie TA, 2009, J CELL MOL MED, V13, P2602, DOI 10.1111/j.1582 4934.2008.00476.x
   Picke AK, 2016, BIOMATERIALS, V96, P11, DOI 10.1016/j.biomaterials.2016.04.013
   Pignolo RJ, 2011, J BONE MINER RES, V26, P1685, DOI 10.1002/jbmr.370
   Pinson ML, 2014, ANN ALLERG ASTHMA IM, V113, P131, DOI 10.1016/j.anai.2014.05.012
   Prapainop K, 2012, J AM CHEM SOC, V134, P4100, DOI 10.1021/ja300537u
   Qin Y. X, 2014, BIOMED RES INT, V2014
   Ramadi KB, 2016, NANOTOXICOLOGY, V10, P1061, DOI 10.3109/17435390.2016.1163743
   Ramalho J, 2016, AM J NEURORADIOL, V37, P1192, DOI 10.3174/ajnr.A4615
   Rapuano BE, 2012, EUR J ORAL SCI, V120, P185, DOI 10.1111/j.1600 0722.2012.954.x
   Ratner BD, 2011, J CARDIOVASC TRANSL, V4, P523, DOI 10.1007/s12265 011 9287 x
   RATNOFF OD, 1958, AM J MED, V25, P160, DOI 10.1016/0002 9343(58)90023 8
   Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186
   Reis LA, 2016, J TISSUE ENG REGEN M, V10, P11, DOI 10.1002/term.1944
   Rezania A, 2000, J BIOMED MATER RES, V52, P595, DOI 10.1002/1097 4636(20001215)52:4<595::AID JBM3>3.3.CO;2 V
   Rice JJ, 2013, ADV HEALTHC MATER, V2, P57, DOI 10.1002/adhm.201200197
   Rico P, 2009, TISSUE ENG PT A, V15, P3271, DOI 10.1089/ten.TEA.2009.0141
   Ruenraroengsak P, 2012, NANOTOXICOLOGY, V6, P94, DOI 10.3109/17435390.2011.558643
   Saber W, 2011, J THROMB HAEMOST, V9, P312, DOI 10.1111/j.1538 7836.2010.04126.x
   Salou L, 2015, ACTA BIOMATER, V11, P494, DOI 10.1016/j.actbio.2014.10.017
   Samelko L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160141
   Sarkar S, 2006, EUR J VASC ENDOVASC, V31, P627, DOI 10.1016/j.ejvs.2006.01.006
   Schmaier AH, 2008, J CLIN INVEST, V118, P3006, DOI 10.1172/JCI36617
   Schmidt Lauber C, 2015, ANN RHEUM DIS, V74, P2062, DOI 10.1136/annrheumdis 2013 204900
   Schutte RJ, 2009, J BIOMED MATER RES A, V88A, P128, DOI 10.1002/jbm.a.31863
   Sefton MV, 2001, J BIOMED MATER RES, V55, P447, DOI 10.1002/1097 4636(20010615)55:4<447::AID JBM1036>3.0.CO;2 5
   Segreto F, 2016, PLAST RECONSTR SURG, V137, P792, DOI 10.1097/01.prs.0000479941.42174.f1
   Seijo F, 2014, ACTA NEUROCHIR, V156, P1505, DOI 10.1007/s00701 014 2082 0
   Seo Jeongdeok, 2016, Journal of Pharmaceutical Investigation, V46, P317, DOI 10.1007/s40005 016 0251 2
   Sgarioto M, 2012, CR BIOL, V335, P520, DOI 10.1016/j.crvi.2012.07.003
   Shah KB, 2011, CLIN CARDIOL, V34, P147, DOI 10.1002/clc.20825
   Shahzad K, 2015, KIDNEY INT, V87, P74, DOI 10.1038/ki.2014.271
   Shao Y, 2015, BIOMATERIALS, V52, P26, DOI 10.1016/j.biomaterials.2015.01.078
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Sieber C, 2009, CYTOKINE GROWTH F R, V20, P343, DOI 10.1016/j.cytogfr.2009.10.007
   Singh N, 2009, BIOMATERIALS, V30, P3891, DOI 10.1016/j.biomaterials.2009.04.009
   Singh P, 2010, ANNU REV CELL DEV BI, V26, P397, DOI 10.1146/annurev cellbio 100109 104020
   Smith RS, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004120
   Spatz JM, 2015, J BIOL CHEM, V290, P16744, DOI 10.1074/jbc.M114.628313
   Sperling C, 2009, BIOMATERIALS, V30, P4447, DOI 10.1016/j.biomaterials.2009.05.044
   Spiller KL, 2011, TISSUE ENG PART B RE, V17, P281, DOI [10.1089/ten.TEB.2011.0077, 10.1089/ten.teb.2011.0077]
   Springer BD, 2013, J ARTHROPLASTY, V28, P714, DOI 10.1016/j.arth.2013.02.011
   Steward AJ, 2015, J ANAT, V227, P717, DOI 10.1111/joa.12243
   Stukel JM, 2016, TISSUE ENG PART B RE, V22, P173, DOI [10.1089/ten.teb.2015.0380, 10.1089/ten.TEB.2015.0380]
   Sun BB, 2013, SMALL, V9, P1595, DOI 10.1002/smll.201201962
   Sun JCJ, 2009, LANCET, V374, P565, DOI 10.1016/S0140 6736(09)60780 7
   Sun MC, 2015, J COLLOID INTERF SCI, V448, P231, DOI 10.1016/j.jcis.2015.01.082
   Surmenev RA, 2014, ACTA BIOMATER, V10, P557, DOI 10.1016/j.actbio.2013.10.036
   Sussman EM, 2014, ANN BIOMED ENG, V42, P1508, DOI 10.1007/s10439 013 0933 0
   Takayama T, 2011, J CARDIOL, V58, P92, DOI 10.1016/j.jjcc.2011.07.003
   Tan XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159275
   Tannoury CA, 2014, SPINE J, V14, P552, DOI 10.1016/j.spinee.2013.08.060
   Taravella MJ, 2011, J CATARACT REFR SURG, V37, P1069, DOI 10.1016/j.jcrs.2010.12.054
   Tenekecioglu E, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872 016 0207 5
   Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181
   Thissen H, 2010, BIOMATERIALS, V31, P5510, DOI 10.1016/j.biomaterials.2010.03.040
   Thorfve A, 2014, ACTA BIOMATER, V10, P1451, DOI 10.1016/j.actbio.2013.12.012
   Tiwari A, 2015, INVEST OPHTH VIS SCI, V56, P272, DOI 10.1167/iovs.14 14934
   Traub S, 2013, BIOMATERIALS, V34, P5958, DOI 10.1016/j.biomaterials.2013.04.050
   Tyler WJ, 2012, NAT REV NEUROSCI, V13, P867, DOI 10.1038/nrn3383
   Vaine CA, 2013, J IMMUNOL, V190, P3525, DOI 10.4049/jimmunol.1200492
   Veiseh O, 2015, NAT MATER, V14, P643, DOI [10.1038/NMAT4290, 10.1038/nmat4290]
   Velasco Ortega E, 2016, MAT SCI ENG C MATER, V64, P1, DOI 10.1016/j.msec.2016.03.049
   Vidovic D, 2006, Hernia, V10, P322, DOI 10.1007/s10029 006 0097 z
   Vilaseca P, 2013, SOFT MATTER, V9, P6978, DOI 10.1039/c3sm50220a
   Vincent TL, 2013, CURR OPIN PHARMACOL, V13, P449, DOI 10.1016/j.coph.2013.01.010
   Virdi AS, 2015, J BONE JOINT SURG AM, V97A, P133, DOI 10.2106/JBJS.N.00654
   Vitkov L, 2016, MED HYPOTHESES, V93, P1, DOI 10.1016/j.mehy.2016.05.004
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   Vogler EA, 1998, ADV COLLOID INTERFAC, V74, P69, DOI 10.1016/S0001 8686(97)00040 7
   Vogler EA, 2009, BIOMATERIALS, V30, P1857, DOI 10.1016/j.biomaterials.2008.12.041
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   VROMAN L, 1962, NATURE, V196, P476, DOI 10.1038/196476a0
   Walters NJ, 2015, ACTA BIOMATER, V11, P3, DOI 10.1016/j.actbio.2014.09.038
   Wan JD, 2011, INTEGR BIOL UK, V3, P972, DOI 10.1039/c1ib00044f
   Wan S, 2015, ACS NANO, V9, P2157, DOI 10.1021/nn506060q
   Wang K, 2015, BIOMATERIALS, V54, P63, DOI 10.1016/j.biomaterials.2015.03.019
   Wang KF, 2012, INTERFACE FOCUS, V2, P259, DOI 10.1098/rsfs.2012.0012
   Watters Tyler Steven, 2010, Am J Clin Pathol, V134, P886, DOI 10.1309/AJCPLTNEUAH8XI4W
   Wei FL, 2014, CELLS TISSUES ORGANS, V199, P353, DOI 10.1159/000369613
   Wei JH, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/4/045002
   Weltz V, 2015, INT UROGYNECOL J, V26, P641, DOI 10.1007/s00192 014 2567 7
   Wick G, 2013, ANNU REV IMMUNOL, V31, P107, DOI 10.1146/annurev immunol 032712 095937
   Wilkinson JM, 2005, J ORTHOP RES, V23, P520, DOI 10.1016/j.orthres.2004.11.005
   Williams C, 2015, ACTA BIOMATER, V14, P84, DOI 10.1016/j.actbio.2014.11.035
   Williams D. F., 2017, KIDNEY TRAN IN PRESS
   Williams D. F, 2014, ESSENTIAL BIOMATERIA
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Williams DF, 2014, BIOMATERIALS, V35, P10009, DOI 10.1016/j.biomaterials.2014.08.035
   Williams DF, 2014, TISSUE ENG PT A, V20, P1129, DOI 10.1089/ten.tea.2013.0769
   Williams DF, 2009, BIOMATERIALS, V30, P5897, DOI 10.1016/j.biomaterials.2009.07.027
   WILLIAMS DF, 1974, J BIOMED MATER RES, V8, P1, DOI 10.1002/jbm.820080303
   Williams DF., 1999, WILLIAMS DICT BIOMAT
   Wilson CJ, 2005, TISSUE ENG, V11, P1, DOI 10.1089/ten.2005.11.1
   Wolfram D, 2012, PLAST RECONSTR SURG, V129, p327E, DOI 10.1097/PRS.0b013e31823aeacf
   Wong VW, 2012, SEMIN CELL DEV BIOL, V23, P981, DOI 10.1016/j.semcdb.2012.09.010
   Wong VW, 2011, FASEB J, V25, P4498, DOI 10.1096/fj.10 178087
   Wu XQ, 2010, ARTERIOSCL THROM VAS, V30, P471, DOI 10.1161/ATVBAHA.109.184259
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Yamamoto A, 2009, MAT SCI ENG C BIO S, V29, P1559, DOI 10.1016/j.msec.2008.12.015
   Yang DY, 2013, BIOMATERIALS, V34, P5747, DOI 10.1016/j.biomaterials.2013.04.028
   Yang M, 2013, SMALL, V9, P4194, DOI 10.1002/smll.201300481
   Yeatts AB, 2013, BBA GEN SUBJECTS, V1830, P2470, DOI 10.1016/j.bbagen.2012.06.007
   Yim EKF, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt132
   Yoon JK, 2016, TISSUE ENG PT A, V22, P654, DOI [10.1089/ten.tea.2015.0417, 10.1089/ten.TEA.2015.0417]
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Zhang HY, 2012, J AM CHEM SOC, V134, P15790, DOI 10.1021/ja304907c
   Zhao CY, 2013, BIOTECHNOL ADV, V31, P654, DOI 10.1016/j.biotechadv.2012.08.001
   Zhao X, 2016, BIOMATERIALS, V102, P187, DOI 10.1016/j.biomaterials.2016.06.032
   Zilla P, 2007, BIOMATERIALS, V28, P5009, DOI 10.1016/j.biomaterials.2007.07.017
   Ziv K, 2014, BIOMATERIALS, V35, P3736, DOI 10.1016/j.biomaterials.2014.01.029
   Zou L, 2012, J BIOL CHEM, V287, P7190, DOI 10.1074/jbc.M111.304972
   Zustiak SP, 2013, TISSUE ENG PART B RE, V19, P160, DOI 10.1089/ten.teb.2012.0458
NR 321
TC 97
Z9 102
U1 4
U2 120
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD JAN
PY 2017
VL 3
IS 1
BP 2
EP 35
DI 10.1021/acsbiomaterials.6b00607
PG 34
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA EH4ZR
UT WOS:000391782900002
PM 33429689
DA 2025 08 17
ER

PT J
AU Ullah, I
   Gloria, A
   Zhang, WC
   Ullah, MW
   Wu, B
   Li, WC
   Domingos, M
   Zhang, XL
AF Ullah, Ismat
   Gloria, Antonio
   Zhang, Wancheng
   Ullah, Muhammad Wajid
   Wu, Bin
   Li, Wenchao
   Domingos, Marco
   Zhang, Xianglin
TI Synthesis and Characterization of Sintered Sr/Fe Modified Hydroxyapatite
   Bioceramics for Bone Tissue Engineering Applications
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE Sr/Fe co substitution; biomechanical properties; polyphasic nature; drug
   release; biocompatibility; osteogenic differentiation
ID BIPHASIC CALCIUM PHOSPHATE; MECHANICAL PROPERTIES; STRONTIUM RANELATE;
   IRON; CEMENT; DIFFERENTIATION; OSTEOCLAST; CERAMICS
AB In the current study, Sr/Fe co substituted hydroxyapatite (HAp) bioceramics were prepared by the sonication assisted aqueous chemical precipitation method followed by sintering at 1100 degrees C for bone tissue regeneration applications. The sintered bioceramics were analyzed for various structural and chemical properties through X ray diffraction, scanning electron microscopy, and Fourier transform infrared spectroscopy, which confirmed the phase purity of HAp and Sr/Fe co substitution into its lattice. The Vickers hardness measurement, high blood compatibility (less than 5% hemolysis), and ability to support the adhesion, proliferation, and osteogenic differentiation of human mesenchymal stem cells suggest the suitability of Sr/Fe:HAp bioceramics for bone implant applications. The physicochemical analysis revealed that the developed Sr/Fe:HAp bioceramics exhibited a polyphasic nature (HAp and beta TCP) with almost identical structural morphology having a particle size less than 0.8 mu m. The dielectric constant (epsilon') and dielectric loss (epsilon") were potentially affected by the incorporated foreign ions together with the polyphasic nature of the material. The Sr/Fe co substituted samples demonstrated extended drug (5 fluorouracil and amoxicillin) release profiles at the pH of physiological medium. The multifunctional properties of the developed HAp bioceramics enabled them to be an auspicious candidate for potential biomedical applications, including targeted drug delivery applications, heating mediator in hyperthermia, and bone tissue repair implants.
C1 [Ullah, Ismat; Zhang, Wancheng; Wu, Bin; Zhang, Xianglin] Huazhong Univ Sci & Technol, State Key Lab Mat Proc & Die Mold Technol, Sch Mat Sci & Engn, Wuhan 430074, Peoples R China.
   [Ullah, Muhammad Wajid] Huazhong Univ Sci & Technol, Dept Biomed Engn, Wuhan 430074, Peoples R China.
   [Gloria, Antonio] Natl Res Council Italy, Inst Polymers Composites & Biomat, Vle JF Kennedy 54 Mostra Oltremare Pad 20, I 80125 Naples, Italy.
   [Li, Wenchao] Nanchang Univ, Sch Mechatron Engn, Nanchang 330031, Jiangxi, Peoples R China.
   [Domingos, Marco] Univ Manchester, Dept Mech Aerosp & Civil Engn, Sch Engn, Fac Sci & Engn, Manchester M13 9PL, Lancs, England.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Consiglio Nazionale delle Ricerche (CNR); Istituto
   per i Polimeri, Compositi e Biomateriali (IPCB CNR); Nanchang
   University; University of Manchester
RP Zhang, XL (通讯作者)，Huazhong Univ Sci & Technol, State Key Lab Mat Proc & Die Mold Technol, Sch Mat Sci & Engn, Wuhan 430074, Peoples R China.
EM hust_zxl@mail.hust.edu.cn
RI ; Li, Wenchao/S 5567 2016; Ullah, Muhammad Wajid/L 9399 2019; Ullah,
   Ismat/ITT 4852 2023; Zhang, Wancheng/HNC 0510 2023; Domingos,
   Marco/H 1543 2015
OI Gloria, Antonio/0000 0001 5233 5687; Zhang,
   Wancheng/0000 0002 4313 1516; Ullah, Muhammad Wajid/0000 0003 2984 0743;
   Ullah, Ismat/0000 0001 5318 1042; Domingos, Marco/0000 0002 6693 790X
FU National Natural Science Foundation of China [81672158]; Analytical and
   Testing Centre of Huazhong University of Science and Technology, Wuhan,
   P.R. China; Engineering and Physical Sciences Research Council
   [EP/R00661X/1, EP/P025021/1, EP/S019367/1] Funding Source: researchfish;
   EPSRC [EP/P025021/1, EP/S019367/1] Funding Source: UKRI
FX This work was financially supported by the National Natural Science
   Foundation of China (81672158). The authors would like to acknowledge
   the Analytical and Testing Centre of Huazhong University of Science and
   Technology, Wuhan, P.R. China, for different characterizations.
CR AL Wafi R, 2016, J ALLOY COMPD, V689, P169, DOI 10.1016/j.jallcom.2016.07.285
   Aljohani W, 2018, INT J BIOL MACROMOL, V107, P261, DOI 10.1016/j.ijbiomac.2017.08.171
   Anee TK, 2004, MATER LETT, V58, P478, DOI 10.1016/S0167 577X(03)00529 9
   [Anonymous], 2013, Bioceram. Dev. B Appl., DOI DOI 10.4172/2090 5025.1000067
   Basu B., 2014, J BIOMEDICAL MAT R B, V103, P1168
   Basu S, 2018, ACS BIOMATER SCI ENG, V4, P857, DOI 10.1021/acsbiomaterials.7b00813
   Bauer S, 2013, PROG MATER SCI, V58, P261, DOI 10.1016/j.pmatsci.2012.09.001
   Best SM, 2008, J EUR CERAM SOC, V28, P1319, DOI 10.1016/j.jeurceramsoc.2007.12.001
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Capuccini C, 2009, J BIOMED MATER RES A, V89A, P594, DOI 10.1002/jbm.a.31975
   Chandra VS, 2012, ACS APPL MATER INTER, V4, P1200, DOI 10.1021/am300140q
   Crichton R., 2001, INORGANIC BIOCH IRON, V1
   da Silva LM, 2015, MATER SCI ENG B ADV, V199, P77, DOI 10.1016/j.mseb.2015.05.003
   Dorozhkin SV, 2010, ACTA BIOMATER, V6, P4457, DOI 10.1016/j.actbio.2010.06.031
   Eddy Jai Poinern G., 2013, AM J BIOMED ENG, V2, P278, DOI [10.5923/j.ajbe.20120206.07, DOI 10.5923/J.AJBE.20120206.07]
   Elayaraja K, 2012, MATER CHEM PHYS, V134, P464, DOI 10.1016/j.matchemphys.2012.03.018
   Erkmen ZE, 2007, J AM CERAM SOC, V90, P2885, DOI 10.1111/j.1551 2916.2007.01849.x
   Garrido C. A., 2011, INT J BIOMATER, V2011, P16
   Gomes S, 2017, ACTA BIOMATER, V50, P78, DOI 10.1016/j.actbio.2016.12.011
   He YF, 2013, BIOL TRACE ELEM RES, V152, P292, DOI 10.1007/s12011 013 9605 z
   Hendriks J, 2007, J TISSUE ENG REGEN M, V1, P170, DOI 10.1002/term.19
   Hoepfner TP, 2003, CERAM INT, V29, P699, DOI 10.1016/S0272 8842(02)00220 1
   Itoh S, 2006, CALCIFIED TISSUE INT, V78, P133, DOI 10.1007/s00223 005 0213 6
   Jiang M, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.224107
   Karthikeyan Krishnamoorthy, 2011, Cancer Nanotechnol, V2, P95, DOI 10.1007/s12645 011 0019 3
   Kaygili O, 2013, CERAM INT, V39, P7779, DOI 10.1016/j.ceramint.2013.03.037
   Kern C, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2018.0638
   Kim TW, 2012, MATER RES BULL, V47, P2506, DOI 10.1016/j.materresbull.2012.05.011
   Kim Y, 2016, J AM CERAM SOC, V99, P1367, DOI 10.1111/jace.14084
   Kolanthai E, 2017, J PHOTOCH PHOTOBIO B, V166, P220, DOI 10.1016/j.jphotobiol.2016.12.005
   Kolanthai E, 2016, MATER TODAY COMMUN, V8, P31, DOI 10.1016/j.mtcomm.2016.03.008
   Komath M, 2003, B MATER SCI, V26, P415, DOI 10.1007/BF02711186
   Li S., 2018, ES Mater. Manuf, V1, P41, DOI DOI 10.30919/ESMM5F120
   Lobo SE, 2010, MATERIALS, V3, P815, DOI 10.3390/ma3020815
   Marie PJ, 2006, BONE, V38, P10, DOI 10.1016/j.bone.2005.07.029
   Panseri S, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477 3155 10 32
   Piattelli A, 1996, BIOMATERIALS, V17, P1767, DOI 10.1016/0142 9612(95)00342 8
   Prasanna APS, 2018, PROG BIOMATER, V7, P289, DOI 10.1007/s40204 018 0103 4
   Prezas PR, 2017, APPL SURF SCI, V424, P28, DOI 10.1016/j.apsusc.2017.02.225
   Quilitz M, 2010, J MATER SCI MATER M, V21, P399, DOI 10.1007/s10856 009 3875 1
   Sabareeswaran A, 2013, BIOMATERIALS, V34, P9278, DOI 10.1016/j.biomaterials.2013.08.070
   Sanyal V, 2016, J NON CRYST SOLIDS, V445, P81, DOI 10.1016/j.jnoncrysol.2016.05.010
   Sarath Chandra V, 2015, CERAM INT, V41, P13153
   Schumacher M, 2013, ACTA BIOMATER, V9, P9547, DOI 10.1016/j.actbio.2013.07.027
   Silva RV, 2005, INT J ORAL MAX SURG, V34, P178, DOI 10.1016/j.ijom.2004.06.005
   Singh B, 2018, J MATER SCI, V53, P8807, DOI 10.1007/s10853 018 2225 4
   Stoch A, 2005, J MOL STRUCT, V744, P633, DOI 10.1016/j.molstruc.2004.10.080
   Suganthi RV, 2011, MAT SCI ENG C MATER, V31, P593, DOI 10.1016/j.msec.2010.11.025
   Sundarabharathi L, 2018, J BIOMED MATER RES B, V106, P2191, DOI 10.1002/jbm.b.34023
   Taha A, 2017, MAT SCI ENG C MATER, V80, P93, DOI 10.1016/j.msec.2017.05.117
   Tampieri A, 2012, ACTA BIOMATER, V8, P843, DOI 10.1016/j.actbio.2011.09.032
   Tekkaya AE, 2000, CIRP ANNALS 2000: MANUFACTURING TECHNOLOGY, P205
   Terra J, 2009, PHYS CHEM CHEM PHYS, V11, P568, DOI 10.1039/b802841a
   Toxqui L, 2015, NUTRIENTS, V7, P2324, DOI 10.3390/nu7042324
   Ul Islam M, 2019, INT J BIOL MACROMOL, V137, P1050, DOI 10.1016/j.ijbiomac.2019.07.050
   Ullah B, 2017, J ALLOY COMPD, V728, P623, DOI 10.1016/j.jallcom.2017.08.292
   Ullah I, 2018, CERAM INT, V44, P21338, DOI 10.1016/j.ceramint.2018.08.187
   Vahabzadeh S, 2017, J BIOMED MATER RES B, V105, P391, DOI 10.1002/jbm.b.33485
   Veerla SC, 2019, MAT SCI ENG C MATER, V98, P311, DOI 10.1016/j.msec.2018.12.148
   Verberckmoes SC, 2004, CALCIFIED TISSUE INT, V75, P405, DOI 10.1007/s00223 004 0260 4
   WANG PE, 1993, J MATER SCI MATER M, V4, P150, DOI 10.1007/BF00120384
   Wu HC, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/16/165601
   Yamashita K, 1996, CHEM MATER, V8, P2697, DOI 10.1021/cm9602858
   Yang C, 2008, J COLLOID INTERF SCI, V328, P203, DOI 10.1016/j.jcis.2008.09.010
   Yashima M, 2011, J PHYS CHEM C, V115, P25077, DOI 10.1021/jp208746y
   Zamiri A, 2011, J MECH BEHAV BIOMED, V4, P146, DOI 10.1016/j.jmbbm.2010.11.001
   Zima A, 2017, J MATER SCI MATER M, V28, DOI 10.1007/s10856 017 5934 3
NR 67
TC 58
Z9 59
U1 4
U2 60
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD JAN
PY 2020
VL 6
IS 1
BP 375
EP 388
DI 10.1021/acsbiomaterials.9b01666
PG 27
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA KC8NV
UT WOS:000507429200034
PM 33463228
DA 2025 08 17
ER

PT J
AU Imai, Y
   Ohta, E
   Takeda, S
   Sunamura, S
   Ishibashi, M
   Tamura, H
   Wang, YH
   Deguchi, A
   Tanaka, J
   Maru, Y
   Motoji, T
AF Imai, Yoichi
   Ohta, Eri
   Takeda, Shu
   Sunamura, Satoko
   Ishibashi, Mariko
   Tamura, Hideto
   Wang, Yan hua
   Deguchi, Atsuko
   Tanaka, Junji
   Maru, Yoshiro
   Motoji, Toshiko
TI Histone deacetylase inhibitor panobinostat induces calcineurin
   degradation in multiple myeloma
SO JCI INSIGHT
LA English
DT Article
ID NF KAPPA B; CELL CELL CONTACT; BORTEZOMIB RESISTANCE; THERAPEUTIC
   STRATEGY; DRUG RESISTANCE; GENE EXPRESSION; HDAC INHIBITORS; STAGING
   SYSTEM; IN VITRO; T CELLS
AB Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies for overcoming of drug resistance. Addition of panobinostat, a histone deacetylase (HDAC) inhibitor, to bortezomib and dexamethasone improved progressionfree survival (PFS) in relapsed and refractory MM patients. Here, we demonstrate how calcineurin, when inhibited by immunosuppressive drugs like FK506, is involved in myeloma cell growth and targeted by panobinostat. mRNA expression of PPP3CA, a catalytic subunit of calcineurin, was high in advanced patients. Panobinostat degraded PPP3CA, a degradation that should have been induced by inhibition of the chaperone function of heat shock protein 90 (HSP90). Cotreatment with HDAC inhibitors and FK506 led to an enhanced antimyeloma effect with a greater PPP3CA reduction compared with HDAC inhibitors alone both in vitro and in vivo. In addition, this combination treatment efficiently blocked osteoclast formation, which results in osteolytic lesions. The poor response and short PFS duration observed in the bortezomib containing therapies of patients with high PPP3CA suggested its relevance to bortezomib resistance. Moreover, bortezomib and HDAC inhibitors synergistically suppressed MM cell viability through PPP3CA inhibition. Our findings underscore the usefulness of calcineurin targeted therapy in MM patients, including patients who are resistant to bortezomib.
C1 [Imai, Yoichi; Ohta, Eri; Wang, Yan hua; Tanaka, Junji; Motoji, Toshiko] Tokyo Womens Med Univ, Dept Hematol, Tokyo, Japan.
   [Takeda, Shu; Sunamura, Satoko] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Physiol & Cell Biol, Tokyo, Japan.
   [Ishibashi, Mariko; Tamura, Hideto] Nippon Med Sch, Div Hematol, Dept Med, Tokyo, Japan.
   [Deguchi, Atsuko; Maru, Yoshiro] Tokyo Womens Med Univ, Dept Pharmacol, Tokyo, Japan.
C3 Tokyo Women's Medical University; Institute of Science Tokyo; Tokyo
   Medical & Dental University (TMDU); Nippon Medical School; Tokyo Women's
   Medical University
RP Imai, Y (通讯作者)，Tokyo Womens Med Univ, Dept Hematol, Shinjuku Ku, 8 1 Kawada Cho, Tokyo 1628666, Japan.
EM imaiyo@twmu.ac.jp
RI ; Tamura, Hideto/AAV 3532 2020; Deguchi, Atsuko/KIL 1800 2024
OI Imai, Yoichi/0000 0002 2938 6133; Ishibashi, Mariko/0000 0001 8292 9283;
   Deguchi, Atsuko/0000 0001 9647 3539; 
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Afshar Sterle S, 2014, NAT MED, V20, P283, DOI 10.1038/nm.3442
   Agnelli L, 2005, J CLIN ONCOL, V23, P7296, DOI 10.1200/JCO.2005.01.3870
   Auner HW, 2013, BONE MARROW TRANSPL, V48, P1395, DOI 10.1038/bmt.2013.73
   Bhattacharyya S, 2011, J EXP MED, V208, P823, DOI 10.1084/jem.20100945
   Bots M, 2014, BLOOD, V123, P1341, DOI 10.1182/blood 2013 03 488114
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Brewin J, 2009, BLOOD, V114, P4792, DOI 10.1182/blood 2009 07 228387
   Buchholz M, 2007, CELL CYCLE, V6, P16, DOI 10.4161/cc.6.1.3650
   Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019
   Catalano MG, 2012, INT J CANCER, V130, P694, DOI 10.1002/ijc.26057
   Catley L, 2006, BLOOD, V108, P3441, DOI 10.1182/blood 2006 04 016055
   Chai RC, 2014, J BIOL CHEM, V289, P13602, DOI 10.1074/jbc.M113.530626
   Chen S, 2014, BLOOD, V124, P2687, DOI 10.1182/blood 2014 03 564534
   Cheng JB, 2011, BIOCHEM BIOPH RES CO, V413, P481, DOI 10.1016/j.bbrc.2011.08.126
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097 0142(197509)36:3<842::AID CNCR2820360303>3.0.CO;2 U
   Fonseca R, 2003, BLOOD, V101, P4569, DOI 10.1182/blood 2002 10 3017
   Fu LC, 2006, BLOOD, V107, P4540, DOI 10.1182/blood 2005 10 4042
   Gachet S, 2009, GEN PHYSIOL BIOPHYS, V28, pF47
   Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Heider U, 2008, EUR J HAEMATOL, V80, P133, DOI 10.1111/j.1600 0609.2007.00995.x
   Hemenway Charles S., 1999, Cell Biochemistry and Biophysics, V30, P115, DOI 10.1007/BF02737887
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Hideshima T, 2011, MOL CANCER THER, V10, P2034, DOI 10.1158/1535 7163.MCT 11 0433
   Hui KF, 2014, INT J CANCER, V135, P2950, DOI 10.1002/ijc.28924
   Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003
   KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood 2007 01 065888
   Kupatt C, 2004, ARTERIOSCL THROM VAS, V24, P1435, DOI 10.1161/01.ATV.0000134300.87476.d1
   Laubach JP, 2015, CLIN CANCER RES, V21, P4767, DOI 10.1158/1078 0432.CCR 15 0530
   Lombardi L, 2007, GENE CHROMOSOME CANC, V46, P226, DOI 10.1002/gcc.20404
   Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008 5472.CAN 05 4186
   Mandawat A, 2010, BLOOD, V116, P5306, DOI 10.1182/blood 2010 05 284414
   Medyouf H, 2007, NAT MED, V13, P736, DOI 10.1038/nm1588
   Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960
   Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood 2006 09 044974
   Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008 5472.CAN 05 2961
   Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078 0432.CCR 11 1000
   New M, 2012, MOL ONCOL, V6, P637, DOI 10.1016/j.molonc.2012.09.003
   Nishioka C, 2008, LEUKEMIA RES, V32, P287, DOI 10.1016/j.leukres.2007.05.026
   Noborio Hatano K, 2009, ONCOGENE, V28, P231, DOI 10.1038/onc.2008.385
   Noll JE, 2014, HAEMATOLOGICA, V99, P163, DOI 10.3324/haematol.2013.090977
   Ocio EM, 2010, HAEMATOL HEMATOL J, V95, P794, DOI 10.3324/haematol.2009.015495
   Oerlemans R, 2008, BLOOD, V112, P2489, DOI 10.1182/blood 2007 08 104950
   Otsuki T, 1999, INT J ONCOL, V15, P1205
   Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267
   Pham LV, 2005, BLOOD, V106, P3940, DOI 10.1182/blood 2005 03 1167
   Qu XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032215
   Richardson PG, 2013, BLOOD, V122, P2331, DOI 10.1182/blood 2013 01 481325
   Richardson PG, 2011, BRIT J HAEMATOL, V152, P367, DOI 10.1111/j.1365 2141.2010.08360.x
   San Miguel JF, 2014, LANCET ONCOL, V15, P1195, DOI 10.1016/S1470 2045(14)70440 1
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood 2011 10 387365
   Sato S, 2007, NAT MED, V13, P1234, DOI 10.1038/nm1640
   Someren JS, 1999, BIOCHEM BIOPH RES CO, V260, P619, DOI 10.1006/bbrc.1999.0800
   Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923
   Wang DP, 2012, BIOL BLOOD MARROW TR, V18, P1182, DOI 10.1016/j.bbmt.2012.06.002
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Xu DH, 2012, BIOCHEM BIOPH RES CO, V428, P518, DOI 10.1016/j.bbrc.2012.10.071
   Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639 5649.2004
   Zawawi MSF, 2012, BIOCHEM BIOPH RES CO, V427, P404, DOI 10.1016/j.bbrc.2012.09.077
   Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413
   Zhu YX, 2011, BLOOD, V117, P3847, DOI 10.1182/blood 2010 08 304022
NR 65
TC 30
Z9 35
U1 1
U2 1
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 2379 3708
J9 JCI INSIGHT
JI JCI Insight
PD APR 21
PY 2016
VL 1
IS 5
AR e85061
DI 10.1172/jci.insight.85061
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA EB1IV
UT WOS:000387104600001
PM 27699258
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ballester, I
   Daddaoua, A
   López Posadas, R
   Nieto, A
   Suárez, MD
   Zarzuelo, A
   Martínez Augustin, O
   de Medina, FS
AF Ballester, I.
   Daddaoua, A.
   Lopez Posadas, R.
   Nieto, A.
   Suarez, M. D.
   Zarzuelo, A.
   Martinez Augustin, O.
   Sanchez de Medina, F.
TI The bisphosphonate alendronate improves the damage associated with
   trinitrobenzenesulfonic acid induced colitis in rats
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE alendronate; trinitrobenzenesulfonic acid; experimental colitis;
   bisphosphonates; inflammatory bowel disease; interleukin 1
ID BONE MINERAL DENSITY; ULCERATIVE COLITIS; OSTEOPOROSIS; INFLAMMATION;
   EXPRESSION; THERAPY; STATINS; MECHANISM; PREVENTS; FLUORIDE
AB Background and purpose: The nitrogen containing bisphosphonates are drugs used successfully in the treatment of osteoporosis. They act inhibiting farnesyl diphosphate synthase. This mechanism may also produce anti inflammatory effects. The therapeutic activity of alendronate was tested in vivo using a model of inflammatory bowel disease.
   Experimental approach: The trinitrobenzenesulfonic acid model of colitis in the rat was used. Rats were treated orally with alendronate and its efficacy compared with that of oral sulphasalazine or vehicle, starting 2 h after colitis induction. The status of the animals was assessed 5 days later.
   Key results: Alendronate treatment ( 25 or 75 mg kg( 1) day( 1)) resulted in a decrease in the colonic damage score and loss of body weight ( at 25 mg kg( 1) day( 1) only). This was associated to a dramatic reduction in the mRNA levels of interleukin 1 beta ( IL 1 beta), monocyte chemoattractant protein 1 ( MCP 1) and interleukin 1 receptor antagonist ( IL 1ra). The magnitude of the beneficial effect was comparable to that of sulphasalazine ( at a 6 20 fold higher dose). Thus sulphasalazine post treatment reduced the mRNA levels of IL 1 beta/IL 1ra and MCP 1 to the same extent as alendronate and additionally lowered colonic alkaline phosphatase activity, but failed to affect body weight loss or colonic damage score. Alendronate failed to exert beneficial effects when administered intraperitoneally.
   Conclusions and Implications: Oral but not intraperitoneal alendronate significantly protected the colon in experimental rat colitis. Inflammatory bowel disease patients might benefit from exposure to oral alendronate.
C1 Univ Granada, Sch Pharm, Dept Pharmacol, CIBEREHD, E 18071 Granada, Spain.
   Univ Granada, Sch Pharm, Dept Biochem & Mol Biol 2, CIBEREHD, E 18071 Granada, Spain.
   Hosp Virgen de las Nieves, Banco Lineas Celulares Andalucia, Granada, Spain.
C3 University of Granada; CIBER   Centro de Investigacion Biomedica en Red;
   CIBEREHD; University of Granada; CIBER   Centro de Investigacion
   Biomedica en Red; CIBEREHD; Hospital Universitario Virgen de las Nieves
RP de Medina, FS (通讯作者)，Univ Granada, Sch Pharm, Dept Pharmacol, CIBEREHD, Campus Cartuja S N, E 18071 Granada, Spain.
EM fsanchez@ugr.es
RI Zarzuelo, Antonio/L 2840 2014; Sanchez de Medina, Fermin/B 3782 2013; de
   Medina, Fermin/B 3782 2013; Martinez Augustin, Olga/K 6720 2014;
   Augustin, Olga/K 6720 2014; Daddaoua, Abdelali/D 6930 2014; Ortega,
   María/H 1240 2015; Suarez Ortega, Maria Dolores/H 1240 2015; Nieto, Ana
   Isabel/AAA 8644 2019
OI Sanchez de Medina, Fermin/0000 0002 4516 5824; Martinez Augustin,
   Olga/0000 0001 8291 3468; Daddaoua, Abdelali/0000 0002 7348 6393; Suarez
   Ortega, Maria Dolores/0000 0003 3197 2518; Nieto Ruiz De Zarate, Ana
   Isabel/0000 0001 9698 3686; 
CR Abeles AM, 2006, ARTHRITIS RHEUM US, V54, P393, DOI 10.1002/art.21521
   Banks C, 2003, J PATHOL, V199, P28, DOI 10.1002/path.1245
   Bartram SA, 2003, ALIMENT PHARM THER, V18, P1121, DOI 10.1111/j.1365 2036.2003.01794.x
   Bernstein CN, 2005, NAT CLIN PRACT GASTR, V2, P232, DOI 10.1038/ncpgasthep0169
   Castells A, 2006, CLIN CANCER RES, V12, P1686, DOI 10.1158/1078 0432.CCR 05 1581
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Daddaoua A, 2005, J NUTR, V135, P1164, DOI 10.1093/jn/135.5.1164
   de Medina FS, 2004, BIOCHEM PHARMACOL, V68, P2317, DOI 10.1016/j.bcp.2004.07.045
   DeMedina FS, 1996, J PHARMACOL EXP THER, V278, P771
   Gonyeau MJ, 2005, PHARMACOTHERAPY, V25, P228, DOI 10.1592/phco.25.2.228.56954
   Green JR, 2004, ONCOLOGIST, V9, P3, DOI 10.1634/theoncologist.9 90004 3
   Haderslev KV, 2000, GASTROENTEROLOGY, V119, P639, DOI 10.1053/gast.2000.16518
   HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0
   HAWTHORNE AB, 1992, GUT, V33, P922, DOI 10.1136/gut.33.7.922
   Koida M, 2004, CURR PHARM DESIGN, V10, P2605, DOI 10.2174/1381612043383827
   KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Lin CL, 2000, CALCIFIED TISSUE INT, V67, P373, DOI 10.1007/s002230001162
   LIN JH, 1994, J PHARM SCI US, V83, P1741, DOI 10.1002/jps.2600831218
   Ludwiczek O, 2004, CLIN EXP IMMUNOL, V138, P323, DOI 10.1111/j.1365 2249.2004.02599.x
   Mathoo Julian M R, 2004, Curr Osteoporos Rep, V2, P17, DOI 10.1007/s11914 004 0010 6
   Monteleone G, 2006, CURR OPIN GASTROEN, V22, P361, DOI 10.1097/01.mog.0000231808.10773.8e
   MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016 5085(89)90904 9
   Neurath M, 2000, Int Rev Immunol, V19, P51, DOI 10.3109/08830180009048389
   Nikolaus S, 2000, HEPATO GASTROENTEROL, V47, P71
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Poulsen SS, 2005, REGUL PEPTIDES, V126, P163, DOI 10.1016/j.regpep.2004.09.007
   RASK MADSEN J, 1992, Agents and Actions, pC37
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Sands BE, 2000, GASTROENTEROLOGY, V118, pS68, DOI 10.1016/S0016 5085(00)70007 2
   Sasaki M, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471 230X 3 3
   Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385/IR:25:3:271
   Siminovitch KA, 2006, SEMIN IMMUNOL, V18, P244, DOI 10.1016/j.smim.2006.03.012
   Stancu C, 2001, J CELL MOL MED, V5, P378, DOI 10.1111/j.1582 4934.2001.tb00172.x
   Stokkers PCF, 1998, GUT, V43, P33, DOI 10.1136/gut.43.1.33
   Stucchi AF, 2000, AM J PHYSIOL GASTR L, V279, pG1298, DOI 10.1152/ajpgi.2000.279.6.G1298
   Van Assche G, 2005, CURR OPIN GASTROEN, V21, P443
   Vandenbroucke K, 2004, GASTROENTEROLOGY, V127, P502, DOI 10.1053/j.gastro.2004.05.020
   VILASECA J, 1990, GUT, V31, P539, DOI 10.1136/gut.31.5.539
   VILASECA J, 1990, GASTROENTEROLOGY, V98, P269, DOI 10.1016/0016 5085(90)90814 H
   Von Tirpitz C, 2003, ALIMENT PHARM THER, V17, P807, DOI 10.1046/j.1365 2036.2003.01448.x
   Woodruff TM, 2005, INT IMMUNOPHARMACOL, V5, P883, DOI 10.1016/j.intimp.2005.01.003
   Yaturu Subhashini, 2003, Endocr Pract, V9, P315
NR 44
TC 30
Z9 30
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAY
PY 2007
VL 151
IS 2
BP 206
EP 215
DI 10.1038/sj.bjp.0707227
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 171GC
UT WOS:000246722300006
PM 17375077
OA Green Published
DA 2025 08 17
ER

PT J
AU Sha, T
   Wang, Z
   Li, JW
   Wu, YH
   Qiang, JB
   Yang, ZM
   Hu, Y
   Zheng, KJ
   Zhang, SY
   Sun, HZ
   Whittaker, AK
   Yang, B
   Sun, HC
   Lin, Q
   Shi, C
AF Sha, Tong
   Wang, Ze
   Li, Jinwei
   Wu, Yahong
   Qiang, Jinbiao
   Yang, Zhenming
   Hu, Yue
   Zheng, Kaijuan
   Zhang, Shuyu
   Sun, Haizhu
   Whittaker, Andrew K.
   Yang, Bai
   Sun, Hongchen
   Lin, Quan
   Shi, Ce
TI One arrow two eagles: Multifunctional nano system for macrophage
   reprogramming and osteoclastogenesis inhibition against inflammatory
   osteolysis
SO MATERIALS TODAY BIO
LA English
DT Article
DE Inflammatory osteolysis; Osteoclastogenesis inhibition; Inflammatory
   microenvironment; Macrophage reprogramming; Drug repurposing
ID NF KAPPA B; CALCITONIN; MECHANISMS
AB Inflammatory osteolysis poses a significant worldwide threat to public health. However, current monotherapies, which target either the prevention of the inflammatory response or the attenuation of osteoclast (OC) formation, have limited efficacy due to the complexity of the bone immune system being overlooked. Herein, by means of modifying salmon calcitonin (sCT), a multifunctional nano system (AuNDs sCT) was designed to synergistically inhibit OC differentiation and reverse the inflammatory microenvironment against inflammatory osteolysis. On the one hand, AuNDs sCT effectively restrained OC differentiation by binding to the calcitonin receptors on the surface of OC precursors, resulting in the down regulation of OC specific genes and proteins. The targeted capacity of AuNDs sCT provided a more durable and precise therapeutic effect. On the other hand, AuNDs sCT exhibited antioxidant and anti inflammatory effects, which regulated the polarization "switch" from the pro  inflammatory M1 phenotype to the anti inflammatory M2 phenotype in macrophages by the inhibition of NF kappa B p65 phosphorylation, thereby effectively reversed the local inflammatory microenvironment. Additionally, AuNDs sCT served as a promising fluorescent probe, enabling real time visualization of the therapeutic process. This capability is expected to optimize drug administration and evaluate therapeutic effects. In summary, by inhibiting OC differentiation and reprogramming macrophages, AuNDs sCT successfully realized drug repurposing and achieved the "one arrow two eagles" therapeutic strategy, which offers a synergistic and effective treatment option for the clinical management of inflammatory osteolysis.
C1 [Sha, Tong; Li, Jinwei; Wu, Yahong; Qiang, Jinbiao; Yang, Zhenming; Zheng, Kaijuan; Zhang, Shuyu; Sun, Hongchen; Shi, Ce] Jilin Univ, Hosp Stomatol, Dept Oral Pathol, Changchun 130021, Peoples R China.
   [Wang, Ze; Yang, Bai; Lin, Quan] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
   [Sha, Tong; Li, Jinwei; Wu, Yahong; Qiang, Jinbiao; Yang, Zhenming; Zheng, Kaijuan; Zhang, Shuyu; Sun, Hongchen; Shi, Ce] Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.
   [Hu, Yue] China Med Univ, Sch & Hosp Stomatol, Shenyang, Peoples R China.
   [Sun, Haizhu] Northeast Normal Univ, Coll Chem, Key Lab Sustained & Adv Funct Mat, Changchun 130024, Peoples R China.
   [Whittaker, Andrew K.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia.
C3 Jilin University; Jilin University; China Medical University; Northeast
   Normal University   China; University of Queensland
RP Shi, C (通讯作者)，Jilin Univ, Hosp Stomatol, Dept Oral Pathol, Changchun 130021, Peoples R China.; Lin, Q (通讯作者)，Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
EM linquan@jlu.edu.cn; ceshi@jlu.edu.cn
RI Sha, Tong/HKE 9876 2023; Zheng, Kai/AAM 2284 2021; zhang,
   shuyu/MFJ 0523 2025; Sun, Hongchen/X 7152 2019
FU National Natural Science Foundation of China [21574018, 51433003];
   National Key Research and Development Program of China [2022YFC2504200];
   Natural Science Foundation of Jilin Province [SKL202302002]; Key
   Research and Development Project of Jilin Provincial Science and
   Technology Department [20210204142YY]; Jilin University Norman Bethune
   Program [2023B28]; Fundamental Research Funds for the Central
   Universities; Natural Science Foundation of Liaoning Province
   [2022BS 123]; Science and Technology Project of Shenyang [21 173 9 34];
   The "Medical + X" Interdisciplinary Innovation Team "Announcement and
   Leadership" Construction Project [2022JBGS08]; National Natural Science
   Foundation of China [21574018, 51433003]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 82270959 and 81970903) , the National Key Research and
   Development Program of China (2022YFC2504200) , the Natural Science
   Foundation of Jilin Province (No. SKL202302002) , the Key Research and
   Development Project of Jilin Provincial Science and Technology
   Department (No. 20210204142YY) , the Jilin University Norman Bethune
   Program (No. 2023B28) , the Fundamental Research Funds for the Central
   Universities, the Natural Science Foundation of Liaoning Province (No.
   2022BS 123) , the Science and Technology Project of Shenyang (No.
   21 173 9 34) , "Medical + X" Interdisciplinary Innovation Team
   "Announcement and Leadership" Construction Project (2022JBGS08) , and
   the National Natural Science Foundation of China (Nos. 21574018 and
   51433003) .
CR Bandeira L, 2016, EXPERT OPIN DRUG MET, V12, P681, DOI 10.1080/17425255.2016.1175436
   Cao SQ, 2017, J CONTROL RELEASE, V256, P182, DOI 10.1016/j.jconrel.2017.04.014
   Chang CF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168945
   Chen H, 2022, J MATER CHEM B, V10, P4789, DOI 10.1039/d2tb00869f
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Deng WD, 2022, PHYTOMEDICINE, V96, DOI 10.1016/j.phymed.2021.153838
   Ding C, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 01128 4
   Eger M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02963
   Feng CL, 2022, ACTA BIOMATER, V150, P324, DOI 10.1016/j.actbio.2022.07.013
   Fu FS, 2019, J CELL PHYSIOL, V234, P11951, DOI 10.1002/jcp.27888
   Gan K, 2024, CELL DEATH DISCOV, V10, DOI 10.1038/s41420 024 01856 0
   Gao FP, 2019, ADV SCI, V6, DOI 10.1002/advs.201801671
   Giridharan S, 2018, J INFLAMM RES, V11, P407, DOI 10.2147/JIR.S140188
   Guo ML, 2023, ACS APPL NANO MATER, V6, P15945, DOI 10.1021/acsanm.3c02888
   Huang HR, 2024, ADV SCI, V11, DOI 10.1002/advs.202400713
   Ikegame M, 2004, BONE, V35, P27, DOI 10.1016/j.bone.2004.03.018
   Lee SM, 2013, ACS NANO, V7, P50, DOI 10.1021/nn301215q
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Liu CP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188317
   Liu YP, 2019, J CONTROL RELEASE, V304, P39, DOI 10.1016/j.jconrel.2019.04.042
   Liu YX, 2022, CHINESE CHEM LETT, V33, P1855, DOI 10.1016/j.cclet.2021.08.117
   Maleitzke T, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2021.103689
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Shapouri Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Su YY, 2023, J COLLOID INTERF SCI, V634, P601, DOI 10.1016/j.jcis.2022.12.043
   Sun YQ, 2018, NANO RES, V11, P2392, DOI 10.1007/s12274 017 1860 4
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev immunol 032414 112220
   Wang S, 2022, SMALL, V18, DOI 10.1002/smll.202104112
   Wang XF, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202301450
   Wang Z, 2023, ACS CENTRAL SCI, V9, P1976, DOI 10.1021/acscentsci.3c00994
   Wang Z, 2023, TALANTA, V256, DOI 10.1016/j.talanta.2023.124255
   Wang Z, 2023, BIOMATER SCI UK, V11, P1116, DOI 10.1039/d2bm01496c
   Wang Z, 2022, J MATER CHEM B, V10, P5182, DOI 10.1039/d2tb00531j
   Wei LH, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106400
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Xie YC, 2019, IMMUNOPHARM IMMUNOT, V41, P319, DOI 10.1080/08923973.2019.1608444
   Xing FZ, 2022, INT IMMUNOPHARMACOL, V112, DOI 10.1016/j.intimp.2022.109278
   Yang DB, 2019, SEMIN IMMUNOPATHOL, V41, P551, DOI 10.1007/s00281 019 00754 3
   Zhou H, 2023, DRUG DES DEV THER, V17, P1933, DOI 10.2147/DDDT.S417563
NR 43
TC 1
Z9 1
U1 10
U2 25
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2590 0064
J9 MATER TODAY BIO
JI Mater. Today Bio
PD DEC
PY 2024
VL 29
AR 101285
DI 10.1016/j.mtbio.2024.101285
EA OCT 2024
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA I8Z4A
UT WOS:001333078800001
PM 39435372
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Hodgson, K
   Orozco Moreno, M
   Goode, EA
   Fisher, M
   Garnham, R
   Beatson, R
   Turner, H
   Livermore, K
   Zhou, YH
   Wilson, L
   Visser, EA
   Pijnenborg, JF
   Eerden, N
   Moons, SJ
   Rossing, E
   Hysenaj, G
   Krishna, R
   Peng, ZQ
   Nangkana, KP
   Schmidt, EN
   Duxfield, A
   Dennis, EP
   Heer, R
   Lawson, MA
   Macauley, M
   Elliott, DJ
   Buell, C
   Scott, E
   Boltje, TJ
   Drake, RR
   Wang, N
   Munkley, J
AF Hodgson, Kirsty
   Orozco Moreno, Margarita
   Goode, Emily Archer
   Fisher, Matthew
   Garnham, Rebecca
   Beatson, Richard
   Turner, Helen
   Livermore, Karen
   Zhou, Yuhan
   Wilson, Laura
   Visser, Eline A.
   Pijnenborg, Johan FA.
   Eerden, Nienke
   Moons, Sam J.
   Rossing, Emiel
   Hysenaj, Gerald
   Krishna, Rashi
   Peng, Ziqian
   Nangkana, Kyla Putri
   Schmidt, Edward N.
   Duxfield, Adam
   Dennis, Ella P.
   Heer, Rakesh
   Lawson, Michelle A.
   Macauley, Matthew
   Elliott, David J.
   Buell, Christian
   Scott, Emma
   Boltje, Thomas J.
   Drake, Richard R.
   Wang, Ning
   Munkley, Jennifer
TI Sialic acid blockade inhibits the metastatic spread of prostate cancer
   to bone
SO EBIOMEDICINE
LA English
DT Article
DE Prostate cancer; Bone metastasis; Glycans; Sialylation; Sialic acid;
   Therapeutics
ID TARGETED THERAPY; TUMOR GROWTH; GLYCOSYLATION; PROGRESSION; RESISTANCE;
   SIGLECS; NICHE
AB Background Bone metastasis is a common consequence of advanced prostate cancer. Bisphosphonates can be used to manage symptoms, but there are currently no curative treatments available. Altered tumour cell glycosylation is a hallmark of cancer and is an important driver of a malignant phenotype. In prostate cancer, the sialyltransferase ST6GAL1 is upregulated, and studies show ST6GAL1 mediated aberrant sialylation of N glycans promotes prostate tumour growth and disease progression. Methods Here, we monitor ST6GAL1 in tumour and serum samples from men with aggressive prostate cancer and using in vitro and in vivo models we investigate the role of ST6GAL1 in prostate cancer bone metastasis. Findings ST6GAL1 is upregulated in patients with prostate cancer with tumours that have spread to the bone and can promote prostate cancer bone metastasis in vivo. The mechanisms involved are multi faceted and involve modification fi cation of the pre metastatic niche towards bone resorption to promote the vicious cycle, promoting the development of M2 like macrophages, and the regulation of immunosuppressive sialoglycans. Furthermore, using syngeneic mouse models, we show that inhibiting sialylation can block the spread of prostate tumours to bone. Interpretation Our study identifies fi es an important role for ST6GAL1 and alpha 2 6 sialylated N glycans in prostate cancer bone metastasis, provides proof of concept data to show that inhibiting sialylation can suppress the spread of prostate tumours to bone, and highlights sialic acid blockade as an exciting new strategy to develop new therapies for patients with advanced prostate cancer. Funding Prostate Cancer Research and the Mark Foundation For Cancer Research, the Medical Research Council and Prostate Cancer UK. Copyright (c) 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Hodgson, Kirsty; Orozco Moreno, Margarita; Goode, Emily Archer; Garnham, Rebecca; Livermore, Karen; Hysenaj, Gerald; Krishna, Rashi; Peng, Ziqian; Nangkana, Kyla Putri; Duxfield, Adam; Elliott, David J.; Scott, Emma; Munkley, Jennifer] Newcastle Univ, Newcastle Univ Ctr Canc, Inst Biosci, Newcastle Upon Tyne NE1 3BZ, England.
   [Fisher, Matthew; Zhou, Yuhan; Lawson, Michelle A.; Wang, Ning] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Div Clin Med, Sheffield, England.
   [Beatson, Richard] Univ Coll London UCL, Ctr Inflammat & Tissue Repair, Div Med, UCL Resp, Rayne 9 Bldg, London WC1E 6JF, England.
   [Turner, Helen] Royal Victoria Infirm, Cellular Pathol, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, England.
   [Wilson, Laura; Heer, Rakesh] Newcastle Univ, Newcastle Univ Ctr Canc, Translat & Clin Res Inst, Paul O Gorman Bldg, Newcastle Upon Tyne NE2 4HH, England.
   [Visser, Eline A.; Eerden, Nienke; Rossing, Emiel; Boltje, Thomas J.] Radboud Univ Nijmegen, Inst Mol & Mat, Synthet Organ Chem, Nijmegen, Netherlands.
   [Pijnenborg, Johan FA.; Eerden, Nienke] GlycoTherapeutics BV, Nijmegen, Netherlands.
   [Moons, Sam J.] Synvenio BV, Nijmegen, Netherlands.
   [Schmidt, Edward N.; Macauley, Matthew] Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
   [Schmidt, Edward N.; Macauley, Matthew] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2E1, Canada.
   [Duxfield, Adam; Dennis, Ella P.] Newcastle Univ, Int Ctr Life Biosci Inst, Newcastle Upon Tyne NE1 3BZ, England.
   [Heer, Rakesh] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, England.
   [Buell, Christian] Radboud Univ Nijmegen, Inst Mol & Mat, Biomol Chem, Nijmegen, Netherlands.
   [Drake, Richard R.] Med Univ South Carolina, Dept Cell & Mol Pharmacol, Charleston, SC USA.
   [Wang, Ning] Univ Leicester, Leicester Canc Res Ctr, Dept Genet & Genome Biol, Leicester LE2 7LX, England.
C3 Newcastle University   UK; University of Sheffield; University of
   London; University College London; Newcastle University   UK; Newcastle
   University   UK; Radboud University Nijmegen; University of Alberta;
   University of Alberta; Newcastle University   UK; Newcastle Upon Tyne
   Hospitals NHS Foundation Trust; Newcastle Freeman Hospital; Radboud
   University Nijmegen; Medical University of South Carolina; University of
   Leicester
RP Munkley, J (通讯作者)，Newcastle Univ, Newcastle Univ Ctr Canc, Inst Biosci, Newcastle Upon Tyne NE1 3BZ, England.; Wang, N (通讯作者)，Univ Leicester, Leicester Canc Res Ctr, Dept Genet & Genome Biol, Leicester LE2 7LX, England.
EM nw208@Leicester.ac.uk; Jennifer.munkley@ncl.ac.uk
RI Bull, Christian/L 9417 2013; Boltje, Thomas/F 9695 2015; Lawson,
   Michelle/M 6095 2019; Beatson, Richard/AAB 8945 2021; Rossing,
   Emiel/E 4054 2019; Moons, Sam/AAC 8707 2020; Wang, Ning/HKO 8446 2023;
   Büll, Christian/L 9417 2013; Garnham, Rebecca/LVS 7133 2024; Scott,
   Emma/HMP 3056 2023
OI Bull, Christian/0000 0001 7785 2920; Zhou, Yuhan/0000 0002 1902 4542;
   WANG, NING/0000 0002 2663 7515; Rossing, Emiel/0000 0002 6381 6475;
   Beatson, Richard/0000 0002 0411 932X; Orozco Moreno,
   Margarita/0000 0002 6180 7882; Duxfield, Adam Anthony
   Cole/0009 0004 4667 1317; Lawson, Michelle/0000 0002 5446 923X;
   Pijnenborg, Johan/0000 0003 3668 2034; Dennis, Ella/0000 0002 3076 703X;
   Hodgson, Kirsty/0000 0003 4348 0430
FU Prostate Cancer Research; Mark Foundation For Cancer Research; Medical
   Research Council; Prostate Cancer UK
FX Funding Prostate Cancer Research and the Mark Foundation For Cancer
   Research, the Medical Research Council and Prostate Cancer UK.
CR Alhamdoosh M, 2017, BIOINFORMATICS, V33, P414, DOI 10.1093/bioinformatics/btw623
   Ao JY, 2017, MOL CANCER THER, V16, P1544, DOI 10.1158/1535 7163.MCT 16 0866
   Archer Goode Emily, 2023, Oncol Lett, V25, P163, DOI 10.3892/ol.2023.13749
   Argyle D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02629
   Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060
   Bai XY, 2024, SCI REP UK, V14, DOI 10.1038/s41598 024 52073 9
   Beatson R, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003 020 01359 5
   Blaschke CRK, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.734280
   Boibessot C, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.581
   Bojar Daniel, 2022, ACS Chem Biol, V17, P2993, DOI 10.1021/acschembio.1c00689
   Bolis M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 26840 5
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150
   Büll C, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026102118
   Büll C, 2018, CANCER RES, V78, P3574, DOI 10.1158/0008 5472.CAN 17 3376
   Büll C, 2015, ACS NANO, V9, P733, DOI 10.1021/nn5061964
   Butler W, 2023, NPJ PRECIS ONCOL, V7, DOI 10.1038/s41698 023 00363 2
   Calcinotto A, 2018, NATURE, V559, P363, DOI 10.1038/s41586 018 0266 0
   Cao J, 2017, ONCOTARGET, V8, P83261, DOI 10.18632/oncotarget.18743
   de Souza Ferreira M, 2023, CELL ONCOL, V46, P481, DOI 10.1007/s13402 023 00770 4
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Dennis EP, 2020, J BONE MINER RES, V35, P1452, DOI 10.1002/jbmr.4010
   DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071
   Dorsett KA, 2021, GLYCOBIOLOGY, V31, P530, DOI 10.1093/glycob/cwaa110
   Drake Richard R, 2018, Curr Protoc Protein Sci, V94, pe68, DOI 10.1002/cpps.68
   Ereño Orbea J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 00836 6
   Escamilla J, 2015, CANCER RES, V75, P950, DOI 10.1158/0008 5472.CAN 14 0992
   Foster BA, 1997, CANCER RES, V57, P3325
   Fujiwara T, 2021, MOL CANCER THER, V20, P1388, DOI 10.1158/1535 7163.MCT 20 0591
   Furesi G, 2021, TRENDS CANCER, V7, P112, DOI 10.1016/j.trecan.2020.09.006
   Garnham R, 2024, COMMUN BIOL, V7, DOI 10.1038/s42003 024 05924 0
   Garnham R, 2019, ONCOL LETT, V18, P983, DOI 10.3892/ol.2019.10458
   Gartland A, 2016, J BONE ONCOL, V5, P100, DOI 10.1016/j.jbo.2016.04.001
   Gray MA, 2020, NAT CHEM BIOL, V16, P1376, DOI 10.1038/s41589 020 0622 x
   Guise T. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P570
   Hait NC, 2022, CANCER GENE THER, V29, P1662, DOI 10.1038/s41417 022 00485 y
   Heise T, 2019, J MED CHEM, V62, P1014, DOI 10.1021/acs.jmedchem.8b01757
   Herrera H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102528
   Hodgson K, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 43019 8
   Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood 2011 09 379214
   Kang JN, 2022, CANCER LETT, V530, P156, DOI 10.1016/j.canlet.2022.01.015
   Keeley T, 2019, TRENDS CANCER, V5, P789, DOI 10.1016/j.trecan.2019.10.013
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Konyalioglu E, 2015, INT BRAZ J UROL, V41, P442, DOI 10.1590/S1677 5538.IBJU.2014.0251
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 2 r29
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liu F, 2022, GENE, V819, DOI 10.1016/j.gene.2022.146240
   Lu XW, 2023, ANAL CHEM, V95, P7475, DOI 10.1021/acs.analchem.2c04882
   Macauley MS, 2014, J BIOL CHEM, V289, P35149, DOI 10.1074/jbc.M114.606517
   Macauley MS, 2014, NAT REV IMMUNOL, V14, P653, DOI 10.1038/nri3737
   Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Mereiter S, 2019, CANCER CELL, V36, P6, DOI 10.1016/j.ccell.2019.06.006
   Miyake H, 2000, CANCER RES, V60, P3058
   Moons SJ, 2022, ACS CHEM BIOL, V17, P590, DOI 10.1021/acschembio.1c00868
   Muliaditan T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05346 7
   Müller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059 017 1362 4
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Munkley J, 2022, CANCERS, V14, DOI 10.3390/cancers14174248
   Munkley Jennifer, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6040102
   Munkley J, 2019, ELIFE, V8, DOI 10.7554/eLife.47678
   Munkley J, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05489 5
   Munkley J, 2016, EBIOMEDICINE, V8, P103, DOI 10.1016/j.ebiom.2016.04.018
   Munkley J, 2016, ONCOTARGET, V7, P35478, DOI 10.18632/oncotarget.8155
   Munkley J, 2016, NAT REV UROL, V13, P324, DOI 10.1038/nrurol.2016.65
   Neubert NJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3311
   Nieder C, 2010, BMC UROL, V10, DOI 10.1186/1471 2490 10 23
   Nouri M, 2020, CLIN CANCER RES, V26, P1678, DOI 10.1158/1078 0432.CCR 19 0098
   Orozco Moreno M, 2023, GLYCOBIOLOGY, V33, P1155, DOI 10.1093/glycob/cwad085
   Ostrovsky AE, 2022, NUCLEIC ACIDS RES, V50, pW345, DOI 10.1093/nar/gkac247
   Pan YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583084
   Park SH, 2019, METHODS MOL BIOL, V1914, P295, DOI 10.1007/978 1 4939 8997 3_16
   Pearce OMT, 2016, GLYCOBIOLOGY, V26, P111, DOI 10.1093/glycob/cwv097
   Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6
   Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982
   Ploussard G, 2011, EUR UROL, V60, P291, DOI 10.1016/j.eururo.2011.05.006
   Power CA, 2009, PROSTATE, V69, P1613, DOI 10.1002/pros.21010
   Rodrigues E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18907 6
   Rodrigues E, 2018, CANCERS, V10, DOI 10.3390/cancers10060207
   Rodriguez E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21550 4
   Rodríguez E, 2018, NAT REV IMMUNOL, V18, P204, DOI 10.1038/nri.2018.3
   Sajina GC, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.962908
   Saudi A, 2023, CANCERS, V15, DOI 10.3390/cancers15030920
   Saunders MJ, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 27634 z
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Scott E, 2023, J PATHOL, V261, P71, DOI 10.1002/path.6152
   Scott E, 2023, ONCOGENE, V42, P926, DOI 10.1038/s41388 023 02604 x
   Scott E, 2020, CLIN CHIM ACTA, V502, P167, DOI 10.1016/j.cca.2019.12.015
   Scott E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061389
   Seif F, 2019, CURR DRUG TARGETS, V20, P789, DOI 10.2174/1389450120666190123141553
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Smith BAH, 2021, NAT REV DRUG DISCOV, V20, P217, DOI 10.1038/s41573 020 00093 1
   Stanczak MA, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj1270
   Stanczak MA, 2023, MOL ASPECTS MED, V90, DOI 10.1016/j.mam.2022.101112
   Steiger P, 2016, CANCER IMAGING, V16, DOI 10.1186/s40644 016 0068 2
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   van de Wall S, 2020, TRENDS IMMUNOL, V41, P274, DOI 10.1016/j.it.2020.02.001
   Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008
   Walker JA, 2008, IMMUNOLOGY, V123, P314, DOI 10.1111/j.1365 2567.2007.02752.x
   Walker SM, 2017, EUR UROL, V72, P509, DOI 10.1016/j.eururo.2017.03.027
   Wallace EN, 2024, SCI REP UK, V14, DOI 10.1038/s41598 023 50957 w
   Warnes G.R., 2015, GPLOTS VARIOUS R PRO
   Wei AW, 2016, ONCOTARGET, V7, P65374, DOI 10.18632/oncotarget.11699
   Weiner AB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 21245 w
   Wen JL, 2020, J PATHOL CLIN RES, V6, P171, DOI 10.1002/cjp2.160
   Whickham H., 2016, GGPLOT2 ELEGANT GRAP
   Woo JR, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 30
   Yang LL, 2012, CARCINOGENESIS, V33, P1863, DOI 10.1093/carcin/bgs226
   Yeon A, 2020, PROSTATE, V80, P424, DOI 10.1002/pros.23957
   Ylitalo EB, 2017, EUR UROL, V71, P776, DOI 10.1016/j.eururo.2016.07.033
   Young MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb 2010 11 2 r14
   Yu GY, 2023, bioRxiv, DOI [10.1101/2023.11.30.569496, 10.1101/2023.11.30.569496, DOI 10.1101/2023.11.30.569496]
   Yue ZY, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI144579
   Zarif JC, 2019, EUR UROL ONCOL, V2, P429, DOI 10.1016/j.euo.2018.09.014
NR 113
TC 15
Z9 16
U1 1
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352 3964
J9 EBIOMEDICINE
JI EBioMedicine
PD JUN
PY 2024
VL 104
AR 105163
DI 10.1016/j.ebiom.2024.105163
EA MAY 2024
PG 19
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA D4M3C
UT WOS:001295934900001
PM 38772281
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yin, ZL
   Shen, J
   Wang, Q
   Wen, LY
   Qu, WJ
   Zhang, YN
AF Yin, Zilong
   Shen, Jian
   Wang, Qiang
   Wen, Liangyuan
   Qu, Wenjing
   Zhang, Yaonan
TI miR 215 5p regulates osteoporosis development and osteogenic
   differentiation by targeting XIAP
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE miR 215 5p; XIAP; Osteoporosis; Osteogenic differentiatioz
ID BONE FORMATION; PROMOTES; APOPTOSIS; CELLS
AB Background Osteoporosis (OP) is a metabolic disease that involves microstructure destruction and fracture damage. The present study probed into the significance of miR 215 5p in OP progression. Methods Serum samples were collected from surgical patients and healthy controls. qRT PCR analysis was utilized to determine the miR 215 5p level in clinical samples and human bone mesenchymal stem cells (hBMSCs) induced by beta glycerol phosphate. A dual luciferase reporter assay was exploited to examine the targeted relationship between miR 215 5p and XIAP. The mineralization and calcium deposition of hBMSCs were assessed by detection of ALP activity, Alizarin red staining, and osteoblast marker expression. Protein expression was determined by western blot analysis. Results MiR 215 5p was significantly reduced in patients with OP and increased in hBMSCs treated with beta glycerophosphate. Enhanced miR 215 5p level triggered augment in osteoblast markers (Alkaline phosphatase/ ALP, Osteocalcin/ OCN, and Runt Related Transcription Factor 2/ Runx2), which was accompanied by the increase of ALP activity in hBMSCs and accumulation of Calcium. Functional experiments show that XIAP was a target of miR 215 5p and negatively modulated by miR 215 5p. XIAP expression levels were increased in OP samples, and decreased XIAP in beta glycerophosphate treated hBMSCs inhibited its' osteogenic differentiation. Functional loss and acquisition experiments depicted that miR 215 5p promoted the differentiation of hBMSCs by inhibiting the XIAP level, playing a protective role in the pathogenesis of OP. Conclusions beta glycerophosphate promoted the osteogenic differentiation of hBMSCs, increased miR 215 5p level, and decreased XIAP. miR 215 5p stimulated osteogenic differentiation of hBMSCs by targeting XIAP, shedding new insights for the detection and therapy of OP.
C1 [Yin, Zilong; Shen, Jian; Wang, Qiang; Wen, Liangyuan; Zhang, Yaonan] Chinese Acad Med Sci, Dept Orthopaed, Beijing Hosp, Natl Ctr Gerontol,Inst Geriatr Med, Beijing, Peoples R China.
   [Qu, Wenjing] Tongzhou Maternal & Child Hlth Hosp Beijing, Dept Surg, 124 Yugiao Middle Rd, Beijing 101100, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Beijing Hospital
RP Qu, WJ (通讯作者)，Tongzhou Maternal & Child Hlth Hosp Beijing, Dept Surg, 124 Yugiao Middle Rd, Beijing 101100, Peoples R China.
EM quwenjing2022@163.com
RI Wang, Qiang/JXK 5225 2024; qu, wenjing/GRE 9548 2022
CR Canalis E, 2013, NAT REV ENDOCRINOL, V9, P575, DOI 10.1038/nrendo.2013.154
   Chang YY, 2020, BONE, V130, DOI 10.1016/j.bone.2019.115072
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Collins FL, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.BAD 0015 2016
   Fan QX, 2020, BIOCHEM BIOPH RES CO, V525, P498, DOI 10.1016/j.bbrc.2020.02.126
   Xiaoling GL, 2020, BMC MED GENET, V21, DOI 10.1186/s12881 020 0948 y
   Gao JB, 2019, FEBS OPEN BIO, V9, P1957, DOI 10.1002/2211 5463.12733
   Ge GQ, 2016, ONCOL REP, V35, P1816, DOI 10.3892/or.2015.4482
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang SH, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190445
   Huang W, 2020, ONCOTARGETS THER, V13, P413, DOI 10.2147/OTT.S237161
   Huang Y, 2020, MOL MED REP, V22, P43, DOI 10.3892/mmr.2020.11122
   Karimi Z, 2020, MOL BIOL REP, V47, P8451, DOI 10.1007/s11033 020 05885 7
   Kim J, 2015, J GINSENG RES, V39, P46, DOI 10.1016/j.jgr.2014.06.001
   Li F, 2019, GENE, V685, P106, DOI 10.1016/j.gene.2018.10.054
   Li Y, 2019, MOL THER NUCL ACIDS, V17, P590, DOI 10.1016/j.omtn.2019.06.023
   Liao CH, 2020, DIFFERENTIATION, V116, P1, DOI 10.1016/j.diff.2020.09.005
   Lin ZY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12688
   Liu SY, 2020, J CELL BIOCHEM, V121, P1475, DOI 10.1002/jcb.29383
   Liu ZH, 2021, J COMPUT ASSIST TOMO, V45, P452, DOI 10.1097/RCT.0000000000001168
   Lu CH, 2021, CANCER BIOTHER RADIO, V36, P728, DOI 10.1089/cbr.2019.3011
   Luo ZW, 2019, NANOSCALE, V11, P20884, DOI 10.1039/c9nr02791b
   Ma ZP, 2019, MED SCI MONITOR, V25, P5312, DOI 10.12659/MSM.915529
   Mandourah AY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26525 y
   Monterde Cruz L, 2018, HUM CELL, V31, P292, DOI 10.1007/s13577 018 0214 1
   Pierce JL, 2019, BONE, V118, P2, DOI 10.1016/j.bone.2018.05.019
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Vychytilova Faltejskova P, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389 017 0006 6
   Wang H, 2020, J ORAL REHABIL, V47, P4, DOI 10.1111/joor.12896
   Wang JQ, 2021, BIOCHEM GENET, V59, P1146, DOI 10.1007/s10528 021 10048 9
   Wang WL, 2021, ONCOTARGETS THER, V14, P3281, DOI 10.2147/OTT.S290270
   Yang C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1168 2
   Yang JX, 2020, CELL SIGNAL, V70, DOI 10.1016/j.cellsig.2019.109504
   Yang XC, 2019, AGING US, V11, P8777, DOI 10.18632/aging.102264
   Yao Q, 2019, CURR OPIN CHEM BIOL, V51, P11, DOI 10.1016/j.cbpa.2019.01.024
   Ye MX, 2015, CANCER LETT, V357, P196, DOI 10.1016/j.canlet.2014.11.028
   Zhang L, 2017, J BONE MINER RES, V32, P2466, DOI 10.1002/jbmr.3230
NR 38
TC 9
Z9 9
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 17
PY 2022
VL 23
IS 1
AR 789
DI 10.1186/s12891 022 05731 w
PG 9
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 3X0VC
UT WOS:000842762800001
PM 35978328
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xie, XK
   Tan, Y
   Xiao, H
   Wen, YX
   Magdalou, J
   Chen, LB
   Wang, H
AF Xie, Xingkui
   Tan, Yang
   Xiao, Hao
   Wen, Yinxian
   Magdalou, Jacques
   Chen, Liaobin
   Wang, Hui
TI Subchondral bone dysplasia mediates susceptibility to osteoarthritis in
   female adult offspring rats induced by prenatal caffeine exposure
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Caffeine; Subchondral bone; Dysplasia; Osteoarthritis
ID OSSIFICATION CENTER FORMATION; SELF REPORTED OSTEOARTHRITIS;
   POSTMENOPAUSAL WOMEN; ARTICULAR CARTILAGE; RISK; PREMATURITY; THERAPY;
   APNEA
AB Our previous studies confirmed that prenatal caffeine exposure (PCE) could induce susceptibility to osteoarthritis in adult offspring rats due to poor chondrocyte differentiation, but its mechanism remains to be further investigated. This study aimed to explore whether subchondral bone dysplasia mediates susceptibility to osteoarthritis in adult offspring rats induced by PCE. Pregnant Wistar rats were treated with caffeine (120 mg/kg.d) or saline from gestational day (GD) 9 to 20. The female offspring were euthanized to collect femurs at GD20, postnatal week (PW) 6, and PW28 (non ovariectomy and ovariectomy groups) to detect osteoarthritis like phenotype, subchondral bone mass, ossification center development, and other evidence. The results showed that PCE increased the Mankin score of pathological articular cartilage, but decreased articular cartilage thickness and subchondral bone mass, which were more obvious after ovariectomy. Meanwhile, the correlation analysis results demonstrated that the Mankin score of articular cartilage was significantly negatively correlated with subchondral bone mass, and the thickness of articular cartilage was significantly positively correlated with subchondral bone mass. Further, the length and area of the primary and secondary ossification centers, the number of osteoblasts, and the related genes' expression of osteogenic differentiation (e.g., Runx2, BSP, ALP, and OCN) were all significantly decreased in the PCE group before and after birth. Taken together, PCE induced susceptibility to osteoarthritis in adult female offspring, which was likely related to the subchondral bone dysplasia and reduction of subchondral bone mass production due to developmental disorder of primary and secondary ossification centers caused by osteoblast differentiation disability before and after birth.
C1 [Xie, Xingkui; Tan, Yang; Xiao, Hao; Wen, Yinxian; Chen, Liaobin] Wuhan Univ, Zhongnan Hosp, Dept Orthoped Surg, Wuhan 430071, Peoples R China.
   [Xie, Xingkui; Wang, Hui] Wuhan Univ, Sch Basic Med Sci, Dept Pharmacol, Wuhan 430071, Peoples R China.
   [Tan, Yang; Wen, Yinxian; Chen, Liaobin; Wang, Hui] Hubei Prov Key Lab Dev Originated Dis, Wuhan 430071, Peoples R China.
   [Magdalou, Jacques] Univ Lorraine, Fac Med, CNRS, UMR 7561, Vandoeuvre Les Nancy, France.
C3 Wuhan University; Wuhan University; Centre National de la Recherche
   Scientifique (CNRS); Universite de Lorraine
RP Chen, LB (通讯作者)，Wuhan Univ, Zhongnan Hosp, Dept Orthoped Surg, Wuhan 430071, Peoples R China.; Wang, H (通讯作者)，Wuhan Univ, Basic Med Sch, Dept Pharmacol, Wuhan 430071, Peoples R China.
EM lbchen@whu.edu.cn; wanghui19@whu.edu.cn
RI tan, yang/HJH 0248 2022
FU National Natural Science Foundation of China [81972036, 81673490,
   81403027, 81603214]; National Key Research and Development Program of
   China [2017YFC1001300]; Medical Science Advancement Program (Basic
   Medical Sciences) of Wuhan University [TFJC2018001]; Hubei Province
   health and family planning scientific research project [WJ2019Q051]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81972036, 81673490, 81403027, 81603214), the
   National Key Research and Development Program of China (No.
   2017YFC1001300), the Medical Science Advancement Program (Basic Medical
   Sciences) of Wuhan University (No. TFJC2018001), and the Hubei Province
   health and family planning scientific research project (No. WJ2019Q051).
CR Atik A, 2017, NEUROTOXICOLOGY, V58, P94, DOI 10.1016/j.neuro.2016.11.012
   Bakker R, 2010, AM J CLIN NUTR, V91, P1691, DOI 10.3945/ajcn.2009.28792
   Bellido M, 2011, OSTEOARTHR CARTILAGE, V19, P1228, DOI 10.1016/j.joca.2011.07.003
   Bellido M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3103
   Bianco D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020475
   Bobinac D, 2013, OSTEOARTHR CARTILAGE, V21, P1724, DOI 10.1016/j.joca.2013.06.030
   Bond S J, 1992, J Ky Med Assoc, V90, P242
   Boylan S, 2008, BMJ BRIT MED J, V337, DOI 10.1136/bmj.a2332
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Cirillo DJ, 2006, ARTHRITIS RHEUM US, V54, P3194, DOI 10.1002/art.22138
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Gait AD, 2016, OSTEOARTHR CARTILAGE, V24, P1392, DOI 10.1016/j.joca.2016.03.015
   Geusens PP, 2016, CURR OPIN RHEUMATOL, V28, P97, DOI 10.1097/BOR.0000000000000256
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Grosso G, 2017, ANNU REV NUTR, V37, P131, DOI 10.1146/annurev nutr 071816 064941
   Guilbert J J, 2003, Educ Health (Abingdon), V16, P230
   Hanna FS, 2004, SEMIN ARTHRITIS RHEU, V34, P631, DOI 10.1016/j.semarthrit.2004.07.007
   Herrero Beaumont G, 2013, NAT REV RHEUMATOL, V9, P448, DOI 10.1038/nrrheum.2013.113
   Hoegh Andersen P, 2004, ARTHRITIS RES THER, V6, pR169, DOI 10.1186/ar1152
   Hu SW, 2019, TOXICOLOGY, V417, P23, DOI 10.1016/j.tox.2019.02.008
   Knight CA, 2006, CAN J DIET PRACT RES, V67, P96, DOI 10.3148/67.2.2006.96
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Luo HW, 2015, SCI REP UK, V5, DOI 10.1038/srep17746
   Maes C, 2010, DEV CELL, V19, P329, DOI 10.1016/j.devcel.2010.07.010
   Marcus CL, 2014, AM J RESP CRIT CARE, V190, P791, DOI 10.1164/rccm.201406 1092OC
   Martel Pelletier J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.72
   Mikkelsen SH, 2017, J PEDIATR US, V189, P120, DOI 10.1016/j.jpeds.2017.06.051
   Papadopoulou E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen 2017 018895
   Partosch F, 2015, FOOD CHEM TOXICOL, V86, P291, DOI 10.1016/j.fct.2015.11.005
   Prieto Alhambra D, 2013, ANN RHEUM DIS, V72, P911, DOI 10.1136/annrheumdis 2012 201451
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Reyes CM, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111772
   Roman Blas JA, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0494 0
   Shangguan YF, 2018, AM J PATHOL, V188, P2863, DOI 10.1016/j.ajpath.2018.08.008
   Srikanth VK, 2005, OSTEOARTHR CARTILAGE, V13, P769, DOI 10.1016/j.joca.2005.04.014
   Tan Y, 2018, TOXICOL LETT, V295, P229, DOI 10.1016/j.toxlet.2018.06.1221
   Tan Y, 2012, TOXICOL LETT, V214, P279, DOI 10.1016/j.toxlet.2012.09.007
   Tong W, 2019, STEM CELLS, V37, P677, DOI 10.1002/stem.2975
   Wang CJ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4601
   Wang YM, 2015, J BONE MINER RES, V30, P2239, DOI 10.1002/jbmr.2563
   Wierzejska R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040806
   Wikoff D, 2017, FOOD CHEM TOXICOL, V109, P585, DOI 10.1016/j.fct.2017.04.002
   Wright NC, 2008, J AM GERIATR SOC, V56, P1736, DOI 10.1111/j.1532 5415.2008.01812.x
   Xiao YP, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1045 7
NR 45
TC 6
Z9 6
U1 0
U2 26
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 4274
EI 1879 3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD MAR 15
PY 2020
VL 321
BP 122
EP 130
DI 10.1016/j.toxlet.2019.12.026
PG 9
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA KB6US
UT WOS:000506628300015
PM 31874197
DA 2025 08 17
ER

PT J
AU Ishioka, M
   Nihashi, Y
   Sunagawa, Y
   Umezawa, K
   Shimosato, T
   Kagami, H
   Morimoto, T
   Takaya, T
AF Ishioka, Mina
   Nihashi, Yuma
   Sunagawa, Yoichi
   Umezawa, Koji
   Shimosato, Takeshi
   Kagami, Hiroshi
   Morimoto, Tatsuya
   Takaya, Tomohide
TI Myogenetic Oligodeoxynucleotide Induces Myocardial Differentiation of
   Murine Pluripotent Stem Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE myogenetic oligodeoxynucleotide (myoDN); aptamer; nucleolin; embryonic
   stem cells; induced pluripotent stem cells; myocardial differentiation
ID MUSCLE REGENERATION; SELF RENEWAL; PROTEIN; HYPERTROPHY; INHIBITION;
   GENERATION; ROLES; GATA4
AB An 18 base myogenetic oligodeoxynucleotide (myoDN), iSN04, acts as an anti nucleolin aptamer and induces myogenic differentiation of skeletal muscle myoblasts. This study investigated the effect of iSN04 on murine embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). In the undifferentiated state, iSN04 inhibited the proliferation of ESCs and iPSCs but did not affect the expression of pluripotent markers. In the differentiating condition, iSN04 treatment of ESCs/iPSCs from day 5 onward dramatically induced differentiation into Nkx2 5+ beating cardiomyocytes with upregulation of Gata4, Isl1, and Nkx2 5, whereas iSN04 treatment from earlier stages completely inhibited cardiomyogenesis. RNA sequencing revealed that iSN04 treatment from day 5 onward contributes to the generation of cardiac progenitors by modulating the Wnt signaling pathway. Immunostaining showed that iSN04 suppressed the cytoplasmic translocation of nucleolin and restricted it to the nucleoli. These results demonstrate that nucleolin inhibition by iSN04 facilitates the terminal differentiation of cardiac mesoderm into cardiomyocytes but interferes with the differentiation of early mesoderm into the cardiac lineage. This is the first report on the generation of cardiomyocytes from pluripotent stem cells using a DNA aptamer. Since iSN04 did not induce hypertrophic responses in primary cultured cardiomyocytes, iSN04 would be useful and safe for the regenerative therapy of heart failure using stem cell derived cardiomyocytes.
C1 [Ishioka, Mina; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, 8304 Minami Minowa, Kami Ina, Nagano 3994598, Japan.
   [Nihashi, Yuma] Natl Inst Adv Ind Sci & Technol, Cellular & Mol Biotechnol Res Inst, Cent 5 41,Higashi 1 1 1, Tsukuba, Ibaraki 3058565, Japan.
   [Sunagawa, Yoichi; Morimoto, Tatsuya] Univ Shizuoka, Sch Pharmaceut Sci, Div Mol Med, 52 1 Yada,Suruga Ku, Shizuoka 4228526, Japan.
   [Umezawa, Koji; Shimosato, Takeshi; Kagami, Hiroshi; Takaya, Tomohide] Shinshu Univ, Fac Agr, Dept Agr & Life Sci, 8304 Minami Minowa, Kami Ina, Nagano 3994598, Japan.
   [Umezawa, Koji; Shimosato, Takeshi; Takaya, Tomohide] Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, 8304 Minami Minowa, Kami Ina, Nagano 3994598, Japan.
C3 Shinshu University; National Institute of Advanced Industrial Science &
   Technology (AIST); University of Shizuoka; Shinshu University; Shinshu
   University
RP Takaya, T (通讯作者)，Shinshu Univ, Grad Sch Sci & Technol, Dept Agr, 8304 Minami Minowa, Kami Ina, Nagano 3994598, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Fac Agr, Dept Agr & Life Sci, 8304 Minami Minowa, Kami Ina, Nagano 3994598, Japan.; Takaya, T (通讯作者)，Shinshu Univ, Inst Biomed Sci, Dept Biomol Innovat, 8304 Minami Minowa, Kami Ina, Nagano 3994598, Japan.
EM 19as101k@shinshu u.ac.jp; y nihashi@aist.go.jp;
   y.sunagawa@u shizuoka ken.ac.jp; koume@shinshu u.ac.jp;
   shimot@shinshu u.ac.jp; kagami@shinshu u.ac.jp;
   morimoto@u shizuoka ken.ac.jp; ttakaya@shinshu u.ac.jp
RI Takaya, Tomohide/D 6372 2012; Sunagawa, Yoichi/AAU 6354 2021; Shimosato,
   Takeshi/ABA 1499 2020
OI Takaya, Tomohide/0000 0002 3610 0906; Nihashi, Yuma/0000 0002 5689 116X;
   Shimosato, Takeshi/0000 0001 8132 1911; Sunagawa,
   Yoichi/0000 0002 4516 2308
FU The preprint has been posted on bioRxiv.; Grants in Aid for Scientific
   Research [22K05554] Funding Source: KAKEN
FX The preprint has been posted on bioRxiv.
CR Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   D'Amato G, 2016, FEBS J, V283, P4223, DOI 10.1111/febs.13773
   Dogan A, 2018, ADV EXP MED BIOL, V1079, P1, DOI 10.1007/5584_2018_175
   Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB
   Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02 0104fje
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jia WY, 2017, LIFE SCI, V186, P1, DOI 10.1016/j.lfs.2017.07.025
   Johansson H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013678
   Kaichi S, 2011, J CELL PHYSIOL, V226, P248, DOI 10.1002/jcp.22336
   Laurincik J, 2004, MOL REPROD DEV, V68, P327, DOI 10.1002/mrd.20088
   Lei H, 2021, HEART FAIL REV, V26, P1505, DOI 10.1007/s10741 020 09959 3
   Li H, 2009, STEM CELLS, V27, P1244, DOI 10.1002/stem.55
   Liu JJ, 2020, CURR MED SCI, V40, P35, DOI 10.1007/s11596 020 2144 x
   Liu WR, 2012, BIOL OPEN, V1, P208, DOI 10.1242/bio.2012038
   Mazzotta S, 2016, STEM CELL REP, V7, P764, DOI 10.1016/j.stemcr.2016.08.008
   Mercola M, 2011, GENE DEV, V25, P299, DOI 10.1101/gad.2018411
   Mizuno Y, 2010, FASEB J, V24, P2245, DOI 10.1096/fj.09 137174
   Mukherjee S, 2022, CELL REP, V40, DOI 10.1016/j.celrep.2022.111247
   Mummery CL, 2012, CIRC RES, V111, P344, DOI 10.1161/CIRCRESAHA.110.227512
   Naito AT, 2006, P NATL ACAD SCI USA, V103, P19812, DOI 10.1073/pnas.0605768103
   Nakamura S, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.679152
   Narita S, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2022.104651
   Nihashi Y, 2022, MUSCLES BASEL, V1, P111, DOI 10.3390/muscles1020012
   Nihashi Y, 2022, NANOMATERIALS BASEL, V12, DOI 10.3390/nano12101680
   Nihashi Y, 2021, ANIM SCI J, V92, DOI 10.1111/asj.13597
   Nohira N, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10112691
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Percharde M, 2018, CELL, V174, P391, DOI 10.1016/j.cell.2018.05.043
   Reister S, 2019, LEUKEMIA, V33, P1052, DOI 10.1038/s41375 019 0401 4
   Sakurai H, 2008, STEM CELLS, V26, P1865, DOI 10.1634/stemcells.2008 0173
   Schmeckpeper J, 2015, J MOL CELL CARDIOL, V85, P215, DOI 10.1016/j.yjmcc.2015.06.003
   Shinji S, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.616706
   Tajbakhsh S, 2009, J INTERN MED, V266, P372, DOI 10.1111/j.1365 2796.2009.02158.x
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takaya T, 2008, J BIOL CHEM, V283, P9828, DOI 10.1074/jbc.M707391200
   Ueki R, 2019, CHEM COMMUN, V55, P2672, DOI 10.1039/c8cc08080a
   Wang T, 2019, BIOTECHNOL ADV, V37, P28, DOI 10.1016/j.biotechadv.2018.11.001
   Wang T, 2015, MOL CELL BIOL, V35, P1281, DOI 10.1128/MCB.01156 14
   Yamamoto M, 2023, BIOCHEM BIOPH RES CO, V664, P1, DOI 10.1016/j.bbrc.2023.04.098
   Yang A, 2011, J BIOL CHEM, V286, P43370, DOI 10.1074/jbc.M111.225185
NR 42
TC 5
Z9 6
U1 1
U2 8
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2023
VL 24
IS 18
AR 14380
DI 10.3390/ijms241814380
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA S7DH1
UT WOS:001072731400001
PM 37762684
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Birlik, M
   Çapar, S
   Akar, S
   Sari, I
   Önen, F
   Akkoç, N
AF Birlik, Merih
   Capar, Sedat
   Akar, Servet
   Sari, Ismail
   Onen, Fatos
   Akkoc, Nurullah
TI Comparison of Glucocorticoid and Nonsteroidal Anti Inflammatory Drug
   Requirement Before and After Tumor Necrosis Factor Inhibitor Treatment
   in Patients With Rheumatoid Arthritis
SO ARCHIVES OF RHEUMATOLOGY
LA English
DT Article
DE Corticosteroid sparing; glucocorticoid; nonsteroidal anti inflammatory
   drug; tumor necrosis factor inhibitor; rheumatoid arthritis
ID DOSE PREDNISONE THERAPY; PEPTIC ULCER DISEASE; BLOOD PRESSURE;
   DOUBLE BLIND; OSTEOPOROSIS; METAANALYSIS; ASSOCIATION; INFECTION; AGENTS
AB Objectives: This study aims to investigate whether use of nonsteroidal anti inflammatory drugs (NSAIDs) or glucocorticoids (GCs) decreases over different time intervals before and after anti tumor necrosis factor (anti TNF) therapy in rheumatoid arthritis (RA) patients.
   Patients and methods: Data were extracted from electronic prescription records of the Pension Fund of Turkey covering records from the years 2000 to 2005 to detect patients aged 18 years or older who were administered anti TNF agents. All TNF blockers, NSAIDs and GCs which were available in the market were our target of investigation. Patients were categorized into three groups defined by duration of continuous anti TNF use (episode 1: >90 days, episode 2: >180 days, episode 3: >365 days). First anti TNF prescription detected in the database was identified as the index prescription and its date was taken as the start date of therapy. GC and NSAID consumptions during the first three, six and 12 months before initiation of anti TNF agents were compared with the subsequent same duration of consumptions after the initiation of anti TNF agents.
   Results: Comparison of GC consumptions in each paired durations of six and 12 months before and after anti TNF therapy revealed significantly decreased mean daily GC intake. Achieved reduction rates were 11% at six months and 30% at 12 months. Initiation of anti TNF therapy was found to be associated with reduced NSAID use. This pattern was similar as that of GC use except for consumption comparisons in the first episode.
   Conclusion: Anti TNF treatment reduced NSAID and GC usage in patients with RA. Evidence of decreased consumption for both medication groups have been reached statistical significance after the first six months of biologic treatment initiation.
C1 [Birlik, Merih; Akar, Servet; Sari, Ismail; Onen, Fatos; Akkoc, Nurullah] Dokuz Eylul Univ, Dept Rheumatol, Fac Med, TR 35340 Izmir, Turkey.
   [Capar, Sedat] Dokuz Eylul Univ, Dept Stat, Fac Sci, TR 35340 Izmir, Turkey.
C3 Dokuz Eylul University; Dokuz Eylul University
RP Birlik, M (通讯作者)，Dokuz Eylul Univ, Tip Fak, Hastaliklari Anabilim Dali, Immunoloji Romatoloji Bilim Dali, TR 35340 Izmir, Turkey.
EM birlikm@gmail.com
RI Birlik, Merih/AIA 2552 2022; Onen, Fatos/AAA 8970 2021; Sari,
   Ismail/E 1778 2011; Akkoc, Nurullah/D 9870 2011; Çapar,
   Sedat/H 9418 2014; Birlik, Ahmet/AIA 2552 2022; Akar, Servet/G 2339 2012
OI Birlik, Merih/0000 0001 5118 9307; Sari, Ismail/0000 0001 7737 4180;
   Akkoc, Nurullah/0000 0002 3718 171X; Onen, Fatos/0000 0002 6341 2622
CR [Anonymous], 1954, Br Med J, V1, P1223
   [Anonymous], 1959, ANN RHEUM DIS, V18, P173
   Armstrong EP, 2003, CLIN THER, V25, P1, DOI 10.1016/S0149 2918(03)90003 8
   CONNELL JMC, 1987, J HYPERTENS, V5, P425
   Dixon WG, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3453
   Donahue KE, 2008, ANN INTERN MED, V148, P124, DOI 10.7326/0003 4819 148 2 200801150 00192
   Geborek P, 2002, ANN RHEUM DIS, V61, P793, DOI 10.1136/ard.61.9.793
   HARRIS ED, 1983, J RHEUMATOL, V10, P713
   Huang JQ, 2002, LANCET, V359, P14, DOI 10.1016/S0140 6736(02)07273 2
   Kawai VK, 2011, ARTHRIT CARE RES, V63, P1415, DOI 10.1002/acr.20550
   KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302
   Kwoh CK, 2002, ARTHRITIS RHEUM US, V46, P328
   KYLE V, 1989, ANN RHEUM DIS, V48, P662, DOI 10.1136/ard.48.8.662
   LANZA FL, 1984, AM J MED, V77, P19, DOI 10.1016/S0002 9343(84)80014 5
   MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473
   MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105
   Naumann L, 2009, ANN RHEUM DIS, V68, P1934, DOI 10.1136/ard.2009.111807
   PIRPIRIS M, 1992, HYPERTENSION, V19, P567, DOI 10.1161/01.HYP.19.6.567
   REID IR, 1989, CLIN ENDOCRINOL, V30, P83, DOI 10.1111/j.1365 2265.1989.tb03730.x
   Rosen J, 2005, ENDOCR REV, V26, P452, DOI 10.1210/er.2005 0002
   Seror R, 2009, CLIN EXP RHEUMATOL, V27, P807
   van Everdingen AA, 2002, ANN INTERN MED, V136, P1, DOI 10.7326/0003 4819 136 1 200201010 00006
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Wei L, 2004, ANN INTERN MED, V141, P764, DOI 10.7326/0003 4819 141 10 200411160 00007
   1957, ANN RHEUM DIS, V16, P277
NR 25
TC 0
Z9 0
U1 0
U2 8
PU TURKISH LEAGUE AGAINST RHEUMATISM
PI ANKARA
PA TALATPASA BULVARI DUMLUPINAR CAD 40 3 CEBECI DORTYOL, ANKARA, 06100,
   TURKEY
SN 1309 0291
EI 2148 5046
J9 ARCH RHEUMATOL
JI Arch. Rheumatol.
PD SEP
PY 2015
VL 30
IS 3
BP 206
EP 213
DI 10.5606/ArchRheumatol.2015.5504
PG 8
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CT8RI
UT WOS:000363083300004
OA hybrid
DA 2025 08 17
ER

PT J
AU Ferreira, A
   Alho, I
   Vendrell, I
   Melo, M
   Brás, R
   Costa, AL
   Sousa, AR
   Mansinho, A
   Abreu, C
   Pulido, C
   Macedo, D
   Pacheco, T
   Correia, L
   Costa, L
   Casimiro, S
AF Ferreira, Arlindo
   Alho, Irina
   Vendrell, Ines
   Melo, Marta
   Bras, Raquel
   Costa, Ana Lucia
   Sousa, Ana Rita
   Mansinho, Andre
   Abreu, Catarina
   Pulido, Catarina
   Macedo, Daniela
   Pacheco, Teresa
   Correia, Lurdes
   Costa, Luis
   Casimiro, Sandra
TI The prognostic role of RANK SNP rs34945627 in breast cancer patients
   with bone metastases
SO ONCOTARGET
LA English
DT Article
DE breast cancer; bone metastases; RANK/RANKL pathway; single nucleotide
   polymorphism; prognostic factor
ID MINERAL DENSITY; CHRONIC PERIODONTITIS; GENE POLYMORPHISMS; IRANIAN
   PATIENTS; MAMMARY CANCER; RECURRENCE; THERAPY; OPG; OSTEOCLAST; PATHWAY
AB Receptor activator of NF kB (RANK) pathway regulates bone remodeling and is involved in breast cancer (BC) progression. Genetic polymorphisms affecting RANK ligand (RANKL) and osteoprotegerin (OPG) have been previously associated with BC risk and bone metastasis (BM) free survival, respectively. In this study we conducted a retrospective analysis of the association of five missense RANK SNPs with clinical characteristics and outcomes in BC patients with BM. SNP rs34945627 had an allelic frequency of 12.5% in BC patients, compared to 1.2% in the control group (P = 0.005). SNP rs34945627 was not associated with any clinicopathological characteristics, but patients presenting SNP rs34945627 had decreased disease free survival (DFS) (log  rank P = 0.039, adjusted HR 2.29, 95% CI 1.04  5.08, P = 0.041), and overall survival (OS) (log  rank P = 0.019, adjusted HR 4.32, 95% CI 1.55 12.04, P = 0.005). No differences were observed regarding bone disease free survival (log  rank P = 0.190, adjusted HR 1.68, 95% CI 0.78 3.66, P = 0.187), time to first skeletalrelated event (log  rank P = 0.753, adjusted HR 1.28, 95% CI 1.42  3.84; P = 0.665), or time to bone progression (log  rank P = 0.618, adjusted HR 0.511, 95% CI 0.17 1.51; P = 0.233). Our analysis shows that RANK SNP rs34945627 has a high allelic frequency in patients with BC and BM, and is associated with decreased DFS and OS.
C1 [Ferreira, Arlindo; Alho, Irina; Melo, Marta; Bras, Raquel; Pacheco, Teresa; Costa, Luis; Casimiro, Sandra] Univ Lisbon, Inst Med Mol, Fac Med, Lisbon, Portugal.
   [Ferreira, Arlindo; Vendrell, Ines; Costa, Ana Lucia; Sousa, Ana Rita; Mansinho, Andre; Abreu, Catarina; Pulido, Catarina; Macedo, Daniela; Pacheco, Teresa; Costa, Luis] Hosp Santa Maria, Div Oncol, Ctr Hosp Lisboa Norte, Lisbon, Portugal.
   [Correia, Lurdes] Hosp Santa Maria, Div Pathol, Ctr Hosp Lisboa Norte, Lisbon, Portugal.
C3 Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria;
   Universidade de Lisboa; Hospital Santa Maria
RP Costa, L; Casimiro, S (通讯作者)，Univ Lisbon, Inst Med Mol, Fac Med, Lisbon, Portugal.; Costa, L (通讯作者)，Hosp Santa Maria, Div Oncol, Ctr Hosp Lisboa Norte, Lisbon, Portugal.
EM luiscosta.oncology@gmail.com; scasimiro@medicina.ulisboa.pt
RI ; Costa, Ana/C 3134 2012; Casimiro, Sandra/J 3332 2013; Costa,
   Luis/E 5117 2015; Alho Duarte, Irina/ISU 0382 2023; Ferreira,
   Arlindo/AAD 6340 2020
OI Casimiro, Sandra/0000 0002 6917 4477; Ferreira,
   Arlindo/0000 0002 1567 9322; Marques, Catarina/0000 0003 3558 3966;
   Vendrell, Ines/0000 0002 1667 5526; Gomes de Melo,
   Marta/0000 0003 2255 7654; Mansinho, Andre/0000 0001 8771 0838; Lopes
   Bras, Raquel/0000 0002 8976 3199
FU GAPIC program of Faculdadc de Medicina da Universidade de Lisboa
FX This work was partially supported by an educational grant from GAPIC
   program of Faculdadc de Medicina da Universidade de Lisboa.
CR Allemani C, 2013, INT J CANCER, V132, P1170, DOI 10.1002/ijc.27725
   [Anonymous], SAN ANT BREAST CANC
   Asselin Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   Assmann G, 2010, J RHEUMATOL, V37, P900, DOI 10.3899/jrheum.091110
   Casimiro S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063153
   Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221
   Cossetti RJD, 2015, J CLIN ONCOL, V33, P65, DOI 10.1200/JCO.2014.57.2461
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Dowsett M, 2013, J CLIN ONCOL, V31, P2783, DOI 10.1200/JCO.2012.46.1558
   Elkin EB, 2015, J CLIN ONCOL, V33, P2837, DOI 10.1200/JCO.2015.62.4890
   Hein A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/842452
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Kadkhodazadeh M, 2013, ARCH ORAL BIOL, V58, P530, DOI 10.1016/j.archoralbio.2012.10.015
   Kadkhodazadeh M, 2012, EUR J ORAL IMPLANTOL, V5, P381
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Mencej Bedrac Simona, 2014, Drug Metabolism and Drug Interactions, V29, P111, DOI 10.1515/dmdi 2013 0066
   Ney JT, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 40
   Omar HS, 2015, MOL CELL BIOCHEM, V403, P219, DOI 10.1007/s11010 015 2352 z
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008 5472.CAN 12 0044
   Piedra M, 2011, BMC MED GENET, V12, DOI 10.1186/1471 2350 12 168
   Santini D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019234
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Sigl V, 2014, CYTOKINE GROWTH F R, V25, P205, DOI 10.1016/j.cytogfr.2014.01.002
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654
   Tu P, 2015, OSTEOPOROSIS INT, V26, P179, DOI 10.1007/s00198 014 2854 7
   Wang JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133964
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   Zheng H, 2016, PHARMACOGENET GENOM, V26, P12, DOI 10.1097/FPC.0000000000000181
NR 32
TC 7
Z9 7
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 5
PY 2016
VL 7
IS 27
BP 41380
EP 41389
DI 10.18632/oncotarget.9356
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA DS7DI
UT WOS:000380942600036
PM 27191503
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Ishikawa, F
   Yoshida, S
   Saito, Y
   Hijikata, A
   Kitamura, H
   Tanaka, S
   Nakamura, R
   Tanaka, T
   Tomiyama, H
   Saito, N
   Fukata, M
   Miyamoto, T
   Lyons, B
   Ohshima, K
   Uchida, N
   Taniguchi, S
   Ohara, O
   Akashi, K
   Harada, M
   Shultz, LD
AF Ishikawa, Fumihiko
   Yoshida, Shuro
   Saito, Yoriko
   Hijikata, Atsushi
   Kitamura, Hiroshi
   Tanaka, Satoshi
   Nakamura, Ryu
   Tanaka, Toru
   Tomiyama, Hiroko
   Saito, Noriyuki
   Fukata, Mitsuhiro
   Miyamoto, Toshihiro
   Lyons, Bonnie
   Ohshima, Koichi
   Uchida, Naoyuki
   Taniguchi, Shuichi
   Ohara, Osamu
   Akashi, Koichi
   Harada, Mine
   Shultz, Leonard D.
TI Chemotherapy resistant human AML stem cells home to and engraft within
   the bone marrow endosteal region
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID ACUTE MYELOID LEUKEMIA; SCID MICE; PROGENITOR CELLS; GENE EXPRESSION;
   NOD/SCID MICE; R PACKAGE; NICHE; CD44; HEMATOPOIESIS; HIERARCHY
AB Acute myelogenous leukemia (AML) is the most common adult leukemia, characterized by the clonal expansion of immature myeloblasts initiating from rare leukemic stem (LS) cells(1 3). To understand the functional properties of human LS cells, we developed a primary human AML xenotransplantation model using newborn nonobese diabetic/severe combined immunodeficient/interleukin (NOD/SCID/IL)2r gamma(null) mice carrying a complete null mutation of the cytokine gamma c upon the SCID background(4). Using this model, we demonstrated that LS cells exclusively recapitulate AML and retain self renewal capacity in vivo. They home to and engraft within the osteoblast rich area of the bone marrow, where AML cells are protected from chemotherapy induced apoptosis. Quiescence of human LS cells may be a mechanism underlying resistance to cell cycle dependent cytotoxic therapy. Global transcriptional profiling identified LS cell specific transcripts that are stable through serial transplantation. These results indicate the potential utility of this AML xenograft model in the development of novel therapeutic strategies targeted at LS cells.
C1 RIKEN, Res Ctr All & Immunol, Res Unit Human Dis Models, Yokohama, Kanagawa 2300045, Japan.
   RIKEN, Res Ctr All & Immunol, Lab Immunogennom, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan.
   Kyushu Univ, Grad Sch, Dept Med & Biosyst Sci, Fukuoka 8128582, Japan.
   Kyushu Univ Hosp, Ctr Cellular & Mol, Higashi Ku, Fukuoka 8128582, Japan.
   Harvard Univ, Massachusetts Gen Hosp, Harvard Med Sch, Dept Pathol, Boston, MA 02114 USA.
   Nippon Becton Dickinson Co, Minato Ku, Tokyo 1070052, Japan.
   Carl Zeisss, Shinjuku Ku, Tokyo, Japan.
   Jackson Lab, Bar Harbor, ME 04609 USA.
   Kurume Univ, Sch Med, Dept Pathol 1, Kurume, Fukuoka 8300003, Japan.
   Toranomon Gen Hosp, Dept Hematol, Minato Ku, Tokyo 14058470, Japan.
   Kazusa DNA Res Inst, Dept Human Genome Technol, Kisarazu 2900818, Japan.
   Harvard Univ, Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol,AIDS, Boston, MA 02115 USA.
C3 RIKEN; RIKEN; Kyushu University; Harvard University; Harvard Medical
   School; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Becton Dickinson; Carl Zeiss AG; Jackson Laboratory; Kurume
   University; Toranomon Hospital; Kazusa DNA Research Institute; Harvard
   University; Harvard University Medical Affiliates; Dana Farber Cancer
   Institute; Harvard Medical School
RP Ishikawa, F (通讯作者)，RIKEN, Res Ctr All & Immunol, Res Unit Human Dis Models, Yokohama, Kanagawa 2300045, Japan.
EM f_ishika@rcai.riken.jp
RI ; Ohara, Osamu/G 5448 2015; Kitamura, Hiroshi/LZF 3631 2025
OI Hijikata, Atsushi/0000 0003 4297 8368; Ohara, Osamu/0000 0002 3328 9571;
   Kitamura, Hiroshi/0000 0001 9643 3211
CR Ailles LE, 1997, BLOOD, V90, P2555, DOI 10.1182/blood.V90.7.2555.2555_2555_2564
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797 730
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074 7613(95)90047 0
   Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518
   Christianson SW, 1997, J IMMUNOL, V158, P3578
   Culhane AC, 2005, BIOINFORMATICS, V21, P2789, DOI 10.1093/bioinformatics/bti394
   Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085
   Feuring Buske M, 2003, LEUKEMIA, V17, P760, DOI 10.1038/sj.leu.2402882
   Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood 2004 10 4135
   Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080
   Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood 2005 02 0516
   Ji P, 2005, ONCOGENE, V24, P2739, DOI 10.1038/sj.onc.1208356
   Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483
   Jones SM, 2006, NAT REV CANCER, V6, P175, DOI 10.1038/nrc1817
   Jordan CT, 2004, ONCOGENE, V23, P7178, DOI 10.1038/sj.onc.1207935
   Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lumkul R, 2002, LEUKEMIA, V16, P1818, DOI 10.1038/sj.leu.2402632
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   Ninomiya M, 2007, LEUKEMIA, V21, P136, DOI 10.1038/sj.leu.2404432
   Passegué E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100
   Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477
   SHULTZ LD, 1995, J IMMUNOL, V154, P180
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117
   Tanner SM, 2001, P NATL ACAD SCI USA, V98, P13901, DOI 10.1073/pnas.241525498
   Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood 2005 03 1072
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 30
TC 783
Z9 932
U1 3
U2 70
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013 1917 USA
SN 1087 0156
EI 1546 1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD NOV
PY 2007
VL 25
IS 11
BP 1315
EP 1321
DI 10.1038/nbt1350
PG 7
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 233JF
UT WOS:000251086500033
PM 17952057
DA 2025 08 17
ER

PT J
AU Shan, S
   Zhou, Y
   Yu, JD
   Yang, QJ
   Pan, DS
   Wang, YA
   Li, LJ
   Zhu, JZ
   Zhang, Y
   Huang, SJ
   Li, ZB
   Ning, ZQ
   Xin, LJ
   Lu, XP
AF Shan, Song
   Zhou, You
   Yu, Jindi
   Yang, Qianjiao
   Pan, Desi
   Wang, Yanan
   Li, Lingjie
   Zhu, Jingzhong
   Zhang, Yu
   Huang, Shengjian
   Li, Zhibin
   Ning, Zhiqiang
   Xin, Lijun
   Lu, Xianping
TI Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor,
   CS12192, in rat and mouse models of rheumatoid arthritis
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
ID JAK INHIBITION; TH17 CELLS; INSIGHTS; TBK1; CYTOKINES; RESPONSES;
   DISEASE; IMMUNE; DAMAGE
AB Rheumatoid arthritis (RA) is a representative autoimmune disease characterized by chronic inflammation and joint destruction. Although biological inhibitors such as TNF alpha and IL 6 antibodies have achieved success in clinical therapy, small molecule inhibitors against the Janus kinases (JAKs) involved in the signaling pathways of various cytokine receptors have gained more attraction as safe and efficacious options. In this study, we identified CS12192 as a novel selective JAK3/JAK1/TBK1 inhibitor and investigated its pharmacological effects on the experimental arthritis models in rat and mouse. We found that CS12192 showed a more selective inhibitory activity on JAK3, and to a less extent on JAK1 and TBK1, that were verified by decreased activation of p STATs and p IRF3 as well as down regulation of IFN gene expression in the cultured cells with relevant stimuli. Furthermore, oral treatment with CS12192 dose dependently ameliorated the disease severity, hind paw swelling, body weight loss, and bone destruction in rat models of adjuvant induced arthritis (AIA) and collagen induced arthritis (CIA). In a mouse CIA model, CS12192 also attenuated the disease severity, which was correlated with the suppressed CD4(+) T cell activation and Th17 function, as well as the reduced cytokine levels in sera and pro inflammatory cytokine and chemokine gene expression in joint tissue. Corroboratively, RANKL induced osteoclast formation was inhibited by CS12192. Thus, these results suggest that CS12192 as a novel selective JAK inhibitor has therapeutic potential for the treatment of RA and may provide a new strategy for the control of autoimmune diseases.
C1 [Shan, Song; Zhou, You; Yu, Jindi; Yang, Qianjiao; Pan, Desi; Wang, Yanan; Li, Lingjie; Zhu, Jingzhong; Zhang, Yu; Huang, Shengjian; Li, Zhibin; Ning, Zhiqiang; Xin, Lijun; Lu, Xianping] Shenzhen Chipscreen Biosci Co Ltd, Shenzhen, Guangdong, Peoples R China.
RP Xin, LJ; Lu, XP (通讯作者)，Shenzhen Chipscreen Biosci Co Ltd, BIO Incubator, Suit 2 601B,Shenzhen Hitech Ind Pk, Shenzhen 518057, Guangdong, Peoples R China.
EM xinlijun@chipscreen.com; xplu@chipscreen.com
RI Li, Lingjie/JZD 8431 2024; Huang, Shengjian/KSL 8436 2024
OI Huang, Shengjian/0000 0002 4666 3788
FU Major Science and Technology Projects of Guangdong Province
   [2013A022100013]; Shenzhen Technology Innovation Project
   [JSGG20170412153957140]
FX This study was supported by the Major Science and Technology Projects of
   Guangdong Province (2013A022100013), and Shenzhen Technology Innovation
   Project (JSGG20170412153957140).
CR Chen X, 2013, J IMMUNOL, V190, P1076, DOI 10.4049/jimmunol.1202659
   Chen YH, 2017, J AUTOIMMUN, V77, P96, DOI 10.1016/j.jaut.2016.11.003
   Cope Andrew P, 2008, Arthritis Res Ther, V10 Suppl 1, pS1, DOI 10.1186/ar2412
   Fridman JS, 2010, J IMMUNOL, V184, P5298, DOI 10.4049/jimmunol.0902819
   Ghoreschi K, 2011, J IMMUNOL, V186, P4234, DOI 10.4049/jimmunol.1003668
   Haan C, 2011, CHEM BIOL, V18, P314, DOI 10.1016/j.chembiol.2011.01.012
   Hammaker D, 2012, RHEUMATOLOGY, V51, P610, DOI 10.1093/rheumatology/ker154
   Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313
   Hasan M, 2016, PHARMACOL RES, V111, P336, DOI 10.1016/j.phrs.2016.04.008
   Hasan M, 2015, J IMMUNOL, V195, P4573, DOI 10.4049/jimmunol.1500162
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407
   Higgs BW, 2011, ANN RHEUM DIS, V70, P2029, DOI 10.1136/ard.2011.150326
   Kalden JR, 2017, NAT REV RHEUMATOL, V13, P707, DOI 10.1038/nrrheum.2017.187
   Karmakar S, 2010, RHEUM DIS CLIN N AM, V36, P385, DOI 10.1016/j.rdc.2010.03.003
   Komatsu N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00077
   Kondo Y, 2018, ARTHRITIS RHEUMATOL, V70, P653, DOI 10.1002/art.40398
   LaBranche TP, 2012, ARTHRITIS RHEUM US, V64, P3531, DOI 10.1002/art.34649
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Louis C, 2019, ARTHRITIS RHEUMATOL, V71, P50, DOI 10.1002/art.40670
   Louis C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00434
   Malmström V, 2017, NAT REV IMMUNOL, V17, P60, DOI 10.1038/nri.2016.124
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Meyer DM, 2010, J INFLAMM LOND, V7, DOI 10.1186/1476 9255 7 41
   Monaco C, 2015, INT IMMUNOL, V27, P55, DOI 10.1093/intimm/dxu102
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Nakajima H, 1997, J EXP MED, V185, P189, DOI 10.1084/jem.185.2.189
   Narazaki M, 2017, EXPERT REV CLIN IMMU, V13, P535, DOI 10.1080/1744666X.2017.1295850
   Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074 7613(95)90066 7
   Pillai S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10072
   Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580
   Rodríguez Carrio J, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.02007
   Rodríguez Carrio J, 2015, CLIN SCI, V128, P449, DOI 10.1042/CS20140554
   Rönnblom L, 2013, CURR OPIN RHEUMATOL, V25, P248, DOI 10.1097/BOR.0b013e32835c7e32
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Schwartz DM, 2016, NAT REV RHEUMATOL, V12, P25, DOI 10.1038/nrrheum.2015.167
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Smith GA, 2016, NAT CHEM BIOL, V12, P373, DOI [10.1038/NCHEMBIO.2056, 10.1038/nchembio.2056]
   Sun QH, 2014, J BONE MINER RES, V29, P90, DOI 10.1002/jbmr.2026
   Taylor PC, 2015, ARTHRITIS RHEUMATOL, V67, P14, DOI 10.1002/art.38893
   Traynor K, 2012, AM J HEALTH SYST PH, V69, P2120, DOI 10.2146/news120088
   Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001
   Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001
   Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200
   Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23
   Yu JY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7074
   Zhang Y, 2015, SCI REP UK, V5, DOI 10.1038/srep13575
NR 47
TC 15
Z9 17
U1 1
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD DEC
PY 2019
VL 77
AR 105914
DI 10.1016/j.intimp.2019.105914
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA JW5NR
UT WOS:000503099100005
PM 31634789
DA 2025 08 17
ER

PT J
AU Debray, J
   Chang, L
   Marquès, S
   Pellet Rostaing, S
   Do, LD
   Mebarek, S
   Buchet, R
   Magne, D
   Popowycz, F
   Lemaire, M
AF Debray, Julien
   Chang, Lei
   Marques, Stephanie
   Pellet Rostaing, Stephane
   Do, Le Duy
   Mebarek, Saida
   Buchet, Rene
   Magne, David
   Popowycz, Florence
   Lemaire, Marc
TI Inhibitors of tissue nonspecific alkaline phosphatase: Design,
   synthesis, kinetics, biomineralization and cellular tests
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Alkaline phosphatase; Benzo[b] thiophen; Enzyme; Inhibitor; Levamisole;
   Vascular calcification
ID VASCULAR CALCIFICATION; MATRIX DEPOSITION; CELLS; PYROPHOSPHATE;
   MINERALIZATION; TETRAMISOLE; MECHANISMS; MORTALITY; THERAPY; DISEASE
AB Chronic kidney disease (CKD) is associated with numerous metabolic and endocrine disturbances, including abnormalities of calcium and phosphate metabolism and an inflammatory syndrome. The latter occurs early in the course of CKD and contributes to the development and progression of vascular calcification. A few therapeutic strategies are today contemplated to target vascular calcification in patients with CKD: vitamin K2, calcimimetics and phosphate binders. However, none has provided complete prevention of vascular calcification and there is an urgent need for alternate efficient treatments. Recent findings indicate that tissue nonspecific alkaline phosphatase (TNAP) may represent a very promising drug target due to its participation in mineralization by vascular smooth muscle cells. We report the synthesis of four levamisole derivatives having better inhibition property on TNAP than levamisole. Their IC50, Ki and water solubility have been determined. We found that the four inhibitors bind to TNAP in an uncompetitive manner and are selective to TNAP. Indeed, they do not inhibit intestinal and placental alkaline phosphatases. Survival MTT tests on human MG 63 and Saos 2 osteoblast like cells have been performed in the presence of inhibitors. All the inhibitors are not toxic at concentrations that block TNAP activity. Moreover, they are able to significantly reduce mineralization in MG63 and Saos 2 osteoblast like cells, indicating that they are promising molecules to prevent vascular calcification. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Debray, Julien; Chang, Lei; Marques, Stephanie; Pellet Rostaing, Stephane; Lemaire, Marc] Univ Lyon 1, CNRS, Equipe Catalyse Synth Environm, Inst Chim & Biochim Mol & Supramol,UMR 5246, F 69622 Villeurbanne, France.
   [Debray, Julien; Do, Le Duy; Mebarek, Saida; Buchet, Rene; Magne, David] Univ Lyon 1, CNRS, Equipe Org & Dynam Membranes Biol, Inst Chim & Biochim Mol & Supramol,UMR 5246, F 69622 Villeurbanne, France.
   [Pellet Rostaing, Stephane] Univ Montpellier 2, CNRS, UMR 5257, Inst Chim Separat Marcoule, F 30207 Bagnols Sur Ceze, France.
   [Do, Le Duy] Polish Acad Sci, Nencki Inst Expt Biol, Dept Biochem, PL 02093 Warsaw, Poland.
   [Popowycz, Florence] CNRS, Equipe Chim Organ & Bioorgan, INSA Lyon, Inst Chim & Biochimie Mol & Supramol,UMR 5246, F 69621 Villeurbanne, France.
C3 Institut National des Sciences Appliquees de Lyon   INSA Lyon;
   Universite Claude Bernard Lyon 1; Centre National de la Recherche
   Scientifique (CNRS); CNRS   Institute of Chemistry (INC); Universite
   Claude Bernard Lyon 1; Centre National de la Recherche Scientifique
   (CNRS); CNRS   Institute of Chemistry (INC); Institut National des
   Sciences Appliquees de Lyon   INSA Lyon; CEA; Centre National de la
   Recherche Scientifique (CNRS); Ecole nationale superieure de chimie de
   Montpellier; Universite de Montpellier; CNRS   Institute of Chemistry
   (INC); Polish Academy of Sciences; Nencki Institute of Experimental
   Biology of the Polish Academy of Sciences; Institut National des
   Sciences Appliquees de Lyon   INSA Lyon; Centre National de la Recherche
   Scientifique (CNRS); CNRS   Institute of Chemistry (INC)
RP Buchet, R (通讯作者)，Univ Lyon 1, CNRS, Equipe Org & Dynam Membranes Biol, Inst Chim & Biochim Mol & Supramol,UMR 5246, F 69622 Villeurbanne, France.
EM rbuchet@univ lyon1.fr
RI PELLET ROSTAING, Stephane/B 7682 2016; Mebarek, Saida/AAI 8237 2020;
   Rene, Buchet/I 9781 2019; PELLET ROSTAING, Stéphane/B 7682 2016
OI PELLET ROSTAING, Stephane/0000 0003 3399 7153; DO, Le
   Duy/0000 0001 7664 533X; Mebarek, Saida/0000 0001 8806 8904; Buchet,
   Rene/0000 0002 7966 3856; Magne, David/0000 0002 6511 9390; 
FU International Ph.D. program in Neurobiology; Lyon Science Transfer
FX Mr. Le Duy Do is a recipient of the fellowship from the International
   Ph.D. program in Neurobiology (Project No. 6: collaborative Ph.D.
   project between the Nencki Institute of Experimental Biology and
   Universite Lyon 1). Dr. Julien Debray is the recipient of Post doctoral
   scholarship from Lyon Science Transfer.
CR Anderson HC., 2007, CURRENT OPINION ORTH, V18, P428, DOI DOI 10.1097/BCO.0B013E3282E9AB49
   [Anonymous], 2012, PCT Int. Appl., Patent No. [WO 2,012,052,668 A1 20,120,426., 2012052668]
   BHARGAVA KK, 1977, J MED CHEM, V20, P563, DOI 10.1021/jm00214a021
   Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358
   Buchet R., 2012, Demande, Patent No. 2966152
   Chang L, 2011, BIOORG MED CHEM LETT, V21, P2297, DOI 10.1016/j.bmcl.2011.02.089
   Chung TDY, 2010, MOLECULES, V15, P3010, DOI 10.3390/molecules15053010
   Dahl R, 2009, J MED CHEM, V52, P6919, DOI 10.1021/jm900383s
   Debray J, 2013, SYNLETT, V24, P37, DOI 10.1055/s 0032 1317674
   Detrano R, 2008, NEW ENGL J MED, V358, P1336, DOI 10.1056/NEJMoa072100
   Doherty TM, 2004, ENDOCR REV, V25, P629, DOI 10.1210/er.2003 0015
   FEDDE KN, 1992, BONE MINER, V17, P145, DOI 10.1016/0169 6009(92)90726 T
   Hausser HJ, 2004, J CELL BIOCHEM, V91, P1062, DOI 10.1002/jcb.20007
   Hsu HHT, 1999, ATHEROSCLEROSIS, V143, P353, DOI 10.1016/S0021 9150(98)00322 0
   KOLASA T, 1993, SYNTHETIC COMMUN, V23, P743, DOI 10.1080/00397919308009834
   Lamandé SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423
   Lanier M, 2010, BIOORGAN MED CHEM, V18, P573, DOI 10.1016/j.bmc.2009.12.012
   Lencel P, 2011, BONE, V48, P242, DOI 10.1016/j.bone.2010.09.001
   Lencel P, 2010, MED HYPOTHESES, V75, P517, DOI 10.1016/j.mehy.2010.07.011
   Li LN, 2009, BIOORGAN MED CHEM, V17, P7290, DOI 10.1016/j.bmc.2009.08.048
   Lomashvili KA, 2008, KIDNEY INT, V73, P1024, DOI 10.1038/ki.2008.26
   London GM, 2003, NEPHROL DIAL TRANSPL, V18, P1731, DOI 10.1093/ndt/gfg414
   MCQUILLAN DJ, 1995, BONE, V16, P415
   Mebarek S, 2011, CURR MED CHEM, V18, P2196, DOI 10.2174/092986711795656153
   Millan J. L., [No title captured], Patent No. [US 2009/0,156,560 A1, 20090156560]
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205
   Narisawa S, 2007, J BONE MINER RES, V22, P1700, DOI 10.1359/JBMR.070714
   O'Neill WC, 2011, KIDNEY INT, V79, P512, DOI 10.1038/ki.2010.461
   Persy VP, 2011, KIDNEY INT, V79, P490, DOI 10.1038/ki.2010.478
   Podea PV, 2008, TETRAHEDRON ASYMMETR, V19, P1959, DOI 10.1016/j.tetasy.2008.07.030
   RAEYMAEK.AH, 1966, J MED CHEM, V9, P545, DOI 10.1021/jm00322a023
   Riser BL, 2011, NEPHROL DIAL TRANSPL, V26, P3349, DOI 10.1093/ndt/gfr039
   Rutsch F, 2001, AM J PATHOL, V158, P543, DOI 10.1016/S0002 9440(10)63996 X
   Schlieper G, 2008, KIDNEY INT, V74, P1582, DOI 10.1038/ki.2008.458
   Sergienko E, 2009, J BIOMOL SCREEN, V14, P824, DOI 10.1177/1087057109338517
   Shao JS, 2006, ARTERIOSCL THROM VAS, V26, P1423, DOI 10.1161/01.ATV.0000220441.42041.20
   Shao JS, 2010, HYPERTENSION, V55, P579, DOI 10.1161/HYPERTENSIONAHA.109.134205
   Shroff RC, 2007, SEMIN DIALYSIS, V20, P103, DOI 10.1111/j.1525 139X.2007.00255.x
   Sidique S, 2009, BIOORG MED CHEM LETT, V19, P222, DOI 10.1016/j.bmcl.2008.10.107
   Sigrist MK, 2007, CLIN J AM SOC NEPHRO, V2, P1241, DOI 10.2215/CJN.02190507
   Son E, 2007, NUTRITION, V23, P745, DOI 10.1016/j.nut.2007.06.013
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Stenvinkel P, 2010, J INTERN MED, V268, P456, DOI 10.1111/j.1365 2796.2010.02269.x
   Vaingankar SM, 2004, AM J PHYSIOL CELL PH, V286, pC1177, DOI 10.1152/ajpcell.00320.2003
   van de Lest C.H., 2007, Current Opinion in Orthopaedics, V18, P434
   Whyte MP, 2012, NEW ENGL J MED, V366, P904, DOI 10.1056/NEJMoa1106173
   Whyte MP, 2010, ANN NY ACAD SCI, V1192, P190, DOI 10.1111/j.1749 6632.2010.05387.x
NR 48
TC 26
Z9 30
U1 0
U2 63
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD DEC 15
PY 2013
VL 21
IS 24
BP 7981
EP 7987
DI 10.1016/j.bmc.2013.09.053
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 262VO
UT WOS:000327766200043
PM 24183741
DA 2025 08 17
ER

PT J
AU Han, NR
   Park, CL
   Kim, NR
   Kim, HY
   Yoou, MS
   Nam, SY
   Moon, PD
   Jeong, HJ
   Kim, HM
AF Han, Na Ra
   Park, Chan Lee
   Kim, Na Rae
   Kim, Hee Yun
   Yoou, Myoung Schook
   Nam, Sun Young
   Moon, Phil Dong
   Jeong, Hyun Ja
   Kim, Hyung Min
TI Protective effect of porcine placenta in a menopausal ovariectomized
   mouse
SO REPRODUCTION
LA English
DT Article
ID HORMONE REPLACEMENT THERAPY; ESTROGEN RECEPTOR BETA; POSTMENOPAUSAL
   WOMEN; CELL PROLIFERATION; BONE MARROW; IN VITRO; L LYSINE;
   DIFFERENTIATION; SUPPLEMENTATION; OSTEOARTHRITIS
AB Menopause is a significant physiological phase that occurs as women's ovaries stop producing ovum and the production of estrogen declines. Human placenta and some amino acids are known to improve menopausal symptoms. In this study, we investigated that porcine placenta extract (PPE) and arginine (Arg), a main amino acid of PPE, would have estrogenic activities in ovariectomized (OVX) mice as a menopause mouse model, human breast cancer cell line (MCF 7) cells, and human osteoblast cell line (MG 63) cells. PPE or Arg significantly inhibited the body weight and increased the vagina weight compared to the OVX mice. PPE or Arg ameliorated the vaginal atrophy in the OVX mice. The levels of 17 beta estradiol and the activities of alkaline phosphatase (ALP) were significantly increased by PPE or Arg in the serum of OVX mice. Trabecular bone parameters such as bone mineral density and porosity were also improved by PPE or Arg in the OVX mice. In the MCF 7 and MG 63 cells, PPE or Arg significantly increased the cell proliferation, estrogen receptor beta mRNA expression, and estrogen response elements luciferase activity. Finally, PPE or Arg increased the activations of ALP and extracellular signal regulated kinase 1/2 in the MG 63 cells. These results indicate that PPE or Arg would have estrogenic and osteoblastic activity. Therefore, PPE or Arg may be useful as new pharmacological tools for treating menopausal symptoms including osteoporosis.
C1 [Han, Na Ra; Park, Chan Lee; Kim, Na Rae; Kim, Hee Yun; Yoou, Myoung Schook; Nam, Sun Young; Moon, Phil Dong; Kim, Hyung Min] Kyung Hee Univ, Coll Korean Med, Dept Pharmacol, Seoul 130701, South Korea.
   [Jeong, Hyun Ja] Hoseo Univ, Inflammatory Dis Res Ctr, Dept Food Technol, Asan 336795, Chungcheongnam, South Korea.
C3 Kyung Hee University; Hoseo University
RP Kim, HM (通讯作者)，Kyung Hee Univ, Coll Korean Med, Dept Pharmacol, 26 Kyungheedae Ro, Seoul 130701, South Korea.
EM hjjeong@hoseo.edu; hmkim@khu.ac.kr
RI Park, Mi Kyung/J 9643 2017; Moon, Phil Dong/T 3634 2018
FU Ministry of Trade, Industry and energy (MOTIE), Korea
FX This research was supported by the Ministry of Trade, Industry and
   energy (MOTIE), Korea, through the Education Support program for
   Creative and Industrial Convergence.
CR Ahmed HH, 2009, REP OPIN, V1, P24
   Al Safi ZA, 2012, CLIN OBSTET GYNAECOL, V29, P548, DOI [doi:10.1016/j.bpobgyn.2014.12.002, DOI 10.1016/J.BPOBGYN.2014.12.002]
   Albertazzi P, 1999, OBSTET GYNECOL, V94, P229, DOI 10.1016/S0029 7844(99)00275 6
   Alvehus M, 2012, CLIN ENDOCRINOL, V77, P684, DOI 10.1111/j.1365 2265.2011.04322.x
   Asawa Y, 2004, J ELECTRON MICROSC, V53, P423, DOI 10.1093/jmicro/dfh057
   Balakrishnan B, 2014, J OSTEOPOROS, V2014, DOI 10.1155/2014/348189
   Burger HG, 2002, RECENT PROG HORM RES, V57, P257, DOI 10.1210/rp.57.1.257
   Chiechi LM, 2003, MATURITAS, V45, P241, DOI 10.1016/S0378 5122(03)00080 X
   Choi HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099421
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   CIVITELLI R, 1992, NUTRITION, V8, P400
   Clegg DJ, 2012, MOL ENDOCRINOL, V26, P1957, DOI 10.1210/me.2012 1284
   D'Amelio P, 2013, IMMUNOL INVEST, V42, P544, DOI 10.3109/08820139.2013.822764
   Dedeoglu EN, 2009, FERTIL STERIL, V91, P425, DOI 10.1016/j.fertnstert.2007.11.061
   Dennerstein L, 2000, OBSTET GYNECOL, V96, P351, DOI 10.1016/S0029 7844(00)00930 3
   DICKSON RB, 1986, CANCER RES, V46, P1707
   Dohi O, 2008, CANCER SCI, V99, P518, DOI 10.1111/j.1349 7006.2007.00673.x
   Fini M, 2001, BIOMED PHARMACOTHER, V55, P213, DOI 10.1016/S0753 3322(01)00054 3
   Giguère V, 1998, STEROIDS, V63, P335, DOI 10.1016/S0039 128X(98)00024 5
   Gougelet A, 2007, J STEROID BIOCHEM, V104, P110, DOI 10.1016/j.jsbmb.2007.03.002
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   Han NR, 2013, NUTRITION, V29, P1381, DOI 10.1016/j.nut.2013.04.016
   Han SY, 2007, J ETHNOPHARMACOL, V114, P400, DOI 10.1016/j.jep.2007.08.019
   Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
   Holm L, 2005, J GERONTOL A BIOL, V60, P1212, DOI 10.1093/gerona/60.9.1212
   Hsieh CY, 1998, CANCER RES, V58, P3833
   Kaaja Risto J, 2008, Menopause Int, V14, P21, DOI 10.1258/mi.2007.007032
   Kong M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/732915
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Królik M, 2012, ADV CLIN EXP MED, V21, P535
   Lagro Janssen ALM, 2010, FAM PRACT, V27, P424, DOI 10.1093/fampra/cmq018
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lee KH, 2013, J ANIM SCI, V91, P2405, DOI 10.2527/jas.2012 5208
   Legler J, 1999, TOXICOL SCI, V48, P55, DOI 10.1093/toxsci/48.1.55
   Luo XH, 2003, ENDOCR RES, V29, P343, DOI 10.1081/ERC 120025041
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Melton LJ, 2004, J BONE MINER RES, V19, P1055, DOI 10.1359/JBMR.040316
   Panay Nick, 2012, Menopause Int, V18, P15, DOI 10.1258/mi.2012.011120
   Pastore LM, 2004, MATURITAS, V49, P292, DOI 10.1016/j.maturitas.2004.06.019
   Pernow Y, 2010, BONE, V47, P959, DOI 10.1016/j.bone.2010.08.017
   김민호, 2014, [CELLMED, 셀메드], V4, P14, DOI 10.5667/tang.2014.0020
   Prins HJ, 2014, STEM CELL RES, V12, P428, DOI 10.1016/j.scr.2013.12.001
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Roman Blas JA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2791
   Schierbeck LL, 2012, BMJ BRIT MED J, V345, DOI 10.1136/bmj.e6409
   Shuid AN, 2011, J ETHNOPHARMACOL, V133, P538, DOI 10.1016/j.jep.2010.10.033
   Takuma K, 2012, J PHARMACOL SCI, V120, P89, DOI 10.1254/jphs.12115FP
   Tang XL, 2008, ENDOCRINE, V34, P29, DOI 10.1007/s12020 008 9099 1
   Tuomikoski P, 2012, CLIMACTERIC, V15, P153, DOI 10.3109/13697137.2011.597894
   van der Woude H, 2005, MOL NUTR FOOD RES, V49, P763, DOI 10.1002/mnfr.200500036
   Veras K, 2014, FEBS OPEN BIO, V4, P141, DOI 10.1016/j.fob.2014.01.005
   Vijayan V, 2014, BRIT J PHARMACOL, V171, P107, DOI 10.1111/bph.12434
   Wang J, 2014, GENET MOL RES, V13, P5055, DOI 10.4238/2014.July.4.21
   Wang MH, 2006, J BIOL CHEM, V281, P8864, DOI 10.1074/jbc.M512865200
   YAMAZAKI I, 1989, J BONE MINER RES, V4, P13
   Yang PY, 2014, EUR J PAIN, V18, P680, DOI 10.1002/j.1532 2149.2013.00406.x
   Yoshizawa M, 2009, AM J PHYSIOL HEART C, V297, pH1899, DOI 10.1152/ajpheart.00433.2009
NR 57
TC 12
Z9 12
U1 0
U2 11
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 1470 1626
J9 REPRODUCTION
JI Reproduction
PD SEP
PY 2015
VL 150
IS 3
BP 173
EP 181
DI 10.1530/REP 15 0157
PG 9
WC Developmental Biology; Reproductive Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology; Reproductive Biology
GA CO7TH
UT WOS:000359364200006
PM 26047835
OA Bronze
DA 2025 08 17
ER

PT J
AU Zhang, ZW
   Wu, HX
   Huang, SH
   Chen, LP
   Chen, XL
   Zhang, W
   Liao, L
   Zhang, XQ
AF Zhang, Zhongwen
   Wu, Hongxia
   Huang, Shuhong
   Chen, Liping
   Chen, Xinlong
   Zhang, Wei
   Liao, Lin
   Zhang, Xiaoqian
TI AMD3465 (hexahydrobromide) rescues the MG63 osteoblasts against the
   apoptosis induced by high glucose
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE AMD3465; Diabetic osteoporosis; MG63 cell; Apoptosis; CXCR4
AB Diabetic osteoporosis (DOP) is a serious complication of diabetes, which brings a heavy burden to patients? families and society. The SDF 1/CXCR4 signal pathway may be a target to prevent articular cartilage degeneration. In this study, we studied the effects of high glucose (20 mmol/L) and CXCR4 antagonist AMD3465 (10 ?mol/L) on the apoptosis and gene expression of osteoblast like cells MG63 to determine a new treatment for DOP. CCK8 and clone formation assays confirmed that AMD3465 resisted the decrease of proliferation caused by high glucose. According to the results of scratch and transwell analysis, AMD3465 could remedy the decrease of cell migration and invasion induced by high glucose. The results of flow cytometry analysis and double staining with Hoechst and PI showed AMD3465 corrected the apoptosis induced by high glucose. In addition, high glucose regulated the expression of cell cycle  and apoptosis related proteins, while AMD3465 blocked the regulation of high glucose. Furthermore, high glucose enhanced the expression levels of SDF 1 and CXCR4 in MG63 cells, as well as the release of MMP1, 3, 9 and 13. AMD3465 inhibited the release of MMPs. The results showed that AMD3465 resisted the apoptosis of MG63 cells induced by high glucose, provided a new strategy for the therapy of DOP.
C1 [Zhang, Zhongwen; Wu, Hongxia; Zhang, Wei; Liao, Lin; Zhang, Xiaoqian] Shandong First Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metabol, Jinan 250014, Shandong, Peoples R China.
   [Zhang, Zhongwen; Wu, Hongxia; Zhang, Wei; Liao, Lin; Zhang, Xiaoqian] Shandong Prov Qianfoshan Hosp, Shandong Inst Nephrol, Shandong Key Lab Rheumat Dis & Translat Med, Jinan 250014, Shandong, Peoples R China.
   [Huang, Shuhong] Shandong First Med Univ, Affiliated Hosp 1, Inst Basic Med, Jinan 250012, Shandong, Peoples R China.
   [Chen, Liping; Zhang, Xiaoqian] Weifang Med Univ, Dept Endocrinol, Weifang 261053, Peoples R China.
   [Chen, Xinlong] Hosp Chengdu Univ Tradit Chinese Med, Dept Dermatol, Chengdu 610072, Sichuan, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong First Medical University & Shandong Academy of
   Medical Sciences; Shandong First Medical University & Shandong Academy
   of Medical Sciences; Shandong Second Medical University; Chengdu
   University of Traditional Chinese Medicine
RP Liao, L; Zhang, XQ (通讯作者)，Shandong First Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metabol, Jinan 250014, Shandong, Peoples R China.; Liao, L; Zhang, XQ (通讯作者)，Shandong Prov Qianfoshan Hosp, Shandong Inst Nephrol, Shandong Key Lab Rheumat Dis & Translat Med, Jinan 250014, Shandong, Peoples R China.
EM zhxqqy@163.com
RI ; Huang, Shuhong/AAI 4151 2021; Zhang, Xiaoqian/LKO 4281 2024
OI Huang, Shu Hong/0000 0001 6298 6192; 
FU Shandong Traditional Chinese Medicine Science and Technology Development
   Plan Project [2017 169]; Shandong Province Medical and Health Science
   and Technology Development Plan Project [2017WS617]; Key Research &
   Development Plan of Shandong Province [2018GSF118176]; Natural Science
   Foundation of China [82000788]; Natural Science Foundation of Shandong
   Province [ZR2016HQ26]
FX This work was supported by Shandong Traditional Chinese Medicine Science
   and Technology Development Plan Project (No. 2017 169), Shandong
   Province Medical and Health Science and Technology Development Plan
   Project (NO. 2017WS617), Key Research & Development Plan of Shandong
   Province (No. 2018GSF118176), Natural Science Foundation of China
   (82000788), Natural Science Foundation of Shandong Province (No.
   ZR2016HQ26).
CR Al Hariri M, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6969040
   Azab A.K., BLOOD, V113
   Franke Sybille, 2007, Archives of Physiology and Biochemistry, V113, P154, DOI 10.1080/13813450701602523
   Gillery P, 2014, CLIN CHEM LAB MED, V52, P935, DOI 10.1515/cclm 2014 0443
   Hamada D, 2016, ARTHRITIS RHEUMATOL, V68, P1392, DOI 10.1002/art.39561
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Kanbe K, 2002, ARTHRITIS RHEUM US, V46, P130, DOI 10.1002/1529 0131(200201)46:1<130::AID ART10020>3.0.CO;2 D
   Kume S., 2021, BIOMED PHARMACOTHER, V138
   Leng QB, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471 2172 9 51
   Ling XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058426
   Lisignoli G, 2006, J CELL PHYSIOL, V206, P78, DOI 10.1002/jcp.20435
   Markovic J, 2015, BIOCHEM CELL BIOL, V93, P54, DOI 10.1139/bcb 2014 0104
   Menke A, 2015, JAMA J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029
   Napoli N, 2017, NAT REV ENDOCRINOL, V13, P208, DOI 10.1038/nrendo.2016.153
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Santiago B, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1900
   Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1
   Wang LM, 2017, JAMA J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   Wei L, 2006, J RHEUMATOL, V33, P1818
NR 19
TC 7
Z9 7
U1 1
U2 15
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUN
PY 2021
VL 138
AR 111476
DI 10.1016/j.biopha.2021.111476
EA MAR 2021
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA RP0BK
UT WOS:000641402100004
PM 33773470
OA gold
DA 2025 08 17
ER

PT J
AU Lucisano, MP
   Nelson, P
   Morse, L
   Battaglino, R
   Watanabe, PCA
   da Silva, RAB
   da Silva, LAB
AF Lucisano, Marilia Pacifico
   Nelson Filho, Paulo
   Morse, Leslie
   Battaglino, Ricardo
   Aranha Watanabe, Plauto Christopher
   Bezerra da Silva, Raquel Assed
   Bezerra da Silva, Lea Assed
TI Radiodensitometric and DXA analyses for the measurement of bone mineral
   density after systemic alendronate therapy
SO BRAZILIAN ORAL RESEARCH
LA English
DT Article
DE Bone Density; Alendronate; Bone Remodeling
ID X RAY ABSORPTIOMETRY; QUANTITATIVE COMPUTED TOMOGRAPHY;
   CLINICAL EFFICACY; IN VIVO; OSTEOPOROSIS; RATS; MICE; BISPHOSPHONATES;
   DEFICIENCY; MECHANISMS
AB Precise techniques for the measurement of maxillary bone mineral density (BMD) are useful for the early diagnosis of systemic diseases. The aim of this study was to compare in vivo the efficacy of dual energy x ray absorptiometry (DXA) and radiographic densitometry for the measurement of BMD after systemic administration of sodium alendronate. Wistar rats were randomly allocated to a control group (n = 5), which received distilled water, and a sodium alendronate group (n = 8), which received two doses of chemically pure sodium alendronate (1 mg/kg) per week. After 8 weeks, the animals were euthanized, the tibias were removed, and the BMD of the proximal tibial metaphysis was analyzed radiographically and by DXA. The data were subjected to statistical analysis by the Kruskal Wallis test at a significance level of 5%. Both of the techniques revealed that the alendronate treated group had a significantly higher BMD (p < 0.05) than the control group after 8 weeks of treatment. Comparing the groups with and without alendronate therapy revealed increases of 14.9% and 29.6% in BMD, as detected radiographically and by DXA, respectively. In conclusion, both of the methods Were able to detect an increase in BMD of the proximal tibial metaphysis after alendronate therapy.
C1 [Lucisano, Marilia Pacifico; Nelson Filho, Paulo; Bezerra da Silva, Raquel Assed; Bezerra da Silva, Lea Assed] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat Clin Prevent & Community Dent, BR 14049 Ribeirao Preto, SP, Brazil.
   [Morse, Leslie] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
   [Battaglino, Ricardo] Forsyth Inst, Dept Skeletal Biol, Cambridge, MA USA.
   [Aranha Watanabe, Plauto Christopher] Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Morphol Stomatol & Physiol, BR 14049 Ribeirao Preto, SP, Brazil.
C3 Universidade de Sao Paulo; Harvard University; Harvard Medical School;
   Harvard University; Harvard University Medical Affiliates; Forsyth
   Institute; Universidade de Sao Paulo
RP Nelson, P (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Dept Pediat Clin Prevent & Community Dent, BR 14049 Ribeirao Preto, SP, Brazil.
EM nelson@forp.usp.br
RI battaglino, ricardo/D 2892 2015; Morse, Leslie/AAU 5608 2020;
   Nelson Filho, Paulo/L 1272 2016; da Silva, Raquel/M 8655 2016; watanabe,
   plauto christopher aranha/C 6881 2015; Bezerra da Silva,
   Raquel/M 8655 2016; Lucisano, Marília/M 9060 2017; Lucisano,
   Marilia/M 9060 2017; Silva, Lea/B 3953 2016; Watanabe,
   Plauto/C 6881 2015
OI Nelson Filho, Paulo/0000 0001 8802 6480; watanabe, plauto christopher
   aranha/0000 0001 5524 1395; Bezerra da Silva,
   Raquel/0000 0002 0230 1347; Lucisano, Marilia/0000 0002 6866 0561;
   Silva, Lea/0000 0001 7118 6859; 
CR AboElAsrar MA, 2012, CYTOKINE, V59, P86, DOI 10.1016/j.cyto.2012.03.019
   [Anonymous], 1993, AM J MED, V95, p5S
   Bartell S. M., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P146
   Breen SA, 1998, LAB ANIM, V32, P467, DOI 10.1258/002367798780599839
   Buyukkaplan US, 2012, GERODONTOLOGY, V29, pE1098, DOI 10.1111/j.1741 2358.2012.00625.x
   Devlin H, 1998, J PROSTHET DENT, V79, P323, DOI 10.1016/S0022 3913(98)70245 8
   Earp JC, 2008, J PHARMACOL EXP THER, V326, P532, DOI 10.1124/jpet.108.137372
   Erdogan Ö, 2009, GERIATR GERONTOL INT, V9, P155, DOI 10.1111/j.1447 0594.2009.00518.x
   Friedlander AH, 2002, J AM DENT ASSOC, V133, P73, DOI 10.14219/jada.archive.2002.0025
   Giro G, 2008, ORAL SURG ORAL MED O, V105, P162, DOI 10.1016/j.tripleo.2007.06.010
   Gondim V, 2013, J PERIODONTOL, V84, P352, DOI 10.1902/jop.2012.120090
   Grados F, 2009, JOINT BONE SPINE, V76, P241, DOI 10.1016/j.jbspin.2008.07.017
   Griffith JF, 2010, ANN NY ACAD SCI, V1192, P45, DOI 10.1111/j.1749 6632.2009.05378.x
   Hildebolt CF, 1997, DENTOMAXILLOFAC RAD, V26, P3, DOI 10.1038/sj.dmfr.4600226
   Kanzaki S, 2009, J BONE MINER RES, V24, P43, DOI [10.1359/jbmr.080812, 10.1359/JBMR.080812]
   Katikaneni R, 2009, TOXICOL MECH METHOD, V19, P225, DOI 10.1080/15376510802499030
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lochmueller E. M., 2001, European Cells & Materials, V1, P43
   Lodder MC, 2004, ANN RHEUM DIS, V63, P285, DOI 10.1136/ard.2002.005678
   Issa JPM, 2008, INT J MORPHOL, V26, P83
   Martínez Maestre MA, 2010, CLIMACTERIC, V13, P523, DOI 10.3109/13697137.2010.500749
   Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47
   Nelson P, 2012, MICROSC RES TECHNIQ, V75, P1265, DOI 10.1002/jemt.22059
   Rowshan HH, 2010, J ORAL MAXIL SURG, V68, P260, DOI 10.1016/j.joms.2009.09.045
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Sakakura CE, 2003, J PERIODONTOL, V74, P976, DOI 10.1902/jop.2003.74.7.976
   Schmidt C, 2003, J BONE MINER RES, V18, P1486, DOI 10.1359/jbmr.2003.18.8.1486
NR 28
TC 6
Z9 6
U1 0
U2 7
PU SOCIEDADE BRASILEIRA DE PESQUISA ODONTOLOGICA
PI SAO PAULO
PA CIDADE UNIV, AV PROF LINEU PRESTES, ARMANDO SALLE OLIVEIRA, AVENIDA
   LINEU PRESTES, 2227, CP 8216, SAO PAULO, SP 05508 900, BRAZIL
SN 1806 8324
J9 BRAZ ORAL RES
JI Braz. Oral Res.
PD MAY JUN
PY 2013
VL 27
IS 3
BP 252
EP 257
DI 10.1590/S1806 83242013000300005
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 139KX
UT WOS:000318582700010
PM 23739782
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Baht, GS
   Nadesan, P
   Silkstone, D
   Alman, BA
AF Baht, Gurpreet S.
   Nadesan, Puviindran
   Silkstone, David
   Alman, Benjamin A.
TI Pharmacologically targeting beta catenin for NF1 associated deficiencies
   in fracture repair
SO BONE
LA English
DT Article
DE Neurofibromatosis type 1; Fracture repair; Osteoblast differentiation;
   Nefopam
ID NEUROFIBROMATOSIS TYPE 1 GENE; BONE MORPHOGENETIC PROTEIN; MANAGEMENT;
   PSEUDOARTHROSIS; BISPHOSPHONATE; ACTIVATION; KYPHOSIS; THERAPY; TIBIA
AB Patients with Neurofibromatosis type 1 display delayed fracture healing and the increased deposition of fibrous tissue at the fracture site. Severe cases can lead to non union and even congenital pseudarthrosis. Neurofibromatosis type 1 is caused by a mutation in the NF1 gene and mice lacking the Nf1 gene show a fracture repair phenotype similar to that seen in patients. Tissue from the fracture site of patients with Neurofibromatosis type 1 and from mice deficient in the Nf1 gene both show elevated levels of beta catenin protein and activation of beta catenin mediated signaling. Constitutively elevated beta catenin leads to a delayed and fibrous fracture repair process, and (RS) 5 methyl 1 phenyl 1,3,4,6 tetrahydro 2,5 benzoxazocine (Nefopam, a centrally acting, non narcotic analgesic agent) inhibits beta catenin mediated signaling during skin wound repair. Here we investigate Nefopam's potential as a modulator of bone repair in mice deficient in Nfl. Mice were treated with Nefopam and investigated for bone fracture repair. Bone marrow stromal cells flushed from the long bones of unfractured mice were treated with Nefopam and investigated for osteogenic potential. Treatment with Nefopam was able to lower the beta catenin level and the Axing transcript level in the fracture calluses of Nfl deficient mice. Cultures from the bone marrow of Nf1( / ) mice had significantly lower osteoblastic colonies and mineralized nodules, which was increased when cells were cultured in the presence of Nefopam. Fracture calluses were harvested and analyzed 14 days and 21 days after injury. Nf1( / ) calluses had less bone, less cartilage, and higher fibrous tissue content than control calluses. Treatment with Nefopam increased the bone and cartilage content and decreased the fibrous tissue content in Nf1( / ) calluses. These findings present a potential treatment for patients with Neurofibromatosis 1 in the context of bone repair. Since Nefopam is already in use in patient care, it could be rapidly translated to the clinical setting. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Baht, Gurpreet S.; Nadesan, Puviindran; Silkstone, David; Alman, Benjamin A.] Duke Univ, Dept Orthopaed Surg, DUMC 2888,200 Trent Dr,Orange Zone 5th Floor, Durham, NC 27710 USA.
   [Baht, Gurpreet S.] Duke Univ, Duke Mol Physiol Inst, Durham, NC USA.
C3 Duke University; Duke University
RP Alman, BA (通讯作者)，Duke Univ, Dept Orthopaed Surg, DUMC 2888,200 Trent Dr,Orange Zone 5th Floor, Durham, NC 27710 USA.
EM ben.alman@duke.edu
FU Department of Defense [W81XWH 13 1 0113]
FX This work was supported by the Department of Defense [W81XWH 13 1 0113].
CR Baht GS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8131
   Baht GS, 2014, J ORTHOP RES, V32, P581, DOI 10.1002/jor.22562
   Bassett JHD, 2012, METHODS MOL BIOL, V816, P499, DOI 10.1007/978 1 61779 415 5_29
   Binder K, 1988, Neurofibromatosis, V1, P85
   Birke O, 2010, J CHILD ORTHOP, V4, P507, DOI 10.1007/s11832 010 0293 3
   Borzunov DY, 2016, INT ORTHOP, V40, P331, DOI 10.1007/s00264 015 3029 7
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Crowe F.W.W.J.S.a.J.V.N., 1956, PUBLICATION BANNERST, V281
   Das SP, 2014, INT ORTHOP, V38, P1987, DOI 10.1007/s00264 014 2361 7
   FAIN P R, 1987, Genomics, V1, P340, DOI 10.1016/0888 7543(87)90034 6
   Friedman JM, 1999, AM J MED GENET, V89, P1
   Ghadakzadeh S., 2016, FASEB J
   Ghadakzadeh S, 2016, FASEB J, V30, P3227, DOI 10.1096/fj.201500190RR
   HOFMAN KJ, 1994, J PEDIATR US, V124, pS1, DOI 10.1016/S0022 3476(05)83163 4
   HOLT JF, 1978, AM J ROENTGENOL, V130, P615, DOI 10.2214/ajr.130.4.615
   HOYT WF, 1969, BRIT J OPHTHALMOL, V53, P793, DOI 10.1136/bjo.53.12.793
   Kawabata S, 2013, J NEUROSURG SPINE, V18, P274, DOI 10.3171/2012.11.SPINE12417
   LAZARO C, 1993, HUM GENET, V92, P429, DOI 10.1007/BF01247353
   Lee DY, 2011, CLIN ORTHOP SURG, V3, P230, DOI 10.4055/cios.2011.3.3.230
   Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078 0432.CCR 13 0780
   MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888 7543(91)90017 9
   Minear S, 2010, J BONE MINER RES, V25, P1196, DOI 10.1002/jbmr.29
   Minear S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000231
   Poon R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037940
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Schindeler A, 2008, J ORTHOP RES, V26, P65, DOI 10.1002/jor.20481
   SEIZINGER B R, 1987, Genomics, V1, P346, DOI 10.1016/0888 7543(87)90035 8
   Stevenson DA, 1999, AM J MED GENET, V84, P413, DOI 10.1002/(SICI)1096 8628(19990611)84:5<413::AID AJMG5>3.0.CO;2 1
   Stoker GE, 2012, SPINE, V37, pE1659, DOI 10.1097/BRS.0b013e3182770aa2
   Upadhyaya M, 1996, AM J MED GENET, V67, P421, DOI 10.1002/(SICI)1096 8628(19960726)67:4<421::AID AJMG20>3.0.CO;2 K
   Velasco O, 2014, BIORESEARCH OPEN ACC, V3, P192, DOI 10.1089/biores.2014.0017
   XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092 8674(90)90024 9
   Zeller T, 2013, J CANCER RES CLIN, V139, P357, DOI 10.1007/s00432 012 1336 6
   Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101
NR 34
TC 19
Z9 21
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2017
VL 98
BP 31
EP 36
DI 10.1016/j.bone.2017.02.012
PG 6
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ET4CV
UT WOS:000400227800005
PM 28254468
OA Bronze
DA 2025 08 17
ER

PT J
AU Xu, MS
   Choudhary, S
   Voznesensky, O
   Gao, Q
   Adams, D
   Diaz Doran, V
   Wu, QA
   Goltzman, D
   Raisz, LG
   Pilbeam, CC
AF Xu, Manshan
   Choudhary, Shilpa
   Voznesensky, Olga
   Gao, Qi
   Adams, Douglas
   Diaz Doran, Vilmaris
   Wu, Qian
   Goltzman, David
   Raisz, Lawrence G.
   Pilbeam, Carol C.
TI Basal bone phenotype and increased anabolic responses to intermittent
   parathyroid hormone in healthy male COX 2 knockout mice
SO BONE
LA English
DT Article
DE Prostaglandin; Bone remodeling; Cyclooxygenase
ID PROSTAGLANDIN G/H SYNTHASE 2; ADENOSINE 3,5 MONOPHOSPHATE MEDIATED
   PATHWAY; NORMOCALCEMIC PRIMARY HYPERPARATHYROIDISM; CANCELLOUS BONE;
   IN VITRO; CYCLOOXYGENASE 2; EXPRESSION; CELLS; GENE; PTH
AB Cyclooxygenase 2 (COX 2) knockout (KO) mice in inbred strains can have renal dysfunction with secondary hyperparathyroidism (HPTH), making direct effects of COX 2 KO on bone difficult to assess. COX 2 KO mice in an outbred CD 1 background did not have renal dysfunction but still had two fold elevated PTH compared to wild type (WT) mice. Compared to WT mice, KO mice had increased serum markers of bone turnover, decreased femoral bone mineral density (BMD) and cortical bone thickness, but no differences in trabecular bone volume by mu CT or dynamic histomorphometry. Because PTH is a potent inducer of COX 2 and prostaglandin (PG) production, we examined the effects of COX 2 KO on bone responses after 3 weeks of intermittent PTH. Intermittent PTH increased femoral BMD and cortical bone area more in KO mice than in WT mice and increased trabecular bone volume in the distal femur in both WT and KO mice. Although not statistically significant, PTH stimulated increases in trabecular bone tended to be greater in KO mice than in WT mice. PTH increased serum markers of bone formation and resorption more in KO than in WT mice but increased the ratio of osteoblastic surface to osteoclastic surface only in KO mice. PTH also increased femoral mineral apposition rates and bone formation rates in MO mice more than in WT mice. Acute mRNA responses to PTH of genes that might mediate some anabolic and catabolic effects of PTH tended to be greater in KO than WT mice. We conclude that (1) the basal bone phenotype in male COX 2 KO mice might reflect HPTH, COX 2 deficiency or both, and (2) increased responses to intermittent PTH in COX 2 KO mice, despite the presence of chronic HPTH, suggest that absence of COX 2 increased sensitivity to PTH. It is possible that manipulation of endogenous PGs could have important clinical implications for anabolic therapy with PTH. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Xu, Manshan; Choudhary, Shilpa; Voznesensky, Olga; Gao, Qi; Adams, Douglas; Diaz Doran, Vilmaris; Raisz, Lawrence G.; Pilbeam, Carol C.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.
   [Wu, Qian] Univ Connecticut, Ctr Hlth, Dept Anat Pathol & Lab Med, Farmington, CT 06030 USA.
   [Goltzman, David] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ 3A 1A1, Canada.
C3 University of Connecticut; University of Connecticut; McGill University
RP Pilbeam, CC (通讯作者)，Univ Connecticut, Ctr Hlth, Dept Med, Room N4051,Med Arts & Res Bldg,263 Farmington Ave, Farmington, CT 06030 USA.
EM pilbeam@nso.uchc.edu
RI Adams, Douglas/KQU 7200 2024
FU NIH [DK48361, AR47673, AR18063]; Canadian Institutes of Health Research
FX We thank Miren Gratton for performing the
   1,25(OH)<INF>2</INF>D<INF>3</INF> assays on serum. This work was
   supported by NIH grants DK48361 and AR47673 (C.P.) and AR18063 (L.G.R.)
   and by grants from the Canadian Institutes of Health Research (D.G.).
CR Alam I, 2005, J BONE MINER RES, V20, P438, DOI 10.1359/JBMR.041124
   Bell CD, 2004, ENDOCR PATHOL, V15, P29, DOI 10.1385/EP:15:1:29
   Bellido T., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P358
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005 0239
   Bikle DD, 2002, J BONE MINER RES, V17, P1570, DOI 10.1359/jbmr.2002.17.9.1570
   BROWN EM, 1985, PROSTAG OTH LIPID M, V29, P35, DOI 10.1016/0090 6980(85)90149 2
   Brown KM, 2004, J BONE JOINT SURG AM, V86A, P116, DOI 10.2106/00004623 200401000 00017
   Chen Q, 2003, CALCIFIED TISSUE INT, V73, P387, DOI 10.1007/s00223 002 0009 x
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   CHIKAZU D, 2002, J BONE MINER RES, V20, P1888
   Choudhary S, 2003, J BONE MINER RES, V18, P1813, DOI 10.1359/jbmr.2003.18.10.1813
   Choudhary S, 2008, BIOCHEM BIOPH RES CO, V372, P536, DOI 10.1016/j.bbrc.2008.05.050
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287
   Einhorn TA, 2003, ARTHRITIS RES THER, V5, P5, DOI 10.1186/ar607
   FayePetersen OM, 1996, PEDIATR PATHOL LAB M, V16, P489, DOI 10.1080/15513819609168686
   FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443
   FOLDES J, 1990, J BONE MINER RES, V5, P1063
   GARDNER DG, 1981, ENDOCRINOLOGY, V109, P1545, DOI 10.1210/endo 109 5 1545
   Gerstenfeld LC, 2007, J BONE JOINT SURG AM, V89A, P114, DOI 10.2106/JBJS.F.00495
   GOMAA AA, 1990, PHARMACOL RES, V22, P59, DOI 10.1016/1043 6618(90)90744 X
   HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095
   Imanishi Y, 2001, J CLIN INVEST, V107, P1093, DOI 10.1172/JCI10523
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097 4644(19990401)73:1<36::AID JCB5>3.3.CO;2 6
   Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018
   KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378
   KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo 86 6 1436
   LANYON LE, 1992, J BONE MINER RES, V7, pS369, DOI 10.1002/jbmr.5650071403
   Lee SK, 2002, BONE, V31, P252, DOI 10.1016/S8756 3282(02)00804 9
   Li L, 2006, CYTOKINE GROWTH F R, V17, P203, DOI 10.1016/j.cytogfr.2006.01.005
   Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756 3282(02)00683 X
   Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092 8674(00)80402 X
   LIN BY, 1994, BONE, V15, P489, DOI 10.1016/8756 3282(94)90272 0
   Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498
   Long IB, 2005, J PHARMACOL SCI, V99, P272, DOI 10.1254/jphs.FPJ05008X
   Lowe H, 2007, J CLIN ENDOCR METAB, V92, P3001, DOI 10.1210/jc.2006 2802
   Martin TJ, 2006, ANN NY ACAD SCI, V1068, P458, DOI 10.1196/annals.1346.043
   Maruani G, 2003, J CLIN ENDOCR METAB, V88, P4641, DOI 10.1210/jc.2002 021404
   McCauley LK, 1997, ENDOCRINOLOGY, V138, P5427, DOI 10.1210/en.138.12.5427
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092 8674(95)90125 6
   Myers LK, 2006, BONE, V39, P1048, DOI 10.1016/j.bone.2006.05.015
   NORRDIN RW, 1988, CALCIFIED TISSUE INT, V42, P363, DOI 10.1007/BF02556354
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Norwood VF, 2000, KIDNEY INT, V58, P2291, DOI 10.1046/j.1523 1755.2000.00413.x
   Nüsing RM, 2001, CLIN PHARMACOL THER, V70, P384, DOI 10.1016/S0009 9236(01)78384 1
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658
   Phelps E, 2005, CALCIFIED TISSUE INT, V77, P96, DOI 10.1007/s00223 004 0239 1
   Pilbeam CC, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1235, DOI 10.1016/B978 0 12 373884 4.00072 0
   Raisz L.G., 1983, BONE MINERAL RES, P286
   Robertson G, 2006, BONE, V39, P767, DOI 10.1016/j.bone.2006.04.006
   SCUTT A, 1995, J BONE MINER RES, V10, P474
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Suda K, 2004, J IMMUNOL, V172, P2504, DOI 10.4049/jimmunol.172.4.2504
   Suponitzky I, 1998, J ENDOCRINOL, V156, P51, DOI 10.1677/joe.0.1560051
   Tanabe T, 2002, PROSTAG OTH LIPID M, V68 9, P95, DOI 10.1016/S0090 6980(02)00024 2
   Tetradis S, 1997, ENDOCRINOLOGY, V138, P3594, DOI 10.1210/en.138.9.3594
   Tetradis S, 1996, ENDOCRINOLOGY, V137, P5435, DOI 10.1210/en.137.12.5435
   Tsukii K, 1998, BIOCHEM BIOPH RES CO, V246, P337, DOI 10.1006/bbrc.1998.8610
   UEDA K, 1980, J PEDIATR US, V97, P834, DOI 10.1016/S0022 3476(80)80282 4
   Wang HB, 2004, J BIOL CHEM, V279, P10649, DOI 10.1074/jbc.M312203200
   Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756 3282(97)00033 1
   Xu MS, 2005, ENDOCRINOLOGY, V146, P1843, DOI 10.1210/en.2004 0734
   Xu Z, 2007, BONE, V41, P68, DOI 10.1016/j.bone.2007.03.009
   Yang D, 2007, BONE, V40, P1453, DOI 10.1016/j.bone.2007.02.001
   Yang DH, 2008, ENDOCRINOLOGY, V149, P1728, DOI 10.1210/en.2007 0826
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhou H, 2003, BONE, V32, P513, DOI 10.1016/S8756 3282(03)00057 7
NR 73
TC 13
Z9 22
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2010
VL 47
IS 2
BP 341
EP 352
DI 10.1016/j.bone.2010.05.006
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 632SW
UT WOS:000280449300021
PM 20471507
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Bae, J
   Park, JW
AF Bae, Joonho
   Park, Jin Woo
TI Preparation of an injectable depot system for long term delivery of
   alendronate and evaluation of its anti osteoporotic effect in an
   ovariectomized rat model
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Alendronate; Osteoporosis; Depot system; Microsphere; Sustained release
ID BONE RESORPTION; BIODEGRADABLE MICROSPHERES; DRUG RELEASE;
   BISPHOSPHONATES; SODIUM; RISEDRONATE; ABSORPTION; PHARMACOKINETICS;
   OSTEOCALCIN; MECHANISMS
AB We prepared an injectable depot system for the long term delivery of alendronate using a solid/water/oil/ water multiple emulsion technique with poly(lactic co glycolic acid) as a carrier. The microparticles were spherical with smooth surfaces, ranging from 20 to 70 mu m in size. The microspheres (ALD HARG504H  MC70) were optimally prepared by introducing a viscous material (hyaluronic acid) and a co solvent system in the inner aqueous and oil phases, respectively, and showed a significantly increased drug encapsulation efficacy (>70%); the initial burst release was <10% after 1 day. In vitro drug release from ALD HA RG504H MC70 followed zero order kinetics for approximately 4 weeks and the alendronate plasma level was maintained for more than 1 month after intramuscular injection in rabbits. The ovariectomized (OVX) rats with ALD HA RG504H MC70 injected intramuscularly (0.9 mg alendronate/kg/4 weeks) had 112% and 482% increased bone mineral density and trabecular area in the tibia than the OVX controls, respectively, and showed significant improvements in trabecular microarchitecture and bone strength. Furthermore, the major biomarkers of bone turnover revealed that ALD HA RG504H MC70 suppressed effectively the progression of osteoporosis and facilitated new bone formation. Therefore, this sustained release depot system may improve patient compliance and therapeutic efficacy by reducing dose amounts and frequency with minimal adverse reactions. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Bae, Joonho] Amorepacific Corp R&D Ctr, Yongin 446729, Gyeonggi Do, South Korea.
   [Park, Jin Woo] Mokpo Natl Univ, Coll Pharm, Jeonnam 534729, South Korea.
   [Park, Jin Woo] Mokpo Natl Univ, Nat Med Res Inst, Jeonnam 534729, South Korea.
C3 Mokpo National University; Mokpo National University
RP Park, JW (通讯作者)，Mokpo Natl Univ, Coll Pharm, 1666 Youngsan Ro, Jeonnam 534729, South Korea.
EM jwpark@mokpo.ac.kr
RI Park, Jin Woo/AGY 9085 2022
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Science, ICT, & Future Planning
   [NRF 2014R1A1A1003122]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF), funded by the
   Ministry of Science, ICT, & Future Planning (NRF 2014R1A1A1003122).
CR Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Allen MR, 2008, EXPERT OPIN DRUG MET, V4, P1371, DOI 10.1517/17425255.4.11.1371 
   Arifin DY, 2006, ADV DRUG DELIVER REV, V58, P1274, DOI 10.1016/j.addr.2006.09.007
   Balas F, 2006, J AM CHEM SOC, V128, P8116, DOI 10.1021/ja062286z
   Blumentals WA, 2009, ANN PHARMACOTHER, V43, P577, DOI 10.1345/aph.1L555
   Christopoulou GE, 2006, J PHARMACEUT BIOMED, V41, P891, DOI 10.1016/j.jpba.2005.12.038
   Cocquyt V, 1999, J CLIN PHARMACOL, V39, P385, DOI 10.1177/00912709922007958
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Cramer JA, 2005, CURR MED RES OPIN, V21, P1453, DOI 10.1185/030079905X61875
   Cremers S, 2002, EUR J CLIN PHARMACOL, V57, P883, DOI 10.1007/s00228 001 0411 8
   DELPINO J, 1991, KLIN WOCHENSCHR, V69, P1135
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Ezra A, 2000, J MED CHEM, V43, P3641, DOI 10.1021/jm980645y
   Faisant N, 2002, EUR J PHARM SCI, V15, P355, DOI 10.1016/S0928 0987(02)00023 4
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   GERTZ BJ, 1993, OSTEOPOROSIS INT, V3, pS13
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Jagtap VR, 2011, INDIAN J CLIN BIOCHE, V26, P70, DOI 10.1007/s12291 010 0074 2
   JANNER M, 1991, CALCIFIED TISSUE INT, V49, P280, DOI 10.1007/BF02556218
   Komatsu K, 2013, J ENDOCRINOL, V219, P145, DOI 10.1530/JOE 13 0040
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIN JH, 1992, DRUG METAB DISPOS, V20, P473
   LIN JH, 1994, J PHARM SCI US, V83, P1741, DOI 10.1002/jps.2600831218
   Miladi K, 2013, INT J PHARMACEUT, V445, P181, DOI 10.1016/j.ijpharm.2013.01.031
   Nafea EH, 2007, J MICROENCAPSUL, V24, P525, DOI 10.1080/02652040701439807
   Nam SH, 2012, BONE, V50, P149, DOI 10.1016/j.bone.2011.10.017
   Nasr M, 2011, EUR J PHARM BIOPHARM, V79, P601, DOI 10.1016/j.ejpb.2011.07.010
   Patashnik S, 1997, J DRUG TARGET, V4, P371, DOI 10.3109/10611869709017894
   Peter CP, 1998, DIGEST DIS SCI, V43, P1998, DOI 10.1023/A:1018894827961
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   POWER MJ, 1991, CRIT REV CL LAB SCI, V28, P287, DOI 10.3109/10408369109106867
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Rizzoli R, 2001, J MOL ENDOCRINOL, V26, P79, DOI 10.1677/jme.0.0260079
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Schnitzer T, 2000, AGING CLIN EXP RES, V12, P1
   Shi XT, 2009, BIOMATERIALS, V30, P3996, DOI 10.1016/j.biomaterials.2009.04.021
   Shi XT, 2009, PHARM RES DORDR, V26, P422, DOI 10.1007/s11095 008 9759 0
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P229, DOI 10.1016/S0169 409X(01)00116 8
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Umeki N, 2010, INT J PHARMACEUT, V392, P42, DOI 10.1016/j.ijpharm.2010.03.020
NR 40
TC 16
Z9 16
U1 0
U2 45
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAR 1
PY 2015
VL 480
IS 1 2
BP 37
EP 47
DI 10.1016/j.ijpharm.2015.01.020
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CC6CS
UT WOS:000350452900005
PM 25595570
DA 2025 08 17
ER

EF